﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Salcedo-Villanueva, G
   Feria-Anzaldo, E
   Romo-Aguas, JC
   Lisker-Cervantes, A
   Gonzalez-Dibildox, A
   Moreno-Paramo, E
   Medina-Andrade, AA
   Velez-Montoya, R
   Garcia-Aguirre, G
   Morales-Canton, V
   Quiroz-Mercado, H
AF Salcedo-Villanueva, Guillermo
   Feria-Anzaldo, Estephania
   Romo-Aguas, Juan C.
   Lisker-Cervantes, Andres
   Gonzalez-Dibildox, Alejandra
   Moreno-Paramo, Edel
   Medina-Andrade, Abraham A.
   Velez-Montoya, Raul
   Garcia-Aguirre, Gerardo
   Morales-Canton, Virgilio
   Quiroz-Mercado, Hugo
TI Anti-VEGF treatment switch in neovascular age-related macular
   degeneration: a comparison of aflibercept versus ranibizumab after a
   single-dose switch
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Bevacizumab; Choroidal neovascularization; Macular
   degeneration; Ranibuzumab
ID INTRAVITREAL BEVACIZUMAB; TACHYPHYLAXIS; VERTEPORFIN
AB Purpose To determine the effect achieved from a single dose of anti-VEGF treatment switch, in patients with nAMD previously treated with bevacizumab, switched to either aflibercept or ranibizumab, and to compare the response between aflibercept and ranibizumab. Methods In retrospective, observational, and comparative study, patients were divided into two groups: Group 1, patients switched to aflibercept; Group 2, patients switched to ranibizumab. Paired samples t test was performed to measure differences in central macular thickness (CMT). To compare whether there were differences between groups mixed-design ANOVA was used. Results In Group 1, CMT changed from 360.51 to 260.16 mu m, presenting a significant mean difference from PreSwitch to PostSwitch of 100.34 mu m (p = 0.002, paired samples t test). In Group 2, CMT changed from 366.33 to 260.72 mu m, showing a significant difference from PreSwitch to PostSwitch of 105.61 mu m (p <= 0.000, paired samples t test). The mixed-design ANOVA compared both groups and resulted in a nonsignificant value of 0.90. Conclusion The effect achieved from a single dose in patients switched to aflibercept or ranibizumab reduced significantly CMT measurements. Comparing aflibercept and ranibizumab, the effect appears to be similar in both drugs, in terms of reduction of CMT.
C1 [Salcedo-Villanueva, Guillermo; Feria-Anzaldo, Estephania; Romo-Aguas, Juan C.; Lisker-Cervantes, Andres; Gonzalez-Dibildox, Alejandra; Moreno-Paramo, Edel; Medina-Andrade, Abraham A.; Velez-Montoya, Raul; Garcia-Aguirre, Gerardo; Morales-Canton, Virgilio] Hosp Dr Luis Sanchez Bulnes, Retina Dept, Asociac Evitar Ceguera Mexico, Vicente Garcia Torres 46, Mexico City 04030, DF, Mexico.
   [Quiroz-Mercado, Hugo] Hosp Dr Luis Sanchez Bulnes, Res Dept, Asociac Evitar Ceguera Mexico, Vicente Garcia Torres 46, Mexico City 04030, DF, Mexico.
RP Salcedo-Villanueva, G (通讯作者)，Hosp Dr Luis Sanchez Bulnes, Retina Dept, Asociac Evitar Ceguera Mexico, Vicente Garcia Torres 46, Mexico City 04030, DF, Mexico.
EM salcedovilla@gmail.com
RI Canton, Virgilio/AAF-7047-2021; Garcia-Aguirre, Gerardo/AAP-6488-2020;
   Salcedo-Villanueva, Guillermo/AAE-9695-2019
OI Salcedo-Villanueva, Guillermo/0000-0003-2526-6342; GONZALEZ DIBILDOX,
   LAURA ALEJANDRA/0000-0002-4948-2384; Romo-Aguas, Juan
   Carlos/0000-0001-5293-8103; Lisker, Andres/0000-0001-6133-0116;
   Garcia-Aguirre, Gerardo/0000-0001-6056-9475
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HUCK SW, 1975, PSYCHOL BULL, V82, P511, DOI 10.1037/h0076767
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maguire MG, 2016, JAMA OPHTHALMOL, V22
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moisseiev E, 2015, RETINA-J RET VIT DIS, V35, P1323, DOI 10.1097/IAE.0000000000000500
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Pinheiro-Costa J, 2014, OPHTHALMOLOGICA, V232, P149, DOI 10.1159/000363422
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Waizel M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0471-x
   Waizel M, 2016, EUR J OPHTHALMOL, V26, P469, DOI 10.5301/ejo.5000781
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 23
TC 4
Z9 4
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD SEP
PY 2019
VL 39
IS 9
BP 2023
EP 2031
DI 10.1007/s10792-018-1038-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IY2PE
UT WOS:000486232500015
PM 30386955
DA 2022-11-30
ER

PT J
AU Stock, MV
   Vollman, DE
   Baze, EF
   Chomsky, AS
   Daly, MK
   Lawrence, MG
AF Stock, Michael V.
   Vollman, David E.
   Baze, Elizabeth F.
   Chomsky, Amy S.
   Daly, Mary K.
   Lawrence, Mary G.
TI Functional Visual Improvement After Cataract Surgery in Eyes With
   Age-Related Macular Degeneration: Results of the Ophthalmic Surgical
   Outcomes Data Project
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE cataract surgery; age-related macular degeneration; visual function;
   visual acuity
ID QUALITY-OF-LIFE; IMPACT; POPULATION; ACUITY; PHACOEMULSIFICATION; RISK
AB PURPOSE. To determine if cataract surgery on eyes with AMD confers as much functional visual improvement as surgery on eyes without retinal pathology.
   METHODS. This is a retrospective analysis of 4924 cataract surgeries from the Veterans Healthcare Administration Ophthalmic Surgical Outcomes Data Project (OSOD). We included cases of eyes with AMD that had both preoperative and postoperative NEI-VFQ-25 questionnaires submitted and compared their outcomes with controls without retinal pathology. We excluded patients with other retinal pathologies (740 patients). The analyses compared changes in visual acuity and overall functional visual improvement and its subscales using t-tests, multivariate logistic regressions, and linear regression modeling.
   RESULTS. Preoperative and postoperative questionnaires were submitted by 58.3% of AMD and 63.8% of no retinal pathology cases (controls). Analysis of overall score showed that cataract surgery on eyes with AMD led to increased visual function (13.8 +/- 2.4 NEI-VFQ units, P < 0.0001); however, increases were significantly less when compared with controls (-6.4 +/- 2.9 NEI-VFQ units, P < 0.0001). Preoperative best-corrected visual acuity (preBCVA) in AMD was predictive of postoperative visual function (r = -0.38, P < 0.0001). In controls, postoperative visual function was only weakly associated with preBCVA (r = -0.075, P = 0.0002). Patients with AMD with vision of 20/40 or better had overall outcomes similar to controls (-2.2 +/- 4.7 NEI-VFQ units, P = 0.37).
   CONCLUSIONS. Cataract surgery on eyes with AMD offers an increase in functional visual improvement; however, the amount of benefit is associated with the eye's preBCVA. For eyes with preBCVA of 20/40 or greater, the improvement is similar to that of patients without retinal pathology. However, if preBCVA is less than 20/40, the amount of improvement was shown to be significantly less and decreased with decreasing preBCVA.
C1 [Stock, Michael V.; Vollman, David E.] VA St Louis Healthcare Syst, St Louis, MO USA.
   [Stock, Michael V.; Vollman, David E.] Washington Univ, Sch Med, St Louis, MO USA.
   [Baze, Elizabeth F.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
   [Baze, Elizabeth F.] Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA.
   [Chomsky, Amy S.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA.
   [Chomsky, Amy S.] Vanderbilt Univ Med, Vanderbilt Eye Inst, Nashville, TN USA.
   [Daly, Mary K.] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Daly, Mary K.] VA Boston Healthcare Syst, Boston, MA USA.
   [Daly, Mary K.] Harvard Univ, Sch Med, Boston, MA USA.
   [Lawrence, Mary G.] DoD VA Vis Ctr Excellence, Crystal City, VA USA.
C3 Washington University (WUSTL); Baylor College of Medicine; Baylor
   College of Medicine; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt
   University; Boston University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Harvard University; VA Boston
   Healthcare System; Harvard University; Harvard Medical School
RP Stock, MV (通讯作者)，660 South Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.
EM stockm@vision.wustl.edu
OI Stock, Michael/0000-0001-5404-1105
CR Amesbury EC, 2009, J CATARACT REFR SURG, V35, P1505, DOI 10.1016/j.jcrs.2009.04.031
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Ayaki M, 2013, REJUV RES, V16, P35, DOI 10.1089/rej.2012.1369
   BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040
   Brown GC, 2013, OPHTHALMOLOGY, V120, P2367, DOI 10.1016/j.ophtha.2013.04.030
   Casparis H, 2012, COCHRANE DB SYST REV, V6
   Chandrasekaran S, 2008, EYE, V22, P479, DOI 10.1038/sj.eye.6702854
   Chang-Godinich A, 1999, J CATARACT REFR SURG, V25, P1226, DOI 10.1016/S0886-3350(99)00193-5
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Durmus B, 2011, BRATISL MED J, V112, P701
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Hejcmanova Dagmar, 2003, Acta Medica (Hradec Kralove), V46, P189
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   To KG, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-16
   Kuo IC, 2011, CAN J OPHTHALMOL, V46, P391, DOI 10.1016/j.jcjo.2011.07.008
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lamoureux EL, 2011, CURR OPIN OPHTHALMOL, V22, P19, DOI 10.1097/ICU.0b013e3283414284
   Lee BS, 2013, OPHTHALMOLOGY, V120, P949, DOI 10.1016/j.ophtha.2012.10.009
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Mamidipudi PR, 2003, J CATARACT REFR SURG, V29, P1143, DOI 10.1016/S0886-3350(03)00043-9
   Monestam E, 2004, AM J OPHTHALMOL, V137, P145, DOI 10.1016/S0002-9394(03)00900-0
   Monestam E, 1999, EYE, V13, P711, DOI 10.1038/eye.1999.213
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Owsley C, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.118547
   Polack S, 2010, OPHTHAL EPIDEMIOL, V17, P387, DOI 10.3109/09286586.2010.528136
   Pomberg ML, 2004, AM J OPHTHALMOL, V138, P125, DOI 10.1016/j.ajo.2004.02.022
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Vollman DE, 2014, AM J OPHTHALMOL, V157, P1130, DOI 10.1016/j.ajo.2014.02.052
NR 33
TC 10
Z9 11
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2015
VL 56
IS 4
BP 2536
EP 2540
DI 10.1167/iovs.14-16069
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ1NP
UT WOS:000355250700050
PM 26066600
DA 2022-11-30
ER

PT J
AU Garcia, CAD
   Yehoshua, Z
   Gregori, G
   Nunes, RP
   Penha, FM
   Moshfeghi, AA
   Zhang, K
   Feuer, W
   Rosenfeld, PJ
AF de Amorim Garcia Filho, Carlos Alexandre
   Yehoshua, Zohar
   Gregori, Giovanni
   Nunes, Renata Portella
   Penha, Fernando M.
   Moshfeghi, Andrew A.
   Zhang, Kang
   Feuer, William
   Rosenfeld, Philip J.
TI Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study
   of Complement Inhibition in Age-related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID PROPHYLACTIC TREATMENT; GRID PHOTOCOAGULATION; ALTERNATIVE PATHWAY;
   GEOGRAPHIC ATROPHY; SEVERITY SCALE; FACTOR-B; LASER; RISK; ECULIZUMAB;
   DISEASE
AB BACKGROUND AND OBJECTIVE: To evaluate the change in drusen volume following treatment with eculizumab, a systemic inhibitor of complement component 5.
   PATIENTS AND METHODS: Single-center, prospective, randomized, double-masked clinical trial. Patients were randomized 2: 1 to receive intravenous eculizumab or placebo over 26 weeks. Main outcome measure: decrease in drusen volume of at least 50% at 26-week follow-up.
   RESULTS: Mean drusen cube root volumes were 0.49 mm and 0.47 mm (P=.64) at baseline and 0.51 mm and 0.42 mm (P=.17) at 26 weeks in the eculizumab and placebo groups, respectively. In the placebo group, one eye had a decrease in drusen volume of at least 50% and two eyes developed neovascularization through 26 weeks.
   CONCLUSION: Systemic complement inhibition with eculizumab did not significantly reduce drusen volume. Drusen growth was dependent on the number of complement at-risk alleles. Future trials should consider the use of a composite clinical trial endpoint in which efficacy is defined by the treatment's ability to prevent drusen growth, neovascularization, and the formation of geographic atrophy over 1 year.
C1 [de Amorim Garcia Filho, Carlos Alexandre; Yehoshua, Zohar; Gregori, Giovanni; Nunes, Renata Portella; Penha, Fernando M.; Moshfeghi, Andrew A.; Feuer, William; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [de Amorim Garcia Filho, Carlos Alexandre; Nunes, Renata Portella; Penha, Fernando M.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Zhang, Kang] Univ Calif San Diego, Inst Genom Med, San Diego, CA 92103 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA 92103 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Universidade Federal
   de Sao Paulo (UNIFESP); University of California System; University of
   California San Diego; University of California System; University of
   California San Diego
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU Alexion Pharmaceuticals; Macula Vision Research Foundation; Carl Zeiss
   Meditec; Research to Prevent Blindness; NEI core center grant [P30
   EY014801]; Department of Defense (DOD) [W81XWH-09-1-0675]; Jerome A.
   Yavitz Charitable Foundation; Emma Clyde Hodge Memorial Foundation;
   Florman Family Foundation; Gemcon Family Foundation; NATIONAL EYE
   INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
FX Supported by Alexion Pharmaceuticals, the Macula Vision Research
   Foundation, Carl Zeiss Meditec, an unrestricted grant from Research to
   Prevent Blindness, NEI core center grant P30 EY014801 to the University
   of Miami, Department of Defense (DOD-Grant#W81XWH-09-1-0675), the Jerome
   A. Yavitz Charitable Foundation, the Emma Clyde Hodge Memorial
   Foundation, the Florman Family Foundation, and the Gemcon Family
   Foundation.
CR Bomback AS, 2012, CLIN J AM SOC NEPHRO, V7, P748, DOI 10.2215/CJN.12901211
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferreira-Gonzalez I, 2007, BRIT MED J, V334, P786, DOI 10.1136/bmj.39136.682083.AE
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hill A, 2005, BLOOD, V106, P2559, DOI 10.1182/blood-2005-02-0564
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Katz MH, 2006, MULTIVARIABLE ANALYSIS: A PRACTICAL GUIDE FOR CLINICIANS, 2ND EDITION, P1, DOI 10.1017/CBO9780511811692
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   LANES SF, 1990, J CLIN EPIDEMIOL, V43, P1379, DOI 10.1016/0895-4356(90)90105-X
   Maguire MG, 2012, OPHTHALMOLOGY, V119, P1501, DOI 10.1016/j.ophtha.2012.03.012
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mullins RF, 2005, ARCH OPHTHALMOL-CHIC, V123, P1588, DOI 10.1001/archopht.123.11.1588
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   POOLE C, 1990, J CLIN EPIDEMIOL, V43, P1270, DOI 10.1016/0895-4356(90)90029-O
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Rothman K J, 1990, Epidemiology, V1, P232, DOI 10.1097/00001648-199005000-00009
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Rothman K J, 1990, Epidemiology, V1, P417, DOI 10.1097/00001648-199011000-00001
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tomlinson G, 2010, JAMA-J AM MED ASSOC, V303, P267, DOI 10.1001/jama.2009.2017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 42
TC 50
Z9 50
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN-FEB
PY 2014
VL 45
IS 1
BP 18
EP 31
DI 10.3928/23258160-20131217-01
PG 14
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AE2OI
UT WOS:000333812200003
PM 24354307
DA 2022-11-30
ER

PT J
AU Dentchev, T
   Hahn, P
   Dunaief, JL
AF Dentchev, T
   Hahn, P
   Dunaief, JL
TI Strong labeling for iron and the iron-handling proteins ferritin and
   ferroportin in the photoreceptor layer in age-related macular
   degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID OVERLOAD
C1 Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
OI Hahn, Paul/0000-0002-6574-388X
CR Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Rouault TA, 2001, NAT GENET, V28, P299, DOI 10.1038/91036
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
NR 9
TC 54
Z9 54
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2005
VL 123
IS 12
BP 1745
EP 1746
DI 10.1001/archopht.123.12.1745
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991BS
UT WOS:000233787800019
PM 16344450
OA Bronze
DA 2022-11-30
ER

PT J
AU Shen, LBL
   Sun, MY
   Khetpal, S
   Nardini, HKG
   Del Priore, LV
AF Shen, Liangbo L.
   Sun, Mengyuan
   Khetpal, Sumun
   Nardini, Holly K. Grossetta
   Del Priore, Lucian, V
TI Topographic Variation of the Growth Rate of Geographic Atrophy in
   Nonexudative Age-Related Macular Degeneration: A Systematic Review and
   Meta-analysis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
DE age-related macular degeneration; geographic atrophy; meta-analysis;
   systematic review
ID NATURAL-HISTORY; UNTREATED EYES; VISUAL-ACUITY; PROGRESSION; SECONDARY;
   DISEASE; PIGMENT; AREA; RISK; CONE
AB PURPOSE. To determine the impact of topographic locations on the progression rate of geographic atrophy (GA).
   METHODS. We searched in five literature databases up to May 3, 2019, for studies that evaluated the growth rates of GA lesions at different retinal regions. We performed random-effects meta-analyses to determine and compare the GA effective radius growth rates in four location groups defined by two separate classification schemes: (1) macular center point involved (CPI) or spared (CPS) in classification 1, and (2) foveal zone involved (FZI) or spared (FZS) in classification 2. We then estimated the GA growth rate in eight topographic zones and used the data to model the GA expansion.
   RESULTS. We included 11 studies with 3254 unique eyes. In studies that used classification 1, the effective radius growth rate was 30.1% higher in the CPS group (0.203 +/- 0.013 mm/year) than in the CPI group (0.156 +/- 0.011 mm/year) (P < 0.001). This trend became significantly more prominent in classification 2, where the growth rate was 61.7% higher in the FZS group (0.215 +/- 0.012 mm/year) than in the FZI group (0.133 +/- 0.009 mm/year) (P < 0.001). The estimated GA effective radius growth rates in eight retinal zones fit a Gaussian function, and the modeling of GA expansion gave rise to various GA configurations comparable to clinical observations.
   CONCLUSIONS. This study indicates that the GA progression rate varies significantly across different retinal locations. Our analysis may shed light on the natural history and underlying mechanism of GA progression.
C1 [Shen, Liangbo L.; Khetpal, Sumun; Del Priore, Lucian, V] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, 40 Temple St,Suite 1B, New Haven, CT 06510 USA.
   [Sun, Mengyuan] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA.
   [Nardini, Holly K. Grossetta] Yale Univ, Harvey Cushing John Hay Whitney Med Lib, New Haven, CT USA.
C3 Yale University; Yale University; Yale University
RP Del Priore, LV (通讯作者)，Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, 40 Temple St,Suite 1B, New Haven, CT 06510 USA.
EM lucian.delpriore@yale.edu
OI Nardini, Holly K/0000-0001-5563-6848; Shen, Liangbo/0000-0002-1823-0854
FU NEI NIH HHS [P30 EY026878] Funding Source: Medline
CR Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHUANG EL, 1987, EYE, V1, P120, DOI 10.1038/eye.1987.18
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gass JDM, 1987, STEREOSCOPIC ATLAS M, P464
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20980
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Luchini C, 2017, WORLD J META-ANAL, V5, P80, DOI 10.13105/wjma.v5.i4.80
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Mones J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.40
   Mones J, 2013, OPHTHALMOLOGY, V120, P829, DOI 10.1016/j.ophtha.2012.09.054
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Riley RD, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k4597
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Shen LB, 2018, OPHTHALMOL RETINA, V2, P914, DOI 10.1016/j.oret.2018.01.019
   Shen LBL, 2019, OPHTHALMOLOGY, V126, P1288, DOI 10.1016/j.ophtha.2019.05.015
   Shen LBL, 2019, OPHTHALMOL RETINA, V3, P305, DOI 10.1016/j.oret.2018.11.013
   Shen LBL, 2019, RETINA-J RET VIT DIS, V39, P1829, DOI 10.1097/IAE.0000000000002480
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wells GA., 2011, NEWCASTLE OTTAWA SCA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 49
TC 19
Z9 19
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2020
VL 61
IS 1
AR 2
DI 10.1167/iovs.61.1.2
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KH7JK
UT WOS:000510826300002
PM 31995152
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Shi, Y
   Tham, YC
   Sabanayagam, C
   Neelam, K
   Wang, JJ
   Mitchell, P
   Cheng, CY
   Wong, TY
   Cheung, CYL
AF Cheung, Chui Ming Gemmy
   Shi, Yuan
   Tham, Yih Chung
   Sabanayagam, Charumathi
   Neelam, Kumari
   Wang, Jie Jin
   Mitchell, Paul
   Cheng, Ching-Yu
   Wong, Tien Yin
   Cheung, Carol Yim Lui
TI Correlation of Color Fundus Photograph Grading with Risks of Early
   Age-related Macular Degeneration by using Automated OCT-derived Drusen
   Measurements
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; HIGH-DOSE SUPPLEMENTATION; SD-OCT;
   SEVERITY SCALE; CLINICAL-TRIAL; BETA-CAROTENE; EYE DISEASE; VISION LOSS;
   VITAMIN-C; SEGMENTATION
AB We evaluated automated OCT-derived drusen volume measures in a population-based study (n = 4,512) aged >= 40 years, and its correlation with conventional color fundus photographs (CFP)-derived early AMD features. Participants had protocol-based assessment to capture medical and ocular history, genotyping for SNPs in CFH, ARMS2, and CETP, CFP-based AMD grading and automated drusen volume based on SD-OCT using built-in software (Cirrus OCT advanced RPE analysis software). Significantly fewer eyes with early AMD features (drusen, hyperpigmentation, soft or reticular drusen) had drusen volume = 0 mm(3) (p < 0.001). In eyes with drusen volume > 0 mm(3), increasing AMD severity was associated with increase in drusen volume (correlation coefficient 0.17, p < 0.001). However 220 (59.14%) of 372 participants with AMD based on CFP grading had drusen volume = 0 mm(3). Factors associated with drusen volume included age (OR 1.42 per 5 years, 95% confidence interval [CI] 2.76, 4.48), systolic blood pressure (OR1.00, 95% CI 1.00, 1.01), ethnic Malay (OR 1.54, 95% CI 1.29, 1.83) and Chinese (OR 1.66, 95% CI 1.37, 2.01) compared to Indian. The ARMS2 rs10490924 T allele was associated with increased drusen volume in subjects with AMD (multivariable adjusted OR1.54, 95% CI 1.08, 2.19). Automated OCT-derived drusen volume is correlated with CFP-based AMD grading in many, but not all subjects. However the agreement is not good. These two modalities provide complementary information and should be incorporated into future studies.
C1 [Cheung, Chui Ming Gemmy; Shi, Yuan; Tham, Yih Chung; Sabanayagam, Charumathi; Wang, Jie Jin; Cheng, Ching-Yu; Wong, Tien Yin; Cheung, Carol Yim Lui] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wang, Jie Jin; Cheng, Ching-Yu; Wong, Tien Yin; Cheung, Carol Yim Lui] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Neelam, Kumari] Khoo Teck Puat Hosp, Ophthalmol & Visual Sci, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
   [Cheung, Carol Yim Lui] Chinese Univ Hong Kong, Dept Ophthalmol, Ma Liu Shui, Hong Kong, Peoples R China.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   University of Sydney; Westmead Institute for Medical Research; Chinese
   University of Hong Kong
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.; Cheung, CMG (通讯作者)，Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Wang, Jie Jin/P-1499-2014; Cheung, Carol Y./G-7895-2016; Sabanayagam,
   Charumathi/C-1294-2011; Cheung, Carol/AAF-1101-2020; Wong, Tien
   Yin/AAC-9724-2020; Chung, Yih/AIF-2414-2022; wang, jie/GRS-0942-2022;
   Cheng, Ching-Yu/Y-2229-2019
OI Wang, Jie Jin/0000-0001-9491-4898; Sabanayagam,
   Charumathi/0000-0002-4042-4719; Cheung, Carol/0000-0002-9672-1819; Wong,
   Tien Yin/0000-0002-8448-1264; Chung, Yih/0000-0002-6752-797X; Cheng,
   Ching-Yu/0000-0003-0655-885X; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU National Medical Research Council [0796/2003]; Biomedical Research
   Council [501/25-5]
FX We thank Prof Cheung Yin Bun for his advice on statistical analysis.
   National Medical Research Council grants no. 0796/2003 and Biomedical
   Research Council Grant no. 501/25-5.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Cheung CMG, 2016, JAMA OPHTHALMOL, V134, P1047, DOI 10.1001/jamaophthalmol.2016.2407
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chuang-Stein C., 1997, TUTORIAL BIOSTATISTI, V16, P2599
   Cornes BK, 2012, HUM MOL GENET, V21, P437, DOI 10.1093/hmg/ddr463
   de Sisternes Luis, 2017, Transl Vis Sci Technol, V6, P12, DOI 10.1167/tvst.6.1.12
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Diniz B, 2015, EYE, V29, P300, DOI 10.1038/eye.2014.307
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   LUI KJ, 1995, STAT MED, V14, P445
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Rosman M, 2012, CLIN EXP OPHTHALMOL, V40, P557, DOI 10.1111/j.1442-9071.2012.02763.x
   Sabanayagam C, 2017, CLIN EXP OPHTHALMOL, V45, P779, DOI 10.1111/ceo.12974
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Tham YC, 2015, OPHTHALMOLOGY, V122, P1149, DOI 10.1016/j.ophtha.2015.01.024
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 38
TC 8
Z9 8
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 28
PY 2018
VL 8
AR 12937
DI 10.1038/s41598-018-31109-x
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GR7YP
UT WOS:000442917500009
PM 30154521
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Told, R
   Sacu, S
   Hecht, A
   Baratsits, M
   Eibenberger, K
   Kroh, ME
   Rezar-Dreindl, S
   Schlanitz, FG
   Weigert, G
   Pollreisz, A
   Schmidt-Erfurth, U
AF Told, Reinhard
   Sacu, Stefan
   Hecht, Alexander
   Baratsits, Magdalena
   Eibenberger, Katharina
   Kroh, Maria E.
   Rezar-Dreindl, Sandra
   Schlanitz, Ferdinand G.
   Weigert, Guenther
   Pollreisz, Andreas
   Schmidt-Erfurth, Ursula
TI Comparison of SD-Optical Coherence Tomography Angiography and
   Indocyanine Green Angiography in Type 1 and 2 Neovascular Age-related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE OCT angiography; ICGA; type 1 AMD; type 2 AMD; neovascular age-related
   macular degeneration
ID RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   SWEPT-SOURCE OCT; SPECTRAL-DOMAIN; EARLY RESPONSE; TIME-COURSE;
   VISUALIZATION; GUIDELINES; MANAGEMENT; THERAPY
AB PURPOSE. The purpose of this study is to compare the ability of spectral domain optical coherence tomography angiography (SD-OCTA) and indocyanine green angiography (ICGA) to detect and measure lesion area in patients with type 1 and 2 choroidal neovascularization (CNV).
   Methods. Types 1 and 2 neovascular AMD (nAMD) were included in this prospective and observational case series. ETDRS best-corrected visual acuity (BCVA). ophthalmic examination with funduscopy, OCTA (AngioVue), fluorescein angiography (FA), ICGA, and OCT (Spectralis) were performed. CNV measurements were done manually by two experienced graders using the systems' innate region selection tools.
   RESULTS. Forty eyes of 39 consecutive patients with nAMD were included. Mean age was 77 +/- 6.4 years, ETDRS IW.'VA was 67 +/- 13 letters, and 1 i eyes were treatment naive. Nineteen CNV lesions were classified as type 1 and 21 as type 2. ICGA was able to identify CNV in all eyes. By contrast, OCTA detected CNV in 95% of type 1 and 86% of type 2 nAMD eyes. Mean overall CNV area (CNV-A) was 2.8 +/- 2.7 mm(2) in ICGA and 2.1 +/- 2.7 mm(2) in OCTA. Both lesion types CNV-A appeared significantly smaller in OCTA compared with ICGA (P < 0.01). Bland-Altman plot revealed a mean difference (bias) between OCTA and ICGA CNV-A of 0.76 +/- 1.74 mm(2). Intraclass correlation coefficient (ICQ for CNV-A was 0.91 and 0.93 for ICGA and OCTA, respectively. ICGA CNV-A in the four OCTA-negative eyes (median 4.7 mm(2)) was not significantly different from the 36 OCTA-positive eyes (median 1.7 mm(2)).
   CONCLUSIONS. Type I and 2 CNV-A were significantly smaller in OCTA than in ICGA. OCTA was generally less successful in detecting CNV than ICGA in patients who were included into this study based on FA and OCT. However, OCTA detected all type 1 lesions except for one, indicating that the SD-OCTA signal is limited by detection limits of blood flow velocity rather than lesion type. Further efforts are needed pushing the limits of lowest detectable and fastest distinguishable flow until OCTA can deliver realistic qualitative and quantitative imaging of type 1 and 2 CNV for diagnosis and monitoring.
C1 [Told, Reinhard; Sacu, Stefan; Hecht, Alexander; Baratsits, Magdalena; Eibenberger, Katharina; Kroh, Maria E.; Rezar-Dreindl, Sandra; Schlanitz, Ferdinand G.; Weigert, Guenther; Pollreisz, Andreas; Schmidt-Erfurth, Ursula] Med Univ Vienna, Vienna Clin Trial Ctr, Dept Ophthalmol & Optometry, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021
OI Told, Reinhard/0000-0003-2046-7081; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
CR Adhi M, 2013, OSLI RETINA, V44, pS40, DOI 10.3928/23258160-20131101-08
   American Academy of Ophthalmology, 2015, AG REL MAC DEG PREF
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass J D, 1994, Trans Am Ophthalmol Soc, V92, P91
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   LIM JI, 1995, INT OPHTHALMOL CLIN, V35, P59, DOI 10.1097/00004397-199503540-00006
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Malihi M, 2017, BRIT J OPHTHALMOL, V101, P45, DOI 10.1136/bjophthalmol-2016-309094
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Say EAT, 2017, RETINA-J RET VIT DIS, V37, P1660, DOI 10.1097/IAE.0000000000001414
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Told R, 2017, SPECTRAL DOMAIN OPTI
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Zacks DN, 2004, ARCH OPHTHALMOL-CHIC, V122, P932, DOI 10.1001/archopht.122.6.932
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
NR 39
TC 28
Z9 30
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2018
VL 59
IS 6
BP 2393
EP 2400
DI 10.1167/iovs.17-22902
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF2WE
UT WOS:000431800100022
PM 29847645
OA gold
DA 2022-11-30
ER

PT J
AU Kim, HM
   Ryoo, NK
   Park, KH
AF Kim, Hyeong Min
   Ryoo, Na-Kyung
   Park, Kyu Hyung
TI Laser and anti-vascular endothelial growth factor treatment for
   drusenoid pigment epithelial detachment in age-related macular
   degeneration: 24-month outcomes
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusenoid pigment epithelial
   detachment; Laser; Anti-vascular endothelial growth factor
ID SOFT DRUSEN; CHOROIDAL NEOVASCULARIZATION; MACULOPATHY;
   PHOTOCOAGULATION; CLASSIFICATION; ATROPHY
AB Purpose After the 12-month interim safety analysis, we investigated the 24-month primary endpoint outcomes of drusenoid pigment epithelial detachment (dPED) after laser and intravitreal anti-VEGF treatment.
   Methods Twenty-one patients with treatment-naive bilateral intermediate AMD with dPED and visual acuity < 83 letters (Snellen 20/23) were enrolled. The subject eye received low-energy PASCAL (R) laser (532 nm) treatment, and the fellow eye was used as the control. Intravitreal injections were administered at 3-month intervals from baseline to 12 months. Treatment outcomes, safety and development of advanced AMD lesions were analyzed.
   Results The mean drusen area and dPED height were significantly reduced (17.3 +/- 2.7% vs. 112.8 +/- 3.1%, P < 0.001 and 11.8 +/- 4.7% vs. 119.1 +/- 4.6%, P < 0.001, respectively) and the mean BCVA improved (5.11 +/- 1.35 vs. 0.83 +/- 1.03 letters, P=0.014) in the study eyes compared to those in the control eyes. Development of parafoveal iRORA (nGA) (67%, 12 of 18 eyes) and cRORA (GA) (22%, 4 of 18 eyes) was observed in the study eyes, whereas three cases of iRORA and cRORA in the control eyes (17%, 3 of 18 eyes; P = 0.010 and P = 0.791, respectively).
   Conclusions Laser and anti-VEGF treatment may be a potential treatment option for intermediate AMD with dPED. However, considering the relatively high rate of secondary iRORA and cRORA development, long-term follow-up is mandatory to clarify the safety and efficacy of this treatment.
C1 [Kim, Hyeong Min; Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.
   [Kim, Hyeong Min; Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Ryoo, Na-Kyung] Vet Hlth Serv Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU);
   Veterans Health Service Medical Center
RP Park, KH (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 173-82 Gumi Ro, Seongnam Si 13620, Gyeonggi Do, South Korea.; Park, KH (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
EM jiani4@snu.ac.kr
OI Park, Kyu Hyung/0000-0002-5516-8121
FU National Research Foundation of Korea (NRF) - Korean government (MSIP)
   [2020R1A2C2011189]
FX This study was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MSIP) (No.
   2020R1A2C2011189). The funding organization had no role in the design or
   conduct of this study.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Flaxel C, 2007, RETINA-J RET VIT DIS, V27, P629, DOI 10.1097/01.iae.0000249561.02567.fd
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   Gallego-Pinazo R, 2011, CLIN OPHTHALMOL, V5, P161, DOI 10.2147/OPTH.S15832
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Jain A, 2008, ARCH OPHTHALMOL-CHIC, V126, P78, DOI 10.1001/archophthalmol.2007.29
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kim MS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71401-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krishnan R, 2010, CAN J OPHTHALMOL, V45, P83, DOI 10.3129/i09-187
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Querques G, 2018, GRAEF ARCH CLIN EXP, V256, P1, DOI 10.1007/s00417-017-3848-x
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Scorolli L, 2003, CAN J OPHTHALMOL, V38, P489, DOI 10.1016/S0008-4182(03)80028-5
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Vessey KA, 2018, INVEST OPHTH VIS SCI, V59, P731, DOI 10.1167/iovs.17-23098
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
NR 31
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 260
IS 8
BP 2549
EP 2559
DI 10.1007/s00417-022-05625-6
EA MAR 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3F5UF
UT WOS:000771542400002
PM 35312870
DA 2022-11-30
ER

PT J
AU Olsen, TW
   Liao, A
   Robinson, HS
   Palejwala, NV
   Sprehe, N
AF Olsen, Timothy W.
   Liao, Albert
   Robinson, Hershonna S.
   Palejwala, Neal V.
   Sprehe, Nicholas
TI The Nine-Step Minnesota Grading System for Eyebank Eyes With Age Related
   Macular Degeneration: A Systematic Approach to Study Disease Stages
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE eyebank; grading system; human tissue
ID RETINAL-PIGMENT EPITHELIUM; UNITED-STATES; PROGRESSIVE STAGES; VISUAL
   IMPAIRMENT; PREVALENCE; MACULOPATHY; PROTEOMICS; ADULTS
AB PURPOSE: To refine the Minnesota Grading System (MGS) using definitions from the Age-Related Eye Disease Studies (AREDS) into a nine-step grading scale (MGS-9).
   METHODS: A nine-step grading scale descriptive analysis using three key phenotypic features (total drusen area, increased, and decreased pigmentation) of human eyebank eyes that were graded according to definitions from the AREDS criteria in order to harmonize studies of disease progression for research involving human tissue. From 2005 through February 2017, we have analyzed 1159 human eyes, procured from two eyebanks. Each macula was imaged using high-resolution, stereoscopic color fundus photography with both direct- and transillumination. Fundus images were digitally overlaid with a grading template and triangulated for foveal centration.
   RESULTS: We documented and stratified risk for each globe by applying the AREDS nine-step grading scale to the key clinical features from the MGS-9. We found a good distribution within the MGS categories (1-9) with few level eight globes. Eyes were processed within 12.1 +/- 6.3, hours from the time of death through imaging, dissection, and freezing or fixation. Applying the MGS-9 to 331 pairs (662 eyes were simultaneously graded), 84% were within one-grading step and 93% within two steps of the fellow eye. We also document reticular pseudodrusen, basal laminar drusen, and pattern dystrophy.
   CONCLUSIONS: The MGS nine-step grading scale enables researchers using human tissue to refine the risk assessment of donor tissue. This analysis will harmonize results among researchers when grading human tissue using MGS criteria. Most importantly, the MGS-9 links directly to the known risk for progression from the AREDS.
C1 [Olsen, Timothy W.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Olsen, Timothy W.; Liao, Albert; Robinson, Hershonna S.] Emory Univ, Dept Ophthalmol, Emory Eye Ctr, Atlanta, GA 30322 USA.
   [Palejwala, Neal V.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Sprehe, Nicholas] LEITR, Tampa Bay, FL USA.
C3 Mayo Clinic; Emory University
RP Olsen, TW (通讯作者)，Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.
EM olsen.timothy@mayo.edu
FU Research to Prevent Blindness (RPB; New York, NY, USA)
FX Supported by an unrestricted departmental grant from Research to Prevent
   Blindness (RPB; New York, NY, USA).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], WORLD POPULATION AGE
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Decanini A, 2008, DIABETOLOGIA, V51, P1051, DOI 10.1007/s00125-008-0991-2
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olsen Timothy W, 2008, Trans Am Ophthalmol Soc, V106, P383
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Olsen TW, 2015, T AM OPHTHAL SOC, V113, P3
   OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
NR 25
TC 5
Z9 5
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2017
VL 58
IS 12
BP 5497
EP 5506
DI 10.1167/iovs.17-22161
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL5JN
UT WOS:000414272100053
PM 29075760
OA gold
DA 2022-11-30
ER

PT J
AU Kim, EC
   Han, K
   Jee, D
AF Kim, Eun Chul
   Han, Kyungdo
   Jee, Donghyun
TI Inverse Relationship Between High Blood 25-Hydroxyvitamin D and Late
   Stage of Age-Related Macular Degeneration in a Representative Korean
   Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE 25-hydroxyvitamin D; age-related macular degeneration; sex difference;
   Korea
ID VITAMIN-D STATUS; SOLAR ULTRAVIOLET-RADIATION; GROWTH-FACTOR-BETA;
   RISK-FACTOR; TGF-BETA; ENDOTHELIAL-CELLS; SUNLIGHT EXPOSURE; D-RECEPTOR;
   FIBROSIS; INFLAMMATION
AB PURPOSE. To investigate the association of 25-hydroxyvitamin D with AMD.
   METHODS. A population-based, cross-sectional study using a nationwide, systemic-stratified, multistage-clustered sampling method involved a total of 17,045 subjects older than 40 years who participated in the Korean National Health and Nutrition Examination Survey 2008 to 2012. All participants underwent standardized interviews, evaluation of blood 25-hydroxyvitamin D levels, and comprehensive ophthalmic examinations. A 45 degrees digital fundus photograph of both eyes was taken under physiologic mydriasis. All fundus photographs were graded using the international classification and grading system.
   RESULTS. Blood 25-hydroxyvitamin D levels were 17.5 ng/mL in women and 20.0 ng/mL in men. After adjusting for potential confounders including age, sex, smoking status, hypertension, heart problems, stroke, and sunlight-exposure time, the odds ratio (OR) for late AMD significantly decreased in the highest blood 25-hydroxyvitamin D quintile (OR, 0.32; 95% confidence interval [CI], 0.12-0.81; P for trend = 0.018) compared with the lowest quintile in men, but not in women. Early AMD was not associated with blood 25-hydroxyvitamin D levels in either sex.
   CONCLUSIONS. High level of blood 25-hydroxyvitamin D was inversely associated with late AMD in men but not women. Considering antiangiogenic and antifibrotic action of vitamin D, association between two variables warrants further studies.
C1 [Kim, Eun Chul] Catholic Univ Korea, Buchon St Marys Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Puchon, South Korea.
   [Han, Kyungdo] Catholic Univ Korea, Coll Med, Dept Prevent Med, Dept Biostat, Seoul 130650, South Korea.
   [Jee, Donghyun] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Catholic
   University of Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Ophthalmol & Visual Sci, 505 Banpo Dong, Seoul 130650, South Korea.
EM donghyunjee@catholic.ac.kr
CR Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Alvarez JA, 2014, CLIN ENDOCRINOL, V81, P458, DOI 10.1111/cen.12449
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Autier P, 2014, LANCET DIABETES ENDO, V2, P76, DOI 10.1016/S2213-8587(13)70165-7
   Bahar-Shany K, 2010, J CELL PHYSIOL, V222, P729, DOI 10.1002/jcp.22004
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chen J, 2014, BMC IMMUNOL, V15, DOI 10.1186/1471-2172-15-6
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chung I, 2009, CANCER RES, V69, P967, DOI 10.1158/0008-5472.CAN-08-2307
   Cullen AP, 2011, EYE CONTACT LENS, V37, P185, DOI 10.1097/ICL.0b013e318223392e
   Eum KD, 2008, SCI TOTAL ENVIRON, V407, P147, DOI 10.1016/j.scitotenv.2008.08.037
   Firrincieli D, 2014, CLIN RES HEPATOL GAS, V38, P5, DOI 10.1016/j.clinre.2013.10.004
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Havakuk O, 2013, ISR MED ASSOC J, V15, P693
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009
   Isik S, 2012, EUR J INTERN MED, V23, P93, DOI 10.1016/j.ejim.2011.09.017
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim K, 2012, ENVIRON RES, V112, P225, DOI 10.1016/j.envres.2011.12.008
   Kim Yangho, 2013, J Prev Med Public Health, V46, P96, DOI 10.3961/jpmph.2013.46.2.96
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lavie CJ, 2013, CIRCULATION, V128, P2404, DOI 10.1161/CIRCULATIONAHA.113.002902
   Lee MS, 2011, ENVIRON RES, V111, P171, DOI 10.1016/j.envres.2010.10.006
   Mangge H, 2015, CURR VASC PHARMACOL, V13, P392, DOI 10.2174/1570161111666131209125454
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Norval M, 2011, PHOTOCH PHOTOBIO SCI, V10, P199, DOI 10.1039/c0pp90044c
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parekh N., 2010, Topics in Clinical Nutrition, V25, P290
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Park HA, 2013, KOREAN J FAM MED, V34, P79, DOI 10.4082/kjfm.2013.34.2.79
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Personne V, 2013, PRESSE MED, V42, P1334, DOI 10.1016/j.lpm.2013.06.013
   Pittas AG, 2007, DIABETES CARE, V30, P980, DOI 10.2337/dc06-1994
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Quraishi MK, 2016, INT J RHEUM DIS, V19, P348, DOI 10.1111/1756-185X.12209
   Roberts JE, 2011, EYE CONTACT LENS, V37, P246, DOI 10.1097/ICL.0b013e31821cbcc9
   Ruiz-Ortega M, 2007, CARDIOVASC RES, V74, P196, DOI 10.1016/j.cardiores.2007.02.008
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Sempos CT, 2012, SCAND J CLIN LAB INV, V72, P32, DOI 10.3109/00365513.2012.681935
   Smith M, 2010, BIOSCI HORIZ, V3, P124
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Toriola AT, 2014, CANCER EPIDEM BIOMAR, V23, P917, DOI 10.1158/1055-9965.EPI-14-0053
   Uberti F, 2014, J CLIN ENDOCR METAB, V99, P1367, DOI 10.1210/jc.2013-2103
   Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056
   Vojnikovic B, 2010, COLLEGIUM ANTROPOL, V34, P5
   Wang QS, 2014, J BIOL CHEM, V289, P11681, DOI 10.1074/jbc.M113.517581
   Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007
   Yilmaz SS, 2013, J REPROD MED, V58, P511
NR 59
TC 40
Z9 40
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2014
VL 55
IS 8
BP 4823
EP 4831
DI 10.1167/iovs.14-14763
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DV
UT WOS:000343145500018
PM 25015360
DA 2022-11-30
ER

PT J
AU Ferrara, DC
   Merriam, JE
   Freund, KB
   Spaide, RF
   Takahashi, BS
   Zhitomirsky, I
   Fine, HF
   Yannuzzi, LA
   Allikmets, R
AF Ferrara, Daniela C.
   Merriam, Joanna E.
   Freund, K. Bailey
   Spaide, Richard F.
   Takahashi, Beatriz S.
   Zhitomirsky, Inna
   Fine, Howard F.
   Yannuzzi, Lawrence A.
   Allikmets, Rando
TI Analysis of Major Alleles Associated With Age-Related Macular
   Degeneration in Patients With Multifocal Choroiditis Strong Association
   With Complement Factor H
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR HY402H POLYMORPHISM; CHLAMYDIA-PNEUMONIAE; SUBRETINAL FIBROSIS;
   DRUSEN; GENE; DISEASE; PANUVEITIS; VARIANT; COMMON; RISK
AB Objective: To analyze the frequency of major agerelated macular degeneration (AMD)-associated alleles in patients with multifocal choroiditis (MFC).
   Methods: A cohort of 48 patients with MFC was compared with previously characterized cohorts of patients with advanced AMD (368 samples) and matched unaffected controls (368 samples). Allele and genotype frequencies of single nucleotide polymorphisms for the following AMD-associated alleles were evaluated: risk alleles in complement factor H (CFH) gene (Y402H and IVS14) and LOC387715/HTRA1 gene on 10q26 (A69S) and protective alleles in CFH (IVS1, IVS6, and del-CFHR1-3) and complement factor B loci (H9L and R32Q).
   Results: Frequencies of all major AMD-associated alleles in the CFH locus indicate a strong, statistically significant association of CFH gene single nucleotide polymorphisms and MFC. However, the same analysis for the single nucleotide polymorphisms in complement factor B and 10q26 loci matched the results in the control group.
   Conclusions: Like AMD, the MFC phenotype is strongly associated with the major alleles/haplotypes in the CFH locus.
   Clinical Relevance: We report compelling evidence of a strong association between CFH polymorphisms and MFC, which contributes to the understanding of MFC
C1 [Freund, K. Bailey; Spaide, Richard F.; Fine, Howard F.; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Ferrara, Daniela C.; Takahashi, Beatriz S.; Yannuzzi, Lawrence A.] Columbia Univ, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Merriam, Joanna E.; Fine, Howard F.; Yannuzzi, Lawrence A.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
   [Zhitomirsky, Inna] NYU, Dept Ophthalmol, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Columbia University;
   Columbia University; Columbia University; New York University
RP Yannuzzi, LA (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM VRMNY@aol.com
RI Spaide, Richard/ABD-7368-2020; Allikmets, Rando/ABD-4533-2021; Freund,
   K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU National Institutes of Health [EY13435, EY017404]; The Macula Foundation
   Inc; Department of Ophthalmology, Columbia University; NATIONAL EYE
   INSTITUTE [R24EY017404, R01EY013435] Funding Source: NIH RePORTER
FX This study was supported by grants from the National Institutes of
   Health (EY13435 and EY017404) and The Macula Foundation Inc, and by an
   unrestricted grant to the Department of Ophthalmology, Columbia
   University, from Research to Prevent Blindness Inc.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Brown J, 1996, OPHTHALMOLOGY, V103, P1100, DOI 10.1016/S0161-6420(96)30561-7
   CANTRILL HL, 1986, AM J OPHTHALMOL, V101, P170, DOI 10.1016/0002-9394(86)90590-8
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DREYER RF, 1984, ARCH OPHTHALMOL-CHIC, V102, P1776, DOI 10.1001/archopht.1984.01040031440019
   Dunlop AAS, 1998, ARCH OPHTHALMOL-CHIC, V116, P801, DOI 10.1001/archopht.116.6.801
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kalayoglu MV, 2007, CLIN EXP OPHTHALMOL, V35, P3, DOI 10.1111/j.1442-9071.2007.01432.x
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MacLaren RE, 2006, CLIN EXP OPHTHALMOL, V34, P233, DOI 10.1111/j.1442-9071.2006.01191.x
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Michel SS, 2002, OPHTHALMOLOGY, V109, P378, DOI 10.1016/S0161-6420(01)00901-0
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neary JJ, 2002, J AM SOC NEPHROL, V13, P2052, DOI 10.1097/01.ASN.0000022006.49966.F8
   Quillen DA, 2004, AM J OPHTHALMOL, V137, P538, DOI 10.1016/j.ajo.2004.01.053
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thorne JE, 2006, OPHTHALMOLOGY, V113, P2310, DOI 10.1016/j.ophtha.2006.05.067
   Vianna RNG, 2004, ACTA OPHTHALMOL SCAN, V82, P748, DOI 10.1111/j.1600-0420.2004.00343.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 46
TC 20
Z9 20
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2008
VL 126
IS 11
BP 1562
EP 1566
DI 10.1001/archopht.126.11.1562
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 370XV
UT WOS:000260797300012
PM 19001225
OA Bronze
DA 2022-11-30
ER

PT J
AU Hatz, K
   Prunte, C
AF Hatz, Katja
   Prunte, Christian
TI Treat and Extend versus Pro Re Nata regimens of ranibizumab in
   neovascular age-related macular degeneration: a comparative 12 Month
   study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE neovascular age; related macular degeneration; pro re nata; ranibizumab;
   treat and extend
ID RETINAL OXYGEN-SATURATION; VESSEL DIAMETER; GLAUCOMA PATIENTS;
   DIABETIC-PATIENTS; OXIMETRY; RELIABILITY; METABOLISM; THICKNESS;
   CHILDREN; VALUES
AB Purpose: To compare outcomes in patients with treatment-naive neovascular agerelated macular degeneration (nAMD) receiving ranibizumab treat and extend (TE) with those receiving ranibizumab pro re nata (PRN) in a clinical setting.
   Methods: During this 12-month retrospective, consecutive, comparative case series, patients received ranibizumab 0.5 mg according to a TE or PRN regimen. Monthly optical coherence tomography (OCT) evaluation was performed during the PRN regimen; retreatment criteria included recurrence of intra-/subretinal fluid, or haemorrhages. During the TE regimen, initial treatment with 4-week intervals was sequentially lengthened by 2 weeks until signs of choroidal neovascularization (CNV) activity recurred. Study end-points included mean change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), mean injection frequency and number of follow-up visits attended.
   Results: Baseline characteristics were similar between the TE (n = 70) and PRN (n = 70) groups. Mean change in BCVA from baseline to Month 12 was significantly greater in the TE group than the PRN group (+0.18 +/- 0.17 versus +0.07 +/- 0.20, p < 0.001). Mean change in CRT from baseline to Month 12 was greater in the TE group than the PRN group (- 116 +/- 132 versus -58 +/- 157 mu m, p = 0.019). The number of follow-up visits attended was significantly higher in the PRN group than the TE group (11.9 +/- 1.1 versus 8.6 +/- 1.9, p < 0.001), while patients in the TE group received more injections during the study than those in the PRN group (8.6 +/- 1.9 versus 6.0 +/- 1.9, p < 0.001).
   Conclusion: Ranibizumab administered using a TE regimen in treatment-naive patients with nAMD provided better visual outcomes with fewer clinic visits, compared with a PRN regimen.
C1 [Hatz, Katja; Prunte, Christian] Vista Klin, CH-4102 Binningen, Switzerland.
   [Hatz, Katja; Prunte, Christian] Kantonsspital Liestal, Dept Ophthalmol, Liestal, Switzerland.
   [Hatz, Katja; Prunte, Christian] Univ Basel, Basel, Switzerland.
C3 Kantonsspital Baselland; University of Basel
RP Prunte, C (通讯作者)，Vista Klin, CH-4102 Binningen, Switzerland.
EM office@pruente.ch
FU Novartis Pharma AG, Basel, Switzerland; Bayer; Novartis; Roche
FX These data have been previously presented at the ARVO Annual Meeting,
   Orlando, May 2014, and the EURETINA Congress, London, September 2014.
   Editorial assistance in the development of this manuscript was provided
   by John Timney of Fishawack Communications Ltd., Knutsford, UK; this
   service was funded by Novartis Pharma AG, Basel, Switzerland. The
   funding organization had no role in the design or conduct of this
   research, nor the preparation of the manuscript.; Christian Prunte
   reports grants from Bayer and Novartis, and is on advisory boards for
   Alcon, Allergen, Bayer, Novartis and Roche. Katja Hatz reports grants,
   personal fees and travel support from Bayer and Novartis; personal fees
   from Roche; and has served on advisory boards for Alcon, Allergen, Bayer
   and Novartis.
CR Alamouti B, 2003, BRIT J OPHTHALMOL, V87, P899, DOI 10.1136/bjo.87.7.899
   Beach JM, 1999, J APPL PHYSIOL, V86, P748, DOI 10.1152/jappl.1999.86.2.748
   Beall C M, 2000, High Alt Med Biol, V1, P25, DOI 10.1089/152702900320658
   Eysteinsson T, 2014, ACTA OPHTHALMOL, V92, P449, DOI 10.1111/aos.12359
   FEKE GT, 1989, INVEST OPHTH VIS SCI, V30, P58
   Fouzas S, 2011, PEDIATRICS, V128, P740, DOI 10.1542/peds.2011-0271
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Geirsdottir A, 2012, INVEST OPHTH VIS SCI, V53, P5433, DOI 10.1167/iovs.12-9912
   Goharian I, 2015, BRIT J OPHTHALMOL, V99, P318, DOI 10.1136/bjophthalmol-2014-305718
   Hammer M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976032
   Hardarson S, 2013, PROTOCOL ACQUISITION
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Hardarson SH, 2013, ACTA OPHTHALMOL, V91, P1, DOI 10.1111/aos.12086
   HICKAM JB, 1960, CIRCULATION, V22, P243, DOI 10.1161/01.CIR.22.2.243
   HICKAM JB, 1966, CIRCULATION, V33, P302, DOI 10.1161/01.CIR.33.2.302
   HICKAM JB, 1963, CIRCULATION, V27, P375, DOI 10.1161/01.CIR.27.3.375
   Jani PD, 2014, RETINA-J RET VIT DIS, V34, P394, DOI 10.1097/IAE.0b013e3182979e7b
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Jorgensen CM, 2014, ACTA OPHTHALMOL, V92, P34, DOI 10.1111/aos.12283
   Khoobehi B, 2013, INVEST OPHTH VIS SCI, V54, P7103, DOI 10.1167/iovs.13-12723
   LITTMANN H, 1982, KLIN MONATSBL AUGENH, V180, P286, DOI 10.1055/s-2008-1055068
   Mau MK, 2005, HAWAII MED J, V64, P44
   Mau Monica K, 2005, Hawaii Med J, V64, P44
   Michelson G, 2006, ACTA OPHTHALMOL SCAN, V84, P289, DOI 10.1111/j.1600-0420.2005.00631.x
   Mohan A, 2016, CURR EYE RES
   Mohan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126179
   O'Connell RA, 2014, OPTOMETRY VISION SCI, V91, P608, DOI 10.1097/OPX.0000000000000257
   Olafsdottir OB, 2014, BRIT J OPHTHALMOL, V98, P329, DOI 10.1136/bjophthalmol-2013-303162
   Palsson O, 2012, INVEST OPHTH VIS SCI, V53, P1729, DOI 10.1167/iovs.11-8621
   Paul JP, 2013, OPTOMETRY VISION SCI, V90, P1104, DOI 10.1097/OPX.0000000000000028
   POETS CF, 1994, PEDIATRICS, V93, P737
   RAASCH T, 1985, AM J OPTOM PHYS OPT, V62, P19
   Salchow DJ, 2006, OPHTHALMOLOGY, V113, P786, DOI 10.1016/j.ophtha.2006.01.036
   Traustason S, 2014, BRIT J OPHTHALMOL, V98, P1208, DOI 10.1136/bjophthalmol-2013-304580
   Vandewalle E, 2013, ACTA OPHTHALMOL, V91, P733, DOI 10.1111/j.1755-3768.2012.02545.x
   Wang JW, 2016, ACTA OPHTHALMOL, V94, P380, DOI 10.1111/aos.12664
   Yang W, 2016, ACTA OPHTHALMOL, V94, P373, DOI 10.1111/aos.12943
   Yip W, 2014, INVEST OPHTH VIS SCI, V55, P7104, DOI 10.1167/iovs.13-13854
   Zheng QS, 2015, OPHTHAL PHYSL OPT, V35, P562, DOI 10.1111/opo.12223
NR 39
TC 50
Z9 50
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2017
VL 95
IS 1
BP E67
EP E72
DI 10.1111/aos.13031
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ4ML
UT WOS:000393191200020
PM 27009503
OA Bronze
DA 2022-11-30
ER

PT J
AU Knudtson, MD
   Klein, BEK
   Klein, R
   Cruickshanks, KJ
   Lee, KE
AF Knudtson, MD
   Klein, BEK
   Klein, R
   Cruickshanks, KJ
   Lee, KE
TI Age-related eye disease, quality of life, and functional activity
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; VISUAL FUNCTION; CATARACT-SURGERY; OLDER-ADULTS;
   HEARING-LOSS; POPULATION; VISION; IMPACT; MACULOPATHY; OUTCOMES
AB Objective: To examine the associations of measures of quality of life (Medical Outcomes Study Short Form Health Survey) and functional activities (activities of daily living, instrumental activities of daily living, and visual function) in persons with and without age-related eye diseases.
   Methods: Two thousand, six hundred seventy persons participated in the 1998 through 2000 examinations of both the Beaver Dam Eye Study and the Epidemiology of Hearing Loss Study. Age-related eye disease (age-related maculopathy, cataract, diabetic retinopathy, glaucoma, macula edema, occlusions, amblyopia, and macular holes) were assessed by fundus, slitlamp, and retroilluminated photographs and self-reported ocular history. Also administered was a standard interview that included the Medical Outcomes Study Short Form Health Survey, activities of daily living, instrumental activities of daily living, and visual function questionnaires and information on other medical conditions.
   Results: After controlling for age and sex, we found that persons with an age-related eye disease had decreased scores in almost all the domains of the Medical Outcomes Study Short Form Health Survey, and persons with eye disease in both eyes had poorer scores than persons with eye disease in only 1 eye. Stratifying by age-related maculopathy and central cataract yielded similar results. Further adjustment for current visual acuity and the number of comorbid conditions explained most associations. Several of the mental scales were still marginally significantly lower (P <.10) in persons with age-related maculopathy after adjustment. Persons with an age-related eye disease were not more likely to have impaired activities of daily living or instrumental activities of daily living. After adjustment for current visual acuity and number of comorbidities, persons who had trouble reading small print or recognizing people across the street were more likely to have an age-related eye disease. Otherwise, there were no significant associations with the visual function questions and any of the specific ocular conditions.
   Conclusions: Many measures of general quality of life and functional activities were related to age-related eye diseases, but few associations remained significant after adjustments for vision and other comorbidities. Our data are compatible with the notion that decreased visual function, irrespective. of the pathologic reason for the decrease, is associated with diminished quality of life and functional activities of living.
C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Sch Med, Dept Populat Hlth Sci, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Knudtson, MD (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,Room 450 WARF, Madison, WI 53726 USA.
EM knudtson@epi.ophth.wisc.edu
FU NEI NIH HHS [EY06594] Funding Source: Medline; NIA NIH HHS [AG11099]
   Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011099,
   R37AG011099] Funding Source: NIH RePORTER
CR [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   [Anonymous], 1999, SAS STAT US GUID VER
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Broman AT, 2002, INVEST OPHTH VIS SCI, V43, P3393
   CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cook R.D., 1999, RESPONSE TRANSFORMAT, DOI DOI 10.1002/9780470316948
   Cruickshanks KJ, 2003, ARCH OTOLARYNGOL, V129, P1041, DOI 10.1001/archotol.129.10.1041
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   GANLEY JP, 1983, VITAL HLTH STAT, V228, P1
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041
   KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20
   Keller S., 1994, SF36 PHYS MENTAL HLT
   Klein B E, 1999, Ophthalmic Epidemiol, V6, P49
   Klein BEK, 1996, OPHTHALMOLOGY, V103, P1727, DOI 10.1016/S0161-6420(96)30434-X
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P350, DOI 10.1016/S0002-9394(00)00544-4
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P58
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179
   Lee BL, 2000, J GLAUCOMA, V9, P87
   Lee PP, 1997, OPHTHALMOLOGY, V104, P390, DOI 10.1016/S0161-6420(97)30303-0
   LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   McCullagh P., 1989, STANDARD BOOK GEN LI
   Nichols KK, 2002, CORNEA, V21, P578, DOI 10.1097/00003226-200208000-00009
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Schiffman RM, 2003, OPHTHALMOLOGY, V110, P1412, DOI 10.1016/S0161-6420(03)00462-7
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Ware J.E., 1993, LINC RI QUAL METR IN
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   1976, PREV MED, V5, P207
NR 44
TC 99
Z9 102
U1 1
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2005
VL 123
IS 6
BP 807
EP 814
DI 10.1001/archopht.123.6.807
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 933LH
UT WOS:000229629400010
PM 15955982
OA Bronze
DA 2022-11-30
ER

PT J
AU Menke, MN
   Zinkernagel, MS
   Ebneter, A
   Wolf, S
AF Menke, Marcel N.
   Zinkernagel, Martin S.
   Ebneter, Andreas
   Wolf, Sebastian
TI Functional and anatomical outcome of eyes with neovascular age-related
   macular degeneration treated with intravitreal ranibizumab following an
   exit strategy regimen
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Aims To assess the functional and morphological outcome of eyes with neovascular AMD treated with intravitreal ranbizumab following an exit strategy treatment regime.
   Methods The Bern treatment regime for neovascular AMD has a fixed injection schedule, even in the non-active stage of the disease. The regimen has been adapted from the PIER study treatment protocol. Eyes with non-active AMD will receive 4 injections in the first year, and 2 injections in the second year of follow-up before treatment stops. Patients that received ranibizumab for treatment and reached the exit criteria were identified, and charts were reviewed to assess functional and morphological outcome.
   Results Only 2.6% of all patients (15 out of 575 patients) reached the exit criteria. Mean change in best corrected ETDRS visual acuity (VA) was 4.5 +/- 16.9 letters when comparing baseline VA to 4 weeks after the last injection (p=0.32). OCT mean foveal thickness was significantly thinner after last treatment (247.9 +/- 43.0 mu m) compared to baseline (332.5 +/- 83.1 mu m, p=0.002). The mean total number of ranibizumab injections was 15.6 +/- 8.0, and the mean total treatment period was 40.9 +/- 18.3 months. Twenty percent of eyes had geographic atrophy present at baseline versus 46.6% at the end of treatment.
   Conclusions Even with a fixed treatment regime and a defined treatment exit strategy, only a small percentage of patients reach exit criteria. Retinal thickness has been significantly reduced by repeated intravitreal ranibizumab injections, and geographic atrophy became more frequent.
C1 Univ Hosp Bern, Dept Ophthalmol, Inselspital, CH-3010 Bern, Switzerland.
   Univ Bern, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern
RP Menke, MN (通讯作者)，Reinhardweg 6, CH-3422 Kirchberg, BE, Switzerland.
EM marcel.menke@gmail.com
RI Wolf, Sebastian/B-8782-2008; Zinkernagel, Martin/C-3799-2017; Ebneter,
   Andreas/C-5226-2017
OI Wolf, Sebastian/0000-0002-7467-7028; Zinkernagel,
   Martin/0000-0002-5622-114X; Ebneter, Andreas/0000-0001-6666-2558; Menke,
   Marcel/0000-0002-6561-6178; Zinkernagel, Martin S./0000-0003-3447-2359
CR AG NP, 2010, PROD MON LUC AMD
   Bolz MS-EU, 2008, VIENN 8 EURETINA C
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menke MN, 2013, OPHTHALMOLOGICA, V229, P168, DOI 10.1159/000346397
   Meyer CHEN, 2008, INVEST OPHTH VIS SCI, V49, P273
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
NR 15
TC 16
Z9 18
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2014
VL 98
IS 9
BP 1197
EP 1200
DI 10.1136/bjophthalmol-2013-304775
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN3QW
UT WOS:000340504400009
PM 24782472
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wang, M
   Hu, FY
   Wu, JH
   Zhang, SH
AF Wang, Min
   Hu, Fangyuan
   Wu, Jihong
   Zhang, Shenghai
TI The Effects of Different Degrees of Hypoxia on Retinal Pigment
   Epithelium
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE AMD; Hypoxia; Retinal Pigment Epithelium; Apoptosis; ERK
ID INDUCED EXPRESSION; OXIDATIVE-STRESS; MESENCHYMAL TRANSITION; MACULAR
   DEGENERATION; INDUCIBLE FACTORS; VEGF; HIF-1-ALPHA; RPE; PATHOGENESIS;
   AUTOPHAGY
AB In age-related macular degeneration (AMD), hypoxia causes abnormal changes in tissue metabolism and retinal pigment epithelium (RPE). However, the changes in cell function and intra-cellular molecules in RPE cells induced by hypoxia are not fully understood. In our study, cell viability, apoptosis, oxidative stress and changes in intracellular molecules at different time points were evaluated in ARPE-19 cells using a hypoxia model. A short period of mild hypoxia stimulated cell proliferation and apoptosis was induced as the period of hypoxia increased and the oxygen concentration decreased. As hypoxia worsened, the mitochondrial reactive oxygen species (ROS) accumulation was often accompanied with increased oxidative stress, increased intracellular HIF-1a accumulation and VEGF secretion to induce neovascularization. Additionally, p-ERK1 and ERK2 level was increased and p-ERK2 was decreased during hypoxia. In conclusion, our results show that the changes in the RPE is a process that depends on the degree of hypoxia and exposure time.
C1 [Zhang, Shenghai] Fudan Univ, Eye & ENT Hosp, Shanghai Med Coll, Dept Ophthalmol & Visual Sci, Shanghai 200031, Peoples R China.
   Fudan Univ, Natl Hlth Commiss, Key Lab Myopia, Chinese Acad Med Sci, Shanghai 200031, Peoples R China.
   Fudan Univ, Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200031, Peoples R China.
C3 Fudan University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Fudan University; Fudan University
RP Zhang, SH (通讯作者)，Fudan Univ, Eye & ENT Hosp, Shanghai Med Coll, Dept Ophthalmol & Visual Sci, Shanghai 200031, Peoples R China.
FU National Natural Science Foundation of China [81470625]
FX Acknowledgments: This work was supported by the National Natural Science
   Foundation of China (81470625) .
CR Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Feng ZL, 2015, GRAEF ARCH CLIN EXP, V253, P875, DOI 10.1007/s00417-014-2922-x
   Fuhrmann DC, 2017, REDOX BIOL, V12, P208, DOI 10.1016/j.redox.2017.02.012
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Haslip M, 2015, ARTERIOSCL THROM VAS, V35, P1166, DOI 10.1161/ATVBAHA.114.304865
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai KR, 2016, BBA-MOL BASIS DIS, V1862, P1594, DOI 10.1016/j.bbadis.2016.05.023
   Liu NN, 2015, IUBMB LIFE, V67, P446, DOI 10.1002/iub.1382
   Liu XJ, 2016, EXP MOL PATHOL, V100, P451, DOI 10.1016/j.yexmp.2016.04.004
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Rosen R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/687386
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Singh A, 2019, MOLECULES, V24, DOI 10.3390/molecules24081583
   Sun YZ, 2017, CELL PHYSIOL BIOCHEM, V44, P1640, DOI 10.1159/000485764
   Tenconi PE, 2019, EXP EYE RES, V184, P243, DOI 10.1016/j.exer.2019.04.028
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 29
TC 0
Z9 0
U1 0
U2 0
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 2157-9083
EI 2157-9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD JUN
PY 2022
VL 12
IS 6
BP 1182
EP 1188
DI 10.1166/jbt.2022.3024
PG 7
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 0F1PO
UT WOS:000777139600002
DA 2022-11-30
ER

PT J
AU Vagge, A
   Desideri, LF
   Del Noce, C
   Di Mola, I
   Sindaco, D
   Traverso, CE
AF Vagge, Aldo
   Ferro Desideri, Lorenzo
   Del Noce, Chiara
   Di Mola, Ilaria
   Sindaco, Daniele
   Traverso, Carlo E.
TI Blue light filtering ophthalmic lenses: A systematic review
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Blue light blocking; Display; Macular changes; Sleep-wake cycle;
   Spectacles
AB Background: Blue blocking (BB) lenses, including spectacles and intraocular lenses, work by attenuating short-wavelength light. BB glasses are being marketed with the aim to reduce eye fatigue symptoms when using digital devices, improve sleep quality and potentially confer protection from retinal phototoxicity. BB intraocular lenses following cataract surgery may be implanted because they are thought to prevent age-related macular degeneration (AMD) progression.
   Methods: The present study is a systematic review aiming to analyze BB lenses clinical efficacy in preventing blue light-related ocular disorders, including AMD progression, eye fatigue, and their impact on sleep quality. We searched Medline, PubMed, Web of Science and the Cochrane Library until May 2020.
   Results:Although several studies have been performed investigating BB lenses, clinical efficacy for preventing or attenuating the above-mentioned ocular disorders is often theorical or based on laboratory or animal experiments. Conclusions: To date, there is a lack of consistent evidence for a larger-sclale introduction of BB lenses in the routine clinical practice.
C1 [Vagge, Aldo; Ferro Desideri, Lorenzo; Del Noce, Chiara; Di Mola, Ilaria; Sindaco, Daniele; Traverso, Carlo E.] IRCCS Polyclin Hosp San Martino, Genoa, Italy.
   [Vagge, Aldo; Ferro Desideri, Lorenzo; Del Noce, Chiara; Di Mola, Ilaria; Sindaco, Daniele; Traverso, Carlo E.] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
C3 University of Genoa
RP Vagge, A (通讯作者)，DiNOGMI Univ Genoa, IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Viale Benedetto XV 5, I-16132 Genoa, GE, Italy.
EM aldo.vagge@unige.it
CR Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Ayaki M, 2016, CHRONOBIOL INT, V33, P134, DOI 10.3109/07420528.2015.1119158
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Brondsted AE, 2017, ACTA OPHTHALMOL, V95, P344, DOI 10.1111/aos.13323
   Burkhart K, 2009, CHRONOBIOL INT, V26, P1602, DOI 10.3109/07420520903523719
   Colombo L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0545-9
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   DIFFEY B, 2002, METHODS, V28
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040307
   Downes SM, 2016, EYE, V30, P215, DOI 10.1038/eye.2015.267
   Downie LE, 2019, JAMA OPHTHALMOL, V137, P694, DOI 10.1001/jamaophthalmol.2019.0019
   Downie LE, 2017, OPHTHAL PHYSL OPT, V37, P640, DOI 10.1111/opo.12414
   Edwards KH, 2010, CLIN EXP OPTOM, V93, P390, DOI 10.1111/j.1444-0938.2010.00538.x
   Esaki Y, 2016, CHRONOBIOL INT, V33, P1037, DOI 10.1080/07420528.2016.1194289
   Figueiro MG, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/829351
   Golebiowski B, 2020, CURR EYE RES, V45, P428, DOI 10.1080/02713683.2019.1663542
   Gowrisankaran S, 2015, WORK, V52, P303, DOI 10.3233/WOR-152162
   GREEN W, 1991, AM J OPHTHALMOL, V112
   Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Hersh D, 2014, ORBIT, V33, P385, DOI 10.3109/01676830.2014.904378
   Hiromoto K, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.3.035004
   ICNIRP, 2020, HEALTH PHYS, V118, P549, DOI 10.1097/HP.0000000000001259
   Ide T, 2015, ASIA-PAC J OPHTHALMO, V4, P80, DOI 10.1097/APO.0000000000000069
   Jaadane I, 2015, FREE RADICAL BIO MED, V84, P373, DOI 10.1016/j.freeradbiomed.2015.03.034
   Jeong SY, 2019, FOOD CHEM TOXICOL, V131, DOI 10.1016/j.fct.2019.06.002
   Kara N, 2011, J CATARACT REFR SURG, V37, P2115, DOI 10.1016/j.jcrs.2011.06.024
   Kiser AK, 2008, CLIN EXP OPHTHALMOL, V36, P514, DOI 10.1111/j.1442-9071.2008.01824.x
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Landers JA, 2009, J CATARACT REFR SURG, V35, P83, DOI 10.1016/j.jcrs.2008.10.015
   Lawrenson JG, 2017, OPHTHAL PHYSL OPT, V37, P644, DOI 10.1111/opo.12406
   Leung TW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169114
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2017, INVEST OPHTH VIS SCI, V58, P442, DOI 10.1167/iovs.16-20663
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Mainster MA, 2009, AM J OPHTHALMOL, V147, P8, DOI 10.1016/j.ajo.2008.08.020
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moon J, 2017, INTEGR BIOL-UK, V9, P436, DOI 10.1039/c7ib00032d
   Muftuoglu O, 2007, J CATARACT REFR SURG, V33, P658, DOI 10.1016/j.jcrs.2006.12.018
   Mukai R, 2012, INVEST OPHTH VIS SCI, V53, P6035, DOI 10.1167/iovs.12-9608
   Nakanishi T, 2013, J NEUROCHEM, V125, P111, DOI 10.1111/jnc.12116
   Narimatsu T, 2014, CLIN EXP OPHTHALMOL, V42, P555, DOI 10.1111/ceo.12253
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   OLSON M, 2006, AM J OPHTHALMOL, V141
   Olson RJ, 2018, AM J OPHTHALMOL, V185, P10, DOI 10.1016/j.ajo.2017.08.020
   Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694
   Palavets T, 2019, OPTOMETRY VISION SCI, V96, P48, DOI 10.1097/OPX.0000000000001318
   Rea MS, 2005, BRAIN RES REV, V50, P213, DOI 10.1016/j.brainresrev.2005.07.002
   Reddy P, 2006, CURR MED RES OPIN, V22, P1311, DOI 10.1185/030079906X115586
   Roberts JE, 2002, INT J TOXICOL, V21, P491, DOI 10.1080/10915810290169918
   Rosenfield M, 2020, WORK, V65, P343, DOI 10.3233/WOR-203086
   SAMPLE PA, 1988, INVEST OPHTH VIS SCI, V29, P1306
   Sasseville A, 2006, J PINEAL RES, V41, P73, DOI 10.1111/j.1600-079X.2006.00332.x
   Schmidinger G, 2008, J CATARACT REFR SURG, V34, P769, DOI 10.1016/j.jcrs.2007.12.034
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Sliney DH, 2002, INT J TOXICOL, V21, P501, DOI 10.1080/10915810290169927
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   VOGEL A, 1994, INVEST OPHTH VIS SCI, V35, P3032
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Zhang T, 2011, P NATL ACAD SCI USA, V108, P8879, DOI 10.1073/pnas.1017127108
NR 60
TC 3
Z9 4
U1 9
U2 26
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD OCT 3
PY 2021
VL 36
IS 7
BP 541
EP 548
DI 10.1080/08820538.2021.1900283
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UN2DV
UT WOS:000630751900001
PM 33734926
DA 2022-11-30
ER

PT J
AU Sharma, A
   Sharma, R
   Zhang, Z
   Liaw, K
   Kambhampati, SP
   Porterfield, JE
   Lin, KC
   DeRidder, LB
   Kannan, S
   Kannan, RM
AF Sharma, Anjali
   Sharma, Rishi
   Zhang, Zhi
   Liaw, Kevin
   Kambhampati, Siva P.
   Porterfield, Joshua E.
   Lin, Ku Chien
   DeRidder, Louis B.
   Kannan, Sujatha
   Kannan, Rangaramanujam M.
TI Dense hydroxyl polyethylene glycol dendrimer targets activated glia in
   multiple CNS disorders
SO SCIENCE ADVANCES
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; CEREBRAL-PALSY; MICROGLIA; INJURY; STRATEGIES;
   BINDING; CANCER
AB Poor transport of neuropharmaceutics through central nervous system (CNS) barriers limits the development of effective treatments for CNS disorders. We present the facile synthesis of a novel neuroinflammation-targeting polyethylene glycol-based dendrimer (PEGOL-60) using an efficient click chemistry approach. PEGOL-60 reduces synthetic burden by achieving high hydroxyl surface density at low generation, which plays a key role in brain penetration and glia targeting of dendrimers in CNS disorders. Systemically administered PEGOL-60 crosses impaired CNS barriers and specifically targets activated microglia/macrophages at the injured site in diverse animal models for cerebral palsy, glioblastoma, and age-related macular degeneration, demonstrating its potential to overcome impaired blood-brain, blood-tumor-brain, and blood-retinal barriers and target key cells in the CNS. PEGOL-60 also exhibits powerful intrinsic anti-oxidant and anti-inflammatory effects in inflamed microglia in vitro. Therefore, PEGOL-60 is an effective vehicle to specifically deliver therapies to sites of CNS injury for enhanced therapeutic outcomes in a range of neuroinflammatory diseases.
C1 [Sharma, Anjali; Sharma, Rishi; Liaw, Kevin; Kambhampati, Siva P.; Porterfield, Joshua E.; Kannan, Sujatha; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Ctr Nanomed, Dept Ophthalmol, Sch Med,Wilmer Eye Inst, Baltimore, MD 21231 USA.
   [Zhang, Zhi; Kannan, Sujatha] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA.
   [Liaw, Kevin; Porterfield, Joshua E.; Lin, Ku Chien; DeRidder, Louis B.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
   [Kannan, Sujatha; Kannan, Rangaramanujam M.] Kennedy Krieger Inc, Hugo W Moser Res Inst, Baltimore, MD 21205 USA.
   [Zhang, Zhi] Univ Michigan, Dept Nat Sci, Dearborn, MI 48128 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins University; University of Michigan System;
   University of Michigan
RP Kannan, RM (通讯作者)，Johns Hopkins Univ, Ctr Nanomed, Dept Ophthalmol, Sch Med,Wilmer Eye Inst, Baltimore, MD 21231 USA.; Kannan, RM (通讯作者)，Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.; Kannan, RM (通讯作者)，Kennedy Krieger Inc, Hugo W Moser Res Inst, Baltimore, MD 21205 USA.
EM krangar1@jhmi.edu
RI Porterfield, Joshua/HCH-8115-2022; Kambhampati, Siva
   Pramodh/AAK-6269-2020
OI Zhang, Zhi/0000-0001-6256-9516; DeRidder, Louis/0000-0001-7390-1481;
   Sharma, Anjali/0000-0003-0748-3001
FU NICHD [R01HD076901]; NEI [RO1 EY025304]; NINDS [R01NS093416]; Wilmer
   core facility and imaging center [P30EY001765]
FX This study was partly funded by the NICHD grant number R01HD076901 (to
   R.M.K.), NEI grant number RO1 EY025304 (to R.M.K.), and NINDS grant
   number R01NS093416 (to S.K.). We also thank the Wilmer core facility and
   imaging center (core grant: P30EY001765) for confocal microscopy
   facilities.
CR Banks WA, 2016, NAT REV DRUG DISCOV, V15, P275, DOI 10.1038/nrd.2015.21
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Caminade AM, 2014, J MATER CHEM B, V2, P4055, DOI 10.1039/c4tb00171k
   Chauhan AS, 2009, BIOMACROMOLECULES, V10, P1195, DOI 10.1021/bm9000298
   Corraliza I, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00262
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Dong XW, 2018, THERANOSTICS, V8, P1481, DOI 10.7150/thno.21254
   Ficker M, 2017, CAN J CHEM, V95, P954, DOI 10.1139/cjc-2017-0108
   Groothuis DR, 2000, NEURO-ONCOLOGY, V2, P45, DOI 10.1093/neuonc/2.1.45
   Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441
   Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456
   Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705
   Hoyle CE, 2010, ANGEW CHEM INT EDIT, V49, P1540, DOI 10.1002/anie.200903924
   Jacobs VL, 2011, ASN NEURO, V3, DOI 10.1042/AN20110014
   Kambhampati SP, 2015, INVEST OPHTH VIS SCI, V56, P4413, DOI 10.1167/iovs.14-16250
   Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162
   Kannan S, 2011, DEV NEUROSCI-BASEL, V33, P231, DOI 10.1159/000328125
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Lei J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06113-2
   Lesniak WG, 2013, MOL PHARMACEUT, V10, P4560, DOI 10.1021/mp400371r
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Mignani S, 2017, PROG POLYM SCI, V64, P23, DOI 10.1016/j.progpolymsci.2016.09.006
   Moses JE, 2007, CHEM SOC REV, V36, P1249, DOI 10.1039/b613014n
   Nance E, 2016, BIOMATERIALS, V101, P96, DOI 10.1016/j.biomaterials.2016.05.044
   Neibert K, 2013, MOL PHARMACEUT, V10, P2502, DOI 10.1021/mp4000508
   O'Callaghan JP, 2008, ANN NY ACAD SCI, V1139, P318, DOI 10.1196/annals.1432.032
   Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013
   Pierson CR, 2007, ACTA NEUROPATHOL, V114, P619, DOI 10.1007/s00401-007-0295-5
   Prabhu S, 2017, NANOSCALE, V9, P10919, DOI 10.1039/c7nr00305f
   Reid SM, 2015, DEV MED CHILD NEUROL, V57, P1159, DOI 10.1111/dmcn.12800
   Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4
   Sharma A, 2018, J CONTROL RELEASE, V283, P175, DOI 10.1016/j.jconrel.2018.06.003
   Sharma R, 2017, BIOCONJUGATE CHEM, V28, P2874, DOI 10.1021/acs.bioconjchem.7b00569
   Sharma R, 2014, CHEM COMMUN, V50, P13300, DOI 10.1039/c4cc06191h
   Sharma R, 2014, POLYM CHEM-UK, V5, P4321, DOI 10.1039/c4py00218k
   Wegener G, 2013, INT J NEUROPSYCHOPH, V16, P1687, DOI 10.1017/S1461145713000345
   Wu SY, 2017, FRONT BIOSCI-LANDMRK, V22, P1805
   Zhang F, 2015, BIOMATERIALS, V52, P507, DOI 10.1016/j.biomaterials.2015.02.053
NR 40
TC 25
Z9 26
U1 3
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JAN
PY 2020
VL 6
IS 4
AR eaay8514
DI 10.1126/sciadv.aay8514
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KE6NP
UT WOS:000508671100014
PM 32010790
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shoval, A
   Markus, A
   Zhou, ZX
   Liu, X
   Cazelles, R
   Willner, I
   Mandel, Y
AF Shoval, Asaf
   Markus, Amos
   Zhou, Zhixin
   Liu, Xia
   Cazelles, Rerm
   Willner, Itamar
   Mandel, Yossi
TI Anti-VEGF-Aptamer Modified C-Dots-A Hybrid Nanocomposite for Topical
   Treatment of Ocular Vascular Disorders
SO SMALL
LA English
DT Article
DE age-related macular degeneration (AMD); diabetic retinopathy; drug
   carriers; nanomedicines; vascular endothelial growth factor (VEGF)
ID INTRAVITREAL BEVACIZUMAB AVASTIN; MIMICKING HORSERADISH-PEROXIDASE;
   CARBON QUANTUM DOTS; DRUG-DELIVERY; DIABETIC-RETINOPATHY; GOLD
   NANOPARTICLES; NUCLEIC-ACIDS; DNA; PHARMACOKINETICS; INJECTION
AB The vascular endothelial growth factor (VEGF) induces pathological angiogenetic ocular diseases. It is a scientific challenge to develop carriers for the controlled release of inhibitors for VEGF present in the back of the eye domain. Carbon dots (C-dots) functionalized with the VEGF aptamer are introduced and the hybrid nanoparticles are used for ocular nanomedicine. The C-dots are applied as effective carriers of the anti-VEGF aptamer across the cornea, yielding therapeutic levels upon topical administration. The hybrids show no toxicity for both in vitro and in vivo murine animal model, and further enable noninvasive intraocular concentration monitoring through the C-dots inherent fluorescence. In addition, the hybrid C-dots effectively inhibit VEGF-stimulated angiogenesis in choroidal blood vessels. This inhibition is comparable to two commercially available anti-VEGF drugs, bevacizumab and aflibercept. The hybrid aptamer-modified C-dots provide a versatile nanomaterial to treat age-related macular degeneration and diabetic retinopathy.
C1 [Shoval, Asaf; Markus, Amos; Mandel, Yossi] Bar Ilan Univ, Fac Life Sci, Sch Optometry & Vis Sci, IL-5290009 Ramat Gan, Israel.
   [Shoval, Asaf; Markus, Amos; Mandel, Yossi] Bar Ilan Univ, Bar Ilans Inst Nanotechnol & Adv Mat BINA, IL-5290009 Ramat Gan, Israel.
   [Zhou, Zhixin; Liu, Xia; Cazelles, Rerm; Willner, Itamar] Hebrew Univ Jerusalem, Minerva Ctr Biohybrid Complex Syst, Inst Chem, IL-91904 Jerusalem, Israel.
C3 Bar Ilan University; Bar Ilan University; Hebrew University of Jerusalem
RP Mandel, Y (通讯作者)，Bar Ilan Univ, Fac Life Sci, Sch Optometry & Vis Sci, IL-5290009 Ramat Gan, Israel.; Mandel, Y (通讯作者)，Bar Ilan Univ, Bar Ilans Inst Nanotechnol & Adv Mat BINA, IL-5290009 Ramat Gan, Israel.; Willner, I (通讯作者)，Hebrew Univ Jerusalem, Minerva Ctr Biohybrid Complex Syst, Inst Chem, IL-91904 Jerusalem, Israel.
EM Itamar.willner@mail.huji.ac.il; yossi.mandel@biu.ac.il
RI Zhou, Zhixin/AAB-8668-2020; Zhou, Zhixin/GSD-7016-2022
OI Zhou, Zhixin/0000-0003-0450-1921; 
FU KAMIN Funding Program; Israeli Innovation Authority
FX A.S., A.M., Z.Z., and X.L. contributed equally to this work. This work
   was supported by KAMIN Funding Program. Israeli Innovation Authority.
CR Angell C, 2016, SMALL, V12, P1117, DOI 10.1002/smll.201502167
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Breaker RR, 1997, NAT BIOTECHNOL, V15, P427, DOI 10.1038/nbt0597-427
   Campochiaro PA, 2007, DRUG TODAY, V43, P529, DOI 10.1358/dot.2007.43.8.1120868
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3
   Chen GY, 2016, CHEM REV, V116, P2826, DOI 10.1021/acs.chemrev.5b00148
   Chen WH, 2018, NANOSCALE, V10, P4650, DOI 10.1039/c8nr00193f
   Chen WH, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201705137
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cho HS, 2012, ACS NANO, V6, P7607, DOI 10.1021/nn203833d
   Chou LYT, 2014, NAT NANOTECHNOL, V9, P148, DOI [10.1038/nnano.2013.309, 10.1038/NNANO.2013.309]
   Dehghani S, 2018, BIOSENS BIOELECTRON, V110, P23, DOI 10.1016/j.bios.2018.03.037
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Ding CQ, 2014, ACCOUNTS CHEM RES, V47, P20, DOI 10.1021/ar400023s
   Ding H, 2016, ACS NANO, V10, P484, DOI 10.1021/acsnano.5b05406
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Elbaz J, 2010, NAT NANOTECHNOL, V5, P417, DOI [10.1038/NNANO.2010.88, 10.1038/nnano.2010.88]
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Freeman R, 2012, ANAL CHEM, V84, P6192, DOI 10.1021/ac3011473
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Gerber HP, 2005, CANCER RES, V65, P671
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Gill R, 2008, ANGEW CHEM INT EDIT, V47, P7602, DOI 10.1002/anie.200800169
   Goel S, 2014, ACS APPL MATER INTER, V6, P21677, DOI 10.1021/am506849p
   Goncalves HMR, 2010, BIOSENS BIOELECTRON, V26, P1302, DOI 10.1016/j.bios.2010.07.018
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   He QJ, 2015, ADV MATER, V27, P6741, DOI 10.1002/adma.201502762
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hsu PC, 2013, J MATER CHEM B, V1, P1774, DOI 10.1039/c3tb00545c
   Huang XL, 2013, ACS NANO, V7, P5684, DOI 10.1021/nn401911k
   Ishikawa K, 2009, EYE, V23, P108, DOI 10.1038/sj.eye.6702983
   Jang B, 2011, ACS NANO, V5, P1086, DOI 10.1021/nn102722z
   KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983
   Kang WJ, 2009, SMALL, V5, P2519, DOI 10.1002/smll.200900848
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Li HL, 2011, CHEM COMMUN, V47, P961, DOI 10.1039/c0cc04326e
   Li HT, 2011, CARBON, V49, P605, DOI 10.1016/j.carbon.2010.10.004
   Li HT, 2010, ANGEW CHEM INT EDIT, V49, P4430, DOI 10.1002/anie.200906154
   Lim SY, 2015, CHEM SOC REV, V44, P362, DOI 10.1039/c4cs00269e
   Liu CJ, 2012, BIOMATERIALS, V33, P3604, DOI 10.1016/j.biomaterials.2012.01.052
   Liu JM, 2012, ANALYST, V137, P2637, DOI 10.1039/c2an35130g
   Liu XQ, 2013, J AM CHEM SOC, V135, P11832, DOI 10.1021/ja403485r
   Liu Z, 2007, ACS NANO, V1, P50, DOI 10.1021/nn700040t
   Lu CH, 2015, ANGEW CHEM INT EDIT, V54, P12212, DOI 10.1002/anie.201503054
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Markus A, 2019, EXP EYE RES, V180, P29, DOI 10.1016/j.exer.2018.11.013
   McHugh KJ, 2018, ADV MATER, V30, DOI 10.1002/adma.201706356
   Michaelides M, 2010, OPHTHALMOLOGY, V117, P1078, DOI 10.1016/j.ophtha.2010.03.045
   Morozan A, 2012, ENERG ENVIRON SCI, V5, P9269, DOI 10.1039/c2ee22989g
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nonaka Y, 2010, MOLECULES, V15, P215, DOI 10.3390/molecules15010215
   Orbach R, 2012, CHEM-EUR J, V18, P14689, DOI 10.1002/chem.201201995
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Park JH, 2003, BIOL REPROD, V69, P2007, DOI 10.1095/biolreprod.103.017467
   Pelaz B, 2017, ACS NANO, V11, P2313, DOI 10.1021/acsnano.6b06040
   Peng H, 2009, CHEM MATER, V21, P5563, DOI 10.1021/cm901593y
   Posthuma-Trumpie GA, 2012, ANAL BIOANAL CHEM, V402, P593, DOI 10.1007/s00216-011-5340-5
   Qu SN, 2012, ANGEW CHEM INT EDIT, V51, P12215, DOI 10.1002/anie.201206791
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Roth DB, 2009, OPHTHALMOLOGY, V116, P1226, DOI 10.1016/j.ophtha.2009.02.011
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sennlaub F., 2013, PLOS ONE, V8
   Shlyahovsky B, 2007, J AM CHEM SOC, V129, P3814, DOI 10.1021/ja069291n
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Sutton A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14700
   Thew M, 2009, CLIN EXP OPTOM, V92, P34, DOI 10.1111/j.1444-0938.2008.00295.x
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vazquez-Gonzalez M, 2018, LANGMUIR, V34, P14692, DOI 10.1021/acs.langmuir.8b00478
   Vazquez-Gonzalez M, 2017, ACS NANO, V11, P3247, DOI 10.1021/acsnano.7b00352
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006-1211
   Waisbourd M, 2011, ACTA OPHTHALMOL, V89, P203, DOI 10.1111/j.1755-3768.2010.02010.x
   Wang F, 2014, CHEM REV, V114, P2881, DOI 10.1021/cr400354z
   Wang FA, 2013, ANAL CHEM, V85, P8196, DOI 10.1021/ac4013094
   Wang J, 2012, ANGEW CHEM INT EDIT, V51, P9297, DOI 10.1002/anie.201204381
   Wang S, 2017, NANO LETT, V17, P2043, DOI 10.1021/acs.nanolett.7b00093
   Weizmann Y, 2006, ANGEW CHEM INT EDIT, V45, P7384, DOI 10.1002/anie.200602754
   Willner I, 2007, ANGEW CHEM INT EDIT, V46, P6408, DOI 10.1002/anie.200604524
   Yang YH, 2012, CHEM COMMUN, V48, P380, DOI 10.1039/c1cc15678k
   Yang ZC, 2011, CARBON, V49, P5207, DOI 10.1016/j.carbon.2011.07.038
   Yu CM, 2013, CHEM COMMUN, V49, P403, DOI 10.1039/c2cc37329g
   Zhang X, 2013, NANOSCALE, V5, P2274, DOI 10.1039/c3nr34142a
   Zheng XX, 2011, ANGEW CHEM INT EDIT, V50, P11994, DOI 10.1002/anie.201105121
   Zhi B, 2018, ACS NANO, V12, P5741, DOI 10.1021/acsnano.8b01619
   Zhou Y, 2014, BIOSENS BIOELECTRON, V52, P317, DOI 10.1016/j.bios.2013.09.022
NR 91
TC 31
Z9 31
U1 15
U2 118
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD OCT
PY 2019
VL 15
IS 40
AR 1902776
DI 10.1002/smll.201902776
EA AUG 2019
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA JB3SR
UT WOS:000480424800001
PM 31402576
DA 2022-11-30
ER

PT J
AU Tuo, SH
AF Tuo, Shouheng
TI FDHE-IW: A Fast Approach for Detecting High-Order Epistasis in
   Genome-Wide Case-Control Studies
SO GENES
LA English
DT Article
DE Single-nucleotide polymorphism; high-order epistasis; interaction weight
ID POLYMORPHISM; ENVIRONMENT; SOFTWARE
AB Detecting high-order epistasis in genome-wide association studies (GWASs) is of importance when characterizing complex human diseases. However, the enormous numbers of possible single-nucleotide polymorphism (SNP) combinations and the diversity among diseases presents a significant computational challenge. Herein, a fast method for detecting high-order epistasis based on an interaction weight (FDHE-IW) method is evaluated in the detection of SNP combinations associated with disease. First, the symmetrical uncertainty (SU) value for each SNP is calculated. Then, the top-k SNPs are isolated as guiders to identify 2-way SNP combinations with significant interaction weight values. Next, a forward search is employed to detect high-order SNP combinations with significant interaction weight values as candidates. Finally, the findings were statistically evaluated using a G-test to isolate true positives. The developed algorithm was used to evaluate 12 simulated datasets and an age-related macular degeneration (AMD) dataset and was shown to perform robustly in the detection of some high-order disease-causing models.
C1 [Tuo, Shouheng] Xian Univ Posts & Telecommun, Sch Comp Sci & Technol, Xian 710121, Shaanxi, Peoples R China.
C3 Xi'an University of Posts & Telecommunications
RP Tuo, SH (通讯作者)，Xian Univ Posts & Telecommun, Sch Comp Sci & Technol, Xian 710121, Shaanxi, Peoples R China.
EM tuo_sh@126.com
RI tuo, shouheng/AAC-1997-2019
OI ShouHeng, Tuo/0000-0002-6696-0085
FU Natural Science Foundation of China [61571341]
FX This work was supported by the Natural Science Foundation of China under
   grant 61571341.
CR Aflakparast M, 2014, HEREDITY, V112, P666, DOI 10.1038/hdy.2014.4
   Burton A, 2013, P NATL ACAD SCI USA, V110, P18970, DOI 10.1073/pnas.1309699110
   Crawford L, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006869
   Crow JF, 1999, GENETICS, V152, P821
   Guo X, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-102
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   Harremoes P, 2012, ARXIV12021125
   Hong Q, 2014, ONCOTARGET, V5, P4779, DOI 10.18632/oncotarget.2029
   Jakulin A., 2004, P 21 INT C MACH LEAR, P409
   Jiang R., 2013, ENCY BEHAV MED, P841, DOI [10.1007/978-1-4419-1005-9_690, DOI 10.1007/978-1-4419-1005-9_690]
   Jiang R, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S1-S65
   Jing PJ, 2015, BIOINFORMATICS, V31, P634, DOI 10.1093/bioinformatics/btu702
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li X, 2017, BIOINFORMATICS, V33, P2829, DOI 10.1093/bioinformatics/btx339
   Liu J, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060153
   Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980
   McDonald J. H, 2014, HDB BIOL STAT, V4 th, P53
   Menezes BAM, 2017, 2017 IEEE LATIN AMERICAN CONFERENCE ON COMPUTATIONAL INTELLIGENCE (LA-CCI)
   Moore JH, 2010, BIOINFORMATICS, V26, P445, DOI 10.1093/bioinformatics/btp713
   Vinh NX, 2016, PATTERN RECOGN, V53, P46, DOI 10.1016/j.patcog.2015.11.007
   Niel C, 2018, BIOINFORMATICS, P673
   Niel C, 2018, BIOINFORMATICS, V34, P2773, DOI 10.1093/bioinformatics/bty154
   Shang JL, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1076-8
   Shang JL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/524821
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shishkin A, 2016, 30 INT C NEUR INF PR, P4644
   Song QB, 2013, IEEE T KNOWL DATA EN, V25, P1, DOI 10.1109/TKDE.2011.181
   Stanfill AG, 2018, BIOL RES NURS, V20, P359, DOI 10.1177/1099800418761098
   Sun YX, 2017, BIODATA MIN, V10, DOI 10.1186/s13040-017-0143-7
   Tuba M., 2012, P WSEAS INT C COMP E
   Tuo SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11064-9
   Tuo SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150669
   Tutz G, 2015, COMPUT STAT DATA AN, V90, P84, DOI 10.1016/j.csda.2015.04.009
   Upton A, 2016, BRIEF BIOINFORM, V17, P368, DOI 10.1093/bib/bbv058
   Urbanowicz RJ, 2012, BIODATA MIN, V5, DOI 10.1186/1756-0381-5-16
   Velez JI, 2013, MOL PSYCHIATR, V18, P568, DOI 10.1038/mp.2012.81
   Wan XA, 2010, AM J HUM GENET, V87, P325, DOI 10.1016/j.ajhg.2010.07.021
   Wang Yupeng, 2010, BMC Res Notes, V3, P117, DOI 10.1186/1756-0500-3-117
   Yang C, 2009, BIOINFORMATICS, V25, P504, DOI 10.1093/bioinformatics/btn652
   Yang GY, 2015, BIOINFORMATICS, V31, P1460, DOI 10.1093/bioinformatics/btu840
   Yung LS, 2011, BIOINFORMATICS, V27, P1309, DOI 10.1093/bioinformatics/btr114
   Zeng ZL, 2015, PATTERN RECOGN, V48, P2656, DOI 10.1016/j.patcog.2015.02.025
   Zhang CC, 2017, ONCOTARGET, V8, P91723, DOI 10.18632/oncotarget.19176
   Zhang Y, 2007, NAT GENET, V39, P1167, DOI 10.1038/ng2110
NR 45
TC 18
Z9 18
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD SEP
PY 2018
VL 9
IS 9
AR 435
DI 10.3390/genes9090435
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GY2UI
UT WOS:000448398700016
PM 30158504
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Vojnikovic, B
   Vojnikovic, D
AF Vojnikovic, Bozo
   Vojnikovic, Davor
TI Benedictine Monastery on the Island of Rab Hides the Mystery of Sunlight
   Influence on Development of Macular Degeneration (AMD). Is a Harmful
   Sunligh, Risk Factor or Cause of Macular Degeneration?
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE age related macular degeneration; sunlight exposure; cumulative effect;
   risk factor
ID CATARACT-SURGERY; PROGRESSION; RADIATION
AB Benedictine Monastery of St. Andrew is probably the oldest existing Benedictine monastery in this area. According to hundreds of years of legend, it was founded in 1018 year. In clinical examination about the possibility of the macular degeneration occurrence in 15 Benedictine sisters, we found the age-related macular degeneration (AMD) in two cases only. In 13 other sisters aging 27, 60, 67 years, the fundus picture was like in a baby, vision, visual field and meridian thresholds were normal. What is the explanation for this phenomenon? Two sisters with AMD work and live as the farm workers, but the other sisters live in closed monastery with very low natural sunlight, approximately 300-500 lx. In conclusion, the earlier author's experimental and clinical works follow the consequence that without exposure of eyes to harmful higher doses of sunlight, it is not possible to develop AMD. The harmful cumulative dose of sunlight is not the risk factor; but the cause, including the inheritance, for AMD development.
C1 [Vojnikovic, Bozo] Daily Eye Clin Dr Bozo Vojnikovic, Rijeka, Croatia.
   [Vojnikovic, Davor] Opt Studio Albert Einstein, Rijeka, Croatia.
RP Vojnikovic, B (通讯作者)，Daily Eye Clin Dr Bozo Vojnikovic, Rijeka, Croatia.
EM decv@decv.com
CR CASDAY R, 1998, VISION LIGHT INDUCED
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   JIAQUIAN N, 2009, MOL CELLULAR PROTEOM, V8, P1921
   Kovacevic D, 2008, COLLEGIUM ANTROPOL, V32, P9
   PERUMALPANDI S, 2006, FEBS J, V273, P481
   SLINEY DH, 1986, INVEST OPHTH VIS SCI, V27, P781
   SMITH S, 2007, OCCUPATIONAL HAZARDS, V17, P256
   VOJNIKOVIC B, 2005, EINSTEINOV ZAKON ELE
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Vojnikovic B, 2008, COLLEGIUM ANTROPOL, V32, P3
   Vojnikovic B, 2009, COLLEGIUM ANTROPOL, V33, P747
   XIAORONG G, 2003, J BIOL CHEM, V10, P1074
NR 12
TC 7
Z9 7
U1 1
U2 8
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2010
VL 34
SU 2
BP 5
EP 8
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 677AI
UT WOS:000283961100002
PM 21302698
DA 2022-11-30
ER

PT J
AU Jin, ZB
   Okamoto, S
   Mandai, M
   Takahashi, M
AF Jin, Zi-Bing
   Okamoto, Satoshi
   Mandai, Michiko
   Takahashi, Masayo
TI Induced pluripotent stem cells for retinal degenerative diseases: a new
   perspective on the challenges
SO JOURNAL OF GENETICS
LA English
DT Review
DE induced pluripotent stem cells; differentiation; age-related macular
   degeneration; retinitis pigmentosa
ID RETINITIS-PIGMENTOSA PATIENTS; IN-VITRO DIFFERENTIATION; HUMAN
   FIBROBLASTS; EPITHELIAL-CELLS; VISUAL FUNCTION; GENERATION;
   TRANSPLANTATION; SUPPLEMENTATION; INDUCTION; MODEL
AB Retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa, are the prodominant causes of human blindness in the world; however, these diseases are difficult to treat. Currently, knowledge on the mechanisms of these diseases is still very limited and no radical drugs are available. Induced pluripotent stem (iPS) cells are an innovative technology that turns somatic cells into embryonic stem (ES)-like cells with pluripotent potential via the exogenous expression of several key genes. It can be used as an unlimited source for cell differentiation or tissue engineering, either of which is a promising therapy for human degenerative diseases. Induced pluripotent cells are both an unlimited source for retinal regeneration and an expectant tool for pharmaprojects and developmental or disease modelling. In this review, we try to summarize the advancement of iPS-based technologies and the potential utility for retinal degenerative diseases. We also discuss the challenges of using this technology in the retinology field.
C1 [Jin, Zi-Bing; Okamoto, Satoshi; Mandai, Michiko; Takahashi, Masayo] RIKEN Ctr Dev Biol, Lab Retinal Regenerat, Chuo Ku, Kobe, Hyogo 6500047, Japan.
C3 RIKEN
RP Takahashi, M (通讯作者)，RIKEN Ctr Dev Biol, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
EM mretina@cdb.riken.jp
RI Okamoto, Satoshi/F-7309-2013; Mandai, Michiko/E-7986-2011; Jin,
   Zi-Bing/J-6810-2014; Jin, Zi-Bing/AAE-4106-2019
OI Okamoto, Satoshi/0000-0003-4071-9696; Jin, Zi-Bing/0000-0003-0515-698X;
   Jin, Zi-Bing/0000-0003-0515-698X
FU RIKEN FPR
FX We thank all members of Takahashi's lab for their discussion on this
   paper. This work is supported by RIKEN FPR Program (ZB.J).
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Amabile G, 2009, TRENDS MOL MED, V15, P59, DOI 10.1016/j.molmed.2008.12.003
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022
   Daley GQ, 2009, CELL STEM CELL, V4, P200, DOI 10.1016/j.stem.2009.02.009
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   del Cerro M, 2000, INVEST OPHTH VIS SCI, V41, P3142
   Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799
   Ezashi T, 2009, P NATL ACAD SCI USA, V106, P10993, DOI 10.1073/pnas.0905284106
   HAIM M, 1993, CLIN GENET, V44, P62
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Ho HY, 2006, REGEN MED, V1, P175, DOI 10.2217/17460751.1.2.175
   Hoffman DR, 2004, AM J OPHTHALMOL, V137, P704, DOI 10.1016/j.ajo.2003.10.045
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Jagatha B, 2009, BIOCHEM BIOPH RES CO, V380, P230, DOI 10.1016/j.bbrc.2009.01.038
   Jin ZB, 2008, J MED GENET, V45, P465, DOI 10.1136/jmg.2007.056416
   Jin ZB, 2007, AM J MED GENET A, V143A, P2544, DOI 10.1002/ajmg.a.31984
   Jorgensen A, 2001, EXP EYE RES, V73, P723, DOI 10.1006/exer.2001.1082
   Judson RL, 2009, NAT BIOTECHNOL, V27, P459, DOI 10.1038/nbt.1535
   Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088
   Kondo M, 2009, INVEST OPHTH VIS SCI, V50, P1371, DOI 10.1167/iovs.08-2863
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808
   Liu HS, 2008, CELL STEM CELL, V3, P587, DOI 10.1016/j.stem.2008.10.014
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lyssiotis CA, 2009, P NATL ACAD SCI USA, V106, P8912, DOI 10.1073/pnas.0903860106
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mali P, 2008, STEM CELLS, V26, P1998, DOI 10.1634/stemcells.2008-0346
   Nakatsuji N, 2008, NAT BIOTECHNOL, V26, P739, DOI 10.1038/nbt0708-739
   OKAMOTO S, 2009, JPN J TRANSPLANT, V44, P231
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Osakada F, 2008, INFLAMM REGEN, V28, P166
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Reh TA, 2006, NATURE, V444, P156, DOI 10.1038/444156a
   Rezai KA, 1997, INVEST OPHTH VIS SCI, V38, P2662
   Schwartz SB, 2003, INVEST OPHTH VIS SCI, V44, P3593, DOI 10.1167/iovs.03-0155
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Suzuki T, 2007, CELL TRANSPLANT, V16, P493, DOI 10.3727/000000007783464966
   Suzuki T, 2006, STEM CELLS, V24, P2406, DOI 10.1634/stemcells.2005-0587
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Varas F, 2009, STEM CELLS, V27, P300, DOI 10.1634/stemcells.2008-0696
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   WLELBER RG, 2006, RETINA, P395
   Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863
   Wu Z, 2009, J MOL CELL BIOL, V1, P46, DOI 10.1093/jmcb/mjp003
   Ye L, 2009, P NATL ACAD SCI USA, V106, P9826, DOI 10.1073/pnas.0904689106
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
NR 62
TC 45
Z9 51
U1 0
U2 34
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0022-1333
EI 0973-7731
J9 J GENET
JI J. Genet.
PD DEC
PY 2009
VL 88
IS 4
SI SI
BP 417
EP 424
DI 10.1007/s12041-009-0063-5
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 553AH
UT WOS:000274336300005
PM 20090205
DA 2022-11-30
ER

PT J
AU Lachmann, PJ
   Smith, RAG
AF Lachmann, P. J.
   Smith, R. A. G.
TI Taking Complement to the Clinic - has the Time Finally Come?
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; SYNTHETIC PEPTIDE INHIBITORS;
   CARDIOPULMONARY BYPASS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   REPERFUSION INJURY; SERINE PROTEASES; NEPHRITIC FACTOR; CARDIAC-SURGERY;
   H DEFICIENCY; HUMAN CR-1
AB Complement has been studied for over a century and its role in promoting the effector side of antibody-mediated immune reactions and of inducing inflammation is well understood. Nevertheless, it has proved surprisingly difficult to translate this information into pharmaceutical agents that can be used to treat immunopathological and inflammatory disease. There are, however, now clear signs that this situation will change. New types of therapeutic agents to interfere with complement function are being developed and it has become apparent quite recently that some common and otherwise untreatable diseases such as age-related macular degeneration are very largely due to mutations in the complement system that leads to a hyperinflammatory state. This has stimulated a renaissance of interest in the complement system as a therapeutic target and in this short review we discuss the possible ways of taking complement to the clinic, and the indications for which this may be carried out.
C1 [Lachmann, P. J.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England.
   [Smith, R. A. G.] Kings Coll London, Guys Hosp, MRC Ctr Transplantat, London WC2R 2LS, England.
C3 University of Cambridge; Guy's & St Thomas' NHS Foundation Trust;
   University of London; King's College London
RP Lachmann, PJ (通讯作者)，Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge CB3 0ES, England.
EM pjl1000@cam.ac.uk
RI Lachmann, P J/I-7968-2019
OI Lachmann, P J/0000-0003-2849-3524
CR AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9
   Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341
   Banz Y, 2007, CARDIOVASC RES, V76, P482, DOI 10.1016/j.cardiores.2007.07.016
   Banz Y, 2007, TRANSPL INT, V20, P722, DOI 10.1111/j.1432-2277.2007.00512.x
   Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X
   Brodsky RA, 2008, BLOOD, V111, P1840, DOI 10.1182/blood-2007-06-094136
   Brook E, 2005, ANN NY ACAD SCI, V1056, P176, DOI 10.1196/annals.1352.033
   BUMPERS HL, 1983, J LAB CLIN MED, V102, P421
   Caliezi C, 2000, PHARMACOL REV, V52, P91
   Christiansen D, 2000, J VIROL, V74, P4672, DOI 10.1128/JVI.74.10.4672-4678.2000
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   FEARON D T, 1991, Clinical and Experimental Immunology, V86, P43
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499
   Halstead SK, 2005, ANN NEUROL, V58, P203, DOI 10.1002/ana.20546
   Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x
   Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200
   Higgins PJ, 1997, J IMMUNOL, V158, P2872
   Hill A, 2006, BLOOD, V107, P2131, DOI 10.1182/blood-2005-02-0782
   Hill A, 2005, BLOOD, V106, P2559, DOI 10.1182/blood-2005-02-0564
   Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Keefe AD, 2008, CURR OPIN PHARMACOL, V8, P147, DOI 10.1016/j.coph.2007.12.005
   Keshavjee S, 2005, J THORAC CARDIOV SUR, V129, P423, DOI 10.1016/j.jtcvs.2004.06.048
   KITANO A, 1992, DIS COLON RECTUM, V35, P560, DOI 10.1007/BF02050536
   Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623
   Lanteri MB, 2000, TRANSPLANTATION, V69, P1128, DOI 10.1097/00007890-200003270-00018
   Lazar HL, 2007, CIRCULATION, V116, pI83, DOI 10.1161/CIRCULATIONAHA.106.677914
   Lazar HL, 2004, CIRCULATION, V110, pII274, DOI 10.1161/01.CIR.0000138315.99788.eb
   LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278
   Li JS, 2004, AM HEART J, V147, P173, DOI 10.1016/j.ahj.2003.07.004
   Linton SM, 2000, ARTHRITIS RHEUM-US, V43, P2590, DOI 10.1002/1529-0131(200011)43:11<2590::AID-ANR29>3.0.CO;2-R
   Makrides SC, 1998, PHARMACOL REV, V50, P59
   MATHIESON PW, 1993, J EXP MED, V177, P1827, DOI 10.1084/jem.177.6.1827
   MIYAGAWA S, 1993, TRANSPLANTATION, V55, P709, DOI 10.1097/00007890-199304000-00004
   MORAN P, 1992, J IMMUNOL, V149, P1736
   Morikis D, 2002, BIOCHEM SOC T, V30, P1026, DOI 10.1042/BST0301026
   Mossakowska D, 1999, EUR J IMMUNOL, V29, P1955, DOI 10.1002/(SICI)1521-4141(199906)29:06<1955::AID-IMMU1955>3.3.CO;2-F
   MOSSAKOWSKA DE, 1996, RECOMBINANT CELL SUR, V209
   Mqadmi A, 2004, BIOCHEM BIOPH RES CO, V325, P1465, DOI 10.1016/j.bbrc.2004.11.002
   PEAKE P, 1990, CLIN EXP IMMUNOL, V79, P454
   Pratt JR, 2003, AM J PATHOL, V163, P1457, DOI 10.1016/S0002-9440(10)63503-1
   Rioux P, 2001, Curr Opin Investig Drugs, V2, P364
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Ross GD, 2000, CRIT REV IMMUNOL, V20, P197
   Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2
   ROSS GD, 1993, CLIN EXP IMMUNOL, V92, P181
   Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344
   Sahu A, 1999, BIOCHEM PHARMACOL, V57, P1439, DOI 10.1016/S0006-2952(99)00044-1
   SCHASTEEN CS, 1991, MOL IMMUNOL, V28, P17, DOI 10.1016/0161-5890(91)90082-U
   SCHASTEEN CS, 1988, MOL IMMUNOL, V25, P1269, DOI 10.1016/0161-5890(88)90041-7
   Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021
   Smith GP, 2001, MOL IMMUNOL, V38, P249, DOI 10.1016/S0161-5890(01)00047-5
   Smith RAG, 2002, BIOCHEM SOC T, V30, P1037, DOI 10.1042/bst0301037
   Smith RAG, 2007, MOL IMMUNOL, V44, P3915, DOI 10.1016/j.molimm.2007.06.021
   Steinmetzer T, 2004, CURR MED CHEM, V11, P2297, DOI 10.2174/0929867043364540
   Tanaka M, 1996, TRANSPLANTATION, V62, P681, DOI 10.1097/00007890-199609150-00025
   Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359
   Testa L, 2008, J THORAC CARDIOV SUR, V136, P884, DOI 10.1016/j.jtcvs.2007.12.062
   THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0
   WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562
   White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 65
TC 28
Z9 31
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD JUN
PY 2009
VL 69
IS 6
BP 471
EP 478
DI 10.1111/j.1365-3083.2009.02258.x
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 437UK
UT WOS:000265512200002
PM 19439007
OA Bronze
DA 2022-11-30
ER

PT J
AU Tsao, YP
   Ho, TC
   Chen, SL
   Cheng, HC
AF Tsao, Yeou-Ping
   Ho, Tsung-Chuan
   Chen, Show-Li
   Cheng, Huey-Chuan
TI Pigment epithelium-derived factor inhibits oxidative stress-induced cell
   death by activation of extracellular signal-regulated kinases in
   cultured retinal pigment epithelial cells
SO LIFE SCIENCES
LA English
DT Article
DE PEDF; oxidative stress; RPE; ARPE-19; ERK1/2
ID KAPPA-B ACTIVATION; HYDROGEN-PEROXIDE; FACTOR PEDF; ENDOTHELIAL-CELLS;
   NADPH OXIDASE; APOPTOSIS; SURVIVAL; DAMAGE; EXPRESSION; PATHWAY
AB Oxidative stress-induced retinal pigment epithelial (RPE) cell death is involved in the pathogenesis of age-related macular degeneration (AMD). Pigment epithelium-derived factor (PEDF) is an anti-angiogenic/neurotropic dual functional factor, and recently it was also shown to mediate anti-oxidative action. In the present study, the influence of PEDF in hydrogen peroxide (H2O2)-induced R-PE cell death was investigated using nontransformed human RPE cell line (ARPE-19). The recombinant PEDF was purified from E. coli. The MTT cell viability assay showed that PEDF rescued ARPE-19 from H2O2-induced cell death in a dose- and time-dependent manner. Western blot analysis revealed that PEDF stimulated the extracellular signal-regulated kinases (ERK1/2) phosphorylation. The PEDF cytoprotective effect was significantly attenuated by the ERK1/2 inhibitor PD98059. In this study, we demonstrate that PEDF induces ERK1/2 phosphorylation and we further suggest that the ERK signal cascade contributes to RPE cell's cytoprotection against oxidative stress. (c) 2006 Elsevier Inc. All rights reserved.
C1 Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan.
   Natl Taiwan Univ, Sch Med, Dept Microbiol, Taipei 10764, Taiwan.
   Mackay Med Nursing & Management Coll, Taipei, Taiwan.
C3 Mackay Memorial Hospital; National Defense Medical Center; National
   Taiwan University; Mackay Junior College of Medicine, Nursing &
   Management
RP Tsao, YP (通讯作者)，Mackay Mem Hosp, Dept Ophthalmol, 92 Chung Shan N Rd,Sec 2, Taipei, Taiwan.
EM yptsao@yahoo.com
CR Amano S, 2005, MICROVASC RES, V69, P45, DOI 10.1016/j.mvr.2004.11.001
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   BECERRA SP, 1993, J BIOL CHEM, V268, P23148
   Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604
   Hecquet C, 2003, INVEST OPHTH VIS SCI, V44, P1320, DOI 10.1167/iovs.02-0519
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Petersen SV, 2003, BIOCHEM J, V374, P199, DOI 10.1042/BJ20030313
   RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   TOMBRANTINK J, 1996, MOL VIS, V2, P1
   Verna LK, 2000, CELL BIOL TOXICOL, V16, P303, DOI 10.1023/A:1026798314217
   Winkler BS, 1999, MOL VIS, V5
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959
   Yabe T, 2005, NEUROSCIENCE, V133, P691, DOI 10.1016/j.neuroscience.2005.03.007
   Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200
   Yamagishi S, 2005, CELL TISSUE RES, V320, P437, DOI 10.1007/s00441-005-1094-8
   Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007
NR 29
TC 78
Z9 87
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JUL 4
PY 2006
VL 79
IS 6
BP 545
EP 550
DI 10.1016/j.lfs.2006.01.041
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 060BV
UT WOS:000238777400006
PM 16504212
DA 2022-11-30
ER

PT J
AU Sreekumar, PG
   Karman, R
   Yaung, J
   Spee, CK
   Ryan, SJ
   Hinton, DR
AF Sreekumar, PG
   Karman, R
   Yaung, J
   Spee, CK
   Ryan, SJ
   Hinton, DR
TI Protection from oxidative stress by methionine sulfoxide reductases in
   RPE cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Msrs; RPE; oxidative stress; mitochondria; apoptosis; AMD; drusen; siRNA
ID ANTIOXIDANT DEFENSE; DNA-DAMAGE; PEPTIDE; EXPRESSION; APOPTOSIS;
   ENZYMES; REPAIR; MSRA; GENE; MITOCHONDRIAL
AB We investigated the role of methionine sulfoxide reductases (Msrs) in oxidant-stress-incluced cell death in retinal pigmented epithelial (RPE) cells. In RPE cells exposed to varying doses of H2O2, gene expression of MsrA and hCBS-1 (the human analog of MsrB2) increased in a dose-dependent and time-dependent manner with maximal increase with 150 mu M H2O2 in 24 h. H2O2 treatment resulted in the generation of reactive oxygen species and activation of caspase 3. Confocal microscopic and protein analysis showed an increase in MsrA expression in cytosol and mitochondria. Silencing of MsrA resulted in caspase 3 induction and accentuated cell death from H2O2. Focal, strong immuno reactivity for MsrA was observed in sub-RPE macular drusen from patients with age-related macular degeneration. In summary, our data show that MsrA and hCBS-1 are up-regulated in oxidative stress to counteract injury to RPE. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ So Calif, Keck Sch Med, Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
EM dhinton@hsc.usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU NEI NIH HHS [EY 03040, EY 02061] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY002061, P30EY003040] Funding Source: NIH RePORTER
CR BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304
   COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Dringen R, 1997, BRAIN RES, V759, P67, DOI 10.1016/S0006-8993(97)00233-3
   Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x
   Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200
   Haendeler J, 2004, FEBS LETT, V577, P427, DOI 10.1016/j.febslet.2004.10.041
   Hansel A, 2005, BBA-PROTEINS PROTEOM, V1703, P239, DOI 10.1016/j.bbapap.2004.09.010
   Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095
   Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x
   JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Jung S, 2002, FEBS LETT, V527, P91, DOI 10.1016/S0014-5793(02)03171-X
   Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011
   Kantorow M, 2004, P NATL ACAD SCI USA, V101, P9654, DOI 10.1073/pnas.0403532101
   Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629
   Kim HY, 2004, BIOCHEM BIOPH RES CO, V320, P1277, DOI 10.1016/j.bbrc.2004.06.078
   Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099
   Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036
   Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056
   Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   MA M, 2003, EXP EYE RES, V79, P411
   Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003
   Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071
   MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995
   Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205
   Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819
   Picot CR, 2004, FEBS LETT, V558, P74, DOI 10.1016/S0014-5793(03)01530-8
   Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199
   Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1
   Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310
   SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Vougier S, 2003, BIOCHEM J, V373, P531, DOI 10.1042/BJ20030443
   Wang GW, 2001, J PHARMACOL EXP THER, V298, P461
   Wang JF, 2004, J BIOL CHEM, V279, P27088, DOI 10.1074/jbc.M314015200
   Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664
   Weissbach H, 2005, BBA-PROTEINS PROTEOM, V1703, P203, DOI 10.1016/j.bbapap.2004.10.004
   Wizemann TM, 1996, P NATL ACAD SCI USA, V93, P7985, DOI 10.1073/pnas.93.15.7985
   Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P1159, DOI 10.1073/pnas.0308215100
NR 45
TC 57
Z9 59
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 19
PY 2005
VL 334
IS 1
BP 245
EP 253
DI 10.1016/j.bbrc.2005.06.081
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 948MH
UT WOS:000230719400035
PM 15993845
DA 2022-11-30
ER

PT J
AU Harvey, PT
AF Harvey, PT
TI Common eye diseases of elderly people: Identifying and treating causes
   of vision loss
SO GERONTOLOGY
LA English
DT Review
DE age-related macular degeneration; cataract; diabetic retinopathy;
   glaucoma; verteporfin therapy
ID CHOROIDAL NEOVASCULAR MEMBRANES; AGE-RELATED MACULOPATHY; BLUE MOUNTAINS
   EYE; QUALITY-OF-LIFE; BEAVER DAM EYE; MACULAR DEGENERATION; IMPAIRED
   VISION; VISUAL FUNCTION; OLDER-PEOPLE; CATARACT
AB Of the 38 million people who are blind, the majority, 22 million, are 60 years of age or older. The most common causes of vision loss in elderly people are age-related macular degeneration (AMD), cataract, glaucoma, and diabetic retinopathy. Of these, AMD is the leading cause of registered blindness in people over the age of 50 years in the western world. However, until recently, the treatment options for people with AMD have been severely limited. Verteporfin therapy is a new treatment that is efficacious and safe in selected patients with AMD who are at high risk of central vision loss. Physicians who are in regular contact with elderly people can help to minimize vision loss in this group of patients by being alert to the symptoms and signs of age-related eye diseases. This paper reviews each of the common eye diseases, with an emphasis on AMD because of the recent advances in treatment. Copyright (C) 2003 S. Karger AG, Basel.
C1 Toronto Western Hosp, Vis Sci Res Programme, Toronto, ON M5T 2S8, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto
RP Harvey, PT (通讯作者)，Med W Med Ctr, 750 Dundas St W,Ste B09, Toronto, ON, Canada.
CR Abyad A, 1997, GERIATRICS-US, V52, P45
   Alexander L J, 1993, J Am Optom Assoc, V64, P822
   ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   *AM OPT ASS CONS P, 1995, OPT CLIN PRACT GUID
   *AM OPT ASS CONS P, 1993, OPT CLIN PRACT GUID
   *AMD ALL INT, 1999, AW RES
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Butler RN, 1997, GERIATRICS, V52, P48
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   COHEN DL, 1990, DIABETIC MED, V7, P615, DOI 10.1111/j.1464-5491.1990.tb01459.x
   Cooppan Ramachandiran, 1996, Comprehensive Therapy, V22, P286
   Cumming RG, 2000, OPHTHALMOLOGY, V107, P450, DOI 10.1016/S0161-6420(99)00024-X
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Evans JR, 2000, COCHRANE DB SYST REV
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Houle J, 2001, INVEST OPHTH VIS SCI, V42, pS437
   Hyman L, 1992, AGE RELATED MACULAR, P1
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MANTON KG, 1991, J GERONTOL, V46, pS170, DOI 10.1093/geronj/46.3.S170
   Mares-Perlman JA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1556, DOI 10.1001/archopht.118.11.1556
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   REVICKI DA, 1993, J CLIN EPIDEMIOL, V46, P5, DOI 10.1016/0895-4356(93)90004-K
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Smeeth L, 1998, FAM PRACT, V15, pS24
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   ZHANG K, 1995, SURV OPHTHALMOL, V40, P51, DOI 10.1016/S0039-6257(95)80047-6
NR 53
TC 38
Z9 40
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
J9 GERONTOLOGY
JI Gerontology
PD JAN-FEB
PY 2003
VL 49
IS 1
BP 1
EP 11
DI 10.1159/000066507
PG 11
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 634LG
UT WOS:000180340400001
PM 12457044
DA 2022-11-30
ER

PT J
AU Lin, CC
   Chiu, CC
   Lee, PY
   Chen, KJ
   He, CX
   Hsu, SK
   Cheng, KC
AF Lin, Chia-Ching
   Chiu, Chien-Chih
   Lee, Po-Yen
   Chen, Kuo-Jen
   He, Chen-Xi
   Hsu, Sheng-Kai
   Cheng, Kai-Chun
TI The Adverse Effects of Air Pollution on the Eye: A Review
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE air pollution; eye diseases; ocular surface diseases; glaucoma;
   cataract; retinal diseases
ID FINE PARTICULATE MATTER; MACULAR DEGENERATION; CIGARETTE-SMOKING;
   CYTOKINE PROFILES; OXIDATIVE STRESS; OCULAR SURFACE; AMBIENT LEVELS;
   TOBACCO-SMOKE; TH17 CELLS; EXPOSURE
AB Air pollution is inevitably the result of human civilization, industrialization, and globalization. It is composed of a mixture of gases and particles at harmful levels. Particulate matter (PM), nitrogen oxides (NOx), and carbon dioxides (CO2) are mainly generated from vehicle emissions and fuel consumption and are the main materials causing outdoor air pollution. Exposure to polluted outdoor air has been proven to be harmful to human eyes. On the other hand, indoor air pollution from environmental tobacco smoking, heating, cooking, or poor indoor ventilation is also related to several eye diseases, including conjunctivitis, glaucoma, cataracts, and age-related macular degeneration (AMD). In the past 30 years, no updated review has provided an overview of the impact of air pollution on the eye. We reviewed reports on air pollution and eye diseases in the last three decades in the PubMed database, Medline databases, and Google Scholar and discussed the effect of various outdoor and indoor pollutants on human eyes.
C1 [Lin, Chia-Ching; Chen, Kuo-Jen; Cheng, Kai-Chun] Kaohsiung Municipal Siaogang Hosp, Dept Ophthalmol, Kaohsiung 807, Taiwan.
   [Lin, Chia-Ching; Lee, Po-Yen; Cheng, Kai-Chun] Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 807, Taiwan.
   [Chiu, Chien-Chih; He, Chen-Xi; Hsu, Sheng-Kai] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung 807, Taiwan.
   [Chiu, Chien-Chih] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 804, Taiwan.
   [Chiu, Chien-Chih; Lee, Po-Yen] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan.
   [Cheng, Kai-Chun] Kaohsiung Med Univ, Sch Med, Dept Ophthalmol, Coll Med, Kaohsiung 812, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital;
   Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; National Sun Yat Sen University; Kaohsiung
   Medical University; Kaohsiung Medical University
RP Cheng, KC (通讯作者)，Kaohsiung Municipal Siaogang Hosp, Dept Ophthalmol, Kaohsiung 807, Taiwan.; Cheng, KC (通讯作者)，Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 807, Taiwan.; Cheng, KC (通讯作者)，Kaohsiung Med Univ, Sch Med, Dept Ophthalmol, Coll Med, Kaohsiung 812, Taiwan.
EM somepp322@gmail.com; cchiu@kmu.edu.tw; maco69@gmail.com;
   0870649@kmhk.org.tw; u106500025@kmu.edu.tw; b043100050@gmail.com;
   pington64@gmail.com
RI Chiu, Chien-Chih/AAW-9861-2020
OI Chiu, Chien-Chih/0000-0001-7307-2468; Cheng,
   Kai-Chun/0000-0002-1240-4219; Lee, Po Yen/0000-0002-1825-0003
CR Abellan R, 2010, ATHEROSCLEROSIS, V211, P203, DOI 10.1016/j.atherosclerosis.2010.01.030
   Al-Aqaba MA, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.05.003
   Annesi-Maesano I, 2004, CLIN EXP ALLERGY, V34, P1017, DOI 10.1111/j.1365-2222.2004.02002.x
   [Anonymous], 2016, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, V109
   [Anonymous], 2004, HLTH CONS SMOK REP S
   [Anonymous], AMBIENT OUTDOOR AIR
   Baccarelli A, 2007, J THROMB HAEMOST, V5, P252, DOI 10.1111/j.1538-7836.2007.02300.x
   Bai YC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.613893
   BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304, DOI 10.1164/ajrccm/143.6.1304
   Blanc PD, 2005, J OCCUP ENVIRON MED, V47, P362, DOI 10.1097/01.jom.0000158708.32491.9d
   Bourcier T, 2003, BRIT J OPHTHALMOL, V87, P809, DOI 10.1136/bjo.87.7.809
   Bron AJ, 2007, OCUL SURF, V5, P108
   Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
   Chang CJ, 2012, INVEST OPHTH VIS SCI, V53, P429, DOI 10.1167/iovs.11-8253
   Chang KH, 2019, J INVEST MED, V67, P1076, DOI 10.1136/jim-2019-001007
   Choi W, 2016, CURR EYE RES, V41, P1143, DOI 10.3109/02713683.2015.1098707
   Chow JC, 2006, J AIR WASTE MANAGE, V56, P1368, DOI 10.1080/10473289.2006.10464485
   Chua SYL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.32
   Chua SYL, 2019, INVEST OPHTH VIS SCI, V60, P4915, DOI 10.1167/iovs.19-28346
   Cohen AJ, 2017, LANCET, V389, P1907, DOI [10.1016/S0140-6736(17)30505-6, 10.1016/s0140-6736(17)30505-6]
   Curnow SJ, 2005, INVEST OPHTH VIS SCI, V46, P4251, DOI 10.1167/iovs.05-0444
   de Juniac A, 2012, INT J ENVIRON HEAL R, V22, P210, DOI 10.1080/09603123.2011.628645
   Di Q, 2017, NEW ENGL J MED, V376, P2513, DOI 10.1056/NEJMoa1702747
   Diaz E, 2007, J EPIDEMIOL COMMUN H, V61, P74, DOI 10.1136/jech.2006.043133
   Eftim SE, 2008, EPIDEMIOLOGY, V19, P209, DOI 10.1097/EDE.0b013e3181632c09
   Escobar T, 2013, INVEST OPHTH VIS SCI, V54, P4017, DOI 10.1167/iovs.13-11937
   Fullerton DG, 2008, T ROY SOC TROP MED H, V102, P843, DOI 10.1016/j.trstmh.2008.05.028
   Gawande S, 2020, INDIAN J OCCUP ENVIR, V24, P30, DOI 10.4103/ijoem.IJOEM_148_19
   Goncalves RB, 2011, INFLAMM RES, V60, P409, DOI 10.1007/s00011-011-0308-7
   Gonzalez MM, 2018, J OPHTHALMIC INFLAMM, V8, DOI 10.1186/s12348-018-0148-5
   Govindaraju VK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182420
   Gupta S, 2020, ANN NY ACAD SCI, V1480, P233, DOI 10.1111/nyas.14514
   Hetland RB, 2005, PART FIBRE TOXICOL, V2, DOI 10.1186/1743-8977-2-4
   Holguin F, 2008, IMMUNOL ALLERGY CLIN, V28, P577, DOI 10.1016/j.iac.2008.03.008
   Hong JX, 2016, SCI REP-UK, V6, DOI 10.1038/srep23858
   Huff RD, 2019, J ALLERGY CLIN IMMUN, V143, P1989, DOI 10.1016/j.jaci.2019.04.012
   Iho S, 2003, J LEUKOCYTE BIOL, V74, P942, DOI 10.1189/jlb.1202626
   Jadidi-Niaragh F, 2011, SCAND J IMMUNOL, V74, P1, DOI 10.1111/j.1365-3083.2011.02536.x
   Jaen C, 2014, J PSYCHOSOM RES, V77, P302, DOI 10.1016/j.jpsychores.2014.07.002
   Jain V, 2017, INT OPHTHALMOL, V37, P291, DOI 10.1007/s10792-016-0245-0
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6
   Jordan RE, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000153
   Kabir E, 2011, J HAZARD MATER, V188, P443, DOI 10.1016/j.jhazmat.2011.01.113
   Kappos AD, 2004, INT J HYG ENVIR HEAL, V207, P399, DOI 10.1078/1438-4639-00306
   Kemp AC, 2011, P NATL ACAD SCI USA, V108, P11017, DOI 10.1073/pnas.1015619108
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khera TK, 2012, CLIN EXP IMMUNOL, V168, P165, DOI 10.1111/j.1365-2249.2012.04567.x
   Koh S, 2018, BRIT J OPHTHALMOL, V102, P1615, DOI 10.1136/bjophthalmol-2018-312333
   Lee AJ, 2003, J GLAUCOMA, V12, P209, DOI 10.1097/00061198-200306000-00005
   Lee H, 2020, ENVIRON POLLUT, V262, DOI 10.1016/j.envpol.2020.114301
   Lee K, 2016, CURR EYE RES, V41, P1367, DOI 10.3109/02713683.2015.1119856
   Li J, 2020, FREE RADICAL BIO MED, V153, P187, DOI 10.1016/j.freeradbiomed.2020.04.007
   Li LP, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-021-00403-4
   Lin P, 2010, OPHTHALMOLOGY, V117, P585, DOI 10.1016/j.ophtha.2009.08.011
   Liu HX, 2009, INVEST OPHTH VIS SCI, V50, P3671, DOI 10.1167/iovs.08-2689
   Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074
   Luengas A, 2015, REV ENVIRON SCI BIO, V14, P499, DOI 10.1007/s11157-015-9363-9
   Martheswaran T, 2021, INT OPHTHALMOL, V41, P2925, DOI 10.1007/s10792-021-01842-w
   McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535
   Mimura T, 2014, SCI TOTAL ENVIRON, V487, P493, DOI 10.1016/j.scitotenv.2014.04.057
   Min KB, 2020, AM J OPHTHALMOL, V211, P176, DOI 10.1016/j.ajo.2019.11.013
   Torricelli AAM, 2011, ARQ BRAS OFTALMOL, V74, P377, DOI 10.1590/S0004-27492011000500016
   Nagata M, 1999, J OCUL PHARMACOL TH, V15, P345, DOI 10.1089/jop.1999.15.345
   Nita M, 2017, CURR PHARM DESIGN, V23, P639, DOI 10.2174/1381612823666170111095723
   Nita M, 2017, CURR PHARM DESIGN, V23, P629, DOI 10.2174/1381612822666161129152041
   Novaes P, 2007, ENVIRON HEALTH PERSP, V115, P1753, DOI 10.1289/ehp.10363
   Pan SC, 2020, ENVIRON RES, V181, DOI 10.1016/j.envres.2019.108960
   Perez-de-Arcelus M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005761
   Pokhrel AK, 2005, INT J EPIDEMIOL, V34, P702, DOI 10.1093/ije/dyi015
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Pope CA, 2004, NEW ENGL J MED, V351, P1132, DOI 10.1056/NEJMe048182
   Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880
   Raju P, 2006, BRIT J OPHTHALMOL, V90, P1374, DOI 10.1136/bjo.2006.097295
   Roesel M, 2011, GRAEF ARCH CLIN EXP, V249, P903, DOI 10.1007/s00417-010-1597-1
   Rushton Lesley, 2004, Reviews on Environmental Health, V19, P291
   Saha A, 2005, OCCUP ENVIRON MED, V62, P66, DOI 10.1136/oem.2004.015636
   Sarigiannis DA, 2011, ENVIRON INT, V37, P743, DOI 10.1016/j.envint.2011.01.005
   Sarir H, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-12
   Saxena R, 2003, ACTA OPHTHALMOL SCAN, V81, P491, DOI 10.1034/j.1600-0420.2003.00119.x
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   Schwela D., 2000, REV ENV HLTH, V15, P13, DOI DOI 10.1515/REVEH.2000.15.1-2.13
   Shan AQ, 2021, ENVIRON INT, V154, DOI 10.1016/j.envint.2021.106568
   Smith CA, 2017, EYE, V31, P209, DOI 10.1038/eye.2016.295
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sun HY, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18041714
   Swenberg JA, 2013, TOXICOL PATHOL, V41, P181, DOI 10.1177/0192623312466459
   Tan G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36181-x
   Torii K, 2011, EXP DERMATOL, V20, P371, DOI 10.1111/j.1600-0625.2010.01224.x
   Tuominen ISJ, 2003, INVEST OPHTH VIS SCI, V44, P2545, DOI 10.1167/iovs.02-1260
   Valentincic NV, 2011, MOL VIS, V17, P2003
   van Hamburg JP, 2011, ARTHRITIS RHEUM-US, V63, P73, DOI 10.1002/art.30093
   Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881
   Versura P, 1999, OPHTHALMOLOGICA, V213, P103, DOI 10.1159/000027401
   Vitoux MA, 2018, TOXICOL SCI, V165, P108, DOI 10.1093/toxsci/kfy125
   Vohra K., 2021, ENVIRON RES, V195, P110754, DOI [DOI 10.1016/j.envres.2021.110754, DOI 10.1016/J.ENVRES.2021.110754]
   Wang RX, 2012, J BIOL CHEM, V287, P36012, DOI 10.1074/jbc.M112.390625
   Wang W, 2019, ACTA OPHTHALMOL, V97, pE349, DOI 10.1111/aos.14044
   Wei CC, 2019, ENVIRON POLLUT, V254, DOI 10.1016/j.envpol.2019.113031
   West SK, 2013, INT J ENV RES PUB HE, V10, P5378, DOI 10.3390/ijerph10115378
   Wolkoff P, 2017, INDOOR AIR, V27, P246, DOI 10.1111/ina.12322
   Wolkoff P, 2013, INT J HYG ENVIR HEAL, V216, P371, DOI 10.1016/j.ijheh.2012.08.001
   XU GT, 1992, EXP EYE RES, V54, P63, DOI 10.1016/0014-4835(92)90070-9
   Yang Q, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109177
   Yoon S, 2018, TOXICOL LETT, V284, P152, DOI 10.1016/j.toxlet.2017.12.012
   Yuen BG, 2015, OPHTHALMOLOGY, V122, P1257, DOI 10.1016/j.ophtha.2015.02.034
   Zeng YX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.607341
   Zhang JF, 2003, BRIT MED BULL, V68, P209, DOI 10.1093/bmb/ldg029
   Zhang L, 2011, J CLIN IMMUNOL, V31, P606, DOI 10.1007/s10875-011-9540-8
   Zhong JY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102269
NR 111
TC 6
Z9 6
U1 13
U2 25
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD FEB
PY 2022
VL 19
IS 3
AR 1186
DI 10.3390/ijerph19031186
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA YZ7SE
UT WOS:000755671300001
PM 35162209
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yang, C
   Xie, LR
   Gu, Q
   Qiu, QH
   Wu, XW
   Yin, LL
AF Yang, Chen
   Xie, Lirong
   Gu, Qing
   Qiu, Qinghua
   Wu, Xingwei
   Yin, Lili
TI 7-Ketocholesterol disturbs RPE cells phagocytosis of the outer segment
   of photoreceptor and induces inflammation through ERK signaling pathway
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE 7-Ketocholesterol; Retinal pigment epithelial cells; Inflammation; ERK;
   Age related macular degeneration
ID LOW-DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; RAT MODEL; CHOROIDAL
   NEOVASCULARIZATION; AUTOPHAGY; DEGENERATION; OXYSTEROLS; RETINA;
   CYTOTOXICITY; CHOLESTEROL
AB 7-Ketocholesterol (7KCh), an oxidized form of cholesterol, is present at a high level in drusen and has been believed to play a role in the pathogenesis of age-related macular degeneration (AMD). Therefore, we developed a rat model to study the direct impact of 7KCh on retina. We delivered 7KCh to the rat retina by intravitreal injection using hydroxypropyl-beta-cyclodextrin as a vehicle. We observed that 7KCh mainly deposited in the retinal pigment epithelial (RPE) cells and induced marked photoreceptor apoptosis. Transmission electron microscope examination demonstrated cytoplasmic vacuoles in RPE cells and the microvilli detached from the outer segment after 7KCh treatment. In vitro experiments also revealed that RPE cells could take up 7KCh in culture. Moreover, 7KCh up-regulated IL-1 beta mRNA, TNF-alpha mRNA, IL-6 mRNA, and IL-1 beta secretion of RPE. U0126, a MEK1/2 inhibitor, down regulated the expression of these inflammation factors. Our findings may help elucidate the potential role of 7KCh in the pathogenesis of AMD.
C1 [Yang, Chen; Xie, Lirong; Gu, Qing; Qiu, Qinghua; Wu, Xingwei; Yin, Lili] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, Shanghai 200080, Peoples R China.
   [Yang, Chen; Xie, Lirong; Gu, Qing; Qiu, Qinghua; Wu, Xingwei; Yin, Lili] Shanghai Key Lab Fundus Dis, 100 Hai Ning Rd, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University
RP Yin, LL (通讯作者)，100 Hai Ning Rd, Shanghai 200080, Peoples R China.
EM yll144@aliyun.com
FU National Natural Science Foundation of China [8120-0702]
FX National Natural Science Foundation of China (No. 8120-0702).
CR Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chang MC, 2016, ONCOTARGET, V7, P74473, DOI 10.18632/oncotarget.12578
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Dasari B, 2013, CURR EYE RES, V38, P1159, DOI 10.3109/02713683.2013.811257
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Huang JD, 2012, BBA-MOL CELL BIOL L, V1821, P637, DOI 10.1016/j.bbalip.2012.01.013
   HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lee JW, 2015, BBA-MOL CELL BIOL L, V1851, P605, DOI 10.1016/j.bbalip.2015.01.007
   Luchetti F, 2015, STEROIDS, V99, P204, DOI 10.1016/j.steroids.2015.02.008
   Lyons MA, 2001, BBA-MOL CELL BIOL L, V1530, P209, DOI 10.1016/S1388-1981(01)00083-X
   Lyons MA, 1999, J LIPID RES, V40, P1846
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Olivier E, 2016, BIOCHIMIE, V127, P70, DOI 10.1016/j.biochi.2016.04.014
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Palczewski K, 2012, J BIOL CHEM, V287, P1612, DOI 10.1074/jbc.R111.301150
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Shi GP, 2015, INVEST OPHTH VIS SCI, V56, P1658, DOI 10.1167/iovs.14-14557
   Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tao LF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0489-7
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071036
   Wavre-Shapton ST, 2014, J CELL SCI, V127, P3852, DOI 10.1242/jcs.154757
   Xu LB, 2012, BBA-MOL CELL BIOL L, V1821, P877, DOI 10.1016/j.bbalip.2012.03.001
   Yin LL, 2012, AM J PATHOL, V180, P541, DOI 10.1016/j.ajpath.2011.10.015
   Yin LL, 2011, CURR EYE RES, V36, P379, DOI 10.3109/02713683.2010.537427
NR 46
TC 12
Z9 12
U1 1
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2019
VL 189
AR 107849
DI 10.1016/j.exer.2019.107849
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JU0SW
UT WOS:000501390500027
PM 31655042
DA 2022-11-30
ER

PT J
AU Chen, YS
   Guo, MY
   Yang, JF
   Chen, JG
   Xie, BJ
   Sun, ZD
AF Chen, Yashu
   Guo, Mengyao
   Yang, Jifang
   Chen, Jigang
   Xie, Bijun
   Sun, Zhida
TI Potential TSPO Ligand and Photooxidation Quencher Isorenieratene from
   Arctic Ocean Rhodococcus sp. B7740
SO MARINE DRUGS
LA English
DT Article
DE isorenieratene; macular xanthophylls; TSPO; EPR; antioxidant and
   anti-UVB radiation
ID TRANSLOCATOR PROTEIN; MACULAR DEGENERATION; INDUCED DAMAGE;
   XANTHOPHYLLS; CAROTENOIDS; ZEAXANTHIN; RADICALS; LUTEIN; DIET
AB Due to its special aromatic structure, isorenieratene is thought to be an active natural antioxidant and photo/UV damage inhibitor. In this work, isorenieratene that was extracted from Rhodococcus sp. B7740 isolated from the Arctic Ocean, showed excellent scavenging ability of both singlet oxygen and hydroxyl radical in the UVB-induced auto-oxidation process using the EPR method. Within an ARPE-19 cell model damaged by UVB radiation, isorenieratene showed fine protective effects (1.13 +/- 0.03 fold) compared with macular xanthophylls (MXs) through upregulating of tspo. The molecular docking was firstly performed to investigate the interaction of isorenieratene with TSPO as a special ligand. Results showed isorenieratene might form a better binding conformation (S-score -8.5438) than MXs and indicate that isorenieratene not only can function as a direct antioxidant but also activate tspo in ARPE-19 cells. Thus, isorenieratene might ease the UV-related damages including age-related macular degeneration (AMD).
C1 [Chen, Yashu; Xie, Bijun; Sun, Zhida] Huazhong Agr Univ, Dept Food Sci & Technol, Nat Prod Lab, Wuhan 430070, Hubei, Peoples R China.
   [Guo, Mengyao] Huazhong Agr Univ, Coll Informat, Agr Bioinformat Key Lab Hubei Prov, Wuhan 430070, Hubei, Peoples R China.
   [Yang, Jifang; Chen, Jigang] Zhejiang Wanli Univ, Coll Biol & Environm Sci, Ningbo 315100, Zhejiang, Peoples R China.
C3 Huazhong Agricultural University; Huazhong Agricultural University;
   Zhejiang Wanli University
RP Sun, ZD (通讯作者)，Huazhong Agr Univ, Dept Food Sci & Technol, Nat Prod Lab, Wuhan 430070, Hubei, Peoples R China.
EM yashuchen@sina.com; guomengyao96@gmail.com; jfkwlq@163.com;
   genomic@163.com; bijunxie@sina.com; sunzhida@mail.hzau.edu.cn
RI chen, Jigang/M-4104-2018
OI chen, Jigang/0000-0002-6799-0171
FU China national Marine Scientific Public Welfare [201405015-5]; Key
   Science and Technology Program of Ningbo City, Zhejiang Province, China
   [2012C10038]
FX This research was funded by The China national Marine Scientific Public
   Welfare (201405015-5) and the Key Science and Technology Program of
   Ningbo City, Zhejiang Province, China (grant no. 2012C10038).
CR Barron AM, 2018, BIOCHEM J, V475, P75, DOI 10.1042/BCJ20170645
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Chen YS, 2018, MAR DRUGS, V16, DOI 10.3390/md16100391
   Chen YS, 2018, FOOD CHEM, V240, P204, DOI 10.1016/j.foodchem.2017.06.067
   Chou WW, 2012, CELL IMMUNOL, V273, P79, DOI 10.1016/j.cellimm.2011.11.003
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Ebegboni VJ, 2019, FOOD CHEM, V272, P117, DOI 10.1016/j.foodchem.2018.08.036
   Sosa-Hernandez JE, 2019, MAR DRUGS, V17, DOI 10.3390/md17030174
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Fuciman M, 2010, PHYS CHEM CHEM PHYS, V12, P3112, DOI 10.1039/b921384h
   Jaremko L, 2014, SCIENCE, V343, P1363, DOI 10.1126/science.1248725
   Jiang SQ, 2019, MAR DRUGS, V17, DOI 10.3390/md17020122
   KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032
   Koizumi J, 2018, MAR DRUGS, V16, DOI 10.3390/md16110426
   Li XP, 2018, FOOD FUNCT, V9, P4651, DOI 10.1039/c8fo01293h
   Mages K, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1424-5
   Martin HD, 2009, ANGEW CHEM INT EDIT, V48, P400, DOI 10.1002/anie.200803668
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Sur A, 2014, P NATL ACAD SCI USA, V111, P16754, DOI 10.1073/pnas.1419576111
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang SY, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703923
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Q, 2015, J AGR FOOD CHEM, V63, P6989, DOI 10.1021/acs.jafc.5b01082
   Xiao YB, 2018, MAR DRUGS, V16, DOI 10.3390/md16080283
   Yin J, 2013, FREE RADICAL RES, V47, P643, DOI 10.3109/10715762.2013.812206
   Youn HY, 2007, J PHOTOCH PHOTOBIO B, V88, P21, DOI 10.1016/j.jphotobiol.2007.04.012
   Zareba M, 2016, FREE RADICAL BIO MED, V101, P446, DOI 10.1016/j.freeradbiomed.2016.11.012
NR 30
TC 6
Z9 6
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD JUN
PY 2019
VL 17
IS 6
DI 10.3390/md17060316
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA II6LP
UT WOS:000475305700005
PM 31146377
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cohen, HS
   Stitz, J
   Sangi-Haghpeykar, H
   Williams, SP
AF Cohen, Helen S.
   Stitz, Jasmine
   Sangi-Haghpeykar, Haleh
   Williams, Susan P.
TI Vision Screening in Adults Across the Life Span
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Article
DE aging; driving; vision screening; well older adults
ID VISUAL-ACUITY; OLDER-ADULTS; FALLS; IMPAIRMENT; RISK
AB Objectives: The goal of this study was to determine whether adults across the life span differ in responses to quick vision screening and how those responses relate to adults' use of specialized eye care.
   Methods: Subjects were 363 community-dwelling ambulatory adults, 21 to 95 years old, who were tested while they wore their corrective lenses during routine visits to a tertiary care facility. No subjects had known neurological impairments, age-related macular degeneration, or other significant eye disease. A wall-mounted Early Treatment in Diabetic Retinopathy Study chart was used.
   Results: Older adults 58 years old or older had significantly worse scores than younger adults. Scores did not differ between subjects who had been tested within or prior to the last 10 months. Older subjects had their vision tested significantly more recently than younger subjects.
   Conclusions: Vision screening is quick, inexpensive, and easily performed by ancillary staff, and it may provide the physician with useful additional information for treatment planning.
C1 [Cohen, Helen S.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, One Baylor Plaza, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Obstet & Ginecol, Houston, TX USA.
   Baylor Coll Med, Dept Med, Houston, TX USA.
   Univ Appl Sci Upper Austria, Linz, Austria.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine
RP Cohen, HS (通讯作者)，Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, One Baylor Plaza, Houston, TX 77030 USA.
EM hcohen@bcm.edu
FU National Institutes of Health [R01DC009031]; Austria Marshall Plan
   Foundation; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION
   DISORDERS [R01DC009031] Funding Source: NIH RePORTER
FX This work was funded by National Institutes of Health grant
   R01DC009031.; J.S. was supported by the Austria Marshall Plan
   Foundation. The remaining authors did not report any financial
   relationships or conflicts of interest.
CR American Medical Association, PHYS GUIDE ASSESSING
   American Optometric Association, COMPR EYE VIS EX
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Reed-Jones RJ, 2013, MATURITAS, V75, P22, DOI 10.1016/j.maturitas.2013.01.019
   Russell MA, 2009, AGE AGEING, V38, P40, DOI 10.1093/ageing/afn196
   Texas Medical Advisory Board, GUID DET DRIV LIM
   Treacy MP, 2015, OPHTHALMOLOGY, V122, P1062, DOI 10.1016/j.ophtha.2014.11.024
   Wu TY, 2013, PREV MED, V57, P511, DOI 10.1016/j.ypmed.2013.07.012
   Yardley L, 2005, AGE AGEING, V34, P614, DOI 10.1093/ageing/afi196
   Yip JLY, 2014, BRIT J OPHTHALMOL, V98, P377, DOI 10.1136/bjophthalmol-2013-304179
NR 11
TC 0
Z9 1
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0038-4348
EI 1541-8243
J9 SOUTH MED J
JI South.Med.J.
PD FEB
PY 2018
VL 111
IS 2
BP 109
EP 112
DI 10.14423/SMJ.0000000000000762
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FU8FJ
UT WOS:000424088400009
PM 29394428
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Jo, DH
   Lee, JH
   Jun, HJ
   Kim, J
   Wen, Q
   Hoang, MH
   Yu, YS
   Kim, JH
   Lee, SJ
AF Jo, D. H.
   Lee, J. H.
   Jun, H. J.
   Kim, J.
   Wen, Q.
   Hoang, M. H.
   Yu, Y. S.
   Kim, J. H.
   Lee, S. J.
TI Gene expression profiles of primary retinal pigment epithelial cells
   from apolipoprotein E knockout and human apolipoprotein E2 transgenic
   mice
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Apolipoprotein E; Lipid metabolism;
   Retinal pigment epithelium
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; GROWTH-FACTOR;
   DIETARY-FAT; PATHOGENESIS; DISEASE; NEOVASCULARIZATION; RECEPTORS;
   PROTEIN; LIPIDS
AB Age-related macular degeneration (AMD) causes visual impairment in the elderly. In non-neovascular AMD, studies involving human subjects have suggested potential involvement of aberrant lipid metabolism. However, there have been no reports on gene expression patterns in animal models of non-neovascular AMD with abnormal lipid metabolism such as apolipoprotein E knockout and human apolipoprotein E2 transgenic mice. Transcriptome analysis was performed using retinal pigment epithelium cells of apoE knockout and apolipoprotein E2 mice using microarray analysis. C57BL/6, Rxrb, Pparbp, Vldlr, and Edf1, which are primarily related to lipid metabolism, were upregulated, while Tgfbr1 and Pdgfb, which are related to pathologic angiogenesis in AMD, were downregulated in both types of mice. Apolipoprotein E knockout and apolipoprotein E2 mice showed characteristic gene expression patterns in the transcriptome analysis of primary retinal pigment epithelium cells. These results suggest that specific genes associated with lipid metabolism and angiogenesis are involved in the pathogenesis and progression of AMD.
C1 [Jo, D. H.; Kim, J.; Yu, Y. S.; Kim, J. H.] Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness Lab, Seoul 110744, South Korea.
   [Jo, D. H.; Kim, J. H.] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
   [Jo, D. H.; Yu, Y. S.; Kim, J. H.] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Lee, J. H.; Jun, H. J.; Wen, Q.; Hoang, M. H.; Lee, S. J.] Korea Univ, Inst Biomed Sci & Safety, Coll Life Sci & Biotechnol, Div Food Biosci & Technol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Korea
   University
RP Lee, SJ (通讯作者)，Korea Univ, Inst Biomed Sci & Safety, Coll Life Sci & Biotechnol, Div Food Biosci & Technol, Seoul, South Korea.
EM junelee@korea.ac.kr
RI Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU Bio-Signal Analysis Technology Innovation Program of MEST/NRF, Republic
   of Korea [2011-0027723]; Mid-Career Researcher Program of MEST/NRF,
   Republic of Korea [2011-0017910]; Basic Science Research Program of
   MEST/NRF, Republic of Korea [2013R1A2A2A01016176]
FX Research supported by the Bio-Signal Analysis Technology Innovation
   Program of MEST/NRF, Republic of Korea (#2011-0027723), the Mid-Career
   Researcher Program of MEST/NRF, Republic of Korea (#2011-0017910), and
   the Basic Science Research Program of MEST/NRF, Republic of Korea
   (#2013R1A2A2A01016176).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dubuquoy L, 2002, LANCET, V360, P1410, DOI 10.1016/S0140-6736(02)11395-X
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gehlbach P, 2009, COCHRANE DB SYST REV, V14
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7
   Herz J, 2006, NAT REV NEUROSCI, V7, P850, DOI 10.1038/nrn2009
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hubble J, 2009, NUCLEIC ACIDS RES, V37, pD898, DOI 10.1093/nar/gkn786
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Leidi M, 2010, EUR J CELL BIOL, V89, P654, DOI 10.1016/j.ejcb.2010.05.001
   Liu YX, 2012, BRIT J NUTR, V108, P16, DOI 10.1017/S000711451100523X
   Ludman A, 2009, PHARMACOL THERAPEUT, V122, P30, DOI 10.1016/j.pharmthera.2009.01.002
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673
   Takahashi Sadao, 2004, J Atheroscler Thromb, V11, P200
   Tolentino MJ, 2009, CURR MOL MED, V9, P973, DOI 10.2174/156652409789712783
   Yu BP, 1996, ANN NY ACAD SCI, V786, P1, DOI 10.1111/j.1749-6632.1996.tb39047.x
NR 38
TC 3
Z9 3
U1 2
U2 7
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2015
VL 14
IS 1
BP 1855
EP 1867
DI 10.4238/2015.March.13.14
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CL7ZV
UT WOS:000357192700035
PM 25867331
OA Bronze
DA 2022-11-30
ER

PT J
AU Kolomeyer, AM
   Zarbin, MA
AF Kolomeyer, Anton M.
   Zarbin, Marco A.
TI Trophic factors in the pathogenesis and therapy for retinal degenerative
   diseases
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE trophic factors; retinal degenerative diseases; age-related macular
   degeneration; retinitis pigmentosa; retinal pigment epithelium
ID FIBROBLAST-GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; CILIARY
   NEUROTROPHIC FACTOR; TRANSCORNEAL ELECTRICAL-STIMULATION; INTRAVITREAL
   BEVACIZUMAB AVASTIN; LEUKEMIA INHIBITORY FACTOR; INDUCED PHOTORECEPTOR
   DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; INTRAOCULAR GENE-TRANSFER;
   INDUCED UP-REGULATION
AB Trophic factors are endogenously secreted proteins that act in an autocrine and/or paracrine fashion to affect vital cellular processes such as proliferation, differentiation, and regeneration, thereby maintaining overall cell homeostasis. In the eye, the major contributors of these molecules are the retinal pigment epithelial (RPE) and Muller cells. The primary paracrine targets of these secreted proteins include the photoreceptors and choriocapillaris. Retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa are characterized by aberrant function and/or eventual death of RPE cells, photoreceptors, choriocapillaris, and other retinal cells. We discuss results of in vitro and in vivo animal studies in which candidate trophic factors, either singly or in combination, were used in an attempt to ameliorate photoreceptor and/or retinal degeneration. We also examine current trophic factor therapies as they relate to the treatment of retinal degenerative diseases in clinical studies. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Kolomeyer, Anton M.] Univ Pittsburgh, Med Ctr, Dept Ophthalmol, Pittsburgh, PA USA.
   [Zarbin, Marco A.] Rutgers State Univ, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ 07101 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Rutgers State University Newark; Rutgers State University
   New Brunswick; Rutgers State University Medical Center
RP Zarbin, MA (通讯作者)，Rutgers State Univ, New Jersey Med Sch, Dept Ophthalmol & Visual Sci, 90 Bergen St,DOC 6155, Newark, NJ 07101 USA.
EM zarbin@njms.rutgers.edu
OI Zarbin, Marco/0000-0002-7811-7132
CR Abe T, 2005, CELL TRANSPLANT, V14, P799, DOI 10.3727/000000005783982549
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Adamus G, 2003, J AUTOIMMUN, V21, P121, DOI 10.1016/S0896-8411(03)00092-1
   Adao-Novaes J, 2010, NEUROCHEM INT, V57, P128, DOI 10.1016/j.neuint.2010.04.021
   Agarwal N, 2002, EXP EYE RES, V74, P445, DOI 10.1006/exer.2001.1145
   Ahuja P, 2001, NEUROREPORT, V12, P2951, DOI 10.1097/00001756-200109170-00039
   Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754
   Akimoto M, 1999, INVEST OPHTH VIS SCI, V40, P273
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   Andrieu-Soler C, 2005, MOL VIS, V11
   Angulo J, 2011, EUR J PHARMACOL, V667, P153, DOI 10.1016/j.ejphar.2011.06.015
   Arroba AI, 2011, INVEST OPHTH VIS SCI, V52, P9124, DOI 10.1167/iovs.11-7736
   Arroba AI, 2009, EUR J NEUROSCI, V30, P975, DOI 10.1111/j.1460-9568.2009.06902.x
   Asai N, 2007, EXP EYE RES, V85, P346, DOI 10.1016/j.exer.2007.05.010
   Averbukh E, 1998, METABOLISM, V47, P1331, DOI 10.1016/S0026-0495(98)90300-6
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Ayalasomayajula SP, 2009, J OCUL PHARMACOL TH, V25, P97, DOI 10.1089/jop.2008.0090
   Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287
   Azadi S, 2007, BRAIN RES, V1129, P116, DOI 10.1016/j.brainres.2006.10.031
   Bai YJ, 2012, J PHARMACOL EXP THER, V342, P131, DOI 10.1124/jpet.112.192575
   BALCIUNIENE J, 1995, GENOMICS, V30, P281, DOI 10.1006/geno.1995.9876
   Barakat MR, 2009, EXPERT OPIN INV DRUG, V18, P637, DOI [10.1517/13543780902855316 , 10.1517/13543780902855316]
   BARDE YA, 1988, TRENDS NEUROSCI, V11, P343, DOI 10.1016/0166-2236(88)90055-0
   Barnstable CJ, 2006, ADV EXP MED BIOL, V572, P291
   BASSNETT S, 1990, INVEST OPHTH VIS SCI, V31, P1637
   Beltran WA, 2009, INVEST OPHTH VIS SCI, V50, P5355, DOI 10.1167/iovs.09-3741
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bespalov MM, 2007, TRENDS PHARMACOL SCI, V28, P68, DOI 10.1016/j.tips.2006.12.005
   Bilak MM, 1999, MOL CELL NEUROSCI, V13, P326, DOI 10.1006/mcne.1999.0756
   Birch DG, 2013, AM J OPHTHALMOL, V156, P283, DOI 10.1016/j.ajo.2013.03.021
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   Bravo-Nuevo A, 2004, INVEST OPHTH VIS SCI, V45, P2005, DOI 10.1167/iovs.03-0842
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200
   Buch PK, 2006, MOL THER, V14, P700, DOI 10.1016/j.ymthe.2006.05.019
   Burgi S, 2009, MOL VIS, V15, P1631
   Bugra K, 1997, J MOL NEUROSCI, V9, P13, DOI 10.1007/BF02789391
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   CAFFE AR, 1993, CURR EYE RES, V12, P719, DOI 10.3109/02713689308995767
   Caffe AR, 2001, INVEST OPHTH VIS SCI, V42, P275
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao W, 1998, INVEST OPHTH VIS SCI, V39, P565
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Carwile ME, 1998, EXP EYE RES, V66, P791, DOI 10.1006/exer.1998.0488
   Casson RJ, 2004, INVEST OPHTH VIS SCI, V45, P685, DOI 10.1167/iovs.03-0674
   Casson RJ, 2003, INVEST OPHTH VIS SCI, V44, P1348, DOI 10.1167/iovs.02-0368
   Catalani E, 2009, CELL TISSUE RES, V336, P423, DOI 10.1007/s00441-009-0787-9
   Caviness JN, 2011, CNS NEUROSCI THER, V17, P32, DOI 10.1111/j.1755-5949.2010.00216.x
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   CHAN CWC, 1991, AUST NZ J OPHTHALMOL, V19, P321, DOI 10.1111/j.1442-9071.1991.tb00680.x
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen WW, 2009, J OCUL PHARMACOL TH, V25, P315, DOI 10.1089/jop.2009.0015
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chin MS, 2006, J AUTOIMMUN, V27, P17, DOI 10.1016/j.jaut.2006.04.002
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Choi JS, 2000, BRAIN RES, V883, P60, DOI 10.1016/S0006-8993(00)02886-9
   Chollangi S, 2009, NEUROBIOL DIS, V34, P535, DOI 10.1016/j.nbd.2009.03.012
   Chong NHV, 1999, INVEST OPHTH VIS SCI, V40, P1298
   Colombo ES, 2007, INVEST OPHTH VIS SCI, V48, P1793, DOI 10.1167/iovs.06-0923
   CONNOLLY SE, 1992, CURR EYE RES, V11, P1005, DOI 10.3109/02713689209033499
   Cuevas Pedro, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr-2012-006619
   Cui Q, 2002, INVEST OPHTH VIS SCI, V43, P1954
   Dalkara D, 2011, MOL THER, V19, P1602, DOI 10.1038/mt.2011.62
   Reis RAD, 2008, NEUROCHEM RES, V33, P1466, DOI 10.1007/s11064-008-9604-1
   Del Rio P, 2011, GLIA, V59, P821, DOI 10.1002/glia.21155
   Delyfer MN, 2005, MOL VIS, V11, P677
   Demetriades AM, 2008, J OCUL PHARMACOL TH, V24, P70, DOI 10.1089/jop.2007.0061
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Do Rhee K, 2007, INVEST OPHTH VIS SCI, V48, P1389, DOI 10.1167/iovs.06-0677
   Dong A, 2007, J NEUROCHEM, V103, P1041, DOI 10.1111/j.1471-4159.2007.04839.x
   Doonan F, 2011, J NEUROCHEM, V118, P915, DOI 10.1111/j.1471-4159.2011.07354.x
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X
   Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742
   El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Farah SE, 2008, OPHTHAL SURG LAS IM, V39, P294, DOI 10.3928/15428877-20080701-05
   Fawcett RJ, 2007, BRAIN RES BULL, V73, P278, DOI 10.1016/j.brainresbull.2007.04.002
   Ferrara N, 2005, ONCOLOGY-BASEL, V69, P11, DOI 10.1159/000088479
   Fontaine V, 1998, J NEUROSCI, V18, P9662
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Frade JM, 1999, MICROSC RES TECHNIQ, V45, P243, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<243::AID-JEMT8>3.0.CO;2-S
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705
   Fuhrmann S, 1998, J COMP NEUROL, V400, P244
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gao H, 2002, ARCH OPHTHALMOL-CHIC, V120, P797
   GAO H, 1995, DEV BIOL, V169, P168, DOI 10.1006/dbio.1995.1135
   Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022
   Garcia M, 2003, HISTOL HISTOPATHOL, V18, P1205, DOI 10.14670/HH-18.1205
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Geller SF, 2001, INVEST OPHTH VIS SCI, V42, P1363
   Gettins PGW, 2002, BIOL CHEM, V383, P1677, DOI 10.1515/BC.2002.188
   Glybina IV, 2010, INVEST OPHTH VIS SCI, V51, P4243, DOI 10.1167/iovs.09-4492
   Glybina IV, 2009, INVEST OPHTH VIS SCI, V50, P4847, DOI 10.1167/iovs.08-2831
   Goliath R, 1996, Mol Vis, V2, P5
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937
   Green ES, 2001, MOL THER, V3, P507, DOI 10.1006/mthe.2001.0289
   Gregory-Evans K, 2009, MOL VIS, V15, P962
   Guerin CJ, 2001, EXP EYE RES, V73, P753, DOI 10.1006/exer.2001.1095
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Hameed A, 2000, INVEST OPHTH VIS SCI, V41, P629
   HANGAI M, 1995, INVEST OPHTH VIS SCI, V36, P571
   Harada C, 2005, INVEST OPHTH VIS SCI, V46, P669, DOI 10.1167/iovs.04-0826
   Harada C, 2003, NEUROSCIENCE, V122, P229, DOI 10.1016/S0306-4522(03)00599-2
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hauck SM, 2006, MOL CELL BIOL, V26, P2746, DOI 10.1128/MCB.26.7.2746-2757.2006
   Hauck SM, 2008, MOL CELL PROTEOMICS, V7, P1349, DOI 10.1074/mcp.M700456-MCP200
   He PM, 1998, BIOCHEM BIOPH RES CO, V249, P253, DOI 10.1006/bbrc.1998.9087
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Heidinger V, 1997, BRAIN RES, V767, P279, DOI 10.1016/S0006-8993(97)00605-7
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Hollborn M, 2006, BIOCHEM BIOPH RES CO, V344, P912, DOI 10.1016/j.bbrc.2006.03.185
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Huo SJ, 2012, CURR EYE RES, V37, P749, DOI 10.3109/02713683.2012.697972
   IKEDA T, 1995, BRAIN RES, V686, P87, DOI 10.1016/0006-8993(95)00473-4
   Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Jablonski MM, 2001, GLIA, V35, P14, DOI 10.1002/glia.1066
   Jin M, 2004, INVEST OPHTH VIS SCI, V45, P323, DOI 10.1167/iovs.03-0355
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Joly S, 2007, INVEST OPHTH VIS SCI, V48, P2311, DOI 10.1167/iovs.06-1205
   Joly S, 2008, J NEUROSCI, V28, P13765, DOI 10.1523/JNEUROSCI.5114-08.2008
   Jomary C, 2004, INVEST OPHTH VIS SCI, V45, P1240, DOI 10.1167/iovs.03-1122
   Jomary C, 1999, INVEST OPHTH VIS SCI, V40, P568
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Julien S, 2008, MOL VIS, V14, P1358
   Kano T, 2002, INVEST OPHTH VIS SCI, V43, P3744
   Keegan DJ, 2003, INVEST OPHTH VIS SCI, V44, P3526, DOI 10.1167/iovs.02-0097
   Kent TL, 2008, INVEST OPHTH VIS SCI, V49, P372, DOI 10.1167/iovs.07-0952
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Kim H, 2009, MOL VIS, V15
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kobayashi S, 2007, BIOL PHARM BULL, V30, P133, DOI 10.1248/bpb.30.133
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Koeberle PD, 2002, NEUROSCIENCE, V110, P555, DOI 10.1016/S0306-4522(01)00557-7
   Koenekoop R, 1999, MOL VIS, V5
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5963, DOI 10.1167/iovs.10-6440
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5973, DOI 10.1167/iovs.10-6965
   Kong L, 2010, NEUROBIOL DIS, V38, P446, DOI 10.1016/j.nbd.2010.03.005
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kurokawa T, 1999, INVEST OPHTH VIS SCI, V40, P3006
   Kusari J, 2010, INVEST OPHTH VIS SCI, V51, P1044, DOI 10.1167/iovs.08-3293
   Lai RK, 2002, VISUAL NEUROSCI, V19, P175, DOI 10.1017/S0952523802191152
   Lambiase A, 1996, GRAEF ARCH CLIN EXP, V234, pS96, DOI 10.1007/BF02343055
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lange C, 2011, NEUROBIOL DIS, V41, P119, DOI 10.1016/j.nbd.2010.08.028
   Lau D, 2000, INVEST OPHTH VIS SCI, V41, P3622
   Lau D, 2003, DOC OPHTHALMOL, V106, P89, DOI 10.1023/A:1022481306146
   LaVail MM, 2008, J COMP NEUROL, V511, P724, DOI 10.1002/cne.21858
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lawrence JM, 2004, INVEST OPHTH VIS SCI, V45, P267, DOI 10.1167/iovs.03-0093
   Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518
   Lee E, 2010, INVEST OPHTH VIS SCI, V51, P3666, DOI 10.1167/iovs.09-3802
   Lee KYC, 2010, MOL VIS, V16, P246
   LEM J, 1992, P NATL ACAD SCI USA, V89, P4422, DOI 10.1073/pnas.89.10.4422
   Lenzi L, 2005, VISION RES, V45, P1491, DOI 10.1016/j.visres.2004.12.020
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Li F, 2003, INVEST OPHTH VIS SCI, V44, P4968, DOI 10.1167/iovs.03-0140
   Li ZY, 1997, VISUAL NEUROSCI, V14, P671, DOI 10.1017/S0952523800012633
   Li ZY, 1997, EXP EYE RES, V65, P855, DOI 10.1006/exer.1997.0387
   Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Lin N, 1997, EXP EYE RES, V64, P239, DOI 10.1006/exer.1996.0208
   Lipinski DM, 2011, INVEST OPHTH VIS SCI, V52, P7340, DOI 10.1167/iovs.11-7996
   LIPTON SA, 1989, ARCH NEUROL-CHICAGO, V46, P1241, DOI 10.1001/archneur.1989.00520470113038
   Liu CD, 1998, J NEUROSCI, V18, P1337
   Llamosas MM, 1997, ANAT EMBRYOL, V195, P337, DOI 10.1007/s004290050053
   Lofqvist C, 2007, P NATL ACAD SCI USA, V104, P10589, DOI 10.1073/pnas.0702031104
   Lofqvist C, 2009, INVEST OPHTH VIS SCI, V50, P1831, DOI 10.1167/iovs.08-2903
   Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706
   Lonngren U, 2006, BRAIN RES BULL, V71, P208, DOI 10.1016/j.brainresbull.2006.09.005
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x
   LUTTY G, 1991, CURR EYE RES, V10, P61, DOI 10.3109/02713689109007611
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Lykissas MG, 2007, CURR NEUROVASC RES, V4, P143, DOI 10.2174/156720207780637216
   Machida S, 2004, INVEST OPHTH VIS SCI, V45, P4174, DOI 10.1167/iovs.04-0455
   Machida S, 2001, INVEST OPHTH VIS SCI, V42, P1087
   Magnussen AL, 2010, INVEST OPHTH VIS SCI, V51, P4273, DOI 10.1167/iovs.09-4296
   Mahtabifard A, 2003, J THORAC CARDIOV SUR, V126, P28, DOI 10.1016/S0022-5223(02)73616-7
   MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MASCARELLI F, 1991, ANN ENDOCRINOL-PARIS, V52, P441
   MASUDA K, 1995, INVEST OPHTH VIS SCI, V36, P2142
   Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591
   MATSUO T, 1992, OPHTHALMIC RES, V24, P213, DOI 10.1159/000267170
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P5756, DOI 10.1167/iovs.07-0054
   McLaren MJ, 1997, FEBS LETT, V412, P21, DOI 10.1016/S0014-5793(97)00566-8
   McLaren MJ, 1996, FEBS LETT, V387, P63, DOI 10.1016/0014-5793(96)00461-9
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Merritt RE, 2004, ANN THORAC SURG, V78, P1042, DOI 10.1016/j.athoracsur.2004.03.021
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5
   Miura Y, 2003, JPN J OPHTHALMOL, V47, P268, DOI 10.1016/S0021-5155(03)00003-0
   Miyamura N, 2001, INVEST OPHTH VIS SCI, V42, P1626
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Miyazaki M, 2008, J GENE MED, V10, P1273, DOI 10.1002/jgm.1257
   Mocko JA, 2011, INVEST OPHTH VIS SCI, V52, P4223, DOI 10.1167/iovs.10-6750
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Morimoto T, 2007, INVEST OPHTH VIS SCI, V48, P4725, DOI 10.1167/iovs.06-1404
   Morimoto T, 2012, INVEST OPHTH VIS SCI, V53, P4254, DOI 10.1167/iovs.11-9067
   Murakami Y, 2008, AM J PATHOL, V173, P1326, DOI 10.2353/ajpath.2008.080466
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Nag TC, 1999, DEV BRAIN RES, V117, P179, DOI 10.1016/S0165-3806(99)00121-2
   Nakamura K, 2005, MOL VIS, V11, P1229
   Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P1168
   Nakazawa T, 2002, J NEUROSCI RES, V68, P668, DOI 10.1002/jnr.10259
   Nakazawa T, 2006, MOL VIS, V12, P867
   Neuner-Jehle M, 2000, HUM GENE THER, V11, P1875, DOI 10.1089/10430340050129495
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Ni YQ, 2008, INVEST OPHTH VIS SCI, V49, P2589, DOI 10.1167/iovs.07-1173
   Ni YQ, 2009, EXP NEUROL, V219, P439, DOI 10.1016/j.expneurol.2009.06.016
   Nir I, 1999, INVEST OPHTH VIS SCI, V40, P2383
   Nir I, 2001, INVEST OPHTH VIS SCI, V42, P842
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Driscoll C, 2008, J NEUROCHEM, V105, P524, DOI 10.1111/j.1471-4159.2007.05189.x
   OCRANT I, 1989, ENDOCRINOLOGY, V125, P2407, DOI 10.1210/endo-125-5-2407
   Ogata N, 2004, AM J OPHTHALMOL, V137, P1129, DOI 10.1016/j.ajo.2003.11.080
   Ogata N, 2001, CURR EYE RES, V22, P245, DOI 10.1076/ceyr.22.4.245.5506
   Ogilvie JM, 2000, EXP NEUROL, V161, P676, DOI 10.1006/exnr.1999.7291
   Ohnaka M, 2012, J NEUROCHEM, V122, P1047, DOI 10.1111/j.1471-4159.2012.07842.x
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Ohtaka K, 2006, CURR EYE RES, V31, P347, DOI 10.1080/02713680600629797
   Okamoto N, 1997, AM J PATHOL, V151, P281
   OKAZAWA H, 1994, ONCOGENE, V9, P1813
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Ozaki S, 2000, INVEST OPHTH VIS SCI, V41, P568
   Ozeki N, 2013, GRAEF ARCH CLIN EXP, V251, P1867, DOI 10.1007/s00417-013-2341-4
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Paskowitz DM, 2007, INVEST OPHTH VIS SCI, V48, P430, DOI 10.1167/iovs.06-0690
   Paskowitz DM, 2004, INVEST OPHTH VIS SCI, V45, P4190, DOI 10.1167/iovs.04-0676
   PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489
   Peng KY, 2011, METABOLISM, V60, P888, DOI 10.1016/j.metabol.2010.08.009
   Perez-Santonja JJ, 2010, AM J OPHTHALMOL, V150, P519, DOI 10.1016/j.ajo.2010.04.024
   PERRY J, 1995, CURR EYE RES, V14, P585, DOI 10.3109/02713689508998406
   Peterson WM, 2000, J NEUROSCI, V20, P4081
   Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809
   RAKOCZY PE, 1993, INVEST OPHTH VIS SCI, V34, P1845
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Raz-Prag D, 2009, INVEST OPHTH VIS SCI, V50, P3897, DOI 10.1167/iovs.08-3153
   Read SP, 2010, MOL THER, V18, P1917, DOI 10.1038/mt.2010.167
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Reh TA, 1996, CIBA F SYMP, V196, P120
   Reich S, 2003, MOL VIS, V9, P210
   Rhee KD, 2004, J NEUROSCI, V24, P9779, DOI 10.1523/JNEUROSCI.1785-04.2004
   Ribatti D, 2011, INT J DEV BIOL, V55, P261, DOI 10.1387/ijdb.103167dr
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rodriguez-de la Rosa L, 2012, NEUROBIOL DIS, V46, P476, DOI 10.1016/j.nbd.2012.02.013
   Rohrer B, 1999, J NEUROSCI, V19, P8919, DOI 10.1523/JNEUROSCI.19-20-08919.1999
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Rudzinski M, 2004, J NEUROBIOL, V58, P341, DOI 10.1002/neu.10293
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Saarma M, 1999, MICROSC RES TECHNIQ, V45, P292, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.3.CO;2-#
   SAGAR SM, 1991, J NEUROSCI RES, V29, P549, DOI 10.1002/jnr.490290416
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Saito T, 2009, CURR EYE RES, V34, P580, DOI 10.1080/02713680902972358
   Sakai T, 2007, INVEST OPHTH VIS SCI, V48, P3381, DOI 10.1167/iovs.06-1242
   Salom D, 2010, INVEST OPHTH VIS SCI, V51, P3157, DOI 10.1167/iovs.09-4390
   Samardzija M, 2012, EXP EYE RES, V99, P17, DOI 10.1016/j.exer.2012.04.004
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Sato M, 2003, BIOCHEM BIOPH RES CO, V306, P826, DOI 10.1016/S0006-291X(03)01092-1
   Savchenko A, 2001, P NATL ACAD SCI USA, V98, P5880, DOI 10.1073/pnas.101524998
   Schallenberg M, 2012, GRAEF ARCH CLIN EXP, V250, P699, DOI 10.1007/s00417-012-1932-9
   Schatz A, 2012, INVEST OPHTH VIS SCI, V53, P5552, DOI 10.1167/iovs.12-10037
   Schatz A, 2011, INVEST OPHTH VIS SCI, V52, P4485, DOI 10.1167/iovs.10-6932
   Schlichtenbrede FC, 2003, GENE THER, V10, P523, DOI 10.1038/sj.gt.3301929
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seigel G, 2000, MOL VIS, V6, P157
   Seigel GM, 2006, J DIABETES COMPLICAT, V20, P196, DOI 10.1016/j.jdiacomp.2005.06.007
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shen JY, 2012, P NATL ACAD SCI USA, V109, P3540, DOI 10.1073/pnas.1119201109
   Shibuki H, 2002, INVEST OPHTH VIS SCI, V43, P528
   Shimoke K, 2004, J BIOCHEM, V135, P439, DOI 10.1093/jb/mvh053
   Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2
   Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Siffroi-Fernandez S, 2008, INVEST OPHTH VIS SCI, V49, P1696, DOI 10.1167/iovs.07-1272
   SILVERMAN MS, 1990, CURR EYE RES, V9, P183, DOI 10.3109/02713689008995205
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Smith SB, 1996, EXP EYE RES, V63, P565, DOI 10.1006/exer.1996.0147
   SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spencer B, 2001, MOL THER, V3, P746, DOI 10.1006/mthe.2001.0307
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spraul CW, 2002, GRAEF ARCH CLIN EXP, V240, P227, DOI 10.1007/s00417-002-0441-7
   Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streichert LC, 1999, J NEUROBIOL, V39, P475, DOI 10.1002/(SICI)1097-4695(19990615)39:4<475::AID-NEU2>3.0.CO;2-#
   Subramanian P, 2010, ADV EXP MED BIOL, V664, P29, DOI 10.1007/978-1-4419-1399-9_4
   Sun W, 1999, BRAIN RES, V851, P46, DOI 10.1016/S0006-8993(99)02097-1
   Sun XD, 2008, OPHTHALMOLOGICA, V222, P58, DOI 10.1159/000109281
   Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416
   Takahata K, 2003, INVEST OPHTH VIS SCI, V44, P1760, DOI 10.1167/iovs.02-0471
   Takano Y, 2004, BIOCHEM BIOPH RES CO, V313, P1015, DOI 10.1016/j.bbrc.2003.12.034
   Takano Y, 2003, CURR EYE RES, V27, P95, DOI 10.1076/ceyr.27.2.95.15953
   Takeuchi K, 2008, EXP EYE RES, V86, P60, DOI 10.1016/j.exer.2007.09.008
   Takita H, 2003, INVEST OPHTH VIS SCI, V44, P4497, DOI 10.1167/iovs.03-0052
   Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873
   Talcott KE, 2011, INVEST OPHTH VIS SCI, V52, P2219, DOI 10.1167/iovs.10-6479
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Teuchner B, 2011, ACTA OPHTHALMOL, V89, P670, DOI 10.1111/j.1755-3768.2009.01828.x
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Touchard E, 2012, GENE THER, V19, P886, DOI 10.1038/gt.2011.154
   Traverso V, 2003, INVEST OPHTH VIS SCI, V44, P4550, DOI 10.1167/iovs.03-0460
   Ueki Y, 2008, J NEUROCHEM, V105, P784, DOI 10.1111/j.1471-4159.2007.05180.x
   Ueki Y, 2010, ADV EXP MED BIOL, V664, P655, DOI 10.1007/978-1-4419-1399-9_75
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907
   Uteza Y, 1999, P NATL ACAD SCI USA, V96, P3126, DOI 10.1073/pnas.96.6.3126
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Valter K, 2003, BRAIN RES, V985, P169, DOI 10.1016/S0006-8993(03)03130-5
   Vidal-Sanz M, 2001, EUR J OPHTHALMOL, V11, pS36, DOI 10.5301/EJO.2008.4056
   Vidal-Sanz M, 2001, SURV OPHTHALMOL, V45, pS261, DOI 10.1016/S0039-6257(01)00205-3
   Virdee K, 1996, J NEUROCHEM, V67, P1801
   von Bartheld CS, 1998, HISTOL HISTOPATHOL, V13, P437, DOI 10.14670/HH-13.437
   Wahlin KJ, 2001, EXP EYE RES, V73, P693, DOI 10.1006/exer.2001.1078
   WALDBILLIG RJ, 1988, EXP EYE RES, V47, P587, DOI 10.1016/0014-4835(88)90097-8
   Walicke P.A, 1988, PROGR BRAIN RES, V78, P333
   Walsh N, 2004, BRAIN RES, V1013, P194, DOI 10.1016/j.brainres.2004.04.030
   Wang L, 2003, MOL THER, V8, P72, DOI 10.1016/S1525-0016(03)00128-X
   Wang R, 2008, BRAIN RES, V1210, P84, DOI 10.1016/j.brainres.2008.01.104
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Wen R, 1996, J NEUROSCI, V16, P5986
   WEN R, 1995, J NEUROSCI, V15, P7377
   Wen R, 1998, CURR EYE RES, V17, P494, DOI 10.1076/ceyr.17.5.494.5186
   West EL, 2012, CELL TRANSPLANT, V21, P871, DOI 10.3727/096368911X623871
   Wexler EM, 1998, VISUAL NEUROSCI, V15, P211, DOI 10.1017/S095252389815201X
   Wheeler L, 2003, SURV OPHTHALMOL, V48, pS47, DOI 10.1016/S0039-6257(03)00004-3
   Willmann G, 2011, INVEST OPHTH VIS SCI, V52, P7529, DOI 10.1167/iovs.11-7838
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
   Wu WC, 2002, INVEST OPHTH VIS SCI, V43, P3480
   Xiao M, 1999, BRIT J OPHTHALMOL, V83, P728, DOI 10.1136/bjo.83.6.728
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu Y, 2010, MOL VIS, V16, P1982
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Yamada H, 1999, J CELL PHYSIOL, V179, P149, DOI 10.1002/(SICI)1097-4652(199905)179:2<149::AID-JCP5>3.3.CO;2-U
   Yamagishi S, 2005, MICROVASC RES, V69, P128, DOI 10.1016/j.mvr.2005.04.001
   Yamazaki H, 2002, INVEST OPHTH VIS SCI, V43, P919
   Yan Q, 1999, J NEUROBIOL, V38, P382, DOI 10.1002/(SICI)1097-4695(19990215)38:3<382::AID-NEU7>3.0.CO;2-5
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Yang PB, 2010, EXP EYE RES, V91, P727, DOI 10.1016/j.exer.2010.08.022
   Yang XM, 2012, J NEUROSCI RES, V90, P257, DOI 10.1002/jnr.22732
   Yi XJ, 2005, J NEUROSCI, V25, P1240, DOI 10.1523/JNEUROSCI.3664-04.2005
   Yoles E, 2001, J NEUROTRAUM, V18, P339, DOI 10.1089/08977150151071017
   Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000
   Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845
   YUE BYJT, 1985, ARCH OPHTHALMOL-CHIC, V103, P1563
   ZAPF J, 1986, HORM RES, V24, P121, DOI 10.1159/000180551
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin Marco, 2007, Optom Vis Sci, V84, P559, DOI 10.1097/OPX.0b013e3180de4dd7
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zeiss CJ, 2006, EXP EYE RES, V82, P395, DOI 10.1016/j.exer.2005.07.014
   Zhang CR, 2011, GRAEF ARCH CLIN EXP, V249, P1493, DOI 10.1007/s00417-011-1709-6
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao Shi-hong, 2004, Zhonghua Yan Ke Za Zhi, V40, P522
   Zhou WT, 2012, EXP NEUROL, V238, P192, DOI 10.1016/j.expneurol.2012.08.029
   ZICK Y, 1987, J BIOL CHEM, V262, P10259
NR 399
TC 67
Z9 81
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2014
VL 59
IS 2
BP 134
EP 165
DI 10.1016/j.survophthal.2013.09.004
PG 32
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB9UV
UT WOS:000332142100002
PM 24417953
DA 2022-11-30
ER

PT J
AU Cho, YC
   Cheng, JH
   Hsu, SL
   Hong, SE
   Lee, TM
   Chang, CMJ
AF Cho, Yueh-Cheng
   Cheng, Jia-Hui
   Hsu, Shih-Lan
   Hong, Siang-En
   Lee, Tse-Min
   Chang, Chieh-Ming J.
TI Supercritical carbon dioxide anti-solvent precipitation of
   anti-oxidative zeaxanthin highly recovered by elution chromatography
   from Nannochloropsis oculata
SO SEPARATION AND PURIFICATION TECHNOLOGY
LA English
DT Article
DE Nannochloropsis oculata; Zeaxanthin; Column fractionation; Supercritical
   anti-solvent precipitation
ID ANTISOLVENT PRECIPITATION; BETA-CAROTENE; MICRONIZATION; EXTRACTION;
   LYCOPENE
AB Zeaxanthin, a kind of xanthophylls, rich in Marigold flowers and a few micro algae, acts as a strong antioxidant capable of protecting human eye-sight from age-related macular degeneration. This study examined elution chromatography coupled with supercritical anti-solvent precipitation applied for generation of zeaxanthin-rich particulates from micro-algal Nannochloropsis oculata species. Crude of the ultrasonic acetone extract subjected to the column fractionation successfully yields a fraction containing 303.02 mg/g (30%) of zeaxanthin with recovery of 90%. Supercritical anti-solvent precipitation of the algal solution at 200 bar and 313K was used in producing submicron-sized particulates of 50% zeaxanthin. These extracts were subjected to tests of antioxidant capacities in 2,2-diphenyl-2-picrylhydrazyl hydrate free-radical assay and human adult retinal pigment epithelium-19 cells. This work provided a fast and environmental benign process to generate anti-oxidative capable algal micronized powders from the N. oculata. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Cho, Yueh-Cheng; Cheng, Jia-Hui; Hong, Siang-En; Chang, Chieh-Ming J.] Natl Chung Hsing Univ, Dept Chem Engn, Taichung 402, Taiwan.
   [Lee, Tse-Min] Natl Sun Yat Sen Univ, Inst Marine Biol, Kaohsiung 80424, Taiwan.
   [Hsu, Shih-Lan] Taichung Vet Gen Hosp, Educ & Res Dept, Taichung, Taiwan.
C3 National Chung Hsing University; National Sun Yat Sen University;
   Taichung Veterans General Hospital
RP Chang, CMJ (通讯作者)，Natl Chung Hsing Univ, Dept Chem Engn, 250 Kuo Kuang Rd, Taichung 402, Taiwan.
EM cmchang@dragon.nchu.edu.tw
RI Lee, Tse-Min/AAD-7660-2020
OI Lee, Tse-Min/0000-0002-0892-4211
FU National Science Council of the Republic of China, Taiwan
   [NSC98-2221-E005-053-MY3]; Taichung Veterans General Hospital; National
   Chung Hsing University, Taiwan [TCVGH-NCHU 977603]; Ministry of
   Education, Taiwan, ROC
FX The authors would like to thank the National Science Council of the
   Republic of China, Taiwan for financially supporting this research
   (NSC98-2221-E005-053-MY3), and the Taichung Veterans General Hospital
   and National Chung Hsing University, Taiwan under Contract No.
   TCVGH-NCHU 977603. This work is also supported in part by the Ministry
   of Education, Taiwan, ROC under the ATU plan.
CR CHANG CJ, 1989, AICHE J, V35, P1876, DOI 10.1002/aic.690351114
   Chen CH, 2011, J TAIWAN INST CHEM E, V42, P124, DOI 10.1016/j.jtice.2010.04.011
   Chen KX, 2005, POWDER TECHNOL, V152, P127, DOI 10.1016/j.powtec.2005.01.009
   Chen PY, 2011, J TAIWAN INST CHEM E, V42, P598, DOI 10.1016/j.jtice.2010.11.011
   Cocero MJ, 2002, J SUPERCRIT FLUID, V22, P237, DOI 10.1016/S0896-8446(01)00125-5
   Fages J, 2004, POWDER TECHNOL, V141, P219, DOI 10.1016/j.powtec.2004.02.007
   He WZ, 2006, IND ENG CHEM RES, V45, P2108, DOI 10.1021/ie050993f
   Herrero M, 2006, FOOD CHEM, V98, P136, DOI 10.1016/j.foodchem.2005.05.058
   Houndonougbo Y, 2007, MOL SIMULAT, V33, P861, DOI 10.1080/08927020701310923
   Kao L, 2007, J SUPERCRIT FLUID, V43, P276, DOI 10.1016/j.supflu.2007.06.007
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Martin A, 2008, ADV DRUG DELIVER REV, V60, P339, DOI 10.1016/j.addr.2007.06.019
   Miguel F, 2006, J SUPERCRIT FLUID, V36, P225, DOI 10.1016/j.supflu.2005.06.009
   Rantakyla M, 2002, J SUPERCRIT FLUID, V24, P251, DOI 10.1016/S0896-8446(02)00034-7
   Reverchon E, 2003, IND ENG CHEM RES, V42, P6406, DOI 10.1021/ie0302138
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shen CT, 2011, J SUPERCRIT FLUID, V55, P955, DOI 10.1016/j.supflu.2010.10.003
   Cardoso MAT, 2009, J CHEM TECHNOL BIOT, V84, P215, DOI 10.1002/jctb.2027
   Topal U, 2006, J AGR FOOD CHEM, V54, P5604, DOI 10.1021/jf0606407
   Wu JJ, 2009, SEP PURIF TECHNOL, V70, P190, DOI 10.1016/j.seppur.2009.09.015
NR 21
TC 18
Z9 18
U1 1
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1383-5866
EI 1873-3794
J9 SEP PURIF TECHNOL
JI Sep. Purif. Technol.
PD APR 29
PY 2011
VL 78
IS 3
BP 274
EP 280
DI 10.1016/j.seppur.2011.02.017
PG 7
WC Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 765IS
UT WOS:000290699500004
DA 2022-11-30
ER

PT J
AU Colella, P
   Auricchio, A
AF Colella, Pasqualina
   Auricchio, Alberto
TI AAV-Mediated Gene Supply for Treatment of Degenerative and Neovascular
   Retinal Diseases
SO CURRENT GENE THERAPY
LA English
DT Review
DE AAV; apoptosis; gene therapy; neurotrophic factors; photoreceptors;
   retina; retinal degeneration; retinal neovascularization
ID EPITHELIUM-DERIVED FACTOR; CILIARY NEUROTROPHIC FACTOR; LEBER CONGENITAL
   AMAUROSIS; PHOTORECEPTOR CELL-DEATH; OCULAR NEOVASCULARIZATION; TRANSFER
   PROTECTS; ANIMAL-MODELS; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; GANGLION-CELLS
AB Common blinding diseases that are currently untreatable include conditions characterized by progressive neuronal degeneration, such as retinitis pigmentosa, Leber congenital amaurosis or glaucoma, and characterized by ocular neovascularization, like wet age-related macular degeneration, proliferative diabetic retinopathy and retinopathy of prematurity. The pathogenic mechanisms underlying either neuronal degeneration or new vessel formation may be similar and independent of the mutation underlying the disease, thus allowing to test therapeutic strategies acting downstream of the primary causative event. Gene supply is the delivery of a gene that can prevent or arrest disease progression without being directly implicated in the disease pathogenesis. To this end, one of the most efficient and safe retinal gene delivery vehicles derives from the small adeno-associated virus (AAV). We review studies on AAV-mediated gene supply of: neurotrophic/antiapoptotic factors to prevent retinal neurons degeneration, and anti-angiogenic molecules to inhibit retinal neovascularization. Successful gene supply may represent a one-fit-all treatment for inherited and acquired blinding diseases.
C1 [Colella, Pasqualina; Auricchio, Alberto] Telethon Inst Genet & Med TIGEM, Naples, Italy.
   [Colella, Pasqualina] Open Univ, Milton Keynes MK7 6AA, Bucks, England.
   [Auricchio, Alberto] Univ Naples Federico II, Dept Pediat, Telethon Inst Genet & Med TIGEM & Med Genet, Naples, Italy.
C3 Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM);
   Open University - UK; Fondazione Telethon; Telethon Institute of
   Genetics & Medicine (TIGEM); University of Naples Federico II
RP Auricchio, A (通讯作者)，Univ Naples Federico II, Dept Pediat, Telethon Inst Genet & Med TIGEM & Med Genet, Naples, Italy.
EM auricchio@tigem.it
RI AURICCHIO, Alberto/AHE-7979-2022; COLELLA, PASQUALINA/I-5478-2017
OI AURICCHIO, Alberto/0000-0002-0832-2472; COLELLA,
   PASQUALINA/0000-0002-4268-2391
FU European Union [FP7-223445]; Fondazione Telethon Funding Source: Custom
FX We thank Graciana Diez-Roux and Luciana Borrelli for the critical
   reading of the manuscript and Simona Fecarotta for providing the artwork
   for Fig. (1). We acknowledge funding from the European Union grant
   AAVEYE (FP7-223445).
CR Abraham NG, 2007, CURR GENE THER, V7, P89, DOI 10.2174/156652307780363134
   Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Allocca M, 2007, INVEST OPHTH VIS SCI, V48, P5199, DOI 10.1167/iovs.07-0140
   Allocca M, 2006, EXPERT OPIN BIOL TH, V6, P1279, DOI 10.1517/14712598.6.12.1279
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Atlasz T, 2009, ANN NY ACAD SCI, V1163, P348, DOI 10.1111/j.1749-6632.2008.03650.x
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   Buch PK, 2007, CURR GENE THER, V7, P434, DOI 10.2174/156652307782793531
   Buch PK, 2006, MOL THER, V14, P700, DOI 10.1016/j.ymthe.2006.05.019
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2007, J CELL PHYSIOL, V210, P575, DOI 10.1002/jcp.20893
   Chen B, 2009, SCIENCE, V323, P256, DOI 10.1126/science.1166226
   Cheng HC, 2007, MOL VIS, V13, P2344
   Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002
   Chong N, 1999, INVEST OPHTH VIS SCI, V40, pS717
   Chung H, 2009, J NEUROSCI RES, V87, P2365, DOI 10.1002/jnr.22046
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Cideciyan AV, 2009, NEW ENGL J MED, V361, P725, DOI 10.1056/NEJMc0903652
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Colella P, 2009, TRENDS MOL MED, V15, P23, DOI 10.1016/j.molmed.2008.11.003
   Corrochano S, 2008, INVEST OPHTH VIS SCI, V49, P4188, DOI 10.1167/iovs.08-2182
   Cronin T, 2007, CURR GENE THER, V7, P121, DOI 10.2174/156652307780363143
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Dougherty CJ, 2008, MOL VIS, V14, P471
   Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072
   Green ES, 2001, MOL THER, V3, P507, DOI 10.1006/mthe.2001.0289
   Hamel CP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-7
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hauck SM, 2006, MOL CELL BIOL, V26, P2746, DOI 10.1128/MCB.26.7.2746-2757.2006
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hojo M, 2004, INVEST OPHTH VIS SCI, V45, P3721, DOI 10.1167/iovs.04-0059
   Ivanova E, 2009, MOL VIS, V15, P1680
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kyhn MV, 2009, EXP EYE RES, V89, P1012, DOI 10.1016/j.exer.2009.08.014
   Lai C, 2001, INVEST OPHTH VIS SCI, V42, pS346
   Lai CC, 2005, OPHTHALMIC RES, V37, P50, DOI 10.1159/000083040
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lau D, 2000, INVEST OPHTH VIS SCI, V41, P3622
   Lau D, 2003, DOC OPHTHALMOL, V106, P89, DOI 10.1023/A:1022481306146
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Liu XY, 2009, SURV OPHTHALMOL, V54, P472, DOI 10.1016/j.survophthal.2009.04.003
   Machida S, 2004, INVEST OPHTH VIS SCI, V45, pU579
   MacLaren RE, 2006, EXP EYE RES, V83, P1118, DOI 10.1016/j.exer.2006.05.019
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Malik JMI, 2005, MOL THER, V11, P373, DOI 10.1016/j.ymthe.2004.11.014
   Marigo V, 2007, CELL CYCLE, V6, P652, DOI 10.4161/cc.6.6.4029
   Martin KR, 2003, INVEST OPHTH VIS SCI, V44, pU295
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P5756, DOI 10.1167/iovs.07-0054
   McKinnon SJ, 2002, MOL THER, V5, P780, DOI 10.1006/mthe.2002.0608
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Parrilla-Reverter G, 2009, EXP EYE RES, V89, P32, DOI 10.1016/j.exer.2009.02.015
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Raz-Prag D, 2009, INVEST OPHTH VIS SCI, V50, P3897, DOI 10.1167/iovs.08-3153
   Renwick J, 2006, GENE THER, V13, P339, DOI 10.1038/sj.gt.3302683
   Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   SAPIEHA P, INT J BIOCH CELL BIO, V42, P5
   Sapieha PS, 2006, J NEUROSCI RES, V83, P985, DOI 10.1002/jnr.20803
   Schlichtenbrede FC, 2003, GENE THER, V10, P523, DOI 10.1038/sj.gt.3301929
   Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1
   Shyong MP, 2007, MOL VIS, V13, P133
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Sima Jing, 2006, Yan Ke Xue Bao, V22, P252
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027
   Stieger K, 2009, ADV DRUG DELIVER REV, V61, P527, DOI 10.1016/j.addr.2008.12.016
   Sun MH, 2007, INVEST OPHTH VIS SCI, V48, P5699, DOI 10.1167/iovs.07-0340
   Surace EM, 2008, VISION RES, V48, P353, DOI 10.1016/j.visres.2007.07.027
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tomita H, 2007, INVEST OPHTH VIS SCI, V48, P3821, DOI 10.1167/iovs.06-1501
   Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Wen R, 2006, J NEUROSCI, V26, P13523, DOI 10.1523/JNEUROSCI.4021-06.2006
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wong WT, 2004, MOL VIS, V10, P837
   Wu WC, 2004, MOL VIS, V10, P93
   Wu WC, 2002, INVEST OPHTH VIS SCI, V43, P3480
   Yang Y, 2009, MOL THER, V17, P787, DOI 10.1038/mt.2009.28
   Yokoi K, 2007, MOL THER, V15, P1917, DOI 10.1038/sj.mt.6300280
   Zhou XH, 2009, MOL VIS, V15, P438
NR 100
TC 18
Z9 20
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5232
EI 1875-5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PD OCT
PY 2010
VL 10
IS 5
BP 371
EP 380
DI 10.2174/156652310793180670
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 685SA
UT WOS:000284647200005
PM 20712580
DA 2022-11-30
ER

PT J
AU Boon, CJE
   Klevering, BJ
   Hoyng, CB
   Zonneveld-Vrieling, MN
   Nabuurs, SB
   Blokland, E
   Cremers, FPM
   den Hollander, AI
AF Boon, Camiel J. E.
   Klevering, B. Jeroen
   Hoyng, Carel B.
   Zonneveld-Vrieling, Marijke N.
   Nabuurs, Sander B.
   Blokland, Ellen
   Cremers, Frans P. M.
   den Hollander, Anneke I.
TI Basal laminar drusen caused by compound heterozygous variants in the CFH
   gene
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE;
   MACULAR DEGENERATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; Y402H
   POLYMORPHISM; MUTATIONS; COMMON; RISK; UPDATE
AB Age-related macular degeneration (AMD) is a multifactorial disease that is strongly associated with the Tyr402His variant in the complement factor H (CFH) gene. Drusen are hallmark lesions of AMD and consist of focal-inflammatory and/or immune-mediated depositions of extracellular material at the interface of the retinal pigment epithelium (RPE) and the Bruch membrane. We evaluated the role of CFH in 30 probands with early-onset drusen and identified heterozygous nonsense, missense, and splice variants in five families. The affected individuals all carried the Tyr402His AMD risk variant on the other allele. This supports an autosomal-recessive disease model in which individuals who carry a CFH mutation on one allele and the Tyr402His variant on the other allele develop drusen. Our findings strongly suggest that monogenic inheritance of CFH variants can result in basal laminar drusen in young adults, and this can progress to maculopathy and severe vision loss later in life.
C1 [Zonneveld-Vrieling, Marijke N.; Blokland, Ellen; Cremers, Frans P. M.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen Ctr Mol Life Sci, NL-6525 GA Nijmegen, Netherlands.
   [Boon, Camiel J. E.; Klevering, B. Jeroen; Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
   [Nabuurs, Sander B.] Radboud Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6525 GA Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen Ctr Mol Life Sci, NL-6525 GA Nijmegen, Netherlands.
EM a.denhollander@antrg.umcn.nl
RI Hollander, Anneke den/N-4911-2014; Boon, Camiel/P-7534-2014; Klevering,
   B.J./L-4434-2015; Hoyng, C.B./H-8050-2014; Cremers, Frans/A-5625-2014
OI Boon, Camiel/0000-0002-6737-7932; Cremers, Frans/0000-0002-4954-5592
CR Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   LEYS A, 1991, PEDIATR NEPHROL, V5, P189, DOI 10.1007/BF01095950
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   ORMSBY RJ, 2007, MOL IMMUNOL, V44, P224
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Scholl HPN, 2007, MOL VIS, V13, P196
   Sidransky E, 2006, CLIN GENET, V70, P275, DOI 10.1111/j.1399-0004.2006.00688.x
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
NR 25
TC 77
Z9 80
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD FEB
PY 2008
VL 82
IS 2
BP 516
EP 523
DI 10.1016/j.ajhg.2007.11.007
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 263NN
UT WOS:000253223900024
PM 18252232
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Kreissig, I
   Spandau, UH
   Harder, B
AF Jonas, JB
   Kreissig, I
   Spandau, UH
   Harder, B
TI Infectious and noninfectious endophthalmitis after intravitreal
   high-dosage triamcinolone acetonide
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To evaluate the rate of infectious and noninfectious endophthalmitis after intravitreal injection of a high-dosage of triamcinolone acetonide.
   DESIGN: Clinical interventional case,series study. METHODS: The study included 1135 intravitreal injections of approximately 20 mg triamcinolone performed for 915 eyes with diabetic macular edema (n = 257), exudative age-related macular degeneration (n = 561), retinal vein occlusions (n = 82), and other reasons. Among the injections were 220 reinjections. Triamcinolone was filtered to remove the solvent agent. Mean follow-up was 8.1 +/- 7.4 months.
   RESULTS: In none of the eyes, signs of an infectious or noninfectious endophthalmitis were observed such as noncrystalline hypopyon, cellular infiltration, or amorphous opacification of the vitreous, retinal infiltration, or pain. One patient developed infectious endophthalmitis 2 days after a traumatic rupture of a previous corneoscleral cataract incision.
   CONCLUSIONS: The rate of infectious or noninfectious endophthalmitis after an intravitreal high dosage triamcinolone injection may be approximately 1:1000, if the solvent agent was removed.
C1 Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@augen.ma.uni-heidelberg.de
CR Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Parke DW, 2003, AM J OPHTHALMOL, V136, P918, DOI 10.1016/j.ajo.2003.08.051
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Westfall AC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1075, DOI 10.1001/archopht.123.8.1075
NR 7
TC 61
Z9 62
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2006
VL 141
IS 3
BP 579
EP 580
DI 10.1016/j.ajo.2005.10.007
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 022LS
UT WOS:000236057900031
PM 16490517
DA 2022-11-30
ER

PT J
AU Hariprasad, SM
   Shah, GK
   Blinder, KJ
AF Hariprasad, SM
   Shah, GK
   Blinder, KJ
TI Short-term intraocular pressure trends following intravitreal Pegaptanib
   (Macugen) injection
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TRIAMCINOLONE
AB PURPOSE: To report the changes and trends in intraocular pressures (IOP) following intravitreal injection of Pegaptanib (Macugen) for the treatment of exudative age, related macular degeneration.
   DESIGN: Retrospective chart review.
   METHODS: Review of 79 patients who underwent 122 consecutive Pegaptanib injections. Analysis of the short, term effect of Pegaptanib injections on IOP was performed.
   RESULTS: Baseline mean IOP was 15.73 +/- 3.41 mm Hg (mean +/- standard deviation) with a range of 9 to 27 mm Hg. Postinjection mean IOP was 24.47 +/- 6.29 mm Hg with a range of 8 to 36 mm Hg. Mean IOP change from baseline to roughly 30 minutes after Pegaptanib injection was 8.74 +/- 7.23 trim Hg. At the 5- to 7,day follow-up visit, IOP had normalized.
   CONCLUSIONS: Pegaptanib injection in this limited series seems to be safe from an IOP standpoint in the short-term. IOP monitoring postinjection may not be necessary.
C1 Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Barnes Retina Inst, St Louis, MO 63144 USA.
   Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 Washington University (WUSTL); University of Chicago
RP Shah, GK (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Barnes Retina Inst, 1600 S Brentwood Blvd,8th Floor, St Louis, MO 63144 USA.
EM gkshah@sbcglobal.net
CR Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Singh IP, 2004, AM J OPHTHALMOL, V138, P286, DOI 10.1016/j.ajo.2004.03.001
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 5
TC 40
Z9 43
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2006
VL 141
IS 1
BP 200
EP 201
DI 10.1016/j.ajo.2005.07.053
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000FQ
UT WOS:000234446700035
PM 16387003
DA 2022-11-30
ER

PT J
AU Marchal, C
   Singh, N
   Batz, Z
   Advani, J
   Jaeger, C
   Corso-Diaz, X
   Swaroop, A
AF Marchal, Claire
   Singh, Nivedita
   Batz, Zachary
   Advani, Jayshree
   Jaeger, Catherine
   Corso-Diaz, Ximena
   Swaroop, Anand
TI High-resolution genome topology of human retina uncovers super
   enhancer-promoter interactions at tissue-specific and multi-factorial
   disease loci
SO NATURE COMMUNICATIONS
LA English
DT Article
ID LONG-RANGE INTERACTIONS; CELL IDENTITY; INSULATED NEIGHBORHOODS;
   TRANSCRIPTION FACTORS; ORGANIZATION; ASSOCIATION; PRINCIPLES; DYNAMICS;
   DELETION; DOMAINS
AB Chromatin organization and enhancer-promoter contacts establish unique spatiotemporal gene expression patterns in distinct cell types. Non-coding genetic variants can influence cellular phenotypes by modifying higher-order transcriptional hubs and consequently gene expression. To elucidate genomic regulation in human retina, we mapped chromatin contacts at high resolution and integrated with super-enhancers (SEs), histone marks, binding of CTCF and select transcription factors. We show that topologically associated domains (TADs) with central SEs exhibit stronger insulation and augmented contact with retinal genes relative to TADs with edge SEs. Merging genome-wide expression quantitative trait loci (eQTLs) with topology map reveals physical links between 100 eQTLs and corresponding eGenes associated with retinal neurodegeneration. Additionally, we uncover candidate genes for susceptibility variants linked to age-related macular degeneration and glaucoma. Our study of high-resolution genomic architecture of human retina provides insights into genetic control of tissue-specific functions, suggests paradigms for missing heritability, and enables the dissection of common blinding disease phenotypes.
C1 [Marchal, Claire; Singh, Nivedita; Batz, Zachary; Advani, Jayshree; Jaeger, Catherine; Corso-Diaz, Ximena; Swaroop, Anand] NEI, Natl Inst Hlth, Neurobiol Neurodegenerat & Repair Lab, MSC0610,6 Ctr Dr, Bethesda, MD 20892 USA.
   [Marchal, Claire] In silichromLtd, First Floor,Angel Court,81 St Clements St, Oxford OX4 1AW, England.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Swaroop, A (通讯作者)，NEI, Natl Inst Hlth, Neurobiol Neurodegenerat & Repair Lab, MSC0610,6 Ctr Dr, Bethesda, MD 20892 USA.
EM swaroopa@nei.nih.gov
OI Jaeger, Catherine/0000-0001-8519-8893; Batz,
   Zachary/0000-0002-4483-2402; Swaroop, Anand/0000-0002-1975-1141; Singh,
   Nivedita/0000-0001-5919-1161
FU Intramural Research Program of the National Eye Institute [ZIAEY000450,
   ZIAEY000546]
FX We are grateful to Freekje van Asten and Benjamin Fadl for help in
   dissection of retinal tissue, Linn Gieser for assistance with next
   generation sequencing, and Matthew Brooks, Laura Campello Blasco, Kamil
   Kruczek, Anupam Mondal and Zepeng Qu for helpful discussions. This work
   was supported by Intramural Research Program of the National Eye
   Institute (ZIAEY000450 and ZIAEY000546) and utilized the highperformance
   computational capabilities of the Biowulf Linux cluster at NIH
   (http://biowulf.nih.gov).
CR Aldiri I, 2017, NEURON, V94, P550, DOI 10.1016/j.neuron.2017.04.022
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Ay F, 2014, GENOME RES, V24, P999, DOI 10.1101/gr.160374.113
   Barzago MM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11752-6
   Batut PJ, 2022, SCIENCE, V375, P566, DOI 10.1126/science.abi7178
   Beagrie RA, 2017, NATURE, V543, P519, DOI 10.1038/nature21411
   Bergstrom A, 2020, SCIENCE, V367, P1339, DOI 10.1126/science.aay5012
   Bintu B, 2018, SCIENCE, V362, P419, DOI 10.1126/science.aau1783
   Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042
   Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109
   Castel SE, 2018, NAT GENET, V50, P1327, DOI 10.1038/s41588-018-0192-y
   Chandra V, 2021, NAT GENET, V53, DOI 10.1038/s41588-020-00745-3
   Cherry TJ, 2020, P NATL ACAD SCI USA, V117, P9001, DOI 10.1073/pnas.1922501117
   Cheung VG, 2009, NAT REV GENET, V10, P595, DOI 10.1038/nrg2630
   Coolen M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00220
   Cooper DN, 2013, HUM GENET, V132, P1077, DOI 10.1007/s00439-013-1331-2
   Cramer P, 2019, NATURE, V573, P45, DOI 10.1038/s41586-019-1517-4
   Dekker J, 2016, CELL, V164, P1110, DOI 10.1016/j.cell.2016.02.007
   Dixon JR, 2015, NATURE, V518, P331, DOI 10.1038/nature14222
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Dowen JM, 2014, CELL, V159, P374, DOI 10.1016/j.cell.2014.09.030
   Durand NC, 2016, CELL SYST, V3, P95, DOI 10.1016/j.cels.2016.07.002
   Ernst J, 2017, NAT PROTOC, V12, P2478, DOI 10.1038/nprot.2017.124
   Espeso-Gil S, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-0715-x
   Fadl BR, 2020, MOL VIS, V26, P705
   Finn EH, 2019, CELL, V176, P1502, DOI 10.1016/j.cell.2019.01.020
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Furlong EEM, 2018, SCIENCE, V361, P1341, DOI 10.1126/science.aau0320
   Gel B, 2016, BIOINFORMATICS, V32, P289, DOI 10.1093/bioinformatics/btv562
   Gharahkhani P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20851-4
   Ghiasvand NM, 2011, NAT NEUROSCI, V14, P578, DOI 10.1038/nn.2798
   Gong YX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03017-1
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Grosveld F, 2021, ANNU REV GENOM HUM G, V22, P127, DOI 10.1146/annurev-genom-122220-093818
   Gu H., 2021, BIORXIV, DOI 10.1101
   Hanany M, 2020, P NATL ACAD SCI USA, V117, P2710, DOI 10.1073/pnas.1913179117
   Heinz S, 2018, CELL, V174, P1522, DOI 10.1016/j.cell.2018.07.047
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hnisz D, 2016, CELL, V167, P1188, DOI 10.1016/j.cell.2016.10.024
   Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053
   Huang JL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03279-9
   Itoh T, 2021, DEV DYNAM, V250, P1618, DOI 10.1002/dvdy.371
   Janssen SM, 2022, NAT REV GENET, V23, P137, DOI 10.1038/s41576-021-00416-x
   Kim-Hellmuth S, 2020, SCIENCE, V369, P1332, DOI 10.1126/science.aaz8528
   Kulakovskiy IV, 2018, NUCLEIC ACIDS RES, V46, pD252, DOI 10.1093/nar/gkx1106
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Li DF, 2019, NUCLEIC ACIDS RES, V47, pW158, DOI 10.1093/nar/gkz348
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li ZJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1642-2
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Marchal C, 2022, NUCLEIC ACIDS RES, V50, DOI 10.1093/nar/gkab1235
   Marchal C, 2019, NAT REV MOL CELL BIO, V20, P721, DOI 10.1038/s41580-019-0162-y
   Maroilley T, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040275
   Martin M., 2011, EMBNET J, V17, P10, DOI [DOI 10.14806/EJ.17.1.200, 10.14806/ej.17.1.200]
   Martino VB, 2016, DIS MODEL MECH, V9, P849, DOI 10.1242/dmm.025262
   Messina G, 2015, CHROMOSOMA, V124, P153, DOI 10.1007/s00412-014-0503-8
   Nagano T, 2017, NATURE, V547, P61, DOI 10.1038/nature23001
   Norrie JL, 2019, NEURON, V104, P512, DOI 10.1016/j.neuron.2019.08.002
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Paulsen J, 2019, NAT GENET, V51, P835, DOI 10.1038/s41588-019-0392-0
   Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47
   Quinodoz SA, 2018, CELL, V174, P744, DOI 10.1016/j.cell.2018.05.024
   Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Robinson JT, 2017, CANCER RES, V77, pE31, DOI 10.1158/0008-5472.CAN-17-0337
   Robson MI, 2019, MOL CELL, V74, P1110, DOI 10.1016/j.molcel.2019.05.032
   Rowley MJ, 2018, NAT REV GENET, V19, P789, DOI 10.1038/s41576-018-0060-8
   Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115
   Schoenfelder S, 2019, NAT REV GENET, V20, P437, DOI 10.1038/s41576-019-0128-0
   Skene PJ, 2017, ELIFE, V6, DOI 10.7554/eLife.21856
   Tam V, 2019, NAT REV GENET, V20, P467, DOI 10.1038/s41576-019-0127-1
   Thibodeau A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14389-7
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   van Steensel B, 2019, NAT REV MOL CELL BIO, V20, P327, DOI 10.1038/s41580-019-0114-6
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
   Wingett Steven, 2015, F1000Res, V4, P1310, DOI 10.12688/f1000research.7334.1
   Yang T, 2017, GENOME RES, V27, P1939, DOI 10.1101/gr.220640.117
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 82
TC 0
Z9 0
U1 4
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 7
PY 2022
VL 13
IS 1
AR 5827
DI 10.1038/s41467-022-33427-1
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 5D7LG
UT WOS:000865117600019
PM 36207300
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Borucki, DM
   Toutonji, A
   Couch, C
   Mallah, K
   Rohrer, B
   Tomlinson, S
AF Borucki, Davis M.
   Toutonji, Amer
   Couch, Christine
   Mallah, Khalil
   Rohrer, Baerbel
   Tomlinson, Stephen
TI Complement-Mediated Microglial Phagocytosis and Pathological Changes in
   the Development and Degeneration of the Visual System
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE complement; synapse; phagocytosis; retina; lateral geniculate nucleus;
   multiple sclerosis; age-related macular degeneration; glaucoma
ID SCAVENGER-RECEPTOR-AI/II; RETINAL GANGLION-CELLS; MYELIN PHAGOCYTOSIS;
   MULTIPLE-SCLEROSIS; C1Q RECEPTOR; MOUSE MODEL; CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; CLASSICAL PATHWAY; APOPTOTIC
   CELLS
AB The focus of this review is the role of complement-mediated phagocytosis in retinal and neurological diseases affecting the visual system. Complement activation products opsonize synaptic material on neurons for phagocytic removal, which is a normal physiological process during development, but a pathological process in several neurodegenerative diseases and conditions. We discuss the role of complement in the refinement and elimination of synapses in the retina and lateral geniculate nucleus, both during development and in disease states. How complement and aberrant phagocytosis promotes injury to the visual system is discussed primarily in the context of multiple sclerosis, where it has been extensively studied, although the role of complement in visual dysfunction in other diseases such as stroke and traumatic brain injury is also highlighted. Retinal diseases are also covered, with a focus on glaucoma and age-related macular degeneration. Finally, we discuss the potential of complement inhibitory strategies to treat diseases affecting the visual system.
C1 [Borucki, Davis M.; Toutonji, Amer] Med Univ South Carolina, Med Scientist Training Program, Charleston, SC 29425 USA.
   [Borucki, Davis M.; Toutonji, Amer; Couch, Christine; Mallah, Khalil; Tomlinson, Stephen] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Borucki, Davis M.; Toutonji, Amer; Rohrer, Baerbel] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   [Couch, Christine] Med Univ South Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA.
   [Rohrer, Baerbel] Med Univ South Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   [Rohrer, Baerbel; Tomlinson, Stephen] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; Medical University of
   South Carolina; Medical University of South Carolina; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson
   VA Medical Center
RP Tomlinson, S (通讯作者)，Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.; Tomlinson, S (通讯作者)，Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
EM tomlinss@musc.edu
OI Mallah, Khalil/0000-0001-7622-8106; Couch, Christine/0000-0002-2667-4746
FU Department of Veterans Affairs [IK6BX005235, 1BX004256, 1RX001141,
   21RX002363]; National Institutes of Health (NIH) [R01EY024581];
   Departments of Veterans Affairs [I01RX000444, I01BX003050, IK6BX004858];
   South Carolina SmartState Endowment; NIH [T32AI132164, 2T32GM008716-21];
   American Heart Association [19PRE34450105]; NIH National Center for
   Advancing Translational Sciences [TL1 TR001451, UL1 TR001450]
FX This work was supported by grants by the Department of Veterans Affairs
   (IK6BX005235, 1BX004256, 1RX001141, and 21RX002363) to ST, grants by the
   National Institutes of Health (NIH) (R01EY024581), the Departments of
   Veterans Affairs (I01RX000444, I01BX003050, and IK6BX004858) and the
   South Carolina SmartState Endowment to BR, an NIH institutional training
   grant (2T32GM008716-21) to DB, an American Heart Association predoctoral
   fellowship (19PRE34450105) to AT, the NIH National Center for Advancing
   Translational Sciences (TL1 TR001451 and UL1 TR001450) to CC, and the
   NIH training grant (T32AI132164) to KM.
CR Alawieh A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao6459
   Alawieh A, 2018, J NEUROSCI, V38, P2519, DOI 10.1523/JNEUROSCI.2197-17.2018
   Alawieh AM, 2020, J NEUROSCI, V40, P4042, DOI 10.1523/JNEUROSCI.2462-19.2020
   Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x
   Anderson SR, 2019, J NEUROSCI, V39, P2025, DOI 10.1523/JNEUROSCI.1854-18.2018
   Annamalai B, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.3
   Armstrong RA, 2018, CLIN EXP OPTOM, V101, P716, DOI 10.1111/cxo.12670
   Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208
   Bao WX, 2018, EXPERT REV MOL DIAGN, V18, P761, DOI 10.1080/14737159.2018.1471985
   Becker S, 2015, OPHTHALMOLOGE, V112, P41, DOI 10.1007/s00347-014-3100-6
   Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605
   Bennett JL, 2017, J NEURO-OPHTHALMOL, V37, P291, DOI 10.1097/WNO.0000000000000508
   Bialas AR, 2013, NAT NEUROSCI, V16, P1773, DOI 10.1038/nn.3560
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bosco A, 2018, MOL THER, V26, P2379, DOI 10.1016/j.ymthe.2018.08.017
   Boven LA, 2006, BRAIN, V129, P517, DOI 10.1093/brain/awh707
   Brodsky RA, 2014, BLOOD, V124, P2804, DOI 10.1182/blood-2014-02-522128
   Burstyn-Cohen T, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0461-0
   Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Cohen G, 2006, GLIA, V53, P538, DOI 10.1002/glia.20304
   Cohen LP, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017236
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Czirr E, 2017, J EXP MED, V214, P1081, DOI 10.1084/jem.20162011
   Demb JB, 2015, ANNU REV VIS SCI, V1, P263, DOI 10.1146/annurev-vision-082114-035334
   Dembla M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201808926
   Dhande OS, 2015, ANNU REV VIS SCI, V1, P291, DOI 10.1146/annurev-vision-082114-035502
   Ding QJ, 2012, INVEST OPHTH VIS SCI, V53, P6370, DOI 10.1167/iovs.12-10442
   Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334
   DiScipio RG., 2018, COMPLEMENT FACTSBOOK, VSecond Edition, P221
   Edelson BT, 2006, BLOOD, V107, P143, DOI 10.1182/blood-2005-06-2218
   Erskine L, 2014, ASN NEURO, V6, DOI 10.1177/1759091414562107
   Evanson NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197346
   Farber K, 2009, J NEUROSCI RES, V87, P644, DOI 10.1002/jnr.21875
   Fitzgerald KC, 2019, BRAIN, V142, P2722, DOI 10.1093/brain/awz188
   Foroozan Rod, 2002, Curr Opin Ophthalmol, V13, P375, DOI 10.1097/00055735-200212000-00006
   Fraser DA, 2010, J NEUROCHEM, V112, P733, DOI 10.1111/j.1471-4159.2009.06494.x
   G eorges A, 2020, TRAUMATIC BRAIN INJU
   Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gilmore CS, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.454
   Gitik M, 2010, FASEB J, V24, P2211, DOI 10.1096/fj.09-146118
   Glushakov AO, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103151
   GODEMENT P, 1984, J COMP NEUROL, V230, P552, DOI 10.1002/cne.902300406
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guerrero BL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00374
   Gyorffy BA, 2018, P NATL ACAD SCI USA, V115, P6303, DOI 10.1073/pnas.1722613115
   HAGA S, 1993, BRAIN RES, V601, P88, DOI 10.1016/0006-8993(93)91698-R
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hendrickx DAE, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-64
   Hepworth L., 2016, OPTHAMOL RES, V5, P1, DOI DOI 10.9734/OR/2016/21767
   Hernandez MX, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0210-z
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373
   Hong YK, 2011, CURR OPIN NEUROBIOL, V21, P228, DOI 10.1016/j.conb.2011.02.007
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Hu XZ, 2012, NEUROSCI LETT, V531, P35, DOI 10.1016/j.neulet.2012.10.012
   Huang WJ, 2017, EXP THER MED, V13, P3163, DOI 10.3892/etm.2017.4410
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Iram T, 2016, J NEUROSCI, V36, P5185, DOI 10.1523/JNEUROSCI.3850-15.2016
   Jarius S, 2014, CLIN EXP IMMUNOL, V176, P149, DOI 10.1111/cei.12271
   Jaubert-Miazza L, 2005, VISUAL NEUROSCI, V22, P661, DOI 10.1017/S0952523805225154
   Jha P, 2011, MOL IMMUNOL, V48, P2151, DOI 10.1016/j.molimm.2011.07.012
   Jin J, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0767-6
   Kamphuis W, 2016, BBA-MOL BASIS DIS, V1862, P1847, DOI 10.1016/j.bbadis.2016.07.007
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kaur C, 2004, ACTA NEUROPATHOL, V107, P204, DOI 10.1007/s00401-003-0798-7
   Kawachi I., 2017, CLIN EXP NEUROIMMUNO, V8, P8, DOI [10.1111/cen3.12354, DOI 10.1111/CEN3.12354]
   Kerschensteiner D, 2017, VISUAL NEUROSCI, V34, DOI 10.1017/S0952523817000062
   Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8
   Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005
   Kreft D, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6935-6
   Kumral E., 2000, J STROKE CEREBROVASC, V9, P287, DOI DOI 10.1053/JSCD.2000.18741
   Lakkaraju A, 2014, ADV EXP MED BIOL, V801, P267, DOI 10.1007/978-1-4614-3209-8_34
   Lassmann H, 2020, GLIA, V68, P830, DOI 10.1002/glia.23726
   Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304
   LEVERE TE, 1978, PHYSIOL PSYCHOL, V6, P142
   Lian H, 2016, J NEUROSCI, V36, P577, DOI 10.1523/JNEUROSCI.2117-15.2016
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Linnartz Bettina, 2010, Int J Alzheimers Dis, V2010, DOI 10.4061/2010/587463
   Linnartz-Gerlach B, 2019, GLIA, V67, P539, DOI 10.1002/glia.23563
   Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001
   Magnin E, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00156
   Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008
   Makranz C, 2006, GLIA, V53, P441, DOI 10.1002/glia.20303
   Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294
   Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0
   Michailidou I, 2015, ANN NEUROL, V77, P1007, DOI 10.1002/ana.24398
   Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Murray SA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012418
   Nakamura M, 2019, NEUROSCIENCE M PLANN
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Orsini F, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00263
   Ovbiagele B, 2011, NEUROTHERAPEUTICS, V8, P319, DOI 10.1007/s13311-011-0053-1
   Patel VC, 2017, EXP NEUROL, V289, P85, DOI 10.1016/j.expneurol.2016.12.012
   PEERSCHKE EIB, 1990, J IMMUNOL, V145, P2984
   PERRY VH, 1990, J NEUROCYTOL, V19, P265, DOI 10.1007/BF01217304
   Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8
   Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866
   Plemel JR, 2013, GLIA, V61, P1471, DOI 10.1002/glia.22535
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Quinn Thomas A, 2011, Front Neurol, V2, P50, DOI 10.3389/fneur.2011.00050
   Raina R, 2019, THER APHER DIAL, V23, P4, DOI 10.1111/1744-9987.12763
   Rambach G, 2010, MOL IMMUNOL, V47, P1438, DOI 10.1016/j.molimm.2010.02.010
   Ramirez-Ortiz ZG, 2013, NAT IMMUNOL, V14, P917, DOI 10.1038/ni.2670
   Rathi S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01868
   Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6
   Reichert F, 1999, EXP NEUROL, V160, P508, DOI 10.1006/exnr.1999.7229
   Reinehr S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01381
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rosales C, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9042851
   Rotshenker S, 2008, GLIA, V56, P1607, DOI 10.1002/glia.20713
   Rus HG, 1996, J IMMUNOL, V156, P4892
   Salton SR, 2019, 2019 NEUR M PLANN
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Shahulhameed S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00154
   Shi QQ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6295
   Shi Y, 2018, NAT REV IMMUNOL, V18, P759, DOI 10.1038/s41577-018-0051-1
   Slobodov U, 2001, EXP NEUROL, V167, P401, DOI 10.1006/exnr.2000.7559
   Smith ME, 2001, MICROSC RES TECHNIQ, V54, P81, DOI 10.1002/jemt.1123
   Son M, 2012, P NATL ACAD SCI USA, V109, pE3160, DOI 10.1073/pnas.1212753109
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Tao XY, 2015, INT J OPHTHALMOL-CHI, V8, P17, DOI 10.3980/j.issn.2222-3959.2015.01.03
   Tassoni A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46232-6
   Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Urich E, 2006, P NATL ACAD SCI USA, V103, P18697, DOI 10.1073/pnas.0607283103
   van den Elsen JMH, 2011, SCIENCE, V332, P608, DOI 10.1126/science.1201954
   Van der Goes A, 1999, J NEUROIMMUNOL, V101, P61, DOI 10.1016/S0165-5728(99)00133-2
   van der Poel M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08976-7
   Vasek MJ, 2016, NATURE, V534, P538, DOI 10.1038/nature18283
   Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003
   Vien L, 2017, OPTOMETRY VISION SCI, V94, P125, DOI 10.1097/OPX.0000000000000899
   Wang C, 2020, SCIENCE, V367, P688, DOI 10.1126/science.aaz2288
   Webster SD, 2000, J LEUKOCYTE BIOL, V67, P109, DOI 10.1002/jlb.67.1.109
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Werneburg S, 2020, IMMUNITY, V52, P167, DOI 10.1016/j.immuni.2019.12.004
   Williams PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0091-6
   WOOD A, 1993, J NEUROSCI, V13, P3319
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Wynford-Thomas R, 2019, J NEUROL, V266, P1280, DOI 10.1007/s00415-018-9122-2
   Yamashita T, 2016, NEUROOPHTHALMOL JAPA, V33, P351, DOI [10.11476/shinkeiganka.33.351, DOI 10.11476/SHINKEIGANKA.33.351]
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yew KS, 2009, AM FAM PHYSICIAN, V80, P33
   Zabel M, 2013, BRAIN PATHOL, V23, P390, DOI 10.1111/bpa.12005
   Zhang X, 2011, BIOINFORM BIOL INSIG, V5, P99, DOI 10.4137/BBI.S6930
   Zrzavy T, 2017, BRAIN, V140, P1900, DOI 10.1093/brain/awx113
NR 157
TC 10
Z9 10
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 24
PY 2020
VL 11
AR 566892
DI 10.3389/fimmu.2020.566892
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA NX7QP
UT WOS:000575901200001
PM 33072106
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, YY
   Soetikno, B
   Furst, J
   Raicu, D
   Fawzi, AA
AF Wang, Yiyang
   Soetikno, Brian
   Furst, Jacob
   Raicu, Daniela
   Fawzi, Amani A.
TI Drusen diagnosis comparison between hyper-spectral and color retinal
   mages
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID MACULAR DEGENERATION; TEXTURE ANALYSIS; FEATURES; AMD; DISEASE; SYSTEM;
   IMAGES
AB Age-related macular degeneration (AMD) is a degenerative aging disorder, which can lead to irreversible vision loss in older individuals. The emergence of clinical applications of retinal hyper-spectral imaging provides a unique opportunity to capture important spectral signatures, with the potential to enhance the molecular diagnosis of retinal diseases. In this study. we use a machine learning classification approach to explore whether hyper-spectral images offer an improved outcome compared to standard RGB images. Our results show that the classifier performs better on hyper-spectral images with improved accuracy and sensitivity for drusen classification compared to standard imaging. By examining the most important features in the classification task. our data suggest that drusen are highly heterogeneous. Our work provides further evidence that hyper-spectral retinal image data are uniquely suited for computer-aided diagnosis and detection techniques. (C) 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Wang, Yiyang; Furst, Jacob; Raicu, Daniela] DePaul Univ, Coll Comp & Digital Media, Chicago, IL 60604 USA.
   [Soetikno, Brian; Fawzi, Amani A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Soetikno, Brian] Northwestern Univ, Dept Biomed Engn, Funct Opt Imaging Lab, Evanston, IL 60208 USA.
C3 DePaul University; Northwestern University; Feinberg School of Medicine;
   Northwestern University
RP Raicu, D (通讯作者)，DePaul Univ, Coll Comp & Digital Media, Chicago, IL 60604 USA.
EM draicu@cdm.depaul.edu; amani.fawzi@northwestern.edu
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558; Soetikno, Brian/0000-0003-4530-4959
FU National Institutes of Health (NIH) [DP3DK108248]
FX National Institutes of Health (NIH) (DP3DK108248).
CR Ali N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203339
   Ali N, 2016, COMPUT ELECTR ENG, V54, P539, DOI 10.1016/j.compeleceng.2016.04.002
   Ali N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157428
   [Anonymous], 2018, MATLAB R2018A
   Bhuiyan A, 2013, IEEE ENG MED BIO, P7392, DOI 10.1109/EMBC.2013.6611266
   BREIMAN L, 2001, MACH LEARN, V0045
   Brynolfsson P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04151-4
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Domingos P, 1997, MACH LEARN, V29, P103, DOI 10.1023/A:1007413511361
   Fawzi AA, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3640813
   Feldman TB, 2018, EYE, V32, P1440, DOI 10.1038/s41433-018-0109-0
   Foubister JJ, 2018, PROC SPIE, V10474, DOI 10.1117/12.2286611
   Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504
   Garcia-Floriano A., 2017, COMPUT ELECT ENG
   Han J, 2012, MOR KAUF D, P1
   HARALICK RM, 1979, P IEEE, V67, P786, DOI 10.1109/PROC.1979.11328
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   Hussain MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198281
   Kaluzny J, 2017, CURR EYE RES, V42, P629, DOI 10.1080/02713683.2016.1221976
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Khalid S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7148245
   Koh JEW, 2017, COMPUT BIOL MED, V84, P89, DOI 10.1016/j.compbiomed.2017.03.008
   Kohavi R., 1995, INT JOINT C ART INT, V14, P1137, DOI DOI 10.1067/MOD.2000.109031
   Kumari K, 2015, J BIOMED ENG MED IMA, V2, P18
   LAYER G, 1990, ULTRASONIC IMAGING, V12, P171, DOI 10.1016/0161-7346(90)90009-M
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee N, 2010, IEEE ENG MED BIO, P5363, DOI 10.1109/IEMBS.2010.5626463
   Li H, 2017, J BIOPHOTONICS, V10, P830, DOI 10.1002/jbio.201600053
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Mittal D, 2015, COMPUT ELECTR ENG, V47, P82, DOI 10.1016/j.compeleceng.2015.08.014
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Nazir A., 2018, PROC INT C COMPUTING, P1, DOI DOI 10.1109/ICOMET.2018.8346343
   Prasath AR, 2015, RES J INF TECHNOL, V7, P70
   Raza G, 2013, P 2013 IEEE JORD C A, P1
   Remeseiro B, 2009, LECT NOTES COMPUT SC, V5717, P187, DOI 10.1007/978-3-642-04772-5_25
   Ren XX, 2018, IEEE ACCESS, V6, P2952, DOI 10.1109/ACCESS.2017.2786271
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Sohrab MA, 2011, SEMIN OPHTHALMOL, V26, P156, DOI 10.3109/08820538.2011.570848
   Phan TV, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5893601
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.1093/biomet/34.1-2.28
   Wong DWK, 2013, I S BIOMED IMAGING, P884
   Yang XF, 2012, MED PHYS, V39, P5732, DOI 10.1118/1.4747526
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang GY, 2012, J APPL STAT, V39, P151, DOI 10.1080/02664763.2011.578621
   Zhao R, 2017, BIOMED OPT EXPRESS, V8, P5049, DOI 10.1364/BOE.8.005049
   Zheng YJ, 2013, I S BIOMED IMAGING, P1448
   Zinovev D, 2009, ALGORITHMS, V2, P1473, DOI 10.3390/a2041473
NR 52
TC 5
Z9 5
U1 0
U2 1
PU Optica Publishing Group
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2019
VL 10
IS 2
BP 914
EP 931
DI 10.1364/BOE.10.000914
PG 18
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA HJ9DZ
UT WOS:000457500300037
PM 30800523
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Idelson, M
   Alper, R
   Obolensky, A
   Yachimovich-Cohen, N
   Rachmilewitz, J
   Ejzenberg, A
   Beider, E
   Banin, E
   Reubinoff, B
AF Idelson, Masha
   Alper, Ruslana
   Obolensky, Alexey
   Yachimovich-Cohen, Nurit
   Rachmilewitz, Jacob
   Ejzenberg, Ayala
   Beider, Ekaterina
   Banin, Eyal
   Reubinoff, Benjamin
TI Immunological Properties of Human Embryonic Stem Cell-Derived Retinal
   Pigment Epithelial Cells
SO STEM CELL REPORTS
LA English
DT Article
ID ACTIVATED T-CELLS; MACULAR DEGENERATION; ADHESION MOLECULE-1;
   EXPRESSION; RPE; INTERLEUKIN-2; CD69; DIFFERENTIATION; INHIBITION;
   CYTOKINES
AB Age-related macular degeneration is caused by dysfunction and loss of retinal pigment epithelium (RPE) cells, and their transplantation may rescue visual functions and delay disease progression. Human embryonic stem cells (hESCs) may be an unlimited source of RPE cells for allotransplantation. We analyzed the immunomodulatory properties of hESC-derived RPE (hESC-RPE) cells, and showed that they inhibited T cell responses. Co-culture experiments showed that RPE cells inhibited interfon-g secretion and proliferation of activated T cells. Furthermore, hESC-RPE cells enhanced T cell apoptosis and secretion of the anti-inflammatory cytokine interleukin-10 (IL-10). In addition, RPE cells altered the expression of T cell activation markers, CD69 and CD25. RPE cells transplanted into RCS rats without immunosuppression survived, provided retinal rescue, and enhanced IL-10 blood levels. Our data suggest that hESC-RPE cells have immunosuppressive properties. Further studies will determine if these properties are sufficient to alleviate the need for immunosuppression therapy after their clinical allotransplantation.
C1 [Idelson, Masha; Yachimovich-Cohen, Nurit; Reubinoff, Benjamin] Hadassah Med Ctr, Goldyne Savad Inst Gene Therapy, Hadassah Human Embryon Stem Cell Res Ctr, IL-91120 Jerusalem, Israel.
   [Reubinoff, Benjamin] Hadassah Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel.
   [Alper, Ruslana; Obolensky, Alexey; Ejzenberg, Ayala; Banin, Eyal] Hadassah Med Ctr, Dept Ophthalmol, Ctr Retinal & Macular Degenerat, IL-91120 Jerusalem, Israel.
   [Beider, Ekaterina] Guy Weinshtock Multiple Myeloma Fdn, Chaim Sheba Med Ctr Hosp Tel Hashomer, Hematol Div, IL-52621 Ramat Gan, Israel.
   [Beider, Ekaterina] Guy Weinshtock Multiple Myeloma Fdn, Chaim Sheba Med Ctr Hosp Tel Hashomer, CBB, IL-52621 Ramat Gan, Israel.
   [Rachmilewitz, Jacob] Hadassah Med Ctr, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center
RP Reubinoff, B (通讯作者)，Hadassah Med Ctr, Goldyne Savad Inst Gene Therapy, Hadassah Human Embryon Stem Cell Res Ctr, IL-91120 Jerusalem, Israel.; Reubinoff, B (通讯作者)，Hadassah Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel.
EM benr@hadassah.org.il
OI Reubinoff, Benjamin/0000-0003-0353-1299
FU Foundation Fighting Blindness Grant [TA-RA-0321-0568-HUJ]; GT Foundation
   Grant; Moxie Foundation Grant; Yedidut Research Grant
FX We gratefully acknowledge Oliver Stevens (Oxford University), Ariel Berl
   (Bar Ilan University), Dr. Michal Gropp, Dr. Etti Ben-Shushan, Dr.
   Hanita Khaner, Prof. Eithan Galun, Evelyne Zeira, Yael Berman-Zaken,
   Hagit Yotvat, Anastasija Birger, Itai Waldhorn, Dr. Elina Zorde, Dr.
   Zohar Bromberg, Dr. Doron Kabiri, and Dr. Matan Elami-Suzin (Hadassah
   Medical Center) for technical support. We thank Shelly Tannenbaum
   (Hadassah Medical Center) for editing the manuscript. We thank Prof.
   Amnon Peled (Hadassah Medical Center) and Dr. Osnat Bohana-Kashtan
   (CellCure Neurosciences) for discussion. This research was supported by
   a kind donation of Judy and Sidney Swartz, The Foundation Fighting
   Blindness Grant (TA-RA-0321-0568-HUJ), a GT Foundation Grant, a Moxie
   Foundation Grant, and a Yedidut Research Grant.
CR de Oliveira CMB, 2011, REV BRAS ANESTESIOL, V61, P255, DOI 10.1016/S0034-7094(11)70029-0
   Chao KH, 2002, MOL HUM REPROD, V8, P667, DOI 10.1093/molehr/8.7.667
   Cortes JR, 2014, J AUTOIMMUN, V55, P51, DOI 10.1016/j.jaut.2014.05.007
   de la Rosa M, 2004, EUR J IMMUNOL, V34, P2480, DOI 10.1002/eji.200425274
   ELNER SG, 1992, LAB INVEST, V66, P200
   Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Imai A, 2012, INVEST OPHTH VIS SCI, V53, P7299, DOI 10.1167/iovs.12-10182
   Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   Kaestel CG, 2002, EXP EYE RES, V74, P627, DOI 10.1006/exer.2002.1183
   Kaestel CG, 2001, EXP CLIN IMMUNOGENET, V18, P34, DOI 10.1159/000049085
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Lin E, 2000, SURGERY, V127, P117, DOI 10.1067/msy.2000.101584
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Martin P, 2014, J AUTOIMMUN, V55, P51
   Morescalchi F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/269787
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Saldanha-Araujo F, 2012, J CELL MOL MED, V16, P1232, DOI 10.1111/j.1582-4934.2011.01391.x
   Sancho D, 1999, BLOOD, V93, P886, DOI 10.1182/blood.V93.3.886.403k10_886_896
   Sancho D, 2005, TRENDS IMMUNOL, V26, P136, DOI 10.1016/j.it.2004.12.006
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Tannenbaum SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035325
   Taylor AW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074488
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Werfel T, 1997, ALLERGY, V52, P465, DOI 10.1111/j.1398-9995.1997.tb01031.x
   Willermain F, 2000, INVEST OPHTH VIS SCI, V41, P3485
   Yachimovich-Cohen N, 2010, J IMMUNOL, V184, P1300, DOI 10.4049/jimmunol.0804261
   Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021
   Zhu J, 2017, CELL STEM CELL, V20, P374, DOI 10.1016/j.stem.2016.11.019
NR 37
TC 25
Z9 26
U1 0
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD SEP 11
PY 2018
VL 11
IS 3
BP 681
EP 695
DI 10.1016/j.stemcr.2018.07.009
PG 15
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GT1WQ
UT WOS:000444268100007
PM 30122442
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cui, KX
   Zhang, SS
   Liu, XJ
   Yan, ZZ
   Huang, LL
   Yang, XW
   Zhu, RR
   Sang, AM
AF Cui, Kaixuan
   Zhang, Shanshan
   Liu, Xiaojuan
   Yan, Zhenzhen
   Huang, Lili
   Yang, Xiaowei
   Zhu, Rongrong
   Sang, Aimin
TI Inhibition of TBK1 reduces choroidal neovascularization in vitro and in
   vivo
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Choroidal neovascularization (CNV); Age-related macular degeneration
   (AMD); TANK-Binding kinase 1 (TBK1); Vascular endothelial growth factor
   (VEGF)
ID MACULAR DEGENERATION; THERAPEUTIC TARGET; ANGIOGENESIS; PATHOGENESIS;
   ACTIVATION
AB choroidal neovascularization (CNV), a characteristic of wet age-related macular degeneration (AMD), causes severe vision loss among elderly patients. TANK-binding kinase 1 (TBK1) is a ubiquitously expressed serine-threonine kinase and is found to induce endothelial cells proliferation, represent a novel mediator of tumor angiogenesis and exert pro-inflammatory effect. However, the role of TBK1 in choroidal neovascularization has not been investigated so far. In this study, we found that the expression of TBK1 and VEGF was up-regulated in RF/6 A cells chemical hypoxia model and laser-induced mouse CNV model. Silencing of TBK1 suppressed the proliferation and tube formation activity of RF/6 A cells. Intravitreal injection of anti-TBK1 monoclonal antibody ameliorates CNV formation. Taken together, these findings exhibit a proangiogenic role for TBK1 via upregulating the expression of VEGF, and may suggest that TBK1 inhibition offers a unique and alternative method for prevention and treatment of AMD. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Yan, Zhenzhen; Yang, Xiaowei; Zhu, Rongrong; Sang, Aimin] Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong 226001, Peoples R China.
   [Cui, Kaixuan] Nantong Univ, Sch Med, Nantong 226001, Jiangsu, Peoples R China.
   [Zhang, Shanshan] Nantong Univ, Nantong, Jiangsu, Peoples R China.
   [Liu, Xiaojuan] Nantong Univ, Med Coll, Dept Pathogen Biol, Nantong 226001, Jiangsu, Peoples R China.
   [Liu, Xiaojuan] Nantong Univ, Med Coll, Jiangsu Prov Key Lab Inflammat & Mol Drug Target, Nantong 226001, Jiangsu, Peoples R China.
   [Huang, Lili] First Peoples Hosp Nantong, Dept Ophthalmol, Nantong 226001, Jiangsu, Peoples R China.
C3 Nantong University; Nantong University; Nantong University; Nantong
   University; Nantong University
RP Zhu, RR; Sang, AM (通讯作者)，Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong 226001, Peoples R China.
EM zrreye@126.com; sangam@ntu.edu.cn
FU Postgraduate Research & Practice Innovation Program of Jiangsu Province
   [SJCX17_0643]
FX This work was supported by the Postgraduate Research & Practice
   Innovation Program of Jiangsu Province (No. SJCX17_0643).
CR Abeyrathna P, 2015, VASC PHARMACOL, V74, P38, DOI 10.1016/j.vph.2015.05.008
   Ahmad L, 2016, TRENDS MOL MED, V22, P511, DOI 10.1016/j.molmed.2016.04.006
   Ao J., 2017, CLIN EXP OPHTHALMOL
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Basavarajappa HD, 2017, EMBO MOL MED, V9, P786, DOI 10.15252/emmm.201606561
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Bodur C, 2018, EMBO J, V37, P19, DOI 10.15252/embj.201696164
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cruz VH, 2018, J CELL COMMUN SIGNAL, V12, P83, DOI 10.1007/s12079-017-0438-y
   Czabanka M, 2008, FRONT BIOSCI, V13, P7243, DOI 10.2741/3225
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fu JL, 2016, ENVIRON TOXICOL PHAR, V41, P241, DOI 10.1016/j.etap.2015.12.012
   Gaddipati S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121185
   Hasan M, 2016, PHARMACOL RES, V111, P336, DOI 10.1016/j.phrs.2016.04.008
   Im M, 2016, INT J ONCOL, V49, P2377, DOI 10.3892/ijo.2016.3742
   Korherr C, 2006, P NATL ACAD SCI USA, V103, P4240, DOI 10.1073/pnas.0511319103
   Lee SH, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0235-z
   Lee SH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/861435
   Lennikov A, 2018, ANGIOGENESIS, V21, P267, DOI 10.1007/s10456-018-9594-9
   Li L, 2017, FRONT PLANT SCI, V8, P1, DOI 10.3389/fpls.2017.00511
   Liang SW, 2017, CANCER LETT, V386, P12, DOI 10.1016/j.canlet.2016.11.003
   Liu XM, 2016, MOL MED REP, V13, P1127, DOI 10.3892/mmr.2015.4663
   Lu HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087530
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Rivera JC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3940241
   Saito K, 2018, CANCER SCI, V109, P132, DOI 10.1111/cas.13441
   Shanmugasundaram K, 2014, J BIOL CHEM, V289, P24691, DOI 10.1074/jbc.M114.568162
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Swamynathan S, 2017, EXP EYE RES, V164, P118, DOI 10.1016/j.exer.2017.08.007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yu JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7074
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
   Zhao W, 2013, FEBS LETT, V587, P542, DOI 10.1016/j.febslet.2013.01.052
NR 38
TC 3
Z9 4
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 3
PY 2018
VL 503
IS 1
BP 202
EP 208
DI 10.1016/j.bbrc.2018.06.003
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GQ1DX
UT WOS:000441367800031
PM 29864423
DA 2022-11-30
ER

PT J
AU Hyttinen, JMT
   Viiri, J
   Kaarniranta, K
   Blasiak, J
AF Hyttinen, Juha M. T.
   Viiri, Johanna
   Kaarniranta, Kai
   Blasiak, Janusz
TI Mitochondrial quality control in AMD: does mitophagy play a pivotal
   role?
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Cell senescence; Mitochondrial DNA damage; Nrf2/PGC-1 alpha axis;
   Oxidative damage; Ubiquitin
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION AMD; E3 UBIQUITIN
   LIGASE; OXIDATIVE STRESS; DNA-DAMAGE; PINK1/PARKIN-MEDIATED MITOPHAGY;
   PARKINSONS-DISEASE; CELLS-IMPLICATIONS; DIRECT PHOSPHORYLATION;
   MECHANISTIC INSIGHTS
AB Age-related macular degeneration (AMD) is the predominant cause of visual loss in old people in the developed world, whose incidence is increasing. This disease is caused by the decrease in macular function, due to the degeneration of retinal pigment epithelium (RPE) cells. The aged retina is characterised by increased levels of reactive oxygen species (ROS), impaired autophagy, and DNA damage that are linked to AMD pathogenesis. Mitophagy, a mitochondria-specific type of autophagy, is an essential part of mitochondrial quality control, the collective mechanism responsible for this organelle's homeostasis. The abundance of ROS, DNA damage, and the excessive energy consumption in the ageing retina all contribute to the degeneration of RPE cells and their mitochondria. We discuss the role of mitophagy in the cell and argue that its impairment may play a role in AMD pathogenesis. Thus, mitophagy as a potential therapeutic target in AMD and other degenerative diseases is as well explored.
C1 [Hyttinen, Juha M. T.; Viiri, Johanna; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 100, Kuopio 70029, Finland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Lodz
RP Hyttinen, JMT (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, Kuopio 70211, Finland.
EM Juha.Hyttinen@uef.fi
OI Blasiak, Janusz/0000-0001-9539-9584; Hyttinen, Juha/0000-0002-3414-4032
CR Ahmad T, 2015, FASEB J, V29, P2912, DOI 10.1096/fj.14-268276
   Ambivero CT, 2014, CELL SIGNAL, V26, P2921, DOI 10.1016/j.cellsig.2014.09.004
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Ben-Meir A, 2015, FERTIL STERIL, V104, P724, DOI 10.1016/j.fertnstert.2015.05.023
   Bernhardt D, 2014, CURR OPIN MICROBIOL, V22, P1, DOI 10.1016/j.mib.2014.09.007
   Bhujabal Z, 2017, EMBO REP, V18, P947, DOI 10.15252/embr.201643147
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Bueno M, 2015, J CLIN INVEST, V125, P521, DOI 10.1172/JCI74942
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Carreras-Sureda A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00055
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034
   Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Choubey V, 2014, AUTOPHAGY, V10, P1105, DOI 10.4161/auto.28615
   Chougnet CA, 2015, J IMMUNOL, V195, P2624, DOI 10.4049/jimmunol.1501006
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236
   Dengjel J, 2017, CELL TISSUE RES, V367, P95, DOI 10.1007/s00441-016-2472-0
   Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537
   Diot A, 2016, MAMM GENOME, V27, P381, DOI 10.1007/s00335-016-9651-x
   Dodson M, 2015, BIOCHEM J, V469, P347, DOI 10.1042/BJ20150568
   Drysdale J, 2002, BLOOD CELL MOL DIS, V29, P376, DOI 10.1006/bcmd.2002.0577
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Esteban-Martinez L, 2017, EMBO J, V36, P1688, DOI 10.15252/embj.201695916
   Farre JC, 2016, NAT REV MOL CELL BIO, V17, P537, DOI 10.1038/nrm.2016.74
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Field MG, 2012, OPHTHAL SURG LAS IM, V43, P358, DOI 10.3928/15428877-20120712-02
   Fivenson EM, 2017, NEUROCHEM INT, V109, P202, DOI 10.1016/j.neuint.2017.02.007
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Fu M, 2013, MOL BIOL CELL, V24, P1153, DOI 10.1091/mbc.E12-08-0607
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Geisler S, 2010, AUTOPHAGY, V6, P871, DOI 10.4161/auto.6.7.13286
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Georgakopoulos ND, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07679-7
   Giovannini L, 2017, NUTRITION, V34, P82, DOI 10.1016/j.nut.2016.09.008
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gouras P, 2016, GRAEF ARCH CLIN EXP, V254, P1221, DOI 10.1007/s00417-016-3342-x
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Harnett MM, 2017, BIOMED J, V40, P9, DOI 10.1016/j.bj.2016.12.004
   Hasson SA, 2015, ACS CHEM BIOL, V10, P1188, DOI 10.1021/cb5010417
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Hertz NT, 2013, CELL, V154, P737, DOI 10.1016/j.cell.2013.07.030
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Ivankovic D, 2016, J NEUROCHEM, V136, P388, DOI 10.1111/jnc.13412
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kane LA, 2014, J CELL BIOL, V205, P143, DOI 10.1083/jcb.201402104
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppila TES, 2017, CELL METAB, V25, P57, DOI 10.1016/j.cmet.2016.09.017
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kazlauskaite A, 2015, EMBO REP, V16, P939, DOI 10.15252/embr.201540352
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kim I, 2011, ANTIOXID REDOX SIGN, V14, P1919, DOI 10.1089/ars.2010.3768
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kim Y, 2008, BIOCHEM BIOPH RES CO, V377, P975, DOI 10.1016/j.bbrc.2008.10.104
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Knuppertz L, 2016, MECH AGEING DEV, V153, P30, DOI 10.1016/j.mad.2016.01.003
   Korolchuk VI, 2017, EBIOMEDICINE, V21, P7, DOI 10.1016/j.ebiom.2017.03.020
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893
   Lazarou M, 2015, IMMUNOL CELL BIOL, V93, P3, DOI 10.1038/icb.2014.75
   Lazarou M, 2012, DEV CELL, V22, P320, DOI 10.1016/j.devcel.2011.12.014
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Lemasters JJ, 2014, REDOX BIOL, V2, P749, DOI 10.1016/j.redox.2014.06.004
   Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Mao K, 2011, J CELL BIOL, V193, P755, DOI 10.1083/jcb.201102092
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   McCord JM, 2005, BIOMED PHARMACOTHER, V59, P139, DOI 10.1016/j.biopha.2005.03.005
   Mena NP, 2015, MITOCHONDRION, V21, P92, DOI 10.1016/j.mito.2015.02.001
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Michel S, 2012, J CELL PHYSIOL, V227, P2297, DOI 10.1002/jcp.23021
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075
   Moore DJ, 2006, BIOCHEM SOC T, V34, P749, DOI 10.1042/BST0340749
   Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8
   Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Novak I, 2012, ANTIOXID REDOX SIGN, V17, P794, DOI 10.1089/ars.2011.4407
   Novak I, 2011, AUTOPHAGY, V7, P301, DOI 10.4161/auto.7.3.14509
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   Ohtsuji M, 2008, J BIOL CHEM, V283, P33554, DOI 10.1074/jbc.M804597200
   Okamoto K, 2012, BBA-GEN SUBJECTS, V1820, P595, DOI 10.1016/j.bbagen.2011.08.001
   Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546
   Palikaras K, 2017, PHARMACOL THERAPEUT, V178, P157, DOI 10.1016/j.pharmthera.2017.04.005
   Pandey R, 2016, SCI REP-UK, V6, DOI 10.1038/srep32348
   Passos JF, 2007, PLOS BIOL, V5, P1138, DOI 10.1371/journal.pbio.0050110
   Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5
   Payne BAI, 2015, BBA-BIOENERGETICS, V1847, P1347, DOI 10.1016/j.bbabio.2015.05.022
   Peng J, 2016, MITOCHONDRION, V28, P49, DOI 10.1016/j.mito.2016.03.007
   Pezze PD, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003728
   Phillipson OT, 2014, NEUROBIOL AGING, V35, P847, DOI 10.1016/j.neurobiolaging.2013.10.073
   Picca A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050933
   Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007
   Ping Z, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/876825
   Reggiori Fulvio, 2012, ISRN Mol Biol, V2012, P738718, DOI 10.5402/2012/738718
   Richter U, 2013, CURR BIOL, V23, P535, DOI 10.1016/j.cub.2013.02.019
   Rogov VV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01258-6
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rozenknop A, 2011, J MOL BIOL, V410, P477, DOI 10.1016/j.jmb.2011.05.003
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Rub C, 2017, CELL TISSUE RES, V367, P111, DOI 10.1007/s00441-016-2485-8
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Ryu D, 2016, NAT MED, V22, P879, DOI 10.1038/nm.4132
   Saisho Y, 2015, ENDOCR METAB IMMUNE, V15, P196, DOI 10.2174/1871530315666150316124019
   Salminen A, 2013, INT J MOL SCI, V14, P3834, DOI 10.3390/ijms14023834
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Song Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111934
   Springer W, 2011, AUTOPHAGY, V7, P266, DOI 10.4161/auto.7.3.14348
   Sripathi Srinivas R, 2017, Int J Sci Eng Res, V8, P680
   Stenirri S, 2012, CLIN CHEM LAB MED, V50, P1021, DOI 10.1515/cclm-2011-0854
   Strappazzon F, 2015, CELL DEATH DIFFER, V22, P419, DOI 10.1038/cdd.2014.139
   Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Sun N, 2016, MOL CELL, V61, P654, DOI 10.1016/j.molcel.2016.01.028
   Sun N, 2015, MOL CELL, V60, P685, DOI 10.1016/j.molcel.2015.10.009
   Szklarczyk R, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0439
   Szymanski J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071576
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang A.L., 2009, PLOS ONE, V4
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang LG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022325
   Wang W, 2016, MOL CELL ENDOCRINOL, V426, P91, DOI 10.1016/j.mce.2016.02.008
   Wang XY, 2016, NEUROBIOL AGING, V47, P168, DOI 10.1016/j.neurobiolaging.2016.07.025
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu WX, 2016, AUTOPHAGY, V12, P1675, DOI 10.1080/15548627.2016.1193656
   Yamano K, 2013, AUTOPHAGY, V9, P1758, DOI 10.4161/auto.24633
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   ZHAO Z, 2011, PRINTING DYEING, V10, P6, DOI DOI 10.1371/J0URN
   Zheng Q, 2018, NEUROSCI LETT, V662, P264, DOI 10.1016/j.neulet.2017.10.051
   Zhou C, 2008, P NATL ACAD SCI USA, V105, P12022, DOI 10.1073/pnas.0802814105
NR 184
TC 45
Z9 48
U1 10
U2 35
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD AUG
PY 2018
VL 75
IS 16
BP 2991
EP 3008
DI 10.1007/s00018-018-2843-7
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GL7ZN
UT WOS:000437429000007
PM 29777261
DA 2022-11-30
ER

PT J
AU Coleman, DJ
   Lee, W
   Chang, S
   Silverman, RH
   Lloyd, HO
   Daly, S
   Tsang, SH
AF Coleman, D. Jackson
   Lee, Winston
   Chang, Stanley
   Silverman, Ronald H.
   Lloyd, Harriet O.
   Daly, Suzanne
   Tsang, Stephen H.
TI Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year
   Trial
SO OPHTHALMOLOGICA
LA English
DT Article
DE Macular degeneration; Sildenafil; Viagra; Phosphodiesterase; Warburg
   glycolysis
ID BLOOD-FLOW; CHOROIDAL PERFUSION; MEMBRANE CHANGE; CITRATE; THICKNESS;
   VIAGRA
AB Objective: To evaluate PDE5/6 inhibition with sildenafil to reduce choroidal ischemia and treat age-related macular degeneration. Methods: Sildenafil was prescribed to treat participants with macular degenerations or macular dystrophies measured by spectral-domain optical coherence tomography, color fundus photography, enhanced depth imaging, and best-corrected visual acuity. Results: No change in calcified drusen was noted. Vitelliform-type soft drusen were not substantially changed. A participant with Best vitelliform macular dystrophy had a significant improvement in vision as well as in photoreceptor and ellipsoid layers. Conclusions: Our research supports sildenafil as a safe treatment for age-related and vitelliform macular degenerations. Thickened Bruch's membrane reduces the beneficial effect of perfusion increase, but all eyes appear to benefit from PDE6. Notably, maintenance or improvement in the photoreceptor layer may be the most significant result of sildenafil and is consistent with PDE6 inhibition. Thus, sildenafil treatment of macular degeneration offers significant potential for vision retention and recovery. (C) 2018 S. Karger AG, Basel
C1 [Coleman, D. Jackson; Lee, Winston; Chang, Stanley; Silverman, Ronald H.; Lloyd, Harriet O.; Daly, Suzanne; Tsang, Stephen H.] Columbia Univ, Dept Ophthalmol, 635 West 165th St, New York, NY 10032 USA.
   [Tsang, Stephen H.] Columbia Univ, Jonas Childrens Vis Care, New York, NY 10032 USA.
   [Tsang, Stephen H.] Columbia Univ, Bernard & Shirlee Brown Glaucoma Lab, New York, NY 10032 USA.
   [Tsang, Stephen H.] Columbia Univ Coll Phys & Surg, Inst Human Nutr, Dept Pathol & Cell Biol, 630 W 168th St, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University
RP Coleman, DJ; Tsang, SH (通讯作者)，Columbia Univ, Dept Ophthalmol, 635 West 165th St, New York, NY 10032 USA.
EM djc2188@columbia.edu; sht2@columbia.edu
RI Silverman, Ronald H/A-5155-2018; Cote, Rick H/G-3363-2013; Chang,
   Stanley/AAL-2741-2021; Lee, Winston/CAA-0102-2022
OI Silverman, Ronald H/0000-0003-1509-3011; Cote, Rick
   H/0000-0002-1573-6526; Lee, Winston/0000-0002-1777-8519
FU National Institutes of Health [5P30EY019007, R01EY018213, R01EY024698,
   R01EY026682, R21AG050437]; National Cancer Institute Core
   [5P30CA013696]; Research to Prevent Blindness (RPB) Physician-Scientist
   Award; RPB, New York, NY, USA; Triad Foundation, Ithaca, NY, USA;
   NATIONAL EYE INSTITUTE [P30EY019007] Funding Source: NIH RePORTER
FX Jonas Children's Vision Care and Bernard and Shirlee Brown Glaucoma
   Laboratory are supported by grants from the National Institutes of
   Health (5P30EY019007, R01EY018213, R01EY024698, R01EY026682,
   R21AG050437), National Cancer Institute Core (5P30CA013696), the
   Research to Prevent Blindness (RPB) Physician-Scientist Award (S.H.T.),
   unrestricted funds from RPB, New York, NY, USA, and Triad Foundation,
   Ithaca, NY, USA. Writing services were provided by Jim Sliney Jr., RMA
   (Columbia University, New York, NY, USA).
CR BIRD AC, 1991, EYE, V5, P1
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Cordell WH, 2009, ARCH OPHTHALMOL-CHIC, V127, P367, DOI 10.1001/archophthalmol.2009.36
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   FRIEDMAN E, 1965, BIBL ANAT, P129
   Galie N, 2005, NEW ENGL J MED, V353, P2148, DOI 10.1056/NEJMoa050010
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Harris A, 2008, BRIT J OPHTHALMOL, V92, P469, DOI 10.1136/bjo.2007.131789
   Hayreh SS, 2009, PROG RETIN EYE RES, V28, P34, DOI 10.1016/j.preteyeres.2008.11.002
   Kim DY, 2013, ACTA OPHTHALMOL, V91, P183, DOI 10.1111/j.1755-3768.2011.02305.x
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurtulan E, 2004, INT J IMPOT RES, V16, P244, DOI 10.1038/sj.ijir.3901189
   Laties AM, 2009, DRUG SAFETY, V32, P1, DOI 10.2165/00002018-200932010-00001
   Lin Michael K, 2015, Taiwan J Ophthalmol, V5, P105, DOI 10.1016/j.tjo.2015.06.002
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Steinle JJ, 2000, AM J PHYSIOL-REG I, V279, pR202, DOI 10.1152/ajpregu.2000.279.1.R202
   Urs R, 2016, INVEST OPHTH VIS SCI, V57, P3810, DOI 10.1167/iovs.16-19538
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P332, DOI 10.1097/IAE.0b013e3181eef0ae
   Wirostko BM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e554
NR 24
TC 10
Z9 10
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 240
IS 1
BP 45
EP 54
DI 10.1159/000486105
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GK2LT
UT WOS:000435962400007
PM 29694963
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Garcia-Garcia, L
   Recalde, S
   Hernandez, M
   Bezunartea, J
   Rodriguez-Madoz, JR
   Johnen, S
   Diarra, S
   Marie, C
   Izsvak, Z
   Ivics, Z
   Scherman, D
   Kropp, M
   Thumann, G
   Prosper, F
   Fernandez-Robredo, P
   Garcia-Layana, A
AF Garcia-Garcia, Laura
   Recalde, Sergio
   Hernandez, Maria
   Bezunartea, Jaione
   Roberto Rodriguez-Madoz, Juan
   Johnen, Sandra
   Diarra, Sabine
   Marie, Corinne
   Izsvak, Zsuzsanna
   Ivics, Zoltan
   Scherman, Daniel
   Kropp, Martina
   Thumann, Gabriele
   Prosper, Felipe
   Fernandez-Robredo, Patricia
   Garcia-Layana, Alfredo
TI Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after
   Sleeping Beauty Transposon-Mediated Gene Delivery
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INDUCED CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; INTRAVITREAL BEVACIZUMAB; TRANSGENE EXPRESSION; VECTOR;
   THERAPY; MODEL; RANIBIZUMAB; SYSTEM
AB Pigment epithelium derived factor (PEDF) is a potent antiangiogenic, neurotrophic, and neuroprotective molecule that is the endogenous inhibitor of vascular endothelial growth factor (VEGF) in the retina. An ex vivo gene therapy approach based on transgenic overexpression of PEDF in the eye is assumed to rebalance the angiogenic-antiangiogenic milieu of the retina, resulting in growth regression of choroidal blood vessels, the hallmark of neovascular age-related macular degeneration. Here, we show that rat pigment epithelial cells can be efficiently transfected with the PEDF-expressing non-viral hyperactive Sleeping Beauty transposon system delivered in a form free of antibiotic resistance marker miniplasmids. The engineered retinal and iris pigment epithelium cells secrete high (141 +/- 13 and 222 +/- 14 ng) PEDF levels in 72 hr in vitro. In vivo studies showed cell survival and insert expression during at least 4 months. Transplantation of the engineered cells to the subretinal space of a rat model of choroidal neovascularization reduces almost 50% of the development of new vessels.
C1 [Garcia-Garcia, Laura; Recalde, Sergio; Hernandez, Maria; Bezunartea, Jaione; Fernandez-Robredo, Patricia; Garcia-Layana, Alfredo] Univ Navarra, Expt Ophthalmol Lab, Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain.
   [Roberto Rodriguez-Madoz, Juan; Prosper, Felipe] Univ Navarra, Navarra Inst Hlth Res, Cell Therapy Program, Ctr Appl Med Res CIMA,IdiSNA, Pamplona 31008, Spain.
   [Johnen, Sandra; Diarra, Sabine] Univ Hosp RWTH Aachen, Dept Ophthalmol, Pauwelsstr 30, D-52074 Aachen, Germany.
   [Marie, Corinne; Scherman, Daniel] CNRS, UTCBS UMR 8258, F-75006 Paris, France.
   [Marie, Corinne; Scherman, Daniel] Univ Paris 05, Sorbonne Paris Cite, UTCBS, F-75006 Paris, France.
   [Marie, Corinne; Scherman, Daniel] PSL Res Univ, Chim ParisTech, UTCBS, F-75005 Paris, France.
   [Marie, Corinne; Scherman, Daniel] INSERM, UTCBS U1022, F-75006 Paris, France.
   [Izsvak, Zsuzsanna] Max Delbruck Ctr Mol Med Helmholtz Soc, D-13125 Berlin, Germany.
   [Ivics, Zoltan] Paul Ehrlich Inst, Div Med Biotechnol, D-63225 Langen, Germany.
   [Kropp, Martina; Thumann, Gabriele] Univ Geneva, Expt Ophthalmol, CH-1205 Geneva, Switzerland.
   [Kropp, Martina; Thumann, Gabriele] Univ Hosp & Sch Med, Dept Ophthalmol, 22 Rue Alcide Jentzer, CH-1205 Geneva, Switzerland.
   [Prosper, Felipe] Univ Navarra, Navarra Inst Hlth Res, Clin Univ Navarra, Area Cell Therapy,IdiSNA, Pamplona 31008, Spain.
   [Garcia-Layana, Alfredo] Clin Univ Navarra, Ophthalmol Dept, Pamplona 31008, Spain.
C3 University of Navarra; University of Navarra; RWTH Aachen University;
   RWTH Aachen University Hospital; Centre National de la Recherche
   Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French
   Research Universities; Universite Paris Cite; UDICE-French Research
   Universities; Universite Paris Cite; UDICE-French Research Universities;
   PSL Research University Paris; Chimie ParisTech; Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; Helmholtz
   Association; Max Delbruck Center for Molecular Medicine; Paul Ehrlich
   Institute; University of Geneva; University of Navarra; University of
   Navarra
RP Fernandez-Robredo, P (通讯作者)，Univ Navarra, Expt Ophthalmol Lab, Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain.
EM pfrobredo@unav.es
RI Johnen, Sandra/ABA-9955-2020; Recalde, Sergio/D-1815-2017;
   Rodriguez-Madoz, Juan Roberto/N-3667-2014; Prosper, Felipe/H-6859-2017;
   Kropp, Martina/H-9260-2018
OI Johnen, Sandra/0000-0003-0028-2557; Recalde, Sergio/0000-0002-9328-9725;
   Rodriguez-Madoz, Juan Roberto/0000-0003-4327-1866; Prosper,
   Felipe/0000-0001-6115-8790; Scherman, Daniel/0000-0003-1207-1298; Kropp,
   Martina/0000-0001-6861-5851; MARIE, Corinne/0000-0001-9619-5700
FU European Union's Seventh Framework Programme for research, technological
   development and demonstration [305134]; Asociacion de Amigos de la
   Universidad de Navarra
FX This project has received funding from the European Union's Seventh
   Framework Programme for research, technological development and
   demonstration under grant agreement number 305134 (TargetAMD). L.G.-G.
   received a predoctoral grant from the Asociacion de Amigos de la
   Universidad de Navarra. Perry Hackett (University of Minnesota) is
   kindly acknowledged for the gift of pT2/BH.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Ivanescu AA, 2015, NUTRIENTS, V7, P5423, DOI 10.3390/nu7075229
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Belay E, 2011, CURR GENE THER, V11, P406
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chung SI, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0423-6
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Fernandez-Robredo P, 2013, MOL VIS, V19, P153
   Garcia-Layana A, 2009, OPHTHALMIC RES, V42, P205, DOI 10.1159/000232946
   Hackett PB, 2010, MOL THER, V18, P674, DOI 10.1038/mt.2010.2
   Haddock LJ, 2014, SEMIN OPHTHALMOL, V29, P257, DOI 10.3109/08820538.2014.959616
   Hartman ZC, 2008, VIRUS RES, V132, P1, DOI 10.1016/j.virusres.2007.10.005
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hudecek M, 2017, CRIT REV BIOCHEM MOL, V52, P355, DOI 10.1080/10409238.2017.1304354
   Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047
   Izsvak Z, 2010, BIOESSAYS, V32, P756, DOI 10.1002/bies.201000027
   Izsvak Z, 2009, METHODS, V49, P287, DOI 10.1016/j.ymeth.2009.07.001
   Jackson TL, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5058
   Johnen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/863845
   Johnen S, 2012, INVEST OPHTH VIS SCI, V53, P4787, DOI 10.1167/iovs.12-9951
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Kwong TQ, 2014, BRIT J CLIN PHARMACO, V78, P699, DOI 10.1111/bcp.12371
   Lambert NG, 2016, EXP EYE RES, V145, P248, DOI 10.1016/j.exer.2016.01.009
   Li FL, 2015, EXP EYE RES, V136, P78, DOI 10.1016/j.exer.2015.05.004
   Liu GY, 2005, J MOL BIOL, V346, P161, DOI 10.1016/j.jmb.2004.09.086
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Marie C, 2010, J GENE MED, V12, P323, DOI 10.1002/jgm.1441
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Riviere C, 2006, GENE THER, V13, P1300, DOI 10.1038/sj.gt.3302766
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Sivaprasad S, 2013, BRIT MED BULL, V105, P201, DOI 10.1093/bmb/ldt004
   Thumann G, 2017, MOL THER-NUCL ACIDS, V6, P302, DOI 10.1016/j.omtn.2017.02.002
   Thumann G, 2012, CURR GENOMICS, V13, P350, DOI 10.2174/138920212801619214
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Turuneni TAK, 2016, MOL THER, V24, P620, DOI 10.1038/mt.2015.221
   Walisko O, 2008, MOL THER, V16, P359, DOI 10.1038/sj.mt.6300366
   Xue XK, 2009, BLOOD, V114, P1319, DOI 10.1182/blood-2009-03-210005
   Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005
   Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568
   Yoshioka Y, 2006, INVEST OPHTH VIS SCI, V47, P745, DOI 10.1167/iovs.05-0398
   Zayed H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024
   Zhang XH, 2015, MOL THER, V23, P226, DOI 10.1038/mt.2014.199
NR 50
TC 12
Z9 13
U1 1
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD DEC 15
PY 2017
VL 9
BP 1
EP 11
DI 10.1016/j.omtn.2017.08.001
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FQ6SJ
UT WOS:000418494000001
PM 29246287
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, J
   Mirando, AC
   Popel, AS
   Green, JJ
AF Kim, Jayoung
   Mirando, Adam C.
   Popel, Aleksander S.
   Green, Jordan J.
TI Gene delivery nanoparticles to modulate angiogenesis
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Non-viral; Gene therapy; Polymeric nanoparticles; Ischemia; Wound
   healing; Tissue engineering; Tumor; Age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MESENCHYMAL
   STEM-CELLS; NITRIC-OXIDE SYNTHASE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA;
   VASCULAR-PERMEABILITY FACTOR; WATER-SOLUBLE LIPOPOLYMER; ENGINEERING
   THICK TISSUES; PLACEBO-CONTROLLED TRIAL; SHORT HAIRPIN RNA
AB Angiogenesis is naturally balanced by many pro- and anti-angiogenic factors while an imbalance of these factors leads to aberrant angiogenesis, which is closely associated with many diseases. Gene therapy has become a promising strategy for the treatment of such a disordered state through the introduction of exogenous nucleic acids that express or silence the target agents, thereby engineering neovascularization in both directions. Numerous non-viral gene delivery nanoparticles have been investigated towards this goal, but their clinical translation has been hampered by issues associated with safety, delivery efficiency, and therapeutic effect This review summarizes key factors targeted for therapeutic angiogenesis and anti-angiogenesis gene therapy, non-viral nano particle-mediated approaches to gene delivery, and recent gene therapy applications in pre-clinical and clinical trials for ischemia, tissue regeneration, cancer, and wet age-related macular degeneration. Enhanced nanoparticle design strategies are also proposed to further improve the efficacy of gene delivery nanoparticles to modulate angiogenesis. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Kim, Jayoung; Mirando, Adam C.; Popel, Aleksander S.; Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21231 USA.
   [Kim, Jayoung; Green, Jordan J.] Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD 21231 USA.
   [Kim, Jayoung; Green, Jordan J.] Johns Hopkins Univ, Sch Med, Inst Nanobiotechnol, Baltimore, MD 21231 USA.
   [Mirando, Adam C.; Popel, Aleksander S.; Green, Jordan J.] Johns Hopkins Univ, Dept Oncol, Sch Med, Baltimore, MD 21231 USA.
   [Mirando, Adam C.; Popel, Aleksander S.; Green, Jordan J.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21231 USA.
   [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Mat Sci & Engn, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins University;
   Johns Hopkins University
RP Green, JJ (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21231 USA.
EM green@jhu.edu
RI Green, Jordan/B-9001-2009; Popel, Aleksander S/A-6724-2009
OI Green, Jordan/0000-0003-4176-3808; Popel, Aleksander/0000-0002-6706-9235
FU National Institutes of Health [R01EB016721, R01HL101200, R21EY026148,
   R01CA138264]; Samsung Scholarship; NATIONAL CANCER INSTITUTE
   [R01CA138264] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R21EY026148] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R01HL101200] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB016721] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institutes of Health
   [R01EB016721, R01HL101200, R21EY026148 and R01CA138264] and a Samsung
   Scholarship to JK.
CR Ahmad S, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-15
   Ahmed RPH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008576
   Akita H, 2015, J CONTROL RELEASE, V200, P97, DOI 10.1016/j.jconrel.2014.12.029
   Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186
   [Anonymous], 2016, SAFETY TOLERABILITY
   [Anonymous], 2016, GENE THERAPY CLIN TR
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Aurora AB, 2010, BLOOD, V116, P475, DOI 10.1182/blood-2009-07-232132
   Awe JP, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt163
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Balaji S, 2014, J SURG RES, V190, P367, DOI 10.1016/j.jss.2014.02.051
   BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176
   Banfi A, 2012, FASEB J, V26, P2486, DOI 10.1096/fj.11-197400
   Barleon Bernhard, 2001, Angiogenesis, V4, P143, DOI 10.1023/A:1012245307884
   Becerra SP, 2013, NAT REV CANCER, V13, P258, DOI 10.1038/nrc3484
   Belch J, 2011, LANCET, V377, P1929, DOI 10.1016/S0140-6736(11)60394-2
   Belkacemi L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0278-7
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bhise NS, 2012, SMALL, V8, P367, DOI 10.1002/smll.201101718
   Bijlsma MF, 2008, EXP BIOL MED, V233, P989, DOI 10.3181/0711-RM-307
   Bishop CJ, 2015, CHEM COMMUN, V51, P12134, DOI 10.1039/c5cc04417k
   Bishop CJ, 2013, J AM CHEM SOC, V135, P6951, DOI 10.1021/ja4002376
   Blanco R, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006569
   Bloomston M, 2002, J SURG RES, V102, P39, DOI 10.1006/jsre.2001.6318
   Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Breunig M, 2005, J GENE MED, V7, P1287, DOI 10.1002/jgm.775
   Bridgewater RE, 2012, J CELL SCI, V125, P3695, DOI 10.1242/jcs.095810
   BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649
   BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629
   Campochiaro PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cano MD, 2009, INVEST OPHTH VIS SCI, V50, P3840, DOI 10.1167/iovs.08-2607
   Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Cassar A, 2009, MAYO CLIN PROC, V84, P1130, DOI 10.4065/mcp.2009.0391
   Chakrabarti S, 2012, J LEUKOCYTE BIOL, V91, P947, DOI 10.1189/jlb.1011513
   Cho EC, 2011, NAT NANOTECHNOL, V6, P385, DOI [10.1038/NNANO.2011.58, 10.1038/nnano.2011.58]
   Cho SW, 2012, J CONTROL RELEASE, V160, P515, DOI 10.1016/j.jconrel.2012.03.006
   Chu HH, 2011, P NATL ACAD SCI USA, V108, P13444, DOI 10.1073/pnas.1110121108
   Chun TH, 1997, HYPERTENSION, V29, P1296, DOI 10.1161/01.HYP.29.6.1296
   Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579
   Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   Curtin CM, 2015, ADV HEALTHC MATER, V4, P223, DOI 10.1002/adhm.201400397
   Dash BC, 2015, BIOMATERIALS, V65, P126, DOI 10.1016/j.biomaterials.2015.06.037
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dehghanian Fariba, 2014, Avicenna Journal of Medical Biotechnology, V6, P192
   DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045
   Devalliere J, 2014, FASEB J, V28, P908, DOI 10.1096/fj.13-238527
   Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
   Ding H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063628
   Ding SL, 2003, BLOOD, V101, P4816, DOI 10.1182/blood-2002-06-1731
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Durymanov MO, 2012, J CONTROL RELEASE, V163, P211, DOI 10.1016/j.jconrel.2012.08.027
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Einmahl S, 2002, INVEST OPHTH VIS SCI, V43, P1533
   El-Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Elangovan S, 2014, BIOMATERIALS, V35, P737, DOI 10.1016/j.biomaterials.2013.10.021
   Elkin M, 2004, JNCI-J NATL CANCER I, V96, P875, DOI 10.1093/jnci/djh140
   Eltoukhy AA, 2013, ADV MATER, V25, P1487, DOI 10.1002/adma.201204346
   Endo-Takahashi Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep03883
   Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6
   Fernandez-Patron C, 1999, CIRC RES, V85, P906
   Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Fujii H, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.20
   Fujii H, 2011, EUR HEART J, V32, P2075, DOI 10.1093/eurheartj/ehq475
   Fujii H, 2009, JACC-CARDIOVASC IMAG, V2, P869, DOI 10.1016/j.jcmg.2009.04.008
   Furuse J, 2008, BIOL-TARGETS THER, V2, P779
   Gabhann FM, 2008, MICROCIRCULATION, V15, P715, DOI 10.1080/10739680802095964
   Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603
   Gao WW, 2015, J DRUG TARGET, V23, P619, DOI 10.3109/1061186X.2015.1052074
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Gaya A, 2012, CANCER TREAT REV, V38, P484, DOI 10.1016/j.ctrv.2011.12.008
   Gianni-Barrera R, 2014, BIOCHEM SOC T, V42, P1637, DOI 10.1042/BST20140234
   Ginn SL, 2013, J GENE MED, V15, P65, DOI 10.1002/jgm.2698
   Giusti II, 2013, HUM GENE THER METHOD, V24, P298, DOI 10.1089/hgtb.2012.221
   Godbey WT, 1999, J BIOMED MATER RES, V45, P268, DOI 10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q
   Gomes RSM, 2013, ACS NANO, V7, P3362, DOI 10.1021/nn400171w
   Green JJ, 2008, ACCOUNTS CHEM RES, V41, P749, DOI 10.1021/ar7002336
   Green JJ, 2006, BIOCONJUGATE CHEM, V17, P1162, DOI 10.1021/bc0600968
   Grines CL, 2003, J AM COLL CARDIOL, V42, P1339, DOI 10.1016/S0735-1097(03)00988-4
   Gubskaya AV, 2011, MACROMOL THEOR SIMUL, V20, P275, DOI 10.1002/mats.201000087
   Guo JF, 2012, BIOMATERIALS, V33, P7775, DOI 10.1016/j.biomaterials.2012.07.012
   Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8
   Han SO, 2001, BIOCONJUGATE CHEM, V12, P337, DOI 10.1021/bc000120w
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Heinl-Green A, 2005, EUR HEART J, V26, P1327, DOI 10.1093/eurheartj/ehi223
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543
   Ho TC, 2007, CARDIOVASC RES, V76, P213, DOI 10.1016/j.cardiores.2007.06.032
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Huang SX, 2013, ACS NANO, V7, P2860, DOI 10.1021/nn400548g
   Huang Z, 2012, LIFE SCI, V91, P1207, DOI 10.1016/j.lfs.2012.09.015
   Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710
   Hyvarinen J, 2010, J BIOL CHEM, V285, P13646, DOI 10.1074/jbc.M109.084855
   Ikenaka Y, 2003, INT J CANCER, V105, P340, DOI 10.1002/ijc.11094
   Iwasaki H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024872
   Iwase T, 2005, CIRCULATION, V111, P356, DOI 10.1161/01.CIR.0000153352.29335.B9
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jeon O, 2008, J CONTROL RELEASE, V132, P236, DOI 10.1016/j.jconrel.2008.05.017
   Jeong GJ, 2007, J CONTROL RELEASE, V118, P118, DOI 10.1016/j.jconrel.2006.12.009
   Jiang X, 2013, ADV MATER, V25, P227, DOI 10.1002/adma.201202932
   Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291
   Jin YN, 2012, GENE THER, V19, P836, DOI 10.1038/gt.2011.128
   Jo JI, 2007, TISSUE ENG, V13, P313, DOI 10.1089/ten.2006.0133
   Johnsen KB, 2014, BBA-REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005
   Kakishita M, 1999, CLIN SCI, V96, P33, DOI 10.1042/CS19980070
   Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209
   Kanazawa T, 2012, EUR J PHARM BIOPHARM, V81, P470, DOI 10.1016/j.ejpb.2012.04.021
   Karagiannis ED, 2008, P NATL ACAD SCI USA, V105, P13775, DOI 10.1073/pnas.0803241105
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Khoshnoodi J, 2008, MICROSC RES TECHNIQ, V71, P357, DOI 10.1002/jemt.20564
   Kido M, 2005, J AM COLL CARDIOL, V46, P2116, DOI 10.1016/j.jacc.2005.08.045
   Kilian EG, 2010, CIRC J, V74, P916, DOI 10.1253/circj.CJ-09-0594
   Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24
   Kim J, 2015, J DRUG TARGET, V23, P627, DOI 10.3109/1061186X.2015.1048519
   Kim J, 2014, BIOCONJUGATE CHEM, V25, P43, DOI 10.1021/bc4002322
   Kim J, 2011, OLIGONUCLEOTIDES, V21, P101, DOI 10.1089/oli.2011.0278
   Kim WJ, 2007, J CONTROL RELEASE, V118, P357, DOI 10.1016/j.jconrel.2006.12.026
   Kim WJ, 2006, J CONTROL RELEASE, V114, P381, DOI 10.1016/j.jconrel.2006.05.029
   King SB, 2010, ANNU REV MED, V61, P199, DOI 10.1146/annurev.med.032309.063039
   Ko H, 2007, EUR CELLS MATER, V14, P18
   Ko HCH, 2007, EUR CELLS MATER, V14, P1
   Koc A, 2014, J BIOMATER APPL, V29, P748, DOI 10.1177/0885328214544769
   Koskimaki JE, 2013, ANGIOGENESIS, V16, P159, DOI 10.1007/s10456-012-9308-7
   Kozielski KL, 2013, CHEM COMMUN, V49, P5319, DOI 10.1039/c3cc40718g
   Kusumanto YH, 2006, HUM GENE THER, V17, P683, DOI 10.1089/hum.2006.17.683
   LEE E, 2014, SCI REP UK, V4
   Lee E, 2013, NEOPLASIA, V15, P112, DOI 10.1593/neo.121638
   Lee E, 2011, INT J BIOCHEM CELL B, V43, P1812, DOI 10.1016/j.biocel.2011.08.020
   Lee SH, 2000, J BIOL CHEM, V275, P33679, DOI 10.1074/jbc.M004994200
   Leifler KS, 2013, J IMMUNOL, V190, P4420, DOI 10.4049/jimmunol.1202610
   Li HL, 2008, GENE THER, V15, P247, DOI 10.1038/sj.gt.3303038
   Li L, 2012, INT J PHARMACEUT, V438, P1, DOI 10.1016/j.ijpharm.2012.08.043
   Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878
   Liss M, 2009, AM J PATHOL, V175, P940, DOI 10.2353/ajpath.2009.081094
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Liu Y, 2007, J PATHOL, V212, P12, DOI 10.1002/path.2155
   Liu YG, 2011, J TRAUMA, V70, P1519, DOI 10.1097/TA.0b013e3181f31595
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899
   Logsdon EA, 2014, J CELL MOL MED, V18, P1491, DOI 10.1111/jcmm.12164
   Luan Q, 2011, CANCER LETT, V308, P100, DOI 10.1016/j.canlet.2011.04.019
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Magnon C, 2005, CANCER RES, V65, P4353, DOI 10.1158/0008-5472.CAN-04-3536
   Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638
   Manalo KB, 2011, EXPERT OPIN THER PAT, V21, P121, DOI 10.1517/13543776.2011.545347
   Mangraviti A, 2016, BIOMATERIALS, V100, P53, DOI 10.1016/j.biomaterials.2016.05.025
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Marelli UK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00222
   Martino MM, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00045
   Mayer CR, 2008, ADV DRUG DELIVER REV, V60, P1177, DOI 10.1016/j.addr.2008.03.004
   Meilander-Lin NJ, 2005, TISSUE ENG, V11, P546, DOI 10.1089/ten.2005.11.546
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   Meyer RA, 2015, SMALL, V11, P1519, DOI 10.1002/smll.201402369
   Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000
   Miller N, 2012, NAT REV DRUG DISCOV, V11, DOI 10.1038/nrd3572-c1
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.ymthe.2005.02.010
   Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200
   Moon HH, 2014, BIOMATERIALS, V35, P1744, DOI 10.1016/j.biomaterials.2013.11.019
   Muona K, 2012, GENE THER, V19, P392, DOI 10.1038/gt.2011.109
   Murakami M, 2011, J CLIN INVEST, V121, P2668, DOI 10.1172/JCI44762
   Nagaya N, 2005, AM J PHYSIOL-REG I, V288, pR1432, DOI 10.1152/ajpregu.00662.2004
   Nauta A, 2013, MOL THER, V21, P445, DOI 10.1038/mt.2012.234
   Nematollahi S, 2009, BIOMED PAP, V153, P125, DOI 10.5507/bp.2009.021
   Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674
   Nikitenko LL, 2003, FASEB J, V17, P1499, DOI 10.1096/fj.02-0993fje
   Nyberg P, 2008, EXP CELL RES, V314, P3292, DOI 10.1016/j.yexcr.2008.08.011
   Oba M, 2010, MOL PHARMACEUT, V7, P501, DOI 10.1021/mp9002317
   Oga M, 2003, INT J ONCOL, V23, P73
   OLINS DE, 1967, J MOL BIOL, V24, P157, DOI 10.1016/0022-2836(67)90324-5
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Mellet CO, 2011, CHEM SOC REV, V40, P1586, DOI 10.1039/c0cs00019a
   Ott P. A., 2016, CLIN CANC RES
   P. W. A. Lions Eye Institute I. Avalanche Biotechnologies, 2014, SAF EFF STUD RAAV SF
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Park HJ, 2012, BIOMATERIALS, V33, P9148, DOI 10.1016/j.biomaterials.2012.09.005
   Park JS, 2016, BIOMATERIALS, V76, P226, DOI 10.1016/j.biomaterials.2015.10.062
   Paulis L, 2015, SCI REP-UK, V5, DOI 10.1038/srep07983
   Pearson S, 2004, NAT BIOTECHNOL, V22, P3, DOI 10.1038/nbt0104-3
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x
   Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083
   Powell RJ, 2008, CIRCULATION, V118, P58, DOI 10.1161/CIRCULATIONAHA.107.727347
   Prea SM, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/201726
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Qi Y., 2015, PLOS ONE, V10
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rajagopalan S, 2003, AM HEART J, V145, P1114, DOI 10.1016/S0002-8703(03)00102-9
   Rakoczy EP, 2014, INVEST OPHTH VIS SCI, V55
   Ratner M, 2014, NAT BIOTECHNOL, V32, P701, DOI 10.1038/nbt0814-701
   Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745
   Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998
   Renmiao Z., RECOMBINANT HUMAN EN
   Ricard-Blum S, 2016, FRONT PHARMACOL, V7, DOI [10.3389/fphar.7016.00011, 10.3389/fphar.2016.00011]
   Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029
   Rodriguez PL, 2013, SCIENCE, V339, P971, DOI 10.1126/science.1229568
   Rosca EV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111901
   Rosca EV, 2012, CHEM BIOL DRUG DES, V80, P27, DOI 10.1111/j.1747-0285.2012.01376.x
   Rosca EV, 2011, CURR PHARM BIOTECHNO, V12, P1101
   Rosca EV, 2012, ANTI-CANCER DRUG, V23, P706, DOI 10.1097/CAD.0b013e3283531041
   Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x
   Rundle CH, 2008, J GENE MED, V10, P229, DOI 10.1002/jgm.1148
   Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369
   Sakurai Y, 2014, J CONTROL RELEASE, V173, P110, DOI 10.1016/j.jconrel.2013.10.003
   Salehi-Had H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018864
   Samura M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19379
   Sasaki M, 2001, MEDIAT INFLAMM, V10, P259, DOI 10.1080/09629350120093731
   Schirmer SH, 2009, HEART, V95, P191, DOI 10.1136/hrt.2007.136119
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8
   Shen QA, 2010, MOL CANCER RES, V8, P939, DOI 10.1158/1541-7786.MCR-09-0523
   Sheu SJ, 2005, EXP EYE RES, V81, P673, DOI 10.1016/j.exer.2005.04.005
   Shigematsu H, 2010, GENE THER, V17, P1152, DOI 10.1038/gt.2010.51
   Shih T, 2006, CLIN THER, V28, P1779, DOI 10.1016/j.clinthera.2006.11.015
   Shmueli RB, 2013, BIOMATERIALS, V34, P7544, DOI 10.1016/j.biomaterials.2013.06.044
   Shmueli RB, 2012, NANOMED-NANOTECHNOL, V8, P1200, DOI 10.1016/j.nano.2012.01.006
   Shyu KG, 2003, LIFE SCI, V73, P563, DOI 10.1016/S0024-3205(03)00318-7
   Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081
   Siegwart DJ, 2011, P NATL ACAD SCI USA, V108, P12996, DOI 10.1073/pnas.1106379108
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Song HM, 2014, INT J NANOMED, V9, P3439, DOI 10.2147/IJN.S65353
   Springer ML, 2003, MOL THER, V7, P441, DOI 10.1016/S1525-0016(03)00010-8
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Staquicini FI, 2011, J CLIN INVEST, V121, P161, DOI 10.1172/JCI44798
   Stewart DJ, 2009, MOL THER, V17, P1109, DOI 10.1038/mt.2009.70
   Storrie H, 2006, ADV DRUG DELIVER REV, V58, P500, DOI 10.1016/j.addr.2006.03.004
   Suk JS, 2016, ADV DRUG DELIVER REV, V99, P28, DOI 10.1016/j.addr.2015.09.012
   Sunshine JC, 2012, MOL PHARMACEUT, V9, P3375, DOI 10.1021/mp3004176
   Sunshine JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037543
   Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tanaka K, 2010, INT J PHARMACEUT, V396, P229, DOI 10.1016/j.ijpharm.2010.06.028
   Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Thomas M, 2007, PHARM RES-DORDR, V24, P1564, DOI 10.1007/s11095-007-9279-3
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tokatlian T, 2015, ADV HEALTHC MATER, V4, P1084, DOI 10.1002/adhm.201400783
   Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779
   Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y
   Verma IM, 2000, MOL THER, V2, P415, DOI 10.1006/mthe.2000.0213
   Vincent L, 2003, INT J CANCER, V105, P419, DOI 10.1002/ijc.11105
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wang HB, 2014, J NEUROPATH EXP NEUR, V73, P548, DOI 10.1097/NEN.0000000000000077
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4
   Wang W., 2016, HUM GENE THER
   Wasungu L, 2006, J CONTROL RELEASE, V116, P255, DOI 10.1016/j.jconrel.2006.06.024
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212
   Whayne TF, 2012, INT J ANGIOL, V21, P187, DOI 10.1055/s-0032-1330232
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187
   Won YW, 2014, NAT MATER, V13, P1157, DOI [10.1038/NMAT4092, 10.1038/nmat4092]
   Woo J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144491
   Woodall BP, 2008, J BIOL CHEM, V283, P2335, DOI 10.1074/jbc.M708364200
   Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x
   Wu YY, 2014, BIOMACROMOLECULES, V15, P1716, DOI 10.1021/bm5001229
   Xi L, 2004, AM J PHYSIOL-HEART C, V287, pH2369, DOI 10.1152/ajpheart.00422.2004
   Xiao JS, 2013, BIOMATERIALS, V34, P5381, DOI 10.1016/j.biomaterials.2013.03.084
   Xu XL, 1998, DEVELOPMENT, V125, P753
   Yamaguchi T, 2007, CANCER SCI, V98, P405, DOI 10.1111/j.1349-7006.2007.00402.x
   Yang F, 2010, P NATL ACAD SCI USA, V107, P3317, DOI 10.1073/pnas.0905432106
   Yang HN, 2012, BIOMATERIALS, V33, P8670, DOI 10.1016/j.biomaterials.2012.08.012
   Yang ZJ, 2010, MOL BIOL REP, V37, P2075, DOI 10.1007/s11033-009-9665-5
   Ye L, 2008, BIOMATERIALS, V29, P2125, DOI 10.1016/j.biomaterials.2008.01.014
   Ye L, 2007, CIRCULATION, V116, pI113, DOI 10.1161/CIRCULATIONAHA.106.680124
   Ye W, 2014, MOL THER, V22, P1221, DOI 10.1038/mt.2014.53
   Yeh TS, 2014, BIOMATERIALS, V35, P174, DOI 10.1016/j.biomaterials.2013.09.080
   Yi F, 2006, J CLIN PHARM THER, V31, P43, DOI 10.1111/j.1365-2710.2006.00702.x
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yockman JW, 2009, GENE THER, V16, P127, DOI 10.1038/gt.2008.146
   Yu B, 2009, AAPS J, V11, P195, DOI 10.1208/s12248-009-9096-1
   Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102
   Yu K, 2016, J EXP NANOSCI, V11, P81, DOI 10.1080/17458080.2015.1029015
   Zhang C, 2010, GENE THER, V17, P338, DOI 10.1038/gt.2009.158
   Zhang Y, 2012, MOL THER, V20, P1298, DOI 10.1038/mt.2012.79
   Zhu K, 2016, BIOMATERIALS, V74, P188, DOI 10.1016/j.biomaterials.2015.10.010
   Zulliger R, 2015, J CONTROL RELEASE, V219, P471, DOI 10.1016/j.jconrel.2015.10.007
   Zymek P, 2006, J AM COLL CARDIOL, V48, P2315, DOI 10.1016/j.jacc.2006.07.060
NR 295
TC 41
Z9 44
U1 3
U2 76
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD SEP 15
PY 2017
VL 119
SI SI
BP 20
EP 43
DI 10.1016/j.addr.2016.11.003
PG 24
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FO1EO
UT WOS:000416499700003
PM 27913120
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Farnoodian, M
   Wang, SJ
   Dietz, J
   Nickells, RW
   Sorenson, CM
   Sheibani, N
AF Farnoodian, Mitra
   Wang, Shoujian
   Dietz, Joel
   Nickells, Robert W.
   Sorenson, Christine M.
   Sheibani, Nader
TI Negative regulators of angiogenesis: important targets for treatment of
   exudative AMD
SO CLINICAL SCIENCE
LA English
DT Review
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE
   SYNTHASE; RETINAL VASCULAR DEVELOPMENT; MEDIATED VESSEL OBLITERATION;
   PIGMENT-EPITHELIUM; MACULAR DEGENERATION; TUMOR-GROWTH; CHOROIDAL
   NEOVASCULARIZATION; INTRAOCULAR-PRESSURE
AB Angiogenesis contributes to the pathogenesis of many diseases including exudative age-related macular degeneration (AMD). It is normally kept in check by a tightly balanced production of pro- and anti-angiogenic factors. The up-regulation of the pro-angiogenic factor, vascular endothelial growth factor (VEGF), is intimately linked to the pathogenesis of exudative AMD, and its antagonism has been effectively targeted for treatment. However, very little is known about potential changes in expression of anti-angiogenic factors and the role they play in choroidal vascular homeostasis and neovascularization associated with AMD. Here, we will discuss the important role of thrombospondins and pigment epithelium-derived factor, two major endogenous inhibitors of angiogenesis, in retinal and choroidal vascular homeostasis and their potential alterations during AMD and choroidal neovascularization (CNV). We will review the cell autonomous function of these proteins in retinal and choroidal vascular cells. We will also discuss the potential targeting of these molecules and use of their mimetic peptides for therapeutic development for exudative AMD.
C1 [Farnoodian, Mitra; Wang, Shoujian; Dietz, Joel; Nickells, Robert W.; Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Sorenson, Christine M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA.
   [Sheibani, Nader] Univ Wisconsin, Dept Biomed Engn, Sch Med & Publ Hlth, Madison, WI 53706 USA.
   [Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Cell & Regenerat Biol, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Sheibani, N (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.; Sheibani, N (通讯作者)，Univ Wisconsin, Dept Biomed Engn, Sch Med & Publ Hlth, Madison, WI 53706 USA.; Sheibani, N (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Cell & Regenerat Biol, Madison, WI 53706 USA.
EM nsheibanikar@wisc.edu
RI Sheibani, Nader/AAG-2379-2020
OI Sheibani, Nader/0000-0003-2723-9217
FU Research to Prevent Blindness; Retina Research Foundation; NIH [P30
   EY016665, P30 CA014520, EPA 83573701, EY022883, EY012223]; RRF/Daniel M.
   Albert Chair; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source:
   NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY022883, R01EY012223,
   R29EY012223, P30EY016665, R01EY026078] Funding Source: NIH RePORTER
FX This work was supported by an unrestricted award from Research to
   Prevent Blindness to the Department of Ophthalmology and Visual Sciences
   and Retina Research Foundation, and NIH grants P30 EY016665, P30
   CA014520, EPA 83573701, EY022883 and EY012223. CMS is supported by the
   RRF/Daniel M. Albert Chair.
CR Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25
   Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5
   Alberdi Elena M, 2003, BMC Biochem, V4, P1, DOI 10.1186/1471-2091-4-1
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2
   BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Brouzas D, 2009, CLIN OPHTHALMOL, V3, P457
   Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2010, AM J OPHTHALMOL, V149, P839, DOI 10.1016/j.ajo.2009.12.005
   Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M
   Cao YH, 2004, SEMIN THROMB HEMOST, V30, P83
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carron JA, 2000, INT J BIOCHEM CELL B, V32, P1137, DOI 10.1016/S1357-2725(00)00065-0
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   CLEZARDIN P, 1993, CANCER RES, V53, P1421
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Damico R, 2015, AM J RESP CRIT CARE, V191, P208, DOI 10.1164/rccm.201409-1742OC
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Del Moral PM, 2006, DEV BIOL, V290, P177, DOI 10.1016/j.ydbio.2005.11.022
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Deryugina EI, 2015, MATRIX BIOL, V44-46, P94, DOI 10.1016/j.matbio.2015.04.004
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Farnoodian M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12266
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Fei P, 2015, J OCUL PHARMACOL TH, V31, P429, DOI 10.1089/jop.2014.0151
   Fei P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116423
   Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gao X, 2014, SCI REP-UK, V4, DOI 10.1038/srep05637
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367
   Hajitou A, 2002, FASEB J, V16, P1802, DOI 10.1096/fj.02-0109fje
   Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Hjelmeland LM, 1999, MOL VIS, V5
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Houenou LJ, 1999, J COMP NEUROL, V412, P506
   Hua J, 2012, MOL VIS, V18, P1045
   Huang Q, 2008, EXP EYE RES, V87, P226, DOI 10.1016/j.exer.2008.06.003
   Isenberg JS, 2009, J BIOL CHEM, V284, P1116, DOI 10.1074/jbc.M804860200
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Karakousis PC, 2001, MOL VIS, V7, P154
   Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8
   Kaur S, 2010, J BIOL CHEM, V285, P38923, DOI 10.1074/jbc.M110.172304
   Kibbe M, 1999, CARDIOVASC RES, V43, P650, DOI 10.1016/S0008-6363(99)00130-3
   Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200
   Kisselev O.G., 2007, THROMBOSPONDIN 1 SIG, P329
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x
   Leal EC, 2007, INVEST OPHTH VIS SCI, V48, P5257, DOI 10.1167/iovs.07-0112
   Li FY, 2000, BIOCHEM BIOPH RES CO, V278, P821, DOI 10.1006/bbrc.2000.3849
   Li Y, 1999, INVEST OPHTH VIS SCI, V40, P1004
   Longeras R, 2012, EXP DIABETES RES, DOI 10.1155/2012/518426
   Lopez-Dee Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/296069
   Ma XY, 2012, EXP CELL RES, V318, P251, DOI 10.1016/j.yexcr.2011.11.002
   Mac Nair CE, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0558-y
   Machalinska Anna, 2012, Klin Oczna, V114, P115
   MAGNUSSON S, 1975, PROTHROMBIN RELATED, P25
   Maik-Rachline G, 2006, BLOOD, V107, P2745, DOI 10.1182/blood-2005-06-2547
   Malchiodi-Albedi F, 1998, INT J DEV NEUROSCI, V16, P423, DOI 10.1016/S0736-5748(98)00014-8
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Mirochnik Y, 2009, CLIN CANCER RES, V15, P1655, DOI 10.1158/1078-0432.CCR-08-2113
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Miyata Y, 2013, INT J MOL SCI, V14, P12249, DOI 10.3390/ijms140612249
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   Mochizuki M, 2010, ACTA OPHTHALMOL, V88, P292, DOI 10.1111/j.1755-3768.2009.01757.x
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798
   Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811
   Mustafi D, 2013, FASEB J, V27, P4585, DOI 10.1096/fj.13-237537
   Nagareddy PR, 2005, AM J PHYSIOL-HEART C, V289, pH2144, DOI 10.1152/ajpheart.00591.2005
   Nguyen TMB, 2009, J CELL MOL MED, V13, P3687, DOI 10.1111/j.1582-4934.2009.00722.x
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ogata N, 2001, CURR EYE RES, V22, P245, DOI 10.1076/ceyr.22.4.245.5506
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Palenski TL, 2013, AM J PHYSIOL-CELL PH, V305, pC1170, DOI 10.1152/ajpcell.00139.2013
   Pan CK, 2013, EXPERT OPIN BIOL TH, V13, P1125, DOI 10.1517/14712598.2013.793304
   Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014
   Poluzzi C, 2016, ADV DRUG DELIVER REV, V97, P156, DOI 10.1016/j.addr.2015.10.012
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Scheef E, 2005, MOL VIS, V11, P613
   Scheef EA, 2009, AM J PHYSIOL-CELL PH, V296, pC724, DOI 10.1152/ajpcell.00409.2008
   Schlamp CL, 2013, MOL VIS, V19, P1387
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shay G, 2015, MATRIX BIOL, V44-46, P200, DOI 10.1016/j.matbio.2015.01.019
   Sheibani N, 1999, HISTOL HISTOPATHOL, V14, P285, DOI 10.14670/HH-14.285
   Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903
   Sheibani N., 2007, THROMBOSPONDIN 1 SIG, P329
   Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com
   Shin ES, 2014, AM J PHYSIOL-LUNG C, V306, pL620, DOI 10.1152/ajplung.00188.2013
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Sodha NR, 2009, AM J PHYSIOL-HEART C, V296, pH428, DOI 10.1152/ajpheart.00283.2008
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100
   Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008
   Tang YX, 2010, AM J PHYSIOL-CELL PH, V298, pC665, DOI 10.1152/ajpcell.00153.2009
   Tang YX, 2009, BLOOD, V113, P744, DOI 10.1182/blood-2008-03-145219
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Vailhe B, 2003, CURR PHARM DESIGN, V9, P583, DOI 10.2174/1381612033391342
   Volpert Katja N, 2009, J Ocul Biol Dis Infor, V2, P1, DOI 10.1007/s12177-009-9014-x
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Walia A, 2015, BBA-GEN SUBJECTS, V1850, P2422, DOI 10.1016/j.bbagen.2015.09.007
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P336, DOI 10.1001/archopthalmol.2011.1503
   Wang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P507, DOI 10.1001/archophthalmol.2009.53
   Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412
   Wang YJ, 2006, MICROVASC RES, V71, P143, DOI 10.1016/j.mvr.2006.02.004
   Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200
   Wickstrom SA, 2001, CANCER RES, V61, P6511
   Wickstrom SA, 2002, CANCER RES, V62, P5580
   Wu ZF, 2006, DEV DYNAM, V235, P1908, DOI 10.1002/dvdy.20837
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   Yang QW, 2007, CANCER RES, V67, P1716, DOI 10.1158/0008-5472.CAN-06-2595
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
   Zhang XF, 2007, MICROVASC RES, V74, P90, DOI 10.1016/j.mvr.2007.04.007
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 148
TC 29
Z9 32
U1 0
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD AUG 1
PY 2017
VL 131
IS 15
BP 1763
EP 1780
DI 10.1042/CS20170066
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FB4VD
UT WOS:000406139100001
PM 28679845
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Agarwal, A
   Invernizzi, A
   Kumari, N
   Singh, R
AF Agarwal, Aniruddha
   Invernizzi, Alessandro
   Kumari, Neha
   Singh, Ramandeep
TI Type II Macular Telangiectasia Presenting as Bilateral Retinochoroidal
   Anastomosis
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; idiopathic macular telangiectasia;
   optical coherence tomography; retinochoroidal anastomosis; retinal
   angiomatous proliferans
ID RETINAL ANGIOMATOUS PROLIFERATION; NEOVASCULARIZATION
AB Purpose Retinochoroidal anastamosis (RCA) is known to be associated with retinal angiomatous proliferans rather than idiopathic macular telangiectasia. The case report describes a rare association of bilateral RCA with type II idiopathic macular telangiectasia in an elderly woman.
   Case Report A 65-year-old female patient presented with decreased vision in both eyes to the ophthalmology clinic. She was diagnosed with bilateral large serous retinal pigment epithelial detachments (PED). Atypical association of PED with IMT led to additional imaging, including fluorescein angiography (FA), spectral-domain optical coherence tomography (SD-OCT), and indocyanine green angiography (ICGA). Multimodal imaging analysis revealed characteristic signs of RCA such as the so-called kissing sign on SD-OCT. The patient was not offered any treatment due to the poor prognosis associated with the condition.
   Conclusions Although more commonly associated with retinal angiomatous proliferans (type III neovascular age-related macular degeneration), RCA can present in type II IMT Stage 5.
C1 [Agarwal, Aniruddha] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA.
   [Invernizzi, Alessandro] Univ Milan, Eye Clin, Dept Biomed & Clin Sci, Luigi Sacco Hosp, Milan, Italy.
   [Kumari, Neha] Ctr Sight, New Delhi, India.
   [Singh, Ramandeep] Post Grad Inst Med Educ & Res, Dept Ophthalmol, Adv Eye Ctr, Sect 12, Chandigarh 160012, India.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Milan; Luigi Sacco Hospital; Post Graduate Institute of
   Medical Education & Research (PGIMER), Chandigarh
RP Singh, R (通讯作者)，Post Grad Inst Med Educ & Res, Dept Ophthalmol, Adv Eye Ctr, Sect 12, Chandigarh 160012, India.
EM mankoo95@yahoo.com
RI Invernizzi, Alessandro/K-8605-2016
OI Invernizzi, Alessandro/0000-0003-3400-1987
CR Li KKW, 2005, CLIN EXP OPHTHALMOL, V33, P542, DOI 10.1111/j.1442-9071.2005.01081.x
   Mezad-Koursh Daphna, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-64
   Narayanan R, 2012, RETINA-J RET VIT DIS, V32, P2001, DOI 10.1097/IAE.0b013e3182625c1d
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Sandali O, 2013, CAN J OPHTHALMOL, V48, pE78, DOI 10.1016/j.jcjo.2013.01.022
   Shanmugam Mahesh P., 2005, Indian Journal of Ophthalmology, V53, P61
   Shibeeb O, 2014, CASE REP OPHTHALMOL, V2014
   Wu L, 2013, SURV OPHTHALMOL, V58, P536, DOI 10.1016/j.survophthal.2012.11.007
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 10
TC 0
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD OCT
PY 2016
VL 93
IS 10
BP 1292
EP 1295
DI 10.1097/OPX.0000000000000952
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ2JJ
UT WOS:000385667800014
PM 27668494
DA 2022-11-30
ER

PT J
AU Ugarte, M
   Geraki, K
   Jeffery, G
AF Ugarte, Marta
   Geraki, Kalotina
   Jeffery, Glen
TI Iron accumulates in the primate choroid of the eye with aging as
   revealed with synchrotron X-ray fluorescence microscopy
SO METALLOMICS
LA English
DT Article
ID MACULAR DEGENERATION; FORMALIN FIXATION; ZINC; AGE; COPPER; HOMEOSTASIS;
   DISEASE; RETINA
AB Aging leads to an increase in iron-loaded cellular structures in the choroid of the eye. This study was carried out to determine the distribution and content of iron, zinc and copper in the macular retina, choroid and retrobulbar optic nerve of young (4-5 years, n = 3) and aged (15-16 years, n = 5) male non-human primates, Macaca fascicularis, whose ocular anatomy is similar to humans. Thirty mm-thick tissue sections were analysed with synchrotron X-ray fluorescence and stained histologically for iron deposition. Quantitative measurements showed high levels of iron, zinc and copper in the choroid and retinal pigment epithelium in the macular area and arachnoid layer in the retrobulbar optic nerve. In aged animals compared to young ones, there was an increase in iron in the choroid with larger deposits and iron-loaded cellular structures. Iron-accumulation within these cellular structures may contribute to choroidal function impairment in aging and age-related macular degeneration.
C1 [Ugarte, Marta] Moorfields Eye Hosp NHS Fdn Trust, London EC1V 2PD, England.
   [Ugarte, Marta] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Ugarte, Marta] UCL Inst Ophthalmol, London, England.
   [Geraki, Kalotina] Harwell Sci & Innovat Campus, Diamond Light Source, I18, Fermi Ave, Didcot OX11 0DE, Oxon, England.
   [Jeffery, Glen] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; Diamond Light Source; University of London;
   University College London
RP Ugarte, M (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, London EC1V 2PD, England.; Ugarte, M (通讯作者)，Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.; Ugarte, M (通讯作者)，UCL Inst Ophthalmol, London, England.
EM mugarte@doctors.org.uk
OI Geraki, Kalotina/0000-0001-6055-7060
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   (BRC) at Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
   Ophthalmology; BBSRC [BB/N000250/1]; Biotechnology and Biological
   Sciences Research Council [BB/N000250/1] Funding Source: researchfish
FX We acknowledge the Diamond Light Source for time on beamline I18 under
   proposal sp11372 and beamline B16 under proposal mt12446, as well as
   funding by the National Institute for Health Research (NIHR) Biomedical
   Research Centre (BRC) at Moorfields Eye Hospital NHS Foundation Trust
   and UCL Institute of Ophthalmology and BBSRC BB/N000250/1.
CR Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Bischoff K, 2008, J VET DIAGN INVEST, V20, P220, DOI 10.1177/104063870802000213
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Daugherty AM, 2015, NEUROPSYCHOL REV, V25, P272, DOI 10.1007/s11065-015-9292-y
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Erie JC, 2009, AM J OPHTHALMOL, V148, P890, DOI 10.1016/j.ajo.2009.07.001
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Ganz T, 2015, NAT REV IMMUNOL, V15, P500, DOI 10.1038/nri3863
   Hadzhieva M, 2014, NEUROPATH APPL NEURO, V40, P240, DOI 10.1111/nan.12096
   Hahn P, 2009, EXP GERONTOL, V44, P594, DOI 10.1016/j.exger.2009.06.006
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Kobayashi H, 2014, EXP ANIM TOKYO, V63, P305, DOI 10.1538/expanim.63.305
   Lansdown ABG, 2011, METAL IONS LIFE SCI, V8, P187, DOI 10.1039/978184973211600187
   Meguro R, 2007, ARCH HISTOL CYTOL, V70, P1, DOI 10.1679/aohc.70.1
   Mosselmans JFW, 2009, J SYNCHROTRON RADIAT, V16, P818, DOI 10.1107/S0909049509032282
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Sawhney KJS, 2010, AIP CONF PROC, V1234, P387, DOI 10.1063/1.3463220
   Schrag M, 2010, BIOMETALS, V23, P1123, DOI 10.1007/s10534-010-9359-4
   Seo AY, 2008, AGING CELL, V7, P706, DOI 10.1111/j.1474-9726.2008.00418.x
   Sole VA, 2007, SPECTROCHIM ACTA B, V62, P63, DOI 10.1016/j.sab.2006.12.002
   Tamano H, 2011, METALLOMICS, V3, P656, DOI 10.1039/c1mt00008j
   Theurl M, 2016, FASEB J, V30, P813, DOI 10.1096/fj.15-276758
   Ugarte M, 2014, METALLOMICS, V6, P274, DOI 10.1039/c3mt00271c
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   White AR, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00127
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Zheng MZ, 2015, TRANSL STROKE RES, V6, P215, DOI 10.1007/s12975-015-0388-8
NR 27
TC 3
Z9 3
U1 0
U2 3
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1756-5901
EI 1756-591X
J9 METALLOMICS
JI Metallomics
PD OCT 1
PY 2016
VL 8
IS 10
BP 1071
EP 1080
DI 10.1039/c6mt00125d
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DZ1JF
UT WOS:000385594000004
PM 27504972
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, JH
   Park, S
   Chung, H
   Oh, S
AF Kim, Joo-Hyun
   Park, Seoyoung
   Chung, Hyewon
   Oh, Sangtaek
TI Wnt5a attenuates the pathogenic effects of the Wnt/beta-catenin pathway
   in human retinal pigment epithelial cells via down-regulating
   beta-catenin and Snail
SO BMB REPORTS
LA English
DT Article
DE Age-related macular degeneration; beta-catenin; Canonical Wnt pathway;
   Retinal pigment epithelial cells; Wnt5a
ID MESENCHYMAL TRANSITION; SIGNALING PATHWAY; AGE; TARGET; INFLAMMATION;
   ACTIVATION; RECEPTOR; EXTRACT; CANCER
AB Activation of the Wnt/beta-catenin pathway plays a pathogenic role in age-related macular degeneration (AMD) and is thus a potential target for the development of therapeutics for this disease. Here, we demonstrated that Wnt5a antagonized beta-catenin response transcription (CRT) induced with Wnt3a by promoting beta-catenin phosphorylation at Ser33/Ser37/Thr41 and its subsequent degradation in human retinal pigment epithelial (RPE) cells. Wnt5a decreased the levels of vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), and nuclear factor-kappa B (NF-kappa B), which was up-regulated by Wnt3a. Furthermore, Wnt5a increased E-cadherin expression and decreased cell migration by down-regulating Snail expression, thereby abrogating the Wnt3a-induced epithelial-mesenchymal transition (EMT) in human RPE cells. Our findings suggest that Wnt5a suppresses the pathogenic effects of canonical Wnt signaling in human RPE cells by promoting beta-catenin phosphorylation and degradation. Therefore, Wnt5a has significant therapeutic potential for the treatment of AMD.
C1 [Kim, Joo-Hyun; Park, Seoyoung; Oh, Sangtaek] Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 02707, South Korea.
   [Chung, Hyewon] Konkuk Univ, Dept Opthalmol, Sch Med, Seoul 05066, South Korea.
C3 Kookmin University; Konkuk University; Konkuk University Medical Center
RP Oh, S (通讯作者)，Kookmin Univ, Dept Bio & Fermentat Convergence Technol, Seoul 02707, South Korea.
EM ohsa@kookmin.ac.kr
FU Fundamental Technology Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [2012M3A9B2028335]
FX This work was supported by the Fundamental Technology Program
   (2012M3A9B2028335) through the National Research Foundation of Korea
   (NRF) funded by the Ministry of Science, ICT & Future Planning.
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Chen HC, 2012, LAB INVEST, V92, P676, DOI 10.1038/labinvest.2011.201
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627
   Dejmek J, 2006, MOL CELL BIOL, V26, P6024, DOI 10.1128/MCB.02354-05
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Easwaran V, 2003, CANCER RES, V63, P3145
   Gwak J, 2006, INT J MOL MED, V17, P1005
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Millar JBA, 2002, GENOME BIOL, V3
   Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729
   Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606
   Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Sunness JS, 1999, MOL VIS, V5
   Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   Winkler B S, 1999, Mol Vis, V5, P32
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 30
TC 18
Z9 23
U1 1
U2 29
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-6696
EI 1976-670X
J9 BMB REP
JI BMB Rep.
PD SEP
PY 2015
VL 48
IS 9
BP 525
EP 530
DI 10.5483/BMBRep.2015.48.9.140
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CT2UD
UT WOS:000362658800008
PM 26246285
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Thuruthumaly, C
   Yee, DC
   Rao, PK
AF Thuruthumaly, Catherine
   Yee, David Chin
   Rao, Prabakar Kumar
TI Presumed ocular histoplasmosis
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE antivascular endothelial growth factor; choroidal neovascularization;
   presumed ocular histoplasmosis
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; PHOTODYNAMIC THERAPY; CAPSULATUM
   DNA; VERTEPORFIN; SUBFOVEAL; MEMBRANES; REMOVAL; LESIONS
AB Purpose of review
   To update the knowledge on the risk factors and treatment options for choroidal neovascular membrane due to ocular histoplasmosis and to provide a treatment algorithm.
   Recent findings
   Smoking has been shown to be a strong risk factor in the development of choroidal neovascularization. Alleles that have been identified as a risk factor for the development of choroidal neovascularization in age-related macular degeneration have not shown to be associated with Presumed Ocular Histoplasmosis Syndrome-related choroidal neovascularization. Treatment has largely moved away from submacular surgery and macular photocoagulation to antivascular endothelial growth factor therapy.
   Summary
   This review highlights the devastating vision loss that may occur in ocular histoplasmosis from the development of an atrophic scar at the fovea or following choroidal neovascularization. Many therapies have been tried with varied amounts of success. Antivascular endothelial growth factor therapy appears to be the gold-standard treatment with the possibility of combined photodynamic therapy in refractory cases.
C1 [Thuruthumaly, Catherine; Yee, David Chin; Rao, Prabakar Kumar] Washington Univ, Dept Ophthalmol & Visual Sci, Sch Med, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Rao, PK (通讯作者)，Washington Univ, Dept Ophthalmol & Visual Sci, 660 South Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.
EM krao@wustl.edu
CR Ala-Kauhaluoma M, 2010, ACTA OPHTHALMOL, V88, P493, DOI 10.1111/j.1755-3768.2008.01454.x
   Amaro Miguel Hage, 2007, Arq. Bras. Oftalmol., V70, P577, DOI 10.1590/S0004-27492007000400003
   [Anonymous], 1987, ARCH OPHTHALMOL-CHIC, V105, P1499
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   BROWN DM, 1996, OCULAR INFECT IMMUNI, P1252
   Busquets MA, 2003, RETINA-J RET VIT DIS, V23, P299, DOI 10.1097/00006982-200306000-00003
   Chheda LV, 2012, OPHTHALMOLOGY, V119, P333, DOI 10.1016/j.ophtha.2011.08.003
   Dabil H, 2003, HUM IMMUNOL, V64, P960, DOI 10.1016/S0198-8859(03)00175-7
   FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1347, DOI 10.1001/archopht.1983.01040020349002
   Fowler Brian, 2011, Digit J Ophthalmol, V17, P31, DOI 10.5693/djo.02.2011.07.002
   Gass J D, 1972, Trans Am Acad Ophthalmol Otolaryngol, V76, P672
   HAWKINS BS, 1989, ARCH OPHTHALMOL-CHIC, V107, P344, DOI 10.1001/archopht.1989.01070010354023
   Hawkins BS, 2001, OCULAR HISTOPLASMOSI
   Hernandez JM, 2012, MED MYCOL, V50, P202, DOI 10.3109/13693786.2011.593050
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Katz BJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1470, DOI 10.1001/archopht.1997.01100160640023
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Liu JC, 2004, RETINA-J RET VIT DIS, V24, P863, DOI 10.1097/00006982-200412000-00004
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Nielsen JS, 2012, RETINA-J RET VIT DIS, V32, P468, DOI 10.1097/IAE.0b013e318229b220
   Oliver Alejandro, 2005, Curr Opin Ophthalmol, V16, P160, DOI 10.1097/01.icu.0000161228.21797.d9
   Ongkosuwito JV, 1999, BRIT J OPHTHALMOL, V83, P535, DOI 10.1136/bjo.83.5.535
   Prasad Anita G, 2005, Curr Opin Ophthalmol, V16, P364, DOI 10.1097/01.icu.0000188321.61101.93
   Ramaiya KJ, 2013, OSLI RETINA, V44, P17, DOI 10.3928/23258160-20121221-07
   Rao P K, 2000, Curr Opin Ophthalmol, V11, P180, DOI 10.1097/00055735-200006000-00005
   Reid D, 1942, J LAB CLIN MED, V27, P419
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   SCHLAEGEL TF, 1966, AM J OPHTHALMOL, V62, P454, DOI 10.1016/0002-9394(66)91324-9
   Shah GK, 2005, RETINA-J RET VIT DIS, V25, P26, DOI 10.1097/00006982-200501000-00003
   Sinha R, 2007, OCUL IMMUNOL INFLAMM, V15, P315, DOI 10.1080/09273940701375428
   SMITH R E, 1971, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V75, P994
   SMITH RE, 1984, INVEST OPHTH VIS SCI, V25, P810
   Spencer WH, 2003, ARCH OPHTHALMOL-CHIC, V121, P1551, DOI 10.1001/archopht.121.11.1551
   Wilkes MF, 2014, OPHTHALMOLOGY, V121, P1487, DOI 10.1016/j.ophtha.2013.01.079
   WONG V G, 1975, International Ophthalmology Clinics, V15, P139, DOI 10.1097/00004397-197501530-00018
   WOODS ALAN C, 1959, TRANS AMER OPHTHALMOL SOC, V57, P318
NR 37
TC 14
Z9 14
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD NOV
PY 2014
VL 25
IS 6
BP 508
EP 512
DI 10.1097/ICU.0000000000000100
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR0XH
UT WOS:000343297400007
PM 25237930
DA 2022-11-30
ER

PT J
AU Miao, X
   Sun, WX
   Miao, LN
   Fu, YW
   Wang, YG
   Su, GF
   Liu, Q
AF Miao, Xiao
   Sun, Weixia
   Miao, Lining
   Fu, Yaowen
   Wang, Yonggang
   Su, Guanfang
   Liu, Quan
TI Zinc and Diabetic Retinopathy
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; INDUCED OXIDATIVE STRESS; NF-KAPPA-B;
   LIPID-PEROXIDATION; MAMMALIAN ZINC; TRANSCRIPTION FACTORS; MACULAR
   DEGENERATION; POSSIBLE PROTECTION; RETINAL METABOLISM; PIGMENT
   EPITHELIUM
AB Zinc (Zn) is an important nutrient that is involved in various physiological metabolisms. Zn dyshomeostasis is often associated with various pathogeneses of chronic diseases, such as metabolic syndrome, diabetes, and related complications. Zn is present in ocular tissue in high concentrations, particularly in the retina and choroid. Zn deficiencies have been shown to affect ocular development, cataracts, age-related macular degeneration, and even diabetic retinopathy. However, the mechanism by which Zn deficiency increases the prevalence of diabetic retinopathy remains unclear. In addition, due to the negative effect of Zn deficiency on the eye, Zn supplementation should prevent diabetic retinopathy; however, limited available data do not always support this notion. Therefore, the goal of this paper was to summarize these pieces of available information regarding Zn prevention of diabetic retinopathy. Current theories and possible mechanisms underlying the role of Zn in the eye-related diseases are discussed. The possible factors that affect the preventive effect of Zn supplementation on diabetic retinopathy were also discussed.
C1 [Miao, Xiao; Miao, Lining; Su, Guanfang] Jilin Univ, Hosp 2, Changchun 130021, Peoples R China.
   [Miao, Xiao; Su, Guanfang] Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun 130041, Peoples R China.
   [Sun, Weixia; Fu, Yaowen; Wang, Yonggang; Liu, Quan] Jilin Univ, Hosp 1, Changchun 130021, Peoples R China.
   [Liu, Quan] Jilin Univ, Hosp 1, Dept Cardiovasc Dis, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Jilin University
RP Su, GF (通讯作者)，Jilin Univ, Hosp 2, Changchun 130021, Peoples R China.
EM sugf@yahoo.com; quanliu888@163.com
CR Adachi T, 2012, ARCH BIOCHEM BIOPHYS, V520, P30, DOI 10.1016/j.abb.2012.01.014
   Adachi Y, 2006, BIOCHEM BIOPH RES CO, V351, P165, DOI 10.1016/j.bbrc.2006.10.014
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Afridi HI, 2011, BIOL TRACE ELEM RES, V142, P323, DOI 10.1007/s12011-010-8789-8
   Agardh CD, 1998, CURR EYE RES, V17, P251, DOI 10.1076/ceyr.17.3.251.5217
   Alscher DM, 2005, KIDNEY BLOOD PRESS R, V28, P127, DOI 10.1159/000084921
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Ansari NH, 1998, J TOXICOL ENV HEAL A, V54, P467
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   BERMAN M B, 1973, Annals of Ophthalmology, V5, P1193
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   BRAY TM, 1990, FREE RADICAL BIO MED, V8, P281, DOI 10.1016/0891-5849(90)90076-U
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Bursell SE, 1999, DIABETES CARE, V22, P1245, DOI 10.2337/diacare.22.8.1245
   Cai L, 2005, CURR MED CHEM, V12, P2753, DOI 10.2174/092986705774462950
   Cai Lu, 2004, Nonlinearity Biol Toxicol Med, V2, P89, DOI 10.1080/15401420490464367
   CALESNICK B, 1988, AM FAM PHYSICIAN, V37, P267
   Centers for Disease Control and Prevention, 2011, NAT EST GEN INF DIAB
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Clermont AC, 1997, AM J OPHTHALMOL, V124, P433, DOI 10.1016/S0002-9394(14)70860-8
   COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341
   DeNiro M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050360
   Duzguner V, 2007, FREE RADICAL BIO MED, V42, P1481, DOI 10.1016/j.freeradbiomed.2007.02.021
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Evans JR, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000254
   FINK RI, 1986, ENDOCRINOLOGY, V118, P1139, DOI 10.1210/endo-118-3-1139
   Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   HANNA PM, 1993, CHEM RES TOXICOL, V6, P711, DOI 10.1021/tx00035a017
   Hasan NA, 2009, SAUDI MED J, V30, P1263
   HUBER AM, 1975, J NUTR, V105, P1486, DOI 10.1093/jn/105.11.1486
   Jeru I, 1997, Oftalmologia, V41, P329
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Kambe T, 2004, CELL MOL LIFE SCI, V61, P49, DOI 10.1007/s00018-003-3148-y
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kim J, 2012, FREE RADICAL BIO MED, V53, P357, DOI 10.1016/j.freeradbiomed.2012.04.030
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   KOWALD A, 1994, J THEOR BIOL, V168, P75, DOI 10.1006/jtbi.1994.1089
   Kowluru RA, 2001, NEUROCHEM INT, V38, P385, DOI 10.1016/S0197-0186(00)00112-1
   Kowluru RA, 2001, EXPERT OPIN INV DRUG, V10, P1665, DOI 10.1517/13543784.10.9.1665
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Kowluru RA, 2000, CURR EYE RES, V21, P814, DOI 10.1076/ceyr.21.4.814.5545
   Lefebvre P, 2005, Rev Med Liege, V60, P273
   Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402
   Millen AE, 2003, AM J EPIDEMIOL, V158, P225, DOI 10.1093/aje/kwg116
   Mochizuki K, 2006, JPN J OPHTHALMOL, V50, P532, DOI 10.1007/s10384-006-0376-3
   MORRISON SA, 1978, AM J CLIN NUTR, V31, P276, DOI 10.1093/ajcn/31.2.276
   MOUSTAFA SA, 1995, GERONTOLOGY, V41, P301, DOI 10.1159/000213699
   Moustafa SA, 2004, TOXICOL APPL PHARM, V201, P149, DOI 10.1016/j.taap.2004.05.014
   Moustafa SA, 2001, INT J TOXICOL, V20, P15, DOI 10.1080/109158101750103332
   Moustafa Sohair A., 1998, Research Communications in Pharmacology and Toxicology, V3, P55
   Muga SJ, 1999, BIOL TRACE ELEM RES, V68, P1, DOI 10.1007/BF02784392
   Nebbioso M, 2012, DIABETES TECHNOL THE, V14, P257, DOI 10.1089/dia.2011.0172
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631
   Olson JH, 2011, SEMIN OPHTHALMOL, V26, P131, DOI 10.3109/08820538.2011.577131
   Organisciak D, 2012, PHOTOCHEM PHOTOBIOL, V88, P1396, DOI 10.1111/j.1751-1097.2012.01134.x
   Palmiter RD, 2004, P NATL ACAD SCI USA, V101, P4918, DOI 10.1073/pnas.0401022101
   PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x
   Pati S K, 1991, Indian J Ophthalmol, V39, P134
   Piconi L, 2003, CLIN CHEM LAB MED, V41, P1144, DOI 10.1515/CCLM.2003.177
   Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S
   Prasad AS, 2008, EXP GERONTOL, V43, P370, DOI 10.1016/j.exger.2007.10.013
   Prasad AS, 2009, CURR OPIN CLIN NUTR, V12, P646, DOI 10.1097/MCO.0b013e3283312956
   Provinciali M, 2002, FREE RADICAL BIO MED, V32, P431, DOI 10.1016/S0891-5849(01)00830-9
   Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3
   Redenti S, 2007, EXP EYE RES, V85, P580, DOI 10.1016/j.exer.2007.07.017
   ROGERS JM, 1987, DEVELOPMENT, V99, P231
   Roussel AM, 2003, J AM COLL NUTR, V22, P316, DOI 10.1080/07315724.2003.10719310
   Rudolf E, 2001, Cesk Fysiol, V50, P201
   Sasaki M, 2012, ARCH OPHTHALMOL-CHIC, V130, P254, DOI 10.1001/archopthalmol.2011.1368
   SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
   St Croix CM, 2002, AM J PHYSIOL-LUNG C, V282, pL185, DOI 10.1152/ajplung.00267.2001
   SUNTRES ZE, 1990, BIOCHEM PHARMACOL, V39, P833, DOI 10.1016/0006-2952(90)90197-S
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   THOMAS JP, 1986, BIOCHIM BIOPHYS ACTA, V884, P448, DOI 10.1016/0304-4165(86)90195-9
   THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6
   Tsuruma K, 2012, INVEST OPHTH VIS SCI, V53, P7896, DOI 10.1167/iovs.12-10165
   Ugarte M, 2012, METALLOMICS, V4, P1245, DOI 10.1039/c2mt20157g
   Uriu-Adams Janet Y., 2005, Molecular Aspects of Medicine, V26, P268, DOI 10.1016/j.mam.2005.07.015
   Uzzo RG, 2006, CARCINOGENESIS, V27, P1980, DOI 10.1093/carcin/bgl034
   VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79
   WALTER RM, 1991, DIABETES CARE, V14, P1050, DOI 10.2337/diacare.14.11.1050
   Wang XQ, 2009, AM J OPHTHALMOL, V148, P883, DOI 10.1016/j.ajo.2009.07.007
   WOOLLARD ACS, 1990, DIABETES, V39, P1347, DOI 10.2337/diabetes.39.11.1347
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312
   Zhang Y, 2002, CANCER RES, V62, P1205
   Zhao YG, 2011, TOXICOL LETT, V200, P100, DOI 10.1016/j.toxlet.2010.11.001
   Zhou ZX, 2002, EXP BIOL MED, V227, P214, DOI 10.1177/153537020222700310
NR 91
TC 29
Z9 32
U1 0
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2013
VL 2013
AR 425854
DI 10.1155/2013/425854
PG 8
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 140CF
UT WOS:000318631200001
PM 23671870
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Wong, RW
   Richa, C
   Hahn, P
   Green, WR
   Dunaief, JL
AF Wong, Robert W.
   Richa, Chimene
   Hahn, Paul
   Green, W. Richard
   Dunaief, Joshua L.
TI Iron toxicity as a potential factor in AMD
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aceruloplasminemia; age-related macular degeneration; hemochromatosis;
   iron chelation; iron toxicity; oxidative stress; pantothenate kinase
   associated neurodegeneration
ID HALLERVORDEN-SPATZ-SYNDROME; FACTOR-H POLYMORPHISM; MACULAR
   DEGENERATION; PIGMENTARY DEGENERATION; RETINAL DEGENERATION; TRANSFERRIN
   RECEPTOR; AGE; HEMOCHROMATOSIS; CERULOPLASMIN; ACERULOPLASMINEMIA
AB While it has been known for years that iron overload is associated with retinal degeneration in the context of ocular siderosis, intraocular hemorrhage, and the hereditary diseases aceruloplasminemia and pantothenate kinase associated neurodegeneration, recent evidence suggests that age-related macular degeneration (AMD) may also be exacerbated by retinal iron overload. In the retina, iron is necessary for normal cellular function. Iron overload, however, can cause retinal toxicity through the generation of oxygen free radicals. Histopathology of eyes with macular degeneration has shown elevated levels of iron in the retinal pigment epithelium, Bruch membrane, and within drusen, some of which was chelatable in vitro with deferoxamine. In this review, the authors summarize the evidence that iron overload may contribute to AMD pathogenesis. It is hoped that continued investigation of the role of iron and, iron associated proteins in the retina will uncover clues to AMD pathogenesis and lead to new preventative or therapeutic options.
C1 Univ Penn, Scheie Eye Inst, Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Dunaief, JL (通讯作者)，305 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
OI Hahn, Paul/0000-0002-6574-388X
FU NATIONAL EYE INSTITUTE [R01EY015240] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY015240] Funding Source: Medline
CR ARDEN GB, 1984, BRIT J OPHTHALMOL, V68, P873, DOI 10.1136/bjo.68.12.873
   Bacon B R, 1999, Adv Intern Med, V44, P91
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   CIBIS PA, 1959, ARCH OPHTHALMOL-CHIC, V62, P180
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DAVIES SC, 1983, LANCET, V2, P181
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472
   Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298
   GANZ T, 2006, HEMATOL-AM SOC HEMAT, V507, P29, DOI DOI 10.1182/ASHEDUCATION-2006.1.29
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Haimovici R, 2002, OPHTHALMOLOGY, V109, P164, DOI 10.1016/S0161-6420(01)00947-2
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539
   Hayflick SJ, 2003, CURR OPIN PEDIATR, V15, P572, DOI 10.1097/00008480-200312000-00005
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koeppen AH, 2001, PEDIATR NEUROL, V25, P148, DOI 10.1016/S0887-8994(01)00269-7
   LAKHANPAL V, 1984, OPHTHALMOLOGY, V91, P443
   Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4
   Lee DW, 2006, MOL INTERV, V6, P89, DOI 10.1124/mi.6.2.6
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leure-duPree A E, 1987, Prog Clin Biol Res, V247, P517
   LI ZL, 1991, CURR EYE RES, V10, P133, DOI 10.3109/02713689109001741
   LUCKENBACH MW, 1983, AM J OPHTHALMOL, V95, P369, DOI 10.1016/S0002-9394(14)78308-4
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Martin PM, 2006, INVEST OPHTH VIS SCI, V47, P4238, DOI 10.1167/iovs.06-0026
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   NEWELL FW, 1979, AM J OPHTHALMOL, V88, P467, DOI 10.1016/0002-9394(79)90648-2
   PEDERSEN OO, 1979, EXP EYE RES, V29, P61, DOI 10.1016/0014-4835(79)90166-0
   Richardson DR, 2004, ANN NY ACAD SCI, V1012, P326, DOI 10.1196/annals.1306.026
   ROTH AM, 1972, ARCH OPHTHALMOL-CHIC, V87, P507
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SHICHI H, 1969, EXP EYE RES, V8, P60, DOI 10.1016/S0014-4835(69)80081-3
   TRESE MT, 1986, OPHTHALMOLOGY, V93, P574
   TSO MOM, 1994, INVEST OPHTH VIS SCI, V35, P2693
   VOGT W, 1991, COMPLEMENT INFLAMMAT, V8, P313, DOI 10.1159/000463202
   Waugh WH, 2004, J APPL RES, V4, P208
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   YOUSSEF TA, 2002, INVEST OPHTHALMOL, V43
   Zacharski LR, 2003, VASC MED, V8, P153, DOI 10.1191/1358863x03vm492ed
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zheng HL, 2005, BIOORGAN MED CHEM, V13, P773, DOI 10.1016/j.bmc.2004.10.037
NR 59
TC 94
Z9 95
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2007
VL 27
IS 8
BP 997
EP 1003
DI 10.1097/IAE.0b013e318074c290
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 225DD
UT WOS:000250496400001
PM 18040235
DA 2022-11-30
ER

PT J
AU Han, M
   Giese, G
   Schmitz-Valckenberg, S
   Bindewald-Wittich, A
   Holz, FG
   Yu, JY
   Bille, JF
   Niemz, MH
AF Han, Meng
   Giese, Guenter
   Schmitz-Valckenberg, Steffen
   Bindewald-Wittich, Almut
   Holz, Frank G.
   Yu, Jiayi
   Bille, Josef F.
   Niemz, Markolf H.
TI Age-related structural abnormalities in the human retina-choroid complex
   revealed by two-photon excited autofluorescence imaging
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE two-photon imaging; autofluorescence; retina; choroid
ID PIGMENT EPITHELIAL-CELLS; HUMAN RPE CELLS; 2ND-HARMONIC GENERATION;
   BRUCHS MEMBRANE; FUNDUS AUTOFLUORESCENCE; LIPOFUSCIN FLUOROPHORE;
   MACULAR DEGENERATION; BLOOD-FLOW; FLUORESCENCE; MICROSCOPY
AB The intensive metabolism of photoreceptors is delicately maintained by the retinal pigment epithelium (RPE) and the choroid. Dysfunction of either the RPE or choroid may lead to severe damage to the retina. Two-photon excited autofluorescence (TPEF) from endogenous fluorophores in the human retina provides a novel opportunity to reveal age-related structural abnormalities in the retinachoroid complex prior to apparent pathological manifestations of age-related retinal diseases. In the photoreceptor layer, the regularity of the macular photoreceptor mosaic is preserved during aging. In the RPE, enlarged lipofuscin granules demonstrate significantly blueshifted autofluorescence, which coincides with the depletion of melanin pigments. Prominent fibrillar structures in elderly Bruch's membrane and choriocapillaries represent choroidal structure and permeability alterations. Requiring neither slicing nor labeling, TPEF imaging is an elegant and highly efficient tool to delineate the thick, fragile, and opaque retina-choroid complex, and may provide clues to the trigger events of age-related macular degeneration. (C) 2007 Society of Photo-Optical Instrumentation Engineers.
C1 Heidelberg Univ, Kirchhoff Inst Phys, D-6900 Heidelberg, Germany.
   Heidelberg Univ, Mannheim Biomed Engn Labs, Fac Clin Med, Heidelberg, Germany.
   Max Planck Inst Met Res, Heidelberg, Germany.
   Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   Heidelberg Univ, Mannheim Biomed Engn Labs, Fac Clin Med, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Deere & Company; Ruprecht Karls
   University Heidelberg; Max Planck Society; University of Bonn; Deere &
   Company; Ruprecht Karls University Heidelberg
RP Han, M (通讯作者)，Heidelberg Univ, Kirchhoff Inst Phys, D-6900 Heidelberg, Germany.
EM mhan@urz.uniheidelberg.de
OI Bindewald-Wittich, Almut/0000-0002-8151-3953
CR Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   Bindewald-Wittich A, 2006, INVEST OPHTH VIS SCI, V47, P4553, DOI 10.1167/iovs.05-1562
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   Boulton M, 2004, PHOTOCH PHOTOBIO SCI, V3, P759, DOI 10.1039/b400108g
   Campagnola PJ, 2003, NAT BIOTECHNOL, V21, P1356, DOI 10.1038/nbt894
   Chen CH, 2005, BIOPHYS J, V88, P2278, DOI 10.1529/biophysj.104.054254
   Cordeiro MF, 2004, P NATL ACAD SCI USA, V101, P13352, DOI 10.1073/pnas.0405479101
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Han M, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2171649
   Han M, 2005, OPT EXPRESS, V13, P5791, DOI 10.1364/OPEX.13.005791
   Han M, 2004, OPT EXPRESS, V12, P4275, DOI 10.1364/OPEX.12.004275
   Han M, 2004, J BIOMED OPT, V9, P760, DOI 10.1117/1.1756919
   Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hopt A, 2001, BIOPHYS J, V80, P2029, DOI 10.1016/S0006-3495(01)76173-5
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Konig K, 2000, J MICROSC-OXFORD, V200, P83, DOI 10.1046/j.1365-2818.2000.00738.x
   Konig K, 1999, OPT LETT, V24, P113, DOI 10.1364/OL.24.000113
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Lyubovitsky JG, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2163254
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   SHEPPARD CJR, 1978, APPL OPTICS, V17, P2879, DOI 10.1364/AO.17.002879
   So PTC, 2000, ANNU REV BIOMED ENG, V2, P399, DOI 10.1146/annurev.bioeng.2.1.399
   Sparrow JR, 2003, P NATL ACAD SCI USA, V100, P4353, DOI 10.1073/pnas.1031478100
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Supatto W, 2005, P NATL ACAD SCI USA, V102, P1047, DOI 10.1073/pnas.0405316102
   Teng SW, 2006, INVEST OPHTH VIS SCI, V47, P1216, DOI 10.1167/iovs.04-1520
   TORNQUIST P, 1990, EYE, V4, P303, DOI 10.1038/eye.1990.41
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629
   Yeh AT, 2002, OPT LETT, V27, P2082, DOI 10.1364/OL.27.002082
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zipfel Warren R., 2003, Nature Biotechnology, V21, P1369, DOI 10.1038/nbt899
   Zipfel WR, 2003, P NATL ACAD SCI USA, V100, P7075, DOI 10.1073/pnas.0832308100
NR 60
TC 47
Z9 47
U1 0
U2 3
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD MAR-APR
PY 2007
VL 12
IS 2
AR 024012
DI 10.1117/1.2717522
PG 7
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 173FW
UT WOS:000246859900028
PM 17477727
OA Green Published
DA 2022-11-30
ER

PT J
AU Fong, HKW
   Lin, MY
   Pandey, S
AF Fong, Henry K. W.
   Lin, Meng-Yin
   Pandey, Sujay
TI Exon-skipping variant of RGR opsin in human retina and pigment
   epithelium
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE rGR opsin; RNA splicing; retinal pigment epithelium; macular
   degeneration; G protein-coupled receptor
ID AGE-RELATED MACULOPATHY; COUPLED-RECEPTOR RGR; MACULAR DEGENERATION;
   VISUAL CYCLE; MORPHOMETRIC ANALYSIS; VERTEBRATE RETINA; BRUCHS MEMBRANE;
   VITAMIN-A; PROTEIN; EYE
AB An extraneous exon-skipping mRNA encodes an altered form of a light-absorbing opsin in human retina and pigment epithelium (RPE). The predicted protein variant differs from full-length RPE-retinal G protein-coupled receptor (RGR) by having an in-frame deletion of exon 6, which contains the entire sixth transmembrane domain. To verify that the exon 6-deleted RGR protein (RGR-d) exists in human retinas, we have produced RGR-d antibody probes. In Western blot assays, the RGR-d protein was detected in retinas of a large proportion (similar to 53%) of individual donors, including patients with age-related macular degeneration (AMD). The relative abundance of RGR-d varied significantly between individuals. The altered protein is expressed in RPE cells and has a more basal subcellular localization that is remarkably different from that of normal RGR opsin. The presence of this exon-skipping variant of RGR in humans may contribute to the progressive derangement of the RPE. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Fong, HKW (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM hfong@usc.edu
FU NATIONAL EYE INSTITUTE [R01EY008364, P30EY003040] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY03040, EY08364] Funding Source: Medline
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRAEKEVELT CR, 1986, ANAT HISTOL EMBRYOL, V15, P205, DOI 10.1111/j.1439-0264.1986.tb00712.x
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2
   Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089
   Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k
   Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085
   HARANISHIMURA I, 1990, FEBS LETT, V271, P106, DOI 10.1016/0014-5793(90)80383-T
   HEWITT AT, 1986, RETINA MODEL CELL 2, P169
   HUGHES BA, 1984, J GEN PHYSIOL, V83, P875, DOI 10.1085/jgp.83.6.875
   JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669
   JIANG MS, 1995, EXP EYE RES, V60, P401, DOI 10.1016/S0014-4835(05)80096-X
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KORNZWEIG AL, 1965, AM J OPHTHALMOL, V60, P835, DOI 10.1016/0002-9394(65)92002-7
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL S, V24, P428
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   MILLER SS, 1982, J MEMBRANE BIOL, V67, P199, DOI 10.1007/BF01868661
   Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496
   PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055
   Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 2001, RETINA, V2, P1064
   SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wenzel A, 2005, J BIOL CHEM, V280, P29874, DOI 10.1074/jbc.M503603200
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Yang M, 2000, MOL VIS, V6, P237
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6
NR 42
TC 8
Z9 8
U1 0
U2 1
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2006
VL 83
IS 1
BP 133
EP 140
DI 10.1016/j.exer.2005.11.013
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 054WD
UT WOS:000238408400015
PM 16530760
DA 2022-11-30
ER

PT J
AU Toutounchian, S
   Ahmadbeigi, N
   Mansouri, V
AF Toutounchian, Samaneh
   Ahmadbeigi, Naser
   Mansouri, Vahid
TI Retinal and Choroidal Neovascularization Antivascular Endothelial Growth
   Factor Treatments: The Role of Gene Therapy
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE choroid neovascularization; VEGF; gene therapy; AAV
ID VASCULAR-PERMEABILITY FACTOR; ANTI-VEGF THERAPY; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; INTRAVITREAL BEVACIZUMAB; EMERGING THERAPIES;
   IMMUNE-RESPONSES; FACTOR RECEPTOR; ABICIPAR-PEGOL; GENOME SURGERY
AB Neovascularization in ocular vessels causes a major disease burden. The most common causes of choroidal neovascularization (CNV) are age-related macular degeneration and diabetic retinopathy, which are the leading causes of irreversible vision loss in the adult population. Vascular endothelial growth factor (VEGF) is critical for the formation of new vessels and is the main regulator in ocular angiogenesis and vascular permeability through its receptors. Laser therapy and antiangiogenic factors have been used for CNV treatment. Bevacizumab, ranibizumab, and aflibercept are commonly used anti-VEGF agents; however, high costs and the need for frequent intraocular injections are major drawbacks of anti-VEGF drugs. Gene therapy, given the potency of one-time treatment and no need for frequent injections offers the real possibility of such a lasting treatment, with fewer adverse effects and higher patient quality of life. Herein, we reviewed the role of gene therapy in the CNV treatment. In addition, we discuss the advantages and challenges of current treatments compared with gene therapy.
C1 [Toutounchian, Samaneh; Ahmadbeigi, Naser; Mansouri, Vahid] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Inst, Gene Therapy Res Ctr, Tehran, Iran.
   [Mansouri, Vahid] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Inst, Gene Therapy Res Ctr, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences
RP Mansouri, V (通讯作者)，Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Inst, Gene Therapy Res Ctr, Tehran, Iran.
EM Mansoury.vahid@gmail.com
OI Mansouri, Vahid/0000-0002-3726-1496
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Allocca M, 2007, J VIROL, V81, P11372, DOI 10.1128/JVI.01327-07
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   [Anonymous], 2018, NAT BIOTECHNOL, V36, P6, DOI 10.1038/nbt0118-6a
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Arabi F, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113324
   Arbabi A, 2019, J OCUL PHARMACOL TH, V35, P79, DOI 10.1089/jop.2018.0087
   Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Avery RL., 2020, RETINA SOC ANN SCI M
   Bates DO, 2002, CANCER RES, V62, P4123
   Bek T, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0909-9
   Beltramo E, 2013, CURR MED CHEM, V20, P3218, DOI 10.2174/09298673113209990022
   Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047
   Biswal MR, 2014, INVEST OPHTH VIS SCI, V55, P8044, DOI 10.1167/iovs.14-13932
   Boon CJF, 2008, VISION RES, V48, P2569, DOI 10.1016/j.visres.2008.01.010
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Brar VS, 2010, MOL VIS, V16, P1848
   Breger L, 2016, METHODS MOL BIOL, V1382, P57, DOI 10.1007/978-1-4939-3271-9_4
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Busbee B, 2021, INVEST OPHTH VIS SCI, V62
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Caruso A, 2020, MOL PHARMACEUT, V17, P695, DOI 10.1021/acs.molpharmaceut.9b01191
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Cohen MN, 2021, BRIT J OPHTHALMOL, V105, P716, DOI 10.1136/bjophthalmol-2020-316511
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Costagliola C, 2019, EXPERT OPIN DRUG SAF, V18, P803, DOI 10.1080/14740338.2019.1643838
   Cox DBT, 2015, NAT MED, V21, P121, DOI 10.1038/nm.3793
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Datta S, 2018, INVEST OPHTH VIS SCI, V59, P4909, DOI 10.1167/iovs.18-24987
   Day TP, 2014, ADV EXP MED BIOL, V801, P687, DOI 10.1007/978-1-4614-3209-8_86
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   de Oliveira Dias Joao Rafael, 2016, Int J Retina Vitreous, V2, P3, DOI 10.1186/s40942-016-0026-y
   DiCarlo JE, 2018, J CLIN INVEST, V128, P2177, DOI 10.1172/JCI120429
   DiCarlo JE, 2017, ADV EXP MED BIOL, V1016, P3, DOI 10.1007/978-3-319-63904-8_1
   Dismuke DJ, 2013, CURR GENE THER, V13, P434
   Do DV, 2020, RETINA-J RET VIT DIS, V40, P643, DOI 10.1097/IAE.0000000000002566
   Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Dubey SK, 2021, INT J PHARMACEUT, V600, DOI 10.1016/j.ijpharm.2021.120499
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Ejaz S, 2008, DIABETES OBES METAB, V10, P53, DOI 10.1111/j.1463-1326.2007.00795.x
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   European Medicines A. European Medicines Agency, 2019, LUXT EPAR
   Fedorov Y, 2006, RNA, V12, P1188, DOI 10.1261/rna.28106
   Fenner BJ, 2022, EYE, V36, P257, DOI 10.1038/s41433-021-01688-7
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Food Drug Administration, 2022, HIGHL PRESCR INF
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Geisler Anja, 2016, World J Exp Med, V6, P37, DOI 10.5493/wjem.v6.i2.37
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Goswami R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00297
   Grimm D, 2017, HUM GENE THER, V28, P1075, DOI 10.1089/hum.2017.172
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   Guha TK, 2017, COMPUT STRUCT BIOTEC, V15, P146, DOI 10.1016/j.csbj.2016.12.006
   Gupta K, 2005, POSTGRAD MED J, V81, P236, DOI 10.1136/pgmj.2004.023309
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Huang H, 2015, DIABETES, V64, P200, DOI 10.2337/db14-0016
   Huang XG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00140-3
   Huang XG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20537
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Ip MS, 2017, OPHTHALMOLOGY, V124, P596, DOI 10.1016/j.ophtha.2017.01.003
   Iwanishi H, 2016, LAB INVEST, V96, P641, DOI 10.1038/labinvest.2016.30
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jolly JK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01076
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Khurana RN, 2021, OPHTHALMOLOGY, V128, P1027, DOI 10.1016/j.ophtha.2020.11.017
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kumaran N, 2018, BRIT MED BULL, V126, P13, DOI 10.1093/bmb/ldy005
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Lee JH, 2019, PROG RETIN EYE RES, V68, P31, DOI 10.1016/j.preteyeres.2018.08.003
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Levy AP, 1998, TRENDS CARDIOVAS MED, V8, P246, DOI 10.1016/S1050-1738(98)00020-6
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin FL, 2020, MOL THER, V28, P2120, DOI 10.1016/j.ymthe.2020.06.029
   Lipinski DM, 2013, PROG RETIN EYE RES, V32, P22, DOI 10.1016/j.preteyeres.2012.09.001
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Lupo G, 2013, BIOCHEM PHARMACOL, V86, P1603, DOI 10.1016/j.bcp.2013.09.008
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514
   Miller JW, 2018, MOL THER, V26, P2081, DOI 10.1016/j.ymthe.2018.08.003
   Mingozzi F, 2011, CURR GENE THER, V11, P321, DOI 10.2174/156652311796150354
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Nair P, 2016, INVEST OPHTH VIS SCI, V57, P5127, DOI 10.1167/iovs.16-20356
   Najafabadi HS, 2017, ARCH IRAN MED, V20, P525
   Naruse K, 2000, EXP EYE RES, V71, P309, DOI 10.1006/exer.2000.0882
   Nentwich MM, 2015, WORLD J DIABETES, V6, P489, DOI 10.4239/wjd.v6.i3.489
   Nittala MG, 2022, JAMA OPHTHALMOL, V140, P243, DOI 10.1001/jamaophthalmol.2021.6067
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Patel P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112436
   Porta M, 2002, DIABETOLOGIA, V45, P1617, DOI 10.1007/s00125-002-0990-7
   Prentice HM, 2011, INVEST OPHTH VIS SCI, V52, P8562, DOI 10.1167/iovs.10-6835
   Qin X, 2022, BIOACT MATER, V14, P134, DOI 10.1016/j.bioactmat.2021.11.031
   Quintino L, 2018, MOL THER-METH CLIN D, V11, P29, DOI 10.1016/j.omtm.2018.08.008
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rasoulinejad SA, 2021, MOL BIOTECHNOL, V63, P768, DOI 10.1007/s12033-021-00345-4
   Reid CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29726-7
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosina C, 2008, CLIN OPHTHALMOL, V2, P485
   SAEEDI P, 2019, DIABETES RES CLIN PR, V157, DOI DOI 10.1016/J.DIABRES.2019.107843
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Sarkar A, 2021, J CONTROL RELEASE, V329, P1262, DOI 10.1016/j.jconrel.2020.10.054
   Schmidt-Erfurth U, 2010, DEV OPHTHALMOL, V46, P21, DOI 10.1159/000320007
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   SHEN H, 1993, BLOOD, V81, P2767
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Shirley M, 2022, DRUGS, V82, P825, DOI 10.1007/s40265-022-01713-3
   SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768
   Siemerink MJ, 2013, J HISTOCHEM CYTOCHEM, V61, P101, DOI 10.1369/0022155412467635
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smalley E, 2017, NAT BIOTECHNOL, V35, P998, DOI 10.1038/nbt1117-998
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Stewart MW, 2017, OPHTHALMOL THER, V6, P33, DOI 10.1007/s40123-017-0083-9
   Thompson DA, 2015, INVEST OPHTH VIS SCI, V56, P918, DOI 10.1167/iovs.14-16049
   Timmers AM, 2020, HUM GENE THER, V31, P80, DOI 10.1089/hum.2019.144
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Trapani I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040287
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Usui Y, 2015, ANNU REV VIS SCI, V1, P155, DOI 10.1146/annurev-vision-082114-035439
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   Wang JH, 2020, CURR DIABETES REP, V20, DOI 10.1007/s11892-020-01308-w
   Wang JH, 2017, PHARMACOL THERAPEUT, V173, P1, DOI 10.1016/j.pharmthera.2017.01.003
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wong TY, 2020, OPHTHALMOLOGICA, V243, P9, DOI 10.1159/000502387
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu WY, 2017, INVEST OPHTH VIS SCI, V58, P6082, DOI 10.1167/iovs.17-21902
   Wykoff CC, 2022, AM J OPHTHALMOL, V235, P131, DOI 10.1016/j.ajo.2021.08.018
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yang SQ, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj2177
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
   Yin HF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31880
   Yiu G, 2016, INVEST OPHTH VIS SCI, V57, P5490, DOI 10.1167/iovs.16-20296
   Yorston David, 2014, Community Eye Health, V27, P44
   Yu CQ, 2008, INVEST OPHTH VIS SCI, V49, P3870, DOI 10.1167/iovs.07-1418
   Zaiss AK, 2005, CURR GENE THER, V5, P323, DOI 10.2174/1566523054065039
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang XY, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-27
   Zhou PX, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.696201
   Zhou YD, 2017, INT J OPHTHALMOL-CHI, V10, P1902, DOI 10.18240/ijo.2017.12.18
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Zysk AM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2793736
NR 194
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT 1
PY 2022
VL 38
IS 8
BP 529
EP 548
DI 10.1089/jop.2022.0022
EA SEP 2022
PG 20
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 5W1HD
UT WOS:000858600300001
PM 36125411
DA 2022-11-30
ER

PT J
AU Ding, SSL
   Subbiah, SK
   Khan, MSA
   Farhana, A
   Mok, PL
AF Ding, Shirley Suet Lee
   Subbiah, Suresh Kumar
   Khan, Mohammed Safwan Ali
   Farhana, Aisha
   Mok, Pooi Ling
TI Empowering Mesenchymal Stem Cells for Ocular Degenerative Disorders
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE mesenchymal stem cells; ocular disorders; degeneration
ID MARROW STROMAL CELLS; MICROBUBBLE-MEDIATED ULTRASOUND;
   PHOTORECEPTOR-LIKE CELLS; GANGLION-LIKE CELLS; BONE-MARROW; KIDNEY
   INJURY; HYDROGEL SCAFFOLDS; ERYTHROPOIETIN; DELIVERY; RAT
AB Multipotent mesenchymal stem cells (MSCs) have been employed in numerous pre-clinical and clinical settings for various diseases. MSCs have been used in treating degenerative disorders pertaining to the eye, for example, age-related macular degeneration, glaucoma, retinitis pigmentosa, diabetic retinopathy, and optic neuritis. Despite the known therapeutic role and mechanisms of MSCs, low cell precision towards the targeted area and cell survivability at tissue needing repair often resulted in a disparity in therapeutic outcomes. In this review, we will discuss the current and feasible strategy options to enhance treatment outcomes with MSC therapy. We will review the application of various types of biomaterials and advances in nanotechnology, which have been employed on MSCs to augment cellular function and differentiation for improving treatment of visual functions. In addition, several modes of gene delivery into MSCs and the types of associated therapeutic genes that are important for modulation of ocular tissue function and repair will be highlighted.
C1 [Ding, Shirley Suet Lee; Khan, Mohammed Safwan Ali; Mok, Pooi Ling] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Malaysia.
   [Subbiah, Suresh Kumar] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med Microbiol & Parasitol, Serdang 43400, Malaysia.
   [Subbiah, Suresh Kumar; Mok, Pooi Ling] Univ Putra Malaysia, Genet & Regenerat Med Res Ctr, Serdang 43400, Malaysia.
   [Subbiah, Suresh Kumar] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Malaysia.
   [Khan, Mohammed Safwan Ali] Texas Univ, Texas A&M Hlth Sci Ctr, Irma Lerma Rangel Coll Pharm, Dept Pharmaceut Sci, College Stn, TX 77843 USA.
   [Farhana, Aisha; Mok, Pooi Ling] Jouf Univ, Coll Appl Med Sci, Dept Clin Lab Sci, POB 2014, Sakaka 72442, Aljouf Province, Saudi Arabia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra
   Malaysia; Universiti Putra Malaysia; Texas A&M University System; Texas
   A&M University College Station; Texas A&M Health Science Center; Al Jouf
   University
RP Mok, PL (通讯作者)，Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Malaysia.; Subbiah, SK (通讯作者)，Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med Microbiol & Parasitol, Serdang 43400, Malaysia.; Subbiah, SK; Mok, PL (通讯作者)，Univ Putra Malaysia, Genet & Regenerat Med Res Ctr, Serdang 43400, Malaysia.; Subbiah, SK (通讯作者)，Univ Putra Malaysia, Inst Biosci, Serdang 43400, Malaysia.; Mok, PL (通讯作者)，Jouf Univ, Coll Appl Med Sci, Dept Clin Lab Sci, POB 2014, Sakaka 72442, Aljouf Province, Saudi Arabia.
EM suetlee.ding@gmail.com; sureshkudsc@gmail.com; safwan.aucp@gmail.com;
   aishafarhana512@gmail.com; rachelmok2005@gmail.com
RI Ali Khan, Mohammed Safwan/HDN-7110-2022; Mok, Pooi Ling/AAJ-7480-2021;
   Farhana, Aisha/AAR-7356-2020; Khan, Mohammed Safwan Ali/U-9132-2017; Ali
   Khan, Mohammed safwan/HCH-3996-2022; Kumar, suresh S/J-2423-2017
OI Ali Khan, Mohammed Safwan/0000-0002-6186-5740; Khan, Mohammed Safwan
   Ali/0000-0002-6186-5740; Kumar, suresh S/0000-0002-0505-7554; Farhana,
   Aisha/0000-0002-4631-2769
FU Ministry of Science, Technology and Innovation (MOSTI), Malaysia through
   the Science Fund [5450817]; Jouf University [40/G/03]
FX This work was supported by the grant from the Ministry of Science,
   Technology and Innovation (MOSTI), Malaysia through the Science Fund,
   under the grant number 5450817. This work was also supported by the Jouf
   University (Grant No.: 40/G/03).
CR Ahmed NEB, 2016, SCI REP-UK, V6, DOI 10.1038/srep35476
   Aliabouzar M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37728
   Alural B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00475
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Baraniak PR, 2012, CELL TISSUE RES, V347, P701, DOI 10.1007/s00441-011-1215-5
   Bernhard JC, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0314-3
   Boura JS, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.41
   Busch S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102013
   Cao J, 2016, STEM CELLS, V34, P367, DOI 10.1002/stem.2239
   Cejka C, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5843809
   Chung H, 2009, J NEUROSCI RES, V87, P2365, DOI 10.1002/jnr.22046
   Cronk SM, 2015, STEM CELL TRANSL MED, V4, P459, DOI 10.5966/sctm.2014-0108
   Cui XF, 2010, BIOTECHNOL BIOENG, V106, P963, DOI 10.1002/bit.22762
   Daga A, 2002, GENE THER, V9, P915, DOI 10.1038/sj.gt.3301727
   Deng WT, 2012, INVEST OPHTH VIS SCI, V53, P1895, DOI 10.1167/iovs.11-8831
   Dhandayuthapani B, 2011, INT J POLYM SCI, V2011, DOI 10.1155/2011/290602
   Ding SLS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081406
   Duan P, 2013, CELL PHYSIOL BIOCHEM, V31, P601, DOI 10.1159/000350080
   El-Sadik AO, 2010, CLIN PHARMACOL-ADV A, V2, P9, DOI 10.2147/CPAA.S8931
   Eliopoulos N, 2011, MOL THER, V19, P2072, DOI 10.1038/mt.2011.162
   English K, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015560
   Fellows CR, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00213
   Friedman T, 2016, SKELETAL RADIOL, V45, P307, DOI 10.1007/s00256-015-2282-6
   Gentile P, 2017, STEM CELLS, V35, P117, DOI 10.1002/stem.2498
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Giannaccini M, 2014, INT J MOL SCI, V15, P1590, DOI 10.3390/ijms15011590
   Gottstein C, 2013, ACS NANO, V7, P4933, DOI 10.1021/nn400243d
   Gu Q, 2016, ADV HEALTHC MATER, V5, P1429, DOI 10.1002/adhm.201600095
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Gunther MI, 2015, ACTA BIOMATER, V27, P140, DOI 10.1016/j.actbio.2015.09.001
   Guo RJ, 2015, BIOMATERIALS, V54, P21, DOI 10.1016/j.biomaterials.2015.03.010
   Harper MM, 2011, INVEST OPHTH VIS SCI, V52, P4506, DOI 10.1167/iovs.11-7346
   Harper MM, 2009, EXP EYE RES, V89, P538, DOI 10.1016/j.exer.2009.05.013
   Hong Y, 2011, INT J OPHTHALMOL-CHI, V4, P466, DOI 10.3980/j.issn.2222-3959.2011.05.02
   Jiang YF, 2014, INT J MOL SCI, V15, P9372, DOI 10.3390/ijms15069372
   Kim KS, 2016, CELL TRANSPLANT, V25, P1145, DOI 10.3727/096368915X688263
   Kolesky DB, 2014, ADV MATER, V26, P3124, DOI 10.1002/adma.201305506
   Nguyen LH, 2017, SCI REP-UK, V7, DOI 10.1038/srep42212
   Lee JY, 2012, TISSUE ENG REGEN MED, V9, P249, DOI 10.1007/s13770-012-0355-3
   Lee J, 2014, CANCER LETT, V347, P46, DOI 10.1016/j.canlet.2014.02.006
   Lee SJ, 2017, TISSUE ENG PT A, V23, P491, DOI [10.1089/ten.tea.2016.0353, 10.1089/ten.TEA.2016.0353]
   Leow SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128973
   Li LP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9682757
   Li PJ, 2013, CELL BIOCHEM BIOPHYS, V66, P775, DOI 10.1007/s12013-013-9523-x
   Lifshitz L, 2009, MOL IMMUNOL, V46, P713, DOI 10.1016/j.molimm.2008.10.004
   Liu L, 2016, SCI REP-UK, V6, DOI 10.1038/srep26271
   Liu NM, 2013, EXP CELL RES, V319, P2019, DOI 10.1016/j.yexcr.2013.04.008
   Liu XJ, 2015, GRAEF ARCH CLIN EXP, V253, P1263, DOI 10.1007/s00417-015-2969-3
   Lorber B, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/1/015001
   Lozano R, 2015, BIOMATERIALS, V67, P264, DOI 10.1016/j.biomaterials.2015.07.022
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Machalinska A, 2013, INVEST OPHTH VIS SCI, V54, P8292, DOI 10.1167/iovs.13-12221
   Mahapatra C, 2017, ACTA BIOMATER, V50, P142, DOI 10.1016/j.actbio.2016.12.014
   Manchineella S, 2016, ACS APPL MATER INTER, V8, P22849, DOI 10.1021/acsami.6b06403
   Manke A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/942916
   Manuguerra-Gagne R, 2013, STEM CELLS, V31, P1136, DOI 10.1002/stem.1364
   Mesentier-Louro LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110722
   Mok PL, 2012, TISSUE CELL, V44, P249, DOI 10.1016/j.tice.2012.04.002
   Mok PL, 2012, CYTOTECHNOLOGY, V64, P203, DOI 10.1007/s10616-011-9413-2
   Mok PL, 2008, CYTOTHERAPY, V10, P116, DOI 10.1080/14653240701816996
   Mok PL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020345
   Mok PL, 2013, MALAYS J PATHOL, V35, P17
   Moradi L, 2017, BIOMATERIALS, V126, P18, DOI 10.1016/j.biomaterials.2017.02.022
   Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958
   Nadri S, 2013, NEUROSCI LETT, V541, P43, DOI 10.1016/j.neulet.2012.12.055
   Nakano M, 2016, SCI REP-UK, V6, DOI 10.1038/srep24805
   Nicoara SD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1236721
   Omoto M, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15413
   Otani K, 2009, J CONTROL RELEASE, V133, P146, DOI 10.1016/j.jconrel.2008.09.088
   Owczarczak AB, 2012, JOVE-J VIS EXP, DOI 10.3791/3681
   Pereira CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep33836
   Rajala A, 2014, NANO LETT, V14, P5257, DOI 10.1021/nl502275s
   Roozafzoon R, 2015, BIOCHEM BIOPH RES CO, V457, P154, DOI 10.1016/j.bbrc.2014.12.069
   Roson-Burgo B, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-910
   Schwenk MH, 2010, PHARMACOTHERAPY, V30, P70, DOI 10.1592/phco.30.1.70
   Shepherd JNH, 2011, ADV FUNCT MATER, V21, P47, DOI 10.1002/adfm.201001746
   Sivan P.P., 2016, STEM CELLS INT, V2016, P1
   Soleimannejad M, 2017, MED HYPOTHESES, V101, P75, DOI 10.1016/j.mehy.2017.02.019
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Swartzlander MD, 2015, BIOMATERIALS, V41, P79, DOI 10.1016/j.biomaterials.2014.11.020
   Tamaddon M, 2017, SCI REP-UK, V7, DOI 10.1038/srep43519
   Tassoni A, 2015, STEM CELLS, V33, P3006, DOI 10.1002/stem.2095
   Teh SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020558
   Tomita H, 2013, GENE THER, V127, P1, DOI DOI 10.5772/52987
   Tzameret A, 2015, STEM CELL RES, V15, P387, DOI 10.1016/j.scr.2015.08.007
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wang G, 2016, ULTRASOUND MED BIOL, V42, P539, DOI 10.1016/j.ultrasmedbio.2015.10.005
   Wang G, 2015, CURR GENE THER, V15, P21
   Wang HY, 2012, CHEM RES CHINESE U, V28, P1041
   Wang K, 2017, ADV MATER, V29, DOI 10.1002/adma.201604600
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Wu MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23396-1
   Wu SZ, 2014, INT J NANOMED, V9, P5639, DOI 10.2147/IJN.S73950
   Wyse RD, 2014, INT J MOL SCI, V15, P1719, DOI 10.3390/ijms15021719
   Xu T, 2009, TISSUE ENG PT A, V15, P95, DOI 10.1089/ten.tea.2008.0095
   Yu B, 2016, SCI REP-UK, V6, DOI 10.1038/srep34562
   Zhang DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep14326
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
NR 99
TC 17
Z9 18
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2019
VL 20
IS 7
AR 1784
DI 10.3390/ijms20071784
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HU4PM
UT WOS:000465258100089
PM 30974904
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Yoshida, S
   Nakama, T
   Ishikawa, K
   Nakao, S
   Sonoda, KH
   Ishibashi, T
AF Yoshida, Shigeo
   Nakama, Takahito
   Ishikawa, Keijiro
   Nakao, Shintaro
   Sonoda, Koh-hei
   Ishibashi, Tatsuro
TI Periostin in vitreoretinal diseases
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Vitreoretinal disease; Genome-wide gene expression profiling;
   Proliferative diabetic retinopathy; Proliferative vitreoretinopathy;
   Age-related macular degeneration; Fibrovascular membranes; Epiretinal
   membranes; Neovascularization; Fibrosis; Retina; Choroid; Mouse model of
   oxygen-induced retinal neovascularization; Mouse model of laser-induced
   choroidal neovascuarization; Single-stranded RNA interference
ID PROLIFERATIVE DIABETIC-RETINOPATHY; OXYGEN-INDUCED RETINOPATHY;
   FIBROVASCULAR MEMBRANE FORMATION; AGENT TARGETING PERIOSTIN; PIGMENT
   EPITHELIAL-CELLS; TOLL-LIKE RECEPTOR-3; MACULAR DEGENERATION; MOUSE
   MODEL; RETINAL NEOVASCULARIZATION; RNA INTERFERENCE
AB Proliferative vitreoretinal diseases such as diabetic retinopathy, proliferative vitreoretinopathy (PVR), and age-related macular degeneration are a leading cause of decreased vision and blindness in developed countries. In these diseases, retinal fibro(vascular) membrane (FVM) formation above and beneath the retina plays an important role. Gene expression profiling of human FVMs revealed significant upregulation of periostin. Subsequent analyses demonstrated increased periostin expression in the vitreous of patients with both proliferative diabetic retinopathy and PVR. Immunohistochemical analysis showed co-localization of periostin with alpha-SMA and M2 macrophage markers in FVMs. In vitro, periostin blockade inhibited migration and adhesion induced by PVR vitreous and transforming growth factor-beta 2 (TGF-beta 2). In vivo, a novel single-stranded RNAi agent targeting periostin showed the inhibitory effect on experimental retinal and choroidal FVM formation without affecting the viability of retinal cells. These results indicated that periostin is a pivotal molecule for FVM formation and a promising therapeutic target for these proliferative vitreoretinal diseases.
C1 [Yoshida, Shigeo; Nakama, Takahito; Ishikawa, Keijiro; Nakao, Shintaro; Sonoda, Koh-hei; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Yoshida, S (通讯作者)，Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan.
EM usyosi@gmail.com
OI Yoshida, Shigeo/0000-0003-1049-8909
FU JSPS [26293374, 26670757, 15H04995, 16K15734]; Grants-in-Aid for
   Scientific Research [17H05101] Funding Source: KAKEN
FX We thank Drs. Kinuko Sasada, Yuki Kubo and Yoshiyuki Kobayashi for their
   fruitful discussions. We also thank Ms. Masayo Eto for her excellent
   technical assistance. This work was supported in part by JSPS KAKENHI
   Grant numbers 26293374, 26670757, 15H04995 and 16K15734.
CR Asato R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054191
   Banerjee S, 2007, INVEST OPHTH VIS SCI, V48, P2203, DOI 10.1167/iovs.06-1358
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Conway SJ, 2008, CURR GENOMICS, V9, P548, DOI 10.2174/138920208786847917
   Dangaria SJ, 2009, DIFFERENTIATION, V78, P79, DOI 10.1016/j.diff.2009.03.005
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   ELNER SG, 1995, CURR EYE RES, V14, P1045, DOI 10.3109/02713689508998529
   Fujita Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03325
   Hamasaki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042655
   Harada C, 2006, PROG RETIN EYE RES, V25, P149, DOI 10.1016/j.preteyeres.2005.09.001
   He SK, 2008, INVEST OPHTH VIS SCI, V49, P4078, DOI 10.1167/iovs.07-1302
   Hiscott P, 2000, EYE, V14, P549, DOI 10.1038/eye.2000.142
   HISCOTT PS, 1984, BRIT J OPHTHALMOL, V68, P708, DOI 10.1136/bjo.68.10.708
   Ishikawa K, 2015, INVEST OPHTH VIS SCI, V56, P932, DOI 10.1167/iovs.14-15589
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Ishikawa K, 2012, LAB INVEST, V92, P91, DOI 10.1038/labinvest.2011.141
   Ishikawa K, 2010, INVEST OPHTH VIS SCI, V51, P4307, DOI 10.1167/iovs.09-4605
   Kirchhof B, 2004, GRAEF ARCH CLIN EXP, V242, P699, DOI 10.1007/s00417-004-0978-8
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kobayashi Y, 2016, LAB INVEST, V96, P1178, DOI 10.1038/labinvest.2016.99
   Kobayashi Y, 2016, MOL VIS, V22, P436
   Kobayashi Y, 2015, BRIT J OPHTHALMOL, V99, P451, DOI 10.1136/bjophthalmol-2014-305321
   Leiderman YI, 2009, SEMIN OPHTHALMOL, V24, P62, DOI 10.1080/08820530902800082
   Li GH, 2006, ATHEROSCLEROSIS, V188, P292, DOI 10.1016/j.atherosclerosis.2005.11.002
   Liu W, 2009, CURR EYE RES, V34, P123, DOI 10.1080/02713680802650369
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978
   Nakama T, 2015, GENE THER, V22, P127, DOI 10.1038/gt.2014.112
   Nakama T, 2017, MOL THER-NUCL ACIDS, V6, P279, DOI 10.1016/j.omtn.2017.01.004
   Nakama T, 2016, EXP EYE RES, V153, P133, DOI 10.1016/j.exer.2016.10.012
   O'Reilly S, 2013, BIOFACTORS, V39, P593, DOI 10.1002/biof.1117
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Ontsuka K, 2012, EXP DERMATOL, V21, P331, DOI 10.1111/j.1600-0625.2012.01454.x
   Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966
   Pennock S, 2011, AM J PATHOL, V179, P2931, DOI 10.1016/j.ajpath.2011.08.043
   Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Shimazaki M, 2008, J EXP MED, V205, P295, DOI 10.1084/jem.20071297
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Sivaprasad S, 2012, SURV OPHTHALMOL, V57, P347, DOI 10.1016/j.survophthal.2012.01.004
   Snead DRJ, 2008, EYE, V22, P1310, DOI 10.1038/eye.2008.36
   Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517
   SUNDERKOTTER C, 1991, AM J PATHOL, V138, P931
   Tachibana T, 2016, ACTA OPHTHALMOL, V94, pE81, DOI 10.1111/aos.12752
   Takanashi M, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.34
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yoshida A, 1999, HISTOL HISTOPATHOL, V14, P1287, DOI 10.14670/HH-14.1287
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Yoshida S, 2015, BRIT J OPHTHALMOL, V99, P960, DOI 10.1136/bjophthalmol-2014-306366
   Yoshida S, 2015, BRIT J OPHTHALMOL, V99, P629, DOI 10.1136/bjophthalmol-2014-305860
   Yoshida Shigeo, 2014, Nippon Ganka Gakkai Zasshi, V118, P241
   Yoshida S, 2012, INVEST OPHTH VIS SCI, V53, P6997, DOI 10.1167/iovs.12-9671
   Yoshida S, 2011, INVEST OPHTH VIS SCI, V52, P5670, DOI 10.1167/iovs.10-6625
   Yoshida S, 2010, BRIT J OPHTHALMOL, V94, P795, DOI 10.1136/bjo.2009.167072
   Yoshida S, 2010, GRAEF ARCH CLIN EXP, V248, P799, DOI 10.1007/s00417-010-1301-5
   Zhou YD, 2015, INVEST OPHTH VIS SCI, V56, P4767, DOI 10.1167/iovs.14-16012
   ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x
NR 65
TC 7
Z9 8
U1 0
U2 8
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD DEC
PY 2017
VL 74
IS 23
BP 4329
EP 4337
DI 10.1007/s00018-017-2651-5
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FL0VE
UT WOS:000413928700009
PM 28913545
DA 2022-11-30
ER

PT J
AU Wright, W
   Gajjeraman, S
   Batabyal, S
   Pradhan, S
   Bhattacharya, S
   Mahapatra, V
   Tripathy, A
   Mohanty, S
AF Wright, Weldon
   Gajjeraman, Sivakumar
   Batabyal, Subrata
   Pradhan, Sanjay
   Bhattacharya, Sulagna
   Mahapatra, Vasu
   Tripathy, Ashutosh
   Mohanty, Samarendra
TI Restoring vision in mice with retinal degeneration using
   multicharacteristic opsin
SO NEUROPHOTONICS
LA English
DT Article
DE vision restoration; optogenetics; retinitis pigmentosa; dry age-related
   macular degeneration
ID MACULAR DEGENERATION; EXCITABLE CELLS; NEURAL CIRCUITS; OPTICAL CONTROL;
   VISUAL FUNCTION; LIGHT; CHANNELRHODOPSIN-2; PROSTHESIS; EXCITATION;
   STIMULATION
AB Retinal degenerative diseases, such as retinitis pigmentosa (RP) and dry age-related macular degeneration, have led to loss of vision in millions of individuals. Currently, no surgical or medical treatment is available, although optogenetic therapies are in clinical development. We demonstrate vision restoration using multicharacteristics opsin (MCO1) in animal models with degenerated retina. MCO1 is reliably delivered to specific retinal cells via intravitreal injection of adeno-associated virus (vMCO1), leading to significant improvement in visually guided behavior conducted using a radial arm water maze. The time to reach the platform and the number of error arms decreased significantly after delivery of MCO1. Notably, the improvement in visually guided behavior was observed even at light intensity levels orders of magnitude lower than that required for channelrhodopsin-2 opsin. Viability of vMCO1-treated retina is not compromised by chronic light exposure. Safe virus-mediated MCO1 delivery has potential for effective gene therapy of diverse retinal degenerations in patients. (C) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Wright, Weldon; Gajjeraman, Sivakumar; Batabyal, Subrata; Pradhan, Sanjay; Bhattacharya, Sulagna; Mahapatra, Vasu; Tripathy, Ashutosh; Mohanty, Samarendra] NanoScope Technol LLC, Bedford, TX 76022 USA.
RP Mohanty, S (通讯作者)，NanoScope Technol LLC, Bedford, TX 76022 USA.
EM smohanty@nanoscopetech.com
FU National Eye Institute [1R43EY025905-01, 1R43EY026483-01,
   3R43EY025905-01S1, 1R01EY025717-01A1]; NATIONAL EYE INSTITUTE
   [R01EY025717, R43EY025905] Funding Source: NIH RePORTER
FX The authors would like to thank the National Eye Institute Grants
   1R43EY025905-01, 1R43EY026483-01, 3R43EY025905-01S1, and
   1R01EY025717-01A1.
CR Batabyal S, 2015, SCI REP-UK, V5, DOI 10.1038/srep17857
   Batabyal S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136958
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   Degenaar P, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/3/035007
   Dhakal K, 2015, LIGHT-SCI APPL, V4, DOI 10.1038/lsa.2015.125
   Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69
   Guo ZV, 2009, NAT METHODS, V6, P891, DOI 10.1038/nmeth.1397
   Hodges H, 1996, COGNITIVE BRAIN RES, V3, P167, DOI 10.1016/0926-6410(96)00004-3
   Horsager A, 2009, INVEST OPHTH VIS SCI, V50, P1483, DOI 10.1167/iovs.08-2595
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Klapoetke NC, 2014, NAT METHODS, V11, P338, DOI [10.1038/NMETH.2836, 10.1038/nmeth.2836]
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lin JY, 2013, NAT NEUROSCI, V16, P1499, DOI 10.1038/nn.3502
   Miller G, 2006, SCIENCE, V314, P1674, DOI 10.1126/science.314.5806.1674
   Mohanty SK, 2008, BIOPHYS J, V95, P3916, DOI 10.1529/biophysj.108.130187
   Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Sengupta A, 2016, EMBO MOL MED, V8, P1248, DOI 10.15252/emmm.201505699
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Zhang F, 2007, NAT REV NEUROSCI, V8, P577, DOI 10.1038/nrn2192
   Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 25
TC 8
Z9 8
U1 0
U2 9
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 2329-423X
EI 2329-4248
J9 NEUROPHOTONICS
JI Neurophotonics
PD OCT-DEC
PY 2017
VL 4
IS 4
AR 041505
DI 10.1117/1.NPh.4.4.041505
PG 8
WC Neurosciences; Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Optics
GA FP9OZ
UT WOS:000417979700017
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Lee, M
   Wathier, M
   Love, JA
   McGeer, E
   McGeer, PL
AF Lee, Moonhee
   Wathier, Matthew
   Love, Jennifer A.
   McGeer, Edith
   McGeer, Patrick L.
TI Inhibition of aberrant complement activation by a dimer of
   acetylsalicylic acid
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Properdin; Factor B; Factor D; C9; Membrane attack complex; Alzheimer's
   disease; Age-related macular degeneration
ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; AMYOTROPHIC-LATERAL-SCLEROSIS;
   FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; PARKINSONS-DISEASE; SYSTEM
AB We here report synthesis for the first time of the acetyl salicylic acid dimer 5,5'-methylenebis(2-acetoxybenzoic acid) (DAS). DAS inhibits aberrant complement activation by selectively blocking factor D of the alternative complement pathway and C9 of the membrane attack complex. We have previously identified aurin tricarboxylic and its oligomers as promising agents in this regard. DAS is much more potent, inhibiting erythrocyte hemolysis by complement-activated serum with an IC50 in the 100-170 nanomolar range. There are numerous conditions where self-damage from the complement system has been implicated in the pathology, including such chronic degenerative diseases of aging as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and age-related macular degeneration. Consequently, there is a high priority for the discovery and development of agents that can successfully treat such conditions. DAS holds considerable promise for being such an agent. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Lee, Moonhee; McGeer, Edith; McGeer, Patrick L.] Univ British Columbia, Kinsmen Lab Neurol Res, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada.
   [Wathier, Matthew; Love, Jennifer A.] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada.
C3 University of British Columbia; University of British Columbia
RP McGeer, PL (通讯作者)，Univ British Columbia, Kinsmen Lab Neurol Res, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
EM mcgeerpl@mail.ubc.ca
FU Natural Sciences and Engineering Research Council of Canada (NSERC);
   Industrial Research Assistance Program of Canada (IRAP) [839486]
FX This research was supported by grants from the Natural Sciences and
   Engineering Research Council of Canada (NSERC) and the Industrial
   Research Assistance Program of Canada (IRAP, grant number: 839486). The
   authors are grateful to Dr. Brian Patrick of the UBC Chemistry
   Department for the X-ray Crystallography analysis.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barnum S.R., 1984, J IMMUNOL METHODS, V67, P307
   Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137
   Dolomanov OV, 2009, J APPL CRYSTALLOGR, V42, P339, DOI 10.1107/S0021889808042726
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrnthaller C, 2011, MOL MED, V17, P317, DOI 10.2119/molmed.2010.00149
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   KAWAMATA T, 1992, AM J PATHOL, V140, P691
   Kelly RJ, 2011, BLOOD, V117, P6786, DOI 10.1182/blood-2011-02-333997
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee M, 2013, NEUROBIOL AGING, V34, P1451, DOI 10.1016/j.neurobiolaging.2012.10.023
   Lee M, 2012, NEUROBIOL AGING, V33, P2237, DOI 10.1016/j.neurobiolaging.2011.12.005
   Luzzatto L, 2006, CURR OPIN GENET DEV, V16, P317, DOI 10.1016/j.gde.2006.04.015
   McGeer EG, 2005, BIODRUGS, V19, P31, DOI 10.2165/00063030-200519010-00004
   McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005
   Orlowsky EW, 2015, J RHEUMATOL, V42, P363, DOI 10.3899/jrheum.140382
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T
   YAMADA T, 1992, ACTA NEUROPATHOL, V84, P100, DOI 10.1007/BF00427222
   Yamada T., 1991, DEMENTIA, V2, P71
   YAMADA T, 1993, NEUROL PSYCHIAT BR, V2, P26
NR 25
TC 5
Z9 6
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD OCT
PY 2015
VL 36
IS 10
BP 2748
EP 2756
DI 10.1016/j.neurobiolaging.2015.06.018
PG 9
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA CQ9JA
UT WOS:000360929100011
PM 26248865
DA 2022-11-30
ER

PT J
AU Vale, TC
   Femandes, LC
   Caramelli, P
AF Vale, Thiago Cardoso
   Femandes, Luciene Chaves
   Caramelli, Paulo
TI Charles Bonnet syndrome: characteristics of its visual hallucinations
   and differential diagnosis
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE Charles Bonnet syndrome; visual hallucinations; sensory hallucinations;
   dementia; low vision
ID VISION
AB Objective: To present an eight-case serie of patients with Charles Bonnet syndrome (CBS). Method: All patients were initially evaluated by an ophthalmologist and then submitted to a neurologic evaluation with exclusion of alternative psychiatric and neurologic diagnoses. Results: Five patients were male (62.5%) and the mean age was 52.3+16.0 years. Two patients suffered from severe myopia and glaucoma, three had retinitis pigmentosa, one had anterior ischemic optic neuropathy, one had age-related macular degeneration and one had toxoplasmic retinochoroiditis. Mean visual acuity in the right eye was 1,12 logMAR and in the left eye 0.57 logMAR. A mean delay of 41.7 months occurred until diagnosis. All hallucinations were complexes and mostly ocurred on a weekly-basis (62.5%) and lasted for seconds (87.5%). Conclusions: Physicians who care for low vision patients should be aware of CBS and appropriately diagnose its hallucinations after exclusion of psychiatric and neurologic diseases.
C1 [Vale, Thiago Cardoso] Univ Fed Juizde de Fora, Fac Med, Univ Hosp, Serv Neurol, Juiz De Fora, MG, Brazil.
   [Femandes, Luciene Chaves] Univ Fed Minas Gerais, Hosp Sao Gerald, BR-30130100 Belo Horizonte, MG, Brazil.
   [Femandes, Luciene Chaves] Soc Pan Amer Baixa Visao, Belo Horizonte, MG, Brazil.
   [Caramelli, Paulo] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, BR-30130100 Belo Horizonte, MG, Brazil.
   [Caramelli, Paulo] Univ Fed Minas Gerais, Hosp Clin, Div Neurol, BR-30130100 Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais
RP Caramelli, P (通讯作者)，Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Hosp Clin, Av Prof Alfredo Balena,190 Sala 246, BR-30130100 Belo Horizonte, MG, Brazil.
RI CARAMELLI, PAULO/H-9735-2012
OI CARAMELLI, PAULO/0000-0002-4786-6990; Vale, Thiago/0000-0001-6145-9868
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq -
   Bolsa de Produtividade em Pesquisa); Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais (Fapemig)
FX Thiago Cardoso Vale and Luciene Chaves Fernandes declare no financial
   disclosure. Paulo Caramelli is research-funded by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq - Bolsa de Produtividade
   em Pesquisa) and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (Fapemig).
CR Adachi N, 2000, PSYCHIAT CLIN NEUROS, V54, P157, DOI 10.1046/j.1440-1819.2000.00652.x
   Bertolucci PHF, 2001, ARQ NEURO-PSIQUIAT, V59, P532, DOI 10.1590/S0004-282X2001000400009
   Brucki Sonia Maria Dozzi, 2009, Dement. neuropsychol., V3, P61, DOI 10.1590/S1980-57642009DN30100012
   CRANE WG, 1994, OPHTHALMOL CLIN N AM, V7, P143
   CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308
   Fahn S, 1987, RECENT DEV PARKINSON, V2
   Ffytche DH, 1998, NAT NEUROSCI, V1, P738, DOI 10.1038/3738
   ffytche DH, 1999, BRAIN, V122, P1247, DOI 10.1093/brain/122.7.1247
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Hart J, 1997, Elder Care, V9, P30
   PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323
   Schadlu AP, 2009, CURR OPIN OPHTHALMOL, V20, P219, DOI 10.1097/ICU.0b013e328329b643
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
NR 13
TC 15
Z9 20
U1 0
U2 21
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD MAY
PY 2014
VL 72
IS 5
BP 333
EP 336
DI 10.1590/0004-282X20140015
PG 4
WC Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA AI4HE
UT WOS:000336825500003
PM 24863507
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chen, YY
   Brown, NJ
   Jones, R
   Lewis, CE
   Mujamammi, AH
   Muthana, M
   Seed, MP
   Barker, MD
AF Chen, Yung-Yi
   Brown, Nicola J.
   Jones, Rita
   Lewis, Claire E.
   Mujamammi, Ahmed H.
   Muthana, Munitta
   Seed, Michael P.
   Barker, Michael D.
TI A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor
   receptors and tumour growth and inflammatory arthritis in mice
SO ANGIOGENESIS
LA English
DT Article
DE TIMP-3; VEGFR2; Receptor; Angiogenesis; Arthritis; Tumour
ID LACKING TISSUE INHIBITOR; SORSBYS-FUNDUS-DYSTROPHY;
   RHEUMATOID-ARTHRITIS; JOINT DESTRUCTION; VEGF RECEPTOR-2; IN-VITRO;
   BINDING; METALLOPROTEINASES-3; MATRIX; COMPLEX
AB The binding of vascular endothelial growth factor (VEGF) to VEGF receptor-2 (VEGFR-2) on the surface of vascular endothelial cells stimulates many steps in the angiogenic pathway. Inhibition of this interaction is proving of value in moderating the neovascularization accompanying age-related macular degeneration and in the treatment of cancer. Tissue inhibitor of metalloproteinases-3 (TIMP-3) has been shown to be a natural VEGFR-2 specific antagonist-an activity that is independent of its ability to inhibit metalloproteinases. In this investigation we localize this activity to the C-terminal domain of the TIMP-3 molecule and characterize a short peptide, corresponding to part of this domain, that not only inhibits all three VEGF-family receptors, but also fibroblast growth factor and platelet-derived growth factor receptors. This multiple-receptor inhibition may explain why the peptide was also seen to be a powerful inhibitor of tumour growth and also a partial inhibitor of arthritic joint inflammation in vivo.
C1 [Chen, Yung-Yi; Brown, Nicola J.; Lewis, Claire E.; Mujamammi, Ahmed H.; Barker, Michael D.] Univ Sheffield, Sch Med, Dept Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Jones, Rita; Seed, Michael P.] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England.
   [Muthana, Munitta] Univ Sheffield, Sch Med, Dept Infect & Immun, Sheffield S10 2RX, S Yorkshire, England.
C3 University of Sheffield; University of London; Queen Mary University
   London; University of Sheffield
RP Barker, MD (通讯作者)，Univ Sheffield, Sch Med, Dept Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM m.barker@sheffield.ac.uk
OI Mujamammi, Ahmed/0000-0002-7473-8281; Seed, Michael/0000-0001-7053-4743;
   Muthana, Munitta/0000-0003-2497-8903; Chen, Yung-Yi/0000-0003-2999-3715;
   Brown, Nicola/0000-0002-2100-1905
FU Yorkshire Cancer Research [S303]; University of Sheffield (Knowledge
   Transfer Fund)
FX This work was supported by grants from Yorkshire Cancer Research (S303)
   and the University of Sheffield (Knowledge Transfer Fund).
CR Alam Chandan, 2008, P99, DOI 10.1007/978-3-7643-7650-5_7
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bootle-Wilbraham CA, 2000, CANCER RES, V60, P4719
   Brozzo MS, 2012, BLOOD, V119, P1781, DOI 10.1182/blood-2011-11-390922
   Cao YH, 2008, J MOL MED, V86, P785, DOI 10.1007/s00109-008-0337-z
   Chabottaux V, 2006, CANCER RES, V66, P5165, DOI 10.1158/0008-5472.CAN-05-3012
   De Bandt M, 2003, J IMMUNOL, V171, P4853, DOI 10.4049/jimmunol.171.9.4853
   Di Benedetto M, 2008, BBA-GEN SUBJECTS, V1780, P723, DOI 10.1016/j.bbagen.2008.01.015
   Ebrahem Q, 2011, INVEST OPHTH VIS SCI, V52, P6117, DOI 10.1167/iovs.10-5899
   Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093
   GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995
   Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200
   Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Kazazi-Hyseni F, 2010, ONCOLOGIST, V15, P819, DOI 10.1634/theoncologist.2009-0317
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Kim A, 2009, ONCOLOGIST, V14, P800, DOI 10.1634/theoncologist.2009-0088
   Kim WU, 2006, J IMMUNOL, V177, P5727, DOI 10.4049/jimmunol.177.8.5727
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012
   Manabe N, 1999, RHEUMATOLOGY, V38, P714, DOI 10.1093/rheumatology/38.8.714
   Maskos K, 2007, J MOL BIOL, V366, P1222, DOI 10.1016/j.jmb.2006.11.072
   Matei D, 2007, CANCER BIOL THER, V6, P1951, DOI 10.4161/cbt.6.12.4976
   Matsumoto Y, 2002, J IMMUNOL, V168, P5824, DOI 10.4049/jimmunol.168.11.5824
   Mintseris J, 2007, PROTEINS, V69, P511, DOI 10.1002/prot.21502
   Patel HB, 2010, FUNDAMENTALS INFLAMM, P384
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Qi JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055667
   Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957
   Rosengren S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2981
   Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x
   Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8
   Sivaprasad S, 2008, AM J OPHTHALMOL, V146, P228, DOI 10.1016/j.ajo.2008.03.024
   Staton CA, 2007, J THROMB HAEMOST, V5, P846, DOI 10.1111/j.1538-7836.2007.02432.x
   Tille JC, 2001, J PHARMACOL EXP THER, V299, P1073
   Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wisniewska M, 2008, J MOL BIOL, V381, P1307, DOI 10.1016/j.jmb.2008.06.088
   Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
NR 45
TC 19
Z9 19
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD JAN
PY 2014
VL 17
IS 1
BP 207
EP 219
DI 10.1007/s10456-013-9389-y
PG 13
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 283EJ
UT WOS:000329228000016
PM 24129822
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Giansanti, V
   Rodriguez, GEV
   Savoldelli, M
   Gioia, R
   Forlino, A
   Mazzini, G
   Pennati, M
   Zaffaroni, N
   Scovassi, AI
   Torriglia, A
AF Giansanti, Vincenzo
   Rodriguez, Gloria E. Villalpando
   Savoldelli, Michelle
   Gioia, Roberta
   Forlino, Antonella
   Mazzini, Giuliano
   Pennati, Marzia
   Zaffaroni, Nadia
   Scovassi, Anna Ivana
   Torriglia, Alicia
TI Characterization of stress response in human retinal epithelial cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE Apoptosis; ARPE-19 cells; autophagy; caspases; HMA; L-DNase II; PARP-1
ID DNASE-II; PIGMENT EPITHELIUM; INDUCED APOPTOSIS; INHIBITION; AUTOPHAGY;
   ARPE-19; ACIDIFICATION; PARP-1; RPE
AB The pathogenesis of age-related macular degeneration (AMD) involves demise of the retinal pigment epithelium and death of photoreceptors. In this article, we investigated the response of human adult retinal pigmented epithelial (ARPE-19) cells to 5-(N,N-hexamethylene)amiloride (HMA), an inhibitor of Na+/H+ exchangers. We observed that ARPE-19 cells treated with HMA are unable to activate classical' apoptosis but they succeed to activate autophagy. In the first 2hrs of HMA exposure, autophagy is efficient in protecting cells from death. Thereafter, autophagy is impaired, as indicated by p62 accumulation, and this protective mechanism becomes the executioner of cell death. This switch in autophagy property as a function of time for a single stimulus is here shown for the first time. The activation of autophagy was observed, at a lesser extent, with etoposide, suggesting that this event might be a general response of ARPE cells to stress and the most important pathway involved in cell resistance to adverse conditions and toxic stimuli.
C1 [Giansanti, Vincenzo; Mazzini, Giuliano; Scovassi, Anna Ivana] CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   [Rodriguez, Gloria E. Villalpando; Torriglia, Alicia] INSERM, Ctr Rech Cordeliers, U872 Eq 17, Paris, France.
   [Rodriguez, Gloria E. Villalpando; Torriglia, Alicia] Univ Paris 06, Ctr Rech Cordeliers, Paris, France.
   [Rodriguez, Gloria E. Villalpando; Torriglia, Alicia] Univ Paris 05, Ctr Rech Cordeliers, Paris, France.
   [Savoldelli, Michelle] Hop Hotel Dieu, Dept Ophtalmol, Paris, France.
   [Gioia, Roberta; Forlino, Antonella] Univ Pavia, Dipartimento Biochim, I-27100 Pavia, Italy.
   [Pennati, Marzia; Zaffaroni, Nadia] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Milan, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica
   Molecolare (IGM-CNR); Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP;
   UDICE-French Research Universities; Universite Paris Cite; University of
   Pavia; Fondazione IRCCS Istituto Nazionale Tumori Milan
RP Torriglia, A (通讯作者)，INSERM, Ctr Rech Cordeliers, U872 Eq 17, Paris, France.
EM alicia.torriglia@inserm.fr
RI Torriglia, Alicia/Q-3509-2019; Forlino, Antonella/H-5385-2015;
   Torriglia, Alicia/L-6957-2017; Zaffaroni, Nadia/J-8178-2016; Pennati,
   Marzia/K-2554-2016
OI Torriglia, Alicia/0000-0003-1181-6710; Forlino,
   Antonella/0000-0002-6385-1182; Zaffaroni, Nadia/0000-0002-4669-0890;
   Pennati, Marzia/0000-0002-6181-2681; Scovassi, Anna
   Ivana/0000-0003-3484-9881
FU Collegio Ghislieri, Pavia, Italy; Mexican goverment fellowship
   (CONACYT); Regione Lombardia, Italy [13810040]; Retina France
FX The authors are indebted to Dr. Miguel Angel Romero for image analysis.
   GV was supported by an 'Investigator Fellowship' from Collegio
   Ghislieri, Pavia, Italy. VRGE was supported by a Mexican goverment
   fellowship (CONACYT) research is partially supported by Regione
   Lombardia, Italy (Project Plant Cell, grant # 13810040 to AIS) and
   Retina France (grant to AT).
CR Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   Altairac S, 2003, CELL DEATH DIFFER, V10, P548, DOI 10.1038/sj.cdd.4401195
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Brossas JY, 2004, MOL VIS, V10, P65
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-10
   Cho YL, 2005, BIOCHEM BIOPH RES CO, V326, P752, DOI 10.1016/j.bbrc.2004.11.109
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Giansanti V, 2012, EUR J HISTOCHEM, V56, P16, DOI 10.4081/ejh.2012.e3
   Giansanti V, 2011, BIOCHEM PHARMACOL, V82, P1304, DOI 10.1016/j.bcp.2011.05.023
   Giansanti V, 2011, APOPTOSIS, V16, P321, DOI 10.1007/s10495-011-0589-x
   Giansanti V, 2009, INT J BIOCHEM CELL B, V41, P1890, DOI 10.1016/j.biocel.2009.04.008
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lepretre C, 2009, INT J BIOCHEM CELL B, V41, P1046, DOI 10.1016/j.biocel.2008.09.026
   Lepretre C, 2009, ANN NY ACAD SCI, V1171, P25, DOI 10.1111/j.1749-6632.2009.04701.x
   Munoz-Gamez JA, 2005, BIOCHEM J, V386, P119, DOI 10.1042/BJ20040776
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Nilsson C, 2006, APOPTOSIS, V11, P1149, DOI 10.1007/s10495-006-7108-5
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Torriglia A, 2008, BIOCHEM PHARMACOL, V76, P1490, DOI 10.1016/j.bcp.2008.07.039
   Wang YF, 2009, EXP NEUROL, V218, P193, DOI 10.1016/j.expneurol.2009.03.020
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 25
TC 22
Z9 24
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN
PY 2013
VL 17
IS 1
BP 103
EP 115
DI 10.1111/j.1582-4934.2012.01652.x
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 084ED
UT WOS:000314518700008
PM 23205553
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nielsen, N
   Jackson, C
   Spurling, G
   Cranstoun, P
AF Nielsen, Nathan
   Jackson, Claire
   Spurling, Geoffrey
   Cranstoun, Peter
TI Nondiabetic retinal pathology Prevalence in diabetic retinopathy
   screening
SO AUSTRALIAN FAMILY PHYSICIAN
LA English
DT Article
DE diabetes mellitus; eye diseases; diabetic retinopathy; screening;
   general practice; health services, indigenous
ID EYE CARE SERVICES; INALA EXPERIENCE; VISION LOSS; PHOTOGRAPHY;
   AUSTRALIANS; POPULATION; PROGRAM; ACCESS; URBAN
AB Objective
   To determine the prevalence of photographic signs of nondiabetic retinal pathology in Australian general practice patients with diabetes.
   Method
   Three hundred and seven patients with diabetes underwent retinal photography at two general practices, one of which was an indigenous health centre. The images were assessed for signs of pathology by an ophthalmologist.
   Results
   Signs of nondiabetic retinal pathology were detected in 31% of subjects with adequate photographs. Features suspicious of glaucoma were detected in 7.7% of subjects. Other abnormalities detected included signs of age related macular degeneration (1.9%), epiretinal membranes (2.4%), vascular pathology (9.6%), chorioretinal lesions (2.9%), and congenital disc anomalies (2.9%). Indigenous Australian patients were more likely to have signs of retinal pathology and glaucoma.
   Conclusion
   Signs of nondiabetic retinal pathology were frequently encountered. In high risk groups, general practice based diabetic retinopathy screening may reduce the incidence of preventable visual impairment, beyond the benefits of detection of diabetic retinopathy alone.
C1 [Nielsen, Nathan] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
   [Jackson, Claire; Spurling, Geoffrey] Univ Queensland, Discipline Gen Practice, Brisbane, Qld 4072, Australia.
   [Cranstoun, Peter] Pine Rivers Eye Ctr, Brisbane, Qld, Australia.
C3 University of Queensland
RP Nielsen, N (通讯作者)，Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
EM nathan.nielsen@uqconnect.edu.au
RI Spurling, Geoffrey K/F-1783-2010; jackson, claire L/A-1986-2011
OI Spurling, Geoffrey K/0000-0002-3525-4663; jackson, claire
   L/0000-0003-1177-1380
CR Askew D, 2009, AUST FAM PHYSICIAN, V38, P650
   *AUSTR BUR STAT, 2006, 2006 AUSTR CENS QUIC
   Bragge P, 2011, ARCH OPHTHALMOL-CHIC, V129, P435, DOI 10.1001/archophthalmol.2010.319
   Bylsma GW, 2004, CLIN EXP OPHTHALMOL, V32, P573, DOI 10.1111/j.1442-9071.2004.00905.x
   Cavallerano AA, 2003, RETINA-J RET VIT DIS, V23, P215, DOI 10.1097/00006982-200304000-00013
   Chow SP, 2006, OPHTHALMOLOGY, V113, P833, DOI 10.1016/j.ophtha.2005.12.025
   CHUA BE, 2010, BR J OPHTHALMOL 1127
   Gerry P, 2006, CLIN EXP OPTOM, V89, P306, DOI 10.1111/j.1444-0938.2006.00047.x
   Hayman NE, 2009, MED J AUSTRALIA, V190, P604, DOI 10.5694/j.1326-5377.2009.tb02581.x
   Keeffe JE, 2002, BRIT J OPHTHALMOL, V86, P24, DOI 10.1136/bjo.86.1.24
   Keltner JL, 2006, OPHTHALMOLOGY, V113, P1603, DOI 10.1016/j.ophtha.2006.05.061
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P93, DOI 10.1167/iovs.05-0936
   Landers JA, 2006, CLIN EXP OPHTHALMOL, V34, P852, DOI 10.1111/j.1442-9071.2006.01344.x
   Leese GP, 2008, DIABETES CARE, V31, P2131, DOI 10.2337/dc08-1098
   McCarty CA, 1998, BRIT J OPHTHALMOL, V82, P410, DOI 10.1136/bjo.82.4.410
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   *SAS I INC, 2008, SAS AC AN SUIT VERS
   Scanlon PH, 2008, BRIT J OPHTHALMOL, V92, P775, DOI 10.1136/bjo.2007.128561
   Spurling GKP, 2010, AUST NZ J PUBL HEAL, V34, pS30, DOI 10.1111/j.1753-6405.2010.00549.x
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Taylor HR, 2009, NATL INDIGENOUS EYE
   Taylor HR, 2010, MED J AUSTRALIA, V192, P312, DOI 10.5694/j.1326-5377.2010.tb03529.x
   Vass C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003167.pub3
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Wang JJ, 2007, EUR HEART J, V28, P1984, DOI 10.1093/eurheartj/ehm221
   Xu L, 2009, EYE, V23, P676, DOI 10.1038/sj.eye.6703104
NR 26
TC 5
Z9 5
U1 0
U2 3
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 0300-8495
J9 AUST FAM PHYSICIAN
JI Aust. Fam. Physician
PD JUL
PY 2011
VL 40
IS 7
BP 529
EP +
PG 4
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 791ZL
UT WOS:000292710200019
PM 21743863
DA 2022-11-30
ER

PT J
AU Mackey, DA
AF Mackey, David A.
TI The 'I' in personalized genetics: 2008 Ian Constable lecture
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE ancestry; genetic testing; glaucoma; Leber's Hereditary Optic Neuropathy
ID OPEN-ANGLE GLAUCOMA; MACULAR DEGENERATION; FAMILY-HISTORY; LINKAGE;
   INHERITANCE; EXPERIENCE; SUSCEPTIBILITY; IDENTIFICATION; HERITABILITY;
   ASSOCIATION
AB P>The completion of the Human Genome Project heralded a new era in human genetic testing to predict individuals at risk from many common diseases. DNA markers can also be used to track one's ancestry. Eye diseases such as age-related macular degeneration and glaucoma have been important examples of the success of genome-wide association studies. Resource-strapped genetic services have been limited in providing DNA testing for many well-established hereditary diseases. Thus, several direct-to-consumer genetic services have arisen to fill the gap. However, there is a major need for research into interpreting the results of such tests of up to one million DNA markers. Studies of population, family and twins sharing common diseases help us clarify the significance of gene-disease associations. However, as identical twins show us, for some conditions our genes do not absolutely determine our destiny and environmental factors interact with our genetic profile.
C1 [Mackey, David A.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Mackey, David A.] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Mackey, David A.] Royal Hobart Hosp, Dept Ophthalmol, Hobart, Tas, Australia.
C3 Lions Eye Institute; University of Western Australia; Centre for Eye
   Research Australia; University of Melbourne; Royal Hobart Hospital
RP Mackey, DA (通讯作者)，Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM davidmackey@lei.org.au
RI Mackey, David A/H-5340-2014
OI Mackey, David A/0000-0001-7914-4709
CR *23 ME, VAR ARE WARR J BUFF
   *AUSTR GOV DEP HLE, MBS ONL MED BEN SCH
   Bellis C, 2008, HEREDITY, V100, P366, DOI 10.1038/sj.hdy.6801083
   Bellis C, 2005, HUM HERED, V60, P211, DOI 10.1159/000090545
   Bellis C, 2008, HUM GENET, V124, P543, DOI 10.1007/s00439-008-0580-y
   Bennett SL, 2007, ARCH OPHTHALMOL-CHIC, V125, P112, DOI 10.1001/archopht.125.1.112
   *BUR ONL, J CONSTABLE
   *CANC AUSTR I HLTH, CANC AUSTR CANC INC
   Craig JE, 2001, OPHTHALMOLOGY, V108, P1607, DOI 10.1016/S0161-6420(01)00654-6
   Daugman J, 2001, P ROY SOC B-BIOL SCI, V268, P1737, DOI 10.1098/rspb.2001.1696
   Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899
   *GEN GEN, GEN SYST
   GILL P, 1994, NAT GENET, V6, P130, DOI 10.1038/ng0294-130
   Green CM, 2007, CLIN EXP OPHTHALMOL, V35, P793, DOI 10.1111/j.1442-9071.2007.01612.x
   Green RC, 2008, NEW ENGL J MED, V359, P2192, DOI 10.1056/NEJMp0808100
   He MG, 2008, INVEST OPHTH VIS SCI, V49, P81, DOI 10.1167/iovs.07-1052
   He MG, 2008, INVEST OPHTH VIS SCI, V49, P1356, DOI 10.1167/iovs.07-1397
   Healey DL, 2004, J GLAUCOMA, V13, P304, DOI 10.1097/00061198-200408000-00008
   Hewitt AW, 2008, HUM MOL GENET, V17, P710, DOI 10.1093/hmg/ddm342
   Hewitt AW, 2007, INVEST OPHTH VIS SCI, V48, P2469, DOI 10.1167/iovs.06-1470
   Hewitt AW, 2007, INVEST OPHTH VIS SCI, V48, P238, DOI 10.1167/iovs.06-0611
   Hewitt AW, 2007, ARCH OPHTHALMOL-CHIC, V125, P98, DOI 10.1001/archopht.125.1.98
   Howell N, 1996, AM J HUM GENET, V59, P501
   Ivanov PL, 1996, NAT GENET, V12, P417, DOI 10.1038/ng0496-417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   *KNOM INC, KNOW THYS
   LEAKE J, 2007, TIMESONLINE
   Mackey D, 1998, AM J HUM GENET, V62, P492, DOI 10.1086/301731
   MACKEY D, RETINITIS PIGMENTOSA
   Mackey DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1172, DOI 10.1001/archopht.121.8.1172
   MACKEY DA, 1992, AUST NZ J OPHTHALMOL, V20, P177, DOI 10.1111/j.1442-9071.1992.tb00937.x
   McNaught AI, 2000, ARCH OPHTHALMOL-CHIC, V118, P900
   Mimiwati Z, 2006, BRIT J OPHTHALMOL, V90, P1505, DOI 10.1136/bjo.2006.092619
   MOTLUK, 2005, NEW SCI
   Ponsonby AL, 2007, OPHTHAL EPIDEMIOL, V14, P351, DOI 10.1080/01658100701486467
   RetNet, GEN MAPP LOC CAUS RE
   Sack J, 1996, OPHTHALMIC GENET, V17, P209, DOI 10.3109/13816819609057895
   SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   STONEKING M, 1995, NAT GENET, V9, P9, DOI 10.1038/ng0195-9
   SUN C, 2009, HYPERTENSION
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   *SURN CONST, INT SURN DAT
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Sykes B, 2000, AM J HUM GENET, V66, P1417, DOI 10.1086/302850
   Sykes B., 2001, 7 DAUGHTERS EVE SCI
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Tiberio G., 1994, Acta Geneticae Medicae et Gemellologiae, V43, P207
   Toh TY, 2005, INVEST OPHTH VIS SCI, V46, P3718, DOI 10.1167/iovs.04-1497
   *US DOE, HUM GEN PROJ INF
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Wharton C, 2006, AUST NZ J PUBL HEAL, V30, P105, DOI 10.1111/j.1467-842X.2006.tb00100.x
   *WIK FREE ENC, IAN CONST LECT
   Wolfs RCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1640, DOI 10.1001/archopht.116.12.1640
   Wu J, 2006, ARCH OPHTHALMOL-CHIC, V124, P950, DOI 10.1001/archopht.124.7.950
   Zerjal T, 2003, AM J HUM GENET, V72, P717, DOI 10.1086/367774
   Zhu G, 2004, TWIN RES, V7, P197, DOI 10.1375/twin.7.2.197
   Zhu G, 2008, OPHTHALMOLOGY, V115, P1053, DOI 10.1016/j.ophtha.2007.08.013
   INT SURNAME DATABASE
NR 59
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2009
VL 37
IS 5
BP 434
EP 443
DI 10.1111/j.1442-9071.2009.02058.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 470BV
UT WOS:000267948600003
PM 19624338
DA 2022-11-30
ER

PT J
AU Underwood, PC
   Read, CY
AF Underwood, Patricia C.
   Read, Catherine Y.
TI Genetic association studies in nursing practice and scholarship
SO JOURNAL OF NURSING SCHOLARSHIP
LA English
DT Article
DE genetic association studies; genomics; nursing; genetic markers; risk
   assessment
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   HYPERTENSION; INCREASES; VARIANT; TRAITS; RISK
AB Purpose: To explore the role of genetic association studies in risk assessment for common complex diseases.
   Organizing Framework: An introduction to the types of genetic association studies is followed by a discussion of their potential use in risk assessment for age-related macular degeneration and type 2 diabetes mellitus. The benefits and limitations of this burgeoning technology are explored and related to nursing practice and scholarship.
   Conclusions: Nurses in practice must be prepared to assist clients with decisions about seeking and interpreting results from genetic association studies and nurse researchers must apply current guidelines for conducting robust studies and applying the results of such studies in clinical practice.
   Clinical Relevance: Data collected from genetic association studies will increasingly be used to identify novel prevention and treatment strategies for many complex diseases. An understanding of the principles that underlie this new science is essential for nurses in all areas of clinical practice as they design, test, and implement appropriate intervention and prevention strategies based on genetic association studies.
C1 [Underwood, Patricia C.; Read, Catherine Y.] Boston Coll, Connell Sch Nursing, Chestnut Hill, MA 02467 USA.
C3 Boston College
RP Underwood, PC (通讯作者)，Boston Coll, Connell Sch Nursing, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.
EM underwpa@bc.edu
FU NINR NIH HHS [F31 NR011108, F31 NR011108-01] Funding Source: Medline;
   NATIONAL INSTITUTE OF NURSING RESEARCH [F31NR011108] Funding Source: NIH
   RePORTER
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Christensen K, 2007, NEW ENGL J MED, V356, P1094, DOI 10.1056/NEJMp068126
   Conley YP, 2007, J NURS SCHOLARSHIP, V39, P17, DOI 10.1111/j.1547-5069.2007.00138.x
   Cupples L. A., 2007, BMC MED GENET S1, V8, P1
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   DERENZO E, 2006, WRITING CLIN RES PRO
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dupuis J, 2007, JAMA-J AM MED ASSOC, V297, P529, DOI 10.1001/jama.297.5.529
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frayling TM, 2008, INT J EPIDEMIOL, V37, P133, DOI 10.1093/ije/dym205
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   *GEN TESTS, 2008, GEN TESTS FUND NAT I
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARTL DL, 2004, GENETICS ANAL GENES
   Hattersley AT, 2005, LANCET, V366, P1315, DOI 10.1016/S0140-6736(05)67531-9
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Jenkins J, 2007, J NURS SCHOLARSHIP, V39, P10, DOI 10.1111/j.1547-5069.2007.00137.x
   Khoury MJ, 2007, PLOS MED, V4, P1129, DOI 10.1371/journal.pmed.0040211
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Manolio TA, 2007, NAT GENET, V39, P1045, DOI 10.1038/ng2127
   Marx J, 2006, SCIENCE, V314, P405
   Minino Arialdi M, 2007, Natl Vital Stat Rep, V55, P1
   *NAT I NURS RES, 2008, SUMM GEN I
   Neel J. V, 1976, GENETICS DIABETES ME, P1
   *NIH, 2006, FACT SHEET GEN WID A
   READ CY, 2001, NURSING SPECTRUM, V5, P9
   RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315
   Schaid DJ, 2004, GENET EPIDEMIOL, V27, P348, DOI 10.1002/gepi.20037
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Wang Z, 2001, HUM MUTAT, V17, P263, DOI 10.1002/humu.22
   *WELLC TRUST CAS C, 2007, NATURE, V477, P661
   WILLIAMS GH, 1994, KIDNEY INT, V46, P1550, DOI 10.1038/ki.1994.443
   WILLIAMS GH, 1992, HYPERTENSION, V20, P788, DOI 10.1161/01.HYP.20.6.788
   Williams GH, 1997, CURR OPIN NEPHROL HY, V6, P199, DOI 10.1097/00041552-199703000-00015
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zeggini E, 2007, DIABETOLOGIA, V50, P1, DOI 10.1007/s00125-006-0507-x
NR 36
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6546
EI 1547-5069
J9 J NURS SCHOLARSHIP
JI J. Nurs. Scholarsh.
PY 2008
VL 40
IS 3
BP 212
EP 218
DI 10.1111/j.1547-5069.2008.00228.x
PG 7
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA 341QW
UT WOS:000258730800003
PM 18840203
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bernstein, PS
   Zhao, DY
   Sharifzadeh, M
   Ermakov, IV
   Gellermann, W
AF Bernstein, PS
   Zhao, DY
   Sharifzadeh, M
   Ermakov, IV
   Gellermann, W
TI Resonance Raman measurement of macular carotenoids in the living human
   eye
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Review
DE resonance Raman spectroscopy; lutein; zeaxanthin; carotenoids; macula;
   age-related macular degeneration; imaging
ID PIGMENT; ZEAXANTHIN; LUTEIN; DEGENERATION
AB There is growing evidence that high levels of the macular xanthophyll carotenoids lutein and zeaxanthin may be protective against visual loss from age-related macular degeneration. To study this protective effect further, it is important to measure macular carotenoid levels noninvasively in a wide variety of subjects. We have developed and validated resonance Raman spectroscopy as a sensitive and specific objective method to measure macular carotenoid levels in the living human eye. In this minireview, the principles and implementation of ocular carotenoid resonance Raman spectroscopy are reviewed, and the results of observational cross-sectional studies and of prospective supplementation studies on subjects with and without macular pathology are summarized. We have recently extended this technology to an imaging mode which will further enhance our understanding of the roles of lutein and zeaxanthin in normal macular function and in the prevention of age-related visual loss. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
   Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
EM paul.bernstein@hsc.utah.edu
FU NEI NIH HHS [R29-EY-11600, R42-EY-12324] Funding Source: Medline; OHS
   HRSA HHS [STTR R41-EY-12324] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R42EY012324, R29EY011600] Funding Source: NIH RePORTER
CR [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Celentano JC, 2002, J NUTR, V132, p535S, DOI 10.1093/jn/132.3.535S
   Gellermann W, 2002, OPT LETT, V27, P833, DOI 10.1364/OL.27.000833
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koyama Y., 1995, CAROTENOIDS B, P135
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1999, CRC MOD NUT, P251
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
NR 19
TC 71
Z9 71
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD OCT 15
PY 2004
VL 430
IS 2
BP 163
EP 169
DI 10.1016/j.abb.2004.07.004
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 857GN
UT WOS:000224104500006
PM 15369814
DA 2022-11-30
ER

PT J
AU Ranson, NT
   Danis, RP
   Ciulla, TA
   Pratt, L
AF Ranson, NT
   Danis, RP
   Ciulla, TA
   Pratt, L
TI Intravitreal triamcinolone in subfoveal recurrence of choroidal
   neovascularisation after laser treatment in macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ACETONIDE
AB Background: Laser treatment of extrafoveal well delineated choroidal neovascularisation in exudative age related macular degeneration has a high rate of failure with subsequent severe vision loss from subfoveal involvement. Laser treatment may limit scotoma size, but is unpalatable because of early persistent vision loss. Intravitreal triamacinolone injection may be an acceptable alternative therapy in such disparate cases.
   Methods: 14 consecutive patients with recurrent neovascularisation were treated with a single 4.0 mg injection of triamacinolone and followed for up to I year. Visual results were compared with published data from the Macular Photocoagulation Study of recurrent neovascularisation.
   Results: Mean visual acuity remained stable at about 20/200 throughout the study period in the treated patients. This is comparable to the outcomes in the Macular Photocoagulation Study for laser retreated patients, and better than the observation group.
   Conclusions: Intravitreal triamcinolone may be an acceptable treatment of subfoveal recurrent neovascularisation while avoiding early persistent vision loss from laser retreatment.
C1 Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis
RP Danis, RP (通讯作者)，Indiana Univ, Sch Med, Dept Ophthalmol, 702 Rotary Circle, Indianapolis, IN 46202 USA.
EM rdanis@iupui.edu
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 9
TC 86
Z9 92
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2002
VL 86
IS 5
BP 527
EP 529
DI 10.1136/bjo.86.5.527
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 547BU
UT WOS:000175313400011
PM 11973247
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Alharbi, AM
   Kilani, MA
   Berendschot, TTJM
AF Alharbi, Abdulrahman M.
   Kilani, Mohammed A.
   Berendschot, Tos T. J. M.
TI Overflow phenomenon in serum lutein after supplementation: a systematic
   review supported with SNPs analyses
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE lutein; macular degeneration; carotenoids; xanthophylls; beta-carotene
   dioxygenase; scavenger receptor class B type I
ID BETA-CAROTENE; VITAMIN-A; ZEAXANTHIN; ABSORPTION; GENE; IDENTIFICATION;
   LOCALIZATION; INFLAMMATION; GATEKEEPER; EXPRESSION
AB Lutein, a type of carotenoids, is found to delay the onset and progression of age-related macular degeneration (AMD). Several lutein supplementation studies showed that after an initial increase, lutein serum levels demonstrated a subsequent decrease despite continuous supplementation. In this systematic literature review, this obscure phenomenon was tried to be explained. The subsequent drop in lutein levels was postulated due to down-regulation of lutein receptors scavenger receptor class B type I (SR-BI) in the gastrointestinal tract, upregulation of lutein degrading enzyme beta-carotene dioxygenase (BCDO2), or perhaps a combination of both. Some single nucleotides polymorphisms (SNPs) that could have influence on the occurrence of this phenomenon. To date, an exact scientific explanation for this phenomenon has not been established. Further research is needed to investigate this phenomenon in depth to reach an irrefutable explanation, giving that lutein is proven to be effective in delaying the onset and progression of AMD and its metabolism in the human body becomes of equal importance.
C1 [Alharbi, Abdulrahman M.] King Saud Univ, Coll Med, Dept Pathol & Lab Med, Clin Biochem Unit, Riyadh 11451, Saudi Arabia.
   [Kilani, Mohammed A.] Publ Hlth Author Saudi Arabia, Riyadh 13352, Saudi Arabia.
   [Berendschot, Tos T. J. M.] Maastricht Univ, Univ Eye Clin, Med Ctr, NL-6229 HX Maastricht, Netherlands.
C3 King Saud University; Maastricht University
RP Berendschot, TTJM (通讯作者)，Maastricht Univ, Univ Eye Clin, Med Ctr, NL-6229 HX Maastricht, Netherlands.
EM t.berendschot@maastrichtuniversity.nl
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X
FU DSR Scholarship Support, King Saud University
FX Supported by DSR Scholarship Support, King Saud University.
CR Amengual J, 2011, FASEB J, V25, P948, DOI 10.1096/fj.10-173906
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Berry SD, 2009, GENETICS, V182, P923, DOI 10.1534/genetics.109.101741
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Boron WF, 2012, MED PHYSL, V2e
   Bovier ER, 2013, NUTRIENTS, V5, P750, DOI 10.3390/nu5030750
   Britton G, 2009, CAROTENOIDS, P235
   Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   CURRANCELENTANO J, 1985, AM J CLIN NUTR, V42, P1183, DOI 10.1093/ajcn/42.6.1183
   Deming DM, 1999, PURE APPL CHEM, V71, P2213, DOI 10.1351/pac199971122213
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kotake-Nara E, 2011, MAR DRUGS, V9, P1024, DOI 10.3390/md9061024
   Li BX, 2017, EXP EYE RES, V159, P123, DOI 10.1016/j.exer.2017.02.016
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Lindqvist A, 2005, J HISTOCHEM CYTOCHEM, V53, P1403, DOI 10.1369/jhc.5A6705.2005
   Lo HW, 2008, MOL CANCER RES, V6, P843, DOI 10.1158/1541-7786.MCR-07-2105
   Lobo GP, 2012, DEVELOPMENT, V139, P2966, DOI 10.1242/dev.079632
   Lobo GP, 2010, FASEB J, V24, P1656, DOI 10.1096/fj.09-150995
   Lobo MVT, 2001, J HISTOCHEM CYTOCHEM, V49, P1253, DOI 10.1177/002215540104901007
   Mein JR, 2011, ARCH BIOCHEM BIOPHYS, V506, P109, DOI 10.1016/j.abb.2010.11.005
   Mescher AL, 2013, JUNQUEIRAS BASIC HIS, P147
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sui XW, 2013, ARCH BIOCHEM BIOPHYS, V539, P203, DOI 10.1016/j.abb.2013.06.012
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tian R, 2010, ANIM GENET, V41, P253, DOI 10.1111/j.1365-2052.2009.01990.x
   Tian Y, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/430741
   Tian Y, 2015, ARCH BIOCHEM BIOPHYS, V572, P49, DOI 10.1016/j.abb.2015.01.019
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Tsai TC, 2005, J BIOL CHEM, V280, P20000, DOI 10.1074/jbc.M412169200
   Vage DI, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-10
   Wei LN, 2004, CURR MED CHEM, V11, P1527, DOI 10.2174/0929867043365017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 40
TC 0
Z9 0
U1 1
U2 5
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUL 18
PY 2021
VL 14
IS 7
BP 1114
EP 1119
DI 10.18240/ijo.2021.07.22
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XD0VC
UT WOS:000722428200022
PM 34282399
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Montazeri, L
   El Zarif, N
   Trenholm, S
   Sawan, M
AF Montazeri, Leila
   El Zarif, Nizar
   Trenholm, Stuart
   Sawan, Mohamad
TI Optogenetic Stimulation for Restoring Vision to Patients Suffering From
   Retinal Degenerative Diseases: Current Strategies and Future Directions
SO IEEE TRANSACTIONS ON BIOMEDICAL CIRCUITS AND SYSTEMS
LA English
DT Article
DE Age-related Macular Degeneration (AMD); Optogenetics; Photostimulator;
   Retinal Degeneration; Retinitis Pigmentosa (RP); Retinal Prosthesis;
   Vision Restoration
ID VISUAL RESPONSES; GANGLION-CELLS; LIGHT RESPONSES; BIPOLAR CELLS;
   ECTOPIC EXPRESSION; HIGH-BRIGHTNESS; GENE-THERAPY; HIGH-DENSITY; LED
   ARRAY; RESTORATION
AB Optogenetic strategies for vision restoration involve photosensitizing surviving retinal neurons following retinal degeneration, using emerging optogenetic techniques. This approach opens the door to a minimally-invasive retinal vision restoration approach. Moreover, light stimulation has the potential to offer better spatial and temporal resolution than conventional retinal electrical prosthetics. Although proof-of-concept studies in animal models have demonstrated the possibility of restoring vision using optogenetic techniques, and initial clinical trials are underway, there are still hurdles to pass before such an approach restores naturalistic vision in humans. One limitation is the development of light stimulation devices to activate optogenetic channels in the retina. Here we review recent progress in the design and implementation of optogenetic stimulation devices and outline the corresponding technological challenges. Finally, while most work to date has focused on providing therapy to patients suffering from retinitis pigmentosa, we provide additional insights into strategies for applying optogenetic vision restoration to patients suffering from age-related macular degeneration.
C1 [Montazeri, Leila; El Zarif, Nizar; Sawan, Mohamad] Polytech Montreal, Polystim Neurotech Lab, Dept Elect Engn, Montreal, PQ H3T 1J4, Canada.
   [Trenholm, Stuart] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada.
   [Sawan, Mohamad] Westlake Univ, Sch Engn, Westlake Inst Adv Study, Hangzhou 310024, Peoples R China.
   [Sawan, Mohamad] Inst Adv Study, Hangzhou 310024, Peoples R China.
C3 Universite de Montreal; Polytechnique Montreal; McGill University;
   Westlake University
RP Montazeri, L (通讯作者)，Polytech Montreal, Polystim Neurotech Lab, Dept Elect Engn, Montreal, PQ H3T 1J4, Canada.
EM leila.montazeri-jouibari@polymtl.ca; nizar.el-zarif@polymtl.ca;
   stuart.trenholm@mcgill.ca; mohamad.sawan@polymtl.ca
OI Trenholm, Stuart/0000-0001-5792-0957; El Zarif,
   Nizar/0000-0001-6303-6201
FU Natural Science and Engineering Research Council of Canada; Microsystems
   Strategic Alliance of Quebec; Canada Research Chair in Smart Medical
   Devices; Canada Research Chair (Tier II) in Neuronal Circuits of Vision
FX This work was supported in part by the Natural Science and Engineering
   Research Council of Canada, a Microsystems Strategic Alliance of Quebec,
   and in part by the Canada Research Chair in Smart Medical Devices to MS,
   and a Canada Research Chair (Tier II) in Neuronal Circuits of Vision to
   ST.
CR Adamantidis A, 2015, NAT NEUROSCI, V18, P1202, DOI 10.1038/nn.4106
   Al-Atabany W, 2013, IEEE T BIO-MED ENG, V60, P781, DOI 10.1109/TBME.2011.2177498
   Al-Atabany WI, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-27
   [Anonymous], 2019, PIXIUM VISION HIGHLI
   Asher A, 2007, IEEE T BIO-MED ENG, V54, P993, DOI 10.1109/TBME.2007.894828
   Baden T, 2016, NATURE, V529, P345, DOI 10.1038/nature16468
   Banghart MR, 2009, ANGEW CHEM INT EDIT, V48, P9097, DOI 10.1002/anie.200904504
   Berry MH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09124-x
   Berry MH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01990-7
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Boyden E. S., 2011, F1000 BIOL REP, V3
   Boyden ES, 2015, NAT NEUROSCI, V18, P1200, DOI 10.1038/nn.4094
   Busskamp V, 2012, GENE THER, V19, P169, DOI 10.1038/gt.2011.155
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Butterwick A, 2007, IEEE T BIO-MED ENG, V54, P2261, DOI 10.1109/TBME.2007.908310
   Cavallotti CAP., 2008, AGE RELATED CHANGES, DOI 10.1007/978-1-59745-507-7
   Cehajic-Kapetanovic J, 2015, CURR BIOL, V25, P2111, DOI 10.1016/j.cub.2015.07.029
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   Chaffiol A, 2017, MOL THER, V25, P2546, DOI 10.1016/j.ymthe.2017.07.011
   Chaudet L., 2013, P SPIE BIOM OPT S IN
   Chemi G, 2019, FUTURE MED CHEM, V11, P463, DOI 10.4155/fmc-2018-0315
   Coffey VC, 2018, OPT PHOTONICS NEWS, V29, P24
   COTTER JR, 1984, INVEST OPHTH VIS SCI, V25, P1366
   Cronin T, 2014, EMBO MOL MED, V6, P1175, DOI 10.15252/emmm.201404077
   da Silveira RA, 2011, CURR OPIN NEUROBIOL, V21, P664, DOI 10.1016/j.conb.2011.05.007
   Dacey D, 2004, COGNITIVE NEUROSCIENCES III, THIRD EDITION, P281
   DACEY DM, 1992, P NATL ACAD SCI USA, V89, P9666, DOI 10.1073/pnas.89.20.9666
   DACEY DM, 1993, J NEUROSCI, V13, P5334, DOI 10.1523/JNEUROSCI.13-12-05334.1993
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Daschner R, 2018, SENSOR MATER, V30, P179, DOI 10.18494/SAM.2018.1726
   Day J, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3615679
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   De Silva SR, 2017, P NATL ACAD SCI USA, V114, P11211, DOI 10.1073/pnas.1701589114
   Degenaar P, 2009, PROC SPIE, V7180, DOI 10.1117/12.823577
   Degenaar P, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/3/035007
   Deisseroth K, 2011, NAT METHODS, V8, P26, DOI 10.1038/NMETH.F.324
   Demb JB, 2012, VISUAL NEUROSCI, V29, P51, DOI 10.1017/S0952523811000368
   Ding K, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9061206
   Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69
   DOWLING JE, 1970, INVEST OPHTH VISUAL, V9, P655
   Fahim AT., 2017, NONSYNDROMIC RETINIT
   Fan B, 2015, LAB CHIP, V15, P3838, DOI 10.1039/c5lc00588d
   Finn AP, 2018, CLIN OPHTHALMOL, V12, P1089, DOI 10.2147/OPTH.S137525
   Franke K, 2017, NATURE, V542, P439, DOI 10.1038/nature21394
   Fujikado T, 2011, INVEST OPHTH VIS SCI, V52, P4726, DOI 10.1167/iovs.10-6836
   Gaub BM, 2015, MOL THER, V23, P1562, DOI 10.1038/mt.2015.121
   Gaub BM, 2014, P NATL ACAD SCI USA, V111, pE5574, DOI 10.1073/pnas.1414162111
   Goetz GA, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/5/056021
   Gollisch T, 2010, NEURON, V65, P150, DOI 10.1016/j.neuron.2009.12.009
   Goodman J, 2008, INTRO FOURIER OPTICS
   Grifantini K, 2017, IEEE PULSE, V8, P35, DOI 10.1109/MPUL.2017.2678738
   Grossman N, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/1/016004
   Gunaydin LA, 2010, NAT NEUROSCI, V13, P387, DOI 10.1038/nn.2495
   Herrnsdorf J, 2015, IEEE T ELECTRON DEV, V62, P1918, DOI 10.1109/TED.2015.2416915
   Herzog M. H., 2016, PLOS BIOL, V14
   Hornbeck LJ, 1997, P SOC PHOTO-OPT INS, V3013, P27, DOI 10.1117/12.273880
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Ivanova E, 2010, INVEST OPHTH VIS SCI, V51, P5288, DOI 10.1167/iovs.10-5389
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Juettner J., 2018, BIORXIV
   Jung JH, 2015, VISION RES, V111, P182, DOI 10.1016/j.visres.2014.10.023
   Khabou H, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96029
   Klapoetke NC, 2014, NAT METHODS, V11, P338, DOI [10.1038/NMETH.2836, 10.1038/nmeth.2836]
   Klapper SD, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00074
   Kleinlogel S, 2011, NAT NEUROSCI, V14, P513, DOI 10.1038/nn.2776
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Leigh RJ, 2015, NEUROLOGY EYE MOVEME
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Lin JY, 2013, NAT NEUROSCI, V16, P1499, DOI 10.1038/nn.3502
   Lin JY, 2009, BIOPHYS J, V96, P1803, DOI 10.1016/j.bpj.2008.11.034
   Lin TC, 2018, TECHNOL INNOV, V19, P605, DOI 10.21300/19.3.2018.605
   Liu ZJ, 2013, J DISP TECHNOL, V9, P678, DOI 10.1109/JDT.2013.2256107
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Luo JW, 2017, IEEE T BIOMED CIRC S, V11, P15, DOI 10.1109/TBCAS.2016.2571339
   Lutz C, 2008, NAT METHODS, V5, P821, DOI [10.1038/nmeth.1241, 10.1038/NMETH.1241]
   Mace E, 2015, MOL THER, V23, P7, DOI 10.1038/mt.2014.154
   Maffioletti SM, 2017, HUM GENE THER, V28, pA2
   Mandel Y., 2015, P SPIE OPT C INT SOC
   Mandel Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2980
   Marc R, 2014, ACS CHEM NEUROSCI, V5, P895, DOI 10.1021/cn5001233
   Mardinly AR, 2018, NAT NEUROSCI, V21, P881, DOI 10.1038/s41593-018-0139-8
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Martersteck EM, 2017, CELL REP, V18, P2058, DOI 10.1016/j.celrep.2017.01.075
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   McGovern B, 2010, IEEE T BIOMED CIRC S, V4, P469, DOI 10.1109/TBCAS.2010.2081988
   Menzel-Severing J, 2012, EYE, V26, P502, DOI 10.1038/eye.2012.35
   Morton A, 2019, ADV BIOSYST, V3, DOI 10.1002/adbi.201800290
   Morton A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31117
   Mourot A, 2011, ACS CHEM NEUROSCI, V2, P536, DOI 10.1021/cn200037p
   Nirenberg S, 2012, P NATL ACAD SCI USA, V109, P15012, DOI 10.1073/pnas.1207035109
   Onural L, 2011, P IEEE, V99, P576, DOI 10.1109/JPROC.2010.2098430
   Packer AM, 2012, NAT METHODS, V9, P1202, DOI [10.1038/nmeth.2249, 10.1038/NMETH.2249]
   Palanker D. V., 2019, OPHTHALMIC TECHNOLOG
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Pan ZH, 2015, ANNU REV VIS SCI, V1, P185, DOI 10.1146/annurev-vision-082114-035532
   Papagiakoumou E, 2010, NAT METHODS, V7, P848, DOI [10.1038/nmeth.1505, 10.1038/NMETH.1505]
   Papagiakoumou E, 2008, OPT EXPRESS, V16, P22039, DOI 10.1364/OE.16.022039
   Pegard NC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01031-3
   Poher V, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/9/094014
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Provis JM, 1998, PROG NEUROBIOL, V54, P549, DOI 10.1016/S0301-0082(97)00079-8
   Reutsky-Gefen I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2500
   Roska B, 2018, NATURE, V557, P359, DOI 10.1038/s41586-018-0076-4
   Roska B, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.7.4
   Sabatier Q., 2018, BIORXIV
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Sengupta A, 2016, EMBO MOL MED, V8, P1248, DOI 10.15252/emmm.201505699
   SILVEIRA LCL, 1991, NEUROSCIENCE, V40, P217, DOI 10.1016/0306-4522(91)90186-R
   Simunovic MP, 2019, EXP EYE RES, V178, P15, DOI 10.1016/j.exer.2018.09.003
   Slinger C, 2005, COMPUTER, V38, P46, DOI 10.1109/MC.2005.260
   Soltan A, 2016, BIOMED CIRC SYST C, P568
   Soltan A, 2017, IEEE T BIOMED CIRC S, V11, P347, DOI 10.1109/TBCAS.2016.2623949
   Soltani A, 2020, COMPUT METHOD BIOMEC, V23, P103, DOI 10.1080/10255842.2019.1703133
   Sotan A., 2018, J NEURAL ENG, V15
   Steude A, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600061
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Theogarajan L, 2012, NEUROSCI LETT, V519, P129, DOI 10.1016/j.neulet.2012.02.001
   Thyagarajan S, 2010, J NEUROSCI, V30, P8745, DOI 10.1523/JNEUROSCI.4417-09.2010
   Tokuda T., 2018, P IEEE INT S CIRC SY, P1
   Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006
   Touchard E, 2012, GENE THER, V19, P886, DOI 10.1038/gt.2011.154
   Toychiev AH, 2013, J NEUROSCI, V33, P13972, DOI 10.1523/JNEUROSCI.2399-13.2013
   Velikay-Parel M, 2009, ACTA OPHTHALMOL, V87, pS244
   Wan CF, 2015, MOL MED REP, V12, P4803, DOI 10.3892/mmr.2015.4054
   Wang ST, 2017, SCI REP-UK, V7, DOI 10.1038/srep39955
   Werblin FS, 2010, VISUAL NEUROSCI, V27, P1, DOI 10.1017/S0952523810000076
   Williams JC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3003100
   Wong IYH, 2011, GRAEF ARCH CLIN EXP, V249, P1439, DOI 10.1007/s00417-011-1764-z
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woods Andrew, 2009, Information Display, V25, P8
   Yang SG, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046002
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
   Yue L, 2016, PROG RETIN EYE RES, V53, P21, DOI 10.1016/j.preteyeres.2016.05.002
   Zahid M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009431
   Zalevsky Z, 1997, APPL OPTICS, V36, P1027, DOI 10.1364/AO.36.001027
   Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936
   Zhang Y, 2009, J NEUROSCI, V29, P9186, DOI 10.1523/JNEUROSCI.0184-09.2009
   Zhou DC, 2013, ADV INTEL SYS RES, V44, P1
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 146
TC 4
Z9 6
U1 3
U2 13
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1932-4545
EI 1940-9990
J9 IEEE T BIOMED CIRC S
JI IEEE Trans. Biomed. Circuits Syst.
PD DEC
PY 2019
VL 13
IS 6
BP 1792
EP 1807
DI 10.1109/TBCAS.2019.2951298
PG 16
WC Engineering, Biomedical; Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA KC6YT
UT WOS:000507321400063
PM 31689206
DA 2022-11-30
ER

PT J
AU Meyer, JG
   Garcia, TY
   Schilling, B
   Gibson, BW
   Lamba, DA
AF Meyer, Jesse G.
   Garcia, Thelma Y.
   Schilling, Birgit
   Gibson, Bradford W.
   Lamba, Deepak A.
TI Proteome and Secretome Dynamics of Human Retinal Pigment Epithelium in
   Response to Reactive Oxygen Species
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DATA-INDEPENDENT ACQUISITION; OXIDATIVE STRESS; APOLIPOPROTEIN-E;
   TGF-BETA; MITOCHONDRIAL SUPEROXIDE; MACULAR DEGENERATION;
   BINDING-PROTEIN; CULTURE MODEL; COMPLEMENT; CELLS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries, and is characterized by slow retinal degeneration linked to chronic reactive oxygen species (ROS) in the retinal pigmented epithelium (RPE). The molecular mechanisms leading to RPE dysfunction in response to ROS are unclear. Here, human stem cell-derived RPE samples were stressed with ROS for 1 or 3 weeks, and both intracellular and secreted proteomes were quantified by mass spectrometry. ROS increased glycolytic proteins but decreased mitochondrial complex I subunits, as well as membrane proteins required for endocytosis. RPE secreted over 1,000 proteins, many of which changed significantly due to ROS. Notably, secreted APOE is decreased 4-fold, and urotensin-II, the strongest known vasoconstrictor, doubled. Furthermore, secreted TGF-beta is increased, and its cognate signaler BMP1 decreased in the secretome. Together, our results paint a detailed molecular picture of the retinal stress response in space and time.
C1 [Meyer, Jesse G.; Garcia, Thelma Y.; Schilling, Birgit; Gibson, Bradford W.; Lamba, Deepak A.] Buck Inst Res Aging, Novato, CA 94945 USA.
   [Meyer, Jesse G.] Univ Wisconsin, Dept Chem, Dept Biomol Chem, Natl Ctr Quantitat Biol Complex Syst, Madison, WI 53706 USA.
   [Gibson, Bradford W.] Amgen Inc, Discovery Attribute Sci, Res, San Francisco, CA 94080 USA.
   [Lamba, Deepak A.] Univ Calif San Francisco, Dept Ophthalmol, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
C3 Buck Institute for Research on Aging; University of Wisconsin System;
   University of Wisconsin Madison; Amgen; University of California System;
   University of California San Francisco
RP Meyer, JG; Lamba, DA (通讯作者)，Buck Inst Res Aging, Novato, CA 94945 USA.; Meyer, JG (通讯作者)，Univ Wisconsin, Dept Chem, Dept Biomol Chem, Natl Ctr Quantitat Biol Complex Syst, Madison, WI 53706 USA.; Lamba, DA (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
EM jessegmeyer@gmail.com; Deepak.Lamba@ucsf.edu
RI Meyer, Jesse/AAC-7591-2019
OI Meyer, Jesse/0000-0003-2753-3926; Schilling, Birgit/0000-0001-9907-2749
FU NIH [1 S10 OD016281, T32 AG000266, EY025779]; Research to Prevent
   Blindness; National Institutes of Health [EY02162]; NATIONAL EYE
   INSTITUTE [P30EY002162, R01EY025779] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [T32AG000266] Funding Source: NIH RePORTER
FX J.G.M. was supported by an NIH training grant (T32 AG000266). Work in
   Dr. Lamba's lab is supported by NIH grant EY025779. The authors
   acknowledge support from the NIH shared instrumentation grant for the
   TripleTOF system at the Buck Institute (1 S10 OD016281). Additional
   support was provided by a core grant from the National Institutes of
   Health (EY02162) and by Research to Prevent Blindness unrestricted
   grants to the UCSF Department of Ophthalmology (to DAL).
CR Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Auer-Grumbach M, 2011, BRAIN, V134, P1839, DOI 10.1093/brain/awr076
   Berry DC, 2012, MOL CELL BIOL, V32, P3164, DOI 10.1128/MCB.00505-12
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Blanco-Ayala T, 2014, FREE RADICAL RES, V48, P623, DOI 10.3109/10715762.2014.899694
   Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514
   BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   Bruderer R, 2015, MOL CELL PROTEOMICS, V14, P1400, DOI 10.1074/mcp.M114.044305
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chen YJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17632
   Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200
   Collins BC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00249-5
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Gil-Yarom N, 2017, P NATL ACAD SCI USA, V114, P562, DOI 10.1073/pnas.1612195114
   Gillet LC, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.016717
   Gong DP, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-31
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Guaiquil V, 2009, MOL CELL BIOL, V29, P2694, DOI 10.1128/MCB.01460-08
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kelstrup CD, 2018, J PROTEOME RES, V17, P727, DOI 10.1021/acs.jproteome.7b00602
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2011, INVEST OPHTH VIS SCI, V52, P4897, DOI 10.1167/iovs.10-6504
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Levin E, 2017, SCIENCE, V355, P733, DOI 10.1126/science.aah4634
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maminishkis Arvydas, 2010, J Vis Exp, DOI 10.3791/2032
   Matsumoto E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212369
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Mello E, 2012, CLIN CHEM LAB MED, V50, P1031, DOI 10.1515/cclm-2011-0859
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Meyer JG, 2017, EXPERT REV PROTEOMIC, V14, P419, DOI 10.1080/14789450.2017.1322904
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Nakayasu E.S., 2016, MSYSTEMS, V1
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   NIELSEN H, 1993, SCAND J IMMUNOL, V37, P39, DOI 10.1111/j.1365-3083.1993.tb01662.x
   Nogami S, 2003, GENES CELLS, V8, P17, DOI 10.1046/j.1365-2443.2003.00612.x
   R Core Team, 2022, R LANG ENV STAT COMP
   Rabin DM, 2013, AGING-US, V5, P51
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   Rosenberger G, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.31
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Schreiber R, 2010, J BIOL CHEM, V285, P7838, DOI 10.1074/jbc.M109.065367
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Singla DK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147897
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Talati M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094119
   Tezel TH, 1998, EXP EYE RES, V66, P807, DOI 10.1006/exer.1998.0492
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Ueki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038690
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153
   Zhang Y, 2015, J PROTEOME RES, V14, P4359, DOI 10.1021/acs.jproteome.5b00543
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 77
TC 12
Z9 12
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 28
PY 2019
VL 9
AR 15440
DI 10.1038/s41598-019-51777-7
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JH5TT
UT WOS:000492832300025
PM 31659173
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, X
   Zhao, L
   Zhang, YK
   Ma, WX
   Gonzalez, SR
   Fan, JG
   Kretschmer, F
   Badea, TC
   Qian, HH
   Wong, WT
AF Wang, Xu
   Zhao, Lian
   Zhang, Yikui
   Ma, Wenxin
   Gonzalez, Shaimar R.
   Fan, Jianguo
   Kretschmer, Friedrich
   Badea, Tudor C.
   Qian, Hao-Hua
   Wong, Wai T.
TI Tamoxifen Provides Structural and Functional Rescue in Murine Models of
   Photoreceptor Degeneration
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE degeneration; microglia; neuroprotection; photoreceptor; retinitis
   pigmentosa; tamoxifen
ID ESTROGEN-RECEPTOR MODULATORS; RETINAL MICROGLIAL ACTIVATION; CHRONIC
   INFLAMMATORY REACTION; OPTICAL COHERENCE TOMOGRAPHY; HUMAN
   RETINITIS-PIGMENTOSA; FOCAL CEREBRAL-ISCHEMIA; LOW-DOSE TAMOXIFEN;
   OCULAR TOXICITY; CELL-DEATH; MOUSE MODEL
AB Photoreceptor degeneration is a cause of irreversible vision loss in incurable blinding retinal diseases including retinitis pigmentosa (RP) and atrophic age-related macular degeneration. We found in two separate mouse models of photoreceptor degeneration that tamoxifen, a selective estrogen receptor modulator and a drug previously linked with retinal toxicity, paradoxically provided potent neuroprotective effects. In a light-induced degeneration model, tamoxifen prevented onset of photoreceptor apoptosis and atrophy and maintained near-normal levels of electroretinographic responses. Rescue effects were correlated with decreased microglial activation and inflammatory cytokine production in the retina in vivo and a reduction of microglia-mediated toxicity to photoreceptors in vitro, indicating a microglia-mediated mechanism of rescue. Tamoxifen also rescued degeneration in a genetic (Pde6b(rd10)) model of RP, significantly improving retinal structure, electrophysiological responses, and visual behavior. These prominent neuroprotective effects warrant the consideration of tamoxifen as a drug suitable for being repurposed to treat photoreceptor degenerative disease.
C1 [Wang, Xu; Zhao, Lian; Zhang, Yikui; Ma, Wenxin; Gonzalez, Shaimar R.; Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bldg 6,Room 217, Bethesda, MD 20892 USA.
   [Fan, Jianguo] NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA.
   [Kretschmer, Friedrich; Badea, Tudor C.] NEI, Retinal Circuit Dev & Genet Unit, NIH, Bethesda, MD 20892 USA.
   [Qian, Hao-Hua] NEI, Visual Funct Core, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bldg 6,Room 217, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Badea, Tudor Constantin/B-1654-2018; Wong, Wai/B-6118-2017
OI Badea, Tudor Constantin/0000-0003-3086-6713; Wong,
   Wai/0000-0003-0681-4016
FU National Eye Institute Intramural Research Program-National Institutes
   of Health; NATIONAL EYE INSTITUTE [ZIAEY000530, ZIAEY000433,
   ZICEY000503, ZIAEY000541, ZIAEY000504] Funding Source: NIH RePORTER
FX This work was supported by funds from the National Eye Institute
   Intramural Research Program-National Institutes of Health.
CR Abdelhamid R, 2011, ACS CHEM NEUROSCI, V2, P256, DOI 10.1021/cn100106a
   Amantea D, 2016, CURR OPIN PHARMACOL, V26, P124, DOI 10.1016/j.coph.2015.11.006
   Arevalo MA, 2012, J NEUROENDOCRINOL, V24, P183, DOI 10.1111/j.1365-2826.2011.02156.x
   Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132
   Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8
   Blasko E, 2009, J NEUROIMMUNOL, V214, P67, DOI 10.1016/j.jneuroim.2009.06.023
   Boneva SK, 2016, NEUROSCIENCE, V325, P188, DOI 10.1016/j.neuroscience.2016.03.050
   Bourla DH, 2007, AM J OPHTHALMOL, V144, P126, DOI 10.1016/j.ajo.2007.03.023
   Cascio C, 2007, EXP EYE RES, V85, P166, DOI 10.1016/j.exer.2007.02.008
   Cascio C, 2015, STEROIDS, V103, P31, DOI 10.1016/j.steroids.2015.08.002
   Chakrabarti M, 2014, BRAIN RES BULL, V109, P22, DOI 10.1016/j.brainresbull.2014.09.004
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   Cho KS, 2012, INVEST OPHTH VIS SCI, V53, P5344, DOI 10.1167/iovs.12-9827
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398
   Cukras CA, 2012, INVEST OPHTH VIS SCI, V53, P3865, DOI 10.1167/iovs.11-9413
   de la Torre Valdovinos B., 2016, J VET MED, V2016
   Denk F, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0255-6
   Elzer JG, 2010, J CEREBR BLOOD F MET, V30, P935, DOI 10.1038/jcbfm.2009.258
   Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124
   Fitts JM, 2011, J PHARMACOL EXP THER, V338, P246, DOI 10.1124/jpet.110.173955
   Rodriguez NEF, 2013, BRAIN RES BULL, V98, P64, DOI 10.1016/j.brainresbull.2013.07.007
   Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531
   Gorin MB, 1998, AM J OPHTHALMOL, V125, P493, DOI 10.1016/S0002-9394(99)80190-1
   Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200
   Gualino V, 2005, AM J OPHTHALMOL, V140, P757, DOI 10.1016/j.ajo.2005.04.042
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   IMPERIA PS, 1989, SURV OPHTHALMOL, V34, P209, DOI 10.1016/0039-6257(89)90105-7
   Ishihara Y, 2015, J STEROID BIOCHEM, V145, P85, DOI 10.1016/j.jsbmb.2014.10.002
   Ismailoglu O, 2010, J CLIN NEUROSCI, V17, P1306, DOI 10.1016/j.jocn.2010.01.049
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   KAISERKUPFER MI, 1978, CANCER TREAT REP, V62, P315
   Khan MM, 2015, J STEROID BIOCHEM, V146, P38, DOI 10.1016/j.jsbmb.2014.05.001
   Kim LA, 2014, INVEST OPHTH VIS SCI, V55, P4747, DOI 10.1167/iovs.13-13662
   Kretschmer F, 2015, J NEUROSCI METH, V256, P91, DOI 10.1016/j.jneumeth.2015.08.007
   Kretschmer F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078058
   Li Y, 2015, HUM MOL GENET, V24, P4417, DOI 10.1093/hmg/ddv178
   Liu JL, 2010, BRAIN RES, V1316, P101, DOI 10.1016/j.brainres.2009.12.055
   Lonard DM, 2002, STEROIDS, V67, P15, DOI 10.1016/S0039-128X(01)00133-7
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   McDonnell DP, 2002, RECENT PROG HORM RES, V57, P295, DOI 10.1210/rp.57.1.295
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   Mendez-Luna D, 2015, J BIOMOL STRUCT DYN, V33, P2161, DOI 10.1080/07391102.2014.994102
   Nayfield SG, 1996, J CLIN ONCOL, V14, P1018, DOI 10.1200/JCO.1996.14.3.1018
   Ni YQ, 2008, INVEST OPHTH VIS SCI, V49, P2589, DOI 10.1167/iovs.07-1173
   Noureddin BN, 1999, EYE, V13, P729, DOI 10.1038/eye.1999.217
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Onishi A, 2010, P NATL ACAD SCI USA, V107, P11579, DOI 10.1073/pnas.1000102107
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   PAVLIDIS NA, 1992, CANCER, V69, P2961, DOI 10.1002/1097-0142(19920615)69:12&lt;2961::AID-CNCR2820691215&gt;3.0.CO;2-W
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Pennesi ME, 2012, INVEST OPHTH VIS SCI, V53, P4644, DOI 10.1167/iovs.12-9611
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Roque RS, 1996, INVEST OPHTH VIS SCI, V37, P196
   Russo R, 2016, EUR J PHARMACOL, V787, P134, DOI 10.1016/j.ejphar.2016.03.064
   Salomao SR, 2007, CURR EYE RES, V32, P345, DOI 10.1080/02713680701229638
   Schaufelberger SA, 2016, AM J PHYSIOL-ENDOC M, V310, pE313, DOI 10.1152/ajpendo.00418.2015
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4
   Watanabe SES, 2010, DOC OPHTHALMOL, V120, P137, DOI 10.1007/s10633-009-9203-8
   Suuronen T, 2005, INFLAMM RES, V54, P194, DOI 10.1007/s00011-005-1343-z
   Tapia-Gonzalez S, 2008, J ENDOCRINOL, V198, P219, DOI 10.1677/JOE-07-0294
   Toler SM, 2004, EXP BIOL MED, V229, P607, DOI 10.1177/153537020422900704
   Tremblay GB, 2001, ENDOCRINOLOGY, V142, P4572, DOI 10.1210/en.142.10.4572
   Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401
   Tsai CL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072999
   Villa A, 2016, ENDOCR REV, V37, P372, DOI 10.1210/er.2016-1007
   Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280
   Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wert KJ, 2014, DEV OPHTHALMOL, V53, P33, DOI 10.1159/000357294
   Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001
   Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yu Y, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0368-7
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344
   Zhang HQ, 2009, BRAIN RES, V1247, P196, DOI 10.1016/j.brainres.2008.10.015
   Zhang YH, 2007, EXP NEUROL, V204, P819, DOI 10.1016/j.expneurol.2007.01.015
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
NR 82
TC 33
Z9 35
U1 5
U2 21
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAR 22
PY 2017
VL 37
IS 12
BP 3294
EP 3310
DI 10.1523/JNEUROSCI.2717-16.2017
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EQ1HA
UT WOS:000397819300017
PM 28235894
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Mimouni, K
   Mimouni, M
   Eldar, I
   Axer-Siegel, R
   Kramer, M
   Shani, L
   Weinberger, D
AF Mimouni, Karin
   Mimouni, Michael
   Eldar, Ido
   Axer-Siegel, Ruth
   Kramer, Michal
   Shani, Ludmila
   Weinberger, Dov
TI Photodynamic Therapy for Pseudophakic Eyes Compared to Eyes With
   Cataract
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; VERTEPORFIN; RANIBIZUMAB; OUTCOMES; DISEASE
AB BACKGROUND AND OBJECTIVE: Verteporfin photodynamic therapy (vPDT) plays a role in the treatment of chorioretinal conditions. The purpose of this study was to compare vPDT outcomes between cataractous and pseudophakic eyes.
   PATIENTS AND METHODS: In this prospective study of consecutive patients with choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD) treated with vPDT, cataract and pseudophakic eyes were compared for number and timing of vPDT treatments, duration of follow-up, angiographic features, and changes in best-corrected visual acuity (BCVA).
   RESULTS: Overall, 103 eyes (n = 95) were included in the final analysis; 44 eyes in the cataract group and 59 eyes in the pseudophakic group. No significant difference in change in BCVA (P = .19) or leakage- free CNV lesions (P = .58) was found between the groups.
   CONCLUSIONS: In this study of vPDT for nAMD, there was no significant difference between eyes with cataract and pseudophakic eyes. It seems that cataract does not clinically alter the effect of vPDT.
C1 [Mimouni, Karin] Rabin Med Ctr, Dept Ophthalmol, Hasharon Campus, IL-4941492 Petah Tiqwa, Israel.
   [Mimouni, Michael] Rambam Hlth Care Campus, Dept Ophthalmol, Haifa, Israel.
   [Mimouni, Karin; Axer-Siegel, Ruth; Kramer, Michal; Weinberger, Dov] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Axer-Siegel, Ruth; Kramer, Michal; Weinberger, Dov] Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, Petah Tiqwa, Israel.
   [Eldar, Ido; Shani, Ludmila] Rabin Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
C3 Rabin Medical Center; Rambam Health Care Campus; Tel Aviv University;
   Sackler Faculty of Medicine; Rabin Medical Center; Rabin Medical Center
RP Mimouni, K (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Hasharon Campus, IL-4941492 Petah Tiqwa, Israel.
EM karinm@clalit.org.il
RI Mimouni, Michael/S-2916-2018
OI Mimouni, Michael/0000-0002-4661-0993
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BERNINI U, 1990, J PHOTOCH PHOTOBIO B, V4, P407, DOI 10.1016/1011-1344(90)85019-S
   Bielski A, 1991, Lens Eye Toxic Res, V8, P101
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boixadera A, 2009, OPHTHALMOLOGY, V116, P100, DOI 10.1016/j.ophtha.2008.08.029
   Braccio L, 1998, CURR EYE RES, V17, P53, DOI 10.1076/ceyr.17.1.53.5259
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Erikitola OC, 2014, EYE, V28, P944, DOI 10.1038/eye.2014.134
   Fujita K, 2015, OPHTHALMOLOGY, V122, P555, DOI 10.1016/j.ophtha.2014.09.034
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Moreau KL, 2012, TRENDS MOL MED, V18, P273, DOI 10.1016/j.molmed.2012.03.005
   NISHIMOTO K, 1995, OPHTHALMIC RES, V27, P1, DOI 10.1159/000267560
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Silva RM, 2013, RETINA-J RET VIT DIS, V33, P309, DOI 10.1097/IAE.0b013e3182670fbe
   Smretschnig E, 2013, RETINA-J RET VIT DIS, V33, P316, DOI 10.1097/IAE.0b013e318280769c
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
NR 24
TC 1
Z9 1
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD DEC
PY 2016
VL 47
IS 12
BP 1132
EP 1136
DI 10.3928/23258160-20161130-07
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3ID
UT WOS:000393104900007
PM 27977836
DA 2022-11-30
ER

PT J
AU Nagaraj, RH
   Linetsky, M
   Stitt, AW
AF Nagaraj, Ram H.
   Linetsky, Mikhail
   Stitt, Alan W.
TI The pathogenic role of Maillard reaction in the aging eye
SO AMINO ACIDS
LA English
DT Review
DE Lens; Retina; Aging; Diabetes; Cataract; Diabetic retinopathy;
   Age-related macular degeneration
ID GLYCATION END-PRODUCTS; ASCORBIC-ACID GLYCATION; PROTEIN CROSS-LINKS;
   RETINAL-PIGMENT EPITHELIUM; HUMAN EXTRACELLULAR-MATRIX;
   ALPHA-B-CRYSTALLIN; CALF LENS PROTEINS; CHAPERONE FUNCTION;
   GLYOXALASE-I; CHEMICAL-MODIFICATION
AB The proteins of the human eye are highly susceptible to the formation of advanced glycation end products (AGEs) from the reaction of sugars and carbonyl compounds. AGEs progressively accumulate in the aging lens and retina and accumulate at a higher rate in diseases that adversely affect vision such as, cataract, diabetic retinopathy and age-related macular degeneration. In the lens AGEs induce irreversible changes in structural proteins, which lead to lens protein aggregation and formation of high-molecular-weight aggregates that scatter light and impede vision. In the retina AGEs modify intra- and extracellular proteins that lead to an increase in oxidative stress and formation of pro-inflammatory cytokines, which promote vascular dysfunction. This review outlines recent advances in AGE research focusing on the mechanisms of their formation and their role in cataract and pathologies of the retina. The therapeutic action and pharmacological strategies of anti-AGE agents that can inhibit or prevent AGE formation in the eye are also discussed.
C1 [Nagaraj, Ram H.; Linetsky, Mikhail] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Stitt, Alan W.] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast BT7 1NN, Antrim, North Ireland.
C3 Case Western Reserve University; Queens University Belfast
RP Nagaraj, RH (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
EM ram.nagaraj@case.edu
RI Stitt, Alan/A-9842-2009
OI Stitt, Alan/0000-0002-8647-9918
FU National Institutes of Health; Ohio Lions Eye Research Foundation;
   Action Medical Research; Juvenile Diabetes Research Foundation (New
   York); Fight for Sight (UK); Medical Research Council; Research to
   Prevent Blindness, New York; MRC [G0600053] Funding Source: UKRI;
   Medical Research Council [G0600053] Funding Source: researchfish; Fight
   for Sight [1871/72] Funding Source: researchfish
FX Studies in Dr. Nagaraj's laboratory were supported by grants from the
   National Institutes of Health, Research to Prevent Blindness, New York,
   and Ohio Lions Eye Research Foundation. Dr. Stitt's laboratory was
   supported by Action Medical Research, Juvenile Diabetes Research
   Foundation (New York), Fight for Sight (UK) and the Medical Research
   Council.
CR Agardh E, 2000, CURR EYE RES, V21, P543, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT543
   Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565
   AHMED MU, 1986, J BIOL CHEM, V261, P4889
   Ahmed N, 2003, INVEST OPHTH VIS SCI, V44, P5287, DOI 10.1167/iovs.03-0573
   ALBON J, 1995, BRIT J OPHTHALMOL, V79, P368, DOI 10.1136/bjo.79.4.368
   Albon J, 2000, BRIT J OPHTHALMOL, V84, P318, DOI 10.1136/bjo.84.3.318
   Amano S, 2001, BRIT J OPHTHALMOL, V85, P52, DOI 10.1136/bjo.85.1.52
   Argirov OK, 2005, ANN NY ACAD SCI, V1043, P166, DOI 10.1196/annals.1333.021
   Argirov OK, 2004, J BIOL CHEM, V279, P6487, DOI 10.1074/jbc.M309090200
   Argirova MD, 2002, FREE RADICAL RES, V36, P1251, DOI 10.1080/1071576021000016481
   Basta G, 2004, CARDIOVASC RES, V63, P582, DOI 10.1016/j.cardiores.2004.05.001
   BAZAN NG, 1982, VISION RES, V22, P1539, DOI 10.1016/0042-6989(82)90221-8
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhattacharyya J, 2007, BIOCHEMISTRY-US, V46, P14682, DOI 10.1021/bi701326b
   Bhatwadekar A, 2007, EXPERT REV OPHTHALMO, V2, P105, DOI 10.1586/17469899.2.1.105
   Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Biswas A, 2006, BIOCHEMISTRY-US, V45, P4569, DOI 10.1021/bi052574s
   Biswas A, 2008, J BIOCHEM, V144, P21, DOI 10.1093/jb/mvn037
   Biswas A, 2008, BIOCHEM J, V409, P771, DOI 10.1042/BJ20071006
   BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259
   Bolton WK, 2004, AM J NEPHROL, V24, P32, DOI 10.1159/000075627
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475
   Brown TR, 2003, BIOCHEM SOC T, V31, P1433
   Calfee CS, 2007, J HEART LUNG TRANSPL, V26, P675, DOI 10.1016/j.healun.2007.04.002
   Catala A, 2006, INT J BIOCHEM CELL B, V38, P1482, DOI 10.1016/j.biocel.2006.02.010
   CEFALU WT, 1995, J GERONTOL A-BIOL, V50, pB337, DOI 10.1093/gerona/50A.6.B337
   Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291
   Cheng RZ, 2006, BBA-MOL BASIS DIS, V1762, P533, DOI 10.1016/j.bbadis.2006.01.009
   Cheng RZ, 2005, ANN NY ACAD SCI, V1043, P184, DOI 10.1196/annals.1333.023
   Cheng RZ, 2004, J BIOL CHEM, V279, P45441, DOI 10.1074/jbc.M405664200
   Cheng RZ, 2001, BBA-MOL BASIS DIS, V1537, P14, DOI 10.1016/S0925-4439(01)00051-5
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Cooper ME, 2004, AM J HYPERTENS, V17, p31S, DOI 10.1016/j.amjhyper.2004.08.021
   Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139
   DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0
   Derham BK, 1997, BIOCHEM J, V328, P763
   Devamanoharan PS, 1997, MOL CELL BIOCHEM, V177, P245, DOI 10.1023/A:1006863322454
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fan XJ, 2008, INVEST OPHTH VIS SCI, V49, P4945, DOI 10.1167/iovs.08-1813
   Fan XJ, 2006, P NATL ACAD SCI USA, V103, P16912, DOI 10.1073/pnas.0605101103
   Fan XJ, 2009, J BIOL CHEM, V284, P34618, DOI 10.1074/jbc.M109.032094
   Franke S, 2003, J CATARACT REFR SURG, V29, P998, DOI 10.1016/S0886-3350(02)01841-2
   Frye EB, 1998, J BIOL CHEM, V273, P18714, DOI 10.1074/jbc.273.30.18714
   Ganea E, 2006, CURR EYE RES, V31, P1, DOI 10.1080/02713680500477347
   Gangadhariah MH, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/274317
   Gangadhariah MH, 2010, BBA-MOL BASIS DIS, V1802, P432, DOI 10.1016/j.bbadis.2010.01.010
   Gardner TA, 2003, J PATHOL, V201, P328, DOI 10.1002/path.1429
   GARLICK RL, 1984, J CLIN INVEST, V74, P1742, DOI 10.1172/JCI111592
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   HAIK GM, 1994, EXP EYE RES, V59, P497, DOI 10.1006/exer.1994.1135
   HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harding J., 1991, CATARACT BIOCH EPIDE
   HARDING JJ, 1992, DRUG AGING, V2, P287, DOI 10.2165/00002512-199202040-00003
   Hartog JWL, 2007, EUR J HEART FAIL, V9, P1146, DOI 10.1016/j.ejheart.2007.09.009
   Harwerth RS, 2008, INVEST OPHTH VIS SCI, V49, P4437, DOI 10.1167/iovs.08-1753
   HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10
   Horwitz J, 2009, EXP EYE RES, V88, P190, DOI 10.1016/j.exer.2008.07.007
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Huijberts MSP, 2008, DIABETES-METAB RES, V24, pS19, DOI 10.1002/dmrr.861
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   JAENICKE R, 1994, NATURWISSENSCHAFTEN, V81, P423
   Jandeleit-Dahm K, 2008, CLIN EXP PHARMACOL P, V35, P329, DOI 10.1111/j.1440-1681.2007.04875.x
   Januszewski AS, 2003, BIOCHEM SOC T, V31, P1413
   Jiaan DB, 1995, WORLD J UROL, V13, P369
   Kaji Y, 2000, INVEST OPHTH VIS SCI, V41, P362
   Kern TS, 2001, DIABETES, V50, P1636, DOI 10.2337/diabetes.50.7.1636
   Kessel L, 2005, ACTA OPHTHALMOL SCAN, V83, P221, DOI 10.1111/j.1600-0420.2005.00388.x
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kumar MS, 2005, BIOCHEM J, V391, P335, DOI 10.1042/BJ20050506
   Kumar MS, 2004, BIOCHEM J, V379, P273, DOI 10.1042/BJ20031633
   Kumar PA, 2007, BIOCHEM J, V408, P251, DOI 10.1042/BJ20070989
   LAL S, 1993, J BIOL CHEM, V268, P7763
   LARSEN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P59, DOI 10.1001/archopht.1989.01070010061028
   Lee KW, 1999, EXP EYE RES, V69, P375, DOI 10.1006/exer.1999.0709
   LIANG JN, 1987, CURR EYE RES, V6, P351, DOI 10.3109/02713688709025187
   Linetsky M, 1996, PHOTOCHEM PHOTOBIOL, V63, P649, DOI 10.1111/j.1751-1097.1996.tb05669.x
   Linetsky MD, 2005, BBA-GEN SUBJECTS, V1724, P181, DOI 10.1016/j.bbagen.2005.04.003
   Linetsky M, 2008, BBA-MOL BASIS DIS, V1782, P22, DOI 10.1016/j.bbadis.2007.10.003
   LO TWC, 1994, J BIOL CHEM, V269, P32299
   LOHMANN W, 1986, NATURWISSENSCHAFTEN, V73, P266, DOI 10.1007/BF00367780
   Lou MF, 2000, J OCUL PHARMACOL TH, V16, P137, DOI 10.1089/jop.2000.16.137
   LUTZE M, 1991, INVEST OPHTH VIS SCI, V32, P194
   LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010
   Mailankot M, 2009, BIOGERONTOLOGY
   MALIK NS, 1992, BIOCHIM BIOPHYS ACTA, V1138, P222, DOI 10.1016/0925-4439(92)90041-K
   McNulty R, 2004, J PHYSIOL-LONDON, V559, P883, DOI 10.1113/jphysiol.2004.068619
   Miller AG, 2006, J BIOL CHEM, V281, P11864, DOI 10.1074/jbc.M513813200
   Monnier VM, 1996, NEPHROL DIAL TRANSPL, V11, P20
   MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36
   Monnier VM, 2005, ANN NY ACAD SCI, V1043, P533, DOI 10.1196/annals.1333.061
   MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377
   Morcos M, 2008, AGING CELL, V7, P260, DOI 10.1111/j.1474-9726.2008.00371.x
   Munch G, 2003, BIOCHEM SOC T, V31, P1397
   Nagaraj RH, 2010, BBA-PROTEINS PROTEOM, V1804, P829, DOI 10.1016/j.bbapap.2009.12.008
   Nagaraj RH, 2003, BIOCHEMISTRY-US, V42, P10746, DOI 10.1021/bi034541n
   NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E
   Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587
   Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338
   Nagaraj RH, 1996, FEBS LETT, V382, P234, DOI 10.1016/0014-5793(96)00142-1
   NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257
   Nagaraj RH, 1999, FEBS LETT, V453, P327, DOI 10.1016/S0014-5793(99)00571-2
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Ohshima H, 2009, SKIN RES TECHNOL, V15, P496, DOI 10.1111/j.1600-0846.2009.00396.x
   OIMOMI M, 1988, EXP EYE RES, V46, P415, DOI 10.1016/S0014-4835(88)80029-0
   Ortwerth BJ, 2009, INVEST OPHTH VIS SCI, V50, P3311, DOI 10.1167/iovs.08-2927
   ORTWERTH BJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P10, DOI 10.1016/0167-4838(88)90292-0
   Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x
   ORTWERTH BJ, 1994, EXP EYE RES, V58, P665, DOI 10.1006/exer.1994.1064
   Ortwerth BJ, 2003, INVEST OPHTH VIS SCI, V44, P3094, DOI 10.1167/iovs.02-0857
   ORTWERTH BJ, 1988, EXP EYE RES, V47, P737, DOI 10.1016/0014-4835(88)90041-3
   ORTWERTH BJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P454, DOI 10.1111/j.1751-1097.1995.tb02368.x
   Oturai PS, 2000, METABOLISM, V49, P996, DOI 10.1053/meta.2000.7731
   Padayatti PS, 2001, INVEST OPHTH VIS SCI, V42, P1299
   Padival S, 2006, OPHTHALMIC RES, V38, P294, DOI 10.1159/000095773
   Parikh RS, 2007, OPHTHALMOLOGY, V114, P921, DOI 10.1016/j.ophtha.2007.01.023
   PERRY RE, 1987, EXP EYE RES, V44, P269, DOI 10.1016/S0014-4835(87)80011-8
   PRABHAKARAM M, 1992, EXP EYE RES, V55, P451, DOI 10.1016/0014-4835(92)90118-C
   Prabhakaram M, 1996, MECH AGEING DEV, V91, P65, DOI 10.1016/0047-6374(96)01781-2
   Puttaiah S, 2006, ARCH BIOCHEM BIOPHYS, V446, P186, DOI 10.1016/j.abb.2005.12.002
   Puttaiah S, 2007, EXP EYE RES, V84, P914, DOI 10.1016/j.exer.2007.01.013
   REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021
   Reddy V Prakash, 2005, Sci Aging Knowledge Environ, V2005, ppe12, DOI 10.1126/sageke.2005.18.pe12
   Ren XY, 2008, J DIABETES COMPLICAT, V22, P357, DOI 10.1016/j.jdiacomp.2007.06.013
   Schlotterer A, 2009, DIABETES, V58, P2450, DOI 10.2337/db09-0567
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Sell David R., 1995, P235
   SELL DR, 1989, J BIOL CHEM, V264, P21597
   Sell DR, 2005, J BIOL CHEM, V280, P12310, DOI 10.1074/jbc.M500733200
   Sell DR, 2004, J BIOL CHEM, V279, P54173, DOI 10.1074/jbc.M408946200
   Sell DR, 2003, J GERONTOL A-BIOL, V58, P508
   Selwood Trevor, 1993, Biochemical Society Transactions, V21, p170S
   Shamsi FA, 1999, CURR EYE RES, V19, P276, DOI 10.1076/ceyr.19.3.276.5315
   Shamsi FA, 2000, EXP EYE RES, V70, P369, DOI 10.1006/exer.1999.0800
   Sharma KK, 2009, BBA-GEN SUBJECTS, V1790, P1095, DOI 10.1016/j.bbagen.2009.05.008
   Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885
   Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195
   Shui YB, 2008, INVEST OPHTH VIS SCI, V49, P1023, DOI 10.1167/iovs.07-1164
   SLIGHT SH, 1990, BIOCHIM BIOPHYS ACTA, V1038, P367, DOI 10.1016/0167-4838(90)90250-J
   Staniszewska MM, 2006, MOL CELL BIOCHEM, V288, P29, DOI 10.1007/s11010-005-9115-1
   Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Stitt AW, 1998, INVEST OPHTH VIS SCI, V39, P2517
   Stitt AW, 2002, EXPERT OPIN INV DRUG, V11, P1205, DOI 10.1517/13543784.11.9.1205
   SUAREZ G, 1988, J CLIN INVEST, V82, P624, DOI 10.1172/JCI113641
   Suarez G, 1989, Prog Clin Biol Res, V304, P141
   SWAMY MS, 1987, INVEST OPHTH VIS SCI, V28, P1693
   Swamy-Mruthinti S, 1999, CURR EYE RES, V18, P423, DOI 10.1076/ceyr.18.6.423.5271
   SwamyMruthinti S, 1996, EXP EYE RES, V62, P505, DOI 10.1006/exer.1996.0061
   Szwergold BS, 2001, DIABETES, V50, P2139, DOI 10.2337/diabetes.50.9.2139
   Takemoto L, 1998, INT J BIOL MACROMOL, V22, P331, DOI 10.1016/S0141-8130(98)00031-2
   Takeuchi M, 2008, CURR PHARM DESIGN, V14, P973, DOI 10.2174/138161208784139693
   TAYLOR A, 1989, FASEB J, V3, P1741, DOI 10.1096/fasebj.3.6.2703107
   Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796
   Tessier F, 1998, INT J VITAM NUTR RES, V68, P309
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Thampi P, 2002, INVEST OPHTH VIS SCI, V43, P3265
   Thornalley PJ, 1999, BIOCHEM PHARMACOL, V57, P303, DOI 10.1016/S0006-2952(98)00284-6
   THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U
   Thornalley PJ, 2005, ANN NY ACAD SCI, V1043, P111, DOI 10.1196/annals.1333.014
   Thornalley PJ, 1998, CHEM-BIOL INTERACT, V112, P137, DOI 10.1016/S0009-2797(97)00157-9
   TOMANA M, 1984, J LAB CLIN MED, V103, P137
   Vasan S, 2003, ARCH BIOCHEM BIOPHYS, V419, P89, DOI 10.1016/j.abb.2003.08.016
   Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0
   Wilker SC, 2001, ANAL BIOCHEM, V290, P353, DOI 10.1006/abio.2001.4992
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamagishi S, 2003, INT J CLIN PHARM RES, V23, P129
   YANO M, 1989, DIABETES RES CLIN PR, V7, P259, DOI 10.1016/0168-8227(89)90013-2
   Yao D, 2007, J BIOL CHEM, V282, P31038, DOI 10.1074/jbc.M704703200
   Zhang X, 2008, DIABETOLOGIA, V51, P1723, DOI 10.1007/s00125-008-1071-3
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 182
TC 91
Z9 95
U1 0
U2 45
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0939-4451
EI 1438-2199
J9 AMINO ACIDS
JI Amino Acids
PD APR
PY 2012
VL 42
IS 4
BP 1205
EP 1220
DI 10.1007/s00726-010-0778-x
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 904GD
UT WOS:000301181400013
PM 20963455
DA 2022-11-30
ER

PT J
AU Dahlin, DC
   Rahimy, MH
AF Dahlin, David C.
   Rahimy, Mohamad H.
TI Pharmacokinetics and metabolism of anecortave acetate in animals and
   humans
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; anecortave acetate; pharmacokinetics;
   posterior juxtascleral depot; retina
ID MACULAR DEGENERATION; RAT MODEL; NEOVASCULARIZATION; PREMATURITY;
   RETINOPATHY; INJECTION
AB The ocular delivery of anecortave acetate was tested in preclinical and clinical pharmacokinetic and metabolism studies. Results of initial studies led to the design of a new cannula that could effectively deliver anecortave acetate as a posterior juxtascleral depot, providing adequate retinal and choroidal drug concentrations for tip to 6 months after a single administration. A counter-pressure device was designed to prevent drug reflux during and immediately after posterior juxtascleral depot administration. Pharmacokinetic studies support the effectiveness of these devices. Anecortave acetate is rapidly hydrolyzed by esterases to pharmacologically active anecortave desacetate, and is further reductively metabolized to one major and several minor products that circulate as glucuronide conjugates. Low levels of these anecortave acetate metabolites were detectable for only approximately 2 weeks in the plasma after a 15-mg posterior juxtascleral depot administration to age-related macular degeneration patients. Studies show that posterior juxtascleral depot administration of anecortave acetate is an effective, minimally invasive method of delivering this drug to the choroid and retina.
C1 Alcon Res Ltd, Dept Pharmacokinet & Drug Metab, Ft Worth, TX 76134 USA.
C3 Novartis; Alcon
RP Dahlin, DC (通讯作者)，Alcon Res Ltd, Dept Pharmacokinet & Drug Metab, 6201 S Freeway, Ft Worth, TX 76134 USA.
CR Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 2007, SURV OPHTHALMOL, V52, pS26, DOI 10.1016/j.survophthal.2006.11.003
   DEFALLER JM, 2000, PTERYGIUM, P159
   FREEMAN WR, 1987, AM J OPHTHALMOL, V103, P281
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   JENKINS JS, 1966, INTRO BIOCH ASPECTS, P23
   Kaiser PK, 2007, SURV OPHTHALMOL, V52, pS62, DOI 10.1016/j.survophthal.2006.10.015
   Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0
   Penn JS, 2003, INVEST OPHTH VIS SCI, V44, P5423, DOI 10.1167/iovs.02-0804
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   PETERSON RE, 1971, HUMAN ADRENAL CORTEX, P96
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SMITH RE, 1989, NONSPECIFIC TREATMEN, P5
   SNEDDON JM, 2001, RETINA, V2, P1039
   TRIPATHI RC, 1984, EYE, P8
NR 17
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN
PY 2007
VL 52
SU 1
BP S49
EP S61
DI 10.1016/j.survophthal.2006.11.002
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 135KZ
UT WOS:000244153800007
PM 17240257
DA 2022-11-30
ER

PT J
AU Zipfel, PF
   Heinen, S
   Jozsi, M
   Skerka, C
AF Zipfel, PF
   Heinen, S
   Jozsi, M
   Skerka, C
TI Complement and diseases: Defective alternative pathway control results
   in kidney and eye diseases
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
DE factor H; membranoproliferative glomerulonephritis (MPGN); hemolytic
   uremic syndrome (HUS); age-related macular degeneration (ARMD);
   complement; alternative pathway control; innate immunity; pattern
   recognition
ID HEMOLYTIC-UREMIC SYNDROME; GLOMERULONEPHRITIS TYPE-II; FACTOR-H
   POLYMORPHISM; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MUTATIONS;
   PROTEIN; GENE; ACTIVATION; TRANSPLANTATION; PREDISPOSE
AB The complement system is a central part of innate immunity and in its normal setting aimed to recognize and eliminate microbes. For elimination toxic activation products are generated locally and are reported directly of the surface of the invading microbe. A deregulation of the alternative pathway results in defective recognition and toxic activation products can be formed on the surface of host tissues and structures. Recent studies have shown that mutated or defective regulators of the alternative pathway of complement are associated with auto immune diseases of the kidney, including the atypical form of hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (MPGN) and also of the eye, such as age-related macular degeneration (ARMD). Current research provides clues how mutations occurring in genes coding for single complement components or the inactivation of single regulators lead to defective alternative pathway amplification, via the convertase C3bBb. These scenarios explain how defects of a single regulator lead to local, organ specific damage. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
C3 Hans Knoll Institute (HKI)
RP Zipfel, PF (通讯作者)，Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11A, D-07745 Jena, Germany.
EM peter.zipfel@hki-jena.de
RI Jozsi, Mihaly/I-7872-2018
OI Jozsi, Mihaly/0000-0002-5520-5535; Heinen, Stefan/0000-0001-5800-6593
CR APPEL GB, 2005, J AM SOC NEPHROL
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   DAHA MR, 1979, J IMMUNOL, V123, P755
   DAHA MR, 1998, COMPLEMENT SYSTEM
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Filler G, 2004, PEDIATR NEPHROL, V19, P908, DOI 10.1007/s00467-004-1526-9
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Gerber A, 2003, PEDIATR NEPHROL, V18, P952, DOI 10.1007/s00467-003-1192-3
   Goodship THJ, 2004, TRENDS MOL MED, V10, P226, DOI 10.1016/j.molmed.2004.03.006
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hegasy GA, 2002, AM J PATHOL, V161, P2027, DOI 10.1016/S0002-9440(10)64481-1
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9
   Jansen JH, 1998, KIDNEY INT, V53, P331, DOI 10.1046/j.1523-1755.1998.00765.x
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   Jozsi M, 2004, HISTOL HISTOPATHOL, V19, P251, DOI 10.14670/HH-19.251
   Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x
   KIRSCHFINK M, 1997, COMPLEMENT SYSTEM
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEYS A, 1991, PEDIATR NEPHROL, V5, P189, DOI 10.1007/BF01095950
   LICHT C, 2005, UNUB DELETION SINGLE
   Loirat C, 2003, PEDIATR NEPHROL, V18, P1095, DOI 10.1007/s00467-003-1289-8
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MATHIESON PW, 1993, J EXP MED, V177, P1827, DOI 10.1084/jem.177.6.1827
   MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939
   Meri T, 2002, INFECT IMMUN, V70, P5185, DOI 10.1128/IAI.70.9.5185-5192.2002
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101
   Noris M, 2005, J AM SOC NEPHROL, V16, P1035, DOI 10.1681/ASN.2004100861
   Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3
   PANGBURA MK, 1998, COMPLEMENT SYSTEM
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Remuzzi G, 2005, AM J TRANSPLANT, V5, P1146, DOI 10.1111/j.1600-6143.2005.00783.x
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Schmidt BZ, 1999, J BIOL CHEM, V274, P11782, DOI 10.1074/jbc.274.17.11782
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   WEST C, 1998, HUMAN COMPLEMENT SYS
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6
   Zipfel PF, 2001, TRENDS IMMUNOL, V22, P345, DOI 10.1016/S1471-4906(01)01972-X
NR 49
TC 167
Z9 170
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JAN
PY 2006
VL 43
IS 1-2
BP 97
EP 106
DI 10.1016/j.molimm.2005.06.015
PG 10
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA 966LO
UT WOS:000232021600011
PM 16026839
DA 2022-11-30
ER

PT J
AU Tsutsumi, C
   Sonoda, KH
   Egashira, K
   Qiao, H
   Hisatomi, T
   Nakao, S
   Ishibashi, M
   Charo, IF
   Sakamoto, T
   Murata, T
   Ishibashi, T
AF Tsutsumi, C
   Sonoda, KH
   Egashira, K
   Qiao, H
   Hisatomi, T
   Nakao, S
   Ishibashi, M
   Charo, IF
   Sakamoto, T
   Murata, T
   Ishibashi, T
TI The critical role of ocular-infiltrating macrophages in the development
   of choroidal neovascularization
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE photocoagulation; age-related macular degeneration; retinal pigment
   epithelium
ID ENDOTHELIAL GROWTH-FACTOR; BRUCHS MEMBRANE; IN-VIVO; ANGIOGENESIS;
   EXPRESSION; CHEMOKINES; CELLS; CCR2; INHIBITION; MONOCYTES
AB Choroidal neovascularization (CNV) is directly related to visual loss in some eye diseases, such as age-related macular degeneration. Although several human histological studies have suggested the participation of macrophages in CNV formation, the precise mechanisms are still not fully understood. In this study, we elucidated the role of ocular-infiltrating macrophages in experimental CNV using CCR2 knockout (KO) mice, wild-type mice, and C57BL/6 (136) mice. CCR2 is the receptor of monocyte chemoattractant protein-1, and the number of infiltrating macrophage and the area of CNV were significantly reduced in CCR2 KO mice. Enriched ocular-infiltrating macrophages from B6 mice actually showed angiogenic ability in a dorsal air sac assay. Moreover, their expression of class II, CD40, B7-1 and B7-2 molecules, and the mRNA for potential angiogenic factors, such as vascular endothelial growth factor, basic fibroblast growth factor, and tumor necrosis factor alpha, was also observed. Collectively, we conclude that ocular-infiltrating macrophages play an important role in CNV generation.
C1 Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Fukuoka 8128582, Japan.
   Univ Calif San Francisco, San Francisco Gen Hosp, Gladstone Inst, Div Cardiovasc, San Francisco, CA 94143 USA.
   Kagoshima Univ, Dept Ophthalmol, Kagoshima 890, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; San Francisco
   General Hospital Medical Center; University of California System;
   University of California San Francisco; The J David Gladstone
   Institutes; Kagoshima University
RP Sonoda, KH (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM sonodak@med.kyushu-u.ac.jp
OI Hisatomi, Toshio/0000-0003-2552-9595
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   COSTA M, 1994, CANCER RES, V54, P9
   Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Dawson TC, 2000, AM J PATHOL, V156, P1951, DOI 10.1016/S0002-9440(10)65068-7
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   DOWNS EC, 1992, J CELL PHYSIOL, V152, P422, DOI 10.1002/jcp.1041520225
   Dunlop AAS, 1998, ARCH OPHTHALMOL-CHIC, V116, P801, DOI 10.1001/archopht.116.6.801
   FURIE MB, 1995, AM J PATHOL, V146, P1287
   Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631
   HIROMATSU K, 1992, J IMMUNOL, V149, P568
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   KAHN HA, 1974, AM J OPHTHALMOL, V78, P58, DOI 10.1016/0002-9394(74)90010-5
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196
   Koshikawa N, 2000, CANCER RES, V60, P2936
   Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423
   LEWIS CE, 1995, J LEUKOCYTE BIOL, V57, P747, DOI 10.1002/jlb.57.5.747
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697
   MBAWUIKE IN, 1988, IMMUNOLOGY, V64, P61
   Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Nieto M, 1998, J IMMUNOL, V161, P3330
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oikawa T, 1997, ANTICANCER RES, V17, P1881
   PLUNKETT ML, 1990, LAB INVEST, V62, P510
   RUTHERFORD MS, 1993, J LEUKOCYTE BIOL, V53, P602, DOI 10.1002/jlb.53.5.602
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Salvesen HB, 1999, INT J CANCER, V84, P539
   SAXE SJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P88, DOI 10.1001/archopht.1993.01090010092033
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   SHAPIRO SD, 1991, J RHEUMATOL, V18, P95
   SIDKY YA, 1987, CANCER RES, V47, P5155
   Sonoda K, 1998, INVEST OPHTH VIS SCI, V39, P2245
   Strieter RM, 1996, J IMMUNOL, V156, P3583
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Sundquist W. I., 1991, Nucleic Acids and Molecular Biology, V5, P1
   Takanami I, 1999, ONCOLOGY-BASEL, V57, P138, DOI 10.1159/000012021
   TANAKA NG, 1989, CANCER RES, V49, P6727
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zhang-Hoover J, 2001, J IMMUNOL, V166, P3556, DOI 10.4049/jimmunol.166.5.3556
NR 55
TC 219
Z9 240
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD JUL
PY 2003
VL 74
IS 1
BP 25
EP 32
DI 10.1189/jlb.0902436
PG 8
WC Cell Biology; Hematology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Hematology; Immunology
GA 755FB
UT WOS:000187367800005
PM 12832439
DA 2022-11-30
ER

PT J
AU Jurek, J
   Owczarek, M
   Godos, J
   La Vignera, S
   Condorelli, RA
   Marventano, S
   Tieri, M
   Ghelfi, F
   Titta, L
   Lafranconi, A
   Gambera, A
   Alonzo, E
   Sciacca, S
   Buscemi, S
   Ray, S
   Del Rio, D
   Galvano, F
   Grosso, G
AF Jurek, Joanna
   Owczarek, Marcin
   Godos, Justyna
   La Vignera, Sandro
   Condorelli, Rosita A.
   Marventano, Stefano
   Tieri, Maria
   Ghelfi, Francesca
   Titta, Lucilla
   Lafranconi, Alessandra
   Gambera, Angelo
   Alonzo, Elena
   Sciacca, Salvatore
   Buscemi, Silvio
   Ray, Sumantra
   Del Rio, Daniele
   Galvano, Fabio
   Grosso, Giuseppe
TI Fish and human health: an umbrella review of observational studies
SO INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION
LA English
DT Review
DE Fish; omega-3; meta-analysis; umbrella review; evidence;
   non-communicable diseases; depression; mortality; cardiovascular
   disease; coronary heart disease; liver cancer
ID POLYUNSATURATED FATTY-ACIDS; DOSE-RESPONSE METAANALYSIS; COGNITIVE
   IMPAIRMENT RISKS; ESOPHAGEAL CANCER-RISK; COLORECTAL-CANCER; MEAT
   CONSUMPTION; DIETARY FACTORS; THYROID-CANCER; HEART-FAILURE; PUFA INTAKE
AB Fish represents one of the most important dietary sources of omega-3 polyunsaturated fatty acids, which are known to be associated with various health benefits. This study aimed to systematically review existing meta-analyses of observational studies exploring the association between fish intake and various health outcomes. A systematic search of electronic databases was conducted to retrieve a total of 63 studies. Evidence was deemed as possible for the association between higher fish intake and decreased risk of the acute coronary syndrome, liver cancer, and depression, and limited for other outcomes (including age-related macular degeneration, Alzheimer's disease, heart failure, all-cause and coronary heart disease mortality, total and ischaemic stroke) due to heterogeneity between results and potential otherwise inexplicable confounding factors. In conclusion, results from epidemiological studies support the mechanistic effects associated with omega-3 fatty acids from high fish consumption, but evidence needs to be further corroborated with more reliable results.
C1 [Jurek, Joanna] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland.
   [Owczarek, Marcin] Ulster Univ, Coleraine, Londonderry, North Ireland.
   [Godos, Justyna; Galvano, Fabio; Grosso, Giuseppe] Univ Catania, Dept Biomed & Biotechnol Sci, Via Santa Sofia 97, I-95123 Catania, Italy.
   [La Vignera, Sandro; Condorelli, Rosita A.] Univ Catania, Dept Clin & Expt Med, Catania, Italy.
   [Marventano, Stefano] AUSL Romagna, Rimini Womens Hlth, Childhood & Adolescent Dept, Rimini, Italy.
   [Tieri, Maria; Titta, Lucilla] IRCCS, European Inst Oncol, IEO, Smart Food Program,Dept Expt Oncol, Milan, Italy.
   [Ghelfi, Francesca] IRCCS Ca Granda Osped Maggiore Policlin, Fdn Marchi Dept Pediat, Milan, Italy.
   [Ghelfi, Francesca; Ray, Sumantra; Del Rio, Daniele; Grosso, Giuseppe] St Johns Innovat Ctr, NNEdPro Global Ctr Nutr & Hlth, Cambridge, England.
   [Lafranconi, Alessandra] Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands.
   [Gambera, Angelo] Azienda Osped Univ Policlin Vittorio Emanuele, Catania, Italy.
   [Alonzo, Elena] ASP Catania, Food & Nutr Secur & Publ Hlth Serv, Catania, Italy.
   [Sciacca, Salvatore] Mediterranean Oncol Inst IOM, Catania, Italy.
   [Buscemi, Silvio] Univ Palermo, Biomed Dept Internal & Specialist Med DIBIMIS, Palermo, Italy.
   [Ray, Sumantra] Univ Ulster, Sch Biomed Sci, Ulster, England.
   [Ray, Sumantra] Univ Cambridge, Sch Humanities & Social Sci, Cambridge, England.
   [Del Rio, Daniele] Univ Parma, Dept Food & Drug, Human Nutr Unit, Parma, Italy.
   [Del Rio, Daniele] Univ Parma, Sch Adv Studies Food & Nutr, Parma, Italy.
C3 University College Cork; Ulster University; University of Catania;
   University of Catania; AUSL della Romagna; IRCCS European Institute of
   Oncology (IEO); IRCCS Ca Granda Ospedale Maggiore Policlinico; St Johns
   Innovation Centre - UK; Maastricht University; Azienda Ospedaliera
   Universitaria Policlinico Vittorio Emanuele Presidio Ferraotto;
   University of Palermo; Ulster University; University of Cambridge;
   University of Parma; University of Parma
RP Grosso, G (通讯作者)，Univ Catania, Dept Biomed & Biotechnol Sci, Via Santa Sofia 97, I-95123 Catania, Italy.
EM giuseppe.grosso@unict.it
RI Del Rio, Daniele/E-8696-2010; Godos, Justyna/AAC-1302-2019
OI Del Rio, Daniele/0000-0001-5394-1259; Godos,
   Justyna/0000-0002-5809-5706; Owczarek, Marcin/0000-0001-9242-4668; La
   Vignera, Sandro/0000-0002-7113-2372
CR Abdelhamid AS, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003177.pub4
   Abel S, 2014, P NUTR SOC, V73, P361, DOI 10.1017/S0029665114000585
   Afshin A, 2019, LANCET, V393, P1958, DOI 10.1016/S0140-6736(19)30041-8
   Bai HW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081939
   Bandera EV, 2007, CANCER CAUSE CONTROL, V18, P967, DOI 10.1007/s10552-007-9038-0
   Bosetti C, 2001, CANCER CAUSE CONTROL, V12, P375, DOI 10.1023/A:1011267123398
   Burns-Whitmore B, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102365
   Caini S, 2016, CRIT REV ONCOL HEMAT, V100, P16, DOI 10.1016/j.critrevonc.2016.02.011
   Calder PC, 2017, BIOCHEM SOC T, V45, P1105, DOI 10.1042/BST20160474
   Cao L, 2016, MOL NEUROBIOL, V53, P6144, DOI 10.1007/s12035-015-9516-4
   Cho YA, 2015, NUTR CANCER, V67, P811, DOI 10.1080/01635581.2015.1040517
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chowdhury R, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6698
   Di Giuseppe D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0446-8
   Djousse L, 2012, CLIN NUTR, V31, P846, DOI 10.1016/j.clnu.2012.05.010
   Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z
   Fang XX, 2015, EUR J CANCER, V51, P2820, DOI 10.1016/j.ejca.2015.09.010
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   Fritsche KL, 2015, ADV NUTR, V6, p293S, DOI 10.3945/an.114.006940
   Gao M, 2015, CANCER CAUSE CONTROL, V26, P367, DOI 10.1007/s10552-014-0512-1
   Geelen A, 2007, AM J EPIDEMIOL, V166, P1116, DOI 10.1093/aje/kwm197
   Godos J, 2017, J HUM NUTR DIET, V30, P349, DOI 10.1111/jhn.12426
   Grosso G, 2022, NUTRIENTS, V14, DOI 10.3390/nu14061137
   Grosso G, 2016, J AFFECT DISORDERS, V205, P269, DOI 10.1016/j.jad.2016.08.011
   Grosso G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096905
   Grosso G, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/313570
   Han YJ, 2013, EUR J CLIN NUTR, V67, P147, DOI 10.1038/ejcn.2012.213
   He K, 2004, CIRCULATION, V109, P2705, DOI 10.1161/01.CIR.0000132503.19410.6B
   He K, 2004, STROKE, V35, P1538, DOI 10.1161/01.STR.0000130856.31468.47
   He XX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162368
   Hennebelle M, 2014, NUTR REV, V72, P99, DOI 10.1111/nure.12088
   Hou LN, 2012, EXP THER MED, V4, P479, DOI 10.3892/etm.2012.605
   Huang RX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0096102
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Afe OHI, 2021, FOOD SCI NUTR, V9, P6903, DOI 10.1002/fsn3.2633
   Innes JK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041362
   Innes JK, 2018, PROSTAG LEUKOTR ESS, V132, P41, DOI 10.1016/j.plefa.2018.03.004
   Ishihara T, 2019, INT IMMUNOL, V31, P559, DOI 10.1093/intimm/dxz001
   Jiang GX, 2016, ASIA-PAC J CLIN ONCO, V12, pE82, DOI 10.1111/ajco.12114
   Jiang PY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094601
   Kalkman HO, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094393
   Kim YS, 2015, NUTRIENTS, V7, P2085, DOI 10.3390/nu7042085
   Koch M, 2016, AM J CLIN NUTR, V104, P537, DOI 10.3945/ajcn.116.133397
   Kolahdooz F, 2010, AM J CLIN NUTR, V91, P1752, DOI 10.3945/ajcn.2009.28415
   Kulczynski B, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090335
   Kwon Y, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201900824
   Larrieu T, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01047
   Larsson SC, 2011, STROKE, V42, P3621, DOI 10.1161/STROKEAHA.111.630319
   Lee KH, 2020, ADV NUTR, V11, P1134, DOI 10.1093/advances/nmaa055
   Li F, 2016, J EPIDEMIOL COMMUN H, V70, P299, DOI 10.1136/jech-2015-206278
   Li KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088103
   Li YH, 2013, CHINESE MED J-PEKING, V126, P942, DOI 10.3760/cma.j.issn.0366-6999.20121943
   Li ZY, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-107
   Liu ZT, 2014, NUTR CANCER, V66, P1165, DOI 10.1080/01635581.2014.951734
   Lorente-Cebrian S, 2015, J PHYSIOL BIOCHEM, V71, P341, DOI 10.1007/s13105-015-0395-y
   Luo J, 2014, ALIMENT PHARM THER, V39, P913, DOI 10.1111/apt.12678
   Marventano S, 2015, INT J FOOD SCI NUTR, V66, P611, DOI 10.3109/09637486.2015.1077790
   Miller V, 2022, LANCET PLANET HEALTH, V6, pE243, DOI 10.1016/S2542-5196(21)00352-1
   Mozaffarian D, 2006, JAMA-J AM MED ASSOC, V296, P1885, DOI 10.1001/jama.296.15.1885
   Muller CP, 2015, BBA-MOL CELL BIOL L, V1851, P1052, DOI 10.1016/j.bbalip.2014.12.014
   Muley A, 2014, CURR DIABETES REV, V10, P158, DOI 10.2174/1573399810666140515113137
   Murray CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2
   Nabavi SF, 2015, CANCER METAST REV, V34, P359, DOI 10.1007/s10555-015-9572-2
   Paluszkiewicz P, 2012, CANCER EPIDEMIOL, V36, P60, DOI 10.1016/j.canep.2011.05.004
   Pusceddu MM, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw078
   Qin B, 2012, J NUTR, V142, P1067, DOI 10.3945/jn.111.156711
   Ross BM, 2009, PROSTAG LEUKOTR ESS, V81, P309, DOI 10.1016/j.plefa.2009.10.004
   Salehi M, 2013, NUTR REV, V71, P257, DOI 10.1111/nure.12028
   Shahidi F, 2018, ANNU REV FOOD SCI T, V9, P345, DOI 10.1146/annurev-food-111317-095850
   Song J, 2014, NUTR CANCER, V66, P539, DOI 10.1080/01635581.2014.894102
   Szymanski KM, 2010, AM J CLIN NUTR, V92, P1223, DOI 10.3945/ajcn.2010.29530
   Wallin A, 2012, DIABETES CARE, V35, P918, DOI 10.2337/dc11-1631
   Wang CB, 2015, INT J CLIN EXP MED, V8, P10825
   Wang YZ, 2015, CANCER CAUSE CONTROL, V26, P1307, DOI 10.1007/s10552-015-0625-1
   Watanabe Y, 2020, J ATHEROSCLER THROMB, V27, P183, DOI 10.5551/jat.50658
   Wei YL, 2021, FOOD FUNCT, V12, P30, DOI [10.1039/d0fo01976c, 10.1039/D0FO01976C]
   Whelton SP, 2004, AM J CARDIOL, V93, P1119, DOI 10.1016/j.amjcard.2004.01.038
   Wu JHY, 2012, BRIT J NUTR, V107, pS214, DOI 10.1017/S0007114512001602
   Wu J, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110730
   Wu SJ, 2012, AM J MED, V125, P551, DOI 10.1016/j.amjmed.2012.01.022
   Wu SJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-26
   Wu SQ, 2015, NEUROSCI BIOBEHAV R, V48, P1, DOI 10.1016/j.neubiorev.2014.11.008
   Wu ZH, 2016, NUTR HOSP, V33, P703, DOI 10.20960/nh.282
   Xu B, 2013, ANN EPIDEMIOL, V23, P215, DOI 10.1016/j.annepidem.2012.12.016
   Xun P, 2012, EUR J CLIN NUTR, V66, P1199, DOI 10.1038/ejcn.2012.133
   Xun PC, 2012, DIABETES CARE, V35, P930, DOI 10.2337/dc11-1869
   Yang B, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010058
   Yang L, 2020, HEMATOLOGY, V25, P194, DOI 10.1179/1607845414Y.0000000215
   Yang WS, 2012, ANN ONCOL, V23, P3163, DOI 10.1093/annonc/mds207
   Yinko SSLL, 2014, AM J MED, V127, P848, DOI 10.1016/j.amjmed.2014.04.016
   Yu XF, 2014, WORLD J GASTROENTERO, V20, P15398, DOI 10.3748/wjg.v20.i41.15398
   Zhang M, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/501015
   Zhang Y, 2016, AM J CLIN NUTR, V103, P330, DOI 10.3945/ajcn.115.124081
   Zhao LG, 2016, EUR J CLIN NUTR, V70, P155, DOI 10.1038/ejcn.2015.72
   Zheng JS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3706
   Zheng JS, 2012, PUBLIC HEALTH NUTR, V15, P725, DOI 10.1017/S1368980011002254
   Zhou YP, 2012, BRIT J NUTR, V108, P408, DOI 10.1017/S0007114512002036
   Zhu HC, 2014, DIGEST DIS SCI, V59, P664, DOI 10.1007/s10620-013-2928-y
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 99
TC 1
Z9 1
U1 7
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0963-7486
EI 1465-3478
J9 INT J FOOD SCI NUTR
JI Int. J. Food Sci. Nutr.
PD OCT 3
PY 2022
VL 73
IS 7
BP 851
EP 860
DI 10.1080/09637486.2022.2090520
EA JUN 2022
PG 10
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 5L6DX
UT WOS:000817272700001
PM 35758202
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Yao, PL
   Peavey, J
   Malek, G
AF Yao, Pei-Li
   Peavey, Jeremy
   Malek, Goldis
TI Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular
   Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE nuclear receptors; angiogenesis; wet age-related macular degeneration;
   proliferative diabetic retinopathy; inflammation
ID PROLIFERATOR-ACTIVATED RECEPTOR; ARYL-HYDROCARBON RECEPTOR;
   VITAMIN-D-RECEPTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; HORMONE
   REPLACEMENT THERAPY; POLYUNSATURATED FATTY-ACIDS; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION
AB Vasculogenesis and angiogenesis are physiological mechanisms occurring throughout the body. Any disruption to the precise balance of blood vessel growth necessary to support healthy tissue, and the inhibition of abnormal vessel sprouting has the potential to negatively impact stages of development and/or healing. Therefore, the identification of key regulators of these vascular processes is critical to identifying therapeutic means by which to target vascular-associated compromises and complications. Nuclear receptors are a family of transcription factors that have been shown to be involved in modulating different aspects of vascular biology in many tissues systems. Most recently, the role of nuclear receptors in ocular biology and vasculopathies has garnered interest. Herein, we review studies that have used in vitro assays and in vivo models to investigate nuclear receptor-driven pathways in two ocular vascular diseases associated with blindness, wet or exudative age-related macular degeneration, and proliferative diabetic retinopathy. The potential therapeutic targeting of nuclear receptors for ocular diseases is also discussed.
C1 [Yao, Pei-Li; Peavey, Jeremy; Malek, Goldis] Duke Univ, Dept Ophthalmol, Duke Eye Ctr, Sch Med, Durham, NC 27503 USA.
   [Malek, Goldis] Duke Univ, Dept Pathol, Sch Med, Durham, NC 27503 USA.
C3 Duke University; Duke University
RP Malek, G (通讯作者)，Duke Univ, Dept Ophthalmol, Duke Eye Ctr, Sch Med, Durham, NC 27503 USA.; Malek, G (通讯作者)，Duke Univ, Dept Pathol, Sch Med, Durham, NC 27503 USA.
EM Peili.yao@duke.edu; jeremy.peavey@duke.edu; gmalek@duke.edu
OI Peavey, Jeremy/0000-0001-5745-364X; Malek, Goldis/0000-0003-0026-2388;
   Yao, Pei-Li/0000-0003-0832-3771
FU National Eye Institute [R01 EY027802, EY028160, P30 EY005722]; Research
   to Prevent Blindness, Inc (RPB) Core grant
FX This research was funded by National Eye Institute grants R01 EY027802
   (to G.M), EY028160 (to G.M) and P30 EY005722 (to Duke Eye Center) and
   Research to Prevent Blindness, Inc (RPB) Core grant (to Duke Eye
   Center).
CR Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Atchison Elizabeth, 2016, Curr Ophthalmol Rep, V4, P84, DOI 10.1007/s40135-016-0098-8
   Augustin A, 2006, CLIN INTERV AGING, V1, P237, DOI 10.2147/ciia.2006.1.3.237
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Ayalasomayajula SP, 2009, J OCUL PHARMACOL TH, V25, P97, DOI 10.1089/jop.2008.0090
   Bakri SJ, 2008, EYE, V22, P978, DOI 10.1038/sj.eye.6703041
   BALLARD DJ, 1986, DIABETES CARE, V9, P334, DOI 10.2337/diacare.9.4.334
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   Besnard S, 2001, CIRC RES, V89, P1209, DOI 10.1161/hh2401.101755
   Besnard S, 2002, FEBS LETT, V511, P36, DOI 10.1016/S0014-5793(01)03275-6
   Bishop-Bailey D, 2008, PPAR RES, V2008, DOI 10.1155/2008/904251
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Bucan K, 2009, COLLEGIUM ANTROPOL, V33, P99
   Busik JV, 2009, J EXP MED, V206, P2897, DOI 10.1084/jem.20090889
   Cain DW, 2017, NAT REV IMMUNOL, V17, P233, DOI 10.1038/nri.2017.1
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Capozzi ME, 2013, INVEST OPHTH VIS SCI, V54, P4197, DOI 10.1167/iovs.13-11608
   Capuano Vittorio, 2019, Retin Cases Brief Rep, V13, P300, DOI 10.1097/ICB.0000000000000592
   Roman AC, 2009, J BIOL CHEM, V284, P25135, DOI 10.1074/jbc.M109.013292
   Chan LSA, 2009, PPAR RES, V2009, DOI 10.1155/2009/925309
   Chang JY, 2008, PPAR RES, V2008, DOI 10.1155/2008/720163
   Cheng HS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0971-9
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Choudhary M, 2018, BBA-MOL BASIS DIS, V1864, P1583, DOI 10.1016/j.bbadis.2018.02.015
   Choudhary M, 2016, J BIOMOL SCREEN, V21, P1007, DOI 10.1177/1087057116659856
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Clark AF, 2007, SURV OPHTHALMOL, V52, pS26, DOI 10.1016/j.survophthal.2006.11.003
   Costa V, 2012, BRIT J PHARMACOL, V165, P1, DOI 10.1111/j.1476-5381.2011.01443.x
   Costa V, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/126917
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Cyganek K, 2006, ACTA DIABETOL, V43, P114, DOI 10.1007/s00592-006-0225-3
   Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048
   Doan TB, 2017, J MOL ENDOCRINOL, V58, pR169, DOI 10.1530/JME-16-0082
   Dolz-Marco Rosa, 2019, Retin Cases Brief Rep, V13, P162, DOI 10.1097/ICB.0000000000000549
   Duez H, 1985, J APPL PHYSIOL, V107, P1972, DOI DOI 10.1152/japplphysiol.00570.2009
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Ehmann D, 2010, CAN J OPHTHALMOL, V45, P36, DOI 10.3129/i09-243
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012
   Felinski EA, 2005, CURR EYE RES, V30, P949, DOI 10.1080/02713680500263598
   Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fessler MB, 2018, PHARMACOL THERAPEUT, V181, P1, DOI 10.1016/j.pharmthera.2017.07.010
   Forrest D, 2012, MOL ENDOCRINOL, V26, P905, DOI 10.1210/me.2012-1010
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Fukushima Y, 2011, J CLIN INVEST, V121, P1974, DOI 10.1172/JCI44900
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Garg R, 2015, DIABETES, V64, P236, DOI 10.2337/db14-0670
   Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022
   Gomez-Sanchez E, 2014, COMPR PHYSIOL, V4, P965, DOI 10.1002/cphy.c130044
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002
   Hamblin M, 2009, ANTIOXID REDOX SIGN, V11, P1415, DOI [10.1089/ars.2008.2280, 10.1089/ARS.2008.2280]
   Hamik A, 2006, ARTERIOSCL THROM VAS, V26, P1936, DOI 10.1161/01.ATV.0000232542.42968.e3
   Hammer SS, 2017, EBIOMEDICINE, V22, P181, DOI 10.1016/j.ebiom.2017.07.008
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Hong F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082189
   Hoshi T., 2017, BIOMED RES CLIN PRAC, V2, P1, DOI [10.15761/BRCP.1000135, DOI 10.15761/BRCP.1000135]
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   Hutchinson CV, 2014, J ENDOCRINOL, V223, pR9, DOI 10.1530/JOE-14-0349
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jensen Lasse Dahl, 2014, Biomol Concepts, V5, P245, DOI 10.1515/bmc-2014-0009
   Jensen LD, 2013, CELL CYCLE, V12, P405, DOI 10.4161/cc.23596
   Jia J, 2015, ARCH MED RES, V46, P572, DOI 10.1016/j.arcmed.2015.09.006
   Jin HL, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/5679517
   Kadian S, 2013, EUR J PHARMACOL, V698, P388, DOI 10.1016/j.ejphar.2012.10.012
   Katome T, 2015, J DIABETES COMPLICAT, V29, P275, DOI 10.1016/j.jdiacomp.2014.10.010
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Kim J, 2011, GENE DEV, V25, P1399, DOI 10.1101/gad.2042011
   Kim K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00215-1
   Kim YW, 2013, J MOL MED, V91, P323, DOI 10.1007/s00109-013-1007-3
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kruger-Genge A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184411
   Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Liu K, 2017, ONCOTARGET, V8, P27603, DOI 10.18632/oncotarget.15178
   Malecki MT, 2008, DIABETES RES CLIN PR, V80, P139, DOI 10.1016/j.diabres.2007.11.001
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Martens B, 2019, J STEROID BIOCHEM, V188, P147, DOI 10.1016/j.jsbmb.2019.01.009
   Merrigan SL, 2017, BRIT J PHARMACOL, V174, P2636, DOI 10.1111/bph.13875
   Mirza AZ, 2019, EUR J MED CHEM, V166, P502, DOI 10.1016/j.ejmech.2019.01.067
   Moriya J, 2010, CIRC RES, V106, P391, DOI 10.1161/CIRCRESAHA.109.210815
   Mukwaya A, 2018, ANGIOGENESIS, V21, P395, DOI 10.1007/s10456-018-9604-y
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Naito H, 2020, INT IMMUNOL, V32, P295, DOI 10.1093/intimm/dxaa008
   Noonan JE, 2013, DIABETES, V62, P3968, DOI 10.2337/db13-0800
   Patel-Hett S, 2011, INT J DEV BIOL, V55, P353, DOI 10.1387/ijdb.103213sp
   Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214
   Piqueras L, 2007, ARTERIOSCL THROM VAS, V27, P63, DOI 10.1161/01.ATV.0000250972.83623.61
   Potente M, 2017, NAT REV MOL CELL BIO, V18, P477, DOI 10.1038/nrm.2017.36
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Ramamoorthy S, 2016, RHEUM DIS CLIN N AM, V42, P15, DOI 10.1016/j.rdc.2015.08.002
   Richardson RV, 2016, TRENDS ENDOCRIN MET, V27, P35, DOI 10.1016/j.tem.2015.10.001
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rubio RG, 2016, DEV OPHTHALMOL, V55, P28, DOI 10.1159/000431129
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Safe S, 2014, MOL ENDOCRINOL, V28, P157, DOI 10.1210/me.2013-1291
   Safi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/801269
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Santori FR, 2015, EUR J IMMUNOL, V45, P2730, DOI 10.1002/eji.201545712
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sherman MH, 2012, CANCER PREV RES, V5, P3, DOI 10.1158/1940-6207.CAPR-11-0528
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Solt LA, 2012, TRENDS ENDOCRIN MET, V23, P619, DOI 10.1016/j.tem.2012.05.012
   Solt LA, 2011, FUTURE MED CHEM, V3, P623, DOI [10.4155/FMC.11.9, 10.4155/fmc.11.9]
   Song XY, 2019, P NATL ACAD SCI USA, V116, P16507, DOI 10.1073/pnas.1904719116
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507
   Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701
   Stahl A, 2012, BLOOD, V120, P2925, DOI 10.1182/blood-2012-04-422527
   Straub RH, 2016, RHEUMATOLOGY, V55, P6, DOI 10.1093/rheumatology/kew348
   Sulaiman RS, 2018, STEROIDS, V133, P60, DOI 10.1016/j.steroids.2017.11.002
   Sun Y, 2017, FASEB J, V31, P4492, DOI 10.1096/fj.201700172R
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Takata S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09898
   Tanemura M, 2004, MOL VIS, V10, P923
   Taverna MJ, 2005, J CLIN ENDOCR METAB, V90, P4803, DOI 10.1210/jc.2004-2407
   Taverna MJ, 2002, DIABETOLOGIA, V45, P436, DOI 10.1007/s00125-001-0769-2
   Tawfik A, 2009, INVEST OPHTH VIS SCI, V50, P878, DOI 10.1167/iovs.08-2005
   Thosar SS, 2018, J CLIN INVEST, V128, P2157, DOI 10.1172/JCI80590
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tyagi S, 2011, J ADV PHARM TECHNOL, V2, P236, DOI 10.4103/2231-4040.90879
   Von Essen M.R., 2018, ENCY SIGNALING MOL
   Wang B, 2018, NAT REV ENDOCRINOL, V14, P452, DOI 10.1038/s41574-018-0037-x
   Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Yin Lei, 2010, Nucl Recept Signal, V8, pe001, DOI 10.1621/nrs.08001
   Zheng SJ, 2015, INVEST OPHTH VIS SCI, V56, P1168, DOI 10.1167/iovs.14-15612
NR 151
TC 5
Z9 5
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2020
VL 21
IS 8
AR 2889
DI 10.3390/ijms21082889
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LR3AC
UT WOS:000535565300231
PM 32326149
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ding, DM
   Zhu, MH
   Liu, XJ
   Jiang, L
   Xu, JW
   Chen, LL
   Liang, J
   Li, LL
   Zhou, TH
   Wang, Y
   Shi, H
   Yuan, Y
   Song, E
AF Ding, Dongmei
   Zhu, Manhui
   Liu, Xiaojuan
   Jiang, Li
   Xu, Jiaowen
   Chen, Lili
   Liang, Juan
   Li, Lele
   Zhou, Taohu
   Wang, Ying
   Shi, Hao
   Yuan, You
   Song, E.
TI Inhibition of TRAF6 alleviates choroidal neovascularization in vivo
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Choroidal neovascularization (CNV); Tumor necrosis factor
   receptor-associated factor 6 (TRAF6); Hypoxia-inducible factor 1 alpha
   (HIF-1 alpha); Vascular endothelial growth factor (VEGF); Macrophage;
   Microglia
ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR-ASSOCIATED FACTOR-6; NF-KAPPA-B;
   MACULAR DEGENERATION; ANGIOGENESIS; ACTIVATION; AUTOPHAGY; CELLS;
   EXPRESSION; HIF-1-ALPHA
AB Choroidal neovascularization (CNV) is a type of wet age-related macular degeneration (AMD) which is a major cause of blindness in elder patients. Tumor necrosis factor receptor-associated factor 6 (TRAF6) promotes tumor angiogenesis via upregulating the expression of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF). Additionally, TRAF6 facilitates the inflammatory response in macrophages and microglia. Here, using mouse laser-induced CNV model and TRAF6 siRNA, the study shows that TRAF6 is a critical player in CNV. The expression of TRAF6, HIF-1 alpha, and VEGF increased in the model. TFAF6 siRNA intravitreal (IVT) injection inhibited CNV formation, as well as expression of HIF-1 alpha and VEGF, activation of macrophages and microglia. Together, our data suggest that TFAF6 inhibition reduces CNV formation via down-regulating expression of HIF-1 alpha and VEGF and activation of macrophages and microglia, demonstrating the unique advantages of TRAF6 inhibition in the alleviation of AMD. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Ding, Dongmei; Jiang, Li] Laizhou City Peoples Hosp, Dept Ophthalmol, Yantai, Shandong, Peoples R China.
   [Zhu, Manhui; Xu, Jiaowen; Chen, Lili; Liang, Juan; Shi, Hao; Yuan, You; Song, E.] Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.
   [Liu, Xiaojuan] Nantong Univ, Dept Pathogen Biol, Med Coll, Nantong, Jiangsu, Peoples R China.
   [Li, Lele] Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong, Jiangsu, Peoples R China.
   [Zhou, Taohu] Nantong Univ, Med Coll, Nantong, Jiangsu, Peoples R China.
   [Wang, Ying] Suzhou Municipal Hosp, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.
C3 Soochow University - China; Nantong University; Nantong University;
   Nantong University
RP Song, E (通讯作者)，Soochow Univ, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.
EM songe@suda.edu.cn
FU 14th Six Talents Peak Project of Jiangsu Province [SWYY-058]; 2018
   Undergraduate Innovation Project of Nantong University [2018149]
FX The study was supported by the 14th Six Talents Peak Project of Jiangsu
   Province (No. SWYY-058), the 2018 Undergraduate Innovation Project of
   Nantong University (No. 2018149).
CR Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Arnold T, 2013, VASC CELL, V5, DOI 10.1186/2045-824X-5-4
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bruneau S, 2012, BIOCHEM BIOPH RES CO, V419, P66, DOI 10.1016/j.bbrc.2012.01.128
   Chen GH, 2017, BIOL CHEM, V398, P499, DOI 10.1515/hsz-2016-0211
   Cho ML, 2007, IMMUNOL LETT, V108, P121, DOI 10.1016/j.imlet.2006.11.005
   Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372
   Dobrogowska DH, 1998, J NEUROCYTOL, V27, P163, DOI 10.1023/A:1006907608230
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gupta A., 2018, COCHRANE DB SYST REV, V5
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707
   Jiang YD, 2017, P NATL ACAD SCI USA, V114, P10737, DOI 10.1073/pnas.1706394114
   Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Konno H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005674
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   Lemstra AW, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-4
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Min Y., 2018, AUTOPHAGY, P1
   Mukundan L, 2005, J IMMUNOL, V174, P1081, DOI 10.4049/jimmunol.174.2.1081
   Mulfaul K, 2018, ADV EXP MED BIOL, V1074, P19, DOI 10.1007/978-3-319-75402-4_3
   Nita M, 2014, MED SCI MONITOR, V20, P875, DOI 10.12659/MSM.890031
   Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894
   Petibone DM, 2017, J APPL TOXICOL, V37, P23, DOI 10.1002/jat.3393
   Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220
   Schirbel A, 2013, GASTROENTEROLOGY, V144, P613, DOI 10.1053/j.gastro.2012.11.005
   Sheets KG, 2013, MOL VIS, V19, P1747
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Song FJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149991
   Sun H, 2013, CANCER RES, V73, P4950, DOI 10.1158/0008-5472.CAN-13-0370
   Takahashi H, 2018, CLIN OPHTHALMOL, V12, P369, DOI 10.2147/OPTH.S151999
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
NR 46
TC 6
Z9 7
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 18
PY 2018
VL 503
IS 4
BP 2742
EP 2748
DI 10.1016/j.bbrc.2018.08.034
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GT8MM
UT WOS:000444791600082
PM 30103950
DA 2022-11-30
ER

PT J
AU Cohen-Tayar, Y
   Cohen, H
   Mitiagin, Y
   Abravanel, Z
   Levy, C
   Idelson, M
   Reubinoff, B
   Itzkovitz, S
   Raviv, S
   Kaestner, KH
   Blinder, P
   Elkon, R
   Ashery-Padan, R
AF Cohen-Tayar, Yamit
   Cohen, Hadar
   Mitiagin, Yulia
   Abravanel, Zohar
   Levy, Carmit
   Idelson, Masha
   Reubinoff, Benjamin
   Itzkovitz, Shalev
   Raviv, Shaul
   Kaestner, Klaus H.
   Blinder, Pablo
   Elkon, Ran
   Ashery-Padan, Ruth
TI Pax6 regulation of Sox9 in the mouse retinal pigmented epithelium
   controls its timely differentiation and choroid vasculature development
SO DEVELOPMENT
LA English
DT Article
DE Retinal pigmented epithelium; Pax6; Sox9; Choroid vasculature;
   Age-related macular degeneration
ID ANGIOPOIETIN-LIKE 4; ENDOTHELIAL-CELLS; SOLUBLE VEGF; STEM-CELLS;
   IN-VITRO; EXPRESSION; LENS; GENE; ANGIOGENESIS; NEURONS
AB The synchronized differentiation of neuronal and vascular tissues is crucial for normal organ development and function, although there is limited information about the mechanisms regulating the coordinated development of these tissues. The choroid vasculature of the eye serves as the main blood supply to the metabolically active photoreceptors, and develops together with the retinal pigmented epithelium (RPE). Here, we describe a novel regulatory relationship between the RPE transcription factors Pax6 and Sox9 that controls the timing of RPE differentiation and the adjacent choroid maturation. We used a novel machine learning algorithm tool to analyze high resolution imaging of the choroid in Pax6 and Sox9 conditional mutant mice. Additional unbiased transcriptomic analyses in mutant mice and RPE cells generated from human embryonic stem cells, as well as chromatin immunoprecipitation and high-throughput analyses, revealed secreted factors that are regulated by Pax6 and Sox9. These factors might be involved in choroid development and in the pathogenesis of the common blinding disease: age-related macular degeneration (AMD).
C1 [Cohen-Tayar, Yamit; Abravanel, Zohar; Levy, Carmit; Raviv, Shaul; Elkon, Ran; Ashery-Padan, Ruth] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.
   [Cohen, Hadar] Tel Aviv Univ, Raymond & Beverly Sackler Sch Phys & Astron, Dept Particle Phys, IL-69978 Tel Aviv, Israel.
   [Mitiagin, Yulia; Blinder, Pablo] Tel Aviv Univ, Biochem & Biophys Sch, Dept Neurobiol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.
   [Idelson, Masha; Reubinoff, Benjamin] Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, Hadassah Human Embryon Stem Cell Res Ctr, IL-9112001 Jerusalem, Israel.
   [Idelson, Masha; Reubinoff, Benjamin] Hadassah Hebrew Univ Med Ctr, Dept Obstet & Gynecol, IL-9112001 Jerusalem, Israel.
   [Itzkovitz, Shalev] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
   [Kaestner, Klaus H.] Univ Penn, Dept Genet, Perelman Sch Med, Smilow Ctr Translat Res 12 126, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
   [Blinder, Pablo; Elkon, Ran; Ashery-Padan, Ruth] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Tel Aviv University; Hebrew University of Jerusalem; Hebrew University
   of Jerusalem; Weizmann Institute of Science; University of Pennsylvania;
   Pennsylvania Medicine; Tel Aviv University
RP Elkon, R; Ashery-Padan, R (通讯作者)，Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.; Elkon, R; Ashery-Padan, R (通讯作者)，Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.
EM ruthash@post.tau.ac.il; ranel@tauex.tau.ac.il
RI Blinder, Pablo/AAX-7980-2020; Blinder, Pablo/GQI-2237-2022
OI Blinder, Pablo/0000-0002-4042-214X; Reubinoff,
   Benjamin/0000-0003-0353-1299
FU Israel Science Foundation [228/14, 1019/15]; Israel National Center for
   Personalized Medicine (INCPM) Israel Science Foundation [2246/16];
   Israel Science Foundation-National Natural Science Foundation of China
   [2469/16]; United States-Israel Binational Science Foundation [2013016];
   Claire and Amedee Maratier Institute for the Study of Blindness and
   Visual Disorders, Sackler Faculty of Medicine, Tel-Aviv University,
   Israel
FX Research in the R.A.-P. laboratory is supported by grants from the
   Israel Science Foundation [228/14], the Israel National Center for
   Personalized Medicine (INCPM) Israel Science Foundation [2246/16], the
   Israel Science Foundation-National Natural Science Foundation of China
   joint research program [2469/16], and the United States-Israel
   Binational Science Foundation [2013016]. P.B. is supported by the Israel
   Science Foundation [1019/15] and by a grant from the Claire and Amedee
   Maratier Institute for the Study of Blindness and Visual Disorders,
   Sackler Faculty of Medicine, Tel-Aviv University, Israel.
CR Ahmad Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144597
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Amram B, 2017, INT J DEV BIOL, V61, P225, DOI 10.1387/ijdb.160393ra
   ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408
   Ashery-Padan R, 2000, GENE DEV, V14, P2701, DOI 10.1101/gad.184000
   Babapoor-Farrokhran S, 2015, P NATL ACAD SCI USA, V112, pE3030, DOI 10.1073/pnas.1423765112
   Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611
   Bailey TL, 2011, BIOINFORMATICS, V27, P1653, DOI 10.1093/bioinformatics/btr261
   Baumer N, 2003, DEVELOPMENT, V130, P2903, DOI 10.1242/dev.00450
   Bhandari RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043380
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bramswig NC, 2013, J CLIN INVEST, V123, P1275, DOI 10.1172/JCI66514
   Carpenter A.C., 2015, WNT LIGANDS EMBRYONI
   COOK J, 2013, INVEST OPHTH VIS SCI, V54
   Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405
   Davis N, 2009, DEV BIOL, V333, P132, DOI 10.1016/j.ydbio.2009.06.023
   Defoe DM, 2003, GENE EXPR PATTERNS, V3, P615, DOI 10.1016/S1567-133X(03)00120-0
   DWORK AJ, 1990, INVEST OPHTH VIS SCI, V31, P489
   Eshkar-Oren I, 2009, DEVELOPMENT, V136, P1263, DOI 10.1242/dev.034199
   Freund Y., 1996, Machine Learning. Proceedings of the Thirteenth International Conference (ICML '96), P148
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   Goodwin AM, 2007, MICROVASC RES, V74, P172, DOI 10.1016/j.mvr.2007.05.006
   Goto S, 2018, ELIFE, V7, DOI 10.7554/eLife.32358
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hagglund AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081158
   Hart AW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054173
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900
   Hingorani M, 2012, EUR J HUM GENET, V20, P1011, DOI 10.1038/ejhg.2012.100
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kadaja M, 2014, GENE DEV, V28, P328, DOI 10.1101/gad.233247.113
   Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101
   Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793
   Klimova L, 2014, DEVELOPMENT, V141, P1292, DOI 10.1242/dev.098822
   Kondoh H, 2010, INT J BIOCHEM CELL B, V42, P391, DOI 10.1016/j.biocel.2009.09.003
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kurihara T, 2016, PROG BRAIN RES, V225, P201, DOI 10.1016/bs.pbr.2016.03.006
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lee HJ, 2013, SEMIN OPHTHALMOL, V28, P306, DOI 10.3109/08820538.2013.825293
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Lyubimova A, 2013, NAT PROTOC, V8, P1743, DOI 10.1038/nprot.2013.109
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Masuda T, 2014, J BIOL CHEM, V289, P12908, DOI 10.1074/jbc.M114.556738
   Masuda T, 2010, J BIOL CHEM, V285, P26933, DOI 10.1074/jbc.M110.130294
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Matsushima D, 2011, DEVELOPMENT, V138, P443, DOI 10.1242/dev.055178
   Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359
   MIRZAYANS F, 1995, AM J HUM GENET, V57, P539
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nunes Raquel J, 2013, J Biol Chem, V288, P31752, DOI 10.1074/jbc.M113.469858
   Oh CD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010113
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Oron-Karni V, 2008, DEVELOPMENT, V135, P4037, DOI 10.1242/dev.028308
   Philips GT, 2005, DEV BIOL, V279, P308, DOI 10.1016/j.ydbio.2004.12.018
   Poche RA, 2008, J COMP NEUROL, V510, P237, DOI 10.1002/cne.21746
   Raviv S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004360
   Remez LA, 2017, DEV BIOL, V432, P140, DOI 10.1016/j.ydbio.2017.09.030
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Sailaja BS, 2012, METHODS MOL BIOL, V809, P353, DOI 10.1007/978-1-61779-376-9_24
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   SELLHEYER K, 1990, EYE, V4, P255, DOI 10.1038/eye.1990.37
   Shaham O, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003357
   Shaham O, 2009, DEVELOPMENT, V136, P2567, DOI 10.1242/dev.032888
   Shi ZC, 2015, NUCLEIC ACIDS RES, V43, P6257, DOI 10.1093/nar/gkv568
   Smith AN, 2009, DEVELOPMENT, V136, P2977, DOI 10.1242/dev.037341
   Sodhi A, 2015, JAMA OPHTHALMOL, V133, P1375, DOI 10.1001/jamaophthalmol.2015.3723
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swisa A, 2017, J CLIN INVEST, V127, P230, DOI 10.1172/JCI88015
   Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519
   Therhaag J, 2012, AIP CONF PROC, V1504, P1013, DOI 10.1063/1.4771869
   TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6
   Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wang Q, 2001, Ophthalmic Genet, V22, P133, DOI 10.1076/opge.22.3.133.2224
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao SL, 2001, MOL VIS, V7, P277
   Zhou YH, 2010, J NEURO-ONCOL, V96, P191, DOI 10.1007/s11060-009-9963-8
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
   ZURDEL J, 2002, INVEST OPHTH VIS S1, V43
NR 92
TC 9
Z9 10
U1 0
U2 6
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0950-1991
EI 1477-9129
J9 DEVELOPMENT
JI Development
PD AUG
PY 2018
VL 145
IS 15
AR dev163691
DI 10.1242/dev.163691
PG 13
WC Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology
GA GS3JU
UT WOS:000443498200007
PM 29986868
OA hybrid
DA 2022-11-30
ER

PT J
AU Sivertsen, MS
   Jorstad, OK
   Grevys, A
   Foss, S
   Moe, MC
   Andersen, JT
AF Sivertsen, Magne Sand
   Jorstad, Oystein Kalsnes
   Grevys, Algirdas
   Foss, Stian
   Moe, Morten Carstens
   Andersen, Jan Terje
TI Pharmaceutical compounding of aflibercept in prefilled syringes does not
   affect structural integrity, stability or VEGF and Fc binding properties
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL INJECTION;
   ZIV-AFLIBERCEPT; METHIONINE OXIDATION; BEVACIZUMAB; RANIBIZUMAB; AGE;
   ENDOPHTHALMITIS; RECEPTOR
AB Macular edema due to neovascular age-related macular degeneration, diabetes or retinal vein occlusion can cause central vision loss. Intravitreal treatment with antibody-based biopharmaceutical compounds designed to neutralize vascular endothelial growth factor (VEGF) has proven to be an efficient strategy to ameliorate macular edema and restore visual acuity. At the same time, the use of anti-VEGF drugs places an economic burden on the health care system; the drugs are expensive, and repeated injections are usually required to maintain the therapeutic effect. Thus, there is an unmet need for more cost-effective procedures. We here describe how the most recently approved anti-VEGF drug, aflibercept, can be compounded into prefilled sterile syringes and stored for up to 4 weeks without compromising its quality, stability or functional properties, including VEGF and neonatal Fc receptor (FcRn) binding. The novel compounding method for repackaging of aflibercept in sterile plastic syringes can greatly reduce both cost and time spent per patient in the injection room.
C1 [Sivertsen, Magne Sand; Jorstad, Oystein Kalsnes; Moe, Morten Carstens] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Sivertsen, Magne Sand; Jorstad, Oystein Kalsnes; Grevys, Algirdas; Foss, Stian; Moe, Morten Carstens; Andersen, Jan Terje] Univ Oslo, Oslo, Norway.
   [Grevys, Algirdas; Foss, Stian; Andersen, Jan Terje] Oslo Univ Hosp, CIR, Oslo, Norway.
   [Grevys, Algirdas; Foss, Stian; Andersen, Jan Terje] Oslo Univ Hosp, Dept Immunol, Oslo, Norway.
   [Grevys, Algirdas; Foss, Stian; Andersen, Jan Terje] Univ Oslo, Dept Biosci, Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; University of Oslo
RP Sivertsen, MS (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
EM UXMASW@ous-hf.no
RI Andersen, Jan Terje/AAB-6209-2020
OI Foss, Stian/0000-0001-6527-051X; Grevys, Algirdas/0000-0001-7350-5841;
   Andersen, Jan Terje/0000-0003-1710-1628
FU South-Eastern Norway Regional Health Authority; Research Council of
   Norway through its Centres of Excellence funding scheme [179573];
   Research Council of Norway [230526/F20, 179573/V40, 251037/F20]
FX The authors would like to thank Dag Fossum, Head of Sterile Production
   and his team at the Hospital Pharmacy Unit, Oslo University Hospital,
   Ulleval, for the excellent collaboration in the continuous development
   and quality control of the compounding procedure. The work is supported
   by innovation grants from the South-Eastern Norway Regional Health
   Authority. J.T.A. was in part supported by the Research Council of
   Norway through its Centres of Excellence funding scheme (project number
   179573) and the Research Council of Norway (Grant no. 230526/F20 and
   179573/V40). S.F. was supported by the Research Council of Norway
   (251037/F20).
CR Andersen JT, 2008, FEBS J, V275, P4097, DOI 10.1111/j.1742-4658.2008.06551.x
   Baker CW, 2016, CURR OPIN OPHTHALMOL, V27, P210, DOI 10.1097/ICU.0000000000000262
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Braimah I. Z., 2017, BRIT J OPHTHALMOLOGY
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cao SJ, 2017, CAN J OPHTHALMOL, V52, P273, DOI 10.1016/j.jcjo.2016.11.012
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   de Andrade GC, 2016, RETINA-J RET VIT DIS, V36, P1640, DOI 10.1097/IAE.0000000000001000
   European Commission, 2008, RUL GOV MED PROD EUR, V4
   Gao X, 2015, J PHARM SCI-US, V104, P368, DOI 10.1002/jps.24136
   Grisanti S, 2010, OPHTHALMOLOGE, V107, P1123, DOI 10.1007/s00347-010-2299-0
   ISO, 2015, 146441 ISO
   Kim H, 2009, MOL VIS, V15
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Merani Rohan, 2015, Int J Retina Vitreous, V1, P9
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Oellers P, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S98853
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Paul M., 2012, Annales Pharmaceutiques Francaises, V70, P139, DOI 10.1016/j.pharma.2012.03.006
   Paulose R, 2016, CLIN OPHTHALMOL, V10, P1853, DOI 10.2147/OPTH.S116343
   Pereboom Marieke, 2015, Int J Pharm Compd, V19, P70
   Phasukkijwatana Nopasak, 2015, Journal of the Medical Association of Thailand, V98, P798
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Signorello L, 2014, CURR PHARM BIOTECHNO, V15, P113, DOI 10.2174/1389201015666140619120834
   Stracke J, 2014, MABS-AUSTIN, V6, P1229, DOI 10.4161/mabs.29601
   Subhi Y., 2016, DANISH MED J, V63
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Videkar Chetan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212988
   Ward ES, 2009, ADV IMMUNOL, V103, P77, DOI 10.1016/S0065-2776(09)03004-1
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Yannuzzi NA, 2015, JAMA OPHTHALMOL, V133, P32, DOI 10.1001/jamaophthalmol.2014.3591
NR 36
TC 22
Z9 24
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 1
PY 2018
VL 8
AR 2101
DI 10.1038/s41598-018-20525-8
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FU3YD
UT WOS:000423787500076
PM 29391560
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kurihara, T
   Westenskow, PD
   Gantner, ML
   Usui, Y
   Schultz, A
   Bravo, S
   Aguilar, E
   Wittgrove, C
   Friedlander, MSH
   Paris, LP
   Chew, E
   Siuzdak, G
   Friedlander, M
AF Kurihara, Toshihide
   Westenskow, Peter D.
   Gantner, Marin L.
   Usui, Yoshihiko
   Schultz, Andrew
   Bravo, Stephen
   Aguilar, Edith
   Wittgrove, Carli
   Friedlander, Mollie S. H.
   Paris, Liliana P.
   Chew, Emily
   Siuzdak, Gary
   Friedlander, Martin
TI Hypoxia-induced metabolic stress in retinal pigment epithelial cells is
   sufficient to induce photoreceptor degeneration
SO ELIFE
LA English
DT Article
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; LIPOFUSCIN FLUOROPHORE;
   MORPHOMETRIC-ANALYSIS; CHOROIDAL THICKNESS; GEOGRAPHIC ATROPHY;
   BLOOD-FLOW; FUNDUS AUTOFLUORESCENCE; HYDRAULIC CONDUCTIVITY;
   APOLIPOPROTEIN-E
AB Photoreceptors are the most numerous and metabolically demanding cells in the retina. Their primary nutrient source is the choriocapillaris, and both the choriocapillaris and photoreceptors require trophic and functional support from retinal pigment epithelium (RPE) cells. Defects in RPE, photoreceptors, and the choriocapillaris are characteristic of age-related macular degeneration (AMD), a common vision-threatening disease. RPE dysfunction or death is a primary event in AMD, but the combination(s) of cellular stresses that affect the function and survival of RPE are incompletely understood. Here, using mouse models in which hypoxia can be genetically triggered in RPE, we show that hypoxia-induced metabolic stress alone leads to photoreceptor atrophy. Glucose and lipid metabolism are radically altered in hypoxic RPE cells; these changes impact nutrient availability for the sensory retina and promote progressive photoreceptor degeneration. Understanding the molecular pathways that control these responses may provide important clues about AMD pathogenesis and inform future therapies.
C1 [Kurihara, Toshihide; Westenskow, Peter D.; Usui, Yoshihiko; Bravo, Stephen; Aguilar, Edith; Wittgrove, Carli; Friedlander, Mollie S. H.; Paris, Liliana P.; Friedlander, Martin] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA USA.
   [Westenskow, Peter D.; Gantner, Marin L.] Lowy Med Res Inst, La Jolla, CA USA.
   [Schultz, Andrew; Siuzdak, Gary] Scripps Res Inst, Ctr Metabol, La Jolla, CA USA.
   [Chew, Emily] NEI, NIH, Bethesda, MD 20892 USA.
   [Kurihara, Toshihide] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Usui, Yoshihiko] Tokyo Med Univ Hosp, Dept Ophthalmol, Shinjuku Ku, Tokyo, Japan.
C3 Scripps Research Institute; Scripps Research Institute; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Keio
   University; Tokyo Medical University
RP Friedlander, M (通讯作者)，Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA USA.
EM friedlan@scripps.edu
RI /AAD-1824-2020; Kurihara, Toshihide/ABA-7058-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; Qian,
   Mollie/0000-0001-7536-9054; Westenskow, Peter/0000-0001-9841-6220;
   Paris, Liliana/0000-0002-9312-9924; Siuzdak, Gary/0000-0002-4749-0014
FU National Eye Institute [EY11254]; Lowy Medical Research Institute MacTel
   Project; Manpei Suzuki Diabetes Foundation; Japan Society for the
   Promotion of Science Postdoctoral Fellowships for Research Abroad;
   National Eye Institute; NATIONAL EYE INSTITUTE [ZIAEY000489,
   R01EY011254, F32EY021416] Funding Source: NIH RePORTER
FX National Eye Institute EY11254 Martin Friedlander; The Lowy Medical
   Research Institute MacTel Project Martin Friedlander; Manpei Suzuki
   Diabetes Foundation Postdoctoral support Toshihide Kurihara; Japan
   Society for the Promotion of Science Postdoctoral Fellowships for
   Research Abroad Postdoctoral support Toshihide Kurihara; National Eye
   Institute Postdoctoral support Peter D Westenskow; The funders had no
   role in study design, data collection and interpretation, or the
   decision to submit the work for publication.
CR Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cao SJ, 2013, MOL VIS, V19, P718
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chertov AO, 2011, J BIOL CHEM, V286, P34700, DOI 10.1074/jbc.M111.279752
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Foulds WS, 1990, EYE 2, V4, pix, DOI [10.1038/eye.1990.34, DOI 10.1038/EYE.1990.34]
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Glunde K, 2008, CANCER RES, V68, P172, DOI 10.1158/0008-5472.CAN-07-2678
   Grassian AR, 2014, CANCER RES, V74, P3317, DOI 10.1158/0008-5472.CAN-14-0772-T
   Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Le YZ, 2010, J NEUROCHEM, V112, P1584, DOI 10.1111/j.1471-4159.2010.06573.x
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Linton JD, 2010, P NATL ACAD SCI USA, V107, P8599, DOI 10.1073/pnas.1002471107
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelo AM, 2015, J CLIN INVEST, V125, P1987, DOI 10.1172/JCI73665
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   MORGADO PB, 1994, OPHTHALMOLOGY, V101, P1220
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nayak BK, 2013, ONCOGENE, V32, P3147, DOI 10.1038/onc.2012.333
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Rinaldo P, 2008, GENET MED, V10, P151, DOI 10.1097/GIM.0b013e3181614289
   Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2
   Rogers JL, 2013, J MED CHEM, V56, P1739, DOI 10.1021/jm301847z
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Ryan HE, 2000, CANCER RES, V60, P4010
   SAGONE AL, 1973, BLOOD, V41, P845, DOI 10.1182/blood.V41.6.845.845
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Scheuermann TH, 2013, NAT CHEM BIOL, V9, P271, DOI [10.1038/nchembio.1185, 10.1038/NCHEMBIO.1185]
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tautenhahn R, 2012, NAT BIOTECHNOL, V30, P826, DOI 10.1038/nbt.2348
   Tautenhahn R, 2012, ANAL CHEM, V84, P5035, DOI 10.1021/ac300698c
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.565
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, p303e1, DOI 10.1016/j.ophtha.2009.07.014
NR 101
TC 114
Z9 117
U1 0
U2 12
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAR 15
PY 2016
VL 5
AR e14319
DI 10.7554/eLife.14319
PG 22
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA DK9DG
UT WOS:000375230100001
PM 26978795
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ichhpujani, P
   Ramasubramanian, A
   Kaushik, S
   Pandav, SS
AF Ichhpujani, Parul
   Ramasubramanian, Aparna
   Kaushik, Sushmita
   Pandav, Surinder S.
TI Bevacizumab in glaucoma: a review
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
DE angiogenesis; bevacizumab; glaucoma; neovascularization; vascular
   endothelial growth factor (VEGF)
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; COHERENCE
   TOMOGRAPHY FINDINGS; INTRAVITREAL BEVACIZUMAB; NEOVASCULAR GLAUCOMA;
   IRIS NEOVASCULARIZATION; CORNEAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; VITREOUS LEVELS; INJECTION
AB Recent research has shown that a large number of growth factors are responsible for neovascularization. Vascular endothelial growth factor has been identified as playing a key role in ocular angiogenesis. Bevacizumab, a humanized monoclonal antibody that binds to all isoforms of vascular endothelial growth factor, has shown promising results in regression of neovascularization. The use of bevacizumab has been reported extensively in various retinal pathologies, including proliferative diabetic retinopathy, cystoid macular edema, neovascular age-related macular degeneration, and neovascular glaucoma, but the clinical use in glaucoma is not yet clear. Glaucoma filtering surgery entails fashioning an external filter for aqueous drainage, and a prerequisite to its optimum functioning is a patent filtering bleb. Since fibroblast function and growth of new vessels is a component of healing of the bleb, there have been attempts to retard this healing by the use of bevacizumab. This article reviews current clinical studies documenting the use of bevacizumab in glaucoma.
C1 Adv Eye Ctr, Postgrad Inst Med Educ & Res, Chandigarh, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh
RP Kaushik, S (通讯作者)，Adv Eye Ctr, Postgrad Inst Med Educ & Res, Chandigarh, India.
EM sushmita_kaushik@yahoo.com
RI Ramasubramanian, Aparna/AAB-1840-2019; Kaushik, Sushmita/AAE-3806-2019;
   Ichhpujani, Parul/AAF-3562-2020
OI Kaushik, Sushmita/0000-0002-9175-5497; Ichhpujani,
   Parul/0000-0001-6256-4002
CR Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   FernandezVigo J, 1997, ACTA OPHTHALMOL SCAN, V75, P89
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Grisanti S, 2006, AM J OPHTHALMOL, V142, P158, DOI 10.1016/j.ajo.2006.02.045
   HANNEKEN A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1005, DOI 10.1001/archopht.1991.01080070117048
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iliev ME, 2006, AM J OPHTHALMOL, V142, P1054, DOI 10.1016/j.ajo.2006.06.066
   Jin J, 2003, CORNEA, V22, P473, DOI 10.1097/00003226-200307000-00015
   Jonas JB, 2007, OPHTHAL RES, V39, P121, DOI 10.1159/000099248
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P148, DOI 10.3928/1542-8877-20060301-12
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P144, DOI 10.3928/1542-8877-20060301-11
   Lee LC, 2000, PRENATAL DIAG, V20, P738, DOI 10.1002/1097-0223(200009)20:9<738::AID-PD917>3.0.CO;2-R
   Loughnan MS, 1996, AUST NZ J OPHTHALMOL, V24, P289, DOI 10.1111/j.1442-9071.1996.tb01596.x
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P839, DOI 10.1097/01.iae.0000230425.31296.3b
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   Michaelson I.C, 1954, BRIT J OPHTHALMOL, V38, P441, DOI [10.1136/bjo.38.7.441, DOI 10.1136/BJO.38.7.441]
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   PATEL B, 1994, BRIT J OPHTHALMOL, V78, P714, DOI 10.1136/bjo.78.9.714
   Paula JS, 2006, ACTA OPHTHALMOL SCAN, V84, P556, DOI 10.1111/j.1600-0420.2006.00721.x
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Senger DR, 1996, AM J PATHOL, V149, P293
   Sivak-Callcott JA, 2001, OPHTHALMOLOGY, V108, P1767, DOI 10.1016/S0161-6420(01)00775-8
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Vatavuk Z, 2007, EUR J OPHTHALMOL, V17, P269, DOI 10.1177/112067210701700220
NR 32
TC 15
Z9 20
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2007
VL 42
IS 6
BP 812
EP 815
DI 10.3129/i07-160
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 241MJ
UT WOS:000251660200005
PM 18026201
DA 2022-11-30
ER

PT J
AU Surace, EM
   Balaggan, KS
   Tessitore, A
   Mussolino, C
   Cotugno, G
   Bonetti, C
   Vitale, A
   Ali, RR
   Auricchio, A
AF Surace, EM
   Balaggan, KS
   Tessitore, A
   Mussolino, C
   Cotugno, G
   Bonetti, C
   Vitale, A
   Ali, RR
   Auricchio, A
TI Inhibition of ocular neovascularization by hedgehog blockade
SO MOLECULAR THERAPY
LA English
DT Article
DE neovascularization; sonic hedgehog; ROP; CNV; cyclopamine
ID SONIC-HEDGEHOG; GROWTH-FACTORS; PATHWAY; EXPRESSION; CANCER;
   ANGIOGENESIS; RETINOPATHY; RETINA; SYSTEM; MOUSE
AB Ocular neovascularization associated with proliferative diabetic retinopathy and age-related macular degeneration is the leading cause of severe visual loss in adults in developed countries. Physiological and pathological retinal angiogenesis may occur independently in postnatal life through the complex activation of pro- and antiangiogenic pathways. We report that the Sonic hedgehog (Shh) pathway is activated in the retina in animal models of retinal and choroidal neovascularization. We show that pharmacological inhibition of the Shh signaling pathway significantly reduces physiological retinal angiogenesis and inhibits pathological vascularization in both models. Under retinal hypoxic conditions, inhibition of the Shh pathway results in reduction of vascular endothelial growth factor (VEGF) level, along with that of Patched-1 (Ptch1), a canonical Shh target, thus placing Shh activation upstream of VEGF in experimental retinal neovascularization. Our data demonstrate the requirement of the Shh pathway for retinal angiogenesis and its inhibition as a potential therapeutic strategy targeting ocular neovascular disease.
C1 Inst Ophthalmol, Div Mol Therapy, London, England.
   Univ Naples Federico II, Dept Pediat, Naples, Italy.
   SEMM, European Sch Mol Med, Naples, Italy.
C3 University of London; University College London; University of Naples
   Federico II
RP Auricchio, A (通讯作者)，Telethon Inst Genet & Med, Via P Castellino 111, I-80131 Naples, Italy.
EM auricchio@tigem.it
RI Cotugno, Gabriella/GYA-2858-2022; AURICCHIO, Alberto/AHE-7979-2022
OI AURICCHIO, Alberto/0000-0002-0832-2472; Surace, Enrico
   Maria/0000-0002-2975-942X; Ali, Robin/0000-0003-3126-6517
FU NEI NIH HHS [P04 1R01EY015136-01] Funding Source: Medline; Telethon
   [TGM06B01, TGM06S01] Funding Source: Medline; Fondazione Telethon
   Funding Source: Custom; NATIONAL EYE INSTITUTE [R01EY015136] Funding
   Source: NIH RePORTER
CR Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733
   Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972
   BRESSLER NM, 2001, RETINA
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302
   Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603
   DAVIS MDB, 2001, RETINA
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229
   Fruttiger M, 1996, NEURON, V17, P1117, DOI 10.1016/S0896-6273(00)80244-5
   Jensen AM, 1997, DEVELOPMENT, V124, P363
   Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200
   Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962
   Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3
   Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020
   Ming JE, 1998, MOL MED TODAY, V4, P343, DOI 10.1016/S1357-4310(98)01299-4
   Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083
   Pola R, 2003, CIRCULATION, V108, P479, DOI 10.1161/01.CIR.0000080338.60981.FA
   Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 2002, ACTA PAEDIATR, V91, P26, DOI 10.1080/08035250260095771
   Takabatake T, 1997, FEBS LETT, V410, P485, DOI 10.1016/S0014-5793(97)00645-5
   Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009
   Tiveron MC, 1996, J NEUROSCI, V16, P7649
   Tripodi M, 2004, DEVELOPMENT, V131, P6119, DOI 10.1242/dev.01530
   Wallace VA, 1999, DEVELOPMENT, V126, P2901
   Wang YP, 2002, NAT NEUROSCI, V5, P831, DOI 10.1038/nn911
   Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
NR 31
TC 41
Z9 45
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD MAR
PY 2006
VL 13
IS 3
BP 573
EP 579
DI 10.1016/j.ymthe.2005.10.010
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 027VX
UT WOS:000236445000013
PM 16343995
OA hybrid
DA 2022-11-30
ER

PT J
AU Ju, YH
   Dai, XC
   Tang, ZM
   Ming, ZZ
   Ni, N
   Zhu, DQ
   Zhang, J
   Ma, B
   Wang, JJ
   Huang, R
   Zhao, SY
   Pang, Y
   Gu, P
AF Ju, Yahan
   Dai, Xiaochan
   Tang, Zhimin
   Ming, Zunzhen
   Ni, Ni
   Zhu, Dongqing
   Zhang, Jing
   Ma, Bo
   Wang, Jiajing
   Huang, Rui
   Zhao, Siyu
   Pang, Yan
   Gu, Ping
TI Verteporfin-mediated on/off photoswitching functions synergistically to
   treat choroidal vascular diseases
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Pathological neovascularization; Photodynamic therapy; Bio-responsive
   release; In situ drug delivery
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; NEOVASCULARIZATION;
   ANGIOGENESIS; RANIBIZUMAB; SAFETY; MMP-2; VASCULOPATHY; MECHANISMS;
   EFFICACY
AB Choroidal vascular diseases, such as age-related macular degeneration, are the leading cause of vision impairment and are characterized by pathological angiogenesis. Verteporfin-mediated photodynamic therapy is a current strategy that selectively occludes choroidal neovasculature. However, the clinically used large-dose systemic administration increases the risk of systemic adverse events, such as phototoxicity to superficial tissues. In this study, we developed an in situ verteporfin delivery system with a photoswitching synergistic function that disassembles in response to intraocular inflammatory enzymes. Under light-on conditions, verteporfin-mediated photodynamic therapy effectively occurs and this leads to vascular occlusion. Under light-off conditions, non-photoactive verteporfin negatively regulates vascular endothelial growth factor-induced angiogenesis as a yes-associated protein inhibitor. Taken together, our system serves as an intraocular verteporfin reservoir to improve the bioavailability of verteporfin by innovatively exploiting its photochemical and biological functions. This work provides a promising strategy with synergistic antiangiogenic effects for the treatment of choroidal vascular diseases.
C1 [Ju, Yahan; Dai, Xiaochan; Tang, Zhimin; Ni, Ni; Zhu, Dongqing; Zhang, Jing; Ma, Bo; Wang, Jiajing; Huang, Rui; Zhao, Siyu; Pang, Yan; Gu, Ping] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Ophthalmol, Sch Med, Shanghai 200011, Peoples R China.
   [Ju, Yahan; Dai, Xiaochan; Tang, Zhimin; Ni, Ni; Zhu, Dongqing; Zhang, Jing; Ma, Bo; Wang, Jiajing; Huang, Rui; Zhao, Siyu; Pang, Yan; Gu, Ping] Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai 200011, Peoples R China.
   [Ming, Zunzhen] Tongji Univ, Shanghai Peoples Hosp 10, Cent Lab, Shanghai 200072, Peoples R China.
C3 Shanghai Jiao Tong University; Tongji University
RP Pang, Y; Gu, P (通讯作者)，639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM yanpang@shsmu.edu.cn; guping2009@126.com
OI Ming, Zunzhen/0000-0002-9837-2675
FU National Natural Science Foundation of China [81870687, 82071004,
   32000972]; National Key R&D program of China [2018YFC1106100]; Key
   program of Shanghai Science and Technology Commission [19JC1415503];
   Municipal Education Commission-Gaofeng Clinical Medicine Grant Support
   [20161316, 20191820]; Cross-disciplinary Research Fund of Shanghai Ninth
   People's Hospital, Shanghai Jiao Tong University School of Medicine
   [JYJC201907]; Science and Technology Commission of Shanghai
   [20DZ2270800]
FX This work was supported by the National Natural Science Foundation of
   China (81870687, 82071004, 32000972) , the National Key R&D program of
   China (2018YFC1106100) , the Key program of Shanghai Science and
   Technology Commission (19JC1415503) , and the Munic-ipal Education
   Commission-Gaofeng Clinical Medicine Grant Support (20161316, 20191820)
   , Cross-disciplinary Research Fund of Shanghai Ninth People's Hospital,
   Shanghai Jiao Tong University School of Medicine (No. JYJC201907) and
   Science and Technology Commission of Shanghai (20DZ2270800) .
CR Agrawal R, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2020.100829
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Azad T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03278-w
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Baranowski P, 2014, SCI WORLD J, DOI 10.1155/2014/861904
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brinks J, 2022, PROG RETIN EYE RES, V87, DOI 10.1016/j.preteyeres.2021.100994
   Campochiaro PA, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100921
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Choi HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7943
   Cooper RC, 2019, J CONTROL RELEASE, V306, P29, DOI 10.1016/j.jconrel.2019.05.034
   Dey A, 2020, NAT REV DRUG DISCOV, V19, P480, DOI 10.1038/s41573-020-0070-z
   Dubrac A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05926-7
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   Ghasemi H, 2018, OCUL IMMUNOL INFLAMM, V26, P37, DOI 10.1080/09273948.2016.1277247
   Gibault F, 2016, CURR MED CHEM, V23, P1171, DOI 10.2174/0929867323666160316125048
   He JL, 2018, CIRC RES, V122, P591, DOI 10.1161/CIRCRESAHA.117.311950
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Jackson CJ, 1997, INT J BIOCHEM CELL B, V29, P1167, DOI 10.1016/S1357-2725(97)00061-7
   Ju YH, 2022, BRIT J PHARMACOL, V179, P1938, DOI 10.1111/bph.15303
   Kim J, 2017, J CLIN INVEST, V127, P3447, DOI 10.1172/JCI93825
   Kirchhof S, 2015, EUR J PHARM BIOPHARM, V95, P227, DOI 10.1016/j.ejpb.2015.05.016
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kokavec J, 2016, CLIN EXP OPHTHALMOL, V44, P597, DOI 10.1111/ceo.12732
   Kurzepa J, 2014, HEPATOB PANCREAT DIS, V13, P570, DOI 10.1016/S1499-3872(14)60261-7
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lynch CR, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00228
   Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829
   Mansoor Naima, 2019, Curr Mol Med, V19, P705, DOI 10.2174/1566524019666190828150625
   Misra JR, 2018, ANNU REV GENET, V52, P65, DOI 10.1146/annurev-genet-120417-031621
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580-018-0086-y
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Parodi MB, 2016, DEV OPHTHALMOL, V55, P330, DOI 10.1159/000434704
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Pulkkinen HH, 2021, ANGIOGENESIS, V24, P129, DOI 10.1007/s10456-020-09748-4
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schnurrbusch UEK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1347, DOI 10.1001/archopht.123.10.1347
   Shah SR, 2019, MOL PHARMACEUT, V16, P1433, DOI 10.1021/acs.molpharmaceut.8b00959
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tang Z., SMALL METHODS, V5
   Tang ZM, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101971
   Tian Y, 2021, NAT BIOMED ENG, V5, P968, DOI 10.1038/s41551-021-00764-3
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
   Wang XH, 2017, DEV CELL, V42, P462, DOI 10.1016/j.devcel.2017.08.002
   Wang Y, 2016, J CANCER RES CLIN, V142, P813, DOI 10.1007/s00432-015-2066-3
   Wei CR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.557429
   Wei HL, 2017, CANCER SCI, V108, P478, DOI 10.1111/cas.13138
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yu LY, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg2106
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
   Zhu XL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.649581
NR 61
TC 1
Z9 1
U1 6
U2 11
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGCHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2452-199X
J9 BIOACT MATER
JI Bioact. Mater.
PD AUG
PY 2022
VL 14
BP 402
EP 415
DI 10.1016/j.bioactmat.2022.01.028
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 0V9LZ
UT WOS:000788661800002
PM 35386820
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zacks, DN
   Kocab, AJ
   Choi, JJ
   Gregory-Ksander, MS
   Cano, M
   Handa, JT
AF Zacks, David N.
   Kocab, Andrew J.
   Choi, Joanne J.
   Gregory-Ksander, Meredith S.
   Cano, Marisol
   Handa, James T.
TI Cell Death in AMD: The Rationale for Targeting Fas
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE macular degeneration; apoptosis; necroptosis; Fas
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; INFLAMMASOME
   ACTIVATION; MOLECULAR-MECHANISMS; GEOGRAPHIC ATROPHY; OXIDATIVE STRESS;
   APOPTOSIS; PHOTORECEPTOR; INHIBITOR; PATHWAY
AB Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the developed world. While great advances have been made in the treatment of the neovascular ("wet") form of the disease, there is still a significant need for therapies that prevent the vision loss associated with the advanced forms of dry, atrophic AMD. In this atrophic form, retinal pigment epithelial (RPE) and photoreceptor cell death is the ultimate cause of vision loss. In this review, we summarize the cell death pathways and their relation to RPE and retinal cell death in AMD. We review the data that support targeting programmed cell death through inhibition of the Fas receptor as a novel approach to preserve these structures and that this effect results from inhibiting both canonical death pathway activation and reducing the associated inflammatory response. These data lay the groundwork for current clinical strategies targeting the Fas pathway in this devastating disease.
C1 [Zacks, David N.; Choi, Joanne J.] Univ Michigan, Dept Ophthalmol & Visual Sci, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
   [Kocab, Andrew J.] ONL Therapeut Inc, Ann Arbor, MI 48104 USA.
   [Gregory-Ksander, Meredith S.] Harvard Med Sch, Massachusetts Eye & Ear, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA.
   [Cano, Marisol; Handa, James T.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 University of Michigan System; University of Michigan; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   Schepens Eye Research Institute; Johns Hopkins University; Johns Hopkins
   Medicine
RP Zacks, DN (通讯作者)，Univ Michigan, Dept Ophthalmol & Visual Sci, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
EM davzacks@umich.edu; akocab@onltherapeutics.com; jochoi@med.wayne.edu;
   meredith_gregory@meei.harvard.edu; mcano1@jhmi.edu; jthanda@jhmi.edu
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Besirli CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046664
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Camelo S, 2016, OPHTHALMOLOGICA, V236, P53, DOI 10.1159/000446587
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3
   Cullen SP, 2013, MOL CELL, V49, P1034, DOI 10.1016/j.molcel.2013.01.025
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gregory MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017659
   Guegan JP, 2018, FEBS J, V285, P809, DOI 10.1111/febs.14292
   Hadian K, 2020, CELL, V181, P1188, DOI 10.1016/j.cell.2020.04.039
   Halawa OA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122580
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Huckfeldt Rachel M, 2013, Int Ophthalmol Clin, V53, P105, DOI 10.1097/IIO.0b013e31829cf08d
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jiang GM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0389-2
   Jiang SN, 2008, INVEST OPHTH VIS SCI, V49, P1345, DOI 10.1167/iovs.07-0308
   Ketelut-Carneiro N, 2022, J MOL BIOL, V434, DOI 10.1016/j.jmb.2021.167378
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Krishnan A, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1576-3
   Krishnan A, 2016, J IMMUNOL, V197, P4626, DOI 10.4049/jimmunol.1601488
   Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Mahmoudzadeh R, 2021, CURR OPIN OPHTHALMOL, V32, P294, DOI 10.1097/ICU.0000000000000746
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mouasni S, 2018, TRENDS IMMUNOL, V39, P1036, DOI 10.1016/j.it.2018.10.005
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Nielsen MK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.28
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pawar M, 2017, CELL DEATH DIFFER, V24, P1799, DOI 10.1038/cdd.2017.109
   Scholl HPN, 2021, OPHTHALMIC RES, V64, P888, DOI 10.1159/000517794
   Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vanden Berghe T, 2013, METHODS, V61, P117, DOI 10.1016/j.ymeth.2013.02.011
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Xiao JH, 2017, INVEST OPHTH VIS SCI, V58, P1801, DOI 10.1167/iovs.16-21392
   Yu HJ, 2021, BIODRUGS, V35, P303, DOI 10.1007/s40259-021-00481-y
   Zacks DN, 2007, ARCH OPHTHALMOL-CHIC, V125, P1389, DOI 10.1001/archopht.125.10.1389
   Zacks DN, 2004, INVEST OPHTH VIS SCI, V45, P4563, DOI 10.1167/iovs.04-0598
NR 57
TC 3
Z9 3
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2022
VL 11
IS 3
AR 592
DI 10.3390/jcm11030592
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YZ7JW
UT WOS:000755649600001
PM 35160044
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nakamura, Y
AF Nakamura, Yoshikazu
TI Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
SO CELLS
LA English
DT Review
DE fibroblast growth factor 2; RNA aptamer; age-related macular
   degeneration; achondroplasia; lung cancer; cancer pain
ID FIBROBLAST-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; MACULAR DEGENERATION;
   MONOCLONAL-ANTIBODIES; NATRIURETIC PEPTIDE; IN-VIVO; RANIBIZUMAB;
   FACTOR-2; RNA; ACHONDROPLASIA
AB Vascular endothelial growth factor (VEGF) plays a pivotal role in angiogenesis, but is not the only player with an angiogenic function. Fibroblast growth factor-2 (FGF2), which was discovered before VEGF, is also an angiogenic growth factor. It has been shown that FGF2 plays positive pathophysiological roles in tissue remodeling, bone health, and regeneration, such as the repair of neuronal damage, skin wound healing, joint protection, and the control of hypertension. Targeting FGF2 as a therapeutic tool in disease treatment through clinically useful inhibitors has not been developed until recently. An isolated inhibitory RNA aptamer against FGF2, named RBM-007, has followed an extensive preclinical study, with two clinical trials in phase 2 and phase 1, respectively, underway to assess the therapeutic impact in age-related macular degeneration (wet AMD) and achondroplasia (ACH), respectively. Moreover, showing broad therapeutic potential, preclinical evidence supports the use of RBM-007 in the treatment of lung cancer and cancer pain.
C1 [Nakamura, Yoshikazu] Univ Tokyo, Inst Med Sci, Div RNA Med Sci, Tokyo 1088639, Japan.
   [Nakamura, Yoshikazu] RIBOMIC Inc, Tokyo 1080071, Japan.
C3 University of Tokyo
RP Nakamura, Y (通讯作者)，Univ Tokyo, Inst Med Sci, Div RNA Med Sci, Tokyo 1088639, Japan.; Nakamura, Y (通讯作者)，RIBOMIC Inc, Tokyo 1080071, Japan.
EM nak@ims.u-tokyo.ac.jp
CR Ahmad I, 2012, BBA-MOL CELL RES, V1823, P850, DOI 10.1016/j.bbamcr.2012.01.004
   Belgore F, 2003, EUR J CLIN INVEST, V33, P833, DOI 10.1046/j.1365-2362.2003.01223.x
   Birsner AE, 2014, JOVE-J VIS EXP, DOI 10.3791/51375
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Cordeiro MF, 2003, GENE THER, V10, P59, DOI 10.1038/sj.gt.3301865
   Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P1975
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Desai A, 2016, J THORAC ONCOL, V11, P9, DOI 10.1016/j.jtho.2015.08.003
   Dong ZY, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107775
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Eda H, 2008, BIOCHEM BIOPH RES CO, V366, P471, DOI 10.1016/j.bbrc.2007.11.140
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferhat L, 1997, EUR J NEUROSCI, V9, P1282, DOI 10.1111/j.1460-9568.1997.tb01483.x
   Gudernova I, 2016, HUM MOL GENET, V25, P9, DOI 10.1093/hmg/ddv441
   Hamamoto J, 2018, BIOCHEM BIOPH RES CO, V503, P1330, DOI 10.1016/j.bbrc.2018.07.044
   He LJ, 2010, J BIOL CHEM, V285, P30103, DOI 10.1074/jbc.M109.094086
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HORI A, 1991, CANCER RES, V51, P6180
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Itoh N, 2011, J BIOCHEM, V149, P121, DOI 10.1093/jb/mvq121
   Jin L, 2016, MOL THER, V24, P1974, DOI 10.1038/mt.2016.158
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kawaguchi H, 2001, J CLIN ENDOCR METAB, V86, P875, DOI 10.1210/jc.86.2.875
   Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kimura T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aba4226
   Komla-Ebri D, 2016, J CLIN INVEST, V126, P1871, DOI 10.1172/JCI83926
   Krejci P, 2009, HUM MUTAT, V30, P1245, DOI 10.1002/humu.21067
   Kuhn H, 2004, LUNG CANCER-J IASLC, V44, P167, DOI 10.1016/j.lungcan.2003.11.005
   Malabanan KP, 2008, CIRC RES, V103, P378, DOI 10.1161/CIRCRESAHA.107.168682
   Marie PJ, 2012, GROWTH FACTORS, V30, P117, DOI 10.3109/08977194.2012.656761
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsuda Y, 2019, MOL THER-NUCL ACIDS, V17, P819, DOI 10.1016/j.omtn.2019.07.018
   MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911
   Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P158, DOI 10.1006/bbrc.1999.1601
   Nakamura Y, 2018, BIOCHIMIE, V145, P22, DOI 10.1016/j.biochi.2017.10.006
   Nassar K, 2011, GRAEF ARCH CLIN EXP, V249, P1649, DOI 10.1007/s00417-011-1730-9
   Nomura Y, 2010, NUCLEIC ACIDS RES, V38, P7822, DOI 10.1093/nar/gkq615
   Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8
   Oladipupo SS, 2014, P NATL ACAD SCI USA, V111, P13379, DOI 10.1073/pnas.1324235111
   ORIOLI IM, 1986, J MED GENET, V23, P328, DOI 10.1136/jmg.23.4.328
   Ornitz DM, 2017, DEV DYNAM, V246, P291, DOI 10.1002/dvdy.24479
   Pejchalova K, 2007, MOL GENET METAB, V92, P210, DOI 10.1016/j.ymgme.2007.06.014
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Rege AA, 1999, GROWTH FACTORS, V16, P161, DOI 10.3109/08977199909002126
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Savarirayan R, 2019, NEW ENGL J MED, V381, P25, DOI 10.1056/NEJMoa1813446
   SCHULTZ G S, 1991, Eye (London), V5, P170
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x
   Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x
   Tomanek RJ, 2001, CIRC RES, V88, P1135, DOI 10.1161/hh1101.091191
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   Wang LH, 2012, MOL CANCER THER, V11, P864, DOI 10.1158/1535-7163.MCT-11-0813
   Wang LLX, 2003, ADV DRUG DELIVER REV, V55, P949, DOI 10.1016/S0169-409X(03)00098-X
   Wendt DJ, 2015, J PHARMACOL EXP THER, V353, P132, DOI 10.1124/jpet.114.218560
   Xue Y, 2014, MOL GENET GENOM MED, V2, P497, DOI 10.1002/mgg3.96
   Yorifuji Tohru, 2018, Pediatr Endocrinol Rev, V16, P123, DOI 10.17458/per.vol16.2018.yhk.ghachondroplasia
NR 63
TC 2
Z9 3
U1 5
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUL
PY 2021
VL 10
IS 7
AR 1617
DI 10.3390/cells10071617
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA TN5XT
UT WOS:000676308000001
PM 34203430
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Aydindogan, G
   Kavakli, K
   Sahin, A
   Artal, P
   Urey, H
AF Aydindogan, Gunes
   Kavakli, Koray
   Sahin, Afsun
   Artal, Pablo
   Urey, Hakan
TI Applications of augmented reality in ophthalmology [Invited]
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Review
ID ADAPTIVE OPTICS SIMULATION; NEAR-EYE DISPLAY; MACULAR DEGENERATION;
   INTRAOCULAR LENSES; CONTOUR ENHANCEMENT; VISION IMPAIRMENT;
   IMAGE-ENHANCEMENT; VISUAL SIMULATOR; OLDER-ADULTS; GLAUCOMA
AB Throughout the last decade, augmented reality (AR) head-mounted displays (HMDs) have gradually become a substantial part of modern life, with increasing applications ranging from gaming and driver assistance to medical training. Owing to the tremendous progress in miniaturized displays, cameras, and sensors, HMDs are now used for the diagnosis, treatment, and follow-up of several eye diseases. In this review, we discuss the current state-of-the-art as well as potential uses of AR in ophthalmology. This review includes the following topics: (i) underlying optical technologies, displays and trackers, holography, and adaptive optics; (ii) accommodation, 3D vision, and related problems such as presbyopia, amblyopia, strabismus, and refractive errors; (iii) AR technologies in lens and corneal disorders, in particular cataract and keratoconus; (iv) AR technologies in retinal disorders including age-related macular degeneration (AMD), glaucoma, color blindness, and vision simulators developed for other types of low-vision patients. (c) 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Aydindogan, Gunes; Kavakli, Koray; Urey, Hakan] Koc Univ, Dept Elect Engn, TR-34450 Istanbul, Turkey.
   [Aydindogan, Gunes; Kavakli, Koray; Sahin, Afsun; Urey, Hakan] Koc Univ, Translat Med Res Ctr KUTTAM, TR-34450 Istanbul, Turkey.
   [Sahin, Afsun] Koc Univ, Sch Med, TR-34450 Istanbul, Turkey.
   [Artal, Pablo] Univ Murcia, Lab Opt, Inst Univ Invest Opt & Nanofis, Campus Espinardo, E-30100 Murcia, Spain.
C3 Koc University; Koc University; Koc University; University of Murcia
RP Urey, H (通讯作者)，Koc Univ, Dept Elect Engn, TR-34450 Istanbul, Turkey.; Urey, H (通讯作者)，Koc Univ, Translat Med Res Ctr KUTTAM, TR-34450 Istanbul, Turkey.
EM hurey@ku.edu.tr
RI Aydındoğan, Güneş/AAH-2293-2019; Artal, Pablo/AGV-7547-2022
OI Aydındoğan, Güneş/0000-0003-4354-633X; Artal, Pablo/0000-0003-1284-6591;
   Kavakli, Koray/0000-0003-4678-2522
FU European Research Council; Agencia Estatal de Investigacion
   [PID2019105684RB-I00]; Fundacion Seneca [19897/GERM/15]
FX European Research Council (acronym EYECAS, ERC-PoC); Agencia Estatal de
   Investigacion (PID2019105684RB-I00); Fundacion Seneca (19897/GERM/15).
CR Akondi V, 2017, BIOMED OPT EXPRESS, V8, P3410, DOI 10.1364/BOE.8.003410
   Allen D, 2006, BMJ-BRIT MED J, V333, P128, DOI 10.1136/bmj.333.7559.128
   Altangerel U, 2009, CAN J OPHTHALMOL, V44, P66, DOI 10.3129/i08-175
   Amirsolaimani B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14507-5
   Angelopoulos AN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47397-w
   [Anonymous], 2017, EUROPEAN TECHNOLOGY, V21
   Apfelbaum HL, 2008, OPHTHAL PHYSL OPT, V28, P204, DOI 10.1111/j.1475-1313.2008.00537.x
   Arias A, 2020, OPTICA, V7, P22, DOI 10.1364/OPTICA.7.000022
   Askarian B, 2019, 2019 IEEE HEALTHCARE INNOVATIONS AND POINT OF CARE TECHNOLOGIES (HI-POCT), P60, DOI 10.1109/HI-POCT45284.2019.8962648
   Ates Halim Cagri, 2015, P 9 INT C TANGIBLE E, P225
   Baerenrodt M., 2019, U.S. Patent, Patent No. [10,386,641, 10386641]
   Baerenrodt M., 2020, U.S. Patent, Patent No. [10,545,341, 10545341]
   Bakker NM, 2013, IEEE T BIO-MED ENG, V60, P3028, DOI 10.1109/TBME.2013.2246161
   Balyen L, 2019, ASIA-PAC J OPHTHALMO, V8, P264, DOI 10.22608/APO.2018479
   Barfield W., 2015, FUNDAMENTALS WEARABL
   Barrett JM, 2014, VISUAL NEUROSCI, V31, P345, DOI 10.1017/S0952523814000212
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   BIRCH J, 1973, VISION RES, V13, P1755, DOI 10.1016/0042-6989(73)90092-8
   Buck GA, 2016, ASTE SER SCI EDUC, P3, DOI 10.1007/978-3-319-32447-0_1
   Cakmakci O., 2005, PRESENT FUTURE HEAD
   Canovas C, 2010, OPT LETT, V35, P196, DOI 10.1364/OL.35.000196
   Carlton J, 2011, EYE, V25, P403, DOI 10.1038/eye.2011.4
   Carmigniani J, 2011, HANDBOOK OF AUGMENTED REALITY, P3, DOI 10.1007/978-1-4614-0064-6_1
   Carmigniani J, 2011, MULTIMED TOOLS APPL, V51, P341, DOI 10.1007/s11042-010-0660-6
   Chakravarthula P, 2018, IEEE T VIS COMPUT GR, V24, P2906, DOI 10.1109/TVCG.2018.2868532
   Chakravarthy U, 2017, OPHTHAL EPIDEMIOL, V24, P239, DOI 10.1080/09286586.2017.1281426
   Chen J., 2016, HDB VISUAL DISPLAY T
   Chen ZH, 2018, HEALTHC TECHNOL LETT, V5, P1, DOI 10.1049/htl.2016.0081
   Chen ZH, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/7692198
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Chow-Wing-Bom H, 2020, VISION RES, V169, P49, DOI 10.1016/j.visres.2019.10.012
   Claesson M, 2013, CORNEA, V32, P1026, DOI 10.1097/ICO.0b013e31828a2810
   Crabb DP, 2013, OPHTHALMOLOGY, V120, P1120, DOI 10.1016/j.ophtha.2012.11.043
   Dinet, 2014, CONTRIBUTION AUGMENT, P182
   Dodgson NA, 2004, PROC SPIE, V5291, P36, DOI 10.1117/12.529999
   Dorronsoro C, 2016, OPTICA, V3, P918, DOI 10.1364/OPTICA.3.000918
   Dunn D, 2017, IEEE T VIS COMPUT GR, V23, P1275, DOI 10.1109/TVCG.2017.2657058
   Eysenbach G, 2001, J MED INTERNET RES, V3, DOI 10.2196/jmir.3.2.e20
   Feldman A, 2005, NINTH IEEE INTERNATIONAL SYMPOSIUM ON WEARABLE COMPUTERS, PROCEEDINGS, P52, DOI 10.1109/ISWC.2005.44
   Fernandes PRB, 2013, OPTOMETRY VISION SCI, V90, P228, DOI 10.1097/OPX.0b013e318282951b
   Fernandez EJ, 2002, J REFRACT SURG, V18, pS634
   Fernandez EJ, 2001, OPT LETT, V26, P746, DOI 10.1364/OL.26.000746
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fuchs H., 2018, MITIGATING VERGENCE
   Geng JS, 2013, ADV OPT PHOTONICS, V5, P456, DOI 10.1364/AOP.5.000456
   Goncalves P, 2020, 2020 IEEE CONFERENCE ON VIRTUAL REALITY AND 3D USER INTERFACES WORKSHOPS (VRW 2020), P731, DOI [10.1109/VRW50115.2020.00-59, 10.1109/VRW50115.2020.00216]
   Guirao A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1143
   Han SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116626
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hicks SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067695
   Ho E, 2019, J VISION, V19, DOI 10.1167/19.13.22
   Hoffman DM, 2008, J VISION, V8, DOI 10.1167/8.3.33
   Holden BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1731, DOI 10.1001/archopht.126.12.1731
   Huang J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210630
   Huang WW, 2017, 2017 4TH INTERNATIONAL CONFERENCE ON ELECTRICAL AND ELECTRONIC ENGINEERING (ICEEE 2017), P177, DOI 10.1109/ICEEE2.2017.7935815
   Hwang AD, 2014, OPTOMETRY VISION SCI, V91, P1021, DOI 10.1097/OPX.0000000000000326
   Ikeda S., 2017, MULTIMODAL TECHNOL I, V22, P1
   Itoh Y., 2015, P 6 AUGM HUM INT C, P1, DOI DOI 10.1145/2735711.2735787
   Jakl A, 2020, 2020 IEEE CONFERENCE ON VIRTUAL REALITY AND 3D USER INTERFACES (VR 2020), P195, DOI [10.1109/VR46266.2020.00-66, 10.1109/VR46266.2020.1581532258804]
   Jang HJ, 2019, J INFORM DISPLAY, V20, P1, DOI 10.1080/15980316.2019.1572662
   Jarosz J, 2019, OPT EXPRESS, V27, P10533, DOI 10.1364/OE.27.010533
   Jefferson L, 2007, CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, VOLS 1 AND 2, P1535
   Jones PR, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0242-6
   Kandel H, 2020, CORNEA, V39, P386, DOI 10.1097/ICO.0000000000002170
   Kazempourradi S, 2019, J INFORM DISPLAY, V20, P45, DOI 10.1080/15980316.2019.1606859
   Kim J, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.6.065004
   Kinateder M, 2018, OPTOMETRY VISION SCI, V95, P727, DOI 10.1097/OPX.0000000000001232
   Koulieris GA, 2017, ACM T GRAPHIC, V36, DOI 10.1145/3072959.3073622
   Kramida G, 2016, IEEE T VIS COMPUT GR, V22, P1912, DOI 10.1109/TVCG.2015.2473855
   Krosl K, 2020, INT SYM MIX AUGMENT, P682, DOI 10.1109/ISMAR50242.2020.00098
   Kwon M, 2012, OPTOMETRY VISION SCI, V89, P1374, DOI 10.1097/OPX.0b013e3182678e52
   Langlotz T, 2018, PROCEEDINGS OF THE 2018 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI 2018), DOI 10.1145/3173574.3173964
   Langlotz T, 2016, IEEE T VIS COMPUT GR, V22, P2385, DOI 10.1109/TVCG.2016.2593781
   Lewis M, 2002, COMMUN ACM, V45, P27
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Little B., 1989, AM J HUM BIOL, V1, P793
   Liu XG, 2019, POINT CARE, V18, P77, DOI 10.1097/POC.0000000000000191
   Lorach H, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.30
   Luo G, 2006, INVEST OPHTH VIS SCI, V47, P4152, DOI 10.1167/iovs.05-1672
   Luppa PB, 2016, BIOTECHNOL ADV, V34, P139, DOI 10.1016/j.biotechadv.2016.01.003
   Lyons SA, 2004, OPTOMETRY VISION SCI, V81, P233, DOI 10.1097/00006324-200404000-00008
   Maimone A, 2013, INT SYM MIX AUGMENT, P29, DOI 10.1109/ISMAR.2013.6671761
   Mansouri K, 2006, OPHTHALMOLOGICA, V220, P101, DOI 10.1159/000090574
   Manzanera S, 2007, OPT EXPRESS, V15, P16177, DOI 10.1364/OE.15.016177
   Marcos S, 2017, VISION RES, V132, P3, DOI 10.1016/j.visres.2017.01.006
   Martinez-Millana A, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16122142
   Mastrangelo, 2017, IMAGING APPL OPTICS
   Mastrangelo C., 2018, LIGHTWEIGHT SMART AU
   Merino-Gracia C., 2011, INT WORKSH CAM BAS D, P29, DOI DOI 10.1007/978-3-642-29364-1_3
   Miao Y, 2020, COMPUT METH PROG BIO, V185, DOI 10.1016/j.cmpb.2019.105132
   Milgram P., 1995, AUGMENTED REALITY CL
   MILLER D, 1973, ARCH OPHTHALMOL-CHIC, V90, P323
   Mitrasinovic S, 2015, TECHNOL HEALTH CARE, V23, P381, DOI 10.3233/THC-150910
   Model D, 2011, IEEE T BIO-MED ENG, V58, P103, DOI 10.1109/TBME.2010.2085000
   Mompean J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77465-5
   Mompean J, 2018, J SUPERCOMPUT, V74, P1836, DOI 10.1007/s11227-017-2193-5
   Moshtael H, 2020, BRIT J VISUAL IMPA, V38, P24, DOI 10.1177/0264619619889998
   Moshtael H, 2016, SMART INNOV SYST TEC, V60, P71, DOI 10.1007/978-3-319-39687-3_7
   Nesaratnam N, 2017, EYE, V31, P1503, DOI 10.1038/eye.2017.97
   Newell, 2002, INT C UN DES
   Nowak A, 2018, FED CONF COMPUT SCI, P279, DOI 10.15439/2018F335
   Padmanaban N, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav6187
   Palanker D, 2018, PHYS TODAY, V71, P26, DOI 10.1063/PT.3.3970
   Palanker DV, 2019, INVEST OPHTH VIS SCI, V60
   Park J.-H., 2017, FRONTIERS OPTICS 201
   Peli E, 2004, J OPT SOC AM A, V21, P937, DOI 10.1364/JOSAA.21.000937
   Peli E, 2001, OPTOMETRY VISION SCI, V78, P304, DOI 10.1097/00006324-200105000-00014
   Peli E, 1999, VISUAL IMPAIRMENT RE, V1, P3, DOI [10.1076/vimr.1.1.3.4449, DOI 10.1076/vimr.1.1.3.4449]
   Peli E., 2007, VISION MULTIPLEXING
   Peli E, 2007, J SOC INF DISPLAY, V15, P1037, DOI 10.1889/1.2825088
   Peli E, 2009, INT J ARTIF INTELL T, V18, P415, DOI 10.1142/S0218213009000214
   Peli E, 2009, INT J ARTIF INTELL T, V18, P365, DOI 10.1142/S0218213009000184
   Pfeiffer, 2013, VIRTUELLE ERWEITERTE
   Piers PA, 2004, INVEST OPHTH VIS SCI, V45, P4601, DOI 10.1167/iovs.04-0234
   Piers PA, 2007, J CATARACT REFR SURG, V33, P1721, DOI 10.1016/j.jcrs.2007.08.001
   Rabinowitz YS, 1998, SURV OPHTHALMOL, V42, P297, DOI 10.1016/S0039-6257(97)00119-7
   Rajagopalan AS, 2006, OPTOMETRY VISION SCI, V83, P611, DOI 10.1097/01.opx.0000232185.00091.45
   Reitmayr G., 2003, P 4 AUSTR US INT C U, P65
   Sainani A., 2013, J CLIN OPHTHALMOL RE, V1, P169
   Sajadi B, 2013, IEEE T VIS COMPUT GR, V19, P118, DOI 10.1109/TVCG.2012.93
   Satgunam P, 2012, OPTOMETRY VISION SCI, V89, pE1364, DOI 10.1097/OPX.0b013e318266f92f
   Schedin S, 2016, APPL OPTICS, V55, P507, DOI 10.1364/AO.55.000507
   Schwiegerling J., 2010, INT IND TRAIN SIM ED
   Sengillo JD, 2016, AM J MED GENET C, V172, P349, DOI 10.1002/ajmg.c.31534
   Shen WY, 2016, ACM T GRAPHIC, V35, DOI 10.1145/2897824.2925878
   Shu LY, 2020, AM J TRANSL RES, V12, P1
   Solebo AL, 2017, ARCH DIS CHILD, V102, P853, DOI 10.1136/archdischild-2016-310532
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020705
   Starner T, 1997, PRESENCE-TELEOP VIRT, V6, P386, DOI 10.1162/pres.1997.6.4.386
   Starner T., 2013, REV HEAD MOUNTED DIS
   Stearns L, 2018, ASSETS'18: PROCEEDINGS OF THE 20TH INTERNATIONAL ACM SIGACCESS CONFERENCE ON COMPUTERS AND ACCESSIBILITY, P28, DOI 10.1145/3234695.3236361
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Suchkov N, 2019, J OPT SOC AM A, V36, P722, DOI 10.1364/JOSAA.36.000722
   Sutton J, 2019, ADJUNCT PROCEEDINGS OF THE 2019 IEEE INTERNATIONAL SYMPOSIUM ON MIXED AND AUGMENTED REALITY (ISMAR-ADJUNCT 2019), P438, DOI 10.1109/ISMAR-Adjunct.2019.00050
   Tang FQ, 2019, OPT EXPRESS, V27, P28204, DOI 10.1364/OE.27.028204
   Tanuwidjaja E, 2014, UBICOMP'14: PROCEEDINGS OF THE 2014 ACM INTERNATIONAL JOINT CONFERENCE ON PERVASIVE AND UBIQUITOUS COMPUTING, P799, DOI 10.1145/2632048.2632091
   *TEDPR GROUP, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tong Y, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00183-6
   Troscianko, 1999, INT J VIRTUAL REALIT, V3, P1, DOI [10.20870/IJVR.1998.3.4.2629, DOI 10.20870/IJVR.1998.3.4.2629]
   Tur VM, 2017, SURV OPHTHALMOL, V62, P770, DOI 10.1016/j.survophthal.2017.06.009
   Ueno T, 2018, OPT EXPRESS, V26, P30703, DOI 10.1364/OE.26.030703
   Urey H., 2017, FAST COMPUTER GENERA
   van Rheede JJ, 2015, INVEST OPHTH VIS SCI, V56, P4802, DOI 10.1167/iovs.14-16311
   Vargas-Martin F, 1998, J OPT SOC AM A, V15, P2552, DOI 10.1364/JOSAA.15.002552
   Vargas-Martin F, 2002, OPTOMETRY VISION SCI, V79, P715, DOI 10.1097/00006324-200211000-00009
   Vashist S. K., 2017, POINT OF CARE DIAGNO
   Villegas EA, 2019, J REFRACT SURG, V35, P126, DOI 10.3928/1081597X-20181212-02
   Vinas M, 2019, BIOMED OPT EXPRESS, V10, P5801, DOI 10.1364/BOE.10.005801
   Wadbro E, 2016, APPL OPTICS, V55, P4378, DOI 10.1364/AO.55.004378
   Wahl Siegfried, 2019, Clin Ophthalmol, V13, P123, DOI 10.2147/OPTH.S188890
   Wittich W, 2018, OPTOMETRY VISION SCI, V95, P774, DOI 10.1097/OPX.0000000000001262
   Wolffsohn JS, 2007, AM J OPHTHALMOL, V144, P436, DOI 10.1016/j.ajo.2007.05.031
   Woods R. L., 2003, Journal of the Society for Information Display, V11, P191, DOI 10.1889/1.1831704
   Wu JY, 2020, OPT EXPRESS, V28, P6225, DOI 10.1364/OE.380945
   Wu YS, 2017, OPT EXPRESS, V25, P8937, DOI 10.1364/OE.25.008937
   Xia XX, 2019, IEEE T VIS COMPUT GR, V25, P3114, DOI 10.1109/TVCG.2019.2932238
   Yaras F, 2009, APPL OPTICS, V48, pH48, DOI 10.1364/AO.48.000H48
   Younis O, 2019, INT J ADV COMPUT SCI, V10, DOI [10.14569/IJACSA.2019.0100201, DOI 10.14569/IJACSA.2019.0100201]
   Zeng L, 2018, APPL OPTICS, V57, P7363, DOI 10.1364/AO.57.007363
   Zhai G, 2015, 2015 IEEE INT C MULT, P1, DOI [10.1109/ICMEW.2015.7169860, DOI 10.1109/ICMEW.2015.7169860]
   Zhao YH, 2016, UBICOMP'16: PROCEEDINGS OF THE 2016 ACM INTERNATIONAL JOINT CONFERENCE ON PERVASIVE AND UBIQUITOUS COMPUTING, P73, DOI 10.1145/2971648.2971730
   Zhao YH, 2015, ASSETS'15: PROCEEDINGS OF THE 17TH INTERNATIONAL ACM SIGACCESS CONFERENCE ON COMPUTERS & ACCESSIBILITY, P239, DOI 10.1145/2700648.2809865
NR 163
TC 15
Z9 15
U1 3
U2 22
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD JAN 1
PY 2021
VL 12
IS 1
BP 511
EP 538
DI 10.1364/BOE.405026
PG 28
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA PO1FM
UT WOS:000604916400002
PM 33659087
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gholami, P
   Roy, P
   Parthasarathy, MK
   Lakshminarayanan, V
AF Gholami, Peyman
   Roy, Priyanka
   Parthasarathy, Mohana Kuppuswamy
   Lakshminarayanan, Vasudevan
TI OCTID: Optical coherence tomography image database
SO COMPUTERS & ELECTRICAL ENGINEERING
LA English
DT Article
DE Optical coherence tomography; Image database; Image processing; Retinal
   disease; Retina; Macular hole; Age-related macular degeneration; Cenrtal
   serous retinopathy; Diabetic retinopathy; Segmentation
ID MACULAR DEGENERATION
AB Optical coherence tomography (OCT) is a non-invasive imaging modality that is widely used in clinical ophthalmology. OCT images are capable of visualizing deep retinal layers which is crucial for early diagnosis of retinal diseases. In this paper, we describe a comprehensive open-access database containing more than 500 high-resolution images categorized into different pathological conditions. The image classes include Normal (NO), Macular Hole (MH), Age-related Macular Degeneration (AMD), Central Serous Retinopathy (CSR), and Diabetic Retinopathy (DR). The images were obtained from a raster scan protocol with a 2 mm scan length and 512 x 1024 pixel resolution. We have also included 25 normal OCT images with their corresponding ground truth delineations which can be used for an accurate evaluation of OCT image segmentation. In addition, we have provided a user friendly GUI which can be used by clinicians for manual (and semi-automated) segmentation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gholami, Peyman; Roy, Priyanka; Parthasarathy, Mohana Kuppuswamy; Lakshminarayanan, Vasudevan] Univ Waterloo, Sch Optometry & Vis Sci, TEEL, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
C3 University of Waterloo
RP Gholami, P (通讯作者)，Univ Waterloo, Sch Optometry & Vis Sci, TEEL, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
EM pgholami@uwaterloo.ca
RI Kuppuswamy Parthasarathy, Mohana/GYD-5247-2022
OI Gholami, Peyman/0000-0003-0006-6774
FU NSERC; Schlumberger Foundation
FX The authors would like to acknowledge Sankara Nethralaya (SN) eye
   hospital, Chennai, India, and in particular Dr. Muna Bhende and Ms.
   Girija for providing the images and diagnosing pathological conditions.
   This research is supported by an NSERC discovery grant to VL MKP was
   supported by a Faculty for the Future fellowship from Schlumberger
   Foundation,
CR Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Carl Zeiss Meditec AG, 2018, CIRRUS HD OCT 5000 5
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Duker JS, 2014, HDB RETINAL OCT OPTI
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fineman M, 2018, RETINA COLOR ATLAS S
   Gholami P, 2018, P SOC PHOTO-OPT INS
   Gholami P, 2018, P SOC PHOTO-OPT INS
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Kagemann L, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772655
   Lakshminarayanan V., 2012, P SOC PHOTO-OPT INS, V8482
   Leopold HA, 2018, DEEP LEARNING METHOD, P329, DOI DOI 10.1201/9781351061223
   Mahmudi T., 2014, P SPIE MED BIOMEDICA, V9038, P15
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Schachar AP, 2017, RYANS RETINA
   Schuman J. S., 2013, OPTICAL COHERENCE TO, V3
   Schuman Joel S, 2008, Trans Am Ophthalmol Soc, V106, P426
   Sengupta S, 2020, ARTIF INTELL MED, V102, DOI 10.1016/j.artmed.2019.101758
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Yazdanfar S, 2003, ARCH OPHTHALMOL-CHIC, V121, P235
NR 21
TC 26
Z9 28
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-7906
EI 1879-0755
J9 COMPUT ELECTR ENG
JI Comput. Electr. Eng.
PD JAN
PY 2020
VL 81
AR 106532
DI 10.1016/j.compeleceng.2019.106532
PG 7
WC Computer Science, Hardware & Architecture; Computer Science,
   Interdisciplinary Applications; Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA KT0BH
UT WOS:000518675000029
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Oltra, M
   Vidal-Gil, L
   Maisto, R
   Sancho-Pelluz, J
   Barcia, JM
AF Oltra, Maria
   Vidal-Gil, Lorena
   Maisto, Rosa
   Sancho-Pelluz, Javier
   Barcia, Jorge M.
TI Oxidative stress-induced angiogenesis is mediated by miR-205-5p
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE angiogenesis; microRNAs; retinal pigment epithelial cells
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS;
   HEPATOCELLULAR-CARCINOMA; MACULAR DEGENERATION; UP-REGULATION; VEGF-A;
   MICRORNA-205; PROTECTS; BEVACIZUMAB; INHIBITION
AB miR-205-5p is known to be involved in VEGF-related angiogenesis and seems to regulate associated cell signalling pathways, such as cell migration, proliferation and apoptosis. Therefore, several studies have focused on the potential role of miR-205-5p as an anti-angiogenic factor. Vascular proliferation is observed in diabetic retinopathy and the 'wet' form of age-related macular degeneration. Today, the most common treatments against these eye-related diseases are anti-VEGF therapies. In addition, both AMD and DR are typically associated with oxidative stress; hence, the use of antioxidant agents is accepted as a co-adjuvant therapy for these patients. According to previous data, ARPE-19 cells release pro-angiogenic factors when exposed to oxidative insult, leading to angiogenesis. Matching these data, results reported here, indicate that miR-205-5p is modulated by oxidative stress and regulates VEGFA-angiogenesis. Hence, miR-205-5p is proposed as a candidate against eye-related proliferative diseases.
C1 [Oltra, Maria; Vidal-Gil, Lorena] Univ Catolica Valencia San Vicente Martir, Escuela Doctorado, Valencia, Spain.
   [Oltra, Maria; Vidal-Gil, Lorena; Sancho-Pelluz, Javier; Barcia, Jorge M.] Univ Catolica Valencia San Vicente Martir, Fac Med & Ciencias Salud, Neurobiol & Neurofisiol, Valencia, Spain.
   [Oltra, Maria; Vidal-Gil, Lorena; Sancho-Pelluz, Javier; Barcia, Jorge M.] Univ Catolica Valencia San Vicente Martir, Ctr Invest Traslac San Alberto Magno, Valencia, Spain.
   [Maisto, Rosa] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
C3 Universidad Catolica de Valencia San Vicente Martir; Universidad
   Catolica de Valencia San Vicente Martir; Universidad Catolica de
   Valencia San Vicente Martir; Universita della Campania Vanvitelli
RP Sancho-Pelluz, J (通讯作者)，Univ Catolica Valencia San Vicente Martir, Ctr Invest Traslac San Alberto Magno, Neurobiol & Neurofisiol, Valencia, Spain.
EM fj.sancho@ucv.es
RI JM, Barcia/ABH-2932-2020; Vidal Gil, Lorena/AAZ-8342-2021; Sanchis,
   Maria Oltra/G-5543-2017; Sancho-Pelluz, Javier/ABG-8588-2020
OI Sanchis, Maria Oltra/0000-0001-6397-2702; maisto,
   rosa/0000-0003-2952-8493; Barcia, Jorge M./0000-0002-3660-7977; Sancho
   Pelluz, Francisco Javier/0000-0001-5409-5760
FU Universidad Catolica de Valencia San Vicente Martir research Fund
   [2018-128-001, 2019-128-001]; Centro de Investigacion Traslacional San
   Alberto Magno, Universidad Catolica de Valencia San Vicente Martir
   [2018-128-001, 2019-128-001]; Escuela de Doctorado Universidad Catolica
   de Valencia San Vicente Martir [EDUCV-PRE-2015-006, EDUCVPRE-2016-005]
FX Universidad Catolica de Valencia San Vicente Martir research Fund and
   Centro de Investigacion Traslacional San Alberto Magno, Universidad
   Catolica de Valencia San Vicente Martir, Grant/Award Number:
   2018-128-001, 2019-128-001; Escuela de Doctorado Universidad Catolica de
   Valencia San Vicente Martir, Grant/Award Number: EDUCV-PRE-2015-006 and
   EDUCVPRE-2016-005
CR An G, 2017, EXP BIOL MED, V242, P275, DOI 10.1177/1535370216669839
   Atienzar-Aroca S, 2018, J CELL MOL MED, V22, P5244, DOI 10.1111/jcmm.13730
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Ayaz L, 2018, CUTAN OCUL TOXICOL, V37, P121, DOI 10.1080/15569527.2017.1355314
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bhaskaran M, 2014, VET PATHOL, V51, P759, DOI 10.1177/0300985813502820
   Brandes AA, 2019, ONCOLOGIST, V24, P521, DOI 10.1634/theoncologist.2018-0290
   Bueno-Beti C, 2013, J CELL MOL MED, V17, P1475, DOI 10.1111/jcmm.12133
   Cao WF, 2019, CANCER BIOMARK, V25, P101, DOI 10.3233/CBM-182380
   Chen Q, 2018, AM J TRANSL RES, V10, P563
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Dinc E., 2018, J OCUL PHARMACOL TH, V34, P1
   Dinc E, 2017, CURR EYE RES, V42, P1659, DOI 10.1080/02713683.2017.1368085
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Frezzetti D, 2017, EXPERT OPIN THER TAR, V21, P959, DOI 10.1080/14728222.2017.1371137
   Hao Yi, 2016, J Clin Exp Ophthalmol, V7
   Hu A, 2019, PHARMAZIE, V74, P154, DOI 10.1691/ph.2019.8908
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kannan R, 2006, MOL VIS, V12, P1649
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   Li DD, 2016, MOL BIOL REP, V43, P1079, DOI 10.1007/s11033-016-4041-8
   Li EH, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160572
   Li LP, 2018, ONCOL LETT, V16, P1715, DOI 10.3892/ol.2018.8862
   Liu G, 2018, CELL MOL BIOL, V64, P1, DOI 10.14715/cmb/2018.64.4.1
   Loizzi V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091967
   Lu Zihong, 2019, Oncol Res, DOI 10.3727/096504018X15452187888839
   Lugrin J, 2014, BIOL CHEM, V395, P203, DOI 10.1515/hsz-2013-0241
   Maisto R, 2019, CELL CYCLE, V18, P413, DOI 10.1080/15384101.2019.1568745
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marneros AG, 2016, ADV EXP MED BIOL, V854, P79, DOI 10.1007/978-3-319-17121-0_12
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Muratsu-Ikeda S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041462
   Patil KS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143969
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Rubio RG, 2016, DEV OPHTHALMOL, V55, P28, DOI 10.1159/000431129
   Ryan D, 2006, MOL VIS, V12, P1175
   Salcedo-Villanueva G, 2019, INT OPHTHALMOL, V39, P2023, DOI 10.1007/s10792-018-1038-4
   Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016
   Shao P, 2017, AM J TRANSL RES, V9, P4300
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Simao S, 2017, ANGIOGENESIS, V20, P175, DOI 10.1007/s10456-016-9526-5
   Tangvarasittichai O, 2018, CURR PHARM DESIGN, V24, P4726, DOI 10.2174/1381612825666190115121531
   Tao W, 2019, MICROVASC RES, V124, P43, DOI 10.1016/j.mvr.2019.03.001
   Tardiolo G, 2018, MOLECULES, V23, DOI 10.3390/molecules23123305
   Tasharrofi N, 2017, J CELL BIOCHEM, V118, P4854, DOI 10.1002/jcb.26160
   Thangapandiyan S, 2014, TOXICOL REP, V1, P12, DOI 10.1016/j.toxrep.2014.01.002
   Wang LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167684
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yue X, 2012, ONCOL REP, V27, P1200, DOI 10.3892/or.2011.1588
   Zhao XY, 2018, ONCOL LETT, V16, P2207, DOI 10.3892/ol.2018.8933
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 55
TC 15
Z9 15
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN
PY 2020
VL 24
IS 2
BP 1428
EP 1436
DI 10.1111/jcmm.14822
EA DEC 2019
PG 9
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KH1OU
UT WOS:000503647700001
PM 31863632
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Karki, RG
   Powers, J
   Mainolfi, N
   Anderson, K
   Belanger, DB
   Liu, DL
   Ji, N
   Jendza, K
   Gelin, CF
   Mac Sweeney, A
   Solovay, C
   Delgado, O
   Crowley, M
   Liao, SM
   Argikar, UA
   Flohr, S
   La Bonte, LR
   Lorthiois, EL
   Vulpetti, A
   Brown, A
   Long, D
   Prentiss, M
   Gradoux, N
   de Erkenez, A
   Cumin, F
   Adams, C
   Jaffee, B
   Mogi, M
AF Karki, Rajeshri G.
   Powers, James
   Mainolfi, Nello
   Anderson, Karen
   Belanger, David B.
   Liu, Donglei
   Ji, Nan
   Jendza, Keith
   Gelin, Christine F.
   Mac Sweeney, Aengus
   Solovay, Catherine
   Delgado, Omar
   Crowley, Maura
   Liao, Sha-Mei
   Argikar, Upendra A.
   Flohr, Stefanie
   La Bonte, Laura R.
   Lorthiois, Edwige L.
   Vulpetti, Anna
   Brown, Ann
   Long, Debby
   Prentiss, Melissa
   Gradoux, Nathalie
   de Erkenez, Andrea
   Cumin, Frederic
   Adams, Christopher
   Jaffee, Bruce
   Mogi, Muneto
TI Design, Synthesis, and Preclinical Characterization of Selective Factor
   D Inhibitors Targeting the Alternative Complement Pathway
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DISCOVERY; POTENT
AB Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system. Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria. Previously, we have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (1 and 2) binding to the open active conformation of FD. In continuation of our drug discovery program, we designed compounds applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases. We report herein the design, synthesis, and medicinal chemistry optimization of the benzylamine series culminating in the discovery of 12, an orally bioavailable and selective FD inhibitor. 12 demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.
C1 [Karki, Rajeshri G.; Powers, James; Mainolfi, Nello; Anderson, Karen; Belanger, David B.; Liu, Donglei; Ji, Nan; Jendza, Keith; Gelin, Christine F.; Solovay, Catherine; Delgado, Omar; Crowley, Maura; Liao, Sha-Mei; Argikar, Upendra A.; La Bonte, Laura R.; Brown, Ann; Long, Debby; Prentiss, Melissa; de Erkenez, Andrea; Adams, Christopher; Jaffee, Bruce; Mogi, Muneto] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
   [Mac Sweeney, Aengus; Flohr, Stefanie; Lorthiois, Edwige L.; Vulpetti, Anna; Gradoux, Nathalie; Cumin, Frederic] Novartis Inst BioMed Res, Novartis Campus, CH-4056 Basel, Switzerland.
   [Belanger, David B.] Kaleido Biosci, 65 Hayden Ave, Lexington, MA 02421 USA.
   [Mainolfi, Nello; Ji, Nan] Kymera Therapeut, 300 Technol Sq, Cambridge, MA 02139 USA.
   [Gelin, Christine F.] Janssen Res & Dev, 3210 Merryfield Row, San Diego, CA 92121 USA.
   [Mac Sweeney, Aengus] Idorsia Pharmaceut Ltd, Drug Discovery Biol, CH-4123 Allschwil, Switzerland.
   [Anderson, Karen] Biogen, 225 Binney St, Cambridge, MA 02142 USA.
C3 Novartis; Novartis; Idorsia Pharmaceuticals Ltd; Biogen
RP Karki, RG (通讯作者)，Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
EM rajeshri.karki@novartis.com
OI Karki, Rajeshri/0000-0003-2210-5789; Vulpetti, Anna/0000-0002-3114-8679
FU Novartis Institutes for BioMedical Research Inc.
FX The authors declare no competing financial interest and all work
   described was funded by Novartis Institutes for BioMedical Research Inc.
CR [Anonymous], 2012, SCHROD REL 2012
   [Anonymous], 2012, SCHROD REL 2012 GLID
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Crowley MA, 2018, INVEST OPHTH VIS SCI, V59, P940, DOI 10.1167/iovs.17-22605
   Greco MN, 2007, J MED CHEM, V50, P1727, DOI 10.1021/jm0700619
   Guo Z, 1999, PDB ID 1ZSJ CRYSTAL
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Kocinsky H, 2018, NEPHROL DIAL TRANSPL, V33, P322
   Kohrt JT, 2005, BIOORG MED CHEM LETT, V15, P4752, DOI 10.1016/j.bmcl.2005.07.059
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Lorthiois E, 2017, J MED CHEM, V60, P5717, DOI 10.1021/acs.jmedchem.7b00425
   Maibaum J, 2016, NAT CHEM BIOL, V12, P1105, DOI [10.1038/NCHEMBIO.2208, 10.1038/nchembio.2208]
   McGrath ME, 2006, BIOCHEMISTRY-US, V45, P5964, DOI 10.1021/bi060173m
   Mutlib AE, 2002, CHEM RES TOXICOL, V15, P48, DOI 10.1021/tx0101191
   Risitano AM, 2013, ADV EXP MED BIOL, V735, P155, DOI 10.1007/978-1-4614-4118-2_10
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stiefl N, 2015, J CHEM INF MODEL, V55, P896, DOI 10.1021/ci500598e
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Vulpetti A, 2018, ACS MED CHEM LETT, V9, P490, DOI 10.1021/acsmedchemlett.8b00104
   Vulpetti A, 2017, J MED CHEM, V60, P1946, DOI 10.1021/acs.jmedchem.6b01684
   West CW, 2009, BIOORG MED CHEM LETT, V19, P5712, DOI 10.1016/j.bmcl.2009.08.008
   Zhao G., 2007, PDB ID 2O8W CRYSTAL
   Zipfel PF, 2015, MOL IMMUNOL, V67, P21, DOI 10.1016/j.molimm.2015.03.012
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   2017, MOL IMMUNOL, V89, P200, DOI DOI 10.1016/J.MOLIMM.2017.06.226
NR 27
TC 12
Z9 12
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 9
PY 2019
VL 62
IS 9
BP 4656
EP 4668
DI 10.1021/acs.jmedchem.9b00271
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA HY0DT
UT WOS:000467781700025
PM 30995036
DA 2022-11-30
ER

PT J
AU Luan, YY
   Yao, YM
AF Luan, Ying-yi
   Yao, Yong-ming
TI The Clinical Significance and Potential Role of C-Reactive Protein in
   Chronic Inflammatory and Neurodegenerative Diseases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE C-reactive protein; chronic inflammation; biomarker; cardiovascular
   disease; diabetes
ID CORONARY-HEART-DISEASE; SPONTANEOUS INTRACEREBRAL HEMORRHAGE;
   CARDIOVASCULAR RISK-FACTORS; TYPE-2 DIABETES-MELLITUS; COMPLEMENT
   FACTOR-H; MACULAR DEGENERATION; ALZHEIMERS-DISEASE;
   MYOCARDIAL-INFARCTION; COGNITIVE IMPAIRMENT; SERUM-LEVELS
AB C-reactive protein (CRP) is an acute-phase protein synthesized by hepatocytes in response to pro-inflammatory cytokines during inflammatory/infectious processes. CRP exists in conformationally distinct forms such as the native pentameric CRP and monomeric CRP (mCRP) and may bind to distinct receptors and lipid rafts and exhibit different functional properties. It is known as a biomarker of acute inflammation, but many large-scale prospective studies demonstrate that CRP is also known to be associated with chronic inflammation. This review is focused on discussing the clinical significance of CRP in chronic inflammatory and neurodegenerative diseases, such as cardiovascular disease, type 2 diabetes mellitus, age-related macular degeneration, hemorrhagic stroke, Alzheimer's disease, and Parkinson's disease, including recent advances on the implication of CRP and its forms specifically on the pathogenesis of these diseases. Overall, we highlight the advances in these areas that may be translated into promising measures for the diagnosis and treatment of inflammatory diseases.
C1 [Luan, Ying-yi; Yao, Yong-ming] Chinese Peoples Liberat Army Gen Hosp, Hosp Affiliated 1, Trauma Res Ctr, Beijing, Peoples R China.
   [Yao, Yong-ming] Chinese Peoples Liberat Army Gen Hosp, State Key Lab Kidney Dis, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital
RP Yao, YM (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Hosp Affiliated 1, Trauma Res Ctr, Beijing, Peoples R China.; Yao, YM (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, State Key Lab Kidney Dis, Beijing, Peoples R China.
EM c_ff@sina.com
FU National Natural Science Foundation [81730057, 81401592]; Beijing Nova
   Program [Z171100001117113]; National Key Research and Development
   Program of China [2017YFC1103302]
FX This study was supported, in part, by grants from the National Natural
   Science Foundation (Nos. 81730057, 81401592), Beijing Nova Program (No.
   Z171100001117113), and National Key Research and Development Program of
   China (No. 2017YFC1103302).
CR Agca R, 2017, J RHEUMATOL, V44, P1362, DOI 10.3899/jrheum.161418
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alexiou A, 2018, CURR PROTEIN PEPT SC, V19, P876, DOI 10.2174/1389203718666170911145321
   Ambreen F, 2015, MOL VIS, V21, P985
   Anchah L, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-016-0583-7
   Andican G, 2012, ACTA NEUROL BELG, V112, P155, DOI 10.1007/s13760-012-0015-3
   Andreozzi F, 2007, DIABETES-METAB RES, V23, P547, DOI 10.1002/dmrr.724
   Azadbakht L, 2008, DIABETES CARE, V31, P648, DOI 10.2337/dc07-2065
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bisoendial RJ, 2005, CIRC RES, V96, P714, DOI 10.1161/01.RES.0000163015.67711.AB
   Cardoso Filipe S, 2015, GE Port J Gastroenterol, V22, P198, DOI 10.1016/j.jpge.2015.03.002
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Colak E, 2017, J CLIN BIOCHEM NUTR, V60, P100, DOI 10.3164/jcbn.16-30
   Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804
   de Rekeneire N, 2006, DIABETES CARE, V29, P1902, DOI 10.2337/dc05-2327
   Devicic S, 2014, PSYCHIAT RES, V220, P970, DOI 10.1016/j.psychres.2014.08.059
   Di Napoli M, 2014, STROKE, V45, P59, DOI 10.1161/STROKEAHA.113.001721
   Di Napoli M, 2012, NEUROLOGY, V79, P690, DOI 10.1212/WNL.0b013e318264e3be
   Di Napoli M, 2011, EXPERT REV CARDIOVAS, V9, P1565, DOI [10.1586/ERC.11.159, 10.1586/erc.11.159]
   Di Napoli M, 2011, STROKE, V42, P1230, DOI 10.1161/STROKEAHA.110.604983
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954
   Fan JB, 2017, CLIN LAB, V63, P427, DOI 10.7754/Clin.Lab.2016.160533
   Gong CG, 2016, AM J ALZHEIMERS DIS, V31, P194, DOI 10.1177/1533317515602087
   Gorska-Ciebiada M, 2015, FRONT AGING NEUROSCI, V7, DOI [10.5589/fnagi.2015.00209, 10.3389/fnagi.2015.00209]
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   Hu L, 2017, APPL IMMUNOHISTO M M, V25, pE61, DOI 10.1097/PAI.0000000000000552
   Iida K, 2017, CORONARY ARTERY DIS, V28, P577, DOI 10.1097/MCA.0000000000000521
   IWAMOTO N, 1994, NEUROSCI LETT, V177, P23, DOI 10.1016/0304-3940(94)90035-3
   Jaber BL, 2005, NEW ENGL J MED, V352, P1604
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kardys I, 2006, EUR HEART J, V27, P1331, DOI 10.1093/eurheartj/ehl018
   Kurtul Bengi Ece, 2016, Korean J Ophthalmol, V30, P377
   Lai WY, 2016, KIDNEY INT, V90, P610, DOI 10.1016/j.kint.2016.06.010
   Lange LA, 2006, JAMA-J AM MED ASSOC, V296, P2703, DOI 10.1001/jama.296.22.2703
   Liao J. K., 2009, CURR ATHEROSCLER REP, V11, P243, DOI DOI 10.1007/S11883-009-0037-3
   Locascio JJ, 2008, ARCH NEUROL-CHICAGO, V65, P776, DOI 10.1001/archneur.65.6.776
   Memar MY, 2019, J MATERN-FETAL NEO M, V32, P143, DOI 10.1080/14767058.2017.1366984
   Miller DT, 2005, ANN HUM GENET, V69, P623, DOI 10.1111/j.1529-8817.2005.00210.x
   Mirhafez SR, 2016, EUR J CLIN NUTR, V70, P1298, DOI 10.1038/ejcn.2016.111
   Nadrowski P, 2016, EXP GERONTOL, V85, P112, DOI 10.1016/j.exger.2016.10.001
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Nilsson K, 2011, CLIN BIOCHEM, V44, P1205, DOI 10.1016/j.clinbiochem.2011.07.011
   Park DW, 2009, CIRCULATION, V120, P1987, DOI 10.1161/CIRCULATIONAHA.109.876763
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Pfutzner Andreas, 2010, J Diabetes Sci Technol, V4, P706
   Phosat C, 2017, BMC ENDOCR DISORD, V17, DOI 10.1186/s12902-017-0189-z
   Pleskovic A, 2017, VASA, V46, P187, DOI 10.1024/0301-1526/a000614
   Prins BP, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001976
   Ragy MM, 2017, NEUROL RES, V39, P587, DOI 10.1080/01616412.2017.1312773
   Rehman SA, 2017, PROTEOMES, V5, DOI 10.3390/proteomes5030021
   Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Roudbary Seyed Ali, 2011, Acta Med Iran, V49, P149
   Sarangi R, 2012, DIABETES METAB SYND, V6, P9, DOI 10.1016/j.dsx.2012.05.015
   Sawada H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134118
   Schulz S, 2016, CYTOKINE, V88, P71, DOI 10.1016/j.cyto.2016.08.021
   Schwedler SB, 2006, AM J KIDNEY DIS, V47, P212, DOI 10.1053/j.ajkd.2005.10.028
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Slevin M, 2015, SCI REP-UK, V5, DOI 10.1038/srep13281
   Soheilian R, 2017, INT OPHTHALMOL, V37, P1161, DOI 10.1007/s10792-016-0373-6
   Song IU, 2015, INT J MED SCI, V12, P613, DOI 10.7150/ijms.12742
   Steiner T, 2006, CEREBROVASC DIS, V22, P294, DOI 10.1159/000094831
   Strang F, 2012, BRAIN PATHOL, V22, P337, DOI 10.1111/j.1750-3639.2011.00539.x
   Taheri S, 2017, J RES MED SCI, V22, DOI 10.4103/jrms.JRMS_282_15
   Tang Y, 2017, CLIN EXP PHARMACOL P, V44, P9, DOI 10.1111/1440-1681.12758
   TEASDALE G, 1974, LANCET, V2, P81
   Towfighi A, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0792-7
   Umemura A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136722
   Vachatova S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5380792
   Vadakayil Asha Ramay, 2015, Indian Dermatol Online J, V6, P322, DOI 10.4103/2229-5178.164483
   Weinstein G, 2017, ARCH GERONTOL GERIAT, V69, P31, DOI 10.1016/j.archger.2016.11.002
   Wensley F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d548
   Wettero J, 2009, CLIN CHIM ACTA, V400, P128, DOI 10.1016/j.cca.2008.10.002
   Wu Y, 2015, BIOL CHEM, V396, P1181, DOI 10.1515/hsz-2015-0149
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   You YK, 2016, SCI REP-UK, V6, DOI 10.1038/srep26740
   Zhou ZW, 2016, CLIN CHIM ACTA, V455, P113, DOI 10.1016/j.cca.2016.02.003
   Zhu J.Q., 2015, CHIN J INTEGR MED, P1
NR 84
TC 106
Z9 108
U1 1
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 7
PY 2018
VL 9
AR 1302
DI 10.3389/fimmu.2018.01302
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GI5MA
UT WOS:000434413400002
PM 29951057
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wartak, A
   Augustin, M
   Haindl, R
   Beer, F
   Salas, M
   Laslandes, M
   Baumann, B
   Pircher, M
   Hitzenberger, CK
AF Wartak, Andreas
   Augustin, Marco
   Haindl, Richard
   Beer, Florian
   Salas, Matthias
   Laslandes, Marie
   Baumann, Bernhard
   Pircher, Michael
   Hitzenberger, Christoph K.
TI Multi-directional optical coherence tomography for retinal imaging
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID NERVE-FIBER LAYER; SPECKLE REDUCTION; PHOTORECEPTOR DIRECTIONALITY;
   ATTENUATION COEFFICIENT; OCT; IMAGES; REFLECTANCE; MICROSCOPY; GLAUCOMA;
   ANGIOGRAPHY
AB We introduce multi-directional optical coherence tomography (OCT), a technique for investigation of the scattering properties of directionally reflective tissue samples. By combining the concepts of multi-channel and directional OCT, this approach enables simultaneous acquisition of multiple reflectivity depth-scans probing a mutual sample location from differing angular orientations. The application of multi-directional OCT in retinal imaging allows for in-depth investigations on the directional reflectivity of the retinal nerve fiber layer, Henle's fiber layer and the photoreceptor layer. Major ophthalmic diseases (such as glaucoma or age-related macular degeneration) have been reported to alter the directional reflectivity properties of these retinal layers. Hence, the concept of multi-directional OCT might help to gain improved understanding of pathology development and progression. As a first step, we demonstrate the capabilities of multi-directional OCT in the eyes of healthy human volunteers. Published by The Optical Society under the terms of the Creative Commons Attribution 4.0 license.
C1 [Wartak, Andreas; Augustin, Marco; Haindl, Richard; Beer, Florian; Salas, Matthias; Laslandes, Marie; Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Wahringer Gurte1 18-20-4L, A-1090 Vienna, Austria.
   [Beer, Florian] Vienna Univ Technol, Inst Appl Phys, Wiedner Hauptstr 8-10-134, A-1040 Vienna, Austria.
C3 Medical University of Vienna
RP Wartak, A (通讯作者)，Med Univ Vienna, Ctr Med Phys & Biomed Engn, Wahringer Gurte1 18-20-4L, A-1090 Vienna, Austria.
EM andreas.wartak@meduntwien.ac.at
OI Michael, Pircher/0000-0001-9285-7527; Wartak,
   Andreas/0000-0003-0825-3187; Haindl, Richard/0000-0003-3471-0986;
   Augustin, Marco/0000-0002-1019-0907; Baumann,
   Bernhard/0000-0001-6419-1932
FU European Unionapos;s Horizon research and innovation program (Marie
   Sklodowska-Curie) [701859]; Austrian Science Fund (FWF) [P26553-N20]
FX This work was supported by the Austrian Science Fund (FWF; grant number:
   P26553-N20) and the European Union's Horizon 2020 research and
   innovation program (Marie Sklodowska-Curie; grant number: 701859).
CR Adler DC, 2004, OPT LETT, V29, P2878, DOI 10.1364/OL.29.002878
   Antony BJ, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.4.3
   Augustin M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164419
   Bachmann AH, 2007, OPT EXPRESS, V15, P9254, DOI 10.1364/OE.15.009254
   Burns SA, 1997, J OPT SOC AM A, V14, P2033, DOI 10.1364/JOSAA.14.002033
   BURNS SA, 1995, J OPT SOC AM A, V12, P2329, DOI 10.1364/JOSAA.12.002329
   Carrasco-Zevallos O, 2015, BIOMED OPT EXPRESS, V6, P3405, DOI 10.1364/BOE.6.003405
   Cense B, 2013, BIOMED OPT EXPRESS, V4, P2296, DOI 10.1364/BOE.4.002296
   Desjardins AE, 2006, OPT EXPRESS, V14, P4736, DOI 10.1364/OE.14.004736
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Eugui P., 2017, P SPIE OSA, V10416
   FANKHAUSER F, 1961, Am J Ophthalmol, V52, P767
   Gao WH, 2008, OPT EXPRESS, V16, P6486, DOI 10.1364/OE.16.006486
   Gardiner SK, 2016, INVEST OPHTH VIS SCI, V57, P1221, DOI 10.1167/iovs.15-18788
   Haindl R, 2015, J MOD OPTIC, V62, P1781, DOI 10.1080/09500340.2014.983569
   Haindl R, 2016, BIOMED OPT EXPRESS, V7, P287, DOI 10.1364/BOE.7.000287
   Holmes J, 2008, PROC SPIE, V6847, DOI 10.1117/12.761655
   Huang XR, 2016, BIOMED OPT EXPRESS, V7, P22, DOI 10.1364/BOE.7.000022
   Huang XR, 2011, INVEST OPHTH VIS SCI, V52, P6737, DOI 10.1167/iovs.11-7665
   Iftimia N, 2003, J BIOMED OPT, V8, P260, DOI 10.1117/1.1559060
   Iftimia NV, 2008, OPT EXPRESS, V16, P13624, DOI 10.1364/OE.16.013624
   International Electrotechnical Commission, 2014, IEC6082512
   Jaillon F, 2012, OPT EXPRESS, V20, P385, DOI 10.1364/OE.20.000385
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Kim YL, 2003, IEEE J SEL TOP QUANT, V9, P243, DOI 10.1109/JSTQE.2003.814183
   Klein T, 2013, BIOMED OPT EXPRESS, V4, P619, DOI 10.1364/BOE.4.000619
   KNIGHTON RW, 1992, INVEST OPHTH VIS SCI, V33, P2603
   LATIES AM, 1971, INVEST OPHTH VISUAL, V10, P69
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Leung MKK, 2009, OPT LETT, V34, P2814, DOI 10.1364/OL.34.002814
   Lichtenegger A, 2017, BIOMED OPT EXPRESS, V8, P4007, DOI 10.1364/BOE.8.004007
   Liu ZL, 2016, INVEST OPHTH VIS SCI, V57, pOCT533, DOI 10.1167/iovs.16-19106
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Makhijani VS, 2013, PROC SPIE, V8571, DOI 10.1117/12.2007141
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Marchand PJ, 2017, BIOMED OPT EXPRESS, V8, P3343, DOI 10.1364/BOE.8.003343
   Morris HJ, 2015, VISION RES, V117, P67, DOI 10.1016/j.visres.2015.10.008
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   Pircher M, 2017, BIOMED OPT EXPRESS, V8, P2536, DOI 10.1364/BOE.8.002536
   Rativa D, 2011, BIOMED OPT EXPRESS, V2, P1423, DOI 10.1364/BOE.2.001423
   Schmitt JM, 1997, PHYS MED BIOL, V42, P1427, DOI 10.1088/0031-9155/42/7/015
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Stiles WS, 1933, P R SOC LOND B-CONTA, V112, P428, DOI 10.1098/rspb.1933.0020
   Subhash HM, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.3.036003
   Suehira N, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.10.106001
   Trasischker W, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.11.116010
   Tsai MT, 2013, J BIOPHOTONICS, V6, P708, DOI 10.1002/jbio.201200164
   van der Schoot J, 2012, INVEST OPHTH VIS SCI, V53, P2424, DOI 10.1167/iovs.11-8436
   Vermeer KA, 2012, INVEST OPHTH VIS SCI, V53, P6102, DOI 10.1167/iovs.12-9933
   Wang BQ, 2013, OPT LETT, V38, P4374, DOI 10.1364/OL.38.004374
   Wartak A., 2017, P OSA, VBoM3A.3
   Wartak A., 2017, P SOC PHOTO-OPT INS
   Wartak A, 2016, BIOMED OPT EXPRESS, V7, P5233, DOI 10.1364/BOE.7.005233
   Werkmeister RM, 2008, OPT LETT, V33, P2967, DOI 10.1364/OL.33.002967
   WESTHEIMER G, 1967, J PHYSIOL-LONDON, V192, P309, DOI 10.1113/jphysiol.1967.sp008301
   Wieser W, 2010, OPT EXPRESS, V18, P14685, DOI 10.1364/OE.18.014685
   Yang VXD, 2004, OPT LETT, V29, P1754, DOI 10.1364/OL.29.001754
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
   Zotter S, 2010, OPT LETT, V35, P3913, DOI 10.1364/OL.35.003913
NR 61
TC 22
Z9 22
U1 1
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD DEC 1
PY 2017
VL 8
IS 12
BP 5560
EP 5578
DI 10.1364/BOE.8.005560
PG 19
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA FP4JV
UT WOS:000417583800017
PM 29296488
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Uppalapati, D
   Boyd, B
   Travas-Sejdic, J
   Svirskis, D
AF Uppalapati, Dedeepya
   Boyd, Ben
   Travas-Sejdic, Jadranka
   Svirskis, Darren
TI Porous conducting polymer prepared through liquid crystal template for
   drug delivery
SO INTERNATIONAL JOURNAL OF NANOTECHNOLOGY
LA English
DT Article
DE conducting polymer; lyotropic liquid crystal; phase transition; scanning
   electron microscopy; SEM; small angle X-ray scattering; SAXS;
   polypyrrole; stimuli responsive drug delivery system
ID PHASE-BEHAVIOR; RELEASE; PHYTANTRIOL; IMPLANTS; SYSTEMS
AB Unlike conventional controlled drug delivery systems where drug is released at a constant pre-programmed rate, drug release from conducting polymers (CPs) can be controlled through electrical stimuli and adjusted based on the patient's needs. However, owing to their low drug loading capacity and limited electrical responsiveness CP systems cannot currently be applied for systemic drug delivery or to treat chronic disease. To overcome that obstacle one approach is to fabricate porous CP structures. In this work, polypyrrole (PPy) was used owing to its electrical responsiveness and biocompatibility. Liquid crystals were used as a template through which PPy was grown. Dexamethasone phosphate was loaded as a dopant into PPy during polymerisation and its release was quantified by HPLC after the removal of liquid crystal; release could be modified by electrical stimulus. This system has potential applications in conditions where required drug dosing changes with time, such as in age-related macular degeneration.
C1 [Uppalapati, Dedeepya; Svirskis, Darren] Univ Auckland, Sch Pharm, FMHS, Pk Rd, Auckland 1023, New Zealand.
   [Boyd, Ben] Drug Delivery Disposit & Dynam, Parkville, Vic 3052, Australia.
   [Boyd, Ben] Monash Univ, Monash Inst Pharmaceut Sci, ARC Ctr Excellence Convergent Bionano Sci & Techn, Parkville Campus, Parkville, Vic 3052, Australia.
   [Travas-Sejdic, Jadranka] Sch Chem Sci, Polymer Elect Res Ctr, Auckland 1010, New Zealand.
   [Travas-Sejdic, Jadranka] Univ Auckland, MacDiarmid Inst Adv Mat & Nanotechnol, Auckland 1010, New Zealand.
C3 University of Auckland; Monash University; University of Auckland
RP Svirskis, D (通讯作者)，Univ Auckland, Sch Pharm, FMHS, Pk Rd, Auckland 1023, New Zealand.
EM d.uppalapati@auckland.ac.nz; ben.boyd@monash.edu;
   j.travas-sejdic@auckland.ac.nz; d.svirskis@auckland.ac.nz
RI Travas-Sejdic, Jadranka/B-5978-2011
OI Boyd, Ben/0000-0001-5434-590X; Svirskis, Darren/0000-0001-9435-1773
FU School of Pharmacy; University of Auckland; The University of Auckland
   Doctoral Scholarship
FX This work was supported by the School of Pharmacy, The University of
   Auckland. Dedeepya Uppalapati is grateful to The University of Auckland
   Doctoral Scholarship for financial assistance. These studies were
   conducted on the SAXS/WAXS beam line at the Australian Synchrotron.
CR Abidian MR, 2006, ADV MATER, V18, P405, DOI 10.1002/adma.200501726
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Barauskas J, 2003, LANGMUIR, V19, P9562, DOI 10.1021/la0350812
   Dong YD, 2008, LANGMUIR, V24, P6998, DOI 10.1021/la8005579
   Fong WK, 2009, J CONTROL RELEASE, V135, P218, DOI 10.1016/j.jconrel.2009.01.009
   George PM, 2005, BIOMATERIALS, V26, P3511, DOI 10.1016/j.biomaterials.2004.09.037
   Gerard M, 2002, BIOSENS BIOELECTRON, V17, P345, DOI 10.1016/S0956-5663(01)00312-8
   Green RA, 2008, BIOMATERIALS, V29, P3393, DOI 10.1016/j.biomaterials.2008.04.047
   Li C, 2009, CHEM SOC REV, V38, P2397, DOI 10.1039/b816681c
   Rizwan SB, 2007, MICRON, V38, P478, DOI 10.1016/j.micron.2006.08.003
   Sharma M, 2013, INT J PHARMACEUT, V443, P163, DOI 10.1016/j.ijpharm.2013.01.006
   Svirskis D, 2010, J CONTROL RELEASE, V146, P6, DOI 10.1016/j.jconrel.2010.03.023
   Svirskis D, 2010, ELECTROANAL, V22, P439, DOI 10.1002/elan.200900401
   Wang GW, 2014, J NANOSCI NANOTECHNO, V14, P596, DOI 10.1166/jnn.2014.9084
   Weaver CL, 2014, ACS NANO, V8, P1834, DOI 10.1021/nn406223e
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
NR 16
TC 0
Z9 0
U1 1
U2 21
PU INDERSCIENCE ENTERPRISES LTD
PI GENEVA
PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 856, CH-1215
   GENEVA, SWITZERLAND
SN 1475-7435
EI 1741-8151
J9 INT J NANOTECHNOL
JI Int. J. Nanotechnol.
PY 2017
VL 14
IS 1-6
SI SI
BP 422
EP 431
DI 10.1504/IJNT.2017.082462
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA EO1ZB
UT WOS:000396495300040
DA 2022-11-30
ER

PT J
AU Jo, DH
   Hong, JW
   Kim, JH
   Han, SW
   Kim, JH
AF Jo, Dong Hyun
   Hong, Jong Wook
   Kim, Jin Hyoung
   Han, Sang Woo
   Kim, Jeong Hun
TI Gold Nanocrystals with Well-Defined Crystallographic {111} Facets
   Suppress Pathological Neovascularization
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Nanocrystal; Vascular Endothelial Growth Factor; Pathological
   Angiogenesis; Nanoparticle-Protein Interaction
ID ENDOTHELIAL GROWTH-FACTOR; NANOPARTICLES; PROLIFERATION; ANGIOGENESIS;
   PROPERTY; DISEASE; CELLS; SIZE
AB Vascular endothelial growth factor (VEGF) is a main factor in pathological neovascularization in various human diseases including age-related macular degeneration, cancer, and diabetic complications. Interestingly, gold nanospheres are known to bind to VEGF and to suppress VEGF-mediated angiogenesis. The anti-angiogenic effects are known to be governed by the size and surface charge of the nanoparticles. However, studies on the role of the shape in biological actions are limited. In this study, we investigate the anti-angiogenic properties of nanocrystals that have well-defined crystallographic {111} facets. Single-crystalline icosahedral and octahedral gold nanocrystals effectively scavenge VEGF just as nanospheres with similar diameter. In addition, they suppress the in vitro VEGF-induced activation of the VEGF receptor and the proliferation of endothelial cells. They also significantly inhibit in vivo VEGF-mediated retinal vascular permeability. These results thus suggest that gold nanocrystals with {111} facets can provide a useful platform for nanoparticle-based treatment of VEGF-driven pathological neovascularization beyond their current optical and catalytic applications.
C1 [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul 03080, South Korea.
   [Jo, Dong Hyun; Kim, Jeong Hun] Seoul Natl Univ, Dept Biomed Sci, Seoul 03080, South Korea.
   [Jo, Dong Hyun; Kim, Jeong Hun] Seoul Natl Univ, Prot Metab Med Res Ctr, Coll Med, Seoul 03080, South Korea.
   [Hong, Jong Wook; Han, Sang Woo] Korea Adv Inst Sci & Technol, Ctr Nanotecton, Dept Chem & KI NanoCentury, Daejeon 34141, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 03080, South Korea.
   [Hong, Jong Wook] Univ Ulsan, Dept Chem, Ulsan 44610, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Korea
   Advanced Institute of Science & Technology (KAIST); Seoul National
   University (SNU); University of Ulsan
RP Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul 03080, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Dept Biomed Sci, Seoul 03080, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Prot Metab Med Res Ctr, Coll Med, Seoul 03080, South Korea.; Han, SW (通讯作者)，Korea Adv Inst Sci & Technol, Ctr Nanotecton, Dept Chem & KI NanoCentury, Daejeon 34141, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 03080, South Korea.
EM steph25@snu.ac.kr; sangwoohan@kaist.ac.kr
RI Han, Sang Woo/C-1789-2011; Jo, Dong Hyun/D-5962-2012
OI Han, Sang Woo/0000-0001-5406-5211; Jo, Dong Hyun/0000-0002-6320-6829;
   Kim, Jeong Hun/0000-0003-2957-1766
FU Bio-Signal Analysis Technology Innovation Program of the National
   Research Foundation - Korean government (MSIP) [2009-0090895]; pioneer
   Research Program of the National Research Foundation - Korean government
   (MSIP) [2012-0009544]; Bio and Medical Technology Development Program of
   the National Research Foundation - Korean government (MSIP)
   [NRF-2015M3A9E6028949]; Basic Science Research Program of the National
   Research Foundation - Korean government (MSIP) [2012-0006019,
   2015R1A3A2033469, 2015M3A7B6027946]
FX This work was supported by the Bio-Signal Analysis Technology Innovation
   Program (2009-0090895), the pioneer Research Program (2012-0009544), the
   Bio and Medical Technology Development Program (NRF-2015M3A9E6028949),
   and the Basic Science Research Program (2012-0006019, 2015R1A3A2033469,
   2015M3A7B6027946) of the National Research Foundation funded by the
   Korean government (MSIP).
CR Arvizo RR, 2013, P NATL ACAD SCI USA, V110, P6700, DOI 10.1073/pnas.1214547110
   Arvizo RR, 2012, CHEM SOC REV, V41, P2943, DOI 10.1039/c2cs15355f
   Arvizo RR, 2011, NANOMED-NANOTECHNOL, V7, P580, DOI 10.1016/j.nano.2011.01.011
   Bhattacharya R, 2004, NANO LETT, V4, P2479, DOI 10.1021/nl0483789
   Euliss LE, 2006, CHEM SOC REV, V35, P1095, DOI 10.1039/b600913c
   Giri K, 2014, BIOCONJUGATE CHEM, V25, P1078, DOI 10.1021/bc500084f
   Heo J, 2008, CHEM COMMUN, P6120, DOI 10.1039/b815925d
   Huang MH, 2014, CHEM COMMUN, V50, P1634, DOI 10.1039/c3cc48527g
   Jo DH, 2014, NANO RES, V7, P844, DOI 10.1007/s12274-014-0445-8
   Jo DH, 2014, NANOMED-NANOTECHNOL, V10, P1109, DOI 10.1016/j.nano.2014.02.007
   Jo DH, 2013, J OCUL PHARMACOL TH, V29, P135, DOI 10.1089/jop.2012.0113
   Jo DH, 2012, NANOMED-NANOTECHNOL, V8, P784, DOI 10.1016/j.nano.2011.09.003
   Kalishwaralal K, 2009, COLLOID SURFACE B, V73, P51, DOI 10.1016/j.colsurfb.2009.04.025
   Kim JH, 2011, BIOMATERIALS, V32, P1865, DOI 10.1016/j.biomaterials.2010.11.030
   Kim M, 2014, CHEM COMMUN, V50, P9454, DOI 10.1039/c4cc02494j
   Kwon K, 2007, J PHYS CHEM C, V111, P1161, DOI 10.1021/jp064317i
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Sau TK, 2010, ADV MATER, V22, P1781, DOI 10.1002/adma.200901271
   Wu HL, 2011, INORG CHEM, V50, P8106, DOI 10.1021/ic200504n
NR 20
TC 5
Z9 5
U1 0
U2 7
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD JUL
PY 2016
VL 12
IS 7
BP 1520
EP 1526
DI 10.1166/jbn.2016.2260
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA DP9AH
UT WOS:000378788600014
PM 29337491
DA 2022-11-30
ER

PT J
AU Kutty, RK
   Samuel, W
   Abay, R
   Cherukuri, A
   Nagineni, CN
   Duncan, T
   Jaworski, C
   Vijayasarathy, C
   Redmond, TM
AF Kutty, R. Krishnan
   Samuel, William
   Abay, Rebecca
   Cherukuri, Aswini
   Nagineni, Chandrasekharam N.
   Duncan, Todd
   Jaworski, Cynthia
   Vijayasarathy, Camasamudram
   Redmond, T. Michael
TI Resveratrol attenuates CXCL11 expression induced by proinflammatory
   cytokines in retinal pigment epithelial cells
SO CYTOKINE
LA English
DT Article
DE Resveratrol; Retinal pigment epithelium; Age-related macular
   degeneration; CXCL11; Nuclear factor-kappa B
ID ACTIVATED T-CELLS; NF-KAPPA-B; MACULAR DEGENERATION; CHEMOKINE;
   DISEASES; ARPE-19; ALPHA
AB Dysfunction of the retinal pigment epithelium (RPE) resulting from chronic inflammation is implicated in the pathogenesis of age-related macular degeneration (AMD). RPE cells adjacent to drusen deposits in the AMD eye are known to contain CXCLI I, a chemokine involved in inflammatory cell recruitment. We investigated the CXCL11 production by the human RPE (ARPE-19) cells under inflammatory conditions and tested its response to resveratrol, a naturally occurring anti-inflammatory antioxidant. A proinflammatory cytokine mixture consisting of IFN-gamma, IL-1 beta and TNF-alpha highly increased CXCL11 mRNA expression and CXCLI I protein secretion by ARPE-19 cells. Resveratrol substantially inhibited the proinflammatory cytokines-induced CXCL11 production while partially blocking nuclear factor-kappa B activation. This inhibitory action of resveratrol was also observed for the cytokines-induced expression of chemokines CXCL9, CCL2 and CCL5. Our results indicate that resveratrol could potentially attenuate RPE inflammatory response implicated in the pathogenesis of AMD. Published by Elsevier Ltd.
C1 [Kutty, R. Krishnan; Samuel, William; Abay, Rebecca; Cherukuri, Aswini; Duncan, Todd; Jaworski, Cynthia; Redmond, T. Michael] NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Nagineni, Chandrasekharam N.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Vijayasarathy, Camasamudram] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Institute on Deafness & Other Communication Disorders (NIDCD)
RP Kutty, RK (通讯作者)，NEI, Lab Retinal Cell & Mol Biol, NIH, Bldg 6,Room 112,6 Ctr Dr,MSC 0608, Bethesda, MD 20892 USA.
EM kuttyk@nei.nih.gov
OI Redmond, T. Michael/0000-0002-1813-5291
FU National Eye Institute, NIH; NATIONAL EYE INSTITUTE [ZIAEY000444,
   ZIAEY000260] Funding Source: NIH RePORTER
FX This study was supported by the Intramural Research Program of the
   National Eye Institute, NIH.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Busch F, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.377028
   Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kutty RK, 2013, MOL VIS, V19, P737
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Svajger U, 2012, INT REV IMMUNOL, V31, P202, DOI 10.3109/08830185.2012.665108
   Wang XC, 1999, INVEST OPHTH VIS SCI, V40, P477
NR 14
TC 14
Z9 14
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD AUG
PY 2015
VL 74
IS 2
BP 335
EP 338
DI 10.1016/j.cyto.2015.03.016
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA CM5CM
UT WOS:000357704400024
PM 25890876
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wegner, A
   Khoramnia, R
AF Wegner, Aharon
   Khoramnia, Ramin
TI Cataract is a self-defence reaction to protect the retina from oxidative
   damage
SO MEDICAL HYPOTHESES
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FILTERING INTRAOCULAR LENSES; MACULAR PIGMENT
   CAROTENOIDS; LIPID-PEROXIDATION PRODUCTS; FACTOR-H POLYMORPHISM;
   LONG-TERM INCIDENCE; RISK-FACTORS; VISUAL IMPAIRMENT; OPTICAL-DENSITY;
   IRON HOMEOSTASIS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. Cataract extraction is the most common surgical procedure in developed countries. Lutein (L) and zeaxanthin (Z), retinal carotenoids, are the most powerful retinal anti-oxidants and absorb the harmful blue light. The depletion of L + Z induces the development of the lens opacification-cataract. Cataract reduces the retinal oxidative stress (OS), which causes a reduction of the probability to develop AMD. Oxidative Stress at the retinal level is the common pathway in the development of AMD and cataract. AMD and cataract are not two independent processes. Cataract is a self-defense reaction of the retina to reduce OS and retinal damage. Restoring the anti-oxidative capabilities of the retina by increasing intake of L + Z reduces the likelihood of AMD and cataract. Extracting the opaque lens elevates the retinal OS and increases the rate of AMD. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Wegner, Aharon; Khoramnia, Ramin] Tech Univ Munich, Klinikum Rechts Isar, Dept Ophthalmol, Glaucoma Serv, D-81675 Munich, Germany.
C3 Technical University of Munich
RP Wegner, A (通讯作者)，Tech Univ Munich, Klinikum Rechts Isar, Dept Ophthalmol, Glaucoma Serv, 22 Ismaninger St, D-81675 Munich, Germany.
EM awegner@yahoo.com
RI Wegner, Aharon/H-8448-2019; Khoramnia, Ramin/AAR-8358-2020
OI Wegner, Aharon/0000-0002-1969-3076; Khoramnia, Ramin/0000-0002-6237-7773
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ao MX, 2010, J CATARACT REFR SURG, V36, P389, DOI 10.1016/j.jcrs.2009.09.038
   Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7
   Bates CJ, 1996, INT J VITAM NUTR RES, V66, P316
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beatty S, 2001, AM J CLIN NUTR, V74, P796
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Curran-Celentano J, 2004, ARCH BIOCHEM BIOPHYS, V430, P70
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Davies NP, 2002, INVEST OPHTH VIS SCI, V43, P281
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dherani M, 2008, INVEST OPHTH VIS SCI, V49, P3328, DOI 10.1167/iovs.07-1202
   Dorey CK, 2005, EXP EYE RES, V81, P464, DOI 10.1016/j.exer.2005.03.007
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Goralska M, 2005, INVEST OPHTH VIS SCI, V46, P3521, DOI 10.1167/iovs.05-0358
   Goralska M, 2003, J BIOL CHEM, V278, P42920, DOI 10.1074/jbc.M305827200
   Goralska M, 2001, INVEST OPHTH VIS SCI, V42, P1721
   Gruber M, 2004, J NUTR, V134, P2387, DOI 10.1093/jn/134.9.2387
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamamichi S, 2003, EXP EYE RES, V77, P575, DOI 10.1016/S0014-4835(03)00193-3
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   KROHN DL, 1981, AM J OPHTHALMOL, V91, P598, DOI 10.1016/0002-9394(81)90057-X
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Lee DH, 2004, CLIN CHEM, V50, P582, DOI 10.1373/clinchem.2003.028852
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Meyers Sanford M, 2004, Trans Am Ophthalmol Soc, V102, P83
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Mukesh BN, 2006, ARCH OPHTHALMOL-CHIC, V124, P79, DOI 10.1001/archopht.124.1.79
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rezai KA, 2008, GRAEF ARCH CLIN EXP, V246, P671, DOI 10.1007/s00417-006-0484-2
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   Rondanelli M, 1997, AGING-CLIN EXP RES, V9, P221, DOI 10.1007/BF03340153
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Suzuki M, 2007, MOL VIS, V13, P772
   Tan AG, 2008, AM J CLIN NUTR, V87, P1899, DOI 10.1093/ajcn/87.6.1899
   Tanito M, 2006, EXP EYE RES, V83, P1493, DOI 10.1016/j.exer.2006.08.006
   Tessier F, 1998, INT J VITAM NUTR RES, V68, P309
   Thurnham DI, 2007, NUTR RES REV, V20, P163, DOI 10.1017/S0954422407842235
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Tucker KL, 1999, J NUTR, V129, P438, DOI 10.1093/jn/129.2.438
   Vu HTV, 2006, INVEST OPHTH VIS SCI, V47, P3783, DOI 10.1167/iovs.05-0587
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   Winkler BS, 1999, MOL VIS, V5
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zigler JS, 2006, DUANES CLIN OPHTHALM, V1
NR 82
TC 13
Z9 14
U1 0
U2 11
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAY
PY 2011
VL 76
IS 5
BP 741
EP 744
DI 10.1016/j.mehy.2011.02.013
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 757KT
UT WOS:000290084600035
PM 21354712
DA 2022-11-30
ER

PT J
AU Kang, KH
   Lemke, G
   Kim, JW
AF Kang, Kyung Hwa
   Lemke, Greg
   Kim, Jin Woo
TI The PI3K-PTEN tug-of-war, oxidative stress and retinal degeneration
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
ID AGE-RELATED MACULOPATHY; GROWTH-FACTOR RECEPTOR; PIGMENT EPITHELIUM;
   REDOX REGULATION; MACULAR DEGENERATION; MOLECULAR-MECHANISMS;
   TUMOR-SUPPRESSOR; BETA-CATENIN; PROTEIN PHOSPHATASES; PHOTORECEPTOR
   CELLS
AB The retinal pigment epithelium (RPE) is indispensable for photoreceptor function, not only because it provides functional photopigments to photoreceptors, but also because it eliminates oxidatively damaged materials from photoreceptors. Maintaining homeostatic antioxidative programs that support a healthy RPE is therefore important for the normal functioning of the eye. These homeostatic mechanisms, however, often fail in aged RPE cells that have been exposed repeatedly to excessive oxidative stress. When RPE cells succumb to oxidative stress, their death contributes to the development of retinal degenerative diseases such as age-related macular degeneration. Recent studies have highlighted the importance of reciprocal phosphoinositide signaling events orchestrated by phosphoinositide 3-kinase (PI3K) and phosphatase and tensin homolog (PTEN) in the homeostatic programs that protect RPE cells against oxidative stress. Here, we discuss the role of PI3K signaling pathways in RPE cells and suggest that they might be crucial targets of oxidative molecules that initiate early pathological events in retinal degenerative diseases.
C1 [Kang, Kyung Hwa; Kim, Jin Woo] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
   [Lemke, Greg] Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.
C3 Korea Advanced Institute of Science & Technology (KAIST); Salk Institute
RP Kim, JW (通讯作者)，Korea Adv Inst Sci & Technol, Dept Biol Sci, 335 Gwahangno, Taejon 305701, South Korea.
EM jinwookim@kaist.ac.kr
RI KIM, JIN WOO/C-1655-2011
OI KIM, JIN WOO/0000-0003-0767-1918
FU Ministry of Health, Welfare and Family Affairs [A084337]; Korean
   Ministry of Education, Science and Technology
   [M10748000222-08N4800-22210, M10641000055-07N4100-05510]; NATIONAL EYE
   INSTITUTE [R01EY017478] Funding Source: NIH RePORTER
FX We appreciate the efforts of Walton Jones (KAIST), who read and edited
   the manuscript. This work was supported by a grant from the Korean
   Health Technology Research and Development Project, Ministry of Health,
   Welfare and Family Affairs (A084337), and by the Research Program for
   New Drug Target Discovery (M10748000222-08N4800-22210) and Stem Cell
   Research (M10641000055-07N4100-05510) grants from the Korean Ministry of
   Education, Science and Technology.
CR Alema S, 2007, BBA-MOL CELL RES, V1773, P47, DOI 10.1016/j.bbamcr.2006.06.001
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Barnstable CJ, 2006, ADV EXP MED BIOL, V572, P291
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chiarugi P, 2005, FREE RADICAL RES, V39, P353, DOI 10.1080/10715760400027987
   Chiarugi P, 2001, IUBMB LIFE, V52, P55, DOI 10.1080/15216540252774775
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Comer FI, 2007, CELL, V128, P239, DOI 10.1016/j.cell.2007.01.010
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cross JV, 2006, ANTIOXID REDOX SIGN, V8, P1819, DOI 10.1089/ars.2006.8.1819
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dinauer MC, 2003, CURR OPIN HEMATOL, V10, P8, DOI 10.1097/00062752-200301000-00003
   Doonan F, 2004, CURR NEUROVASC RES, V1, P41, DOI 10.2174/1567202043480215
   Ellson C, 2006, EMBO J, V25, P4468, DOI 10.1038/sj.emboj.7601346
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7
   Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481
   Gaudry CA, 2001, J BIOL CHEM, V276, P24871, DOI 10.1074/jbc.M102731200
   Gosbell AD, 2006, INVEST OPHTH VIS SCI, V47, P2613, DOI 10.1167/iovs.05-0962
   GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335
   GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863
   Hawkins PT, 2007, BIOCHEM SOC SYMP, V74, P59, DOI 10.1042/BSS2007c06
   Herve JC, 2002, BIOL CELL, V94, P423, DOI 10.1016/S0248-4900(02)00017-5
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jin MH, 2009, J NEUROSCI, V29, P1486, DOI 10.1523/JNEUROSCI.3882-08.2009
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Kohli R, 2007, J BIOL CHEM, V282, P21327, DOI 10.1074/jbc.M701759200
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje
   Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109
   Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513
   Li GY, 2007, J NEUROSCI, V27, P203, DOI 10.1523/JNEUROSCI.0445-06.2007
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lien S., 2008, V181, P131
   Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009
   Luo Y, 2006, BRAIN RES, V1110, P55, DOI 10.1016/j.brainres.2006.06.059
   Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051
   McKay BS, 1997, EXP EYE RES, V65, P661, DOI 10.1006/exer.1997.0374
   Meng TC, 2004, J BIOL CHEM, V279, P37716, DOI 10.1074/jbc.M404606200
   Monga SPS, 2002, CANCER RES, V62, P2064
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Pacione LR, 2003, ANNU REV NEUROSCI, V26, P657, DOI 10.1146/annurev.neuro.26.041002.131416
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068
   Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009
   RANDO RR, 1992, PHOTOCHEM PHOTOBIOL, V56, P1145, DOI 10.1111/j.1751-1097.1992.tb09739.x
   Rao NA, 2008, INVEST OPHTH VIS SCI, V49, P1161, DOI 10.1167/iovs.07-1259
   Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593
   Ross SH, 2007, CELL SIGNAL, V19, P1521, DOI 10.1016/j.cellsig.2007.01.026
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Sarangarajan R, 2005, MOL VIS, V11, P482
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Seo JH, 2005, MOL BIOL CELL, V16, P348, DOI 10.1091/mbc.e04-05-0369
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x
   Taddei ML, 2002, CANCER RES, V62, P6489
   Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P1162
   TORNQUIST P, 1990, EYE, V4, P303, DOI 10.1038/eye.1990.41
   Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000
   Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594
   von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720
   Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Winkler BS, 2008, INVEST OPHTH VIS SCI, V49, P3259, DOI 10.1167/iovs.08-1785
   Winkler BS, 1999, MOL VIS, V5
   Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6
   Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P2242, DOI 10.1167/iovs.06-0560
   Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang JY, 2005, J CELL PHYSIOL, V204, P470, DOI 10.1002/jcp.20303
NR 100
TC 37
Z9 38
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD MAY
PY 2009
VL 15
IS 5
BP 191
EP 198
DI 10.1016/j.molmed.2009.03.005
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 455GE
UT WOS:000266745600001
PM 19380252
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Baker, ML
   Hand, PJ
   Wang, JJ
   Wong, TY
AF Baker, Michelle L.
   Hand, Peter J.
   Wang, Jie Jin
   Wong, Tien Y.
TI Retinal signs and stroke - Revisiting the link between the eye and brain
SO STROKE
LA English
DT Review
DE stroke; mortality; hypertensive retinopathy; diabetic retinopathy;
   population-based cohort
ID AGE-RELATED MACULOPATHY; POOLED DATA-ANALYSIS; ATHEROSCLEROSIS RISK;
   VEIN OCCLUSION; MICROVASCULAR ABNORMALITIES; CARDIOVASCULAR-DISEASE;
   VESSEL DIAMETERS; HYPERTENSIVE RETINOPATHY; DIABETIC-RETINOPATHY;
   MACULAR DEGENERATION
AB Background and Purpose-The retinal and cerebral vasculature share similar anatomic, physiological, and embryologicalcharacteristics. We reviewed the literature, focusing particularly on recent population-based studies, to examine the relationship between retinal signs and stroke.
   Summary of Review-Hypertensive retinopathy signs ( eg, focal retinal arteriolar narrowing, arterio-venous nicking) were associated with prevalent stroke, incident stroke, and stroke mortality, independent of blood pressure and other cerebrovascular risk factors. Diabetic retinopathy signs ( eg, microaneurysms, hard exudates) were similarly associated with incident stroke and stroke mortality. Retinal arteriolar emboli were associated with stroke mortality but not incident stroke. There were fewer studies on the association of other retinal signs such as retinal vein occlusion and age-related macular degeneration with stroke, and the results were less consistent.
   Conclusion-Many retinal conditions are associated with stroke, reflecting possible concomitant pathophysiological processes affecting both the eye and the brain. However, the incremental value of a retinal examination for prediction of future stroke risk remains to be determined.
C1 [Baker, Michelle L.; Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Baker, Michelle L.; Hand, Peter J.] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Sydney; Royal Melbourne Hospital; National University of Singapore;
   Singapore National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Cerviño, Alejandro/L-5853-2014; wang,
   jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Cerviño,
   Alejandro/0000-0001-8014-3279; Wang, Jie Jin/0000-0001-9491-4898
CR BOCK KD, 1984, HYPERTENSION, V6, P158
   BRUNO A, 1992, STROKE, V23, P900, DOI 10.1161/01.STR.23.6.900
   Cheung N, 2007, STROKE, V38, P398, DOI 10.1161/01.STR.0000254547.91276.50
   Chua B, 2005, AM J OPHTHALMOL, V139, P181, DOI 10.1016/j.ajo.2004.06.084
   Cooper LS, 2006, STROKE, V37, P82, DOI 10.1161/01.STR.0000195134.04355.e5
   Couper DJ, 2002, AM J OPHTHALMOL, V133, P78, DOI 10.1016/S0002-9394(01)01315-0
   Cugati S, 2006, EYE, V20, P1239, DOI 10.1038/sj.eye.6702085
   Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726
   Cugati S, 2006, STROKE, V37, P908, DOI 10.1161/01.STR.0000204118.87477.46
   Cugati S, 2007, OPHTHALMOLOGY, V114, P520, DOI 10.1016/j.ophtha.2006.06.061
   Davis TME, 1999, ARCH INTERN MED, V159, P1097, DOI 10.1001/archinte.159.10.1097
   DIMMITT SB, 1989, LANCET, V1, P1103
   Dodson PM, 1996, J HUM HYPERTENS, V10, P93
   DOZONO K, 1991, STROKE, V22, P993, DOI 10.1161/01.STR.22.8.993
   ELMAN MJ, 1990, OPHTHALMOLOGY, V97, P1543
   Gottlieb JL, 1998, ARCH OPHTHALMOL-CHIC, V116, P577, DOI 10.1001/archopht.116.5.577
   Greiner K, 1999, AM J OPHTHALMOL, V128, P69, DOI 10.1016/S0002-9394(99)00074-4
   Gunn RM, 1892, T OPHTHAL SOC UK, V12, P124
   Hamada Yoh, 1993, Nippon Ganka Gakkai Zasshi, V97, P690
   Hayreh SS, 2005, PROG RETIN EYE RES, V24, P493, DOI 10.1016/j.preteyeres.2004.12.001
   HAYREH SS, 1989, OPHTHALMOLOGICA, V198, P247, DOI 10.1159/000310002
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   IINO K, 1993, DIABETES CARE, V16, P1405, DOI 10.2337/diacare.16.10.1405
   Ikram MK, 2006, NEUROLOGY, V66, P1339, DOI 10.1212/01.wnl.0000210533.24338.ea
   Ikram MK, 2006, BRAIN, V129, P182, DOI 10.1093/brain/awh688
   Ikram MK, 2004, INVEST OPHTH VIS SCI, V45, P2129, DOI 10.1167/iovs.03-1390
   Kaushik S, 2007, OPHTHALMOLOGY, V114, P113, DOI 10.1016/j.ophtha.2006.06.046
   Keith NM, 1939, AM J MED SCI, V197, P332, DOI 10.1097/00000441-193903000-00006
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026
   KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1487
   Klein R, 1997, Trans Am Ophthalmol Soc, V95, P329
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1446, DOI 10.1001/archopht.121.10.1446
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1063
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2002, OPHTHALMOLOGY, V109, P1225, DOI 10.1016/S0161-6420(02)01074-6
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644
   KLEIN R, 1997, T AM OPHTHAL SOC, V95, P348
   Klein R, 2000, T AM OPHTHAL SOC, V98, P133
   KLEIN R, 1999, ARCH OPHTHALMOL-CHIC, P117
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klijn CJM, 2002, STROKE, V33, P695, DOI 10.1161/hs0302.104619
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Longstreth WT, 2007, AM J EPIDEMIOL, V165, P78, DOI 10.1093/aje/kwj350
   MANSOUR AM, 1992, OPHTHALMOLOGICA, V204, P199, DOI 10.1159/000310294
   Marcucci R, 2001, THROMB HAEMOSTASIS, V86, P772
   Mitchell P, 1997, STROKE, V28, P63, DOI 10.1161/01.STR.28.1.63
   Mitchell P, 2000, CLIN EXP OPHTHALMOL, V28, P13, DOI 10.1046/j.1442-9071.2000.00218.x
   Mitchell P, 2005, NEUROLOGY, V65, P1005, DOI 10.1212/01.wnl.0000179177.15900.ca
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   NEWSOM RSB, 1992, GRAEF ARCH CLIN EXP, V230, P221, DOI 10.1007/BF00176292
   ODONNELL BA, 1992, AUST NZ J OPHTHALMOL, V20, P11, DOI 10.1111/j.1442-9071.1992.tb00697.x
   Pantoni L, 1997, STROKE, V28, P652, DOI 10.1161/01.STR.28.3.652
   PARR JC, 1974, AM J OPHTHALMOL, V77, P472, DOI 10.1016/0002-9394(74)90457-7
   Patton N, 2005, J ANAT, V206, P319, DOI 10.1111/j.1469-7580.2005.00395.x
   PETITTI DB, 1995, STROKE, V26, P593, DOI 10.1161/01.STR.26.4.593
   Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1
   RUBINSTEIN K, 1976, BRIT J OPHTHALMOL, V60, P148, DOI 10.1136/bjo.60.2.148
   Sabbatini M, 2002, CLIN EXP HYPERTENS, V24, P727, DOI 10.1081/CEH-120015348
   SCHEIE HG, 1953, AMA ARCH OPHTHALMOL, V49, P117
   Sherry LM, 2002, CLIN EXP OPHTHALMOL, V30, P179, DOI 10.1046/j.1442-9071.2002.00520.x
   SUZUKI A, 1995, MED HIST, V39, P1
   Tsaloumas MD, 2000, EYE, V14, P821, DOI 10.1038/eye.2000.230
   TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132
   Ueda Y, 2002, JPN J OPHTHALMOL, V46, P209, DOI 10.1016/S0021-5155(01)00500-7
   Varona JF, 2007, EUR NEUROL, V57, P212, DOI 10.1159/000099161
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WALSH JB, 1982, OPHTHALMOLOGY, V89, P1127
   Wang JJ, 2006, STROKE, V37, P1833, DOI 10.1161/01.STR.0000226929.23297.75
   WANG JJ, 2007, EUR HEART J
   Wise G.N., 1975, RETINAL CIRCULATION
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2007, AM J OPHTHALMOL, V143, P970, DOI 10.1016/j.ajo.2007.02.020
   Wong TY, 2006, ARCH INTERN MED, V166, P2388, DOI 10.1001/archinte.166.21.2388
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong Tien Yin, 2002, Curr Opin Ophthalmol, V13, P142, DOI 10.1097/00055735-200206000-00002
   Wong TY, 2002, JAMA-J AM MED ASSOC, V288, P67, DOI 10.1001/jama.288.1.67
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2003, INVEST OPHTH VIS SCI, V44, P4644, DOI 10.1167/iovs.03-0079
   Wong TY, 2003, OPHTHALMOLOGY, V110, P933, DOI 10.1016/S0161-6420(03)00084-8
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
NR 92
TC 148
Z9 152
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD APR
PY 2008
VL 39
IS 4
BP 1371
EP 1379
DI 10.1161/STROKEAHA.107.496091
PG 9
WC Clinical Neurology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 283JQ
UT WOS:000254632900054
PM 18309171
OA Bronze
DA 2022-11-30
ER

PT J
AU Niu, ZY
   Shi, YP
   Li, JD
   Qiao, SF
   Du, SB
   Chen, LC
   Tian, HB
   Wei, L
   Cao, HW
   Wang, J
   Gao, L
AF Niu, Zhanyu
   Shi, Yongpeng
   Li, Jiande
   Qiao, Shufan
   Du, Shaobo
   Chen, Linchi
   Tian, Huanbing
   Wei, Li
   Cao, Hanwen
   Wang, Ji
   Gao, Lan
TI Protective effect of rapamycin in models of retinal degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Rapamycin; Protective effect; Retinal degeneration; Inflammatory
   response; Oxidative stress
ID IODATE-INDUCED MODEL; SODIUM-IODATE; PIGMENT EPITHELIUM; MACULAR
   DEGENERATION; GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; METABOLISM;
   SIROLIMUS; DAMAGE; CELLS
AB Age-related macular degeneration (AMD) is a complex retinal disease with no viable treatment strategy. The causative mechanistic pathway for this disease is not yet clear. Therefore, it is highly warranted to screen effective drugs to treat AMD. Rapamycin are known to inhibit inflammation and has been widely used in the clinic as an immunosuppressant. This study aimed to investigate the protective effect of rapamycin on the AMD retinal degeneration model. The AMD models were established by injection of 35 mg/kg sodium iodate (NaIO3) into the tail vein. Then the treated mice intraperitoneally received rapamycin (2 mg/kg) once a day. The histomorphological analysis showed that rapamycin could inhibit retinal structure damage and apoptosis. Experiments revealed that rapamycin significantly attenuated inflammatory response and oxidative stress. Our experimental results demonstrated that rapamycin has protected the retinal against degeneration induced by NaIO3. The therapeutic effect was more significant after 7 days of treatment. Therefore, our study potentially provides a powerful experimental support for the treatment of AMD.
C1 [Niu, Zhanyu; Shi, Yongpeng; Li, Jiande; Chen, Linchi; Tian, Huanbing; Wei, Li; Cao, Hanwen; Wang, Ji; Gao, Lan] Lanzhou Univ, Sch Life Sci, Lanzhou 730000, Peoples R China.
   [Qiao, Shufan] Northwest Normal Univ, Coll Life Sci, Lanzhou 730000, Peoples R China.
   [Du, Shaobo] Lanzhou Univ, Sch Stomatol, Lanzhou 730000, Peoples R China.
C3 Lanzhou University; Northwest Normal University - China; Lanzhou
   University
RP Gao, L (通讯作者)，Lanzhou Univ, Sch Life Sci, Lanzhou 730000, Peoples R China.
EM niuzhy18@lzu.edu.cn; shiyp17@lzu.edu.cn; lijd14@lzu.edu.cn;
   494000364@qq.com; dusb@lzu.edu.cn; chenlch14@lzu.edu.cn;
   tianhb19@lzu.edu.cn; weil18@lzu.edu.cn; caohw20@lzu.edu.cn;
   jwang2020@lzu.edu.cn; gaolan@lzu.edu.cn
OI Du, Shaobo/0000-0003-4534-386X
FU National Natural Science Foundation of China [31471953]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 31471953). The funders had no role in the design of the
   study; collection, analysis and interpretation of data; and writing of
   the manuscript.
CR Alexander NS, 2017, J BIOL CHEM, V292, P10983, DOI 10.1074/jbc.M117.780478
   Alsaeedi HA, 2019, J PHOTOCH PHOTOBIO B, V198, DOI 10.1016/j.jphotobiol.2019.111561
   Asare-Bediako B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020464
   Berkowitz BA, 2017, INVEST OPHTH VIS SCI, V58, P3286, DOI 10.1167/iovs.17-21850
   Bermudez V, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00154
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Chen YY, 2018, EXP EYE RES, V167, P145, DOI 10.1016/j.exer.2017.11.001
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Go YM, 2020, FASEB J, V34, P12502, DOI 10.1096/fj.202000612R
   Hariri S, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.026017
   He JN, 2019, MOL NEUROBIOL, V56, P6586, DOI 10.1007/s12035-019-1559-5
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Ichikawa A, 2014, J NEUROSCI RES, V92, P692, DOI 10.1002/jnr.23358
   Jiang F, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-1325-5
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Liang JM, 2013, MOLECULES, V18, P12777, DOI 10.3390/molecules181012777
   Liu XM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193006
   Liu YL, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00389
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Mao XY, 2018, BIOMED PHARMACOTHER, V103, P517, DOI 10.1016/j.biopha.2018.04.038
   McVicar CM, 2011, DIABETES, V60, P2995, DOI 10.2337/db11-0026
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P1007
   Obata R, 2005, EYE, V19, P464, DOI 10.1038/sj.eye.6701531
   Okamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146517
   Palanisamy K, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4333-x
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Rai R, 2004, FEMS YEAST RES, V5, P29, DOI 10.1016/j.femsyr.2004.06.004
   Reddy B, 2015, GENET RES INT, V2015, DOI 10.1155/2015/638679
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Shi YP, 2020, TOXICOL LETT, V334, P66, DOI 10.1016/j.toxlet.2020.09.018
   Singh VB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10241-0
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Wang FF, 2020, EUR J PHARMACOL, V884, DOI 10.1016/j.ejphar.2020.173369
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wei HY, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0209-z
   Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012
   Weichhart T, 2009, TRENDS IMMUNOL, V30, P218, DOI 10.1016/j.it.2009.02.002
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang H, 2016, J GINSENG RES, V40, P1, DOI 10.1016/j.jgr.2015.03.003
   Yang JY, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0380-0
   Yang YP, 2016, SCI REP-UK, V6, DOI 10.1038/srep29546
   Zhang JL, 2015, INT J MOL SCI, V16, P1644, DOI 10.3390/ijms16011644
   Zhang XL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000252
   Zieger M, 2016, ONCOTARGET, V7, P9620, DOI 10.18632/oncotarget.7330
NR 52
TC 1
Z9 1
U1 1
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2021
VL 210
AR 108700
DI 10.1016/j.exer.2021.108700
EA JUL 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UO7XI
UT WOS:000694905500002
PM 34245755
DA 2022-11-30
ER

PT J
AU Narendran, S
   Pereira, F
   Yerramothu, P
   Apicella, I
   Wang, SB
   Ambati, K
   Hirahara, S
   Kim, Y
   Ambati, M
   Ambati, VL
   Huang, PR
   Varshney, A
   Nagasaka, Y
   Fukuda, S
   Baker, KL
   Marion, KM
   Deussing, JM
   Sadda, SR
   Gelfand, BD
   Ambati, J
AF Narendran, Siddharth
   Pereira, Felipe
   Yerramothu, Praveen
   Apicella, Ivana
   Wang, Shao-bin
   Ambati, Kameshwari
   Hirahara, Shuichiro
   Kim, Younghee
   Ambati, Meenakshi
   Ambati, Vidya L.
   Huang, Peirong
   Varshney, Akhil
   Nagasaka, Yosuke
   Fukuda, Shinichi
   Baker, Kirstie L.
   Marion, Kenneth M.
   Deussing, Jan M.
   Sadda, Srinivas R.
   Gelfand, Bradley D.
   Ambati, Jayakrishna
TI Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit
   amyloid-beta induced retinal pigmented epithelium degeneration
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID NLRP3 INFLAMMASOME ACTIVATION; FACTOR-H POLYMORPHISM; MACULAR
   DEGENERATION; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT-SYSTEM; OXIDATIVE
   STRESS; AGE; TOXICITY; CELLS; MOUSE
AB Nonfibrillar amyloid-beta oligomers (A beta Os) are a major component of drusen, the sub-retinal pigmented epithelium (RPE) extracellular deposits characteristic of age-related macular degeneration (AMD), a common cause of global blindness. We report that A beta Os induce RPE degeneration, a clinical hallmark of geographic atrophy (GA), a vision-threatening late stage of AMD that is currently untreatable. We demonstrate that A beta Os induce activation of the NLRP3 inflammasome in the mouse RPE in vivo and that RPE expression of the purinergic ATP receptor P2RX7, an upstream mediator of NLRP3 inflammasome activation, is required for A beta O-induced RPE degeneration. Two classes of small molecule inflammasome inhibitors-nucleoside reverse transcriptase inhibitors (NRTIs) and their antiretrovirally inert modified analog Kamuvudines-both inhibit A beta Os-induced RPE degeneration. These findings crystallize the importance of P2RX7 and NLRP3 in a disease-relevant model of AMD and identify inflammasome inhibitors as potential treatments for GA.
C1 [Narendran, Siddharth; Pereira, Felipe; Yerramothu, Praveen; Apicella, Ivana; Wang, Shao-bin; Ambati, Kameshwari; Hirahara, Shuichiro; Kim, Younghee; Ambati, Meenakshi; Huang, Peirong; Varshney, Akhil; Nagasaka, Yosuke; Fukuda, Shinichi; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22908 USA.
   [Narendran, Siddharth; Pereira, Felipe; Yerramothu, Praveen; Apicella, Ivana; Wang, Shao-bin; Ambati, Kameshwari; Hirahara, Shuichiro; Kim, Younghee; Ambati, Meenakshi; Huang, Peirong; Varshney, Akhil; Nagasaka, Yosuke; Fukuda, Shinichi; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Narendran, Siddharth] Aravind Eye Care Syst, Madurai, Tamil Nadu, India.
   [Pereira, Felipe] Univ Fed Sao Paulo, Escola Paulista Med, Dept Oftalmol & Ciencias Visuais, Sao Paulo, Brazil.
   [Ambati, Meenakshi; Ambati, Vidya L.] Ctr Digital Image Evaluat, Charlottesville, VA USA.
   [Baker, Kirstie L.; Marion, Kenneth M.; Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Deussing, Jan M.] Max Planck Inst Psychiat, Dept Stress Neurobiol & Neurogenet, Mol Neurogenet, Munich, Germany.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Gelfand, Bradley D.] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
C3 University of Virginia; University of Virginia; Universidade Federal de
   Sao Paulo (UNIFESP); Doheny Eye Institute; Max Planck Society;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Virginia; University of Virginia;
   University of Virginia
RP Ambati, J (通讯作者)，Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22908 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
EM ja9qr@virginia.edu
RI WANG, SHAO-BIN/Z-1810-2018; Deussing, Jan M/ABB-5993-2021
OI WANG, SHAO-BIN/0000-0002-6699-9406; Yerramothu,
   Praveen/0000-0001-6635-6681; PEREIRA, FELIPE/0000-0001-8884-2816
FU NIH [R01EY028027, R01EY29799, R01EY031039]; DuPont Guerry, III,
   Professorship; University of Virginia Strategic Investment Fund;
   BrightFocus Foundation; Owens Family Foundation
FX We thank G.S. Bloom, V.M. Dixit, F. Martinon, G. Nunez, and P. Schneider
   for reagents, mice, and technical guidance; and D. Robertson, G.
   Pattison, and K.A. Fox for their technical assistance. J.A. has received
   support from NIH grants (R01EY028027, R01EY29799, R01EY031039), DuPont
   Guerry, III, Professorship, a gift from Mr. and Mrs. Eli W. Tullis, and
   the University of Virginia Strategic Investment Fund; B.D.G. has
   received support from NIH grants (R01EY028027 and R01EY031039),
   BrightFocus Foundation, and the Owens Family Foundation. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH. The funders had no role in
   study design, data collection, and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Khalidi R, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0530-4
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18528-z
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Camell CD, 2019, CELL METAB, V30, P1024, DOI 10.1016/j.cmet.2019.10.006
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Carver KA, 2017, BIOCHEM BIOPH RES CO, V482, P81, DOI 10.1016/j.bbrc.2016.10.140
   Chiozzi P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42931-2
   De Cecco M, 2019, NATURE, V566, P73, DOI 10.1038/s41586-018-0784-9
   Deora V, 2020, GLIA, V68, P407, DOI 10.1002/glia.23728
   Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fekete C, 2019, NEUROSCIENCE, V405, P35, DOI 10.1016/j.neuroscience.2018.02.046
   Fontana L, 2014, NATURE, V511, P405, DOI 10.1038/511405a
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gombault A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00414
   Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490
   Hou YJ, 2019, NAT REV NEUROL, V15, P565, DOI 10.1038/s41582-019-0244-7
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   Johnson SC, 2015, AGING CELL, V14, P809, DOI 10.1111/acel.12362
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x
   Latz E, 2018, SEMIN IMMUNOL, V40, P61, DOI 10.1016/j.smim.2018.09.001
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lu A, 2014, CELL, V156, P1193, DOI 10.1016/j.cell.2014.02.008
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Metzger MW, 2017, PURINERG SIGNAL, V13, P153, DOI 10.1007/s11302-016-9546-z
   Mizutani T, 2015, INVEST OPHTH VIS SCI, V56, P7122, DOI 10.1167/iovs.15-17440
   Nakanishi A, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232-018-0085-6
   Narendran S, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.4
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Gadad BS, 2011, J ALZHEIMERS DIS, V24, P223, DOI 10.3233/JAD-2011-110182
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Sun JR, 2020, THERANOSTICS, V10, P11637, DOI 10.7150/thno.48064
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tzeng TC, 2016, CELL REP, V16, P571, DOI 10.1016/j.celrep.2016.06.011
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Yang Dongli, 2017, Vision (Basel), V1, DOI 10.3390/vision1020011
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 64
TC 4
Z9 5
U1 1
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD APR 14
PY 2021
VL 6
IS 1
AR 149
DI 10.1038/s41392-021-00537-z
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA RN5DL
UT WOS:000640371700002
PM 33850097
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mesquita, J
   Castro-de-Sousa, JP
   Vaz-Pereira, S
   Neves, A
   Passarinha, LA
   Tomaz, CT
AF Mesquita, Joana
   Paulo Castro-de-Sousa, Joao
   Vaz-Pereira, Sara
   Neves, Arminda
   Passarinha, Luis A.
   Tomaz, Candida T.
TI Vascular endothelial growth factors and placenta growth factor in
   retinal vasculopathies: Current research and future perspectives
SO CYTOKINE & GROWTH FACTOR REVIEWS
LA English
DT Review
DE Angiogenesis; Neovascularization; Ophthalmic disorders; Placental growth
   factor (PIGF); Vascular endothelial growth factor A (VEGF-A); Vascular
   endothelial growth factor B (VEGF-B)
ID FACTOR-B; VEGF-B; DIABETIC-RETINOPATHY; VITREOUS LEVELS; INCREASED
   EXPRESSION; VESSEL DEVELOPMENT; TYROSINE KINASE; FACTOR THERAPY;
   NITRIC-OXIDE; FACTOR-I
AB Vision loss due to disease or degeneration of the eye (retina, choroid, retinal veins, or macula) is a leading cause of blindness worldwide. In most cases, vision-threatening ocular diseases are accompanied by abnormal changes in the vasculature of the eye, especially the retina, and these conditions are collectively referred to as retinal vasculopathies. Impaired blood supply or hypoxia stimulates angiogenesis in the vascular and non-vascular sections of the eye, which results in neovascularization, leading to conditions such as diabetic retinopathy or age-related macular degeneration. Studies show that vascular endothelial growth factors: VEGF-A, VEGF-B, and placental growth factor (PlGF) are elevated in these diseases, and hence, these factors could be used as markers for disease prognosis and therapy. In this review, we discuss the function of these growth factors in normal development and disease, with focus on ocular disorders and emphasize the importance of accurately determining their levels in the vitreous and serum of patients for correct diagnosis and therapy.
C1 [Mesquita, Joana; Passarinha, Luis A.; Tomaz, Candida T.] UBI Univ Beira Interior, CICS Ctr Invest Ciencias Saude, Av Infante D Henrique, P-6201506 Covilha, Portugal.
   [Paulo Castro-de-Sousa, Joao; Passarinha, Luis A.] Univ Beira Interior, Fac Med Sci, Covilha, Portugal.
   [Paulo Castro-de-Sousa, Joao; Neves, Arminda] Ctr Hosp Leiria, Dept Ophthalmol, P-2410197 Leiria, Portugal.
   [Vaz-Pereira, Sara] Hosp Santa Maria, Dept Ophthalmol, Av Prof Egas Moniz, P-1649035 Lisbon, Portugal.
   [Vaz-Pereira, Sara] Univ Lisbon, Fac Med, Dept Ophthalmol, Av Prof Egas Moniz, P-1649035 Lisbon, Portugal.
C3 Universidade da Beira Interior; Universidade de Lisboa; Hospital Santa
   Maria; Universidade de Lisboa
RP Tomaz, CT (通讯作者)，UBI Univ Beira Interior, CICS Ctr Invest Ciencias Saude, Av Infante D Henrique, P-6201506 Covilha, Portugal.
EM joanamesquita3@gmail.com; jpcastrosousa@netcabo.pt;
   saravazpereira@gmail.com; armindaneves@hotmail.com;
   lpassarinha@fcsaude.ubi.pt; ctomaz@ubi.pt
RI Tomaz, Cândida Teixeira/F-9367-2014; Vaz-Pereira, Sara/P-5777-2019;
   Mesquita, Joana/P-8249-2017
OI Tomaz, Cândida Teixeira/0000-0002-0927-2331; Vaz-Pereira,
   Sara/0000-0001-6125-5486; Mesquita, Joana/0000-0003-0667-0809;
   Passarinha, Luis/0000-0001-6910-7576; Castro de Sousa, Joao
   Paulo/0000-0002-0025-1841
CR Aase K, 1999, DEV DYNAM, V215, P12, DOI 10.1002/(SICI)1097-0177(199905)215:1<12::AID-DVDY3>3.3.CO;2-E
   Abdel-Moety Doaa Attia, 2017, OPEN J OPHTHALMOL, V7, P79
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al Kahtani E, 2017, EYE, V31, P529, DOI 10.1038/eye.2016.246
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 1997, ARCH OPHTHALMOL-CHIC, V115, P1161, DOI 10.1001/archopht.1997.01100160331011
   Ando R, 2014, ACTA OPHTHALMOL, V92, pE245, DOI 10.1111/aos.12251
   Angi M., 2012, MEDIAT INFLAMM, V2012, P1, DOI DOI 10.1155/2012/148039
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Baharivand N, 2012, CLIN OPHTHALMOL, V6, P185, DOI 10.2147/OPTH.S27423
   Bakakos P, 2016, CURR TOP MED CHEM, V16, P1599, DOI 10.2174/1568026616666150930121157
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Bhardwaj S, 2003, HUM GENE THER, V14, P1451, DOI 10.1089/104303403769211664
   BREIER G, 1992, DEVELOPMENT, V114, P521
   Bry M, 2010, CIRCULATION, V122, P1725, DOI 10.1161/CIRCULATIONAHA.110.957332
   Burgos R, 1997, DIABETOLOGIA, V40, P1107, DOI 10.1007/s001250050794
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Cehofski L., 2017, INT J MOL SCI, V18, P1
   Celik T, 2005, CLIN CARDIOL, V28, P384, DOI 10.1002/clc.4960280808
   Chen SD, 2015, ACTA OPHTHALMOL, V93, pE556, DOI 10.1111/aos.12624
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   De Falco S, 2012, EXP MOL MED, V44, P1, DOI 10.3858/emm.2012.44.1.025
   Deng J, 1999, Yan Ke Xue Bao, V15, P17
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dewerchin M, 2012, COLD SPRING HARB PER, V2
   Di Bartolomeo M, 2015, CLIN INTERV AGING, V10, P127, DOI 10.2147/CIA.S54675
   Donnini S, 1999, J PATHOL, V189, P66, DOI 10.1002/(SICI)1096-9896(199909)189:1<66::AID-PATH390>3.0.CO;2-X
   Drugs U. S. Food & Drug Administration, 2017, DRUGS
   Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090
   Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4
   Fahmy I. A., 2008, INT J MED MED SCI, V3, P100
   Falkevall A, 2017, CELL METAB, V25, P713, DOI 10.1016/j.cmet.2017.01.004
   Feeney SA, 2003, INVEST OPHTH VIS SCI, V44, P839, DOI 10.1167/iovs.02-0040
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   FERRARA N, 1995, LAB INVEST, V72, P615
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Funatsu H, 2002, BRIT J OPHTHALMOL, V86, P311, DOI 10.1136/bjo.86.3.311
   Gao XX, 2016, RETINA-J RET VIT DIS, V36, P812, DOI 10.1097/IAE.0000000000000784
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445-2197.2007.04175.x
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   GOTO F, 1993, LAB INVEST, V69, P508
   Gryziewicz L, 2005, ADV DRUG DELIVER REV, V57, P2092, DOI 10.1016/j.addr.2005.09.009
   Guaiquil VH, 2014, P NATL ACAD SCI USA, V111, P17272, DOI 10.1073/pnas.1407227111
   Hagberg CE, 2010, NATURE, V464, P917, DOI 10.1038/nature08945
   Hailiang W, 2017, J OPHTHALMOL, V2017, P1
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Hernandez C, 2002, DIABETIC MED, V19, P655, DOI 10.1046/j.1464-5491.2002.00768.x
   Hernandez C, 2001, DIABETES CARE, V24, P516, DOI 10.2337/diacare.24.3.516
   Huang H, 2015, DIABETES, V64, P200, DOI 10.2337/db14-0016
   Huo XC, 2015, CELL PHYSIOL BIOCHEM, V35, P1787, DOI 10.1159/000373990
   Izaguirre M, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0866-3
   Karpanen T, 2008, CIRC RES, V103, P1018, DOI 10.1161/CIRCRESAHA.108.178459
   Khaliq A, 1998, LAB INVEST, V78, P109
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Kowalczuk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017462
   Krizova L, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/478509
   Lahteenvuo JE, 2009, CIRCULATION, V119, P845, DOI 10.1161/CIRCULATIONAHA.108.816454
   Lal N, 2017, AM J PHYSIOL-HEART C, V312, pH1163, DOI 10.1152/ajpheart.00659.2016
   Lee IG, 2006, EYE, V20, P546, DOI 10.1038/sj.eye.6701920
   Li X, 2008, ARTERIOSCL THROM VAS, V28, P1614, DOI 10.1161/ATVBAHA.107.158725
   Li XR, 2012, TRENDS MOL MED, V18, P119, DOI 10.1016/j.molmed.2011.11.006
   Liang L, 2017, CELL PHYSIOL BIOCHEM, V42, P407, DOI 10.1159/000477485
   Liu E, 2007, J AM SOC NEPHROL, V18, P2094, DOI 10.1681/ASN.2006010075
   Loukovaara S, 2015, J PROTEOME RES, V14, P5131, DOI 10.1021/acs.jproteome.5b00900
   Malik RA, 2005, J CELL MOL MED, V9, P692, DOI 10.1111/j.1582-4934.2005.tb00499.x
   Marneros AG, 2016, EMBO MOL MED, V8, P208, DOI 10.15252/emmm.201505613
   Mecollari V, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00328
   Merlak M, 2008, COLLEGIUM ANTROPOL, V32, P39
   Mesquita J., 2015, INVEST OPHTHALMOL VI
   Mesquita J., 2017, MED SCI, V5, P1
   Mesquita J, 2017, INVEST OPHTH VIS SCI, V58
   Mesquita J, 2016, INVEST OPHTH VIS SCI, V57
   Mitamura Y, 2002, DIABETES CARE, V25, P2352, DOI 10.2337/diacare.25.12.2352
   Mohamed TA, 2010, INT J OPHTHALMOL-CHI, V3, P19, DOI 10.3980/j.issn.2222-3959.2010.01.05
   Mould AW, 2003, ARTHRITIS RHEUM-US, V48, P2660, DOI 10.1002/art.11232
   Nauck M, 1997, AM J RESP CELL MOL, V16, P398, DOI 10.1165/ajrcmb.16.4.9115750
   Noma H, 2008, EUR J OPHTHALMOL, V18, P1017, DOI 10.1177/112067210801800628
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516
   Ozturk BT, 2009, MOL VIS, V15, P1906
   Paradowska-Gorycka A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160769
   Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639
   Porta R, 2017, CRIT REV ONCOL HEMAT, V113, P256, DOI 10.1016/j.critrevonc.2017.02.018
   Praidou A, 2009, CURR EYE RES, V34, P152, DOI 10.1080/02713680802585920
   Prior BM, 2004, J APPL PHYSIOL, V97, P1119, DOI 10.1152/japplphysiol.00035.2004
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Reddi AH, 2009, CYTOKINE GROWTH F R, V20, P341, DOI 10.1016/j.cytogfr.2009.10.015
   Reichelt M, 2003, CLIN EXP OPHTHALMOL, V31, P61, DOI 10.1046/j.1442-9071.2003.00602.x
   Riaz Syeda Kiran, 2015, Asian Pac J Cancer Prev, V16, P1677
   Ronca R, 2015, EXPERT OPIN THER TAR, V19, P1361, DOI 10.1517/14728222.2015.1062475
   Roskoski R, 2017, PHARMACOL RES, V120, P116, DOI 10.1016/j.phrs.2017.03.010
   Shimada H, 2009, INVEST OPHTH VIS SCI, V50, P2953, DOI 10.1167/iovs.08-2870
   Simo R, 2002, AM J OPHTHALMOL, V134, P376, DOI 10.1016/S0002-9394(02)01538-6
   Simpson DAC, 1999, BIOCHEM BIOPH RES CO, V262, P333, DOI 10.1006/bbrc.1999.1201
   Singh NK, 2013, BLOOD, V121, P1911, DOI 10.1182/blood-2012-03-419234
   Steeghs N, 2007, ANN SURG ONCOL, V14, P942, DOI 10.1245/s10434-006-9227-1
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Sun YJ, 2004, J CEREBR BLOOD F MET, V24, P1146, DOI 10.1097/01.WCB.0000134477.38980.38
   Tabakci BN, 2017, TURK OFTALMOL DERG, V47, P156, DOI 10.4274/tjo.56338
   Tah V., 2015, J OPHTHALMOL, V2015, P1
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tan GS, 2017, LANCET DIABETES ENDO, V5, P143, DOI 10.1016/S2213-8587(16)30052-3
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   van Buggenum IMH, 2002, DIABETOLOGIA, V45, P203, DOI 10.1007/s00125-001-0747-8
   Wang JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096899
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Yamashita H, 1999, EYE, V13, P372, DOI 10.1038/eye.1999.95
   Yamazaki Y, 2009, J BIOL CHEM, V284, P9885, DOI 10.1074/jbc.M809071200
   Yang W, 2003, J REPROD IMMUNOL, V60, P53, DOI 10.1016/S0165-0378(03)00082-2
   Yang XJ, 2015, P NATL ACAD SCI USA, V112, pE2900, DOI 10.1073/pnas.1503500112
   Yang XJ, 2013, P NATL ACAD SCI USA, V110, P13932, DOI 10.1073/pnas.1309629110
   Yokoi M, 2007, BRIT J OPHTHALMOL, V91, P397, DOI 10.1136/bjo.2006.100198
   Yorio T., 2007, OCULAR THERAPEUTICS
   Yun EJ, 2016, AM J PHYSIOL-LUNG C, V310, P1287, DOI 10.1152/ajplung.00229.2015
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
   Zhong XF, 2011, MOL VIS, V17, P492
   Zhou HC, 1997, CHIN J OPHTHALMOL, V33, P247
NR 128
TC 25
Z9 32
U1 0
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6101
EI 1879-0305
J9 CYTOKINE GROWTH F R
JI Cytokine Growth Factor Rev.
PD FEB
PY 2018
VL 39
BP 102
EP 115
DI 10.1016/j.cytogfr.2017.11.005
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GD0IY
UT WOS:000430185700009
PM 29248329
DA 2022-11-30
ER

PT J
AU Zhao, YT
   Zhao, JL
   Yang, J
   Liu, YH
   Zhao, YF
   Zheng, YL
   Xia, LK
   Wang, YT
AF Zhao, Yitian
   Zhao, Jingliang
   Yang, Jian
   Liu, Yonghuai
   Zhao, Yifan
   Zheng, Yalin
   Xia, Likun
   Wang, Yongtian
TI Saliency driven vasculature segmentation with infinite perimeter active
   contour model
SO NEUROCOMPUTING
LA English
DT Article
DE Saliency; Retinex; Active contour; Vascular segmentation
ID BLOOD-VESSEL SEGMENTATION; AUTOMATED DETECTION; RETINAL IMAGES; LEVEL;
   EXTRACTION
AB Automated detection of retinal blood vessels plays an important role in advancing the understanding of the mechanism, diagnosis and treatment of cardiovascular disease and many systemic diseases, such as diabetic retinopathy and age-related macular degeneration. Here, we propose a new framework for precisely segmenting retinal vasculatures. The proposed framework consists of three steps. A non-local total variation model is adapted to the Retinex theory, which aims to address challenges presented by intensity inhomogeneities, and the relatively low contrast of thin vessels compared to the background. The image is then divided into superpixels, and a compactness-based saliency detection method is proposed to locate the object of interest. For better general segmentation performance, we then make use of a new infinite active contour model to segment the vessels in each superpixel. The proposed framework has wide applications, and the results show that our model outperforms its competitors. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Zhao, Yitian; Zhao, Jingliang; Yang, Jian; Xia, Likun; Wang, Yongtian] Beijing Inst Technol, Sch Opt & Elect, Beijing Engn Res Ctr Mixed Real & Adv Display, Beijing 100081, Peoples R China.
   [Liu, Yonghuai] Aberystwyth Univ, Dept Comp Sci, Aberystwyth SY23 3DB, Dyfed, Wales.
   [Zhao, Yifan] Cranfield Univ, EPSRC Ctr Innovat Mfg Life Engn Serv, Cranfield MK43 0AL, Beds, England.
   [Zheng, Yalin] Univ Liverpool, Dept Eye & Vis Sci, Liverpool L69 3GA, Merseyside, England.
C3 Beijing Institute of Technology; Aberystwyth University; Cranfield
   University; UK Research & Innovation (UKRI); Engineering & Physical
   Sciences Research Council (EPSRC); University of Liverpool
RP Zhao, YT (通讯作者)，Beijing Inst Technol, Sch Opt & Elect, Beijing Engn Res Ctr Mixed Real & Adv Display, Beijing 100081, Peoples R China.
EM yitian.zhao@bit.edu.cn
RI Zhao, Yifan/ADE-5116-2022; Zheng, Yalin/N-6432-2017; Liu,
   Yonghuai/ABF-3794-2020; Zhao, Jingliang/AFQ-2878-2022
OI Zhao, Yifan/0000-0003-2383-5724; Zheng, Yalin/0000-0002-7873-0922; Zhao,
   Jingliang/0000-0002-1464-9105
FU National Basic Research Program of China [2013CB328806]; National
   Natural Science Foundation of China [81430039, 61572076]; Key Projects
   in the National Science & Technology Pillar Program [2013BAI01B01];
   National Hi-Tech Research and Development Program [2015AA043203]; China
   Postdoctoral Science Foundation [2015M570940]; Key Laboratory of
   Photoelectronic Imaging Technology and System, Beijing Institute of
   Technology Ministry of Education of China [2016OEIOF03]; EPSRC
   [EP/I033246/1] Funding Source: UKRI; Engineering and Physical Sciences
   Research Council [EP/I033246/1] Funding Source: researchfish
FX The project was supported by National Basic Research Program of China
   (2013CB328806), National Natural Science Foundation of China (81430039,
   61572076), the Key Projects in the National Science & Technology Pillar
   Program (2013BAI01B01), National Hi-Tech Research and Development
   Program (2015AA043203), and China Postdoctoral Science Foundation Grant
   (2015M570940), the Key Laboratory of Photoelectronic Imaging Technology
   and System, Beijing Institute of Technology Ministry of Education of
   China (2016OEIOF03).
CR Achanta R, 2012, IEEE T PATTERN ANAL, V34, P2274, DOI 10.1109/TPAMI.2012.120
   Al-Diri B, 2009, IEEE T MED IMAGING, V28, P1488, DOI 10.1109/TMI.2009.2017941
   [Anonymous], 2012, P ICVIP
   Bankhead P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032435
   Barchiesi M, 2010, MULTISCALE MODEL SIM, V8, P1715, DOI 10.1137/090773659
   Chan TF, 2001, IEEE T IMAGE PROCESS, V10, P266, DOI 10.1109/83.902291
   Chen L., 2011, P INT C IM GRAPH, P12
   Cheng MM, 2011, PROC CVPR IEEE, P409, DOI 10.1109/CVPR.2011.5995344
   Dizdaroglu Bekir, 2012, IEEE Int Workshop Mach Learn Signal Process, P1
   Elad M, 2005, LECT NOTES COMPUT SC, V3459, P217
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   Gao D, 2008, J VISION, V8, DOI 10.1167/8.7.13
   Hou X., 2007, IEEE C COMP VIS PATT, V1, P1, DOI [DOI 10.1109/CVPR.2007.383267, 10.1109/CVPR.2007.383267]
   Itti L, 1998, IEEE T PATTERN ANAL, V20, P1254, DOI 10.1109/34.730558
   Kirbas C, 2004, ACM COMPUT SURV, V36, P81, DOI 10.1145/1031120.1031121
   Lathen G, 2010, PATTERN RECOGN LETT, V31, P762, DOI 10.1016/j.patrec.2009.09.020
   Lesage D, 2009, MED IMAGE ANAL, V13, P819, DOI 10.1016/j.media.2009.07.011
   Li CM, 2008, IEEE T IMAGE PROCESS, V17, P1940, DOI 10.1109/TIP.2008.2002304
   Li CM, 2010, IEEE T IMAGE PROCESS, V19, P3243, DOI 10.1109/TIP.2010.2069690
   Luo G, 2008, IEEE T BIOMED ENG, V49, P168
   Lupascu CA, 2010, IEEE T INF TECHNOL B, V14, P1267, DOI 10.1109/TITB.2010.2052282
   Mahapatra D, 2011, IEEE T BIO-MED ENG, V58, P991, DOI 10.1109/TBME.2010.2093576
   Marin D, 2011, IEEE T MED IMAGING, V30, P146, DOI 10.1109/TMI.2010.2064333
   Martinez-Perez ME, 2007, MED IMAGE ANAL, V11, P47, DOI 10.1016/j.media.2006.11.004
   Mendonca AM, 2006, IEEE T MED IMAGING, V25, P1200, DOI 10.1109/TMI.2006.879955
   Narasimha-Iyer H, 2008, IEEE T INF TECHNOL B, V12, P406, DOI 10.1109/TITB.2007.897782
   Ng MK, 2011, SIAM J IMAGING SCI, V4, P345, DOI 10.1137/100806588
   Nguyen UTV, 2013, PATTERN RECOGN, V46, P703, DOI 10.1016/j.patcog.2012.08.009
   Orlando JI, 2014, LECT NOTES COMPUT SC, V8673, P634, DOI 10.1007/978-3-319-10404-1_79
   Palomera-Perez MA, 2010, IEEE T INF TECHNOL B, V14, P500, DOI 10.1109/TITB.2009.2036604
   Ricci E, 2007, IEEE T MED IMAGING, V26, P1357, DOI 10.1109/TMI.2007.898551
   Rossant F, 2011, J MED IMAG HEALTH IN, V1, P42, DOI 10.1166/jmihi.2011.1006
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Sum KW, 2008, IEEE T BIO-MED ENG, V55, P358, DOI 10.1109/TBME.2007.896587
   Sun KQ, 2012, IEEE T BIO-MED ENG, V59, P464, DOI 10.1109/TBME.2011.2174362
   Ujjwal, 2013, I S BIOMED IMAGING, P1436
   Wang SL, 2015, NEUROCOMPUTING, V149, P708, DOI 10.1016/j.neucom.2014.07.059
   Wang XF, 2016, NEUROCOMPUTING, V188, P90, DOI 10.1016/j.neucom.2014.10.112
   Wang YF, 2013, PATTERN RECOGN, V46, P2117, DOI 10.1016/j.patcog.2012.12.014
   You XG, 2011, PATTERN RECOGN, V44, P2314, DOI 10.1016/j.patcog.2011.01.007
   Yuan YX, 2015, IEEE T MED IMAGING, V34, P2046, DOI 10.1109/TMI.2015.2418534
   Zhang B, 2010, COMPUT BIOL MED, V40, P438, DOI 10.1016/j.compbiomed.2010.02.008
   ZHAO Y, 2015, SCI REP, V5
   Zhao YT, 2016, NEUROCOMPUTING, V197, P1, DOI 10.1016/j.neucom.2016.01.012
   Zhao YT, 2015, IEEE T MED IMAGING, V34, P1797, DOI 10.1109/TMI.2015.2409024
   Zhao YT, 2015, SCI REP-UK, V5, DOI 10.1038/srep11154
   Zhao YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122332
   Zhao YT, 2011, INT SYMP IMAGE SIG, P230
   Zhou SP, 2016, NEUROCOMPUTING, V186, P107, DOI 10.1016/j.neucom.2015.12.073
NR 52
TC 42
Z9 45
U1 1
U2 37
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-2312
EI 1872-8286
J9 NEUROCOMPUTING
JI Neurocomputing
PD OCT 11
PY 2017
VL 259
SI SI
BP 201
EP 209
DI 10.1016/j.neucom.2016.07.077
PG 9
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA FA9KP
UT WOS:000405764800022
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Fung, FKC
   Law, BYK
   Lo, ACY
AF Fung, Frederic K. C.
   Law, Betty Y. K.
   Lo, Amy C. Y.
TI Lutein Attenuates Both Apoptosis and Autophagy upon Cobalt (II)
   Chloride-Induced Hypoxia in Rat Muller Cells
SO PLOS ONE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; RETINAL GANGLION-CELLS; MACULAR
   DEGENERATION; OXIDATIVE STRESS; PROTECTS; ZEAXANTHIN; PATHWAY; PIGMENT;
   ISCHEMIA/REPERFUSION; RETINOPATHY
AB Retinal ischemia/reperfusion injury is a common feature of various retinal diseases such as glaucoma and diabetic retinopathy. Lutein, a potent anti-oxidant, is used to improve visual function in patients with age-related macular degeneration (AMD). Lutein attenuates apoptosis, oxidative stress and inflammation in animal models of acute retinal ischemia/hypoxia. Here, we further show that lutein improved Muller cell viability and enhanced cell survival upon hypoxia-induced cell death through regulation of intrinsic apoptotic pathway. Moreover, autophagy was activated upon treatment of cobalt (II) chloride, indicating that hypoxic injury not only triggered apoptosis but also autophagy in our in vitro model. Most importantly, we report for the first time that lutein treatment suppressed autophagosome formation after hypoxic insult and lutein administration could inhibit autophagic event after activation of autophagy by a pharmacological approach (rapamycin). Taken together, lutein may have a beneficial role in enhancing glial cell survival after hypoxic injury through regulating both apoptosis and autophagy.
C1 [Fung, Frederic K. C.; Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Law, Betty Y. K.] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
   [Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; Macau University of Science & Technology;
   University of Hong Kong
RP Lo, ACY (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.; Lo, ACY (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China.
EM amylo@hku.hk
RI Lo, Amy C. Y./C-1195-2009
OI Lo, Amy C. Y./0000-0003-4239-6851
FU Hong Kong Research Grants Council (GRF) [HKU773210M]; FDCT grant from
   the Science and Technology Development Fund of Macao [090/2013/A3]
FX Support was provided by Hong Kong Research Grants Council
   (GRF#HKU773210M) and an FDCT grant from the Science and Technology
   Development Fund of Macao (Project code: 090/2013/A3). Both funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of manuscript.
CR Barber AJ, 2011, INVEST OPHTH VIS SCI, V52, P1156, DOI 10.1167/iovs.10-6293
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bian QN, 2012, ADV EXP MED BIOL, V723, P43, DOI 10.1007/978-1-4614-0631-0_7
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Chang CL, 2013, J DENT SCI, V8, P8, DOI 10.1016/j.jds.2012.09.006
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Gallo S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.155
   Gao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046092
   Garcia M, 2003, ROLE MULLER GLIA NEU
   Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832
   Jin XH, 2006, INVEST OPHTH VIS SCI, V47, P2562, DOI 10.1167/iovs.05-1429
   Jung JY, 2008, BRAIN RES BULL, V76, P579, DOI 10.1016/j.brainresbull.2008.04.006
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kawasaki A, 2000, INVEST OPHTH VIS SCI, V41, P3444
   Khan SA, 2006, J MOL CELL CARDIOL, V41, P256, DOI 10.1016/j.yjmcc.2006.04.014
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koh PO, 2008, NEUROSCI LETT, V444, P74, DOI 10.1016/j.neulet.2008.08.024
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krishnaswamy R, 2010, FREE RADICAL BIO MED, V49, P50, DOI 10.1016/j.freeradbiomed.2010.03.016
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Li HF, 2015, NEUROSCI LETT, V588, P178, DOI 10.1016/j.neulet.2015.01.007
   Li L, 2013, INFLAMM RES, V62, P387, DOI 10.1007/s00011-013-0590-7
   Li SJ, 2012, APPL MATH COMPUT, V218, P6874, DOI 10.1016/j.amc.2011.12.064
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Li SY, 2010, INT J MOL SCI, V11, P2109, DOI 10.3390/ijms11052109
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Nataraj J, 2015, NUTR NEUROSCIENCE
   OJIMA F, 1993, FREE RADICAL BIO MED, V15, P377, DOI 10.1016/0891-5849(93)90037-U
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Peng PH, 2008, EXP EYE RES, V86, P637, DOI 10.1016/j.exer.2008.01.008
   Piras A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022514
   Produit-Zengaffinen N, 2014, AUTOPHAGY INDUCTION, P677
   Qin L, 2014, INVESTIGATIVE OPHTHA
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Shi GD, 2011, BIOCHEM BIOPH RES CO, V404, P941, DOI 10.1016/j.bbrc.2010.12.085
   Shinjo SK, 2007, CLIN RHEUMATOL, V26, P1248, DOI 10.1007/s10067-006-0478-9
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Song H, 2015, LIFE SCI, V126, P69, DOI 10.1016/j.lfs.2015.02.004
   Song ZC, 2012, CELL PROLIFERAT, V45, P239, DOI 10.1111/j.1365-2184.2012.00810.x
   Tian H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116453
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang M., 2015, MATH PROBL ENG, V2015, P1, DOI DOI 10.1155/2015/892549
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Wei T, 2015, EXP THER MED, V9, P476, DOI 10.3892/etm.2014.2084
   Willcox JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090864
   Woo TTY, 2013, GRAEF ARCH CLIN EXP, V251, P41, DOI 10.1007/s00417-012-2128-z
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xu HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063232
   Yang L, 2012, CELL MOL NEUROBIOL, V32, P1275, DOI 10.1007/s10571-012-9852-0
   Yao J, 2014, CELL PHYSIOL BIOCHEM, V33, P107, DOI 10.1159/000356654
   Zheng YQ, 2014, J PHARMACOL SCI, V124, P354, DOI 10.1254/jphs.13220FP
NR 60
TC 33
Z9 34
U1 1
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2016
VL 11
IS 12
AR e0167828
DI 10.1371/journal.pone.0167828
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EE4PU
UT WOS:000389587100209
PM 27936094
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kiser, PD
   Zhang, JY
   Badiee, M
   Li, QJ
   Shi, WX
   Sui, XW
   Golczak, M
   Tochtrop, GP
   Palczewski, K
AF Kiser, Philip D.
   Zhang, Jianye
   Badiee, Mohsen
   Li, Qingjiang
   Shi, Wuxian
   Sui, Xuewu
   Golczak, Marcin
   Tochtrop, Gregory P.
   Palczewski, Krzysztof
TI Catalytic mechanism of a retinoid isomerase essential for vertebrate
   vision
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; CRYSTAL-STRUCTURE; VISUAL CYCLE; KEY RESIDUES;
   VITAMIN-A; RPE65; ISOMERIZATION; SPECIFICITY; ISOMEROHYDROLASE;
   IDENTIFICATION
AB Visual function in vertebrates is dependent on the membrane-bound retinoid isomerase RPE65, an essential component of the retinoid cycle pathway that regenerates 11-cis-retinal for rod and cone opsins. The mechanism by which RPE65 catalyzes stereoselective retinoid isomerization has remained elusive because of uncertainty about how retinoids bind to its active site. Here we present crystal structures of RPE65 in complex with retinoid-mimetic compounds, one of which is in clinical trials for the treatment of age-related macular degeneration. The structures reveal the active site retinoid-binding cavity located near the membrane-interacting surface of the enzyme as well as an Fe-bound palmitate ligand positioned in an adjacent pocket. With the geometry of the RPE65-substrate complex clarified, we delineate a mechanism of catalysis that reconciles the extensive biochemical and structural research on this enzyme. These data provide molecular foundations for understanding a key process in vision and pharmacological inhibition of RPE65 with small molecules.
C1 [Kiser, Philip D.; Zhang, Jianye; Sui, Xuewu; Golczak, Marcin; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Cleveland Ctr Membrane & Struct Biol, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Badiee, Mohsen; Li, Qingjiang; Tochtrop, Gregory P.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Shi, Wuxian] Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA.
   [Shi, Wuxian] Case Western Reserve Univ, Sch Med, Case Ctr Synchrotron Biosci, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University; State
   University of New York (SUNY) System; United States Department of Energy
   (DOE); Brookhaven National Laboratory; Case Western Reserve University
RP Kiser, PD (通讯作者)，Case Western Reserve Univ, Sch Med, Cleveland Ctr Membrane & Struct Biol, Dept Pharmacol, Cleveland, OH 44106 USA.
EM kxp65@case.edu
OI Badiee, Mohsen/0000-0003-3722-4609
FU US National Institutes of Health [EY023948, EY009339, EY021126,
   CA157735]; Department of Veterans Affairs [IK2BX002683]; National
   Science Foundation [MCB-084480]; Office of Biological and Environmental
   Research of US Department of Energy (DOE); National Center for Research
   Resources [P41RR012408]; National Institute of General Medical Sciences
   of National Institutes of Health [P41GM103473]; National Institute of
   Biomedical Imaging and Bioengineering [P30-EB-09998]; National Institute
   of General Medical Sciences [P41 GM103403]; DOE Office of Science
   [DE-AC02-06CH11357]; Office of Basic Energy Sciences of US Department of
   Energy (DOE); NATIONAL CANCER INSTITUTE [R01CA157735] Funding Source:
   NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY023948,
   R01EY009339, R24EY021126, P30EY011373] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [P41GM103473] Funding Source: NIH RePORTER
FX We thank L.T. Webster Jr. for helpful comments on this manuscript. This
   work was supported by funding from US National Institutes of Health
   grants EY023948 (M.G.), EY009339 (K.P.), EY021126 (K.P.) and CA157735
   (G.P.T.), Department of Veterans Affairs IK2BX002683 (P.D.K.) and
   National Science Foundation MCB-084480 (G.P.T.). Data for this study
   were measured at beamline X29 of the National Synchrotron Light Source.
   Financial support came principally from the Offices of Biological and
   Environmental Research and of Basic Energy Sciences of the US Department
   of Energy (DOE) and from the National Center for Research Resources
   (P41RR012408), the National Institute of General Medical Sciences
   (P41GM103473) of the National Institutes of Health and the National
   Institute of Biomedical Imaging and Bioengineering (P30-EB-09998). We
   thank the staff at the Advanced Photon Source Northeastern Collaborative
   Access Team beamlines, supported by a grant from the National Institute
   of General Medical Sciences (P41 GM103403), for assistance with
   collection of preliminary diffraction data. This research used resources
   of the Advanced Photon Source, a US DOE Office of Science User Facility
   operated for the DOE Office of Science by Argonne National Laboratory
   under contract no. DE-AC02-06CH11357. K.P. is John H. Hord Professor of
   Pharmacology.
CR Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Bhat S, 2006, PROTEINS, V62, P244, DOI 10.1002/prot.20682
   Blatz P. E., 1968, CHEM COMMUN, V176
   BLATZ PE, 1968, J AM CHEM SOC, V90, P1296, DOI 10.1021/ja01007a033
   Caspi DD, 2004, ADV SYNTH CATAL, V346, P185, DOI 10.1002/adsc.200303188
   Chander P, 2012, J BIOL CHEM, V287, P30552, DOI 10.1074/jbc.M112.364596
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Crombie BS, 2001, J CHEM SOC PERK T 1, P206, DOI 10.1039/b005617k
   DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688
   Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Golczak M, 2010, J BIOL CHEM, V285, P9667, DOI 10.1074/jbc.M109.063941
   Jang GF, 2000, J BIOL CHEM, V275, P28128
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kirby AJ., 1972, COMPR CHEM KINETICS, V10, P57, DOI 10.1016/s0069-8040(08)70344-3
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Kiser PD, 2012, P NATL ACAD SCI USA, V109, pE2747, DOI 10.1073/pnas.1212025109
   Kiser PD, 2009, P NATL ACAD SCI USA, V106, P17325, DOI 10.1073/pnas.0906600106
   Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   LAW WC, 1988, BIOCHEMISTRY-US, V27, P4147, DOI 10.1021/bi00411a037
   Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c
   Messing SAJ, 2010, PLANT CELL, V22, P2970, DOI 10.1105/tpc.110.074815
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Pakhomova S, 2001, NAT STRUCT BIOL, V8, P447, DOI 10.1038/87617
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Read RJ, 2011, STRUCTURE, V19, P1395, DOI 10.1016/j.str.2011.08.006
   Redmond TM, 2010, J BIOL CHEM, V285, P1919, DOI 10.1074/jbc.M109.027458
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Scott I. L., 2010, WO Patent, Patent No. 2010048332
   Scott I. L., 2009, WO Patent, Patent No. 2009045479
   Smith M. B., 2001, MARCHS ADV ORGANIC C, V5th, P389
   SRIKRISHNA A, 1993, J CHEM SOC PERK T 1, P667, DOI 10.1039/p19930000667
   Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577
   Sui XW, 2014, J BIOL CHEM, V289, P12286, DOI 10.1074/jbc.M114.552836
   Takahashi Y, 2012, BIOCHEMISTRY-US, V51, P4217, DOI 10.1021/bi300144n
   Tickle IJ, 2012, ACTA CRYSTALLOGR D, V68, P454, DOI 10.1107/S0907444911035918
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230
   Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Zwart PH, 2008, ACTA CRYSTALLOGR D, V64, P99, DOI 10.1107/S090744490705531X
NR 50
TC 49
Z9 49
U1 0
U2 26
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
EI 1552-4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD JUN
PY 2015
VL 11
IS 6
BP 409
EP +
DI 10.1038/NCHEMBIO.1799
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CI1XW
UT WOS:000354539400011
PM 25894083
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Weiland, JD
   Cho, AK
   Humayun, MS
AF Weiland, James D.
   Cho, Alice K.
   Humayun, Mark S.
TI Retinal Prostheses: Current Clinical Results and Future Needs
SO OPHTHALMOLOGY
LA English
DT Review
ID ELECTRICAL-STIMULATION; GANGLION-CELLS; PERCEPTUAL THRESHOLDS;
   MORPHOMETRIC-ANALYSIS; RETINITIS-PIGMENTOSA; ARTIFICIAL VISION;
   VISUAL-PERCEPTION; MOUSE MODEL; AGE; IMPLANTATION
AB Degenerative diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP) primarily affect the photoreceptors, ultimately resulting in significant loss of vision. Retinal prostheses aim to elicit neural activity in the remaining retinal cells by detecting and converting light into electrical stimuli that can then be delivered to the retina. The concept of visual prostheses has existed for more than 50 years and recent progress shows promise, yet much remains to be understood about how the visual system will respond to artificial input after years of blindness that necessitate this type of prosthesis. This review focuses on 3 major areas: the histopathologic features of human retina affected by AMD and RP, current results from clinical trials, and challenges to overcome for continued improvement of retinal prostheses.
   Financial Disclosure(s) Proprietary or commercial disclosures may be found after the references. Ophthalmology 2011;118:2227-2237 (C) 2011 by the American Academy of Ophthalmology.
C1 [Weiland, James D.; Humayun, Mark S.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Cho, Alice K.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Humayun, MS (通讯作者)，1355 San Pablo St,DVRC 100, Los Angeles, CA 90033 USA.
EM humayun@usc.edu
OI Weiland, James/0000-0003-3453-9074
FU Second Sight Medical Products, Inc.; National Science Foundation,
   Arlington, Virginia [EEC-0310723]; Department of Energy, Washington, DC
   [DE-FC02-04ER63735]
FX Dr. Humayun is an equity/share holder in Second Sight Medical Products,
   Inc. Dr. Humayun is a consultant for Second Sight Medical Products, Inc.
   Drs. Humayun and Weiland have received grant funding from Second Sight
   Medical Products, Inc.; Supported by the National Science Foundation,
   Arlington, Virginia (grant no.: EEC-0310723); and the Department of
   Energy, Washington, DC (grant no.: DE-FC02-04ER63735). The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Ahuja AK, 2011, BRIT J OPHTHALMOL, V95, P539, DOI 10.1136/bjo.2010.179622
   Besch D, 2008, BRIT J OPHTHALMOL, V92, P1361, DOI 10.1136/bjo.2007.131961
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   Caspi A, 2009, ARCH OPHTHALMOL-CHIC, V127, P398, DOI 10.1001/archophthalmol.2009.20
   Chan LLH, 2011, J NEUROPHYSIOL, V105, P2687, DOI 10.1152/jn.00619.2010
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Ciavatta VT, 2009, INVEST OPHTH VIS SCI, V50, P4523, DOI 10.1167/iovs.08-2072
   Coffey RJ, 2009, ARTIF ORGANS, V33, P208, DOI 10.1111/j.1525-1594.2008.00620.x
   Cohen LG, 1999, ANN NEUROL, V45, P451, DOI 10.1002/1531-8249(199904)45:4<451::AID-ANA6>3.0.CO;2-B
   Cuenca N, 2004, NEUROSCIENCE, V127, P301, DOI 10.1016/j.neuroscience.2004.04.042
   Cuenca N, 2005, EUR J NEUROSCI, V22, P1057, DOI 10.1111/j.1460-9568.2005.04300.x
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   del Cerro M, 2000, INVEST OPHTH VIS SCI, V41, P3142
   Duncan JL, 2007, INVEST OPHTH VIS SCI, V48, P3283, DOI 10.1167/iovs.06-1422
   Fine I, 2003, NAT NEUROSCI, V6, P915, DOI 10.1038/nn1102
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   GRILL WM, 1995, IEEE ENG MED BIOL, V14, P375, DOI 10.1109/51.395310
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hood DC, 2009, INVEST OPHTH VIS SCI, V50, P2328, DOI 10.1167/iovs.08-2936
   Hornig R, 2007, ARTIFICIAL SIGHT BAS, P111, DOI [10.1007/978-0-387-49331-2_6, DOI 10.1007/978-0-387-49331-2_6]
   Hornig R, 2005, J NEURAL ENG, V2, pS129, DOI 10.1088/1741-2560/2/1/014
   Horsager A, 2009, INVEST OPHTH VIS SCI, V50, P1483, DOI 10.1167/iovs.08-2595
   Huang CB, 2008, P NATL ACAD SCI USA, V105, P4068, DOI 10.1073/pnas.0800824105
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Jacobson SG, 2010, INVEST OPHTH VIS SCI, V51, P1079, DOI 10.1167/iovs.09-4372
   Jensen RJ, 2008, VISION RES, V48, P1562, DOI 10.1016/j.visres.2008.04.016
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Klauke S, 2011, INVEST OPHTH VIS SCI, V52, P449, DOI 10.1167/iovs.09-4410
   Kolomiets B, 2010, NEUROBIOL DIS, V38, P47, DOI 10.1016/j.nbd.2009.12.025
   Mahadevappa M, 2005, IEEE T NEUR SYS REH, V13, P201, DOI 10.1109/TNSRE.2005.848687
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   MARG E, 1991, OPTOMETRY VISION SCI, V68, P427, DOI 10.1097/00006324-199106000-00004
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Merabet LB, 2005, NAT REV NEUROSCI, V6, P71, DOI 10.1038/nrn1586
   Merrill DR, 2005, J NEUROSCI METH, V141, P171, DOI 10.1016/j.jneumeth.2004.10.020
   Michelson R, 1986, Method and apparatus for visual prosthesis. U. S. patent, Patent No. 4628933
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Peterman MC, 2003, ARTIF ORGANS, V27, P975, DOI 10.1046/j.1525-1594.2003.07307.x
   Pu ML, 2006, INVEST OPHTH VIS SCI, V47, P3579, DOI 10.1167/iovs.05-1450
   Rattay F, 1999, NEUROSCIENCE, V89, P335, DOI 10.1016/S0306-4522(98)00330-3
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5355, DOI 10.1167/iovs.02-0819
   Roessler G, 2009, INVEST OPHTH VIS SCI, V50, P3003, DOI 10.1167/iovs.08-2752
   Sakaguchi H, 2009, J ARTIF ORGANS, V12, P206, DOI 10.1007/s10047-009-0467-2
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sekirnjak C, 2009, J NEUROPHYSIOL, V102, P3260, DOI 10.1152/jn.00663.2009
   Sommerhalder J, 2004, VISION RES, V44, P1693, DOI 10.1016/j.visres.2004.01.017
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Tassicker GE, 1956, Retinal stimulator. U. S. patent, Patent No. 2760483
   Thompson RW, 2003, INVEST OPHTH VIS SCI, V44, P5035, DOI 10.1167/iovs.03-0341
   Torab K, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/035001
   Tunc M, 2008, RETINA-J RET VIT DIS, V28, P1338, DOI 10.1097/IAE.0b013e31817b6b42
   Weiland JD, 2005, ANNU REV BIOMED ENG, V7, P361, DOI 10.1146/annurev.bioeng.7.060804.100435
   Weiland JD, 1999, GRAEF ARCH CLIN EXP, V237, P1007, DOI 10.1007/s004170050337
   Wilson BS, 2008, J REHABIL RES DEV, V45, P695, DOI 10.1682/JRRD.2007.10.0173
   Yanai D, 2007, AM J OPHTHALMOL, V143, P820, DOI 10.1016/j.ajo.2007.01.027
   Zhou CQ, 2010, ARTIF ORGANS, V34, P518, DOI 10.1111/j.1525-1594.2009.00915.x
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 68
TC 143
Z9 148
U1 1
U2 94
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2011
VL 118
IS 11
BP 2227
EP 2237
DI 10.1016/j.ophtha.2011.08.042
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 842EG
UT WOS:000296573500019
PM 22047893
DA 2022-11-30
ER

PT J
AU Zheng, MH
   Zhang, ZF
   Zhao, XC
   Ding, YQ
   Han, H
AF Zheng, Minhua
   Zhang, Zifeng
   Zhao, Xingcheng
   Ding, Yuqiang
   Han, Hua
TI The Notch signaling pathway in retinal dysplasia and retina vascular
   homeostasis
SO JOURNAL OF GENETICS AND GENOMICS
LA English
DT Article
DE Notch signaling; retinal dysplasia; vascular homeostasis;
   neovascularization; knockout mice
ID NEURAL STEM-CELLS; MOUSE RETINA; EMBRYONIC LETHALITY; GANGLION-CELL;
   DIFFERENTIATION; ANGIOGENESIS; MICE; PHOTORECEPTORS; MORPHOGENESIS;
   MECHANISMS
AB The retina is one of the most essential elements of vision pathway in vertebrate. The dysplasia of retina cause congenital blindness or vision disability in individuals, and the misbalance in adult retinal vascular homeostasis leads to neovascularization-associated diseases in adults, such as diabetic retinopathy or age-related macular degeneration. Many developmental signaling pathways are involved in the process of retinal development and vascular homeostasis. Among them, Notch signaling pathway has long been studied, and Notch signaling-interfered mouse models show both neural retina dysplasia and vascular abnormality. In this review, we discuss the roles of Notch signaling in the maintenance of retinal progenitor cells, specification of retinal neurons and glial cells, and the sustaining of retina vascular homeostasis, especially from the aspects of conditional knockout mouse models. The potential of Notch signal manipulation may provide a powerful cell fate-and neovascularization-controlling tool that could have important applications in treatment of retinal diseases.
C1 [Zheng, Minhua; Zhao, Xingcheng; Han, Hua] Fourth Mil Med Univ, Dept Med Genet & Dev Biol, Xian 710032, Peoples R China.
   [Zhang, Zifeng] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Ding, Yuqiang] Tongji Univ, Dept Anat & Neurobiol, Sch Med, Shanghai 200092, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Tongji University
RP Han, H (通讯作者)，Fourth Mil Med Univ, Dept Med Genet & Dev Biol, Xian 710032, Peoples R China.
EM huahan@fmmu.edu.cn
OI Ding, Yu-Qiang/0000-0003-1202-4635
FU Natural Science Foundation of China [30770693, 30830067]; Ministry of
   Science and Technology of China [2009CB521706]
FX This work was supported by the grants from the Natural Science
   Foundation of China (Nos. 30770693 and 30830067) and the Ministry of
   Science and Technology of China (No. 2009CB521706). And we thank the
   FASEB Journal and BioMed Central for their permission of reproduction
   and publication of their originally published data.
CR Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661
   Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255
   Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080
   DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4
   Dou GR, 2008, FASEB J, V22, P1606, DOI 10.1096/fj.07-9998com
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Fu XY, 2006, DEV BIOL, V299, P424, DOI 10.1016/j.ydbio.2006.08.015
   Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101
   Gao F, 2009, MOL CELL NEUROSCI, V40, P442, DOI 10.1016/j.mcn.2008.12.008
   Gariano RF, 2003, PROG RETIN EYE RES, V22, P295, DOI 10.1016/S1350-9462(02)00062-9
   Gerhart J, 1999, TERATOLOGY, V60, P226
   Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374
   Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228
   Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030
   Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005
   Hayward P, 2008, DEVELOPMENT, V135, P411, DOI 10.1242/dev.000505
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   HINDS JW, 1979, J COMP NEUROL, V187, P495, DOI 10.1002/cne.901870303
   HINDS JW, 1974, DEV BIOL, V37, P381, DOI 10.1016/0012-1606(74)90156-0
   Hojo M, 2000, DEVELOPMENT, V127, P2515
   Ilagan Maria Xenia G, 2007, Cell, V128, P1246
   Jadhav AR, 2006, DEVELOPMENT, V133, P913, DOI 10.1242/dev.02245
   Jadhav AP, 2006, P NATL ACAD SCI USA, V103, P18998, DOI 10.1073/pnas.0608155103
   Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Krebs LT, 2000, GENE DEV, V14, P1343
   Kume T, 2009, VASC CELL, V1, DOI 10.1186/2040-2384-1-8
   Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3
   Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244
   Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD
   Liu ZJ, 2006, FASEB J, V20, P1009, DOI 10.1096/fj.05-4880fje
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847
   Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2
   Neumann CJ, 2001, SEMIN CELL DEV BIOL, V12, P485, DOI 10.1006/scdb.2001.0272
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Poggi L, 2005, CURR OPIN CELL BIOL, V17, P676, DOI 10.1016/j.ceb.2005.09.004
   Radtke F, 2010, IMMUNITY, V32, P14, DOI 10.1016/j.immuni.2010.01.004
   Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104
   Riesenberg AN, 2009, J NEUROSCI, V29, P12865, DOI 10.1523/JNEUROSCI.3382-09.2009
   Rocha SF, 2009, DEV BIOL, V328, P54, DOI 10.1016/j.ydbio.2009.01.011
   Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   Takatsuka K, 2004, BRAIN RES, V1004, P148, DOI 10.1016/j.brainres.2004.01.045
   Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
   Yaron O, 2006, DEVELOPMENT, V133, P1367, DOI 10.1242/dev.02311
   Zheng MH, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-38
NR 55
TC 18
Z9 24
U1 1
U2 11
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1673-8527
J9 J GENET GENOMICS
JI J. Genet. Genomics
PD SEP
PY 2010
VL 37
IS 9
BP 573
EP 582
DI 10.1016/S1673-8527(09)60077-1
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 660WY
UT WOS:000282678400003
PM 20933211
DA 2022-11-30
ER

PT J
AU Wolf, S
AF Wolf, Sebastian
TI Current status of anti-vascular endothelial growth factor therapy in
   Europe
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; pegaptanib; ranibizumab; vascular
   endothelial growth factor; visual acuity
ID RANDOMIZED CLINICAL-TRIALS; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION;
   BEVACIZUMAB AVASTIN; PEGAPTANIB SODIUM; NONHUMAN PRIMATE; RANIBIZUMAB;
   VERTEPORFIN
AB Vascular endothelial growth factor (VEGF) is an important modulator of angiogenesis, and has been implicated in the pathology of a number of conditions, including age-related macular degeneration (AMD), diabetic retinopathy, and cancer. AMD is a progressive disease of the macula and the third major cause of blindness worldwide. If not treated appropriately, AMD can progress rapidly, causing legal blindness within months of the second eye becoming affected. Until recently, the treatment options for AMD have been limited, with photodynamic therapy (PDT) the mainstay treatment. Although PDT is effective at slowing disease progression, it rarely results in improved vision. Pegaptanib and ranibizumab are both anti-VEGF therapies licensed for the treatment of neovascular AMD in Europe; however, these drugs are not yet available in Japan. This article reviews the available clinical data on anti-VEGF therapies for the treatment of neovascular AMD in Europe, and considers the future of this exciting therapy.
C1 Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Wolf, S (通讯作者)，Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
FU Novartis Pharma AG
FX The author would like to thank Sarah Feaver, Ph. D., of Complete Medical
   Communications, who provided editorial support funded by Novartis Pharma
   AG.
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Bauer P, 2008, KLIN MONATSBL AUGENH, V225, P376, DOI 10.1055/s-2008-1027264
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo-Gonzalez C, 2008, BRIT J OPHTHALMOL, V92, P74, DOI 10.1136/bjo.2007.128942
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MEYER CH, 2008, INVEST OPHT IN PRESS, V49
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   *OSI EYET INC, 2006, MAC PEG SOD INJ PRES
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
NR 32
TC 26
Z9 27
U1 0
U2 5
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2008
VL 52
IS 6
BP 433
EP 439
DI 10.1007/s10384-008-0580-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 385CB
UT WOS:000261789400001
PM 19089562
OA Green Published
DA 2022-11-30
ER

PT J
AU Sharifzadeh, M
   Zhao, DY
   Bernstein, PS
   Gellermann, W
AF Sharifzadeh, Mohsen
   Zhao, Da-You
   Bernstein, Paul S.
   Gellermann, Werner
TI Resonance Raman imaging of macular pigment distributions in the human
   retina
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article
ID SPATIAL-DISTRIBUTION; OPTICAL-DENSITY; LUTEIN; AUTOFLUORESCENCE;
   ZEAXANTHIN; CAROTENOIDS; RISK; REFLECTOMETRY; DEGENERATION; PREVALENCE
AB We describe resonance Raman imaging (RRI) of macular pigment (MP) distributions in the living human eye. MP consists of the antioxidant carotenoid compounds lutein and zeaxanthin, is typically present in high concentrations in the healthy human macula relative to the peripheral retina, and is thought to protect this important central region from age-related macular degeneration. We demonstrate that RRI is capable of quantifying and imaging the spatially strongly varying MP distribution in the human retina. Using laser excitation of the MP molecules at 488 nm, and sequential camera detection of light emitted back from the retina at the MP's strongest Raman peak position and at an off-peak position, RRI maps of MP are obtained at a resolution below 50 mu m within a fraction of a second per exposure. RRI imaging can be carried out with undilated pupils and provides a highly molecule-specific diagnostic imaging approach for MP distributions in human subjects. (C) 2008 Optical Society of America.
C1 [Sharifzadeh, Mohsen; Gellermann, Werner] Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
   [Zhao, Da-You; Bernstein, Paul S.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Gellermann, W (通讯作者)，Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
EM werner@physics.utah.edu
FU NATIONAL EYE INSTITUTE [R01EY011600, R29EY011600] Funding Source: NIH
   RePORTER; NEI NIH HHS [R29 EY011600, R01 EY011600, EY11600, R01
   EY011600-06A2] Funding Source: Medline
CR *AM NAT STAND I, ANSIZ13612000
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   BERNSTEIN PS, 2007, MORAN EYE CTR
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   Chang Y, 2002, MED PHYS, V29, P2621, DOI 10.1118/1.1515761
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   Elsner AE, 2000, OPT EXPRESS, V6, P243, DOI 10.1364/OE.6.000243
   Ermakov I, 2004, J BIOMED OPT, V9, P139, DOI 10.1117/1.1627776
   Ermakov IV, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2139974
   *EY DIS CAS CONTR, 1994, JAMA-J AM MED ASSOC, V272, P1413
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gellermann W, 2002, OPT LETT, V27, P833, DOI 10.1364/OL.27.000833
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Savage GL, 2001, OPTOMETRY VISION SCI, V78, P386, DOI 10.1097/00006324-200106000-00010
   Sharifzadeh M, 2006, J OPT SOC AM A, V23, P2373, DOI 10.1364/JOSAA.23.002373
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van de Kraats J, 2007, J OPT SOC AM A, V24, P1842, DOI 10.1364/JOSAA.24.001842
   Zagers NPA, 2004, J OPT SOC AM A, V21, P2257, DOI 10.1364/JOSAA.21.002257
NR 42
TC 44
Z9 45
U1 0
U2 11
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1084-7529
EI 1520-8532
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD APR
PY 2008
VL 25
IS 4
BP 947
EP 957
DI 10.1364/JOSAA.25.000947
PG 11
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 292WP
UT WOS:000255297100014
PM 18382494
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Isola, V
   Pece, A
   Parodi, MB
AF Isola, Vincenzo
   Pece, Alfredo
   Parodi, Maurizio Battaglia
TI Choroidal ischemia after photodynamic therapy with verteporfin for
   choroidal neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION
AB PURPOSE: To report delay in choroidal perfusion suggestive of ischemia after photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV).
   DESIGN: Observational case series.
   METHODs: Retrospective review of all patients who developed choroidal ischemia after PDT.
   RESULTS: This vascular change was found in eight (2.1%) of 373 eyes of patients treated for CNV as a result of age-related macular degeneration (AMD) and in one (0.9%) of 114 eyes treated for pathologic myopia. A decrease of 3 lines of vision was reported to occur one week after treatment in patients with AMD. At the 12-month examination, patients did not exhibit any marked changes in visual acuity.
   CONCLUSIONS: Choroidal ischemia was an uncommon manifestation owing to the selectivity of verteporfin therapy and the existence of abundant anastomotic vascular connections in the choroid. The low incidence of this vascular event should not preclude counseling PDT in eyes that could benefit greatly from this therapy.
C1 Melegnano Hosp, Dept Ophthalmol, Retina & Angiog Serv, I-20077 Milan, Italy.
   Univ Trieste, Sch Med & Surg, Eye Clin, Trieste, Italy.
C3 University of Trieste
RP Isola, V (通讯作者)，Melegnano Hosp, Dept Ophthalmol, Retina & Angiog Serv, Via Pandina 1, I-20077 Milan, Italy.
EM isolavincenzo@aliceposta.it
RI Parodi, Maurizio Battaglia/K-7876-2016
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   ISOLA V, 2004, RETINA, V4, P618
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
NR 6
TC 36
Z9 39
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2006
VL 142
IS 4
BP 680
EP 683
DI 10.1016/j.ajo.2006.04.028
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092LS
UT WOS:000241098900026
PM 17011867
DA 2022-11-30
ER

PT J
AU Lebherz, C
   Maguire, AM
   Auricchio, A
   Tang, WX
   Aleman, TS
   Wei, ZY
   Grant, R
   Cideciyan, AV
   Jacobson, SG
   Wilson, JM
   Bennett, J
AF Lebherz, C
   Maguire, AM
   Auricchio, A
   Tang, WX
   Aleman, TS
   Wei, ZY
   Grant, R
   Cideciyan, AV
   Jacobson, SG
   Wilson, JM
   Bennett, J
TI Nonhuman primate models for diabetic ocular neovaseularization using
   AAV2-mediated overexpression of vascular endothelial growth factor
SO DIABETES
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   DOMINANT RETINITIS-PIGMENTOSA; OPTICAL COHERENCE TOMOGRAPHY; MEDIATED
   GENE-TRANSFER; RETINAL NEOVASCULARIZATION; MACULAR DEGENERATION; LASER
   PHOTOCOAGULATION; SUBRETINAL NEOVASCULARIZATION; RHODOPSIN MUTATION
AB Neovascularization leads to blindness in numerous ocular diseases, including diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, and sickle cell disease. More effective and stable treatments for ocular neovascularization are needed, yet there are major limitations in the present animal models. To develop primate models of diabetic retinopathy and choroidal neovascularization, rhesus monkeys were injected subretinally or intravitreally with an adeno-associated virus (AAV)-2 vector carrying the cDNA encoding human vascular endothelial growth factor (VEGF). Overexpression of VEGF was measured by intraocular fluid sampling over time. Neovascularization was evaluated by ophthalmoscopy through angiography, optical coherence tomography, and ultimately histopathology. Overexpression of VEGF through AAV2 results in rapid development of features of diabetic retinopathy or macular edema, depending on the targeted cell type/mode of production of VEGF and diffusion of VEGF. Nonhuman primate models will be useful in testing long-term safety and efficacy of novel therapeutic agents for blinding neovascular diseases.
C1 Univ Penn, Dept Med Genet, Philadelphia, PA 19104 USA.
   Univ Penn, Dept Ophthalmol, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   Telethon Inst Genet & Med, Naples, Italy.
C3 University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Medicine; Fondazione Telethon; Telethon Institute of Genetics & Medicine
   (TIGEM)
RP Bennett, J (通讯作者)，Univ Penn, Dept Med Genet, 310 Stellar Chance Bldg,422 curie Blvd, Philadelphia, PA 19104 USA.
EM jebennet@mail.med.upenn.edu
RI Cideciyan, Artur V/A-1075-2007; AURICCHIO, Alberto/AHE-7979-2022;
   Wilson, James M/F-9220-2011
OI Cideciyan, Artur V/0000-0002-2018-0905; AURICCHIO,
   Alberto/0000-0002-0832-2472; Wilson, James M/0000-0002-9630-3131;
   Jacobson, Samuel/0000-0003-2122-169X
FU NEI NIH HHS [EY13385, R01 EY12156, R01 EY10820, EY13203] Funding Source:
   Medline; NIDDK NIH HHS [5-P30-DK-47747-10] Funding Source: Medline;
   Telethon [TGM03P04, TGM06C03, TGM06S01, TGT06S01] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R01EY013203, R01EY013385, R01EY012156,
   R01EY010820] Funding Source: NIH RePORTER
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Auricchio A, 2001, HUM GENE THER, V12, P71, DOI 10.1089/104303401450988
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Bainbridge JWB, 2003, CLIN SCI, V104, P561, DOI 10.1042/CS20020314
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Cunningham S, 2000, INVEST OPHTH VIS SCI, V41, P4275
   Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Ishida K, 1999, INVEST OPHTH VIS SCI, V40, P1512
   Kaplan H, 1996, BRIT J OPHTHALMOL, V80, P101, DOI 10.1136/bjo.80.2.101
   Kijas JW, 2002, P NATL ACAD SCI USA, V99, P6328, DOI 10.1073/pnas.082714499
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   KUSAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P1070, DOI 10.1016/0006-291X(91)91529-L
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Meneses PI, 2001, GENE THER, V8, P646, DOI 10.1038/sj.gt.3301423
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mitamura Y, 2002, DIABETES CARE, V25, P2352, DOI 10.2337/diacare.25.12.2352
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Okamoto N, 1997, AM J PATHOL, V151, P281
   OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   PENN J, 1994, PEDIATR RES, P724
   Rakoczy PE, 2003, DIABETES, V52, P857, DOI 10.2337/diabetes.52.3.857
   Reich S, 2003, MOL VIS, V9, P210
   ROBINSON LM, 2001, EXP EYE RES, V74
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yu MJT, 1999, AUST NZ J OPHTHALMOL, V27, P250, DOI 10.1046/j.1440-1606.1999.00182.x
NR 45
TC 50
Z9 60
U1 0
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD APR
PY 2005
VL 54
IS 4
BP 1141
EP 1149
DI 10.2337/diabetes.54.4.1141
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 912QM
UT WOS:000228094300027
PM 15793254
DA 2022-11-30
ER

PT J
AU Kovacs, KD
   Ciulla, TA
   Kiss, S
AF Kovacs, Kyle D.
   Ciulla, Thomas A.
   Kiss, Szilard
TI Advancements in ocular gene therapy delivery: vectors and subretinal,
   intravitreal, and suprachoroidal techniques
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE Gene therapy; genome editing; inherited retinal disease; intravitreal;
   non-viral gene therapy; subretinal; suprachoroidal
ID HUMORAL IMMUNE-RESPONSE; COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN;
   MACULAR DEGENERATION; VISION IMPAIRMENT; OPEN-LABEL; INFLAMMATION;
   PROFILES; DISEASES; PHASE-1
AB Introduction Ocular gene therapy represents fertile ground for rapid innovation, with ever-expanding therapeutic strategies, molecular targets, and indications. Areas covered Potential indications for ocular gene therapy have classically focused on inherited retinal disease (IRD) but more recently include acquired retinal diseases, such as neovascular age-related macular degeneration, geographic atrophy, and diabetic retinopathy. Ocular gene therapy strategies have proliferated recently, and include gene augmentation, gene inactivation, gene editing, RNA modulation, and gene-independent gene augmentation. Viral vector therapeutic constructs include adeno-associated virus and lentivirus and continue to evolve through directed evolution and rationale design. Ocular gene therapy administration techniques have expanded beyond pars plana vitrectomy with subretinal injection to intravitreal injection and suprachoroidal injection. Expert opinion The success of treatment for IRD, paired with the promise of clinical research in acquired retinal diseases and in administration techniques, has raised the possibility of in-office gene therapy for common retinal disorders within the next 5 to 10 years.
C1 [Kovacs, Kyle D.; Kiss, Szilard] Weill Cornell Med Coll, Dept Ophthalmol, Retina Serv, 1305 York Ave,11th Floor, New York, NY 10021 USA.
   [Ciulla, Thomas A.] Indiana Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN USA.
C3 Cornell University; Indiana University System; Indiana University
   Bloomington
RP Kiss, S (通讯作者)，Weill Cornell Med Coll, Dept Ophthalmol, Retina Serv, 1305 York Ave,11th Floor, New York, NY 10021 USA.
EM szk7001@med.cornell.edu
OI Ciulla, Thomas/0000-0001-5557-6777; Kiss, Szilard/0000-0003-3433-8432
CR Amato A, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.750586
   [Anonymous], AAVCAGS59 TREATM WET
   [Anonymous], TREATM ADV DRY AG RE
   [Anonymous], EXPLORE PHAS 2 STUD
   [Anonymous], HORIZON PHAS 2 STUD
   Balaggan KS, 2006, J GENE MED, V8, P275, DOI 10.1002/jgm.845
   Berry MH, 2022, CURR OPIN PHARMACOL, V65, DOI 10.1016/j.coph.2022.102259
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bohm S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5614
   Calcedo R, 2011, CLIN VACCINE IMMUNOL, V18, P1586, DOI 10.1128/CVI.05107-11
   Campochiaro PA., 2021, PRESENTED ANGIOGENES
   Campochiaro PA, 2018, OPHTHALMOL RETINA, V2, P320, DOI 10.1016/j.oret.2017.07.013
   Carvalho LS, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00503
   Chan YK, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd3438
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Cho GY, 2019, MOL DIAGN THER, V23, P113, DOI 10.1007/s40291-018-0377-1
   Chung SH, 2021, HUM GENE THER, V32, P682, DOI 10.1089/hum.2020.281
   Cideciyan AV, 2021, NAT MED, V27, P785, DOI 10.1038/s41591-021-01297-7
   Cideciyan AV, 2018, P NATL ACAD SCI USA, V115, pE8547, DOI 10.1073/pnas.1805055115
   Ciulla Thomas, 2021, Int Ophthalmol Clin, V61, P1, DOI 10.1097/IIO.0000000000000372
   Ciulla Thomas, 2021, Int Ophthalmol Clin, V61, P3, DOI 10.1097/IIO.0000000000000359
   clinicaltrials.gov, SEARCH ACT RET GEN T
   Curcio CA, 2017, JAMA OPHTHALMOL, V135, P843, DOI 10.1001/jamaophthalmol.2017.2008
   Davis JL, 2018, AM J OPHTHALMOL, V196, pXXV, DOI 10.1016/j.ajo.2018.08.038
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   EMI K, 1989, INVEST OPHTH VIS SCI, V30, P233
   Fenner BJ, 2022, FRONT GENET, V12, DOI 10.3389/fgene.2021.794805
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fry LE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030777
   Gange WS, 2022, OPHTHALMOL RETINA, V6, P58, DOI 10.1016/j.oret.2021.03.016
   Garoon RB, 2016, CURR OPIN OPHTHALMOL, V27, P268, DOI 10.1097/ICU.0000000000000256
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Han IC, 2019, HUM GENE THER, V30, P1371, DOI 10.1089/hum.2019.159
   Jeffery RCH, 2021, OPHTHALMIC GENET, V42, P431, DOI 10.1080/13816810.2021.1913610
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hernandez-Juarez J, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.698521
   Ho A., 2021, PRESENTED RETINA SOC
   Ho AC., 2021, ANG EX DEG 2021 C
   Hu ML, 2021, CLIN EXP OPTOM, V104, P444, DOI 10.1080/08164622.2021.1880863
   Hung SS, 2018, METHODS MOL BIOL, V1715, P113, DOI 10.1007/978-1-4939-7522-8_9
   Hussain RM, 2018, EXPERT OPIN BIOL TH, V18, P1049, DOI 10.1080/14712598.2018.1513486
   Jiang DJ, 2018, GENES-BASEL, V9, DOI 10.3390/genes9120575
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jolly JK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01076
   Kalesnykas G, 2017, CURR GENE THER, V17, P235, DOI 10.2174/1566523217666171003170348
   Khanani AM, 2021, ADVM 022 INTRAVITREA
   Khanani AM, 2022, EYE, V36, P303, DOI 10.1038/s41433-021-01842-1
   Kim YC, 2014, INVEST OPHTH VIS SCI, V55, P7387, DOI 10.1167/iovs.14-14651
   Kotterman MA, 2015, GENE THER, V22, P116, DOI 10.1038/gt.2014.115
   Kumar M, 2001, HUM GENE THER, V12, P1893, DOI 10.1089/104303401753153947
   Ladha R, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.846782
   Lam BL, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-02145-0
   Lam S, 2014, GENES DIS, V1, P227, DOI 10.1016/j.gendis.2014.09.002
   Leroy BP, 2021, RETINA-J RET VIT DIS, V41, P898, DOI 10.1097/IAE.0000000000003133
   Li QH, 2008, MOL VIS, V14, P1760
   Liew G, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004015
   London NJS., 2021, ANN M RETINA SOC SEP
   Lu YC, 2020, NATURE, V588, P124, DOI 10.1038/s41586-020-2975-4
   Maeder ML, 2019, NAT MED, V25, P229, DOI 10.1038/s41591-018-0327-9
   McDougald DS, 2019, MOL THER, V27, P1313, DOI 10.1016/j.ymthe.2019.04.009
   Mehta Neesurg, 2021, Int Ophthalmol Clin, V61, P151, DOI 10.1097/IIO.0000000000000366
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Moreno AM, 2018, MOL THER, V26, P1818, DOI 10.1016/j.ymthe.2018.04.017
   Mowat FM, 2014, GENE THER, V21, P96, DOI 10.1038/gt.2013.64
   Olivares-Gonzalez L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042096
   Patrizi C, 2021, AM J HUM GENET, V108, P295, DOI 10.1016/j.ajhg.2021.01.006
   Pavlou M, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013392
   Pennesi ME., 2022, OPHTHALMOL RETINA
   Petrs-Silva H, 2011, MOL THER, V19, P293, DOI 10.1038/mt.2010.234
   Pieramici D., 2021, PRESENTED ANN M AM S
   Pinilla I, 2022, ANTIOXIDANTS-BASEL, V11, DOI 10.3390/antiox11061086
   Prosseda PP, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020269
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Puppo A, 2014, GENE THER, V21, P855, DOI 10.1038/gt.2014.57
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Reichel FF, 2018, INVEST OPHTH VIS SCI, V59, P1910, DOI 10.1167/iovs.17-22494
   Riedmayr LM, 2022, NAT PROTOC, V17, P781, DOI 10.1038/s41596-021-00666-3
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Russell SR, 2022, NAT MED, V28, P1014, DOI 10.1038/s41591-022-01755-w
   Sahel JA, 2021, NAT MED, V27, P1223, DOI 10.1038/s41591-021-01351-4
   Seitz IP, 2017, INVEST OPHTH VIS SCI, V58, P5784, DOI 10.1167/iovs.17-22473
   Sengillo JD, 2022, OPHTHALMOL RETINA, V6, P273, DOI 10.1016/j.oret.2021.11.005
   Sengillo JD, 2016, AM J MED GENET C, V172, P349, DOI 10.1002/ajmg.c.31534
   Takahashi VKL, 2018, OPHTHALMIC GENET, V39, P560, DOI 10.1080/13816810.2018.1495745
   Tan TE, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.795010
   Trapani I, 2021, GENE THER, V28, P220, DOI 10.1038/s41434-020-0174-4
   Trapani I, 2014, PROG RETIN EYE RES, V43, P108, DOI 10.1016/j.preteyeres.2014.08.001
   Tsai YT, 2018, OPHTHALMOLOGY, V125, P1421, DOI 10.1016/j.ophtha.2018.04.001
   Vajzovic L, 2019, RETINA-J RET VIT DIS, V39, P194, DOI 10.1097/IAE.0000000000002518
   Vasconcelos HM, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00216-1
   Waheed N., 2022, PRESENTED ANGIOGENES
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodard KT, 2016, J VIROL, V90, P9878, DOI 10.1128/JVI.01568-16
   Wu DM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145029
   Wykoff CC, 2021, INTRAVITREAL GENE TH
   Xu D, 2021, ASIA-PAC J OPHTHALMO, V10, P5, DOI 10.1097/APO.0000000000000362
   Xue KM, 2018, NAT MED, V24, P1507, DOI 10.1038/s41591-018-0185-5
   Xue YL, 2021, ELIFE, V10, DOI 10.7554/eLife.66240
   Yeh S, 2019, RETINA-J RET VIT DIS, V39, P1880, DOI 10.1097/IAE.0000000000002279
   Yiu G, 2020, MOL THER-METH CLIN D, V16, P179, DOI 10.1016/j.omtm.2020.01.002
   Zhu J, 2017, CELL RES, V27, P830, DOI 10.1038/cr.2017.57
   Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998
NR 104
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD SEP 2
PY 2022
VL 22
IS 9
BP 1193
EP 1208
DI 10.1080/14712598.2022.2121646
PG 16
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 4S0QA
UT WOS:000857155500011
PM 36062410
DA 2022-11-30
ER

PT J
AU Yang, DC
   Chung, T
   Kim, D
AF Yang, Dongchan
   Chung, Taesu
   Kim, Dongsup
TI DeepLUCIA: predicting tissue-specific chromatin loops using Deep
   Learning-based Universal Chromatin Interaction Annotator
SO BIOINFORMATICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HI-C DATA; RESOLUTION; COMMON; RARE; 3DIV
AB Motivation: The importance of chromatin loops in gene regulation is broadly accepted. There are mainly two approaches to predict chromatin loops: transcription factor (TF) binding-dependent approach and genomic variation-based approach. However, neither of these approaches provides an adequate understanding of gene regulation in human tissues. To address this issue, we developed a deep learning-based chromatin loop prediction model called Deep Learning-based Universal Chromatin Interaction Annotator (DeepLUCIA).
   Results: Although DeepLUCIA does not use TF binding profile data which previous TF binding-dependent methods critically rely on, its prediction accuracies are comparable to those of the previous TF binding-dependent methods. More importantly, DeepLUCIA enables the tissue-specific chromatin loop predictions from tissue-specific epigenomes that cannot be handled by genomic variation-based approach. We demonstrated the utility of the DeepLUCIA by predicting several novel target genes of SNPs identified in genome-wide association studies targeting Brugada syndrome, COVID-19 severity and age-related macular degeneration.
C1 [Yang, Dongchan; Kim, Dongsup] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 34141, South Korea.
   [Chung, Taesu] KIPO, Convergence Technol Examinat Bur, Biotechnol & Healthcare Examinat Div, Daejeon 35208, South Korea.
C3 Korea Advanced Institute of Science & Technology (KAIST)
RP Kim, D (通讯作者)，Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 34141, South Korea.
EM kds@kaist.ac.kr
OI Kim, Dongsup/0000-0002-5916-6799
FU National Research Foundation of Korea (NRF) - Korean Government (The
   Ministry of Science and ICT) [NRF-2021M3H9A2097443,
   NRF-2022R1A2C1006609, NRF-2022R1C1C2009549]
FX This work was supported by the National Research Foundation of Korea
   (NRF) [NRF-2021M3H9A2097443, NRF-2022R1A2C1006609 and
   NRF-2022R1C1C2009549] funded by the Korean Government (The Ministry of
   Science and ICT).
CR Al Bkhetan Z, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23276-8
   Boudellioua I, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2633-8
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012
   Cantalupo S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105372
   Chen SQ, 2021, GENOM PROTEOM BIOINF, V19, P565, DOI 10.1016/j.gpb.2019.04.006
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   Claussnitzer M, 2015, NEW ENGL J MED, V373, P895, DOI 10.1056/NEJMoa1502214
   Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6
   Dao LTM, 2018, TRANSCR-AUSTIN, V9, P307, DOI 10.1080/21541264.2018.1486150
   Dapas M, 2020, PLOS MED, V17, DOI [10.1371/journal.pmed.1003132, 10.1371/journal.pmed.1003132.r001, 10.1371/journal.pmed.1003132.r002, 10.1371/journal.pmed.1003132.r003, 10.1371/journal.pmed.1003132.r004]
   de Souza N, 2012, NAT METHODS, V9, P1046, DOI 10.1038/nmeth.2238
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Dekker J, 2017, NATURE, V549, P219, DOI 10.1038/nature23884
   di Iulio J, 2018, NAT GENET, V50, P333, DOI 10.1038/s41588-018-0062-7
   Evans DS, 2016, HUM MOL GENET, V25, P4350, DOI 10.1093/hmg/ddw284
   Freyermuth F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11067
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fudenberg G, 2020, NAT METHODS, V17, P1111, DOI 10.1038/s41592-020-0958-x
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Jaganathan K, 2019, CELL, V176, P535, DOI 10.1016/j.cell.2018.12.015
   Jansen R, 2017, HUM MOL GENET, V26, P1444, DOI 10.1093/hmg/ddx043
   Jung I, 2019, NAT GENET, V51, P1442, DOI 10.1038/s41588-019-0494-8
   Kai Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06664-6
   Khalil BA, 2021, COMPUT STRUCT BIOTEC, V19, P976, DOI 10.1016/j.csbj.2021.01.034
   Kim K, 2021, NUCLEIC ACIDS RES, V49, pD38, DOI 10.1093/nar/gkaa1078
   Kuang SZ, 2021, J COMPUT BIOL, V28, P133, DOI 10.1089/cmb.2020.0225
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Li WR, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz167
   Liu Q, 2019, BIOINFORMATICS, V35, pI99, DOI 10.1093/bioinformatics/btz317
   Makarawate P, 2020, HEART RHYTHM, V17, P2145, DOI 10.1016/j.hrthm.2020.06.027
   Man JCK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12856-5
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Morita H, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.116.004765
   Poplin R, 2018, NAT BIOTECHNOL, V36, P983, DOI 10.1038/nbt.4235
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Schwessinger R, 2020, NAT METHODS, V17, P1118, DOI 10.1038/s41592-020-0960-3
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Trieu T, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-01987-4
   van der Harst P, 2016, J AM COLL CARDIOL, V68, P1435, DOI 10.1016/j.jacc.2016.07.729
   van Hoorn F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042037
   Xiao ML, 2020, GENES-BASEL, V11, DOI 10.3390/genes11010041
   Yang DC, 2018, NUCLEIC ACIDS RES, V46, pD52, DOI 10.1093/nar/gkx1017
   Zeng WW, 2021, NUCLEIC ACIDS RES, V49, pD221, DOI 10.1093/nar/gkaa839
   Zhang RC, 2018, BIOINFORMATICS, V34, P133, DOI 10.1093/bioinformatics/bty248
   Zhang SL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13423-8
   Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03113-2
NR 49
TC 0
Z9 0
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD JUL 11
PY 2022
VL 38
IS 14
BP 3501
EP 3512
DI 10.1093/bioinformatics/btac373
EA MAY 2022
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA 2U0TT
UT WOS:000807456400001
PM 35640981
DA 2022-11-30
ER

PT J
AU Zhang, KR
   Baumann, B
   Song, Y
   Sterling, J
   Erler, EA
   Guttha, S
   Kozmik, Z
   Dunaief, JL
AF Zhang, Kevin R.
   Baumann, Bailey
   Song, Ying
   Sterling, Jacob
   Erler, Elizabeth A.
   Guttha, Samyuktha
   Kozmik, Zbynek
   Dunaief, Joshua L.
TI Conditional knockout of hephaestin in the neural retina disrupts retinal
   iron homeostasis
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Retina; Iron; Ferrous; Ceruloplasmin; Hephaestin; Age-related macular
   degeneration
ID MACULAR DEGENERATION; CELLS; ACERULOPLASMINEMIA; CERULOPLASMIN;
   FERROPORTIN; EXPRESSION; OVERLOAD; FEATURES; PROTEIN; GENE
AB Iron accumulation has been implicated in degenerative retinal diseases. It can catalyze the production of damaging reactive oxygen species. Previous work has demonstrated iron accumulation in multiple retinal diseases, including age-related macular degeneration and diabetic retinopathy. In mice, systemic knockout of the ferroxidases ceruloplasmin (Cp) and hephaestin (Heph), which oxidize iron, results in retinal iron accumulation and iron-induced degeneration. To determine the role of Heph in the retina, we generated a neural retina-specific Heph knockout on a background of systemic Cp knockout. This resulted in elevated neural retina iron. Conversely, retinal ganglion cells had elevated transferrin receptor and decreased ferritin, suggesting diminished iron levels. The retinal degeneration observed in systemic Cp-/-, Heph- /- mice did not occur. These findings indicate that Heph has a local role in regulating neural retina iron homeostasis, but also suggest that preserved Heph function in either the RPE or systemically mitigates the degeneration phenotype observed in the systemic Cp- /-, Heph-/- mice.
C1 [Zhang, Kevin R.; Baumann, Bailey; Song, Ying; Sterling, Jacob; Erler, Elizabeth A.; Guttha, Samyuktha; Dunaief, Joshua L.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med, 305 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.
   [Kozmik, Zbynek] Acad Sci Czech Republ, Inst Mol Genet, ASCR, Vvi, Videnska 1083, Prague 14220 4, Czech Republic.
C3 University of Pennsylvania; Pennsylvania Medicine; Czech Academy of
   Sciences; Institute of Molecular Genetics of the Czech Academy of
   Sciences
RP Dunaief, JL (通讯作者)，Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med, 305 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM Kevin.Zhang3@pennmedicine.upenn.edu; bbaum@vet.upenn.edu;
   yingsong@pennmedicine.upenn.edu; jacob.sterling@pennmedicine.upenn.edu;
   elizabeth.erler@pennmedicine.upenn.edu; samyukthag@gmail.com;
   zbynek.kozmik@img.cas.cz; jdunaief@pennmedicine.upenn.edu
OI Kozmik, Zbynek/0000-0002-5850-2105
FU NIH/NEI [EY015240]; UPenn Vision Science Training Grant
   [5T32EY007035-37]; Research to Prevent Blindness; F.M. Kirby Foundation;
   Paul and Evanina Bell Mackall Foundation Trust
FX Acknowledgements Funding from NIH/NEI EY015240, the UPenn Vision Science
   Training Grant (5T32EY007035-37) , Research to Prevent Blindness, the
   F.M. Kirby Foundation, a gift in memory of Lee F. Mauger, MD, and the
   Paul and Evanina Bell Mackall Foundation Trust.
CR Beard JL, 2001, J NUTR, V131, p568S, DOI 10.1093/jn/131.2.568S
   Casini G, 2021, DOC OPHTHALMOL, V142, P133, DOI 10.1007/s10633-020-09792-x
   De Domenico I, 2007, EMBO J, V26, P2823, DOI 10.1038/sj.emboj.7601735
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   Klimova L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063029
   Liu YR, 2022, EXP EYE RES, V218, DOI 10.1016/j.exer.2022.108988
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   PIRIE A, 1965, NATURE, V205, P500, DOI 10.1038/205500a0
   Rivera S, 2005, BLOOD, V106, P2196, DOI 10.1182/blood-2005-04-1766
   ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schleicher RL, 2009, AM J CLIN NUTR, V90, P1252, DOI 10.3945/ajcn.2008.27016
   Shu WT, 2019, INVEST OPHTH VIS SCI, V60, P4378, DOI 10.1167/iovs.19-28250
   Sterling J, 2017, EXP EYE RES, V155, P15, DOI 10.1016/j.exer.2016.12.008
   Syed BA, 2002, PROTEIN ENG, V15, P205, DOI 10.1093/protein/15.3.205
   Wolkow N, 2012, AM J PATHOL, V180, P1614, DOI 10.1016/j.ajpath.2011.12.041
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Zhao J, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100259
   Zhao NN, 2014, P NATL ACAD SCI USA, V111, P9175, DOI 10.1073/pnas.1405355111
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2022
VL 218
AR 109028
DI 10.1016/j.exer.2022.109028
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1T5TB
UT WOS:000804789500008
PM 35271829
DA 2022-11-30
ER

PT J
AU Fang, Y
   Taubitz, T
   Tschulakow, AV
   Heiduschka, P
   Szewczyk, G
   Burnet, M
   Peters, T
   Biesemeier, A
   Sarna, T
   Schraermeyer, U
   Julien-Schraermeyer, S
AF Fang, Yuan
   Taubitz, Tatjana
   Tschulakow, Alexander, V
   Heiduschka, Peter
   Szewczyk, Grzegorz
   Burnet, Michael
   Peters, Tobias
   Biesemeier, Antje
   Sarna, Tadeusz
   Schraermeyer, Ulrich
   Julien-Schraermeyer, Sylvie
TI Removal of RPE lipofuscin results in rescue from retinal degeneration in
   a mouse model of advanced Stargardt disease: Role of reactive oxygen
   species
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Stargardt disease; Age-related macular degeneration; Lipofuscin;
   Pharmacological therapy; Mouse model; Retinal pigment epithelium;
   Reactive oxygen species
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; A2E; COMPONENT;
   ACCUMULATION; DEGRADATION; MELANOSOMES; LYSOSOMES; APOPTOSIS; MELANIN
AB Accumulation of lipofuscin in the retinal pigment epithelium (RPE) is a hallmark of aging and is associated with retinal degeneration encountered in age-related macular degeneration (AMD) and Stargardt disease (SD). Currently, treatment for lipofuscin-induced retinal degeneration is unavailable. Here, we report that Remofuscin (INN: soraprazan, a tetrahydropyridoether small molecule) reverses lipofuscin accumulation in aged primary human RPE cells and is non-cytotoxic in aged SD mouse RPE cells in vitro. In addition, we show that the removal of lipofuscin after a single intravitreal injection of Remofuscin results in a rescue from retinal degeneration in a mouse model of advanced SD which is even accompanied by an amelioration of the retinal dysfunction. Finally, we demonstrate that the mechanism causing lipofuscinolysis may involve the reactive oxygen species generated via the presence of Remofuscin. These data suggest a possible therapeutic approach to untreatable lipofuscinmediated diseases like AMD, SD and lipofuscinopathies in neurodegenerative diseases.
C1 [Fang, Yuan] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Tubingen, Germany.
   [Taubitz, Tatjana; Biesemeier, Antje] STZ Ocutox, Preclin Drug Assessment, Hechingen, Germany.
   [Heiduschka, Peter] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Biophys, Krakow, Poland.
   [Burnet, Michael] Synovo GmbH, Tubingen, Germany.
   [Peters, Tobias] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany.
   [Fang, Yuan; Taubitz, Tatjana; Tschulakow, Alexander, V; Heiduschka, Peter; Biesemeier, Antje; Schraermeyer, Ulrich; Julien-Schraermeyer, Sylvie] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing, Peoples R China.
   [Tschulakow, Alexander, V; Schraermeyer, Ulrich; Julien-Schraermeyer, Sylvie] Luxembourg Inst Sci & Technol, Advanc Instrumentat NanoAnalyt AINA, MRT Dept, Luxembourg, Luxembourg.
   [Szewczyk, Grzegorz; Sarna, Tadeusz] Univ Munster, Med Sch, Dept Ophthalmol, Munster, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Jagiellonian University; Synovo GmbH; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital; Nanjing
   Medical University; Luxembourg Institute of Science & Technology;
   University of Munster
RP Julien-Schraermeyer, S (通讯作者)，Inst Ophthalm Res, Div Expt Vitreoretinal Surg, Ctr Ophthalmol, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM Sylvie.Julien@med.uni-tuebingen.de
RI Taubitz, Tatjana/AAA-2941-2021
OI Taubitz, Tatjana/0000-0002-6747-4484; Szewczyk,
   Grzegorz/0000-0003-0834-1080; Julien-Schraermeyer,
   Sylvie/0000-0002-2322-511X
FU Bundesministerium fur Bildung und Forschung [01GQ1422B]; China
   Scholarship Council [CSC201608080087]
FX The authors thank Dr. Barbara Illing, Sabine Hofmeister, Monika Rittgarn
   and Sigrid Schultheiss for their technical assistance. This work was
   partially supported by the Bundesministerium fur Bildung und Forschung
   (grant numbers 01GQ1422B) and the China Scholarship Council
   (CSC201608080087; to Yuan Fang). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Cantrell A, 2001, J PHOTOCH PHOTOBIO B, V64, P162, DOI 10.1016/S1011-1344(01)00224-X
   Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103
   Clement JL, 2005, J ORG CHEM, V70, P1198, DOI 10.1021/jo048518z
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Fang Y, 2020, FASEB J, V34, P3693, DOI 10.1096/fj.201901784RR
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Giaccone G, 2011, DEMENT GER COGN D EX, V1, P292, DOI 10.1159/000329544
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Johnen S, 2011, INVEST OPHTH VIS SCI, V52, P2817, DOI 10.1167/iovs.10-6429
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Julien-Schraermeyer S, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.683
   KENNEDY AR, 1987, CARCINOGENESIS, V8, P683, DOI 10.1093/carcin/8.5.683
   KRISHNA CM, 1991, PHOTOCHEM PHOTOBIOL, V54, P51, DOI 10.1111/j.1751-1097.1991.tb01984.x
   Laskar A, 2010, J CARDIOVASC PHARM, V56, P263, DOI 10.1097/FJC.0b013e3181eb3063
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Olchawa MM, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111044
   Olchawa MM, 2021, PIGM CELL MELANOMA R, V34, P670, DOI 10.1111/pcmr.12914
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Simon WA, 2007, J PHARMACOL EXP THER, V321, P866, DOI 10.1124/jpet.107.120428
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taubit T, 2018, PEERJ, V6, DOI 10.7717/peerj.5215
   Taubitz T, 2019, EBIOMEDICINE, V48, P592, DOI 10.1016/j.ebiom.2019.09.048
   Warburton S, 2007, MOL VIS, V13, P318
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wellings TP, 2017, EXP BRAIN RES, V235, P3695, DOI 10.1007/s00221-017-5092-3
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   YIN DZ, 1991, MECH AGEING DEV, V59, P95, DOI 10.1016/0047-6374(91)90076-C
   Yogalingam G, 2017, J BIOL CHEM, V292, P4255, DOI 10.1074/jbc.M116.739441
   Zadlo A, 2009, PHOTOCH PHOTOBIO SCI, V8, P830, DOI 10.1039/b901820d
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
NR 55
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAR
PY 2022
VL 182
BP 132
EP 149
DI 10.1016/j.freeradbiomed.2022.02.025
PG 18
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 0Y7NZ
UT WOS:000790574600003
PM 35219849
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Mahon, N
   Slater, K
   O'Brien, J
   Alvarez, Y
   Reynolds, A
   Kennedy, B
AF Mahon, Niamh
   Slater, Kayleigh
   O'Brien, Justine
   Alvarez, Yolanda
   Reynolds, Alison
   Kennedy, Breandan
TI Discovery and Development of the Quininib Series of Ocular Drugs
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE quininib drug series; ocular angiogenesis; cysteinyl leukotriene
   receptors; zebrafish; phenotype-based drug discovery
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; DEXAMETHASONE
   INTRAVITREAL IMPLANT; BEVACIZUMAB AVASTIN; ORAL MONTELUKAST; VEGF TRAP;
   RANIBIZUMAB; ZEBRAFISH; DEGENERATION; ANGIOGENESIS
AB The quininib series is a novel collection of small-molecule drugs with antiangiogenic, antivascular permeability, anti-inflammatory, and antiproliferative activity. Quininib was initially identified as a drug hit during a random chemical library screen for determinants of developmental ocular angiogenesis in zebrafish. To enhance drug efficacy, novel quininib analogs were designed by applying medicinal chemistry approaches. The resulting quininib drug series has efficacy in in vitro and ex vivo models of angiogenesis utilizing human cell lines and tissues. In vivo, quininib drugs reduce pathological angiogenesis and retinal vascular permeability in rodent models. Quininib acts as a cysteinyl leukotriene (CysLT) receptor antagonist, revealing new roles of these G-protein-coupled receptors in developmental angiogenesis of the eye and unexpectedly in uveal melanoma (UM). The quininib series highlighted the potential of CysLT receptors as therapeutic targets for retinal vasculopathies (e.g., neovascular age-related macular degeneration, diabetic retinopathy, and diabetic macular edema) and ocular cancers (e.g., UM).
C1 [Mahon, Niamh; Slater, Kayleigh; O'Brien, Justine; Alvarez, Yolanda; Kennedy, Breandan] Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin D04 V1W8, Ireland.
   [Mahon, Niamh; Slater, Kayleigh; O'Brien, Justine; Alvarez, Yolanda; Reynolds, Alison; Kennedy, Breandan] Univ Coll Dublin, UCD Conway Inst, Dublin, Ireland.
   [Reynolds, Alison] Univ Coll Dublin, Vet Sci Ctr, UCD Sch Vet Med, Dublin, Ireland.
C3 University College Dublin; University College Dublin; University College
   Dublin
RP Kennedy, B (通讯作者)，Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin D04 V1W8, Ireland.
EM brendan.kennedy@ucd.ie
OI Mahon, Niamh/0000-0003-2929-4471; Kennedy, Breandan/0000-0001-7991-4689;
   Reynolds, Alison/0000-0002-3147-0094
CR ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748
   Al-Ghananeem AM, 2009, AAPS PHARMSCITECH, V10, P410, DOI 10.1208/s12249-009-9222-5
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Alvarez Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007867
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barajas-Espinosa A, 2012, FASEB J, V26, P1100, DOI 10.1096/fj.11-195792
   Boucher JM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15699
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Burton MJ, 2021, LANCET GLOB HEALTH, V9, pE489, DOI 10.1016/S2214-109X(20)30488-5
   Butler CT, 2017, J BIOL CHEM, V292, P3552, DOI 10.1074/jbc.M116.747766
   Campochiaro PA, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100921
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Castet F, 2019, CANCERS, V11, DOI 10.3390/cancers11060834
   Chan J, 2002, CANCER CELL, V1, P257, DOI 10.1016/S1535-6108(02)00042-9
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P302, DOI 10.1016/j.jcjo.2016.04.020
   Chhetri J, 2014, EYE, V28, P367, DOI 10.1038/eye.2014.19
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E
   Dai C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094809
   Dandapani Sivaraman, 2012, Curr Protoc Chem Biol, V4, P177
   DENIS D, 1982, PROSTAG OTH LIPID M, V24, P801, DOI 10.1016/0090-6980(82)90060-0
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   el Filali M, 2012, MOL VIS, V18, P2454
   el Filali M, 2012, DEV OPHTHALMOL, V49, P117, DOI 10.1159/000329591
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foss AJE, 1996, CANCER RES, V56, P2900
   Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Gagnidze K, 2008, J MED CHEM, V51, P3378, DOI 10.1021/jm7015478
   Galvin O, 2016, J CONTROL RELEASE, V233, P198, DOI 10.1016/j.jconrel.2016.04.004
   Ganzen L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89482-z
   Garcia-Mulero S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052669
   Genentech, 2021, FDA APPR GEN SUSV 1
   Giurdanella G, 2015, BIOCHEM PHARMACOL, V96, P278, DOI 10.1016/j.bcp.2015.05.017
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2016, JAMA OPHTHALMOL, V134, P95, DOI 10.1001/jamaophthalmol.2015.4110
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Howard M, 2014, ACS NANO, V8, P4100, DOI 10.1021/nn500136z
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jager MJ, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0158-0
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kaliki S, 2017, EYE, V31, P241, DOI 10.1038/eye.2016.275
   Karaca I, 2021, INVEST OPHTH VIS SCI, V62
   Kitambi SS, 2009, MECH DEVELOP, V126, P464, DOI 10.1016/j.mod.2009.01.002
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711
   Lee SH, 2010, EYE, V24, P226, DOI 10.1038/eye.2009.86
   Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091
   Lima BR, 2011, AM J OPHTHALMOL, V151, P323, DOI 10.1016/j.ajo.2010.08.040
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lutty GA, 2018, PROG RETIN EYE RES, V62, P58, DOI 10.1016/j.preteyeres.2017.10.001
   MacRae CA, 2015, NAT REV DRUG DISCOV, V14, P721, DOI 10.1038/nrd4627
   Makitie T, 1999, INVEST OPHTH VIS SCI, V40, P2471
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer RD, 2006, J BIOL CHEM, V281, P867, DOI 10.1074/jbc.M506454200
   Montuschi P, 2010, CLIN EXP ALLERGY, V40, P1732, DOI 10.1111/j.1365-2222.2010.03630.x
   Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549
   Moreno TA, 2016, SEMIN OPHTHALMOL, V31, P378, DOI 10.3109/08820538.2016.1154174
   Murphy A.G, 2016, SCI REP-UK, V6, P1
   National Institute for Care Excellence (UK), 2018, AGE RELATED MACULAR
   Ohnesorge N, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00508
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pardo-Martin C, 2010, NAT METHODS, V7, P634, DOI [10.1038/NMETH.1481, 10.1038/nmeth.1481]
   Pham B, 2021, INVEST OPHTH VIS SCI, V62
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Reynolds AL, 2016, J BIOL CHEM, V291, P7242, DOI 10.1074/jbc.M115.710665
   Robert L, 2010, PATHOL BIOL, V58, P187, DOI 10.1016/j.patbio.2009.09.010
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Scaldaferri F, 2009, GASTROENTEROLOGY, V136, P585, DOI 10.1053/j.gastro.2008.09.064
   Selvam S, 2018, PROG RETIN EYE RES, V63, P1, DOI 10.1016/j.preteyeres.2017.11.001
   Shang J, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0212-4
   Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669
   Slater K, 2018, CANCER METAST REV, V37, P335, DOI 10.1007/s10555-018-9751-z
   Slater K, 2020, CANCERS, V12, DOI 10.3390/cancers12102950
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Swinney DC, 2013, CLIN PHARMACOL THER, V93, P299, DOI 10.1038/clpt.2012.236
   Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480
   Tamayo T, 2014, DIABETES RES CLIN PR, V103, P206, DOI 10.1016/j.diabres.2013.11.007
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584
   van Rooijen E, 2011, METHOD CELL BIOL, V105, P163, DOI 10.1016/B978-0-12-381320-6.00007-2
   Volochnyuk DM, 2019, DRUG DISCOV TODAY, V24, P390, DOI 10.1016/j.drudis.2018.10.016
   Wang CY, 2010, EUR UROL, V58, P418, DOI 10.1016/j.eururo.2010.05.024
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Xu LT, 2019, OCUL ONCOL PATHOL, V5, P323, DOI 10.1159/000495113
   Yang H, 2010, INVEST OPHTH VIS SCI, V51, P2835, DOI 10.1167/iovs.09-4755
   Yun YH, 2004, BIOMATERIALS, V25, P147, DOI 10.1016/S0142-9612(03)00467-8
   ZAMBONI R, 1992, J MED CHEM, V35, P3832, DOI 10.1021/jm00099a011
NR 99
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JAN 1
PY 2022
VL 38
IS 1
BP 33
EP 42
DI 10.1089/jop.2021.0074
PG 10
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA YY2SL
UT WOS:000754642800003
PM 35089801
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Griesemer, D
   Xue, JR
   Reilly, SK
   Ulirsch, JC
   Kukreja, K
   Davis, JR
   Kanai, M
   Yang, DK
   Butts, JC
   Guney, MH
   Luban, J
   Montgomery, SB
   Finucane, HK
   Novina, CD
   Tewhey, R
   Sabeti, PC
AF Griesemer, Dustin
   Xue, James R.
   Reilly, Steven K.
   Ulirsch, Jacob C.
   Kukreja, Kalki
   Davis, Joe R.
   Kanai, Masahiro
   Yang, David K.
   Butts, John C.
   Guney, Mehmet H.
   Luban, Jeremy
   Montgomery, Stephen B.
   Finucane, Hilary K.
   Novina, Carl D.
   Tewhey, Ryan
   Sabeti, Pardis C.
TI Genome-wide functional screen of 3 ' UTR variants uncovers causal
   variants for human disease and evolution
SO CELL
LA English
DT Article
ID RNA-BINDING PROTEIN; GENETIC-VARIATION; MESSENGER-RNAS; 3' UTRS;
   IDENTIFICATION; TRANSCRIPTOME; ASSOCIATION; RISK; ADAPTATIONS;
   ANNOTATION
AB 3' untranslated region (3'UTR) variants are strongly associated with human traits and diseases, yet few have been causally identified. We developed the massively parallel reporter assay for 3'UTRs (MPRAu) to sensitively assay 12,173 3'UTR variants. We applied MPRAu to six human cell lines, focusing on genetic variants associated with genome-wide association studies (GWAS) and human evolutionary adaptation. MPRAu expands our understanding of 3'UTR function, suggesting that simple sequences predominately explain 3'UTR regulatory activity. We adapt MPRAu to uncover diverse molecular mechanisms at base pair resolution, including an adenylate-uridylate (AU)-rich element of LEPR linked to potential metabolic evolutionary adaptations in East Asians. We nominate hundreds of 3'UTR causal variants with genetically fine-mapped phenotype associations. Using endogenous allelic replacements, we characterize one variant that disrupts a miRNA site regulating the viral defense gene TRIM14 and one that alters PILRB abundance, nominating a causal variant underlying transcriptional changes in age-related macular degeneration.
C1 [Griesemer, Dustin; Xue, James R.; Reilly, Steven K.; Ulirsch, Jacob C.; Kanai, Masahiro; Yang, David K.; Luban, Jeremy; Finucane, Hilary K.; Novina, Carl D.; Sabeti, Pardis C.] Broad Inst MIT & Harvard, Cambridge, MA 02143 USA.
   [Griesemer, Dustin; Kanai, Masahiro] Harvard Med Sch, Program Bioinformat & Integrat Genom, Boston, MA 02115 USA.
   [Griesemer, Dustin] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
   [Xue, James R.; Reilly, Steven K.; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02143 USA.
   [Ulirsch, Jacob C.] Harvard Med Sch, Program Biol & Biomed Sci, Boston, MA 02115 USA.
   [Ulirsch, Jacob C.; Kanai, Masahiro; Finucane, Hilary K.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Kukreja, Kalki] Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA.
   [Davis, Joe R.] BigHat Biosci, San Carlos, CA 94070 USA.
   [Butts, John C.; Tewhey, Ryan] Jackson Lab, Bar Harbor, ME 04609 USA.
   [Butts, John C.; Tewhey, Ryan] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME 04469 USA.
   [Guney, Mehmet H.; Luban, Jeremy] Univ Massachusetts, Program Mol Med, Med Sch, Worcester, MA 01655 USA.
   [Luban, Jeremy] Univ Massachusetts, Dept Biochem & Mol Pharmacol, Med Sch, Worcester, MA 01655 USA.
   [Montgomery, Stephen B.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
   [Montgomery, Stephen B.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.
   [Novina, Carl D.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA.
   [Novina, Carl D.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
   [Tewhey, Ryan] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Sabeti, Pardis C.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
   [Reilly, Steven K.] Yale Sch Med, Dept Genet, New Haven, CT 06510 USA.
C3 Harvard University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Harvard University; Harvard Medical School; Harvard
   University; Brigham & Women's Hospital; Harvard University; Harvard
   University; Harvard Medical School; Harvard University; Massachusetts
   General Hospital; Harvard University; Jackson Laboratory; University of
   Maine System; University of Maine Orono; University of Massachusetts
   System; University of Massachusetts Worcester; University of
   Massachusetts System; University of Massachusetts Worcester; Stanford
   University; Stanford University; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Harvard Medical School; Tufts University;
   Howard Hughes Medical Institute; Yale University
RP Xue, JR (通讯作者)，Broad Inst MIT & Harvard, Cambridge, MA 02143 USA.; Xue, JR (通讯作者)，Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02143 USA.
EM jxue@broadinstitute.org
RI Kanai, Masahiro/AAD-6726-2021; Sabeti, Pardis/GQH-8610-2022
OI Kanai, Masahiro/0000-0001-5165-4408; Montgomery,
   Stephen/0000-0002-5200-3903; Reilly, Steven/0000-0003-3140-1483; Butts,
   John/0000-0001-9456-4509; Davis, Joe/0000-0003-2544-388X;
   /0000-0003-4265-7935; Ulirsch, Jacob/0000-0002-7947-0827
FU ENCODE Functional Characterization Center grant [UM1HG009435]; Broad
   SPARC; Howard Hughes Medical Institute; NSF [DEB-1401237]; NIH-NIGMS
   [F30GM114940]; NIH-NHGRI [K99HG010669, F32HG009226, R00HG008179];
   NIH-NIAID [R37AI147868]
FX We thank S. Schaffner, S. Gosai, S. Weingarten-Gabbay, A.E. Lin, D.
   Kotliar, C. Myhrvold, and C. Tomkins-Tinch for thoughtful conversations
   and help with editing the manuscript. We thank D.P. Bartel as well as
   his lab for thoughtful discussions. We thank I. Shlyakhter and J. Vitti
   for providing the CMS regions. This work was supported by an ENCODE
   Functional Characterization Center grant (UM1HG009435), Broad SPARC, and
   the Howard Hughes Medical Institute. D.G. was partially supported by
   DEB-1401237 from NSF and F30GM114940 from NIH-NIGMS. S.K.R. was
   partially supported by K99HG010669 from NIH-NHGRI and F32HG009226 from
   NIH-NHGRI. J.L. is supported by R37AI147868 from NIH-NIAID. R.T. is
   supported by R00HG008179 from NIH-NHGRI.
CR Abella V, 2017, NAT REV RHEUMATOL, V13, P100, DOI 10.1038/nrrheum.2016.209
   Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Andreassi C, 2009, TRENDS CELL BIOL, V19, P465, DOI 10.1016/j.tcb.2009.06.001
   Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246
   Ban HJ, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-26
   Battle A, 2015, SCIENCE, V347, P664, DOI 10.1126/science.1260793
   Benner C, 2016, BIOINFORMATICS, V32, P1493, DOI 10.1093/bioinformatics/btw018
   Berkovits BD, 2015, NATURE, V522, P363, DOI 10.1038/nature14321
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bogard N, 2019, CELL, V178, P91, DOI 10.1016/j.cell.2019.04.046
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025
   Chick JM, 2016, NATURE, V534, P500, DOI 10.1038/nature18270
   Choi JY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16590-1
   Clement K, 2019, NAT BIOTECHNOL, V37, P224, DOI 10.1038/s41587-019-0032-3
   Dey KK, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2489-3
   Dominguez D, 2018, MOL CELL, V70, P854, DOI 10.1016/j.molcel.2018.05.001
   Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404
   Friedlander MR, 2012, NUCLEIC ACIDS RES, V40, P37, DOI 10.1093/nar/gkr688
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galgano A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003164
   Grossman SR, 2013, CELL, V152, P703, DOI 10.1016/j.cell.2013.01.035
   Grossman SR, 2010, SCIENCE, V327, P883, DOI 10.1126/science.1183863
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188
   Gusev A., 2014, SCHIZOPHRENIA WORKIN
   Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009
   Hoffpauir CT, 2020, J IMMUNOL, V205, P153, DOI 10.4049/jimmunol.1901511
   Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410
   Kemp JP, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004423
   Kerimov N., 2020, EQTL CATALOGUE COMPE, DOI 10.1101/2020.01.29.924266
   Kircher M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11526-w
   Klein JC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10439-y
   Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531
   Li H., 2013, ALIGNING SEQUENCE RE
   Li L, 2021, NAT GENET, V53, P994, DOI 10.1038/s41588-021-00864-5
   Li X, 2017, NATURE, V550, P239, DOI 10.1038/nature24267
   Litterman AJ, 2019, GENOME RES, V29, P896, DOI 10.1101/gr.242552.118
   Liu S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1322-z
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lundberg SM, 2017, ADV NEUR IN, V30
   Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507
   Marbach D, 2016, NAT METHODS, V13, P366, DOI [10.1038/NMETH.3799, 10.1038/nmeth.3799]
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   Miller CL, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004263
   Morris AR, 2008, MOL CELL BIOL, V28, P4093, DOI 10.1128/MCB.00155-08
   Munzberg H, 2015, METABOLISM, V64, P13, DOI 10.1016/j.metabol.2014.09.010
   Mukherjee N, 2019, NUCLEIC ACIDS RES, V47, P570, DOI 10.1093/nar/gky1185
   Nouioua S, 2013, NEUROMUSCULAR DISORD, V23, P670, DOI 10.1016/j.nmd.2013.04.011
   Oikonomou P, 2014, CELL REP, V7, P281, DOI 10.1016/j.celrep.2014.03.001
   Orenstein Y, 2016, BIOINFORMATICS, V32, P351, DOI 10.1093/bioinformatics/btw259
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Parker SCJ, 2013, P NATL ACAD SCI USA, V110, P17921, DOI 10.1073/pnas.1317023110
   Pembleton LW, 2013, MOL ECOL RESOUR, V13, P946, DOI 10.1111/1755-0998.12129
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Richardson K, 2013, AM J HUM GENET, V92, P5, DOI 10.1016/j.ajhg.2012.10.020
   Sample PJ, 2019, NAT BIOTECHNOL, V37, P803, DOI 10.1038/s41587-019-0164-5
   Sazzini M, 2014, HEREDITY, V113, P259, DOI 10.1038/hdy.2014.24
   Schmiedel BJ, 2018, CELL, V175, P1701, DOI 10.1016/j.cell.2018.10.022
   Shalem O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005147
   Shi YY, 2011, NAT GENET, V43, P1224, DOI 10.1038/ng.980
   Siegel D.A., 2020, MASSIVELY PARALLEL A, DOI [10.1101/2020.02.12.945063, DOI 10.1101/2020.02.12.945063]
   Slutskin IV, 2019, GENOME RES, V29, P1635, DOI 10.1101/gr.247312.118
   Slutskin IV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02980-z
   Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103
   Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528
   Tan P, 2017, MOL CELL, V68, P293, DOI 10.1016/j.molcel.2017.09.035
   Tang WH, 2010, CIRC-CARDIOVASC GENE, V3, P179, DOI 10.1161/CIRCGENETICS.109.913426
   Tewhey R, 2016, CELL, V165, P1519, DOI 10.1016/j.cell.2016.04.027
   Tushev G, 2018, NEURON, V98, P495, DOI 10.1016/j.neuron.2018.03.030
   Ulirsch JC, 2016, CELL, V165, P1530, DOI 10.1016/j.cell.2016.04.048
   Urbut SM, 2019, NAT GENET, V51, P187, DOI 10.1038/s41588-018-0268-8
   van Arensbergen J, 2019, NAT GENET, V51, P1160, DOI 10.1038/s41588-019-0455-2
   Van Nostrand EL, 2016, NAT METHODS, V13, P508, DOI [10.1038/nmeth.3810, 10.1038/NMETH.3810]
   Vlasova IA, 2008, MOL CELL, V29, P263, DOI 10.1016/j.molcel.2007.11.024
   Wang G, 2020, J R STAT SOC B, V82, P1273, DOI 10.1111/rssb.12388
   Wang Q.S., 2020, LEVERAGING SUPERVISE, DOI [10.1101/2020.10.20.347294, DOI 10.1101/2020.10.20.347294]
   Wang W, 2021, J MACH LEARN RES, V22, P1
   Ward LD, 2016, NUCLEIC ACIDS RES, V44, pD877, DOI 10.1093/nar/gkv1340
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   White EK, 2001, RNA, V7, P1855
   Wiegerinck CL, 2014, GASTROENTEROLOGY, V147, P65, DOI 10.1053/j.gastro.2014.04.002
   Wu XW, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00344
   Zhao WX, 2014, NAT BIOTECHNOL, V32, P387, DOI 10.1038/nbt.2851
   Zhou Z, 2014, P NATL ACAD SCI USA, V111, pE245, DOI 10.1073/pnas.1316941111
NR 87
TC 12
Z9 12
U1 16
U2 50
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD SEP 30
PY 2021
VL 184
IS 20
BP 5247
EP +
DI 10.1016/j.cell.2021.08.025
EA OCT 2021
PG 33
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA WC7PG
UT WOS:000704445700018
PM 34534445
OA Green Accepted, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Jager, MJ
   Seddon, JM
AF Jager, Martine J.
   Seddon, Johanna M.
TI Eye Diseases Direct Interest to Complement Pathway and Macrophages as
   Regulators of Inflammation in COVID-19
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE complement; COVID-19; inflammation; lifestyles; macrophages; macular
   degeneration
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; BODY-MASS INDEX; MACULAR
   DEGENERATION; HIGH-RISK; PROGRESSION; ASSOCIATION; SMOKING; CFH;
   ACTIVATION
AB Many of the risk factors for developing severe coronavirus disease 2019 (COVID-19) are also risk factors for eye diseases such as age-related macular degeneration (AMD). During the past decades, macro-phages and the complement pathway (as a part of the innate immune system) have been identified as important contributors to the development of AMD, and we suggest that these mechanisms are of similar importance for the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Based on the experience with AMD, we discuss how behavioral factors such as diet, smoking and higher body mass index, as well as genetic determinants such as the complement and immune pathway genes may lead to the overactive inflammatory phenotypes seen in some patients with COVID-19, and may in part explain the heterogeneity of disease manifestations and outcomes. Based on this experience, we discuss potential genetic research projects and elaborate on preventive and treatment approaches related to COVID-19.
C1 [Jager, Martine J.] LUMC, Dept Ophthalmol, Leiden, Netherlands.
   [Seddon, Johanna M.] Univ Massachusetts, Sch Med, Dept Ophthalmol & Visual Sci, Worcester, MA USA.
C3 Leiden University; Leiden University Medical Center (LUMC); University
   of Massachusetts System; University of Massachusetts Worcester
RP Jager, MJ (通讯作者)，Leiden Univ, Dept Ophthalmol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands.
EM m.j.jatzer@lumc.nl
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Amarnani D, 2017, INVEST OPHTH VIS SCI, V58, P3940, DOI 10.1167/iovs.16-20912
   [Anonymous], WEBSITE WHO EMRO REP
   Avery RL, 2010, OPHTHALMOLOGY, V117, P2442, DOI 10.1016/j.ophtha.2010.08.052
   Bazzan E, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0522-0
   Bronkhorst IHG, 2011, INVEST OPHTH VIS SCI, V52, P643, DOI 10.1167/iovs.10-5979
   Chand S, 2020, J INTENSIVE CARE MED, V35, P963, DOI 10.1177/0885066620946692
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2013, INVEST OPHTH VIS SCI, V54, P7439, DOI 10.1167/iovs.13-12546
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gold JAW, 2020, MMWR-MORBID MORTAL W, V69, P545, DOI 10.15585/mmwr.mm6918e1
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Jager MJ, 2011, PROG RETIN EYE RES, V30, P129, DOI 10.1016/j.preteyeres.2010.11.004
   Kaku Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087400
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kodukula P, 1999, J IMMUNOL, V162, P2895
   Kotani N, 2000, ANESTHESIOLOGY, V92, P1268, DOI 10.1097/00000542-200005000-00014
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li X, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00089
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01112-2020
   Ly LV, 2010, J IMMUNOL, V185, P3481, DOI 10.4049/jimmunol.0903479
   Maghbooli Z, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239799
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Oikonomopoulou K, 2012, SEMIN IMMUNOPATHOL, V34, P151, DOI 10.1007/s00281-011-0280-x
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ramlall V, 2020, NAT MED, V26, P1609, DOI 10.1038/s41591-020-1021-2
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson DP, 2021, BRIT J NUTR, V125, P678, DOI 10.1017/S000711452000330X
   Risitano AM, 2020, NAT REV IMMUNOL, V20, P343, DOI 10.1038/s41577-020-0320-7
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   van der Made CI, 2020, JAMA-J AM MED ASSOC, V324, P663, DOI 10.1001/jama.2020.13719
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JCC, 2015, MOL VIS, V21, P264
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 70
TC 2
Z9 2
U1 0
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD JAN-FEB
PY 2021
VL 10
IS 1
BP 114
EP 120
DI 10.1097/APO.0000000000000346
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RI6UD
UT WOS:000637043300016
PM 33290288
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jin, J
   Wang, T
   Park, W
   Li, W
   Kim, W
   Park, SK
   Kang, KP
AF Jin, Jixiu
   Wang, Tian
   Park, Woong
   Li, Wenjia
   Kim, Won
   Park, Sung Kwang
   Kang, Kyung Pyo
TI Inhibition of Yes-Associated Protein by Verteporfin Ameliorates
   Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial
   Inflammation and Fibrosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE kidney fibrosis; inflammation; myofibroblast activation; extracellular
   matrix; Hippo pathway; verteporfin
ID HIPPO PATHWAY; TGF-BETA; FIBROBLAST ACTIVATION; EXTRACELLULAR-MATRIX;
   YAP; KIDNEY; MECHANISMS; TAZ; DISRUPTION; RECEPTOR
AB Yes-associated protein (YAP) activation after acute ischemic kidney injury might be related to interstitial fibrosis and impaired renal tubular regeneration. Verteporfin (VP) is a photosensitizer used in photodynamic therapy to treat age-related macular degeneration. In cancer cells, VP inhibits TEA domain family member (TEAD)-YAP interactions without light stimulation. The protective role of VP in unilateral ureteral obstruction (UUO)-induced renal fibrosis and related mechanisms remains unclear. In this study, we investigate the protective effects of VP on UUO-induced renal tubulointerstitial inflammation and fibrosis and its regulation of the transforming growth factor-beta 1 (TGF-beta 1)/Smad signaling pathway. We find that VP decreased the UUO-induced increase in tubular injury, inflammation, and extracellular matrix deposition in mice. VP also decreased myofibroblast activation and proliferation in UUO kidneys and NRK-49F cells by modulating Smad2 and Smad3 phosphorylation. Therefore, YAP inhibition might have beneficial effects on UUO-induced tubulointerstitial inflammation and fibrosis by regulating the TGF-beta 1/Smad signaling pathway.
C1 [Jin, Jixiu; Wang, Tian; Park, Woong; Li, Wenjia; Kim, Won; Park, Sung Kwang; Kang, Kyung Pyo] Jeonbuk Natl Univ, Res Inst Clin Med, Dept Internal Med, Med Sch, Jeonju 54907, South Korea.
   [Kim, Won; Park, Sung Kwang; Kang, Kyung Pyo] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Jeonju 54907, South Korea.
RP Park, SK; Kang, KP (通讯作者)，Jeonbuk Natl Univ, Res Inst Clin Med, Dept Internal Med, Med Sch, Jeonju 54907, South Korea.; Park, SK; Kang, KP (通讯作者)，Jeonbuk Natl Univ Hosp, Biomed Res Inst, Jeonju 54907, South Korea.
EM gilsoo1215@gmail.com; tianw0000@outlook.com; mnipw@hanmail.net;
   liwenjia1214@gmail.com; kwon@jbnu.ac.kr; parksk@jbnu.ac.kr;
   kpkang@jbnu.ac.kr
RI Kang, Kyung Pyo/ABG-3614-2020
OI Kang, Kyung Pyo/0000-0001-8720-9701
FU National Research Foundation of Korea (NRF) - Korean government
   [NRF-2018R1D1A1B07045790, NRF-2017R1D1A3B03035494]; Fund of Biomedical
   Research Institute, Jeonbuk National University Hospital [CUH2020-0014]
FX This research was supported by the National Research Foundation of Korea
   (NRF) funded by the Korean government (NRF-2018R1D1A1B07045790 to K.P.K
   and NRF-2017R1D1A3B03035494 to S.K.P) and by the Fund of Biomedical
   Research Institute, Jeonbuk National University Hospital (CUH2020-0014,
   to S.K.P).
CR [Anonymous], 2013, Kidney Int Suppl (2011), V3, P19
   Anorga S, 2018, FASEB J, V32, P2644, DOI 10.1096/fj.201700722R
   Boor P, 2010, NAT REV NEPHROL, V6, P643, DOI 10.1038/nrneph.2010.120
   Brigstock DR, 2010, J CELL COMMUN SIGNAL, V4, P1, DOI 10.1007/s12079-009-0071-5
   Chen JC, 2016, J AM SOC NEPHROL, V27, P1689, DOI 10.1681/ASN.2015040415
   Chen WS, 2015, BIOCHEM BIOPH RES CO, V466, P221, DOI 10.1016/j.bbrc.2015.09.012
   Finnson KW, 2020, SEMIN CELL DEV BIOL, V101, P115, DOI 10.1016/j.semcdb.2019.11.013
   Grams ME, 2013, AM J KIDNEY DIS, V62, P245, DOI 10.1053/j.ajkd.2013.03.009
   Grande MT, 2009, NAT REV NEPHROL, V5, P319, DOI 10.1038/nrneph.2009.74
   Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5
   Happe H, 2011, J PATHOL, V224, P133, DOI 10.1002/path.2856
   He Weichun, 2015, Curr Pathobiol Rep, V3, P183
   Herrera J, 2018, J CLIN INVEST, V128, P45, DOI 10.1172/JCI93557
   Hossain Z, 2007, P NATL ACAD SCI USA, V104, P1631, DOI 10.1073/pnas.0605266104
   Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778
   Kim D, 2014, NEPHROL DIAL TRANSPL, V29, P2043, DOI 10.1093/ndt/gfu240
   Kim KM, 2019, KIDNEY RES CLIN PRAC, V38, P382, DOI 10.23876/j.krcp.18.0128
   Li PKT, 2020, KIDNEY INT, V97, P226, DOI 10.1016/j.kint.2019.12.002
   Liu F, 2015, AM J PHYSIOL-LUNG C, V308, pL344, DOI 10.1152/ajplung.00300.2014
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48
   Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115
   Moon S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101184
   Morin-Kensicki EM, 2006, MOL CELL BIOL, V26, P77, DOI 10.1128/MCB.26.1.77-87.2006
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059
   Quan Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020402
   Raghunathan VK, 2013, INVEST OPHTH VIS SCI, V54, P378, DOI 10.1167/iovs.12-11007
   Reginensi A, 2015, DEVELOPMENT, V142, P2696, DOI 10.1242/dev.122044
   Sahin H, 2013, BBA-MOL BASIS DIS, V1832, P1041, DOI 10.1016/j.bbadis.2012.11.004
   Saito A, 2015, AM J PHYSIOL-LUNG C, V309, pL756, DOI 10.1152/ajplung.00238.2015
   Schutte U, 2014, TRANSL ONCOL, V7, P309, DOI 10.1016/j.tranon.2014.02.005
   Schwartzman M, 2016, J AM SOC NEPHROL, V27, P216, DOI 10.1681/ASN.2014090916
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Sureshbabu A, 2016, AM J PHYSIOL-RENAL, V310, pF596, DOI 10.1152/ajprenal.00365.2015
   Szeto SG, 2016, J AM SOC NEPHROL, V27, P3117, DOI 10.1681/ASN.2015050499
   Tung NT, 2018, INT J MOL MED, V41, P95, DOI 10.3892/ijmm.2017.3218
   Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
   Wong JS, 2016, AM J PHYSIOL-RENAL, V311, pF241, DOI 10.1152/ajprenal.00500.2015
   Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807
   Xu J, 2016, CLIN SCI, V130, P349, DOI 10.1042/CS20150385
   Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551
   Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210
NR 44
TC 8
Z9 8
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 21
AR 8184
DI 10.3390/ijms21218184
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OQ9ZL
UT WOS:000589135100001
PM 33142952
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Radomska-Lesniewska, DM
   Osiecka-Iwan, A
   Hyc, A
   Gozdz, A
   Dabrowska, AM
   Skopinski, P
AF Radomska-Lesniewska, Dorota M.
   Osiecka-Iwan, Anna
   Hyc, Anna
   Gozdz, Agata
   Dabrowska, Anna M.
   Skopinski, Piotr
TI Therapeutic potential of curcumin in eye diseases
SO CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
DE curcumin; angiogenesis; glaucoma; diabetic retinopathy; conjunctivitis;
   cataract; eye disease; reactive oxygen species (ROS); age-related
   macular degeneration (AMD)
ID MOLECULAR-MECHANISMS; HEME OXYGENASE-1; IN-VIVO; ANTIINFLAMMATORY
   PROPERTIES; INDUCED CATARACTOGENESIS; ENDOTHELIAL-CELLS;
   DIABETIC-PATIENTS; OXIDATIVE STRESS; NADPH OXIDASE; TNF-ALPHA
AB Curcumin (diferuloylmethane) derived from the rhizome of Curcuma longa L. has been used for thousands of years in traditional Chinese medicine and Ayurvedic medicine in Asian countries to treat liver diseases, rheumatoid diseases, diabetes, atherosclerosis, infectious diseases and cancer. It exhibits a wide range of pharmacological properties, which include antioxidant, anti-inflammatory, antimutagenic, antimicrobial and anticancer activity. Herein the mechanisms of curcumin impact on oxidative stress, angiogenesis and inflammatory processes are described indicating that curcumin use may inhibit those pathological conditions and restore body homeostasis. Its effectiveness was also proved for major eye diseases. In this review, the influence of curcumin on eye diseases, such as glaucoma, cataract, age-related macular degeneration, diabetic retinopathy, corneal neovascularization, corneal wound healing, dry eye disease, conjunctivitis, pterygium, anterior uveitis are reported. The analysis of a number of clinical and preclinical investigations indicates that curcumin may be used as a therapeutic agent in the treatment of various eye disorders.
C1 [Radomska-Lesniewska, Dorota M.; Osiecka-Iwan, Anna; Hyc, Anna; Gozdz, Agata; Skopinski, Piotr] Med Univ Warsaw, Dept Histol & Embryol, 5 Chalubinskiego St, PL-02004 Warsaw, Poland.
   [Dabrowska, Anna M.] Med Univ Warsaw, Fac Med 2, Dept Ophthalmol, Warsaw, Poland.
C3 Medical University of Warsaw; Medical University of Warsaw
RP Skopinski, P (通讯作者)，Med Univ Warsaw, Dept Histol & Embryol, 5 Chalubinskiego St, PL-02004 Warsaw, Poland.
EM pskopin@wp.pl
RI Gozdz, Agata/AAD-2974-2022
OI Gozdz, Agata/0000-0001-8421-0598
CR Agarwal R, 2013, INDIAN J EXP BIOL, V51, P797
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93
   Aggarwal BB, 2009, INT J BIOCHEM CELL B, V41, P40, DOI 10.1016/j.biocel.2008.06.010
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744
   Azari AA, 2013, JAMA-J AM MED ASSOC, V310, P1721, DOI 10.1001/jama.2013.280318
   Barber AJ, 2015, SCI CHINA LIFE SCI, V58, P541, DOI 10.1007/s11427-015-4856-x
   Bellon G, 2004, CRIT REV ONCOL HEMAT, V49, P203, DOI 10.1016/j.critrevonc.2003.10.004
   Bhandarkar SS, 2007, ADV EXP MED BIOL, V595, P185
   Biswas NR, 2001, PHYTOTHER RES, V15, P618, DOI 10.1002/ptr.896
   Brambilla D, 2008, NUTR J, V7, DOI 10.1186/1475-2891-7-29
   Burugula B, 2011, INVEST OPHTH VIS SCI, V52, P4263, DOI 10.1167/iovs.10-7103
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chen M, 2010, EXP EYE RES, V90, P437, DOI 10.1016/j.exer.2009.12.004
   Chen WH, 2005, CHINESE MED J-PEKING, V118, P2052
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Chhunchha B, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.121
   Chung SH, 2012, MOL VIS, V18, P1966
   Devasagayam TPA, 2006, JAPI, V52, P794
   Fong GH, 2008, ANGIOGENESIS, V11, P121, DOI 10.1007/s10456-008-9107-3
   Gao Y, 2015, INT J OPHTHALMOL-CHI, V8, P358, DOI 10.3980/j.issn.2222-3959.2015.02.26
   Guo CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29753
   Gupta SK, 2008, INVEST OPHTH VIS SCI, V49, P4036, DOI 10.1167/iovs.07-1186
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Gururaj AE, 2002, BIOCHEM BIOPH RES CO, V297, P934, DOI 10.1016/S0006-291X(02)02306-9
   Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841
   Hewlings SJ, 2017, FOODS, V6, DOI 10.3390/foods6100092
   Jurenka JS, 2009, ALTERN MED REV, V14, P141
   Khimmaktong Wipapan, 2014, Journal of the Medical Association of Thailand, V97, pS39
   Kim JS, 2010, CURR EYE RES, V35, P274, DOI 10.3109/02713680903528345
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   Kohli K., 2005, Indian Journal of Pharmacology, V37, P141
   Lal B, 1999, PHYTOTHER RES, V13, P318, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;318::AID-PTR445&gt;3.0.CO;2-7
   Li DQ, 2006, EXP EYE RES, V82, P588, DOI 10.1016/j.exer.2005.08.019
   Li H, 2005, HUM GENE THER, V16, P1157, DOI 10.1089/hum.2005.16.1157
   Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300
   Lin YG, 2007, CLIN CANCER RES, V13, P3423, DOI 10.1158/1078-0432.CCR-06-3072
   Loboda A, 2008, ANTIOXID REDOX SIGN, V10, P1767, DOI 10.1089/ars.2008.2043
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Manea A, 2010, CELL TISSUE RES, V342, P325, DOI 10.1007/s00441-010-1060-y
   Manikandan R, 2011, MOL VIS, V17, P388
   Manikandan R, 2010, CURR EYE RES, V35, P122, DOI 10.3109/02713680903447884
   Manikandan R, 2009, CHEM-BIOL INTERACT, V181, P202, DOI 10.1016/j.cbi.2009.05.011
   Mantravadi AV, 2015, PRIMARY CARE, V42, P437, DOI 10.1016/j.pop.2015.05.008
   Marchiani A, 2014, CURR MED CHEM, V21, P204
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Millanta F, 2006, BREAST CANCER RES TR, V98, P115, DOI 10.1007/s10549-005-9138-z
   Milligan SA, 1996, AM J PHYSIOL-LUNG C, V271, pL114, DOI 10.1152/ajplung.1996.271.1.L114
   Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405
   Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X
   Murugan P, 2006, LIFE SCI, V79, P1720, DOI 10.1016/j.lfs.2006.06.001
   Niederkorn JY, 2006, J IMMUNOL, V176, P3950, DOI 10.4049/jimmunol.176.7.3950
   Noorafshan A, 2013, CURR PHARM DESIGN, V19, P2032
   Ohori H, 2006, MOL CANCER THER, V5, P2563, DOI 10.1158/1535-7163.MCT-06-0174
   Padmaja S., 2004, Indian Journal of Experimental Biology, V42, P601
   Panahi Y, 2016, BIOMED PHARMACOTHER, V82, P578, DOI 10.1016/j.biopha.2016.05.037
   Payton F, 2007, J NAT PROD, V70, P143, DOI 10.1021/np060263s
   Piwocka K, 2001, FREE RADICAL BIO MED, V31, P670, DOI 10.1016/S0891-5849(01)00629-3
   Polaczek-Krupa B, 2005, PRZEW LEK, V8, P45
   Pradhan N, 2015, J MOL MED, V93, P1095, DOI 10.1007/s00109-015-1277-z
   Priyadarsini KI, 2003, FREE RADICAL BIO MED, V35, P475, DOI 10.1016/S0891-5849(03)00325-3
   Radomska-Lesniewska DM, 2016, PHARMACOL REP, V68, P462, DOI 10.1016/j.pharep.2015.10.002
   Radomska-Lesniewska DM, 2015, CENT EUR J IMMUNOL, V40, P249, DOI 10.5114/ceji.2015.52839
   Radomska-Lesniewska DM, 2017, CENT EUR J IMMUNOL, V42, P370, DOI 10.5114/ceji.2017.72804
   Santibanez JF, 2000, NUTR CANCER, V37, P49, DOI 10.1207/S15327914NC3701_6
   Schaffer M, 2011, CURR OPIN CLIN NUTR, V14, P588, DOI 10.1097/MCO.0b013e32834bfe94
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Skopinski P, 2004, INT J MOL MED, V14, P707
   Srinivas C, 1989, Anc Sci Life, V8, P279
   Stone JR, 2002, ENDOTHELIUM-J ENDOTH, V9, P231, DOI 10.1080/10623320214733
   Suryanarayana P, 2005, INVEST OPHTH VIS SCI, V46, P2092, DOI 10.1167/iovs.04-1304
   Tilak JC, 2004, PHYTOTHER RES, V18, P798, DOI 10.1002/ptr.1553
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Wan TT, 2015, BIOMED PHARMACOTHER, V74, P145, DOI 10.1016/j.biopha.2015.08.002
   Wang CY, 2012, DIABETES-METAB RES, V28, P329, DOI 10.1002/dmrr.2279
   Wang LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023194
   Woo JM, 2012, MOL VIS, V18, P901
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Yoysungnoen P, 2006, CLIN HEMORHEOL MICRO, V34, P109
   Yue YK, 2014, J OCUL PHARMACOL TH, V30, P657, DOI 10.1089/jop.2014.0022
   Zhang MC, 2007, J HUAZHONG U SCI-MED, V27, P339, DOI 10.1007/s11596-007-0332-6
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
NR 85
TC 46
Z9 48
U1 3
U2 17
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1426-3912
EI 1644-4124
J9 CENT EUR J IMMUNOL
JI Central Eur. J. Immunol.
PY 2019
VL 44
IS 2
BP 181
EP 189
DI 10.5114/ceji.2019.87070
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA IR4LX
UT WOS:000481404600010
PM 31530988
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Clark, SJ
   Bishop, PN
AF Clark, Simon J.
   Bishop, Paul N.
TI The eye as a complement dysregulation hotspot
SO SEMINARS IN IMMUNOPATHOLOGY
LA English
DT Review
DE Age-related macular degeneration; Complement dysregulation; Retinal
   disease; Inflammation; Immune tolerance; Clinical trials; Complement
   therapies
ID C-REACTIVE PROTEIN; MEMBRANE ATTACK COMPLEX; FACTOR-H POLYMORPHISM;
   MACULAR-DEGENERATION; REGULATORY PROTEINS; BRUCHS MEMBRANE; GLOBAL
   PREVALENCE; HIGH-RISK; GENETIC-VARIANTS; AGE
AB Complement turnover is tightly regulated throughout the human body in order to prevent over-activation and subsequent damage from inflammation. In the eye, low-level complement activation is maintained to provide immune tolerance in this immune privileged organ. Conversely, the complement system is suppressed in the cornea to protect it from continuous immunological insult. Over-activation of the complement cascade has been implicated in the disease progression of glaucoma and diabetic retinopathy and is now known to be a central driver in the pathogenesis of age-related macular degeneration (AMD). Indeed, it is with AMD where the most recent and exciting work has been carried out with complement-based therapies entering into clinical trials. However, the success of these trials will depend upon delivering the therapeutics to the correct anatomical sites within the eye, so a full understanding of how complement regulation is compartmentalized in the eye is required, a topic that will be highlighted in this review.
C1 [Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Evolut & Genom Med, Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 University of Manchester; Manchester Royal Eye Hospital; University of
   Manchester
RP Clark, SJ (通讯作者)，Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Evolut & Genom Med, Oxford Rd, Manchester M13 9PT, Lancs, England.
EM simon.clark-3@manchester.ac.uk
OI Clark, Simon/0000-0001-8394-8355
FU MRC Career Development Fellowship [MR/K024418/1]; MRC [MR/P025838/1];
   Fight for Sight [1852/53, 1517/18]; Macular Society [12928]; Medical
   Research Council [MR/K024418/1, MR/P025838/1] Funding Source:
   researchfish; MRC [MR/K024418/1] Funding Source: UKRI
FX Simon Clark is a recipient of an MRC Career Development Fellowship (ref.
   MR/K024418/1), and both Simon Clark and Paul Bishop are supported with
   grants from MRC (ref. MR/P025838/1), Fight for Sight (refs. 1852/53 and
   1517/18), and the Macular Society (ref. 12928).
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bartel G, 2013, TRANSPL INT, V26, P99, DOI 10.1111/tri.12006
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Black JRM, 2016, GENET MED
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Cantsilieris Stuart, 2009, Recent Pat DNA Gene Seq, V3, P102
   Caspi R.R., 2006, DRUG DISCOV TODAY, V3, P199, DOI 10.1016/j.ddmec.2006.05.006.
   Clark SJ, 2017, MOL IMMUNOL, V89, P200, DOI 10.1016/j.molimm.2017.06.225
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Clark SJ, 2014, J IMMUNOL
   Cocuzzi E, 2000, CURR EYE RES, V21, P856, DOI 10.1076/ceyr.21.5.856.5539
   Davies CS, 2005, IMMUNOLOGY, V114, P280, DOI 10.1111/j.1365-2567.2004.02086.x
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Ghosh P, 2015, ENDOCR REV, V36, P272, DOI 10.1210/er.2014-1099
   Giles JL, 2015, J IMMUNOL, V194, P3029, DOI 10.4049/jimmunol.1402956
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Jha P, 2006, INVEST OPHTH VIS SCI, V47, P1030, DOI 10.1167/iovs.05-1062
   Jha P, 2006, J IMMUNOL, V176, P7221, DOI 10.4049/jimmunol.176.12.7221
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   McHarg S, 2015, MOL IMMUNOL
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Miyahara T, 2003, INVEST OPHTH VIS SCI, V44, P4347, DOI 10.1167/iovs.02-1032
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mondino BJ, 1996, INVEST OPHTH VIS SCI, V37, P1576
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Niederkorn Jerry Y, 2007, Chem Immunol Allergy, V92, P27, DOI 10.1159/000099251
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2013, J IMMUNOL, V190, P3839, DOI 10.4049/jimmunol.1203200
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Sahebjada Srujana, 2011, Recent Pat DNA Gene Seq, V5, P185
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schmidt J, 2006, CANCER IMMUNOL IMMUN, V55, P31, DOI 10.1007/s00262-005-0690-5
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shields MB, 2008, CURR OPIN OPHTHALMOL, V19, P85, DOI 10.1097/ICU.0b013e3282f3919b
   Silva AS, 2012, MOL VIS, V18, P2288
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Tang AH, 2009, INVEST OPHTH VIS SCI, V50, P3794, DOI 10.1167/iovs.08-3107
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Whitcup SM, 2013, INT J INFLAM, V2013, P1
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Williams PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0091-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu DF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149704
   Yang MM, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/5412084
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhang A, 2002, DIABETES, V51, P3499
NR 84
TC 64
Z9 68
U1 1
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2297
EI 1863-2300
J9 SEMIN IMMUNOPATHOL
JI Semin. Immunopathol.
PD JAN
PY 2018
VL 40
IS 1
BP 65
EP 74
DI 10.1007/s00281-017-0649-6
PG 10
WC Immunology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pathology
GA FU7US
UT WOS:000424058800006
PM 28948331
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sun, Y
   Liegl, R
   Gong, Y
   Buhler, A
   Cakir, B
   Meng, SS
   Burnim, SB
   Liu, CH
   Reuer, T
   Zhang, PP
   Walz, JM
   Ludwig, F
   Lange, C
   Agostini, H
   Bohringer, D
   Schlunck, G
   Smith, LEH
   Stahl, A
AF Sun, Ye
   Liegl, Raffael
   Gong, Yan
   Buehler, Anima
   Cakir, Bertan
   Meng, Steven S.
   Burnim, Samuel B.
   Liu, Chi-Hsiu
   Reuer, Tristan
   Zhang, Peipei
   Walz, Johanna M.
   Ludwig, Franziska
   Lange, Clemens
   Agostini, Hansjuergen
   Boehringer, Daniel
   Schlunck, Guenther
   Smith, Lois E. H.
   Stahl, Andreas
TI Sema3f Protects Against Subretinal Neovascularization In Vivo
SO EBIOMEDICINE
LA English
DT Article
DE AMD; CNV; RAP; Laser-CNV; Semaphorin; Sema3f; VLDLR; Neovascularization;
   Retina
ID GROWTH-FACTOR; ANGIOGENESIS; RANIBIZUMAB; RECEPTOR; OUTCOMES; CELLS;
   GENE; RNA
AB Pathological neovascularization of the outer retina is the hallmark of neovascular age-related macular degeneration (nAMD). Building on our previous observations that semaphorin 3F (Sema3f) is expressed in the outer retina and demonstrates anti-angiogenic potential, we have investigated whether Sema3f can be used to protect against subretinal neovascularization in twomousemodels. Both in the very low-density lipid-receptor knockout (Vldlr(-/-)) model of spontaneous subretinal neovascularization as well as in the mouse model of laser-induced choroidal neovascularization (CNV), we found protective effects of Sema3f against the formation of pathologic neovascularization. In the Vldlr-/-model, AAV-induced overexpression of Sema3f reduced the size of pathologic neovascularization by 56%. In the laser-induced CNV model, intravitreally injected Sema3f reduced pathologic neovascularization by 30%. Combined, these results provide the first evidence from two distinct in vivo models for a use of Sema3f in protecting the outer retina against subretinal neovascularization. (C) 2017 The Authors. Published by Elsevier B.V.
C1 [Sun, Ye; Liegl, Raffael; Gong, Yan; Meng, Steven S.; Burnim, Samuel B.; Liu, Chi-Hsiu; Smith, Lois E. H.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
   [Buehler, Anima; Cakir, Bertan; Reuer, Tristan; Zhang, Peipei; Walz, Johanna M.; Ludwig, Franziska; Lange, Clemens; Agostini, Hansjuergen; Boehringer, Daniel; Schlunck, Guenther; Stahl, Andreas] Univ Freiburg, Eye Ctr, Med Ctr, Fac Med, Killianstr 5, D-79106 Freiburg, Germany.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of Freiburg
RP Stahl, A (通讯作者)，Univ Freiburg, Eye Ctr, Med Ctr, Fac Med, Killianstr 5, D-79106 Freiburg, Germany.
EM andreas.stahl@uniklinik-freiburg.de
OI Gong, Yan/0000-0002-4805-0459; Pfeil, Johanna
   Madeleine/0000-0002-2731-6094; Sun, Ye/0000-0002-7674-9056
FU DFG [STA 1102/5-1]; National Institutes of Health/National Eye Institute
   [R01 EY024864, EY017017, P01 HD18655]; Lowy Medical Research Institute
   [84134]; European Commission FP7 [305485]; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY024864,
   R01EY017017] Funding Source: NIH RePORTER
FX This work was supported by the DFG (STA 1102/5-1) for AS and the
   National Institutes of Health/National Eye Institute (R01 EY024864,
   EY017017, and P01 HD18655), Lowy Medical Research Institute (84134) and
   the European Commission FP7 PREVENTROP project (305485) for LEHS. The
   funding sources had no role in howthe research was conducted.
CR Ajlan RS, 2016, SEMIN OPHTHALMOL, V31, P40, DOI 10.3109/08820538.2015.1114833
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buehler A, 2013, FEBS LETT, V587, P1650, DOI 10.1016/j.febslet.2013.04.008
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Fukushima Y, 2011, J CLIN INVEST, V121, P1974, DOI 10.1172/JCI44900
   Gaur P, 2009, CLIN CANCER RES, V15, P6763, DOI 10.1158/1078-0432.CCR-09-1810
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   GULATMARNAY C, 1989, J NEUROCHEM, V53, P519, DOI 10.1111/j.1471-4159.1989.tb07364.x
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Joyal JS, 2011, BLOOD, V117, P6024, DOI 10.1182/blood-2010-10-311589
   Li J, 2014, INVEST OPHTH VIS SCI, V55, P8267, DOI 10.1167/iovs.14-15623
   LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Meyer CH, 2016, DEV OPHTHALMOL, V55, P63, DOI 10.1159/000431143
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Stahl A, 2009, ANGIOGENESIS, V12, P297, DOI 10.1007/s10456-009-9155-3
   Sulzbacher F., 2017, ACTA OPHTHALMOL
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Vandenberghe LH, 2010, HUM GENE THER, V21, P1251, DOI 10.1089/hum.2010.107
   Wang S, 2014, DEV CELL, V30, P513, DOI 10.1016/j.devcel.2014.07.018
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 31
TC 13
Z9 13
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD APR
PY 2017
VL 18
BP 281
EP 287
DI 10.1016/j.ebiom.2017.03.026
PG 7
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA EV9KO
UT WOS:000402105100039
PM 28373097
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nakamura, R
   Sene, A
   Santeford, A
   Gdoura, A
   Kubota, S
   Zapata, N
   Apte, RS
AF Nakamura, Rei
   Sene, Abdoulaye
   Santeford, Andrea
   Gdoura, Abdelaziz
   Kubota, Shunsuke
   Zapata, Nicole
   Apte, Rajendra S.
TI IL10-driven STAT3 signalling in senescent macrophages promotes
   pathological eye angiogenesis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; CHOLESTEROL EFFLUX;
   IL-10 PRODUCTION; TRANSCRIPTION 3; POLARIZATION; SOCS3; ACTIVATION;
   RECEPTOR; CELLS
AB Macrophage dysfunction plays a pivotal role during neovascular proliferation in diseases of ageing including cancers, atherosclerosis and blinding eye disease. In the eye, choroidal neovascularization (CNV) causes blindness in patients with age-related macular degeneration (AMD). Here we report that increased IL10, not IL4 or IL13, in senescent eyes activates STAT3 signalling that induces the alternative activation of macrophages and vascular proliferation. Targeted inhibition of both IL10 receptor-mediated signalling and STAT3 activation in macrophages reverses the ageing phenotype. In addition, adoptive transfer of STAT3-deficient macrophages into eyes of old mice significantly reduces the amount of CNV. Systemic and CD163(+) eye macrophages obtained from AMD patients also demonstrate STAT3 activation. Our studies demonstrate that impaired SOCS3 feedback leads to permissive IL10/STAT3 signalling that promotes alternative macrophage activation and pathological neovascularization. These findings have significant implications for our understanding of the pathobiology of age-associated diseases and may guide targeted immunotherapy.
C1 [Nakamura, Rei; Sene, Abdoulaye; Santeford, Andrea; Gdoura, Abdelaziz; Kubota, Shunsuke; Zapata, Nicole; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 South Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM Apte@vision.wustl.edu
FU National Institutes of Health (NIH) [R01EY019287]; NIH Vision Core Grant
   [P30EY02687]; Carl Marshall Reeves and Mildred Almen Reeves Foundation
   Inc. Award; Physician Scientist Award; Research to Prevent Blindness
   Inc. Career Development Award; International Retina Research Foundation;
   American Health Assistance Foundation; Thome Foundation; Research to
   Prevent Blindness Inc.; NATIONAL EYE INSTITUTE [P30EY002687,
   R01EY019287] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health (NIH) Grant
   R01EY019287 (RSA), NIH Vision Core Grant P30EY02687, Carl Marshall
   Reeves and Mildred Almen Reeves Foundation Inc. Award and Physician
   Scientist Award (R.S.A.), Research to Prevent Blindness Inc. Career
   Development Award (R.S.A.), International Retina Research Foundation
   (R.S.A.), American Health Assistance Foundation (R.S.A.), Thome
   Foundation (R.S.A.) and Research to Prevent Blindness Inc. Unrestricted
   Grant to Washington University. We acknowledge the insights and
   constructive input of Drs Shiming Chen, Vladimir Kefalov, Juan Pablo De
   Rivero Vaccari, Abigail Hackam, Steve Teitelbaum, Emil Unanue and Greg
   Wu regarding these studies.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Babon JJ, 2012, IMMUNITY, V36, P239, DOI 10.1016/j.immuni.2011.12.015
   Barros MHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080908
   Braun DA, 2013, J BIOL CHEM, V288, P2986, DOI 10.1074/jbc.M112.386573
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chambers SEJ, 2013, IMMUNOBIOLOGY, V218, P1370, DOI 10.1016/j.imbio.2013.06.010
   Chen PW, 2013, INT REV CEL MOL BIO, V301, P1, DOI 10.1016/B978-0-12-407704-1.00001-4
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Costa PZ, 2013, LIFE SCI, V92, P1037, DOI 10.1016/j.lfs.2013.04.001
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dace DS, 2008, REJUV RES, V11, P177, DOI 10.1089/rej.2007.0614
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fridman WH, 2011, CURR TOP MICROBIOL, V344, P1, DOI 10.1007/82_2010_46
   Gimenez E, 2001, LAB ANIM-UK, V35, P153, DOI 10.1258/0023677011911525
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hara R, 2010, CURR EYE RES, V35, P1012, DOI 10.3109/02713683.2010.500112
   He LZ, 2014, J BIOL CHEM, V289, P8019, DOI 10.1074/jbc.M113.535765
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6
   Karp CL, 2012, J EXP MED, V209, P427, DOI 10.1084/jem.20120295
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Khan AA, 2008, IMMUNOBIOLOGY, V213, P695, DOI 10.1016/j.imbio.2008.07.014
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kono Y, 2014, BIOL PHARM BULL, V37, P137, DOI 10.1248/bpb.b13-00659
   Kowal K, 2011, FOLIA HISTOCHEM CYTO, V49, P365, DOI 10.5603/FHC.2011.0052
   Lai HS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067868
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630
   Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978-0-12-417028-5.00006-5
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Murray PJ, 2014, IMMUNITY, V41, P339, DOI 10.1016/j.immuni.2014.07.009
   Narayanan SP, 2013, PROG RETIN EYE RES, V36, P260, DOI 10.1016/j.preteyeres.2013.06.002
   Nemeth ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260
   Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281
   Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Qualls JE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000955
   Romacho T, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/946427
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571
   Stahl A, 2012, BLOOD, V120, P2925, DOI 10.1182/blood-2012-04-422527
   Striz I, 2014, CLIN SCI, V126, P593, DOI 10.1042/CS20130497
   Takeda K, 1998, J IMMUNOL, V161, P4652
   Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Uehara Y, 2009, BIOCHEM BIOPH RES CO, V380, P627, DOI 10.1016/j.bbrc.2009.01.137
   Ugel S, 2009, CURR OPIN PHARMACOL, V9, P470, DOI 10.1016/j.coph.2009.06.014
   Wang AL, 2010, VISION RES, V50, P638, DOI 10.1016/j.visres.2009.08.029
   Wang H, 2011, INT J BIOL SCI, V7, P536, DOI 10.7150/ijbs.7.536
   Wang XC, 2012, INT J ONCOL, V41, P1181, DOI 10.3892/ijo.2012.1568
   Williams L, 2002, J LEUKOCYTE BIOL, V72, P800
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938
   Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093
NR 66
TC 117
Z9 121
U1 2
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG
PY 2015
VL 6
AR 7847
DI 10.1038/ncomms8847
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CQ1FR
UT WOS:000360343200004
PM 26260587
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mao, YX
   Kiss, S
   Boyer, JL
   Hackett, NR
   Qiu, JP
   Carbone, A
   Mezey, JG
   Kaminsky, SM
   D'Amico, DJ
   Crystal, RG
AF Mao, Yanxiong
   Kiss, Szilard
   Boyer, Julie L.
   Hackett, Neil R.
   Qiu, Jianping
   Carbone, Andrew
   Mezey, Jason G.
   Kaminsky, Stephen M.
   D'Amico, Donald J.
   Crystal, Ronald G.
TI Persistent Suppression of Ocular Neovascularization with Intravitreal
   Administration of AAVrh.10 Coding for Bevacizumab
SO HUMAN GENE THERAPY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MEDIATED GENE-THERAPY; ANTI-VEGF ANTIBODY;
   ADENOASSOCIATED VIRUS; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   CONGENITAL AMAUROSIS; RANIBIZUMAB; EXPRESSION; MOUSE
AB Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. Bevacizumab, an anti-VEGF monoclonal antibody, is efficacious for these disorders, but requires monthly intravitreal administration, with associated discomfort, cost, and adverse event risk. We hypothesized that a single intravitreal administration of adeno-associated virus (AAV) vector expressing bevacizumab would result in persistent eye expression of bevacizumab and suppress VEGF-induced retinal neovascularization. We constructed an AAV rhesus serotype rh. 10 vector to deliver bevacizumab (AAVrh.10BevMab) and assessed its ability to suppress neovascularization in transgenic mice overexpressing human VEGF165 in photoreceptors. Intravitreal AAVrh.10BevMab directed long-term bevacizumab expression in the retinal pigmented epithelium. Treated homozygous mice had reduced levels of neovascularization, with 90 +/- 4% reduction 168 days following treatment. Thus, a single administration of AAVrh.10BevMab provides long-term suppression of neovascularization without the costs and risks associated with the multiple administrations required for the current conventional bevacizumab monoclonal drug delivery.
C1 [Mao, Yanxiong] Sichuan Univ, W China Hosp, Dept Resp Med, Chengdu 610041, Sichuan, Peoples R China.
   [Mao, Yanxiong; Boyer, Julie L.; Hackett, Neil R.; Qiu, Jianping; Carbone, Andrew; Mezey, Jason G.; Kaminsky, Stephen M.; Crystal, Ronald G.] Weill Cornell Med Coll, Dept Med Genet, New York, NY 10065 USA.
   [Kiss, Szilard; D'Amico, Donald J.] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY 10065 USA.
   [Mezey, Jason G.] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA.
C3 Sichuan University; Cornell University; Cornell University; Cornell
   University
RP Mao, YX (通讯作者)，Cornell Univ Med Coll, Dept Med Genet, 1300 York Ave,Box 96, New York, NY 10065 USA.
EM geneticmedicine@med.cornell.edu
RI Mao, Yanxiong/AAB-6907-2022; Kaminsky, Stephen/J-5141-2016
OI Mao, Yanxiong/0000-0002-7033-3383; Kaminsky,
   Stephen/0000-0003-1869-834X; Kiss, Szilard/0000-0003-3433-8432
FU Research to Prevent Blindness, New York, NY;  [P50 HL084936];  [T32
   HL094284];  [UL1-RR024996]; NATIONAL CENTER FOR RESEARCH RESOURCES
   [UL1RR024996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [T32HL094284, P50HL084936] Funding Source: NIH RePORTER
FX We thank Stacey Chen for help with the analysis and N. Mohamed for help
   in preparing the manuscript. These studies were supported, in part, by
   P50 HL084936, T32 HL094284, and UL1-RR024996, and Research to Prevent
   Blindness, New York, NY.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2003, CLIN SCI, V104, P561, DOI 10.1042/CS20020314
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch PK, 2008, GENE THER, V15, P849, DOI 10.1038/gt.2008.66
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   *CLINICALTRIALS, 2011, SAF TOL STUD AAV2 SF
   Daly TM, 1999, P NATL ACAD SCI USA, V96, P2296, DOI 10.1073/pnas.96.5.2296
   De BP, 2006, MOL THER, V13, P67, DOI 10.1016/j.ymthe.2005.09.003
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Fang JM, 2005, NAT BIOTECHNOL, V23, P584, DOI 10.1038/nbt1087
   Arevalo JF, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/584238
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299
   Giove TJ, 2010, EXP EYE RES, V91, P652, DOI 10.1016/j.exer.2010.08.011
   Gulkilik Gokhan, 2010, International Ophthalmology, V30, P697, DOI 10.1007/s10792-010-9403-y
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Miki K, 2009, OPHTHALMOLOGY, V116, P1748, DOI 10.1016/j.ophtha.2009.05.020
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Montero JA, 2011, CURR DIABETES REV, V7, P176, DOI 10.2174/157339911795843104
   Nicholson BP, 2010, GRAEF ARCH CLIN EXP, V248, P915, DOI 10.1007/s00417-010-1315-z
   NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Ozturk BT, 2011, J OCUL PHARMACOL TH, V27, P373, DOI 10.1089/jop.2010.0195
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy K, 2010, HUM GENE THER, V21, P915, DOI 10.1089/hum.2010.041
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Salam A, 2011, ACTA OPHTHALMOL, V89, P405, DOI 10.1111/j.1755-3768.2010.02079.x
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Sondhi D, 2007, MOL THER, V15, P481, DOI 10.1038/sj.mt.6300049
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Waisbourd M, 2011, ACTA OPHTHALMOL, V89, P203, DOI 10.1111/j.1755-3768.2010.02010.x
   Wang G, 2010, CANCER GENE THER, V17, P559, DOI 10.1038/cgt.2010.11
   Watanabe M, 2008, HUM GENE THER, V19, P300, DOI 10.1089/hum.2007.109
   Witkin AJ, 2011, CURR OPIN OPHTHALMOL, V22, P185, DOI 10.1097/ICU.0b013e3283459724
   Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998
NR 49
TC 19
Z9 32
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD DEC
PY 2011
VL 22
IS 12
BP 1525
EP 1535
DI 10.1089/hum.2011.090
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 865XH
UT WOS:000298343700007
PM 21801028
OA Green Published
DA 2022-11-30
ER

PT J
AU Jin, HX
   Randazzo, J
   Zhang, P
   Kador, PF
AF Jin, Hongxia
   Randazzo, James
   Zhang, Peng
   Kador, Peter F.
TI Multifunctional Antioxidants for the Treatment of Age-Related Diseases
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; MACULAR DEGENERATION;
   CRYSTALLIN PROTEINS; FIBRIL FORMATION; POTENTIAL FACTOR; A-BETA; IRON;
   COPPER; CATARACT
AB Analogues of N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-l-sulfonamide possessing a free radical scavenger group (FRS), chelating groups (CHL), or both (FRS + CHL) have been synthesized. Electrospray ionization mass spectrometry studies indicate that select members of this series bind ions in the relative order of Cu1+ = Cu2+ >Fe2+ = Fe3+ > Zn2+ with no binding of Ca2+ or Mg2+ observed. In vitro evaluation of these compounds in human lens epithelial, human retinal pigmented epithelial, and human hippocampal astrocyte cell lines indicates that all analogues possessing the FRS group as well as the water-soluble vitamin E analogue 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid protect these cells against decreased cell viability and glutathione levels induced by hydrogen peroxide. In addition, those compounds possessing CHL groups also protected these cells against hydroxyl radicals generated by the Fenton reaction. These compounds are good candidates for the preventive treatment of cataract, age-related macular degeneration (AMD), and Alzheimer's dementia (AD).
C1 [Jin, Hongxia; Randazzo, James; Zhang, Peng; Kador, Peter F.] Univ Nebraska Med Ctr, Coll Nursing, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center
RP Kador, PF (通讯作者)，Univ Nebraska Med Ctr, Coll Nursing, 985330 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM pkador@unmc.edu
FU National Institutes of Health [EY016460]; NATIONAL EYE INSTITUTE
   [R21EY016460] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grant EY016460.
CR Adlard PA, 2008, NEURON, V59, P43, DOI 10.1016/j.neuron.2008.06.018
   Allsop D, 2008, BIOCHEM SOC T, V36, P1293, DOI 10.1042/BST0361293
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Avunduk AM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1368, DOI 10.1001/archopht.117.10.1368
   Bakalbassis EG, 2003, J PHYS CHEM A, V107, P8594, DOI 10.1021/jp034400v
   Baron D, 1998, J ENVIRON QUAL, V27, P844, DOI 10.2134/jeq1998.00472425002700040019x
   Binienda Z, 2005, ANN NY ACAD SCI, V1053, P174, DOI 10.1196/annals.1344.015
   Bolognesi ML, 2006, MINI-REV MED CHEM, V6, P1269, DOI 10.2174/138955706778742731
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Brewer GJ, 2008, CURR OPIN CLIN NUTR, V11, P727, DOI 10.1097/MCO.0b013e328314b678
   Brewer GJ, 2007, EXP BIOL MED, V232, P323
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Bush AI, 2008, NEUROTHERAPEUTICS, V5, P421, DOI 10.1016/j.nurt.2008.05.001
   Crouch PJ, 2006, DRUG NEWS PERSPECT, V19, P469, DOI 10.1358/dnp.2006.19.8.1021492
   Cuajungco MP, 1998, BRAIN RES, V799, P97, DOI 10.1016/S0006-8993(98)00482-X
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ecroyd H, 2009, CELL MOL LIFE SCI, V66, P62, DOI 10.1007/s00018-008-8327-4
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Finefrock AE, 2003, J AM GERIATR SOC, V51, P1143, DOI 10.1046/j.1532-5415.2003.51368.x
   Forni GL, 2008, MOVEMENT DISORD, V23, P905, DOI 10.1002/mds.22002
   FOURMAINTRAUX E, 1999, HETEROCYCL COMMUN, V33, P313
   Frank Bradford, 2005, Ann Clin Psychiatry, V17, P269, DOI 10.1080/10401230500296428
   Garcia-Arencibia M, 2007, BRAIN RES, V1134, P162, DOI 10.1016/j.brainres.2006.11.063
   Garner B, 1999, REDOX REP, V4, P313, DOI 10.1179/135100099101535007
   Gilca M, 2007, J POSTGRAD MED, V53, P207, DOI 10.4103/0022-3859.33869
   GINO A, 2001, J AM CHEM SOC, V123, P4625
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   Gupta SK, 2009, INDIAN J OPHTHALMOL, V57, P175, DOI 10.4103/0301-4738.49390
   HENRY DW, 1966, J HETEROCYCLIC CHEM, V3, P503, DOI 10.1002/jhet.5570030423
   House E, 2004, J ALZHEIMERS DIS, V6, P291
   HUANG CY, 1982, METHOD ENZYMOL, V87, P509
   Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551
   Jenagaratnam L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005380.pub2
   Jinno S, 1998, CHEM PHARM BULL, V46, P1688
   Julia M, 1996, B SOC CHIM FR, V133, P15
   Kador PF, 2004, J OCUL PHARMACOL TH, V20, P333, DOI 10.1089/1080768041725281
   KADOR PF, 2009, Patent No. 20090105269
   KIZNER TA, 1990, CHEM HETEROCYCL COMP, V6, P668
   Kruck TR, 2008, NEUROREPORT, V19, P245, DOI 10.1097/WNR.0b013e3282f4cb7e
   Kruck TPA, 2002, J INORG BIOCHEM, V88, P19, DOI 10.1016/S0162-0134(01)00372-5
   Kupershmidt L, 2009, FASEB J, V23, P3766, DOI 10.1096/fj.09-130047
   Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4
   Lee JY, 2004, NEUROBIOL AGING, V25, P1315, DOI 10.1016/j.neurobiolaging.2004.01.005
   Lee S, 2005, PROTEIN SCI, V14, P593, DOI 10.1110/ps.041020705
   LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K
   Meehan S, 2004, J BIOL CHEM, V279, P3413, DOI 10.1074/jbc.M308203200
   Melov S, 2005, FREE RADICAL BIO MED, V38, P258, DOI 10.1016/j.freeradbiomed.2004.10.023
   Narayanan S, 2006, FEBS LETT, V580, P5941, DOI 10.1016/j.febslet.2006.09.063
   *NIH, CNS DRUG DELIVERY NI
   PARKER KA, 1987, J ORG CHEM, V52, P674, DOI 10.1021/jo00380a034
   PEDULLI GF, 2001, TRENDS ORG CHEM, V9, P97
   Perluigi M, 2006, NEUROSCIENCE, V138, P1161, DOI 10.1016/j.neuroscience.2005.12.004
   PRIEWE H, 1963, Patent No. 1145622
   Raman B, 2005, J BIOL CHEM, V280, P16157, DOI 10.1074/jbc.M500309200
   Richer Stuart, 2002, Am J Ther, V9, P25, DOI 10.1097/00045391-200201000-00006
   ROSE FC, 1984, ACTA NEUROL SCAND, V70, P137
   Scott LE, 2009, CHEM REV, V109, P4885, DOI 10.1021/cr9000176
   Silver H, 2009, NEUROTHERAPEUTICS, V6, P86, DOI 10.1016/j.nurt.2008.10.034
   Skulachev VP, 2009, BBA-BIOENERGETICS, V1787, P437, DOI 10.1016/j.bbabio.2008.12.008
   Smith DG, 2007, BBA-BIOMEMBRANES, V1768, P1976, DOI 10.1016/j.bbamem.2007.02.002
   Stadtman E R, 1988, Basic Life Sci, V49, P331
   Surolia I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002927
   Tauskela JS, 2007, IDRUGS, V10, P399
   Treiber C, 2004, J BIOL CHEM, V279, P51958, DOI 10.1074/jbc.M407410200
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Weinreb O, 2009, NEUROTHERAPEUTICS, V6, P163, DOI 10.1016/j.nurt.2008.10.030
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   ZAIDI SA, 1993, INORG MET ORG CHEM, V23, P1571
NR 73
TC 31
Z9 33
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 11
PY 2010
VL 53
IS 3
BP 1117
EP 1127
DI 10.1021/jm901381j
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 552EN
UT WOS:000274270900019
PM 20078105
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sparrow, JR
   Wu, YL
   Kim, CY
   Zhou, JL
AF Sparrow, Janet R.
   Wu, Yalin
   Kim, Chul Y.
   Zhou, Jilin
TI Phospholipid meets all-trans-retinal: the making of RPE bisretinoids
SO JOURNAL OF LIPID RESEARCH
LA English
DT Review
DE bisretinoids; photooxidation; fluorescence; lipofuscin; retina; light;
   visible spectrum; absorbance; all-trans-retinal dimer; retinal pigment
   epithelium
ID PIGMENT EPITHELIAL-CELLS; LIGHT-INDUCED DAMAGE; ROD OUTER SEGMENTS;
   LYSOSOMAL DEGRADATIVE FUNCTIONS; RECESSIVE STARGARDT-DISEASE;
   PROTEIN-COUPLED RECEPTOR; ABC TRANSPORTER ABCA4; FACTOR-H POLYMORPHISM;
   MACULAR DEGENERATION; BLUE-LIGHT
AB The lipid phase of the photoreceptor outer segment membrane is essential to the photon capturing and signaling functions of rhodopsin. Rearrangement of phospholipids in the bilayer accompanies the formation of the active intermediates of rhodopsin following photon absorption. Furthermore, evidence for the formation of a condensation product between the photolyzed chromophore all-trans-retinal and phosphatidylethanolamine indicates that phospholipid may also participate in the movement of the retinoid in the membrane. The downside of these interactions is the formation of bisretinoid-phosphatidylethanolamine compounds that accumulate in retinal pigment epithelial cells with age and that are particularly abundant in some retinal disorders. The propensity of these compounds to negatively impact on the cells has been linked to the pathogenesis of some retinal disorders including juvenile onset recessive Stargardt disease and age-related macular degeneration.-Sparrow, J. R., Y. Wu, C. Y. Kim, and J. Zhou. Phospholipid meets all-trans-retinal: the making of RPE bisretinoids. J. Lipid Res. 2010. 51: 247-261.
C1 [Sparrow, Janet R.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Sparrow, JR (通讯作者)，Columbia Univ, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.
EM jrs88@columbia.edu
FU National Institutes of Health [EY 12951]; Kaplen Foundation; Research to
   Prevent Blindness to the Department of Ophthalmology, Columbia
   University; NATIONAL EYE INSTITUTE [R01EY012951, P30EY019007] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institutes of Health Grant EY
   12951 (J.R.S.), the Kaplen Foundation (J.R.S.), and unrestricted funds
   from Research to Prevent Blindness to the Department of Ophthalmology,
   Columbia University. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of the
   National Institutes of Health. J.R.S. is a recipient of an RPB Senior
   Scientist Award.
CR Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019
   Beck M, 1998, FEBS LETT, V436, P304, DOI 10.1016/S0014-5793(98)01156-9
   Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bermann M, 2001, EXP EYE RES, V72, P191
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   BOK D, 1993, J CELL SCI, P189
   BORGES J, 1990, ARCH OPHTHALMOL-CHIC, V108, P727, DOI 10.1001/archopht.1990.01070070113047
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   BOULTON M, 1998, MELANIN RETINAL PIGM
   BUNTMILAM AH, 1983, INVEST OPHTH VIS SCI, V24, P458
   Busch EM, 1999, PHOTOCHEM PHOTOBIOL, V70, P353, DOI 10.1562/0031-8655(1999)070<0353:TEOTSO>2.3.CO;2
   Cantrell A, 2001, J PHOTOCH PHOTOBIO B, V64, P162, DOI 10.1016/S1011-1344(01)00224-X
   Chalupa L.M., 2008, EYE RETINA VISUAL SY, P539
   Chrispell JD, 2009, J BIOL CHEM, V284, P21468, DOI 10.1074/jbc.M109.020966
   Cideciyan AV, 2009, HUM MOL GENET, V18, P931, DOI 10.1093/hmg/ddn421
   Clancy CMR, 2000, J PHYS CHEM B, V104, P12098, DOI 10.1021/jp0030544
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Cuervo AM, 2008, TRENDS GENET, V24, P604, DOI 10.1016/j.tig.2008.10.002
   DALVIE D, 1992, J ORG CHEM, V57, P7321, DOI 10.1021/jo00052a056
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fishkin N, 2004, CHIRALITY, V16, P637, DOI 10.1002/chir.20084
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V80, P265, DOI 10.1001/archopht.1968.00980050267022
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Grayson C, 2005, J BIOL CHEM, V280, P32521, DOI 10.1074/jbc.M503411200
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   HAM WTJ, 1986, CRC OPTICAL RAD VISU, P43
   Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   Hessel E, 2001, J BIOL CHEM, V276, P2538, DOI 10.1074/jbc.M009061200
   HICKS D, 1989, EXP EYE RES, V49, P13, DOI 10.1016/0014-4835(89)90072-9
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   HOPPELER T, 1988, CURR EYE RES, V7, P849, DOI 10.3109/02713688808997242
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394
   Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jastrzebska B, 2009, BIOCHEMISTRY-US, V48, P5159, DOI 10.1021/bi900284x
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Kanofsky JR, 2003, PHOTOCHEM PHOTOBIOL, V77, P235, DOI 10.1562/0031-8655(2003)077<0235:SOGFA>2.0.CO;2
   Karan G, 2005, MOL VIS, V11, P657
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P37
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   KATZ ML, 1986, MECH AGEING DEV, V35, P291, DOI 10.1016/0047-6374(86)90131-4
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kim SR, 2007, BIOCHEMISTRY-US, V46, P10122, DOI 10.1021/bi7009635
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Lamb LE, 2001, J PHYS CHEM B, V105, P11507, DOI 10.1021/jp0123177
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lei B, 2006, EXP EYE RES, V83, P610, DOI 10.1016/j.exer.2006.02.013
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Lorenz B, 2004, OPHTHALMOLOGY, V111, P1585, DOI 10.1016/j.ophtha.2004.01.033
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Lyubarsky AL, 2005, BIOCHEMISTRY-US, V44, P9880, DOI 10.1021/bi0505363
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Molday RS, 2007, J BIOENERG BIOMEMBR, V39, P507, DOI 10.1007/s10863-007-9118-6
   Molday RS, 2009, BBA-MOL CELL BIOL L, V1791, P573, DOI 10.1016/j.bbalip.2009.02.004
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Nusinowitz S, 2003, EXP EYE RES, V77, P627, DOI 10.1016/S0014-4835(03)00217-3
   ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5
   PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PAULTLER EL, 1989, INHERITED ENV INDUCE, P555
   PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c
   Rattner A, 2008, J NEUROSCI, V28, P9880, DOI 10.1523/JNEUROSCI.2401-08.2008
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   REME CE, 1998, LIGHT DAMAGE RETINA
   ROBISON WG, 1980, INVEST OPHTH VIS SCI, V19, P1030
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 2006, ADV EXP MED BIOL, V572, P63
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   SZAMIER RB, 1977, INVEST OPHTH VIS SCI, V16, P947
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tanito M, 2006, EXP EYE RES, V83, P1493, DOI 10.1016/j.exer.2006.08.006
   Tanito M, 2009, J LIPID RES, V50, P807, DOI 10.1194/jlr.M800170-JLR200
   Tombran-Tink J, 2007, RETINAL DEGENERATION, P213
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G
   Vasireddy V, 2005, MOL VIS, V11, P665
   VASIREDDY V, 2009, EXP EYE RES IN PRESS
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   WILLIAMS TP, 1983, INVEST OPHTH VIS SCI, V24, P285
   WU L, 2009, ADV EXP MED IN PRESS
   WU Y, 2009, J BIOL CHEM IN PRESS
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
   Zhong M, 2009, J BIOL CHEM, V284, P3640, DOI 10.1074/jbc.M806580200
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2006, REJUV RES, V9, P256, DOI 10.1089/rej.2006.9.256
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 158
TC 135
Z9 160
U1 1
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD FEB
PY 2010
VL 51
IS 2
BP 247
EP 261
DI 10.1194/jlr.R000687
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 543ZG
UT WOS:000273620000003
PM 19666736
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Doshi, AB
   Moshfeghi, DM
   Jack, RL
AF Doshi, AB
   Moshfeghi, DM
   Jack, RL
TI Anaphylactoid reaction after verteporfin therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ADVERSE REACTION
AB PURPOSE: To report a case of anaphylactoid reaction in a woman after initial exposure to verteporfin and to alert physicians of this potentially life-threatening reaction.
   DESIGN: Interventional case report.
   METHODS: An 80-year-old woman who was found to have exudative age,related macular degeneration on clinical examination and fluorescein angiography underwent treatment with verteporfin photodynamic therapy (PDT). Thirty minutes after verteporfin PDT infusion, the patient experienced throat constriction, swelling of her hands, and severe shortness of breath. She received immediate intravenous treatment with methylprednisolone, diphenhydramine, and famotidine and was admitted for observation.
   RESULTS: The patient's symptoms resolved, and she experienced no long-term side effects related to PDT. Routine noninvasive pulse oximetry, however, did result in finger discoloration and superficial burn. Evaluation revealed that her symptoms were noncardiac in origin.
   CONCLUSION: Verteporfin can result in an anaphylactoid reaction. Treating physicians should be advised of possible photosensitizing reactions once the patient has received verteporfin PDT.
C1 Stanford Univ, Sch Med, Dept Ophthalmol, Calif Vitreoretinal Ctr, Stanford, CA 94305 USA.
C3 Stanford University
RP Moshfeghi, DM (通讯作者)，1225 Crane St, Menlo Pk, CA 94025 USA.
EM dariusm@stanford.edu
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X
CR Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2002, AM J OPHTHALMOL, V134, P281, DOI 10.1016/S0002-9394(02)01475-7
   Noffke AS, 2001, ARCH OPHTHALMOL-CHIC, V119, P143
   Noone MC, 2003, OTOLARYNG CLIN N AM, V36, P1009, DOI 10.1016/S0030-6665(03)00062-8
NR 5
TC 7
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2005
VL 140
IS 5
BP 936
EP 937
DI 10.1016/j.ajo.2005.05.033
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 990PL
UT WOS:000233755600032
PM 16310483
DA 2022-11-30
ER

PT J
AU Stefansson, E
   Zetterstrom, C
   Ehlers, N
   Kiilgaard, JF
   la Cour, M
   Sigurdsson, H
   Gudmundsdottir, E
   Prause, JU
   Heijl, A
AF Stefansson, E
   Zetterstrom, C
   Ehlers, N
   Kiilgaard, JF
   la Cour, M
   Sigurdsson, H
   Gudmundsdottir, E
   Prause, JU
   Heijl, A
TI Nordic research in ophthalmology
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Review
DE eye research; cornea; cataract; paediatric ophthalmology; glaucoma;
   diabetic eye disease; age-related macular degeneration; ophthalmic
   oncology
ID RETINAL CELL TRANSPLANTS; ANTERIOR LENS CAPSULE; RPE ALLOGRAFTS; ORBITAL
   DECOMPRESSION; MACULAR DEGENERATION; SUBRETINAL SPACE; EYELID SURGERY;
   RABBIT RETINA; GENE-THERAPY; TERM
AB Purpose: To provide an overview of some of the current activities in eye research in the Nordic countries.
   Methods: The presentations at the biannual Nordic Congress of Ophthalmology, held in Tampere, Finland in 2002, were reviewed and the contributions found most noteworthy are included in this article along with a limited discussion of each research field. However, space requirements prevented the inclusion of many interesting scientific contributions.
   Results: Important contributions in various subfields of eye research and ophthalmology are reviewed. These include cornea, cataract, paediatric ophthalmology, glaucoma, diabetic eye disease, age-related macular degeneration, physiology and pharmacology and oncology.
   Conclusions: Eye research is very active in the Nordic countries and significant contributions are being made to ophthalmology in several fields on a world scale. We hope to continue to review Nordic contributions to eye research after each Nordic Congress of Ophthalmology and plan to make the reviews more systematic and comprehensive in the future.
C1 Univ Iceland, Landspitali Haskolasjukrahus Augndeild, IS-101 Reykjavik, Iceland.
   St Eriks Eye Hosp, Stockholm, Sweden.
   Univ Aarhus, DK-8000 Aarhus C, Denmark.
   Univ Copenhagen, DK-1168 Copenhagen, Denmark.
   Malmo Univ Hosp, Malmo, Sweden.
C3 University of Iceland; Aarhus University; University of Copenhagen; Lund
   University; Skane University Hospital
RP Stefansson, E (通讯作者)，Univ Iceland, Landspitali Haskolasjukrahus Augndeild, IS-101 Reykjavik, Iceland.
EM einarste@landspitali.is
RI la Cour, Morten/L-1600-2013; Heijl, Anders/AAV-3077-2021; Kiilgaard,
   Jens Folke/H-3943-2019
OI Kiilgaard, Jens Folke/0000-0003-1054-1460; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
CR ADOLPH AR, 1994, J NEURAL TRANSP PLAS, V5, P147, DOI 10.1155/NP.1994.147
   Agardh E, 2002, ACTA OPHTHALMOL SCAN, V80, P524, DOI 10.1034/j.1600-0420.2002.800512.x
   AIRAKSINEN PJ, 2002, ACTA OPHTHALMOL SCAN, V80, P414
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   ALM A, 2002, ACTA OPHTHALMOL SCAN, V80, P458
   ALYAHYA GA, 2002, ACTA OPHTHALMOL SCAN, V80, P682
   Andersen SR, 2002, ACTA OPHTHALMOL SCAN, V80, P6, DOI 10.1034/j.1600-0420.80.s234.2.x
   ARAMANT R, 1988, INVEST OPHTH VIS SCI, V29, P498
   ARAMANT R, 1990, DEV BRAIN RES, V53, P47, DOI 10.1016/0165-3806(90)90123-G
   Bek T, 2002, ACTA OPHTHALMOL SCAN, V80, P69, DOI 10.1034/j.1600-0420.2002.800114.x
   Bengtsson B, 1998, ACTA OPHTHALMOL SCAN, V76, P431, DOI 10.1034/j.1600-0420.1998.760408.x
   Bengtsson B, 2003, INVEST OPHTH VIS SCI, V44, P1388, DOI 10.1167/iovs.02-0169
   Bengtsson B, 1998, ACTA OPHTHALMOL SCAN, V76, P268, DOI 10.1034/j.1600-0420.1998.760303.x
   Bengtsson B, 2002, ACTA OPHTHALMOL SCAN, V80, P620, DOI 10.1034/j.1600-0420.2002.800612.x
   Bengtsson B, 1997, ACTA OPHTHALMOL SCAN, V75, P368
   BERGMAN L, 2002, ACTA OPHTHALMOL SCAN, V80, P680
   BERGSTROM A, 1994, EXP EYE RES, V58, P301, DOI 10.1006/exer.1994.1021
   COLLIN JRO, 1994, BRIT J OPHTHALMOL, V78, P167, DOI 10.1136/bjo.78.3.167
   CORYDON L, 2002, ACTA OPHTHALMOL SCAN, V80, P411
   CORYDON L, 2002, ACTA OPHTHALMOL SCAN, V80, P410
   Crafoord S, 1999, ACTA OPHTHALMOL SCAN, V77, P247, DOI 10.1034/j.1600-0420.1999.770301.x
   Crafoord S, 2000, GRAEF ARCH CLIN EXP, V238, P682, DOI 10.1007/s004170000131
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Crafoord S, 2001, ACTA OPHTHALMOL SCAN, V79, P509, DOI 10.1034/j.1600-0420.2001.790517.x
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   DINPARVAR D, 2002, ACTA OPHTHALMOL SCAN, V80, P437
   Ege BM, 2002, ACTA OPHTHALMOL SCAN, V80, P485, DOI 10.1034/j.1600-0420.2002.800505.x
   EHINGER B, 1991, EXP EYE RES, V53, P447, DOI 10.1016/0014-4835(91)90162-8
   Ek U, 2002, ACTA OPHTHALMOL SCAN, V80, P294, DOI 10.1034/j.1600-0420.2002.800312.x
   ESKELIN S, 2002, ACTA OPHTHALMOL SCAN, V80, P681
   Eysteinsson T, 2002, ACTA OPHTHALMOL SCAN, V80, P11, DOI 10.1034/j.1600-0420.2002.800103.x
   FAGERHOLM P, 2002, ACTA OPHTHALMOL SCAN, V80, P431
   Fledelius HC, 2002, ACTA OPHTHALMOL SCAN, V80, P202, DOI 10.1034/j.1600-0420.2002.800216.x
   FLOREN I, 2002, ACTA OPHTHALMOL SCAN, V80, P678
   FRENNESSON C, 2002, ACTA OPHTHALMOL SCAN, V80, P415
   Ghosh F, 2002, RETINA-J RET VIT DIS, V22, P478, DOI 10.1097/00006982-200208000-00013
   Ghosh F, 1999, OPHTHALMIC RES, V31, P5, DOI 10.1159/000055507
   Ghosh F, 1999, INVEST OPHTH VIS SCI, V40, P133
   Ghosh F, 1998, RETINA-J RET VIT DIS, V18, P136, DOI 10.1097/00006982-199818020-00007
   Ghosh F, 1999, INVEST OPHTH VIS SCI, V40, P126
   Grodum K, 2002, ACTA OPHTHALMOL SCAN, V80, P627, DOI 10.1034/j.1600-0420.2002.800613.x
   Hansson-Lundblad C, 2002, ACTA OPHTHALMOL SCAN, V80, P310, DOI 10.1034/j.1600-0420.2002.800315.x
   Haugen OH, 2001, BRIT J OPHTHALMOL, V85, P714, DOI 10.1136/bjo.85.6.714
   HAUGEN OH, 2002, ACTA OPHTHALMOL SCAN, V80, P433
   HEDIN A, 1988, EYE, V2, P201, DOI 10.1038/eye.1988.37
   HEEGAARD S, 2002, ACTA OPHTHALMOL SCAN, V80, P681
   HESELLUND A, 2002, ACTA OPHTHALMOL SCAN, V80, P425
   Hietanen J, 2002, ACTA OPHTHALMOL SCAN, V80, P617, DOI 10.1034/j.1600-0420.2002.800611.x
   HJORTDAL, 2002, ACTA OPHTHALMOL SCAN, V80, P60
   HOLMSTROM G, 1993, ACTA OPHTHALMOL, V71, P44
   Jacobi C, 2002, EUR EAT DISORD REV, V10, P179, DOI 10.1002/erv.452
   JAKOBSEN JE, 2002, ACTA OPHTHALMOL SCAN, V80, P407
   JEPPESEN P, 2002, ACTA OPHTHALMOL SCAN, V80, P425
   JULIUSSON B, 1993, CELL TRANSPLANT, V2, P411, DOI 10.1177/096368979300200509
   JULIUSSON B, 1994, EXP EYE RES, V58, P615, DOI 10.1006/exer.1994.1056
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   KIILGAARD JF, 2003, INVEST OPHTH VIS SCI, V80, P681
   KIVELA T, 2002, ACTA OPHTHALMOL SCAN, V80, P456
   KIVELA T, 2002, ACTA OPHTHALMOL SCAN, V80, P413
   KOIVULA A, 2002, ACTA OPHTHALMOL SCAN, V80, P684
   Krohn J, 2002, ACTA OPHTHALMOL SCAN, V80, P642, DOI 10.1034/j.1600-0420.2002.800616.x
   KUELBERG M, 2002, ACTA OPHTHALMOL SCAN, V80, P420
   KUGELBERG M, 2002, ACTA OPHTHALMOL SCAN, V80, P420
   KUGELBERG U, 2002, ACTA OPHTHALMOL SCAN, V80, P420
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Larsson E, 2002, BRIT J OPHTHALMOL, V86, P1122, DOI 10.1136/bjo.86.10.1122
   Larsson J, 1998, ACTA OPHTHALMOL SCAN, V76, P417, DOI 10.1034/j.1600-0420.1998.760406.x
   LARSSON LI, 2002, ACTA OPHTHALMOL SCAN, V80, P458
   Linnet J, 2001, ACTA OPHTHALMOL SCAN, V79, P49, DOI 10.1034/j.1600-0420.2001.079001049.x
   Loftsson T, 2002, ACTA OPHTHALMOL SCAN, V80, P144, DOI 10.1034/j.1600-0420.2002.800205.x
   LUNDSTROM M, 2002, ACTA OPHTHALMOL SCAN, V80, P410
   Lundvall A, 2002, ACTA OPHTHALMOL SCAN, V80, P588, DOI 10.1034/j.1600-0420.2002.800606.x
   LUNDVALL A, 2002, ACTA OPHTHALMOL SCAN, V80, P420
   MAKINEN P, 2002, ACTA OPHTHALMOL SCAN, V80, P421
   MIKA H, 2002, ACTA OPHTHALMOL SCAN, V80, P417
   Montan P, 2002, ACTA OPHTHALMOL SCAN, V80, P258, DOI 10.1034/j.1600-0420.2002.800305.x
   Mourits MP, 1999, BRIT J OPHTHALMOL, V83, P81, DOI 10.1136/bjo.83.1.81
   Narfstrom K, 2003, J HERED, V94, P31, DOI 10.1093/jhered/esg015
   Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   NILSON SEG, 2002, ACTA OPHTHALMOL SCAN, V80, P415
   OHRSTROM A, 2002, ACTA OPHTHALMOL SCAN, V80, P684
   PEDERSEN DB, 2002, ACTA OPHTHALMOL SCAN, V80, P424
   PEDERSEN TM, 2002, ACTA OPHTHALMOL SCAN, V80, P430
   Prause JU, 2002, ACTA OPHTHALMOL SCAN, V80, P49, DOI 10.1034/j.1600-0420.80.s234.11.x
   PUSKA PM, 2002, ACTA OPHTHALMOL SCAN, V80, P417
   Ritland JS, 2002, ACTA OPHTHALMOL SCAN, V80, P172, DOI 10.1034/j.1600-0420.2002.800210.x
   Rosenberg ME, 2002, CORNEA, V21, P265, DOI 10.1097/00003226-200204000-00006
   SEREGARD S, 2002, ACTA OPHTHALMOL SCAN, V80, P456
   Sharma RK, 2000, ACTA OPHTHALMOL SCAN, V78, P396, DOI 10.1034/j.1600-0420.2000.078004396.x
   Sharma RK, 1997, EXP EYE RES, V64, P97, DOI 10.1006/exer.1996.0189
   Sharma RK, 1997, CELL TRANSPLANT, V6, P141, DOI 10.1016/S0963-6897(96)00256-4
   Sharma RK, 1997, ACTA OPHTHALMOL SCAN, V75, P3
   SHATOS MA, 2003, INVEST OPHTHALMOL VI, V44
   Shields CL, 2001, OPHTHALMOLOGY, V108, P979, DOI 10.1016/S0161-6420(01)00547-4
   SIRPA L, 2002, ACTA OPHTHALMOL SCAN, V80, P445
   SJO NC, 2002, ACTA OPHTHALMOL SCAN, V80, P681
   Sjolie AK, 2002, ACTA OPHTHALMOL SCAN, V80, P5, DOI 10.1034/j.1600-0420.80.s234.1.x
   Stefansson E, 2000, ACTA OPHTHALMOL SCAN, V78, P374, DOI 10.1034/j.1600-0420.2000.078004374.x
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Stenevi U, 2002, ACTA OPHTHALMOL SCAN, V80, P105, DOI 10.1034/j.1600-0420.2002.800122.x
   Tallstedt L, 2000, ACTA OPHTHALMOL SCAN, V78, P206, DOI 10.1034/j.1600-0420.2000.078002206.x
   THYGESEN J, 2002, ACTA OPHTHALMOL SCAN, V80, P407
   THYGESEN J, 2002, ACTA OPHTHALMOL SCAN, V80, P459
   UUSITALO R, 2002, ACTA OPHTHALMOL SCAN, V80, P411
   Vainio-Jylha E, 2002, ACTA OPHTHALMOL SCAN, V80, P495, DOI 10.1034/j.1600-0420.2002.800507.x
   VALIMAKI J, 2002, ACTA OPHTHALMOL SCAN, V80, P414
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   VIRTAMO T, 2002, ACTA OPHTHALMOL SCAN, V80, P452
   VONWENDT GC, 2002, ACTA OPHTHALMOL SCAN, V80, P453
   WARFINGE K, 2003, INVEST OPHTHALMOL VI
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P2632
   WEJDE G, 2002, ACTA OPHTHALMOL SCAN, V80, P426
   Wiencke AK, 2003, ACTA OPHTHALMOL SCAN, V81, P170, DOI 10.1034/j.1600-0420.2003.00030.x
   ZETTERSTROM C, 2002, ACTA OPHTHALMOL SCAN, V80, P420
   Zhang YQ, 1999, INVEST OPHTH VIS SCI, V40, P3062
   Zhang YQ, 2003, INVEST OPHTH VIS SCI, V44, P324, DOI 10.1167/iovs.02-0132
   ZUCKER CL, 1994, J NEURAL TRANSP PLAS, V5, P17, DOI 10.1155/NP.1994.17
NR 120
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2003
VL 81
IS 6
BP 556
EP 566
DI 10.1111/j.1395-3907.2003.00177.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 748UD
UT WOS:000186878700002
PM 14641254
DA 2022-11-30
ER

PT J
AU Volkner, M
   Wagner, F
   Steinheuer, LM
   Carido, M
   Kurth, T
   Yazbeck, A
   Schor, J
   Wieneke, S
   Ebner, LJA
   Runzer, CD
   Taborsky, D
   Zoschke, K
   Vogt, M
   Canzler, S
   Hermann, A
   Khattak, S
   Hackermuller, J
   Karl, MO
AF Voelkner, Manuela
   Wagner, Felix
   Steinheuer, Lisa Maria
   Carido, Madalena
   Kurth, Thomas
   Yazbeck, Ali
   Schor, Jana
   Wieneke, Stephanie
   Ebner, Lynn J. A.
   Runzer, Claudia Del Toro
   Taborsky, David
   Zoschke, Katja
   Vogt, Marlen
   Canzler, Sebastian
   Hermann, Andreas
   Khattak, Shahryar
   Hackermueller, Joerg
   Karl, Mike O.
TI HBEGF-TNF induce a complex outer retinal pathology with photoreceptor
   cell extrusion in human organoids
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; CONE PHOTORECEPTORS; PIGMENT
   EPITHELIUM; MULLER GLIA; HUMAN FETAL; MUTATION; HISTOPATHOLOGY;
   TRANSCRIPTOME; EXPRESSION
AB Human organoids could facilitate research of complex and currently incurable neuropathologies, such as age-related macular degeneration (AMD) which causes blindness. Here, we establish a human retinal organoid system reproducing several parameters of the human retina, including some within the macula, to model a complex combination of photoreceptor and glial pathologies. We show that combined application of TNF and HBEGF, factors associated with neuropathologies, is sufficient to induce photoreceptor degeneration, glial pathologies, dyslamination, and scar formation: These develop simultaneously and progressively as one complex phenotype. Histologic, transcriptome, live-imaging, and mechanistic studies reveal a previously unknown pathomechanism: Photoreceptor neurodegeneration via cell extrusion. This could be relevant for aging, AMD, and some inherited diseases. Pharmacological inhibitors of the mechanosensor PIEZO1, MAPK, and actomyosin each avert pathogenesis; a PIEZO1 activator induces photoreceptor extrusion. Our model offers mechanistic insights, hypotheses for neuropathologies, and it could be used to develop therapies to prevent vision loss or to regenerate the retina in patients suffering from AMD and other diseases.
C1 [Voelkner, Manuela; Wagner, Felix; Carido, Madalena; Vogt, Marlen; Hermann, Andreas; Khattak, Shahryar; Karl, Mike O.] Tech Univ Dresden, Ctr Regenerat Therapies Dresden CRTD, Dresden, Germany.
   [Voelkner, Manuela; Wagner, Felix; Wieneke, Stephanie; Ebner, Lynn J. A.; Runzer, Claudia Del Toro; Taborsky, David; Zoschke, Katja; Hermann, Andreas; Karl, Mike O.] German Ctr Neurodegenerat Dis DZNE Dresden, Dresden, Germany.
   [Steinheuer, Lisa Maria; Yazbeck, Ali; Schor, Jana; Canzler, Sebastian; Hackermueller, Joerg] UFZ Helmholtz Ctr Environm Res, Dept Computat Biol, Leipzig, Germany.
   [Kurth, Thomas; Khattak, Shahryar] Tech Univ Dresden, Ctr Mol & Cellular Bioengn CMCB, Technol Platform Core Facil Electron Microscopy &, Dresden, Germany.
   [Hermann, Andreas] Tech Univ Dresden, Dept Neurol, D-01307 Dresden, Germany.
   [Hackermueller, Joerg] Univ Leipzig, Dept Comp Sci, Leipzig, Germany.
C3 Technische Universitat Dresden; Helmholtz Association; German Center for
   Neurodegenerative Diseases (DZNE); Technische Universitat Dresden;
   Helmholtz Association; Helmholtz Center for Environmental Research
   (UFZ); Technische Universitat Dresden; Technische Universitat Dresden;
   Leipzig University
RP Karl, MO (通讯作者)，Tech Univ Dresden, Ctr Regenerat Therapies Dresden CRTD, Dresden, Germany.; Karl, MO (通讯作者)，German Ctr Neurodegenerat Dis DZNE Dresden, Dresden, Germany.
EM mike_o.karl@tu-dresden.de
RI Karl, Mike O./E-7246-2010
OI Karl, Mike O./0000-0002-0926-6556; Ebner, Lynn Jenny
   Alix/0000-0002-9665-9197; Del Toro Runzer, Claudia/0000-0003-4284-7368;
   Wagner, Felix/0000-0001-8786-2647; Kurth, Thomas/0000-0001-5624-1717
FU TU Dresden CRTD; DZNE Helmholtz; Deutsche Forschungsgemeinschaft (DFG,
   German Research Foundation) [SPP1738 KA2794/3-1, 399487982, SPP2127
   KA2794/5-1, KA2794/5-2]; Helmholtz Association within the Network of
   Excellence [007]; Bundesministerium fur Bildung und Forschung (BMBF)
   [01EK1613A]; ERA-NET Neuron ReDiMoAMD [01EW2106]; MedDrive Grant TU
   Dresden, Medical Faculty Carl Gustav Carus; EyeNovative Award (Novartis
   Pharma GmbH); NCL Foundation, Hamburg, Germany; TU Dresden CRTD Seed
   Grant; TU Dresden, CRTD Stem Cell Engineering Facility; EFRE [ZT-I-0007]
FX We thank Robert Haase (DFG Cluster of Excellence Physics of Life, TU
   Dresden) for support with Clij software for pattern (voronoi) analysis,
   Christopher Schmied (DZNE Imaging Facility) for support with Fiji
   macros, Susanne Kretschmar (EM Facility), the Flow Cytometry Facility
   (both CMCB TU Dresden), Stephan Schreiber (UFZ Leipzig) for technical
   support, and Robert Herber (UKD Eye Clinic) for eye fundus photography;
   Elly Tanaka (TU Dresden, Germany) and Peter MacLeish (Morehouse School
   of Medicine, USA) for RAX and CRX, and ARR3 antibodies, respectively.
   Fibroblasts "Theo", used for generating CRTD1 hiPSCs, were a gift from
   Prof. Dr. med. Min Ae Lee-Kirsch, University Hospital Carl Gustav Carus,
   Dresden. CD34-positive cells, used for generating CRTD2 hiPSCs, were a
   gift from Prof. Dr. Frank Buchholz and Prof. Dr. med. Martin Bornhauser,
   University Hospital Carl Gustav Carus, Dresden. Reprogramming and
   characterization of CRTD1 and CRTD2 hiPSCs were performed at the CMCB
   Stem Cell Engineering Facility at Technische Universitat Dresden. We
   thank the Dresden Concept Genome Center, CMCB Stem Cell Engineering
   Facility at Technische Universitat Dresden, light microscopy facility
   (DZNE), and the MOKALAB, particularly the organoid team and Anne Wagner,
   for their excellent support. We thank Xikun Han (Harvard T.H. Chan
   School of Public Health, USA) for the discussion about genetic AMD risk
   factors. We thank Gerd Kempermann (DZNE Dresden, Germany), Volker
   Busskamp (University of Bonn, Germany), Triantafyllos Chavakis (TU
   Dresden, Germany), and Sara Oakeley (Basel, Switzerland) for helpful
   comments on the manuscript. Supported by the Funding Programs for TU
   Dresden CRTD (M.K.); DZNE Helmholtz (M.K.); Deutsche
   Forschungsgemeinschaft (DFG, German Research Foundation) - SPP1738
   KA2794/3-1, 399487982 (SPP2127 KA2794/5-1, KA2794/5-2) (M.K.); Helmholtz
   Association within the Network of Excellence: HGF ExNet-007 (M.K.);
   Bundesministerium fur Bildung und Forschung (BMBF): ReSight (01EK1613A)
   (M.K.), and ERA-NET Neuron ReDiMoAMD (01EW2106) (M.K.); MedDrive Grant
   TU Dresden, Medical Faculty Carl Gustav Carus (M.K.); EyeNovative Award
   (Novartis Pharma GmbH) (M.K.); NCL Foundation, Hamburg, Germany (M.K.
   and A.H.); TU Dresden CRTD Seed Grant (M.C.); TU Dresden, CRTD Stem Cell
   Engineering Facility (S.K.); EFRE (EM Facility, T.K.); incubator grant
   sparse2big (ZT-I-0007; J.H.).
CR Aguirre GD, 2002, EXP EYE RES, V75, P431, DOI 10.1006/exer.2002.2037
   Aleman TS, 2007, INVEST OPHTH VIS SCI, V48, P4759, DOI 10.1167/iovs.07-0453
   Alhamdoosh M, 2017, BIOINFORMATICS, V33, P414, DOI 10.1093/bioinformatics/btw623
   Alves CH, 2014, PROG RETIN EYE RES, V40, P35, DOI 10.1016/j.preteyeres.2014.01.001
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Araki H, 2012, FEBS OPEN BIO, V2, P76, DOI 10.1016/j.fob.2012.04.003
   Bell CM, 2020, ANNU REV VIS SCI, V6, P91, DOI 10.1146/annurev-vision-121219-081855
   Beltran WA, 2006, INVEST OPHTH VIS SCI, V47, P1669, DOI 10.1167/iovs.05-0845
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Cheung AYL, 2011, HUM MOL GENET, V20, P2103, DOI 10.1093/hmg/ddr093
   Clarke LE, 2018, P NATL ACAD SCI USA, V115, pE1896, DOI 10.1073/pnas.1800165115
   Coste B, 2013, P NATL ACAD SCI USA, V110, P4667, DOI 10.1073/pnas.1221400110
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010070
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Fabig G, 2012, METHOD CELL BIOL, V111, P75, DOI 10.1016/B978-0-12-416026-2.00005-4
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   GARTNER S, 1982, OPHTHALMOLOGY, V89, P1425
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gudipaty SA, 2017, NATURE, V543, P118, DOI 10.1038/nature21407
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Haase R., 2020, BIORXIV, DOI [10.1101/2020.11.19.386565v1.full, DOI 10.1101/2020.11.19.386565V1.FULL]
   Haase R, 2020, NAT METHODS, V17, P5, DOI 10.1038/s41592-019-0650-1
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Inoue Y, 2013, INVEST OPHTH VIS SCI, V54, P3815, DOI 10.1167/iovs.12-11236
   Jacobson SG, 2006, INVEST OPHTH VIS SCI, V47, P4113, DOI 10.1167/iovs.06-0424
   Janes KA, 2006, CELL, V124, P1225, DOI 10.1016/j.cell.2006.01.041
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kampf C, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3219-1
   Kaewkhaw R, 2015, STEM CELLS, V33, P3504, DOI 10.1002/stem.2122
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Kim S, 2019, P NATL ACAD SCI USA, V116, P10824, DOI 10.1073/pnas.1901572116
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lahne M, 2020, ANNU REV VIS SCI, V6, P171, DOI 10.1146/annurev-vision-121219-081808
   LAI YL, 1982, EXP EYE RES, V34, P219, DOI 10.1016/0014-4835(82)90056-2
   Lewis GP, 2010, MOL VIS, V16, P1361
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li ML, 2021, EYE, V35, P548, DOI 10.1038/s41433-020-0896-y
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Liang QN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12917-9
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Lojewski X, 2014, HUM MOL GENET, V23, P2005, DOI 10.1093/hmg/ddt596
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Lyu YF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95122-3
   Martin M., 2011, EMBNET J, V17, P10, DOI [DOI 10.14806/EJ.17.1.200, 10.14806/ej.17.1.200]
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   NORK TM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1066, DOI 10.1001/archopht.1995.01100080118039
   Ohsawa S, 2018, DEV CELL, V44, P284, DOI 10.1016/j.devcel.2018.01.009
   Olivares-Gonzalez L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042096
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   Quinn PM, 2019, STEM CELL REP, V12, P906, DOI 10.1016/j.stemcr.2019.03.002
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Reichenbach A, 2020, GLIA, V68, P768, DOI 10.1002/glia.23727
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saddala MS, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0199-1
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schafer P, 2017, GLIA, V65, P828, DOI 10.1002/glia.23130
   Schmied C., 2022, ZENODO, DOI [10.5281/zenodo.5188650, DOI 10.5281/ZENODO.5188650]
   Scoles D, 2017, RETINA-J RET VIT DIS, V37, P741, DOI 10.1097/IAE.0000000000001203
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Slot JW, 2007, NAT PROTOC, V2, P2480, DOI 10.1038/nprot.2007.365
   Sridhar A, 2020, CELL REP, V30, P1644, DOI 10.1016/j.celrep.2020.01.007
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sudharsan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18236-7
   Surun D, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050511
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Velasco-Estevez M, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00332
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Volkner M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.645704
   Volkner M, 2021, HUM GENE THER, V32, P694, DOI 10.1089/hum.2020.321
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Wagner BD, 2022, OPHTHAL EPIDEMIOL, V29, P139, DOI 10.1080/09286586.2021.1910314
   Wagner F., 2022, FELWAG FELWAG PHOTOR, DOI [10.5281/zenodo.7040860, DOI 10.5281/ZENODO.7040860]
   Welby E, 2017, STEM CELL REP, V9, P1898, DOI 10.1016/j.stemcr.2017.10.018
   Wolf C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11752
   Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yan WJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66092-9
   Yi WY, 2021, NATL SCI REV, V8, DOI 10.1093/nsr/nwaa179
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zhao M, 2015, J NEUROSCI, V35, P6093, DOI 10.1523/JNEUROSCI.3412-14.2015
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
NR 110
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 19
PY 2022
VL 13
IS 1
AR 6183
DI 10.1038/s41467-022-33848-y
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 5L5CK
UT WOS:000870431200014
PM 36261438
OA Green Published
DA 2022-11-30
ER

PT J
AU Han, WT
   Li, HY
   Chen, BH
AF Han, Wentao
   Li, Haoyu
   Chen, Baihua
TI Research Progress and Potential Applications of Spermidine in Ocular
   Diseases
SO PHARMACEUTICS
LA English
DT Review
DE spermidine; ocular diseases; eye; biomarker; therapeutic agent
ID ENDOTOXIN-INDUCED UVEITIS; OXIDATIVE STRESS; AQUEOUS-HUMOR;
   UP-REGULATION; POLYAMINES; RAT; MODEL; NEUROTOXICITY; TRANSPORT; EYE
AB Spermidine, a natural polyamine, exists in almost all human tissues, exhibiting broad properties like anti-aging, autophagy induction, anti-inflammation, anti-oxidation, cell proliferation activation, and ion channel regulation. Considering that spermidine is already present in human nutrition, recent studies targeting supplementing exogenous sources of this polyamine appear feasible. The protective role of spermidine in various systems has been illuminated in the literature, while recent progress of spermidine administration in ocular diseases remains to be clarified. This study shows the current landscape of studies on spermidine and its potential to become a promising therapeutic agent to treat ocular diseases: glaucoma, optic nerve injury, age-related macular degeneration (AMD), cataracts, dry eye syndrome, and bacterial keratitis. It also has the potential to become a potent biomarker to predict keratoconus (KC), cataracts, uveitis, glaucoma, proliferative diabetic retinopathy (PDR), proliferative vitreoretinopathy (PVR), and retinopathy of prematurity (ROP). We also summarize the routes of administration and the effects of spermidine at different doses.
C1 [Han, Wentao; Li, Haoyu; Chen, Baihua] Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha 410011, Peoples R China.
   [Han, Wentao; Li, Haoyu; Chen, Baihua] Hunan Clin Res Ctr Ophthalm Dis, Changsha 410011, Peoples R China.
C3 Central South University
RP Chen, BH (通讯作者)，Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha 410011, Peoples R China.; Chen, BH (通讯作者)，Hunan Clin Res Ctr Ophthalm Dis, Changsha 410011, Peoples R China.
EM hanwentao1998@163.com; med.dr.lihy@gmail.com; chenbaihua2017@csu.edu.cn
OI Li, Haoyu/0000-0002-9826-181X; chen, baihua/0000-0001-6367-9119; Han,
   Wentao/0000-0003-2650-0233
FU National Natural Science Foundation of China [82171030, 81870678]
FX This research was funded by grants from the National Natural Science
   Foundation of China, grant numbers 82171030 and 81870678.
CR Alfarhan M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042133
   Baek AR, 2020, EXP MOL MED, V52, P2034, DOI 10.1038/s12276-020-00545-z
   Bispo PJM, 2022, OPHTHALMOL THER, V11, P503, DOI 10.1007/s40123-021-00449-9
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9
   Carriche GM, 2021, J ALLERGY CLIN IMMUN, V147, P335, DOI 10.1016/j.jaci.2020.04.037
   Carta F, 2010, J MED CHEM, V53, P5511, DOI 10.1021/jm1003667
   Celik VK, 2017, ENDOCR CONNECT, V6, P574, DOI 10.1530/EC-17-0137
   Cong HR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146270
   D'Adamo S, 2020, FREE RADICAL BIO MED, V153, P159, DOI 10.1016/j.freeradbiomed.2020.03.029
   de la Barca JMC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21116
   Deng KW, 2009, J NEUROSCI, V29, P9545, DOI 10.1523/JNEUROSCI.1175-09.2009
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073484
   DUNCAN G, 1984, CIBA F SYMP, V106, P132
   Duncan G, 1999, EYE, V13, P480, DOI 10.1038/eye.1999.125
   Eisenberg T, 2017, AUTOPHAGY, V13, P767, DOI 10.1080/15548627.2017.1280225
   Eisenberg T, 2016, NAT MED, V22, P1428, DOI 10.1038/nm.4222
   Fan JJ, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104943
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Fuwa M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56905-x
   Ghisalberti CA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00147
   Ghosh I, 2020, NEUROPEPTIDES, V83, DOI 10.1016/j.npep.2020.102083
   GILAD GM, 1989, LIFE SCI, V44, P1963, DOI 10.1016/0024-3205(89)90409-8
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Gralek M, 1999, GRAEF ARCH CLIN EXP, V237, P781, DOI 10.1007/s004170050312
   Gralek M, 1995, Klin Oczna, V97, P182
   Guo X, 2003, AM J PHYSIOL-CELL PH, V285, pC1174, DOI 10.1152/ajpcell.00015.2003
   Guo XL, 2011, INVEST OPHTH VIS SCI, V52, P2696, DOI 10.1167/iovs.10-6015
   Harada T, 2007, J CLIN INVEST, V117, P1763, DOI 10.1172/JCI30178
   Hofer SJ, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.717343
   Hofer SJ, 2021, AUTOPHAGY, V17, P2037, DOI 10.1080/15548627.2021.1933299
   Hou W.-K., 2001, ACTA ACAD MED SHANDO, V39, P231, DOI [10.3969/j.issn.1671-7554.2001.03.015, DOI 10.3969/J.ISSN.1671-7554.2001.03.015]
   Hume EBH, 2001, INVEST OPHTH VIS SCI, V42, P2904
   Igarashi K, 2006, AMINO ACIDS, V31, P477, DOI 10.1007/s00726-006-0264-7
   Igarashi K, 2010, PLANT PHYSIOL BIOCH, V48, P506, DOI 10.1016/j.plaphy.2010.01.017
   Jamerson EC, 2020, EYE CONTACT LENS, V46, pS57, DOI 10.1097/ICL.0000000000000668
   Jamwal S, 2015, NEUROTOX RES, V28, P171, DOI 10.1007/s12640-015-9535-y
   Jian HJ, 2017, ACS NANO, V11, P6703, DOI 10.1021/acsnano.7b01023
   Jiang DM, 2021, THERIOGENOLOGY, V168, P25, DOI 10.1016/j.theriogenology.2021.03.026
   Johnson DA, 2002, INVEST OPHTH VIS SCI, V43, P1228
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Kalac P, 2014, FOOD CHEM, V161, P27, DOI 10.1016/j.foodchem.2014.03.102
   Kaneko S, 2007, INVEST OPHTH VIS SCI, V48, P455, DOI 10.1167/iovs.06-0379
   Kang X, 2021, J ADV RES, V27, P31, DOI 10.1016/j.jare.2020.06.007
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaushik S, 2021, AGEING RES REV, V72, DOI 10.1016/j.arr.2021.101468
   Kenney MC, 1997, CORNEA, V16, P345
   Kim DH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031361
   KREMZNER LT, 1983, EXP EYE RES, V37, P649, DOI 10.1016/0014-4835(83)90139-2
   Kwon DH, 2007, ANTIMICROB AGENTS CH, V51, P2070, DOI 10.1128/AAC.01472-06
   Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730
   Lee H, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091439
   Leidal AM, 2018, NAT CELL BIOL, V20, P1338, DOI 10.1038/s41556-018-0235-8
   Lentini A, 2011, PROTEIN J, V30, P109, DOI 10.1007/s10930-011-9311-7
   Leruez S, 2018, INVEST OPHTH VIS SCI, V59, P4355, DOI 10.1167/iovs.18-24938
   Leruez S, 2018, INVEST OPHTH VIS SCI, V59, P1025, DOI 10.1167/iovs.17-23055
   Li JY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.737242
   Liu R, 2020, FREE RADICAL BIO MED, V161, P339, DOI 10.1016/j.freeradbiomed.2020.10.029
   Ma LY, 2021, J AGR FOOD CHEM, V69, P1864, DOI 10.1021/acs.jafc.0c07095
   Ma LY, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1832857
   MACAIONE S, 1984, J NEUROCHEM, V43, P303, DOI 10.1111/j.1471-4159.1984.tb00901.x
   Mackeh R, 2014, J BIOL CHEM, V289, P11816, DOI 10.1074/jbc.M113.507400
   Madeo F, 2018, SCIENCE, V359, P410, DOI 10.1126/science.aan2788
   Madeo F, 2014, NAT REV DRUG DISCOV, V13, P727, DOI 10.1038/nrd4391
   MAEKAWA S, 1989, BIOCHIM BIOPHYS ACTA, V993, P199, DOI 10.1016/0304-4165(89)90164-5
   MAEKAWA S, 1986, BIOCHIM BIOPHYS ACTA, V883, P501
   Malone L, 2013, INT J ANTIMICROB AG, V41, P70, DOI 10.1016/j.ijantimicag.2012.08.009
   Malpica-Nieves CJ, 2020, AMINO ACIDS, V52, P1169, DOI 10.1007/s00726-020-02881-w
   McKay TB, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082076
   Messerer J, 2021, J ANAT, DOI 10.1111/joa.13618
   Minois N, 2011, AGING-US, V3, P716, DOI 10.18632/aging.100361
   Mischiati C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155427
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moreau JM, 2001, INVEST OPHTH VIS SCI, V42, P2347
   Moriyama Y, 2020, BBA-BIOMEMBRANES, V1862, DOI 10.1016/j.bbamem.2020.183208
   Moron B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073703
   Munoz-Esparza NC, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00108
   Muth A, 2014, J MED CHEM, V57, P348, DOI 10.1021/jm401174a
   Nakamura A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22212-1
   Ni YQ, 2021, AGING DIS, V12, P1948, DOI 10.14336/AD.2021.0603
   Nicoletti R, 2003, BRIT J OPHTHALMOL, V87, P1038, DOI 10.1136/bjo.87.8.1038
   Noro T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.93
   Noro T, 2015, INVEST OPHTH VIS SCI, V56, P5012, DOI 10.1167/iovs.15-17142
   Ohashi K, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4128061
   Pallmann N, 2015, J BIOL CHEM, V290, P18343, DOI 10.1074/jbc.M115.664490
   Pan CW, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01452-7
   Pang YL, 2020, INT J MOL MED, V46, P1707, DOI 10.3892/ijmm.2020.4711
   Partridge L, 2020, NAT REV DRUG DISCOV, V19, P513, DOI 10.1038/s41573-020-0067-7
   Patocka J, 2000, Acta Medica (Hradec Kralove), V43, P119
   Pegg AE, 2016, J BIOL CHEM, V291, P14904, DOI 10.1074/jbc.R116.731661
   Pegg AE, 2011, METHODS MOL BIOL, V720, P3, DOI 10.1007/978-1-61779-034-8_1
   Petrillo F, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8071033
   Rabinowitz YS, 1998, SURV OPHTHALMOL, V42, P297, DOI 10.1016/S0039-6257(97)00119-7
   Ramot Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022564
   Rinaldi C, 2021, LIFE-BASEL, V11, DOI 10.3390/life11080767
   Schroeder S, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108985
   Scimone C, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108641
   Scozzafava A, 2016, MOLECULES, V21, DOI 10.3390/molecules21121726
   SEGHIERI G, 1992, DIABETES CARE, V15, P543, DOI 10.2337/diacare.15.4.543
   Sen P, 2020, EYE, V34, P632, DOI 10.1038/s41433-019-0643-4
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Sharif NA, 1999, BRIT J OPHTHALMOL, V83, P236, DOI 10.1136/bjo.83.2.236
   SLOTKIN TA, 1982, J PHARMACOL EXP THER, V222, P741
   Soulet D, 2004, J BIOL CHEM, V279, P49355, DOI 10.1074/jbc.M401287200
   Stepp MA, 2021, TRANSL RES, V236, P52, DOI 10.1016/j.trsl.2021.05.005
   Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P781, DOI 10.1080/13543776.2019.1679117
   Taryam MO, 2020, BRIT J OPHTHALMOL, V104, P752, DOI 10.1136/bjophthalmol-2019-314572
   Valentino TL, 1996, BRAIN RES, V713, P278, DOI 10.1016/0006-8993(95)01558-2
   Verstappen GM, 2018, J AUTOIMMUN, V87, P16, DOI 10.1016/j.jaut.2017.11.003
   Wang CK, 2022, NEUROL-NEUROIMMUNOL, V9, DOI 10.1212/NXI.0000000000001133
   Wang JY, 2020, AGING-US, V12, P650, DOI 10.18632/aging.102647
   Wang YL, 2001, CANCER RES, V61, P5370
   Wareham LK, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00452
   WICKSTROM K, 1991, CURR EYE RES, V10, P463, DOI 10.3109/02713689109001753
   WICKSTROM K, 1992, OPHTHALMIC RES, V24, P175, DOI 10.1159/000267165
   WICKSTROM K, 1992, ACTA OPHTHALMOL, V70, P506
   Wildner G, 2019, SEMIN IMMUNOPATHOL, V41, P727, DOI 10.1007/s00281-019-00758-z
   Williams K, 1997, CELL SIGNAL, V9, P1, DOI 10.1016/S0898-6568(96)00089-7
   Withrow C, 2002, INVEST OPHTH VIS SCI, V43, P3081
   Xu TL, 2020, LANCET PUBLIC HEALTH, V5, pE682, DOI 10.1016/S2468-2667(20)30254-1
   Yanagihara N, 1996, INVEST OPHTH VIS SCI, V37, P1975
   Yang Q, 2016, CELL DEATH DIFFER, V23, P1850, DOI 10.1038/cdd.2016.71
   [杨钦钦 Yang Qinqin], 2021, [中华糖尿病杂志, Chinese Journal of Diabetes Mellitus], V13, P490
   Yuan H, 2021, J INFLAMM RES, V14, P2713, DOI 10.2147/JIR.S313179
   Yuan XY, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00614-4
   Zhang HL, 2019, MOL CELL, V76, P110, DOI 10.1016/j.molcel.2019.08.005
   Zhang S, 2000, GRAEF ARCH CLIN EXP, V238, P846, DOI 10.1007/s004170000185
   Zhang Y, 2017, NEUROL RES, V39, P248, DOI 10.1080/01616412.2017.1283830
   Zhang ZJ, 2022, ANTIBIOTICS-BASEL, V11, DOI 10.3390/antibiotics11020238
   Zhao J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175519
   Zou DA, 2022, COMPR REV FOOD SCI F, V21, P2820, DOI 10.1111/1541-4337.12963
   Zukerman R, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010055
NR 134
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JUL
PY 2022
VL 14
IS 7
AR 1500
DI 10.3390/pharmaceutics14071500
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 3H6CV
UT WOS:000832123000001
PM 35890394
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Fitzpatrick, N
   Chachay, V
   Bowtell, J
   Jackman, S
   Capra, S
   Shore, A
   Briskey, D
AF Fitzpatrick, Naomi
   Chachay, Veronique
   Bowtell, Joanna
   Jackman, Sarah
   Capra, Sandra
   Shore, Angela
   Briskey, David
TI An appraisal of trials investigating the effects on macular pigment
   optical density of lutein and zeaxanthin dietary interventions: a
   narrative review
SO NUTRITION REVIEWS
LA English
DT Review
DE dietary intervention; lutein; macula; macular pigment optical density;
   zeaxanthin
ID HETEROCHROMATIC FLICKER PHOTOMETRY; SERUM ZEAXANTHIN; MESO-ZEAXANTHIN;
   SUPPLEMENTATION; DEGENERATION; SPINACH; AMD
AB Lutein and zeaxanthin (L/Z), xanthophylls obtained from the diet, are deposited in the macula of the eye. The macular concentration of L/Z is quantifiable as macular pigment optical density (MPOD). The aim of this review was to critically appraise the effect on MPOD of increasing L/Z intake by dietary intervention in adults. Pubmed, Cochrane Library, Web of Science, and Cinahl were searched up to April 2020. Ten studies investigating populations with and without age-related macular degeneration were included. MPOD increased significantly in 2 of the 8 controlled studies. Studies varied largely in the prescribed dietary L/Z dosage, duration, and participant characteristics. No relationships between types of dietary L/Z interventions and MPOD response could be determined. Limited monitoring of habitual dietary L/Z intake was identified as a major limitation of all 10 studies. Habitual dietary L/Z intake should be closely monitored in future studies to account for their effects on MPOD response to dietary L/Z interventions.
C1 [Fitzpatrick, Naomi; Chachay, Veronique; Capra, Sandra; Briskey, David] Univ Queensland, Fac Hlth & Behav Sci, Sch Human Movement & Nutr Sci, St Lucia, Qld, Australia.
   [Bowtell, Joanna; Jackman, Sarah] Univ Exeter, Coll Life & Environm Sci, Sport & Hlth Sci, Exeter, Devon, England.
   [Shore, Angela] Univ Exeter, Coll Med & Hlth, Sch Med, Exeter, Devon, England.
C3 University of Queensland; University of Exeter; University of Exeter
RP Fitzpatrick, N (通讯作者)，Univ Queensland, Sch Human Movement & Nutr Sci, Connell Bldg,Blair Dr, St Lucia, Qld 4072, Australia.
EM N.fitzpatrick@uq.edu.au
RI Chachay, Veronique/L-6969-2013
OI Chachay, Veronique/0000-0002-0765-5371; Fitzpatrick,
   Naomi/0000-0003-0010-0899; Shore, Angela/0000-0003-3039-308X
FU Australian Government Research Training Program (RTP) scholarship
FX N.F. is supported by an Australian Government Research Training Program
   (RTP) scholarship. The RTP support played no role in the conception and
   writing of the manuscript.
CR Academy of Nutrition and Dietetics, 2016, EV AN MAN STEPS AC E
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416
   Bohn T, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600685
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bovier ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108178
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Edwards CG, 2020, INT J PSYCHOPHYSIOL, V148, P13, DOI 10.1016/j.ijpsycho.2019.12.006
   Ferrari R., 2015, MED WRIT, V24, P230, DOI [10.1179/2047480615Z.000000000329, DOI 10.1179/2047480615Z.000000000329]
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Howells O, 2013, GRAEF ARCH CLIN EXP, V251, P871, DOI 10.1007/s00417-012-2127-0
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Jia YP, 2017, MOLECULES, V22, DOI 10.3390/molecules22040610
   Kelly D, 2017, BRIT J NUTR, V117, P108, DOI 10.1017/S0007114516003895
   Kelly ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092659
   Kopsell DA, 2006, J AGR FOOD CHEM, V54, P7998, DOI 10.1021/jf0614802
   Kumari N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203868
   Li S, 2018, INT J OPHTHALMOL-CHI, V11, P970, DOI 10.18240/ijo.2018.06.12
   Liu T, 2017, CELL BIOL TOXICOL, V33, P57, DOI 10.1007/s10565-016-9360-y
   Lupton JR, 2014, EUR J NUTR, V53, P1, DOI 10.1007/s00394-014-0666-3
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Mares J, 2016, ANNU REV NUTR, V36, P571, DOI 10.1146/annurev-nutr-071715-051110
   Marra MV, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030345
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Murphy SP, 2016, ADV NUTR, V7, P157, DOI 10.3945/an.115.010322
   National Institutes of Health, 2004, FED REGISTER, V69, P55821
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Putnam CM, 2017, CLIN EXP OPTOM, V100, P333, DOI 10.1111/cxo.12500
   Ranard KM, 2017, EUR J NUTR, V56, P537, DOI 10.1007/s00394-017-1580-2
   Scott TM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090919
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   van der Made SM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/9035745
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
NR 49
TC 4
Z9 4
U1 4
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD FEB 10
PY 2022
VL 80
IS 3
BP 513
EP 524
DI 10.1093/nutrit/nuab038
EA AUG 2021
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA YW7GT
UT WOS:000753584100014
PM 34339515
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lin, JB
   Halawa, OA
   Miller, JW
   Vavvas, DG
AF Lin, Jonathan B.
   Halawa, Omar A.
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Complement Inhibition for Geographic Atrophy: A Tempting Target with
   Mixed Results
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; complement;
   retina; drusen
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; BETA-CAROTENE; RISK;
   DRUSEN; ZINC; PROGRESSION; VARIANT; VISION; RETINA
AB Age-related macular degeneration (AMD) is a leading cause of blindness in older adults. One of the strongest genetic risk factors for AMD is a complement factor H (CFH) gene polymorphism characterized by a tyrosine-histidine change at amino acid position 402 (Y402H). The magnitude of this association between the Y402H variant and AMD is among the strongest that has been identified for any complex, multifactorial human disease. This strong association has motivated researchers to investigate a potential link between various elements of the complement pathway and AMD pathogenesis. Given the possible contribution of complement dysregulation to AMD, complement inhibition has emerged as a therapeutic strategy for slowing geographic atrophy (GA). Randomized clinical trials thus far have yielded mixed results. In this article, we provide the historical context for complement inhibition as a strategy for treating GA, discuss potential advantages and disadvantages of complement inhibition, and highlight the questions that must be addressed before complement inhibition can take center stage as a therapy for AMD.
C1 [Lin, Jonathan B.; Halawa, Omar A.; Miller, Joan W.; Vavvas, Demetrios G.] Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Lin, Jonathan B.; Halawa, Omar A.; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Med Sch, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School
RP Miller, JW; Vavvas, DG (通讯作者)，Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
EM jblin6@gmail.com; omar_halawa@hms.harvard.edu;
   joan_miller@meei.harvard.edu; demetrios_vavvas@meei.harvard.edu
OI Lin, Jonathan/0000-0002-2792-7821
FU Monte J. Wallace Chair in Retina; Ines and Fred Yeatts Retina Research
   lab fund; MLS Foundation; American Macular Degeneration Foundation; NIH
   [R01 EY030088]
FX D.G.V. was supported by the Monte J. Wallace Chair in Retina, the Ines
   and Fred Yeatts Retina Research lab fund, the MLS Foundation, and the
   American Macular Degeneration Foundation. J.W.M. was supported by NIH
   Grant R01 EY030088.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Ebrahimi KB, 2018, ANTIOXID REDOX SIGN, V29, P389, DOI 10.1089/ars.2017.7084
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2019, JAMA OPHTHALMOL, V137, P867, DOI 10.1001/jamaophthalmol.2019.1318
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim BJ, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100936
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin JB, 2018, PROG RETIN EYE RES, V67, P118, DOI 10.1016/j.preteyeres.2018.06.002
   Lin JB, 2016, CELL REP, V17, P69, DOI 10.1016/j.celrep.2016.08.073
   Mukai R, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00015
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Reis ES, 2019, NAT REV IMMUNOL, V19, P503, DOI 10.1038/s41577-019-0168-x
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Silverman SM, 2019, J EXP MED, V216, P1925, DOI 10.1084/jem.20190009
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2021, OPHTHALMOLOGY, V128, P1325, DOI 10.1016/j.ophtha.2021.02.025
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
NR 47
TC 2
Z9 2
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2021
VL 10
IS 13
AR 2890
DI 10.3390/jcm10132890
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TG0HV
UT WOS:000671095200001
PM 34209660
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gupta, P
   Yadav, KS
AF Gupta, Pallavi
   Yadav, Khushwant S.
TI Applications of microneedles in delivering drugs for various ocular
   diseases
SO LIFE SCIENCES
LA English
DT Review
DE Solid coated microneedles; Hollow microneedles; Dissolving polymeric
   microneedles; Glaucoma; Age related macular degeneration; Uveitis;
   Retinal vascular occlusion; Retinitis pigmentosa
ID RETINAL VEIN OCCLUSION; TISSUE-PLASMINOGEN ACTIVATOR; MACULAR
   DEGENERATION AMD; ANTI-VEGF THERAPY; INTRAVITREAL INJECTION; TOWER
   MICRONEEDLE; GENE-THERAPY; MOUSE MODEL; UVEITIS; PATHOPHYSIOLOGY
AB Treatment of majority of eye diseases involve the use of eye drops or eye ointments, which have major drawbacks of needing frequent administration, lower bioavailability and inability to cross the various eye barriers. This necessitates the use of novel delivery systems. Microneedles (MNs) as an alternate novel delivery system facilitate drug delivery to various ocular diseases with promising approaches in healthcare. Advances in pharmaceutical technology have made MNs provide localized, effective, less invasive and targeted drug delivery in the eye. The purpose of this review is to provide an insight to efficacious therapeutic applications the MNs can bring in various ocular diseases. Out of which, glaucoma, age-related macular degeneration, uveitis, retinal vascular occlusion and retinitis pigmentosa are majorly discussed. Among the various types of MNs; solid coated, hollow and dissolving polymeric MNs are specifically focused for their applications in ocular diseases. In addition, MNs shows improvement in the visual acuity and decreases the progression of the different ocular diseases.
C1 [Gupta, Pallavi; Yadav, Khushwant S.] SVKMs NMIMS Deemed Univ, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Vile Parle West, Mumbai, Maharashtra, India.
C3 SVKM's NMIMS (Deemed to be University)
RP Yadav, KS (通讯作者)，SVKMs NMIMS Deemed Univ, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Vile Parle West, Mumbai, Maharashtra, India.
EM khush.yadav@gmail.com
RI Yadav, Khushwant S./C-3039-2013
OI Yadav, Khushwant S./0000-0002-1620-0547
CR Agarwal R, 2009, INDIAN J OPHTHALMOL, V57, P257, DOI 10.4103/0301-4738.53049
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   Bariya SH, 2012, J PHARM PHARMACOL, V64, P11, DOI 10.1111/j.2042-7158.2011.01369.x
   Bhartiya Shibal, 2015, J Curr Glaucoma Pract, V9, P51, DOI 10.5005/jp-journals-10008-1184
   BILL ANDERS, 1965, INVEST OPHTHALMOL, V4, P920
   BLOCHMICHEL E, 1987, AM J OPHTHALMOL, V103, P234, DOI 10.1016/S0002-9394(14)74235-7
   Bodaghi B, 2001, MEDICINE, V80, P263, DOI 10.1097/00005792-200107000-00005
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Buch PK, 2007, CURR GENE THER, V7, P434, DOI 10.2174/156652307782793531
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Chadderton N, 2009, MOL THER, V17, P593, DOI 10.1038/mt.2008.301
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Dalkara D, 2016, HUM GENE THER, V27, P134, DOI 10.1089/hum.2015.147
   de Smet MD, 2011, PROG RETIN EYE RES, V30, P452, DOI 10.1016/j.preteyeres.2011.06.005
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DESMET MD, 1993, INT OPHTHALMOL CLIN, V33, P31, DOI 10.1097/00004397-199303340-00005
   Dias Marina Franca, 2018, Prog Retin Eye Res, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Dunlevy JR, 2004, INVEST OPHTH VIS SCI, V45, P3849, DOI 10.1167/iovs.04-0496
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Eigeldinger-Berthou S, 2012, RETINA-J RET VIT DIS, V32, P617, DOI 10.1097/IAE.0b013e31821e2070
   Esmaili Daniel D, 2018, F1000Res, V7, P467, DOI 10.12688/f1000research.12886.1
   FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gardeniers HJGE, 2003, J MICROELECTROMECH S, V12, P855, DOI 10.1109/JMEMS.2003.820293
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Gilger BC, 2013, INVEST OPHTH VIS SCI, V54, P2483, DOI 10.1167/iovs.13-11747
   Glacet-Bernard A, 2000, BRIT J OPHTHALMOL, V84, P609, DOI 10.1136/bjo.84.6.609
   Gulati N, 2011, BRIT J OPHTHALMOL, V95, P162, DOI 10.1136/bjo.2009.177279
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hashemian MN, 2011, CORNEA, V30, P215, DOI 10.1097/ICO.0b013e3181e291a6
   Hayreh SS, 2005, PROG RETIN EYE RES, V24, P493, DOI 10.1016/j.preteyeres.2004.12.001
   Healthline, 2017, RET VASC OCCL
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jiang J, 2007, INVEST OPHTH VIS SCI, V48, P4038, DOI 10.1167/iovs.07-0066
   Kacmaz RO, 2010, OPHTHALMOLOGY, V117, P576, DOI 10.1016/j.ophtha.2009.08.010
   Kadonosono K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19747-7
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kadonosono K, 2013, JAMA OPHTHALMOL, V131, P783, DOI 10.1001/jamaophthalmol.2013.2585
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kim Sang Woo, 2008, Ophthalmology, V115, pe33, DOI 10.1016/j.ophtha.2008.02.013
   Kim YC, 2012, ADV DRUG DELIVER REV, V64, P1547, DOI 10.1016/j.addr.2012.04.005
   Kim YC, 2014, INVEST OPHTH VIS SCI, V55, P7376, DOI 10.1167/iovs.14-15257
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Kuno N, 2011, POLYMERS-BASEL, V3, P193, DOI 10.3390/polym3010193
   Larouche K., 2005, EVALUATION PHOTODYNA
   Lattanzio R, 2011, OPHTHALMOLOGICA, V225, P135, DOI 10.1159/000314718
   Lee CY, 2015, BIOCHIP J, V9, P232, DOI 10.1007/s13206-015-9305-9
   Lee CY, 2013, BIOMED MICRODEVICES, V15, P841, DOI 10.1007/s10544-013-9771-y
   Lee CY, 2013, ADV HEALTHC MATER, V2, P812, DOI 10.1002/adhm.201200239
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Lee SS, 2009, CURR OPIN OPHTHALMOL, V20, P511, DOI 10.1097/ICU.0b013e328330ccb9
   Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67
   Leeming JP, 1999, CLIN PHARMACOKINET, V37, P351, DOI 10.2165/00003088-199937050-00001
   Lin TC, 2015, J CHIN MED ASSOC, V78, P501, DOI 10.1016/j.jcma.2015.05.010
   Ling TE, 2017, OPEN OPHTHALMOL J, V11, P31, DOI 10.2174/1874364101711010031
   Maddula S, 2011, OPHTHALMOLOGY, V118, P591, DOI 10.1016/j.ophtha.2011.01.041
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Marshall Leisa L, 2013, Consult Pharm, V28, P723, DOI 10.4140/TCP.n.2013.723
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   MIKKELSON TJ, 1973, J PHARM SCI-US, V62, P1942, DOI 10.1002/jps.2600621207
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Modorati G, 2012, DEV OPHTHALMOL, V51, P110, DOI 10.1159/000336471
   Moffatt K, 2017, CURR OPIN PHARMACOL, V36, P14, DOI 10.1016/j.coph.2017.07.007
   Mogusala N.R., 2015, AM J DRUG DELIV THER, P2349
   Musarella MA, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/753547
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Reilly M, 2008, VISION RES, V48, P386, DOI 10.1016/j.visres.2007.08.014
   Oh JY, 2009, CORNEA, V28, P1070, DOI 10.1097/ICO.0b013e31819839f9
   Park JH, 2005, J CONTROL RELEASE, V104, P51, DOI 10.1016/j.jconrel.2005.02.002
   Parodi MB, 2009, OPHTHALMOLOGICA, V223, P298, DOI 10.1159/000213640
   Patel SR, 2011, AAPS ADV PHARM SCI, V2, P331, DOI 10.1007/978-1-4419-9920-7_14
   Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y
   Piano I, 2013, EUR J NEUROSCI, V37, P1853, DOI 10.1111/ejn.12196
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Prausnitz MR, 1998, J PHARM SCI, V87, P1479, DOI 10.1021/js9802594
   Rathore K.S., INT J ADV RES PHARM, V2, P70
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rehak J, 2008, CURR EYE RES, V33, P111, DOI 10.1080/02713680701851902
   Rishi E, 2012, INDIAN J OPHTHALMOL, V60, P521, DOI 10.4103/0301-4738.103779
   Ronday MJH, 1996, BRIT J OPHTHALMOL, V80, P956, DOI 10.1136/bjo.80.11.956
   Sanchez-Vallejo V, 2015, PHARMACOL RES, V99, P276, DOI 10.1016/j.phrs.2015.06.019
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Singh RRT, 2017, EXPERT OPIN DRUG DEL, V14, P525, DOI 10.1080/17425247.2016.1218460
   Sit Arthur J., 2009, Molecular & Cellular Biomechanics, V6, P57
   Soheilian M, 2010, OPHTHALMOLOGY, V117, DOI 10.1016/j.ophtha.2009.10.012
   Song HB, 2015, J CONTROL RELEASE, V209, P272, DOI 10.1016/j.jconrel.2015.04.041
   Tamm ER, 2009, EXP EYE RES, V88, P648, DOI 10.1016/j.exer.2009.02.007
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Thakur RRS, 2016, DRUG DELIV TRANSL RE, V6, P800, DOI 10.1007/s13346-016-0332-9
   Than A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06981-w
   Turello M, 2010, J THROMB THROMBOLYS, V29, P459, DOI 10.1007/s11239-009-0384-5
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Wang QL, 2016, MAT SCI ENG C-MATER, V65, P135, DOI 10.1016/j.msec.2016.03.097
   Williamson TH, 1997, BRIT J OPHTHALMOL, V81, P698, DOI 10.1136/bjo.81.8.698
   Willoughby CE, 2010, CLIN EXP OPHTHALMOL, V38, P2, DOI 10.1111/j.1442-9071.2010.02363.x
   Yadav KS, 2019, EUR J PHARM SCI, V133, P1, DOI 10.1016/j.ejps.2019.03.007
   Yadav KS, 2019, LIFE SCI, V221, P362, DOI 10.1016/j.lfs.2019.02.029
   Yeung SN, 2011, CORNEA, V30, P1110, DOI 10.1097/ICO.0b013e31821379aa
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zhang QJ, 2016, ASIA-PAC J OPHTHALMO, V5, P265, DOI 10.1097/APO.0000000000000227
NR 115
TC 22
Z9 24
U1 2
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD NOV 15
PY 2019
VL 237
AR 116907
DI 10.1016/j.lfs.2019.116907
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JQ0WH
UT WOS:000498674800003
PM 31606378
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Sarraf, D
   Freund, KB
   Sadda, SR
AF Borrelli, Enrico
   Sarraf, David
   Freund, K. Bailey
   Sadda, Srinivas R.
TI OCT angiography and evaluation of the choroid and choroidal vascular
   disorders
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Optical coherence tomography angiography; Choroid; Choriocapillaris
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE-GREEN VIDEOANGIOGRAPHY;
   PIGMENT EPITHELIAL DETACHMENTS; SCANNING-ELECTRON-MICROSCOPY; SUBRETINAL
   HYPERREFLECTIVE MATERIAL; CENTRAL SEROUS CHORIORETINOPATHY; WHITE DOT
   SYNDROME; MACULAR DEGENERATION; SWEPT-SOURCE; TYPE-3 NEOVASCULARIZATION
AB The recent introduction of optical coherence tomography angiography (OCTA) has remarkably expanded our knowledge of the choroid through in vivo investigation of the anatomical and pathological features of this important vascular layer. New insights elucidating the morphological features of the choroid, in both physiological and pathological conditions, indicate that this vascular structure plays a crucial role in many chorioretinal disorders. In this article, a review of the salient histological and anatomical features of the choroid, essential for the proper interpretation of in vivo imaging, is followed by a discussion of the fundamental principles of OCTA and the application of this advanced imaging modality to study and understand the choroid. The current limitations of OCTA and potential advancements that may improve the widespread adoption of this tool are also discussed. A detailed review of the OCTA features of the choroid in the healthy eye is followed by relevant findings in major chorioretinal diseases, including age-related macular degeneration, central serous chorioretinopathy, uveitis, and inherited retinal disorders.
C1 [Borrelli, Enrico; Sarraf, David; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Borrelli, Enrico; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Borrelli, Enrico] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
   [Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Doheny Eye Institute; G d'Annunzio University of
   Chieti-Pescara; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los
   Angeles Healthcare System; Vitreous Retina Macula Consultants of New
   York; Manhattan Eye Ear & Throat Hospital; New York University
RP Sadda, SR (通讯作者)，1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Borrelli, Enrico/AAR-3693-2020; Freund, K. Bailey/V-7488-2018
OI Borrelli, Enrico/0000-0003-2815-5031; Freund, K.
   Bailey/0000-0002-7888-9773
FU Research to Prevent Blindness (RPB) Inc; Macula Foundation Inc, New York
   NY
FX This work is supported by Research to Prevent Blindness (RPB) Inc (DS),
   and New York NY and Macula Foundation Inc (KBF, DS), New York NY.
CR Abbouda A, 2018, EYE, V32, P563, DOI 10.1038/eye.2017.242
   AGGARWAL K, 2016, OCUL IMMUNOL INFLAMM, V20, P1, DOI DOI 10.1080/09273948.2016.1195001
   Akyol N, 1996, CAN J OPHTHALMOL, V31, P113
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Al-Sheikh M, 2017, OSLI RETINA, V48, P623, DOI 10.3928/23258160-20170802-04
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Astroz P, 2018, RETINA-J RET VIT DIS, V38, P299, DOI 10.1097/IAE.0000000000001617
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BENSON WE, 1975, AM J OPHTHALMOL, V79, P59, DOI 10.1016/0002-9394(75)90457-2
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002
   Borrelli E, 2018, RETINA, V39, P1216, DOI DOI 10.1097/IAE.0000000000002123
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Bruyere E, 2017, RETINA-J RET VIT DIS, V37, P2095, DOI 10.1097/IAE.0000000000001456
   BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6
   Burke TR, 2017, EYE, V31, P1399, DOI 10.1038/eye.2017.180
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Cheng L, 2016, AM J OPHTHALMOL, V169, P145, DOI 10.1016/j.ajo.2016.06.029
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Choi W, 2017, RETINA-J RET VIT DIS, V37, P11, DOI 10.1097/IAE.0000000000001250
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   De Carlo TE, 2015, RETINA-J RET VIT DIS, V35, P2392, DOI 10.1097/IAE.0000000000000744
   De Stefano ME, 1997, ANAT EMBRYOL, V195, P393, DOI 10.1007/s004290050060
   Dell'Omo R, 2010, BRIT J OPHTHALMOL, V94, P59, DOI 10.1136/bjo.2009.163550
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   DEUTMAN AF, 1972, BRIT J OPHTHALMOL, V56, P863, DOI 10.1136/bjo.56.12.863
   Dhoot DS, 2013, BRIT J OPHTHALMOL, V97, P66, DOI 10.1136/bjophthalmol-2012-301917
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dodo Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05663-9
   Dolz-Marco Rosa, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS136, DOI 10.1097/ICB.0000000000000473
   DREYER RF, 1984, ARCH OPHTHALMOL-CHIC, V102, P1776, DOI 10.1001/archopht.1984.01040031440019
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Falsini B, 2011, INVEST OPHTH VIS SCI, V52, P1064, DOI 10.1167/iovs.10-5964
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   FLANNERY JG, 1990, INVEST OPHTH VIS SCI, V31, P229
   Flitcroft DI, 2012, PROG RETIN EYE RES, V31, P622, DOI 10.1016/j.preteyeres.2012.06.004
   Forrester J.V., 2008, EYE BASIC SCI PRACTI, V568, DOI [10.1038/nrg1202.J, DOI 10.1038/NRG1202.J]
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   FRYCZKOWSKI AW, 1989, INT OPHTHALMOL, V13, P269, DOI 10.1007/BF02280087
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   FRYCZKOWSKI AW, 1988, ACTA ANAT, V132, P265
   Gal-Or O, 2018, RETINA-J RET VIT DIS, V38, P1984, DOI 10.1097/IAE.0000000000002051
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Garrity ST, 2017, OSLI RETINA, V48, P668, DOI 10.3928/23258160-20170802-10
   GASS JDM, 1968, ARCH OPHTHALMOL-CHIC, V80, P177
   GELISKEN O, 1985, INT OPHTHALMOL, V8, P225, DOI 10.1007/BF00137651
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Gorczynska I, 2016, BIOMED OPT EXPRESS, V7, P911, DOI 10.1364/BOE.7.000911
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hirashima T, 2017, INVEST OPHTH VIS SCI, V58, P3871, DOI 10.1167/iovs.17-21515
   Hirata A, 1998, GRAEF ARCH CLIN EXP, V236, P132, DOI 10.1007/s004170050053
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain N, 2016, JAMA OPHTHALMOL, V134, P697, DOI 10.1001/jamaophthalmol.2016.0874
   JAMPOL LM, 1984, ARCH OPHTHALMOL-CHIC, V102, P671, DOI 10.1001/archopht.1984.01040030527008
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   KAISERKUPFER MI, 1994, AM J OPHTHALMOL, V118, P569, DOI 10.1016/S0002-9394(14)76572-9
   Karti O, 2019, RETINA-J RET VIT DIS, V39, P964, DOI 10.1097/IAE.0000000000002058
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Klufas MA, 2017, OPHTHALMOL RETINA, V1, P77, DOI 10.1016/j.oret.2016.08.008
   Konieczka K, 2012, EPMA J, V3, DOI 10.1186/1878-5085-3-17
   KREBS W, 1988, ARCH OPHTHALMOL-CHIC, V106, P1615, DOI 10.1001/archopht.1988.01060140783055
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Leveziel N, 2013, AM J OPHTHALMOL, V155, P913, DOI 10.1016/j.ajo.2012.11.021
   Levison AL, 2017, BRIT J OPHTHALMOL, V101, P616, DOI 10.1136/bjophthalmol-2016-308806
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Li AR, 2004, AM J HUM GENET, V74, P817, DOI 10.1086/383228
   Li XQ, 2016, INVEST OPHTH VIS SCI, V57, pOCT371, DOI 10.1167/iovs.15-18884
   Long AW, 2015, SOFT MATTER, V11, P8141, DOI 10.1039/c5sm01981h
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   MAMES RN, 1991, OPHTHALMOLOGY, V98, P527
   Mandadi SKR, 2017, RETINA-J RET VIT DIS, V37, P1647, DOI 10.1097/IAE.0000000000001412
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   MCBRIEN NA, 1987, ACTA OPHTHALMOL, V65, P461
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   MILLER SA, 1976, AM J OPHTHALMOL, V82, P252, DOI 10.1016/0002-9394(76)90428-1
   Miyata M, 2018, BRIT J OPHTHALMOL, V102, P1208, DOI 10.1136/bjophthalmol-2017-311313
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   MOORTHY RS, 1995, SURV OPHTHALMOL, V39, P265, DOI 10.1016/S0039-6257(05)80105-5
   Morgan JIW, 2014, INVEST OPHTH VIS SCI, V55, P6381, DOI 10.1167/iovs.13-13454
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mrejen S, 2016, OSLI RETINA, V47, P20, DOI 10.3928/23258160-20151214-03
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Naysan Jonathan, 2015, Int J Retina Vitreous, V1, P8
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Nemiroff Julia, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS113, DOI 10.1097/ICB.0000000000000442
   Nesper PL, 2017, INVEST OPHTH VIS SCI, V58, P307, DOI 10.1167/iovs.17-21787
   Nesper PL, 2018, RETINA-J RET VIT DIS, V38, P1289, DOI 10.1097/IAE.0000000000001863
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Ozawa G., 2009, OPTOMETRY VISION SCI, DOI [10.1097/OPX.0b013e3181b3la29, DOI 10.1097/OPX.0B013E3181B3LA29]
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pappuru RR, 2012, OPHTHAL SURG LAS IM, V43, P63, DOI 10.3928/15428877-20110908-02
   Parodi MB, 2017, BRIT J OPHTHALMOL, V101, P780, DOI 10.1136/bjophthalmol-2016-308869
   PARVER L M, 1991, Eye (London), V5, P181
   Patel RC, 2016, RETINA-J RET VIT DIS, V36, P2339, DOI 10.1097/IAE.0000000000001159
   Pavan PR, 1996, OPHTHALMOLOGY, V103, P586, DOI 10.1016/S0161-6420(96)30649-0
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Phasukkijwatana Nopasak, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS68, DOI 10.1097/ICB.0000000000000418
   Pichi F., 2016, MACULAR ISCHEMIA INA
   Pichi F, 2017, PROG RETIN EYE RES, V59, P178, DOI 10.1016/j.preteyeres.2017.04.005
   Pichi F, 2016, RETINA-J RET VIT DIS, V36, pS178, DOI 10.1097/IAE.0000000000001255
   Ploner SB, 2016, RETINA-J RET VIT DIS, V36, pS118, DOI 10.1097/IAE.0000000000001328
   Poddar R, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.10.106018
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Provis JM, 2013, PROG RETIN EYE RES, V35, P63, DOI 10.1016/j.preteyeres.2013.01.005
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P4678, DOI 10.1167/iovs.10-6500
   Querques L, 2017, BRIT J OPHTHALMOL, V101, P609, DOI 10.1136/bjophthalmol-2016-309162
   Rada JAS, 2012, INVEST OPHTH VIS SCI, V53, P1649, DOI 10.1167/iovs.11-8444
   Rao Narsing A., 2007, International Ophthalmology, V27, P81, DOI 10.1007/s10792-006-9029-2
   Reddy Shantan, 2011, Retin Cases Brief Rep, V5, P91, DOI 10.1097/ICB.0b013e3181e2506f
   Rezaei KA, 2017, GRAEF ARCH CLIN EXP, V255, P1287, DOI 10.1007/s00417-017-3633-x
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosa N, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3120941
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sayanagi K, 2017, BRIT J OPHTHALMOL, V101, P1524, DOI 10.1136/bjophthalmol-2016-309628
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Seddon Johanna M, 2016, JAMA Ophthalmol, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shah KH, 2005, SURV OPHTHALMOL, V50, P519, DOI 10.1016/j.survophthal.2005.08.004
   Sheard C., 1943, OPTOMETRY VISION SCI, DOI [10.1097/00006324-194301000-00005, DOI 10.1097/00006324-194301000-00005]
   SIEVING PA, 1984, ARCH OPHTHALMOL-CHIC, V102, P675, DOI 10.1001/archopht.1984.01040030531009
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2161, DOI 10.1097/IAE.0000000000000881
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spraul CW, 2002, VISION RES, V42, P923, DOI 10.1016/S0042-6989(02)00022-6
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P1544, DOI 10.1097/IAE.0000000000001402
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Tan CS, 2016, BRIT J OPHTHALMOL, V100, P995, DOI 10.1136/bjophthalmol-2015-307541
   Teussink MM, 2015, INVEST OPHTH VIS SCI, V56, P5229, DOI 10.1167/iovs.15-17140
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Toto L, 2016, INVEST OPHTH VIS SCI, V57, P6360, DOI 10.1167/iovs.16-20544
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Vasconcelos-Santos DV, 2010, ARCH OPHTHALMOL-CHIC, V128, P853, DOI 10.1001/archophthalmol.2010.116
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   WILSON DJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P213, DOI 10.1001/archopht.1989.01070010219026
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Xu YS, 2017, OPHTHALMOLOGICA, V237, P167, DOI 10.1159/000456676
   Yamamoto S, 2003, DOC OPHTHALMOL, V106, P117, DOI 10.1023/A:1022599618698
   Yannuzzi L A, 1994, Eur J Ophthalmol, V4, P69
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi NA, 2017, OSLI RETINA, V48, P69, DOI 10.3928/23258160-20161219-10
   Zahid S, 2017, RETINA-J RET VIT DIS, V37, P1451, DOI 10.1097/IAE.0000000000001381
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zerbib Jennyfer, 2014, Retin Cases Brief Rep, V8, P130, DOI 10.1097/ICB.0000000000000022
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2017, INVEST OPHTH VIS SCI, V58, P5098, DOI 10.1167/iovs.17-22506
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zinkernagel MS, 2015, CLIN OPHTHALMOL, V9, P2195, DOI 10.2147/OPTH.S65732
NR 249
TC 154
Z9 158
U1 7
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2018
VL 67
BP 30
EP 55
DI 10.1016/j.preteyeres.2018.07.002
PG 26
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD5OJ
UT WOS:000452579500002
PM 30059755
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Lin, TC
   Chang, HM
   Hsu, CC
   Hung, KH
   Chen, YT
   Chen, SY
   Chen, SJ
AF Lin, Tai-Chi
   Chang, Hua-Ming
   Hsu, Chih-Chien
   Hung, Kuo-Hsuan
   Chen, Yan-Ting
   Chen, Szu-Yu
   Chen, Shih-Jen
TI Retinal prostheses in degenerative retinal diseases
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Review
DE age-related macular degeneration; epiretinal implants; retinal
   prosthesis; retinitis pigmentosa; subretinal implants
ID MORPHOMETRIC-ANALYSIS; RETINITIS-PIGMENTOSA; VISION; IMPLANTS;
   EXPLANTATION; STIMULATION; EYES
AB Degenerative retinal diseases may lead to significant loss of vision. Age-related macular degeneration (AMD) and retinitis pigmentosa (RP), which eventually affect the photoreceptors, are the two most common retinal degenerative diseases. Once the photoreceptorcells are lost, there are no known effective therapies for AMD or RR The concept of retinal prosthesis is to elicit neural activity in the remaining retinal neurons by detecting light and converting it into electrical stimuli using artificial devices. Subretinal, epiretinal, and other retinal prostheses implants are currently designed to restore functional vision in retinal degenerative diseases. In this review, we have summarized different types of retinal prostheses, implant locations, and visual outcomes. Our discussions will further elucidate the results from clinical trials, and the challenges that will need to be overcome to more efficaciously assist patients with AMD and RP in the future. Copyright (C) 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
C1 [Lin, Tai-Chi; Hsu, Chih-Chien; Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Lin, Tai-Chi; Hsu, Chih-Chien; Hung, Kuo-Hsuan; Chen, Yan-Ting] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Chang, Hua-Ming; Chen, Szu-Yu] Natl Cent Univ, Dept Opt & Photon, Taoyuan, Taiwan.
   [Chang, Hua-Ming] Bade Vet Home, Taoyuan, Taiwan.
   [Hung, Kuo-Hsuan] Natl Yang Ming Univ Hosp, Dept Ophthalmol, Yilan, Taiwan.
   [Chen, Yan-Ting] Changhua Christian Hosp, Dept Ophthalmol, Changhua, Taiwan.
   [Chen, Yan-Ting] Cent Taiwan Univ Sci & Technol, Dept Optometry, Taichung, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Central University; Changhua Christian Hospital;
   Central Taiwan University Science & Technology
RP Chen, SJ (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
EM sjchen@vghtpe.gov.tw
CR Barry MP, 2012, INVEST OPHTH VIS SCI, V53, P5095, DOI 10.1167/iovs.12-9536
   Benav H, 2010, IEEE ENG MED BIO, P5919, DOI 10.1109/IEMBS.2010.5627549
   Caspi A, 2009, ARCH OPHTHALMOL-CHIC, V127, P398, DOI 10.1001/archophthalmol.2009.20
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Chuang AT, 2014, BRIT J OPHTHALMOL, V98, P852, DOI 10.1136/bjophthalmol-2013-303708
   Ciavatta VT, 2009, INVEST OPHTH VIS SCI, V50, P4523, DOI 10.1167/iovs.08-2072
   del Cerro M, 2000, INVEST OPHTH VIS SCI, V41, P3142
   Dorn JD, 2013, JAMA OPHTHALMOL, V131, P183, DOI 10.1001/2013.jamaophthalmol.221
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Guenther T, 2012, EXPERT REV MED DEVIC, V9, P33, DOI 10.1586/ERD.11.58
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Ivastinovic D, 2010, ACTA OPHTHALMOL, V88, pe285, DOI 10.1111/j.1755-3768.2009.01694.x
   Keseru M, 2012, ACTA OPHTHALMOL, V90, pE1, DOI 10.1111/j.1755-3768.2011.02288.x
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Klauke S, 2011, INVEST OPHTH VIS SCI, V52, P449, DOI 10.1167/iovs.09-4410
   Kusnyerik A, 2012, INVEST OPHTH VIS SCI, V53, P3748, DOI 10.1167/iovs.11-9409
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Matthaei M, 2011, OPHTHALMOLOGICA, V225, P187, DOI 10.1159/000318042
   Menzel-Severing J, 2012, EYE, V26, P502, DOI 10.1038/eye.2012.35
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Mokwa W, 2008, IEEE ENG MED BIO, P5790, DOI 10.1109/IEMBS.2008.4650530
   Roessler G, 2009, INVEST OPHTH VIS SCI, V50, P3003, DOI 10.1167/iovs.08-2752
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Stingl K, 2013, OPHTHALMIC RES, V50, P215, DOI 10.1159/000354424
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Weiland JD, 2011, OPHTHALMOLOGY, V118, P2227, DOI 10.1016/j.ophtha.2011.08.042
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
   Zrenner E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007399
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 30
TC 17
Z9 20
U1 2
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD SEP
PY 2015
VL 78
IS 9
BP 501
EP 505
DI 10.1016/j.jcma.2015.05.010
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CS9BE
UT WOS:000362383300002
PM 26142056
DA 2022-11-30
ER

PT J
AU Klegeris, A
   McGeer, PL
AF Klegeris, Andis
   McGeer, Patrick L.
TI Complement activation by islet amyloid polypeptide (IAPP) and
   alpha-synuclein 112
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Alzheimer amyloid beta peptide; Alzheimer disease; amylin; IgG;
   Parkinson disease; synucleinopathies; type 1 diabetes mellitus; type 2
   diabetes mellitus
ID C-REACTIVE PROTEIN; ALPHA-SYNUCLEIN; DIABETES-MELLITUS;
   PARKINSONS-DISEASE; LEWY BODIES; SUBSTANTIA-NIGRA; INFLAMMATION;
   DEMENTIA; SYSTEM; RISK
AB Complement can damage host tissue when overactivated. Evidence of complement self damage exists for Alzheimer disease (AD), age-related macular degeneration, type 1 diabetes mellitus (T1DM), and Parkinson disease (PD). Known complement activators include A beta, found in AD, and IgG found in T1DM. We compared their complement activating ability in vitro with those of islet amyloid polypeptide (IAPP), which aggregates in the pancreas of T2DM, and alpha-synuclein (alpha-Syn), which aggregates in PD. We found that IAPP and the alternatively spliced alpha-Syn 112 form, but not full-length alpha-Syn 140, activated complement in vitro. Complement activation may contribute to death of insulin-secreting cells in T2DM or to neuronal death in Parkinson disease (PD) and related synucleinopathies where alpha-Syn 112 occurs. This suggests the possibility of anti-inflammatory treatment in these pathologies. It also suggests that blockers of complement activation may be an appropriate therapeutic target for a range of age-related degenerative diseases. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ British Columbia, KInsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada.
C3 University of British Columbia
RP McGeer, PL (通讯作者)，Univ British Columbia, KInsmen Lab Neurol Res, 2222 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
EM mcgeerpl@interchange.ubc.ca
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Akomolafe A, 2006, ARCH NEUROL-CHICAGO, V63, P1551, DOI 10.1001/archneur.63.11.1551
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beyer K, 2006, ACTA NEUROPATHOL, V112, P237, DOI 10.1007/s00401-006-0104-6
   Chaplin H Jr, 2005, Immunohematology, V21, P85
   Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1
   Clark A, 2004, DIABETOLOGIA, V47, P157, DOI 10.1007/s00125-003-1304-4
   de Koning EJP, 1998, AMYLOID, V5, P247, DOI 10.3109/13506129809007297
   FIGUEREDO A, 1993, DIABETES CARE, V16, P445, DOI 10.2337/diacare.16.2.445
   Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733
   Hull RL, 2004, J CLIN ENDOCR METAB, V89, P3629, DOI 10.1210/jc.2004-0405
   ISHIZAKA K, 1960, J IMMUNOL, V85, P163
   Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241
   Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X
   Klegeris A, 2002, IMMUNOLOGY, V106, P381, DOI 10.1046/j.1365-2567.2002.01425.x
   Knight JD, 2006, BIOCHEMISTRY-US, V45, P9496, DOI 10.1021/bi060579z
   Kolb H, 2005, DIABETOLOGIA, V48, P1038, DOI 10.1007/s00125-005-1764-9
   Kuusisto E, 2003, J NEUROPATH EXP NEUR, V62, P1241, DOI 10.1093/jnen/62.12.1241
   Leibson CL, 1997, AM J EPIDEMIOL, V145, P301
   Loeffler DA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-29
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005
   MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285
   McGeer PL, 1997, BRAIN RES, V749, P135, DOI 10.1016/S0006-8993(96)01324-8
   MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8
   Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43
   MORIMOTO Y, 1988, DIABETES RES CLIN PR, V5, P233, DOI 10.1016/S0168-8227(88)80093-7
   Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937
   Paulsson JF, 2006, DIABETOLOGIA, V49, P1237, DOI 10.1007/s00125-006-0206-7
   Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Rozemuller AJM, 2000, ACTA NEUROPATHOL, V100, P701, DOI 10.1007/s004010000225
   Schulze MB, 2005, AM J CLIN NUTR, V82, P675, DOI 10.1093/ajcn/82.3.675
   Singhrao SK, 1996, J NEUROPATH EXP NEUR, V55, P578, DOI 10.1097/00005072-199605000-00010
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278
   Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469
   Westermark Per, 2005, Curr Diab Rep, V5, P184, DOI 10.1007/s11892-005-0007-2
   YAMADA T, 1992, ACTA NEUROPATHOL, V84, P100, DOI 10.1007/BF00427222
NR 39
TC 21
Z9 22
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 15
PY 2007
VL 357
IS 4
BP 1096
EP 1099
DI 10.1016/j.bbrc.2007.04.055
PG 4
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 170FP
UT WOS:000246648400044
PM 17459337
DA 2022-11-30
ER

PT J
AU Vicuna-Kojchen, J
   Banin, E
   Averbukh, E
   Barzel, I
   Shulman, M
   Hemo, I
   Pe'er, J
   Chowers, I
AF Vicuna-Kojchen, Joaquin
   Banin, Eyal
   Averbukh, Edward
   Barzel, Israel
   Shulman, Marina
   Hemo, Itzhak
   Pe'er, Jacob
   Chowers, Itay
TI Application of the standard photodynamic treatment protocol for
   symptomatic circumscribed choroidal hemangioma
SO OPHTHALMOLOGICA
LA English
DT Article
DE choroidal hemangioma; photodynamic therapy
ID THERAPY; VERTEPORFIN; NEOVASCULARIZATION
AB To describe the results of photodynamic therapy (PDT) using a standard protocol, developed for treating choroidal neovascularization (CNV), for the treatment of circumscribed choroidal hemangioma (CCH). Methods: A prospective, uncontrolled, consecutive case series of patients with symptomatic CCH that were treated using the standard PDT protocol was evaluated periodically with ophthalmic exams and echography. Results: Nine CCH patients were included in the study. Mean tumor height decreased from 2.7 mm before treatment to 0.8 mm at the end of the follow-up period. Mean visual acuity improved from 6/15 to 6/12. Six patients required one PDT session, two patients two sessions, and one patient three sessions. Side effects included transient visual disturbances in two patients. One patient, who concomitantly presented with age-related macular degeneration, developed CNV. Conclusions: The standard PDT protocol is effective for the treatment of CCH. Complications are uncommon. Further studies should assess the optimal PDT protocol for the treatment of CCH. Copyright (c) 2006 S. Karger AG, Basel.
C1 Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Chowers, I (通讯作者)，Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@md.huji.ac.il
CR Augsburger JJ, 1997, FRONT RADIAT THER ON, V30, P265
   Barbazetto I, 2000, GRAEF ARCH CLIN EXP, V238, P214, DOI 10.1007/s004170050346
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Gunduz K, 2004, SURV OPHTHALMOL, V49, P316, DOI 10.1016/j.survophthal.2004.02.009
   Gupta M, 2004, EYE, V18, P139, DOI 10.1038/sj.eye.6700597
   Jurklies B, 2005, GRAEF ARCH CLIN EXP, V243, P393, DOI 10.1007/s00417-004-1100-y
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Landau IME, 2002, ACTA OPHTHALMOL SCAN, V80, P531, DOI 10.1034/j.1600-0420.2002.800513.x
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   Mashayekhi Arman, 2003, Curr Opin Ophthalmol, V14, P142, DOI 10.1097/00055735-200306000-00006
   Mennel S, 2005, AM J OPHTHALMOL, V140, P758, DOI 10.1016/j.ajo.2005.04.041
   Mennel S, 2005, OPHTHALMOLOGE, V102, P58, DOI 10.1007/s00347-004-1065-6
   Nicolo M, 2003, EUR J OPHTHALMOL, V13, P656, DOI 10.1177/112067210301300711
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Schilling H, 1998, Curr Opin Ophthalmol, V9, P51, DOI 10.1097/00055735-199806000-00009
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Shields CL, 2001, OPHTHALMOLOGY, V108, P2237, DOI 10.1016/S0161-6420(01)00812-0
   Singh AD, 2004, BRIT J OPHTHALMOL, V88, P1414, DOI 10.1136/bjo.2004.044396
   Verbraak FD, 2003, GRAEF ARCH CLIN EXP, V241, P891, DOI 10.1007/s00417-003-0765-y
NR 19
TC 21
Z9 26
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2006
VL 220
IS 6
BP 351
EP 355
DI 10.1159/000095859
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 104GC
UT WOS:000241944400001
PM 17095878
DA 2022-11-30
ER

PT J
AU Sterling, JK
   Baumann, B
   Foshe, S
   Voigt, A
   Guttha, S
   Alnemri, A
   McCright, SJ
   Li, MY
   Zauhar, RJ
   Montezuma, SR
   Kapphahn, RJ
   Chavali, VRM
   Hill, DA
   Ferrington, DA
   Stambolian, D
   Mullins, RF
   Merrick, D
   Dunaief, JL
AF Sterling, Jacob K.
   Baumann, Bailey
   Foshe, Sierra
   Voigt, Andrew
   Guttha, Samyuktha
   Alnemri, Ahab
   McCright, Sam J.
   Li, Mingyao
   Zauhar, Randy J.
   Montezuma, Sandra R.
   Kapphahn, Rebecca J.
   Chavali, Venkata R. M.
   Hill, David A.
   Ferrington, Deborah A.
   Stambolian, Dwight
   Mullins, Robert F.
   Merrick, David
   Dunaief, Joshua L.
TI Inflammatory adipose activates a nutritional immunity pathway leading to
   retinal dysfunction
SO CELL REPORTS
LA English
DT Article
ID CHELATOR DEFERIPRONE PROTECTS; H Y402H POLYMORPHISM; MACULAR
   DEGENERATION; OXIDATIVE STRESS; NLRP3 INFLAMMASOME; DIETARY-FAT;
   TRANSFERRIN GENE; IRON OVERLOAD; ALU RNA; AGE
AB Age-related macular degeneration (AMD), the leading cause of irreversible blindness among Americans over 50, is characterized by dysfunction and death of retinal pigment epithelial (RPE) cells. The RPE accumulates iron in AMD, and iron overload triggers RPE cell death in vitro and in vivo. However, the mechanism of RPE iron accumulation in AMD is unknown, We show that high-fat-diet-induced obesity, a risk factor for AMD, drives systemic and local inflammatory circuits upregulating interleukin-1 beta (IL-1 beta). IL-1 beta upregulates RPE iron importers and downregulates iron exporters, causing iron accumulation, oxidative stress, and dysfunction. We term this maladaptive, chronic activation of a nutritional immunity pathway the cellular iron sequestration response (CISR). RNA sequencing (RNA-seq) analysis of choroid and retina from human donors revealed that hallmarks of this pathway are present in AMD microglia and macrophages. Together, these data suggest that inflamed adipose tissue, through the CISR, can lead to RPE pathology in AMD.
C1 [Sterling, Jacob K.; Baumann, Bailey; Foshe, Sierra; Guttha, Samyuktha; Alnemri, Ahab; Chavali, Venkata R. M.; Stambolian, Dwight; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Sterling, Jacob K.; Baumann, Bailey; McCright, Sam J.] Univ Penn, Perelman Sch Med, Med Scientist Training Program, Philadelphia, PA 19104 USA.
   [Voigt, Andrew; Mullins, Robert F.] Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
   [Voigt, Andrew; Mullins, Robert F.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [McCright, Sam J.; Hill, David A.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA.
   [Li, Mingyao] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA.
   [Zauhar, Randy J.] Univ Sci, Dept Chem & Biochem, Philadelphia, PA 19104 USA.
   [Montezuma, Sandra R.; Kapphahn, Rebecca J.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Merrick, David] Univ Penn, Perelman Sch Med, Dept Med, Div Endocrinol, Philadelphia, PA 19104 USA.
   [Hill, David A.; Merrick, David] Univ Penn, Perelman Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
   [Guttha, Samyuktha] NYU, Grossman Sch Med, Dept Ophthalmol, New York, NY 10016 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Iowa; University of
   Iowa; University of Pennsylvania; Pennsylvania Medicine; Childrens
   Hospital of Philadelphia; University of Pennsylvania; Pennsylvania
   Medicine; University of Minnesota System; University of Minnesota Twin
   Cities; University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; New York University
RP Dunaief, JL (通讯作者)，Univ Penn, Scheie Eye Inst, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
EM jdunaief@pennmedicine.upenn.edu
OI Montezuma, Sandra/0000-0003-3731-8082; McCright,
   Sam/0000-0002-4295-9290; Foshe, Sierra/0000-0001-7055-2001; Sterling,
   Jacob/0000-0001-7535-1073; Ferrington, Deborah/0000-0003-2561-7464
FU National Institutes of Health/National Eye Institute [R01EY031209,
   F30EY032339, R01EY028916, R21EY028273, R01EY030192, R21EY031877,
   K08DK122099]; Research to Prevent Blindness; FM Kirby Foundation; Paul
   and Evanina Bell Mackall Foundation Trust; Graduate Training in
   Neuroscience [T32NS105607]; Michael Brown Fellowship; National
   Institutes of Health [K08 DK116668]; Elaine and Robert Larson Endowed
   Vision Research Chair and Helen Lindsay Family Foundation; Knobloch
   Chair Professorship
FX Funding for J.K.S. was provided by the National Institutes of
   Health/National Eye Institute (F30EY032339). Funding for J.K.S., B.B.,
   S.F., S.G., A.A., and J.L.D. was provided by the National Institutes of
   Health/National Eye Institute (R01EY028916), Research to Prevent
   Blindness, the FM Kirby Foundation, the Paul and Evanina Bell Mackall
   Foundation Trust, and a gift in memory of Lee F. Mauger, MD. Funding for
   S.F. was provided by Graduate Training in Neuroscience (T32NS105607).
   Funding for S.J.M. was provided by the Michael Brown Fellowship. Funding
   for D.A.H. and S.J.M. was provided by the National Institutes of Health
   (K08 DK116668). Funding for S.R.M., R.J.K., and D.A.F. was provided by
   the National Institutes of Health/National Eye Institute (R01EY026012),
   Elaine and Robert Larson Endowed Vision Research Chair and Helen Lindsay
   Family Foundation, and the Knobloch Chair Professorship. Funding for
   V.R.M.C. was provided by the National Institutes of Health/National Eye
   Institute (R21EY028273). Funding for M.L. was provided by the National
   Institutes of Health/National Eye Institute (R01EY030192, R21EY031877,
   and R01EY031209). Funding for D.S. was provided by the National
   Institutes of Health/National Eye Institute (R01EY031209). Funding for
   D.M. was provided by the National Institutes of Health/National
   Institute of Diabetes and Digestive and Kidney Disease (K08DK122099).
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benani A, 2012, J NEUROSCI, V32, P11970, DOI 10.1523/JNEUROSCI.0624-12.2012
   Bhoiwala DL, 2016, SURV OPHTHALMOL, V61, P33, DOI 10.1016/j.survophthal.2015.08.005
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Budiene B, 2018, OPHTHALMIC GENET, V39, P463, DOI 10.1080/13816810.2018.1484928
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111
   Daher R, 2017, TRANSFUS CLIN BIOL, V24, P115, DOI 10.1016/j.tracli.2017.06.015
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391
   Guo DH, 2020, J CLIN INVEST, V130, P1961, DOI 10.1172/JCI126078
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hadziahmetovic M, 2012, TRANSL VIS SCI TECHN, V1, DOI 10.1167/tvst.1.3.2
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463
   Jiang H, 2017, MOL NEUROBIOL, V54, P3078, DOI 10.1007/s12035-016-9879-1
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kanamori Y, 2017, J BIOL CHEM, V292, P10275, DOI 10.1074/jbc.M116.770974
   Keenan TD, 2020, OPHTHALMOL RETINA, V4, P3, DOI 10.1016/j.oret.2019.06.001
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lane DJR, 2010, BIOCHEM J, V432, P123, DOI 10.1042/BJ20101317
   Leruez S, 2014, REV NEUROL-FRANCE, V170, P344, DOI 10.1016/j.neurol.2014.03.009
   Li YF, 2015, J BIOL CHEM, V290, P11918, DOI 10.1074/jbc.M115.645903
   Liuzzi JP, 2006, P NATL ACAD SCI USA, V103, P13612, DOI 10.1073/pnas.0606424103
   Lopez CA, 2018, CELL HOST MICROBE, V23, P737, DOI 10.1016/j.chom.2018.05.008
   Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Lyu YF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95122-3
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1
   MCCORD JM, 1974, SCIENCE, V185, P529, DOI 10.1126/science.185.4150.529
   Monteleone M, 2018, CELL REP, V24, P1425, DOI 10.1016/j.celrep.2018.07.027
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Nnah IC, 2020, J NEUROCHEM, V154, P177, DOI 10.1111/jnc.14906
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roddy GW, 2020, CURR EYE RES, V45, P726, DOI 10.1080/02713683.2019.1694156
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shanmugam NKN, 2015, J BIOL CHEM, V290, P30637, DOI 10.1074/jbc.M115.689190
   Silva I, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101209
   Soares MP, 2016, IMMUNITY, V44, P492, DOI 10.1016/j.immuni.2016.02.016
   Soares MP, 2015, EMBO REP, V16, P1482, DOI 10.15252/embr.201540558
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sterling JK, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110358
   Sterling JK, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108271
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279
   Voigt AP, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108204
   Voigt AP, 2020, MICROVASC RES, V131, DOI 10.1016/j.mvr.2020.104031
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1
   Weiss G, 2019, BLOOD, V133, P40, DOI 10.1182/blood-2018-06-856500
   Wood Heather, 2020, Nat Rev Neurol, V16, P184, DOI 10.1038/s41582-020-0339-1
   Wu HZ, 2020, CIRC RES, V126, P1549, DOI 10.1161/CIRCRESAHA.119.315896
   Wu J, 2004, J NEUROPHYSIOL, V91, P1134, DOI 10.1152/jn.00958.2003
   Wysokinski D, 2015, ACTA BIOCHIM POL, V62, P177, DOI 10.18388/abp.2014_843
   Wysokinski D, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/507356
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 92
TC 1
Z9 1
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUN 14
PY 2022
VL 39
IS 11
AR 110942
DI 10.1016/j.celrep.2022.110942
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 2M6FP
UT WOS:000817793600005
PM 35705048
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Zhao, M
   Li, SQ
   Matsubara, JA
AF Zhao, Mary
   Li, Siqi
   Matsubara, Joanne A.
TI Targeting Pyroptotic Cell Death Pathways in Retinal Disease
SO FRONTIERS IN MEDICINE
LA English
DT Review
DE pyroptosis; cell death; NLRP3; caspase-1; GSDMD; age-related macular
   degeneration; diabetic retinopathy; glaucoma
ID NLRP3 INFLAMMASOME ACTIVATION; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; GLOBAL PREVALENCE; GASDERMIN D; GLAUCOMA; GSDMD;
   AUTOINHIBITION; CONTRIBUTES; CASPASE-11
AB Pyroptosis is a gasdermin-mediated, pro-inflammatory form of cell death distinct from apoptosis. In recent years, increasing attention has shifted toward pyroptosis as more studies demonstrate its involvement in diverse inflammatory disease states, including retinal diseases. This review discusses how currently known pyroptotic cell death pathways have been implicated in models of age-related macular degeneration, diabetic retinopathy, and glaucoma. We also identify potential future therapeutic strategies for these retinopathies that target drivers of pyroptotic cell death. Presently, the drivers of pyroptosis that have been studied the most in retinal cells are the nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, caspase-1, and gasdermin D (GSDMD). Targeting these proteins may help us develop new drug therapies, or supplement existing therapies, in the treatment of retinal diseases. As novel mechanisms of pyroptosis come to light, including those involving other inflammatory caspases and members of the gasdermin protein family, more targets for pyroptosis-mediated therapies in retinal disease can be explored.
C1 [Zhao, Mary; Li, Siqi; Matsubara, Joanne A.] Univ British Columbia, Fac Med, Eye Care Ctr, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
C3 University of British Columbia
RP Zhao, M (通讯作者)，Univ British Columbia, Fac Med, Eye Care Ctr, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
EM zhaomary@student.ubc.ca
FU Canadian Institutes of Health Research; Natural Science and Engineering
   Research Council; National Institutes of Health Research
FX Authors acknowledge funding from Canadian Institutes of Health Research,
   Natural Science and Engineering Research Council, and National
   Institutes of Health Research.
CR Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Carty M, 2019, IMMUNITY, V50, P1412, DOI 10.1016/j.immuni.2019.04.005
   Chaurasia SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21198-z
   Chen H, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00372-w
   Chen H, 2018, INVEST OPHTH VIS SCI, V59, P978, DOI 10.1167/iovs.17-22816
   Chen W, 2017, INFLAMM RES, V66, P157, DOI 10.1007/s00011-016-1002-6
   Cheng XY, 2020, BIOCHEM BIOPH RES CO, V522, P647, DOI 10.1016/j.bbrc.2019.11.141
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Dong LD, 2018, MOL MED REP, V17, P2289, DOI 10.3892/mmr.2017.8137
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Du JX, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108065
   Feenstra Derrick J, 2013, J Clin Exp Ophthalmol, V4, P298
   Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Gan JH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4510628
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gu CF, 2019, INVEST OPHTH VIS SCI, V60, P4215, DOI 10.1167/iovs.19-27825
   Hu ZZ, 2019, J CELL PHYSIOL, V234, P18849, DOI 10.1002/jcp.28523
   Jiang MX, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00349-0
   Jiang YD, 2019, J INFLAMM RES, V12, P153, DOI 10.2147/JIR.S210441
   Jiang YD, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/2860956
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16
   Kayagaki N, 2021, NATURE, V591, P131, DOI 10.1038/s41586-021-03218-7
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Krizaj D, 2014, CURR EYE RES, V39, P105, DOI 10.3109/02713683.2013.836541
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kuang SY, 2017, P NATL ACAD SCI USA, V114, P10642, DOI 10.1073/pnas.1708194114
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Levy M, 2015, CELL, V163, P1428, DOI 10.1016/j.cell.2015.10.048
   Li SQ, 2019, INVEST OPHTH VIS SCI, V60
   Liao Y, 2019, INVEST OPHTH VIS SCI, V60, P3034, DOI 10.1167/iovs.18-26360
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Liu ZH, 2019, IMMUNITY, V51, P43, DOI 10.1016/j.immuni.2019.04.017
   Loukovaara S, 2017, ACTA OPHTHALMOL, V95, P803, DOI 10.1111/aos.13427
   Lu WN, 2017, J NEUROCHEM, V141, P436, DOI 10.1111/jnc.13998
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nagata S, 2017, NAT REV IMMUNOL, V17, P333, DOI 10.1038/nri.2016.153
   Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818
   Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191
   Peng JJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107922
   Place DE, 2018, CURR OPIN IMMUNOL, V50, P32, DOI 10.1016/j.coi.2017.10.011
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Pronin A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00036
   Qi Y, 2014, INVEST OPHTH VIS SCI, V55, P5466, DOI 10.1167/iovs.14-14380
   Reme CE, 2000, NEWS PHYSIOL SCI, V15, P120, DOI 10.1152/physiologyonline.2000.15.3.120
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128
   Ruan JB, 2018, NATURE, V557, P62, DOI 10.1038/s41586-018-0058-6
   Sarhan J, 2018, P NATL ACAD SCI USA, V115, pE10888, DOI 10.1073/pnas.1809548115
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683
   Stokes L, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00258
   Sun HJ, 2020, PHARMACOLOGY, V105, P28, DOI 10.1159/000502614
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   von Herrmann KM, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0061-5
   Wan PX, 2020, CELL DEATH DIFFER, V27, P176, DOI 10.1038/s41418-019-0351-4
   Wang M, 2019, CANCERS, V11, DOI 10.3390/cancers11091313
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Weaver C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.13.27
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xi XT, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109924
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134658
   Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014
   Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Yu P, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00507-5
   Yu XY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108300
   Zha X, 2020, AGING-US, V12, P8137, DOI 10.18632/aging.103130
   Zhang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.308
   Zhang YJ, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107771
   Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9
   Zhen PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep20998
   Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548
NR 94
TC 0
Z9 0
U1 1
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JAN 3
PY 2022
VL 8
AR 802063
DI 10.3389/fmed.2021.802063
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YL1NM
UT WOS:000745665900001
PM 35047535
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hwang, PH
   Longstreth, WT
   Thielke, SM
   Francis, CE
   Carone, M
   Kuller, LH
   Fitzpatrick, AL
AF Hwang, Phillip H.
   Longstreth Jr, Will T.
   Thielke, Stephen M.
   Francis, Courtney E.
   Carone, Marco
   Kuller, Lewis H.
   Fitzpatrick, Annette L.
TI Ophthalmic conditions associated with dementia risk: The Cardiovascular
   Health Study
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Age&#8208; related macular degeneration; Alzheimer&apos; s disease;
   Cardiovascular Health Study; Cataracts; Dementia; Diabetic retinopathy;
   Epidemiology; Glaucoma
AB Introduction Ophthalmic conditions and dementia appear to overlap and may share common pathways, but research has not differentiated dementia subtypes.
   Methods Diagnoses of cataracts, age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma were based on medical histories and International Classification of Diseases, Ninth Revision (ICD-9) codes for 3375 participants from the Cardiovascular Health Study. Dementia, including Alzheimer's disease (AD) and vascular dementia (VaD), was classified using standardized research criteria.
   Results Cataracts were associated with AD (hazard ratio [HR] = 1.34; 95% confidence interval [CI] = 1.01-1.80) and VaD/mixed dementia (HR = 1.41; 95% CI = 1.02-1.95). AMD was associated with AD only (HR = 1.87; 95% CI = 1.13-3.09), whereas DR was associated with VaD/mixed dementia only (HR = 2.63; 95% CI = 1.10-6.27).
   Discussion Differential associations between specific ophthalmic conditions and dementia subtypes may elucidate pathophysiologic pathways. Lack of association between glaucoma and dementia was most surprising from these analyses.
C1 [Hwang, Phillip H.; Longstreth Jr, Will T.; Fitzpatrick, Annette L.] Univ Washington, Dept Epidemiol, 3980 15th Ave Northeast,Box 351619, Seattle, WA 98195 USA.
   [Longstreth Jr, Will T.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
   [Thielke, Stephen M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Thielke, Stephen M.] Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
   [Francis, Courtney E.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Carone, Marco] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Kuller, Lewis H.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Fitzpatrick, Annette L.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Fitzpatrick, Annette L.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of
   Washington; University of Washington Seattle; Geriatric Research
   Education & Clinical Center; University of Washington; University of
   Washington Seattle; University of Washington; University of Washington
   Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; University of Washington; University of
   Washington Seattle; University of Washington; University of Washington
   Seattle
RP Hwang, PH (通讯作者)，Univ Washington, Dept Epidemiol, 3980 15th Ave Northeast,Box 351619, Seattle, WA 98195 USA.
EM phillh@uw.edu
OI Francis, Courtney/0000-0001-6156-3585
FU National Heart, Lung, and Blood Institute [HHSN268201200036C,
   HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079,
   N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295,
   U01HL130114]; National Institute of Neurological Disorders and Stroke;
   National Institute on Aging [R01AG023629, R01AG15928]
FX National Heart, Lung, and Blood Institute, Grant/AwardNumbers:
   HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222,
   N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086,
   U01HL080295, U01HL130114; National Institute ofNeurological Disorders
   and Stroke; National Institute onAging, Grant/Award Numbers:
   R01AG023629, R01AG15928
CR Alber J, 2020, ALZHEIMERS DEMENT, V16, P229, DOI 10.1002/alz.12006
   [Anonymous], 2020, ALZHEIMERS DEMENT, V16, P391, DOI 10.1002/alz.12068
   APA, 1994, DIAGNOSTIC STAT MANU
   Baker ML, 2007, STROKE, V38, P2041, DOI 10.1161/STROKEAHA.107.483586
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   Biessels GJ, 2014, LANCET DIABETES ENDO, V2, P246, DOI 10.1016/S2213-8587(13)70088-3
   Cheung CY, 2019, CURR OPIN NEUROL, V32, P82, DOI 10.1097/WCO.0000000000000645
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473
   Chung SD, 2015, EYE, V29, P1340, DOI 10.1038/eye.2015.120
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Deal JA, 2019, ALZHEIMERS DEMENT, V15, P477, DOI 10.1016/j.jalz.2018.10.002
   Exalto LG, 2014, J ALZHEIMERS DIS, V42, pS109, DOI 10.3233/JAD-132570
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fitzpatrick AL, 2004, J AM GERIATR SOC, V52, P195, DOI 10.1111/j.1532-5415.2004.52058.x
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Helmer C, 2013, ANN NEUROL, V74, P171, DOI 10.1002/ana.23926
   Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6
   Jones-Odeh E, 2015, EYE, V29, P1270, DOI 10.1038/eye.2015.158
   Keenan TDL, 2015, BRIT J OPHTHALMOL, V99, P524, DOI 10.1136/bjophthalmol-2014-305863
   Kerbage C, 2015, AM J ALZHEIMERS DIS, V30, P738, DOI 10.1177/1533317513520214
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388
   Kuller LH, 2005, NEUROLOGY, V64, P1548, DOI 10.1212/01.WNL.0000160115.55756.DE
   Lee CS, 2019, J ALZHEIMERS DIS, V68, P647, DOI 10.3233/JAD-181087
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Lee MJ, 2019, J AM GERIATR SOC, V67, P1197, DOI 10.1111/jgs.15795
   Lim JKH, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00536
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lopez OL, 2003, NEUROEPIDEMIOLOGY, V22, P1, DOI 10.1159/000067110
   Lynch SK, 2017, VISION RES, V139, P101, DOI 10.1016/j.visres.2017.03.003
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Ou Y, 2012, OPHTHAL EPIDEMIOL, V19, P285, DOI 10.3109/09286586.2011.649228
   Pelletier AL, 2016, AM FAM PHYSICIAN, V94, P219
   Qiu C, 2010, NEUROLOGY, V75, P2221, DOI 10.1212/WNL.0b013e3182020349
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Schrijvers EMC, 2012, NEUROLOGY, V79, P365, DOI 10.1212/WNL.0b013e318260cd7e
   Shah TM, 2017, MOL PSYCHIATR, V22, P353, DOI 10.1038/mp.2016.251
   Singh AK, 2020, INDIAN J OPHTHALMOL, V68, P555, DOI 10.4103/ijo.IJO_999_19
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Smilnak GJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223199
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   van der Flier WM, 2005, J NEUROL NEUROSUR PS, V76, pV2, DOI 10.1136/jnnp.2005.082867
   van Wijngaarden P, 2017, CLIN EXP OPHTHALMOL, V45, P54, DOI 10.1111/ceo.12872
   White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067
   Williams MA, 2015, AM J GERIAT PSYCHIAT, V23, P1290, DOI 10.1016/j.jagp.2015.06.005
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
NR 50
TC 5
Z9 5
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD SEP
PY 2021
VL 17
IS 9
BP 1442
EP 1451
DI 10.1002/alz.12313
EA MAR 2021
PG 10
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA UW9YM
UT WOS:000636434200001
PM 33788406
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nita, M
   Grzybowski, A
AF Nita, Malgorzata
   Grzybowski, Andrzej
TI The Role of the Reactive Oxygen Species and Oxidative Stress in the
   Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies
   of the Anterior and Posterior Eye Segments in Adults
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID HUMAN TRABECULAR MESHWORK; MITOCHONDRIAL-DNA DAMAGE; ENDOTHELIAL
   CORNEAL-DYSTROPHY; LIPID-PEROXIDATION PRODUCTS; RETINAL-PIGMENT
   EPITHELIUM; CHOROIDAL BLOOD-FLOW; LIGHT-INDUCED DAMAGE; OPEN-ANGLE
   GLAUCOMA; OPTIC-NERVE; MACULAR DEGENERATION
AB The reactive oxygen species (ROS) form under normal physiological conditions and may have both beneficial and harmful role. We search the literature and current knowledge in the aspect of ROS participation in the pathogenesis of anterior and posterior eye segment diseases in adults. ROS take part in the pathogenesis of keratoconus, Fuchs endothelial corneal dystrophy, and granular corneal dystrophy type 2, stimulating apoptosis of corneal cells. ROS play a role in the pathogenesis of glaucoma stimulating apoptotic and inflammatory pathways on the level of the trabecular meshwork and promoting retinal ganglion cells apoptosis and glial dysfunction in the posterior eye segment. ROS play a role in the pathogenesis of Leber's hereditary optic neuropathy and traumatic optic neuropathy. ROS induce apoptosis of human lens epithelial cells. ROS promote apoptosis of vascular and neuronal cells and stimulate inflammation and pathological angiogenesis in the course of diabetic retinopathy. ROS are associated with the pathophysiological parainflammation and autophagy process in the course of the age-related macular degeneration.
C1 [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed, Ulica Bohaterow Monte Cassino 3, PL-40231 Katowice, Poland.
   [Grzybowski, Andrzej] Poznan City Hosp, Dept Ophthalmol, Ulica Szwajcarska 3, PL-61285 Poznan, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Fac Med, Chair Ophthalmol, Ulica Zolnierska 14 C, PL-10719 Olsztyn, Poland.
C3 University of Warmia & Mazury
RP Grzybowski, A (通讯作者)，Poznan City Hosp, Dept Ophthalmol, Ulica Szwajcarska 3, PL-61285 Poznan, Poland.; Grzybowski, A (通讯作者)，Univ Warmia & Mazury, Fac Med, Chair Ophthalmol, Ulica Zolnierska 14 C, PL-10719 Olsztyn, Poland.
EM ae.grzybowski@gmail.com
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391
CR Abu-Amero KK, 2014, INVEST OPHTH VIS SCI, V55, P2827, DOI 10.1167/iovs.14-14300
   Ahmad S, 2014, J NEUROIMMUNOL, V277, P96, DOI 10.1016/j.jneuroim.2014.10.006
   Ahmad S, 2013, J NEUROIMMUNOL, V264, P54, DOI 10.1016/j.jneuroim.2013.09.015
   ALVARADO J, 1984, OPHTHALMOLOGY, V91, P564
   Alvarado JA, 2005, BRIT J OPHTHALMOL, V89, P1500, DOI 10.1136/bjo.2005.081307
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   ARAIE M, 1988, INVEST OPHTH VIS SCI, V29, P1884
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Arnal E, 2011, INVEST OPHTH VIS SCI, V52, P8592, DOI 10.1167/iovs.11-7732
   ARSTILA AU, 1972, SCIENCE, V175, P530, DOI 10.1126/science.175.4021.530
   Aslan M, 2008, FREE RADICAL BIO MED, V45, P367, DOI 10.1016/j.freeradbiomed.2008.04.026
   Atilano SR, 2005, INVEST OPHTH VIS SCI, V46, P1256, DOI 10.1167/iovs.04-1395
   Augustin A, 2010, DEV OPHTHALMOL, V47, P10, DOI 10.1159/000320071
   Azizi B, 2011, INVEST OPHTH VIS SCI, V52, P9291, DOI 10.1167/iovs.11-8312
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P124, DOI 10.1016/0005-2760(89)90222-1
   Babizhayev MA, 2011, CELL BIOCHEM FUNCT, V29, P183, DOI 10.1002/cbf.1737
   Bantseev V, 2003, TOXICOL SCI, V73, P98, DOI 10.1093/toxsci/kfg060
   Bek T, 2009, ACTA OPHTHALMOL, V87, P362, DOI 10.1111/j.1755-3768.2008.01429.x
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Berlau J, 2002, J CATARACT REFR SURG, V28, P611, DOI 10.1016/S0886-3350(01)01227-5
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Brancato R, 2002, J REFRACT SURG, V18, P135
   Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   Brown DJ, 2004, MOL VIS, V10, P281
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Bryan N, 2012, EUR CELLS MATER, V24, P249, DOI 10.22203/eCM.v024a18
   Buddi R, 2002, J HISTOCHEM CYTOCHEM, V50, P341, DOI 10.1177/002215540205000306
   Burdon KP, 2013, CLIN EXP OPTOM, V96, P146, DOI 10.1111/cxo.12024
   Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6
   Chandler HL, 2010, INVEST OPHTH VIS SCI, V51, P172, DOI 10.1167/iovs.09-3996
   Chilelli NC, 2013, NUTR METAB CARDIOVAS, V23, P913, DOI 10.1016/j.numecd.2013.04.004
   Choi SI, 2011, J PINEAL RES, V51, P94, DOI 10.1111/j.1600-079X.2011.00866.x
   Choi SI, 2009, AM J PATHOL, V175, P248, DOI 10.2353/ajpath.2009.081001
   Chwa M, 2008, INVEST OPHTH VIS SCI, V49, P4361, DOI 10.1167/iovs.08-1969
   Chwa M, 2006, INVEST OPHTH VIS SCI, V47, P1902, DOI 10.1167/iovs.05-0828
   Colin J, 2003, J CATARACT REFR SURG, V29, P379, DOI 10.1016/S0886-3350(02)01968-5
   Cristina Kenney M, 2003, Cont Lens Anterior Eye, V26, P139
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Dahl BJ, 2012, OPTOMETRY, V83, P33, DOI 10.1016/j.optm.2011.09.011
   Davies MJ, 2001, J PHOTOCH PHOTOBIO B, V63, P114, DOI 10.1016/S1011-1344(01)00208-1
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Delcourt C, 2000, ARCH OPHTHALMOL-CHIC, V118, P385, DOI 10.1001/archopht.118.3.385
   Doig RLO, 2014, EXP NEUROL, V261, P136, DOI 10.1016/j.expneurol.2014.06.007
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127
   Duran-Jimenez B, 2009, DIABETES, V58, P2893, DOI 10.2337/db09-0320
   Edwards M, 2001, CLIN EXP OPHTHALMOL, V29, P345, DOI 10.1046/j.1442-9071.2001.d01-16.x
   Elhalis H, 2010, OCUL SURF, V8, P173, DOI 10.1016/S1542-0124(12)70232-X
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Feng JY, 2014, OPHTHALMIC RES, V52, P224, DOI 10.1159/000363387
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026
   Flammer J, 2001, PROG RETIN EYE RES, V20, P319, DOI 10.1016/S1350-9462(00)00028-8
   Fletcher EL, 2007, CURR PHARM DESIGN, V13, P2699, DOI 10.2174/138161207781662920
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Genuth S, 2005, DIABETES, V54, P3103, DOI 10.2337/diabetes.54.11.3103
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gorin Y, 2013, FREE RADICAL BIO MED, V61, P130, DOI 10.1016/j.freeradbiomed.2013.03.014
   Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920
   Gredilla Ricardo, 2010, J Aging Res, V2011, P257093, DOI 10.4061/2011/257093
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guillot-Sestier MV, 2009, J BIOL CHEM, V284, P35973, DOI 10.1074/jbc.M109.051086
   Gupta N, 2006, BRIT J OPHTHALMOL, V90, P674, DOI 10.1136/bjo.2005.086769
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hao XD, 2015, EXP EYE RES, V132, P59, DOI 10.1016/j.exer.2015.01.016
   He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2
   He Y, 2011, J OCUL BIOL DIS INFO, V3, P92
   Hoegger MJ, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-4
   Hogg P, 2000, INVEST OPHTH VIS SCI, V41, P1091
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Huang L, 2008, CURR EYE RES, V33, P575, DOI 10.1080/02713680802167554
   Huang ZT, 2008, FREE RADICAL BIO MED, V44, P1935, DOI 10.1016/j.freeradbiomed.2008.02.016
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Ihnat MA, 2007, DIABETOLOGIA, V50, P1523, DOI 10.1007/s00125-007-0684-2
   Izzotti A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014567
   Izzotti A, 2010, ARCH OPHTHALMOL-CHIC, V128, P724, DOI 10.1001/archophthalmol.2010.87
   Izzotti A, 2009, INVEST OPHTH VIS SCI, V50, P5251, DOI 10.1167/iovs.09-3871
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   JOSE J G, 1977, Experimental Eye Research, V24, P113, DOI 10.1016/0014-4835(77)90252-4
   Joyce NC, 2012, EXP EYE RES, V95, P16, DOI 10.1016/j.exer.2011.08.014
   Jurkunas UV, 2008, INVEST OPHTH VIS SCI, V49, P2956, DOI 10.1167/iovs.07-1529
   Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   KAHN MG, 1983, INVEST OPHTH VIS SCI, V24, P1283
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kernt M, 2010, ACTA OPHTHALMOL, V88, pe78, DOI 10.1111/j.1755-3768.2010.01875.x
   Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010
   Kim JI, 2001, ANN NY ACAD SCI, V928, P182, DOI 10.1111/j.1749-6632.2001.tb05648.x
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Korvatska E, 2000, J BIOL CHEM, V275, P11465, DOI 10.1074/jbc.275.15.11465
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Lappas M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/597514
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200
   Li GR, 2007, MOL VIS, V13, P2282
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169
   Lieven CJ, 2006, INVEST OPHTH VIS SCI, V47, P1477, DOI 10.1167/iovs.05-0921
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Linsenmayer TF, 2005, PROG RETIN EYE RES, V24, P139, DOI 10.1016/j.preteyeres.2004.08.004
   Liton P, 2006, MOL VIS, V12, P774
   Liton PB, 2005, BIOCHEM BIOPH RES CO, V337, P1229, DOI 10.1016/j.bbrc.2005.09.182
   Liu R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/902842
   Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400
   Maatta M, 2006, CORNEA, V25, P341
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   MANN RM, 1995, INVEST OPHTH VIS SCI, V36, P925
   Marchitti SA, 2011, EYE CONTACT LENS, V37, P206, DOI 10.1097/ICL.0b013e3182212642
   Matthaei M, 2014, EXP EYE RES, V129, P13, DOI 10.1016/j.exer.2014.10.011
   McElnea EM, 2011, MOL VIS, V17, P1182
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Mochizuki H, 2012, INVEST OPHTH VIS SCI, V53, P1734, DOI 10.1167/iovs.12-7938
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Mozaffarieh M, 2008, MOL VIS, V14, P224
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367
   Nakamura S, 2007, INVEST OPHTH VIS SCI, V48, P1552, DOI 10.1167/iovs.06-1027
   NATHANSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1774
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nolan CJ, 2011, LANCET, V378, P169, DOI 10.1016/S0140-6736(11)60614-4
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olofsson EM, 2007, MOL VIS, V13, P1285
   Onyango IG, 2008, NEUROCHEM RES, V33, P589, DOI 10.1007/s11064-007-9482-y
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Ozawa Y, 2011, EXP DIABETES RES, DOI 10.1155/2011/108328
   Pande J, 2002, EXP EYE RES, V75, P359, DOI 10.1006/exer.2002.2038
   PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S
   Piarulli F, 2009, DIABETOLOGIA, V52, P1419, DOI 10.1007/s00125-009-1367-y
   Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quinlan CL, 2014, J BIOL CHEM, V289, P8312, DOI 10.1074/jbc.M113.545301
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29
   Sacca SC, 2008, PROG BRAIN RES, V173, P385, DOI 10.1016/S0079-6123(08)01127-8
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   Sacca SC, 2014, CELL MOL LIFE SCI, V71, P2197, DOI 10.1007/s00018-013-1493-z
   Saee-Rad S, 2011, MOL VIS, V17, P3128
   Samanta A, 2014, BRIT J OPHTHALMOL, V98, P1266, DOI 10.1136/bjophthalmol-2013-304438
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Santos JM, 2012, FREE RADICAL BIO MED, V53, P1729, DOI 10.1016/j.freeradbiomed.2012.08.588
   Santos JM, 2011, FREE RADICAL BIO MED, V51, P1849, DOI 10.1016/j.freeradbiomed.2011.08.017
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Schafer M, 2008, PHARMACOL RES, V58, P165, DOI 10.1016/j.phrs.2008.06.004
   Schmedt T, 2012, EXP EYE RES, V95, P24, DOI 10.1016/j.exer.2011.08.002
   Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2
   Schoeler S, 2007, NEUROBIOL DIS, V25, P536, DOI 10.1016/j.nbd.2006.10.014
   Sherwin T, 2004, CLIN EXP OPHTHALMOL, V32, P211, DOI 10.1111/j.1442-9071.2004.00805.x
   Shin AH, 2006, ARCH PHARM RES, V29, P577, DOI 10.1007/BF02969268
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   SIES H, 1995, AM J CLIN NUTR, V62, P1315
   SMITH VA, 1995, EYE, V9, P429, DOI 10.1038/eye.1995.100
   Sorkhabi R, 2011, MOL VIS, V17, P41
   Sorte K, 2011, MOL VIS, V17, P1
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stabuc-Silih M, 2010, ACTA DERMATOVEN ALP, V19, P3
   Stabuc-Silih M, 2009, MOL VIS, V15, P2848
   Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142
   Steinsapir KD, 2011, AM J OPHTHALMOL, V151, P928, DOI 10.1016/j.ajo.2011.02.007
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Suh MH, 2008, CORNEA, V27, P916, DOI 10.1097/ICO.0b013e31816f7068
   Swanson KI, 2005, INVEST OPHTH VIS SCI, V46, P3737, DOI 10.1167/iovs.05-0155
   Taarnhoj NCBB, 2005, INVEST OPHTH VIS SCI, V46, P3850, DOI 10.1167/iovs.05-0177
   Tabner BJ, 2005, BIOCHEM SOC T, V33, P1082, DOI 10.1042/BST0331082
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tewari S, 2012, ANTIOXID REDOX SIGN, V17, P492, DOI 10.1089/ars.2011.4333
   Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P705, DOI 10.1167/iovs.06-0810
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Varma SD, 2011, EYE CONTACT LENS, V37, P233, DOI 10.1097/ICL.0b013e31821ec4f2
   Wang H, 2011, EYE BRAIN, V3, P19, DOI 10.2147/EB.S24951
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Yao K, 2008, MOL VIS, V14, P217
   Yildirim Z, 2009, BIOL TRACE ELEM RES, V128, P135, DOI 10.1007/s12011-008-8258-9
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeitz O, 2006, BRIT J OPHTHALMOL, V90, P1245, DOI 10.1136/bjo.2006.093633
   Zeitz O, 2007, GRAEF ARCH CLIN EXP, V245, P1327, DOI 10.1007/s00417-006-0526-9
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang Y, 2011, MOL VIS, V17, P2325
   Zheng L., 2006, FRONTIERS BIOSCIENCE, V14, P3974
   Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041
   Zhong Q, 2011, INVEST OPHTH VIS SCI, V52, P8739, DOI 10.1167/iovs.11-8045
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
   Ziaei A, 2013, INVEST OPHTH VIS SCI, V54, P6724, DOI 10.1167/iovs.13-12699
NR 219
TC 574
Z9 592
U1 7
U2 32
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
VL 2016
AR 3164734
DI 10.1155/2016/3164734
PG 23
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DI4DL
UT WOS:000373450400001
OA gold, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Uddin, MI
   Evans, SM
   Craft, JR
   Marnet, LJ
   Uddin, MJ
   Jayagopal, A
AF Uddin, Md Imam
   Evans, Stephanie M.
   Craft, Jason R.
   Marnet, Lawrence J.
   Uddin, Md Jashim
   Jayagopal, Ashwath
TI Applications of Azo-Based Probes for Imaging Retinal Hypoxia
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Hypoxia; imaging agents; retina; retinal imaging; retinal hypoxia;
   molecular imaging
ID INDUCED CHOROIDAL NEOVASCULARIZATION; OXYGEN-INDUCED RETINOPATHY;
   FLUORESCENCE PROBE; TUMOR HYPOXIA; CELL-LINE; VEGF; EXPRESSION;
   OXIMETRY; MOUSE; MODEL
AB We report the design and synthesis of an activatable molecular imaging probe to detect hypoxia in mouse models of retinal vascular diseases. Hypoxia of the retina has been associated with the initiation and progression of blinding retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity. In vivo retinal imaging of hypoxia may be useful for early detection and timely treatment of retinal diseases. To achieve this goal, we synthesized HYPOX-3, a near-infrared (NIR) imaging agent coupled to a dark quencher, Black Hole Quencher 3 (BHQ3), which has been previously reported to contain a hypoxia-sensitive cleavable azo-bond. HYPOX-3 was cleaved in hypoxic retinal cell culture and animal models, enabling detection of hypoxia with high signal-to-noise ratios without acute toxicity. HYPOX-3 fluorescences in hypoxic cells and tissues and was undetectable under normoxia. These imaging agents are promising candidates for imaging retinal hypoxia in preclinical disease models and patients.
C1 [Uddin, Md Imam; Evans, Stephanie M.; Craft, Jason R.; Jayagopal, Ashwath] Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   [Jayagopal, Ashwath] Vanderbilt Univ, Sch Med, Mol Physiol & Biophys, Nashville, TN 37232 USA.
   [Marnet, Lawrence J.; Uddin, Md Jashim] Vanderbilt Univ, Dept Biochem Chem & Pharmacol, AB Hancock Jr Mem Lab Canc Res, Vanderbilt Inst Chem Biol,Ctr Mol Toxicol,Sch Med, Nashville, TN 37232 USA.
   [Marnet, Lawrence J.; Uddin, Md Jashim] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University
RP Jayagopal, A (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
EM jashim.uddin@vanderbilt.edu; ash.jayagopal@vanderbilt.edu
OI Uddin, Dr. Md. Jashim/0000-0002-3243-3455; Uddin, Md.
   Jashim/0000-0003-0020-4866; Uddin, MD Imam/0000-0001-5611-9666
FU National Institutes of Health [R01EY23397, P30EY008126, U24DK059637,
   CA128323]; American Diabetes Association; Research to Prevent Blindness
FX This work was supported by the National Institutes of Health (R01EY23397
   (to A.J.), P30EY008126, U24DK059637, CA128323 (to M.J.U.), the American
   Diabetes Association (to A.J.), and Research to Prevent Blindness (Dolly
   Green Special Scholar Award (to A.J.) and Unrestricted Grant to
   Vanderbilt Eye Institute).
CR Busk M, 2013, ACTA ONCOL, V52, P1300, DOI 10.3109/0284186X.2013.815797
   Dai CX, 2013, INVEST OPHTH VIS SCI, V54, P7998, DOI 10.1167/iovs.13-12318
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Evans SM, 2014, BIOCONJUGATE CHEM, V25, P2030, DOI 10.1021/bc500400z
   Genetos DC, 2010, J MOL NEUROSCI, V40, P360, DOI 10.1007/s12031-009-9326-0
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kiyose K, 2010, J AM CHEM SOC, V132, P15846, DOI 10.1021/ja105937q
   Kizaka-Kondoh S, 2009, CANCER SCI, V100, P1366, DOI 10.1111/j.1349-7006.2009.01195.x
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Li SY, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/426769
   Linder KE, 2011, BIOCONJUGATE CHEM, V22, P1287, DOI 10.1021/bc100457s
   Lu HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087530
   Mowat FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011103
   Myochin T, 2012, J AM CHEM SOC, V134, P13730, DOI 10.1021/ja303931b
   Piao W, 2013, ANGEW CHEM INT EDIT, V52, P13028, DOI 10.1002/anie.201305784
   Ross D, 1996, BRIT J CANCER, V74, pS1
   Scott A, 2010, EYE, V24, P416, DOI 10.1038/eye.2009.306
   Seigel GM, 1997, IN VITRO CELL DEV-AN, V33, P499
   Shahidi M, 2006, CURR EYE RES, V31, P357, DOI 10.1080/02713680600599446
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Takahashi S, 2012, J AM CHEM SOC, V134, P19588, DOI 10.1021/ja310049d
   Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Yang Y, 2012, DIABETIC MED, V29, P501, DOI 10.1111/j.1464-5491.2011.03440.x
   Yanni SE, 2010, EXP EYE RES, V91, P34, DOI 10.1016/j.exer.2010.03.019
   Zhang P, 2011, INT J OPHTHALMOL-CHI, V4, P14, DOI 10.3980/j.issn.2222-3959.2011.01.03
NR 28
TC 54
Z9 56
U1 2
U2 98
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD APR
PY 2015
VL 6
IS 4
BP 445
EP 449
DI 10.1021/ml5005206
PG 5
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA CG2IO
UT WOS:000353098300015
PM 25893047
OA Green Published
DA 2022-11-30
ER

PT J
AU Tolppanen, AM
   Kolehmainen, M
   Pulkkinen, L
   Uusitupa, M
AF Tolppanen, Anna-Maija
   Kolehmainen, Marjukka
   Pulkkinen, Leena
   Uusitupa, Matti
TI Tenomodulin gene and obesity-related phenotypes
SO ANNALS OF MEDICINE
LA English
DT Review
DE Adipose tissue; angiogenesis; obesity; tenomodulin
ID ENDOPLASMIC-RETICULUM STRESS; AGE-RELATED MACULOPATHY; ADIPOSE-TISSUE;
   CHONDROMODULIN-I; MOLECULAR-CLONING; MODULATES ADIPOGENESIS;
   ANGIOGENESIS INHIBITOR; MACULAR DEGENERATION; DIABETES PREVENTION;
   INSULIN-RESISTANCE
AB Different cells of adipose tissue secrete compounds which regulate various biological processes. Changes in body weight, body composition, and amount of fat mass can alter the secretory profile and function of adipose tissue. Comparison of adipose tissue mRNA expression profiles before versus after weight loss or between obese and lean subjects has promoted the identification of novel adipokines. Weight loss decreases the expression of the tenomodulin (TNMD) mRNA in the adipose tissue, and the expression level is strongly correlated with body mass index. TNMD (locus Xq22) is expressed in both adipocyte and stromal vascular fraction of adipose tissue. Tenomodulin inhibits angiogenesis, but its specific function in adipose tissue is still unknown. We have reported modest association between TNMD sequence variation and different obesity-related phenotypes, including anthropometric measurements, inflammation, glucose and lipid metabolism, and age-related macular degeneration. In this review, the potential mechanisms that could link TNMD with the pathogenesis of obesity and related disorders are discussed.
C1 [Tolppanen, Anna-Maija] Univ Eastern Finland, Dept Clin Nutr, FIN-70211 Kuopio, Finland.
   Univ Eastern Finland, Food & Hlth Res Ctr, Inst Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland
RP Tolppanen, AM (通讯作者)，Univ Eastern Finland, Dept Clin Nutr, POB 1627, FIN-70211 Kuopio, Finland.
EM am.tolppanen@bristol.ac.uk
RI Uusitupa, Matti Ilmari Julius/AAX-4929-2020
FU MRC [G0600705] Funding Source: UKRI; Medical Research Council [G0600705]
   Funding Source: Medline
CR Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34
   Boden G, 2008, DIABETES, V57, P2438, DOI 10.2337/db08-0604
   Bouloumie A, 2002, ANN ENDOCRINOL-PARIS, V63, P91
   Brakenhielm E, 2004, CIRC RES, V94, P1579, DOI 10.1161/01.RES.0000132745.76882.70
   Brandau O, 2001, DEV DYNAM, V221, P72, DOI 10.1002/dvdy.1126
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798
   Cao Y, 2007, J CLIN INVEST, V117, P2362, DOI 10.1172/JCI32239
   Comuzzie AG, 2001, J MOL MED, V79, P57, DOI 10.1007/s001090100202
   CRANDALL DL, 1986, AM J PHYSIOL, V251, pR314, DOI 10.1152/ajpregu.1986.251.2.R314
   Cros N, 2001, J CELL BIOCHEM, V83, P508, DOI 10.1002/jcb.1248
   Dahlman I, 2005, AM J CLIN NUTR, V81, P1275
   Das SK, 2008, AM J PHYSIOL-ENDOC M, V295, pE393, DOI 10.1152/ajpendo.90355.2008
   Docheva D, 2005, MOL CELL BIOL, V25, P699, DOI 10.1128/MCB.25.2.699-705.2005
   Eriksson J, 1999, DIABETOLOGIA, V42, P793, DOI 10.1007/s001250051229
   Feldman BJ, 2006, P NATL ACAD SCI USA, V103, P15675, DOI 10.1073/pnas.0607501103
   Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391
   Haque WA, 2002, J CLIN ENDOCR METAB, V87, P2395, DOI 10.1210/jc.87.5.2395
   HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5
   Hiraki Y, 2005, CONNECT TISSUE RES, V46, P44, DOI 10.1080/03008200590935547
   Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910
   Kampf C, 2005, DIABETES, V54, P2620, DOI 10.2337/diabetes.54.9.2620
   Kimura N, 2008, CIRCULATION, V118, P1737, DOI 10.1161/CIRCULATIONAHA.108.780031
   Kloting N, 2006, BIOCHEM BIOPH RES CO, V339, P430, DOI 10.1016/j.bbrc.2005.11.039
   Kolehmainen M, 2008, INT J OBESITY, V32, P292, DOI 10.1038/sj.ijo.0803718
   Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048
   Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780
   Ledoux S, 2008, DIABETES, V57, P3247, DOI 10.2337/db07-1812
   Lin J, 2002, BIOCHEM BIOPH RES CO, V291, P701, DOI 10.1006/bbrc.2002.6500
   Manley PN, 2006, MED HYPOTHESES, V66, P784, DOI 10.1016/j.mehy.2005.10.018
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562
   Mendias CL, 2008, P NATL ACAD SCI USA, V105, P388, DOI 10.1073/pnas.0707069105
   Meyer EP, 2008, P NATL ACAD SCI USA, V105, P3587, DOI 10.1073/pnas.0709788105
   Milan G, 2004, J CLIN ENDOCR METAB, V89, P2724, DOI 10.1210/jc.2003-032047
   Mulugeta S, 2005, AM J RESP CELL MOL, V32, P521, DOI 10.1165/rcmb.2005-0009OC
   Oshima Y, 2004, J CELL SCI, V117, P2731, DOI 10.1242/jcs.01112
   Oshima Y, 2003, INVEST OPHTH VIS SCI, V44, P1814, DOI 10.1167/iovs.02-0664
   Ozawa K, 2001, CANCER RES, V61, P4206
   Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61
   Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003
   Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799
   Saiki A, 2009, J CLIN ENDOCR METAB, V94, P3987, DOI 10.1210/jc.2009-0292
   Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P329, DOI 10.1016/S0968-0004(02)02134-5
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   Schweitzer R, 2001, DEVELOPMENT, V128, P3855
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shukunami C, 2005, BIOCHEM BIOPH RES CO, V333, P299, DOI 10.1016/j.bbrc.2005.05.133
   Shukunami C, 2001, BIOCHEM BIOPH RES CO, V280, P1323, DOI 10.1006/bbrc.2001.4271
   Shukunami C, 2007, CURR PHARM DESIGN, V13, P2101
   Shukunami C, 2006, DEV BIOL, V298, P234, DOI 10.1016/j.ydbio.2006.06.036
   SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4
   Smith U, 2002, INT J OBESITY, V26, P897, DOI 10.1038/sj.ijo.0802028
   Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199
   Thirumangalakudi L, 2006, J ALZHEIMERS DIS, V10, P111
   Tolppanen AM, 2008, INT J OBESITY, V32, P1868, DOI 10.1038/ijo.2008.217
   TOLPPANEN AM, 2009, NEUROBIOL AGING 0611
   Tolppanen AM, 2008, GENET MED, V10, P536, DOI [10.1097/GIM.0b013e3181772129, 10.1097GIM.0b013e3181772129]
   Tolppanen AM, 2007, OBESITY, V15, P1082, DOI 10.1038/oby.2007.613
   Tolppanen AM, 2009, MOL VIS, V15, P762
   Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Varma V, 2008, DIABETES, V57, P432, DOI 10.2337/db07-0840
   Voros G, 2005, ENDOCRINOLOGY, V146, P4545, DOI 10.1210/en.2005-0532
   Wang J, 2007, DIABETOLOGIA, V50, P1192, DOI 10.1007/s00125-007-0656-6
   Wang P, 2008, J CELL PHYSIOL, V216, P3, DOI 10.1002/jcp.21386
   Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379
   Yamana K, 2001, BIOCHEM BIOPH RES CO, V280, P1101, DOI 10.1006/bbrc.2000.4245
NR 75
TC 9
Z9 9
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PD MAY
PY 2010
VL 42
IS 4
BP 265
EP 275
DI 10.3109/07853891003801123
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 611IP
UT WOS:000278809100003
PM 20429799
DA 2022-11-30
ER

PT J
AU Ribatti, D
AF Ribatti, Domenico
TI Napoleone Ferrara and the saga of vascular endothelial growth factor
SO ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH
LA English
DT Review
DE angiogenesis; history of medicine; tumor growth; vascular endothelial
   growth factor/vascular permeability factor
ID GLAND-DERIVED VEGF; PERMEABILITY FACTOR; MONOCLONAL-ANTIBODY; COMPLETE
   INHIBITION; RANDOMIZED-TRIAL; CELLS SECRETE; TUMOR-GROWTH; IN-VIVO;
   ANGIOGENESIS; RECEPTOR
AB Napoleone Ferrara and his colleagues at Genentech were the first to isolate and clone vascular endothelial growth factor (VEGF) in 1989. His laboratory has investigated many aspects of VEGF biochemistry and molecular biology. In 1993, Ferrara reported that inhibition of VEGF-induced angiogenesis by specific monoclonal antibodies resulted in dramatic suppression of the growth of a variety of tumors in vivo. These findings provided an important evidence that inhibition of angiogenesis may suppress tumor growth and blocking VEGF action could have therapeutic value for a variety of malignancies and validate the notion introduced in 1971 by Judah Folkman that inhibition of tumor angiogenesis might be a valid approach to control tumor growth. A further development was the design in a rational fashion in 1997 of a humanized anti-VEGF monoclonal antibody (Avastin), now in clinical trials as a treatment for several solid tumors and also outside of cancer, for example, in the treatment of age-related macular degeneration.
C1 Univ Bari, Dept Human Anat & Histol, Sch Med, I-70124 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro
RP Ribatti, D (通讯作者)，Univ Bari, Dept Human Anat & Histol, Sch Med, Piazza Giulio Cesare 11, I-70124 Bari, Italy.
EM ribatti@anitomia.uniba.it
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Bogaert E, 2006, MUSCLE NERVE, V34, P391, DOI 10.1002/mus.20609
   Borgstrom P, 1998, PROSTATE, V35, P1
   Borgstrom P, 1999, ANTICANCER RES, V19, P4203
   Borgstrom P, 1996, CANCER RES, V56, P4032
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661
   COLLINS PD, 1993, BRIT J PHARMACOL, V109, P195, DOI 10.1111/j.1476-5381.1993.tb13553.x
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DVORAK HF, 1979, J IMMUNOL, V122, P166
   DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 2003, AM J PATHOL, V162, P1881, DOI 10.1016/S0002-9440(10)64322-2
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FERRARA N, 1987, AM J PHYSIOL, V252, pE304, DOI 10.1152/ajpendo.1987.252.3.E304
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerhardt H, 2004, DEV DYNAM, V231, P503, DOI 10.1002/dvdy.20148
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481
   HORWITZ H, 2006, SEMINARS ONCOLOGY, V33, pS26
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kukk E, 1996, DEVELOPMENT, V122, P3829
   Lambrechts D, 2006, BBA-MOL BASIS DIS, V1762, P1109, DOI 10.1016/j.bbadis.2006.04.005
   Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   LeCouter J, 2002, NAT MED, V8, P913, DOI 10.1038/nm0902-913
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851
   Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6
   Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363
   NAGY JA, 1995, CANCER RES, V55, P360
   Nico B, 2008, MICROVASC RES, V75, P135, DOI 10.1016/j.mvr.2007.07.004
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965
   Presta LG, 1997, CANCER RES, V57, P4593
   Raab S, 2007, ACTA NEUROPATHOL, V113, P607, DOI 10.1007/s00401-007-0228-3
   RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SENGER DR, 1990, CANCER RES, V50, P1774
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857
   Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
NR 56
TC 10
Z9 10
U1 0
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1062-3329
EI 1029-2373
J9 ENDOTHELIUM-J ENDOTH
JI Endothelium
PD JAN-APR
PY 2008
VL 15
IS 1-2
BP 1
EP 8
DI 10.1080/10623320802092377
PG 8
WC Cell Biology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Cardiovascular System & Cardiology
GA 313VN
UT WOS:000256768200001
PM 18568940
DA 2022-11-30
ER

PT J
AU Hunt, S
AF Hunt, S.
TI Increased dietary intake of omega-3-PUFA reduces pathological retinal
   angiogenesis
SO OPHTHALMOLOGE
LA English
DT Article
DE dietary supplement; omega-3-polyunsaturated fatty acids; retinal
   neovascularization; retinopathy of prematurity; age-related macular
   degeneration
AB According to a recent publication in Nature Medicine [1] an increased dietary intake of omega-3-polyunsaturated fatty acids (PUFA) may protect against the development and progression of retinal neovascularization. The study conducted by L. Smith et al. of the Children's Hospital Boston attracts world-wide attention. In a mouse model of oxygen-induced retinopathy the researchers were able to demonstrate that neonatal mice kept on a "Japanese diet" (i.e. rich in omega-3-PUFA) developed about 50% less retinal neovascularization as compared to mice kept on a "Western diet" (rich in omega-6-PUFA). The results are now being followed-up by a clinical study [2] with the aim to investigate whether prematurely born infants with a high risk of developing ROP may benefit from a diet supplemented with omega-3-PUFA. In addition, the AREDS2-Study which commenced in October 2006 is examining the role of omega-3-PUFA in the development and progression of age-related macular degeneration [3].
C1 Univ Augen Klin, D-53127 Bonn, Germany.
C3 University of Bonn
RP Hunt, S (通讯作者)，Univ Augen Klin, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Suzan.Hunt@ukb.uni-bonn.de
CR Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
NR 1
TC 10
Z9 11
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0941-293X
J9 OPHTHALMOLOGE
JI Ophthalmologe
PD AUG
PY 2007
VL 104
IS 8
BP 727
EP 729
DI 10.1007/s00347-007-1607-9
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 203LE
UT WOS:000248975300014
PM 17674004
DA 2022-11-30
ER

PT J
AU Ho, QT
   Kuo, CJ
AF Ho, Quoc T.
   Kuo, Calvin J.
TI Vascular endothelial growth factor: Biology and therapeutic applications
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE VEGF; bevacizumab; angiogenesis; sunitinib; sorafenib; pegaptinib;
   ranibizumab; anti-angiogenic therapy
ID TYROSINE KINASE; FACTOR VEGF; TUMOR-CELLS; FACTOR EXPRESSION;
   ANGIOGENESIS; RECEPTORS; BEVACIZUMAB; CANCER; RANIBIZUMAB; SURVIVAL
AB While the development of anti-angiogenic therapy, as it pertains to cancer treatment, may still be in its infancy relative to well-established modalities such as chemotherapy, radiation, and surgery, major strides made in the past several decades have allowed translation of basic science discoveries in this field into clinical reality. The discovery of key molecular modulators of angiogenesis, notably vascular endothelial growth factor (VEGF), has catalyzed the development of numerous neutralizing therapeutic agents. The validity of VEGF inhibition as a therapeutic strategy has been well supported in randomized clinical trials, as well as U.S. Food and Drug Administration approval of the VEGF antagonists bevacizumab, sunitinib malate, sorafenib, pegaptinib and ranibizumab. Accordingly, this review will (1) briefly review the basic molecular biology of VEGF and (2) summarize recent progress in targeting the VEGF molecular pathway as therapy for angiogenic diseases such as cancer and age-related macular degeneration. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA.
C3 Stanford University
RP Kuo, CJ (通讯作者)，Stanford Univ, Sch Med, Div Hematol, 269 Campus Dr,CCSR 1155, Stanford, CA 94305 USA.
EM cjkuo@stanford.edu
OI Kuo, Calvin/0000-0002-7427-5985
FU NCI NIH HHS [1R01 CA 95654-01, R01 CA095654, R01 CA095654-05] Funding
   Source: Medline; NHLBI NIH HHS [R01 HL074267-04, 1R01 HL 074267-01, R01
   HL074267] Funding Source: Medline; NINDS NIH HHS [1R01 NS 052830-01, R01
   NS052830-04, R01 NS052830] Funding Source: Medline; NATIONAL CANCER
   INSTITUTE [R01CA095654] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL074267] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052830]
   Funding Source: NIH RePORTER
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Baldwin ME, 2001, J BIOL CHEM, V276, P44307, DOI 10.1074/jbc.M106188200
   BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A
   Berger DP, 1995, ANN ONCOL, V6, P817, DOI 10.1093/oxfordjournals.annonc.a059322
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x
   Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DIANTONIO BJ, 2005, STUDY E3200 ABSTR, pA169
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   Easwaran V, 2003, CANCER RES, V63, P3145
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   EGGINTON S, 2003, CARDIOVASC RES, V49, P634
   Eming SA, 2006, J INVEST DERM SYMP P, V11, P79, DOI 10.1038/sj.jidsymp.5650016
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481
   Herbst Roy S, 2006, Expert Opin Emerg Drugs, V11, P635, DOI 10.1517/14728214.11.4.635
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Jacobi J, 2004, CIRCULATION, V110, P2424, DOI 10.1161/01.CIR.0000145142.85645.EA
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lashkari K, 2000, AM J PATHOL, V156, P1337, DOI 10.1016/S0002-9440(10)65004-3
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   Miao HQ, 2006, BIOCHEM BIOPH RES CO, V345, P438, DOI 10.1016/j.bbrc.2006.04.119
   Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   MILLER KD, 2005, SAN ANT BREAST CANC
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Siemeister G, 1996, CANCER RES, V56, P2299
   Sivak-Callcott JA, 2001, OPHTHALMOLOGY, V108, P1767, DOI 10.1016/S0161-6420(01)00775-8
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053
NR 64
TC 124
Z9 151
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PY 2007
VL 39
IS 7-8
BP 1349
EP 1357
DI 10.1016/j.biocel.2007.04.010
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 197PB
UT WOS:000248566700011
PM 17537667
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Szczepan, M
   Llorian-Salvador, M
   Chen, M
   Xu, HP
AF Szczepan, Manon
   Llorian-Salvador, Maria
   Chen, Mei
   Xu, Heping
TI Immune Cells in Subretinal Wound Healing and Fibrosis
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE retina; inflammation; innate immunity; adaptive immunity; age-related
   macular degeneration; macular fibrosis; proliferative vitroretinopathy
ID PIGMENT EPITHELIAL-CELLS; CHOROIDAL NEOVASCULARIZATION; MULLER CELLS;
   MAST-CELLS; PROLIFERATIVE VITREORETINOPATHY; COMPLEMENT EXPRESSION;
   RETINAL-DETACHMENT; DENDRITIC CELLS; LIVER FIBROSIS; B-LYMPHOCYTES
AB The subretinal space is devoid of any immune cells under normal conditions and is an immune privileged site. When photoreceptors and/or retinal pigment epithelial cells suffer from an injury, a wound healing process will be initiated. Retinal microglia and the complement system, as the first line of retinal defense, are activated to participate in the wound healing process. If the injury is severe or persists for a prolonged period, they may fail to heal the damage and circulating immune cells will be summoned leading to chronic inflammation and abnormal wound healing, i.e., subretinal or intraretinal fibrosis, a sight-threatening condition frequently observed in rhematogenous retinal detachment, age-related macular degeneration and recurrent uveoretinitis. Here, we discussed the principles of subretinal wound healing with a strong focus on the conditions whereby the damage is beyond the healing capacity of the retinal defense system and highlighted the roles of circulating immune cells in subretinal wound healing and fibrosis.
C1 [Szczepan, Manon; Llorian-Salvador, Maria; Chen, Mei; Xu, Heping] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, North Ireland.
   [Xu, Heping] Aier Inst Optometry & Vis Sci, Changsha, Peoples R China.
   [Llorian-Salvador, Maria] Univ Autonoma Barcelona, Vall Hebron Res Inst, Diabet & Metab Res Unit, Barcelona, Spain.
C3 Queens University Belfast; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)
RP Xu, HP (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, North Ireland.; Xu, HP (通讯作者)，Aier Inst Optometry & Vis Sci, Changsha, Peoples R China.
EM heping.xu@qub.ac.uk
RI Llorián-Salvador, Maía/HDM-6846-2022; Llorian Salvador,
   Maria/GYV-1848-2022
OI SZCZEPAN, Manon/0000-0003-1438-8504
CR Aceves SS, 2014, DIGEST DIS, V32, P15, DOI 10.1159/000357004
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Adler M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100841
   Ahadome SD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87012
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Arras M, 2006, AM J RESP CELL MOL, V34, P573, DOI 10.1165/rcmb.2004-0383OC
   Baxter SL, 2013, AM J OPHTHALMOL, V156, P468, DOI 10.1016/j.ajo.2013.04.040
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bi JC, 2022, CELL MOL IMMUNOL, V19, P127, DOI 10.1038/s41423-021-00825-2
   Binet F, 2020, SCIENCE, V369, P934, DOI 10.1126/science.aay5356
   Blasiak J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041684
   Bocchino M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664109
   Borcherding L, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.761372
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   CHARTERIS DG, 1993, OPHTHALMOLOGY, V100, P43
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00205-w
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P1629, DOI 10.23812/20-2EDIT
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Davis PA, 2001, BRIT J SURG, V88, P298, DOI 10.1046/j.1365-2168.2001.01665.x
   Detrick B, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P101, DOI 10.1007/978-3-030-28384-1_6
   Duquesne N, 1996, GRAEF ARCH CLIN EXP, V234, P677, DOI 10.1007/BF00292353
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   Forrester JV, 2008, MUCOSAL IMMUNOL, V1, P372, DOI 10.1038/mi.2008.27
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   GRIERSON I, 1994, EYE, V8, P255, DOI 10.1038/eye.1994.54
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   GUYER DR, 1992, AM J OPHTHALMOL, V113, P652
   HAMZAOUI K, 1990, CLIN EXP IMMUNOL, V79, P28
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hijioka K, 2008, BIOCHEM BIOPH RES CO, V374, P38, DOI 10.1016/j.bbrc.2008.06.080
   Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0071808, 10.1371/journal.pone.0076982]
   Idrees Sana, 2019, Int Ophthalmol Clin, V59, P221, DOI 10.1097/IIO.0000000000000258
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Karl MO, 2010, TRENDS MOL MED, V16, P193, DOI 10.1016/j.molmed.2010.02.003
   Karlen SJ, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1365-4
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Kim DM, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109798
   KIM MK, 1987, AM J OPHTHALMOL, V104, P15, DOI 10.1016/0002-9394(87)90287-X
   Krishnaswamy Guha, 2006, Methods Mol Biol, V315, P13
   Kryczka J, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/652035
   Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620
   Kucuksezer UC, 2015, CLIN EXP RHEUMATOL, V33, pS24
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lau CH, 2009, OCUL IMMUNOL INFLAMM, V17, P380, DOI 10.3109/09273940903118642
   Le Moine A, 1999, J CLIN INVEST, V103, P1659, DOI 10.1172/JCI5504
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lehmann U, 2010, NEUROBIOL DIS, V40, P177, DOI 10.1016/j.nbd.2010.05.022
   Levinson RD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160392
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Little K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.3
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu B, 2013, INVEST OPHTH VIS SCI, V54, P444, DOI 10.1167/iovs.12-10774
   Liu J, 2020, J NEUROSCI RES, V98, P1498, DOI 10.1002/jnr.24618
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Liu K, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-019-0132-8
   Luo C, 2018, AGING-US, V10, P1380, DOI 10.18632/aging.101474
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo C, 2012, INFLAMMATION, V35, P1448, DOI 10.1007/s10753-012-9458-1
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Martinez-Aleman SR, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00104
   Matsuda K, 2017, J CLIN INVEST, V127, P3987, DOI 10.1172/JCI89893
   Matzinger P, 2011, NAT REV IMMUNOL, V11, P221, DOI 10.1038/nri2940
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   McMenamin PG, 1997, EYE, V11, P183, DOI 10.1038/eye.1997.49
   Meng XM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.402
   Montero JA, 2010, CURR DRUG TARGETS, V11, P630
   Monument MJ, 2015, ADV WOUND CARE, V4, P137, DOI 10.1089/wound.2013.0509
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nosbaum A, 2016, J IMMUNOL, V196, P2010, DOI 10.4049/jimmunol.1502139
   Obasanmi G, 2020, CURR EYE RES, V45, P1144, DOI 10.1080/02713683.2020.1718165
   Oberyszyn TM, 2007, FRONT BIOSCI-LANDMRK, V12, P2993, DOI 10.2741/2289
   Ohno-Matsui K, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.5.5
   Overed-Sayer C, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00174
   Page C, 2012, J VIROL, V86, P13334, DOI 10.1128/JVI.01689-12
   Planul A, 2017, ANNU REV VIS SCI, V3, P121, DOI 10.1146/annurev-vision-102016-061413
   Ponsioen TL, 2008, MOL VIS, V14, P652
   Radaeva S, 2006, GASTROENTEROLOGY, V130, P435, DOI 10.1053/j.gastro.2005.10.055
   Rahman AH, 2013, BBA-MOL BASIS DIS, V1832, P998, DOI 10.1016/j.bbadis.2013.01.005
   Rishi P, 2013, EYE, V27, P1158, DOI 10.1038/eye.2013.155
   ROCKEY JH, 1979, INVEST OPHTH VIS SCI, V18, P1172
   Roy S, 2016, EXP EYE RES, V142, P71, DOI 10.1016/j.exer.2015.04.004
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sato T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211438
   Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shen P, 2015, NAT REV IMMUNOL, V15, P441, DOI 10.1038/nri3857
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Smith JR, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.2
   Sonoda KH, 2011, ACTA OPHTHALMOL, V89, pE180, DOI 10.1111/j.1755-3768.2010.01953.x
   SPRY CJF, 1989, SPRINGER SEMIN IMMUN, V11, P471
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P1719, DOI 10.1167/iovs.17-22703
   TANG S, 1993, OPHTHALMIC RES, V25, P177, DOI 10.1159/000267287
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
   Thapa M, 2015, HEPATOLOGY, V61, P2067, DOI 10.1002/hep.27761
   Tonade D, 2017, DIABETOLOGIA, V60, P2111, DOI 10.1007/s00125-017-4381-5
   TORIS CB, 1985, ARCH OPHTHALMOL-CHIC, V103, P266, DOI 10.1001/archopht.1985.01050020118033
   TROCME SD, 1991, ARCH OPHTHALMOL-CHIC, V109, P1585, DOI 10.1001/archopht.1991.01080110121049
   TROCME SD, 1994, SURV OPHTHALMOL, V39, P241, DOI 10.1016/0039-6257(94)90197-X
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Turner JE, 2017, KIDNEY INT, V92, P9, DOI 10.1016/j.kint.2017.03.011
   Wang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02063
   Wang YY, 2017, J AM SOC NEPHROL, V28, P2053, DOI 10.1681/ASN.2016050573
   Wendisch D, 2021, CELL, V184, P6243, DOI 10.1016/j.cell.2021.11.033
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wieghofer P, 2021, EMBO J, V40, DOI 10.15252/embj.2020105123
   Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3
   Wu YY, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242900
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamamoto T, 2000, IMMUNOLOGY, V99, P435, DOI 10.1046/j.1365-2567.2000.00973.x
   Yang S, 2015, DISCOV MED, V20, P207
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Yu Y, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0251-z
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zhang MJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01142
   Zhao JW, 2014, INVEST OPHTH VIS SCI, V55, P7572, DOI 10.1167/iovs.14-15495
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
   Zhu FG, 2017, J CELL COMMUN SIGNAL, V11, P213, DOI 10.1007/s12079-017-0382-x
   Zhu LY, 2017, CELL BIOL INT, V41, P960, DOI 10.1002/cbin.10788
NR 140
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD JUN 10
PY 2022
VL 16
AR 916719
DI 10.3389/fncel.2022.916719
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 2J5GW
UT WOS:000815686200001
PM 35755781
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Karasavvidou, EM
   Tranos, P
   Panos, GD
AF Karasavvidou, Evdoxia-Maria
   Tranos, Paris
   Panos, Georgios D.
TI Brolucizumab for the Treatment of Degenerative Macular Conditions: A
   Review of Clinical Studies
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE degenerative macular disorders; brolucizumab; anti-VEGF; efficacy;
   safety; intravitreal treatment
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL VEIN OCCLUSION; ANTI-VEGF
   TREATMENT; SINGLE-CHAIN FV; DIABETIC-RETINOPATHY; CASE SERIES;
   AFLIBERCEPT; RANIBIZUMAB; OUTCOMES; PATHOGENESIS
AB Age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion represent some of the commonest degenerative conditions that lead to severe vision impairment in the developed countries. The gold standard treatment of complications associated with these conditions is the intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents. Brolucizumab is a newly developed, humanised, single-chain fragment of a monoclonal antibody binding all VEGF-A isoforms, which was recently approved for the treatment of neovascular AMD. Intravitreal brolucizumab promises to reduce treatment burden for nAMD patients by achieving comparable therapeutic outcomes with fewer clinic visits. Promising also appears its use for the treatment of more challenging maculopathies like diabetic macular oedema (DMO). The aim of this review is to describe the special pharmacological properties of brolucizumab and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of degenerative macular disorders.
C1 [Karasavvidou, Evdoxia-Maria] Karasavvidou Eye Ctr, Naousa, Greece.
   [Tranos, Paris] Ophthalm Eye Inst, Thessaloniki, Greece.
   [Panos, Georgios D.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Dept Ophthalmol, Nottingham, England.
   [Panos, Georgios D.] Queens Med Ctr, Dept Ophthalmol, Derby Rd, Nottingham NG7 2UH, England.
C3 Nottingham University Hospital NHS Trust; University of Nottingham;
   University of Nottingham
RP Panos, GD (通讯作者)，Queens Med Ctr, Dept Ophthalmol, Derby Rd, Nottingham NG7 2UH, England.
EM gdpanos@gmail.com
RI Panos, Georgios D./AFS-1807-2022
OI Panos, Georgios D./0000-0001-8399-7456
CR Airaldi Matteo, 2022, Can J Ophthalmol, V57, pe163, DOI 10.1016/j.jcjo.2021.09.001
   Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Awh CC, 2022, RETINA-J RET VIT DIS, V42, P899, DOI 10.1097/IAE.0000000000003418
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bandello F, 2017, DEV OPHTHALMOL, V58, P102, DOI 10.1159/000455277
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Berger BB, 2015, INVEST OPHTH VIS SCI, V56
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184153
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132758
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112425
   Borras L, 2010, J BIOL CHEM, V285, P9054, DOI 10.1074/jbc.M109.072876
   BRESNICK GH, 1986, OPHTHALMOLOGY, V93, P989
   Brown D, 2022, AM J OPHTHALMOL, V238, P157, DOI 10.1016/j.ajo.2022.01.004
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Chakraborty D, 2022, EYE, V36, P358, DOI 10.1038/s41433-021-01816-3
   Chakraborty D, 2021, CLIN OPHTHALMOL, V15, P3787, DOI 10.2147/OPTH.S328160
   Chakraborty Debdulal, 2021, Am J Ophthalmol Case Rep, V24, P101197, DOI 10.1016/j.ajoc.2021.101197
   Chakraborty S, 2022, CASE REP OPHTHALMOL, V2022, DOI 10.1155/2022/3755249
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Corradetti Giulia, 2020, Am J Ophthalmol Case Rep, V20, P100981, DOI 10.1016/j.ajoc.2020.100981
   Daniel E, 2017, OPHTHALMOL RETINA, V1, P25, DOI 10.1016/j.oret.2016.09.001
   de Oliveira Dias Joao Rafael, 2016, Int J Retina Vitreous, V2, P3, DOI 10.1186/s40942-016-0026-y
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fenner BJ, 2022, EYE, V36, P257, DOI 10.1038/s41433-021-01688-7
   Ferrante N, 2022, BMC HEALTH SERV RES, V22, DOI 10.1186/s12913-022-07972-w
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Fukuda Y, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091164
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Girach A, 2007, INT J CLIN PRACT, V61, P88, DOI 10.1111/j.1742-1241.2006.01211.x
   Goldhardt R, 2019, CURR OPHTHALMOL REP, V7, P66, DOI 10.1007/s40135-019-00201-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grant MB, 2004, EXPERT OPIN INV DRUG, V13, P1275, DOI 10.1517/13543784.13.10.1275
   Group RS, 2022, ASSESSING EFFICACY S
   Haensli C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122666
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2022, GRAEF ARCH CLIN EXP, V260, P2695, DOI 10.1007/s00417-022-05591-z
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hussain RM, 2021, THER ADV OPHTHALMOL, V13, DOI 10.1177/25158414211055964
   Ip M, 2018, ASIA-PAC J OPHTHALMO, V7, P40, DOI 10.22608/APO.2017442
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Khanani AM, 2022, JAMA OPHTHALMOL, V140, P20, DOI 10.1001/jamaophthalmol.2021.4585
   Kilmartin DJ, 2022, IRISH J MED SCI, DOI 10.1007/s11845-022-02929-8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mahaling B, 2018, NANOSCALE, V10, DOI 10.1039/c8nr00058a
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Michalska-Malecka K, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18168450
   Miller BR, 2010, PROTEIN ENG DES SEL, V23, P549, DOI 10.1093/protein/gzq028
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Montesel A, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.720345
   Mukai RG, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259879
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Murray JE, 2021, CLIN OPHTHALMOL, V15, P4731, DOI 10.2147/OPTH.S339393
   Nguyen HV, 2022, EUR J OPHTHALMOL, V32, P2747, DOI 10.1177/11206721211059332
   Novartis, 2021, NOV REP ON YEAR RES
   O'Mahoney PRA, 2008, ARCH OPHTHALMOL-CHIC, V126, P692, DOI 10.1001/archopht.126.5.692
   Ogura Y, 2022, BRIT J OPHTHALMOL, V106, P994, DOI 10.1136/bjophthalmol-2021-319090
   Panigrahi PK, 2022, PHOTODIAGN PHOTODYN, V37, DOI 10.1016/j.pdpdt.2021.102694
   Patel Nimesh A, 2020, Am J Ophthalmol Case Rep, V19, P100815, DOI 10.1016/j.ajoc.2020.100815
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sarkar A, 2021, J CONTROL RELEASE, V329, P1262, DOI 10.1016/j.jconrel.2020.10.054
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Sharma A, 2020, EYE, V34, P1318, DOI 10.1038/s41433-020-0842-z
   Singh RP, 2022, OPHTHALMOL RETINA, V6, P377, DOI 10.1016/j.oret.2021.12.014
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Tamashiro T, 2022, GRAEF ARCH CLIN EXP, V260, P1857, DOI 10.1007/s00417-021-05517-1
   Triantafylla M, 2014, CLIN OPHTHALMOL, V8, P1187, DOI 10.2147/OPTH.S40350
   Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476
   Witkin Andre J, 2021, J Vitreoretin Dis, V5, P326, DOI 10.1177/2474126420975303
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2010, NEW ENGL J MED, V363, P2135, DOI 10.1056/NEJMcp1003934
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yen YC, 2013, BRIT J OPHTHALMOL, V97, P1192, DOI 10.1136/bjophthalmol-2013-303265
   YOKOTA T, 1992, CANCER RES, V52, P3402
   Yu JS, 2021, J MANAG CARE SPEC PH, V27, P743, DOI 10.18553/jmcp.2021.27.6.743
NR 96
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2022
VL 16
BP 2659
EP 2680
DI 10.2147/DDDT.S378450
PG 22
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 5A3FZ
UT WOS:000862776900001
PM 35971530
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ye, SS
   Tang, Y
   Song, JT
AF Ye, Shan-Shan
   Tang, Yong
   Song, Jian-Tao
TI ATP and Adenosine in the Retina and Retinal Diseases
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE ATP; adenosine; age-related macular degeneration; glaucoma; diabetic
   retinopathy
ID A(2A) RECEPTOR ANTAGONIST; INDUCED PHOTORECEPTOR DEATH;
   INTRAOCULAR-PRESSURE; GANGLION-CELLS; MICROGLIAL ACTIVATION; PURINERGIC
   RECEPTORS; MULLER CELLS; NEUROINFLAMMATION; STIMULATION; INVOLVEMENT
AB Extracellular ATP and its ultimate degradation product adenosine are potent extracellular signaling molecules that elicit a variety of pathophysiological pathways in retina through the activation of P2 and P1 purinoceptors, respectively. Excessive build-up of extracellular ATP accelerates pathologic responses in retinal diseases, whereas accumulation of adenosine protects retinal cells against degeneration or inflammation. This mini-review focuses on the roles of ATP and adenosine in three types of blinding diseases including age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR). Several agonists and antagonists of ATP receptors and adenosine receptors (ARs) have been developed for the potential treatment of glaucoma, DR and AMD: antagonists of P2X7 receptor (P2X7R) (BBG, MRS2540) prevent ATP-induced neuronal apoptosis in glaucoma, DR, and AMD; A1 receptor (A1R) agonists (INO-8875) lower intraocular pressure in glaucoma; A2A receptor (A2AR) agonists (CGS21680) or antagonists (SCH58261, ZM241385) reduce neuroinflammation in glaucoma, DR, and AMD; A3 receptor (A3R) agonists (2-Cl-lB-MECA, MRS3558) protect retinal ganglion cells (RGCs) from apoptosis in glaucoma.
C1 [Ye, Shan-Shan; Song, Jian-Tao] China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.
   [Tang, Yong] Chengdu Univ Tradit Chinese Med, Int Collaborat Ctr Big Sci Plan Purinerg Signalli, Chengdu, Peoples R China.
   [Tang, Yong] Acupuncture & Chronobiol Key Lab Sichuan Prov, Chengdu, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Eye Hospital, CACMS; Chengdu
   University of Traditional Chinese Medicine
RP Song, JT (通讯作者)，China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.; Tang, Y (通讯作者)，Chengdu Univ Tradit Chinese Med, Int Collaborat Ctr Big Sci Plan Purinerg Signalli, Chengdu, Peoples R China.; Tang, Y (通讯作者)，Acupuncture & Chronobiol Key Lab Sichuan Prov, Chengdu, Peoples R China.
EM jangts@163.com; tangyong@cdutcm.edu.cn
FU Capital Health Development Scientific Research Special Project
   [2016-2-4138]; Eye Hospital of China Academy of Chinese Medical Sciences
   Scientific Research fund [201607]; Project First-Class Disciplines
   Development of Chengdu University of Traditional Chinese Medicine
   [CZYHW1901]; Science and Technology Program of Sichuan Province, China
   [2019YFH0108]
FX This work was supported by grants from Capital Health Development
   Scientific Research Special Project (2016-2-4138), Eye Hospital of China
   Academy of Chinese Medical Sciences Scientific Research fund (201607),
   the Project First-Class Disciplines Development of Chengdu University of
   Traditional Chinese Medicine (CZYHW1901), and Science and Technology
   Program of Sichuan Province, China (2019YFH0108).
CR Ahmad S, 2013, J NEUROIMMUNOL, V264, P54, DOI 10.1016/j.jneuroim.2013.09.015
   Aires ID, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53627-y
   Aires ID, 2019, GLIA, V67, P896, DOI 10.1002/glia.23579
   Aplin FP, 2014, INVEST OPHTH VIS SCI, V55, P8319, DOI 10.1167/iovs.14-15732
   Baudouin C, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100916
   Beckel JM, 2014, GLIA, V62, P1486, DOI 10.1002/glia.22695
   Boia R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2593-y
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Brito R, 2016, J NEUROCHEM, V138, P557, DOI 10.1111/jnc.13683
   Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5
   Burnstock G, 2013, PURINERG SIGNAL, V9, P307, DOI 10.1007/s11302-013-9359-2
   Burnstock G, 2018, BIOCHEM PHARMACOL, V151, P157, DOI 10.1016/j.bcp.2017.07.016
   Chen JF, 2014, INT REV NEUROBIOL, V119, P1, DOI 10.1016/B978-0-12-801022-8.00001-5
   Dai SS, 2011, REV NEUROSCIENCE, V22, P231, DOI 10.1515/RNS.2011.020
   Dong LD, 2018, MOL MED REP, V17, P2289, DOI 10.3892/mmr.2017.8137
   dos Santos-Rodrigues A, 2015, VITAM HORM, V98, P487, DOI 10.1016/bs.vh.2014.12.014
   Dwyer KM, 2020, NAT REV NEPHROL, V16, P509, DOI 10.1038/s41581-020-0304-7
   Fletcher EL, 2020, CLIN EXP OPTOM, V103, P723, DOI 10.1111/cxo.13146
   Fletcher EL, 2010, OPTOMETRY VISION SCI, V87, P269, DOI 10.1097/OPX.0b013e3181c9132b
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Galvao J, 2015, EXP EYE RES, V140, P65, DOI 10.1016/j.exer.2015.08.009
   Ginsburg-Shmuel T, 2012, BIOORGAN MED CHEM, V20, P5483, DOI 10.1016/j.bmc.2012.07.042
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Hartwick ATE, 2004, INVEST OPHTH VIS SCI, V45, P3740, DOI 10.1167/iovs.04-0214
   Huang Z, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00553-z
   Ibrahim AS, 2011, AM J PATHOL, V178, P2136, DOI 10.1016/j.ajpath.2011.01.018
   Illes P, 2021, BRIT J PHARMACOL, V178, P489, DOI 10.1111/bph.15299
   Jacobson KA, 2020, BRIT J PHARMACOL, V177, P2413, DOI [10.1111/bph.1500510.1111/bph.15005, 10.1111/bph.15005]
   Jacobson KA, 2016, J OCUL PHARMACOL TH, V32, P534, DOI 10.1089/jop.2016.0090
   Jamwal S, 2019, CURR PHARM DESIGN, V25, P2892, DOI 10.2174/1381612825666190716112319
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim J, 2021, OPHTHALMOLOGY, V128, P866, DOI 10.1016/j.ophtha.2020.12.009
   Kukulski F, 2011, ADV PHARMACOL, V61, P263, DOI 10.1016/B978-0-12-385526-8.00009-6
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675
   Liu XH, 2016, INVEST OPHTH VIS SCI, V57, P776, DOI 10.1167/iovs.15-18024
   Loukovaara S, 2017, J MOL MED, V95, P193, DOI 10.1007/s00109-016-1472-6
   Lu LJ, 2017, YALE J BIOL MED, V90, P111
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Madeira MH, 2016, TRANSL RES, V169, P112, DOI 10.1016/j.trsl.2015.11.005
   Markovskaya A, 2008, EUR J PHARMACOL, V579, P93, DOI 10.1016/j.ejphar.2007.10.040
   Ventura ALM, 2019, BRAIN RES BULL, V151, P92, DOI 10.1016/j.brainresbull.2018.10.016
   Maugeri G, 2017, J CELL BIOCHEM, V118, P2371, DOI 10.1002/jcb.25899
   Niyadurupola N, 2013, INVEST OPHTH VIS SCI, V54, P2163, DOI 10.1167/iovs.12-10968
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Notomi S, 2011, AM J PATHOL, V179, P2798, DOI 10.1016/j.ajpath.2011.08.035
   Paes-de-Carvalho R, 2003, NEUROCHEM RES, V28, P1583, DOI 10.1023/A:1025686812298
   Pannicke T, 2004, MOL CELL NEUROSCI, V26, P493, DOI 10.1016/j.mcn.2004.04.005
   Puthussery T, 2009, J COMP NEUROL, V513, P430, DOI 10.1002/cne.21964
   Reichenbach A, 2016, J OCUL PHARMACOL TH, V32, P518, DOI 10.1089/jop.2016.0131
   Reigada D, 2008, NEUROSCIENCE, V157, P396, DOI 10.1016/j.neuroscience.2008.08.036
   Sakamoto K, 2015, EUR J PHARMACOL, V756, P52, DOI 10.1016/j.ejphar.2015.03.008
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Santiago AR, 2020, PHARMACOL THERAPEUT, V210, DOI 10.1016/j.pharmthera.2020.107513
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1723, DOI 10.2147/OPTH.S115546
   Solino M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198838
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Sugiyama T, 2013, MOL VIS, V19, P2080
   Uckermann O, 2005, J PHARMACOL EXP THER, V315, P1036, DOI 10.1124/jpet.105.092353
   Vessey KA, 2014, J COMP NEUROL, V522, P2928, DOI 10.1002/cne.23558
   Vogler S, 2013, J NEUROCHEM, V126, P372, DOI 10.1111/jnc.12307
   Ward MM, 2010, ADV EXP MED BIOL, V664, P385, DOI 10.1007/978-1-4419-1399-9_44
   Weick M, 2005, INVEST OPHTH VIS SCI, V46, P1525, DOI 10.1167/iovs.04-0417
   Wurm A, 2008, EXP EYE RES, V87, P385, DOI 10.1016/j.exer.2008.07.004
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P1522, DOI 10.1167/iovs.10-6172
   Zhang M, 2010, NEUROCHEM INT, V56, P35, DOI 10.1016/j.neuint.2009.08.011
   Zhang X, 2007, EXP EYE RES, V85, P637, DOI 10.1016/j.exer.2007.07.016
   Zhang XL, 2005, INVEST OPHTH VIS SCI, V46, P2183, DOI 10.1167/iovs.05-0052
NR 68
TC 6
Z9 7
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 15
PY 2021
VL 12
AR 654445
DI 10.3389/fphar.2021.654445
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TB0VJ
UT WOS:000667661100001
PM 34211393
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Starr, MR
   Xu, D
   Boucher, N
   Saroj, N
   Patel, LG
   Ammar, M
   Pandit, RR
   Jenkins, TL
   Ho, AC
AF Starr, Matthew R.
   Xu, David
   Boucher, Nicholas
   Saroj, Namrata
   Patel, Luv G.
   Ammar, Michael
   Pandit, Ravi R.
   Jenkins, Thomas L.
   Ho, Allen C.
TI Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients
   Treated With Intravitreal Anti-VEGF Injections
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB BACKGROUND AND OBJECTIVE: The purpose of this study was to assess the real-world incidence of conversion to bilateral neovascular age-related macular degeneration (nAMD) following treatment initiation of nAMD in the initial eye.
   PATIENTS AND METHODS: This was a retrospective cohort of electronic health records from retinal centers across the United States (Vestrum Database) of all patients with unilateral nAMD treated with anti-vascular endothelial growth factor therapy.
   RESULTS: A total of 22,553 patients with unilateral nAMD were included. Fellow eyes of 8,522 patients (38%) converted to nAMD. Among these, 2,639 (12%), 2,030 (9%), and 1,802 (8%) patients converted in Years 1, 2, and 3, respectively, after diagnosis in the first eye. Fellow eyes had better vision at conversion and 1 year following conversion.
   CONCLUSIONS: The fellow eye should be monitored at regular intervals to detect signs of neovascularization. Fellow eyes presented with significantly better vision at diagnosis than the initial eye and maintained better visual acuity with less injections.
C1 [Starr, Matthew R.; Xu, David; Patel, Luv G.; Ammar, Michael; Pandit, Ravi R.; Jenkins, Thomas L.; Ho, Allen C.] Thomas Jefferson Univ, Retina Serv, Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
   [Boucher, Nicholas] Vestrum Hlth, Naperville, IL USA.
   [Saroj, Namrata] All Eyes Consulting LLC, New York, NY USA.
C3 Jefferson University
RP Ho, AC (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, Mid Atlantic Retina, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM acho@midatlanticretina.com
OI Starr, Matthew/0000-0002-3021-5630; Ho, Allen/0000-0003-3921-608X
CR Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bek T, 2018, GRAEF ARCH CLIN EXP, V256, P2061, DOI 10.1007/s00417-018-4100-z
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dugel PU, 2012, RETINA-J RET VIT DIS, V32, P1761, DOI 10.1097/IAE.0b013e3182456f4d
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier J., 2019, AM SOC RET SPEC ANN
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Khurana RN, 2017, RETINA-J RET VIT DIS, V37, P1073, DOI 10.1097/IAE.0000000000001307
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Major JC, 2014, RETINA-J RET VIT DIS, V34, P48, DOI 10.1097/IAE.0b013e3182965743
   Mimura K, 2018, OPHTHALMOLOGICA, V239, P121, DOI 10.1159/000484099
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schneider EW, 2018, CURR OPIN OPHTHALMOL, V29, P217, DOI 10.1097/ICU.0000000000000469
   Stem MS, 2018, JAMA OPHTHALMOL, V136, P820, DOI 10.1001/jamaophthalmol.2018.1534
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
NR 27
TC 1
Z9 1
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2021
VL 52
IS 3
BP 123
EP 128
DI 10.3928/23258160-20210302-02
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA RF6FC
UT WOS:000634936500002
PM 34038686
DA 2022-11-30
ER

PT J
AU Bicer, O
   Demirel, S
   Yavuz, Z
   Batioglu, F
   Ozmert, E
AF Bicer, Ozlem
   Demirel, Sibel
   Yavuz, Zeynep
   Batioglu, Figen
   Ozmert, Emin
TI Comparison of Morphological Features of Type 1 CNV in AMD and
   Pachychoroid Neovasculopathy: An OCTA Study
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; ANGIOGRAPHY
AB BACKGROUND AND OBJECTIVE: The purpose of this study is to compare the morphological features of type 1 choroidal neovascularization (CNV) in eyes with age-related macular degeneration (AMD) and pachychoroid neovasculopathy (PNV) using optical coherence tomography angiography (OCTA).
   PATIENTS AND METHODS: Nineteen eyes of 17 patients with PNV and 30 eyes of 30 patients with AMD were evaluated. The size and area of CNV and morphological patterns during a 6-month period were analyzed using optical coherence tomography angiography.
   RESULTS: The presence of a feeder vessel was more common in AMD than in PNV. Indistinct pattern was more common in PNV than AMD. Pruned vascular tree pattern was rare in PNV eyes during follow-up. The mean size and flow of selected CNV area was significantly smaller in PNV group.
   CONCLUSION: This study demonstrated that type 1 CNVs in the PNV group is characterized by a smaller area. Morphologic pattern differences between them might be explained by different etiopathogenesis under these circumstances.
C1 [Bicer, Ozlem] Bogazliyan State Hosp, Dept Ophthalmol, Yozgat, Turkey.
   [Demirel, Sibel; Batioglu, Figen; Ozmert, Emin] Ankara Univ, Fac Med, Dept Ophthalmol, Ankara, Turkey.
   [Yavuz, Zeynep] Ankara Univ, Dept Biostat, Fac Med, Ankara, Turkey.
C3 Yozgat Bogazliyan State Hospital; Ankara University; Ankara University
RP Demirel, S (通讯作者)，Vehbi Koc Eye Hosp, Dept Ophthalmol, Mamak St, Ankara, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI DEMIREL, SIBEL/GQH-3232-2022
OI DEMIREL, SIBEL/0000-0002-2477-9974
CR Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
NR 18
TC 3
Z9 5
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV
PY 2020
VL 51
IS 11
BP 640
EP 647
DI 10.3928/23258160-20201104-06
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA PA2RK
UT WOS:000595480800006
PM 33231697
DA 2022-11-30
ER

PT J
AU Kauppinen, A
AF Kauppinen, Anu
TI Introduction to the multi-author review on macular degeneration
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Age-related macular degeneration; Senescence; Immune cells; Epigenetics;
   Hypoxia; Lipocalin
ID DISEASE
AB Prolonged life expectancies contribute to the increasing prevalence of age-related macular degeneration (AMD) that is already the leading cause of severe vision loss among the elderly in developed countries. In dry AMD, the disease culminates into vast retinal atrophy, whereas the wet form is characterized by retinal edema and sudden vision loss due to neovascularization originating from the choroid beneath the Bruch's membrane. There is no treatment for dry AMD and despite intravitreal injections of anti-vascular endothelial growth factor (VEGF) that suppress the neovessel formation, also wet AMD needs new therapies to prevent the disease progression and to serve patients lacking of positive response to current medicines. Knowledge on disease mechanisms is a prerequisite for the drug development, which is hindered by the multifactorial nature of AMD. Numerous distinguished publications have revealed AMD mechanisms at the cellular and molecular level and in this multi-author review, we take a bit broader look at the topic with some novel aspects.
C1 [Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland.
C3 University of Eastern Finland
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland.
EM anu.kauppinen@uef.fi
FU University of Eastern Finland (UEF) including Kuopio University Hospital
FX Open access funding provided by University of Eastern Finland (UEF)
   including Kuopio University Hospital.
CR Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Alizadeh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123846
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Kauppinen A., 2018, HDB IMMUNOSENESCENCE, P1
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Lefevere E, 2017, MITOCHONDRION, V36, P66, DOI 10.1016/j.mito.2017.03.006
   Li DH, 2020, BASIC CLIN PHARMACOL, V127, P142, DOI 10.1111/bcpt.13332
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Salminen A, 2012, CELL MOL LIFE SCI, V69, P2999, DOI 10.1007/s00018-012-0962-0
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Weinhold B, 2006, ENVIRON HEALTH PERSP, V114, pA160, DOI 10.1289/ehp.114-a160
NR 21
TC 7
Z9 7
U1 0
U2 4
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2020
VL 77
IS 5
BP 779
EP 780
DI 10.1007/s00018-019-03418-5
EA JAN 2020
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KS7QS
UT WOS:000505379200003
PM 31897540
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sanchez-Corral, P
   Pouw, RB
   Lopez-Trascasa, M
   Jozsi, M
AF Sanchez-Corral, Pilar
   Pouw, Richard B.
   Lopez-Trascasa, Margarita
   Jozsi, Mihaly
TI Self-Damage Caused by Dysregulation of the Complement Alternative
   Pathway: Relevance of the Factor H Protein Family
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE age-related macular degeneration; atypical hemolytic uremic syndrome; C3
   glomerulopathy; complement activation; complement de-regulation; factor
   H; factor H-related protein; opsonization
ID HEMOLYTIC-UREMIC SYNDROME; C-REACTIVE-PROTEIN; SHORT CONSENSUS REPEAT;
   TRANSLATIONAL MINIREVIEW SERIES; GENOME-WIDE ASSOCIATION;
   HEPARIN-BINDING DOMAIN; COPY NUMBER VARIATION; LONG PENTRAXIN PTX3;
   MACULAR DEGENERATION; ENDOTHELIAL-CELLS
AB The alternative pathway is a continuously active surveillance arm of the complement system, and it can also enhance complement activation initiated by the classical and the lectin pathways. Various membrane-bound and plasma regulatory proteins control the activation of the potentially deleterious complement system. Among the regulators, the plasma glycoprotein factor H (FH) is the main inhibitor of the alternative pathway and its powerful amplification loop. FH belongs to a protein family that also includes FH-like protein 1 and five factor H-related (FHR-1 to FHR-5) proteins. Genetic variants and abnormal rearrangements involving the FH protein family have been linked to numerous systemic and organ-specific diseases, including age-related macular degeneration, and the renal pathologies atypical hemolytic uremic syndrome, C3 glomerulopathies, and IgA nephropathy. This review covers the known and recently emerged ligands and interactions of the human FH family proteins associated with disease and discuss the very recent experimental data that suggest FH-antagonistic and complement-activating functions for the FHR proteins.
C1 [Sanchez-Corral, Pilar; Lopez-Trascasa, Margarita] Ctr Biomed Network Res Rare Dis CIBERER, Complement Res Grp, Hosp La Paz, Inst Hlth Res IdiPAZ,La Paz Univ Hosp, Madrid, Spain.
   [Pouw, Richard B.] Univ Basel, Dept Pharmaceut Sci, Basel, Switzerland.
   [Lopez-Trascasa, Margarita] Univ Autonoma Madrid, Dept Med, Madrid, Spain.
   [Jozsi, Mihaly] Eotvos Lorand Univ, Dept Immunol, Complement Res Grp, Budapest, Hungary.
   [Jozsi, Mihaly] Hungarian Acad Sci, MTA SE Res Grp Immunol & Hematol, Budapest, Hungary.
   [Jozsi, Mihaly] Semmelweis Univ, Budapest, Hungary.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital
   Universitario La Paz; University of Basel; Autonomous University of
   Madrid; Eotvos Lorand University; Hungarian Academy of Sciences;
   Semmelweis University
RP Jozsi, M (通讯作者)，Eotvos Lorand Univ, Dept Immunol, Complement Res Grp, Budapest, Hungary.; Jozsi, M (通讯作者)，Hungarian Acad Sci, MTA SE Res Grp Immunol & Hematol, Budapest, Hungary.; Jozsi, M (通讯作者)，Semmelweis Univ, Budapest, Hungary.
EM mihaly.jozsi@ttk.elte.hu
RI Jozsi, Mihaly/I-7872-2018; Pouw, Richard/AAE-1042-2020; López-Trascasa,
   Margarita/L-2699-2014; Sánchez-Corral, Pilar/GLR-0387-2022
OI Jozsi, Mihaly/0000-0002-5520-5535; Pouw, Richard/0000-0003-3469-8454;
   López-Trascasa, Margarita/0000-0001-8594-282X; 
FU Spanish Ministerio de Economia y Competitividad/ISCIII, and European
   Program FEDER [PI16/00723, PI15/00255]; Complement II-CM network from
   the Comunidad de Madrid [B2017/BMD3673]; National Research, Development
   and Innovation Fund of Hungary (NKFIA) [K 109055, K 125219]; Kidneeds
   Foundation, Iowa, US; Institutional Excellence Program of the Ministry
   of Human Capacities of Hungary
FX PS-C and ML-T are funded by grants PI16/00723 and PI15/00255 (Spanish
   Ministerio de Economia y Competitividad/ISCIII, and European Program
   FEDER) and B2017/BMD3673 (Complement II-CM network from the Comunidad de
   Madrid). MJ is supported by the National Research, Development and
   Innovation Fund of Hungary (NKFIA grants K 109055 and K 125219), the
   Kidneeds Foundation, Iowa, US, and by the Institutional Excellence
   Program of the Ministry of Human Capacities of Hungary.
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Agarwal V, 2010, J BIOL CHEM, V285, P23484, DOI 10.1074/jbc.M110.142703
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Antonioli AH, 2018, J IMMUNOL, V200, P316, DOI 10.4049/jimmunol.1602017
   Athanasiou Y, 2011, CLIN J AM SOC NEPHRO, V6, P1436, DOI 10.2215/CJN.09541010
   Bernabeu-Herrero ME, 2015, MOL IMMUNOL, V67, P276, DOI 10.1016/j.molimm.2015.06.021
   Bhattacharjee A, 2015, J BIOL CHEM, V290, P9500, DOI 10.1074/jbc.M114.630871
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Blanc C, 2015, J IMMUNOL, V194, P5129, DOI 10.4049/jimmunol.1402770
   Blanc C, 2012, J IMMUNOL, V189, P3528, DOI 10.4049/jimmunol.1200679
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305
   Braunschweig A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023991
   BROOIMANS RA, 1990, J IMMUNOL, V144, P3835
   Buhlmann D, 2016, J IMMUNOL, V197, P620, DOI 10.4049/jimmunol.1600053
   Caesar JJE, 2014, ELIFE, V3, DOI 10.7554/eLife.04008
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cantsilieris S, 2018, P NATL ACAD SCI USA, V115, pE4433, DOI 10.1073/pnas.1717600115
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Challis RC, 2016, J AM SOC NEPHROL, V27, P1617, DOI 10.1681/ASN.2015010100
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen Q, 2016, J AM SOC NEPHROL, V27, P1413, DOI 10.1681/ASN.2015020212
   Chen Q, 2014, J CLIN INVEST, V124, P145, DOI 10.1172/JCI71866
   Chen SF, 2018, RHEUMATOLOGY, V57, P2213, DOI 10.1093/rheumatology/kex529
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Cserhalmi M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01145
   Csincsi AI, 2017, J IMMUNOL, V199, P292, DOI 10.4049/jimmunol.1600483
   Csincsi AI, 2015, J IMMUNOL, V194, P4963, DOI 10.4049/jimmunol.1403121
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jorge EG, 2018, J AM SOC NEPHROL, V29, P240, DOI 10.1681/ASN.2017050518
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Deban L, 2011, CELL TISSUE RES, V343, P237, DOI 10.1007/s00441-010-1018-0
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Delvaeye M, 2009, NEW ENGL J MED, V361, P345, DOI 10.1056/NEJMoa0810739
   DEVINE DV, 1987, P NATL ACAD SCI USA, V84, P5873, DOI 10.1073/pnas.84.16.5873
   DiScipio RG, 1998, J IMMUNOL, V160, P4057
   Dixon KO, 2017, EUR J IMMUNOL, V47, P470, DOI 10.1002/eji.201646703
   Dragon-Durey MA, 2009, J MED GENET, V46, P447, DOI 10.1136/jmg.2008.064766
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Dragon-Durey MA, 2010, SEMIN THROMB HEMOST, V36, P633, DOI 10.1055/s-0030-1262885
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   ERDEI A, 1987, BIOCHEM J, V246, P149, DOI 10.1042/bj2460149
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   ESTALLER C, 1991, J IMMUNOL, V146, P3190
   Eyler SJ, 2013, PEDIATR NEPHROL, V28, P2221, DOI 10.1007/s00467-013-2560-2
   Feng SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073715
   Francis NJ, 2012, BLOOD, V119, P591, DOI 10.1182/blood-2011-03-339903
   Friese MA, 2000, CLIN EXP IMMUNOL, V121, P406, DOI 10.1046/j.1365-2249.2000.01285.x
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Frimat M, 2013, BLOOD, V122, P282, DOI 10.1182/blood-2013-03-489245
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787
   Goodship THJ, 2017, KIDNEY INT, V91, P539, DOI 10.1016/j.kint.2016.10.005
   Goodship THJ, 2012, MOL IMMUNOL, V52, P200, DOI 10.1016/j.molimm.2012.05.009
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Haapasalo K, 2015, J BIOL CHEM, V290, P28977, DOI 10.1074/jbc.M115.669226
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   HAMMANN KP, 1981, IMMUNOBIOLOGY, V160, P289, DOI 10.1016/S0171-2985(81)80055-1
   Hannan JP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166200
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Hebecker M, 2013, J IMMUNOL, V191, P912, DOI 10.4049/jimmunol.1300269
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Hebecker M, 2010, MOL IMMUNOL, V47, P1347, DOI 10.1016/j.molimm.2009.12.005
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Heurich M, 2016, THROMB RES, V145, P84, DOI 10.1016/j.thromres.2016.07.017
   Holmes LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060352
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hyvarinen S, 2016, BLOOD, V127, P2701, DOI 10.1182/blood-2015-11-680009
   Hyvarinen S, 2014, J BIOL CHEM, V289, P4295, DOI 10.1074/jbc.M113.527416
   IFERROUDJENE D, 1991, EUR J IMMUNOL, V21, P967, DOI 10.1002/eji.1830210416
   Inforzato A, 2010, J BIOL CHEM, V285, P17681, DOI 10.1074/jbc.M109.085639
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   Jozsi M, 2005, EUR J HUM GENET, V13, P321, DOI 10.1038/sj.ejhg.5201324
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, MOL IMMUNOL, V44, P2697, DOI 10.1016/j.molimm.2006.12.001
   Jozsi M, 2019, SEMIN CELL DEV BIOL, V85, P122, DOI 10.1016/j.semcdb.2017.12.018
   Jozsi M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00571
   Jozsi M, 2015, TRENDS IMMUNOL, V36, P374, DOI 10.1016/j.it.2015.04.008
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   KATZ Y, 1988, J IMMUNOL, V141, P559
   Kopczynska M, 2019, SCHIZOPHR RES, V204, P16, DOI 10.1016/j.schres.2017.12.012
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   Kubista KE, 2011, MOL VIS, V17, P2080
   KUHN S, 1995, J IMMUNOL, V155, P5663
   LAMBRIS JD, 1980, J EXP MED, V152, P1625, DOI 10.1084/jem.152.6.1625
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   Ma YJ, 2011, J BIOL CHEM, V286, P3405, DOI 10.1074/jbc.M110.190637
   Maga TK, 2011, NEPHROL DIAL TRANSPL, V26, P739, DOI 10.1093/ndt/gfq658
   Maillard N, 2015, J AM SOC NEPHROL, V26, P1503, DOI 10.1681/ASN.2014101000
   Malik TH, 2012, J AM SOC NEPHROL, V23, P1155, DOI 10.1681/ASN.2012020166
   Martin M, 2016, IMMUNOL REV, V274, P218, DOI 10.1111/imr.12462
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200
   Medjeral-Thomas N, 2014, KIDNEY INT, V85, P933, DOI 10.1038/ki.2013.348
   Medjeral-Thomas NR, 2017, KIDNEY INT, V92, P942, DOI 10.1016/j.kint.2017.03.043
   MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939
   Meri S, 2016, FEBS LETT, V590, P2418, DOI 10.1002/1873-3468.12284
   Meszaros T, 2016, NANOMED-NANOTECHNOL, V12, P1023, DOI 10.1016/j.nano.2015.11.019
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Mihlan M, 2009, MOL IMMUNOL, V46, P335, DOI 10.1016/j.molimm.2008.10.029
   MISASI R, 1989, EUR J IMMUNOL, V19, P1765, DOI 10.1002/eji.1830190936
   Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377
   Nauta AJ, 2003, EUR J IMMUNOL, V33, P465, DOI 10.1002/immu.200310022
   Nester CM, 2015, MOL IMMUNOL, V67, P31, DOI 10.1016/j.molimm.2015.03.246
   Nolasco L, 2013, ARTERIOSCL THROM VAS, V33, P2524, DOI 10.1161/ATVBAHA.113.302280
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Nozal P, 2016, MOL IMMUNOL, V70, P47, DOI 10.1016/j.molimm.2015.12.005
   Nozal P, 2014, MOL IMMUNOL, V58, P194, DOI 10.1016/j.molimm.2013.11.021
   Nozal P, 2012, CLIN KIDNEY J, V5, P133, DOI 10.1093/ckj/sfs002
   OHTSUKA H, 1993, IMMUNOLOGY, V80, P140
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Olivar R, 2016, J IMMUNOL, V196, P4274, DOI 10.4049/jimmunol.1500455
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pouw RB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00848
   Pouw RB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00729
   Pouw RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152164
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rayes J, 2014, BLOOD, V123, P121, DOI 10.1182/blood-2013-04-495853
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156
   Riley-Vargas RC, 2005, J CLIN INVEST, V115, P1241, DOI 10.1172/JCI200523213
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Roumenina LT, 2016, IMMUNOL REV, V274, P307, DOI 10.1111/imr.12479
   Rudnick RB, 2018, J IMMUNOL, V200, P2280, DOI 10.4049/jimmunol.1701641
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schafer N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00542
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schneider AE, 2016, MOL IMMUNOL, V72, P37, DOI 10.1016/j.molimm.2016.02.011
   SCHOPF RE, 1982, IMMUNOLOGY, V46, P307
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003
   Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612
   SKERKA C, 1991, J BIOL CHEM, V266, P12015
   SKERKA C, 1992, J IMMUNOL, V148, P3313
   SKERKA C, 1993, J BIOL CHEM, V268, P2904
   Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Sofat R, 2013, J IMMUNOL METHODS, V390, P63, DOI 10.1016/j.jim.2013.01.009
   Strobel S, 2011, KIDNEY INT, V80, P397, DOI 10.1038/ki.2011.152
   Strobel S, 2010, NEPHROL DIAL TRANSPL, V25, P136, DOI 10.1093/ndt/gfp388
   Suzuki H, 2011, J AM SOC NEPHROL, V22, P1795, DOI 10.1681/ASN.2011050464
   Svoboda E, 2015, IMMUNOL LETT, V168, P13, DOI 10.1016/j.imlet.2015.08.009
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Tateishi K, 2016, BIOSCI TRENDS, V10, P231, DOI 10.5582/bst.2016.01052
   Timar KK, 2006, MOL IMMUNOL, V43, P317, DOI 10.1016/j.molimm.2005.02.009
   TIMMANN C, 1991, J IMMUNOL, V146, P1265
   Tortajada A, 2017, KIDNEY INT, V92, P953, DOI 10.1016/j.kint.2017.03.041
   Tortajada A, 2017, MOL IMMUNOL, V89, P181, DOI 10.1016/j.molimm.2017.06.169
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200
   TSOKOS GC, 1985, IMMUNOLOGY, V55, P419
   Valoti E, 2015, J AM SOC NEPHROL, V26, P209, DOI 10.1681/ASN.2013121339
   van Beek AE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01328
   VANDENDOBBELSTEEN MEA, 1994, CLIN EXP IMMUNOL, V95, P173
   Venables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431
   Vernon KA, 2011, AM J TRANSPLANT, V11, P152, DOI 10.1111/j.1600-6143.2010.03333.x
   Vernon KA, 2012, AM J KIDNEY DIS, V60, P121, DOI 10.1053/j.ajkd.2012.02.329
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501
   Wong L, 2016, CLIN KIDNEY J, V9, P403, DOI 10.1093/ckj/sfw020
   Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427
   Zadura AF, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4016
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang P, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600237
   Zhao J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002079
   Zhu L, 2015, J AM SOC NEPHROL, V26, P1195, DOI 10.1681/ASN.2014010096
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 198
TC 29
Z9 30
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 12
PY 2018
VL 9
AR 1607
DI 10.3389/fimmu.2018.01607
PG 19
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GM7RD
UT WOS:000438390400001
PM 30050540
OA gold, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Hatcher, JM
   Wu, GW
   Zeng, CY
   Zhu, J
   Meng, F
   Patel, S
   Wang, WQ
   Ficarro, SB
   Leggett, AL
   Powell, CE
   Marto, JA
   Zhang, K
   Ngo, JCK
   Fu, XD
   Zhang, TH
   Gray, NS
AF Hatcher, John M.
   Wu, Guowei
   Zeng, Chuyue
   Zhu, Jie
   Meng, Fan
   Patel, Sherrina
   Wang, Wenqiu
   Ficarro, Scott B.
   Leggett, Alan L.
   Powell, Chelsea E.
   Marto, Jarrod A.
   Zhang, Kang
   Ngo, Jacky Chi Ki
   Fu, Xiang-Dong
   Zhang, Tinghu
   Gray, Nathanael S.
TI SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from
   Pro-angiogenic to Anti-angiogenic Isoform
SO CELL CHEMICAL BIOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RNA SPLICING FACTORS; MESSENGER-RNA; MACULAR
   DEGENERATION; SR PROTEINS; DRUG DISCOVERY; NUCLEAR IMPORT; IN-VIVO;
   KINASE; PHOSPHORYLATION
AB The SRPK family of kinases regulates pre-mRNA splicing by phosphorylating serine/arginine (SR)-rich splicing factors, signals splicing control in response to extracellular stimuli, and contributes to tumorigenesis, suggesting that these splicing kinases are potential therapeutic targets. Here, we report the development of the first irreversible SRPK inhibitor, SRPKIN-1, which is also the first kinase inhibitor that forms a covalent bond with a tyrosine phenol group in the ATP-binding pocket. Kinome-wide profiling demonstrates its selectivity for SRPK1/2, and SRPKIN-1 attenuates SR protein phosphorylation at submicromolar concentrations. Vascular endothelial growth factor (VEGF) is a known target for SRPK-regulated splicing and, relative to the first-generation SRPK inhibitor SRPIN340 or small interfering RNA-mediated SRPK knockdown, SRPKIN-1 is more potent in converting the pro-angiogenic VEGF-A165a to the anti-angiogenic VEGF-A165b isoform and in blocking laser-induced neovascularization in a murine retinal model. These findings encourage further development of SRPK inhibitors for treatment of age-related macular degeneration.
C1 [Hatcher, John M.; Ficarro, Scott B.; Leggett, Alan L.; Powell, Chelsea E.; Marto, Jarrod A.; Zhang, Tinghu; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
   [Hatcher, John M.; Powell, Chelsea E.; Zhang, Tinghu; Gray, Nathanael S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   [Wu, Guowei; Meng, Fan; Fu, Xiang-Dong] Univ Calif San Diego, Inst Genom Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   [Zeng, Chuyue; Ngo, Jacky Chi Ki] Chinese Univ Hong Kong, Sch Life Sci, Shatin, Hong Kong, Peoples R China.
   [Zhu, Jie; Patel, Sherrina; Wang, Wenqiu; Zhang, Kang] Univ Calif San Diego, Shiley Eye Inst, Inst Engn Med, Inst Genom Med, La Jolla, CA 92093 USA.
   [Zhu, Jie] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou 510623, Guangdong, Peoples R China.
   [Ficarro, Scott B.; Marto, Jarrod A.] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA.
   [Ficarro, Scott B.; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA.
   [Ficarro, Scott B.; Marto, Jarrod A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard Medical School; University of California System; University of
   California San Diego; Chinese University of Hong Kong; University of
   California System; University of California San Diego; Guangzhou Medical
   University; Harvard University; Dana-Farber Cancer Institute; Harvard
   University; Dana-Farber Cancer Institute; Harvard University; Brigham &
   Women's Hospital; Harvard Medical School
RP Zhang, TH; Gray, NS (通讯作者)，Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.; Zhang, TH; Gray, NS (通讯作者)，Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.; Fu, XD (通讯作者)，Univ Calif San Diego, Inst Genom Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
EM xdfu@ucsd.edu; tinghu_zhang@dfci.harvard.edu;
   nathanael_gray@dfci.harvard.edu
RI Ngo, Jacky C/O-8093-2017; Zhang, Kang/Y-2740-2019; Zhu,
   Jie/AAD-1330-2022
OI Ngo, Jacky C/0000-0002-6004-7041; Zhang, Kang/0000-0002-4549-1697; Zhu,
   Jie/0000-0001-6862-9022; Powell, Chelsea/0000-0001-7624-1116
FU Research Grants Council of Hong Kong SAR [14122615]; NCI [CA067754]; NIH
   [GM052872, R01 CA136851-07, CA188881]; NATIONAL CANCER INSTITUTE
   [T32CA067754, R21CA188881, R01CA136851] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052872] Funding
   Source: NIH RePORTER
FX We thank Walter Massefski in the core facility of NMR in Dana-Farber for
   the help on the compound NMR spectrumdata collection and Nicholas
   Kwiatkowski and Calla M. Olson for critical reading of the manuscript,
   and to Jeffrey Kelly for advice regarding sulfonyl fluorides. C.Z. and
   J.C.K.N. were supported by a General Research Fund (14122615) from the
   Research Grants Council of Hong Kong SAR. G.W. was partially supported
   by a NCI training grant (CA067754). This work was supported by NIH
   grants GM052872 (to X.-D.F.), R01 CA136851-07 (to N.S.G.), and CA188881
   (to J.A.M.).
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016
   Askenazi M, 2009, NAT METHODS, V6, P240, DOI 10.1038/nmeth0409-240
   Aubol BE, 2016, MOL CELL, V63, P218, DOI 10.1016/j.molcel.2016.05.034
   Bates DO, 2002, CANCER RES, V62, P4123
   Batson J, 2017, ACS CHEM BIOL, V12, P825, DOI 10.1021/acschembio.6b01048
   Bauer RA, 2015, DRUG DISCOV TODAY, V20, P1061, DOI 10.1016/j.drudis.2015.05.005
   Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011
   Davids MS, 2014, FUTURE ONCOL, V10, P957, DOI 10.2217/fon.14.51
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Duda DG, 2007, TRENDS MOL MED, V13, P223, DOI 10.1016/j.molmed.2007.04.001
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Finlay MRV, 2014, J MED CHEM, V57, P8249, DOI 10.1021/jm500973a
   Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103
   Gammons MV, 2014, BRIT J CANCER, V111, P477, DOI 10.1038/bjc.2014.342
   Gammons MV, 2013, INVEST OPHTH VIS SCI, V54, P6052, DOI 10.1167/iovs.13-12422
   Ghosh G, 2011, FEBS J, V278, P587, DOI 10.1111/j.1742-4658.2010.07992.x
   Gout S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046539
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0
   GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Hatcher JM, 2015, J MED CHEM, V58, P9296, DOI 10.1021/acs.jmedchem.5b01136
   Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969
   Hett EC, 2015, ACS CHEM BIOL, V10, P1094, DOI 10.1021/cb5009475
   Houck K. A., 1991, ENDOCRINOLOGY, V5, P1806, DOI [10.1210/mend-5-12-1806, DOI 10.1210/MEND-5-12-1806]
   Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3
   Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7
   Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130
   Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145
   Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393
   Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098
   Larkins E, 2016, CLIN CANCER RES, V22, P5171, DOI 10.1158/1078-0432.CCR-16-1293
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li Xiang, 2014, ScientificWorldJournal, V2014, P540496, DOI 10.1155/2014/540496
   Manetti M, 2011, CIRC RES, V109, pE14, DOI 10.1161/CIRCRESAHA.111.242057
   Mavrou A, 2015, ONCOGENE, V34, P4311, DOI 10.1038/onc.2014.360
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297
   Morooka S, 2015, MOL PHARMACOL, V88, P316, DOI 10.1124/mol.114.097345
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Nakagawa O, 2005, GENE DEV, V19, P2066, DOI 10.1101/gad.1338705
   Ngo JCK, 2007, STRUCTURE, V15, P123, DOI 10.1016/j.str.2006.11.011
   Ngo JCK, 2005, MOL CELL, V20, P77, DOI 10.1016/j.molcel.2005.08.025
   Nomanbhoy TK, 2016, BIOCHEMISTRY-US, V55, P5434, DOI 10.1021/acs.biochem.6b00629
   Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pandit S, 2013, MOL CELL, V50, P223, DOI 10.1016/j.molcel.2013.03.001
   Parikh JR, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-364
   Patricelli MP, 2007, BIOCHEMISTRY-US, V46, P350, DOI 10.1021/bi062142x
   Patricelli MP, 2011, CHEM BIOL, V18, P699, DOI 10.1016/j.chembiol.2011.04.011
   Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309
   Richards Lisa, 2011, Nat Rev Clin Oncol, V8, P194, DOI 10.1038/nrclinonc.2011.28
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217
   Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440
   Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410
   Siqueira RP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134882
   Szekelyhidi Z, 2005, BIOORG MED CHEM LETT, V15, P3241, DOI 10.1016/j.bmcl.2005.04.064
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009
   Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164
   Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang ZQ, 1998, J AM SOC MASS SPECTR, V9, P225, DOI 10.1016/S1044-0305(97)00284-5
   Zhong XY, 2009, GENE DEV, V23, P482, DOI 10.1101/gad.1752109
   Zhou ZH, 2013, CHROMOSOMA, V122, P191, DOI 10.1007/s00412-013-0407-z
   Zhou ZH, 2012, MOL CELL, V47, P422, DOI 10.1016/j.molcel.2012.05.014
NR 72
TC 64
Z9 66
U1 2
U2 37
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2451-9448
J9 CELL CHEM BIOL
JI Cell Chem. Biol.
PD APR 19
PY 2018
VL 25
IS 4
BP 460
EP +
DI 10.1016/j.chembiol.2018.01.013
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GD7GQ
UT WOS:000430679100012
PM 29478907
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Cabral, T
   Toral, MA
   Velez, G
   DiCarlo, JE
   Gore, AM
   Mahajan, M
   Tsang, SH
   Bassuk, AG
   Mahajan, VB
AF Cabral, Thiago
   Toral, Marcus A.
   Velez, Gabriel
   DiCarlo, James E.
   Gore, Anuradha M.
   Mahajan, MaryAnn
   Tsang, Stephen H.
   Bassuk, Alexander G.
   Mahajan, Vinit B.
TI Dissection of Human Retina and RPE-Choroid for Proteomic Analysis
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Human; retina; dissection; retinal pigmented epithelium; choroid;
   proteomics
ID PIGMENT EPITHELIUM; DISEASE; BRAIN
AB The human retina is composed of the sensory neuroretina and the underlying retinal pigmented epithelium (RPE), which is firmly complexed to the vascular choroid layer. Different regions of the retina are anatomically and molecularly distinct, facilitating unique functions and demonstrating differential susceptibility to disease. Proteomic analysis of each of these regions and layers can provide vital insights into the molecular process of many diseases, including Age-Related Macular Degeneration (AMD), diabetes mellitus, and glaucoma. However, separation of retinal regions and layers is essential before quantitative proteomic analysis can be accomplished. Here, we describe a method for dissection and collection of the foveal, macular, and peripheral retinal regions and underlying RPE-choroid complex, involving regional punch biopsies and manual removal of tissue layers from a human eye. One-dimensional SDS-PAGE as well as downstream proteomic analysis, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), can be used to identify proteins in each dissected retinal layer, revealing molecular biomarkers for retinal disease.
C1 [Cabral, Thiago; DiCarlo, James E.; Tsang, Stephen H.] Columbia Univ, Dept Pathol & Cell Biol, Inst Human Nutr, Coll Phys & Surg,Barbara & Donald Jonas Stem Cell, New York, NY 10027 USA.
   [Cabral, Thiago; DiCarlo, James E.; Tsang, Stephen H.] Columbia Univ, Dept Pathol & Cell Biol, Inst Human Nutr, Coll Phys & Surg,Bernard & Shirlee Brown Glaucoma, New York, NY 10027 USA.
   [Cabral, Thiago; DiCarlo, James E.; Tsang, Stephen H.] New York Presbyterian Hosp, Edward S Harkness Eye Inst, New York, NY USA.
   [Toral, Marcus A.; Velez, Gabriel; Gore, Anuradha M.; Mahajan, MaryAnn; Mahajan, Vinit B.] Stanford Univ, Dept Ophthalmol, Omics Lab, Byers Eye Inst, Stanford, CA 94305 USA.
   [Toral, Marcus A.; Velez, Gabriel] Univ Iowa, Med Scientist Training Program, Iowa City, IA 52242 USA.
   [Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [Bassuk, Alexander G.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA.
   [Cabral, Thiago] Fed Univ Sao Paulo UNIFESP, Dept Ophthalmol, Sao Paulo, Brazil.
   [Cabral, Thiago] Fed Univ EspIrito Santo UFES, Dept Ophthalmol, Vitoria, ES, Spain.
   [Mahajan, Vinit B.] Palo Alto Vet Adm, Palo Alto, CA 94303 USA.
C3 Columbia University; Columbia University; NewYork-Presbyterian Hospital;
   Stanford University; University of Iowa; University of Iowa; University
   of Iowa; Universidade Federal de Sao Paulo (UNIFESP)
RP Mahajan, VB (通讯作者)，Stanford Univ, Dept Ophthalmol, Omics Lab, Byers Eye Inst, Stanford, CA 94305 USA.; Mahajan, VB (通讯作者)，Palo Alto Vet Adm, Palo Alto, CA 94303 USA.
EM vinit.mahajan@stanford.edu
RI DiCarlo, James/AAJ-1579-2021; Cabral, Thiago/AAD-4857-2019
OI DiCarlo, James/0000-0003-4728-3186; Cabral, Thiago/0000-0002-1201-8772;
   Velez, Gabriel/0000-0003-0819-5933; Bassuk,
   Alexander/0000-0002-4067-2157; Mahajan, Vinit/0000-0003-1886-1741
FU NIH [K08EY020530, R01EY024665, R01EY025225, R01EY024698, R21AG050437,
   T32GM007337]; Doris Duke Charitable Foundation [2013103]; Research to
   Prevent Blindness (RPB), New York, NY; NATIONAL EYE INSTITUTE
   [R01EY024665, R01EY024698, K08EY020530, R01EY025225] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG050437]
   Funding Source: NIH RePORTER
FX VBM is supported by NIH grants [K08EY020530, R01EY024665, R01EY025225,
   R01EY024698 and R21AG050437], Doris Duke Charitable Foundation Grant #:
   2013103, and Research to Prevent Blindness (RPB), New York, NY. MT and
   GV are supported by NIH grant T32GM007337.
CR Ahmed MM, 2011, J NEUROSCI METH, V196, P99, DOI 10.1016/j.jneumeth.2011.01.004
   Chirco K. R., 2016, EYE LOND
   Crecelius A, 2008, PROTEOMICS, V8, P1276, DOI 10.1002/pmic.200700728
   de Heer J., 2008, DIABETOLOGIA, V51, P2263, DOI [DOI 10.1007/S00125-008-0991-2, 10.1007/s00125-008-1149-y, DOI 10.1007/S00125-008-1149-Y]
   Decanini A, 2008, DIABETOLOGIA, V51, P1051, DOI 10.1007/s00125-008-0991-2
   Ferrer I, 2007, J NEUROPATH EXP NEUR, V66, P35, DOI 10.1097/nen.0b013e31802c3e7d
   Funke S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29759
   Kanshin E, 2015, J PROTEOME RES, V14, P2998, DOI 10.1021/acs.jproteome.5b00404
   Mahajan VB, 2014, PROTEOM CLIN APPL, V8, P204, DOI 10.1002/prca.201300062
   Mukherjee Sumana, 2013, Methods Mol Biol, V1002, P71, DOI 10.1007/978-1-62703-360-2_6
   Nagy C, 2015, J NEUROPATH EXP NEUR, V74, P459, DOI 10.1097/NEN.0000000000000190
   Oka T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021405
   Skeie JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127567
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Skeie JM, 2014, PROTEOM CLIN APPL, V8, P209, DOI 10.1002/prca.201300043
   Skeie JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082140
   Skeie JM, 2012, RETINA-J RET VIT DIS, V32, P2141, DOI 10.1097/IAE.0b013e3182562017
   Velez Gabriel, 2017, Am J Ophthalmol Case Rep, V5, P107, DOI 10.1016/j.ajoc.2016.12.023
   Velez G, 2016, JAMA OPHTHALMOL, V134, P444, DOI 10.1001/jamaophthalmol.2015.5934
   Zhang PB, 2016, PROTEOMICS, V16, P1146, DOI 10.1002/pmic.201500188
NR 20
TC 4
Z9 4
U1 0
U2 8
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD NOV
PY 2017
IS 129
AR e56203
DI 10.3791/56203
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FP5UP
UT WOS:000417688700031
PM 29155757
OA Green Published
DA 2022-11-30
ER

PT J
AU Cabrera, AC
   Melo, E
   Roth, D
   Topp, A
   Delobel, F
   Stucki, C
   Chen, CY
   Jakob, P
   Banfai, B
   Dunkley, T
   Schilling, O
   Huber, S
   Iacone, R
   Petrone, P
AF Cabrera, Alvaro Cortes
   Melo, Esther
   Roth, Doris
   Topp, Andreas
   Delobel, Frederic
   Stucki, Corinne
   Chen, Chia-yi
   Jakob, Peter
   Banfai, Balazs
   Dunkley, Tom
   Schilling, Oliver
   Huber, Sylwia
   Iacone, Roberto
   Petrone, Paula
TI HtrA1 activation is driven by an allosteric mechanism of inter-monomer
   communication
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SERINE-PROTEASE HTRA1; HIGH-TEMPERATURE REQUIREMENT; DEGS PROTEASE;
   PEPTIDES; IDENTIFICATION; MUTATIONS; BINDING; REVEAL; FAMILY; SITE
AB The human protease family HtrA is responsible for preventing protein misfolding and mislocalization, and a key player in several cellular processes. Among these, HtrA1 is implicated in several cancers, cerebrovascular disease and age-related macular degeneration. Currently, HtrA1 activation is not fully characterized and relevant for drug-targeting this protease. Our work provides a mechanistic step-by-step description of HtrA1 activation and regulation. We report that the HtrA1 trimer is regulated by an allosteric mechanism by which monomers relay the activation signal to each other, in a PDZ-domain independent fashion. Notably, we show that inhibitor binding is precluded if HtrA1 monomers cannot communicate with each other. Our study establishes how HtrA1 trimerization plays a fundamental role in proteolytic activity. Moreover, it offers a structural explanation for HtrA1-defective pathologies as well as mechanistic insights into the degradation of complex extracellular fibrils such as tubulin, amyloid beta and tau that belong to the repertoire of HtrA1.
C1 [Cabrera, Alvaro Cortes; Melo, Esther; Roth, Doris; Topp, Andreas; Delobel, Frederic; Stucki, Corinne; Jakob, Peter; Banfai, Balazs; Dunkley, Tom; Huber, Sylwia; Iacone, Roberto; Petrone, Paula] Roche Innovat Ctr Basel, pRED, Basel, Switzerland.
   [Chen, Chia-yi; Schilling, Oliver] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany.
   [Banfai, Balazs] Soladis GmbH, CH-4052 Basel, Switzerland.
   [Schilling, Oliver] Univ Freiburg, BIOSS Ctr Biol Signaling Studies, D-79104 Freiburg, Germany.
   [Petrone, Paula] Barcelonabeta Brain Res Ctr, Fdn Pascual Maragall, Carrer Wellington,30, Barcelona 08005, Spain.
C3 Roche Holding; University of Freiburg; University of Freiburg
RP Petrone, P (通讯作者)，Roche Innovat Ctr Basel, pRED, Basel, Switzerland.; Petrone, P (通讯作者)，Barcelonabeta Brain Res Ctr, Fdn Pascual Maragall, Carrer Wellington,30, Barcelona 08005, Spain.
EM ppetrone@fpmaragall.org
RI Schilling, O/AAC-8302-2019; Cortes Cabrera, Alvaro/B-3748-2016
OI Schilling, Oliver/0000-0001-7678-7653; Cortes Cabrera,
   Alvaro/0000-0003-4635-6267; Banfai, Balazs/0000-0003-0422-7977; Petrone,
   Paula/0000-0002-5030-1915
FU DFG [SCHI 871/11-1, EXC 294]; Roche Postdoctoral Fellowship program
FX A.C. and E.M. acknowledge the support of the Roche Postdoctoral
   Fellowship program. P.P. gratefully thanks Juan Domingo Gispert, Jose
   Luis Molinuevo, and the team at BarcelonaBeta Brain Research Center for
   their support. Authors thank Sascha Fauser, Vice President of pRED
   Ophthalmology, Martin Strahm, Martin Erkens, Andrew Thomas, Josiane
   Kohler and Carlos Fenoy. We thank Klaus Muller for inspiration and
   encouragement. OS acknowledges support from grants DFG (SCHI 871/11-1)
   and (EXC 294, BIOSS).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Bowman GR, 2012, P NATL ACAD SCI USA, V109, P11681, DOI 10.1073/pnas.1209309109
   Chen Y, 2013, J INT MED RES, V41, P1445, DOI 10.1177/0300060513480926
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Chien J, 2009, J CELL BIOCHEM, V107, P253, DOI 10.1002/jcb.22121
   Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065
   de Regt AK, 2015, P NATL ACAD SCI USA, V112, P3326, DOI 10.1073/pnas.1502372112
   de Regt AK, 2015, STRUCTURE, V23, P517, DOI 10.1016/j.str.2015.01.012
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261
   Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946
   Jiang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046058
   Jomaa A, 2009, J BACTERIOL, V191, P1924, DOI 10.1128/JB.01187-08
   Kim S, 2012, P NATL ACAD SCI USA, V109, P7263, DOI 10.1073/pnas.1204791109
   Krojer T, 2010, NAT STRUCT MOL BIOL, V17, P844, DOI 10.1038/nsmb.1840
   Lane TJ, 2011, J AM CHEM SOC, V133, P18413, DOI 10.1021/ja207470h
   Malmstrom RD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8588
   Mauldin RV, 2013, NAT CHEM BIOL, V9, P90, DOI [10.1038/NCHEMBIO.1135, 10.1038/nchembio.1135]
   McClendon CL, 2014, P NATL ACAD SCI USA, V111, pE4623, DOI 10.1073/pnas.1418402111
   McClendon CL, 2009, J CHEM THEORY COMPUT, V5, P2486, DOI 10.1021/ct9001812
   Neuweiler H, 2003, J AM CHEM SOC, V125, P5324, DOI 10.1021/ja034040p
   Peisach E, 1999, BIOCHEMISTRY-US, V38, P11180, DOI 10.1021/bi991130r
   Poepsel S, 2015, NAT CHEM BIOL, V11, P862, DOI [10.1038/NCHEMBIO.1931, 10.1038/nchembio.1931]
   Sohn J, 2007, CELL, V131, P572, DOI 10.1016/j.cell.2007.08.044
   Sohn J, 2010, J BIOL CHEM, V285, P34039, DOI 10.1074/jbc.M110.135541
   Sohn J, 2009, MOL CELL, V33, P64, DOI 10.1016/j.molcel.2008.12.017
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938
   Team RC, 2018, R LANGUAGE ENV STAT
   Tennstaedt A, 2012, J BIOL CHEM, V287, P20931, DOI 10.1074/jbc.M111.316232
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Verdura E, 2015, BRAIN, V138, P2347, DOI 10.1093/brain/awv155
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Weski J, 2012, CHEMBIOCHEM, V13, P402, DOI 10.1002/cbic.201100643
NR 39
TC 16
Z9 16
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 1
PY 2017
VL 7
AR 14804
DI 10.1038/s41598-017-14208-z
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FL4XB
UT WOS:000414233700024
PM 29093542
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Mathis, T
   Housset, M
   Eandi, C
   Beguier, F
   Touhami, S
   Reichman, S
   Augustin, S
   Gondouin, P
   Sahel, JA
   Kodjikian, L
   Goureau, O
   Guillonneau, X
   Sennlaub, F
AF Mathis, Thibaud
   Housset, Michael
   Eandi, Chiara
   Beguier, Fanny
   Touhami, Sara
   Reichman, Sacha
   Augustin, Sebastien
   Gondouin, Pauline
   Sahel, Jose-Alain
   Kodjikian, Laurent
   Goureau, Olivier
   Guillonneau, Xavier
   Sennlaub, Florian
TI Activated monocytes resist elimination by retinal pigment epithelium and
   downregulate their OTX2 expression via TNF-alpha
SO AGING CELL
LA English
DT Article
DE age-related macular degeneration; monocytes; OTX2; retinal pigment
   epithelium; TNF-alpha; visual cycle
ID MACULAR DEGENERATION; DARK-ADAPTATION; PHOTORECEPTOR DEGENERATION;
   SUBRETINAL INFLAMMATION; MICROGLIA; APOPTOSIS; GENE; DIFFERENTIATION;
   CYTOKINES; ROD
AB Orthodenticle homeobox 2 (OTX2) controls essential, homeostatic retinal pigment epithelial (RPE) genes in the adult. Using cocultures of human CD14(+) blood monocytes (Mos) and primary porcine RPE cells and a fully humanized system using human-induced pluripotent stem cell-derived RPE cells, we show that activated Mos markedly inhibit RPE OTX2 expression and resist elimination in contact with the immunosuppressive RPE. Mechanistically, we demonstrate that TNF-alpha, secreted from activated Mos, mediates the downregulation of OTX2 and essential RPE genes of the visual cycle among others. Our data show how subretinal, chronic inflammation and in particular TNF-alpha can affect RPE function, which might contribute to the visual dysfunctions in diseases such as age-related macular degeneration (AMD) where subretinal macrophages are observed. Our findings provide important mechanistic insights into the regulation of OTX2 under inflammatory conditions. Therapeutic restoration of OTX2 expression might help revive RPE and visual function in retinal diseases such as AMD.
C1 [Mathis, Thibaud; Housset, Michael; Eandi, Chiara; Beguier, Fanny; Touhami, Sara; Reichman, Sacha; Augustin, Sebastien; Gondouin, Pauline; Sahel, Jose-Alain; Goureau, Olivier; Guillonneau, Xavier; Sennlaub, Florian] Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
   [Mathis, Thibaud; Housset, Michael; Eandi, Chiara; Beguier, Fanny; Touhami, Sara; Reichman, Sacha; Augustin, Sebastien; Gondouin, Pauline; Sahel, Jose-Alain; Goureau, Olivier; Guillonneau, Xavier; Sennlaub, Florian] UPMC Univ Paris 06, INSERM, CNRS, Sorbonne Univ, Paris, France.
   [Mathis, Thibaud; Kodjikian, Laurent] Univ Med Lyon 1, Croix Rousse Univ Hosp, Hosp Civils Lyon, Dept Ophthalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
   [Eandi, Chiara] Univ Turin, Dept Clin Sci, Eye Clin, Turin, Italy.
C3 UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; CHU Lyon; University of
   Turin
RP Mathis, T (通讯作者)，Croix Rousse Univ Hosp, Lyon, France.; Sennlaub, F (通讯作者)，Inst Vis, F-75012 Paris, France.
EM mathisthibaud@hotmail.fr; florian.sennlaub@inserm.fr
RI guillonneau, xavier/AAF-9495-2021; Mathis, Thibaud/AAK-5745-2021; Sahel,
   Jose-Alain/F-3172-2017; Mathis, Thibaud/R-3696-2016; GOUREAU,
   Olivier/ABH-9547-2020; GOUREAU, Olivier/F-2752-2017; Reichman,
   Sacha/R-7581-2017; Guillonneau, xavier/E-3995-2017; Sennlaub,
   Florian/F-2756-2017; Touhami, Sara/AAF-7836-2021; Beguier,
   Fanny/AAY-8581-2020
OI guillonneau, xavier/0000-0001-7379-3935; Sahel,
   Jose-Alain/0000-0002-4831-1153; Mathis, Thibaud/0000-0002-1418-1872;
   GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU,
   Olivier/0000-0001-7730-9143; Reichman, Sacha/0000-0003-1776-6339;
   Guillonneau, xavier/0000-0001-7379-3935; Sennlaub,
   Florian/0000-0003-4412-1341; Beguier, Fanny/0000-0002-6123-2978
FU INSERM; ANR MACLEAR [ANR-15-CE14-0015-01]; Labex Lifesenses; Carnot;
   Association de Prevoyance Sante de ALLIANZ; ANR within Investissements
   d'Avenir program [ANR-10-LABX-65, ANR-11-IDEX-0004-02]
FX This work was supported by grants from INSERM, ANR MACLEAR
   (ANR-15-CE14-0015-01), Labex Lifesenses, Carnot, and by the Association
   de Prevoyance Sante de ALLIANZ. This work was performed in the frame of
   the LABEX LIFESENSES [ANR-10-LABX-65] supported by the ANR within the
   Investissements d'Avenir program [ANR-11-IDEX-0004-02].
CR ACAMPORA D, 1995, DEVELOPMENT, V121, P3279
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Beby F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011673
   Becroft D M, 1981, Perspect Pediatr Pathol, V6, P203
   Cantos R, 2000, P NATL ACAD SCI USA, V97, P11707, DOI 10.1073/pnas.97.22.11707
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   CAVALLARO T, 1990, INVEST OPHTH VIS SCI, V31, P497
   Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Del Blanco DG, 2012, EUR J ENDOCRINOL, V167, P441, DOI 10.1530/EJE-12-0333
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Elner SG, 2003, T AM OPHTHAL SOC, V101, P89
   Elner Susan G, 2003, Trans Am Ophthalmol Soc, V101, P77
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fossat N, 2006, EMBO REP, V7, P824, DOI 10.1038/sj.embor.7400751
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Housset M, 2013, J NEUROSCI, V33, P9890, DOI 10.1523/JNEUROSCI.1099-13.2013
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   Masuda T, 2014, J BIOL CHEM, V289, P12908, DOI 10.1074/jbc.M114.556738
   Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Picard E, 2015, FREE RADICAL BIO MED, V89, P1105, DOI 10.1016/j.freeradbiomed.2015.08.018
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   SMITH PD, 1992, J CLIN INVEST, V90, P1642, DOI 10.1172/JCI116035
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yang DL, 2009, INVEST OPHTH VIS SCI, V50, P4998, DOI 10.1167/iovs.09-3620
NR 37
TC 27
Z9 27
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9726
J9 AGING CELL
JI Aging Cell
PD FEB
PY 2017
VL 16
IS 1
BP 173
EP 182
DI 10.1111/acel.12540
PG 10
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA EI2AG
UT WOS:000392287700016
PM 27660103
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Dabrowska, AM
   Skopinski, P
AF Dabrowska, Anna M.
   Skopinski, Piotr
TI Stem cells in regenerative medicine - from laboratory to clinical
   application - the eye
SO CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE stem cells; tissue engineering; regenerative medicine; eye; biomarkers;
   AMD; glaucoma; timbal stem cell deficiency; ophthalmology
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; IN-VITRO; AMNIOTIC
   MEMBRANE; PARTHENOGENETIC BLASTOCYSTS; TRABECULAR MESHWORK; IPS CELLS;
   TRANSPLANTATION; DIFFERENTIATION; LINES
AB Stem cells are currently one of the most researched and explored subject in science. They consstitue a very promising part of regenerative medicine and have many potential clinical applications. Harnessing their ability to replicate and differentiate into many cell types can enable successful treatment of diseases that were incurable until now. There are numerous types of stem cells (e.g. ESCs, FSCs, ASCs, iPSCs) and many different methods of deriving and cultivating them in order to obtain viable material. The eye is one of the most interesting targets for stem cell therapies. In this article we summarise different aspects of stem cells, discussing their characteristics, sources and methods of culture. We also demonstrate the most recent clinical applications in ophthalmology based on an extensive current literature review. Tissue engineering techniques developed for corneal limbal stem cell deficiency, age-related macular degeneration (AMD) and glaucoma are among those presented. Both laboratory and clinical aspects of stem cells are discussed.
C1 [Dabrowska, Anna M.; Skopinski, Piotr] Warsaw Med Univ, Fac Med 2, Dept Ophthalmol, Warsaw, Poland.
   [Skopinski, Piotr] Warsaw Med Univ, Biostruct Ctr, Dept Histol & Embriol, Warsaw, Poland.
C3 Medical University of Warsaw; Medical University of Warsaw
RP Dabrowska, AM (通讯作者)，Warsaw Med Univ, Fac Med 2, Dept Ophthalmol, Warsaw, Poland.
EM anna.m.dabrowska@gmail.com
OI Skopinski, Piotr/0000-0001-5794-9346
CR Abad M, 2013, NATURE, V502, P340, DOI 10.1038/nature12586
   Abu-Hassan DW, 2015, STEM CELLS, V33, P751, DOI 10.1002/stem.1885
   Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318
   Ahmad S, 2008, STEM CELLS, V26, P1609, DOI 10.1634/stemcells.2007-0782
   Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Borestrom C, 2014, STEM CELL TRANSL MED, V3, P433, DOI 10.5966/sctm.2013-0138
   Brevini IAL, 2008, CELL PROLIFERAT, V41, P20, DOI 10.1111/j.1365-2184.2008.00485.x
   Bull ND, 2008, INVEST OPHTH VIS SCI, V49, P3449, DOI 10.1167/iovs.08-1770
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Chen MF, 2010, INVEST OPHTH VIS SCI, V51, P5970, DOI 10.1167/iovs.09-4504
   Chen Z, 2004, STEM CELLS, V22, P355, DOI 10.1634/stemcells.22-3-355
   Choi HY, 2016, J CONTROL RELEASE, V235, P222, DOI 10.1016/j.jconrel.2016.06.007
   Chung Y, 2008, CELL STEM CELL, V2, P113, DOI 10.1016/j.stem.2007.12.013
   Cooke Jessica A, 2015, Curr Ophthalmol Rep, V3, P200
   Dabrowski FA, 2017, GYNECOL OBSTET INVES, V82, P267, DOI 10.1159/000449199
   Ding QJ, 2014, INVEST OPHTH VIS SCI, V55, P7065, DOI 10.1167/iovs.14-14800
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Du YQ, 2013, INVEST OPHTH VIS SCI, V54, P1450, DOI 10.1167/iovs.12-11056
   Du YQ, 2012, INVEST OPHTH VIS SCI, V53, P1566, DOI 10.1167/iovs.11-9134
   Ebrahimi Marzieh, 2009, J Ophthalmic Vis Res, V4, P40
   EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Gotherstrom C, 2004, AM J OBSTET GYNECOL, V190, P239, DOI 10.1016/j.ajog.2003.07.022
   Hambright D, 2012, MOL VIS, V18, P920
   Hayashi R, 2016, NATURE, V531, P376, DOI 10.1038/nature17000
   Hayashi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045435
   Karussis D, 2008, J NEUROL SCI, V265, P131, DOI 10.1016/j.jns.2007.05.005
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   KENYON KR, 1989, OPHTHALMOLOGY, V96, P709
   Khan Wasim S, 2012, J Stem Cells, V7, P75
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Klimanskaya I, 2007, NAT PROTOC, V2, P1963, DOI 10.1038/nprot.2007.274
   Kolios G, 2013, RESPIRATION, V85, P3, DOI 10.1159/000345615
   Leaver SG, 2006, GLIA, V53, P467, DOI 10.1002/glia.20311
   Lehrer MS, 1998, J CELL SCI, V111, P2867
   Li Y, 2003, J NEUROSCI, V23, P7783
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   Liu JB, 2011, AM J OPHTHALMOL, V152, P739, DOI 10.1016/j.ajo.2011.03.037
   Lodi D, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-9
   Lohmann M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037839
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Ma H, 2014, NATURE, V511, P177, DOI 10.1038/nature13551
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Maekawa Y, 2016, CURR EYE RES, V41, P558, DOI 10.3109/02713683.2015.1038359
   Mai QY, 2007, CELL RES, V17, P1008, DOI 10.1038/cr.2007.102
   Manuguerra-Gagne R, 2013, STEM CELLS, V31, P1136, DOI 10.1002/stem.1364
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Martinez-Morales JR, 2005, DEV CELL, V8, P565, DOI 10.1016/j.devcel.2005.01.022
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Mikhailova A, 2014, STEM CELL REP, V2, P219, DOI 10.1016/j.stemcr.2013.12.014
   Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001
   Mormone E, 2014, STEM CELLS DEV, V23, P2626, DOI 10.1089/scd.2014.0151
   Murray IR, 2014, CELL MOL LIFE SCI, V71, P1353, DOI 10.1007/s00018-013-1462-6
   Nagano K, 2008, PROTEOMICS, V8, P4025, DOI 10.1002/pmic.200800073
   O'Donoghue K, 2004, BEST PRACT RES CL OB, V18, P853, DOI 10.1016/j.bpobgyn.2004.06.010
   Ouyang H, 2014, NATURE, V511, P358, DOI 10.1038/nature13465
   Park Un Chul, 2011, Clin Exp Reprod Med, V38, P216, DOI 10.5653/cerm.2011.38.4.216
   Pellegrini G, 1999, TRANSPLANTATION, V68, P868, DOI 10.1097/00007890-199909270-00021
   Rama P, 2001, TRANSPLANTATION, V72, P1478, DOI 10.1097/00007890-200111150-00002
   Revazova ES, 2008, CLONING STEM CELLS, V10, P11, DOI 10.1089/clo.2007.0063
   Riazifar H, 2014, STEM CELL TRANSL MED, V3, P424, DOI 10.5966/sctm.2013-0147
   Rojewski MT, 2008, TRANSFUS MED HEMOTH, V35, P168, DOI 10.1159/000129013
   Rossant J, 2001, STEM CELLS, V19, P477, DOI 10.1634/stemcells.19-6-477
   Sakamoto N, 2007, BLOOD, V110, P501, DOI 10.1182/blood-2007-01-066522
   Schlotzer-Schrehardt U, 2005, EXP EYE RES, V81, P247, DOI 10.1016/j.exer.2005.02.016
   Schwab M, 2009, ENCY CANC, P3511
   Schwab M, 2009, ENCY CANC, P3028
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Singhal S, 2012, STEM CELL TRANSL MED, V1, P188, DOI 10.5966/sctm.2011-0005
   Skipper M, 2010, NATURE, V465, P703, DOI 10.1038/465703a
   Smith A, 2006, NATURE, V441, P1060, DOI 10.1038/nature04954
   Son JL, 2010, GLIA, V58, P780, DOI 10.1002/glia.20962
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Sun Y, 2015, SURV OPHTHALMOL, V60, P93, DOI 10.1016/j.survophthal.2014.07.001
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takeuchi K, 2012, EYE, V26, P52, DOI 10.1038/eye.2011.302
   Tay CY, 2012, STEM CELLS DEV, V21, P1381, DOI 10.1089/scd.2011.0655
   Thomas PB, 2007, MOL VIS, V13, P337
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vazirani J, 2014, AM J OPHTHALMOL, V157, P584, DOI 10.1016/j.ajo.2013.11.011
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Watanabe M, 2002, J NEUROSCI RES, V69, P826, DOI 10.1002/jnr.10338
   Wilkins A, 2001, GLIA, V36, P48, DOI 10.1002/glia.1094
   Wilkins A, 2003, J NEUROSCI, V23, P4967, DOI 10.1523/jneurosci.23-12-04967.2003
   Wilson KD, 2015, JAMA-J AM MED ASSOC, V313, P1613, DOI 10.1001/jama.2015.1846
   Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003
   Woronkowicz M, 2010, CENT EUR J IMMUNOL, V35, P267
   Woronkowicz M, 2010, CENT EUR J IMMUNOL, V35, P179
   Xie BB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112175
   Yu JY, 2014, PRINCIPLES OF TISSUE ENGINEERING, 4TH EDITION, P581, DOI 10.1016/B978-0-12-398358-9.00030-6
   Zhang YS, 2012, J ASSIST REPROD GEN, V29, P735, DOI 10.1007/s10815-012-9802-2
   Zhao Y, 2015, CORNEA, V34, P592, DOI 10.1097/ICO.0000000000000398
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
NR 96
TC 7
Z9 7
U1 0
U2 5
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1426-3912
EI 1644-4124
J9 CENT EUR J IMMUNOL
JI Central Eur. J. Immunol.
PY 2017
VL 42
IS 2
BP 173
EP 180
DI 10.5114/ceji.2017.69360
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA FE2WE
UT WOS:000408077100009
PM 28860936
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Li, SJ
   Shang, JL
   Chen, QL
   Sun, Y
   Liu, JX
AF Li, Shengjun
   Shang, Junliang
   Chen, Qinliang
   Sun, Yan
   Liu, Jin-Xing
TI A compressed sensing based two-stage method for detecting epistatic
   interactions
SO INTERNATIONAL JOURNAL OF DATA MINING AND BIOINFORMATICS
LA English
DT Article
DE epistatic interactions; SNP; single nucleotide polymorphism; compressed
   sensing; sparse representation; mutual information
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; MUTUAL INFORMATION;
   SELECTION; POLYMORPHISM
AB Epistatic interactions of single nucleotide polymorphisms (SNPs) are believed to be important in revealing missing heritability of complex diseases. Detection of them is of great challenge since it is a high-dimensional and small-sample-size problem. In this paper, we propose a compressed sensing (CS) based two-stage method CSMiner for detecting epistatic interactions. It consists of two stages: screening stage and detecting stage. In screening stage, SNP selection is equivalent to CS reconstruction by considering SNP data and class labels as sensing matrix and measurement vector, respectively. Here, top ranking SNPs with high signal weights are retained. In detecting stage, mutual information is employed to exhaustively search epistatic interactions within the retained SNPs. Experiments of CSMiner are performed on both simulation data sets and a real age-related macular degeneration data set. Results demonstrate that CSMiner is effective and efficient in detecting epistatic interactions, and might be an alternative to existing methods.
C1 [Li, Shengjun; Shang, Junliang; Chen, Qinliang; Sun, Yan; Liu, Jin-Xing] Qufu Normal Univ, Sch Informat Sci & Engn, Rizhao 276826, Peoples R China.
   [Liu, Jin-Xing] Harbin Inst Technol, Shenzhen Grad Sch, Biocomp Res Ctr, Shenzhen 518055, Peoples R China.
C3 Qufu Normal University; Harbin Institute of Technology; University Town
   of Shenzhen
RP Shang, JL (通讯作者)，Qufu Normal Univ, Sch Informat Sci & Engn, Rizhao 276826, Peoples R China.
EM qfnulsj@163.com; shangjunliang110@163.com; helloworld.c@foxmail.com;
   sunyan225@126.com; sdcavell@126.com
RI Liu, Jin-Xing/AAU-7257-2020
FU National Natural Science Foundation of China [61502272, 61572284,
   61572283]; Award Foundation Project of Excellent Young Scientists in
   Shandong Province [BS2014DX004, BS2014DX005]; Science and Technology
   Planning Project of Qufu Normal University [xkj201524]; Elaborate
   Experiment Project of Qufu Normal University [jp2015005]; Innovation and
   Entrepreneurship Training Project for College Students of Qufu Normal
   University [2015A059]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 61502272, 61572284, 61572283); the Award Foundation
   Project of Excellent Young Scientists in Shandong Province (BS2014DX004,
   BS2014DX005); the Science and Technology Planning Project of Qufu Normal
   University (xkj201524); the Elaborate Experiment Project of Qufu Normal
   University (jp2015005) and the Innovation and Entrepreneurship Training
   Project for College Students of Qufu Normal University (2015A059).
CR [Anonymous], ARXIV13053002
   Baraniuk RG, 2007, IEEE SIGNAL PROC MAG, V24, P118, DOI 10.1109/MSP.2007.4286571
   Baraniuk RG, 2010, IEEE T INFORM THEORY, V56, P1982, DOI 10.1109/TIT.2010.2040894
   Cao HB, 2013, I S BIOMED IMAGING, P756
   Changyi Ma, 2014, 2014 8th International Conference on Systems Biology (ISB), P151, DOI 10.1109/ISB.2014.6990748
   Chen L, 2009, IEEE INT C BIO BIO W, P25
   Chen SSB, 1998, SIAM J SCI COMPUT, V20, P33, DOI 10.1137/S1064827596304010
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XJ, 2015, IEEE ACM T COMPUT BI, V12, P695, DOI 10.1109/TCBB.2014.2363459
   Donoho DL, 2006, IEEE T INFORM THEORY, V52, P1289, DOI 10.1109/TIT.2006.871582
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Duarte MF, 2011, IEEE T SIGNAL PROCES, V59, P4053, DOI 10.1109/TSP.2011.2161982
   Ebermann I, 2009, J MED GENET, V46, P277, DOI 10.1136/jmg.2008.059626
   Foithong S, 2012, EXPERT SYST APPL, V39, P574, DOI 10.1016/j.eswa.2011.07.048
   Fontanarosa J, 2010, IEEE INT C BIO BIO W, P330, DOI 10.1109/BIBMW.2010.5703823
   [耿耀君 Geng YaoJun], 2013, [模式识别与人工智能, Pattern Recognition and Artificial Intelligence], V26, P106
   Gholami A, 2010, GEOPHYS J INT, V180, P871, DOI 10.1111/j.1365-246X.2009.04453.x
   Guo X, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-102
   Ho C. M., 2014, ARXIV14086583
   Huh IS, 2011, IEEE INT C BIO BIO W, P708, DOI 10.1109/BIBMW.2011.6112457
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kwon MS, 2012, INT J DATA MIN BIOIN, V6, P471, DOI 10.1504/IJDMB.2012.049301
   Vinh LT, 2012, APPL INTELL, V37, P100, DOI 10.1007/s10489-011-0315-y
   Liu H, 2005, IEEE T KNOWL DATA EN, V17, P491, DOI 10.1109/TKDE.2005.66
   Lorente-Galdos B, 2012, INT J DATA MIN BIOIN, V6, P324, DOI 10.1504/IJDMB.2012.049249
   Luan Yi-Zhao, 2013, Yichuan, V35, P1331, DOI 10.3724/SP.J.1005.2013.01331
   Miller DJ, 2009, BIOINFORMATICS, V25, P2478, DOI 10.1093/bioinformatics/btp435
   Oh S, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S9-S5
   Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159
   Poon SK, 2011, INT J DATA MIN BIOIN, V5, P353, DOI 10.1504/IJDMB.2011.041553
   Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344
   Seshadri S, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S15
   Shang JL, 2014, DIGIT SIGNAL PROCESS, V24, P1, DOI 10.1016/j.dsp.2013.08.007
   Shang JL, 2013, GENES GENOM, V35, P305, DOI 10.1007/s13258-013-0081-9
   Shang JL, 2012, GENES GENOM, V34, P321, DOI 10.1007/s13258-012-0003-2
   Shang JL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-475
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Tang WW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000464
   Tang Wenlong, 2012, Adv Genet Eng, V1, P101
   Tang WL, 2011, J BIOINF COMPUT BIOL, V9, P631, DOI 10.1142/S0219720011005689
   Trocan M, 2014, MULTIMED TOOLS APPL, V72, P95, DOI 10.1007/s11042-012-1330-7
   van den Berg E., 2007, SPARCO TESTING FRAME
   Vattikuti S, 2014, GIGASCIENCE, V3, DOI 10.1186/2047-217X-3-10
   Wan XA, 2010, AM J HUM GENET, V87, P325, DOI 10.1016/j.ajhg.2010.07.021
   Wan X, 2010, BIOINFORMATICS, V26, P30, DOI 10.1093/bioinformatics/btp622
   Wang M., 2009, STAT BIOPHARMACEUTIC, V1
   Wang Yupeng, 2010, BMC Res Notes, V3, P117, DOI 10.1186/1756-0500-3-117
   Wei WH, 2014, NAT REV GENET, V15, P722, DOI 10.1038/nrg3747
   Yu L, 2009, INT J DATA MIN BIOIN, V3, P177, DOI 10.1504/IJDMB.2009.024850
   Zhang QR, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003627
   Zhang X, 2010, BIOINFORMATICS, V26, pi217, DOI 10.1093/bioinformatics/btq186
   Zhang Y, 2010, INT J DATA MIN BIOIN, V4, P348, DOI 10.1504/IJDMB.2010.033525
NR 52
TC 2
Z9 2
U1 1
U2 22
PU INDERSCIENCE ENTERPRISES LTD
PI GENEVA
PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 856, CH-1215
   GENEVA, SWITZERLAND
SN 1748-5673
EI 1748-5681
J9 INT J DATA MIN BIOIN
JI Int. J. Data Min. Bioinform.
PY 2016
VL 14
IS 4
BP 354
EP 372
DI 10.1504/IJDMB.2016.075821
PG 19
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA DM1NI
UT WOS:000376111900005
DA 2022-11-30
ER

PT J
AU Gelfand, BD
   Wright, CB
   Kim, Y
   Yasuma, T
   Yasuma, R
   Li, SJ
   Fowler, BJ
   Bastos-Carvalho, A
   Kerur, N
   Uittenbogaard, A
   Han, YS
   Lou, DY
   Kleinman, ME
   McDonald, WH
   Nunez, G
   Georgel, P
   Dunaief, JL
   Ambati, J
AF Gelfand, Bradley D.
   Wright, Charles B.
   Kim, Younghee
   Yasuma, Tetsuhiro
   Yasuma, Reo
   Li, Shengjian
   Fowler, Benjamin J.
   Bastos-Carvalho, Ana
   Kerur, Nagaraj
   Uittenbogaard, Annette
   Han, Youn Seon
   Lou, Dingyuan
   Kleinman, Mark E.
   McDonald, W. Hayes
   Nunez, Gabriel
   Georgel, Philippe
   Dunaief, Joshua L.
   Ambati, Jayakrishna
TI Iron Toxicity in the Retina Requires Alu RNA and the NLRP3 Inflammasome
SO CELL REPORTS
LA English
DT Article
ID BINDING-PROTEIN 2; MACULAR DEGENERATION; ALZHEIMERS-DISEASE; ACTIVATION;
   PCBP2; CELLS; IDENTIFICATION; ACCUMULATION; INDUCTION; FEATURES
AB Excess iron induces tissue damage and is implicated in age-related macular degeneration (AMD). Iron toxicity is widely attributed to hydroxyl radical formation through Fenton's reaction. We report that excess iron, but not other Fenton catalytic metals, induces activation of the NLRP3 inflammasome, a pathway also implicated in AMD. Additionally, iron-induced degeneration of the retinal pigmented epithelium (RPE) is suppressed in mice lacking inflammasome components caspase-1/11 or Nlrp3 or by inhibition of caspase-1. Iron overload increases abundance of RNAs transcribed from short interspersed nuclear elements (SINEs): Alu RNAs and the rodent equivalent B1 and B2 RNAs, which are inflammasome agonists. Targeting Alu or B2 RNA prevents iron-induced inflammasome activation and RPE degeneration. Iron-induced SINE RNA accumulation is due to suppression of DICER1 via sequestration of the co-factor poly(C)-binding protein 2 (PCBP2). These findings reveal an unexpected mechanism of iron toxicity, with implications for AMD and neurodegenerative diseases associated with excess iron.
C1 [Gelfand, Bradley D.; Wright, Charles B.; Kim, Younghee; Yasuma, Tetsuhiro; Yasuma, Reo; Li, Shengjian; Fowler, Benjamin J.; Bastos-Carvalho, Ana; Kerur, Nagaraj; Uittenbogaard, Annette; Han, Youn Seon; Lou, Dingyuan; Kleinman, Mark E.; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40536 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Microbiol Immunol & Human Genet, Lexington, KY 40536 USA.
   [Fowler, Benjamin J.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
   [McDonald, W. Hayes] Vanderbilt Univ, Sch Med, Prote Lab, Mass Spectrometry Res Ctr, Nashville, TN 37205 USA.
   [McDonald, W. Hayes] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37205 USA.
   [Nunez, Gabriel] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Nunez, Gabriel] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Georgel, Philippe] Univ Strasbourg, Federat Med Translat FMTS, INSERM, UMR S 1109, F-67085 Strasbourg, France.
   [Dunaief, Joshua L.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Kentucky; Vanderbilt University; Vanderbilt University;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg; University of Pennsylvania; Pennsylvania
   Medicine
RP Gelfand, BD (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
EM brad.gelfand@uky.edu
RI McDonald, W. Hayes/B-4109-2016; Nuñez, Gabriel/A-7160-2014; Gelfand,
   Brad/L-3926-2019; georgel, philippe/P-5676-2016
OI McDonald, W. Hayes/0000-0002-3510-426X; georgel,
   philippe/0000-0001-6853-7080; Kleinman, Mark/0000-0001-8557-7949
FU Fight for Sight postdoctoral award; NIH [DP1GM114862, R01EY018350,
   R01EY018836, R01EY020672, R01EY022238, R01EY024068, T32HL091812,
   UL1RR033173, K99EY024336]; Doris Duke Distinguished Clinical Scientist
   Award; Burroughs WellcomeFund Clinical Scientist Award in Translational
   Research; Ellison Medical Foundation Senior Scholar in Aging Award;
   Foundation Fighting Blindness Individual Investigator Research Award;
   Harrington Discovery Institute Scholar-Innovator Award; Dr. E. Vernon
   Smith and Eloise C. Smith Macular Degeneration Endowed Chair; Research
   to Prevent Blindness departmental unrestricted grant; Programme for
   Advanced Medical Education; Fundacao Calouste Gulbenkian; Fundacao
   Champalimaud; Ministerio da Saude; Fundacao para a Ciencia e Tecnologia,
   Portugal; Bayer Global Ophthalmology Research Award; Alcon Japan
   Research award; Beckman Initiative for Macular Research; Loris and David
   Rich Postdoctoral Scholar Award (IRRF); NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR000117] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR033173] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [K99EY024336, R01EY022238, R01EY018836,
   R01EY020672, R01EY015240, K08EY021757, R01EY024068, R01EY018350] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [T32HL091812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [DP1GM114862] Funding Source: NIH RePORTER
FX Vector to express recombinant human PCBP2 was provided by Dr. Peng Jin
   (Emory University). L. Toll, G.R. Pattison, R. King, L. Xu, M.
   McConnell, C. Payne, D. Robertson, and G. Botzet provided technical
   assistance. B.D.G. was supported by American Heart Association and
   International Retinal Research Foundation (IRRF); T.Y. was supported by
   Fight for Sight postdoctoral award; J.A. was supported by NIH grants
   (DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238, and
   R01EY024068), Doris Duke Distinguished Clinical Scientist Award,
   Burroughs WellcomeFund Clinical Scientist Award in Translational
   Research, Ellison Medical Foundation Senior Scholar in Aging Award,
   Foundation Fighting Blindness Individual Investigator Research Award,
   Harrington Discovery Institute Scholar-Innovator Award, Dr. E. Vernon
   Smith and Eloise C. Smith Macular Degeneration Endowed Chair, and
   Research to Prevent Blindness departmental unrestricted grant; B.J.F.
   was supported by NIH T32HL091812 and UL1RR033173; A.B.-C. was supported
   by the Programme for Advanced Medical Education (sponsored by Fundacao
   Calouste Gulbenkian, Fundacao Champalimaud, Ministerio da Saude, and
   Fundacao para a Ciencia e Tecnologia, Portugal) and Bayer Global
   Ophthalmology Research Award; Y.K. was supported by Alcon Japan Research
   award; N.K. was supported by Beckman Initiative for Macular Research and
   NIH K99EY024336; and C.B.W. was supported by The Loris and David Rich
   Postdoctoral Scholar Award (IRRF). J.A. and B.J.F. are named as
   inventors on patent applications relating to the treatment of macular
   degeneration filed by their employer, the University of Kentucky. J.A.
   is a co-founder of iVeena (Holdings, Pharma, Delivery), which has
   licensed some of this technology from the University of Kentucky. J.A.
   has received honoraria from Allergan.
CR Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ayton S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/581256
   Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997
   Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115
   Chan C., 2013, SEATTL WA ARVO ANN M
   Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375
   Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120
   DEXTER DT, 1987, LANCET, V2, P1219
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Freeman D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062143
   Ghosh D, 2008, P NATL ACAD SCI USA, V105, P11673, DOI 10.1073/pnas.0803182105
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Han W, 2013, J CLIN INVEST, V123, P2103, DOI 10.1172/JCI61820
   Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729
   Hu CE, 2014, BIOCHEM BIOPH RES CO, V448, P437, DOI 10.1016/j.bbrc.2014.04.124
   Hu QD, 2012, NAT STRUCT MOL BIOL, V19, P1168, DOI 10.1038/nsmb.2400
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Jurka J, 2005, CYTOGENET GENOME RES, V110, P117, DOI 10.1159/000084943
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Lane Darius J R, 2014, Biochem J, V462, pe1, DOI 10.1042/BJ20140720
   Li YJ, 2012, CELL METAB, V15, P895, DOI 10.1016/j.cmet.2012.04.021
   Lin M, 1997, AM J PHYSIOL-GASTR L, V272, pG1355
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mori MA, 2012, CELL METAB, V16, P336, DOI 10.1016/j.cmet.2012.07.017
   Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532
   Quintana C, 2006, J STRUCT BIOL, V153, P42, DOI 10.1016/j.jsb.2005.11.001
   Ren YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056950
   Ren YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040705
   Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x
   Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Urrutia PJ, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00038
   Waggoner SA, 2009, J BIOL CHEM, V284, P9039, DOI 10.1074/jbc.M806986200
   Wiesen JL, 2009, MOL IMMUNOL, V46, P1222, DOI 10.1016/j.molimm.2008.11.012
   Xin ZS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025419
   Xiong S, 2008, AM J PHYSIOL-GASTR L, V295, pG512, DOI 10.1152/ajpgi.90327.2008
   Yan YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080029
   You FP, 2009, NAT IMMUNOL, V10, P1300, DOI 10.1038/ni.1815
NR 48
TC 52
Z9 52
U1 1
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUN 23
PY 2015
VL 11
IS 11
BP 1686
EP 1693
DI 10.1016/j.celrep.2015.05.023
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CL3PW
UT WOS:000356863600002
PM 26074074
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Xue, CY
   Rosen, R
   Jordan, A
   Hu, DN
AF Xue, Chunyan
   Rosen, Richard
   Jordan, Adrienne
   Hu, Dan-Ning
TI Management of Ocular Diseases Using Lutein and Zeaxanthin: What Have We
   Learned from Experimental Animal Studies?
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID MACULAR DEGENERATION; DIETARY ANTIOXIDANTS; ISCHEMIA-REPERFUSION; VEGF
   EXPRESSION; INDUCED UVEITIS; FATTY-ACIDS; CELL-DEATH; AGE; PIGMENT;
   MODEL
AB Zeaxanthin and lutein are two carotenoid pigments that concentrated in the retina, especially in the macula. The effects of lutein and zeaxanthin on the prevention and treatment of various eye diseases, including age- related macular degeneration, diabetic retinopathy and cataract, ischemic/hypoxia induced retinopathy, light damage of the retina, retinitis pigmentosa, retinal detachment, and uveitis, have been studied in different experimental animal models. In these animal models, lutein and zeaxanthin have been reported to have beneficial effects in protecting ocular tissues and cells (especially the retinal neurons) against damage caused by different etiological factors. The mechanisms responsible for these effects of lutein and zeaxanthin include prevention of phototoxic damage by absorption of blue light, reduction of oxidative stress through antioxidant activity and free radical scavenging, and their anti-inflammatory and antiangiogenic properties. The results of these experimental animal studies may provide new preventive and therapeutic procedures for clinical management of various vision-threatening diseases.
C1 [Xue, Chunyan] Nanjing Univ, Sch Med, Jinling Hosp, Dept Ophthalmol, Nanjing 210002, Jiangsu, Peoples R China.
   [Rosen, Richard; Hu, Dan-Ning] Ichan Sch Med Mt Sinai, New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY 10003 USA.
   [Jordan, Adrienne; Hu, Dan-Ning] Ichan Sch Med Mt Sinai, New York Eye & Ear Infirm Mt Sinai, Dept Pathol, New York, NY 10003 USA.
C3 Nanjing University; Icahn School of Medicine at Mount Sinai; New York
   Eye & Ear Infirmary of Mount Sinai; Icahn School of Medicine at Mount
   Sinai; New York Eye & Ear Infirmary of Mount Sinai
RP Rosen, R (通讯作者)，Nanjing Univ, Sch Med, Jinling Hosp, Dept Ophthalmol, Nanjing 210002, Jiangsu, Peoples R China.
EM rrosen@nyee.edu; hu2095@yahoo.com
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   [Anonymous], 2005, Altern Med Rev, V10, P128
   Arnal E, 2009, GRAEF ARCH CLIN EXP, V247, P115, DOI 10.1007/s00417-008-0935-z
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Barker FM, 2010, CURR MED RES OPIN, V26, P2011, DOI 10.1185/03007995.2010.494549
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bohm F, 2012, ACTA BIOCHIM POL, V59, P27
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choi JS, 2006, NUTRITION, V22, P668, DOI 10.1016/j.nut.2005.08.011
   Dilsiz N, 2006, GRAEF ARCH CLIN EXP, V244, P627, DOI 10.1007/s00417-005-0084-6
   Fernandez-Robredo P, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/213505
   Fernandez-Robredo P, 2009, CURR EYE RES, V34, P543, DOI 10.1080/02713680902963142
   Gong XM, 2015, ARCH BIOCHEM BIOPHYS, V572, P40, DOI 10.1016/j.abb.2015.02.004
   He RR, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-38
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jin XH, 2006, INVEST OPHTH VIS SCI, V47, P2562, DOI 10.1167/iovs.05-1429
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Kowluru RA, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-8
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Li SY, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/426769
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   Lu N, 1999, CURR EYE RES, V19, P403, DOI 10.1076/ceyr.19.5.403.5290
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Miranda M, 2010, FREE RADICAL BIO MED, V48, P216, DOI 10.1016/j.freeradbiomed.2009.10.042
   Muriach M, 2006, FREE RADICAL BIO MED, V41, P979, DOI 10.1016/j.freeradbiomed.2006.06.023
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sanz MM, 2007, NEUROSCIENCE, V145, P1120, DOI 10.1016/j.neuroscience.2006.12.034
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tang L, 2011, EXP BIOL MED, V236, P1051, DOI 10.1258/ebm.2011.010400
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Woo TTY, 2013, GRAEF ARCH CLIN EXP, V251, P41, DOI 10.1007/s00417-012-2128-z
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Yu HF, 2013, MOL NUTR FOOD RES, V57, P1158, DOI 10.1002/mnfr.201200642
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
NR 57
TC 21
Z9 21
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 523027
DI 10.1155/2015/523027
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW2WD
UT WOS:000364852900001
PM 26617995
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Papakyriakou, A
   Kefalos, P
   Sarantis, P
   Tsiamantas, C
   Xanthopoulos, KP
   Vourloumis, D
   Beis, D
AF Papakyriakou, Athanasios
   Kefalos, Panagiotis
   Sarantis, Panagiotis
   Tsiamantas, Christos
   Xanthopoulos, Kleanthis P.
   Vourloumis, Dionisios
   Beis, Dimitris
TI A Zebrafish In Vivo Phenotypic Assay to Identify
   3-Aminothiophene-2-Carboxylic Acid-Based Angiogenesis Inhibitors
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
ID DISCOVERY; ALGORITHM; MODEL; VEGF
AB Small molecules that inhibit angiogenesis are attractive drug candidates for cancer, retinopathies, and age-related macular degeneration. In vivo, phenotypic screening in zebrafish (Danio rerio) emerges as a powerful methodology to identify and optimize novel compounds with pharmacological activity. Zebrafish provides several advantages for in vivo phenotypic screens especially for angiogenesis, since it develops rapidly, externally, and does not rely on a functional cardiovascular system to survive for several days during development. In this study, we utilize a transgenic line that allows the noninvasive monitoring of angiogenesis at a cellular level. The inhibition of angiogenesis can be observed under a fluorescent stereoscope and quantified. To exemplify the versatility and robustness of the zebrafish screen, we have employed a series of 60 novel compounds that were designed based on a potent VEGFR2 inhibitor. Herein, we report their structure-based design, synthesis, and in vivo zebrafish screening for optimal activity, toxicity, and off-target effects, which revealed six reversible inhibitors of angiogenesis.
C1 [Papakyriakou, Athanasios; Tsiamantas, Christos; Xanthopoulos, Kleanthis P.; Vourloumis, Dionisios] NCSR Demokritos, Lab Chem Biol Nat Prod & Designed Mol, Athens 15310, Greece.
   [Kefalos, Panagiotis; Sarantis, Panagiotis; Beis, Dimitris] Acad Athens, Biomed Res Fdn, Athens 11527, Greece.
C3 National Centre of Scientific Research "Demokritos"; Academy of Athens
RP Beis, D (通讯作者)，Acad Athens, Biomed Res Fdn, Athens 11527, Greece.
EM vourloumis@chem.demokritos.gr; dbeis@bioacademy.gr
RI Papakyriakou, Athanasios/K-7033-2012; Sarantis,
   Panagiotis/AAF-4774-2021; Xanthopoulos, Kleanthis/AAG-7438-2020
OI Papakyriakou, Athanasios/0000-0003-3931-6232; Sarantis,
   Panagiotis/0000-0001-5848-7905; Xanthopoulos,
   Kleanthis/0000-0002-0578-492X; Beis, Dimitris/0000-0003-2579-7848
FU General Secretariat of Research and Technology; European Social Fund;
   National Funds (Aristia I grant); TransMed, an FP7 REGPOT Capacities
   [245928]
FX This work was supported by the General Secretariat of Research and
   Technology, European Social Fund and National Funds (Aristia I grant to
   DB), and TransMed, an FP7 REGPOT Capacities (grant no. 245928). All
   authors have read the journal's authorship agreement.
CR Bowman TV, 2010, ACS CHEM BIOL, V5, P159, DOI 10.1021/cb100029t
   Bussmann J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000064
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Cee VJ, 2009, BIOORG MED CHEM LETT, V19, P424, DOI 10.1016/j.bmcl.2008.11.056
   Chang DJ, 2012, J MED CHEM, V55, P10863, DOI 10.1021/jm301488q
   Chen T, 2012, MOLECULES, V17, P6249, DOI 10.3390/molecules17066249
   Covassin LD, 2009, DEV BIOL, V329, P212, DOI 10.1016/j.ydbio.2009.02.031
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753
   Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Herzog W, 2009, CIRC RES, V104, P1260, DOI 10.1161/CIRCRESAHA.108.191718
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jinn SW, 2005, DEVELOPMENT, V132, P5199, DOI 10.1242/dev.02087
   Letamendia A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036690
   McMahon G, 2000, Oncologist, V5 Suppl 1, P3
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Moshal KS, 2010, TRENDS CARDIOVAS MED, V20, P114, DOI 10.1016/j.tcm.2010.10.001
   Papakyriakou A, 2010, CHEMMEDCHEM, V5, P118, DOI 10.1002/cmdc.200900373
   Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121
   Sehnert AJ, 2002, NAT GENET, V31, P106, DOI 10.1038/ng875
   Snaar-Jagalska BE, 2009, ZEBRAFISH, V6, P441, DOI 10.1089/zeb.2009.0614
   STAINIER DYR, 1995, DEVELOPMENT, V121, P3141
   Tran TC, 2007, CANCER RES, V67, P11386, DOI 10.1158/0008-5472.CAN-07-3126
   Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E
   Westerfield M., 2007, ZEBRAFISH BOOK
   Wu XR, 2006, ARTERIOSCL THROM VAS, V26, P2414, DOI 10.1161/01.ATV.0000238361.07225.fc
   Yang LL, 2013, J MED CHEM, V56, P1641, DOI 10.1021/jm301537p
NR 30
TC 14
Z9 14
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD DEC 1
PY 2014
VL 12
IS 9-10
BP 527
EP 535
DI 10.1089/adt.2014.606
PG 9
WC Biochemical Research Methods; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AW5TN
UT WOS:000346336800004
PM 25506802
OA Green Published
DA 2022-11-30
ER

PT J
AU Pan, CK
   Heilweil, G
   Lanza, R
   Schwartz, SD
AF Pan, Carolyn K.
   Heilweil, Gad
   Lanza, Robert
   Schwartz, Steven D.
TI Embryonic stem cells as a treatment for macular degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE hereditary retinal degenerations; human embryonic stem cells; macular
   degeneration; retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; HUMAN BRUCHS MEMBRANE; AGE-RELATED-CHANGES;
   SUBRETINAL SPACE; RCS RATS; BONE-MARROW; PHOTORECEPTOR PRECURSORS;
   NEOVASCULAR MEMBRANES; AMNIOTIC MEMBRANE; VISUAL FUNCTION
AB Introduction: Retinal degenerations are typically characterized by loss of highly differentiated cell types within the neurosensory retina, such as photoreceptors, or retinal pigment epithelium (RPE). RPE loss is the final common pathway in a number of degenerations including the leading cause of new blindness in the developed world: age-related macular degeneration (AMD).
   Areas covered: This paper presents the pathophysiologic case for RPE transplantation with stem cell (SC)-derived tissue, a review of the preclinical data substantiating the hypothesis and the initial clinical trials safety data from early human trials.
   Expert opinion: Targeting the RPE for transplantation with SC-derived tissue presents a reasonable therapeutic opportunity in a variety of important, otherwise untreatable, blinding conditions. Success of cellular replacement strategies is contingent on finding a viable source of replacement cells, establishing a safe technique for delivery and survival of transplanted cells within the host, restoration of normal retinal architecture and stabilization or improvement of vision.
C1 [Pan, Carolyn K.; Heilweil, Gad; Schwartz, Steven D.] Univ Calif Los Angeles, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90095 USA.
   [Lanza, Robert] Adv Cell Technol, Marlborough, MA 01605 USA.
C3 University of California System; University of California Los Angeles
RP Schwartz, SD (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, Retina Div, 200 Stein Plaza, Los Angeles, CA 90095 USA.
EM schwartz@jsei.ucla.edu
OI Pan, Carolyn/0000-0002-1031-7488; Lanza, Robert/0000-0002-3047-3074
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 2000, CURR EYE RES, V20, P268
   Ahmad I, 2004, SEMIN CELL DEV BIOL, V15, P53, DOI 10.1016/j.semcdb.2003.09.003
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Assadoullina A, 2004, MACULA: DIAGNOSIS, TREATMENT AND FUTURE TRENDS, P45
   Beutel J, 2007, GRAEF ARCH CLIN EXP, V245, P1469, DOI 10.1007/s00417-007-0566-9
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Blacharski P., 1988, RETINAL DYSTROPHIES
   BOK D, 1993, J CELL SCI, P189
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Cai H, 2006, ARCH OPHTHALMOL-CHIC, V124, P1276, DOI 10.1001/archopht.124.9.1276
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Carlson A, 1999, INVEST OPHTH VIS SCI, V40, P533
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Crafoord S, 1999, ACTA OPHTHALMOL SCAN, V77, P247, DOI 10.1034/j.1600-0420.1999.770301.x
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Farrokh-Siar L, 1999, CURR EYE RES, V19, P89, DOI 10.1076/ceyr.19.2.89.5331
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P326, DOI 10.1007/s004170050240
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   Haruta Masathoshi, 2005, Semin Ophthalmol, V20, P17, DOI 10.1080/08820530590921846
   Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Koenekoop RK, 2007, CLIN EXP OPHTHALMOL, V35, P473, DOI 10.1111/j.1442-9071.2007.01534.x
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lawrence JM, 2004, INVEST OPHTH VIS SCI, V45, P267, DOI 10.1167/iovs.03-0093
   Leveillard T, 2007, M S-MED SCI, V23, P240, DOI 10.1051/medsci/2007233240
   Li Y, 2007, INVEST OPHTH VIS SCI, V48, P4321, DOI 10.1167/iovs.06-1015
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Lu B, 2012, BIOMED MICRODEVICES
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacNeil A, 2007, STEM CELLS, V25, P2430, DOI 10.1634/stemcells.2007-0035
   Marmor MF, 2005, RYANS RETINA, V4th, P1891
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   Ohno-Matsui K, 2006, MOL VIS, V12, P1022
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Ratajczak MZ, 2004, LEUKEMIA, V18, P29, DOI 10.1038/sj.leu.2403184
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schraermeyer U, 2001, CELL TRANSPLANT, V10, P673, DOI 10.3727/000000001783986215
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Singhal Shweta, 2005, Indian Journal of Ophthalmology, V53, P109
   Sohocki MM, 2001, HUM MUTAT, V17, P42, DOI 10.1002/1098-1004(2001)17:1<42::AID-HUMU5>3.0.CO;2-K
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Srivastava GK, 2011, J BIOMED MATER RES A, V97A, P243, DOI 10.1002/jbm.a.33050
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P1345, DOI 10.1167/iovs.10-6112
   Tamai M, 1999, RETINA CURRENT PRACT, P151
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823
   Wong IYH, 2011, GRAEF ARCH CLIN EXP, V249, P1439, DOI 10.1007/s00417-011-1764-z
   WONGPICHEDCHAI S, 1992, INVEST OPHTH VIS SCI, V33, P3341
   YAMAMOTO S, 1993, INVEST OPHTH VIS SCI, V34, P3068
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 98
TC 26
Z9 27
U1 0
U2 46
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD AUG
PY 2013
VL 13
IS 8
BP 1125
EP 1133
DI 10.1517/14712598.2013.793304
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 180GM
UT WOS:000321581900005
PM 23705996
DA 2022-11-30
ER

PT J
AU Zhuang, P
   Shen, Y
   Chiou, GCY
AF Zhuang, Pei
   Shen, Yi
   Chiou, George C. Y.
TI Effect of flavone on the ocular blood flow and formation of choroidal
   neovascularization
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE flavone; age-related macular degeneration; ocular blood flow; choroidal
   neovascularization
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; PATHOGENESIS
AB AIM: To investigate the effect of flavone on ocular blood flow in rabbit eyes and the formation of choroidal neovascularization (CNV) in rat model of age-related macular degeneration (AMD).
   METHODS: In in vivo studies, colored microsphere technique was used to determine the ocular blood flow in ocular hypertensive rabbit eyes. The rat eyes were treated with 0.5% flavone eye drops 3 times a day for 1 week before and 4 weeks after laser-induced injury of Bruch's membrane. The development of CNV was determined by fluorescein angiography (FA) performed on weeks 2 and 4. In vitro studies, the effect of flavone on the viability of HUVECs was measured by MTT assay.
   RESULTS: The ocular blood flow in rabbit eyes was significantly increased after flavone instillation. Flavone significantly inhibited the formation of laser induced CNV. In vitro results showed that flavone inhibited the proliferation of HUVECs.
   CONCLUSION: Flavone could increase ocular blood flow and inhibit the formation of CNV.
C1 [Zhuang, Pei; Shen, Yi; Chiou, George C. Y.] Texas A&M Hlth Sci Ctr, Coll Med, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center
RP Chiou, GCY (通讯作者)，Texas A&M Hlth Sci Ctr, Coll Med, Inst Ocular Pharmacol, College Stn, TX 77843 USA.
EM chiou@medicine.tamhsc.edu
CR Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Duthie SJ, 1999, EUR J NUTR, V38, P28, DOI 10.1007/s003940050043
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Joussen AM, 2004, GRAEF ARCH CLIN EXP, V242, P1, DOI 10.1007/s00417-003-0794-6
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   LIN B, 2008, INT J OPHTHALMOL, V8, P1963
   Lutty G, 1999, MOL VIS, V5
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   UWE W, 2000, CANCER RES, V60, P3823
   Xuan B, 2003, J OCUL PHARMACOL TH, V19, P247, DOI 10.1089/108076803321908365
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 15
TC 0
Z9 0
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2010
VL 3
IS 2
BP 95
EP 98
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BQ
UT WOS:000282934300001
PM 22553528
DA 2022-11-30
ER

PT J
AU Raoul, W
   Keller, N
   Rodero, M
   Behar-Cohen, F
   Sennlaub, F
   Combadiere, C
AF Raoul, William
   Keller, Nicole
   Rodero, Mathieu
   Behar-Cohen, Francine
   Sennlaub, Florian
   Combadiere, Christophe
TI Role of the chemokine receptor CX3CR1 in the mobilization of phagocytic
   retinal microglial cells
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; RATS
AB We recently showed that subretinal CX3CR1-dependent microglial cell (MC) accumulation may lead to age-related macular degeneration. The fate of MC after engulfing retinal debris is poorly understood. Severe photoreceptor degeneration was observed 40days after exposure to bright light in CX3CR1-deficient but not control mice, and more MCS accumulated in the subretinal space of the former than the latter. To study the fate of subretinal MCs in CX3CR1 competent animals, we used a dystrophic rat model in which abundant subretinal MC accumulation is observed secondary to retinal degeneration. In dystrophic rats. MCs containing rhodopsin or rod outer segment (ROS) debris were found outside the outer retina at sites suggesting choroidal and ciliary egress. In conclusion. our data indicate that MC accumulation at injury sites is independent of CX3CR1 and precedes photoreceptor degeneration. The ectopic presence of rhodopsin-positive MCs suggests that CX3CR1 participates in MC egress from the outer retina. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Raoul, William; Keller, Nicole; Behar-Cohen, Francine; Sennlaub, Florian] Ctr Tech Cordeliers, INSERM, UMR S 872, Equoe 17, F-75006 Paris, France.
   [Raoul, William; Keller, Nicole; Behar-Cohen, Francine; Sennlaub, Florian] Univ Paris 06, UPMC, UMR S 872, F-75006 Paris, France.
   [Raoul, William; Keller, Nicole; Behar-Cohen, Francine; Sennlaub, Florian] Univ Paris 05, UMR S 872, F-75006 Paris, France.
   [Rodero, Mathieu; Combadiere, Christophe] INSERM, Lab Immunol Cellulaire, U543, F-75013 Paris, France.
   [Behar-Cohen, Francine] AP HP, Ctr Rech Ophtalmol, Serv Ophtalmol, Hotel Dieu, Paris, France.
   [Combadiere, Christophe] Grp Hosp Pitie Salpetriere, AP HP, Serv Immunol, F-75013 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; UDICE-French
   Research Universities; Sorbonne Universite; Universite Paris Cite;
   UDICE-French Research Universities; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne
   Universite
RP Raoul, W (通讯作者)，Ctr Tech Cordeliers, INSERM, UMR S 872, Equoe 17, 15 Rue Ecole Med, F-75006 Paris, France.
EM william.raoul@crc.jussieu.fr; combad@crc.jussieu.fr
RI rodero, mathieu/C-8083-2011; Combadiere, Christophe/I-5639-2013;
   Sennlaub, Florian/F-2756-2017; Raoul, William/H-2118-2018
OI rodero, mathieu/0000-0002-1300-0187; Combadiere,
   Christophe/0000-0002-1755-4531; Sennlaub, Florian/0000-0003-4412-1341;
   Raoul, William/0000-0002-5040-3372
FU INSERM; ANR [AO5088DS, AO5120DD]; European Grant [LSHB-CT-2005-518167];
   PNR vision [AO6004SP]; Fondation NRJ-Institut de France; Assistance
   Publique-Hopitaux de Paris
FX This work was supported by grants from INSERM, ANR "Cardiovasculaire
   obesite et diabete" (AO5088DS), ANR "blanc" (AO5120DD), European Grant
   "Innochem" (LSHB-CT-2005-518167). PNR vision (AO6004SP) and by the
   Fondation NRJ-Institut de France. C.C. is a recipient of a contract
   "Interface" from Assistance Publique-Hopitaux de Paris. W.R. received a
   fellowship from ANR "Blanc" (AO5120DD).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   COMBOURIEU B, 2003, RES ADV MICROBIOL, V3, P1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Pham VT, 2005, BRIT J OPHTHALMOL, V89, P753, DOI 10.1136/bjo.2004.057828
   Ransohoff RM, 2007, INT REV NEUROBIOL, V82, P187, DOI 10.1016/S0074-7742(07)82010-1
   Roque RS, 1996, INVEST OPHTH VIS SCI, V37, P196
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   TSO MOM, 1994, INVEST OPHTH VIS SCI, V35, P2693
NR 15
TC 42
Z9 43
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD JUL 31
PY 2008
VL 198
IS 1-2
BP 56
EP 61
DI 10.1016/j.jneuroim.2008.04.014
PG 6
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 342QL
UT WOS:000258798500009
PM 18508131
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Michels, S
   Pircher, M
   Geitzenauer, W
   Simader, C
   Gotzinger, E
   Findl, O
   Schmidt-Erfurth, U
   Hitzenberger, CK
AF Michels, S.
   Pircher, M.
   Geitzenauer, W.
   Simader, C.
   Goetzinger, E.
   Findl, O.
   Schmidt-Erfurth, U.
   Hitzenberger, C. K.
TI Value of polarisation-sensitive optical coherence tomography in diseases
   affecting the retinal pigment epithelium
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER POLARIMETRY; MACULAR DEGENERATION; IN-VIVO;
   BIREFRINGENCE; RISK
AB Objectives: To evaluate pathological changes of retinal pigment epithelium (RPE) by polarisation-sensitive optical coherence tomography (PS-OCT).
   Methods: Forty-four eyes (22 patients) with significant pathologies of the RPE were evaluated using PS-OCT. A transversal scanning time domain OCT system was used for two-dimensional cross-sectional imaging of retinal polarisation properties.
   Results: The RPE scrambles the polarisation state of backscattered light (ie, acts as a depolarising layer), while the polarisation state of transmitted light is maintained. In patients with RPE pathologies irregularity, elevation, thickening or absence of the RPE is readily visualised by exploiting the depolarisation information. Polarisation scrambling in the sensory retina can be found in cases with advanced dry age-related macular degeneration. Sclera and fibrosis show characteristic birefringence in PS-OCT.
   Conclusion: PS-OCT allows tissue identification based on polarisation scrambling and birefringence, providing additional information on RPE pathologies. It is a promising new tool for diagnosis, disease follow-up and evaluation of new treatment strategies.
C1 [Michels, S.] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Michels, S.; Geitzenauer, W.; Simader, C.; Schmidt-Erfurth, U.] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Pircher, M.; Goetzinger, E.; Hitzenberger, C. K.] Med Univ Vienna, Ctr Biomed Engn & Phys, Vienna, Austria.
   [Findl, O.] Moorfields Eye Hosp, London, England.
C3 University of Zurich; University Zurich Hospital; Medical University of
   Vienna; Medical University of Vienna; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Michels, S (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklinstr 24, CH-8091 Zurich, Switzerland.
EM michels@usz.ch
OI Michael, Pircher/0000-0001-9285-7527; Hitzenberger,
   Christoph/0000-0002-6608-8821
CR Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   deBoer JF, 1997, OPT LETT, V22, P934, DOI 10.1364/OL.22.000934
   DREHER AW, 1992, APPL OPTICS, V31, P3730, DOI 10.1364/AO.31.003730
   Fercher A. F., 2002, PROGR OPTICS, V44, DOI [10.1016/S0079-6638(02)80017-8, DOI 10.1016/S0079-6638(02)80017-8]
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Gotzinger E, 2005, OPT EXPRESS, V13, P10217, DOI 10.1364/OPEX.13.010217
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Knighton RW, 2002, INVEST OPHTH VIS SCI, V43, P383
   Meitinger D, 2001, EXP EYE RES, V73, P681, DOI 10.1006/exer.2001.1079
   Pircher M, 2004, PHYS MED BIOL, V49, P1257, DOI 10.1088/0031-9155/49/7/013
   Pircher M, 2004, OPT EXPRESS, V12, P5940, DOI 10.1364/OPEX.12.005940
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   SHAKIB M, 1972, AM J OPHTHALMOL, V74, P206, DOI 10.1016/0002-9394(72)90536-3
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Weinreb RN, 2003, ARCH OPHTHALMOL-CHIC, V121, P218
NR 21
TC 59
Z9 59
U1 1
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2008
VL 92
IS 2
BP 204
EP 209
DI 10.1136/bjo.2007.130047
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 256GH
UT WOS:000252715200011
PM 18227201
DA 2022-11-30
ER

PT J
AU Theodossiadis, PG
   Grigoropoulos, VG
   Emfietzoglou, I
   Vergados, J
   Chalkiadakis, J
   Theodossiadis, GP
AF Theodossiadis, P. G.
   Grigoropoulos, V. G.
   Emfietzoglou, I.
   Vergados, J.
   Chalkiadakis, J.
   Theodossiadis, G. P.
TI Intravitreal bevacizumab for the treatment of feeder vessel of subfoveal
   choroidal neovascularization
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; feeder vessel;
   fluorescein angiography; optical coherence tomography; subfoveal
   neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION
AB PURPOSE. To report in a single case the effectiveness of bevacizumab in the treatment of feeder vessels (FVs) of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   METHODS. One patient received intravitreal bevacizumab (Avastin) (1.25 mg) which was repeated 4 weeks after the first intravitreal injection. Fluorescein angiography and optical coherence tomography (OCT) were performed. Visual acuity (VA) was also checked.
   RESULTS. Occlusion of the FVS was observed 4 weeks after starting treatment. During the follow-up period and in the final examination 13 months after the first injection, the FVs remained occluded. Complete resolution of macular edema and improvement of the VA were noticed after the second bevacizumab intravitreal injection.
   CONCLUSIONS. This report documents the successful occlusion of FVs of subfoveal neovascularization after two intravitreal bevacizumab injections in a patient who was followed up for 1 year after the occlusion. Further long-term investigation is warranted given the promising 12-month results.
C1 [Theodossiadis, P. G.; Vergados, J.] Univ Athens, Dept Ophthalmol 2, Athens, Greece.
   [Grigoropoulos, V. G.; Emfietzoglou, I.; Chalkiadakis, J.; Theodossiadis, G. P.] Henry Dunant Hosp, Dept Ophthalmol 2, Athens, Greece.
C3 National & Kapodistrian University of Athens; Henry Dunant Hospital
RP Theodossiadis, PG (通讯作者)，13 Likiou St, Athens 10674, Greece.
EM george@hellasnet.gr
RI Halkiadakis, Ioannis/O-5286-2014
OI Halkiadakis, Ioannis/0000-0001-8403-7721
CR Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Coscas F, 2003, J FR OPHTALMOL, V26, P602
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Kozak I, 2006, BRIT J OPHTHALMOL, V90, P1152, DOI 10.1136/bjo.2006.095141
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
NR 7
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2007
VL 17
IS 5
BP 853
EP 856
DI 10.1177/112067210701700528
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 251GJ
UT WOS:000252360300028
PM 17932868
DA 2022-11-30
ER

PT J
AU Li, L
   Qin, J
   Yin, S
   Tang, GW
AF Li, Lei
   Qin, Jian
   Yin, Shi-an
   Tang, Guangwen
TI Effects of mobile phase ratios on the separation of plant carotenoids by
   HPLC with a C30 column
SO CHROMATOGRAPHIA
LA English
DT Article
DE column liquid chromatography; hyphenated technique; carotenoids; lutein
   and zeaxanthin in plant products
ID MACULAR DEGENERATION; PLASMA; VEGETABLES; LUTEIN
AB Plant products are dietary sources of lutein and zeaxanthin. Lutein and zeaxanthin have been implicated in the protection of age related macular degeneration (AMD) and in cardiovascular diseases. However, xanthophylls and unidentified components (lambda(max) = 423 and 468 nm) in plant products are often not separated well, and affect an accurate quantitative determination of lutein and zeaxanthin. A high performance liquid chromatography (HPLC) system equipped with a Bischoff C30 column and a mobile phase of methanol, metkyl-tert-butyl ether (MTBE) and water was used to separate lutein, zeaxanthin and other unidentified components in plant products. Mobile phase A containing methanol, MTBE and water with a ratio of 60:33:7 by volume (1.5% ammonium acetate, NH4Ac), combined with mobile phase B with a ratio of 8:90:2 by volume (1.0% NH4Ac) is optimal for the separation. This method was successfully applied to the quantitative determination of lutein and zeaxanthin in extracts of plant products, such as chlorella, spirulina, celery and mallow.
C1 Chinese Ctr Dis Control & Prevent, Nutr & Food Safety Inst, Dept Maternal & Child Hlth, Beijing 100050, Peoples R China.
   Tufts Univ, USDA, Human Nutr Res Ctr Aging, Carotenoids & Hlth Lab, Boston, MA 02111 USA.
C3 Chinese Center for Disease Control & Prevention; Tufts University;
   United States Department of Agriculture (USDA)
RP Tang, GW (通讯作者)，Chinese Ctr Dis Control & Prevent, Nutr & Food Safety Inst, Dept Maternal & Child Hlth, Beijing 100050, Peoples R China.
EM Guangwen.tang@tufts.edu
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BUDOWSKI P, 1963, Science, V142, P969, DOI 10.1126/science.142.3594.969
   Careri M, 2001, J CHROMATOGR A, V912, P61, DOI 10.1016/S0021-9673(01)00545-3
   Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Inbaraj BS, 2006, J CHROMATOGR A, V1102, P193, DOI 10.1016/j.chroma.2005.10.055
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Riso P, 1997, INT J VITAM NUTR RES, V67, P47
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
NR 12
TC 10
Z9 10
U1 1
U2 27
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0009-5893
EI 1612-1112
J9 CHROMATOGRAPHIA
JI Chromatographia
PD JAN
PY 2007
VL 65
IS 1-2
BP 91
EP 94
DI 10.1365/s10337-006-0100-y
PG 4
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 131WE
UT WOS:000243900900016
DA 2022-11-30
ER

PT J
AU Lim, C
   Kang, JK
   Jung, CE
   Sim, T
   Her, J
   Kang, K
   Lee, ES
   Youn, YS
   Choi, HG
   Oh, KT
AF Lim, Chaemin
   Kang, Jin Kook
   Jung, Chan Eun
   Sim, Taehoon
   Her, Jaewon
   Kang, Kioh
   Lee, Eun Seong
   Youn, Yu Seok
   Choi, Han-Gon
   Oh, Kyung Taek
TI Preparation and Characterization of a Lutein Solid Dispersion to Improve
   Its Solubility and Stability
SO AAPS PHARMSCITECH
LA English
DT Article
DE lutein; bioavailability; absorption; stability; degradation; oral drug
   delivery; pH sensitivity; solid dispersion
ID ZEAXANTHIN; EYE; BIOAVAILABILITY; FORMULATION; MIXTURES; SYSTEM; SHELL
AB Lutein has been used as a dietary supplement for the treatment of eye diseases, especially age-related macular degeneration. For oral formulations, we investigated lutein stability in artificial set-ups mimicking different physiological conditions and found that lutein was degraded over time under acidic conditions. To enhance the stability of lutein upon oral intake, we developed enteric-coated lutein solid dispersions (SD) by applying a polymer, hydroxypropyl methylcellulose acetate succinate (HPMCAS-LF), through a solvent-controlled precipitation method. The SD were characterized in crystallinity, morphology, and drug entrapment. In the dissolution profile of lutein SD, a F80 formulation showed resistance toward the acidic environment under simulated gastric conditions while exhibiting a bursting drug release under simulated intestinal conditions. Our results highlight the potential use of HPMCAS-LF as an effective matrix to enhance lutein bioavailability during oral delivery and to provide novel insights into the eye-care supplement industry, with direct benefits for the health of patients.
C1 [Lim, Chaemin; Kang, Jin Kook; Jung, Chan Eun; Sim, Taehoon; Her, Jaewon; Kang, Kioh; Oh, Kyung Taek] Chung Ang Univ, Coll Pharm, 221 Heukseok Dong, Seoul 06974, South Korea.
   [Lim, Chaemin] Univ North Carolina Chapel Hill, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA.
   [Lim, Chaemin] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Lee, Eun Seong] Catholic Univ Korea, Div Biotechnol, Bucheon, South Korea.
   [Youn, Yu Seok] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea.
   [Choi, Han-Gon] Hanyang Univ, Coll Pharm, Ansan, South Korea.
C3 Chung Ang University; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina School of Medicine;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Catholic University of
   Korea; Sungkyunkwan University (SKKU); Hanyang University
RP Oh, KT (通讯作者)，Chung Ang Univ, Coll Pharm, 221 Heukseok Dong, Seoul 06974, South Korea.
EM kyungoh@cau.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [2015R1A5A1008958, 16173MFDS542]; Ministry of Food and Drug Safety
FX This research was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MSIT) (2015R1A5A1008958)
   and a 2019 grant (16173MFDS542) from the Ministry of Food and Drug
   Safety.
CR Aruna G, 2009, J FOOD COMPOS ANAL, V22, P632, DOI 10.1016/j.jfca.2009.03.006
   Baird JA, 2012, ADV DRUG DELIVER REV, V64, P396, DOI 10.1016/j.addr.2011.07.009
   Bourduche F, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01824-8
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bruni G, 2010, J THERM ANAL CALORIM, V102, P193, DOI 10.1007/s10973-009-0382-z
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   CRAFT NE, 1992, J AGR FOOD CHEM, V40, P431, DOI 10.1021/jf00015a013
   Curatolo W, 2009, PHARM RES-DORD, V26, P1419, DOI 10.1007/s11095-009-9852-z
   Deli J, 2004, BIOORG MED CHEM LETT, V14, P925, DOI 10.1016/j.bmcl.2003.12.012
   Friesen DT, 2008, MOL PHARMACEUT, V5, P1003, DOI 10.1021/mp8000793
   Fukui E, 2001, J CONTROL RELEASE, V70, P97, DOI 10.1016/S0168-3659(00)00332-1
   Hadjal T, 2013, FOOD CHEM, V138, P2442, DOI 10.1016/j.foodchem.2012.12.022
   He YM, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01711-2
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kamil A, 2016, FOOD CHEM, V192, P915, DOI 10.1016/j.foodchem.2015.07.106
   KHACHIK F, 1995, J CHROMATOGR B, V670, P219, DOI 10.1016/0378-4347(95)00169-7
   Kotake-Nara E, 2011, MAR DRUGS, V9, P1024, DOI 10.3390/md9061024
   Lee ES, 2012, INT J PHARMACEUT, V439, P342, DOI 10.1016/j.ijpharm.2012.08.054
   Lichtenthaler HK., 2001, CURR PROTOC FOOD ANA, V1, pF4.3.1, DOI [10.1002/0471142913.faf0403s01, DOI 10.1002/0471142913.FAF0403S01]
   Lim C, 2019, J CONTROL RELEASE, V295, P164, DOI 10.1016/j.jconrel.2018.12.043
   Lim C, 2016, J DRUG DELIV SCI TEC, V36, P168, DOI 10.1016/j.jddst.2016.10.009
   Lim Ji-Ho, 2019, Journal of Pharmaceutical Investigation, V49, P271, DOI 10.1007/s40005-018-0402-8
   Liu L, 2017, DRUG DELIV, V24, P569, DOI 10.1080/10717544.2017.1279238
   Mitri K, 2011, INT J PHARMACEUT, V420, P141, DOI 10.1016/j.ijpharm.2011.08.026
   Mondal J, 2020, J PHARM INVEST, V50, P209, DOI 10.1007/s40005-019-00466-8
   Murdande SB, 2011, J PHARM SCI-US, V100, P4349, DOI 10.1002/jps.22643
   Nair AR, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01849-z
   Newman A, 2008, J PHARM SCI-US, V97, P4840, DOI 10.1002/jps.21352
   Riccioni G, 2012, NUTRITION, V28, P605, DOI 10.1016/j.nut.2011.11.028
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Roberts RL, 2009, CLIN DERMATOL, V27, P195, DOI 10.1016/j.clindermatol.2008.01.011
   Saboo S, 2019, J CONTROL RELEASE, V298, P68, DOI 10.1016/j.jconrel.2019.01.039
   Sato Y, 2011, BIOPHARM DRUG DISPOS, V32, P151, DOI 10.1002/bdd.746
   Shi XM, 1997, NAHRUNG, V41, P38, DOI 10.1002/food.19970410110
   Slavin M, 2012, FOOD CHEM, V135, P2789, DOI 10.1016/j.foodchem.2012.06.043
   Son Gi-Ho, 2019, Journal of Pharmaceutical Investigation, V49, P625, DOI 10.1007/s40005-018-00417-9
   Stringham JM, 2005, NUTR REV, V63, P59, DOI 10.1111/j.1753-4887.2005.tb00122.x
   Tan C, 2013, J AGR FOOD CHEM, V61, P8175, DOI 10.1021/jf402085f
   Thapaliya Rocky, 2019, Journal of Pharmaceutical Investigation, V49, P553, DOI 10.1007/s40005-019-00425-3
   Vasconcelos T, 2007, DRUG DISCOV TODAY, V12, P1068, DOI 10.1016/j.drudis.2007.09.005
   Alvarez-Henao MV, 2018, FOOD CHEM, V256, P181, DOI 10.1016/j.foodchem.2018.02.059
   Xu JH, 2021, AAPS PHARMSCITECH, V22, DOI 10.1208/s12249-020-01878-8
   Yoon Sung-Won, 2019, Journal of Pharmaceutical Investigation, V49, P477, DOI 10.1007/s40005-019-00432-4
   Yuan YK, 2019, J AGR FOOD CHEM, V67, P11977, DOI 10.1021/acs.jafc.9b05175
   Zhao CD, 2014, FOOD CHEM, V156, P123, DOI 10.1016/j.foodchem.2014.01.086
NR 47
TC 2
Z9 2
U1 11
U2 27
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD JUN 2
PY 2021
VL 22
IS 5
AR 169
DI 10.1208/s12249-021-02036-4
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZO5ZN
UT WOS:000765803400001
PM 34080086
DA 2022-11-30
ER

PT J
AU Charreyron, SL
   Boehler, Q
   Danun, AN
   Mesot, A
   Becker, M
   Nelson, BJ
AF Charreyron, Samuel L.
   Boehler, Quentin
   Danun, Aschraf N.
   Mesot, Alexandre
   Becker, Matthias
   Nelson, Bradley J.
TI A Magnetically Navigated Microcannula for Subretinal Injections
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Retina; Robots; Lighting; Magnetic resonance imaging; Tools; Microscopy;
   Surgery; Catheters; drug delivery; medical robotics; robot control;
   robot kinematics; soft robotics; surgical instruments
ID RETINAL GENE-THERAPY; DELIVERY; DISEASE; SYSTEM
AB Retinal disorders, including age-related macular degeneration, are leading causes of vision loss worldwide. New treatments, such as gene therapies and stem cell regeneration, require therapeutics to be introduced to the subretinal space due to poor diffusion to the active component of the retina. Subretinal injections are a difficult and risky surgical procedure and have been suggested as a candidate for robot-assisted surgery. We propose a different actuation paradigm to existing robotic approaches using remote magnetic navigation to control a flexible microcannula. A flexible cannula allows for high dexterity and considerable safety advantages over rigid tools, while maintaining the benefits of micrometer precision, hand tremor removal, and telemanipulation. The position of the cannula is tracked in real-time using near-infrared tip illumination, allowing for semi-automatic placement of the cannula and an intuitive user interface. Using this tool, we successfully performed several subretinal injections in ex-vivo porcine eyes under both microscope and optical coherence tomography visualization.
C1 [Charreyron, Samuel L.; Boehler, Quentin; Nelson, Bradley J.] Swiss Fed Inst Technol, Multi Scale Robot Lab, CH-8092 Zurich, Switzerland.
   [Danun, Aschraf N.] Swiss Fed Inst Technol, Prod Dev Grp, Zurich, Switzerland.
   [Mesot, Alexandre] Zurich D MAVT, Zurich, Switzerland.
   [Becker, Matthias] Triemli Municipal Hosp, Augenklin, Zurich, Switzerland.
C3 Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal
   Institutes of Technology Domain; ETH Zurich; Triemli Hospital
RP Charreyron, SL (通讯作者)，Swiss Fed Inst Technol, Multi Scale Robot Lab, CH-8092 Zurich, Switzerland.
EM samuelch@ethz.ch
RI Nelson, Bradley/B-7761-2013; Boehler, Quentin/AAN-4759-2020
OI Nelson, Bradley/0000-0001-9070-6987; Boehler,
   Quentin/0000-0001-7573-3135; Danun, Aschraf/0000-0001-6543-5468;
   Charreyron, Samuel/0000-0003-4636-3096
FU Swiss National Science Foundation [200021_165564]; ERC [743217]
FX This work was supported in part by the Swiss National Science Foundation
   under Grant 200021_165564 and in part by the ERC Advanced Grant 743217
   Soft Micro Robotics (SOMBOT).
CR Bekerman I, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/503645
   Belendez T, 2002, EUR J PHYS, V23, P371, DOI 10.1088/0143-0807/23/3/317
   Bradski G., 1999, DR DOBBS J SOFTW TOO
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Charreyron Samuel L., 2017, 2017 IEEE International Conference on Robotics and Automation (ICRA), P4843, DOI 10.1109/ICRA.2017.7989563
   Charreyron S. L., 2018, ROBOT AUTOM LETT, V4, P284
   Chautems C., 2019, THESIS
   Clinicaltrials.gov, 2019, RGX 314 GEN THER NEO
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis JL, 2019, RETINA-J RET VIT DIS, V39, P2, DOI 10.1097/IAE.0000000000002609
   de Smet MD, 2019, ACTA OPHTHALMOL, V97, P672, DOI 10.1111/aos.14003
   de Smet MD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162037
   Edwards TL, 2018, NAT BIOMED ENG, V2, P649, DOI 10.1038/s41551-018-0248-4
   Fischer MD, 2016, HUM GENE THER METHOD, V27, P150, DOI 10.1089/hgtb.2016.086
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Hartley R., 2003, MULITPLE VIEW GEOMET
   He CY, 2018, IEEE ROMAN, P174, DOI 10.1109/ROMAN.2018.8525638
   Humayun MS, 2016, OPHTHALMOLOGY, V123, pS89, DOI 10.1016/j.ophtha.2016.06.044
   Jagtap AD, 2004, P ANN INT IEEE EMBS, V26, P2771
   Kiernan DF, 2009, EXPERT OPIN PHARMACO, V10, P2511, DOI 10.1517/14656560903160671
   Kummer MP, 2010, IEEE T ROBOT, V26, P1006, DOI 10.1109/TRO.2010.2073030
   Madanagopalan VG, 2018, INDIAN J OPHTHALMOL, V66, P1809, DOI 10.4103/ijo.IJO_458_18
   Nasseri MA, 2017, IEEE ENG MED BIO, P4333, DOI 10.1109/EMBC.2017.8037815
   Ong T, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2564-5
   Petruska AJ, 2017, IEEE T MAGN, V53, DOI 10.1109/TMAG.2017.2653080
   Roska B, 2018, NATURE, V557, P359, DOI 10.1038/s41586-018-0076-4
   Sanchez I, 2011, GRAEF ARCH CLIN EXP, V249, P475, DOI 10.1007/s00417-011-1617-9
   Singh SPN, 2002, PROCEEDINGS OF THE IEEE 28TH ANNUAL NORTHEAST BIOENGINEERING CONFERENCE, P171, DOI 10.1109/NEBC.2002.999520
   Smits J., 2019, P 2018 HAML S MED RO, P91
   Tadayoni R, 2018, OPHTHALMOL RETINA, V2, P261, DOI 10.1016/j.oret.2017.11.011
   Thakur SS, 2014, EXPERT OPIN DRUG DEL, V11, P1575, DOI 10.1517/17425247.2014.927864
   Tunay I, 2004, P ANN INT IEEE EMBS, V26, P2006
   Tunay I, 2004, ICM '04: PROCEEDINGS OF THE IEEE INTERNATIONAL CONFERENCE ON MECHATRONICS 2004, P392, DOI 10.1109/ICMECH.2004.1364471
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
NR 35
TC 22
Z9 23
U1 4
U2 33
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
EI 1558-2531
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD JAN
PY 2021
VL 68
IS 1
BP 119
EP 129
DI 10.1109/TBME.2020.2996013
PG 11
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA PK8MF
UT WOS:000602691200013
PM 32746007
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bai, J
   Khajavi, M
   Sui, LF
   Fu, HJ
   Krishnaji, ST
   Birsner, AE
   Bazinet, L
   Kamm, RD
   D'Amato, RJ
AF Bai, Jing
   Khajavi, Mehrdad
   Sui, Lufei
   Fu, Haojie
   Tarakkad Krishnaji, Subrahmanian
   Birsner, Amy E.
   Bazinet, Lauren
   Kamm, Roger D.
   D'Amato, Robert J.
TI Angiogenic responses in a 3D micro-engineered environment of primary
   endothelial cells and pericytes
SO ANGIOGENESIS
LA English
DT Article
DE Microfluidic; Angiogenesis; Primary endothelial cell; Pericyte; 3D cell
   culture
ID NOTCH; VEGF; PATHWAYS; AGENTS
AB Angiogenesis plays a key role in the pathology of diseases such as cancer, diabetic retinopathy, and age-related macular degeneration. Understanding the driving forces of endothelial cell migration and organization, as well as the time frame of these processes, can elucidate mechanisms of action of important pathological pathways. Herein, we have developed an organ-specific microfluidic platform recapitulating the in vivo angiogenic microenvironment by co-culturing mouse primary brain endothelial cells with brain pericytes in a three-dimensional (3D) collagen scaffold. As a proof of concept, we show that this model can be used for studying the angiogenic process and further comparing the angiogenic properties between two different common inbred mouse strains, C57BL/6J and 129S1/SvlmJ. We further show that the newly discovered angiogenesis-regulating genePadi2promotes angiogenesis throughDll4/Notch1signaling by an on-chip mechanistic study. Analysis of the interplay between primary endothelial cells and pericytes in a 3D microfluidic environment assists in the elucidation of the angiogenic response.
C1 [Bai, Jing; Khajavi, Mehrdad; Sui, Lufei; Fu, Haojie; Tarakkad Krishnaji, Subrahmanian; Birsner, Amy E.; Bazinet, Lauren; D'Amato, Robert J.] Harvard Med Sch, Vasc Biol Program, Boston Childrens Hosp, Boston, MA 02115 USA.
   [Bai, Jing; Khajavi, Mehrdad; Sui, Lufei; Fu, Haojie; Tarakkad Krishnaji, Subrahmanian; Birsner, Amy E.; Bazinet, Lauren; D'Amato, Robert J.] Harvard Med Sch, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA.
   [D'Amato, Robert J.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Bai, Jing; Kamm, Roger D.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Harvard Medical School; Massachusetts Institute of
   Technology (MIT)
RP Bai, J (通讯作者)，Harvard Med Sch, Vasc Biol Program, Boston Childrens Hosp, Boston, MA 02115 USA.; Bai, J (通讯作者)，Harvard Med Sch, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA.; Bai, J (通讯作者)，MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
EM baij0005@e.ntu.edu.sg
RI Kamm, Roger D/I-7630-2012
OI Tarakkad Krishnaji, Subrahmanian/0000-0001-8950-6072;
   /0000-0002-7232-304X
FU NIH National Eye Institute [R01EY012726-12]
FX This study was supported, in part, by the NIH National Eye Institute.
   Award Number R01EY012726-12 (to RJD).
CR Andrejecsk JW, 2018, CURR OPIN BIOMED ENG, V5, P74, DOI 10.1016/j.cobme.2018.02.002
   Aref AR, 2013, INTEGR BIOL-UK, V5, P381, DOI 10.1039/c2ib20209c
   Avendano A, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00006
   BAI J, 2020, FRONT PHARM
   Bai J, 2015, ONCOTARGET, V6, P36603, DOI 10.18632/oncotarget.5464
   Bai J, 2015, ONCOTARGET, V6, P25295, DOI 10.18632/oncotarget.4716
   Bajaj P, 2014, ANNU REV BIOMED ENG, V16, P247, DOI 10.1146/annurev-bioeng-071813-105155
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Blanco R, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006569
   Bodnar RJ, 2013, ARTERIOSCL THROM VAS, V33, P2818, DOI 10.1161/ATVBAHA.113.302012
   Chen MB, 2018, P NATL ACAD SCI USA, V115, P7022, DOI 10.1073/pnas.1715932115
   Craig LE, 1998, MICROVASC RES, V55, P65, DOI 10.1006/mvre.1997.2045
   Darrah E, 2012, ANN RHEUM DIS, V71, P92, DOI 10.1136/ard.2011.151712
   Falcao AM, 2019, CELL REP, V27, P1090, DOI 10.1016/j.celrep.2019.03.108
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917
   Haase K, 2017, REGEN MED, V12, P285, DOI 10.2217/rme-2016-0152
   Horbach SPJM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186281
   Kamm RD, 2018, APL BIOENG, V2, DOI 10.1063/1.5038337
   Khajavi M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006848
   Koch MW, 2013, NAT REV NEUROL, V9, P35, DOI 10.1038/nrneurol.2012.226
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Lobov I, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3565292
   McElwee JL, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-500
   Moscarello MA, 2007, NEUROCHEM RES, V32, P251, DOI 10.1007/s11064-006-9144-5
   Motherwell J, 2018, NAT BIOMED ENG, V2, P349, DOI 10.1038/s41551-018-0251-9
   Ostergaard L, 2016, J CEREBR BLOOD F MET, V36, P302, DOI 10.1177/0271678X15606723
   Perez RA, 2016, MAT SCI ENG C-MATER, V61, P922, DOI 10.1016/j.msec.2015.12.087
   Perriere N, 2005, J NEUROCHEM, V93, P279, DOI 10.1111/j.1471-4159.2004.03020.x
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   Song JW, 2011, P NATL ACAD SCI USA, V108, P15342, DOI 10.1073/pnas.1105316108
   Thurston G, 2008, BRIT J CANCER, V99, P1204, DOI 10.1038/sj.bjc.6604484
   Tigges U, 2012, MICROVASC RES, V84, P74, DOI 10.1016/j.mvr.2012.03.008
   van Duinen V, 2019, ANGIOGENESIS, V22, P157, DOI 10.1007/s10456-018-9647-0
   van Duinen V, 2015, CURR OPIN BIOTECH, V35, P118, DOI 10.1016/j.copbio.2015.05.002
   Vanzan L, 2017, HANDBOOK OF EPIGENETICS: THE NEW MOLECULAR AND MEDICAL GENETICS, 2ND EDITION, P25, DOI 10.1016/B978-0-12-805388-1.00003-1
   Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357
   Wang L, 2017, CANCER RES, V77, P5755, DOI 10.1158/0008-5472.CAN-17-0150
   Yeon JH, 2012, LAB CHIP, V12, P2815, DOI [10.1039/c2lc40131b, 10.1039/C2LC40131B]
   Zeinali S, 2018, ANGIOGENESIS, V21, P861, DOI 10.1007/s10456-018-9631-8
   Zhang XS, 2012, P NATL ACAD SCI USA, V109, P13331, DOI 10.1073/pnas.1203280109
   Ziolkowska K, 2011, NEW J CHEM, V35, P979, DOI 10.1039/c0nj00709a
NR 45
TC 18
Z9 18
U1 4
U2 30
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD FEB
PY 2021
VL 24
IS 1
BP 111
EP 127
DI 10.1007/s10456-020-09746-6
EA SEP 2020
PG 17
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA QP8LS
UT WOS:000571732000001
PM 32955682
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, J
   Jo, YU
   Na, K
AF Kim, Jiyoung
   Jo, Young-um
   Na, Kun
TI Photodynamic therapy with smart nanomedicine
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Review
DE Photodynamic therapy; Photosensitizer; Drug delivery; Nanotechnology;
   Nanomedicine
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CYTOSOLIC DRUG-DELIVERY; HIGHLY
   EFFICIENT; CANCER; PHOTOSENSITIZER; HEMATOPORPHYRIN; VERTEPORFIN;
   NANOCARRIER; CONJUGATE; DIAGNOSIS
AB For several decades, clinical demands for utilization of photodynamic therapy (PDT) have been increasing. Notably, PDT was mainly applied for cancer therapy, and most photosensitizers (PSs) were developed to treat cancer. The advantages of PDT, such as minimal invasiveness and local treatment by topical light irradiation, have made it possible to widen the range of target diseases. Thus, PDT has been clinically used for treatment of various diseases (e.g., cancer, acne, and age-related macular degeneration). However, PS, which is the main component of PDT, exhibits several shortcomings such as low solubility, low bioavailability, and lack of lesion selectivity for use as a therapeutic agent. Therefore, many research projects have been performed to develop smart PS. To increase therapeutic efficacy and to decrease adverse effects in normal tissue at the same time, PS incorporation within nanoscaled delivery systems is evolving. This review provides a comprehensive explanation of PDT in smart nanomedicine, which is academically and clinically utilized in the treatment of various diseases.
C1 [Kim, Jiyoung; Jo, Young-um; Na, Kun] Catholic Univ Korea, Dept Biotechnol, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi, South Korea.
   [Na, Kun] Catholic Univ Korea, Dept Biomed Chem Engn, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Na, K (通讯作者)，Catholic Univ Korea, Dept Biotechnol, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi, South Korea.; Na, K (通讯作者)，Catholic Univ Korea, Dept Biomed Chem Engn, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi, South Korea.
EM kna6997@catholic.ac.kr
FU National Research Foundation of Korea (NRF) - Ministry of Science and
   ICT (MSIT) [NRF-2017R1A2B3010038]
FX This work was supported by the Strategic Research (NRF-2017R1A2B3010038)
   through the National Research Foundation of Korea (NRF) Grant funded by
   the Ministry of Science and ICT (MSIT).
CR Abbas M, 2017, ADV MATER, V29, DOI 10.1002/adma.201605021
   Vera DMA, 2012, PHOTOCHEM PHOTOBIOL, V88, P499, DOI 10.1111/j.1751-1097.2012.01087.x
   Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Barr H, 2001, ALIMENT PHARM THER, V15, P311, DOI 10.1046/j.1365-2036.2001.00936.x
   Baskaran Rengarajan, 2018, Biomater Res, V22, P25, DOI 10.1186/s40824-018-0140-z
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Choi Jong Hoon, 2017, Journal of Pharmaceutical Investigation, V47, P51, DOI 10.1007/s40005-016-0297-1
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   DANIELL MD, 1991, AUST NZ J SURG, V61, P340, DOI 10.1111/j.1445-2197.1991.tb00230.x
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Fabian ID, 2017, EYE, V31, P520, DOI 10.1038/eye.2017.22
   Finsen N R, 1895, Br Med J, V2, P1412
   Guan MR, 2016, BIOMATERIALS, V103, P75, DOI 10.1016/j.biomaterials.2016.06.023
   Han J, 2018, BIOMATERIALS, V182, P259, DOI 10.1016/j.biomaterials.2018.08.024
   Hong Suk Ho, 2018, Journal of Pharmaceutical Investigation, V48, P3, DOI 10.1007/s40005-017-0356-2
   Hwang Hee Sook, 2018, Journal of Pharmaceutical Investigation, V48, P143, DOI 10.1007/s40005-017-0377-x
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Jeon Geunwoo, 2019, Journal of Pharmaceutical Investigation, V49, P1, DOI 10.1007/s40005-017-0363-3
   Jeong S, 2017, BIOMATERIALS, V141, P243, DOI 10.1016/j.biomaterials.2017.07.009
   Jo YU, 2020, MACROMOL RES, V28, P67, DOI 10.1007/s13233-020-8003-6
   KELLY JF, 1976, J UROLOGY, V115, P150, DOI 10.1016/S0022-5347(17)59108-9
   Kim DH, 2018, BIOMACROMOLECULES, V19, P3301, DOI 10.1021/acs.biomac.8b00607
   Kim J, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201900084
   Kim J, 2015, MACROMOL BIOSCI, V15, P1081, DOI 10.1002/mabi.201500060
   Kim K, 2016, CHEM COMMUN, V52, P2839, DOI 10.1039/c5cc09239f
   Kim KS, 2018, BIOMATER SCI-UK, V6, P1217, DOI 10.1039/c7bm01084b
   KLIMAN GH, 1994, LASER SURG MED, V15, P11, DOI 10.1002/lsm.1900150104
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee CS, 2014, BIOMACROMOLECULES, V15, P4228, DOI 10.1021/bm501258s
   Lee CS, 2014, CHEM COMMUN, V50, P4354, DOI 10.1039/c4cc00746h
   Lee CS, 2013, BIOMATERIALS, V34, P9227, DOI 10.1016/j.biomaterials.2013.08.037
   Lee JH, 2019, RETINA-J RET VIT DIS, V39, P127, DOI 10.1097/IAE.0000000000001913
   Li X.S., 2018, ANGEW CHEM, V130, P10033, DOI DOI 10.1002/anie.201806551
   Li XS, 2018, ANGEW CHEM INT EDIT, V57, P11522, DOI 10.1002/anie.201805138
   Li X, 2018, CHEM SOC REV, V47, P1174, DOI 10.1039/c7cs00594f
   Li XS, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201604053
   LIPSON RL, 1961, J NATL CANCER I, V26, P1
   LIPSON RL, 1960, ARCH DERMATOL, V82, P508, DOI 10.1001/archderm.1960.01580040026005
   Maisch T, 2015, PHOTOCH PHOTOBIO SCI, V14, P1518, DOI 10.1039/c5pp00037h
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitri Zahi, 2012, Chemother Res Pract, V2012, P743193, DOI 10.1155/2012/743193
   Park H, 2016, ADV HEALTHC MATER, V5, P3139, DOI 10.1002/adhm.201600815
   Park SJ, 2015, ADV FUNCT MATER, V25, P3472, DOI 10.1002/adfm.201500737
   Park W, 2016, J AM CHEM SOC, V138, P10734, DOI 10.1021/jacs.6b04875
   Pointdujour-Lim R, 2017, RETINA-J RET VIT DIS, V37, P718, DOI 10.1097/IAE.0000000000001202
   Raab O, 1900, Z BIOL-MUNICH, V39, P524
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Youn Yu Seok, 2017, Journal of Pharmaceutical Investigation, V47, P1, DOI 10.1007/s40005-016-0282-8
   Zhu HJ, 2018, NANO LETT, V18, P586, DOI 10.1021/acs.nanolett.7b04759
   Zuluaga MF, 2007, INVEST OPHTH VIS SCI, V48, P1767, DOI 10.1167/iovs.06-1224
NR 55
TC 36
Z9 38
U1 3
U2 35
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD JAN
PY 2020
VL 43
IS 1
SI SI
BP 22
EP 31
DI 10.1007/s12272-020-01214-5
EA JAN 2020
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KV1IK
UT WOS:000515620600002
PM 31989479
DA 2022-11-30
ER

PT J
AU Nashine, S
   Nesburn, AB
   Kuppermann, BD
   Kenney, MC
AF Nashine, Sonali
   Nesburn, Anthony B.
   Kuppermann, Baruch D.
   Kenney, Maria Cristina
TI Role of Resveratrol in Transmitochondrial AMD RPE Cells
SO NUTRIENTS
LA English
DT Article
DE resveratrol; nutraceutical; stilbenoid; phytoalexin; age-related macular
   degeneration; AMD; macular degeneration; retina; retinal pigment
   epithelial cells; RPE; cybrids; over-the-counter nutritional supplements
ID OXYGEN; ROS
AB Resveratrol is a phytoalexin, stilbenoid compound with antioxidant properties attributable to its bioactive trans-resveratrol content. This study characterized the effects of over-the-counter (OTC) resveratrol nutritional supplements and a HPLC-purified resveratrol formulation, in human transmitochondrial age-related macular degeneration (AMD) retinal pigment epithelial (RPE) patient cell lines. These cell lines, which were created by fusing blood platelets obtained from dry and wet AMD patients with mitochondria-deficient (Rho0) ARPE-19 cells, had identical nuclei (derived from ARPE-19 cells) but different mitochondria that were derived from AMD patients. After resveratrol treatment, the levels of cell viability and reactive oxygen species production were measured. Results demonstrated that treatment with different resveratrol formulations improved cell viability and decreased reactive oxygen species generation in each AMD patient cell line. Although further studies are required to establish the cytoprotective potential of resveratrol under different physiological conditions, this novel study established the positive effects of OTC resveratrol supplements in macular degeneration patient cybrid cell lines in vitro.
C1 [Nashine, Sonali; Nesburn, Anthony B.; Kuppermann, Baruch D.; Kenney, Maria Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 92697 USA.
   [Kenney, Maria Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine; Cedars
   Sinai Medical Center; University of California System; University of
   California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM snashine@uci.edu; anesburn@uci.edu; bdkupper@uci.edu; mkenney@uci.edu
FU Arnold and Mabel Beckman foundation; UCI School of Medicine, Discovery
   Eye Foundation; Iris and B. Gerald Cantor Foundation; Research to
   Prevent Blindness; NEI [R01 EY0127363]; Institute for Clinical and
   Translational Science (ICTS) at University of California Irvine; 2017
   Genentech/ARVO AMD Translational Research Fellowship; 2016 RPB pilot
   research grant
FX This research was funded by Arnold and Mabel Beckman foundation, UCI
   School of Medicine, Discovery Eye Foundation, Polly and Michael Smith,
   Edith and Roy Carver, Iris and B. Gerald Cantor Foundation, Unrestricted
   Departmental Grant from Research to Prevent Blindness and NEI R01
   EY0127363, and support of the Institute for Clinical and Translational
   Science (ICTS) at University of California Irvine. S.N. is a recipient
   of the 2017 Genentech/ARVO AMD Translational Research Fellowship and the
   2016 RPB pilot research grant.
CR Andres S, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700447
   Anisimova NYU, 2011, CHEM CENT J, V5, DOI 10.1186/1752-153X-5-88
   Bilski P, 2002, FREE RADICAL BIO MED, V33, P938, DOI 10.1016/S0891-5849(02)00982-6
   Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364
   Chang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026405
   Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1
   Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202
   Howells LM, 2011, CANCER PREV RES, V4, P1419, DOI 10.1158/1940-6207.CAPR-11-0148
   Kurgvietiene L, 2016, MEDICINA-LITHUANIA, V52, P148, DOI 10.1016/j.medici.2016.03.003
   Kurutas EB, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0186-5
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Li YB, 2006, PHARMACOL RES, V53, P6, DOI 10.1016/j.phrs.2005.08.002
   Lindsey JD, 2015, NEUROBIOL AGING, V36, P1969, DOI 10.1016/j.neurobiolaging.2014.12.021
   Luo HD, 2018, INVEST OPHTH VIS SCI, V59, P3879, DOI 10.1167/iovs.18-23806
   Means JC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071521
   Nashine S, 2019, AGING-US, V11, P6691, DOI 10.18632/aging.102179
   Nashine S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107701
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Orallo F, 2008, CURR MED CHEM, V15, P1887, DOI 10.2174/092986708785132951
   Sanz Alberto, 2008, Curr Aging Sci, V1, P10
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Seong H, 2017, CURR EYE RES, V42, P1650, DOI 10.1080/02713683.2017.1344713
   Shang YJ, 2009, J ORG CHEM, V74, P5025, DOI 10.1021/jo9007095
   Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749-6632.2010.05842.x
   Wang N, 2019, AGING-US, V11, P3117, DOI 10.18632/aging.101966
   Wang XL, 2017, DIABETES RES CLIN PR, V126, P172, DOI 10.1016/j.diabres.2016.12.005
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Xin XR, 2017, INT J MED SCI, V14, P943, DOI 10.7150/ijms.19391
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 32
TC 6
Z9 6
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JAN
PY 2020
VL 12
IS 1
AR 159
DI 10.3390/nu12010159
PG 30
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA KQ3KN
UT WOS:000516825500159
PM 31935891
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Tanaka, M
   Kuse, Y
   Nakamura, S
   Hara, H
   Shimazawa, M
AF Tanaka, Miruto
   Kuse, Yoshiki
   Nakamura, Shinsuke
   Hara, Hideaki
   Shimazawa, Masamitsu
TI Potential effects of progranulin and granulins against retinal
   photoreceptor cell degeneration
SO MOLECULAR VISION
LA English
DT Article
ID GROWTH-FACTOR; EPITHELIN PRECURSOR; CANCER-CELLS; PROTEIN; LIGHT; MICE;
   CONVERSION; ACROGRANIN; INHIBITOR; OUTGROWTH
AB Purpose: The authors previously reported that progranulin attenuated retinal degeneration. The present study focused on the role of progranulin and its cleavage products, granulins, in the pathogenesis of photoreceptor degeneration.
   Methods: Photoreceptor degeneration was induced with excessive exposure of murine photoreceptor cells and the retinas of albino mice to white fluorescent light. Damaged photoreceptor cells and retinas were examined using a cell death assay, western blotting, and immunostaining.
   Results: Even after proteolytic cleavage, treatment with progranulin or its cleavage products or both exerted protective effects on photoreceptors against light exposure. In the murine retina, the expression levels of granulins and the macrophage and microglia marker Iba-1 were increased at 48 h after light exposure. Additionally, progranulin(+) and Iba-1(+) double-positive cells had accumulated in the outer nuclear layer, the primary location of photoreceptor cells.
   Conclusions: These results suggest that progranulin or its cleavage products, granulins, or both may be therapeutic targets for age-related macular degeneration and other neurodegenerative diseases.
C1 [Tanaka, Miruto; Kuse, Yoshiki; Nakamura, Shinsuke; Hara, Hideaki; Shimazawa, Masamitsu] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Shimazawa, M (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM shimazawa@gifu-pu.ac.jp
RI Kuse, Yoshiki/AAB-7445-2021
OI Hara, Hideaki/0000-0003-2046-9001
CR ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681
   ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317
   Ashcroft GS, 2000, NAT MED, V6, P1147, DOI 10.1038/80489
   Bai XH, 2009, MOL CELL BIOL, V29, P4201, DOI 10.1128/MCB.00056-09
   Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016
   Beel S, 2017, HUM MOL GENET, V26, P2850, DOI 10.1093/hmg/ddx162
   Butler GS, 2008, MOL CELL BIOL, V28, P4896, DOI 10.1128/MCB.01775-07
   Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017
   Egashira Y, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-105
   He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3
   He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816
   Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034
   Kao AW, 2017, NAT REV NEUROSCI, V18, P325, DOI 10.1038/nrn.2017.36
   Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020
   Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694
   Kuse Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01933-8
   Kuse Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23811
   Laird AS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013368
   Matsubara T, 2012, CELL METAB, V15, P38, DOI 10.1016/j.cmet.2011.12.002
   Minami SS, 2014, NAT MED, V20, P1157, DOI 10.1038/nm.3672
   Ojino K, 2014, BIOL PHARM BULL, V37, P424, DOI 10.1248/bpb.b13-00778
   Okura H, 2010, J ATHEROSCLER THROMB, V17, P568, DOI 10.5551/jat.3921
   Petkau TL, 2010, J COMP NEUROL, V518, P3931, DOI 10.1002/cne.22430
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rosen EY, 2011, NEURON, V71, P1030, DOI 10.1016/j.neuron.2011.07.021
   Ryan CL, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-130
   Salazar DA, 2015, J NEUROSCI, V35, P9315, DOI 10.1523/JNEUROSCI.4808-14.2015
   SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912
   Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021
   Suh HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035115
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214
   Tao J, 2012, BRAIN RES, V1436, P130, DOI 10.1016/j.brainres.2011.11.063
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Tsuruma K, 2014, STEM CELL TRANSL MED, V3, P42, DOI 10.5966/sctm.2013-0020
   Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039
   Van Kampen JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097032
   Xu DM, 2008, MOL CELL PROTEOMICS, V7, P2215, DOI 10.1074/mcp.M800095-MCP200
   Zanocco-Marani T, 1999, CANCER RES, V59, P5331
   ZHOU J, 1993, J BIOL CHEM, V268, P10863
   Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8
NR 43
TC 2
Z9 2
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 31
PY 2019
VL 25
BP 902
EP 911
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA KA2AJ
UT WOS:000505599900002
PM 32025182
DA 2022-11-30
ER

PT J
AU Gopfert, JC
   Reiser, A
   Yanez, VAC
   Pohle, A
   Wessels, U
   Heine, A
   Joos, TO
   Petit-Frere, C
   Nogoceke, E
   Stubenrauch, KG
AF Goepfert, Jens C.
   Reiser, Astrid
   Yanez, Viviana A. Carcamo
   Pohle, Annelie
   Wessels, Uwe
   Heine, Anne
   Joos, Thomas O.
   Petit-Frere, Corinne
   Nogoceke, Everson
   Stubenrauch, Kay-Gunnar
TI Development and evaluation of an ultrasensitive free VEGF-A immunoassay
   for analysis of human aqueous humor
SO BIOANALYSIS
LA English
DT Article
DE aqueous humor; biomarker; diabetic macular edema (DME); Faricimab;
   immunoassay; ophthalmology; single molecule array (Simoa); soluble
   target; VA2 CrossMAb; vascular endothelial growth factor A (VEGF-A)
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; TECHNOLOGIES; AAPS
AB Aim: Novel bifunctional VEGF-A neutralizing therapies are being developed for the treatment of retinal vascular diseases such as age-related macular degeneration and diabetic retinopathy. In developing new therapeutic drugs, only small aqueous humor sample volumes are available for analyzing several parameters. Highly sensitive detection methods must be applied in analyzing VEGF-A levels in ocular fluids in order to demonstrate VEGF-A suppression following drug administration. Experimental: A highly sensitive immunoassay for VEGF-A was developed on the single molecule array (Simoa) platform, and validated before being used for the analysis of clinical aqueous humor samples from patients treated with anti-VEGFA therapeutics. Results: This highly sensitive immunoassay allows the detection of baseline VEGF-A levels and suppression effects after drug administration, even in sample volumes as low as 12 mu l. Conclusion: The Simoa VEGF-A assay is a valuable tool for the reliable monitoring of VEGF-A suppression after intravitreal administration of anti-VEGF-A drugs.
C1 [Goepfert, Jens C.; Yanez, Viviana A. Carcamo; Pohle, Annelie; Heine, Anne; Joos, Thomas O.] Nat & Med Sci Inst, Biochem Dept, Markwiesenstr 55, D-72770 Reutlingen, Germany.
   [Reiser, Astrid; Wessels, Uwe; Stubenrauch, Kay-Gunnar] Roche Innovat Ctr Munich, Large Mol Bioanalyt Sci, Roche Pharma Res & Early Dev, D-82377 Penzberg, Germany.
   [Petit-Frere, Corinne] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Large Mol Regulated Bioanal, Grenzacherstr 124, CH-4070 Basel, Switzerland.
   [Nogoceke, Everson] Roche Innovat Ctr, Roche Pharma Res & Early Dev, Neurosci Ophthalmol & Rare Dis Discovery & Transl, Grenzacherstr 124, CH-4070 Basel, Switzerland.
C3 Roche Holding; Roche Holding
RP Gopfert, JC (通讯作者)，Nat & Med Sci Inst, Biochem Dept, Markwiesenstr 55, D-72770 Reutlingen, Germany.
EM jens.goepfert@nmi.de
CR Andreasson U, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00179
   Arnold ME, 2016, AAPS J, V18, P1366, DOI 10.1208/s12248-016-9946-6
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Carcamo Yanez Viviana A, 2017, High Throughput, V6, DOI 10.3390/ht6040018
   Cowan KJ, 2017, BIOANALYSIS, V9, P937, DOI 10.4155/bio-2017-0024
   EMA, 2011, GUID BIOAN METH VAL
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   FDA, 2018, GUID IND BIOAN METH
   Fenn S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061953
   Klein C, 2016, MABS-AUSTIN, V8, P1010, DOI 10.1080/19420862.2016.1197457
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lowes S, 2016, BIOANALYSIS, V8, P163, DOI 10.4155/bio.15.251
   Muether PS, 2014, BRIT J OPHTHALMOL, V98, P179, DOI 10.1136/bjophthalmol-2013-303954
   PASSING H, 1983, J CLIN CHEM CLIN BIO, V21, P709
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Purushothama S, 2018, BIOANALYSIS, V10, P181, DOI 10.4155/bio-2017-0196
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Regula JT, 2018, PROTEIN ENG DES SEL, V31, P289, DOI 10.1093/protein/gzy021
   Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b
   Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641
   Roman J, 2011, J PHARMACOL TOX MET, V63, P227, DOI 10.1016/j.vascn.2010.12.002
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaefer W, 2016, MABS-AUSTIN, V8, P49, DOI 10.1080/19420862.2015.1111498
   Sumner G, 2019, BIOANALYSIS, V11, P381, DOI 10.4155/bio-2018-0096
   Williams K, 2017, BIOANALYSIS, V9, P1207, DOI 10.4155/bio-2017-0102
   Wilson DH, 2016, JALA-J LAB AUTOM, V21, P533, DOI 10.1177/2211068215589580
   Yeung D, 2016, J IMMUNOL METHODS, V437, P53, DOI 10.1016/j.jim.2016.08.003
NR 31
TC 2
Z9 2
U1 0
U2 15
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1757-6180
EI 1757-6199
J9 BIOANALYSIS
JI Bioanalysis
PD MAY
PY 2019
VL 11
IS 9
BP 875
EP 886
DI 10.4155/bio-2019-0044
PG 12
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IC3GW
UT WOS:000470848600006
PM 31070047
DA 2022-11-30
ER

PT J
AU Baim, AD
   Movahedan, A
   Farooq, AV
   Skondra, D
AF Baim, Adam D.
   Movahedan, Asadolah
   Farooq, Asim V.
   Skondra, Dimitra
TI The microbiome and ophthalmic disease
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Microbiota; ophthalmology; pathophysiology; metabolism; inflammation;
   biomedical
ID PRIMARY OPEN-ANGLE; HELICOBACTER-PYLORI INFECTION; OCULAR SURFACE; GUT
   MICROBIOTA; CONTACT-LENS; ANTIBIOTIC-RESISTANCE; MACULAR DEGENERATION;
   CONJUNCTIVAL FLORA; WIDE ASSOCIATION; ORAL MICROBIOME
AB Progress in microbiome research has accelerated in recent years. Through the use of 16S rRNA assays and other genomic sequencing techniques, researchers have provided new insights about the communities of microorganisms that inhabit human and animal hosts. There is mounting evidence about the importance of these 'microbiotas' in a wide variety of disease states, suggesting potential targets for preventative and therapeutic interventions. Until recently, however, the microbiome received relatively little attention in ophthalmology. This review explores emerging research on the roles that ocular and extraocular microbiotas may play in the pathogenesis and treatment of ophthalmic diseases. These include diseases of the ocular surface as well as autoimmune uveitis, age-related macular degeneration, and primary open angle glaucoma. Many questions remain about the potential impacts of microbiome research on the diagnosis, treatment, and prevention of ophthalmic disease. In light of current findings, we suggest directions for future study as this exciting area of research continues to expand.
C1 [Baim, Adam D.; Movahedan, Asadolah; Farooq, Asim V.; Skondra, Dimitra] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 University of Chicago
RP Skondra, D (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
EM dskondra@bsd.uchicago.edu
CR Albietz JM, 2006, CORNEA, V25, P1012, DOI 10.1097/01.ico.0000225716.85382.7b
   AlFaleh K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005496.pub4
   Andermann TM, 2016, CURR HEMATOL MALIG R, V11, P19, DOI 10.1007/s11899-016-0302-9
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Aron-Wisnewsky J, 2016, NAT REV NEPHROL, V12, P169, DOI 10.1038/nrneph.2015.191
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   Beli E, 2018, DIABETES, V67, P1867, DOI 10.2337/db18-0158
   Bermudez-Brito M, 2012, ANN NUTR METAB, V61, P160, DOI 10.1159/000342079
   Boost M, 2017, CLIN EXP OPTOM, V100, P459, DOI 10.1111/cxo.12582
   Bordon Y, 2015, NAT REV IMMUNOL, V15, P595, DOI 10.1038/nri3911
   Caspi RR, 2016, J IMMUNOL, V196
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Conlon MA, 2015, NUTRIENTS, V7, P17, DOI 10.3390/nu7010017
   Dash S, 2015, CURR OPIN PSYCHIATR, V28, P1, DOI 10.1097/YCO.0000000000000117
   Dave SB, 2013, OPHTHALMOLOGY, V120, P937, DOI 10.1016/j.ophtha.2012.11.005
   de Paiva CS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23561
   Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225
   Doan T, 2016, INVEST OPHTH VIS SCI, V57, P5116, DOI 10.1167/iovs.16-19803
   Dong QF, 2011, INVEST OPHTH VIS SCI, V52, P5408, DOI 10.1167/iovs.10-6939
   Duran-Pinedo AE, 2015, MICROBES INFECT, V17, P505, DOI 10.1016/j.micinf.2015.03.014
   Dzutsev A, 2017, ANNU REV IMMUNOL, V35, P199, DOI 10.1146/annurev-immunol-051116-052133
   Ford AC, 2014, AM J GASTROENTEROL, V109, P1547, DOI 10.1038/ajg.2014.202
   Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766
   Franzosa EA, 2015, NAT REV MICROBIOL, V13, P360, DOI 10.1038/nrmicro3451
   Fujimoto C, 2008, OPHTHAL RES, V40, P193, DOI 10.1159/000119875
   Galletti JG, 2017, IMMUNOLOGY, V150, P397, DOI 10.1111/imm.12716
   Ghaisas S, 2016, PHARMACOL THERAPEUT, V158, P52, DOI 10.1016/j.pharmthera.2015.11.012
   Gilbert JA, 2016, NATURE, V535, P94, DOI 10.1038/nature18850
   Gilbert JA, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0069-1
   Gorshein E, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.12947
   Graham Joanna E, 2007, Invest Ophthalmol Vis Sci, V48, P5616
   Grzybowski A, 2017, GRAEF ARCH CLIN EXP, V255, P851, DOI 10.1007/s00417-017-3608-y
   Gupta A, 2015, MED HYPOTHESES, V85, P699, DOI 10.1016/j.mehy.2015.07.015
   Haluzik M, 2018, DIABETES, V67, P1745, DOI 10.2337/dbi18-0022
   Ham B, 2018, CURR EYE RES, V43, P314, DOI 10.1080/02713683.2017.1406528
   Heissigerova J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5065703
   Hempel S, 2012, JAMA-J AM MED ASSOC, V307, P1959, DOI 10.1001/jama.2012.3507
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848
   Horai R, 2017, EXPERT REV CLIN IMMU, V13, P291, DOI 10.1080/1744666X.2017.1288098
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Hsu HY, 2013, AM J OPHTHALMOL, V155, P36, DOI 10.1016/j.ajo.2012.06.024
   Huang XY, 2018, INVEST OPHTH VIS SCI, V59, P1523, DOI 10.1167/iovs.17-22677
   Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007-JLR200
   Iovieno A, 2008, GRAEF ARCH CLIN EXP, V246, P435, DOI 10.1007/s00417-007-0682-6
   Jangi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12015
   Jassim SH, 2015, INVEST OPHTH VIS SCI, V56, P4689, DOI 10.1167/iovs.15-17101
   Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiang L, 2017, INVEST OPHTH VIS SCI, V58
   Kim JM, 2011, INVEST OPHTH VIS SCI, V52, P665, DOI 10.1167/iovs.10-6096
   Knight R, 2017, ANNU REV GENOM HUM G, V18, P65, DOI 10.1146/annurev-genom-083115-022438
   Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014
   Kountouras J, 2002, ARCH INTERN MED, V162, P1237, DOI 10.1001/archinte.162.11.1237
   Kountouras J, 2003, GRAEF ARCH CLIN EXP, V241, P884, DOI 10.1007/s00417-003-0779-5
   Kugadas A, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005855
   Kugadas Abirami, 2016, Ocul Surf, V14, P342, DOI 10.1016/j.jtos.2016.04.004
   Kurtz S, 2008, J GLAUCOMA, V17, P223, DOI 10.1097/IJG.0b013e31815a34ac
   Lee AY, 2015, OPHTHALMOLOGY, V122, P524, DOI 10.1016/j.ophtha.2014.09.001
   Lee SH, 2012, INVEST OPHTH VIS SCI, V53, P5585, DOI 10.1167/iovs.12-9922
   Lewis BB, 2017, ANNU REV MICROBIOL, V71, P157, DOI 10.1146/annurev-micro-090816-093549
   Lim B, 2017, CELL, V169, P547, DOI 10.1016/j.cell.2017.03.045
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   Lin P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105684
   Lu Louise J., 2016, Yale Journal of Biology and Medicine, V89, P325
   Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400
   McDermott AM, 2013, EXP EYE RES, V117, P53, DOI 10.1016/j.exer.2013.07.014
   Nakamura YK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12163-3
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Narayanan S, 2013, OCUL SURF, V11, P75, DOI 10.1016/j.jtos.2012.12.002
   Ochoa-Reparaz J, 2010, MUCOSAL IMMUNOL, V3, P487, DOI 10.1038/mi.2010.29
   Ohtani S, 2017, INVEST OPHTH VIS SCI, V58, P3991, DOI 10.1167/iovs.16-20853
   Oresic M, 2009, EXP EYE RES, V89, P604, DOI 10.1016/j.exer.2009.06.018
   Owji N, 2009, OPHTHAL PLAST RECONS, V25, P136, DOI 10.1097/IOP.0b013e31819a4255
   Ozkan J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10494-9
   Pasquale LR, 2016, OPHTHALMOLOGY, V123, P2318, DOI 10.1016/j.ophtha.2016.07.014
   Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109
   Polla D, 2017, J GLAUCOMA, V26, P320, DOI 10.1097/IJG.0000000000000465
   Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450
   Rajilic-Stojanovic M, 2015, AM J GASTROENTEROL, V110, P278, DOI 10.1038/ajg.2014.427
   Rosenbaum JT, 2016, OCUL IMMUNOL INFLAMM, V24, P440, DOI 10.3109/09273948.2016.1142574
   Rosenbaum JT, 2016, JPN J OPHTHALMOL, V60, P1, DOI 10.1007/s10384-015-0416-y
   Rowan S, 2018, ADV EXP MED BIOL, V1074, P429, DOI 10.1007/978-3-319-75402-4_53
   Rowan S, 2018, GUT MICROBES, V9, P452, DOI 10.1080/19490976.2018.1435247
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sacca SC, 2006, INVEST OPHTH VIS SCI, V47, P501, DOI 10.1167/iovs.05-0323
   Sacca SC, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000216
   SanMiguel A, 2015, CELL MOL LIFE SCI, V72, P1499, DOI 10.1007/s00018-014-1812-z
   Scher JU, 2016, ARTHRITIS RHEUMATOL, V68, P35, DOI 10.1002/art.39259
   Sen HN, 2017, INVEST OPHTH VIS SCI, V58
   Sheehan D, 2015, J GASTROENTEROL, V50, P495, DOI 10.1007/s00535-015-1064-1
   SHIN H, 2016, CHANGES, V7, DOI DOI 10.1128/MBIO.00198-16
   Skondra D., 2007, INVESTIG OPHTHALMOL, V48, P1768
   St Leger AJ, 2017, IMMUNITY, V47, P148, DOI 10.1016/j.immuni.2017.06.014
   STAPLETON F, 1995, INFECT IMMUN, V63, P4501, DOI 10.1128/IAI.63.11.4501-4505.1995
   Stephens B, 2016, MSYSTEMS, V1, DOI 10.1128/mSystems.00083-16
   Suto Chikako, 2012, Infect Drug Resist, V5, P37, DOI 10.2147/IDR.S27937
   Tai NW, 2015, REV ENDOCR METAB DIS, V16, P55, DOI 10.1007/s11154-015-9309-0
   Terzulli M, 2015, J OCUL PHARMACOL TH, V31, P413, DOI 10.1089/jop.2015.0017
   Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847
   Theriot CM, 2015, ANNU REV MICROBIOL, V69, P445, DOI 10.1146/annurev-micro-091014-104115
   Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Ursell LK, 2012, NUTR REV, V70, pS38, DOI 10.1111/j.1753-4887.2012.00493.x
   Watters GA, 2017, CLIN EXP OPHTHALMOL, V45, P105, DOI 10.1111/ceo.12810
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Wen XF, 2017, INVEST OPHTH VIS SCI, V58, P6030, DOI 10.1167/iovs.17-22957
   Willcox MDP, 2013, EXP EYE RES, V117, P99, DOI 10.1016/j.exer.2013.06.003
   Yamauchi Y, 2005, OCUL IMMUNOL INFLAMM, V13, P301, DOI 10.1080/09273940590951106
   Yang C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133021
   Yin VT, 2013, JAMA OPHTHALMOL, V131, P456, DOI 10.1001/jamaophthalmol.2013.2379
   Zarate-Blades CR, 2017, GUT MICROBES, V8, P59, DOI 10.1080/19490976.2016.1273996
   Zavos C, 2012, OPHTHALMIC RES, V47, P150, DOI 10.1159/000330053
   Zegans ME, 2014, AM J OPHTHALMOL, V158, P420, DOI 10.1016/j.ajo.2014.06.014
   Zeng J, 2015, INVEST OPHTH VIS SCI, V56, P5238, DOI 10.1167/iovs.15-17059
   Zhang HK, 2017, INVEST OPHTH VIS SCI, V58, P128, DOI 10.1167/iovs.16-20231
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zullo A, 2012, DIGEST LIVER DIS, V44, P627, DOI 10.1016/j.dld.2012.03.011
NR 120
TC 27
Z9 29
U1 1
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD APR
PY 2019
VL 244
IS 6
SI SI
BP 419
EP 429
DI 10.1177/1535370218813616
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HW2UE
UT WOS:000466543300003
PM 30463439
OA Green Published
DA 2022-11-30
ER

PT J
AU Sharma, R
   Khristov, V
   Rising, A
   Jha, BS
   Dejene, R
   Hotaling, N
   Li, YC
   Stoddard, J
   Stankewicz, C
   Wan, Q
   Zhang, CN
   Campos, MM
   Miyagishima, KJ
   McGaughey, D
   Villasmil, R
   Mattapallil, M
   Stanzel, B
   Qian, HH
   Wong, W
   Chase, L
   Charles, S
   McGill, T
   Miller, S
   Maminishkis, A
   Amaral, J
   Bharti, K
AF Sharma, Ruchi
   Khristov, Vladimir
   Rising, Aaron
   Jha, Balendu Shekhar
   Dejene, Roba
   Hotaling, Nathan
   Li, Yichao
   Stoddard, Jonathan
   Stankewicz, Casey
   Wan, Qin
   Zhang, Connie
   Campos, Mercedes Maria
   Miyagishima, Kiyoharu J.
   McGaughey, David
   Villasmil, Rafael
   Mattapallil, Mary
   Stanzel, Boris
   Qian, Haohua
   Wong, Wai
   Chase, Lucas
   Charles, Steve
   McGill, Trevor
   Miller, Sheldon
   Maminishkis, Arvydas
   Amaral, Juan
   Bharti, Kapil
TI Clinical-grade stem cell-derived retinal pigment epithelium patch
   rescues retinal degeneration in rodents and pigs
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID EFFICIENT GENERATION; MACULAR DEGENERATION; THERAPY; DIFFERENTIATION;
   ACTIVATION; MONOLAYERS; LACTATE; PATIENT; MATRIX
AB Considerable progress has been made in testing stem cell-derived retinal pigment epithelium (RPE) as a potential therapy for age-related macular degeneration (AMD). However, the recent reports of oncogenic mutations in induced pluripotent stem cells (iPSCs) underlie the need for robust manufacturing and functional validation of clinical-grade iPSC-derived RPE before transplantation. Here, we developed oncogenic mutation-free clinical-grade iPSCs from three AMD patients and differentiated them into clinical-grade iPSC-RPE patches on biodegradable scaffolds. Functional validation of clinical-grade iPSC-RPE patches revealed specific features that distinguished transplantable from nontransplantable patches. Compared to RPE cells in suspension, our biodegradable scaffold approach improved integration and functionality of RPE patches in rats and in a porcine laser-induced RPE injury model that mimics AMD-like eye conditions. Our results suggest that the in vitro and in vivo preclinical functional validation of iPSC-RPE patches developed here might ultimately be useful for evaluation and optimization of autologous iPSC-based therapies.
C1 [Sharma, Ruchi; Jha, Balendu Shekhar; Dejene, Roba; Hotaling, Nathan; Bharti, Kapil] NEI, Unit Ocular & Stem Cell Translat Res, NIH, Bethesda, MD 20892 USA.
   [Khristov, Vladimir; Rising, Aaron; Wan, Qin; Zhang, Connie; Miyagishima, Kiyoharu J.; Miller, Sheldon; Maminishkis, Arvydas] NEI, Sect Epithelial & Retinal Physiol & Dis, NIH, Bethesda, MD 20892 USA.
   [Li, Yichao; Qian, Haohua] NEI, Visual Funct Core, NIH, Bethesda, MD 20892 USA.
   [Stoddard, Jonathan; McGill, Trevor] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Stankewicz, Casey; Chase, Lucas] Cellular Dynam Int Inc, Madison, WI 53711 USA.
   [Campos, Mercedes Maria] NEI, Histol Core, NIH, Bethesda, MD 20892 USA.
   [McGaughey, David] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
   [Villasmil, Rafael] NEI, Flow Cytometry Core, NIH, Bethesda, MD 20892 USA.
   [Mattapallil, Mary] NEI, Lab Immunol, NIH, Bethesda, MD 20892 USA.
   [Stanzel, Boris] Sulzbach Knappschaft Eye Clin, Macula Ctr Saar, D-66280 Sulzbach, Germany.
   [Wong, Wai] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Charles, Steve] Charles Retina Inst, Germantown, TN 38138 USA.
   [Amaral, Juan] NEI, Off Sci Director, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Oregon Health & Science University; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI)
RP Bharti, K (通讯作者)，NEI, Unit Ocular & Stem Cell Translat Res, NIH, Bethesda, MD 20892 USA.
EM Kapilbharti@nei.nih.gov
RI Stanzel, Boris/ADP-9221-2022; Stanzel, Boris/AAG-7010-2022; Khristov,
   Vladimir/R-9875-2017
OI Stanzel, Boris/0000-0002-4316-1539; Stanzel, Boris/0000-0002-4316-1539;
   Miyagishima, Kiyoharu/0000-0002-9744-3152; Jha, Balendu
   Shekhar/0000-0002-6509-8171; Khristov, Vladimir/0000-0002-7778-3993;
   Rising, Aaron/0000-0002-0725-9758; McGaughey, David/0000-0002-9224-2888
FU NEI IRP funds; Common Fund Therapeutic Challenge Award; NATIONAL EYE
   INSTITUTE [ZIAEY000530, ZIAEY000456, ZICEY000503, ZICEY000461,
   ZIAEY000542] Funding Source: NIH RePORTER
FX This work was supported by NEI IRP funds and Common Fund Therapeutic
   Challenge Award to K.B. and S.M.
CR ADLER AJ, 1992, OPHTHALMIC RES, V24, P243, DOI 10.1159/000267174
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Badenes SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155296
   Badenes SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151264
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166
   Fischbach MA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005568
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Greene WA, 2017, J OCUL PHARMACOL TH, V33, P132, DOI 10.1089/jop.2016.0070
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Kajiwara M, 2012, P NATL ACAD SCI USA, V109, P12538, DOI 10.1073/pnas.1209979109
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kang EJ, 2016, CELL STEM CELL, V18, P625, DOI 10.1016/j.stem.2016.02.005
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kwon EM, 2017, P NATL ACAD SCI USA, V114, P1964, DOI 10.1073/pnas.1616035114
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Mack AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027956
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   McGill TJ, 2004, VISION RES, V44, P2559, DOI 10.1016/j.visres.2004.05.025
   McGill TJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.17
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Reh TA, 2010, METHODS MOL BIOL, V636, P139, DOI 10.1007/978-1-60761-691-7_9
   Santa-Cecilia FV, 2016, NEUROTOX RES, V29, P447, DOI 10.1007/s12640-015-9592-2
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sivaprasad S, 2010, SURV OPHTHALMOL, V55, P516, DOI 10.1016/j.survophthal.2010.02.005
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Swijnenburg RJ, 2008, P NATL ACAD SCI USA, V105, P12991, DOI 10.1073/pnas.0805802105
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Wacharasint P, 2012, SHOCK, V38, P4, DOI 10.1097/SHK.0b013e318254d41a
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Xian BK, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0167-1
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 54
TC 128
Z9 130
U1 10
U2 53
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JAN 16
PY 2019
VL 11
IS 475
AR eaat5580
DI 10.1126/scitranslmed.aat5580
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HH7OB
UT WOS:000455919100003
PM 30651323
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Bonadiman, BDR
   Cadona, FC
   Assmann, CE
   Weis, GCC
   Alves, AD
   Durte, MF
   Chaves, CM
   Chaves, CD
   Motta, KMD
   Ribeiro, EE
   Bagatini, MD
   da Cruz, IBM
AF Rosa Bonadiman, Beatriz da Silva
   Cadona, Francine Carla
   Assmann, Charles Elias
   Cezimbra Weis, Grazielle Castagna
   Alves, Audrei de Oliveira
   Durte, Marta Frescura
   Chaves, Claudia Maria
   Chaves, Claudio do Carmo
   dos Santos Motta, Kennya Marcia
   Ribeiro, Euler Esteves
   Bagatini, Margarete Dulce
   Manica da Cruz, Ivana Beatrice
TI Guarana (Paullinia cupana): Cytoprotective effects on age-related eye
   dysfunction
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Riparian elderly; Guarana; Eye disorders; Visual loss; Macular
   degeneration; Eye quality
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; VAR.-SORBILIS; IN-VITRO;
   CAFFEINE; APOPTOSIS; PRODUCTS; PROLIFERATION; DEGENERATION; EXPRESSION
AB Ageing can cause disorders such as age-related macular degeneration (AMD), which leads to irreversible visual loss in elderly people. Given that nutrition may influence some age-related disorders, this study investigated, in vivo, the association between self-reported eyesight quality and daily guarana intake in riparian elderly subjects and, in vitro, the effects of guarana (Paullinia cupana) on retinal pigmented epithelium (RPE) cells exposed to paraquat. Just over half of the elderly subjects self-reported poor vision (n = 320, 50.8%), 234 (37.1%) self-reported regular eyesight, whereas just 76 (12.1%) self-reported good vision. Subjects that self-reported good vision presented a higher frequency of habitual guarana consumption. Guarana treatment was able to decrease apoptosis and necrosis events and differentially modulate gene expression and protein levels of caspases 1, 3 and 8 in RPE cells. This work provides new perspectives on the potential use of guarana against eye diseases due to its cytoprotective effects. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Rosa Bonadiman, Beatriz da Silva; Alves, Audrei de Oliveira; Durte, Marta Frescura; Manica da Cruz, Ivana Beatrice] Univ Fed Santa Maria, Grad Program Pharmacol, BR-97105900 Santa Maria, RS, Brazil.
   [Cadona, Francine Carla; Assmann, Charles Elias; Manica da Cruz, Ivana Beatrice] Univ Fed Santa Maria, Grad Program Biol Sci Toxicol Biochem, BR-97105900 Santa Maria, RS, Brazil.
   [Cezimbra Weis, Grazielle Castagna] Univ Fed Santa Maria, Grad Program Food Sci & Technol, BR-97105900 Santa Maria, RS, Brazil.
   [Chaves, Claudia Maria; Chaves, Claudio do Carmo] Ophthalmol Inst Manaus, BR-69005141 Manaus, Amazonas, Brazil.
   [dos Santos Motta, Kennya Marcia; Manica da Cruz, Ivana Beatrice] Univ Fed Santa Maria, Grad Program Gerontol, BR-97105900 Santa Maria, RS, Brazil.
   [Ribeiro, Euler Esteves] Open Univ Third Age, BR-69065001 Manaus, Amazonas, Brazil.
   [Bagatini, Margarete Dulce] Fed Univ Fronteira Sul, Acad Coordinat, Campus Chapeco, BR-89815899 Chapeco, Brazil.
   [Rosa Bonadiman, Beatriz da Silva; Cadona, Francine Carla; Assmann, Charles Elias; Cezimbra Weis, Grazielle Castagna; Alves, Audrei de Oliveira; dos Santos Motta, Kennya Marcia; Manica da Cruz, Ivana Beatrice] Univ Fed Santa Maria, Hlth Sci Ctr, Dept Morphol, Lab Biogen, BR-97105900 Santa Maria, RS, Brazil.
C3 Universidade Federal de Santa Maria (UFSM); Universidade Federal de
   Santa Maria (UFSM); Universidade Federal de Santa Maria (UFSM);
   Universidade Federal de Santa Maria (UFSM); Universidade Federal da
   Fronteira Sul; Universidade Federal de Santa Maria (UFSM)
RP da Cruz, IBM (通讯作者)，Univ Fed Santa Maria, 1000 Roraima Ave,Bldg 19,Room 3101, BR-97105900 Santa Maria, RS, Brazil.
EM ibmcruz@hotmail.com
RI Assmann, Charles Elias/E-8936-2015; Bagatini, Margarete/K-3756-2016; da
   Cruz, Ivana BM/G-4329-2012; Assmann, Charles/AAM-8039-2021
OI Assmann, Charles Elias/0000-0002-3524-3446; Bagatini,
   Margarete/0000-0001-9263-4980; da Cruz, Ivana BM/0000-0003-3008-6899; 
FU National Counsel of Technological and Scientific Development (CNPq)
   [402325/2013-3, 490760/2013-9, 311446/2012-4]
FX This study was funded by the National Counsel of Technological and
   Scientific Development (CNPq), Grant Nos. 402325/2013-3, 490760/2013-9
   and 311446/2012-4. The funding source had no role in data collection and
   analysis, preparation of the manuscript or submission to the journal.
CR Andrews KW, 2007, ANAL BIOANAL CHEM, V389, P231, DOI 10.1007/s00216-007-1437-2
   Angelo PCSA, 2008, PLANT CELL REP, V27, P117, DOI 10.1007/s00299-007-0456-y
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beharry KD, 2016, SEMIN PERINATOL, V40, P189, DOI 10.1053/j.semperi.2015.12.006
   BELLIARDO F, 1985, Z LEBENSM UNTERS FOR, V180, P398, DOI 10.1007/BF01027774
   BEMPONG DK, 1992, J PHARM PHARMACOL, V44, P769, DOI 10.1111/j.2042-7158.1992.tb05517.x
   Bittencourt LS, 2013, FOOD CHEM TOXICOL, V53, P119, DOI 10.1016/j.fct.2012.11.041
   Bittencourt LD, 2014, PHYTOTHER RES, V28, P1615, DOI 10.1002/ptr.5173
   Boia R, 2016, OPHTHALMIC RES, V55, P212, DOI 10.1159/000443893
   Brand MD, 2013, BRIT J DERMATOL, V169, P1, DOI 10.1111/bjd.12208
   Cadona FC, 2016, ANTI-CANCER AGENT ME, V16, P1055, DOI 10.2174/1871520616666151217121138
   Campos AR, 2003, PHYTOTHER RES, V17, P1199, DOI 10.1002/ptr.1212
   Chader G. J., 2013, INVEST OPHTHALMOL, V54, P1, DOI DOI 10.1167/I0VS.13-12993
   Chen A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046473
   Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200
   Cumberland PM, 2016, JAMA OPHTHALMOL, V134, P794, DOI 10.1001/jamaophthalmol.2016.1275
   Datta S., 2017, PROG RETIN EYE RES, V17, P30012
   de Oliveira DM, 2011, HUM EXP TOXICOL, V30, P1382, DOI 10.1177/0960327110389837
   Duchan E, 2010, PHYSICIAN SPORTSMED, V38, P171, DOI 10.3810/psm.2010.06.1796
   Fukui M, 2010, EUR J CANCER, V46, P1882, DOI 10.1016/j.ejca.2010.02.004
   Fukumasu H, 2008, BRAZ J MED BIOL RES, V41, P305, DOI 10.1590/S0100-879X2008000400008
   Graphpad Software, 2014, GRAPHPAD PRISM VERS
   Halliwell B, 2007, BIOCHEM SOC T, V35, P1147, DOI 10.1042/BST0351147
   Hao LN, 2011, INT J OPHTHALMOL-CHI, V4, P474, DOI 10.3980/j.issn.2222-3959.2011.05.03
   Hoeg TB, 2016, OPHTHAL EPIDEMIOL, V23, P53, DOI 10.3109/09286586.2015.1066396
   Hou RR, 2008, CELL BIOL INT, V32, P22, DOI 10.1016/j.cellbi.2007.08.007
   Jaroonwitchawan T, 2017, NEUROSCI LETT, V636, P40, DOI 10.1016/j.neulet.2016.10.050
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kang JH, 2015, INVEST OPHTH VIS SCI, V56, P2439, DOI 10.1167/iovs.14-16088
   Kang JH, 2008, INVEST OPHTH VIS SCI, V49, P1924, DOI 10.1167/iovs.07-1425
   Khan N, 2007, LIFE SCI, V81, P519, DOI 10.1016/j.lfs.2007.06.011
   Khazaeli AA, 2000, GENETICA, V109, P245, DOI 10.1023/A:1017569318401
   Kim SJ, 2004, MOL CELLS, V17, P102
   Kober H, 2016, DRUG CHEM TOXICOL, V39, P48, DOI 10.3109/01480545.2015.1020546
   Krewer CD, 2014, EUR FOOD RES TECHNOL, V239, P49, DOI 10.1007/s00217-014-2182-3
   Krewer CD, 2011, PHYTOTHER RES, V25, P1367, DOI 10.1002/ptr.3437
   Leite RP, 2011, BIOL TRACE ELEM RES, V141, P262, DOI 10.1007/s12011-010-8729-7
   Liu Z. H., 2015, HIGHWAY, V2015, P1, DOI DOI 10.1016/J.FUPR0C.2015.01.025
   Luo GH, 2016, SCI REP-UK, V6, P1, DOI [10.1038/srep35231, 10.1038/s41598-016-0027-y]
   Machado AK, 2015, FOOD RES INT, V67, P426, DOI 10.1016/j.foodres.2014.11.056
   Ribeiro EAM, 2013, ARCH GERONTOL GERIAT, V56, P350, DOI 10.1016/j.archger.2012.08.015
   Manikandan R, 2016, FITOTERAPIA, V109, P58, DOI 10.1016/j.fitote.2015.12.009
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martinez-Garcia J. J., 2013, J ENG, V2013, P1
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moran JM, 2010, J BIOCHEM MOL TOXIC, V24, P402, DOI 10.1002/jbt.20348
   Narayanasamy SK, 2014, PROTEOMICS, V14, P2566, DOI 10.1002/pmic.201400192
   Pan C. W., 2016, J OPHTHALMOLOGY, V2016, P1
   Patel AK, 2016, NUTRITION, V32, P384, DOI 10.1016/j.nut.2015.09.017
   Pescosolido N, 2016, INT J OPHTHALMOL-CHI, V9, P1506, DOI 10.18240/ijo.2016.10.23
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Portella RD, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-12
   Sampath C, 2016, PHYTOMEDICINE, V23, P200, DOI 10.1016/j.phymed.2015.12.013
   Santa Maria A, 1998, ECOTOX ENVIRON SAFE, V39, P164, DOI 10.1006/eesa.1997.1576
   Schimpl FC, 2013, J ETHNOPHARMACOL, V150, P14, DOI 10.1016/j.jep.2013.08.023
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   Silva TO, 2015, FREE RADICAL RES, V49, P204, DOI 10.3109/10715762.2014.992895
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Tarry-Adkins JL, 2014, P NUTR SOC, V73, P289, DOI 10.1017/S002966511300387X
   Tawara T, 1996, ARCH TOXICOL, V70, P585, DOI 10.1007/s002040050316
   Varma SD, 2016, CLIN OPHTHALMOL, V10, P213, DOI 10.2147/OPTH.S96394
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang W, 2008, J TOXICOL ENV HEAL A, V71, P289, DOI 10.1080/15287390701738467
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Zhao X, 2014, INT J CLIN EXP MED, V7, P1204
NR 67
TC 11
Z9 11
U1 0
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD SEP
PY 2017
VL 36
BP 375
EP 386
DI 10.1016/j.jff.2017.07.027
PG 12
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA FE9IV
UT WOS:000408518300042
DA 2022-11-30
ER

PT J
AU Calippe, B
   Augustin, S
   Beguier, F
   Charles-Messance, H
   Poupel, L
   Conart, JB
   Hu, SLJ
   Lavalette, S
   Fauvet, A
   Rayes, J
   Levy, O
   Raoul, W
   Fitting, C
   Denefle, T
   Pickering, MC
   Harris, C
   Jorieux, S
   Sullivan, PM
   Sahel, JA
   Karoyan, P
   Sapieha, P
   Guillonneau, X
   Gautier, EL
   Sennlaub, F
AF Calippe, Bertrand
   Augustin, Sebastien
   Beguier, Fanny
   Charles-Messance, Hugo
   Poupel, Lucie
   Conart, Jean-Baptiste
   Hu, Shulong J.
   Lavalette, Sophie
   Fauvet, Alexandre
   Rayes, Julie
   Levy, Olivier
   Raoul, William
   Fitting, Catherine
   Denefle, Thomas
   Pickering, Matthew C.
   Harris, Claire
   Jorieux, Sylvie
   Sullivan, Patrick M.
   Sahel, Jose -Alain
   Karoyan, Philippe
   Sapieha, Przemyslaw
   Guillonneau, Xavier
   Gautier, Emmanuel L.
   Sennlaub, Florian
TI Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation
SO IMMUNITY
LA English
DT Article
ID MACULAR DEGENERATION; SUBRETINAL INFLAMMATION; GENE-EXPRESSION;
   UP-REGULATION; SPINAL-CORD; MICROGLIA; DISEASE; MACROPHAGES;
   ANGIOGENESIS; ACTIVATION
AB Variants of the CFH gene, encoding complement factor H (CFH), show strong association with age-related macular degeneration (AMD), a major cause of blindness. Here, we used murine models of AMD to examine the contribution of CFH to disease etiology. Cfh deletion protected the mice from the pathogenic subretinal accumulation of mononuclear phagocytes (MP) that characterize AMD and showed accelerated resolution of inflammation. MP persistence arose secondary to binding of CFH to CD11b, which obstructed the homeostatic elimination of MPs from the subretinal space mediated by thrombospsondin-1 (TSP-1) activation of CD47. The AMD-associated CFH(H402) variant markedly increased this inhibitory effect on microglial cells, supporting a causal link to disease etiology. This mechanism is not restricted to the eye, as similar results were observed in a model of acute sterile peritonitis. Pharmacological activation of CD47 accelerated resolution of both subretinal and peritoneal inflammation, with implications for the treatment of chronic inflammatory disease.
C1 [Calippe, Bertrand; Augustin, Sebastien; Beguier, Fanny; Charles-Messance, Hugo; Conart, Jean-Baptiste; Hu, Shulong J.; Lavalette, Sophie; Fauvet, Alexandre; Levy, Olivier; Raoul, William; Sahel, Jose -Alain; Guillonneau, Xavier; Sennlaub, Florian] UPMC Univ Paris 06, Sorbonne Univ, Inst Vis, INSERM,CNRS, 17 Rue Moreau, F-75012 Paris, France.
   [Poupel, Lucie; Gautier, Emmanuel L.] UPMC Univ Paris 06, Sorbonne Univ, INSERM, UMR S 1166,Fac Med Pitie Salpetriere, 91 Blvd Hop, F-75013 Paris, France.
   [Rayes, Julie] Univ Paris 05, Unite Mixte Rech Sante 872, Ctr Rech Cordeliers, F-75006 Paris, France.
   [Pickering, Matthew C.] Imperial Coll, Ctr Complement & Inflammat Res, Dept Med, London W12 0NN, England.
   [Harris, Claire] Cardiff Univ, Inst Infect & Immun, Cardiff CF10 3XQ, S Glam, Wales.
   [Jorieux, Sylvie] LFB Biotechnol, F-59000 Lille, France.
   [Sullivan, Patrick M.] Duke Univ, Dept Med, Ctr Aging, Durham, NC 27710 USA.
   [Sullivan, Patrick M.] Duke Univ, Dept Med, Ctr Geriatr Res Educ, Durham, NC 27710 USA.
   [Sullivan, Patrick M.] Duke Univ, Dept Med, Ctr Clin, Durham Veteran Affairs Med Ctr, Durham, NC 27710 USA.
   [Denefle, Thomas; Karoyan, Philippe] Univ Paris 06, Sorbonne Univ, Lab Biomol, UMR 7203, Paris, France.
   [Denefle, Thomas; Karoyan, Philippe] Univ Paris 06, Sorbonne Univ, FR 2769, Paris, France.
   [Denefle, Thomas; Karoyan, Philippe] CNRS, UMR 7203, Paris, France.
   [Denefle, Thomas; Karoyan, Philippe] Ecole Normale Super, Dept Chim, F-75005 Paris, France.
   [Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H3T 1J4, Canada.
   [Fitting, Catherine] Inst Pasteur, Dept Infect & Epidemiol, Unite Cytokines & Inflammat, F-75015 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere
   - APHP; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Imperial College London; Cardiff University; Duke
   University; Duke University; Geriatric Research Education & Clinical
   Center; Duke University; Centre National de la Recherche Scientifique
   (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research
   Universities; Sorbonne Universite; Institut de Recherche pour le
   Developpement (IRD); Museum National d'Histoire Naturelle (MNHN); Centre
   National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); UDICE-French Research Universities; Sorbonne
   Universite; Centre National de la Recherche Scientifique (CNRS); CNRS -
   Institute of Chemistry (INC); UDICE-French Research Universities;
   Sorbonne Universite; Institut de Recherche pour le Developpement (IRD);
   Museum National d'Histoire Naturelle (MNHN); Universite Paris Cite;
   UDICE-French Research Universities; PSL Research University Paris; Ecole
   Normale Superieure (ENS); Universite de Montreal; Le Reseau
   International des Instituts Pasteur (RIIP); Institut Pasteur Paris
RP Sennlaub, F (通讯作者)，UPMC Univ Paris 06, Sorbonne Univ, Inst Vis, INSERM,CNRS, 17 Rue Moreau, F-75012 Paris, France.
EM florian.sennlaub@inserm.fr
RI Raoul, William/H-2118-2018; Guillonneau, xavier/E-3995-2017; Gautier,
   Emmanuel L./E-2259-2017; Sennlaub, Florian/F-2756-2017; Denèfle,
   Thomas/Q-3767-2017; Beguier, Fanny/AAY-8581-2020; Sahel,
   Jose-Alain/F-3172-2017; Conart, Jean-Baptiste/AAD-8547-2019;
   guillonneau, xavier/AAF-9495-2021
OI Raoul, William/0000-0002-5040-3372; Guillonneau,
   xavier/0000-0001-7379-3935; Gautier, Emmanuel L./0000-0003-2976-7566;
   Sennlaub, Florian/0000-0003-4412-1341; Denèfle,
   Thomas/0000-0003-1342-7997; Beguier, Fanny/0000-0002-6123-2978; Sahel,
   Jose-Alain/0000-0002-4831-1153; guillonneau, xavier/0000-0001-7379-3935;
   Rayes, Julie/0000-0003-0499-6880; Michaelides,
   Michel/0000-0002-1552-7046; Poupel, Lucie/0000-0001-7015-8450;
   CHARLES-MESSANCE, Hugo/0000-0002-6627-2098
FU INSERM; ANR Geno [R09099DS]; ANR MACLEAR [ANR-15-CE14-0015-01]; LABEX
   LIFESENSES [ANR-10-LABX-65]; ANR (Investissements d'Avenir programme
   [ANR-11-IDEX-0004-02]; Carnot; ERC [ERC-2007 St. G. 210345]; Association
   de Prevoyance Sante de ALLIANZ
FX This work was supported by grants from INSERM, ANR Geno 2009 (R09099DS),
   ANR MACLEAR (ANR-15-CE14-0015-01), LABEX LIFESENSES [ANR-10-LABX-65]
   supported by the ANR (Investissements d'Avenir programme
   [ANR-11-IDEX-0004-02]), Carnot, and ERC starting Grant (ERC-2007 St. G.
   210345), the Association de Prevoyance Sante de ALLIANZ, and a generous
   donation by Doris and Michael Bunte.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Appelboom G, 2011, J CLIN NEUROSCI, V18, P1439, DOI 10.1016/j.jocn.2011.04.001
   Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Denefle T, 2016, J MED CHEM, V59, P8412, DOI 10.1021/acs.jmedchem.6b00781
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   DiScipio RG, 1998, J IMMUNOL, V160, P4057
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002
   Kang YH, 2012, IMMUNOBIOLOGY, V217, P455, DOI 10.1016/j.imbio.2011.10.008
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lim HY, 2007, IMMUNOLOGY, V122, P47, DOI 10.1111/j.1365-2567.2007.02611.x
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   Luo C, 2011, MOL VIS, V17, P1588
   Manna PP, 2005, J BIOL CHEM, V280, P29637, DOI 10.1074/jbc.M500922200
   Martin M, 2016, IMMUNOL REV, V274, P218, DOI 10.1111/imr.12462
   Mastellos D, 2004, MOL IMMUNOL, V40, P1213, DOI 10.1016/j.molimm.2003.10.019
   Matsui H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.479
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Ng TF, 2009, INVEST OPHTH VIS SCI, V50, P5472, DOI 10.1167/iovs.08-2877
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Quesada AJ, 2005, CELL DEATH DIFFER, V12, P649, DOI 10.1038/sj.cdd.4401615
   Rayes J, 2014, BLOOD, V123, P121, DOI 10.1182/blood-2013-04-495853
   Rayes J, 2010, BLOOD, V115, P4870, DOI 10.1182/blood-2009-11-254193
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schlaf G, 2001, MOL IMMUNOL, V38, P231, DOI 10.1016/S0161-5890(01)00045-1
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Tedesco D, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/230386
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wilms H, 1999, J NEUROIMMUNOL, V98, P89, DOI 10.1016/S0165-5728(99)00066-1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang Z, 2012, CANCER EPIDEMIOL, V36, pE111, DOI 10.1016/j.canep.2011.11.004
NR 54
TC 89
Z9 92
U1 2
U2 24
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD FEB 21
PY 2017
VL 46
IS 2
BP 261
EP 272
DI 10.1016/j.immuni.2017.01.006
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA EO0TM
UT WOS:000396410900014
PM 28228282
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Yang, CY
   Phillips, JG
   Stuckey, JA
   Bai, LC
   Sun, HY
   Delproposto, J
   Brown, WC
   Chinnaswamy, K
AF Yang, Chao-Yie
   Phillips, James G.
   Stuckey, Jeanne A.
   Bai, Longchuan
   Sun, Haiying
   Delproposto, James
   Brown, William Clay
   Chinnaswamy, Krishnapriya
TI Buried Hydrogen Bond Interactions Contribute to the High Potency of
   Complement Factor D Inhibitors
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Paroxysmal nocturnal hemoglobinuria; age-related macular degeneration;
   complement system; complement factor D inhibitors; serine protease;
   enzyme inhibition assay; biolayer interferometry assay; crystal
   structure; quantum chemistry calculations; thermodynamic integration
   method; computational docking; molecular dynamics simulations; hemolysis
   assay
ID MEMBRANE ATTACK COMPLEX; SERINE-PROTEASE; STRUCTURAL BASIS; ACTIVATION;
   CONVERTASE
AB Aberrant activation of the complement system is associated with diseases, including paroxysmal nocturnal hemoglobinuria and age-related macular degeneration. Complement factor D is the rate-limiting enzyme for activating the alternative pathway in the complement system. Recent development led to a class of potent amide containing pyrrolidine derived factor D inhibitors. Here, we used biochemical enzymatic and biolayer interferometry assays to demonstrate that the amide group improves the inhibitor potency by more than 80-fold. Our crystal structures revealed buried hydrogen bond interactions are important. Molecular orbital analysis from quantum chemistry calculations dissects the chemical groups participating in these interactions. Free energy calculation supports the differential contributions of the amide group to the binding affinities of these inhibitors. Cell-based hemolysis assay confirmed these compounds inhibit factor D mediated complement activation via the alternative pathway. Our study highlights the important interactions contributing to the high potency of factor D inhibitors reported recently.
C1 [Yang, Chao-Yie; Bai, Longchuan] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Stuckey, Jeanne A.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.
   [Stuckey, Jeanne A.; Delproposto, James; Brown, William Clay] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.
   [Phillips, James G.] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44195 USA.
   [Sun, Haiying] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Jiansu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Cleveland Clinic Foundation; China
   Pharmaceutical University
RP Yang, CY (通讯作者)，Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
EM chaoyie@umich.edu
RI Yang, Chao-Yie/A-3930-2015
OI Yang, Chao-Yie/0000-0002-5445-0109
FU Aplastic Anemia MDS international Foundation; National Institutes of
   Health through the University of Michigan Cancer Center Support Grant by
   Cancer Center Core: Center of Structural Biology [P30CA046592]; U.S.
   Department of Energy, Office of Science, Office of Basic Energy Sciences
   [DE-AC02-06CH11357]; Michigan Economic Development Corporation; Michigan
   Technology Tri-Corridor [085P1000817]
FX We are grateful for financial support from the Aplastic Anemia MDS
   international Foundation and from the National Institutes of Health
   through the University of Michigan Cancer Center Support Grant
   (P30CA046592) by the use of the following Cancer Center Core: Center of
   Structural Biology. Use of the Advanced Photon Source was supported by
   the U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences, under Contract No. DE-AC02-06CH11357. Use of the LS-CAT Sector
   21 was supported by the Michigan Economic Development Corporation and
   the Michigan Technology Tri-Corridor for the support of this research
   program (Grant 085P1000817).
CR Belanger D. B., 2015, Aminomethyl-biaryl derivatives as complement factor D inhibitors and uses thereof, Patent No. [WO 2015/009977 A1, 2015009977]
   Brodsky RA, 2015, BLOOD, V126, P2459, DOI 10.1182/blood-2015-06-640995
   Cole LB, 1998, ACTA CRYSTALLOGR D, V54, P711, DOI 10.1107/S0907444997010457
   Di Cera E, 2009, IUBMB LIFE, V61, P510, DOI 10.1002/iub.186
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x
   Hommel U., 2014, Patent No. [W02014/002057, 2014002057]
   Jing H, 1998, J MOL BIOL, V282, P1061, DOI 10.1006/jmbi.1998.2089
   Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   KIM S, 1995, J BIOL CHEM, V270, P24399, DOI 10.1074/jbc.270.41.24399
   Kinoshita T, 1993, Nihon Saikingaku Zasshi, V48, P533
   KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004
   Kukic P, 2013, J AM CHEM SOC, V135, P16968, DOI 10.1021/ja406995j
   Lee M, 2013, NEUROBIOL AGING, V34, P1451, DOI 10.1016/j.neurobiolaging.2012.10.023
   Lee M, 2012, NEUROBIOL AGING, V33, P2237, DOI 10.1016/j.neurobiolaging.2011.12.005
   Mastellos DC, 2014, EXPERT REV HEMATOL, V7, P583, DOI 10.1586/17474086.2014.953926
   Nishimura J, 2014, NEW ENGL J MED, V370, P632, DOI 10.1056/NEJMoa1311084
   Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717
   Ricklin D, 2013, ADV EXP MED BIOL, V735, P1, DOI 10.1007/978-1-4614-4118-2_1
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344
   Serna M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10587
   Subasinghe NL, 2004, BIOORG MED CHEM LETT, V14, P3043, DOI 10.1016/j.bmcl.2004.04.034
   Tomasi J, 2005, CHEM REV, V105, P2999, DOI 10.1021/cr9904009
   Tomita M, 1999, BBA-MOL BASIS DIS, V1455, P269, DOI 10.1016/S0925-4439(99)00068-X
   Wilcken R, 2013, J MED CHEM, V56, P1363, DOI 10.1021/jm3012068
NR 27
TC 10
Z9 11
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD DEC
PY 2016
VL 7
IS 12
BP 1092
EP 1096
DI 10.1021/acsmedchemlett.6b00299
PG 5
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EE5CK
UT WOS:000389622100021
PM 27994744
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Li, L
   Li, Y
   Ijaz, M
   Shahbaz, M
   Lian, QQ
   Wang, FS
AF Li, Lian
   Li, Yan
   Ijaz, Muhammad
   Shahbaz, Muhammad
   Lian, Qianqian
   Wang, Fengshan
TI Review on complement analysis method and the roles of glycosaminoglycans
   in the complement system
SO CARBOHYDRATE POLYMERS
LA English
DT Review
DE Complement; Glycosaminoglycan; Analytical method; Anti-complement
   activity
ID MANNOSE-BINDING LECTIN; ALTERNATIVE PATHWAY; CHONDROITIN SULFATE;
   FACTOR-H; HEPARAN-SULFATE; RHEUMATOID-ARTHRITIS; CLASSICAL PATHWAY;
   DERMATAN SULFATE; PLASMA-LEVELS; C1 INHIBITOR
AB Complement system is composed of over 30 proteins and it plays important roles in self-defence and inflammation. There are three activation pathways, including classical pathway, alternative pathway and lectin pathway, in complement system, and they are associated with many diseases such as osteoarthritis and age-related macular degeneration. Modulation of the complement system may be a promising strategy in the treatment of related diseases. Glycosaminoglycans are anionic linear polysaccharides without branches. They are one kind of multi-functional macromolecules which have great potential in regulating complement system. This review is organized around two aspects between the introduction of complement system and the interaction of glycosaminoglycans with complement system. Three complement activation pathways and the biological significance were introduced first. Then functional analysis methods were compared to provide a strategy for potential glycosaminoglycans screen. Finally, the roles of glycosaminoglycans played in the complement system were summed up. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Li, Lian; Li, Yan; Ijaz, Muhammad; Lian, Qianqian; Wang, Fengshan] Shandong Univ, Sch Pharmaceut Sci, Jinan 250012, Peoples R China.
   [Shahbaz, Muhammad] Shandong Univ, Qilu Hosp, Dept Hepatobiliary Surg, Jinan 250012, Peoples R China.
C3 Shandong University; Shandong University
RP Wang, FS (通讯作者)，Shandong Univ, Sch Pharmaceut Sci, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China.
EM fswang@sdu.edu.cn
FU Ministry of Science and Technology of China [2012CB822102]; Taishan
   Scholar Scheme (Special Term Expert for Pharmacy) [2012GSF30022]
FX This work was supported by the "973" grant from the Ministry of Science
   and Technology of China (2012CB822102) and the Taishan Scholar Scheme
   (Special Term Expert for Pharmacy) (2012GSF30022).
CR Ammitzboll CG, 2012, RHEUMATOL INT, V32, P1457, DOI 10.1007/s00296-011-1879-x
   Bergamaschini L, 2009, THESCIENTIFICWORLDJO, V9, P891, DOI 10.1100/tsw.2009.100
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   BreitnerRuddock S, 1997, MED MICROBIOL IMMUN, V185, P253, DOI 10.1007/s004300050038
   Brunner J, 2012, RHEUMATOL INT, V32, P1815, DOI 10.1007/s00296-011-1973-0
   Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1
   Casu B., 2006, ANN NY ACAD SCI, V556, P1
   CHANG NS, 1985, MOL IMMUNOL, V22, P391
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   COFRANCESCO E, 1979, THROMB RES, V14, P179, DOI 10.1016/0049-3848(79)90036-7
   Costabile M., 2010, JOVE-J VIS EXP, V37, P1
   Csuka D, 2013, J IMMUNOL METHODS, V387, P237, DOI 10.1016/j.jim.2012.10.018
   Davies NP, 2008, J AGR FOOD CHEM, V56, P343, DOI 10.1021/jf072624v
   Ecker EE, 1929, J INFECT DIS, V44, P250, DOI 10.1093/infdis/44.3.250
   Ehrnthaller C, 2011, MOL MED, V17, P317, DOI 10.2119/molmed.2010.00149
   Endo Y, 2006, IMMUNOBIOLOGY, V211, P283, DOI 10.1016/j.imbio.2006.01.003
   FISHELSON Z, 1984, J IMMUNOL, V132, P1430
   Frauenknecht V, 2013, CLIN EXP IMMUNOL, V173, P112, DOI 10.1111/cei.12093
   Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951
   Fure H, 1997, SCAND J IMMUNOL, V46, P553, DOI 10.1046/j.1365-3083.1997.d01-168.x
   Gandhi NS, 2008, CHEM BIOL DRUG DES, V72, P455, DOI 10.1111/j.1747-0285.2008.00741.x
   Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x
   Harboe M, 2011, ADV DRUG DELIVER REV, V63, P976, DOI 10.1016/j.addr.2011.05.010
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hong TT, 2005, INT IMMUNOPHARMACOL, V5, P381, DOI 10.1016/j.intimp.2004.10.013
   Hummelshoj T, 2008, MOL IMMUNOL, V45, P1623, DOI 10.1016/j.molimm.2007.10.006
   JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481
   Janssen BJC, 2007, MOL IMMUNOL, V44, P3, DOI 10.1016/j.molimm.2006.06.017
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Jaskowski TD, 1999, CLIN DIAGN LAB IMMUN, V6, P137, DOI 10.1128/CDLI.6.1.137-139.1999
   Jenny L, 2015, CLIN EXP IMMUNOL, V180, P227, DOI 10.1111/cei.12574
   KAZATCHKINE MD, 1981, J CLIN INVEST, V67, P223, DOI 10.1172/JCI110017
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Khan S, 2013, J BIOL CHEM, V288, P27737, DOI 10.1074/jbc.M113.492223
   KLERX JPAM, 1983, J IMMUNOL METHODS, V63, P215, DOI 10.1016/0022-1759(83)90425-8
   Kuipers S, 2002, J IMMUNOL METHODS, V268, P149, DOI 10.1016/S0022-1759(02)00192-8
   Kwok JY, 2011, J NEUROIMMUNOL, V239, P98, DOI 10.1016/j.jneuroim.2011.08.018
   Lamari F., 2006, STRUCTURE CHONDROITI, P33
   Li BZ, 2009, BIOCHEM PHARMACOL, V78, P292, DOI 10.1016/j.bcp.2009.04.012
   Loeven MA, 2015, MOL IMMUNOL, V63, P203, DOI 10.1016/j.molimm.2014.08.005
   Maillet F., 1983, MOL IMMUNOL, V20, P1401
   MARTIN A, 1976, IMMUNOCHEMISTRY, V13, P317, DOI 10.1016/0019-2791(76)90341-4
   MAYER MM, 1958, PROG ALLERGY, V5, P215, DOI 10.1159/000277646
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   Michalski M, 2015, IMMUNOBIOLOGY, V220, P711, DOI 10.1016/j.imbio.2015.01.003
   Moskovich O., 2014, COMPLEMENT SYSTEM, V1100
   Munthe-Fog L, 2008, MOL IMMUNOL, V45, P2660, DOI 10.1016/j.molimm.2007.12.012
   Nadkarni VD, 1996, CARBOHYD RES, V290, P87, DOI 10.1016/0008-6215(96)00129-2
   Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000
   Nicholson-Weller A., 1993, J IMMUNOL RES, V12, P244
   Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008
   Nozal P, 2014, MOL IMMUNOL, V58, P194, DOI 10.1016/j.molimm.2013.11.021
   NUIJENS JH, 1988, BLOOD, V72, P1841
   Okroj M, 2007, ANN MED, V39, P517, DOI 10.1080/07853890701477546
   Olszowski T, 2014, IMMUNOBIOLOGY, V219, P261, DOI 10.1016/j.imbio.2013.10.009
   Onat A, 2011, CLIN CHIM ACTA, V412, P1171, DOI 10.1016/j.cca.2011.03.005
   Perkins SJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00126
   Qu H, 2009, MOL IMMUNOL, V47, P185, DOI 10.1016/j.molimm.2009.08.032
   RATNOFF OD, 1969, J EXP MED, V129, P315, DOI 10.1084/jem.129.2.315
   RENT R, 1976, CLIN EXP IMMUNOL, V23, P264
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200
   SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q
   Sakai S, 2007, CHEM PHARM BULL, V55, P299, DOI 10.1248/cpb.55.299
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Seelen MA, 2005, J IMMUNOL METHODS, V296, P187, DOI 10.1016/j.jim.2004.11.016
   SHARATH MD, 1985, IMMUNOPHARMACOLOGY, V9, P73, DOI 10.1016/0162-3109(85)90002-5
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Skliris A, 2011, EUR J IMMUNOL, V41, P437, DOI 10.1002/eji.201040429
   Sridhar Rao PN, 2006, COMPLEMENT
   Stevenson HL, 2013, TRANSPL IMMUNOL, V28, P73, DOI 10.1016/j.trim.2013.02.002
   STRONG WM, 1978, J CLIN PATHOL, V31, P527, DOI 10.1136/jcp.31.6.527
   Suankratay C., 1998, J IMMUNOL, V160, P3006
   Sweigard JH, 2014, FASEB J, V28, P3171, DOI 10.1096/fj.14-251041
   Thiel S, 2002, IMMUNOBIOLOGY, V205, P446, DOI 10.1078/0171-2985-00145
   Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066
   Turner MW, 2003, MOL IMMUNOL, V40, P423, DOI 10.1016/S0161-5890(03)00155-X
   VANDIJK H, 1980, J IMMUNOL METHODS, V36, P29, DOI 10.1016/0022-1759(80)90091-5
   Volpi N, 2004, CARBOHYD POLYM, V55, P273, DOI 10.1016/j.carbpol.2003.09.010
   Wallis R, 2007, IMMUNOBIOLOGY, V212, P289, DOI 10.1016/j.imbio.2006.11.004
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409
   WEILER JM, 1992, J IMMUNOL, V148, P3210
   Wuillemin WA, 1997, J IMMUNOL, V159, P1953
   Yu HN, 2005, BBA-GEN SUBJECTS, V1726, P168, DOI 10.1016/j.bbagen.2005.08.003
   Zaferani A, 2011, J BIOL CHEM, V286, P5359, DOI 10.1074/jbc.M110.167825
   Zang HC, 2012, J PHARMACEUT BIOMED, V61, P224, DOI 10.1016/j.jpba.2011.12.011
   Zhang YZ, 2012, CLIN J AM SOC NEPHRO, V7, P265, DOI 10.2215/CJN.07900811
   Zhou ZH, 2007, CELL HOST MICROBE, V1, P51, DOI 10.1016/j.chom.2007.01.002
   Zhou ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047296
   Zimmermann-Nielsen E., 2001, J IMMUNOL METHODS, V249, P43
NR 96
TC 12
Z9 13
U1 0
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
EI 1879-1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD DEC 10
PY 2015
VL 134
BP 590
EP 597
DI 10.1016/j.carbpol.2015.08.028
PG 8
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Polymer Science
GA CV4SC
UT WOS:000364255800071
PM 26428162
DA 2022-11-30
ER

PT J
AU Buchholz, DE
   Pennington, BO
   Croze, RH
   Hinman, CR
   Coffey, PJ
   Clegg, DO
AF Buchholz, David E.
   Pennington, Britney O.
   Croze, Roxanne H.
   Hinman, Cassidy R.
   Coffey, Peter J.
   Clegg, Dennis O.
TI Rapid and Efficient Directed Differentiation of Human Pluripotent Stem
   Cells Into Retinal Pigmented Epithelium
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Cellular therapy; Differentiation; Embryonic stem cells; Pluripotent
   stem cells; Induced pluripotent stem cells; Retinal pigmented epithelium
ID ROCK INHIBITOR; MACULAR TRANSLOCATION; GROWTH-FACTOR; TRANSCRIPTION;
   DEGENERATION; INDUCTION; PATHWAYS; EYE
AB Controlling the differentiation of human pluripotent stem cells is the goal of many laboratories, both to study normal human development and to generate cells for transplantation. One important cell type under investigation is the retinal pigmented epithelium (RPE). Age-related macular degeneration (AMD), the leading cause of blindness in the Western world, is caused by dysfunction and death of the RPE. Currently, RPE derived from human embryonic stem cells are in clinical trials for the treatment of AMD. Although protocols to generate RPE from human pluripotent stem cells have become more efficient since the first report in 2004, they are still time-consuming and relatively inefficient. We have found that the addition of defined factors at specific times leads to conversion of approximately 80% of the cells to an RPE phenotype in only 14 days. This protocol should be useful for rapidly generating RPE for transplantation as well as for studying RPE development in vitro. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:384-393
C1 [Buchholz, David E.; Pennington, Britney O.; Croze, Roxanne H.; Hinman, Cassidy R.; Coffey, Peter J.; Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
   [Buchholz, David E.; Pennington, Britney O.; Croze, Roxanne H.; Hinman, Cassidy R.; Coffey, Peter J.; Clegg, Dennis O.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   [Buchholz, David E.; Pennington, Britney O.; Croze, Roxanne H.; Clegg, Dennis O.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
   [Coffey, Peter J.; Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara
RP Clegg, DO (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM peter.coffey@lifesci.ucsb.edu; clegg@lifesci.ucsb.edu
OI Coffey, Peter/0000-0002-5427-2939
FU California Institute for Regenerative Medicine (CIRM) [CL1-00521,
   DR1-01444, FA1-006161, TG2-01151]; CIRM; Institute for Collaborative
   Biotechnologies through U.S. Army Research Office [W911NF-09-0001];
   Allergan; Medical Research Council [G1000730] Funding Source:
   researchfish; MRC [G1000730] Funding Source: UKRI
FX We thank Sherry Hikita and Monte Radeke for their guidance and the
   University of California, Santa Barbara, Center for Stem Cell Biology
   and Engineering staff for support. This work was supported by Grants
   CL1-00521, DR1-01444, FA1-006161, and TG2-01151 from the California
   Institute for Regenerative Medicine (CIRM). B.O.P. was supported by a
   CIRM scholarship, and P.J.C. was supported by a CIRM Leadership Award.
   Further support was provided by the Institute for Collaborative
   Biotechnologies through Grant W911NF-09-0001 from the U.S. Army Research
   Office. The content of the information does not necessarily reflect the
   position or the policy of the government, and no official endorsement
   should be inferred.; A U.S. patent application has been filed for the
   protocol reported herein. D.O.C. has compensated honoraria and
   uncompensated research funding from Allergan. D.O.C. is a cofounder of
   Regenerative Patch Technologies (uncompensated employment and
   uncompensated ownership interest) and also has uncompensated
   intellectual property rights and is an uncompensated consultant for
   Regenerative Patch Technologies.
CR Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004-0279
   Ben-David U, 2012, CELL STEM CELL, V10, P10, DOI 10.1016/j.stem.2011.12.007
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chapman S, 2010, J CLIN INVEST, V120, P2619, DOI 10.1172/JCI42297
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Cimadamore F, 2009, STEM CELLS, V27, P1772, DOI 10.1002/stem.107
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Koh SWM, 2000, PROG RETIN EYE RES, V19, P669, DOI 10.1016/S1350-9462(00)00010-0
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Ohgushi M, 2011, TRENDS CELL BIOL, V21, P274, DOI 10.1016/j.tcb.2011.02.004
   Okumura N, 2012, AM J PATHOL, V181, P268, DOI 10.1016/j.ajpath.2012.03.033
   Pera EM, 2001, DEV CELL, V1, P655, DOI 10.1016/S1534-5807(01)00069-7
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Vaca P, 2008, EXP CELL RES, V314, P969, DOI 10.1016/j.yexcr.2007.11.019
   Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553
   Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310
   Woo THS, 1999, J MICROBIOL METH, V35, P23, DOI 10.1016/S0167-7012(98)00095-5
   Xiao L, 2006, STEM CELLS, V24, P1476, DOI 10.1634/stemcells.2005-0299
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
NR 39
TC 183
Z9 205
U1 0
U2 58
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD MAY
PY 2013
VL 2
IS 5
BP 384
EP 393
DI 10.5966/sctm.2012-0163
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 139MB
UT WOS:000318585700014
PM 23599499
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kose, C
   Ikibas, C
AF Kose, Cemal
   Ikibas, Cevat
TI Statistical Techniques for Detection of Optic Disc and Macula and
   Parameters Measurement in Retinal Fundus Images
SO JOURNAL OF MEDICAL AND BIOLOGICAL ENGINEERING
LA English
DT Article
DE Retinal images; Optic disc detection; Quantification of fundus images;
   Segmentation
ID BLOOD-VESSELS; NERVE; SEGMENTATION; DEGENERATION; DIAGNOSIS
AB Morphological structures such as the optic disc and macula have been extensively utilized in automatic diagnosis and screening systems for diseases such as diabetic retinopathy (DR), age-related macular degeneration (ARMD), and glaucoma. This paper proposes simple statistical techniques for the detection of the optic disc and macula for calculating the diameter of the optic disc and the distance between the optic disc and macula. The results can be used in automatic diagnosis or monitoring systems developed for retinal diseases. A tool is provided for verifying the location of the optic disc and macula to increase reliability. This study also uses the weighted-distance method to extend the healthy parts of a retinal image. About four hundred retinal fundus images of different qualities are used for testing the system. A detection rate of 97% of the optic disc and macula, an accuracy of 95% of the diameter of the optic disc, and an accuracy of 97% of the positions of the optic disc and macula are obtained.
C1 [Kose, Cemal; Ikibas, Cevat] Karadeniz Tech Univ, Fac Engn, Dept Comp Engn, TR-61080 Trabzon, Turkey.
C3 Karadeniz Technical University
RP Kose, C (通讯作者)，Karadeniz Tech Univ, Fac Engn, Dept Comp Engn, TR-61080 Trabzon, Turkey.
EM ckose@ktu.edu.tr
RI KÖSE, Cemal/V-9731-2017
OI KÖSE, Cemal/0000-0002-5982-4771
CR Al-Rawi M, 2007, COMPUT BIOL MED, V37, P262, DOI 10.1016/j.compbiomed.2006.03.003
   Baroni M, 2007, MED ENG PHYS, V29, P432, DOI 10.1016/j.medengphy.2006.06.003
   Barrett S F, 2001, Biomed Sci Instrum, V37, P81
   Foracchia M, 2004, IEEE T MED IMAGING, V23, P1189, DOI 10.1109/TMI.2004.829331
   Foroozan R, 2005, J DIABETES COMPLICAT, V19, P165, DOI 10.1016/j.jdiacomp.2004.09.003
   Gagnon L, 2001, PROC SPIE, V4322, P1218, DOI 10.1117/12.430999
   Goldbaum M, 1996, INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, PROCEEDINGS - VOL III, P695, DOI 10.1109/ICIP.1996.560760
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Hoover A, 1998, PROC CVPR IEEE, P716, DOI 10.1109/CVPR.1998.698682
   Kande GB, 2009, J MED BIOL ENG, V29, P122
   Kara S, 2006, COMPUT BIOL MED, V36, P428, DOI 10.1016/j.compbiomed.2005.01.003
   Kayikcioglu T, 2002, PATTERN RECOGN LETT, V23, P783, DOI 10.1016/S0167-8655(01)00156-8
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2009, EXPERT SYST APPL, V36, P1208, DOI 10.1016/j.eswa.2007.11.036
   Kose C., 2008, INT S COMP INF SCI I, V1, P1
   Kose C, 2006, LECT NOTES COMPUT SC, V4109, P74
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Lalonde M, 2001, IEEE T MED IMAGING, V20, P1193, DOI 10.1109/42.963823
   Li HQ, 2004, IEEE T BIO-MED ENG, V51, P246, DOI 10.1109/TBME.2003.820400
   Li HQ, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL II, PROCEEDINGS, P837, DOI 10.1109/ICIP.2001.958624
   Lowell J, 2004, IEEE T MED IMAGING, V23, P256, DOI 10.1109/TMI.2003.823261
   Lowell J., 2004, IEEE T MED IMAG, V23
   Mendels F, 1999, P IRISH MACHINE VISI, P103
   Mendels F., 1999, P C 1 JOINT BMES EMB, V1, P1139
   Narasimha-Iyer H, 2007, IEEE T BIO-MED ENG, V54, P1427, DOI 10.1109/TBME.2007.900804
   Narasimha-Iyer H, 2006, IEEE T BIO-MED ENG, V53, P1084, DOI 10.1109/TBME.2005.863971
   Niemeijer M, 2007, IEEE T MED IMAGING, V26, P116, DOI 10.1109/TMI.2006.885336
   Osareh A, 2002, INT C PATT RECOG, P743, DOI 10.1109/ICPR.2002.1044865
   OSAREH A, 2004, THESIS U BRISTOL UK
   Osareh A., 2002, P 6 MED IM UND AN C, P21
   Park J, 2007, INT C INTELL COMP CO, P237
   Park M., 2006, P INT C COMP GRAPH I, P141, DOI DOI 10.1109/CGIV.2006.63
   Riveron EMF, 2004, LECT NOTES COMPUT SC, V3287, P661
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Stewart CV, 2005, LECT NOTES COMPUT SC, V3765, P31
   ter Haar F., 2005, THESIS UTRECHT U UTR
   Walter T., 2001, P 2 INT S MED DAT AN, V2199, P282, DOI DOI 10.1007/3-540-45497-7_43
   Wu D, 2006, IEEE T BIO-MED ENG, V53, P341, DOI 10.1109/TBME.2005.862571
   Xu J, 2007, IEEE T BIO-MED ENG, V54, P473, DOI 10.1109/TBME.2006.888831
   Youssif AAHAR, 2008, IEEE T MED IMAGING, V27, P11, DOI 10.1109/TMI.2007.900326
NR 40
TC 12
Z9 12
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1609-0985
EI 2199-4757
J9 J MED BIOL ENG
JI J. Med. Biol. Eng.
PY 2011
VL 31
IS 6
BP 395
EP 404
DI 10.5405/jmbe.724
PG 10
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 848DV
UT WOS:000297030100004
DA 2022-11-30
ER

PT J
AU Palczewska, G
   Maeda, T
   Imanishi, Y
   Sun, WY
   Chen, Y
   Williams, DR
   Piston, DW
   Maeda, A
   Palczewski, K
AF Palczewska, Grazyna
   Maeda, Tadao
   Imanishi, Yoshikazu
   Sun, Wenyu
   Chen, Yu
   Williams, David R.
   Piston, David W.
   Maeda, Akiko
   Palczewski, Krzysztof
TI Noninvasive multiphoton fluorescence microscopy resolves retinol and
   retinal condensation products in mouse eyes
SO NATURE MEDICINE
LA English
DT Article
ID COMPLEMENT ACTIVATION; VISUAL FUNCTIONS; 2-PHOTON; EXCITATION; PIGMENT;
   CELLS; LIGHT; MODEL; FLUOROPHORES; ACCUMULATION
AB Multiphoton excitation fluorescence microscopy (MPM) can image certain molecular processes in vivo. In the eye, fluorescent retinyl esters in subcellular structures called retinosomes mediate regeneration of the visual chromophore, 11-cis-retinal, by the visual cycle. But harmful fluorescent condensation products of retinoids also occur in the retina. We report that in wild-type mice, excitation with a wavelength of similar to 730 nm identified retinosomes in the retinal pigment epithelium, and excitation with a wavelength of similar to 910 nm revealed at least one additional retinal fluorophore. The latter fluorescence was absent in eyes of genetically modified mice lacking a functional visual cycle, but accentuated in eyes of older wild-type mice and mice with defective clearance of all-trans-retinal, an intermediate in the visual cycle. MPM, a noninvasive imaging modality that facilitates concurrent monitoring of retinosomes along with potentially harmful products in aging eyes, has the potential to detect early molecular changes due to age-related macular degeneration and other defects in retinoid metabolism.
C1 [Palczewska, Grazyna; Sun, Wenyu; Palczewski, Krzysztof] Polgenix, Cleveland, OH USA.
   [Maeda, Tadao; Maeda, Akiko] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Maeda, Tadao; Imanishi, Yoshikazu; Chen, Yu; Maeda, Akiko; Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Williams, David R.] Univ Rochester, Ctr Visual Sci, Rochester, NY 14627 USA.
   [Williams, David R.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
C3 Case Western Reserve University; Case Western Reserve University;
   University of Rochester; Vanderbilt University
RP Palczewski, K (通讯作者)，Polgenix, Cleveland, OH USA.
EM gpalczewska@polgenixinc.com; kxp65@case.edu
RI Imanishi, Yoshikazu/E-8178-2010
OI Imanishi, Yoshikazu/0000-0003-4696-4836
FU US National Institutes of Health [EY008061, EY009339, EY019880,
   EY019031, EY020715, P30 EY11373]; State of Ohio Department of
   Development and Third Frontier Commission [TECH 09-004]; European Life
   Scientist Organization; Klaus Tschira Foundation; NATIONAL EYE INSTITUTE
   [R01EY009339, K08EY019031, R01EY008061, K08EY019880, R43EY020715,
   P30EY011373, R29EY008061] Funding Source: NIH RePORTER
FX We would like to thank M. Golczak for help during the course of this
   study and Z. Dong for expert handling of mice. We also thank L. T.
   Webster and members of Palczewski laboratory for critical comments on
   the manuscript. Rpe65<SUP>-/-</SUP> mice were a kind gift from M.
   Redmond ( US National Eye Institute). This research was supported in
   part by grants EY008061, EY009339, EY019880, EY019031, EY020715 and P30
   EY11373 from the US National Institutes of Health, TECH 09-004 from the
   State of Ohio Department of Development and Third Frontier Commission,
   the European Life Scientist Organization and the Klaus Tschira
   Foundation.
CR Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333
   Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200
   DaCosta RS, 2005, CURR OPIN GASTROEN, V21, P70
   DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027
   DRABENT R, 1997, J FLUORESC, V7, P347, DOI DOI 10.1023/A:1022594329601
   Evgenov NV, 2006, NAT MED, V12, P144, DOI 10.1038/nm1316
   Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Imanishi Y, 2008, J BIOL CHEM, V283, P25091, DOI 10.1074/jbc.M802981200
   Imanishi Y, 2007, BIOCHEMISTRY-US, V46, P9674, DOI 10.1021/bi701055g
   Imanishi Y, 2010, METHODS MOL BIOL, V652, P247, DOI 10.1007/978-1-60327-325-1_14
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim JS, 2008, SCIENCE, V321, P1472, DOI 10.1126/science.1161517
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, INVEST OPHTH VIS SCI, V50, P5435, DOI 10.1167/iovs.09-3944
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P322, DOI 10.1167/iovs.08-2301
   Maiti S, 1997, SCIENCE, V275, P530, DOI 10.1126/science.275.5299.530
   Piston DW, 1999, TRENDS CELL BIOL, V9, P66, DOI 10.1016/S0962-8924(98)01432-9
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Schenke-Layland K, 2006, ADV DRUG DELIVER REV, V58, P878, DOI 10.1016/j.addr.2006.07.004
   Shoham D, 1999, NEURON, V24, P791, DOI 10.1016/S0896-6273(00)81027-2
   So PTC, 2000, ANNU REV BIOMED ENG, V2, P399, DOI 10.1146/annurev.bioeng.2.1.399
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JM, 1999, INVEST OPHTH VIS SCI, V40, pS195
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297
   Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200
   von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763
   Xu C, 1996, J OPT SOC AM B, V13, P481, DOI 10.1364/JOSAB.13.000481
   Zhang EZ, 2009, PHYS MED BIOL, V54, P1035, DOI 10.1088/0031-9155/54/4/014
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zipfel WR, 2003, P NATL ACAD SCI USA, V100, P7075, DOI 10.1073/pnas.0832308100
NR 40
TC 59
Z9 60
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD DEC
PY 2010
VL 16
IS 12
BP 1444
EP U130
DI 10.1038/nm.2260
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 690ZH
UT WOS:000285048900040
PM 21076393
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sharts-Hopko, NC
AF Sharts-Hopko, Nancy C.
TI Lifestyle Strategies for the Prevention of Vision Loss
SO HOLISTIC NURSING PRACTICE
LA English
DT Article
DE blindness; eye disease prevention; lifestyle modification; nutrition;
   vision loss
ID AGE-RELATED CATARACT; BODY-MASS INDEX; VIGOROUS PHYSICAL-ACTIVITY;
   OCULAR BLOOD-FLOW; MACULAR DEGENERATION; INTRAOCULAR-PRESSURE; 10-YEAR
   INCIDENCE; RISK-FACTORS; EYE DISEASE; HEALTH
AB As the baby boom generation ages, it is anticipated that half a million cases per year will be added to the 19 to 21 million Americans not living in institutions or serving in the military who have low vision or blindness. The 4 major causes of vision loss and blindness in the United States are cataract, diabetic retinopathy, glaucoma, and age-related macular degeneration. All 4 diseases involve change in the microcirculation in eye structures. Holistic approaches to health incorporate attention to individuals' lifestyle choices. Relevant research literature was reviewed to identify strategies for lifestyle modification that nurses can use to prevent or slow progression of these diseases. Prevention strategies in general are those that promote avoidance of cardiovascular disease and diabetes. Because vision loss has been shown to be associated with diminished quality of life and increased mortality, lifestyle changes that prevent or moderate the impact of these diseases are an important focus of nursing care.
C1 Villanova Univ, Villanova, PA 19085 USA.
C3 Villanova University
RP Sharts-Hopko, NC (通讯作者)，Villanova Univ, Villanova, PA 19085 USA.
EM Nancy.sharts-hopko@villanova.edu
CR *AM AC OPHTH, 2007, EY DIS RIS OLD AM FE
   *AM HOL MED ASS, PRINC HOL MED
   *AM OPT SOC, 2010, DIAB LEAD CAUS BLIND
   American Holistic Nurses Association, WHAT IS HOL NURS
   Bartlett HE, 2008, OPHTHAL PHYSL OPT, V28, P503, DOI 10.1111/j.1475-1313.2008.00595.x
   BUTCHER HK, SCI UNITARY HUMAN BE, pCH7
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   *CDCP, 2008, DIS LIM
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Christen WG, 2005, AM J CLIN NUTR, V81, P1417
   Christen WG, 2003, ARCH OPHTHALMOL-CHIC, V121, P372, DOI 10.1001/archopht.121.3.372
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P405, DOI 10.1001/archopht.119.3.405
   Christen W, 2008, ARCH OPHTHALMOL-CHIC, V126, P1607, DOI 10.1001/archopht.126.11.1607-a
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Coccheri S, 2007, DRUGS, V67, P997, DOI 10.2165/00003495-200767070-00005
   Coleman Anne L, 2009, Open Ophthalmol J, V3, P38, DOI 10.2174/1874364100903020038
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cundiff David K, 2005, MedGenMed, V7, P3
   De Block CEM, 2005, DIABETES CARE, V28, P1649, DOI 10.2337/diacare.28.7.1649
   Gale J, 2009, SURV OPHTHALMOL, V54, P349, DOI 10.1016/j.survophthal.2009.02.005
   Glynn RJ, 2009, OPHTHAL EPIDEMIOL, V16, P98, DOI 10.1080/09286580902737532
   *GREENB QUINL ROSN, 2007, NAT SURV RES AM EY H
   Henricsson M, 2003, DIABETES CARE, V26, P349, DOI 10.2337/diacare.26.2.349
   Jacques PF, 2003, AM J CLIN NUTR, V78, P400, DOI 10.1093/ajcn/78.3.400
   JUNTILLIANEN A, 2007, DIABETES CARE, V30, P292
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kuang TM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1109, DOI 10.1001/archopht.123.8.1109
   Lee DJ, 2007, J AGING HEALTH, V19, P382, DOI 10.1177/0898264307300174
   Lyle BJ, 1999, AM J CLIN NUTR, V69, P272
   Massof RW, 2002, OPTOMETRY VISION SCI, V79, P31, DOI 10.1097/00006324-200201000-00010
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mozaffarieh M, 2007, EXPERT OPIN EMERG DR, V12, P195, DOI 10.1517/14728214.12.2.195
   *NAT EY I, 2010, FACTS CAT
   *NAT EY I, 2008, AREDS FORM AG REL MA
   Nationa Eye Institute N.I.o.H., 2010, FACTS AG REL MAC DEG
   Oh SW, 2005, DIABETES-METAB RES, V21, P434, DOI 10.1002/dmrr.529
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Risner D, 2009, J GLAUCOMA, V18, P429, DOI 10.1097/IJG.0b013e31818fa5f3
   Robman L, 2005, EYE, V19, P1074, DOI 10.1038/sj.eye.6701964
   Roy MS, 2010, ARCH OPHTHALMOL-CHIC, V128, P33, DOI 10.1001/archophthalmol.2009.358
   Ryskulova A, 2008, AM J PUBLIC HEALTH, V98, P454, DOI 10.2105/AJPH.2006.098202
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sharts-Hopko N, 2009, HOLIST NURS PRACT, V23, P94, DOI 10.1097/HNP.0b013e3181a110bb
   Sharts-Hopko NC, 2010, CLIN NURSE SPEC, V24, P149, DOI 10.1097/NUR.0b013e3181d82b89
   Tan AG, 2008, AM J CLIN NUTR, V87, P1899, DOI 10.1093/ajcn/87.6.1899
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tsai JC, 2008, CAN J OPHTHALMOL, V43, P347, DOI 10.3129/i08-035
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Wang SQ, 2008, SURV OPHTHALMOL, V53, P512, DOI 10.1016/j.survophthal.2008.06.003
   Weintraub JM, 2002, INT J OBESITY, V26, P1588, DOI 10.1038/sj.ijo.0802158
   Williams PT, 2009, MED SCI SPORT EXER, V41, P1566, DOI 10.1249/MSS.0b013e31819e420f
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P95, DOI 10.1167/iovs.08-1797
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   Yoshida M, 2003, JPN J OPHTHALMOL, V47, P191, DOI 10.1016/S0021-5155(02)00666-4
   Zanon-Moreno V, 2009, MOL VIS, V15, P2953
NR 60
TC 4
Z9 4
U1 1
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0887-9311
EI 1550-5138
J9 HOLIST NURS PRACT
JI Holist. Nurs. Pract.
PD SEP-OCT
PY 2010
VL 24
IS 5
BP 284
EP 291
DI 10.1097/HNP.0b013e3181f1ac5c
PG 8
WC Integrative & Complementary Medicine; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Integrative & Complementary Medicine; Nursing
GA 785BH
UT WOS:000292201900006
PM 20706090
DA 2022-11-30
ER

PT J
AU Barisic, A
   Dekaris, I
   Gabric, N
   Bosnar, D
   Lazic, R
   Martinovic, ZK
   Krstonijevic, EK
AF Barisic, Ante
   Dekaris, Iva
   Gabric, Nikica
   Bosnar, Damir
   Lazic, Ratimir
   Martinovic, Zeljka Karaman
   Krstonijevic, Edita Kondza
TI Blue light filtering intraocular lenses in phacoemulsification cataract
   surgery
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE light; lenses; intraocular; phacoemulsification; pseudophakia; macular
   degeneration
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; BEAVER DAM; EYE;
   LIPOFUSCIN; A2E
AB Blue light can damage retina and cause age related macular degeneration. After cataract surgery and lens removal retina stays unprotected. Blue light filtering intraocular lenses (IOL) increase protection of the retina. In our prospective study we investigated clinical results after billateral implantation of Acrysof Natural IOL to 30 patients (N=60 eyes). In a control group (N=60 eyes, 30 patients), standard acrysof IOL was implanted bilaterally. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA) and Nd YAG laser capsulotomy rate were measured and compared with control group. Subjective patient's satisfaction and subjective colour perception were also investigated. There was no significant difference in UCVA, BCVA and Nd YAG laser capsulotomy rate between the two groups. High patient's satisfaction was noticed (96,7% of patients would implant Acrysof Natural IOL again). Acrysof Natural IOL enables good visual acuity VA, low rate of Nd YAG laser capsulotomy and high patient's satisfaction without colour perception disturbances.
C1 Univ Zagreb, Dept Ophthalmol, Gen Hosp Sveti Duh, Zagreb, Croatia.
   Eye Clin Svjetlost, Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb, School of Dental Medicine
RP Barisic, A (通讯作者)，Univ Zagreb, Dept Ophthalmol, Gen Hosp Sveti Duh, Zagreb, Croatia.
EM antebarisic@yahoo.com
RI Dekaris, Iva/AAM-8799-2020
CR Bullough JD, 2000, J ILLUM ENG SOC, V29, P6, DOI 10.1080/00994480.2000.10748312
   Cionni RJ, 2006, J CATARACT REFR SURG, V32, P236, DOI 10.1016/j.jcrs.2005.12.129
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Ernest PH, 2004, J CATARACT REFR SURG, V30, P1755, DOI 10.1016/j.jcrs.2003.12.054
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Leibovitch I, 2006, ACTA OPHTHALMOL SCAN, V84, P95, DOI 10.1111/j.1600-0420.2005.00607.x
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
NR 14
TC 8
Z9 8
U1 0
U2 2
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 57
EP 60
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800014
PM 17469752
DA 2022-11-30
ER

PT J
AU Chader, GJ
AF Chader, GJ
TI Animal models in research on retinal degenerations: past progress and
   future hope
SO VISION RESEARCH
LA English
DT Article
DE animal models; retinal degeneration; retinitis pigmentosa; macular
   degeneration; photoreceptor cell
ID DOMINANT RETINITIS-PIGMENTOSA; FIBROBLAST-GROWTH-FACTOR; SLOW RDS GENE;
   TRANSGENIC MICE; PHOTORECEPTOR DEGENERATION; STARGARDTS-DISEASE; RIM
   PROTEIN; MOUSE MODEL; RCS RAT; MUTATIONS
AB The retinal degenerations (RDs) are a family of inherited retinal degenerative diseases (dystrophies) that lead to vision loss. Although phenotypically very different. the RDs have several characteristics in common. They all are caused by gene mutations or at least have a genetic component in the etiology, They all lead to photoreceptor dysfunction, many leading to the death of both rod and cone photoreceptors. The mechanism of cell death in most of the RDs seems to be through the process of apoptosis. It is estimated that more than fifteen million people around the world have vision loss due to an inherited RD. Many of these are patients with the dry form of age-related macular degeneration (AMD) who retain partial functional vision. However, some have other degenerative conditions such as retinitis pigmentosa. Leber congenital amaurosis or wet AMD and can suffer front severe vision loss or total blindness. (C) 2002 Published by Elsevier Science Ltd.
C1 Fdn Fighting Blindness, Owings Mills, MD 21117 USA.
RP Chader, GJ (通讯作者)，Fdn Fighting Blindness, 11435 Cronhill Dr, Owings Mills, MD 21117 USA.
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   AGUIRRE G, 1978, EXP EYE RES, V26, P233, DOI 10.1016/0014-4835(78)90072-6
   Aguirre GD, 1997, INVEST OPHTH VIS SCI, V38, P2387
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   BARNETT KC, 1985, J HERED, V76, P168, DOI 10.1093/oxfordjournals.jhered.a110058
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   Bourne M C, 1938, Br J Ophthalmol, V22, P613, DOI 10.1136/bjo.22.10.613
   BROCKERHOFF SE, 1995, P NATL ACAD SCI USA, V92, P10545, DOI 10.1073/pnas.92.23.10545
   Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848
   DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73
   Dudus L, 1999, VISION RES, V39, P2545, DOI 10.1016/S0042-6989(98)00308-3
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Hong DH, 2000, P NATL ACAD SCI USA, V97, P3649, DOI 10.1073/pnas.060037497
   Keeler CE, 1924, P NATL ACAD SCI USA, V10, P329, DOI 10.1073/pnas.10.7.329
   Keen TJ, 1996, HUM MUTAT, V8, P297
   Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476
   KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177
   LaVail MM, 2000, P NATL ACAD SCI USA, V97, P11488, DOI 10.1073/pnas.210319397
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967
   LI LX, 1988, EXP EYE RES, V47, P771, DOI 10.1016/0014-4835(88)90044-9
   Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   NAASH MI, 1993, P NATL ACAD SCI USA, V90, P5499, DOI 10.1073/pnas.90.12.5499
   Naash ML, 1996, INVEST OPHTH VIS SCI, V37, P775
   NARFSTROM K, 1983, J HERED, V74, P273, DOI 10.1093/oxfordjournals.jhered.a109782
   Neuner-Jehle M, 2000, HUM GENE THER, V11, P1875, DOI 10.1089/10430340050129495
   Nir I, 2000, J NEUROSCI, V20, P2150
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Okamoto N, 1997, AM J PATHOL, V151, P281
   ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599
   ORGANISCIAK DT, 1991, RETINAL DEGENERATION, P189
   PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340
   Pearce-Kelling SE, 2001, MOL VIS, V7, P42
   Petters RM, 1997, NAT BIOTECHNOL, V15, P965, DOI 10.1038/nbt1097-965
   PITTLER SJ, 1993, P NATL ACAD SCI USA, V90, P9616, DOI 10.1073/pnas.90.20.9616
   Radner W, 2001, INVEST OPHTH VIS SCI, V42, P1057
   SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3
   Semple-Rowland SL, 2000, METHOD ENZYMOL, V316, P526
   Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0
   TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G
   Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297
   VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
NR 59
TC 113
Z9 124
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
J9 VISION RES
JI Vision Res.
PD FEB
PY 2002
VL 42
IS 4
BP 393
EP 399
AR PII S0043-6989(01)00212-7
DI 10.1016/S0042-6989(01)00212-7
PG 7
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 534JK
UT WOS:000174581900001
PM 11853755
DA 2022-11-30
ER

PT J
AU Wang, GF
   Chen, XS
   Tian, G
   Yang, JS
AF Wang, Guanfang
   Chen, Xianshan
   Tian, Geng
   Yang, Jiasheng
TI A Novel N-Gram-Based Image Classification Model and Its Applications in
   Diagnosing Thyroid Nodule and Retinal OCT Images
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID COMPUTER-AIDED DIAGNOSIS; FEATURES
AB Imbalanced classes and dimensional disasters are critical challenges in medical image classification. As a classical machine learning model, the n-gram model has shown excellent performance in addressing this issue in text classification. In this study, we proposed an algorithm to classify medical images by extracting their n-gram semantic features. This algorithm first converts an image classification problem to a text classification problem by building an n-gram corpus for an image. After that, the algorithm was based on the n-gram model to classify images. The algorithm was evaluated by two independent public datasets. The first experiment is to diagnose benign and malignant thyroid nodules. The best area under the curve (AUC) is 0.989. The second experiment is to diagnose the type of fundus lesion. The best result is that it correctly identified 86.667% of patients with dry age-related macular degeneration (AMD), 93.333% of patients with diabetic macular edema (DME), and 93.333% of normal individuals.
C1 [Wang, Guanfang; Tian, Geng] Genies Beijing Co Ltd, Beijing 100102, Peoples R China.
   [Chen, Xianshan] Hainan Gen Hosp, Dept Thorac Surg, Haikou 570311, Hainan, Peoples R China.
   [Yang, Jiasheng] Anhui Univ Technol, Sch Elect & Informat Engn, Maanshan 243002, Anhui, Peoples R China.
C3 Anhui University of Technology
RP Tian, G (通讯作者)，Genies Beijing Co Ltd, Beijing 100102, Peoples R China.; Yang, JS (通讯作者)，Anhui Univ Technol, Sch Elect & Informat Engn, Maanshan 243002, Anhui, Peoples R China.
EM wanggf1206@163.com; cxs2004@126.com; tiang@geneis.cn;
   jsyang.mcc@gmail.com
OI Tian, Geng/0000-0001-5752-4436; Wang, Guanfang/0000-0002-3825-6808
CR Abdolali F, 2020, COMPUT BIOL MED, V122, DOI 10.1016/j.compbiomed.2020.103871
   Agarwal S, 2004, IEEE T PATTERN ANAL, V26, P1475, DOI 10.1109/TPAMI.2004.108
   Algan G., 2020, LABEL NOISE TYPES TH
   Alharan AFH., 2019, INDONESIAN J ELECT E, V14, P1433, DOI 10.11591/ijeecs.v14.i3.pp1433-1442
   Ardakani AA, 2018, EUR J RADIOL, V101, P170, DOI 10.1016/j.ejrad.2018.02.010
   Bai B, 2021, EXPERT SYST APPL, V169, DOI 10.1016/j.eswa.2020.114162
   Broder AZ, 1997, COMPUT NETWORKS ISDN, V29, P1157, DOI 10.1016/S0169-7552(97)00031-7
   Brown P. F., 1992, Computational Linguistics, V18, P467
   Chang C.-C., 2011, ACM T INTEL SYST TEC, V2, P1, DOI [10.1145/1961189.1961199, DOI 10.1145/1961189.1961199]
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Doi K, 1999, EUR J RADIOL, V31, P97, DOI 10.1016/S0720-048X(99)00016-9
   Farhoodi M., 7 INT C DIG CONT MUL
   Forsyth D, 2014, COMPUTER, V47, P6, DOI 10.1109/MC.2014.42
   Frid-Adar M, 2018, NEUROCOMPUTING, V321, P321, DOI 10.1016/j.neucom.2018.09.013
   Fu XS, 2020, OPTIK, V224, DOI 10.1016/j.ijleo.2020.165651
   Gong X, 2021, IEEE WINT CONF APPL, P4003, DOI 10.1109/WACV48630.2021.00405
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   Kauer-Bonin J, 2022, COMPUT BIOL MED, V141, DOI 10.1016/j.compbiomed.2021.104822
   Koundal D, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103776
   Lai ZF, 2018, COMPUT INTEL NEUROSC, V2018, DOI 10.1155/2018/2061516
   Lan M, 2009, IEEE T PATTERN ANAL, V31, P721, DOI 10.1109/TPAMI.2008.110
   Lee H, 2017, J DIGIT IMAGING, V30, P427, DOI 10.1007/s10278-017-9955-8
   Li M, 2022, INFORM SCIENCES, V589, P478, DOI 10.1016/j.ins.2021.12.122
   Li W, 2021, ARCH COMPUT METHOD E, V28, P3781, DOI 10.1007/s11831-021-09562-1
   Li ZY, 2022, CANCER MANAG RES, V14, P1131, DOI 10.2147/CMAR.S353877
   Liu HY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.619330
   Long HX, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092817
   Luo FL, 2019, BIOINFORMATICS, V35, P2766, DOI 10.1093/bioinformatics/bty1051
   Ma XS, 2020, CURR BIOINFORM, V15, P349, DOI 10.2174/1574893614666191017091959
   MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
   Milicka J, 2021, LANG CONTRAST, V21, P217, DOI 10.1075/lic.19018.mil
   Miller E, 1999, INTERNATIONAL CONFERENCE ON PARALLEL AND DISTRIBUTED PROCESSING TECHNIQUES AND APPLICATIONS, VOLS I-V, PROCEEDINGS, P1410
   Mladenic D, 1999, MACHINE LEARNING, PROCEEDINGS, P258
   Nandagopal U., 2021, INT J INTELLIGENT EN, V14
   Pekala M, 2019, COMPUT BIOL MED, V114, DOI 10.1016/j.compbiomed.2019.103445
   PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205
   Quekel LGBA, 1999, CHEST, V115, P720, DOI 10.1378/chest.115.3.720
   Raghavendra U, 2018, COMPUT BIOL MED, V95, P55, DOI 10.1016/j.compbiomed.2018.02.002
   Raghavendra U, 2017, ULTRASONICS, V77, P110, DOI 10.1016/j.ultras.2017.02.003
   RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0
   Sabra S., 2020 INT C COMP SCI
   Shaoul C, 2014, MENT LEX, V9, P437, DOI 10.1075/ml.9.3.04sha
   Sivic J, 2003, NINTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOLS I AND II, PROCEEDINGS, P1470, DOI 10.1109/iccv.2003.1238663
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sun HD, 2021, COMPLEXITY, V2021, DOI 10.1155/2021/5556899
   Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037
   Wang C, 2015, IMAGE VISION COMPUT, V38, P65, DOI 10.1016/j.imavis.2014.10.013
   Wang RQ, 2022, EXPERT SYST APPL, V188, DOI 10.1016/j.eswa.2021.116036
   Wu ZD, 2020, IEEE T VEH TECHNOL, V69, P5244, DOI 10.1109/TVT.2020.2981633
   Wu ZD, 2020, KNOWL-BASED SYST, V195, DOI 10.1016/j.knosys.2020.105679
   Wu ZD, 2020, J ASSOC INF SCI TECH, V71, P183, DOI 10.1002/asi.24227
   Wu ZD, 2017, EXPERT SYST APPL, V84, P12, DOI 10.1016/j.eswa.2017.04.054
   Wu ZD, 2017, INFORM SCIENCES, V393, P15, DOI 10.1016/j.ins.2017.02.009
   Yan WH, 2020, WORLD WIDE WEB, V23, P3055, DOI 10.1007/s11280-020-00820-z
   Yu M, 2022, COMPUT BIOL MED, V144, DOI 10.1016/j.compbiomed.2022.105347
   Yu Q, 2017, EUR ARCH OTO-RHINO-L, V274, P2891, DOI 10.1007/s00405-017-4562-3
   Yu YJ, 2002, IEEE T IMAGE PROCESS, V11, P1260, DOI 10.1109/TIP.2002.804279
   Zebari R., 2020, J APPL SCI TECHNOL T, V1, P56, DOI [10.38094/jastt1224, DOI 10.38094/JASTT1224]
   Zhang DS, 2012, PATTERN RECOGN, V45, P346, DOI 10.1016/j.patcog.2011.05.013
NR 60
TC 0
Z9 0
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD MAY 2
PY 2022
VL 2022
AR 3151554
DI 10.1155/2022/3151554
PG 9
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA 1J1GJ
UT WOS:000797672400007
PM 35547561
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sugita, S
   Iwasaki, Y
   Makabe, K
   Kimura, T
   Futagami, T
   Suegami, S
   Takahashi, M
AF Sugita, Sunao
   Iwasaki, Yuko
   Makabe, Kenichi
   Kimura, Takafumi
   Futagami, Takaomi
   Suegami, Shinji
   Takahashi, Masayo
TI Lack of T Cell Response to iPSC-Derived Retinal Pigment Epithelial Cells
   from HLA Homozygous Donors
SO STEM CELL REPORTS
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; IMMUNE PRIVILEGE; ACTIVATION; EXPRESSION; BLOOD
AB Allografts of retinal pigment epithelial (RPE) cells have been considered for the treatment of ocular diseases. We recently started the transplantation of induced pluripotent stem cell (iPSC)-derived RPE cells for patients with age-related macular degeneration (autogenic grafts). However, there are at least two problems with this approach: (1) high cost, and (2) uselessness for acute patients. To resolve these issues, we established RPE cells from induced iPSCs in HLA homozygote donors. In vitro, human T cells directly recognized allogeneic iPSC-derived RPE cells that expressed HLA class I/II antigens. However, these T cells failed to respond to HLA-A, -B, and -DRB1-matched iPSC-derived RPE cells from HLA homozygous donors. Because of the lack of T cell response to iPSC-derived RPE cells from HLA homozygous donors, we can use these allogeneic iPSC-derived RPE cells in future clinical trials if the recipient and donor are HLA matched.
C1 [Sugita, Sunao; Iwasaki, Yuko; Makabe, Kenichi; Takahashi, Masayo] RIKEN Ctr Dev Biol, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
   [Iwasaki, Yuko] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol & Visual Sci, Tokyo 1138519, Japan.
   [Kimura, Takafumi; Futagami, Takaomi; Suegami, Shinji] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Fundamental Cell Technol, Kyoto 6068507, Japan.
   [Futagami, Takaomi; Suegami, Shinji] HLA Fdn Lab, Kyoto 6008813, Japan.
C3 RIKEN; Tokyo Medical & Dental University (TMDU); Kyoto University
RP Takahashi, M (通讯作者)，RIKEN Ctr Dev Biol, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
EM mretina@cdb.riken.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [25293357]; Charitable Trust Fund for Ophthalmic Research in
   Commemoration of Santen Pharmaceutical's Founder; MEXT
FX We appreciate the expert technical assistance of N. Hayashi, K. Iseki,
   T. Hashiguchi, W. Ohashi, M. Kawahara, C. Yamada, H. Kitajima, and C.
   Morinaga (Laboratory for Retinal Regeneration, Center for Developmental
   Biology, RIKEN, Kobe) and Drs. M. Sawada and T. Maeda (Healios KK,
   Kobe). We appreciate Dr. S. Okamoto (Department of Physiology, Keio
   University School of Medicine, Tokyo) for the establishment of iPSCs and
   RPE cells. This work was supported by a Scientific Research Grant (B,
   25293357) from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan, by the Charitable Trust Fund for Ophthalmic
   Research in Commemoration of Santen Pharmaceutical's Founder, and by a
   grant from the Project for Realization of Regenerative Medicine from
   MEXT.
CR Algvere PV, 1997, ACTA OPHTHALMOL SCAN, V75, P1
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0
   Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299
   Enzmann V, 1999, TRANSPL IMMUNOL, V7, P9, DOI 10.1016/S0966-3274(99)80013-6
   Hamrah P, 2002, INVEST OPHTH VIS SCI, V43, P639
   Horie S, 2010, CLIN IMMUNOL, V136, P83, DOI 10.1016/j.clim.2010.03.001
   Huber C, 1988, Bibl Cardiol, P103
   Imai A, 2012, INVEST OPHTH VIS SCI, V53, P7299, DOI 10.1167/iovs.12-10182
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Suarez-Alvarez B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010192
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P2862, DOI 10.1167/iovs.08-2846
   Usui Y, 2008, EXP EYE RES, V86, P52, DOI 10.1016/j.exer.2007.09.007
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
NR 22
TC 70
Z9 72
U1 1
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD OCT 11
PY 2016
VL 7
IS 4
BP 619
EP 634
DI 10.1016/j.stemcr.2016.08.011
PG 16
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EE3QF
UT WOS:000389508600004
PM 27641646
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maruotti, J
   Sripathi, SR
   Bharti, K
   Fuller, J
   Wahlin, KJ
   Ranganathan, V
   Sluch, VM
   Berlinicke, CA
   Davis, J
   Kim, C
   Zhao, LJ
   Wan, J
   Qian, J
   Corneo, B
   Temple, S
   Dubey, R
   Olenyuk, BZ
   Bhutto, I
   Lutty, GA
   Zack, DJ
AF Maruotti, Julien
   Sripathi, Srinivas R.
   Bharti, Kapil
   Fuller, John
   Wahlin, Karl J.
   Ranganathan, Vinod
   Sluch, Valentin M.
   Berlinicke, Cynthia A.
   Davis, Janine
   Kim, Catherine
   Zhao, Lijun
   Wan, Jun
   Qian, Jiang
   Corneo, Barbara
   Temple, Sally
   Dubey, Ramin
   Olenyuk, Bogdan Z.
   Bhutto, Imran
   Lutty, Gerard A.
   Zack, Donald J.
TI Small-molecule-directed, efficient generation of retinal pigment
   epithelium from human pluripotent stem cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE retinal pigment epithelium; pluripotent stem cells; high-throughput
   screening; differentiation; age-related macular degeneration
ID DIFFERENTIATION; EXPRESSION; DERIVATION; MEMBRANE; PATHWAY; DISEASE; RPE
AB Age-related macular degeneration (AMD) is associated with dysfunction and death of retinal pigment epithelial (RPE) cells. Cell-based approaches using RPE-like cells derived from human pluripotent stem cells (hPSCs) are being developed for AMD treatment. However, most efficient RPE differentiation protocols rely on complex, stepwise treatments and addition of growth factors, whereas small-molecule-only approaches developed to date display reduced yields. To identify new compounds that promote RPE differentiation, we developed and performed a high-throughput quantitative PCR screen complemented by a novel orthogonal human induced pluripotent stem cell (hiPSC)-based RPE reporter assay. Chetomin, an inhibitor of hypoxia-inducible factors, was found to strongly increase RPE differentiation; combination with nicotinamide resulted in conversion of over one-half of the differentiating cells into RPE. Single passage of the whole culture yielded a highly pure hPSC-RPE cell population that displayed many of the morphological, molecular, and functional characteristics of native RPE.
C1 [Maruotti, Julien; Sripathi, Srinivas R.; Fuller, John; Wahlin, Karl J.; Ranganathan, Vinod; Sluch, Valentin M.; Berlinicke, Cynthia A.; Kim, Catherine; Zhao, Lijun; Wan, Jun; Qian, Jiang; Bhutto, Imran; Lutty, Gerard A.; Zack, Donald J.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Bharti, Kapil; Davis, Janine] NEI, Unit Ocular & Stem Cell Translat Res, NIH, Bethesda, MD 20892 USA.
   [Corneo, Barbara] Columbia Univ, Stem Cell Core Facil, New York, NY 10032 USA.
   [Temple, Sally] Neural Stem Cell Inst, Rensselaer, NY 12144 USA.
   [Dubey, Ramin] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
   [Dubey, Ramin] Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.
   [Olenyuk, Bogdan Z.] Univ So Calif, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21287 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21287 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Inst Genet Med, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Columbia
   University; Stanford University; Stanford University; University of
   Southern California; Johns Hopkins University; Johns Hopkins University;
   Johns Hopkins University
RP Zack, DJ (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
EM dzack@jhmi.edu
RI Wan, Jun/H-7132-2013; Wan, Jun/AAN-1337-2020; Jaskula-Ranga,
   Vinod/T-1021-2016
OI Wan, Jun/0000-0001-9286-6562; Wan, Jun/0000-0001-9286-6562;
   Jaskula-Ranga, Vinod/0000-0003-1202-634X; Corneo,
   Barbara/0000-0001-5189-6749; Fuller, John/0000-0002-6587-146X; Dubey,
   Ramin/0000-0002-0687-5831
FU Foundation Fighting Blindness Wynn-Gund Translational Acceleration
   Program; Bright Focus Macular Degeneration Research Program; NIH
   [5R21EY023812-02, P30EY001765]; Research to Prevent Blindness, Inc.;
   NATIONAL EYE INSTITUTE [R21EY023812, R01EY024249, ZIAEY000542,
   ZIAEY000533, ZIAEY000532, P30EY001765] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445] Funding
   Source: NIH RePORTER
FX We thank Dr. Linzhao Cheng (The Johns Hopkins University) for providing
   hiPSC BC1, and Dr. Emeline Nandrot (Institut de la Vision) for providing
   FITC-POS. This work was supported by grants from Foundation Fighting
   Blindness Wynn-Gund Translational Acceleration Program, Bright Focus
   Macular Degeneration Research Program, NIH Grants 5R21EY023812-02 and
   P30EY001765, unrestricted funds from Research to Prevent Blindness,
   Inc., and generous gifts from the Guerrieri Family Foundation, Mr. and
   Mrs. Robert and Clarice Smith, and the Raab Family Foundation.
CR Bharti K, 2012, INVEST OPHTHALMOL VI, V53
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   BREWER D, 1972, CAN J MICROBIOL, V18, P1129, DOI 10.1139/m72-174
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Chou BK, 2011, CELL RES, V21, P518, DOI 10.1038/cr.2011.12
   Cimadamore F, 2009, STEM CELLS, V27, P1772, DOI 10.1002/stem.107
   Cyranoski D, 2014, NATURE, DOI [10.1038/nature.2014.15915, DOI 10.1038/NATURE.2014.15915]
   Dykhuizen EC, 2012, J BIOMOL SCREEN, V17, P1221, DOI 10.1177/1087057112455060
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Gamm DM, 2008, INVEST OPHTH VIS SCI, V49, P788, DOI 10.1167/iovs.07-0777
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Klimanskaya I, 2008, NAT REV DRUG DISCOV, V7, P131, DOI 10.1038/nrd2403
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kung AL, 2004, CANCER CELL, V6, P33, DOI 10.1016/j.ccr.2004.06.009
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Li WL, 2013, CELL RES, V23, P81, DOI 10.1038/cr.2012.182
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Murisier F, 2007, DEV BIOL, V303, P838, DOI 10.1016/j.ydbio.2006.11.038
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Synnergren J, 2007, STEM CELLS, V25, P473, DOI 10.1634/stemcells.2006-0247
   Thorne N, 2010, CURR OPIN CHEM BIOL, V14, P315, DOI 10.1016/j.cbpa.2010.03.020
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Xu T, 2013, STEM CELL TRANSL MED, V2, P355, DOI 10.5966/sctm.2012-0172
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
NR 30
TC 85
Z9 86
U1 0
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 1
PY 2015
VL 112
IS 35
BP 10950
EP 10955
DI 10.1073/pnas.1422818112
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CQ1TV
UT WOS:000360383200049
PM 26269569
OA Green Published
DA 2022-11-30
ER

PT J
AU Cardarelli, WJ
   Smith, RA
AF Cardarelli, William J.
   Smith, Roderick A.
TI Managed Care Implications of Age-Related Ocular Conditions
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID DIABETIC MACULAR EDEMA; VEGF TRAP-EYE; COST-EFFECTIVENESS; RESOURCE USE;
   RANIBIZUMAB; IMPACT; DEGENERATION; BEVACIZUMAB; AFLIBERCEPT; GLAUCOMA
AB The economic costs of age-related ocular diseases and vision loss are increasing rapidly as our society ages. In addition to the direct costs of treating age-related eye diseases, elderly persons with vision loss are at significantly increased risk for falls and fractures, experiencing social isolation, and suffering from an array of comorbid medical conditions compared with individuals with normal vision. Recent studies estimate the total economic burden (direct and indirect costs) of adult vision impairment in the United States at $51.4 billion. This figure is expected to increase as the baby boomer generation continues to age. While a number of highly effective new therapies have caused a paradigm shift in the management of several major age-related ocular diseases in recent years, these treatments come at a substantial cost. This article reviews the economic burdens and treatment-related costs of 4 major ocular diseases of aging-glaucoma, age-related macular degeneration, diabetic retinopathy, and dry eye disease-and the implications for managed care.
C1 [Cardarelli, William J.; Smith, Roderick A.] Atrius Hlth Harvard Vanguard Med Associates, Watertown, MA USA.
C3 Harvard Vanguard Medical Associates
RP Cardarelli, WJ (通讯作者)，Atrius Hlth Harvard Vanguard Med Associates, Watertown, MA USA.
EM William_Cardarelli@vmed.org
FU Allergan, Inc
FX This activity is supported by an educational grant from Allergan, Inc.
CR [Anonymous], AM J MANAGED CARE WE
   [Anonymous], XAL GOES GEN LANDM E
   Bramley T, 2008, ARCH OPHTHALMOL-CHIC, V126, P849, DOI 10.1001/archopht.126.6.849
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Crews JE, 2001, J VISUAL IMPAIR BLIN, V95, P453, DOI 10.1177/0145482X0109500802
   Crews JE, 2006, J VISUAL IMPAIR BLIN, V100, P824
   Dewan V, 2012, OPHTHALMOLOGY, V119, P1679, DOI 10.1016/j.ophtha.2012.01.049
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Fiscella Richard G, 2008, Am J Manag Care, V14, pS107
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Galor A, 2012, CORNEA, V31, P1403, DOI 10.1097/ICO.0b013e31823cc0b7
   Lam BL, 2011, ARCH OPHTHALMOL-CHIC, V129, P1345, DOI 10.1001/archophthalmol.2011.142
   Lee PP, 2006, ARCH OPHTHALMOL-CHIC, V124, P12, DOI 10.1001/archopht.124.1.12
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michaelides M, 2010, OPHTHALMOLOGY, V117, P1078, DOI 10.1016/j.ophtha.2010.03.045
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Neumann PJ, 2010, NEW ENGL J MED, V363, P1495, DOI 10.1056/NEJMp1007168
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Prevent blindness America, 2007, EC IMP VIS PROBL TOL
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Shea AM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1748, DOI 10.1001/archopht.126.12.1748
   Smiddy WE, 2012, OPHTHALMOLOGY, V119, P2558, DOI 10.1016/j.ophtha.2012.09.015
   Smiddy WE, 2011, OPHTHALMOLOGY, V118, P1827, DOI 10.1016/j.ophtha.2010.12.034
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Yu JH, 2011, CORNEA, V30, P379, DOI 10.1097/ICO.0b013e3181f7f363
NR 31
TC 17
Z9 17
U1 0
U2 3
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2013
VL 19
IS 5
SU S
BP S85
EP S91
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA 162VE
UT WOS:000320293300003
PM 23725500
DA 2022-11-30
ER

PT J
AU Karagiannis, DA
   Mitropoulos, P
   Ladas, ID
AF Karagiannis, Dimitrios A.
   Mitropoulos, Panagiotis
   Ladas, Ioannis D.
TI Large Subretinal Haemorrhage following Change from Intravitreal
   Bevacizumab to Ranibizumab
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Ranibizumab; Subretinal
   haemorrhage
ID MACULAR DEGENERATION; PHARMACOKINETICS; AVASTIN; TRIAL
AB Background: To report 2 cases of large subretinal haemorrhage in 2 patients with age-related macular degeneration when the intravitreal injections were changed from bevacizumab (Avastin) to ranibizumab (Lucentis). Methods: Both patients were treated initially with intravitreal bevacizumab 1.25 mg for 4 months ( 4 injections) and then switched to 0.5 mg ranibizumab which continued for another 6 months. Best-corrected visual acuity measurements, slit-lamp examination, contact lens biomicroscopy, optical coherence tomography and fluorescein angiography were performed at baseline examination and every month. Results: Both patients showed initial improvement when treated with intravitreal bevacizumab followed by deterioration and development of a large subretinal haemorrhage when changing to intravitreal ranibizumab. Conclusions: There is not enough experience switching from one anti-vascular-endothelial-growth-factor agent to another. A prospective study with large series of patients and controls may be necessary in order to determine whether it is safe enough to change from one medication to another. Copyright (C) 2009 S. Karger AG, Basel
C1 [Ladas, Ioannis D.] Univ Athens, Sch Med, Dept Ophthalmol 1, GR-11527 Athens, Greece.
   [Karagiannis, Dimitrios A.; Mitropoulos, Panagiotis] Univ Athens, Sch Med, Eye Hosp Athens, Dept Ophthalmiatrio 2, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; National & Kapodistrian University of Athens
RP Karagiannis, DA (通讯作者)，15 Ariadnis St, GR-14563 Kifisia, Greece.
EM dimitrioskaragiannis@doctors.org.uk
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
NR 14
TC 18
Z9 19
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 4
BP 279
EP 282
DI 10.1159/000213644
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 462RE
UT WOS:000267372500012
PM 19390227
OA Bronze
DA 2022-11-30
ER

PT J
AU Marinec, PS
   Landgraf, KE
   Uppalapati, M
   Chen, G
   Xie, D
   Jiang, QY
   Zhao, YL
   Petriello, A
   Deshayes, K
   Kent, SBH
   Ault-Riche, D
   Sidhu, SS
AF Marinec, Paul S.
   Landgraf, Kyle E.
   Uppalapati, Maruti
   Chen, Gang
   Xie, Daniel
   Jiang, Qiyang
   Zhao, Yanlong
   Petriello, Annalise
   Deshayes, Kurt
   Kent, Stephen B. H.
   Ault-Riche, Dana
   Sidhu, Sachdev S.
TI A Non-immunogenic Bivalent D-Protein Potently Inhibits Retinal
   Vascularization and Tumor Growth
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
AB We report a general approach to engineering multivalent D-proteins with antibody-like activities in vivo. Mirror-image phage display and structure-guided design were utilized to create a D-protein that uses receptor mimicry to antagonize vascular endothelial growth factor A (VEGF-A). Selections against the D-protein form of VEGF-A using phage-displayed libraries of two different domain scaffolds yielded two proteins that bound distinct receptor interaction sites on VEGF-A. X-ray crystal structures of the D-protein/VEGF-A complexes were used to guide affinity maturation and to construct a heterodimeric D-protein VEGF-A antagonist with picomolar activity. The D-protein VEGF-A antagonist prevented vascular leakage in a rabbit eye model of wet age-related macular degeneration and slowed tumor growth in the MC38 syngeneic mouse tumor model with efficacies comparable to those of approved antibody drugs, and in contrast with antibodies, the D-protein was non-immunogenic during treatment and following subcutaneous immunizations.
C1 [Marinec, Paul S.; Landgraf, Kyle E.; Uppalapati, Maruti; Chen, Gang; Deshayes, Kurt; Kent, Stephen B. H.; Ault-Riche, Dana; Sidhu, Sachdev S.] Reflex Pharmaceut, Incline Village, NV 89451 USA.
   [Uppalapati, Maruti; Chen, Gang; Sidhu, Sachdev S.] Univ Toronto, Donnelly Ctr, Dept Mol Genet, Toronto, ON M5S 3E1, Canada.
   [Xie, Daniel] Chinese Peptide Co, Hangzhou 310018, Peoples R China.
   [Jiang, Qiyang; Zhao, Yanlong] Viva Biotech, Zhangjiang High Tech Pk, Shanghai 201203, Peoples R China.
   [Petriello, Annalise] iQ Biosci, Berkeley, CA 94710 USA.
C3 University of Toronto
RP Ault-Riche, D; Sidhu, SS (通讯作者)，Reflex Pharmaceut, Incline Village, NV 89451 USA.; Sidhu, SS (通讯作者)，Univ Toronto, Donnelly Ctr, Dept Mol Genet, Toronto, ON M5S 3E1, Canada.
EM aultriche@reflexionpharma.com; sidhu@reflexionpharma.com
RI zhao, yan/GWC-9174-2022
OI Uppalapati, Maruti/0000-0003-0101-2030
FU Reflexion Pharmaceuticals, Inc.; Hangzhou Ditai Bio-Tech Co., Ltd.
FX This work was funded by Reflexion Pharmaceuticals, Inc., and Hangzhou
   Ditai Bio-Tech Co., Ltd.
CR Brozzo MS, 2012, BLOOD, V119, P1781, DOI 10.1182/blood-2011-11-390922
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629
   Dingman R, 2019, J PHARM SCI-US, V108, P1637, DOI 10.1016/j.xphs.2018.12.014
   DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342
   Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Katoh T, 2017, CELL CHEM BIOL, V24, P46, DOI 10.1016/j.chembiol.2016.11.012
   Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399
   Krishna M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00021
   Lejon S, 2004, J BIOL CHEM, V279, P42924, DOI 10.1074/jbc.M406957200
   Liu M, 2010, P NATL ACAD SCI USA, V107, P14321, DOI 10.1073/pnas.1008930107
   Mandal K, 2012, P NATL ACAD SCI USA, V109, P14779, DOI 10.1073/pnas.1210483109
   Mandal K, 2011, ANGEW CHEM INT EDIT, V50, P8029, DOI 10.1002/anie.201103237
   Markovic-Mueller S, 2017, STRUCTURE, V25, P341, DOI 10.1016/j.str.2016.12.012
   MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320
   Mones J, 2020, OPHTHALMOLOGY, V20, P31075
   Olsen T. W, 2016, AM ACAD OPHTHALMOLOG
   Presta LG, 1997, CANCER RES, V57, P4593
   Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0
   Sauerborn M, 2010, TRENDS PHARMACOL SCI, V31, P53, DOI 10.1016/j.tips.2009.11.001
   Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854
   Sethi A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002192
   Tashiro M, 1997, J MOL BIOL, V272, P573, DOI 10.1006/jmbi.1997.1265
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Uppalapati M, 2016, ACS CHEM BIOL, V11, P1058, DOI 10.1021/acschembio.5b01006
   van Groen T, 2008, CHEMMEDCHEM, V3, P1848, DOI 10.1002/cmdc.200800273
   Wallin JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12624
   Welch BD, 2007, P NATL ACAD SCI USA, V104, P16828, DOI 10.1073/pnas.0708109104
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Zhao L, 2014, CURR OPIN CHEM BIOL, V22, P56, DOI 10.1016/j.cbpa.2014.09.019
NR 36
TC 1
Z9 1
U1 2
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD MAR 19
PY 2021
VL 16
IS 3
BP 548
EP 556
DI 10.1021/acschembio.1c00017
EA FEB 2021
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA RA5BG
UT WOS:000631431900013
PM 33621466
DA 2022-11-30
ER

PT J
AU Hirakata, T
   Matsuda, A
   Yokomizo, T
AF Hirakata, Toshiaki
   Matsuda, Akira
   Yokomizo, Takehiko
TI Leukotriene B-4 receptors as therapeutic targets for ophthalmic diseases
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Review
DE LTB4; Lipid mediators; BLT1; BLT2; Eye; Age related macular
   degeneration; Allergic conjunctivitis
ID ENDOTOXIN-INDUCED UVEITIS; ATOPIC-DERMATITIS; ARACHIDONIC-ACID; LIPID
   MEDIATORS; A(4) HYDROLASE; NEUTROPHIL RECRUITMENT; INFLAMMATORY
   MEDIATORS; LIPOXYGENASE PRODUCTS; MOLECULAR-MECHANISMS; CORNEAL INJURY
AB Leukotriene B-4 (LTB4) is an inflammatory lipid mediator produced from arachidonic acid by multiple reactions catalyzed by two enzymes 5-lipoxygenase (5-LOX) and LTA(4) hydrolase (LTA(4)H). The two receptors for LTB4 have been identified: a high-affinity receptor, BLT1, and a low-affinity receptor, BLT2. Our group identified 12(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid (12-HHT) as a high-affinity BLT2 ligand. Numerous studies have revealed critical roles for LTB4 and its receptors in various systemic diseases. Recently, we also reported the roles of LTB4, BLT1 and BLT2 in the murine ophthalmic disease models of mice including cornea wound, allergic conjunctivitis, and age-related macular degeneration. Moreover, other groups revealed the evidence of the ocular function of LTB4. In the present review, we introduce the roles of LTB4 and its receptors both in ophthalmic diseases and systemic inflammatory diseases. LTB4 and its receptors are putative novel therapeutic targets for systemic and ophthalmic diseases.
C1 [Hirakata, Toshiaki; Matsuda, Akira] Juntendo Univ, Dept Ophthalmol, Grad Sch Med, Bunkyo Ku, Hongo 2-1-1, Tokyo, Japan.
   [Hirakata, Toshiaki; Yokomizo, Takehiko] Juntendo Univ, Dept Biochem, Grad Sch Med, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.
C3 Juntendo University; Juntendo University
RP Yokomizo, T (通讯作者)，Juntendo Univ, Dept Biochem, Grad Sch Med, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.
EM yokomizo-tky@umin.ac.jp
RI Matsuda, Akira/A-9981-2010
OI Matsuda, Akira/0000-0002-0792-3663
FU MEXT/JSPS KAKENHI [19K23851, 20K18395, 19K09980, 15H05904, 15H04708,
   18H02627]; Naito Foundation; Ono Medical Research Foundation; Uehara
   Memorial Foundation; Mitsubishi Foundation; Takeda Science Foundation;
   Foundation of Strategic Research Projects in Private Universities from
   the MEXT [S1311011]
FX This work was supported by MEXT/JSPS KAKENHI (19K23851 and 20K18395 (to
   T.H.), 19K09980 (to A.M.), and 15H05904, 15H04708, and 18H02627 (to
   T.Y.)), and grants from the Naito Foundation, the Ono Medical Research
   Foundation, the Uehara Memorial Foundation, the Mitsubishi Foundation,
   and the Takeda Science Foundation. This study was supported in part by a
   Grant-in-Aid (S1311011) from the Foundation of Strategic Research
   Projects in Private Universities from the MEXT.
CR Adrian TE, 2008, PPAR RES, V2008, DOI 10.1155/2008/827096
   AHMADZADEH N, 1991, INFLAMMATION, V15, P497, DOI 10.1007/BF00923346
   Akman A, 1998, OCUL IMMUNOL INFLAMM, V6, P179, DOI 10.1076/ocii.6.3.179.4042
   Akman A, 1998, EYE, V12, P291, DOI 10.1038/eye.1998.67
   Ambaw YA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29568-3
   Andoh T, 2017, ACTA DERM-VENEREOL, V97, P922, DOI 10.2340/00015555-2697
   Andoh T, 2014, PHARMACOL REP, V66, P699, DOI 10.1016/j.pharep.2014.01.003
   Andoh T, 2012, EXP EYE RES, V98, P97, DOI 10.1016/j.exer.2012.03.021
   Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102
   Back M, 2011, PHARMACOL REV, V63, P539, DOI 10.1124/pr.110.004184
   BAZAN HEP, 1987, INVEST OPHTH VIS SCI, V28, P314
   BAZAN HEP, 1984, CURR EYE RES, V3, P1313, DOI 10.3109/02713688409007418
   BAZAN NG, 1990, INT OPHTHALMOL, V14, P335, DOI 10.1007/BF00163553
   BHATTACHERJEE P, 1981, EUR J PHARMACOL, V73, P21, DOI 10.1016/0014-2999(81)90141-2
   Bouchareychas L, 2017, J IMMUNOL, V198, P452, DOI 10.4049/jimmunol.1601346
   BRAIN SD, 1984, BRIT J PHARMACOL, V83, P313, DOI 10.1111/j.1476-5381.1984.tb10148.x
   CSUKAS S, 1990, INVEST OPHTH VIS SCI, V31, P382
   Cuevas M, 2012, CURR EYE RES, V37, P855, DOI 10.3109/02713683.2012.683508
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dai LL, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107737
   Elgin CY, 2016, CURR EYE RES, V41, P441, DOI 10.3109/02713683.2015.1037001
   English JT, 2017, PROSTAG LEUKOTR ESS, V117, P17, DOI 10.1016/j.plefa.2017.01.004
   Fanning LB, 2013, ANN ALLERG ASTHMA IM, V111, P155, DOI 10.1016/j.anai.2013.06.031
   Fernandes ES, 2013, FASEB J, V27, P1664, DOI 10.1096/fj.12-221218
   FOGH K, 1989, J ALLERGY CLIN IMMUN, V83, P450, DOI 10.1016/0091-6749(89)90132-2
   Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972
   Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3
   GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517
   Gronert K, 2005, PROSTAG LEUKOTR ESS, V73, P221, DOI 10.1016/j.plefa.2005.05.009
   Haeggstrom JZ, 2018, J CLIN INVEST, V128, P2680, DOI 10.1172/JCI97945
   Hashimoto A, 2003, J RHEUMATOL, V30, P1712
   HERBORT CP, 1988, GRAEF ARCH CLIN EXP, V226, P553, DOI 10.1007/BF02169204
   Hicks A, 2010, PROSTAG OTH LIPID M, V92, P33, DOI 10.1016/j.prostaglandins.2010.02.003
   Hirakata T, 2019, FASEB J, V33, P3392, DOI 10.1096/fj.201801805R
   Hodges RR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36124
   Honda T, 2019, INT IMMUNOL, V31, P589, DOI 10.1093/intimm/dxy087
   Hori T, 2018, NAT CHEM BIOL, V14, P262, DOI [10.1038/NCHEMBIO.2547, 10.1038/nchembio.2547]
   Iizuka Y, 2010, FASEB J, V24, P4678, DOI 10.1096/fj.10-165050
   Ishii Y, 2016, FASEB J, V30, P933, DOI 10.1096/fj.15-279653
   Iwamoto S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13122-8
   Jo-Watanabe A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143580
   Kamohara M, 2000, J BIOL CHEM, V275, P27000
   Kari O, 2010, J ASTHMA ALLERGY, V3, P149, DOI 10.2147/JAA.S13705
   Kazani S, 2013, J ALLERGY CLIN IMMUN, V132, P547, DOI 10.1016/j.jaci.2013.01.058
   Keane-Myers A, 2001, Curr Allergy Asthma Rep, V1, P550, DOI 10.1007/s11882-001-0064-9
   Kenchegowda S, 2010, J LIPID RES, V51, P879, DOI 10.1194/jlr.R001347
   Ketelhuth DFJ, 2015, PROSTAG OTH LIPID M, V121, P105, DOI 10.1016/j.prostaglandins.2015.05.007
   Kim GY, 2009, ARTERIOSCL THROM VAS, V29, P915, DOI 10.1161/ATVBAHA.109.185793
   Kim ND, 2006, J EXP MED, V203, P829, DOI 10.1084/jem.20052349
   Konstan MW, 2014, J CYST FIBROS, V13, P148, DOI 10.1016/j.jcf.2013.12.009
   KULKARNI PS, 1984, INVEST OPHTH VIS SCI, V25, P221
   Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175
   Landriscina A, 2015, J AM ACAD DERMATOL, V73, P521, DOI 10.1016/j.jaad.2015.06.036
   Li N, 2010, J OCUL PHARMACOL TH, V26, P431, DOI 10.1089/jop.2010.0019
   Liao TJ, 2006, INVEST OPHTH VIS SCI, V47, P1543, DOI 10.1167/iovs.05-1238
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu M, 2014, J EXP MED, V211, P1063, DOI 10.1084/jem.20132063
   Livne-Bar I, 2017, J CLIN INVEST, V127, P4403, DOI 10.1172/JCI77398
   Luna-Gomes T, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00027
   MANCINI JA, 1995, EUR J BIOCHEM, V231, P65, DOI 10.1111/j.1432-1033.1995.0065f.x
   Mathis SP, 2010, J IMMUNOL, V185, P3049, DOI 10.4049/jimmunol.1001031
   Matsumoto Y, 2020, J PHARMACOL EXP THER, V373, P1, DOI 10.1124/jpet.119.263145
   Matsunaga Y, 2013, FASEB J, V27, P3306, DOI 10.1096/fj.12-217000
   Medeiros R, 2008, MOL PHARMACOL, V74, P154, DOI 10.1124/mol.108.046870
   Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054
   Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289
   Nakamura M, 2011, CHEM REV, V111, P6231, DOI 10.1021/cr100392s
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Naveh N, 2000, CURR EYE RES, V21, P554, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT554
   Ohashi R, 2004, TRENDS CARDIOVAS MED, V14, P187, DOI 10.1016/j.tcm.2004.04.002
   OKUMURA A, 1990, INT OPHTHALMOL, V14, P31, DOI 10.1007/BF00131166
   Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329
   Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042
   Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971
   Oyoshi MK, 2012, IMMUNITY, V37, P747, DOI 10.1016/j.immuni.2012.06.018
   Pang YM, 2019, ATHEROSCLEROSIS, V284, P50, DOI 10.1016/j.atherosclerosis.2019.02.017
   PARKER JA, 1986, ARCH OPHTHALMOL-CHIC, V104, P722
   Pelikan Z, 2013, BRIT J OPHTHALMOL, V97, P820, DOI 10.1136/bjophthalmol-2012-302829
   Pfister RR, 1998, INVEST OPHTH VIS SCI, V39, P1744
   Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103
   Rolando M, 2001, SURV OPHTHALMOL, V45, pS203, DOI 10.1016/S0039-6257(00)00203-4
   Rzodkiewicz Przemyslaw, 2016, Reumatologia (Warsaw), V54, P161, DOI 10.5114/reum.2016.62469
   Sadik CD, 2013, EXP DERMATOL, V22, P705, DOI 10.1111/exd.12239
   Saeki K, 2017, SEMIN IMMUNOL, V33, P30, DOI 10.1016/j.smim.2017.07.010
   Sasaki F, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96902
   Sasaki F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185133
   Sawada Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30373-1
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Seve P, 2017, AUTOIMMUN REV, V16, P1254, DOI 10.1016/j.autrev.2017.10.010
   Shigematsu M, 2016, SCI REP-UK, V6, DOI 10.1038/srep34560
   Singh K, 2010, J ALLERGY CLIN IMMUN, V126, P778, DOI 10.1016/j.jaci.2010.06.050
   Smith JR, 1998, IMMUNOL CELL BIOL, V76, P497, DOI 10.1046/j.1440-1711.1998.00783.x
   Smith JR, 2004, BRIT J OPHTHALMOL, V88, P273, DOI 10.1136/bjo.2003.027243
   Snelgrove RJ, 2010, SCIENCE, V330, P90, DOI 10.1126/science.1190594
   SPADA CS, 1988, AM J PATHOL, V130, P354
   Subbarao K, 2004, ARTERIOSCL THROM VAS, V24, P369, DOI 10.1161/01.ATV.0000110503.16605.15
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Sumida H, 2014, J IMMUNOL, V192, P4361, DOI 10.4049/jimmunol.1302959
   Suzumura A, 2020, DIABETES, V69, P724, DOI 10.2337/db19-0550
   Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970
   Tager AM, 2003, PROSTAG LEUKOTR ESS, V69, P123, DOI 10.1016/S0952-3278(03)00073-5
   Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217
   Toda A, 2010, BIOCHIMIE, V92, P682, DOI 10.1016/j.biochi.2009.12.002
   Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426
   Wang SK, 2000, J BIOL CHEM, V275, P40686, DOI 10.1074/jbc.M004512200
   Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010
   Woodward DF, 1996, J PHARMACOL EXP THER, V279, P137
   Yokomizo T, 2001, LIFE SCI, V68, P2207, DOI 10.1016/S0024-3205(01)01007-4
   Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506
   Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200
   Yokomizo T, 2018, J CLIN INVEST, V128, P2691, DOI 10.1172/JCI97946
   Yoshida S, 2016, J MED INVESTIG, V63, P187, DOI 10.2152/jmi.63.187
   Zaitsu M, 2003, J ASTHMA, V40, P147, DOI 10.1081/JAS-120017985
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zheng LX, 2019, CLIN EXP RHEUMATOL, V37, P872
NR 116
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 1879-2618
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD SEP
PY 2020
VL 1865
IS 9
AR 158756
DI 10.1016/j.bbalip.2020.158756
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA MQ2EV
UT WOS:000552710900016
PM 32535236
DA 2022-11-30
ER

PT J
AU Wu, CS
   Chung, TJ
   Lee, YJ
   Hsu, JD
   Lee, HJ
AF Wu, Chiao-Sen
   Chung, Tai-Jung
   Lee, Yi-Ju
   Hsu, Jeng-Dong
   Lee, Huei-Jane
TI Mulberry supplementation reduces lipid deposition and protects hamster
   retina from oxLDL damage
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Mulberry; Retina; Adult retinal pigment epithelial cell; Oxidized
   low-density lipoprotein; High fat diet
ID LOW-DENSITY-LIPOPROTEIN; ANTIOXIDANT ACTIVITY; ACCUMULATION; AGE;
   ANTHOCYANINS; LIPOGENESIS; INFLAMMATION; DYSFUNCTION; REDUCTION;
   PROMOTION
AB Patients with age-related macular degeneration typically exhibit an accumulation of oxidized low-density lipoprotein (oxLDL) in the retinal Bruch's membrane. Retinal pigment epithelial (RPE) cells were found to engulf oxLDL, triggering apoptosis. Mulberry and its anthocyanin might reduce oxLDL and lipid deposition in individuals consuming high-cholesterol diet. To investigate the relationship between mulberry water extract (MWE) intake and oxLDL in eye protection, Syrian hamsters fed a high fat diet (HFD) were used herein. After 8 weeks of treatment, MWE was found to reduce lipid deposition in hamsters' retinas. MWE also reduced the level of oxLDL and lipid peroxidation in eye specimens. Mulberry protected RPE cells from oxLDL-induced cell death and could inhibit the entry of oxLDL into cells by reducing the oxLDL receptor. Taken together, our results indicate that both in HFD fed hamsters and in oxLDL-treated ARPE cells, mulberry can reduce oxLDL accumulation to protect the retina from oxLDL-induced damage.
C1 [Wu, Chiao-Sen] Tungs Hosp, Dept Surg, Div Colorectal Surg, 699,Sec 8,Taiwan Blvd, Taichung 435, Taiwan.
   [Chung, Tai-Jung; Lee, Huei-Jane] Chung Shan Med Univ, Coll Med, Inst Biochem Microbiol & Immunol, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.
   [Lee, Yi-Ju; Hsu, Jeng-Dong] Chung Shan Med Univ, Dept Pathol, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.
   [Lee, Huei-Jane] Chung Shan Med Univ Hosp, Dept Clin Biochem, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.
   [Lee, Huei-Jane] Chung Shan Med Univ, Coll Med, Sch Med, Dept Biochem, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University; Chung Shan Medical University Hospital; Chung Shan
   Medical University
RP Lee, HJ (通讯作者)，Chung Shan Med Univ, Coll Med, Inst Biochem Microbiol & Immunol, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.; Hsu, JD (通讯作者)，Chung Shan Med Univ, Dept Pathol, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.; Lee, HJ (通讯作者)，Chung Shan Med Univ Hosp, Dept Clin Biochem, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.
EM t7734@ms.sltung.com.tw; breeze0221@yahoo.com.tw; jasmine.lyl@gmail.com;
   dongdong@csmu.edu.tw; lhj@csmu.edu.tw
FU Ministry of Science and Technology, Taiwan [MOST107-2320-B-040-005];
   Chung Shan Medical University and Tung's Hospital Grant, Taiwan
   [CSMU-TTM-102-02]; Chung Shan Medical University Hospital, Taiwan
   [CSH-2013-C-027, CSH-2013-C-022]
FX This work was supported by the grant of Ministry of Science and
   Technology, Taiwan (MOST107-2320-B-040-005); and partially from the
   grant of Chung Shan Medical University and Tung's Hospital Grant, Taiwan
   (CSMU-TTM-102-02) and Chung Shan Medical University Hospital, Taiwan
   (CSH-2013-C-022). We also thank Mrs Chi-Ping Wang to offer the fund from
   Chung Shan Medical University Hospital, Taiwan (CSH-2013-C-027) for
   analyzing blood lipid. This manuscript was edited by Wallace Academic
   Editing.
CR Al-Gayyar MMH, 2011, DIABETOLOGIA, V54, P669, DOI 10.1007/s00125-010-1994-3
   Almatrafi MM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071330
   Andallu B., 2002, Indian Journal of Experimental Biology, V40, P791
   Chang JJ, 2013, J AGR FOOD CHEM, V61, P6069, DOI 10.1021/jf401171k
   Chang RCA, 2015, INVEST OPHTH VIS SCI, V56, P2367, DOI 10.1167/iovs.14-16143
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   FULEKI T, 1968, J FOOD SCI, V33, P72, DOI 10.1111/j.1365-2621.1968.tb00887.x
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   He XY, 2019, J FUNCT FOODS, V63, DOI 10.1016/j.jff.2019.103505
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jao H. Y., 2016, FOOD FUNCT, V7, P1
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kakkar S., 2014, ISRN PHARM
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Liu LK, 2008, J FOOD SCI, V73, pH113, DOI 10.1111/j.1750-3841.2008.00801.x
   Mancini JE, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-14
   McCusker MM, 2016, CLIN DERMATOL, V34, P276, DOI 10.1016/j.clindermatol.2015.11.009
   Miller YI, 2017, TRENDS ENDOCRIN MET, V28, P143, DOI 10.1016/j.tem.2016.11.002
   Missaglia S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020187
   Nabavi SF, 2015, CURR MED CHEM, V22, P51
   Ou TT, 2013, J SCI FOOD AGR, V93, P1880, DOI 10.1002/jsfa.5984
   Ou TT, 2011, J SCI FOOD AGR, V91, P2740, DOI 10.1002/jsfa.4489
   Padro T, 2018, CURR PHARM DESIGN, V24, P2921, DOI 10.2174/1381612824666180702154129
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   Sanchez-Salcedo EM, 2015, J FUNCT FOODS, V18, P1039, DOI 10.1016/j.jff.2015.03.053
   Sanderson J., 2011, FREE RADICAL BIO MED, V26, P639
   Shahidi F, 2015, J FUNCT FOODS, V18, P820, DOI 10.1016/j.jff.2015.06.018
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Tsuda T, 1998, LIPIDS, V33, P583, DOI 10.1007/s11745-998-0243-5
   Veeramani C, 2017, BIOMED PHARMACOTHER, V96, P1349, DOI 10.1016/j.biopha.2017.11.072
   Yan GG, 2017, INT J CLIN EXP PATHO, V10, P1619
   Yang Y, 2019, J ORTHOP TRANSL, V16, P14, DOI 10.1016/j.jot.2018.07.003
   Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050
NR 41
TC 3
Z9 4
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD AUG
PY 2020
VL 71
AR 104007
DI 10.1016/j.jff.2020.104007
PG 10
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA MH7XU
UT WOS:000546937800011
OA gold
DA 2022-11-30
ER

PT J
AU Murali, A
   Krishnakumar, S
   Subramanian, A
   Parameswaran, S
AF Murali, Aishwarya
   Krishnakumar, Subramanian
   Subramanian, Anuradha
   Parameswaran, Sowmya
TI Bruch's membrane pathology: A mechanistic perspective
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Bruch's membrane; extracellular matrix; degeneration; drusen;
   angiogenesis; complement; inflammation; oxidative stress; advanced
   glycation end products; age-related macular degeneration; collagen;
   matrix metalloproteinases
ID RETINAL-PIGMENT EPITHELIUM; GLYCATION END-PRODUCTS; COMPLEMENT FACTOR-H;
   CENTRAL SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION; ANGIOTENSIN-II;
   APOLIPOPROTEIN-E; CHOROIDAL NEOVASCULARIZATION; OXIDATIVE STRESS;
   BINDING-PROTEIN
AB Bruch's membrane, an extracellular matrix located between the retinal pigment epithelium and the choroid, plays a vital role as structural and functional support to the retinal pigment epithelium. Dysfunction of Bruch's membrane in both age-related macular degeneration and other ocular diseases is caused mostly by extracellular matrix degeneration, deposit formation, and angiogenesis. Although these factors are dealt in greater detail with respect to the cells that are degenerated such as the retinal pigment epithelium and the endothelial cells, the pathology involving the Bruch's membrane is often underrated. Since in most of the macular degenerations early degenerative changes are also observed in the Bruch's membrane, addressing only the cellular component without the underlying membrane will not yield an ideal clinical benefit. This review aims to discuss the factors and the mechanisms affecting the integrity of the Bruch's membrane, which would aid in developing an effective therapy for these pathologies.
C1 [Murali, Aishwarya; Krishnakumar, Subramanian; Parameswaran, Sowmya] Vis Res Fdn, Kamalnayan Bajaj Inst Res Vis & Ophthalmol, Radheshyam Kanoi Stem Cell Lab, 18 Coll Rd, Chennai 600006, Tamil Nadu, India.
   [Subramanian, Anuradha] SASTRA Univ, Ctr Nanotechnol & Adv Biomat, Sch Chem & Biotechnol, Thanjavur, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA)
RP Parameswaran, S (通讯作者)，Vis Res Fdn, Kamalnayan Bajaj Inst Res Vis & Ophthalmol, Radheshyam Kanoi Stem Cell Lab, 18 Coll Rd, Chennai 600006, Tamil Nadu, India.
EM psowmya79ind@gmail.com
RI Sowmya, Parameswaran/GZK-8635-2022
OI Subramanian, Anuradha/0000-0001-7333-0244
FU Department of Biotechnology, Ministry of Science and Technology,
   Government of India [BT/PR26760/NNT/28/1433/2017]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   article was a part of the study supported by Department of
   Biotechnology, Ministry of Science and Technology, Government of India
   [File no. BT/PR26760/NNT/28/1433/2017].
CR Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand-Apte B, 2019, J NEUROSCI RES, V97, P88, DOI 10.1002/jnr.24317
   Baba SP, 2009, DIABETES, V58, P2486, DOI 10.2337/db09-0375
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Cano M, 2011, AM J PATHOL, V179, P850, DOI 10.1016/j.ajpath.2011.04.010
   Chen SD, 2005, NEPHROL DIAL TRANSPL, V20, P1320, DOI 10.1093/ndt/gfh837
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Fornoni A, 2002, J AM SOC NEPHROL, V13, P2068, DOI 10.1097/01.ASN.0000022421.86757.8D
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P81
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   Gkogkolou P, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.22028
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gorgels TGMF, 2012, EXP EYE RES, V104, P59, DOI 10.1016/j.exer.2012.09.009
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Hosoda Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03649-3
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hughes AE, 2011, MOL VIS, V17, P983
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hussain AA, 2010, INVEST OPHTH VIS SCI, V51, P2363, DOI 10.1167/iovs.09-4259
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Klein T, 2011, AMINO ACIDS, V41, P271, DOI 10.1007/s00726-010-0689-x
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Liutkeviciene R, 2016, OPHTHALMIC GENET, V37, P170, DOI 10.3109/13816810.2015.1020556
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Marneros AG, 2005, FASEB J, V19, P716, DOI 10.1096/fj.04-2134rev
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Nenna Antonio, 2015, Res Cardiovasc Med, V4, pe26949, DOI 10.5812/cardiovascmed.4(2)2015.26949
   Nguyen AD, 2004, CIRC RES, V95, P1067, DOI 10.1161/01.RES.0000149568.85071.FB
   Norouzpour A, 2016, INT J OPHTHALMOL-CHI, V9, P312, DOI 10.18240/ijo.2016.02.25
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P29, DOI 10.1097/00006982-199616010-00006
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   SANCHEZLOPEZ E, 2008, AM J PHYSIOL-RENAL, V294
   Schachat AP., 2018, RYANS RETINA, V6
   Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885
   Striker GE, 2008, AM J PHYSIOL-CELL PH, V295, pC1633, DOI 10.1152/ajpcell.00092.2008
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   Walia A, 2015, BBA-GEN SUBJECTS, V1850, P2422, DOI 10.1016/j.bbagen.2015.09.007
   Warwick A, 2016, EYE, V30, P488, DOI 10.1038/eye.2015.204
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Wright John W, 2013, Front Endocrinol (Lausanne), V4, P158, DOI 10.3389/fendo.2013.00158
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Xue MZ, 2011, SEMIN CELL DEV BIOL, V22, P293, DOI 10.1016/j.semcdb.2011.02.013
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamagishi S, 2015, MOL MED, V21, pS32, DOI 10.2119/molmed.2015.00067
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zayas-Santiago A, 2017, INVEST OPHTH VIS SCI, V58, P3046, DOI 10.1167/iovs.17-21720
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
NR 78
TC 9
Z9 9
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2020
VL 30
IS 6
BP 1195
EP 1206
AR 1120672120919337
DI 10.1177/1120672120919337
EA APR 2020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PF7SQ
UT WOS:000533971500001
PM 32345040
DA 2022-11-30
ER

PT J
AU Gu, BJ
   Wiley, JS
AF Gu, Ben J.
   Wiley, James S.
TI P2X7 as a scavenger receptor for innate phagocytosis in the brain
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
ID BRILLIANT BLUE G; PREVENTS ATP EXCITOTOXICITY; PURINERGIC P2X(7)
   RECEPTOR; SCLEROSIS SPINAL-CORD; NF-KAPPA-B; APOPTOTIC CELLS;
   ALZHEIMERS-DISEASE; EXTRACELLULAR ATP; CONCISE GUIDE; ANIMAL-MODEL
AB The P2X7 receptor has been widely studied for its ATP-induced pro-inflammatory effect, but in the absence of a ligand, P2X7 has a second function as a scavenger receptor, which is active in the development of the human brain. The scavenger activity of P2X7 is only evident in the absence of serum but is fully active in cerebrospinal fluid. P2X7 on the cell surface is present as a membrane complex, and an attachment to non-muscle myosin of the cytoskeleton is required for particle engulfment. Selective antagonists of P2X7 pro-inflammatory function have little effect on phagocytosis, but inheritance of a variant haplotype spanning the P2RX7 and P2RX4 genes has been associated with loss of P2X7-mediated phagocytosis. Recent studies in mice suggest that the innate phagocytosis mediated by P2X7 receptors declines with ageing. Thus, defective P2X7-mediated phagocytosis may contribute to age-related neuro-degenerative diseases including Alzheimer's disease, age-related macular degeneration and primary progressive multiple sclerosis.
C1 [Gu, Ben J.; Wiley, James S.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia.
C3 Florey Institute of Neuroscience & Mental Health; University of
   Melbourne
RP Wiley, JS (通讯作者)，Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia.
EM james.wiley@florey.edu.au
OI Gu, Ben/0000-0001-5500-4453; Wiley, James/0000-0001-9421-4154
CR Adinolfi E, 2003, J BIOL CHEM, V278, P37344, DOI 10.1074/jbc.M301508200
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS225, DOI 10.1111/bph.13876
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13877, 10.1111/bph.13882]
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS130, DOI 10.1111/bph.13879
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS17, DOI 10.1111/bph.13878
   Ali Z, 2013, BRIT J CLIN PHARMACO, V75, P197, DOI 10.1111/j.1365-2125.2012.04320.x
   Allsopp RC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00732-5
   Amores-Iniesta J, 2017, CELL REP, V21, P3414, DOI 10.1016/j.celrep.2017.11.079
   Apolloni S, 2014, DIS MODEL MECH, V7, P1101, DOI 10.1242/dmm.017038
   Apolloni S, 2013, HUM MOL GENET, V22, P4102, DOI 10.1093/hmg/ddt259
   Aprahamian T, 2008, CLIN EXP IMMUNOL, V152, P448, DOI 10.1111/j.1365-2249.2008.03658.x
   Arbeloa J, 2012, NEUROBIOL DIS, V45, P954, DOI 10.1016/j.nbd.2011.12.014
   Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206
   Bartlett R, 2017, PEERJ, V5, DOI 10.7717/peerj.3064
   Bhattacharya A, 2016, GLIA, V64, P1772, DOI 10.1002/glia.23001
   Bieniek M, 2006, J NEUROL NEUROSUR PS, V77, P1036, DOI 10.1136/jnnp.2006.094748
   Bindra CS, 2014, MOL CELL BIOCHEM, V390, P161, DOI 10.1007/s11010-014-1967-9
   Blaschke AJ, 1996, DEVELOPMENT, V122, P1165
   Bradshaw EM, 2013, NAT NEUROSCI, V16, P848, DOI 10.1038/nn.3435
   Carmo MRS, 2014, NEUROPHARMACOLOGY, V81, P142, DOI 10.1016/j.neuropharm.2014.01.045
   Carver KA, 2017, BIOCHEM BIOPH RES CO, V482, P81, DOI 10.1016/j.bbrc.2016.10.140
   Cervetto C, 2013, TOXICOLOGY, V311, P69, DOI 10.1016/j.tox.2013.04.004
   Chen LF, 2006, J IMMUNOL, V176, P3115, DOI 10.4049/jimmunol.176.5.3115
   Chen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089042
   Chen X, 2014, NEUROSCIENCE, V279, P94, DOI 10.1016/j.neuroscience.2014.08.036
   Cisneros-Mejorado A, 2015, J CEREBR BLOOD F MET, V35, P843, DOI 10.1038/jcbfm.2014.262
   CLINE MJ, 1968, BLOOD, V32, P423, DOI 10.1182/blood.V32.3.423.423
   Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8
   Cvetanovic M, 2006, J BIOL CHEM, V281, P20055, DOI 10.1074/jbc.M603920200
   Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002
   Di Virgilio F, 2016, METHODS MOL BIOL, V1417, P115, DOI 10.1007/978-1-4939-3566-6_7
   Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3
   Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438
   Eser A, 2015, INFLAMM BOWEL DIS, V21, P2247, DOI 10.1097/MIB.0000000000000514
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300
   Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635
   Ferrazoli EG, 2017, CELL TRANSPLANT, V26, P669, DOI 10.3727/096368917X695227
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Gu B, 1998, BLOOD, V92, P946
   Gu BJ, 2006, BLOOD, V107, P4946, DOI 10.1182/blood-2005-07-2994
   Gu BJ, 2016, ACTA NEUROPATHOL, V132, P377, DOI 10.1007/s00401-016-1596-3
   Gu BJ, 2015, HUM MOL GENET, V24, P5644, DOI 10.1093/hmg/ddv278
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2012, J BIOL CHEM, V287, P17318, DOI 10.1074/jbc.M112.340885
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744
   Gu BJ, 2009, AM J PHYSIOL-CELL PH, V297, pC430, DOI 10.1152/ajpcell.00079.2009
   Gu BJ, 2004, J BIOL CHEM, V279, P31287, DOI 10.1074/jbc.M313902200
   Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189
   Gu BJ, 2015, RECEPTOR CLIN INVEST, V2, pe699
   Guo C, 2007, MOL PHARMACOL, V72, P1447, DOI 10.1124/mol.107.035980
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hamilton N, 2010, GLIA, V58, P66, DOI 10.1002/glia.20902
   Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Hayashi H, 2007, J NEUROSCI, V27, P1933, DOI 10.1523/JNEUROSCI.5471-06.2007
   Hendrickx DAE, 2013, J NEUROPATH EXP NEUR, V72, P106, DOI 10.1097/NEN.0b013e31827fd9e8
   Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729
   Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880
   Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803
   Hracsko Z, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-28
   Huizinga R, 2012, GLIA, V60, P422, DOI 10.1002/glia.22276
   Diaz-Hernandez JI, 2012, NEUROBIOL AGING, V33, P1816, DOI 10.1016/j.neurobiolaging.2011.09.040
   Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322
   Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103
   Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714
   Karasawa A, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2544
   Karasawa A, 2016, ELIFE, V5, DOI 10.7554/eLife.22153
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Keystone EC, 2012, ANN RHEUM DIS, V71, P1630, DOI 10.1136/annrheumdis-2011-143578
   Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347
   Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108
   Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271
   Kumar S, 2017, NEUROCHEM RES, V42, P3414, DOI 10.1007/s11064-017-2383-9
   Kusner DJ, 2001, J IMMUNOL, V167, P3308, DOI 10.4049/jimmunol.167.6.3308
   Leeson HC, 2018, STEM CELLS, V36, P1764, DOI 10.1002/stem.2894
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Lieury A, 2014, GLIA, V62, P1645, DOI 10.1002/glia.22705
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Linehan E, 2014, AGING CELL, V13, P699, DOI 10.1111/acel.12223
   Lovelace MD, 2015, STEM CELLS, V33, P526, DOI 10.1002/stem.1864
   Lu ZJ, 2011, NAT CELL BIOL, V13, P1076, DOI 10.1038/ncb2299
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   Marcellino D, 2010, J NEURAL TRANSM, V117, P681, DOI 10.1007/s00702-010-0400-0
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007
   McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3
   Mizutani T, 2015, INVEST OPHTH VIS SCI, V56, P7122, DOI 10.1167/iovs.15-17440
   Monif M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0621-8
   Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009
   Mueller TD, 2012, FEBS LETT, V586, P1846, DOI 10.1016/j.febslet.2012.02.043
   Nandi S, 2012, DEV BIOL, V367, P100, DOI 10.1016/j.ydbio.2012.03.026
   Natrajan MS, 2015, BRAIN, V138, P3581, DOI 10.1093/brain/awv289
   Ou A, 2018, BBA-MOL BASIS DIS, V1864, P1051, DOI 10.1016/j.bbadis.2018.01.012
   Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001
   Parisi C, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/2989548
   Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329
   Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106
   Pizzirani C, 2007, BLOOD, V109, P3856, DOI 10.1182/blood-2005-06-031377
   Portillo JAC, 2016, INVEST OPHTH VIS SCI, V57, P6278, DOI 10.1167/iovs.16-20301
   Pupovac A, 2016, CELL MOL LIFE SCI, V73, P4159, DOI 10.1007/s00018-016-2274-2
   Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913
   Rampe D, 2004, J NEUROIMMUNOL, V147, P56, DOI 10.1016/j.jneuroim.2003.10.014
   Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338
   Rigato C, 2012, J NEUROSCI, V32, P11559, DOI 10.1523/JNEUROSCI.1042-12.2012
   Ryu JK, 2008, NEUROREPORT, V19, P1715, DOI 10.1097/WNR.0b013e3283179333
   Sadovnick AD, 2017, HUM MUTAT, V38, P736, DOI 10.1002/humu.23218
   Safaiyan S, 2016, NAT NEUROSCI, V19, P995, DOI 10.1038/nn.4325
   Sanz JM, 2009, J IMMUNOL, V182, P4378, DOI 10.4049/jimmunol.0803612
   Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957
   Sharp AJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-33
   Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004
   Sluyter R, 2004, GENES IMMUN, V5, P588, DOI 10.1038/sj.gene.6364127
   Sorge RE, 2012, NAT MED, V18, P595, DOI 10.1038/nm.2710
   Stock TC, 2012, J RHEUMATOL, V39, P720, DOI 10.3899/jrheum.110874
   Strick DJ, 2009, INVEST OPHTH VIS SCI, V50, P2427, DOI 10.1167/iovs.08-3058
   Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5
   Verhoef PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/jimmunol.170.11.5728
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659
   Wakx A, 2016, APPL BIOCHEM BIOTECH, V178, P368, DOI 10.1007/s12010-015-1878-6
   Walker TL, 2007, J NEUROSCI, V27, P3734, DOI 10.1523/JNEUROSCI.5060-06.2007
   Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082
   Wang XH, 2017, MOL MED REP, V15, P768, DOI 10.3892/mmr.2016.6070
   Wang YC, 2015, MOL MED REP, V12, P2149, DOI 10.3892/mmr.2015.3607
   Yamamoto M, 2013, BIOCHEM BIOPH RES CO, V439, P90, DOI 10.1016/j.bbrc.2013.08.022
   Yan YL, 2015, AM J PHYSIOL-CELL PH, V308, pC463, DOI 10.1152/ajpcell.00245.2014
   Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12
   Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398
   Zhao HL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23286
NR 133
TC 31
Z9 31
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2018
VL 175
IS 22
BP 4195
EP 4208
DI 10.1111/bph.14470
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GX5AS
UT WOS:000447752700001
PM 30098011
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Noorani, B
   Tabandeh, F
   Yazdian, F
   Soheili, ZS
   Shakibaie, M
   Rahmani, S
AF Noorani, Behnam
   Tabandeh, Fatemeh
   Yazdian, Fatemeh
   Soheili, Zahra-Soheila
   Shakibaie, Mehdi
   Rahmani, Shiva
TI Thin natural gelatin/chitosan nanofibrous scaffolds for retinal pigment
   epithelium cells
SO INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS
LA English
DT Article
DE AMD; chitosan; gelatin; RPE; scaffold
ID MACULAR DEGENERATION; CHITOSAN; GELATIN; RABBIT; TRANSPLANTATION;
   CHITIN; FABRICATION; ACID); SKIN; RPE
AB Damage of the retinal pigmented epithelial cells causes various diseases such as age-related macular degeneration in retinal tissue. Nowadays, scientists are attempting to replace lost retinal cells with healthy and efficient cells that provide better conditions for recovering and preventing blindness. In this study, gelatin/chitosan nanofibrous scaffolds with mean diameters of 180nm were fabricated for subretinal space through electrospinning. Thickness and morphology of the gelatin-chitosan scaffolds were analyzed by scanning electron microscopy (SEM). The results showed that the high rate of degradation, i.e., 90% damage was obtained after 1 month. The cell viability of gelatin/chitosan nanofibers were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The SEM results of cultured RPE on gelatin/chitosan scaffolds showed the appropriate adhesion of cells on the substrate. The results of the identity of RPE cells cultured on the scaffolds indicated that a large number of cells strongly expressed RPE65 and cytokeratin 8/18.
   [GRAPHICS]
   .
C1 [Noorani, Behnam; Tabandeh, Fatemeh; Shakibaie, Mehdi; Rahmani, Shiva] NIGEB, Ind & Environm Biotechnol Dept, Tehran 14965161, Iran.
   [Noorani, Behnam; Rahmani, Shiva] Univ Tehran, Fac New Sci & Technol, Dept Biomed Engn, Tehran, Iran.
   [Yazdian, Fatemeh] Univ Tehran, Fac New Sci & Technol, Dept Life Sci Engn, Tehran, Iran.
   [Soheili, Zahra-Soheila] NIGEB, Dept Mol Med, Tehran, Iran.
C3 University of Tehran; University of Tehran
RP Tabandeh, F (通讯作者)，NIGEB, Ind & Environm Biotechnol Dept, Tehran 14965161, Iran.
EM taban_f@nigeb.ac.ir
RI Noorani, Behnam/AAJ-5120-2020; Noorani, Behnam/AAD-7515-2021; Shakibaie,
   Mehdi/AAI-5122-2021; Soheili, Zahra-Soheila/W-8316-2018
OI Noorani, Behnam/0000-0002-7845-5027; Noorani,
   Behnam/0000-0002-5736-5989; Soheili, Zahra-Soheila/0000-0003-1292-465X;
   Shakibaie, Mehdi/0000-0002-6541-4242
CR AKIN H, 1995, J APPL POLYM SCI, V58, P95, DOI 10.1002/app.1995.070580110
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   Choi YS, 1999, BIOMATERIALS, V20, P409, DOI 10.1016/S0142-9612(98)00180-X
   Christiansen A T, 2012, Stem Cells Int, V2012, P454295, DOI 10.1155/2012/454295
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Dhandayuthapani B, 2010, J BIOMED MATER RES B, V94B, P264, DOI 10.1002/jbm.b.31651
   ELDIRINI AA, 1992, GRAEF ARCH CLIN EXP, V230, P292, DOI 10.1007/BF00176307
   Green W R, 1999, Mol Vis, V5, P27
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   He JK, 2009, ACTA BIOMATER, V5, P453, DOI 10.1016/j.actbio.2008.07.002
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Hsiue GH, 2002, J BIOMED MATER RES, V61, P19, DOI 10.1002/jbm.2000
   Jafari J, 2011, BIO-MED MATER ENG, V21, P99, DOI 10.3233/BME-2011-0660
   Khor E, 2003, BIOMATERIALS, V24, P2339, DOI 10.1016/S0142-9612(03)00026-7
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Li MY, 2005, BIOMATERIALS, V26, P5999, DOI 10.1016/j.biomaterials.2005.03.030
   LOPEZ R, 1987, INVEST OPHTH VIS SCI, V28, P1131
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142-9612(99)00011-3
   Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220
   Mao JS, 2004, BIOMATERIALS, V25, P3973, DOI 10.1016/j.biomaterials.2003.10.080
   Murugan R, 2007, TISSUE ENG, V13, P1845, DOI 10.1089/ten.2006.0078
   Noh HK, 2006, BIOMATERIALS, V27, P3934, DOI 10.1016/j.biomaterials.2006.03.016
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Pritchard CD, 2010, BIOMATERIALS, V31, P2153, DOI 10.1016/j.biomaterials.2009.11.074
   Qian YF, 2011, J BIOMAT SCI-POLYM E, V22, P1099, DOI 10.1163/092050610X499447
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001
   Saini JS, 2016, ADV EXP MED BIOL, V854, P557, DOI 10.1007/978-3-319-17121-0_74
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 37
TC 24
Z9 24
U1 1
U2 9
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0091-4037
EI 1563-535X
J9 INT J POLYM MATER PO
JI Int. J. Polym. Mater. Polym. Biomat.
PY 2018
VL 67
IS 12
BP 754
EP 763
DI 10.1080/00914037.2017.1362639
PG 10
WC Materials Science, Biomaterials; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science; Polymer Science
GA GP3HC
UT WOS:000440732800007
DA 2022-11-30
ER

PT J
AU Ding, SLS
   Kumar, S
   Mok, PL
AF Ding, Suet Lee Shirley
   Kumar, Suresh
   Mok, Pooi Ling
TI Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal
   Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE mesenchymal stem cells; retinal degenerative diseases; MSC
   differentiation; paracrine activity; anti-inflammatory;
   immunomodulatory; anti-angiogenesis
ID DIABETIC MACULAR EDEMA; ADIPOSE-TISSUE; RODENT MODEL; RAT MODEL;
   THERAPEUTIC STRATEGY; STEM/STROMAL CELLS; MUSE CELLS; IN-VITRO;
   DEGENERATION; TRANSPLANTATION
AB The use of multipotent mesenchymal stem cells (MSCs) has been reported as promising for the treatment of numerous degenerative disorders including the eye. In retinal degenerative diseases, MSCs exhibit the potential to regenerate into retinal neurons and retinal pigmented epithelial cells in both in vitro and in vivo studies. Delivery of MSCs was found to improve retinal morphology and function and delay retinal degeneration. In this review, we revisit the therapeutic role of MSCs in the diseased eye. Furthermore, we reveal the possible cellular mechanisms and identify the associated signaling pathways of MSCs in reversing the pathological conditions of various ocular disorders such as age-related macular degeneration (AMD), retinitis pigmentosa, diabetic retinopathy, and glaucoma. Current stem cell treatment can be dispensed as an independent cell treatment format or with the combination of other approaches. Hence, the improvement of the treatment strategy is largely subjected by our understanding of MSCs mechanism of action.
C1 [Ding, Suet Lee Shirley; Mok, Pooi Ling] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Upm Serdang 43400, Selangor, Malaysia.
   [Kumar, Suresh] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med Microbiol & Parasitol, Upm Serdang 43400, Selangor, Malaysia.
   [Kumar, Suresh; Mok, Pooi Ling] Univ Putra Malaysia, Genet & Regenerat Med Res Ctr, Upm Serdang 43400, Selangor, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra
   Malaysia
RP Mok, PL (通讯作者)，Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Upm Serdang 43400, Selangor, Malaysia.; Mok, PL (通讯作者)，Univ Putra Malaysia, Genet & Regenerat Med Res Ctr, Upm Serdang 43400, Selangor, Malaysia.
EM suetlee.ding@gmail.com; sureshkudsc@gmail.com; rachelmok2005@gmail.com
RI Mok, Pooi Ling/AAJ-7480-2021; Kumar S, Suresh/J-2423-2017
OI Kumar S, Suresh/0000-0002-0505-7554
FU Ministry of Science, Technology and Innovation (MOSTI), Malaysia
   [5450817]; Ministry of Education, Malaysia [5524401]; Universiti Putra
   Malaysia, Malaysia [9436300, 9503900]
FX This research was completely supported by the grant from the Ministry of
   Science, Technology and Innovation (MOSTI), Malaysia through the Science
   Fund, under the grant number 5450817. This work was also supported by
   the Fundamental Research Grants Scheme (FRGS), Ministry of Education,
   Malaysia (Grant No.: 5524401), and the Putra Grants of Universiti Putra
   Malaysia, Malaysia (Grant No.: 9436300 and 9503900).
CR Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Athanasiou D, 2013, FEBS LETT, V587, P2008, DOI 10.1016/j.febslet.2013.05.020
   Bakondi B, 2017, STEM CELL TRANSL MED, V6, P444, DOI 10.5966/sctm.2016-0181
   Boyer DS, 2013, THER ADV ENDOCRINOL, V4, P151, DOI 10.1177/2042018813512360
   Burrello J, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00083
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Cejka C, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5843809
   Cejkova J, 2013, EXP EYE RES, V116, P312, DOI 10.1016/j.exer.2013.10.002
   Cerman E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156495
   Chader GJ, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.16-19125
   Choi SW, 2017, J VET SCI, V18, P59, DOI 10.4142/jvs.2017.18.1.59
   Choi SW, 2016, ONCOTARGET, V7, P42139, DOI 10.18632/oncotarget.9882
   Choi YS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172642
   Christodoulou I, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/246134
   Chu LY, 2013, BLOOD, V122, P1822, DOI 10.1182/blood-2013-01-482315
   Chung S, 2016, INT J MOL MED, V37, P1170, DOI 10.3892/ijmm.2016.2532
   Contreras-Ruiz L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075937
   Cui Y, 2017, IN VITRO CELL DEV-AN, V53, P328, DOI 10.1007/s11626-016-0115-0
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   Das UN, 2016, ARCH MED SCI, V12, P1142, DOI 10.5114/aoms.2016.61918
   Davis BM, 2016, ACTA NEUROPATHOL, V132, P807, DOI 10.1007/s00401-016-1609-2
   Dezawa M, 2016, CELL TRANSPLANT, V25, P849, DOI 10.3727/096368916X690881
   Ding SLS, 2016, EYE, V30, P1293, DOI 10.1038/eye.2016.94
   Divya MS, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt148
   Eguizabal C, 2013, SEMIN REPROD MED, V31, P82, DOI 10.1055/s-0032-1331802
   Emre E, 2015, CYTOTHERAPY, V17, P543, DOI 10.1016/j.jcyt.2014.12.005
   Ezquer M, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0299-y
   Farnoodian M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12266
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Gao F, 2016, ANGIOGENESIS, V19, P107, DOI 10.1007/s10456-016-9497-6
   Ghazaryan E, 2016, MOL MED REP, V14, P3104, DOI 10.3892/mmr.2016.5621
   Gramlich OW, 2016, SCI REP-UK, V6, DOI 10.1038/srep26463
   Greenemeier L., 2013, NATURE, V15, p26 , DOI [10.1038/nature.2013.12439, DOI 10.1038/NATURE.2013.12439]
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12
   Hernandez C, 2016, J DIABETES RES, V2016, DOI DOI 10.1155/2016/9508541
   Hou HY, 2010, MOL THER, V18, P1837, DOI 10.1038/mt.2010.144
   Hsieh CT, 2016, J IMMUNOTHER, V39, P153, DOI 10.1097/CJI.0000000000000117
   Hu L, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/438243
   Itakura G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116413
   Jia Z, 2012, EXP EYE RES, V102, P44, DOI 10.1016/j.exer.2012.06.008
   Jones GN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043395
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   Kanno Hiroshi, 2013, World J Stem Cells, V5, P163, DOI 10.4252/wjsc.v5.i4.163
   Katagiri H, 2016, AM J TRANSPLANT, V16, P468, DOI 10.1111/ajt.13537
   Kawamura A, 2016, SCI REP-UK, V6, DOI 10.1038/srep19464
   Kim KS, 2016, CELL TRANSPLANT, V25, P1145, DOI 10.3727/096368915X688263
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klassen H, 2016, EXPERT OPIN BIOL TH, V16, P7, DOI 10.1517/14712598.2016.1093110
   Lai RC, 2015, SEMIN CELL DEV BIOL, V40, P82, DOI 10.1016/j.semcdb.2015.03.001
   Lee MJ, 2015, MOL THER, V23, P139, DOI 10.1038/mt.2014.159
   Leow SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128973
   Li Y, 2013, STEM CELLS DEV, V22, P1147, DOI 10.1089/scd.2012.0428
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Mannu GS, 2014, NEUROSCIENCES, V19, P275
   Mead B, 2016, CYTOTHERAPY, V18, P487, DOI 10.1016/j.jcyt.2015.12.002
   Mead B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109305
   Mok PL, 2013, MALAYS J PATHOL, V35, P17
   Munemasa Yasunari, 2012, Front Cell Neurosci, V6, P60, DOI 10.3389/fncel.2012.00060
   Nadri S, 2013, NEUROSCI LETT, V541, P43, DOI 10.1016/j.neulet.2012.12.055
   Nakano M, 2016, SCI REP-UK, V6, DOI 10.1038/srep24805
   Nakano-Okuno M, 2014, STEM CELL REV REP, V10, P743, DOI 10.1007/s12015-014-9536-x
   Narayan DS, 2016, ACTA OPHTHALMOL, V94, P748, DOI 10.1111/aos.13141
   Ng TK, 2015, SCI REP-UK, V5, DOI 10.1038/srep16429
   Nicoara SD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1236721
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Palczewski K, 2012, J BIOL CHEM, V287, P1612, DOI 10.1074/jbc.R111.301150
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Reed BT, 2017, CURR ALZHEIMER RES, V14, P6, DOI 10.2174/1567205013666160819131904
   Rezanejad H, 2014, CELL TISSUE RES, V356, P65, DOI 10.1007/s00441-014-1795-y
   Ribot J., 2016, J CELL MOL MED, DOI [10.1111/jcmm.1296927641937, DOI 10.1111/JCMM.1296927641937]
   Roth S, 2016, INVEST OPHTH VIS SCI, V57, P3926, DOI 10.1167/iovs.15-17381a
   Sabapathy V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093726
   Schafer R, 2016, TRANSFUS MED HEMOTH, V43, P256, DOI 10.1159/000447458
   Scheiner ZS, 2014, J BIOL CHEM, V289, P4571, DOI 10.1074/jbc.R113.509588
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seki T, 2015, WORLD J STEM CELLS, V7, P116, DOI 10.4252/wjsc.v7.i1.116
   Semeraro F, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/582060
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Simerman AA, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1463258
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Steinberg GK, 2016, STROKE, V47, P1817, DOI 10.1161/STROKEAHA.116.012995
   Takahashi K, 2013, DEVELOPMENT, V140, P2457, DOI 10.1242/dev.092551
   Tasso R, 2012, INVEST OPHTH VIS SCI, V53, P786, DOI 10.1167/iovs.11-8211
   Trivanovic D, 2015, LIFE SCI, V141, P61, DOI 10.1016/j.lfs.2015.09.019
   Trivino A., 2012, EFFECTS HYPERCHOLEST
   Tzameret A, 2015, STEM CELL RES, V15, P387, DOI 10.1016/j.scr.2015.08.007
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   van Norren D, 2016, EYE, V30, P169, DOI 10.1038/eye.2015.218
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Vossmerbaeumer U, 2009, CYTOTHERAPY, V11, P177, DOI 10.1080/14653240802714819
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Weng YH, 2017, ACTA PHARM SIN B, V7, P281, DOI 10.1016/j.apsb.2016.09.001
   Worthington KS, 2016, BIOMACROMOLECULES, V17, P1684, DOI 10.1021/acs.biomac.6b00098
   Wyse RD, 2014, INT J MOL SCI, V15, P1719, DOI 10.3390/ijms15021719
   Yafai Y, 2014, OPHTHALMIC RES, V52, P81, DOI 10.1159/000362371
   Yu B, 2016, SCI REP-UK, V6, DOI 10.1038/srep34562
   Yuan J, 2016, NEURAL REGEN RES, V11, P846, DOI 10.4103/1673-5374.182764
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zeng X, 2016, J BIOMED MATER RES A, V104, P1902, DOI 10.1002/jbm.a.35720
   Zhang LJ, 2014, INVEST OPHTH VIS SCI, V55, P5561, DOI 10.1167/iovs.14-14788
   Zhao PT, 2016, INT J OPHTHALMOL-CHI, V9, P1381, DOI 10.18240/ijo.2016.10.03
   Zhao Q, 2016, J CELL IMMUNOTHER, V2, P3, DOI DOI 10.1016/J.JOCIT.2014.12.001
NR 113
TC 49
Z9 49
U1 2
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2017
VL 18
IS 8
AR 1406
DI 10.3390/ijms18081406
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF4HB
UT WOS:000408897400001
PM 28788088
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Yamaguchi, M
   Nakao, S
   Arima, M
   Wada, I
   Kaizu, Y
   Hao, F
   Yoshida, S
   Sonoda, KH
AF Yamaguchi, Muneo
   Nakao, Shintaro
   Arima, Mitsuru
   Wada, Iori
   Kaizu, Yoshihiro
   Hao, Feng
   Yoshida, Shigeo
   Sonoda, Koh-hei
TI Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; INHIBITOR RIPASUDIL K-115; DIABETIC MACULAR
   EDEMA; ROCK INHIBITOR; PROLIFERATIVE VITREORETINOPATHY; RETINAL
   NEOVASCULARIZATION; INTRAOCULAR-PRESSURE; THERAPEUTIC TARGET; KEY ROLE;
   IN-VIVO
AB Rho-associated kinase (Rho-kinase/ROCK) was originally identified as an effector protein of the G protein Rho. Its involvement in various diseases, particularly cancer and cardiovascular disease, has been elucidated, and ROCK inhibitors have already been applied clinically for cerebral vasospasm and glaucoma. Vitreoretinal diseases including diabetic retinopathy, age-related macular degeneration, and proliferative vitreoretinoapthy are still a major cause of blindness. While anti-VEGF therapy has recently been widely used for vitreoretinal disorders due to its efficacy, attention has been drawn to new unmet needs. The importance of ROCK in pathological vitreoretinal conditions has also been elucidated and is attracting attention as a potential therapeutic target. ROCK is involved in angiogenesis and hyperpermeability and also in the pathogenesis of various pathologies such as inflammation and fibrosis. It has been expected that ROCK inhibitors will become new molecular target drugs for vitreoretinal diseases. This review summarizes the recent progress on the mechanisms of action of ROCK and their applications in disease treatment.
C1 [Yamaguchi, Muneo; Nakao, Shintaro; Arima, Mitsuru; Wada, Iori; Kaizu, Yoshihiro; Hao, Feng; Yoshida, Shigeo; Sonoda, Koh-hei] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Nakao, S (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM snakao@med.kyushu-u.ac.jp
OI Yoshida, Shigeo/0000-0003-1049-8909
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Ahmadieh H, 2013, JAMA OPHTHALMOL, V131, P923, DOI 10.1001/jamaophthalmol.2013.143
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arita R, 2013, INVEST OPHTH VIS SCI, V54, P2373, DOI 10.1167/iovs.12-10757
   Arita R, 2009, DIABETES, V58, P215, DOI 10.2337/db08-0762
   Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Enaida Hiroshi, 2010, Ophthalmic Surg Lasers Imaging, V41 Online, pe1, DOI 10.3928/15428877-20101124-11
   Fang XY, 2011, CURR EYE RES, V36, P1028, DOI 10.3109/02713683.2011.593110
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Futakuchi A, 2016, EXP EYE RES, V149, P107, DOI 10.1016/j.exer.2016.07.001
   Hata Y, 2008, JPN J OPHTHALMOL, V52, P16, DOI 10.1007/s10384-007-0487-5
   Hirata A, 2008, GRAEF ARCH CLIN EXP, V246, P51, DOI 10.1007/s00417-007-0666-6
   Hollanders K, 2017, CURR EYE RES, V42, P260, DOI 10.1080/02713683.2016.1183030
   Hollanders K, 2015, INVEST OPHTH VIS SCI, V56, P1335, DOI 10.1167/iovs.14-15681
   Honjo M, 2001, INVEST OPHTH VIS SCI, V42, P137
   Hwang J. C., 2011, OPHTHAL SURG LAS IM, V42, P6
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x
   Isobe T, 2014, CURR EYE RES, V39, P813, DOI 10.3109/02713683.2013.874444
   Itoh Y, 2007, EXP EYE RES, V84, P464, DOI 10.1016/j.exer.2006.10.017
   Jain RK, 2013, J CLIN ONCOL, V31, P2205, DOI 10.1200/JCO.2012.46.3653
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Kita T, 2007, DIABETES, V56, P231, DOI 10.2337/db06-0581
   Kitaoka Y, 2004, BRAIN RES, V1018, P111, DOI 10.1016/j.brainres.2004.05.070
   Kon CH, 1999, INVEST OPHTH VIS SCI, V40, P705
   Kroll J, 2009, AM J PHYSIOL-HEART C, V296, pH893, DOI 10.1152/ajpheart.01038.2008
   Lee J, 2008, J CELL PHYSIOL, V216, P520, DOI 10.1002/jcp.21424
   Leung T, 1996, MOL CELL BIOL, V16, P5313
   Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23
   Lutty GA, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12979
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Masumoto A, 2002, CIRCULATION, V105, P1545, DOI 10.1161/hc1002.105938
   Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x
   Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021
   Mckenzie JAG, 2007, J CELL PHYSIOL, V213, P221, DOI 10.1002/jcp.21114
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Miura M, 2006, EXP EYE RES, V82, P849, DOI 10.1016/j.exer.2005.09.024
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Moysidis SN, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/815937
   Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719
   Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Murata T, 1996, LAB INVEST, V74, P819
   Nagaoka T, 2007, INVEST OPHTH VIS SCI, V48, P825, DOI 10.1167/iovs.06-0856
   Nakabayashi S, 2015, EXP EYE RES, V139, P132, DOI 10.1016/j.exer.2015.07.008
   Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3
   Nakao S, 2013, RETINA-J RET VIT DIS, V33, P957, DOI 10.1097/IAE.0b013e3182753b41
   Nakao S, 2012, NUTRITIONAL AND THERAPEUTIC INTERVENTIONS FOR DIABETES AND METABOLIC SYNDROME, P159, DOI 10.1016/B978-0-12-385083-6.00013-9
   Nakao S, 2012, INVEST OPHTH VIS SCI, V53, P4323, DOI 10.1167/iovs.11-9119
   Newman DK, 2010, EYE, V24, P441, DOI 10.1038/eye.2009.325
   Noda K, 2014, FASEB J, V28, P2038, DOI 10.1096/fj.12-215715
   Noda K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/279037
   Nourinia Ramin, 2013, J Ophthalmic Vis Res, V8, P337
   Nwariaku FE, 2003, J APPL PHYSIOL, V95, P1889, DOI 10.1152/japplphysiol.00225.2003
   PEER J, 1995, LAB INVEST, V72, P638
   Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127
   Ross EL, 2016, JAMA OPHTHALMOL, V134, P888, DOI 10.1001/jamaophthalmol.2016.1669
   RYAN SJ, 1985, AM J OPHTHALMOL, V100, P188, DOI 10.1016/S0002-9394(14)75004-4
   Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   SHIBUYA M, 1992, J NEUROSURG, V76, P571, DOI 10.3171/jns.1992.76.4.0571
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Shimokawa H, 2005, ARTERIOSCL THROM VAS, V25, P1767, DOI 10.1161/01.ATV.0000176193.83629.c8
   Shimokawa H, 2002, J CARDIOVASC PHARM, V39, P319, DOI 10.1097/00005344-200203000-00001
   Sivaprasad S, 2012, SURV OPHTHALMOL, V57, P347, DOI 10.1016/j.survophthal.2012.01.004
   Song HS, 2011, INT J MOL MED, V28, P193, DOI 10.3892/ijmm.2011.659
   Sun HR, 2006, MICROCIRCULATION, V13, P237, DOI 10.1080/10739680600556944
   Tanihara H, 2015, JAMA OPHTHALMOL, V133, P755, DOI 10.1001/jamaophthalmol.2015.0525
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   WIEDEMANN P, 1984, J PHARMACOL METHOD, V12, P69, DOI 10.1016/0160-5402(84)90008-1
   WOLTER JR, 1961, AM J OPHTHALMOL, V51, P1123
   Yamaguchi M, 2016, INVEST OPHTH VIS SCI, V57, P2264, DOI 10.1167/iovs.15-17411
   Yamamoto K, 2014, INVEST OPHTH VIS SCI, V55, P7126, DOI 10.1167/iovs.13-13842
   Yokota T, 2007, JPN J OPHTHALMOL, V51, P424, DOI 10.1007/s10384-007-0471-0
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zheng YP, 2004, INVEST OPHTH VIS SCI, V45, P668, DOI 10.1167/iovs.02-0808
NR 89
TC 18
Z9 18
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2017
VL 2017
AR 8543592
DI 10.1155/2017/8543592
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2QY
UT WOS:000402342300001
PM 28596919
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Morooka, S
   Hoshina, M
   Kii, I
   Okabe, T
   Kojima, H
   Inoue, N
   Okuno, Y
   Denawa, M
   Yoshida, S
   Fukuhara, J
   Ninomiya, K
   Ikura, T
   Furuya, T
   Nagano, T
   Noda, K
   Ishida, S
   Hosoya, T
   Ito, N
   Yoshimura, N
   Hagiwara, M
AF Morooka, Satoshi
   Hoshina, Mitsuteru
   Kii, Isao
   Okabe, Takayoshi
   Kojima, Hirotatsu
   Inoue, Naoko
   Okuno, Yukiko
   Denawa, Masatsugu
   Yoshida, Suguru
   Fukuhara, Junichi
   Ninomiya, Kensuke
   Ikura, Teikichi
   Furuya, Toshio
   Nagano, Tetsuo
   Noda, Kousuke
   Ishida, Susumu
   Hosoya, Takamitsu
   Ito, Nobutoshi
   Yoshimura, Nagahisa
   Hagiwara, Masatoshi
TI Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates
   Pathological Angiogenesis of Macular Degeneration in Mice
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID PROTEIN-KINASE CK2; ENDOTHELIAL-CELLS; CASEIN KINASE-2; MAP KINASE;
   VEGF; PHOSPHORYLATION; MACROPHAGE; EXPRESSION; CANCER;
   NEOVASCULARIZATION
AB Excessive angiogenesis contributes to numerous diseases, including cancer and blinding retinopathy. Antibodies against vascular endothelial growth factor (VEGF) have been approved and are widely used in clinical treatment. Our previous studies using SRPIN340, a small molecule inhibitor of SRPK1 (serine-arginine protein kinase 1), demonstrated that SRPK1 is a potential target for the development of antiangiogenic drugs. In this study, we solved the structure of SRPK1 bound to SRPIN340 by X-ray crystallography. Using pharmacophore docking models followed by in vitro kinase assays, we screened a large-scale chemical library, and thus identified a new inhibitor of SRPK1. This inhibitor, SRPIN803, prevented VEGF production more effectively than SRPIN340 owing to the dual inhibition of SRPK1 and CK2 (casein kinase 2). In a mouse model of age-related macular degeneration, topical administration of eye ointment containing SRPIN803 significantly inhibited choroidal neovascularization, suggesting a clinical potential of SRPIN803 as a topical ointment for ocular neovascularization. Thus SRPIN803 merits further investigation as a novel inhibitor of VEGF.
C1 [Morooka, Satoshi; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068501, Japan.
   [Morooka, Satoshi; Kii, Isao; Ninomiya, Kensuke; Hagiwara, Masatoshi] Kyoto Univ, Grad Sch Med, Dept Anat & Dev Biol, Kyoto 6068501, Japan.
   [Okuno, Yukiko; Denawa, Masatsugu] Kyoto Univ, Grad Sch Med, Med Res Support Ctr, Kyoto 6068501, Japan.
   [Hoshina, Mitsuteru; Ikura, Teikichi; Ito, Nobutoshi] Tokyo Med & Dent Univ, Med Res Inst, Struct Biol Lab, Tokyo, Japan.
   [Yoshida, Suguru; Hosoya, Takamitsu] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Lab Chem Biosci, Tokyo, Japan.
   [Okabe, Takayoshi; Kojima, Hirotatsu; Nagano, Tetsuo] Univ Tokyo, Open Innovat Ctr Drug Discovery, Tokyo, Japan.
   [Inoue, Naoko; Furuya, Toshio] PharmaDesign Inc, Tokyo, Japan.
   [Fukuhara, Junichi; Noda, Kousuke; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Sapporo, Hokkaido, Japan.
C3 Kyoto University; Kyoto University; Kyoto University; Tokyo Medical &
   Dental University (TMDU); Tokyo Medical & Dental University (TMDU);
   University of Tokyo; Hokkaido University
RP Hagiwara, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Anat & Dev Biol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.
EM hagiwara.masatoshi.8c@kyoto-u.ac.jp
RI Hosoya, Takamitsu/N-7762-2015; Ikura, Teikichi/T-5912-2019; KII,
   Isao/C-4117-2017; Ikura, Teikichi/N-1490-2015
OI Hosoya, Takamitsu/0000-0002-7270-351X; KII, Isao/0000-0002-6153-6250;
   Ikura, Teikichi/0000-0003-2377-5434; Yoshida,
   Suguru/0000-0001-5888-9330; Denawa, Masatsugu/0000-0001-5808-8197
CR Aguilar E, 2008, METHOD ENZYMOL, V444, P115, DOI 10.1016/S0076-6879(08)02806-1
   Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Daub H, 2002, J VIROL, V76, P8124, DOI 10.1128/JVI.76.16.8124-8137.2002
   De Moliner E, 2003, J BIOL CHEM, V278, P1831, DOI 10.1074/jbc.M209367200
   Dong ZY, 2013, MOL VIS, V19, P536
   Dulak J, 2008, CIRCULATION, V117, P231, DOI 10.1161/CIRCULATIONAHA.107.698316
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Feng DL, 2012, ANGIOGENESIS, V15, P243, DOI 10.1007/s10456-012-9256-2
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fitzgerald CE, 2003, NAT STRUCT BIOL, V10, P764, DOI 10.1038/nsb949
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103
   Gammons MV, 2014, BRIT J CANCER, V111, P477, DOI 10.1038/bjc.2014.342
   Gammons MVR, 2013, INVEST OPHTH VIS SCI, V54, P5797, DOI 10.1167/iovs.13-11634
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hu SI, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002466
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kramerov AA, 2008, MOL CELL BIOCHEM, V316, P177, DOI 10.1007/s11010-008-9831-4
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469
   Ljubimov AV, 2004, INVEST OPHTH VIS SCI, V45, P4583, DOI 10.1167/iovs.04-0686
   Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev
   MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066
   Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Mylonis I, 2003, BIOCHEM BIOPH RES CO, V301, P650, DOI 10.1016/S0006-291X(02)03055-3
   Ngo JCK, 2007, STRUCTURE, V15, P123, DOI 10.1016/j.str.2006.11.011
   Ngo JCK, 2005, MOL CELL, V20, P77, DOI 10.1016/j.molcel.2005.08.025
   Nikolakaki E, 2008, BBA-GEN SUBJECTS, V1780, P214, DOI 10.1016/j.bbagen.2007.10.014
   Nishida A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1306
   Nolen B, 2003, BIOCHEMISTRY-US, V42, P9575, DOI 10.1021/bi0344331
   Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930
   Noy P, 2012, NUCLEIC ACIDS RES, V40, P9008, DOI 10.1093/nar/gks687
   Noy P, 2012, LEUKEMIA RES, V36, P1434, DOI 10.1016/j.leukres.2012.07.013
   Ogawa Y, 2012, PHARMACOL THERAPEUT, V134, P298, DOI 10.1016/j.pharmthera.2012.02.001
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Olsten MEK, 2004, BIOCHEM CELL BIOL, V82, P681, DOI 10.1139/O04-116
   PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X
   Pollreisz A, 2013, EXP EYE RES, V116, P177, DOI 10.1016/j.exer.2013.08.021
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Wang PP, 2014, MOL CELL, V54, P378, DOI 10.1016/j.molcel.2014.03.007
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470
   Xu J, 2008, J CELL MOL MED, V12, P2395, DOI 10.1111/j.1582-4934.2008.00266.x
   Xue YF, 2013, CHEMMEDCHEM, V8, P1846, DOI 10.1002/cmdc.201300274
NR 64
TC 29
Z9 31
U1 1
U2 26
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD AUG
PY 2015
VL 88
IS 2
BP 316
EP 325
DI 10.1124/mol.114.097345
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CL6QR
UT WOS:000357092600011
PM 25993998
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Stanzel, BV
   Liu, ZP
   Somboonthanakij, S
   Wongsawad, W
   Brinken, R
   Eter, N
   Corneo, B
   Holz, FG
   Temple, S
   Stern, JH
   Blenkinsop, TA
AF Stanzel, Boris V.
   Liu, Zengping
   Somboonthanakij, Sudawadee
   Wongsawad, Warapat
   Brinken, Ralf
   Eter, Nicole
   Corneo, Barbara
   Holz, Frank G.
   Temple, Sally
   Stern, Jeffrey H.
   Blenkinsop, Timothy A.
TI Human RPE Stem Cells Grown into Polarized RPE Monolayers on a Polyester
   Matrix Are Maintained after Grafting into Rabbit Subretinal Space
SO STEM CELL REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; IMMUNE-RESPONSE;
   TRANSPLANTATION; MODEL; IMMUNOSUPPRESSION; IMPLANTATION; XENOGRAFTS;
   GENERATION; DETACHMENT
AB Transplantation of the retinal pigment epithelium (RPE) is being developed as a cell- replacement therapy for age-related macular degeneration. Human embryonic stem cell (hESC) and induced pluripotent stem cell (iPSC)-derived RPE are currently translating toward clinic. We introduce the adult human RPE stem cell (hRPESC) as an alternative RPE source. Polarized monolayers of adult hRPESC-derived RPE grown on polyester (PET) membranes had near-native characteristics. Trephined pieces of RPE monolayers on PET were transplanted subretinally in the rabbit, a large-eyed animal model. After 4 days, retinal edema was observed above the implant, detected by spectral domain optical coherence tomography (SD-OCT) and fundoscopy. At 1 week, retinal atrophy overlying the fetal or adult transplant was observed, remaining stable thereafter. Histology obtained 4 weeks after implantation confirmed a continuous polarized human RPE monolayer on PET. Taken together, the xeno-RPE survived with retained characteristics in the subretinal space. These experiments support that adult hRPESC-derived RPE are a potential source for transplantation therapies.
C1 [Stanzel, Boris V.; Liu, Zengping; Somboonthanakij, Sudawadee; Wongsawad, Warapat; Brinken, Ralf; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Somboonthanakij, Sudawadee; Wongsawad, Warapat] Mettapracharak Eye Inst, Raikhing 73210, Nakhon Pathom, Thailand.
   [Eter, Nicole] Univ Munster, Dept Ophthalmol, D-48149 Munster, Germany.
   [Corneo, Barbara; Temple, Sally; Stern, Jeffrey H.; Blenkinsop, Timothy A.] Neural Stem Cell Inst, Rensselaer, NY 12144 USA.
C3 University of Bonn; University of Munster
RP Stanzel, BV (通讯作者)，Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
EM stanzel@uni-bonn.de
RI Liu, Zengping/GQO-9030-2022; Stanzel, Boris/AAG-7010-2022; Stanzel,
   Boris/ADP-9221-2022
OI Stanzel, Boris/0000-0002-4316-1539; Stanzel, Boris/0000-0002-4316-1539;
   Corneo, Barbara/0000-0001-5189-6749; Liu, Zengping/0000-0002-2578-293X
FU BONFOR/Gerok Scholarships [O-137.0015]; Ruediger Foundation grants;
   State Scholarship Fund/Chinese Scholarship Council [2008627116]; NIH -
   National Eye Institute [5R01EY022079-02]; NYSDOH contract - Empire State
   Stem Cell Fund [C028504]; NATIONAL EYE INSTITUTE [R01EY022079] Funding
   Source: NIH RePORTER
FX This work was supported by BONFOR/Gerok Scholarships O-137.0015 (to
   B.V.S.), Ruediger Foundation grants (to B.V.S.), State Scholarship
   Fund/Chinese Scholarship Council 2008627116 (to Z.L.), NIH - National
   Eye Institute 5R01EY022079-02 (to S.T.), and NYSDOH contract C028504 (to
   S.T. and J.H.S.) supported by the Empire State Stem Cell Fund. Opinions
   expressed here are solely those of the authors and do not necessarily
   reflect those of the National Institutes of Health, Empire State Stem
   Cell Board, the New York State Department of Health, or the state of New
   York. A European patent application on the shooter instrument was
   submitted by B.V.S., Z.L., R.B., N.E. and F.G.H. (PCT/EP2012/ 058083).
   S.T. and J.H.S. have a granted US patent on aRPESC (application number
   12/428,456). This paper was presented in part at the 20th ISER meeting
   in July 2012 and the 3rd TERMIS World congress in September 2012. C.
   Strack assisted with histologic processing, and J. Bedorf at the
   Institute of Pathology, University of Bonn was very helpful in obtaining
   transmission electron micro-graphs. Dr. Andrea Lohmer of HET facility,
   University Clinics Bonn, Bonn, Germany is gratefully acknowledged for
   her veterinarian services. N. Braun of Geuder AG Heidelberg, Germany
   provided support for instrumentation used in rabbits. We thank Carol
   Charniga for invaluable help with RPE dissections and culture
   maintenance.
CR Abe T, 1999, TOHOKU J EXP MED, V189, P179, DOI 10.1620/tjem.189.179
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Enzmann V, 2000, CURR EYE RES, V21, P530, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT530
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P326, DOI 10.1007/s004170050240
   HE SK, 1994, CURR EYE RES, V13, P257, DOI 10.3109/02713689408995786
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu J, 2001, MOL VIS, V7, P14
   Huang JC, 1998, CURR EYE RES, V17, P573, DOI 10.1076/ceyr.17.6.573.5184
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Jeklova E, 2008, VET IMMUNOL IMMUNOP, V122, P231, DOI 10.1016/j.vetimm.2007.11.011
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   Kearns V, 2012, J MATER SCI-MATER M, V23, P2013, DOI 10.1007/s10856-012-4675-6
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lai CC, 2000, INVEST OPHTH VIS SCI, V41, P3134
   Lai JY, 2009, INT J MOL SCI, V10, P3442, DOI 10.3390/ijms10083442
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu ZP, 2013, INVEST OPHTH VIS SCI, V54
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Peng SM, 2011, INVEST OPHTH VIS SCI, V52, P1392, DOI 10.1167/iovs.10-5984
   Philp NJ, 1998, AM J PHYSIOL-REG I, V274, pR1824, DOI 10.1152/ajpregu.1998.274.6.R1824
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rezai KA, 2000, GRAEF ARCH CLIN EXP, V238, P352, DOI 10.1007/s004170050364
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Stanzel B. V., 2012, OPHTHALMIC SURG PRIN
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Szurman P, 2006, INVEST OPHTH VIS SCI, V47, P4983, DOI 10.1167/iovs.06-0491
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   VERSTRAETEN TC, 1993, ARCH OPHTHALMOL-CHIC, V111, P849, DOI 10.1001/archopht.1993.01090060139038
   Wang F, 2002, ACTA BIOCH BIOPH SIN, V34, P643
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 53
TC 115
Z9 118
U1 0
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD JAN 14
PY 2014
VL 2
IS 1
BP 64
EP 77
DI 10.1016/j.stemcr.2013.11.005
PG 14
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AI1XA
UT WOS:000336647300008
PM 24511471
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Plisek, J
   Krcmova, LK
   Aufartova, J
   Morales, TV
   Esponda, SM
   Oros, R
   Kasalova, E
   Santana-Rodriguez, JJ
   Sobotka, L
   Solich, P
   Solichova, D
AF Plisek, Jiri
   Krcmova, Lenka Kujovska
   Aufartova, Jana
   Morales, Tanausu V.
   Esponda, Sarah M.
   Oros, Roman
   Kasalova, Eva
   Santana-Rodriguez, Jose J.
   Sobotka, Lubos
   Solich, Petr
   Solichova, Dagmar
TI New approach for the clinical monitoring of 25-hydroxyvitamin D-3 and
   25-hydroxyvitamin D-2 by ultra high performance liquid chromatography
   with MS/MS based on the standard reference material 972
SO JOURNAL OF SEPARATION SCIENCE
LA English
DT Article
DE Clinical research; Mass spectrometry; Standard reference material 972;
   Vitamin D
ID TANDEM MASS-SPECTROMETRY; VITAMIN-D; DIASORIN LIAISON; HUMAN PLASMA;
   LC-MS/MS; QUANTIFICATION; EXTRACTION; SERUM; METABOLITES; ASSAY
AB Biomarkers, 25-hydroxyvitamin D-3 and 25-hydroxyvitamin D-2, are important indicators of the vitamin D general status and are monitored in several pathophysiological disorders, such as osteoporosis, diabetes, heart disease, etc. A novel ultra-HPLC with MS/MS methodology for the analysis of 25-hydroxyvitamin D derivatives coupled with a very simple and highly rapid sample preparation step was developed. Analytical parameters obtained showed linearity (R-2) above 0.999 for both vitamins with accuracies between 95.8 and 102%. The LODs were as low as 0.22 and 0.67 nmol/L for 25-hydroxyvitamin D-3 and 25-hydroxyvitamin D-2, respectively. Intra-assay precision (%RSD) was lower than 4.5%, and inter-assay precision (%RSD) was lower than 6.5%. The feasibility of the developed methodology to be applied in clinical routine analysis has been proved by its application in blood samples from non-agenarian patients, patients with familial hypercholesterolemia and patients suffering from age-related macular degeneration.
C1 [Plisek, Jiri; Krcmova, Lenka Kujovska; Aufartova, Jana; Kasalova, Eva; Solich, Petr] Charles Univ Prague, Fac Pharm, Dept Analyt Chem, CS-50165 Hradec Kralove, Czech Republic.
   [Plisek, Jiri; Krcmova, Lenka Kujovska; Aufartova, Jana; Kasalova, Eva; Sobotka, Lubos; Solichova, Dagmar] Univ Hosp, Internal Gerontometabol Clin 3, Hradec Kralove 50005, Czech Republic.
   [Morales, Tanausu V.; Esponda, Sarah M.; Santana-Rodriguez, Jose J.] Univ Las Palmas Gran Canaria, Dept Chem, Las Palmas De Gc, Spain.
   [Oros, Roman] Shimadzu Austria, Korneuburg, Austria.
C3 Charles University Prague; Universidad de Las Palmas de Gran Canaria
RP Krcmova, LK (通讯作者)，Univ Hosp, Internal Gerontometabol Clin 3, Sokolska 581, Hradec Kralove 50005, Czech Republic.
EM LenkaKrcmova@seznam.cz
RI Sobotka, Lubos/V-2620-2017; RODRIGUEZ, JOSE JUAN SANTANA/M-6268-2014;
   Montesdeoca-Esponda, Sarah/I-9943-2018; Solich, Petr/B-1851-2009;
   Kujovska Krcmova, Lenka/S-7188-2017
OI Sobotka, Lubos/0000-0002-0372-5790; RODRIGUEZ, JOSE JUAN
   SANTANA/0000-0002-5635-7215; Montesdeoca-Esponda,
   Sarah/0000-0001-9872-5293; Solich, Petr/0000-0003-4611-2051; Kujovska
   Krcmova, Lenka/0000-0003-3825-0294
FU Charles University in Prague [SVV 2013-267-002]; project (Ministry of
   Health, Czech Republic) for conceptual development of research
   organisation MH-CZ-DRO (UHHK) [00179906]; European Social Fund; state
   budget of the Czech Republic [CZ.1.07/2.3.00/30.0061]; IGA Ministry of
   Health, Czech Republic [NT/14265-3/2013, PRVOUK P37/12]
FX The authors gratefully acknowledge Prof. MUDr. Milan Blaha CSc. Boena
   Jurakova, Ph.D. for the clinical samples and Shimadzu Austria (Laaer
   Strasse 7-9, 2100 Korneuburg, Austria) for the technical support. The
   authors also acknowledge the financial support of Charles University in
   Prague - Project SVV 2013-267-002, project (Ministry of Health, Czech
   Republic) for conceptual development of research organisation MH-CZ-DRO
   (UHHK, 00179906), the European Social Fund and the state budget of the
   Czech Republic (Project no. CZ.1.07/2.3.00/30.0061) and IGA Ministry of
   Health, Czech Republic NT/14265-3/2013 and PRVOUK P37/12.
CR Adamec J, 2011, J SEP SCI, V34, P11, DOI 10.1002/jssc.201000410
   Bianchi S, 2012, CLIN BIOCHEM, V45, P1652, DOI 10.1016/j.clinbiochem.2012.08.003
   BLIESNER D, 2006, VALIDATING CHROMATOG
   Bruce SJ, 2013, RAPID COMMUN MASS SP, V27, P200, DOI 10.1002/rcm.6439
   Bunch DR, 2009, CLIN CHEM LAB MED, V47, P1565, DOI 10.1515/CCLM.2009.342
   Chen HP, 2008, CLIN CHIM ACTA, V391, P6, DOI 10.1016/j.cca.2008.01.017
   Combs G.F., 2008, VITAMINS FUNDAMENTAL, V3rd
   de Koning L, 2013, CLIN CHIM ACTA, V415, P54, DOI 10.1016/j.cca.2012.09.002
   El-Khoury JM, 2011, CLIN BIOCHEM, V44, P66, DOI 10.1016/j.clinbiochem.2010.05.007
   Higashi T, 2003, ANAL SCI, V19, P941, DOI 10.2116/analsci.19.941
   Higashi T, 2008, ANAL BIOANAL CHEM, V391, P229, DOI 10.1007/s00216-007-1780-3
   Higashi T, 2011, J SEP SCI, V34, P725, DOI 10.1002/jssc.201000911
   Hojskov CS, 2010, CLIN CHIM ACTA, V411, P114, DOI 10.1016/j.cca.2009.10.010
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holmoy T, 2009, MULT SCLER, V15, P1280, DOI 10.1177/1352458509107008
   Kamao M, 2007, J CHROMATOGR B, V859, P192, DOI 10.1016/j.jchromb.2007.09.023
   Knox S, 2009, ANN CLIN BIOCHEM, V46, P226, DOI 10.1258/acb.2009.008206
   Kulie T, 2009, J AM BOARD FAM MED, V22, P698, DOI 10.3122/jabfm.2009.06.090037
   Maunsell Z, 2005, CLIN CHEM, V51, P1683, DOI 10.1373/clinchem.2005.052936
   Norman AW, 2007, J STEROID BIOCHEM, V103, P204, DOI 10.1016/j.jsbmb.2006.12.071
   Phinney KW, 2008, AM J CLIN NUTR, V88, p511S, DOI 10.1093/ajcn/88.2.511S
   Priego Capote F., 2007, MASS SPECTROM, V21, P1745
   Saenger AK, 2006, AM J CLIN PATHOL, V125, P914, DOI 10.1309/J32UF7GTQPWN25AP
   Singh RJ, 2006, J CLIN ENDOCR METAB, V91, P3055, DOI 10.1210/jc.2006-0710
   Strobel N, 2013, FOOD CHEM, V138, P1042, DOI 10.1016/j.foodchem.2012.08.041
   Thibeault D, 2012, J CHROMATOGR B, V883, P120, DOI 10.1016/j.jchromb.2011.12.021
   Tsugawa N, 2005, ANAL CHEM, V77, P3001, DOI 10.1021/ac048249c
   Vogeser M, 2004, CLIN CHEM, V50, P1415, DOI 10.1373/clinchem.2004.031831
   Wang SH, 2009, NUTR RES REV, V22, P188, DOI 10.1017/S0954422409990151
NR 29
TC 9
Z9 9
U1 0
U2 44
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1615-9306
EI 1615-9314
J9 J SEP SCI
JI J. Sep. Sci.
PD DEC
PY 2013
VL 36
IS 23
BP 3702
EP 3708
DI 10.1002/jssc.201300553
PG 7
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 259WF
UT WOS:000327556300008
PM 24123838
DA 2022-11-30
ER

PT J
AU Juel, HB
   Kaestel, C
   Folkersen, L
   Faber, C
   Heegaard, NHH
   Borup, R
   Nissen, MH
AF Juel, Helene B.
   Kaestel, Charlotte
   Folkersen, Lasse
   Faber, Carsten
   Heegaard, Niels H. H.
   Borup, Rehannah
   Nissen, Mogens H.
TI Retinal pigment epithelial cells upregulate expression of complement
   factors after co-culture with activated T cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE complement; retinal pigment epithelium; T cells; age-related macular
   degeneration; uveitis
ID C-REACTIVE PROTEIN; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   FACTOR-H; IMMUNE PRIVILEGE; CILIARY BODY; FACTOR B; INFLAMMATION;
   MARKERS; DYSFUNCTION
AB In this study we examined the effect of T cell-derived cytokines on retinal pigment epithelial (RPE) cells with respect to expression of complement components. We used an in vitro co-culture system in which CD3/CD28-activated human T cells were separated from the human RPE cell line (ARPE-19) by a membrane. Differential gene expression in the RPE cells of complement factor genes was identified using gene arrays, and selected gene transcripts were validated by q-RT-PCR. Protein expression was determined by ELISA and immunoblotting. Co-culture with activated T cells increased RPE mRNA and/or protein expression of complement components C3, factors B, H, H-like 1, CD46, CD55, CD59, and clusterin, in a dose-dependent manner. Soluble factors derived from activated T cells are capable of increasing expression of complement components in RPE cells. This is important for the further understanding of inflammatory ocular diseases such as uveitis and age-related macular degeneration. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Juel, Helene B.; Kaestel, Charlotte; Faber, Carsten; Nissen, Mogens H.] Univ Copenhagen, Eye Res Unit, Dept Int Hlth Immunol & Microbiol, DK-2100 Copenhagen, Denmark.
   [Folkersen, Lasse] Karolinska Inst, Dept Med, Stockholm, Sweden.
   [Heegaard, Niels H. H.] Statens Serum Inst, Dept Clin Biochem & Immunol, DK-2300 Copenhagen, Denmark.
   [Borup, Rehannah] Copenhagen Univ Hosp, Rigshosp Microarray Ctr, Copenhagen, Denmark.
C3 University of Copenhagen; Karolinska Institutet; Statens Serum Institut;
   University of Copenhagen
RP Juel, HB (通讯作者)，Univ Copenhagen, Eye Res Unit, Dept Int Hlth Immunol & Microbiol, ISIM 18-3,Blegdamsvej 3, DK-2100 Copenhagen, Denmark.
EM hjuel@sund.ku.dk; charlotte.kaestel@gmail.com; lasse.folkersen@ki.se;
   cfaber@sund.ku.dk; nhe@ssi.dk; rehannah.borup@rh.regionh.dk;
   mhni@sund.ku.dk
RI Nissen, Mogens/B-4825-2008; Faber, Carsten/N-3210-2019; Faber,
   Carsten/I-4150-2013; Juel, Helene/AAD-2843-2020
OI Nissen, Mogens/0000-0001-7729-8667; Faber, Carsten/0000-0002-2517-7270;
   Faber, Carsten/0000-0002-2517-7270; Folkersen,
   Lasse/0000-0003-0708-9530; Juel, Helene B/0000-0002-5763-8545
FU Velux Fonden; Vaern om Synet; Ojenfonden
FX The authors would like to thank Mette Pries, Maja Udsen, Asli Er, and
   Mohammed-Samir Belmaati for excellent technical assistance and Grazyna
   Hahn Poulsen for assistance in preparation of figures. This work was
   funded by grants from Velux Fonden, Vaern om Synet, and Ojenfonden.
CR ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   An EK, 2007, J PROTEOME RES, V6, P1615, DOI 10.1021/pr078003z
   An EY, 2008, MOL VIS, V14, P2292
   An FQ, 2009, INVEST OPHTH VIS SCI, V50, P3778, DOI 10.1167/iovs.08-3264
   ANDERSON DH, 2009, PROG RETIN EYE RES
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   Folkersen L, 2009, BIOINFORMATICS, V25, P1978, DOI 10.1093/bioinformatics/btp279
   Futagami Y, 2007, J IMMUNOL, V178, P6994, DOI 10.4049/jimmunol.178.11.6994
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Ishida K, 2003, OCUL IMMUNOL INFLAMM, V11, P91, DOI 10.1076/ocii.11.2.91.15914
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   LIVERSIDGE J, 1993, CELL IMMUNOL, V149, P315, DOI 10.1006/cimm.1993.1158
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Mahesh SP, 2006, EUR J IMMUNOL, V36, P2128, DOI 10.1002/eji.200635893
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mitchell R, 2003, MOL THER, V8, P674, DOI 10.1016/S1525-0016(03)00215-6
   Montalvo V, 2007, CURR EYE RES, V32, P917, DOI 10.1080/02713680701656343
   R Core Team, 2022, R LANG ENV STAT COMP
   Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011
   REYNOLDS R, 2009, INVEST OPHTHALMOL VI
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Serinsoz E, 2005, AM J TRANSPLANT, V5, P1490, DOI 10.1111/j.1600-6143.2005.00873.x
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001
   Sugita S, 2006, EXP EYE RES, V83, P1459, DOI 10.1016/j.exer.2006.08.005
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Tian J, 2004, PHYSIOL GENOMICS, V17, P170, DOI 10.1152/physiolgenomics.00179.2003
   Usui Y, 2008, EXP EYE RES, V86, P52, DOI 10.1016/j.exer.2007.09.007
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
NR 50
TC 29
Z9 31
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2011
VL 92
IS 3
BP 180
EP 188
DI 10.1016/j.exer.2011.01.003
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 735KV
UT WOS:000288414100004
PM 21255569
DA 2022-11-30
ER

PT J
AU Zou, LH
   Lai, HY
   Zhou, Q
   Xiao, F
AF Zou, Lihui
   Lai, Huiying
   Zhou, Qi
   Xiao, Fei
TI Lasting Controversy on Ranibizumab and Bevacizumab
SO THERANOSTICS
LA English
DT Review
DE Ranibizumab; Bevacizumab; vascular endothelial growth factor (VEGF);
   age-related macular degeneration; angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL
   BEVACIZUMAB; NITRIC-OXIDE; ANGIOGENESIS; PEGAPTANIB; AVASTIN; VEGF;
   NEOVASCULARIZATION; INJECTION
AB Vascular endothelial growth factor (VEGF), an important angiogenic factor that is able to stimulate the proliferation and migration of endothelial cells, is the best-studied hallmark of angiogenesis. Neovascularization is a major cause of age-related macular degeneration (AMD) which is a leading cause of blindness in the elderly population. Specific molecular inhibitors of VEGF have been proved to be useful in the treatment of AMD. Ranibizumab and Bevacizumab are structurally similar to anti-VEGF drugs in the treatment of AMD. Many studies have indicated that Ranibizumab and Bevacizumab are of roughly equal short-term efficacy and safety, Bevacizumab is an attractive alternative to Ranibizumab due to its lower cost. However, only Ranibizumab has received Food and Drug Administration (FDA) approval for the treatment of macular degeneration. More multicenter clinical trials are required to compare the relative efficacy and safety of these two drugs and some progress has been achieved. This review discusses the clinical effectiveness, safety, cost and other practical implications of Ranibizumab and Bevacizumab.
C1 [Zou, Lihui; Xiao, Fei] Beijing Hosp, Beijing Inst Geriatr, Key Lab Geriatr, Beijing 100730, Peoples R China.
   [Zou, Lihui; Xiao, Fei] Minist Hlth, Beijing Inst Geriatr, Beijing 100730, Peoples R China.
   [Lai, Huiying; Xiao, Fei] Minist Hlth, Dept Lab Med, Beijing Hosp, Beijing 100730, Peoples R China.
   [Zhou, Qi] Minist Hlth, Natl Ctr Clin Labs, Beijing 100730, Peoples R China.
C3 Beijing Hospital; Beijing Hospital
RP Xiao, F (通讯作者)，Beijing Hosp, Beijing Inst Geriatr, Key Lab Geriatr, Beijing 100730, Peoples R China.
EM xiaofei@bjhmoh.cn
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Aisenbrey S, 2006, OPHTHALMOLOGY, V245, P941
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Avci B, 2009, INVEST OPHTH VIS SCI, V50, P3438, DOI 10.1167/iovs.08-2871
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Cheng JW, 2011, NEW ENGL J MED, V364, P582, DOI 10.1056/NEJMc1013316
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Fernando NH, 2004, ONCOLOGIST, V9, P11, DOI 10.1634/theoncologist.9-suppl_1-11
   Ferrara DC, 2007, AM J OPHTHALMOL, V144, P864, DOI 10.1016/j.ajo.2007.07.038
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gasperini JL, 2011, BR J OPHTHALMOL
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Kigel B, 2011, BLOOD, V118, P4285, DOI 10.1182/blood-2011-03-341388
   KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   Machalinska A, 2011, J OCUL PHARMACOL TH, V27, P471, DOI 10.1089/jop.2011.0091
   Magdelaine-Beuzelin C, 2010, MABS-AUSTIN, V2, P176, DOI 10.4161/mabs.2.2.11205
   Maragoudakis ME, 2000, GEN PHARMACOL-VASC S, V35, P225, DOI 10.1016/S0306-3623(01)00111-2
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   ORTEGA N, 1999, FRONT BIOSCI, V4, P141
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sassa Y, 2010, CLIN OPHTHALMOL, V4, P275
   Sato T, 2010, OPHTHALMOLOGY, V117, P512, DOI 10.1016/j.ophtha.2009.07.041
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zarbin M, 2007, OPTOMETRY VISION SCI, V84, pE559, DOI 10.1097/OPX.0b013e3180de4dd7
NR 54
TC 27
Z9 27
U1 1
U2 14
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2011
VL 1
BP 395
EP 402
DI 10.7150/thno/v01p0395
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 876PX
UT WOS:000299121000033
PM 22211145
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Jo, DH
   Kim, JH
   Kim, JH
AF Jo, Dong Hyun
   Kim, Jin Hyoung
   Kim, Jeong Hun
TI How to Overcome Retinal Neuropathy: The Fight against
   Angiogenesis-related Blindness
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Review
DE Angiogenesis-related blindness; Age-related macular degeneration;
   Diabetic retinopathy; Retinoblastoma; Retinopathy of prematurity
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; DIABETIC MACULAR
   EDEMA; CLINICAL RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION; OCULAR
   NEOVASCULARIZATION; MONOCLONAL-ANTIBODY; VESSEL MATURATION; BARRIER
   BREAKDOWN; UNITED-STATES
AB The retina consists of neuronal cells of high metabolic activity that are supplied by an abundant vasculature. It is a main theme of ophthalmologic research, because retinopathies are common causes of blindness in all age groups: age-related macular degeneration in the elderly, diabetic retinopathy in the middle aged, and retinopathy of prematurity and retinoblastoma in children. Interestingly, angiogenesis underlies the pathogenesis of all these diseases, and breakdown of the blood-retinal barrier is also thought to play an important role before and throughout the process of new vessel formation. However, so far, most treatments have targeted angiogenesis only, especially vascular endothelial growth factor. Consideration of the restoration of the blood-retinal barrier should be required. In this review, we discuss the clinical manifestation, pathogenesis, and current treatment options for angiogenesis-related blindness. In addition, because of the recent introduction of novel strategies, we describe pathogenesis-based treatment options to treat angiogenesis-related blindness.
C1 [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, FARB Lab, Seoul 110744, South Korea.
   [Jo, Dong Hyun; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU)
RP Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, FARB Lab, Seoul 110744, South Korea.
EM steph25@snu.ac.kr
RI Kim, Jeong Hun/J-2748-2012; Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU MEST [2010-0009050]; MEST/NRF [2010-0020645]
FX This study was supported by Mid-Career Researcher Program (2010-0009050)
   through grant funded by MEST and by the Bio-Signal Analysis Technology
   Innovation Program (2010-0020645) of MEST/NRF.
CR Abcouwer SF, 2008, INVEST OPHTH VIS SCI, V49, P5581, DOI 10.1167/iovs.07-1032
   Abramson DH, 2004, RETINA-J RET VIT DIS, V24, P828, DOI 10.1097/00006982-200412000-00002
   ABRAN D, 1995, AM J PHYSIOL-HEART C, V268, pH628, DOI 10.1152/ajpheart.1995.268.2.H628
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Beutel J, 2009, EXPERT OPIN EMERG DR, V14, P341, DOI [10.1517/14728210902824141, 10.1517/14728210902824141 ]
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Davidson JA, 2007, ENDOCRINE, V32, P107, DOI 10.1007/s12020-007-0040-9
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Good WV, 2005, PEDIATRICS, V116, P15, DOI 10.1542/peds.2004-1413
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1087, DOI 10.1016/j.ophtha.2009.10.040
   Heidary G, 2009, SEMIN OPHTHALMOL, V24, P77, DOI 10.1080/08820530902800314
   Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hubbard GB, 2008, CURR OPIN OPHTHALMOL, V19, P384, DOI 10.1097/ICU.0b013e328309f1a5
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joussen AM, 2009, MOL VIS, V15, P1418
   Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje
   Kaiser PK, 2009, BRIT J OPHTHALMOL, V93, P135, DOI 10.1136/bjo.2008.144071
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kim JH, 2008, J CELL MOL MED, V12, P2407, DOI 10.1111/j.1582-4934.2008.00243.x
   Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339
   Kim JH, 2009, MOL PHARMACEUT, V6, P513, DOI 10.1021/mp800178b
   Kim JH, 2010, AM J PATHOL, V176, P1517, DOI 10.2353/ajpath.2010.090398
   Kim JH, 2004, OPHTHAL SURG LAS IM, V35, P446, DOI 10.3928/1542-8877-20041101-03
   Kim JH, 2009, J CEREBR BLOOD F MET, V29, P1559, DOI 10.1038/jcbfm.2009.78
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, EXP EYE RES, V63, P511, DOI 10.1006/exer.1996.0141
   Lee SY, 2008, ARCH OPHTHALMOL-CHIC, V126, P953, DOI 10.1001/archopht.126.7.953
   Lin P, 2009, AM J OPHTHALMOL, V148, P192, DOI 10.1016/j.ajo.2009.04.004
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mantagos IS, 2009, SEMIN OPHTHALMOL, V24, P82, DOI 10.1080/08820530902800322
   Mintz-Hittner HA, 2010, J AAPOS, V14, P2, DOI 10.1016/j.jaapos.2009.12.002
   Miyamoto N, 2008, OPHTHALMIC RES, V40, P203, DOI 10.1159/000119877
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Oh SH, 2007, J NATL CANCER I, V99, P949, DOI 10.1093/jnci/djm007
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   PALMER EA, 1991, OPHTHALMOLOGY, V98, P1628
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pina Y, 2009, INVEST OPHTH VIS SCI, V50, P1020, DOI 10.1167/iovs.08-2654
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Quiram PA, 2007, CURR OPIN OPHTHALMOL, V18, P228, DOI 10.1097/ICU.0b013e3281107fd3
   Repka MX, 2006, ARCH OPHTHALMOL-CHIC, V124, P24, DOI 10.1001/archopht.124.1.24
   Ricart AD, 2008, CLIN CANCER RES, V14, P7924, DOI 10.1158/1078-0432.CCR-08-0378
   Rishi Ekta, 2009, Retina, V29, P284, DOI 10.1097/IAE.0b013e31818a1ee7
   Sapieha P, 2010, INT J BIOCHEM CELL B, V42, P5, DOI 10.1016/j.biocel.2009.10.006
   Sato T, 2009, OPHTHALMOLOGY, V116, P2165, DOI 10.1016/j.ophtha.2009.04.026
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Sfikakis PP, 2005, DIABETES CARE, V28, P445, DOI 10.2337/diacare.28.2.445
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHIELDS CL, 1993, BRIT J OPHTHALMOL, V77, P544, DOI 10.1136/bjo.77.9.544
   SHIELDS CL, 1994, CANCER, V73, P692, DOI 10.1002/1097-0142(19940201)73:3<692::AID-CNCR2820730331>3.0.CO;2-8
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Slakter Jason S, 2006, Ophthalmol Clin North Am, V19, P373
   Smiddy WE, 1999, SURV OPHTHALMOL, V43, P491, DOI 10.1016/S0039-6257(99)00036-3
   Stitt AW, 1998, J PATHOL, V186, P306, DOI 10.1002/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   TIAN N, 2004, VISION RES, V44, P3307
   Tolentino MJ, 2009, CURR MOL MED, V9, P973, DOI 10.2174/156652409789712783
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
NR 80
TC 39
Z9 42
U1 0
U2 6
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD OCT
PY 2010
VL 33
IS 10
SI SI
BP 1557
EP 1565
DI 10.1007/s12272-010-1007-6
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 672DM
UT WOS:000283563200009
PM 21052933
DA 2022-11-30
ER

PT J
AU Gautier, B
   Goncalves, V
   Diana, D
   Di Stasi, R
   Teillet, F
   Lenoir, C
   Huguenot, F
   Garbay, C
   Fattorusso, R
   D'Andrea, LD
   Vidal, M
   Inguimbert, N
AF Gautier, Benoit
   Goncalves, Victor
   Diana, Donatella
   Di Stasi, Rossella
   Teillet, Florence
   Lenoir, Christine
   Huguenot, Florent
   Garbay, Christiane
   Fattorusso, Roberto
   D'Andrea, Luca Domenico
   Vidal, Michel
   Inguimbert, Nicolas
TI Biochemical and Structural Analysis of the Binding Determinants of a
   Vascular Endothelial Growth Factor Receptor Peptidic Antagonist
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SOLID-PHASE SYNTHESIS; CRYSTAL-STRUCTURE; VEGF-BINDING; DOMAIN;
   ANGIOGENESIS; CANCER; FLT-1; IDENTIFICATION; GENERATION; ACTIVATION
AB Cyclic peptide antagonist c[YYDEGLEE1-NH2, which disrupts the interaction between vascular endothelial growth factor (VEGF) and its receptors (VEGERs), represents a promising tool in the fight against cancer and age-related macular degeneration. Furthermore, coupled to a cyclen derivative, this ligand could be used as a medicinal imaging agent. Nevertheless, before generating such molecular probes, son-le preliminary studies need to be undertaken in order to define the more suitable positions for introduction of the cyclen macrocycle. Through an Ala-scan study on this peptide, we identified its binding motif, and an NMR study highlights its binding sites on the VEGFR-1D2 Ig-like domain. Guided by the structural relationship results deduced from the effect of the peptides on endothelial cells, new peptides were synthesized and grafted on beads. Used in a pull-down assay, these new peptides trap the VEGFRs, thus confirming that the identified amino acid positions are suitable for further derivatization.
C1 [Gautier, Benoit; Goncalves, Victor; Lenoir, Christine; Huguenot, Florent; Garbay, Christiane; Vidal, Michel; Inguimbert, Nicolas] Univ Paris 05, UFR Biomed, INSERM, Lab Pharmacochim Mol & Cellulaire,U648, F-75006 Paris, France.
   [Diana, Donatella; Fattorusso, Roberto] Univ Naples 2, Dipartimento Sci Ambientali, I-81100 Caserta, Italy.
   [Di Stasi, Rossella; D'Andrea, Luca Domenico] CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy.
   [Teillet, Florence] Univ Paris 05, UFR Biomed, Lab Pharmacol Toxicol & Signalisat Cellulaire, INSERM,UMR S 747, F-75006 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; Universita
   della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Biostrutture e Bioimmagini (IBB-CNR); Institut National de
   la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite Paris Cite
RP Inguimbert, N (通讯作者)，Univ Perpignan, Lab Chim Biomol & Environm, Via Domitia,52,Ave Paul Alduy, F-66860 Perpignan, France.
EM michel.vidal@parisdescartes.fr; nicolas.inguimbert@univ-perp.fr
RI Inguimbert, Nicolas/N-3703-2015; Vidal, Michel/ABA-3396-2020; Goncalves,
   Victor/O-1099-2019; Goncalves, Victor/B-7560-2009
OI Inguimbert, Nicolas/0000-0002-0309-9048; Goncalves,
   Victor/0000-0001-9854-4409; Goncalves, Victor/0000-0001-9854-4409;
   huguenot, florent/0000-0001-8400-0857; Fattorusso,
   Roberto/0000-0002-3539-5343; Gautier, Benoit/0000-0002-8249-2525;
   D'ANDREA, LUCA DOMENICO/0000-0002-2589-216X
FU Ligue Nationale Contre le Cancer; University Paris Descartes
   'Bonus-Qualite-Recherche'
FX Financial support for this work was provided by the Ligue Nationale
   Contre le Cancer and the University Paris Descartes
   'Bonus-Qualite-Recherche' grant.
CR Barleon B, 1997, J BIOL CHEM, V272, P10382
   Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chamorro C, 2009, CHEM COMMUN, P821, DOI 10.1039/b817357e
   CHANG CD, 1978, INT J PEPT PROT RES, V11, P246
   Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200
   D'Andrea LD, 2009, CURR PHARM DESIGN, V15, P2414, DOI 10.2174/138161209788682235
   De Paepe B, 2009, RECENT PAT ANTI-CANC, V4, P180, DOI 10.2174/157489209788452821
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200
   Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200
   Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q
   GAUTIER B, UNPUB
   Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311
   Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064
   GONCALVES V, 2006, PHARMACHEM, P15
   GONCALVES V, 2007, J PEPT SCI
   Goncalves V, 2007, BIOORG MED CHEM LETT, V17, P5590, DOI 10.1016/j.bmcl.2007.07.087
   Goncalves V, 2007, J MED CHEM, V50, P5135, DOI 10.1021/jm0706970
   Goncalves V, 2007, ANAL BIOCHEM, V366, P108, DOI 10.1016/j.ab.2007.03.027
   Goncalves V, 2009, J PEPT SCI, V15, P417, DOI 10.1002/psc.1133
   Hajduk PJ, 1999, Q REV BIOPHYS, V32, P211, DOI 10.1017/S0033583500003528
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Johnson T, 2000, J CHEM SOC PERK T 1, P2811, DOI 10.1039/b001694m
   KATES SA, 1993, TETRAHEDRON LETT, V34, P1549, DOI 10.1016/0040-4039(93)85003-F
   Keller R., 2004, COMPUTER AIDED RESON
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Lacal PM, 2008, EUR J CANCER, V44, P1914, DOI 10.1016/j.ejca.2008.06.032
   Lau SC, 2005, CURR OPIN MOL THER, V7, P493
   Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107
   Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Posey JA, 2003, CLIN CANCER RES, V9, P1323
   ROSKOSKI R, 2007, CRIT REV ONCOL HEMAT
   Shinkaruk S., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P95, DOI 10.2174/1568011033353452
   Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134
   Starzec A, 2007, PEPTIDES, V28, P2397, DOI 10.1016/j.peptides.2007.09.013
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Veselovsky AV, 2007, CURR COMPUT-AID DRUG, V3, P51, DOI 10.2174/157340907780058754
   Vidal M, 2004, BIOCHEMISTRY-US, V43, P7336, DOI 10.1021/bi030252n
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Yongye AB, 2009, J COMPUT AID MOL DES, V23, P677, DOI 10.1007/s10822-009-9295-y
NR 55
TC 30
Z9 32
U1 0
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 10
PY 2010
VL 53
IS 11
BP 4428
EP 4440
DI 10.1021/jm1002167
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 604SK
UT WOS:000278298600010
PM 20462213
DA 2022-11-30
ER

PT J
AU Lyzogubov, VV
   Tytarenko, RG
   Thotakura, S
   Viswanathan, T
   Bora, NS
   Bora, PS
AF Lyzogubov, Valeriy V.
   Tytarenko, Ruslana G.
   Thotakura, Sushma
   Viswanathan, Tito
   Bora, Nalini S.
   Bora, Puran S.
TI Inhibition of new vessel growth in mouse model of laser-induced
   choroidal neovascularization by adiponectin peptide II
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE Adiponectin; Angiogenesis; Macular degeneration; Neovascularization;
   Proliferation
ID ENDOTHELIAL-CELL APOPTOSIS; MACULAR DEGENERATION; INSULIN-RESISTANCE;
   METABOLIC SYNDROME; PLASMA-PROTEIN; RECEPTORS; ACRP30/ADIPONECTIN;
   COMPLEMENT; EXPRESSION; GENERATION
AB We have investigated the effect of adiponectin (APN) peptide II on new vessel growth in mouse model of choroidal neovascularization (CNV) or wet type age-related macular degeneration (AMD). Mice were injected intraperitoneally with APN peptide II, control peptide, or PBS on day 1-7 or day 5-14. APN, AdipoR1, PCNA, and VEGF localization was investigated using confocal microscopy, immunohistochemistry, and RT-PCR. APN peptide II decreased the relative area of FITC-dextran perfused vessels by 4-fold, PCNA expression by 3-fold, and the number of PCNA stained HUVEC and MAVEC cells by 38 and 46%, respectively. We concluded that APN peptide II inhibits CNV size on days 7 and 14 by inhibiting the proliferation of endothelial cells in vivo and in vitro. APN peptide II may have therapeutic potential to inhibit CNV or wet AMD. (c) 2009 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.
C1 [Lyzogubov, Valeriy V.; Tytarenko, Ruslana G.; Bora, Nalini S.; Bora, Puran S.] Univ Arkansas Med Sci Hosp, Dept Ophthalmol, Jones Eye Inst, Pat & Willard Walker Eye Res Ctr, Little Rock, AR 72205 USA.
   [Thotakura, Sushma; Viswanathan, Tito] Univ Arkansas, Dept Chem, Little Rock, AR 72204 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Fayetteville;
   University of Arkansas Little Rock
RP Bora, PS (通讯作者)，Univ Arkansas Med Sci Hosp, Dept Ophthalmol, Jones Eye Inst, Pat & Willard Walker Eye Res Ctr, 4301 W Markham St, Little Rock, AR 72205 USA.
EM pbora@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU NIH [EY 014623, EY 13335]; NATIONAL EYE INSTITUTE [R01EY014623,
   R01EY013335] Funding Source: NIH RePORTER
FX We thank Dr Purushottam Jha for the critical review of the manuscript
   and Ms. Cynthia Bond for editing the manuscript. This study was
   supported in part by NIH grants EY 014623, EY 13335 and the Pat &
   Willard Walker Eye Research Center, Jones Eye Institute, University of
   Arkansas for Medical Sciences (Little Rock, AR).
CR Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Bora PS, 2007, FEBS LETT, V581, P1977, DOI 10.1016/j.febslet.2007.04.024
   Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chen J, 2006, DIABETOLOGIA, V49, P1292, DOI 10.1007/s00125-006-0194-7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126
   Kaser S, 2005, GUT, V54, P117, DOI 10.1136/gut.2003.037010
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   Motoshima H, 2004, BIOCHEM BIOPH RES CO, V315, P264, DOI 10.1016/j.bbrc.2004.01.049
   Nishiyama T, 2007, J VASC RES, V44, P138, DOI 10.1159/000098520
   Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296
   Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200
   Rovin BH, 2005, KIDNEY INT, V68, P1825, DOI 10.1111/j.1523-1755.2005.00601.x
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   Shibata R, 2004, J BIOL CHEM, V279, P28670, DOI 10.1074/jbc.M402558200
   Tsao TS, 2003, J BIOL CHEM, V278, P50810, DOI 10.1074/jbc.M309469200
   Vasseur F, 2006, PHARMACOL RES, V53, P478, DOI 10.1016/j.phrs.2006.03.013
   Waki H, 2005, ENDOCRINOLOGY, V146, P790, DOI 10.1210/en.2004-1096
   Wittchen F, 2007, J MOL MED, V85, P253, DOI 10.1007/s00109-006-0122-9
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 28
TC 14
Z9 16
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-6995
EI 1095-8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD JUL
PY 2009
VL 33
IS 7
BP 765
EP 771
DI 10.1016/j.cellbi.2009.04.013
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 463YV
UT WOS:000267471100010
PM 19422927
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Dayani, PN
   Siddiqi, OK
   Holekamp, NM
AF Dayani, Pouya N.
   Siddiqi, Omar K.
   Holekamp, Nancy M.
TI Safety of intravitreal injections in patients receiving warfarin
   anticoagulation
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To evaluate the safety of intravitreal Macugen (OSI/Eyetech, New York, New York, USA) injections among patients receiving warfarin anticoagulation.
   DESIGN: Retrospective chart review.
   METHODS: A search was conducted for patients treated with intravitreal Macugen for choroidal neovascularization resulting from age-related macular degeneration (AMD). Inclusion criteria included patients receiving warfarin anticoagulation in whom therapy was maintained.
   RESULTS: The review identified 31 patients (32 eyes) who underwent 102 intravitreal Macugen injections while receiving warfarin anticoagulation. The mean and median number of Macugen injections per patient was three. No intraoperative or immediate postoperative hemorrhagic complications were noted. One patient experienced an acute submacular hemorrhage 35 days after the third Macugen injection. There were no other hemorrhagic events among the remaining patients.
   CONCLUSIONS: The retrospective chart review of patients treated with intravitreal Macugen for choroidal neovascularization resulting from AMD while receiving warfarin therapy suggests that patients may undergo intravitreal injections safely without cessation of anticoagulation therapy.
C1 Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Holekamp, NM (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
EM nholekamp@pol.net
OI Siddiqi, Omar/0000-0001-7813-1623
CR Genewein U, 1996, BRIT J HAEMATOL, V92, P479, DOI 10.1046/j.1365-2141.1996.d01-1499.x
   PALARETI G, 1994, THROMB HAEMOSTASIS, V72, P222
   POLLER L, 1964, LANCET, V2, P62
NR 3
TC 22
Z9 22
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2007
VL 144
IS 3
BP 451
EP 453
DI 10.1016/j.ajo.2007.05.006
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209TW
UT WOS:000249411900021
PM 17765427
DA 2022-11-30
ER

PT J
AU Panagiotidis, D
   Karagiannis, DA
   Baltatzis, S
AF Panagiotidis, D.
   Karagiannis, D. A.
   Baltatzis, S.
TI Photodynamic therapy in retinal angiomatous proliferation stage I
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE photodynamic therapy; retinal angiomatous proliferation
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION;
   TRANSPUPILLARY THERMOTHERAPY; VERTEPORFIN; TEAR
AB PURPOSE. To report a case of photodynamic therapy (PDT) treatment in an 85-year-old patient with retinal angiomatous proliferation (RAP) stage I.
   METHODS. According to Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy study guidelines, two sessions of PDT with verteporfin were performed, which was activated by a diode laser light at 690 nm.
   RESULTS. The left eye was treated with PDT because of RAP stage I. Even in the early stage of RAP, PDT treatment did not alter the natural course of the disease. In particular, the lesion evolved towards stage III, being initially in stage I, with the final result of development of retinal pigment epithelial (RPE) tear after the second session of PDT treatment.
   CONCLUSIONS. Even in the early stage of RAP, PDT treatment did not alter the natural course of the disease, with the final result of RPE tear after the second session of PDT treatment.
C1 Univ Athens, Sch Med, Dept Ophthalmol, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens
RP Baltatzis, S (通讯作者)，19 Skoufa Str, GR-10673 Athens, Greece.
EM sbaltatz@med.uoa.gr
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 7
TC 20
Z9 20
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2006
VL 16
IS 2
BP 326
EP 329
DI 10.1177/112067210601600221
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 053NV
UT WOS:000238312800021
PM 16703554
DA 2022-11-30
ER

PT J
AU Schutt, F
   Ueberle, B
   Schnolzer, M
   Holz, FG
   Kopitz, J
AF Schutt, F
   Ueberle, B
   Schnolzer, M
   Holz, FG
   Kopitz, J
TI Proteome analysis of lipofuscin in human retinal pigment epithelial
   cells
SO FEBS LETTERS
LA English
DT Article
DE lipofuscin; proteome; retinal pigment epithelium; age-related macular
   degeneration
ID LYSOSOMAL DEGRADATIVE FUNCTIONS; MACULAR DEGENERATION; DISEASE;
   FLUORESCENCE; INHIBITION; COMPONENT; MICE
AB Excessive accumulation of lipofuscin in postmitotic retinal pigment epithelial cells is a common pathogenetic pathway in various blinding retinal diseases including age-related macular degeneration, which is now the most common cause of registerable blindness in the industrialized nations. To better understand the role of lipofuscin accumulation and to manipulate the pathogenetic mechanisms on both experimental and therapeutic levels we analyzed the proteome of isolated human ocular lipofuscin granules from human RPE cells. After homogenization and fractionation by gradient ultracentrifugation of the RPE/choroid complex from 10 pairs of human donors, protein compounds were separated by 2D gel electrophoresis and analyzed using matrix-assisted laser desorption/ionization mass spectrometry and HPLC-coupled electrospray tandem mass spectrometry. Besides a better understanding of downstream pathways, this approach may provide new targets for therapeutic interventions in a currently untreatable disease. (C) 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
C1 Dept Ophthalmol, D-69120 Heidelberg, Germany.
   Univ Heidelberg, Dept Pathochem & Neurochem, D-69120 Heidelberg, Germany.
   German Canc Res Ctr, Prot Anal Facil, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ)
RP Schutt, F (通讯作者)，Dept Ophthalmol, INF 400, D-69120 Heidelberg, Germany.
CR ANDERSON RE, 1994, ADV EXP MED BIOL, V366, P73
   Bermann M, 2001, EXP EYE RES, V72, P191
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   BOULTON M, 1985, EXP EYE RES, V41, P209, DOI 10.1016/0014-4835(85)90026-0
   BRIZZEE KR, 1981, AGE PIGMENTS, P101
   BRONSON RT, 1993, ANN NEUROL, V33, P381, DOI 10.1002/ana.410330408
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1991, FREE RADICAL BIO MED, V10, P445, DOI 10.1016/0891-5849(91)90054-7
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HANDELMAN GJ, 1986, ADV FREE RADICAL BIO, V2, P1, DOI 10.1016/S8755-9668(86)80024-2
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   HOLZ FG, 2002, IN PRESS GRAEFES ARC
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P109
   Katz ML, 1997, INVEST OPHTH VIS SCI, V38, P2375
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   MCGINNIS JF, 1993, MAMM GENOME, V4, P43, DOI 10.1007/BF00364662
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823
   White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   YAMADA E, 1973, ELECT MICROSCOPIC AT
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
NR 30
TC 72
Z9 82
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD SEP 25
PY 2002
VL 528
IS 1-3
BP 217
EP 221
AR PII S0014-5793(02)03312-4
DI 10.1016/S0014-5793(02)03312-4
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 598NL
UT WOS:000178282500041
PM 12297308
DA 2022-11-30
ER

PT J
AU Avraham, D
   Yitzhaky, Y
AF Avraham, David
   Yitzhaky, Yitzhak
TI Effects of Depth-Based Object Isolation in Simulated Retinal Prosthetic
   Vision
SO SYMMETRY-BASEL
LA English
DT Article
DE retina; visual prosthesis; vision rehabilitation; perception; phosphene
   vision; integral imaging; object isolation
ID ELECTRICAL-STIMULATION; PERCEPTUAL THRESHOLDS; VISUAL-PERCEPTION;
   RECOGNITION; PERFORMANCE; DESIGN
AB Visual retinal prostheses aim to restore vision for blind individuals who suffer from outer retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration. Perception through retinal prostheses is very limited, but it can be improved by applying object isolation. We used an object isolation algorithm based on integral imaging to isolate objects of interest according to their depth from the camera and applied image processing manipulation to the isolated-object images. Subsequently, we applied a spatial prosthetic vision simulation that converted the isolated-object images to phosphene images. We compared the phosphene images for two types of input images, the original image (before applying object isolation), and the isolated-object image to illustrate the effects of object isolation on simulated prosthetic vision without and with multiple spatial variations of phosphenes, such as size and shape variations, spatial shifts, and dropout rate. The results show an improvement in the perceived shape, contrast, and dynamic range (number of gray levels) of objects in the phosphene image.
C1 [Avraham, David; Yitzhaky, Yitzhak] Ben Gurion Univ Negev, Sch Elect & Comp Engn, Dept Electroopt Engn, IL-84105 Beer Sheva, Israel.
C3 Ben Gurion University
RP Avraham, D (通讯作者)，Ben Gurion Univ Negev, Sch Elect & Comp Engn, Dept Electroopt Engn, IL-84105 Beer Sheva, Israel.
EM davav@post.bgu.ac.il; ytshak@bgu.ac.il
RI Yitzhaky, Yitzhak/AAD-6839-2022; Avraham, David/AAY-7046-2021
OI Avraham, David/0000-0002-3910-8911; yitzhaky,
   yitzhak/0000-0002-4974-9683
FU Israel Science Foundation [1519/20]
FX FundingThis research was supported by the Israel Science Foundation
   (grant no. 1519/20).
CR Aloni D, 2015, APPL OPTICS, V54, P6717, DOI 10.1364/AO.54.006717
   Aloni D, 2014, IEEE PHOTONIC TECH L, V26, P726, DOI 10.1109/LPT.2014.2304883
   Avraham D, 2021, J NEURAL ENG, V18, DOI 10.1088/1741-2552/ac1b6c
   Ayton LN, 2020, CLIN NEUROPHYSIOL, V131, P1383, DOI 10.1016/j.clinph.2019.11.029
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Bandello F., 2010, AMD AGE RELATED MACU
   Behrend MR, 2011, IEEE T NEUR SYS REH, V19, P436, DOI 10.1109/TNSRE.2011.2140132
   Beyeler M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45416-4
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   BRUMMER SB, 1977, IEEE T BIO-MED ENG, V24, P440, DOI 10.1109/TBME.1977.326179
   Caspi A, 2009, ARCH OPHTHALMOL-CHIC, V127, P398, DOI 10.1001/archophthalmol.2009.20
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   Chai XY, 2007, ARTIF ORGANS, V31, P175, DOI 10.1111/j.1525-1594.2007.00362.x
   Chen SC, 2009, VISION RES, V49, P1493, DOI 10.1016/j.visres.2009.02.003
   Cogan SF, 2005, IEEE T BIO-MED ENG, V52, P1612, DOI 10.1109/TBME.2005.851503
   Dagnelie G, 2006, INVEST OPHTH VIS SCI, V47, P1241, DOI 10.1167/iovs.05-0157
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   Farahani Navid, 2016, J Pathol Inform, V7, P22, DOI 10.4103/2153-3539.181766
   Fornos AP, 2012, INVEST OPHTH VIS SCI, V53, P2720, DOI 10.1167/iovs.11-9344
   Grosberg LE, 2017, J NEUROPHYSIOL, V118, P1457, DOI 10.1152/jn.00750.2016
   Guo H, 2010, ARTIF ORGANS, V34, P846, DOI 10.1111/j.1525-1594.2009.00976.x
   Han N., 2021, 210200297 ARXIV
   Hao Wu, 2014, 2014 International Conference on Information Science, Electronics and Electrical Engineering (ISEEE), P425, DOI 10.1109/InfoSEEE.2014.6948145
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hornig R, 2007, ARTIFICIAL SIGHT BAS, P111, DOI [10.1007/978-0-387-49331-2_6, DOI 10.1007/978-0-387-49331-2_6]
   Horsager A, 2010, INVEST OPHTH VIS SCI, V51, P1223, DOI 10.1167/iovs.09-3746
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Jung JH, 2015, VISION RES, V111, P182, DOI 10.1016/j.visres.2014.10.023
   Lippmann G., 1908, J PHYS THEOR APPL, V7, P821, DOI DOI 10.1051/JPHYSTAP:019080070082100
   Loudin JD, 2007, J NEURAL ENG, V4, pS72, DOI 10.1088/1741-2560/4/1/S09
   Luo YHL, 2016, PROG RETIN EYE RES, V50, P89, DOI 10.1016/j.preteyeres.2015.09.003
   Mahadevappa M, 2005, IEEE T NEUR SYS REH, V13, P201, DOI 10.1109/TNSRE.2005.848687
   Moleirinho S, 2021, J NEURAL ENG, V18, DOI 10.1088/1741-2552/abecf1
   Nanduri D, 2008, IEEE ENG MED BIO, P1785, DOI 10.1109/IEMBS.2008.4649524
   Nanduri D, 2012, INVEST OPHTH VIS SCI, V53, P205, DOI 10.1167/iovs.11-8401
   Narayan DS, 2016, ACTA OPHTHALMOL, V94, P748, DOI 10.1111/aos.13141
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5355, DOI 10.1167/iovs.02-0819
   Roessler G, 2009, INVEST OPHTH VIS SCI, V50, P3003, DOI 10.1167/iovs.08-2752
   Second Sight, 2013, ARG 2 RET PROSTH SYS
   Sinclair NC, 2016, INVEST OPHTH VIS SCI, V57, P4948, DOI 10.1167/iovs.15-18991
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Stronks HC, 2014, EXPERT REV MED DEVIC, V11, P23, DOI 10.1586/17434440.2014.862494
   Tavakoli B, 2008, OPT EXPRESS, V16, P4426, DOI 10.1364/OE.16.004426
   Wang Angeline L, 2019, Int Ophthalmol Clin, V59, P263, DOI 10.1097/IIO.0000000000000256
   Weiland JD, 2014, IEEE T BIO-MED ENG, V61, P1412, DOI 10.1109/TBME.2014.2314733
   Weiland JD, 2003, P ANN INT IEEE EMBS, V25, P2021, DOI 10.1109/IEMBS.2003.1280131
   Xia P, 2015, ARTIF ORGANS, V39, P1038, DOI 10.1111/aor.12504
   Yanai D, 2007, AM J OPHTHALMOL, V143, P820, DOI 10.1016/j.ajo.2007.01.027
NR 53
TC 3
Z9 3
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-8994
J9 SYMMETRY-BASEL
JI Symmetry-Basel
PD OCT
PY 2021
VL 13
IS 10
AR 1763
DI 10.3390/sym13101763
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WN0UH
UT WOS:000711491400001
OA gold
DA 2022-11-30
ER

PT J
AU Malsy, J
   Alvarado, AC
   Lamontagne, JO
   Strittmatter, K
   Marneros, AG
AF Malsy, Jakob
   Alvarado, Andrea C.
   Lamontagne, Joseph O.
   Strittmatter, Karin
   Marneros, Alexander G.
TI Distinct effects of complement and of NLRP3-and non-NLRP3 inflammasomes
   for choroidal neovascularization
SO ELIFE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; MEMBRANE ATTACK COMPLEX; MACULAR-DEGENERATION;
   VEGF; ACTIVATION; IL-1-BETA; INDUCTION; MONOCYTES; DISEASES; RETINA
AB NLRP3 inflammasome activation and complement-mediated inflammation have been implicated in promoting choroidal neovascularization (CNV) in age-related macular degeneration (AMD), but central questions regarding their contributions to AMD pathogenesis remain unanswered. Key open questions are (1) whether NLRP3 inflammasome activation mainly in retinal pigment epithelium (RPE) or rather in non-RPE cells promotes CNV, (2) whether inflammasome activation in CNV occurs via NLRP3 or also through NLRP3-independent mechanisms, and (3) whether complement activation induces inflammasome activation in CNV. Here we show in a neovascular AMD mouse model that NLRP3 inflammasome activation in non-RPE cells but not in RPE cells promotes CNV. We demonstrate that both NLRP3-dependent and NLRP3-independent inflammasome activation mechanisms induce CNV. Finally, we find that complement and inflammasomes promote CNV through independent mechanisms. Our findings uncover an unexpected role of non-NLRP3 inflammasomes for CNV and suggest that combination therapies targeting inflammasomes and complement may offer synergistic benefits to inhibit CNV.
C1 [Malsy, Jakob; Alvarado, Andrea C.; Lamontagne, Joseph O.; Strittmatter, Karin; Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
   [Malsy, Jakob; Alvarado, Andrea C.; Lamontagne, Joseph O.; Strittmatter, Karin; Marneros, Alexander G.] Harvard Med Sch, Boston, MA 02115 USA.
   [Malsy, Jakob] Univ Halle, Dept Ophthalmol, Halle, Germany.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School; Martin Luther University Halle Wittenberg
RP Marneros, AG (通讯作者)，Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.; Marneros, AG (通讯作者)，Harvard Med Sch, Boston, MA 02115 USA.
EM amarneros@mgh.harvard.edu
FU National Institutes of Health [R21EY027104]
FX National Institutes of Health R21EY027104 Joseph O Lamontagne Karin
   Strittmatter Alexander G Marneros; BrightFocus Foundation Alexander G
   Marneros; Hans-Bockler-Stiftung Scholarship Jakob Malsy; Alpha Omega
   Alpha Carolyn L. Kucklein Student Andrea C Alvarado Research Fellowship;
   The funders had no role in study design, data collection and
   interpretation, or the decision to submit the work for publication.
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brydges SD, 2009, IMMUNITY, V30, P875, DOI 10.1016/j.immuni.2009.05.005
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   He LZ, 2014, AM J PATHOL, V184, P1660, DOI 10.1016/j.ajpath.2014.02.007
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Hollborn M, 2018, MOL VIS, V24, P518
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kotimaa J, 2016, MOL IMMUNOL, V76, P13, DOI 10.1016/j.molimm.2016.06.004
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li JY, 2007, NAT CELL BIOL, V9, P276, DOI 10.1038/ncb1541
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   Marneros AG, 2016, EMBO MOL MED, V8, P208, DOI 10.15252/emmm.201505613
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355
   Mukai R, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00015
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Suresh R, 2016, J CELL SCI, V129, P1928, DOI 10.1242/jcs.179291
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wang LP, 2019, J MOL MED, V97, P523, DOI 10.1007/s00109-019-01753-5
   WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P1149, DOI DOI 10.1073/PNAS.92.25.11490
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
NR 42
TC 7
Z9 7
U1 1
U2 5
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD DEC 11
PY 2020
VL 9
AR e60194
DI 10.7554/eLife.60194
PG 22
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA PG1PL
UT WOS:000599514700001
PM 33305736
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fuchs, HR
   Meister, R
   Lotke, R
   Framme, C
AF Fuchs, Heiko R.
   Meister, Roland
   Lotke, Rishikesh
   Framme, Carsten
TI The microRNAs miR-302d and miR-93 inhibit TGFB-mediated EMT and VEGFA
   secretion from ARPE-19 cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE microRNA; TGFB; EMT; miR-302; miR-93; PVR; VEGFA; AMD; RPE; ARPE-19
ID EPITHELIAL-MESENCHYMAL TRANSITION; RETINAL-PIGMENT EPITHELIUM;
   ENDOTHELIAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; HUMAN FIBROBLASTS;
   AQUEOUS-HUMOR; EXPRESSION; PROMOTES; TARGETS; CYTOKINES
AB The transforming growth factor-beta (TGFB) plays an essential role in the pathogenesis of some ophthalmologic diseases, including neovascular age-related macular degeneration (nAMD) and proliferative vitreoretinopathy (PVR). TGFB activates the transcription factors SMAD2 and SMAD3 via the TGFB receptor, which together activate several genes, including VEGFA. TGFB treated ARPE-19 cells show an increased proliferation rate and undergo epithelial to mesenchymal transition (EMT). Since microRNAs (miRNAs) are capable of inhibiting the translation of multiple genes, we screened for miRNAs that regulate the TGFB signalling pathways at multiple levels. In this study, we focused on two miRNAs, miR-302d and miR-93, which inhibit TGFB signalling pathway and therefore TGFB-induced EMT transition as well as VEGFA secretion from ARPE-19 cells. Furthermore, we could show that both miRNAs can retransform TGFB-stimulated mesenchymal ARPE-19 cells towards the morphological epithelial-like state. Taken together, transient overexpression of these miRNAs in RPE cells might be a promising approach for further translational strategies.
C1 [Fuchs, Heiko R.; Meister, Roland; Lotke, Rishikesh; Framme, Carsten] Hannover Med Sch, Univ Eye Hosp, Inst Expt Ophthalmol, D-30625 Hannover, Germany.
C3 Hannover Medical School
RP Fuchs, HR (通讯作者)，Hannover Med Sch, Univ Eye Hosp, Inst Expt Ophthalmol, D-30625 Hannover, Germany.
EM fuchs.heiko@mh-hannover.de
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Banerjee S, 2007, INVEST OPHTH VIS SCI, V48, P2203, DOI 10.1167/iovs.06-1358
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Carrington L, 2000, INVEST OPHTH VIS SCI, V41, P1210
   Chakraborty C, 2017, MOL THER-NUCL ACIDS, V8, P132, DOI 10.1016/j.omtn.2017.06.005
   Chen R, 2016, BIOL OPEN, V5, P669, DOI 10.1242/bio.015552
   Chen SD, 2019, CLIN EXP OPHTHALMOL, V47, P925, DOI 10.1111/ceo.13554
   Cheng HC, 2008, MOL VIS, V14, P95
   De S, 2017, EXP CELL RES, V361, P85, DOI 10.1016/j.yexcr.2017.10.005
   Eichhorn SW, 2014, MOL CELL, V56, P104, DOI 10.1016/j.molcel.2014.08.028
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465
   Fransvea E, 2011, CANCER CHEMOTH PHARM, V68, P79, DOI 10.1007/s00280-010-1459-x
   Gamulescu MA, 2006, EXP EYE RES, V83, P212, DOI 10.1016/j.exer.2005.12.007
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Herbertz S, 2015, DRUG DES DEV THER, V9, P4479, DOI 10.2147/DDDT.S86621
   Hoerster R, 2014, GRAEF ARCH CLIN EXP, V252, P11, DOI 10.1007/s00417-013-2377-5
   Hoerster R, 2013, BRIT J OPHTHALMOL, V97, P450, DOI 10.1136/bjophthalmol-2012-302636
   Jayaram H, 2017, INVEST OPHTH VIS SCI, V58, P4989, DOI 10.1167/iovs.17-22866
   Ji CM, 2017, BIOTECHNOL LETT, V39, P1621, DOI 10.1007/s10529-017-2403-5
   Jiang LL, 2015, ONCOTARGET, V6, P8286, DOI 10.18632/oncotarget.3221
   Jun JH, 2016, INVEST OPHTH VIS SCI, V57, P12, DOI 10.1167/iovs.15-17111
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130194
   Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x
   Martinez B, 2019, NEURAL REGEN RES, V14, P1858, DOI 10.4103/1673-5374.259602
   Mony S, 2013, EXP EYE RES, V115, P113, DOI 10.1016/j.exer.2013.06.007
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Pan YY, 2014, CURR PHARM DESIGN, V20, P5260, DOI 10.2174/1381612820666140128211724
   Qu MH, 2016, TUMOR BIOL, V37, P5645, DOI 10.1007/s13277-015-4328-8
   Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Subramanyam D, 2011, NAT BIOTECHNOL, V29, P443, DOI 10.1038/nbt.1862
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Wei QQ, 2018, MOL MED REP, V17, P5878, DOI 10.3892/mmr.2018.8556
   Wilson KD, 2009, STEM CELLS DEV, V18, P749, DOI 10.1089/scd.2008.0247
   Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
   Xiang Y, 2017, EXP CELL RES, V357, P135, DOI 10.1016/j.yexcr.2017.05.007
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zeng Aiping, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P363
   Zhao N, 2015, CIRC RES, V116, P23, DOI 10.1161/CIRCRESAHA.115.303970
NR 44
TC 12
Z9 12
U1 1
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2020
VL 201
AR 108258
DI 10.1016/j.exer.2020.108258
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PI4FE
UT WOS:000601047600005
PM 32980316
DA 2022-11-30
ER

PT J
AU Kanoungi, G
   Nothnagel, M
   Becker, T
   Drichel, D
AF Kanoungi, George
   Nothnagel, Michael
   Becker, Tim
   Drichel, Dmitriy
TI The exhaustive genomic scan approach, with an application to
   rare-variant association analysis
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID MACULAR DEGENERATION; SEQUENCE; COMMON; REGIONS; HTRA1
AB Region-based genome-wide scans are usually performed by use of a priori chosen analysis regions. Such an approach will likely miss the region comprising the strongest signal and, thus, may result in increased type II error rates and decreased power. Here, we propose a genomic exhaustive scan approach that analyzes all possible subsequences and does not rely on a prior definition of the analysis regions. As a prime instance, we present a computationally ultraefficient implementation using the rare-variant collapsing test for phenotypic association, the genomic exhaustive collapsing scan (GECS). Our implementation allows for the identification of regions comprising the strongest signals in large, genome-wide rare-variant association studies while controlling the family-wise error rate via permutation. Application of GECS to two genomic data sets revealed several novel significantly associated regions for age-related macular degeneration and for schizophrenia. Our approach also offers a high potential to improve genome-wide scans for selection, methylation, and other analyses.
C1 [Kanoungi, George; Nothnagel, Michael; Drichel, Dmitriy] Univ Cologne, Fac Med, Weyertal 115b, D-50931 Cologne, Germany.
   [Kanoungi, George; Nothnagel, Michael; Drichel, Dmitriy] Univ Cologne, Univ Hosp Cologne, CCG, Weyertal 115b, D-50931 Cologne, Germany.
   [Becker, Tim] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany.
   [Becker, Tim] xValue GmbH, Willich, Germany.
   [Drichel, Dmitriy] Drichel Analyt, Alexanderstr 6, D-53111 Bonn, Germany.
C3 University of Cologne; University of Cologne; Ernst Moritz Arndt
   Universitat Greifswald
RP Drichel, D (通讯作者)，Univ Cologne, Fac Med, Weyertal 115b, D-50931 Cologne, Germany.; Drichel, D (通讯作者)，Univ Cologne, Univ Hosp Cologne, CCG, Weyertal 115b, D-50931 Cologne, Germany.; Drichel, D (通讯作者)，Drichel Analyt, Alexanderstr 6, D-53111 Bonn, Germany.
EM ddrichel@uni-koeln.de
RI Nothnagel, Michael/G-6545-2014
OI Drichel, Dmitriy/0000-0001-5978-3458; Nothnagel,
   Michael/0000-0001-8305-7114; Kanoungi, George/0000-0002-2452-8526
FU German Research Foundation [BE 38/28/9-1]; Projekt DEAL
FX The work was supported by the German Research Foundation grant BE
   38/28/9-1. The funding organization did not have any influence on the
   design, conduct, or conclusions of the study. Open Access Funding
   provided by Projekt DEAL.
CR Akey JM, 2009, GENOME RES, V19, P711, DOI 10.1101/gr.086652.108
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Auer PL, 2017, EUR J HUM GENET, V25, P395, DOI 10.1038/ejhg.2016.206
   Basu S, 2011, GENET EPIDEMIOL, V35, P606, DOI 10.1002/gepi.20609
   Chen SY, 2017, J THORAC DIS, V9, P1725, DOI 10.21037/jtd.2017.05.34
   Christophersen IE, 2017, NAT GENET, V49, P946, DOI 10.1038/ng.3843
   Drichel D, 2014, HUM HERED, V78, P164, DOI 10.1159/000368676
   Excoffier L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003905
   Feldman MW, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0064
   Fier H, 2012, BIOINFORMATICS, V28, P3027, DOI 10.1093/bioinformatics/bts568
   Freedman R, 2003, NEW ENGL J MED, V349, P1738, DOI 10.1056/NEJMra035458
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fumagalli M, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00941
   Gazave E, 2014, P NATL ACAD SCI USA, V111, P757, DOI 10.1073/pnas.1310398110
   Geerlings MJ, 2018, MOL VIS, V24, P75
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Jaffe AE, 2012, INT J EPIDEMIOL, V41, P200, DOI 10.1093/ije/dyr238
   Kelleher J, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004842
   Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009
   Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Meinshausen N, 2011, ANN STAT, V39, P3369, DOI 10.1214/11-AOS946
   Ng TK, 2012, ASIA-PAC J OPHTHALMO, V1, P51, DOI 10.1097/APO.0b013e31823e57fe
   Nielsen R, 2005, GENOME RES, V15, P1566, DOI 10.1101/gr.4252305
   Price AL, 2010, AM J HUM GENET, V86, P832, DOI 10.1016/j.ajhg.2010.04.005
   Pulit SL, 2017, GENET EPIDEMIOL, V41, P145, DOI 10.1002/gepi.22032
   Timpson NJ, 2018, NAT REV GENET, V19, P110, DOI 10.1038/nrg.2017.101
   Becerri EV, 2009, CELL MOL IMMUNOL, V6, P303, DOI 10.1038/cmi.2009.40
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Wu MC, 2010, AM J HUM GENET, V86, P929, DOI 10.1016/j.ajhg.2010.05.002
   Zawistowski M, 2010, AM J HUM GENET, V87, P604, DOI 10.1016/j.ajhg.2010.10.012
NR 33
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD SEP
PY 2020
VL 28
IS 9
BP 1283
EP 1291
DI 10.1038/s41431-020-0639-3
EA MAY 2020
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA NH9KO
UT WOS:000533059600003
PM 32415273
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Smith, EN
   D'Antonio-Chronowska, A
   Greenwald, WW
   Borja, V
   Aguiar, LR
   Pogue, R
   Matsui, H
   Benaglio, P
   Borooah, S
   D'Antonio, M
   Ayyagari, R
   Frazer, KA
AF Smith, Erin N.
   D'Antonio-Chronowska, Agnieszka
   Greenwald, William W.
   Borja, Victor
   Aguiar, Lana R.
   Pogue, Robert
   Matsui, Hiroko
   Benaglio, Paola
   Borooah, Shyamanga
   D'Antonio, Matteo
   Ayyagari, Radha
   Frazer, Kelly A.
TI Human iPSC-Derived Retinal Pigment Epithelium: A Model System for
   Prioritizing and Functionally Characterizing Causal Variants at AMD Risk
   Loci
SO STEM CELL REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; MACULAR DEGENERATION; MOLECULAR SIGNATURE;
   GENETIC-VARIATION; EXPRESSION; VEGFA; RARE; EYE
AB We evaluate whether human induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells can be used to prioritize and functionally characterize causal variants at age-related macular degeneration (AMD) risk loci. We generated iPSC-RPE from six subjects and show that they have morphological and molecular characteristics similar to those of native RPE. We generated RNA-seq, ATAC-seq, and H3K27ac ChIP-seq data and observed high similarity in gene expression and enriched transcription factor motif profiles between iPSC-RPE and human fetal RPE. We performed fine mapping of AMD risk loci by integrating molecular data from the iPSC-RPE, adult retina, and adult RPE, which identified rs943080 as the probable causal variant at VEGFA. We show that rs943080 is associated with altered chromatin accessibility of a distal ATAC-seq peak, decreased overall gene expression of VEGFA, and allele-specific expression of a non-coding transcript. Our study thus provides a potential mechanism underlying the association of the VEGFA locus with AMD.
C1 [Smith, Erin N.; Benaglio, Paola; Frazer, Kelly A.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA.
   [D'Antonio-Chronowska, Agnieszka; Borja, Victor; Aguiar, Lana R.; Matsui, Hiroko; D'Antonio, Matteo; Frazer, Kelly A.] Univ Calif San Diego, Inst Genom Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.
   [Greenwald, William W.] Univ Calif San Diego, Bioinformat & Syst Biol Grad Program, La Jolla, CA 92093 USA.
   [Aguiar, Lana R.; Pogue, Robert] Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Brasilia, DF, Brazil.
   [Borooah, Shyamanga] Univ Edinburgh, Ctr Clin Brain Sci, Sch Clin Sci, Edinburgh, Midlothian, Scotland.
   [Borooah, Shyamanga; Ayyagari, Radha] Univ Calif San Diego, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Frazer, Kelly A.] Cellular & Mol Med East, 9500 Gilman Dr 0761, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Universidade Catolica de Brasilia; University of Edinburgh; University
   of California System; University of California San Diego
RP Frazer, KA (通讯作者)，Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA.; Frazer, KA (通讯作者)，Univ Calif San Diego, Inst Genom Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.; Frazer, KA (通讯作者)，Cellular & Mol Med East, 9500 Gilman Dr 0761, La Jolla, CA 92093 USA.
EM kafrazer@ucsd.edu
RI Aguiar, Lana Ribeiro/L-8630-2018; Pogue, Robert/C-3860-2016; D'Antonio,
   Matteo/H-5245-2019; Borooah, Shyamanga/AAM-6581-2021
OI Aguiar, Lana Ribeiro/0000-0002-9566-7363; Pogue,
   Robert/0000-0002-8789-3512; D'Antonio, Matteo/0000-0001-5844-6433;
   Frazer, Kelly/0000-0002-6060-8902; D'Antonio-Chronowska,
   Agnieszka/0000-0003-1653-4106
FU CIRM [GC1R-06673]; NIH [HG008118, HL107442, DK105541, DK112155,
   EY021237, P30CA023100]; National Heart, Lung, and Blood Institute of the
   National Institutes of Health [F31HL142151]; Brazilian Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fulbright-Fight
   for Sight scholarship; Foundation Fighting Blindness Career Development
   Award; NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY021237] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F31HL142151,
   U01HL107442] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTE [R44HG008118, R41HG008118] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [U01DK105541, DP3DK112155] Funding Source: NIH RePORTER
FX This work was supported in part by a CIRM grant GC1R-06673 and NIH
   grants HG008118, HL107442, DK105541, DK112155, and EY021237. RNA-seq was
   performed at the UCSD IGM Genomics Center with support from NIH grant
   P30CA023100. W.W.Y.G. was supported by the National Heart, Lung, and
   Blood Institute of the National Institutes of Health under award number
   F31HL142151. L.R.A. was funded by a scholarship from the Brazilian
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). S.
   B. was funded by a Fulbright-Fight for Sight scholarship and a
   Foundation Fighting Blindness Career Development Award.
CR Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Albert FW, 2015, NAT REV GENET, V16, P197, DOI 10.1038/nrg3891
   CDC, 2018, VIS HLTH IN VHI NAT
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   DeBoever C, 2017, CELL STEM CELL, V20, P533, DOI 10.1016/j.stem.2017.03.009
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gallagher MD, 2018, AM J HUM GENET, V102, P717, DOI 10.1016/j.ajhg.2018.04.002
   Gamazon ER, 2018, NAT GENET, V50, P956, DOI 10.1038/s41588-018-0154-4
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greenwald WW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08940-5
   Gusev A, 2014, AM J HUM GENET, V95, P535, DOI 10.1016/j.ajhg.2014.10.004
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kremlitzka M, 2018, HUM MOL GENET, V27, P2678, DOI 10.1093/hmg/ddy178
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Melo E, 2018, EBIOMEDICINE, V27, P258, DOI 10.1016/j.ebiom.2017.12.011
   Oberstein A, 2017, P NATL ACAD SCI USA, V114, pE8244, DOI 10.1073/pnas.1710799114
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Panopoulos AD, 2017, STEM CELL REP, V8, P1086, DOI 10.1016/j.stemcr.2017.03.012
   Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037
   Pickrell JK, 2014, AM J HUM GENET, V94, P559, DOI 10.1016/j.ajhg.2014.03.004
   Ray PS, 2009, NATURE, V457, P915, DOI 10.1038/nature07598
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Smemo S, 2014, NATURE, V507, P371, DOI 10.1038/nature13138
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tang K, 2015, BBA-GENE REGUL MECH, V1849, P201, DOI 10.1016/j.bbagrm.2014.05.022
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Zhang JH, 2004, DEVELOPMENT, V131, P1553, DOI 10.1242/dev.01041
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 42
TC 20
Z9 19
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD JUN 11
PY 2019
VL 12
IS 6
BP 1342
EP 1353
DI 10.1016/j.stemcr.2019.04.012
PG 12
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IC5KY
UT WOS:000471007700018
PM 31080113
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, J
   Kim, H
   Roh, H
   Kwon, Y
AF Kim, Jihyun
   Kim, Hyunhee
   Roh, Heewon
   Kwon, Youngjoo
TI Causes of hyperhomocysteinemia and its pathological significance
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Review
DE Homocysteine; Hyperhomocysteinemia; Disease caused by
   hyperhomocysteinemia
ID CHRONIC HEART-FAILURE; FOLIC-ACID; PLASMA HOMOCYSTEINE; MACULAR
   DEGENERATION; RENAL-DISEASE; RISK-FACTOR; HEMODIALYSIS-PATIENTS;
   CARDIOVASCULAR RISK; ALZHEIMERS-DISEASE; SERUM HOMOCYSTEINE
AB In the last 10 years, homocysteine has been regarded as a marker of cardiovascular disease and a definite risk factor for many other diseases. Homocysteine is biosynthesized from methionine through multiple steps and then goes through one of two major metabolic pathways: remethylation and transsulfuration. Hyperhomocysteinemia is a state in which too much homocysteine is present in the body. The main cause of hyperhomocysteinemia is a dysfunction of enzymes and cofactors associated with the process of homocysteine biosynthesis. Other causes include excessive methionine intake, certain diseases and side effects of some drugs. Hyperhomocysteinemia is a trigger for many diseases, such as atherosclerosis, congestive heart failure, age-related macular degeneration, Alzheimer's disease and hearing loss. There are many studies showing a positive relationship between homocysteine level and various symptoms. We speculate that a high level of homocysteine can be the sole reason or an aggravating factor in numerous diseases for which causal links are not fully understood.
C1 [Kim, Jihyun; Kim, Hyunhee; Roh, Heewon; Kwon, Youngjoo] Ewha Womans Univ, Ewha Inst Global Pharm Leadership, Coll Pharm, Seoul 120750, South Korea.
C3 Ewha Womans University
RP Kwon, Y (通讯作者)，Ewha Womans Univ, Ewha Inst Global Pharm Leadership, Coll Pharm, Seoul 120750, South Korea.
EM ykwon@ewha.ac.kr
RI Kwon, Youngjoo/AAF-6120-2020
OI Kwon, Youngjoo/0000-0001-6256-3042
FU Grant of the Korean Health Technology R&D Project, Ministry of Health &
   Welfare, Republic of Korea [HI14C2469]
FX This study was supported by a Grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (HI14C2469).
CR ALLEN RH, 1993, METABOLISM, V42, P1448, DOI 10.1016/0026-0495(93)90198-W
   Almadori G, 2002, CANCER, V94, P1006, DOI 10.1002/cncr.10343
   Asfar S, 2007, J CARDIOVASC SURG, V48, P601
   Bamashmoos SA, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-423
   Blacher J, 1999, J NEPHROL, V12, P248
   Blom HJ, 2006, NAT REV NEUROSCI, V7, P724, DOI 10.1038/nrn1986
   Blom HJ, 2011, J INHERIT METAB DIS, V34, P75, DOI 10.1007/s10545-010-9177-4
   Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894
   Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337
   Carmel R, 2006, COBALAMIN VITAMIN B, P482
   Carmel R, 2008, BLOOD, V112, P2214, DOI 10.1182/blood-2008-03-040253
   Catargi B, 1999, THYROID, V9, P1163, DOI 10.1089/thy.1999.9.1163
   Champe P., 2008, BIOCH LIPPINCOTTS IL
   Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Chwatko G, 2007, FASEB J, V21, P1707, DOI 10.1096/fj.06-7435com
   Cicone F, 2018, J ENDOCRINOL INVEST, V41, P831, DOI 10.1007/s40618-017-0811-y
   Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449
   Clayton PT, 2006, J INHERIT METAB DIS, V29, P317, DOI 10.1007/s10545-005-0243-2
   Cooke GE, 2000, J AM COLL CARDIOL, V36, P509, DOI 10.1016/S0735-1097(00)00756-7
   Corona G, 1997, EUR J CANCER, V33, P1284, DOI 10.1016/S0959-8049(97)00121-4
   Desouza C, 2002, DRUGS, V62, P605, DOI 10.2165/00003495-200262040-00005
   Ducloux D, 2002, NEPHROL DIAL TRANSPL, V17, P865, DOI 10.1093/ndt/17.5.865
   Dutta S, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-25
   Esse R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055483
   Fasano T, 2017, LARYNGOSCOPE, V127, P2375, DOI 10.1002/lary.26514
   Fournier P, 2015, CLIN LAB, V61, P1137, DOI 10.7754/Clin.Lab.2015.141238
   Fowler B, 2005, Ther Umsch, V62, P641, DOI 10.1024/0040-5930.62.9.641
   Ganguly P, 2015, NUTR J, V14, DOI 10.1186/1475-2891-14-6
   Ghandour H, 2002, KIDNEY INT, V62, P2246, DOI 10.1046/j.1523-1755.2002.00666.x
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Gocer C, 2009, J INT ADV OTOL, V5, P340
   Healthline, 2016, WHAT MEG AN
   Hooper C, 2017, J NUTR HEALTH AGING, V21, P1075, DOI 10.1007/s12603-017-0989-x
   Houston DK, 1999, AM J CLIN NUTR, V69, P564
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Humphrey LL, 2008, MAYO CLIN PROC, V83, P1203, DOI 10.4065/83.11.1203
   Iqbal NS, 2012, J CARD FAIL, V18, pS87, DOI 10.1016/j.cardfail.2012.06.521
   Iroku-Malize Tochi, 2016, FP Essent, V445, P24
   Karolczak K, 2009, PHYSIOL RES, V58, P623, DOI 10.33549/physiolres.931566
   Kato I, 1999, BRIT J CANCER, V79, P1917, DOI 10.1038/sj.bjc.6690305
   Keshteli AH, 2015, WORLD J GASTROENTERO, V21, P1081, DOI 10.3748/wjg.v21.i4.1081
   Kozyraki R, 2013, BIOCHIMIE, V95, P1002, DOI 10.1016/j.biochi.2012.11.004
   Kruger WD, 2000, MOL GENET METAB, V70, P53, DOI 10.1006/mgme.2000.2993
   Kundu S, 2012, HEARING RES, V284, P42, DOI 10.1016/j.heares.2011.12.006
   LAIDLAW SA, 1994, AM J KIDNEY DIS, V23, P504, DOI 10.1016/S0272-6386(12)80371-4
   Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059
   Lentz SR, 2002, BLOOD, V100, P2108, DOI 10.1182/blood-2002-03-0727
   Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851
   Loehrer FMT, 1998, NEPHROL DIAL TRANSPL, V13, P656, DOI 10.1093/ndt/13.3.656
   Loprinzi PD, 2012, HEAR J, V65, P30, DOI [10.1097/01.HJ.0000416274.98729.66, DOI 10.1097/01.HJ.0000416274.98729.66]
   Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776
   Lowenthal EA, 2000, J AM COLL NUTR, V19, P608, DOI 10.1080/07315724.2000.10718958
   MALINOW MR, 1994, J LAB CLIN MED, V123, P421
   Maron BA, 2009, ANNU REV MED, V60, P39, DOI 10.1146/annurev.med.60.041807.123308
   Martinez-Vega R, 2015, FASEB J, V29, P418, DOI 10.1096/fj.14-259283
   McCaddon A, 1998, INT J GERIATR PSYCH, V13, P235, DOI 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.3.CO;2-#
   Miller A, 2002, AM J HYPERTENS, V15, P157, DOI 10.1016/S0895-7061(01)02286-5
   Miller Alan L, 2003, Altern Med Rev, V8, P7
   Miller JW, 2013, AM J CLIN NUTR, V97, P827, DOI 10.3945/ajcn.112.049932
   MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033
   Mohamed R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09731-y
   Morris MS, 2001, ATHEROSCLEROSIS, V155, P195, DOI 10.1016/S0021-9150(00)00537-2
   MUDD SH, 1958, J BIOL CHEM, V231, P481
   Nakanishi T, 2002, AM J KIDNEY DIS, V40, P909, DOI 10.1053/ajkd.2002.36320
   Natural Kidney Association, 2015, GLOM FILTR RAT GFR
   Norouzi V, 2011, ANADOLU KARDIYOL DER, V11, P698, DOI 10.5152/akd.2011.191
   Orzechowska-Pawilojc A, 2009, ENDOKRYNOL POL, V60, P443
   Pajares MA, 2006, CELL MOL LIFE SCI, V63, P2792, DOI 10.1007/s00018-006-6249-6
   Pietrzik K, 2010, CLIN PHARMACOKINET, V49, P535, DOI 10.2165/11532990-000000000-00000
   Pinna A, 2018, ACTA OPHTHALMOL, V96, pE269, DOI 10.1111/aos.13343
   Plazar N, 2010, RADIOL ONCOL, V44, P79, DOI 10.2478/v10019-010-0022-z
   Prasad A, 1999, J AM COLL CARDIOL, V34, P507, DOI 10.1016/S0735-1097(99)00216-8
   Qin XH, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-2
   Quere I, 1999, BIOCHEM BIOPH RES CO, V254, P127, DOI 10.1006/bbrc.1998.9079
   Qujeq D, 2001, CLIN BIOCHEM, V34, P97, DOI 10.1016/S0009-9120(01)00187-4
   Qureshi Mabood, 2003, Exp Clin Cardiol, V8, P147
   REFSUM H, 1985, CLIN CHEM, V31, P624
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Sadananda Adiga MN, 2008, INDIAN J PEDIATR, V75, P235, DOI 10.1007/s12098-008-0051-4
   Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217
   Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613
   Sreckovic B, 2016, DIAB MET SYNDR S, V1871-4021, P30200
   STEEGERSTHEUNISSEN RPM, 1992, CONTRACEPTION, V45, P129, DOI 10.1016/0010-7824(92)90047-W
   Suliman ME, 1997, NEPHROL DIAL TRANSPL, V12, P2332, DOI 10.1093/ndt/12.11.2332
   Sun CF, 2002, CLIN CHIM ACTA, V321, P55, DOI 10.1016/S0009-8981(02)00092-X
   Toroser D, 2007, BIOCHEM J, V405, P583, DOI 10.1042/BJ20061868
   van Guldener C, 2006, NEPHROL DIAL TRANSPL, V21, P1161, DOI 10.1093/ndt/gfl044
   van Guldener C, 2001, KIDNEY INT, V59, pS234, DOI 10.1046/j.1523-1755.2001.59780234.x
   van Guldener C, 2000, SEMIN THROMB HEMOST, V26, P313, DOI 10.1055/s-2000-8407
   Veldman BAJ, 2005, DIABETIC MED, V22, P301, DOI 10.1111/j.1464-5491.2005.01415.x
   Vitvitsky V, 2003, REDOX REP, V8, P57, DOI 10.1179/135100003125001260
   Vizzardi Enrico, 2009, Recent Pat Cardiovasc Drug Discov, V4, P15
   Weekman EM, 2017, ASN NEURO, V9, DOI 10.1177/1759091417742296
   Wierzbicki Anthony S, 2007, Diab Vasc Dis Res, V4, P143
   Wu LL, 2002, CLIN CHIM ACTA, V322, P21, DOI 10.1016/S0009-8981(02)00174-2
   Wu XY, 2014, HERED CANCER CLIN PR, V12, DOI 10.1186/1897-4287-12-2
   Yakub M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033222
   Yakub M, 2010, PAK J MED SCI, V26, P923
   Zhang DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123423
   Zhang DH, 2012, J MOL CELL CARDIOL, V53, P487, DOI 10.1016/j.yjmcc.2012.07.010
   Zhao JJ, 2017, J STROKE CEREBROVASC, V26, P2695, DOI 10.1016/j.jstrokecerebrovasdis.2016.10.012
NR 102
TC 88
Z9 92
U1 3
U2 27
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD APR
PY 2018
VL 41
IS 4
BP 372
EP 383
DI 10.1007/s12272-018-1016-4
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GD9YT
UT WOS:000430869800002
PM 29552692
DA 2022-11-30
ER

PT J
AU Fernandez-Godino, R
   Bujakowska, KM
   Pierce, EA
AF Fernandez-Godino, Rosario
   Bujakowska, Kinga M.
   Pierce, Eric A.
TI Changes in extracellular matrix cause RPE cells to make basal deposits
   and activate the alternative complement pathway
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR-DEGENERATION; BRUCHS MEMBRANE;
   MALATTIA LEVENTINESE; TISSUE INHIBITOR; FACTOR-H; DRUSEN; EFEMP1; C3;
   METALLOPROTEINASES
AB The design of efficient therapies for age-related macular degeneration (AMD) is limited by our understanding of the pathogenesis of basal deposits, which form between retinal pigment epithelium (RPE) and Bruch's membrane (BrM) early in disease, and involve activation of the complement system. To investigate the roles of BrM, RPE and complement in an AMD, we generated abnormal extracellular matrix (ECM) using CRISPR-edited ARPE-19 cells. We introduced to these cells the p.R345W mutation in EFEMP1, which causes early-onset macular degeneration. The abnormal ECM binds active complement C3 and causes the formation of basal deposits by normal human fetal (hf)RPE cells. Human fetal RPE (hfRPE) cells grown on abnormal ECM or BrM explants from AMD donors show chronic activation of the alternative complement pathway by excessive deposition of C3b. This process is exacerbated by impaired ECM turnover via increased matrix metalloproteinase-2 activity. The local cleavage of C3 via convertase-independent mechanisms can be a new therapeutic target for early AMD.
C1 [Fernandez-Godino, Rosario; Bujakowska, Kinga M.; Pierce, Eric A.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Ocular Genom Inst, Boston, MA 02114 USA.
   [Fernandez-Godino, Rosario; Bujakowska, Kinga M.; Pierce, Eric A.] Harvard Med Sch, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School
RP Pierce, EA (通讯作者)，Massachusetts Eye & Ear Infirm, Ocular Genom Inst, 243 Charles St, Boston, MA 02114 USA.
EM eric_pierce@meei.harvard.edu
RI Bujakowska, Kinga Maria/AGL-1293-2022
OI FERNANDEZ GODINO, ROSARIO/0000-0002-8831-7189
FU Ocular Genomics Institute; NATIONAL EYE INSTITUTE [P30EY014104] Funding
   Source: NIH RePORTER
FX This work was supported by the Ocular Genomics Institute.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andersson J, 2005, BIOMATERIALS, V26, P1477, DOI 10.1016/j.biomaterials.2004.05.011
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817
   Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Deryugina EI, 1998, CANCER RES, V58, P3743
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hindmarsh EJ, 1998, J IMMUNOL, V160, P6128
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hulleman JD, 2011, MOL BIOL CELL, V22, P4765, DOI 10.1091/mbc.E11-08-0695
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   LEIVO I, 1986, J CELL BIOL, V103, P1091, DOI 10.1083/jcb.103.3.1091
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Maminishkis A, 2010, JOVE-J VIS EXP, V45, P2032, DOI DOI 10.3791/2032
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   Maruyama T, 2015, NAT BIOTECHNOL, V33, P538, DOI 10.1038/nbt.3190
   Mastellos D, 2004, MOL IMMUNOL, V40, P1213, DOI 10.1016/j.molimm.2003.10.019
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Morrison CJ, 2009, CURR OPIN CELL BIOL, V21, P645, DOI 10.1016/j.ceb.2009.06.006
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   MURPHY G, 1994, J BIOL CHEM, V269, P6632
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821
   PANGBURN MK, 1983, FED PROC, V42, P139
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Qu HC, 2013, IMMUNOBIOLOGY, V218, P496, DOI 10.1016/j.imbio.2012.06.003
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shipley JM, 1996, J BIOL CHEM, V271, P4335
   Sivakumar P, 2008, INFLAMM RES, V57, P410, DOI 10.1007/s00011-008-7166-y
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tan RJ, 2012, AM J PHYSIOL-RENAL, V302, pF1351, DOI 10.1152/ajprenal.00037.2012
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tziakas DN, 2005, CARDIOVASC DRUG THER, V19, P399, DOI 10.1007/s10557-005-5417-5
   Chu VT, 2015, NAT BIOTECHNOL, V33, P543, DOI 10.1038/nbt.3198
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 72
TC 40
Z9 40
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 1
PY 2018
VL 27
IS 1
BP 147
EP 159
DI 10.1093/hmg/ddx392
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FS1YV
UT WOS:000419575800012
PM 29095988
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Davis, RJ
   Alam, NM
   Zhao, CP
   Mueller, M
   Saini, JS
   Blenkinsop, TA
   Mazzoni, F
   Campbell, M
   Borden, SM
   Charniga, CJ
   Lederman, PL
   Aguilar, V
   Naimark, M
   Fiske, M
   Boles, N
   Temple, S
   Finnemann, SC
   Prusky, GT
   Stern, JH
AF Davis, Richard J.
   Alam, Nazia M.
   Zhao, Cuiping
   Mueller, Claudia
   Saini, Janmeet S.
   Blenkinsop, Timothy A.
   Mazzoni, Francesca
   Campbell, Melissa
   Borden, Susan M.
   Charniga, Carol J.
   Lederman, Patty L.
   Aguilar, Vanessa
   Naimark, Michael
   Fiske, Michael
   Boles, Nathan
   Temple, Sally
   Finnemann, Silvia C.
   Prusky, Glen T.
   Stern, Jeffrey H.
TI The Developmental Stage of Adult Human Stem Cell-Derived Retinal Pigment
   Epithelium Cells Influences Transplant Efficacy for Vision Rescue
SO STEM CELL REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; HUMAN RPE; SPATIAL VISION; ROYAL-COLLEGE; RAT;
   QUANTIFICATION; MONOLAYERS; NEURONS
AB Age-related macular degeneration (AMD) is a common cause of central visual loss in the elderly. Retinal pigment epithelial (RPE) cell loss occurs early in the course of AMD and RPE cell transplantation holds promise to slow disease progression. We report that subretinal transplantation of RPE stem cell (RPESC)-derived RPE cells (RPESC-RPE) preserved vision in a rat model of RPE cell dysfunction. Importantly, the stage of differentiation that RPESC-RPE acquired prior to transplantation influenced the efficacy of vision rescue. Whereas cells at all stages of differentiation tested rescued photoreceptor layer morphology, an intermediate stage of RPESC-RPE differentiation obtained after 4 weeks of culture was more consistent at vision rescue than progeny that were differentiated for 2 weeks or 8 weeks of culture. Our results indicate that the developmental stage of RPESC-RPE significantly influences the efficacy of RPE cell replacement, which affects the therapeutic application of these cells for AMD.
C1 [Davis, Richard J.; Zhao, Cuiping; Saini, Janmeet S.; Campbell, Melissa; Borden, Susan M.; Charniga, Carol J.; Lederman, Patty L.; Aguilar, Vanessa; Naimark, Michael; Boles, Nathan; Temple, Sally; Stern, Jeffrey H.] Regenerat Res Fdn, Neural Stem Cell Inst, One Discovery Dr, Rensselaer, NY 12144 USA.
   [Blenkinsop, Timothy A.] Icahn Sch Med Mt Sinai, Cell Dev & Regenerat Biol, New York, NY 10029 USA.
   [Alam, Nazia M.; Prusky, Glen T.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10605 USA.
   [Mueller, Claudia; Mazzoni, Francesca; Finnemann, Silvia C.] Fordham Univ, Ctr Canc Genet Dis & Gene Regulat, Dept Biol Sci, Bronx, NY 10458 USA.
   [Fiske, Michael] Univ Rochester, Med Ctr, Upstate Stem Cell cGMP Facil, Rochester, NY 14642 USA.
   [Alam, Nazia M.; Prusky, Glen T.] Burke Med Res Inst, Ctr Visual Restorat, 785 Mamaroneck Ave, White Plains, NY 10605 USA.
C3 Icahn School of Medicine at Mount Sinai; Cornell University; Fordham
   University; University of Rochester
RP Stern, JH (通讯作者)，Regenerat Res Fdn, Neural Stem Cell Inst, One Discovery Dr, Rensselaer, NY 12144 USA.
EM jeffreystern@neuralsci.org
RI Mazzoni, Francesca/T-9044-2019
OI Mazzoni, Francesca/0000-0002-7826-2786
FU Empire State Stem Cell Fund through New York State Department of Health
   [C028504]; NATIONAL EYE INSTITUTE [R01EY026215] Funding Source: NIH
   RePORTER
FX We thank Drs. Shaomei Wang and Bin Lu for the RCS rats and help in
   establishing subretinal transplant surgery, and Dr. Matthew LaVail for
   advice on phenotypic analysis of the RCS rat. This work was funded by
   the Empire State Stem Cell Fund through New York State Department of
   Health contract no. C028504. Opinions expressed here are solely those of
   the authors and do not necessarily reflect those of the Empire State
   Stem Cell Board, the New York State Department of Health, or the State
   of New York. Drs. Temple and Stern are shareholder in Athghin
   Biotechnology, Inc. Dr. Glen Prusky is a shareholder in Cerebral
   Mechanics, Inc.
CR Alam NM, 2015, INVEST OPHTH VIS SCI, V56, P1842, DOI 10.1167/iovs.14-15644
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Bourne MC, 1939, J HERED, V30, P131, DOI 10.1093/oxfordjournals.jhered.a104695
   BRUNDIN P, 1986, EXP BRAIN RES, V65, P235
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Conboy IM, 2015, AGING-US, V7, P754, DOI 10.18632/aging.100819
   Davis RJ, 2016, J OCUL PHARMACOL TH, V32, P304, DOI 10.1089/jop.2015.0162
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Ganat YM, 2012, J CLIN INVEST, V122, P2928, DOI 10.1172/JCI58767
   Gass J.D., 1997, STEREOSCOPIC ATLAS M, V4
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   LaVail M M, 2001, Prog Brain Res, V131, P617
   LAVAIL MM, 1975, J HERED, V66, P242, DOI 10.1093/oxfordjournals.jhered.a108621
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   McGill TJ, 2004, INVEST OPHTH VIS SCI, V45, P932, DOI 10.1167/iovs.03-0964
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P1906, DOI 10.1167/iovs.06-1117
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 31
TC 34
Z9 34
U1 1
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD JUL 11
PY 2017
VL 9
IS 1
BP 42
EP 49
DI 10.1016/j.stemcr.2017.05.016
PG 8
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FA1DC
UT WOS:000405178400006
PM 28625537
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ramsey, DJ
   Haddock, LJ
   Young, LH
   Eliott, D
AF Ramsey, David J.
   Haddock, Luis J.
   Young, Lucy H.
   Eliott, Dean
TI Complications of Subspecialty Ophthalmic Care: Systemic Complications
   from the Intravitreal Administration of Agents that Target the Vascular
   Endothelial Growth Factor Pathway
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Angiogenesis; choroidal neovascularization; intravitreal injection;
   systemic side effects; vascular endothelial growth factor
ID PACLITAXEL PLUS BEVACIZUMAB; DIABETIC MACULAR EDEMA; ANTI-VEGF
   THERAPIES; CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR PHARMACOKINETICS;
   PEGAPTANIB SODIUM; ADVERSE EVENTS; IN-VITRO; THROMBOTIC MICROANGIOPATHY;
   CEREBROVASCULAR ACCIDENTS
AB The treatment of neovascular age-related macular degeneration (AMD) and other pathologic ocular conditions that overexpress the vascular endothelial growth factor (VEGF) has been revolutionized in the last decade by the introduction of intravitreal agents that target the VEGF pathway. Since treatment trials are designed primarily to assess the prevention of vision loss caused by ocular conditions, they are inadequate for detecting rare, but potentially serious, systemic side effects. The aim of this article is to present what the ophthalmologist needs to know about systemic complications from anti-VEGF therapy and review the likelihood that these side effects occur in the context of small, but often-repeated, intravitreal doses of these potent biological medications. Preferred practice patterns need to be developed that weigh the ability of these medications to mitigate potentially blinding conditions, while at the same time minimizing the risk of adverse outcomes in specific patient populations that possess multiple and often interrelated medical comorbidities.
C1 [Eliott, Dean] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Massachusetts General Hospital
RP Eliott, D (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM Dean_Eliott@meei.harvard.edu
RI Ramsey, David/AAW-2081-2021
OI Ramsey, David/0000-0002-5504-812X; Haddock, Luis/0000-0003-4179-6992;
   Young, Lucy/0000-0001-8634-7512
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   [Anonymous], 2013, AV BEV PACK INS
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Avery R. L., 2006, OPHTHALMOLOGY, V113, pe1
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023
   Barron H, 2005, GENENTECH IMPORTANT
   Barron H, 2007, GENENTECH IMPORTANT
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Braithwaite T, 2014, COCHRANE DB SYST REV, V5
   BREIER G, 1992, DEVELOPMENT, V114, P521
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brouillet S, 2012, TRENDS ENDOCRIN MET, V23, P501, DOI 10.1016/j.tem.2012.05.006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Choi K, 1998, DEVELOPMENT, V125, P725
   Christoforidis JB, 2013, CURR EYE RES, V38, P761, DOI 10.3109/02713683.2013.763988
   Chuang LH, 2011, OPHTHALMIC RES, V45, P31, DOI 10.1159/000315617
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Cross Sarah N, 2012, Rev Obstet Gynecol, V5, P2
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Cudmore MJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1977
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Davidovic SP, 2012, EUR J OPHTHALMOL, V22, P792, DOI 10.5301/ejo.5000118
   Davis A, 2012, ACTA OPHTHALMOL, V90, pe162, DOI 10.1111/j.1755-3768.2011.02117.x
   Dombi T, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-37
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Enseleit F, 2010, CURR HYPERTENS REP, V12, P33, DOI 10.1007/s11906-009-0082-x
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7
   Eylea (afilbercept), 2014, EYL AF PACK INS
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f
   Georgalas I, 2014, CURRENT DRUG SAFETY
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gora-Kupilas K, 2005, FOLIA NEUROPATHOL, V43, P31
   Gordon JD, 1996, J CLIN ENDOCR METAB, V81, P353, DOI 10.1210/jc.81.1.353
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higashide T, 2012, GRAEF ARCH CLIN EXP, V250, P603, DOI 10.1007/s00417-011-1865-8
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Introini U, 2012, J OCUL PHARMACOL TH, V28, P553, DOI 10.1089/jop.2012.0067
   Izzedine H, 2007, NEPHROL DIAL TRANSPL, V22, P1481, DOI 10.1093/ndt/gfl565
   Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001
   Jamrozy-Witkowska Agnieszka, 2011, Klin Oczna, V113, P127
   Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kapiteijn E, 2007, ANN ONCOL, V18, P1745, DOI 10.1093/annonc/mdm454
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lang GE, 2013, OPHTHALMOLOGY, V120, P2004, DOI 10.1016/j.ophtha.2013.02.019
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Lucentis (ranibizumab), 2014, LUC RAN PACK INS
   Luo JC, 2011, J MOL MED, V89, P635, DOI 10.1007/s00109-011-0739-1
   Macugen (pegaptanib), 2008, MAC PEG PACK INS
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Meyer CH, 2012, ACTA OPHTHALMOL, V90, P68, DOI 10.1111/j.1755-3768.2009.01842.x
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mitry D, 2013, COCHRANE DB SYST REV, V1
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nicholson BP, 2010, GRAEF ARCH CLIN EXP, V248, P915, DOI 10.1007/s00417-010-1315-z
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930
   Nuzzi R., 2013, SEMINARS OPHTHALMOLO
   Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915
   Petrou P, 2010, ACTA OPHTHALMOL, V88, pe136, DOI 10.1111/j.1755-3768.2009.01572.x
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Qian J, 2011, RETINA-J RET VIT DIS, V31, P161, DOI 10.1097/IAE.0b013e3181e46ad8
   Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Reff Mitchell E, 2002, Cancer Control, V9, P152
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saif MW, 2006, EXPERT OPIN DRUG SAF, V5, P553, DOI 10.1517/14740338.5.4.553
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salman AG, 2013, SAUDI J OPHTHALMOL, V27, DOI 10.1016/j.sjopt.2012.02.005
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Scartozzi R, 2009, EYE, V23, P1229, DOI 10.1038/eye.2008.162
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   SHELL JW, 1982, SURV OPHTHALMOL, V26, P207, DOI 10.1016/0039-6257(82)90081-9
   Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
   Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Simha A, 2013, COCHRANE DB SYST REV, V10
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Snider KL, 2009, TARGET ONCOL, V4, P67, DOI 10.1007/s11523-009-0106-0
   Steffensmeier ACG, 2007, AM J OPHTHALMOL, V143, P512, DOI 10.1016/j.ajo.2006.10.007
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Sullivan L, 2014, EYE, V28, P492, DOI 10.1038/eye.2013.311
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tarantola RM, 2010, RETINA-J RET VIT DIS, V30, P1405, DOI 10.1097/IAE.0b013e3181f57d58
   Toklu Y, 2012, CUTAN OCUL TOXICOL, V31, P85, DOI 10.3109/15569527.2011.609207
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Vedula SS, 2008, COCHRANE DB SYST REV, V2
   Velez-Montoya R, 2009, RETINA-J RET VIT DIS, V29, P20, DOI 10.1097/IAE.0b013e318186c64e
   Virgili G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub3
   Wang Donghyun, 2014, Korean J Ophthalmol, V28, P32, DOI 10.3341/kjo.2014.28.1.32
   Xu L JN, 2006, AM ASS PHARM SCI M S
   Yohendran J, 2010, MIDDLE EAST AFR J OP, V17, P281, DOI 10.4103/0974-9233.65497
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zucchiatti I, 2011, EUR J OPHTHALMOL, V21, P336, DOI 10.5301/EJO.2010.5819
NR 145
TC 6
Z9 6
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2014
VL 29
IS 5-6
SI SI
BP 263
EP 275
DI 10.3109/08820538.2014.959195
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS0ZW
UT WOS:000344006400002
PM 25325852
DA 2022-11-30
ER

PT J
AU Sharma, K
   Sharma, NK
   Anand, A
AF Sharma, Kaushal
   Sharma, Neel Kamal
   Anand, Akshay
TI Why AMD is a disease of ageing and not of development: mechanisms and
   insights
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Review
DE age related macular degeneration; metabolism; 7-ketocholesterol;
   angiogenic proteins; VEGF; degenerative diseases; complement factors;
   developmental disorders
ID ENDOTHELIAL GROWTH-FACTOR; LOW-DENSITY-LIPOPROTEIN; HUMAN BRUCHS
   MEMBRANE; E-DEFICIENT MICE; MACULAR DEGENERATION; APOLIPOPROTEIN-E;
   ALZHEIMERS-DISEASE; CHOROIDAL NEOVASCULARIZATION; CRYSTALLINE
   CHOLESTEROL; COMPLEMENT ACTIVATION
AB Ageing disorders can be defined as the progressive and cumulative outcome of several defective cellular mechanisms as well as metabolic pathways, consequently resulting in degeneration. Environment plays an important role in its pathogenesis. In contrast, developmental disorders arise from inherited mutations and usually the role of environmental factors in development of disease is minimal. Age related macular degeneration (AMD) is one such retinal degenerative disorder which starts with the progression of age. Metabolism plays an important role in initiation of such diseases of ageing. Cholesterol metabolism and their oxidized products like 7-ketocholesterol have been shown to adversely impact retinal pigment epithelium (RPE) cells. These molecules can initiate mitochondrial apoptotic processes and also influence the complements factors and expression of angiogenic proteins like VEGF etc. In this review we highlight why and how AMD is an ageing disorder and not a developmental disease substantiated by disrupted cholesterol metabolism common to several age related diseases.
C1 [Sharma, Kaushal; Anand, Akshay] Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
   [Sharma, Neel Kamal] NEI, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD 20892 USA.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Anand, A (通讯作者)，Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
EM akshay1anand@rediffmail.com
CR ALVING CR, 1977, J IMMUNOL, V118, P342
   Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Anand A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04114
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arlt A, 2011, EUR J CELL BIOL, V90, P545, DOI 10.1016/j.ejcb.2010.10.002
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Brown AJ, 1996, J LIPID RES, V37, P320
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Calkin AC, 2010, ARTERIOSCL THROM VAS, V30, P1513, DOI 10.1161/ATVBAHA.109.191197
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6
   Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027
   Erridge C, 2007, FREE RADICAL RES, V41, P260, DOI 10.1080/10715760601070091
   FRIEDMAN DB, 1988, GENETICS, V118, P75
   HASSELBACHER P, 1980, ATHEROSCLEROSIS, V37, P239, DOI 10.1016/0021-9150(80)90009-X
   Hernandez L, 2010, DEV CELL, V19, P413, DOI 10.1016/j.devcel.2010.08.013
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Huang JD, 2012, BBA-MOL CELL BIOL L, V1821, P637, DOI 10.1016/j.bbalip.2012.01.013
   Ignacio R., 2010, J LIPID RES, V51, P2847, DOI [10.1194/jlr.r004820, DOI 10.1194/JLR.R004820]
   Im SS, 2011, CIRC RES, V108, P996, DOI 10.1161/CIRCRESAHA.110.226878
   Ji Y, 2001, J ALZHEIMERS DIS, V3, P23, DOI 10.3233/JAD-2001-3105
   Kalaria RN, 1997, LANCET, V349, P1174, DOI 10.1016/S0140-6736(05)63052-8
   KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1
   KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lauderback CM, 2001, BIOCHEMISTRY-US, V40, P2548, DOI 10.1021/bi002312k
   Lee WH, 2009, Z NATURFORSCH C, V64, P307
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Lemaire-Ewing S, 2009, CELL BIOL TOXICOL, V25, P127, DOI 10.1007/s10565-008-9063-0
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Lim Unhee, 2012, Methods Mol Biol, V863, P359, DOI 10.1007/978-1-61779-612-8_23
   Luoma PV, 2008, EUR J CLIN PHARMACOL, V64, P841, DOI 10.1007/s00228-008-0515-5
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Martins IJ, 2006, MOL PSYCHIATR, V11, P721, DOI 10.1038/sj.mp.4001854
   Miguet-Alfonsi C, 2002, BIOCHEM PHARMACOL, V64, P527, DOI 10.1016/S0006-2952(02)01110-3
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Sasada T, 2008, ANN SURG ONCOL, V15, P609, DOI 10.1245/s10434-007-9669-0
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   SEIFERT PS, 1987, MOL IMMUNOL, V24, P1303, DOI 10.1016/0161-5890(87)90125-8
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   THOMAS JP, 1987, CANCER LETT, V35, P295, DOI 10.1016/0304-3835(87)90131-5
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Vejux A, 2008, BRAZ J MED BIOL RES, V41, P545, DOI 10.1590/S0100-879X2008000700001
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   VOGT W, 1985, MOL IMMUNOL, V22, P101, DOI 10.1016/S0161-5890(85)80003-1
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weller RO, 2003, NEUROL RES, V25, P611, DOI 10.1179/016164103101202057
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543
NR 86
TC 34
Z9 35
U1 0
U2 5
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD JUL 10
PY 2014
VL 6
AR 151
DI 10.3389/fnagi.2014.00151
PG 11
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA AN8ZT
UT WOS:000340895600001
PM 25071560
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Martin-Gonzalez, A
   Kotliar, K
   Rios-Martinez, J
   Lanzl, I
   Navab, N
AF Martin-Gonzalez, Anabel
   Kotliar, Konstantin
   Rios-Martinez, Jorge
   Lanzl, Ines
   Navab, Nassir
TI Mediated-reality magnification for macular degeneration rehabilitation
SO JOURNAL OF MODERN OPTICS
LA English
DT Article
DE age-related macular degeneration; central vision loss; low vision
   rehabilitation; mediated reality; head-mounted display
ID AGE-RELATED MACULOPATHY; VISION REHABILITATION; VISUAL IMPAIRMENT;
   DEVICES; SYSTEM
AB Age-related macular degeneration (AMD) is a gradually progressive eye condition, which is one of the leading causes of blindness and low vision in the Western world. Prevailing optical visual aids compensate part of the lost visual function, but omitting helpful complementary information. This paper proposes an efficient magnification technique, which can be implemented on a head-mounted display, for improving vision of patients with AMD, by preserving global information of the scene. Performance of the magnification approach is evaluated by simulating central vision loss in normally sighted subjects. Visual perception was measured as a function of text reading speed and map route following speed. Statistical analysis of experimental results suggests that our magnification method improves reading speed 1.2 times and spatial orientation to find routes on a map 1.5 times compared to a conventional magnification approach, being capable to enhance peripheral vision of AMD subjects along with their life quality.
C1 [Martin-Gonzalez, Anabel; Navab, Nassir] Tech Univ Munich, Chair Comp Aided Med Procedures, D-80290 Munich, Germany.
   [Kotliar, Konstantin; Lanzl, Ines] Tech Univ Munich, Klinikum Rechts Isar, Dept Ophthalmol, D-80290 Munich, Germany.
   [Rios-Martinez, Jorge] INRIA, Lab Informat Grenoble, Grenoble, France.
C3 Technical University of Munich; Technical University of Munich; Inria;
   UDICE-French Research Universities; Communaute Universite Grenoble
   Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble
   Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)
RP Martin-Gonzalez, A (通讯作者)，Tech Univ Munich, Chair Comp Aided Med Procedures, D-80290 Munich, Germany.
EM martingo@in.tum.de
RI Rios-Martinez, Jorge A/H-1139-2018
OI Rios-Martinez, Jorge A/0000-0003-4208-0515; Kotliar,
   Konstantin/0000-0003-2087-957X; Martin-Gonzalez,
   Anabel/0000-0002-6512-1060
FU Bayerische Forschungsstiftung (BFS); Secretaria de Educacion Publica de
   Mexico (SEP); TUM-Graduate School (TUM-GS); TUM Gender Center
FX This work was supported, in part, by Bayerische Forschungsstiftung
   (BFS), Secretaria de Educacion Publica de Mexico (SEP), TUM-Graduate
   School (TUM-GS), and TUM Gender Center.
CR ANSTIS SM, 1974, VISION RES, V14, P589, DOI 10.1016/0042-6989(74)90049-2
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Damiano A. M., 1998, IOVS, V39, pS602
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Everingham MR, 2003, INT J HUM-COMPUT INT, V15, P231, DOI 10.1207/S15327590IJHC1502_3
   Farago P, 2005, LECT NOTES COMPUT SC, V3514, P727
   Harper R, 1999, BRIT J OPHTHALMOL, V83, P495, DOI 10.1136/bjo.83.4.495
   Hicks SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067695
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Keahey TA, 1996, IEEE SYMPOSIUM ON INFORMATION VISUALIZATION '96, PROCEEDINGS, P38, DOI 10.1109/INFVIS.1996.559214
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li Y, 2011, QUAL LIFE RES, V20, P845, DOI 10.1007/s11136-010-9825-z
   LOSHIN DS, 1989, OPTOMETRY VISION SCI, V66, P389, DOI 10.1097/00006324-198906000-00009
   Mann S., 1994, 260 TR MIT MED LAB P
   MASSOF RW, 1992, OPTOMETRY VISION SCI, V69, P32, DOI 10.1097/00006324-199201000-00005
   Peli E, 2007, J SOC INF DISPLAY, V15, P1037, DOI 10.1889/1.2825088
   Peli E, 2009, INT J ARTIF INTELL T, V18, P365, DOI 10.1142/S0218213009000184
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Schuchard RA, 1994, CLIN EYE VISION CARE, V6, P101
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   WAHL HW, 2000, LIGHTHOUSE HDB VISIO, P1069
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 25
TC 8
Z9 8
U1 3
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0950-0340
EI 1362-3044
J9 J MOD OPTIC
JI J. Mod. Opt.
PY 2014
VL 61
IS 17
BP 1400
EP 1408
DI 10.1080/09500340.2014.936110
PG 9
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA AO9TO
UT WOS:000341700400005
DA 2022-11-30
ER

PT J
AU Stahl, A
   Paschek, L
   Martin, G
   Feltgen, N
   Hansen, LL
   Agostini, HT
AF Stahl, Andreas
   Paschek, Lilija
   Martin, Gottfried
   Feltgen, Nicolas
   Hansen, Lutz L.
   Agostini, Hansjuergen T.
TI Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF
   inhibition in an in vitro model of RPE-induced angiogenesis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Angiogenesis; Spheroid; RPE; Endothelial; CNV; AMD; Retina; Bevacizumab
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULAR MEMBRANES; INTRAVITREAL BEVACIZUMAB AVASTIN; SPHEROIDAL
   COCULTURE MODEL; SMOOTH-MUSCLE CELLS; MACULAR DEGENERATION; FACTOR
   SECRETION; EXPRESSION; LOCALIZATION
AB Choroidal neovascularisation (CNV) as a feature of exudative age-related macular degeneration (AMD) is partially regulated by retinal pigment epithelium (RPE). In this study, the effect of combinatory anti-angiogenic treatment was evaluated using a novel in vitro assay of RPE-induced angiogenesis.
   RPE isolated from surgically excised CNV-membranes (CNV-RPE) was used to stimulate sprouting of endothelial cell (EC) spheroids in a 3D collagen matrix. The anti-angiogenic effect of solitary anti-VEGF antibodies (bevacizumab) was compared to a combinatory treatment with anti-VEGF and anti-FGF2 antibodies.
   Anti-VEGF treatment inactivated all RPE-derived VEGF but was unable to fully inhibit EC sprouting induced by CNV-RPE. Combined anti-VEGF/anti-FGF treatment inactivated both growth factors and reduced EC sprouting significantly.
   RPE from CNV patients expresses angiogenic growth factors that act in part independently of VEGF. Targeted combinatory therapy can be superior to solitary anti-VEGF therapy. One possible candidate for combinatory therapy is FGF2.
C1 [Agostini, Hansjuergen T.] Univ Freiburg, Dept Ophthalmol, D-79106 Freiburg, Germany.
   [Stahl, Andreas; Paschek, Lilija; Martin, Gottfried; Feltgen, Nicolas; Hansen, Lutz L.; Agostini, Hansjuergen T.] Univ Eye Hosp Freiburg, Cell Biol Lab, D-79106 Freiburg, Germany.
C3 University of Freiburg; University of Freiburg
RP Agostini, HT (通讯作者)，Univ Freiburg, Dept Ophthalmol, Killianstr 5, D-79106 Freiburg, Germany.
EM hansjuergen.agostini@uniklinik-freiburg.de
RI Hansen, Lutz L/A-1390-2011
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   HUNT RC, 1990, J CELL PHYSIOL, V145, P187, DOI 10.1002/jcp.1041450202
   Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100
   ISHIGOOKA H, 1992, EXP EYE RES, V55, P203, DOI 10.1016/0014-4835(92)90184-T
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341
   Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00-0139com
   Korff T, 1999, J CELL SCI, V112, P3249
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ni M, 2005, EXP EYE RES, V81, P286, DOI 10.1016/j.exer.2005.01.027
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Relf M, 1997, CANCER RES, V57, P963
   Rosenthal R, 2003, ADV EXP MED BIOL, V533, P107
   Rosenthal R, 2007, MOL VIS, V13, P443
   SAKAMOTO T, 1995, CURR EYE RES, V14, P621, DOI 10.3109/02713689508998488
   Schlunck G, 2002, EXP EYE RES, V74, P571, DOI 10.1006/exer.2001.1148
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stahl A, 2005, FEBS LETT, V579, P5338, DOI 10.1016/j.febslet.2005.09.005
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   Takeda Y, 2007, BLOOD, V109, P1524, DOI 10.1182/blood-2006-08-041970
   Wenger A, 2004, TISSUE ENG, V10, P1536, DOI 10.1089/ten.2004.10.1536
   Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231
NR 40
TC 35
Z9 38
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2009
VL 247
IS 6
BP 767
EP 773
DI 10.1007/s00417-009-1058-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 440MP
UT WOS:000265704700007
PM 19247683
DA 2022-11-30
ER

PT J
AU Shu, XH
   Tulloch, B
   Lennon, A
   Vlachantoni, D
   Zhou, XZ
   Hayward, C
   Wright, AF
AF Shu, XH
   Tulloch, B
   Lennon, A
   Vlachantoni, D
   Zhou, XZ
   Hayward, C
   Wright, AF
TI Disease mechanisms in late-onset retinal macular degeneration associated
   with mutation in C1QTNF5
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SORSBYS FUNDUS DYSTROPHY; FRIZZLED-RELATED PROTEIN; PIGMENT
   EPITHELIAL-CELLS; AGE-RELATED MACULOPATHY; ENDOPLASMIC-RETICULUM; TISSUE
   INHIBITOR; BRUCHS MEMBRANE; QUALITY-CONTROL; GENE; DRUSEN
AB Late-onset retinal macular degeneration (L-ORMD) is an autosomal dominant condition resembling age-related macular degeneration (AMD) in which a key pathological feature is a thick extracellular sub-retinal pigment epithelial (RPE) deposit. L-ORMD is caused by mutation in the C1QTNF5 (CTRP5) short-chain collagen gene, but the disease mechanism is unknown. Here, we first show that wild-type C1QTNF5 is secreted, whereas mutant C1QTNF5 is misfolded and retained within the endoplasmic reticulum (ER). Secondly, the ER retained mutant protein has a shorter half-life than wild-type C1QTNF5 and is preferentially degraded by proteasomes. Thirdly, C1QTNF5 is shown to interact with the membrane-type frizzled related protein (MFRP), on the basis of yeast two-hybrid, protein pull-down and co-immunoprecipitation assays and RPE co-localization. These data suggest that L-ORMD is due to insufficient levels of secreted C1QTNF5, compromised RPE cell function resulting from ER retention of the mutant protein or both mechanisms.
C1 Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh
RP Shu, XH (通讯作者)，Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
EM xinhua.shu@hgu.mrc.ac.uk
RI Hayward, Caroline/M-8818-2016
OI Hayward, Caroline/0000-0002-9405-9550
FU MRC [MC_U127584475] Funding Source: UKRI; Medical Research Council
   [MC_U127584475] Funding Source: Medline
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Ayyagari R, 2000, ARCH OPHTHALMOL-CHIC, V118, P85
   Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q
   BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9
   Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Katoh M, 2001, BIOCHEM BIOPH RES CO, V282, P116, DOI 10.1006/bbrc.2001.4551
   Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Schambony A, 2004, DIFFERENTIATION, V72, P307, DOI 10.1111/j.1432-0436.2004.07207002.x
   Shu X, 2005, HUM MOL GENET, V14, P1183, DOI 10.1093/hmg/ddi129
   Shu XH, 2006, INVEST OPHTH VIS SCI, V47, P348, DOI 10.1167/iovs.05-0858
   Stephan S, 2004, J BIOL CHEM, V279, P21469, DOI 10.1074/jbc.M305805200
   Sundin OH, 2005, P NATL ACAD SCI USA, V102, P9553, DOI 10.1073/pnas.0501451102
   Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9
NR 34
TC 48
Z9 48
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2006
VL 15
IS 10
BP 1680
EP 1689
DI 10.1093/hmg/ddl091
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 039QB
UT WOS:000237320200013
PM 16600989
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Weller, P
   Breithaupt, DE
AF Weller, P
   Breithaupt, DE
TI Identification and quantification of zeaxanthin esters in plants using
   liquid chromatography-mass spectrometry
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE zeaxanthin esters; LC-(APCI)MS; zeaxanthin oleoresin
ID GOU-QI-ZI; CAROTENOID ESTERS; MACULAR PIGMENT; LUTEIN; FRUITS;
   VEGETABLES; COLOR; ACIDS; L.
AB It has been suggested that lutein and zeaxanthin may decrease the risk for age-related macular degeneration. Surprisingly, oleoresins rich in zeaxanthin are not yet available on the market. Several authors have reported enhanced stability of esterified xanthophylls, so plants containing zeaxanthin esters were investigated to establish valuable sources for the production of durable oleoresins. Liquid chromatography-atmospheric pressure chemical ionization mass spectrometry [LC-(APCI)MS] was used to unequivocally identify zeaxanthin esters of a standard mixture and in several plant extracts. Zeaxanthin esters were quantified on the basis of their respective molecular masses using zeaxanthin for calibration; total zeaxanthin was determined after saponification of aliquots of the extracts. Thus, dried wolfberries (Lycium barbarum), Chinese lanterns (Physalis alkekengi), orange pepper (Capsicum annuum), and sea buckthorn (Hippophae rhamnoides) proved to be valuable zeaxanthin ester sources. The present LC-MS method allows for an even more detailed analysis of zeaxanthin esters than reported previously.
C1 Univ Hohenheim, Inst Lebensmittelchem, D-70599 Stuttgart, Germany.
C3 University Hohenheim
RP Breithaupt, DE (通讯作者)，Univ Hohenheim, Inst Lebensmittelchem, Garbenstr 28, D-70599 Stuttgart, Germany.
EM breithau@uni-hohenheim.de
CR ALTYMYSHEV AA, 1985, IZ AKAD NAUK KIRG SS, V5, P37
   Barua AB, 2001, J CHROMATOGR A, V936, P71, DOI 10.1016/S0021-9673(01)01145-1
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BIACS PA, 1989, J AGR FOOD CHEM, V37, P350, DOI 10.1021/jf00086a017
   BIACS PA, 1994, J PLANT PHYSIOL, V143, P520, DOI 10.1016/S0176-1617(11)81816-X
   BOOTH VH, 1964, BIOCHIM BIOPHYS ACTA, V84, P188, DOI 10.1016/0926-6542(64)90076-9
   Breithaupt DE, 2000, EUR FOOD RES TECHNOL, V211, P52, DOI 10.1007/s002170050588
   Breithaupt DE, 2002, J AGR FOOD CHEM, V50, P66, DOI 10.1021/jf010970l
   Breithaupt DE, 2001, J AGR FOOD CHEM, V49, P2064, DOI 10.1021/jf001276t
   BRITTON G, 1998, CAROTENOIDS BIOSYNTH, V3, P163
   CIURDAR G, 1995, Patent No. 86881
   DAOOD HG, 1992, FOOD CHEM, V45, P151, DOI 10.1016/0308-8146(92)90027-Y
   DAVIES BH, 1970, PHYTOCHEMISTRY, V9, P797, DOI 10.1016/S0031-9422(00)85183-3
   Goda Y, 1996, J FOOD HYG SOC JPN, V37, P20
   GREGG RG, 1986, COLD SPRING HARB SYM, V51, P1093, DOI 10.1101/SQB.1986.051.01.127
   HAMILTON PB, 1990, POULTRY SCI, V69, P462, DOI 10.3382/ps.0690462
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Karrer P, 1932, HELV CHIM ACTA, V15, P1195, DOI 10.1002/hlca.193201501134
   KHACHIK F, 1999, Patent No. 9920587
   Kim HP, 2002, BIOL PHARM BULL, V25, P390, DOI 10.1248/bpb.25.390
   KOST HP, 1988, CRC HDB CHROMATOGRAP, V1, P129
   Lam KW, 1999, FOOD CHEM, V67, P173, DOI 10.1016/S0308-8146(99)00119-3
   Leung IYF, 1999, INVEST OPHTH VIS SCI, V40, pS608
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   LI Z, 1998, CHIN J CHROMATOGR, V16, P340
   LI Z, 1999, ZHIWU ZIYUAN YU HUAN, V8, P57
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Murkovic M., 2000, Journal of Food Composition and Analysis, V13, P435, DOI 10.1006/jfca.2000.0909
   NEAMTU G, 1966, REV ROUM BIOCHIM, V3, P305
   NOVRUZOV EN, 1981, KHIM PRIR SOEDIN, V1, P98
   PHILIP T, 1971, J FOOD SCI, V36, P98, DOI 10.1111/j.1365-2621.1971.tb02045.x
   Piccaglia R, 1998, IND CROP PROD, V8, P45, DOI 10.1016/S0926-6690(97)10005-X
   Pintea A, 2001, PHYTOCHEM ANALYSIS, V12, P293, DOI 10.1002/pca.600
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   SCHWEPPE H, 1993, HDB NATURFARBSTOFFE, P167
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   USDA-NCC, 1998, CAR DAT US FOODS
   Werklust B.V., 2000, WHY DIETARY ZEAXANTH, Patent No. 19950327
   Wingerath T, 1996, J AGR FOOD CHEM, V44, P2006, DOI 10.1021/jf960057y
   Zaripheh S, 2002, J NUTR, V132, p531S, DOI 10.1093/jn/132.3.531S
NR 42
TC 119
Z9 135
U1 4
U2 85
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV 19
PY 2003
VL 51
IS 24
BP 7044
EP 7049
DI 10.1021/jf034803s
PG 6
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 743NT
UT WOS:000186580100023
PM 14611169
DA 2022-11-30
ER

PT J
AU Tang, ZM
   Huo, MF
   Ju, YH
   Dai, XC
   Ni, N
   Liu, Y
   Gao, HQ
   Zhang, DD
   Sun, H
   Fan, XQ
   Chen, Y
   Gu, P
AF Tang, Zhimin
   Huo, Minfeng
   Ju, Yahan
   Dai, Xiaochan
   Ni, Ni
   Liu, Yan
   Gao, Huiqin
   Zhang, Dandan
   Sun, Hao
   Fan, Xianqun
   Chen, Yu
   Gu, Ping
TI Nanoprotection Against Retinal Pigment Epithelium Degeneration via
   Ferroptosis Inhibition
SO SMALL METHODS
LA English
DT Article
DE age-related macular degeneration; ferroptosis; iron-binding; Prussian
   blue analogue; retinal pigment epithelium
ID MODELS; IRON
AB Lethal oxidative stress and ferrous ion accumulation-mediated degeneration/death in retinal pigment epithelium (RPE) exert an indispensable impact on retinal degenerative diseases with irreversible visual impairment, especially in age-related macular degeneration (AMD), but corresponding pathogenesis-oriented medical intervention remains controversial. In this study, the potent iron-binding nanoscale Prussian blue analogue KCa[Fe-III(CN)(6)] (CaPB) with high biocompatibility is designed to inhibit RPE death and subsequently photoreceptor cell degeneration. In mice, CaPB effectively prevents RPE degeneration and ultimately fulfills superior therapeutic outcomes upon a single intravitreal injection: significant rescue of retinal structures and visual function. Through high-throughput RNA sequencing and sophisticated biochemistry evaluations, the findings initially unveil that CaPB nanoparticles protect against RPE degradation by inhibiting ferroptotic cell fate. Together with the facile, large-scale preparations and in vivo biosafety, it is believed that the synthesized CaPB therapeutic nanoparticles are promising for future clinical treatment of diverse retinal diseases involving pathological iron-dependent ferroptosis, including AMD.
C1 [Tang, Zhimin; Ju, Yahan; Dai, Xiaochan; Ni, Ni; Liu, Yan; Gao, Huiqin; Zhang, Dandan; Sun, Hao; Fan, Xianqun; Gu, Ping] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, Shanghai 200011, Peoples R China.
   [Tang, Zhimin; Ju, Yahan; Dai, Xiaochan; Ni, Ni; Liu, Yan; Gao, Huiqin; Zhang, Dandan; Sun, Hao; Fan, Xianqun; Gu, Ping] Shanghai Key Lab Orbital Dis & Ocular Oncol Shang, Shanghai 200011, Peoples R China.
   [Huo, Minfeng] Chinese Acad Sci, State Key Lab High Performance Ceram & Superfine, Shanghai Inst Ceram, Shanghai 200050, Peoples R China.
   [Chen, Yu] Shanghai Univ, Sch Life Sci, Materdicine Lab, Shanghai 200444, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Ceramics, CAS; Shanghai University
RP Fan, XQ; Gu, P (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, Shanghai 200011, Peoples R China.; Fan, XQ; Gu, P (通讯作者)，Shanghai Key Lab Orbital Dis & Ocular Oncol Shang, Shanghai 200011, Peoples R China.; Chen, Y (通讯作者)，Shanghai Univ, Sch Life Sci, Materdicine Lab, Shanghai 200444, Peoples R China.
EM fanxq@sjtu.edu.cn; chenyuedu@shu.edu.cn; guping2009@sjtu.edu.cn
RI Chen, Yu/N-8463-2015; Huo, Minfeng/GRO-0124-2022
OI Chen, Yu/0000-0002-8206-3325; Huo, Minfeng/0000-0001-5717-1845
FU National Natural Science Foundations of China [82071004, 81870687,
   51672303, 51722211, 22005327]; National Key R&D program of China
   [2018YFC1106100, 2016YFA0203700]; Program of Shanghai Subject Chief
   Scientist [18XD1404300]; Key program of Shanghai Science and Technology
   Commission [19JC1415503]; Municipal Education Commission-Gaofeng
   Clinical Medicine Grant Support [20161316]; Science and Technology
   Commission of Shanghai [20DZ2270800]
FX The research was supported by the National Natural Science Foundations
   of China (Grant No. 82071004, 81870687, 51672303, 51722211, and
   22005327), National Key R&D program of China (Grant No. 2018YFC1106100,
   2016YFA0203700), Program of Shanghai Subject Chief Scientist (Grant No.
   18XD1404300), Key program of Shanghai Science and Technology Commission
   (19JC1415503), Municipal Education Commission-Gaofeng Clinical Medicine
   Grant Support (20161316), and Science and Technology Commission of
   Shanghai (20DZ2270800). The authors thank Prof. G. Astrid Limb (Leader
   of Retinal Regeneration Group, Divisions of Pathology and Cell Biology
   Institute of Ophthalmology, University College London) for providing the
   human primary Muller cells.
CR Aung KH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.566699
   Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Gao JL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25632-1
   George SM, 2021, PROG RETIN EYE RES, V85, DOI 10.1016/j.preteyeres.2021.100969
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HALLAWAY PE, 1989, P NATL ACAD SCI USA, V86, P10108, DOI 10.1073/pnas.86.24.10108
   Ju YH, 2022, BRIT J PHARMACOL, V179, P1938, DOI 10.1111/bph.15303
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Li K, 2021, SMALL, V17, DOI 10.1002/smll.202102046
   Liu BH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03520-2
   Manian KV, 2021, CELL STEM CELL, V28, P978, DOI 10.1016/j.stem.2021.03.024
   Maya-Vetencourt JF, 2020, NAT NANOTECHNOL, V15, P698, DOI 10.1038/s41565-020-0696-3
   Menon A.V., 2021, BLOOD
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Mohamed R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09731-y
   Mohammad A, 2015, J PHARMACEUT BIOMED, V103, P85, DOI 10.1016/j.jpba.2014.10.030
   Ngo MT, 2019, BIOMATERIALS, V198, P122, DOI 10.1016/j.biomaterials.2018.06.013
   Persson HL, 2003, FREE RADICAL BIO MED, V34, P1295, DOI 10.1016/S0891-5849(03)00106-0
   Schnabolk G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.11
   Shu WT, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101469
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Song DL, 2019, RETINA-J RET VIT DIS, V39, P1965, DOI 10.1097/IAE.0000000000002295
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tang ZM, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101971
   Tang ZM, 2019, BIOMATERIALS, V194, P57, DOI 10.1016/j.biomaterials.2018.12.015
   Wang XY, 2016, NEUROBIOL AGING, V47, P168, DOI 10.1016/j.neurobiolaging.2016.07.025
   Wang YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02955-3
   Wang ZX, 2018, ANGEW CHEM INT EDIT, V57, P2214, DOI 10.1002/anie.201713177
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Wu HA, 2019, ACS NANO, V13, P14013, DOI 10.1021/acsnano.9b06134
   You GX, 2021, REV ENVIRON CONTAM T, V253, P155, DOI 10.1007/398_2020_42
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Zhang N, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.8.10
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhang QH, 2020, ADV SCI, V7, DOI 10.1002/advs.201902576
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zou T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08961-0
NR 39
TC 6
Z9 6
U1 20
U2 41
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2366-9608
J9 SMALL METHODS
JI Small Methods
PD DEC
PY 2021
VL 5
IS 12
AR 2100848
DI 10.1002/smtd.202100848
EA NOV 2021
PG 14
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA XN6IX
UT WOS:000716789400001
PM 34928015
DA 2022-11-30
ER

PT J
AU Canioni, R
   Reynaud, F
   Leite-Nascimento, T
   Gueutin, C
   Guiblin, N
   Ghermani, NE
   Jayat, C
   Daull, P
   Garrigue, JS
   Fattal, E
   Tsapis, N
AF Canioni, Romain
   Reynaud, Franceline
   Leite-Nascimento, Thais
   Gueutin, Claire
   Guiblin, Nicolas
   Ghermani, Nour-Eddine
   Jayat, Christine
   Daull, Philippe
   Garrigue, Jean-Sebastien
   Fattal, Elias
   Tsapis, Nicolas
TI Tiny dexamethasone palmitate nanoparticles for intravitreal injection:
   Optimization and in vivo evaluation
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Dexamethasone palmitate; Nanoparticles; Intravitreal injection; Retinal
   disease
ID MACULAR DEGENERATION; ALBUMIN NANOPARTICLES; SUSTAINED-RELEASE; DRUG;
   DELIVERY; IMPLANT; ENCAPSULATION; POLYETHYLENIMINE; TRIAMCINOLONE;
   MANAGEMENT
AB Tiny nanoparticles of dexamethasone palmitate (DXP) were designed as transparent suspensions for intravitreal administration to treat age-related macular degeneration (AMD). The influence of three surfactants (PEG-40-stearate and Pluronic block copolymers F68 and F127) on nanoparticles size and stability was investigated and led to an optimal formulation based on Pluronic F127 stabilizing DXP nanoparticles. Size measurements and TEM revealed tiny nanoparticles (around 35 nm) with a low opacity, compatible with further intravitreal injection. X-Ray powder diffraction (XRPD) and transmission electronic microscopy (TEM) performed on freeze-dried samples showed that DXP nanoparticles were rather monodisperse and amorphous. The efficacy of DXP nanoparticles was assessed in vivo on pigmented rabbits with unilateral intravitreal injections. After breakdown of the blood-retinal barrier (BRB) induced by injection of rhVEGF165 with carrier protein, DXP nanoparticles induced a restoration of the BRB 1 month after their intravitreal injection. However, their efficacy was limited in time most probably by clearance of DXP nanoparticles after 2 months due to their small size.
C1 [Canioni, Romain; Reynaud, Franceline; Leite-Nascimento, Thais; Gueutin, Claire; Ghermani, Nour-Eddine; Fattal, Elias; Tsapis, Nicolas] Univ Paris Saclay, Inst Galien Paris Saclay, CNRS, F-92296 Chatenay Malabry, France.
   [Reynaud, Franceline] Univ Fed Rio de Janeiro, Sch Pharm, BR-2194459 Rio De Janeiro, Brazil.
   [Leite-Nascimento, Thais] Univ Fed Goias, Sch Pharm, Lab Pharmaceut Nanotechnol & Drug Delivery Syst, Goiania, Go, Brazil.
   [Guiblin, Nicolas; Ghermani, Nour-Eddine] Univ Paris Saclay, Lab SPMS, CNRS, Cent Supelec, F-91190 Gif Sur Yvette, France.
   [Jayat, Christine; Daull, Philippe; Garrigue, Jean-Sebastien] Santen SAS, 1 Rue Pierre Fontaine, F-91000 Evry, France.
C3 Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Universite Paris Saclay; Universidade Federal do
   Rio de Janeiro; Universidade Federal de Goias; Centre National de la
   Recherche Scientifique (CNRS); UDICE-French Research Universities;
   Universite Paris Saclay
RP Tsapis, N (通讯作者)，Univ Paris Saclay, Inst Galien Paris Saclay, CNRS, F-92296 Chatenay Malabry, France.
EM nicolas.tsapis@universite-paris-saclay.fr
RI Tsapis, Nicolas/D-5606-2009; Nascimento, Thais Leite/M-3512-2013
OI Tsapis, Nicolas/0000-0003-2095-2626; Nascimento, Thais
   Leite/0000-0002-2656-7609; Reynaud, Franceline/0000-0002-9053-0931;
   Guiblin, nicolas/0000-0002-4418-0547
FU CNRS; l'Agence Nationale de la Recherche [ANR-11-EQPX-0029/Morphoscope,
   ANR-10-INBS-04/FranceBioImaging, ANR-11-IDEX-0003-02/Saclay Plant
   Sciences]
FX This research received support from CNRS. The present work has benefited
   from Imagerie-Gif core facility supported by l'Agence Nationale de la
   Recherche (ANR-11-EQPX-0029/Morphoscope,
   ANR-10-INBS-04/FranceBioImaging; ANR-11-IDEX-0003-02/Saclay Plant
   Sciences) with the precious help of C. Boulogne. Authors would like to
   acknowledge fruitful discussions with F. Agnely. Servier Medical Art is
   acknowledged for the rabbit illustration.
CR (AAO) A.A. of O, 2006, AG REL MAC DEG PREV
   ALEXANDRIDIS P, 1995, COLLOID SURFACE A, V96, P1, DOI 10.1016/0927-7757(94)03028-X
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Boissenot T, 2016, EUR J PHARM BIOPHARM, V108, P136, DOI 10.1016/j.ejpb.2016.08.017
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   de Kozak Y, 2004, EUR J IMMUNOL, V34, P3702, DOI 10.1002/eji.200425022
   DOI M, 1989, J PHARM SCI, V78, P417, DOI 10.1002/jps.2600780515
   dos Santos ALG, 2006, PHARM RES-DORDR, V23, P770, DOI 10.1007/s11095-006-9748-0
   Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4
   Fattal E., 2018, NANOPARTICULATE PROD, Patent No. WO 2018 (054953), A1
   Ferrante P, 2004, CLIN EXP OPHTHALMOL, V32, P563, DOI 10.1111/j.1442-9071.2004.00902.x
   FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   dos Santos ALG, 2006, J CONTROL RELEASE, V112, P369, DOI 10.1016/j.jconrel.2006.02.010
   Gomez-Gaete C, 2008, J CONTROL RELEASE, V128, P41, DOI 10.1016/j.jconrel.2008.02.008
   Gomez-Graete C, 2007, INT J PHARMACEUT, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Grzybowski A, 2019, J OCUL PHARMACOL TH, V35, P525, DOI 10.1089/jop.2019.0072
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Irache JM, 2005, MINI-REV MED CHEM, V5, P293, DOI 10.2174/1389557053175335
   Ishihara T, 2010, INT J PHARMACEUT, V385, P170, DOI 10.1016/j.ijpharm.2009.10.025
   Ishihara T, 2009, INT J PHARM, V365, P200, DOI 10.1016/j.ijpharm.2008.08.030
   Kassem MA, 2007, INT J PHARMACEUT, V340, P126, DOI 10.1016/j.ijpharm.2007.03.011
   Kertes PJ, 2005, CAN J OPHTHALMOL, V40, P573, DOI 10.1016/S0008-4182(05)80049-3
   Kim DH, 2006, BIOMATERIALS, V27, P3031, DOI 10.1016/j.biomaterials.2005.12.021
   Kim JK, 2011, ACS NANO, V5, P209, DOI 10.1021/nn102357y
   Kleinberg TT, 2011, SURV OPHTHALMOL, V56, P300, DOI 10.1016/j.survophthal.2010.09.001
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lian RY, 2011, AAPS PHARMSCITECH, V12, P1234, DOI 10.1208/s12249-011-9666-2
   Lorscheider M, 2019, MOL PHARMACEUT, V16, P2999, DOI 10.1021/acs.molpharmaceut.9b00237
   Lorscheider M, 2019, J CONTROL RELEASE, V296, P179, DOI 10.1016/j.jconrel.2019.01.015
   Lu XL, 2008, AAPS J, V10, P133, DOI 10.1208/s12248-008-9013-z
   Malcles A., 2013, PSEUDOPHAKE
   Merodio M, 2002, BIOMATERIALS, V23, P1587, DOI 10.1016/S0142-9612(01)00284-8
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Munoz-Fernandez S, 2006, BEST PRACT RES CL RH, V20, P487, DOI 10.1016/j.berh.2006.03.008
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Teeranachaideekul V, 2008, INT J PHARMACEUT, V354, P227, DOI 10.1016/j.ijpharm.2007.11.062
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Vela Jose I., 2012, International Ophthalmology, V32, P583, DOI 10.1007/s10792-012-9604-7
   Zucchiatti I, 2012, OPHTHALMOLOGICA, V228, P117, DOI 10.1159/000336225
NR 48
TC 1
Z9 1
U1 4
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 1
PY 2021
VL 600
AR 120509
DI 10.1016/j.ijpharm.2021.120509
EA MAR 2021
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RY2KA
UT WOS:000647745000003
PM 33766637
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Park, YG
   Cha, E
   An, HS
   Lee, KP
   Song, MH
   Kim, HK
   Park, JU
AF Park, Young-Geun
   Cha, Eunkyung
   An, Hyeon Seok
   Lee, Kyoung-Pil
   Song, Myoung Hoon
   Kim, Hong Kyun
   Park, Jang-Ung
TI Wireless phototherapeutic contact lenses and glasses with red
   light-emitting diodes
SO NANO RESEARCH
LA English
DT Article
DE transparent electronics; wearable healthcare; red light-emitting diodes;
   phototherapies
ID INDUCED DAMAGE; PHOTORECEPTOR; PHOTOBIOMODULATION; TRANSPARENT;
   ELECTRODES; ULTRATHIN; THERAPY; SYSTEMS; SENSOR; A2E
AB Light-mediated therapeutics have attracted considerable attention as a method for the treatment of ophthalmologic diseases, such as age-related macular degeneration, because of their non-invasiveness and the effectiveness to ameliorate the oxidative stress of retinal cells. However, the current phototherapeutic devices are opaque, bulky, and tethered forms, so they are not feasible for use in continuous treatment during the patient's daily life. Herein, we report wireless, wearable phototherapeutic devices with red light-emitting diodes for continuous treatments. Red light-emitting diodes were formed to be conformal to three-dimensional surfaces of glasses and contact lenses. Furthermore, fabricated light-emitting diodes had either transparency or a miniaturized size so that the user's view is not obstructed. Also, these devices were operated wirelessly with control of the light intensity. In addition, in-vitro and in-vivo tests using human retinal epithelial cells and a live rabbit demonstrated the effectiveness and reliable operation as phototherapeutic devices.
C1 [Park, Young-Geun; Cha, Eunkyung; An, Hyeon Seok; Park, Jang-Ung] Yonsei Univ, Nano Sci Technol Inst, Dept Mat Sci & Engn, Seoul 03722, South Korea.
   [Park, Young-Geun; Cha, Eunkyung; An, Hyeon Seok; Park, Jang-Ung] Inst Basic Sci IBS, Ctr Nanomed, Seoul 03722, South Korea.
   [Lee, Kyoung-Pil; Kim, Hong Kyun] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu 41944, South Korea.
   [Song, Myoung Hoon] Ulsan Natl Inst Sci & Technol UNIST, Sch Mat Sci & Engn, Ulsan 44919, South Korea.
C3 Yonsei University; Institute for Basic Science - Korea (IBS); Kyungpook
   National University; Ulsan National Institute of Science & Technology
   (UNIST)
RP Park, JU (通讯作者)，Yonsei Univ, Nano Sci Technol Inst, Dept Mat Sci & Engn, Seoul 03722, South Korea.; Park, JU (通讯作者)，Inst Basic Sci IBS, Ctr Nanomed, Seoul 03722, South Korea.; Kim, HK (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu 41944, South Korea.
EM okeye@knu.ac.kr; jang-ung@yonsei.ac.kr
RI An, Hyeon Seok/GSD-2030-2022; Park, Jang-Ung/E-9224-2010; Park,
   Young-Geun/GLV-4849-2022; Song, Myoung Hoon/F-3766-2010
OI An, Hyeon Seok/0000-0002-0342-3901; Park, Jang-Ung/0000-0003-1522-4958;
   Park, Young-Geun/0000-0003-1579-0220; 
CR Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   An BW, 2016, NANO LETT, V16, P471, DOI 10.1021/acs.nanolett.5b04134
   An HS, 2019, ADV SCI, V6, DOI 10.1002/advs.201901603
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Chen GZ, 2013, SENSOR ACTUAT A-PHYS, V203, P112, DOI 10.1016/j.sna.2013.08.029
   Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033
   Ferlauto L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03386-7
   Ferraresi C, 2015, J BIOPHOTONICS, V8, P740, DOI 10.1002/jbio.201400087
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Flores T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47082-y
   Fu RX, 2018, ADV OPT MATER, V6, DOI 10.1002/adom.201700941
   Fuma S, 2015, MOL VIS, V21, P883
   GRECO M, 1989, BIOCHEM BIOPH RES CO, V163, P1428, DOI 10.1016/0006-291X(89)91138-8
   Gutruf P, 2018, NAT ELECTRON, V1, P652, DOI 10.1038/s41928-018-0175-0
   Jang J, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.172
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Kim J, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600418
   Kim J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14997
   Ledesma HA, 2019, NAT NANOTECHNOL, V14, P645, DOI 10.1038/s41565-019-0487-x
   Lee HE, 2018, ADV MATER, V30, DOI 10.1002/adma.201800649
   Lee MS, 2013, NANO LETT, V13, P2814, DOI 10.1021/nl401070p
   Luo ZQ, 2018, NANO RES, V11, P3009, DOI 10.1007/s12274-018-2004-1
   Mehta JS, 2005, BRIT J OPHTHALMOL, V89, P1356, DOI 10.1136/bjo.2004.064147
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Park JU, 2007, NAT MATER, V6, P782, DOI 10.1038/nmat1974
   Park J, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap9841
   Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42
   Rim YS, 2015, ACS NANO, V9, P12174, DOI 10.1021/acsnano.5b05325
   Rogers JA, 2010, SCIENCE, V327, P1603, DOI 10.1126/science.1182383
   Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257
   Salvatore GA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3982
   Silveira PCL, 2016, INFLAMMATION, V39, P1395, DOI 10.1007/s10753-016-0371-x
   Son D, 2018, NAT NANOTECHNOL, V13, P1057, DOI 10.1038/s41565-018-0244-6
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Vijayaraghavan P, 2014, ADV MATER, V26, P6689, DOI 10.1002/adma.201400703
   White MS, 2013, NAT PHOTONICS, V7, P811, DOI [10.1038/nphoton.2013.188, 10.1038/NPHOTON.2013.188]
   Xu JW, 2018, J CONTROL RELEASE, V281, P97, DOI 10.1016/j.jconrel.2018.05.020
NR 41
TC 18
Z9 18
U1 5
U2 29
PU TSINGHUA UNIV PRESS
PI BEIJING
PA B605D, XUE YAN BUILDING, BEIJING, 100084, PEOPLES R CHINA
SN 1998-0124
EI 1998-0000
J9 NANO RES
JI Nano Res.
PD MAY
PY 2020
VL 13
IS 5
BP 1347
EP 1353
DI 10.1007/s12274-019-2595-1
PG 7
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA LT0FY
UT WOS:000536754100015
DA 2022-11-30
ER

PT J
AU Moshfeghi, AA
   Lanitis, T
   Kropat, G
   Kuznik, A
   Gibson, A
   Feng, HD
   Prenner, J
AF Moshfeghi, Andrew A.
   Lanitis, Tereza
   Kropat, Georg
   Kuznik, Andreas
   Gibson, Andrea
   Feng, Haidong
   Prenner, Jonathan
TI Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the
   United States in 2020
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VISUAL IMPAIRMENT; MACULAR DEGENERATION; INTRAVITREAL AFLIBERCEPT;
   PANRETINAL PHOTOCOAGULATION; GLOBAL CAUSES; VISION LOSS; DEVICE USE;
   AGE; IMPACT; INDIVIDUALS
AB BACKGROUND AND OBJECTIVE: To estimate the social cost of blindness due to wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR) in the United Stales in 2020.
   PATIENTS AND METHODS: Excess costs that occur because of blindness were estimated as the difference in costs in blind versus non-blind individuals. Per-patient costs were aggregated using the number of cases of blindness due to wAMD, DME, and PDR projected in 2020.
   RESULTS: Associated annual excess direct costs, indirect costs, and quality-adjusted life year loss per blind individual were $4,944, $54,614, and 0.214, respectively. Combining estimates with 246,423 projected cases of blindness due to wAMD, DME, and PDR translated to total societal costs of $20 billion in 2020, estimated to triple by 2050.
   CONCLUSION: Excess social costs associated with blindness in individuals with wAMD, DME, and PDR are substantial, with more than half of the burden attributed to indirect costs.
C1 [Moshfeghi, Andrew A.] Univ Southern Calif, Keck Sch Med, Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA 90007 USA.
   [Lanitis, Tereza; Kropat, Georg] Evidera, London, England.
   [Kuznik, Andreas; Gibson, Andrea] Regeneron Pharmaceut, Tarrytown, NY USA.
   [Feng, Haidong] Evidera, Waltham, MA USA.
   [Prenner, Jonathan] Rutgers Robert Wood Johnson Med Sch, Dept Ophthalmol, 10 Plum St, New Brunswick, NJ 08901 USA.
C3 University of Southern California; Evidera; Regeneron; Evidera; Rutgers
   State University New Brunswick; Rutgers State University Medical Center
RP Prenner, J (通讯作者)，Rutgers Robert Wood Johnson Med Sch, Dept Ophthalmol, 10 Plum St, New Brunswick, NJ 08901 USA.
EM jonathanprenner@gmail.com
OI Kuznik, Andreas/0000-0002-8634-8360
FU Regeneron Pharmaceuticals; Research to Prevent Blindness (New York, NY)
FX Supported by by Regeneron Pharmaceuticals and, in part, by an
   unrestricted grant to the Department of Ophthalmology at the University
   of Southern California Keck School of Medicine from Research to Prevent
   Blindness (New York, NY).
CR American Foundation for the Blind, 2017, FIN CONS STAT FINAN
   Arias E, 2017, NATL VITAL STAT REPO, V66
   BrightFocus Foundation, AG REL MAC DEG FACTS
   Brown Gary C, 2017, Int J Retina Vitreous, V3, P5, DOI 10.1186/s40942-016-0058-3
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Bureau of Labor Statistics, 2017, NAT OCC EMPL MENT WA
   Bureau of Labor Statistics, 2017, NAT OCC EMPL WAG EST
   Chan T, 2018, JAMA OPHTHALMOL, V136, P12, DOI 10.1001/jamaophthalmol.2017.4655
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Christ SL, 2008, INVEST OPHTH VIS SCI, V49, P3318, DOI 10.1167/iovs.08-1676
   Claxton L, 2017, PHARMACOECONOMICS, V35, P237, DOI 10.1007/s40273-016-0459-z
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cummins E, AFLIBERCEPT SOLUTION
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Erickson, 2015, DISABILITY STATUS RE
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Gray KF, 2015, SNAP16CHAR
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Hirai FE, 2008, AM J OPHTHALMOL, V145, P700, DOI 10.1016/j.ajo.2007.11.019
   Institute for Clinical and Economic Review (ICER), OV ICER VAL ASS FRAM
   Ip Michael S, 2008, Retina, V28, P919, DOI 10.1097/IAE.0b013e31818144a7
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kiss S, 2014, CLIN OPHTHALMOL, V8, P1611, DOI 10.2147/OPTH.S60893
   Koberlein J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003471
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Mason H, 2009, HEALTH ECON, V18, P933, DOI 10.1002/hec.1416
   Moran MJ, 2016, GUIDANCE TREATMENT V
   Rice J C, 2015, SAMJ, S. Afr. med. j., V105, P496, DOI 10.7196/SAMJ.9203
   Sabanayagam C, 2017, LANCET GLOB HEALTH, V5, pE1164, DOI 10.1016/S2214-109X(17)30412-6
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Schmier JK, 2006, DISABIL REHABIL, V28, P1331, DOI 10.1080/09638280600621436
   Schmier JK, 2009, DISABIL REHABIL, V31, P659, DOI 10.1080/09638280802239391
   Sivaprasad S, 2017, LANCET, V389, P2193, DOI 10.1016/S0140-6736(17)31193-5
   Social Security Administration, 2016, 1311826 SSA, V13-11826
   Social Security Administration, 2016, 1311700 SSA, V13-11700
   Stewart MW, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0510-4
   The International Agency for the Prevention of Blindness, WHAT IS VIS 2020
   United States Census Bureau, 2014, NAT POP PROJ TABL
   United States Department of Education, IND LIV SERV OLD IND
   van Hecke MV, 2005, DIABETES CARE, V28, P1383, DOI 10.2337/diacare.28.6.1383
   Wirth KE, 2008, OPHTHAL EPIDEMIOL, V15, P92, DOI 10.1080/09286580801939353
   Wittenborn J, 2013, COST VISION PROBLEMS
   World Health Organization, WHAT VIS 2020
   World Health Organization, 2017, FACT SHEETS VIS IMP
NR 49
TC 3
Z9 4
U1 1
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2020
VL 51
IS 4
SU S
BP S6
EP +
DI 10.3928/23258160-20200401-01
PG 21
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology; Surgery
GA NJ2AW
UT WOS:000565848800001
PM 32348529
DA 2022-11-30
ER

PT J
AU Liu, J
   Jiang, F
   Jiang, Y
   Wang, YC
   Li, ZL
   Shi, XF
   Zhu, YP
   Wang, HB
   Zhang, ZH
AF Liu, Jia
   Jiang, Feng
   Jiang, Yu
   Wang, Yicheng
   Li, Zelin
   Shi, Xuefeng
   Zhu, Yanping
   Wang, Hongbo
   Zhang, Zhuhong
TI Roles of Exosomes in Ocular Diseases
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE extracellular vesicles; exosomes; retina; ocular diseases; drug delivery
ID CELL-DERIVED EXOSOMES; MESENCHYMAL STEM-CELLS; EXTRACELLULAR VESICLES;
   OXIDATIVE STRESS; UVEAL MELANOMA; TRANSFERRIN RECEPTOR; DELIVERY
   VEHICLES; AQUEOUS-HUMOR; GLOBAL CAUSES; BIOGENESIS
AB Exosomes, nanoscale vesicles with a diameter of 30 to 150 nm, are composed of a lipid bilayer, protein, and genetic material. Exosomes are secreted by virtually all types of cells in the human body. They have key functions in cell-to-cell communication, immune regulation, inflammatory response, and neovascularization. Mounting evidence indicates that exosomes play an important role in various diseases, such as cancer, cardiovascular diseases, and brain diseases; however, the role that exosomes play in eye diseases has not yet been rigorously studied. This review covers current exosome research as it relates to ocular diseases including diabetic retinopathy, age-related macular degeneration, autoimmune uveitis, glaucoma, traumatic optic neuropathies, corneal diseases, retinopathy of prematurity, and uveal melanoma. In addition, we discuss recent advances in the biological functions of exosomes, focusing on the toxicity of exosomes and the use of exosomes as biomarkers and drug delivery vesicles. Finally, we summarize the primary considerations and challenges to be taken into account for the effective applications of exosomes.
C1 [Liu, Jia; Jiang, Yu; Wang, Yicheng; Li, Zelin; Zhu, Yanping; Wang, Hongbo; Zhang, Zhuhong] Yantai Univ, Collaborat Innovat Ctr Adv Drug Delivery Syst & B, Key Lab Mol Pharmacol & Drug Evaluat, Minist Educ,Sch Pharm, Yantai 264005, Peoples R China.
   [Jiang, Feng] Tianjin Med Univ, Dept Ophthalmol, Gen Hosp, Tianjin 300052, Peoples R China.
   [Shi, Xuefeng] Tianjin Eye Hosp, Dept Pediat Ophthalmol & Strabismus, Tianjin 300020, Peoples R China.
   [Shi, Xuefeng] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
   [Shi, Xuefeng] Tianjin Med Univ, Clin Coll Ophthalmol, Tianjin 300020, Peoples R China.
   [Shi, Xuefeng] Tianjin Eye Inst, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin 300020, Peoples R China.
C3 Yantai University; Tianjin Medical University; Tianjin Medical
   University; Nankai University; Tianjin Medical University
RP Zhang, ZH (通讯作者)，Yantai Univ, Collaborat Innovat Ctr Adv Drug Delivery Syst & B, Key Lab Mol Pharmacol & Drug Evaluat, Minist Educ,Sch Pharm, Yantai 264005, Peoples R China.
EM zhzhang0608@ytu.edu.cn
RI Wang, Hongbo/AHC-7831-2022
OI Wang, Hongbo/0000-0001-8530-2339
FU National Natural Science Foundation of China [81800853, 81970826];
   Talent Induction Program for Youth Innovation Teams in Colleges and
   University of Shandong Province
FX This work was supported by the National Natural Science Foundation of
   China (81970826) to Zhuhong Zhang, Talent Induction Program for Youth
   Innovation Teams in Colleges and University of Shandong Province to
   Yanping Zhu, and National Natural Science Foundation of China (81800853)
   to Feng Jiang.
CR Abels ER, 2016, CELL MOL NEUROBIOL, V36, P301, DOI 10.1007/s10571-016-0366-z
   Akbari A, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117447
   Alenquer M, 2015, VIRUSES-BASEL, V7, P5066, DOI 10.3390/v7092862
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   An MR, 2018, J PROTEOME RES, V17, P3599, DOI 10.1021/acs.jproteome.8b00479
   Atienzar-Aroca S, 2018, J CELL MOL MED, V22, P5244, DOI 10.1111/jcmm.13730
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Bai LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04559-y
   Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502
   Baranyai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145686
   Barclay RA, 2017, J BIOL CHEM, V292, P11682, DOI 10.1074/jbc.M117.793521
   Barile L, 2017, PHARMACOL THERAPEUT, V174, P63, DOI 10.1016/j.pharmthera.2017.02.020
   Betzer O, 2017, ACS NANO, V11, P10883, DOI 10.1021/acsnano.7b04495
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Bjorge IM, 2017, BIOMATER SCI-UK, V6, P60, DOI 10.1039/c7bm00479f
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brinton LT, 2015, CELL MOL LIFE SCI, V72, P659, DOI 10.1007/s00018-014-1764-3
   Carvajal RD, 2017, BRIT J OPHTHALMOL, V101, P38, DOI 10.1136/bjophthalmol-2016-309034
   Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P341, DOI 10.1111/j.1442-9071.2012.02773.x
   Chattopadhyay C, 2016, CANCER-AM CANCER SOC, V122, P2299, DOI 10.1002/cncr.29727
   Chen B, 2017, STEM CELL TRANSL MED, V6, P1753, DOI 10.1002/sctm.16-0477
   Chen LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07006-2
   Chen L, 2018, J CELL COMMUN SIGNAL, V12, P343, DOI 10.1007/s12079-017-0421-7
   Chen R, 2019, SMALL, V15, DOI 10.1002/smll.201902686
   Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3
   Chettimada S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25515-4
   Cho S, 2019, BIOSENS BIOELECTRON, V146, DOI 10.1016/j.bios.2019.111749
   Cho YE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34309-7
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Colombo M, 2013, J CELL SCI, V126, P5553, DOI 10.1242/jcs.128868
   Coulson-Thomas VJ, 2013, STEM CELLS, V31, P2116, DOI 10.1002/stem.1481
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davis BM, 2016, ACTA NEUROPATHOL, V132, P807, DOI 10.1007/s00401-016-1609-2
   DelMonte DW, 2011, J CATARACT REFR SURG, V37, P588, DOI 10.1016/j.jcrs.2010.12.037
   Dismuke WM, 2015, EXP EYE RES, V132, P73, DOI 10.1016/j.exer.2015.01.019
   Ebneter A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20474
   Edgar JR, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0268-z
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   Eldh M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-962
   Farooqi AA, 2018, BIOTECHNOL ADV, V36, P328, DOI 10.1016/j.biotechadv.2017.12.010
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Forrester JV, 2018, AM J OPHTHALMOL, V189, P77, DOI 10.1016/j.ajo.2018.02.019
   French KC, 2017, SEMIN CELL DEV BIOL, V67, P48, DOI 10.1016/j.semcdb.2017.01.002
   Fricke TR, 2018, OPHTHALMOLOGY, V125, P1492, DOI 10.1016/j.ophtha.2018.04.013
   Fu W, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10852-3
   Fulton AB, 2009, PROG RETIN EYE RES, V28, P452, DOI 10.1016/j.preteyeres.2009.06.003
   Gao M, 2020, ENVIRON POLLUT, V258, DOI 10.1016/j.envpol.2019.113717
   Gao XJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0195
   Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009
   Greening DW, 2015, METHODS MOL BIOL, V1295, P179, DOI 10.1007/978-1-4939-2550-6_15
   Gupta S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0923-0
   Gurunathan S, 2019, CELLS, V8, DOI [10.3390/ce11s8040307, DOI 10.3390/CE11S8040307]
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Hajrasouliha AR, 2013, J BIOL CHEM, V288, P28058, DOI 10.1074/jbc.M113.470765
   Han KY, 2015, INVEST OPHTH VIS SCI, V56, P5323, DOI 10.1167/iovs.14-14417
   Haney MJ, 2015, J CONTROL RELEASE, V207, P18, DOI 10.1016/j.jconrel.2015.03.033
   Hansen RM, 2017, PROG RETIN EYE RES, V56, P32, DOI 10.1016/j.preteyeres.2016.09.004
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973
   Harrell CR, 2018, ADV EXP MED BIOL, V1089, P47, DOI 10.1007/5584_2018_219
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Hesari A, 2018, J CELL BIOCHEM, V119, P4236, DOI 10.1002/jcb.26364
   Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9
   Hikita T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39882-z
   Horibe S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3958-1
   Hsu MY, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8050310
   Hu CX, 2019, J MOL MED, V97, P1065, DOI 10.1007/s00109-019-01804-x
   Huang C, 2018, DIABETES, V67, P1639, DOI 10.2337/db17-1587
   Hyenne Vincent, 2018, Small GTPases, V9, P445, DOI 10.1080/21541248.2016.1251378
   Hyung S, 2020, BIOTECHNOL BIOENG, V117, P2658, DOI 10.1002/bit.27447
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Juan T, 2018, SEMIN CELL DEV BIOL, V74, P66, DOI 10.1016/j.semcdb.2017.08.022
   Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135
   Kamalden TA, 2017, ANTIOXID REDOX SIGN, V27, P913, DOI 10.1089/ars.2016.6844
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kang XH, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01149
   Katome T, 2015, J DIABETES COMPLICAT, V29, P275, DOI 10.1016/j.jdiacomp.2014.10.010
   Ke YF, 2020, J CELL BIOCHEM, V121, P4849, DOI 10.1002/jcb.29713
   Kibria G, 2018, MOL PHARMACEUT, V15, P3625, DOI 10.1021/acs.molpharmaceut.8b00277
   Kim SH, 2005, J IMMUNOL, V174, P6440, DOI 10.4049/jimmunol.174.10.6440
   Klingeborn M, 2019, ADV EXP MED BIOL, V1185, P21, DOI 10.1007/978-3-030-27378-1_4
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Knickelbein JE, 2016, INVEST OPHTH VIS SCI, V57, P4101, DOI 10.1167/iovs.15-18353
   Kojima M, 2018, J TRAUMA ACUTE CARE, V84, P257, DOI 10.1097/TA.0000000000001748
   Kong LK, 2012, J AAPOS, V16, P501, DOI 10.1016/j.jaapos.2012.09.004
   Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641
   Kurywchak P, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0535-4
   Lande K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197055
   Lerner N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176105
   Lerner N, 2020, J CELL MOL MED, V24, P4646, DOI 10.1111/jcmm.15129
   Lerner N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171153
   Li K, 2018, METHODS MOL BIOL, V1740, P69, DOI 10.1007/978-1-4939-7652-2_7
   Li N, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1372-0
   Li P, 2017, THERANOSTICS, V7, P789, DOI 10.7150/thno.18133
   Li SL, 2018, NUCLEIC ACIDS RES, V46, pD106, DOI 10.1093/nar/gkx891
   Li SF, 2020, INT J OPHTHALMOL-CHI, V13, P1493, DOI 10.18240/ijo.2020.09.23
   Li W, 2021, J ENDOCRINOL INVEST, V44, P1193, DOI 10.1007/s40618-020-01405-3
   Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82
   Liu C, 2019, P NATL ACAD SCI USA, V116, P7455, DOI 10.1073/pnas.1814874116
   Liu L, 2016, BRAIN RES, V1646, P327, DOI 10.1016/j.brainres.2016.05.037
   Liu YT, 2016, INVEST OPHTH VIS SCI, V57, P4528, DOI 10.1167/iovs.16-19688
   Liu YT, 2013, INVEST OPHTH VIS SCI, V54, P6382, DOI 10.1167/iovs.13-12128
   Livshts MA, 2015, SCI REP-UK, V5, DOI 10.1038/srep17319
   Lobb R, 2017, METHODS MOL BIOL, V1660, P105, DOI 10.1007/978-1-4939-7253-1_9
   Luan X, 2017, ACTA PHARMACOL SIN, V38, P754, DOI 10.1038/aps.2017.12
   Lucchetti D, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201700716
   Maisto R, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00235
   Martins TS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198820
   Mathew B, 2019, BIOMATERIALS, V197, P146, DOI 10.1016/j.biomaterials.2019.01.016
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   McKay TB, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051080
   McKelvey Kelly J, 2015, J Circ Biomark, V4, P7, DOI 10.5772/61186
   Mead B, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100849
   Mead B, 2018, INVEST OPHTH VIS SCI, V59, P5473, DOI 10.1167/iovs.18-25310
   Mead B, 2017, STEM CELL TRANSL MED, V6, P1273, DOI 10.1002/sctm.16-0428
   Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581
   Mincheva-Nilsson Lucia, 2016, Curr Protoc Immunol, V115, DOI 10.1002/cpim.17
   Moisseiev E, 2017, CURR EYE RES, V42, P1358, DOI 10.1080/02713683.2017.1319491
   Momen-Heravi F, 2017, METHODS MOL BIOL, V1660, P25, DOI 10.1007/978-1-4939-7253-1_3
   Monguio-Tortajada M, 2019, CELL MOL LIFE SCI, V76, P2369, DOI 10.1007/s00018-019-03071-y
   Mu H, 2018, J CELL MOL MED, V22, P5008, DOI 10.1111/jcmm.13768
   Mueller SK, 2018, NANOMED-NANOTECHNOL, V14, P269, DOI 10.1016/j.nano.2017.10.008
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Murrow L, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2015.1039191
   Naga SHA, 2015, EXP EYE RES, V131, P29, DOI 10.1016/j.exer.2014.12.010
   Nedaeinia R, 2017, CANCER GENE THER, V24, P48, DOI 10.1038/cgt.2016.77
   Nojima H, 2016, J HEPATOL, V64, P60, DOI 10.1016/j.jhep.2015.07.030
   Oksvold MP, 2015, METHODS MOL BIOL, V1218, P465, DOI 10.1007/978-1-4939-1538-5_27
   PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942
   PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5
   Pan DY, 2019, J CHEM NEUROANAT, V96, P134, DOI 10.1016/j.jchemneu.2019.01.006
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev-biochem-013118-111902
   Purushothaman A, 2019, METHODS MOL BIOL, V1952, P233, DOI 10.1007/978-1-4939-9133-4_19
   Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021
   Ran N, 2020, BIOMATERIALS, V236, DOI 10.1016/j.biomaterials.2020.119826
   Razeghinejad MR, 2011, AM J MED, V124, P20, DOI 10.1016/j.amjmed.2010.08.011
   Ren R, 2019, ARTIF CELL NANOMED B, V47, P2918, DOI 10.1080/21691401.2019.1640713
   Sabanayagam C, 2017, LANCET GLOB HEALTH, V5, pE1164, DOI 10.1016/S2214-109X(17)30412-6
   Saeed-Zidane M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187569
   Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008
   Samaeekia R, 2018, INVEST OPHTH VIS SCI, V59, P5194, DOI 10.1167/iovs.18-24803
   Shah N, 2018, BBA-MOL BASIS DIS, V1864, P2610, DOI 10.1016/j.bbadis.2018.04.016
   Sies H, 2015, REDOX BIOL, V4, P180, DOI 10.1016/j.redox.2015.01.002
   Sinha MS, 2018, ACTA NEUROPATHOL, V136, P41, DOI 10.1007/s00401-018-1868-1
   Skotland T, 2017, PROG LIPID RES, V66, P30, DOI 10.1016/j.plipres.2017.03.001
   Skotland T, 2017, EUR J CANCER, V70, P122, DOI 10.1016/j.ejca.2016.10.011
   Stamer WD, 2011, J PROTEOMICS, V74, P796, DOI 10.1016/j.jprot.2011.02.024
   Sterzenbach U, 2017, MOL THER, V25, P1269, DOI 10.1016/j.ymthe.2017.03.030
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Tkach M, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0479
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Tokarz Aleksandra, 2015, Folia Med Cracov, V55, P35
   Tong Y, 2016, MED HYPOTHESES, V97, P98, DOI 10.1016/j.mehy.2016.10.027
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Vallabh NA, 2017, MITOCHONDRION, V36, P103, DOI 10.1016/j.mito.2017.05.009
   Villarroya-Beltri C, 2014, SEMIN CANCER BIOL, V28, P3, DOI 10.1016/j.semcancer.2014.04.009
   Walker Rosie, 2004, Br J Community Nurs, V9, P545
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang QL, 2018, THERANOSTICS, V8, P4912, DOI 10.7150/thno.27608
   Wassmer SJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep45329
   Weirffeb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI [10.1001/jama.2014.3192, DOI 10.1001/JAMA.2014.3192]
   Weng YJ, 2016, ANALYST, V141, P4640, DOI 10.1039/c6an00892e
   Whiteside TL, 2016, ADV CLIN CHEM, V74, P103, DOI 10.1016/bs.acc.2015.12.005
   Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136
   Witwer KW, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1648167
   WONG TY, 2016, NAT REV DIS PRIMERS, V2, DOI DOI 10.1038/NI-DP.2016.12
   Xia XH, 2019, PROG NEUROBIOL, V183, DOI 10.1016/j.pneurobio.2019.101694
   Xiao J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.181
   Xiao Y, 2019, CLIN CHIM ACTA, V490, P186, DOI 10.1016/j.cca.2018.09.007
   Xu WQ, 2019, MOL THER-NUCL ACIDS, V16, P778, DOI 10.1016/j.omtn.2019.04.029
   Yamashita T, 2018, BIOL PHARM BULL, V41, P835, DOI 10.1248/bpb.b18-00133
   Yim N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12277
   Yoon S, 2017, IMMUNITY, V47, P51, DOI 10.1016/j.immuni.2017.06.001
   Yu B, 2020, WORLD J STEM CELLS, V12, P178, DOI 10.4252/wjsc.v12.i3.178
   Yu B, 2014, INT J MOL SCI, V15, P4142, DOI 10.3390/ijms15034142
   Yue YJ, 2017, TISSUE ENG PT A, V23, P1241, DOI [10.1089/ten.tea.2017.0084, 10.1089/ten.TEA.2017.0084]
   Zhang JY, 2015, ACCIDENT ANAL PREV, V76, P166, DOI 10.1016/j.aap.2014.12.003
   Zhang LM, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3753485
   Zhang SP, 2018, BIOMATERIALS, V156, P16, DOI 10.1016/j.biomaterials.2017.11.028
   Zhang W, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107813
   Zhang W, 2019, INVEST OPHTH VIS SCI, V60, P294, DOI 10.1167/iovs.18-25617
   Zhao YJ, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.6
NR 188
TC 21
Z9 21
U1 10
U2 46
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2020
VL 15
BP 10519
EP 10538
DI 10.2147/IJN.S277190
PG 20
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA PL8XJ
UT WOS:000603397100003
PM 33402823
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chrzanowska, M
   Modrzejewska, A
   Modrzejewska, M
AF Chrzanowska, Martyna
   Modrzejewska, Anna
   Modrzejewska, Monika
TI New insight into the role of the complement in the most common types of
   retinopathy-current literature review
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; diabetic retinopathy; factors of the
   complement system; retinopathy of prematurity; single nucleotide
   polymorphism
ID PIGMENT EPITHELIAL-CELLS; MANNOSE-BINDING LECTIN; C-REACTIVE PROTEIN;
   MACULAR DEGENERATION; FACTOR-H; HIGH-RISK; DIABETIC-RETINOPATHY;
   FACTOR-B; CHOROIDAL NEOVASCULARIZATION; CHRONIC INFLAMMATION
AB Pathological neovascularisation, which is a critical component of diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR) and retinopathy of prematurity (ROP), is a frequent cause of compromised vision or blindness. Researchers continuously investigate the role of the complement system in the pathogenesis of retinopathy. Studies have confirmed the role of factors H and I in the development of AMD, and factors H and B in the development of DR. Other components, such as C2, C3, and C5, have also been considered. However, findings on the involvement of the complement system in the pathogenesis of ROP are still inconclusive. This paper presents a review of the current literature data, pointing to the novel results and achievements from research into the role of complement components in the development of retinopathy. There is still a need to continue research in new directions, and to gather more detailed information about this problem which will be useful in the treatment of these diseases.
C1 [Chrzanowska, Martyna; Modrzejewska, Anna; Modrzejewska, Monika] Pomeranian Med Univ, Dept Ophthalmol, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University
RP Modrzejewska, M (通讯作者)，PMU Szczecin, Dept Ophthalmol 2, Al Powstaticow Wielkopolskich 72, PL-70111 Szczecin, Poland.
EM monika_modrzej@op.pl
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Avichezer D, 2003, J EXP MED, V198, P1665, DOI 10.1084/jem.20030413
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Butler JM, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3964-3
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cheng LJ, 2013, INVEST OPHTH VIS SCI, V54, P8191, DOI 10.1167/iovs.13-12428
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujita T, 2013, DIABETES-METAB RES, V29, P220, DOI 10.1002/dmrr.2380
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Garcia-Ramirez M, 2007, DIABETOLOGIA, V50, P1294, DOI 10.1007/s00125-007-0627-y
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geng PL, 2015, DIABETES CARE, V38, P868, DOI 10.2337/dc14-1873
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Ghosh P, 2015, ENDOCR REV, V36, P272, DOI 10.1210/er.2014-1099
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guan LZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119699
   Hansen TK, 2010, DIABETOLOGIA, V53, P1517, DOI 10.1007/s00125-010-1742-8
   Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P4857, DOI 10.1210/jc.2003-030742
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hess K, 2014, DIABETOLOGIA, V57, P1737, DOI 10.1007/s00125-014-3267-z
   Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877
   Jasinska A, 2010, J LABOR DIAGN, V46, P331
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kim C, 2016, FASEB J, V30, P1300, DOI 10.1096/fj.15-280834
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kleinman ME, 2016, DEV OPHTHALMOL, V55, P46, DOI 10.1159/000431141
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Li Y, 2012, INVEST OPHTH VIS SCI, V53, P5520, DOI 10.1167/iovs.12-10010
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo C, 2011, MOL VIS, V17, P1588
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mellbin LG, 2012, DIABETES CARE, V35, P911, DOI 10.2337/dc11-1642
   MORGAN BP, 1999, COMPLEMENT REGULATOR, P1
   Muramatsu D, 2013, GRAEF ARCH CLIN EXP, V251, P15, DOI 10.1007/s00417-012-2024-6
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   PATZ A, 1982, AM J OPHTHALMOL, V94, P715, DOI 10.1016/0002-9394(82)90297-5
   Qin XB, 2004, DIABETES, V53, P2653, DOI 10.2337/diabetes.53.10.2653
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rivera JC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3940241
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schmidt MI, 1999, LANCET, V353, P1649, DOI 10.1016/S0140-6736(99)01046-6
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Streilein JW, 1999, PROG RETIN EYE RES, V18, P357, DOI 10.1016/S1350-9462(98)00022-6
   Sweigard JH, 2014, FASEB J, V28, P3171, DOI 10.1096/fj.14-251041
   Tao XY, 2015, INT J OPHTHALMOL-CHI, V8, P17, DOI 10.3980/j.issn.2222-3959.2015.01.03
   Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Toni M, 2012, AN SIST SANIT NAVAR, V35, P425, DOI 10.4321/s1137-66272012000300008
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Wang H, 2013, EXP EYE RES, V108, P110, DOI 10.1016/j.exer.2012.11.023
   Wang J, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/748435
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Xu DF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149704
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yanai R, 2012, ADV EXP MED BIOL, V946, P161, DOI 10.1007/978-1-4614-0106-3_10
   Yang MM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/1313027
   Zhang LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20341
   Zhang PB, 2017, CLIN PROTEOM, V14, DOI 10.1186/s12014-017-9172-y
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 90
TC 10
Z9 11
U1 0
U2 11
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD NOV 18
PY 2018
VL 11
IS 11
BP 1856
EP 1864
DI 10.18240/ijo.2018.11.19
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA1NB
UT WOS:000449979000019
PM 30450319
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Guillonneau, X
   Eandi, CM
   Paques, M
   Sahel, JA
   Sapieha, P
   Sennlaub, F
AF Guillonneau, Xavier
   Eandi, Chiara M.
   Paques, Michel
   Sahel, Jose-Alain
   Sapieha, Przemyslaw
   Sennlaub, Florian
TI On phagocytes and macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID COMPLEMENT FACTOR-H; MONOCYTE CHEMOATTRACTANT PROTEIN-1; RETINAL-PIGMENT
   EPITHELIUM; AGE-RELATED MACULOPATHY; CCL2/CX3CR1 CHEMOKINE DEFICIENCIES;
   CHOROIDAL NEOVASCULAR MEMBRANE; REVERSE CHOLESTEROL TRANSPORT;
   SUBRETINAL DRUSENOID DEPOSITS; APOLIPOPROTEIN-E POLYMORPHISM; MEDIATED
   DARK-ADAPTATION
AB Age related macular degeneration (AMD) is a complex multifactorial disease caused by the interplay of age and genetic and environmental risk factors. A common feature observed in early and both forms of late AMD is the breakdown of the physiologically immunosuppressive subretinal environment and the protracted accumulation of mononuclear phagocytes (MP). We here discuss the origin and nature of subretinal MPs, the mechanisms that lead to their accumulation, the inflammatory mediators they produce as well as the consequences of their chronic presence on photoreceptors, retinal pigment epithelium and choroid. Recent advances highlight how both genetic and environmental risk factors directly promote subretinal inflammation and tip the balance from a beneficial inflammation that helps control debris accumulation to detrimental chronic inflammation and destructive late AMD. Finally, we discuss how changes in life style or pharmacological intervention can help to break the vicious cycle of inflammation and degeneration, restore the immunosuppressive properties of the subretinal space, and reestablish homeostasis. (c) 2017 Elsevier Ltd. All rights reserved.
C1 [Guillonneau, Xavier; Paques, Michel; Sahel, Jose-Alain; Sennlaub, Florian] UPMC Univ Paris 06, Sorbonne Univ, CNRS, INSERM,Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
   [Eandi, Chiara M.] Univ Turin, Dept Surg Sci, Eye Clin, Turin, Italy.
   [Paques, Michel; Sahel, Jose-Alain] Ctr Hosp Natl Ophtalmol QuinzeVingts, INSERM, DHOS CIC 503, Paris, France.
   [Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Ophthalmol, Res Ctr, Quebec City, PQ, Canada.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; University of
   Turin; CHNO des Quinze-Vingts; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite de Montreal
RP Sennlaub, F (通讯作者)，INSERM, Inst Vis, UMR S 968, F-75012 Paris, France.
EM florian.sennlaub@inserm.fr
RI Sennlaub, Florian/F-2756-2017; guillonneau, xavier/AAF-9495-2021;
   Guillonneau, xavier/E-3995-2017; Sahel, Jose-Alain/F-3172-2017
OI Sennlaub, Florian/0000-0003-4412-1341; guillonneau,
   xavier/0000-0001-7379-3935; Guillonneau, xavier/0000-0001-7379-3935;
   Sahel, Jose-Alain/0000-0002-4831-1153; Michaelides,
   Michel/0000-0002-1552-7046; Sapieha, Przemyslaw/0000-0002-9171-2825
FU INSERM; ANR Geno [R09099DS]; ANR MACLEAR [ANR-15-CE14-0015-01]; LABEX
   LIFESENSES [ANR-10-LABX-65]; ANR (Investissements dapos;Avenir
   programme) [ANR-11-IDEX-0004-02]; Carnot; ERC starting Grant [210345];
   Association de Prevoyance Sante de ALLIANZ
FX This work was supported by grants from INSERM, ANR Geno 2009 (R09099DS),
   ANR MACLEAR (ANR-15-CE14-0015-01), LABEX LIFESENSES [ANR-10-LABX-65]
   supported by the ANR (Investissements d'Avenir programme
   [ANR-11-IDEX-0004-02]), Carnot, and ERC starting Grant (ERC-2007 St.G.
   210345), the Association de Prevoyance Sante de ALLIANZ, and a generous
   donation by Doris and Michael Bunte.
CR ACAMPORA D, 1995, DEVELOPMENT, V121, P3279
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664
   ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043
   Appelboom G, 2011, J CLIN NEUROSCI, V18, P1439, DOI 10.1016/j.jocn.2011.04.001
   Arnold L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9972
   Arnson Y, 2010, J AUTOIMMUN, V34, pJ258, DOI 10.1016/j.jaut.2009.12.003
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Azzam KM, 2012, TRENDS ENDOCRIN MET, V23, P169, DOI 10.1016/j.tem.2012.02.001
   Bales KR, 2009, J NEUROSCI, V29, P6771, DOI 10.1523/JNEUROSCI.0887-09.2009
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Becroft D M, 1981, Perspect Pediatr Pathol, V6, P203
   Beli E, 2016, J MOL MED, V94, P1255, DOI 10.1007/s00109-016-1433-0
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749
   Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Bujakowska K, 2012, HUM MUTAT, V33, P306, DOI 10.1002/humu.21653
   Burt TD, 2008, P NATL ACAD SCI USA, V105, P8718, DOI 10.1073/pnas.0803526105
   Caesar R, 2010, J INTERN MED, V268, P320, DOI 10.1111/j.1365-2796.2010.02270.x
   Caesar R, 2015, CELL METAB, V22, P658, DOI 10.1016/j.cmet.2015.07.026
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Camelo S, 2016, OPHTHALMOLOGICA, V236, P53, DOI 10.1159/000446587
   Camelo S, 2012, ANGIOGENESIS, V15, P609, DOI 10.1007/s10456-012-9290-0
   Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Cantos R, 2000, P NATL ACAD SCI USA, V97, P11707, DOI 10.1073/pnas.97.22.11707
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Cardona SM, 2015, ASN NEURO, V7, DOI 10.1177/1759091415608204
   Caspi Rachel R, 2002, Int Rev Immunol, V21, P197, DOI 10.1080/08830180212063
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Chong DY, 2008, INVEST OPHTH VIS SCI, V49, P3193, DOI 10.1167/iovs.07-1641
   Chow A, 2011, NAT REV IMMUNOL, V11, P788, DOI 10.1038/nri3087
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Combadiere C, 2013, EXP EYE RES, V111, P134, DOI 10.1016/j.exer.2013.02.002
   Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crowley M., 2016, INVEST OPHTH VIS SCI, V57, P2629
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2016, GRAEF ARCH CLIN EXP, V254, P1237, DOI 10.1007/s00417-016-3300-7
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   de Bont N, 1999, J LIPID RES, V40, P680
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   DiScipio RG, 1998, J IMMUNOL, V160, P4057
   Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El Kasmi KC, 2015, SEMIN IMMUNOL, V27, P267, DOI 10.1016/j.smim.2015.09.001
   ELNER SG, 1991, LAB INVEST, V64, P819
   EZEKOWITZ RAB, 1984, J EXP MED, V159, P244, DOI 10.1084/jem.159.1.244
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Fenn AM, 2013, NEUROBIOL AGING, V34, P2748, DOI 10.1016/j.neurobiolaging.2013.06.007
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Flierman R, 2007, IMMUNOBIOLOGY, V212, P363, DOI 10.1016/j.imbio.2006.11.005
   Fordham JB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00512
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Fossat N, 2006, EMBO REP, V7, P824, DOI 10.1038/sj.embor.7400751
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GAGNON L, 1989, AGENTS ACTIONS, V26, P141, DOI 10.1007/BF02126587
   Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004
   GARN SM, 1986, AM J CLIN NUTR, V44, P996, DOI 10.1093/ajcn/44.6.996
   Gautier EL, 2014, IMMUNOL REV, V262, P85, DOI 10.1111/imr.12231
   Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016
   Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Hearps AC, 2012, AGING CELL, V11, P867, DOI 10.1111/j.1474-9726.2012.00851.x
   Heeren J, 2004, J BIOL CHEM, V279, P55483, DOI 10.1074/jbc.M409324200
   Hegner C., 1916, KLIN MONATSBL AUGENH, V57, P27
   Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809
   Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221
   Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, P1716, DOI 10.1053/j.gastro.2009.08.042
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Horie S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03072
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hou YZ, 2013, ARTHRITIS RHEUM-US, V65, P2835, DOI 10.1002/art.38124
   Housset M, 2015, J OCUL PHARMACOL TH, V31, P406, DOI 10.1089/jop.2015.0023
   Housset M, 2013, J NEUROSCI, V33, P9890, DOI 10.1523/JNEUROSCI.1099-13.2013
   Hu G, 2006, NEUROLOGY, V67, P1955, DOI 10.1212/01.wnl.0000247052.18422.e5
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Hu ZZ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.363
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Ivanovic I, 2011, INVEST OPHTH VIS SCI, V52, P6355, DOI 10.1167/iovs.10-7138
   Ivanovic I, 2011, INVEST OPHTH VIS SCI, V52, P3775, DOI 10.1167/iovs.10-7139
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Janssen WJ, 2011, AM J RESP CRIT CARE, V184, P547, DOI 10.1164/rccm.201011-1891OC
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738
   Kang YH, 2012, IMMUNOBIOLOGY, V217, P455, DOI 10.1016/j.imbio.2011.10.008
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68
   Kerr EC, 2008, PROG RETIN EYE RES, V27, P527, DOI 10.1016/j.preteyeres.2008.07.001
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P854, DOI 10.1167/iovs.12-10876
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein BEK, 2007, AM J OPHTHALMOL, V144, P961, DOI 10.1016/j.ajo.2007.08.016
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kohno H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0408-3
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a
   Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263
   Liao SM, 2013, INVEST OPHTH VIS SCI, V54
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liew FY, 2002, NAT REV IMMUNOL, V2, P55, DOI 10.1038/nri705
   Lim HY, 2007, IMMUNOLOGY, V122, P47, DOI 10.1111/j.1365-2567.2007.02611.x
   Limatola C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00229
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez-Dee Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/296069
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   Luhmann UFO, 2015, HUM MOL GENET, V24, P128, DOI 10.1093/hmg/ddu424
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo C, 2011, MOL VIS, V17, P1588
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200
   Mahley RW, 2006, J CLIN INVEST, V116, P1226, DOI 10.1172/JCI28632
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Manna PP, 2005, J BIOL CHEM, V280, P29637, DOI 10.1074/jbc.M500922200
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Marrie RA, 2014, NEUROLOGY, V82, P826, DOI 10.1212/WNL.0000000000000195
   Martin ASG, 2006, AM J CLIN NUTR, V83, p461S, DOI 10.1093/ajcn/83.2.461s
   Martin M, 2016, IMMUNOL REV, V274, P218, DOI 10.1111/imr.12462
   Martinez-Torres AC, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001796
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2
   Matsui H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.479
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McDonald JF, 2003, BIOCHEMISTRY-US, V42, P10001, DOI 10.1021/bi0341408
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   McGuinness OP, 2005, ANNU REV NUTR, V25, P9, DOI 10.1146/annurev.nutr.24.012003.132159
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCMENAMIN PG, 1990, ANAT REC, V227, P245, DOI 10.1002/ar.1092270213
   MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Meir KS, 2004, ARTERIOSCL THROM VAS, V24, P1006, DOI 10.1161/01.ATV.0000128849.12617.f4
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Mendiola AS, 2017, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00303
   Miao H, 2012, MOL VIS, V18, P574
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Navarro-Alvarez N, 2011, CELL MOL IMMUNOL, V8, P285, DOI 10.1038/cmi.2010.83
   Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ng TF, 2009, INVEST OPHTH VIS SCI, V50, P5472, DOI 10.1167/iovs.08-2877
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   O'Toole PW, 2015, SCIENCE, V350, P1214, DOI 10.1126/science.aac8469
   Odegaard JI, 2013, SCIENCE, V339, P172, DOI 10.1126/science.1230721
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohta K, 2000, INVEST OPHTH VIS SCI, V41, P2591
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Peri F, 2008, CELL, V133, P916, DOI 10.1016/j.cell.2008.04.037
   Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Quesada AJ, 2005, CELL DEATH DIFFER, V12, P649, DOI 10.1038/sj.cdd.4401615
   Raichlen DA, 2014, TRENDS NEUROSCI, V37, P247, DOI 10.1016/j.tins.2014.03.001
   Rajala A, 2013, J BIOL CHEM, V288, P19503, DOI 10.1074/jbc.M113.469064
   Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338
   Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615
   Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   ROBINSON DR, 1989, CLIN EXP RHEUMATOL, V7, pS155
   Roerink ME, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0796-7
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Romero-Corral A, 2008, INT J OBESITY, V32, P959, DOI 10.1038/ijo.2008.11
   Roselaar SE, 1998, J LIPID RES, V39, P1740
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sanchez RN, 2003, INVEST OPHTH VIS SCI, V44, P4006, DOI 10.1167/iovs.03-0040
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schlaf G, 2001, MOL IMMUNOL, V38, P231, DOI 10.1016/S0161-5890(01)00045-1
   Schmitz G, 2002, CURR OPIN LIPIDOL, V13, P513, DOI 10.1097/00041433-200210000-00007
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Schweighofer B, 2009, THROMB HAEMOSTASIS, V102, P544, DOI 10.1160/TH08-12-0830
   Scott KP, 2013, PHARMACOL RES, V69, P52, DOI 10.1016/j.phrs.2012.10.020
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122
   Simi A, 2007, NEUROPHARMACOLOGY, V52, P1563, DOI 10.1016/j.neuropharm.2007.02.011
   Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   SMIT M, 1988, HUM GENET, V80, P287, DOI 10.1007/BF01790099
   SMITH PD, 1992, J CLIN INVEST, V90, P1642, DOI 10.1172/JCI116035
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006
   Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974
   Spanogiannopoulos P, 2016, NAT REV MICROBIOL, V14, P273, DOI 10.1038/nrmicro.2016.17
   Spielman LJ, 2016, BRAIN RES BULL, V125, P19, DOI 10.1016/j.brainresbull.2016.03.012
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sullivan PM, 2011, NEUROBIOL AGING, V32, P791, DOI 10.1016/j.neurobiolaging.2009.05.011
   Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tall AR, 2000, ARTERIOSCL THROM VAS, V20, P1185, DOI 10.1161/01.ATV.20.5.1185
   Taubes G, 2009, SCIENCE, V325, P256, DOI 10.1126/science.325_256
   Tedesco D, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/230386
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322
   van de Pavert SA, 2004, J CELL SCI, V117, P4169, DOI 10.1242/jcs.01301
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang K, 2014, GLIA, V62, P1943, DOI 10.1002/glia.22715
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   White DT, 2017, P NATL ACAD SCI USA, V114, pE3719, DOI 10.1073/pnas.1617721114
   Wilms H, 1999, J NEUROIMMUNOL, V98, P89, DOI 10.1016/S0165-5728(99)00066-1
   Wolf Y, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00026
   Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yu CE, 2013, HUM MOL GENET, V22, P5036, DOI 10.1093/hmg/ddt354
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zabel MK, 2013, AGEING RES REV, V12, P749, DOI 10.1016/j.arr.2013.02.001
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang R, 2015, INVEST OPHTH VIS SCI, V56, P5590, DOI 10.1167/iovs.15-16830
   Zhang Z, 2012, CANCER EPIDEMIOL, V36, pE111, DOI 10.1016/j.canep.2011.11.004
   Zhao H, 2013, INVEST OPHTH VIS SCI, V54, P5321, DOI 10.1167/iovs.13-12122
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zieger M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106562
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 391
TC 86
Z9 89
U1 0
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2017
VL 61
BP 98
EP 128
DI 10.1016/j.preteyeres.2017.06.002
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FN7KA
UT WOS:000416195900006
PM 28602950
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Scott, LJ
   Chakravarthy, U
   Reeves, BC
   Rogers, CA
AF Scott, Lauren J.
   Chakravarthy, Usha
   Reeves, Barnaby C.
   Rogers, Chris A.
TI Systemic safety of anti-VEGF drugs: a commentary
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE aflibercept; anti-VEGF drug safety; bevacizumab; ranibizumab; systemic
   serious adverse events; VEGF
ID GROWTH-FACTOR INHIBITORS; VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; MYOCARDIAL-INFARCTION; RANIBIZUMAB; BEVACIZUMAB; TRIAL;
   STROKE; AFLIBERCEPT; OUTCOMES
AB Introduction: VEGF is a mediator of angiogenesis. Thus, concerns have been expressed following the use of VEGF inhibitors for the treatment of neovascular age-related macular degeneration (nAMD). Ranibizumab, and more recently aflibercept, are VEGF inhibitors licensed for the treatment of nAMD. Bevacizumab is also used but unlicensed for this application.
   Areas covered: A non-systematic review of nAMD trials was undertaken to investigate four outcomes: all-cause mortality, all systemic serious adverse events (SSAEs), arteriothrombotic events (ATEs) and gastrointestinal (GI) complications. Differences in event rates with injections of ranibizunnab compared to bevacizunnab, aflibercept, photodynannic therapy (PDT) and sham were explored and quantified using fixed-effect meta-analyses.
   Expert opinion: Anti-VEGF agents can influence vascular health; however, the data suggest no difference in the risk of an ATE or death between anti-VEGF agents. Clinical trials are limited in their size and eligibility criteria and databases of patients treated in routine practice should also be scrutinized.
C1 [Scott, Lauren J.; Rogers, Chris A.] Univ Bristol, Bristol Royal Infirm, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol BS2 8HW, Avon, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Expt Med Dent & Biomed Sci, Ophthalmol & Vis Sci, Belfast, Antrim, North Ireland.
   [Reeves, Barnaby C.] Univ Bristol, Bristol Royal Infirm, Sch Clin Sci, Clin Trials & Evaluat Unit,Hlth Serv Res, Bristol BS2 8HW, Avon, England.
   [Rogers, Chris A.] Univ Bristol, Bristol Royal Infirm, Sch Clin Sci, Clin Trials & Evaluat Unit,Med Stat, Bristol BS2 8HW, Avon, England.
C3 Bristol Royal Infirmary; University of Bristol; Queens University
   Belfast; Bristol Royal Infirmary; University of Bristol; Bristol Royal
   Infirmary; University of Bristol
RP Rogers, CA (通讯作者)，Univ Bristol, Bristol Royal Infirm, Sch Clin Sci, Clin Trials & Evaluat Unit,Med Stat, Level 7,Queens Bldg, Bristol BS2 8HW, Avon, England.
EM chris.rogers@bristol.ac.uk
OI Reeves, Barnaby/0000-0002-5101-9487; Chakravarthy,
   Usha/0000-0002-2606-3734
FU National Institute for Health Research (NIHR); British Heart Foundation
   (BHF); Novartis; Bayer; Roche; Janssen-Cilag
FX This work was supported by the National Institute for Health Research
   (NIHR) and the British Heart Foundation (BHF). CA Rogers has received
   financial support from Novartis. U Chakravarthy has received
   institutional support from Novartis and institutional and consultant
   support from Bayer and Roche. BC Reeves has received financial support
   from Janssen-Cilag. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript. This includes employment, consultancies,
   honoraria, stock ownership or options, expert testimony, grants or
   patents received or pending, or royalties.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Berg K, 2014, OPHTHALMOLOGY
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Zisa D, 2009, BIOCHEM BIOPH RES CO, V390, P834, DOI 10.1016/j.bbrc.2009.10.058
NR 30
TC 15
Z9 15
U1 1
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD MAR
PY 2015
VL 14
IS 3
BP 379
EP 388
DI 10.1517/14740338.2015.991712
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CC3SF
UT WOS:000350269000004
PM 25489638
DA 2022-11-30
ER

PT J
AU Yang, Y
   Takeda, A
   Yoshimura, T
   Oshima, Y
   Sonoda, KH
   Ishibashi, T
AF Yang, Yang
   Takeda, Atsunobu
   Yoshimura, Takeru
   Oshima, Yuji
   Sonoda, Koh-Hei
   Ishibashi, Tatsuro
TI IL-10 Is Significantly Involved in HSP70-Regulation of Experimental
   Subretinal Fibrosis
SO PLOS ONE
LA English
DT Article
ID HEAT-SHOCK PROTEINS; TUMOR-NECROSIS-FACTOR; IN-VITRO;
   HEAT-SHOCK-PROTEIN-70; EXPRESSION; HSP70; ACTIVATION; PATHWAY;
   INFLAMMATION; INDUCTION
AB Subretinal fibrosis is directly related to severe visual loss, especially if occurs in the macula, and is frequently observed in advanced age-related macular degeneration and other refractory eye disorders such as diabetic retinopathy and uveitis. In this study, we analyzed the immunosuppressive mechanism of subretinal fibrosis using the novel animal model recently demonstrated. Both TLR2 and TLR4 deficient mice showed significant enlargement of subretinal fibrotic area as compared with wild-type mice. A single intraocular administration of heat shock protein 70 (HSP70), which is an endogenous ligand for TLR2 and TLR4, inhibited subretinal fibrosis in wild-type mice but not in TLR2 and TLR4-deficient mice. Additionally, HSP70 induced IL-10 production in eyes from wild-type mice but was impaired in both TLR2- and TLR4-deficient mice, indicating that HSP70-TLR2/TLR4 axis plays an immunomodulatory role in subretinal fibrosis. Thus, these results suggest that HSP70-TLR2/TLR4 axis is a new therapeutic target for subretinal fibrosis due to prognostic CNV.
C1 [Yang, Yang; Takeda, Atsunobu; Yoshimura, Takeru; Oshima, Yuji; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 812, Japan.
   [Sonoda, Koh-Hei] Yamaguchi Univ, Sch Med, Dept Ophthalmol, Ube, Yamaguchi 755, Japan.
C3 Kyushu University; Yamaguchi University
RP Yoshimura, T (通讯作者)，Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 812, Japan.
EM takeruy@med.kyushu-u.ac.jp
OI Yoshimura, Takeru/0000-0002-5983-7193
FU Grants-in-Aid for Scientific Research [23689071] Funding Source: KAKEN
CR Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2
   Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   Bobryshev YV, 2002, J VASC SURG, V35, P368, DOI 10.1067/mva.2002.121067
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Broquet AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   De AK, 2000, J IMMUNOL, V165, P3951, DOI 10.4049/jimmunol.165.7.3951
   Dybdahl B, 2002, CIRCULATION, V105, P685, DOI 10.1161/hc0602.103617
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200
   Greene CM, 2005, J IMMUNOL, V174, P1638, DOI 10.4049/jimmunol.174.3.1638
   Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Johnson BJ, 2005, J BIOL CHEM, V280, P4037, DOI 10.1074/jbc.M411569200
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200
   Ludwig D, 1999, DIGEST DIS SCI, V44, P1440, DOI 10.1023/A:1026616221950
   Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849
   Mansilla MJ, 2012, HEAT SHOCK PROTEIN 7
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Missotten GS, 2003, INVEST OPHTH VIS SCI, V44, P3059, DOI 10.1167/iovs.02-1038
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097
   Prakken BJ, 2001, J IMMUNOL, V167, P4147, DOI 10.4049/jimmunol.167.8.4147
   Quintana FJ, 2005, J IMMUNOL, V175, P2777, DOI 10.4049/jimmunol.175.5.2777
   Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002
   Satoh M, 2006, EUR J HEART FAIL, V8, P810, DOI 10.1016/j.ejheart.2006.03.004
   Seibl R, 2003, AM J PATHOL, V162, P1221, DOI 10.1016/S0002-9440(10)63918-1
   Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663
   SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800
   Stramer BM, 2007, J INVEST DERMATOL, V127, P1009, DOI 10.1038/sj.jid.5700811
   Sugita S, 2003, J EXP MED, V198, P161, DOI 10.1084/jem.20030097
   Tanaka KI, 2010, BIOCHEM PHARMACOL, V80, P920, DOI 10.1016/j.bcp.2010.05.025
   Tsan MF, 2009, J LEUKOCYTE BIOL, V85, P905, DOI 10.1189/jlb.0109005
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593
   Wang MH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-173
   Yoo BC, 1999, J NEURAL TRANSM-SUPP, P315
   Zanin-Zhorov A, 2005, J IMMUNOL, V174, P3227, DOI 10.4049/jimmunol.174.6.3227
   Zhou J, 2005, IMMUNOLOGY, V114, P522, DOI 10.1111/j.1365-2567.2004.02112.x
NR 43
TC 32
Z9 33
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2013
VL 8
IS 12
AR e80288
DI 10.1371/journal.pone.0080288
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 276IX
UT WOS:000328745100002
PM 24376495
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Jo, DH
   Kim, JH
   Lee, TG
   Kim, JH
AF Jo, Dong Hyun
   Kim, Jin Hyoung
   Lee, Tae Geol
   Kim, Jeong Hun
TI Nanoparticles in the Treatment of Angiogenesis-Related Blindness
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
ID ANTI-VEGF; ALBUMIN NANOPARTICLES; EFFICACY; DELIVERY; BEVACIZUMAB;
   TOXICITY; NEOVASCULARIZATION; PREMATURITY; RETINOPATHY; INHIBITION
AB Nanoparticles can be used for the treatment of various retinal diseases. Due to small sizes, they can improve bioavailability of therapeutic agents and pass through biological barriers of the eye, such as the cornea, conjunctiva, sclera, and even more, blood-retinal barriers. Another important characteristic of nanoparticles is the ability to be fabricated based on the researchers' design through chemical processes. In this regard, they can act as a novel drug delivery system, enabling targeted therapies for angiogenesis-related blindness (ARB). With these possibilities, many researchers have utilized nanoparticles as novel therapeutic options for the treatment of exudative age-related macular degeneration and diabetic retinopathy, both of which are characterized by pathologic neovascularization. In this review, we summarize various attempts and rationales in using nanoparticles to treat ARB. After that, we discuss the toxicity of nanoparticles on the retina. We expect this review to be a stepping stone for novel therapeutics for ARB, resulting in improvement in visual outcomes.
C1 [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Clin Res Inst, FARB Lab, Seoul 110744, South Korea.
   [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
   [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ, Global Core Res Ctr, Tumor Microenvironm Res Ctr, Seoul 110744, South Korea.
   [Lee, Tae Geol] Korea Res Inst Stand & Sci, Ctr Nanobio Convergence, World Class Lab, Taejon, South Korea.
   [Lee, Tae Geol] Univ Sci & Technol, Dept Nano & Bio Surface Sci, Taejon, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Korea
   Research Institute of Standards & Science (KRISS)
RP Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
EM steph25@snu.ac.kr
RI Kim, Jeong Hun/J-2748-2012; Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU Bio-Signal Analysis Technology Innovation Program of MEST/NRF, Republic
   of Korea [2012-0006058]; Mid-Career Researcher Program of MEST/NRF,
   Republic of Korea [2012-0004931]; Global Core Research Center (GCRC)
   grant from NRF/MEST, Republic of Korea [2012-0001187]
FX This study was supported by the Bio-Signal Analysis Technology
   Innovation Program of MEST/NRF, Republic of Korea (2012-0006058), the
   Mid-Career Researcher Program of MEST/NRF, Republic of Korea
   (2012-0004931), and the Global Core Research Center (GCRC) grant from
   NRF/MEST, Republic of Korea (2012-0001187).
CR Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Arvizo RR, 2011, NANOMED-NANOTECHNOL, V7, P580, DOI 10.1016/j.nano.2011.01.011
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P147, DOI 10.1097/IAE.0b013e3180dc9360
   Blair M, 2012, OPHTHALMOLOGY, V119, P431, DOI 10.1016/j.ophtha.2011.11.021
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bressler NM, 2011, NEW ENGL J MED, V365, P1520, DOI 10.1056/NEJMct0908432
   Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35
   de Kozak Y, 2004, EUR J IMMUNOL, V34, P3702, DOI 10.1002/eji.200425022
   Ding XQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007410
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Hafelli UO, 2009, MOL PHARMACEUT, V6, P1417, DOI 10.1021/mp900083m
   Heo JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033456
   Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651
   Hu J, 2012, ARCH OPHTHALMOL-CHIC, V130, P1000, DOI 10.1001/archophthalmol.2012.592
   Jin J, 2011, INVEST OPHTH VIS SCI, V52, P6230, DOI 10.1167/iovs.10-6229
   Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215
   Jo D. H., 2011, NANOMEDICINE, V8, P784
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Kalishwaralal K, 2009, COLLOID SURFACE B, V73, P51, DOI 10.1016/j.colsurfb.2009.04.025
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim H, 2009, PHARM RES-DORDR, V26, P329, DOI 10.1007/s11095-008-9745-6
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Kim JH, 2011, BIOMATERIALS, V32, P1865, DOI 10.1016/j.biomaterials.2010.11.030
   Koirala A, 2011, BIOMATERIALS, V32, P9483, DOI 10.1016/j.biomaterials.2011.08.062
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Merodio M, 2002, BIOMATERIALS, V23, P1587, DOI 10.1016/S0142-9612(01)00284-8
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Park K, 2009, DIABETES, V58, P1902, DOI 10.2337/db08-1327
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Prow TW, 2008, NANOMED-NANOTECHNOL, V4, P340, DOI 10.1016/j.nano.2008.06.003
   Sakai T, 2006, EXP EYE RES, V82, P657, DOI 10.1016/j.exer.2005.09.003
   Salehi-Had H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018864
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Sanders K, 2012, TOXICOL APPL PHARM, V258, P226, DOI 10.1016/j.taap.2011.10.023
   Sheikpranbabu S, 2010, BIOMATERIALS, V31, P2260, DOI 10.1016/j.biomaterials.2009.11.076
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Skaf AR, 2011, SEMIN OPHTHALMOL, V26, P181, DOI 10.3109/08820538.2011.577133
   Strettoi E, 2010, P NATL ACAD SCI USA, V107, P18706, DOI 10.1073/pnas.1007644107
   Sun FY, 2005, J NEUROSCI RES, V79, P180, DOI 10.1002/jnr.20321
   Wielgus AR, 2010, TOXICOL APPL PHARM, V242, P79, DOI 10.1016/j.taap.2009.09.021
   Zechmeister-Koss I, 2012, BRIT J OPHTHALMOL, V96, P167, DOI 10.1136/bjophthalmol-2011-300674
   Zhang C, 2010, GENE THER, V17, P338, DOI 10.1038/gt.2009.158
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
NR 45
TC 5
Z9 5
U1 0
U2 25
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAR
PY 2013
VL 29
IS 2
SI SI
BP 135
EP 142
DI 10.1089/jop.2012.0113
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 106CI
UT WOS:000316118600006
PM 23145865
DA 2022-11-30
ER

PT J
AU Gerona, G
   Lopez, D
   Palmero, M
   Maneu, V
AF Gerona, Guillermo
   Lopez, Damian
   Palmero, Mercedes
   Maneu, Victoria
TI Antioxidant N-Acetyl-Cysteine Protects Retinal Pigmented Epithelial
   Cells from Long-Term Hypoxia Changes in Gene Expression
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID MITOCHONDRIAL-DNA DAMAGE; AGE-RELATED MACULOPATHY; OXIDATIVE STRESS;
   INDUCED APOPTOSIS; IN-VITRO; P53-DEPENDENT TRANSACTIVATION; BCL-2
   OVEREXPRESSION; P53; ACTIVATION; INHIBITION
AB Purpose: To further know the signaling pathways involved in hypoxia-induced apoptosis in retinal pigmented epithelial (RPE) cells and to improve the understanding of the antioxidant N-acetyl-cysteine (NAC) treatment effect.
   Methods: We analyzed the expression levels of several apoptosis-related genes by semiquantitative reverse transcriptase-polymerase chain reaction in RPE after 72 h of maintained hypoxia, with or without 10 mM NAC treatment.
   Results: Under hypoxic conditions, we detected a higher expression level of p53 and CASP8. Cell treatment with NAC 10mM prevented this increase. Other apoptosis-related genes such as bax, CASP3, CASP4, CASP7, and fas did not show an increase in expression levels in hypoxia.
   Conclusions: NAC prevents the increased expression levels of p53 and CASP8 induced by long-term maintained hypoxia. The supply of antioxidants could be a useful preventive approach in protecting RPE from the effects of chronic oxygen stress, which is of great interest in oxygen stress-related diseases such as age-related macular degeneration and other senescence-associated pathologies.
C1 [Maneu, Victoria] Univ Alicante, Dept Opt Farmacol & Anat, Area Farmacol, San Vicente Del Raspeig 03690, Alicante, Spain.
   [Lopez, Damian] Univ Politecn Valencia, Dept Sistemas Informat & Computac, E-46071 Valencia, Spain.
   [Maneu, Victoria] Univ Autonoma Madrid, Inst Teofilo Hernando ID Medicamento, Madrid, Spain.
C3 Universitat d'Alacant; Universitat Politecnica de Valencia; Autonomous
   University of Madrid
RP Maneu, V (通讯作者)，Univ Alicante, Dept Opt Farmacol & Anat, Area Farmacol, Pabellon 13,Carretera S Vte Del Raspeig S-N, San Vicente Del Raspeig 03690, Alicante, Spain.
EM vmaneu@ua.es
RI Maneu, Victoria/N-4147-2014; PALMERO, MERCEDES/Z-5585-2019; López,
   Damián/F-9900-2019
OI Maneu, Victoria/0000-0002-5265-1361; López, Damián/0000-0003-3633-3862;
   PALMERO, MERCEDES/0000-0001-6229-2529
FU University of Alicante [GRE0410]; Spanish Ministerio de Ciencia e
   Innovacion [TIN2007-60769];  [BFU 2007-60658/BFI]
FX We thank Miguel Angel Company for his technical assistance. This work
   was partially supported by grant BFU 2007-60658/BFI (Spain) and by the
   University of Alicante (GRE0410, Ayudas a Grupos Emergentes). Damian
   Lopez is partially supported by Spanish Ministerio de Ciencia e
   Innovacion under contracts TIN2007-60769.
CR Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Augustin AJ, 1996, GRAEF ARCH CLIN EXP, V234, P58, DOI 10.1007/BF00186520
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Castillo M, 2002, OPHTHALMIC RES, V34, P338, DOI 10.1159/000067050
   De la Fuente M, 1998, MECH AGEING DEV, V104, P213, DOI 10.1016/S0047-6374(98)00071-2
   Deas O, 1997, INT IMMUNOL, V9, P117, DOI 10.1093/intimm/9.1.117
   Delneste Y, 1996, EUR J IMMUNOL, V26, P2981, DOI 10.1002/eji.1830261225
   Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187
   Fink T, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-98
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264
   Inoue T, 2002, J NEUROSCI, V22, P4468, DOI 10.1523/JNEUROSCI.22-11-04468.2002
   Jiang S, 2002, INVEST OPHTH VIS SCI, V43, P2546
   Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kim YS, 2008, J IMMUNOL, V181, P6158, DOI 10.4049/jimmunol.181.9.6158
   Kin H, 2008, SHOCK, V29, P761, DOI 10.1097/SHK.0b013e31815cfd5a
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kopke RD, 2007, HEARING RES, V226, P114, DOI 10.1016/j.heares.2006.10.008
   Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001
   Kumar S, 2009, LIFE SCI, V84, P328, DOI 10.1016/j.lfs.2008.12.016
   Lattanzio FA, 2005, CARDIOVASC TOXICOL, V5, P377, DOI 10.1385/CT:5:4:377
   Liu T, 2007, CELL DEATH DIFFER, V14, P411, DOI 10.1038/sj.cdd.4402022
   Maron JL, 2008, J MATERN-FETAL NEO M, V21, P443, DOI 10.1080/14767050802104843
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   MIQUEL J, 1995, EUR J PHARM-ENVIRON, V292, P333, DOI 10.1016/0926-6917(95)90041-1
   Miquel J, 1998, EXP GERONTOL, V33, P113, DOI 10.1016/S0531-5565(97)00060-0
   NEWSOME DA, 1983, T OPHTHAL SOC UK, V103, P458
   Ravishankar S, 2001, BRAIN RES, V901, P23, DOI 10.1016/S0006-8993(01)02109-6
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   SANETO RP, 1982, BIOCHEM J, V205, P213, DOI 10.1042/bj2050213
   Sheth DS, 2009, BRAIN RES, V1285, P14, DOI 10.1016/j.brainres.2009.06.029
   Shimada K, 2009, CIRC J, V73, P1337, DOI 10.1253/circj.CJ-08-1148
   Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039
   Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02
   Usha Chakravarthy J.E., 2010, BMJ-BRIT MED J, V340, P526
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vogel JS, 2007, INVEST OPHTH VIS SCI, V48, P3872, DOI 10.1167/iovs.06-1523
   Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013
   Wilson SE, 1999, EXP EYE RES, V69, P255, DOI 10.1006/exer.1999.0698
   Wood JPM, 1997, NEUROCHEM INT, V31, P261, DOI 10.1016/S0197-0186(96)00157-X
   Wu YJ, 2005, J PHARMACOL EXP THER, V312, P424, DOI 10.1124/jpet.104.075119
   Yam HF, 2003, INVEST OPHTH VIS SCI, V44, P370, DOI 10.1167/iovs.01-1113
   Yuan YQ, 2003, THERIOGENOLOGY, V59, P1585, DOI 10.1016/S0093-691X(02)01204-9
   Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200
NR 52
TC 7
Z9 7
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD AUG
PY 2010
VL 26
IS 4
BP 309
EP 314
DI 10.1089/jop.2009.0101
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 637FY
UT WOS:000280802900001
PM 20653475
DA 2022-11-30
ER

PT J
AU Bazan, NG
AF Bazan, Nicolas G.
TI Cell survival matters: docosahexaenoic acid signaling, neuroprotection
   and photoreceptors
SO TRENDS IN NEUROSCIENCES
LA English
DT Review
ID POLYUNSATURATED FATTY-ACIDS; PIGMENT EPITHELIAL-CELLS; ROD OUTER
   SEGMENTS; RETINAL PHOTORECEPTORS; RETINITIS-PIGMENTOSA; GENE-EXPRESSION;
   BRAIN ISCHEMIA; APOPTOSIS; RHODOPSIN; DEATH
AB Recent data have provided important clues about the molecular mechanisms underlying certain retinal degenerative diseases, including retinitis pigmentosa and age-related macular degeneration. Photoreceptor cell degeneration is a feature common to these diseases, and the death of these cells in many instances seems to involve the closely associated retinal pigment epithelial (RPE) cells. Under normal circumstances, both cell types are subject to potentially damaging stimuli (e.g. sunlight and high oxygen tension). However, the mechanism or mechanisms by which homeostasis is maintained in this part of the eye, which is crucial for sight, are an unsolved riddle. The omega-3 fatty acid family member docosahexaenoic acid (DHA), which is enriched in these cells, is the precursor of neuroprotectin D1 (NPD1). NPD1 inhibits oxidative-stress-mediated proinflammatory gene induction and apoptosis, and consequently promotes RPE cell survival. This enhanced understanding of the molecular basis of endogenous anti-inflammatory and neuroprotective signaling in the RPE presents an opportunity for the development of therapies for retinal degenerative diseases.
C1 Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr Excellence, Sch Med, New Orleans, LA 70112 USA.
   Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, Sch Med, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans
RP Bazan, NG (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr Excellence, Sch Med, New Orleans, LA 70112 USA.
EM nbazan@lsuhsc.edu
RI Robles-Sardin, Alma E/M-7714-2015; Bazan, Nicolas/AAN-4121-2020
OI Robles-Sardin, Alma E/0000-0003-2044-7793; Bazan,
   Nicolas/0000-0002-9243-5444
FU NATIONAL EYE INSTITUTE [R01EY005121] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY 05121] Funding Source: Medline
CR Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102
   Anderson RE, 2002, MOL VIS, V8, P351
   AVELDANO MI, 1974, FEBS LETT, V40, P53, DOI 10.1016/0014-5793(74)80892-6
   AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024
   AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9
   AVELDANO MI, 1983, J LIPID RES, V24, P620
   BARREIRO SG, 2005, INVEST OPHTHALMOL VI, V46
   Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Bazan NG, 2003, J LIPID RES, V44, P2221, DOI 10.1194/jlr.R300013-JLR200
   BAZAN NG, 1986, BIOCHEM BIOPH RES CO, V141, P600, DOI 10.1016/S0006-291X(86)80215-7
   BAZAN NG, 1984, BIOCHEM BIOPH RES CO, V125, P741, DOI 10.1016/0006-291X(84)90601-6
   BAZAN NG, 2005, INVEST OPHTHALMOL VI, V46
   BAZAN NG, 1985, RETINAL DEGENERATION, P159
   Belayev L, 2005, STROKE, V36, P118, DOI 10.1161/01.STR.0000149620.74770.2e
   Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1306, DOI 10.1001/archopht.122.9.1306
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311
   Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BOK D, 1993, J CELL SCI, P189
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067
   Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200
   Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   CHOE HG, 1990, EXP EYE RES, V51, P159, DOI 10.1016/0014-4835(90)90068-6
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Caldironi M I, 1977, Adv Exp Med Biol, V83, P397
   Dentchev T, 2003, MOL VIS, V9, P184
   Deretic D, 2004, REC ADV HUM BIOL, V10, P29
   deTurco EBR, 1997, J BIOL CHEM, V272, P10491
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Ershov AV, 1996, J BIOL CHEM, V271, P28458, DOI 10.1074/jbc.271.45.28458
   Ershov AV, 1999, J NEUROSCI RES, V58, P254, DOI 10.1002/(SICI)1097-4547(19991015)58:2<254::AID-JNR5>3.0.CO;2-U
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fliesler SJ, 1999, TRENDS CELL BIOL, V9, P280, DOI 10.1016/S0962-8924(99)01582-2
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GONG JX, 1992, INVEST OPHTH VIS SCI, V33, P2596
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   HOFFMAN DR, 1995, INVEST OPHTH VIS SCI, V36, P1009
   HORROCKS LA, 1994, CELL SIGNAL TRANSDUCTION, SECOND MESSENGERS, AND PROTEIN PHOSPHORYLATION IN HEALTH AND DISEASE, P113
   Li F, 2001, EXP EYE RES, V73, P569, DOI 10.1006/exer.2001.1068
   Liang Y, 2000, CURR EYE RES, V20, P25, DOI 10.1076/0271-3683(200001)2011-HFT025
   Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200
   Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420
   Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Marszalek JR, 2005, ANNU REV CELL DEV BI, V21, P633, DOI 10.1146/annurev.cellbio.21.122303.120624
   MATTSON MP, 2006, BASIC NEUROCHEMISTRY, P603
   MCCOLL AJ, 1995, PROG LIPID RES, V34, P1, DOI 10.1016/0163-7827(94)00004-6
   McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6
   Mendes HF, 2005, TRENDS MOL MED, V11, P177, DOI 10.1016/j.molmed.2005.02.007
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202
   Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   Osborne NN, 1997, INVEST OPHTH VIS SCI, V38, P1390
   Papermaster DS, 2002, INVEST OPHTH VIS SCI, V43, P1300
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   REDDY TS, 1984, CURR EYE RES, V3, P1225, DOI 10.3109/02713688409000826
   Rotstein NP, 1997, J NEUROCHEM, V69, P504
   Rotstein NP, 1996, J NEUROCHEM, V66, P1851
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SCHAEFER EJ, 1995, J LIPID RES, V36, P1427
   SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903
   SCOTT BL, 1988, J NEUROSCI RES, V20, P202, DOI 10.1002/jnr.490200209
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081
   STINSON AM, 1991, J LIPID RES, V32, P2009
   Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200
   UAUY RD, 1990, PEDIATR RES, V28, P485, DOI 10.1203/00006450-199011000-00014
   Zhang C, 2001, J POROUS MEDIA, V4, P89
NR 82
TC 262
Z9 283
U1 0
U2 24
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0166-2236
EI 1878-108X
J9 TRENDS NEUROSCI
JI Trends Neurosci.
PD MAY
PY 2006
VL 29
IS 5
BP 263
EP 271
DI 10.1016/j.tins.2006.03.005
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 047YB
UT WOS:000237913500004
PM 16580739
DA 2022-11-30
ER

PT J
AU Tian, Y
   Zhang, F
   Qiu, YF
   Wang, S
   Li, F
   Zhao, JW
   Pan, C
   Tao, Y
   Yu, D
   Wei, W
AF Tian, Ying
   Zhang, Fan
   Qiu, Yefeng
   Wang, Shuang
   Li, Feng
   Zhao, Jiawei
   Pan, Chao
   Tao, Yong
   Yu, Di
   Wei, Wei
TI Reduction of choroidal neovascularization via cleavable VEGF antibodies
   conjugated to exosomes derived from regulatory T cells
SO NATURE BIOMEDICAL ENGINEERING
LA English
DT Article
ID MACULAR DEGENERATION; INFLAMMATORY CYTOKINES; INTRAVITREAL
   DEXAMETHASONE; AQUEOUS-HUMOR; BEVACIZUMAB; RANIBIZUMAB; MODELS; NAIVE
AB Intravitreally injected exosomes derived from regulatory T cells and conjugated with an antibody for vascular endothelial growth factor via a cleavable linker markedly suppress ocular neovascularization in mice and non-human primates.
   Choroidal neovascularization induced by age-related macular degeneration and retinal neovascularization induced by diabetic retinopathy-two leading causes of blindness-are often treated using antibodies targeting vascular endothelial growth factor (VEGF). Here we report a strong association between inflammation and high VEGF expression in aqueous humour samples from patients with choroidal or retinal neovascularization, and show that intravitreally injected exosomes derived from regulatory T cells and conjugated with an anti-VEGF antibody via a peptide linker that is cleavable by matrix metalloproteinases markedly suppressed ocular neovascularization in mouse and non-human primate models of choroidal neovascularization. The engineered exosomes, which selectively accumulate in the neovascularization lesions, could be adapted for other combination therapies of therapeutic antibodies and anti-inflammatory cargo.
C1 [Tian, Ying; Tao, Yong] Capital Med Univ, Beijing Chaoyang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Tian, Ying; Zhang, Fan; Wang, Shuang; Li, Feng; Zhao, Jiawei; Wei, Wei] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing, Peoples R China.
   [Zhang, Fan] Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen, Peoples R China.
   [Qiu, Yefeng] Acad Mil Med Sci, Anim Ctr, Beijing, Peoples R China.
   [Li, Feng; Wei, Wei] Univ Chinese Acad Sci, Sch Chem Engn, Beijing, Peoples R China.
   [Pan, Chao] Beijing Inst Biotechnol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.
   [Yu, Di] Univ Queensland, Fac Med, Diamantina Inst, Brisbane, Qld, Australia.
C3 Capital Medical University; Chinese Academy of Sciences; Institute of
   Process Engineering, CAS; Sun Yat Sen University; Academy of Military
   Medical Sciences - China; Chinese Academy of Sciences; University of
   Chinese Academy of Sciences, CAS; University of Queensland
RP Tao, Y (通讯作者)，Capital Med Univ, Beijing Chaoyang Hosp, Dept Ophthalmol, Beijing, Peoples R China.; Wei, W (通讯作者)，Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing, Peoples R China.; Wei, W (通讯作者)，Univ Chinese Acad Sci, Sch Chem Engn, Beijing, Peoples R China.; Yu, D (通讯作者)，Univ Queensland, Fac Med, Diamantina Inst, Brisbane, Qld, Australia.
EM drtaoyong@163.com; di.yu@uq.edu.au; weiwei@ipe.ac.cn
OI Yu, Di/0000-0003-1721-8922; Wei, Wei/0000-0002-6244-3187; Tao,
   Yong/0000-0003-1443-2667
FU National Natural Science Foundation of China [82070948, U2001224];
   Beijing Chaoyang 1351 talent training programme [CYXX-2017-21];
   Scientific Research Program of Beijing Municipal Commission of Education
   [KM202010025020]
FX This work was supported by the National Natural Science Foundation of
   China (82070948, U2001224), the Beijing Chaoyang 1351 talent training
   programme (CYXX-2017-21) and the Scientific Research Program of Beijing
   Municipal Commission of Education (KM202010025020).
CR Arima M, 2020, DIABETES, V69, P981, DOI 10.2337/db19-1121
   Barakat MR, 2021, OPHTHALMOL RETINA, V5, P60, DOI 10.1016/j.oret.2020.08.007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burnouf T, 2019, INT J NANOMED, V14, P8847, DOI 10.2147/IJN.S225453
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Chatila TA, 2014, IMMUNITY, V41, P3, DOI 10.1016/j.immuni.2014.07.001
   Chen H, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0572-6
   Chung EJ, 2009, BRIT J OPHTHALMOL, V93, P958, DOI 10.1136/bjo.2008.149187
   Criswell MH, 2005, INVEST OPHTH VIS SCI, V46, P2168, DOI 10.1167/iovs.04-1442
   Dante JP, 2019, RETIN PHYS, V16, P46
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dorner T, 2019, LANCET, V393, P2344, DOI 10.1016/S0140-6736(19)30546-X
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   El Baradie KBY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00181
   Fantini MC, 2007, NAT PROTOC, V2, P1789, DOI 10.1038/nprot.2007.258
   Farnoodian M, 2018, AM J PHYSIOL-CELL PH, V314, pC456, DOI 10.1152/ajpcell.00259.2017
   Feng SF, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8546423
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P2473, DOI 10.1016/j.ophtha.2014.07.002
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158839
   Jafari D, 2020, CRIT REV BIOTECHNOL, V40, P1098, DOI 10.1080/07388551.2020.1805406
   Jiang J, 2018, EUR J PHARM SCI, V121, P251, DOI 10.1016/j.ejps.2018.04.043
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Luaces-Rodriguez A, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118767
   Luckoff A, 2017, NAT PROTOC, V12, P1136, DOI 10.1038/nprot.2017.032
   Maberley D, 2009, OPHTHALMOLOGY, V116, P2149, DOI 10.1016/j.ophtha.2009.04.032
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miao H, 2012, MOL VIS, V18, P574
   Mu HJ, 2018, DRUG DELIV, V25, P1372, DOI 10.1080/10717544.2018.1474967
   Okoye IS, 2014, IMMUNITY, V41, P89, DOI [10.1016/j.immuni.2014.05.019, 10.1016/j.immuni.2014.08.008]
   Pineda-Torra I, 2015, METHODS MOL BIOL, V1339, P101, DOI 10.1007/978-1-4939-2929-0_6
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Richert E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23163
   Robbie SJ, 2013, INVEST OPHTH VIS SCI, V54, P1490, DOI 10.1167/iovs.12-10169
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Romano M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00043
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Song S, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2020.107641
   Sugita S, 2008, J IMMUNOL, V181, P7525, DOI 10.4049/jimmunol.181.11.7525
   Taylor AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00037
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Thorne JE, 2019, OPHTHALMOLOGY, V126, P283, DOI 10.1016/j.ophtha.2018.08.021
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   Xuan QH, 2020, ADV SCI, V7, DOI 10.1002/advs.202001714
   Yamamoto Y, 2015, RETINA-J RET VIT DIS, V35, P344, DOI 10.1097/IAE.0000000000000311
   Yang Q, 2019, J CONTROL RELEASE, V308, P29, DOI 10.1016/j.jconrel.2019.06.031
   Zhang J, 2013, J AM CHEM SOC, V135, P5068, DOI 10.1021/ja312004m
NR 60
TC 13
Z9 14
U1 29
U2 91
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2157-846X
J9 NAT BIOMED ENG
JI Nat. Biomed. Eng
PD SEP
PY 2021
VL 5
IS 9
BP 968
EP +
DI 10.1038/s41551-021-00764-3
EA JUL 2021
PG 19
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA WC1KI
UT WOS:000677707300002
PM 34312509
DA 2022-11-30
ER

PT J
AU Arjunan, P
AF Arjunan, Pachiappan
TI Eye on the Enigmatic Link: Dysbiotic Oral Pathogens in Ocular Diseases;
   The Flip Side
SO INTERNATIONAL REVIEWS OF IMMUNOLOGY
LA English
DT Review
DE Age-related macular degeneration; angiogenesis; chronic inflammation;
   drusen; immune response; inflammation; oral microbiome; pathogens;
   periodontitis; retinal degeneration
ID PORPHYROMONAS-GINGIVALIS; PERIODONTAL-DISEASE; DENDRITIC CELLS; MACULAR
   DEGENERATION; SJOGRENS-SYNDROME; ALZHEIMERS-DISEASE; AGE; HEALTH;
   MICROBIOME; INFLAMMATION
AB Mouth and associated structures were regarded as separate entities from the rest of the body. However, there is a paradigm shift in this conception and oral health is now considered as a fundamental part of overall well-being. In recent years, the subject of oral-foci of infection has attained a resurgence in terms of systemic morbidities while limited observations denote the implication of chronic oral inflammation in the pathogenesis of eye diseases. Hitherto, there is a paucity for mechanistic insights underlying the reported link between periodontal disease (PD) and ocular comorbidities. In light of prevailing scientific evidence, this review article will focus on the understudied theme, that is, the impact of oral dysbiosis in the induction and/or progression of inflammatory eye diseases like diabetic retinopathy, scleritis, uveitis, glaucoma, age-related macular degeneration (AMD). Furthermore, the plausible mechanisms by which periodontal microbiota may trigger immune dysfunction in the Oro-optic-network and promote the development of PD-associated AMD have been discussed.
C1 [Arjunan, Pachiappan] Dent Coll Georgia, Dept Periodont, Augusta, GA 30912 USA.
   [Arjunan, Pachiappan] Augusta Univ, James & Jean Culver Vis Discovery Inst, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University
RP Arjunan, P (通讯作者)，Dent Coll Georgia, Dept Periodont, Augusta, GA 30912 USA.; Arjunan, P (通讯作者)，Augusta Univ, James & Jean Culver Vis Discovery Inst, Augusta, GA 30912 USA.
EM PARJUNAN@augusta.edu
RI Arjunan, Pachiappan/AAG-3297-2021
FU DCG Startup Fund; AU Intra-Mural Grant
FX Supported by the DCG Startup Fund and AU Intra-Mural Grant (to P.A).
CR Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005
   Abbayya K, 2015, N AM J MED SCI, V7, P241, DOI 10.4103/1947-2714.159325
   Agrawal R, 2014, INDIAN J OPHTHALMOL, V62, P74, DOI 10.4103/0301-4738.126187
   Ahn JK, 2006, AM J OPHTHALMOL, V142, P429, DOI 10.1016/j.ajo.2006.04.016
   Akcali A, 2016, J CLIN PERIODONTOL, V43, P637, DOI 10.1111/jcpe.12555
   Akman A, 2007, J CLIN PERIODONTOL, V34, P485, DOI 10.1111/j.1600-051X.2007.01085.x
   Alagl AS, 2017, J INVESTIG CLIN DENT, V8, DOI 10.1111/jicd.12217
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Amiri AA, 2014, N AM J MED SCI, V6, P139, DOI 10.4103/1947-2714.128476
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   [Anonymous], 2017, J ADV MED DENT SCI R
   Arabaci T, 2009, J PERIODONTAL RES, V44, P718, DOI 10.1111/j.1600-0765.2008.01183.x
   Arjunan P, 2016, MOL ORAL MICROBIOL, V31, P78, DOI 10.1111/omi.12131
   Arjunan P., 2018, INVESTIGATING ENIGMA
   Arjunan P., 2020, EC OPHTHALMOL, V11
   Arjunan P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64449-8
   Arjunan P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35126-8
   Arjunan P, 2018, P NATL ACAD SCI USA, V115, P10351, DOI 10.1073/pnas.1801379115
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   Avila M, 2009, DNA CELL BIOL, V28, P405, DOI 10.1089/dna.2009.0874
   Azam S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01000
   Bartold PM, 2013, PERIODONTOL 2000, V62, P203, DOI 10.1111/j.1600-0757.2012.00450.x
   Bascones-Martinez A, 2015, MED CLIN-BARCELONA, V145, P31, DOI 10.1016/j.medcli.2014.07.019
   Ambrosio LMB, 2017, BRAZ ORAL RES, V31, DOI 10.1590/1807-3107BOR-2017.vol31.0008
   Bhat UG, 2014, J PERIODONTOL, V85, P1629, DOI 10.1902/jop.2014.140070
   Brennan CA, 2019, NAT REV MICROBIOL, V17, P156, DOI 10.1038/s41579-018-0129-6
   Brook I, 2010, ANAEROBE, V16, P183, DOI 10.1016/j.anaerobe.2009.12.001
   Brzozowska Aleksandra, 2012, Klin Oczna, V114, P29
   Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394
   Burleson GR, 2017, TOXICOL PATHOL, V45, P146, DOI 10.1177/0192623316677070
   Burns R, 1922, Cal State J Med, V20, P120
   Cahill TJ, 2016, LANCET, V387, P882, DOI 10.1016/S0140-6736(15)00067-7
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Artese HPC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128344
   Carrion J, 2012, J IMMUNOL, V189, P3178, DOI 10.4049/jimmunol.1201053
   Casanova L, 2014, BRIT DENT J, V217, P433, DOI 10.1038/sj.bdj.2014.907
   Celenligil H, 1998, J PERIODONTOL, V69, P571, DOI 10.1902/jop.1998.69.5.571
   Celenligil-Nazliel H, 1999, J PERIODONTOL, V70, P1449, DOI 10.1902/jop.1999.70.12.1449
   Chang PC, 2012, J DENT SCI, V7, P272, DOI 10.1016/j.jds.2012.02.002
   Chen YJ, 2018, MOL MED REP, V18, P97, DOI 10.3892/mmr.2018.8983
   Chiu C, 2019, INVEST OPHTH VIS SCI, V60
   Coit P, 2016, CLIN IMMUNOL, V169, P28, DOI 10.1016/j.clim.2016.06.002
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cutler CW, 1999, J PERIODONTAL RES, V34, P406, DOI 10.1111/j.1600-0765.1999.tb02274.x
   D'Aiuto F, 2004, J DENT RES, V83, P156, DOI 10.1177/154405910408300214
   Darveau RP, 1997, PERIODONTOL 2000, V14, P12, DOI 10.1111/j.1600-0757.1997.tb00190.x
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   De Luca F, 2019, CLIN EXP IMMUNOL, V195, P74, DOI 10.1111/cei.13158
   DEBELIAN GJ, 1994, ENDOD DENT TRAUMATOL, V10, P57
   Demmer RT, 2008, J CLIN PERIODONTOL, V35, P479, DOI 10.1111/j.1600-051X.2008.01232.x
   Detert J, 2010, Z RHEUMATOL, V69, P109, DOI 10.1007/s00393-009-0560-1
   Devine L, 1996, IMMUNOLOGY, V88, P456, DOI 10.1046/j.1365-2567.1996.d01-666.x
   Ding Y, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0110-7
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Duran-Pinedo AE, 2015, MICROBES INFECT, V17, P505, DOI 10.1016/j.micinf.2015.03.014
   Eke PI, 2020, PERIODONTOL 2000, V82, P257, DOI 10.1111/prd.12323
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   Entezami P, 2011, HAND CLIN, V27, P1, DOI 10.1016/j.hcl.2010.09.006
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Carrizales-Sepulveda EF, 2018, HEART LUNG CIRC, V27, P1327, DOI 10.1016/j.hlc.2018.05.102
   Gendron R, 2000, MICROBES INFECT, V2, P897, DOI 10.1016/S1286-4579(00)00391-9
   Ghizoni JS, 2012, J APPL ORAL SCI, V20, P104, DOI 10.1590/S1678-77572012000100019
   Grant-Theule D A, 1996, J West Soc Periodontol Periodontal Abstr, V44, P69
   Graves DT, 2008, FRONT BIOSCI-LANDMRK, V13, P1227, DOI 10.2741/2757
   Graves Dana T, 2004, Compend Contin Educ Dent, V25, P38
   Griffen AL, 1998, J CLIN MICROBIOL, V36, P3239, DOI 10.1128/JCM.36.11.3239-3242.1998
   Grover AK, 2015, IRAN J EARTH SCI, V7, P1
   Grzybowski A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030761
   Gul A, 2001, CLIN EXP RHEUMATOL, V19, pS6
   Guncu Guliz Nigar, 2011, Eur J Dent, V5, P337
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   H R Veena, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6040104
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873
   Hajishengallis G, 2011, NAT REV IMMUNOL, V11, P187, DOI 10.1038/nri2918
   Hajishengallis G, 2009, MICROBES INFECT, V11, P637, DOI 10.1016/j.micinf.2009.03.009
   Heron E, 2017, J FR OPHTALMOL, V40, P681, DOI 10.1016/j.jfo.2017.04.007
   Heuss ND, 2012, J IMMUNOL, V188, P1191, DOI 10.4049/jimmunol.1101621
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Hughes Christopher, 2020, Eur J Case Rep Intern Med, V7, P001691, DOI 10.12890/2020_001691
   Iacopino A M, 2001, Ann Periodontol, V6, P125, DOI 10.1902/annals.2001.6.1.125
   Igari K, 2014, ORAL BIOL DENT, V2, P1, DOI [10.7243/2053-5775-2-4, DOI 10.7243/2053-5775-2-4]
   Ignat F, 2001, Oftalmologia, V52, P67
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Javed F, 2021, ACTA OPHTHALMOL, V99, P351, DOI 10.1111/aos.14629
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jotwani R, 2004, INFECT IMMUN, V72, P1725, DOI 10.1128/IAI.72.3.1725-1732.2004
   Jung HS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188286
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kimura S, 2000, J PERIODONTOL, V71, P1167, DOI 10.1902/jop.2000.71.7.1167
   Kinane DF, 1999, J PERIODONTOL, V70, P1, DOI 10.1902/jop.1999.70.1.1
   Kingman S, 2004, B WORLD HEALTH ORGAN, V82, P887
   Konkel JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01403
   Kozarov E, 2012, FUTUR CARDIOL, V8, P123, DOI [10.2217/fca.11.75, 10.2217/FCA.11.75]
   Kuboniwa M, 2010, PERIODONTOL 2000, V52, P38, DOI 10.1111/j.1600-0757.2009.00311.x
   Kuboniwa M, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-98
   Kwok SK, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3780
   Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579-018-0089-x
   Lamont RJ, 2000, ORAL MICROBIOL IMMUN, V15, P341, DOI 10.1034/j.1399-302x.2000.150601.x
   Larsen T, 2017, APMIS, V125, P376, DOI 10.1111/apm.12688
   Leccese P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01067
   Lehner T, 1997, Int Rev Immunol, V14, P21, DOI 10.3109/08830189709116842
   Li XJ, 2000, CLIN MICROBIOL REV, V13, P547, DOI 10.1128/CMR.13.4.547-558.2000
   Liang HY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063983, 10.1371/journal.pone.0074121]
   Lin CY, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050771
   Lin P, 2019, CLIN EXP OPHTHALMOL, V47, P418, DOI 10.1111/ceo.13493
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   Lin TC, 2018, PEERJ, V6, DOI 10.7717/peerj.5109
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Maarse F, 2019, CLIN EXP RHEUMATOL, V37, pS225
   MacNevin M.G., 1922, ABSTRACT LIT MOUTH I
   Majumdar Utpal, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr.12.2011.5320
   Marsh PD., 2006, BMC ORAL HEALTH, V6, P1, DOI DOI 10.1186/1472-6831-6-S1-S14
   Marsh Philip D., 2000, Microbial Ecology in Health and Disease, V12, P130, DOI 10.1080/089106000750051800
   Mays Jacqueline W, 2012, J Evid Based Dent Pract, V12, P265, DOI 10.1016/S1532-3382(12)70051-9
   Mesquida M, 2014, CLIN EXP IMMUNOL, V176, P301, DOI 10.1111/cei.12295
   Michaud DS, 2017, EPIDEMIOL REV, V39, P49, DOI 10.1093/epirev/mxx006
   Michaud DS, 2013, CARCINOGENESIS, V34, P2193, DOI 10.1093/carcin/bgt249
   Miller W., 1891, LANCET, V138, P340, DOI [DOI 10.1016/S0140-6736(02)01387-9, 10.1016/S0140-6736(02)01387-9]
   Miyauchi M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21072-y
   Morita F, 2017, IDCases, V7, P6, DOI 10.1016/j.idcr.2016.11.003
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Murata T, 1997, DIABETOLOGIA, V40, P764, DOI 10.1007/s001250050747
   Najera MP, 1997, ORAL SURG ORAL MED O, V83, P453, DOI 10.1016/S1079-2104(97)90144-X
   Napenas JJ, 2014, ORAL MAXIL SURG CLIN, V26, P55, DOI 10.1016/j.coms.2013.09.004
   Nayar G, 2016, ANAEROBE, V38, P70, DOI 10.1016/j.anaerobe.2015.10.005
   Nayyar A, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00257-5
   NEI, AG REL MAC DEG AMD D
   Nitta H, 2017, J DIABETES INVEST, V8, P677, DOI 10.1111/jdi.12633
   Noma H, 2004, DIABETES CARE, V27, P615, DOI 10.2337/diacare.27.2.615
   Offenbacher S, 1996, Ann Periodontol, V1, P821, DOI 10.1902/annals.1996.1.1.821
   Ohira S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147080
   Ohlrich Edward J, 2010, J Oral Microbiol, V2, DOI 10.3402/jom.v2i0.5818
   Olate S, 2014, INT J CLIN EXP MED, V7, P1140
   Page R C, 1998, Ann Periodontol, V3, P108, DOI 10.1902/annals.1998.3.1.108
   PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x
   Pappas G, 2008, INT J INFECT DIS, V12, P347, DOI 10.1016/j.ijid.2007.11.003
   Pasquale LR, 2016, OPHTHALMOLOGY, V123, P2318, DOI 10.1016/j.ophtha.2016.07.014
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Pockpa ZAD, 2019, PERM J, V23
   Polla D, 2017, J GLAUCOMA, V26, P320, DOI 10.1097/IJG.0000000000000465
   Popova C, 2013, BIOTECHNOL BIOTEC EQ, V27, P3754, DOI 10.5504/BBEQ.2013.0027
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Pradeep AR, 2011, CYTOKINE, V54, P200, DOI 10.1016/j.cyto.2011.02.010
   Pritchard AB, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00336
   Ramsey DT, 1996, J AM ANIM HOSP ASSOC, V32, P215, DOI 10.5326/15473317-32-3-215
   Rath H, 2017, FEMS MICROBIOL ECOL, V93, DOI 10.1093/femsec/fix010
   Horliana ACRT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098271
   Redanz S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027827
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roca-Millan E, 2018, MED ORAL PATOL ORAL, V23, pE681, DOI 10.4317/medoral.22725
   Rosenow EC, 1919, J DENT RES, V1, P205, DOI [DOI 10.1177/00220345190010030101, 10.1177/00220345190010030101]
   Rullo J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60674-3
   Sadzeviciene Renata, 2005, Stomatologija, V7, P121
   Sampaio-Maia B, 2016, ADV APPL MICROBIOL, V97, P171, DOI 10.1016/bs.aambs.2016.08.002
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sen HN, 2017, INVEST OPHTH VIS SCI, V58
   Shiboski CH, 2017, ANN RHEUM DIS, V76, P9, DOI [10.1136/annrheumdis-2016-210571, 10.1002/art.39859]
   Shijo T, 2020, INT OPHTHALMOL, V40, P2735, DOI 10.1007/s10792-020-01460-y
   Shimizu E, 2019, OCUL SURF, V17, P265, DOI 10.1016/j.jtos.2019.02.001
   Shin YU, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006418
   Singh Priyanka, 2014, J Oral Maxillofac Pathol, V18, pS167, DOI [10.4103/0972-124X.134566, 10.4103/0973-029X.141376]
   Singhrao SK, 2018, J ALZHEIMERS DIS REP, V2, P219, DOI 10.3233/ADR-180080
   Smith KA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00068
   Soares LD, 2018, OR SURG OR MED OR PA, V125, P223, DOI 10.1016/j.oooo.2017.11.018
   SOCRANSKY SS, 1991, J CLIN PERIODONTOL, V18, P766, DOI 10.1111/j.1600-051X.1991.tb00070.x
   Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600-051X.1998.tb02419.x
   Somma F, 2011, EUR REV MED PHARMACO, V15, P35
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sun KT, 2019, RETINA
   Sutedjo W, 2015, INDONESIAN J TROP IN, V3
   Swidsinski A, 2011, GUT, V60, P34, DOI 10.1136/gut.2009.191320
   Szmigielska Agnieszka, 2016, Dev Period Med, V20, P105
   Takii R, 2005, INFECT IMMUN, V73, P883, DOI 10.1128/IAI.73.2.883-893.2005
   Tlaskalova-Hogenova H, 2004, IMMUNOL LETT, V93, P97, DOI 10.1016/j.imlet.2004.02.005
   Topcuoglu N, 2015, ANAEROBE, V35, P35, DOI 10.1016/j.anaerobe.2015.01.011
   Trujillo-Vargas CM, 2020, OCUL SURF, V18, P335, DOI 10.1016/j.jtos.2019.10.006
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Velsko IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097811
   Verhulst MJL, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00056
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   Wang X, 2013, DIABETES CARE, V36, P166, DOI 10.2337/dc12-0702
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029
   Wijarnpreecha K, 2016, N AM J MED SCI, V8, P197, DOI 10.4103/1947-2714.179961
   Willcox MDP, 2013, EXP EYE RES, V117, P99, DOI 10.1016/j.exer.2013.06.003
   Winning Lewis, 2017, Curr Oral Health Rep, V4, P1, DOI 10.1007/s40496-017-0121-7
   Wong WL, 2014, LANCET GLOBAL HLTH, V2, pe106
   Wu HZ, 2017, J CLIN INVEST, V127, P43, DOI [10.1172/JCI88880, 10.1172/jci88880]
   Yalcin ED, 2019, NIGER J CLIN PRACT, V22, P1026, DOI 10.4103/njcp.njcp_615_18
   Yanik M, 2017, PROG RETIN EYE RES, V56, P1, DOI 10.1016/j.preteyeres.2016.09.001
   Yucel-Lindberg T, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.8
   Zambon J J, 1996, Ann Periodontol, V1, P879, DOI 10.1902/annals.1996.1.1.879
   Zhang YH, 2018, BIOMED PHARMACOTHER, V99, P883, DOI 10.1016/j.biopha.2018.01.146
   Zheng WN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02399-4
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 201
TC 5
Z9 6
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0883-0185
EI 1563-5244
J9 INT REV IMMUNOL
JI Int. Rev. Immunol.
PD SEP 8
PY 2021
VL 40
IS 6
BP 409
EP 432
DI 10.1080/08830185.2020.1845330
EA NOV 2020
PG 24
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA UM6GC
UT WOS:000588810300001
PM 33179994
DA 2022-11-30
ER

PT J
AU Zhang, CS
   Hu, JH
   Yu, YB
AF Zhang, Chengshou
   Hu, Jianghua
   Yu, Yibo
TI CircRNA Is a Rising Star in Researches of Ocular Diseases
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE circular RNA; noncoding RNA; microRNA sponge; ocular diseases;
   ophthalmology
ID RETINAL-PIGMENT EPITHELIUM; CIRCULAR RNA EXPRESSION; PROLIFERATIVE
   VITREORETINOPATHY; CELL-PROLIFERATION; RISK-FACTORS; PROTEIN; MELANOMA;
   DEGENERATION; PATHOGENESIS; TRANSLATION
AB A newly rediscovered subclass of noncoding RNAs, circular RNAs (circRNAs), is produced by a back-splicing mechanism with a covalently closed loop structure. They not only serve as the sponge for microRNAs (miRNAs) and proteins but also regulate gene expression and epigenetic modification, translate into peptides, and generate pseudogenes. Dysregulation of circRNA expression has opened a new chapter in the etiology of various human disorders, including cancer and cardiovascular, neurodegenerative, and ocular diseases. Recent studies recognized the vital roles that circRNAs played in the pathogenesis of various eye diseases, highlighting circRNAs as promising biomarkers for diagnosis and assessment of progression and prognosis. Interventions targeting circRNAs provide insights for developing novel treatments for these ocular diseases. This review summarizes our current perception of the properties, biogenesis, and functions of circRNAs and the development of circRNA researches related to ophthalmologic diseases, including diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, glaucoma, corneal neovascularization, cataract, pterygium, proliferative vitreoretinopathy, retinoblastoma, and ocular melanoma.
C1 [Zhang, Chengshou; Hu, Jianghua; Yu, Yibo] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou, Peoples R China.
   [Hu, Jianghua] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Ophthalmol,Jiande Branch, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Yu, YB (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou, Peoples R China.
EM yuyibo@zju.edu.cn
FU National Natural Science Foundation of China [81470612, 81670832];
   Natural Science Foundation of Zhejiang Province [LY20H120011]
FX This project was supported by the National Natural Science Foundation of
   China (Grant Nos. 81470612 and 81670832) and Natural Science Foundation
   of Zhejiang Province (Grant No. LY20H120011). The funding agency had no
   role in the preparation of the manuscript or the decision to publish.
CR Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788
   Ajith TA, 2015, CLIN CHIM ACTA, V450, P316, DOI 10.1016/j.cca.2015.09.007
   Andley UP, 2009, CURR MOL MED, V9, P887, DOI 10.2174/156652409789105598
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019
   Aufiero S, 2019, NAT REV CARDIOL, V16, P503, DOI 10.1038/s41569-019-0185-2
   Bachmann B, 2010, OPHTHALMOLOGY, V117, P1300, DOI 10.1016/j.ophtha.2010.01.039
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Barrett SP, 2015, ELIFE, V4, DOI 10.7554/eLife.07540
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Cao MJ, 2019, INT J MED SCI, V16, P1356, DOI 10.7150/ijms.35149
   CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Casey R, 1997, AM J OPHTHALMOL, V124, P521, DOI 10.1016/S0002-9394(14)70868-2
   Chan-Ling T, 2018, PROG RETIN EYE RES, V62, P77, DOI 10.1016/j.preteyeres.2017.09.002
   Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002
   Charteris DG, 2002, EYE, V16, P369, DOI 10.1038/sj.eye.6700194
   CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271
   Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y
   Chen X, 2020, MOL THER, V28, P929, DOI 10.1016/j.ymthe.2020.01.010
   Chen XJ, 2020, MOL THER-NUCL ACIDS, V19, P339, DOI 10.1016/j.omtn.2019.11.016
   COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559
   Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014
   Conn VM, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.53
   Cost NG, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2014.1002712
   Dietrich P, 2018, PIGM CELL MELANOMA R, V31, P614, DOI 10.1111/pcmr.12698
   Dimaras H, 2012, LANCET, V379, P1436, DOI 10.1016/S0140-6736(11)61137-9
   Dong R, 2016, CELL RES, V26, P747, DOI 10.1038/cr.2016.42
   Du WW, 2017, THERANOSTICS, V7, P4183, DOI 10.7150/thno.21299
   Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001
   Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133
   Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fan CX, 2019, GENE, V710, P170, DOI 10.1016/j.gene.2019.05.054
   George AK, 2019, CAN J PHYSIOL PHARM, V97, P463, DOI 10.1139/cjpp-2018-0505
   Gu YH, 2017, OPHTHALMIC RES, V58, P176, DOI 10.1159/000479156
   Gu YY, 2017, PROTEIN CELL, V8, P455, DOI 10.1007/s13238-017-0393-7
   Guillot N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039406
   Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z
   Guo N, 2019, INT J MED SCI, V16, P513, DOI 10.7150/ijms.29750
   Hacioglu D, 2017, INT OPHTHALMOL, V37, P1073, DOI 10.1007/s10792-016-0358-5
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Han B, 2018, PHARMACOL THERAPEUT, V187, P31, DOI 10.1016/j.pharmthera.2018.01.010
   Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359
   HARDING JJ, 1993, BRIT J OPHTHALMOL, V77, P2, DOI 10.1136/bjo.77.1.2
   He M, 2020, ACTA DIABETOL, V57, P479, DOI 10.1007/s00592-019-01448-w
   Huang C, 2018, GENE DEV, V32, P639, DOI 10.1101/gad.314856.118
   Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566
   Jiang Q, 2020, J CLIN INVEST, V130, P3833, DOI 10.1172/JCI123353
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Kingman S, 2004, B WORLD HEALTH ORGAN, V82, P887
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115
   Krantz BA, 2017, CLIN OPHTHALMOL, V11, P279, DOI 10.2147/OPTH.S89591
   Kumar L, 2017, MOL NEUROBIOL, V54, P7224, DOI 10.1007/s12035-016-0213-8
   Lasda E, 2014, RNA, V20, P1829, DOI 10.1261/rna.047126.114
   Lee EJ, 2011, BIOCHEM BIOPH RES CO, V414, P384, DOI 10.1016/j.bbrc.2011.09.083
   Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Li X, 2017, MOL CELL, V67, P214, DOI 10.1016/j.molcel.2017.05.023
   Li XM, 2018, CELL PHYSIOL BIOCHEM, V47, P1630, DOI 10.1159/000490982
   Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82
   Li Y, 2014, CHINESE MED J-PEKING, V127, P1410, DOI 10.3760/cma.j.issn.0366-6999.20133206
   Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959
   Liang DM, 2017, MOL CELL, V68, P940, DOI 10.1016/j.molcel.2017.10.034
   Liang DM, 2014, GENE DEV, V28, P2233, DOI 10.1101/gad.251926.114
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu C, 2019, P NATL ACAD SCI USA, V116, P7455, DOI 10.1073/pnas.1814874116
   Liu C, 2017, THERANOSTICS, V7, P2863, DOI 10.7150/thno.19353
   Liu J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0630-y
   Liu T, 2013, CURR EYE RES, V38, P1191, DOI 10.3109/02713683.2013.823212
   Liu X, 2020, CURR EYE RES, V45, P1173, DOI 10.1080/02713683.2020.1722179
   Liu X, 2018, BIOCHEM BIOPH RES CO, V503, P2277, DOI 10.1016/j.bbrc.2018.06.149
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Lu XJ, 2015, J MED GENET, V52, P17, DOI 10.1136/jmedgenet-2014-102785
   Lyu J, 2019, EXP EYE RES, V184, P278, DOI 10.1016/j.exer.2019.03.017
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Michael R, 2011, PHILOS T R SOC B, V366, P1278, DOI 10.1098/rstb.2010.0300
   Nishino J, 2004, EMBO J, V23, P1998, DOI 10.1038/sj.emboj.7600202
   Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021
   Patop IL, 2019, EMBO J, V38, DOI 10.15252/embj.2018100836
   Pollreisz A, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/608751
   Potenza MA, 2009, CURR MED CHEM, V16, P94, DOI 10.2174/092986709787002853
   Rao GN, 2011, CURR OPIN OPHTHALMOL, V22, P4, DOI 10.1097/ICU.0b013e3283414fc8
   Reis Adriana H. O., 2012, Frontiers in Genetics, V3, P284, DOI 10.3389/fgene.2012.00284
   Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027
   Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777
   Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733
   SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852
   Schalkwijk CG, 2005, CLIN SCI, V109, P143, DOI 10.1042/CS20050025
   Scott A, 2010, EYE, V24, P416, DOI 10.1038/eye.2009.306
   Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004
   Shang QF, 2019, EPIGENOMICS-UK, V11, P787, DOI 10.2217/epi-2019-0029
   Shi XF, 2020, MOL THER-NUCL ACIDS, V19, P384, DOI 10.1016/j.omtn.2019.11.023
   Shields C. L., 2010, YB OPHTHALMOL, V2010, DOI [10.1016/S0084-392X(10)79224-8, DOI 10.1016/S0084-392X(10)79224-8]
   Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1497
   Singh M, 2019, CURR EYE RES, V44, P287, DOI 10.1080/02713683.2018.1542005
   Singh M, 2018, EXP EYE RES, V174, P80, DOI 10.1016/j.exer.2018.05.026
   Starke S, 2015, CELL REP, V10, P103, DOI 10.1016/j.celrep.2014.12.002
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1002-6
   Sun LF, 2019, RNA BIOL, V16, P821, DOI 10.1080/15476286.2019.1591034
   Suzuki H, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl151
   Szabo L, 2016, GENOME BIOL, V17, DOI [10.1186/s13059-015-0690-5, 10.1186/s13059-016-1123-9]
   Veno MT, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0801-3
   Wang JJ, 2018, THERANOSTICS, V8, P3408, DOI 10.7150/thno.25156
   Wang JJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0597-7
   Wang MT, 2019, ISCIENCE, V20, P237, DOI 10.1016/j.isci.2019.08.058
   Wang PL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090859
   Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Westholm JO, 2014, CELL REP, V9, P1966, DOI 10.1016/j.celrep.2014.10.062
   Wu PC, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107937
   Xie YM, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2019.117252
   Xing LC, 2018, BIOMED PHARMACOTHER, V105, P326, DOI 10.1016/j.biopha.2018.05.141
   Xu Y, 2018, BIOCHEM BIOPH RES CO, V496, P455, DOI 10.1016/j.bbrc.2018.01.077
   Yang X, 2018, CHINESE J CANCER RES, V30, P656, DOI 10.21147/j.issn.1000-9604.2018.06.10
   Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31
   Yao J, 2019, BIOMED PHARMACOTHER, V111, P548, DOI 10.1016/j.biopha.2018.12.044
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   You XT, 2015, NAT NEUROSCI, V18, P603, DOI 10.1038/nn.3975
   Zagami CJ, 2009, J CELL BIOCHEM, V107, P1063, DOI 10.1002/jcb.22221
   Zhang L, 2017, ONCOTARGET, V8, P77360, DOI 10.18632/oncotarget.20483
   Zhang SJ, 2017, INVEST OPHTH VIS SCI, V58, P6500, DOI 10.1167/iovs.17-22698
   Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001
   Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao WB, 2020, J CELL BIOCHEM, V121, P3516, DOI 10.1002/jcb.29631
   Zhou HT, 2019, EXP THER MED, V18, P2037, DOI 10.3892/etm.2019.7819
   Zhou RM, 2020, THERANOSTICS, V10, P3293, DOI 10.7150/thno.39488
   Zhou YF, 2019, CORNEA, V38, P1443, DOI 10.1097/ICO.0000000000002089
   Zhu K, 2019, EBIOMEDICINE, V49, P341, DOI 10.1016/j.ebiom.2019.10.004
NR 139
TC 36
Z9 37
U1 6
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD SEP 3
PY 2020
VL 8
AR 850
DI 10.3389/fcell.2020.00850
PG 15
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA NQ0VI
UT WOS:000570586000001
PM 33015046
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ramlogan-Steel, CA
   Murali, A
   Andrzejewski, S
   Dhungel, B
   Steel, JC
   Layton, CJ
AF Ramlogan-Steel, Charmaine A.
   Murali, Aparna
   Andrzejewski, Slawomir
   Dhungel, Bijay
   Steel, Jason C.
   Layton, Christopher J.
TI Gene therapy and the adeno-associated virus in the treatment of genetic
   and acquired ophthalmic diseases in humans: Trials, future directions
   and safety considerations
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; drug trial; gene expression; gene
   therapy; molecular genetics
ID LEBER CONGENITAL AMAUROSIS; HEREDITARY OPTIC NEUROPATHY;
   EPITHELIUM-DERIVED FACTOR; RCS RAT MODEL; PIGMENT-EPITHELIUM; MACULAR
   DEGENERATION; RETINITIS-PIGMENTOSA; DIABETIC-RETINOPATHY; MOUSE MODEL;
   SUBRETINAL INJECTION
AB Voretigene neparvovec-rzyl was recently approved for the treatment of Leber congenital amaurosis, and the use of gene therapy for eye disease is attracting even greater interest. The eye has immune privileged status, is easily accessible, requires a reduced dosage of therapy due to its size and is highly compartmentalized, significantly reducing systemic spread. Adeno-associated virus (AAV), with its low pathogenicity, prolonged expression profile and ability to transduce multiple cell types, has become the leading gene therapy vector. Target diseases have moved beyond currently untreatable inherited dystrophies to common, partially treatable acquired conditions such as exudative age-related macular degeneration and glaucoma, but use of the technology in these conditions imposes added obligations for caution in vector design. This review discusses the current status of AAV gene therapy trials in genetic and acquired ocular diseases, and explores new scientific developments, which could help ensure effective and safe use of the therapy in the future.
C1 [Ramlogan-Steel, Charmaine A.; Murali, Aparna; Andrzejewski, Slawomir; Layton, Christopher J.] Translat Res Inst, LVF Ophthalmol Res Ctr, Brisbane, Qld 4102, Australia.
   [Ramlogan-Steel, Charmaine A.; Murali, Aparna; Andrzejewski, Slawomir; Dhungel, Bijay; Layton, Christopher J.] Univ Queensland, Greenslopes Hosp, Fac Med, Greenslopes Clin Sch, Brisbane, Qld, Australia.
   [Ramlogan-Steel, Charmaine A.; Steel, Jason C.] Cent Queensland Univ, Sch Hlth, Med & Appl Sci, Rockhampton, Qld, Australia.
C3 University of Queensland; Central Queensland University
RP Layton, CJ (通讯作者)，Translat Res Inst, LVF Ophthalmol Res Ctr, Brisbane, Qld 4102, Australia.
EM c.layton@uq.edu.au
RI Layton, Christopher J/I-5888-2012; Dhungel, Bijay P./ABH-8518-2020;
   Steel, Jason/D-1805-2013
OI Layton, Christopher J/0000-0001-6933-9991; Dhungel, Bijay
   P./0000-0001-5130-5224; Murali, Aparna/0000-0002-1567-3430;
   Andrzejewski, Slawomir/0000-0001-6599-127X; Steel,
   Jason/0000-0003-3608-7542
FU Layton Vision Foundation; Gallipoli Medical Research Foundation
FX Layton Vision Foundation; Gallipoli Medical Research Foundation
CR Aboshiha J, 2016, BRIT J OPHTHALMOL, V100, P115, DOI 10.1136/bjophthalmol-2014-306505
   Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Aleman TS, 2017, OPHTHALMOLOGY, V124, P359, DOI 10.1016/j.ophtha.2016.10.022
   Alexander JJ, 2007, NAT MED, V13, P685, DOI 10.1038/nm1596
   Annear MJ, 2011, GENE THER, V18, P53, DOI 10.1038/gt.2010.111
   Annear MJ, 2013, HUM GENE THER, V24, P883, DOI 10.1089/hum.2013.146
   [Anonymous], 2018, MED LETT DRUGS THER, V60, P53
   [Anonymous], 2018, GENSIGHT BIOL ANNOUN
   [Anonymous], 2018, GENSIGHT BIOL REPORT
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Balakrishnan B, 2014, CURR GENE THER, V14, P86, DOI 10.2174/1566523214666140302193709
   Baracca A, 2005, ARCH NEUROL-CHICAGO, V62, P730, DOI 10.1001/archneur.62.5.730
   Beltran WA, 2012, P NATL ACAD SCI USA, V109, P2132, DOI 10.1073/pnas.1118847109
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Biel M, 2007, MOL NEUROBIOL, V35, P266, DOI 10.1007/s12035-007-0025-y
   Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135
   Black A, 2014, J GENE MED, V16, P122, DOI 10.1002/jgm.2768
   Boutin S, 2010, HUM GENE THER, V21, P704, DOI 10.1089/hum.2009.182
   Buch PK, 2008, GENE THER, V15, P849, DOI 10.1038/gt.2008.66
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chang B, 2009, P NATL ACAD SCI USA, V106, P19581, DOI 10.1073/pnas.0907720106
   Churchill JD, 2013, INVEST OPHTH VIS SCI, V54, P1411, DOI 10.1167/iovs.12-11541
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cwerman-Thibault H, 2017, MOL THER-METH CLIN D, V5, P200, DOI 10.1016/j.omtm.2017.04.008
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Daiger S. P., 1998, IOVS, V39, pS295
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160, DOI 10.1210/jcem-68-1-160
   DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Day TP, 2014, ADV EXP MED BIOL, V801, P687, DOI 10.1007/978-1-4614-3209-8_86
   Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08
   de Moraes G, 2016, CLIN EXP OPHTHALMOL, V44, P838, DOI 10.1111/ceo.12795
   Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978
   Diaz-Lezama N, 2016, LAB INVEST, V96, P283, DOI 10.1038/labinvest.2015.135
   Dominguez JM, 2016, AM J PATHOL, V186, P1688, DOI 10.1016/j.ajpath.2016.01.023
   Doyle SR, 2008, HUM GENE THER, V19, P1335, DOI [10.1089/hum.2008.090, 10.1089/hgt.2008.090]
   Dyka FM, 2014, HUM GENE THER METHOD, V25, P166, DOI 10.1089/hgtb.2013.212
   Edwards TL, 2016, NEW ENGL J MED, V374, P1996, DOI 10.1056/NEJMc1509501
   El-Amraoui A, 2005, J CELL SCI, V118, P4593, DOI 10.1242/jcs.02636
   Fischer MD, 2016, OPHTHALMOLOGICA, V236, P30
   Chacon-Camacho OF, 2015, WORLD J CLIN CASES, V3, P112, DOI 10.12998/wjcc.v3.i2.112
   GEORGE NDL, 1995, BRIT J OPHTHALMOL, V79, P697, DOI 10.1136/bjo.79.7.697
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Gruenert AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152589
   HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hippert C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035318
   Ideno J, 2007, INT J MOL MED, V19, P75
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jaijo T, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.045377
   Jain A, 2017, P NATL ACAD SCI USA, V114, P11199, DOI 10.1073/pnas.1706193114
   Karanjia R, 2015, EXPERT OPIN ORPHAN D, V3, P1439, DOI 10.1517/21678707.2015.1098531
   KARNA J, 1986, ACTA OPHTHALMOL, V64, P1
   Kim JH, 2009, J CEREBR BLOOD F MET, V29, P621, DOI 10.1038/jcbfm.2008.154
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Koenekoop RK, 2004, SURV OPHTHALMOL, V49, P379, DOI 10.1016/j.survophthal.2004.04.003
   Kohl S, 2005, EUR J HUM GENET, V13, P302, DOI 10.1038/sj.ejhg.5201269
   Kohl S, 2002, AM J HUM GENET, V71, P422, DOI 10.1086/341835
   Kohl S, 1998, NAT GENET, V19, P257, DOI 10.1038/935
   Kohl S, 2000, HUM MOL GENET, V9, P2107, DOI 10.1093/hmg/9.14.2107
   Kohl S, 2015, NAT GENET, V47, P757, DOI 10.1038/ng.3319
   Kohl S, 2012, AM J HUM GENET, V91, P527, DOI 10.1016/j.ajhg.2012.07.006
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Lam BL, 2014, JAMA OPHTHALMOL, V132, P428, DOI 10.1001/jamaophthalmol.2013.7971
   Layton C, 2006, ASPECTS DIABETIC RET
   Le Meur G, 2007, GENE THER, V14, P292, DOI 10.1038/sj.gt.3302861
   Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791
   Lechauve C, 2009, J MOL BIOL, V388, P968, DOI 10.1016/j.jmb.2009.03.047
   Lee J.H, 2018, PROG RETIN EYE RES
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Li RC, 2010, J CEREBR BLOOD F MET, V30, P1874, DOI 10.1038/jcbfm.2010.90
   Liu MM, 2011, BRIT J OPHTHALMOL, V95, P604, DOI 10.1136/bjo.2009.174912
   Lopes VS, 2013, GENE THER, V20, P824, DOI 10.1038/gt.2013.3
   MacDonald IM, 2004, EXPERT REV MOL DIAGN, V4, P478, DOI 10.1586/14737159.4.4.478
   MacDonald IM, 1998, OPHTHALMOLOGY, V105, P1637, DOI 10.1016/S0161-6420(98)99031-5
   MacDonald IM, 1993, CHOROIDEREMIA
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maddalena A, 2018, MOL THER, V26, P524, DOI 10.1016/j.ymthe.2017.11.019
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244
   McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514
   McClements ME, 2017, YALE J BIOL MED, V90, P611
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Molday LL, 2006, ADV EXP MED BIOL, V572, P283
   Moore CBT, 2018, PROG RETIN EYE RES, V65, P147, DOI 10.1016/j.preteyeres.2018.01.004
   Moore NA, 2018, EXPERT OPIN BIOL TH, V18, P37, DOI 10.1080/14712598.2018.1389886
   Morgan JIW, 2014, INVEST OPHTH VIS SCI, V55, P6381, DOI 10.1167/iovs.13-13454
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Morrison C, 2015, NAT BIOTECHNOL, V33, P217, DOI 10.1038/nbt0315-217
   Mowat FM, 2013, GENE THER, V20, P545, DOI 10.1038/gt.2012.63
   Narfstrom K, 2005, DOC OPHTHALMOL, V111, P39, DOI [10.1007/s10633-005-3159-0, 10.1007/S10633-005-3159-0]
   Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595
   Park TK, 2009, GENE THER, V16, P916, DOI 10.1038/gt.2009.61
   Pawlyk BS, 2016, GENE THER, V23, P196, DOI 10.1038/gt.2015.93
   Pease ME, 2009, INVEST OPHTH VIS SCI, V50, P2194, DOI 10.1167/iovs.08-3013
   Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Petit L, 2016, HUM GENE THER, V27, P563, DOI 10.1089/hum.2016.040
   Pierce EA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017285
   Porto FBO, 2002, J GENE MED, V4, P390, DOI 10.1002/jgm.278
   Preising MN, 2009, OPHTHALMOLOGY, V116, P1201, DOI 10.1016/j.ophtha.2009.01.016
   Puomila A, 2007, EUR J HUM GENET, V15, P1079, DOI 10.1038/sj.ejhg.5201828
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rao P, 2018, ASIA-PAC J OPHTHALMO, V7, P169, DOI 10.22608/APO.201803
   Rasool N, 2016, SEMIN OPHTHALMOL, V31, P107, DOI 10.3109/08820538.2015.1115251
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Ren RT, 2012, INVEST OPHTH VIS SCI, V53, P1003, DOI 10.1167/iovs.11-8484
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Sanchez-Alcudia R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151943
   Sarfarazi M, 2000, EYE, V14, P422, DOI 10.1038/eye.2000.126
   Schmidt F, 2015, BIOTECHNOL J, V10, P258, DOI 10.1002/biot.201400529
   Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   Srivastava A, 2008, J CELL BIOCHEM, V105, P17, DOI 10.1002/jcb.21819
   Syed N, 2001, OPHTHALMOLOGY, V108, P711, DOI 10.1016/S0161-6420(00)00643-6
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tolmachova T, 2010, INVEST OPHTH VIS SCI, V51, P4913, DOI 10.1167/iovs.09-4892
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460
   Udovichenko IP, 2002, J CELL SCI, V115, P445
   Vance M, 2016, SCI REP-UK, V6, DOI 10.1038/srep22131
   Vandenberghe LH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002103
   Verma A, 2012, MOL THER, V20, P28, DOI 10.1038/mt.2011.155
   Vignal C, 2018, OPHTHALMOLOGY, V125, P945, DOI 10.1016/j.ophtha.2017.12.036
   Vincent KA, 1997, J VIROL, V71, P1897, DOI 10.1128/JVI.71.3.1897-1905.1997
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wang JH, 2017, PHARMACOL THERAPEUT, V173, P1, DOI 10.1016/j.pharmthera.2017.01.003
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Weleber R.G., 1993, LEBER CONGENITAL AMA
   Weleber RG, 2016, OPHTHALMOLOGY, V123, P1606, DOI 10.1016/j.ophtha.2016.03.003
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Wilson AM, 2012, GENE THER, V19, P127, DOI 10.1038/gt.2011.142
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JQ, 2007, HUM GENE THER, V18, P171, DOI 10.1089/hum.2006.088
   Yang S, 2016, EBIOMEDICINE, V10, P258, DOI 10.1016/j.ebiom.2016.07.002
   Yla-Herttuala S, 2012, MOL THER, V20, P1831, DOI 10.1038/mt.2012.194
   Yu-Wai-Man P., 1993, LEBER HEREDITARY OPT
   Zallocchi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094272
   Zhang QJ, 2016, ASIA-PAC J OPHTHALMO, V5, P265, DOI 10.1097/APO.0000000000000227
   Zhang T, 2015, HUM MOL GENET, V24, P1755, DOI 10.1093/hmg/ddu588
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
NR 155
TC 33
Z9 33
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY
PY 2019
VL 47
IS 4
BP 521
EP 536
DI 10.1111/ceo.13416
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID6ZT
UT WOS:000471831500014
PM 30345694
DA 2022-11-30
ER

PT J
AU Ma, WX
   Silverman, SM
   Zhao, L
   Villasmil, R
   Campos, MM
   Amaral, J
   Wong, WT
AF Ma, Wenxin
   Silverman, Sean M.
   Zhao, Lian
   Villasmil, Rafael
   Campos, Maria M.
   Amaral, Juan
   Wong, Wai T.
TI Absence of TGF beta signaling in retinal microglia induces retinal
   degeneration and exacerbates choroidal neovascularization
SO ELIFE
LA English
DT Article
ID GROWTH-FACTOR-BETA; SUBRETINAL MICROGLIA; ACTIVATION; CELLS;
   ACCUMULATION; MAINTENANCE; PHENOTYPE; DELETION; MOUSE; MICE
AB Constitutive TGF beta signaling is important in maintaining retinal neurons and blood vessels and is a factor contributing to the risk for age-related macular degeneration (AMD), a retinal disease involving neurodegeneration and microglial activation. How TGF beta signaling to microglia influences pathological retinal neuroinflammation is unclear. We discovered that ablation of the TGF beta receptor, TGFBR2, in retinal microglia of adult mice induced abnormal microglial numbers, distribution, morphology, and activation status, and promoted a pathological microglial gene expression profile. TGFBR2-deficient retinal microglia induced secondary gliotic changes in Muller cells, neuronal apoptosis, and decreased light-evoked retinal function reflecting abnormal synaptic transmission. While retinal vasculature was unaffected, TGFBR2-deficient microglia demonstrated exaggerated responses to laser-induced injury that was associated with increased choroidal neovascularization, a hallmark of advanced exudative AMD. These findings demonstrate that deficiencies in TGF beta-mediated microglial regulation can drive neuroinflammatory contributions to AMD-related neurodegeneration and neovascularization, highlighting TGF beta signaling as a potential therapeutic target.
C1 [Ma, Wenxin; Silverman, Sean M.; Zhao, Lian; Wong, Wai T.] NEI, Unit NeuronGlia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Villasmil, Rafael] NEI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA.
   [Campos, Maria M.] NEI, Sect Histopathol, NIH, Bethesda, MD 20892 USA.
   [Amaral, Juan] NEI, Unit Ocular Stem Cell & Translat Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Unit NeuronGlia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI ; Wong, Wai/B-6118-2017
OI Ma, Wenxin/0000-0001-8396-6625; Wong, Wai/0000-0003-0681-4016
FU National Eye Institute; FOGARTY INTERNATIONAL CENTER [R21TW011108]
   Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R00CA207866]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [ZICEY000461,
   ZIAEY000541] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTE [R21HG010065] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [R01AR073966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB022787] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
   [R01NS097492, F31NS105457, F31NS100370] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG059595, R01AG049465] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION
   DISORDERS [R01DC016293] Funding Source: NIH RePORTER
FX National Eye Institute Intramural Research Program Wai T Wong; The
   funders had no role in study design, data collection and interpretation,
   or the decision to submit the work for publication.
CR Abutbul S, 2012, GLIA, V60, P1160, DOI 10.1002/glia.22343
   Allinson KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039336
   ANDERSON DH, 1995, J NEUROSCI RES, V42, P63, DOI 10.1002/jnr.490420108
   Arroba AI, 2017, ACTA DIABETOL, V54, P527, DOI 10.1007/s00592-017-0984-z
   Bell K, 2018, CURR NEUROPHARMACOL, V16, P942, DOI 10.2174/1570159X15666170720094529
   Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113
   Bohlen CJ, 2017, NEURON, V94, P759, DOI 10.1016/j.neuron.2017.04.043
   Braunger BM, 2015, AM J PATHOL, V185, P1749, DOI 10.1016/j.ajpath.2015.02.007
   Braunger BM, 2013, J NEUROSCI, V33, P14246, DOI 10.1523/JNEUROSCI.0991-13.2013
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   Buttgereit A, 2016, NAT IMMUNOL, V17, P1397, DOI 10.1038/ni.3585
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Carter DA, 2004, CURR EYE RES, V28, P427, DOI 10.1080/02713680490503778
   Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046
   Clarke LE, 2018, P NATL ACAD SCI USA, V115, pE1896, DOI 10.1073/pnas.1800165115
   Close JL, 2005, DEVELOPMENT, V132, P3015, DOI 10.1242/dev.01882
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crespo-Garcia S, 2015, EXP EYE RES, V139, P13, DOI 10.1016/j.exer.2015.07.012
   De Feo D, 2017, J CLIN INVEST, V127, P3937, DOI 10.1172/JCI92387
   Fabregat I, 2014, CURR PHARM DESIGN, V20, P2934, DOI 10.2174/13816128113199990591
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kang SS, 2018, J EXP MED, V215, P2235, DOI 10.1084/jem.20180653
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kochat V, 2018, SCI ADV, V4, DOI 10.1126/sciadv.1701373
   Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008
   Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Lund H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07295-7
   Lund H, 2018, NAT IMMUNOL, V19, P435, DOI 10.1038/s41590-018-0091-5
   LUTTY G, 1991, CURR EYE RES, V10, P61, DOI 10.3109/02713689109007611
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mendes-Jorge L, 2009, INVEST OPHTH VIS SCI, V50, P5997, DOI 10.1167/iovs.09-3515
   Nagamoto-Combs K, 2010, J NEUROSCI, V30, P9641, DOI 10.1523/JNEUROSCI.0828-10.2010
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Obata H, 1999, ACTA OPHTHALMOL SCAN, V77, P151, DOI 10.1034/j.1600-0420.1999.770207.x
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Platania CBM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102076
   Portillo JAC, 2017, DIABETES, V66, P483, DOI 10.2337/db16-0051
   Qin Y, 2018, CELL, V174, P156, DOI 10.1016/j.cell.2018.05.027
   Rozovsky I, 1998, NEUROBIOL AGING, V19, P97, DOI 10.1016/S0197-4580(97)00169-3
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Schlecht A, 2017, AM J PATHOL, V187, P2570, DOI 10.1016/j.ajpath.2017.06.018
   Siegert S, 2012, NAT NEUROSCI, V15, P487, DOI 10.1038/nn.3032
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Taylor RA, 2017, J CLIN INVEST, V127, P280, DOI 10.1172/JCI88647
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28203-5
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257
   Walshe TE, 2011, NEUROSCIENCE, V189, P123, DOI 10.1016/j.neuroscience.2011.05.020
   Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149
   Wang MH, 2014, ADV EXP MED BIOL, V801, P333, DOI 10.1007/978-1-4614-3209-8_42
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang MH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-173
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Williams PA, 2017, EXP EYE RES, V157, P20, DOI 10.1016/j.exer.2017.02.014
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2017, VISION RES, V139, P39, DOI 10.1016/j.visres.2017.04.013
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zoller T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06224-y
NR 79
TC 50
Z9 50
U1 1
U2 11
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JAN 22
PY 2019
VL 8
AR e42049
DI 10.7554/eLife.42049
PG 28
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA HI1XF
UT WOS:000456237700001
PM 30666961
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hwang, DE
   Ryou, JH
   Oh, JR
   Han, JW
   Park, TK
   Kim, HS
AF Hwang, Da-Eun
   Ryou, Jeong-Hyun
   Oh, Jong Rok
   Han, Jung Woo
   Park, Tae Kwann
   Kim, Hak-Sung
TI Anti-Human VEGF Repebody Effectively Suppresses Choroidal
   Neovascularization and Vascular Leakage
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; PROTEIN BINDER; BASIC
   SCIENCE; ANGIOGENESIS; RANIBIZUMAB; BEVACIZUMAB; MECHANISMS; ANTIBODIES;
   PROGRESS
AB Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness among people over the age of 60. Vascular endothelial growth factor (VEGF) plays a major role in pathological angiogenesis in AMD. Herein, we present the development of an antihuman VEGF repebody, which is a small-sized protein binder consisting of leucine-rich repeat (LRR) modules. The anti-VEGF repebody selected through a phage-display was shown to have a high affinity and specificity for human VEGF. We demonstrate that this repebody effectively inhibits in vitro angiogenic cellular processes, such as proliferation and migration, by blocking the VEGF-mediated signaling pathway. The repebody was also shown to have a strong suppression effect on choroidal neovascularization (CNV) and vascular leakage in vivo. Our results indicate that the anti-VEGF repebody has a therapeutic potential for treating neovascular AMD as well as other VEGF-involved diseases including diabetic retinopathy and metastatic cancers.
C1 [Hwang, Da-Eun; Ryou, Jeong-Hyun; Kim, Hak-Sung] Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 305701, South Korea.
   [Ryou, Jeong-Hyun] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, 291 Daehak Ro, Daejeon 305701, South Korea.
   [Oh, Jong Rok; Han, Jung Woo; Park, Tae Kwann] Soonchunhyang Univ, Coll Med, Bucheon Hosp, Dept Ophthalmol, Bucheon, South Korea.
C3 Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced
   Institute of Science & Technology (KAIST); Soonchunhyang University
RP Kim, HS (通讯作者)，Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 305701, South Korea.
EM hskim76@kaist.ac.kr
RI Kim, Hak-Sung/C-1929-2011
FU Mid career Researcher Program of the National Research Foundation (NRF)
   - Ministry of Science, ICT & Future Planning [NRF-2014R1A2A1A01004198];
   Global Research Laboratory of the National Research Foundation (NRF) -
   Ministry of Science, ICT & Future Planning [NRF-2015K1A1A2033346]; Brain
   Korea 21 - Ministry of Education
FX This research was supported by the Mid career Researcher Program
   (NRF-2014R1A2A1A01004198) and Global Research Laboratory
   (NRF-2015K1A1A2033346) of the National Research Foundation (NRF) funded
   by the Ministry of Science, ICT & Future Planning, and Brain Korea 21
   funded by the Ministry of Education.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Frokjaer S, 2005, NAT REV DRUG DISCOV, V4, P298, DOI 10.1038/nrd1695
   Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200
   Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110
   Haller CA, 2008, CLIN PHARMACOL THER, V84, P624, DOI 10.1038/clpt.2008.158
   Heu W, 2014, ANAL CHEM, V86, P6019, DOI 10.1021/ac501158t
   Hey T, 2005, TRENDS BIOTECHNOL, V23, P514, DOI 10.1016/j.tibtech.2005.07.007
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jo DH, 2014, BIOMATERIALS, V35, P3052, DOI 10.1016/j.biomaterials.2013.12.031
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee CMY, 2007, NAT PROTOC, V2, P3001, DOI 10.1038/nprot.2007.448
   Lee JJ, 2015, ANGEW CHEM INT EDIT, V54, P11020, DOI 10.1002/anie.201505964
   Lee JJ, 2014, MOL THER, V22, P1254, DOI 10.1038/mt.2014.59
   Lee SC, 2012, P NATL ACAD SCI USA, V109, P3299, DOI 10.1073/pnas.1113193109
   Lien S., 2008, V181, P131
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   Meyer T, 2016, FUNCTIONAL CHARACTER, P79, DOI [10.1007/s10456-015-9490-5, DOI 10.1007/S10456-015-9490-5]
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ratner M, 2008, NAT BIOTECHNOL, V26, P867, DOI 10.1038/nbt0808-867
   Skerra A, 2007, CURR OPIN BIOTECH, V18, P295, DOI 10.1016/j.copbio.2007.04.010
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Zhang Y, 2010, ONCOGENE, V29, P5404, DOI 10.1038/onc.2010.270
NR 33
TC 23
Z9 26
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2016
VL 11
IS 3
AR e0152522
DI 10.1371/journal.pone.0152522
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DH3TE
UT WOS:000372708900072
PM 27015541
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Sachdeva, MM
   Eliott, D
AF Sachdeva, Mira M.
   Eliott, Dean
TI Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium:
   From Bench to Bedside
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE transplantation; stem cells; stargardt's macular dystrophy; retinal
   pigment epithelium; Age-related macular degeneration
ID LONG-TERM SAFETY; MACULAR DEGENERATION; DIRECTED DIFFERENTIATION;
   CHOROID GRAFT; TRANSPLANTATION; INHIBITION; TRANSLOCATION; ACTIVATION;
   DERIVATION; SECONDARY
AB Age-related macular degeneration (AMD) represents a leading cause of blindness in the elderly, and Stargardt's macular dystrophy (SMD) is the most common form of juvenile-onset macular degeneration. Dry AMD and SMD share an underlying pathophysiology, namely dysfunction and ultimately loss of the retinal pigment epithelium (RPE), suggesting that RPE transplantation may offer a potential treatment strategy for both patient populations. Stem cells have emerged as a promising source of replacement RPE. During the past 15 years, extraordinary strides have been made in the identification, characterization, and differentiation of stem cells. Recently, this large body of basic science and preclinical research has been translated to patient care with the publication of results from Phase 1/2 trials demonstrating safety of transplantation of human embryonic stem cell (hESC)-derived RPE into patients with AMD and SMD. While significant challenges remain before dry AMD and SMD become treatable diseases, the goal has become more tangible.
C1 [Sachdeva, Mira M.; Eliott, Dean] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Sachdeva, MM (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM Mira_Sachdeva@meei.harvard.edu
CR Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Auricchio A, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017301
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Desai N, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0005-4
   Hayashi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045435
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma Rajesh K, 2005, BMC Ophthalmol, V5, P25, DOI 10.1186/1471-2415-5-25
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   van Zeeburg EJT, 2015, OPHTHALMOLOGICA, V233, P134, DOI 10.1159/000380829
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
NR 39
TC 15
Z9 16
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAR 3
PY 2016
VL 31
IS 1-2
SI SI
BP 25
EP 29
DI 10.3109/08820538.2015.1115253
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG5NZ
UT WOS:000372126400004
PM 26959126
DA 2022-11-30
ER

PT J
AU Kaszubski, P
   Ben Ami, T
   Saade, C
   Smith, RT
AF Kaszubski, Patrick
   Ben Ami, Tal
   Saade, Celine
   Smith, R. Theodore
TI Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A
   Review
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Geographic atrophy; Choroidal neovascularization; Age-related macular
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   RISK-FACTORS; INTRAVITREAL RANIBIZUMAB; BETA-CAROTENE; DRUSEN;
   PROGRESSION
AB Geographic atrophy (GA) and choroidal neovascularization (CNV), the two late forms of age-related macular degeneration, are generally considered two distinct entities. However, GA and CNV can occur simultaneously in the same eye, with GA usually occurring first. The prevalence of this combined entity is higher in histological studies than in clinical studies. No distinct systemic or genetic risk characteristics are associated with the combined GA/CNV entity, although on clinical examination and retinal imaging it can feature drusen or subretinal drusenoid deposits. GA and CNV may exist within the spectrum of a single disease, or they may be two very different diseases. Therapy with antivascular endothelial growth factor (anti-VEGF) is often successful for CNV, but some evidence suggests increased rates of GA development in eyes treated with anti-VEGF. In this article, we review the current literature regarding the epidemiology, clinical presentation, and treatment options for patients with the combined GA/CNV entity. (C) 2016 S. Karger AG, Basel
C1 [Kaszubski, Patrick; Ben Ami, Tal; Saade, Celine; Smith, R. Theodore] NYU, Dept Ophthalmol, Sch Med, 462 First Ave,NBV 5N18, New York, NY 10016 USA.
C3 New York University
RP Smith, RT (通讯作者)，NYU, Dept Ophthalmol, Sch Med, 462 First Ave,NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
RI Mitchell, Paul/P-1498-2014
OI smith, theodore/0000-0002-1693-943X
FU Foundation Fighting Blindness; National Institutes of Health/National
   Eye Institute [R01 EY015520]; Research to Prevent Blindness; NATIONAL
   EYE INSTITUTE [R01EY015520] Funding Source: NIH RePORTER
FX This work was supported by an individual investigator research award
   from the Foundation Fighting Blindness (R.T.S.), a National Institutes
   of Health/National Eye Institute grant (R01 EY015520; R.T.S.), and
   unrestricted funds from Research to Prevent Blindness (R.T.S.). The
   funding organizations had no role in the study design, in the
   collection, analysis, and interpretation of the data, in the writing of
   the report or in the decision to submit for publication. The authors
   wish to thank Jennifer Dalberth for her help in editing the manuscript.
CR ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Amaro MH, 2012, ARQ BRAS OFTALMOL, V75, P273, DOI 10.1590/S0004-27492012000400011
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Brader HS, 2013, OPHTHALMOLOGY, V120, P1871, DOI 10.1016/j.ophtha.2013.01.049
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Choudhry N, 2010, SEMIN OPHTHALMOL, V25, P206, DOI 10.3109/08820538.2010.518121
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grob S, 2012, EYE, V26, P1106, DOI 10.1038/eye.2012.107
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Saade C, 2014, BRIT J OPHTHALMOL, V98, P1729, DOI 10.1136/bjophthalmol-2014-305005
   Saint-Geniez M, 2009, INVEST OPHTH VIS SCI, V50, P311, DOI 10.1167/iovs.08-2461
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sophie R, 2014, OPHTHALMOLOGY, V121, pE34, DOI 10.1016/j.ophtha.2013.12.043
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 80
TC 30
Z9 33
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 4
BP 185
EP 193
DI 10.1159/000443209
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI1IB
UT WOS:000373248700004
PM 26871899
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nimalaratne, C
   Savard, P
   Gauthier, SF
   Schieber, A
   Wu, JP
AF Nimalaratne, Chamila
   Savard, Patricia
   Gauthier, Sylvie F.
   Schieber, Andreas
   Wu, Jianping
TI Bioaccessibility and Digestive Stability of Carotenoids in Cooked Eggs
   Studied Using a Dynamic in Vitro Gastrointestinal Model
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE egg carotenoids; cooking; bioaccessibility; digestive stability; TIM-1
   gastrointestinal model
ID LUTEIN BIOAVAILABILITY; PARTICLE-SIZE; FATTY-ACIDS; ABSORPTION;
   ZEAXANTHIN; XANTHOPHYLLS; TOCOPHEROLS; CHALLENGES; SPINACH; STOMACH
AB Among dietary carotenoids, lutein and zeaxanthin are known to protect against age-related macular degeneration; a leading cause of irreversible vision loss in the elderly. Egg yolk is rich in lutein and zeaxanthin, however, the effect of cooking and gastrointestinal digestion on yolk carotenoids is poorly understood: An in vitro dynamic gastrointestinal model (TIM-1) was used to investigate the digestive stability and bioaccessibility of carotenoids from boiled, fried, and scrambled eggs. Bioaccessibility but not digestive stability was significantly affected by the method of cooking. The main egg carotenoids, all-E-lutein and all-E-zeaxanthin, were stable during the digestion with average recoveries of 90 and 88%, respectively. No trans-cis isomerization of catotenoids was observed during digestion. Both all-E-lutein and all-E-zeaxanthin from scrambled eggs showed significantly lower bioaccessibility compared to boiled eggs. The results indicate that the bioaccessibility of egg carotenoids can be affected by different food preparation methods.
C1 [Nimalaratne, Chamila; Schieber, Andreas; Wu, Jianping] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2P5, Canada.
   [Gauthier, Sylvie F.] Univ Laval, Dept Food Sci & Nutr, Quebec City, PQ, Canada.
   [Savard, Patricia; Gauthier, Sylvie F.] Univ Laval, Inst Nutr & Funct Foods INAF, Quebec City, PQ, Canada.
   [Schieber, Andreas] Univ Bonn, Dept Nutr & Food Sci, D-53117 Bonn, Germany.
C3 University of Alberta; Laval University; Laval University; University of
   Bonn
RP Wu, JP (通讯作者)，Univ Alberta, Dept Agr Food & Nutr Sci, Agr Forestry Bldg, Edmonton, AB T6G 2P5, Canada.
EM jwu3@ualberta.ca
RI Wu, Jian/AAU-5221-2020; Nimalaratne, Chamila/AAE-2879-2020
OI Wu, Jian/0000-0001-9933-7364; Nimalaratne, Chamila/0000-0002-1414-510X
FU Egg Farmers of Canada (EFC); Alberta Egg Producers (AEP); Agriculture
   and Food Council; Food for Health Initiative (Vitamin Fund) of the
   Faculty of Agricultural, Life and Environmental Science of the
   University of Alberta; Burnbrae Farms Limited; Poultry Industry Council;
   Natural Sciences and Engineering Research Council (NSERC) of Canada
FX This research was funded by grants from Egg Farmers of Canada (EFC),
   Alberta Egg Producers (AEP), the Agriculture and Food Council, which is
   responsible for delivering Agriculture and Agri-Food Canada's Advancing
   Canadian Agriculture and Agri-Food (ACAAF) Program in Alberta, Food for
   Health Initiative (Vitamin Fund) of the Faculty of Agricultural, Life
   and Environmental Science of the University of Alberta, Burnbrae Farms
   Limited, Poultry Industry Council, and Natural Sciences and Engineering
   Research Council (NSERC) of Canada to J. Wu.
CR Blanquet-Diot S, 2009, J NUTR, V139, P876, DOI 10.3945/jn.108.103655
   Britton George, 2008, V4, P189, DOI 10.1007/978-3-7643-7499-0_10
   Chitchumroonchokchai C, 2004, J NUTR, V134, P2280, DOI 10.1093/jn/134.9.2280
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cortinas L, 2003, J SCI FOOD AGR, V83, P820, DOI 10.1002/jsfa.1418
   Deat E, 2009, J AGR FOOD CHEM, V57, P11314, DOI 10.1021/jf902392a
   Etcheverry P, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00317
   Faulks RM, 2005, BBA-MOL BASIS DIS, V1740, P95, DOI 10.1016/j.bbadis.2004.11.012
   Faulks RM, 2004, EUR J NUTR, V43, P15, DOI 10.1007/s00394-004-0434-x
   Garrett DA, 1999, J AGR FOOD CHEM, V47, P4301, DOI 10.1021/jf9903298
   Gleize B, 2013, BRIT J NUTR, V110, P1, DOI 10.1017/S0007114512004813
   Goltz SR, 2012, MOL NUTR FOOD RES, V56, P866, DOI 10.1002/mnfr.201100687
   Granado F, 2006, EXP BIOL MED, V231, P1733, DOI 10.1177/153537020623101110
   Granado-Lorencio F, 2007, J AGR FOOD CHEM, V55, P6387, DOI 10.1021/jf070301t
   Granado-Lorencio F, 2007, FOOD CHEM, V102, P641, DOI 10.1016/j.foodchem.2006.05.043
   Granado-Lorencio F, 2010, FOOD CHEM, V120, P741, DOI 10.1016/j.foodchem.2009.11.005
   Guerra A, 2012, TRENDS BIOTECHNOL, V30, P591, DOI 10.1016/j.tibtech.2012.08.001
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Hur SJ, 2011, FOOD CHEM, V125, P1, DOI 10.1016/j.foodchem.2010.08.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kostewicz ES, 2014, EUR J PHARM SCI, V57, P342, DOI 10.1016/j.ejps.2013.08.024
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lipkie TE, 2014, MOL NUTR FOOD RES, V58, P2014, DOI 10.1002/mnfr.201400126
   MINEKUS M, 1995, ATLA-ALTERN LAB ANIM, V23, P197
   Minekus M, 2005, BIOSCI BIOTECH BIOCH, V69, P932, DOI 10.1271/bbb.69.932
   Moelants KRN, 2012, J AGR FOOD CHEM, V60, P11995, DOI 10.1021/jf303502h
   Nidhi B, 2011, J AM OIL CHEM SOC, V88, P367, DOI 10.1007/s11746-010-1677-8
   Nimalaratne C, 2012, J AGR FOOD CHEM, V60, P12547, DOI 10.1021/jf303828n
   O'Connell OF, 2007, NUTR RES, V27, P258, DOI 10.1016/j.nutres.2007.04.002
   Xavier AAO, 2014, FOOD RES INT, V65, P171, DOI 10.1016/j.foodres.2014.06.016
   Panozzo A, 2013, FOOD CHEM, V141, P4094, DOI 10.1016/j.foodchem.2013.06.099
   Reboul E, 2006, J AGR FOOD CHEM, V54, P8749, DOI 10.1021/jf061818s
   Reis PM, 2008, FOOD BIOPHYS, V3, P370, DOI 10.1007/s11483-008-9091-6
   Ribnicky DM, 2014, FOOD CHEM, V142, P349, DOI 10.1016/j.foodchem.2013.07.073
   Richelle M, 2010, BRIT J NUTR, V103, P1800, DOI 10.1017/S0007114510000103
   Rodriguez-Amaya Delia B, 2003, Forum Nutr, V56, P35
   Ryan L, 2008, PLANT FOOD HUM NUTR, V63, P127, DOI 10.1007/s11130-008-0081-0
   Schlatterer J, 2006, J AGR FOOD CHEM, V54, P2267, DOI 10.1021/jf053204d
   Schweiggert RM, 2014, BRIT J NUTR, V111, P490, DOI 10.1017/S0007114513002596
   Speranza A, 2013, J AGR FOOD CHEM, V61, P6505, DOI 10.1021/jf401548r
   Stinco CM, 2012, J AGR FOOD CHEM, V60, P1447, DOI 10.1021/jf2043949
   Surai PF, 2000, EUR J CLIN NUTR, V54, P298, DOI 10.1038/sj.ejcn.1600939
   Tyssandier V, 2003, AM J PHYSIOL-GASTR L, V284, pG913, DOI 10.1152/ajpgi.00410.2002
   US Department of Agriculture, NAT NUTR DAT STAND R
   van het Hof KH, 1999, AM J CLIN NUTR, V70, P261
   Van Loo-Bouwman CA, 2014, J AGR FOOD CHEM, V62, P950, DOI 10.1021/jf403312v
   Werner S, 2011, J AGR FOOD CHEM, V59, P1163, DOI 10.1021/jf103892y
NR 48
TC 29
Z9 30
U1 3
U2 84
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD MAR 25
PY 2015
VL 63
IS 11
BP 2956
EP 2962
DI 10.1021/jf505615w
PG 7
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA CE6TY
UT WOS:000351972300014
PM 25748723
DA 2022-11-30
ER

PT J
AU Yvon, C
   Ramsden, CM
   Lane, A
   Powner, MB
   da Cruz, L
   Coffey, PJ
   Carr, AJF
AF Yvon, Camille
   Ramsden, Conor M.
   Lane, Amelia
   Powner, Michael B.
   da Cruz, Lyndon
   Coffey, Peter J.
   Carr, Amanda-Jayne F.
TI Using Stem Cells to Model Diseases of the Outer Retina
SO COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
LA English
DT Review
DE Disease models; Induced pluripotent stem cells; Retinitis pigmentosa;
   Age related macular degeneration; Leber congenital amaurosis; Inherited
   retinopathy
ID LEBER CONGENITAL AMAUROSIS; PIGMENT EPITHELIUM-CELLS; VESICLE-LIKE
   STRUCTURES; GENE-THERAPY; MACULAR DEGENERATION; VISUAL FUNCTION;
   DIRECTED DIFFERENTIATION; BEST-DISEASE; GENERATION; MUTATIONS
AB Retinal degeneration arises from the loss of photoreceptors or retinal pigment epithelium (RPE). It is one of the leading causes of irreversible blindness worldwide with limited effective treatment options. Generation of induced pluripotent stem cell (IPSC)-derived retinal cells and tissues from individuals with retinal degeneration is a rapidly evolving technology that holds a great potential for its use in disease modelling. IPSCs provide an ideal platform to investigate normal and pathological retinogenesis, but also deliver a valuable source of retinal cell types for drug screening and cell therapy. In this review, we will provide some examples of the ways in which IPSCs have been used to model diseases of the outer retina including retinitis pigmentosa (RP), Usher syndrome (USH), Leber congenital amaurosis (LCA), gyrate atrophy (GA), juvenile neuronal ceroid lipofuscinosis (NCL), Best vitelliform macular dystrophy (BVMD) and age related macular degeneration (AMD). (C) 2015 Yvon et al. Published by Elsevier B.V.
C1 [Yvon, Camille; Ramsden, Conor M.; Lane, Amelia; Powner, Michael B.; da Cruz, Lyndon; Coffey, Peter J.; Carr, Amanda-Jayne F.] UCL, Div ORBIT, Inst Ophthalmol, London Project Cure Blindness, London EC1V 9EL, England.
   [Ramsden, Conor M.; da Cruz, Lyndon] UCL Inst Ophthalmol, Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 2PD, England.
   [Coffey, Peter J.] UC, NRI, Ctr Stem Cell Biol & Engn, Santa Barbara, CA USA.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of California System; University of California Santa Barbara
RP Ramsden, CM (通讯作者)，UCL, Div ORBIT, Inst Ophthalmol, London Project Cure Blindness, 11-43 Bath St, London EC1V 9EL, England.
EM conor.ramsden.09@ucl.ac.uk
RI Carr, Amanda/ABG-6282-2020; Powner, Michael/CAG-7455-2022
OI Carr, Amanda/0000-0002-5469-0030; Coffey, Peter/0000-0002-5427-2939;
   Powner, Michael/0000-0003-4913-1004
CR Abyzov A, 2012, NATURE, V492, P438, DOI 10.1038/nature11629
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Baehr W, 2009, VISION RES, V49, P2636, DOI 10.1016/j.visres.2009.04.008
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chen KG, 2014, CELL STEM CELL, V14, P13, DOI 10.1016/j.stem.2013.12.005
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Coppieters F, 2010, HUM MUTAT, V31, P1097, DOI 10.1002/humu.21337
   Craige B, 2010, J CELL BIOL, V190, P927, DOI 10.1083/jcb.201006105
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de los Reyes E, 2004, J CHILD NEUROL, V19, P42, DOI 10.1177/08830738040190010703
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Drivas TG, 2013, J CLIN INVEST, V123, P4525, DOI 10.1172/JCI69448
   Enver T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hendrickson A, 2008, EXP EYE RES, V87, P415, DOI 10.1016/j.exer.2008.07.016
   Hims MM, 2003, DEV OPHTHALMOL, V37, P109
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107
   Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Katz ML, 1999, J NEUROSCI RES, V57, P551
   Kay CN, 2012, ARCH OPHTHALMOL-CHIC, V130, P357, DOI 10.1001/archophthalmol.2011.363
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Liang GY, 2013, CELL STEM CELL, V13, P149, DOI 10.1016/j.stem.2013.07.001
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liew G, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004015
   Lojewski X, 2014, HUM MOL GENET, V23, P2005, DOI 10.1093/hmg/ddt596
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lustremant C, 2013, CELL REPROGRAM, V15, P233, DOI 10.1089/cell.2012.0076
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   McEwen DP, 2007, P NATL ACAD SCI USA, V104, P15917, DOI 10.1073/pnas.0704140104
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nayerossadat Nouri, 2012, Adv Biomed Res, V1, P27, DOI 10.4103/2277-9175.98152
   Nishino K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002085
   Osafune K, 2008, NAT BIOTECHNOL, V26, P313, DOI 10.1038/nbt1383
   Petrs-Silva H, 2014, CLIN OPHTHALMOL, V8, P127, DOI 10.2147/OPTH.S38041
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Ramsden CM, 2014, DEV OPHTHALMOL, V53, P97, DOI 10.1159/000357363
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rivolta C, 2002, HUM MOL GENET, V11, P1219, DOI 10.1093/hmg/11.10.1219
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Santostefano KE, 2015, LAB INVEST, V95, P4, DOI 10.1038/labinvest.2014.104
   Schwarz N, 2015, HUM MOL GENET, V24, P972, DOI 10.1093/hmg/ddu509
   Seehafer SS, 2011, J NEUROIMMUNOL, V230, P169, DOI 10.1016/j.jneuroim.2010.08.024
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Stieger K, 2011, METHODS MOL BIOL, V807, P179, DOI 10.1007/978-1-61779-370-7_8
   Stone EM, 2011, INVEST OPHTH VIS SCI, V52, P9665, DOI 10.1167/iovs.11-8527
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanaka T, 2015, SCI REP-UK, V5, DOI 10.1038/srep08344
   Terai M, 2013, TISSUE CELL, V45, P407, DOI 10.1016/j.tice.2013.07.003
   Tsang WY, 2008, DEV CELL, V15, P187, DOI 10.1016/j.devcel.2008.07.004
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yoshida T, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-45
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 77
TC 17
Z9 21
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2001-0370
J9 COMPUT STRUCT BIOTEC
JI Comp. Struct. Biotechnol. J..
PY 2015
VL 13
BP 382
EP 389
DI 10.1016/j.csbj.2015.05.001
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA DA4EJ
UT WOS:000367752600046
PM 26106463
OA gold, Green Published, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Mazumder, MAJ
   Fitzpatrick, SD
   Muirhead, B
   Sheardown, H
AF Mazumder, M. A. Jafar
   Fitzpatrick, Scott D.
   Muirhead, Ben
   Sheardown, Heather
TI Cell-adhesive thermogelling PNIPAAm/hyaluronic acid cell delivery
   hydrogels for potential application as minimally invasive retinal
   therapeutics
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE thermally responsive; retina; cell delivery;
   poly(N-isopropylacrylamide); hyaluronic acid
ID HYALURONIC-ACID; BRUCHS MEMBRANE; TRANSPLANTATION; EPITHELIUM;
   ATTACHMENT; POLYMERS; COLLAGEN; CARRIERS
AB Copolymers of N-isopropylacrylamide (NIPAAm) and acrylic acid N-hydroxysuccinimide (NAS) were synthesized via free radical polymerization and conjugated with amine-functionalized hyaluronic acid (HA) and cell adhesive RGDS peptides. These novel copolymers were designed to facilitate noninvasive delivery of a liquid suspension of cells into the delicate subretinal space for treatment of retinal degenerative diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. The various synthesized copolymers all displayed subphysiological phase transition temperatures, thereby allowing temperature-induced scaffold formation and subsequent entrapment of transplanted cells within an adhesive support matrix. Successful grafting of HA and RGDS peptides were confirmed with Fourier Transform Infrared (FTIR) spectroscopy and quantified with 1H Nuclear Magnetic Resonance (NMR) spectroscopy. All copolymers demonstrated excellent compatibility with retinal pigment epithelial (RPE) cells in culture and minimal host response was observed following subcutaneous implantation into hairless SKH1-E mice (strain code 447). (C) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A 2012.
C1 [Mazumder, M. A. Jafar; Sheardown, Heather] McMaster Univ, Dept Chem Engn, Hamilton, ON L8S 4L7, Canada.
   [Fitzpatrick, Scott D.; Muirhead, Ben; Sheardown, Heather] McMaster Univ, Sch Biomed Engn, Hamilton, ON L8S 4L7, Canada.
C3 McMaster University; McMaster University
RP Sheardown, H (通讯作者)，McMaster Univ, Dept Chem Engn, 1280 Main St W, Hamilton, ON L8S 4L7, Canada.
EM sheardow@mcmaster.ca
RI Jafar Mazumder, Mohammad/G-2014-2015
OI Jafar Mazumder, Mohammad/0000-0002-2241-9596
FU NSERC; 20/20 NSERC Ophthalmic Materials Network
FX Contract grant sponsors: NSERC, 20/20 NSERC Ophthalmic Materials Network
CR Aragona P, 2002, BRIT J OPHTHALMOL, V86, P181, DOI 10.1136/bjo.86.2.181
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Cui ZW, 2007, BIOMACROMOLECULES, V8, P1280, DOI 10.1021/bm061045g
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Fitzpatrick SD, 2010, BIOMACROMOLECULES, V11, P2261, DOI 10.1021/bm100299j
   GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   Guan JJ, 2008, BIOMACROMOLECULES, V9, P1283, DOI 10.1021/bm701265j
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Gutowska A, 2001, ANAT RECORD, V263, P342, DOI 10.1002/ar.1115
   Holy CE, 2001, BIOMATERIALS, V22, P25, DOI 10.1016/S0142-9612(00)00136-8
   Jardeleza MSR, 2009, SEMIN OPHTHALMOL, V24, P87, DOI 10.1080/08820530902800330
   Khademhosseini A, 2006, J BIOMED MATER RES A, V79A, P522, DOI 10.1002/jbm.a.30821
   Kim J, 2009, J BIOMED MATER RES A, V88A, P967, DOI 10.1002/jbm.a.31947
   LANE C, 1989, EYE, V3, P27, DOI 10.1038/eye.1989.4
   LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592
   Li F, 2005, BIOMATERIALS, V26, P3093, DOI 10.1016/j.biomaterials.2004.07.063
   LIMBERG MB, 1987, AM J OPHTHALMOL, V103, P194, DOI 10.1016/S0002-9394(14)74226-6
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marchetti V, 2010, J CLIN INVEST, V120, P3012, DOI 10.1172/JCI42951
   Ming M, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-53
   Mooney DJ, 2008, CELL STEM CELL, V2, P205, DOI 10.1016/j.stem.2008.02.005
   NISHIDA T, 1991, EXP EYE RES, V53, P753, DOI 10.1016/0014-4835(91)90110-Z
   Ohya S, 2005, BIOMATERIALS, V26, P655, DOI 10.1016/j.biomaterials.2004.03.002
   Oliviero G, 2008, ANAL CHIM ACTA, V630, P161, DOI 10.1016/j.aca.2008.09.069
   Quan CY, 2010, ACS NANO, V4, P4211, DOI 10.1021/nn100534q
   Smith E, 2005, BIOMATERIALS, V26, P7329, DOI 10.1016/j.biomaterials.2005.05.060
   Smith E, 2003, J POLYM SCI POL CHEM, V41, P3989, DOI 10.1002/pola.10965
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan HP, 2009, BIOMATERIALS, V30, P6844, DOI 10.1016/j.biomaterials.2009.08.058
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thomson HA, 2010, J BIOMED MATER RES A, V95A, P1233, DOI 10.1002/jbm.a.32940
   Uludag H, 2001, BIOTECHNOL BIOENG, V73, P510, DOI 10.1002/bit.1086
   Van Beek M, 2008, BIOMATERIALS, V29, P780, DOI 10.1016/j.biomaterials.2007.10.039
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   West EL, 2009, PROG BRAIN RES, V175, P3, DOI 10.1016/S0079-6123(09)17501-5
   Xu JT, 2011, MACROMOLECULES, V44, P299, DOI 10.1021/ma102386j
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zeng F, 1999, SCI CHINA SER B, V42, P290, DOI 10.1007/BF02874245
NR 44
TC 43
Z9 46
U1 2
U2 69
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUL
PY 2012
VL 100A
IS 7
BP 1877
EP 1887
DI 10.1002/jbm.a.34021
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 946ZN
UT WOS:000304396500028
PM 22492502
DA 2022-11-30
ER

PT J
AU De Falco, S
AF De Falco, Sandro
TI The discovery of placenta growth factor and its biological activity
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Review
DE angiogenesis inducing agents; anoxia; endothelial cells; hypoxia;
   macrophages; neovascularization, pathologic; placenta growth factor;
   vascular endothelial growth factors
ID BONE-MARROW MICROENVIRONMENT; HYPOXIA-INDUCIBLE FACTOR-1; ADIPOSE-TISSUE
   DEVELOPMENT; ALPHA-CONVERTING ENZYME; FACTOR GENE-EXPRESSION;
   TRANSCRIPTION FACTOR-I; 5 UNTRANSLATED REGION; ENDOTHELIAL-CELLS;
   CRYSTAL-STRUCTURE; CARDIAC-HYPERTROPHY
AB Angiogenesis is a complex biological phenomenon crucial for a correct embryonic development and for post-natal growth. In adult life, it is a tightly regulated process confined to the uterus and ovary during the different phases of the menstrual cycle and to the heart and skeletal muscles after prolonged and sustained physical exercise. Conversly, angiogenesis is one of the major pathological changes associated with several complex diseases like cancer, atherosclerosis, arthritis, diabetic retinopathy and age-related macular degeneration. Among the several molecular players involved in angiogenesis, some members of VEGF family, VEGF-A, VEGF-B and placenta growth factor (PIGF), and the related receptors VEGF receptor 1 (VEGFR-1, also known as Flt-1) and VEGF receptor 2 (VEGFR-2, also known as Flk-1 in mice and KDR in human) have a decisive role. In this review, we describe the discovery and molecular characteristics of PIGF, and discuss the biological role of this growth factor in physiological and pathological conditions.
C1 [De Falco, Sandro] CNR, Angiogenesis Lab, Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy.
   [De Falco, Sandro] CNR, Stem Cell Fate Lab, Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e
   Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale
   delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano
   Buzzati-Traverso" (IGB-CNR)
RP De Falco, S (通讯作者)，CNR, Angiogenesis Lab, Inst Genet & Biophys Adriano Buzzati Traverso, Via Pietro Castellino 111, I-80131 Naples, Italy.
EM sandro.defalco@igb.cnr.it
RI De Falco, Sandro/P-6724-2015
OI De Falco, Sandro/0000-0002-6501-1697
FU AIRC (Associazione Italiana Ricerca sul Cancro) [IG 11420]; Telethon -
   Italy [GGP08062]; Italian Ministry of Scientific Research
FX The author declares no conflict of interests. This work was supported by
   grants from: AIRC (Associazione Italiana Ricerca sul Cancro, grant
   number IG 11420), Telethon - Italy (grant number GGP08062), Italian
   Ministry of Scientific Research (grant MERIT, Medical Research in
   Italy). The author thanks Anna Maria Aliperti for manuscript editing.
CR Achen MG, 1997, GROWTH FACTORS, V15, P69, DOI 10.3109/08977199709002113
   Adini A, 2002, CANCER RES, V62, P2749
   ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033
   Bellik L, 2005, BRIT J PHARMACOL, V146, P568, DOI 10.1038/sj.bjp.0706347
   Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Carnevale D, 2011, CIRCULATION, V124, P1337, DOI 10.1161/CIRCULATIONAHA.111.050500
   Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Cramer M, 2005, BIOL CHEM, V386, P865, DOI 10.1515/BC.2005.101
   Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216
   De Ceuninck F, 2004, BIOCHEM BIOPH RES CO, V323, P960, DOI 10.1016/j.bbrc.2004.08.184
   De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Ding YP, 2010, J IMMUNOL, V184, P2593, DOI 10.4049/jimmunol.0902378
   DiPalma T, 1996, MAMM GENOME, V7, P6, DOI 10.1007/s003359900003
   DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717
   Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243
   Gaur P, 2009, CLIN CANCER RES, V15, P6763, DOI 10.1158/1078-0432.CCR-09-1810
   Gigante B, 2006, FASEB J, V20, P970, DOI 10.1096/fj.05-4481fje
   Gigante Bruna, 2004, Angiogenesis, V7, P277, DOI 10.1007/s10456-004-4179-1
   Green CJ, 2001, CANCER RES, V61, P2696
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586
   Hollborn M, 2006, GRAEF ARCH CLIN EXP, V244, P732, DOI 10.1007/s00417-005-0154-9
   Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706
   Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200
   Iyer S, 2010, J BIOL CHEM, V285, P23779, DOI 10.1074/jbc.M110.130658
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Khaliq A, 1996, GROWTH FACTORS, V13, P243, DOI 10.3109/08977199609003225
   KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125
   Larcher F, 2003, MOL CARCINOGEN, V37, P83, DOI 10.1002/mc.10126
   Lijnen HR, 2006, DIABETES, V55, P2698, DOI 10.2337/db06-0526
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Maes C, 2006, J CLIN INVEST, V116, P1230, DOI 10.1172/JCI26772
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   MAGLIONE D, 1993, ONCOGENE, V8, P925
   MAGLIONE D, 1993, GROWTH FACTORS, V8, P141, DOI 10.3109/08977199309046934
   Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Martinsson-Niskanen T, 2011, CLIN THER, V33, P1142, DOI 10.1016/j.clinthera.2011.08.007
   Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   Mohammed KA, 2007, AM J PHYSIOL-LUNG C, V292, pL559, DOI 10.1152/ajplung.00075.2006
   MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234
   Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0
   Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560
   Odorisio T, 2006, J DERMATOL SCI, V41, P11, DOI 10.1016/j.jdermsci.2005.08.008
   Odorisio T, 2002, J CELL SCI, V115, P2559
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875
   Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022
   Persico MG, 1999, CURR TOP MICROBIOL, V237, P31
   Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72
   Ponticelli S, 2008, J BIOL CHEM, V283, P34250, DOI 10.1074/jbc.M806607200
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Rafii S, 2003, ANN NY ACAD SCI, V996, P49, DOI 10.1111/j.1749-6632.2003.tb03232.x
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009
   Scholz D, 2003, J MOL CELL CARDIOL, V35, P177, DOI 10.1016/S0022-2828(02)00304-8
   Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tarallo V, 2010, CANCER RES, V70, P1804, DOI 10.1158/0008-5472.CAN-09-2609
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Vanhoutte D, 2010, J MOL CELL CARDIOL, V48, P445, DOI 10.1016/j.yjmcc.2009.09.013
   VIGLIETTO G, 1995, ONCOGENE, V11, P1569
   Voros G, 2005, ENDOCRINOLOGY, V146, P4545, DOI 10.1210/en.2005-0532
   Vuorela P, 1997, BIOL REPROD, V56, P489, DOI 10.1095/biolreprod56.2.489
   Wang X, 2009, HYPERTENSION, V54, P575, DOI 10.1161/HYPERTENSIONAHA.108.127670
   Wei SC, 2005, GUT, V54, P666, DOI 10.1136/gut.2004.050831
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Yamakawa M, 2003, CIRC RES, V93, P664, DOI 10.1161/01.RES.0000093984.48643.D7
   Yang W, 2003, J REPROD IMMUNOL, V60, P53, DOI 10.1016/S0165-0378(03)00082-2
   Yao YG, 2005, FEBS LETT, V579, P1227, DOI 10.1016/j.febslet.2005.01.017
   Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172
   Yoo SA, 2009, ARTHRITIS RHEUM-US, V60, P345, DOI 10.1002/art.24289
   Zhang H, 2003, CURR BIOL, V13, P1625, DOI 10.1016/j.cub.2003.08.054
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
   Ziche M, 1997, LAB INVEST, V76, P517
NR 94
TC 253
Z9 260
U1 1
U2 43
PU KOREAN SOC MED BIOCHEMISTRY MOLECULAR BIOLOGY
PI SEOUL
PA #812 KOFST, 635-4 YOKSAM-DONG KANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1226-3613
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JAN 31
PY 2012
VL 44
IS 1
BP 1
EP 9
DI 10.3858/emm.2012.44.1.025
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 885GA
UT WOS:000299765300001
PM 22228176
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Agte, V
   Tarwadi, K
AF Agte, Vaishali
   Tarwadi, Kirtan
TI The Importance of Nutrition in the Prevention of Ocular Disease with
   Special Reference to Cataract
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Micronutrients; Antioxidants; Oxidative stress; Cataract; Ocular disease
ID LIPID-PEROXIDATION; OXIDATIVE STRESS; LENS OPACITIES; CLINICAL-TRIAL;
   ANTIOXIDANT; VITAMIN; SUPPLEMENTATION; GLUTATHIONE; SENILE; BLOOD
AB Background: The lens is the ocular structure most susceptible to oxidative damage. Antioxidants, micronutrients and phytochemicals have been extensively studied for their possible effects to prevent or delay the progression of various eye diseases. Objectives: A brief overview of the updated literature on the role of antioxidants and micronutrients in the prevention and treatment of ocular diseases is to be presented with an emphasis on cataract. Data Sources: Pub-Med search and individual papers from journals. Data Synthesis: The review discusses linkages of various micronutrients and antioxidants as well as oxidative stress with cataract. Dietary interventions as strategy for prevention of cataract and other ocular disorders are also reviewed. Conclusions: Consumption of food-based antioxidants like beta-carotene lutein and zeaxanthin seem to be useful for the treatment of macular degeneration and cataracts. Supplements of vitamin A, vitamin C, vitamin E and zinc may prevent advanced age-related macular degeneration only in high-risk individuals. Copyright (C) 2010 S. Karger AG, Basel
C1 [Agte, Vaishali; Tarwadi, Kirtan] Agharkar Res Inst, Pune 411004, Maharashtra, India.
C3 Department of Science & Technology (India); Agharkar Research Institute
   (ARI)
RP Agte, V (通讯作者)，Agharkar Res Inst, GG Agharkar Rd, Pune 411004, Maharashtra, India.
EM vaishaliagte@hotmail.com
CR Acar N, 2009, EXP EYE RES, V89, P840, DOI 10.1016/j.exer.2009.07.008
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Agte VV, 2008, NUTRITION, V24, P617, DOI 10.1016/j.nut.2008.03.005
   Balasubramanian D, 2000, J OCUL PHARMACOL TH, V16, P285, DOI 10.1089/jop.2000.16.285
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P339, DOI 10.1111/j.1475-1313.2004.00218.x
   Bartlett HE, 2008, OPHTHAL PHYSL OPT, V28, P503, DOI 10.1111/j.1475-1313.2008.00595.x
   BHAT KS, 1983, CURR EYE RES, V2, P829, DOI 10.3109/02713688209020018
   Bhat KS., 1991, OCULAR PHARM RECENT, P32
   BHAT KS, 1988, AFRO ASIAN J OPHTHAL, V7, P89
   Blodi Barbara A, 2004, Insight, V29, P15
   Casado A, 2001, GERONTOLOGY, V47, P186, DOI 10.1159/000052796
   Chen C Z, 1992, Zhonghua Yan Ke Za Zhi, V28, P355
   Christen W, 2008, ARCH OPHTHALMOL-CHIC, V126, P1607, DOI 10.1001/archopht.126.11.1607-a
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   Creuzot-Garcher C, 2008, J FR OPHTALMOL, V31, P65
   Cumming RG, 2000, OPHTHALMOLOGY, V107, P450, DOI 10.1016/S0161-6420(99)00024-X
   Dawczynski J, 2002, BIOL TRACE ELEM RES, V90, P15, DOI 10.1385/BTER:90:1-3:15
   DEVAMANOHARAN PS, 1991, EXP EYE RES, V52, P563, DOI 10.1016/0014-4835(91)90057-L
   Donma O, 2002, CURR EYE RES, V25, P9, DOI 10.1076/ceyr.25.1.9.9960
   Evans JR, 1998, INVEST OPHTH VIS SCI, V39, P1740
   Fernandez MM, 2008, CURR OPIN OPHTHALMOL, V19, P66, DOI 10.1097/ICU.0b013e3282f2d7b6
   Giblin FJ, 2000, J OCUL PHARMACOL TH, V16, P121, DOI 10.1089/jop.2000.16.121
   Hamulka Jadwiga, 2008, Rocz Panstw Zakl Hig, V59, P47
   HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335
   Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911
   JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Knekt P, 1997, AM J EPIDEMIOL, V146, P223, DOI 10.1093/oxfordjournals.aje.a009257
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P1113, DOI 10.1001/archopht.1995.01100090039020
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   RAO PV, 1989, J CLIN BIOCHEM NUTR, V6, P195
   RASI V, 1992, ANN OPHTHALMOL, V24, P459
   Rauf A., 1996, Investigative Ophthalmology and Visual Science, V37, pS237
   SETHI A, 1987, P INT S PAR FRANC 19, P151
   Shamsi FA, 2000, EXP EYE RES, V70, P369, DOI 10.1006/exer.1999.0800
   Shukla N, 1996, SCI TOTAL ENVIRON, V181, P161, DOI 10.1016/0048-9697(95)05006-X
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   SRIVASTAVA VK, 1992, ACTA OPHTHALMOL, V70, P839
   STANOJEVICPAOVIC A, 1987, OPHTHALMIC RES, V19, P230, DOI 10.1159/000265499
   Sun J, 2002, J AGR FOOD CHEM, V50, P7449, DOI 10.1021/jf0207530
   SWANSON AA, 1971, BIOCHEM BIOPH RES CO, V45, P1488, DOI 10.1016/0006-291X(71)90188-4
   Tarwadi K, 2003, INT J FOOD SCI NUTR, V54, P417, DOI 10.1080/09637480310001622297
   Taylor A, 1997, Adv Pharmacol, V38, P515
   Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634
   Veach J, 2004, BRIT J NUTR, V91, P809, DOI 10.1079/BJN20041113
   West AL, 2006, AM J OPHTHALMOL, V141, P157, DOI 10.1016/j.ajo.2005.07.033
NR 46
TC 31
Z9 32
U1 2
U2 17
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2010
VL 44
IS 3
BP 166
EP 172
DI 10.1159/000316477
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 652AN
UT WOS:000281972300004
PM 20829640
DA 2022-11-30
ER

PT J
AU Rattner, A
   Toulabi, L
   Williams, J
   Yu, HM
   Nathans, J
AF Rattner, Amir
   Toulabi, Leila
   Williams, John
   Yu, Huimin
   Nathans, Jeremy
TI The genomic response of the retinal pigment epithelium to light damage
   and retinal detachment
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE retinal pigment epithelium; transcription; microarray; mouse; ocular
   disease; light damage; retinal detachment
ID LEBERS CONGENITAL AMAUROSIS; MACULAR DEGENERATION; INDUCED APOPTOSIS;
   GENE-EXPRESSION; RD MOUSE; MICE; CELLS; PROLIFERATION; DISEASE; INJURY
AB The retinal pigment epithelium (RPE) plays an essential role in maintaining the health of the retina. The RPE is also the site of pathologic processes in a wide variety of retinal disorders including monogenic retinal dystrophies, age-related macular degeneration, and retinal detachment. Despite intense interest in the RPE, little is known about its molecular response to ocular damage or disease. We have conducted a comprehensive analysis of changes in transcript abundance (the "genomic response") in the murine RPE after light damage. Several dozen transcripts, many related to cell-cell signaling, show significant increases in abundance in response to bright light; transcripts encoding visual cycle proteins show a decrease in abundance. Similar changes are induced by retinal detachment. Environmental and genetic perturbations that modulate the RPE response to bright light suggest that this response is controlled by the retina. In contrast to the response to bright light, the RPE response to retinal detachment overrides these modulatory affects.
C1 [Rattner, Amir; Toulabi, Leila; Williams, John; Yu, Huimin; Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
   [Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
   [Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Williams, John; Nathans, Jeremy] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Howard Hughes Medical Institute; Johns Hopkins University
RP Nathans, J (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.
EM jnathans@jhmi.edu
OI Rattner, Amir/0000-0001-9542-6212; Nathans, Jeremy/0000-0001-8106-5460
FU Foundation Fighting Blindness; National Eye Institute; Howard Hughes
   Medical Institute; NATIONAL EYE INSTITUTE [R01EY014363] Funding Source:
   NIH RePORTER
FX This work was supported by the Foundation Fighting Blindness, the
   National Eye Institute (A. R.), and the Howard Hughes Medical Institute
   (J. N.). We thank Hugh Cahill, Janice Lem, T. Michael Redmond, and Lelei
   Zhang for advice and/or materials, and Yanshu Wang and an anonymous
   reviewer for helpful comments on this manuscript.
CR ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0
   Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Danciger M, 2000, MAMM GENOME, V11, P422, DOI 10.1007/s003350010081
   Dinculescu A, 2005, HUM GENE THER, V16, P649, DOI 10.1089/hum.2005.16.649
   FARBER DB, 1991, EXP EYE RES, V53, P781, DOI 10.1016/0014-4835(91)90114-T
   Farjo R, 2008, INVEST OPHTH VIS SCI, V49, P511, DOI 10.1167/iovs.07-1013
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Ganti R, 2007, INVEST OPHTH VIS SCI, V48, P1853, DOI 10.1167/iovs.06-0198
   Geller SF, 2001, INVEST OPHTH VIS SCI, V42, P1363
   Green CB, 2004, J BIOL RHYTHM, V19, P91, DOI 10.1177/0748730404263002
   Hafezi F, 1998, INVEST OPHTH VIS SCI, V39, P2239
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Li CKF, 2004, J IMMUNOL, V173, P5171, DOI 10.4049/jimmunol.173.8.5171
   Li F, 2003, INVEST OPHTH VIS SCI, V44, P4968, DOI 10.1167/iovs.03-0140
   Liu CD, 1998, J NEUROSCI, V18, P1337
   Luke CJ, 2007, CELL, V130, P1108, DOI 10.1016/j.cell.2007.07.013
   MACHEMER R, 1975, AM J OPHTHALMOL, V80, P1
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086
   Orchard GE, 1999, BRIT J BIOMED SCI, V56, P188
   ORGANISCIAK DT, 1991, EXP EYE RES, V53, P773, DOI 10.1016/0014-4835(91)90113-S
   Pastor JC, 2002, PROG RETIN EYE RES, V21, P127, DOI 10.1016/S1350-9462(01)00023-4
   Rattner A, 2005, J NEUROSCI, V25, P4540, DOI 10.1523/JNEUROSCI.0492-05.2005
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Redmond TM, 2007, MOL VIS, V13, P1813
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   SANYAL S, 1984, EXPERIENTIA, V40, P852, DOI 10.1007/BF01951991
   SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823
   Sipione S, 2006, J IMMUNOL, V177, P5051, DOI 10.4049/jimmunol.177.8.5051
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893
   Swiderski RE, 2007, INVEST OPHTH VIS SCI, V48, P3329, DOI 10.1167/iovs.06-1477
   Szurman P, 2006, INVEST OPHTH VIS SCI, V47, P4983, DOI 10.1167/iovs.06-0491
   Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367
   Vansaun M, 2003, J NEUROCYTOL, V32, P1129, DOI 10.1023/B:NEUR.0000021907.68461.9c
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   Zacks DN, 2006, INVEST OPHTH VIS SCI, V47, P1691, DOI 10.1167/iovs.05-1209
   Zhang HB, 2008, J NEUROSCI, V28, P4008, DOI 10.1523/JNEUROSCI.0317-08.2008
NR 47
TC 35
Z9 37
U1 0
U2 9
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD SEP 24
PY 2008
VL 28
IS 39
BP 9880
EP 9889
DI 10.1523/JNEUROSCI.2401-08.2008
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 352MG
UT WOS:000259500700027
PM 18815272
OA Green Published, Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Sorbera, LA
AF Sorbera, L. A.
TI Aflibercept - Antiangiogenic agent vascular endothelial growth factor
   inhibitor
SO DRUGS OF THE FUTURE
LA English
DT Article
ID POTENT VEGF BLOCKADE; OVARIAN-CANCER MODEL; FACTOR-TRAP; CHOROIDAL
   NEOVASCULARIZATION; ESTABLISHED TUMORS; ANGIOGENESIS; REGRESSION;
   SURVIVAL; VESSELS; ANTIBODIES
AB The proangiogenic cytokine vascular endothelial growth factor (VEGF) is involved in several adult angiogenic pathologies, including the progression of solid tumor growth and age-related macular degeneration (AMD). Inhibition of VEGF signaling thus represents a potentially effective therapeutic strategy to block pathological angiogenesis in these indications. Several strategies to inhibit VEGF signaling are available, including direct targeting of VEGF, interference with VEGF binding to its receptors and inhibition of VEGF receptor (VEGFR) tyrosine kinase activity. A novel approach consisting of decoy VEGF receptors was designed and may optimize VEGF inhibition. From a series of recombinant VEGF decoy receptors, aflibercept (VEGF Trap(R1/R2)) emerged as the most promising agent, exhibiting superior pharmacokinetics, high-affinity binding to VEGF and potent antiangiogenic effects in preclinical models of cancer and pathological ocular neovascularization. Moreover, the clinical efficacy and safety of aflibercept were demonstrated in these indications. Aflibercept is presently in clinical testing for the treatment of solid tumors, wet AMD and diabetic macular edema (DME).
C1 Prous Sci, E-08080 Barcelona, Spain.
RP Sorbera, LA (通讯作者)，Prous Sci, POB 540, E-08080 Barcelona, Spain.
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   BACHMANN BO, 2005, ANN M ASS RES VIS OP
   Byrne AT, 2003, CLIN CANCER RES, V9, P5721
   CAO J, 2005, ANN M ASS RES VIS OP
   CHIRON M, 2005, P AM ASS CANC RES AA, V46
   Cursiefen C, 2004, INVEST OPHTH VIS SCI, V45, P2666, DOI 10.1167/iovs.03-1380
   Dalal S, 2005, CLIN CANCER RES, V11, P2364, DOI 10.1158/1078-0432.CCR-04-1201
   Drevs J, 2002, CANCER RES, V62, P4015
   DUPONT J, 2003, P AM SOC CLIN ASCO
   DUPONT J, 2005, 41 ANN M AM SOC CLIN
   DUPONT J, 2004, EUR J CANC S, V2
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Fong TAT, 1999, CANCER RES, V59, P99
   Fraser HM, 2005, J CLIN ENDOCR METAB, V90, P5811, DOI 10.1210/jc.2005-1199
   Fraser HM, 2005, J CLIN ENDOCR METAB, V90, P1114, DOI 10.1210/jc.2004-1572
   Frischer JS, 2004, INT J ONCOL, V25, P549
   Fukasawa M, 2004, CLIN CANCER RES, V10, P3327, DOI 10.1158/1078-0432.CCR-03-0820
   Furfine E, 2006, ANN M ASS RES VIS OP
   Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hu LM, 2005, CLIN CANCER RES, V11, P6966, DOI 10.1158/1078-0432.CCR-05-0910
   Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100
   HULOWE D, 2002, P AM ASS CANC RES AA
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399
   Laird AD, 2000, CANCER RES, V60, P4152
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   LIU Y, 2006, ANN M ASS RES VIS OP
   LOCKHART AC, 2005, 17 AACR NCI EORTC IN
   MULAY M, 2006, J CLIN ONCOL S, V24
   NGUYEN QD, 2006, ANN M AM AC OPTH NOV
   NGUYEN QD, 2006, ANN M ASS RES VIS OP
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Prewett M, 1999, CANCER RES, V59, P5209
   *PROUS SCI R D BRI, 2007, AG REL MAC DEG
   RENARD RA, 2006, ANN M ASS RES VIS OP
   Rudge JS, 2005, COLD SH Q B, V70, P411, DOI 10.1101/sqb.2005.70.052
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   SHAH SM, 2006, ANN M ASS RES VIS OP
   Smith JK, 2004, ONCOL RES, V14, P175, DOI 10.3727/000000003772462298
   SONG H, 2005, ANN M ASS RES VIS OP
   Tseng JF, 2002, SURGERY, V132, P857, DOI 10.1067/msy.2002.127680
   van Hinsbergh VWM, 1999, ANN ONCOL, V10, P60, DOI 10.1023/A:1008340820288
   WACHSBERGER PR, 2005, 17 AACR NCI EORTC IN
   WANG Q, 2002, ANN M ASS RES VIS OP
   WEN R, 2005, ANN M ASS RES VIS OP
   WIEGAND SJ, 2005, ANN M ASS RES VIS OP
   Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427
   Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797
   ZHAO L, 2005, ANN M ASS RES VIS OP
   ZIMMER E, 2006, ANN M ASS RES VIS OP
   2006, DAILYDRUGSNEWS  1013
   2004, DAILYDRUGSNEWS  0301
NR 55
TC 2
Z9 2
U1 0
U2 7
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0377-8282
J9 DRUG FUTURE
JI Drug Future
PD FEB
PY 2007
VL 32
IS 2
BP 109
EP 117
DI 10.1358/dof.2007.032.02.1079533
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 157DN
UT WOS:000245698900001
DA 2022-11-30
ER

PT J
AU Wood, JPM
   Osborne, NN
AF Wood, JPM
   Osborne, NN
TI Zinc and energy requirements in induction of oxidative stress to retinal
   pigmented epithelial cells
SO NEUROCHEMICAL RESEARCH
LA English
DT Article
DE zinc; antioxidant; apoptosis; retinal pigmented epithelium; age-related
   macular degeneration; pyruvate
ID NF-KAPPA-B; CULTURED HUMAN; BETA(1)-ADRENOCEPTOR ANTAGONIST; NEURONAL
   DEATH; DEFICIENCY; PROTECTION; BETAXOLOL; SURVIVAL; DAMAGE;
   PROLIFERATION
AB In age-related macular degeneration (AMD), retinal pigmented epithelium (RPE) cells are believed to be detrimentally affected. It is thought that zinc may play a part in this process. In the past, therefore, zinc supplementation has been suggested as a treatment for AMD. Experimental data shown here confound this view by indicating that whereas low amounts of zinc do protect RPE cells in culture from stress-induced effects, greater amounts of zinc have the opposite influence. These effects are partly dependent upon the "health status" of the cells. Experimental data presented herein also show that zinc-induced death of RPE cells can, however, be attenuated by compounds such as antioxidants (alpha-tocopherol, trolox, and metipranolol), or cellular energy substrates ( pyruvate and oxaloacetate). It is therefore concluded that a combination of zinc and antioxidants or energy substrates rather that zinc alone should provide a safer and more effective way to treat a disease such as AMD.
C1 Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX2 6AW, England.
C3 University of Oxford
RP Osborne, NN (通讯作者)，Univ Oxford, Nuffield Lab Ophthalmol, Walton St, Oxford OX2 6AW, England.
EM neville.Osborne@eye.ox.ac.uk
CR Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548
   Boland MP, 2001, BIOCHEM SOC T, V29, P674, DOI 10.1042/BST0290674
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chidlow G, 2000, BRIT J PHARMACOL, V130, P759, DOI 10.1038/sj.bjp.0703369
   Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347
   COLOME AML, 1994, CURR EYE RES, V13, P553
   DAVIDSON PC, 1994, INVEST OPHTH VIS SCI, V35, P2843
   EVANS GW, 1986, CLIN PHYSIOL BIOCH, V4, P94
   Foo SY, 1999, TRENDS GENET, V15, P229
   Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281
   Hoste AM, 1998, J CARDIOVASC PHARM, V32, P390, DOI 10.1097/00005344-199809000-00009
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jampol LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1533
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kimura E, 2000, J BIOL INORG CHEM, V5, P139, DOI 10.1007/s007750050359
   Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099
   KROTKIEWSKA B, 1992, INT J BIOCHEM, V24, P1501, DOI 10.1016/0020-711X(92)90078-F
   LEUREDUPREE AE, 1982, INVEST OPHTH VIS SCI, V23, P425
   Lobner D, 2000, CELL MOL BIOL, V46, P797
   Lovell MA, 1999, BRAIN RES, V823, P88, DOI 10.1016/S0006-8993(99)01114-2
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Melena J, 1999, EUR J PHARMACOL, V378, P317, DOI 10.1016/S0014-2999(99)00459-8
   MELENA J, IN PRESS CRAEPES ARC
   MENZANO E, 1994, ALCOHOL CLIN EXP RES, V18, P895, DOI 10.1111/j.1530-0277.1994.tb00057.x
   Mocchegiani E, 2000, BIOGERONTOLOGY, V1, P133, DOI 10.1023/A:1010095930854
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NAKANO M, 1993, IMMUNOBIOLOGY, V187, P272, DOI 10.1016/S0171-2985(11)80344-X
   Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6
   Philp NJ, 1998, AM J PHYSIOL-REG I, V274, pR1824, DOI 10.1152/ajpregu.1998.274.6.R1824
   Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Tate DJ, 1999, FREE RADICAL BIO MED, V26, P704, DOI 10.1016/S0891-5849(98)00253-6
   To CH, 1998, COMP BIOCHEM PHYS A, V121, P441, DOI 10.1016/S1095-6433(98)10156-3
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Ugarte M, 1998, GEN PHARMACOL-VASC S, V30, P297, DOI 10.1016/S0306-3623(97)00358-3
   Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8
   Wood JPM, 1996, EXP EYE RES, V63, P113, DOI 10.1006/exer.1996.0097
   Wood JPM, 2003, EXP EYE RES, V76, P505, DOI 10.1016/S0014-4835(02)00335-4
   Wood JPM, 2001, ARCH OPHTHALMOL-CHIC, V119, P81
   Wood JPM, 1997, NEUROCHEM INT, V31, P261, DOI 10.1016/S0197-0186(96)00157-X
NR 45
TC 19
Z9 22
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 1573-6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD OCT
PY 2003
VL 28
IS 10
BP 1525
EP 1533
DI 10.1023/A:1025622425501
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 719QF
UT WOS:000185214400011
PM 14570397
DA 2022-11-30
ER

PT J
AU Finnemann, SC
   Leung, LW
   Rodriguez-Boulan, E
AF Finnemann, SC
   Leung, LW
   Rodriguez-Boulan, E
TI The lipofuscin component A2E selectively inhibits phagolysosomal
   degradation of photoreceptor phospholipid by the retinal pigment
   epithelium
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID MACULAR DEGENERATION; OUTER SEGMENTS; AGE PIGMENT; RPE CELLS;
   PHAGOCYTOSIS; RHODOPSIN; CULTURE; BINDING; PROTEIN; A2-E
AB Daily phagocytosis of spent photoreceptor outer segments is a critical maintenance function performed by the retinal pigment epithelium (RPE) to preserve vision. Aging RPE accumulates lipofuscin, which includes N-retinylidene-N-retinylethanolamine (A2E) as the major autofluorescent component. We studied the effect of physiological levels of A2E in RPE cultures on their ability to phagocytose outer segments. A2E localized to lysosomes in cultured RIPE as well as in human RPE in situ. A2E-loaded RPE cells in culture bound and internalized identical numbers of outer segments as control RPE indicating that A2E does not alter early steps of phagocytosis. A2E-loaded RPE degraded outer segment proteins efficiently but, strikingly, failed to completely digest phospholipids within 24 h. Because of the circadian rhythm of RIPE phagocytosis in the eye, a delay in lipid degradation would likely result in a build up of undigested material in RIPE that could contribute to the development of age-related macular degeneration.
C1 Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10021 USA.
   Cornell Univ, Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA.
C3 Cornell University; Cornell University
RP Rodriguez-Boulan, E (通讯作者)，Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, Box 233,1300 York Ave, New York, NY 10021 USA.
EM boulan@mail.med.cornell.edu
RI Leung, Lawrence/E-4439-2010
OI Leung, Lawrence/0000-0003-3333-3242
FU NEI NIH HHS [EY08538, R01 EY008538] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER
CR ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H
   ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019
   BERGMANN M, 2001, EXP EYE RES, V72, P191
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   DELAEY JJ, 1995, RETINA-J RET VIT DIS, V15, P399, DOI 10.1097/00006982-199515050-00005
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115
   Geng LJ, 1999, EXP EYE RES, V69, P539, DOI 10.1006/exer.1999.0735
   Hall MO, 1996, EXP EYE RES, V63, P255, DOI 10.1006/exer.1996.0114
   HENDRICKSON HS, 1994, ANAL BIOCHEM, V219, P1, DOI 10.1006/abio.1994.1223
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   NABI IR, 1993, J CELL SCI, V104, P37
   NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Winkler BS, 1999, MOL VIS, V5
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 34
TC 218
Z9 227
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 19
PY 2002
VL 99
IS 6
BP 3842
EP 3847
DI 10.1073/pnas.052025899
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 533CC
UT WOS:000174511000087
PM 11904436
OA Green Published
DA 2022-11-30
ER

PT J
AU Li, X
   Wang, JQ
   Wang, LY
   Gao, YX
   Feng, GH
   Li, G
   Zou, J
   Yu, MX
   Li, YF
   Liu, C
   Yuan, XW
   Zhao, L
   Ouyang, H
   Zhu, JK
   Li, W
   Zhou, Q
   Zhang, K
AF Li, Xin
   Wang, Jiaqiang
   Wang, LeYun
   Gao, Yuanxu
   Feng, Guihai
   Li, Gen
   Zou, Jun
   Yu, Meixin
   Li, Yu Fei
   Liu, Chao
   Yuan, Xue Wei
   Zhao, Ling
   Ouyang, Hong
   Zhu, Jian-Kang
   Li, Wei
   Zhou, Qi
   Zhang, Kang
TI Lipid metabolism dysfunction induced by age-dependent DNA methylation
   accelerates aging
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID PROTEIN STRUCTURES; SYSTEMIC DHA; ELOVL2; RESOLUTION; DAMAGE;
   SENESCENCE; PREDICTION; MEDIATORS; PROFILES; FEATURES
AB Epigenetic alterations and metabolic dysfunction are two hallmarks of aging. However, the mechanism of how their interaction regulates aging, particularly in mammals, remains largely unknown. Here we show ELOVL fatty acid elongase 2 (Elovl2), a gene whose epigenetic alterations are most highly correlated with age prediction, contributes to aging by regulating lipid metabolism. We applied artificial intelligence to predict the protein structure of ELOVL2 and the interaction with its substrate. Impaired Elovl2 function disturbs lipid synthesis with increased endoplasmic reticulum stress and mitochondrial dysfunction, leading to key aging phenotypes at both cellular and physiological level. Furthermore, restoration of mitochondrial activity can rescue age-related macular degeneration (AMD) phenotypes induced by Elovl2 deficiency in human retinal pigmental epithelial (RPE) cells; this indicates a conservative mechanism in both human and mouse. Taken together, we revealed an epigenetic-metabolism axis contributing to aging and illustrate the power of an AI-based approach in structure-function studies.
C1 [Li, Xin; Wang, Jiaqiang; Wang, LeYun; Feng, Guihai; Li, Yu Fei; Liu, Chao; Yuan, Xue Wei; Li, Wei; Zhou, Qi] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
   [Li, Xin] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92037 USA.
   [Li, Xin; Zhang, Kang] Macau Univ Sci & Technol, Fac Med, Tapai 999078, Macau, Peoples R China.
   [Gao, Yuanxu] Macau Univ Sci & Technol, State Key Lab Lunar & Planetary Sci, Tapai 999078, Macau, Peoples R China.
   [Gao, Yuanxu; Zou, Jun] Sichuan Univ, West China Hosp, Clin Translat Innovat Ctr, Chengdu 610041, Peoples R China.
   [Li, Gen; Yu, Meixin] Guangzhou Med Univ, Guangzhou Women & Children Med Ctr, Guangzhou 510623, Peoples R China.
   [Zhao, Ling; Ouyang, Hong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Peoples R China.
   [Zhu, Jian-Kang] Southern Univ Sci & Technol, Inst Adv Biotechnol, Shenzhen 518055, Peoples R China.
   [Zhu, Jian-Kang] Southern Univ Sci & Technol, Sch Life Sci, Shenzhen 518055, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Zoology, CAS; University of
   California System; University of California San Diego; Macau University
   of Science & Technology; Macau University of Science & Technology;
   Sichuan University; Guangzhou Medical University; Sun Yat Sen
   University; Southern University of Science & Technology; Southern
   University of Science & Technology
RP Li, W; Zhou, Q (通讯作者)，Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.; Zhang, K (通讯作者)，Macau Univ Sci & Technol, Fac Med, Tapai 999078, Macau, Peoples R China.; Zhu, JK (通讯作者)，Southern Univ Sci & Technol, Inst Adv Biotechnol, Shenzhen 518055, Peoples R China.; Zhu, JK (通讯作者)，Southern Univ Sci & Technol, Sch Life Sci, Shenzhen 518055, Peoples R China.
EM zhujk@sustech.edu.cn; liwei@ioz.ac.cn; qzhou@ioz.ac.cn;
   kang.zhang@gmail.com
RI Gao, Yuanxu/GMW-9983-2022
OI Zou, Jun/0000-0002-5395-6052; Zhao, Ling/0000-0002-6644-2886
FU Strategic Priority Research Program of the Chinese Academy of Sciences
   [XDA16030400]; National Natural Science Foundation of China [31621004,
   31471395, 31701286]; Key Research Projects of the Frontier Science of
   the Chinese Academy of Sciences [QYZDY-SSW-SMC002]; Key deployment
   projects of the Chinese Academy of Sciences [ZDRW-ZS-2017-4]; National
   Basic Research Program of China [2014cB964801]; China Postdoctoral
   Science Foundation [2017M610990, 2017T100107]; China National
   Postdoctoral Program for Innovative Talents [BX201700243]; National Key
   Research and Development Program [2017YFA0103803]; Guangzhou Laboratory
FX We thank Q.C. and J.L. from Beijing Health OLight technology Co. Ltd for
   their help with OCT and ERG services. We thank C.L., W.G. and T.L. from
   Institute of Materia Medica, Chinese Academy of Medical Sciences and
   Peking Union Medical College for their Help with Pathological section
   and MRI services. We thank Shiwen Li and Xili Zhu from the Institute of
   Zoology, Chinese Academy of Sciences for their technical assistance. We
   thank Z.L., Z.X., Q.Q., C.Z., J.X., and Q.W. for their help and
   assistance in data analysis. We thank Eppendorf, Leica, and Beckman for
   supplying the devices. This work was supported by grants from the
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (XDA16030400 to Q.Z. and W.L.), National Natural Science Foundation of
   China (31621004 to Q.Z. and W.L., 31471395 to Q.Z., and 31701286 to
   G.F.), Guangzhou Laboratory (to K.Z.), the Key Research Projects of the
   Frontier Science of the Chinese Academy of Sciences (QYZDY-SSW-SMC002 to
   Q.Z.), the Key deployment projects of the Chinese Academy of Sciences
   (ZDRW-ZS-2017-4 to W.L.), the National Basic Research Program of China
   (2014cB964801 to W.L.), the China Postdoctoral Science Foundation
   (2017M610990 and 2017T100107 to J.W.), the China National Postdoctoral
   Program for Innovative Talents (BX201700243 to L.W.), and the National
   Key Research and Development Program (2017YFA0103803 to Q.Z.).
CR Alkhouri Naim, 2009, Expert Rev Gastroenterol Hepatol, V3, P445, DOI 10.1586/egh.09.32
   Baek M, 2021, SCIENCE, V373, P871, DOI 10.1126/science.abj8754
   Behrens A, 2014, NAT CELL BIOL, V16, P201, DOI 10.1038/ncb2928
   Bell CG, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1824-y
   Benayoun BA, 2015, NAT REV MOL CELL BIO, V16, P593, DOI 10.1038/nrm4048
   Booth LN, 2016, MOL CELL, V62, P728, DOI 10.1016/j.molcel.2016.05.013
   Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009
   Chaudhury S, 2010, BIOINFORMATICS, V26, P689, DOI 10.1093/bioinformatics/btq007
   Chen D, 2020, AGING CELL, V19, DOI 10.1111/acel.13100
   Chen JH, 2007, NUCLEIC ACIDS RES, V35, P7417, DOI 10.1093/nar/gkm681
   Choi JY, 2016, INT J OBESITY, V40, P1452, DOI 10.1038/ijo.2016.70
   Correia-Melo C, 2016, EMBO J, V35, P724, DOI 10.15252/embj.201592862
   Cruciani-Guglielmacci C, 2017, MOL METAB, V6, P340, DOI 10.1016/j.molmet.2017.01.009
   Ferre P, 2010, DIABETES OBES METAB, V12, P83, DOI 10.1111/j.1463-1326.2010.01275.x
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Guarente L, 2014, CELL METAB, V20, P706, DOI 10.1016/j.cmet.2014.10.015
   Han S, 2017, NATURE, V544, P185, DOI 10.1038/nature21686
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Issa JP, 2003, CLIN IMMUNOL, V109, P103, DOI 10.1016/S1521-6616(03)00203-1
   Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2
   Lee YS, 2014, CELL, V157, P1339, DOI 10.1016/j.cell.2014.05.012
   Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Mariani V, 2013, BIOINFORMATICS, V29, P2722, DOI 10.1093/bioinformatics/btt473
   Mitchell SJ, 2015, ANNU REV ANIM BIOSCI, V3, P283, DOI 10.1146/annurev-animal-022114-110829
   Mohrin M, 2015, SCIENCE, V347, P1374, DOI 10.1126/science.aaa2361
   Nie LY, 2021, NAT STRUCT MOL BIOL, V28, P512, DOI 10.1038/s41594-021-00605-6
   Oishi Y, 2017, CELL METAB, V25, P412, DOI 10.1016/j.cmet.2016.11.009
   Pauter AM, 2017, J LIPID RES, V58, P111, DOI 10.1194/jlr.M070862
   Pauter AM, 2014, J LIPID RES, V55, P718, DOI 10.1194/jlr.M046151
   Salvado L, 2015, TRENDS ENDOCRIN MET, V26, P438, DOI 10.1016/j.tem.2015.05.007
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Slieker RC, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0191-3
   Sorrentino V, 2017, NATURE, V552, P187, DOI 10.1038/nature25143
   Steinegger M, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3019-7
   Stubbs TM, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1203-5
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   White RR, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2061-8
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005
   Zadravec D, 2011, J LIPID RES, V52, P245, DOI 10.1194/jlr.M011346
   Zbiec-Piekarska R, 2015, FORENSIC SCI INT-GEN, V14, P161, DOI 10.1016/j.fsigen.2014.10.002
   Zhu TY, 2018, AGING-US, V10, P3541, DOI 10.18632/aging.101666
NR 49
TC 0
Z9 0
U1 22
U2 26
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD MAY 25
PY 2022
VL 7
IS 1
AR 162
DI 10.1038/s41392-022-00964-6
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 1M2RJ
UT WOS:000799821000001
PM 35610223
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xia, WY
   Li, C
   Chen, QJ
   Huang, JC
   Zhao, ZH
   Liu, PX
   Xu, K
   Li, L
   Hu, FY
   Zhang, SJ
   Sun, T
   Jiang, C
   Zhao, C
AF Xia, Weiyi
   Li, Chao
   Chen, Qinjun
   Huang, Jiancheng
   Zhao, Zhenhao
   Liu, Peixin
   Xu, Kai
   Li, Lei
   Hu, Fangyuan
   Zhang, Shujie
   Sun, Tao
   Jiang, Chen
   Zhao, Chen
TI Intravenous route to choroidal neovascularization by
   macrophage-disguised nanocarriers for mTOR modulation
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE Choroidal; Age-related macular; Biomimetic nanoparticles; Targeted drug
   delivery; Inflammation; mTOR signaling; Rapamycin; Macrophage membrane
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; ADHESION MOLECULES;
   MAMMALIAN TARGET; INTRAVITREAL SIROLIMUS; GEOGRAPHIC ATROPHY; OXIDATIVE
   STRESS; INFLAMMATION; AUTOPHAGY; RAPAMYCIN
AB Retinal pigment epithelial (RPE) is primarily impaired in age-related macular degeneration (AMD), leading to progressive loss of photoreceptors and sometimes choroidal neovascularization (CNV). mTOR has been proposed as a promising therapeutic target, while the usage of its specific inhibitor, rapamycin, was greatly limited. To mediate the mTOR pathway in the retina by a noninvasive approach, we developed novel biomimetic nanocomplexes where rapamycin-loaded nanoparticles were coated with cell membrane derived from macrophages (termed as MRaNPs). Taking advantage of the macrophage-inherited property, intravenous injection of MRaNPs exhibited significantly enhanced accumulation in the CNV lesions, thereby increasing the local concentration of rapamycin. Consequently, MRaNPs effectively downregulated the mTOR pathway and attenuate angiogenesis in the eye. Particularly, MRaNPs also efficiently activated autophagy in the RPE, which was acknowledged to rescue RPE in response to deleterious stimuli. Overall, we design and prepare macrophage-disguised rapamycin nanocarriers and demonstrate the therapeutic advantages of employing biomimetic cell membrane materials for treatment of AMD.
C1 [Xia, Weiyi; Huang, Jiancheng; Xu, Kai; Li, Lei; Hu, Fangyuan; Zhang, Shujie; Zhao, Chen] Fudan Univ, Eye & ENT Hosp, Shanghai Med Sch, Dept Ophthalmol & Vis Sci, Shanghai 200031, Peoples R China.
   [Li, Chao; Chen, Qinjun; Zhao, Zhenhao; Liu, Peixin; Sun, Tao; Jiang, Chen] Fudan Univ, Sch Pharm, Dept Pharmaceut, Key Lab Smart Drug Delivery,Minist Educ, Shanghai 201203, Peoples R China.
C3 Fudan University; Fudan University
RP Zhao, C (通讯作者)，Fudan Univ, Eye & ENT Hosp, Shanghai Med Sch, Dept Ophthalmol & Vis Sci, Shanghai 200031, Peoples R China.; Jiang, C (通讯作者)，Fudan Univ, Sch Pharm, Dept Pharmaceut, Key Lab Smart Drug Delivery,Minist Educ, Shanghai 201203, Peoples R China.
EM jiangchen@shmu.edu.cn; dr_zhaochen@163.com
FU National Natural Science Foundation of China [81525006]; Program of
   Shanghai Academic Research Leader (China) [18XD1401000]; Shanghai
   Outstanding Academic Leaders (China) [2017BR013]
FX This work was supported by the grants from National Natural Science
   Foundation of China (Grant No. 81525006) , Program of Shanghai Academic
   Research Leader (Grant No. 18XD1401000, China) and Shanghai Outstanding
   Academic Leaders (Grant No. 2017BR013, China) .
CR Agrahari V, 2017, EXPERT OPIN DRUG DEL, V14, P1145, DOI 10.1080/17425247.2017.1272569
   Antikainen H, 2017, AGING CELL, V16, P1219, DOI 10.1111/acel.12689
   Baker B, 2015, J BIOL CHEM, V290, P6670, DOI 10.1074/jbc.M114.611442
   Behrendt D, 2002, AM J CARDIOL, V90, p40L, DOI 10.1016/S0002-9149(02)02963-6
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Chen YW, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay9526
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Du ZJ, 2016, GRAEF ARCH CLIN EXP, V254, P2469, DOI 10.1007/s00417-016-3508-6
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Guo Q, 2020, ACS APPL MATER INTER, V12, P57757, DOI 10.1021/acsami.0c18361
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1442, DOI 10.1152/ajpcell.2001.281.5.C1442
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lentsch AB, 2000, J PATHOL, V190, P343
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li MJ, 2021, ACS NANO, V15, P9808, DOI 10.1021/acsnano.1c00680
   Liu NN, 2015, IUBMB LIFE, V67, P446, DOI 10.1002/iub.1382
   Lyu QH, 2021, BIOMATERIALS, V270, DOI 10.1016/j.biomaterials.2021.120682
   Macias-Ceja DC, 2017, BRIT J PHARMACOL, V174, P2501, DOI 10.1111/bph.13860
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109
   MEERSCHAERT J, 1995, J IMMUNOL, V154, P4099
   MEERSCHAERT J, 1994, J IMMUNOL, V152, P1915
   Merrill PT, 2020, OPHTHALMOLOGY, V127, P1405, DOI 10.1016/j.ophtha.2020.03.033
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mudumba S, 2012, J OCUL PHARMACOL TH, V28, P507, DOI 10.1089/jop.2011.0226
   Mullins RF, 2006, MOL VIS, V12, P224
   Murakami Y, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100778
   Nagata M, 1999, CLIN EXP ALLERGY, V29, P550
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Paschalis EI, 2018, P NATL ACAD SCI USA, V115, pE11359, DOI 10.1073/pnas.1807123115
   Peynshaert K, 2018, ADV DRUG DELIVER REV, V126, P44, DOI 10.1016/j.addr.2017.09.007
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Shah M, 2017, INVEST OPHTH VIS SCI, V58, P372, DOI 10.1167/iovs.16-19159
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Stewart MW, 2013, EXPERT REV OPHTHALMO, V8, P527, DOI 10.1586/17469899.2013.854705
   Thamphiwatana S, 2017, P NATL ACAD SCI USA, V114, P11488, DOI 10.1073/pnas.1714267114
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang Y, 2019, ADV SCI, V6, DOI 10.1002/advs.201900172
   Weber C, 2007, NAT REV IMMUNOL, V7, P467, DOI 10.1038/nri2096
   Wei C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02283
   Wei J, 2016, CELL PHYSIOL BIOCHEM, V40, P1570, DOI 10.1159/000453207
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang JY, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0380-0
   Yao AN, 2020, CLIN EXP OPHTHALMOL, V48, P1072, DOI 10.1111/ceo.13819
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Yerramothu Praveen, 2018, Vision (Basel), V2, DOI 10.3390/vision2030031
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang Y, 2018, NANO LETT, V18, P1908, DOI 10.1021/acs.nanolett.7b05263
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou MX, 2018, EBIOMEDICINE, V35, P345, DOI 10.1016/j.ebiom.2018.08.035
NR 66
TC 4
Z9 4
U1 14
U2 14
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD MAY
PY 2022
VL 12
IS 5
BP 2506
EP 2521
DI 10.1016/j.apsb.2021.10.022
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2C5PW
UT WOS:000810921300005
PM 35646523
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cai, ZY
   Fu, MD
   Liu, K
   Duan, XC
AF Cai, Zi-Yan
   Fu, Meng-Die
   Liu, Ke
   Duan, Xuan-Chu
TI Therapeutic effect of Keap1-Nrf2-ARE pathway-related drugs on
   age-related eye diseases through anti-oxidative stress
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE oxidative stress; Keap1-Nrf2-ARE pathway; age-related eye diseases
ID NF-KAPPA-B; POLYPHENOL-ENRICHED FRACTION; UNFOLDED PROTEIN RESPONSE;
   PIGMENT EPITHELIAL-CELLS; RETINAL GANGLION-CELLS; OXIDATIVE STRESS;
   DIABETIC-RETINOPATHY; CALCIUM DOBESILATE; MOLECULAR-MECHANISMS; IN-VITRO
AB Age-related eye diseases, including cataract, glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD), are the leading causes of vision loss in the world. Several studies have shown that the occurrence and development of these diseases have an important relationship with oxidative stress in the eye. The Keap1-Nrf2-ARE pathway is a classical pathway that resists oxidative stress and inflammation in the body. This pathway is also active in the development of age-related eye diseases. A variety of drugs have been shown to treat age-related eye diseases through the Keap1-Nrf2-ARE (Kelch-like ECH-Associating protein 1- nuclear factor erythroid 2 related factor 2-antioxidant response element) pathway. This review describes the role of oxidative stress in the development of age-related eye diseases, the function and regulation of the Keap1-Nrf2-ARE pathway, and the therapeutic effects of drugs associated with this pathway on age-related eye diseases.
C1 [Cai, Zi-Yan; Fu, Meng-Die; Liu, Ke; Duan, Xuan-Chu] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410011, Hunan, Peoples R China.
   [Duan, Xuan-Chu] Changsha Aier Eye Hosp, Dept Ophthalmol, Changsha 410011, Hunan, Peoples R China.
C3 Central South University
RP Duan, XC (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410011, Hunan, Peoples R China.
EM duanxchu@csu.edu.cn
FU National Natural Science Foundation of China [81970801, 81670859];
   Natural Science Foundation of Hunan Province [2019JJ40001]; Key Project
   of Changsha Science and Technology Bureau [kh1801229]
FX Supported by National Natural Science Foundation of China (No.81970801;
   No.81670859); Natural Science Foundation of Hunan Province (No.
   2019JJ40001); Key Project of Changsha Science and Technology Bureau (No.
   kh1801229).
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Alamri A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061387
   Angapelly S, 2018, CHEMMEDCHEM, V13, P1165, DOI 10.1002/cmdc.201800180
   Arora R, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0550-2
   Arumugam B, 2019, MOL VIS, V25, P47
   Babizhayev MA, 2016, AM J THER, V23, pE98, DOI 10.1097/MJT.0b013e3181ea31ff
   Bagnis A, 2012, DIGEST LIVER DIS, V44, P963, DOI 10.1016/j.dld.2012.05.009
   Barros MP, 2018, J AGR FOOD CHEM, V66, P5733, DOI 10.1021/acs.jafc.8b00866
   Bizrah M, 2019, OPHTHALMOL THER, V8, P137, DOI 10.1007/s40123-019-0165-y
   Bogdanov P, 2017, J DIABETES COMPLICAT, V31, P1481, DOI 10.1016/j.jdiacomp.2017.07.009
   Bucolo C, 2009, INVEST OPHTH VIS SCI, V50, P3846, DOI 10.1167/iovs.08-3328
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Calderon GD, 2017, EYE, V31, P1122, DOI 10.1038/eye.2017.64
   Chen RY, 2019, PHARMACOL RES, V143, P33, DOI 10.1016/j.phrs.2019.03.002
   Chen XL, 2006, AM J PHYSIOL-HEART C, V290, pH1862, DOI 10.1152/ajpheart.00651.2005
   Cheng JT, 2017, EXP THER MED, V14, P791, DOI 10.3892/etm.2017.4543
   Cheng Y, 2019, DIABETOLOGIA, V62, P1074, DOI 10.1007/s00125-019-4838-9
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Choi JI, 2019, MOL VIS, V25, P118
   Choi M, 2019, TOXICOL IN VITRO, V61, DOI 10.1016/j.tiv.2019.104602
   Choi RJ, 2014, REDOX BIOL, V2, P504, DOI 10.1016/j.redox.2014.02.001
   Copple IM, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8165458
   Deshmukh Prashant, 2017, Biophys Rev, V9, P41, DOI 10.1007/s12551-016-0244-4
   Dinkova-Kostova AT, 2017, NEURODEGENER DIS MAN, V7, P97, DOI 10.2217/nmt-2017-0011
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Du SS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0224251
   Du ZJ, 2019, J CELL BIOCHEM, V120, P10413, DOI 10.1002/jcb.28326
   Durasevic S, 2019, FOOD FUNCT, V10, P2114, DOI [10.1039/c9fo00107g, 10.1039/C9FO00107G]
   Eggler AL, 2008, MOL NUTR FOOD RES, V52, pS84, DOI 10.1002/mnfr.200700249
   Fan YZ, 2020, CHEM-BIOL INTERACT, V324, DOI 10.1016/j.cbi.2020.109086
   de Vega RG, 2018, METALLOMICS, V10, P83, DOI [10.1039/c7mt00209b, 10.1039/C7MT00209B]
   Gothai S, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080461
   Gu LH, 2020, ENVIRON TOXICOL, V35, P738, DOI 10.1002/tox.22908
   Hassanein EHM, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1675957
   Hassanein EHM, 2018, FOOD CHEM TOXICOL, V116, P152, DOI 10.1016/j.fct.2018.03.041
   He JN, 2019, MOL NEUROBIOL, V56, P6586, DOI 10.1007/s12035-019-1559-5
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P1447, DOI 10.1167/iovs.07-1361
   Higashi K, 2019, PHARMACOLOGY, V103, P212, DOI 10.1159/000496055
   Himori N, 2013, J NEUROCHEM, V127, P669, DOI 10.1111/jnc.12325
   Hou YA, 2019, J AGR FOOD CHEM, V67, P8227, DOI 10.1021/acs.jafc.9b02680
   Hu LF, 2016, TOXICOL IN VITRO, V37, P97, DOI 10.1016/j.tiv.2016.09.002
   Huang JL, 2019, AGING-US, V11, P8542, DOI 10.18632/aging.102337
   Huang YY, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102-865020190010000003
   Hur W, 2011, CURR OPIN CHEM BIOL, V15, P162, DOI 10.1016/j.cbpa.2010.12.009
   Jafarey M, 2014, IRAN J KIDNEY DIS, V8, P46
   Jin HL, 2017, J FUNCT FOODS, V39, P28, DOI 10.1016/j.jff.2017.10.009
   Kesarwani P, 2013, ANTIOXID REDOX SIGN, V18, P1497, DOI 10.1089/ars.2011.4073
   Khan M, 2020, FOOD RES INT, V130, DOI 10.1016/j.foodres.2019.108933
   Kim CS, 2016, BIOMOL THER, V24, P178, DOI 10.4062/biomolther.2015.101
   Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385
   Koriyama Y, 2013, BRAIN RES, V1499, P145, DOI 10.1016/j.brainres.2012.12.041
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kowluru RA, 2017, FREE RADICAL BIO MED, V103, P155, DOI 10.1016/j.freeradbiomed.2016.12.030
   Kowluru RA, 2016, METABOLISM, V65, P1570, DOI 10.1016/j.metabol.2016.07.012
   Lampiasi N, 2018, IMMUNOBIOLOGY, V223, P349, DOI 10.1016/j.imbio.2017.10.046
   Lau M, 2019, EUR J PHARM SCI, V138, DOI 10.1016/j.ejps.2019.105038
   Leal EC, 2010, DIABETES, V59, P2637, DOI 10.2337/db09-1421
   Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025
   Lee J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226769
   Lenox AR, 2015, NEUROSCI LETT, V609, P30, DOI 10.1016/j.neulet.2015.10.019
   Li B, 2019, J CELL PHYSIOL, V234, P561, DOI 10.1002/jcp.26769
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Li T, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6069390
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Linnewiel-Hermoni K, 2014, FREE RADICAL BIO MED, V75, P105, DOI 10.1016/j.freeradbiomed.2014.07.024
   Liu HW, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3862509
   Liu J, 2019, LIFE SCI, V221, P348, DOI 10.1016/j.lfs.2019.02.023
   Liu L, 2020, NEURAL REGEN RES, V15, P1526, DOI 10.4103/1673-5374.274349
   Liu LH, 2017, IRAN J BASIC MED SCI, V20, P813, DOI 10.22038/IJBMS.2017.9017
   Liu QY, 2017, SCI REP-UK, V7, DOI 10.1038/srep41854
   Liu XF, 2017, AGING CELL, V16, P934, DOI 10.1111/acel.12645
   Liu YL, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00389
   Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396
   Magesh S, 2012, MED RES REV, V32, P687, DOI 10.1002/med.21257
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mathew MC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004567.pub2
   Maurya N, 2016, CELL BIOL INT, V40, P107, DOI 10.1002/cbin.10561
   McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200
   McMonnies Charles W, 2017, J Optom, V10, P71, DOI 10.1016/j.optom.2016.02.003
   Mooranian A, 2020, NANOTECHNOL SCI APPL, V13, P1, DOI 10.2147/NSA.S212323
   Mooranian A, 2019, PHARM DEV TECHNOL, V24, P1272, DOI 10.1080/10837450.2019.1665069
   Nakagawa S, 2020, MOL NEUROBIOL, V57, P1594, DOI 10.1007/s12035-019-01844-x
   Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9
   Nielsen FS, 2008, EUR J PHARM BIOPHARM, V69, P553, DOI 10.1016/j.ejpb.2007.12.020
   Njau F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0218494
   Ozal SA, 2018, CURR EYE RES, V43, P1169, DOI 10.1080/02713683.2018.1481517
   Periyasamy P, 2017, PROG RETIN EYE RES, V60, P1, DOI 10.1016/j.preteyeres.2017.08.003
   Prasanna G, 2016, EUR J PHARMACOL, V787, P47, DOI 10.1016/j.ejphar.2016.03.003
   Qi HY, 2012, NEUROPHARMACOLOGY, V62, P1659, DOI 10.1016/j.neuropharm.2011.11.012
   Qin T, 2019, INT J BIOL MACROMOL, V125, P534, DOI 10.1016/j.ijbiomac.2018.12.025
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Raghunath A, 2019, BASIC CLIN PHARMACOL, V125, P259, DOI 10.1111/bcpt.13222
   Ramirez-Perez G, 2020, MITOCHONDRION, V52, P212, DOI 10.1016/j.mito.2020.04.004
   Robles-Rivera RR, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3096470
   Rodriguez-Concepcion M, 2018, PROG LIPID RES, V70, P62, DOI 10.1016/j.plipres.2018.04.004
   Sacca SC, 2020, ALTEX-ALTERN ANIM EX, V37, P265, DOI 10.14573/altex.1909262
   Sacca SC, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020239
   Sadik NAH, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13230
   Sahin K, 2019, BIOCHEM BIOPH RES CO, V516, P163, DOI 10.1016/j.bbrc.2019.06.032
   Satoh Takumi, 2017, F1000Res, V6, P2138, DOI 10.12688/f1000research.12111.1
   Shah SZA, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00310
   Shao ZQ, 2021, NEURAL REGEN RES, V16, P1044, DOI 10.4103/1673-5374.300725
   Sheu SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213932
   Shi Q, 2020, J BIOCHEM MOL TOXIC, V34, DOI 10.1002/jbt.22489
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   Silva MD, 2018, MOLECULES, V23, DOI 10.3390/molecules23071803
   Sun JF, 2018, EXP THER MED, V15, P719, DOI 10.3892/etm.2017.5435
   Taira J, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8120621
   Tale S, 2017, MOL PHARMACEUT, V14, P4121, DOI 10.1021/acs.molpharmaceut.7b00458
   Testa CM, 2005, MOL BRAIN RES, V134, P109, DOI 10.1016/j.molbrainres.2004.11.007
   Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006
   Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   Ursini F, 2016, REDOX BIOL, V8, P205, DOI 10.1016/j.redox.2016.01.010
   Uruno A, 2011, NITRIC OXIDE-BIOL CH, V25, P153, DOI 10.1016/j.niox.2011.02.007
   Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Wan HQ, 2019, PHYTOMEDICINE, V57, P282, DOI 10.1016/j.phymed.2018.12.044
   Wan WJ, 2019, J CATARACT REFR SURG, V45, P1717, DOI 10.1016/j.jcrs.2019.07.029
   Wang HL, 2021, NEURAL REGEN RES, V16, P1011, DOI 10.4103/1673-5374.300454
   Wang X, 2019, INT OPHTHALMOL, V39, P2303, DOI 10.1007/s10792-018-01071-8
   Wang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.265
   Wang YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160309
   Wang Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00886
   Waugh DT, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050856
   Wei XD, 2020, PHYTOMEDICINE, V76, DOI 10.1016/j.phymed.2020.153257
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xia HK, 2015, INVEST OPHTH VIS SCI, V56, P6638, DOI 10.1167/iovs.15-17301
   Xiao X, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1284804
   Yakushiji E, 2016, ARTERIOSCL THROM VAS, V36, P591, DOI 10.1161/ATVBAHA.115.306376
   Yang QS, 2020, GEN PHYSIOL BIOPHYS, V39, P169, DOI 10.4149/gpb_2019058
   Yang Y, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.922519
   Yao HK, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127490
   Yarmohammadi F, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22683
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yoshida M, 2005, EUR J PHARMACOL, V513, P159, DOI 10.1016/j.ejphar.2005.03.004
   Yu JN, 2019, CHEM-BIOL INTERACT, V300, P151, DOI 10.1016/j.cbi.2019.01.018
   Yu MZ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070842
   Zhang Q, 2010, TOXICOL APPL PHARM, V244, P84, DOI 10.1016/j.taap.2009.08.018
   Zhao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128502
   Zheng HN, 2019, PHYTOTHER RES, V33, P1150, DOI 10.1002/ptr.6310
   Zhou XX, 2019, INT OPHTHALMOL, V39, P2833, DOI 10.1007/s10792-019-01130-8
   Zhu BB, 2018, MOL MED REP, V17, P1289, DOI 10.3892/mmr.2017.7935
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
   Zhuang Q, 2019, CURR PROTEIN PEPT SC, V20, P844, DOI 10.2174/1389203720666190305165722
NR 147
TC 5
Z9 5
U1 6
U2 23
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD AUG 18
PY 2021
VL 14
IS 8
BP 1260
EP 1273
DI 10.18240/ijo.2021.08.19
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TY4LS
UT WOS:000683756800019
PM 34414093
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Vega, R
   Carretero, M
   Bonilla, LL
AF Vega, Rocio
   Carretero, Manuel
   Bonilla, Luis L.
TI Anomalous Angiogenesis in Retina
SO BIOMEDICINES
LA English
DT Article
DE cellular potts model; exudative age-related macular degeneration;
   angiogenesis; notch signaling pathway; systems biology
AB Age-related macular degeneration (AMD) may cause severe loss of vision or blindness, particularly in elderly people. Exudative AMD is characterized by the angiogenesis of blood vessels growing from underneath the macula, crossing the blood-retina barrier (which comprises Bruch's membrane (BM) and the retinal pigmentation epithelium (RPE)), leaking blood and fluid into the retina and knocking off photoreceptors. Here, we simulate a computational model of angiogenesis from the choroid blood vessels via a cellular Potts model, as well as BM, RPE cells, drusen deposits and photoreceptors. Our results indicate that improving AMD may require fixing the impaired lateral adhesion between RPE cells and with BM, as well as diminishing Vessel Endothelial Growth Factor (VEGF) and Jagged proteins that affect the Notch signaling pathway. Our numerical simulations suggest that anti-VEGF and anti-Jagged therapies could temporarily halt exudative AMD while addressing impaired cellular adhesion, which could be more effective over a longer time-span.
C1 [Vega, Rocio; Carretero, Manuel; Bonilla, Luis L.] Univ Carlos III Madrid, Gregorio Millan Inst Fluid Dynam Nanosci & Ind Ma, Dept Math, Leganes 28911, Spain.
C3 Universidad Carlos III de Madrid
RP Bonilla, LL (通讯作者)，Univ Carlos III Madrid, Gregorio Millan Inst Fluid Dynam Nanosci & Ind Ma, Dept Math, Leganes 28911, Spain.
EM rvega@ing.uc3m.es; manuel.carretero@uc3m.es; bonilla@ing.uc3m.es
RI Bonilla, Luis L./B-6658-2008; CARRETERO CERRAJERO, MANUEL/K-3545-2017
OI Bonilla, Luis L./0000-0002-7687-8595; VEGA, ROCIO/0000-0002-1878-6721;
   CARRETERO CERRAJERO, MANUEL/0000-0002-3517-4241
FU FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal
   de Investigacion [MTM2017-84446-C2-2-R]
FX This research was funded by FEDER/Ministerio de Ciencia, Innovacion y
   Universidades-Agencia Estatal de Investigacion grant number
   MTM2017-84446-C2-2-R.
CR Arima S, 2011, DEVELOPMENT, V138, P4763, DOI 10.1242/dev.068023
   Bai HX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182080
   Bauer AL, 2007, BIOPHYS J, V92, P3105, DOI 10.1529/biophysj.106.101501
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Boareto M, 2015, P NATL ACAD SCI USA, V112, pE3836, DOI 10.1073/pnas.1511814112
   Bonilla LL, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008407
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Cheng DL, 2017, CURR EYE RES, V42, P334, DOI 10.1080/02713683.2016.1270326
   Coscas G., 2015, ATLAS OCT ANGIOGRAPH
   Davies AE, 2020, INTERFACE FOCUS, V10, DOI 10.1098/rsfs.2019.0132
   Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227
   Figg W.D., 2008, INTEGRATIVE APPROACH
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Franco CA, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002125
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Gagliardi G, 2019, PROG RETIN EYE RES, V71, P1, DOI 10.1016/j.preteyeres.2019.03.001
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gebala V, 2016, NAT CELL BIOL, V18, P443, DOI 10.1038/ncb3320
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   GRANER F, 1992, PHYS REV LETT, V69, P2013, DOI 10.1103/PhysRevLett.69.2013
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jemni-Damer N, 2020, J NEURAL ENG, V17, DOI 10.1088/1741-2552/abb9c0
   Jolly MK, 2015, NEW J PHYS, V17, DOI 10.1088/1367-2630/17/5/055021
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Laforest T, 2020, NAT PHOTONICS, V14, P439, DOI 10.1038/s41566-020-0608-y
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Mantzaris NV, 2004, J MATH BIOL, V49, P111, DOI 10.1007/s00285-003-0262-2
   Maya-Vetencourt JF, 2017, NAT MATER, V16, P681, DOI [10.1038/NMAT4874, 10.1038/nmat4874]
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Page DJ, 2019, CELL REP, V27, P3139, DOI 10.1016/j.celrep.2019.05.052
   Parolini B., 2020, MACULAR SURG, P401
   Poh S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63063-y
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Ramos JRD, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.012408
   Roberts PA, 2016, PROG RETIN EYE RES, V53, P48, DOI 10.1016/j.preteyeres.2016.04.001
   Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863
   Selvam S, 2018, PROG RETIN EYE RES, V63, P1, DOI 10.1016/j.preteyeres.2017.11.001
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Sierra RA, 2017, CANCER RES, V77, P5628, DOI 10.1158/0008-5472.CAN-17-0357
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Stieger K, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P265, DOI 10.1007/978-3-030-28384-1_15
   Sugihara K, 2015, CELL REP, V13, P1814, DOI 10.1016/j.celrep.2015.10.051
   Szymborska A, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029223
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03212-0
   Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x
   van Oers RFM, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003774
   Vega R, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1006919
   West J.W., 2019, U.S. Patent, Patent No. [10,301,380, 10301380]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhou MC, 2020, IEEE T IND ELECTRON, V67, P6617, DOI 10.1109/TIE.2019.2937041
NR 63
TC 2
Z9 2
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD FEB
PY 2021
VL 9
IS 2
AR 224
DI 10.3390/biomedicines9020224
PG 20
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA QM9XT
UT WOS:000622126800001
PM 33671578
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Wolf, A
   Herb, M
   Schramm, M
   Langmann, T
AF Wolf, Anne
   Herb, Marc
   Schramm, Michael
   Langmann, Thomas
TI The TSPO-NOX1 axis controls phagocyte-triggered pathological
   angiogenesis in the eye
SO NATURE COMMUNICATIONS
LA English
DT Article
ID NADPH OXIDASE 2; BENZODIAZEPINE-RECEPTOR; TRANSLOCATOR PROTEIN; MACULAR
   DEGENERATION; REACTIVE OXYGEN; MOUSE MODEL; MICROGLIAL ACTIVATION; TSPO
   LIGAND; REGENERATION; CALCIUM
AB Aberrant immune responses including reactive phagocytes are implicated in the etiology of age-related macular degeneration (AMD), a major cause of blindness in the elderly. The translocator protein (18kDa) (TSPO) is described as a biomarker for reactive gliosis, but its biological functions in retinal diseases remain elusive. Here, we report that tamoxifen-induced conditional deletion of TSPO in resident microglia using Cx3cr1(CreERT2):TSPOfl/fl mice or targeting the protein with the synthetic ligand XBD173 prevents reactivity of phagocytes in the laser-induced mouse model of neovascular AMD. Concomitantly, the subsequent neoangiogenesis and vascular leakage are prevented by TSPO knockout or XBD173 treatment. Using different NADPH oxidase-deficient mice, we show that TSPO is a key regulator of NOX1-dependent neurotoxic ROS production in the retina. These data define a distinct role for TSPO in retinal phagocyte reactivity and highlight the protein as a drug target for immunomodulatory and antioxidant therapies for AMD.
C1 [Wolf, Anne; Langmann, Thomas] Univ Cologne, Lab Expt Immunol Eye, Dept Ophthalmol, Fac Med, D-50931 Cologne, Germany.
   [Wolf, Anne; Langmann, Thomas] Univ Hosp Cologne, D-50931 Cologne, Germany.
   [Herb, Marc; Schramm, Michael] Inst Med Microbiol Immunol & Hyg, D-50931 Cologne, Germany.
   [Langmann, Thomas] Univ Cologne, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany.
C3 University of Cologne; University of Cologne; University of Cologne;
   University of Cologne
RP Langmann, T (通讯作者)，Univ Cologne, Lab Expt Immunol Eye, Dept Ophthalmol, Fac Med, D-50931 Cologne, Germany.; Langmann, T (通讯作者)，Univ Hosp Cologne, D-50931 Cologne, Germany.; Langmann, T (通讯作者)，Univ Cologne, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany.
EM thomas.langmann@uk-koeln.de
RI Herb, Marc/AAF-2341-2021
OI Herb, Marc/0000-0002-7533-0288; Wolf, Anne/0000-0003-2551-9821; Schramm,
   Michael/0000-0003-0226-9129
FU Deutsche Forschungsgemeinschaft [FOR2240]; Velux Foundation; Pro Retina
   Foundation; Erhard Ruther Foundation
FX This research was supported by the Deutsche Forschungsgemeinschaft
   (FOR2240, project 6), the Velux Foundation, the Pro Retina Foundation,
   and the Erhard Ruther Foundation. We thank C. Bismar, U. Esendik, U.
   Karow, and E. Scheiffert for technical assistance. We also thank J.
   Muhlnikel, M. Retzlaff, C. Strassner, A. Jansen, and A. Lierz for
   support in animal caretaking. We thank Prof Marco Prinz (Institute of
   Neuropathology and BIOSS Center for Biological Signaling Studies,
   University of Freiburg, Germany) for providing Cx3cr1<SUP>CreERT2</SUP>
   mice.
CR Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Altenhofer S, 2015, ANTIOXID REDOX SIGN, V23, P406, DOI 10.1089/ars.2013.5814
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Appukuttan B, 2018, CLIN EXP OPHTHALMOL, V46, P652, DOI 10.1111/ceo.13155
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bader S, 2019, PSYCHONEUROENDOCRINO, V106, P65, DOI 10.1016/j.psyneuen.2019.03.029
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013
   Berridge MJ, 2012, BIOCHEM SOC T, V40, P297, DOI 10.1042/BST20110766
   Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127
   Carnesecchi S, 2011, ANTIOXID REDOX SIGN, V15, P607, DOI 10.1089/ars.2010.3829
   Chan EC, 2016, CLIN SCI, V130, P683, DOI 10.1042/CS20150103
   Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8
   Cheng L, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1289-z
   Daugherty DJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22556
   Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124
   Delavoie F, 2003, BIOCHEMISTRY-US, V42, P4506, DOI 10.1021/bi0267487
   Demaurex N, 2009, BBA-BIOENERGETICS, V1787, P1383, DOI 10.1016/j.bbabio.2008.12.012
   Diaz F, 2012, MOL CELL BIOL, V32, P415, DOI 10.1128/MCB.06051-11
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gatliff J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.186
   Gatliff J, 2014, AUTOPHAGY, V10, P2279, DOI 10.4161/15548627.2014.991665
   Gavazzi G, 2006, FEBS LETT, V580, P497, DOI 10.1016/j.febslet.2005.12.049
   Girard C, 2012, J NEUROENDOCRINOL, V24, P71, DOI 10.1111/j.1365-2826.2011.02215.x
   Girard C, 2009, GLIA, V57, pS159
   Gong J, 2019, J NEUROSCI, V39, P3752, DOI 10.1523/JNEUROSCI.2070-18.2019
   Gordeeva AV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1077, DOI 10.1023/A:1026398310003
   Guilarte TR, 2016, TRENDS PHARMACOL SCI, V37, P334, DOI 10.1016/j.tips.2016.02.008
   Haslund-Vinding J, 2017, BRIT J PHARMACOL, V174, P1733, DOI 10.1111/bph.13425
   Herb M, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aar5926
   Hou LY, 2018, REDOX BIOL, V14, P600, DOI 10.1016/j.redox.2017.11.010
   Issop L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152919
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Lambeth JD, 2014, ANNU REV PATHOL-MECH, V9, P119, DOI 10.1146/annurev-pathol-012513-104651
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Liu GJ, 2017, CELL CYCLE, V16, P436, DOI 10.1080/15384101.2017.1281477
   Luckoff A, 2017, NAT PROTOC, V12, P1136, DOI 10.1038/nprot.2017.032
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Ma MW, 2018, FREE RADICAL BIO MED, V117, P66, DOI 10.1016/j.freeradbiomed.2018.01.031
   Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609
   Mages K, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1424-5
   Milenkovic VM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133359
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nakano Y, 2008, J CLIN INVEST, V118, P1176, DOI 10.1172/JCI33835
   Papadopoulos V, 2006, NEUROSCIENCE, V138, P749, DOI 10.1016/j.neuroscience.2005.05.063
   Papadopoulos V, 2009, EXP NEUROL, V219, P53, DOI 10.1016/j.expneurol.2009.04.016
   POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Sileikyte J, 2014, J BIOL CHEM, V289, P13769, DOI 10.1074/jbc.M114.549634
   Thai PN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34451-2
   Tu LN, 2014, J BIOL CHEM, V289, P27444, DOI 10.1074/jbc.M114.578286
   Wang J, 2017, FREE RADICAL BIO MED, V113, P119, DOI 10.1016/j.freeradbiomed.2017.09.017
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   WHALIN ME, 1994, J RECEPTOR RES, V14, P217, DOI 10.3109/10799899409066033
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yokota H, 2011, INVEST OPHTH VIS SCI, V52, P8123, DOI 10.1167/iovs.11-8318
   Zeng H, 2014, NEUROSCIENCE, V275, P54, DOI 10.1016/j.neuroscience.2014.05.065
   Zeng XZ, 2018, CELL PHYSIOL BIOCHEM, V50, P783, DOI 10.1159/000494243
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
NR 65
TC 29
Z9 29
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 1
PY 2020
VL 11
IS 1
AR 2709
DI 10.1038/s41467-020-16400-8
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MC0JC
UT WOS:000542983000001
PM 32483169
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Huang, JL
   Gharib, M
AF Huang, Jinglin
   Gharib, Morteza
TI Thermal Effects on Fluid Mixing in the Eye
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Vitreous; Age-related macular degeneration (AMD); Particle imaging
   velocimetry (PIV); Drug delivery; Intravitreal injections;
   Thermally-induced convection; Flow in the human eye
AB Age-related macular degeneration (AMD) is the leading cause of central vision loss in the developed world. Wet AMD can be managed through serial intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents. However, sometimes the treatment is ineffective. Given that the half-life of the drug is limited, inefficient mixing of the injected drug in the vitreous chamber of the eye may contribute to the ineffectiveness. Here, we introduce thermal heating as a means of enhancing the mixing-process in the vitreous chamber and investigate parameters that potentially influence its effectiveness. Our in vitro studies reveal the importance of the heating location on the eye. A significant increase in the mixing and delivery of drugs to the targeted area (the macula) could be achieved by placing heating pads to induce a current, against gravity, in the vitreous. The presented results can potentially help in the development of a better strategy for intravitreal injection, subsequently improving the quality of patient care.
C1 [Huang, Jinglin; Gharib, Morteza] CALTECH, Dept Med Engn, 1200 E Calif Blvd,MC 105-50, Pasadena, CA 91125 USA.
C3 California Institute of Technology
RP Huang, JL (通讯作者)，CALTECH, Dept Med Engn, 1200 E Calif Blvd,MC 105-50, Pasadena, CA 91125 USA.
EM alicehuang0904@gmail.com
OI Huang, Jinglin/0000-0003-0760-4950; Gharib, Mohammed/0000-0001-9611-1693
FU Charyk Family Foundation
FX We thank the Charyk Family Foundation for the funding support for this
   work. We are grateful to Alessio Tamborini for his support in the
   refractive index experiment, and to Dr. Cong Wang and Dr. Chris Roh for
   productive discussions.
CR Balazs EA, 1994, FUNCTIONAL ANATOMY V, P1
   Bonfiglio A, 2013, PHYS MED BIOL, V58, P1969, DOI 10.1088/0031-9155/58/6/1969
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Dewhirst MW, 2003, INT J HYPERTHER, V19, P267, DOI 10.1080/0265673031000119006
   Eisner G, 1994, CLIN ANATOMY VITREOU, P17
   Haddrill M., WHAT IS AGE RELATED
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   LOCKE JOHN C., 1965, TRANS AMER OPHTHALMOL SOC, V63, P129
   Maurice D.M., 1984, OCULAR PHARMACOKINET, P16
   Murthy KR, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-29
   Phillips R., 2015, CELL BIOL NUMBERS
   Purves D, 2001, NEUROSCIENCE, P2
   Remington LA, 2011, CLIN ANATOMY VISUAL
   Scott KS, 1999, MED SCI LAW, V39, P77, DOI 10.1177/002580249903900114
   Shah SS, 2010, EXPERT REV OPHTHALMO, V5, P75, DOI 10.1586/EOP.09.70
   Stocchino A, 2010, PHYS MED BIOL, V55, P453, DOI 10.1088/0031-9155/55/2/008
   Wessapan T, 2015, NUMER HEAT TR A-APPL, V68, P566, DOI 10.1080/10407782.2014.986393
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wilson M. E., 2013, GIVE INTRAVITREAL IN
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yorston David, 2014, Community Eye Health, V27, P44
NR 22
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0090-6964
EI 1573-9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD JAN
PY 2021
VL 49
IS 1
BP 251
EP 261
DI 10.1007/s10439-020-02534-9
EA MAY 2020
PG 11
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA PM7II
UT WOS:000556461300001
PM 32458221
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yang, X
   Zhao, L
   Campos, MM
   Abu-Asab, M
   Ortolan, D
   Hotaling, N
   Bharti, K
   Wong, WT
AF Yang, Xiao
   Zhao, Lian
   Campos, Maria M.
   Abu-Asab, Mones
   Ortolan, Davide
   Hotaling, Nathan
   Bharti, Kapil
   Wong, Wai T.
TI CSF1R blockade induces macrophage ablation and results in mouse
   choroidal vascular atrophy and RPE disorganization
SO ELIFE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; DENDRITIC CELLS; BRUCHS MEMBRANE; HUMAN EYES; AGE;
   EXPRESSION; CHORIOCAPILLARIS; MICROGLIA
AB The choroid, which provides vascular supply to the outer retina, demonstrates progressive degeneration in aging and age-related macular degeneration (AMD). However mechanisms that maintain or compromise choroidal homeostasis are obscure. We discovered that the ablation of choroidal macrophages via CSF1R blockade was associated with choroidal vascular atrophy and retinal pigment epithelial (RPE) changes including structural disruption, downregulation of visual cycle genes, and altered angiogenic factor expression. Suspending CSF1R blockade following ablation enabled spontaneous macrophage regeneration, which fully restored original macrophage distributions and morphologies. Macrophage regeneration was accompanied by arrested vascular degeneration and ameliorated pathological RPE alterations. These findings suggest that choroidal macrophages play a previously unappreciated trophic role in maintaining choroidal vasculature and RPE cells, implicating insufficiency in choroidal macrophage function as a factor in aging- and AMD-associated pathology. Modulating macrophage function may constitute a strategy for the therapeutic preservation of the choroid and RPE in age-related retinal disorders.
C1 [Yang, Xiao; Zhao, Lian; Wong, Wai T.] NEI, Sect Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Campos, Maria M.; Abu-Asab, Mones] NEI, Sect Histopathol, NIH, Bethesda, MD 20892 USA.
   [Ortolan, Davide; Hotaling, Nathan; Bharti, Kapil] NEI, Sect Ocular & Stem Cell Translat Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Sect Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
EM wongw@alum.mit.edu
RI Ortolan, Davide/AFP-8878-2022; Wong, Wai/B-6118-2017
OI Ortolan, Davide/0000-0002-8236-9391; Wong, Wai/0000-0003-0681-4016
FU National Eye Institute
FX National Eye Institute Intramural Research Program Xiao Yang Lian Zhao
   Maria M Campos Mones Abu-Asab Davide Ortolan Nathan Hotaling Kapil
   Bharti; The funders had no role in study design, data collection and
   interpretation, or the decision to submit the work for publication.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Amaral J, 2010, INVEST OPHTH VIS SCI, V51, P1318, DOI 10.1167/iovs.09-4455
   Arnold T, 2013, VASC CELL, V5, DOI 10.1186/2045-824X-5-4
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bhatia SK, 2016, MOL VIS, V22, P898
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Coleman DJ, 2018, OPHTHALMOLOGICA, V240, P45, DOI 10.1159/000486105
   Condren AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053386
   Dagher NN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0366-9
   De Schepper S, 2018, CELL, V175, P400, DOI 10.1016/j.cell.2018.07.048
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040
   Entezari M, 2018, J OPHTHAL VIS RES, V13, P39, DOI 10.4103/jovr.jovr_148_16
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Gattoussi S, 2019, RETINA-J RET VIT DIS, V39, P34, DOI 10.1097/IAE.0000000000002237
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Halder SK, 2019, P NATL ACAD SCI USA, V116, P26029, DOI 10.1073/pnas.1912178116
   Hayashi A, 1999, GRAEF ARCH CLIN EXP, V237, P668, DOI 10.1007/s004170050295
   Huang YB, 2018, NAT NEUROSCI, V21, P530, DOI 10.1038/s41593-018-0090-8
   Huen SC, 2013, AM J PHYSIOL-RENAL, V305, pF477, DOI 10.1152/ajprenal.00624.2012
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jarosz-Biej M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191012
   Jiang HR, 1999, INVEST OPHTH VIS SCI, V40, P3177
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kutty RK, 2016, MOL VIS, V22, P1156
   Kwong KY, 2006, LIFE SCI, V79, P2349, DOI 10.1016/j.lfs.2006.07.040
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   LEWIS B, 2019, BIOMED PHYS ENG EXPR, V5, DOI DOI 10.1016/J.PRETEYERES.2019.100803
   Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   MacDonald KPA, 2010, BLOOD, V116, P3955, DOI 10.1182/blood-2010-02-266296
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   McMenamin PG, 1999, J COMP NEUROL, V405, P553, DOI 10.1002/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Ogilvy AJ, 2014, ULTRASTRUCT PATHOL, V38, P335, DOI 10.3109/01913123.2014.927406
   Pollina EA, 2008, CELL CYCLE, V7, P2056, DOI 10.4161/cc.7.13.6240
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spangenberg E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11674-z
   Spangenberg EE, 2017, BRAIN BEHAV IMMUN, V61, P1, DOI 10.1016/j.bbi.2016.07.003
   Stefater JA, 2011, NATURE, V474, P511, DOI 10.1038/nature10085
   Van Hove H, 2019, NAT NEUROSCI, V22, P1021, DOI 10.1038/s41593-019-0393-4
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang JCC, 2015, MOL VIS, V21, P264
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Yamawaki T, 2016, INVEST OPHTH VIS SCI, V57, P5945, DOI 10.1167/iovs.16-20604
   Zhang CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109683
   Zhang YK, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap8492
NR 77
TC 18
Z9 19
U1 1
U2 2
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD APR 1
PY 2020
VL 9
AR e55564
DI 10.7554/eLife.55564
PG 27
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA LD5FB
UT WOS:000526053600001
PM 32234210
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Batteux, B
   Gras, V
   Mahboud, Y
   Liabeuf, S
   Bennis, Y
   Masmoudi, K
AF Batteux, Benjamin
   Gras, Valerie
   Mahboud, Yanis
   Liabeuf, Sophie
   Bennis, Youssef
   Masmoudi, Kamel
TI Ischaemic colitis associated with intravitreal administration of
   aflibercept: A first case report
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE adverse effect; intravitreal aflibercept; ischaemic colitis;
   pharmacovigilance
ID ARTERIAL THROMBOEMBOLIC EVENTS; ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF
   AGENTS; MACULAR DEGENERATION; ADVERSE EVENTS; INJECTION; SAFETY; DRUGS
AB In patients with age-related macular degeneration (AMD), the intravitreal injection of antivascular endothelial growth factor (anti-VEGF) agents reduces disease progression and choroidal neovascularization. We report on a first case of ischaemic colitis associated with intravitreal injection of the anti-VEGF agent aflibercept in an 80-year-old female patient. Conservative treatment resulted in a favourable clinical outcome. The anti-VEGF agent was discontinued, and the symptoms did not recur. Although the intravitreal injection of anti-VEGF agents has not previously been linked to the occurrence of ischaemic colitis, consideration of aflibercept's pharmacological properties and the chronological relationship between the administration of this anti-VEGF agent and the occurrence of this systemic adverse event are strongly suggestive of a causal relationship in the present case. Although systemic complications have been rarely associated with intravitreal injections of anti-VEGF agents, physicians should be aware that novel adverse events can still occur in AMD patients treated with anti-VEGF agents.
C1 [Batteux, Benjamin; Gras, Valerie; Mahboud, Yanis; Liabeuf, Sophie; Masmoudi, Kamel] CHU Amiens Picardie, Serv Pharmacol Clin, Ctr Reg Pharmacovigilance, Amiens, France.
   [Bennis, Youssef] CHU Amiens Picardie, Serv Pharmacol Clin, Lab Pharmacol, Amiens, France.
   [Liabeuf, Sophie; Bennis, Youssef] Univ Picardie Jules Verne, INSERM, U1088, Amiens, France.
C3 Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU
   Amiens; Picardie Universites; Universite de Picardie Jules Verne (UPJV);
   CHU Amiens; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Picardie Universites; Universite de Picardie Jules Verne
   (UPJV)
RP Batteux, B (通讯作者)，Ctr Biol Humaine, Ctr Reg Pharmacovigilance, Serv Pharmacol Clin, F-80054 Amiens, France.
EM batteux.benjamin@chu-amiens.fr
RI Bennis, Youssef/F-3662-2015; , liabeuf/AFB-7848-2022; Bennis,
   Youssef/ABC-8816-2020
OI Bennis, Youssef/0000-0002-0186-4797; liabeuf, sophie/0000-0001-5384-9006
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Cutroneo PM, 2017, DRUG SAFETY, V40, P1131, DOI 10.1007/s40264-017-0553-y
   European Medicines Agency Eylea, 2017, EYL INN AFL
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Lindquist M, 2008, DRUG INF J, V42, P409, DOI 10.1177/009286150804200501
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Onoda Y, 2015, CASE REP OPHTHALM, V6, P110, DOI 10.1159/000381257
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
NR 20
TC 3
Z9 3
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD APR
PY 2019
VL 85
IS 4
BP 845
EP 848
DI 10.1111/bcp.13853
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HP7UM
UT WOS:000461895700021
PM 30610744
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wei, QQ
   Hu, WN
   Lou, QY
   Yu, J
AF Wei, Qingquan
   Hu, Weinan
   Lou, Qiyang
   Yu, Jing
TI NAD(+) Inhibits the Metabolic Reprogramming of RPE Cells in Early AMD by
   Upregulating Mitophagy
SO DISCOVERY MEDICINE
LA English
DT Article
ID LIGHT-INDUCED PHOTORECEPTOR; MACULAR DEGENERATION; NICOTINAMIDE
   RIBOSIDE; DISEASE; MITOCHONDRIA; CANCER; MODEL; HOMEOSTASIS; ACTIVATION;
   SECONDARY
AB Age-related macular degeneration (AMD) is a leading cause of blindness and is becoming a global crisis, with the number of affected people expected to reach 288 million by 2040 worldwide. Retinal pigment epithelium (RPE) performs a number of highly diverse functions that are essential to maintaining the normal health and function of the retina. Alterations to retinal metabolism and remodeling are an early feature of AMD. The pathology of AMD is associated with mitochondrial dysfunction. Mitophagy is vital to promote a metabolic shift towards glycolysis that is required for cell differentiation. Nicotinamide adenine dinucleotide (NAD(+)) acts as a central metabolic cofactor, plays a pivotal role in regulating cellular metabolism and energy homeostasis, and may aid disease treatment. Therefore, we hypothesized that NAD(+) may restore homeostasis by inducing mitophagy in AMD, thereby reducing the damage caused by metabolic reprogramming. Since NAD(+) has shown promise as a novel and inexpensive cytoprotective agent in the treatment of oxidative stress-related disease, patients with AMD may benefit from NAD(+) treatment.
C1 [Wei, Qingquan; Yu, Jing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
   [Hu, Weinan] Anhui Univ Sci & Technol, Dept Ophthalmol, Huainan 232001, Anhui, Peoples R China.
   [Lou, Qiyang; Yu, Jing] Ninghai First Hosp, Dept Ophthalmol, Ninghai 315600, Zhejiang, Peoples R China.
C3 Tongji University; Anhui University of Science & Technology
RP Yu, J (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.; Lou, QY; Yu, J (通讯作者)，Ninghai First Hosp, Dept Ophthalmol, Ninghai 315600, Zhejiang, Peoples R China.
EM 13777297361@163.com; dryujing@aliyun.com
FU National Natural Science Foundation of China [81470648]; Fundamental
   Research Funds for the Central Universities
FX This work was supported by the National Natural Science Foundation of
   China in 2014 (project number: 81470648) and the Fundamental Research
   Funds for the Central Universities. The authors also thank A.J.E. for
   English editing.
CR Agostini M, 2016, CELL DEATH DIFFER, V23, P1502, DOI 10.1038/cdd.2016.36
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bai S, 2013, EXP EYE RES, V108, P76, DOI 10.1016/j.exer.2012.12.007
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006
   Bogan KL, 2008, ANNU REV NUTR, V28, P115, DOI 10.1146/annurev.nutr.28.061807.155443
   Braidy N, 2013, BRAIN RES, V1537, P267, DOI 10.1016/j.brainres.2013.08.025
   Braidy N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019194
   Carelli V, 2014, NEURON, V84, P1126, DOI 10.1016/j.neuron.2014.11.022
   Cerutti R, 2014, CELL METAB, V19, P1042, DOI 10.1016/j.cmet.2014.04.001
   Chandel NS, 2016, NAT CELL BIOL, V18, P823, DOI 10.1038/ncb3385
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curtin NJ, 2013, MOL ASPECTS MED, V34, P1217, DOI 10.1016/j.mam.2013.01.006
   Ding DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079817
   Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231
   Elhassan YS, 2017, J ENDOCR SOC, V1, P816, DOI 10.1210/js.2017-00092
   Esteban-Martinez L, 2018, AUTOPHAGY, V14, P915, DOI 10.1080/15548627.2017.1332567
   Esteban-Martinez L, 2017, EMBO J, V36, P1688, DOI 10.15252/embj.201695916
   Fakouri N.B., 2018, FEBS J
   Fivenson EM, 2017, NEUROCHEM INT, V109, P202, DOI 10.1016/j.neuint.2017.02.007
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985
   Guarente L, 2014, CELL METAB, V20, P706, DOI 10.1016/j.cmet.2014.10.015
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hsu CP, 2009, CIRC RES, V105, P481, DOI 10.1161/CIRCRESAHA.109.203703
   Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002
   Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Jones BW, 2011, J COMP NEUROL, V519, P2713, DOI 10.1002/cne.22703
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Jun S, 2018, EXP EYE RES
   Khan NA, 2014, EMBO MOL MED, V6, P721, DOI 10.1002/emmm.201403943
   KWAK DH, 2018, AUTOPHAGY, P1
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Liu L, 2014, FUND CLIN PHARMACOL, V28, P180, DOI 10.1111/fcp.12016
   Marc RE, 2008, MOL VIS, V14, P782
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Medkour Y, 2016, AGING-US, V8, P212, DOI 10.18632/aging.100914
   Mericskay M, 2016, ARCH CARDIOVASC DIS, V109, P207, DOI 10.1016/j.acvd.2015.10.004
   Ng SK, 2015, CLIN EXP OPHTHALMOL, V43, P367, DOI 10.1111/ceo.12462
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Peek CB, 2013, SCIENCE, V342, P591, DOI 10.1126/science.1243417
   Picard M, 2013, AM J PHYSIOL-REG I, V304, pR393, DOI 10.1152/ajpregu.00584.2012
   Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200
   Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Schrepfer E, 2016, MOL CELL, V61, P683, DOI 10.1016/j.molcel.2016.02.022
   Sheline CT, 2010, MOL VIS, V16, P2639
   Srivastava S, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0104-7
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Tao K, 2014, DEV NEUROBIOL, V74, P557, DOI 10.1002/dneu.22149
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Verdin E, 2015, SCIENCE, V350, P1208, DOI 10.1126/science.aac4854
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Wu MF, 2014, FREE RADICAL RES, V48, P794, DOI 10.3109/10715762.2014.907889
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Zhang MC, 2019, ANTIOXID REDOX SIGN, V30, P890, DOI 10.1089/ars.2017.7445
   Zhang PJ, 2016, EUR ARCH OTO-RHINO-L, V273, P735, DOI 10.1007/s00405-015-3572-2
   Zhu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26322
NR 70
TC 7
Z9 7
U1 1
U2 6
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD APR-MAY
PY 2019
VL 27
IS 149
BP 189
EP 196
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IT3TE
UT WOS:000482778000002
PM 31361981
DA 2022-11-30
ER

PT J
AU Shu, WT
   Dunaief, JL
AF Shu, Wanting
   Dunaief, Joshua L.
TI Potential Treatment of Retinal Diseases with Iron Chelators
SO PHARMACEUTICALS
LA English
DT Review
DE chelation; iron; retina; age-related macular degeneration (AMD)
ID MACULAR DEGENERATION; ISONICOTINOYL HYDRAZONE; DEFERIPRONE PROTECTS;
   OCULAR TOXICITY; PIGMENTARY DEGENERATION; SYSTEMATIC ANALYSIS;
   LIPID-PEROXIDATION; HANDLING PROTEINS; TRACE-ELEMENTS; BETA-CAROTENE
AB Iron is essential for life, while excess iron can be toxic. Iron generates hydroxyl radical, which is the most reactive free radical, causing oxidative stress. Since iron is absorbed through the diet but not excreted from the body, it accumulates with age in tissues, including the retina, consequently leading to age-related toxicity. This accumulation is further promoted by inflammation. Hereditary diseases such as aceruloplasminemia, Friedreich's ataxia, pantothenate kinase-associated neurodegeneration, and posterior column ataxia with retinitis pigmentosa involve retinal degeneration associated with iron dysregulation. In addition to hereditary causes, dietary or parenteral iron supplementation has been recently reported to elevate iron levels in the retinal pigment epithelium (RPE) and promote retinal degeneration. Ocular siderosis from intraocular foreign bodies or subretinal hemorrhage can also lead to retinopathy. Evidence from mice and humans suggests that iron toxicity may contribute to age-related macular degeneration pathogenesis. Iron chelators can protect photoreceptors and RPE in various mouse models. The therapeutic potential for iron chelators is under investigation.
C1 [Shu, Wanting; Dunaief, Joshua L.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med, 305 Stellar Chance Lab, Philadelphia, PA 19104 USA.
   [Shu, Wanting] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol,Sch Med, Shanghai Key Lab Ocular Fundus Dis,Shanghai Engn, Shanghai 200080, Peoples R China.
C3 University of Pennsylvania; Pennsylvania Medicine; Shanghai Jiao Tong
   University
RP Dunaief, JL (通讯作者)，Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med, 305 Stellar Chance Lab, Philadelphia, PA 19104 USA.
EM shuwanting@sjtu.edu.cn; jdunaief@pennmedicine.upenn.edu
FU NIH [EY015240]; Research to Prevent Blindness; China Scholarship Council
   (CSC) [201706230076]; Paul and Evanina Bell Mackall Foundation Trust;
   FMKirby Foundation; NATIONAL EYE INSTITUTE [P30EY001583] Funding Source:
   NIH RePORTER
FX This research was supported by NIH EY015240, Research to Prevent
   Blindness, the China Scholarship Council (CSC, No. 201706230076), the
   Paul and Evanina Bell Mackall Foundation Trust, and the FMKirby
   Foundation.
CR Abrahao A, 2015, NEUROGENETICS, V16, P151, DOI 10.1007/s10048-015-0439-z
   BENE C, 1989, CLIN NEPHROL, V31, P45
   BENSHACHAR D, 1991, J NEUROCHEM, V57, P1609, DOI 10.1111/j.1471-4159.1991.tb06358.x
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bhoiwala DL, 2015, INVEST OPHTH VIS SCI, V56, P5344, DOI 10.1167/iovs.15-17026
   Bhoiwala DL, 2016, SURV OPHTHALMOL, V61, P33, DOI 10.1016/j.survophthal.2015.08.005
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   BLOOMFIELD SE, 1978, J PEDIAT OPHTH STRAB, V15, P154
   Brittenham GM, 2011, NEW ENGL J MED, V364, P146, DOI 10.1056/NEJMct1004810
   Buss JL, 2003, BBA-GEN SUBJECTS, V1619, P177, DOI 10.1016/S0304-4165(02)00478-6
   Cappellini MD, 2011, BLOOD, V118, P884, DOI 10.1182/blood-2010-11-316646
   Cappellini MD, 2010, HAEMATOL-HEMATOL J, V95, P557, DOI 10.3324/haematol.2009.014696
   Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182/blood-2005-08-3430
   Caro AA, 2015, BBA-GEN SUBJECTS, V1850, P2256, DOI 10.1016/j.bbagen.2015.08.005
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   CIBIS PA, 1959, ARCH OPHTHALMOL-CHIC, V62, P180
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cross AJ, 2003, CANCER RES, V63, P2358
   DAVIES SC, 1983, LANCET, V2, P181
   DECLERCQ SS, 1977, ARCH OPHTHALMOL-CHIC, V95, P1051, DOI 10.1001/archopht.1977.04450060138014
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   DEVIRGILIIS S, 1988, ARCH DIS CHILD, V63, P250, DOI 10.1136/adc.63.3.250
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Fonseca AM, 2003, FREE RADICAL BIO MED, V35, P1404, DOI 10.1016/j.freeradbiomed.2003.08.011
   Fraenkel PG, 2017, MED CLIN N AM, V101, P285, DOI 10.1016/j.mcna.2016.09.005
   Galanello R, 2003, J CLIN PHARMACOL, V43, P565, DOI 10.1177/0091270003253350
   Galanello Renzo, 2007, Ther Clin Risk Manag, V3, P795
   GARTAGANIS S, 1989, AM J OPHTHALMOL, V108, P699, DOI 10.1016/0002-9394(89)90864-7
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gnana-Prakasam JP, 2012, BIOCHEM J, V441, P599, DOI 10.1042/BJ20111148
   Gnana-Prakasam JP, 2009, BIOCHEM J, V424, P243, DOI 10.1042/BJ20090424
   Gnana-Prakasam JP, 2009, BIOCHEM J, V419, P533, DOI 10.1042/BJ20082240
   Grolez G, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0331-3
   Hadziahmetovic M, 2012, TRANSL VIS SCI TECHN, V1, DOI 10.1167/tvst.1.3.2
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001
   HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539
   Haskova P, 2011, FREE RADICAL BIO MED, V50, P537, DOI 10.1016/j.freeradbiomed.2010.12.004
   Hunt RC, 1996, J CELL PHYSIOL, V168, P81, DOI 10.1002/(SICI)1097-4652(199607)168:1<81::AID-JCP10>3.0.CO;2-S
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Jansova H, 2016, TOXICOLOGY, V350, P15, DOI 10.1016/j.tox.2016.03.004
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kassebaum NJ, 2014, BLOOD, V123, P615, DOI 10.1182/blood-2013-06-508325
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KNAVE B, 1969, EXPERIENTIA, V25, P379, DOI 10.1007/BF01899931
   Koeppen AH, 2001, PEDIATR NEUROL, V25, P148, DOI 10.1016/S0887-8994(01)00269-7
   Kumar P, 2017, TOXICOLOGY, V392, P22, DOI 10.1016/j.tox.2017.10.005
   Kuo YM, 2005, HUM MOL GENET, V14, P49, DOI 10.1093/hmg/ddi005
   LAKHANPAL V, 1984, OPHTHALMOLOGY, V91, P443
   Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4
   LI ZL, 1991, CURR EYE RES, V10, P133, DOI 10.3109/02713689109001741
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   LUCKENBACH MW, 1983, AM J OPHTHALMOL, V95, P369, DOI 10.1016/S0002-9394(14)78308-4
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Martin PM, 2006, INVEST OPHTH VIS SCI, V47, P4238, DOI 10.1167/iovs.06-0026
   MASCIULLI L, 1972, AM J OPHTHALMOL, V74, P638, DOI 10.1016/0002-9394(72)90826-4
   McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   NEWELL FW, 1979, AM J OPHTHALMOL, V88, P467, DOI 10.1016/0002-9394(79)90648-2
   Obolensky A, 2011, FREE RADICAL BIO MED, V51, P1482, DOI 10.1016/j.freeradbiomed.2011.07.014
   Onken JE, 2014, TRANSFUSION, V54, P306, DOI 10.1111/trf.12289
   Pietrangelo A, 2005, SEMIN LIVER DIS, V25, P450, DOI 10.1055/s-2005-923316
   Pietrangelo A, 2006, BBA-MOL CELL RES, V1763, P700, DOI 10.1016/j.bbamcr.2006.05.013
   Porter N, 2007, ARCH OPHTHALMOL-CHIC, V125, P273, DOI 10.1001/archopht.125.2.273
   Richardson DR, 2004, ANN NY ACAD SCI, V1012, P326, DOI 10.1196/annals.1306.026
   ROTH AM, 1972, ARCH OPHTHALMOL-CHIC, V87, P507
   Sharma A, 2015, J PHARMACOL PHARMACO, V6, P105, DOI 10.4103/0976-500X.155491
   SHICHI H, 1969, EXP EYE RES, V8, P60, DOI 10.1016/S0014-4835(69)80081-3
   Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866
   SNEED SR, 1988, ARCH OPHTHALMOL-CHIC, V106, P997
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Song DL, 2014, INVEST OPHTH VIS SCI, V55, P4525, DOI 10.1167/iovs.14-14568
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sorcinelli R, 1990, Metab Pediatr Syst Ophthalmol (1985), V13, P23
   Sterba M, 2007, TOXICOLOGY, V235, P150, DOI 10.1016/j.tox.2007.03.020
   Stevens GA, 2013, LANCET GLOB HEALTH, V1, pE16, DOI 10.1016/S2214-109X(13)70001-9
   TALAMO JH, 1985, OPHTHALMOLOGY, V92, P1675
   Ugarte M, 2012, METALLOMICS, V4, P1245, DOI 10.1039/c2mt20157g
   Vadhan-Raj S, 2014, AM J HEMATOL, V89, P7, DOI 10.1002/ajh.23582
   VanOrden HE, 2006, ANN PHARMACOTHER, V40, P1110, DOI 10.1345/aph.1G566
   Velasco-Sanchez D, 2011, CEREBELLUM, V10, P1, DOI 10.1007/s12311-010-0212-7
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Xu XY, 2004, ANN NY ACAD SCI, V1012, P299, DOI 10.1196/annals.1306.024
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yang L, 2012, BBA-MOL BASIS DIS, V1822, P500, DOI 10.1016/j.bbadis.2011.12.004
   YOUSSEF TA, 2002, INVEST OPHTH VIS S2, V43
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao LL, 2014, AM J PATHOL, V184, P2862, DOI 10.1016/j.ajpath.2014.07.008
   Zheng HL, 2005, BIOCHEM PHARMACOL, V70, P1642, DOI 10.1016/j.bcp.2005.09.003
   Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572
   Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
NR 103
TC 22
Z9 22
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD DEC
PY 2018
VL 11
IS 4
AR 112
DI 10.3390/ph11040112
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HH3NN
UT WOS:000455626400023
PM 30360383
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ryu, SJ
   Kang, MH
   Seong, M
   Cho, H
   Shin, YU
AF Ryu, So Jung
   Kang, Min Ho
   Seong, Mincheol
   Cho, Heeyoon
   Shin, Yong Un
TI Anterior scleritis following intravitreal injections in a patient with
   rheumatoid arthritis A case report
SO MEDICINE
LA English
DT Article
DE intravitreal injection; rheumatoid arthritis; scleritis
ID INDUCED NECROTIZING SCLERITIS; CATARACT-EXTRACTION; SURGERY; DISEASE;
   INFLAMMATION
AB Rationale: Surgically induced scleritis is a rare complication following ophthalmologic surgery such as cataract surgery, pterygium excision, strabismus surgery, and retinal detachment repair. Rheumatoid arthritis (RA) is the connective tissue disease most commonly associated with scleritis.
   Patient concerns: A 70-year-old woman visited our clinic with complaint of visual disturbance, ocular pain, and conjunctival injection in her right eye of 1 month's duration. She had a stable state of rheumatoid factor positive RA and had a history of multiple intravitreal injections placed in the symptomatic right eye due to age-related macular degeneration.
   Diagnoses: Anterior scleritis induced by multiple intravitreal injections.
   Interventions: Topical and systemic steroids were administered.
   Outcomes: Her symptoms and signs were relieved and no significant recurrence has been occurred with the maintenance of low dose oral steroid.
   Lessons: Surgically induced scleritis can also be induced by not only major surgical trauma but also by relatively minor trauma such as intravitreal injection (especially in patients who have connective tissue disease such as RA).
C1 [Ryu, So Jung; Kang, Min Ho; Seong, Mincheol; Cho, Heeyoon; Shin, Yong Un] Hanyang Univ, Coll Med, Dept Ophthalmol, 222 Wangimni Ro, Seoul 04763, South Korea.
C3 Hanyang University
RP Shin, YU (通讯作者)，Hanyang Univ, Coll Med, Dept Ophthalmol, 222 Wangimni Ro, Seoul 04763, South Korea.
EM syu2000@hanmail.net
RI SHIN, Yong-Un/AAI-9824-2020; SHIN, Yong Un/V-7668-2017
OI SHIN, Yong Un/0000-0003-1251-8985
FU Basic Science Research Program through the National Research Foundation
   of Korea - Ministry of Education [NRF-2017R1D1A1B03030905]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea funded by the Ministry of
   Education (NRF-2017R1D1A1B03030905).
CR Akpek EK, 2004, OPHTHALMOLOGY, V111, P501, DOI 10.1016/j.ophtha.2003.06.006
   Fauci AS, 2008, HARRISONS PRINCIPLES, V2
   FONG LP, 1991, OPHTHALMOLOGY, V98, P472
   Gokhale Nikhil S., 2007, Indian Journal of Ophthalmology, V55, P144
   Jabs DA, 2000, AM J OPHTHALMOL, V130, P469, DOI 10.1016/S0002-9394(00)00710-8
   JONES RR, 1992, CORNEA, V11, P148, DOI 10.1097/00003226-199203000-00009
   Karia N, 1999, J CATARACT REFR SURG, V25, P597, DOI 10.1016/S0886-3350(99)80064-9
   Kaufman L M, 1989, J Pediatr Ophthalmol Strabismus, V26, P236
   Kim MJ, 1998, J KOREAN OPHTHALMOL, V39, P777
   MAFFETT MJ, 1990, CORNEA, V9, P279
   MATSUO T, 1995, BRIT J OPHTHALMOL, V79, P549, DOI 10.1136/bjo.79.6.549
   ODONOGHUE E, 1992, BRIT J OPHTHALMOL, V76, P17, DOI 10.1136/bjo.76.1.17
   Okhravi N, 2005, SURV OPHTHALMOL, V50, P351, DOI 10.1016/j.survophthal.2005.04.001
   Perez Victor L, 2002, Semin Ophthalmol, V17, P124, DOI 10.1076/soph.17.3.124.14740
   SCOTT JA, 1994, EYE, V8, P292, DOI 10.1038/eye.1994.60
   Smith JR, 2007, NAT CLIN PRACT RHEUM, V3, P219, DOI 10.1038/ncprheum0454
   WATSON PG, 1982, T OPHTHAL SOC UK, V102, P257
   Wilhelmus K., 1994, SCLERITIS ASS RHEUMA, V101, P1287
NR 18
TC 5
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV
PY 2017
VL 96
IS 47
AR e8925
DI 10.1097/MD.0000000000008925
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FP5FP
UT WOS:000417645700122
PM 29382031
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kernt, M
   Staehler, M
   Stief, C
   Kampik, A
   Neubauer, AS
AF Kernt, Marcus
   Staehler, Michael
   Stief, Christian
   Kampik, Anselm
   Neubauer, Aljoscha S.
TI Resolution of macular oedema in occult choroidal neovascularization
   under oral Sorafenib (R) treatment
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration (AMD); vascular endothelial growth
   factor (VEGF); protein kinase inhibitor
ID PROGRESSION
AB Purpose: To report on the effect of oral nexavar (Sorafenib (R)) treatment in one patient with neovascular age-related macular degeneration (AMD) and advanced renal cell cancer (RCC).
   Methods: After two intravitreal injections of bevacizumab (1.25 mg) for occult choroidal neovascularization (CNV) in AMD, the patient was started on oral Sorafenib (R) (400 mg twice daily) treatment for RCC.
   Results: Visual acuity (VA) was 20/80 in the left eye and optical coherence tomography (OCT) demonstrated persistent central thickening to 251 mu m after bevacizumab. After 6 weeks of oral Sorafenib (R) treatment, VA had increased to 20/70 and a significant decrease in retinal thickness to 208 mu m was observed on OCT. The patient remained stable during a further 3 months of follow-up.
   Conclusions: Resolution of macular oedema and stabilization of VA under oral treatment with the multikinase inhibitor Sorafenib (R) was observed. This observation warrants further investigation.
C1 [Kernt, Marcus; Kampik, Anselm; Neubauer, Aljoscha S.] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
   [Staehler, Michael; Stief, Christian] Univ Munich, Dept Urol, D-80336 Munich, Germany.
C3 University of Munich; University of Munich
RP Neubauer, AS (通讯作者)，Univ Munich, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM aljoscha.neubauer@med.unimuenchen.de
RI Staehler, Michael/AGY-6799-2022
OI Staehler, Michael/0000-0002-4574-6522
CR Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Williams AJ, 2006, AM J OPHTHALMOL, V142, P683, DOI 10.1016/j.ajo.2006.04.032
NR 11
TC 23
Z9 25
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2008
VL 86
IS 4
BP 456
EP 458
DI 10.1111/j.1600-0420.2007.01014.x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 309YT
UT WOS:000256496800018
PM 17908257
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Choi, YK
   Kim, YM
AF Choi, Yoon Kyung
   Kim, Young-Myeong
TI Beneficial and Detrimental Roles of Heme Oxygenase-1 in the
   Neurovascular System
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE heme oxygenase; carbon monoxide; iron; bilirubin; ferroptosis;
   regeneration
ID HUMAN BILIVERDIN REDUCTASE; HYPOXIA-INDUCIBLE FACTORS; ACTIVATED
   PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; CARBON-MONOXIDE; NITRIC-OXIDE;
   MITOCHONDRIAL BIOGENESIS; OXIDATIVE STRESS; VEGF EXPRESSION; CA2+
   CHANNELS
AB Heme oxygenase (HO) has both beneficial and detrimental effects via its metabolites, including carbon monoxide (CO), biliverdin or bilirubin, and ferrous iron. HO-1 is an inducible form of HO that is upregulated by oxidative stress, nitric oxide, CO, and hypoxia, whereas HO-2 is a constitutive form that regulates vascular tone and homeostasis. In brains injured by trauma, ischemia-reperfusion, or Alzheimer's disease (AD), the long-term expression of HO-1 can be detected, which can lead to cytotoxic ferroptosis via iron accumulation. In contrast, the transient induction of HO-1 in the peri-injured region may have regenerative potential (e.g., angiogenesis, neurogenesis, and mitochondrial biogenesis) and neurovascular protective effects through the CO-mediated signaling pathway, the antioxidant properties of bilirubin, and the iron-mediated ferritin synthesis. In this review, we discuss the dual roles of HO-1 and its metabolites in various neurovascular diseases, including age-related macular degeneration, ischemia-reperfusion injury, traumatic brain injury, Gilbert's syndrome, and AD.
C1 [Choi, Yoon Kyung] Konkuk Univ, Dept Biosci & Biotechnol, Bio Mol Informat Ctr, Seoul 05029, South Korea.
   [Kim, Young-Myeong] Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 24341, South Korea.
C3 Konkuk University; Kangwon National University
RP Choi, YK (通讯作者)，Konkuk Univ, Dept Biosci & Biotechnol, Bio Mol Informat Ctr, Seoul 05029, South Korea.; Kim, YM (通讯作者)，Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 24341, South Korea.
EM ykchoi@konkuk.ac.kr; ymkim@kangwon.ac.kr
RI Choi, Yoon Kyung/AGX-0481-2022
OI Choi, Yoon Kyung/0000-0003-0242-9612; Kim,
   Young-Myeong/0000-0002-8326-7768
FU National Research Foundation of Korea (NRF) - Korea Government (MSIP)
   [2020R1A2C1004397, 2022R1A2C3005747]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea Government (MSIP) (Y.K.C.:
   2020R1A2C1004397 and Y.M.K.: 2022R1A2C3005747).
CR Adedoyin O, 2018, AM J PHYSIOL-RENAL, V314, pF702, DOI 10.1152/ajprenal.00044.2017
   Ahmad Z, 2002, J BIOL CHEM, V277, P9226, DOI 10.1074/jbc.M108239200
   Ai W, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021212
   Ansong-Assoku B., 2022, STATPEARLS
   Arai-Gaun S, 2004, INVEST OPHTH VIS SCI, V45, P4226, DOI 10.1167/iovs.04-0450
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Araujo JA, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00119
   Ayton S, 2020, MOL PSYCHIATR, V25, P2932, DOI 10.1038/s41380-019-0375-7
   Bao WD, 2021, CELL DEATH DIFFER, V28, P1548, DOI 10.1038/s41418-020-00685-9
   Baranano DE, 2000, J BIOL CHEM, V275, P15166, DOI 10.1074/jbc.275.20.15166
   Barone E, 2012, FREE RADICAL BIO MED, V52, P2292, DOI 10.1016/j.freeradbiomed.2012.03.020
   Barone E, 2011, J ALZHEIMERS DIS, V25, P623, DOI 10.3233/JAD-2011-110092
   Barone E, 2011, BBA-MOL BASIS DIS, V1812, P480, DOI 10.1016/j.bbadis.2011.01.005
   Basuroy S, 2013, AM J PHYSIOL-CELL PH, V304, pC1105, DOI 10.1152/ajpcell.00023.2013
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202
   Bindu S, 2011, J BIOL CHEM, V286, P39387, DOI 10.1074/jbc.M111.279893
   Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc
   Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049
   Brissot P, 2012, BBA-GEN SUBJECTS, V1820, P403, DOI 10.1016/j.bbagen.2011.07.014
   Cairo Gaetano, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000531
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395
   Chen LJ, 2015, J BIOL CHEM, V290, P28097, DOI 10.1074/jbc.M115.680090
   Chen QM, 2021, TRENDS PHARMACOL SCI, V42, P729, DOI 10.1016/j.tips.2021.06.005
   Chen X, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.590226
   Cheng AW, 2003, DEV BIOL, V258, P319, DOI 10.1016/S0012-1606(03)00120-9
   Chiang SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010039
   Choi YK, 2008, BMB REP, V41, P345, DOI 10.5483/BMBRep.2008.41.5.345
   Choi YK, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.649630
   Choi YK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202039
   Choi YK, 2017, ANTIOXID REDOX SIGN, V27, P21, DOI 10.1089/ars.2016.6684
   Choi YK, 2016, NAT MED, V22, P1335, DOI 10.1038/nm.4188
   Choi YK, 2016, BIOCHEM BIOPH RES CO, V479, P297, DOI 10.1016/j.bbrc.2016.09.063
   Choi YK, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/794237
   Choi YK, 2010, J BIOL CHEM, V285, P32116, DOI 10.1074/jbc.M110.131284
   Codazzi F, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00018
   CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x
   Crielaard BJ, 2017, NAT REV DRUG DISCOV, V16, P400, DOI 10.1038/nrd.2016.248
   Daglas M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00981
   DeGregorio-Rocasolano N, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00085
   Diouf I, 2019, NEUROBIOL DIS, V124, P335, DOI 10.1016/j.nbd.2018.12.010
   Dohi K, 2005, IN VIVO, V19, P855
   Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445
   Fan WW, 2018, CELL REP, V22, P2521, DOI 10.1016/j.celrep.2018.02.047
   Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072
   Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]
   Flynn JM, 2013, FREE RADICAL BIO MED, V62, P4, DOI 10.1016/j.freeradbiomed.2013.05.027
   Gill D, 2018, STROKE, V49, P2815, DOI 10.1161/STROKEAHA.118.022701
   Gureev AP, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00435
   GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hansen TWR, 2020, PHYSIOL REV, V100, P1291, DOI 10.1152/physrev.00004.2019
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HERSHKO C, 1978, BRIT J HAEMATOL, V40, P255, DOI 10.1111/j.1365-2141.1978.tb03662.x
   Hettiarachchi NT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.529
   Hettiarachchi NT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.276
   Hota SK, 2008, EXP NEUROL, V212, P5, DOI 10.1016/j.expneurol.2008.01.030
   Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038
   Hui Y, 2011, J ALZHEIMERS DIS, V26, P299, DOI 10.3233/JAD-2011-102061
   Imuta N, 2007, ANTIOXID REDOX SIGN, V9, P543, DOI 10.1089/ars.2006.1519
   Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jiang XY, 2018, PROG NEUROBIOL, V163, P144, DOI 10.1016/j.pneurobio.2017.10.001
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Kim M, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11050892
   Kim M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222313081
   Kinoshita H, 2020, TOXICOL REP, V7, P169, DOI 10.1016/j.toxrep.2020.01.005
   Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200
   Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039
   Lee BS, 2006, BIOCHEM BIOPH RES CO, V343, P965, DOI 10.1016/j.bbrc.2006.03.058
   Lee H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010078
   Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1
   Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375
   Leick L, 2009, AM J PHYSIOL-ENDOC M, V297, pE92, DOI 10.1152/ajpendo.00076.2009
   Lerner-Marmarosh N, 2005, P NATL ACAD SCI USA, V102, P7109, DOI 10.1073/pnas.0502173102
   Lim I, 2005, AM J PHYSIOL-GASTR L, V288, pG7, DOI 10.1152/ajpgi.00205.2004
   Liu JL, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00632
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Ma CS, 2021, ACTA PHARMACOL SIN, V42, P613, DOI 10.1038/s41401-020-0443-1
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   Mancuso C, 2003, BIOCHEM PHARMACOL, V66, P2355, DOI 10.1016/j.bcp.2003.08.022
   Mancuso C, 2008, J NEUROSCI RES, V86, P2235, DOI 10.1002/jnr.21665
   Moon S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168543
   Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228
   Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560
   Navarro E, 2017, ANTIOXID REDOX SIGN, V27, P93, DOI 10.1089/ars.2016.6698
   Nitti M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00023
   Nitti M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082260
   Oh SH, 2007, J NATL CANCER I, V99, P949, DOI 10.1093/jnci/djm007
   Peng YJ, 2014, P NATL ACAD SCI USA, V111, P1174, DOI 10.1073/pnas.1322172111
   Peyssonnaux C, 2008, CELL CYCLE, V7, P28, DOI 10.4161/cc.7.1.5145
   Portbury SD, 2017, METALLOMICS, V9, P402, DOI 10.1039/c6mt00260a
   Portbury SD, 2016, METALLOMICS, V8, P193, DOI 10.1039/c5mt00234f
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Prabhakar NR, 2015, PHYSIOLOGY, V30, P340, DOI 10.1152/physiol.00022.2015
   PREMKUMAR DRD, 1995, J NEUROCHEM, V65, P1399
   Qi DS, 2014, BRAIN RES, V1577, P69, DOI 10.1016/j.brainres.2014.06.031
   Qiao HY, 2014, AM J EPIDEMIOL, V179, P1039, DOI 10.1093/aje/kwu024
   Radhakrishnan N, 2011, J PEDIAT HEMATOL ONC, V33, P74, DOI 10.1097/MPH.0b013e3181fd2aae
   Rensvold JW, 2013, CELL REP, V3, P237, DOI 10.1016/j.celrep.2012.11.029
   Rochette L, 2018, TRENDS ENDOCRIN MET, V29, P74, DOI 10.1016/j.tem.2017.11.005
   Rozanov C, 1999, BRAIN RES, V833, P101, DOI 10.1016/S0006-8993(99)01405-5
   Sanchez M, 2007, NAT STRUCT MOL BIOL, V14, P420, DOI 10.1038/nsmb1222
   Scheiblich H, 2015, DEV NEUROBIOL, V75, P854, DOI 10.1002/dneu.22253
   Schipper HM, 2019, PROG NEUROBIOL, V172, P40, DOI 10.1016/j.pneurobio.2018.06.008
   Schipper HM, 1999, NEUROTOX RES, V1, P57, DOI 10.1007/BF03033339
   Scragg JL, 2008, J BIOL CHEM, V283, P24412, DOI 10.1074/jbc.M803037200
   Shah YM, 2014, GASTROENTEROLOGY, V146, P630, DOI 10.1053/j.gastro.2013.12.031
   Silva MJME, 1995, J PHYSIOL-LONDON, V489, P689, DOI 10.1113/jphysiol.1995.sp021083
   Sliwinski Tomasz, 2013, Klin Oczna, V115, P96
   Song XH, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00267
   Sonoda J, 2007, P NATL ACAD SCI USA, V104, P5223, DOI 10.1073/pnas.0611623104
   Stifter J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188444
   Suliman HB, 2007, J CLIN INVEST, V117, P3730, DOI 10.1172/JCI32967
   Tang ZM, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101971
   Torralba D, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00107
   Tsoyi K, 2009, INFLAMMATION, V32, P364, DOI 10.1007/s10753-009-9144-0
   Tudor C, 2008, BIOCHEM J, V413, P405, DOI 10.1042/BJ20080018
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   Vasavda C, 2019, CELL CHEM BIOL, V26, P1450, DOI 10.1016/j.chembiol.2019.07.006
   Wagner KH, 2018, CRIT REV CL LAB SCI, V55, P129, DOI 10.1080/10408363.2018.1428526
   Wallner M, 2013, EUR J CLIN INVEST, V43, P912, DOI 10.1111/eci.12120
   Wang B, 2011, STROKE, V42, P2605, DOI 10.1161/STROKEAHA.110.607101
   Wang JP, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1226-1
   Watson William D, 2013, Front Neuroenergetics, V5, P12, DOI 10.3389/fnene.2013.00012
   Wegiel B, 2011, P NATL ACAD SCI USA, V108, P18849, DOI 10.1073/pnas.1108571108
   WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407
   Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165
   Yamamoto A, 2002, J NEUROCHEM, V82, P1137
   Yet SF, 2003, FASEB J, V17, P1759, DOI 10.1096/fj.03-0187fje
   Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163
   Yu XJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24200
   Yuan GX, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005846
   Zelenka J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6190609
   ZETTERSTROM R, 1956, NATURE, V178, P1335, DOI 10.1038/1781335a0
   Zhang DL, 2018, SCIENCE, V359, P1520, DOI 10.1126/science.aal2022
   Zhang YJ, 2006, ARTERIOSCL THROM VAS, V26, P1281, DOI 10.1161/01.ATV.0000221230.08596.98
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 145
TC 1
Z9 1
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2022
VL 23
IS 13
AR 7041
DI 10.3390/ijms23137041
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 2Y0SA
UT WOS:000825603200001
PM 35806040
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Daibert-Nido, M
   Pyatova, Y
   Markowitz, M
   Markowitz, SN
AF Daibert-Nido, Monica
   Pyatova, Yulia
   Markowitz, Michelle
   Markowitz, Samuel N.
TI Visual outcomes of audio-luminous biofeedback training for a child with
   idiopathic nystagmus
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Nystagmus, pathologic/rehabilitation; Biofeedback, psychology; Low
   vision; Visual field tests
AB Microperimetry biofeedback training is a vision rehabilitation method that involves the training of attention and oculomotor control, and the rehabilitation of poorly located and non-functional preferred retinal loci. It can significantly improve distance and near visual acuity in age-related macular degeneration. Previous studies have shown that biofeedback training using electrical nystagmography can reduce nystagmus amplitude and increase foveation time. However, these improvements have not been sustained following training sessions. We hereby report a pediatric case of idiopathic nystagmus in an 11-year old patient treated with microperimetric biofeedback to improve visual acuity and fixation stability. The training had a beneficial impact, positively affecting fixation stability as well as distance and near reading vision. Subjectively, improvement in quality of life was also reported. Conversely to previous studies, the positive effects in this case were maintained for as long as twelve months following therapy. To the best of our knowledge, this is the first case with long-term benefits to be reported in the literature.
C1 [Daibert-Nido, Monica; Pyatova, Yulia; Markowitz, Samuel N.] Univ Toronto, Dept Ophthalmol & Vis Sci, Univ Hlth Network Hosp, Low Vis Serv, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto
RP Markowitz, SN (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, Univ Hlth Network Hosp, Low Vis Serv, Toronto, ON, Canada.
EM snm1@rogers.com
CR ABADI RV, 1980, BRIT J OPHTHALMOL, V64, P2, DOI 10.1136/bjo.64.1.2
   Abadi RV, 2002, BRIT J OPHTHALMOL, V86, P1152, DOI 10.1136/bjo.86.10.1152
   Cate AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004645
   CIUFFREDA KJ, 1982, AM J OPTOM PHYS OPT, V59, P396
   Daibert-Nido M, 2019, CAN J OPHTHALMOL, V54, P328, DOI 10.1016/j.jcjo.2018.10.016
   Grenga PL, 2013, CAN J OPHTHALMOL, V48, pE105, DOI 10.1016/j.jcjo.2012.11.011
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Rucker Janet C, 2005, Curr Treat Options Neurol, V7, P69, DOI 10.1007/s11940-005-0008-0
   Sharma P, 2000, J AAPOS, V4, P287, DOI 10.1067/mpa.2000.107900
NR 10
TC 1
Z9 1
U1 0
U2 6
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2021
VL 84
IS 2
BP 179
EP 182
DI 10.5935/0004-2749.20210026
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RF5TF
UT WOS:000634900200014
PM 33567015
OA gold
DA 2022-11-30
ER

PT J
AU Moine, E
   Boukhallat, M
   Cia, D
   Jacquemot, N
   Guillou, L
   Durand, T
   Vercauteren, J
   Brabet, P
   Crauste, C
AF Moine, Esperance
   Boukhallat, Manel
   Cia, David
   Jacquemot, Nathalie
   Guillou, Laurent
   Durand, Thierry
   Vercauteren, Joseph
   Brabet, Philippe
   Crauste, Celine
TI New lipophenols prevent carbonyl and oxidative stresses involved in
   macular degeneration
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Lipophenol; PUFA; Carbonyl stress; Antioxidant; Macular degeneration;
   Structure-activity relationship
ID PIGMENT EPITHELIAL-CELLS; POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC
   ACID; ANTIOXIDANT ACTIVITY; PLANT POLYPHENOLS; INDUCED APOPTOSIS;
   IN-VIVO; A2E; FLAVONOIDS; RESVERATROL
AB Dry age-related macular degeneration and Stargardt disease undergo a known toxic mechanism caused by carbonyl and oxidative stresses (COS). This is responsible for accumulation in the retinal pigment epithelium (RPE) of A2E, a main toxic pyridinium bis-retinoid lipofuscin component. Previous studies have shown that carbonyl stress in retinal cells could be reduced by an alkyl-phloroglucinol-DHA conjugate (lipophenol). Here, we performed a rational design of different families of lipophenols to conserve anti-carbonyl stress activities and improve antioxidant properties. Five synthetic pathways leading to alkyl-(poly)phenol derivatives, with phloroglucinol, resveratrol, catechin and quercetin as the main backbone, linked to poly-unsaturated fatty acid, are presented. These lipophenols were evaluated in ARPE-19 cell line for their anti-COS properties and a structure-activity relationship study is proposed. Protection of ARPE-19 cells against A2E toxicity was assessed for the four best candidates. Finally, interesting anti-COS properties of the most promising quercetin lipophenol were confirmed in primary RPE cells.
C1 [Moine, Esperance; Boukhallat, Manel; Durand, Thierry; Vercauteren, Joseph; Crauste, Celine] Univ Montpellier, Inst Biomol Max Mousseron IBMM, ENSCM, CNRS, F-34093 Montpellier, France.
   [Guillou, Laurent; Brabet, Philippe] Univ Montpellier, Inst Neurosci Montpellier, INSERM U1051, F-34091 Montpellier, France.
   [Cia, David; Jacquemot, Nathalie] Fac Med & Pharm, Lab Biophys Neurosensorielle, UMR INSERM 1107, F-63000 Clermont Ferrand, France.
C3 Centre National de la Recherche Scientifique (CNRS); Ecole nationale
   superieure de chimie de Montpellier; Universite de Montpellier; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Franche-Comte
RP Moine, E; Crauste, C (通讯作者)，Univ Montpellier, Inst Biomol Max Mousseron IBMM, ENSCM, CNRS, F-34093 Montpellier, France.
EM esperance.moine@umontpellier.fr; celine.crauste@umontpellier.fr
OI Cia, David/0000-0002-1146-7904; Boukhallat, Manel/0000-0002-0470-0683;
   Brabet, Philippe/0000-0003-2739-1622; Moine,
   Esperance/0000-0002-4579-1323
FU University of Montpellier; SATT AxLR [181088BU]; ANR [LipoPheRet
   -ANR-18-CE18-0017]; Inserm; CNRS
FX This research was funded by University of Montpellier, SATT AxLR
   (181088BU) and ANR (LipoPheRet -ANR-18-CE18-0017). Inserm and CNRS are
   thanked for their support.
CR Alaimo A, 2020, ARCH TOXICOL, V94, P553, DOI 10.1007/s00204-019-02637-w
   Banjarnahor SDS, 2014, MED J INDONES, V23, P239, DOI 10.13181/mji.v23i4.1015
   Belal SA, 2018, ANIM CELLS SYST, V22, P324, DOI 10.1080/19768354.2018.1517824
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Brabet P, 2017, INVEST OPHTH VIS SCI, V58
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cia D, 2016, J CELL MOL MED, V20, P1651, DOI 10.1111/jcmm.12857
   Cia D, 2014, CURR EYE RES, V39, P944, DOI 10.3109/02713683.2014.885532
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Crauste C, 2016, BIOCHIMIE, V120, P62, DOI 10.1016/j.biochi.2015.07.018
   Crauste C, 2014, EUR J ORG CHEM, V2014, P4548, DOI 10.1002/ejoc.201402282
   Cren-Olive C, 2002, J CHEM SOC PERK T 1, P821, DOI 10.1039/b107340k
   Cubizolle A, 2020, J CELL MOL MED, V24, P5057, DOI 10.1111/jcmm.15135
   Dugas AJ, 2000, J NAT PROD, V63, P327, DOI 10.1021/np990352n
   Feeney OM, 2016, ADV DRUG DELIVER REV, V101, P167, DOI 10.1016/j.addr.2016.04.007
   Forman HJ, 2014, FREE RADICAL BIO MED, V66, P24, DOI 10.1016/j.freeradbiomed.2013.05.045
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Gia O, 1996, J MED CHEM, V39, P4489, DOI 10.1021/jm960117r
   Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955-2863(02)00208-5
   Hong S, 2016, FOOD CHEM, V197, P415, DOI 10.1016/j.foodchem.2015.10.134
   Howard NI, 2015, CHEMMEDCHEM, V10, P116, DOI 10.1002/cmdc.201402298
   Huang Y, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-40
   Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6
   Ishikado A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069415
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kalantari Heibatullah, 2018, J Tradit Complement Med, V8, P120, DOI 10.1016/j.jtcme.2017.04.010
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Kang JH, 2016, ARCH PHARM RES, V39, P1703, DOI 10.1007/s12272-016-0839-0
   Khursheed R, 2020, DRUG DISCOV TODAY, V25, P209, DOI 10.1016/j.drudis.2019.11.001
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Kuznetsova AV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/801787
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Li M, 2003, J ORG CHEM, V68, P6842, DOI 10.1021/jo034553e
   Li WN, 2016, INT J FOOD SCI NUTR, V67, P650, DOI 10.1080/09637486.2016.1189886
   Lo CY, 2006, MOL NUTR FOOD RES, V50, P1118, DOI 10.1002/mnfr.200600094
   Lo CY, 2011, J FOOD SCI, V76, pH90, DOI 10.1111/j.1750-3841.2011.02067.x
   Martinez Leo E. E., 2018, BIOACTIVE MOL FOOD, P1
   Moine E, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7120197
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Odjakova M, 2012, GLYCOSYLATION, P223, DOI 10.5772/48186
   Papuc C, 2017, COMPR REV FOOD SCI F, V16, P1243, DOI 10.1111/1541-4337.12298
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Pawlowska E., 2019, OXID MED CELL LONGEV, V2019, P1
   Peng XF, 2008, J AGR FOOD CHEM, V56, P1907, DOI 10.1021/jf073065v
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928-0987(00)00167-6
   Quideau S, 2011, ANGEW CHEM INT EDIT, V50, P586, DOI 10.1002/anie.201000044
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Sadowska-Bartosz I, 2015, MOLECULES, V20, P3309, DOI 10.3390/molecules20023309
   Sang S, 2007, CHEM RES TOXICOL, V20, P1862, DOI 10.1021/tx700190s
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Shamseddin A., 2018, BIOSCI REP
   Shao X, 2014, J AGR FOOD CHEM, V62, P3202, DOI 10.1021/jf500204s
   Shen YX, 2017, FOOD CHEM, V216, P153, DOI 10.1016/j.foodchem.2016.08.034
   Sheu SJ, 2013, INVEST OPHTH VIS SCI, V54, P6426, DOI 10.1167/iovs.13-12024
   So Mi Jung, 2014, Prev Nutr Food Sci, V19, P129, DOI 10.3746/pnf.2014.19.3.129
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Suh M, 1996, LIPIDS, V31, P61, DOI 10.1007/BF02522412
   Sun Z, 2010, FOOD CHEM, V120, P261, DOI 10.1016/j.foodchem.2009.10.018
   Szwergold B, 2017, MED HYPOTHESES, V109, P153, DOI 10.1016/j.mehy.2017.10.007
   Tachikawa M, 2018, BIOL PHARM BULL, V41, P1384, DOI 10.1248/bpb.b18-00185
   Taveau N, 2020, EXP MOL MED, V52, P1090, DOI 10.1038/s12276-020-0460-7
   Uesato S, 2003, CHEM PHARM BULL, V51, P1448, DOI 10.1248/cpb.51.1448
   Vestergaard M, 2019, INT J ANTIMICROB AG, V53, P716, DOI 10.1016/j.ijantimicag.2019.02.015
   Vlachogianni IC, 2015, FOOD CHEM, V177, P165, DOI 10.1016/j.foodchem.2014.12.092
   Wang W., 2010, THESIS U FLORIDA, P1
   Wang WX, 2015, J AGR FOOD CHEM, V63, P9488, DOI 10.1021/acs.jafc.5b03949
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Wolfe KL, 2008, J AGR FOOD CHEM, V56, P8404, DOI 10.1021/jf8013074
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Xie YX, 2013, CURR DRUG METAB, V14, P414, DOI 10.2174/1389200211314040005
   Yang B, 2019, METABOLITES, V9, DOI 10.3390/metabo9030040
   Yin FW, 2020, J AGR FOOD CHEM, V68, P1248, DOI 10.1021/acs.jafc.9b05112
   Zhu H., 2019, FOOD CHEM, V298, P1
   Zhu Q, 2009, CHEM RES TOXICOL, V22, P1721, DOI 10.1021/tx900221s
NR 85
TC 10
Z9 10
U1 4
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN
PY 2021
VL 162
BP 367
EP 382
DI 10.1016/j.freeradbiomed.2020.10.316
EA FEB 2021
PG 16
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA QH9XI
UT WOS:000618628700005
PM 33129975
OA Green Published
DA 2022-11-30
ER

PT J
AU Liu, ZP
   Parikh, BH
   Tan, QSW
   Wong, DSL
   Ong, KH
   Yu, WM
   Seah, I
   Holder, GE
   Hunziker, W
   Tan, GSW
   Barathi, VA
   Lingam, G
   Stanzel, BV
   Blenkinsop, TA
   Su, XY
AF Liu, Zengping
   Parikh, Bhav Harshad
   Tan, Queenie Shu Woon
   Wong, Daniel Soo Lin
   Ong, Kok Haur
   Yu, Weimiao
   Seah, Ivan
   Holder, Graham E.
   Hunziker, Walter
   Tan, Gavin S. W.
   Barathi, Veluchamy Amutha
   Lingam, Gopal
   Stanzel, Boris, V
   Blenkinsop, Timothy A.
   Su, Xinyi
TI Surgical Transplantation of Human RPE Stem Cell-Derived RPE Monolayers
   into Non-Human Primates with Immunosuppression
SO STEM CELL REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; GENE-EXPRESSION;
   SURVIVAL; DELIVERY
AB Recent trials of retinal pigment epithelium (RPE) transplantation for the treatment of disorders such as age-related macular degeneration have been promising. However, limitations of existing strategies include the uncertain survival of RPE cells delivered by cell suspension and the inherent risk of uncontrolled cell proliferation in the vitreous cavity. Human RPE stem cell-derived RPE (hRPESC-RPE) transplantation can rescue vision ina rat model of retinal dystrophy and survive in the rabbit retina for at least 1 month. The present study placed hRPESC-RPE monolayers under the macula of a non-human primate model for 3 months. The transplant was able to recover in vivo and maintained healthy photoreceptors. Importantly, there was no evidence that subretinally transplanted monolayers underwent an epithelial-mesenchymal transition. Neither gliosis in adjacent retina nor epiretinal membranes were observed. These findings suggest that hRPESC-RPE monolayers are safe and may be a useful source for RPE cell replacement therapy.
C1 [Liu, Zengping; Parikh, Bhav Harshad; Tan, Queenie Shu Woon; Ong, Kok Haur; Yu, Weimiao; Hunziker, Walter; Su, Xinyi] ASTAR, Inst Mol & Cell Biol IMCB, Singapore, Singapore.
   [Liu, Zengping; Parikh, Bhav Harshad; Wong, Daniel Soo Lin; Holder, Graham E.; Barathi, Veluchamy Amutha; Lingam, Gopal; Stanzel, Boris, V; Su, Xinyi] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Liu, Zengping; Tan, Gavin S. W.; Barathi, Veluchamy Amutha; Lingam, Gopal; Su, Xinyi] Singapore Eye Res Inst SERI, Singapore, Singapore.
   [Seah, Ivan; Holder, Graham E.; Lingam, Gopal; Su, Xinyi] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore.
   [Stanzel, Boris, V] Knappschaft Hosp Saar, Macula Ctr Saar, Eye Clin Sulzbach, Sulzbach, Saar, Germany.
   [Blenkinsop, Timothy A.] Icahn Sch Med Mt Sinai, Dept Cellular Dev & Regenerat Biol, New York, NY 10029 USA.
   [Holder, Graham E.] UCL Inst Ophthalmol, London, England.
   [Hunziker, Walter] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore.
   [Tan, Gavin S. W.; Barathi, Veluchamy Amutha] Duke NUS Med Sch, Acad Clin Program Ophthalmol, Singapore, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Institute of
   Molecular & Cell Biology (IMCB); National University of Singapore;
   National University of Singapore; Icahn School of Medicine at Mount
   Sinai; University of London; University College London; National
   University of Singapore; National University of Singapore
RP Su, XY (通讯作者)，ASTAR, Inst Mol & Cell Biol IMCB, Singapore, Singapore.; Stanzel, BV; Su, XY (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.; Su, XY (通讯作者)，Singapore Eye Res Inst SERI, Singapore, Singapore.; Su, XY (通讯作者)，Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore.; Stanzel, BV (通讯作者)，Knappschaft Hosp Saar, Macula Ctr Saar, Eye Clin Sulzbach, Sulzbach, Saar, Germany.; Blenkinsop, TA (通讯作者)，Icahn Sch Med Mt Sinai, Dept Cellular Dev & Regenerat Biol, New York, NY 10029 USA.
EM boris.stanzel@kksaar.de; timothy.blenkinsop@mssm.edu;
   xysu@imcb.a-star.edu.sg
RI Hunziker, Walter/GSM-8190-2022; Liu, Zengping/GQO-9030-2022; Stanzel,
   Boris/ADP-9221-2022; Stanzel, Boris/AAG-7010-2022; Seah,
   Ivan/AAK-6341-2020
OI Stanzel, Boris/0000-0002-4316-1539; Stanzel, Boris/0000-0002-4316-1539;
   Seah, Ivan/0000-0001-7843-1917; Parikh, Bhav/0000-0003-3835-8887; Liu,
   Zengping/0000-0002-2578-293X
FU IAF-PP (HMBS Domain) (OrBID: Ocular Biomaterials and Device), A*STAR,
   Singapore [H17/01/a0/013]; National University of Singapore
   [NUHSRO/2016/100/SU/01]; National University Health System Clinical
   Scientist Program grant (Singapore); Hong Leong Endowed Professorship of
   the National University of Singapore funds (Singapore)
FX This study was supported by IAF-PP (HMBS Domain) (OrBID: Ocular
   Biomaterials and Device), A*STAR, Singapore (H17/01/a0/013); a National
   University of Singapore start-up grant, Singapore
   (NUHSRO/2016/100/SU/01); and a National University Health System
   Clinical Scientist Program grant (Singapore) to X.S.; and by Hong Leong
   Endowed Professorship of the National University of Singapore funds
   (Singapore) to G.E.H. and B.V.S. We would like to acknowledge the
   veterinary team at the Translational Pre-clinical Model Platform
   (Singapore Eye Research Institute, Singapore) for providing support in
   NHP surgery preparation and animal follow-up.
CR Al-Nawaiseh S, 2016, JOVE-J VIS EXP, DOI 10.3791/53927
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Bovolenta P, 1997, J NEUROSCI, V17, P4243
   CHARTERIS DG, 1995, BRIT J OPHTHALMOL, V79, P953, DOI 10.1136/bjo.79.10.953
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Fernandes Marie, 2018, Curr Protoc Stem Cell Biol, V45, pe53, DOI 10.1002/cpsc.53
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Ilmarinen T, 2019, ACTA OPHTHALMOL, V97, pE688, DOI 10.1111/aos.14004
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Liu ZP, 2019, NAT BIOMED ENG, V3, P598, DOI 10.1038/s41551-019-0382-7
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Masuda T, 2014, J BIOL CHEM, V289, P12908, DOI 10.1074/jbc.M114.556738
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Patteson AE, 2019, J CELL BIOL, V218, P4079, DOI 10.1083/jcb.201902046
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Samuel W, 2017, MOL VIS, V23, P60
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stanzel B, 2019, ADV EXP MED BIOL, V1186, P141, DOI 10.1007/978-3-030-28471-8_6
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Thieltges F, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.11
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73
NR 40
TC 12
Z9 12
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD FEB 9
PY 2021
VL 16
IS 2
BP 237
EP 251
DI 10.1016/j.stemcr.2020.12.007
EA FEB 2021
PG 15
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA YJ0TZ
UT WOS:000744253200004
PM 33450191
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bhat, I
   Yathisha, UG
   Karunasagar, I
   Mamatha, BS
AF Bhat, Ishani
   Yathisha, Undiganalu Gangadharappa
   Karunasagar, Iddya
   Mamatha, Bangera Sheshappa
TI Nutraceutical approach to enhance lutein bioavailability via
   nanodelivery systems
SO NUTRITION REVIEWS
LA English
DT Review
DE adjuvants; bioavailability; lutein; nanofoods; nutraceutical
ID SOLVENT DISPLACEMENT METHOD; IN-VITRO BIOACCESSIBILITY; BETA-CAROTENE;
   MACULAR PIGMENT; COGNITIVE FUNCTION; DOUBLE-BLIND;
   INTESTINAL-ABSORPTION; VISUAL FUNCTION; ALPHA-CAROTENE; PLASMA LUTEIN
AB Lutein, a potent dietary carotenoid, has considerable biological activity and confers protection against age-related macular degeneration. Its bioavailability following consumption, however, depends on its rate of degradation. Nanodelivery systems with improved efficacy and stability are currently being developed to increase the bioavailability of lutein. This review examines nutraceutical approaches used in the development of such nanodelivery systems. It describes the methods of lutein preparation, the characteristics of various delivery systems, and the lutein delivery profile. In order to enhance lutein loading, provide electrostatic stabilization, and achieve the controlled release of lutein, adjuvants such as dextran moieties, whey proteins, medium-chain triglycerides, and chitosan polymers can be used to effectively reduce the particle size (< 70 nm) and improve encapsulation efficiency (to 99.5%). The improved bioavailability of lutein via nanociystals incorporated into rapidly dissolving films for oral consumption is a new area of exploratory research. This review aims to provide clarity about current research aimed at enhancing the bioavailability of lutein through the development of nanodelivery systems.
C1 [Bhat, Ishani; Yathisha, Undiganalu Gangadharappa; Mamatha, Bangera Sheshappa] Nitte Deemed Univ, Nitte Univ, Dept Food Safety & Nutr, Ctr Sci Educ & Res, Paneer Campus, Mangaluru, Karnataka, India.
   [Karunasagar, Iddya] Nitte Deemed Univ, Mangaluru, Karnataka, India.
C3 NITTE (Deemed to be University); Nitte University Center for Science
   Education & Research (NUCSER); NITTE (Deemed to be University)
RP Mamatha, BS (通讯作者)，Nitte Deemed Univ, Dept Food Safety & Nutr, Nitte Univ Ctr Sci Educ & Res NUCSER, Paneer Campus, Mangaluru, Karnataka, India.
EM mamatha.bs@nitte.edu.in
RI Bangera, Mamatha/AAL-9883-2021
OI Bangera, Mamatha/0000-0002-4957-9098; Bhat, Ishani/0000-0003-1925-9760
CR [Anonymous], 2006, NAN TASK FORC REP
   Arteni AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135779
   Aruna G, 2009, J FOOD COMPOS ANAL, V22, P632, DOI 10.1016/j.jfca.2009.03.006
   Arunkumar R, 2015, J PHARM SCI-US, V104, P2085, DOI 10.1002/jps.24436
   Arunkumar R, 2013, FOOD CHEM, V141, P327, DOI 10.1016/j.foodchem.2013.02.108
   Bhadkariya N, 2017, WORLD J PHARM RES, V6, P467
   Borel P, 2014, AM J CLIN NUTR, V100, P168, DOI 10.3945/ajcn.114.085720
   Chang RR, 2017, FOOD HYDROCOLLOID, V67, P14, DOI 10.1016/j.foodhyd.2016.12.023
   Chen HD, 2011, TRENDS FOOD SCI TECH, V22, P585, DOI 10.1016/j.tifs.2011.09.004
   Chen H, 2017, FOOD RES INT, V97, P258, DOI 10.1016/j.foodres.2017.04.021
   Chuacharoen T, 2016, COLLOID SURFACE A, V503, P11, DOI 10.1016/j.colsurfa.2016.04.038
   Cilla A, 2018, J FOOD COMPOS ANAL, V68, P3, DOI 10.1016/j.jfca.2017.01.009
   Coles D, 2013, TRENDS FOOD SCI TECH, V34, P32, DOI 10.1016/j.tifs.2013.08.006
   Dall'Osto L, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.33
   Silva JTD, 2017, MAT SCI ENG C-MATER, V76, P1005, DOI 10.1016/j.msec.2017.03.212
   Silva JTD, 2017, FOOD CHEM, V230, P336, DOI 10.1016/j.foodchem.2017.03.059
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Fatani AJ, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0693-5
   Feeney J, 2017, J GERONTOL A-BIOL, V72, P1431, DOI 10.1093/gerona/glw330
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Golin CB, 2013, J CHEM HEALTH SAF, V20, P9, DOI 10.1016/j.jchas.2013.02.014
   Goni I, 2006, J AGR FOOD CHEM, V54, P5382, DOI 10.1021/jf0609835
   Granado-Lorencio F, 2010, J NUTR BIOCHEM, V21, P133, DOI 10.1016/j.jnutbio.2008.12.002
   Gutierrez-Uribe JA, 2014, CEREAL CHEM, V91, P508, DOI 10.1094/CCHEM-07-13-0145-R
   Han H, 2015, LIPIDS, V50, P261, DOI 10.1007/s11745-015-3992-1
   He XJ, 2016, J FOOD DRUG ANAL, V24, P671, DOI 10.1016/j.jfda.2016.06.001
   Hu DD, 2012, J FOOD ENG, V109, P545, DOI 10.1016/j.jfoodeng.2011.10.025
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Huebbe P, 2016, BIOFACTORS, V42, P388, DOI 10.1002/biof.1284
   Jiao Y, 2018, FOOD FUNCT, V9, P117, DOI [10.1039/c7fo01652b, 10.1039/C7FO01652B]
   Jin HY, 2009, CHINESE J CHEM ENG, V17, P672, DOI 10.1016/S1004-9541(08)60262-1
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Johnson Elizabeth J, 2013, J Aging Res, V2013, P951786, DOI 10.1155/2013/951786
   Justo-Hanani R, 2016, GLOBAL ENVIRON POLIT, V16, P79, DOI 10.1162/GLEP_a_00337
   Juturu V, 2016, CLIN COSMET INVESTI, V9, P325, DOI 10.2147/CCID.S115519
   Kamil A, 2016, FOOD CHEM, V192, P915, DOI 10.1016/j.foodchem.2015.07.106
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kean EG, 2008, J AGR FOOD CHEM, V56, P9918, DOI 10.1021/jf8018613
   Kijlstra A., 2017, J FOOD NUTR RES, V5, P362
   Kishimoto Y, 2017, FOOD RES INT, V99, P944, DOI 10.1016/j.foodres.2017.03.003
   Kopec RE, 2017, FOOD FUNCT, V8, P1494, DOI [10.1039/c7fo00021a, 10.1039/C7FO00021A]
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Lacatusu I, 2013, J FUNCT FOODS, V5, P1260, DOI 10.1016/j.jff.2013.04.010
   Lefsrud M, 2007, SCI HORTIC-AMSTERDAM, V112, P136, DOI 10.1016/j.scienta.2006.12.026
   Liu C, 2017, AAPS PHARMSCITECH, V18, P2957, DOI 10.1208/s12249-017-0777-2
   Liu CH, 2015, CHEM PHARM BULL, V63, P59, DOI 10.1248/cpb.c14-00318
   Liu CH, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/304694
   Liu CH, 2010, COLLOID SURFACE A, V353, P149, DOI 10.1016/j.colsurfa.2009.11.006
   Ma TT, 2015, J FUNCT FOODS, V16, P104, DOI 10.1016/j.jff.2015.04.020
   Maldonado-Valderrama J, 2011, ADV COLLOID INTERFAC, V165, P36, DOI 10.1016/j.cis.2010.12.002
   Mamatha BS, 2012, FOOD BIOPROCESS TECH, V5, P1355, DOI 10.1007/s11947-010-0403-8
   Mamatha BS, 2011, NUTRITION, V27, P960, DOI 10.1016/j.nut.2010.10.011
   Mamatha BS, 2011, INT J FOOD SCI TECH, V46, P315, DOI 10.1111/j.1365-2621.2010.02481.x
   Marriage BJ, 2017, BRIT J NUTR, V118, P813, DOI 10.1017/S0007114517002963
   Mitri K, 2011, INT J PHARMACEUT, V414, P267, DOI 10.1016/j.ijpharm.2011.05.008
   Mohn ES, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186767
   Muhoza B, 2018, J FUNCT FOODS, V45, P1, DOI 10.1016/j.jff.2018.03.035
   Mukerjee A., 2015, J PHARM SCI PHARM, V2, DOI [10.1166/jpsp.2015.1067, DOI 10.1166/JPSP.2015.1067]
   MURILLO AG, 2016, FASEB J S1, V30
   Murillo AG, 2016, J NUTR, V146, P1961, DOI 10.3945/jn.116.235374
   Nidhi B, 2014, EUR J NUTR, V53, P117, DOI 10.1007/s00394-013-0507-9
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   Xavier AAO, 2018, J FOOD COMPOS ANAL, V68, P60, DOI 10.1016/j.jfca.2017.01.015
   Xavier AAO, 2014, FOOD RES INT, V65, P171, DOI 10.1016/j.foodres.2014.06.016
   Panova IG, 2017, EXP EYE RES, V160, P31, DOI 10.1016/j.exer.2017.04.008
   Peng ML, 2016, J FUNCT FOODS, V24, P122, DOI 10.1016/j.jff.2016.04.006
   Poorani TR, 2017, INT J PHARM SCI RES, V8, P4159, DOI 10.13040/IJPSR.0975-8232.8(10).4159-71
   Qiu X, 2015, WORLD J GASTROENTERO, V21, P8061, DOI 10.3748/wjg.v21.i26.8061
   Ranganathan A, 2019, DRUG DELIV TRANSL RE, V9, P178, DOI 10.1007/s13346-018-0590-9
   Ranganathan A, 2016, MAT SCI ENG C-MATER, V69, P1318, DOI 10.1016/j.msec.2016.08.029
   Read A, 2015, FOOD CHEM, V174, P263, DOI 10.1016/j.foodchem.2014.11.074
   Reboul E, 2007, BRIT J NUTR, V97, P440, DOI 10.1017/S0007114507352604
   Renzi-Hammond LM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111246
   Riedl J, 1999, J NUTR, V129, P2170, DOI 10.1093/jn/129.12.2170
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   Salvia-Trujillo L, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6010017
   Sanchez C, 2014, FOOD CHEM, V163, P37, DOI 10.1016/j.foodchem.2014.04.041
   Brum AAS, 2017, COLLOID SURFACE A, V522, P477, DOI 10.1016/j.colsurfa.2017.03.041
   Severins N, 2015, NUTR METAB CARDIOVAS, V25, P210, DOI 10.1016/j.numecd.2014.10.003
   Sharavana G, 2017, J FUNCT FOODS, V31, P97, DOI 10.1016/j.jff.2017.01.023
   Shen R, 2015, J CEREAL SCI, V61, P86, DOI 10.1016/j.jcs.2014.10.009
   Tan C, 2013, J AGR FOOD CHEM, V61, P8175, DOI 10.1021/jf402085f
   Tan TB, 2016, J FOOD ENG, V177, P65, DOI 10.1016/j.jfoodeng.2015.12.020
   Tan TB, 2016, FOOD CHEM, V194, P416, DOI 10.1016/j.foodchem.2015.08.045
   Teo A, 2017, FOOD CHEM, V221, P1269, DOI 10.1016/j.foodchem.2016.11.030
   van der Made SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01370-7
   Vishwanathan R., 2009, NANO BIOMED ENG, V1, P38, DOI [10.5101/nbe.v1i1.p38-49, DOI 10.5101/NBE.V1I1.P38-49]
   Vishwanathan R, 2014, J PEDIATR GASTR NUTR, V59, P659, DOI 10.1097/MPG.0000000000000389
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Yang R, 2016, RSC ADV, V6, P35267, DOI 10.1039/c6ra04058f
   Zhang DX, 2018, J DRUG DELIV SCI TEC, V45, P281, DOI 10.1016/j.jddst.2018.03.023
   Zhao CD, 2014, FOOD CHEM, V156, P123, DOI 10.1016/j.foodchem.2014.01.086
   Zhao LS, 2017, FOOD RES INT, V100, P168, DOI 10.1016/j.foodres.2017.06.055
   김동명, 2006, [Tissue Engineering and Regenerative Medicine, 조직공학과 재생의학], V3, P464
NR 97
TC 7
Z9 8
U1 16
U2 53
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD SEP
PY 2020
VL 78
IS 9
BP 709
EP 724
DI 10.1093/nutrit/nuz096
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA OW8JC
UT WOS:000593125100002
PM 31925437
DA 2022-11-30
ER

PT J
AU Araki, H
   Miura, F
   Watanabe, A
   Morinaga, C
   Kitaoka, F
   Kitano, Y
   Sakai, N
   Shibata, Y
   Terada, M
   Goto, S
   Yamanaka, S
   Takahashi, M
   Ito, T
AF Araki, Hiromitsu
   Miura, Fumihito
   Watanabe, Akira
   Morinaga, Chikako
   Kitaoka, Fumiyo
   Kitano, Yuko
   Sakai, Noriko
   Shibata, Yumiko
   Terada, Motoki
   Goto, So
   Yamanaka, Shinya
   Takahashi, Masayo
   Ito, Takashi
TI Base-Resolution Methylome of Retinal Pigment Epithelial Cells Used in
   the First Trial of Human Induced Pluripotent Stem Cell-Based Autologous
   Transplantation
SO STEM CELL REPORTS
LA English
DT Article
ID MOLECULAR SIGNATURE; VISUAL CYCLE; METHYLATION; INACTIVATION; ENZYMES
AB The first-in-human trial of induced pluripotent stem cell (iPSC)-based autologous transplantation was successfully performed on a female patient with age-related macular degeneration. Here we delineated the base-resolution methylome of the iPSC-derived retinal pigment epithelium (iRPE) used in this trial. The methylome of iRPE closely resembled that of native RPE (nRPE), although partially methylated domains (PMDs) emerged in iRPE but not nRPE. Most differentially methylated regions between iRPE and nRPE appeared to originate from (de)methylation errors during differentiation, whereas errors at reprogramming resulted in aberrant genomic imprinting and X chromosome reactivation. Moreover, non-CpG methylation was prominent in nRPE but not iRPE. Intriguingly, xenotransplantation to mouse remodeled the iRPE methylome to demethylate a subset of suppressed genes and accumulate non-CpG methylation, but failed to resolve PMDs and hypermethylated CpG islands. Although the impacts of these alterations remain elusive, our findings should provide a useful guide for methylome analyses of other iPSC-derived cells.
C1 [Araki, Hiromitsu; Miura, Fumihito; Ito, Takashi] Kyushu Univ, Grad Sch Med Sci, Dept Biochem, Fukuoka, Fukuoka 8128582, Japan.
   [Watanabe, Akira; Kitaoka, Fumiyo; Kitano, Yuko; Yamanaka, Shinya] Kyoto Univ, Ctr iPS Cell Res & Applicat, Kyoto 6068507, Japan.
   [Morinaga, Chikako; Sakai, Noriko; Shibata, Yumiko; Terada, Motoki; Goto, So; Takahashi, Masayo] RIKEN, Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
C3 Kyushu University; Kyoto University; RIKEN
RP Ito, T (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Biochem, Fukuoka, Fukuoka 8128582, Japan.
EM tito@med.kyushu-u.ac.jp
RI Miura, Fumihito/AAZ-5474-2021
OI Miura, Fumihito/0000-0003-2656-486X; Ito, Takashi/0000-0001-6097-2803
FU Japan Agency for Medical Research and Development (AMED) [JP16am0101059,
   JP18am0101103]; Japan Society for the Promotion of Science (JSPS)
   KAKENHI [17H06305]
FX We appreciate the technical assistance from The Research Support Center,
   Research Center for Human Disease Modeling, Kyushu University Graduate
   School of Medical Sciences. This work was partly supported by the Japan
   Agency for Medical Research and Development (AMED) under grant numbers
   JP16am0101059 and JP18am0101103, and by the Japan Society for the
   Promotion of Science (JSPS) KAKENHI 17H06305.
CR Alexa A., 2022, TOPGO ENRICHMENT ANA
   Balaton BP, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0053-7
   Bar S, 2017, CELL REP, V19, P957, DOI 10.1016/j.celrep.2017.04.020
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Court F, 2014, GENOME RES, V24, P554, DOI 10.1101/gr.164913.113
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Guo JU, 2014, NAT NEUROSCI, V17, P215, DOI 10.1038/nn.3607
   He YP, 2015, ANNU REV GENOM HUM G, V16, P55, DOI 10.1146/annurev-genom-090413-025437
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Housset M, 2013, J NEUROSCI, V33, P9890, DOI 10.1523/JNEUROSCI.1099-13.2013
   Huo JS, 2014, CURR OPIN GENET DEV, V28, P43, DOI 10.1016/j.gde.2014.09.008
   Hyvarinen A, 2000, NEURAL NETWORKS, V13, P411, DOI 10.1016/S0893-6080(00)00026-5
   Inoue H, 2014, EMBO J, V33, P409, DOI 10.1002/embj.201387098
   Juhling F, 2016, GENOME RES, V26, P256, DOI 10.1101/gr.196394.115
   Kagami M, 2017, GENET MED, V19, P476, DOI 10.1038/gim.2016.123
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Liang GY, 2013, CELL STEM CELL, V13, P149, DOI 10.1016/j.stem.2013.07.001
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu ZS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091416
   Lorincz MC, 2017, DEV CELL, V43, P257, DOI 10.1016/j.devcel.2017.10.009
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Miura F, 2018, METHODS MOL BIOL, V1708, P123, DOI 10.1007/978-1-4939-7481-8_7
   Miura F, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks454
   Pasque V, 2015, CURR OPIN CELL BIOL, V37, P75, DOI 10.1016/j.ceb.2015.10.006
   Patel S, 2017, CELL REP, V18, P54, DOI 10.1016/j.celrep.2016.11.054
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ruiz S, 2012, P NATL ACAD SCI USA, V109, P16196, DOI 10.1073/pnas.1202352109
   Schultz MD, 2015, NATURE, V523, P212, DOI 10.1038/nature14465
   Smith ZD, 2017, NATURE, V549, P543, DOI 10.1038/nature23891
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tapia N, 2016, CELL STEM CELL, V19, P298, DOI 10.1016/j.stem.2016.06.017
   Trounson A, 2016, NAT REV MOL CELL BIO, V17, P194, DOI 10.1038/nrm.2016.10
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   Yokoyama T, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1809-5
NR 39
TC 10
Z9 10
U1 0
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD OCT 8
PY 2019
VL 13
IS 4
BP 761
EP 774
DI 10.1016/j.stemcr.2019.08.014
PG 14
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JC5LA
UT WOS:000489322400014
PM 31564644
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wojnarowicz, PM
   Silva, RLE
   Ohnaka, M
   Lee, SB
   Chin, Y
   Kulukian, A
   Chang, SH
   Desai, B
   Escolano, MG
   Shah, R
   Garcia-Cao, M
   Xu, SJ
   Kadam, R
   Goldgur, Y
   Miller, MA
   Ouerfelli, O
   Yang, G
   Arakawa, T
   Albanese, SK
   Garland, WA
   Stoller, G
   Chaudhary, J
   Norton, L
   Soni, RK
   Philip, J
   Hendrickson, RC
   Iavarone, A
   Dannenberg, AJ
   Chodera, JD
   Pavletich, N
   Lasorella, A
   Campochiaro, PA
   Benezra, R
AF Wojnarowicz, Paulina M.
   Lima e Silva, Raquel
   Ohnaka, Masayuki
   Lee, Sang Bae
   Chin, Yvette
   Kulukian, Anita
   Chang, Sung-Hee
   Desai, Bina
   Escolano, Marta Garcia
   Shah, Riddhi
   Garcia-Cao, Marta
   Xu, Sijia
   Kadam, Rashmi
   Goldgur, Yehuda
   Miller, Meredith A.
   Ouerfelli, Ouathek
   Yang, Guangli
   Arakawa, Tsutomu
   Albanese, Steven K.
   Garland, William A.
   Stoller, Glenn
   Chaudhary, Jaideep
   Norton, Larry
   Soni, Rajesh Kumar
   Philip, John
   Hendrickson, Ronald C.
   Iavarone, Antonio
   Dannenberg, Andrew J.
   Chodera, John D.
   Pavletich, Nikola
   Lasorella, Anna
   Campochiaro, Peter A.
   Benezra, Robert
TI A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular
   Neovascularization
SO CELL REPORTS
LA English
DT Article
ID HELIX PROTEIN ID1; CELL-CYCLE ARREST; CHOROIDAL NEOVASCULARIZATION;
   TRANSCRIPTIONAL REGULATOR; MACULAR DEGENERATION; ACCURATE DOCKING;
   DNA-BINDING; ANGIOGENESIS; STEM; DIFFERENTIATION
AB Id helix-loop-helix (HLH) proteins (Id1-4) bind E protein bHLH transcription factors, preventing them from forming active transcription complexes that drive changes in cell states. Id proteins are primarily expressed during development to inhibit differentiation, but they become re-expressed in adult tissues in diseases of the vasculature and cancer. We show that the genetic loss of Id1/Id3 reduces ocular neovascularization in mouse models of wet age-related macular degeneration (AMD) and retinopathy of prematurity (ROP). An in silico screen identifies AGX51, a small-molecule Id antagonist. AGX51 inhibits the Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduced viability. AGX51 is well-tolerated in mice and phenocopies the genetic loss of Id expression in AMD and ROP models by inhibiting retinal neovascularization. Thus, AGX51 is a first-in-class compound that antagonizes an interaction formerly considered undruggable and that may have utility in the management of multiple diseases.
C1 [Wojnarowicz, Paulina M.; Chin, Yvette; Kulukian, Anita; Desai, Bina; Escolano, Marta Garcia; Shah, Riddhi; Garcia-Cao, Marta; Xu, Sijia; Kadam, Rashmi; Benezra, Robert] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.
   [Lima e Silva, Raquel; Ohnaka, Masayuki; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Lima e Silva, Raquel; Ohnaka, Masayuki; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
   [Lee, Sang Bae] Columbia Univ, Med Ctr, Inst Canc Genet, New York, NY 10032 USA.
   [Chang, Sung-Hee; Dannenberg, Andrew J.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.
   [Goldgur, Yehuda; Miller, Meredith A.; Pavletich, Nikola] Mem Sloan Kettering Canc Ctr, Struct Biol Program, Sloan Kettering Inst, New York, NY 10065 USA.
   [Ouerfelli, Ouathek; Yang, Guangli] Mem Sloan Kettering Canc Ctr, Organ Synth Core Facil, New York, NY 10065 USA.
   [Arakawa, Tsutomu] Alliance Prot Labs, San Diego, CA 92121 USA.
   [Albanese, Steven K.; Chodera, John D.] Mem Sloan Kettering Canc Ctr, Computat Biol Program, Sloan Kettering Inst, New York, NY 10065 USA.
   [Garland, William A.] Tosk Inc, Mountain View, CA 94043 USA.
   [Stoller, Glenn] Ophthalm Consultants Long Isl, Lynbrook, NY 11563 USA.
   [Chaudhary, Jaideep] Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Atlanta, GA 30314 USA.
   [Norton, Larry] Mem Sloan Kettering Canc Ctr, Evelyn H Lauder Breast Ctr, New York, NY 10065 USA.
   [Soni, Rajesh Kumar; Philip, John; Hendrickson, Ronald C.] Mem Sloan Kettering Canc Ctr, Prote & Microchem Core Facil, New York, NY 10065 USA.
   [Iavarone, Antonio] Columbia Univ, Med Ctr, Inst Canc Genet, Dept Neurol,Dept Pathol, New York, NY 10032 USA.
   [Lasorella, Anna] Columbia Univ, Med Ctr, Inst Canc Genet, Dept Pediat,Dept Pathol, New York, NY 10032 USA.
C3 Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns
   Hopkins University; Columbia University; Cornell University; Memorial
   Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center;
   Memorial Sloan Kettering Cancer Center; Clark Atlanta University;
   Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; Columbia University; Columbia University
RP Benezra, R (通讯作者)，Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.
EM benezrar@mskcc.org
RI Desai, Bina/AAT-4017-2020
OI LEE, SANG BAE/0000-0002-4031-8051; Albanese, Steven/0000-0003-0973-5030;
   Desai, Bina/0000-0003-0454-7583
FU Sloan Kettering Institute; NIH [R01CA101644, R01CA131126, P30 CA008748];
   NCI [PO1 CA094060]; Breast Cancer Research Foundation; Louis V.
   Gerstner, Jr. Graduate School of Biomedical Sciences; NCI/NIH
   [1R43CA150448-01]; Human Frontier Science Program (HFSP); Spanish
   Ministry of Education and Science (MEC); Fonds de Recherche du
   Quebec-Sante; (FRQS); Valencian Government of Spain (GVA); European
   Social Fund [ACIF/2018/004, BEFPI/2018/029]; Angiogenex, Inc.; NATIONAL
   CANCER INSTITUTE [P01CA094060, P30CA008748] Funding Source: NIH RePORTER
FX The authors are grateful to members of the Benezra Lab, past and
   present, for helpful discussions throughout the course of this work. We
   are also grateful to Andrea Rizzi for additional supportive modeling
   work of AGX51 interactions and Drs. Gary Cook and Gary Novack for expert
   guidance on the ophthalmic studies. We thank Elisa de Stanchina and the
   MSKCC Antitumor Assessment Core Facility for assistance with
   pharmacokinetic and bioavailability assays, Nicholas Socci and the MSKCC
   Bioinformatics Core Facility for additional statistical analyses, and
   Jorge Gandara of the Weill Cornell Medical College Microbiome Core for
   assistance with the GloMax instrument. For expert guidance in
   implementing and executing the NanoBRET assay, we wish to thank Dan
   McKay and William Forrester at Novartis and James Vasta at Promega. R.B.
   and J.D.C. gratefully acknowledge support from the Sloan Kettering
   Institute and NIH grant P30 CA008748. R.B. is also supported by grants
   from the NCI (PO1 CA094060) and The Breast Cancer Research Foundation.
   A.J.D. is supported by funding from The Breast Cancer Research
   Foundation. S.K.A. was supported by the Louis V. Gerstner, Jr. Graduate
   School of Biomedical Sciences. Work was partially supported by
   1R43CA150448-01 from NCI/NIH to W.A.G. and NIH grants to A.I.
   (R01CA101644 and R01CA131126). M.G.-C. was funded by fellowships from
   the Human Frontier Science Program (HFSP) and the Spanish Ministry of
   Education and Science (MEC). P.M.W. is a recipient of a Postdoctoral
   Training Award from the Fonds de Recherche du Quebec-Sante; (FRQS).
   M.G.E. was supported by fellowships issued by the Valencian Government
   of Spain (GVA) and the European Social Fund (ACIF/2018/004 and
   BEFPI/2018/029). Financial support was also provided by Angiogenex, Inc.
   to the R.B. Laboratory.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Ahmadpour F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032136
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023
   [Anonymous], 2016, SMALL MOL DRUG DISC
   [Anonymous], 2016, SCHROD REL 2016 1 LI
   BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y
   BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1
   Bhattacharya A, 2011, CELL, V147, P881, DOI 10.1016/j.cell.2011.08.055
   Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257
   Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796
   Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795
   Ciarrocchi A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001338
   Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603
   Ding BS, 2010, NATURE, V468, P310, DOI 10.1038/nature09493
   El Omari K, 2013, CELL REP, V4, P135, DOI 10.1016/j.celrep.2013.06.008
   Fletcher S, 2015, BBA-GENE REGUL MECH, V1849, P525, DOI 10.1016/j.bbagrm.2014.03.005
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224
   Gao H, 2015, J CELL SCI, V128, P2340, DOI 10.1242/jcs.167874
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822-010-9349-1
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Heier JS, 2016, JAMA OPHTHALMOL, V134, P95, DOI 10.1001/jamaophthalmol.2015.4110
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Henke E, 2008, NAT BIOTECHNOL, V26, P91, DOI 10.1038/nbt1366
   Jankovic V, 2007, P NATL ACAD SCI USA, V104, P1260, DOI 10.1073/pnas.0607894104
   Jones S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-226
   Kee BL, 2009, NAT REV IMMUNOL, V9, P175, DOI 10.1038/nri2507
   Kjorholt C, 2005, DIABETES, V54, P2755, DOI 10.2337/diabetes.54.9.2755
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638
   Ling F, 2014, CURR TOP DEV BIOL, V110, P189, DOI 10.1016/B978-0-12-405943-6.00005-1
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Longo A, 2008, BIOCHEMISTRY-US, V47, P218, DOI 10.1021/bi701527r
   Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Mern DS, 2010, BRIT J CANCER, V103, P1237, DOI 10.1038/sj.bjc.6605897
   Mern DS, 2010, BREAST CANCER RES TR, V124, P623, DOI 10.1007/s10549-010-0810-6
   Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T
   Murase R, 2014, BRIT J PHARMACOL, V171, P4464, DOI 10.1111/bph.12803
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Peddada S, 2006, HUM MOL GENET, V15, P2003, DOI 10.1093/hmg/ddl124
   Perry SS, 2007, BLOOD, V110, P2351, DOI 10.1182/blood-2007-01-069914
   PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874
   Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Soroceanu L, 2013, CANCER RES, V73, P1559, DOI 10.1158/0008-5472.CAN-12-1943
   Suh HC, 2009, BLOOD, V114, P1186, DOI 10.1182/blood-2008-09-179788
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tournay O, 1996, MOL CELL BIOL, V16, P2418
   Wang LH, 2015, DEV CELL, V35, P269, DOI 10.1016/j.devcel.2015.10.019
   Wang LJ, 2000, BIOCHEM BIOPH RES CO, V276, P346, DOI 10.1006/bbrc.2000.3472
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zhang MY, 1997, BLOOD, V90, P2068, DOI 10.1182/blood.V90.5.2068
   Zhang N, 2014, STEM CELL REP, V3, P716, DOI 10.1016/j.stemcr.2014.09.012
NR 64
TC 17
Z9 18
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD OCT 1
PY 2019
VL 29
IS 1
BP 62
EP +
DI 10.1016/j.celrep.2019.08.073
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JB5OO
UT WOS:000488614600006
PM 31577956
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Amram, AL
   Mandviwala, MM
   Ou, WC
   Wykoff, CC
   Shah, AR
AF Amram, Alec L.
   Mandviwala, Murtaza M.
   Ou, William C.
   Wykoff, Charles C.
   Shah, Ankoor R.
TI Predictors of Visual Acuity Outcomes Following Vitrectomy for Idiopathic
   Macular Hole
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID SURGERY
AB BACKGROUND AND OBJECTIVE: To investigate predictors of visual outcomes in patients who underwent vitrectomy for full-thickness macular hole (FTMH) with at least 1 year of follow-up.
   PATIENTS AND METHODS: Retrospective, noncomparative, consecutive case series of 132 eyes of 122 patients who underwent surgical repair of idiopathic FTMH with at least 1 year of follow-up. Predictors of visual acuity (VA) outcomes were analyzed using linear regression.
   RESULTS: Mean follow-up time was 22.2 months. Twenty-three eyes (17.4%) had age-related macular degeneration (AMD), of which 17 (73.9%) cases were mild and nonexudative. At final follow-up, poor preoperative VA (P < .001), perioporative complications (P < .001), AMD (P < .001), and delay from preoperative evaluation to surgery (P = .037) were significant predictors of final VA. In multiple regression, these variables remained significant (P < .001, P = .011, P < .001, and P = .002, respectively).
   CONCLUSION: Poor preoperative VA, perioperative complications, AMD, and delay to surgery were significant predictors of final VA following FTMH repair.
C1 [Amram, Alec L.; Mandviwala, Murtaza M.] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Ou, William C.; Wykoff, Charles C.; Shah, Ankoor R.] Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
   [Wykoff, Charles C.; Shah, Ankoor R.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX USA.
   [Wykoff, Charles C.; Shah, Ankoor R.] Weill Cornell Med Coll, Houston, TX USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; The Methodist Hospital System; The Methodist Hospital -
   Houston; Cornell University
RP Shah, AR (通讯作者)，Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM arsmd@houston-retina.com
OI Ou, William/0000-0003-1997-1360
CR Benson WE, 2001, OPHTHALMOLOGY, V108, P1328, DOI 10.1016/S0161-6420(01)00731-X
   Berinstein DM, 2000, OPHTHALMOLOGY, V107, P2233, DOI 10.1016/S0161-6420(00)00417-6
   Ezra E, 2004, ARCH OPHTHALMOL-CHIC, V122, P224, DOI 10.1001/archopht.122.2.224
   Haritoglou C, 2007, CLIN EXP OPHTHALMOL, V35, P208, DOI 10.1111/j.1442-9071.2006.01445.x
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   McCannel CA, 2009, OPHTHALMOLOGY, V116, P1366, DOI 10.1016/j.ophtha.2009.01.052
   Parravano M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009080.pub2
   Patel A, 1994, SEMIN OPHTHALMOL, V9, P47
   Rao P, 2017, OPHTHALMOL RETINA, V1, P158, DOI 10.1016/j.oret.2016.09.014
   Recchia FM, 2010, OPHTHALMOLOGY, V117, P1851, DOI 10.1016/j.ophtha.2010.06.014
   Smiddy WE, 2001, OPHTHALMOLOGY, V108, P1471, DOI 10.1016/S0161-6420(00)00645-X
   Steel DHW, 2013, EYE, V27, pS1, DOI 10.1038/eye.2013.212
   WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1671
   Williams GA, 2006, RETINA-J RET VIT DIS, V26, pS9, DOI 10.1097/00006982-200607001-00003
NR 14
TC 1
Z9 1
U1 1
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD AUG
PY 2018
VL 49
IS 8
BP 566
EP 570
DI 10.3928/23258160-20180803-03
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GQ7OX
UT WOS:000441934200004
PM 30114300
DA 2022-11-30
ER

PT J
AU Baek, K
   Yu, J
   Jeong, J
   Sim, SJ
   Bae, S
   Jin, E
AF Baek, Kwangryul
   Yu, Jihyeon
   Jeong, Jooyeon
   Sim, Sang Jun
   Bae, Sangsu
   Jin, EonSeon
TI Photoautotrophic production of macular pigment in a Chlamydomonas
   reinhardtii strain generated by using DNA-free CRISPR-Cas9 RNP-mediated
   mutagenesis
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE algal biotechnology; Chlamydomonas reinhardtii; CRISPR-Cas9; lutein;
   zeaxanthin
ID LUTEIN; CAROTENOIDS; MICROALGAE; ZEAXANTHIN; XANTHOPHYLLS; ACCUMULATION;
   EGG
AB Lutein and zeaxanthin are dietary carotenoids reported to be protective against age-related macular degeneration. Recently, the green alga Chlamydomonas reinhardtii has received attention as a photosynthetic cell factory, but the potential of this alga for carotenoid production has not yet been evaluated. In this study, we selected the C. reinhardtii CC-4349 strain as the best candidate among seven laboratory strains tested for carotenoid production. A knock-out mutant of the zeaxanthin epoxidase gene induced by preassembled DNA-free CRISPR-Cas9 ribonucleoproteins in the CC-4349 strain had a significantly higher zeaxanthin content (56-fold) and productivity (47-fold) than the wild type without the reduction in lutein level. Furthermore, we produced eggs fortified with lutein (2-fold) and zeaxanthin (2.2-fold) by feeding hens a diet containing the mutant. Our results clearly demonstrate the possibility of cost-effective commercial use of microalgal mutants induced by DNA-free CRISPR-Cas9 ribonucleoproteins in algal biotechnology for the production of high-value products.
C1 [Baek, Kwangryul; Jeong, Jooyeon; Jin, EonSeon] Hanyang Univ, Dept Life Sci, Seoul, South Korea.
   [Yu, Jihyeon] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea.
   [Sim, Sang Jun] Korea Univ, Dept Chem & Biol Engn, Seoul, South Korea.
   [Bae, Sangsu] Hanyang Univ, Dept Chem, Seoul, South Korea.
C3 Hanyang University; Seoul National University (SNU); Korea University;
   Hanyang University
RP Jin, E (通讯作者)，Hanyang Univ, Dept Life Sci, Seoul, South Korea.
EM esjin@hanyang.ac.kr
RI Jin, EonSeon/AAW-6839-2020; Sim, Sang Jun/F-6697-2013; Yu,
   Jihyeon/U-4150-2019; Bae, Sangsu/E-5324-2017
OI Jin, EonSeon/0000-0001-5691-0124; Sim, Sang Jun/0000-0003-1045-0286; Yu,
   Jihyeon/0000-0003-0247-7753; Bae, Sangsu/0000-0003-3615-8566
FU Ministry of Science, ICT & Future Planning, Korea
   [KCRC-2014M1A8A1049273]; Ministry of Oceans and Fisheries, Korea
   [20090267]; Plant Molecular Breeding Center, Korea [PJ01119201]
FX Ministry of Science, ICT & Future Planning, Korea, Grant number: Korea
   CCS R&D Center (Korea CCS 2020 Project) (KCRC-2014M1A8A1049273);
   Ministry of Oceans and Fisheries, Korea, Grant number: Marine
   Biotechnology Program (20090267); Plant Molecular Breeding Center,
   Korea, Grant number: Next Generation BioGreen 21 Program (PJ01119201)
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048
   Baek K, 2016, SCI REP-UK, V6, DOI 10.1038/srep30620
   Bajhaiya AK, 2017, TRENDS BIOTECHNOL, V35, P95, DOI 10.1016/j.tibtech.2016.06.001
   Baroli I, 2003, PLANT CELL, V15, P992, DOI 10.1105/tpc.010405
   Cazzonelli CI, 2011, FUNCT PLANT BIOL, V38, P833, DOI 10.1071/FP11192
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Cordero BF, 2011, MAR DRUGS, V9, P1607, DOI 10.3390/md9091607
   DAVIES DR, 1971, GENET RES, V17, P33, DOI 10.1017/S0016672300012015
   Del Campo JA, 2000, J BIOTECHNOL, V76, P51, DOI 10.1016/S0168-1656(99)00178-9
   Garcia-Gonzalez M, 2005, J BIOTECHNOL, V115, P81, DOI 10.1016/j.jbiotec.2004.07.010
   Gong MY, 2016, BIOTECHNOL ADV, V34, P1396, DOI 10.1016/j.biotechadv.2016.10.005
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Ho SH, 2014, BIORESOURCE TECHNOL, V152, P275, DOI 10.1016/j.biortech.2013.11.031
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Jang I, 2014, J POULT SCI, V51, P58, DOI 10.2141/jpsa.0130017
   Jeon JY, 2012, KOREAN J FOOD SCI AN, V32, P13, DOI 10.5851/kosfa.2012.32.1.13
   Jin E, 2003, J MICROBIOL BIOTECHN, V13, P165
   Jin ES, 2003, BIOTECHNOL BIOENG, V81, P115, DOI 10.1002/bit.10459
   Karadas F, 2006, BRIT POULTRY SCI, V47, P561, DOI 10.1080/00071660600962976
   Kim J, 2016, NAT BIOTECHNOL, V34, P1014, DOI 10.1038/nbt.3680
   Kim J, 2013, BIOTECHNOL ADV, V31, P862, DOI 10.1016/j.biotechadv.2013.04.006
   Kim S, 2014, GENOME RES, V24, P1012, DOI 10.1101/gr.171322.113
   Koller M, 2014, ALGAL RES, V6, P52, DOI 10.1016/j.algal.2014.09.002
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350
   Lin JH, 2015, BIORESOURCE TECHNOL, V184, P421, DOI 10.1016/j.biortech.2014.09.099
   Lloyd AC, 2013, CELL, V154, P1194, DOI 10.1016/j.cell.2013.08.053
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   McMillan JR, 2013, APPL ENERG, V103, P128, DOI 10.1016/j.apenergy.2012.09.020
   Miyake K, 2014, BIOTECHNOL BIOFUELS, V7, DOI 10.1186/1754-6834-7-56
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Nisar N, 2015, MOL PLANT, V8, P68, DOI 10.1016/j.molp.2014.12.007
   Niyogi KK, 1997, P NATL ACAD SCI USA, V94, P14162, DOI 10.1073/pnas.94.25.14162
   Niyogi KK, 1997, PLANT CELL, V9, P1369, DOI 10.2307/3870388
   Paliwal C, 2016, ALGAL RES, V15, P24, DOI 10.1016/j.algal.2016.01.017
   Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561
   Park JY, 2015, BIORESOURCE TECHNOL, V184, P267, DOI 10.1016/j.biortech.2014.10.089
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Polle JEW, 2001, PLANT CELL PHYSIOL, V42, P482, DOI 10.1093/pcp/pce058
   Rosales-Mendoza S, 2012, PLANT CELL REP, V31, P479, DOI 10.1007/s00299-011-1186-8
   Sasso S, 2012, FEMS MICROBIOL REV, V36, P761, DOI 10.1111/j.1574-6976.2011.00304.x
   Scaife MA, 2015, PLANT J, V82, P532, DOI 10.1111/tpj.12781
   Scranton MA, 2015, PLANT J, V82, P523, DOI 10.1111/tpj.12780
   Siaut M, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-7
   Spolaore P, 2006, J BIOSCI BIOENG, V101, P87, DOI 10.1263/jbb.101.87
   Takaichi S, 2011, MAR DRUGS, V9, P1101, DOI 10.3390/md9061101
   Varela JC, 2015, PHOTOSYNTH RES, V125, P423, DOI 10.1007/s11120-015-0149-2
   VISHWANATHAN R, 2009, THE AMERICAN JOURNAL, V90, P1272
NR 49
TC 53
Z9 56
U1 3
U2 92
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3592
EI 1097-0290
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD MAR
PY 2018
VL 115
IS 3
BP 719
EP 728
DI 10.1002/bit.26499
PG 10
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA FU2II
UT WOS:000423672800018
PM 29150930
DA 2022-11-30
ER

PT J
AU Kim, E
   Koo, T
   Park, SW
   Kim, D
   Kim, K
   Cho, HY
   Song, DW
   Lee, KJ
   Jung, MH
   Kim, S
   Kim, JH
   Kim, JH
   Kim, JS
AF Kim, Eunji
   Koo, Taeyoung
   Park, Sung Wook
   Kim, Daesik
   Kim, Kyoungmi
   Cho, Hee-Yeon
   Song, Dong Woo
   Lee, Kyu Jun
   Jung, Min Hee
   Kim, Seokjoong
   Kim, Jin Hyoung
   Kim, Jeong Hun
   Kim, Jin-Soo
TI In vivo genome editing with a small Cas9 orthologue derived from
   Campylobacter jejuni
SO NATURE COMMUNICATIONS
LA English
DT Article
ID STAPHYLOCOCCUS-AUREUS CAS9; RNA-GUIDED ENDONUCLEASES; HUMAN-CELLS;
   CHOROIDAL NEOVASCULARIZATION; GENE KNOCKOUT; MICE; MODEL;
   RIBONUCLEOPROTEINS; TRANSCRIPTION; MUTATIONS
AB Several CRISPR-Cas9 orthologues have been used for genome editing. Here, we present the smallest Cas9 orthologue characterized to date, derived from Campylobacter jejuni (CjCas9), for efficient genome editing in vivo. After determining protospacer-adjacent motif (PAM) sequences and optimizing single-guide RNA (sgRNA) length, we package the CjCas9 gene, its sgRNA sequence, and a marker gene in an all-in-one adeno-associated virus (AAV) vector and produce the resulting virus at a high titer. CjCas9 is highly specific, cleaving only a limited number of sites in the human or mouse genome. CjCas9, delivered via AAV, induces targeted mutations at high frequencies in mouse muscle cells or retinal pigment epithelium (RPE) cells. Furthermore, CjCas9 targeted to the Vegfa or Hif1a gene in RPE cells reduces the size of laser-induced choroidal neovascularization, suggesting that in vivo genome editing with CjCas9 is a new option for the treatment of age-related macular degeneration.
C1 [Kim, Eunji; Koo, Taeyoung; Kim, Daesik; Kim, Kyoungmi; Cho, Hee-Yeon; Kim, Jin-Soo] Inst for Basic Sci Korea, Ctr Genome Engn, Seoul 08826, South Korea.
   [Kim, Eunji; Song, Dong Woo; Lee, Kyu Jun; Jung, Min Hee; Kim, Seokjoong] ToolGen, Byucksan Digital Valley 6 Cha, Seoul 08501, South Korea.
   [Koo, Taeyoung; Kim, Jin-Soo] Univ Sci & Technol, Dept Funct Genom, Daejeon 34113, South Korea.
   [Park, Sung Wook; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul 03080, South Korea.
   [Park, Sung Wook; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, FARB Lab, Biomed Res Inst, Seoul 03082, South Korea.
   [Kim, Daesik; Kim, Jin-Soo] Seoul Natl Univ, Dept Chem, Seoul 08826, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul 03080, South Korea.
C3 Institute for Basic Science - Korea (IBS); University of Science &
   Technology (UST); Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University Hospital; Seoul National
   University (SNU); Seoul National University (SNU)
RP Kim, JS (通讯作者)，Inst for Basic Sci Korea, Ctr Genome Engn, Seoul 08826, South Korea.; Kim, JS (通讯作者)，Univ Sci & Technol, Dept Funct Genom, Daejeon 34113, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul 03080, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ Hosp, FARB Lab, Biomed Res Inst, Seoul 03082, South Korea.; Kim, JS (通讯作者)，Seoul Natl Univ, Dept Chem, Seoul 08826, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul 03080, South Korea.
EM steph25@snu.ac.kr; jskim01@snu.ac.kr
RI Kim, Kyoungmi/AAR-3964-2020; KIM, Jin-Soo/M-6918-2013; Park, Sung
   Wook/D-5541-2012; Kim, Daesik/AFH-7798-2022
OI Kim, Kyoungmi/0000-0003-0941-806X; KIM, Jin-Soo/0000-0003-4847-1306;
   Park, Sung Wook/0000-0001-8151-6663; Song, Dong Woo/0000-0001-9700-7759;
   Kim, Jeong Hun/0000-0003-2957-1766
FU Korea Health technology R&D Project through the Korea Health Industry
   Development Institute [HI16C0426]; Pioneer Research Program of NRF/MEST
   [2012-0009544]; Bio & Medical Technology Development Program of the
   National Research Foundation; MSIP [NRF-2015M3A9E6028949]; 
   [IBS-R021-D1]
FX This work was supported by IBS-R021-D1 (to J.-S.K.), the Korea Health
   technology R&D Project through the Korea Health Industry Development
   Institute (Grant Number: HI16C0426 to S.K.), the Pioneer Research
   Program of NRF/MEST (2012-0009544 to Je.H.K.), the Bio & Medical
   Technology Development Program of the National Research Foundation and
   MSIP (NRF-2015M3A9E6028949 to Je.H.K.). We thank Kwang-eun Kim for
   experimental support.
CR Anders C, 2014, NATURE, V513, P569, DOI 10.1038/nature13579
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048
   Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993
   Cho SW, 2013, GENETICS, V195, P1177, DOI 10.1534/genetics.113.155853
   Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Esvelt KM, 2013, NAT METHODS, V10, P1116, DOI [10.1038/NMETH.2681, 10.1038/nmeth.2681]
   Fonfara I, 2014, NUCLEIC ACIDS RES, V42, P2577, DOI 10.1093/nar/gkt1074
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Hur JK, 2016, NAT BIOTECHNOL, V34, P807, DOI 10.1038/nbt.3596
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kim D, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888a
   Kim D, 2015, NAT METHODS, V12, P237, DOI [10.1038/NMETH.3284, 10.1038/nmeth.3284]
   Kim H, 2011, NAT METHODS, V8, P941, DOI [10.1038/NMETH.1733, 10.1038/nmeth.1733]
   Kim H, 2014, NAT REV GENET, V15, P321, DOI 10.1038/nrg3686
   Kleinstiver BP, 2016, NAT BIOTECHNOL, V34, P869, DOI 10.1038/nbt.3620
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Long CZ, 2016, SCIENCE, V351, P400, DOI 10.1126/science.aad5725
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Nishimasu H, 2015, CELL, V162, P1113, DOI 10.1016/j.cell.2015.08.007
   Raczy C, 2013, BIOINFORMATICS, V29, P2041, DOI 10.1093/bioinformatics/btt314
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Sung YH, 2014, GENOME RES, V24, P125, DOI 10.1101/gr.163394.113
   Swiech L, 2015, NAT BIOTECHNOL, V33, P102, DOI 10.1038/nbt.3055
   Truong DJJ, 2015, NUCLEIC ACIDS RES, V43, P6450, DOI 10.1093/nar/gkv601
   Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025
   Wei H, 2016, EXP EYE RES, V145, P450, DOI 10.1016/j.exer.2015.09.015
   Wright AV, 2015, P NATL ACAD SCI USA, V112, P2984, DOI 10.1073/pnas.1501698112
   Wu ZJ, 2006, MOL THER, V14, P316, DOI 10.1016/j.ymthe.2006.05.009
   Wu ZJ, 2010, MOL THER, V18, P80, DOI 10.1038/mt.2009.255
   Zetsche B, 2015, NAT BIOTECHNOL, V33, P139, DOI 10.1038/nbt.3149
NR 35
TC 346
Z9 378
U1 2
U2 69
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 21
PY 2017
VL 8
AR 14500
DI 10.1038/ncomms14500
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EL3DE
UT WOS:000394499000001
PM 28220790
OA Green Published, gold, Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Tian, Y
   Kijlstra, A
   Renes, J
   Wabitsch, M
   Webers, CAB
   Berendschot, TTJM
AF Tian, Yuan
   Kijlstra, Aize
   Renes, Johan
   Wabitsch, Martin
   Webers, Carroll A. B.
   Berendschot, Tos T. J. M.
TI Lutein Leads to a Decrease of Factor D Secretion by Cultured Mature
   Human Adipocytes
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-D; AGE-RELATED MACULOPATHY; FACTOR-H POLYMORPHISM;
   MACULAR DEGENERATION; ALTERNATIVE PATHWAY; RISK-FACTORS;
   GENE-EXPRESSION; IN-VIVO; PIGMENT; CAROTENOIDS
AB Purpose. Complement plays an important role in the pathogenesis of age related macular degeneration (AMD) and trials are currently being conducted to investigate the effect of complement inhibition on AMD progression. We previously found that the plasma level of factor D (FD), which is the rate limiting enzyme of the complement alternative pathway, was significantly decreased following lutein supplementation. FD is synthesized by adipose tissue, which is also the main storage site of lutein. In view of these findings we tested the hypothesis whether lutein could affect FD synthesis by adipocytes. Methods. A cell line of mature human adipocytes was incubated with 50 mu g/mL lutein for 24 and 48 h, whereafter FD mRNA and protein expression were measured. Results. Lutein significantly inhibited adipocyte FD mRNA expression and FD protein release into adipocyte culture supernatants. Conclusions. Our earlier observations showing that a daily lutein supplement in individuals with early signs of AMD lowered the level of circulating FD might be caused by blocking adipocyte FD production.
C1 [Tian, Yuan; Kijlstra, Aize; Webers, Carroll A. B.; Berendschot, Tos T. J. M.] Univ Eye Clin Maastricht, NL-6202 AZ Maastricht, Netherlands.
   [Renes, Johan] Maastricht Univ, NUTRIM Sch Nutr Toxicol & Metab, Dept Human Biol, Maastricht, Netherlands.
   [Wabitsch, Martin] Univ Ulm, Sekt Padiatr Endokrinol & Diabetol, D-89069 Ulm, Germany.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Maastricht University; Maastricht University Medical Centre (MUMC); Ulm
   University
RP Berendschot, TTJM (通讯作者)，Univ Eye Clin Maastricht, Postbus 5800, NL-6202 AZ Maastricht, Netherlands.
EM t.berendschot@maastrichtuniversity.nl
RI Berendschot, Tos TJM/M-8509-2016; Webers, Carroll A.B./D-1130-2010
OI Berendschot, Tos TJM/0000-0002-8101-939X; 
FU Chinese Scholarship Council (CSC); MD Fonds; Novartis; ANVVB; LSBS
FX This work was supported by a personal grant (Yuan Tian) from the Chinese
   Scholarship Council (CSC). The study was further supported by the
   following foundations: MD Fonds, Novartis, ANVVB, and LSBS that
   contributed through UitZicht. The funding organizations had no role in
   the design or conduct of this research. They provided unrestricted
   grants.
CR ANTRAS J, 1991, J BIOL CHEM, V266, P1157
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Bamashmus MA, 2004, EYE, V18, P257, DOI 10.1038/sj.eye.6700606
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bovier ER, 2013, NUTRIENTS, V5, P750, DOI 10.3390/nu5030750
   Brazionis L, 2009, BRIT J NUTR, V101, P270, DOI 10.1017/S0007114508006545
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Campbell WD, 2002, MICROBIOL IMMUNOL, V46, P131, DOI 10.1111/j.1348-0421.2002.tb02669.x
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chung HY, 2009, AM J CLIN NUTR, V90, P533, DOI 10.3945/ajcn.2009.27712
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   DEMARCO P, 1992, J OPT SOC AM A, V9, P1465, DOI 10.1364/JOSAA.9.001465
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Fischer-Posovszky P, 2008, OBESITY FACTS, V1, P184, DOI 10.1159/000145784
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Furr HC, 1997, J NUTR BIOCHEM, V8, P364, DOI 10.1016/S0955-2863(97)00060-0
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hertle E, 2014, MOL IMMUNOL, V61, P135, DOI 10.1016/j.molimm.2014.06.031
   Hesterberg K, 2012, J BIOPHOTONICS, V5, P33, DOI 10.1002/jbio.201100036
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jager R. D., 2008, NEW ENGL J MED, V358, P2544
   Jin XH, 2006, INVEST OPHTH VIS SCI, V47, P2562, DOI 10.1167/iovs.05-1429
   Jing H, 1998, J MOL BIOL, V282, P1061, DOI 10.1006/jmbi.1998.2089
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Li SY, 2010, INT J MOL SCI, V11, P2109, DOI 10.3390/ijms11052109
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Maslowska M, 2005, VITAM HORM, V70, P309, DOI 10.1016/S0083-6729(05)70010-8
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Muriach M, 2006, FREE RADICAL BIO MED, V41, P979, DOI 10.1016/j.freeradbiomed.2006.06.023
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OLSON JA, 1984, J NATL CANCER I, V73, P1439
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rosenow A, 2010, J PROTEOME RES, V9, P5389, DOI 10.1021/pr100621g
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sharpe LT, 1998, VISION RES, V38, P3233, DOI 10.1016/S0042-6989(97)00457-4
   Silva AS, 2012, MOL VIS, V18, P2288
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tian Y, 2015, ARCH BIOCHEM BIOPHYS, V572, P49, DOI 10.1016/j.abb.2015.01.019
   Tian Y, 2015, ACTA OPHTHALMOL, V93, P141, DOI 10.1111/aos.12535
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520
   WHITE RT, 1992, J BIOL CHEM, V267, P9210
NR 70
TC 1
Z9 1
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 430741
DI 10.1155/2015/430741
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT9TT
UT WOS:000363160200001
PM 26504594
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Kearney, FM
   Fagan, XJ
   Al-Qureshi, S
AF Kearney, Frances M.
   Fagan, Xavier J.
   Al-Qureshi, Salmaan
TI Review of the role of refined dietary sugars (fructose and glucose) in
   the genesis of retinal disease
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE diabetic retinopathy; fructose; metabolic syndrome; retinal vascular
   disease; sugar
ID ENDOTHELIAL GROWTH-FACTOR; CARDIOVASCULAR RISK-FACTORS;
   DIABETIC-RETINOPATHY; ADVANCED GLYCATION; METABOLIC SYNDROME;
   ATHEROSCLEROSIS RISK; INSULIN-RESISTANCE; BLOOD-PRESSURE; MACULAR
   DEGENERATION; INDUCED ACTIVATION
AB This review examines the current evidence of the relationship between sugar consumption and the development of retinal and other eye diseases including diabetic retinopathy, hypertensive retinopathy, age-related macular degeneration, non-arteritic anterior ischaemic optic neuropathy and cataract. Sucrose is comprised of fructose and glucose. Sugar consumption has increased five-fold over the last century, with high quantities of sucrose and high-fructose corn syrup found in processed food and soft drinks. This increased consumption is increasingly recognized as a central factor in the rapidly rising rates of obesity and type 2 diabetes. The body metabolizes fructose and glucose differently, with fructose appearing to have the greater propensity to contribute to the metabolic syndrome. This review examines the effect of high rates of dietary consumption of refined carbohydrates on the eye, including the effect of chronic hyperglycaemia on microvascular disease in diabetic retinopathy, and the pathophysiological changes in the retinal circulation in hypertensive retinopathy.
C1 [Kearney, Frances M.; Fagan, Xavier J.; Al-Qureshi, Salmaan] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Kearney, Frances M.] Vis Ctr Gold Coast, Southport, Qld, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Kearney, FM (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
EM drfranceskearney@gmail.com
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Alwan A, 2011, NONCOMMUNICABLE DIS
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2013, AUSTR DIET GUID
   Arnold AC, 2003, J NEURO-OPHTHALMOL, V23, P157, DOI 10.1097/00041327-200306000-00012
   Basu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057873
   BLASS EM, 1991, PEDIATRICS, V87, P215
   BOYER PD, 1986, ENZYMES A, V17
   Bray GA, 2004, AM J CLIN NUTR, V79, P537
   Bray GA, 2007, AM J CLIN NUTR, V86, P895, DOI 10.1093/ajcn/86.4.895
   Bremer AA, 2012, PEDIATRICS, V129, P557, DOI 10.1542/peds.2011-2912
   Bremer AA, 2011, CTS-CLIN TRANSL SCI, V4, P243, DOI 10.1111/j.1752-8062.2011.00298.x
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Casson RJ, 2004, BRIT J OPHTHALMOL, V88, P816, DOI 10.1136/bjo.2003.024661
   Chanmugam P, 2003, J AM DIET ASSOC, V103, P867, DOI 10.1016/S0002-8223(03)00381-X
   Chibber R, 2003, DIABETES, V52, P1519, DOI 10.2337/diabetes.52.6.1519
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   COAG Reform Council, 2013, HEALTHC 2011 12 COMP
   DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811
   Decombaz J, 2011, MED SCI SPORT EXER, V43, P1964, DOI 10.1249/MSS.0b013e318218ca5a
   Duffey KJ, 2008, AM J CLIN NUTR, V88, p1722S, DOI 10.3945/ajcn.2008.25825C
   EMMERSON BT, 1974, ANN RHEUM DIS, V33, P276, DOI 10.1136/ard.33.3.276
   Gopinath B, 2013, J HUM HYPERTENS, V27, P523, DOI 10.1038/jhh.2013.15
   Gopinath B, 2012, AM J CLIN NUTR, V95, P1215, DOI 10.3945/ajcn.111.031641
   Green Pool Commodity Specialists, 2012, SUG CONS AUSTR STAT
   GRUNSTEIN R, 1993, INT J OBESITY, V17, P533
   HABER GB, 1977, LANCET, V2, P679
   Hayreh SS, 2009, OPHTHALMOLOGY, V116, P1928, DOI 10.1016/j.ophtha.2009.03.006
   HAYREH SS, 1994, AM J OPHTHALMOL, V118, P766, DOI 10.1016/S0002-9394(14)72557-7
   HAYREH SS, 1981, OPHTHALMOLOGICA, V182, P13, DOI 10.1159/000309084
   Hudgins LC, 2011, J CLIN ENDOCR METAB, V96, P861, DOI 10.1210/jc.2010-2007
   HWANG IS, 1987, HYPERTENSION, V10, P512, DOI 10.1161/01.HYP.10.5.512
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   KEYS A, 1970, CIRCULATION, V41, pI1
   Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138
   Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644
   Kok N, 1996, METABOLISM, V45, P1547, DOI 10.1016/S0026-0495(96)90186-9
   Kowluru RA, 2002, FREE RADICAL RES, V36, P993, DOI 10.1080/1071576021000006572
   Krause M. V., 1984, FOOD NUTR DIET THERA, V7th
   Leung H, 2005, EYE, V19, P861, DOI 10.1038/sj.eye.6701668
   Levin LA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1582, DOI 10.1001/archopht.126.11.1582
   Li LJ, 2011, OPHTHALMOLOGY, V118, P1459, DOI 10.1016/j.ophtha.2010.12.007
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   Lustig R., 2012, FAT CHANCE BEATING O
   Lustig RH, 2013, ADV NUTR, V4, P226, DOI 10.3945/an.112.002998
   Lustig RH, 2012, NATURE, V482, P27, DOI 10.1038/482027a
   Lustig RH, 2010, J AM DIET ASSOC, V110, P1307, DOI 10.1016/j.jada.2010.06.008
   Lyons TJ, 2004, INVEST OPHTH VIS SCI, V45, P910, DOI 10.1167/iovs.02-0648
   Maersk M, 2012, AM J CLIN NUTR, V95, P283, DOI 10.3945/ajcn.111.022533
   Mazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839
   McLennon W, 1995, NATL NUTR SURVEY FOO
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Mojon DS, 2002, ARCH OPHTHALMOL-CHIC, V120, P601, DOI 10.1001/archopht.120.5.601
   Monash Obesity & Diabetes Institute, 2013, FACTS FIG
   Moodie R, 2013, LANCET, V381, P670, DOI 10.1016/S0140-6736(12)62089-3
   Moore MC, 2001, DIABETES CARE, V24, P1882, DOI 10.2337/diacare.24.11.1882
   Mule G, 2005, J INTERN MED, V257, P503, DOI 10.1111/j.1365-2796.2005.01493.x
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x
   PANTON RW, 1990, BRIT J OPHTHALMOL, V74, P595, DOI 10.1136/bjo.74.10.595
   PERHEENT.J, 1967, LANCET, V2, P528
   REPKA MX, 1983, AM J OPHTHALMOL, V96, P478, DOI 10.1016/S0002-9394(14)77911-5
   Rikkers W, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-668
   Rizkalla SW, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-82
   SCHORIN MD, 2005, NUTR TODAY, V40, P248
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   SHIBA T, 1993, AM J PHYSIOL, V265, pE783, DOI 10.1152/ajpendo.1993.265.5.E783
   Stanhope KL, 2009, J CLIN INVEST, V119, P1322, DOI 10.1172/JCI37385
   Stanhope KL, 2008, AM J CLIN NUTR, V88, p1733S, DOI 10.3945/ajcn.2008.25825D
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Stitt AW, 2004, DIABETOLOGIA, V47, P1735, DOI 10.1007/s00125-004-1523-3
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Stitt AW, 1997, AM J PATHOL, V150, P523
   Takagi C, 1996, INVEST OPHTH VIS SCI, V37, P2504
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tappy L, 2010, PHYSIOL REV, V90, P23, DOI 10.1152/physrev.00019.2009
   Teff KL, 2004, J CLIN ENDOCR METAB, V89, P2963, DOI 10.1210/jc.2003-031855
   THORBURN AW, 1989, AM J CLIN NUTR, V49, P1155, DOI 10.1093/ajcn/49.6.1155
   Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109
   TOPPING DL, 1971, NUTR METAB, V13, P331
   TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vartanian LR, 2007, AM J PUBLIC HEALTH, V97, P667, DOI 10.2105/AJPH.2005.083782
   VINORES SA, 1988, DIABETES, V37, P1658, DOI 10.2337/diabetes.37.12.1658
   Vos Miriam B, 2008, Medscape J Med, V10, P160
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2004, INVEST OPHTH VIS SCI, V45, P2949, DOI 10.1167/iovs.04-0069
   Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855
NR 97
TC 8
Z9 8
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2014
VL 42
IS 6
BP 564
EP 573
DI 10.1111/ceo.12290
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR8LC
UT WOS:000343825600008
PM 24373051
DA 2022-11-30
ER

PT J
AU Lam, RF
   Rao, SK
   Fan, DSP
   Lau, FTC
   Lam, DSC
AF Lam, RF
   Rao, SK
   Fan, DSP
   Lau, FTC
   Lam, DSC
TI Macular pigment optical density in a Chinese sample
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; Chinese; densitometer; macular pigment
ID AGE-RELATED MACULOPATHY; LUTEIN; CAROTENOIDS; ZEAXANTHIN; SERUM; EYES
AB Purpose: Extensive efforts have been devoted to determining the macular pigment optical density(MPOD) in Caucasian subjects. Unfortunately, no such data in ethnic groups with naturally dark irises are currently available. In this study, we report the values in a sample of Chinese subjects. Methods: The MPOD was measured psychophysically using a densitometer at 0.25 degrees, 0.50 degrees, 1.00 degrees, and 2.00 degrees eccentricity from the foveal center in 92 Chinese subjects. Results: The spatial profile for the averaged MPOD was approximately exponential in form and showed a decline with age (r = -0.23). Subjects aged below 60 years had significantly higher averaged MPOD than those aged 60 years or above. Significant gender differences, in favor of males, were also found in the middle-age groups. Conclusions: Our study reports for the first time the MPOD in a Chinese population. Baseline information on MPOD would aid future research in preventive measures against age-related macular degeneration.
C1 Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lam, DSC (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp 3F, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM dennislam_pub@cuhk.edu.hk
RI Lam, Dennis/AAL-1211-2020
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bieber ML, 1999, INVEST OPHTH VIS SCI, V40, pS353
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Celentano JC, 2002, J NUTR, V132, p535S, DOI 10.1093/jn/132.3.535S
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Pratt S, 1999, J Am Optom Assoc, V70, P39
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   WEITER JJ, 1998, AM J OPHTHALMOL, V106, P287
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 32
TC 20
Z9 20
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP
PY 2005
VL 30
IS 9
BP 799
EP 805
DI 10.1080/02713680590968439
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965VB
UT WOS:000231977400010
PM 16123016
DA 2022-11-30
ER

PT J
AU Grant, MB
   Bernstein, PS
   Boesze-Battaglia, K
   Chew, E
   Curcio, CA
   Kenney, MC
   Klaver, C
   Philp, NJ
   Rowan, S
   Sparrow, J
   Spaide, RF
   Taylor, A
AF Grant, Maria B.
   Bernstein, Paul S.
   Boesze-Battaglia, Kathleen
   Chew, Emily
   Curcio, Christine A.
   Kenney, M. Cristina
   Klaver, Caroline
   Philp, Nancy J.
   Rowan, Sheldon
   Sparrow, Janet
   Spaide, Richard F.
   Taylor, Allen
TI Inside out: Relations between the microbiome, nutrition, and eye health
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
ID MACULAR DEGENERATION; GUT MICROBIOTA; INTESTINAL MICROBIOME;
   MEDITERRANEAN DIET; BONE-MARROW; FATTY-ACIDS; FISH INTAKE; VITAMIN-C;
   PROGRESSION; DISEASE
AB Age-related macular degeneration (AMD) is a complex disease with increasing numbers of individuals being afflicted and treatment modalities limited. There are strong interactions between diet, age, the metabolome, and gut microbiota, and all of these have roles in the pathogenesis of AMD. Communication axes exist between the gut microbiota and the eye, therefore, knowing how the microbiota influences the host metabolism during aging could guide a better understanding of AMD pathogenesis. While considerable experimental evidence exists for a diet-gut-eye axis from murine models of human ocular diseases, human diet-microbiome-metabolome studies are needed to elucidate changes in the gut microbiome at the taxonomic and functional levels that are functionally related to ocular pathology. Such studies will reveal new ways to diminish risk for progression of- or incidence of- AMD. Current data suggest that consuming diets rich in dark fish, fruits, vegetables, and low in glycemic index are most retina-healthful during aging.
C1 [Grant, Maria B.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
   [Bernstein, Paul S.] Univ Utah, Moran Eye Ctr, Dept Ophthalmol, Salt Lake City, UT 84112 USA.
   [Boesze-Battaglia, Kathleen] Univ Penn, Dept Biochem, Philadelphia, PA USA.
   [Chew, Emily; Spaide, Richard F.] NEI, Div Epidemiol & Clin Applicat, Bethesda, MD USA.
   [Curcio, Christine A.] Univ Calif Irvine, Dept Ophthalmol, Irvine, CA USA.
   [Klaver, Caroline] Erasmus MC, Dept Ophthalmol, Dept Epidemiol, Rotterdam, Netherlands.
   [Klaver, Caroline] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Klaver, Caroline] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
   [Philp, Nancy J.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 21218 USA.
   [Rowan, Sheldon; Taylor, Allen] Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Boston, MA USA.
   [Sparrow, Janet] Columbia Univ, Dept Ophthalmol, New York, NY USA.
   [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Taylor, Allen] Univ Alabama Birmingham, 1670 Univ BLVD, VH490, Birmingham, AL 35294 USA.
   [Taylor, Allen] Tufts Univ, USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
C3 University of Alabama System; University of Alabama Birmingham; Utah
   System of Higher Education; University of Utah; University of
   Pennsylvania; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); University of California System; University of
   California Irvine; Erasmus University Rotterdam; Erasmus MC; Radboud
   University Nijmegen; Jefferson University; Tufts University; United
   States Department of Agriculture (USDA); Columbia University; Vitreous
   Retina Macula Consultants of New York; University of Alabama System;
   University of Alabama Birmingham; Tufts University; United States
   Department of Agriculture (USDA)
RP Grant, MB (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.; Taylor, A (通讯作者)，Univ Alabama Birmingham, 1670 Univ BLVD, VH490, Birmingham, AL 35294 USA.; Taylor, A (通讯作者)，Tufts Univ, USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM mariagrant@uabmc.edu; allen.taylor@tufts.edu
OI Philp, Nancy/0000-0001-7028-0448
FU [EY12606];  [EY032753];  [EY028037];  [RO1EY12951];  [P30EY019007]; 
   [EY-026525]
FX Funding EY12606, EY032753, EY028037 to MBG; RO1EY12951, P30EY019007 to
   JRS; EY-026525 to KBB/NJP. We would like to acknowledge Dr. Sergio Li
   Calzi for his help in preparation of the manuscript.
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Albenberg L, 2014, GASTROENTEROLOGY, V147, P1055, DOI 10.1053/j.gastro.2014.07.020
   Albenberg LG, 2014, GASTROENTEROLOGY, V146, P1564, DOI 10.1053/j.gastro.2014.01.058
   Alhajri N, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9102013
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Badal VD, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123759
   Balmer ML, 2014, J IMMUNOL, V193, P5273, DOI 10.4049/jimmunol.1400762
   Barber C, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082638
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Barton Wiley, 2019, F1000Res, V8, DOI 10.12688/f1000research.19481.1
   Beam A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082795
   Bielik V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136803
   Blaak EE, 2020, BENEF MICROBES, V11, P411, DOI 10.3920/BM2020.0057
   Bosco N, 2021, GENES IMMUN, V22, P289, DOI 10.1038/s41435-021-00126-8
   Buford TW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0296-0
   Cardona F, 2013, J NUTR BIOCHEM, V24, P1415, DOI 10.1016/j.jnutbio.2013.05.001
   Chew EY, 2017, OPHTHALMOLOGICA, V238, P1, DOI 10.1159/000473865
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Clark JS, 2022, BRIT J NUTR, V128, P1299, DOI 10.1017/S0007114521003251
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Conway J, 2021, AGEING RES REV, V68, DOI 10.1016/j.arr.2021.101323
   Cordain L, 2005, AM J CLIN NUTR, V81, P341, DOI 10.1093/ajcn.81.2.341
   Cox JR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.670471
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dave JM, 2019, AM J CLIN NUTR, V109, P5, DOI 10.1093/ajcn/nqy339
   DeJong EN, 2020, CELL HOST MICROBE, V28, P180, DOI 10.1016/j.chom.2020.07.013
   Deng YH, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00245-6
   Duvallet C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01973-8
   Edlund A, 2015, ISME J, V9, P2605, DOI 10.1038/ismej.2015.72
   Filosa S, 2018, NEURAL REGEN RES, V13, P2055, DOI 10.4103/1673-5374.241429
   Flint HJ, 2008, NAT REV MICROBIOL, V6, P121, DOI 10.1038/nrmicro1817
   Fragiotta S, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/6096017
   Francisco SG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092862
   Friedman ES, 2018, P NATL ACAD SCI USA, V115, P4170, DOI 10.1073/pnas.1718635115
   Froger N, 2014, PROG RETIN EYE RES, V41, P44, DOI 10.1016/j.preteyeres.2014.03.001
   Gibbons SM, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005364
   Gribble FM, 2019, NAT REV ENDOCRINOL, V15, P226, DOI 10.1038/s41574-019-0168-8
   Harrison EH, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801046
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hujoel P, 2009, J DENT RES, V88, P490, DOI 10.1177/0022034509337700
   Hung SC, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005022
   Jeffery IB, 2016, ISME J, V10, P170, DOI 10.1038/ismej.2015.88
   Johnson AJ, 2019, CELL HOST MICROBE, V25, P789, DOI 10.1016/j.chom.2019.05.005
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   JOSHI JH, 1979, P SOC EXP BIOL MED, V162, P44
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Keppler SJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.670290
   Khosravi A, 2014, CELL HOST MICROBE, V15, P374, DOI 10.1016/j.chom.2014.02.006
   Krebs-Smith SM, 2018, J ACAD NUTR DIET, V118, P1591, DOI 10.1016/j.jand.2018.05.021
   Kuan V, 2021, JAMA OPHTHALMOL, V139, P1299, DOI 10.1001/jamaophthalmol.2021.4601
   Lamichhane S, 2021, METABOLITES, V11, DOI 10.3390/metabo11010055
   Landowski M, 2022, J OCUL PHARMACOL TH, V38, P3, DOI 10.1089/jop.2021.0067
   Langfeld LQ, 2021, EUR J MICROBIOL IMMU, V11, P50, DOI 10.1556/1886.2021.00005
   Lin P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102072
   Lin P, 2019, CLIN EXP OPHTHALMOL, V47, P418, DOI 10.1111/ceo.13493
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Martin GM, 2007, PLOS GENET, V3, P1121, DOI 10.1371/journal.pgen.0030125
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mills S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040923
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Mosconi I, 2013, MUCOSAL IMMUNOL, V6, P1157, DOI 10.1038/mi.2013.12
   Muegge BD, 2011, SCIENCE, V332, P970, DOI 10.1126/science.1198719
   Najeeb S, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090530
   Nicaise P, 1998, SCAND J IMMUNOL, V48, P585
   O'Toole PW, 2015, SCIENCE, V350, P1214, DOI 10.1126/science.aac8469
   Odamaki T, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0708-5
   Pajarillo EAB, 2021, ANIM NUTR, V7, P750, DOI 10.1016/j.aninu.2021.03.005
   Pakpour S, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0368-1
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Patterson E, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/539426
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Pollreisz A, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.26
   Poyet M, 2019, NAT MED, V25, P1442, DOI 10.1038/s41591-019-0559-3
   Prasad R, 2022, INVEST OPHTH VIS SCI, V63, DOI 10.1167/iovs.63.1.5
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1236, DOI 10.1097/IAE.0000000000002995
   Rothschild D, 2018, NATURE, V555, P210, DOI 10.1038/nature25973
   Rowan S, 2020, FREE RADICAL BIO MED, V150, P75, DOI 10.1016/j.freeradbiomed.2020.02.010
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sedghi L, 2019, DENT J-BASEL, V7, DOI 10.3390/dj7020058
   Sholl J, 2021, MBIO, V12, DOI 10.1128/mBio.00579-21
   Snetselaar Linda G, 2021, Nutr Today, V56, P287, DOI 10.1097/NT.0000000000000512
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tada T, 1996, CELL IMMUNOL, V173, P155, DOI 10.1006/cimm.1996.0261
   Vinolo MAR, 2011, NUTRIENTS, V3, P858, DOI 10.3390/nu3100858
   Wall R, 2010, NUTR REV, V68, P280, DOI 10.1111/j.1753-4887.2010.00287.x
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang Lan, 2006, Yan Ke Xue Bao, V22, P244
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Wilmanski T, 2019, NAT BIOTECHNOL, V37, P1217, DOI 10.1038/s41587-019-0233-9
   Xiao SW, 2020, APPL MICROBIOL BIOT, V104, P589, DOI 10.1007/s00253-019-10312-4
   Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zoetendal EG, 2012, ISME J, V6, P1415, DOI 10.1038/ismej.2011.212
   Zysset-Burri DC, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00141-0
NR 111
TC 0
Z9 0
U1 2
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2022
VL 224
AR 109216
DI 10.1016/j.exer.2022.109216
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4Y0BE
UT WOS:000861199100008
PM 36041509
DA 2022-11-30
ER

PT J
AU Hammer, M
   Simon, R
   Meller, D
   Klemm, M
AF Hammer, Martin
   Simon, Rowena
   Meller, Daniel
   Klemm, Matthias
TI Combining fluorescence lifetime with spectral information in
   fluorescence lifetime imaging ophthalmoscopy (FLIO)
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE LIFETIMES; RETINAL-PIGMENT EPITHELIUM; MACULAR
   DEGENERATION; PROGRESSION; DRUSEN
AB Fluorescence lifetime imaging ophthalmoscopy (FLIO) provides information on fluorescence lifetimes in two spectral channels as well as the peak emission wavelength (PEW) of the fluorescence. Here, we combine these measures in an integral three-dimensional lifetime -PEW metric vector and determine a normal range for this vector from measurements in young healthy subjects. While for these control subjects 97 (+/- 8) % (median (interquartile range)) of all para-macular pixels were covered by this normal vector range, it was 67 (+/- 55) % for the elderly healthy, 38 (+/- 43) % for age-related macular degeneration (AMD)-suspect subjects, and only 6 (+/- 4) % for AMD patients. The vectors were significantly different for retinal pigment epithelium (RPE) lesions in AMD patients from that of non-affected tissue (p < 0.001). Lifetime-PEW plots allowed to identify possibly pathologic fundus areas by fluorescence parameters outside a 95% quantile per subject. In a patient follow-up, changes in fluorescence parameters could be traced in the lifetime-PEW metric, showing their change over disease progression.
C1 [Hammer, Martin; Simon, Rowena; Meller, Daniel] Univ Hosp Jena, Dept Ophthalmol, Jena, Germany.
   [Hammer, Martin] Univ Jena, Ctr Med Opt & Photon, Jena, Germany.
   [Klemm, Matthias] Tech Univ Ilmenau, Inst Biomed Engn & Informat, Ilmenau, Germany.
C3 Friedrich Schiller University of Jena; Friedrich Schiller University of
   Jena; Technische Universitat Ilmenau
RP Hammer, M (通讯作者)，Univ Hosp Jena, Dept Ophthalmol, Jena, Germany.; Hammer, M (通讯作者)，Univ Jena, Ctr Med Opt & Photon, Jena, Germany.
EM martin.hammer@med.uni-jena.de
FU Thueringer Aufbaubank [2019 FGR 0083]
FX Thueringer Aufbaubank (2019 FGR 0083).
CR Andersen KM, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.20
   Berezin MY, 2010, CHEM REV, V110, P2641, DOI 10.1021/cr900343z
   Borrelli E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082388
   Borrelli E, 2018, BRIT J OPHTHALMOL, V102, P827, DOI 10.1136/bjophthalmol-2017-310881
   Brauer JL, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.13
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Dysli C, 2019, INVEST OPHTH VIS SCI, V60, P274, DOI 10.1167/iovs.18-25755
   Dysli C, 2018, INVEST OPHTH VIS SCI, V59, P1769, DOI 10.1167/iovs.17-23336
   Dysli C, 2017, RETINA-J RET VIT DIS, V37, P2151, DOI 10.1097/IAE.0000000000001452
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P6714, DOI 10.1167/iovs.16-20392
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P832, DOI 10.1167/iovs.15-18033
   Dysli C, 2015, INVEST OPHTH VIS SCI, V56, P3329, DOI 10.1167/iovs.14-16203
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Feldman TB, 2018, EYE, V32, P1440, DOI 10.1038/s41433-018-0109-0
   Hammer M, 2008, GRAEF ARCH CLIN EXP, V246, P105, DOI 10.1007/s00417-007-0639-9
   Hammer M, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.12.2
   Hammer M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.5.20
   Jaggi D, 2020, RETINA-J RET VIT DIS, V40, P1929, DOI 10.1097/IAE.0000000000002718
   Klemm M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131640
   Malacrida L, 2021, ANNU REV BIOPHYS, V50, P575, DOI 10.1146/annurev-biophys-062920-063631
   Muller PL, 2020, RETINA-J RET VIT DIS, V40, P2332, DOI 10.1097/IAE.0000000000002726
   Nam HS, 2018, BIOMED OPT EXPRESS, V9, P1930, DOI 10.1364/BOE.9.001930
   Sauer L, 2021, EYE, V35, P93, DOI 10.1038/s41433-020-01287-y
   Sauer L, 2020, RETINA-J RET VIT DIS, V40, P695, DOI 10.1097/IAE.0000000000002646
   Sauer L, 2019, OPHTHALMOL RETINA, V3, P814, DOI 10.1016/j.oret.2019.04.025
   Sauer L, 2019, INVEST OPHTH VIS SCI, V60, P3054, DOI 10.1167/iovs.19-26835
   Sauer L, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.9.091415
   Sauer L, 2018, OPHTHALMOL RETINA, V2, P587, DOI 10.1016/j.oret.2017.10.008
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, pAMD65, DOI 10.1167/iovs.17-23764
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Sauer L, 2017, ACTA OPHTHALMOL, V95, P481, DOI 10.1111/aos.13269
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schmidt J, 2017, ACTA OPHTHALMOL, V95, P33, DOI 10.1111/aos.13174
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schultz R., 2021, ACTA OPHTHALMOL, V20, P18
   Schultz R, 2022, ACTA OPHTHALMOL, V100, pE841, DOI 10.1111/aos.14963
   Schultz R, 2022, ACTA OPHTHALMOL, V100, pE612, DOI 10.1111/aos.14950
   Schultz R, 2021, ACTA OPHTHALMOL, V99, pE970, DOI 10.1111/aos.14694
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Solberg Y, 2020, OPHTHALMOLOGICA, V243, P195, DOI 10.1159/000503567
   Solberg Y, 2019, INVEST OPHTH VIS SCI, V60, P2165, DOI 10.1167/iovs.18-26079
   Solberg Y, 2020, RETINA-J RET VIT DIS, V40, P99, DOI 10.1097/IAE.0000000000002411
   Vitale AS, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.33
NR 49
TC 0
Z9 0
U1 0
U2 0
PU Optica Publishing Group
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD OCT 1
PY 2022
VL 13
IS 10
BP 5483
EP 5494
DI 10.1364/BOE.457946
PG 12
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 5T3ID
UT WOS:000875763900002
PM 36425633
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hanineva, A
   Park, KS
   Wang, JJ
   DeAngelis, MM
   Farkas, MH
   Zhang, SX
AF Hanineva, Aneliya
   Park, Karen Sophia
   Wang, Joshua J.
   DeAngelis, Margaret M.
   Farkas, Michael H.
   Zhang, Sarah X.
TI Emerging roles of circular RNAs in retinal diseases
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE age-related macular degeneration; circular RNA; diabetic retinopathy;
   glaucoma; microRNA; proliferative vitreoretinopathy; retina
ID PROLIFERATIVE VITREORETINOPATHY; MACULAR DEGENERATION; PROTEIN;
   IDENTIFICATION; PATHOGENESIS; RETINOPATHY; BIOMARKER; REVEALS; SPONGES
AB Retinal disorders are a group of ocular diseases whose onset is associated with a number of aberrant molecular and cellular processes or physical damages that affect retinal structure and function resulting in neural and vascular degeneration in the retina. Current research has primarily focused on delaying retinal disease with minimal success in preventing or reversing neuronal degeneration. In this review, we explore a relatively new field of research involving circular RNAs, whose potential roles as biomarkers and mediators of retinal disease pathogenesis have only just emerged. While knowledge of circular RNAs function is limited given its novelty, current evidence has highlighted their roles as modulators of microRNAs, regulators of gene transcription, and biomarkers of disease development and progression. Here, we summarize how circular RNAs may be implicated in the pathogenesis of common retinal diseases including diabetic retinopathy, glaucoma, proliferative vitreoretinopathy, and age-related macular degeneration. Further, we explore the potential of circular RNAs as novel biomarkers and therapeutic targets for the diagnosis and treatment of retinal diseases.
C1 [Hanineva, Aneliya; Park, Karen Sophia; Wang, Joshua J.; DeAngelis, Margaret M.; Farkas, Michael H.; Zhang, Sarah X.] Univ Buffalo State Univ New York, Dept Ophthalmol, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
   [Hanineva, Aneliya; Park, Karen Sophia; Wang, Joshua J.; DeAngelis, Margaret M.; Farkas, Michael H.; Zhang, Sarah X.] Univ Buffalo State Univ New York, Ross Eye Inst, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
   [DeAngelis, Margaret M.; Farkas, Michael H.] Vet Adm Western New York Healthcare Syst, Res Serv, Buffalo, NY USA.
   [Farkas, Michael H.; Zhang, Sarah X.] Univ Buffalo State Univ New York, Dept Biochem, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; State University of New York (SUNY) System; State
   University of New York (SUNY) Buffalo; State University of New York
   (SUNY) System; State University of New York (SUNY) Buffalo
RP Zhang, SX (通讯作者)，Univ Buffalo State Univ New York, Dept Ophthalmol, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.; Zhang, SX (通讯作者)，Univ Buffalo State Univ New York, Ross Eye Inst, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.; Zhang, SX (通讯作者)，Univ Buffalo State Univ New York, Dept Biochem, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
EM xzhang38@buffalo.edu
FU NIH/NEI [EY019949, EY025061, EY030970]; Brightfocus Foundation [NGR
   G2019302]; Research to Prevent Blindness
FX This work was supported, in part, by NIH/NEI Grants EY019949, EY025061,
   EY030970 (to SXZ), a research grant NGR G2019302 from the Brightfocus
   Foundation (to SXZ), and an Unrestricted Grant from Research to Prevent
   Blindness to the Department of Ophthalmology, the State University of
   New York at Buffalo.
CR Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Cao MJ, 2019, INT J MED SCI, V16, P1356, DOI 10.7150/ijms.35149
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Charteris DG, 2002, EYE, V16, P369, DOI 10.1038/sj.eye.6700194
   Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y
   Chen X, 2020, MOL THER, V28, P929, DOI 10.1016/j.ymthe.2020.01.010
   Chen XJ, 2020, MOL THER-NUCL ACIDS, V19, P339, DOI 10.1016/j.omtn.2019.11.016
   Cheng J, 2016, BIOINFORMATICS, V32, P1094, DOI 10.1093/bioinformatics/btv656
   Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014
   D'Orazi FD, 2014, TRENDS NEUROSCI, V37, P594, DOI 10.1016/j.tins.2014.07.009
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dong R, 2017, RNA BIOL, V14, P1064, DOI 10.1080/15476286.2016.1269999
   Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007
   Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao Y, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0571-3
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Han B, 2018, PHARMACOL THERAPEUT, V187, P31, DOI 10.1016/j.pharmthera.2018.01.010
   He M, 2021, CURR EYE RES, V46, P277, DOI 10.1080/02713683.2020.1812086
   Hoffmann S, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r34
   Hong HX, 2019, BIOCHEM BIOPH RES CO, V517, P491, DOI 10.1016/j.bbrc.2019.07.095
   Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019
   Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Jiang Q, 2020, J CLIN INVEST, V130, P3833, DOI 10.1172/JCI123353
   Konkel MK, 2015, GENOME BIOL EVOL, V7, P2608, DOI 10.1093/gbe/evv167
   Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7
   Kulcheski FR, 2016, J BIOTECHNOL, V238, P42, DOI 10.1016/j.jbiotec.2016.09.011
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee ECS, 2019, BIOMED PHARMACOTHER, V111, P198, DOI 10.1016/j.biopha.2018.12.052
   Li L, 2019, FEBS LETT, V593, P1179, DOI 10.1002/1873-3468.13423
   Li PF, 2015, CLIN CHIM ACTA, V444, P132, DOI 10.1016/j.cca.2015.02.018
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Li X, 2017, MOL CELL, V67, P214, DOI 10.1016/j.molcel.2017.05.023
   Lima JF, 2018, RNA BIOL, V15, P338, DOI 10.1080/15476286.2018.1445959
   Lin YC, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2966-3
   Liu C, 2019, P NATL ACAD SCI USA, V116, P7455, DOI 10.1073/pnas.1814874116
   Liu C, 2017, THERANOSTICS, V7, P2863, DOI 10.7150/thno.19353
   Ma J, 2019, BIOCHEM BIOPH RES CO, V518, P219, DOI 10.1016/j.bbrc.2019.08.035
   McLaughlin T, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060906
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Metge F, 2017, PEERJ, V5, DOI 10.7717/peerj.2934
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Nishino J, 2004, EMBO J, V23, P1998, DOI 10.1038/sj.emboj.7600202
   Qin ML, 2016, CANCER BIOMARK, V16, P161, DOI 10.3233/CBM-150552
   Schreiner S, 2020, NUCLEIC ACIDS RES, V48, P12326, DOI 10.1093/nar/gkaa1085
   Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004
   Song XF, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw075
   Striglia E, 2020, EXPERT OPIN EMERG DR, V25, P261, DOI 10.1080/14728214.2020.1801631
   Syc-Mazurek SB, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.002
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Uhr K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27987-w
   Wang JJ, 2018, THERANOSTICS, V8, P3408, DOI 10.7150/thno.25156
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622
   Westholm JO, 2014, CELL REP, V9, P1966, DOI 10.1016/j.celrep.2014.10.062
   Wong TY, 2009, DIABETES CARE, V32, P2307, DOI 10.2337/dc09-0615
   Yang L, 2020, CIRCULATION, V142, P556, DOI 10.1161/CIRCULATIONAHA.120.045765
   Yao J, 2019, BIOMED PHARMACOTHER, V111, P548, DOI 10.1016/j.biopha.2018.12.044
   You XT, 2016, SCI REP-UK, V6, DOI 10.1038/srep38820
   Yu CY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0523-z
   Zhang SX, 2015, PROG RETIN EYE RES, V45, P111, DOI 10.1016/j.preteyeres.2014.12.001
   Zhang SJ, 2017, INVEST OPHTH VIS SCI, V58, P6500, DOI 10.1167/iovs.17-22698
   Zhang XO, 2016, GENOME RES, V26, P1277, DOI 10.1101/gr.202895.115
   Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou RM, 2015, BIOCHEM BIOPH RES CO, V465, P324, DOI 10.1016/j.bbrc.2015.07.120
   Zhu K, 2019, EBIOMEDICINE, V49, P341, DOI 10.1016/j.ebiom.2019.10.004
NR 68
TC 2
Z9 2
U1 5
U2 8
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD SEP
PY 2022
VL 17
IS 9
BP 1875
EP 1880
DI 10.4103/1673-5374.335691
PG 6
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 1P7KU
UT WOS:000802184600003
PM 35142661
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Butler, JM
   Supharattanasitthi, W
   Yang, YC
   Paraoan, L
AF Butler, Joe M.
   Supharattanasitthi, Wasu
   Yang, Yit C.
   Paraoan, Luminita
TI RNA-seq analysis of ageing human retinal pigment epithelium: Unexpected
   up-regulation of visual cycle gene transcription
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE A2E; ageing; LRAT; macular degeneration; retinal pigment epithelium;
   retinol metabolism; RNA&#8208; seq; RDH5; RDH10; RDH11; RPE65; visual
   cycle
ID VITAMIN-A; R/BIOCONDUCTOR PACKAGE; ACIDIC RETINOIDS; DEFICIENT MICE;
   LIPOFUSCIN; A2E; EXPRESSION; CELLS; ACCUMULATION; FLUORESCENCE
AB Ageing presents adverse effects on the retina and is the primary risk factor for age-related macular degeneration (AMD). We report the first RNA-seq analysis of age-related transcriptional changes in the human retinal pigment epithelium (RPE), the primary site of AMD pathogenesis. Whole transcriptome sequencing of RPE from human donors ranging in age from 31 to 93 reveals that ageing is associated with increasing transcription of main RPE-associated visual cycle genes (including LRAT, RPE65, RDH5, RDH10, RDH11; pathway enrichment BH-adjusted P = 4.6 x 10(-6)). This positive correlation is replicated in an independent set of 28 donors and a microarray dataset of 50 donors previously published. LRAT expression is positively regulated by retinoid by-products of the visual cycle (A2E and all-trans-retinal) involving modulation by retinoic acid receptor alpha transcription factor. The results substantiate a novel age-related positive feedback mechanism between accumulation of retinoid by-products in the RPE and the up-regulation of visual cycle genes.
C1 [Butler, Joe M.; Supharattanasitthi, Wasu; Paraoan, Luminita] Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, 6 West Derby St, Liverpool L7 8TX, Merseyside, England.
   [Yang, Yit C.] Wolverhampton Eye Infirm, Dept Ophthalmol, New Cross Hosp, Wolverhampton, England.
   [Butler, Joe M.] Amsterdam UMC, Ctr Expt & Mol Med, Amsterdam, Netherlands.
   [Supharattanasitthi, Wasu] Mahidol Univ, Fac Pharm, Dept Physiol, Bangkok, Thailand.
C3 University of Liverpool; New Cross Hospital; University of Amsterdam;
   Mahidol University
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, 6 West Derby St, Liverpool L7 8TX, Merseyside, England.
EM lparaoan@liverpool.ac.uk
OI Butler, Joe/0000-0001-6781-6408
FU R&D Royal Wolverhampton NHS Trust, Wolverhampton, UK
FX We thank the donors, their families and the Manchester Eye Bank for
   their generous role in this research. We thank Drs Sheldon Miller and
   Arvydas Maminishkis of NEI, NIH, USA for generously providing hfRPE
   cells and valuable advice for their use, and Dr T. Michael Redmond for
   the kind gift of A2E. We also acknowledge the support received from R&D
   Royal Wolverhampton NHS Trust, Wolverhampton, UK.
CR Abdelmohsen K, 2013, AGING CELL, V12, P890, DOI 10.1111/acel.12115
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Acar N, 2007, EXP EYE RES, V84, P143, DOI 10.1016/j.exer.2006.09.009
   Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Andrews S., 2010, BABRAHAM BIOINFORMAT
   Bai XY, 2009, MATRIX BIOL, V28, P194, DOI 10.1016/j.matbio.2009.02.004
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Cai H, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00008
   Cai K, 2009, INT J BIOCHEM CELL B, V41, P546, DOI 10.1016/j.biocel.2008.06.007
   Chang Q, 2014, J BIOL CHEM, V289, P8337, DOI 10.1074/jbc.M113.507152
   Chen CH, 2012, J BIOL CHEM, V287, P24662, DOI 10.1074/jbc.M112.354514
   Cioffi CL, 2020, J MED CHEM, V63, P11054, DOI 10.1021/acs.jmedchem.0c00996
   Damek-Poprawa M, 2009, J BIOL CHEM, V284, P10877, DOI 10.1074/jbc.M808857200
   Davies L, 2009, J CELL MOL MED, V13, P1995, DOI 10.1111/j.1582-4934.2008.00590.x
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Fabregat A, 2018, BIOINFORMATICS, V34, P1208, DOI 10.1093/bioinformatics/btx752
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hu Y, 2011, INVEST OPHTH VIS SCI, V52, P5507, DOI 10.1167/iovs.10-7118
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   KATZ ML, 1986, MECH AGEING DEV, V35, P291, DOI 10.1016/0047-6374(86)90131-4
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446
   Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, INVEST OPHTH VIS SCI, V50, P5435, DOI 10.1167/iovs.09-3944
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200
   Masuda T, 2014, J BIOL CHEM, V289, P12908, DOI 10.1074/jbc.M114.556738
   McCaffery P, 1996, P NATL ACAD SCI USA, V93, P12570, DOI 10.1073/pnas.93.22.12570
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Mitry D, 2010, BRIT J OPHTHALMOL, V94, P678, DOI 10.1136/bjo.2009.157727
   Mondul AM, 2011, HUM MOL GENET, V20, P4724, DOI 10.1093/hmg/ddr387
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Passeron T, 2009, J CLIN INVEST, V119, P954, DOI 10.1172/JCI34015
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Poliakov E, 2014, MOL VIS, V20, P285
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Saddala MS, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0199-1
   Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wimmers S, 2007, INVEST OPHTH VIS SCI, V48, P5767, DOI 10.1167/iovs.07-0412
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wolfson M, 2009, INT J BIOCHEM CELL B, V41, P516, DOI 10.1016/j.biocel.2008.08.026
   Wu LL, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-72
   Wu LL, 2010, J LIPID RES, V51, P378, DOI 10.1194/jlr.M001222
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e
NR 74
TC 8
Z9 8
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2021
VL 25
IS 12
BP 5572
EP 5585
DI 10.1111/jcmm.16569
EA MAY 2021
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA SN7XS
UT WOS:000645958300001
PM 33934486
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rinella, NT
   Zhou, H
   Zhang, QQ
   Keiner, C
   Oldenburg, CE
   Duncan, JL
   Wang, RKK
   Schwartz, DM
AF Rinella, Nicholas T.
   Zhou, Hao
   Zhang, Qinqin
   Keiner, Cathrine
   Oldenburg, Catherine E.
   Duncan, Jacque L.
   Wang, Ruikang K.
   Schwartz, Daniel M.
TI Quantifying Choriocapillaris Flow Voids in Patients With Geographic
   Atrophy Using Swept-Source OCT Angiography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; SPECTRAL-DOMAIN; MACULAR DEGENERATION;
   VASCULATURE; EYES; RPE
AB BACKGROUND AND OBJECTIVE: To compare choriocapillaris (CC) flow voids (FVs) throughout the macula in patients with age-related macular degeneration (AMD) and geographic atrophy (GA) to age-similar controls using swept-source optical coherence tomography angiography (SS-OCTA).
   PATIENTS AND METHODS: In this cross-sectional study, 12 subjects with GA secondary to nonexudative AMD and 12 age-similar controls participated. SS-OCTA was performed using a 6 mm x 6 mm scanning pattern. CC FVs were calculated using a one-standard deviation thresholding method developed from a normal database.
   RESULTS: CC FVs were significantly increased in patients with GA compared with age-similar controls (P < .001). FVs within 2 degrees of GA were significantly increased compared with the area outside 2 degrees (P < .001). FVs beyond 2 degrees of GA were significantly increased compared with age-similar controls (P < .001).
   CONCLUSIONS: FV analysis of in vivo CC images revealed diffuse CC perfusion deficits throughout the macular region in subjects with GA secondary to nonextidative AMD.
C1 [Rinella, Nicholas T.; Keiner, Cathrine; Oldenburg, Catherine E.; Duncan, Jacque L.; Schwartz, Daniel M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Zhou, Hao; Zhang, Qinqin; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Oldenburg, Catherine E.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of Washington; University of Washington Seattle; University
   of California System; University of California San Francisco
RP Schwartz, DM (通讯作者)，10 Koret Way, San Francisco, CA 94117 USA.
EM Dan.Schwartz@ucsf.edu
RI Wang, Ruikang/L-3889-2019; Zhou, Hao/U-7850-2017
OI Wang, Ruikang/0000-0001-5169-8822; Zhou, Hao/0000-0003-0068-5102
FU National Institutes of Health [EY002162, EY024239, EY24158]; U.S. Food
   and Drug Administration [R01-41001]; L.L. Hillblom Foundation; That Man
   May See, Inc.; Foundation Fighting Blindness; Research to Prevent
   Blindness; Bernard A. Newcomb Macular Degeneration Fund; Hope for
   Vision; Beckman Initiative [1201]; Claire Giannini Fund; Hedco
   Foundation; Pritzker Foundation; Advanced Retina Imaging Network;
   NATIONAL EYE INSTITUTE [R01EY024239, R01EY024158] Funding Source: NIH
   RePORTER
FX Supported by the National Institutes of Health (EY002162, EY024239,
   EY24158), U.S. Food and Drug Administration (R01-41001), L.L. Hillblom
   Foundation Research Network Grant, That Man May See, Inc., Foundation
   Fighting Blindness, Research to Prevent Blindness, Bernard A. Newcomb
   Macular Degeneration Fund, Hope for Vision, Beckman Initiative for
   Macular Research [1201], Claire Giannini Fund, Hedco Foundation,
   Pritzker Foundation, and Advanced Retina Imaging Network.
CR An L, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3369811
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Gorczynska I, 2017, PROC SPIE, V10045, DOI 10.1117/12.2251704
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Wang RKK, 2016, OPT LETT, V41, P2330, DOI 10.1364/OL.41.002330
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   WYBAR KC, 1954, J ANAT, V88, P94
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 31
TC 5
Z9 5
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2019
VL 50
IS 9
BP E229
EP E235
DI 10.3928/23258160-20190905-14
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA JC5LI
UT WOS:000489323500002
PM 31589763
DA 2022-11-30
ER

PT J
AU Sun, T
   Liu, Y
   Cook, RJ
   Chen, W
   Ding, Y
AF Sun, Tao
   Liu, Yi
   Cook, Richard J.
   Chen, Wei
   Ding, Ying
TI Copula-based score test for bivariate time-to-event data, with
   application to a genetic study of AMD progression
SO LIFETIME DATA ANALYSIS
LA English
DT Article
DE AMD progression; Bivariate time-to-event; Copula; GWAS; Generalized
   score test
ID MACULAR DEGENERATION; DISEASE
AB Motivated by a genome-wide association study to discover risk variants for the progression of Age-related Macular Degeneration (AMD), we develop a computationally efficient copula-based score test, in which the dependence between bivariate progression times is taken into account. Specifically, a two-step estimation approach with numerical derivatives to approximate the score function and observed information matrix is proposed. Both parametric and weakly parametric marginal distributions under the proportional hazards assumption are considered. Extensive simulation studies are conducted to evaluate the Type I error control and power performance of the proposed method. Finally, we apply our method to a large randomized trial data, the Age-related Eye Disease Study, to identify susceptible risk variants for AMD progression. The top variants identified on Chromosome 10 show significantly differential progression profiles for different genetic groups, which are critical in characterizing and predicting the risk of progression-to-late-AMD for patients with mild to moderate AMD.
C1 [Sun, Tao; Liu, Yi; Ding, Ying] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Cook, Richard J.] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON, Canada.
   [Chen, Wei] Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Waterloo; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh
RP Ding, Y (通讯作者)，Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
EM tao.sun@pitt.edu; yiliu8927@gmail.com; rjcook@uwaterloo.ca;
   wei.chen@chp.edu; yingding@pitt.edu
RI Chen, Wei/AAX-5994-2020
OI Chen, Wei/0000-0001-7196-8703; Cook, Richard/0000-0002-1414-4908; Sun,
   Tao/0000-0003-4447-3005
FU National Institute of Health [EY024226]; NATIONAL EYE INSTITUTE
   [R01EY024226] Funding Source: NIH RePORTER
FX This research is supported by the National Institute of Health
   (EY024226). We would like to thank the participants in the AREDS study,
   who made this research possible, and International AMD Genomics
   Consortium for generating the genetic data and performing quality check.
CR Akaike H, 1998, SELECTED PAPERS HIRO, P477
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Breslow NE., 1972, COX J ROY STAT SOC S, V34, P216, DOI [10.1111/j.2517-6161.1972.tb00900.x, DOI 10.1111/J.2517-6161.1972.TB00900.X]
   Cantor RM, 2010, AM J HUM GENET, V86, P6, DOI 10.1016/j.ajhg.2009.11.017
   Chen XH, 2010, J ECONOMETRICS, V157, P129, DOI 10.1016/j.jeconom.2009.10.021
   Chen Zhengzhang, 2012, THESIS
   CLAYTON DG, 1978, BIOMETRIKA, V65, P141, DOI 10.2307/2335289
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cox DR, 1979, THEOR STAT
   Ding Y., 2011, ANN STAT, V39, P2795
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goethals K, 2008, J APPL STAT, V35, P1071, DOI 10.1080/02664760802271389
   GUMBEL EJ, 1960, J AM STAT ASSOC, V55, P698, DOI 10.2307/2281591
   He WQ, 2003, BIOMETRICS, V59, P837, DOI 10.1111/j.0006-341X.2003.00098.x
   Hougaard P, 2000, ANAL MULTIVAR SURVIV
   Joe H., 1997, MULTIVARIATE MODELS
   Kim G, 2007, COMPUT STAT DATA AN, V51, P2836, DOI 10.1016/j.csda.2006.10.009
   Lawless JF, 2011, BIOMETRICAL J, V53, P779, DOI 10.1002/bimj.201000131
   Lee EW, 1992, SURVIVAL ANAL STATE, P237, DOI [DOI 10.1007/978-94-015-7983-4_14, 10.1007/978-94-015-7983-4_14]
   Lindfield GR., 1989, MICROCOMPUTERS NUMER
   Mei M, 2016, THESIS
   Nelson R.B., 2006, INTRO COPULAS
   OAKES D, 1922, J R STAT SOC B, V44, P414
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sha QY, 2011, GENET EPIDEMIOL, V35, P350, DOI 10.1002/gepi.20583
   Shih JH, 1995, BIOMETRICS, V51, P1384, DOI 10.2307/2533269
   Sklar M., 1959, FONCTIONS REPARTITIO, DOI DOI 10.1007/978-3-642-33590-7
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Wang WJ, 2000, J AM STAT ASSOC, V95, P62
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Zhang SL, 2016, J ECONOMETRICS, V193, P215, DOI 10.1016/j.jeconom.2016.02.017
NR 37
TC 8
Z9 8
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1380-7870
EI 1572-9249
J9 LIFETIME DATA ANAL
JI Lifetime Data Anal.
PD JUL
PY 2019
VL 25
IS 3
BP 546
EP 568
DI 10.1007/s10985-018-09459-5
PG 23
WC Mathematics, Interdisciplinary Applications; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematics
GA IC5YM
UT WOS:000471045500008
PM 30560439
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gong, Y
   Fu, ZJ
   Liegl, R
   Chen, J
   Hellstrom, A
   Smith, LEH
AF Gong, Yan
   Fu, Zhongjie
   Liegl, Raffael
   Chen, Jing
   Hellstrom, Ann
   Smith, Lois E. H.
TI omega-3 and omega-6 long-chain PUFAs and their enzymatic metabolites in
   neovascular eye diseases
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Review
DE lipid metabolism; long-chain polyunsaturated fatty acid; retinopathy of
   prematurity; diabetic retinopathy; age-related macular degeneration
ID POLYUNSATURATED FATTY-ACIDS; ENDOTHELIAL GROWTH-FACTOR; DOCOSAHEXAENOIC
   ACID; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; RETINAL NEURODEGENERATION; EMULSION SUPPLEMENTATION;
   PRO12ALA POLYMORPHISM; PRETERM INFANTS
AB Neovascular eye diseases, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration, threaten the visual health of children and adults. Current treatment options, including anti-vascular endothelial growth factor therapy and laser retinal photocoagulation, have limitations and are associated with adverse effects; therefore, the identification of additional therapies is highly desirable. Both clinical and experimental studies show that dietary omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFAs) reduce retinal and choroidal angiogenesis. The omega-3 LC-PUFA metabolites from 2 groups of enzymes, cyclooxygenases and lipoxygenases, inhibit [and the omega-6 (n-6) LC-PUFA metabolites promote] inflammation and angiogenesis. However, both of the omega-3 and the omega-6 lipid products of cytochrome P450 oxidase 2C promote neovascularization in both the retina and choroid, which suggests that inhibition of this pathway might be beneficial. This review summarizes our current understanding of the roles of omega-3 and omega-6 LC-PUFAs and their enzymatic metabolites in neovascular eye diseases.
C1 [Gong, Yan; Fu, Zhongjie; Liegl, Raffael; Chen, Jing; Smith, Lois E. H.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
   [Hellstrom, Ann] Univ Gothenburg, Sahlgrenska Acad, Dept Ophthalmol, Gothenburg, Sweden.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of Gothenburg
RP Smith, LEH (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
EM lois.smith@childrens.harvard.edu
OI Smith, Lois/0000-0001-7644-6410; Gong, Yan/0000-0002-4805-0459
FU NIH/National Eye Institute [EY017017, EY024864, HD18655, EY024963]; Lowy
   Medical Research Institute; European Commission [305485]; Knights
   Templar Eye Foundation [76293]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY024864, R01EY024963,
   R01EY017017] Funding Source: NIH RePORTER
FX Supported by the NIH/National Eye Institute [EY017017, EY024864, and
   HD18655; EY024963 (to JC)], the Lowy Medical Research Institute, the
   European Commission FP7 PREVENT-ROP project 305485 (LEHS), and the
   Knights Templar Eye Foundation 76293 (to ZF).
CR Abcouwer SF, 2014, ANN NY ACAD SCI, V1311, P174, DOI 10.1111/nyas.12412
   Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Agostoni C, 2008, PEDIATR RES, V64, P298, DOI 10.1203/PDR.0b013e31817d9c23
   Alhouayek M, 2014, TRENDS PHARMACOL SCI, V35, P284, DOI 10.1016/j.tips.2014.03.001
   Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ansquer JC, 2009, CURR PHARM DESIGN, V15, P537, DOI 10.2174/138161209787315701
   Arnold C, 2010, PHARMACOL REP, V62, P536, DOI 10.1016/S1734-1140(10)70311-X
   Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Avraham-Davidi I, 2013, EXP CELL RES, V319, P1298, DOI 10.1016/j.yexcr.2013.01.009
   BAILEY JNC, 2014, COLD SPRING HARBOR P, V4
   Barnett JM, 2010, INVEST OPHTH VIS SCI, V51, P1136, DOI 10.1167/iovs.09-3691
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2009, PROSTAG LEUKOTR ESS, V81, P205, DOI 10.1016/j.plefa.2009.05.024
   Beauchamp MH, 2001, J APPL PHYSIOL, V90, P2279, DOI 10.1152/jappl.2001.90.6.2279
   Bennett LD, 2014, INVEST OPHTH VIS SCI, V55, P3150, DOI 10.1167/iovs.14-13995
   Berry KAZ, 2014, J LIPID RES, V55, P504, DOI 10.1194/jlr.M044990
   Bogdanov P, 2015, ACTA DIABETOL, V52, P113, DOI 10.1007/s00592-014-0610-2
   Calandria JM, 2009, J BIOL CHEM, V284, P17877, DOI 10.1074/jbc.M109.003988
   Carlo WA, 2010, NEW ENGL J MED, V362, P1959, DOI 10.1056/NEJMoa0911781
   Chang Yo-Chen, 2013, Rev Diabet Stud, V10, P121, DOI 10.1900/RDS.2013.10.121
   Chen WQ, 2007, INVEST OPHTH VIS SCI, V48, P18, DOI 10.1167/iovs.06-0619
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Chen WQ, 2003, INVEST OPHTH VIS SCI, V44, P5016, DOI 10.1167/iovs.03-0418
   Cheranov SY, 2008, BLOOD, V111, P5581, DOI 10.1182/blood-2007-11-126680
   Cheung CMG, 2012, MOL VIS, V18, P830
   Cheung N, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2970
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2443, DOI 10.1016/j.ophtha.2014.07.019
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Crosby-Nwaobi R, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/191382
   Das UN, 2013, NUTRITION, V29, P1, DOI 10.1016/j.nut.2012.02.003
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520
   Eftekhari Mohammad Hassan, 2014, Adv Biomed Res, V3, P15, DOI 10.4103/2277-9175.124644
   Elbein SC, 2011, DIABETES, V60, P1019, DOI 10.2337/db10-1270
   Fu ZF, 2016, BBA-MOL BASIS DIS, V1862, P1392, DOI 10.1016/j.bbadis.2016.05.002
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Gong Y, 2016, ARTERIOSCL THROM VAS, V36, P1919, DOI 10.1161/ATVBAHA.116.307558
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Gonzalez-Casanova I, 2016, AM J CLIN NUTR, V103, P1171, DOI 10.3945/ajcn.115.121244
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Gubitosi-Klug RA, 2008, DIABETES, V57, P1387, DOI 10.2337/db07-1217
   Harkewicz R, 2012, J BIOL CHEM, V287, P11469, DOI 10.1074/jbc.M111.256073
   Harris WS, 2015, J PERINATOL, V35, P1, DOI 10.1038/jp.2014.195
   Hartnett ME, 2012, NEW ENGL J MED, V367, P2515, DOI 10.1056/NEJMra1208129
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hoffman DR, 2015, INVEST OPHTH VIS SCI, V56, P6646, DOI 10.1167/iovs.15-17786
   Hombrebueno JR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18316
   Imig JD, 2012, PHYSIOL REV, V92, P101, DOI 10.1152/physrev.00021.2011
   Inamori T, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-4
   Innis SM, 2005, PLACENTA, V26, pS70, DOI 10.1016/j.placenta.2005.01.005
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Koleva-Georgieva Desislava N, 2011, Folia Med (Plovdiv), V53, P44
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0
   Lapillonne A, 2013, J PEDIATR-US, V162, pS37, DOI 10.1016/j.jpeds.2012.11.052
   Lapillonne A, 2009, PROSTAG LEUKOTR ESS, V81, P143, DOI 10.1016/j.plefa.2009.05.014
   Le HD, 2009, PROSTAG LEUKOTR ESS, V81, P165, DOI 10.1016/j.plefa.2009.05.020
   Ma JL, 2012, MOL VIS, V18, P2352
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin CR, 2011, J PEDIATR-US, V159, P743, DOI 10.1016/j.jpeds.2011.04.039
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Panigrahy D, 2013, P NATL ACAD SCI USA, V110, P13528, DOI 10.1073/pnas.1311565110
   Patel CK, 2013, EYE, V27, P589, DOI 10.1038/eye.2013.45
   Pawlik D, 2014, JPEN-PARENTER ENTER, V38, P711, DOI 10.1177/0148607113499373
   Pawlik D, 2011, PEDIATRICS, V127, P223, DOI 10.1542/peds.2010-2427
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Puskas LG, 2004, BIOCHIMIE, V86, P817, DOI 10.1016/j.biochi.2004.10.004
   Rahmani E, 2017, MOL CELL ENDOCRINOL, V439, P247, DOI [10.1016/j.mce.2016.09.008, 10]
   REINBOTH JJ, 1995, CURR EYE RES, V14, P1001, DOI 10.3109/02713689508998521
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Rogers LK, 2013, PHARMACOL RES, V70, P13, DOI 10.1016/j.phrs.2012.12.003
   Saito Y, 2008, ATHEROSCLEROSIS, V200, P135, DOI 10.1016/j.atherosclerosis.2008.06.003
   Sala-Vila A, 2016, JAMA OPHTHALMOL, V134, P1142, DOI 10.1001/jamaophthalmol.2016.2906
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.10
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x
   Schwartzman ML, 2010, DIABETES, V59, P1780, DOI 10.2337/db10-0110
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Shao BL, 2014, REDOX BIOL, V2, P694, DOI 10.1016/j.redox.2014.05.005
   Shao Z, 2014, ARTERIOSCL THROM VAS, V34, P581, DOI 10.1161/ATVBAHA.113.302927
   Sheets KG, 2013, MOL VIS, V19, P1747
   Shen JH, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-90
   Shin Eui Seok, 2014, J Ophthalmic Vis Res, V9, P362, DOI 10.4103/2008-322X.143378
   Simo R, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0599-0
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Smith LEH, 2008, INVEST OPHTH VIS SCI, V49, P5177, DOI 10.1167/iovs.08-2584
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Stahl A, 2011, OPHTHALMOLOGE, V108, P777, DOI 10.1007/s00347-011-2371-4
   Stahl A, 2011, BRIT J OPHTHALMOL, V95, P1496, DOI 10.1136/bjo.2010.194241
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   STEVENS MK, 1988, J CEREBR BLOOD F MET, V8, P790, DOI 10.1038/jcbfm.1988.134
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Szymczak M, 2008, BLOOD, V111, P3514, DOI 10.1182/blood-2007-08-109934
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tanaka T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000338
   Tariq K, 2013, MOL VIS, V19, P710
   Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560
   Thakran S, 2015, INVEST OPHTH VIS SCI, V56, P177, DOI 10.1167/iovs.14-15550
   Tikhonenko M, 2010, DIABETES, V59, P219, DOI 10.2337/db09-0728
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Walsky RL, 2005, J CLIN PHARMACOL, V45, P68, DOI 10.1177/0091270004270642
   Wang Y, 2005, J LIPID RES, V46, P706, DOI 10.1194/jlr.M400335-JLR200
   Wang Y, 2006, J LIPID RES, V47, P2028, DOI 10.1194/jlr.M600177-JLR200
   Wong BH, 2016, J BIOL CHEM, V291, P10501, DOI 10.1074/jbc.M116.721340
   Yee P, 2010, INVEST OPHTH VIS SCI, V51, P1755, DOI 10.1167/iovs.09-3792
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200
   Zhang GD, 2013, P NATL ACAD SCI USA, V110, P6530, DOI 10.1073/pnas.1304321110
   Zheng SJ, 2015, INVEST OPHTH VIS SCI, V56, P1168, DOI 10.1167/iovs.14-15612
NR 133
TC 42
Z9 43
U1 1
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUL 1
PY 2017
VL 106
IS 1
BP 16
EP 26
DI 10.3945/ajcn.117.153825
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA EZ3EQ
UT WOS:000404593900005
PM 28515072
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU van Breemen, RB
   Dong, LL
   Pajkovic, ND
AF van Breemen, Richard B.
   Dong, Linlin
   Pajkovic, Natasa D.
TI Atmospheric pressure chemical ionization tandem mass spectrometry of
   carotenoids
SO INTERNATIONAL JOURNAL OF MASS SPECTROMETRY
LA English
DT Article
DE Carotenoid; Carotene; Xanthophyll; Lycopene; APCI; Tandem mass
   spectrometry
ID LYCOPENE
AB Carotenoids are natural pigments synthesized by plants and photosynthetic microorganisms, some of which, like beta-carotene, are precursors of vitamin A, and others such as lutein and lycopene might function in the prevention of age-related macular degeneration and prostate cancer, respectively. Mass spectrometry provides high sensitivity and selectivity for the identification and quantitative analysis of carotenoids in biological samples, and previous studies have described how atmospheric pressure chemical ionization (APCI) offers distinct advantages over electrospray and fast atom bombardment for the analysis of specific carotenoids. Since APCI product ion tandem mass spectra have been reported for only a few carotenoids, a detailed investigation of twelve carotenes and xanthophylls was carried out using both positive ion and negative ion APCI tandem mass spectrometry with collision-induced dissociation. Using protonated molecules as precursor ions in positive ion mode and radical anions in negative ion mode, characteristic fragment ions were identified that may be used to distinguish between carotenoids. (C) 2011 Elsevier B.V. All rights reserved.
C1 [van Breemen, Richard B.; Dong, Linlin; Pajkovic, Natasa D.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP van Breemen, RB (通讯作者)，Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, 833 S Wood St, Chicago, IL 60612 USA.
EM Breemen@uic.edu
RI van Breemen, Richard/AAO-2875-2020
OI van Breemen, Richard/0000-0003-2016-0063
FU National Cancer Institute [R01 CA101052]; Office of Dietary Supplements
   [P50 AT00155]; National Center for Complementary and Alternative
   Medicine; NATIONAL CANCER INSTITUTE [R01CA101052] Funding Source: NIH
   RePORTER; National Center for Complementary & Integrative Health
   [P50AT000155] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCES [S10RR023785] Funding Source: NIH RePORTER
FX This research was supported by grants R01 CA101052 from the National
   Cancer Institute and P50 AT00155 provided to the UIC/NIH Center for
   Botanical Dietary Supplements Research by the Office of Dietary
   Supplements and the National Center for Complementary and Alternative
   Medicine.
CR Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   DemmigAdams B, 1996, FASEB J, V10, P403, DOI 10.1096/fasebj.10.4.8647339
   ENZELL CR, 1969, ACTA CHEM SCAND, V23, P727, DOI 10.3891/acta.chem.scand.23-0727
   Fang LQ, 2003, ANAL CHEM, V75, P812, DOI 10.1021/ac026118a
   SCHMITZ HH, 1992, METHOD ENZYMOL, V213, P322
   SCHWIETE.U, 1965, CHIMIA, V19, P294
   STRAUB O, 1987, KEY CAROTENOIDS
   van Breemen RB, 2008, CANCER LETT, V269, P339, DOI 10.1016/j.canlet.2008.05.016
   vanBreemen RB, 1996, J MASS SPECTROM, V31, P975, DOI 10.1002/(SICI)1096-9888(199609)31:9<975::AID-JMS380>3.0.CO;2-S
   vanBreemen RB, 1997, PURE APPL CHEM, V69, P2061, DOI 10.1351/pac199769102061
   vanBreemen RB, 1996, ANAL CHEM, V68, pA299, DOI 10.1021/ac961911n
   VANBREEMEN RB, 1995, ANAL CHEM, V67, P2004, DOI 10.1021/ac00109a016
   VANBREEMEN RB, 1993, ANAL CHEM, V65, P965, DOI 10.1021/ac00056a003
   VANBREEMEN RB, 1995, J AGR FOOD CHEM, V43, P384, DOI 10.1021/jf00050a024
NR 15
TC 128
Z9 128
U1 1
U2 61
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-3806
J9 INT J MASS SPECTROM
JI Int. J. Mass Spectrom.
PD FEB 15
PY 2012
VL 312
SI SI
BP 163
EP 172
DI 10.1016/j.ijms.2011.07.030
PG 10
WC Physics, Atomic, Molecular & Chemical; Spectroscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physics; Spectroscopy
GA 911BL
UT WOS:000301692200020
PM 22408388
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Niu, N
   Zhang, J
   Sun, YG
   Wang, SN
   Sun, YH
   Korteweg, C
   Gao, WW
   Gu, J
AF Niu, Na
   Zhang, Jie
   Sun, Yingui
   Wang, Shuna
   Sun, Yonghong
   Korteweg, Christine
   Gao, Weiwei
   Gu, Jiang
TI Expression and distribution of immunoglobulin G and its receptors in an
   immune privileged site: the eye
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Immunoglobulin G; IgG receptors; Age-related macular degeneration; Fuchs
   heterochromic cyclitis; Eye; Human; Murine
ID NEONATAL FC-RECEPTOR; AQUEOUS-HUMOR; MACULAR DEGENERATION; IGG; BRAIN;
   MOUSE; BLOOD; CELLS; RECOMBINATION; UVEITIS
AB It has recently been demonstrated that not only mature B lymphocytes, but also non-lymphoid cells, including cancer cells and neurons, express IgG. In the eye, an important immune privileged site, the presence of IgG has been ascribed to IgG entering the eye through breaches of the blood-ocular barrier. Here we demonstrate that the eye itself can produce IgG intrinsically. Applying immunohistochemistry, in situ hybridization, and RT-PCR, several intraocular structures were found to express proteins and mRNA transcripts of IgG heavy chains, light chains, V(D)J rearrangements, and enzymes required for V(D)J recombination. IgG receptors were also detected in the intraocular epithelium and endothelium. The extensive distribution of IgG and its receptors in intraocular structures indicates that locally produced IgG could play a significant role in maintaining the ocular microenvironment and protection of the eyes, and it might also be involved in the pathogenesis of age-related macular degeneration and some inflammatory diseases.
C1 [Korteweg, Christine; Gu, Jiang] Shantou Univ Med Coll, Dept Pathol, Shantou 515041, Peoples R China.
   [Niu, Na; Gao, Weiwei; Gu, Jiang] Peking Univ, Sch Basic Med Sci, Dept Pathol, Beijing 100191, Peoples R China.
   [Niu, Na] Weifang Med Univ, Dept Pathol, Weifang 261042, Peoples R China.
   [Zhang, Jie] Weifang Med Univ, Dept Human Anat, Weifang 261042, Peoples R China.
   [Sun, Yingui] Weifang Med Univ, Dept Anesthesia, Weifang 261042, Peoples R China.
   [Wang, Shuna] Weifang Med Univ, Affiliated Hosp, Dept Ophthalmol, Weifang 261031, Peoples R China.
   [Sun, Yonghong] Weifang Med Univ, Affiliated Hosp, Dept Pathol, Weifang 261031, Peoples R China.
C3 Peking University; Weifang Medical University; Weifang Medical
   University; Weifang Medical University; Weifang Medical University;
   Weifang Medical University
RP Gu, J (通讯作者)，Shantou Univ Med Coll, Dept Pathol, Shantou 515041, Peoples R China.
EM jianggudrive@gmail.com
RI Niu, Na/A-2915-2016
OI Niu, Na/0000-0003-1016-7851; Gu, Jiang/0000-0002-0706-8329
FU National Natural Science Foundation of China [30570686]; Ministry of
   Education, China [B07001]
FX This work was supported by grants from the National Natural Science
   Foundation of China (code: 30570686), Project 111 (B07001) of the
   Ministry of Education, China to Dr. Jiang Gu.
CR ALLANSMITH MR, 1973, ARCH OPHTHALMOL-CHIC, V89, P36, DOI 10.1001/archopht.1973.01000040038010
   ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andoh T, 2004, FASEB J, V18, P182, DOI 10.1096/fj.02-1169fje
   Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104
   Bloch-Michel E, 1997, INT OPHTHALMOL, V21, P187, DOI 10.1023/A:1005909331778
   BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Chen ZS, 2007, FASEB J, V21, P2931, DOI 10.1096/fj.07-8073com
   Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Deane R, 2005, J NEUROSCI, V25, P11495, DOI 10.1523/JNEUROSCI.3697-05.2005
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Ferguson TA, 2006, IMMUNOL REV, V213, P228, DOI 10.1111/j.1600-065X.2006.00430.x
   Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739
   Huang J, 2008, INT J BIOCHEM CELL B, V40, P1604, DOI 10.1016/j.biocel.2007.12.004
   Hulse RE, 2008, J NEUROSCI, V28, P12199, DOI 10.1523/JNEUROSCI.3856-08.2008
   KENNEDY PGE, 1980, LAB INVEST, V43, P342
   Kerschensteiner M, 2009, NEUROSCIENCE, V158, P1122, DOI 10.1016/j.neuroscience.2008.09.009
   Kim H, 2008, INVEST OPHTH VIS SCI, V49, P2025, DOI 10.1167/iovs.07-0871
   Kim H, 2009, MOL VIS, V15
   Kim J, 2009, J IMMUNOL, V182, P2583, DOI 10.4049/jimmunol.0803247
   KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0
   Lee HO, 2002, J IMMUNOL, V169, P4739, DOI 10.4049/jimmunol.169.9.4739
   MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7
   Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7
   MURRAY PI, 1990, INVEST OPHTH VIS SCI, V31, P2129
   Niu N, 2009, LAB INVEST, V89, P636, DOI 10.1038/labinvest.2009.28
   Qiu XY, 2003, CANCER RES, V63, P6488
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Schlachetzki F, 2002, J NEUROCHEM, V81, P203, DOI 10.1046/j.1471-4159.2002.00840.x
   SEN DK, 1977, BRIT J OPHTHALMOL, V61, P216, DOI 10.1136/bjo.61.3.216
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Taylor AW, 2009, EYE, V23, P1885, DOI 10.1038/eye.2008.382
   TITUS JA, 1987, J IMMUNOL, V139, P3153
   VONSALLMANN L, 1948, ARCH OPHTHALMOL-CHIC, V40, P279
   Waldrep J C, 1989, Reg Immunol, V2, P22
   YOUNG JDE, 1984, P NATL ACAD SCI-BIOL, V81, P5430, DOI 10.1073/pnas.81.17.5430
   Zhang Y, 2001, J NEUROIMMUNOL, V114, P168, DOI 10.1016/S0165-5728(01)00242-9
NR 41
TC 44
Z9 47
U1 1
U2 9
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JUL
PY 2011
VL 68
IS 14
BP 2481
EP 2492
DI 10.1007/s00018-010-0572-7
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 782VY
UT WOS:000292042000014
PM 21061041
DA 2022-11-30
ER

PT J
AU Chan, CK
   Lin, SG
AF Chan, C. K.
   Lin, S. G.
TI Retinal pigment epithelial tear after ranibizumab therapy for subfoveal
   fibrovascular pigment epithelial detachment
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; intravitreal injection; Lucentis (R); ranibizumab; retinal
   pigment epithelial rips; retinal pigment epithelial tears
ID CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION
AB PURPOSE. To describe the unusual complication of retinal pigment epithelial (RPE) tear after intravitreal ranibizumab (Lucentis (R)) for subfoveal fibrovascular pigment epithelial detachment (PED) and its effective management.
   METHODS. Chart review for case report of RPE tear after ranibizumab.
   RESULTS. An inferior RPE tear was documented by fluorescein angiography, fundus photography, and optical coherence tomography (OCT) 1 month after receiving repeat ranibizumab injection in the right eye of a patient with bilateral subfoveal fibrovascular PED. He had undergone multiple bevacizumab followed by ranibizumab injections for neovascular age-related macular degeneration (AMD) in both eyes, starting 6 months previously. Subsequent antivascular endothelial growth factor (VEGF) therapy improved vision of right eye from 20/200 to 20/40, despite RPE tear.
   CONCLUSIONS. RPE tear may form after anti-VEGF therapy, including ranibizumab injection. Further anti-VEGF therapy may preserve or improve vision. To the authors' knowledge, this is first case report of effective suppression of neovascular activity with bevacizumab after an RPE tear following ranibizumab therapy.
C1 So Calif Desert Retina Consultants, Palm Springs, CA USA.
   Loma Linda Univ, Dept Ophthalmol, Loma Linda, CA 92350 USA.
C3 Loma Linda University
RP Chan, CK (通讯作者)，POB 2467, Palm Springs, CA 92263 USA.
EM cchan@desertretina.com
CR Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
NR 4
TC 29
Z9 31
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2007
VL 17
IS 4
BP 674
EP 676
DI 10.1177/112067210701700432
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 220FX
UT WOS:000250143700032
PM 17671950
DA 2022-11-30
ER

PT J
AU Mailhot, N
   Cheriton, R
   Vyas, K
   Cook, J
   Prawer, S
   Hinzer, K
   Spinello, D
AF Mailhot, Nathaniel
   Cheriton, Ross
   Vyas, Kaustubh
   Cook, John
   Prawer, Steven
   Hinzer, Karin
   Spinello, Davide
TI Eighty-Five Percent of Improved Optical Power Delivery to Epiretinal
   Prostheses Using Rigid Body Compensation Algorithm
SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
ID RETINAL-PROSTHESIS; BIONIC DEVICES; VISION; RESTORATION; STIMULATION;
   FABRICATION; REFLECTION; IMPLANTS; DIAMOND
AB Vision impairment caused by degenerative retinal pathologies such as age-related macular degeneration can be treated using retinal implants. Such devices receive power and data using cables passing through a permanent surgical incision in the eye wall (sclera), which increases the risk to patients and surgical costs. A recently developed retinal implant design eliminates the necessity of the implant cable using a photonic power converter (PPC), which receives optical power and data through the pupil and is directed by an ellipsoidal reflector and micro-electromechanical mirror. We present a misalignment compensation algorithm model that accounts for rigid-body motions of the reflector relative to the eye and applies the correction to the mirror coordinates in the presence of angular misalignment of the reflector. We demonstrate that up to 85% of the nominal optical power can be delivered to the implant with axial reflector misalignments up to 30 deg using the compensation algorithm.
C1 [Mailhot, Nathaniel; Spinello, Davide] Univ Ottawa, Dept Mech Engn, Ottawa, ON K1N 6M6, Canada.
   [Cheriton, Ross] Natl Res Council Canada, Ottawa, ON K1N 6M6, Canada.
   [Vyas, Kaustubh; Cook, John; Hinzer, Karin] Univ Ottawa, Elect Engn & Comp Sci, Ottawa, ON K1N 6M6, Canada.
   [Prawer, Steven] Univ Melbourne, Dept Phys, Melbourne, Vic 3010, Australia.
C3 University of Ottawa; National Research Council Canada; University of
   Ottawa; University of Melbourne
RP Mailhot, N (通讯作者)，Univ Ottawa, Dept Mech Engn, Ottawa, ON K1N 6M6, Canada.
EM nmail084@uottawa.ca; ross.cheriton@nrc-cnrc.gc.ca; kvyas027@uottawa.ca;
   John.Cook@uottawa.ca; s.prawer@unimelb.edu.au; khinzer@uottawa.ca;
   dspinell@uottawa.ca
OI PRAWER, STEVEN/0000-0002-4959-0828
FU NSERC [EGP506146-2016, RGPIN/057832014]; OCE [31074]
FX NSERC (Grant Nos. EGP506146-2016 and RGPIN/057832014; Funder ID:
   10.13039/501100000038).; OCE (Grant No. 31074; Funder ID:
   10.13039/100009011).
CR Ackermann D Michael, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2932
   Ahnood A, 2016, BIOSENS BIOELECTRON, V77, P589, DOI 10.1016/j.bios.2015.10.022
   Ahnood A, 2015, BIOMED MICRODEVICES, V17, DOI 10.1007/s10544-015-9952-y
   Asher A, 2007, IEEE T BIO-MED ENG, V54, P993, DOI 10.1109/TBME.2007.894828
   Babayeva M, 2015, IEEE T MED IMAGING, V34, P1879, DOI 10.1109/TMI.2015.2413211
   Broehan AM, 2011, IEEE T BIO-MED ENG, V58, P2816, DOI 10.1109/TBME.2011.2159860
   Bruneau A.L., 2019, U.S. Patent App, Patent No. [16/317,374, 16317374]
   Buzurovic Ivan, 2010, 2010 International Conference on BioInformatics and BioEngineering (BIBE), P273, DOI 10.1109/BIBE.2010.52
   Buzurovic I, 2011, IEEE ENG MED BIO, P2156, DOI 10.1109/IEMBS.2011.6090404
   Caspi A, 2018, INVEST OPHTH VIS SCI, V59, P792, DOI 10.1167/iovs.17-22377
   Cheng DL, 2017, CURR EYE RES, V42, P334, DOI 10.1080/02713683.2016.1270326
   Chuang AT, 2014, BRIT J OPHTHALMOL, V98, P852, DOI 10.1136/bjophthalmol-2013-303708
   Dagnelie G, 2017, CLIN EXP OPHTHALMOL, V45, P152, DOI 10.1111/ceo.12812
   Donaldson Paul J, 2017, Prog Retin Eye Res, V56, pe1, DOI 10.1016/j.preteyeres.2016.09.002
   Dutta J, 2013, I S BIOMED IMAGING, P800
   Fafard S, 2016, APPL PHYS LETT, V108, DOI 10.1063/1.4941240
   Ganesan K, 2014, BIOMATERIALS, V35, P908, DOI 10.1016/j.biomaterials.2013.10.040
   Gerding H, 2007, J NEURAL ENG, V4, pS30, DOI 10.1088/1741-2560/4/1/S05
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Gu CZ, 2012, IEEE T BIO-MED ENG, V59, P3117, DOI 10.1109/TBME.2012.2206591
   Jeong J, 2015, IEEE T BIO-MED ENG, V62, P982, DOI 10.1109/TBME.2014.2377197
   JOHANSSON T, 1992, IEEE T BIO-MED ENG, V39, P1292, DOI 10.1109/10.184705
   Johnson KO, 2011, IEEE T MED IMAGING, V30, P655, DOI 10.1109/TMI.2010.2091146
   Jones CE, 2005, VISION RES, V45, P2352, DOI 10.1016/j.visres.2005.03.008
   Kelly SK, 2011, IEEE T BIO-MED ENG, V58, P3197, DOI 10.1109/TBME.2011.2165713
   Kim K, 2010, IEEE T MED IMAGING, V29, P146, DOI 10.1109/TMI.2009.2030679
   Klauke S, 2011, INVEST OPHTH VIS SCI, V52, P449, DOI 10.1167/iovs.09-4410
   Lewis PM, 2016, ANZ J SURG, V86, P654, DOI 10.1111/ans.13616
   Lewis PM, 2015, BRAIN RES, V1595, P51, DOI 10.1016/j.brainres.2014.11.020
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Luo YHL, 2014, BRIT MED BULL, V109, P31, DOI 10.1093/bmb/ldu002
   MASSEY GA, 1969, APPL OPTICS, V8, P975, DOI 10.1364/AO.8.000975
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Mills JO, 2017, EYE, V31, P1383, DOI 10.1038/eye.2017.65
   Moon E, 2017, IEEE T ELECTRON DEV, V64, P2432, DOI 10.1109/TED.2017.2681694
   MURPHY JA, 1987, INT J INFRARED MILLI, V8, P1165, DOI 10.1007/BF01010819
   Schanze T, 2007, IEEE T BIO-MED ENG, V54, P983, DOI 10.1109/TBME.2007.895866
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Teo T, 2016, IEEE CONF IMAGING SY, P77, DOI 10.1109/IST.2016.7738201
   Wei LD, 2018, OPT EXPRESS, V26, P8550, DOI 10.1364/OE.26.008550
   Weiland JD, 2014, IEEE T BIO-MED ENG, V61, P1412, DOI 10.1109/TBME.2014.2314733
   Wilkins MM, 2019, IEEE T POWER ELECTR, V34, P1054, DOI 10.1109/TPEL.2018.2843158
   Zawadzki RJ, 2014, IEEE J SEL TOP QUANT, V20, DOI 10.1109/JSTQE.2013.2288302
NR 43
TC 0
Z9 0
U1 0
U2 1
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0148-0731
EI 1528-8951
J9 J BIOMECH ENG-T ASME
JI J. Biomech. Eng.-Trans. ASME
PD JUN 1
PY 2021
VL 143
IS 6
AR 061009
DI 10.1115/1.4050026
PG 11
WC Biophysics; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Engineering
GA RX3OO
UT WOS:000647136700001
PM 33537711
DA 2022-11-30
ER

PT J
AU Schreiter, S
   Vafia, K
   Barsacchi, R
   Tsang, SH
   Bickle, M
   Ader, M
   Karl, MO
   Tanaka, EM
   Almedawar, S
AF Schreiter, Sven
   Vafia, Katerina
   Barsacchi, Rico
   Tsang, Stephen H.
   Bickle, Marc
   Ader, Marius
   Karl, Mike O.
   Tanaka, Elly M.
   Almedawar, Seba
TI A Human Retinal Pigment Epithelium-Based Screening Platform Reveals
   Inducers of Photoreceptor Outer Segments Phagocytosis
SO STEM CELL REPORTS
LA English
DT Article
ID ALPHA-V-BETA-5 INTEGRIN; ZINC PYRITHIONE; CELLS; EXPRESSION; JUXTANODIN;
   MORPHOLOGY; MECHANISM; CHANNELS; MERTK
AB Phagocytosis is a key function in various cells throughout the body. A deficiency in photoreceptor outer segment (POS) phagocytosis by the retinal pigment epithelium (RPE) causes vision loss in inherited retinal diseases and possibly age-related macular degeneration. To date, there are no effective therapies available aiming at recovering the lost phagocytosis function. Here, we developed a high-throughput screening assay based on RPE derived from human embryonic stem cells (hRPE) to reveal enhancers of POS phagocytosis. One of the hits, ramoplanin (RM), reproducibly enhanced POS phagocytosis and ensheathment in hRPE, and enhanced the expression of proteins known to regulate membrane dynamics and ensheathment in other cell systems. Additionally, RM rescued POS internalization defect in Mer receptor tyrosine kinase (MERTK) mutant hRPE, derived from retinitis pigmentosa patient induced pluripotent stem cells. Our platform, including a primary phenotypic screening phagocytosis assay together with orthogonal assays, establishes a basis for RPE-based therapy discovery aiming at a broad patient spectrum.
C1 [Schreiter, Sven; Vafia, Katerina; Ader, Marius; Karl, Mike O.; Almedawar, Seba] Tech Univ Dresden, Ctr Mol & Cellular Bioengn CMCB, Ctr Regenerat Therapies Dresden CRTD, Fetscherstr 105, D-01307 Dresden, Germany.
   [Barsacchi, Rico; Bickle, Marc] Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.
   [Karl, Mike O.] German Ctr Neurodegenerat Dis DZNE Dresden, Tatzberg 41, D-01307 Dresden, Germany.
   [Tsang, Stephen H.] CUMC Edward S Harkness Eye Inst, 635 West 165th St, New York, NY 10032 USA.
   [Tanaka, Elly M.] Vienna Bioctr VBC, Res Inst Mol Pathol IMP, Campus Vienna Bioctr 1, A-1030 Vienna, Austria.
C3 Technische Universitat Dresden; Max Planck Society; Helmholtz
   Association; German Center for Neurodegenerative Diseases (DZNE);
   Technische Universitat Dresden; Vienna Biocenter (VBC); Research
   Institute of Molecular Pathology (IMP)
RP Almedawar, S (通讯作者)，Tech Univ Dresden, Ctr Mol & Cellular Bioengn CMCB, Ctr Regenerat Therapies Dresden CRTD, Fetscherstr 105, D-01307 Dresden, Germany.
EM seba.almedawar@tu-dresden.de
RI Karl, Mike O./E-7246-2010
OI Karl, Mike O./0000-0002-0926-6556
FU Federal Ministry of Education and Research (BMBF) [03VP01220]; SMWK,
   state of Saxony [TG70]; DFG, Cluster of Excellence (CRTD); TU Dresden
   CRTD; DZNE Helmholtz; HGF [ExNet-0007-Phase2]
FX We would like to acknowledge the Federal Ministry of Education and
   Research (BMBF) for funding this project under the VIP+ program (project
   name and number: Cleansight, 03VP01220), and the TG70 grant by the SMWK,
   state of Saxony. M.K. and E.T. were supported by DFG, Cluster of
   Excellence (CRTD), TU Dresden CRTD; and M.K. by DZNE Helmholtz and HGF
   ExNet-0007-Phase2. We appreciate the support in cell culture from other
   members of the Cleansight team, especially Susanne Luft (MSc) and Dr.
   Dominic Eberle. Additionally, we would like to acknowledge the core
   facilities of the CMCB Technology Platform, especially advanced imaging,
   deep sequencing, flow cytometry, and stem cell engineering facilities
   for providing high-end services.
CR Almedawar S, 2020, STEM CELL REP, V14, P374, DOI 10.1016/j.stemcr.2020.02.004
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Brockschnieder D, 2006, J NEUROSCI, V26, P757, DOI 10.1523/JNEUROSCI.4317-05.2006
   Cai H, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.04.009
   Eid BG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192699
   Fang X, 2006, MOL BIOSYST, V2, P69, DOI 10.1039/b515328j
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Fryer RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052985
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Guziewicz KE, 2017, PROG RETIN EYE RES, V58, P70, DOI 10.1016/j.preteyeres.2017.01.005
   Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Iversen P.W., 2012, ASSAY GUIDANCE MANUA, P1089
   Kinch MS, 2014, DRUG DISCOV TODAY, V19, P1033, DOI 10.1016/j.drudis.2014.03.018
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257
   Law AL, 2015, J BIOL CHEM, V290, P4941, DOI 10.1074/jbc.M114.628297
   Liang FY, 2018, J COMP NEUROL, V526, P205, DOI 10.1002/cne.24301
   Malo N, 2006, NAT BIOTECHNOL, V24, P167, DOI 10.1038/nbt1186
   Miranda GE, 2009, INVEST OPHTH VIS SCI, V50, P4416, DOI 10.1167/iovs.09-3388
   Muller C, 2018, STEM CELL REP, V10, P1075, DOI 10.1016/j.stemcr.2018.01.017
   Muller C, 2014, CELL SIGNAL, V26, P968, DOI 10.1016/j.cellsig.2013.12.021
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Naska S, 2016, STEM CELL REP, V6, P74, DOI 10.1016/j.stemcr.2015.12.002
   Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551
   Priest BT, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00264
   Reeder NL, 2011, BRIT J DERMATOL, V165, P9, DOI 10.1111/j.1365-2133.2011.10571.x
   Schwartz JR, 2016, J DRUGS DERMATOL, V15, P140
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swinney DC, 2013, CLIN PHARMACOL THER, V93, P299, DOI 10.1038/clpt.2012.236
   Tang J, 2009, NEUROSCIENCE, V161, P249, DOI 10.1016/j.neuroscience.2009.03.051
   Thokala S, 2017, BIOMED PHARMACOTHER, V88, P309, DOI 10.1016/j.biopha.2017.01.065
   Valentine WJ, 2010, CELL SIGNAL, V22, P1543, DOI 10.1016/j.cellsig.2010.05.023
   Vestri A, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00296
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang JZ, 2016, PHARMACOL RES, V104, P124, DOI 10.1016/j.phrs.2015.12.024
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   WONG BH, 2016, DEVELOPMENT, V291, P10501, DOI DOI 10.1074/JBC.M116.721340
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
NR 39
TC 2
Z9 2
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD DEC 8
PY 2020
VL 15
IS 6
BP 1347
EP 1361
DI 10.1016/j.stemcr.2020.10.013
PG 15
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PG3CL
UT WOS:000599616800005
PM 33242397
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Li, Y
   Alhendi, AMN
   Yeh, MC
   Elahy, M
   Santiago, FS
   Deshpande, NP
   Wu, B
   Chan, E
   Inam, S
   Prado-Lourenco, L
   Marchand, J
   Joyce, RD
   Wilkinson-White, LE
   Raftery, MJ
   Zhu, MD
   Adamson, SJ
   Barnat, F
   Viaud-Quentric, K
   Sockler, J
   Mackay, JP
   Chang, A
   Mitchell, P
   Marcuccio, SM
   Khachigian, LM
AF Li, Yue
   Alhendi, Ahmad M. N.
   Yeh, Mei-Chun
   Elahy, Mina
   Santiago, Fernando S.
   Deshpande, Nandan P.
   Wu, Ben
   Chan, Enoch
   Inam, Shafqat
   Prado-Lourenco, Leonel
   Marchand, Jessica
   Joyce, Rohan D.
   Wilkinson-White, Lorna E.
   Raftery, Mark J.
   Zhu, Meidong
   Adamson, Samuel J.
   Barnat, Francois
   Viaud-Quentric, Karen
   Sockler, Jim
   Mackay, Joel P.
   Chang, Andrew
   Mitchell, Paul
   Marcuccio, Sebastian M.
   Khachigian, Levon M.
TI Thermostable small-molecule inhibitor of angiogenesis and vascular
   permeability that suppresses a pERK-FosB/Delta FosB-VCAM-1 axis
SO SCIENCE ADVANCES
LA English
DT Article
ID DIABETIC MACULAR EDEMA; GROWTH-FACTOR THERAPY; ANIMAL-MODELS; ACTIVATOR
   PROTEIN-1; ADHESION MOLECULES; MULLER CELLS; C-FOS; VEGF; BEVACIZUMAB;
   RANIBIZUMAB
AB Vascular permeability and angiogenesis underpin neovascular age-related macular degeneration and diabetic retinopathy. While anti-VEGF therapies are widely used clinically, many patients do not respond optimally, or at all, and small-molecule therapies are lacking. Here, we identified a dibenzoxazepinone BT2 that inhibits endothelial cell proliferation, migration, wound repair in vitro, network formation, and angiogenesis in mice bearing Matrigel plugs. BT2 interacts with MEK1 and inhibits ERK phosphorylation and the expression of FosB/Delta FosB, VCAM-1, and many genes involved in proliferation, migration, angiogenesis, and inflammation. BT2 reduced retinal vascular leakage following rat choroidal laser trauma and rabbit intravitreal VEGF-A(165) administration. BT2 suppressed retinal CD31, pERK, VCAM-1, and VEGF-A(165) expression. BT2 reduced retinal leakage in rats at least as effectively as aflibercept, a first-line therapy for nAMD/DR. BT2 withstands boiling or autoclaving and several months' storage at 22 degrees C. BT2 is a new small-molecule inhibitor of vascular permeability and angiogenesis.
C1 [Li, Yue; Alhendi, Ahmad M. N.; Yeh, Mei-Chun; Elahy, Mina; Santiago, Fernando S.; Wu, Ben; Chan, Enoch; Inam, Shafqat; Prado-Lourenco, Leonel; Khachigian, Levon M.] Univ New South Wales, Sch Med Sci, Vasc Biol & Translat Res, Sydney, NSW 2052, Australia.
   [Li, Yue; Alhendi, Ahmad M. N.; Yeh, Mei-Chun; Elahy, Mina; Santiago, Fernando S.; Wu, Ben; Chan, Enoch; Inam, Shafqat; Prado-Lourenco, Leonel; Khachigian, Levon M.] Univ New South Wales, UNSW Med, Sydney, NSW 2052, Australia.
   [Deshpande, Nandan P.] Univ New South Wales, Sch Biotechnol & Biomol Sci, Syst Biol Initiat, Sydney, NSW 2052, Australia.
   [Marchand, Jessica; Joyce, Rohan D.; Marcuccio, Sebastian M.] Adv Mol Technol Pty Ltd, Scoresby, Vic 3179, Australia.
   [Wilkinson-White, Lorna E.] Univ Sydney, Sydney Analyt Core Facil, Sydney, NSW 2006, Australia.
   [Raftery, Mark J.] Univ New South Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW 2052, Australia.
   [Zhu, Meidong] South Eastern Sydney Local Hlth Dist, New South Wales Organ & Tissue Donat Serv, New South Wales Tissue Bank, Kogarah, NSW 2217, Australia.
   [Zhu, Meidong; Chang, Andrew] Univ Sydney, Save Sight Inst, Discipline Clin Ophthalmol & Eye Hlth, Sydney, NSW 2006, Australia.
   [Zhu, Meidong; Adamson, Samuel J.; Chang, Andrew] GreenLight Clin Pty Ltd, Woolloomooloo, NSW 2011, Australia.
   [Barnat, Francois; Viaud-Quentric, Karen] Iris Pharma, F-06610 La Gaude, France.
   [Sockler, Jim] Datapharm Australia Pty Ltd, Stat Operat & Programming, Drummoyne, NSW 2047, Australia.
   [Mackay, Joel P.] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW 2006, Australia.
   [Chang, Andrew] Sydney Eye Hosp, Sydney, NSW 2000, Australia.
   [Chang, Andrew] Univ Sydney, Sydney, NSW 2006, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Hosp, Westmead Inst Med Res, Dept Ophthalmol,Ctr Vis Res, Westmead, NSW 2145, Australia.
   [Marcuccio, Sebastian M.] La Trobe Univ, La Trobe Inst Mol Sci, Melbourne, Vic 3086, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney; University of New South Wales Sydney; University of Sydney;
   University of New South Wales Sydney; University of Sydney; University
   of Sydney; University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; La Trobe University
RP Khachigian, LM (通讯作者)，Univ New South Wales, Sch Med Sci, Vasc Biol & Translat Res, Sydney, NSW 2052, Australia.; Khachigian, LM (通讯作者)，Univ New South Wales, UNSW Med, Sydney, NSW 2052, Australia.
EM l.khachigian@unsw.edu.au
RI Khachigian, Levon/AAZ-7458-2020; Inam, Shafqat/GMW-9458-2022; Mackay,
   Joel/D-6834-2011
OI Mackay, Joel/0000-0001-7508-8033; Li, Yue/0000-0002-5304-9188
FU National Health and Medical Research Council of Australia (NHMRC);
   Cancer Institute New South Wales (CINSW)
FX This work was supported by grants from the National Health and Medical
   Research Council of Australia (NHMRC) and Cancer Institute New South
   Wales (CINSW).
CR Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456-009-9146-4
   Australian Government, 2018, SUMM PHARM BEN SCHEM
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bahrami B, 2016, DIABETOLOGIA, V59, P1594, DOI 10.1007/s00125-016-3974-8
   Barile GR, 1999, CURR EYE RES, V19, P219, DOI 10.1076/ceyr.19.3.219.5314
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Chen SD, 2014, EXPERT REV OPHTHALMO, V9, P285, DOI 10.1586/17469899.2014.939171
   Chen XQ, 2018, J PHARM SCI-US, V107, P1352, DOI 10.1016/j.xphs.2018.01.003
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419
   Dong N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125329
   DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686
   Foureaux G, 2015, BRAZ J MED BIOL RES, V48, P1109, DOI [10.1590/1414-431x20154583, 10.1590/1414-431X20154583]
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hussain S, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-7
   Jia J, 2016, MICROVASC RES, V105, P103, DOI 10.1016/j.mvr.2016.02.004
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Jones FS, 1927, J EXP MED, V46, P291, DOI 10.1084/jem.46.2.291
   Ju X, 2019, CLIN EXP PHARMACOL P, V46, P75, DOI 10.1111/1440-1681.13029
   Khalfaoui T, 2008, J MOL HISTOL, V39, P243, DOI 10.1007/s10735-007-9159-5
   Khoder M, 2018, PHARM DEV TECHNOL, V23, P732, DOI 10.1080/10837450.2017.1364267
   Kim JY, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010011
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Krebs A., 1991, European Patent Office, Patent No. [EP0230224B1, 0230224]
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lamy S, 2002, CANCER RES, V62, P381
   Liu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep21319
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Makhoul M, 2012, EXP EYE RES, V101, P27, DOI 10.1016/j.exer.2012.05.012
   Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671
   Mishra M, 2016, J CELL PHYSIOL, V231, P1709, DOI 10.1002/jcp.25268
   Mitamura Y, 2006, DIABETOLOGIA, V49, P209, DOI 10.1007/s00125-005-0059-5
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975
   Nestler EJ, 2015, EUR J PHARMACOL, V753, P66, DOI [10.1016/j.ejphar.2014.1.0.034, 10.1016/j.ejphar.2014.10.034]
   Oshitari T, 2014, CURR EYE RES, V39, P527, DOI 10.3109/02713683.2013.833248
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Pedrosa AC, 2016, CLIN OPHTHALMOL, V10, P541, DOI 10.2147/OPTH.S90913
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Puhlmann M, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-37
   Robinson R, 2012, DIS MODEL MECH, V5, P444, DOI 10.1242/dmm.009597
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Shao R, 2004, BIOCHEM BIOPH RES CO, V321, P788, DOI 10.1016/j.bbrc.2004.07.033
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Takeda M, 2002, INVEST OPHTH VIS SCI, V43, P907
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Vinores SA, 2007, J NEUROIMMUNOL, V182, P73, DOI 10.1016/j.jneuroim.2006.09.015
   Wang X, 2007, INT J MOL SCI, V8, P61, DOI 10.3390/i8010061
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Ye N, 2014, J MED CHEM, V57, P6930, DOI 10.1021/jm5004733
   Ye XF, 2012, INVEST OPHTH VIS SCI, V53, P3481, DOI 10.1167/iovs.11-9076
NR 60
TC 7
Z9 7
U1 3
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JUL
PY 2020
VL 6
IS 31
AR eaaz7815
DI 10.1126/sciadv.aaz7815
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MV7OU
UT WOS:000556543100008
PM 32923607
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Luo, XT
   Yang, SQ
   Liang, JQ
   Zhai, YX
   Shen, MR
   Sun, JJ
   Feng, YJ
   Lu, XM
   Zhu, H
   Wang, FH
   Sun, XD
AF Luo, Xueting
   Yang, Shiqi
   Liang, Jian
   Zhai, Yuanqi
   Shen, Mengxi
   Sun, Junran
   Feng, Yiji
   Lu, Xinmin
   Zhu, Hong
   Wang, Fenghua
   Sun, Xiaodong
TI Choroidal pericytes promote subretinal fibrosis after experimental
   photocoagulation
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Age-related macular degeneration; Fibrosis; Pericyte
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; GROWTH-FACTOR;
   PERIVASCULAR FIBROBLASTS; GENE-EXPRESSION; RANIBIZUMAB; MECHANISMS;
   ANGIOGENESIS; SCAR
AB Subretinal fibrosis results in local destruction of retinal structures and permanent vision loss, representing the end stage of neovascular age-related macular degeneration (AMD). Histological examination of fibrotic specimens from AMD patients has uncovered a wide range of cellular and acellular components. However, their origins and roles in fibrosis remain largely unexplored. Using a laser-induced photocoagulation model with collagen 1 alpha 1-GFP reporter mice, we demonstrate, by cell-lineage tracing, that pericytes associating with choroidal microvasculature are activated upon injury and infiltrate into the subretinal space as significant components of fibrotic lesions. In contrast to their choroidal precursors, infiltrating pericytes acquire stellate-like structures, upregulate expression of fibrogenic molecules and colocalize with extracellular fibrotic scar. Collectively, our results identify the choroidal perivascular niche as a novel source of subretinal fibrosis after photocoagulation, and suggest that collagen 1-expressing pericytes are potential targets for therapeutic intervention to suppress subretinal fibrosis and preserve vision.
C1 [Luo, Xueting; Yang, Shiqi; Liang, Jian; Zhai, Yuanqi; Shen, Mengxi; Sun, Junran; Feng, Yiji; Lu, Xinmin; Zhu, Hong; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol,Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Luo, Xueting; Liang, Jian; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Luo, Xueting; Zhai, Yuanqi; Zhu, Hong; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Gen Hosp, Shanghai Peoples Hosp 1,Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Luo, XT; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol,Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.; Luo, XT; Sun, XD (通讯作者)，Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.; Luo, XT; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Gen Hosp, Shanghai Peoples Hosp 1,Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM xtluo@sjtu.edu.cn; xdsun@sjtu.edu.cn
RI Yang, Shiqi/CAI-7690-2022; Shen, Mengxi/ABC-6941-2021
OI Shen, Mengxi/0000-0002-1336-1695; Sun, Xiaodong/0000-0001-5015-0945
FU National Natural Science Foundation of China [81425006, 81470640,
   81400413]; Science and Technology Commission of Shanghai Municipality
   [16140900800, 16dz2251500]; Creative Foundation for Translational
   Medicine from School of Medicine, Shanghai Jiao Tong University
   [15ZH4005]; Program for Eastern Young Scholar at Shanghai Institutions
   of Higher Learning [QD2016003]; Shanghai Rising-Star Program
   [17QA1402800]; Shanghai Pujiang Program [16PJ1408500]; Chenxing Project
   from Shanghai Jiao Tong University
FX This work was supported by the National Natural Science Foundation of
   China (81425006, 81470640, 81400413), Science and Technology Commission
   of Shanghai Municipality (16140900800, 16dz2251500), Creative Foundation
   for Translational Medicine from School of Medicine, Shanghai Jiao Tong
   University (15ZH4005), Program for Eastern Young Scholar at Shanghai
   Institutions of Higher Learning (QD2016003), Shanghai Rising-Star
   Program (17QA1402800), Shanghai Pujiang Program (16PJ1408500) and
   Chenxing Project from Shanghai Jiao Tong University.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Giuliano S, 2013, BIOCHIMIE, V95, P1110, DOI 10.1016/j.biochi.2013.03.002
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Hinz Boris, 2010, F1000 Biol Rep, V2, P78, DOI 10.3410/B2-78
   Hou X, 2010, P NATL ACAD SCI USA, V107, P12216, DOI 10.1073/pnas.1004143107
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Krempen K, 1999, GENE EXPRESSION, V8, P151
   Kumar A, 2010, J BIOL CHEM, V285, P15500, DOI 10.1074/jbc.M110.113787
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ribatti D, 2011, INT J DEV BIOL, V55, P261, DOI 10.1387/ijdb.103167dr
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Soderblom C, 2013, J NEUROSCI, V33, P13882, DOI 10.1523/JNEUROSCI.2524-13.2013
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807
   YAMAUCHI K, 1987, J CLIN INVEST, V80, P1720, DOI 10.1172/JCI113263
   Yata Y, 2003, HEPATOLOGY, V37, P267, DOI 10.1053/jhep.2003.50067
NR 33
TC 17
Z9 18
U1 0
U2 5
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD APR
PY 2018
VL 11
IS 4
AR dmm032060
DI 10.1242/dmm.032060
PG 8
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA GF0UV
UT WOS:000431647500005
PM 29622551
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Li, MY
   Zauhar, RJ
   Grazal, C
   Curcio, CA
   DeAngelis, MM
   Stambolian, D
AF Li, Mingyao
   Zauhar, Randy J.
   Grazal, Clare
   Curcio, Christine A.
   DeAngelis, Margaret M.
   Stambolian, Dwight
TI RNA expression in human retina
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   GENE-EXPRESSION; HUMAN TRANSCRIPTOME; EPITHELIAL-CELLS; DISEASE;
   VARIANTS; TECHNOLOGY; BIOGENESIS
AB Recent Genome-wide Association Studies (GWASs) for eye diseases/ traits have delivered a number of novel findings across a diverse range of diseases, including age-related macular degeneration (AMD), glaucoma and refractive error. However, despite this astonishing rate of success, the major challenge still remains to not only confirm that the genes implicated in these studies are truly the genes conferring protection from or risk of disease but also to define the functional roles these genes play in disease. Ongoing evidence is accumulating that the single nucleotide polymorphisms (SNPs) used in GWAS and fine mapping studies have causal effects through their influence on gene expression rather than affecting protein function. The biological interpretation of SNP regulatory effects for a tissue requires knowledge of the transcriptome for that tissue. We summarize the reasons to characterize the complete retinal transcriptome as well as the evidence to include an assessment of differences in regional retinal expression.
C1 [Li, Mingyao] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA.
   [Zauhar, Randy J.] Univ Sci Philadelphia, Dept Chem & Biochem, Philadelphia, PA 19104 USA.
   [Grazal, Clare; Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   [DeAngelis, Margaret M.] Univ Utah, Sch Med, Dept Ophthalmol, Salt Lake City, UT 84132 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Alabama System;
   University of Alabama Birmingham; Utah System of Higher Education;
   University of Utah
RP Stambolian, D (通讯作者)，Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM stamboli@mail.med.upenn.edu
FU [R01EY023164];  [R01GM108600]; NATIONAL EYE INSTITUTE [R01EY023164]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [R01GM108600] Funding Source: NIH RePORTER
FX This research was supported by R01EY023164 to D.S. and R01GM108600 to
   M.L. The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Institutes
   of Health.
CR Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Brennecke P, 2013, NAT METHODS, V10, P1093, DOI [10.1038/nmeth.2645, 10.1038/NMETH.2645]
   Cerase A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0733-y
   Chaitankar V, 2016, PROG RETIN EYE RES, V55, P1, DOI 10.1016/j.preteyeres.2016.06.001
   Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gamazon ER, 2012, AM J HUM GENET, V90, P1046, DOI 10.1016/j.ajhg.2012.04.023
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Hou Q, 2013, INVEST OPHTH VIS SCI, V54, P6481, DOI 10.1167/iovs.13-11873
   Jiang YC, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1200-8
   Karunakaran DKP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075964
   Kitano H, 2004, NAT REV GENET, V5, P826, DOI 10.1038/nrg1471
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolodziejczyk AA, 2015, MOL CELL, V58, P610, DOI 10.1016/j.molcel.2015.04.005
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Li YI, 2016, SCIENCE, V352, P600, DOI 10.1126/science.aad9417
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lukiw WJ, 2012, MOL NEUROBIOL, V46, P11, DOI 10.1007/s12035-012-8234-4
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355
   Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014
   Mondal T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8743
   Morgan DJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017210
   Pinelli M, 2016, NUCLEIC ACIDS RES, V44, P5773, DOI 10.1093/nar/gkw486
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Rivas MA, 2015, SCIENCE, V348, P666, DOI 10.1126/science.1261877
   Sanes JR, 2010, NEURON, V66, P15, DOI 10.1016/j.neuron.2010.01.018
   Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054
   Smith SM, 2012, METHODS MOL BIOL, V823, P119, DOI 10.1007/978-1-60327-216-2_9
   Svensson V, 2017, NAT METHODS, V14, P381, DOI 10.1038/nmeth.4220
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Vance KW, 2014, TRENDS GENET, V30, P348, DOI 10.1016/j.tig.2014.06.001
   Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509
   Wills QF, 2013, NAT BIOTECHNOL, V31, P748, DOI 10.1038/nbt.2642
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
NR 44
TC 5
Z9 5
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2017
VL 26
IS R1
BP R68
EP R74
DI 10.1093/hmg/ddx219
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FC4EW
UT WOS:000406792500010
PM 28854577
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sparrow, JR
AF Sparrow, Janet R.
TI Vitamin A-aldehyde adducts: AMD risk and targeted therapeutics
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; vitamin A-aldehyde adducts;
   bisretinoids; retinal pigment epithelium; photoreceptor cells
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; SUNLIGHT EXPOSURE; BINDING-PROTEIN; MOUSE MODEL; EMIXUSTAT
   HYDROCHLORIDE; GEOGRAPHIC ATROPHY; VISUAL CYCLE; LIPOFUSCIN
AB Although currently available treatment options for age-related macular degeneration (AMD) are limited, particularly for atrophic AMD, the identification of predisposing genetic variations has informed clinical studies addressing therapeutic options such as complement inhibitors and anti-inflammatory agents. To lower risk of early AMD, recommended lifestyle interventions such as the avoidance of smoking and the intake of low glycemic antioxidant-rich diets have largely followed from the identification of nongenetic modifiable factors. On the other hand, the challenge of understanding the complex relationship between aging and cumulative damage leading to AMD has fueled investigations of the visual cycle adducts that accumulate in retinal pigment epithelial (RPE) cells and are a hallmark of aging retina. These studies have revealed properties of these compounds that provide insights into processes that may compromise RPE and could contribute to disease mechanisms in AMD. This work has also led to the design of targeted therapeutics that are currently under investigation.
C1 [Sparrow, Janet R.] Columbia Univ, Dept Ophthalmol, Med Ctr, New York, NY 10032 USA.
   [Sparrow, Janet R.] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Sparrow, JR (通讯作者)，Columbia Univ, Dept Ophthalmol, Med Ctr, New York, NY 10032 USA.; Sparrow, JR (通讯作者)，Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY 10032 USA.
EM jrs88@cumc.columbia.edu
FU National Eye Institute Grants [EY12951, EY024091]; Foundation Fighting
   Blindness; grant from Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [R01EY012951, R01EY024091] Funding Source: NIH RePORTER
FX This work was supported by National Eye Institute Grants EY12951 and
   EY024091; Foundation Fighting Blindness; and a grant from Research to
   Prevent Blindness to the Department of Ophthalmology, Columbia
   University.
CR Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Brady RO, 2006, REJUV RES, V9, P237, DOI 10.1089/rej.2006.9.237
   Caruso RC, 1998, ARCH OPHTHALMOL-CHIC, V116, P759, DOI 10.1001/archopht.116.6.759
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Cioffi CL, 2015, J MED CHEM, V58, P5863, DOI 10.1021/acs.jmedchem.5b00423
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaufman Y, 2011, J BIOL CHEM, V286, P7958, DOI 10.1074/jbc.M110.178640
   Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244
   Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101
   Kiser PD, 2015, NAT CHEM BIOL, V11, P409, DOI [10.1038/NCHEMBIO.1799, 10.1038/nchembio.1799]
   Klein BEK, 2014, INVEST OPHTH VIS SCI, V55, P5855, DOI 10.1167/iovs.14-14602
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mata NL, 2010, CURR OPIN OPHTHALMOL, V21, P190, DOI 10.1097/ICU.0b013e32833866c8
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Quadro L, 2003, MOL ASPECTS MED, V24, P421, DOI 10.1016/S0098-2997(03)00038-4
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sparrow JR, 2003, P NATL ACAD SCI USA, V100, P4353, DOI 10.1073/pnas.1031478100
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Teussink MM, 2015, AM J OPHTHALMOL, V159, P964, DOI 10.1016/j.ajo.2015.02.004
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Zhang JY, 2015, MOL PHARMACOL, V87, P477, DOI 10.1124/mol.114.096560
   Zhou JL, 2006, REJUV RES, V9, P256, DOI 10.1089/rej.2006.9.256
   Zhou JL, 2015, J BIOL CHEM, V290, P27215, DOI 10.1074/jbc.M115.680363
NR 75
TC 27
Z9 28
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 26
PY 2016
VL 113
IS 17
BP 4564
EP 4569
DI 10.1073/pnas.1600474113
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DK2MK
UT WOS:000374748400026
PM 27071115
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Zhang, PP
   Su, Y
   Liu, F
AF Zhang, Peipei
   Su, Yan
   Liu, Fang
TI The relationship between intervention in the CD40 signal pathway and
   choroidal neovascularization
SO ONCOTARGETS AND THERAPY
LA English
DT Review
DE choroidal neovascularization; NV; CD40; angiogenesis factor
ID ENDOTHELIAL GROWTH-FACTOR; LYMPHOCYTE-INDUCED ANGIOGENESIS;
   RETINAL-PIGMENT EPITHELIUM; T-CELL-ACTIVATION; MACULAR DEGENERATION;
   IMMUNE PRIVILEGE; HUMAN-MONOCYTES; IN-VIVO; EXPRESSION; INFLAMMATION
AB Age-related macular degeneration, pathologic myopia, ocular trauma, and other eye diseases can cause choroidal neovascularization (CNV). In recent years, photodynamic therapy (PDT), anti-vascular endothelial growth factor (anti-VEGF) medications, laser treatment, and other measures against CNV have been gradually applied in the clinical setting and in some cases have achieved good results. However, the pathogenesis of CNV has not been fully elucidated. The costimulatory system made up of cluster of differentiation 40 protein (CD40) and its ligand (CD40L) is an important signal transduction pathway among immune cells. The activation of CD40 can also stimulate the secretion of a variety of angiogenic growth factors (eg, VEGF) and basic fibroblast growth factors that might lead to CNV. The high level expression of CD40 and CD40L has been detected in CNV diseases. Interference with the CD40 signaling pathway may become a new target for CNV treatment. We review the relationship between CD40, CD40L, and CNV.
C1 [Zhang, Peipei; Su, Yan; Liu, Fang] Tongji Univ, Shanghai Peoples Hosp 10, Shanghai 20072, Peoples R China.
   [Zhang, Peipei; Su, Yan; Liu, Fang] Wenzhou Med Coll, Wenzhou Ophthalmol & Optometry Hosp, Wenzhou, Peoples R China.
C3 Tongji University; Wenzhou Medical University
RP Liu, F (通讯作者)，Tongji Univ, Peoples Hosp 10, 301 YanChang Rd, Shanghai 20072, Peoples R China.
EM fangliu_2004@yahoo.com
CR AUERBACH R, 1979, J IMMUNOL, V123, P751
   BROWN LF, 1997, EXS, V79, P233
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chakrabarti S, 2010, VASC PHARMACOL, V53, P130, DOI 10.1016/j.vph.2010.05.003
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dormond O, 2008, J IMMUNOL, V181, P8088, DOI 10.4049/jimmunol.181.11.8088
   Flaxenburg JA, 2004, J IMMUNOL, V172, P7503, DOI 10.4049/jimmunol.172.12.7503
   Grisanti S, 1997, INVEST OPHTH VIS SCI, V38, P1619
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hoerster R, 2012, GRAEF ARCH CLIN EXP, V250, P1579, DOI 10.1007/s00417-012-1990-z
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Ishida K, 2003, OCUL IMMUNOL INFLAMM, V11, P91, DOI 10.1076/ocii.11.2.91.15914
   Karimi MH, 2012, IRAN J ALLERGY ASTHM, V11, P1, DOI 011.01/ijaai.113
   Kawabe T, 2011, NAGOYA J MED SCI, V73, P69
   Kelley SK, 2006, BRIT J PHARMACOL, V148, P1116, DOI 10.1038/sj.bjp.0706828
   KOCH AE, 1986, J LEUKOCYTE BIOL, V39, P233, DOI 10.1002/jlb.39.2.233
   Moulton KS, 1999, TRANSPLANTATION, V67, P1626, DOI 10.1097/00007890-199906270-00020
   Phipps RP, 2000, P NATL ACAD SCI USA, V97, P6930, DOI 10.1073/pnas.97.13.6930
   POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0
   Portillo JAC, 2008, J IMMUNOL, V181, P8719, DOI 10.4049/jimmunol.181.12.8719
   Qiu Li, 1999, CHINESE J PEDIAT, V37, P123
   Reinders MEJ, 2003, J IMMUNOL, V171, P1534, DOI 10.4049/jimmunol.171.3.1534
   Shi Y, 2011, INT J INF TECH DECIS, V10, P1, DOI 10.1142/S0219622011004294
   SIDKY YA, 1975, J EXP MED, V141, P1084, DOI 10.1084/jem.141.5.1084
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   UCKUN FM, 1990, BLOOD, V76, P2449
   Willermain F, 2000, INVEST OPHTH VIS SCI, V41, P3485
   WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X
   Xie F, 2010, J NEUROIMMUNOL, V222, P62, DOI 10.1016/j.jneuroim.2009.12.004
   Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862
   Zhao H, 2013, INVEST OPHTH VIS SCI, V54, P5321, DOI 10.1167/iovs.13-12122
NR 33
TC 4
Z9 4
U1 2
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2014
VL 7
BP 263
EP 267
DI 10.2147/OTT.S56909
PG 5
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA AB5PM
UT WOS:000331840800001
PM 24627638
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chavala, SH
   Kim, Y
   Tudisco, L
   Cicatiello, V
   Milde, T
   Kerur, N
   Claros, N
   Yanni, S
   Guaiqui, VH
   Hauswirth, WW
   Penn, JS
   Rafii, S
   De Falco, S
   Lee, TC
   Ambati, J
AF Chavala, Sai H.
   Kim, Younghee
   Tudisco, Laura
   Cicatiello, Valeria
   Milde, Till
   Kerur, Nagaraj
   Claros, Nidia
   Yanni, Susan
   Guaiqui, Victor H.
   Hauswirth, William W.
   Penn, John S.
   Rafii, Shahin
   De Falco, Sandro
   Lee, Thomas C.
   Ambati, Jayakrishna
TI Retinal angiogenesis suppression through small molecule activation of
   p53
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID THERAPY; HYPOXIA; RANIBIZUMAB; IRRADIATION; ANTAGONIST; EXPRESSION;
   SAFETY; MDM2
AB Neovascular age-related macular degeneration is a leading cause of irreversible vision loss in the Western world. Cytokine-targeted therapies (such as anti-vascular endothelial growth factor) are effective in treating pathologic ocular angiogenesis, but have not led to a durable effect and often require indefinite treatment. Here, we show that Nutlin-3, a small molecule antagonist of the E3 ubiquitin protein ligase MDM2, inhibited angiogenesis in several model systems. We found that a functional p53 pathway was essential for Nutlin-3-mediated retinal antiangiogenesis and disruption of the p53 transcriptional network abolished the antiangiogenic activity of Nutlin-3. Nutlin-3 did not inhibit established, mature blood vessels in the adult mouse retina, suggesting that only proliferating retinal vessels are sensitive to Nutlin-3. Furthermore, Nutlin-3 inhibited angiogenesis in nonretinal models such as the hind limb ischemia model. Our work demonstrates that Nutlin-3 functions through an antiproliferative pathway with conceivable advantages over existing cytokine-targeted antiangiogenesis therapies.
C1 [Chavala, Sai H.] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
   [Kim, Younghee; Kerur, Nagaraj; Ambati, Jayakrishna] Univ Kentucky, Coll Med, Dept Ophthalmol & Visual Sci, Lexington, KY USA.
   [Cicatiello, Valeria; De Falco, Sandro] CNR, Inst Genet & Biophys, Angiogenesis Lab, I-80125 Naples, Italy.
   [Milde, Till; Claros, Nidia; Rafii, Shahin] Cornell Univ, Weill Med Coll, Howard Hughes Med Inst, Ansary Ctr Stem Cell Therapeut,Dept Genet Med, New York, NY 10021 USA.
   [Milde, Till] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, Heidelberg, Germany.
   [Yanni, Susan; Penn, John S.] Vanderbilt Univ, Vanderbilt Eye Inst, Nashville, TN 37235 USA.
   [Guaiqui, Victor H.] Hosp Special Surg, Lab Soft Tissue Res, New York, NY 10021 USA.
   [Hauswirth, William W.] Univ Florida, Towel Gene Therapy Ctr, Dept Ophthalmol & Pediat, Gainesville, FL USA.
   [Lee, Thomas C.] Childrens Hosp, Vis Ctr, Retina Inst, Los Angeles, CA 90027 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of Kentucky; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR);
   Cornell University; Howard Hughes Medical Institute; Helmholtz
   Association; German Cancer Research Center (DKFZ); Vanderbilt
   University; State University System of Florida; University of Florida;
   Children's Hospital Los Angeles
RP Chavala, SH (通讯作者)，Univ N Carolina, 5151 Bioinformat Bldg,CB7040, Chapel Hill, NC 27599 USA.
EM schavala@med.unc.edu; jayakrishna.ambati@uky.edu
RI Milde, Till/AAR-4528-2021; De Falco, Sandro/P-6724-2015; Milde,
   Till/L-7755-2015
OI Milde, Till/0000-0002-7267-1052; hauswirth, william/0000-0002-3244-4947;
   De Falco, Sandro/0000-0002-6501-1697
FU T.J. Martell Foundation for Leukemia, Cancer, and AIDS Research; Starr
   Foundation; Fred Gluck Foundation; Heed Foundation; Charles Kelman
   Retinal Research Scholar Award; International Retinal Research
   Foundation; Hope for Vision; Research to Prevent Blindness Career
   Development Award; NEI-T32 Vision training grant;
   Mildred-Scheel-Stiftung; Deutsche Krebshilfe, Bonn, Germany;
   Associazione Italiana Ricerca sul Cancro (AIRC) [IG 11420]; NEI/NIH
   [R01EY018836, R01EY020672, R01EY022238]; Doris Duke Distinguished
   Clinical Scientist Award; Burroughs Wellcome Fund Clinical Scientist
   Award in Translational Research; Ellison Medical Foundation Senior
   Scholar in Aging Award; Research to Prevent Blindness departmental
   unrestricted grant; Dr. E. Vernon Smith and Eloise C. Smith Macular
   Degeneration Endowed Chair; Carl Marshall Reeves Foundation; Beckman
   Initiative for Macular Research Fellowship; NATIONAL EYE INSTITUTE
   [R01EY018836, R01EY022238, R01EY020672, K08EY021171] Funding Source: NIH
   RePORTER
FX We would like to acknowledge David Cobrinik for his help with siRNA
   infection of HUVECs, Sing Your Li for retinal vessel quantification,
   Loic Vincent for instruction in the Matrigel tube assay, and Dena
   Almeida for help with immunofluorescence staining. This study was
   supported in part by grants from the T.J. Martell Foundation for
   Leukemia, Cancer, and AIDS Research (to T.C. Lee), the Starr Foundation
   (to T.C. Lee), the Fred Gluck Foundation (to T.C. Lee), the Heed
   Foundation (to S.H. Chavala), the Charles Kelman Retinal Research
   Scholar Award (to S.H. Chavala), the International Retinal Research
   Foundation (to S.H. Chavala), Hope for Vision (to S.H. Chavala), the
   Research to Prevent Blindness Career Development Award (to S.H.
   Chavala), a NEI-T32 Vision training grant (to S.H. Chavala), the
   Mildred-Scheel-Stiftung (to T. Milde), the Deutsche Krebshilfe, Bonn,
   Germany (to T. Milde), and Associazione Italiana Ricerca sul Cancro
   (AIRC) grant IG 11420 (to S. De Falco). J. Ambati was supported by
   NEI/NIH grants R01EY018836, R01EY020672, R01EY022238, the Doris Duke
   Distinguished Clinical Scientist Award, the Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research, the Ellison Medical
   Foundation Senior Scholar in Aging Award, a Dr. E. Vernon Smith and
   Eloise C. Smith Macular Degeneration Endowed Chair, a Research to
   Prevent Blindness departmental unrestricted grant, and the Carl Marshall
   Reeves Foundation; N. Kerur was supported by Beckman Initiative for
   Macular Research Fellowship.
CR Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Gigante B, 2006, FASEB J, V20, P970, DOI 10.1096/fj.05-4481fje
   Gilson MM, 2007, OPHTHALMOLOGY, V114, P1713, DOI 10.1016/j.ophtha.2007.03.071
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hauswirth WW, 2000, METHOD ENZYMOL, V316, P743
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710
   Lee YM, 2009, CARCINOGENESIS, V30, P1768, DOI 10.1093/carcin/bgp196
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Park CY, 2008, INVEST OPHTH VIS SCI, V49, P399, DOI 10.1167/iovs.07-0619
   PARSONS JT, 1983, INT J RADIAT ONCOL, V9, P609, DOI 10.1016/0360-3016(83)90225-0
   Patterson DM, 2011, ANGIOGENESIS, V14, P255, DOI 10.1007/s10456-011-9210-8
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Rashi-Elkeles S, 2011, MOL ONCOL, V5, P336, DOI 10.1016/j.molonc.2011.06.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Secchiero P, 2007, CIRC RES, V100, P61, DOI 10.1161/01.RES.0000253975.76198.ff
   Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48
   Song HJ, 2012, MOL BIOL REP, V39, P4017, DOI 10.1007/s11033-011-1182-7
   Stromblad S, 2002, J BIOL CHEM, V277, P13371, DOI 10.1074/jbc.C200044200
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Zhang C, 2010, GENE THER, V17, P338, DOI 10.1038/gt.2009.158
   Zhang F, 2011, DRUG METAB DISPOS, V39, P15, DOI 10.1124/dmd.110.035915
NR 26
TC 23
Z9 23
U1 1
U2 11
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2013
VL 123
IS 10
BP 4170
EP 4181
DI 10.1172/JCI67315
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 231UE
UT WOS:000325443100014
PM 24018558
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Yao, J
   Bi, HE
   Sheng, Y
   Cheng, LB
   Wendu, RL
   Wang, CH
   Cao, GF
   Jiang, Q
AF Yao, Jin
   Bi, Hui-E
   Sheng, Yi
   Cheng, Li-Bo
   Wendu, Ri-Le
   Wang, Cheng-Hu
   Cao, Guo-Fan
   Jiang, Qin
TI Ultraviolet (UV) and Hydrogen Peroxide Activate Ceramide-ER Stress-AMPK
   Signaling Axis to Promote Retinal Pigment Epithelium (RPE) Cell
   Apoptosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration (AMD); UV; ROS; RPE cell apoptosis;
   ceramide; ER stress and AMPK
ID PROTEIN-KINASE; SPHINGOLIPID BIOSYNTHESIS; ENDOPLASMIC-RETICULUM;
   MACULAR DEGENERATION; MTORC1 INHIBITION; GROWTH; CONTRIBUTES; LIGHT;
   PHOSPHORYLATION; AUTOPHAGY
AB Ultraviolet (UV) radiation and reactive oxygen species (ROS) impair the physiological functions of retinal pigment epithelium (RPE) cells by inducing cell apoptosis, which is the main cause of age-related macular degeneration (AMD). The mechanism by which UV/ROS induces RPE cell death is not fully addressed. Here, we observed the activation of a ceramide-endoplasmic reticulum (ER) stress-AMP activated protein kinase (AMPK) signaling axis in UV and hydrogen peroxide (H2O2)-treated RPE cells. UV and H2O2 induced an early ceramide production, profound ER stress and AMPK activation. Pharmacological inhibitors against ER stress (salubrinal), ceramide production (fumonisin B1) and AMPK activation (compound C) suppressed UV- and H2O2-induced RPE cell apoptosis. Conversely, cell permeable short-chain C6 ceramide and AMPK activator AICAR (5-amino-1-beta-D-ribofuranosyl-imidazole-4-carboxamide) mimicked UV and H2O2's effects and promoted RPE cell apoptosis. Together, these results suggest that UV/H2O2 activates the ceramide-ER stress-AMPK signaling axis to promote RPE cell apoptosis.
C1 [Yao, Jin; Bi, Hui-E; Sheng, Yi; Cheng, Li-Bo; Wendu, Ri-Le; Wang, Cheng-Hu; Cao, Guo-Fan; Jiang, Qin] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing 210029, Jiangsu, Peoples R China.
   [Cheng, Li-Bo] Li Yang City Hosp Tradit Chinese Med, Eye Dept, Li Yang City 213300, Peoples R China.
C3 Nanjing Medical University
RP Yao, J (通讯作者)，Nanjing Med Univ, Affiliated Eye Hosp, Nanjing 210029, Jiangsu, Peoples R China.
EM dryaojin@yahoo.com; bihuie@yahoo.cn; shenyi1983@sina.com;
   caocong1111@163.com; wendurile187@yahoo.com.cn; tengyu33@yahoo.com;
   caoguofan587@163.com; Jqin710@vip.sina.com
FU National Natural Science Foundation of China [81070744, 81271028];
   post-doc fund of Jiangsu Province [1002009B]; Medical Science and
   Technology Development Project Fund of Nanjing [ZKX12047, YKK12208,
   YKK12207]
FX This work was generously supported by grants from the National Natural
   Science Foundation of China (Nos. 81070744, 81271028), the post-doc fund
   of Jiangsu Province (No. 1002009B) and the Medical Science and
   Technology Development Project Fund of Nanjing (ZKX12047, YKK12208,
   YKK12207). We appreciate Cong Cao for proof reading the manuscript.
CR Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Cao C, 2008, J BIOL CHEM, V283, P28897, DOI 10.1074/jbc.M804144200
   Cao GF, 2011, BIOCHEM BIOPH RES CO, V414, P499, DOI 10.1016/j.bbrc.2011.09.094
   Chen L, 2010, LAB INVEST, V90, P762, DOI 10.1038/labinvest.2010.36
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goldkorn T, 1998, J CELL SCI, V111, P3209
   HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6
   Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Ji C, 2010, ONCOGENE, V29, P6557, DOI 10.1038/onc.2010.379
   Ji C, 2012, CELL SIGNAL, V24, P1781, DOI 10.1016/j.cellsig.2012.05.003
   Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164
   Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552
   Liang Y, 2000, CURR EYE RES, V20, P25, DOI 10.1076/0271-3683(200001)2011-HFT025
   Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1
   MERRILL AH, 1993, J BIOL CHEM, V268, P27299
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   PACIFICI RE, 1991, GERONTOLOGY, V37, P166
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Vakana E, 2012, J CELL BIOCHEM, V113, P404, DOI 10.1002/jcb.23369
   van Lummel M, 2011, FASEB J, V25, P280, DOI 10.1096/fj.10-163709
   WANG E, 1991, J BIOL CHEM, V266, P14486
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Wlodkowic D, 2009, LEUKEMIA RES, V33, P1440, DOI 10.1016/j.leukres.2009.05.025
   Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zhang WB, 2010, J BIOL CHEM, V285, P40461, DOI 10.1074/jbc.M110.164046
   Zheng QY, 2012, BIOCHEM BIOPH RES CO, V419, P741, DOI 10.1016/j.bbrc.2012.02.093
   Zhu QY, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.96
NR 35
TC 63
Z9 63
U1 1
U2 31
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2013
VL 14
IS 5
BP 10355
EP 10368
DI 10.3390/ijms140510355
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 151DS
UT WOS:000319441500094
PM 23685869
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Sivak, JM
AF Sivak, Jeremy M.
TI The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's
   Brain and Retinal Disease
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
ID OPTIC-NERVE HEAD; OPEN-ANGLE GLAUCOMA; ELEVATED INTRAOCULAR-PRESSURE;
   AMYLOID CASCADE HYPOTHESIS; GANGLION-CELL SURVIVAL; APOLIPOPROTEIN-E
   GENE; MACULAR DEGENERATION; NEUROTROPHIC FACTOR; IN-VIVO; MOUSE MODEL
AB Alzheimer's disease (AD) is a common, incurable, and progressive dementia, characterized by loss of learning and memory and the neuropathologic accumulation of amyloid plaques and neurofibrillary tangles in the brain. A number of similarities between AD pathology and several distinct retinal degenerations have been described, particularly with respect to either glaucoma or age-related macular degeneration (AMD), each a leading cause of vision loss and blindness worldwide. Although comparisons between these diseases may provide important new insights into their pathogenic mechanisms, glaucoma and AMD result in markedly different degenerations. Therefore, analyses of the differences and the similarities between these conditions may prove equally productive. Common mechanisms that appear to underlie all three diseases are explored here, as well as potential use of the retina as a biomarker for AD diagnosis and progression. Based on this comparison, past and current efforts to transfer therapeutic strategies between diseases are discussed. (Invest Ophthalmol Vis Sci. 2013;54:871-880) DOI:10.1167/iovs.12-10827
C1 [Sivak, Jeremy M.] Univ Hlth Network, Toronto Western Res Inst, Toronto, ON, Canada.
   [Sivak, Jeremy M.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; University of Toronto
RP Sivak, JM (通讯作者)，Toronto Western Hosp, 399 Bathurst St,FP 6-204, Toronto, ON M5T 2S8, Canada.
EM jsivak@uhnres.utoronto.ca
RI Sivak, Jeremy/AAA-3467-2022
OI Sivak, Jeremy/0000-0002-8776-223X
FU Canadian National Institute for the Blind (CNIB); Glaucoma Research
   Society of Canada (GRSC); Canadian Institutes of Health Research (CIHR)
FX Supported by the Canadian National Institute for the Blind (CNIB), the
   Glaucoma Research Society of Canada (GRSC), and the Canadian Institutes
   of Health Research (CIHR). Dr Sivak is the Toronto General and Western
   Hospital Foundation Glaucoma Research Chair.
CR Allen SJ, 2011, CURR NEUROPHARMACOL, V9, P559, DOI 10.2174/157015911798376190
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Almasieh M, 2011, J NEUROCHEM, V118, P1075, DOI 10.1111/j.1471-4159.2011.07382.x
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0
   Bach-Holm D, 2012, ACTA OPHTHALMOL, V90, P683, DOI 10.1111/j.1755-3768.2011.02125.x
   Bakalash S, 2005, J MOL MED, V83, P904, DOI 10.1007/s00109-005-0689-6
   Bakalash S, 2011, INVEST OPHTH VIS SCI, V52, P9033, DOI 10.1167/iovs.11-7498
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Baptiste DC, 2005, NEUROSCIENCE, V134, P575, DOI 10.1016/j.neuroscience.2005.04.011
   Barres B., 2010, ASTROCYTES GLAUCOMAT
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   BIGNAMI A, 1979, EXP EYE RES, V28, P63
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   Bordji K, 2011, REV NEUROSCIENCE, V22, P285, DOI 10.1515/RNS.2011.029
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103
   Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2
   Caprioli Joseph, 2009, Trans Am Ophthalmol Soc, V107, P161
   Castellani RJ, 2012, BIOFACTORS, V38, P133, DOI 10.1002/biof.1010
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   CHANDRA V, 1986, NEUROLOGY, V36, P209, DOI 10.1212/WNL.36.2.209
   CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569
   Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002
   Chiu K, 2012, AGE, V34, P633, DOI 10.1007/s11357-011-9260-2
   CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180
   CRONINGOLOMB A, 1991, ANN NEUROL, V29, P41, DOI 10.1002/ana.410290110
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Danesh-Meyer HV, 2006, NEUROLOGY, V67, P1852, DOI 10.1212/01.wnl.0000244490.07925.8b
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dentchev T, 2003, MOL VIS, V9, P184
   Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397
   Fan W, 2010, OPHTHALMOL EYE DIS, V2, P23
   Ferrer I, 1999, J NEUROPATH EXP NEUR, V58, P729, DOI 10.1097/00005072-199907000-00007
   Flammer J, 2007, SURV OPHTHALMOL, V52, pS162, DOI 10.1016/j.survophthal.2007.08.012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garcia P, 2010, J NEUROSCI, V30, P7516, DOI 10.1523/JNEUROSCI.4182-09.2010
   Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x
   Garzon D, 2002, J NEUROCHEM, V82, P1058, DOI 10.1046/j.1471-4159.2002.01030.x
   Gasparini L, 2011, NEUROBIOL AGING, V32, P419, DOI 10.1016/j.neurobiolaging.2009.03.002
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Gupta N, 2009, BRIT J OPHTHALMOL, V93, P56, DOI 10.1136/bjo.2008.138172
   Gupta N, 2008, CAN J OPHTHALMOL, V43, P53, DOI 10.3129/i07-185
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   Hare W, 2001, SURV OPHTHALMOL, V45, pS284, DOI 10.1016/S0039-6257(01)00200-4
   Hashimoto K, 2011, ANN NEUROL, V69, P739, DOI 10.1002/ana.22378
   Hedges TR, 1996, ACTA OPHTHALMOL SCAN, V74, P271
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Heneka MT, 2001, J NEUROPATH EXP NEUR, V60, P906, DOI 10.1093/jnen/60.9.906
   Hernandez MR, 2008, PROG BRAIN RES, V173, P353, DOI 10.1016/S0079-6123(08)01125-4
   HERNANDEZ MR, 1988, INVEST OPHTH VIS SCI, V29, P78
   Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu Y, 2010, INVEST OPHTH VIS SCI, V51, P1747, DOI 10.1167/iovs.09-4450
   Iliffe S, 2007, CNS DRUGS, V21, P177, DOI 10.2165/00023210-200721030-00001
   Jack CR, 2012, RADIOLOGY, V263, P343, DOI 10.1148/radiol.12110433
   Janciauskiene S, 2011, EUR J OPHTHALMOL, V21, P104, DOI 10.5301/EJO.2010.2108
   Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x
   Johnson EC, 1996, EXP EYE RES, V62, P663, DOI 10.1006/exer.1996.0077
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kang JH, 2003, AM J EPIDEMIOL, V158, P337, DOI 10.1093/aje/kwg167
   Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kessing LV, 2007, J GLAUCOMA, V16, P47, DOI 10.1097/IJG.0b013e31802b3527
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058
   Koronyo Y, 2012, NEURODEGENER DIS, V10, P285, DOI 10.1159/000335154
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Kruck TP, 2004, CELL MOL NEUROBIOL, V24, P443, DOI 10.1023/B:CEMN.0000022773.70722.b2
   KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lee DA, 2005, AM J HEALTH-SYST PH, V62, P691, DOI 10.1093/ajhp/62.7.691
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48
   Li YK, 2003, J NEUROSCI, V23, P1605
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   LOEFFLER KU, 1993, INVEST OPHTH VIS SCI, V34, P2600
   Lukiw WJ., EXPERT OPIN EMERG DR
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632
   Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McKinnon SJ, 2002, INVEST OPHTH VIS SCI, V43, P1077
   McKinnon SJ, 2012, INVEST OPHTH VIS SCI, V53, P2485, DOI 10.1167/iovs.12-9483j
   MCLACHLAN DRC, 1991, CAN MED ASSOC J, V145, P793
   MENDEZ MF, 1990, NEUROLOGY, V40, P439, DOI 10.1212/WNL.40.3_Part_1.439
   MENDOLA JD, 1995, OPTOMETRY VISION SCI, V72, P155, DOI 10.1097/00006324-199503000-00003
   Millar Wayne J, 2004, Health Rep, V16, P45
   Moore D, 2008, CLIN OPHTHALMOL, V2, P849
   Moschos MM, 2012, CURR ALZHEIMER RES, V9, P782
   Mount C, 2006, NAT MED, V12, P780, DOI 10.1038/nm0706-780
   Mrak RE, 2012, INT J ALZHEIMERS DIS, V2012, P165021, DOI DOI 10.1155/2012
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olabarria M, 2010, GLIA, V58, P831, DOI 10.1002/glia.20967
   Orgul S, 2007, BRIT J OPHTHALMOL, V91, P3, DOI 10.1136/bjo.2006.103010
   Parachikova A, 2010, J ALZHEIMERS DIS, V21, P527, DOI 10.3233/JAD-2010-100204
   Parpura V, 2012, J NEUROCHEM, V121, P4, DOI 10.1111/j.1471-4159.2012.07664.x
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pease ME, 2009, INVEST OPHTH VIS SCI, V50, P2194, DOI 10.1167/iovs.08-3013
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2012, CURR OPIN OPHTHALMOL, V23, P144, DOI 10.1097/ICU.0b013e32834ff490
   Reddy PH, 2011, BRAIN RES, V1415, P136, DOI 10.1016/j.brainres.2011.07.052
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685
   Rizzo M, 2000, NEUROPSYCHOLOGIA, V38, P1157, DOI 10.1016/S0028-3932(00)00023-3
   Roberts BR, 2012, J NEUROCHEM, V120, P149, DOI 10.1111/j.1471-4159.2011.07500.x
   Rogers RS, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012302
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seki M, 2008, PROG BRAIN RES, V173, P495, DOI 10.1016/S0079-6123(08)01134-5
   Shen Y, 1998, BRAIN RES, V796, P187, DOI 10.1016/S0006-8993(98)00346-1
   Shields MB, 2008, CURR OPIN OPHTHALMOL, V19, P85, DOI 10.1097/ICU.0b013e3282f3919b
   Shimazawa M, 2005, BRAIN RES, V1053, P185, DOI 10.1016/j.brainres.2005.06.053
   Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866
   Song Y, 2006, BRAIN RES, V1085, P57, DOI 10.1016/j.brainres.2006.02.042
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Sunderland T, 2003, JAMA-J AM MED ASSOC, V289, P2094, DOI 10.1001/jama.289.16.2094
   Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009
   Tanihara H, 1997, ARCH OPHTHALMOL-CHIC, V115, P752, DOI 10.1001/archopht.1997.01100150754011
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Tezel G, 2009, INVEST OPHTH VIS SCI, V50, P1001, DOI 10.1167/iovs.08-2717
   Thal LJ, 2006, ALZ DIS ASSOC DIS, V20, P6, DOI 10.1097/01.wad.0000191420.61260.a8
   Tiraboschi P, 2004, NEUROLOGY, V62, P1984, DOI 10.1212/01.WNL.0000129697.01779.0A
   TSAI CS, 1991, ARCH OPHTHALMOL-CHIC, V109, P199, DOI 10.1001/archopht.1991.01080020045040
   Tsolaki F, 2011, CLIN OPHTHALMOL, V5, P887, DOI 10.2147/OPTH.S22485
   UHLMANN RF, 1991, J GEN INTERN MED, V6, P126, DOI 10.1007/BF02598307
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360
   Wilkinson JT, 2011, DRUGS, V71, P2421, DOI 10.2165/11596840-000000000-00000
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200
   Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0
   Yochim BP, 2012, J GLAUCOMA, V21, P250, DOI 10.1097/IJG.0b013e3182071b7e
   Yoneda S, 2005, JPN J OPHTHALMOL, V49, P106, DOI 10.1007/s10384-004-0156-x
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 161
TC 145
Z9 154
U1 1
U2 51
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2013
VL 54
IS 1
BP 871
EP 880
DI 10.1167/iovs.12-10827
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 081QX
UT WOS:000314338400115
PM 23364356
DA 2022-11-30
ER

PT J
AU Moshfeghi, AA
   Canton, VM
   Quiroz-Mercado, H
   Velez-Montoya, R
   Lopez-Miranda, MJ
   Shusterman, EM
   Kaiser, PK
   Sanislo, SR
   Gertner, M
   Moshfeghi, DM
AF Moshfeghi, Andrew A.
   Canton, Virgilio Morales
   Quiroz-Mercado, Hugo
   Velez-Montoya, Raul
   Lopez-Miranda, Miriam J.
   Shusterman, Eugene M.
   Kaiser, Peter K.
   Sanislo, Steven R.
   Gertner, Michael
   Moshfeghi, Darius M.
TI 16-Gy Low-Voltage X-ray Irradiation Followed by As-Needed Ranibizumab
   Therapy for AMD: 6-Month Outcomes of a "Radiation-First" Strategy
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EXTERNAL-BEAM RADIOTHERAPY;
   MACULAR DEGENERATION; PLAQUE RADIOTHERAPY; TRIAL; MEMBRANES; SECONDARY;
   BRACHYTHERAPY; SAFETY
AB BACKGROUND AND OBJECTIVE: To describe the effect of a "radiation-first" combination treatment strategy for neovascular age-related macular degeneration (AMD) with ranibizumab rescue therapy.
   PATIENTS AND METHODS: Non-invasive, externally delivered low-voltage x-ray irradiation at a dose of 16 Gy was given in a single session through three locations in the inferior pars plana in a consecutive series of patients with neovascular AMD. Ranibizumab was administered according to prospectively determined criteria.
   RESULTS: Thirteen patients completed a 6-month follow-up. All patients lost 15 or fewer ETDRS letters, 7 gained 0 or more ETDRS letters, and 0 gained more than 15 ETDRS letters. Patients received a total of 15 ranibizumab injections following x-ray irradiation at baseline. Two patients received no ranibizumab injections, seven patients received 1 injection, and four patients received 2 injections.
   CONCLUSION: Low-voltage x-ray treatment followed by ranibizumab rescue demonstrates an independent visual acuity stabilizing effect for patients with wet AMD.
C1 [Sanislo, Steven R.; Moshfeghi, Darius M.] Stanford Univ, Sch Med, Byers Eye Inst, Horngren Family Vitreoretinal Ctr,Dept Ophthalmol, Palo Alto, CA 94303 USA.
   [Moshfeghi, Andrew A.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Palm Beach Gardens, FL USA.
   [Canton, Virgilio Morales; Quiroz-Mercado, Hugo; Velez-Montoya, Raul; Lopez-Miranda, Miriam J.] IAP, Assoc Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   [Shusterman, Eugene M.; Gertner, Michael] Oraya Therapeut Inc, Newark, CA USA.
   [Quiroz-Mercado, Hugo; Velez-Montoya, Raul] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Stanford University; Bascom Palmer Eye Institute; University of Colorado
   System; University of Colorado Denver; Cleveland Clinic Foundation
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst Stanford, Horngren Family Vitreoretinal Ctr,Dept Ophthalmol, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
RI Canton, Virgilio/AAF-7047-2021; Velez-Montoya, Raul/K-3819-2015
OI Kaiser, Peter/0000-0001-5126-045X; Velez-Montoya,
   Raul/0000-0002-6457-4578; Moshfeghi, Darius Mohammad/0000-0003-2254-292X
FU Thrombogenics, Inc.
FX Drs. D. Moshfeghi and Kaiser are consultants and have equity, Drs.
   Canton, Quiroz-Mercado, and Sanislo are consultants, Dr. Shusterman is
   an employee and has equity, and Dr. Gertner has equity and intellectual
   property at Oraya Therapeutics, Inc. Dr. A. Moshfeghi is a consultant
   and speaker for Genentech, Inc., Allergan, Inc., and Bausch & Lomb,
   Inc.; is a consultant for Eyetech, Inc., and Alimera, Inc.; and receives
   research funding from Thrombogenics, Inc. Drs. Velez-Montoyo and
   Lopez-Miranda have no financial or proprietary interest in the materials
   presented herein.
CR Aisenbrey S, 2003, GRAEF ARCH CLIN EXP, V241, P269, DOI 10.1007/s00417-003-0634-8
   Akmansu M, 1998, INT J RADIAT ONCOL, V40, P923, DOI 10.1016/S0360-3016(97)00859-6
   [Anonymous], 2003, Nippon Ganka Gakkai Zasshi, V107, P326
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Barak A, 2005, BRIT J RADIOL, V78, P827, DOI 10.1259/bjr/17631422
   BERGINK GJ, 1994, GRAEF ARCH CLIN EXP, V232, P591, DOI 10.1007/BF00193119
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Berson AM, 1999, SEMIN RADIAT ONCOL, V9, P155, DOI 10.1016/S1053-4296(99)80005-8
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   Brenner DJ, 1999, PHYS MED BIOL, V44, P323, DOI 10.1088/0031-9155/44/2/002
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Donati G, 1999, BRIT J OPHTHALMOL, V83, P646, DOI 10.1136/bjo.83.6.646
   Emery RS, 1998, MED PHYS, V25, P1491, DOI 10.1118/1.598324
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Furdova A, 2000, Bratisl Lek Listy, V101, P234
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Jaakkola A, 2001, EUR J OPHTHALMOL, V11, P269, DOI 10.1177/112067210101100310
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   Krott R, 1998, GRAEF ARCH CLIN EXP, V236, P916, DOI 10.1007/s004170050180
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2004, BRIT J OPHTHALMOL, V88, P114, DOI 10.1136/bjo.88.1.114
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Prettenhofer U, 2004, STRAHLENTHER ONKOL, V180, P91, DOI 10.1007/s00066-004-1177-6
   Roos DE, 1999, INT J RADIAT ONCOL, V43, P1071, DOI 10.1016/S0360-3016(98)00493-3
   Saric B, 2001, COLLEGIUM ANTROPOL, V25, P89
   Sasai K, 1997, INT J RADIAT ONCOL, V39, P173, DOI 10.1016/S0360-3016(97)00296-4
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Staar S, 1999, INT J RADIAT ONCOL, V45, P467, DOI 10.1016/S0360-3016(99)00186-8
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
NR 38
TC 11
Z9 12
U1 0
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2011
VL 42
IS 6
BP 460
EP 467
DI 10.3928/15428877-20110804-03
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 959UZ
UT WOS:000305342500003
PM 21830745
DA 2022-11-30
ER

PT J
AU Li, Y
   Lee, HJ
   Corn, RM
AF Li, Yuan
   Lee, Hye Jin
   Corn, Robert M.
TI Detection of protein biomarkers using RNA aptamer microarrays and
   enzymatically amplified surface plasmon resonance imaging
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID RECEPTOR-BINDING; HUMAN THROMBIN; EMERGING CLASS; ARRAYS; ANTIBODY;
   IMMUNOASSAY; CANCER; DNA; THERAPY; LIGANDS
AB A methodology for the detection of protein biomarkers at picomolar concentrations that utilizes surface plasmon resonance imaging (SPRI) measurements of RNA aptamer microarrays is developed. The adsorption of proteins onto the RNA microarray is detected by the formation of a surface aptamer-protein-antibody complex. The SPRI response signal is then amplified using a localized precipitation reaction catalyzed by the enzyme horseradish peroxidase that is conjugated to the antibody. This enzymatically amplified SPRI methodology is first characterized by the detection of human thrombin at a concentration of 500 fM; the appropriate thrombin aptamer for the sandwich assay is identified from a microarray of three potential thrombin aptamer candidates. The SPRI method is then used to detect the protein vascular endothelial growth factor (VEGF) at a biologically relevant concentration of 1 pM. VEGF is a signaling protein that has been used as a serum biomarker for rheumatoid arthritis, breast cancer, lung cancer, and colorectal cancer and is also associated with age-related macular degeneration.
C1 Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine
RP Corn, RM (通讯作者)，Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.
EM rcorn@uci.edu
OI Corn, Robert/0000-0002-4756-2161
FU NIGMS NIH HHS [R01 GM059622-06, R01 GM059622-05, 2R01 GM059622-04, R01
   GM059622-07, R01 GM059622-04A1, R01 GM059622-08, R01 GM059622] Funding
   Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R01GM059622] Funding Source: NIH RePORTER
CR Adams J, 2000, CANCER RES, V60, P2898
   Bock C, 2004, PROTEOMICS, V4, P609, DOI 10.1002/pmic.200300631
   Brockman JM, 1999, J AM CHEM SOC, V121, P8044, DOI 10.1021/ja991608e
   Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5
   Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458
   Collett JR, 2005, ANAL BIOCHEM, V338, P113, DOI 10.1016/j.ab.2004.11.027
   Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f
   de Seny D, 2005, ARTHRITIS RHEUM-US, V52, P3801, DOI 10.1002/art.21607
   Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S
   Drolet DW, 1996, NAT BIOTECHNOL, V14, P1021, DOI 10.1038/nbt0896-1021
   Goodrich TT, 2004, ANAL CHEM, V76, P6173, DOI 10.1021/ac0490898
   Huang RP, 2001, J IMMUNOL METHODS, V255, P1, DOI 10.1016/S0022-1759(01)00394-5
   Jackson MR, 2001, AM J SURG, V182, p1S, DOI 10.1016/S0002-9610(01)00770-X
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   Kanda V, 2004, ANAL CHEM, V76, P7257, DOI 10.1021/ac049318q
   Kim MG, 2005, J IMMUNOL METHODS, V297, P125, DOI 10.1016/j.jim.2004.12.007
   Kim SD, 2005, SENSOR ACTUAT B-CHEM, V111, P463, DOI 10.1016/j.snb.2005.03.057
   Kuramochi H, 2006, CLIN CANCER RES, V12, P29, DOI 10.1158/1078-0432.CCR-05-1275
   Lee HJ, 2006, ANAL CHEM, V78, P6504, DOI 10.1021/ac060881d
   LI Y, IN PRESS NUCL ACIDS
   Liu XM, 2004, FEBS LETT, V562, P125, DOI 10.1016/S0014-5793(04)00197-8
   McCauley TG, 2003, ANAL BIOCHEM, V319, P244, DOI 10.1016/S0003-2697(03)00297-5
   Nakahara H, 2003, ARTHRITIS RHEUM-US, V48, P1521, DOI 10.1002/art.11143
   Nelson BP, 2001, ANAL CHEM, V73, P1, DOI 10.1021/ac0010431
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Phillips KS, 2006, J AM CHEM SOC, V128, P9590, DOI 10.1021/ja0628102
   Poon TCW, 2006, GASTROENTEROLOGY, V130, P1858, DOI 10.1053/j.gastro.2006.02.011
   Raben D, 2005, CLIN LUNG CANCER, V7, P175, DOI 10.3816/CLC.2005.n.032
   Roda A, 2006, ANAL BIOANAL CHEM, V384, P1269, DOI 10.1007/s00216-006-0308-6
   Sapsford KE, 2002, ANAL CHEM, V74, P1061, DOI 10.1021/ac0157268
   Shumaker-Parry JS, 2004, ANAL CHEM, V76, P907, DOI 10.1021/ac034962a
   Silzel JW, 1998, CLIN CHEM, V44, P2036
   Stadtherr K, 2005, ANAL CHEM, V77, P3437, DOI 10.1021/ac0483421
   Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275
   Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200
   White R, 2001, MOL THER, V4, P567, DOI 10.1006/mthe.2001.0495
   Wolf LK, 2005, J AM CHEM SOC, V127, P17453, DOI 10.1021/ja056422w
   Zhong XB, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni123
NR 39
TC 232
Z9 249
U1 3
U2 184
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD FEB 1
PY 2007
VL 79
IS 3
BP 1082
EP 1088
DI 10.1021/ac061849m
PG 7
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 131AK
UT WOS:000243839900034
PM 17263339
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhao, BW
   Huang, JQ
   Lou, XT
   Yao, K
   Ye, M
   Mou, QX
   Wen, Z
   Duan, QM
   Zhang, H
   Zhao, Y
AF Zhao, Bowen
   Huang, Jingqiu
   Lou, Xiaotong
   Yao, Ke
   Ye, Meng
   Mou, Qianxue
   Wen, Zheng
   Duan, Qiming
   Zhang, Hong
   Zhao, Yin
TI Endothelial CYP2J2 overexpression restores the BRB via METTL3-mediated
   ANXA1 upregulation
SO FASEB JOURNAL
LA English
DT Article
DE ANXA1; BRB; endothelial junctions; vascular development; vascular
   integrity
ID GROWTH-FACTOR EXPRESSION; NEURODEGENERATIVE DISEASES; NEUROVASCULAR
   UNIT; BARRIER FUNCTION; CELL JUNCTIONS; VE-CADHERIN; PROTEIN;
   PERMEABILITY; INTEGRITY; ACTIN
AB Blood-retinal barrier (BRB) breakdown is responsible for multiple ocular diseases, such as diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusive diseases. Increased vascular permeability contributes to vasogenic edema and tissue damage, with consequent adverse effects on vision. Herein, we found that endothelial CYP2J2 overexpression maintained BRB integrity after ischemia-reperfusion injury and consequently protected against retinal ganglion cell loss. Oxidative stress repressed endothelial ANXA1 expression in vivo and in vitro. CYP2J2 upregulated methyltransferase-like 3 (METTL3) expression and hence promoted ANXA1 translation via ANXA1 m(6)A modification in endothelium under oxidative stress. CYP2J2 maintained the distribution of endothelial tight junctions and adherens junctions in an ANXA1-dependent manner. Endothelial ANXA1 plays an indispensable role in vascular homeostasis and stabilization during development. Endothelial ANXA1 deletion disrupted retinal vascular perfusion as well as BRB integrity. CYP2J2 metabolites restored BRB integrity in the presence of ANXA1. Our findings identified the CYP2J2-METTL3-ANXA1 pathway as a potential therapeutic target for relieving BRB impairments.
C1 [Zhao, Bowen; Lou, Xiaotong; Yao, Ke; Ye, Meng; Mou, Qianxue; Zhang, Hong; Zhao, Yin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan 430030, Peoples R China.
   [Huang, Jingqiu] Wuhan Univ, Dept Ophthalmol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Wen, Zheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol, Wuhan, Peoples R China.
   [Duan, Qiming] Gladstone Inst, San Francisco, CA USA.
C3 Huazhong University of Science & Technology; Wuhan University; Huazhong
   University of Science & Technology; University of California System;
   University of California San Francisco; The J David Gladstone Institutes
RP Zhang, H; Zhao, Y (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan 430030, Peoples R China.
EM tjyksys@163.com; zhaoyin85@hust.edu.cn
FU National Natural Science Foundation of China [82070965]; Tongji Hospital
   (HUST) Foundation for Excellent Young Scientist [2020YQ18]
FX The current study was supported by funding from the National Natural
   Science Foundation of China (grant no. 31800868) and Tongji Hospital
   (HUST) Foundation for Excellent Young Scientist (grant no. 2020YQ18 to
   Dr. Yin Zhao), and the National Natural Science Foundation of China
   (grant no. 82070965 to Dr. Hong Zhang).
CR Aliwarga T, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8060144
   Amadio M, 2012, MOL VIS, V18, P2153
   An YY, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01500-4
   Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4
   Baker DJ, 2018, J CLIN INVEST, V128, P1208, DOI 10.1172/JCI95145
   Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678
   Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003
   Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016
   Cahill MT, 2003, AM J OPHTHALMOL, V136, P1136, DOI 10.1016/S0002-9394(03)00571-3
   Cai W, 2017, AGEING RES REV, V34, P77, DOI 10.1016/j.arr.2016.09.006
   Cao J, 2021, REDOX BIOL, V45, DOI 10.1016/j.redox.2021.102031
   Chen Q, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001374
   Claesson-Welsh L, 2021, TRENDS MOL MED, V27, P314, DOI 10.1016/j.molmed.2020.11.006
   Cristante E, 2013, P NATL ACAD SCI USA, V110, P832, DOI 10.1073/pnas.1209362110
   Csortos C, 2007, AM J PHYSIOL-LUNG C, V293, pL843, DOI 10.1152/ajplung.00120.2007
   Curtis TM, 2018, JOVE-J VIS EXP, DOI 10.3791/57944
   Dalli J, 2008, BLOOD, V112, P2512, DOI 10.1182/blood-2008-02-140533
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Delorme S, 2021, AM J CANCER RES, V11, P1600
   Ding Y, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01891-w
   Duplancic R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88101-1
   Evangelista EA, 2018, DRUG METAB DISPOS, V46, P380, DOI 10.1124/dmd.117.078840
   Geng HX, 2017, NEUROCHEM RES, V42, P2841, DOI 10.1007/s11064-017-2297-6
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Giurdanella G, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11010051
   Giurdanella G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207528
   Grant ZL, 2020, J CLIN INVEST, V130, P4235, DOI 10.1172/JCI127668
   Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje
   Huang JQ, 2019, FASEB J, V33, P11194, DOI 10.1096/fj.201900756R
   Hui QY, 2020, FREE RADICAL BIO MED, V146, P181, DOI 10.1016/j.freeradbiomed.2019.10.414
   Iadecola C, 2017, NEURON, V96, P17, DOI 10.1016/j.neuron.2017.07.030
   Ji LY, 2021, CELL MOL LIFE SCI, V78, P5977, DOI 10.1007/s00018-021-03893-9
   Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kida T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81482-3
   Kom C, 2015, DEV CELL, V34, P5, DOI 10.1016/j.devcel.2015.06.004
   Komarova YA, 2017, CIRC RES, V120, P179, DOI 10.1161/CIRCRESAHA.116.306534
   Kulikauskas MR, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-021-04033-z
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Lenard A, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002126
   Li XG, 2020, J CELL MOL MED, V24, P862, DOI 10.1111/jcmm.14796
   Liu H, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.627110
   Lou ZL, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8836058
   Luo Y, 2005, J CELL BIOL, V169, P29, DOI 10.1083/jcb.200411127
   Minhas G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00444
   Mukwaya A, 2021, EXP MOL MED, V53, P189, DOI 10.1038/s12276-021-00566-2
   Murakami T, 2012, DIABETES, V61, P1573, DOI 10.2337/db11-1367
   Musch MW, 2006, AM J PHYSIOL-GASTR L, V290, pG222, DOI 10.1152/ajpgi.00301.2005
   Park JC, 2017, AGING CELL, V16, P149, DOI 10.1111/acel.12530
   Pellicani R, 2020, MATRIX BIOL, V87, P11, DOI 10.1016/j.matbio.2019.08.002
   Ries M, 2021, BRAIN, V144, P1526, DOI 10.1093/brain/awab050
   Segarra M, 2018, SCIENCE, V361, DOI 10.1126/science.aao2861
   Sharma M, 2009, PROSTAG OTH LIPID M, V89, P43, DOI 10.1016/j.prostaglandins.2009.04.004
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200
   Wettschureck N, 2019, PHYSIOL REV, V99, P1467, DOI 10.1152/physrev.00037.2018
   Williams JM, 2007, AM J PHYSIOL-RENAL, V293, pF501, DOI 10.1152/ajprenal.00131.2007
   Xiang J, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00864-9
   Xu Q, 2017, FREE RADICAL BIO MED, V109, P84, DOI 10.1016/j.freeradbiomed.2017.03.004
   Xu X, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02174-3
   Yamazaki Y, 2016, STROKE, V47, P1068, DOI 10.1161/STROKEAHA.115.010835
   Yang Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12718
   Yi M, 2009, P NATL ACAD SCI USA, V106, P17886, DOI 10.1073/pnas.0901324106
   Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5
   Zhang CZ, 2020, ONCOGENE, V39, P4507, DOI 10.1038/s41388-020-1303-7
   Zhao QS, 2018, J MOL CELL CARDIOL, V123, P118, DOI 10.1016/j.yjmcc.2018.08.027
   Zheng B, 2017, MOL THER, V25, P1279, DOI 10.1016/j.ymthe.2017.03.031
   Zhuang MR, 2019, NUCLEIC ACIDS RES, V47, P4765, DOI 10.1093/nar/gkz157
NR 68
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2022
VL 36
IS 11
AR e22619
DI 10.1096/fj.202201061RR
PG 20
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 5M0IN
UT WOS:000870790600001
PM 36269280
DA 2022-11-30
ER

PT J
AU Banc, A
   Marzoli, SB
AF Banc, Ana
   Marzoli, Stefania Bianchi
TI Parapapillary atrophy in optic neuropathies: Histology and clinical
   relevance
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Parapapillary atrophy; histology; optic neuropathy; optical coherence
   tomography
ID BETA-ZONE; ASSOCIATION
AB Parapapillary atrophy is one of the parameters of the optic nerve head area which are assessed during the ophthalmoscopic examination particularly useful to characterize glaucomatous optic neuropathy. Optical coherence tomography evaluation provides high-resolution images of the optic nerve head and surrounding area, and can be used to study parapapillary atrophy. Different parapapillary atrophy zones were described depending on their histological features and research has been conducted to investigate the possible association between the presence and/ or size of parapapillary atrophy zones and several optic nerve disorders. In this review we discuss the histology and the clinical findings related to parapapillary atrophy in patients with glaucomatous optic neuropathy, non-glaucomatous optic neuropathies (e.g. arteritic and non-arteritic anterior ischemic optic neuropathies; suprasellar and parasellar tumors), and other ocular conditions (e.g. high myopia; age-related macular degeneration). Two different histologic classifications were identified. Parapapillary atrophy was demonstrated in glaucoma and glaucoma-like neuropathies, but not in other types of optic nerve disorders.
C1 [Banc, Ana] Iuliu Hatieganu Univ Med & Pharm, Dept Ophthalmol, Clin St 3-5, Cluj Napoca 400006, Romania.
   [Marzoli, Stefania Bianchi] Ist Auxol Italiano IRCCS Capitanio Hosp, Neuroophthalmol Ctr, Milan, Italy.
   [Marzoli, Stefania Bianchi] Ist Auxol Italiano IRCCS Capitanio Hosp, Ocular Electrophysiol Lab, Milan, Italy.
C3 Iuliu Hatieganu University of Medicine & Pharmacy
RP Banc, A (通讯作者)，Iuliu Hatieganu Univ Med & Pharm, Dept Ophthalmol, Clin St 3-5, Cluj Napoca 400006, Romania.
EM ana.banc@umfcluj.ro
RI Banc, Ana/V-5972-2018
OI Banc, Ana/0000-0003-2157-7741
CR Ahmad SS, 2020, TAIWAN J OPHTHALMOL, V10, P243, DOI 10.4103/tjo.tjo_64_19
   Bak E, 2020, OPHTHALMOLOGY, V127, P1054, DOI 10.1016/j.ophtha.2020.01.057
   BIANCHIMARZOLI S, 1995, OPHTHALMOLOGY, V102, P436
   Blumenthal EZ, 2006, NEURO-OPHTHALMOLOGY, V30, P111, DOI 10.1080/01658100600980974
   Cennamo G, 2015, EYE, V29, P797, DOI 10.1038/eye.2015.35
   Denniston AK, 2015, INVEST OPHTH VIS SCI, V56, P3955, DOI 10.1167/iovs.15-17243
   Guo XX, 2020, INT J OPHTHALMOL-CHI, V13, P1272, DOI 10.18240/ijo.2020.08.14
   Ha A, 2021, BRIT J OPHTHALMOL, V105, P361, DOI 10.1136/bjophthalmol-2019-315477
   Hayreh SS, 2001, OPHTHALMOLOGY, V108, P1586, DOI 10.1016/S0161-6420(01)00649-2
   Hu XX, 2021, EYE, V35, P455, DOI 10.1038/s41433-020-0872-6
   JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Jonas JB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175120
   Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237
   Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037499
   Jung EH, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/6279689
   Kim HR, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.17
   KUBOTA T, 1993, BRIT J OPHTHALMOL, V77, P103, DOI 10.1136/bjo.77.2.103
   Manalastas PIC, 2018, AM J OPHTHALMOL, V191, P140, DOI 10.1016/j.ajo.2018.04.021
   Mestre H, 2020, TRENDS NEUROSCI, V43, P458, DOI 10.1016/j.tins.2020.04.003
   Newman NJ., 2005, WALSH HOYTS CLIN NEU, P151
   Qu YZ, 2011, ACTA OPHTHALMOL, V89, pE428, DOI 10.1111/j.1755-3768.2011.02118.x
   Suh MH, 2019, INVEST OPHTH VIS SCI, V60, P3768, DOI 10.1167/iovs.18-26286
   Sullivan-Mee M, 2015, AM J OPHTHALMOL, V160, P637, DOI 10.1016/j.ajo.2015.06.024
   Wang YX, 2013, ACTA OPHTHALMOL, V91, P521, DOI 10.1111/j.1755-3768.2012.02454.x
   Wang YX, 2008, GRAEF ARCH CLIN EXP, V246, P1391, DOI 10.1007/s00417-008-0882-8
   Wostyn P, 2021, EYE, V35, P2905, DOI 10.1038/s41433-020-01219-w
NR 27
TC 0
Z9 0
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 95
EP 101
AR 11206721211060655
DI 10.1177/11206721211060655
EA NOV 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000718337300001
PM 34761686
DA 2022-11-30
ER

PT J
AU Alvarez-Henao, MV
   Saavedra, N
   Medina, S
   Cartagena, CJ
   Alzate, LM
   Londono-Londono, J
AF Victoria Alvarez-Henao, Maria
   Saavedra, Nataly
   Medina, Sonia
   Jimenez Cartagena, Claudio
   Maria Alzate, Luz
   Londono-Londono, Julian
TI Microencapsulation of lutein by spray-drying: Characterization and
   stability analyses to promote its use as a functional ingredient
SO FOOD CHEMISTRY
LA English
DT Article
DE Lutein; Encapsulation; Spray-drying; Stability; Formulations
ID PHYSICOCHEMICAL PROPERTIES; ENCAPSULATION; ASTAXANTHIN; LYCOPENE;
   STARCH; FOOD; VARIETIES; QUALITY; SIZE
AB Lutein, a xanthophyll, is associated to decreased risk of age-related macular degeneration, atherosclerosis and other diseases (Bovier et al., 2013; El-raey, Ibrahim, & Eldahshan, 2013). When lutein is extracted, it becomes highly unstable, reducing its functionality as an antioxidant. The aim of this research was to improve the stability of lutein using maltodextrin, arabic gum and a modified starch, to obtain micro-particles using spray-drying. Each of the formulations was characterized in terms of yield, encapsulation efficiency, particle size distribution, water activity and moisture content.
   The formulations with arabic gum (100%) and arabic gum: maltodextrin: modified starch (33.3:33.3:33.3%), with encapsulation efficiencies of 91.94 +/- 6.88 and 65.72 +/- 0.93%, respectively, were selected to study stability at 45 degrees C and 75% RH (relative humidity). Based on our results, encapsulation could be considered as an alternative for the generation of high value-added functional ingredients that can be used in different industries.
C1 [Victoria Alvarez-Henao, Maria; Saavedra, Nataly; Medina, Sonia; Jimenez Cartagena, Claudio; Maria Alzate, Luz; Londono-Londono, Julian] Corp Univ Lasallista, Fac Engn, Caldas, Antioquia, Colombia.
RP Alvarez-Henao, MV (通讯作者)，Corp Univ Lasallista, Fac Engn, Food Engn Program, Carrera 51 118 Sur 57, Caldas, Antioquia, Colombia.
EM mariavictoriaah@gmail.com
RI Medina, Sonia/M-2479-2014; Alzate-Tamayo, Luz-Maria/I-2754-2013
OI Medina, Sonia/0000-0002-7231-6480; Londono-Londono,
   Julian/0000-0001-6793-0585; Alzate-Tamayo, Luz-Maria/0000-0002-3030-4801
FU Government of Antioquia-Secretary of Agriculture and Rural Development
   through the Science and Technology Fund (General System of Royalties)
   [4600001050]; Research Department of the Corporacion Universitaria
   Lasallista
FX This work was supported by the Government of Antioquia-Secretary of
   Agriculture and Rural Development, through the Science and Technology
   Fund (General System of Royalties) (Contract 4600001050) and the
   Research Department of the Corporacion Universitaria Lasallista. All
   authors report no conflicts of interest.
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Birchal VS, 2005, DRY TECHNOL, V23, P611, DOI 10.1081/DRT-200054153
   Bovier ER, 2013, NUTRIENTS, V5, P750, DOI 10.3390/nu5030750
   Bustamante A, 2016, FOOD CHEM, V190, P1013, DOI 10.1016/j.foodchem.2015.06.062
   Bustos-Garza C, 2013, FOOD RES INT, V54, P641, DOI 10.1016/j.foodres.2013.07.061
   Decagon Devices, 2006, FUND WAT ACT
   Dima A, 2015, FOOD ENG REV, V7, P417, DOI 10.1007/s12393-015-9115-1
   Dordevic V., 2014, FOOD ENG REV, V7
   El-Raey M.A., 2013, REV THEIR CHEM, V2, P245
   Ezhilarasi PN, 2013, FOOD BIOPROCESS TECH, V6, P628, DOI 10.1007/s11947-012-0944-0
   Fang ZX, 2010, TRENDS FOOD SCI TECH, V21, P510, DOI 10.1016/j.tifs.2010.08.003
   Fernandez-Sevilla JM, 2010, APPL MICROBIOL BIOT, V86, P27, DOI 10.1007/s00253-009-2420-y
   Gamboa-Santos J, 2013, FOOD CHEM, V141, P616, DOI 10.1016/j.foodchem.2013.03.028
   Giuffrida D, 2011, FOOD CHEM, V124, P1119, DOI 10.1016/j.foodchem.2010.07.012
   Giuffrida D, 2010, FRUITS, V65, P277, DOI 10.1051/fruits/2010023
   Goula AM, 2012, DRY TECHNOL, V30, P641, DOI 10.1080/07373937.2012.655871
   Gutierrez G, 2014, COLLOID SURFACE A, V442, P111, DOI 10.1016/j.colsurfa.2013.05.077
   Khalil M, 2012, J FUNCT FOODS, V4, P602, DOI 10.1016/j.jff.2012.03.006
   Koc B, 2014, FOODBALT, P243
   Koc M, 2011, J FOOD SCI TECH MYS, V48, P141, DOI 10.1007/s13197-010-0159-1
   Krishnan S, 2005, CARBOHYD POLYM, V62, P309, DOI 10.1016/j.carbpol.2005.03.020
   Kuang PQ, 2015, J FOOD SCI, V80, pE359, DOI 10.1111/1750-3841.12776
   Loksuwan J, 2007, FOOD HYDROCOLLOID, V21, P928, DOI 10.1016/j.foodhyd.2006.10.011
   Nunes IL, 2007, BRAZ ARCH BIOL TECHN, V50, P893, DOI 10.1590/S1516-89132007000500018
   Park JH, 2005, MOLECULES, V10, P146, DOI 10.3390/10010146
   Park SA, 2014, LWT-FOOD SCI TECHNOL, V55, P638, DOI 10.1016/j.lwt.2013.09.021
   Pu JN, 2011, BIOSYST ENG, V108, P121, DOI 10.1016/j.biosystemseng.2010.11.005
   Quek SY, 2007, CHEM ENG PROCESS, V46, P386, DOI 10.1016/j.cep.2006.06.020
   Qv XY, 2011, FOOD HYDROCOLLOID, V25, P1596, DOI 10.1016/j.foodhyd.2011.01.006
   Sachin Kausadikar, 2015, Advances in Applied Science Research, V6, P69
   Saenz C, 2009, FOOD CHEM, V114, P616, DOI 10.1016/j.foodchem.2008.09.095
   Shen Q, 2014, J FOOD ENG, V123, P165, DOI 10.1016/j.jfoodeng.2013.09.002
   Shi XM, 1997, NAHRUNG, V41, P38, DOI 10.1002/food.19970410110
   Shu B, 2006, J FOOD ENG, V76, P664, DOI 10.1016/j.jfoodeng.2005.05.062
   Spada JC, 2012, CARBOHYD POLYM, V89, P1166, DOI 10.1016/j.carbpol.2012.03.090
   Tonon RV, 2008, J FOOD ENG, V88, P411, DOI 10.1016/j.jfoodeng.2008.02.029
   Alvarez MV, 2015, PHYTOCHEM REV, V14, P891, DOI 10.1007/s11101-015-9434-0
   Wang YF, 2012, EUR FOOD RES TECHNOL, V234, P157, DOI 10.1007/s00217-011-1630-6
   Guadarrama-Lezama AY, 2012, J FOOD ENG, V112, P29, DOI 10.1016/j.jfoodeng.2012.03.032
   Zhao CD, 2014, FOOD CHEM, V156, P123, DOI 10.1016/j.foodchem.2014.01.086
NR 40
TC 52
Z9 53
U1 10
U2 118
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PD AUG 1
PY 2018
VL 256
BP 181
EP 187
DI 10.1016/j.foodchem.2018.02.059
PG 7
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA GB1YD
UT WOS:000428846700025
PM 29606436
DA 2022-11-30
ER

PT J
AU Fantin, A
   Lampropoulou, A
   Senatore, V
   Brash, JT
   Prahst, C
   Lange, CA
   Liyanage, SE
   Raimondi, C
   Bainbridge, JW
   Augustin, HG
   Ruhrberg, C
AF Fantin, Alessandro
   Lampropoulou, Anastasia
   Senatore, Valentina
   Brash, James T.
   Prahst, Claudia
   Lange, Clemens A.
   Liyanage, Sidath E.
   Raimondi, Claudio
   Bainbridge, James W.
   Augustin, Hellmut G.
   Ruhrberg, Christiana
TI VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC
   family kinase activation
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; IN-VIVO; CARDIOVASCULAR
   DEVELOPMENT; RECEPTOR-2 ACTIVATION; TYROSINE KINASES; SEMAPHORIN 3A;
   ANTI-VEGF; NEUROPILIN-1; ANGIOGENESIS
AB The vascular endothelial growth factor (VEGF) isoform VEGF165 stimulates vascular growth and hyperpermeability. Whereas blood vessel growth is essential to sustain organ health, chronic hyperpermeability causes damaging tissue edema. By combining in vivo and tissue culture models, we show here that VEGF165-induced vascular leakage requires both VEG FR2 and NRP1, including the VEGF164-binding site of NRP1 and the NRP1 cytoplasmic domain (NCD), but not the known NCD interactor GIPC1. In the VEGF165-bound receptor complex, the NCD promotes ABL kinase activation, which in turn is required to activate VEG FR2-recruited SRC family kinases (SFKs). These results elucidate the receptor complex and signaling hierarchy of downstream kinases that transduce the permeability response to VEGF165. In a mouse model with choroidal neovascularisation akin to age-related macular degeneration, NCD loss attenuated vessel leakage without affecting neovascularisation. These findings raise the possibility that targeting NRP1 or its NCD interactors may be a useful therapeutic strategy in neovascular disease to reduce VEGF165-induced edema without compromising vessel growth.
C1 [Fantin, Alessandro; Lampropoulou, Anastasia; Senatore, Valentina; Brash, James T.; Lange, Clemens A.; Liyanage, Sidath E.; Raimondi, Claudio; Bainbridge, James W.; Ruhrberg, Christiana] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Prahst, Claudia] Yale Cardiovasc Res Ctr, New Haven, CT 06511 USA.
   [Augustin, Hellmut G.] DKFZ ZMBH Alliance, German Canc Res Ctr, Div Vasc Oncol & Metastasis, D-69120 Heidelberg, Germany.
   [Augustin, Hellmut G.] Heidelberg Univ, Med Fac Mannheim, Dept Vasc Biol & Tumor Angiogenesis CBTM, D-68167 Mannheim, Germany.
   [Prahst, Claudia] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA.
   [Lange, Clemens A.] Univ Hosp Freiburg, Ctr Eye, D-79106 Freiburg, Germany.
   [Raimondi, Claudio] Imperial Coll London, Hammersmith Hosp, Natl Heart & Lung Inst Vasc Sci, London W12 0NN, England.
C3 University of London; University College London; Helmholtz Association;
   German Cancer Research Center (DKFZ); Ruprecht Karls University
   Heidelberg; Harvard University; Beth Israel Deaconess Medical Center;
   University of Freiburg; Imperial College London
RP Fantin, A; Ruhrberg, C (通讯作者)，UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
EM a.fantin@ucl.ac.uk; c.ruhrberg@ucl.ac.uk
RI Ruhrberg, Christiana/C-6404-2009; Augustin, Hellmut/AAA-5246-2020;
   Raimondi, Claudio/AAJ-4335-2020; Fantin, Alessandro/R-4601-2017
OI Ruhrberg, Christiana/0000-0002-3212-9381; Augustin,
   Hellmut/0000-0002-7173-4242; Raimondi, Claudio/0000-0002-1419-6855;
   Fantin, Alessandro/0000-0002-5517-6068; Bainbridge,
   James/0000-0003-1318-8201
FU Wellcome Trust [095623/Z/11/Z]; British Heart Foundation
   [PG/11/61/29008, PG/14/81/31119, FS/13/60/30457, FS/13/59/30649];
   Medical Research Council [MR/N011511/1]; MRC [MR/N011511/1,
   MR/K003003/1] Funding Source: UKRI; British Heart Foundation
   [FS/13/35/30148] Funding Source: researchfish; Medical Research Council
   [MR/K003003/1] Funding Source: researchfish; National Institute for
   Health Research [NIHR-RP-011-003] Funding Source: researchfish; Fight
   for Sight [1333/34] Funding Source: researchfish
FX This work was supported by a Wellcome Trust Investigator Award
   (095623/Z/11/Z), British Heart Foundation grants (PG/11/61/29008 and
   PG/14/81/31119) and a Medical Research Council grant (MR/N011511/1) to
   C. Ruhrberg and British Heart Foundation PhD studentships to A.
   Lamproupolou (FS/13/60/30457) and J.T. Brash (FS/13/59/30649).
CR Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205
   Aman J, 2012, CIRCULATION, V126, P2728, DOI 10.1161/CIRCULATIONAHA.112.134304
   Anselmi F, 2012, ANGIOGENESIS, V15, P187, DOI 10.1007/s10456-012-9252-6
   Aspalter IM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8264
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Barratt S, 2014, RESPIRATION, V87, P329, DOI 10.1159/000356034
   Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9
   Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49
   Brkovic A, 2007, J CELL BIOCHEM, V100, P727, DOI 10.1002/jcb.21124
   Buchdunger E, 1996, CANCER RES, V56, P100
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cariboni A, 2011, DEVELOPMENT, V138, P3723, DOI 10.1242/dev.063362
   Cerani A, 2013, CELL METAB, V18, P505, DOI 10.1016/j.cmet.2013.09.003
   Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002
   Chislock EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085231
   Chittenden TW, 2006, DEV CELL, V10, P783, DOI 10.1016/j.devcel.2006.03.012
   Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990
   Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Epstein JA, 2015, CELL METAB, V21, P163, DOI 10.1016/j.cmet.2014.12.015
   Fantin A, 2015, CELL REP, V11, P1577, DOI 10.1016/j.celrep.2015.05.018
   Fantin A, 2014, DEVELOPMENT, V141, P556, DOI 10.1242/dev.103028
   Fantin A, 2013, BLOOD, V121, P2352, DOI 10.1182/blood-2012-05-424713
   Fantin A, 2011, DEVELOPMENT, V138, P4185, DOI 10.1242/dev.070037
   Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832
   Gao YH, 2013, BIOCHEM J, V451, P313, DOI 10.1042/BJ20121418
   Gelfand MV, 2014, ELIFE, V3, DOI 10.7554/eLife.03720
   Greenberg DA, 2013, CELL MOL LIFE SCI, V70, P1753, DOI 10.1007/s00018-013-1282-8
   Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2
   Hudson N, 2014, DEV CELL, V30, P541, DOI 10.1016/j.devcel.2014.06.027
   Kawasaki T, 1999, DEVELOPMENT, V126, P4895
   Kluger MS, 2013, ARTERIOSCL THROM VAS, V33, P489, DOI 10.1161/ATVBAHA.112.300893
   Lampropoulou A, 2014, BIOCHEM SOC T, V42, P1623, DOI 10.1042/BST20140244
   Lanahan A, 2013, DEV CELL, V25, P156, DOI 10.1016/j.devcel.2013.03.019
   Li XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11017
   Ma YH, 2012, J NEUROSCI RES, V90, P1873, DOI 10.1002/jnr.23088
   MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789
   Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Prahst C, 2008, J BIOL CHEM, V283, P25110, DOI 10.1074/jbc.C800137200
   Raimondi C, 2016, PROG RETIN EYE RES, V52, P64, DOI 10.1016/j.preteyeres.2016.02.003
   Raimondi C, 2014, J EXP MED, V211, P1167, DOI 10.1084/jem.20132330
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth L, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad3812
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884
   Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343
   Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Vinores SA, 1997, HISTOL HISTOPATHOL, V12, P99
   Wang J. Q., 2015, SCI WORLD J, V2015, P1, DOI [DOI 10.1371/J0URNAL.P0NE.0124261, DOI 10.2118/174392-MS]
   Wang JYJ, 2014, MOL CELL BIOL, V34, P1188, DOI 10.1128/MCB.01454-13
   Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Wodicka LM, 2010, CHEM BIOL, V17, P1241, DOI 10.1016/j.chembiol.2010.09.010
   Wood JM, 2000, CANCER RES, V60, P2178
   Yaqoob U, 2012, CANCER RES, V72, P4047, DOI 10.1158/0008-5472.CAN-11-3907
   Zarkada G, 2015, P NATL ACAD SCI USA, V112, P761, DOI 10.1073/pnas.1423278112
NR 69
TC 33
Z9 36
U1 0
U2 11
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD APR
PY 2017
VL 214
IS 4
BP 1049
EP 1064
DI 10.1084/jem.20160311
PG 16
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA EQ4MH
UT WOS:000398051100013
PM 28289053
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Binder, CJ
   Papac-Milicevic, N
   Witztum, JL
AF Binder, Christoph J.
   Papac-Milicevic, Nikolina
   Witztum, Joseph L.
TI Innate sensing of oxidation-specific epitopes in health and disease
SO NATURE REVIEWS IMMUNOLOGY
LA English
DT Review
ID LOW-DENSITY-LIPOPROTEIN; C-REACTIVE PROTEIN; COMPLEMENT FACTOR-H;
   RETINAL-PIGMENT EPITHELIUM; TOLL-LIKE RECEPTOR-4; APOPTOTIC CELLS;
   OXIDIZED PHOSPHOLIPIDS; MACULAR DEGENERATION; SCAVENGER RECEPTORS;
   NONALCOHOLIC STEATOHEPATITIS
AB Ageing, infections and inflammation result in oxidative stress that can irreversibly damage cellular structures. The oxidative damage of lipids in membranes or lipoproteins is one of these deleterious consequences that not only alters lipid function but also leads to the formation of neo-self epitopes - oxidation-specific epitopes (OSEs) - which are present on dying cells and damaged proteins. OSEs represent endogenous damage-associated molecular patterns that are recognized by pattern recognition receptors and the proteins of the innate immune system, and thereby enable the host to sense and remove dangerous biological waste and to maintain homeostasis. If this system is dysfunctional or overwhelmed, the accumulation of OSEs can trigger chronic inflammation and the development of diseases, such as atherosclerosis and age-related macular degeneration. Understanding the molecular components and mechanisms that are involved in this process will help to identify individuals with an increased risk of developing chronic inflammation, and will also help to indicate novel modes of therapeutic intervention.
C1 [Binder, Christoph J.; Papac-Milicevic, Nikolina] Med Univ Vienna, Dept Lab Med, Lazarettgasse 14,AKH BT 25-2, A-1090 Vienna, Austria.
   [Binder, Christoph J.; Papac-Milicevic, Nikolina] Austrian Acad Sci, Res Ctr Mol Med, Lazarettgasse 14,AKH BT 25-3, A-1090 Vienna, Austria.
   [Witztum, Joseph L.] Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA.
C3 Medical University of Vienna; Austrian Academy of Sciences; University
   of California System; University of California San Diego
RP Binder, CJ (通讯作者)，Med Univ Vienna, Dept Lab Med, Lazarettgasse 14,AKH BT 25-2, A-1090 Vienna, Austria.; Binder, CJ (通讯作者)，Austrian Acad Sci, Res Ctr Mol Med, Lazarettgasse 14,AKH BT 25-3, A-1090 Vienna, Austria.
EM christoph.binder@meduniwien.ac.at
OI Papac-Milicevic, Nikolina/0000-0002-8187-7677; Binder, Christoph
   J./0000-0001-8313-7050
FU Austrian Science Fund [SFB-30, SFB-54]; US National Institutes of Health
   [HL086559, HL119828, HL055798]; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTE [R01HL086559, P01HL055798, R01HL119828] Funding Source: NIH
   RePORTER
FX The work carried out in the authors' laboratories related to this Review
   is supported by the Austrian Science Fund (SFB-30 and SFB-54 to C.J.B.)
   and the US National Institutes of Health (grants HL086559, HL119828 and
   HL055798 to J.L.W.). The authors thank V. Krajina for help with the
   illustrations.
CR Almyroudis NG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00045
   Amarilyo G, 2010, EUR J IMMUNOL, V40, P699, DOI 10.1002/eji.200838951
   Ameziane N, 2003, ARTERIOSCL THROM VAS, V23, pE61, DOI 10.1161/01.ATV.0000101191.92392.1D
   Amir S, 2012, J LIPID RES, V53, P1316, DOI 10.1194/jlr.M025445
   Arandjelovic S, 2015, NAT IMMUNOL, V16, P907, DOI 10.1038/ni.3253
   Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Bae YS, 2011, MOL CELLS, V32, P491, DOI 10.1007/s10059-011-0276-3
   Bauer J, 2014, BRIT J PHARMACOL, V171, P3115, DOI 10.1111/bph.12677
   Besler C, 2011, J CLIN INVEST, V121, P2693, DOI 10.1172/JCI42946
   Bieghs V, 2012, HEPATOLOGY, V56, P894, DOI 10.1002/hep.25660
   Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034378
   Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876
   Biro E, 2007, ANN RHEUM DIS, V66, P1085, DOI 10.1136/ard.2006.061309
   Biswas S., 2016, BLOOD
   Bochkov VN, 2010, ANTIOXID REDOX SIGN, V12, P1009, DOI 10.1089/ars.2009.2597
   Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023
   Boes M, 2000, P NATL ACAD SCI USA, V97, P1184, DOI 10.1073/pnas.97.3.1184
   Borisenko GG, 2004, CELL DEATH DIFFER, V11, P943, DOI 10.1038/sj.cdd.4401421
   Boullier A, 2005, J LIPID RES, V46, P969, DOI 10.1194/jlr.M400496-JLR200
   Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163
   Bretscher P, 2015, EMBO MOL MED, V7, P593, DOI 10.15252/emmm.201404702
   BRILES DE, 1982, J EXP MED, V156, P1177, DOI 10.1084/jem.156.4.1177
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763
   Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Chen YF, 2009, J IMMUNOL, V183, P1346, DOI 10.4049/jimmunol.0900948
   Chen YF, 2009, J IMMUNOL, V182, P6031, DOI 10.4049/jimmunol.0804191
   Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003
   Choi SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083145
   Choi SH, 2009, CIRC RES, V104, P1355, DOI 10.1161/CIRCRESAHA.108.192880
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Clark SR, 2013, P NATL ACAD SCI USA, V110, P5875, DOI 10.1073/pnas.1222419110
   Cyster JG, 2014, NAT REV IMMUNOL, V14, P731, DOI 10.1038/nri3755
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Duryee MJ, 2005, MOL PHARMACOL, V68, P1423, DOI 10.1124/mol.105.016121
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Fadeel B, 2010, BIOCHEM BIOPH RES CO, V396, P7, DOI 10.1016/j.bbrc.2010.02.106
   Fadok VA, 1998, J IMMUNOL, V161, P6250
   Faria-Neto JR, 2006, ATHEROSCLEROSIS, V189, P83, DOI 10.1016/j.atherosclerosis.2005.11.033
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6
   Gargiulo S, 2015, AGING CELL, V14, P569, DOI 10.1111/acel.12322
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474
   Greaves DR, 2009, J LIPID RES, V50, pS282, DOI 10.1194/jlr.R800066-JLR200
   Greenberg ME, 2008, J BIOL CHEM, V283, P2385, DOI 10.1074/jbc.M707348200
   Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370
   Gresham HD, 2000, J EXP MED, V191, P515, DOI 10.1084/jem.191.3.515
   Gruber S, 2016, CELL REP, V14, P2348, DOI 10.1016/j.celrep.2016.02.027
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Harkewicz R, 2008, J BIOL CHEM, V283, P10241, DOI 10.1074/jbc.M709006200
   Harnett W, 1999, IMMUNOL TODAY, V20, P125, DOI 10.1016/S0167-5699(98)01419-4
   Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533
   Huber J, 2002, ARTERIOSCL THROM VAS, V22, P101, DOI 10.1161/hq0102.101525
   Hyvarinen S, 2014, J BIOL CHEM, V289, P4295, DOI 10.1074/jbc.M113.527416
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689
   Kadl A, 2011, FREE RADICAL BIO MED, V51, P1903, DOI 10.1016/j.freeradbiomed.2011.08.026
   Kang YH, 2012, IMMUNOBIOLOGY, V217, P455, DOI 10.1016/j.imbio.2011.10.008
   Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291
   Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673
   Kim YW, 2015, CIRC RES, V117, P321, DOI 10.1161/CIRCRESAHA.117.305925
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Krieg P, 2013, J INVEST DERMATOL, V133, P172, DOI 10.1038/jid.2012.250
   Kris-Etherton PM, 2004, CIRCULATION, V110, P637, DOI 10.1161/01.CIR.0000137822.39831.F1
   Kumano-Kuramochi M, 2012, BIOCHEM J, V442, P171, DOI 10.1042/BJ20111029
   Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lee S, 2012, CIRC RES, V111, P778, DOI 10.1161/CIRCRESAHA.111.256859
   Li XM, 2007, BIOCHEMISTRY-US, V46, P5009, DOI 10.1021/bi700163y
   Libby P, 2013, IMMUNITY, V38, P1092, DOI 10.1016/j.immuni.2013.06.009
   Linkermann A, 2014, NAT REV IMMUNOL, V14, P759, DOI 10.1038/nri3743
   Litvack ML, 2010, INNATE IMMUN-LONDON, V16, P191, DOI 10.1177/1753425910369271
   Liu ML, 2012, ARTERIOSCL THROM VAS, V32, P2113, DOI 10.1161/ATVBAHA.112.255471
   Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.004
   Matt U, 2013, J CLIN INVEST, V123, P3014, DOI 10.1172/JCI60681
   Mauerhofer C, 2016, MOL ASPECTS MED, V49, P78, DOI 10.1016/j.mam.2016.02.003
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mehta JL, 2007, CIRC RES, V100, P1634, DOI 10.1161/CIRCRESAHA.107.149724
   Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520
   Mullick AE, 2008, J EXP MED, V205, P373, DOI 10.1084/jem.20071096
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Nathan C, 2013, NAT REV IMMUNOL, V13, P349, DOI 10.1038/nri3423
   Nicholls SJ, 2009, J LIPID RES, V50, pS346, DOI 10.1194/jlr.R800086-JLR200
   Niki E, 2005, BIOCHEM BIOPH RES CO, V338, P668, DOI 10.1016/j.bbrc.2005.08.072
   O'Donnell VB, 2012, BLOOD, V120, P1985, DOI 10.1182/blood-2012-04-402826
   Ogden CA, 2005, AUTOIMMUNITY, V38, P259, DOI 10.1080/08916930500124452
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853
   Peng YF, 2005, MOL IMMUNOL, V42, P781, DOI 10.1016/j.molimm.2004.07.045
   Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607
   POTTER M, 1970, J EXP MED, V132, P737, DOI 10.1084/jem.132.4.737
   Rautou PE, 2011, CIRC RES, V109, P593, DOI 10.1161/CIRCRESAHA.110.233163
   Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004
   Rothe T, 2015, J CLIN INVEST, V125, P1944, DOI 10.1172/JCI78490
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Saeed AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106421
   Salomon RG, 2012, CIRC RES, V111, P930, DOI 10.1161/CIRCRESAHA.112.275388
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Seimon TA, 2010, CELL METAB, V12, P467, DOI 10.1016/j.cmet.2010.09.010
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   SHECHTER I, 1981, J LIPID RES, V22, P63
   Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681
   Sparrow JR, 1997, EXP EYE RES, V64, P45, DOI 10.1006/exer.1996.0177
   Steinberg D, 2010, ARTERIOSCL THROM VAS, V30, P2311, DOI 10.1161/ATVBAHA.108.179697
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Tanigaki K, 2015, CIRC RES, V116, P368, DOI 10.1161/CIRCRESAHA.116.302795
   Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359
   Thomas CP, 2012, CURR OPIN PHARMACOL, V12, P471, DOI 10.1016/j.coph.2012.02.013
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200
   Tsiantoulas D, 2015, J LIPID RES, V56, P440, DOI 10.1194/jlr.P054569
   Tsiantoulas D, 2014, CIRC RES, V114, P1743, DOI 10.1161/CIRCRESAHA.113.301145
   Tuominen A, 2006, ARTERIOSCL THROM VAS, V26, P2096, DOI 10.1161/01.ATV.0000233333.07991.4a
   Turunen SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034910
   Uderhardt S, 2012, IMMUNITY, V36, P834, DOI 10.1016/j.immuni.2012.03.010
   van Dijk RA, 2012, J LIPID RES, V53, P2773, DOI 10.1194/jlr.P030890
   Veneskoski M, 2011, FREE RADICAL BIO MED, V51, P834, DOI 10.1016/j.freeradbiomed.2011.05.029
   Verma S, 2005, NAT CLIN PRACT CARD, V2, P29, DOI 10.1038/ncpcardio0074
   VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Walenbergh SMA, 2013, J HEPATOL, V58, P801, DOI 10.1016/j.jhep.2012.11.014
   Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200
   Wan M, 2014, ATHEROSCLEROSIS, V235, P592, DOI 10.1016/j.atherosclerosis.2014.05.913
   Wang GD, 2012, FREE RADICAL RES, V46, P1472, DOI 10.3109/10715762.2012.727209
   Wang H, 2015, CHEM RES TOXICOL, V28, P967, DOI 10.1021/acs.chemrestox.5b00001
   Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Witztum JL, 2014, ANNU REV PATHOL-MECH, V9, P73, DOI 10.1146/annurev-pathol-020712-163936
   Wyatt TA, 2012, ALCOHOL, V46, P51, DOI 10.1016/j.alcohol.2011.09.001
   YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271
   Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 151
TC 194
Z9 202
U1 1
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1733
EI 1474-1741
J9 NAT REV IMMUNOL
JI Nat. Rev. Immunol.
PD AUG
PY 2016
VL 16
IS 8
BP 485
EP 497
DI 10.1038/nri.2016.63
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA DS8CT
UT WOS:000381011200009
PM 27346802
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Robbie, SJ
   Georgiadis, A
   Barker, SE
   Duran, Y
   Smith, AJ
   Ali, RR
   Luhmann, UFO
   Bainbridge, JW
AF Robbie, Scott J.
   Georgiadis, Anastasios
   Barker, Susie E.
   Duran, Yanai
   Smith, Alexander J.
   Ali, Robin R.
   Luhmann, Ulrich F. O.
   Bainbridge, James W.
TI Enhanced Ccl2-Ccr2 signaling drives more severe choroidal
   neovascularization with aging
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Aging; Choroid; Retina; Myeloid cells; CCL2; Choroidal
   neovascularization
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACULAR DEGENERATION; MYELOID CELLS;
   AGE; INFLAMMATION; RECEPTOR; MICE; MICROENVIRONMENT; MACROPHAGES;
   ACTIVATION
AB The impact of many inflammatory diseases is influenced by age-related changes in the activation of resident and circulating myeloid cells. In the eye, a major sight-threatening consequence of age-related macular degeneration is the development of severe choroidal neovascularization (CNV). To identify the molecular pathways and myeloid cell populations involved in this increased neovascular response, we characterized the immune status of murine choroid and retina during aging and in the context of experimental CNV. In the choroid, but not in the retina, advancing age is associated with proinflammatory upregulation of CCL2-CCR2 signaling. Genetic excision of CCL2 diminishes age-related inflammatory changes in the choroid, with reduced recruitment of proinflammatory myeloid cells and attenuation of CNV. These findings indicate that CCL2-driven recruitment of myeloid cells contributes to increased severity of CNV with age. Similar mechanisms may be involved in other age-related inflammatory diseases. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Robbie, Scott J.; Georgiadis, Anastasios; Barker, Susie E.; Duran, Yanai; Smith, Alexander J.; Ali, Robin R.; Luhmann, Ulrich F. O.; Bainbridge, James W.] UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
   [Robbie, Scott J.; Ali, Robin R.; Bainbridge, James W.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Robbie, Scott J.; Ali, Robin R.; Bainbridge, James W.] UCL Inst Ophthalmol, London, England.
   [Luhmann, Ulrich F. O.] Roche Innovat Ctr Basel, Ophthalmol Discovery & Biomarkers, Roche Pharmaceut Res & Early Dev, Basel, Switzerland.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Roche Holding
RP Bainbridge, JW (通讯作者)，UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.; Luhmann, UFO (通讯作者)，F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Ophthalmol Discovery & Biomarkers, Roche Pharmaceut Res & Early Dev, Grenzacherstr 124,Bldg 68-303a, CH-4070 Basel, Switzerland.
EM ulrich.luhmann@roche.com; J.bainbridge@ucl.ac.uk
RI ; Georgiadis, Anastasios/G-8777-2012
OI Luhmann, Ulrich F.O./0000-0002-1993-1951; Georgiadis,
   Anastasios/0000-0001-5079-3588; Bainbridge, James/0000-0003-1318-8201;
   Ali, Robin/0000-0003-3126-6517
FU Department of Health's National Institute for Health Research (NIHR)
   Moorfields Biomedical Research Centre; Alcon Research Institute; NIHR;
   NIHR Moorfields Biomedical Research Centre; MRC [MR/L022699/1] Funding
   Source: UKRI; Medical Research Council [MR/L022699/1] Funding Source:
   researchfish; National Institute for Health Research [NF-SI-0508-10130,
   NIHR-RP-011-003, NF-SI-0513-10074] Funding Source: researchfish
FX Robin R. Ali is partly funded by the Department of Health's National
   Institute for Health Research (NIHR) Moorfields Biomedical Research
   Centre, and Alcon Research Institute; James W. Bainbridge is supported
   by an NIHR Research professorship; Scott J. Robbie is supported by NIHR
   Moorfields Biomedical Research Centre.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Azizi G, 2014, AM J ALZHEIMERS DIS
   Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Christoffersson G, 2012, BLOOD, V120, P4653, DOI 10.1182/blood-2012-04-421040
   Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Enioutina EY, 2011, J IMMUNOL, V186, P697, DOI 10.4049/jimmunol.1002987
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Espinosa-Heidmann DG, 2013, INVEST OPHTH VIS SCI, V54, P7439, DOI 10.1167/iovs.13-12546
   Fan XD, 2007, J BIOL CHEM, V282, P11658, DOI 10.1074/jbc.M607705200
   Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832
   Gavard J, 2009, MOL CELL BIOL, V29, P2469, DOI 10.1128/MCB.01304-08
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067
   Johnston B, 1999, J CLIN INVEST, V103, P1269, DOI 10.1172/JCI5208
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757
   London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2012, ADV EXP MED BIOL, V723, P17, DOI 10.1007/978-1-4614-0631-0_3
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mirabelli-Badenier M, 2011, THROMB HAEMOSTASIS, V105, P409, DOI 10.1160/TH10-10-0662
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Ohno-Matsui Kyoko, 2004, Curr Opin Ophthalmol, V15, P197, DOI 10.1097/01.icu.0000120709.35941.e9
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Robertson MJ, 2002, INVEST OPHTH VIS SCI, V43, P2250
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30
   Selenica MLB, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-86
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
NR 40
TC 16
Z9 16
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD APR
PY 2016
VL 40
BP 110
EP 119
DI 10.1016/j.neurobiolaging.2015.12.019
PG 10
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA DG2OZ
UT WOS:000371908400012
PM 26973110
DA 2022-11-30
ER

PT J
AU Zhang, HM
   He, SK
   Spee, C
   Ishikawa, K
   Hinton, DR
AF Zhang, Huiming
   He, Shikun
   Spee, Christine
   Ishikawa, Keijiro
   Hinton, David R.
TI SIRT1 mediated inhibition of VEGF/VEGFR2 signaling by Resveratrol and
   its relevance to choroidal neovascularization
SO CYTOKINE
LA English
DT Article
DE RPE; SIRT1; Resveratrol; VEGFR2; HIF-1 alpha; CNV
ID MACULAR DEGENERATION; ANGIOGENESIS; CELLS
AB SIRT1, a NAD(+)-dependent histone deacetylase, has been shown to act as a key regulator of angiogenesis. The purpose of this study was to determine the effects of resveratrol (RSV, a SIRT1 activator) on the vascular endothelial growth factor receptor 2 (VEGFR2) signaling pathway and to establish its relevance to choroidal neovascularization (CNV), a blinding complication of age-related macular degeneration. Western blot and ELISA assay showed that RSV inhibited hypoxia-inducible factor (HIF)-1 alpha accumulation and VEGF secretion induced by cobalt chloride (CoCl2) through SIRT1 in human retinal pigment epithelial (hRPE) cells. Furthermore, RSV down-regulated VEGFR2 phosphorylation and activation induced by VEGF in endothelial cells via SIRT1. Thus, the inhibitory effect of RSV on the HIF-1 alpha/VEGF/VEGFR2 signaling axis is mediated, at least in part, through SIRT1. The results suggest that targeting SIRT1 could have therapeutic potential for the treatment of CNV. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Zhang, Huiming] Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Zhang, Huiming; He, Shikun; Spee, Christine; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Ophthalmol, Los Angeles, CA 90089 USA.
   [Ishikawa, Keijiro] Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 Central South University; University of Southern California; Doheny Eye
   Institute
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, Ophthalmol, 2011 Zonal Ave HMR 209, Los Angeles, CA 90089 USA.
EM dhinton@usc.edu
FU NIH [EY01545, EY03040]; Research to Prevent Blindness, Inc.; China
   Scholarship Council (CSC program); NATIONAL EYE INSTITUTE [R01EY001545,
   P30EY003040] Funding Source: NIH RePORTER
FX Grant information: NIH grants EY01545, EY03040; Research to Prevent
   Blindness, Inc.; China Scholarship Council (CSC program).
CR Balaiya S, 2013, MOL VIS, V19, P2385
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Chen LK, 2013, ACTA PHARMACOL SIN, V34, P1174, DOI 10.1038/aps.2013.60
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Kanavi MR, 2014, MOLECULES, V19, P17578, DOI 10.3390/molecules191117578
   Kulkarni S. S., 2014, BIOCH BIOPHYS ACTA
   Nagai N, 2014, J NUTR BIOCH
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yang ZH, 2014, AM J PATHOL, V184, P1230, DOI 10.1016/j.ajpath.2013.12.023
NR 12
TC 29
Z9 33
U1 2
U2 26
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD DEC
PY 2015
VL 76
IS 2
BP 549
EP 552
DI 10.1016/j.cyto.2015.06.019
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA CV4NS
UT WOS:000364244400056
PM 26174951
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nimalaratne, C
   Lopes-Lutz, D
   Schieber, A
   Wu, JP
AF Nimalaratne, Chamila
   Lopes-Lutz, Daise
   Schieber, Andreas
   Wu, Jianping
TI Effect of Domestic Cooking Methods on Egg Yolk Xanthophylls
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE egg yolk; xanthophylls; domestic cooking methods; LC-(APCI)-MS/MS
ID TRANS-CIS-ISOMERIZATION; BETA-CAROTENE; LUTEIN; DEGRADATION;
   PASTEURIZATION; ISOMERS; STORAGE; HPLC; FOOD
AB Xanthophylls are a class of bioactive compounds known to play an important role in preventing age-related macular degeneration. Egg yolk is a rich source of highly bioavailable xanthophylls including lutein and zeaxanthin. The effects of domestic cooking methods (boiling, frying, microwaving) on egg yolk xanthophyll content were investigated. A LC-(APCI)-MS/MS method was used to identify and quantify all-E- and Z-isomers of lutein, zeaxanthin, canthaxanthin, and beta-apo-8'-carotenoic acid ethyl ester in fresh and cooked egg yolks. Both fresh and cooked yolks showed similar xanthophyll profiles but with higher contents of Z-isomers in cooked samples. All-E-lutein was the most affected, with 22.5%, 16.7%, and 19.3% reductions in boiled, microwaved, and fried yolk extracts, respectively. Total xanthophyll losses ranged from 6% to 18%. The results presented here could be useful in calculating the dietary intake of xanthophylls and also in assessing the xanthophyll profiles and contents of egg-containing products.
C1 [Nimalaratne, Chamila; Lopes-Lutz, Daise; Schieber, Andreas; Wu, Jianping] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2P5, Canada.
   [Schieber, Andreas] Univ Bonn, Dept Nutr & Food Sci, D-53117 Bonn, Germany.
C3 University of Alberta; University of Bonn
RP Schieber, A (通讯作者)，Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2P5, Canada.
EM schieber@uni-bonn.de; jwu3@ualberta.ca
RI Wu, Jian/AAU-5221-2020
OI Wu, Jian/0000-0001-9933-7364; Nimalaratne, Chamila/0000-0002-1414-510X
FU Egg Farmers of Canada (EFC); Alberta Egg Producers (AEP); Agriculture
   and Food Council; Food for Health Initiative (Vitamin Fund) of the
   Faculty of Agricultural, Life & Environmental Science of the University
   of Alberta; Burnbrae Farms Limited; Poultry Industry Council; Natural
   Sciences, and Engineering Research Council (NSERC) of Canada
FX This research was funded by grants from Egg Farmers of Canada (EFC),
   Alberta Egg Producers (AEP), the Agriculture and Food Council, which is
   responsible for delivering Agriculture and Agri-Food Canada's Advancing
   Canadian Agriculture and Agri-Food (ACAAF) Program in Alberta, Food for
   Health Initiative (Vitamin Fund) of the Faculty of Agricultural, Life &
   Environmental Science of the University of Alberta, Burnbrae Farms
   Limited, Poultry Industry Council and Natural Sciences, and Engineering
   Research Council (NSERC) of Canada to J.W.
CR Aman R, 2005, J AGR FOOD CHEM, V53, P9512, DOI 10.1021/jf050926w
   Aman R, 2005, FOOD CHEM, V92, P753, DOI 10.1016/j.foodchem.2004.10.031
   Breithaupt Dietmar E., 2008, V4, P255, DOI 10.1007/978-3-7643-7499-0_13
   CHEN BH, 1995, J AGR FOOD CHEM, V43, P1912, DOI 10.1021/jf00055a029
   Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375
   Dugo P, 2006, ANAL CHEM, V78, P7743, DOI 10.1021/ac061290q
   Fratianni A, 2010, LWT-FOOD SCI TECHNOL, V43, P867, DOI 10.1016/j.lwt.2010.01.011
   GORDON HT, 1982, CRC CR REV FOOD SCI, V18, P59, DOI 10.1080/10408398209527357
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   International Conference on Harmonization (ICH) Q2B, 1997, US FDA FED REG, V62, P27463
   Marx M, 2003, FOOD CHEM, V83, P609, DOI 10.1016/S0308-8146(03)00255-3
   NELIS HJCF, 1984, J BIOL CHEM, V259, P6063
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Rios JJ, 2008, FOOD CHEM, V106, P1145, DOI 10.1016/j.foodchem.2007.07.045
   Rodriguez-Amaya Delia B, 2003, Forum Nutr, V56, P35
   Schieber A, 2005, TRENDS FOOD SCI TECH, V16, P416, DOI 10.1016/j.tifs.2005.03.018
   Schlatterer J, 2006, J AGR FOOD CHEM, V54, P2267, DOI 10.1021/jf053204d
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Sunwoo H. H., 2006, AMAZING EGG NATURES, P95
   Surai PF, 2000, EUR J CLIN NUTR, V54, P298, DOI 10.1038/sj.ejcn.1600939
   Gama JJT, 2007, FOOD CHEM, V100, P1686, DOI 10.1016/j.foodchem.2005.01.062
   Updike AA, 2003, J AGR FOOD CHEM, V51, P6184, DOI 10.1021/jf030350f
   Voutilainen S, 2006, AM J CLIN NUTR, V83, P1265
   Wenzel M, 2011, FOOD CHEM, V124, P1343, DOI 10.1016/j.foodchem.2010.07.085
   Wenzel M, 2010, J AGR FOOD CHEM, V58, P1726, DOI 10.1021/jf903488b
   Zepka LQ, 2009, FOOD CHEM, V117, P28, DOI 10.1016/j.foodchem.2009.03.071
NR 26
TC 38
Z9 40
U1 1
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD DEC 26
PY 2012
VL 60
IS 51
BP 12547
EP 12552
DI 10.1021/jf303828n
PG 6
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 065MS
UT WOS:000313153200017
PM 23205520
DA 2022-11-30
ER

PT J
AU Tamamis, P
   Lopez de Victoria, A
   Gorham, RD
   Bellows-Peterson, ML
   Pierou, P
   Floudas, CA
   Morikis, D
   Archontis, G
AF Tamamis, Phanourios
   Lopez de Victoria, Aliana
   Gorham, Ronald D., Jr.
   Bellows-Peterson, Meghan L.
   Pierou, Panayiota
   Floudas, Christodoulos A.
   Morikis, Dimitrios
   Archontis, Georgios
TI Molecular Dynamics in Drug Design: New Generations of Compstatin Analogs
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE complement system; C3; mechanism-based drug design; molecular modeling;
   compstatin; structure-based drug design
ID NOVO PROTEIN DESIGN; BINDING FREE-ENERGY; COMPLEMENT INHIBITOR;
   PHARMACOPHORE MODEL; PEPTIDE ANALOGS; ACTIVATION; C3; OPTIMIZATION;
   SIMULATIONS; PREDICTIONS
AB We report the computational and rational design of new generations of potential peptide-based inhibitors of the complement protein C3 from the compstatin family. The binding efficacy of the peptides is tested by extensive molecular dynamics-based structural and physicochemical analysis, using 32 atomic detail trajectories in explicit water for 22 peptides bound to human, rat or mouse target protein C3, with a total of 257 ns. The criteria for the new design are: (i) optimization for C3 affinity and for the balance between hydrophobicity and polarity to improve solubility compared to known compstatin analogs; and (ii) development of dual specificity, human-rat/mouse C3 inhibitors, which could be used in animal disease models. Three of the new analogs are analyzed in more detail as they possess strong and novel binding characteristics and are promising candidates for further optimization. This work paves the way for the development of an improved therapeutic for age-related macular degeneration, and other complement system-mediated diseases, compared to known compstatin variants.
C1 [Tamamis, Phanourios; Pierou, Panayiota; Archontis, Georgios] Univ Cyprus, Dept Phys, CY-1678 Nicosia, Cyprus.
   [Tamamis, Phanourios; Lopez de Victoria, Aliana; Gorham, Ronald D., Jr.; Morikis, Dimitrios] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
   [Tamamis, Phanourios; Bellows-Peterson, Meghan L.; Floudas, Christodoulos A.] Princeton Univ, Dept Chem & Biol Engn, Princeton, NJ 08544 USA.
C3 University of Cyprus; University of California System; University of
   California Riverside; Princeton University
RP Archontis, G (通讯作者)，Univ Cyprus, Dept Phys, PO20537, CY-1678 Nicosia, Cyprus.
EM floudas@titan.princeton.edu; dmorikis@engr.ucr.edu; archonti@ucy.ac.cy
RI Morikis, Dimitrios/L-8527-2013
OI Morikis, Dimitrios/0000-0003-0083-4665; Tamamis,
   Phanourios/0000-0002-3342-2651; Gorham, Ronald/0000-0002-0261-6699
FU Cyprus Fulbright Commission; Cyprus Research Promotion Foundation
   [INFRASTRUCTURE/STRATEGIC/0308/31]; European Regional Development fund;
   University of Cyprus; DoD; Air Force Office of Scientific Research;
   National Defense Science and Engineering Graduate (NDSEG) [32 CFR 168a];
   National Institutes of Health [5R01GM052032]; Beckman Initiative for
   Macular Degeneration [1112]; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [R01GM052032] Funding Source: NIH RePORTER
FX Most of the MD simulations were performed on Linux clusters of the
   Biophysics group at the University of Cyprus. Some MD simulations were
   performed at an IBM cluster at the Cyprus Institute and a Linux cluster
   of the BioMoDeL group at the University of California at Riverside. The
   peptide design calculations were performed in a Linux cluster of the
   CASL group at Princeton University. PT acknowledges support from a
   senior Fulbright Scholarship by the Cyprus Fulbright Commission. GA and
   PT acknowledge support from the Cyprus Research Promotion Foundation
   grant INFRASTRUCTURE/STRATEGIC/0308/31, 'Cy-Tera: A Multi- Teraflop/s
   computing facility for Science and Technology in Cyprus', that is
   co-funded by the European Regional Development fund. GA and PT also
   acknowledge a research grant from the University of Cyprus. MLBP
   acknowledges Government support under and awarded by DoD, Air Force
   Office of Scientific Research, National Defense Science and Engineering
   Graduate (NDSEG) Fellowship, 32 CFR 168a. CAF acknowledges financial
   support from the National Institutes of Health (grant 5R01GM052032). DM
   acknowledges financial support from the Beckman Initiative for Macular
   Degeneration (grant 1112). GA and PT would like to thank Prof. Roland
   Dunbrack for the SCWRL4 program. The authors acknowledge useful
   discussions with Chris A. Kieslich.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bellows ML, 2010, BIOPHYS J, V99, P3445, DOI 10.1016/j.bpj.2010.09.050
   Bellows ML, 2010, BIOPHYS J, V98, P2337, DOI 10.1016/j.bpj.2010.01.057
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Chen JH, 2006, J AM CHEM SOC, V128, P3728, DOI 10.1021/ja057216r
   Chiu TL, 2008, CHEM BIOL DRUG DES, V72, P249, DOI 10.1111/j.1747-0285.2008.00709.x
   Daily MD, 2005, PROTEINS, V60, P181, DOI 10.1002/prot.20555
   DiMaggio PA, 2010, J GLOBAL OPTIM, V47, P343, DOI 10.1007/s10898-008-9349-z
   DiMaggio PA, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-458
   Eswar Narayanan, 2006, Curr Protoc Bioinformatics, VChapter 5, pUnit, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/cpbi.3, 10.1002/0471250953.bi0506s15]
   Fung HK, 2007, OPTIM METHOD SOFTW, V22, P51, DOI 10.1080/10556780600882041
   Fung HK, 2008, BIOPHYS J, V94, P584, DOI 10.1529/biophysj.107.110627
   Furlong ST, 2000, IMMUNOPHARMACOLOGY, V48, P199, DOI 10.1016/S0162-3109(00)00205-8
   Gilson MK, 2007, ANNU REV BIOPH BIOM, V36, P21, DOI 10.1146/annurev.biophys.36.040306.132550
   Gohlke H, 2004, J COMPUT CHEM, V25, P238, DOI [10.1002/jcc.10379, 10.1022/jcc.10379]
   Gray JJ, 2003, J MOL BIOL, V331, P281, DOI 10.1016/S0022-2836(03)00670-3
   Gray JJ, 2003, PROTEINS, V52, P118, DOI 10.1002/prot.10384
   Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231
   Holland M Claire H, 2004, Curr Opin Investig Drugs, V5, P1164
   Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Klepeis JL, 2004, IND ENG CHEM RES, V43, P3817, DOI 10.1021/ie0340995
   Klepeis JL, 2003, J AM CHEM SOC, V125, P8422, DOI 10.1021/ja034846p
   Klepeis JL, 1999, J COMPUT CHEM, V20, P1354, DOI 10.1002/(SICI)1096-987X(199910)20:13<1354::AID-JCC3>3.3.CO;2-E
   Krivov GG, 2009, PROTEINS, V77, P778, DOI 10.1002/prot.22488
   Lazaridis T, 2002, PROTEINS, V47, P194, DOI 10.1002/prot.10086
   Lee MR, 2001, J AM CHEM SOC, V123, P1040, DOI 10.1021/ja003150i
   Lopez de Victoria A, 2011, CHEM BIOL DRUG DES, V77, P431, DOI 10.1111/j.1747-0285.2011.01111.x
   Macias AT, 2005, J COMPUT CHEM, V26, P1452, DOI 10.1002/jcc.20281
   Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Mallik B, 2005, J AM CHEM SOC, V127, P10967, DOI 10.1021/ja051004c
   Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531
   Mallik B, 2003, PROTEINS, V53, P130, DOI 10.1002/prot.10491
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Morikis D, 2005, LECT NOTES COMPUT SC, V3515, P680
   Morikis D, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P317
   Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311
   Morikis D, 2004, BIOCHEM SOC T, V32, P28, DOI 10.1042/BST0320028
   Morikis D, 2002, BIOCHEM SOC T, V30, P1026, DOI 10.1042/BST0301026
   Morikis D., 2006, WSEAS Transactions on Biology and Biomedicine, V3, P408
   Morikis D, 2002, J BIOL CHEM, V277, P14942, DOI 10.1074/jbc.M200021200
   Muller-Eberhard H.J., 2002, INFLAMMATION BASIC P, P21
   Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104
   Page CS, 2006, J COMPUT CHEM, V27, P1990, DOI 10.1002/jcc.20534
   Qu HC, 2011, MOL IMMUNOL, V48, P481, DOI 10.1016/j.molimm.2010.10.004
   Rajgaria R, 2008, PROTEINS, V70, P950, DOI 10.1002/prot.21561
   Rajgaria R, 2006, PROTEINS, V65, P726, DOI 10.1002/prot.21149
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Rohl CA, 2004, METHOD ENZYMOL, V383, P66
   Rohl CA, 2002, J AM CHEM SOC, V124, P2723, DOI 10.1021/ja016880e
   Sahu A, 1996, J IMMUNOL, V157, P884
   Sahu A, 2003, MOL IMMUNOL, V39, P557, DOI 10.1016/S0161-5890(02)00212-2
   Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491
   Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4
   Seeber M, 2007, BIOINFORMATICS, V23, P2625, DOI 10.1093/bioinformatics/btm378
   Singh N, 2010, PROTEINS, V78, P1705, DOI 10.1002/prot.22687
   Soulika AM, 2003, J IMMUNOL, V171, P1881, DOI 10.4049/jimmunol.171.4.1881
   Soulika AM, 2006, MOL IMMUNOL, V43, P2023, DOI 10.1016/j.molimm.2005.12.002
   Tamamis P., 2011, BIOMED ENG RES, V1, P14
   Tamamis P, 2007, J MOL GRAPH MODEL, V26, P571, DOI 10.1016/j.jmgm.2007.03.014
   Tamamis P, 2011, PROTEINS, V79, P3166, DOI 10.1002/prot.23149
   Tamamis P, 2010, PROTEINS, V78, P2655, DOI 10.1002/prot.22780
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Zoete V, 2010, J MOL RECOGNIT, V23, P142, DOI 10.1002/jmr.1005
NR 65
TC 34
Z9 35
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
EI 1747-0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD MAY
PY 2012
VL 79
IS 5
BP 703
EP 718
DI 10.1111/j.1747-0285.2012.01324.x
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 919BX
UT WOS:000302296700009
PM 22233517
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Saviranta, NMM
   Veeroos, L
   Granlund, LJ
   Hassinen, VH
   Kaarniranta, K
   Karjalainen, RO
AF Saviranta, Niina M. M.
   Veeroos, Laura
   Granlund, Lars J.
   Hassinen, Viivi H.
   Kaarniranta, Kai
   Karjalainen, Reijo O.
TI Plant flavonol quercetin and isoflavone biochanin A differentially
   induce protection against oxidative stress and inflammation in ARPE-19
   cells
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE Functional ingredients; Oxidative stress; Inflammation; Eye health;
   Quercetin; Biochanin A
ID NF-KAPPA-B; GENE-EXPRESSION; MACULAR DEGENERATION; HEME OXYGENASE-1;
   NRF2; ACTIVATION; ANTIOXIDANT
AB In this work, differential ability of plant flavonol quercetin and plant isoflavone biochanin A to modulate oxidative stress and inhibit inflammation-related responses was investigated using human retinal pigment epithelial cells (RPE) at gene expression level. Quercetin protected cells from oxidative stress-induced cell death, whereas biochanin A had no statistically significant protective effects. Quercetin reduced the expression of cytokines IL-6 and IL-1 beta in cells treated with H2O2, and expression levels of Nrf2 and HO-1 were increased by quercetin treatment suggesting protective function against oxidative stress. Our data indicate that quercetin may protect cells by inhibiting the production of pro-inflammatory factors such as IL-6, and by inducing the expression of ROS-catalyzing phase II proteins such as HO-1. Therefore, plant extracts rich in flavonol quercetin may be an interesting resource for functional food products and other foods targeted for reduced risks of age-related macular degeneration. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Saviranta, Niina M. M.; Veeroos, Laura; Granlund, Lars J.; Hassinen, Viivi H.; Karjalainen, Reijo O.] Univ Eastern Finland, Dept Biosci, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70211, Finland.
   [Karjalainen, Reijo O.] AgriFood Res Finland, Jokioinen 31600, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Natural Resources Institute Finland (Luke)
RP Karjalainen, RO (通讯作者)，Univ Eastern Finland, Dept Biosci, POB 1627, Kuopio 70211, Finland.
EM reijo.karjalainen@uef.fi
OI Kaarniranta, Kai/0000-0003-2600-8679
FU Northern Savo ELY-center [3021]; EC [SME-2007-1, 222503]
FX This work was funded by Northern Savo ELY-center (project 3021) and the
   EC FP7 project "BrainHealthFood" (SME-2007-1 project 222503). We thank
   Antero Salminen for the comments for the manuscript.
CR Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008
   Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gonzalez-Molina E, 2009, FOOD CHEM, V115, P1364, DOI 10.1016/j.foodchem.2009.01.056
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Heinonen SM, 2004, J AGR FOOD CHEM, V52, P6802, DOI 10.1021/jf0492767
   Ho L, 2009, J ALZHEIMERS DIS, V16, P59, DOI 10.3233/JAD-2009-0916
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   Johnson J, 2009, INVEST OPHTH VIS SCI, V50, P2398, DOI 10.1167/iovs.08-2088
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kang HJ, 2009, BREAST J, V15, P223, DOI 10.1111/j.1524-4741.2009.00709.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kimura S, 2009, BIOCHEM BIOPH RES CO, V387, P109, DOI 10.1016/j.bbrc.2009.06.136
   Knekt P, 2002, AM J CLIN NUTR, V76, P560, DOI 10.1093/ajcn/76.3.560
   Kokot A, 2009, ENDOCRINOLOGY, V150, P3197, DOI 10.1210/en.2008-1315
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017
   Liu RH, 2003, AM J CLIN NUTR, V78, p517S, DOI 10.1093/ajcn/78.3.517S
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maher P, 2005, INVEST OPHTH VIS SCI, V46, P4796, DOI 10.1167/iovs.05-0397
   Malinen M, 2008, NUCLEIC ACIDS RES, V36, P121, DOI 10.1093/nar/gkm913
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Miyamura N, 2004, INVEST OPHTH VIS SCI, V45, P1562, DOI 10.1167/iovs.02-0761
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Occhiuto F, 2009, PHYTOTHER RES, V23, P192, DOI 10.1002/ptr.2584
   Park HJ, 2008, J MED FOOD, V11, P773, DOI 10.1089/jmf.2008.0077
   Reiterer G, 2004, J NUTR, V134, P771, DOI 10.1093/jn/134.4.771
   Saviranta NM, 2008, J SCI FOOD AGR, V88, P125, DOI 10.1002/jsfa.3056
   Surh YJ, 2008, GENES NUTR, V2, P313, DOI 10.1007/s12263-007-0063-0
   Zafrilla P, 2009, NAT PROD COMMUN, V4, P719
NR 35
TC 40
Z9 42
U1 3
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0963-9969
EI 1873-7145
J9 FOOD RES INT
JI Food Res. Int.
PD JAN
PY 2011
VL 44
IS 1
BP 109
EP 113
DI 10.1016/j.foodres.2010.10.056
PG 5
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 734AZ
UT WOS:000288306900016
DA 2022-11-30
ER

PT J
AU Campa, C
   Costagliola, C
   Incorvaia, C
   Sheridan, C
   Semeraro, F
   De Nadai, K
   Sebastiani, A
   Parmeggiani, F
AF Campa, Claudio
   Costagliola, Ciro
   Incorvaia, Carlo
   Sheridan, Carl
   Semeraro, Francesco
   De Nadai, Katia
   Sebastiani, Adolfo
   Parmeggiani, Francesco
TI Inflammatory Mediators and Angiogenic Factors in Choroidal
   Neovascularization: Pathogenetic Interactions and Therapeutic
   Implications
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT-FACTOR-H; RETINAL-PIGMENT
   EPITHELIUM; INTRAVITREAL BEVACIZUMAB AVASTIN; MACULAR DEGENERATION;
   PHOTODYNAMIC THERAPY; MATRIX METALLOPROTEINASES; RANIBIZUMAB LUCENTIS;
   LOC387715 GENOTYPES; GENE POLYMORPHISMS
AB Choroidal neovascularization (CNV) is a common and severe complication in heterogeneous diseases affecting the posterior segment of the eye, the most frequent being represented by age-related macular degeneration. Although the term may suggest just a vascular pathological condition, CNV is more properly definable as an aberrant tissue invasion of endothelial and inflammatory cells, in which both angiogenesis and inflammation are involved. Experimental and clinical evidences show that vascular endothelial growth factor is a key signal in promoting angiogenesis. However, many other molecules, distinctive of the inflammatory response, act as neovascular activators in CNV. These include fibroblast growth factor, transforming growth factor, tumor necrosis factor, interleukins, and complement. This paper reviews the role of inflammatory mediators and angiogenic factors in the development of CNV, proposing pathogenetic assumptions of mutual interaction. As an extension of this concept, new therapeutic approaches geared to have an effect on both the vascular and the extravascular components of CNV are discussed.
C1 [Campa, Claudio; Incorvaia, Carlo; De Nadai, Katia; Sebastiani, Adolfo; Parmeggiani, Francesco] Univ Ferrara, Dept Ophthalmol, I-44121 Ferrara, Italy.
   [Campa, Claudio; Sheridan, Carl] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
   [Semeraro, Francesco] Univ Brescia, Dept Ophthalmol, Brescia, Italy.
   [De Nadai, Katia] Camposampiero Hosp, Ctr Retinitis Pigmentosa Veneto Reg, Camposampiero, Italy.
C3 University of Ferrara; Royal Liverpool & Broadgreen University Hospitals
   NHS Trust; Royal Liverpool University Hospital; University of Liverpool;
   University of Molise; University of Brescia; ULSS 6 Euganea; Ospedale di
   Camposampiero
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Dept Ophthalmol, Corso Giovecca 203, I-44121 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Costagliola, Ciro/G-5707-2012; Sheridan, Carl/AAH-3607-2021; Semeraro,
   Francesco fs/K-8667-2016
OI Costagliola, Ciro/0000-0001-8477-6188; Sheridan,
   Carl/0000-0003-0100-9587; Semeraro, Francesco fs/0000-0002-2275-4917
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   BAROUCH FC, 2006, OPHTHALMOLOGY CLINIC, V3, P401
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BOYER DS, 2009, INVESTIGATIVE OPHTHA, V50
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cano MD, 2009, INVEST OPHTH VIS SCI, V50, P3840, DOI 10.1167/iovs.08-2607
   CAPONE A, 2009, INVESTIGATIVE OPHTHA, V50
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chowers I, 2008, MOL VIS, V14, P2263
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DE CORDOBA, 2008, CLIN EXP IMMUNOL, V151, P1
   De la Paz MA, 1998, INVEST OPHTH VIS SCI, V39, P1256
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dejneka NS, 2004, MOL VIS, V10, P964
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, MOL VIS, V14, P1395
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fu YL, 2007, INVEST OPHTH VIS SCI, V48, P5184, DOI 10.1167/iovs.07-0469
   Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521
   GASS JDM, 1997, STEREOSCOPIC ATLAS O, V1
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kent D, 2003, MOL VIS, V9, P747
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Kim IK, 2008, MOL VIS, V14, P1487
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Parmeggiani F, 2010, OPHTHALMOLOGY, V117, P517, DOI 10.1016/j.ophtha.2009.08.028
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Siemann DW, 2009, EXPERT OPIN INV DRUG, V18, P189, DOI [10.1517/13543780802691068, 10.1517/13543780802691068 ]
   SLAKTER S, 2009, INVEST OPHTHALMOL, V50, P1890
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Thomas M, 2009, ANGIOGENESIS, V12, P125, DOI 10.1007/s10456-009-9147-3
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Xu YL, 2008, MOL VIS, V14, P1373
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
NR 157
TC 55
Z9 56
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2010
VL 2010
AR 546826
DI 10.1155/2010/546826
PG 14
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 664OP
UT WOS:000282971900001
PM 20871825
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Yasukawa, T
   Ogura, Y
   Sakurai, E
   Tabata, Y
   Kimura, H
AF Yasukawa, T
   Ogura, Y
   Sakurai, E
   Tabata, Y
   Kimura, H
TI Intraocular sustained drug delivery using implantable polymeric devices
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE age-related macular degeneration; drug delivery system; implants;
   sustained release; vitreoretinal diseases
ID BIODEGRADABLE SCLERAL IMPLANT; EXPERIMENTAL PROLIFERATIVE
   VITREORETINOPATHY; INTRAVITREAL CONTROLLED-RELEASE; MACULAR
   DEGENERATION; SUBMACULAR SURGERY; GANCICLOVIR; PLUG; NEOVASCULARIZATION;
   DEXAMETHASONE; BETAMETHASONE
AB Vitreoretinal diseases involving age-related macular degeneration (AMD) are refractory to most topical or systemic drugs. The retina and the vitreous cavity have a unique position regarding pharmacokinetics in that the inner and outer blood retinal barriers separate the retina and vitreous from the systemic circulation. Eye drops achieve minimal therapeutic concentrations in the vitreoretinal tissue. Drug delivery systems are a strategy to address this. Intraocular sustained drug release using implantable devices has been investigated to treat vitreoretinal diseases. Possible targeted diseases include those in which repeated intraocular injections are effective (cytomegalovirus retinitis, uveitis), diseases requiring surgery (proliferative vitreoretinopathy), and chronic diseases (AMD, macular edema, retinitis pigmentosa). Hydrophobic or hydrophilic polymers shaped into a sheet, disc, rod, plug, or a larger device can be implanted into the subretinal space, intrascleral space, vitreous space, peribulbar space, or at the pars plana. Many researchers suggest the feasibility of these implants to treat AMD. (c) 2005 Elsevier B.V. All rights reserved.
C1 Nagoya City Univ, Sch Med, Dept Ophthalmol, Aichi 4678601, Japan.
   Kurashiki Cent Hosp, Kurashiki, Okayama 7108602, Japan.
   Kyoto Univ, Inst Frontier Med Sch, Kyoto 6068507, Japan.
   Nagata Eye Clin, Nara 6310844, Japan.
C3 Nagoya City University; Kurashiki Central Hospital; Kyoto University
RP Ogura, Y (通讯作者)，Nagoya City Univ, Sch Med, Dept Ophthalmol, Aichi 4678601, Japan.
EM ogura@med.nagoya-cu.ac.jp
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   BAUM J, 1982, SURV OPHTHALMOL, V26, P204
   Bochot A, 2000, PROG RETIN EYE RES, V19, P131, DOI 10.1016/S1350-9462(99)00014-2
   Bressler NM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1071, DOI 10.1001/archopht.1997.01100160241017
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   HASHIZOE M, 1994, ARCH OPHTHALMOL-CHIC, V112, P1380, DOI 10.1001/archopht.1994.01090220130035
   Hashizoe M, 1997, CURR EYE RES, V16, P633, DOI 10.1076/ceyr.16.7.633.5063
   HASHIZOE M, 1995, CURR EYE RES, V14, P473, DOI 10.3109/02713689509003758
   HORA MS, 1990, PHARMACEUT RES, V7, P1190, DOI 10.1023/A:1015948829632
   Ip M, 1996, AM J OPHTHALMOL, V122, P594, DOI 10.1016/S0002-9394(14)72131-2
   Jaffe GJ, 2000, RETINA-J RET VIT DIS, V20, P402, DOI 10.1097/00006982-200004000-00015
   Jaffe GJ, 1998, OPHTHALMOLOGY, V105, P46, DOI 10.1016/S0161-6420(98)91176-9
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Kaplan H, 1996, BRIT J OPHTHALMOL, V80, P101, DOI 10.1136/bjo.80.2.101
   KIMURA H, 1994, INVEST OPHTH VIS SCI, V35, P2815
   Kimura H, 2001, OPHTHALMOLOGICA, V215, P143, DOI 10.1159/000050849
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kunou N, 2000, J CONTROL RELEASE, V68, P263, DOI 10.1016/S0168-3659(00)00267-4
   KUNOU N, 1995, J CONTROL RELEASE, V37, P143, DOI 10.1016/0168-3659(95)00074-I
   LANG JC, 1995, ADV DRUG DELIVER REV, V16, P39, DOI 10.1016/0169-409X(95)00012-V
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Maguire MG, 2001, INVEST OPHTH VIS SCI, V42, pS233
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Maurice D. M., 1984, HANDB EXP PHARM, P19
   Miyamoto H, 1997, CURR EYE RES, V16, P930, DOI 10.1076/ceyr.16.9.930.5042
   Morita Y, 1998, BIOL PHARM BULL, V21, P188
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   OGAWA Y, 1988, CHEM PHARM BULL, V36, P2576
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Okabe K, 2003, INVEST OPHTH VIS SCI, V44, P2702, DOI 10.1167/iovs.02-0956
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1987, RETINA-J RET VIT DIS, V7, P227, DOI 10.1097/00006982-198707040-00005
   PITT CG, 1979, J PHARM SCI, V68, P1534, DOI 10.1002/jps.2600681219
   RUBSAMEN PE, 1994, ARCH OPHTHALMOL-CHIC, V112, P407, DOI 10.1001/archopht.1994.01090150137036
   RYAN SJ, 1994, RETINA, P1027
   Sakurai E, 2001, INVEST OPHTH VIS SCI, V42, P2043
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P4845, DOI 10.1167/iovs.02-1228
   SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023
   SANDERS LM, 1984, J PHARM SCI, V73, P1294, DOI 10.1002/jps.2600730927
   Sasai K, 1997, INT J RADIAT ONCOL, V39, P173, DOI 10.1016/S0360-3016(97)00296-4
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Tabata Y, 1998, ADV DRUG DELIVER REV, V31, P287, DOI 10.1016/S0169-409X(97)00125-7
   Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166
   USSERY FM, 1988, OPHTHALMOLOGY, V95, P640
   Yang CF, 2000, OPHTHALMIC RES, V32, P19, DOI 10.1159/000055582
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Yasukawa T, 2000, GRAEF ARCH CLIN EXP, V238, P186, DOI 10.1007/s004170050031
   Yasukawa T, 2002, GRAEF ARCH CLIN EXP, V240, P672, DOI 10.1007/s00417-002-0484-9
   Yasukawa T, 2001, ADV DRUG DELIVER REV, V52, P25, DOI 10.1016/S0169-409X(01)00192-2
   Zhou TH, 1998, J CONTROL RELEASE, V55, P281, DOI 10.1016/S0168-3659(98)00061-3
NR 59
TC 101
Z9 111
U1 0
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 13
PY 2005
VL 57
IS 14
BP 2033
EP 2046
DI 10.1016/j.addr.2005.09.005
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 996QD
UT WOS:000234188300004
PM 16263193
DA 2022-11-30
ER

PT J
AU Furuta, M
   Iida, T
   Maruko, I
   Kishi, S
   Sekiryu, T
AF Furuta, Minoru
   Iida, Tomohiro
   Maruko, Ichiro
   Kishi, Shoji
   Sekiryu, Tetsuju
TI SUBMACULAR CHOROIDAL NEOVASCULARIZATION AT THE MARGIN OF STAPHYLOMA IN
   TILTED DISK SYNDROME
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE tilted disk syndrome; choroidal neovascularization; polypoidal choroidal
   vasculopathy; macular degeneration; high myopia; posterior staphyloma;
   indocyanine green angiography; fluorescein angiography; choroidal
   circulation
ID GREEN ANGIOGRAPHIC FEATURES; MACULAR COMPLICATIONS; SUBRETINAL LEAKAGE;
   DETACHMENT; RUPTURE; BORDER; EYES
AB Purpose: To clarify the nature of submacular choroidal neovascularization (CNV) and underlying choroidal circulatory disturbances in tilted disk syndrome.
   Methods: We retrospectively examined patients with submacular CNV associated with tilted disk syndrome using fluorescein angiography and indocyanine green angiography in this observational case series. The axial lengths were measured by ultrasonography. Eyes with myopia exceeding -6.0 diopters were excluded.
   Results: Eleven consecutive eyes (mean patient age +/- standard deviation, 60.5 +/- 12.1 years) were included. The axial lengths ranged from 21.7 mm to 24.6 mm (mean, 23.61 +/- 0.95 mm). Classic CNV in nine eyes and polypoidal choroidal vasculopathy in two eyes developed at the macula along the superior margin of the inferior posterior staphyloma that crossed the macula in all eyes. The superior margin of the inferior posterior staphyloma was hyperfluorescent on fluorescein angiography and hypofluorescent on indocyanine green angiography, with the latter larger than the former. The inferior staphyloma contained fewer and smaller choroidal arteries and veins. During follow-up, the submacular CNV and polypoidal choroidal vasculopathy spontaneously regressed and the subretinal hemorrhage resorbed, leaving a fibrotic scar in eight eyes. Newly developed CNV at the initial no-leakage site on fluorescein angiography developed in one eye and the CNV located in the area of band-shaped hypofluorescence on indocyanine green angiography.
   Conclusion: Stretching of the ocular wall might result in occluded choriocapillaris and degeneration of the retinal pigment epithelium. These changes along the border of the inferior posterior staphyloma predispose to submacular CNV and polypoidal choroidal vasculopathy in tilted disk syndrome. RETINA 33:71-76, 2013
C1 [Furuta, Minoru; Iida, Tomohiro; Maruko, Ichiro; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo 1628666, Japan.
   [Kishi, Shoji] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 371, Japan.
C3 Fukushima Medical University; Tokyo Women's Medical University; Gunma
   University
RP Iida, T (通讯作者)，Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo 1628666, Japan.
EM iida@oph.twmu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022; Furuta, Minoru/L-4877-2019; Furuta,
   Minoru/L-5012-2019
OI Maruko, Ichiro/0000-0001-5647-6372; Sekiryu,
   Tetsuju/0000-0001-8042-2729; Furuta, Minoru/0000-0003-2193-8279
CR AGUILAR JP, 1984, RETINA-J RET VIT DIS, V4, P269, DOI 10.1097/00006982-198400440-00011
   Arias L, 2010, CLIN OPHTHALMOL, V4, P227
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Cohen SY, 1998, OPHTHALMOLOGY, V105, P1831, DOI 10.1016/S0161-6420(98)91024-7
   FRIED M, 1981, DOC OPHTHALMOL P SER, V28, P215
   FULLER B, 1973, ARCH OPHTHALMOL-CHIC, V89, P354, DOI 10.1001/archopht.1973.01000040356020
   GIUFFRE G, 1991, INT OPHTHALMOL, V15, P1, DOI 10.1007/BF00150971
   Iida T, 1998, AM J OPHTHALMOL, V126, P70, DOI 10.1016/S0002-9394(98)00167-6
   KLEIN RM, 1988, AM J OPHTHALMOL, V106, P282, DOI 10.1016/0002-9394(88)90362-5
   KLEIN RM, 1975, AM J OPHTHALMOL, V79, P386, DOI 10.1016/0002-9394(75)90611-X
   Kohno T, 2000, AM J OPHTHALMOL, V129, P38, DOI 10.1016/S0002-9394(99)00273-1
   Leys AM, 2002, RETINA-J RET VIT DIS, V22, P659, DOI 10.1097/00006982-200210000-00025
   Maruko I, 2011, INVEST OPHTH VIS SCI, V52, P8763, DOI 10.1167/iovs.11-8195
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Milani P, 2009, GRAEF ARCH CLIN EXP, V247, P1179, DOI 10.1007/s00417-009-1096-4
   Nakanishi H, 2008, RETINA-J RET VIT DIS, V28, P1493, DOI 10.1097/IAE.0b013e318183589c
   PROST M, 1988, INT OPHTHALMOL, V12, P131, DOI 10.1007/BF00137139
   Quaranta M, 1996, AM J OPHTHALMOL, V122, P663, DOI 10.1016/S0002-9394(14)70484-2
   SMITH RE, 1974, AM J OPHTHALMOL, V77, P650, DOI 10.1016/0002-9394(74)90526-1
   STUR M, 1988, AM J OPHTHALMOL, V105, P98, DOI 10.1016/0002-9394(88)90135-3
   Theodossiadis PG, 2006, GRAEF ARCH CLIN EXP, V244, P122, DOI 10.1007/s00417-005-0018-3
   Tosti G, 1999, OPHTHALMOLOGY, V106, P1453, DOI 10.1016/S0161-6420(99)90472-4
   TSUBOI S, 1984, BRIT J OPHTHALMOL, V68, P869, DOI 10.1136/bjo.68.12.869
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
   YOUNG SE, 1976, AM J OPHTHALMOL, V82, P16, DOI 10.1016/0002-9394(76)90658-9
NR 25
TC 9
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2013
VL 33
IS 1
BP 71
EP 76
DI 10.1097/IAE.0b013e318263ceb4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069GE
UT WOS:000313422500009
PM 23269406
DA 2022-11-30
ER

PT J
AU Shree, J
   Choudhary, R
   Bodakhe, SH
AF Shree, Jaya
   Choudhary, Rajesh
   Bodakhe, Surendra H.
TI Losartan delays the progression of streptozotocin-induced diabetic
   cataracts in albino rats
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE diabetic cataract; losartan; ocular renin-angiotensin system; oxidative
   stress
ID RENIN-ANGIOTENSIN SYSTEM; ALDOSE REDUCTASE; RECEPTOR BLOCKERS; CALCIUM;
   ASSAY; EYE; CATARACTOGENESIS; RETINOPATHY; INHIBITION; MODULATION
AB The ocular renin-angiotensin system has become an interesting target for ocular diseases because it has been implicated in various ocular diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration, uveitis, and hypertensive cataracts. In the present study, we explored the effect of topically and orally administered losartan (an angiotensin receptor blocker) on streptozotocin-induced diabetic cataract in albino rats. Topical treatment with losartan modulated neither the blood glucose level nor the polyol content but oral treatment with losartan decreased both. Topical and oral treatment with losartan significantly increased the antioxidants (glutathione, glutathione peroxidase, superoxide dismutase, and catalase), decreased the lipid peroxidant malondialdehyde, and restored soluble protein, and insoluble protein and various ions (Na+, K+, and Ca2+) in the lens; however, topical treatment had a better effect than oral treatment. These findings demonstrate that topical administration of losartan significantly reduces the risk of cataract formation without affecting either the blood glucose level or polyol contents.
C1 [Shree, Jaya; Choudhary, Rajesh; Bodakhe, Surendra H.] Guru Ghasidas Vishwavidyalaya, SLT Inst Pharmaceut Sci, Dept Pharmacol, Bilaspur 495009, Chhattisgarh, India.
C3 Guru Ghasidas Vishwavidyalaya
RP Bodakhe, SH (通讯作者)，Guru Ghasidas Vishwavidyalaya, SLT Inst Pharmaceut Sci, Dept Pharmacol, Bilaspur 495009, Chhattisgarh, India.
EM drbodakhe@gmail.com
OI Choudhary, Rajesh/0000-0001-8627-3613; bodakhe,
   surendra/0000-0002-9399-8337
CR Babizhayev MA, 2016, AM J THER, V23, pE98, DOI 10.1097/MJT.0b013e3181ea31ff
   Barreras Amy, 2003, Proc (Bayl Univ Med Cent), V16, P123
   Behl T, 2017, LIFE SCI, V176, P1, DOI 10.1016/j.lfs.2017.03.020
   BENEDETTI A, 1984, BIOCHIM BIOPHYS ACTA, V793, P489, DOI 10.1016/0005-2760(84)90268-6
   Bhadada SV, 2016, CURR EYE RES, V41, P222, DOI 10.3109/02713683.2015.1011281
   BHUYAN KC, 1992, FREE RADICAL BIO MED, V12, P251, DOI 10.1016/0891-5849(92)90112-T
   Choudhary R, 2017, J CURR OPHTHALMOL, V29, P7, DOI 10.1016/j.joco.2016.09.009
   Choudhary R, 2016, LIFE SCI, V167, P105, DOI 10.1016/j.lfs.2016.10.012
   DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160, DOI 10.1210/jcem-68-1-160
   Das Gupta P, 2004, ACTA PHARMACOL SIN, V25, P1250
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Fletcher EL, 2010, PROG RETIN EYE RES, V29, P284, DOI 10.1016/j.preteyeres.2010.03.003
   Harman-Boehm I, 2007, DIABETES RES CLIN PR, V78, pS51, DOI 10.1016/j.diabres.2007.09.023
   Jablecka A, 2009, MED SCI MONITOR, V15, pBR334
   Javadi Mohammad-Ali, 2008, J Ophthalmic Vis Res, V3, P52
   KAKKAR P, 1984, INDIAN J BIOCHEM BIO, V21, P130
   Kamper M, 2010, TRANSL RES, V156, P26, DOI 10.1016/j.trsl.2010.05.004
   Kato S, 2001, AM J OPHTHALMOL, V131, P301, DOI 10.1016/S0002-9394(00)00804-7
   Khan Sajida Begum, 2017, PharmaNutrition, V5, P127, DOI 10.1016/j.phanu.2017.10.001
   Khan SA, 2016, J CURR OPHTHALMOL, V28, P123, DOI 10.1016/j.joco.2016.05.001
   Kilari EK, 2017, CUTAN OCUL TOXICOL, V36, P52, DOI 10.3109/15569527.2016.1144610
   KLEIN BEK, 1995, AM J OPHTHALMOL, V119, P295, DOI 10.1016/S0002-9394(14)71170-5
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Kurihara T, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/581695
   LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Manikandan R, 2010, FREE RADICAL BIO MED, V48, P483, DOI 10.1016/j.freeradbiomed.2009.11.011
   Mathebula SD, 2015, AFR VIS EYE HEALTH J, V74, DOI 10.4102/aveh.v74i1.13
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476
   Obrosova IG, 2010, DIABETES-METAB RES, V26, P172, DOI 10.1002/dmrr.1075
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   OLD SE, 1995, INVEST OPHTH VIS SCI, V36, P88
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pescosolido N, 2016, INT J OPHTHALMOL-CHI, V9, P1506, DOI 10.18240/ijo.2016.10.23
   Petrovic D, 2014, J DIABETES COMPLICAT, V28, P120, DOI 10.1016/j.jdiacomp.2013.11.002
   Pollreisz A, 2010, J OPHTHALMOL, V2010, P8
   Qian W, 2000, EXP EYE RES, V71, P567, DOI 10.1006/exer.2000.0914
   Reddy VS, 2016, BBA-GEN SUBJECTS, V1860, P269, DOI 10.1016/j.bbagen.2015.05.009
   Sabanayagam C, 2011, INVEST OPHTH VIS SCI, V52, P2397, DOI 10.1167/iovs.10-6373
   Sayin N, 2015, WORLD J DIABETES, V6, P92, DOI 10.4239/wjd.v6.i1.92
   SINHA AK, 1972, ANAL BIOCHEM, V47, P389, DOI 10.1016/0003-2697(72)90132-7
   Sjolie AK, 2007, DIABETES RES CLIN PR, V76, pS31, DOI 10.1016/j.diabres.2007.01.015
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Strain WD, 2002, J RENIN-ANGIO-ALDO S, V3, P243, DOI 10.3317/jraas.2002.045
   Tappel A L, 1978, Methods Enzymol, V52, P506
   Thiraphatthanavong P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/507435
   Vaajanen A, 2011, BASIC CLIN PHARMACOL, V109, P217, DOI 10.1111/j.1742-7843.2011.00729.x
   VanHaeringen NJ, 1996, BRIT J OPHTHALMOL, V80, P99, DOI 10.1136/bjo.80.2.99
   Varsha MKNS, 2014, EXP EYE RES, V128, P73, DOI 10.1016/j.exer.2014.09.007
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P59, DOI 10.1177/1470320314549791
   Wright AD, 2010, EYE, V24, P1, DOI 10.1038/eye.2009.189
   Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21
   Yadav A, 2018, CURR EYE RES, V43, P1454, DOI 10.1080/02713683.2018.1501490
NR 55
TC 4
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD AUG
PY 2019
VL 33
IS 8
AR e22342
DI 10.1002/jbt.22342
PG 9
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA IQ3BK
UT WOS:000480625200012
PM 30958922
DA 2022-11-30
ER

PT J
AU Chatziralli, I
   Theodossiadis, G
   Panagiotidis, D
   Pousoulidi, P
   Theodossiadis, P
AF Chatziralli, Irini
   Theodossiadis, George
   Panagiotidis, Dimitrios
   Pousoulidi, Paraskevi
   Theodossiadis, Panagiotis
TI Choriocapillaris Vascular Density Changes in Patients with Drusen:
   Cross-Sectional Study Based on Optical Coherence Tomography Angiography
   Findings
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Choriocapillaris; Drusen; Ellipsoid zone; OCTA
ID MACULAR DEGENERATION; PREVALENCE; RESTORATION; DISEASE; EYES
AB Introduction: The purpose of this study was to investigate the extent and morphology of the choriocapillaris' density defect in patients with drusen in non-neovascular age-related macular degeneration (AMD).
   Methods: Participants in this study were 36 patients with non-neovascular AMD and drusen. All patients underwent best-corrected visual acuity, slit-lamp examination, spectral domain-optical coherence tomography (SD-OCT), and optical coherence tomography angiography (OCTA).
   Results: In all studied cases, the presence of drusen was associated with choriocapillaris' reduced blood flow signal of different extent and severity. Three types of choriocapillaris' non-perfusion were observed, along with an association between the size of drusen and the morphology of choriocapillaris' density defect. Moreover, the extent of choriocapillaris' density change has been related to ellipsoid zone disruption and therefore to visual impairment.
   Conclusions: Our study showed that in patients with drusen due to non-neovascular AMD, there is choriocapillaris' impairment of different morphology in OCTA, which is mainly related to the size and location of the drusen.
C1 [Chatziralli, Irini; Theodossiadis, George; Theodossiadis, Panagiotis] Univ Athens, Dept Ophthalmol 2, Athens, Greece.
   [Panagiotidis, Dimitrios; Pousoulidi, Paraskevi] Macula Ctr, Athens, Greece.
C3 National & Kapodistrian University of Athens
RP Chatziralli, I (通讯作者)，Univ Athens, Dept Ophthalmol 2, Athens, Greece.
EM eirchat@yahoo.gr
RI Chatziralli, Irini/AAG-4779-2020
OI Chatziralli, Irini/0000-0001-8523-1024
CR Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Louzada RN, 2017, CAN J OPHTHALMOL, V52, P419, DOI 10.1016/j.jcjo.2016.12.012
   Lutty G, 1999, MOL VIS, V5
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Theodossiadis GP, 2012, GRAEF ARCH CLIN EXP, V250, P971, DOI 10.1007/s00417-011-1918-z
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 20
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD JUN
PY 2018
VL 7
IS 1
BP 101
EP 107
DI 10.1007/s40123-018-0119-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GJ2VS
UT WOS:000435132600008
PM 29383674
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Umfress, AC
   Brantley, MA
AF Umfress, Allison C.
   Brantley, Milam A., Jr.
TI Eye Care Disparities and Health-Related Consequences in Elderly Patients
   with Age-Related Eye Disease
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; cataracts; elderly; eye disease;
   glaucoma; health-care disparities
ID QUALITY-OF-LIFE; NURSING-HOME RESIDENTS; FIELD LOSS INCREASES; VISUAL
   IMPAIRMENT; OLDER-ADULTS; MACULAR DEGENERATION; DEPRESSIVE SYMPTOMS;
   VISION LOSS; PHYSICAL-DISABILITY; RISK-FACTOR
AB The elderly population in the United States (age 65 and older) is growing rapidly, estimated by the U.S. Census Department to reach 83.7 million by 2050.(1) Visual impairment increases with age among all racial and ethnic groups.(2) In the elderly, the most common culprits for vision loss are cataract, glaucoma, and age-related macular degeneration (AMD).(2) In the developed world, vision loss from cataract has been dramatically reduced by increased access to cataract surgery. However, AMD and glaucoma lead to irreversible vision loss without early diagnosis and intervention. In the U.S., cases of AMD are expected to double by 2050, reaching 17.8 million among patients age 50 or older.(3) Similarly, cases of glaucoma are expected to reach 5.5 million by 2050, an increase of over 90% from 2014.(3) The visually impaired elderly face disparities in access to eye care, and subsequent general medical and psychosocial complications.
C1 [Umfress, Allison C.; Brantley, Milam A., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN USA.
C3 Vanderbilt University
RP Umfress, AC (通讯作者)，Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM milam.brantley@vanderbilt.edu
FU NEI [EY22618]; BrightFocus Foundation; Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [R01EY022618] Funding Source: NIH RePORTER
FX The authors acknowledge funding from NEI grant EY22618 (MAB), the
   BrightFocus Foundation (MAB) and an unrestricted departmental award from
   Research to Prevent Blindness.
CR Administration on Aging Administration for Community Living US Department of Health and Human Services, 2012, PROF OLD AM 2012
   American Foundation for the Blind, ACC DRUG LAB SURV RE
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bevil C W, 1981, J N Y State Nurses Assoc, V12, P19
   Black AA, 2011, OPTOMETRY VISION SCI, V88, P1275, DOI 10.1097/OPX.0b013e31822f4d6a
   BRANCH LG, 1989, GERONTOLOGIST, V29, P359, DOI 10.1093/geront/29.3.359
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796
   Centers for Disease Control and Prevention, 2011, STAT VIS AG PUBL HLT
   Centers for Disease Control and Prevention, 2014, NAT VIT STAT REP
   Centers for Disease Control and Prevention (CDC), 2014, NAT CTR HLTH STAT NC, V2015
   Chou CF, 2012, AM J OPHTHALMOL, V154, pS45, DOI 10.1016/j.ajo.2011.09.025
   Connors E., 2014, THESIS
   Covinsky KE, 1999, ANN INTERN MED, V130, P563, DOI 10.7326/0003-4819-130-7-199904060-00004
   Crews J, 2009, J VISUAL IMPAIRMENT, V100, P824
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Elliott DB, 1997, BRIT J OPHTHALMOL, V81, P889, DOI 10.1136/bjo.81.10.889
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   FAGERSTROM R, 1994, PSYCHOL REP, V75, P115, DOI 10.2466/pr0.1994.75.1.115
   Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326
   Freeman EE, 2009, CAN J OPHTHALMOL, V44, P171, DOI 10.3129/i09-001
   Friedman DS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1581, DOI 10.1001/archopht.123.11.1581
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   HOROWITZ A, 1994, GERONTOLOGIST, V34, P316, DOI 10.1093/geront/34.3.316
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Jones GC, 2009, REHABIL PSYCHOL, V54, P164, DOI 10.1037/a0015910
   Keller B K, 2001, J Am Med Dir Assoc, V2, P15, DOI 10.1097/00130535-200101000-00004
   Kelly M, 1996, GERIATR NURS, V17, P60, DOI 10.1016/S0197-4572(96)80169-8
   Kilmer G, 2010, J RURAL HEALTH, V26, P30, DOI 10.1111/j.1748-0361.2009.00262.x
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Laforge R.G., 1992, J AGING HEALTH, V4, P126, DOI [10.1177/089826439200400108, DOI 10.1177/089826439200400108]
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   Marek K. D, 2008, PATIENT SAFETY QUALI, P499
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   MCDANIEL JS, 1995, ARCH GEN PSYCHIAT, V52, P89
   MURRAY MD, 1993, ANN PHARMACOTHER, V27, P616
   NEWELL SW, 1985, ANN OPHTHALMOL, V17, P186
   Ortman JM, 2014, CURRENT POPULATION R
   Penninx BWJH, 1999, AM J PUBLIC HEALTH, V89, P1346, DOI 10.2105/AJPH.89.9.1346
   Prevent Blindness, 2014, FUT VIS FOR PREV COS
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Resnick HE, 1997, J GERONTOL B-PSYCHOL, V52, pS135, DOI 10.1093/geronb/52B.3.S135
   Steffens DC, 1999, STROKE, V30, P2159, DOI 10.1161/01.STR.30.10.2159
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   WANG F, 1994, ARCH INTERN MED, V154, P1821, DOI 10.1001/archinte.154.16.1821
   WARE GJ, 1991, NEW ZEAL MED J, V104, P495
   Watanabe R K, 1994, J Am Optom Assoc, V65, P32
   West CG, 2002, J AM GERIATR SOC, V50, P136, DOI 10.1046/j.1532-5415.2002.50019.x
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   WONG BSM, 1987, J AM GERIATR SOC, V35, P21, DOI 10.1111/j.1532-5415.1987.tb01314.x
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   World Health Organisation, 2010, GLOB BURD DIS STUD
   Yagoda L, 2005, NASW SPECIALTY PRACT, V4
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zheng DD, 2014, INVEST OPHTH VIS SCI, V55, P5144, DOI 10.1167/iovs.14-14202
NR 59
TC 16
Z9 17
U1 4
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2016
VL 31
IS 4
SI SI
BP 432
EP 438
DI 10.3109/08820538.2016.1154171
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA DT3SR
UT WOS:000381401700020
PM 27116323
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wiley, LA
   Burnight, ER
   Mullins, RF
   Stone, EM
   Tucker, BA
AF Wiley, Luke A.
   Burnight, Erin R.
   Mullins, Robert F.
   Stone, Edwin M.
   Tucker, Budd A.
TI Stem Cells as Tools for Studying the Genetics of Inherited Retinal
   Degenerations
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; MEMBRANE ATTACK COMPLEX;
   MACULAR DEGENERATION; RISK; SUSCEPTIBILITY; DRUSEN; INSIGHTS; THERAPY;
   VARIANT
AB The ability to provide early clinical intervention for inherited disorders is heavily dependent on knowledge of a patient's disease-causing mutations and the resultant pathophysiologic mechanism(s). Without knowing a patient's disease-causing gene, and how gene mutations alter the health and functionality of affected cells, itwould be difficult to develop and deliver patient-specific molecular or small molecule therapies. Many believe that the field of stem cell biology holds the keys to the future development of disease-, patient-, and cell-specific therapies. In the case of the eye, which is susceptible to an extremely common late-onset degenerative disease known as age-related macular degeneration, stem cell-based therapies could increase the quality of life for millions of patientsworldwide. Furthermore, autologous, patient-specific induced pluripotent stem cells could be a viable source to treat rare Mendelian retinal degenerative diseases such as retinitis pigmentosa, Stargardt disease, and Best disease, to name a few.
C1 [Wiley, Luke A.; Burnight, Erin R.; Mullins, Robert F.; Stone, Edwin M.; Tucker, Budd A.] Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa
RP Tucker, BA (通讯作者)，Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
EM budd-tucker@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Stone, Edwin M./0000-0003-3343-4414; Wiley, Luke/0000-0003-0136-2364;
   Tucker, Budd/0000-0003-2178-1742; Mullins, Robert/0000-0002-5006-0891
FU National Institutes of Health (NIH) Directors New Innovator Award
   [1-DP2-OD007483-01]; NEI [EY017451, F32 EY022834]; Howard Hughes Medical
   Institute; Foundation Fighting Blindness; Stephen A. Wynn Foundation;
   Grousbeck Family Foundation; Leo, Jacques & Marion Hauser Family Vision
   Restoration Fund; NATIONAL EYE INSTITUTE [F32EY022834, R01EY017451]
   Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL
   INSTITUTES OF HEALTH [DP2OD007483] Funding Source: NIH RePORTER
FX The authors acknowledge grant support from National Institutes of Health
   (NIH) Directors New Innovator Award 1-DP2-OD007483-01, NEI EY017451, F32
   EY022834, Howard Hughes Medical Institute, Foundation Fighting
   Blindness, Stephen A. Wynn Foundation, Grousbeck Family Foundation, Leo,
   Jacques & Marion Hauser Family Vision Restoration Fund.
CR Abramoff MD, 2013, INVEST OPHTH VIS SCI, V54, P3721, DOI 10.1167/iovs.13-11812
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Al-Saikhan FI, 2013, SAUDI J OPHTHALMOL, V27, P107, DOI 10.1016/j.sjopt.2013.02.001
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Braun TA, 2013, HUM MOL GENET, V22, P5136, DOI 10.1093/hmg/ddt367
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   DAVANGER M, 1971, NATURE, V229, P560, DOI 10.1038/229560a0
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garg SJ, 2013, CURR OPIN OPHTHALMOL, V24, P407, DOI 10.1097/ICU.0b013e328363829b
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joung JK, 2013, NAT REV MOL CELL BIO, V14, P49, DOI 10.1038/nrm3486
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Loudin JD, 2007, J NEURAL ENG, V4, pS72, DOI 10.1088/1741-2560/4/1/S09
   McClements ME, 2013, TRANSL RES, V161, P241, DOI 10.1016/j.trsl.2012.12.007
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Packer AM, 2013, NAT NEUROSCI, V16, P805, DOI 10.1038/nn.3427
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   Schindler EI, 2010, HUM MOL GENET, V19, P3693, DOI 10.1093/hmg/ddq284
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Sheffield VC, 2011, NEW ENGL J MED, V364, P1932, DOI 10.1056/NEJMra1012354
   Shepherd RK, 2013, TRENDS BIOTECHNOL, V31, P562, DOI 10.1016/j.tibtech.2013.07.001
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tang PH, 2013, PROG RETIN EYE RES, V32, P48, DOI 10.1016/j.preteyeres.2012.09.002
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Yamanaka Shinya, 2006, Tanpakushitsu Kakusan Koso, V51, P2346
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yao J, 2011, BIOMATERIALS, V32, P1041, DOI 10.1016/j.biomaterials.2010.09.063
   Yonehara K, 2013, NEURON, V79, P1078, DOI 10.1016/j.neuron.2013.08.005
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 60
TC 7
Z9 7
U1 0
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD MAY
PY 2015
VL 5
IS 5
AR a017160
DI 10.1101/cshperspect.a017160
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CJ0WB
UT WOS:000355198800001
PM 25502747
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Blatter, C
   Klein, T
   Grajciar, B
   Schmoll, T
   Wieser, W
   Andre, R
   Huber, R
   Leitgeb, RA
AF Blatter, Cedric
   Klein, Thomas
   Grajciar, Branislav
   Schmoll, Tilman
   Wieser, Wolfgang
   Andre, Raphael
   Huber, Robert
   Leitgeb, Rainer A.
TI Ultrahigh-speed non-invasive widefield angiography
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE biomedical optics; biophotonics coherent; optical systems; imaging;
   coherence ophthalmology
ID OPTICAL COHERENCE TOMOGRAPHY; RETINA
AB Retinal and choroidal vascular imaging is an important diagnostic benefit for ocular diseases such as age-related macular degeneration. The current gold standard for vessel visualization is fluorescence angiography. We present a potential non-invasive alternative to image blood vessels based on functional Fourier domain optical coherence tomography (OCT). For OCT to compete with the field of view and resolution of angiography while maintaining motion artifacts to a minimum, ultrahigh-speed imaging has to be introduced. We employ Fourier domain mode locking swept source technology that offers high quality imaging at an A-scan rate of up to 1.68 MHz. We present retinal angiogram over similar to 48 deg acquired in a few seconds in a single recording without the need of image stitching. OCT at 1060 nm allows for high penetration in the choroid and efficient separate characterization of the retinal and choroidal vascularization. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.7.070505]
C1 [Leitgeb, Rainer A.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Grp Biomed Opt, A-1090 Vienna, Austria.
   [Klein, Thomas; Wieser, Wolfgang; Andre, Raphael; Huber, Robert] Univ Munich, Lehrstuhl BioMol Opt, D-80538 Munich, Germany.
C3 Medical University of Vienna; University of Munich
RP Leitgeb, RA (通讯作者)，Med Univ Vienna, Ctr Med Phys & Biomed Engn, Grp Biomed Opt, Waehringerguertel 18-20, A-1090 Vienna, Austria.
EM rainer.leitgeb@meduniwien.ac.at
RI Huber, Robert A/B-9419-2008
OI Huber, Robert A/0000-0001-9785-6574; Leitgeb, Rainer/0000-0002-0131-4111
FU EU FP7 program (FUN OCT) [201880]; Austrian Christian Doppler
   Association
FX Funding from the EU FP7 program is acknowledged (FUN OCT, Grant No.
   201880). BG is funded by the Austrian Christian Doppler Association.
CR Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Jaillon F, 2012, OPT EXPRESS, V20, P385, DOI 10.1364/OE.20.000385
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Klein T, 2011, OPT EXPRESS, V19, P3044, DOI 10.1364/OE.19.003044
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Schmoll T, 2011, BIOMED OPT EXPRESS, V2, P1159, DOI 10.1364/BOE2.001159
   Schmoll T, 2009, OPT EXPRESS, V17, P4166, DOI 10.1364/OE.17.004166
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
NR 9
TC 94
Z9 98
U1 1
U2 22
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JUL
PY 2012
VL 17
IS 7
AR 070505
DI 10.1117/1.JBO.17.7.070505
PG 3
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 995EA
UT WOS:000307989500005
PM 22894461
OA Bronze
DA 2022-11-30
ER

PT J
AU Siqueira, RC
   Voltarelli, JC
   Messias, AMV
   Jorge, R
AF Siqueira, Rubens Camargo
   Voltarelli, Julio Cesar
   Vieira Messias, Andre Marcio
   Jorge, Rodrigo
TI Possible mechanisms of retinal function recovery with the use of cell
   therapy with bone marrow-derived stem cells
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Retinitis pigmentosa; Retinal degeneration; Stem cell; Bone marrow
ID PIGMENT EPITHELIUM; PROGENITOR CELLS; GROWTH-FACTOR; TRANSPLANTATION;
   ACTIVATION; SURVIVAL; REPAIR; DIFFERENTIATION; DEGENERATION
AB Bone marrow has been proposed as a potential source of stem cells for regenerative medicine. In the eye, degeneration of neural cells in the retina is a hallmark of such widespread ocular diseases as age-related macular degeneration (AMD) and retinitis pigmentosa. Bone marrow is an ideal tissue for studying stem cells mainly because of its accessibility. Furthermore, there are a number of well-defined mouse models and cell surface markers that allow effective study of hematopoiesis in healthy and injured mice. Because of these characteristics and the experience of bone marrow transplantation in the treatment of hematological disease such as leukemia, bone marrow-derived stem cells have also become a major tool in regenerative medicine. Those cells may be able to restore the retina function through different mechanisms: A) cellular differentiation, B) paracrine effect, and C) retinal pigment epithelium repair. In this review, we described these possible mechanisms of recovery of retinal function with the use of cell therapy with bone marrow-derived stem cells.
C1 [Siqueira, Rubens Camargo; Voltarelli, Julio Cesar; Vieira Messias, Andre Marcio; Jorge, Rodrigo] Ctr Pesquisa Rubens Siqueira, Sao Jose Do Rio Preto, SP, Brazil.
RP Siqueira, RC (通讯作者)，Rua Saldanha Marinho 2-815,Sala 42, BR-15010100 Sao Jose Do Rio Preto, SP, Brazil.
EM rubenssiqueira@terra.com.br
RI Messias, Andre MV/C-1560-2012; Jorge, Rodrigo/AAK-7615-2021; Messias,
   Andre/H-5801-2012; Jorge, Rodrigo/H-3930-2012
OI Messias, Andre MV/0000-0002-5328-9608; Jorge,
   Rodrigo/0000-0002-2652-0720; Messias, Andre/0000-0002-5328-9608; Jorge,
   Rodrigo/0000-0002-2652-0720; Siqueira, Rubens/0000-0003-4563-1570
CR Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Castanheira P, 2008, ARQ BRAS OFTALMOL, V71, P644, DOI 10.1590/S0004-27492008000500007
   Challen GA, 2009, CYTOM PART A, V75A, P14, DOI 10.1002/cyto.a.20674
   Cheng AS, 2008, SEMIN THORAC CARDIOV, V20, P94, DOI 10.1053/j.semtcvs.2008.04.003
   ClinicalTrials.gov, 2010, NCT01068561 CLINICAL
   Crisostomo PR, 2008, SURGERY, V143, P577, DOI 10.1016/j.surg.2007.10.015
   Enzmann V, 2009, ARCH OPHTHALMOL-CHIC, V127, P563, DOI 10.1001/archophthalmol.2009.65
   Gomei Y, 2010, EXP HEMATOL, V38, P82, DOI 10.1016/j.exphem.2009.11.007
   Harris JR, 2009, STEM CELLS, V27, P457, DOI 10.1634/stemcells.2008-0836
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P225, DOI 10.1111/j.1600-0420.2007.00987.x
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe22, DOI 10.1111/j.1755-3768.2008.01453.x
   Koontongkaew S, 2009, CELL BIOL INT, V33, P165, DOI 10.1016/j.cellbi.2008.10.009
   Kuci S, 2009, CURR STEM CELL RES T, V4, P107, DOI 10.2174/157488809788167427
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lanza R, 2004, SCI AM, V290, P92, DOI 10.1038/scientificamerican0604-92
   Li N, 2009, GRAEF ARCH CLIN EXP, V247, P503, DOI 10.1007/s00417-008-1009-y
   LORENZ E, 1952, RADIOLOGY, V58, P863, DOI 10.1148/58.6.863
   Machalinska A, 2009, CURR EYE RES, V34, P748, DOI 10.1080/02713680903050592
   Markel TA, 2008, AM J PHYSIOL-REG I, V295, pR1124, DOI 10.1152/ajpregu.90508.2008
   Markel TA, 2007, AM J PHYSIOL-GASTR L, V293, pG657, DOI 10.1152/ajpgi.00230.2007
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Mimeault M, 2006, STEM CELLS, V24, P2319, DOI 10.1634/stemcells.2006-0066
   Muller-Sieburg CE, 2002, BLOOD, V100, P1302, DOI 10.1182/blood.V100.4.1302.h81602001302_1302_1309
   Nielsen JS, 2009, MICROCIRCULATION, V16, P487, DOI 10.1080/10739680902941737
   Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737
   Ortiz-Gonzalez XR, 2004, CURR NEUROVASC RES, V1, P207, DOI 10.2174/1567202043362342
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637
   Ratajczak MZ, 2004, LEUKEMIA, V18, P29, DOI 10.1038/sj.leu.2403184
   Saini V, 2010, CANCER SCI, V101, P16, DOI 10.1111/j.1349-7006.2009.01371.x
   Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024
   Schuetz E, 2004, CURR DRUG TARGETS, V5, P619, DOI 10.2174/1389450043345164
   Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307
   Siqueira RC, 2010, CYTOTHERAPY S1, V12, P58
   Siqueira RC, 2008, INVEST OPHTH VIS SCI, V49, P536
   Siqueira Rubens C., 2009, Rev. Bras. Hematol. Hemoter., V31, P120
   Siqueira RC, 2009, ARQ BRAS OFTALMOL, V72, P123, DOI 10.1590/S0004-27492009000100027
   SPANGRUDE GJ, 1989, SCIENCE, V244, P1030
   SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810
   TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Trounson A, 2006, ENDOCR REV, V27, P208, DOI 10.1210/er.2005-0016
   Uteza Y, 1999, P NATL ACAD SCI USA, V96, P3126, DOI 10.1073/pnas.96.6.3126
   Vandervelde S, 2005, J MOL CELL CARDIOL, V39, P363, DOI 10.1016/j.yjmcc.2005.05.012
   Voltarelli JC, 2003, BONE MARROW TRANSPL, V32, pS69, DOI 10.1038/sj.bmt.1703947
   Voltarelli JC, 2000, MEM I OSWALDO CRUZ, V95, P403, DOI 10.1590/S0074-02762000000300018
   Wang HC, 2010, VISION RES, V50, P665, DOI 10.1016/j.visres.2009.09.003
   Wang MJ, 2006, SHOCK, V25, P454, DOI 10.1097/01.shk.0000209536.68682.90
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Wu Y, 2008, WOUND REPAIR REGEN, V16, P582
   Wu YJ, 2007, WOUND REPAIR REGEN, V15, pS18, DOI 10.1111/j.1524-475X.2007.00221.x
   Zhang P, 2009, ACTA ANAESTH SCAND, V53, P1184, DOI 10.1111/j.1399-6576.2009.02024.x
   Zhang Y, 2010, INVEST OPHTH VIS SCI, V51, P3742, DOI 10.1167/iovs.08-3314
NR 57
TC 29
Z9 33
U1 1
U2 16
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD SEP-OCT
PY 2010
VL 73
IS 5
BP 474
EP 479
DI 10.1590/S0004-27492010000500019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 705DH
UT WOS:000286108600019
PM 21225138
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Meng, WH
   Hughes, A
   Patterson, CC
   Belton, C
   Kamaruddin, MS
   Horan, PG
   Kee, F
   McKeown, PP
AF Meng, Weihua
   Hughes, Anne
   Patterson, Chris C.
   Belton, Christine
   Kamaruddin, Muhammad S.
   Horan, Paul G.
   Kee, Frank
   McKeown, Pascal P.
TI Genetic variants of complement factor H gene are not associated with
   premature coronary heart disease: a family-based study in the Irish
   population
SO BMC MEDICAL GENETICS
LA English
DT Article
ID C-REACTIVE PROTEIN; MACULAR DEGENERATION; MYOCARDIAL-INFARCTION;
   ARTERY-DISEASE; POLYMORPHISM; RISK; ATHEROSCLEROSIS; ACTIVATION;
   HAPLOTYPE
AB Background: The complement factor H (CFH) gene has been recently confirmed to play an essential role in the development of age-related macular degeneration (AMD). There are conflicting reports of its role in coronary heart disease. This study was designed to investigate if, using a family-based approach, there was an association between genetic variants of the CFH gene and risk of early-onset coronary heart disease.
   Methods: We evaluated 6 SNPs and 5 common haplotypes in the CFH gene amongst 1494 individuals in 580 Irish families with at least one member prematurely affected with coronary heart disease. Genotypes were determined by multiplex SNaPshot technology.
   Results: Using the TDT/S-TDT test, we did not find an association between any of the individual SNPs or any of the 5 haplotypes and early-onset coronary heart disease.
   Conclusion: In this family-based study, we found no association between the CFH gene and early-onset coronary heart disease.
C1 Queens Univ Belfast, Inst Clin Sci, Ctr Clin & Populat Sci, Belfast BT12 6BJ, Antrim, North Ireland.
   Royal Victoria Hosp, Reg Med Cardiol Ctr, Belfast BT12 6BA, Antrim, North Ireland.
   Queens Univ Belfast, Inst Clin Sci, Dept Med, Belfast BT12 6BJ, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP McKeown, PP (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Ctr Clin & Populat Sci, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.
EM wmeng01@qub.ac.uk; a.hughes@qub.ac.uk; c.patterson@qub.ac.uk;
   c.belton@qub.ac.uk; mshafie_kamaruddin@yahoo.co.uk;
   paul_horan@lineone.net; f.kee@qub.ac.uk; p.p.mckeown@qub.ac.uk
RI Kamaruddin, Shafie/AAS-6434-2021
CR BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Goverdhan SV, 2006, ATHEROSCLEROSIS, V188, P213, DOI 10.1016/j.atherosclerosis.2006.04.013
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Morgan TM, 2007, JAMA-J AM MED ASSOC, V297, P1551, DOI 10.1001/jama.297.14.1551
   Moukarbel GV, 2001, CLIN CARDIOL, V24, P506, DOI 10.1002/clc.4960240718
   Napoli C, 1999, CIRCULATION, V99, P2003, DOI 10.1161/01.CIR.99.15.2003
   Nicaud V, 2007, J MOL MED-JMM, V85, P771, DOI 10.1007/s00109-007-0185-2
   Oksjoki R, 2003, CURR OPIN LIPIDOL, V14, P477, DOI 10.1097/00041433-200310000-00008
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   ROSE GA, 1982, WHO CARDIOVASCULAR S
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Spence MS, 2002, ATHEROSCLEROSIS, V165, P293, DOI 10.1016/S0021-9150(02)00239-3
   Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714
   Topol EJ, 2006, HUM MOL GENET, V15, pR117, DOI 10.1093/hmg/ddl183
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   SPIELMAN LAB TDT STD
NR 24
TC 11
Z9 13
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD SEP 18
PY 2007
VL 8
AR 62
DI 10.1186/1471-2350-8-62
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 228ID
UT WOS:000250722700001
PM 17877809
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sweitzer, R
   Scholz, C
   Montezuma, S
   Rizzo, JF
AF Sweitzer, R
   Scholz, C
   Montezuma, S
   Rizzo, JF
TI Evaluation of subretinal implants coated with amorphous aluminum oxide
   and diamond-like carbon
SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
LA English
DT Article
DE rentinal prosthesis; biomaterials; diamond-like carbon; amorphous
   aluminium oxide
ID CENTRIFUGAL BLOOD PUMP; IN-VITRO; COATINGS; BIOCOMPATIBILITY;
   ACTIVATION; FILMS; COMPATIBILITY; MACROPHAGES; THRESHOLDS; DEPOSITION
AB Retinal prostheses may be used to support patients suffering from age-related macular degeneration (AMD) or retinitis pigmentosa (RP). A hermetic encapsulation of the poly(imide) (PI)-based prosthesis is important in order to prevent the leakage of water and ions into the electric circuitry embedded in the poly(imide) matrix. The deposition of amorphous aluminum oxide (by sputtering) and diamond like carbon (by pulsed laser ablation) were made for applications in retinal prostheses. The thin films obtained were characterized for composition, thickness, adhesion and smoothness by scanning electron microscopy-energy dispersive spectroscopy, atomic force microscopy, profilometry and light microscopy. Biocompatibility was tested in vivo by implanting coated specimen subretinally in the eye of Yucatan pigs. While amorphous aluminum oxide is more readily deposited with sufficient adhesion quality, superior biocompatibility behavior was shown by diamond-like carbon. Amorphous aluminum oxide had more adverse effects and caused more severe damage to the retinal tissue.
C1 Univ Alabama, Dept Chem, Huntsville, AL 35899 USA.
   Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   VA Ctr Innovat Visual Rehabil, Boston, MA USA.
C3 University of Alabama System; University of Alabama Huntsville; Harvard
   University; Massachusetts Eye & Ear Infirmary
RP Scholz, C (通讯作者)，Univ Alabama, Dept Chem, Huntsville, AL 35899 USA.
EM cscholz@chemistry.uah.edu
CR Alanazi A, 2000, ASAIO J, V46, P440, DOI 10.1097/00002480-200007000-00014
   Alanazi A, 2000, ARTIF ORGANS, V24, P624, DOI 10.1046/j.1525-1594.2000.06576.x
   Allen M, 2001, J BIOMED MATER RES, V58, P319, DOI 10.1002/1097-4636(2001)58:3<319::AID-JBM1024>3.0.CO;2-F
   Allen Matthew, 1994, Clinical Materials, V17, P1, DOI 10.1016/0267-6605(94)90041-8
   ANGUS JC, 1988, SCIENCE, V241, P913, DOI 10.1126/science.241.4868.913
   CAMATA RP, 1998, ADV LASER ABLATION, P526
   Cui FZ, 2000, SURF COAT TECH, V131, P481, DOI 10.1016/S0257-8972(00)00809-4
   De Scheerder I, 2000, J INVASIVE CARDIOL, V12, P389
   DEBROY T, 1994, DIAM RELAT MATER, V4, P69, DOI 10.1016/0925-9635(94)90071-X
   Dion I., 1993, Bio-Medical Materials and Engineering, V3, P51
   Dumkum C, 1997, DIAM RELAT MATER, V6, P802, DOI 10.1016/S0925-9635(96)00762-5
   Elinson VM, 1999, DIAM RELAT MATER, V8, P2103, DOI 10.1016/S0925-9635(99)00177-6
   Gentle C R, 1984, Eng Med, V13, P79
   GENTLE CR, 1995, BIOMATERIALS, V16, P245, DOI 10.1016/0142-9612(95)92124-O
   GENTLE CR, 1987, USE CERAMICS PROSTHE, V16, P115
   Gutensohn K, 2000, THROMB RES, V99, P577, DOI 10.1016/S0049-3848(00)00295-4
   Hamadouche M, 2002, J BONE JOINT SURG AM, V84A, P69, DOI 10.2106/00004623-200201000-00011
   Henry BM, 1999, THIN SOLID FILMS, V355, P500, DOI 10.1016/S0040-6090(99)00461-7
   Jensen RJ, 2003, INVEST OPHTH VIS SCI, V44, P3533, DOI 10.1167/iovs.02-1041
   JONES JI, 2000, J BIOMED MATER RES, P413
   Kumar S, 1999, J APPL PHYS, V85, P3866, DOI 10.1063/1.369758
   Lee C, 2002, J POLYM SCI POL PHYS, V40, P2190, DOI 10.1002/polb.10277
   LIFSHITZ Y, 1998, AMORPHOUS CARBON STA, P32
   Linder S, 2002, BIOMATERIALS, V23, P767, DOI 10.1016/S0142-9612(01)00182-X
   Lu Luo, 1993, Bio-Medical Materials and Engineering, V3, P223
   MCLAUGHLINE JA, P 20 ANN INT C IEEE, V20, P2879
   MONAGHAN DP, 1993, SURF COAT TECH, V60, P525, DOI 10.1016/0257-8972(93)90146-F
   Montezuma SR, 2004, INVEST OPHTH VIS SCI, V45, pU379
   Monties JR, 1997, ARTIF ORGANS, V21, P730, DOI 10.1111/j.1525-1594.1997.tb03731.x
   Moore AC, 2001, CIVIL ENG, V71, P6
   MOSS J, 1999, THESIS MIT
   Qualtrough Alison J E, 2002, Dent Update, V29, P25
   Sun JK, 2004, INVEST OPHTH VIS SCI, V45, pU382
   THOMSON LA, 1991, BIOMATERIALS, V12, P37
   Tran HS, 1999, J INVEST SURG, V12, P133
   Wei Q, 2001, SURF COAT TECH, V146, P250, DOI 10.1016/S0257-8972(01)01394-9
   Wyatt J, 1996, IEEE SPECTRUM, V33, P47, DOI 10.1109/6.490056
   Yamada-Takamura Y, 2002, SURF COAT TECH, V153, P114, DOI 10.1016/S0257-8972(01)01697-8
   Yamauchi Y, 2005, J NEURAL ENG, V2, pS48, DOI 10.1088/1741-2560/2/1/007
   Yamazaki K, 1998, ARTIF ORGANS, V22, P466, DOI 10.1046/j.1525-1594.1998.06156.x
   Yamazaki K, 1997, ASAIO J, V43, pM686, DOI 10.1097/00002480-199709000-00072
   YUHTA T, 1994, J BIOMED MATER RES, V28, P217, DOI 10.1002/jbm.820280212
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
NR 44
TC 12
Z9 13
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0883-9115
EI 1530-8030
J9 J BIOACT COMPAT POL
JI J. Bioact. Compat. Polym.
PD JAN
PY 2006
VL 21
IS 1
BP 5
EP 22
DI 10.1177/0883911506060202
PG 18
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science
GA 002ZX
UT WOS:000234652500001
DA 2022-11-30
ER

PT J
AU Unterhuber, A
   Povazay, B
   Hermann, B
   Sattmann, H
   Chavez-Pirson, A
   Drexler, W
AF Unterhuber, A
   Povazay, B
   Hermann, B
   Sattmann, H
   Chavez-Pirson, A
   Drexler, W
TI In vivo retinal optical coherence tomography at 1040 nm-enhanced
   penetration into the choroid
SO OPTICS EXPRESS
LA English
DT Article
ID ULTRAHIGH-RESOLUTION; VISUALIZATION; PATHOLOGY
AB For the first time in vivo retinal imaging has been performed with a new compact, low noise Yb-based ASE source operating in the 1 mu m range (NP Photonics, lambda(c) = 1040 nm, Delta lambda = 50 nm, P-out = 30 mW) at the dispersion minimum of water with similar to 7 mu m axial resolution. OCT tomograms acquired at 800 nm are compared to those achieved at 1040 nm showing about 200 mu m deeper penetration into the choroid below the retinal pigment epithelium. Retinal OCT at longer wavelengths significantly improves the visualization of the retinal pigment epithelium/choriocapillaris/choroid interface and superficial choroidal layers as well as reduces the scattering through turbid media and therefore might provide a better diagnosis tool for early stages of retinal pathologies such as age related macular degeneration which is accompanied by choroidal neovascularization, i.e. extensive growth of new blood vessels in the choroid and retina. (C) 2005 Optical Society of America.
C1 Med Univ Vienna, Christian Doppler Lab, Ctr Biomed Engn & Phys, Vienna, Austria.
   NP Photon, Tucson, AZ 85747 USA.
C3 Medical University of Vienna
RP Unterhuber, A (通讯作者)，Med Univ Vienna, Christian Doppler Lab, Ctr Biomed Engn & Phys, Vienna, Austria.
EM wolfgang.drexler@meduniwien.ac.at
RI Považay, Boris/F-6258-2012
OI Unterhuber, Angelika/0000-0002-1251-3001; Povazay,
   Boris/0000-0001-5571-5116
CR American National Standards Institute American National Standard for the Safe Use of Lasers, 2000, Z1361 ANSI
   Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   Ergun E, 2005, INVEST OPHTH VIS SCI, V46, P310, DOI 10.1167/iovs.04-0212
   Fercher A F, 1996, J Biomed Opt, V1, P157, DOI 10.1117/12.231361
   FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   HALE GM, 1973, APPL OPTICS, V12, P555, DOI 10.1364/AO.12.000555
   HAMMER M, 1995, PHYS MED BIOL, V40, P963, DOI 10.1088/0031-9155/40/6/001
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   *INT COMM NON RAD, 2000, HLTH PHY, V79, P432
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Povazay B, 2003, OPT EXPRESS, V11, P1980, DOI 10.1364/OE.11.001980
   Povazay B, 2002, OPT LETT, V27, P1800, DOI 10.1364/OL.27.001800
   Unterhuber A, 2003, OPT LETT, V28, P905, DOI 10.1364/OL.28.000905
   Wollstein G, 2005, OPHTHALMOLOGY, V112, P229, DOI 10.1016/j.ophtha.2004.08.021
   Yun SH, 2003, OPT EXPRESS, V11, P3598, DOI 10.1364/OE.11.003598
NR 19
TC 256
Z9 264
U1 0
U2 15
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD MAY 2
PY 2005
VL 13
IS 9
BP 3252
EP 3258
DI 10.1364/OPEX.13.003252
PG 7
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 923FW
UT WOS:000228896200008
PM 19495226
OA gold
DA 2022-11-30
ER

PT J
AU Tseng, RMWW
   Tham, YC
   Rim, TH
   Cheng, CY
AF Tseng, Rachel Marjorie Wei Wen
   Tham, Yih-Chung
   Rim, Tyler Hyungtaek
   Cheng, Ching-Yu
TI Emergence of non-artificial intelligence digital health innovations in
   ophthalmology: A systematic review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE digital health; mHealth; ophthalmology; virtual reality; wearables
ID VISUAL-FIELD DEFECTS; MACULAR DEGENERATION; COLLISION-AVOIDANCE;
   GLAUCOMA; ACUITY; IMPAIRMENT; VALIDATION; CHILDREN; HOME
AB The prominent rise of digital health in ophthalmology is evident in the current age of Industry 4.0. Despite the many facets of digital health, there has been a greater slant in interest and focus on artificial intelligence recently. Other major elements of digital health like wearables could also substantially impact patient-focused outcomes but have been relatively less explored and discussed. In this review, we comprehensively evaluate the use of non-artificial intelligence digital health tools in ophthalmology. 53 papers were included in this systematic review - 25 papers discuss virtual or augmented reality, 14 discuss mobile applications and 14 discuss wearables. Most papers focused on the use of technologies to detect or rehabilitate visual impairment, glaucoma and age-related macular degeneration. Overall, the findings on patient-focused outcomes with the adoption of these technologies are encouraging. Further validation, large-scale studies and earlier consideration of real-world barriers are warranted to enable better real-world implementation.
C1 [Tseng, Rachel Marjorie Wei Wen; Tham, Yih-Chung; Rim, Tyler Hyungtaek; Cheng, Ching-Yu] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Tham, Yih-Chung; Rim, Tyler Hyungtaek; Cheng, Ching-Yu] Duke NUS Med Sch, Singapore, Singapore.
   [Cheng, Ching-Yu] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Cheng, Ching-Yu] Natl Univ Hlth Syst, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore
RP Cheng, CY (通讯作者)，Singapore Eye Res Inst, The Acad, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.
EM chingyu.cheng@duke-nus.edu.sg
RI Chung, Yih/AIF-2414-2022; Cheng, Ching-Yu/Y-2229-2019
OI Chung, Yih/0000-0002-6752-797X; Cheng, Ching-Yu/0000-0003-0655-885X;
   Tseng, Rachel/0000-0003-2849-1799
CR Adebiyi A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170531
   [Anonymous], 2020, SYSTEMATIC REV EFFEC
   [Anonymous], 2021, ARTIFICIAL INTELLIGE
   [Anonymous], 2020, THE ECONOMIST
   [Anonymous], 2020, WHAT IS DIG HLTH
   [Anonymous], 2021, DIGITAL HLTH MARKET
   Bastawrous A, 2015, JAMA OPHTHALMOL, V133, P930, DOI 10.1001/jamaophthalmol.2015.1468
   Boland MV, 2014, JAMA OPHTHALMOL, V132, P845, DOI 10.1001/jamaophthalmol.2014.857
   Brodie FL, 2017, CLIN OPHTHALMOL, V11, P939, DOI 10.2147/OPTH.S135128
   Brown FE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223755
   Cao YP, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000017992
   Chen JY, 2020, J MED INTERNET RES, V22, DOI 10.2196/21476
   Cheung R, 2022, EYE, V36, P994, DOI 10.1038/s41433-021-01540-y
   Chew EY, 2016, RETINA-J RET VIT DIS, V36, P1542, DOI 10.1097/IAE.0000000000000940
   Chung SA, 2021, EYE, V35, P1758, DOI 10.1038/s41433-020-01160-y
   Crossland MD, 2019, OPHTHAL PHYSL OPT, V39, P422, DOI 10.1111/opo.12646
   Daga FB, 2017, INVEST OPHTH VIS SCI, V58, P3343, DOI 10.1167/iovs.17-21849
   Devalla SK, 2020, BRIT J OPHTHALMOL, V104, P301, DOI 10.1136/bjophthalmol-2019-315016
   Diniz A, 2015, OPHTHALMOLOGY, V122, P1131, DOI 10.1016/j.ophtha.2015.02.010
   Gao YB, 2015, P I MECH ENG H, V229, P681, DOI 10.1177/0954411915599017
   Goh RLZ, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.10
   Handa T, 2009, EYE, V23, P2094, DOI 10.1038/eye.2008.359
   Hazari H, 2022, J TELEMED TELECARE, V28, P680, DOI 10.1177/1357633X20960640
   Herbison N, 2016, BRIT J OPHTHALMOL, V100, P1511, DOI 10.1136/bjophthalmol-2015-307798
   Ho E, 2019, J VISION, V19, DOI 10.1167/19.13.22
   Ichhpujani P, 2021, INDIAN J OPHTHALMOL, V69, P87, DOI 10.4103/ijo.IJO_1847_19
   Ikeda Y, 2019, JPN J OPHTHALMOL, V63, P181, DOI 10.1007/s10384-018-00644-5
   Ikeda Y, 2015, JPN J OPHTHALMOL, V59, P43, DOI 10.1007/s10384-014-0354-0
   Jung JH, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.35
   Kubler TC, 2015, OPTOMETRY VISION SCI, V92, P1037, DOI 10.1097/OPX.0000000000000702
   Lam AKN, 2020, JAMA OPHTHALMOL, V138, P490, DOI 10.1001/jamaophthalmol.2020.0392
   Landis EG, 2018, INVEST OPHTH VIS SCI, V59, P4804, DOI 10.1167/iovs.18-24415
   Li BB, 2020, CYBERPSYCH BEH SOC N, V23, P179, DOI 10.1089/cyber.2020.0083
   Li X, 2019, CYBERPSYCH BEH SOC N, V22, P22, DOI 10.1089/cyber.2018.0259
   Merabet LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044958
   Miao Y, 2020, COMPUT METH PROG BIO, V185, DOI 10.1016/j.cmpb.2019.105132
   Miki A, 2020, JPN J OPHTHALMOL, V64, P127, DOI 10.1007/s10384-020-00723-6
   Nagendran M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m689
   Narasimhan S, 2012, VISION RES, V66, P1, DOI 10.1016/j.visres.2012.06.007
   Neugebauer A, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11020223
   Nguyen BJ, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.30
   Papageorgiou E, 2012, VISION RES, V65, P25, DOI 10.1016/j.visres.2012.06.004
   Papageorgiou E, 2012, VISION RES, V52, P20, DOI 10.1016/j.visres.2011.10.019
   Park K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.21
   Phanphruk W, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.2.9
   Randall D, 2020, CURR EYE RES, V45, P1611, DOI 10.1080/02713683.2020.1772834
   Rim TH, 2022, BRIT J OPHTHALMOL, V106, P1301, DOI 10.1136/bjophthalmol-2020-317817
   Rim TH, 2021, BRIT J OPHTHALMOL, V105, P1133, DOI 10.1136/bjophthalmol-2020-316984
   Rono HK, 2018, LANCET GLOB HEALTH, V6, pE924, DOI [10.1016/S2214-109X(18)30244-4, 10.1016/s2214-109x(18)30244-4]
   Safadi K, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000487
   Schmid MK, 2019, EYE, V33, P1584, DOI 10.1038/s41433-019-0455-6
   Secinaro S, 2021, BMC MED INFORM DECIS, V21, DOI 10.1186/s12911-021-01488-9
   Sorkin N, 2016, OPTOMETRY VISION SCI, V93, P667, DOI 10.1097/OPX.0000000000000873
   Stohr M, 2020, CLIN OPHTHALMOL, V14, P4115, DOI 10.2147/OPTH.S273810
   Tan F, 2020, CYBERPSYCH BEH SOC N, V23, P871, DOI 10.1089/cyber.2020.0837
   Thakur S, 2018, EYE, V32, P1392, DOI 10.1038/s41433-018-0099-y
   Tham YC, 2021, LANCET DIGIT HEALTH, V3, pE29, DOI 10.1016/S2589-7500(20)30271-5
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Toner KN, 2014, J AAPOS, V18, P258, DOI 10.1016/j.jaapos.2014.01.011
   Tsapakis S, 2017, CLIN OPHTHALMOL, V11, P1431, DOI 10.2147/OPTH.S131160
   Ungewiss J, 2018, GRAEF ARCH CLIN EXP, V256, P2429, DOI 10.1007/s00417-018-4148-9
   Waddingham PE, 2006, EYE, V20, P375, DOI 10.1038/sj.eye.6701883
   Wen LB, 2020, BRIT J OPHTHALMOL, V104, P1542, DOI 10.1136/bjophthalmol-2019-315258
   Wen LB, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.15
   Whelton Paul K, 2018, Hypertension, V71, pe13, DOI [10.1016/j.jash.2018.06.010, 10.1161/HYP.0000000000000065]
   Wisse RPL, 2019, J MED INTERNET RES, V21, DOI 10.2196/14808
   Xu L, 2019, CYBERPSYCH BEH SOC N, V22, P127, DOI 10.1089/cyber.2019.0020
   Yu HJ, 2021, OPHTHALMOL RETINA, V5, P348, DOI 10.1016/j.oret.2020.08.003
   Zhao L, 2019, J PEDIATR-US, V213, P203, DOI 10.1016/j.jpeds.2019.06.021
NR 69
TC 0
Z9 0
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 49
IS 7
BP 741
EP 756
DI 10.1111/ceo.13971
EA JUL 2021
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WA3UL
UT WOS:000673214400001
PM 34235833
DA 2022-11-30
ER

PT J
AU Manian, KV
   Galloway, CA
   Dalvi, S
   Emanuel, AA
   Mereness, JA
   Black, W
   Winschel, L
   Soto, C
   Li, YM
   Song, YH
   DeMaria, W
   Kumar, A
   Slukvin, I
   Schwartz, MP
   Murphy, WL
   Anand-Apte, B
   Chung, MN
   Benoit, DSW
   Singh, R
AF Manian, Kannan, V
   Galloway, Chad A.
   Dalvi, Sonal
   Emanuel, Anthony A.
   Mereness, Jared A.
   Black, Whitney
   Winschel, Lauren
   Soto, Celia
   Li, Yiming
   Song, Yuanhui
   DeMaria, William
   Kumar, Akhilesh
   Slukvin, Igor
   Schwartz, Michael P.
   Murphy, William L.
   Anand-Apte, Bela
   Chung, Mina
   Benoit, Danielle S. W.
   Singh, Ruchira
TI 3D iPSC modeling of the retinal pigment epithelium-choriocapillaris
   complex identifies factors involved in the pathology of macular
   degeneration
SO CELL STEM CELL
LA English
DT Article
ID POLY(ETHYLENE GLYCOL) HYDROGELS; ENDOTHELIAL-CELLS; MESENCHYMAL STEM;
   NEURAL-TUBE; RPE; EXPRESSION; DISEASE; VEGF; LOCALIZATION; ANGIOGENESIS
AB The retinal pigment epithelium (RPE)-choriocapillaris (CC) complex in the eye is compromised in age-related macular degeneration (AMD) and related macular dystrophies (MDs), yet in vitro models of RPE-CC complex that enable investigation of AMD/MD pathophysiology are lacking. By incorporating iPSC-derived cells into a hydrogel-based extracellular matrix, we developed a 3D RPE-CC model that recapitulates key features of both healthy and AMD/MD eyes and provides modular control over RPE and CC layers. Using this 3D RPE-CC model, we demonstrated that both RPE- and mesenchyme-secreted factors are necessary for the formation of fenestrated CC-like vasculature. Our data show that choroidal neovascularization (CNV) and CC atrophy occur in the absence of endothelial cell dysfunction and are not necessarily secondary to drusen deposits underneath RPE cells, and CC atrophy and/or CNV can be initiated systemically by patient serum or locally by mutant RPE-secreted factors. Finally, we identify FGF2 and matrix metalloproteinases as potential therapeutic targets for AMD/MDs.
C1 [Manian, Kannan, V; Galloway, Chad A.; Dalvi, Sonal; Emanuel, Anthony A.; Black, Whitney; Winschel, Lauren; Soto, Celia; Chung, Mina; Singh, Ruchira] Univ Rochester, Dept Ophthalmol, Rochester, NY 14620 USA.
   [Manian, Kannan, V; Galloway, Chad A.; Dalvi, Sonal; Emanuel, Anthony A.; Black, Whitney; Winschel, Lauren; Soto, Celia; Benoit, Danielle S. W.; Singh, Ruchira] Univ Rochester, Dept Biomed Genet, Rochester, NY 14620 USA.
   [Galloway, Chad A.; Benoit, Danielle S. W.] Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14620 USA.
   [Mereness, Jared A.; Li, Yiming; Song, Yuanhui; DeMaria, William; Benoit, Danielle S. W.] Univ Rochester, Dept Biomed Engn, Robert B Goergen Hall, Rochester, NY 14627 USA.
   [Mereness, Jared A.; Benoit, Danielle S. W.; Singh, Ruchira] Univ Rochester, Dept Orthoped, Rochester, NY 14642 USA.
   [Mereness, Jared A.; Benoit, Danielle S. W.; Singh, Ruchira] Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Mereness, Jared A.; Benoit, Danielle S. W.] Univ Rochester, Ctr Oral Biol, Rochester, NY 14642 USA.
   [Mereness, Jared A.; Benoit, Danielle S. W.] Univ Rochester, Dept Environm Med, Rochester, NY 14642 USA.
   [Kumar, Akhilesh; Slukvin, Igor] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
   [Slukvin, Igor] Univ Wisconsin, Dept Cell & Regenerat Biol, Sch Med & Publ Hlth, Madison, WI 53715 USA.
   [Schwartz, Michael P.] Univ Wisconsin, NSF Ctr Sustainable Nanotechnol, Dept Chem, Madison, WI 53706 USA.
   [Schwartz, Michael P.; Murphy, William L.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53715 USA.
   [Murphy, William L.] Univ Wisconsin, Dept Orthoped & Rehabil, Madison, WI 53715 USA.
   [Anand-Apte, Bela] Cleveland Clin, Dept Ophthalm Res, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Anand-Apte, Bela] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Chung, Mina; Singh, Ruchira] Univ Rochester, Ctr Visual Sci, Rochester, NY 14620 USA.
   [Benoit, Danielle S. W.; Singh, Ruchira] UR Stem Cell & Regenerat Med Ctr, Rochester, NY 14620 USA.
   [Benoit, Danielle S. W.] Univ Rochester, Mat Sci Program, Rochester, NY 14620 USA.
   [Benoit, Danielle S. W.] Univ Rochester, Dept Chem Engn, Rochester, NY 14620 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester; University of Rochester; University of Rochester; University
   of Rochester; University of Rochester; University of Rochester;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of
   Rochester; University of Rochester; University of Rochester
RP Singh, R (通讯作者)，Univ Rochester, Dept Ophthalmol, Rochester, NY 14620 USA.; Singh, R (通讯作者)，Univ Rochester, Dept Biomed Genet, Rochester, NY 14620 USA.; Singh, R (通讯作者)，Univ Rochester, Dept Orthoped, Rochester, NY 14642 USA.; Singh, R (通讯作者)，Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.; Singh, R (通讯作者)，Univ Rochester, Ctr Visual Sci, Rochester, NY 14620 USA.; Singh, R (通讯作者)，UR Stem Cell & Regenerat Med Ctr, Rochester, NY 14620 USA.
EM ruchira_singh@urmc.rochester.edu
RI Dalvi, Sonal/GSD-5839-2022; V Manian, Kannan/CAG-4157-2022; Song,
   Yuanhui/GRE-6326-2022; Schwartz, Michael/GNW-3991-2022; Kumar,
   Akhilesh/L-3749-2017
OI V Manian, Kannan/0000-0003-1764-2424; Schwartz,
   Michael/0000-0003-3785-6606; Kumar, Akhilesh/0000-0003-2757-5181; Soto,
   Celia/0000-0003-1787-3249
FU BrightFocus Foundation Macular Degeneration Grant; Cleveland Eye Bank
   Foundation; David Bryant Trust; Foundation Fighting Blindness Individual
   Investigator Award; Knights Templar eye foundation; Retina Research
   Foundation; Research to Prevent Blindness; National Institutes of Health
   [R01EY028167, R01EY030183, R21EY027750, 5T32ES007026-43, R01NS109427,
   EY027083, EY026181, P30EY025585]
FX This work was supported by a BrightFocus Foundation Macular Degeneration
   Grant (to R.S.), Cleveland Eye Bank Foundation Grant (B.A-A.), the David
   Bryant Trust (to R.S.), a Foundation Fighting Blindness Individual
   Investigator Award (to R.S.), a Knights Templar eye foundation grant (to
   R.S.), and the Retina Research Foundation and Research to Prevent
   Blindness (Career Development Award to R.S. and an unrestricted
   challenge grant to the Department of Ophthalmology at the University of
   Rochester and the Department of Ophthalmic Research at Cleveland
   Clinic). This work was also supported by National Institutes of Health
   grants R01EY028167 (to R.S.), R01EY030183 (to R.S.), R21EY027750 (to
   D.S.W.B. and R.S.), 5T32ES007026-43 (to J.A.M.), R01NS109427 (to
   W.L.M.), EY027083 and EY026181 (to B.A.-A.), and P30EY025585 (to the
   Cleveland Clinic Foundation).
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Aziz AH, 2017, J MECH BEHAV BIOMED, V65, P454, DOI 10.1016/j.jmbbm.2016.09.007
   Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989
   Bhise NS, 2014, J CONTROL RELEASE, V190, P82, DOI 10.1016/j.jconrel.2014.05.004
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bugno M, 1999, FEBS LETT, V448, P9, DOI 10.1016/S0014-5793(99)00323-3
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Chen LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03788-5
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chwalek K, 2014, SCI REP-UK, V4, DOI 10.1038/srep04414
   Cruz-Acuna R, 2018, NAT PROTOC, V13, P2102, DOI 10.1038/s41596-018-0036-3
   Dardik R, 2010, INVEST OPHTH VIS SCI, V51, P6188, DOI 10.1167/iovs.09-5095
   Dickson KM, 2001, CALCIFIED TISSUE INT, V68, P304, DOI 10.1007/BF02390838
   Esch EW, 2015, NAT REV DRUG DISCOV, V14, P248, DOI 10.1038/nrd4539
   Fairbanks BD, 2009, ADV MATER, V21, P5005, DOI 10.1002/adma.200901808
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Gage PJ, 2005, INVEST OPHTH VIS SCI, V46, P4200, DOI 10.1167/iovs.05-0691
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Gourier HCY, 2015, J CLIN MED, V4, P874, DOI 10.3390/jcm4050874
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Hoffman MD, 2013, BIOMATERIALS, V34, P8887, DOI 10.1016/j.biomaterials.2013.08.005
   Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016
   Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046
   Khoo CP, 2011, TISSUE ENG PART C-ME, V17, P895, DOI [10.1089/ten.tec.2011.0150, 10.1089/ten.TEC.2011.0150]
   Kim SA, 2020, BIOCHEM BIOPH RES CO, V522, P240, DOI 10.1016/j.bbrc.2019.11.085
   Komez A, 2016, J BIOMED MATER RES A, V104, P2166, DOI 10.1002/jbm.a.35756
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kraehenbuehl TP, 2008, BIOMATERIALS, V29, P2757, DOI 10.1016/j.biomaterials.2008.03.016
   Kraehenbuehl TP, 2009, BIOMATERIALS, V30, P4318, DOI 10.1016/j.biomaterials.2009.04.057
   Kumar R, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-27
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lu HY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7537589
   Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meinhardt A, 2014, STEM CELL REP, V3, P987, DOI 10.1016/j.stemcr.2014.09.020
   Moon JJ, 2010, BIOMATERIALS, V31, P3840, DOI 10.1016/j.biomaterials.2010.01.104
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Peters EB, 2016, CELL MOL BIOENG, V9, P38, DOI 10.1007/s12195-015-0423-6
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Qi JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53433-6
   Ranga A, 2016, P NATL ACAD SCI USA, V113, pE6831, DOI 10.1073/pnas.1603529113
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Schwartz MP, 2015, P NATL ACAD SCI USA, V112, P12516, DOI 10.1073/pnas.1516645112
   Seliktar D, 2004, J BIOMED MATER RES A, V68A, P704, DOI 10.1002/jbm.a.20091
   SELLHEYER K, 1990, EYE, V4, P255, DOI 10.1038/eye.1990.37
   Shokoohmand A, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700221
   Shubin AD, 2015, TISSUE ENG PT A, V21, P1733, DOI [10.1089/ten.tea.2014.0674, 10.1089/ten.TEA.2014.0674]
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Spencer C, 2017, J CELL MOL MED, V21, P2542, DOI 10.1111/jcmm.13175
   Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383
   Stratman AN, 2012, MICROSC MICROANAL, V18, P68, DOI 10.1017/S1431927611012402
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Van Hove AH, 2014, BIOMATERIALS, V35, P9719, DOI 10.1016/j.biomaterials.2014.08.019
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zanotelli MR, 2016, ACTA BIOMATER, V35, P32, DOI 10.1016/j.actbio.2016.03.001
   Zhang J, 2017, STEM CELL REP, V8, P907, DOI 10.1016/j.stemcr.2017.02.014
NR 84
TC 9
Z9 9
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 6
PY 2021
VL 28
IS 5
BP 846
EP +
DI 10.1016/j.stem.2021.02.006
EA MAY 2021
PG 25
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RZ0IG
UT WOS:000648283600016
PM 33784497
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Morizur, L
   Herardot, E
   Monville, C
   Ben M'Barek, K
AF Morizur, Lise
   Herardot, Elise
   Monville, Christelle
   Ben M'Barek, Karim
TI Human pluripotent stem cells: A toolbox to understand and treat retinal
   degeneration
SO MOLECULAR AND CELLULAR NEUROSCIENCE
LA English
DT Review
DE Human pluripotent stem cells; Retinopathies; Cell therapy; Disease
   modeling; Age-related Macular Degeneration; Retinitis Pigmentosa
ID PIGMENT EPITHELIAL-CELLS; TRANSLATIONAL READ-THROUGH; GENOME-WIDE
   ASSOCIATION; GROWTH-FACTOR SECRETION; MACULAR DEGENERATION;
   PHOTORECEPTOR PRECURSORS; RETINITIS-PIGMENTOSA; VISUAL FUNCTION;
   XENO-FREE; DIRECTED DIFFERENTIATION
AB Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) are retinal degenerative disorders that dramatically damage the retina. As there is no therapeutic option for the majority of patients, vision is progressively and irremediably lost. Owing to their unlimited renewal and potency to give rise to any cell type of the human adult body, human pluripotent stem cells (hPSCs) have been extensively studied in recent years to develop more physiologically relevant in vitro cellular models. Such models open new perspectives to investigate the pathological molecular mechanisms of AMD and RP but also in drug screening. Moreover, proof-of-concept of hPSC-derived retinal cell therapy in animal models have led to first clinical trials. This review outlines the recent advances in the use of hPSCs in pathological modeling of retinal degeneration and their use in regenerative medicine. We also address the associated limitations and challenges that need to be overcome when using hPSCs.
C1 [Morizur, Lise; Herardot, Elise; Monville, Christelle; Ben M'Barek, Karim] Inst Stem Cell Therapy & Explorat Monogen Dis, AFM, I Stem, INSERM U861, F-91100 Corbeil Essonnes, France.
   [Morizur, Lise; Herardot, Elise; Monville, Christelle; Ben M'Barek, Karim] Univ Paris Saclay, Univ Evry, U861, F-91100 Corbeil Essonnes, France.
   [Morizur, Lise; Ben M'Barek, Karim] Ctr Etud Cellules Souches, F-91100 Corbeil Essonnes, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Saclay;
   UDICE-French Research Universities; Universite Paris Saclay
RP Monville, C; Ben M'Barek, K (通讯作者)，Inst Stem Cell Therapy & Explorat Monogen Dis, AFM, I Stem, INSERM U861, F-91100 Corbeil Essonnes, France.
EM cmonville@istem.fr; kbenmbarek@istem.fr
RI M'BAREK, Karim BEN/K-1389-2019
OI M'BAREK, Karim BEN/0000-0002-2556-0325; Morizur,
   Lise/0000-0001-7400-3018
FU ANR [ANR-19-CE18-0004]; Fondation pour la Recherche Medicale
   (Transplantation and cell therapy) [PME201906008797]; NeurATRIS: A
   Translational Research Infrastructure for Biotherapies in Neurosciences
   (Investissements d'Avenir) [ANR-11-INBS-0011]; INGESTEM: the National
   Infrastructure Engineering for Pluripotent and differentiated Stem cells
   (Investissements d'Avenir) [ANR-11-INBS-000]; Association Francaise
   contre les Myopathies-Telethon
FX This work was supported by grants from the ANR [RebuildingRETINA:
   ANR-19-CE18-0004] and the Fondation pour la Recherche Medicale
   (Transplantation and cell therapy - PME201906008797) to KB. It was
   supported by NeurATRIS: A Translational Research Infrastructure for
   Biotherapies in Neurosciences (Investissements d'Avenir -
   ANR-11-INBS-0011) and INGESTEM: the National Infrastructure Engineering
   for Pluripotent and differentiated Stem cells (Investissements d'Avenir
   - ANR-11-INBS-000) to CM. I-Stem is part of the Biotherapies Institute
   for Rare Diseases supported by the Association Francaise contre les
   Myopathies-Telethon.
CR Aasen DM, 2020, J OCUL PHARMACOL TH, V36, P18, DOI 10.1089/jop.2018.0140
   Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Achberger K, 2019, ADV DRUG DELIVER REV, V140, P33, DOI 10.1016/j.addr.2018.05.005
   Ahmad I, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100824
   Akhtar T, 2019, STEM CELL RES, V39, DOI 10.1016/j.scr.2019.101491
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Auffarth GU, 1997, OPHTHALMOLOGE, V94, P642, DOI 10.1007/s003470050175
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bayyoud T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002616
   Ben M'Barek K, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119603
   Ben M'Barek K, 2018, JOVE-J VIS EXP, DOI 10.3791/58216
   Ben M'Barek K, 2018, ADV EXP MED BIOL, V1074, P625, DOI 10.1007/978-3-319-75402-4_76
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   BIRD AC, 1975, BRIT J OPHTHALMOL, V59, P177, DOI 10.1136/bjo.59.4.177
   Bittner AK, 2012, EYE, V26, P101, DOI 10.1038/eye.2011.247
   Bittner AK, 2009, RETINA-J RET VIT DIS, V29, P1513, DOI 10.1097/IAE.0b013e3181af0d57
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Breuer DK, 2002, AM J HUM GENET, V70, P1545, DOI 10.1086/340848
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Brydon EM, 2019, MOL THER-METH CLIN D, V15, P392, DOI 10.1016/j.omtm.2019.10.014
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Buskin A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06448-y
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Cai H, 2018, JOVE-J VIS EXP, DOI 10.3791/57084
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cehajic-Kapetanovic J, 2015, CURR BIOL, V25, P2111, DOI 10.1016/j.cub.2015.07.029
   Chaffiol A, 2017, MOL THER, V25, P2546, DOI 10.1016/j.ymthe.2017.07.011
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Collin J, 2019, STEM CELLS, V37, P609, DOI 10.1002/stem.2974
   Crombie DE, 2017, SLAS DISCOV, V22, P1016, DOI 10.1177/2472555217696797
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Decembrini S, 2017, MOL THER, V25, P634, DOI 10.1016/j.ymthe.2016.12.015
   Deng WL, 2018, STEM CELL REP, V10, P1267, DOI 10.1016/j.stemcr.2018.02.003
   Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dorgau B, 2019, BIOMATERIALS, V199, P63, DOI 10.1016/j.biomaterials.2019.01.028
   Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69
   Eberle D, 2011, INVEST OPHTH VIS SCI, V52, P6462, DOI 10.1167/iovs.11-7399
   Elitt MS, 2018, HUM MOL GENET, V27, pR89, DOI 10.1093/hmg/ddy186
   Engle SJ, 2014, J BIOL CHEM, V289, P4562, DOI 10.1074/jbc.R113.529156
   Fang Y, 2017, SLAS DISCOV, V22, P456, DOI 10.1177/1087057117696795
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Ferguson Lee R, 2015, J Stem Cells, V10, P159
   Fernandes Rodrigo A Brant, 2017, Int J Retina Vitreous, V3, P41, DOI 10.1186/s40942-017-0095-6
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foltz LP, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124127
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Fuhrmann Sabine, 2008, Organogenesis, V4, P60
   Gagliardi G, 2019, PROG RETIN EYE RES, V71, P1, DOI 10.1016/j.preteyeres.2019.03.001
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gao ML, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00128
   Garita-Hernandez M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12330-2
   Garita-Hernandez M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00789
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gourraud PA, 2012, STEM CELLS, V30, P180, DOI 10.1002/stem.772
   Guo YL, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00361
   Gupta A., 2017, DELHI J OPHTHALMOL, V27, P243, DOI DOI 10.7869/DJ0.258
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Han X, 2019, P NATL ACAD SCI USA, V116, P10441, DOI 10.1073/pnas.1902566116
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hardcastle AJ, 1999, AM J HUM GENET, V64, P1210, DOI 10.1086/302325
   Hartong DT, 2004, INVEST OPHTH VIS SCI, V45, P1725, DOI 10.1167/iovs.03-1061
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hori K, 2019, J TISSUE ENG REGEN M, V13, P459, DOI 10.1002/term.2805
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hussain AA, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100775
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Iftikhar M, 2019, BRIT J OPHTHALMOL, V103, P1595, DOI 10.1136/bjophthalmol-2018-313669
   Ikeda Y, 2019, JPN J OPHTHALMOL, V63, P181, DOI 10.1007/s10384-018-00644-5
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Jung YH, 2018, ADV MATER, V30, DOI 10.1002/adma.201803550
   Kallman A, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0808-5
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khabou H, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96029
   Klapper SD, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00074
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Koh HK, 2010, NEW ENGL J MED, V362, P1653, DOI 10.1056/NEJMp1001601
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lakowski J, 2018, STEM CELLS, V36, P709, DOI 10.1002/stem.2775
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Langhans SA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00006
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Llonch S, 2018, DEV BIOL, V433, P132, DOI 10.1016/j.ydbio.2017.09.028
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lukovic D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12910
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mace E, 2015, MOL THER, V23, P7, DOI 10.1038/mt.2014.154
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Matsumoto E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212369
   MBAREK A, 2019, STEM CELLS INT, V2019, DOI DOI 10.1155/2019/4568979
   McGill TJ, 2018, INVEST OPHTH VIS SCI, V59, P1374, DOI 10.1167/iovs.17-22467
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Megaw R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00111-8
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morrison MA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00238
   Murphy AR, 2020, ACTA BIOMATER, V104, P1, DOI 10.1016/j.actbio.2020.01.013
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Ortin-Martinez A, 2017, STEM CELLS, V35, P932, DOI 10.1002/stem.2552
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Ramsden CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00142-7
   Rayapudi S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008428.pub2
   Regent F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47123-6
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Riera M, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.10
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Schaub NJ, 2020, J CLIN INVEST, V130, P1010, DOI 10.1172/JCI131187
   Schwartz S.D., 2016, INVEST OPHTH VIS SCI, V57, DOI [10.1167/iovs.15-18681.ORSFc1-9., DOI 10.1167/IOVS.15-18681.ORSFC1-9]
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Schwarz N, 2017, HUM MOL GENET, V26, P2480, DOI 10.1093/hmg/ddx143
   Schwarz N, 2015, HUM MOL GENET, V24, P972, DOI 10.1093/hmg/ddu509
   Sengupta A, 2016, EMBO MOL MED, V8, P1248, DOI 10.15252/emmm.201505699
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sharma TP, 2017, STEM CELL RES, V21, P58, DOI 10.1016/j.scr.2017.03.005
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Smith JR, 2008, DEV BIOL, V313, P107, DOI 10.1016/j.ydbio.2007.10.003
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014
   Taylor CJ, 2011, PHILOS T R SOC B, V366, P2312, DOI 10.1098/rstb.2011.0030
   Thompson JR, 2019, ACTA BIOMATER, V94, P204, DOI 10.1016/j.actbio.2019.04.057
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   Vaajasaari H, 2011, MOL VIS, V17, P558
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Vergara MN, 2017, DEVELOPMENT, V144, P3698, DOI 10.1242/dev.146290
   Warre-Cornish K, 2014, STEM CELLS DEV, V23, P941, DOI 10.1089/scd.2013.0471
   Welby E, 2017, STEM CELL REP, V9, P1898, DOI 10.1016/j.stemcr.2017.10.018
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Wiley LA, 2016, SCI REP-UK, V6, DOI 10.1038/srep30742
   Wong CH, 2019, BIOSTATISTICS, V20, P273, DOI 10.1093/biostatistics/kxx069
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worthington KS, 2017, ACTA BIOMATER, V55, P385, DOI 10.1016/j.actbio.2017.03.039
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yoshida T, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-45
   Zhang Y, 2009, J NEUROSCI, V29, P9186, DOI 10.1523/JNEUROSCI.0184-09.2009
   Zhao CP, 2017, DEVELOPMENT, V144, P1368, DOI 10.1242/dev.133108
   Zhao Y, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/8524607
   Zheng W, 2013, DRUG DISCOV TODAY, V18, P1067, DOI 10.1016/j.drudis.2013.07.001
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhu J, 2017, CELL STEM CELL, V20, P374, DOI 10.1016/j.stem.2016.11.019
NR 191
TC 11
Z9 12
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1044-7431
EI 1095-9327
J9 MOL CELL NEUROSCI
JI Mol. Cell. Neurosci.
PD SEP
PY 2020
VL 107
AR 103523
DI 10.1016/j.mcn.2020.103523
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA NP4OR
UT WOS:000570157600009
PM 32634576
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Abduljabbar, TN
   Sharp, BL
   Reid, HJ
   Barzegar-Befroeid, N
   Peto, T
   Lengyel, I
AF Abduljabbar, Tharwat N.
   Sharp, Barry L.
   Reid, Helen J.
   Barzegar-Befroeid, Neda
   Peto, Tunde
   Lengyel, Imre
TI Determination of Zn, Cu and Fe in human patients' serum using micro
   sampling ICP-MS and sample dilution
SO TALANTA
LA English
DT Article
DE AD; AMD; ICP-MS; Serum analysis; Trace elements
ID PLASMA-MASS SPECTROMETRY; TRACE-ELEMENTS; ALZHEIMERS-DISEASE; MACULAR
   DEGENERATION; BLOOD-SAMPLES; WHOLE-BLOOD; ZINC; COPPER; AGE; IRON
AB A high-throughput, sensitive and rapid method was developed for the determination of Zn, Cu and Fe in small volumes (30 mu L) of human serum using inductively coupled plasma mass spectrometry (ICP-MS). The sample preparation procedure employed simple 100-fold dilution of the serum samples with 1.0% butanol, 0.5% v/v ammonia, 0.02% v/v Triton X-100 and 0.01% v/v HNO3. The reliability of the method was evaluated using serum UTAK certified reference material, and the results matched well with the certified values. The method was applied to determine Zn, Cu and Fe in 81 human serum samples from participants in Alzheimer disease (AD) and age-related macular degeneration (AMD) studies. No significant differences were found in Zn and Cu levels between age matched controls, AD and AMD patients. Whilst iron levels appeared marginally higher in the AMD group, compared with the AD group, iron showed larger overall variability than the other two elements.
C1 [Abduljabbar, Tharwat N.] King Abdulaziz Univ, Fac Sci, Dept Chem, POB 80200, Jeddah 21589, Saudi Arabia.
   [Abduljabbar, Tharwat N.; Sharp, Barry L.; Reid, Helen J.] Loughborough Univ, Ctr Analyt Sci, Dept Chem, Loughborough LE11 3TU, Leics, England.
   [Barzegar-Befroeid, Neda; Lengyel, Imre] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Peto, Tunde; Lengyel, Imre] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Belfast BT7 1NN, Antrim, North Ireland.
   [Peto, Tunde] NHS Fdn Trust, Moorfields Eye Hosp, London EC1V 2PD, England.
C3 King Abdulaziz University; Loughborough University; University of
   London; University College London; Queens University Belfast; Oxford
   University Hospitals NHS Foundation Trust; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Abduljabbar, TN (通讯作者)，King Abdulaziz Univ, Fac Sci, Dept Chem, POB 80200, Jeddah 21589, Saudi Arabia.
EM Tabduljabbar@kau.edu.sa
RI Lengyel, Imre/B-5217-2009; Abduljabbar, Tharwat/ABD-1908-2020
OI Lengyel, Imre/0000-0001-7467-2174; 
FU Bill Brown Charitable Trust; Mercer Fund
FX Special thanks to Mrs Dagmar Koller, Biomineral Research Group, Medical
   Research Council Human Nutrition Research in Cambridge for her useful
   advice and discussion regarding sample preparation during the European
   Winter Conference on Plasma Spectrochemistry, 2015 in Munster. This
   research was supported by Bill Brown Charitable Trust, MEH Special
   Trustees and Mercer Fund (I.L). The authors are grateful for the
   participants who donated their blood samples.
CR Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Azhdarzadeh M, 2013, SCI REP-UK, V3, DOI 10.1038/srep02782
   Barany E, 1997, J ANAL ATOM SPECTROM, V12, P1005, DOI 10.1039/a700904f
   Baum L, 2010, BIOMETALS, V23, P173, DOI 10.1007/s10534-009-9277-5
   Begerow J, 2000, J ANAL ATOM SPECTROM, V15, P347, DOI 10.1039/a909056h
   Bravo IDB, 2007, J TRACE ELEM MED BIO, V21, P14, DOI 10.1016/j.jtemb.2007.09.017
   Cai BA, 2017, ANAL LETT, V50, P554, DOI 10.1080/00032719.2016.1189928
   Cerman E, 2015, TURK J MED SCI, V45, P1004, DOI 10.3906/sag-1406-146
   Dong J, 2008, J ALZHEIMERS DIS, V15, P443
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Forrer R, 2001, BIOL TRACE ELEM RES, V80, P77, DOI 10.1385/BTER:80:1:77
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Gerhardsson L, 2008, DEMENT GERIATR COGN, V25, P508, DOI 10.1159/000129365
   Giacconi R, 2017, EUR J NUTR, V56, P2457, DOI 10.1007/s00394-016-1281-2
   Gonzalez C, 1999, EUR J CLIN INVEST, V29, P637
   Goulle JP, 2005, FORENSIC SCI INT, V153, P39, DOI 10.1016/j.forsciint.2005.04.020
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Harrington JM, 2014, BIOL TRACE ELEM RES, V160, P132, DOI 10.1007/s12011-014-0033-5
   He M, 2017, ANAL CHIM ACTA, V973, P1, DOI 10.1016/j.aca.2017.03.047
   Heitland P, 2006, J TRACE ELEM MED BIO, V20, P253, DOI 10.1016/j.jtemb.2006.08.001
   JOHNSON PE, 1992, AM J CLIN NUTR, V56, P917, DOI 10.1093/ajcn/56.5.917
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Konz T, 2017, J PROTEOME RES, V16, P2080, DOI 10.1021/acs.jproteome.7b00055
   Kozlowski H, 2009, COORDIN CHEM REV, V253, P2665, DOI 10.1016/j.ccr.2009.05.011
   Krachler M, 1999, J TRACE ELEM MED BIO, V13, P157, DOI 10.1016/S0946-672X(99)80006-6
   Li DD, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00300
   Li G, 2012, AM J ANAL CHEM, V3, P646, DOI DOI 10.4236/AJAC.2012.39084
   Lin T, 2017, J TRACE ELEM MED BIO, V43, P202, DOI 10.1016/j.jtemb.2017.03.010
   Liu XB, 2014, J ANAL METHODS CHEM, V2014, DOI 10.1155/2014/975820
   Loef M, 2012, BRIT J NUTR, V107, P7, DOI 10.1017/S000711451100376X
   Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6
   Lu Y, 2015, CLIN BIOCHEM, V48, P140, DOI 10.1016/j.clinbiochem.2014.12.003
   Maekawa M, 2004, CLIN CHEM, V50, P1480, DOI 10.1373/clinchem.2004.035139
   Memon ZM, 2017, ENVIRON SCI POLLUT R, V24, P26513, DOI 10.1007/s11356-017-0236-3
   Muniz CS, 1999, J ANAL ATOM SPECTROM, V14, P193, DOI 10.1039/a807360k
   Muniz CS, 2001, BIOL TRACE ELEM RES, V82, P259, DOI 10.1385/BTER:82:1-3:259
   Nobrega JA, 2006, SPECTROCHIM ACTA B, V61, P465, DOI 10.1016/j.sab.2006.02.006
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ozcankaya R, 2002, CROAT MED J, V43, P28
   REA IM, 1989, NUTR RES, V9, P121, DOI 10.1016/S0271-5317(89)80110-1
   Rembach A, 2014, METALLOMICS, V6, P1216, DOI 10.1039/c4mt00060a
   Rulon LL, 2000, BIOL TRACE ELEM RES, V75, P79, DOI 10.1385/BTER:75:1-3:79
   Szpunar J, 1997, TALANTA, V44, P1389, DOI 10.1016/S0039-9140(97)00009-X
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Ventriglia M, 2015, J ALZHEIMERS DIS, V46, P75, DOI 10.3233/JAD-141296
   Vural H, 2010, J TRACE ELEM MED BIO, V24, P169, DOI 10.1016/j.jtemb.2010.02.002
   Wang ZX, 2015, J ALZHEIMERS DIS, V47, P565, DOI 10.3233/JAD-143108
   Yu XX, 2018, TALANTA, V179, P279, DOI 10.1016/j.talanta.2017.11.013
   Zablocka-Slowinska K, 2018, J TRACE ELEM MED BIO, V45, P78, DOI 10.1016/j.jtemb.2017.09.024
NR 50
TC 19
Z9 21
U1 6
U2 54
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD NOV 1
PY 2019
VL 204
BP 663
EP 669
DI 10.1016/j.talanta.2019.05.098
PG 7
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA IQ3PS
UT WOS:000480664200082
PM 31357350
DA 2022-11-30
ER

PT J
AU Liu, BX
   Calton, MA
   Abell, NS
   Benchorin, G
   Gloudemans, MJ
   Chen, M
   Hu, JN
   Li, X
   Balliu, B
   Bok, D
   Montgomery, SB
   Vollrath, D
AF Liu, Boxiang
   Calton, Melissa A.
   Abell, Nathan S.
   Benchorin, Gillie
   Gloudemans, Michael J.
   Chen, Ming
   Hu, Jane
   Li, Xin
   Balliu, Brunilda
   Bok, Dean
   Montgomery, Stephen B.
   Vollrath, Douglas
TI Genetic analyses of human fetal retinal pigment epithelium gene
   expression suggest ocular disease mechanisms
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID MOLECULAR SIGNATURE; MUTATIONS; GENOME; DEHYDROGENASE; PROTEIN; CELLS;
   RPE; HERITABILITY; LOCALIZATION; CHOLESTEROL
AB The retinal pigment epithelium (RPE) serves vital roles in ocular development and retinal homeostasis but has limited representation in large-scale functional genomics datasets. Understanding how common human genetic variants affect RPE gene expression could elucidate the sources of phenotypic variability in selected monogenic ocular diseases and pinpoint causal genes at genome-wide association study (GWAS) loci. We interrogated the genetics of gene expression of cultured human fetal RPE (fRPE) cells under two metabolic conditions and discovered hundreds of shared or condition-specific expression or splice quantitative trait loci (e/sQTLs). Co-localizations of fRPE e/sQTLs with age-related macular degeneration (AMD) and myopia GWAS data suggest new candidate genes, and mechanisms by which a common RDH5 allele contributes to both increased AMD risk and decreased myopia risk. Our study highlights the unique transcriptomic characteristics of fRPE and provides a resource to connect e/sQTLs in a critical ocular cell type to monogenic and complex eye disorders.
C1 [Liu, Boxiang] Stanford Univ, Dept Biol, Stanford, CA 94305 USA.
   [Calton, Melissa A.; Abell, Nathan S.; Benchorin, Gillie; Chen, Ming; Montgomery, Stephen B.; Vollrath, Douglas] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.
   [Gloudemans, Michael J.] Stanford Univ, Program Biomed Informat, Sch Med, Stanford, CA 94305 USA.
   [Hu, Jane; Bok, Dean] Univ Calif Los Angeles, Dept Ophthalmol, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Li, Xin; Balliu, Brunilda; Montgomery, Stephen B.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University;
   University of California System; University of California Los Angeles;
   Stanford University
RP Montgomery, SB; Vollrath, D (通讯作者)，Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.; Montgomery, SB (通讯作者)，Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
EM smontgom@stanford.edu; vollrath@stanford.edu
OI Montgomery, Stephen/0000-0002-5200-3903; Liu,
   Boxiang/0000-0002-2595-4463; Li, Xin/0000-0002-2122-7461; Gloudemans,
   Michael/0000-0002-9924-9943
FU Stanford Center for Computational, Evolutionary and Human Genomics
   Predoctoral Fellowship; National Key R&D Program of China
   [2016YFD0400800]; Edward Mallinckrodt Jr. Foundation; NIH [R33HL120757,
   U01HG009431, R01MH101814, R01HG008150]; Macular Degeneration Research
   Program of the BrightFocus Foundation; Foundation Fighting Blindness; 
   [T32EY20485];  [R01EY025790];  [P30EY026877]
FX This work was supported by a Stanford Center for Computational,
   Evolutionary and Human Genomics Predoctoral Fellowship and the National
   Key R&D Program of China (2016YFD0400800) (to B.L.); T32EY20485 (to
   M.A.C.); the Edward Mallinckrodt Jr. Foundation and NIH grants
   R33HL120757, U01HG009431, R01MH101814, and R01HG008150 (to S.B.M.); The
   Macular Degeneration Research Program of the BrightFocus Foundation, the
   Foundation Fighting Blindness, and R01EY025790 (to D.V.); and
   P30EY026877. D.B. is the Dolly Green Professor of Ophthalmology at UCLA.
   The authors thank 23andMe employees and participants for providing
   summary statistics for the myopia GWAS and Baidu USA for providing
   critical support to B.L.
CR Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Aledo R, 2001, HUM GENET, V109, P19, DOI 10.1007/s004390100554
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Ashikawa Y, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00266
   Barreiro LB, 2012, P NATL ACAD SCI USA, V109, P1204, DOI 10.1073/pnas.1115761109
   Benner C, 2016, BIOINFORMATICS, V32, P1493, DOI 10.1093/bioinformatics/btw018
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Browning BL, 2016, AM J HUM GENET, V98, P116, DOI 10.1016/j.ajhg.2015.11.020
   Browning BL, 2009, AM J HUM GENET, V85, P847, DOI 10.1016/j.ajhg.2009.11.004
   CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   Chen YH, 2014, NAT GENET, V46, P1115, DOI 10.1038/ng.3078
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Consugar MB, 2015, GENET MED, V17, P253, DOI 10.1038/gim.2014.172
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196
   Dobin A., 2012, BIOINFORMATICS, V29
   Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x
   Enzo E, 2015, EMBO J, V34, P1349, DOI 10.15252/embj.201490379
   Farkas MH, 2014, AM J PATHOL, V184, P2641, DOI 10.1016/j.ajpath.2014.06.026
   Finucane HK, 2018, NAT GENET, V50, P621, DOI 10.1038/s41588-018-0081-4
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gohil VM, 2010, NAT BIOTECHNOL, V28, P249, DOI 10.1038/nbt.1606
   Gusev A, 2014, AM J HUM GENET, V95, P535, DOI 10.1016/j.ajhg.2014.10.004
   Hanna RA, 2008, NATURE, V456, P409, DOI 10.1038/nature07451
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Hu J, 2010, METHODS MOL BIOL, V652, P55, DOI 10.1007/978-1-60327-325-1_2
   Jun G, 2012, AM J HUM GENET, V91, P839, DOI 10.1016/j.ajhg.2012.09.004
   Kanska J, 2017, ONCOTARGET, V8, P26200, DOI 10.18632/oncotarget.15429
   Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2
   Kiefer AK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003299
   Kumasaka N, 2016, NAT GENET, V48, P206, DOI 10.1038/ng.3467
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Li YI, 2018, NAT GENET, V50, P151, DOI 10.1038/s41588-017-0004-9
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Llavona P, 2017, GENES-BASEL, V8, DOI 10.3390/genes8100283
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Luo HBR, 1999, RNA, V5, P893, DOI 10.1017/S1355838299990520
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   McFadden SA, 2004, VISION RES, V44, P643, DOI 10.1016/j.visres.2003.11.002
   McKusick VA, 2007, AM J HUM GENET, V80, P588, DOI 10.1086/514346
   Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496
   Nadauld LD, 2006, P NATL ACAD SCI USA, V103, P13409, DOI 10.1073/pnas.0601634103
   Nakahara K, 2012, MOL CELL, V46, P461, DOI 10.1016/j.molcel.2012.04.033
   Nash BM, 2015, TRANSL PEDIATR, V4, P139, DOI 10.3978/j.issn.2224-4336.2015.04.03
   Nica AC, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0362
   Nickless A, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0153-7
   Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888
   NILSSON SEG, 1987, BRIT J OPHTHALMOL, V71, P224, DOI 10.1136/bjo.71.3.224
   Noh JH, 2016, GENE DEV, V30, P1224, DOI 10.1101/gad.276022.115
   Ongen H, 2016, BIOINFORMATICS, V32, P1479, DOI 10.1093/bioinformatics/btv722
   Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008
   Paunescu K, 2007, OPHTHALMOLOGY, V114, P1348, DOI 10.1016/j.ophtha.2006.10.034
   Peterson CB, 2016, BIOINFORMATICS, V32, P2556, DOI 10.1093/bioinformatics/btw198
   Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7
   Reinisalo M, 2012, MOL VIS, V18, P38
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   Ruzycki PA, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0732-z
   Sahu B, 2016, FORUM NUTR, V8, P746
   Samuel W, 2001, J BIOL CHEM, V276, P28744, DOI 10.1074/jbc.M103587200
   Samuel W, 2017, MOL VIS, V23, P60
   Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006
   Sergouniotis PI, 2011, OPHTHALMOLOGY, V118, P1661, DOI 10.1016/j.ophtha.2010.12.031
   Slowikowski K, 2014, BIOINFORMATICS, V30, P2496, DOI 10.1093/bioinformatics/btu326
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sundin OH, 2005, P NATL ACAD SCI USA, V102, P9553, DOI 10.1073/pnas.0501451102
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tanackovic G, 2011, HUM MOL GENET, V20, P2116, DOI 10.1093/hmg/ddr094
   Tedja MS, 2018, NAT GENET, V50, P834, DOI 10.1038/s41588-018-0127-7
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Vaclavik V, 2010, MOL VIS, V16, P467
   Vollrath D, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005723
   Yamamoto H, 2003, AM J OPHTHALMOL, V136, P572, DOI 10.1016/S0002-9394(03)00332-5
   Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707
   Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3
   Zhang Y, 2015, PROG MOL BIOL TRANSL, V134, P221, DOI 10.1016/bs.pmbts.2015.06.014
NR 92
TC 11
Z9 11
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD MAY 20
PY 2019
VL 2
AR 186
DI 10.1038/s42003-019-0430-6
PG 13
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA HZ5CX
UT WOS:000468869400001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rivera, JC
   Dabouz, R
   Noueihed, B
   Omri, S
   Tahiri, H
   Chemtob, S
AF Rivera, Jose Carlos
   Dabouz, Rabah
   Noueihed, Baraa
   Omri, Samy
   Tahiri, Houda
   Chemtob, Sylvain
TI Ischemic Retinopathies: Oxidative Stress and Inflammation
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; VITAMIN-C
   SUPPLEMENTATION; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; HIGH
   GLUCOSE; CELL APOPTOSIS; PRETERM INFANTS; TNF-ALPHA; MICROVASCULAR
   DEGENERATION
AB Ischemic retinopathies (IRs), such as retinopathy of prematurity (ROP), diabetic retinopathy (DR), and (in many cases) age-related macular degeneration (AMD), are ocular disorders characterized by an initial phase of microvascular changes that results in ischemia, followed by a second phase of abnormal neovascularization that may culminate into retinal detachment and blindness. IRs are complex retinal conditions in which several factors play a key role during the development of the different pathological stages of the disease. Increasing evidence reveals that oxidative stress and inflammatory processes are important contributors to the pathogenesis of IRs. Despite the beneficial effects of the photocoagulation and anti-VEGF therapy during neovascularization phase, the need to identify novel targets to prevent initial phases of these ocular pathologies is still needed. In this review, we provide an update on the involvement of oxidative stress and inflammation in the progression of IRs and address some therapeutic interventions by using antioxidants and anti- inflammatory agents.
C1 [Rivera, Jose Carlos; Dabouz, Rabah; Noueihed, Baraa; Omri, Samy; Tahiri, Houda; Chemtob, Sylvain] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Ophthalmol, Res Ctr, Montreal, PQ, Canada.
   [Rivera, Jose Carlos; Chemtob, Sylvain] CHU St Justine, Res Ctr, Dept Pediat Ophthalmol & Pharmacol, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Centre Hospitalier
   Universitaire Sainte-Justine
RP Rivera, JC (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp, Dept Ophthalmol, Res Ctr, Montreal, PQ, Canada.; Rivera, JC (通讯作者)，CHU St Justine, Res Ctr, Dept Pediat Ophthalmol & Pharmacol, Montreal, PQ, Canada.
EM jc.rivera@umontreal.ca
RI Dabouz, Rabah/AAC-6455-2020
OI Dabouz, Rabah/0000-0003-3572-428X
FU Canadian Institutes of Health Research
FX Sylvain Chemtob holds a Canada Research Chair (Translational Research in
   Vision) and the Leopoldine Wolfe Chair in translational research in
   age-related macular degeneration. Work related to ROP has been supported
   by Canadian Institutes of Health Research (Sylvain Chemtob).
CR Acar U, 2017, OCUL IMMUNOL INFLAMM, V25, P323, DOI 10.3109/09273948.2015.1116587
   Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   [Anonymous], 1995, CMAJ, V152, P1765
   Arden GB, 2001, BRIT J OPHTHALMOL, V85, P366, DOI 10.1136/bjo.85.3.366
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Avila-Vazquez Medardo, 2004, BMC Pediatr, V4, P15, DOI 10.1186/1471-2431-4-15
   Balazy M, 2008, PHARMACOL THERAPEUT, V119, P275, DOI 10.1016/j.pharmthera.2008.05.003
   Beauchamp MH, 2004, FREE RADICAL BIO MED, V37, P1885, DOI 10.1016/j.freeradbiomed.2004.09.008
   Beauchamp MH, 2002, INVEST OPHTH VIS SCI, V43, P3327
   Beauchamp MH, 2001, J APPL PHYSIOL, V90, P2279, DOI 10.1152/jappl.2001.90.6.2279
   Behl Y, 2008, AM J PATHOL, V172, P1411, DOI 10.2353/ajpath.2008.071070
   Behl Y, 2009, DIABETES, V58, P917, DOI 10.2337/db08-0537
   Bergamini C. M., CURRENT PHARM DESIGN, V10, P1611
   Berger TM, 1996, REDOX REP, V2, P257, DOI 10.1080/13510002.1996.11747058
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Brault S, 2007, AM J PHYSIOL-REG I, V292, pR1174, DOI 10.1152/ajpregu.00619.2006
   Brion LP., 2003, COCHRANE DB SYST REV, V(4), pCd003665, DOI [DOI 10.1002/14651858.CD003665, 10.1002/14651858.CD003665]
   Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Chen H, 2012, MOL VIS, V18, P1325
   Chen ML, 2011, INVEST OPHTH VIS SCI, V52, P7052, DOI 10.1167/iovs.11-7380
   Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Coll T, 2010, ENDOCRINOLOGY, V151, P537, DOI 10.1210/en.2009-0874
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Darlow BA, 2005, ARCH DIS CHILD-FETAL, V90, P117, DOI 10.1136/adc.2004.056440
   Dasu MR, 2008, DIABETES, V57, P3090, DOI 10.2337/db08-0564
   Dasu MR, 2011, AM J PHYSIOL-ENDOC M, V300, pE145, DOI 10.1152/ajpendo.00490.2010
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Gooyer TE, 2006, INVEST OPHTH VIS SCI, V47, P5561, DOI 10.1167/iovs.06-0647
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Devi TS, 2013, EXP CELL RES, V319, P1001, DOI 10.1016/j.yexcr.2013.01.012
   Dordelmann M, 2006, NEUROPEDIATRICS, V37, P130, DOI 10.1055/s-2006-924554
   Doyle LW, 2010, NEONATOLOGY, V98, P217, DOI 10.1159/000286210
   Droge W., PHYSL REV, V82, P47
   Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222
   Du YP, 2004, AM J PHYSIOL-REG I, V287, pR735, DOI 10.1152/ajpregu.00080.2003
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Ducharme E, 2008, EXPERT OPIN BIOL TH, V8, P491, DOI [10.1517/14712598.8.4.491, 10.1517/14712598.8.4.491 ]
   Edgar KS, 2015, AM J PATHOL, V185, P1769, DOI 10.1016/j.ajpath.2015.02.021
   ELASRAR AM, 1992, AM J OPHTHALMOL, V114, P731, DOI 10.1016/S0002-9394(14)74052-8
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Fulton AB, 2009, PROG RETIN EYE RES, V28, P452, DOI 10.1016/j.preteyeres.2009.06.003
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052
   Gergely K, 2010, BRATISL MED J, V111, P514
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066
   HAMIL BM, 1947, AM J DIS CHILD, V74, P417
   Hammes HP, 1997, DIABETOLOGIA, V40, P629, DOI 10.1007/s001250050726
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Haskins K, 2003, ANN NY ACAD SCI, V1005, P43, DOI 10.1196/annals.1288.006
   Hellgren G, 2010, NEONATOLOGY, V98, P409, DOI 10.1159/000317779
   Hellstrom A, 2003, PEDIATRICS, V112, P1016, DOI 10.1542/peds.112.5.1016
   Higgins RD, 1998, ARCH OPHTHALMOL-CHIC, V116, P601, DOI 10.1001/archopht.116.5.601
   HITTNER HM, 1984, OPHTHALMOLOGY, V91, P1512
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holmstrom G, 2015, ACTA OPHTHALMOL, V93, P265, DOI 10.1111/aos.12506
   Hong HK, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-87
   Honore JC, 2013, ARTERIOSCL THROM VAS, V33, P954, DOI 10.1161/ATVBAHA.112.300943
   Jariyapongskul A, 2007, MICROVASC RES, V74, P32, DOI 10.1016/j.mvr.2007.03.002
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Garcia-Medina JJ, 2011, EUR J OPHTHALMOL, V21, P637, DOI 10.5301/EJO.2010.6212
   Jialal I, 2012, CURR DIABETES REP, V12, P172, DOI 10.1007/s11892-012-0258-7
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Johnsen-Soriano S, 2008, FREE RADICAL RES, V42, P613, DOI 10.1080/10715760802206791
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2002, FASEB J, V16, P76, DOI 10.1096/fj.02-0157fje
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Joussen AM, 2009, MOL VIS, V15, P1418
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kempen J. H., ARCH OPHTHALMOLOGY, V122, P552
   Kermorvant-Duchemin E, 2005, NAT MED, V11, P1339, DOI 10.1038/nm1336
   Kern TS, 2015, J DIABETES INVEST, V6, P371, DOI 10.1111/jdi.12312
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim SH, 2013, MOL VIS, V19, P1667
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kowluru RA, 2004, INVEST OPHTH VIS SCI, V45, P4161, DOI 10.1167/iovs.04-0633
   Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kowluru RA, 2006, FREE RADICAL BIO MED, V41, P1191, DOI 10.1016/j.freeradbiomed.2006.01.012
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010
   Kumar B, 2012, OPHTHALMIC RES, V47, P103, DOI 10.1159/000330051
   Kutty R. K., MOL VISION, V22, P1156
   Lee J, 2012, SEMIN FETAL NEONAT M, V17, P26, DOI 10.1016/j.siny.2011.08.007
   Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168
   Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803
   Liu WH, 2010, J CELL PHYSIOL, V224, P775, DOI 10.1002/jcp.22180
   Liu XF, 2014, INFLAMMATION, V37, P1486, DOI 10.1007/s10753-014-9874-5
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Mayer-Davis EJ, 1998, OPHTHALMOLOGY, V105, P2264, DOI 10.1016/S0161-6420(98)91227-1
   Miceli M. V., EXPT CELL RES, V214, P242
   Millen AE, 2003, AM J EPIDEMIOL, V158, P225, DOI 10.1093/aje/kwg116
   Miwa K, 2003, DIABETES RES CLIN PR, V60, P1, DOI 10.1016/S0168-8227(02)00248-6
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   MOISON RM, 1995, PEDIATR RES, V37, pA343
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   MULLER DPR, 1992, EYE, V6, P221, DOI 10.1038/eye.1992.43
   Mustata GT, 2005, DIABETES, V54, P517, DOI 10.2337/diabetes.54.2.517
   Narayanan SP, 2013, PROG RETIN EYE RES, V36, P260, DOI 10.1016/j.preteyeres.2013.06.002
   NIELSEN JC, 1988, INVEST OPHTH VIS SCI, V29, P22
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Neill S, 2015, REDOX BIOL, V6, P135, DOI 10.1016/j.redox.2015.07.009
   Ogurtsova K, 2017, DIABETES RES CLIN PR, V128, P40, DOI 10.1016/j.diabres.2017.03.024
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162
   Pawlik D, 2014, JPEN-PARENTER ENTER, V38, P711, DOI 10.1177/0148607113499373
   Pazdro R, 2010, MECH AGEING DEV, V131, P276, DOI 10.1016/j.mad.2010.03.005
   Perrone S, 2010, J MATERN-FETAL NEO M, V23, P63, DOI 10.3109/14767058.2010.509940
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Powers MR, 2005, CURR EYE RES, V30, P299, DOI 10.1080/02713680590923276
   Qawasmi A, 2013, PEDIATRICS, V131, pE262, DOI 10.1542/peds.2012-0517
   Raju TNK, 1997, J PEDIATR-US, V131, P844, DOI 10.1016/S0022-3476(97)70031-3
   Ren JL, 2009, CELL SIGNAL, V21, P378, DOI 10.1016/j.cellsig.2008.10.011
   Rivera JC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0955-x
   Rivera JC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0943-1
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Rivera JC, 2011, NEONATOLOGY, V100, P343, DOI 10.1159/000330174
   Roberts LJ, 2005, BRAIN PATHOL, V15, P143
   Rodts-Palenik S, 2004, AM J OBSTET GYNECOL, V191, P1387, DOI 10.1016/j.ajog.2004.06.093
   Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241
   Roy S, 2017, AM J PATHOL, V187, P9, DOI 10.1016/j.ajpath.2016.08.022
   Rusnak S, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/424783
   Sahir N, 2004, J MOL NEUROSCI, V24, P201, DOI 10.1385/JMN:24:2:201
   Sapieha P, 2010, INT J BIOCHEM CELL B, V42, P5, DOI 10.1016/j.biocel.2009.10.006
   Sato T, 2009, OPHTHALMOLOGY, V116, P2165, DOI 10.1016/j.ophtha.2009.04.026
   Scarpulla RC, 2012, BBA-GENE REGUL MECH, V1819, P1088, DOI 10.1016/j.bbagrm.2011.10.011
   Schmidt B, 2007, NEW ENGL J MED, V357, P1893, DOI 10.1056/NEJMoa073679
   Semeraro F, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/582060
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898
   Shim So-Yeon, 2013, Korean J Pediatr, V56, P107, DOI 10.3345/kjp.2013.56.3.107
   Silveira RC, 2011, INVEST OPHTH VIS SCI, V52, P1297, DOI 10.1167/iovs.10-6279
   SILVERS KM, 1994, ARCH DIS CHILD-FETAL, V71, pF40, DOI 10.1136/fn.71.1.F40
   Silvers KM, 1998, ARCH DIS CHILD-FETAL, V78, pF214, DOI 10.1136/fn.78.3.F214
   Sivakumar V, 2011, J PATHOL, V224, P245, DOI 10.1002/path.2858
   Sluis K.B., P 14 ANN C AUSTR PER
   Sood BG, 2010, PEDIATR RES, V67, P394, DOI 10.1203/PDR.0b013e3181d01a36
   Soufi F. Ghadiri, CLIN EXPT PHARM PHYS, V42, P63
   Stark A. R., NEW ENGLAND J MED, V344, P95
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   STREETER ML, 1981, AM J CLIN NUTR, V34, P1706, DOI 10.1093/ajcn/34.9.1706
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tolsma KW, 2011, ARCH OPHTHALMOL-CHIC, V129, P1555, DOI 10.1001/archophthalmol.2011.319
   Tremblay S, 2013, INVEST OPHTH VIS SCI, V54, P8125, DOI 10.1167/iovs.13-12496
   Tsilimbaris Miltiadis K, 2007, Semin Ophthalmol, V22, P75, DOI 10.1080/08820530701418243
   Varma SD, 2010, MOL VIS, V16, P501
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Wang HB, 2013, JAMA OPHTHALMOL, V131, P80, DOI 10.1001/jamaophthalmol.2013.986
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Waterbury LD, 2006, CURR MED RES OPIN, V22, P1133, DOI 10.1185/030079906X112471
   Winkler BS, 1999, MOL VIS, V5
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wong TY, 2012, AM J OPHTHALMOL, V154, P6, DOI 10.1016/j.ajo.2012.03.013
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo J. M., MOL VISION, V18, P901
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Yamagishi S, 2012, BBA-GEN SUBJECTS, V1820, P663, DOI 10.1016/j.bbagen.2011.03.014
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yao Y, 2014, CELL MOL LIFE SCI, V71, P683, DOI 10.1007/s00018-013-1459-1
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Yoshimura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008158
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Yu HH, 2014, APMIS, V122, P818, DOI 10.1111/apm.12223
   Yulek F, 2007, ARCH MED RES, V38, P503, DOI 10.1016/j.arcmed.2007.02.006
   Zeng XX, 2000, VISUAL NEUROSCI, V17, P463, DOI 10.1017/S0952523800173122
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
   Zhang XY, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-27
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao SZ, 2015, MOL MED REP, V12, P6112, DOI 10.3892/mmr.2015.4164
   Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou TWE, 2016, AM J PATHOL, V186, P3100, DOI 10.1016/j.ajpath.2016.08.004
NR 207
TC 79
Z9 81
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 3940241
DI 10.1155/2017/3940241
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FR4RI
UT WOS:000419053000001
PM 29410732
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Lipinski, DM
   Reid, CA
   Boye, SL
   Peterson, JJ
   Qi, XP
   Boye, SE
   Boulton, ME
   Hauswirth, WW
AF Lipinski, Daniel M.
   Reid, Chris A.
   Boye, Sanford L.
   Peterson, James J.
   Qi, Xiaoping
   Boye, Shannon E.
   Boulton, Michael E.
   Hauswirth, William W.
TI Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus
   After Intravenous Injection
SO HUMAN GENE THERAPY
LA English
DT Article
ID ENDOTHELIAL DYSFUNCTION; GENE-TRANSFER; NITRIC-OXIDE; NEUTRALIZING
   ANTIBODIES; RECEPTOR ANTAGONISM; DIABETES-MELLITUS; AAV VECTORS;
   THERAPY; CELLS; HYPERTENSION
AB The ability to effectively deliver genetic material to vascular endothelial cells remains one of the greatest unmet challenges facing the development of gene therapies to prevent diseases with underlying vascular etiology, such as diabetes, atherosclerosis, and age-related macular degeneration. Herein, we assess the effectiveness of an rAAV2-based capsid mutant vector (Y272F, Y444F, Y500F, Y730F, T491V; termed QuadYF+TV) with strong endothelial cell tropism at transducing the vasculature after systemic administration. Intravenous injection of QuadYF+TV resulted in widespread transduction throughout the vasculature of several major organ systems, as assessed by in vivo bioluminescence imaging and postmortem histology. Robust transduction of lung tissue was observed in QuadYF+TV-injected mice, indicating a role for intravenous gene delivery in the treatment of chronic diseases presenting with pulmonary complications, such as (1)-antitrypsin deficiency. The QuadYF+TV vector cross-reacted strongly with AAV2 neutralizing antibodies, however, indicating that a targeted delivery strategy may be required to maximize clinical translatability.
C1 [Lipinski, Daniel M.; Reid, Chris A.; Boye, Sanford L.; Peterson, James J.; Boye, Shannon E.; Hauswirth, William W.] Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Lipinski, Daniel M.] Univ Oxford, Nuffield Lab Ophthalmol, Dept Clin Neurosci, Oxford OX2 6AW, England.
   [Qi, Xiaoping; Boulton, Michael E.] Indiana Univ, Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN USA.
C3 State University System of Florida; University of Florida; University of
   Oxford; Indiana University System; Indiana University Bloomington;
   Indiana University-Purdue University Indianapolis
RP Lipinski, DM (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
EM dlipinski@ufl.edu
OI Reid, Christopher/0000-0001-9816-7244; Lipinski,
   Daniel/0000-0001-7828-614X; Boye, Shannon/0000-0002-7312-3197;
   hauswirth, william/0000-0002-3244-4947
FU Juvenile Diabetes Research Foundation (JDRF) [1-PNF-20140120-A-N]; NIH
   [P30EY021721]; Macular Vision Research Foundation; Foundation Fighting
   Blindness; Overstreet Fund; Research to Prevent Blindness, Inc.;
   Fulbright-Fight for Sight UK Research Scholarship [1396]; Research to
   Prevent Blindness;  [R01 EY024280];  [EY018358]; NATIONAL EYE INSTITUTE
   [R01EY024280, P30EY021721, R01EY018358] Funding Source: NIH RePORTER
FX Funding was contributed by the Juvenile Diabetes Research Foundation
   (JDRF; Innovative grant 1-PNF-20140120-A-N); by NIH grant P30EY021721;
   and by the Macular Vision Research Foundation, Foundation Fighting
   Blindness, Overstreet Fund, and Research to Prevent Blindness, Inc.
   D.M.L. was funded through a Fulbright-Fight for Sight UK Research
   Scholarship (#1396); S.E.B. was funded by the Foundation Fighting
   Blindness and by R01 EY024280. M.E.B. was funded by EY018358 and by a
   Research to Prevent Blindness unrestricted grant. The authors thank Dr.
   W. Clay Smith for providing the rabbit anti-GFP antibody and the Retinal
   Gene Therapy Vector Laboratory (University of Florida) for AAV vector
   production. Technical assistance from Jingfen Sun, Yuping Sun, and
   Zhonghong Zhang is also gratefully acknowledged. D.M.L. also
   acknowledges Dr. Bally for assistance during the preparation of this
   manuscript.
CR Aslanidi G, 2009, P NATL ACAD SCI USA, V106, P5059, DOI 10.1073/pnas.0810614106
   Bello A, 2014, SCI REP-UK, V4, DOI 10.1038/srep06644
   Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842
   Boye SE, 2012, HUM GENE THER, V23, P1101, DOI 10.1089/hum.2012.125
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200
   Chen SF, 2005, HUM GENE THER, V16, P235, DOI 10.1089/hum.2005.16.235
   Clement N, 2009, HUM GENE THER, V20, P796, DOI 10.1089/hum.2009.094
   Hadi HAR, 2005, VASC HEALTH RISK MAN, V1, P183
   Halbert CL, 2006, HUM GENE THER, V17, P440, DOI 10.1089/hum.2006.17.440
   Hamilton Sandra J, 2013, Rev Diabet Stud, V10, P133, DOI 10.1900/RDS.2013.10.133
   Heitzer T, 2000, DIABETOLOGIA, V43, P1435, DOI 10.1007/s001250051551
   Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983
   Higashi Y, 2002, AM J HYPERTENS, V15, P326, DOI 10.1016/S0895-7061(01)02317-2
   Hornig B, 2001, CIRCULATION, V103, P799, DOI 10.1161/01.CIR.103.6.799
   Huda F, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.32
   Hurlbut GD, 2010, MOL THER, V18, P1983, DOI 10.1038/mt.2010.175
   Iida A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/974819
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   Li CW, 2012, J VIROL, V86, P7752, DOI 10.1128/JVI.00675-12
   Li HG, 2014, ATHEROSCLEROSIS, V237, P208, DOI 10.1016/j.atherosclerosis.2014.09.001
   Lu ZH, 2014, LAB INVEST, V94, P881, DOI 10.1038/labinvest.2014.78
   Manickan E, 2006, MOL THER, V13, P108, DOI 10.1016/j.ymthe.2005.08.007
   Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358
   McFarlane R, 1999, DIABETIC MED, V16, P62, DOI 10.1046/j.1464-5491.1999.00021.x
   Mingozzi F, 2013, GENE THER, V20, P417, DOI 10.1038/gt.2012.55
   Mingozzi F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005795
   Monteilhet V, 2011, MOL THER, V19, P2084, DOI 10.1038/mt.2011.108
   Mori S, 2006, JPN J INFECT DIS, V59, P285
   Moskalenko M, 2000, J VIROL, V74, P1761, DOI 10.1128/JVI.74.4.1761-1766.2000
   Nettelbeck DM, 2001, MOL THER, V3, P882, DOI 10.1006/mthe.2001.0342
   Ogura T, 2006, J GENE MED, V8, P990, DOI 10.1002/jgm.916
   Petrs-Silva H, 2009, MOL THER, V17, P463, DOI 10.1038/mt.2008.269
   Pistrosch F, 2004, DIABETES CARE, V27, P484, DOI 10.2337/diacare.27.2.484
   Prasad A, 2000, CIRCULATION, V101, P2349, DOI 10.1161/01.CIR.101.20.2349
   Puddu P, 2000, ACTA CARDIOL, V55, P221, DOI 10.2143/AC.55.4.2005744
   Qiao CP, 2010, HUM GENE THER, V21, P1343, DOI 10.1089/hum.2010.003
   Quyyumi AA, 1997, J AM COLL CARDIOL, V30, P1220, DOI 10.1016/S0735-1097(97)00279-9
   Ryals RC, 2011, MOL VIS, V17, P1090
   Schiedner G, 2003, HUM GENE THER, V14, P1631, DOI 10.1089/104303403322542275
   Schiffrin EL, 2000, CIRCULATION, V101, P1653
   Schiffrin EL, 1996, J CARDIOVASC PHARM, V27, pS13
   Smith RH, 2009, MOL THER, V17, P1888, DOI 10.1038/mt.2009.128
   Stasi R, 2004, MAYO CLIN PROC, V79, P504, DOI 10.4065/79.4.504
   Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131
   Tian XL, 2014, J GENET GENOMICS, V41, P485, DOI 10.1016/j.jgg.2014.08.001
   Tseng YS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00009
   YAMASHITA T, 1980, Okajimas Folia Anatomica Japonica, V56, P329
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
NR 48
TC 9
Z9 9
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD NOV 1
PY 2015
VL 26
IS 11
BP 767
EP 776
DI 10.1089/hum.2015.097
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA CV6SQ
UT WOS:000364401200006
PM 26359319
OA Green Published
DA 2022-11-30
ER

PT J
AU Shepard, AR
   Conrow, RE
   Pang, IH
   Jacobson, N
   Rezwan, M
   Rutschmann, K
   Auerbach, D
   SriRamaratnam, R
   Cornish, VW
AF Shepard, Allan R.
   Conrow, Raymond E.
   Pang, Iok-Hou
   Jacobson, Nasreen
   Rezwan, Mandana
   Rutschmann, Katrin
   Auerbach, Daniel
   SriRamaratnam, Rohitha
   Cornish, Virginia W.
TI Identification of PDE6D as a Molecular Target of Anecortave Acetate via
   a Methotrexate-Anchored Yeast Three-Hybrid Screen
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID PRENYL-BINDING PROTEIN; MACULAR DEGENERATION; INTRAOCULAR-PRESSURE;
   DELTA-SUBUNIT; CHOROIDAL NEOVASCULARIZATION; CATALYTIC SUBUNITS;
   CLINICAL-OUTCOMES; RECEPTOR; SYSTEM; GLAUCOMA
AB Glaucoma and age-related macular degeneration are ocular diseases targeted clinically by anecortave acetate (AA). AA and its deacetylated metabolite, anecortave desacetate (AdesA), are intraocular pressure (IOP)-lowering and angiostatic cortisenes devoid of glucocorticoid activity but with an unknown mechanism of action. We used a methotrexate-anchored yeast three-hybrid (Y3H) technology to search for binding targets for AA in human trabecular meshwork (TM) cells, the target cell type that controls IOP, a major risk factor in glaucoma. Y3H hits were filtered by competitive Y3H screens and coimmunoprecipitation experiments and verified by surface plasmon resonance analysis to yield a single target, phosphodiesterase 6-delta (PDE6D). PDE6D is a prenyl-binding protein with additional function outside the PDE6 phototransduction system. Overexpression of PDE6D in mouse eyes caused elevated IOP, and this elevation was reversed by topical ocular application of either AA or AdesA. The identification of PDE6D as the molecular binding partner of AA provides insight into the role of this drug candidate in treating glaucoma.
C1 [Shepard, Allan R.; Conrow, Raymond E.; Pang, Iok-Hou; Jacobson, Nasreen] Alcon Labs Inc, Ft Worth, TX 76134 USA.
   [Rezwan, Mandana; Rutschmann, Katrin; Auerbach, Daniel] Dualsyst Biotech AG, Schlieren, Switzerland.
   [SriRamaratnam, Rohitha; Cornish, Virginia W.] Columbia Univ, Dept Chem, New York, NY 10027 USA.
C3 Novartis; Alcon; Columbia University
RP Shepard, AR (通讯作者)，Alcon Labs Inc, Ft Worth, TX 76134 USA.
EM allan.shepard@novartis.com; vc114@columbia.edu
FU Alcon Research, Ltd.
FX We acknowledge B. Zimmermann and colleagues at Biaffin GmbH & Co. KG for
   the surface plasmon resonance work, AMRI for CID synthesis, and J.C.
   Millar for help with the in vivo analysis of Ad.PDE6D. This study was
   wholly supported by Alcon Research, Ltd.
CR Abida WM, 2002, CHEMBIOCHEM, V3, P887, DOI 10.1002/1439-7633(20020902)3:9<887::AID-CBIC887>3.0.CO;2-F
   Althoff EA, 2002, ANGEW CHEM INT EDIT, V41, P2327, DOI 10.1002/1521-3773(20020703)41:13<2327::AID-ANIE2327>3.0.CO;2-U
   Augustin A, 2006, CLIN INTERV AGING, V1, P237, DOI 10.2147/ciia.2006.1.3.237
   Becker F, 2004, CHEM BIOL, V11, P211, DOI 10.1016/j.chembiol.2004.02.001
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bot I, 2011, ATHEROSCLEROSIS, V214, P295, DOI 10.1016/j.atherosclerosis.2010.11.008
   Bruckner A, 2009, INT J MOL SCI, V10, P2763, DOI 10.3390/ijms10062763
   Caligluri M, 2005, CHEM BIOL, V12, P1103, DOI 10.1016/j.chembiol.2005.08.008
   Candia OA, 2010, ARCH OPHTHALMOL-CHIC, V128, P338, DOI 10.1001/archophthalmol.2009.387
   Chidley C, 2011, NAT CHEM BIOL, V7, P375, DOI [10.1038/nchembio.557, 10.1038/NCHEMBIO.557]
   Clark AF, 2007, SURV OPHTHALMOL, V52, pS26, DOI 10.1016/j.survophthal.2006.11.003
   Conrow RE, 2002, J ORG CHEM, V67, P6835, DOI 10.1021/jo020282g
   Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l
   Dadvar P, 2009, MOL BIOSYST, V5, P472, DOI 10.1039/b815709j
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0
   Gallant JA, 1998, P NATL ACAD SCI USA, V95, P13771, DOI 10.1073/pnas.95.23.13771
   GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245
   Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095
   Henthorn DC, 2002, BIOCHEM PHARMACOL, V63, P1619, DOI 10.1016/S0006-2952(02)00884-5
   Hoyng P F, 1989, Prog Clin Biol Res, V312, P369
   Klais CM, 2006, RETINA-J RET VIT DIS, V26, P773, DOI 10.1097/01.iae.0000244261.52901.67
   Kley N, 2004, CHEM BIOL, V11, P599, DOI 10.1016/j.chembiol.2003.09.017
   Lefurgy S, 2004, CHEM BIOL, V11, P151, DOI 10.1016/j.chembiol.2004.02.005
   Nicolas L, 2008, EXPERT OPIN THER TAR, V12, P505, DOI [10.1517/14728222.12.4.505 , 10.1517/14728222.12.4.505]
   Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817
   Lin HN, 2000, J AM CHEM SOC, V122, P4247, DOI 10.1021/ja9941532
   Liu Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr600
   Millar JC, 2008, MOL VIS, V14, P10
   Missel P, 2010, J OCUL PHARMACOL TH, V26, P137, DOI 10.1089/jop.2009.0132
   Nikolova S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-146
   PANG IH, 1994, CURR EYE RES, V13, P51, DOI 10.3109/02713689409042398
   Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C
   Prata TS, 2010, J GLAUCOMA, V19, P488, DOI 10.1097/IJG.0b013e3181c4b0e8
   Rao VP, 2007, BIODRUGS, V21, P167, DOI 10.2165/00063030-200721030-00004
   Robin AL, 2009, AM J OPHTHALMOL, V147, P45, DOI 10.1016/j.ajo.2008.07.039
   Robin AL, 2009, ARCH OPHTHALMOL-CHIC, V127, P173, DOI 10.1001/archophthalmol.2008.595
   Robinson CR, 1998, P NATL ACAD SCI USA, V95, P5929, DOI 10.1073/pnas.95.11.5929
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Shepard AR, 2007, HUM MOL GENET, V16, P609, DOI 10.1093/hmg/ddm001
   Shepard AR, 2010, INVEST OPHTH VIS SCI, V51, P2067, DOI 10.1167/iovs.09-4567
   Wilson SJ, 2006, J BIOL CHEM, V281, P11780, DOI 10.1074/jbc.M513110200
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Zhang H, 2007, P NATL ACAD SCI USA, V104, P8857, DOI 10.1073/pnas.0701681104
   Zhang HB, 2005, METHOD ENZYMOL, V403, P42, DOI 10.1016/S0076-6879(05)03005-3
   Zhang HB, 2004, J BIOL CHEM, V279, P407, DOI 10.1074/jbc.M306559200
NR 48
TC 12
Z9 13
U1 0
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD MAR
PY 2013
VL 8
IS 3
BP 549
EP 558
DI 10.1021/cb300296m
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 109NO
UT WOS:000316375500011
PM 23301619
DA 2022-11-30
ER

PT J
AU Pyne, NJ
   Dubois, G
   Pyne, S
AF Pyne, Nigel J.
   Dubois, Gerald
   Pyne, Susan
TI Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Review
DE Sphingosine 1-phosphate; Lysophosphatidic acid; Fibrosis; TGF beta;
   Signalling; Connective tissue growth factor
ID TISSUE GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATIC
   STELLATE CELLS; ACTIVATED-RECEPTOR-GAMMA; BREAST-CANCER-CELLS;
   IDIOPATHIC PULMONARY-FIBROSIS; LIPID PHOSPHATE PHOSPHATASES; VASCULAR
   ENDOTHELIAL-CELLS; HUMAN MONOCYTE CHEMOTAXIS; CL-CURRENT ACTIVITY
AB This review highlights an emerging role for sphingosine 1-phosphate (SIP) and lysophosphatidic acid (LPA) in many different types of fibrosis. Indeed, both LPA and SIP are involved in the multi-process pathogenesis of fibrosis, being implicated in promoting the well-established process of differentiation of fibroblasts to myofibroblasts and the more controversial epithelial-mesenchymal transition and homing of fibrocytes to fibrotic lesions. Therefore, targeting the production of these bioactive lysolipids or blocking their sites/mechanisms of action has therapeutic potential. Indeed, LPA receptor 1 (LPA(1)) selective antagonists are currently being developed for the treatment of fibrosis of the lung as well as a neutralising anti-Si P antibody that is currently in Phase 1 clinical trials for treatment of age related macular degeneration. Thus, LPA- and Sip-directed therapeutics may not be too far from the clinic. This article is part of a Special Issue entitled Advances in Lysophospholipid Research. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Pyne, Nigel J.; Pyne, Susan] Univ Strathclyde, Cell Biol Grp, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland.
   [Dubois, Gerald] Novartis Inst Biomed Res, Horsham, W Sussex, England.
C3 University of Strathclyde; Novartis
RP Pyne, S (通讯作者)，Univ Strathclyde, Cell Biol Grp, Strathclyde Inst Pharm & Biomed Sci, 161 Cathedral St, Glasgow G4 0RE, Lanark, Scotland.
EM n.j.pyne@strath.ac.uk; gerald.dubois@novartis.com;
   susan.pyne@strath.ac.uk
OI Pyne, Nigel/0000-0002-5657-4578; Pyne, Susan/0000-0002-6608-9584
CR Abers HMHG, 2011, J MED CHEM, V54, P4619, DOI 10.1021/jm200310q
   Albers HMHG, 2010, P NATL ACAD SCI USA, V107, P7257, DOI 10.1073/pnas.1001529107
   Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128
   Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje
   Aoki J, 2008, BBA-MOL CELL BIOL L, V1781, P513, DOI 10.1016/j.bbalip.2008.06.005
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Bu Shizhong, 2006, FASEB J, V20, P184
   Bu SZ, 2010, ARTHRITIS RHEUM-US, V62, P2117, DOI 10.1002/art.27463
   Bu S, 2008, J BIOL CHEM, V283, P19593, DOI 10.1074/jbc.M802417200
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cabello-Verrugio C, 2011, CELL SIGNAL, V23, P449, DOI 10.1016/j.cellsig.2010.10.019
   Canbay A, 2004, HEPATOLOGY, V39, P273, DOI 10.1002/hep.20051
   Carnevale KA, 2001, J IMMUNOL, V167, P3414, DOI 10.4049/jimmunol.167.6.3414
   Castelino FV, 2011, ARTHRITIS RHEUM-US, V63, P1405, DOI 10.1002/art.30262
   Cencetti F, 2010, MOL BIOL CELL, V21, P1111, DOI 10.1091/mbc.E09-09-0812
   Chun J, 2010, PHARMACOL REV, V62, P579, DOI 10.1124/pr.110.003111
   Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200
   Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200
   Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200
   Dhami R, 2010, CELL PHYSIOL BIOCHEM, V26, P749, DOI 10.1159/000322342
   French KJ, 2003, CANCER RES, V63, P5962
   Gallois C, 2000, ANN NY ACAD SCI, V905, P311
   Gan L, 2011, BIOCHEM BIOPH RES CO, V409, P7, DOI 10.1016/j.bbrc.2011.04.084
   Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056
   Giacomini MM, 2012, EXP CELL RES, V318, P716, DOI 10.1016/j.yexcr.2012.01.020
   Goppelt-Struebe M, 2001, J CLIN PATHOL-MOL PA, V54, P176, DOI 10.1136/mp.54.3.176
   Gorshkova I, 2012, J LIPID RES, V53, P1553, DOI 10.1194/jlr.M026039
   Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje
   Graness A, 2006, KIDNEY INT, V69, P1341, DOI 10.1038/sj.ki.5000296
   Grieb G, 2011, INT REV CEL MOL BIO, V291, P1, DOI 10.1016/B978-0-12-386035-4.00001-X
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359
   Hansen MC, 2013, SCIENCE, V342, P850, DOI [10.1126/science.1244693, 10.1126/science.1215904]
   Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847
   Hausmann J, 2011, NAT STRUCT MOL BIOL, V18, P198, DOI 10.1038/nsmb.1980
   Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173
   Henson PM, 2003, AM J RESP CELL MOL, V29, pS70
   Hiramatsu T, 2003, J BIOL CHEM, V278, P49438, DOI 10.1074/jbc.M213018200
   Hisano Y, 2011, J BIOL CHEM, V286, P1758, DOI 10.1074/jbc.M110.171116
   Hong KM, 2007, J BIOL CHEM, V282, P22910, DOI 10.1074/jbc.M703597200
   Huang L, 2011, AM J RESP CRIT CARE, V183, pA2152
   Humphreys BD, 2010, AM J PATHOL, V176, P85, DOI 10.2353/ajpath.2010.090517
   Huwiler A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022436
   Igarashi J, 2009, AM J PHYSIOL-CELL PH, V297, pC1263, DOI 10.1152/ajpcell.00109.2009
   Ikeda H, 1998, BIOCHEM BIOPH RES CO, V248, P436, DOI 10.1006/bbrc.1998.8983
   Ikeda H, 2003, AM J PHYSIOL-GASTR L, V285, pG880, DOI 10.1152/ajpgi.00039.2003
   Ikeda H, 2009, J LIPID RES, V50, P556, DOI 10.1194/jlr.M800496-JLR200
   Ikegami T, 2007, CELLS TISSUES ORGANS, V185, P213, DOI 10.1159/000101322
   Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018
   Iwazu Y, 2011, J HYPERTENS, V29, P2440, DOI 10.1097/HJH.0b013e32834c31f5
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kano K., 2000, J ANTIBIOT TOKYO, V53, P459
   Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664
   Keller CD, 2007, AM J PATHOL, V170, P281, DOI 10.2353/ajpath.2007.060485
   Kim JY, 2005, TRANSPLANTATION, V80, P1323, DOI 10.1097/01.tp.0000189709.21474.33
   King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4
   Kisseleva T, 2006, J HEPATOL, V45, P429, DOI 10.1016/j.jhep.2006.04.014
   Koide Y, 2007, J MED CHEM, V50, P442, DOI 10.1021/jm060834d
   Kono K, 2001, J ANTIBIOT, V54, P415, DOI 10.7164/antibiotics.54.415
   Kono K, 2000, J ANTIBIOT, V53, P759, DOI 10.7164/antibiotics.53.759
   Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC
   Kumar A, 2009, EXPERT OPIN THER TAR, V13, P1013, DOI 10.1517/14728220903039722
   Kuwano K, 2004, HISTOL HISTOPATHOL, V19, P867, DOI 10.14670/HH-19.867
   Lakota K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3827
   Lei WW, 2010, INT J BIOCHEM CELL B, V42, P1489, DOI 10.1016/j.biocel.2010.05.006
   Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028
   Li CY, 2009, AM J PATHOL, V175, P1464, DOI 10.2353/ajpath.2009.090037
   Li CY, 2009, J HEPATOL, V50, P1174, DOI 10.1016/j.jhep.2009.01.028
   Li MH, 2008, MOL CANCER RES, V6, P1649, DOI 10.1158/1541-7786.MCR-07-2048
   Lim KG, 2011, J BIOL CHEM, V286, P18633, DOI 10.1074/jbc.M111.220756
   Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433
   Liu XH, 2011, J CELL PHYSIOL, V226, P2370, DOI 10.1002/jcp.22572
   Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945
   Loveridge C, 2010, J BIOL CHEM, V285, P38841, DOI 10.1074/jbc.M110.127993
   Maceyka M, 2008, MOL CELL BIOL, V28, P5687, DOI 10.1128/MCB.00465-08
   Marumo T, 2010, AM J PHYSIOL-RENAL, V298, pF133, DOI 10.1152/ajprenal.00400.2009
   Meerschaert K, 1998, EMBO J, V17, P5923, DOI 10.1093/emboj/17.20.5923
   Messadi DV, 2004, ARCH DERMATOL RES, V296, P125, DOI 10.1007/s00403-004-0487-y
   Milara J, 2012, THORAX, V67, P147, DOI 10.1136/thoraxjnl-2011-200026
   Mintzer E, 2006, BBA-BIOMEMBRANES, V1758, P85, DOI 10.1016/j.bbamem.2005.12.009
   Mishra RS, 2008, J EXP MED, V205, P347, DOI 10.1084/jem.20071243
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0
   Nakagawa H, 2011, CLIN CHIM ACTA, V412, P1201, DOI 10.1016/j.cca.2011.03.014
   Nishimasu H, 2011, NAT STRUCT MOL BIOL, V18, P205, DOI 10.1038/nsmb.1998
   Oikonomou N, 2009, THORAX, V64, P467, DOI 10.1136/thx.2008.107946
   Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2
   Pchejetski D., 2011, EUR HEART J
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Pitkin SL, 2010, PHARMACOL REV, V62, P331, DOI 10.1124/pr.110.002949
   Pradere JP, 2007, J AM SOC NEPHROL, V18, P3110, DOI 10.1681/ASN.2007020196
   Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875
   Pyne S, 2005, BIOCHEM SOC T, V33, P1370, DOI 10.1042/BST0331370
   Pyne S, 2011, TRENDS MOL MED, V17, P463, DOI 10.1016/j.molmed.2011.03.002
   Pyne S, 2009, CELL SIGNAL, V21, P14, DOI 10.1016/j.cellsig.2008.08.008
   Quan H, 2011, CELL PHYSIOL BIOCHEM, V27, P91, DOI 10.1159/000325209
   Ratajczak MZ, 2010, LEUKEMIA, V24, P976, DOI 10.1038/leu.2010.53
   Ren SY, 2009, KIDNEY INT, V76, P857, DOI 10.1038/ki.2009.297
   Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108
   Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200
   Sanchez T, 2007, ARTERIOSCL THROM VAS, V27, P1312, DOI 10.1161/ATVBAHA.107.143735
   Sato K, 2007, J NEUROCHEM, V103, P2610, DOI 10.1111/j.1471-4159.2007.04958.x
   Sato M, 2003, J BIOL CHEM, V278, P9276, DOI 10.1074/jbc.M211529200
   Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380
   Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812
   Shea BS, 2010, AM J RESP CELL MOL, V43, P662, DOI 10.1165/rcmb.2009-0345OC
   Sime PJ, 2008, J INVEST MED, V56, P534, DOI 10.2310/JIM.0b013e31816464e9
   Sonoda H, 2002, J BIOL CHEM, V277, P34254, DOI 10.1074/jbc.M201659200
   Strub GM, 2011, FASEB J, V25, P600, DOI 10.1096/fj.10-167502
   Swaney JS, 2011, J PHARMACOL EXP THER, V336, P693, DOI 10.1124/jpet.110.175901
   Swaney JS, 2010, BRIT J PHARMACOL, V160, P1699, DOI 10.1111/j.1476-5381.2010.00828.x
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162
   Takuwa N, 2010, CARDIOVASC RES, V85, P484, DOI 10.1093/cvr/cvp312
   Tangkijvanich P, 2002, EXP CELL RES, V281, P140, DOI 10.1006/excr.2002.5657
   Taura K, 2010, HEPATOLOGY, V51, P1027, DOI 10.1002/hep.23368
   Tigyi G., 2011, BRIT J PHARMACOL, V161, P241
   Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200
   Tokumura A, 2009, INT J MED SCI, V6, P168
   Tomar A, 2009, J BIOL CHEM, V284, P35278, DOI 10.1074/jbc.C109.060830
   Tonelli F, 2010, CELL SIGNAL, V22, P1536, DOI 10.1016/j.cellsig.2010.05.022
   Tsukahara T, 2006, J BIOL CHEM, V281, P3398, DOI 10.1074/jbc.M510843200
   Uhal BD, 2003, EUR RESPIR J, V22, p7S, DOI 10.1183/09031936.03.00000303
   Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026
   Valentine WJ, 2010, CELL SIGNAL, V22, P1543, DOI 10.1016/j.cellsig.2010.05.023
   Vial C, 2008, J CELL PHYSIOL, V215, P410, DOI 10.1002/jcp.21324
   Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023
   Wang JC, 2008, LEUKEMIA LYMPHOMA, V49, P2321, DOI 10.1080/10428190802527699
   Watanabe N, 2007, LIFE SCI, V81, P1009, DOI 10.1016/j.lfs.2007.08.013
   Watanabe N, 2007, J CLIN GASTROENTEROL, V41, P616, DOI 10.1097/01.mcg.0000225642.90898.0e
   Wu Z, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-1
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Xin CY, 2006, BRIT J PHARMACOL, V147, P164, DOI 10.1038/sj.bjp.0706452
   Xu MY, 2009, AM J PATHOL, V174, P1264, DOI 10.2353/ajpath.2009.080160
   Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200
   Yin ZH, 2008, AM J PHYSIOL-CELL PH, V294, pC535, DOI 10.1152/ajpcell.00291.2007
   Yin ZH, 2010, RHEUMATOLOGY, V49, P2290, DOI 10.1093/rheumatology/keq260
   Zhang F, 2012, CELL SIGNAL, V24, P596, DOI 10.1016/j.cellsig.2011.11.008
NR 141
TC 42
Z9 43
U1 1
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 0006-3002
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD JAN
PY 2013
VL 1831
IS 1
SI SI
BP 228
EP 238
DI 10.1016/j.bbalip.2012.07.003
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 044CI
UT WOS:000311596600027
PM 22801038
DA 2022-11-30
ER

PT J
AU Katschke, KJ
   Wu, P
   Ganesan, R
   Kelley, RF
   Mathieu, MA
   Hass, PE
   Murray, J
   Kirchhofer, D
   Wiesmann, C
   Campagne, MV
AF Katschke, Kenneth J., Jr.
   Wu, Ping
   Ganesan, Rajkumar
   Kelley, Robert F.
   Mathieu, Mary A.
   Hass, Philip E.
   Murray, Jeremy
   Kirchhofer, Daniel
   Wiesmann, Christian
   Campagne, Menno van Lookeren
TI Inhibiting Alternative Pathway Complement Activation by Targeting the
   Factor D Exosite
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID D MONOCLONAL-ANTIBODY; MACULAR DEGENERATION; CARDIOPULMONARY BYPASS;
   PROTEIN FAMILY; INSIGHT; MECHANISM; SYSTEM; C3B; REFINEMENT; COMPSTATIN
AB By virtue of its amplifying property, the alternative complement pathway has been implicated in a number of inflammatory diseases and constitutes an attractive therapeutic target. An anti-factor D Fab fragment (AFD) was generated to inhibit the alternative complement pathway in advanced dry age-related macular degeneration. AFD potently prevented factor D (FD)-mediated proteolytic activation of its macromolecular substrate C3bB, but not proteolysis of a small synthetic substrate, indicating that AFD did not block access of the substrate to the catalytic site. The crystal structures of AFD in complex with human and cynomolgus FD (at 2.4 and 2.3 angstrom, respectively) revealed the molecular details of the inhibitory mechanism. The structures show that the AFD-binding site includes surface loops of FD that form part of the FD exosite. Thus, AFD inhibits FD proteolytic function by interfering with macromolecular substrate access rather than by inhibiting FD catalysis, providing the molecular basis of AFD-mediated inhibition of a rate-limiting step in the alternative complement pathway.
C1 [Katschke, Kenneth J., Jr.; Campagne, Menno van Lookeren] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
   [Ganesan, Rajkumar; Kirchhofer, Daniel] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA.
   [Kelley, Robert F.; Mathieu, Mary A.] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA.
   [Hass, Philip E.] Genentech Inc, Dept Biol Chem, San Francisco, CA 94080 USA.
   [Wu, Ping; Murray, Jeremy; Wiesmann, Christian] Genentech Inc, Dept Biol Struct, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech; Roche Holding; Genentech
RP Campagne, MV (通讯作者)，Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
EM menno@gene.com
RI Ganesan, Rajkumar/B-1093-2008
OI Ganesan, Rajkumar/0000-0002-3431-9664; Wiesmann,
   Christian/0000-0002-4092-9880
CR BARNUM SR, 1984, J IMMUNOL METHODS, V67, P303, DOI 10.1016/0022-1759(84)90470-8
   Chen H, 2010, P NATL ACAD SCI USA, V107, P17621, DOI 10.1073/pnas.1003750107
   Cole LB, 1997, ACTA CRYSTALLOGR D, V53, P143, DOI 10.1107/S0907444996012991
   Cole LB, 1998, ACTA CRYSTALLOGR D, V54, P711, DOI 10.1107/S0907444997010457
   DeLano WL., 2002, CCP4 NEWSL PROTEIN C
   Farady CJ, 2007, J MOL BIOL, V369, P1041, DOI 10.1016/j.jmb.2007.03.078
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Fredslund F, 2008, NAT IMMUNOL, V9, P753, DOI 10.1038/ni.1625
   Fung M, 2001, J THORAC CARDIOV SUR, V122, P113, DOI 10.1067/mtc.2001.114777
   Ganesan R, 2011, MOL CANCER RES, V9, P1175, DOI 10.1158/1541-7786.MCR-11-0004
   Ganesan R, 2010, BIOCHEM J, V430, P179, DOI 10.1042/BJ20100634
   Garcia BL, 2012, J BIOL CHEM, V287, P628, DOI 10.1074/jbc.M111.298984
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Jing H, 1998, J MOL BIOL, V282, P1061, DOI 10.1006/jmbi.1998.2089
   Katschke KJ, 2009, J BIOL CHEM, V284, P10473, DOI 10.1074/jbc.M809106200
   KIM SH, 1995, J IMMUNOL, V154, P6073
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   NARAYANA SVL, 1994, J MOL BIOL, V235, P695, DOI 10.1006/jmbi.1994.1021
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2009, J IMMUNOL, V183, P2565, DOI 10.4049/jimmunol.0901443
   Rooijakkers SHM, 2009, NAT IMMUNOL, V10, P721, DOI 10.1038/ni.1756
   Roversi P, 2007, J MOL BIOL, V369, P784, DOI 10.1016/j.jmb.2007.03.064
   SANDERS PW, 1986, J CLIN INVEST, V77, P1299, DOI 10.1172/JCI112434
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Tanhehco EJ, 1999, TRANSPLANT P, V31, P2168, DOI 10.1016/S0041-1345(99)00297-3
   Undar A, 2002, ANN THORAC SURG, V74, P355, DOI 10.1016/S0003-4975(02)03656-1
   Undar A, 2002, EUR J CARDIO-THORAC, V22, P330, DOI 10.1016/S1010-7940(02)00298-1
   VOLANAKIS JE, 1985, NEW ENGL J MED, V312, P395, DOI 10.1056/NEJM198502143120702
   Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263
   Wu Y, 2007, P NATL ACAD SCI USA, V104, P19784, DOI 10.1073/pnas.0708251104
NR 39
TC 60
Z9 72
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 13
PY 2012
VL 287
IS 16
BP 12886
EP 12892
DI 10.1074/jbc.M112.345082
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 927JO
UT WOS:000302903700028
PM 22362762
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Chen, PM
   Gombart, ZJ
   Chen, JW
AF Chen, Patrick M.
   Gombart, Zoe J.
   Chen, Jeff W.
TI Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and
   intracellular lipid accumulation: possible implications of lysosomal
   dysfunction in macular degeneration
SO CELL AND BIOSCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED-CHANGES; RPE; MEMBRANE; LAMP-2;
   EPIDEMIOLOGY; PATHOGENESIS; BIOGENESIS; PHAGOSOME; PROTEINS
AB Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people over 60. The pathogenesis is still unclear. It has been suggested that lysosomal stress may lead to drusen formation, a biomarker of AMD. In this study, ARPE-19 cells were treated with chloroquine to inhibit lysosomal function.
   Results: Chloroquine-treated ARPE-19 cells demonstrate a marked increase in vacuolation and dense intracellular debris. These are identified as chloroquine-dilated lysosomes and lipid bodies with LAMP-2 and LipidTOX co-localization, respectively. Dilation is an indicator of lysosomal dysfunction. Chloroquine disrupts uptake of exogenously applied rhodamine-labeled dextran by these cells. This suggests a disruption in the phagocytic pathway. The increase in LAMP protein levels, as assessed by Western blots, suggests the possible involvement in autophagy. Oxidative stress with H2O2 does not induce vacuolation or lipid accumulation.
   Conclusion: These findings suggest a possible role for lysosomes in AMD. Chloroquine treatment of RPE cells may provide insights into the cellular mechanisms underlying AMD.
C1 [Chen, Patrick M.; Gombart, Zoe J.; Chen, Jeff W.] Legacy Clin Res & Technol Ctr, Dept Neurol Surg, Portland, OR 97232 USA.
   [Chen, Patrick M.] Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA.
C3 Dartmouth College
RP Chen, JW (通讯作者)，Legacy Clin Res & Technol Ctr, Dept Neurol Surg, 1225 NE 2nd Ave, Portland, OR 97232 USA.
EM jchen@lhs.org
RI Chen, Patrick M./AAX-9264-2020; Chen, Patrick/HGA-3011-2022; Chen,
   Patrick M./GWU-5435-2022
OI Chen, Patrick M./0000-0003-4505-964X; Chen, Patrick
   M./0000-0003-4505-964X
FU Oregon Research and Education Foundation; Legacy Foundation
FX We thank Dr. Zhi-Gang Xiong (Dow Neurobiology laboratory, Legacy
   Holladay Park Research Center, Portland, Oregon) for helpful discussions
   and technical assistance with instrumentation and Mr. Jeff Gadette
   (Oregon Episcopal School (OES), Portland, Oregon) for his advice on
   statistics. Furthermore, we thank Dr. Robert Maue (Dartmouth College,
   Hanover, NH), Dr. Bill Lamb (OES), Mr. Peter Langley (OES), and Dr.
   Tanja Horvat (OES) for critiquing this manuscript. Funding for this
   study was obtained in part from grants from the Oregon Research and
   Education Foundation and The Legacy Foundation Research Fund.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen JW, 2001, J BIOMED SCI, V8, P365, DOI 10.1159/000054056
   Cingle KA, 1996, CURR EYE RES, V15, P433, DOI 10.3109/02713689608995834
   Claudepierre T, 2010, MOL CELL NEUROSCI, V43, P164, DOI 10.1016/j.mcn.2009.10.007
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Girish V, 2004, Indian J Cancer, V41, P47
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   GOLDENTHAL KL, 1985, J HISTOCHEM CYTOCHEM, V33, P813, DOI 10.1177/33.8.3894499
   Hoppe G, 2004, CELL MOL LIFE SCI, V61, P1664, DOI 10.1007/s00018-004-4080-5
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kader D. H. A., 2007, Journal of Medical Sciences (Pakistan), V7, P1225
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Liu J, 2009, INVEST OPHTH VIS SCI, V49, P772
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Mahon GJ, 2004, CURR EYE RES, V28, P277, DOI 10.1076/ceyr.28.4.277.27835
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Molday RS, 2009, BBA-MOL CELL BIOL L, V1791, P573, DOI 10.1016/j.bbalip.2009.02.004
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665
   RAINES MF, 1989, INVEST OPHTH VIS SCI, V30, P1726
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rakoczy PE, 1999, EXP EYE RES, V69, P367, DOI 10.1006/exer.1999.0700
   ROSENTHAL AR, 1978, INVEST OPHTH VIS SCI, V17, P1158
   Saftig P, 2008, AUTOPHAGY, V4, P510, DOI 10.4161/auto.5724
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin SP, 2002, APMIS, V110, P481, DOI 10.1034/j.1600-0463.2002.100606.x
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Terman A, 2006, CHEM-BIOL INTERACT, V16, P29
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Yoon Y, 2010, INVEST OPHTH VIS SCI, V51, P11
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Young RW, 1971, J CELL BIOL, V39, P303
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
NR 46
TC 109
Z9 109
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD MAR 8
PY 2011
VL 1
AR 10
DI 10.1186/2045-3701-1-10
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 982NV
UT WOS:000307053100001
PM 21711726
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Marticorena, J
   Di Leva, V
   Cennamo, GL
   de Crecchio, G
AF Marticorena, J.
   Di Leva, V.
   Cennamo, G. L.
   de Crecchio, G.
TI Retinal Angiomatous Proliferation
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Retinal angiomatous proliferation; choroidal neovascularization;
   age-related macular degeneration; photodynamic therapy; antiVEGF;
   triamcinolone; combined therapy
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB;
   TYPE-3 NEOVASCULARIZATION; CHORIORETINAL ANASTOMOSIS; FELLOW EYE;
   TRIAMCINOLONE; RANIBIZUMAB
AB Retinal angiomatous proliferation (RAP) is a distinct form of choroidal neovascularization which may complicate a wet age related macular degeneration (AMD). This exudative-AMD has a peculiar clinical history and prognosis. RAP accounts from 8% to 22% of newly diagnosed cases among patients previously diagnosed as exudative AMD, and up to 25% of the occult or minimally classic CNV. The disease is more prevalent in women (90% of cases) and in elderly patients (around 75 years), and is characterized by a very poor prognosis. The neovascular process, whose retinal or choroidal origin is still object of discussion, often hesitates in the formation of a disciform scar, that evolves into a severe loss of central vision.
   Treatment for RAP is not yet well established; herein are described the most used therapeutic strategies, starting from laser photocoagulation until the nearest anti VEGF. The opportunity of combination among various treatments to obtain a better effectiveness and a lower frequency of recurrence is also discussed.
C1 [Marticorena, J.] Inst Tecnol Oftalmol, Santiago De Compostela 15705, Spain.
   [Di Leva, V.; Cennamo, G. L.; de Crecchio, G.] Univ Naples Federico 2, Eye Clin, Naples, Italy.
C3 University of Naples Federico II
RP Marticorena, J (通讯作者)，Hosp Nuestra Senora Esperanza, Inst Tecnol Oftalmol, Av Burgas 2, Santiago De Compostela 15705, Spain.
EM jmarticorena@gmail.com
RI Marticorena, Joaquín/AGZ-4368-2022
CR Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Borrillo JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P558, DOI 10.1001/archopht.121.4.558
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bressler NM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1741, DOI 10.1001/archopht.123.12.1741
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Johnson TM, 2006, RETINA-J RET VIT DIS, V26, P765, DOI 10.1097/01.iae.0000244264.98642.af
   Klais CM, 2006, RETINA-J RET VIT DIS, V26, P773, DOI 10.1097/01.iae.0000244261.52901.67
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lo Giudice G, 2009, RETINA-J RET VIT DIS, V29, P949, DOI 10.1097/IAE.0b013e3181af106d
   Panagiotidis D, 2006, EUR J OPHTHALMOL, V16, P326, DOI 10.1177/112067210601600221
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   Saito M, 2010, AM J OPHTHALMOL, V149, P472, DOI 10.1016/j.ajo.2009.09.016
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   van de Moere A, 2007, AM J OPHTHALMOL, V143, P701, DOI 10.1016/j.ajo.2006.10.045
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 30
TC 7
Z9 7
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 199
EP 205
DI 10.2174/138945011794182683
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000007
PM 20887242
DA 2022-11-30
ER

PT J
AU Cuthbertson, FM
   Peirson, SN
   Wulff, K
   Foster, RG
   Downes, SM
AF Cuthbertson, Fiona M.
   Peirson, Stuart N.
   Wulff, Katharina
   Foster, Russell G.
   Downes, Susan M.
TI Blue light-filtering intraocular lenses: Review of potential benefits
   and side effects
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Review
ID AGE-RELATED MACULOPATHY; RETINAL-PIGMENT EPITHELIUM; C-REACTIVE PROTEIN;
   MACULAR DEGENERATION; COLOR-VISION; CATARACT-SURGERY; VISUAL FUNCTION;
   RISK-FACTORS; BEAVER DAM; SPECTRAL TRANSMISSION
AB Blue light-filtering intraocular lenses (IOLs) have become part of the modern cataract surgeon's armamentarium and are widely used. Their advocates suggest they may protect against light-induced retinal damage and also affect the development or progression of age-related macular degeneration. Much of the evidence for photoprotection is theoretical or based on observations in cell culture or animal experiments, with little clinical information to date. Although arguments remain theoretical, there is now emerging clinical data on the use of these IOLs in patients looking at the benefits and potential side effects. In this review, we consider the background to the development of these IOLs, the evidence for a reduction in short-wavelength light exposure protecting retinal cells and function, and the possible disadvantages of IOLs resulting from their reduced light transmission. We place this information in context with regard to patients having cataract surgery and the day-to-day conditions in which they live.
C1 [Cuthbertson, Fiona M.; Downes, Susan M.] John Radcliffe Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
   [Cuthbertson, Fiona M.; Peirson, Stuart N.; Wulff, Katharina; Foster, Russell G.; Downes, Susan M.] Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX2 6AW, England.
C3 University of Oxford; University of Oxford
RP Downes, SM (通讯作者)，John Radcliffe Hosp, Oxford Eye Hosp, Headley Way, Oxford OX3 9DU, England.
EM susan.downes@orh.nhs.uk
OI Wulff, Katharina/0000-0003-2480-3329; FOSTER,
   RUSSELL/0000-0001-6055-2067
FU NIHR Biomedical Research Centre Programme; Oxford, United Kingdom;
   Wellcome Trust (UK) Programme [069714]; Nuffield Laboratory of
   Ophthalmology, University of Oxford
FX Funded in part by NIHR Biomedical Research Centre Programme, Oxford,
   United Kingdom, and the Wellcome Trust (UK) Programme Grant 069714, and
   by a bursary from the Nuffield Laboratory of Ophthalmology, University
   of Oxford (Dr. Cuthbertson), United Kingdom.
CR AARNISALO EA, 1988, AM J OPHTHALMOL, V105, P408, DOI 10.1016/0002-9394(88)90307-8
   *ADV GROUP NON RAD, 2002, HLTH EFF ULTR RAD, V13
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Asplund R, 2004, ARCH GERONTOL GERIAT, V38, P69, DOI 10.1016/j.archger.2003.08.001
   Asplund R, 2002, ARCH GERONTOL GERIAT, V35, P179, DOI 10.1016/S0167-4943(02)00022-5
   Augustin AJ, 2008, RETINA-J RET VIT DIS, V28, P1179, DOI 10.1097/IAE.0b013e3181835885
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Barisic A, 2007, COLLEGIUM ANTROPOL, V31, P57
   Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652
   Bhattacharjee H, 2006, J CATARACT REFR SURG, V32, P451, DOI 10.1016/j.jcrs.2005.12.136
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BOYCE P, 1987, BIOL PSYCHIAT, V22, P473, DOI 10.1016/0006-3223(87)90169-7
   Brainard GC, 2001, J CLIN ENDOCR METAB, V86, P433, DOI 10.1210/jc.86.1.433
   Brainard GC, 2008, J BIOL RHYTHM, V23, P379, DOI 10.1177/0748730408323089
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475
   Burkle A, 2001, EYE, V15, P371, DOI 10.1038/eye.2001.139
   Burns ER, 2000, ANAT RECORD, V261, P141, DOI 10.1002/1097-0185(20000815)261:4<141::AID-AR3>3.0.CO;2-C
   Carson D, 2008, J CATARACT REFR SURG, V34, P1785, DOI 10.1016/j.jcrs.2008.06.034
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Charman WN, 1997, OPHTHAL PHYSL OPT, V17, P371, DOI 10.1111/j.1475-1313.1997.tb00070.x
   Charman WN, 2003, OPHTHAL PHYSL OPT, V23, P181, DOI 10.1046/j.1475-1313.2003.00105.x
   Cionni RJ, 2006, J CATARACT REFR SURG, V32, P236, DOI 10.1016/j.jcrs.2005.12.129
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Dacey DM, 2005, NATURE, V433, P749, DOI 10.1038/nature03387
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Davison James A., 2005, International Ophthalmology Clinics, V45, P55
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   DIJK DJ, 2001, AM J PHYSIOL-REG I, V18, pR1647
   Dillon J, 2000, PHOTOCHEM PHOTOBIOL, V71, P225, DOI 10.1562/0031-8655(2000)071<0225:TSOLTT>2.0.CO;2
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   Dkhissi-Benyahya O, 2007, NEURON, V53, P677, DOI 10.1016/j.neuron.2007.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Ernest PH, 2004, J CATARACT REFR SURG, V30, P1755, DOI 10.1016/j.jcrs.2003.12.054
   Espindle D, 2005, J CATARACT REFR SURG, V31, P1952, DOI 10.1016/j.jcrs.2005.03.060
   Falkner-Radler CI, 2008, AM J OPHTHALMOL, V145, P499, DOI 10.1016/j.ajo.2007.10.021
   FARIZA E, 1994, NEW ENGL J MED, V330, P1320
   FARIZA E, 1993, NEW ENGL J MED, V329, P1505, DOI 10.1056/NEJM199311113292020
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Foster RG, 2005, NAT REV NEUROSCI, V6, P407, DOI 10.1038/nrn1670
   Foster RG, 2007, CURR BIOL, V17, pR746, DOI 10.1016/j.cub.2007.07.007
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036
   Green CB, 2004, J BIOL RHYTHM, V19, P91, DOI 10.1177/0748730404263002
   Greenstein VC, 2007, J CATARACT REFR SURG, V33, P667, DOI 10.1016/j.jcrs.2006.12.012
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Grimm C, 2000, MOL VIS, V6, P252
   GRISWOLD MS, 1992, VISION RES, V32, P1739, DOI 10.1016/0042-6989(92)90166-G
   GUNKEL RD, 1963, ARCH OPHTHALMOL-CHIC, V69, P4
   HAM WT, 1979, PHOTOCHEM PHOTOBIOL, V29, P735, DOI 10.1111/j.1751-1097.1979.tb07759.x
   HAM WT, 1980, VISION RES, V20, P1105, DOI 10.1016/0042-6989(80)90047-4
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Hankins MW, 2008, TRENDS NEUROSCI, V31, P27, DOI 10.1016/j.tins.2007.11.002
   Hankins MW, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P93, DOI 10.1002/352760510X.ch5
   Hankins MW, 2002, CURR BIOL, V12, P191, DOI 10.1016/S0960-9822(02)00659-0
   Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984
   Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761
   Hawkins BS, 1999, MOL VIS, V5
   Hawse P, 2006, BRIT J OPHTHALMOL, V90, P939, DOI 10.1136/bjo.2006.095653
   Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hofman MA, 2006, AGEING RES REV, V5, P33, DOI 10.1016/j.arr.2005.07.001
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   ICHIKAWA K, 1990, COLOR VISION DEFICIENCIES, P237
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Klein B E, 1999, Ophthalmic Epidemiol, V6, P49
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Koide Ryouhei, 2001, Nippon Ganka Gakkai Zasshi, V105, P687
   KUDO H, 1990, RINSHO GANKA, V44, P473
   Lack Leon C, 2007, Behav Sleep Med, V5, P57, DOI 10.1207/s15402010bsm0501_4
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Landers J, 2007, CLIN EXP OPHTHALMOL, V35, P152, DOI 10.1111/j.1442-9071.2006.01434.x
   Lawwill T, 1982, Trans Am Ophthalmol Soc, V80, P517
   Leibovitch I, 2006, ACTA OPHTHALMOL SCAN, V84, P95, DOI 10.1111/j.1600-0420.2005.00607.x
   LERMAN S, 1983, J GERONTOL, V38, P293, DOI 10.1093/geronj/38.3.293
   LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030
   Li F, 2001, EXP EYE RES, V73, P569, DOI 10.1006/exer.2001.1068
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   MAINSTER MA, 1987, EYE-T OPHTH SOC UK, V1, P304, DOI 10.1038/eye.1987.49
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   Mainster MA, 2006, J CATARACT REFR SURG, V32, P1403, DOI 10.1016/j.jcrs.2006.06.014
   Mantyjarvi M, 1997, ACTA OPHTHALMOL SCAN, V75, P166
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   MARSHALL J, 1985, OPHTHAL PHYSL OPT, V5, P241, DOI 10.1111/j.1475-1313.1985.tb00666.x
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCINTYRE IM, 1989, J PINEAL RES, V6, P149
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   MELLERIO J, 1987, VISION RES, V27, P1581, DOI 10.1016/0042-6989(87)90166-0
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   Mester U, 2008, J CATARACT REFR SURG, V34, P608, DOI 10.1016/j.jcrs.2007.11.049
   Meyers Sanford M, 2004, Trans Am Ophthalmol Soc, V102, P83
   MEYERS SM, 2004, T AM OPHTHAL SOC, V102, P93
   Middleton B, 2002, NEUROSCI LETT, V329, P41, DOI 10.1016/S0304-3940(02)00574-8
   Miyake K, 1999, J CATARACT REFR SURG, V25, P891, DOI 10.1016/S0886-3350(99)00069-3
   Mrosovsky N, 2003, J COMP PHYSIOL A, V189, P69, DOI 10.1007/s00359-002-0378-7
   Muftuoglu O, 2007, J CATARACT REFR SURG, V33, P658, DOI 10.1016/j.jcrs.2006.12.018
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nilsson S E, 1989, Prog Clin Biol Res, V314, P539
   Nilsson SE, 2004, ACTA OPHTHALMOL SCAN, V82, P123, DOI 10.1111/j.1600-0420.2004.00248.x
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Niwa K, 1996, OPHTHAL PHYSL OPT, V16, P297, DOI 10.1046/j.1475-1313.1996.95001182.x
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   NORREN DV, 1974, VISION RES, V14, P1237, DOI 10.1016/0042-6989(74)90222-3
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848
   Patel JI, 2007, CURR OPIN OPHTHALMOL, V18, P9, DOI 10.1097/ICU.0b013e3280112a0f
   Paul MA, 2007, AVIAT SPACE ENVIR MD, V78, P645
   PAUTLER EL, 1990, PHOTOCHEM PHOTOBIOL, V51, P599, DOI 10.1111/j.1751-1097.1990.tb01972.x
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   Pokorny J, 1997, DOC OPHTH P, V59, P491
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Pons A, 2007, J OPT SOC AM A, V24, P1545, DOI 10.1364/JOSAA.24.001545
   Raj SM, 2005, J CATARACT REFR SURG, V31, P2324, DOI 10.1016/j.jcrs.2005.08.052
   Reme C, 1996, GRAEF ARCH CLIN EXP, V234, P2, DOI 10.1007/BF00186512
   Reme C, 2005, INVEST OPHTH VIS SCI, V46, P2672, DOI 10.1167/iovs.04-1095
   Reme CE, 2000, NEWS PHYSIOL SCI, V15, P120, DOI 10.1152/physiologyonline.2000.15.3.120
   Rezai KA, 2008, GRAEF ARCH CLIN EXP, V246, P671, DOI 10.1007/s00417-006-0484-2
   Riemersma-van Der Lek RF, 2008, JAMA-J AM MED ASSOC, V299, P2642, DOI 10.1001/jama.299.22.2642
   Robson AG, 2005, PERCEPTION, V34, P1029, DOI 10.1068/p5196
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P2088, DOI 10.1016/j.jcrs.2005.04.029
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schefrin BE, 1999, VISION RES, V39, P3728, DOI 10.1016/S0042-6989(99)00072-3
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schwiegerling J, 2006, J CATARACT REFR SURG, V32, P141, DOI 10.1016/j.jcrs.2005.11.021
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shah SA, 2005, AM J OPHTHALMOL, V140, P941, DOI 10.1016/j.ajo.2005.05.043
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shochat T, 2000, J SLEEP RES, V9, P373, DOI 10.1046/j.1365-2869.2000.00221.x
   SIMONS K, 1993, ARCH OPHTHALMOL-CHIC, V111, P297, DOI 10.1001/archopht.1993.01090030015002
   Sliney DH, 2007, BRIT J OPHTHALMOL, V91, P1261, DOI 10.1136/bjo.2007.120329
   Sloane PD, 2007, J AM GERIATR SOC, V55, P1524, DOI 10.1111/j.1532-5415.2007.01358.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taylor B, 2009, GENDER WORK ORGAN, V16, P173, DOI 10.1111/j.1468-0432.2008.00435_1.x
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thapan K, 2001, J PHYSIOL-LONDON, V535, P261, DOI 10.1111/j.1469-7793.2001.t01-1-00261.x
   Thompson S, 2008, EUR J NEUROSCI, V27, P1973, DOI 10.1111/j.1460-9568.2008.06168.x
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tosini G, 2002, CELL TISSUE RES, V309, P119, DOI 10.1007/s00441-002-0578-z
   Turner PL, 2008, BRIT J OPHTHALMOL, V92, P1439, DOI 10.1136/bjo.2008.141747
   *UN DEP EC SOC AFF, 1998, WORLD POP PROJ 2150
   van Norren D, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.117903
   Van Someren EJW, 1999, CHRONOBIOL INT, V16, P505, DOI 10.3109/07420529908998724
   Van Someren EJW, 2002, PROG BRAIN RES, V138, P205, DOI 10.1016/S0079-6123(02)38080-4
   vanBest JA, 1997, MICROSC RES TECHNIQ, V36, P77, DOI 10.1002/(SICI)1097-0029(19970115)36:2<77::AID-JEMT1>3.0.CO;2-S
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Vuori ML, 2006, ACTA OPHTHALMOL SCAN, V84, P92, DOI 10.1111/j.1600-0420.2005.00579.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   WILLIAMS TP, 1983, INVEST OPHTH VIS SCI, V24, P285
   WINKLER BS, OXIDATIVE DAMAGE AGE
   WITTENBERG S, 1986, AM J OPTOM PHYS OPT, V63, P676
   Wohlfart C, 2007, KLIN MONATSBL AUGENH, V224, P23, DOI 10.1055/s-2006-927275
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wyszecki G., 2000, COLOR SCI CONCEPTS M, Vsecond
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yokoyama Yuichi, 2006, J Artif Organs, V9, P71, DOI 10.1007/s10047-005-0324-x
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zaidi FH, 2007, CURR BIOL, V17, P2122, DOI 10.1016/j.cub.2007.11.034
   Zaliuniene D, 2007, EUR J OPHTHALMOL, V17, P919, DOI 10.1177/112067210701700609
   Zeitzer JM, 2000, J PHYSIOL-LONDON, V526, P695, DOI 10.1111/j.1469-7793.2000.00695.x
NR 226
TC 62
Z9 65
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUL
PY 2009
VL 35
IS 7
BP 1281
EP 1297
DI 10.1016/j.jcrs.2009.04.017
PG 17
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 468VZ
UT WOS:000267853800023
PM 19545821
DA 2022-11-30
ER

PT J
AU Castillo, M
   Bellot, JL
   Garcia-Cabanes, C
   Miquel, J
   Orts, A
   Palmero, M
AF Castillo, M
   Bellot, JL
   Garcia-Cabanes, C
   Miquel, J
   Orts, A
   Palmero, M
TI Effects of hypoxia on retinal pigmented epithelium cells: Protection by
   antioxidants
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE RPE cells; free radicals; hypoxia; antioxidants; vitamin C;
   N-acetyl-cysteine
ID STRESS; DAMAGE
AB Age-related macular degeneration and other eye diseases, such as diabetic retinopathy, are probably linked to the effects of oxygen radicals derived from light or metabolic reactions. We have investigated the effects of hypoxia on bovine retinal pigmented epithelial cells (RPE) and the response of these cells to two antioxidants that have previously shown a beneficial action against free radical-linked senescent involution. The main results of the study were as follows: (i) Hypoxia induced apoptotic damage on RIPE cells, with LDH leakage and ATP reduction; (ii) both vitamin C (VC) and N-acetyl-cysteine (NAC) treatment protected against hypoxia-induced apoptosis, with less DNA fragmentation. In our opinion, these findings justify further experimental and clinical work to investigate the role of hypoxia in the mechanisms of age-related RPE injury and death as well as the potential of antioxidant administration to prevent or delay retinal degenerative processes caused by oxygen-dependent pathophysiological conditions. Copyright (C) 2002 S. Karger AG, Basel.
C1 Univ Alicante, Dept Interuniv Opt, E-03080 Alicante, Spain.
C3 Universitat d'Alacant
RP Palmero, M (通讯作者)，Univ Alicante, Dept Interuniv Opt, Apto 99, E-03080 Alicante, Spain.
EM mpalmero@ua.es
RI PALMERO, MERCEDES/Z-5585-2019
OI PALMERO, MERCEDES/0000-0001-6229-2529
CR Augustin AJ, 1996, GRAEF ARCH CLIN EXP, V234, P58, DOI 10.1007/BF00186520
   Banaclocha MM, 1999, BRAIN RES, V842, P249, DOI 10.1016/S0006-8993(99)01819-3
   BASINGER SF, 1983, BIOCH EYE, P256
   BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157
   BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chida M, 1999, OPHTHALMIC RES, V31, P407, DOI 10.1159/000055565
   De la Fuente M, 1998, MECH AGEING DEV, V104, P213, DOI 10.1016/S0047-6374(98)00071-2
   EMERIT J, 1998, HDB FREE RADICAL ANT
   HOLLIS AL, 1992, EXP EYE RES, V54, P671, DOI 10.1016/0014-4835(92)90022-K
   KATZ ML, 1986, FREE RADICALS AGING, P221
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   MIQUEL J, 1995, EUR J PHARM-ENVIRON, V292, P333, DOI 10.1016/0926-6917(95)90041-1
   Miquel J, 1998, EXP GERONTOL, V33, P113, DOI 10.1016/S0531-5565(97)00060-0
   MIQUEL J, 1990, GLUTATHIONE METABOLI, P187
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Palmero M, 2000, MECH AGEING DEV, V114, P185, DOI 10.1016/S0047-6374(00)00100-7
   Rego AC, 1996, J NEUROCHEM, V66, P2506
   Steinberg R.H., 1979, RETINAL PIGMENT EPIT, P205
   Trevithick JR, 1997, BIOCHEM MOL BIOL INT, V41, P695
   Ueda T, 1996, OPHTHALMIC RES, V28, P184, DOI 10.1159/000267901
   Wood JPM, 1997, NEUROCHEM INT, V31, P261, DOI 10.1016/S0197-0186(96)00157-X
NR 22
TC 20
Z9 23
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD NOV-DEC
PY 2002
VL 34
IS 6
BP 338
EP 342
DI 10.1159/000067050
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 637TR
UT WOS:000180530300002
PM 12483020
DA 2022-11-30
ER

PT J
AU Kim, TH
   Ding, J
   Yao, XC
AF Kim, Tae-Hoon
   Ding, Jie
   Yao, Xincheng
TI Intrinsic signal optoretinography of dark adaptation kinetics
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; OUTER RETINAL BANDS; MACULAR DEGENERATION;
   HUMAN CONE; RESPONSES; PHOTOTRANSDUCTION; REGENERATION; ANGIOGRAPHY;
   SCATTERING; FUSION
AB Delayed dark adaptation due to impaired rod photoreceptor homeostasis has been reported as the earliest symptom of eye diseases such as age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa. Objective measurement of dark adaptation can facilitate early diagnosis to enable prompt intervention to prevent vision loss. However, there is a lack of noninvasive methods capable of spatiotemporal monitoring of photoreceptor changes during dark adaptation. Here we demonstrate functional optical coherence tomography (OCT) for in vivo intrinsic signal optoretinography (ORG) of dark adaptation kinetics in the C57BL/6J mouse retina. Functional OCT revealed a shortening of the outer retina, a rearrangement of the cone and rod photoreceptor interdigitation zone, and a reduction in intrinsic signal amplitude at the photoreceptor inner segment ellipsoid (ISe). A strong positive correlation between the outer retinal shortening and ISe intensity reduction was also confirmed. Functional OCT of dark adaptation kinetics promises an objective method for rapid ORG assessment of physiological integrity of retinal photoreceptors.
C1 [Kim, Tae-Hoon; Ding, Jie; Yao, Xincheng] Univ Illinois, Dept Biomed Engn, Chicago, IL 60607 USA.
   [Yao, Xincheng] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Yao, XC (通讯作者)，Univ Illinois, Dept Biomed Engn, Chicago, IL 60607 USA.; Yao, XC (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
EM xcy@uic.edu
FU National Institutes of Health (NIH) [R01EY023522, R01EY030101,
   R01EY030842, R01EY029673, P30EY001792]; Chicago Biomedical Consortium;
   Searle Funds at the Chicago Community Trust; Richard and Loan Hill
   endowment; Research to Prevent Blindness
FX This research was supported in part by the National Institutes of Health
   (NIH) Grants R01EY023522, R01EY030101, R01EY030842, R01EY029673, and
   P30EY001792; by the Chicago Biomedical Consortium with support from the
   Searle Funds at the Chicago Community Trust; by the Richard and Loan
   Hill endowment; and by an unrestricted grant from Research to Prevent
   Blindness.
CR Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Azimipour M, 2020, OPT LETT, V45, P4658, DOI 10.1364/OL.398868
   Ball JM., 2021, BIORXIV, DOI [10.1101/2021.02.11.430818, DOI 10.1101/2021.02.11.430818]
   Berkowitz BA, 2021, EXP BIOL MED, V246, P2151, DOI 10.1177/15353702211013799
   Berkowitz BA, 2018, INVEST OPHTH VIS SCI, V59, P5957, DOI 10.1167/iovs.18-25682
   Bloom SM, 2021, RETINA-J RET VIT DIS, V41, P181, DOI 10.1097/IAE.0000000000002792
   Calvert PD, 2006, TRENDS CELL BIOL, V16, P560, DOI 10.1016/j.tcb.2006.09.001
   Cao W, 1996, INVEST OPHTH VIS SCI, V37, P586
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong SP, 2018, BIOMED OPT EXPRESS, V9, P1477, DOI 10.1364/BOE.9.001477
   Cooper RF, 2020, OPT EXPRESS, V28, P39326, DOI 10.1364/OE.409193
   Cuenca N, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100828
   Eric MM, 2017, J BIOMED OPT, V22, P1
   Fu YB, 2007, PFLUG ARCH EUR J PHY, V454, P805, DOI 10.1007/s00424-006-0194-y
   Gao SS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89599-1
   Guziewicz KE, 2018, P NATL ACAD SCI USA, V115, pE2839, DOI 10.1073/pnas.1720662115
   Haseda K, 2015, BIOMED OPT EXPRESS, V6, P859, DOI 10.1364/BOE.6.000859
   Herse Peter, 2005, Clin Exp Optom, V88, P335
   Hillmann D, 2016, P NATL ACAD SCI USA, V113, P13138, DOI 10.1073/pnas.1606428113
   Hsiao CC, 2019, GRAEF ARCH CLIN EXP, V257, P1401, DOI 10.1007/s00417-019-04321-2
   Hunter JJ, 2019, ANNU REV VIS SCI, V5, P15, DOI 10.1146/annurev-vision-091517-034239
   Ingram NT, 2020, P NATL ACAD SCI USA, V117, P19599, DOI 10.1073/pnas.2001776117
   Ishikawa M, 2015, EXP EYE RES, V133, P3, DOI 10.1016/j.exer.2015.02.017
   Jackson GR., 2014, INVEST OPHTH VIS SCI, V55, p1427 1431
   Janssen BJA, 2004, AM J PHYSIOL-HEART C, V287, pH1618, DOI 10.1152/ajpheart.01192.2003
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim TH, 2021, NEUROPHOTONICS, V8, DOI 10.1117/1.NPh.8.3.035002
   Kim TH, 2020, BIOMED OPT EXPRESS, V11, P5306, DOI 10.1364/BOE.399334
   Kim TH, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.42
   Kocaoglu OP, 2016, BIOMED OPT EXPRESS, V7, P4554, DOI 10.1364/BOE.7.004554
   Kwan CC, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.38
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lassoued A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2107444118
   Lee KE, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.12.27
   Li YC, 2018, INVEST OPHTH VIS SCI, V59, P1084, DOI 10.1167/iovs.17-23011
   Li YC, 2016, INVEST OPHTH VIS SCI, V57, pOCT105, DOI 10.1167/iovs.15-18539
   Linton JD, 2010, P NATL ACAD SCI USA, V107, P8599, DOI 10.1073/pnas.1002471107
   Liu ZL, 2016, INVEST OPHTH VIS SCI, V57, pOCT533, DOI 10.1167/iovs.16-19106
   Lu CD, 2017, INVEST OPHTH VIS SCI, V58, P4632, DOI 10.1167/iovs.17-22171
   Ma GY, 2021, J BIOPHOTONICS, V14, DOI 10.1002/jbio.202000462
   Mahroo OAR, 2004, J PHYSIOL-LONDON, V554, P417, DOI 10.1113/jphysiol.2003.051250
   MARMOR MF, 1993, PROG RETIN RES, V12, P179, DOI 10.1016/0278-4327(93)90009-I
   Messner A., ANN NY ACAD SCI, V1-13
   Nandrot EF, 2006, AM J PHYSIOL-CELL PH, V290, pC1256, DOI 10.1152/ajpcell.00480.2005
   OWCZAREK FR, 1975, INVEST OPHTH VISUAL, V14, P353
   Pandiyan VP, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1124
   Son T, 2021, EXP BIOL MED, V246, P639, DOI 10.1177/1535370220978898
   Son T, 2016, BIOMED OPT EXPRESS, V7, P3151, DOI 10.1364/BOE.7.003151
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Suppiej A, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0760-5
   Tychinsky V, 2009, J BIOPHOTONICS, V2, P494, DOI 10.1002/jbio.200910042
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Westermann B, 2012, BBA-BIOENERGETICS, V1817, P1833, DOI 10.1016/j.bbabio.2012.02.033
   Wolfensberger TJ, 1999, DOC OPHTHALMOL, V97, P261, DOI 10.1023/A:1002496223131
   Yang GQ, 2015, INT J OPHTHALMOL-CHI, V8, P1245, DOI 10.3980/j.issn.2222-3959.2015.06.31
   Yao XC, 2005, APPL OPTICS, V44, P2019, DOI 10.1364/AO.44.002019
   Yao XC, 2021, EXP BIOL MED, V246, P2140, DOI 10.1177/15353702211022674
   Yao XC, 2020, EXP BIOL MED, V245, P1087, DOI 10.1177/1535370220935406
   Yao XC, 2018, EXP BIOL MED, V243, P1256, DOI 10.1177/1535370218816517
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zhang LJ, 2022, J BIOPHOTONICS, V15, DOI 10.1002/jbio.202100252
   Zhang PF, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.9
   Zhang PF, 2017, P NATL ACAD SCI USA, V114, pE2937, DOI 10.1073/pnas.1620572114
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
NR 66
TC 2
Z9 2
U1 1
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 15
PY 2022
VL 12
IS 1
AR 2475
DI 10.1038/s41598-022-06562-4
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZB2TX
UT WOS:000756701900072
PM 35169239
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Woogeng, IN
   Kaczkowski, B
   Abugessaisa, I
   Hu, HM
   Tachibana, A
   Sahara, Y
   Hon, CC
   Hasegawa, A
   Sakai, N
   Nishida, M
   Sanyal, H
   Sho, J
   Kajita, K
   Kasukawa, T
   Takasato, M
   Carninci, P
   Maeda, A
   Mandai, M
   Arner, E
   Takahashi, M
   Kime, C
AF Woogeng, Ivo Ngundu
   Kaczkowski, Bogumil
   Abugessaisa, Imad
   Hu, Haiming
   Tachibana, Akihiro
   Sahara, Yoshiki
   Hon, Chung-Chau
   Hasegawa, Akira
   Sakai, Noriko
   Nishida, Mitsuhiro
   Sanyal, Hashimita
   Sho, Junki
   Kajita, Keisuke
   Kasukawa, Takeya
   Takasato, Minoru
   Carninci, Piero
   Maeda, Akiko
   Mandai, Michiko
   Arner, Erik
   Takahashi, Masayo
   Kime, Cody
TI Inducing human retinal pigment epithelium-like cells from somatic tissue
SO STEM CELL REPORTS
LA English
DT Article
ID PIONEER TRANSCRIPTION FACTORS; PLURIPOTENT STEM-CELLS; HUMAN
   FIBROBLASTS; BEST1 EXPRESSION; FACTOR MITF; IN-VITRO; GENE;
   DIFFERENTIATION; IMPEDIMENTS; CONVERSION
AB Regenerative medicine relies on basic research outcomes that are only practical when cost effective. The human eyeball requires the retinal pigment epithelium (RPE) to interface the neural retina and the choroid at large. Millions of people suffer from age-related macular degeneration (AMD), a blinding multifactor genetic disease among RPE degradation pathologies. Recently, autologous pluripotent stemcell-derived RPE cells were prohibitively expensive due to time; therefore, we developed a faster reprogramming system. We stably induced RPE-like cells (iRPE) from human fibroblasts (Fibs) by conditional overexpression of both broad plasticity and lineage-specific transcription factors (TFs). iRPE cells displayed critical RPE benchmarks and significant in vivo integration in transplanted retinas. Herein, we detail the iRPE system with comprehensive single-cell RNA sequencing (scRNA-seq) profiling to interpret and characterize its best cells. We anticipate that our system may enable robust retinal cell induction for basic research and affordable autologous human RPE tissue for regenerative cell therapy.
C1 [Woogeng, Ivo Ngundu; Hu, Haiming; Tachibana, Akihiro; Sahara, Yoshiki; Sakai, Noriko; Nishida, Mitsuhiro; Sanyal, Hashimita; Sho, Junki; Kajita, Keisuke; Takasato, Minoru; Maeda, Akiko; Mandai, Michiko; Takahashi, Masayo; Kime, Cody] RIKEN, Ctr Biosyst Dynam Res, Kobe, Hyogo 6500047, Japan.
   [Kaczkowski, Bogumil; Abugessaisa, Imad; Hon, Chung-Chau; Hasegawa, Akira; Kasukawa, Takeya; Carninci, Piero; Arner, Erik] RIKEN, Ctr Integrat Med Sci, Yokohama, Kanagawa 2300045, Japan.
   [Sahara, Yoshiki; Takasato, Minoru] Kyoto Univ, Grad Sch Biostudies, Dept Anim Dev & Physiol, Lab Mol Cell Biol & Dev, Kyoto 6068501, Japan.
   [Sahara, Yoshiki] Otsuka Pharmaceut Co Ltd, New Drug Res Div, Dept Renal & Cardiovasc Res, Tokushima 7710192, Japan.
   [Carninci, Piero] Human Technopole, Via Rita Levi Montalcini 1, Milan, Italy.
C3 RIKEN; RIKEN; Kyoto University; Otsuka Pharmaceutical; Human Technopole
RP Kime, C (通讯作者)，RIKEN, Ctr Biosyst Dynam Res, Kobe, Hyogo 6500047, Japan.
EM cody.kime@a.riken.jp
RI Kasukawa, Takeya/N-5070-2015; Carninci, Piero/K-1568-2014
OI Kasukawa, Takeya/0000-0001-5085-0802; Carninci,
   Piero/0000-0001-7202-7243; Hon, Chung-Chau/0000-0002-3741-7577
CR Abugessaisa I., 2020, QUALITY ASSESSMENT S, DOI [10.1101/2019.12.31.890269, DOI 10.1101/2019.12.31.890269]
   Adijanto J, 2012, J BIOL CHEM, V287, P20491, DOI 10.1074/jbc.M112.354761
   Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Buecker C, 2014, CELL STEM CELL, V14, P838, DOI 10.1016/j.stem.2014.04.003
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   D'Alessio AC, 2015, STEM CELL REP, V5, P763, DOI 10.1016/j.stemcr.2015.09.016
   Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058
   Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200
   Esumi N, 2009, HUM MOL GENET, V18, P128, DOI 10.1093/hmg/ddn323
   Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Hansson ML, 2015, J BIOL CHEM, V290, P5661, DOI 10.1074/jbc.M114.618835
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hever AM, 2006, CLIN GENET, V69, P459, DOI 10.1111/j.1399-0004.2006.00619.x
   Iwafuchi-Doi M, 2014, GENE DEV, V28, P2679, DOI 10.1101/gad.253443.114
   Iwasaki Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158282
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kareta MS, 2015, CELL STEM CELL, V16, P39, DOI 10.1016/j.stem.2014.10.019
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6
   Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lidgerwood GE, 2021, GENOM PROTEOM BIOINF, V19, P223, DOI 10.1016/j.gpb.2020.08.002
   Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746
   Luz-Madrigal A, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-28
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Masuda T, 2010, J BIOL CHEM, V285, P26933, DOI 10.1074/jbc.M110.130294
   McInnes L., 2020, UMAP UNIFORM MANIFOL, DOI [DOI 10.21105/JOSS.00861, 10.48550/arXiv.1802.03426]
   Miki K, 2015, CELL STEM CELL, V16, P699, DOI 10.1016/j.stem.2015.04.005
   Najm FJ, 2013, NAT BIOTECHNOL, V31, P426, DOI 10.1038/nbt.2561
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Ota S, 2018, SCIENCE, V360, P1246, DOI 10.1126/science.aan0096
   Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Petukhov V, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1449-6
   Rackham OJL, 2016, NAT GENET, V48, P331, DOI 10.1038/ng.3487
   Reyes AP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15326-5
   Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015
   Shahbazi MN, 2017, NATURE, V552, P239, DOI 10.1038/nature24675
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soufi A, 2015, CELL, V161, P555, DOI 10.1016/j.cell.2015.03.017
   Soufi A, 2013, CELL CYCLE, V12, P1487, DOI 10.4161/cc.24663
   Soufi A, 2012, CELL, V151, P994, DOI 10.1016/j.cell.2012.09.045
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomson J.A., 2012, US Patent, Patent No. [8,183,038, 8183038]
   Tomaru Y, 2014, NUCLEIC ACIDS RES, V42, P8905, DOI 10.1093/nar/gku567
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Williams LA, 2012, CELL, V149, P1174, DOI 10.1016/j.cell.2012.05.015
   Zhang KJ, 2014, PROTEIN CELL, V5, P48, DOI 10.1007/s13238-013-0011-2
   Zhao Y, 2015, CELL, V163, P1678, DOI 10.1016/j.cell.2015.11.017
NR 62
TC 1
Z9 1
U1 1
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD FEB 8
PY 2022
VL 17
IS 2
BP 289
EP 306
DI 10.1016/j.stemcr.2021.12.008
PG 18
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA YX9EG
UT WOS:000754397100008
PM 35030321
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fukuda, S
   Narendran, S
   Varshney, A
   Nagasaka, Y
   Wang, SB
   Ambati, K
   Apicella, I
   Pereira, F
   Fowler, BJ
   Yasuma, T
   Hirahara, S
   Yasuma, R
   Huang, P
   Yerramothu, P
   Makin, RD
   Wang, M
   Baker, KL
   Marion, KM
   Huang, XW
   Baghdasaryan, E
   Ambati, M
   Ambati, VL
   Banerjee, D
   Bonilha, VL
   Tolstonog, GV
   Held, U
   Ogura, Y
   Terasaki, H
   Oshika, T
   Bhattarai, D
   Kim, KB
   Feldman, SH
   Aguirre, JI
   Hinton, DR
   Kerur, N
   Sadda, SR
   Schumann, GG
   Gelfand, BD
   Ambati, J
AF Fukuda, Shinichi
   Narendran, Siddharth
   Varshney, Akhil
   Nagasaka, Yosuke
   Wang, Shao-Bin
   Ambati, Kameshwari
   Apicella, Ivana
   Pereira, Felipe
   Fowler, Benjamin J.
   Yasuma, Tetsuhiro
   Hirahara, Shuichiro
   Yasuma, Reo
   Huang, Peirong
   Yerramothu, Praveen
   Makin, Ryan D.
   Wang, Mo
   Baker, Kirstie L.
   Marion, Kenneth M.
   Huang, Xiwen
   Baghdasaryan, Elmira
   Ambati, Meenakshi
   Ambati, Vidya L.
   Banerjee, Daipayan
   Bonilha, Vera L.
   Tolstonog, Genrich, V
   Held, Ulrike
   Ogura, Yuichiro
   Terasaki, Hiroko
   Oshika, Tetsuro
   Bhattarai, Deepak
   Kim, Kyung Bo
   Feldman, Sanford H.
   Aguirre, J. Ignacio
   Hinton, David R.
   Kerur, Nagaraj
   Sadda, Srinivas R.
   Schumann, Gerald G.
   Gelfand, Bradley D.
   Ambati, Jayakrishna
TI Alu complementary DNA is enriched in atrophic macular degeneration and
   triggers retinal pigmented epithelium toxicity via cytosolic innate
   immunity
SO SCIENCE ADVANCES
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; GEOGRAPHIC ATROPHY; INFLAMMASOME
   ACTIVATION; L1 RETROTRANSPOSITION; NLRP3 INFLAMMASOME; STRESS; EYES;
   LINE; EXTINCTION; INDUCE
AB Long interspersed nuclear element-1 (L1)-mediated reverse transcription (RT) of AN RNA into cytoplasmic AN complementary DNA (cDNA) has been implicated in retinal pigmented epithelium (RPE) degeneration. The mechanism of AN cDNA-induced cytotoxicity and its relevance to human disease are unknown. Here we report that AN cDNA is highly enriched in the RPE of human eyes with geographic atrophy, an untreatable form of age-related macular degeneration. We demonstrate that the DNA sensor cGAS engages Alu cDNA to induce cytosolic mitochondria! DNA escape, which amplifies cGAS activation, triggering RPE degeneration via the inflammasome. The L1-extinct rice rat was resistant to AN RNA-inducedAlu cDNA synthesis and RPE degeneration, which were enabled upon L1-RT overexpression. Nucleoside RT inhibitors (NRTIs), which inhibit both L1-RT and inflammasome activity, and NRTI derivatives (Kamuvudines) that inhibit inflammasome, but not RT, both block AN cDNA toxicity, identifying inflammasome activation as the terminal effector of RPE degeneration.
C1 [Fukuda, Shinichi; Narendran, Siddharth; Varshney, Akhil; Nagasaka, Yosuke; Wang, Shao-Bin; Ambati, Kameshwari; Apicella, Ivana; Pereira, Felipe; Hirahara, Shuichiro; Yasuma, Reo; Huang, Peirong; Yerramothu, Praveen; Makin, Ryan D.; Ambati, Meenakshi; Banerjee, Daipayan; Kerur, Nagaraj; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22908 USA.
   [Fukuda, Shinichi; Narendran, Siddharth; Varshney, Akhil; Nagasaka, Yosuke; Wang, Shao-Bin; Ambati, Kameshwari; Apicella, Ivana; Pereira, Felipe; Hirahara, Shuichiro; Yasuma, Reo; Huang, Peirong; Yerramothu, Praveen; Makin, Ryan D.; Ambati, Meenakshi; Banerjee, Daipayan; Kerur, Nagaraj; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Fukuda, Shinichi; Oshika, Tetsuro] Univ Tsukuba, Dept Ophthalmol, Tsukuba, Ibaraki 3058575, Japan.
   [Narendran, Siddharth] Aravind Eye Hosp Syst, Madurai, Tamil Nadu, India.
   [Nagasaka, Yosuke; Yasuma, Tetsuhiro; Yasuma, Reo; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Pereira, Felipe; Yasuma, Tetsuhiro] Univ Fed Sao Paulo, Dept Oftalmol & Ciencias Visuais, Escola Paulista Med, BR-04023062 Sao Paulo, Brazil.
   [Fowler, Benjamin J.] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY USA.
   [Hirahara, Shuichiro; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Huang, Peirong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Wang, Mo; Baker, Kirstie L.; Marion, Kenneth M.; Huang, Xiwen; Baghdasaryan, Elmira; Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Baghdasaryan, Elmira; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Ambati, Meenakshi; Ambati, Vidya L.] Ctr Digital Image Evaluat, Charlottesville, VA USA.
   [Bonilha, Vera L.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Tolstonog, Genrich, V] Lausanne Univ Hosp, Dept Otolaryngol Head & Neck Surg, Lausanne, Switzerland.
   [Tolstonog, Genrich, V] Univ Lausanne, Lausanne, Switzerland.
   [Held, Ulrike; Schumann, Gerald G.] Paul Ehrlich Inst, Dept Med Biotechnol, Langen, Germany.
   [Bhattarai, Deepak; Kim, Kyung Bo] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA.
   [Feldman, Sanford H.] Univ Virginia, Sch Med, Ctr Comparat Med, Charlottesville, VA 22908 USA.
   [Aguirre, J. Ignacio] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Dept Pathol, Los Angeles, CA 90007 USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA 90007 USA.
   [Kerur, Nagaraj; Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.
   [Kerur, Nagaraj] Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA.
   [Gelfand, Bradley D.] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
   [Varshney, Akhil] Dr Shroffs Char Eye Hosp Delhi, 5027 Daryaganj, New Delhi, India.
C3 University of Virginia; University of Virginia; University of Tsukuba;
   Nagoya University; Universidade Federal de Sao Paulo (UNIFESP);
   University of Kentucky; Nagoya City University; Shanghai Jiao Tong
   University; Doheny Eye Institute; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA;
   Cleveland Clinic Foundation; University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV); University of Lausanne; Paul Ehrlich
   Institute; University of Kentucky; University of Virginia; State
   University System of Florida; University of Florida; University of
   Southern California; University of Southern California; University of
   Virginia; University of Virginia; University of Virginia; University of
   Virginia
RP Ambati, J (通讯作者)，Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22908 USA.
EM ja9qr@virginia.edu
RI WANG, SHAO-BIN/Z-1810-2018
OI WANG, SHAO-BIN/0000-0002-6699-9406; Yerramothu,
   Praveen/0000-0001-6635-6681; PEREIRA, FELIPE/0000-0001-8884-2816
FU U.S. National Institutes of Health (NIH) [DP1GM114862, R01EY022238,
   R01EY024068, R01EY028027, R01EY029799, R01EY031039]; John Templeton
   Foundation [60763]; DuPont Guerry, III, Professorship; Japan Eye Bank
   Association; NIH [R01EY028027, R01EY031039, K99EY024336, R00EY024336,
   R01AI48741, T32HL091812, UL1RR033173, R21EY030651, R01EY027750,
   P30EY025585, R01EY001545, R01EY032512]; Beckman Initiative for Macular
   Research grant; Association for Research in Vision and Ophthalmology
   (ARVO)/Alcon Early Career Clinician-Scientist Research Award; Fight for
   Sight postdoctoral award; Research to Prevent Blindness; Cole Eye
   Institute; BrightFocus Foundation; Owens Family Foundation; Japan Eye
   Bank Association Research Grant; FFB; UVA Strategic Investment Fund
FX J.A. was supported by the UVA Strategic Investment Fund, U.S. National
   Institutes of Health (NIH) grants (DP1GM114862, R01EY022238,
   R01EY024068, R01EY028027, R01EY029799, and R01EY031039), John Templeton
   Foundation Grant 60763, DuPont Guerry, III, Professorship, and a gift
   from Mr. and Mrs. Eli W. Tullis; S.F. by JSPS Fund for the Promotion of
   Joint International Research (Home-Returning Researcher Development
   Research) and Research Grant of Japan Eye Bank Association; N.K. by NIH
   grants (K99EY024336, R00EY024336, R01AI48741, and R21EY030651) and
   Beckman Initiative for Macular Research grant; B.J.F. by NIH grants
   (T32HL091812 and UL1RR033173); R.Y. by Association for Research in
   Vision and Ophthalmology (ARVO)/Alcon Early Career Clinician-Scientist
   Research Award; T.Y. by Fight for Sight postdoctoral award; V.L.B. by
   NIH grants R01EY027750 and P30EY025585, an unrestricted grant from
   Research to Prevent Blindness, and the FFB and Cole Eye Institute for
   the establishment and maintenance of the collection of eyes with retinal
   degenerations; D.R.H. by NIH R01EY001545 and an unrestricted
   departmental grant from Research to Prevent Blindness; B.D.G. by NIH
   grants (R01EY028027, R01EY031039, and R01EY032512), the BrightFocus
   Foundation, and the Owens Family Foundation; S.F. by Japan Eye Bank
   Association Research Grant. The funders had no role in study design or
   conduct, data collection, analysis, or interpretation, manuscript
   writing, or the decision to submit the manuscript for publication. The
   content of this article is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J., 2016, Patent, Patent No. [WO2016138425A1, 2016138425]
   Ambati J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18528-z
   Ardeljan D, 2020, NAT STRUCT MOL BIOL, V27, P168, DOI 10.1038/s41594-020-0372-1
   Ardeljan D, 2019, MOBILE DNA-UK, V11, DOI 10.1186/s13100-019-0191-2
   Bonilha V L, 2015, Austin J Clin Ophthalmol, V2
   Bonilha VL, 2016, OPHTHALMIC GENET, V37, P150, DOI 10.3109/13816810.2014.958861
   Bonilha VL, 2015, GRAEF ARCH CLIN EXP, V253, P295, DOI 10.1007/s00417-014-2868-z
   Bonilha VL, 2011, INVEST OPHTH VIS SCI, V52, P8381, DOI 10.1167/iovs.11-7973
   Casavant NC, 2000, GENETICS, V154, P1809
   Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592
   Dai Lixin, 2014, Mob Genet Elements, V4, pe29319
   Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18
   Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   Doucet AJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001150
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Fukuda S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022751118
   Garcia-Perez JL, 2010, NATURE, V466, P769, DOI 10.1038/nature09209
   Grahn RA, 2005, CYTOGENET GENOME RES, V110, P407, DOI 10.1159/000084973
   Grossniklaus HE, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12711
   Hagan CR, 2003, NAT GENET, V35, P219, DOI 10.1038/ng1259
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Heinrich MJ, 2019, J AUTOIMMUN, V100, P40, DOI 10.1016/j.jaut.2019.02.003
   Herzner AM, 2015, NAT IMMUNOL, V16, P1025, DOI 10.1038/ni.3267
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Huang JY, 2018, EYE CONTACT LENS, V44, pS144, DOI 10.1097/ICL.0000000000000362
   Hung T, 2015, SCIENCE, V350, P455, DOI 10.1126/science.aac7442
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kazazian HH, 2017, NEW ENGL J MED, V377, P361, DOI 10.1056/NEJMra1510092
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Kirilyuk A, 2008, NUCLEIC ACIDS RES, V36, P648, DOI 10.1093/nar/gkm1045
   Kotecki M, 1999, EXP CELL RES, V252, P273, DOI 10.1006/excr.1999.4656
   Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758
   Mackenzie KJ, 2016, EMBO J, V35, P831, DOI 10.15252/embj.201593339
   Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4
   Narendran S, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00537-z
   Raiz J, 2012, NUCLEIC ACIDS RES, V40, P1666, DOI 10.1093/nar/gkr863
   Rinehart TA, 2005, CYTOGENET GENOME RES, V110, P416, DOI 10.1159/000084974
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seo SU, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9010
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Taylor MS, 2016, METHODS MOL BIOL, V1400, P311, DOI 10.1007/978-1-4939-3372-3_20
   Taylor MS, 2013, CELL, V155, P1034, DOI 10.1016/j.cell.2013.10.021
   ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0
   Wakimoto Y., 2014, CURR PROTOC MOL BIOL, V107, P1
   Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang L, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004395
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 60
TC 4
Z9 4
U1 2
U2 3
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD OCT
PY 2021
VL 7
IS 40
AR eabj3658
DI 10.1126/sciadv.abj3658
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WA7US
UT WOS:000703091100032
PM 34586848
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ji, MH
   Kreymerman, A
   Belle, K
   Ghiam, BK
   Muscat, SP
   Mahajan, VB
   Enns, GM
   Mercola, M
   Wood, EH
AF Ji, Marco H.
   Kreymerman, Alexander
   Belle, Kinsley
   Ghiam, Benjamin K.
   Muscat, Stephanie P.
   Mahajan, Vinit B.
   Enns, Gregory M.
   Mercola, Mark
   Wood, Edward H.
TI The Present and Future of Mitochondrial-Based Therapeutics for Eye
   Disease
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Review
DE mitochondria; retina; gene therapy
ID HEREDITARY OPTIC NEUROPATHY; PIGMENT EPITHELIAL-CELLS; THERAPY IMPROVES
   VISION; OXIDATIVE STRESS; GENE-THERAPY; GEOGRAPHIC ATROPHY;
   VISUAL-ACUITY; 670 NM; BIOGENESIS; LIGHT
AB Mitochondrial dysfunction within the eye contributes to primarily mitochondrial diseases affecting the visual system such as Leber hereditary optic neuropathy (LHON) as well as more common ocular diseases, including glaucoma, diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration (AMD). For these reasons, druggable targets and gene therapies for improving mitochondrial function have been of significant interest within scientific and pharmaceutical endeavors seeking to improve visual outcomes in ocular disease. These therapies modulate mitochondrial functions, including mitochondrial membrane potential and membrane stability, redox signaling and oxidative stress, mitochondrial quality control including fusion/fission and biogenesis/mitophagy, apoptosis, and mitochondrial genetic-based therapies. As of now, several mitochondrial-targeted therapies have been approved in a limited number of countries, including photobiomodulation for AMD, idebenone for LHON, and SkQ1 for dry eye disease. Elamipretide for nonexudative AMD and gene therapy with GS010 for LHON have additionally shown encouraging results within clinical trials.
   Translational Relevance: Mitochondria are viable therapeutic targets for a broad spectrum of ocular diseases.
C1 [Ji, Marco H.; Kreymerman, Alexander; Belle, Kinsley; Muscat, Stephanie P.; Mahajan, Vinit B.; Wood, Edward H.] Stanford Univ, Sch Med, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA.
   [Kreymerman, Alexander; Mercola, Mark; Wood, Edward H.] Stanford Univ, Sch Med, Stanford Cardiovasc Inst, Palo Alto, CA 94304 USA.
   [Ghiam, Benjamin K.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Enns, Gregory M.] Stanford Univ, Sch Med, Div Med Genet, Dept Pediat, Palo Alto, CA 94304 USA.
C3 Stanford University; Stanford University; Case Western Reserve
   University; Stanford University
RP Wood, EH (通讯作者)，2452 Watson Ct, Palo Alto, CA 94303 USA.
EM ehw@stanford.edu
RI Ji, Marco H./Q-3807-2017
OI Ji, Marco H./0000-0002-7033-7763; Kreymerman,
   Alexander/0000-0001-6361-6804; Wood, Edward/0000-0001-8915-8346
FU Research to Prevent Blindness; NEI [P30EY026877]
FX Supported by an unrestricted grant from Research to Prevent Blindness
   and NEI P30EY026877. The authors have not received any additional grant
   support or research funding for this project and do not have any
   proprietary interests in the materials described in the article. The
   manuscript has not been submitted to another journal or presented at a
   meeting.
CR Abrahan Carolina, 2016, Adv Exp Med Biol, V854, P403, DOI 10.1007/978-3-319-17121-0_53
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Alam NM, 2015, DIS MODEL MECH, V8, P701, DOI 10.1242/dmm.020248
   Albarracin RS, 2012, ADV EXP MED BIOL, V723, P121, DOI 10.1007/978-1-4614-0631-0_17
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreux PA, 2019, NAT METAB, V1, P595, DOI 10.1038/s42255-019-0073-4
   Anguela XM, 2019, ANNU REV MED, V70, P273, DOI 10.1146/annurev-med-012017-043332
   Apinyawasisuk S, 2016, INVEST OPHTH VIS SCI, V57
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Artika IM, 2020, GENES DIS, V7, P578, DOI 10.1016/j.gendis.2019.08.001
   Ates O, 2008, EURASIAN J MED, V40, P1
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Bababeygy SR, 2012, J NEURO-OPHTHALMOL, V32, P386, DOI 10.1097/WNO.0b013e318273c102
   Bacman SR, 2018, NAT MED, V24, P1696, DOI 10.1038/s41591-018-0166-8
   Bacman SR, 2013, NAT MED, V19, P1111, DOI 10.1038/nm.3261
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Barboni P, 2013, BRAIN, V136, DOI 10.1093/brain/aws280
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Biswal MR, 2015, EXP EYE RES, V140, P94, DOI 10.1016/j.exer.2015.07.022
   Board on Health Sciences Policy Institute of Medicine National Academies of Sciences Engineering and Medicine & Committee on the Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases, MITOCHONDRIAL REPLAC
   Boyle KA, 2018, J BIOL CHEM, V293, P14891, DOI 10.1074/jbc.RA117.001469
   Briere JJ, 2004, BIOCHEM BIOPH RES CO, V316, P1138, DOI 10.1016/j.bbrc.2004.03.002
   Brzheskiy VV, 2015, ADV THER, V32, P1263, DOI 10.1007/s12325-015-0273-6
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Carelli V, 2012, MITOCHONDRION, V12, P581, DOI 10.1016/j.mito.2012.07.079
   Chan DC, 2020, ANNU REV PATHOL-MECH, V15, P235, DOI 10.1146/annurev-pathmechdis-012419-032711
   Chan DC, 2012, ANNU REV GENET, V46, P265, DOI 10.1146/annurev-genet-110410-132529
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Chinnery PF, 2020, NEW ENGL J MED, V382, P1855, DOI 10.1056/NEJMcibr2002015
   Cohen J, 1997, LANCET, V350, P186, DOI 10.1016/S0140-6736(05)62353-7
   Cousins SW, 2019, INVEST OPHTH VIS SCI, V60
   Cousins SW, 2016, INVEST OPHTH VIS SCI, V57
   Csiszar A, 2009, AM J PHYSIOL-HEART C, V297, pH13, DOI 10.1152/ajpheart.00368.2009
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Do YJ, 2017, EXP CELL RES, V359, P30, DOI 10.1016/j.yexcr.2017.08.012
   Dombi E, 2018, CURR MED CHEM, V25, P5597, DOI 10.2174/0929867324666170616101741
   Dudek J, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00090
   Eells JT, 2016, ADV EXP MED BIOL, V854, P437, DOI 10.1007/978-3-319-17121-0_58
   Ellouze S, 2008, AM J HUM GENET, V83, P373, DOI 10.1016/j.ajhg.2008.08.013
   Enns GM, 2012, MOL GENET METAB, V105, P91, DOI 10.1016/j.ymgme.2011.10.009
   Esposti MD, 1996, ARCH BIOCHEM BIOPHYS, V330, P395, DOI 10.1006/abbi.1996.0267
   Fernandez-de-Cossio-Diaz J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26724-7
   Feuer WJ, 2016, OPHTHALMOLOGY, V123, P558, DOI 10.1016/j.ophtha.2015.10.025
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fort PE, 2011, EXP EYE RES, V92, P98, DOI 10.1016/j.exer.2010.11.008
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Funk JA, 2010, J PHARMACOL EXP THER, V333, P593, DOI 10.1124/jpet.109.161992
   Garrido-Maraver J, 2015, BBA-MOL BASIS DIS, V1852, P2535, DOI 10.1016/j.bbadis.2015.08.027
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Guy J, 2009, INVEST OPHTH VIS SCI, V50, P4205, DOI 10.1167/iovs.08-3214
   HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153
   Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337
   Hamblin MR, 2016, J BIOPHOTONICS, V9, P1122, DOI 10.1002/jbio.201670113
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Hashimoto M, 2015, MOL THER, V23, P1592, DOI 10.1038/mt.2015.126
   Herbert M, 2017, NEW ENGL J MED, V376, P171, DOI 10.1056/NEJMcibr1615669
   Heyck M, 2019, EXP BIOL MED, V244, P1485, DOI 10.1177/1535370219881623
   Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Hombrebueno JR, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129760
   Ishihara N, 2009, NAT CELL BIOL, V11, P958, DOI 10.1038/ncb1907
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Ivandic BT, 2014, PHOTOMED LASER SURG, V32, P181, DOI 10.1089/pho.2013.3535
   Ivandic BT, 2012, PHOTOMED LASER SURG, V30, P167, DOI 10.1089/pho.2011.3089
   Jariyakosol K, 2011, J HEALTH RES, V25, P105
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850
   Jiang WM, 2016, AM J TRANSL RES, V8, P799
   Karanjia R, 2019, MTP 131 TOPICAL OPHT
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim KY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.180
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kirk DK, 2013, SPIE
   Klopstock T, 2013, BRAIN, V136, DOI 10.1093/brain/aws279
   Klopstock T, 2016, NEUROLOGY, V86
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Koilkonda RD, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/179412
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lenaers G, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-46
   Leruez S, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0773-y
   Lewis CJ, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2020.101429
   Li JA, 2017, PHARMACOLOGY, V100, P83, DOI 10.1159/000458760
   Liu HL, 2020, ACTA OPHTHALMOL, V98, pE730, DOI 10.1111/aos.14379
   Macmillan C, 2000, AM J HUM GENET, V66, P332, DOI 10.1086/302716
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Markowitz SN, 2019, RETINA-J RET VIT DIS
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   Menzies KJ, 2013, J BIOL CHEM, V288, P6968, DOI 10.1074/jbc.M112.431155
   Merrill PT, 2020, OPHTHALMOLOGY
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Miret-Casals L, 2018, CELL CHEM BIOL, V25, P268, DOI 10.1016/j.chembiol.2017.12.001
   Moehle EA, 2019, J BIOL CHEM, V294, P5396, DOI 10.1074/jbc.TM117.000893
   Mok BY, 2020, NATURE, V583, P631, DOI 10.1038/s41586-020-2477-4
   Moore T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240517
   Mulkidjanian AY, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1263, DOI 10.1134/S0006297918100115
   Nagata S, 2018, ANNU REV IMMUNOL, V36, P489, DOI 10.1146/annurev-immunol-042617-053010
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Newman NJ, 2020, J NEURO-OPHTHALMOL, V40, P547, DOI 10.1097/WNO.0000000000001045
   Newman NJ, OPHTHALMOLOGY
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Park SW, 2011, INVEST OPHTH VIS SCI, V52, P2837, DOI 10.1167/iovs.09-5010
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Petrov A, 2016, ADV THER, V33, P96, DOI 10.1007/s12325-015-0274-5
   Picca A, 2018, NAT REV CARDIOL, V15, P543, DOI 10.1038/s41569-018-0059-z
   Pisano A, 2015, HUM MOL GENET, V24, P6921, DOI 10.1093/hmg/ddv396
   Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42
   Rawle MJ, 2013, CASE REP NEUROL, V5, P204, DOI 10.1159/000357518
   Reme CE, 2000, NEWS PHYSIOL SCI, V15, P120, DOI 10.1152/physiologyonline.2000.15.3.120
   Rocha AG, 2018, SCIENCE, V360, P336, DOI 10.1126/science.aao1785
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101
   Schrier SA, 2011, CURR OPIN OPHTHALMOL, V22, P325, DOI 10.1097/ICU.0b013e328349419d
   Schwartz LM, 2018, JAMA INTERN MED, V178, P181, DOI 10.1001/jamainternmed.2017.7904
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Shrader WD, 2011, BIOORG MED CHEM LETT, V21, P3693, DOI 10.1016/j.bmcl.2011.04.085
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   Sivapathasuntharam C, 2017, NEUROBIOL AGING, V52, P66, DOI 10.1016/j.neurobiolaging.2017.01.001
   Skulachev VP, 2009, BBA-BIOENERGETICS, V1787, P437, DOI 10.1016/j.bbabio.2008.12.008
   Song YM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010122
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Szabo A, 2018, BIOCHEM PHARMACOL, V150, P86, DOI 10.1016/j.bcp.2018.01.038
   Tachibana M, 2009, NATURE, V461, P367, DOI 10.1038/nature08368
   Tang J, 2013, INVEST OPHTH VIS SCI, V54, P3681, DOI 10.1167/iovs.12-11018
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Vallabh NA, 2017, MITOCHONDRION, V36, P103, DOI 10.1016/j.mito.2017.05.009
   Vial G, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00294
   Vignal C, 2018, OPHTHALMOLOGY, V125, P945, DOI 10.1016/j.ophtha.2017.12.036
   Voloboueva LA, 2007, FASEB J, V21, P4077, DOI 10.1096/fj.07-8396com
   Wan X, 2016, SCI REP-UK, V6, DOI 10.1038/srep21587
   Weiss Jeffrey N, 2019, Stem Cell Investig, V6, P41, DOI 10.21037/sci.2019.11.01
   Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664
   Whitaker RM, 2016, ANNU REV PHARMACOL, V56, P229, DOI 10.1146/annurev-pharmtox-010715-103155
   Williams Pete A, 2018, Commun Integr Biol, V11, pe1356956, DOI 10.1080/19420889.2017.1356956
   Yang S, 2016, EBIOMEDICINE, V10, P258, DOI 10.1016/j.ebiom.2016.07.002
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Yu-Wai-Man P, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz7423
   Yu-Wai-Man P, 2017, HUM MOL GENET, V26, pR12, DOI 10.1093/hmg/ddx182
   Yuan JJ, 2020, OPHTHALMOLOGY, V127, P1125, DOI 10.1016/j.ophtha.2020.02.023
   Zachari M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00171
   Zhang J, 2017, REPROD BIOMED ONLINE, V34, P361, DOI 10.1016/j.rbmo.2017.01.013
   Zhou P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030213
   Zorova LD, 2018, ANAL BIOCHEM, V552, P50, DOI 10.1016/j.ab.2017.07.009
   Zuchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 152
TC 4
Z9 4
U1 1
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2021
VL 10
IS 8
AR 4
DI 10.1167/tvst.10.8.4
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TW6RN
UT WOS:000682524600007
PM 34232272
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ribeiro, J
   Procyk, CA
   West, EL
   O'Hara-Wright, M
   Martins, MF
   Khorasani, MM
   Hare, A
   Basche, M
   Fernando, M
   Goh, D
   Jumbo, N
   Rizzi, M
   Powell, K
   Tariq, M
   Michaelides, M
   Bainbridge, JWB
   Smith, AJ
   Pearson, RA
   Gonzalez-Cordero, A
   Ali, RR
AF Ribeiro, Joana
   Procyk, Christopher A.
   West, Emma L.
   O'Hara-Wright, Michelle
   Martins, Monica F.
   Khorasani, Majid Moshtagh
   Hare, Aura
   Basche, Mark
   Fernando, Milan
   Goh, Debbie
   Jumbo, Neeraj
   Rizzi, Matteo
   Powell, Kate
   Tariq, Menahil
   Michaelides, Michel
   Bainbridge, James W. B.
   Smith, Alexander J.
   Pearson, Rachael A.
   Gonzalez-Cordero, Anai
   Ali, Robin R.
TI Restoration of visual function in advanced disease after transplantation
   of purified human pluripotent stem cell-derived cone photoreceptors
SO CELL REPORTS
LA English
DT Article
ID STAGE RETINAL-DEGENERATION; GANGLION-CELL; BIPOLAR CELLS; MOUSE MODEL;
   ACHROMATOPSIA; SHEETS; MICE; INTEGRATION; MECHANISM; RESTORES
AB Age-related macular degeneration and other macular diseases result in the loss of light-sensing cone photo-receptors, causing irreversible sight impairment. Photoreceptor replacement may restore vision by transplanting healthy cells, which must form new synaptic connections with the recipient retina. Despite recent advances, convincing evidence of functional connectivity arising from transplanted human cone photoreceptors in advanced retinal degeneration is lacking. Here, we show restoration of visual function after transplantation of purified human pluripotent stem cell-derived cones into a mouse model of advanced degeneration. Transplanted human cones elaborate nascent outer segments and make putative synapses with recipient murine bipolar cells (BCs), which themselves undergo significant remodeling. Electrophysiological and behavioral assessments demonstrate restoration of surprisingly complex light-evoked retinal ganglion cell responses and improved light-evoked behaviors in treated animals. Stringent controls exclude alternative explanations, including material transfer and neuroprotection. These data provide crucial validation for photoreceptor replacement therapy and for the potential to rescue cone-mediated vision.
C1 [Ribeiro, Joana; Procyk, Christopher A.; West, Emma L.; O'Hara-Wright, Michelle; Martins, Monica F.; Khorasani, Majid Moshtagh; Hare, Aura; Basche, Mark; Fernando, Milan; Goh, Debbie; Jumbo, Neeraj; Rizzi, Matteo; Powell, Kate; Tariq, Menahil; Michaelides, Michel; Bainbridge, James W. B.; Smith, Alexander J.; Pearson, Rachael A.; Gonzalez-Cordero, Anai; Ali, Robin R.] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Ali, Robin R.] Univ Michigan, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.
   [Ribeiro, Joana] Stanford Univ, Lorry I Lokey Stem Cell Res Bldg,265 Campus Dr, Palo Alto, CA USA.
   [Procyk, Christopher A.; West, Emma L.; Khorasani, Majid Moshtagh; Hare, Aura; Basche, Mark; Rizzi, Matteo; Powell, Kate; Smith, Alexander J.; Pearson, Rachael A.; Ali, Robin R.] Kings Coll London, Guys Hosp, Ctr Cell & Gene Therapy, Tower Wing, London SE1 9RT, England.
   [Gonzalez-Cordero, Anai] Univ Sydney, Childrens Med Res Inst, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.
C3 University of London; University College London; University of Michigan
   System; University of Michigan; Stanford University; Guy's & St Thomas'
   NHS Foundation Trust; University of London; King's College London;
   Children's Medical Research Institute - Australia; University of Sydney
RP Ali, RR (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.; Ali, RR (通讯作者)，Univ Michigan, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.; Ali, RR (通讯作者)，Kings Coll London, Guys Hosp, Ctr Cell & Gene Therapy, Tower Wing, London SE1 9RT, England.
EM robin.ali@kcl.ac.uk
RI Procyk, Christopher Anthony/ABB-3253-2021; Pearson, Rachael/Y-3339-2018
OI Procyk, Christopher Anthony/0000-0002-6754-4665; Bainbridge,
   James/0000-0003-1318-8201; Pearson, Rachael/0000-0002-1107-1969; Ali,
   Robin/0000-0003-3126-6517; Gonzalez Cordero, Anai/0000-0002-1818-0375;
   Claudio RIbeiro, Joana Filipa/0000-0002-9290-6023; Powell,
   Kate/0000-0001-5372-9880; Goh, Debbie/0000-0002-2510-3503;
   O'Hara-Wright, Michelle/0000-0002-2467-3790
FU Medical Research Council UK [MR/T002735/1, MR/J004553/1]; European
   Research Council [323147-STEMRD]; Retina UK; MRC [MR/R015651/1] Funding
   Source: UKRI
FX We thank the Institute of Ophthalmology (IoO) vector production and
   electron microscopy facilities and IoO and Institute of Child Health
   FACS facilities for technical support. The graphical abstract was
   generated using BioRender (https://biorender.com/).This work was
   supported by grants from the Medical Research Council UK (MR/T002735/1
   and MR/J004553/1), European Research Council (323147-STEMRD), and Retina
   UK, and by generous donations from The Miller's Trust, Otto van der
   Wyck, and F. Gargash.
CR Aghaizu ND, 2017, PROG BRAIN RES, V231, P191, DOI 10.1016/bs.pbr.2017.01.001
   Akiba R, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00016
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Beier C, 2017, J NEUROSCI, V37, P4635, DOI 10.1523/JNEUROSCI.2570-16.2017
   Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897
   Cao Y, 2015, NEURON, V87, P1248, DOI 10.1016/j.neuron.2015.09.002
   D'Orazi FD, 2014, TRENDS NEUROSCI, V37, P594, DOI 10.1016/j.tins.2014.07.009
   Davis KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123424
   Dubis AM, 2014, INVEST OPHTH VIS SCI, V55, P7303, DOI 10.1167/iovs.14-14225
   Eleftheriou CG, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00320
   Foik AT, 2018, J NEUROSCI, V38, P10709, DOI 10.1523/JNEUROSCI.1279-18.2018
   Garita-Hernandez M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12330-2
   Gonzalez-Cordero A, 2018, HUM GENE THER, V29, P1124, DOI 10.1089/hum.2018.027
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Hirji N, 2018, OPHTHALMIC GENET, V39, P149, DOI 10.1080/13816810.2017.1418389
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Klimczak RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007467
   Kruczek K, 2017, STEM CELL REP, V8, P1659, DOI 10.1016/j.stemcr.2017.04.030
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Laver CRJ, 2017, EXP EYE RES, V159, P156, DOI 10.1016/j.exer.2017.03.005
   Lin B, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.34
   Lin B, 2009, EXP EYE RES, V88, P589, DOI 10.1016/j.exer.2008.11.022
   Liu CM, 2013, MOL VIS, V19, P1268
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mahato B, 2020, NATURE, V581, P83, DOI 10.1038/s41586-020-2201-4
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nickerson PEB, 2018, FRONT NEURAL CIRCUIT, V12, DOI 10.3389/fncir.2018.00017
   Nishiguchi KM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7006
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Opalka N, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000483
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Peng CH, 2003, J BIOL CHEM, V278, P34533, DOI 10.1074/jbc.M305102200
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Procyk CA, 2015, J NEUROPHYSIOL, V114, P1321, DOI 10.1152/jn.00368.2015
   Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000
   Puthussery T, 2009, EUR J NEUROSCI, V29, P1533, DOI 10.1111/j.1460-9568.2009.06728.x
   Reh TA, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17659
   Ruediger T, 2007, ADV EXP MED BIOL, V621, P104, DOI 10.1007/978-0-387-76715-4_8
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Sarin S, 2018, NEURON, V98, P109, DOI 10.1016/j.neuron.2018.03.004
   Schroeder MM, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00203
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Stefanov A, 2020, J COMP NEUROL, V528, P1502, DOI 10.1002/cne.24838
   Strettoi E, 2004, J NEUROSCI, V24, P7576, DOI 10.1523/JNEUROSCI.2245-04.2004
   Strettoi E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00494
   Tufford AR, 2018, CELL REP, V23, P2416, DOI 10.1016/j.celrep.2018.04.086
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C
   West EL, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a035683
   Wong KY, 2007, J PHYSIOL-LONDON, V582, P279, DOI 10.1113/jphysiol.2007.133751
   Wong KY, 2012, J NEUROSCI, V32, P11478, DOI 10.1523/JNEUROSCI.1423-12.2012
   Wurm A, 2011, PROG RETIN EYE RES, V30, P324, DOI 10.1016/j.preteyeres.2011.06.001
   Zhang D.-Q., 2009, INVEST OPHTH VIS SCI, V50, P5684
   Zhao XW, 2014, J PHYSIOL-LONDON, V592, P1619, DOI 10.1113/jphysiol.2013.262782
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhu J, 2017, CELL STEM CELL, V20, P374, DOI 10.1016/j.stem.2016.11.019
NR 68
TC 21
Z9 21
U1 1
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD APR 20
PY 2021
VL 35
IS 3
AR 109022
DI 10.1016/j.celrep.2021.109022
EA APR 2021
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RQ1EH
UT WOS:000642161700019
PM 33882303
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kuiper, JJW
   Beretta, L
   Nierkens, S
   van Leeuwen, R
   ten Dam-van Loon, NH
   Norel, JOV
   Bartels, MC
   de Groot-Mijnes, JDF
   Schellekens, P
   de Boer, JH
   Radstake, TRDJ
AF Kuiper, J. J. W.
   Beretta, L.
   Nierkens, S.
   van Leeuwen, R.
   ten Dam-van Loon, N. H.
   Ossewaarde-van Norel, J.
   Bartels, M. C.
   de Groot-Mijnes, J. D. F.
   Schellekens, P.
   de Boer, J. H.
   Radstake, T. R. D. J.
TI An Ocular Protein Triad Can Classify Four Complex Retinal Diseases
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; AQUEOUS-HUMOR; EXPRESSION PROFILE;
   CYTOKINE PROFILES; DISTINCT CYTOKINE; UVEITIS; GROWTH; PLASMA; IL-10;
   IL-21
AB Retinal diseases generally are vision-threatening conditions that warrant appropriate clinical decision-making which currently solely dependents upon extensive clinical screening by specialized ophthalmologists. In the era where molecular assessment has improved dramatically, we aimed at the identification of biomarkers in 175 ocular fluids to classify four archetypical ocular conditions affecting the retina (age-related macular degeneration, idiopathic non-infectious uveitis, primary vitreoretinal lymphoma, and rhegmatogenous retinal detachment) with one single test. Unsupervised clustering of ocular proteins revealed a classification strikingly similar to the clinical phenotypes of each disease group studied. We developed and independently validated a parsimonious model based merely on three proteins; interleukin (IL)-10, IL-21, and angiotensin converting enzyme (ACE) that could correctly classify patients with an overall accuracy, sensitivity and specificity of respectively, 86.7%, 79.4% and 92.5%. Here, we provide proof-of-concept for molecular profiling as a diagnostic aid for ophthalmologists in the care for patients with retinal conditions.
C1 [Kuiper, J. J. W.; Nierkens, S.; de Boer, J. H.; Radstake, T. R. D. J.] Univ Med Ctr Utrecht, Dept Immunol, Lab Translat Immunol, Utrecht, Netherlands.
   [Kuiper, J. J. W.; van Leeuwen, R.; ten Dam-van Loon, N. H.; Ossewaarde-van Norel, J.; de Groot-Mijnes, J. D. F.; Schellekens, P.; de Boer, J. H.] Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands.
   [Beretta, L.] Fdn IRCCS Ca Granda Osped Maggiore Policlin Milan, Referral Ctr System Autoimmune Dis, Milan, Italy.
   [Bartels, M. C.] Deventer Hosp, Dept Ophthalmol, Deventer, Netherlands.
   [de Groot-Mijnes, J. D. F.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands.
   [Radstake, T. R. D. J.] Univ Med Ctr Utrecht, Dept Clin Immunol & Rheumatol, Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University; Utrecht University Medical Center; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; Deventer Hospital; Utrecht University; Utrecht
   University Medical Center; Utrecht University; Utrecht University
   Medical Center
RP Kuiper, JJW (通讯作者)，Univ Med Ctr Utrecht, Dept Immunol, Lab Translat Immunol, Utrecht, Netherlands.; Kuiper, JJW (通讯作者)，Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands.
EM J.J.W.Kuiper@umcutrecht.nl
RI Beretta, Lorenzo/AAB-8605-2019; Nierkens, Stefan/AAQ-5564-2021
OI Beretta, Lorenzo/0000-0002-6529-6258; Nierkens,
   Stefan/0000-0003-3406-817X
CR Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Aydin E, 2010, CURR EYE RES, V35, P230, DOI 10.3109/02713680903484242
   Barbas-Bernardos C., 2016, J PHARM BIOMED ANAL
   Beatty PR, 1997, J IMMUNOL, V158, P4045
   Bernstein K. E., 2016, F1000RES, V5
   Besharse J., 2011, RETINA ITS DISORDERS
   Bhatt S., 2016, LEUK LYMPHOMA
   Cassoux N, 2007, INVEST OPHTH VIS SCI, V48, P3253, DOI 10.1167/iovs.06-0031
   Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
   Chawla NV., 2004, SIGKDD EXPLOR, V6, P1, DOI [DOI 10.1145/1007730.1007733, 10.1145/1007730.1007733]
   Chen W, 2015, CURR MOL MED, V15, P543, DOI 10.2174/1566524015666150731100012
   Cheung CMG, 2004, BRIT J OPHTHALMOL, V88, P582, DOI 10.1136/bjo.2003.027219
   Coupland SE, 2009, OCUL IMMUNOL INFLAMM, V17, P227, DOI 10.1080/09273940903168696
   Curnow SJ, 2005, INVEST OPHTH VIS SCI, V46, P4251, DOI 10.1167/iovs.05-0444
   de Jager W, 2005, J IMMUNOL METHODS, V300, P124, DOI 10.1016/j.jim.2005.03.009
   Demsar J, 2004, LECT NOTES ARTIF INT, V3202, P537
   den Hollander AI, 2016, INVEST OPHTH VIS SCI, V57, P1378, DOI 10.1167/iovs.15-18167
   Ecker SM, 2011, MOL VIS, V17, P2856
   Fisson S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052385
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gundlach E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147258
   Haasnoot AMJW, 2016, ARTHRITIS RHEUMATOL, V68, P1769, DOI 10.1002/art.39621
   Hall M., 2009, SIGKDD EXPLORATIONS, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Hoerster R, 2013, BRIT J OPHTHALMOL, V97, P450, DOI 10.1136/bjophthalmol-2012-302636
   Hoffman P, 1997, VISUALIZATION '97 - PROCEEDINGS, P437, DOI 10.1109/VISUAL.1997.663916
   Kim YS, 2016, INTEGR MED RES, V5, P22, DOI 10.1016/j.imr.2016.01.001
   Kuiper J, 2015, ACTA OPHTHALMOL, V93, pE680, DOI 10.1111/aos.12733
   Kuiper JJW, 2011, AM J OPHTHALMOL, V152, P177, DOI 10.1016/j.ajo.2011.01.031
   Landau Klara, 2011, Handb Clin Neurol, V102, P97, DOI 10.1016/B978-0-444-52903-9.00010-8
   Leonard Warren J, 2016, F1000Res, V5, DOI 10.12688/f1000research.7634.1
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lu T., 2016, ONCOTARGET
   Mischak H, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001249
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Porter LF, 2014, CLIN GENET, V86, P1, DOI 10.1111/cge.12389
   Quinlan J.R, 1993, C4 5 PROGRAMS MACHIN
   Ricker LJAG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019141
   Rothova A, 1996, BRIT J OPHTHALMOL, V80, P332, DOI 10.1136/bjo.80.4.332
   Schaftenaar E, 2015, SAMJ S AFR MED J, V105, P628, DOI [10.7196/SAMJnew.7816, 10.7196/SAMJNEW.7816, 10.7196/samj.9552]
   Shen XZ, 2007, AM J PATHOL, V170, P2122, DOI 10.2353/ajpath.2007.061205
   Skeie JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127567
   Tanaka Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05089
   Trivedi D, 2011, CLIN EXP OPHTHALMOL, V39, P725, DOI 10.1111/j.1442-9071.2011.02565.x
   Valentincic NV, 2011, MOL VIS, V17, P2003
   van Kooij B, 2006, AM J OPHTHALMOL, V142, P192, DOI 10.1016/j.ajo.2006.02.052
   VanderLelij A, 1997, BRIT J OPHTHALMOL, V81, P976, DOI 10.1136/bjo.81.11.976
   Velez G, 2016, JAMA OPHTHALMOL, V134, P444, DOI 10.1001/jamaophthalmol.2015.5934
   Wang L, 2011, P NATL ACAD SCI USA, V108, P9542, DOI 10.1073/pnas.1018182108
   Wecker T., 2016, INVEST OPHTHALMOL VI, V4
   Wolf LA, 2003, OPHTHALMOLOGY, V110, P1671, DOI 10.1016/S0161-6420(03)00811-X
   Xia JG, 2011, NAT PROTOC, V6, P743, DOI 10.1038/nprot.2011.319
   Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021
   Zhao BB, 2015, EXP EYE RES, V138, P80, DOI 10.1016/j.exer.2015.06.018
NR 53
TC 12
Z9 12
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 27
PY 2017
VL 7
AR 41595
DI 10.1038/srep41595
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EJ0CQ
UT WOS:000392876600001
PM 28128370
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mariotti, C
   Lazzarini, R
   Nicolai, M
   Saitta, A
   Orsini, E
   Orciani, M
   Di Primio, R
AF Mariotti, Cesare
   Lazzarini, Raffaella
   Nicolai, Michele
   Saitta, Andrea
   Orsini, Emanuele
   Orciani, Monia
   Di Primio, Roberto
TI Comparative study between amniotic-fluid mesenchymal stem cells and
   retinal pigmented epithelium (RPE) stem cells ability to differentiate
   towards RPE cells
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Mesenchymal stem cells; Retinal pigmented ephitelium (RPE); Amniotic
   fluid; Age-related macular degeneration (AMD)
ID MACULAR DEGENERATION; PROGENITOR CELLS; STROMAL CELLS; THERAPY;
   TRANSPLANTATION; SYSTEM
AB Dysfunction of the retinal pigmented epithelium (RPE) is one of the first effects of dry age-related macular degeneration (AMD) with consequent blindness. Hence, patients affected by this retinal disorder could benefit from a cell-based transplantation strategy for RPE. Actually, an effective protocol to approach this problem is lacking, though recently, it has been postulated the existence of a subpopulation of RPE stem cells (RPESCs) derived from adult RPE and able to reconstitute a functional RPE. On the other hand, the evidence related to the differentiative potential of human mesenchymal stem cells (MSCs) is continuously increasing. Among others, amniotic fluid-derived MSCs (AF-MSCs) may be a promising candidate, since these cells are characterized by high proliferation and differentiative potential. In this study, AF-MSCs and RPESCs were isolated, characterized to assay their stemness and induced to neuronal/retinal differentiation; specific RPE markers were then analyzed. Our results indicate that RPESCs are more suitable candidates for RPE replacement than AF-MSCs.
C1 [Mariotti, Cesare; Nicolai, Michele; Saitta, Andrea; Orsini, Emanuele] Ophthalmol Clin, Dept Expt & Clin Med, Ancona, Italy.
   [Lazzarini, Raffaella; Orciani, Monia; Di Primio, Roberto] Univ Politecn Marche, Dept Clin & Mol Sci Histol, I-60020 Ancona, Italy.
C3 Marche Polytechnic University
RP Orciani, M (通讯作者)，Univ Politecn Marche, Dept Clin & Mol Sci Histol, Via Tronto 10-A, I-60020 Ancona, Italy.
EM m.orciani@univpm.it
OI Nicolai, Michele/0000-0001-8302-6107; di primio,
   roberto/0000-0003-3044-1731; orciani, monia/0000-0003-4503-3693; Saitta,
   Andrea/0000-0003-4849-8381
FU Ministero dell'Istruzione, dell'Universita e della Ricerca, Rome, Italy
   [FIRB-RBAP10MLK7_003, FIRB-RBAP1153LS_004, PRIN 201098WFZ2_006]
FX This work was supported by grants FIRB-RBAP10MLK7_003,
   FIRB-RBAP1153LS_004 and PRIN 201098WFZ2_006 from the Ministero
   dell'Istruzione, dell'Universita e della Ricerca, Rome, Italy.
CR Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Decembrini S, 2011, STEM CELLS DEV, V20, P851, DOI 10.1089/scd.2010.0291
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duan P, 2013, CELL PHYSIOL BIOCHEM, V31, P601, DOI 10.1159/000350080
   Ferretti C, 2012, STEM CELL REV REP, V8, P882, DOI 10.1007/s12015-012-9374-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hartmann K, 2013, AM J STEM CELLS, V2, P108
   Kim J, 2007, CELL PROLIFERAT, V40, P75
   Lazzarini R, 2014, CELL TISSUE RES, V355, P121, DOI 10.1007/s00441-013-1725-4
   Moviglia GA, 2012, OPHTHALMIC RES, V48, P1, DOI 10.1159/000339839
   Orciani M, 2008, INT J IMMUNOPATH PH, V21, P595, DOI 10.1177/039463200802100312
   Orciani M, 2015, CANCER GENE THER, V22, P9, DOI 10.1038/cgt.2014.63
   Orciani M, 2011, J BIOL REG HOMEOS AG, V25, P115
   Orciani M, 2013, PLAST RECONSTR SURG, V132, p899E, DOI 10.1097/01.prs.0000434401.98939.60
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rennie K, 2013, BIOCHEM CELL BIOL, V91, P271, DOI 10.1139/bcb-2013-0019
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Salvolini E, 2011, EUR J CLIN INVEST, V41, P23, DOI 10.1111/j.1365-2362.2010.02370.x
   Sanie-Jahromi Fatemeh, 2012, BMC Res Notes, V5, P182, DOI 10.1186/1756-0500-5-182
   Stern JH, 2011, NEUROTHERAPEUTICS, V8, P736, DOI 10.1007/s13311-011-0077-6
   Zagoura DS, 2012, GUT, V61, P894, DOI 10.1136/gutjnl-2011-300908
NR 28
TC 14
Z9 14
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
EI 1432-0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD OCT
PY 2015
VL 362
IS 1
BP 21
EP 31
DI 10.1007/s00441-015-2185-9
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CR6PQ
UT WOS:000361470000003
PM 25916690
DA 2022-11-30
ER

PT J
AU Schnebelen-Berthier, C
   Acar, N
   Pouillart, P
   Thabuis, C
   Rodriguez, B
   Depeint, F
   Clerc, E
   Mathiaud, A
   Bourdillon, A
   Baert, B
   Bretillon, L
   Lecerf, JM
AF Schnebelen-Berthier, Coralie
   Acar, Niyazi
   Pouillart, Philippe
   Thabuis, Clementine
   Rodriguez, Bertrand
   Depeint, Flore
   Clerc, Elise
   Mathiaud, Adeline
   Bourdillon, Anne
   Baert, Blandine
   Bretillon, Lionel
   Lecerf, Jean-Michel
TI Incorporation of lutein and docosahexaenoic acid from dietary microalgae
   into the retina in quail
SO INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION
LA English
DT Article
DE Age-related macular degeneration; DHA; lutein; microalgae; quail; retina
ID AGE-RELATED MACULOPATHY; POLYUNSATURATED FATTY-ACIDS; MACULAR PIGMENT;
   ALZHEIMERS-DISEASE; OXIDATIVE STRESS; FISH CONSUMPTION; OCULAR-TISSUES;
   CAROTENOIDS; ZEAXANTHIN; PLASMA
AB Lutein and docosahexaenoic acid (DHA) are associated with the prevention of age-related macular degeneration (AMD). Since microalgae are potent natural sources of these nutrients, their nutritional value should be evaluated based on the bioavailability of lutein and DHA for the retina via the plasmatic compartment. In this study, quail were fed for 5 months either with a diet supplemented or deprived with microalgae rich in lutein and DHA. In the microalgae-fed group, the retinal concentrations of lutein and zeaxanthin gradually increased whereas in plasma, these compounds started to increase from the first month of supplementation. We also observed a significant increase in retinal and plasmatic levels of DHA in the microalgae-fed group. In conclusion, the plasmatic and retinal contents of lutein and DHA were significantly increased in quail fed with lutein-and DHA-rich microalgae. Food fortification with microalgae may be an innovative way to increase lutein and DHA consumption in humans.
C1 [Schnebelen-Berthier, Coralie; Clerc, Elise; Lecerf, Jean-Michel] Inst Pasteur, Serv Nutr, 1 Rue Pr Calmette,BP 245, F-59019 Lille, France.
   [Acar, Niyazi; Bretillon, Lionel] CNRS, Ctr Sci Gout & Alimentat, Equipe OEil Nutr & Signalisat, UMR6265, Dijon, France.
   [Acar, Niyazi; Bretillon, Lionel] INRA, Ctr Sci Gout & Alimentat, Equipe OEil Nutr & Signalisat, UMR1324, F-21034 Dijon, France.
   [Acar, Niyazi; Bretillon, Lionel] Univ Bourgogne, Equipe OEil Nutr & Signalisat, Ctr Sci Gout & Alimentat, Dijon, France.
   [Pouillart, Philippe; Depeint, Flore] Inst Polytech LaSalle Beauvais, Beauvais, France.
   [Thabuis, Clementine; Rodriguez, Bertrand; Baert, Blandine] ROQUETTE, Lestrem, France.
   [Mathiaud, Adeline; Bourdillon, Anne] ZAC Cice Blossac, Ctr Affaires Odyssee, SANDERS, Bruz, France.
C3 Le Reseau International des Instituts Pasteur (RIIP); Universite de
   Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Institut Agro; AgroSup Dijon; Universite de Bourgogne; INRAE; Institut
   Agro; AgroSup Dijon; Centre National de la Recherche Scientifique
   (CNRS); Universite de Bourgogne; Institut Agro; AgroSup Dijon; Centre
   National de la Recherche Scientifique (CNRS); Universite de Bourgogne;
   UniLaSalle
RP Lecerf, JM (通讯作者)，Inst Pasteur, Serv Nutr, 1 Rue Pr Calmette,BP 245, F-59019 Lille, France.
EM jean-michel.lecerf@pasteur-lille.fr
OI Bretillon, Lionel/0000-0002-6957-100X
FU French public institution OSEO
FX The authors would like to thank the French public institution OSEO for
   their generous financial support in the ALGOHUB (R) Program. The authors
   gratefully acknowledge Stephane Gregoire, Lucy Martine, Camille Boroch
   and Jean-Yves Madec for their technical support.
CR Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Acar N, 2009, EXP EYE RES, V89, P840, DOI 10.1016/j.exer.2009.07.008
   Al MDM, 2000, AM J CLIN NUTR, V71, p285S, DOI 10.1093/ajcn/71.1.285s
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bhosale P, 2007, BIOCHEMISTRY-US, V46, P9050, DOI 10.1021/bi700558f
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Breslow JL, 2006, AM J CLIN NUTR, V83, p1477S, DOI 10.1093/ajcn/83.6.1477S
   Calder PC, 2012, J NUTR, V142, p592S, DOI 10.3945/jn.111.155259
   Guedes AC, 2011, BIOTECHNOL PROGR, V27, P597, DOI 10.1002/btpr.575
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hooijmans CR, 2012, J ALZHEIMERS DIS, V28, P191, DOI 10.3233/JAD-2011-111217
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   JUANEDA P, 1985, LIPIDS, V20, P40, DOI 10.1007/BF02534360
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F, 2012, ACTA BIOCHIM POL, V59, P75
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim JE, 2012, NUTR RES PRACT, V6, P113, DOI 10.4162/nrp.2012.6.2.113
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lecerf JM, 2010, CAH NUTR DIET, V45, P144, DOI 10.1016/j.cnd.2009.12.003
   Lyan B, 2001, J CHROMATOGR B, V751, P297, DOI 10.1016/S0378-4347(00)00488-6
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   MOILANEN T, 1981, CLIN CHIM ACTA, V114, P111, DOI 10.1016/0009-8981(81)90235-7
   MORRISON WR, 1964, J LIPID RES, V5, P600
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Obulesu M, 2011, NEUROCHEM INT, V59, P535, DOI 10.1016/j.neuint.2011.04.004
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schnebelen C, 2009, OPHTHALMIC RES, V41, P216, DOI 10.1159/000217726
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Spolaore P, 2006, J BIOSCI BIOENG, V101, P87, DOI 10.1263/jbb.101.87
   Swanson D, 2012, ADV NUTR, V3, P1, DOI 10.3945/an.111.000893
   Sy C, 2012, MOL NUTR FOOD RES, V56, P1385, DOI 10.1002/mnfr.201200041
   Toomey MB, 2007, INVEST OPHTH VIS SCI, V48, P3976, DOI 10.1167/iovs.07-0208
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Vidgren HM, 1997, LIPIDS, V32, P697, DOI 10.1007/s11745-997-0089-x
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   WEISINGER HS, 1995, LIPIDS, V30, P471, DOI 10.1007/BF02536307
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
NR 56
TC 3
Z9 3
U1 3
U2 25
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0963-7486
EI 1465-3478
J9 INT J FOOD SCI NUTR
JI Int. J. Food Sci. Nutr.
PD MAR
PY 2015
VL 66
IS 2
BP 222
EP 229
DI 10.3109/09637486.2014.971227
PG 8
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA CD9YK
UT WOS:000351456900014
PM 25657100
DA 2022-11-30
ER

PT J
AU Yehoshua, Z
   Garcia, CAA
   Penha, FM
   Gregori, G
   Stetson, PF
   Feuer, WJ
   Rosenfeld, PJ
AF Yehoshua, Zohar
   Garcia Filho, Carlos Alexandre A.
   Penha, Fernando M.
   Gregori, Giovanni
   Stetson, Paul F.
   Feuer, William J.
   Rosenfeld, Philip J.
TI Comparison of Geographic Atrophy Measurements from the OCT Fundus Image
   and the Sub-RPE Slab Image
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; AGE-RELATED MACULOPATHY; RETINAL-PIGMENT
   EPITHELIUM; MACULAR DEGENERATION; HIGH-RESOLUTION; RISK-FACTORS;
   VISUAL-LOSS; AUTOFLUORESCENCE; PROGRESSION
AB PURPOSE: To compare two different approaches to measuring areas of geographic atrophy (GA) using spectral-domain optical coherence tomography (SD-OCT).
   METHODS: Fifty eyes with GA were imaged with an SD-OCT instrument. OCT fundus images and sub-retinal pigment epithelium (RPE) slab images were generated. Three graders manually drew the GA boundaries on both en face images. An automated algorithm was used to segment the GA boundaries from the sub-RPE slabs.
   RESULTS: The agreement between the three manual measurements on both OCT fundus images (ICC = .998) and sub-RPE slabs (ICC = .999) was excellent. Area measurements from OCT fundus images and sub-RPE slabs were highly correlated. The agreement between manual and automated measurements on the sub-RPE slabs was very good (ICC = .795).
   CONCLUSION: Both OCT fundus images and sub-RPE slab images proved useful for measuring GA in age-related macular degeneration. The automated algorithm typically provided useful measurements of GA area from the sub-RPE slabs.
C1 [Gregori, Giovanni] Univ Miami, Coral Gables, FL 33124 USA.
C3 University of Miami
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
FU Carl Zeiss Meditec; Research to Prevent Blindness; NEI core center [P30
   EY014801]; Department of Defense Grant [W81XWH-09-1-0675]; Macula Vision
   Research Foundation; Jerome A. Yavitz Charitable Foundation; Feig Family
   Foundation; Emma Clyde Hodge Memorial Foundation; NATIONAL EYE INSTITUTE
   [P30EY014801] Funding Source: NIH RePORTER
FX The research was supported by a grant from Carl Zeiss Meditec, an
   unrestricted grant from Research to Prevent Blindness, NEI core center
   grant P30 EY014801, and Department of Defense Grant W81XWH-09-1-0675 to
   the University of Miami, the Macula Vision Research Foundation, the
   Jerome A. Yavitz Charitable Foundation, Feig Family Foundation, and the
   Emma Clyde Hodge Memorial Foundation.
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Li Y, 2011, OPT EXPRESS, V19, P26239, DOI 10.1364/OE.19.026239
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   POTTER JW, 1981, J AM OPTOM ASSOC, V52, P503
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schutze C, 2011, ACTA OPHTHALMOL, V89, P235, DOI 10.1111/j.1755-3768.2010.01955.x
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 26
TC 47
Z9 49
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR-APR
PY 2013
VL 44
IS 2
BP 127
EP 132
DI 10.3928/23258160-20130313-05
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 172PS
UT WOS:000321017200005
PM 23510038
DA 2022-11-30
ER

PT J
AU Maci, S
AF Maci, Samanta
TI Lutein and Zeaxanthin in the eye From protection to performance
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR PIGMENT; CAROTENOIDS; SUPPLEMENTATION;
   DEGENERATION; IDENTIFICATION; RETINA
AB Lutein and zeaxanthin are the only two dietary carotenoids selectively concentrated in the macula lutea of the eye and represent the key components of the macular pigment (MP). The ability of lutein and zeaxanthin to stabilize membrane integrity, to act as antioxidants and to filter short wavelengths of visible light, support the beneficial role that MP may specifically have in the retina, a tissue particularly susceptible to light damage and oxidative stress. Observational studies and clinical trials have shown inverse associations between high lutein and zeaxanthin intake, high macular pigment optical density (MPOD) and risk of degenerative eye diseases such as age-related macular degeneration (AMD). Aside from this protective function, the blue-light filtering properties of the MP have recently gained a renewed interest and researchers are focusing their attention and investigations on the role of MP in improving visual performance not only in AMD patients but also in healthy adults.
C1 Kemin Hlth Europe, P-2795242 Linda A Velha, Portugal.
RP Maci, S (通讯作者)，Kemin Hlth Europe, Ed Cent Pk,Rua Alexandre Herculano 1-1A, P-2795242 Linda A Velha, Portugal.
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   STAHL W, 1996, NUTURAL ANTIOXIIDANT, P95
   *STETH MARK RES, LUT SURV 2009 2010 K
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   AGE RELATED EYE DIS
NR 23
TC 2
Z9 2
U1 0
U2 5
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722-6996
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD SEP-OCT
PY 2010
VL 21
IS 5
SU S
BP 18
EP 20
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 694AM
UT WOS:000285267200005
DA 2022-11-30
ER

PT J
AU Hijioka, K
   Sonoda, KH
   Tsutsumi-Miyahara, C
   Fujimoto, T
   Oshima, Y
   Taniguchi, M
   Ishibashi, T
AF Hijioka, Kuniaki
   Sonoda, Koh-Hei
   Tsutsumi-Miyahara, Chikako
   Fujimoto, Takeshi
   Oshima, Yuji
   Taniguchi, Masaru
   Ishibashi, Tatsuro
TI Investigation of the role of CD1d-restricted invariant NKT cells in
   experimental choroidal neovascularization
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE choroidal neovascularization; age-related macular degeneration; natural
   killer T cell; vascular endothelial growth factor; innate immunity
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   T-CELLS; ANGIOGENESIS; EXPRESSION; INCREASES; IL-4; MICE
AB Choroidal neovascularization (CNV) is directly related to visual loss in age-related macular degeneration and other macular disorders. We have investigated the role of CD1d-restricted invariant natural killer T (NKT) cells in laser-induced experimental CNV. Quantitative real-time PCR detected increased expression of NKT cell-related genes (Va14 and CXCL16) in whole eyes undergoing CNV, indicating local accumulation of NKT cells. We found a significant reduction of CNV and lower concentrations of vascular endothelial growth factor (VEGF) in ocular fluid in two different NKT cell-deficient mice, CD1d knockout (KO) and J alpha 18 KO mice. We also established in vitro co-cultures of retinal pigment epithelial cells and splenic NKT cells, and confirmed NKT cells could produce VEGF in the dish. Moreover, inoculating a-galactosylceramide, the ligand for NKT cells, into the vitreous cavity of C57BL/6 mice promoted CNV. We concluded that NKT cells play an important role in CNV as an inducer of VEGF. (C) 2008 Elsevier Inc. All right reserved.
C1 [Hijioka, Kuniaki; Sonoda, Koh-Hei; Tsutsumi-Miyahara, Chikako; Fujimoto, Takeshi; Oshima, Yuji; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan.
   [Taniguchi, Masaru] RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Kanagawa 2300045, Japan.
C3 Kyushu University; RIKEN
RP Sonoda, KH (通讯作者)，Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM sonodak@med.kyushu-u.ac.jp
CR BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697
   Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hatzi E, 2002, ONCOGENE, V21, P3552, DOI 10.1038/sj.onc.1205440
   Huang SP, 2004, J BIOMED SCI, V11, P517, DOI 10.1159/000077902
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jiang XF, 2005, J IMMUNOL, V175, P2051, DOI 10.4049/jimmunol.175.4.2051
   Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3
   Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Shimamura M, 1997, EUR J IMMUNOL, V27, P1576, DOI 10.1002/eji.1830270638
   Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Wilson MT, 2003, P NATL ACAD SCI USA, V100, P10913, DOI 10.1073/pnas.1833166100
   YI X, 1997, ARCH CLIN EXP OPHTHA, V235, P313
NR 20
TC 14
Z9 15
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 12
PY 2008
VL 374
IS 1
BP 38
EP 43
DI 10.1016/j.bbrc.2008.06.080
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 342QN
UT WOS:000258798700008
PM 18606153
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Spandau, UHM
   Schlichtenbrede, F
   Libondi, T
   Vossmerbaeumer, U
   Von Baltz, S
AF Jonas, Jost B.
   Spandau, Ulrich H. M.
   Schlichtenbrede, Frank
   Libondi, Teodosio
   Vossmerbaeumer, Urs
   Von Baltz, Stefan
TI Intravitreal bevacizumab combined with cataract surgery for treatment of
   exudative macular degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID COHERENCE TOMOGRAPHY FINDINGS; RETINAL VEIN OCCLUSION; INJECTION;
   AVASTIN(R); EDEMA
AB Purpose: The aim of this study was to report on the combination of an intravitreal injection of bevacizumab and cataract surgery in patients with exudative age-related macular degeneration (AMD).
   Methods: The interventional case series study included 11 patients (11 eyes) who received an intravitreal injection of 1.5 mg bevacizumab as treatment of exudative AMD (n = 10) or exudative myopic macular degeneration (n = 1), combined with a routine phacoemulsification and posterior chamber lens implantation for treatment of cataract.
   Results: Intraoperatively and during the follow-up of 150 +/- 77.5 days, there were no complications related to the intravitreal application of bevacizumab combined with cataract surgery, such as wound dehiscence and leakage, delayed wound healing, corneal edema, dislocation of the pseudophakos, rupture of the posterior lens capsule, or rhegmatogenous retinal detachment.
   Conclusions: The results of this pilot study suggest that from a safety point of view, intravitreal injections of bevacizumab may be combined with routine cataract surgery.
C1 Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.jonas@augen.ma.uni-heidelberg.de
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P329, DOI 10.1177/112067210501500303
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
NR 5
TC 12
Z9 14
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC
PY 2007
VL 23
IS 6
BP 599
EP 600
DI 10.1089/jop.2007.0050
PG 2
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 238GB
UT WOS:000251434300011
PM 18020962
DA 2022-11-30
ER

PT J
AU Gullapalli, VK
   Zarbin, MA
AF Gullapalli, Vamsi K.
   Zarbin, Marco A.
TI New Prospects for Retinal Pigment Epithelium Transplantation
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; cell-based therapy; RPE transplant;
   Stargardt disease; stem cells
ID EMBRYONIC STEM-CELLS; ANTERIOR LENS CAPSULE; MACULAR DEGENERATION;
   BRUCHS MEMBRANE; IN-VITRO; SUBRETINAL SPACE; HUMAN RPE; GEOGRAPHIC
   ATROPHY; OUTER SEGMENTS; ROYAL-COLLEGE
AB Retinal pigment epithelium (RPE) transplants rescue photoreceptors in selected animal models of retinal degenerative disease. Early clinical studies of RPE transplants as treatment for age-related macular degeneration (AMD) included autologous and allogeneic transplants of RPE suspensions and RPE sheets for atrophic and neovascular complications of AMD. Subsequent studies explored autologous RPE-Bruch membrane-choroid transplants in patients with neovascular AMD with occasional marked visual benefit, which establishes a rationale for RPE transplants in late-stage AMD. More recent work has involved transplantation of autologous and allogeneic stem cell-derived RPE for patients with AMD and those with Stargardt disease. These early-stage clinical trials have employed RPE suspensions and RPE monolayers on biocompatible scaffolds. Safety has been well documented, but evidence of efficacy is variable. Current research involves development of better scaffolds, improved modulation of immune surveillance, and modification of the extracellular milieu to improve RPE survival and integration with host retina.
C1 [Gullapalli, Vamsi K.] Univ Rochester, Flaum Eye Inst, Rochester, NY USA.
   [Zarbin, Marco A.] Rutgers State Univ, Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ 07102 USA.
C3 University of Rochester; Rutgers State University Newark; Rutgers State
   University New Brunswick; Rutgers State University Medical Center
RP Zarbin, MA (通讯作者)，Rutgers, DOC 6th Floor,6th Ave, Newark, NJ 07103 USA.
EM zarbin@earthlink.net
FU Joseph J and Marguerite DiSepio Retina Research Fund; English Family
   Foundation
FX Supported by the Joseph J and Marguerite DiSepio Retina Research Fund
   and the English Family Foundation.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Andrews PW, 2017, STEM CELL REP, V9, P1, DOI 10.1016/j.stemcr.2017.05.029
   Angunawela RI, 2005, BRIT J OPHTHALMOL, V89, P386, DOI 10.1136/bjo.2004.050716
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Beutel J, 2007, GRAEF ARCH CLIN EXP, V245, P1469, DOI 10.1007/s00417-007-0566-9
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Boyd AS, 2010, EXPERT REV CLIN IMMU, V6, P435, DOI [10.1586/eci.10.20, 10.1586/ECI.10.20]
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brochard V, 2021, METHODS MOL BIOL, V2214, P109, DOI 10.1007/978-1-0716-0958-3_8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calejo MT, 2020, ACTA BIOMATER, V101, P327, DOI 10.1016/j.actbio.2019.11.002
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   CHIHARA E, 1985, GRAEF ARCH CLIN EXP, V223, P202, DOI 10.1007/BF02174060
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Chung Y, 2008, CELL STEM CELL, V2, P113, DOI 10.1016/j.stem.2007.12.013
   Chung YG, 2014, CELL STEM CELL, V14, P777, DOI 10.1016/j.stem.2014.03.015
   Coghlan A., 2015, NEW SCI
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   da Silva GR, 2011, INT J ARTIF ORGANS, V34, P198, DOI 10.5301/IJAO.2011.6398
   Davis RJ, 2016, J OCUL PHARMACOL TH, V32, P304, DOI 10.1089/jop.2015.0162
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Delmonico FL., 1989, CONTEMP ISS NEPHROL, P129
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3
   Deuse T, 2015, CELL STEM CELL, V16, P33, DOI 10.1016/j.stem.2014.11.003
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fernandes Marie, 2018, Curr Protoc Stem Cell Biol, V45, pe53, DOI 10.1002/cpsc.53
   Fernandes Rodrigo A Brant, 2017, Int J Retina Vitreous, V3, P41, DOI 10.1186/s40942-017-0095-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Gandhi JK, 2018, ACTA BIOMATER, V67, P134, DOI 10.1016/j.actbio.2017.11.058
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256
   Han X, 2019, P NATL ACAD SCI USA, V116, P10441, DOI 10.1073/pnas.1902566116
   Handa JT., 2018, RYANS RETINA, V6, P451
   Harris JR, 2009, STEM CELLS, V27, P457, DOI 10.1634/stemcells.2008-0836
   Harris TI, 2019, ACS BIOMATER SCI ENG, V5, P4023, DOI 10.1021/acsbiomaterials.9b00183
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HOLLYFIELD JG, 1974, J EXP ZOOL, V189, P357, DOI 10.1002/jez.1401890309
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Hsiue GH, 2002, J BIOMED MATER RES, V61, P19, DOI 10.1002/jbm.2000
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Huang Q, 2021, CURR MED SCI, V41, P145, DOI 10.1007/s11596-021-2329-y
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Ishida K, 2003, OCUL IMMUNOL INFLAMM, V11, P91, DOI 10.1076/ocii.11.2.91.15914
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jemni-Damer N, 2020, J NEURAL ENG, V17, DOI 10.1088/1741-2552/abb9c0
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Jung SK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179238
   Kadkhodaeian HA, 2019, TISSUE ENG REGEN MED, V16, P253, DOI 10.1007/s13770-019-00183-1
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kang EJ, 2016, CELL STEM CELL, V18, P625, DOI 10.1016/j.stem.2016.02.005
   Kanuga N, 2002, INVEST OPHTH VIS SCI, V43, P546
   Kaplan HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1168, DOI 10.1001/archopht.1997.01100160338012
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   Kim HM, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010108
   Kim J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031095
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Klimanskaya I, 2006, NATURE, V444, P481, DOI 10.1038/nature05142
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5973, DOI 10.1167/iovs.10-6965
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Krishna Y, 2007, J BIOMED MATER RES A, V80A, P669, DOI 10.1002/jbm.a.30953
   Lai CC, 1999, INVEST OPHTH VIS SCI, V40, P2141
   Lee CJ, 2007, BIOMATERIALS, V28, P2192, DOI 10.1016/j.biomaterials.2007.01.018
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Lin TW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020241
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Liu ZP, 2021, STEM CELL REP, V16, P237, DOI 10.1016/j.stemcr.2020.12.007
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Loh YH, 2009, BLOOD, V113, P5476, DOI 10.1182/blood-2009-02-204800
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Lu B, 2014, DEV OPHTHALMOL, V53, P155, DOI 10.1159/000357375
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu Y, 2017, ACTA OPHTHALMOL, V95, pE443, DOI 10.1111/aos.13054
   Ma H, 2014, NATURE, V511, P177, DOI 10.1038/nature13551
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Mack AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027956
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   McBain VA, 2012, AM J OPHTHALMOL, V154, P146, DOI 10.1016/j.ajo.2012.01.019
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   Mittal R, 1997, NEPHRON, V77, P186, DOI 10.1159/000190271
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Molday RS, 2009, BBA-MOL CELL BIOL L, V1791, P573, DOI 10.1016/j.bbalip.2009.02.004
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nakatsuji N, 2008, NAT BIOTECHNOL, V26, P739, DOI 10.1038/nbt0708-739
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   Ohno-Matsui K, 2006, MOL VIS, V12, P1022
   Paolin A, 2016, CELL TISSUE BANK, V17, P51, DOI 10.1007/s10561-015-9520-y
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   Petrus-Reurer S, 2020, STEM CELL TRANSL MED, V9, P936, DOI 10.1002/sctm.19-0396
   Petrus-Reurer S, 2020, STEM CELL REP, V14, P648, DOI 10.1016/j.stemcr.2020.02.006
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Phelan MA, 2020, TISSUE ENG PART C-ME, V26, P433, DOI [10.1089/ten.tec.2020.0072, 10.1089/ten.TEC.2020.0072]
   Qi XP, 2017, MOL THER, V25, P917, DOI 10.1016/j.ymthe.2017.01.015
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Reyes AP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15326-5
   Rim MA, 2020, ACS APPL BIO MATER, V3, P6079, DOI 10.1021/acsabm.0c00672
   Robertson NJ, 2007, P NATL ACAD SCI USA, V104, P20920, DOI 10.1073/pnas.0710265105
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Scheiner ZS, 2014, J BIOL CHEM, V289, P4571, DOI 10.1074/jbc.R113.509588
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V386, P30, DOI 10.1016/S0140-6736(15)61203-X
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sengupta N, 2009, MOL THER, V17, P1594, DOI 10.1038/mt.2009.145
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Shi L, 2020, STEM CELLS, V38, P1423, DOI 10.1002/stem.3269
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sorkio AE, 2015, BIOMATERIALS, V51, P257, DOI 10.1016/j.biomaterials.2015.02.005
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stevanovic M., 2019, CELL BASED THERAPY D, P109
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Surucu S, 2016, APPL SURF SCI, V385, P400, DOI 10.1016/j.apsusc.2016.05.123
   Tachibana M, 2013, CELL, V153, P1228, DOI 10.1016/j.cell.2013.05.006
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6
   Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014
   Tena A, 2014, DEV OPHTHALMOL, V53, P122, DOI 10.1159/000357360
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thackaberry EA, 2017, INVEST OPHTH VIS SCI, V58, P4274, DOI 10.1167/iovs.16-21334
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   Turner M, 2013, CELL STEM CELL, V13, P382, DOI 10.1016/j.stem.2013.08.003
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   van Zeeburg EJT, 2015, OPHTHALMOLOGICA, V233, P134, DOI 10.1159/000380829
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Wendland RJ, 2021, EXP EYE RES, V207, DOI 10.1016/j.exer.2021.108566
   White C, 2017, J BIOMED MATER RES A, V105, P1260, DOI 10.1002/jbm.a.35992
   Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yabut O, 2011, AGING-US, V3, P494, DOI 10.18632/aging.100328
   Yamada M, 2014, NATURE, V510, P533, DOI 10.1038/nature13287
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zarbin MA, 2008, AM J OPHTHALMOL, V146, P151, DOI 10.1016/j.ajo.2008.05.027
   Zeng ZQ, 2021, ANN BIOMED ENG, V49, P1633, DOI 10.1007/s10439-021-02756-5
   Zernant J, 2017, J MED GENET, V54, P404, DOI 10.1136/jmedgenet-2017-104540
   Zimmermann A, 2012, STEM CELLS DEV, V21, P2364, DOI 10.1089/scd.2012.0088
NR 189
TC 1
Z9 1
U1 1
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD JUL-AUG
PY 2022
VL 11
IS 4
BP 302
EP 313
DI 10.1097/APO.0000000000000521
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4E0DB
UT WOS:000847504200002
PM 36041145
OA gold
DA 2022-11-30
ER

PT J
AU Jeong, Y
   Hong, YJ
   Han, JH
AF Jeong, Yeonwoo
   Hong, Yu-Jin
   Han, Jae-Ho
TI Review of Machine Learning Applications Using Retinal Fundus Images
SO DIAGNOSTICS
LA English
DT Article
DE deep learning; fundus image; machine learning; retinal image
ID OPEN-ANGLE GLAUCOMA; NERVE-FIBER LAYER; DIABETIC-RETINOPATHY; MACULAR
   DEGENERATION; BLOOD-VESSELS; CLASSIFICATION; PERFORMANCE; AGREEMENT;
   FEATURES; NETWORK
AB Automating screening and diagnosis in the medical field saves time and reduces the chances of misdiagnosis while saving on labor and cost for physicians. With the feasibility and development of deep learning methods, machines are now able to interpret complex features in medical data, which leads to rapid advancements in automation. Such efforts have been made in ophthalmology to analyze retinal images and build frameworks based on analysis for the identification of retinopathy and the assessment of its severity. This paper reviews recent state-of-the-art works utilizing the color fundus image taken from one of the imaging modalities used in ophthalmology. Specifically, the deep learning methods of automated screening and diagnosis for diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma are investigated. In addition, the machine learning techniques applied to the retinal vasculature extraction from the fundus image are covered. The challenges in developing these systems are also discussed.
C1 [Jeong, Yeonwoo; Han, Jae-Ho] Korea Univ, Dept Brain & Cognit Engn, 145 Anam Rd, Seoul 02841, South Korea.
   [Hong, Yu-Jin] Hoseo Univ, Div Elect & Display Engn, 20 Hoseo Ro79beon Gil, Asan 31066, South Korea.
   [Han, Jae-Ho] Korea Univ, Dept Artificial Intelligence, 145 Anam Rd, Seoul 02841, South Korea.
C3 Korea University; Hoseo University; Korea University
RP Han, JH (通讯作者)，Korea Univ, Dept Brain & Cognit Engn, 145 Anam Rd, Seoul 02841, South Korea.; Han, JH (通讯作者)，Korea Univ, Dept Artificial Intelligence, 145 Anam Rd, Seoul 02841, South Korea.
EM boyjeong@korea.ac.kr; yjhong@hoseo.edu; hanjaeho@korea.ac.kr
OI HAN, JAE HO/0000-0002-6490-9825
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [NRF-2020R1A4A1018309]; MSIT (Ministry of Science and ICT), Korea
   [IITP-2021-2020-0-01819]
FX This work was supported in part by the National Research Foundation of
   Korea (NRF) grant funded by the Korean government (MSIT)
   (NRF-2020R1A4A1018309). This research was supported in part by the MSIT
   (Ministry of Science and ICT), Korea, under the ICT Creative Consilience
   program(IITP-2021-2020-0-01819) supervised by the IITP(Institute for
   Information & communications Technology Planning & Evaluation).
CR ABRAMS LS, 1994, OPHTHALMOLOGY, V101, P1662
   Adem K, 2018, EXPERT SYST APPL, V114, P289, DOI 10.1016/j.eswa.2018.07.053
   Alyoubi WL, 2021, SENSORS-BASEL, V21, DOI 10.3390/s21113704
   Alyoubi WL., 2020, INFORM MED UNLOCKED, V20, P100377
   Zapata MA, 2020, CLIN OPHTHALMOL, V14, P419, DOI 10.2147/OPTH.S235751
   Anowar F, 2021, COMPUT SCI REV, V40, DOI 10.1016/j.cosrev.2021.100378
   Badar M, 2020, COMPUT SCI REV, V35, DOI 10.1016/j.cosrev.2019.100203
   Barros DMS, 2020, BIOMED ENG ONLINE, V19, DOI 10.1186/s12938-020-00767-2
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Billheimer J, 2019, SCREEN CLASSIC, P59
   BROWN GC, 1985, RETINA-J RET VIT DIS, V5, P206, DOI 10.1097/00006982-198500540-00003
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Chen CH, 2021, IEEE ACCESS, V9, P111985, DOI 10.1109/ACCESS.2021.3102176
   Cheng J, 2013, IEEE T MED IMAGING, V32, P1019, DOI 10.1109/TMI.2013.2247770
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   Christopher M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35044-9
   Chu AA, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8841927
   Chudzik P, 2018, COMPUT METH PROG BIO, V158, P185, DOI 10.1016/j.cmpb.2018.02.016
   Cina A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89102-w
   Coates Adam, 2012, Neural Networks: Tricks of the Trade. Second Edition: LNCS 7700, P561, DOI 10.1007/978-3-642-35289-8_30
   Cui SJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70629-3
   Dar SUH, 2019, IEEE T MED IMAGING, V38, P2375, DOI 10.1109/TMI.2019.2901750
   Dasgupta A, 2017, I S BIOMED IMAGING, P248, DOI 10.1109/ISBI.2017.7950512
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deng Z, 2017, J INSTRUM, V12, DOI 10.1088/1748-0221/12/05/P05009
   Dong L, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100875
   Dunn J. C., 1973, Journal of Cybernetics, V3, P32
   Dutta S, 2018, INT J GRID DISTRIB, V11, P89, DOI 10.14257/ijgdc.2018.11.1.09
   Ebrahimkhani S, 2020, ARTIF INTELL MED, V106, DOI 10.1016/j.artmed.2020.101851
   ESMANN V, 1963, ACTA MED SCAND, V174, P375
   Fingeret Murray, 2005, Optometry, V76, P661, DOI 10.1016/j.optm.2005.08.029
   Foracchia M, 2005, MED IMAGE ANAL, V9, P179, DOI 10.1016/j.media.2004.07.001
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Frid-Adar M, 2018, NEUROCOMPUTING, V321, P321, DOI 10.1016/j.neucom.2018.09.013
   Fu HZ, 2016, I S BIOMED IMAGING, P698, DOI 10.1109/ISBI.2016.7493362
   Girard F, 2019, ARTIF INTELL MED, V94, P96, DOI 10.1016/j.artmed.2019.02.004
   GOLDBERG DE, 1989, GENETIC ALGORITHMS S, P59
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hollands H, 2013, JAMA-J AM MED ASSOC, V309, P2035, DOI 10.1001/jama.2013.5099
   Howard AG, 2017, ARXIV PREPRINT ARXIV, DOI 10.48550/arXiv.1704.04861
   Hu K, 2018, NEUROCOMPUTING, V309, P179, DOI 10.1016/j.neucom.2018.05.011
   Hu Q, 2015, J MED IMAGING, V2, DOI 10.1117/1.JMI.2.4.044001
   Huang F, 2018, MACH VISION APPL, V29, P23, DOI 10.1007/s00138-017-0867-x
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Huazhu Fu, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P132, DOI 10.1007/978-3-319-46723-8_16
   Hussain MA, 2018, 2018 JOINT 7TH INTERNATIONAL CONFERENCE ON INFORMATICS, ELECTRONICS & VISION (ICIEV) AND 2018 2ND INTERNATIONAL CONFERENCE ON IMAGING, VISION & PATTERN RECOGNITION (ICIVPR), P394, DOI 10.1109/ICIEV.2018.8641078
   Iandola F.N., 2016, ARXIV, DOI DOI 10.1007/978-3-319-24553-9
   Ilginis T, 2014, BRIT MED BULL, V111, P77, DOI 10.1093/bmb/ldu022
   Jampel HD, 2009, AM J OPHTHALMOL, V147, P39, DOI 10.1016/j.ajo.2008.07.023
   Jiang HY, 2019, IEEE ENG MED BIO, P2045, DOI 10.1109/EMBC.2019.8857160
   Jiang Z, 2020, BIOMED OPT EXPRESS, V11, P1580, DOI 10.1364/BOE.387807
   Jo T, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00220
   Joshi GD, 2008, SIXTH INDIAN CONFERENCE ON COMPUTER VISION, GRAPHICS & IMAGE PROCESSING ICVGIP 2008, P591, DOI 10.1109/ICVGIP.2008.70
   Keel S, 2019, CLIN EXP OPHTHALMOL, V47, P1009, DOI 10.1111/ceo.13575
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1533, DOI 10.1016/j.ophtha.2019.06.005
   Kim M, 2018, IEEE INT C BIOINFORM, P2357, DOI 10.1109/BIBM.2018.8621168
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kumar V., 2009, ROBBINS COTRAN PATHO, V69, P1616
   Lakhani P, 2017, RADIOLOGY, V284, P574, DOI 10.1148/radiol.2017162326
   Lee H., 2011, P 14 INT C ART INT S, P215, DOI DOI 10.1177/1753193410390845
   Leung CKS, 2009, OPHTHALMOLOGY, V116, P1257, DOI 10.1016/j.ophtha.2009.04.013
   Li CM, 2008, IEEE T IMAGE PROCESS, V17, P1940, DOI 10.1109/TIP.2008.2002304
   Li F, 2020, GRAEF ARCH CLIN EXP, V258, P851, DOI 10.1007/s00417-020-04609-8
   Li T, 2021, MED IMAGE ANAL, V69, DOI 10.1016/j.media.2021.101971
   Li T, 2019, INFORM SCIENCES, V501, P511, DOI 10.1016/j.ins.2019.06.011
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Liu HR, 2019, JAMA OPHTHALMOL, V137, P1353, DOI 10.1001/jamaophthalmol.2019.3501
   Lundervold AS, 2019, Z MED PHYS, V29, P102, DOI 10.1016/j.zemedi.2018.11.002
   Luo YS, 2017, COMM COM INF SC, V710, P157, DOI 10.1007/978-981-10-5230-9_17
   Maji D, 2015, IEEE ENG MED BIO, P3029, DOI 10.1109/EMBC.2015.7319030
   Mao XD, 2017, IEEE I CONF COMP VIS, P2813, DOI 10.1109/ICCV.2017.304
   Medeiros FA, 2019, OPHTHALMOLOGY, V126, P513, DOI 10.1016/j.ophtha.2018.12.033
   Meyer MI, 2017, LECT NOTES COMPUT SC, V10317, P507, DOI 10.1007/978-3-319-59876-5_56
   Ministry of Defense, 2016, DEF JAP 2016, P9
   Mirsharif Q, 2013, COMPUT MED IMAG GRAP, V37, P607, DOI 10.1016/j.compmedimag.2013.06.003
   Mobeen-ur-Rehman, 2019, PROCEEDINGS 2019 AMITY INTERNATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE (AICAI), P244, DOI 10.1109/AICAI.2019.8701231
   Mookiah MRK, 2021, MED IMAGE ANAL, V68, DOI 10.1016/j.media.2020.101905
   Neely KA, 1998, AM J PATHOL, V153, P665, DOI 10.1016/S0002-9440(10)65607-6
   Neuroanatomy, RETINA-J RET VIT DIS
   Nuzzi R, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.710329
   O'Byrne C, 2021, CURR OPIN OPHTHALMOL, V32, P406, DOI 10.1097/ICU.0000000000000779
   Oh K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81539-3
   Oliveira WS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149943
   Park KB, 2020, IEEE ACCESS, V8, P146308, DOI 10.1109/ACCESS.2020.3015108
   Pavan M, 2007, IEEE T PATTERN ANAL, V29, P167, DOI 10.1109/TPAMI.2007.250608
   Pekala M., 2018, P ASIAN C COMPUTER V, P316
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Perdomo Charry Oscar Julián, 2020, Cienc. Ing. Neogranad., V30, P9, DOI 10.18359/rcin.4242
   Phene S, 2019, OPHTHALMOLOGY, V126, P1627, DOI 10.1016/j.ophtha.2019.07.024
   Pires R, 2019, ARTIF INTELL MED, V96, P93, DOI 10.1016/j.artmed.2019.03.009
   Prum Bruce E Jr, 2016, Ophthalmology, V123, pP41, DOI 10.1016/j.ophtha.2015.10.053
   Ranjbarzadeh R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90428-8
   Redmon J., 2018, ARXIV
   Reed S., 2015, P IEEE C COMP VIS PA, P1
   Reznicek L, 2017, INT J OPHTHALMOL-CHI, V10, P1534, DOI 10.18240/ijo.2017.10.09
   Rizzi A, 2003, PATTERN RECOGN LETT, V24, P1663, DOI 10.1016/S0167-8655(02)00323-9
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Selvam S, 2018, PROG RETIN EYE RES, V63, P1, DOI 10.1016/j.preteyeres.2017.11.001
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Sermanet P., 2014, P ICLR
   Shanthi T, 2019, COMPUT ELECTR ENG, V76, P56, DOI 10.1016/j.compeleceng.2019.03.004
   Shibata N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33013-w
   Shinde Rutuja, 2021, INTELLIGENCEBASED ME, V5, DOI [10.1016/j.ibmed.2021.100038, DOI 10.1016/J.IBMED.2021.100038]
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Singh LK, 2021, MED BIOL ENG COMPUT, V59, P333, DOI 10.1007/s11517-020-02307-5
   Sisson C. P., 2014, ANAL CELL PATHOL, V2014
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Srinidhi CL, 2019, IEEE T IMAGE PROCESS, V28, P2705, DOI 10.1109/TIP.2018.2889534
   Srinidhi CL, 2018, BIOMED SIGNAL PROCES, V44, P110, DOI 10.1016/j.bspc.2018.04.016
   Srinidhi CL, 2017, I S BIOMED IMAGING, P882, DOI 10.1109/ISBI.2017.7950657
   Szegedy C, P IEEE C COMP VIS PA, P2818
   Szegedy C, 2017, AAAI CONF ARTIF INTE, P4278
   Tan MX, 2019, PR MACH LEARN RES, V97
   Tatham AJ, 2017, OPHTHALMOLOGY, V124, pS57, DOI 10.1016/j.ophtha.2017.07.015
   Thomas R, 2011, INDIAN J OPHTHALMOL, V59, pS43, DOI 10.4103/0301-4738.73688
   Thompson AC, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.42
   Thompson AC, 2019, AM J OPHTHALMOL, V201, P9, DOI 10.1016/j.ajo.2019.01.011
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   Vijayakumar V, 2016, IEEE ENG MED BIO, P1320, DOI 10.1109/EMBC.2016.7590950
   Wang H, 2020, COMPUT METH PROG BIO, V191, DOI 10.1016/j.cmpb.2020.105398
   Wang SL, 2015, NEUROCOMPUTING, V149, P708, DOI 10.1016/j.neucom.2014.07.059
   Wang XL, 2018, 2018 IEEE INTERNATIONAL CONFERENCE ON INFORMATION REUSE AND INTEGRATION (IRI), P465, DOI 10.1109/IRI.2018.00074
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Welikala RA, 2017, COMPUT BIOL MED, V90, P23, DOI 10.1016/j.compbiomed.2017.09.005
   Xu XY, 2017, COMPUT METH PROG BIO, V141, P3, DOI 10.1016/j.cmpb.2017.01.007
   Yan ZQ, 2019, IEEE J BIOMED HEALTH, V23, P1427, DOI 10.1109/JBHI.2018.2872813
   Yang JW, 2020, INTERDISCIP SCI, V12, P323, DOI 10.1007/s12539-020-00385-5
   Zago GT, 2020, COMPUT BIOL MED, V116, DOI 10.1016/j.compbiomed.2019.103537
   Zeng CY, 2020, FRONT NEUROINFORM, V14, DOI 10.3389/fninf.2020.610967
   Zhang W, 2019, KNOWL-BASED SYST, V175, P12, DOI 10.1016/j.knosys.2019.03.016
   Zhao H, 2018, MED IMAGE ANAL, V49, P14, DOI 10.1016/j.media.2018.07.001
   Zhao YT, 2020, IEEE T MED IMAGING, V39, P341, DOI 10.1109/TMI.2019.2926492
   Zhao YT, 2015, IEEE T MED IMAGING, V34, P1797, DOI 10.1109/TMI.2015.2409024
   Zhou B, 2016, PROC CVPR IEEE, P2921, DOI 10.1109/CVPR.2016.319
   Zoph B, 2018, PROC CVPR IEEE, P8697, DOI 10.1109/CVPR.2018.00907
NR 139
TC 3
Z9 3
U1 7
U2 20
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD JAN
PY 2022
VL 12
IS 1
AR 134
DI 10.3390/diagnostics12010134
PG 27
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YO2UQ
UT WOS:000747800700001
PM 35054301
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, BJ
   Mastellos, DC
   Li, YF
   Dunaief, JL
   Lambris, JD
AF Kim, Benjamin J.
   Mastellos, Dimitrios C.
   Li, Yafeng
   Dunaief, Joshua L.
   Lambris, John D.
TI Targeting complement components C3 and C5 for the retina: Key concepts
   and lingering questions
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Geographic atrophy; Complement; C3;
   C5; Retina
ID PIGMENT EPITHELIAL-CELLS; MEMBRANE ATTACK COMPLEX; GEOGRAPHIC ATROPHY
   SECONDARY; FACTOR-H POLYMORPHISM; CHOROIDAL BLOOD-FLOW;
   MACULAR-DEGENERATION; ALTERNATIVE PATHWAY; NLRP3 INFLAMMASOME; OXIDATIVE
   STRESS; FACTOR-B
AB Age-related macular degeneration (AMD) remains a major cause of legal blindness, and treatment for the geographic atrophy form of AMD is a significant unmet need. Dysregulation of the complement cascade is thought to be instrumental for AMD pathophysiology. In particular, C3 and C5 are pivotal components of the complement cascade and have become leading therapeutic targets for AMD. In this article, we discuss C3 and C5 in detail, including their roles in AMD, biochemical and structural aspects, locations of expression, and the functions of C3 and C5 fragments. Further, the article critically reviews developing therapeutics aimed at C3 and C5, underscoring the potential effects of broad inhibition of complement at the level of C3 versus more specific inhibition at C5. The relationships of complement biology to the inflammasome and microglia/macrophage activity are highlighted. Concepts of C3 and C5 biology will be emphasized, while we point out questions that need to be settled and directions for future investigations.
C1 [Kim, Benjamin J.; Li, Yafeng; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mastellos, Dimitrios C.] Natl Ctr Sci Res Demokritos, Athens, Greece.
   [Lambris, John D.] Univ Penn, Dept Lab Med & Pathol, Perelman Sch Med, Philadelphia, PA USA.
C3 University of Pennsylvania; Pennsylvania Medicine; National Centre of
   Scientific Research "Demokritos"; University of Pennsylvania;
   Pennsylvania Medicine
RP Kim, BJ (通讯作者)，Univ Penn, Perelman Sch Med, Scheie Eye Inst, 51 North 39th St, Philadelphia, PA 19104 USA.
EM benjamin.kim@pennmedicine.upenn.edu
OI Li, Yafeng/0000-0002-6208-2801; Mastellos, Dimitrios/0000-0002-6634-3271
FU National Institutes of Health [R01EY028916]; Research to Prevent
   Blindness (New York, NY); Paul and Evanina Bell Mackall Foundation
   (Chicago, IL)
FX This work was supported by the National Institutes of Health
   [R01EY028916 (J.L.D.) ] ; funding was also provided in the form of block
   research grants to the Scheie Eye Institute from Research to Prevent
   Blindness (New York, NY) and the Paul and Evanina Bell Mackall
   Foundation (Chicago, IL) .
CR Alcorlo M, 2015, FEBS J, V282, P3883, DOI 10.1111/febs.13399
   Alcorlo M, 2013, P NATL ACAD SCI USA, V110, P13504, DOI 10.1073/pnas.1309618110
   Alcorlo M, 2011, P NATL ACAD SCI USA, V108, P13236, DOI 10.1073/pnas.1106746108
   Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arbore G, 2016, SCIENCE, V352, DOI 10.1126/science.aad1210
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Bajic G, 2013, P NATL ACAD SCI USA, V110, P16426, DOI 10.1073/pnas.1311261110
   Berger N, 2018, J MED CHEM, V61, P6153, DOI 10.1021/acs.jmedchem.8b00560
   Bergmann-Leitner ES, 2006, CLIN IMMUNOL, V121, P177, DOI 10.1016/j.clim.2006.07.001
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bosco A, 2018, MOL THER, V26, P2379, DOI 10.1016/j.ymthe.2018.08.017
   BOTTO M, 1992, P NATL ACAD SCI USA, V89, P4957, DOI 10.1073/pnas.89.11.4957
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Campagne MV, 2007, CELL MICROBIOL, V9, P2095, DOI 10.1111/j.1462-5822.2007.00981.x
   Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Catalyst Biosciences, PIP COMPL
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chen, 2017, BLOOMBERG BUSINESSWE
   Chen ZA, 2016, MOL CELL PROTEOMICS, V15, P2730, DOI 10.1074/mcp.M115.056473
   Cheng LJ, 2013, INVEST OPHTH VIS SCI, V54, P8191, DOI 10.1167/iovs.13-12428
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Castro C, 2020, AM J HEMATOL, V95, P1334, DOI 10.1002/ajh.25960
   DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Delanghe JR, 2014, PATHOLOGY, V46, P1, DOI 10.1097/PAT.0000000000000042
   Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dolgin E, 2017, NAT BIOTECHNOL, V35, P1000, DOI 10.1038/nbt1117-1000
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Duval D, 2020, GENES-BASEL, V11, DOI 10.3390/genes11010069
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ekdahl KN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02237
   Elvington M, 2017, J CLIN INVEST, V127, P970, DOI 10.1172/JCI89412
   Elvington ML, 2016, IMMUNOBIOLOGY, V221, P1197, DOI 10.1016/j.imbio.2016.06.160
   Emlen W, 2010, SEMIN THROMB HEMOST, V36, P660, DOI 10.1055/s-0030-1262888
   Erdei A, 2016, IMMUNOL REV, V274, P127, DOI 10.1111/imr.12498
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Frampton JE, 2020, DRUGS, V80, P719, DOI 10.1007/s40265-020-01297-w
   Fredslund F, 2008, NAT IMMUNOL, V9, P753, DOI 10.1038/ni.1625
   Freeley S, 2016, IMMUNOL REV, V274, P16, DOI 10.1111/imr.12472
   FREI Y, 1987, MOL CELL PROBE, V1, P141, DOI 10.1016/0890-8508(87)90022-3
   Furfine E, 2019, INVEST OPHTH VIS SCI, V60
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Geller A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01074
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Grossman TR, 2017, MOL VIS, V23, P561
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guymer RH, 2018, OPHTHALMOL RETINA, V2, P515, DOI 10.1016/j.oret.2018.03.004
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hajishengallis G, 2017, NAT IMMUNOL, V18, P1288, DOI 10.1038/ni.3858
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hannan JP, 2016, CURR PROTEIN PEPT SC, V17, P463, DOI 10.2174/1389203717666151201192124
   Harboe M, 2017, P NATL ACAD SCI USA, V114, pE534, DOI 10.1073/pnas.1612385114
   Harboe M, 2009, MOL IMMUNOL, V47, P373, DOI 10.1016/j.molimm.2009.09.005
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Haynes T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3312
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   Hourcade DE, 2002, J BIOL CHEM, V277, P1107, DOI 10.1074/jbc.M109322200
   Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068
   HUBER R, 1980, H-S Z PHYSIOL CHEM, V361, P1389, DOI 10.1515/bchm2.1980.361.2.1389
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   HUGHES AL, 1994, MOL BIOL EVOL, V11, P417
   Hughes S, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108391
   Irmscher S, 2018, J INNATE IMMUN, V10, P94, DOI 10.1159/000484257
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Jevsevar S, 2010, BIOTECHNOL J, V5, P113, DOI 10.1002/biot.200900218
   Jore MM, 2016, NAT STRUCT MOL BIOL, V23, P378, DOI 10.1038/nsmb.3196
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Karki RG, 2019, J MED CHEM, V62, P4656, DOI 10.1021/acs.jmedchem.9b00271
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027
   Kouser L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00093
   Krishnan V, 2009, STRUCTURE, V17, P611, DOI 10.1016/j.str.2009.01.015
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Law SKA, 1997, PROTEIN SCI, V6, P263
   Lay E, 2015, CLIN EXP IMMUNOL, V181, P314, DOI 10.1111/cei.12437
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Leslie RGQ, 2003, EUR J IMMUNOL, V33, P3311, DOI 10.1002/eji.200324330
   Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7
   Li R, 2013, FASEB J, V27, P855, DOI 10.1096/fj.12-220509
   Li YF, 2015, J BIOL CHEM, V290, P11918, DOI 10.1074/jbc.M115.645903
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin ZE, 2015, BLOOD, V126, P891, DOI 10.1182/blood-2015-02-625871
   Liszewski MK, 2017, MOL IMMUNOL, V84, P2, DOI 10.1016/j.molimm.2017.01.004
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Liu D, 2009, IMMUNOPHARM IMMUNOT, V31, P524, DOI 10.3109/08923970902845768
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lyubchenko T, 2005, J IMMUNOL, V174, P3264, DOI 10.4049/jimmunol.174.6.3264
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Maguire MG, 2012, OPHTHALMOLOGY, V119, P1501, DOI 10.1016/j.ophtha.2012.03.012
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mastellos DC, 2020, CLIN IMMUNOL, V220, DOI 10.1016/j.clim.2020.108598
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   Mastellos DC, 2017, TRENDS IMMUNOL, V38, P383, DOI 10.1016/j.it.2017.03.003
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   McDonnell T, 2014, RHEUMATOLOGY, V53, P391, DOI 10.1093/rheumatology/ket278
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Milder FJ, 2007, NAT STRUCT MOL BIOL, V14, P224, DOI 10.1038/nsmb1210
   MISUMI Y, 1984, FEBS LETT, V175, P63, DOI 10.1016/0014-5793(84)80570-0
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   MORRIS KM, 1982, SCIENCE, V215, P399, DOI 10.1126/science.7199205
   Mukai R, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00015
   Mulfaul K, 2020, CELL REP, V30, P2209, DOI 10.1016/j.celrep.2020.01.064
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okura Y, 2016, J ALLERGY CLIN IMMUN, V137, P640, DOI 10.1016/j.jaci.2015.08.017
   PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Papanastasiou M, 2017, J IMMUNOL, V198, P3326, DOI 10.4049/jimmunol.1601864
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Prohaszka Z, 2016, IMMUNOBIOLOGY, V221, P1247, DOI 10.1016/j.imbio.2016.06.008
   Puliafito CA, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00221-4
   Radu, 2020, REDOX BIOL
   Reis ES, 2006, INFLAMM RES, V55, P179, DOI 10.1007/s00011-006-0068-y
   Reis ES, 2019, NAT REV IMMUNOL, V19, P503, DOI 10.1038/s41577-019-0168-x
   Reis ES, 2012, J IMMUNOL, V189, P4797, DOI 10.4049/jimmunol.1200834
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156
   Ricklin D, 2016, IMMUNOL REV, V274, P33, DOI 10.1111/imr.12500
   Ricklin D, 2016, NAT REV NEPHROL, V12, P383, DOI 10.1038/nrneph.2016.70
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Risitano AM, 2020, NAT REV IMMUNOL, V20, P343, DOI 10.1038/s41577-020-0320-7
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Roguska M, 2014, INVEST OPHTH VIS SCI, V55
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer B, 2018, ADV EXP MED BIOL, V1074, P45, DOI 10.1007/978-3-319-75402-4_6
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rondelli T, 2014, HAEMATOLOGICA, V99, P262, DOI 10.3324/haematol.2013.090001
   Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344
   Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x
   Sahu A, 1996, J IMMUNOL, V157, P884
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Schatz-Jakobsen JA, 2016, J IMMUNOL, V197, P337, DOI 10.4049/jimmunol.1600280
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schmidt CQ, 2013, J IMMUNOL, V190, P5712, DOI 10.4049/jimmunol.1203548
   Schnabolk G, 2017, J OCUL PHARMACOL TH, V33, P400, DOI 10.1089/jop.2016.0101
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schultz H, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.05.026
   SCHWAEBLE W, 1993, J IMMUNOL, V151, P2521
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shahulhameed S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00154
   Shields KJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174577
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Skendros P, 2020, J CLIN INVEST, V130, P6151, DOI 10.1172/JCI141374
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Song DL, 2017, MOL VIS, V23, P210
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374
   Sun X, 2014, JAMA-J AM MED ASSOC, V311, P405, DOI 10.1001/jama.2013.285063
   Sunyer JO, 1998, IMMUNOL TODAY, V19, P519
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Toapanta FR, 2006, IMMUNOL RES, V36, P197, DOI 10.1385/IR:36:1:197
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Troldborg A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00581
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Ueda K, 2018, P NATL ACAD SCI USA, V115, P4963, DOI 10.1073/pnas.1722601115
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Vorup-Jensen T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02716
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Winters MS, 2005, J IMMUNOL, V174, P3469, DOI 10.4049/jimmunol.174.6.3469
   Wong WT, 2020, OPHTHALMOLOGY, V127, P196, DOI 10.1016/j.ophtha.2019.09.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   World Health Organization, 2020, PRIOR EYE DIS
   Wu XB, 2018, J IMMUNOL, V200, P2786, DOI 10.4049/jimmunol.1701668
   Xie CB, 2020, AM J PATHOL, V190, P1138, DOI 10.1016/j.ajpath.2020.02.006
   Xie CB, 2019, CIRC RES, V124, P1747, DOI 10.1161/CIRCRESAHA.119.314845
   Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yeh S, 2020, OPHTHALMOLOGY, V127, P948, DOI 10.1016/j.ophtha.2020.01.006
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 228
TC 9
Z9 9
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2021
VL 83
AR 100936
DI 10.1016/j.preteyeres.2020.100936
EA JUL 2021
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TM9WH
UT WOS:000675896500001
PM 33321207
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Abbasi, A
   Monadjemi, A
   Fang, LY
   Rabbani, H
   Zhang, Y
AF Abbasi, Ashkan
   Monadjemi, Amirhassan
   Fang, Leyuan
   Rabbani, Hossein
   Zhang, Yi
TI Three-dimensional optical coherence tomography image denoising through
   multi-input fully-convolutional networks
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Fully convolutional network (FCN); Multi-input FCN; Image denoising;
   Optical coherence tomography (OCT)
ID SPARSE; RESTORATION; REDUCTION
AB In recent years, there has been a growing interest in applying convolutional neural networks (CNNs) to low-level vision tasks such as denoising and super-resolution. Due to the coherent nature of the image formation process, the optical coherence tomography (OCT) images are inevitably affected by noise. This paper proposes a new method named the multi-input fully-convolutional networks (MIFCN) for denoising of OCT images. In contrast to recently proposed natural image denoising CNNs, the proposed architecture allows the exploitation of high degrees of correlation and complementary information among neighboring OCT images through pixel by pixel fusion of multiple FCNs. The parameters of the proposed multi-input architecture are learned by considering the consistency between the overall output and the contribution of each input image. The proposed MIFCN method is compared with the state-of-the-art denoising methods adopted on OCT images of normal and age-related macular degeneration eyes in a quantitative and qualitative manner.
C1 [Abbasi, Ashkan; Monadjemi, Amirhassan] Univ Isfahan, Artificial Intelligence Dept, Fac Comp Engn, Esfahan, Iran.
   [Fang, Leyuan] Hunan Univ, Coll Elect & Informat Engn, Changsha, Hunan, Peoples R China.
   [Rabbani, Hossein] Isfahan Univ Med Sci, Sch Adv Technol Med, Med Image & Signal Proc Res Ctr, Dept Biomed Engn, Esfahan, Iran.
   [Zhang, Yi] Sichuan Univ, Coll Comp Sci, Chengdu, Sichuan, Peoples R China.
C3 University of Isfahan; Hunan University; Isfahan University Medical
   Science; Sichuan University
RP Monadjemi, A (通讯作者)，Univ Isfahan, Artificial Intelligence Dept, Fac Comp Engn, Esfahan, Iran.; Fang, LY (通讯作者)，Hunan Univ, Coll Elect & Informat Engn, Changsha, Hunan, Peoples R China.
EM monadjemi@eng.ui.ac.ir; leyuan_fang@hnu.edu.cn
RI Rabbani, Hossein/H-7515-2014
OI Rabbani, Hossein/0000-0002-0551-3636; Zhang, Yi/0000-0001-7201-2092;
   abbasi, ashkan/0000-0003-3833-1393
FU National Natural Science Foundation of China [61501180 61771192]
FX This work was supported by the National Natural Science Foundation of
   China under Grants 61501180 61771192.
CR Abbasi A, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.3.036011
   Amini Z, 2016, IEEE T MED IMAGING, V35, P1544, DOI 10.1109/TMI.2016.2519439
   Amini Z, 2016, CURR MED IMAGING, V12, P130, DOI 10.2174/1573394711666150827203543
   Baghaie A, 2017, MED IMAGE ANAL, V37, P129, DOI 10.1016/j.media.2017.02.002
   Bao P, 2003, IEEE T MED IMAGING, V22, P1089, DOI 10.1109/TMI.2003.816958
   Bell T., 2016, TUNNEL FIELD EFFECT, P1, DOI DOI 10.1002/047134608X.W8298
   Buades A, 2005, AVSS 2005: ADVANCED VIDEO AND SIGNAL BASED SURVEILLANCE, PROCEEDINGS, P70
   Buades A, 2005, PROC CVPR IEEE, P60, DOI 10.1109/cvpr.2005.38
   BURGER HC, 2012, PROC CVPR IEEE, P2392, DOI DOI 10.1109/CVPR.2012.6247952
   Chen QF, 2017, IEEE I CONF COMP VIS, P2516, DOI 10.1109/ICCV.2017.273
   Cincotti G, 2001, IEEE T MED IMAGING, V20, P764, DOI 10.1109/42.938244
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   Dong WS, 2013, IEEE T IMAGE PROCESS, V22, P700, DOI 10.1109/TIP.2012.2221729
   Elad M, 2006, IEEE T IMAGE PROCESS, V15, P3736, DOI 10.1109/TIP.2006.881969
   Fang LY, 2017, IEEE T MED IMAGING, V36, P407, DOI 10.1109/TMI.2016.2611503
   Fang LY, 2013, IEEE T MED IMAGING, V32, P2034, DOI 10.1109/TMI.2013.2271904
   Fang LY, 2012, BIOMED OPT EXPRESS, V3, P927, DOI 10.1364/BOE.3.000927
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Jain V, 2009, ADV NEURAL INFORM PR, P769
   Kafieh R, 2015, IEEE T MED IMAGING, V34, P1042, DOI 10.1109/TMI.2014.2374354
   Kingma J., 2014, ARXIV
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Maas Andrew L, 2013, P 30 INT C MACH LEAR, V30, P3, DOI DOI 10.1016/0010-0277(84)90022-2
   Maggioni M, 2013, IEEE T IMAGE PROCESS, V22, P119, DOI 10.1109/TIP.2012.2210725
   Niknejad M, 2015, IEEE T IMAGE PROCESS, V24, P3624, DOI 10.1109/TIP.2015.2447836
   Ozcan A, 2007, J OPT SOC AM A, V24, P1901, DOI 10.1364/JOSAA.24.001901
   Paul A, 2019, IEEE J BIOMED HEALTH, V23, P264, DOI 10.1109/JBHI.2018.2791624
   Pizurica A, 2008, CURR MED IMAGING REV, V4, P270, DOI 10.2174/157340508786404044
   Protter M, 2009, IEEE T IMAGE PROCESS, V18, P36, DOI 10.1109/TIP.2008.2008067
   Rabbani H, 2009, IEEE T BIO-MED ENG, V56, P2826, DOI 10.1109/TBME.2009.2028876
   Robinson M. D., 2010, SUPER RESOLUTION IMA, P384
   Roth S, 2009, INT J COMPUT VISION, V82, P205, DOI 10.1007/s11263-008-0197-6
   Szkulmowski M, 2013, OPT EXPRESS, V21, P9757, DOI 10.1364/OE.21.009757
   Wu J., 2017, RELATION COLOR IMAGE
   Xu J, 2015, IEEE I CONF COMP VIS, P244, DOI 10.1109/ICCV.2015.36
   Yu F, 2015, ARXIV PREPRINT ARXIV, DOI DOI 10.1006/JMBI.1990.9999
   Yu G., 2010, IEEE T IMAGE PROCESS, V21, P2481
   Zhang K., 2017, PROC CVPR IEEE, P3929, DOI DOI 10.1109/CVPR.2017.300
   Zhang KH, 2017, IEEE T IMAGE PROCESS, V26, P4193, DOI [10.1109/TIP.2017.2689999, 10.1109/TIP.2016.2621478]
NR 41
TC 17
Z9 18
U1 4
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD MAY
PY 2019
VL 108
BP 1
EP 8
DI 10.1016/j.compbiomed.2019.01.010
PG 8
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA ID0FA
UT WOS:000471357900001
PM 30901625
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Liu, LB
   Wu, XW
AF Liu, Libin
   Wu, Xing Wei
TI Nobiletin protects human retinal pigment epithelial cells from hydrogen
   peroxide-induced oxidative damage
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE age-related macular degeneration; hydrogen peroxide (H2O2); nobiletin;
   retinal pigment epithelium cells
ID HUMAN RPE CELLS; MACULAR DEGENERATION; MITOCHONDRIAL DYSFUNCTION;
   ARPE-19 CELLS; STRESS; PI3K/AKT; ACTIVATION; EXPRESSION; APOPTOSIS;
   PROLIFERATION
AB Nobiletin(3,4,5,6,7,8-hexamethoxyflavone), a dietary polymethoxylated flavonoid found inCitrusfruits, has been reported to have antioxidant effect. However, the effect of nobiletin on human retinal pigment epithelium (RPE) cells induced by hydrogen peroxide (H2O2) is still unclear.Therefore, we investigated the protective effect of nobiletin against H2O2-induced cell death in RPE cells. Our results demonstrated that nobiletin significantly increased cell viability from oxidative stress. Nobiletin inhibited H2O2-induced ROS production and caspase-3/7 activity in ARPE-19 cells. Furthermore, nobiletin significantly increased Akt phosphorylation in ARPE-19 cells exposed to H2O2. Meanwhile, LY294002, an inhibitor of PI3K/Akt, abolished the protective effect of nobiletin against H2O2-induced decreased cell viability and increased caspase-3/7 activity in ARPE-19 cells. In summary, these data show that nobiletin protects RPE cells against oxidative stress through activation of the Akt-signaling pathway. Thus, nobiletin should be an oxidant that attenuates the development of age-related macular degeneration.
C1 [Liu, Libin; Wu, Xing Wei] Nanjing Med Univ, Dept Ophthalmol, Shanghai Gen Hosp, Shanghai 200080, Peoples R China.
   [Liu, Libin] Third Peoples Hosp Jingdezhen, Dept Ophthalmol, Jingdezhen 333000, Peoples R China.
C3 Nanjing Medical University
RP Wu, XW (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Shanghai Gen Hosp, Shanghai 200080, Peoples R China.
EM xingwei_wush@126.com
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cai N, 2012, INT J OPHTHALMOL-CHI, V5, P675, DOI 10.3980/j.issn.2222-3959.2012.06.05
   Huang H., 2016, EVID-BASED COMPL ALT, V2016
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Li ZR, 2013, MOL VIS, V19, P1656
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Lu YH, 2010, NEUROSCI LETT, V484, P6, DOI 10.1016/j.neulet.2010.07.078
   Moon JY, 2013, NUTR CANCER, V65, P286, DOI 10.1080/01635581.2013.756529
   MUKAI FH, 1976, SCIENCE, V191, P868, DOI 10.1126/science.766187
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Phil M., 2000, SURV OPHTHALMOL, V45, P115
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Proulx S, 2003, MOL VIS, V9, P473
   Qin D, 2013, MOL VIS, V19, P2227
   Sasaki K, 2002, BIOL PHARM BULL, V25, P806, DOI 10.1248/bpb.25.806
   Trushina E, 2007, NEUROSCIENCE, V145, P1233, DOI 10.1016/j.neuroscience.2006.10.056
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Winkler BS, 1999, MOL VIS, V5
   Yan TQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0154-3
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
   Zha X, 2015, CELL PHYSIOL BIOCHEM, V36, P2217, DOI 10.1159/000430186
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang L, 2016, BRAIN RES, V1636, P130, DOI 10.1016/j.brainres.2016.02.013
   Zheng LL, 2016, MOL CELL BIOCHEM, V416, P1, DOI 10.1007/s11010-016-2684-3
NR 29
TC 11
Z9 11
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD MAY
PY 2018
VL 32
IS 5
AR e22052
DI 10.1002/jbt.22052
PG 6
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA GI1JZ
UT WOS:000434128000006
PM 29687528
DA 2022-11-30
ER

PT J
AU Seiple, W
   Overbury, O
   Rosenthal, B
   Arango, T
   Odom, JV
   Morse, AR
AF Seiple, William
   Overbury, Olga
   Rosenthal, Bruce
   Arango, Tiffany
   Odom, J. Vernon
   Morse, Alan R.
TI Effects of Lighting on Reading Speed as a Function of Letter Size
SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; LOW-VISION; MACULAR DEGENERATION; LUMINANCE;
   ILLUMINATION; DISEASES; PEOPLE; ACUITY
AB OBJECTIVE. We sought to determine under what conditions brighter lighting improves reading performance.
   METHOD. Thirteen participants with typical sight and 9 participants with age-related macular degeneration (AMD) read sentences ranging from 0.0 to 1.3 logMAR under luminance levels ranging from 3.5 to 696 cd/m(2).
   RESULTS. At the dimmest luminance level (3.5 cd/m(2)), reading speeds were slowest at the smaller letter sizes and reached an asymptote for larger sizes. When luminance was increased to 30 cd/m(2), reading speed increased only for the smaller letter sizes. Additional lighting did not increase reading speeds for any letter size. Similar size-related effects of luminance were observed in participants with AMD.
   CONCLUSION. In some instances, performance on acuity-limited tasks might be improved by brighter lighting. However, brighter lighting does not always improve reading; the magnitude of the effect depends on the text size and the relative changes in light level.
C1 [Seiple, William; Rosenthal, Bruce; Arango, Tiffany; Morse, Alan R.] Lighthouse Guild, New York, NY 10023 USA.
   [Seiple, William] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Seiple, William] Inst Vis, Aging Vis & Act, Paris, France.
   [Overbury, Olga] Univ Montreal, Sch Optometry, Montreal, PQ, Canada.
   [Odom, J. Vernon] West Virginia Univ, Inst Eye, Dept Ophthalmol, Morgantown, WV USA.
C3 New York University; UDICE-French Research Universities; Sorbonne
   Universite; Universite de Montreal; West Virginia University
RP Seiple, W (通讯作者)，Lighthouse Guild, New York, NY 10023 USA.; Seiple, W (通讯作者)，NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.; Seiple, W (通讯作者)，Inst Vis, Aging Vis & Act, Paris, France.
EM whs4@nyu.edu
RI Odom, J Vernon/ABA-8150-2021
OI Morse, Alan R./0000-0002-5285-7626
FU U.S. Department of Veterans Affairs
FX The work was supported in part by a grant from the U.S. Department of
   Veterans Affairs.
CR Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   Brilliant R., 1999, ESSENTIALS LOW VISIO
   Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030
   Brunnstrom G, 2004, OPHTHAL PHYSL OPT, V24, P274, DOI 10.1111/j.1475-1313.2004.00192.x
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   CAMPBELL FW, 1968, J PHYSIOL-LONDON, V197, P551, DOI 10.1113/jphysiol.1968.sp008574
   CORNELISSEN FW, 1995, VISION RES, V35, P161, DOI 10.1016/0042-6989(94)00183-M
   DEVALOIS RL, 1974, VISION RES, V14, P75, DOI 10.1016/0042-6989(74)90118-7
   ELDRED KB, 1992, OPTOMETRY VISION SCI, V69, P46, DOI 10.1097/00006324-199201000-00007
   EPERJESI F, 1995, OPHTHAL PHYSL OPT, V15, P561, DOI 10.1046/j.1475-1313.1995.9400011n.x
   Eperjesi F, 2007, OPHTHAL PHYSL OPT, V27, P93, DOI 10.1111/j.1475-1313.2006.00431.x
   Ferree C E, 1921, Trans Am Ophthalmol Soc, V19, P269
   Fosse P., 2004, J VISUAL IMPAIR BLIN, V98, P1
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   Jackson A. J., 2007, LOW VISION MANUAL
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   SLOAN LL, 1973, AM J OPHTHALMOL, V76, P745, DOI 10.1016/0002-9394(73)90572-2
   SLOAN LL, 1968, VISION RES, V8, P901, DOI 10.1016/0042-6989(68)90139-9
   SLOAN LL, 1969, DOC OPHTHALMOL, V26, P384, DOI 10.1007/BF00943999
   Terlizzi J., LIGHTHOUSE BLOG
   TINKER M A, 1954, Am J Optom Arch Am Acad Optom, V31, P55
   Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE
   World Medical Association. World Medical Association Declaration of Helsinki, 2013, ETH PRINC MED RES IN
NR 23
TC 7
Z9 7
U1 1
U2 16
PU AMER OCCUPATIONAL THERAPY ASSOC, INC
PI BETHESDA
PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA
SN 0272-9490
EI 1943-7676
J9 AM J OCCUP THER
JI Am. J. Occup. Ther.
PD MAR-APR
PY 2018
VL 72
IS 2
AR 7202345020
DI 10.5014/ajot.2018.021873
PG 7
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA GA1FL
UT WOS:000428060900016
PM 29426392
OA Green Published
DA 2022-11-30
ER

PT J
AU Gahn, GM
   Khanani, AM
AF Gahn, G. M.
   Khanani, A. M.
TI The potential role of Tie2 activators in the treatment of macular edema
SO DRUGS OF THE FUTURE
LA English
DT Review
DE Tie2 activator; Macular edema; Retinopathy; RG-7716; AKB-9778;
   Nesvacumab
ID ENDOTHELIAL GROWTH-FACTOR; TYROSINE PHOSPHATASE; ANGIOPOIETIN 2;
   RANIBIZUMAB; ANGIOGENESIS; EXPRESSION; EYE
AB Macular edema is a pathological condition that is seen in a number of retinal vasculopathies such as diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion. Increased fluid in the macula can cause a progressive decline in visual acuity. Intraocular injections of anti-vascular growth factor (anti-VEGF) agents have been the standard of care for many years; however, these agents may not be effective in all patients with macular edema. Agents such as AKB-9778, RG-7716 and nesvacumab may provide patients with a promising alternative mechanism to reduce vascular leakage by targeting the Tie2 pathway. There is ample preclinical evidence to support the development of these drugs in treating retinal diseases and the focus has now turned towards identifying the safety and efficacy of targeting the Tie2 pathway in a clinical setting. A number of clinical studies are ongoing to evaluate the potential benefits of these molecules.
C1 [Gahn, G. M.] Univ Nevada, Reno, NV 89557 USA.
   [Khanani, A. M.] Sierra Eye Associates, 950 Ryland St, Reno, NV 89502 USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno
RP Khanani, AM (通讯作者)，Sierra Eye Associates, 950 Ryland St, Reno, NV 89502 USA.
EM arshad.khanani@gmail.com
FU Aerpio; Alcon; Allergan; DigiSight; Genentech; Novartis; Ophthotech;
   Thrombogenics
FX A.M. Khanani is a consultant/advisor for Aerpio, Alcon, Alimera,
   Allergan, Genentech, Novartis and ThromboGenics; a speaker for Allergan,
   Genentech and Novartis; and receives research support from Aerpio,
   Alcon, Allergan, DigiSight, Genentech, Novartis, Ophthotech and
   Thrombogenics. G.M. Gahn has no disclosures.
CR Brown D.M, 2016, ANN M AM AC OPHTH OC
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, P1722, DOI 10.1016/j.ophtha.2016.04.025
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P545, DOI 10.1016/j.ophtha.2014.09.023
   Channa R, 2014, EYE, V28, P269, DOI 10.1038/eye.2013.245
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7
   Do DV, 2013, JAMA OPHTHALMOL, V131, P139, DOI 10.1001/2013.jamaophthalmol.91
   Dugel P., 2016, ANN M AM SOC RET SPE
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Huang JZ, 2009, INT J ONCOL, V34, P79, DOI 10.3892/ijo_00000131
   Khanani A, 2016, INVEST OPHTH VIS SCI, V57
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Papadopoulos KP, 2016, CLIN CANCER RES, V22, P1348, DOI 10.1158/1078-0432.CCR-15-1221
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Yacyshyn OK, 2009, ANGIOGENESIS, V12, P25, DOI 10.1007/s10456-008-9126-0
   Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08
NR 26
TC 0
Z9 0
U1 0
U2 7
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD NOV
PY 2017
VL 42
IS 11
BP 693
EP 697
DI 10.1358/dof.2017.042.11.2720229
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FV3UT
UT WOS:000424496300003
DA 2022-11-30
ER

PT J
AU Lorthiois, E
   Anderson, K
   Vulpetti, A
   Rogel, O
   Cumin, F
   Ostermann, N
   Steinbacher, S
   Mac Sweeney, A
   Delgado, O
   Liao, SM
   Randl, S
   Rudisser, S
   Dussauge, S
   Fettis, K
   Kieffer, L
   de Erkenez, A
   Yang, L
   Hartwieg, C
   Argikar, UA
   La Bonte, LR
   Newton, R
   Kansara, V
   Flohr, S
   Hommel, U
   Jaffee, B
   Maibaum, J
AF Lorthiois, Edwige
   Anderson, Karen
   Vulpetti, Anna
   Rogel, Olivier
   Cumin, Frederic
   Ostermann, Nils
   Steinbacher, Stefan
   Mac Sweeney, Aengus
   Delgado, Omar
   Liao, Sha-Mei
   Randl, Stefan
   Rudisser, Simon
   Dussauge, Solene
   Fettis, Kamal
   Kieffer, Laurence
   de Erkenez, Andrea
   Yang, Louis
   Hartwieg, Constanze
   Argikar, Upendra A.
   La Bonte, Laura R.
   Newton, Ronald
   Kansara, Viral
   Flohr, Stefanie
   Hommel, Ulrich
   Jaffee, Bruce
   Maibaum, Jurgen
TI Discovery of Highly Potent and Selective Small-Molecule Reversible
   Factor D Inhibitors Demonstrating Alternative Complement Pathway
   Inhibition in Vivo
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID LIPOPHILIC EFFICIENCY LIPE; MEDICINAL CHEMISTRY; SERINE-PROTEASE;
   HALOGEN BONDS; LIGAND EFFICIENCY; DRUG DISCOVERY; HYDROGEN-BONDS;
   FLUORINE; ACTIVATION; DESIGN
AB The highly specific 51 serine protease factor D (FD) plays a central role in the amplification of the complement alternative pathway (AP) of the innate immune system. Genetic associations in humans have implicated AP activation in age related macular degeneration (AMD), and AP dysfunction predisposes individuals to disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The combination of structure-based hit identification and subsequent optimization of the center (S)-proline-based lead 7 has led to the discovery of noncovalent reversible and selective human factor D (FD) inhibitors with drug-like properties. The orally bioavailable compound 2 exerted excellent potency in 50% human whole blood in vitro and blocked AP activity ex vivo after oral administration to monkeys as demonstrated by inhibition of membrane attack complex (MAC) formation. Inhibitor 2 demonstrated sustained oral and ocular efficacy in a model of lipopolysaccharide (LPS)-induced systemic AP activation in mice expressing human FD.
C1 [Lorthiois, Edwige; Vulpetti, Anna; Rogel, Olivier; Cumin, Frederic; Ostermann, Nils; Mac Sweeney, Aengus; Randl, Stefan; Rudisser, Simon; Dussauge, Solene; Fettis, Kamal; Kieffer, Laurence; Hartwieg, Constanze; Flohr, Stefanie; Hommel, Ulrich; Maibaum, Jurgen] Novartis Pharma AG, Novartis Inst BioMed Res, Novartis Campus, CH-4056 Basel, Switzerland.
   [Anderson, Karen; Delgado, Omar; Liao, Sha-Mei; de Erkenez, Andrea; Yang, Louis; Argikar, Upendra A.; La Bonte, Laura R.; Newton, Ronald; Kansara, Viral; Jaffee, Bruce] Novartis Pharma AG, Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
   [Steinbacher, Stefan] Proteros Biostruct GmbH, D-82152 Planegg Martinsried, Germany.
   [Randl, Stefan] Evonik Japan Co Ltd, Shinjuku Ku, Shinjuku Monolith 12F,2-3-1,Nishi Shinjuku, Tokyo 1630938, Japan.
   [Mac Sweeney, Aengus] Actel Pharmaceut Ltd, Drug Discovery Dept, CH-4123 Allschwil, Switzerland.
C3 Novartis; Novartis; Actelion Pharmaceuticals Ltd
RP Lorthiois, E; Maibaum, J (通讯作者)，Novartis Pharma AG, Novartis Inst BioMed Res, Novartis Campus, CH-4056 Basel, Switzerland.
EM edwige.lorthiois@novartis.com; juergen_klaus.maibaum@novartis.com
OI Fettis, Kamal/0000-0001-5908-792X; Argikar, Upendra/0000-0002-0939-0813;
   Lorthiois, Edwige/0000-0002-6147-9321; Rudisser,
   Simon/0000-0002-1107-6196; Vulpetti, Anna/0000-0002-3114-8679
CR Abad-Zapatero C, 2005, DRUG DISCOV TODAY, V10, P464, DOI 10.1016/S1359-6446(05)03386-6
   Auffinger P, 2004, P NATL ACAD SCI USA, V101, P16789, DOI 10.1073/pnas.0407607101
   Bohm HJ, 2004, CHEMBIOCHEM, V5, P637, DOI 10.1002/cbic.200301023
   Conrow RE, 2008, ORG PROCESS RES DEV, V12, P1285, DOI 10.1021/op8000977
   Dalvit C, 2012, CHEMMEDCHEM, V7, P262, DOI 10.1002/cmdc.201100483
   Escobar PA, 2013, MUTAT RES-REV MUTAT, V752, P99, DOI 10.1016/j.mrrev.2012.12.002
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Frieauff W, 2013, MUTAGENESIS, V28, P15, DOI 10.1093/mutage/ges047
   Gillis EP, 2015, J MED CHEM, V58, P8315, DOI 10.1021/acs.jmedchem.5b00258
   Gleeson MP, 2008, J MED CHEM, V51, P817, DOI 10.1021/jm701122q
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Jing H, 1998, J MOL BIOL, V282, P1061, DOI 10.1006/jmbi.1998.2089
   Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997
   Leeson PD, 2007, NAT REV DRUG DISCOV, V6, P881, DOI 10.1038/nrd2445
   Maibaum J, 2016, NAT CHEM BIOL, V12, P1105, DOI [10.1038/NCHEMBIO.2208, 10.1038/nchembio.2208]
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   Morikis D, 2002, BIOCHEM SOC T, V30, P1026, DOI 10.1042/BST0301026
   Muller K, 2007, SCIENCE, V317, P1881, DOI 10.1126/science.1131943
   Parisini E, 2011, CHEM SOC REV, V40, P2267, DOI 10.1039/c0cs00177e
   Perola E, 2010, J MED CHEM, V53, P2986, DOI 10.1021/jm100118x
   Reynolds CH, 2007, BIOORG MED CHEM LETT, V17, P4258, DOI 10.1016/j.bmcl.2007.05.038
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Riley KE, 2013, J MOL MODEL, V19, P4651, DOI 10.1007/s00894-012-1428-x
   Riley KE, 2011, J MOL MODEL, V17, P3309, DOI 10.1007/s00894-011-1015-6
   Riley KE, 2011, CRYST GROWTH DES, V11, P4272, DOI 10.1021/cg200882f
   Ryckmans T, 2009, BIOORG MED CHEM LETT, V19, P4406, DOI 10.1016/j.bmcl.2009.05.062
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Shultz MD, 2013, BIOORG MED CHEM LETT, V23, P5992, DOI 10.1016/j.bmcl.2013.08.030
   Taylor FR, 1999, BIOCHEMISTRY-US, V38, P2849, DOI 10.1021/bi982140f
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Voth AR, 2009, NAT CHEM, V1, P74, DOI [10.1038/NCHEM.112, 10.1038/nchem.112]
   Vulpetti A, 2017, J MED CHEM, V60, P1946, DOI 10.1021/acs.jmedchem.6b01684
   Wilcken R, 2013, J MED CHEM, V56, P1363, DOI 10.1021/jm3012068
   Xing L, 2015, CHEMMEDCHEM, V10, P715, DOI 10.1002/cmdc.201402555
   Yang CY, 2016, ACS MED CHEM LETT, V7, P1092, DOI 10.1021/acsmedchemlett.6b00299
   Yuan X, 2017, HAEMATOLOGICA, V102, P466, DOI 10.3324/haematol.2016.153312
   Zarkadis IK, 2001, DEV COMP IMMUNOL, V25, P745, DOI 10.1016/S0145-305X(01)00034-9
NR 40
TC 20
Z9 21
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 13
PY 2017
VL 60
IS 13
BP 5717
EP 5735
DI 10.1021/acs.jmedchem.7b00425
PG 19
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA FA9KQ
UT WOS:000405764900029
PM 28621538
DA 2022-11-30
ER

PT J
AU Song, WK
   Park, KM
   Kim, HJ
   Lee, JH
   Choi, J
   Chong, SY
   Shim, SH
   Del Priore, LV
   Lanza, R
AF Song, Won Kyung
   Park, Kyung-Mi
   Kim, Hyun-Ju
   Lee, Jae Ho
   Choi, Jinjung
   Chong, So Young
   Shim, Sung Han
   Del Priore, Lucian V.
   Lanza, Robert
TI Treatment of Macular Degeneration Using Embryonic Stem Cell-Derived
   Retinal Pigment Epithelium: Preliminary Results in Asian Patients
SO STEM CELL REPORTS
LA English
DT Article
ID FACTOR-H GENE; POLYPOIDAL CHOROIDAL VASCULOPATHY; GEOGRAPHIC ATROPHY;
   VISUAL FUNCTION; POLYMORPHISMS; RPE; ASSOCIATION; TRANSPLANTATION;
   CHINESE; SAFETY
AB Embryonic stem cells hold great promise for various diseases because of their unlimited capacity for self-renewal and ability to differentiate into any cell type in the body. However, despite over 3 decades of research, there have been no reports on the safety and potential efficacy of pluripotent stem cell progeny in Asian patients with any disease. Here, we report the safety and tolerability of subretinal transplantation of human embryonic-stem-cell (hESC)-derived retinal pigment epithelium in four Asian patients: two with dry age-related macular degeneration and two with Stargardt macular dystrophy. They were followed for 1 year. There was no evidence of adverse proliferation, tumorigenicity, ectopic tissue formation, or other serious safety issues related to the transplanted cells. Visual acuity improved 9-19 letters in three patients and remained stable (+1 letter) in one patient. The results confirmed that hESC-derived cells could serve as a potentially safe new source for regenerative medicine.
C1 [Song, Won Kyung] CHA Univ, CHA Bundang Med Ctr, Dept Ophthalmol, Songnam 463712, Gyeonggi Do, South Korea.
   [Park, Kyung-Mi; Kim, Hyun-Ju] CHA Biotech Co Ltd, Dev Div, Seoul 135907, South Korea.
   [Lee, Jae Ho] CHA Biotech Co Ltd, CHA Stem Cell Inst, Seoul 135907, South Korea.
   [Choi, Jinjung] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Div Rheumatol, Songnam 463712, Gyeonggi Do, South Korea.
   [Chong, So Young] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Div Hematol Oncol, Songnam 463712, Gyeonggi Do, South Korea.
   [Shim, Sung Han] CHA Univ, Dept Biomed Sci, Seoul 135081, South Korea.
   [Del Priore, Lucian V.] Med Univ S Carolina, Albert Florens Storm Eye Inst, Charleston, SC 29425 USA.
   [Lanza, Robert] Ocata Therapeut, Marlborough, MA 01752 USA.
C3 Pochon Cha University; Pochon Cha University; Pochon Cha University;
   Pochon Cha University; Pochon Cha University; Medical University of
   South Carolina
RP Song, WK (通讯作者)，CHA Univ, CHA Bundang Med Ctr, Dept Ophthalmol, Songnam 463712, Gyeonggi Do, South Korea.
EM songwkmd@daum.net; rlanza@ocata.com
OI Lanza, Robert/0000-0002-3047-3074
FU CHA Biotech Co., Ltd.; Korea Health Technology R&D Project through the
   Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   & Welfare, Republic of Korea [HI12C1794(A121941), HI12C0447(A120506)]
FX We express sincere gratitude to Sung Woo Ha, MD, and Kyung Soon Kim,
   PhD, for their efforts in the Korean protocol development and securing
   Korean MFDS and IRB approval; the Independent Data Monitoring Committee,
   Sung Chul Lee, Oh Woong Kwon, Kwang Soo Kim, and Hyonggin An;
   co-investigator Hee Jung Kwon for surgical assistance, co-investigator
   Sung Woo Choi for mfERG analysis; clinical research coordinators Myung
   Hee Choi, Yona Bae, Ju Eun Lee, and Su Youn Kim; and the pioneering
   patients and their families. This research was supported by the CHA
   Biotech Co., Ltd., by their grant of the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health & Welfare, Republic of Korea: grant
   numbers HI12C1794(A121941) and HI12C0447(A120506). The sponsor (CHA
   Biotech Co., Ltd.) participated in hESC-RPE manufacture and
   in-use-protocol process, study design, and partial report preparation.
   Kyung-Mi Park is an employee of CHA Biotech. Hyun Ju Kim and Jae Ho Lee
   are employees of CHA Biotech and have received stock options.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   [Anonymous], 2002, OPHTHALMOL CLIN N AM
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Chen LJ, 2006, MOL VIS, V12, P1536
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Glazer Liane Clamen, 2002, Ophthalmol Clin North Am, V15, P93, DOI 10.1016/S0896-1549(01)00011-6
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim K., 2010, J KOREAN SOC TRANSPL, V24, P93
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klimanskaya I, 2005, LANCET, V365, P1636, DOI 10.1016/S0140-6736(05)66473-2
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Lanza R, 2009, ESSENTIALS OF STEM CELL BIOLOGY, 2ND EDITION, pXV, DOI 10.1016/B978-0-12-374729-7.00073-1
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tsang WK, 2000, TRANSPLANT P, V32, P1755, DOI 10.1016/S0041-1345(00)01389-0
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Wickham L., 2013, RETINA-J RET VIT DIS, P1954
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
NR 35
TC 233
Z9 249
U1 2
U2 24
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD MAY 12
PY 2015
VL 4
IS 5
BP 860
EP 872
DI 10.1016/j.stemcr.2015.04.005
PG 13
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CI0DO
UT WOS:000354406400009
PM 25937371
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mrejen, S
   Sarraf, D
   Mukkamala, K
   Freund, KB
AF Mrejen, Sarah
   Sarraf, David
   Mukkamala, Krishna
   Freund, K. Bailey
TI MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT A Guide to
   Evaluation
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE retinal pigment epithelial detachment; age-related macular degeneration;
   drusenoid pigment epithelial detachment; serous pigment epithelial
   detachment; vascularized pigment epithelial detachment; retinal
   angiomatous proliferation; polypoidal choroidal vasculopathy; multimodal
   imaging; central serous chorioretinopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY; RETINAL
   ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   INDOCYANINE-GREEN VIDEOANGIOGRAPHY; COMBINED INTRAVITREAL RANIBIZUMAB;
   SCANNING LASER OPHTHALMOSCOPE; GROWTH-FACTOR THERAPY; TERM-FOLLOW-UP;
   MACULAR DEGENERATION
AB Purpose: To describe the spectrum of pigment epithelial detachments (PEDs) occurring mainly in age-related macular degeneration and central serous chorioretinopathy and also in other inflammatory, neoplastic and iatrogenic, retinal, and systemic disorders.
   Methods: Pigment epithelial detachments are divided into drusenoid, serous, vascularized, or mixed categories.
   Results: The clinical presentation, classification, and natural history of PEDs are reviewed as illustrated with multimodal imaging combining traditional and novel imaging techniques, including fluorescein angiography, indocyanine green angiography, fundus autofluorescence, and spectral domain optical coherence tomography. Most PEDs occur because of pathophysiologic mechanisms taking place below the retinal pigment epithelium that are difficult to identify with conventional imaging modalities. Enhanced depth imaging optical coherence tomography and indocyanine green angiography allow a better analysis of the subretinal pigment epithelium compartment.
   Conclusion: The differentiation between various kinds of PEDs is essential because each PED type is a distinct entity that has a specific pathogenesis, natural history, prognosis, and optimal treatment strategy.
C1 [Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Mrejen, Sarah; Mukkamala, Krishna; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; University of California System; University of
   California Los Angeles; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA Greater Los Angeles Healthcare System
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.
FX Supported in part by the Macula Foundation, Inc.
CR Anand S, 2003, EYE, V17, P524, DOI 10.1038/sj.eye.6700381
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Awan MA, 2008, CLIN EXP OPTOM, V91, P476, DOI 10.1111/j.1444-0938.2008.00268.x
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Bandello F, 2000, OPHTHALMOLOGICA, V214, P362, DOI 10.1159/000027522
   Besada E, 2004, OPTOMETRY VISION SCI, V81, P578, DOI 10.1097/01.opx.0000141792.16683.91
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bourcier T, 1998, BRIT J OPHTHALMOL, V82, P585
   BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2012, EYE, V26, P882, DOI 10.1038/eye.2012.90
   Chan CK, 2012, EYE LOND
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   Cohen SM, 1996, RETINA-J RET VIT DIS, V16, P467, DOI 10.1097/00006982-199616060-00001
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dasanu Constantin A, 2009, J Oncol Pharm Pract, V15, P119, DOI 10.1177/1078155208097632
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   ERNST BB, 1991, OPHTHALMOLOGY, V98, P1272
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   FRIBERG TR, 1990, GRAEF ARCH CLIN EXP, V228, P305, DOI 10.1007/BF00920052
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gass JDM, 2005, RETINA-J RET VIT DIS, V25, P304, DOI 10.1097/00006982-200504000-00009
   Gass JD, 1997, STEREOSCOPIC ATLAS D, P880
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GASS JDM, 1992, GRAEF ARCH CLIN EXP, V230, P454
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   Goncu T, 2011, OPTOMETRY, V82, P556, DOI 10.1016/j.optm.2011.04.103
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Ho AC, 2000, OPHTHALMOLOGY, V107, P1099, DOI 10.1016/S0161-6420(00)00118-4
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   JABS DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P230
   Jampol LM, 2002, OPHTHALMOLOGY, V109, P1765, DOI 10.1016/S0161-6420(02)01303-9
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Laatikainen L, 1991, Eur J Ophthalmol, V1, P79
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lee MY, 2012, AM J OPHTHALMOL, V153, P1004, DOI 10.1016/j.ajo.2012.01.028
   Lee MY, 2011, RETINA-J RET VIT DIS, V31, P65, DOI 10.1097/IAE.0b013e3181e586e3
   LEWIS ML, 1978, ARCH OPHTHALMOL-CHIC, V96, P620
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Mudvari SS, 2007, RETINA-J RET VIT DIS, V27, P1168, DOI 10.1097/IAE.0b013e318156db8a
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ogata N, 2000, OPHTHALMIC SURG LAS, V31, P248
   Oshima Y, 2009, OPHTHALMOLOGY, V116, P927, DOI 10.1016/j.ophtha.2008.11.005
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Perkins SL, 2002, OPHTHALMOLOGY, V109, P262, DOI 10.1016/S0161-6420(01)00951-4
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Querques G, 2011, GRAEF ARCH CLIN EXP, V249, P1617, DOI 10.1007/s00417-011-1702-0
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Ritter M, 2010, BRIT J OPHTHALMOL, V94, P1112, DOI 10.1136/bjo.2009.159475
   Roberts D K, 1991, J Am Optom Assoc, V62, P464
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth F, 2007, ATLAS FUNDUS AUTOFLU, P165
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Saito M, 2012, JPN J OPHTHALMOL
   Saito M, 2012, AM J OPHTHALMOL, V153, P504, DOI 10.1016/j.ajo.2011.08.038
   Salchow DJ, 2006, OCUL IMMUNOL INFLAMM, V14, P245, DOI 10.1080/09273940600826489
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Sawa M, 2005, ARCH OPHTHALMOL-CHIC, V123, P122, DOI 10.1001/archopht.123.1.122
   Say EAT, 2012, J OPHTHALMOL, V2012
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Sheth Hiten G., 2009, International Ophthalmology, V29, P179, DOI 10.1007/s10792-007-9185-z
   Shields CL, 2005, RETINA-J RET VIT DIS, V25, P243, DOI 10.1097/00006982-200504000-00001
   SIEGEL MJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P845
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Souied EH, 2006, AM J OPHTHALMOL, V141, P404, DOI 10.1016/j.ajo.2005.09.001
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sun Jinghua, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P313
   SUNNESS JS, 1993, ARCH OPHTHALMOL-CHIC, V111, P360, DOI 10.1001/archopht.1993.01090030078043
   Theelen T, 2010, ESSENT OPHTHALMOL, P77, DOI 10.1007/978-3-540-85540-8_8
   Thill M, 2006, EYE, V20, P851, DOI 10.1038/sj.eye.6702025
   Tittl MK, 1999, AM J OPHTHALMOL, V128, P63, DOI 10.1016/S0002-9394(99)00075-6
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Troiano P, 1998, NEPHROL DIAL TRANSPL, V13, P2135, DOI 10.1093/ndt/13.8.2135
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WOLF S, 1993, RETINA-J RET VIT DIS, V13, P266, DOI 10.1097/00006982-199313030-00025
   Wolfensberger T J, 2000, Curr Opin Ophthalmol, V11, P455, DOI 10.1097/00055735-200012000-00012
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 1997, INDOCYANINE GREEN AN
   Yu-Key FT, 2010, J OPHTHALMOL, V35, P40
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
NR 150
TC 97
Z9 101
U1 1
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1735
EP 1762
DI 10.1097/IAE.0b013e3182993f66
PG 28
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500002
PM 23873168
DA 2022-11-30
ER

PT J
AU Wang, GF
   Dubovy, SR
   Kovach, JL
   Schwartz, SG
   Agarwal, A
   Scott, WK
   Haines, JL
   Pericak-Vance, MA
AF Wang, Gaofeng
   Dubovy, Sander R.
   Kovach, Jaclyn L.
   Schwartz, Stephen G.
   Agarwal, Anita
   Scott, William K.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Variants at chromosome 10q26 locus and the expression of HTRA1 in the
   retina
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; HTRA1; ARMS2; genetic variant;
   promoter
ID MACULAR DEGENERATION; ARMS2; LOC387715/ARMS2; POLYMORPHISM; SMOKING;
   ALTER; RISK
AB Variations in a locus at chromosome 10q26 are strongly associated with the risk of age-related macular degeneration (AMD). The most significantly associated haplotype includes a nonsynonymous SNP rs10490924 in the exon 1 of ARMS2 and rs11200638 in the promoter region of HTRA1. It is under debate which gene(s), ARMS2, HTRA1 or some other genes are functionally responsible for the genetic association. To verify whether the associated variants correlate with a higher HTRA1 expression level as previously reported, HTRA1 mRNA and protein were measured in a larger human retina-RPE-choroid samples (n = 82). Results show there is no significant change of HTRA1 mRNA level among genotypes at rs11200638, rs10490924 or an indel variant of ARMS2. Furthermore, two AMD-associated synonymous SNPs rs1049331 and rs2293870 in HTRA1 exon 1 do not change its protein level either. These results suggest that the AMD-associated variants in the chromosome 10q26 locus do not significantly affect the expression of HTRA1. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Wang, Gaofeng; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Wang, Gaofeng; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn Dept Human Genet, Miami, FL 33136 USA.
   [Dubovy, Sander R.; Kovach, Jaclyn L.; Schwartz, Stephen G.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Dept Ophthalmol, Nashville, TN 37232 USA.
   [Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37232 USA.
C3 University of Miami; University of Miami; Bascom Palmer Eye Institute;
   University of Miami; Vanderbilt University; Vanderbilt University
RP Wang, GF (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave, Miami, FL 33136 USA.
EM gwang@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Institutes of Health [2R01EY012118-11, P30-EY014801]; Research
   to Prevent Blindness, New York, NY; NATIONAL EYE INSTITUTE [R01EY012118,
   P30EY014801] Funding Source: NIH RePORTER
FX We thank all the individuals and their families who donated eyes for the
   study. We would also like to thank the Florida Lions Eye Bank which
   provided eye tissues for this research. This research was supported by
   National Institutes of Health grants (2R01EY012118-11 to M.A.P.-V.,
   J.L.H., W.K.S and A.A.) and was partially supported by NIH center grant
   P30-EY014801 and by an unrestricted grant to the University of Miami
   from Research to Prevent Blindness, New York, NY.
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chowers I, 2008, MOL VIS, V14, P2263
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hamada M, 2009, BIOINFORMATICS, V25, P465, DOI 10.1093/bioinformatics/btn601
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Lavner Y, 2005, GENE, V345, P127, DOI 10.1016/j.gene.2004.11.035
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang G., 2013, JAMA OPHTHALMOL, P1
   Wang GF, 2010, ARCH OPHTHALMOL-CHIC, V128, P1491, DOI 10.1001/archophthalmol.2010.256
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 22
TC 19
Z9 19
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2013
VL 112
BP 102
EP 105
DI 10.1016/j.exer.2013.04.019
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 180OS
UT WOS:000321605100012
PM 23644223
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, KH
   Kim, JH
   Yu, YS
   Kim, YM
   Kim, KW
   Kwon, HJ
AF Kim, Jeong Hun
   Kim, Ki Hyun
   Kim, Jin Hyoung
   Yu, Young Suk
   Kim, Young-Myeong
   Kim, Kyu-Won
   Kwon, Ho Jeong
TI Homoisoflavanone inhibits retinal neovascularization through cell cycle
   arrest with decrease of cdc2 expression
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE homoisoflavanone; retinal neovascularization; cell cycle arrest; cdc2;
   p21(WAF1)
ID VASCULAR DEVELOPMENT; RETINOPATHY; P53
AB Neovascularization in the eye is the most common cause of blindness in all age groups; retinopathy of prematurity (ROP), diabetic retinopathy, and age-related macular degeneration. Despite current advances in surgical treatments, ROP remains as the most serious problem of vision loss in children. Here, we report that homoisoflavanone, a natural product from Cremastra appendiculata, significantly reduces retinal neovascularization in a mouse model of ROP. Homoisoflavanone inhibited the cell growth of HUVECs, but its cytotoxic effect was not observed in a concentration range of 1-20 mu M. HUVECs population gradually increased in G(2)/M phase and reduced in G(0)/G(1) and S phases after exposure to the compound. Homoisoflavanone decreased the level of cdc2 expression whereas the level of p21(WAF1) expression was increased in a dose-dependent manner. These data demonstrate that homoisoflavanone could inhibit retinal neovascularization and be applied in the treatment of other vasoproliferative retinopathies. (c) 2007 Elsevier Inc. All rights reserved.
C1 Yonsei Univ, Coll Engn, Dept Biotechnol, Chem Genom Lab, Seoul 120749, South Korea.
   Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Seoul Artificial Eye Ctr Clin Res Inst, Seoul 110744, South Korea.
   Seoul Natl Univ, Coll Pharm, NeuroVasc Coordinat Res Ctr, Seoul 151742, South Korea.
   Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.
   Kangwon Natl Univ, Vasc Syst Res Ctr, Sch Med, Chunchon 200701, South Korea.
C3 Yonsei University; Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University Hospital; Seoul National
   University (SNU); Seoul National University (SNU); Kangwon National
   University
RP Kwon, HJ (通讯作者)，Yonsei Univ, Coll Engn, Dept Biotechnol, Chem Genom Lab, Seoul 120749, South Korea.
EM kwonhj@yonsei.ac.kr
RI Yu, Young Suk/J-5551-2012; Kim, Jeong Hun/J-2748-2012; 권,
   호정/AAS-3642-2021; Kim, Kyu Won/AAJ-7213-2020
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Chae Seoung Wan, 2002, Cancer Res Treat, V34, P252, DOI 10.4143/crt.2002.34.4.252
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   KIM JH, IN PRESS BR J OPHTHA
   ROTH AM, 1977, AM J OPHTHALMOL, V84, P636, DOI 10.1016/0002-9394(77)90377-4
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
   SILVERMAN WA, 1980, RETROLENTAL FIBROFIB
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Taylor BF, 2006, J PHARMACOL EXP THER, V318, P142, DOI 10.1124/jpet.106.103077
   Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607
   Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412
   Zhang D, 2001, DIABETOLOGIA, V44, P757, DOI 10.1007/s001250051685
NR 13
TC 30
Z9 33
U1 2
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 3
PY 2007
VL 362
IS 4
BP 848
EP 852
DI 10.1016/j.bbrc.2007.08.100
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 215HK
UT WOS:000249798800012
PM 17803958
DA 2022-11-30
ER

PT J
AU Kallitsis, A
   Moschos, MM
   Ladas, ID
AF Kallitsis, Anastasios
   Moschos, Marilita M.
   Ladas, Ioannis D.
TI Photodynamic therapy versus thermal laser photocoagulation for the
   treatment of recurrent choroidal neovascularization due to AMD
SO IN VIVO
LA English
DT Article
DE recurrent choroidal neovascularization; thermal laser photocoagulation;
   photodynamic therapy
ID MEMBRANES
AB The aim of this study was to compare the effectiveness of thermal laser photocoagulation (TLP) to that of photodynamic therapy (PDT) for the treatment of recurrent choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD). Patients and Methods: We prospectively studied 38 patients (40 eyes) with AMD presented with recurrent CNV after TLP. The study eyes were assigned to one of the two groups according to their treatment (repetition of TLP or PDT). PDT was performed according to the standard protocol. The follow-up time ranged from 9 months to 9 years. Results: The mean best-corrected visual acuity (VA) was statistically significantly lower compared to that of the baseline in both groups of the study. There were no statistically significant differences between the two groups with regard to the stabilization, improvement or decline of the best-corrected VA. Conclusion: According to our results TLP and PDT are equally ineffective for the treatment of recurrent CNV in patients with AMD.
C1 [Kallitsis, Anastasios; Moschos, Marilita M.; Ladas, Ioannis D.] Univ Athens, Sch Med, Dept Ophthalmol 1, Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens
RP Kallitsis, A (通讯作者)，18 Thasso Str, Athens 11257, Greece.
EM ladas@ath.forthnet.gr
CR [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gabel-Pfisterer A, 2005, OPHTHALMOLOGE, V102, P592, DOI 10.1007/s00347-004-1146-6
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HAWKINS BS, 1989, ARCH OPHTHALMOL-CHIC, V107, P344, DOI 10.1001/archopht.1989.01070010354023
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MONAHAN PM, 1993, RETINA-J RET VIT DIS, V13, P196, DOI 10.1097/00006982-199313030-00002
   OLK RJ, 1985, OPHTHALMOLOGY, V92, P1035
   Regillo CD, 1998, OPHTHALMOLOGY, V105, P1821, DOI 10.1016/S0161-6420(98)91022-3
   SORENSON JA, 1985, OPHTHALMOLOGY, V92, P1059
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
NR 18
TC 3
Z9 3
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD NOV-DEC
PY 2007
VL 21
IS 6
BP 1049
EP 1052
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 241TA
UT WOS:000251677500014
PM 18210754
DA 2022-11-30
ER

PT J
AU Gamulescu, MA
   Framme, C
   Sachs, H
AF Gamulescu, Maria Andreea
   Framme, Carsten
   Sachs, Helmut
TI RPE-rip after intravitreal bevacizumab (Avastin) treatment for
   vascularised PED secondary to AMD
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; Avastin; Bevacizumab; pigment
   epithelial detachment
ID PIGMENT EPITHELIAL TEAR; CHOROIDAL NEOVASCULARIZATION SECONDARY; MACULAR
   DEGENERATION; INJECTION
AB Background Retinal pigment epithelial (RPE)-rips in age-related macular degeneration (AMD)-associated pigment epithelial detachment (PED) occur in the natural course of the disease but also after therapy (e.g. laser photocoagulation, photodynamic therapy), possibly triggered by the specific therapy. We report here on four patients that received intravitreal bevacizumab (Avastin) for AMD-associated vascularised PED and developed RPE-rips during the follow-up.
   Methods The case reports of four consecutive patients that developed RPE-rips after intravitreal injection of bevacizumab at 1 mg/0.1 ml were reviewed.
   Results The RPE-rips occurred in all patients between 1 week and 1 month following intravitreal injection. Two of the four patients improved in vision despite the rip, but 3 months after the initial intervention, three patients suffered deterioration in visual acuity and had to be re-injected.
   Conclusion Improvement in visual acuity may occur following intravitreal bevacizumab despite RPE-rips, but the patients need close follow-up and eventual re-treatment in the case of deterioration.
C1 Univ Eye Clin, D-93053 Regensburg, Germany.
C3 University of Regensburg
RP Gamulescu, MA (通讯作者)，Univ Eye Clin, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM gamulescu@eye-regensburg.de
CR BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 11
TC 36
Z9 39
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2007
VL 245
IS 7
BP 1037
EP 1040
DI 10.1007/s00417-007-0551-3
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 182KP
UT WOS:000247503800017
PM 17318562
DA 2022-11-30
ER

PT J
AU Wong, T
   Mitchell, P
AF Wong, Tien
   Mitchell, Paul
TI The eye in hypertension
SO LANCET
LA English
DT Review
ID OPEN-ANGLE GLAUCOMA; RETINAL MICROVASCULAR ABNORMALITIES; AGE-RELATED
   MACULOPATHY; SYSTEMIC BLOOD-PRESSURE; ENDOTHELIAL GROWTH-FACTOR; TYPE-2
   DIABETES-MELLITUS; CORONARY HEART-DISEASE; VASCULAR RISK-FACTORS; BLUE
   MOUNTAINS EYE; VESSEL WALL SIGNS
AB Hypertension has a range of effects on the eye. Hypertensive retinopathy refers to retinal microvascular signs that develop in response to raised blood pressure. Signs of hypertensive retinopathy are frequently seen in adults 40 years and older, and are predictive of incident stroke, congestive heart failure, and cardiovascular mortality-independently of traditional risk factors. Hypertension is also a major risk factor for the development of other retinal vascular diseases, such as retinal vein and artery occlusion, and ischaemic optic neuropathy. High blood pressure increases the risk of both development of diabetic retinopathy and its progression. Adequate control of blood pressure has been proven in randomised clinical trials to reduce vision loss associated with diabetic retinopathy. Finally, hypertension has been implicated in the pathogenesis of glaucoma and age-related macular degeneration. Recognition of the ocular effects of blood pressure could allow physicians to better manage patients with hypertension, and to monitor its end-organ effects.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore.
   Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; National
   University of Singapore; Singapore National Eye Center; University of
   Sydney
RP Wong, T (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Mitchell, Paul/P-1498-2014; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL077166] Funding Source:
   NIH RePORTER
CR Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412
   [Anonymous], 1986, Arch Ophthalmol, V104, P34
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   Arnold M, 2005, J NEUROL NEUROSUR PS, V76, P196, DOI 10.1136/jnnp.2004.037135
   Atebara NH, 1995, OPHTHALMOLOGY, V102, P2029, DOI 10.1016/S0161-6420(95)30758-0
   BOCK KD, 1984, HYPERTENSION, V6, P158
   Bonomi L, 2000, OPHTHALMOLOGY, V107, P1287, DOI 10.1016/S0161-6420(00)00138-X
   BROWN DM, 1994, BRIT J OPHTHALMOL, V78, P534, DOI 10.1136/bjo.78.7.534
   BRUNO A, 1995, ANN INTERN MED, V122, P249, DOI 10.7326/0003-4819-122-4-199502150-00002
   BRUNO A, 1992, STROKE, V23, P900, DOI 10.1161/01.STR.23.6.900
   Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Chua B, 2005, AM J OPHTHALMOL, V139, P181, DOI 10.1016/j.ajo.2004.06.084
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1434
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726
   Cugati S, 2006, STROKE, V37, P908, DOI 10.1161/01.STR.0000204118.87477.46
   Cuspidi C, 2004, J HYPERTENS, V22, P2095, DOI 10.1097/00004872-200411000-00010
   DEBONO DP, 1981, LANCET, V1, P343
   Delles C, 2004, STROKE, V35, P1289, DOI 10.1161/01.STR.0000126597.11534.3b
   DICKERSIN K, 1995, JAMA-J AM MED ASSOC, V273, P625, DOI 10.1001/jama.1995.03520320035038
   DIELEMANS I, 1995, OPHTHALMOLOGY, V102, P54
   DIMMITT SB, 1989, LANCET, V1, P1103
   Duncan BB, 2002, BRIT J OPHTHALMOL, V86, P1002, DOI 10.1136/bjo.86.9.1002
   Estacio RO, 2000, DIABETES CARE, V23, pB54
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Foster PJ, 2003, INVEST OPHTH VIS SCI, V44, P3885, DOI 10.1167/iovs.03-0012
   Fuchsjager-Mayrl G, 2004, INVEST OPHTH VIS SCI, V45, P834, DOI 10.1167/iovs.03-0461
   Gaede P, 1999, LANCET, V353, P617, DOI 10.1016/S0140-6736(98)07368-1
   Gottlieb JL, 1998, ARCH OPHTHALMOL-CHIC, V116, P577, DOI 10.1001/archopht.116.5.577
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAHAM SL, 1995, OPHTHALMOLOGY, V102, P61
   Greiner K, 1999, AM J OPHTHALMOL, V128, P69, DOI 10.1016/S0002-9394(99)00074-4
   GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1690
   GUYER DR, 1985, ARCH OPHTHALMOL-CHIC, V103, P1136
   HANKEY GJ, 1991, BMJ-BRIT MED J, V302, P499, DOI 10.1136/bmj.302.6775.499
   Harris MI, 1998, DIABETES CARE, V21, P1230, DOI 10.2337/diacare.21.8.1230
   Hattenhauer MG, 1997, AM J OPHTHALMOL, V123, P103, DOI 10.1016/S0002-9394(14)70999-7
   Hayreh SS, 1999, SURV OPHTHALMOL, V43, pS27, DOI 10.1016/S0039-6257(99)00018-1
   Hayreh SS, 2005, PROG RETIN EYE RES, V24, P493, DOI 10.1016/j.preteyeres.2004.12.001
   HAYREH SS, 1994, AM J OPHTHALMOL, V118, P766, DOI 10.1016/S0002-9394(14)72557-7
   HAYREH SS, 1994, AM J OPHTHALMOL, V117, P603, DOI 10.1016/S0002-9394(14)70067-4
   Hayreh SS, 2001, AM J OPHTHALMOL, V131, P61, DOI 10.1016/S0002-9394(00)00709-1
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P595, DOI 10.1016/S1350-9462(01)00005-2
   Hennis A, 2003, OPHTHALMOLOGY, V110, P908, DOI 10.1016/S0161-6420(03)00075-7
   HOLLENHORST R, 1961, JAMA-J AM MED ASSOC, V178, P23, DOI 10.1001/jama.1961.03040400025005
   HSUEH WA, 1992, HYPERTENSION, V20, P253, DOI 10.1161/01.HYP.20.2.253
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ivanisevic M, 2001, OPHTHALMOLOGICA, V215, P245, DOI 10.1159/000050868
   Jacobson DM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1403, DOI 10.1001/archopht.1997.01100160573008
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1599
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   KEITH NM, 1974, AM J MED SCI, V268, P336, DOI 10.1097/00000441-197412000-00004
   Klein BEK, 2005, BRIT J OPHTHALMOL, V89, P284, DOI 10.1136/bjo.2004.048710
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026
   Klein R, 1997, Trans Am Ophthalmol Soc, V95, P329
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1446, DOI 10.1001/archopht.121.10.1446
   KLEIN R, 1989, ARCH INTERN MED, V149, P2427, DOI 10.1001/archinte.149.11.2427
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1063
   Klein R, 2002, BRIT J OPHTHALMOL, V86, P84, DOI 10.1136/bjo.86.1.84
   Klein R, 2002, OPHTHALMOLOGY, V109, P1225, DOI 10.1016/S0161-6420(02)01074-6
   Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2000, T AM OPHTHAL SOC, V98, P133
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   KOSTRABA JN, 1991, AM J EPIDEMIOL, V133, P381, DOI 10.1093/oxfordjournals.aje.a115892
   Kwa VIH, 2002, NEUROLOGY, V59, P1536, DOI 10.1212/01.WNL.0000033093.16450.5C
   Langman MJS, 2005, BRIT J OPHTHALMOL, V89, P960, DOI 10.1136/bjo.2004.053397
   Le A, 2003, INVEST OPHTH VIS SCI, V44, P3783, DOI 10.1167/iovs.03-0077
   Leske MC, 2002, ARCH OPHTHALMOL-CHIC, V120, P954, DOI 10.1001/archopht.120.7.954
   Leung H, 2004, J HYPERTENS, V22, P1543, DOI 10.1097/01.hjh.0000125455.28861.3f
   Logan JFJ, 2004, BRIT J OPHTHALMOL, V88, P1049, DOI 10.1136/bjo.2003.034884
   Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631
   MICHELSON EL, 1979, ARCH INTERN MED, V139, P1139, DOI 10.1001/archinte.139.10.1139
   Mitchell P, 1997, STROKE, V28, P63, DOI 10.1161/01.STR.28.1.63
   Mitchell P, 2000, CLIN EXP OPHTHALMOL, V28, P13, DOI 10.1046/j.1442-9071.2000.00218.x
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P712, DOI 10.1016/S0161-6420(97)30247-4
   Mitchell P, 2005, NEUROLOGY, V65, P1005, DOI 10.1212/01.wnl.0000179177.15900.ca
   Mitchell P, 2005, AM J OPHTHALMOL, V140, P131, DOI 10.1016/j.ajo.2004.12.088
   Mitchell P, 2005, OPHTHALMOLOGY, V112, P245, DOI 10.1016/j.ophtha.2004.08.015
   Mitchell P, 2004, J GLAUCOMA, V13, P319, DOI 10.1097/00061198-200408000-00010
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Morishita R, 1992, Blood Press Suppl, V3, P41
   Mueller AJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P1377, DOI 10.1001/archopht.121.10.1377
   Nakamura M, 2005, OPHTHALMOLOGICA, V219, P1, DOI 10.1159/000081775
   Newman NJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P1366
   PANTON RW, 1990, BRIT J OPHTHALMOL, V74, P595, DOI 10.1136/bjo.74.10.595
   Patton N, 2005, J ANAT, V206, P319, DOI 10.1111/j.1469-7580.2005.00395.x
   PATZ A, 1978, NEW ENGL J MED, V298, P1451, DOI 10.1056/NEJM197806292982605
   Piltz-Seymour IR, 2001, AM J OPHTHALMOL, V132, P63, DOI 10.1016/S0002-9394(01)00871-6
   RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9
   RASSAM SMB, 1995, EXP PHYSIOL, V80, P53, DOI 10.1113/expphysiol.1995.sp003834
   Recchia F M, 2000, Curr Opin Ophthalmol, V11, P462, DOI 10.1097/00055735-200012000-00013
   Rucker JC, 2004, CURR OPIN NEUROL, V17, P27, DOI 10.1097/00019052-200402000-00006
   Rumelt S, 1999, AM J OPHTHALMOL, V128, P733, DOI 10.1016/S0002-9394(99)00359-1
   Saitoh M, 1998, INTERNAL MED, V37, P576, DOI 10.2169/internalmedicine.37.576
   SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sharma S, 1998, ARCH OPHTHALMOL-CHIC, V116, P1602, DOI 10.1001/archopht.116.12.1602
   Sharma S, 1996, ARCH OPHTHALMOL-CHIC, V114, P1189, DOI 10.1001/archopht.1996.01100140389004
   Sharrett AR, 1999, AM J EPIDEMIOL, V150, P263
   Smith W, 2004, HYPERTENSION, V44, P442, DOI 10.1161/01.HYP.0000140772.40322.ec
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P216, DOI 10.1001/archopht.1995.01100020100038
   Tsai WC, 2005, CLIN SCI, V109, P39, DOI 10.1042/CS20040307
   Tsaloumas MD, 2000, EYE, V14, P821, DOI 10.1038/eye.2000.230
   TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132
   Ueda Y, 2002, JPN J OPHTHALMOL, V46, P209, DOI 10.1016/S0021-5155(01)00500-7
   van den Born BJH, 2005, BMJ-BRIT MED J, V331, P73, DOI 10.1136/bmj.331.7508.73
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wang JJ, 2003, HYPERTENSION, V42, P534, DOI 10.1161/01.HYP.0000090122.38230.41
   Weber J, 1998, STROKE, V29, P2076, DOI 10.1161/01.STR.29.10.2076
   Wijman CAC, 2004, STROKE, V35, pE100, DOI 10.1161/01.STR.0000125009.05353.7c
   Williams B, 2004, BMJ-BRIT MED J, V328, P634, DOI 10.1136/bmj.328.7440.634
   WILSON LA, 1979, LANCET, V1, P292
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong Tien Yin, 2002, Curr Opin Ophthalmol, V13, P142, DOI 10.1097/00055735-200206000-00002
   Wong TY, 2002, JAMA-J AM MED ASSOC, V288, P67, DOI 10.1001/jama.288.1.67
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Wong TY, 2005, JAMA-J AM MED ASSOC, V293, P63, DOI 10.1001/jama.293.1.63
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2004, J AM SOC NEPHROL, V15, P2469, DOI 10.1097/01.ASN.0000136133.28194.E4
   Wong TY, 2004, BMJ-BRIT MED J, V329, P79, DOI 10.1136/bmj.38124.682523.55
   Wong TY, 2004, OPHTHALMOLOGY, V111, P1183, DOI 10.1016/j.ophtha.2003.09.039
   Wong TY, 2004, ANN INTERN MED, V140, P248, DOI 10.7326/0003-4819-140-4-200402170-00006
   Wong TY, 2003, INVEST OPHTH VIS SCI, V44, P4644, DOI 10.1167/iovs.03-0079
   Wong TY, 2003, NEUROLOGY, V61, P806, DOI 10.1212/01.WNL.0000086372.05488.8D
   Wong TY, 2003, OPHTHALMOLOGY, V110, P933, DOI 10.1016/S0161-6420(03)00084-8
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P1007, DOI 10.1136/bjo.86.9.1007
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153
   Wong TY, 2002, STROKE, V33, P1487, DOI 10.1161/01.STR.0000016789.56668.43
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
   Wu SY, 1997, ARCH OPHTHALMOL-CHIC, V115, P1572, DOI 10.1001/archopht.1997.01100160742012
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yu T, 1998, ARCH OPHTHALMOL-CHIC, V116, P83, DOI 10.1001/archopht.116.1.83
   2000, OPHTHALMOL, V107, P2224
NR 152
TC 400
Z9 415
U1 1
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD FEB 3
PY 2007
VL 369
IS 9559
BP 425
EP 435
DI 10.1016/S0140-6736(07)60198-6
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 132LN
UT WOS:000243944400036
PM 17276782
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Degenring, R
   Kreissig, I
   Akkoyun, I
AF Jonas, JB
   Degenring, R
   Kreissig, I
   Akkoyun, I
TI Safety of intravitreal high-dose reinjections of triamcinolone acetonide
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; INJECTION
AB PURPOSE: To report side effects after intravitreal high, dose reinjections of triamcinolone acetonide.
   DESIGN: Clinical interventional case series.
   METHODS: Forty-six patients (47 eyes) received at least two intravitreal injections of approximately 20 to 25 mg triamcinolone acetonide for treatment of diabetic macular edema (n = 6 eyes), exudative age,related macular degeneration (n = 23), and other diseases. Intervals between injections were 6.7 +/- 3.4 months, 8.0 +/- 4.6 months, and 10.2 months, respectively, before the second (n = 47 eyes), third (n = 9), and fourth (n = 2) injection. Mean follow,up was 20.7 +/- 8.9 months.
   RESULTS: After no reinjection were complications detected, other than those known to occur after a single intravitreal injection. After the first, second, and third injection, respectively, intraocular pressure remained normal in 24 (51%) 25 (53%), and 5 (56%) eyes.
   CONCLUSIONS: Intravitreal high,dosage reinjections of triamcinolone acetonide may be tolerated within a mean follow-up of approximately 21 months. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   Univ Heidelberg, Med Fac Mannheim, Hosp Eye, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI AKKOYUN, IMREN VARDARLI/AAK-7713-2021
OI AKKOYUN, IMREN VARDARLI/0000-0002-2860-7424
CR Benz MS, 2003, ARCH OPHTHALMOL-CHIC, V121, P271
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
NR 5
TC 50
Z9 51
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2004
VL 138
IS 6
BP 1054
EP 1055
DI 10.1016/j.ajo.2004.06.041
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 882TC
UT WOS:000225960200027
PM 15629306
DA 2022-11-30
ER

PT J
AU Semba, RD
   Dagnelie, G
AF Semba, RD
   Dagnelie, G
TI Are lutein and zeaxanthin conditionally essential nutrients for eye
   health?
SO MEDICAL HYPOTHESES
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; MACULAR PIGMENT; PROTECTIVE ROLE; SINGLET
   OXYGEN; CAROTENOIDS; IDENTIFICATION; RETINA; DEGENERATION; SENSITIVITY;
   ABSORPTION
AB The carotenoids lutein and zeaxanthin are found in the macula in high concentrations and may play a role in the pathogenesis of age-related macular degeneration (ARMD). Lutein and zeaxanthin may protect the macula and photoreceptor outer segments throughout the retina from oxidative stress and play a role in an antioxidant cascade that safely disarms the energy of reactive oxygen species. Although lutein and zeaxanthin are not essential nutrients, studies are beginning to suggest that they fit the criteria for conditionally essential nutrients. Low plasma lutein and zeaxanthin concentrations or dietary intake are associated with low macular pigment density and increased risk of ARMD. Dietary deprivation of lutein and zeaxanthin in primates causes pathological changes in the macula. Should controlled clinical trials show lutein and/or zeaxanthin supplementation protects against the development or progression of ARMD and other eye diseases, then lutein and zeaxanthin could be considered as conditionally essential nutrients for humans. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
C3 Johns Hopkins University
RP Semba, RD (通讯作者)，550 N Broadway,Suite 700, Baltimore, MD 21205 USA.
EM rdsemba@jhmi.edu
RI Barickman, Thomas/I-6993-2012
FU NCCIH NIH HHS [R21 AT00292, R21 AT000292] Funding Source: Medline; NEI
   NIH HHS [R03 EY014416] Funding Source: Medline; NIA NIH HHS [R37
   AG019905] Funding Source: Medline; NICHD NIH HHS [R01 HD30047] Funding
   Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE
   [R21AT000292] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R03EY014416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R37AG019905] Funding Source: NIH RePORTER
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BENDICH A, 1989, J NUTR, V119, P112, DOI 10.1093/jn/119.1.112
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   BROWN PK, 1963, NATURE, V200, P37, DOI 10.1038/200037a0
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156
   Buzzi F., 1782, OPUSCOLI SCELTI SCI, V5, P87
   Chan C, 1998, CURR EYE RES, V17, P890, DOI 10.1076/ceyr.17.9.890.5141
   Crabtree DV, 2001, BIOORGAN MED CHEM, V9, P1967, DOI 10.1016/S0968-0896(01)00103-1
   Dagnelie G, 2000, Optometry, V71, P147
   Feeney-Burns L, 1989, Prog Clin Biol Res, V314, P601
   FOOTE CS, 1968, J AM CHEM SOC, V90, P6233, DOI 10.1021/ja01024a061
   FRANK HA, 1993, ANN NY ACAD SCI, V691, P1, DOI 10.1111/j.1749-6632.1993.tb26152.x
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Harper AlfredE., 1999, MODERN NUTR HLTH DIS, P3
   Holden Joanne M., 1999, Journal of Food Composition and Analysis, V12, P169, DOI 10.1006/jfca.1999.0827
   Home E., 1798, PHILOS T R SOC LON 2, P332
   IOM (Institute of Medicine),, 2000, DIET REF INT VIT C V
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Karrer P, 1929, HELV CHIM ACTA, V12, P790, DOI 10.1002/hlca.19290120178
   Karrer P, 1932, HELV CHIM ACTA, V15, P490, DOI 10.1002/hlca.19320150144
   Karrer P, 1931, HELV CHIM ACTA, V14, P614, DOI 10.1002/hlca.19310140159
   KARRER P, 1930, HELV CHIM ACTA, V13, P268
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KRINSKY NI, 1982, J NATL CANCER I, V69, P205
   KRINSKY NI, 1999, ENCY HUMAN NUTR, V1, P304
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   LIEBLER DC, 1993, ANN NY ACAD SCI, V691, P20, DOI 10.1111/j.1749-6632.1993.tb26154.x
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MATHEWSROTH MM, 1974, PHOTOCHEM PHOTOBIOL, V19, P217, DOI 10.1111/j.1751-1097.1974.tb06501.x
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   PFANDER H, 1992, METHOD ENZYMOL, V213, P3
   PUTTING BJ, 1992, INVEST OPHTH VIS SCI, V33, P3385
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Robison WG, 2000, J OCUL PHARMACOL TH, V16, P109, DOI 10.1089/jop.2000.16.109
   Rozanowska MB, 2000, INVEST OPHTH VIS SCI, V41, pS601
   RUDMAN D, 1986, J AM COLL NUTR, V5, P101
   SCHALCH W, 1999, CRC MOD NUT, P215
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Soemmering S. T., 1799, COMMENT SOC REG SCI, V13, P3
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   STAHL W, 1993, ANN NY ACAD SCI, V691, P10, DOI 10.1111/j.1749-6632.1993.tb26153.x
   THUDICHUM JLW, 1869, P ROY SOC LONDON, V17, P253
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WANG XD, 1994, J AM COLL NUTR, V13, P314, DOI 10.1080/07315724.1994.10718416
   WILLIAMS DS, 1992, INVEST OPHTH VIS SCI, V33, P3005
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 77
TC 61
Z9 65
U1 0
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2003
VL 61
IS 4
BP 465
EP 472
DI 10.1016/S0306-9877(03)00198-1
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 728DK
UT WOS:000185699800011
PM 13679014
DA 2022-11-30
ER

PT J
AU Kirwan, JF
   Constable, PH
   Murdoch, IE
   Khaw, PT
AF Kirwan, JF
   Constable, PH
   Murdoch, IE
   Khaw, PT
TI Beta irradiation: new uses for an old treatment: a review
SO EYE
LA English
DT Article
DE beta radiation; p53; glaucoma; pterygium
ID MITOMYCIN-C; MACULAR DEGENERATION; RADIATION-THERAPY; PTERYGIUM
   EXCISION; ARTERIOVENOUS-MALFORMATIONS; ANTIPROLIFERATIVE AGENTS;
   NEOVASCULAR MEMBRANES; CAPSULE FIBROBLASTS; LATE COMPLICATIONS;
   RANDOMIZED TRIAL
AB Beta radiation has a long history as a treatment modality in ophthalmology. It is a convenient and practical method of applying radiation and has the advantage of minimal tissue penetration. There has been a recent resurgence in the use of beta radiation in other areas in medicine, such as the prevention of restenosis after coronary artery stenting. Beta radiation has been shown in vitro and in vivo to inhibit proliferation of human Tenon's fibroblasts, which enter a period of growth arrest but do not die. Effects on the cell cycle controller p53 have been shown to be important in this process.
   In ophthalmology, beta radiation has been used widely for the treatment of pterygium and is under evaluation for treatment of age-related macular degeneration and for controlling wound healing after glaucoma drainage surgery. In this latter role, beta radiation may be particularly appropriate for use in developing countries to improve the results of trabeculectomy while potentially avoiding some of the side effects of other antimetabolites.
C1 Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, London EC1V 9EL, England.
   Inst Ophthalmol, Wound Healing Res Unit, London, England.
   Royal Berkshire Hosp, Dept Ophthalmol, Reading RG1 5AN, Berks, England.
   Moorfields Eye Hosp, London, England.
C3 University of London; University College London; University of London;
   University College London; Royal Berkshire Hospital; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Kirwan, JF (通讯作者)，Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, 11-43 Bath St, London EC1V 9EL, England.
RI Khaw, Peng T/C-1881-2008; Murdoch, Ian/Z-2527-2019
OI Khaw, Sir Peng Tee/0000-0002-8087-2268
CR Alward WLM, 1996, AM J OPHTHALMOL, V121, P349
   Amano S, 2000, BRIT J OPHTHALMOL, V84, P618, DOI 10.1136/bjo.84.6.618
   ARLETT CF, 1980, CANCER RES, V40, P926
   ASWAD MI, 1987, OPHTHALMOLOGY, V94, P1450
   Barnes RM, 2000, CLIN EXP OPHTHALMOL, V28, P259, DOI 10.1046/j.1442-9071.2000.00317.x
   Barron A., 1970, T AM OPHTHAL SOC, V68, P112
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BINDER S, 1994, GRAEF ARCH CLIN EXP, V232, P211, DOI 10.1007/BF00184007
   BROWN GC, 1982, OPHTHALMOLOGY, V89, P1494
   BURNAM CF, 1940, SO M J, V33, P279
   Cameron M E, 1970, Trans Aust Coll Ophthalmol, V2, P53
   Casterella P J, 1999, Cardiol Rev, V7, P219, DOI 10.1097/00045415-199907000-00014
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chalupecky H, 1897, ZENTRALBL PRAKT AUGE, V21, P234
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Chen PP, 1997, J GLAUCOMA, V6, P192
   COHEN LB, 1959, AM J OPHTHALMOL, V47, P53
   Constable PH, 1998, BRIT J OPHTHALMOL, V82, P448, DOI 10.1136/bjo.82.4.448
   CONSTABLE PH, 1999, THESIS U CAMBRIDGE
   Cordeiro MF, 1997, INVEST OPHTH VIS SCI, V38, P1639
   Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P2225
   de Keizer R. J. W., 1997, International Ophthalmology, V21, P335, DOI 10.1023/A:1006070503345
   Desjardins AU, 1932, SCIENCE, V75, P569
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   FRANKS W A, 1991, Eye (London), V5, P385
   FRIEDELL HL, 1950, AM J OPHTHALMOL, V33, P525, DOI 10.1016/0002-9394(50)90445-4
   FRIEDMAN S M, 1986, Investigative Ophthalmology and Visual Science, V27, P212
   FRIEDMAN S M, 1987, Investigative Ophthalmology and Visual Science, V28, P272
   Gleckler M, 1998, MED PHYS, V25, P29, DOI 10.1118/1.598434
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Hayasaka S, 2000, BRIT J OPHTHALMOL, V84, P1081
   HERBSTEIN AU, 1968, BRIT J OPHTHALMOL, V52, P162, DOI 10.1136/bjo.52.2.162
   HILGERS JHC, 1966, ARCH OPHTHALMOL-CHIC, V76, P329, DOI 10.1001/archopht.1966.03850010331005
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   ILIFF CE, 1947, ARCH OPHTHALMOL-CHIC, V38, P415
   ILIFF CE, 1944, AM J OPHTHALMOL, V27, P731
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   Kassir MS, 1999, J FR OPHTALMOL, V22, P776
   KHAW PT, 1991, BRIT J OPHTHALMOL, V75, P580, DOI 10.1136/bjo.75.10.580
   KHAW PT, 1995, BRIT J OPHTHALMOL, V79, P627, DOI 10.1136/bjo.79.7.627
   LAI J, 1994, INVEST OPHTH VIS SCI, V34, P1432
   LEDERMAN M, 1952, J FAC RADIOL-LONDON, V4, P97, DOI 10.1016/S0368-2242(52)80028-4
   Lommatzsch P, 1974, Surv Ophthalmol, V19, P85
   LOMMATZSCH PK, 1973, T OPHTHAL SOC UK, V93, P119
   Lommatzsch PK, 2000, GRAEF ARCH CLIN EXP, V238, P129, DOI 10.1007/PL00007880
   LUNSFORD LD, 1991, J NEUROSURG, V75, P512, DOI 10.3171/jns.1991.75.4.0512
   MACINTYRE J, 2003, BRIT MED J, V2, P1526
   MACKENZIE FD, 1991, OPHTHALMOLOGY, V98, P1776
   MANN WA, 1958, AM J OPHTHALMOL, V45, P137, DOI 10.1016/0002-9394(58)90235-6
   MEAD K W, 1956, Trans Ophthalmol Soc Aust, V16, P101
   MEREDITH TA, 1988, ARCH OPHTHALMOL-CHIC, V106, P673
   Merriam GR., 1972, FRONT RAD THER ONCOL, P346
   MILLER MH, 1991, BRIT J OPHTHALMOL, V75, P584, DOI 10.1136/bjo.75.10.584
   MORIARTY AP, 1993, EYE, V7, P525, DOI 10.1038/eye.1993.114
   MORIARTY AP, 1993, ARCH OPHTHALMOL-CHIC, V111, P947, DOI 10.1001/archopht.1993.01090070065021
   MORRISON DR, 1971, INVEST OPHTH VISUAL, V10, P826
   NEVAREZ JA, 1987, CURR EYE RES, V6, P719, DOI 10.3109/02713688709034835
   OCCLESTON NL, 1994, INVEST OPHTH VIS SCI, V35, P3681
   ODONOGHUE H, 1994, INVEST OPHTH VIS SCI, V35, P1432
   PARYANI SB, 1994, INT J RADIAT ONCOL, V28, P101, DOI 10.1016/0360-3016(94)90146-5
   PERRERSTAYLOR M, 1965, ACTA RADIOL THER PHY, V3, P431, DOI 10.3109/02841866509133117
   PUCK TT, 1957, J EXP MED, V106, P485, DOI 10.1084/jem.106.4.485
   Raizner AE, 2000, CIRCULATION, V102, P951, DOI 10.1161/01.CIR.102.9.951
   REINHOLD HS, 1973, BRIT J RADIOL, V46, P54, DOI 10.1259/0007-1285-46-541-54
   RUBINFELD RS, 1992, OPHTHALMOLOGY, V99, P1647
   Sanchez-Thorin JC, 1998, BRIT J OPHTHALMOL, V82, P661, DOI 10.1136/bjo.82.6.661
   SHIELDS MB, 1993, AM J OPHTHALMOL, V116, P673, DOI 10.1016/S0002-9394(14)73465-8
   Simsek T, 2001, EUR J OPHTHALMOL, V11, P126
   Snibson G. R., 1996, Investigative Ophthalmology and Visual Science, V37, pS703
   STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001
   TARR KH, 1980, BRIT J OPHTHALMOL, V64, P496, DOI 10.1136/bjo.64.7.496
   THOMAS CI, 1962, RADIOLOGY, V79, P588, DOI 10.1148/79.4.588
   TONG ECK, 1969, AMER J ROENTGENOL RA, V106, P848, DOI 10.2214/ajr.106.4.848
   VONSALLMANN L, 1953, AMA ARCH OPHTHALMOL, V50, P727
   Wilkins MR, 2000, BRIT J OPHTHALMOL, V84, P92, DOI 10.1136/bjo.84.1.92
   WOLNER B, 1991, OPHTHALMOLOGY, V98, P1053
   ZACHARIA PT, 1993, AM J OPHTHALMOL, V116, P314, DOI 10.1016/S0002-9394(14)71349-2
NR 77
TC 55
Z9 56
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAR
PY 2003
VL 17
IS 2
BP 207
EP 215
DI 10.1038/sj.eye.6700306
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 677EJ
UT WOS:000182793700016
PM 12640408
OA Bronze
DA 2022-11-30
ER

PT J
AU Li, JY
   Qiu, C
   Wei, Y
   Yuan, WX
   Liu, J
   Cui, WY
   Zhou, JY
   Qiu, C
   Guo, LH
   Huang, LQ
   Ge, Z
   Yu, LY
AF Li, Jinying
   Qiu, Chen
   Wei, Yang
   Yuan, Weixin
   Liu, Jia
   Cui, Wenyu
   Zhou, Jiayi
   Qiu, Cong
   Guo, Lihe
   Huang, Liquan
   Ge, Zhen
   Yu, Luyang
TI Human Amniotic Epithelial Stem Cell-Derived Retinal Pigment Epithelium
   Cells Repair Retinal Degeneration
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE immune privilege; retinal pigment epithelium; retinal degeneration;
   human amniotic epithelial stem cells; cell therapy
ID IN-VITRO DIFFERENTIATION; MACULAR DEGENERATION; GENERATION; THERAPIES;
   TRIALS
AB Age-related macular degeneration (AMD), featured with dysfunction and loss of retinal pigment epithelium (RPE), is lacking efficient therapeutic approaches. According to our previous studies, human amniotic epithelial stem cells (hAESCs) may serve as a potential seed cell source of RPE cells for therapy because they have no ethical concerns, no tumorigenicity, and little immunogenicity. Herein, trichostatin A and nicotinamide can direct hAESCs differentiation into RPE like cells. The differentiated cells display the morphology, marker expression and cellular function of the native RPE cells, and noticeably express little MHC class II antigens and high level of HLA-G. Moreover, visual function and retinal structure of Royal College of Surgeon (RCS) rats, a classical animal model of retinal degeneration, were rescued after subretinal transplantation with the hAESCs-derived RPE like cells. Our study possibly makes some contribution to the resource of functional RPE cells for cell therapy. Subretinal transplantation of hAESCs-RPE could be an optional therapeutic strategy for retinal degeneration diseases.</p>
C1 [Li, Jinying; Qiu, Chen; Yuan, Weixin; Liu, Jia; Cui, Wenyu; Zhou, Jiayi; Qiu, Cong; Yu, Luyang] Zhejiang Univ, Coll Life Sci, MOE Lab Biosyst Homeostasis & Protect, Sir Run Run Shaw Hosp,Key Lab Cardiovasc Interven, Hangzhou, Peoples R China.
   [Li, Jinying; Qiu, Chen; Liu, Jia; Cui, Wenyu; Zhou, Jiayi; Qiu, Cong; Huang, Liquan; Yu, Luyang] Zhejiang Univ, Joint Res Ctr Engn Biol, iCell Biotechnol Regenerat Biomed Lab, Coll Life Sci,Zhejiang Univ Univ Edinburgh Inst, Haining, Peoples R China.
   [Wei, Yang; Ge, Zhen] Hangzhou Med Coll, Sch Pharmaceut Sci, Hangzhou, Peoples R China.
   [Guo, Lihe] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
C3 Zhejiang University; Zhejiang University; Hangzhou Medical College;
   Chinese Academy of Sciences; Shanghai Institutes for Biological
   Sciences, CAS
RP Yu, LY (通讯作者)，Zhejiang Univ, Coll Life Sci, MOE Lab Biosyst Homeostasis & Protect, Sir Run Run Shaw Hosp,Key Lab Cardiovasc Interven, Hangzhou, Peoples R China.; Yu, LY (通讯作者)，Zhejiang Univ, Joint Res Ctr Engn Biol, iCell Biotechnol Regenerat Biomed Lab, Coll Life Sci,Zhejiang Univ Univ Edinburgh Inst, Haining, Peoples R China.; Ge, Z (通讯作者)，Hangzhou Med Coll, Sch Pharmaceut Sci, Hangzhou, Peoples R China.
EM 2020000291@hmc.edu.cn; luyangyu@zju.edu.cn
OI Huang, Liquan/0000-0003-3400-0685
FU National Natural Science Foundation of China [81770444, 81600354,
   81970372]; National Key R&D Program of China [2018YFA0800504]; Zhejiang
   Provincial Natural Science Foundation of China [LZ20H020002]; Medical
   and Health Science and Technology Program of Health Commission of
   Zhejiang Province, China [2021KY633]; Project of Health Collaborative
   Innovation of Guangzhou City [201704020214]; China Postdoctoral Science
   Foundation [2019M662036]; Fundamental Research Funds for the Central
   Universities of China
FX This work was supported by the National Natural Science Foundation of
   China (81770444 and 81600354, 81970372), the National Key R&D Program of
   China (2018YFA0800504), the Zhejiang Provincial Natural Science
   Foundation of China (LZ20H020002), the Medical and Health Science and
   Technology Program of Health Commission of Zhejiang Province, China
   (2021KY633), the Project of Health Collaborative Innovation of Guangzhou
   City (201704020214), the China Postdoctoral Science Foundation
   (2019M662036), and the Fundamental Research Funds for the Central
   Universities of China.
CR AKLE CA, 1981, LANCET, V2, P1003
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Barkholt L, 2013, CYTOTHERAPY, V15, P753, DOI 10.1016/j.jcyt.2013.03.005
   Casiraghi F, 2013, STEM CELL REV REP, V9, P65, DOI 10.1007/s12015-011-9345-4
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   Huo SJ, 2012, CURR EYE RES, V37, P749, DOI 10.3109/02713683.2012.697972
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Li JY, 2018, CELL TRANSPLANT, V27, P1504, DOI 10.1177/0963689718796196
   Luthert PJ., 2011, DIAGN HISTOPATHOL, V17, P10, DOI [10.1016/j.mpdhp.2010.10.004, DOI 10.1016/J.MPDHP.2010.10.004]
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Miki T, 2005, STEM CELLS, V23, P1549, DOI 10.1634/stemcells.2004-0357
   Miki T, 2006, STEM CELL REV, V2, P133, DOI 10.1007/s12015-006-0020-0
   Miki T, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13003
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moviglia GA, 2012, OPHTHALMIC RES, V48, P1, DOI 10.1159/000339839
   Parolini O, 2008, STEM CELLS, V26, P300, DOI 10.1634/stemcells.2007-0594
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rezanejad H, 2014, CELL TISSUE RES, V356, P65, DOI 10.1007/s00441-014-1795-y
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Strom SC, 2016, HUM IMMUNOL, V77, P734, DOI 10.1016/j.humimm.2016.07.002
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Tan B, 2018, CYTOTHERAPY, V20, P1247, DOI 10.1016/j.jcyt.2018.04.001
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Veceric-Haler Z, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/7304643
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang PJ, 2018, ACTA PHARMACOL SIN, V39, P1305, DOI 10.1038/aps.2018.22
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
NR 39
TC 4
Z9 5
U1 2
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD SEP 28
PY 2021
VL 9
AR 737242
DI 10.3389/fcell.2021.737242
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA WF6VT
UT WOS:000706441600001
PM 34650985
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Li, N
   Wu, XT
   Zhuang, W
   Xia, L
   Chen, Y
   Wang, Y
   Wu, CC
   Rao, ZY
   Du, L
   Zhao, R
   Yi, MS
   Wan, QY
   Zhou, Y
AF Li, Ni
   Wu, Xiaoting
   Zhuang, Wen
   Xia, Lin
   Chen, Yi
   Wang, Yong
   Wu, Chuncheng
   Rao, Zhiyong
   Du, Liang
   Zhao, Rui
   Yi, Mengshi
   Wan, Qianyi
   Zhou, Yong
TI Green leafy vegetable and lutein intake and multiple health outcomes
SO FOOD CHEMISTRY
LA English
DT Article
DE Green leafy vegetables; Lutein; Health; Meta-analysis; Umbrella review
ID CAROTENOID INTAKE; POOLED ANALYSIS; CANCER-RISK; FRUIT; CONSUMPTION;
   METAANALYSIS; ASSOCIATION; DISEASE
AB Green leafy vegetables (GLVs) are a key element of healthy eating patterns and are an important source of lutein. To clarify the evidence for associations between GLVs and lutein intake and multiple health outcomes, we performed a review. A total of 24 meta-analyses with 29 health outcomes were identified by eligibility criteria. Dose-response analyses revealed that, per 100 g/d GLV intake was associated with a decreased risk (ca. 25%) of all-cause mortality, coronary heart disease and stroke. Beneficial effects of GLV intake were found for cardiovascular disease and bladder and oral cancer. Dietary lutein intake was inversely associated with age-related macular degeneration, age-related cataracts, coronary heart disease, stroke, oesophageal cancer, non-Hodgkin lymphoma, metabolic syndrome, and amyotrophic lateral sclerosis. Caution was warranted for contamination with potentially pathogenic organisms, specifically Escherichia coli. GLV consumption and lutein intake therein are generally safe and beneficial for multiple health outcomes in humans.
C1 [Li, Ni] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
   [Wu, Xiaoting; Zhuang, Wen; Xia, Lin; Chen, Yi; Wang, Yong; Zhao, Rui; Yi, Mengshi; Wan, Qianyi; Zhou, Yong] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, 37 Guo Xue Rd, Chengdu 610041, Peoples R China.
   [Wu, Chuncheng] Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu 610041, Peoples R China.
   [Rao, Zhiyong] Sichuan Univ, West China Hosp, Dept Clin Nutr, Chengdu 610041, Peoples R China.
   [Du, Liang] Chinese Evidence Based Med Cochrane Ctr, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University
RP Zhou, Y (通讯作者)，Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, 37 Guo Xue Rd, Chengdu 610041, Peoples R China.
EM nutritioner@hotmail.com
OI Du, Liang/0000-0003-1855-9139
FU Chinese Medical Board Grant on Evidence-Based Medicine, New York, USA
   [98-680]; National Natural Science Foundation of China [30901427];
   Sichuan Provincial Science and Technology Support Project [2016SZ0047]
FX This work was supported by Chinese Medical Board Grant on EvidenceBased
   Medicine, New York, USA (No. 98680) , National Natural Science
   Foundation of China (No.30901427) and Sichuan Provincial Science and
   Technology Support Project (2016SZ0047) .
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Aune D, 2017, INT J EPIDEMIOL, V46, P1029, DOI 10.1093/ije/dyw319
   Bae JM, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016024
   Bonequi P, 2013, CANCER CAUSE CONTROL, V24, P217, DOI 10.1007/s10552-012-0110-z
   Capeding R, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-22
   Carter P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4229
   Chen FF, 2017, ANN HEMATOL, V96, P957, DOI 10.1007/s00277-016-2898-1
   Chen GC, 2018, BRIT J NUTR, V119, P1057, DOI [10.1017/S0007114518000119, 10.1017/s0007114518000119]
   Chen JM, 2016, INT J FOOD SCI NUTR, V67, P744, DOI 10.1080/09637486.2016.1197892
   Conrad Z, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101377
   Cota F, 2022, J MATERN-FETAL NEO M, V35, P175, DOI 10.1080/14767058.2020.1712700
   Fitzgerald KC, 2013, ANN NEUROL, V73, P236, DOI 10.1002/ana.23820
   Gallicchio L, 2008, AM J CLIN NUTR, V88, P372, DOI 10.1093/ajcn/88.2.372
   Ge XX, 2013, ASIAN PAC J CANCER P, V14, P1911, DOI 10.7314/APJCP.2013.14.3.1911
   GOH KT, 1990, ARCH ENVIRON HEALTH, V45, P180, DOI 10.1080/00039896.1990.9936713
   Hariprasad P, 2013, FOOD CHEM, V138, P1908, DOI 10.1016/j.foodchem.2012.11.093
   He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0
   Jayedi A, 2018, ADV NUTR, V9, P701, DOI 10.1093/advances/nmy040
   Jiang H, 2019, AM J CLIN NUTR, V109, P43, DOI 10.1093/ajcn/nqy270
   John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6
   Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233
   Leermakers ETM, 2016, AM J CLIN NUTR, V103, P481, DOI 10.3945/ajcn.115.120931
   Mannisto S, 2007, AM J EPIDEMIOL, V165, P246, DOI 10.1093/aje/kwk009
   Miller V, 2017, LANCET, V390, P2037, DOI [10.1016/S0140-6736(17)32253-5, 10.1016/s0140-6736(17)32253-5]
   Mogren L, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01965
   Oyebode O, 2014, J EPIDEMIOL COMMUN H, V68, P856, DOI 10.1136/jech-2013-203500
   Pavia M, 2006, AM J CLIN NUTR, V83, P1126, DOI 10.1093/ajcn/83.5.1126
   Prez VE, 2018, SCI TOTAL ENVIRON, V637, P665, DOI 10.1016/j.scitotenv.2018.05.044
   Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769
   Takeda A, 2014, NEUROEPIDEMIOLOGY, V42, P25, DOI 10.1159/000355849
   Turner K, 2019, J FOOD PROTECT, V82, P405, DOI 10.4315/0362-028X.JFP-18-316
   Vizon Khryst Celine C., 2019, Journal of Parasitic Diseases, V43, P651, DOI 10.1007/s12639-019-01144-0
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu SH, 2020, ADV NUTR, V11, P630, DOI 10.1093/advances/nmz120
   Xu C, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000759
   Xu JH, 2017, ONCOTARGET, V8, P2391, DOI 10.18632/oncotarget.13678
   Zhou YP, 2016, CLIN NUTR, V35, P109, DOI 10.1016/j.clnu.2015.02.003
NR 38
TC 13
Z9 13
U1 4
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PD OCT 30
PY 2021
VL 360
AR 130145
DI 10.1016/j.foodchem.2021.130145
EA MAY 2021
PG 7
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA SV4EB
UT WOS:000663772400005
PM 34034049
DA 2022-11-30
ER

PT J
AU Kumar, V
   Surve, A
   Kumawat, D
   Takkar, B
   Azad, S
   Chawla, R
   Shroff, D
   Arora, A
   Singh, R
   Venkatesh, P
AF Kumar, Vinod
   Surve, Abhidnya
   Kumawat, Devesh
   Takkar, Brijesh
   Azad, Shorya
   Chawla, Rohan
   Shroff, Daraius
   Arora, Atul
   Singh, Ramandeep
   Venkatesh, Pradeep
TI Ultra-wide field retinal imaging: A wider clinical perspective
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Retinal imaging; retinal disorders; Ultra-widefield; UWF
   autofluorescence; UWF fluorescein angiography; UWF Indocyanine
   angiography
ID SCANNING LASER OPHTHALMOSCOPY; WIDEFIELD FLUORESCEIN ANGIOGRAPHY;
   DIABETIC-RETINOPATHY; FUNDUS AUTOFLUORESCENCE; PERIPHERAL LESIONS;
   TREATMENT RESPONSE; VEIN OCCLUSION; MACULAR EDEMA; NON-PERFUSION;
   MANAGEMENT
AB The peripheral retina is affected in a variety of retinal disorders. Traditional fundus cameras capture only a part of the fundus even when montaging techniques are used. Ultra-wide field imaging enables us to delve into the retinal periphery in greater detail. It not only facilitates assessing color images of the fundus, but also fluorescein angiography, indocyanine green angiography, fundus autofluorescence, and red and green free images. In this review, a literature search using the keywords "ultra-widefield imaging", "widefield imaging", and "peripheral retinal imaging" in English and non-English languages was done and the relevant articles were included. Ultra-wide field imaging has made new observations in the normal population as well as in eyes with retinal disorders including vascular diseases, degenerative diseases, uveitis, age-related macular degeneration, retinal and choroidal tumors and hereditary retinal dystrophies. This review aims to describe the utility of ultra-wide field imaging in various retinal disorders.
C1 [Kumar, Vinod; Surve, Abhidnya; Azad, Shorya; Chawla, Rohan; Venkatesh, Pradeep] AIIMS, RP Ctr, New Delhi, India.
   [Kumawat, Devesh] AIIMS Rishikesh, Rishikesh, Uttarakhand, India.
   [Takkar, Brijesh] LV Prasad Eye Inst, Hyderabad, Telangana, India.
   [Shroff, Daraius] Shroff Eye Ctr, Delhi, India.
   [Arora, Atul; Singh, Ramandeep] PGIMER, Chandigarh, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences; All India Institute of Medical
   Sciences (AIIMS) Rishikesh; L. V. Prasad Eye Institute; Post Graduate
   Institute of Medical Education & Research (PGIMER), Chandigarh
RP Kumar, V (通讯作者)，All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Vitreoretina Uvea & ROP Serv, New Delhi, India.
EM drvinod_agg@yahoo.com
RI Surve, Abhidnya/P-8903-2017
OI Surve, Abhidnya/0000-0003-3719-4112; Takkar, Brijesh/0000-0001-5779-7645
CR Aggarwal K, 2016, OCUL IMMUNOL INFLAMM, V24, P631, DOI 10.3109/09273948.2015.1099681
   Aghdam KA, 2016, INT J OPHTHALMOL-CHI, V9, P858, DOI 10.18240/ijo.2016.06.12
   [Anonymous], 1991, Ophthalmology, V98, P786
   Ayres B, 2017, OSLI RETINA, V48, P459, DOI 10.3928/23258160-20170601-03
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Callaway NF, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0196-5
   Chen Wendy S., 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P4036
   Chen XT, 2018, RETINA-J RET VIT DIS, V38, P748, DOI 10.1097/IAE.0000000000001601
   Chi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122749
   Choudhry N, 2019, OPHTHALMOL RETINA, V3, P843, DOI 10.1016/j.oret.2019.05.007
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   Corbelli E, 2020, GRAEF ARCH CLIN EXP, V258, P543, DOI 10.1007/s00417-019-04586-7
   Diabetic Retinopathy Clinical Research Network, PERIPHERAL DIABETIC
   Dickson D, 2016, J OPHTHALMIC INFLAMM, V6, DOI 10.1186/s12348-016-0105-0
   Fogliato G, 2019, OSLI RETINA, V50, P544, DOI 10.3928/23258160-20190905-02
   Forshaw TRJ, 2019, OPHTHALMOL RETINA, V3, P734, DOI 10.1016/j.oret.2019.04.014
   Goel S, 2019, INDIAN J OPHTHALMOL, V67, P1105, DOI 10.4103/ijo.IJO_1364_18
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Hariri AH, 2018, OPHTHALMOL RETINA, V2, P735, DOI 10.1016/j.oret.2017.10.018
   Hashimoto H, 2015, AM J OPHTHALMOL, V159, P698, DOI 10.1016/j.ajo.2015.01.015
   Heimann H, 2013, EYE, V27, P208, DOI 10.1038/eye.2012.251
   Inoue M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0510-7
   Jain S, 2018, INDIAN J OPHTHALMOL, V66, P997, DOI 10.4103/ijo.IJO_1109_17
   Kaneko Y, 2014, INVEST OPHTH VIS SCI, V55, P1432, DOI 10.1167/iovs.13-13706
   Kang KB, 2013, J PEDIAT OPHTH STRAB, V50, P282, DOI 10.3928/01913913-20130528-04
   Kashani AH, 2014, OPHTHALMOLOGY, V121, P2220, DOI 10.1016/j.ophtha.2014.05.029
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P829
   Kim DY, 2014, INVEST OPHTH VIS SCI, V55, P7040, DOI 10.1167/iovs.14-15112
   Kim P, 2019, BRIT J OPHTHALMOL, V103, P942, DOI 10.1136/bjophthalmol-2018-312569
   Klufas MA, 2018, RETINA-J RET VIT DIS, V38, P403, DOI 10.1097/IAE.0000000000001567
   Knickelbein JE, 2016, RETINA-J RET VIT DIS, V36, P2213, DOI 10.1097/IAE.0000000000001050
   Kornberg DL, 2016, SEMIN OPHTHALMOL, V31, P505, DOI 10.3109/08820538.2014.981551
   Kornberg DL, 2016, RETINA-J RET VIT DIS, V36, P1101, DOI 10.1097/IAE.0000000000000833
   Kumar P, 2019, INDIAN J OPHTHALMOL, V67, P2029, DOI 10.4103/ijo.IJO_802_19
   Kumar V, 2015, BMJ CASE REPORTS
   Kumar V, 2019, EUR J OPHTHALMOL, V29, P444, DOI 10.1177/1120672118795056
   Kumar V, 2017, JAMA OPHTHALMOL, V135, DOI 10.1001/jamaophthalmol.2017.3236
   Kumar V, 2017, GRAEF ARCH CLIN EXP, V255, P1917, DOI 10.1007/s00417-017-3736-4
   Kumar V, 2017, SAUDI J OPHTHALMOL, V31, P122, DOI 10.1016/j.sjopt.2017.02.007
   Kumar V, 2017, CLIN EXP OPTOM, V100, P79, DOI 10.1111/cxo.12418
   Kumar Vinod, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-218303
   Kumar V, 2016, INDIAN J OPHTHALMOL, V64, P504, DOI 10.4103/0301-4738.190138
   Kusumi Yumi, 2016, Nippon Ganka Gakkai Zasshi, V120, P35
   Kwon S, 2018, BRIT J OPHTHALMOL, V102, P1066, DOI 10.1136/bjophthalmol-2017-311475
   Laovirojjanakul W, 2019, OCUL IMMUNOL INFLAMM, V27, P356, DOI 10.1080/09273948.2017.1371764
   Leder HA, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-30
   Lee E, 2015, GRAEF ARCH CLIN EXP, V253, P359, DOI 10.1007/s00417-014-2710-7
   Lei BY, 2020, EYE, V34, P864, DOI 10.1038/s41433-019-0587-8
   LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1
   Lu J, 2017, AM J OPHTHALMOL, V173, P84, DOI 10.1016/j.ajo.2016.09.024
   Lyu J, 2017, GRAEF ARCH CLIN EXP, V255, P39, DOI 10.1007/s00417-016-3415-x
   Marchese A, 2019, BRIT J OPHTHALMOL, V103, P1656, DOI 10.1136/bjophthalmol-2018-313491
   Mesquida M, 2014, RETINA-J RET VIT DIS, V34, P2121, DOI 10.1097/IAE.0000000000000197
   Mrejen S, 2016, OSLI RETINA, V47, P20, DOI 10.3928/23258160-20151214-03
   Muqit MMK, 2013, BRIT J OPHTHALMOL, V97, P220, DOI 10.1136/bjophthalmol-2012-302189
   Muqit MMK, 2013, ACTA OPHTHALMOL, V91, P251, DOI 10.1111/j.1755-3768.2011.02307.x
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Nicholson BP, 2014, AM J OPHTHALMOL, V157, P673, DOI 10.1016/j.ajo.2013.12.005
   Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035
   Oliver SCN, 2010, SEMIN OPHTHALMOL, V25, P27, DOI 10.3109/08820538.2010.481239
   Patel CK, 2013, EYE, V27, P589, DOI 10.1038/eye.2013.45
   Patel RD, 2013, AM J OPHTHALMOL, V155, P1038, DOI 10.1016/j.ajo.2013.01.007
   Prasad PS, 2010, OPHTHALMOLOGY, V117, P780, DOI 10.1016/j.ophtha.2009.09.019
   Price LD, 2015, CLIN OPHTHALMOL, V9, P527, DOI 10.2147/OPTH.S79448
   Rabiolo A, 2017, GRAEF ARCH CLIN EXP, V255, P1881, DOI 10.1007/s00417-017-3794-7
   Rasmussen ML, 2015, J DIABETES COMPLICAT, V29, P99, DOI 10.1016/j.jdiacomp.2014.08.009
   Reznicek L, 2014, INT J OPHTHALMOL-CHI, V7, P697, DOI 10.3980/j.issn.2222-3959.2014.04.21
   Richter GM, 2009, SURV OPHTHALMOL, V54, P671, DOI 10.1016/j.survophthal.2009.02.020
   Salvanos P, 2013, RETINA-J RET VIT DIS, V33, P1421, DOI 10.1097/IAE.0b013e318283138d
   Shah AR, 2016, RETINA-J RET VIT DIS, V36, P1087, DOI 10.1097/IAE.0000000000000878
   Sheemar A, 2019, OCUL IMMUNOL INFLAMM, V27, P383, DOI 10.1080/09273948.2018.1508729
   Shifera AS, 2017, RETINA-J RET VIT DIS, V37, P1104, DOI 10.1097/IAE.0000000000001311
   Shoughy SS, 2015, INDIAN J OPHTHALMOL, V63, P575, DOI 10.4103/0301-4738.167122
   Silva PS, 2015, OPHTHALMOLOGY, V122, P2465, DOI 10.1016/j.ophtha.2015.07.034
   Silva PS, 2015, OPHTHALMOLOGY, V122, P949, DOI 10.1016/j.ophtha.2015.01.008
   Silva PS, 2013, OPHTHALMOLOGY, V120, P2587, DOI 10.1016/j.ophtha.2013.05.004
   Sim DA, 2014, AM J OPHTHALMOL, V158, P144, DOI 10.1016/j.ajo.2014.03.009
   Singer M, 2016, OPHTHALMOLOGY, V123, P1053, DOI 10.1016/j.ophtha.2016.01.022
   Singer M, 2014, RETINA-J RET VIT DIS, V34, P1736, DOI 10.1097/IAE.0000000000000148
   Singer MA, 2015, CLIN OPHTHALMOL, V9, P337, DOI 10.2147/OPTH.S75842
   Singh RP, 2019, OSLI RETINA, V50, P639, DOI 10.3928/23258160-20191009-07
   Smith SM, 2019, OPHTHALMIC GENET, V40, P403, DOI 10.1080/13816810.2019.1678177
   Tadepalli S, 2020, OCUL IMMUNOL INFLAMM, V28, P446, DOI 10.1080/09273948.2019.1595671
   Tan CS, 2016, BRIT J OPHTHALMOL, V100, P235, DOI 10.1136/bjophthalmol-2015-306652
   Tanaka R, 2021, OCUL IMMUNOL INFLAMM, V29, P1398, DOI 10.1080/09273948.2020.1737141
   Trese MT, 2008, RETINA-J RET VIT DIS, V28, pS1, DOI 10.1097/IAE.0b013e31816a5587
   Trichonas G, 2017, OPHTHALMIC GENET, V38, P320, DOI 10.1080/13816810.2016.1227450
   Tripathy K, 2018, J CURR OPHTHALMOL, V30, P263, DOI 10.1016/j.joco.2018.06.006
   Tsui I, 2013, OPHTHAL SURG LAS IM, V44, P59, DOI 10.3928/23258160-20121221-14
   Tsui I, 2011, RETINA-J RET VIT DIS, V31, P105, DOI 10.1097/IAE.0b013e3181e36c6d
   Tsui I, 2009, SEMIN OPHTHALMOL, V24, P25, DOI 10.1080/08820530802520178
   Tsui I, 2009, SEMIN OPHTHALMOL, V24, P29, DOI 10.1080/08820530802520186
   Venkatesh P, 2019, OPHTHALMIC RES, V61, P115, DOI 10.1159/000494498
   Vinekar A, 2015, SEMIN FETAL NEONAT M, V20, P335, DOI 10.1016/j.siny.2015.05.002
   Wessel MM, 2012, BRIT J OPHTHALMOL, V96, P694, DOI 10.1136/bjophthalmol-2011-300774
   Wessel MM, 2012, RETINA-J RET VIT DIS, V32, P785, DOI 10.1097/IAE.0b013e3182278b64
   Witmer MT, 2012, EYE, V26, P1209, DOI 10.1038/eye.2012.122
   Writing Committee for the OPTOS PEripheral RetinA (OPERA) study (Ancillary Study of Age-Related Eye Disease Study 2), 2017, Ophthalmology, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Yang ML, 2019, OCUL IMMUNOL INFLAMM, V27, P371, DOI 10.1080/09273948.2017.1394469
   Ye PP, 2019, INT J OPHTHALMOL-CHI, V12, P1978, DOI 10.18240/ijo.2019.12.22
   Yuan Alex, 2010, Ophthalmic Surg Lasers Imaging, V41 Online, pe1, DOI 10.3928/15428877-20101025-10
   Zhao PY, 2018, AM J OPHTHALMOL, V188, P104, DOI 10.1016/j.ajo.2017.12.011
   1984, AM J OPHTHALMOL, V9, P271
NR 103
TC 9
Z9 9
U1 5
U2 10
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD APR
PY 2021
VL 69
IS 4
BP 824
EP 835
DI 10.4103/ijo.IJO_1403_20
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RF1YF
UT WOS:000634641100010
PM 33727441
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wooff, Y
   Fernando, N
   Wong, JHC
   Dietrich, C
   Aggio-Bruce, R
   Chu-Tan, JA
   Robertson, AAB
   Doyle, SL
   Man, SM
   Natoli, R
AF Wooff, Yvette
   Fernando, Nilisha
   Wong, Josephine H. C.
   Dietrich, Catherine
   Aggio-Bruce, Riemke
   Chu-Tan, Joshua A.
   Robertson, Avril A. B.
   Doyle, Sarah L.
   Man, Si Ming
   Natoli, Riccardo
TI Caspase-1-dependent inflammasomes mediate photoreceptor cell death in
   photo-oxidative damage-induced retinal degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NLRP3 INFLAMMASOME; MACULAR DEGENERATION; OXIDATIVE STRESS; INNATE
   IMMUNITY; IN-VIVO; ALU RNA; ACTIVATION; EXPRESSION; PATHOGENESIS; MODEL
AB Activation of the inflammasome is involved in the progression of retinal degenerative diseases, in particular, in the pathogenesis of Age-Related Macular Degeneration (AMD), with NLRP3 activation the focus of many investigations. In this study, we used genetic and pharmacological approaches to explore the role of the inflammasome in a mouse model of retinal degeneration. We identify that Casp1/11(-/-) mice have better-preserved retinal function, reduced inflammation and increased photoreceptor survivability. While Nlrp3(-/-) mice display some level of preservation of retinal function compared to controls, pharmacological inhibition of NLRP3 did not protect against photoreceptor cell death. Further, Aim2(-/-), Nlrc4(-/-), Asc(-/-), and Casp11(-/-) mice show no substantial retinal protection. We propose that CASP-1-associated photoreceptor cell death occurs largely independently of NLRP3 and other established inflammasome sensor proteins, or that inhibition of a single sensor is not sufficient to repress the inflammatory cascade. Therapeutic targeting of CASP-1 may offer a more promising avenue to delay the progression of retinal degenerations.
C1 [Wooff, Yvette; Fernando, Nilisha; Wong, Josephine H. C.; Dietrich, Catherine; Aggio-Bruce, Riemke; Chu-Tan, Joshua A.; Man, Si Ming; Natoli, Riccardo] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia.
   [Wooff, Yvette; Chu-Tan, Joshua A.; Natoli, Riccardo] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia.
   [Robertson, Avril A. B.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.
   [Doyle, Sarah L.] Trinity Coll Dublin, Inst Neurosci, Sch Med, Dept Clin Med, Dublin, Ireland.
   [Doyle, Sarah L.] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin, Ireland.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University; University of Queensland; Trinity
   College Dublin; National Children's Research Centre (NCRC); Our Ladys
   Children Hospital Crumlin; Trinity College Dublin
RP Natoli, R (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia.; Natoli, R (通讯作者)，Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia.
EM Riccardo.natoli@anu.edu.au
RI Man, Si Ming/AAE-9168-2019; Robertson, Avril/A-4043-2012
OI Man, Si Ming/0000-0002-5079-2857; wooff, yvette/0000-0003-2074-2194;
   Natoli, Riccardo/0000-0002-9350-0439; Wong,
   Josephine/0000-0003-1399-9258; Chu-Tan, Joshua/0000-0001-7936-8972;
   Robertson, Avril/0000-0002-9652-8357; Aggio-Bruce,
   Riemke/0000-0003-3086-2739; Fernando, Nilisha/0000-0002-8488-1348
FU Ophthalmic Research Institute of Australia; National Health and Medical
   Research Council of Australia [NHMRC: 1127705, APP1141504, APP1146864,
   APP1162103, APP1163358]; ANU Translational Fellowship; Australian
   National University; Gretel and Gordon Bootes Medical Research
   Foundation; R.D. Wright Career Development Fellowship [APP1162025]
FX This work was funded by grants from the Ophthalmic Research Institute of
   Australia awarded to N.F (ORIA - New Investigator Grant, 2018), and the
   National Health and Medical Research Council of Australia (NHMRC:
   1127705) and the ANU Translational Fellowship awarded to R.N. S.M.M. is
   supported by the Australian National University, The Gretel and Gordon
   Bootes Medical Research Foundation, and the National Health and Medical
   Research Council of Australia under Project Grants (APP1141504,
   APP1146864, APP1162103 and APP1163358) and the R.D. Wright Career
   Development Fellowship (APP1162025).
CR ALLIOT F, 1984, BRAIN RES, V306, P283, DOI 10.1016/0006-8993(84)90377-9
   ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Appelbaum T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177224
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Campbell M, 2013, J MOL MED, V91, P1059, DOI 10.1007/s00109-013-1050-0
   CHAN CC, 2013, INVEST OPHTH VIS SCI, V0054
   Chaurasia SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21198-z
   Coll R. C., 2019, NAT CHEM BIOL, V1
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Cornish EE, 2005, VISUAL NEUROSCI, V22, P447, DOI 10.1017/S0952523805224069
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Flores J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06449-x
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gombault A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00414
   Grimm C, 2000, MOL VIS, V6, P252
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Gustin A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130624
   Janik-Papis Katarzyna, 2009, Klin Oczna, V111, P168
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
   Jones JW, 2010, P NATL ACAD SCI USA, V107, P9771, DOI 10.1073/pnas.1003738107
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kovarova M, 2012, J IMMUNOL, V189, P2006, DOI 10.4049/jimmunol.1201065
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   Ling CB, 2019, EYE, V33, P777, DOI 10.1038/s41433-018-0318-6
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lu YT, 2018, EXP EYE RES, V169, P1, DOI 10.1016/j.exer.2018.01.011
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Man SM, 2016, CELL, V167, P382, DOI 10.1016/j.cell.2016.09.012
   Man SM, 2016, EUR J IMMUNOL, V46, P269, DOI 10.1002/eji.201545839
   Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7
   Man SM, 2015, IMMUNOL REV, V265, P6, DOI 10.1111/imr.12296
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Marneros AG, 2016, ADV EXP MED BIOL, V854, P79, DOI 10.1007/978-3-319-17121-0_12
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McKenzie BA, 2018, P NATL ACAD SCI USA, V115, pE6065, DOI 10.1073/pnas.1722041115
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Natoli R, 2016, EXP EYE RES, V147, P114, DOI 10.1016/j.exer.2016.04.015
   Natoli R, 2010, MOL VIS, V16, P1801
   Perche O, 2007, INVEST OPHTH VIS SCI, V48, P2753, DOI 10.1167/iovs.06-1258
   Perera AP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26775-w
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Pronin A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00036
   Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041
   Ruland J, 2014, CELL, V156, P1127, DOI 10.1016/j.cell.2014.02.038
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Samardzija M, 2006, INVEST OPHTH VIS SCI, V47, P5181, DOI 10.1167/iovs.06-0556
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schroder K, 2009, CURR BIOL, V19, pR262, DOI 10.1016/j.cub.2009.02.011
   Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Sutterwala FS, 2014, ANN NY ACAD SCI, V1319, P82, DOI 10.1111/nyas.12458
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K., 2013, J CELL SCI JCS
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van der Heijden T, 2017, ARTERIOSCL THROM VAS, V37, P1457, DOI 10.1161/ATVBAHA.117.309575
   van Hout GPJ, 2017, EUR HEART J, V38, P828, DOI 10.1093/eurheartj/ehw247
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang L., 2019, EFFICACY NOVEL SELEC, P1
   Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5
   Wang YC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071036
   Wu TH, 2003, BRAIN RES, V967, P19, DOI 10.1016/S0006-8993(02)04125-2
   Yerramothu P., 2017, EYE LONDON, V32, P491, DOI 10.1038/eye.2017.241
   Young B. M., 2019, MOL THERAPY METHODS
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zhang Y., 2017, CELL DEATH DIS, V8, pe2611, DOI 10.1038/cddis.2016.491
   Zhao Y, 2011, NATURE, V477, P596, DOI 10.1038/nature10510
NR 92
TC 16
Z9 16
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 10
PY 2020
VL 10
IS 1
AR 2263
DI 10.1038/s41598-020-58849-z
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NB7LA
UT WOS:000560694800016
PM 32041990
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Canto, A
   Olivar, T
   Romero, FJ
   Miranda, M
AF Canto, Antolin
   Olivar, Teresa
   Romero, Francisco Javier
   Miranda, Maria
TI Nitrosative Stress in Retinal Pathologies: Review
SO ANTIOXIDANTS
LA English
DT Review
DE nitric oxide; peroxynitrite; nitric oxide synthase; retina; diabetes;
   retinitis pigmentosa; glaucoma; age related macular degeneration
ID NITRIC-OXIDE SYNTHASE; CONE CELL-DEATH; DIABETIC-RETINOPATHY; MACULAR
   DEGENERATION; PHOTORECEPTOR DEATH; GLOBAL PREVALENCE; AQUEOUS-HUMOR;
   BETA-SUBUNIT; RAT RETINA; MODEL
AB Nitric oxide (NO) is a gas molecule with diverse physiological and cellular functions. In the eye, NO is used to maintain normal visual function as it is involved in photoreceptor light transduction. In addition, NO acts as a rapid vascular endothelial relaxant, is involved in the control of retinal blood flow under basal conditions and mediates the vasodilator responses of different substances such as acetylcholine, bradykinin, histamine, substance P or insulin. However, the retina is rich in polyunsaturated lipid membranes and is sensitive to the action of reactive oxygen and nitrogen species. Products generated from NO (i.e., dinitrogen trioxide (N2O3) and peroxynitrite) have great oxidative damaging effects. Oxygen and nitrogen species can react with biomolecules (lipids, proteins and DNA), potentially leading to cell death, and this is particularly important in the retina. This review focuses on the role of NO in several ocular diseases, including diabetic retinopathy, retinitis pigmentosa, glaucoma or age-related macular degeneration (AMD).
C1 [Canto, Antolin; Olivar, Teresa; Miranda, Maria] Univ Cardenal Herrera CEU, CEU Univ, Fac Ciencias Salud, Dept Ciencias Biomed, Valencia 64315, Spain.
   [Romero, Francisco Javier] Univ Europea Valencia, Dept Ciencias Biomed, Valencia 46010, Spain.
C3 Universidad CEU Cardenal Herrera
RP Miranda, M (通讯作者)，Univ Cardenal Herrera CEU, CEU Univ, Fac Ciencias Salud, Dept Ciencias Biomed, Valencia 64315, Spain.
EM antolin.cantocatala@uchceu.es; tolivar@uchceu.es;
   jromerogomez@gmail.com; mmiranda@uchceu.es
RI Miranda, María/ABG-5343-2020
OI Miranda, María/0000-0002-3738-367X; Romero, Francisco
   J/0000-0001-8701-5907
FU Cardenal Herrera CEU and University; San Pablo CEU Foundation University
   [INDI 18/31]; Generalitat Valenciana [PROMETEO 94/2016]
FX Cardenal Herrera CEU and University and San Pablo CEU Foundation
   University, grant numbers: INDI 18/31 and Consolidacion 2018/19 and
   grant PROMETEO 94/2016 from Generalitat Valenciana.
CR Abu El-Asrar AM, 2004, EYE, V18, P306, DOI 10.1038/sj.eye.6700642
   Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593
   Aliancy J, 2017, OPHTHALMOL THER, V6, P221, DOI 10.1007/s40123-017-0094-6
   Arnal E, 2009, CURR EYE RES, V34, P928, DOI 10.3109/02713680903205238
   Aslan M, 2008, FREE RADICAL BIO MED, V45, P367, DOI 10.1016/j.freeradbiomed.2008.04.026
   Bailey A, 2007, AM J CARDIOVASC DRUG, V7, P337, DOI 10.2165/00129784-200707050-00003
   Benlloch-Navarro S, 2019, J STEROID BIOCHEM, V189, P291, DOI 10.1016/j.jsbmb.2019.01.007
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Blom J, 2012, J COMP NEUROL, V520, P4204, DOI 10.1002/cne.23148
   BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955
   Bradley SA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5681036
   BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682
   Bucolo C, 2018, CURR NEUROPHARMACOL, V16, P978, DOI 10.2174/1570159X15666170915142727
   Carr BC, 2017, RETINA-J RET VIT DIS, V37, P22, DOI 10.1097/IAE.0000000000001133
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   Chang CJ, 2000, J OCUL PHARMACOL TH, V16, P399, DOI 10.1089/jop.2000.16.399
   Cheon EW, 2003, NEUROREPORT, V14, P329, DOI 10.1097/01.wnr.0000058034.29600.6d
   Cossenza M, 2014, VITAM HORM, V96, P79, DOI 10.1016/B978-0-12-800254-4.00005-2
   De Cilla S, 2017, CELL PHYSIOL BIOCHEM, V42, P1725, DOI 10.1159/000479441
   Dismuke WM, 2014, EXP EYE RES, V120, P28, DOI 10.1016/j.exer.2013.12.012
   Doganay S, 2002, EUR J OPHTHALMOL, V12, P44, DOI 10.1177/112067210201200109
   Dreyer EB, 1998, J GLAUCOMA, V7, P62
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Giove TJ, 2009, J NEUROSCI RES, V87, P3134, DOI 10.1002/jnr.22133
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   Grunwald JE, 1997, AM J OPHTHALMOL, V123, P753, DOI 10.1016/S0002-9394(14)71123-7
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Haverkamp S, 1998, NEUROREPORT, V9, P2231, DOI 10.1097/00001756-199807130-00015
   Hernandez-Ramirez E, 2017, CELL PHYSIOL BIOCHEM, V42, P2353, DOI 10.1159/000480007
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Kanan Y, 2019, J NEUROCHEM, V148, P307, DOI 10.1111/jnc.14613
   Kang JH, 2010, INVEST OPHTH VIS SCI, V51, P971, DOI 10.1167/iovs.09-4266
   Kanski J., 2007, CLIN OPHTHALMOLOGY S
   Knott AB, 2009, ANTIOXID REDOX SIGN, V11, P541, DOI [10.1089/ars.2008.2234, 10.1089/ARS.2008.2234]
   KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249
   Komeima K, 2008, FREE RADICAL BIO MED, V45, P905, DOI 10.1016/j.freeradbiomed.2008.06.020
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kowluru RA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1266, DOI 10.1001/archopht.126.9.1266
   Kowluru RA, 2011, INVEST OPHTH VIS SCI, V52, P8665, DOI 10.1167/iovs.10-6768
   Kulaksizoglu S, 2016, CAN J DIABETES, V40, P115, DOI 10.1016/j.jcjd.2015.07.002
   Li QH, 2010, INVEST OPHTH VIS SCI, V51, P5240, DOI 10.1167/iovs.09-5147
   Lima MG, 2014, NITRIC OXIDE-BIOL CH, V36, P44, DOI 10.1016/j.niox.2013.10.011
   Loewen CJR, 2001, J BIOL CHEM, V276, P22388, DOI 10.1074/jbc.M011710200
   Mahajan N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8458472
   Martinez-Ruiz A, 2011, FREE RADICAL BIO MED, V51, P17, DOI 10.1016/j.freeradbiomed.2011.04.010
   McBean GJ, 2017, BRIT J PHARMACOL, V174, P1750, DOI 10.1111/bph.13551
   McLeod DS, 2012, GRAEF ARCH CLIN EXP, V250, P839, DOI 10.1007/s00417-012-1969-9
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Narayanan SP, 2013, PROG RETIN EYE RES, V36, P260, DOI 10.1016/j.preteyeres.2013.06.002
   NATHANSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1774
   Othman R, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00300
   Pang IH, 2005, INVEST OPHTH VIS SCI, V46, P1313, DOI 10.1167/iovs.04-0829
   Pang JJ, 2010, J COMP NEUROL, V518, P2456, DOI 10.1002/cne.22347
   Ramirez-Lamelas DT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00469
   Regillo C., 2014, BASIC CLIN SCI COURS
   Rossino MG, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040771
   Sanchez-Vallejo V, 2015, PHARMACOL RES, V99, P276, DOI 10.1016/j.phrs.2015.06.019
   Sanchez-Vallejo V, 2016, FREE RADICAL BIO MED, V96, P245, DOI 10.1016/j.freeradbiomed.2016.04.195
   Schmetterer L, 2001, PROG RETIN EYE RES, V20, P823, DOI 10.1016/S1350-9462(01)00014-3
   Sennlaub F, 2001, J CLIN INVEST, V107, P717, DOI 10.1172/JCI10874
   Sharma S, 2015, CLIN EXP OPHTHALMOL, V43, P429, DOI 10.1111/ceo.12506
   Stringham JM, 2015, FOODS, V4, P678, DOI 10.3390/foods4040678
   Tekmen-Clark M, 2013, VISUAL NEUROSCI, V30, P91, DOI 10.1017/S0952523813000126
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Toda N, 2007, PROG RETIN EYE RES, V26, P205, DOI 10.1016/j.preteyeres.2007.01.004
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Yϋksel, 2015, J Ophthalmic Vis Res, V10, P151, DOI 10.4103/2008-322X.163765
   Trachsel-Moncho L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0855-8
   Vielma AH, 2012, BRAIN RES, V1430, P112, DOI 10.1016/j.brainres.2011.10.045
   WALDMAN SA, 1987, PHARMACOL REV, V39, P163
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Yang LP, 2007, MOL VIS, V13, P1073
   Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845
   Zhang M, 2007, INVEST OPHTH VIS SCI, V48, P285, DOI 10.1167/iovs.06-0792
   Zheng L, 2007, DIABETOLOGIA, V50, P1987, DOI 10.1007/s00125-007-0734-9
   Zheng L, 2009, FRONT BIOSCI-LANDMRK, V14, P3974, DOI [10.2735/3505, 10.2741/3505]
NR 81
TC 18
Z9 18
U1 3
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD NOV
PY 2019
VL 8
IS 11
AR 543
DI 10.3390/antiox8110543
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA JV3LS
UT WOS:000502268400039
PM 31717957
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dolar-Szczasny, J
   Swiech, A
   Flieger, J
   Tatarczak-Michalewska, M
   Niedzielski, P
   Proch, J
   Majerek, D
   Kawka, J
   Mackiewicz, J
AF Dolar-Szczasny, Joanna
   Swiech, Anna
   Flieger, Jolanta
   Tatarczak-Michalewska, Malgorzata
   Niedzielski, Przemyslaw
   Proch, Jedrzej
   Majerek, Dariusz
   Kawka, Justyna
   Mackiewicz, Jerzy
TI Levels of Trace Elements in the Aqueous Humor of Cataract Patients
   Measured by the Inductively Coupled Plasma Optical Emission Spectrometry
SO MOLECULES
LA English
DT Article
DE trace elements; ICP-OES; cataract; the aqueous humor
ID DISPERSED PARTICLE EXTRACTION; RARE-EARTH-ELEMENTS; SPECIATION ANALYSIS;
   THALLIUM; ALUMINUM; DISEASE; PRECONCENTRATION; TOXICITY; SAMPLES;
   QUANTIFICATION
AB Trace elements play an important role in the pathogenesis of several serious ophthalmological disorders, such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, cataract, etc. This study aimed to measure alterations of chemical elements' (67) levels in the aqueous humor of patients undergoing cataract surgery. The pilot study included 115 patients, (age 74 +/- 7.27, female 64.35%, male 35.65%). The aqueous levels of elements were measured by the use of the inductively coupled plasma optical emission spectrometry (ICP-OES), quality controlled with certified standards. The classification of elements based on their concentration was achieved by hierarchical cluster analysis. This is the first screening study that quantifies over 60 elements which are present in the fluid from the anterior chamber of the eye of cataract patients. The obtained results can be suitable for understanding and identifying the causes that may play a role in the initiation and progression of lens opacity.
C1 [Dolar-Szczasny, Joanna; Swiech, Anna; Mackiewicz, Jerzy] Med Univ Lublin, Dept Retina & Vitreo & Nd Surg, Chmielna 1, PL-20079 Lublin, Poland.
   [Flieger, Jolanta; Tatarczak-Michalewska, Malgorzata; Kawka, Justyna] Med Univ Lublin, Dept Analyt Chem, Chodzki 4A, PL-20093 Lublin, Poland.
   [Niedzielski, Przemyslaw; Proch, Jedrzej] Adam Mickiewicz Univ, Fac Chem, Dept Analyt Chem, 89B Umultowska St, PL-61614 Poznan, Poland.
   [Majerek, Dariusz] Univ Technol, Dept Appl Math, Nadbystrzycka 38D, PL-20618 Lublin, Poland.
C3 Medical University of Lublin; Medical University of Lublin; Adam
   Mickiewicz University; Lublin University of Technology
RP Flieger, J (通讯作者)，Med Univ Lublin, Dept Analyt Chem, Chodzki 4A, PL-20093 Lublin, Poland.
EM joannaszczasny@op.pl; anna.zub@umlub.pl; j.flieger@umlub.pl;
   malgorzatatatarczakmichalewska@umlub.pl; pnied@amu.edu.pl;
   jed.proch@gmail.com; d.majerek@pollub.pl; justynakawka@umlub.pl;
   jerzy.mackiewicz@umlub.pl
RI Niedzielski, Przemyslaw/A-6316-2009; Majerek, Dariusz/D-3457-2017;
   Proch, Jędrzej/AAB-9429-2020
OI Niedzielski, Przemyslaw/0000-0002-2787-9057; Majerek,
   Dariusz/0000-0002-0035-7187; Proch, Jędrzej/0000-0003-0023-044X;
   Flieger, Jolanta/0000-0001-6881-3161; Mackiewicz,
   Jerzy/0000-0003-0984-8908; Tatarczak-Michalewska,
   Malgorzata/0000-0001-5353-9091; Swiech-Zubilewicz,
   Anna/0000-0002-2238-6966; Dolar-Szczasny, Joanna/0000-0003-4206-4371
CR AKYOL N, 1990, BRIT J OPHTHALMOL, V74, P661, DOI 10.1136/bjo.74.11.661
   [Anonymous], 1999, ANAL VARIANCE
   Bauer G, 2013, TALANTA, V103, P145, DOI 10.1016/j.talanta.2012.10.023
   Bisaglia M, 2009, NEUROMOL MED, V11, P239, DOI 10.1007/s12017-009-8082-1
   Brian G, 2001, B WORLD HEALTH ORGAN, V79, P249
   Burtis C.A., 1994, TIETZ TXB CLIN CHEM, V2nd ed.
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   CHAUSSIDON M, 1993, NEPHRON, V65, P559, DOI 10.1159/000187563
   Corona C, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.57
   Cowan J.A., 1994, INORGANIC BIOCH INTR
   DeToma AS, 2014, BIOMETALS, V27, P1291, DOI 10.1007/s10534-014-9790-z
   DeToma AS, 2012, CHEM SOC REV, V41, P608, DOI 10.1039/c1cs15112f
   DEXTER DT, 1992, ANN NEUROL, V32, pS94, DOI 10.1002/ana.410320716
   Donati GL, 2017, J ANAL ATOM SPECTROM, V32, P1283, DOI 10.1039/c7ja00103g
   EDWARDSON JA, 1993, LANCET, V342, P211, DOI 10.1016/0140-6736(93)92301-9
   Emsley J., 2006, ELEMENTS MURDER HIST
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   EVERITT B, 1980, QUAL QUANT, V14, P75, DOI 10.1007/BF00154794
   EXLEY C, 1991, J THEOR BIOL, V151, P417, DOI 10.1016/S0022-5193(05)80389-3
   Gareth J., 2015, INTRO STAT LEARNING
   Gomez-Ayala AE, 1998, LAB ANIM, V32, P72, DOI 10.1258/002367798780559374
   Grochowski C, 2019, MOLECULES, V24, DOI 10.3390/molecules24091721
   Gupta S., 2018, MOJ BIOORG ORG CHEM, V2, P221, DOI [10.15406/mojboc.2018.02.00085, DOI 10.15406/MOJBOC.2018.02.00085]
   Hadley W., 2016, GGPLOT2 ELEGANT GRAP
   Hohberger B, 2018, J TRACE ELEM MED BIO, V45, P150, DOI 10.1016/j.jtemb.2017.10.003
   Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390
   Hosseinzadegan S, 2019, MICROCHEM J, V146, P339, DOI 10.1016/j.microc.2019.01.029
   Hosseinzadegan S, 2016, ANAL METHODS-UK, V8, P7808, DOI [10.1039/C6AY02189A, 10.1039/c6ay02189a]
   Janski R, 2014, RAPID COMMUN MASS SP, V28, P1329, DOI 10.1002/rcm.6905
   Jaworowski Z., 1996, WIEDZA ZYCIE, V5, P24
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kassambara A., FACTOEXTRA EXTRACT V
   Kepp KP, 2012, CHEM REV, V112, P5193, DOI 10.1021/cr300009x
   Khan A, 2004, J INORG BIOCHEM, V98, P2006, DOI 10.1016/j.jinorgbio.2004.09.004
   Langford-Smith A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147576
   Leung KM, 2000, CHEMOSPHERE, V41, P155, DOI 10.1016/S0045-6535(99)00404-X
   Lippard S. J., 1994, PRINCIPLES BIOINORGA
   Lukaszewski Z, 2010, ELECTROANAL, V22, P1963, DOI 10.1002/elan.201000151
   LYDAHL E, 1984, ACTA OPHTHALMOL, P1
   Marcinkowska M, 2016, TALANTA, V161, P177, DOI 10.1016/j.talanta.2016.08.034
   McCarty CA, 1999, BRIT J OPHTHALMOL, V83, P62, DOI 10.1136/bjo.83.1.62
   McSheehy S, 2009, SPECTROSCOPY, V24, P14
   Montgomery Douglas C., 2010, APPL STAT PROBABILIT
   Muma NA, 1996, NEUROTOXICOL TERATOL, V18, P679, DOI 10.1016/S0892-0362(96)00126-2
   Murayama H, 1999, AM J PATHOL, V155, P877, DOI 10.1016/S0002-9440(10)65187-5
   Murray L., 2010, BIOSTATISTICAL DESIG
   Nischkauer W, 2015, MICROCHIM ACTA, V182, P2369, DOI 10.1007/s00604-015-1643-0
   Nordberg GF, 2007, HANDBOOK ON THE TOXICOLOGY OF METALS, 3RD EDITION, P445, DOI 10.1016/B978-012369413-3/50078-1
   Paoletti P, 2009, NEUROSCIENCE, V158, P126, DOI 10.1016/j.neuroscience.2008.01.061
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peter ALJ, 2005, ENVIRON INT, V31, P493, DOI 10.1016/j.envint.2004.09.003
   Pithadia AS, 2012, CURR OPIN CHEM BIOL, V16, P67, DOI 10.1016/j.cbpa.2012.01.016
   Rodella LF, 2008, HISTOL HISTOPATHOL, V23, P433, DOI 10.14670/HH-23.433
   ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7
   SABBIONI E, 1994, SCI TOTAL ENVIRON, V158, P227, DOI 10.1016/0048-9697(94)04142-A
   Savelieff MG, 2013, ACS CHEM BIOL, V8, P856, DOI 10.1021/cb400080f
   Schmeling M, 2014, POWDER DIFFR, V29, P155, DOI 10.1017/S0885715614000281
   Sessions D, 2013, J ALTERN COMPLEM MED, V19, P973, DOI 10.1089/acm.2012.0745
   Sigel A., 2006, NEURODEGENERATIVE DI, V1
   Sigel H., 1982, METAL IONS BIOL SYST
   SOURKES TL, 1972, PHARMACOL REV, V24, P349
   Spano N, 2005, ANAL CHIM ACTA, V553, P201, DOI 10.1016/j.aca.2005.08.003
   Sperling M, 2018, TRAC-TREND ANAL CHEM, V104, P1, DOI 10.1016/j.trac.2018.04.006
   Sudhof T.C., 2012, COLD SPRING HARB PER, V4
   Team RC, 2013, R LANG ENV STAT COMP
   Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200
   Vanek A, 2013, J GEOCHEM EXPLOR, V124, P176, DOI 10.1016/j.gexplo.2012.09.002
   WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967
   Xie Y., 2015, DYNAMIC DOCUMENTS R
   Ye J, 2012, INVEST OPHTH VIS SCI, V53, P3885, DOI 10.1167/iovs.12-9820
   Yu XP, 2019, MOLECULES, V24, DOI 10.3390/molecules24050926
NR 72
TC 14
Z9 14
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2019
VL 24
IS 22
AR 4127
DI 10.3390/molecules24224127
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JU2TU
UT WOS:000501529700116
PM 31739645
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Storti, F
   Klee, K
   Todorova, V
   Steiner, R
   Othman, A
   van der Velde-Visser, S
   Samardzija, M
   Meneau, I
   Barben, M
   Karademir, D
   Pauzuolyte, V
   Boye, SL
   Blaser, F
   Ullmer, C
   Dunaief, JL
   Hornemann, T
   Rohrer, L
   den Hollander, A
   von Eckardstein, A
   Fingerle, J
   Maugeais, C
   Grimm, C
AF Storti, Federica
   Klee, Katrin
   Todorova, Vyara
   Steiner, Regula
   Othman, Alaa
   van der Velde-Visser, Saskia
   Samardzija, Marijana
   Meneau, Isabelle
   Barben, Maya
   Karademir, Duygu
   Pauzuolyte, Valda
   Boye, Sanford L.
   Blaser, Frank
   Ullmer, Christoph
   Dunaief, Joshua L.
   Hornemann, Thorsten
   Rohrer, Lucia
   den Hollander, Anneke
   von Eckardstein, Arnold
   Fingerle, Juergen
   Maugeais, Cyrille
   Grimm, Christian
TI Impaired ABCA1/ABCG1-mediated lipid efflux in the mouse retinal pigment
   epithelium (RPE) leads to retinal degeneration
SO ELIFE
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; CASSETTE TRANSPORTERS A1; MEDIATED
   DARK-ADAPTATION; MACULAR DEGENERATION; CHOLESTEROL EFFLUX; ACCELERATES
   ATHEROSCLEROSIS; GENETIC-VARIANTS; CONDITIONAL LOSS; BRUCHS MEMBRANE;
   ABCA1
AB Age-related macular degeneration (AMD) is a progressive disease of the retinal pigment epithelium (RPE) and the retina leading to loss of central vision. Polymorphisms in genes involved in lipid metabolism, including the ATP-binding cassette transporter A1 (ABCA1), have been associated with AMD risk. However, the significance of retinal lipid handling for AMD pathogenesis remains elusive. Here, we study the contribution of lipid efflux in the RPE by generating a mouse model lacking ABCA1 and its partner ABCG1 specifically in this layer. Mutant mice show lipid accumulation in the RPE, reduced RPE and retinal function, retinal inflammation and RPE/photoreceptor degeneration. Data from human cell lines indicate that the ABCA1 AMD risk-conferring allele decreases ABCA1 expression, identifying the potential molecular cause that underlies the genetic risk for AMD. Our results highlight the essential homeostatic role for lipid efflux in the RPE and suggest a pathogenic contribution of reduced ABCA1 function to AMD.
C1 [Storti, Federica; Klee, Katrin; Todorova, Vyara; Samardzija, Marijana; Barben, Maya; Karademir, Duygu; Pauzuolyte, Valda; Grimm, Christian] Univ Zurich, Lab Retinal Cell Biol, Dept Ophthalmol, Schlieren, Switzerland.
   [Klee, Katrin; Karademir, Duygu; Grimm, Christian] Univ Zurich, Ctr Integrat Human Physiol, Zurich, Switzerland.
   [Todorova, Vyara; Grimm, Christian] Univ Zurich, Neurosci Ctr Zurich, Zurich, Switzerland.
   [Steiner, Regula; Othman, Alaa; Hornemann, Thorsten; Rohrer, Lucia; von Eckardstein, Arnold] Univ Zurich, Inst Clin Chem, Schlieren, Switzerland.
   [van der Velde-Visser, Saskia; den Hollander, Anneke] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Meneau, Isabelle; Blaser, Frank] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Boye, Sanford L.] Univ Florida, Dept Ophthalmol, Gainesville, FL USA.
   [Ullmer, Christoph; Maugeais, Cyrille] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Basel, Switzerland.
   [Dunaief, Joshua L.] Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [den Hollander, Anneke] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Fingerle, Juergen] Univ Tubingen, Nat & Med Sci Inst, Tubingen, Germany.
   [Pauzuolyte, Valda] UCL Great Ormond St Inst Child Hlth, Stem Cells & Regenerat Med Sect, London, England.
C3 University of Zurich; Zurich Center Integrative Human Physiology (ZIHP);
   University of Zurich; Radboud University Nijmegen; University of Zurich;
   University Zurich Hospital; State University System of Florida;
   University of Florida; Roche Holding; University of Pennsylvania;
   Pennsylvania Medicine; Radboud University Nijmegen; Eberhard Karls
   University of Tubingen; University of London; University College London
RP Grimm, C (通讯作者)，Univ Zurich, Lab Retinal Cell Biol, Dept Ophthalmol, Schlieren, Switzerland.; Grimm, C (通讯作者)，Univ Zurich, Ctr Integrat Human Physiol, Zurich, Switzerland.; Grimm, C (通讯作者)，Univ Zurich, Neurosci Ctr Zurich, Zurich, Switzerland.
EM cgrimm@opht.uzh.ch
RI Samardzija, Marijana/B-9245-2008; Othman, Alaa/AAE-5897-2019
OI Samardzija, Marijana/0000-0003-0991-4653; Othman,
   Alaa/0000-0002-0092-5594; Storti, Federica/0000-0002-5764-1656;
   Todorova, Vyara/0000-0002-3120-110X; Grimm,
   Christian/0000-0001-9318-4352; Karademir, Duygu/0000-0002-3314-0734
FU Vontobel-Stiftung Federica Storti Roche RPF 378 Federica Storti
   Christian Grimm Schweizerischer Nationalfonds zur Forderung der
   Wissenschaftlichen Forschung [31003A_173008]; NATIONAL EYE INSTITUTE
   [P30EY001583] Funding Source: NIH RePORTER
FX Vontobel-Stiftung Federica Storti Roche RPF 378 Federica Storti
   Christian Grimm Schweizerischer Nationalfonds zur Forderung der
   Wissenschaftlichen Forschung 31003A_173008 Vyara Todorova Marijana
   Samardzija Maya Barben Christian Grimm The funders had no role in study
   design, data collection and interpretation, or the decision to submit
   the work for publication.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   [Anonymous], J BIOL
   Arguello G, 2015, BBA-MOL BASIS DIS, V1852, P1765, DOI 10.1016/j.bbadis.2015.05.015
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Ban N, 2018, J LIPID RES, V59, P1414, DOI 10.1194/jlr.M084442
   Barben M, 2018, CELL DEATH DIFFER, V25, P2071, DOI 10.1038/s41418-018-0094-7
   Barben M, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0243-y
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Brandl C, 2019, METHODS MOL BIOL, V1834, P87, DOI 10.1007/978-1-4939-8669-9_6
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Cao Y., 2022, NATURE, DOI 10.1038/s41586-020-2012-7
   Cavelier C, 2006, BBA-MOL CELL BIOL L, V1761, P655, DOI 10.1016/j.bbalip.2006.04.012
   Chai AB, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0526-9
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chung Soonkyu, 2010, J Biol Chem, V285, P12197, DOI 10.1074/jbc.M109.096933
   Cooper David N, 2010, Hum Genomics, V4, P284
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Eblimit A, 2018, EXP EYE RES, V166, P120, DOI 10.1016/j.exer.2017.10.015
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Favari E, 2015, HANDB EXP PHARMACOL, V224, P181, DOI 10.1007/978-3-319-09665-0_4
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FLIESLER SJ, 1982, BIOCHIM BIOPHYS ACTA, V711, P138, DOI 10.1016/0005-2760(82)90020-0
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   He LZ, 2014, AM J PATHOL, V184, P1660, DOI 10.1016/j.ajpath.2014.02.007
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Iqbal J, 2018, J LIPID RES, V59, P2084, DOI 10.1194/jlr.M087502
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Jiang Y, 2014, ADV EXP MED BIOL, V801, P601, DOI 10.1007/978-1-4614-3209-8_76
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Karasinska JM, 2013, NEUROBIOL DIS, V54, P445, DOI 10.1016/j.nbd.2013.01.018
   Kast B, 2016, EXP EYE RES, V146, P60, DOI 10.1016/j.exer.2015.12.008
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Koldamova R, 2014, NEUROBIOL DIS, V72, P13, DOI 10.1016/j.nbd.2014.05.007
   Kruit JK, 2012, DIABETES, V61, P659, DOI 10.2337/db11-1341
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Li Ge, 2013, IUBMB Life, V65, P505, DOI [10.1002/iub.01165, 10.1002/iub.1165]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207
   Masuda T, 2010, J BIOL CHEM, V285, P26933, DOI 10.1074/jbc.M110.130294
   Milenkovic A, 2015, P NATL ACAD SCI USA, V112, pE2630, DOI 10.1073/pnas.1418840112
   Nagai H, 1996, EXP EYE RES, V62, P55, DOI 10.1006/exer.1996.0007
   Narvaez-Rivas M, 2016, J CHROMATOGR A, V1440, P123, DOI 10.1016/j.chroma.2016.02.054
   Oczos J, 2014, INVEST OPHTH VIS SCI, V55, P4714, DOI 10.1167/iovs.14-14332
   Olofsson SO, 2009, BBA-MOL CELL BIOL L, V1791, P448, DOI 10.1016/j.bbalip.2008.08.001
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Panday N, 2006, BIOORG MED CHEM LETT, V16, P5231, DOI 10.1016/j.bmcl.2006.06.081
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pellegrino RM, 2014, ANAL BIOANAL CHEM, V406, P7937, DOI 10.1007/s00216-014-8255-0
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Quazi F, 2011, ESSAYS BIOCHEM, V50, P265, DOI [10.1042/BSE0500265, 10.1042/bse0500265]
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rhyne J, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-1
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Roman D, 2018, EXP EYE RES, V176, P219, DOI 10.1016/j.exer.2018.07.014
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Samardzija M, 2008, HUM MOL GENET, V17, P281, DOI 10.1093/hmg/ddm304
   Samardzija M, 2006, FASEB J, V20, P2411, DOI 10.1096/fj.06-5895fje
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Schaefer EJ, 2016, PROG CARDIOVASC DIS, V59, P97, DOI 10.1016/j.pcad.2016.08.006
   Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundermeier TR, 2017, J BIOL CHEM, V292, P3366, DOI 10.1074/jbc.M116.770024
   Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452
   Thanos A, 2012, AM J PATHOL, V180, P1917, DOI 10.1016/j.ajpath.2012.01.017
   Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   WALL FE, 1995, IN VITRO CELL DEV-AN, V31, P156
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wei H, 2016, EXP EYE RES, V145, P450, DOI 10.1016/j.exer.2015.09.015
   Wenzel A, 2005, J BIOL CHEM, V280, P29874, DOI 10.1074/jbc.M503603200
   Westerterp M, 2016, ARTERIOSCL THROM VAS, V36, P1328, DOI 10.1161/ATVBAHA.115.306670
   Westerterp M, 2013, CIRC RES, V112, P1456, DOI 10.1161/CIRCRESAHA.113.301086
   Westerterp M, 2012, CELL STEM CELL, V11, P195, DOI 10.1016/j.stem.2012.04.024
   Winder AF, 1996, J CLIN PATHOL, V49, P407, DOI 10.1136/jcp.49.5.407
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191279
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 98
TC 38
Z9 40
U1 0
U2 2
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAR 13
PY 2019
VL 8
AR e45100
DI 10.7554/eLife.45100
PG 32
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA HQ6ND
UT WOS:000462531700001
PM 30864945
OA Green Published, Green Accepted, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lapierre-Landry, M
   Carroll, J
   Skala, MC
AF Lapierre-Landry, Maryse
   Carroll, Joseph
   Skala, Melissa C.
TI Imaging retinal melanin: a review of current technologies
SO JOURNAL OF BIOLOGICAL ENGINEERING
LA English
DT Review
DE Retina; Retinal pigment epithelium; Choroid; Fundus reflectometry;
   Photoacoustic; Autofluorescence; Near-infrared; Optical coherence
   tomography; Photothermal; Polarization
ID OPTICAL COHERENCE TOMOGRAPHY; NEAR-INFRARED AUTOFLUORESCENCE;
   SHORT-WAVELENGTH AUTOFLUORESCENCE; ELECTRON-SPIN RESONANCE; PIGMENT
   EPITHELIUM; FUNDUS AUTOFLUORESCENCE; IN-VIVO; MACULAR PIGMENT;
   PHOTOACOUSTIC OPHTHALMOSCOPY; POLARIZATION PROPERTIES
AB The retinal pigment epithelium (RPE) is essential to the health of the retina and the proper functioning of the photoreceptors. The RPE is rich in melanosomes, which contain the pigment melanin. Changes in RPE pigmentation are seen with normal aging and in diseases such as albinism and age-related macular degeneration. However, most techniques used to this day to detect and quantify ocular melanin are performed ex vivo and are destructive to the tissue. There is a need for in vivo imaging of melanin both at the clinical and pre-clinical level to study how pigmentation changes can inform disease progression. In this manuscript, we review in vivo imaging techniques such as fundus photography, fundus reflectometry, near-infrared autofluorescence imaging, photoacoustic imaging, and functional optical coherence tomography that specifically detect melanin in the retina. These methods use different contrast mechanisms to detect melanin and provide images with different resolutions and field-of-views, making them complementary to each other.
C1 [Lapierre-Landry, Maryse; Skala, Melissa C.] Morgridge Inst Res, Madison, WI 53715 USA.
   [Lapierre-Landry, Maryse] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
   [Carroll, Joseph] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.
   [Carroll, Joseph] Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, Milwaukee, WI 53226 USA.
   [Skala, Melissa C.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.
   [Lapierre-Landry, Maryse] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; The
   Morgridge Institute for Research, Inc.; Vanderbilt University; Medical
   College of Wisconsin; Medical College of Wisconsin; University of
   Wisconsin System; University of Wisconsin Madison; Case Western Reserve
   University
RP Skala, MC (通讯作者)，Morgridge Inst Res, Madison, WI 53715 USA.; Skala, MC (通讯作者)，Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.
EM mcskala@wisc.edu
OI Lapierre-Landry, Maryse/0000-0002-9583-6876
FU National Eye Institute of the NIH [R01EY024969]; Alcon Research
   Institute; Morgridge Institute for Research; NATIONAL EYE INSTITUTE
   [R01EY024969] Funding Source: NIH RePORTER
FX This work was supported by the National Eye Institute of the NIH under
   award number R01EY024969, the Alcon Research Institute and the Morgridge
   Institute for Research.
CR Adler DC, 2008, OPT EXPRESS, V16, P4376, DOI 10.1364/OE.16.004376
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Aleman TS, 2008, INVEST OPHTH VIS SCI, V49, P1580, DOI 10.1167/iovs.07-1110
   Armenti ST, 2016, JOVE-J VIS EXP, V109, P53577
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Ayata A, 2009, BRIT J OPHTHALMOL, V93, P79, DOI 10.1136/bjo.2008.141564
   Azuma S, 2018, BIOMED OPT EXPRESS, V9, P2955, DOI 10.1364/BOE.9.002955
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Baumann B, 2015, INVEST OPHTH VIS SCI, V56, P7462, DOI 10.1167/iovs.15-17742
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2012, OPT EXPRESS, V20, DOI 10.1364/OE.20.010229
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Baumann B, 2009, J BIOPHOTONICS, V2, P426, DOI 10.1002/jbio.200910031
   Berendschot TTJM, 2003, PROG RETIN EYE RES, V22, P171, DOI 10.1016/S1350-9462(02)00060-5
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BLOIS MS, 1964, BIOPHYS J, V4, P471, DOI 10.1016/S0006-3495(64)86797-7
   Bone RA, 2007, VISION RES, V47, P3259, DOI 10.1016/j.visres.2007.09.002
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Boulton M, 1998, DOC OPHTH P, V62, P19
   Calvo-Maroto AM, 2018, CLIN OPTOM, V10, P25, DOI 10.2147/OPTO.S134637
   Centers for Disease Control and Prevention, 2015, COMM EYE DIS
   Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457
   deBoer JF, 1997, OPT LETT, V22, P934, DOI 10.1364/OL.22.000934
   DeHoog E, 2009, APPL OPTICS, V48, P221, DOI 10.1364/AO.48.000221
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P8134, DOI 10.1167/iovs.14-14848
   Duncker T, 2013, INVEST OPHTH VIS SCI, V54, P585, DOI 10.1167/iovs.12-11176
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, EXP EYE RES, V153, P178, DOI 10.1016/j.exer.2016.10.018
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P7206, DOI 10.1167/iovs.14-14445
   Ehlers A, 2007, MICROSC RES TECHNIQ, V70, P154, DOI 10.1002/jemt.20395
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fialova S, 2016, BIOMED OPT EXPRESS, V7, P1479, DOI 10.1364/BOE.7.001479
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V79, P315, DOI 10.1001/archopht.1968.03850040317017
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Gabai A, 2015, INDIAN J OPHTHALMOL, V63, P406, DOI 10.4103/0301-4738.159868
   Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Gotzinger E, 2007, INVEST OPHTH VIS SCI, V48, P3551, DOI 10.1167/iovs.06-0727
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Hammer M, 2002, PHYS MED BIOL, V47, P179, DOI 10.1088/0031-9155/47/2/301
   Harper DJ, 2018, BIOMED OPT EXPRESS, V9, P2115, DOI 10.1364/BOE.9.002115
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Herrera W, 2008, INVEST OPHTH VIS SCI, V49, P2651, DOI 10.1167/iovs.07-1505
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P645, DOI 10.1111/j.1751-1097.2007.00228.x
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang ZW, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2204007
   Ilginis T, 2014, BRIT MED BULL, V111, P77, DOI 10.1093/bmb/ldu022
   Ito S, 2000, PIGM CELL RES, V13, P103, DOI 10.1034/j.1600-0749.13.s8.19.x
   Jiao SL, 2010, OPT EXPRESS, V18, P3967, DOI 10.1364/OE.18.003967
   Kanis MJ, 2007, EXP EYE RES, V84, P934, DOI 10.1016/j.exer.2007.01.020
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner S, 2009, AM J OPHTHALMOL, V147, P895, DOI 10.1016/j.ajo.2008.12.023
   Kellner U, 2009, EYE, V23, P1349, DOI 10.1038/eye.2008.280
   Kellner U, 2008, DOC OPHTHALMOL, V116, P119, DOI 10.1007/s10633-007-9105-6
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Lapierre-Landry M, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.4
   Lapierre-Landry M, 2018, OPT LETT, V43, P2470, DOI 10.1364/OL.43.002470
   Lapierre-Landry M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10050-5
   Liu T, 2013, CURR EYE RES, V38, P1229, DOI 10.3109/02713683.2013.815219
   Liu T, 2012, BIOMED OPT EXPRESS, V3, P792, DOI 10.1364/BOE.3.000792
   Liu WZ, 2016, PHOTOACOUSTICS, V4, P112, DOI 10.1016/j.pacs.2016.05.001
   Liu XJ, 2015, OPT LETT, V40, P1370, DOI 10.1364/OL.40.001370
   MAINSTER MA, 1982, OPHTHALMOLOGY, V89, P852, DOI 10.1016/s0161-6420(82)34714-4
   Makita S, 2015, BIOMED OPT EXPRESS, V6, P1707, DOI 10.1364/BOE.6.001707
   Makita S, 2014, OPT LETT, V39, P6783, DOI 10.1364/OL.39.006783
   Marsiglia M, 2015, JAMA OPHTHALMOL, V133, P219, DOI 10.1001/jamaophthalmol.2014.4507
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Nadler Z, 2012, OPTOMETRY VISION SCI, V89, pE543, DOI 10.1097/OPX.0b013e31824f164d
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Panwar N, 2016, TELEMED E-HEALTH, V22, P198, DOI 10.1089/tmj.2015.0068
   Parodi MB, 2014, AM J OPHTHALMOL, V158, P1086, DOI 10.1016/j.ajo.2014.07.026
   Piccolino FC, 1996, OPHTHALMOLOGY, V103, P1837
   Pilotto E, 2013, INT OPHTHALMOL, V33, P71, DOI 10.1007/s10792-012-9618-1
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Pircher M, 2004, OPT EXPRESS, V12, P5940, DOI 10.1364/OPEX.12.005940
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Schmitz-Valckenberg S, 2011, BRIT J OPHTHALMOL, V95, P1134, DOI 10.1136/bjo.2010.189498
   Schustze C, 2014, RETINA-J RET VIT DIS, V34, P2208, DOI 10.1097/IAE.0000000000000224
   SEALY RC, 1982, SCIENCE, V217, P545, DOI 10.1126/science.6283638
   Sekiryu T, 2010, INVEST OPHTH VIS SCI, V51, P4956, DOI 10.1167/iovs.09-5009
   Shu X, 2017, BIOMED OPT EXPRESS, V8, P2851, DOI 10.1364/BOE.8.002851
   Shu X, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.106005
   Silverman RH, 2010, ULTRASOUND MED BIOL, V36, P733, DOI 10.1016/j.ultrasmedbio.2010.02.006
   Skala MC, 2008, NANO LETT, V8, P3461, DOI 10.1021/nl802351p
   Song W, 2013, J BIOPHOTONICS, V6, P505, DOI 10.1002/jbio.201200061
   Song W, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.061206
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugiyama S, 2015, BIOMED OPT EXPRESS, V6, P4951, DOI 10.1364/BOE.6.004951
   Theelen T, 2008, OPHTHALMOLOGE, V105, P1013, DOI 10.1007/s00347-008-1695-1
   Toju R, 2012, AM J OPHTHALMOL, V153, P314, DOI 10.1016/j.ajo.2011.06.026
   Tomlins PH, 2005, J PHYS D APPL PHYS, V38, P2519, DOI 10.1088/0022-3727/38/15/002
   Torzicky T, 2012, OPT EXPRESS, V20, P7564, DOI 10.1364/OE.20.007564
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   VANNORREN D, 1989, VISION RES, V29, P369, DOI 10.1016/0042-6989(89)90085-0
   Viator JA, 2004, J INVEST DERMATOL, V122, P1432, DOI 10.1111/j.0022-202X.2004.22610.x
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wilk MA, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.8
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Xia J, 2014, PROG ELECTROMAGN RES, V147, P1, DOI 10.2528/PIER14032303
   Yoshitake S, 2014, OPHTHALMOLOGY, V121, P1036, DOI 10.1016/j.ophtha.2013.11.033
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
   Zhang X, 2011, ACTA PHYS SIN-CH ED, V60
   Zhang XY, 2010, OPT LETT, V35, P4018, DOI 10.1364/OL.35.004018
NR 123
TC 27
Z9 26
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-1611
J9 J BIOL ENG
JI J. Biol. Eng.
PD DEC 4
PY 2018
VL 12
AR 29
DI 10.1186/s13036-018-0124-5
PG 13
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA HD2HF
UT WOS:000452331000001
PM 30534199
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maibaum, J
   Liao, SM
   Vulpetti, A
   Ostermann, N
   Randl, S
   Rudisser, S
   Lorthiois, E
   Erbel, P
   Kinzel, B
   Kolb, FA
   Barbieri, S
   Wagner, J
   Durand, C
   Fettis, K
   Dussauge, S
   Hughes, N
   Delgado, O
   Hommel, U
   Gould, T
   Mac Sweeney, A
   Gerhartz, B
   Cumin, F
   Flohr, S
   Schubart, A
   Jaffee, B
   Harrison, R
   Risitano, AM
   Eder, J
   Anderson, K
AF Maibaum, Jurgen
   Liao, Sha-Mei
   Vulpetti, Anna
   Ostermann, Nils
   Randl, Stefan
   Rudisser, Simon
   Lorthiois, Edwige
   Erbel, Paul
   Kinzel, Bernd
   Kolb, Fabrice A.
   Barbieri, Samuel
   Wagner, Julia
   Durand, Corinne
   Fettis, Kamal
   Dussauge, Solene
   Hughes, Nicola
   Delgado, Omar
   Hommel, Ulrich
   Gould, Ty
   Mac Sweeney, Aengus
   Gerhartz, Bernd
   Cumin, Frederic
   Flohr, Stefanie
   Schubart, Anna
   Jaffee, Bruce
   Harrison, Richard
   Risitano, Antonio Maria
   Eder, Jorg
   Anderson, Karen
TI Small-molecule factor D inhibitors targeting the alternative complement
   pathway
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; MAXIMUM-LIKELIHOOD; WATER
   SUPPRESSION; DIFFRACTION DATA; ACTIVE-SITE; ACTIVATION; BINDING;
   REFINEMENT; EXPRESSION; GENERATION
AB Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination. Complement component 3 (C3) is the central component of the system. Activation of C3 can be initiated by three distinct routes-the classical, the lectin and the alternative pathways-with the alternative pathway also acting as an amplification loop for the other two pathways. The protease factor D (FD) is essential for this amplification process, which, when dysregulated, predisposes individuals to diverse disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH). Here we describe the identification of potent and selective small-molecule inhibitors of FD. These inhibitors efficiently block alternative pathway (AP) activation and prevent both C3 deposition onto, and lysis of, PNH erythrocytes. Their oral administration inhibited lipopolysaccharide-induced AP activation in FD-humanized mice. These data demonstrate the feasibility of inhibiting the AP with small-molecule antagonists and support the development of FD inhibitors for the treatment of complement-mediated diseases.
C1 [Maibaum, Jurgen; Vulpetti, Anna; Ostermann, Nils; Rudisser, Simon; Lorthiois, Edwige; Erbel, Paul; Kinzel, Bernd; Barbieri, Samuel; Wagner, Julia; Durand, Corinne; Fettis, Kamal; Dussauge, Solene; Hughes, Nicola; Hommel, Ulrich; Gerhartz, Bernd; Cumin, Frederic; Flohr, Stefanie; Schubart, Anna; Eder, Jorg] Novartis Pharma AG, Novartis Inst BioMed Res, Novartis Campus, Basel, Switzerland.
   [Liao, Sha-Mei; Delgado, Omar; Gould, Ty; Jaffee, Bruce; Anderson, Karen] Novartis Inst BioMed Res, Cambridge, MA USA.
   [Randl, Stefan] Evonik Japan Co, Shinjuku Ku, Tokyo, Japan.
   [Kolb, Fabrice A.] Roche Innovat Ctr Basel, Pharma Res & Early Dev, Basel, Switzerland.
   [Mac Sweeney, Aengus] Actelion Pharmaceut Ltd, Drug Discovery Dept, Allschwil, Switzerland.
   [Harrison, Richard] Cardiff Univ, Sch Med, Inst Infect & Immun, Henry Wellcome Bldg,Heath Pk, Cardiff, S Glam, Wales.
   [Risitano, Antonio Maria] Univ Naples Federico II, Dept Clin Med & Surg, Div Hematol, Naples, Italy.
C3 Novartis; Novartis; Roche Holding; Actelion Pharmaceuticals Ltd; Cardiff
   University; University of Naples Federico II
RP Maibaum, J (通讯作者)，Novartis Pharma AG, Novartis Inst BioMed Res, Novartis Campus, Basel, Switzerland.
EM juergen_klaus.maibaum@novartis.com; karen.anderson@novartis.com
OI Harrison, Richard Alexander/0000-0002-2408-6043; Rudisser,
   Simon/0000-0002-1107-6196; Wagner, Julia/0000-0002-5019-6932; Vulpetti,
   Anna/0000-0002-3114-8679; Fettis, Kamal/0000-0001-5908-792X
CR [Anonymous], 2002, PYMOL MOL GRAPH SYST
   Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427
   BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8
   Cole LB, 1998, ACTA CRYSTALLOGR D, V54, P711, DOI 10.1107/S0907444997010457
   Dalvit C, 2000, J BIOMOL NMR, V18, P65, DOI 10.1023/A:1008354229396
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Ferreira VP, 2007, BLOOD, V110, P2190, DOI 10.1182/blood-2007-04-083170
   FISHELSON Z, 1987, J IMMUNOL, V138, P3392
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hann MM, 2001, J CHEM INF COMP SCI, V41, P856, DOI 10.1021/ci000403i
   Harris CL, 2002, J IMMUNOL METHODS, V268, P245, DOI 10.1016/S0022-1759(02)00207-7
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hillmen P, 2013, BRIT J HAEMATOL, V162, P62, DOI 10.1111/bjh.12347
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047
   IKARI N, 1983, IMMUNOLOGY, V49, P685
   Jagle U, 2007, GENESIS, V45, P659, DOI 10.1002/dvg.20342
   KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588
   KAM CM, 1987, J BIOL CHEM, V262, P3444
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Maeda H, 2005, ANGEW CHEM INT EDIT, V44, P2922, DOI 10.1002/anie.200500114
   MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879
   MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109
   Morikis D, 2002, BIOCHEM SOC T, V30, P1026, DOI 10.1042/BST0301026
   Murray CW, 2010, CURR OPIN STRUC BIOL, V20, P497, DOI 10.1016/j.sbi.2010.04.003
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Ram S, 2010, CLIN MICROBIOL REV, V23, P740, DOI 10.1128/CMR.00048-09
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Risitano AM, 2013, ADV EXP MED BIOL, V735, P155, DOI 10.1007/978-1-4614-4118-2_10
   Risitano AM, 2009, BLOOD, V113, P4094, DOI 10.1182/blood-2008-11-189944
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098
   Skolnik S, 2010, J PHARM SCI-US, V99, P3246, DOI 10.1002/jps.22080
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Xu YY, 2001, P NATL ACAD SCI USA, V98, P14577, DOI 10.1073/pnas.261428398
   Zipfel PF, 2015, MOL IMMUNOL, V67, P21, DOI 10.1016/j.molimm.2015.03.012
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 50
TC 50
Z9 51
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
EI 1552-4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD DEC
PY 2016
VL 12
IS 12
BP 1105
EP +
DI 10.1038/NCHEMBIO.2208
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA ED1CZ
UT WOS:000388582900021
PM 27775713
DA 2022-11-30
ER

PT J
AU Wood, JM
   Black, AA
AF Wood, Joanne M.
   Black, Alex A.
TI Ocular disease and driving
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE age-related macular degeneration; cataract; diabetes; driver's vision;
   glaucoma
ID MOTOR-VEHICLE COLLISIONS; VISUAL-FIELD LOSS; AGE-RELATED MACULOPATHY;
   OPEN-ANGLE GLAUCOMA; QUALITY-OF-LIFE; CATARACT-SURGERY; OLDER DRIVERS;
   CRASH INVOLVEMENT; DIABETIC-RETINOPATHY; MACULAR DEGENERATION
AB As the driving population ages, the number of drivers with visual impairment resulting from ocular disease will increase given the age-related prevalence of ocular disease. The increase in visual impairment in the driving population has a number of implications for driving outcomes. This review summarises current research regarding the impact of common ocular diseases on driving ability and safety, with particular focus on cataract, glaucoma, age-related macular degeneration, hemianopia and diabetic retinopathy. The evidence considered includes self-reported driving outcomes, driving performance (on-road and simulator-based) and various motor vehicle crash indices. Collectively, this review demonstrates that driving ability and safety are negatively affected by ocular disease; however, further research is needed in this area. Older drivers with ocular disease need to be aware of the negative consequences of their ocular condition and in the case where treatment options are available, encouraged to seek these earlier for optimum driving safety and quality of life benefits.
C1 [Wood, Joanne M.; Black, Alex A.] Queensland Univ Technol, Sch Optometry & Vis Sci, Kelvin Grove, Qld, Australia.
C3 Queensland University of Technology (QUT)
RP Wood, JM (通讯作者)，Queensland Univ Technol, Sch Optometry & Vis Sci, Kelvin Grove, Qld, Australia.
EM j.wood@qut.edu.au
RI Black, Alex/I-9727-2012
OI Black, Alex/0000-0002-8671-5167
FU NHMRC [1008145, 1045024]
FX Preparation of this paper was supported by NHMRC 1008145 and NHMRC
   1045024.
CR Alberti CF, 2014, INVEST OPHTH VIS SCI, V55, P368, DOI 10.1167/iovs.13-12737
   Anstey KJ, 2011, NEUROPSYCHOLOGY, V25, P613, DOI 10.1037/a0023835
   Anstey KJ, 2005, CLIN PSYCHOL REV, V25, P45, DOI 10.1016/j.cpr.2004.07.008
   Australian Bureau of Statistics, POP PROJ AUSTR 2012
   Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Bechetoille A, 2008, ACTA OPHTHALMOL, V86, P71, DOI 10.1111/j.1600-0420.2007.00999.x
   Bohensky M, 2008, TRAFFIC INJ PREV, V9, P304, DOI 10.1080/15389580801895277
   Bowers A, 2005, OPTOMETRY VISION SCI, V82, P657, DOI 10.1097/01.opx.0000175558.33268.b5
   Bowers AR, 2014, INVEST OPHTH VIS SCI, V55, P1540, DOI 10.1167/iovs.13-12748
   Bowers AR, 2010, INVEST OPHTH VIS SCI, V51, P6605, DOI 10.1167/iovs.10-5310
   Bowers AR, 2009, INVEST OPHTH VIS SCI, V50, P5137, DOI 10.1167/iovs.09-3799
   Bronstad PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136517
   Bronstad PM, 2013, JAMA OPHTHALMOL, V131, P303, DOI 10.1001/jamaophthalmol.2013.1443
   BUCKLEY S, 1992, DOC OPHTHALMOL, V82, P317, DOI 10.1007/BF00161019
   Coyne KS, 2004, FAM PRACT, V21, P447, DOI 10.1093/fampra/cmh417
   FOLEY DJ, 1995, J AM GERIATR SOC, V43, P776, DOI 10.1111/j.1532-5415.1995.tb07049.x
   Fraser ML, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-45
   Fraser ML, 2013, ACCIDENT ANAL PREV, V58, P10, DOI 10.1016/j.aap.2013.04.015
   Freeman EE, 2008, OPHTHALMOLOGY, V115, P233, DOI 10.1016/j.ophtha.2007.04.050
   Hakamies-Blomqvist L, 1998, ACCIDENT ANAL PREV, V30, P305, DOI 10.1016/S0001-4575(97)00106-1
   Haymes SA, 2008, INVEST OPHTH VIS SCI, V49, P3035, DOI 10.1167/iovs.07-1609
   Haymes SA, 2007, INVEST OPHTH VIS SCI, V48, P1149, DOI 10.1167/iovs.06-0886
   Hirai FE, 2011, OPHTHALMOLOGY, V118, P353, DOI 10.1016/j.ophtha.2010.06.022
   Janz NK, 2009, INVEST OPHTH VIS SCI, V50, P1718, DOI 10.1167/iovs.08-2575
   Kasneci E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087470
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Kunimatsu-Sanuki S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006379
   Kwon M, 2016, OPHTHALMOLOGY, V123, P109, DOI 10.1016/j.ophtha.2015.08.043
   Lacherez P, 2014, J GERONTOL A-BIOL, V69, P240, DOI 10.1093/gerona/glt173
   Mackie SW, 1998, OPHTHAL PHYSL OPT, V18, P173, DOI 10.1016/S0275-5408(97)00083-5
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MCCLOSKEY LW, 1994, AGE AGEING, V23, P267, DOI 10.1093/ageing/23.4.267
   McGwin G, 2005, INVEST OPHTH VIS SCI, V46, P4437, DOI 10.1167/iovs.05-0750
   McGwin G, 2004, INVEST OPHTH VIS SCI, V45, P3934, DOI 10.1167/iovs.04-0524
   McGwin G, 1999, DIABETES CARE, V22, P220, DOI 10.2337/diacare.22.2.220
   McGwin G, 1998, ACCIDENT ANAL PREV, V30, P781, DOI 10.1016/S0001-4575(98)00031-1
   McGwin G, 2015, J GLAUCOMA, V24, P138, DOI 10.1097/IJG.0b013e3182a0761c
   McGwin G, 2013, BRIT J OPHTHALMOL, V97, P1173, DOI 10.1136/bjophthalmol-2013-303601
   Mennemeyer ST, 2013, ACCIDENT ANAL PREV, V61, P203, DOI 10.1016/j.aap.2013.01.002
   Meuleners LB, 2006, ACCIDENT ANAL PREV, V38, P1006, DOI 10.1016/j.aap.2006.04.005
   Meuleners LB, 2012, CLIN EXP OPHTHALMOL, V40, P591, DOI 10.1111/j.1442-9071.2011.02751.x
   Meuleners LB, 2012, OPHTHAL EPIDEMIOL, V19, P23, DOI 10.3109/09286586.2011.628776
   Monestam E, 1999, ACTA OPHTHALMOL SCAN, V77, P729
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Musch DC, 2009, OPHTHALMOLOGY, V116, P200, DOI 10.1016/j.ophtha.2008.08.051
   NSW Road and Maritime Services, LIC ISS NSW
   Ono T, 2015, OPTOMETRY VISION SCI, V92, P357, DOI 10.1097/OPX.0000000000000493
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Owsley C, 2015, SURV OPHTHALMOL, V60, P250, DOI 10.1016/j.survophthal.2015.01.005
   Owsley C, 2010, VISION RES, V50, P2348, DOI 10.1016/j.visres.2010.05.021
   Pager CK, 2004, CLIN EXP OPHTHALMOL, V32, P388, DOI 10.1111/j.1442-9071.2004.00843.x
   Papageorgiou E, 2012, ACTA OPHTHALMOL, V90, pe198, DOI 10.1111/j.1755-3768.2011.02315.x
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Racette L, 2005, OPTOMETRY VISION SCI, V82, P668, DOI 10.1097/01.opx.0000174719.25799.37
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033
   Rochtchina E, 2003, CLIN EXP OPHTHALMOL, V31, P233, DOI 10.1046/j.1442-9071.2003.00635.x
   Sagberg F, 2006, ACCIDENT ANAL PREV, V38, P28, DOI 10.1016/j.aap.2005.06.018
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Subzwari S, 2008, INJURY PREV, V14, P324, DOI 10.1136/ip.2007.017830
   SZLYK JP, 1993, OPTOMETRY VISION SCI, V70, P1031, DOI 10.1097/00006324-199312000-00007
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   SZLYK JP, 1995, HUM FACTORS, V37, P430, DOI 10.1518/001872095779064645
   Szlyk JP, 2005, J GLAUCOMA, V14, P145, DOI 10.1097/01.ijg.0000151686.89162.28
   Szlyk JP, 2004, J REHABIL RES DEV, V41, P347, DOI 10.1682/JRRD.2003.06.0096
   Szlyk JP, 2002, J REHABIL RES DEV, V39, P467
   Tanabe S, 2011, INVEST OPHTH VIS SCI, V52, P4177, DOI 10.1167/iovs.10-6264
   Tant MLM, 2002, NEUROPSYCHOL REHABIL, V12, P419, DOI 10.1080/09602010244000183
   Tatham AJ, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.5
   Vega RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077294
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Weih LM, 2001, OPHTHALMOLOGY, V108, P1966, DOI 10.1016/S0161-6420(01)00799-0
   Wood JM, 2006, BRIT J OPHTHALMOL, V90, P1277, DOI 10.1136/bjo.2006.096057
   WOOD JM, 1995, OPTOMETRY VISION SCI, V72, P115, DOI 10.1097/00006324-199502000-00010
   Wood JM, 2004, TRANSPORT RES REC, P7
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
   WOOD JM, 1994, HUM FACTORS, V36, P476, DOI 10.1177/001872089403600305
   Wood JM, 2001, OPTOMETRY VISION SCI, V78, P343, DOI 10.1097/00006324-200105000-00018
   Wood JM, 2009, INVEST OPHTHALMOL VI, V50
   Wood JM, 2008, J AM GERIATR SOC, V56, P986, DOI 10.1111/j.1532-5415.2008.01709.x
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P1220, DOI 10.1167/iovs.10-6296
   Yuki K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115572
   Zhang XJ, 2006, J NEURO-OPHTHALMOL, V26, P180, DOI 10.1097/01.wno.0000235587.41040.39
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 91
TC 23
Z9 23
U1 0
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2016
VL 99
IS 5
SI SI
BP 395
EP 401
DI 10.1111/cxo.12391
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW4NN
UT WOS:000383620100002
PM 27156178
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Leach, LL
   Clegg, DO
AF Leach, Lyndsay L.
   Clegg, Dennis O.
TI Concise Review: Making Stem Cells Retinal: Methods for Deriving Retinal
   Pigment Epithelium and Implications for Patients With Ocular Disease
SO STEM CELLS
LA English
DT Article
DE Retinal pigment epithelium; Embryonic stem cells; Induced pluripotent
   stem cells; Retinal diseases; Macular degeneration; Cell differentiation
ID IN-VITRO DIFFERENTIATION; VESICLE-LIKE STRUCTURES; HUMAN IPS CELLS;
   DIRECTED DIFFERENTIATION; MACULAR DEGENERATION; RETINITIS-PIGMENTOSA;
   OPTIC VESICLE; NEURAL RETINA; FUNCTIONAL-ANALYSIS; CLINICAL-TRIALS
AB Stem cells provide a potentially unlimited source of cells for treating a plethora of human diseases. Regenerative therapies for retinal degenerative diseases are at the forefront of translation to the clinic, with stem cell-derived retinal pigment epithelium (RPE)-based treatments for age-related macular degeneration (AMD) already showing promise in human patients. Despite our expanding knowledge of stem cell biology, methods for deriving cells, including RPE have remained inefficient. Thus, there has been a push in recent years to develop more directed approaches to deriving cells for therapy. In this concise review, we summarize recent efforts that have been successful in improving RPE derivation efficiency by directing differentiation from human pluripotent stem cells using developmental cues important for normal RPE specification and maturation in vivo. In addition, potential obstacles for clinical translation are discussed. Finally, we review how derivation of RPE from human induced pluripotent stem cells (hiPSCs) provides in vitro models for studying mechanisms of retinal disease and discovering new avenues for treatment.
C1 [Leach, Lyndsay L.; Clegg, Dennis O.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Stem Cell Biol & Engn, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara
RP Clegg, DO (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM clegg@lifesci.ucsb.edu
FU California Institute for Regenerative Medicine (CIRM) [DR1-01444,
   CL1-00521, TB1-01177, TG2-01151]; Fight for Sight; Foundation Fighting
   Blindness Wynn-Gund Translational Research Acceleration Program; U.S.
   Army Research Office [W911NF-09-0001]; CIRM Major Facilities
   [FA1-00616]; Garland Initiative for Vision; Vermont Community Foundation
FX This work was supported by the Garland Initiative for Vision, the
   California Institute for Regenerative Medicine (CIRM; grants DR1-01444,
   CL1-00521, TB1-01177, and TG2-01151 [to D.O.C.]), Fight for Sight, the
   Foundation Fighting Blindness Wynn-Gund Translational Research
   Acceleration Program, the University of California Santa Barbara
   Institute for Collaborative Biotechnologies from the U.S. Army Research
   Office (Grant W911NF-09-0001), and CIRM Major Facilities Grant
   (FA1-00616). L.L.L. was a fellow of the Vermont Community Foundation.
   The content within does not necessarily reflect the policy or position
   of the government, and no official endorsement should be inferred.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Au P, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004131
   Bailey AM, 2014, NAT BIOTECHNOL, V32, P721, DOI 10.1038/nbt.2971
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Borooah S, 2013, PROG RETIN EYE RES, V37, P163, DOI 10.1016/j.preteyeres.2013.09.002
   Bravery CA, 2013, CYTOTHERAPY, V15, P9, DOI 10.1016/j.jcyt.2012.10.008
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Cereso N, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.11
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Clegg DO, 2013, STEM CELLS HDB, P411
   Cyranoski D., 2014, NATURE, DOI [10.1038/nature.2014.15897, DOI 10.1038/NATURE.2014.15897]
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Evans RJ, 2010, HUM MOL GENET, V19, P1358, DOI 10.1093/hmg/ddq012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gamm DM, 2013, EXPERT REV OPHTHALMO, V8, P213, DOI 10.1586/EOP.13.14
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerrard L, 2005, STEM CELLS, V23, P1234, DOI 10.1634/stemcells.2005-0110
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Hagglund AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081158
   HAYASAKA S, 1981, BRIT J OPHTHALMOL, V65, P478, DOI 10.1136/bjo.65.7.478
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jayasundera T, 2010, ARCH OPHTHALMOL-CHIC, V128, P915, DOI 10.1001/archophthalmol.2010.122
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   KENNAWAY NG, 1980, AM J HUM GENET, V32, P529
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Lee MH, 2010, TISSUE ENG PART B-RE, V16, P41, DOI 10.1089/ten.TEB.2009.0449
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Mendicino M, 2014, CELL STEM CELL, V14, P141, DOI 10.1016/j.stem.2014.01.013
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nistor G, 2010, J NEUROSCI METH, V190, P63, DOI 10.1016/j.jneumeth.2010.04.025
   Okada Y, 2004, DEV BIOL, V275, P124, DOI 10.1016/j.ydbio.2004.07.038
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   OTONKOSKI T, 1993, J CLIN INVEST, V92, P1459, DOI 10.1172/JCI116723
   Parvini M, 2014, MOL NEUROBIOL, V50, P597, DOI 10.1007/s12035-014-8684-y
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Perron M, 2003, DEVELOPMENT, V130, P1565, DOI 10.1242/dev.00391
   Phelan JK, 2000, MOL VIS, V6, P116
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Pittack C, 1997, DEVELOPMENT, V124, P805
   Polinati PP, 2015, INVEST OPHTH VIS SCI, V56, P3371, DOI 10.1167/iovs.14-14007
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Reynolds J, 2014, EXP EYE RES, V123, P151, DOI 10.1016/j.exer.2013.07.010
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Sakuma R, 2002, GENES CELLS, V7, P401, DOI 10.1046/j.1365-2443.2002.00528.x
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Schwarz N, 2015, HUM MOL GENET, V24, P972, DOI 10.1093/hmg/ddu509
   SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sridhar A, 2013, STEM CELL TRANSL MED, V2, P255, DOI 10.5966/sctm.2012-0101
   Steinfeld J, 2013, DEVELOPMENT, V140, P4959, DOI 10.1242/dev.096990
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Torrez LB, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/417865
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
NR 90
TC 37
Z9 40
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD AUG
PY 2015
VL 33
IS 8
BP 2363
EP 2373
DI 10.1002/stem.2010
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA CN1UP
UT WOS:000358206000001
PM 25809736
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Potgieter, FJ
   Claoue, CMP
AF Potgieter, Frederik J.
   Claoue, Charles M. P.
TI Safety and efficacy of an intraocular Fresnel prism intraocular lens in
   patients with advanced macular disease: Initial clinical experience
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID DEGENERATION; TRANSLOCATION
AB PURPOSE: To perform a pilot study of a new in-the-bag Fresnol prism intraocular lens (IOL) designed to deviate the image from diseased to healthy retina in eyes with bilateral age-related macular degeneration (AMD).
   SETTING: Anterior segment subspeciality practice, Pretoria, South Africa.
   DESIGN: Prospective nonmasked trial.
   METHOD: Cataract surgery and unilateral implantation of the prismatic IOL were performed in patients with bilateral AMD and cataract. Outcomes were surgical complications, subjective and objective visual improvement, and undesirable optical effects.
   RESULTS: Three eyes of 3 patients were evaluated. All patients reported displacement of the scotoma, and no patient reported diplopia. The only complication was posterior capsule opacification (1 eye).
   CONCLUSIONS: Patients noted improved vision and no diplopia. This pilot was performed using a prototype IOL with single power and single angle of deviation; however, there is scope for individual patient optimization. This new technology merits further research and development because it may benefit large numbers of patients with stable end-stage AMD.
C1 [Potgieter, Frederik J.] Optimed Eye & Laser Ctr, Pretoria, South Africa.
   [Claoue, Charles M. P.] Barking Havering & Redbridge Univ Hosp, Queens Hosp, London, England.
RP Claoue, CMP (通讯作者)，DBCG UK Ltd, FEBO, 36 New Atlas Wharf,Arnhem Pl, London E14 3SS, England.
EM eyes@dbcg.co.uk
CR Al-Karmi R, 2006, CAN J OPHTHALMOL, V41, P313, DOI 10.1139/I06-016
   Bishop PO, 1987, ADLERS PHYSL EYE CLI, P622
   Bopp S, 2007, BRIT J OPHTHALMOL, V91, P1259, DOI 10.1136/bjo.2007.120303
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Cooper J, 2005, J PEDIAT OPHTH STRAB, V42, P89
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   Figueroa M, 2004, BRIT J OPHTHALMOL, V88, P792, DOI 10.1136/bjo.2003.033837
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Ohtsuki H, 2004, AM J OPHTHALMOL, V137, P125, DOI 10.1016/S0002-9394(03)00846-8
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Tasman W, 2005, CAN J OPHTHALMOL, V40, P389, DOI 10.1016/S0008-4182(05)80082-1
   Vander J F, 2000, Curr Opin Ophthalmol, V11, P159, DOI 10.1097/00055735-200006000-00001
   WATSON GR, 1992, J VISUAL IMPAIR BLIN, V86, P37
NR 17
TC 13
Z9 14
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUL
PY 2014
VL 40
IS 7
BP 1085
EP 1091
DI 10.1016/j.jcrs.2013.10.049
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AL3NJ
UT WOS:000339035100006
PM 24957430
DA 2022-11-30
ER

PT J
AU Zhang, QX
   Lu, RW
   Messinger, JD
   Curcio, CA
   Guarcello, V
   Yao, XC
AF Zhang, Qiu-Xiang
   Lu, Rong-Wen
   Messinger, Jeffrey D.
   Curcio, Christine A.
   Guarcello, Vincenzo
   Yao, Xin-Cheng
TI In vivo Optical Coherence Tomography of Light-Driven Melanosome
   Translocation in Retinal Pigment Epithelium
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CIRCADIAN RETINOMOTOR MOVEMENTS; MACULAR DEGENERATION;
   ULTRAHIGH-RESOLUTION; THICKNESS MEASUREMENTS; VISUAL IMPAIRMENT;
   UNITED-STATES; HIGH-SPEED; MELANIN; SKIN; PREVALENCE
AB Optical coherence tomography (OCT) may revolutionize fundamental investigation and clinical management of age-related macular degeneration and other eye diseases. However, quantitative OCT interpretation is hampered due to uncertain sub-cellular correlates of reflectivity in the retinal pigment epithelium (RPE) and photoreceptor. The purpose of this study was twofold: 1) to test OCT correlates in the RPE, and 2) to demonstrate the feasibility of longitudinal OCT monitoring of sub-cellular RPE dynamics. A high resolution OCT was constructed to achieve dynamic imaging of frog eyes, in which light-driven translocation of RPE melanosomes occurred within the RPE cell body and apical processes. Comparative histological examination of dark- and light-adapted eyes indicated that the RPE melanin granule, i.e., melanosome, was a primary OCT correlate. In vivo OCT imaging of RPE melanosomes opens the opportunity for quantitative assessment of RPE abnormalities associated with disease, and enables longitudinal investigation of RPE kinetics correlated with visual function.
C1 [Zhang, Qiu-Xiang; Lu, Rong-Wen; Yao, Xin-Cheng] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
   [Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Guarcello, Vincenzo; Yao, Xin-Cheng] Univ Alabama Birmingham, Vis Sci Res Ctr, Birmingham, AL 35294 USA.
   [Yao, Xin-Cheng] Univ Alabama Birmingham, Dept Vis Sci, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Yao, XC (通讯作者)，Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
EM xcy@uab.edu
RI Lu, Rongwen/B-4261-2015; Yao, Xincheng/ABA-1526-2020; Lu,
   Rongwen/J-6169-2015
OI Lu, Rongwen/0000-0002-1167-6001; 
FU NSF [CBET-1055889]; NIH [R21 EB012264, R01 EY06109]; UASOM I3 Pilot
   Award; Vision Sciences Core grant [NIH P30 EY03039]; NATIONAL EYE
   INSTITUTE [P30EY003039, R01EY006109] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [R21EB012264] Funding Source: NIH RePORTER
FX The authors wish to thank Dr. Shuliang Jiao for his valuable advice on
   OCT construction, and thank Cham K. Yao for preparing the cartoon
   illustration in Fig. 1. Q.X.Z., R. W. L. and X.C.Y. are supported by NSF
   CBET-1055889, NIH R21 EB012264, and UASOM I3 Pilot Award. CAC and JDM
   are supported by NIH R01 EY06109 and institutional support from the
   Eyesight Foundation of Alabama and Research to Prevent Blindness, Inc.
   V. G. is supported by Vision Sciences Core grant NIH P30 EY03039.
CR Abramoff MD, 2013, INVEST OPHTH VIS SCI, V54, P3721, DOI 10.1167/iovs.13-11812
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Barton JK, 2003, TECHNOL CANCER RES T, V2, P525, DOI 10.1177/153303460300200605
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BOK D, 1993, J CELL SCI, P189
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   BOK D, 1990, EYE, V4, P326, DOI 10.1038/eye.1990.44
   Boppart SA, 1998, NEUROSURGERY, V43, P834, DOI 10.1097/00006123-199810000-00068
   BURNSIDE B, 1983, INVEST OPHTH VIS SCI, V24, P1
   Burnside B, 2001, Prog Brain Res, V131, P477
   Cakir Y, 2005, PHARMACOL REP, V57, P467
   Cense B, 2009, OPT EXPRESS, V17, P21634, DOI 10.1364/OE.17.021634
   Choi WJ, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.3.036010
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Konno S, 2001, RETINA-J RET VIT DIS, V21, P57, DOI 10.1097/00006982-200102000-00010
   Koozekanani D, 2001, IEEE T MED IMAGING, V20, P900, DOI 10.1109/42.952728
   Korde VR, 2007, LASER SURG MED, V39, P687, DOI 10.1002/lsm.20573
   LYTHGOE JN, 1983, INVEST OPHTH VIS SCI, V24, P1203
   Menger GJ, 2005, VISUAL NEUROSCI, V22, P203, DOI 10.1017/S0952523805222083
   MONDRAGON R, 1989, EXP EYE RES, V48, P589, DOI 10.1016/0014-4835(89)90002-X
   Panthier C, 2013, OSLI RETINA, V44, P208, DOI 10.3928/23258160-20130213-01
   RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Srinivasan VJ, 2006, INVEST OPHTH VIS SCI, V47, P5522, DOI 10.1167/iovs.06-0195
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   WANG XJ, 1995, OPT LETT, V20, P524, DOI 10.1364/OL.20.000524
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Zhang QX, 2012, INVEST OPHTH VIS SCI, V53, P8139, DOI 10.1167/iovs.12-10732
NR 40
TC 58
Z9 59
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 12
PY 2013
VL 3
AR 2644
DI 10.1038/srep02644
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 215RZ
UT WOS:000324229300007
PM 24025778
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Knecht, PB
   Kordic, H
   Kurz-Levin, M
   Sturm, V
   Menke, MN
AF Knecht, Pascal B.
   Kordic, Helena
   Kurz-Levin, Malaika
   Sturm, Veit
   Menke, Marcel N.
TI Inter-observer agreement for spectral- and time-domain optical coherence
   tomography image grading: a prospective study
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION;
   ULTRAHIGH-RESOLUTION; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   BEVACIZUMAB; PHOTODYNAMIC THERAPY; HIGH-SPEED; THICKNESS MEASUREMENTS;
   CLINICAL-APPLICATION; REPRODUCIBILITY
AB The purpose of this study was to compare inter-observer agreement of Stratus (TM) OCT versus Spectralis (TM) OCT image grading in patients with neovascular age-related macular degeneration (AMD). Thirty eyes with neovascular AMD were examined with Stratus (TM) OCT and Spectralis (TM) OCT. Four different scan protocols were used for imaging. Three observers graded the images for the presence of various pathologies. Inter-observer agreement between OCT models was assessed by calculating intra-class correlation coefficients (ICC). In Stratus (TM) OCT highest interobserver agreement was found for subretinal fluid (ICC: 0.79), and in Spectralis (TM) OCT for intraretinal cysts (IRC) (ICC: 0.93). Spectralis (TM) OCT showed superior interobserver agreement for IRC and epiretinal membranes (ERM) (ICCStratus (TM): for IRC 0.61; for ERM 0.56; ICCSpectralis (TM): for IRC 0.93; for ERM 0.84). Increased image resolution of Spectralis (TM) OCT did improve the inter-observer agreement for grading intraretinal cysts and epiretinal membranes but not for other retinal changes.
RP Menke, MN (通讯作者)，Univ Hosp Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM marcel.menke@gmail.com
OI Menke, Marcel/0000-0002-6561-6178
CR Ahlers C, 2008, OPHTHALMOLOGE, V105, P248, DOI 10.1007/s00347-007-1597-7
   Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Eter N, 2004, OPHTHALMOLOGE, V101, P794, DOI 10.1007/s0034-004-1052-y
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Legarreta JE, 2008, OPHTHAL SURG LAS IM, V39, pS43, DOI 10.3928/15428877-20080715-02
   Menke MN, 2008, BRIT J OPHTHALMOL, V92, P1492, DOI 10.1136/bjo.2008.141242
   Menke MN, 2009, AM J OPHTHALMOL, V147, P467, DOI 10.1016/j.ajo.2008.09.005
   Menke MN, 2005, OPHTHAL SURG LAS IM, V36, P310, DOI 10.3928/1542-8877-20050701-10
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Spraul CW, 1998, KLIN MONATSBL AUGENH, V212, P141, DOI 10.1055/s-2008-1034850
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Tangelder GJM, 2008, INVEST OPHTH VIS SCI, V49, P2627, DOI 10.1167/iovs.07-0820
   Tatlipinar S, 2007, OPHTHALMOLOGICA, V221, P227, DOI 10.1159/000101923
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Wojtkowski M, 2005, 2005 Conference on Lasers & Electro-Optics (CLEO), Vols 1-3, P2058
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 38
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2013
VL 33
IS 1
BP 47
EP 52
DI 10.1007/s10792-012-9628-z
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063NK
UT WOS:000313006400009
PM 23001716
OA Green Submitted, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Wozniak, K
   Szaflik, JP
   Zaras, M
   Sklodowska, A
   Janik-Papis, K
   Poplawski, TR
   Blasiak, J
   Szaflik, J
AF Wozniak, Katarzyna
   Szaflik, Jacek P.
   Zaras, Malgorzata
   Sklodowska, Anna
   Janik-Papis, Katarzyna
   Poplawski, Tomasz R.
   Blasiak, Janusz
   Szaflik, Jerzy
TI DNA Damage/Repair and Polymorphism of the hOGG1 Gene in Lymphocytes of
   AMD Patients
SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; AGE-RELATED
   MACULOPATHY; BASE EXCISION-REPAIR; MACULAR DEGENERATION;
   OXIDATIVE-STRESS; CANCER RISK; SER326CYS POLYMORPHISM; HUMAN-CELLS;
   ASSOCIATION
AB Oxidative stress is thought to play a role in the pathogenesis of age-related macular degeneration (AMD). We determined the extent of oxidative DNA damage and the kinetics of its removal as well as the genotypes of the Ser326Cys polymorphism of the hOGG1 gene in lymphocytes of 30 wet AMD patients and 30 controls. Oxidative DNA damage induced by hydrogen peroxide and its repair were evaluated by the comet assay and DNA repair enzymes. We observed a higher extent of endogenous oxidative DNA damage and a lower efficacy of its repair in AMD patients as compared with the controls. We did not find any correlation between the extent of DNA damage and efficacy of DNA repair with genotypes of the Ser326Cys polymorphism. The results obtained suggest that oxidative DNA damage and inefficient DNA repair can be associated with AMD and the variability of the hOOG1 gene may not contribute to this association. Copyright (C) 2009 Katarzyna Wozniak et al.
C1 [Wozniak, Katarzyna; Janik-Papis, Katarzyna; Poplawski, Tomasz R.; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90237 Lodz, Poland.
   [Szaflik, Jacek P.; Zaras, Malgorzata; Sklodowska, Anna; Szaflik, Jerzy] Med Univ Warsaw, Dept Ophthalmol, PL-03709 Warsaw, Poland.
C3 University of Lodz; Medical University of Warsaw
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, PL-90237 Lodz, Poland.
EM januszb@biol.uni.lodz.pl
RI Wozniak, Katarzyna/R-9226-2018; Poplawski, Tomasz/Q-8760-2018;
   Poplawski, Tomasz/K-3295-2012; Janik-Superson, Katarzyna/ABA-2571-2021
OI Wozniak, Katarzyna/0000-0001-6666-7973; Poplawski,
   Tomasz/0000-0003-2300-7339; Janik-Superson,
   Katarzyna/0000-0001-9692-7238; Szaflik, Jerzy/0000-0002-7601-1326;
   Blasiak, Janusz/0000-0001-9539-9584
FU Ministry of Science and Higher Education [402 071 32/2210]
FX This work was supported by the Grant no. 402 071 32/2210 of Ministry of
   Science and Higher Education. The authors would like to thank Aleksandra
   Malinowska, Anna Krzyzanowska, and Monika Kicinska for technical
   assistance.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2000, MUTAT RES-GEN TOX EN, V469, P135, DOI 10.1016/S1383-5718(00)00065-6
   Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Cargill M, 2000, Pharmacogenomics, V1, P27, DOI 10.1517/14622416.1.1.27
   Chen L, 2003, J UROLOGY, V170, P2471, DOI 10.1097/01.ju.0000087498.23008.bb
   COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733
   COLLINS AR, 2007, MUTAT RES, V681, P24
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1047
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elahi A, 2002, CARCINOGENESIS, V23, P1229, DOI 10.1093/carcin/23.7.1229
   EVANS MD, 1995, BIOCHEM SOC T, V23, pS434, DOI 10.1042/bst023434s
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 2003, DEV OPHTHALMOL, V37, P155
   Krokan HE, 1997, BIOCHEM J, V325, P1
   Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shinmura K, 2000, INT J ONCOL, V16, P701
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Takezaki T, 2002, INT J CANCER, V99, P624, DOI 10.1002/ijc.10400
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200
   Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7
   Wang AL, 2008, MOL VIS, V14, P644
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Winkler BS, 1999, MOL VIS, V5
   Xing DY, 2001, INT J CANCER, V95, P140, DOI 10.1002/1097-0215(20010520)95:3&lt;140::AID-IJC1024&gt;3.0.CO;2-2
   Yang N, 2006, DNA REPAIR, V5, P43, DOI 10.1016/j.dnarep.2005.07.003
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 45
TC 22
Z9 23
U1 1
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1110-7243
EI 1110-7251
J9 J BIOMED BIOTECHNOL
JI J. Biomed. Biotechnol.
PY 2009
AR 827562
DI 10.1155/2009/827562
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 518ON
UT WOS:000271702400001
PM 19885394
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Bocci, V
AF Bocci, V.
TI The case for oxygen-ozonetherapy
SO BRITISH JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Review
DE communicable diseases; ischemia; lung diseases; macular degeneration;
   neoplasms; ozone
ID EXTRACORPOREAL BLOOD OXYGENATION; OZONE THERAPY; OZONATED
   AUTOHEMOTHERAPY; OXIDATIVE STRESS; ATHEROSCLEROTIC ISCHEMIA;
   HEMODIALYZED PATIENTS; MACULAR DEGENERATION; LOWER-LIMBS; INDUCTION;
   DISEASE
AB Ozone is a very reactive gas that is toxic to the respiratory system. However, under controlled conditions, it can be therapeutically useful in several human diseases. An unfavourable combination of factors (ozone is one of the worst troposphere pollutants) and past misuse have led to misgivings about ozonetherapy. However, basic and clinical work developed over the past 10 years has clarified the fundamental mechanisms of action of ozone in biology and medicine. Interestingly, judicious doses of ozone dissolved in blood trigger a cascade of well-defined chemical compounds acting on multiple cellular targets according to well-known molecular, biochemical and pharmacological pathways. Ozonetherapy is proving to be very useful in age-related macular degeneration, ischaemic and infectious diseases, and in wound healing disorders, where conventional medicine has failed. Critical evaluation of the potential therapeutic utility of this simple, inexpensive medical application by national and international health authorities is warranted and may lead to clinical benefit for a large proportion of the world's population.
C1 Univ Siena, Dept Physiol, I-53100 Siena, Italy.
C3 University of Siena
RP Bocci, V (通讯作者)，Univ Siena, Dept Physiol, Via Moro 2, I-53100 Siena, Italy.
EM bocci@unisi.it
OI bocci, velio/0000-0002-2153-6248
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Andreula CF, 2003, AM J NEURORADIOL, V24, P996
   [Anonymous], 2004, LANCET, V363, P745
   Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2
   Barber E, 1999, MEDIAT INFLAMM, V8, P37, DOI 10.1080/09629359990702
   Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202
   Baysan A, 2000, CARIES RES, V34, P498, DOI 10.1159/000016630
   BEARDSLEY S, 2005, SCI AM, V292, P9
   Biedunkiewicz B, 2004, INT J ARTIF ORGANS, V27, P29, DOI 10.1177/039139880402700107
   Bocci V, 2005, J ALTERN COMPLEM MED, V11, P257, DOI 10.1089/acm.2005.11.257
   Bocci V, 2004, MEDIAT INFLAMM, V13, P3, DOI 10.1080/0962935062000197083
   Bocci V, 1996, MED HYPOTHESES, V46, P150, DOI 10.1016/S0306-9877(96)90016-X
   Bocci V, 1998, FORSCH KOMPLEMENTMED, V5, P54, DOI 10.1159/000021077
   Bocci V, 1998, MEDIAT INFLAMM, V7, P313, DOI 10.1080/09629359890820
   BOCCI V, 1993, LYMPHOKINE CYTOK RES, V12, P121
   Bocci V, 1999, BRIT J BIOMED SCI, V56, P270
   BOCCI V., 2005, OZONE NEW MED DRUG
   Bocci V., 2002, OXYGEN OZONE THERAPY
   BOCCI V, 2000, INT J MED BIOL ENV, V28, P109
   Bocci VA, 2006, ARCH MED RES, V37, P425, DOI 10.1016/j.arcmed.2005.08.006
   Bocci V, 2006, TOXICOL APPL PHARM, V216, P493, DOI 10.1016/j.taap.2006.06.009
   Bocci V, 2006, J BIOCHEM MOL TOXIC, V20, P133, DOI 10.1002/jbt.20124
   Bocci Velio, 1998, Clin Microbiol Infect, V4, P667, DOI 10.1111/j.1469-0691.1998.tb00355.x
   Bochkov VN, 2003, J MOL MED, V81, P613, DOI 10.1007/s00109-003-0467-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calabrese EJ, 2005, ENVIRON POLLUT, V138, P378, DOI 10.1016/j.envpol.2004.10.001
   CARPENDALE MTF, 1991, ANTIVIR RES, V16, P281, DOI 10.1016/0166-3542(91)90007-E
   Check E, 2004, NATURE, V432, P136, DOI 10.1038/432136b
   Clavo B, 2003, J ALTERN COMPLEM MED, V9, P251, DOI 10.1089/10755530360623365
   Clavo B, 2004, EVID-BASED COMPL ALT, V1, P93, DOI 10.1093/ecam/neh009
   Clavo B, 2004, EVID-BASED COMPL ALT, V1, P321, DOI 10.1093/ecam/neh038
   Clavo B, 2004, EVID-BASED COMPL ALT, V1, P315, DOI 10.1093/ecam/neh039
   de Monte A, 2005, J ALTERN COMPLEM MED, V11, P363
   Di Paolo N, 2005, INT J ARTIF ORGANS, V28, P1039, DOI 10.1177/039139880502801012
   Di Paolo N, 2002, INT J ARTIF ORGANS, V25, P1194, DOI 10.1177/039139880202501212
   Dianzani Mario Umberto, 2003, Molecular Aspects of Medicine, V24, P263
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Giunta R, 2001, ANN HEMATOL, V80, P745, DOI 10.1007/s002770100377
   GOLDSTEIN BD, 1967, P SOC EXP BIOL MED, V126, P356
   Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7
   HERNANDEZ F, 1995, FREE RADICAL BIO MED, V19, P115, DOI 10.1016/0891-5849(94)00201-T
   Hultqvist M, 2004, P NATL ACAD SCI USA, V101, P12646, DOI 10.1073/pnas.0403831101
   Hultqvist M, 2006, PLOS MED, V3, P1625, DOI 10.1371/journal.pmed.0030348
   JACOBS MT, 1982, OZONACHRICHTEN, V1, P5
   Johnson N, 2004, OZONE: THE REVOLUTION IN DENTISTRY, P67
   Jordan Liz, 2002, Eur J Oncol Nurs, V6, P220, DOI 10.1054/ejon.2002.0201
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Larini A, 2005, TOXICOL IN VITRO, V19, P55, DOI 10.1016/j.tiv.2004.06.007
   Larini A, 2004, FREE RADICAL RES, V38, P509, DOI 10.1080/10715760410001684649
   Larini A, 2003, FREE RADICAL RES, V37, P1163, DOI 10.1080/10715760310001604170
   Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7
   Leon OS, 1998, MEDIAT INFLAMM, V7, P289, DOI 10.1080/09629359890983
   LIPPMANN M, 1989, JAPCA J AIR WASTE MA, V39, P672, DOI 10.1080/08940630.1989.10466554
   Martinez-Sanchez G, 2005, EUR J PHARMACOL, V523, P151, DOI 10.1016/j.ejphar.2005.08.020
   MATSUMOTO A, 2001, P 15 OZ WORLD C LOND, V1, P77
   *MEDT INS, 1997, RP181303 MEDT INS
   Mendiratta S, 1998, FREE RADICAL BIO MED, V24, P789, DOI 10.1016/S0891-5849(97)00351-1
   Muto M, 2004, J NEURORADIOLOGY, V31, P183, DOI 10.1016/S0150-9861(04)96989-1
   Nieva J, 2004, TRENDS BIOCHEM SCI, V29, P274, DOI 10.1016/j.tibs.2004.03.009
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   RICE RG, 2001, P 15 OZ WORLD C LOND, V1, P1
   Rokitanscy O., 1982, HOSPITALIS, V52, P643
   Rosales FAH, 2005, ARCH MED RES, V36, P549, DOI 10.1016/j.arcmed.2005.04.021
   Sechi LA, 2001, J APPL MICROBIOL, V90, P279, DOI 10.1046/j.1365-2672.2001.01235.x
   Servaes P, 2002, EUR J CANCER, V38, P27, DOI 10.1016/S0959-8049(01)00332-X
   Tamoto K, 2005, P 17 WORLD OZONE ASS, P37
   Thanomsub B, 2002, J GEN APPL MICROBIOL, V48, P193, DOI 10.2323/jgam.48.193
   Travagli V, 2006, INT J BIOL MACROMOL, V39, P317, DOI 10.1016/j.ijbiomac.2006.03.024
   Tylicki L, 2004, ARTIF ORGANS, V28, P234, DOI 10.1111/j.1525-1594.2003.47211.x
   Tylicki L, 2003, INT J ARTIF ORGANS, V26, P297, DOI 10.1177/039139880302600404
   Tylicki L, 2001, INT J ARTIF ORGANS, V24, P79, DOI 10.1177/039139880102400204
   Valacchi G, 2005, BRIT J DERMATOL, V153, P1096, DOI 10.1111/j.1365-2133.2005.06939.x
   Zuckerbraun BS, 2003, HEPATOLOGY, V37, P742, DOI 10.1053/jhep.2003.50139
NR 76
TC 51
Z9 59
U1 1
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0967-4845
J9 BRIT J BIOMED SCI
JI Br. J. Biomed. Sci.
PY 2007
VL 64
IS 1
BP 44
EP 49
DI 10.1080/09674845.2007.11732755
PG 6
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 179MK
UT WOS:000247293700010
PM 17444419
DA 2022-11-30
ER

PT J
AU Lundmark, PO
   Pandi-Perumal, SR
   Srinivasan, V
   Cardinal, DP
AF Lundmark, Per O.
   Pandi-Perumal, Seithikurippu R.
   Srinivasan, Venkataramanujan
   Cardinal, Daniel P.
TI Role of melatonin in the eye and ocular dysfunctions
SO VISUAL NEUROSCIENCE
LA English
DT Review
DE melatonin; retinal phototransduction; intraocular pressure; corneal
   epithelium; antioxidants
ID ARYLALKYLAMINE N-ACETYLTRANSFERASE; RETINAL CELL-CULTURES;
   HYDROXYINDOLE-O-METHYLTRANSFERASE; RECEPTOR MESSENGER-RNA;
   CIRCADIAN-RHYTHMS; RAT RETINA; PHOTORECEPTOR CELLS; GANGLION-CELLS;
   AMACRINE CELLS; PINEAL-GLAND
AB Melatonin is a ubiquitous molecule and widely distributed in nature, with functional activity occurring in unicellular organisms, plants, fungi, and animals. Several studies have indicated that melatonin synthesis occurs in the retina of most vertebrates, including mammals. The retinal biosynthesis of melatonin and the mechanisms involved in the regulation of this process have been extensively studied. Circadian clocks located in the photoreceptors and retinal neurons regulate melatonin synthesis in the eye. Photoreceptors, dopaminergic amacrine neurons, and horizontal cells of the retina, corneal epithelium, stroma endothelium, and the sclera all have melatonin receptors, indicating a widespread ocular function for melatonin. In addition, melatonin is an effective antioxidant which scavenges free radicals and up-regulates several antioxidant enzymes. It also has a strong antiapoptotic signaling function, an effect that it exerts even during ischemia. Melatonin cytoprotective properties may have practical implications in the treatment of ocular diseases, like glaucoma and age-related macular degeneration.
C1 Univ Buenos Aires, Fac Med, Dept Fisiol, RA-1121 Buenos Aires, DF, Argentina.
   Buskerud Univ Coll, Dept Optometry & Vis Sci, Kongsberg, Norway.
   Mt Sinai Sch Med, Comprehens Ctr Sleep Med, Dept Pulm Crit Care & Sleep Med, New York, NY USA.
   Univ Sains Malaysia, Sch Med Sci, Dept Physiol, Kubang Kerian, Kelantan, Malaysia.
C3 University of Buenos Aires; University College of Southeast Norway;
   Icahn School of Medicine at Mount Sinai; Universiti Sains Malaysia
RP Cardinal, DP (通讯作者)，Univ Buenos Aires, Fac Med, Dept Fisiol, Paraguay 2155, RA-1121 Buenos Aires, DF, Argentina.
EM dcardinali@fmed.uba.ar
RI Pandi-Perumal, Seithikurippu R/HDM-2070-2022; Ratnas, Pandi-Perumal
   Seithikurippu/C-6767-2008; Pandi-Perumal, Seithikurippu R./Q-8281-2016
OI Ratnas, Pandi-Perumal Seithikurippu/0000-0002-8686-7259; Pandi-Perumal,
   Seithikurippu R./0000-0002-8686-7259
CR Adachi A, 1999, BRAIN RES, V815, P435, DOI 10.1016/S0006-8993(98)01077-4
   ALONSOGOMEZ AL, 1995, J NEUROCHEM, V65, P1054
   Arendt J, 2005, SLEEP MED REV, V9, P25, DOI 10.1016/j.smrv.2004.05.002
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341
   Bailey MJ, 2002, FEBS LETT, V513, P169, DOI 10.1016/S0014-5793(02)02276-7
   Bayarri MJ, 2003, BRAIN RES, V969, P175, DOI 10.1016/S0006-8993(03)02297-2
   BenitezKing G, 1996, BBA-GEN SUBJECTS, V1290, P191, DOI 10.1016/0304-4165(96)00025-6
   Bernard M, 1999, REPROD NUTR DEV, V39, P325, DOI 10.1051/rnd:19990305
   Bernard M, 1997, P NATL ACAD SCI USA, V94, P304, DOI 10.1073/pnas.94.1.304
   BERNARD M, 1995, BRAIN RES, V696, P37, DOI 10.1016/0006-8993(95)00651-6
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Berson DM, 2003, TRENDS NEUROSCI, V26, P314, DOI 10.1016/S0166-2236(03)00130-9
   BESHARSE JC, 1983, SCIENCE, V219, P1341, DOI 10.1126/science.6828862
   Brainard GC, 2001, J CLIN ENDOCR METAB, V86, P433, DOI 10.1210/jc.86.1.433
   Brainard GC, 2001, J NEUROSCI, V21, P6405
   BRUN J, 1995, CEPHALALGIA, V15, P136, DOI 10.1046/j.1468-2982.1995.015002136.x
   Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025
   Brydon L, 1999, REPROD NUTR DEV, V39, P315, DOI 10.1051/rnd:19990304
   BUNIN AY, 1992, VESTN OFTALMOL, V108, P13
   Cagnacci A, 2005, AM J HYPERTENS, V18, P1614, DOI 10.1016/j.amjhyper.2005.05.008
   CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x
   CARDINAL.DP, 1971, ENDOCRINOLOGY, V89, P301, DOI 10.1210/endo-89-1-301
   CARDINALI DP, 1971, J NEUROCHEM, V18, P1769, DOI 10.1111/j.1471-4159.1971.tb03752.x
   CARDINALI DP, 1975, MOL CELL ENDOCRINOL, V2, P317, DOI 10.1016/0303-7207(75)90019-2
   Carrillo-Vico A, 2003, CELL MOL LIFE SCI, V60, P2272, DOI 10.1007/s00018-003-3207-4
   Chaurasia SS, 2005, J NEUROCHEM, V92, P158, DOI 10.1111/j.1471-4159.2004.02874.x
   CHAZOT G, 1984, CEPHALALGIA, V4, P213, DOI 10.1046/j.1468-2982.1984.0404213.x
   Chen GF, 2003, LIFE SCI, V73, P19, DOI 10.1016/S0024-3205(03)00252-2
   Chen W, 2000, MOL BRAIN RES, V81, P43, DOI 10.1016/S0169-328X(00)00160-1
   Chong NW, 1998, MOL BRAIN RES, V61, P243, DOI 10.1016/S0169-328X(98)00219-8
   Chronicle EP, 1996, CEPHALALGIA, V16, P525, DOI 10.1046/j.1468-2982.1996.1608525.x
   Claustrat B, 2005, SLEEP MED REV, V9, P11, DOI 10.1016/j.smrv.2004.08.001
   Claustrat B, 2004, CEPHALALGIA, V24, P128, DOI 10.1111/j.1468-2982.2004.00645.x
   CLAUSTRAT B, 1989, HEADACHE, V29, P242, DOI 10.1111/j.1526-4610.1989.hed22904242.x
   Coon SL, 2002, J CLIN ENDOCR METAB, V87, P4699, DOI 10.1210/jc.2002-020683
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Cuzzocrea Salvatore, 2002, Current Topics in Medicinal Chemistry, V2, P153
   Deshmukh VD, 2006, MED HYPOTHESES, V66, P1146, DOI 10.1016/j.mehy.2005.12.026
   Dodick DW, 2003, HEADACHE, V43, P282, DOI 10.1046/j.1526-4610.2003.03055.x
   DOUGHTY MJ, 1990, AM J ANAT, V189, P316, DOI 10.1002/aja.1001890404
   DREYER EB, 1994, NEUROREPORT, V5, P629, DOI 10.1097/00001756-199401000-00024
   Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012
   Dubocovich ML, 2005, ENDOCRINE, V27, P101, DOI 10.1385/ENDO:27:2:101
   Dubocovich ML, 2005, J PINEAL RES, V39, P113, DOI 10.1111/j.1600-079X.2005.00230.x
   Dubocovich ML, 1998, FASEB J, V12, P1211, DOI 10.1096/fasebj.12.12.1211
   DUBOCOVICH ML, 1984, EUR J PHARMACOL, V105, P193, DOI 10.1016/0014-2999(84)90668-X
   Esquifino Ana I, 2004, CLIN APPL IMMUNOL RE, V4, P423, DOI [DOI 10.1016/J.CAIR.2004.08.002, 10.1016/j.cair.2004.08.002]
   Foster RG, 2002, PROG RETIN EYE RES, V21, P507, DOI 10.1016/S1350-9462(02)00036-8
   Fujieda H, 1999, NEUROSCIENCE, V93, P793, DOI 10.1016/S0306-4522(99)00111-6
   Fujieda H, 2000, VISUAL NEUROSCI, V17, P63, DOI 10.1017/S0952523800171068
   Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004
   Fukuhara C, 2004, MOL BRAIN RES, V130, P109, DOI 10.1016/j.molbrainres.2004.07.014
   Fukuhara C, 2002, NEUROSIGNALS, V11, P103, DOI 10.1159/000058547
   Fukuhara C, 2001, NEUROREPORT, V12, P3833, DOI 10.1097/00001756-200112040-00046
   GAN JW, 1995, NEUROCHEM INT, V27, P147, DOI 10.1016/0197-0186(95)00035-7
   Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824
   Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768
   GREEN CB, 1995, BRAIN RES, V677, P283, DOI 10.1016/0006-8993(95)00166-N
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Green W Richard, 2005, Retina, V25, P615, DOI 10.1097/00006982-200507001-00011
   Greve P, 1999, J NEUROCHEM, V73, P1894
   Guerrero Juan M., 2002, Current Topics in Medicinal Chemistry, V2, P167, DOI 10.2174/1568026023394335
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   HAMPSON ECGM, 1992, J NEUROSCI, V12, P4911
   Haque R, 2002, NEUROREPORT, V13, P2247, DOI 10.1097/00001756-200212030-00016
   Hardeland R, 2006, INT J BIOCHEM CELL B, V38, P313, DOI 10.1016/j.biocel.2005.08.020
   Hardeland R, 2003, CHRONOBIOL INT, V20, P921, DOI 10.1081/CBI-120025245
   Hardeland R, 1996, ADV EXP MED BIOL, V398, P279
   Hardeland Rudiger, 2005, Nutr Metab (Lond), V2, P22, DOI 10.1186/1743-7075-2-22
   Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609
   HAY KM, 1994, HEADACHE, V34, P166, DOI 10.1111/j.1526-4610.1994.hed3403166.x
   Hoffmann M, 1996, NEUROCHEM INT, V28, P95, DOI 10.1016/0197-0186(95)00050-I
   Hughes RJ, 1997, SLEEP, V20, P124, DOI 10.1093/sleep/20.2.124
   Hunt AE, 2001, AM J PHYSIOL-CELL PH, V280, pC110, DOI 10.1152/ajpcell.2001.280.1.C110
   IUVONE PM, 1995, J NEUROSCI, V15, P2179, DOI 10.1523/JNEUROSCI.15-03-02179.1995
   Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003
   IUVONE PM, 1991, J NEUROCHEM, V57, P615, DOI 10.1111/j.1471-4159.1991.tb03792.x
   Iuvone PM, 2002, INVEST OPHTH VIS SCI, V43, P564
   Iuvone PM, 1999, ADV EXP MED BIOL, V460, P31
   Ivanova TN, 2003, BRAIN RES, V973, P56, DOI 10.1016/S0006-8993(03)02540-X
   Ivanova TN, 2003, BRAIN RES, V991, P96, DOI 10.1016/j.brainres.2003.08.003
   Jaliffa CO, 2001, BRAIN RES, V912, P195, DOI 10.1016/S0006-8993(01)02736-6
   Jaliffa CO, 1999, J NEUROCHEM, V72, P1999, DOI 10.1046/j.1471-4159.1999.0721999.x
   Jaliffa CO, 2000, J PHARMACOL EXP THER, V293, P91
   Karasek M, 2004, EXP GERONTOL, V39, P1723, DOI 10.1016/j.exger.2004.04.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Knepper PA, 1996, INVEST OPHTH VIS SCI, V37, P1360
   Kvetnoy I, 2002, NEUROENDOCRINOL LETT, V23, P92
   LERNER AB, 1960, FED PROC, V19, P590
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liang FQ, 2001, NEUROREPORT, V12, P1011, DOI 10.1097/00001756-200104170-00029
   Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5
   Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Martin X D, 1992, Eur J Ophthalmol, V2, P67
   McArthur AJ, 1997, ENDOCRINOLOGY, V138, P627, DOI 10.1210/en.138.2.627
   McGoogan JM, 1999, AM J PHYSIOL-REG I, V277, pR1418, DOI 10.1152/ajpregu.1999.277.5.R1418
   Meyer P, 2002, BRIT J OPHTHALMOL, V86, P1053, DOI 10.1136/bjo.86.9.1053
   MHATRE MC, 1988, BIOCHEM BIOPH RES CO, V153, P1186, DOI 10.1016/S0006-291X(88)81353-6
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Namihira M, 2001, NEUROREPORT, V12, P471, DOI 10.1097/00001756-200103050-00010
   Natesan AK, 2002, VISUAL NEUROSCI, V19, P265, DOI 10.1017/S0952523802192042
   NguyenLegros J, 1996, J NEUROCHEM, V67, P2514
   Nickells RW, 1996, J GLAUCOMA, V5, P345
   Niki T, 1998, BIOCHEM BIOPH RES CO, V248, P115, DOI 10.1006/bbrc.1998.8916
   Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200
   Nosjean O, 2001, BIOCHEM PHARMACOL, V61, P1369, DOI 10.1016/S0006-2952(01)00615-3
   OISHI T, 1996, CIRCADIAN CLOCK ZEIT, P45
   Osborne N N, 1999, Curr Opin Ophthalmol, V10, P82, DOI 10.1097/00055735-199904000-00002
   Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x
   Pandi-Perumal SR, 2005, EXP GERONTOL, V40, P911, DOI 10.1016/j.exger.2005.08.009
   Peres MFP, 2005, CEPHALALGIA, V25, P403, DOI 10.1111/j.1468-2982.2005.00889.x
   Peres MFP, 2006, EXPERT OPIN INV DRUG, V15, P367, DOI 10.1517/13543784.15.4.367
   Peres MFP, 2004, NEUROLOGY, V63, P757, DOI 10.1212/01.WNL.0000134653.35587.24
   Peres MFP, 2001, J NEUROL NEUROSUR PS, V71, P747, DOI 10.1136/jnnp.71.6.747
   Peters JL, 2005, J PINEAL RES, V38, P209, DOI 10.1111/j.1600-079X.2004.00195.x
   Petit L, 1999, BIOCHEM PHARMACOL, V58, P633, DOI 10.1016/S0006-2952(99)00134-3
   PIERCE ME, 1985, J GEN PHYSIOL, V86, P671, DOI 10.1085/jgp.86.5.671
   Pintor J, 2001, EUR J PHARMACOL, V416, P251, DOI 10.1016/S0014-2999(01)00864-0
   RAGER G, 1979, J COMP NEUROL, V188, P225, DOI 10.1002/cne.901880203
   Rea MS, 2001, NEUROSCI LETT, V299, P45, DOI 10.1016/S0304-3940(01)01512-9
   REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571
   Reiter R J, 1980, Endocr Rev, V1, P109
   Reiter RJ, 2005, J PINEAL RES, V39, P215, DOI 10.1111/j.1600-079X.2005.00261.x
   Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2
   Reiter RJ, 2002, ANN NY ACAD SCI, V957, P341, DOI 10.1111/j.1749-6632.2002.tb02938.x
   REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734
   REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8
   Ribelayga C, 2004, J PHYSIOL-LONDON, V554, P467, DOI 10.1113/jphysiol.2003.053710
   Ritch R, 2000, Curr Opin Ophthalmol, V11, P78, DOI 10.1097/00055735-200004000-00002
   RODRIGUEZ IR, 1994, J BIOL CHEM, V269, P31969
   Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014
   Rufiange M, 2002, INVEST OPHTH VIS SCI, V43, P2491
   Sakamoto K, 2000, NEUROREPORT, V11, P3995, DOI 10.1097/00001756-200012180-00018
   Sakamoto K, 2004, J NEUROCHEM, V90, P1019, DOI 10.1111/j.1471-4159.2004.02571.x
   SAMPLES JR, 1988, CURR EYE RES, V7, P649, DOI 10.3109/02713688809033192
   SASAKI M, 1995, J COMP PHYSIOL A, V176, P465
   Savaskan E, 2002, J HISTOCHEM CYTOCHEM, V50, P519, DOI 10.1177/002215540205000408
   Scheer FAJL, 2004, HYPERTENSION, V43, P192, DOI 10.1161/01.HYP.0000113293.15186.3b
   Scher J, 2003, EXP EYE RES, V77, P375, DOI 10.1016/S0014-4835(03)00123-4
   Scher J, 2002, INVEST OPHTH VIS SCI, V43, P889
   Sekaran S, 2003, CURR BIOL, V13, P1290, DOI 10.1016/S0960-9822(03)00510-4
   Serle JB, 2004, J GLAUCOMA, V13, P385, DOI 10.1097/01.ijg.0000133150.44686.0b
   Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x
   Srinivasan V., 2006, P269, DOI 10.1007/0-387-23692-9_14
   Srinivasan V, 2005, NEUROTOX RES, V7, P293, DOI 10.1007/BF03033887
   Srinivasan V, 2005, Immun Ageing, V2, P17
   Strettoi E, 1996, P NATL ACAD SCI USA, V93, P14906, DOI 10.1073/pnas.93.25.14906
   TERMAN JS, 1993, BRAIN RES, V605, P256
   Thomas KB, 1998, NEUROREPORT, V9, P4041, DOI 10.1097/00001756-199812210-00010
   Thompson CL, 2004, MOL BRAIN RES, V122, P158, DOI 10.1016/j.molbrainres.2003.12.006
   Tilden AR, 1997, J PINEAL RES, V22, P102, DOI 10.1111/j.1600-079X.1997.tb00310.x
   TOGLIA JU, 1986, ITAL J NEUROL SCI, V7, P319, DOI 10.1007/BF02340869
   Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419
   Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7
   Tosini G, 2002, CELL TISSUE RES, V309, P119, DOI 10.1007/s00441-002-0578-z
   Tosini G, 2000, NEUROSCI LETT, V286, P119, DOI 10.1016/S0304-3940(00)01117-4
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   Uchida K, 1999, MOL VIS, V5, pU1
   Van den Top M, 2001, NEUROSCIENCE, V107, P99, DOI 10.1016/S0306-4522(01)00346-3
   von Gall C, 2002, CELL TISSUE RES, V309, P151, DOI 10.1007/s00441-002-0581-4
   Wan Q, 1999, NAT NEUROSCI, V2, P401, DOI 10.1038/8062
   WHITE MP, 1989, VISION RES, V29, P167, DOI 10.1016/0042-6989(89)90122-3
   Wiechmann AF, 2003, INVEST OPHTH VIS SCI, V44, P4522, DOI 10.1167/iovs.03-0329
   Wiechmann AF, 2003, EXP EYE RES, V77, P219, DOI 10.1016/S0014-4835(03)00126-X
   Witkovsky P, 2003, J NEUROSCI, V23, P7670
   Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Zaunreiter M, 1998, NEUROREPORT, V9, P1205, DOI 10.1097/00001756-199804200-00045
   Zawilska Jolanta B., 1992, Polish Journal of Pharmacology and Pharmacy, V44, P627
   Zurak N, 1997, CEPHALALGIA, V17, P723, DOI 10.1046/j.1468-2982.1997.1707723.x
NR 176
TC 42
Z9 48
U1 0
U2 12
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0952-5238
EI 1469-8714
J9 VISUAL NEUROSCI
JI Visual Neurosci.
PD NOV-DEC
PY 2006
VL 23
IS 6
BP 853
EP 862
DI 10.1017/S0952523806230189
PG 10
WC Neurosciences; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA 137EK
UT WOS:000244275600002
PM 17266777
DA 2022-11-30
ER

PT J
AU Dhalla, MS
   Blinder, KJ
   Tewari, A
   Hariprasad, SA
   Apte, RS
AF Dhalla, MS
   Blinder, KJ
   Tewari, A
   Hariprasad, SA
   Apte, RS
TI Retinal pigment epithelial tear following intravitreal pegaptanib sodium
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PATHOGENESIS
AB PURPOSE: To report two cases of a retinal pigment epithelial tear after intravitreal injection of pegaptanib sodium. To our knowledge, this is the first report of this finding after intraocular antivascular endothelial growth factor therapy.
   DESIGN: Observational case reports.
   METHODS: Two patients presented with occult choroidal neovascularization and associated serous pigment epithelial detachment that was a result of age-related macular degeneration. Both patients were treated with an intravitreal injection of pegaptanib sodium.
   RESULTS: One patient developed a retinal pigment epithelium tear one week after the intravitreal injection. The second patient developed a retinal pigment epithelium tear eight weeks after treatment.
   CONCLUSIONS: Although these cases may represent natural history, there should be a high index of suspicion for retinal pigment epithelium tears in patients who report significant visual deterioration after intravitreal injection of pegaptanib sodium. Further studies are needed to determine whether angiographic subtypes of choroidal neovascular membranes are more susceptible to developing retinal pigment epithelium tears after treatment with antivascular endothelial growth factor agents.
C1 Barnes Retina Inst, St Louis, MO USA.
   Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); University
   of Chicago
RP Apte, RS (通讯作者)，660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
CR BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   KRISHAN NR, 1985, AM J OPHTHALMOL, V100, P698, DOI 10.1016/0002-9394(85)90626-9
NR 7
TC 68
Z9 73
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2006
VL 141
IS 4
BP 752
EP 754
DI 10.1016/j.ajo.2005.10.053
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030GG
UT WOS:000236621800027
PM 16564819
DA 2022-11-30
ER

PT J
AU Gellermann, W
   Ermakov, IV
   Ermakova, MR
   McClane, RW
   Zhao, DY
   Bernstein, PS
AF Gellermann, W
   Ermakov, IV
   Ermakova, MR
   McClane, RW
   Zhao, DY
   Bernstein, PS
TI In vivo resonant Raman measurement of macular carotenoid pigments in the
   young and the aging human retina
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article
ID SPECTRAL REFLECTANCE; AGE; LUTEIN; LIGHT; CONE; IDENTIFICATION;
   REFLECTOMETRY; TRANSMISSION; PATHOGENESIS; ABSORPTION
AB We have used resonant Raman scattering spectroscopy as a novel, noninvasive, in vivo optical technique to measure the concentration of the macular carotenoid pigments lutein and zeaxanthin in the living human retina of Young and elderly adults. Using a backscattering geometry and resonant molecular excitation in the visible wavelength range, we measure the Raman signals originating from the single- and double-bond stretch vibrations of the pi-conjugated molecule's carbon backbone. The Raman signals scale linearly with carotenoid content, and the required laser excitation is well below safety limits for macular exposure. Furthermore, the signals decline significantly with increasing age in normal eyes. The Raman technique is objective and quantitative and may lead to a new method for rapid screening of carotenoid pigment levels in large populations at risk for vision loss from age-related macular degeneration, the leading cause of blindness in the elderly in the United States. (C) 2002 Optical Society of America.
C1 Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
   Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   Univ Utah, Dixon Laser Inst, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP Gellermann, W (通讯作者)，Univ Utah, Dept Phys, 115 S 1400 E, Salt Lake City, UT 84112 USA.
EM werner@physics.utah.edu
FU NATIONAL EYE INSTITUTE [R41EY012324, R42EY012324, R29EY011600] Funding
   Source: NIH RePORTER; NEI NIH HHS [2 R42 EY12324-02, R29-EY11600, 1 R41
   EY12324-01] Funding Source: Medline
CR ALBRECHT AC, 1961, J CHEM PHYS, V34, P1476, DOI 10.1063/1.1701032
   APT L, 1980, AM J OPHTHALMOL, V89, P553, DOI 10.1016/0002-9394(80)90065-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BERENDSHOT T, 1999, VISUAL SCI S, V39, pS314
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BERNSTEIN PS, 2000, ENV STRESSORS EFFECT, P423
   BERNSTEIN PS, 1999, Patent No. 5873831
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   DELORI FC, 1980, VISION RES, V20, P1099, DOI 10.1016/0042-6989(80)90046-2
   DELORI FC, 1993, OSA TECHNICAL DIGEST, V3, P240
   Dillon J, 2000, PHOTOCHEM PHOTOBIOL, V71, P225, DOI 10.1562/0031-8655(2000)071<0225:TSOLTT>2.0.CO;2
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   ELSNER AE, 1992, APPL OPTICS, V31, P3697, DOI 10.1364/AO.31.003697
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   ELSNER AE, 1990, LASER SCANNING OPHTH
   Ermakov IV, 2001, OPT LETT, V26, P202, DOI 10.1364/OL.26.000202
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Gellermann W, 1998, P SOC PHOTO-OPT INS, V3250, P8, DOI 10.1117/12.305368
   GELLERMANN W, 2001, Patent No. 6205354
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Hammond CJ, 2000, BRIT J OPHTHALMOL, V84, P1173, DOI 10.1136/bjo.84.10.1173
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   Hata TR, 2000, J INVEST DERMATOL, V115, P441, DOI 10.1046/j.1523-1747.2000.00060.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KIEFER W, 1995, INFRARED RAMAN SPECT, P468
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   KOYAMA Y, 1988, J RAMAN SPECTROSC, V19, P37, DOI 10.1002/jrs.1250190107
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   SAMPLE PA, 1988, INVEST OPHTH VIS SCI, V29, P1306
   SCHALCH W, 1999, CRC MOD NUT, P215
   SCHWEITZER D, 1998, VISUAL SCI, V39, P2001
   Sebag J, 1999, Diabetes Technol Ther, V1, P169, DOI 10.1089/152091599317387
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SHREVE AP, 1991, CHEM PHYS LETT, V178, P89, DOI 10.1016/0009-2614(91)85058-5
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1999, CRC MOD NUT, P251
   SOMMERBERG OG, 1999, CURR EYE RES, V19, P502
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   VANNORREN D, 1989, VISION RES, V29, P1825, DOI 10.1016/0042-6989(89)90163-6
   VANNORREN D, 1986, VISION RES, V26, P313, DOI 10.1016/0042-6989(86)90028-3
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
   [No title captured]
NR 65
TC 106
Z9 106
U1 0
U2 14
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1084-7529
EI 1520-8532
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD JUN
PY 2002
VL 19
IS 6
BP 1172
EP 1186
DI 10.1364/JOSAA.19.001172
PG 15
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 556RJ
UT WOS:000175862500014
PM 12049355
DA 2022-11-30
ER

PT J
AU Petrus-Reurer, S
   Lederer, AR
   Baque-Vidal, L
   Douagi, I
   Pannagel, B
   Khven, I
   Aronsson, M
   Bartuma, H
   Wagner, M
   Wrona, A
   Efstathopoulos, P
   Jaberi, E
   Willenbrock, H
   Shimizu, Y
   Villaescusa, JC
   Andre, H
   Sundstrom, E
   Bhaduri, A
   Kriegstein, A
   Kvanta, A
   La Manno, G
   Lanner, F
AF Petrus-Reurer, Sandra
   Lederer, Alex R.
   Baque-Vidal, Laura
   Douagi, Iyadh
   Pannagel, Belinda
   Khven, Irina
   Aronsson, Monica
   Bartuma, Hammurabi
   Wagner, Magdalena
   Wrona, Andreas
   Efstathopoulos, Paschalis
   Jaberi, Elham
   Willenbrock, Hanni
   Shimizu, Yutaka
   Villaescusa, J. Carlos
   Andre, Helder
   Sundstrom, Erik
   Bhaduri, Aparna
   Kriegstein, Arnold
   Kvanta, Anders
   La Manno, Gioele
   Lanner, Fredrik
TI Molecular profiling of stem cell-derived retinal pigment epithelial cell
   differentiation established for clinical translation
SO STEM CELL REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; XENO-FREE; TRANSPLANTATION; MOUSE
AB Human embryonic stem cell-derived retinal pigment epithelial cells (hESC-RPE) are a promising cell source to treat age-related macular degeneration (AMD). Despite several ongoing clinical studies, a detailed mapping of transient cellular states during in vitro differentiation has not been performed. Here, we conduct single-cell transcriptomic profiling of an hESC-RPE differentiation protocol that has been developed for clinical use. Differentiation progressed through a culture diversification recapitulating early embryonic development, whereby cells rapidly acquired a rostral embryo patterning signature before converging toward the RPE lineage. At intermediate steps, we identified and examined the potency of an NCAM1(+) retinal progenitor population and showed the ability of the protocol to suppress non-RPE fates. We demonstrated that the method produces a pure RPE pool capable of maturing further after subretinal transplantation in a large-eyed animal model. Our evaluation of hESC-RPE differentiation supports the development of safe and efficient pluripotent stem cell-based therapies for AMD.
C1 [Petrus-Reurer, Sandra; Baque-Vidal, Laura; Wagner, Magdalena; Lanner, Fredrik] Karolinska Inst, Dept Clin Sci Intervent & Technol, S-17177 Stockholm, Sweden.
   [Petrus-Reurer, Sandra; Baque-Vidal, Laura; Wagner, Magdalena; Lanner, Fredrik] Karolinska Univ Sjukhuset, Gynecol & Reprod Med, S-14186 Stockholm, Sweden.
   [Petrus-Reurer, Sandra; Aronsson, Monica; Bartuma, Hammurabi; Andre, Helder; Kvanta, Anders] Karolinska Inst, Dept Clin Neurosci, Div Eye & Vis, St Erik Eye Hosp, S-11282 Stockholm, Sweden.
   [Lederer, Alex R.; Khven, Irina; La Manno, Gioele] Ecole Polytech Fed Lausanne EPFL, Brain Mind Inst, Lab Neurodev Syst Biol, Sch Life Sci, CH-1015 Lausanne, Switzerland.
   [Douagi, Iyadh; Pannagel, Belinda] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, S-17177 Stockholm, Sweden.
   [Wrona, Andreas; Efstathopoulos, Paschalis; Jaberi, Elham; Willenbrock, Hanni; Shimizu, Yutaka; Villaescusa, J. Carlos] Novo Nordisk AS, Cell Therapy R&D, DK-2760 Malov, Denmark.
   [Sundstrom, Erik] Karolinska Inst, Dept Neurobiol Care Sci & Soc, S-17177 Stockholm, Sweden.
   [Bhaduri, Aparna; Kriegstein, Arnold] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Bhaduri, Aparna; Kriegstein, Arnold] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA USA.
   [Lanner, Fredrik] Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Stockholm Node, S-17177 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; Swiss Federal Institutes
   of Technology Domain; Ecole Polytechnique Federale de Lausanne;
   Karolinska Institutet; Novo Nordisk; Karolinska Institutet; University
   of California System; University of California San Francisco; University
   of California System; University of California San Francisco; Karolinska
   Institutet
RP Lanner, F (通讯作者)，Karolinska Inst, Dept Clin Sci Intervent & Technol, S-17177 Stockholm, Sweden.; Lanner, F (通讯作者)，Karolinska Univ Sjukhuset, Gynecol & Reprod Med, S-14186 Stockholm, Sweden.; La Manno, G (通讯作者)，Ecole Polytech Fed Lausanne EPFL, Brain Mind Inst, Lab Neurodev Syst Biol, Sch Life Sci, CH-1015 Lausanne, Switzerland.
EM gioele.lamanno@epfl.ch; fredrik.lanner@ki.se
FU Swedish Research Council; Ragnar Soderberg Foundation; MingWai Lau
   Center for Reparative Medicine; Center for Innovative Medicine;
   Wallenberg Academy Fellow; Strategic Research Area Stem Cells and
   Regenerative Medicine; Vinnova; Stockholm County Council (ALF project);
   Karolinska Institutet; Crown Princess Margareta's Foundation for the
   Visually Impaired; ARMEC Lindeberg Foundation; Ulla och Ingemar Dahlberg
   Foundation; King Gustav V and Queen Victoria Foundation; Compton
   Foundation; Swiss National Science Foundation [CRSK-3_190495,
   PZ00P3_193445]; Chan Zuckerberg Initiative [CZF2019002427]; Knut and
   Alice Wallenberg Foundation; Centre for Innovative Medicine; Jonasson
   donation; KI/SLL; board of research at the KI; research committee at the
   Karolinska Hospital
FX We thank ErnestArenas, Pierre Fabre, IgorAdameyko, PierreGonczy, Felix
   Naef, and Bart Deplancke for helpful feedback on the manuscript. We also
   thank the EPFLHistology Core Facility team, particularly Jessica
   Dessimoz, Gian-Filippo Mancini, and Nathalie Muller, for their
   assistance with immunostaining. The work was supported by grants from
   the Swedish Research Council, Ragnar Soderberg Foundation, MingWai Lau
   Center for Reparative Medicine, Center for Innovative Medicine,
   Wallenberg Academy Fellow, Strategic Research Area Stem Cells and
   Regenerative Medicine, Vinnova, Stockholm County Council (ALF project),
   Karolinska Institutet, Crown Princess Margareta's Foundation for the
   Visually Impaired, ARMEC Lindeberg Foundation, the Ulla och Ingemar
   Dahlberg Foundation, and King Gustav V and Queen Victoria Foundation,
   Compton Foundation, the Swiss National Science Foundation grants
   CRSK-3_190495 and PZ00P3_193445, and grant CZF2019002427 from the Chan
   Zuckerberg Initiative. This study was performed at the Live Cell Imaging
   unit/Nikon Center of Excellence, BioNut, and KI, supported by Knut and
   Alice Wallenberg Foundation, Swedish Research Council, Centre for
   Innovative Medicine and the Jonasson donation. Flow cytometry was
   performed at the MedH Flow Cytometry core facility, and prenatal human
   tissue was acquired through the Developmental Tissue Bank core facility,
   bothsupported byKI/SLL. Sequencing was performed at ESCG Infrastructure
   in Stockholm at Science for Life Laboratory (funded by the Knut and
   Alice Wallenberg Foundation and the Swedish Research Council) and
   Bioinformatics and Expression Analysis (supported by the board of
   research at the KI and the research committee at the Karolinska
   Hospital) with assistance from SNIC/Uppsala Multidisciplinary Center for
   Advanced Computational Science with massively parallel sequencing and
   access to the UPPMAX computational infrastructure.
CR Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bartuma H, 2015, INVEST OPHTH VIS SCI, V56, P2423, DOI 10.1167/iovs.14-16208
   Begbie J, 2013, COMPREHENSIVE DEVELOPMENTAL NEUROSCIENCE: PATTERNING AND CELL TYPE SPECIFICATION IN THE DEVELOPING CNS AND PNS, P239, DOI 10.1016/B978-0-12-397265-1.00212-4
   Bhatia B, 2010, OPEN OPHTHALMOL J, V4, P30, DOI 10.2174/1874364101004010030
   Bosze B., 2020, PATTERNING CELL TYPE, VSecond, P481
   Brodie-Kommit J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe4983
   Choudhary P, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0380-6
   Cuomo ASE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14457-z
   David FPA, 2020, NUCLEIC ACIDS RES, V48, pW403, DOI 10.1093/nar/gkaa412
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gao ZG, 2014, DEV NEUROBIOL, V74, P1123, DOI 10.1002/dneu.22188
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hu YQ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000365
   Joshi R, 2016, J OCUL PHARMACOL TH, V32, P331, DOI 10.1089/jop.2015.0163
   Kulkarni A, 2019, CURR OPIN BIOTECH, V58, P129, DOI 10.1016/j.copbio.2019.03.001
   Kumar P, 2017, DEVELOPMENT, V144, P17, DOI 10.1242/dev.133058
   La Manno G, 2021, NATURE, V596, P92, DOI 10.1038/s41586-021-03775-x
   La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6
   La Manno G, 2016, CELL, V167, P566, DOI 10.1016/j.cell.2016.09.027
   Lederer AR, 2020, CURR OPIN BIOTECH, V63, P70, DOI 10.1016/j.copbio.2019.12.005
   Lidgerwood GE, 2021, GENOM PROTEOM BIOINF, V19, P223, DOI 10.1016/j.gpb.2020.08.002
   Lukowski SW, 2019, EMBO J, V38, DOI 10.15252/embj.2018100811
   Maeda T, 2022, TRENDS MOL MED, V28, P388, DOI 10.1016/j.molmed.2022.03.001
   Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1
   Petrus-Reurer S, 2018, JOVE-J VIS EXP, DOI 10.3791/56702
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Plaza Reyes A., 2020, PROTOC EXCH, DOI [10.21203/rs.3.pex-635/v1, DOI 10.21203/RS.3.PEX-635/V1]
   Quake S. R., 2021, BIORXIV, DOI 10.1101/2021.07.19.452956
   Reyes AP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15326-5
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rodin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4195
   Shao JZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep42363
   Streit A, 2007, INT J DEV BIOL, V51, P447, DOI 10.1387/ijdb.072327as
   Sunness JS, 1999, MOL VIS, V5
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02955-3
   Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zeisel A, 2018, CELL, V174, P999, DOI 10.1016/j.cell.2018.06.021
NR 40
TC 1
Z9 1
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD JUN 14
PY 2022
VL 17
IS 6
BP 1458
EP 1475
DI 10.1016/j.stemcr.2022.05.005
PG 18
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 3B8DQ
UT WOS:000828166800001
PM 35705015
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gilger, BC
   Hirsch, ML
AF Gilger, Brian C.
   Hirsch, Matthew L.
TI Therapeutic Applications of Adeno-Associated Virus (AAV) Gene Transfer
   of HLA-G in the Eye
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE AAV; HLA-G; dry eye; ocular graft vs; host disease; corneal transplant
   rejection; uveitis; gene therapy
ID VERSUS-HOST-DISEASE; DRY EYE; CLASS-I; UVEITIS; TRANSPLANTATION;
   EXPRESSION; COMPLICATIONS; TRANSCRIPTS; ACTIVATION; CRITERIA
AB The purpose of this paper is to review human leukocyte antigen G (HLA-G) in the eye, its role in immune tolerance, and the potential therapeutic use of AAV gene transfer and expression of HLA-G in various ocular tissues. Several studies are reviewed that demonstrate efficacy in animal models of disease, including intracorneal delivery of AAV-HLA-G to treat corneal inflammation and prevent corneal graft rejection, subconjunctival injection of AAV-HLA-G for ocular graft vs. host disease and potentially dry eye disease, and intravitreal injection of AAV-HLA-G to inhibit uveitis. Furthermore, due to the anti-vascular function of HLA-G, AAV-HLA-G may be an effective therapy for posterior ocular diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization. Therefore, AAV-mediated gene transfer of HLA-G may be an effective treatment for common immune-mediated, inflammatory, and neovascular diseases of the eye.
C1 [Gilger, Brian C.] North Carolina State Univ, Dept Clin Sci, Raleigh, NC 27607 USA.
   [Hirsch, Matthew L.] Univ N Carolina, Sch Med, Ophthalmol, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; North Carolina State University;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine
RP Gilger, BC (通讯作者)，North Carolina State Univ, Dept Clin Sci, Raleigh, NC 27607 USA.
EM bgilger@ncsu.edu; mhirsch@email.unc.edu
RI Gilger, Brian/D-8776-2014
OI Gilger, Brian/0000-0002-7771-9166
FU M.L.H. National Institutes of Health [R41EY031625]
FX The authors thank Beth Salmon for her contributions to this publication.
   This research was funded by M.L.H. National Institutes of Health, grant
   number R41EY031625.
CR Abud TB, 2016, OPHTHALMOLOGY, V123, P1449, DOI 10.1016/j.ophtha.2016.02.044
   Agarwal Rajeev K, 2012, Methods Mol Biol, V900, P443, DOI 10.1007/978-1-60761-720-4_22
   Bastola P, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080767
   Bohringer D, 2018, DTSCH ARZTEBL INT, V115, P259, DOI 10.3238/arztebl.2018.0259
   Carosella ED, 2015, ADV IMMUNOL, V127, P33, DOI 10.1016/bs.ai.2015.04.001
   Caspi R. R., 2006, DRUG DISCOV TODAY, V3, P3
   Chandler LC, 2021, MOL THER-METH CLIN D, V22, DOI 10.1016/j.omtm.2021.05.011
   Chang JH, 2012, SURV OPHTHALMOL, V57, P415, DOI 10.1016/j.survophthal.2012.01.007
   Chu CJ, 2012, OCUL IMMUNOL INFLAMM, V20, P394, DOI 10.3109/09273948.2012.726392
   Chung SH, 2021, HUM GENE THER, V32, P682, DOI 10.1089/hum.2020.281
   Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023
   Crabtree E, 2021, INVEST OPHTH VIS SCI, V62
   Crabtree E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56462-3
   Cukras C, 2018, MOL THER, V26, P2282, DOI 10.1016/j.ymthe.2018.05.025
   Cursiefen Claus, 2007, Chem Immunol Allergy, V92, P50, DOI 10.1159/000099253
   Deeg CA, 2008, OPHTHAL RES, V40, P151, DOI 10.1159/000119867
   Dias FC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00009
   Farkouh A, 2016, CLIN OPHTHALMOL, V10, P2433, DOI 10.2147/OPTH.S118409
   Fons P, 2006, BLOOD, V108, P2608, DOI 10.1182/blood-2005-12-019919
   Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776
   Gilger BC, 2018, ILAR J, V59, P352, DOI 10.1093/ilar/ily002
   Gilger BC, 2018, INVEST OPHTH VIS SCI, V59
   Hirsch ML, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18002-9
   Hunt JS, 2005, FASEB J, V19, P681, DOI 10.1096/fj.04-2078rev
   Ildefonso CJ, 2015, MOL THER, V23, P875, DOI 10.1038/mt.2015.30
   Inamoto Y, 2019, BONE MARROW TRANSPL, V54, P662, DOI 10.1038/s41409-018-0340-0
   Inamoto Y, 2012, BIOL BLOOD MARROW TR, V18, P1517, DOI 10.1016/j.bbmt.2012.05.016
   ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947
   Jones NP, 2015, OCUL IMMUNOL INFLAMM, V23, P127, DOI 10.3109/09273948.2014.968671
   Keating AM, 2011, OCUL SURF, V9, P227, DOI 10.1016/S1542-0124(11)70035-0
   Le Discorde M, 2003, HUM IMMUNOL, V64, P1039, DOI 10.1016/j.humimm.2003.08.346
   Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576-019-0205-4
   Martin-Villa JM, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.796054
   Martinez-Carrasco R, 2017, EXP EYE RES, V154, P64, DOI 10.1016/j.exer.2016.11.004
   Niederkorn JY, 2010, CURR OPIN ALLERGY CL, V10, P493, DOI 10.1097/ACI.0b013e32833dfa11
   Niederkorn JY, 2006, NAT IMMUNOL, V7, P354, DOI 10.1038/ni1328
   Nilles J, 2021, INVEST OPHTH VIS SCI, V62
   Ogawa Y, 2003, INVEST OPHTH VIS SCI, V44, P1888, DOI 10.1167/iovs.02-0699
   Perez VL, 2016, BIOL BLOOD MARROW TR, V22, P1765, DOI 10.1016/j.bbmt.2016.07.012
   Prakash V, 2017, GENE THER, V24, P497, DOI 10.1038/gt.2017.59
   Qiu YG, 2016, SCI REP-UK, V6, DOI 10.1038/srep31912
   Robert PY, 1999, EUR J IMMUNOGENET, V26, P271, DOI 10.1046/j.1365-2370.1999.00145.x
   Shamloo K, 2019, INVEST OPHTH VIS SCI, V60, P4511, DOI 10.1167/iovs.19-27843
   Song LJ, 2018, GENE THER, V25, P402, DOI 10.1038/s41434-018-0035-6
   Srivastava A, 2010, CLIN CHIM ACTA, V411, P1165, DOI 10.1016/j.cca.2010.04.017
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Svendsen SG, 2017, HUM IMMUNOL, V78, P414, DOI 10.1016/j.humimm.2017.04.007
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Taylor AW, 2018, J LEUKOCYTE BIOL, V103, P1179, DOI 10.1002/JLB.3MIR0817-337R
   Thorne JE, 2016, JAMA OPHTHALMOL, V134, P1237, DOI 10.1001/jamaophthalmol.2016.3229
   Tummala G, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.41
   Utine CA, 2010, OCUL IMMUNOL INFLAMM, V18, P352, DOI 10.3109/09273948.2010.498657
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Wang Leying, 2021, Transl Vis Sci Technol, V10, P11, DOI 10.1167/tvst.10.11.11
   Westeneng AC, 2010, CORNEA, V29, P758, DOI 10.1097/ICO.0b013e3181ca321c
   Willermain F, 2012, PROG RETIN EYE RES, V31, P182, DOI 10.1016/j.preteyeres.2011.11.004
   Wilson SE, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108272
   Xiong WJ, 2019, P NATL ACAD SCI USA, V116, P5785, DOI 10.1073/pnas.1821000116
   Zhong W, 2018, SURV OPHTHALMOL, V63, P453, DOI 10.1016/j.survophthal.2017.12.008
NR 59
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2022
VL 23
IS 7
AR 3465
DI 10.3390/ijms23073465
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0M1SR
UT WOS:000781942400001
PM 35408825
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hsu, D
   Kwon, JH
   Ng, R
   Makita, S
   Yasuno, Y
   Sarunic, MV
   Ju, MJ
AF Hsu, Destiny
   Kwon, Ji Hoon
   Ng, Ringo
   Makita, Shuichi
   Yasuno, Yoshiaki
   Sarunic, Marinko V.
   Ju, Myeong Jin
TI Quantitative multi-contrast in vivo mouse imaging with polarization
   diversity optical coherence tomography and angiography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
AB Retinal microvasculature and the retinal pigment epithelium (RPE) play vital roles in maintaining the health and metabolic activity of the eye. Visualization of these retina structures is essential for pre-clinical studies of vision-robbing diseases, such as age-related macular degeneration (AMD). We have developed a quantitative multi-contrast polarization diversity OCT and angiography (QMC-PD-OCTA) system for imaging and visualizing pigment in the RPE using degree of polarization uniformity (DOPU), along with flow in the retinal capillaries using OCT angiography (OCTA). An adaptive DOPU averaging kernel was developed to increase quantifiable values from visual data, and QMC en face images permit simultaneous visualization of vessel location, depth, melanin region thickness, and mean DOPU values, allowing rapid identification and differentiation of disease symptoms. The retina of five different mice strains were measured in vivo, with results demonstrating potential for pre-clinical studies of retinal disorders. (c) 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Hsu, Destiny; Kwon, Ji Hoon; Ng, Ringo; Sarunic, Marinko V.; Ju, Myeong Jin] Simon Fraser Univ, Biomed Opt Res Grp, Dept Engn Sci, Burnaby, BC, Canada.
   [Makita, Shuichi; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Inst Appl Phys, Tsukuba, Ibaraki, Japan.
   [Ju, Myeong Jin] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Ju, Myeong Jin] Univ British Columbia, Sch Biomed Engn, Vancouver, BC, Canada.
C3 Simon Fraser University; University of Tsukuba; University of British
   Columbia; University of British Columbia
RP Ju, MJ (通讯作者)，Simon Fraser Univ, Biomed Opt Res Grp, Dept Engn Sci, Burnaby, BC, Canada.; Ju, MJ (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.; Ju, MJ (通讯作者)，Univ British Columbia, Sch Biomed Engn, Vancouver, BC, Canada.
EM myeongjin.ju@ubc.ca
RI Makita, Shuichi/G-3806-2011; Yasuno, Yoshiaki/F-2586-2011
OI Makita, Shuichi/0000-0002-6614-3640; Sarunic,
   Marinko/0000-0002-5636-9056; Yasuno, Yoshiaki/0000-0003-1645-7948
FU Canadian Institutes of Health Research; Natural Sciences and Engineering
   Research Council of Canada
FX Canadian Institutes of Health Research; Natural Sciences and Engineering
   Research Council of Canada.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ahn SJ, 2001, PATTERN RECOGN, V34, P2283, DOI 10.1016/S0031-3203(00)00152-7
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Augustin M, 2018, INVEST OPHTH VIS SCI, V59, P2054, DOI 10.1167/iovs.17-23208
   Augustin M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164419
   Baumann B, 2015, INVEST OPHTH VIS SCI, V56, P7462, DOI 10.1167/iovs.15-17742
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bo E, 2017, OPTICA, V4, P701, DOI 10.1364/OPTICA.4.000701
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Caruso RC, 2010, INVEST OPHTH VIS SCI, V51, P5304, DOI 10.1167/iovs.10-5559
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Geng Y, 2011, BIOMED OPT EXPRESS, V2, P717, DOI 10.1364/BOE.2.000717
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Harper DJ, 2020, NEUROPHOTONICS, V7, DOI 10.1117/1.NPh.7.1.015006
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Huber G, 2009, INVEST OPHTH VIS SCI, V50, P5888, DOI 10.1167/iovs.09-3724
   Ju M.J., 2019, J BIOMED OPT, V22, P1
   Ju MJ, 2018, BIOMED OPT EXPRESS, V9, P2336, DOI 10.1364/BOE.9.002336
   Ju MJ, 2013, OPT EXPRESS, V21, P19412, DOI 10.1364/OE.21.019412
   Lapierre-Landry M, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0124-5
   Makita S, 2018, BIOMED OPT EXPRESS, V9, P4372, DOI 10.1364/BOE.9.004372
   Makita S, 2014, OPT LETT, V39, P6783, DOI 10.1364/OL.39.006783
   Meleppat RK, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.6.066011
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Petersen-Jones SM, 1998, EYE, V12, P566, DOI 10.1038/eye.1998.146
   Pircher M, 2017, BIOMED OPT EXPRESS, V8, P2536, DOI 10.1364/BOE.8.002536
   Pyakurel A, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00295-17
   Tanabu R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210439
   Thompson DA, 2003, DEV OPHTHALMOL, V37, P141
   Verstraete HRGW, 2017, BIOMED OPT EXPRESS, V8, P2261, DOI 10.1364/BOE.8.002261
   Wahl DJ, 2016, IEEE PHOTON CONF, P130, DOI 10.1109/IPCon.2016.7831010
   Wahl DJ, 2016, BIOMED OPT EXPRESS, V7, P1, DOI [10.1364/BOE.7.000001, 10.1364/BOE.7.00001]
   Xu JJ, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aa94bc
   Yasuno Y, 2005, OPT EXPRESS, V13, P10652, DOI 10.1364/OPEX.13.010652
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
   Zhang PF, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.12.126005
NR 41
TC 4
Z9 4
U1 1
U2 3
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD DEC 1
PY 2020
VL 11
IS 12
BP 6945
EP 6961
DI 10.1364/BOE.403209
PG 17
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA PB4TB
UT WOS:000596313900011
PM 33408972
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ren, XX
   Zheng, XW
   Dong, X
   Cui, XC
AF Ren, Xiuxiu
   Zheng, Xiangwei
   Dong, Xiao
   Cui, Xinchun
TI Deep feature extraction via adaptive collaborative learning for drusen
   segmentation from fundus images
SO SIGNAL IMAGE AND VIDEO PROCESSING
LA English
DT Article
DE Drusen segmentation; Fundus images; Adaptive collaborative learning;
   Deep feature extraction
AB Drusen are an early sign of non-neovascular age-related macular degeneration which is a major factor of irreversible blindness. Drusen segmentation plays a vital role in proper diagnosis and prevention of further complications. However, most of the existing drusen segmentation approaches rely on handcrafted features which are not always guaranteed to be discriminative and therefore lead to limited performance. In this paper, we propose a deep feature extraction framework for drusen segmentation. It is formulated as a deep model which can automatically extract discriminative features. Specifically, the framework is mainly composed of three components, including feature learning, loss function and classification. The effectiveness of our method lies in the fact that the deep feature learning procedures are driven by an adaptive collaborative similarity learning technique in loss function. We evaluate the framework on STARE and DRIVE datasets, and the quantitative comparison with the state-of-the-art methods in terms of sensitivity, specificity and accuracy demonstrates the superiority of the proposed method.
C1 [Ren, Xiuxiu; Zheng, Xiangwei; Dong, Xiao] Shandong Normal Univ, Sch Informat Sci & Engn, Jinan, Peoples R China.
   [Ren, Xiuxiu; Zheng, Xiangwei] Shandong Normal Univ, Shandong Prov Key Lab Distributed Comp Software N, Jinan, Peoples R China.
   [Cui, Xinchun] Qufu Normal Univ, Sch Informat Sci & Engn, Rizhao, Peoples R China.
C3 Shandong Normal University; Shandong Normal University; Qufu Normal
   University
RP Zheng, XW (通讯作者)，Shandong Normal Univ, Sch Informat Sci & Engn, Jinan, Peoples R China.; Zheng, XW (通讯作者)，Shandong Normal Univ, Shandong Prov Key Lab Distributed Comp Software N, Jinan, Peoples R China.
EM xwzhengcn@163.com
FU National Natural Science Foundation of China [61373149, 61672329]
FX This work has been supported by the National Natural Science Foundation
   of China (61373149, 61672329).
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Belkin M, 2002, ADV NEUR IN, V14, P585
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chatfield K, 2011, PROCEEDINGS OF THE BRITISH MACHINE VISION CONFERENCE 2011, DOI 10.5244/C.25.76
   Cheng J, 2012, IEEE IMAGE PROC, P2805, DOI 10.1109/ICIP.2012.6467482
   Dong X, 2018, PROCEEDINGS OF THE TWENTY-SEVENTH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE, P2064
   FAN K, 1949, P NATL ACAD SCI USA, V35, P652, DOI 10.1073/pnas.35.11.652
   Huang L, 2019, SIGNAL IMAGE VIDEO P, V13, P431, DOI 10.1007/s11760-018-01410-3
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khowaja SA, 2019, SIGNAL IMAGE VIDEO P, V13, P379, DOI 10.1007/s11760-018-1366-x
   Kim YJ, 2018, COMPUT MATH METHOD M, V2018, DOI 10.1155/2018/6084798
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Liu H., 2014, P AS C COMP VIS, P483
   Mohar B., 1991, GRAPH THEORY COMB AP, V2, P871, DOI 10.1016/j.camwa.2004.05.005
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Ren XX, 2018, IEEE ACCESS, V6, P2952, DOI 10.1109/ACCESS.2017.2786271
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sui XD, 2017, NEUROCOMPUTING, V237, P332, DOI 10.1016/j.neucom.2017.01.023
   Ujjwal, 2013, I S BIOMED IMAGING, P1436
   van Grinsven MJJP, 2016, BIOMED OPT EXPRESS, V7, P709, DOI 10.1364/BOE.7.000709
   Yan F, 2018, LECT NOTES COMPUT SC, V11071, P48, DOI 10.1007/978-3-030-00934-2_6
   Zhang J, 2019, IEEE T MED IMAGING, V38, P435, DOI 10.1109/TMI.2018.2865671
   Zhu PF, 2015, PATTERN RECOGN, V48, P438, DOI 10.1016/j.patcog.2014.08.006
NR 25
TC 2
Z9 2
U1 2
U2 6
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1863-1703
EI 1863-1711
J9 SIGNAL IMAGE VIDEO P
JI Signal Image Video Process.
PD JUL
PY 2021
VL 15
IS 5
BP 895
EP 902
DI 10.1007/s11760-020-01812-2
EA NOV 2020
PG 8
WC Engineering, Electrical & Electronic; Imaging Science & Photographic
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Imaging Science & Photographic Technology
GA TA3RU
UT WOS:000591135200001
DA 2022-11-30
ER

PT J
AU Shen, JK
   Kim, J
   Tzeng, SY
   Ding, K
   Hafiz, Z
   Long, D
   Wang, JX
   Green, JJ
   Campochiaro, PA
AF Shen, Jikui
   Kim, Jayoung
   Tzeng, Stephany Y.
   Ding, Kun
   Hafiz, Zibran
   Long, Da
   Wang, Jiangxia
   Green, Jordan J.
   Campochiaro, Peter A.
TI Suprachoroidal gene transfer with nonviral nanoparticles
SO SCIENCE ADVANCES
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; POLYMERIC NANOPARTICLES; MACULAR
   DEGENERATION; RPE65 MUTATIONS; IMMUNE-RESPONSE; THERAPY; INJECTION;
   DELIVERY; PHASE-1; SAFETY
AB Subretinal injections of viral vectors provide great benefits but have limited cargo capacity; they induce innate and adaptive immune responses, which may cause damage and preclude repeated injections; and they pose administration risks. As a new biotechnology, suprachoroidal injections of biodegradable nanoparticles (NPs) containing a reporter plasmid induce reporter expression in rat photoreceptors and RPE throughout the entire eye and maintain expression for at least 8 months. Multiple injections markedly increase expression. Suprachoroidal injection of NPs containing a VEGF expression plasmid caused severe subretinal neovascularization progressing to subretinal fibrosis, similar to what occurs in untreated patients with neovascular age-related macular degeneration, providing a new model and proof of concept for level and duration of expression. Suprachoroidal injection of NPs containing a VEGF-binding protein expression plasmid significantly suppressed VEGF-induced vascular leakage and neovascularization demonstrating therapeutic potential. These data suggest that nonviral NP suprachoroidal gene transfer may provide a noninvasive, repeatable alternative to subretinal injection of viral vectors.
C1 [Shen, Jikui; Ding, Kun; Hafiz, Zibran; Long, Da; Green, Jordan J.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Kim, Jayoung; Tzeng, Stephany Y.; Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Kim, Jayoung; Tzeng, Stephany Y.; Green, Jordan J.] Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD 21205 USA.
   [Wang, Jiangxia] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Biostat Ctr, Baltimore, MD USA.
   [Green, Jordan J.] Johns Hopkins Univ, Inst Nanobiotechnol, Baltimore, MD 21205 USA.
   [Green, Jordan J.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21205 USA.
   [Green, Jordan J.] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.
   [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins University; Johns Hopkins University; Johns Hopkins University
RP Green, JJ; Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.; Green, JJ (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.; Green, JJ (通讯作者)，Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD 21205 USA.; Green, JJ (通讯作者)，Johns Hopkins Univ, Inst Nanobiotechnol, Baltimore, MD 21205 USA.; Green, JJ (通讯作者)，Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21205 USA.; Green, JJ (通讯作者)，Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.; Green, JJ (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.; Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
EM green@jhu.edu; pcampo@jhmi.edu
RI Green, Jordan/B-9001-2009
OI Green, Jordan/0000-0003-4176-3808; Campochiaro,
   Peter/0000-0003-2531-8229; Tzeng, Stephany/0000-0002-7561-482X; Kim,
   Jayoung/0000-0002-4883-2768; SHEN, JIKUI/0000-0002-5262-5606
FU NIH [EY01765, R01EY031097, R21EY026148, R01EY028996, R01EB022148]; Dr.
   H. James and Carole Free Catalyst Award; Research to Prevent Blindness;
   Louis B. Thalheimer Translational Fund; Barth Foundation; Samsung
FX This work was supported by R01EY031097, R21EY026148, R01EY028996, and
   R01EB022148 from the NIH and Biostatistics Core Grant EY01765 to the
   Wilmer Eye Institute from the NIH. It was also supported by the Dr. H.
   James and Carole Free Catalyst Award and unrestricted grant from
   Research to Prevent Blindness; the Louis B. Thalheimer Translational
   Fund; a grant from the Barth Foundation; a scholarship to J.K. from
   Samsung; and unrestricted grants from Conrad and Lois Aschenbach, Per
   Bang-Jensen, Andrew and Yvette Marriott, and Jean Lake.
CR Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Barua S, 2014, NANO TODAY, V9, P223, DOI 10.1016/j.nantod.2014.04.008
   Bennett J, 2016, LANCET, V388, P661, DOI 10.1016/S0140-6736(16)30371-3
   Bhise NS, 2012, SMALL, V8, P367, DOI 10.1002/smll.201101718
   Campochiaro P. A., 2016, GENE THER, V28, P99, DOI [10.1089/hum.2016.11727710144, DOI 10.1089/HUM.2016.11727710144]
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2018, OPHTHALMOL RETINA, V2, P320, DOI 10.1016/j.oret.2017.07.013
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   Chen M, 2015, J CONTROL RELEASE, V203, P109, DOI 10.1016/j.jconrel.2015.02.021
   CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Green JJ, 2008, ACCOUNTS CHEM RES, V41, P749, DOI 10.1021/ar7002336
   Guerrero-Cazares H, 2014, ACS NANO, V8, P5141, DOI 10.1021/nn501197v
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Kim J, 2016, ACTA BIOMATER, V41, P293, DOI 10.1016/j.actbio.2016.05.040
   Kim YC, 2015, EUR J PHARM BIOPHARM, V95, P398, DOI 10.1016/j.ejpb.2015.05.020
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Li QH, 2008, MOL VIS, V14, P1760
   Liu YY, 2018, MOL THER, V26, P542, DOI 10.1016/j.ymthe.2017.12.002
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mangraviti A, 2015, ACS NANO, V9, P1236, DOI 10.1021/nn504905q
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Patel SR, 2012, INVEST OPHTH VIS SCI, V53, P4433, DOI 10.1167/iovs.12-9872
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Reichel FF, 2017, MOL THER, V25, P2648, DOI 10.1016/j.ymthe.2017.08.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shmueli RB, 2012, NANOMED-NANOTECHNOL, V8, P1200, DOI 10.1016/j.nano.2012.01.006
   Slivac I, 2017, EXPERT OPIN BIOL TH, V17, P105, DOI 10.1080/14712598.2017.1248941
   Sunshine JC, 2012, MOL PHARMACEUT, V9, P3375, DOI 10.1021/mp3004176
   Sunshine JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037543
   Takahashi K, 2017, MOL THER, V25, P296, DOI 10.1016/j.ymthe.2016.10.008
   Tzeng S. Y., 2018, GENE THER, V7, P42
   Xue KM, 2018, NAT MED, V24, P1507, DOI 10.1038/s41591-018-0185-5
   Yeh S., 2018, RETINA, V39, P1880
NR 38
TC 22
Z9 23
U1 0
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JUL
PY 2020
VL 6
IS 27
AR eaba1606
DI 10.1126/sciadv.aba1606
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MK4DR
UT WOS:000548735500018
PM 32937452
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Martinez-Solis, I
   Acero, N
   Bosch-Morell, F
   Castillo, E
   Gonzalez-Rosende, ME
   Munoz-Mingarro, D
   Ortega, T
   Sanahuja, MA
   Villagrasa, V
AF Martinez-Solis, Isabel
   Acero, Nuria
   Bosch-Morell, Francisco
   Castillo, Encarna
   Eugenia Gonzalez-Rosende, Maria
   Munoz-Mingarro, Dolores
   Ortega, Teresa
   Amparo Sanahuja, Maria
   Villagrasa, Victoria
TI Neuroprotective Potential of Ginkgo biloba in Retinal Diseases
SO PLANTA MEDICA
LA English
DT Review
DE Ginkgo biloba; Ginkgoaceae; neurodegeneration; retinal diseases;
   age-related macular degeneration; diabetic retinopathy; glaucoma;
   ischaemic retinal disease
ID EXTRACT EGB 761; POLYUNSATURATED FATTY-ACIDS; PIGMENT EPITHELIAL-CELLS;
   FREE-RADICAL SCAVENGERS; OCULAR BLOOD-FLOW; MACULAR DEGENERATION;
   SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; NERVE REGENERATION;
   EXPERIMENTAL-MODEL
AB Like other tissues of the central nervous system, the retina is susceptible to damage by oxidative processes that result in several neurodegenerative disease such as age-related macular degeneration, diabetic retinopathy, glaucoma, ischaemic retinal disease, retinal disease produced by light oxidation, and detached retina, among other diseases. The use of antioxidant substances is a solution to some health problems caused by oxidative stress, because they regulate redox homeostasis and reduce oxidative stress. This is important for neurodegeneration linked to oxidation processes. In line with this, Ginkgo biloba is a medicinal plant with excellent antioxidant properties whose effects have been demonstrated in several degenerative processes, including retinal diseases associated with neurodegeneration. This review describes the current literature on the role of ginkgo in retinal diseases associated with neurodegeneration. The information leads to the conclusion that G. biloba extracts might be a good option to improve certain neurodegenerative retinal diseases, but more research is needed to determine the safety and efficacy of G. biloba in these retinal degenerative processes.
C1 [Martinez-Solis, Isabel; Bosch-Morell, Francisco] CEU Univ, Univ Cardenal Herrera CEU, Biomed Sci Inst, Valencia, Spain.
   [Martinez-Solis, Isabel; Castillo, Encarna; Eugenia Gonzalez-Rosende, Maria; Amparo Sanahuja, Maria; Villagrasa, Victoria] CEU Univ, Univ Cardenal Herrera CEU, Fac Hlth Sci, Dept Pharm, C Ramon y Cajal S-N, Valencia 46115, Spain.
   [Martinez-Solis, Isabel] Univ Valencia, Bot Garden, Valencia, Spain.
   [Acero, Nuria] CEU Univ, Univ San Pablo CEU, Fac Pharm, Dept Pharmaceut & Hlth Sci, Madrid, Spain.
   [Bosch-Morell, Francisco] CEU Univ, Univ Cardenal Herrera CEU, Fac Hlth Sci, Dept Biomed Sci, Valencia, Spain.
   [Munoz-Mingarro, Dolores] CEU Univ, Univ San Pablo CEU, Fac Pharm, Dept Chem & Biochem, Madrid, Spain.
   [Ortega, Teresa] Univ Complutense Madrid, Dept Pharmacol & Bot, Madrid, Spain.
C3 Universidad CEU Cardenal Herrera; Universidad CEU Cardenal Herrera;
   University of Valencia; San Pablo CEU University; Universidad CEU
   Cardenal Herrera; San Pablo CEU University; Complutense University of
   Madrid
RP Martinez-Solis, I (通讯作者)，CEU Univ, Univ Cardenal Herrera CEU, Fac Hlth Sci, Dept Pharm, C Ramon y Cajal S-N, Valencia 46115, Spain.
EM isolis@uchceu.es
RI Solis, Isabel Martínez/K-4045-2017; Villagrasa, Victoria/AAQ-3989-2020;
   Morell, Francisco Bosch/AAA-8355-2019; Acero, N./H-3627-2017; Mingarro,
   Dolores Muñoz -/K-5910-2016
OI Morell, Francisco Bosch/0000-0002-8681-9230; Acero,
   N./0000-0001-9307-3839; 
CR 31 National Eye Institute (NEI) National Institutes of Health (NIH), RES TOD VIS TOM AG R
   33 National Eye Institute (NEI) National Institutes of Health (NIH), RES TODAY VISION TOM
   Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Ahlemeyer B, 2003, CELL MOL LIFE SCI, V60, P1779, DOI 10.1007/s00018-003-3080-1
   Ahlemeyer B, 2001, EUR J PHARMACOL, V430, P1, DOI 10.1016/S0014-2999(01)01237-7
   [Anonymous], 2014, TAIWAN J OPHTHALMOL, DOI DOI 10.1016/J.TJO.2014.03.005
   Athanasiou D, 2013, FEBS LETT, V587, P2008, DOI 10.1016/j.febslet.2013.05.020
   Bachinskaya N, 2011, NEUROPSYCH DIS TREAT, V7, P209, DOI 10.2147/NDT.S18741
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Bartlett H., 2005, Current Topics in Nutraceutical Research, V3, P231
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P339, DOI 10.1111/j.1475-1313.2004.00218.x
   BAUDOUIN C, 1994, EXP EYE RES, V59, P697, DOI 10.1006/exer.1994.1155
   Baudouin C, 1999, GRAEF ARCH CLIN EXP, V237, P58, DOI 10.1007/s004170050195
   Beck S, 2016, PHYTOCHEMISTRY, V130, P201, DOI 10.1016/j.phytochem.2016.05.005
   Behl T, 2017, J PHARM PHARMACOL, V69, P223, DOI 10.1111/jphp.12683
   BILGIHAN A, 1994, INT OPHTHALMOL, V18, P21, DOI 10.1007/BF00919409
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Bucolo C, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/432695
   Carelli V, 2017, HUM MOL GENET, V26, pR139, DOI 10.1093/hmg/ddx273
   Castilho AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042428
   Chan KKW, 2016, BMJ OPEN OPHTHALMOL, V1, DOI 10.1136/bmjophth-2016-000032
   Chang CH, 2017, PHARM BIOL, V55, P571, DOI 10.1080/13880209.2016.1263344
   Chhunchha B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113520
   Chung HS, 1999, J OCUL PHARMACOL TH, V15, P233, DOI 10.1089/jop.1999.15.233
   Chung SY, 2006, AM J CHINESE MED, V34, P803, DOI 10.1142/S0192415X06004302
   Clostre F, 2001, THERAPIE, V56, P595
   Clostre F, 1999, ANN PHARM FR S1, V57, p1S8
   Cybulska-Heinrich AK, 2012, MOL VIS, V18, P390
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Diamond BJ, 2000, ARCH PHYS MED REHAB, V81, P668, DOI 10.1016/S0003-9993(00)90052-2
   Drieu K, 2000, PROSTAG LEUKOTR ESS, V63, P293, DOI 10.1054/plef.2000.0217
   DroyLefaix MT, 1997, AGE, V20, P141, DOI 10.1007/s11357-997-0013-1
   DROYLEFAIX MT, 1995, TRANSPLANT P, V27, P2861
   DroyLefaix MT, 1995, INT J TISSUE REACT, V17, P93
   Dubey A-K, 2004, Kathmandu Univ Med J (KUMJ), V2, P225
   DUMONT E, 1995, METHOD FIND EXP CLIN, V17, P83
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Fernandez-Sanchez L, 2015, MOLECULES, V20, P13875, DOI 10.3390/molecules200813875
   Fies P, 2002, Wien Med Wochenschr, V152, P423, DOI 10.1046/j.1563-258X.2002.02066.x
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gonzalez Aguaviva B, 2011, MED NATUR, V5, P93
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Grosche J, 1997, J BRAIN RES, V38, P459
   Gupta N, 2013, OPEN OPHTHALMOL J, V7, P4, DOI 10.2174/1874364101307010004
   Harris A, 2018, ACTA OPHTHALMOL, V96, pe237, DOI 10.1111/aos.13530
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P1447, DOI 10.1167/iovs.07-1361
   Huckfeldt Rachel M, 2013, Int Ophthalmol Clin, V53, P105, DOI 10.1097/IIO.0b013e31829cf08d
   Ibarra M, 2003, PLANTA MED, V69, P995, DOI 10.1055/s-2003-45144
   Ilieva I, 2004, EXP EYE RES, V79, P181, DOI 10.1016/j.exer.2004.03.009
   IMO (Instituto de Microcirugia Ocular), GLAUC IMO
   Ishihara T, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050593
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jalali Subhadra, 2003, Community Eye Health, V16, P25
   Juarez CP, 2000, EUR J OPHTHALMOL, V10, P51, DOI 10.1177/112067210001000109
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Kang JM, 2018, CURR OPIN OPHTHALMOL, V29, P116, DOI 10.1097/ICU.0000000000000459
   Kaur S, 2018, INFLAMMOPHARMACOLOGY, V26, P87, DOI 10.1007/s10787-017-0396-2
   Kim SY, 1998, OPHTHALMOLOGICA, V212, P268, DOI 10.1159/000027305
   Kortuem K, 2000, INVEST OPHTH VIS SCI, V41, P3176
   Kose K, 1997, JPN J PHARMACOL, V75, P253, DOI 10.1254/jjp.75.253
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Kubota Y, 2006, J PHARM PHARMACOL, V58, P243, DOI 10.1211/jpp.58.2.0012
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   LEBUISSON DA, 1986, PRESSE MED, V15, P1556
   Lerman S, 1985, EFFECTS SUNLIGHT EYE, P79
   Lesk MR, 2008, CAN J OPHTHALMOL, V43, P351, DOI 10.3129/i08-057
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Li T, 2019, BRIT J PHARMACOL, V176, P801, DOI 10.1111/bph.14565
   Lin H, 2007, MICROSURG, V27, P673, DOI 10.1002/micr.20430
   Liu Xiao-Ping, 2009, Zhong Yao Cai, V32, P736
   Loskutova E, 2019, SURV OPHTHALMOL, V64, P195, DOI 10.1016/j.survophthal.2018.09.005
   Ma K, 2010, ACTA OPHTHALMOL, V88, P553, DOI 10.1111/j.1755-3768.2008.01486.x
   Maclennan KM, 2002, PROG NEUROBIOL, V67, P235, DOI 10.1016/S0301-0082(02)00015-1
   MacVie OP, 2005, BRIT J OPHTHALMOL, V89, P1378, DOI 10.1136/bjo.2005.072454
   Mahadevan S, 2008, J FOOD SCI, V73, pR14, DOI 10.1111/j.1750-3841.2007.00597.x
   Manisha Singh, 2012, Journal of Pharmacy Research, V5, P5028
   MARCOCCI L, 1994, BIOCHEM BIOPH RES CO, V201, P748, DOI 10.1006/bbrc.1994.1764
   McKenna DJ, 2001, ALTERN THER HEALTH M, V7, P70
   Menerath JM, 1997, J OCUL PHARMACOL TH, V13, P81, DOI 10.1089/jop.1997.13.81
   Mohanta TK, 2014, NAT PROD RES, V28, P746, DOI 10.1080/14786419.2013.879303
   Mojaverrostami S, 2018, ADV PHARM BULL, V8, P575, DOI 10.15171/apb.2018.066
   Montes P, 2015, CNS NEUROL DISORD-DR, V14, P132, DOI 10.2174/1871527314666150202151440
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nuhu A A, 2014, J APPL PHARM SCI, V4, P96
   Oh JH, 2013, CURR EYE RES, V38, P1072, DOI 10.3109/02713683.2013.804093
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Paasche G, 2000, OPHTHALMIC RES, V32, P229, DOI 10.1159/000055618
   Park JY, 2011, J MECH SCI TECHNOL, V25, P323, DOI [10.1007/s12206-010-1218-2, 10.3341/kjo.2011.25.5.323]
   Park SI, 2017, J PHARM PHARMACOL, V69, P334, DOI 10.1111/jphp.12691
   Park YH, 2004, J OCUL PHARMACOL TH, V20, P35
   Pescosolido N, 2014, PLANTA MED, V80, P249, DOI 10.1055/s-0033-1351074
   Pinazo-Duran MD, 2018, CURR NEUROPHARMACOL, V16, P903, DOI 10.2174/1570159X15666170705101910
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   PRITZHOHMEIER S, 1994, OPHTHALMIC RES, V26, P80, DOI 10.1159/000267396
   Qiu QH, 2012, CHINESE MED J-PEKING, V125, P2306, DOI 10.3760/cma.j.issn.0366-6999.2012.13.012
   Rahman K, 2007, CLIN INTERV AGING, V2, P219
   RAMASSAMY C, 1990, J PHARM PHARMACOL, V42, P785, DOI 10.1111/j.2042-7158.1990.tb07021.x
   Ranchon I, 1999, INVEST OPHTH VIS SCI, V40, P1191
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Roh MI, 2011, INVEST OPHTH VIS SCI, V52, P3825, DOI 10.1167/iovs.10-6797
   Rohowetz LJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113362
   Rojas C, 2015, CURR TOP NUTRACEUT R, V13, P105
   Rojas C, 2014, CURR TOP NUTRACEUT R, V12, P57
   Rojas P, 2009, NUTRITION, V25, P482, DOI 10.1016/j.nut.2008.10.013
   Sastre J, 1998, FREE RADICAL BIO MED, V24, P298, DOI 10.1016/S0891-5849(97)00228-1
   Schmidt KG, 2008, CURR NEUROPHARMACOL, V6, P164, DOI 10.2174/157015908784533851
   Shim SH, 2012, J MED FOOD, V15, P818, DOI 10.1089/jmf.2012.2241
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Spadiene A, 2013, CENT EUR J MED, V8, P736, DOI 10.2478/s11536-012-0146-1
   Sun BL, 2009, INT J NEUROSCI, V119, P995, DOI 10.1080/00207450902815842
   SZABO ME, 1995, OPHTHALMIC RES, V27, P102, DOI 10.1159/000267606
   Szabo ME, 1997, CLIN NEUROSCI, V4, P240
   SZABO ME, 1991, OPHTHALMIC RES, V23, P225, DOI 10.1159/000267107
   Tachikawa M, 2018, BIOL PHARM BULL, V41, P1384, DOI 10.1248/bpb.b18-00185
   Thiagarajan G, 2002, EXP EYE RES, V75, P421, DOI 10.1006/exer.2002.2035
   Tian JF, 2017, CURR VASC PHARMACOL, V15, P532, DOI 10.2174/1570161115666170713095545
   Huynh TP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/549174
   Varga E, 1999, J CARDIOVASC PHARM, V34, P711, DOI 10.1097/00005344-199911000-00013
   Vasudevan SK, 2011, INDIAN J OPHTHALMOL, V59, pS102, DOI 10.4103/0301-4738.73700
   Wang J, 2016, J SEP SCI, V39, P4158, DOI 10.1002/jssc.201600679
   Whiteside CL, 2005, CURR HYPERTENS REP, V7, P148, DOI 10.1007/s11906-005-0090-4
   Wilkinson JT, 2011, DRUGS, V71, P2421, DOI 10.2165/11596840-000000000-00000
   Wimpissinger B, 2007, ACTA OPHTHALMOL SCAN, V85, P445, DOI 10.1111/j.1600-0420.2007.00887.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, BLINDN VIS IMP PREV
   Wu YZ, 2008, PHYTOMEDICINE, V15, P164, DOI 10.1016/j.phymed.2007.12.002
   Xie ZG, 2007, CURR EYE RES, V32, P471, DOI 10.1080/02713680701257621
   Yin B, 2014, AM J CHINESE MED, V42, P769, DOI 10.1142/S0192415X14500499
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Yuan QJ, 2017, J ETHNOPHARMACOL, V195, P1, DOI 10.1016/j.jep.2016.12.005
   Zhao M, 2014, GENET MOL RES, V13, P220, DOI 10.4238/2014.January.14.1
   Zhao Y, 2018, COMPLEMENT THER MED, V40, P120, DOI 10.1016/j.ctim.2018.08.007
   Zhao Y, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/7931314
   Zhou YY, 2014, INT J OPHTHALMOL-CHI, V7, P8, DOI 10.3980/j.issn.2222-3959.2014.01.02
   Zhu ZW, 2015, CELL MOL NEUROBIOL, V35, P273, DOI 10.1007/s10571-014-0122-1
NR 144
TC 22
Z9 22
U1 1
U2 17
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD NOV
PY 2019
VL 85
IS 17
BP 1292
EP 1303
DI 10.1055/a-0947-5712
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA JU4CA
UT WOS:000501623800002
PM 31266069
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Dahbash, M
   Sella, R
   Megiddo-Barnir, E
   Nisgav, Y
   Tarasenko, N
   Weinberger, D
   Rephaeli, A
   Livnat, T
AF Dahbash, Mor
   Sella, Ruti
   Megiddo-Barnir, Elinor
   Nisgav, Yael
   Tarasenko, Nataly
   Weinberger, Dov
   Rephaeli, Ada
   Livnat, Tami
TI The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal
   Neovascularization in a Mouse Model
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AN7; bevacizumab; choroidal neovascularization; histone acetylation;
   histone deacetylase inhibitor; hypoxia; mouse model; retinal pigmented
   epithelium; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; DIETHYL PHOSPHATE AN-7; VALPROIC ACID;
   BUTYRIC-ACID; ANTICANCER; ACETYLATION; CHROMATIN; ANGIOGENESIS;
   PROTECTS; PROLIFERATION
AB Choroidal neovascularization (CNV) is a complication of age-related macular degeneration and a major contributing factor to vision loss. In this paper, we show that in a mouse model of laser-induced CNV, systemic administration of Butyroyloxymethyl-diethyl phosphate (AN7), a histone deacetylase inhibitor (HDACi), significantly reduced CNV area and vascular leakage, as measured by choroidal flatmounts and fluorescein angiography. CNV area reduction by systemic AN7 treatment was similar to that achieved by intravitreal bevacizumab treatment. The expression of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF-2), and the endothelial cells marker CD31, was lower in the AN7 treated group in comparison to the control group at the laser lesion site. In vitro, AN7 facilitated retinal pigmented epithelium (RPE) cells tight junctions' integrity during hypoxia, by protecting the hexagonal pattern of ZO-1 protein in the cell borders, hence reducing RPE permeability. In conclusion, systemic AN7 should be further investigated as a possible effective treatment for CNV.
C1 [Dahbash, Mor; Sella, Ruti; Tarasenko, Nataly; Weinberger, Dov; Rephaeli, Ada; Livnat, Tami] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Dahbash, Mor; Nisgav, Yael; Weinberger, Dov; Livnat, Tami] Felsenstein Med Res Ctr, Lab Eye Res, IL-49100 Petah Tiqwa, Israel.
   [Sella, Ruti; Megiddo-Barnir, Elinor; Weinberger, Dov] Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   [Tarasenko, Nataly; Rephaeli, Ada] Felsenstein Med Res Ctr, Lab Expt Pharmacol & Oncol, IL-49100 Petah Tiqwa, Israel.
   [Livnat, Tami] Sheba Med Ctr, Natl Hemophilia Ctr, Inst Thrombosis, IL-52621 Tel Hashomer, Israel.
   [Livnat, Tami] Sheba Med Ctr, Amalia Biron Res Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Rabin Medical Center; Tel Aviv University; Chaim Sheba Medical Center;
   Chaim Sheba Medical Center
RP Livnat, T (通讯作者)，Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.; Livnat, T (通讯作者)，Felsenstein Med Res Ctr, Lab Eye Res, IL-49100 Petah Tiqwa, Israel.; Livnat, T (通讯作者)，Sheba Med Ctr, Natl Hemophilia Ctr, Inst Thrombosis, IL-52621 Tel Hashomer, Israel.; Livnat, T (通讯作者)，Sheba Med Ctr, Amalia Biron Res Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel.
EM mor.dachbash@gmail.com; rutibd@gmail.com; emegiddo@gmail.com;
   ynisgav@gmail.com; nataliyt@post.tau.ac.il; dwin@zahav.net.il;
   Adarephaeli@gmail.com; tami.livnat@sheba.health.gov.il
OI Dahbash, Mor/0000-0002-7119-0943
FU Claire and Amedee Maratier Institute for the Study of Blindness and
   Visual Disorders, Sackler Faculty of Medicine, Tel Aviv University,
   Israel
FX This study was supported by a grant from the Claire and Amedee Maratier
   Institute for the Study of Blindness and Visual Disorders, Sackler
   Faculty of Medicine, Tel Aviv University, Israel. Mor Dahbash carried
   out this work as part of the requirements for an MSc degree from Sackler
   School of Medicine, Tel Aviv University, Israel. The authors would like
   to thank Dalia Sela for her professional assistance at all times.
CR Alsarraf O, 2014, EXP EYE RES, V127, P124, DOI 10.1016/j.exer.2014.07.012
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson KW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126592
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P526, DOI 10.1167/iovs.09-3903
   Blank-Porat D, 2007, CANCER LETT, V256, P39, DOI 10.1016/j.canlet.2007.05.011
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Casey R, 1997, AM J OPHTHALMOL, V124, P521, DOI 10.1016/S0002-9394(14)70868-2
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120587
   Chen B, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-78
   Chen PS, 2007, NEUROSCIENCE, V149, P203, DOI 10.1016/j.neuroscience.2007.06.053
   Chindasub P, 2013, INVEST OPHTH VIS SCI, V54, P96, DOI 10.1167/iovs.12-10850
   Clemson CM, 2011, BRIT J OPHTHALMOL, V95, P89, DOI 10.1136/bjo.2009.175356
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Desjardins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162596
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Fan J, 2013, INVEST OPHTH VIS SCI, V54, P4072, DOI 10.1167/iovs.12-11529
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/FMC.12.3, 10.4155/fmc.12.3]
   Gunda Venugopal, 2013, J Cancer Sci Ther, V5, P417
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695
   Kim JH, 2009, MOL PHARMACEUT, V6, P513, DOI 10.1021/mp800178b
   Kim SJ, 2010, EXP EYE RES, V91, P537, DOI 10.1016/j.exer.2010.07.011
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Mercurio C, 2010, PHARMACOL RES, V62, P18, DOI 10.1016/j.phrs.2010.02.010
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Nudelman A, 2005, J MED CHEM, V48, P1042, DOI 10.1021/jm049428p
   Nudelman A, 2001, EUR J MED CHEM, V36, P63, DOI 10.1016/S0223-5234(00)01199-5
   Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785
   Ratay ML, 2018, ACTA BIOMATER, V71, P261, DOI 10.1016/j.actbio.2018.03.002
   Rephaeli A, 2006, INVEST NEW DRUG, V24, P383, DOI 10.1007/s10637-006-6213-1
   Rephaeli A, 2005, INT J CANCER, V116, P226, DOI 10.1002/ijc.21030
   REPHAELI A, 2020, DDR, V50, P379, DOI DOI 10.1002/1098-2299(200007/08)50:3/4
   Rosato RR, 2004, EXPERT OPIN INV DRUG, V13, P21, DOI 10.1517/eoid.13.1.21.25283
   Rusnati M, 2007, CURR PHARM DESIGN, V13, P2025
   Schaap-Fogler M, 2017, J OCUL PHARMACOL TH, V33, P480, DOI 10.1089/jop.2016.0017
   Schwechter BR, 2007, INVEST OPHTH VIS SCI, V48, P2845, DOI 10.1167/iovs.06-1364
   Sung MS, 2018, INVEST OPHTH VIS SCI, V59, P3115, DOI 10.1167/iovs.18-23826
   Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092
   Tarasenko N, 2008, CLIN EXP METASTAS, V25, P703, DOI 10.1007/s10585-008-9179-x
   Tarasenko N, 2018, J CELL BIOCHEM, V119, P3417, DOI 10.1002/jcb.26512
   Tarasenko N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031393
   Tarasenko N, 2012, INVEST NEW DRUG, V30, P130, DOI 10.1007/s10637-010-9542-z
   Weinberger D, 2017, CURR EYE RES, V42, P1545, DOI 10.1080/02713683.2017.1349154
   Xu Q, 2016, AM J PHYSIOL-HEART C, V311, pH1139, DOI 10.1152/ajpheart.00156.2016
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhang H, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/250812
   Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231
NR 65
TC 4
Z9 4
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB 1
PY 2019
VL 20
IS 3
AR 714
DI 10.3390/ijms20030714
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HQ4WR
UT WOS:000462412500258
PM 30736437
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kishore, K
   Brown, JA
   Satar, JM
   Hahn, JM
   Bond, WI
AF Kishore, Kamal
   Brown, Jeffrey A.
   Satar, Jennifer M.
   Hahn, John M.
   Bond, William I.
TI Acute-onset postoperative endophthalmitis after cataract surgery and
   transzonular intravitreal triamcinolone-moxifloxacin
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID INTRACAMERAL CEFUROXIME; PROPHYLAXIS; INJECTION; OUTCOMES;
   PHACOEMULSIFICATION; ANTIBIOTICS; PREVENTION; SAFETY
AB Purpose: To report 4 cases of acute postoperative endophthalmitis (POE) after uneventful temporal clear corneal topical dropless cataract surgery involving intravitreal triamcinolone-moxifloxacin (TriMoxi).
   Setting: Private practice in Peoria, IL, USA.
   Design: Retrospective noncomparative case series.
   Methods: Charts of patients presenting with POE after an uneventful temporal clear corneal phacoemulsification with in-the bag implantation of a posterior chamber intraocular lens over a 15-month period were reviewed.
   Results: Patients presented with typical signs and symptoms of acute POE 3 to 14 days after cataract surgery. The POE resolved after 25-gauge pars plana vitrectomy and injection of intravitreal vancomycin, ceftazidime, and dexamethasone. Two of 4 eyes were culture-positive for coagulase-negative Staphylococcus. The corrected distance visual acuity at the last follow-up visit was 20/40 or better in 3 eyes, and 20/400 in 1 eye because of underlying atrophic age-related macular degeneration.
   Conclusion: Postoperative endophthalmitis can occur after dropless cataract surgery with intravitreal triamcinolone-moxifloxacin. (C) 2018 ASCRS and ESCRS
C1 [Kishore, Kamal; Satar, Jennifer M.] Illinois Retina & Eye Associates, Peoria, IL USA.
   [Kishore, Kamal; Brown, Jeffrey A.] Univ Illinois, Coll Med, Dept Surg, Peoria Campus, Peoria, IL 61656 USA.
   [Hahn, John M.] CGH Med Ctr, Dept Ophthalmol, Sterling, England.
   [Bond, William I.] Bond Eyes Associates, Pekin, IL USA.
   [Satar, Jennifer M.] West Virginia Sch Osteopath Med, Lewisburg, WV USA.
C3 University of Illinois System; University of Illinois Peoria
RP Kishore, K (通讯作者)，4505 N Rockwood Dr,Suite 1, Peoria, IL 61615 USA.
EM Kamal.kishore1963@gmail.com
OI Kishore, Kamal/0000-0002-0648-2413
CR AGUILAR HE, 1995, RETINA-J RET VIT DIS, V15, P428
   An JA, 2014, J CATARACT REFR SURG, V40, P1857, DOI 10.1016/j.jcrs.2014.02.037
   [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   Barry P, 2007, J CATARACT REFR SURG, V33, P978, DOI 10.1016/j.jcrs.2007.02.032
   Beselga D, 2014, EUR J OPHTHALMOL, V24, P516, DOI 10.5301/ejo.5000417
   Chang DF, 2015, J CATARACT REFR SURG, V41, P1300, DOI 10.1016/j.jcrs.2015.01.014
   Chiquet C, 2008, INVEST OPHTH VIS SCI, V49, P1971, DOI 10.1167/iovs.07-1377
   Ciulla TA, 2002, OPHTHALMOLOGY, V109, P13, DOI 10.1016/S0161-6420(01)00899-5
   Colleaux KM, 2000, CAN J OPHTHALMOL, V35, P373, DOI 10.1016/S0008-4182(00)80124-6
   Creuzot-Garcher C, 2016, OPHTHALMOLOGY, V123, P1414, DOI 10.1016/j.ophtha.2016.02.019
   Ehmann David S, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS155, DOI 10.1097/ICB.0000000000000389
   Espiritu CRG, 2007, J CATARACT REFR SURG, V33, P63, DOI 10.1016/j.jcrs.2006.09.019
   Gan IM, 2005, GRAEF ARCH CLIN EXP, V243, P1186, DOI 10.1007/s00417-005-1182-1
   George NK, 2018, OPHTHALMOL THER
   Gower EW, 2015, OPHTHALMOLOGY, V122, P1625, DOI 10.1016/j.ophtha.2015.04.036
   Haripriya A, 2017, OPHTHALMOLOGY, V124, P768, DOI 10.1016/j.ophtha.2017.01.026
   Hashemian H, 2016, J CURR OPHTHALMOL, V28, P101, DOI 10.1016/j.joco.2016.05.002
   Herretes S, 2005, AM J OPHTHALMOL, V140, P737, DOI 10.1016/j.ajo.2005.03.069
   Iyer Mohan N, 2005, Trans Am Ophthalmol Soc, V103, P76
   Jacobs DJ, 2013, CLIN OPHTHALMOL, V7, P1727, DOI 10.2147/OPTH.S44212
   Jensen MK, 2008, J CATARACT REFR SURG, V34, P1460, DOI 10.1016/j.jcrs.2008.05.045
   Katz G, 2015, GRAEF ARCH CLIN EXP, V253, P1729, DOI 10.1007/s00417-015-3009-z
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P303, DOI 10.1111/aos.12684
   Kindle T, 2018, J CATARACT REFR SURG, V44, P56, DOI 10.1016/j.jcrs.2017.10.040
   Lalwani GA, 2008, OPHTHALMOLOGY, V115, P473, DOI 10.1016/j.ophtha.2007.06.006
   Lindstrom RL, 2017, CURR PHARM DESIGN, V23, P558, DOI 10.2174/1381612822666161129150628
   lyer MN, 2005, T AM OPHTHAL SOC, V103, P81
   Mamalis N, 2006, J CATARACT REFR SURG, V32, P324, DOI 10.1016/j.jcrs.2006.01.065
   Mamalis N, 2008, J CATARACT REFR SURG, V34, P339, DOI 10.1016/j.jcrs.2008.01.001
   Miller JJ, 2005, AM J OPHTHALMOL, V139, P983, DOI 10.1016/j.ajo.2005.01.025
   Ng ALK, 2016, GRAEF ARCH CLIN EXP, V254, P1987, DOI 10.1007/s00417-016-3473-0
   Packer M, 2011, J CATARACT REFR SURG, V37, P1699, DOI 10.1016/j.jcrs.2011.06.018
   PEYMAN GA, 1977, BRIT J OPHTHALMOL, V61, P260, DOI 10.1136/bjo.61.4.260
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769
   Stringham JD, 2017, JAMA OPHTHALMOL, V135, P814, DOI 10.1001/jamaophthalmol.2017.1826
   Stringham JD, 2016, AM J OPHTHALMOL, V164, pVIII, DOI 10.1016/j.ajo.2016.02.001
   Tyson SL, 2017, CURR OPIN OPHTHALMOL, V28, P73, DOI 10.1097/ICU.0000000000000329
   Vasavada V, 2013, J CATARACT REFR SURG, V39, P563, DOI 10.1016/j.jcrs.2012.11.018
   Vieira IV, 2017, ARQ BRAS OFTALMOL, V80, P165, DOI 10.5935/0004-2749.20170040
   Witkin AJ, 2017, OPHTHALMOLOGY, V124, P583, DOI 10.1016/j.ophtha.2016.11.042
NR 40
TC 11
Z9 11
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD DEC
PY 2018
VL 44
IS 12
BP 1436
EP 1440
DI 10.1016/j.jcrs.2018.07.055
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HE0CW
UT WOS:000452935400006
PM 30241719
DA 2022-11-30
ER

PT J
AU Fang, LY
   Wang, C
   Li, ST
   Yan, J
   Chen, XD
   Rabbani, H
AF Fang, Leyuan
   Wang, Chong
   Li, Shutao
   Yan, Jun
   Chen, Xiangdong
   Rabbani, Hossein
TI Automatic classification of retinal three-dimensional optical coherence
   tomography images using principal component analysis network with
   composite kernels
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE optical coherence tomography; principal component analysis network;
   composite kernel; retinal disease; image classification
ID DIABETIC MACULAR EDEMA; EXTREME LEARNING-MACHINE; OCT IMAGES;
   DEGENERATION; RETINOPATHY; AMD
AB We present an automatic method, termed as the principal component analysis network with composite kernel (PCANet-CK), for the classification of three-dimensional (3-D) retinal optical coherence tomography (OCT) images. Specifically, the proposed PCANet-CK method first utilizes the PCANet to automatically learn features from each B-scan of the 3-D retinal OCT images. Then, multiple kernels are separately applied to a set of very important features of the B-scans and these kernels are fused together, which can jointly exploit the correlations among features of the 3-D OCT images. Finally, the fused (composite) kernel is incorporated into an extreme learning machine for the OCT image classification. We tested our proposed algorithm on two real 3-D spectral domain OCT (SD-OCT) datasets (of normal subjects and subjects with the macular edema and age-related macular degeneration), which demonstrated its effectiveness. (C) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Fang, Leyuan; Wang, Chong; Li, Shutao; Yan, Jun] Hunan Univ, Coll Elect & Informat Engn, Changsha, Hunan, Peoples R China.
   [Chen, Xiangdong] Hunan Univ Chinese Med, Dept Ophthalmol, Affiliated Hosp 1, Changsha, Hunan, Peoples R China.
   [Rabbani, Hossein] Isfahan Univ Med Sci, Med Image & Signal Proc Res Ctr, Esfahan, Iran.
C3 Hunan University; Hunan University of Chinese Medicine; Isfahan
   University Medical Science
RP Li, ST (通讯作者)，Hunan Univ, Coll Elect & Informat Engn, Changsha, Hunan, Peoples R China.
EM shutao_li@hnu.edu.cn
RI Rabbani, Hossein/O-4987-2019; Rabbani, Hossein/H-7515-2014
OI Rabbani, Hossein/0000-0002-0551-3636; Rabbani,
   Hossein/0000-0002-0551-3636; Wang, Chong/0000-0003-0022-0217
FU National Natural Science Foundation of China [61325007]; National
   Natural Science Foundation [61771192, 61471167]; National Natural
   Science Foundation for Young Scientist of China [61501180]; China
   Postdoctoral Science Foundation funded Project [2017T100597]
FX This paper was supported by the National Natural Science Foundation of
   China for Distinguished Young Scholars under Grant Nos. 61325007, the
   National Natural Science Foundation under Grant Nos. 61771192 and
   61471167, the National Natural Science Foundation for Young Scientist of
   China under Grant No. 61501180, and China Postdoctoral Science
   Foundation funded Project No. 2017T100597.
CR Adler DC, 2009, OPT EXPRESS, V17, P784, DOI 10.1364/OE.17.000784
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bengio Y, 2013, IEEE T PATTERN ANAL, V35, P1798, DOI 10.1109/TPAMI.2013.50
   Chan TH, 2015, IEEE T IMAGE PROCESS, V24, P5017, DOI 10.1109/TIP.2015.2475625
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Fang LY, 2018, NEUROCOMPUTING, V273, P171, DOI 10.1016/j.neucom.2017.08.019
   Fang LY, 2017, IEEE T INSTRUM MEAS, V66, P1646, DOI 10.1109/TIM.2017.2664480
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fang LY, 2017, IEEE T MED IMAGING, V36, P407, DOI 10.1109/TMI.2016.2611503
   Fang LY, 2015, IEEE T GEOSCI REMOTE, V53, P6663, DOI 10.1109/TGRS.2015.2445767
   Fang LY, 2015, IEEE T GEOSCI REMOTE, V53, P4186, DOI 10.1109/TGRS.2015.2392755
   Gao SS, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.076010
   Hassan B, 2016, J OPT SOC AM A, V33, P455, DOI 10.1364/JOSAA.33.000455
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Hirai FE, 2008, AM J OPHTHALMOL, V145, P700, DOI 10.1016/j.ajo.2007.11.019
   Hitzenberger CK, 2003, OPT EXPRESS, V11, P2753, DOI 10.1364/OE.11.002753
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang GB, 2006, NEUROCOMPUTING, V70, P489, DOI 10.1016/j.neucom.2005.12.126
   Huang GB, 2012, IEEE T SYST MAN CY B, V42, P513, DOI 10.1109/TSMCB.2011.2168604
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Liu XW, 2015, NEUROCOMPUTING, V149, P253, DOI 10.1016/j.neucom.2013.09.072
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Mogensen M, 2009, J BIOPHOTONICS, V2, P442, DOI 10.1002/jbio.200910020
   Muller KR, 2001, IEEE T NEURAL NETWOR, V12, P181, DOI 10.1109/72.914517
   Prentasic P, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.075008
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Sugmk J, 2014, 7 2014 BIOM ENG INT, P1, DOI DOI 10.1109/BMEICON.2014.7017441
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Tearney GJ, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192697
   Venhuizen FG, 2015, PROC SPIE, V9414, DOI 10.1117/12.2081521
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Zawadzki RJ, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772658
   Zysk AM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2793736
NR 44
TC 13
Z9 14
U1 4
U2 17
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD NOV
PY 2017
VL 22
IS 11
AR 116011
DI 10.1117/1.JBO.22.11.116011
PG 10
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA FQ0RL
UT WOS:000418064300020
PM 29188661
OA gold
DA 2022-11-30
ER

PT J
AU Crauste, C
   Vigor, C
   Brabet, P
   Picq, M
   Lagarde, M
   Hamel, C
   Durand, T
   Vercauteren, J
AF Crauste, Celine
   Vigor, Claire
   Brabet, Philippe
   Picq, Madeleine
   Lagarde, Michel
   Hamel, Christian
   Durand, Thierry
   Vercauteren, Joseph
TI Synthesis and Evaluation of Polyunsaturated Fatty Acid-Phenol Conjugates
   as Anti-Carbonyl-Stress Lipophenols
SO EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
DE Medicinal chemistry; Drug design; Fatty acids; Lipids; Polyphenols;
   Carbonyl stress
ID OXIDATIVE STRESS; BIOLOGICAL-ACTIVITIES; LIPOFUSCIN; DHA;
   PHLOROGLUCINOL; DISEASE; BISRETINOIDS; ACCUMULATION; DEGENERATION;
   POLYPHENOLS
AB Carbonyl and oxidative stress play a substantial role in various neurodegenerative diseases such as Alzheimer's Disease, Parkinsonism, and Age-related Macular Degeneration (AMD). In retinal pathologies, both mechanisms are involved in the transformation of all-trans-retinal (AtR, reactive aldehyde) into bis-retinoid A2E. Since an accumulation of AtR and A2E contributes to photoreceptor apoptosis, we designed and synthesized a series of O-alkylated resorcinol derivatives featuring enhanced anti-carbonyl-stress properties. Additionally, these phenolic structures are linked to a poly-unsaturated fatty acid such as docosahexaenoic acid (C22:6 n-3; DHA) or to a lysophosphatidylcholine-DHA conjugate, in order to specifically increase their bioavailability, and thus, to target the retina. Selective syntheses of phloroglucinol-DHA, resveratrol-DHA, and phloroglucinol-DHA-PC (PC = phosphatidylcholine) conjugates using silyl protecting group strategies are presented, along with results of testing that demonstrate their ability to lower AtR toxicity in ARPE-19 cell lines.
C1 [Crauste, Celine; Vigor, Claire; Durand, Thierry; Vercauteren, Joseph] Fac Pharm Montpellier, IBMM, CNRS, UMR5247,UM1,UM2,ENSCM, F-34093 Montpellier, France.
   [Brabet, Philippe; Hamel, Christian] INSERM, U1051, Inst Neurosci Montpellier, UM1,UM2, F-34295 Montpellier, France.
   [Picq, Madeleine; Lagarde, Michel] Univ Lyon, INSERM, UMR CarMeN 1060, INSA Lyon,IMBL, F-69621 Villeurbanne, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); Ecole nationale superieure de chimie de Montpellier;
   Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Institut
   National des Sciences Appliquees de Lyon - INSA Lyon
RP Vercauteren, J (通讯作者)，Fac Pharm Montpellier, IBMM, CNRS, UMR5247,UM1,UM2,ENSCM, 15 Av C Flahault, F-34093 Montpellier, France.
EM jvercauteren@univ-montp1.fr
RI Vercauteren, Joseph/AAF-7151-2019; Brabet, Philippe/AAO-8522-2020
OI Vercauteren, Joseph/0000-0002-0201-1235; Brabet,
   Philippe/0000-0003-2739-1622; Crauste, Celine/0000-0002-5714-8749;
   VIGOR, Claire/0000-0002-1569-0425
FU University of Montpellier; Centre National de la Recherche Scientifique
   (CNRS)
FX The authors thank Dr Eric Spokas of Sebastian, FL, for proofreading the
   manuscript. The University of Montpellier and the Centre National de la
   Recherche Scientifique (CNRS) are thanked for their support.
CR Altenburg JD, 2011, BIOCHEM BIOPH RES CO, V411, P427, DOI 10.1016/j.bbrc.2011.06.172
   [Anonymous], 2011, ANGEW CHEM, V123, P610
   Bradley MO, 2001, J CONTROL RELEASE, V74, P233, DOI 10.1016/S0168-3659(01)00321-2
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Dangles O, 2012, CURR ORG CHEM, V16, P692, DOI 10.2174/138527212799957995
   Danihelova M, 2012, ACTA CHIM SLOVACA, V5, P59, DOI 10.2478/v10188-012-0010-6
   Deffieux D, 2009, TETRAHEDRON LETT, V50, P6567, DOI 10.1016/j.tetlet.2009.09.045
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Gallardo-Godoy A, 2005, J MED CHEM, V48, P2407, DOI 10.1021/jm0493109
   Gamez-Meza N, 2003, FOOD RES INT, V36, P721, DOI 10.1016/S0963-9969(03)00052-8
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Guil-Guerrero JL, 2007, J AM OIL CHEM SOC, V84, P357, DOI 10.1007/s11746-007-1041-9
   Harris RA, 2011, CNS NEUROL DISORD-DR, V10, P82
   Harvey KA, 2010, BIOORGAN MED CHEM, V18, P1866, DOI 10.1016/j.bmc.2010.01.045
   Jayasundera KP, 2007, TETRAHEDRON, V63, P10077, DOI 10.1016/j.tet.2007.07.042
   Jones RJ, 2008, CANCER CHEMOTH PHARM, V61, P435, DOI 10.1007/s00280-007-0486-8
   Kampa M, 2011, J PHARMACOL EXP THER, V337, P24, DOI 10.1124/jpet.110.177246
   Kang KA, 2006, J CELL BIOCHEM, V97, P609, DOI 10.1002/jcb.20668
   Kim MM, 2010, FOOD CHEM TOXICOL, V48, P2925, DOI 10.1016/j.fct.2010.07.029
   Liu HY, 2012, J AGR FOOD CHEM, V60, P1326, DOI 10.1021/jf204112f
   Lo CY, 2011, J FOOD SCI, V76, pH90, DOI 10.1111/j.1750-3841.2011.02067.x
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Mata NL, 2000, INVEST OPHTH VIS SCI, V41, pS144
   MEDINA AR, 1995, J AM OIL CHEM SOC, V72, P575, DOI 10.1007/BF02638859
   Nicolosi G, 2002, J MOL CATAL B-ENZYM, V16, P223, DOI 10.1016/S1381-1177(01)00066-2
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Picq M, 2010, MOL NEUROBIOL, V42, P48, DOI 10.1007/s12035-010-8131-7
   Quideau S, 2011, ANGEW CHEM INT EDIT, V50, P586, DOI 10.1002/anie.201000044
   Shenvi RA, 2010, ORG LETT, V12, P3548, DOI 10.1021/ol101410g
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suh M, 1996, LIPIDS, V31, P61, DOI 10.1007/BF02522412
   Teng RW, 2005, BIOCATAL BIOTRANSFOR, V23, P109, DOI 10.1080/1024220500132508
   THIES F, 1994, AM J PHYSIOL-REG I, V267, pR1273, DOI 10.1152/ajpregu.1994.267.5.R1273
   THOMSEN I, 1991, ACTA CHEM SCAND, V45, P539, DOI 10.3891/acta.chem.scand.45-0539
   Vauzour D, 2010, NUTRIENTS, V2, P1106, DOI 10.3390/nu2111106
   Vercauteren J., 2008, PCTIB2008054818
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Zhong Y, 2011, J AGR FOOD CHEM, V59, P6526, DOI 10.1021/jf201050j
   Zhu Q, 2009, CHEM RES TOXICOL, V22, P1721, DOI 10.1021/tx900221s
NR 43
TC 23
Z9 24
U1 2
U2 40
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1434-193X
EI 1099-0690
J9 EUR J ORG CHEM
JI Eur. J. Org. Chem.
PD JUL
PY 2014
VL 2014
IS 21
BP 4548
EP 4561
DI 10.1002/ejoc.201402282
PG 14
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Chemistry
GA AL9WF
UT WOS:000339493400014
OA Green Published
DA 2022-11-30
ER

PT J
AU Poljsak, B
   Fink, R
AF Poljsak, Borut
   Fink, Rok
TI The Protective Role of Antioxidants in the Defence against
   ROS/RNS-Mediated Environmental Pollution
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID INDUCED OXIDATIVE STRESS; INDUCED LUNG INJURY; INDUCED
   LIPID-PEROXIDATION; SULFUR-DIOXIDE INHALATION; TOTAL-BODY IRRADIATION;
   INDUCED DNA-DAMAGE; TETRACHLORIDE-INDUCED HEPATOTOXICITY; VITAMIN-E
   SUPPLEMENTATION; MEMBRANE-BOUND ATPASES; CARBON-TETRACHLORIDE
AB Overproduction of reactive oxygen and nitrogen species can result from exposure to environmental pollutants, such as ionising and nonionising radiation, ultraviolet radiation, elevated concentrations of ozone, nitrogen oxides, sulphur dioxide, cigarette smoke, asbestos, particulate matter, pesticides, dioxins and furans, polycyclic aromatic hydrocarbons, and many other compounds present in the environment. It appears that increased oxidative/nitrosative stress is often neglected mechanism by which environmental pollutants affect human health. Oxidation of and oxidative damage to cellular components and biomolecules have been suggested to be involved in the aetiology of several chronic diseases, including cancer, cardiovascular disease, cataracts, age-related macular degeneration, and aging. Several studies have demonstrated that the human body can alleviate oxidative stress using exogenous antioxidants. However, not all dietary antioxidant supplements display protective effects, for example, beta-carotene for lung cancer prevention in smokers or tocopherols for photooxidative stress. In this review, we explore the increases in oxidative stress caused by exposure to environmental pollutants and the protective effects of antioxidants.
C1 [Poljsak, Borut; Fink, Rok] Univ Ljubljana, Fac Hlth Sci, SI-1000 Ljubljana, Slovenia.
C3 University of Ljubljana
RP Fink, R (通讯作者)，Univ Ljubljana, Fac Hlth Sci, Zdravstvena Pot 5, SI-1000 Ljubljana, Slovenia.
EM rok.fink@zf.uni-lj.si
OI Fink, Assoc. Prof. Dr. Rok/0000-0003-1554-5030
CR Adaramoye O A, 2009, Pak J Biol Sci, V12, P1146, DOI 10.3923/pjbs.2009.1146.1151
   Afaq F, 2002, SKIN PHARMACOL APPL, V15, P297, DOI 10.1159/000064533
   Akturk O, 2006, CELL BIOL TOXICOL, V22, P455, DOI 10.1007/s10565-006-0138-5
   Albanes D, 1999, AM J CLIN NUTR, V69, p1345S
   Almurshed KS, 2006, SAUDI MED J, V27, P1804
   Alsharif NZ, 2004, BASIC CLIN PHARMACOL, V95, P131, DOI 10.1111/j.1742-7843.2004.950305.x
   Altuntas I, 2002, HUM EXP TOXICOL, V21, P681, DOI 10.1191/0960327102ht304oa
   Ames BN, 2004, ANN NY ACAD SCI, V1019, P406, DOI 10.1196/annals.1297.073
   AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251
   Andrade ER, 2011, FOOD CHEM TOXICOL, V49, P1026, DOI 10.1016/j.fct.2011.01.011
   Annadurai T, 2011, J PHYSIOL BIOCHEM, V67, P519, DOI 10.1007/s13105-011-0097-z
   AONO M, 1995, PLANT PHYSIOL, V107, P645, DOI 10.1104/pp.107.2.645
   Aranda M, 2010, J PINEAL RES, V49, P78, DOI 10.1111/j.1600-079X.2010.00769.x
   Arguello-Garcia R, 2010, J AGR FOOD CHEM, V58, P11226, DOI 10.1021/jf102423w
   Aust O, 2005, INT J VITAM NUTR RES, V75, P54, DOI 10.1024/0300-9831.75.1.54
   Aycicek A, 2005, PEDIATR INT, V47, P635, DOI 10.1111/j.1442-200x.2005.02137.x
   Bachowski S, 1998, TOXICOL APPL PHARM, V150, P301, DOI 10.1006/taap.1998.8372
   Bagchi D, 1996, TOXICOLOGY, V112, P57, DOI 10.1016/0300-483X(96)03350-1
   Bagchi D, 1995, TOXICOLOGY, V104, P129, DOI 10.1016/0300-483X(95)03156-A
   Ballinger CA, 2005, FREE RADICAL BIO MED, V38, P515, DOI 10.1016/j.freeradbiomed.2004.11.009
   Banerjee K K, 1998, Indian J Public Health, V42, P20
   Banerjee S, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-21
   Banudevi S, 2006, FOOD CHEM TOXICOL, V44, P2040, DOI 10.1016/j.fct.2006.07.017
   Basu S, 2003, TOXICOLOGY, V189, P113, DOI 10.1016/S0300-483X(03)00157-4
   BEEHLER BC, 1992, CARCINOGENESIS, V13, P2003, DOI 10.1093/carcin/13.11.2003
   Benkovic V, 2009, ARH HIG RADA TOKSIKO, V60, P129, DOI 10.2478/10004-1254-60-2009-1908
   Berbee M, 2009, RADIAT RES, V171, P596, DOI 10.1667/RR1632.1
   Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984
   Bhadauria M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/235358
   Bjelakovic G, 2004, LANCET, V364, P1219, DOI 10.1016/S0140-6736(04)17138-9
   Bloomer RJ, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-39
   Bohm F, 2001, J PHOTOCH PHOTOBIO B, V64, P176, DOI 10.1016/S1011-1344(01)00221-4
   Bonina F, 1996, INT J PHARMACEUT, V145, P87, DOI 10.1016/S0378-5173(96)04728-X
   Boveris A, 1982, FREE RADIC BIOL, P65
   BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P173, DOI 10.3109/15563659309000384
   Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8
   BUS JS, 1976, ENVIRON HEALTH PERSP, V16, P139, DOI 10.2307/3428594
   Carr AC, 2000, BIOCHEM J, V346, P491, DOI 10.1042/0264-6021:3460491
   Chang Jun-Rui, 2006, Wei Sheng Yan Jiu, V35, P653
   Chavez Jennifier, 2007, Am J Ther, V14, P189
   Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070
   Cherubini A, 2005, CURR PHARM DESIGN, V11, P2017, DOI 10.2174/1381612054065783
   Cho BO, 2011, J AGR FOOD CHEM, V59, P11442, DOI 10.1021/jf2021804
   Cho S, 2010, DERMATOLOGY, V221, P160, DOI 10.1159/000305548
   CHUNG FL, 1993, ANN NY ACAD SCI, V686, P186, DOI 10.1111/j.1749-6632.1993.tb39174.x
   Chung FL, 1999, P SOC EXP BIOL MED, V220, P244, DOI 10.1046/j.1525-1373.1999.d01-42.x
   Ciftci O, 2011, TOXICOL IND HEALTH, V27, P447, DOI 10.1177/0748233710388452
   Ciftci O, 2010, IMMUNOPHARM IMMUNOT, V32, P99, DOI 10.3109/08923970903164318
   COMBS GF, 1983, J NUTR, V113, P538, DOI 10.1093/jn/113.3.538
   Cross CE, 2002, AM J RESP CRIT CARE, V166, pS44, DOI 10.1164/rccm.2206015
   Cutler R. G., 2003, OXIDATIVE STRESS AGI
   Cutler R. G., 2003, CRITICAL REV OXIDATI
   Cavalli VLDO, 2013, FREE RADICAL BIO MED, V65, P335, DOI 10.1016/j.freeradbiomed.2013.06.043
   Demirel R, 2009, EUR J GEN MED, V6, P20, DOI [10.29333/ejgm/82631, DOI 10.29333/EJGM/82631]
   Dietrich M, 2003, AM J CLIN NUTR, V77, P160, DOI 10.1093/ajcn/77.1.160
   El-Missiry MA, 2007, ECOTOX ENVIRON SAFE, V66, P278, DOI 10.1016/j.ecoenv.2006.03.008
   Elumalai P, 2009, REPROD TOXICOL, V27, P41, DOI 10.1016/j.reprotox.2008.11.053
   Ergonul Z, 2007, INHAL TOXICOL, V19, P161, DOI 10.1080/08958370601051883
   Eroglu S, 2013, BIOL RES, V46, P33, DOI 10.4067/S0716-97602013000100005
   Etlik O, 1995, ENVIRON RES, V71, P25, DOI 10.1006/enrs.1995.1063
   Etlik Ozdal, 1997, Journal of Basic and Clinical Physiology and Pharmacology, V8, P31
   Ewert DL, 2012, HEARING RES, V285, P29, DOI 10.1016/j.heares.2012.01.013
   Fattman CL, 2006, FREE RADICAL BIO MED, V40, P601, DOI 10.1016/j.freeradbiomed.2005.09.030
   Fechter LD, 2005, ENVIRON TOXICOL PHAR, V19, P543, DOI 10.1016/j.etap.2004.12.017
   Floyd R. A., 1995, OXYGEN PARADOX, P89
   Friedberg EC, 1995, DNA REPAIR MUTAGENES
   Furukawa A, 2003, BIOCHEM PHARMACOL, V66, P1769, DOI 10.1016/S0006-2952(03)00541-0
   Garmyn M, 1995, Exp Dermatol, V4, P104, DOI 10.1111/j.1600-0625.1995.tb00231.x
   GLASS M, 1985, J APPL PHYSIOL, V59, P619, DOI 10.1152/jappl.1985.59.2.619
   Goel A, 2005, CHEM-BIOL INTERACT, V156, P131, DOI 10.1016/j.cbi.2005.08.004
   Gonzalez-Flecha Beatriz, 2004, Molecular Aspects of Medicine, V25, P169, DOI 10.1016/j.mam.2004.02.017
   Greenwell LL, 2003, J BIOSCIENCES, V28, P101, DOI 10.1007/BF02970139
   Grievink L., 1997, European Respiratory Journal Supplement, V10, p229S
   Grievink L, 1999, AM J EPIDEMIOL, V149, P306, DOI 10.1093/oxfordjournals.aje.a009814
   Grievink L, 2000, CLIN EXP ALLERGY, V30, P1344, DOI 10.1046/j.1365-2222.2000.00835.x
   Guler G, 2008, INT J RADIAT BIOL, V84, P669, DOI 10.1080/09553000802241747
   Gultekin F, 2001, ARCH TOXICOL, V75, P88, DOI 10.1007/s002040100219
   Guney M, 2007, TOXICOL IND HEALTH, V23, P411, DOI 10.1177/0748233707080906
   GUTH DJ, 1986, TOXICOL APPL PHARM, V84, P304, DOI 10.1016/0041-008X(86)90138-9
   Guthrie OW, 2012, INT J NEUROSCI, V122, P757, DOI 10.3109/00207454.2012.721828
   HACKNEY JD, 1981, J TOXICOL ENV HEALTH, V7, P383, DOI 10.1080/15287398109529989
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Hassan MH, 2012, TOXICOL IND HEALTH, V28, P428, DOI 10.1177/0748233711413801
   HASSOUN E, 1993, COMP BIOCHEM PHYS C, V104, P427, DOI 10.1016/0742-8413(93)90013-B
   Hassoun EA, 2003, COMP BIOCHEM PHYS C, V135, P119, DOI 10.1016/S1532-0456(03)00082-6
   HATCH GE, 1995, AM J CLIN NUTR, V61, p625S, DOI 10.1093/ajcn/61.3.625S
   Hatzis C, 2006, ENVIRON SCI TECHNOL, V40, P2805, DOI 10.1021/es0518732
   Hei TK, 2006, INHAL TOXICOL, V18, P985, DOI 10.1080/08958370600835310
   Heinrich U, 2003, J NUTR, V133, P98, DOI 10.1093/jn/133.1.98
   Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3
   Hsu YW, 2010, FOOD CHEM TOXICOL, V48, P1644, DOI 10.1016/j.fct.2010.03.039
   Hu Y, 2011, PHYTOMEDICINE, V18, P970, DOI 10.1016/j.phymed.2011.02.012
   Humbert PG, 2003, EXP DERMATOL, V12, P237, DOI 10.1034/j.1600-0625.2003.00008.x
   Hung YC, 2006, BIOL PHARM BULL, V29, P2284, DOI 10.1248/bpb.29.2284
   HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5
   Ilhan A, 2004, CLIN CHIM ACTA, V340, P153, DOI 10.1016/j.cccn.2003.10.012
   Ishida T, 2009, BIOL PHARM BULL, V32, P876, DOI 10.1248/bpb.32.876
   Jagetia GC, 2007, ADV EXP MED BIOL, V595, P301
   Jajte J, 2001, MUTAT RES-FUND MOL M, V483, P57, DOI 10.1016/S0027-5107(01)00230-5
   Jha J C, 2007, Kathmandu Univ Med J (KUMJ), V5, P511
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y
   Karatas F, 2008, BIOL TRACE ELEM RES, V126, P214, DOI 10.1007/s12011-008-8202-z
   Karbownik M, 2000, P SOC EXP BIOL MED, V225, P9, DOI 10.1046/j.1525-1373.2000.22502.x
   Katiyar Santosh K., 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P234, DOI 10.2174/1568008033340171
   Katiyar SK, 2010, CANCER PREV RES, V3, P179, DOI 10.1158/1940-6207.CAPR-09-0044
   Katiyar SK, 2000, ARCH DERMATOL, V136, P989, DOI 10.1001/archderm.136.8.989
   Kawai Y, 2008, CHEM RES TOXICOL, V21, P1407, DOI 10.1021/tx800069e
   Kelly FJ, 2003, AMINO ACIDS, V25, P375, DOI 10.1007/s00726-003-0024-x
   Kelly FJ, 1997, BIOCHEM J, V325, P95, DOI 10.1042/bj3250095
   Kelly FJ, 1996, AM J RESP CRIT CARE, V154, P1700, DOI 10.1164/ajrccm.154.6.8970358
   Kesavachandran C, 2006, REDOX REP, V11, P159, DOI 10.1179/135100006X116673
   Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635
   Khopde SM, 1998, FREE RADICAL BIO MED, V25, P66, DOI 10.1016/S0891-5849(98)00046-X
   KIENAST K, 1994, ARCH ENVIRON HEALTH, V49, P246, DOI 10.1080/00039896.1994.9937474
   Kilciksiz S, 2011, J BUON, V16, P154
   Kilciksiz S, 2008, ACTA MED OKAYAMA, V62, P403
   Kisby GE, 2009, J AGROMEDICINE, V14, P206, DOI 10.1080/10599240902824042
   Klaunig JE, 1995, TOXICOL LETT, V82-3, P683, DOI 10.1016/0378-4274(95)03514-1
   KLIGMAN LH, 1986, PHOTODERMATOLOGY, V3, P215
   Kohen R, 1985, Free Radic Res Commun, V1, P79, DOI 10.3109/10715768509056540
   KORBASHI P, 1986, J BIOL CHEM, V261, P2472
   Kose E, 2012, ANDROLOGIA, V44, P342, DOI 10.1111/j.1439-0272.2011.01187.x
   Kovacic P, 2010, J RECEPT SIG TRANSD, V30, P214, DOI 10.3109/10799893.2010.488650
   Krishnamoorthy G, 2007, REPROD TOXICOL, V23, P239, DOI 10.1016/j.reprotox.2006.12.004
   LangleyEvans SC, 1996, COMP BIOCHEM PHYS C, V114, P89, DOI 10.1016/0742-8413(96)00012-6
   LAST JA, 1994, ENVIRON HEALTH PERSP, V102, P179, DOI 10.2307/3432236
   Latchoumycandane C, 2002, J APPL TOXICOL, V22, P345, DOI 10.1002/jat.866
   Lee HS, 2010, J MICROBIOL BIOTECHN, V20, P1331, DOI 10.4014/jmb.1002.03010
   Lee J, 2000, P SOC EXP BIOL MED, V223, P170, DOI 10.1046/j.1525-1373.2000.22323.x
   Leustik M, 2008, AM J PHYSIOL-LUNG C, V295, pL733, DOI 10.1152/ajplung.90240.2008
   Lewczuk Ewa, 1992, Medycyna Pracy, V43, P335
   Li G, 1996, AM J PATHOL, V148, P1113
   Lorito G, 2006, Acta Otorhinolaryngol Ital, V26, P133
   Lotito SB, 2006, FREE RADICAL BIO MED, V41, P1727, DOI 10.1016/j.freeradbiomed.2006.04.033
   Lu YP, 2008, CANCER RES, V68, P2523, DOI 10.1158/0008-5472.CAN-07-5955
   Luo Su-Qiong, 1995, Biomedical and Environmental Sciences, V8, P54
   Manikandan S, 2005, BIOL PHARM BULL, V28, P2327, DOI 10.1248/bpb.28.2327
   Manikandan S, 2005, PHARMACOL RES, V52, P467, DOI 10.1016/j.phrs.2005.07.007
   Marczynski B, 2000, MUTAT RES-GEN TOX EN, V468, P195, DOI 10.1016/S1383-5718(00)00053-X
   Masaki H, 2010, J DERMATOL SCI, V58, P85, DOI 10.1016/j.jdermsci.2010.03.003
   Mayne ST, 1999, AM J CLIN NUTR, V69, P1292
   McArdle F, 2004, AM J CLIN NUTR, V80, P1270, DOI 10.1093/ajcn/80.5.1270
   McArdle F, 2002, FREE RADICAL BIO MED, V33, P1355, DOI 10.1016/S0891-5849(02)01042-0
   Medina-Campos ON, 2007, FOOD CHEM TOXICOL, V45, P2030, DOI 10.1016/j.fct.2007.05.002
   Meng ZQ, 2004, ENVIRON RES, V96, P298, DOI 10.1016/j.envres.2004.04.008
   Meng ZQ, 2003, ENVIRON RES, V93, P285, DOI 10.1016/S0013-9351(03)00045-8
   MENZEL DB, 1994, TOXICOL LETT, V72, P269, DOI 10.1016/0378-4274(94)90038-8
   MIDGETTE AS, 1993, AM J EPIDEMIOL, V137, P521, DOI 10.1093/oxfordjournals.aje.a116705
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   MOHSENIN V, 1987, AM REV RESPIR DIS, V136, P1408, DOI 10.1164/ajrccm/136.6.1408
   MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143
   Mudway IS, 1996, FREE RADICAL RES, V25, P499, DOI 10.3109/10715769609149072
   Murugesan P, 2005, FREE RADICAL RES, V39, P1259, DOI 10.1080/10715760500308154
   Musaev A V, 2004, Vopr Kurortol Fizioter Lech Fiz Kult, P19
   Nair Cherupally Krishnan K., 2003, Indian Journal of Experimental Biology, V41, P1365
   Nair GG, 2010, CANCER BIOTHER RADIO, V25, P629, DOI 10.1089/cbr.2010.0803
   Naziroglu M, 2009, INT J RADIAT BIOL, V85, P680, DOI 10.1080/09553000903009530
   Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752
   Neuhouser ML, 2003, CANCER EPIDEM BIOMAR, V12, P350
   Noaman E, 2002, BIOL TRACE ELEM RES, V86, P55, DOI 10.1385/BTER:86:1:55
   Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9
   Olgun S, 2006, MOL CELL BIOCHEM, V290, P137, DOI 10.1007/s11010-006-9178-7
   Oliva M, 2012, ECOTOX ENVIRON SAFE, V75, P151, DOI 10.1016/j.ecoenv.2011.08.017
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ozguner F, 2005, TOXICOL IND HEALTH, V21, P223, DOI 10.1191/0748233705th228oa
   Ozguner F, 2006, MOL CELL BIOCHEM, V282, P83, DOI 10.1007/s11010-006-1267-0
   Ozgur E, 2010, INT J RADIAT BIOL, V86, P935, DOI 10.3109/09553002.2010.496029
   Ozturk F, 2009, BRIT J NUTR, V102, P1767, DOI 10.1017/S0007114509991322
   Packer L, 2002, SKIN PHARMACOL APPL, V15, P282, DOI 10.1159/000064531
   Packer L, 2001, J NUTR, V131, p369S, DOI 10.1093/jn/131.2.369S
   Possamai FP, 2010, ENVIRON TOXICOL PHAR, V30, P175, DOI 10.1016/j.etap.2010.05.006
   Palozza P, 1998, NUTR REV, V56, P257, DOI 10.1111/j.1753-4887.1998.tb01762.x
   Park SH, 2010, TOXICOLOGY, V278, P131, DOI 10.1016/j.tox.2010.04.003
   Peak J. G., 1988, PHOTOCHEM PHOTOBIOL, V41, P295
   Pelclova D, 2008, IND HEALTH, V46, P484, DOI 10.2486/indhealth.46.484
   Peng HY, 2009, IN VIVO, V23, P747
   Perez-Maldonado IN, 2005, ENVIRON RES, V98, P177, DOI 10.1016/j.envres.2004.11.001
   Pinho RA, 2005, ENVIRON RES, V99, P355, DOI 10.1016/j.envres.2005.03.005
   Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308
   Polidori MC, 2003, BRIT J NUTR, V90, P147, DOI 10.1079/BJN2003890
   Poljsak B, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/480895
   Poljsak B, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/956792
   Prahalad AK, 2001, CHEM RES TOXICOL, V14, P879, DOI 10.1021/tx010022e
   PRYOR WA, 1992, FREE RADICAL BIO MED, V12, P83, DOI 10.1016/0891-5849(92)90060-T
   PRYOR WA, 1991, FREE RADICAL BIO MED, V11, P41, DOI 10.1016/0891-5849(91)90186-7
   Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7
   Ramadass P, 2003, TOXICOL SCI, V76, P212, DOI 10.1093/toxsci/kfg227
   Reiter Russel J., 1994, Reviews on Environmental Health, V10, P171
   Rezk BM, 2004, J BIOL CHEM, V279, P9693, DOI 10.1074/jbc.M312289200
   RIBAYAMERCADO JD, 1995, J NUTR, V125, P1854, DOI 10.1093/jn/125.7.1854
   RIETJENS IMCM, 1986, J TOXICOL ENV HEALTH, V19, P555, DOI 10.1080/15287398609530952
   Risom L, 2005, MUTAT RES-FUND MOL M, V592, P119, DOI 10.1016/j.mrfmmm.2005.06.012
   Ritter EF, 1997, PLAST RECONSTR SURG, V100, P973, DOI 10.1097/00006534-199709001-00021
   Romieu I, 1998, AM J RESP CRIT CARE, V158, P226, DOI 10.1164/ajrccm.158.1.9712053
   Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074
   Ruano-Ravina A, 2006, CURR PHARM DESIGN, V12, P599, DOI 10.2174/138161206775474396
   Sakano K, 2004, BIOCHEM PHARMACOL, V68, P1869, DOI 10.1016/j.bcp.2004.06.016
   Salganik RI, 2001, J AM COLL NUTR, V20, p464S, DOI 10.1080/07315724.2001.10719185
   Saliou C, 2001, FREE RADICAL BIO MED, V30, P154, DOI 10.1016/S0891-5849(00)00445-7
   Samet JM, 2001, AM J RESP CRIT CARE, V164, P819, DOI 10.1164/ajrccm.164.5.2008003
   Schaffer S, 2004, LIPIDS, V39, P1239, DOI 10.1007/s11745-004-1353-9
   Schlesinger RB, 2006, INHAL TOXICOL, V18, P95, DOI 10.1080/08958370500306016
   Senft AP, 2002, TOXICOL APPL PHARM, V178, P15, DOI 10.1006/taap.2001.9314
   SEVANIAN A, 1982, LIPIDS, V17, P269, DOI 10.1007/BF02534941
   SEVANIAN A, 1982, J TOXICOL ENV HEALTH, V10, P743, DOI 10.1080/15287398209530292
   Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468
   Shimizu K, 2007, J APPL TOXICOL, V27, P195, DOI 10.1002/jat.1205
   Shimizu Kazuhiro, 2007, Fukuoka Acta Medica, V98, P141
   SHINDO Y, 1993, J INVEST DERMATOL, V100, P260, DOI 10.1111/1523-1747.ep12469048
   Sies H, 2004, PHOTOCH PHOTOBIO SCI, V3, P749, DOI 10.1039/b316082c
   Simko M, 2004, J CELL BIOCHEM, V93, P83, DOI 10.1002/jcb.20198
   Simko M, 2007, CURR MED CHEM, V14, P1141, DOI 10.2174/092986707780362835
   Sindhu ER, 2010, J PHARM PHARMACOL, V62, P1054, DOI 10.1111/j.2042-7158.2010.01123.x
   Singh RP, 2002, ANTIOXID REDOX SIGN, V4, P655, DOI 10.1089/15230860260220166
   Song NH, 2007, CHEMOSPHERE, V68, P1779, DOI 10.1016/j.chemosphere.2007.03.023
   Song Y, 2008, CHEM RES TOXICOL, V21, P1359, DOI 10.1021/tx8000175
   Speakman JR, 2003, AGING CELL, V2, P265, DOI 10.1046/j.1474-9728.2003.00061.x
   Sperati A, 1999, ENVIRON HEALTH PERSP, V107, P213, DOI 10.2307/3434511
   Sridevi N, 2007, BIOMED PHARMACOTHER, V61, P435, DOI 10.1016/j.biopha.2007.03.003
   Srinivasan M, 2009, TOXICOLOGY, V262, P43, DOI 10.1016/j.tox.2009.05.004
   Stahl W, 1998, FEBS LETT, V427, P305, DOI 10.1016/S0014-5793(98)00434-7
   Stahl W, 2000, AM J CLIN NUTR, V71, P795, DOI 10.1093/ajcn/71.3.795
   Stahl W., 2006, SKIN AGING
   Stevenson DE, 1999, TOXICOL LETT, V109, P123, DOI 10.1016/S0378-4274(99)00132-0
   STEVENSON DE, 1995, TOXICOL LETT, V75, P177, DOI 10.1016/0378-4274(94)03178-A
   STOHS SJ, 1990, FREE RADICAL BIO MED, V9, P79, DOI 10.1016/0891-5849(90)90052-K
   Strosova M, 2009, GEN PHYSIOL BIOPHYS, V28, P195, DOI 10.4149/gpb_2009_02_195
   Tak JK, 2009, FREE RADICAL BIO MED, V46, P1177, DOI 10.1016/j.freeradbiomed.2009.01.023
   Takizawa M, 2007, TOXICOL IN VITRO, V21, P355, DOI 10.1016/j.tiv.2006.09.003
   Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Thiele JJ, 2001, SKIN PHARMACOL APPL, V14, P87, DOI 10.1159/000056395
   Tsai CF, 2009, FOOD CHEM TOXICOL, V47, P2031, DOI 10.1016/j.fct.2009.05.021
   Tsuchiya M, 2002, CIRCULATION, V105, P1155, DOI 10.1161/hc1002.105935
   Turkez H, 2013, TOXICOL IND HEALTH, V29, P677, DOI 10.1177/0748233712440139
   Valavanidis A, 2006, ECOTOX ENVIRON SAFE, V64, P178, DOI 10.1016/j.ecoenv.2005.03.013
   Van Campen LE, 2002, HEARING RES, V164, P29, DOI 10.1016/S0378-5955(01)00391-4
   van Helden YGJ, 2009, FREE RADICAL BIO MED, V46, P299, DOI 10.1016/j.freeradbiomed.2008.10.038
   Venkataraman P, 2008, INT J DEV NEUROSCI, V26, P585, DOI 10.1016/j.ijdevneu.2008.05.002
   VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P
   Verma RS, 2007, PESTIC BIOCHEM PHYS, V88, P191, DOI 10.1016/j.pestbp.2006.11.002
   WALKER C, 1992, AM J IND MED, V21, P253, DOI 10.1002/ajim.4700210214
   Wambi CO, 2009, RADIAT RES, V172, P175, DOI [10.1667/RR1708.1, 10.1667/RR1589.1]
   WEI HC, 1995, P SOC EXP BIOL MED, V208, P124
   Wen S, 2008, ENVIRON SCI TECHNOL, V42, P4202, DOI 10.1021/es800044m
   Wilhelm D, 2010, ECOTOXICOLOGY, V19, P1193, DOI 10.1007/s10646-010-0503-2
   Willett WC, 2006, PUBLIC HEALTH NUTR, V9, P105, DOI 10.1079/PHN2005931
   WOLF C, 1988, J INVEST DERMATOL, V90, P55, DOI 10.1111/1523-1747.ep12462564
   Wolf FI, 2005, EXP GERONTOL, V40, P181, DOI 10.1016/j.exger.2004.11.002
   Wu DM, 2003, ARCH ENVIRON CON TOX, V45, P423, DOI 10.1007/s00244-003-2157-z
   Xing HJ, 2012, PESTIC BIOCHEM PHYS, V103, P74, DOI 10.1016/j.pestbp.2012.03.007
   XU Y, 1992, CANCER RES, V52, P3875
   Yadav Amit K, 2010, Proc Am Thorac Soc, V7, P278, DOI 10.1513/pats.201001-009SM
   Yang UJ, 2013, J TOXICOL ENV HEAL A, V76, P1307, DOI 10.1080/15287394.2013.851632
   Yeh SL, 2005, EUR J NUTR, V44, P365, DOI 10.1007/s00394-004-0536-5
   Yi XH, 2007, CHEMOSPHERE, V68, P1576, DOI 10.1016/j.chemosphere.2007.02.035
   Zararsiz I, 2007, TOXICOL IND HEALTH, V23, P573, DOI 10.1177/0748233708089022
   Zararsiz I, 2011, TOXICOL IND HEALTH, V27, P489, DOI 10.1177/0748233710389852
   Zarogiannis SG, 2011, AM J RESP CELL MOL, V45, P386, DOI 10.1165/rcmb.2010-0432OC
   Zhao HP, 2008, INHAL TOXICOL, V20, P865, DOI [10.1080/08958370701861512, 10.1080/08958370701861512 ]
   Zhao JQ, 2009, INDIAN J EXP BIOL, V47, P264
   Zhou CQ, 2005, TOXICOL IN VITRO, V19, P665, DOI 10.1016/j.tiv.2005.03.010
   Zhou J, 1997, Zhonghua Yu Fang Yi Xue Za Zhi, V31, P67
   Zhou JF, 2000, BIOMED ENVIRON SCI, V13, P44
   Zhu YM, 2009, FREE RADICAL BIO MED, V47, P1762, DOI 10.1016/j.freeradbiomed.2009.09.024
NR 266
TC 81
Z9 86
U1 2
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2014
VL 2014
AR 671539
DI 10.1155/2014/671539
PG 22
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AN0QT
UT WOS:000340289800001
PM 25140198
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Athanasiou, D
   Aguila, M
   Bevilacqua, D
   Novoselov, SS
   Parfitt, DA
   Cheetham, ME
AF Athanasiou, Dimitra
   Aguila, Monica
   Bevilacqua, Dalila
   Novoselov, Sergey S.
   Parfitt, David A.
   Cheetham, Michael E.
TI The cell stress machinery and retinal degeneration
SO FEBS LETTERS
LA English
DT Review
DE Molecular chaperones; Cell stress; Neurodegeneration; Retinal
   degeneration photoreceptor; Rhodopsin ERAD; Autophagy; Retinitis
   pigmentosa; Glaucoma; Age-related macular degeneration
ID ENDOPLASMIC-RETICULUM STRESS; RETINITIS-PIGMENTOSA; ER STRESS; OXIDATIVE
   STRESS; MITOCHONDRIAL DYSFUNCTION; DIABETIC-RETINOPATHY; MOLECULAR
   CHAPERONE; CHEMICAL CHAPERONE; MUTANT RHODOPSIN; QUALITY-CONTROL
AB Retinal degenerations are a group of clinically and genetically heterogeneous disorders characterised by progressive loss of vision due to neurodegeneration. The retina is a highly specialised tissue with a unique architecture and maintaining homeostasis in all the different retinal cell types is crucial for healthy vision. The retina can be exposed to a variety of environmental insults and stress, including light-induced damage, oxidative stress and inherited mutations that can lead to protein misfolding. Within retinal cells there are different mechanisms to cope with disturbances in proteostasis, such as the heat shock response, the unfolded protein response and autophagy. In this review, we discuss the multiple responses of the retina to different types of stress involved in retinal degenerations, such as retinitis pigmentosa, age-related macular degeneration and glaucoma. Understanding the mechanisms that maintain and re-establish proteostasis in the retina is important for developing new therapeutic approaches to fight blindness. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Athanasiou, Dimitra; Aguila, Monica; Bevilacqua, Dalila; Novoselov, Sergey S.; Parfitt, David A.; Cheetham, Michael E.] UCL Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London
RP Cheetham, ME (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM michael.cheetham@ucl.ac.uk
OI Cheetham, Michael/0000-0001-6429-654X; Novoselov,
   Sergey/0000-0002-5491-7522; Parfitt, David/0000-0001-5095-0766
FU Wellcome Trust; RP Fighting Blindness; BIG Lottery Fund (BLF); Fight for
   Sight; MRC [G0700412] Funding Source: UKRI; Medical Research Council
   [G0700412] Funding Source: researchfish
FX Research in the Cheetham lab on cell stress in the retina is supported
   by The Wellcome Trust, RP Fighting Blindness, the BIG Lottery Fund (BLF)
   and Fight for Sight.
CR Ahn J, 2008, NEUROSCI LETT, V433, P11, DOI 10.1016/j.neulet.2007.12.045
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Athanasiou D, 2012, MOL BIOL CELL, V23, P3522, DOI 10.1091/mbc.E12-02-0168
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448
   Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07
   BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1297, DOI 10.1001/archopht.122.9.1297
   Boatright Jeffrey H, 2009, J Ocul Biol Dis Infor, V2, P149
   Bringmann A, 2009, GRAEF ARCH CLIN EXP, V247, P865, DOI 10.1007/s00417-009-1082-x
   Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9
   Calandrella N, 2007, MOL CELL BIOCHEM, V301, P155, DOI 10.1007/s11010-006-9407-0
   Caprioli Joseph, 2003, Trans Am Ophthalmol Soc, V101, P39
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200
   Chiang WC, 2012, INVEST OPHTH VIS SCI, V53, P7159, DOI 10.1167/iovs.12-10222
   Chiang WC, 2012, MOL BIOL CELL, V23, P758, DOI 10.1091/mbc.E11-08-0663
   Churchill JD, 2013, INVEST OPHTH VIS SCI, V54, P1411, DOI 10.1167/iovs.12-11541
   Clemson CM, 2011, BRIT J OPHTHALMOL, V95, P89, DOI 10.1136/bjo.2009.175356
   COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070
   Daiger SP, 2007, ARCH OPHTHALMOL-CHIC, V125, P151, DOI 10.1001/archopht.125.2.151
   Dean DO, 2001, INVEST OPHTH VIS SCI, V42, P3031
   Dejneka NS, 2004, MOL VIS, V10, P964
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903
   Fernandez-Sanchez L, 2011, INVEST OPHTH VIS SCI, V52, P4998, DOI 10.1167/iovs.11-7496
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Griciuc A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001075
   Griciuc A, 2010, BBA-MOL CELL RES, V1803, P424, DOI 10.1016/j.bbamcr.2010.01.008
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Herrmann R, 2011, NEURON, V72, P101, DOI 10.1016/j.neuron.2011.07.030
   Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI [10.1242/jcs.02745, 10.1242/jcs.053850]
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Huang W, 2007, INVEST OPHTH VIS SCI, V48, P4129, DOI 10.1167/iovs.06-0606
   Ishii Y, 2003, INVEST OPHTH VIS SCI, V44, P1982, DOI 10.1167/iovs.02-0912
   Jia LY, 2009, INVEST OPHTH VIS SCI, V50, P3743, DOI 10.1167/iovs.08-3151
   Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162
   Joly S, 2008, J NEUROSCI, V28, P13765, DOI 10.1523/JNEUROSCI.5114-08.2008
   Kamermans M, 1999, VISION RES, V39, P2449, DOI 10.1016/S0042-6989(99)00043-7
   Kang MJ, 2009, P NATL ACAD SCI USA, V106, P17043, DOI 10.1073/pnas.0905566106
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kaushal Shalesh, 2006, Trans Am Ophthalmol Soc, V104, P517
   Keats BJB, 2004, AM J MED GENET A, V130A, P13, DOI 10.1002/ajmg.a.30052
   KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kosmaoglou M, 2009, J CELL SCI, V122, P4465, DOI 10.1242/jcs.055228
   Kosmaoglou M, 2008, MOL VIS, V14, P2466
   Kraus A, 2010, J BIOL CHEM, V285, P18928, DOI 10.1074/jbc.M110.107201
   Krebs MP, 2010, J MOL BIOL, V395, P1063, DOI 10.1016/j.jmb.2009.11.015
   Kroeger H, 2012, INVEST OPHTH VIS SCI, V53, P7590, DOI 10.1167/iovs.12-10221
   Krueger-Naug AMR, 2002, NEUROSCIENCE, V110, P653, DOI 10.1016/S0306-4522(01)00453-5
   Kunte MM, 2012, INVEST OPHTH VIS SCI, V53, P3792, DOI 10.1167/iovs.11-9235
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003
   Lee H, 2011, INT J BIOL MACROMOL, V48, P194, DOI 10.1016/j.ijbiomac.2010.11.006
   Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015
   Li Y, 2003, INVEST OPHTH VIS SCI, V44, P1299, DOI 10.1167/iovs.02-0235
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Lindqvist N, 2010, INVEST OPHTH VIS SCI, V51, P1683, DOI 10.1167/iovs.09-4159
   Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200
   Liu CY, 2003, J BIOL CHEM, V278, P17680, DOI 10.1074/jbc.M300418200
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Mendes HF, 2005, TRENDS MOL MED, V11, P177, DOI 10.1016/j.molmed.2005.02.007
   Mendes HF, 2008, HUM MOL GENET, V17, P3043, DOI 10.1093/hmg/ddn202
   Mihaly K, 1998, CELL MOL LIFE SCI, V54, P1154, DOI 10.1007/s000180050243
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Monemi S, 2005, HUM MOL GENET, V14, P725, DOI 10.1093/hmg/ddi068
   Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587
   Mulhern ML, 2007, MOL VIS, V13, P1397
   Murray AR, 2009, OPHTHALMIC GENET, V30, P109, DOI 10.1080/13816810902962405
   Nagashima M, 2011, NEUROCHEM INT, V58, P888, DOI 10.1016/j.neuint.2011.02.017
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200
   Noorwez SM, 2009, J BIOL CHEM, V284, P33333, DOI 10.1074/jbc.M109.043364
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Okuda-Shimizu Y, 2007, MOL CELL, V28, P544, DOI 10.1016/j.molcel.2007.09.012
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Outeiro Tiago Fleming, 2007, Semin Pediatr Neurol, V14, P15, DOI 10.1016/j.spen.2006.11.005
   Oveson BC, 2011, J NEUROCHEM, V116, P144, DOI 10.1111/j.1471-4159.2010.07092.x
   Park KH, 2001, INVEST OPHTH VIS SCI, V42, P1522
   Paskowitz DM, 2006, BRIT J OPHTHALMOL, V90, P1060, DOI 10.1136/bjo.2006.097436
   Peters CM, 2003, EXP NEUROL, V180, P1, DOI 10.1016/S0014-4886(02)00023-7
   Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012
   QUIGLEY HA, 1983, AM J OPHTHALMOL, V95, P673, DOI 10.1016/0002-9394(83)90389-6
   Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002
   Rapoport TA, 2007, NATURE, V450, P663, DOI 10.1038/nature06384
   Rattner A, 2005, J NEUROSCI, V25, P4540, DOI 10.1523/JNEUROSCI.0492-05.2005
   Ravikumar B, 2009, J CELL SCI, V122, P1707, DOI 10.1242/jcs.031773
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Rosenbaum EE, 2006, NEURON, V49, P229, DOI 10.1016/j.neuron.2005.12.011
   Rosenbaum EE, 2011, NEURON, V72, P602, DOI 10.1016/j.neuron.2011.09.016
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Sandberg MA, 2011, BRIT J OPHTHALMOL, V95, P744, DOI 10.1136/bjo.2010.198176
   Schallenberg M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033593
   Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096
   Schwartz L, 2003, MED HYPOTHESES, V60, P644, DOI 10.1016/S0306-9877(02)00391-2
   Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4
   Shen XA, 2011, J BIOL CHEM, V286, P3618, DOI 10.1074/jbc.M110.175810
   Shinde VM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033266
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Sisk RA, 2012, BRIT J OPHTHALMOL, V96, P1154, DOI 10.1136/bjophthalmol-2012-301950
   Sreekumar PG, 2013, INVEST OPHTH VIS SCI, V54, P2787, DOI 10.1167/iovs.12-11571
   STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Suntharalingam A, 2012, J BIOL CHEM, V287, P40661, DOI 10.1074/jbc.M112.384800
   Tam LCS, 2010, HUM MOL GENET, V19, P4421, DOI 10.1093/hmg/ddq369
   Tamm ER, 2002, PROG RETIN EYE RES, V21, P395, DOI 10.1016/S1350-9462(02)00010-1
   Taylor SC, 2003, EMBO REP, V4, P405, DOI 10.1038/sj.embor.embor797
   Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6
   Vabulas RM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004390
   Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yam GHT, 2007, INVEST OPHTH VIS SCI, V48, P1683, DOI 10.1167/iovs.06-0943
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656
   Zode GS, 2011, J CLIN INVEST, V121, P3542, DOI 10.1172/JCI58183
NR 129
TC 100
Z9 102
U1 1
U2 47
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD JUN 27
PY 2013
VL 587
IS 13
SI SI
BP 2008
EP 2017
DI 10.1016/j.febslet.2013.05.020
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 171FK
UT WOS:000320910300024
PM 23684651
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Weinberger, AWA
   Thiel, M
   Mohammadi, B
   Theofylaktopoulos, L
   Thumann, G
   Walter, P
AF Weinberger, Andreas W. A.
   Thiel, Mirjam
   Mohammadi, Babak
   Theofylaktopoulos, Loannis
   Thumann, Gabriele
   Walter, Peter
TI Retinal pigment epithelium tears after intravitreal bevacizumab in
   pigment epithelium detachment
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; MACULAR DEGENERATION; INJECTION
AB PURPOSE: To evaluate pigment epithelium detachment (PED) secondary to exudative age-related macular degeneration (AMD) treated with intravitreal injection of bevacizumab with regard to incidence of retinal pigment epithelium tears (RIPs).
   DESIGN: Retrospective, interventional case series.
   METHODS: Institutional study of 31 eyes with PED in exudative AMD receiving intravitreal bevacizumab. Main outcome measures were Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity, PED vascularization and size measured by angiography and optical coherence tomography (OCT) imaging, and incidence of RIP.
   RESULTS: Vision improved in six eyes and remained stable in 22 eyes (follow-up, 12.3 +/- 10.3 weeks). Twenty-eight eyes showed a vascularized PED. Four eyes (12.9%) experienced an RIP without vision loss. All RIP cases were vascularized in more than 50% of total lesion size.
   CONCLUSIONS: In short-term follow-up the risk for RIP after bevacizumab injection in eyes with PED seems to be moderately, but not statistically significantly, increased in PED lesions vascularized more than 50%.
C1 Rhein Westfal TH Aachen, Dept Ophthalmol, D-52074 Aachen, Germany.
C3 RWTH Aachen University
RP Weinberger, AWA (通讯作者)，Rhein Westfal TH Aachen, Dept Ophthalmol, Pauwelsstr 30, D-52074 Aachen, Germany.
EM aweinberger@ukaachen.de
RI Walter, Peter/L-5982-2018
OI Walter, Peter/0000-0001-8745-6593
CR Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 5
TC 28
Z9 30
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2007
VL 144
IS 2
BP 294
EP 296
DI 10.1016/j.ajo.2007.03.024
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196ZI
UT WOS:000248521800023
PM 17659961
DA 2022-11-30
ER

PT J
AU Desai, D
   Dugel, PU
AF Desai, Dhaval
   Dugel, Pravin U.
TI Complement cascade inhibition in geographic atrophy: a review
SO EYE
LA English
DT Review
ID MACULAR DEGENERATION; VISUAL-ACUITY; EYE DISEASE; FACTOR-H; SYSTEM;
   PATHWAY; ACTIVATION; SECONDARY; HTRA1; RISK
AB The pathophysiology of dry age-related macular degeneration (AMD) and specifically geographic atrophy (GA) has been linked to the complement cascade. This cascade is part of the innate immune system and is made up of the classical, alternative, and lectin pathways. The pathways comprise a system of plasma and membrane-associated serum proteins that are activated with identification of a nonself entity. A number of these proteins have been implicated in the development and progression of dry AMD. The three pathways converge at C3 and cascade down through C5, making both of these proteins viable targets for the treatment of dry AMD. In addition, there are a number of complement factors, CFB, CFD, CFH, and CFI, which are potential therapeutic targets as well. Several different complement-directed therapeutics are being studied for the treatment of dry AMD with the hope that one of these approaches will emerge as the first approved treatment for GA.
C1 [Desai, Dhaval; Dugel, Pravin U.] Iver Bio, 1249 South River Rd,Suite 107, Cranbury, NJ 08512 USA.
RP Dugel, PU (通讯作者)，Iver Bio, 1249 South River Rd,Suite 107, Cranbury, NJ 08512 USA.
EM pravin.dugel@ivericbio.com
FU Iveric Bio
FX Medical writing assistance was provided by i2Vision (San Diego, CA) and
   funded by Iveric Bio.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Coulthard LG, 2015, J IMMUNOL, V194, P3542, DOI 10.4049/jimmunol.1403068
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Jong PTVM, 2018, EYE, V32, P904, DOI 10.1038/eye.2017.298
   Dobo J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01851
   Dobo J, 2016, IMMUNOL REV, V274, P98, DOI 10.1111/imr.12460
   Dreismann AK, 2021, GENE THER, V28, P265, DOI 10.1038/s41434-021-00239-9
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hato T, 2015, CLIN J AM SOC NEPHRO, V10, P1459, DOI 10.2215/CJN.04680514
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Ibbett P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43906-z
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kim BJ, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100936
   Laishram M, 2017, J CLIN DIAGN RES, V11, pNC08, DOI 10.7860/JCDR/2017/25799.10213
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liu K, 2019, EYE VISION, V6, DOI 10.1186/s40662-019-0161-2
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pilotti C, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.19
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rossi V, 2014, METHODS MOL BIOL, V1100, P43, DOI 10.1007/978-1-62703-724-2_4
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sepah YJ, 2014, SAUDI J OPHTHALMOL, V28, P111, DOI 10.1016/j.sjopt.2014.03.008
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Suresh R, 2016, J CELL SCI, V129, P1928, DOI 10.1242/jcs.179291
   Triantafilou M, 2016, IMMUNOLOGY, V147, P152, DOI 10.1111/imm.12556
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Vignesh P, 2017, CLIN CHIM ACTA, V465, P123, DOI 10.1016/j.cca.2016.12.017
   Waheed NK., ANG EX DEG 2021 VIRT
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
NR 54
TC 6
Z9 6
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2022
VL 36
IS 2
BP 294
EP 302
DI 10.1038/s41433-021-01765-x
EA JAN 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ7VR
UT WOS:000740410700003
PM 34999723
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Cioffi, CL
   Muthuraman, P
   Raja, A
   Varadi, A
   Racz, B
   Petrukhin, K
AF Cioffi, Christopher L.
   Muthuraman, Parthasarathy
   Raja, Arun
   Varadi, Andras
   Racz, Boglarka
   Petrukhin, Konstantin
TI Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That
   Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization,
   and Preclinical Pharmacological Evaluation as a Potential Therapy for
   Two Common Age-Related Comorbidities
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SENILE SYSTEMIC AMYLOIDOSIS; VITAMIN-A; GEOGRAPHIC ATROPHY; SERUM
   RETINOL-BINDING-PROTEIN-4; FUNDUS AUTOFLUORESCENCE; CARDIAC AMYLOIDOSIS;
   3-DIMENSIONAL STRUCTURE; KINETIC STABILIZATION; MACULAR DEGENERATION;
   INSULIN-RESISTANCE
AB Accumulation of cytotoxic lipofuscin bisretinoids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis. Retinal bisretinoid synthesis depends on the influx of serum all-trans-retinol (1) delivered via a tertiary retinol binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. We previously identified selective RBP4 antagonists that dissociate circulating RBP4-TTR-retinol complexes, reduce serum RBP4 levels, and inhibit bisretinoid synthesis in models of enhanced retinal lipofuscinogenesis. However, the release of TTR by selective RBP4 antagonists may be associated with TTR tetramer destabilization and, potentially, TTR amyloid formation. We describe herein the identification of bispecific RBP4 antagonist-TTR tetramer kinetic stabilizers. Standout analogue (+/-)-44 possesses suitable potency for both targets, significantly lowers mouse plasma RBP4 levels, and prevents TTR aggregation in a gel-based assay. This new class of bispecific compounds may be especially important as a therapy for dry AMD patients who have another common age-related comorbidity, senile systemic amyloidosis, a nongenetic disease associated with wild-type TTR misfolding.
C1 [Cioffi, Christopher L.; Muthuraman, Parthasarathy; Raja, Arun] Albany Coll Pharm & Hlth Sci, Dept Basic & Clin Sci, Albany, NY 12208 USA.
   [Cioffi, Christopher L.; Muthuraman, Parthasarathy; Raja, Arun] Albany Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Albany, NY 12208 USA.
   [Varadi, Andras; Racz, Boglarka; Petrukhin, Konstantin] Columbia Univ, Med Ctr, Dept Ophthalmol, New York, NY 10032 USA.
C3 Albany College of Pharmacy & Health Sciences; Albany College of Pharmacy
   & Health Sciences; Columbia University
RP Cioffi, CL (通讯作者)，Albany Coll Pharm & Hlth Sci, Dept Basic & Clin Sci, Albany, NY 12208 USA.; Cioffi, CL (通讯作者)，Albany Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Albany, NY 12208 USA.; Petrukhin, K (通讯作者)，Columbia Univ, Med Ctr, Dept Ophthalmol, New York, NY 10032 USA.
EM christopher.cioffi@acphs.edu; kep4@cumc.columbia.edu
OI Cioffi, Christopher/0000-0003-0642-7905; Petrukhin,
   Konstantin/0000-0002-5545-6924
FU National Eye Institute of the National Institutes of Health
   [R01EY028549]; National Eye Institute; National Institutes of Health;
   Department of Health and Human Services, NIH [R01EY028549]; NIH [P30
   EY019007]; Research to Prevent Blindness (New York, NY); Mary
   Jaharis-John Catsimatidis Scholarship Fund; Kaplen Foundation; Eye
   Surgery Fund; Burch Family Foundation
FX The research reported in this publication was supported by the National
   Eye Institute of the National Institutes of Health under award number
   R01EY028549. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health. This project has been funded in whole or in part
   with Federal funds from the National Eye Institute, the National
   Institutes of Health, and the Department of Health and Human Services,
   NIH Grant R01EY028549 (to K.P. and C.L.C.). This study was supported by
   NIH Grant P30 EY019007 (Core Support for Vision Research) and
   unrestricted funds from the Research to Prevent Blindness (New York, NY)
   to the Department of Ophthalmology, Columbia University. The authors
   thank The Burch Family Foundation, the Mary Jaharis-John Catsimatidis
   Scholarship Fund, the Kaplen Foundation, and the Eye Surgery Fund for
   gifts supporting this study.
CR Adams D, 2016, EXPERT OPIN PHARMACO, V17, P791, DOI 10.1517/14656566.2016.1145664
   ADAMS WR, 1995, P SOC EXP BIOL MED, V208, P178, DOI 10.3181/00379727-208-43849
   Aeberli I, 2007, J CLIN ENDOCR METAB, V92, P4359, DOI 10.1210/jc.2007-0468
   Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159
   Alexander KM, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.116.003489
   Alhamadsheh MM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002473
   Almeida M. R., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P587, DOI 10.2174/156800705774322076
   Almeida MR, 2004, BIOCHEM J, V381, P351, DOI 10.1042/BJ20040011
   Basaiawmoit R. V., 2009, BIOGERONTOLOGY, V10, P95
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Berk JL, 2012, AMYLOID, V19, P37, DOI 10.3109/13506129.2012.678509
   BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O
   BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6
   Bobbert T, 2010, ATHEROSCLEROSIS, V213, P549, DOI 10.1016/j.atherosclerosis.2010.07.063
   Brunjes DL, 2016, J CARD FAIL, V22, P996, DOI 10.1016/j.cardfail.2016.10.008
   Bulawa CE, 2012, P NATL ACAD SCI USA, V109, P9629, DOI 10.1073/pnas.1121005109
   Buxbaum JN, 2017, GENET MED, V19, P733, DOI 10.1038/gim.2016.200
   Cioffi CL, 2019, J MED CHEM, V62, P5470, DOI 10.1021/acs.jmedchem.9b00352
   Cioffi CL, 2015, J MED CHEM, V58, P5863, DOI 10.1021/acs.jmedchem.5b00423
   Cioffi CL, 2014, J MED CHEM, V57, P7731, DOI 10.1021/jm5010013
   Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E
   Coelho T, 2016, NEUROL THER, V5, P1, DOI 10.1007/s40120-016-0040-x
   Connors LH, 2011, AMYLOID, V18, P157, DOI 10.3109/13506129.2011.574354059
   COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Delori FC, 1998, DOC OPHTH P, V62, P37
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Dontsov AE, 2009, DOKL BIOCHEM BIOPHYS, V425, P98, DOI 10.1134/S1607672909020112
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Foss TR, 2005, BIOCHEMISTRY-US, V44, P15525, DOI 10.1021/bi051608t
   Gales L, 2005, BIOCHEM J, V388, P615, DOI 10.1042/BJ20042035
   Gimeno A, 2017, J MED CHEM, V60, P5749, DOI 10.1021/acs.jmedchem.7b00428
   Green NS, 2005, P NATL ACAD SCI USA, V102, P14545, DOI 10.1073/pnas.0501609102
   Hamilton JA, 2001, CELL MOL LIFE SCI, V58, P1491, DOI 10.1007/PL00000791
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l
   Hyung SJ, 2010, ACS CHEM BIOL, V5, P1137, DOI 10.1021/cb100144v
   Johnson SM, 2005, ACCOUNTS CHEM RES, V38, P911, DOI 10.1021/ar020073i
   Judge DP, 2019, J AM COLL CARDIOL, V74, P285, DOI 10.1016/j.jacc.2019.03.012
   KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889
   Kawaguchi R, 2015, MEMBRANES, V5, P425, DOI 10.3390/membranes5030425
   Kerschen P, 2016, CURR TREAT OPTION NE, V18, DOI 10.1007/s11940-016-0436-z
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Klabunde T, 2000, NAT STRUCT BIOL, V7, P312
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kowalska I, 2008, J CLIN ENDOCR METAB, V93, P2786, DOI 10.1210/jc.2008-0077
   Lamb YN, 2019, DRUGS, V79, P863, DOI 10.1007/s40265-019-01129-6
   Lee SA, 2016, HEPATOLOGY, V64, P1534, DOI 10.1002/hep.28659
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Miller M, 2018, J MED CHEM, V61, P7862, DOI 10.1021/acs.jmedchem.8b00817
   Monaco HL, 2000, BBA-PROTEIN STRUCT M, V1482, P65, DOI 10.1016/S0167-4838(00)00140-0
   MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382
   Monaco HL, 2002, CLIN CHEM LAB MED, V40, P1229, DOI 10.1515/CCLM.2002.213
   Motani A, 2009, J BIOL CHEM, V284, P7673, DOI 10.1074/jbc.M809654200
   Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i
   Nencetti S, 2012, CURR MED CHEM, V19, P2356, DOI 10.2174/092986712800269326
   Nencetti S, 2013, CHEMMEDCHEM, V8, P1617, DOI 10.1002/cmdc.201300245
   NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x
   Niemietz C, 2018, J CELL SCI, V131, DOI 10.1242/jcs.219824
   NILSSON SF, 1975, J BIOL CHEM, V250, P8554
   Norseen J, 2012, MOL CELL BIOL, V32, P2010, DOI 10.1128/MCB.06193-11
   NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023
   NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012
   Palaninathan SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006290
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Penchala SC, 2013, P NATL ACAD SCI USA, V110, P9992, DOI 10.1073/pnas.1300761110
   Petrassi HM, 2000, J AM CHEM SOC, V122, P2178, DOI 10.1021/ja993309v
   Petrassi HM, 2005, J AM CHEM SOC, V127, P6662, DOI 10.1021/ja044351f
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633
   Quadro L, 2003, MOL ASPECTS MED, V24, P421, DOI 10.1016/S0098-2997(03)00038-4
   Racz B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228291
   Racz B, 2018, J BIOL CHEM, V293, P11574, DOI 10.1074/jbc.RA118.002062
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rodrigues D. A, 2008, DRUG DRUG INTERACTIO
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ruberg FL, 2012, CIRCULATION, V126, P1286, DOI 10.1161/CIRCULATIONAHA.111.078915
   Sant'Anna R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10787
   Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Seeliger MW, 1999, INVEST OPHTH VIS SCI, V40, P3
   Sekijima Y, 2003, LAB INVEST, V83, P409, DOI 10.1097/01.LAB.0000059937.11023.1F
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498
   Ton VK, 2014, CLIN MED INSIGHTS-CA, V8, P39, DOI 10.4137/CMC.S15719
   Tsin A, 2018, J BIOL CHEM, V293, P13016, DOI 10.1074/jbc.AW118.003228
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843
   Westermark P, 2003, AMYLOID, V10, P48
   White JT, 2001, P NATL ACAD SCI USA, V98, P13019, DOI 10.1073/pnas.241406698
   Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046
   Wolf G, 1999, NUTR REV, V57, P258
   WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873
   WOLF G, 1995, NUTR REV, V53, P98
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zanotti G, 2008, FEBS J, V275, P5841, DOI 10.1111/j.1742-4658.2008.06705.x
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 114
TC 7
Z9 7
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD OCT 8
PY 2020
VL 63
IS 19
BP 11054
EP 11084
DI 10.1021/acs.jmedchem.0c00996
PG 31
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA OE5GM
UT WOS:000580558700024
PM 32878437
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Dhivya, MA
   Aberami, S
   Nikhalashree, S
   Biswas, J
   Liu, WJ
   Irudayaraj, J
   Sulochana, KN
   Coral, K
   Devi, SRB
AF Dhivya, M. Aloysius
   Aberami, S.
   Nikhalashree, Sampath
   Biswas, J.
   Liu, Wenjie
   Irudayaraj, Joseph
   Sulochana, K. N.
   Coral, Karunakaran
   Devi, S. R. Bharathi
TI Copper mediates mitochondrial biogenesis in retinal pigment epithelial
   cells
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Copper; AMD; Mitochondrial biogenesis
ID NUCLEAR RESPIRATORY FACTORS; OXIDATIVE STRESS; TRANSCRIPTION FACTOR;
   GENE-EXPRESSION; AGE; IRON; DEGENERATION; ZINC; NRF2; ACCUMULATION
AB Age related macular degeneration (AMD) is a multifactorial disease with genetic, biochemical and environmental risk factors. We observed a significant increase in copper levels in choroid-RPE from donor eyeballs with AMD. Adult retinal pigment epithelial cells (ARPE19 cells) exposed to copper in-vitro showed a 2-fold increase in copper influx transporter CTR1 and copper uptake at 50 mu M concentration. Further there was 2-fold increase in cytochrome C oxidase activity and a 2-fold increase in the mRNA expression of NRF 2 with copper treatment. There was a significant increase in mitochondrial biogenesis markers PGC1 beta and TFAM which was confirmed by mitochondrial mass and copy number. On the contrary, in AMD choroid-RPE, the CTR1 mRNA was found to be significantly down-regulated compared to its respective controls. SCO1 and PGC1 beta mRNA showed an increase in choroid-RPE. Our study proposes copper to play an important role in mitochondrial biogenesis in RPE cells.
C1 [Dhivya, M. Aloysius; Aberami, S.; Nikhalashree, Sampath; Sulochana, K. N.; Coral, Karunakaran; Devi, S. R. Bharathi] Sankara Nethralaya, RS Mehta Jain Dept Biochem & Cell Biol, KBIRVO, Vis Res Fdn, Coll Rd, Chennai 6, Tamil Nadu, India.
   [Dhivya, M. Aloysius; Nikhalashree, Sampath] SASTRA Deemed Be Univ, Trichy Tanjore Rd, Thanjavur 613401, Tamil Nadu, India.
   [Biswas, J.] Med Res Fdn, Dept Uveitis, Chennai, Tamil Nadu, India.
   [Liu, Wenjie; Irudayaraj, Joseph] Univ Illinois, Canc Ctr Illinois, Dept Bioengn, Micro & Nanotechnol Lab, Urbana, IL 61801 USA.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA);
   University of Illinois System; University of Illinois Urbana-Champaign
RP Coral, K; Devi, SRB (通讯作者)，Sankara Nethralaya, RS Mehta Jain Dept Biochem & Cell Biol, KBIRVO, Vis Res Fdn, Coll Rd, Chennai 6, Tamil Nadu, India.
EM drkc@snmail.org; drbarathi@snmail.org
RI Coral, Karunakaran/AAK-2880-2021
FU DST [SB/YS/LS-122/2014]; CSIR [27 (0264/12/EMR-II)]
FX This research was funded by DST sanction number SB/YS/LS-122/2014 and
   CSIR sanction number 27 (0264/12/EMR-II). Our sincere thanks to Dr.
   Joseph Irudayaraj Founder Professor of Bioengineering, Department of
   Bioengineering, UIUC, Urbana-Champaign, IL for his support to perform
   the SCO1 and CTR1 FLIM FRET analysis in his lab. We thank TRPVB, TANUVAS
   for helping us with the confocal imaging.
CR Aberami S, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107718
   Baker ZN, 2017, METALLOMICS, V9, P1501, DOI 10.1039/c7mt00221a
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Biswas Jyotirmay, 2002, Indian Journal of Ophthalmology, V50, P201
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chitra L, 2014, RESP PHYSIOL NEUROBI, V192, P74, DOI 10.1016/j.resp.2013.12.007
   Coussee E, 2011, CELL CALCIUM, V49, P217, DOI 10.1016/j.ceca.2011.02.004
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dinkova-Kostova AT, 2015, FREE RADICAL BIO MED, V88, P179, DOI 10.1016/j.freeradbiomed.2015.04.036
   Eigentler A., LAB PROTOCOL CITRATE
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Guo XM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00640
   Hageman GS, 1995, AGE RELATED MACULAR
   Haglund B, 1996, DIABETES CARE, V19, P873, DOI 10.2337/diacare.19.8.873
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Han DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33552-2
   Hegde N, 2006, TEX HEART I J, V33, P340
   Hlynialuk CJ, 2015, CELL REP, V10, P933, DOI 10.1016/j.celrep.2015.01.019
   Igarashi J, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12742
   Irrcher I, 2003, SPORTS MED, V33, P783, DOI 10.2165/00007256-200333110-00001
   Joo NS, 2009, BIOL TRACE ELEM RES, V129, P28, DOI 10.1007/s12011-008-8281-x
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim BE, 2010, CELL METAB, V11, P353, DOI 10.1016/j.cmet.2010.04.003
   Kocabey AE, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.101079
   Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091
   Leary SC, 2009, BBA-MOL CELL RES, V1793, P146, DOI 10.1016/j.bbamcr.2008.05.002
   Liesa M, 2013, CELL METAB, V17, P491, DOI 10.1016/j.cmet.2013.03.002
   Liesa M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003613
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Liu WJ, 2020, EMBO REP, V21, DOI 10.15252/embr.201948211
   Liu WJ, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0620-6
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Matos L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3793817
   Narayanan R, 2017, CURR PHARM DESIGN, V23, P542, DOI 10.2174/1381612822666161221154424
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ohrvik H, 2014, ANN NY ACAD SCI, V1314, P32, DOI 10.1111/nyas.12371
   Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149
   Potocki S, 2012, CURR MED CHEM, V19, P2738, DOI 10.2174/092986712800609698
   Rajapakse D, 2017, EXP CELL RES, V361, P333, DOI 10.1016/j.yexcr.2017.10.036
   Ramamoorthy TG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10210
   Ranhotra HS, 2015, J RECEPT SIG TRANSD, V35, P386, DOI 10.3109/10799893.2014.959592
   Reboucas ED, 2013, BRAZ ARCH BIOL TECHN, V56, P143, DOI 10.1590/S1516-89132013000100019
   Robledinos-Anton N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9372182
   Rooney JP, 2015, METHODS MOL BIOL, V1241, P23, DOI 10.1007/978-1-4939-1875-1_3
   Rowe GC, 2011, AM J PHYSIOL-ENDOC M, V301, pE155, DOI 10.1152/ajpendo.00681.2010
   Ryoo IG, 2018, TOXICOL APPL PHARM, V359, P24, DOI 10.1016/j.taap.2018.09.014
   Saada A, 2004, ANAL BIOCHEM, V335, P66, DOI 10.1016/j.ab.2004.08.015
   Saleh F, 2011, BIOL TRACE ELEM RES, V141, P96, DOI 10.1007/s12011-010-8724-z
   Schrepfer E, 2016, MOL CELL, V61, P683, DOI 10.1016/j.molcel.2016.02.022
   Shao D, 2010, MITOCHONDRION, V10, P516, DOI 10.1016/j.mito.2010.05.012
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Song MO, 2014, EXP CELL RES, V322, P39, DOI 10.1016/j.yexcr.2014.01.013
   Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subramani M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12496-z
   Terman A, 2006, CHEM-BIOL INTERACT, V163, P29, DOI 10.1016/j.cbi.2006.04.013
   Timon-Gomez A, 2018, SEMIN CELL DEV BIOL, V76, P163, DOI 10.1016/j.semcdb.2017.08.055
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Xu WJ, 2013, CELL METAB, V17, P319, DOI 10.1016/j.cmet.2013.02.004
   Yin W, 2018, CARDIOVASC TOXICOL, V18, P365, DOI 10.1007/s12012-018-9447-1
NR 69
TC 3
Z9 3
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD OCT 1
PY 2020
VL 1866
IS 10
AR 165843
DI 10.1016/j.bbadis.2020.165843
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA NA7FW
UT WOS:000559983700010
PM 32454166
OA Bronze
DA 2022-11-30
ER

PT J
AU Natoli, R
   Mason, E
   Jiao, HH
   Chuah, A
   Patel, H
   Fernando, N
   Valter, K
   Wells, CA
   Provis, J
   Rutar, M
AF Natoli, Riccardo
   Mason, Elizabeth
   Jiao, Haihan
   Chuah, Aaron
   Patel, Hardip
   Fernando, Nilisha
   Valter, Krisztina
   Wells, Christine A.
   Provis, Jan
   Rutar, Matt
TI Dynamic Interplay of Innate and Adaptive Immunity During Sterile Retinal
   Inflammation: Insights From the Transcriptome
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE retinal diseases; macular degeneration; neuroinflammation; sterile
   inflammation; leukocytes recruitment; complement system proteins; innate
   immunity; network analysis
ID COMPLEMENT FACTOR-H; SENILE MACULAR DEGENERATION;
   CENTRAL-NERVOUS-SYSTEM; PHOTORECEPTOR DEGENERATION; MICROGLIAL
   ACTIVATION; DIABETIC-RETINOPATHY; DISEASED RETINA; RAT RETINA; 2 PARTS;
   MACROPHAGES
AB The pathogenesis of many retinal degenerations, such as age-related macular degeneration (AMD), is punctuated by an ill-defined network of sterile inflammatory responses. The delineation of innate and adaptive immune milieu among the broad leukocyte infiltrate, and the gene networks, which construct these responses, are poorly described in the eye. Using photo-oxidative damage in a rodent model of subretinal inflammation, we employed a novel RNA-sequencing framework to map the global gene network signature of retinal leukocytes. This revealed a previously uncharted interplay of adaptive immunity during subretinal inflammation, including prolonged enrichment of myeloid and lymphocyte migration, antigen presentation, and the alternative arm of the complement cascade involving Factor B. We demonstrate Factor B-deficient mice are protected against macrophage infiltration and subretinal inflammation. Suppressing the drivers of retinal leukocyte proliferation, or their capacity to elicit complement responses, may help preserve retinal structure and function during sterile inflammation in diseases such as AMD.
C1 [Natoli, Riccardo; Jiao, Haihan; Chuah, Aaron; Patel, Hardip; Fernando, Nilisha; Valter, Krisztina; Provis, Jan] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia.
   [Natoli, Riccardo; Valter, Krisztina; Provis, Jan] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia.
   [Mason, Elizabeth; Wells, Christine A.; Rutar, Matt] Univ Melbourne, Dept Anat & Neurosci, Ctr Stem Cell Syst, Melbourne, Vic, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University; University of Melbourne
RP Rutar, M (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Ctr Stem Cell Syst, Melbourne, Vic, Australia.
EM matthew.rutar@unimelb.edu.au
RI Patel, Hardip R/K-6376-2012; Valter, Krisztina/L-3015-2016; Mason,
   Elizabeth A/C-6193-2012; Chuah, Aaron/G-2281-2016; Mason,
   Elizabeth/AAH-6851-2020; Wells, Christine/A-5071-2010
OI Mason, Elizabeth A/0000-0002-8823-0024; Chuah,
   Aaron/0000-0003-3066-701X; Fernando, Nilisha/0000-0002-8488-1348;
   Valter, Krisztina/0000-0002-2033-0408; Jiao, Haihan/0000-0002-5404-9307;
   Natoli, Riccardo/0000-0002-9350-0439; Rutar,
   Matthew/0000-0002-8893-5120; Patel, Hardip/0000-0003-3169-049X; Wells,
   Christine/0000-0003-3133-3628
FU Retina Australia
FX We would like to thank the members of the ANU Bioinformatics Consultancy
   Unit, JCSMR, for their help in the analysis of the RNAseq data, as well
   as the funding agency Retina Australia for supporting this work.
CR Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8
   Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   Bryant VL, 2015, IMMUNOL CELL BIOL, V93, P364, DOI 10.1038/icb.2015.23
   Cai L, 2012, CELL DEV BIOL, V1, pe113, DOI DOI 10.4172/2168-9296.1000E113
   Calippe B, 2014, CR BIOL, V337, P178, DOI 10.1016/j.crvi.2013.12.003
   Camelo S, 2015, MOL VIS, V21, P1051
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Chang CJ, 2005, OPHTHALMIC RES, V37, P202, DOI 10.1159/000086610
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   DICK AD, 1995, BRIT J OPHTHALMOL, V79, P834, DOI 10.1136/bjo.79.9.834
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Fernando N, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0514-x
   Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Grigsby JG, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/705783
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lei Y, 2012, MICROBES INFECT, V14, P262, DOI 10.1016/j.micinf.2011.10.003
   Lewis GP, 2005, MOL VIS, V11, P491
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125
   Loetscher P, 2000, Adv Immunol, V74, P127
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8
   Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667
   Michell-Robinson MA, 2015, BRAIN, V138, P1138, DOI 10.1093/brain/awv066
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219
   Mrdjen D, 2018, IMMUNITY, V48, P599, DOI 10.1016/j.immuni.2018.02.014
   Mustafi D, 2012, J CLIN INVEST, V122, P2989, DOI 10.1172/JCI64427
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Natoli R, 2016, EXP EYE RES, V147, P114, DOI 10.1016/j.exer.2016.04.015
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ni YQ, 2008, INVEST OPHTH VIS SCI, V49, P2589, DOI 10.1167/iovs.07-1173
   Nilsson B, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/962702
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Ohta T, 2016, SCI REP-UK, V6, DOI 10.1038/srep23505
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989
   Perry VH, 1998, J NEUROIMMUNOL, V90, P113
   Portillo JAC, 2009, MOL VIS, V15, P1383
   Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923
   Pujol-Lereis LM, 2016, ADV EXP MED BIOL, V854, P87, DOI 10.1007/978-3-319-17121-0_13
   Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sunagar K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081827
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Toapanta FR, 2006, IMMUNOL RES, V36, P197, DOI 10.1385/IR:36:1:197
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   VRABEC F, 1975, A GRAEF ARCH KLIN EX, V196, P49, DOI 10.1007/BF00410026
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamazaki C, 2010, BIOCHEM BIOPH RES CO, V397, P756, DOI 10.1016/j.bbrc.2010.06.029
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang C, 2005, MOL VIS, V11, P887
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 97
TC 6
Z9 6
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 18
PY 2018
VL 9
AR 1666
DI 10.3389/fimmu.2018.01666
PG 17
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GN5AO
UT WOS:000439054500002
PM 30073000
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Gueven, N
   Nadikudi, M
   Daniel, A
   Chhetri, J
AF Gueven, Nuri
   Nadikudi, Monila
   Daniel, Abraham
   Chhetri, Jamuna
TI Targeting mitochondrial function to treat optic neuropathy
SO MITOCHONDRION
LA English
DT Article
DE Retinopathy; Optic neuropathy; Age-related macular degeneration;
   Diabetic retinopathy; Glaucoma; Leber's hereditary optic neuropathy
   (LHON); Mitochondrial dysfunction; CoQ(10); Idebenone; EPI-743; MitoQ;
   SkQl; Ocluvia; MTP-131
ID THERAPY IMPROVES VISION; OXIDATIVE STRESS; ALLOTOPIC EXPRESSION;
   METHYLENE-BLUE; GENE-THERAPY; MOUSE MODEL; PLASTOQUINONE DERIVATIVES;
   PEPTIDE ANTIOXIDANTS; INTERRUPT EXECUTION; LIPOPHILIC CATIONS
AB Many reports have illustrated a tight connection between vision and mitochondrial function. Not only are most mitochondrial diseases associated with some form of vision impairment, many ophthalmological disorders such as glaucoma, age-related macular degeneration and diabetic retinopathy also show signs of mitochondrial dysfunction. Despite a vast amount of evidence, vision loss is still only treated symptomatically, which is only partially a consequence of resistance to acknowledge that mitochondria could be the common denominator and hence a promising therapeutic target. More importantly, clinical support of this concept is only emerging. Moreover, only a few drug candidates and treatment strategies are in development or approved that selectively aim to restore mitochondrial function. This review rationalizes the currently developed therapeutic approaches that target mitochondrial function by discussing their proposed mode(s) of action and provides an overview on their development status with regards to optic neuropathies. (C) 2016 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Gueven, Nuri; Nadikudi, Monila; Daniel, Abraham; Chhetri, Jamuna] Univ Tasmania, Sch Med, Pharm, Hobart, Tas, Australia.
C3 University of Tasmania
RP Gueven, N (通讯作者)，Univ Tasmania, Fac Hlth, Sch Med, Pharm, Hobart, Tas, Australia.
EM nguven@utas.edu.au
OI Nadikudi, Monila/0000-0002-1933-7039; Guven, Nuri/0000-0003-3782-767X;
   Daniel, Abraham/0000-0002-3650-7837
FU Faculty of Health, University of Tasmania
FX We would like to thank the Faculty of Health, University of Tasmania for
   their financial support with regards to scholarships for AD, JC and MN.
   We thank Krystel Woolley for generating the chemical structures.
CR Aguilaniu H, 2005, GENE DEV, V19, P2399, DOI 10.1101/gad.1366505
   Alam NM, 2015, DIS MODEL MECH, V8, P701, DOI 10.1242/dmm.020248
   Ali RR, 1998, HUM GENE THER, V9, P81, DOI 10.1089/hum.1998.9.1-81
   Anisimov VN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1329, DOI 10.1134/S0006297908120055
   Atamna H, 2010, J ALZHEIMERS DIS, V20, pS439, DOI 10.3233/JAD-2010-100414
   Bababeygy SR, 2012, J NEURO-OPHTHALMOL, V32, P386, DOI 10.1097/WNO.0b013e318273c102
   BARBONI P, 2013, BRAIN 2, V136, DOI DOI 10.1093/BRAIN/AWS280
   Bellingrath JS, 2015, OPHTHALMOLOGE, V112, P720, DOI 10.1007/s00347-015-0121-8
   Birk AV, 2013, J AM SOC NEPHROL, V24, P1250, DOI 10.1681/ASN.2012121216
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Brzheskiy VV, 2015, ADV THER, V32, P1263, DOI 10.1007/s12325-015-0273-6
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2
   Carelli V, 2007, BIOSCIENCE REP, V27, P173, DOI 10.1007/s10540-007-9045-0
   Carelli V, 2011, BRAIN, V134, DOI 10.1093/brain/awr180
   Chaplot SP, 2014, J PHARM PHARMACOL, V66, P542, DOI 10.1111/jphp.12104
   Chhetri J, 2016, EXPER OPIN THER TAR, P1
   Chicani CF, 2013, CAN J OPHTHALMOL, V48, pE130, DOI 10.1016/j.jcjo.2013.05.011
   Colella P, 2009, TRENDS MOL MED, V15, P23, DOI 10.1016/j.molmed.2008.11.003
   Cousins SW, 2015, RETINA TODAY, P83
   Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063
   Doughan AK, 2007, ANTIOXID REDOX SIGN, V9, P1825, DOI 10.1089/ars.2007.1693
   Ellouze S, 2008, AM J HUM GENET, V83, P373, DOI 10.1016/j.ajhg.2008.08.013
   Elrod JW, 2010, J CLIN INVEST, V120, P3680, DOI 10.1172/JCI43171
   Enns GM, 2012, MOL GENET METAB, V105, P91, DOI 10.1016/j.ymgme.2011.10.009
   Erb M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036153
   Feuer WJ, 2016, OPHTHALMOLOGY, V123, P558, DOI 10.1016/j.ophtha.2015.10.025
   Figueroa-Martinez F, 2011, MITOCHONDRION, V11, P147, DOI 10.1016/j.mito.2010.09.003
   Fraser JA, 2010, SURV OPHTHALMOL, V55, P299, DOI 10.1016/j.survophthal.2009.10.002
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Giorgio V, 2012, BBA-BIOENERGETICS, V1817, P363, DOI 10.1016/j.bbabio.2011.10.012
   Gruber J, 2013, BIOTECHNOL ADV, V31, P563, DOI 10.1016/j.biotechadv.2012.09.005
   Gueven N, 2016, DRUG TODAY, V52, P173, DOI 10.1358/dot.2016.52.3.2463564
   Gueven N., 2014, BIOL MED, V1, P2
   Gueyen N, 2015, REDOX BIOL, V4, P289, DOI 10.1016/j.redox.2015.01.009
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Haefeli RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017963
   Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5
   Heitz FD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045182
   Hofherr SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023376
   Howell N, 1998, VISION RES, V38, P1495, DOI 10.1016/S0042-6989(97)00444-6
   Huang J, 2013, CURR MOL MED, V13, P935, DOI 10.2174/15665240113139990049
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Ivandic BT, 2014, PHOTOMED LASER SURG, V32, P181, DOI 10.1089/pho.2013.3535
   James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200
   Jariyakosol K., 2011, J HLTH RES, V25
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   Kernt M, 2010, ACTA OPHTHALMOL, V88, pe78, DOI 10.1111/j.1755-3768.2010.01875.x
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Koilkonda R, 2014, INVEST OPHTH VIS SCI, V55, P7739, DOI 10.1167/iovs.14-15388
   Lands LC, 1999, J APPL PHYSIOL, V87, P1381, DOI 10.1152/jappl.1999.87.4.1381
   Lee S, 2012, INVEST OPHTH VIS SCI, V53, P2431, DOI 10.1167/iovs.12-9596
   Li JQ, 2011, BIOCHEM BIOPH RES CO, V404, P349, DOI 10.1016/j.bbrc.2010.11.122
   Mancuso M, 2010, J NEUROL, V257, P774, DOI 10.1007/s00415-009-5409-7
   Mao PZ, 2013, BBA-MOL BASIS DIS, V1832, P2322, DOI 10.1016/j.bbadis.2013.09.005
   Martin KRG, 2004, EYE, V18, P1049, DOI 10.1038/sj.eye.6701579
   McManus MJ, 2011, J NEUROSCI, V31, P15703, DOI 10.1523/JNEUROSCI.0552-11.2011
   Metz G, 2015, ACTA OPHTHALMOL, V93, DOI 10.1111/j.1755-3768.2015.0429
   Metz G., 2014, ACTA OPHTHALMOL, V92, P5253
   Murphy MP, 2007, ANNU REV PHARMACOL, V47, P629, DOI 10.1146/annurev.pharmtox.47.120505.105110
   Murphy MP, 2001, EXPERT OPIN BIOL TH, V1, P753, DOI 10.1517/14712598.1.5.753
   Navas P, 2007, MITOCHONDRION, V7, pS34, DOI 10.1016/j.mito.2007.02.010
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Nunomura A., 2007, CNS & Neurological Disorders-Drug Targets, V6, P411, DOI 10.2174/187152707783399201
   Oca-Cossio J, 2003, GENETICS, V165, P707
   Papucci L, 2003, J BIOL CHEM, V278, P28220, DOI 10.1074/jbc.M302297200
   Pastore A, 2013, MOL GENET METAB, V109, P208, DOI 10.1016/j.ymgme.2013.03.011
   PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002
   Perales-Clemente E, 2011, NUCLEIC ACIDS RES, V39, P225, DOI 10.1093/nar/gkq769
   Petrov A, 2016, ADV THER, V33, P96, DOI 10.1007/s12325-015-0274-5
   Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42
   Qu JF, 2009, INVEST OPHTH VIS SCI, V50, P1814, DOI 10.1167/iovs.08-2656
   Ramsay RR, 2007, BRIT J PHARMACOL, V152, P946, DOI 10.1038/sj.bjp.0707430
   Rauchova H, 2012, PHYSIOL RES, V61, P259, DOI 10.33549/physiolres.932318
   Rengelshausen J, 2004, EUR J CLIN PHARMACOL, V60, P709, DOI 10.1007/s00228-004-0818-0
   Rizzo G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050230
   Roestenberg P, 2012, MITOCHONDRION, V12, P57, DOI 10.1016/j.mito.2011.06.011
   Rojas JC, 2009, NEUROTOX RES, V15, P260, DOI 10.1007/s12640-009-9027-z
   Sadun AA, 2012, ARCH NEUROL-CHICAGO, V69, P331, DOI 10.1001/archneurol.2011.2972
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Shimoyama M, 2001, J PHARMACOL EXP THER, V297, P364
   Shrader WD, 2011, BIOORG MED CHEM LETT, V21, P3693, DOI 10.1016/j.bmcl.2011.04.085
   Skulachev VP, 2009, BBA-BIOENERGETICS, V1787, P437, DOI 10.1016/j.bbabio.2008.12.008
   Smith RAJ, 2004, METHOD ENZYMOL, V382, P45
   Snow BJ, 2010, MOVEMENT DISORD, V25, P1670, DOI 10.1002/mds.23148
   Szeto HH, 2006, AAPS J, V8, pE277, DOI 10.1007/BF02854898
   Szeto HH, 2014, BRIT J PHARMACOL, V171, P2029, DOI 10.1111/bph.12461
   Tang J, 2014, BRIT J OPHTHALMOL, V98, P1013, DOI 10.1136/bjophthalmol-2013-304477
   Tang J, 2013, INVEST OPHTH VIS SCI, V54, P3681, DOI 10.1167/iovs.12-11018
   Valero T, 2014, CURR PHARM DESIGN, V20, P5507, DOI 10.2174/138161282035140911142118
   Vlachantoni D, 2011, HUM MOL GENET, V20, P322, DOI 10.1093/hmg/ddq467
   Wan X, 2016, SCI REP-UK, V6, DOI 10.1038/srep21587
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Yang S. H., 2015, PROG NEUROBIOL
   Yu H, 2012, P NATL ACAD SCI USA, V109, pE1238, DOI 10.1073/pnas.1119577109
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
   Zhang XA, 2006, NEUROTOX RES, V9, P47, DOI 10.1007/BF03033307
   Zhang YO, 2003, J INVEST DERMATOL, V120, P849, DOI 10.1046/j.1523-1747.2003.12133.x
   Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200
   Zhao KS, 2003, J PHARMACOL EXP THER, V304, P425, DOI 10.1124/jpet.102.040147
NR 104
TC 24
Z9 25
U1 1
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP
PY 2017
VL 36
SI SI
BP 7
EP 14
DI 10.1016/j.mito.2016.07.013
PG 8
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA FL0FW
UT WOS:000413888000003
PM 27476756
DA 2022-11-30
ER

PT J
AU Holan, V
   Hermankova, B
   Kossl, J
AF Holan, Vladimir
   Hermankova, Barbora
   Kossl, Jan
TI Perspectives of Stem Cell-Based Therapy for Age-Related Retinal
   Degenerative Diseases
SO CELL TRANSPLANTATION
LA English
DT Article
DE age-related retinal degenerative diseases; mesenchymal stem cells; stem
   cell therapy
ID IN-VITRO; DIFFERENTIATION; LIMBAL
AB Retinal degenerative diseases, which include age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and glaucoma, mostly affect the elderly population and are the most common cause of decreased quality of vision or even blindness. So far, there is no satisfactory treatment protocol to prevent, stop, or cure these disorders. A great hope and promise for patients suffering from retinal diseases is represented by stem cell-based therapy that could replace diseased or missing retinal cells and support regeneration. In this respect, mesenchymal stem cells (MSCs) that can be obtained from the particular patient and used as autologous cells have turned out to be a promising stem cell type for treatment. Here we show that MSCs can differentiate into cells expressing markers of retinal cells, inhibit production of pro-inflammatory cytokines by retinal tissue, and produce a number of growth and neuroprotective factors for retinal regeneration. All of these properties make MSCs a prospective cell type for cell-based therapy of age-related retinal degenerative diseases.
C1 [Holan, Vladimir; Hermankova, Barbora; Kossl, Jan] Czech Acad Sci, Inst Expt Med, Dept Transplantat Immunol, Videnska 1083, Prague 14220 4, Czech Republic.
   [Holan, Vladimir; Hermankova, Barbora; Kossl, Jan] Charles Univ Prague, Fac Nat Sci, Dept Cell Biol, Prague, Czech Republic.
C3 Czech Academy of Sciences; Charles University Prague
RP Holan, V (通讯作者)，Czech Acad Sci, Inst Expt Med, Dept Transplantat Immunol, Videnska 1083, Prague 14220 4, Czech Republic.
EM holan@biomed.cas.cz
RI Hermankova, Barbora/U-8852-2017; Kössl, Jan/N-7871-2019
OI Hermankova, Barbora/0000-0002-8236-0012; Kössl, Jan/0000-0001-7503-4131;
   Holan, Vladimir/0000-0002-2011-3390
FU Grant Agency of the Czech Republic [17-04800S]; Grant Agency of the
   Charles University [80815];  [SVV 260206];  [CZ.1.05/1.1.00/02.0109]; 
   [CZ.2.16/3.1.00/21528];  [NPUI: LO1309]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by grant 17-04800S from the Grant Agency of the Czech
   Republic, project 80815 from the Grant Agency of the Charles University
   and by the projects SVV 260206, CZ.1.05/1.1.00/02.0109,
   CZ.2.16/3.1.00/21528, and NPUI: LO1309.
CR Abumaree M, 2012, STEM CELL REV REP, V8, P375, DOI 10.1007/s12015-011-9312-0
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Chudickova M, 2017, J TISSUE ENG REGEN M, V11, P1588, DOI 10.1002/term.2059
   English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56
   Holan V, 2015, STEM CELL TRANSL MED, V4, P1052, DOI 10.5966/sctm.2015-0039
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Javorkova E, 2014, STEM CELLS DEV, V23, P2490, DOI 10.1089/scd.2013.0568
   Mathivanan I, 2015, EXP CELL RES, V333, P11, DOI 10.1016/j.yexcr.2015.02.001
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Ng TK, 2015, SM OPHTHALMOL J, V1, P1003
   Park SS, 2017, PROG RETIN EYE RES, V56, P148, DOI 10.1016/j.preteyeres.2016.10.002
   Zajicova A, 2010, CELL TRANSPLANT, V19, P1281, DOI 10.3727/096368910X509040
NR 12
TC 14
Z9 15
U1 2
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PD SEP
PY 2017
VL 26
IS 9
SI SI
BP 1538
EP 1541
DI 10.1177/0963689717721227
PG 4
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA FM3LJ
UT WOS:000414907000006
PM 29113466
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ullrich, F
   Michels, S
   Lehmann, D
   Pieters, RS
   Becker, M
   Nelson, BJ
AF Ullrich, Franziska
   Michels, Stephan
   Lehmann, Daniel
   Pieters, Roel S.
   Becker, Matthias
   Nelson, Bradley J.
TI Assistive Device for Efficient Intravitreal Injections
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; ROBOTIC SURGERY; VITREORETINAL SURGERY; DA-VINCI;
   RANIBIZUMAB; SYSTEM; LASER; TOOL
AB Intravitreal therapy is the most common treatment for many chronic ophthalmic diseases, such as age-related macular degeneration. Due to the increasing worldwide demand for intravitreal injections, there exists a need to render this medical procedure more time-and cost-efficient while increasing patient safety. The authors propose a medical assistive device that injects medication intravitreally. Compared to the manual intravitreal injection procedure, an automated device has the potential to increase safety for patients, decrease procedure times, allow for integrated data storage and documentation, and reduce costs for medical staff and expensive operating rooms. This work demonstrates the development of an assistive injection system that is coarsely positioned over the patient's head by the human operator, followed by automatic fine positioning and intravitreal injection through the pars plana. Several safety features, such as continuous eye tracking and iris recognition, have been implemented. The functioning system is demonstrated through ex vivo experiments with porcine eyes.
C1 [Ullrich, Franziska; Lehmann, Daniel; Pieters, Roel S.; Nelson, Bradley J.] ETH, Multiscale Robot Lab, Zurich, Switzerland.
   [Michels, Stephan; Becker, Matthias] Triemli Hosp Zurich, Dept Ophthalmol, Birmensdorferstr 497, CH-8063 Zurich, Switzerland.
   [Michels, Stephan] Univ Zurich, Zurich, Switzerland.
   [Becker, Matthias] Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
C3 Swiss Federal Institutes of Technology Domain; ETH Zurich; Triemli
   Hospital; University of Zurich; Ruprecht Karls University Heidelberg
RP Michels, S (通讯作者)，Triemli Hosp Zurich, Dept Ophthalmol, Birmensdorferstr 497, CH-8063 Zurich, Switzerland.
EM stephan.michels@triemli.zuerich.ch
RI Mathis-Ullrich, Franziska/ABH-5608-2020; Becker, Matthias/A-8733-2014
OI Mathis-Ullrich, Franziska/0000-0001-5239-5305; Pieters,
   Roel/0000-0001-6728-304X
FU Novartis Switzerland AG
FX Drs. Becker, Michels, Nelson, and Ullrich report a connection with
   Ophthorobotics AG, including a pending patent. Ophthorobotics was
   financially supported by Novartis Switzerland AG. The remaining authors
   report no relevant financial disclosures.
CR Badran M, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/902873
   Ballantyne GH, 2002, SURG ENDOSC, V16, P1389, DOI 10.1007/s00464-001-8283-7
   Bergeles C, 2014, IEEE T BIO-MED ENG, V61, P1565, DOI 10.1109/TBME.2013.2293815
   Bergeles C, 2012, IEEE T ROBOT, V28, P798, DOI 10.1109/TRO.2012.2188165
   Bourla DH, 2008, RETINA-J RET VIT DIS, V28, P154, DOI 10.1097/IAE.0b013e318068de46
   DAUGMAN JG, 1985, J OPT SOC AM A, V2, P1160, DOI 10.1364/JOSAA.2.001160
   DAUGMAN JG, 1993, IEEE T PATTERN ANAL, V15, P1148, DOI 10.1109/34.244676
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Dharan S, 2002, J HOSP INFECT, V51, P79, DOI 10.1053/jhin.2002.1217
   Golder L, BEGLEITSTUDIE ANLASS
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gudeman J, 2013, DRUGS R&D, V13, P1, DOI 10.1007/s40268-013-0005-9
   Gupta PK, 1999, LECT NOTES COMPUT SC, V1679, P1218
   Hussain A, 2014, INT J CLIN PRACT, V68, P1376, DOI 10.1111/ijcp.12492
   Jagtap AD, 2004, P ANN INT IEEE EMBS, V26, P2771
   Kummer MP, 2010, IEEE T ROBOT, V26, P1006, DOI 10.1109/TRO.2010.2073030
   KWOH YS, 1988, IEEE T BIO-MED ENG, V35, P153, DOI 10.1109/10.1354
   Lanfranco AR, 2004, ANN SURG, V239, P14, DOI 10.1097/01.sla.0000103020.19595.7d
   MacLachlan RA, 2012, IEEE T ROBOT, V28, P195, DOI 10.1109/TRO.2011.2169634
   Matthews JL, 2014, OPHTHALMOLOGY, V121, P702, DOI 10.1016/j.ophtha.2013.10.015
   McKay R, 2000, BRIT J OPHTHALMOL, V84, P865, DOI 10.1136/bjo.84.8.865
   Meenink HCM, 2012, WOODH PUBL SER BIOM, V51, P185
   Michels S, 2012, SPEKTRUM AUGENHEILKD, V26, P2, DOI 10.1007/s00717-012-0072-2
   MUNNERLYN CR, 1988, J CATARACT REFR SURG, V14, P46, DOI 10.1016/S0886-3350(88)80063-4
   Nagy Z, 2009, J REFRACT SURG, V25, P1053, DOI 10.3928/1081597X-20091117-04
   Nakano T, 2009, INT J COMPUT ASS RAD, V4, P517, DOI 10.1007/s11548-009-0374-2
   Pitcher J. D., 2012, J COMPUT SCI SYST BI, V3, P1, DOI DOI 10.4172/JCSB.S3-001
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Souied E, 2015, EUR J OPHTHALMOL, V25, P529, DOI 10.5301/ejo.5000629
   Uneri A, 2010, P IEEE RAS-EMBS INT, P814, DOI 10.1109/BIOROB.2010.5625991
   Ullrich F, 2013, INVEST OPHTH VIS SCI, V54, P2853, DOI 10.1167/iovs.13-11825
   Yates DR, 2011, BJU INT, V108, P1708, DOI 10.1111/j.1464-410X.2011.10576.x
NR 33
TC 6
Z9 6
U1 2
U2 11
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD AUG
PY 2016
VL 47
IS 8
BP 752
EP 762
DI 10.3928/23258160-20160808-09
PG 11
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3GQ
UT WOS:000393101000009
PM 27548453
DA 2022-11-30
ER

PT J
AU Mainolfi, N
   Powers, J
   Meredith, E
   Elliott, J
   Gunderson, KG
   Poor, S
   Liu, F
   Anderson, K
AF Mainolfi, Nello
   Powers, James
   Meredith, Erik
   Elliott, Jason
   Gunderson, Karl G.
   Poor, Stephen
   Liu, Fang
   Anderson, Karen
TI Core Replacements in a Potent Series of VEGFR-2 Inhibitors and Their
   Impact on Potency, Solubility, and hERG
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Vascular endothelial growth factor receptor 2; VEGF; KDR; bicyclic core;
   scaffold morphing; AMD
ID ENDOTHELIAL GROWTH-FACTOR; TORSADE-DE-POINTES; MACULAR DEGENERATION;
   DRUG DEVELOPMENT; SAFETY; DESIGN; PROLONGATION; DERIVATIVES; CHANNEL;
   BIOLOGY
AB Anti-VEGF therapy has been a clinically validated treatment of age-related macular degeneration (AMD). We have recently reported the discovery of indole based oral VEGFR-2 inhibitors that provide sustained ocular retention and efficacy in models of wet-AMD. We disclose herein the synthesis and the biological evaluation of a series of novel core replacements as an expansion of the reported indole based VEGFR-2 inhibitor series. Addition of heteroatoms to the existing core and/or rearranging the heteroatoms around the 6-5 bicyclic ring structure produced a series of compounds that generally retained good on-target potency and an improved solubility profile. The hERG affinity was proven not be dependent on the change in lipophilicity through alteration of the core structure. A serendipitous discovery led to the identification of a new indole-pyrimidine connectivity: from 5-hydroxy to 6-hydroxyindole with potentially vast implication on the in vitro/in vivo properties of this class of compounds.
C1 [Mainolfi, Nello; Powers, James; Meredith, Erik; Elliott, Jason; Gunderson, Karl G.] Novartis Inst Biomed Res, Global Discovery Chem, 100 Technol Sq, Cambridge, MA 02139 USA.
   [Poor, Stephen; Liu, Fang; Anderson, Karen] Novartis Inst Biomed Res, Ophthalmol, 500 Technol Sq, Cambridge, MA 02139 USA.
   [Mainolfi, Nello] Raze Therapeut, 400 Technol Sq, Cambridge, MA 02139 USA.
C3 Novartis; Novartis
RP Mainolfi, N; Powers, J (通讯作者)，Novartis Inst Biomed Res, Global Discovery Chem, 100 Technol Sq, Cambridge, MA 02139 USA.; Mainolfi, N (通讯作者)，Raze Therapeut, 400 Technol Sq, Cambridge, MA 02139 USA.
EM nello@razetx.com; james.powers@novartis.com
CR Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Bell IM, 2001, J MED CHEM, V44, P2933, DOI 10.1021/jm010156p
   Borchard U, 2000, Z KARDIOL, V89, P6
   BRAGG DR, 1962, J CHEM SOC, P2627, DOI 10.1039/jr9620002627
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   HAYASHIDA M, 1990, HETEROCYCLES, V31, P1325
   Ikemoto T, 2002, TETRAHEDRON, V58, P489, DOI 10.1016/S0040-4020(01)01171-1
   Jamieson C, 2006, J MED CHEM, V49, P5029, DOI 10.1021/jm060379l
   Keith JM, 2010, J ORG CHEM, V75, P2722, DOI 10.1021/jo1001017
   Kerr JS, 2010, INT J TOXICOL, V29, P3, DOI 10.1177/1091581809352111
   Lagrutta AA, 2008, CURR TOP MED CHEM, V8, P1102, DOI 10.2174/156802608785700016
   LAMONTAGNE MP, 1989, J MED CHEM, V32, P1728, DOI 10.1021/jm00128a010
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Meanwell NA, 2011, CHEM RES TOXICOL, V24, P1420, DOI 10.1021/tx200211v
   Meredith EL, 2015, J MED CHEM, V58, P9273, DOI 10.1021/acs.jmedchem.5b01227
   Munster PN, 2009, CLIN CANCER RES, V15, P7077, DOI 10.1158/1078-0432.CCR-09-1214
   Recanatini M, 2005, MED RES REV, V25, P133, DOI 10.1002/med.20019
   Redfern WS, 2003, CARDIOVASC RES, V58, P32, DOI 10.1016/S0008-6363(02)00846-5
   Ritchie TJ, 2012, MEDCHEMCOMM, V3, P1062, DOI 10.1039/c2md20111a
   Shultz MD, 2011, J MED CHEM, V54, P4752, DOI 10.1021/jm200388e
   Siu T, 2008, BIOORG MED CHEM LETT, V18, P4191, DOI 10.1016/j.bmcl.2008.05.084
   Solekhova MA, 2002, RUSS J ORG CHEM+, V38, P1192, DOI 10.1023/A:1020913929185
   Storz T, 2008, SYNTHESIS-STUTTGART, P201, DOI 10.1055/s-2007-1000853
   Tamargo J, 2000, JPN J PHARMACOL, V83, P1, DOI 10.1254/jjp.83.1
   Wan ZK, 2007, J ORG CHEM, V72, P10194, DOI 10.1021/jo7020373
   Witchel HJ, 2000, CLIN EXP PHARMACOL P, V27, P753, DOI 10.1046/j.1440-1681.2000.03337.x
   Yin JJ, 2007, J ORG CHEM, V72, P4554, DOI 10.1021/jo070189y
NR 28
TC 6
Z9 6
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD APR
PY 2016
VL 7
IS 4
BP 357
EP 362
DI 10.1021/acsmedchemlett.6b00018
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DJ8BI
UT WOS:000374436700005
PM 27096041
OA Green Published
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Chang, A
   Grigg, J
   McCluskey, P
AF Broadhead, G. K.
   Chang, A.
   Grigg, J.
   McCluskey, P.
TI Efficacy and Safety of Saffron Supplementation: Current Clinical
   Findings
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE Saffron; clinical studies; carotenoids; antioxidant
ID CROCUS-SATIVUS L.; TO-MODERATE DEPRESSION; DOUBLE-BLIND; ACTIVE
   CONSTITUENTS; EXPERIMENTAL ATHEROSCLEROSIS; ERECTILE DYSFUNCTION; MEMORY
   IMPAIRMENTS; ALZHEIMERS-DISEASE; STIGMAS EXTRACT; ANIMAL-MODEL
AB Saffron (Crocus savitus) is a Middle-Eastern herb with strong antioxidant properties. Its major constituents, safranal, crocin, and crocetin, are also antioxidants and bear structural similarities to other well-known natural antixodant substances, such as zeaxanthin. Given the role of oxidative stress in many diseases, considerable interest has been shown into the potential role of saffron supplementation as a treatment for a range of diseases. In vitro and animal studies have provided evidence that saffron and its constituents may be potent therapies for a range of pathologies, including Alzheimer's disease, age-related macular degeneration (AMD) and cardiac ischemia. Whether these findings translate into clinical efficacy, however, has as of yet been incompletely assessed. This makes assessing the role of saffron supplementation in these diseases difficult. Here, we review the current human clinical evidence supporting saffron supplementation as a treatment for a range of pathologies and the underlying science supporting its use.
C1 [Broadhead, G. K.; Chang, A.; Grigg, J.; McCluskey, P.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
C3 University of Sydney
RP Broadhead, GK (通讯作者)，Level 13,Pk House 187 Macquarie St, Sydney, NSW, Australia.
EM gbro8081@uni.sydney.edu.au
RI McCluskey, Peter J/H-7607-2013; Grigg, John/A-6851-2013
OI McCluskey, Peter J/0000-0002-8177-1637; Grigg, John/0000-0002-6763-8119
CR Agha-Hosseini M, 2008, BJOG-INT J OBSTET GY, V115, P515, DOI 10.1111/j.1471-0528.2007.01652.x
   Ahmad AS, 2005, PHARMACOL BIOCHEM BE, V81, P805, DOI 10.1016/j.pbb.2005.06.007
   Akhondzadeh S, 2005, PHYTOTHER RES, V19, P148, DOI 10.1002/ptr.1647
   Akhondzadeh S, 2010, J CLIN PHARM THER, V35, P581, DOI 10.1111/j.1365-2710.2009.01133.x
   Akhondzadeh Shahin, 2004, BMC Complement Altern Med, V4, P12, DOI 10.1186/1472-6882-4-12
   Akhondzadeh S, 2010, PSYCHOPHARMACOLOGY, V207, P637, DOI 10.1007/s00213-009-1706-1
   Asdaq SMB, 2010, APPL BIOCHEM BIOTECH, V162, P358, DOI 10.1007/s12010-009-8740-7
   Assimopoulou AN, 2005, PHYTOTHER RES, V19, P997, DOI 10.1002/ptr.1749
   Ayatollahi H., 2013, PHYTOTHER RES
   Babu YPR, 2012, MED SCI LAW, V52, P205, DOI 10.1258/msl.2012.012025
   Basti AA, 2007, PROG NEURO-PSYCHOPH, V31, P439, DOI 10.1016/j.pnpbp.2006.11.010
   Bathaie SZ, 2010, CRIT REV FOOD SCI, V50, P761, DOI 10.1080/10408390902773003
   Berger F, 2011, NEUROSCIENCE, V180, P238, DOI 10.1016/j.neuroscience.2011.02.037
   Bharti S, 2012, EUR J NUTR, V51, P719, DOI 10.1007/s00394-011-0251-y
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Ebrahim-Habibi MB, 2010, BIOPOLYMERS, V93, P854, DOI 10.1002/bip.21477
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Feo F, 1997, ALLERGY, V52, P633, DOI 10.1111/j.1398-9995.1997.tb01042.x
   Fernandez-Sanchez L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043074
   Fukui H, 2011, PHYTOMEDICINE, V18, P726, DOI 10.1016/j.phymed.2010.11.013
   Georgiadou G, 2012, NEUROSCI LETT, V528, P27, DOI 10.1016/j.neulet.2012.08.081
   Geromichalos GD, 2012, J AGR FOOD CHEM, V60, P6131, DOI 10.1021/jf300589c
   Ghahghaei A., 2013, CELL MOL BIOL LETT
   Gomez-Gomez L, 2010, J INVEST ALLERG CLIN, V20, P407
   Gout B, 2010, NUTR RES, V30, P305, DOI 10.1016/j.nutres.2010.04.008
   He SY, 2007, EUR J PHARMACOL, V554, P191, DOI 10.1016/j.ejphar.2006.09.071
   He SY, 2005, LIFE SCI, V77, P907, DOI 10.1016/j.lfs.2005.02.006
   Heidary Mohammad, 2008, Urol J, V5, P255
   HIMENO H, 1987, AGR BIOL CHEM TOKYO, V51, P2395
   Hosseinzadeh H, 2008, PHYTOMEDICINE, V15, P491, DOI 10.1016/j.phymed.2007.09.020
   Hosseinzadeh H, 2010, PHYTOTHER RES, V24, P726, DOI 10.1002/ptr.3011
   Hosseinzadeh H, 2009, PHYTOTHER RES, V23, P768, DOI 10.1002/ptr.2597
   Javadi B, 2013, IRAN J BASIC MED SCI, V16, P1
   Joukar S, 2013, PHARM BIOL, V51, P836, DOI 10.3109/13880209.2013.767362
   Joukar S, 2010, CARDIOVASC TOXICOL, V10, P66, DOI 10.1007/s12012-010-9063-1
   Kanakis CD, 2007, J AGR FOOD CHEM, V55, P970, DOI 10.1021/jf062638l
   Karimi E, 2010, MOLECULES, V15, P6244, DOI 10.3390/molecules15096244
   Kashani L, 2013, HUM PSYCHOPHARM CLIN, V28, P54, DOI 10.1002/hup.2282
   Khalili Mohsen, 2010, Iran Biomed J, V14, P59
   Khori V, 2012, PHYTOTHER RES, V26, P826, DOI 10.1002/ptr.3643
   Kianbakht S, 2011, PHYTOTHER RES, V25, P1801, DOI 10.1002/ptr.3484
   Kuratsune H, 2010, PHYTOMEDICINE, V17, P840, DOI 10.1016/j.phymed.2010.03.025
   Lechtenberg M, 2008, PLANTA MED, V74, P764, DOI 10.1055/s-2008-1074535
   Lee IA, 2005, BIOL PHARM BULL, V28, P2106, DOI 10.1248/bpb.28.2106
   Lev E, 2008, J ETHNOPHARMACOL, V119, P24, DOI 10.1016/j.jep.2008.05.042
   Liu Z, 2012, CNS NEUROSCI THER, V18, P623, DOI 10.1111/j.1755-5949.2012.00334.x
   Lucas C D, 2001, Adv Food Nutr Res, V43, P195, DOI 10.1016/S1043-4526(01)43005-1
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Makri OE, 2013, MOL VIS, V19, P1188
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Masaki M, 2012, MOL NUTR FOOD RES, V56, P304, DOI 10.1002/mnfr.201100181
   Mehdizadeh R, 2013, IRAN J BASIC MED SCI, V16, P56
   Modabbernia A, 2012, PSYCHOPHARMACOLOGY, V223, P381, DOI 10.1007/s00213-012-2729-6
   Mohamadpour AH, 2013, IRAN J BASIC MED SCI, V16, P39
   Moneret-Vautrin D A, 2002, Allerg Immunol (Paris), V34, P135
   Moshiri E, 2006, PHYTOMEDICINE, V13, P607, DOI 10.1016/j.phymed.2006.08.006
   Nahid K, 2009, J MIDWIFERY WOM HEAL, V54, P401, DOI 10.1016/j.jmwh.2008.12.006
   Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Ordoudi SA, 2009, J AGR FOOD CHEM, V57, P3080, DOI 10.1021/jf804041g
   Pan T. L., 2013, PROTEOMICS
   Papandreou MA, 2006, J AGR FOOD CHEM, V54, P8762, DOI 10.1021/jf061932a
   PFANDER H, 1982, PHYTOCHEMISTRY, V21, P1039, DOI 10.1016/S0031-9422(00)82412-7
   Pfister S. M., 1996, J AGR FOOD CHEM, V44, P4
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Pitsikas N, 2008, PHYTOMEDICINE, V15, P1135, DOI 10.1016/j.phymed.2008.06.005
   Pitsikas N, 2006, BEHAV BRAIN RES, V173, P112, DOI 10.1016/j.bbr.2006.06.005
   Purushothuman S, 2013, J PARKINSON DIS, V3, P77, DOI 10.3233/JPD-130173
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Razavi BM, 2013, CHEM-BIOL INTERACT, V203, P547, DOI 10.1016/j.cbi.2013.03.010
   Safarinejad MR, 2010, INT J IMPOT RES, V22, P240, DOI 10.1038/ijir.2010.10
   Safarinejad MR, 2011, PHYTOTHER RES, V25, P508, DOI 10.1002/ptr.3294
   Samarghandian S, 2013, J PHARM PHARM SCI, V16, P352, DOI 10.18433/J3ZS3Q
   Sanocka D, 1997, INT J ANDROL, V20, P255, DOI 10.1046/j.1365-2605.1997.00050.x
   Schmidt M, 2007, WIEN MED WOCHENSCHR, V157, P315, DOI 10.1007/s10354-007-0428-4
   Shamsa A, 2009, PHYTOMEDICINE, V16, P690, DOI 10.1016/j.phymed.2009.03.008
   Sheng L, 2006, EUR J PHARMACOL, V543, P116, DOI 10.1016/j.ejphar.2006.05.038
   Shirali S, 2013, PHYTOTHER RES, V27, P1042, DOI 10.1002/ptr.4836
   Tamaddonfard E, 2013, IRAN J BASIC MED SCI, V16, P91
   Tang FT, 2006, BIOCHEM PHARMACOL, V72, P558, DOI 10.1016/j.bcp.2006.05.018
   Tarantilis PA, 1997, J AGR FOOD CHEM, V45, P459, DOI 10.1021/jf960105e
   Verma S K, 1998, Indian J Med Sci, V52, P205
   Martinez FV, 2007, CONTACT DERMATITIS, V57, p284A, DOI 10.1111/j.1600-0536.2007.01129.x
   Winterhalter P., 2001, FOOD REV INT, V16, P21
   Wuthrich B, 1997, ALLERGY, V52, P476, DOI 10.1111/j.1398-9995.1997.tb01034.x
   Xuan B, 1999, J OCUL PHARMACOL TH, V15, P143, DOI 10.1089/jop.1999.15.143
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yan JL, 2010, SHOCK, V33, P83, DOI 10.1097/SHK.0b013e3181a98f55
   Zhang ZY, 2013, PHARM BIOL, V51, P920, DOI 10.3109/13880209.2013.771190
   Zheng SG, 2006, J CARDIOVASC PHARM, V47, P70, DOI 10.1097/01.fjc.0000194686.11712.02
   Zheng SG, 2005, BIOCHEM PHARMACOL, V70, P1192, DOI 10.1016/j.bcp.2005.07.034
NR 91
TC 27
Z9 28
U1 1
U2 39
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 2016
VL 56
IS 16
BP 2767
EP 2776
DI 10.1080/10408398.2013.879467
PG 10
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA DV5LP
UT WOS:000382969000010
PM 25875654
DA 2022-11-30
ER

PT J
AU Jiang, M
   Esteve-Rudd, J
   Lopes, VS
   Diemer, T
   Lillo, C
   Rump, A
   Williams, DS
AF Jiang, Mei
   Esteve-Rudd, Julian
   Lopes, Vanda S.
   Diemer, Tanja
   Lillo, Concepcion
   Rump, Agrani
   Williams, David S.
TI Microtubule motors transport phagosomes in the RPE, and lack of KLC1
   leads to AMD-like pathogenesis
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; TUG-OF-WAR; MACULAR DEGENERATION;
   AXONAL-TRANSPORT; MYOSIN VIIA; USHER-SYNDROME; IN-VIVO; KINESIN;
   PROTEIN; CELLS
AB The degradation of phagosomes, derived from the ingestion of photoreceptor outer segment (POS) disk membranes, is a major role of the retinal pigment epithelium (RPE). Here, POS phagosomes were observed to associate with myosin-7 alpha, and then kinesin-1, as they moved from the apical region of the RPE. Live-cell imaging showed that the phagosomes moved bidirectionally along microtubules in RPE cells, with kinesin-1 light chain 1 (KLC1) remaining associated in both directions and during pauses. Lack of KLC1 did not inhibit phagosome speed, but run length was decreased, and phagosome localization and degradation were impaired. In old mice, lack of KLC1 resulted in RPE pathogenesis that was strikingly comparable to aspects of age-related macular degeneration (AMD), with an excessive accumulation of RPE and sub-RPE deposits, as well as oxidative and inflammatory stress responses. These results elucidate mechanisms of POS phagosome transport in relation to degradation, and demonstrate that defective microtubule motor transport in the RPE leads to phenotypes associated with AMD.
C1 [Jiang, Mei; Esteve-Rudd, Julian; Lopes, Vanda S.; Diemer, Tanja; Rump, Agrani; Williams, David S.] Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Williams, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
   [Williams, David S.] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA.
   [Williams, David S.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA.
   [Lopes, Vanda S.] Univ Coimbra, Fac Med, Inst Biomed Imaging & Life Sci, Ctr Ophthalmol, P-3000548 Coimbra, Portugal.
   [Lillo, Concepcion; Williams, David S.] Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Williams, David S.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; Universidade de Coimbra; University of
   California System; University of California San Diego; University of
   California System; University of California San Diego
RP Williams, DS (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM dswilliams@ucla.edu
RI Lillo, Concepcion/A-6321-2009
OI Lillo, Concepcion/0000-0001-5814-9826
FU National Science Foundation Major Research Instrumentation grant
   [CHE-0722519]; National Institutes of Health (NIH) R01 [EY13408,
   EY07042]; NIH core [EY00331]; RPB Jules and Doris Stein Professorship;
   NATIONAL EYE INSTITUTE [P30EY000331, R01EY013408] Funding Source: NIH
   RePORTER
FX STED microscopy was performed at the California NanoSystems Institute
   Advanced Light Microscopy/Spectroscopy Shared Resource Facility at UCLA,
   supported in part by funding from a National Science Foundation Major
   Research Instrumentation grant (CHE-0722519); we thank Laurent Bentolila
   for assistance. The research was supported by National Institutes of
   Health (NIH) R01 grants EY13408 and EY07042, NIH core grant EY00331, and
   an RPB Jules and Doris Stein Professorship (to D.S. Williams).
CR Al-Haddad AH, 2001, MOL BIOL CELL, V12, P2742, DOI 10.1091/mbc.12.9.2742
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andersson ME, 2007, MOL VIS, V13, P993
   Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889
   BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817
   Blocker A, 1996, J BIOL CHEM, V271, P3803
   Blocker A, 1998, J CELL SCI, V111, P303
   Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677
   Diemer T, 2008, ADV EXP MED BIOL, V613, P321, DOI 10.1007/978-0-387-74904-4_37
   Encalada SE, 2011, CELL, V144, P551, DOI 10.1016/j.cell.2011.01.021
   Esteve-Rudd J, 2014, ADV EXP MED BIOL, V801, P85, DOI 10.1007/978-1-4614-3209-8_11
   EUTENEUER U, 1980, J CELL BIOL, V87, P509, DOI 10.1083/jcb.87.2.509
   Fan SL, 2004, CURR BIOL, V14, P1451, DOI 10.1016/j.cub.2004.08.025
   FEENEY L, 1973, INVEST OPHTH VISUAL, V12, P635
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008
   Frost L.S., 2014, MOL NEUROBIOL IN PRE
   Fu MM, 2014, TRENDS CELL BIOL, V24, P564, DOI 10.1016/j.tcb.2014.05.002
   Fu MM, 2014, DEV CELL, V29, P577, DOI 10.1016/j.devcel.2014.04.015
   Fu MM, 2013, J CELL BIOL, V202, P495, DOI 10.1083/jcb.201302078
   Futter CE, 2004, MOL BIOL CELL, V15, P2264, DOI 10.1091/mbc.E03-10-0772
   Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580
   Gibbs D, 2003, ADV EXP MED BIOL, V533, P347
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275
   Gordiyenko NV, 2010, INVEST OPHTH VIS SCI, V51, P1143, DOI 10.1167/iovs.09-4117
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hendricks AG, 2010, CURR BIOL, V20, P697, DOI 10.1016/j.cub.2010.02.058
   HERMAN KG, 1982, INVEST OPHTH VIS SCI, V23, P277
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hosein RE, 2005, CELL MOTIL CYTOSKEL, V61, P49, DOI 10.1002/cm.20065
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Krock BL, 2007, P NATL ACAD SCI USA, V104, P4600, DOI 10.1073/pnas.0605818104
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Liu XR, 1999, J NEUROSCI, V19, P6267
   Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2
   Lopes VS, 2007, TRAFFIC, V8, P486, DOI 10.1111/j.1600-0854.2007.00548.x
   Lopes VS, 2011, HUM MOL GENET, V20, P2560, DOI 10.1093/hmg/ddr155
   Lopes VS, 2010, MOL BIOL CELL, V21, P4076, DOI 10.1091/mbc.E10-08-0715
   Luhmann UFO, 2015, HUM MOL GENET, V24, P128, DOI 10.1093/hmg/ddu424
   Maday S, 2012, J CELL BIOL, V196, P407, DOI 10.1083/jcb.201106120
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Muller MJI, 2008, P NATL ACAD SCI USA, V105, P4609, DOI 10.1073/pnas.0706825105
   Nishiyama K, 2002, ANAT REC, V267, P196, DOI 10.1002/ar.10102
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   Pernigo S, 2013, SCIENCE, V340, P356, DOI 10.1126/science.1234264
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95
   Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395
   Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Reis GF, 2012, MOL BIOL CELL, V23, P1700, DOI 10.1091/mbc.E11-11-0938
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   RIZZOLO LJ, 1993, DEV BIOL, V157, P147, DOI 10.1006/dbio.1993.1119
   Saxton WM, 2012, J CELL SCI, V125, P2095, DOI 10.1242/jcs.053850
   SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507
   SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shi H, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-83
   Soppina V, 2009, P NATL ACAD SCI USA, V106, P19381, DOI 10.1073/pnas.0906524106
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   TROUTT LL, 1988, J CELL BIOL, V107, P1461, DOI 10.1083/jcb.107.4.1461
   Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117
   Tuma MC, 1998, J CELL BIOL, V143, P1547, DOI 10.1083/jcb.143.6.1547
   Udovichenko IP, 2002, J CELL SCI, V115, P445
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053
   Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wavre-Shapton ST, 2014, J CELL SCI, V127, P3852, DOI 10.1242/jcs.154757
   Wavre-Shapton ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057769
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Welte MA, 2004, CURR BIOL, V14, pR525, DOI 10.1016/j.cub.2004.06.045
   Williams DS, 2008, VISION RES, V48, P433, DOI 10.1016/j.visres.2007.08.015
   Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 93
TC 46
Z9 46
U1 1
U2 9
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD AUG 17
PY 2015
VL 210
IS 4
BP 595
EP 611
DI 10.1083/jcb.201410112
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CP3BD
UT WOS:000359750900010
PM 26261180
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Pipis, A
   Touliou, E
   Augustin, AJ
AF Pipis, Antonios
   Touliou, Eftychia
   Augustin, Albert J.
TI Macular Pigment Optical Density in a Central European Population
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID SPATIAL PROFILE; CONSTITUENT CAROTENOIDS; SERUM CONCENTRATIONS; AGE;
   ZEAXANTHIN; LUTEIN; DISTRIBUTIONS; DEGENERATION; DIET
AB BACKGROUND AND OBJECTIVE: The purpose of this study is to measure the macular pigment optical density and study its spatial profile as well as identify its determinant factors in a Central European population.
   PATIENTS AND METHODS: The macular pigment optical density (MPOD) and its distribution were assessed in 228 eyes of 129 subjects using fundus reflectometry with the Visucam 500 (Carl Zeiss Meditec, Jena, Germany).
   RESULTS: A statistically significant positive association between a diet rich in xanthophylls and all MPOD values was found. A positive monotonic relationship was demonstrated between an increasing degree in pigment distribution eccentricity and age, as well as all MPOD values except for area.
   CONCLUSION: Assuming that macular pigment is protective against age-related macular degeneration, our study highlights the role of nutritional counseling and intervention in preventing this disease. Furthermore, MPOD appears to increase with age, and the distribution of macular pigment appears to form more eccentric profiles.
C1 [Pipis, Antonios; Touliou, Eftychia; Augustin, Albert J.] Klinikum Karlsruhe, Augenklin, D-76133 Karlsruhe, Germany.
C3 Municipal Hospital Karlsruhe; University of Hamburg; University Medical
   Center Hamburg-Eppendorf
RP Pipis, A (通讯作者)，Staedt Klinikum Karlsruhe, Augenklin, Moltkestr 90, D-76133 Karlsruhe, Germany.
EM antoniospipis@hotmail.com
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   [Anonymous], 2010, VIS DIG FUND CAM ADD
   Augustin AG, 2010, SEHSCHADEN VORBEUGEN, P21
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Chang Y, 2002, MED PHYS, V29, P2621, DOI 10.1118/1.1515761
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P8016, DOI 10.1167/iovs.11-7610
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   McArthur C, 2011, OPTICIAN, P18
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Pocock G, 2011, J VISION, V11, P57
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   Sharifzadeh M, 2008, J OPT SOC AM A, V25, P947, DOI 10.1364/JOSAA.25.000947
   Sharifzadeh M, 2006, J OPT SOC AM A, V23, P2373, DOI 10.1364/JOSAA.23.002373
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
NR 34
TC 7
Z9 7
U1 0
U2 10
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY-JUN
PY 2013
VL 44
IS 3
BP 260
EP 267
DI 10.3928/23258160-20130503-09
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 172QV
UT WOS:000321020100008
PM 23676228
DA 2022-11-30
ER

PT J
AU Wong, WT
AF Wong, Wai T.
TI Microglial aging in the healthy CNS: phenotypes, drivers, and
   rejuvenation
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE microglia; aging; priming; neurodegeneration; rejuvenation;
   inflammation; activation; senescence
ID LONG-TERM POTENTIATION; ADULT HIPPOCAMPAL NEUROGENESIS;
   CENTRAL-NERVOUS-SYSTEM; AMYOTROPHIC-LATERAL-SCLEROSIS;
   ALZHEIMERS-DISEASE BRAIN; NEURAL PRECURSOR CELLS; TRANSCRIPTION
   FACTOR-A; AGE-RELATED DECLINE; ACTIVATION IN-VIVO; RAT-BRAIN
AB Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and age-related macular degeneration (AMD), share two characteristics in common: (1) a disease prevalence that increases markedly with advancing age, and (2) neuroinflammatory changes in which microglia, the primary resident immune cell of the CNS, feature prominently. These characteristics have led to the hypothesis that pathogenic mechanisms underlying age-related neurodegenerative disease involve aging changes in microglia. If correct, targeting features of microglial senescence may constitute a feasible therapeutic strategy. This review explores this hypothesis and its implications by considering the current knowledge on how microglia undergo change during aging and how the emergence of these aging phenotypes relate to significant alterations in microglial function. Evidence and theories on cellular mechanisms implicated in driving senescence in microglia are reviewed, as are rejuvenative measures and strategies that aim to reverse or ameliorate the aging microglial phenotype. Understanding and controlling microglial aging may represent an opportunity for elucidating disease mechanisms and for formulating novel therapies.
C1 NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Wong, WT (通讯作者)，NEI, Unit Neuron Glia Interact Retinal Dis, NIH, 6 Ctr Dr,6-217, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016
FU National Eye Institute Intramural Research Program; Macular Degeneration
   Research (MDR); BrightFocus Foundation; NATIONAL EYE INSTITUTE
   [ZIAEY000505, ZIAEY000463] Funding Source: NIH RePORTER
FX Research in our laboratory is supported by the National Eye Institute
   Intramural Research Program. Acknowledgment is made for grant support to
   the donors of Macular Degeneration Research (MDR), a program of the
   American Health Assistance Foundation (AHAF, now the BrightFocus
   Foundation).
CR Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100
   Abraham J, 2008, NEUROBIOL AGING, V29, P614, DOI 10.1016/j.neurobiolaging.2006.11.002
   Abraham J, 2009, REJUV RES, V12, P445, DOI 10.1089/rej.2009.0888
   Abraham J, 2009, BRAIN BEHAV IMMUN, V23, P396, DOI 10.1016/j.bbi.2008.12.008
   Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022
   Barrientos RM, 2004, J NEUROIMMUNOL, V155, P119, DOI 10.1016/j.jneuroim.2004.06.009
   Barrientos RM, 2012, J NEUROSCI, V32, P14641, DOI 10.1523/JNEUROSCI.2173-12.2012
   Barrientos RM, 2011, J NEUROSCI, V31, P11578, DOI 10.1523/JNEUROSCI.2266-11.2011
   Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016
   Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P46, DOI 10.1016/j.bbi.2008.07.002
   Bartzokis G, 1997, MAGN RESON IMAGING, V15, P29, DOI 10.1016/S0730-725X(96)00234-2
   Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x
   BENKOVIC SA, 1993, J COMP NEUROL, V338, P97, DOI 10.1002/cne.903380108
   Berg BM, 2005, J NUTR, V135, P1157, DOI 10.1093/jn/135.5.1157
   Bian QN, 2012, ADV EXP MED BIOL, V723, P43, DOI 10.1007/978-1-4614-0631-0_7
   Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007
   Blackmore DG, 2009, STEM CELLS, V27, P2044, DOI 10.1002/stem.120
   Boscia F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006486
   Buchanan JB, 2008, PSYCHONEUROENDOCRINO, V33, P755, DOI 10.1016/j.psyneuen.2008.02.013
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006
   Cacci E, 2008, GLIA, V56, P412, DOI 10.1002/glia.20616
   Cai Z, 2012, J NEUROSCI RES, V90, P1105, DOI 10.1002/jnr.23011
   Campuzano O, 2008, J NEUROSCI RES, V86, P3170, DOI 10.1002/jnr.21751
   Capotondo A, 2012, P NATL ACAD SCI USA, V109, P15018, DOI 10.1073/pnas.1205858109
   Chapman TR, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.015
   Chapman TR, 2010, J NEUROSCI, V30, P7598, DOI 10.1523/JNEUROSCI.5172-09.2010
   Cheepsunthorn P, 1998, J COMP NEUROL, V400, P73
   Chen M. F., 2012, J PHYSL, V591, P985
   Chen SK, 2010, CELL, V141, P775, DOI 10.1016/j.cell.2010.03.055
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chong ZZ, 2012, PROG NEUROBIOL, V99, P128, DOI 10.1016/j.pneurobio.2012.08.001
   Clarke RM, 2008, J BIOL CHEM, V283, P1808, DOI 10.1074/jbc.M707442200
   Comalada M, 2006, BIOCHEM PHARMACOL, V72, P1010, DOI 10.1016/j.bcp.2006.07.016
   Conde JR, 2006, NEUROBIOL AGING, V27, P1451, DOI 10.1016/j.neurobiolaging.2005.07.012
   Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cox FF, 2012, BRAIN BEHAV IMMUN, V26, P789, DOI 10.1016/j.bbi.2011.10.004
   Crain JM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-24
   D'Haese JG, 2012, EXPERT OPIN THER TAR, V16, P613, DOI 10.1517/14728222.2012.682574
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   Dello Russo C, 2013, GLIA, V61, P301, DOI 10.1002/glia.22433
   Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907
   Dheen ST, 2005, GLIA, V50, P21, DOI 10.1002/glia.20153
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Donati Alessio, 2006, Molecular Aspects of Medicine, V27, P455, DOI 10.1016/j.mam.2006.08.003
   Donati A, 2006, REJUV RES, V9, P408, DOI 10.1089/rej.2006.9.408
   Downer EJ, 2010, NEUROBIOL AGING, V31, P118, DOI 10.1016/j.neurobiolaging.2008.03.017
   Downer EJ, 2009, J NEUROCHEM, V109, P1516, DOI 10.1111/j.1471-4159.2009.06076.x
   Duan HL, 2003, CEREB CORTEX, V13, P950, DOI 10.1093/cercor/13.9.950
   Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100
   Encinas JM, 2012, BEHAV BRAIN RES, V227, P433, DOI 10.1016/j.bbr.2011.10.010
   Farber K, 2006, PFLUG ARCH EUR J PHY, V452, P615, DOI 10.1007/s00424-006-0064-7
   Fitzner D, 2011, J CELL SCI, V124, P447, DOI 10.1242/jcs.074088
   Flanary BE, 2007, REJUV RES, V10, P61, DOI 10.1089/rej.2006.9096
   Flanary BE, 2005, J NEUROSCI RES, V82, P160, DOI 10.1002/jnr.20636
   Flanary BE, 2004, GLIA, V45, P75, DOI 10.1002/glia.10301
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Frank MG, 2010, BRAIN BEHAV IMMUN, V24, P254, DOI 10.1016/j.bbi.2009.10.005
   Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013
   Gemma C, 2002, J NEUROSCI, V22, P6114
   Griffin R, 2006, J NEUROCHEM, V99, P1263, DOI 10.1111/j.1471-4159.2006.04165.x
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hayashi Y, 2008, J NEUROSCI, V28, P8624, DOI 10.1523/JNEUROSCI.1957-08.2008
   Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805
   Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   Hughes V, 2012, NATURE, V485, P570, DOI 10.1038/485570a
   Hunter Randy L, 2008, Curr Aging Sci, V1, P112
   Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362
   Izzi V, 2012, FRONT BIOSCI-LANDMRK, V17, P2396, DOI 10.2741/4061
   Jang S, 2008, P NATL ACAD SCI USA, V105, P7534, DOI 10.1073/pnas.0802865105
   Jang S, 2010, NUTR REV, V68, P719, DOI 10.1111/j.1753-4887.2010.00336.x
   Jang S, 2010, J NUTR, V140, P1892, DOI 10.3945/jn.110.123273
   Kabaso D, 2009, CEREB CORTEX, V19, P2248, DOI 10.1093/cercor/bhn242
   KANEKO Y, 1989, ACTA NEUROPATHOL, V79, P129, DOI 10.1007/BF00294369
   Kang J, 2007, J CELL BIOL, V179, P1219, DOI 10.1083/jcb.200705046
   Kanki T, 2004, ANN NY ACAD SCI, V1011, P61, DOI 10.1196/annals.1293.007
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040
   Kim JH, 2008, FREE RADICAL BIO MED, V45, P885, DOI 10.1016/j.freeradbiomed.2008.06.019
   Kim YH, 2010, INT IMMUNOPHARMACOL, V10, P1560, DOI 10.1016/j.intimp.2010.09.007
   Kim YP, 2004, NEUROSCI LETT, V355, P152, DOI 10.1016/j.neulet.2003.11.005
   Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203
   Kohman RA, 2012, BRAIN BEHAV IMMUN, V26, P803, DOI 10.1016/j.bbi.2011.10.006
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Kuhn HG, 1996, J NEUROSCI, V16, P2027
   Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009
   Kwan JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035241
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009
   Lauro C, 2010, NEUROPSYCHOPHARMACOL, V35, P1550, DOI 10.1038/npp.2010.26
   LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2
   Lee D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047098
   Lee JC, 2012, BIOCHEM BIOPH RES CO, V418, P359, DOI 10.1016/j.bbrc.2012.01.026
   Leem YH, 2011, BIOCHEM BIOPH RES CO, V406, P359, DOI 10.1016/j.bbrc.2011.02.046
   Letiembre M, 2007, NEUROSCIENCE, V146, P248, DOI 10.1016/j.neuroscience.2007.01.004
   Li Y, 2012, DEV CELL, V23, P1189, DOI 10.1016/j.devcel.2012.10.027
   Lin C, 2013, NEUROSCIENCE, V231, P216, DOI 10.1016/j.neuroscience.2012.11.051
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Liu X, 2012, NEUROSCIENCE, V216, P133, DOI 10.1016/j.neuroscience.2012.04.050
   Lopes KO, 2008, GLIA, V56, P1048, DOI 10.1002/glia.20678
   Lyons A, 2007, J NEUROSCI, V27, P8309, DOI 10.1523/JNEUROSCI.1781-07.2007
   Lyons A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-27
   Lyons A, 2009, BRAIN BEHAV IMMUN, V23, P1020, DOI 10.1016/j.bbi.2009.05.060
   Lyons A, 2009, J NEUROCHEM, V110, P1547, DOI 10.1111/j.1471-4159.2009.06253.x
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mata N. L., 2012, RETINA, V33, P498
   McGahon BM, 1999, NEUROBIOL AGING, V20, P643, DOI 10.1016/S0197-4580(99)00027-5
   McPherson CA, 2011, BRAIN BEHAV IMMUN, V25, P850, DOI 10.1016/j.bbi.2010.09.003
   Medrano S, 2009, NEUROBIOL AGING, V30, P483, DOI 10.1016/j.neurobiolaging.2007.07.016
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015
   Miller KR, 2007, NEURON GLIA BIOL, V3, P245, DOI 10.1017/S1740925X08000136
   Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417
   Montero M, 2009, BRAIN RES, V1291, P140, DOI 10.1016/j.brainres.2009.06.097
   Moore ME, 2005, BIOCHEM SOC T, V33, P573, DOI 10.1042/BST0330573
   Morrison JH, 2012, NAT REV NEUROSCI, V13, P240, DOI 10.1038/nrn3200
   Mouton PR, 2002, BRAIN RES, V956, P30, DOI 10.1016/S0006-8993(02)03475-3
   Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161
   Nakanishi H, 2011, NEURON GLIA BIOL, V7, P17, DOI 10.1017/S1740925X1100010X
   Nakanishi H, 2009, BEHAV BRAIN RES, V201, P1, DOI 10.1016/j.bbr.2009.02.001
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008
   Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200
   Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x
   OGURA K, 1994, NEUROREPORT, V5, P1224, DOI 10.1097/00001756-199406020-00016
   Ojo B, 2012, BRAIN BEHAV IMMUN, V26, P778, DOI 10.1016/j.bbi.2011.09.013
   Olovnikov AM, 1996, EXP GERONTOL, V31, P443, DOI 10.1016/0531-5565(96)00005-8
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109
   Peinado MA, 1998, MICROSC RES TECHNIQ, V43, P34, DOI 10.1002/(SICI)1097-0029(19981001)43:1<34::AID-JEMT6>3.3.CO;2-7
   PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111
   Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191
   Persson M, 2012, AMINO ACIDS, V42, P207, DOI 10.1007/s00726-011-0865-7
   Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191
   Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363
   Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001
   ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4
   Rosczyk HA, 2008, EXP GERONTOL, V43, P840, DOI 10.1016/j.exger.2008.06.004
   Saijo K, 2013, GLIA, V61, P104, DOI 10.1002/glia.22423
   Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050
   Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Schuitemaker A, 2012, NEUROBIOL AGING, V33, P1067, DOI 10.1016/j.neurobiolaging.2010.09.016
   Selvaraj V, 2012, FRONT BIOSCI-LANDMRK, V17, P65, DOI 10.2741/3916
   Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792
   Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468
   Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014
   Simard AR, 2004, FASEB J, V18, P998, DOI 10.1096/fj.04-1517fje
   Simmons DA, 2007, GLIA, V55, P1074, DOI 10.1002/glia.20526
   Sparkman NL, 2005, BEHAV BRAIN RES, V159, P145, DOI 10.1016/j.bbr.2004.10.011
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319
   Streit WJ, 2010, AGING DIS, V1, P254
   Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5
   Streit WJ, 2009, ACTA NEUROPATHOL, V118, P475, DOI 10.1007/s00401-009-0556-6
   Sugama S, 2003, BRAIN RES, V964, P288, DOI 10.1016/S0006-8993(02)04085-4
   Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001
   TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328
   Tremblay ME, 2012, GLIA, V60, P541, DOI 10.1002/glia.22287
   Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527
   van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005
   van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368
   van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8
   Varvel NH, 2012, P NATL ACAD SCI USA, V109, P18150, DOI 10.1073/pnas.1210150109
   Verri M, 2012, INT J IMMUNOPATH PH, V25, P345, DOI 10.1177/039463201202500204
   Vetterli L, 2011, J BIOL CHEM, V286, P6049, DOI 10.1074/jbc.M110.176842
   Vinet J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-27
   Vukovic J, 2012, J NEUROSCI, V32, P6435, DOI 10.1523/JNEUROSCI.5925-11.2012
   Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009
   Walton NM, 2006, GLIA, V54, P815, DOI 10.1002/glia.20419
   Ward RJ, 2011, J NEURAL TRANSM, V118, P315, DOI 10.1007/s00702-010-0479-3
   Wasserman JK, 2008, EUR J NEUROSCI, V28, P1316, DOI 10.1111/j.1460-9568.2008.06442.x
   Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010
   Widmer R, 2005, BIOFACTORS, V24, P247, DOI 10.1002/biof.5520240129
   Woods JA, 2005, BRAIN BEHAV IMMUN, V19, P369, DOI 10.1016/j.bbi.2005.04.007
   Wynne AM, 2010, BRAIN BEHAV IMMUN, V24, P1190, DOI 10.1016/j.bbi.2010.05.011
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HH, 2006, J NEUROIMMUNOL, V171, P135, DOI 10.1016/j.jneuroim.2005.10.004
   Yang Z, 2012, OBES REV, V13, P58, DOI 10.1111/j.1467-789X.2012.01038.x
   Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025
   Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3
   Yi CX, 2012, PHYSIOL BEHAV, V106, P485, DOI 10.1016/j.physbeh.2012.03.021
   Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496
   Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769
   Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629
NR 194
TC 154
Z9 157
U1 2
U2 39
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD MAR 13
PY 2013
VL 7
AR 22
DI 10.3389/fncel.2013.00022
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 111TQ
UT WOS:000316544100001
PM 23493481
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fijalkowski, N
   Pershing, S
   Moshfeghi, DM
AF Fijalkowski, Natalia
   Pershing, Suzann
   Moshfeghi, Darius M.
TI The Importance of Keeping a Broad Differential in Retina Clinic: The
   Spectrum of Ophthalmic Disease Seen by Retina Specialists in a Tertiary
   Outpatient Clinic Setting
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID STANFORD-UNIVERSITY NETWORK; VISUAL IMPAIRMENT; UNITED-STATES;
   PREMATURITY; RETINOPATHY; EXPERIENCE; DIAGNOSIS; COST
AB BACKGROUND AND OBJECTIVE: To describe the new patient population referred to retina specialists at tertiary ophthalmic academic centers in the United States.
   STUDY DESIGN AND METHODS: Retrospective chart review of all new patients seen by retina specialists at Stanford University from 2008 to 2011.
   RESULTS: Retina specialists saw 7,197 new patients during the study period, with a mean age of 52.2 +/- 25.6 years (range: 0 to 108 years). Younger patients (0 to 10 years) were more likely male (P < .001) while older patients were more likely female (P < .01 for 61 to 70, 81+ years). The most common diagnoses were diabetic eye disease (17.0%), retinopathy of prematurity (9.9%) and age-related macular degeneration (9.5%).
   CONCLUSION: Retina specialists treat patients of all ages, and the most common diagnoses vary with age and gender. Patients present to retinal clinic with a vast spectrum of disease from various ophthalmic and systemic etiologies; therefore, it is important to maintain a broad differential diagnosis.
C1 [Fijalkowski, Natalia; Pershing, Suzann; Moshfeghi, Darius M.] Stanford Univ, Sch Med, Horngren Family Vitreoretinal Ctr, Byers Eye Inst,Dept Ophthalmol, Palo Alto, CA 94303 USA.
C3 Stanford University
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Horngren Family Vitreoretinal Ctr, Byers Eye Inst,Dept Ophthalmol, 2452 Watson Court,Rm 2277, Palo Alto, CA 94303 USA.
OI Callaway, Natalia/0000-0002-9788-9605; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X
CR Abou-Gareeb I, 2001, Ophthalmic Epidemiol, V8, P39, DOI 10.1076/opep.8.1.39.1540
   Chiang A, 2010, CURR OPIN OPHTHALMOL, V21, P197, DOI 10.1097/ICU.0b013e32833866db
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Eze BI, 2010, MIDDLE EAST AFR J OP, V17, P246, DOI 10.4103/0974-9233.65491
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Jacobson L, 2009, ACTA PAEDIATR, V98, P261, DOI 10.1111/j.1651-2227.2008.01045.x
   Lad EM, 2008, BRIT J OPHTHALMOL, V92, P320, DOI 10.1136/bjo.2007.126201
   Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92
   Lesniak SP, 2012, J PEDIAT OPHTH STRAB, V49, P73, DOI 10.3928/01913913-20110712-02
   Murakami Y, 2008, BRIT J OPHTHALMOL, V92, P1456, DOI 10.1136/bjo.2008.138867
   Murakami Y, 2010, ACTA OPHTHALMOL, V88, P317, DOI 10.1111/j.1755-3768.2009.01715.x
   Nwosu S N, 2000, Ophthalmic Epidemiol, V7, P41, DOI 10.1076/0928-6586(200003)7:1;1-2;FT041
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Silva RA, 2011, OPHTHAL SURG LAS IM, V42, P1, DOI 10.3928/15428877-20100929-08
   Silva RA, 2009, GRAEF ARCH CLIN EXP, V247, P129, DOI 10.1007/s00417-008-0943-z
   Thapa R, 2011, NEPAL J OPHTHALMOL, V3, P102, DOI [http://dx.doi.org/10.3126/nepjoph.v3i2.5260, http://dx.doi.org/10.3126/nepjoph.v3i2.5263, 10.3126/nepjoph.v4i1.5844]
NR 16
TC 5
Z9 5
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR-APR
PY 2013
VL 44
IS 2
BP 133
EP 139
DI 10.3928/23258160-20130313-06
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 172PS
UT WOS:000321017200006
PM 23510039
DA 2022-11-30
ER

PT J
AU Zhang, SX
   Ma, JX
AF Zhang, Sarah X.
   Ma, Jian-xing
TI Ocular neovascularization: Implication of endogenous angiogenic
   inhibitors and potential therapy
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; KALLIKREIN-BINDING
   PROTEIN; VASCULAR-PERMEABILITY FACTOR; RETINAL-PIGMENT EPITHELIUM;
   OXYGEN-INDUCED RETINOPATHY; PROLIFERATIVE DIABETIC-RETINOPATHY; MONOCYTE
   CHEMOTACTIC PROTEIN-1; THROMBIN-SENSITIVE PROTEIN; CHOROIDAL
   NEOVASCULARIZATION
AB Ocular neovascularization (NV) is the primary cause of blindness in a wide range of ocular diseases, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). The exact mechanism underlying the pathogenesis of ocular NV is not yet well understood, and as a consequence, there is no satisfactory therapy for ocular NV. In the last 10 years, a number of studies provided increasing evidence demonstrating that the imbalance between angiogenic stimulating factors and angiogenic inhibitors is a major contributor to the angiogenesis induced by various insults, such as hypoxia or ischemia, inflammation and tumor. The angiogenic inhibitors alone or in combination with other existing therapies are, therefore, believed to be promising in the treatment of ocular NV in the near future. This article reviews recent progress in studies on the mechanisms and treatment of ocular NV, focusing on the implication and therapeutic potential of endogenous angiogenic inhibitors in ocular NV. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   Univ Oklahoma, Hlth Sci Ctr, Dept Med Endocrinol, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center
RP Ma, JX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, 941 Stanton L Young Bldg,BSEB 328B, Oklahoma City, OK 73104 USA.
EM jian-xing-ma@ouhsc.edu
CR Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009
   Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x
   Alm A., 1992, ADLERS PHYSL EYE, P198
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Ambati BK, 2002, ARCH OPHTHALMOL-CHIC, V120, P1063
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   Ambati J, 1997, ARCH OPHTHALMOL-CHIC, V115, P1161, DOI 10.1001/archopht.1997.01100160331011
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Arakaki N, 2003, MOL CANCER RES, V1, P931
   Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.0.CO;2-F
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Ash JD, 2000, DEV BIOL, V223, P383, DOI 10.1006/dbio.2000.9755
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240
   BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723
   BATTEGAY EJ, 1995, J MOL MED, V73, P333
   Becerra SP, 1997, ADV EXP MED BIOL, V425, P223
   BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992
   Benelli R, 2001, FASEB J, V15, P267, DOI 10.1096/fj.01-0651fje
   BENEZRA D, 1993, INVEST OPHTH VIS SCI, V34, P3601
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Braun L, 2001, LIFE SCI, V69, P2533, DOI 10.1016/S0024-3205(01)01327-3
   Braun RD, 1997, AM J PHYSIOL-HEART C, V272, pH1444, DOI 10.1152/ajpheart.1997.272.3.H1444
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Campochiaro PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653
   CANFIELD AE, 1995, J CELL SCI, V108, P797
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Cao YH, 2004, SEMIN THROMB HEMOST, V30, P83
   Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924
   Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461
   CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113
   Castellino FJ, 1997, CIBA F SYMP, V212, P46
   CHAI KX, 1991, J BIOL CHEM, V266, P16029
   Chan WK, 1996, AM J OPHTHALMOL, V121, P540, DOI 10.1016/S0002-9394(14)75428-5
   Chan-Ling T, 2004, INVEST OPHTH VIS SCI, V45, P2020, DOI 10.1167/iovs.03-1169
   CHAO J, 1990, J BIOL CHEM, V265, P16394
   CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325
   Chong ZZ, 2002, J HEMATOTH STEM CELL, V11, P863, DOI 10.1089/152581602321080529
   Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579
   Clausen P, 2000, DIABETIC MED, V17, P644, DOI 10.1046/j.1464-5491.2000.00347.x
   Colby K. A., 1996, Investigative Ophthalmology and Visual Science, V37, pS593
   Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9
   Cursiefen C, 2004, INVEST OPHTH VIS SCI, V45, P2666, DOI 10.1167/iovs.03-1380
   Cursiefen C, 2004, INVEST OPHTH VIS SCI, V45, P1117, DOI 10.1167/iovs.03-0940
   Das A, 2003, LAB INVEST, V83, P1637, DOI 10.1097/01.LAB.0000097189.79233.D8
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DILLY PN, 1985, T OPHTHAL SOC UK, V104, P381
   Djonov V, 2003, CELL TISSUE RES, V314, P107, DOI 10.1007/s00441-003-0784-3
   Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286
   Dorey CK, 1996, ARCH OPHTHALMOL-CHIC, V114, P1210, DOI 10.1001/archopht.1996.01100140410008
   Drew AF, 2000, INVEST OPHTH VIS SCI, V41, P67
   Drixler TA, 2001, INVEST OPHTH VIS SCI, V42, P3325
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255
   Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869
   ENGERMAN RL, 1995, DIABETES METAB REV, V11, P109, DOI 10.1002/dmr.5610110203
   EPSTEIN RJ, 1987, CORNEA, V6, P250, DOI 10.1097/00003226-198706040-00004
   Erbayraktar Serhat, 2003, Curr Hematol Rep, V2, P465
   Esemuede N, 2004, J SURG RES, V122, P135, DOI 10.1016/j.jss.2004.05.015
   FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FLOWER RW, 1985, INVEST OPHTH VIS SCI, V26, P957
   Folkman J, 1992, Semin Cancer Biol, V3, P89
   Fong DS, 2003, DIABETES CARE, V26, P226, DOI 10.2337/diacare.26.1.226
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P41, DOI 10.1007/s004170000205
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Funatsu H, 2001, JPN J OPHTHALMOL, V45, P577, DOI 10.1016/S0021-5155(01)00420-8
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Gabison E, 2004, EXP EYE RES, V78, P579, DOI 10.1016/j.exer.2003.09.005
   Gao G, 2003, DIABETOLOGIA, V46, P689, DOI 10.1007/s00125-003-1085-9
   Gao GQ, 2002, DRUG DISCOV TODAY, V7, P171, DOI 10.1016/S1359-6446(01)02160-2
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gipson IK, 1998, ADV EXP MED BIOL, V438, P221
   Gonzalez-Gronow M, 2003, J BIOL CHEM, V278, P27312, DOI 10.1074/jbc.M303172200
   GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624
   GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   HANNEKEN A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1005, DOI 10.1001/archopht.1991.01080070117048
   Hatcher HC, 1997, INVEST OPHTH VIS SCI, V38, P658
   Hattenbach LO, 2005, OPHTHALMIC RES, V37, P341, DOI 10.1159/000088263
   HAYREH SS, 1983, OPHTHALMOLOGY, V90, P488
   Hellstrom A, 2002, J CLIN ENDOCR METAB, V87, P3413, DOI 10.1210/jc.87.7.3413
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hiscott P, 2006, PROG RETIN EYE RES, V25, P1, DOI 10.1016/j.preteyeres.2005.05.001
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Ito Y, 2003, CANCER RES, V63, P6651
   Jablonski MM, 2001, GLIA, V35, P14, DOI 10.1002/glia.1066
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Jin J, 2003, CORNEA, V22, P473, DOI 10.1097/00003226-200307000-00015
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kao WWY, 1998, INVEST OPHTH VIS SCI, V39, P502
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625
   Kermorvant-Duchemin E, 2005, NAT MED, V11, P1339, DOI 10.1038/nm1336
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kim JH, 1999, EXP MOL MED, V31, P203, DOI 10.1038/emm.1999.33
   Kim K S, 1996, Korean J Ophthalmol, V10, P76
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200
   Kinose F, 2005, MOL VIS, V11, P366
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KRANTZ SB, 1991, BLOOD, V77, P419
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lai CC, 2005, OPHTHALMIC RES, V37, P50, DOI 10.1159/000083040
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Lee DH, 2001, CORNEA, V20, P738, DOI 10.1097/00003226-200110000-00013
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Liesegang Thomas J., 2002, CLAO Journal, V28, P12
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638
   Loughnan MS, 1996, AUST NZ J OPHTHALMOL, V24, P289, DOI 10.1111/j.1442-9071.1996.tb01596.x
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Lu M, 1999, INVEST OPHTH VIS SCI, V40, P3281
   Lu M, 1999, INVEST OPHTH VIS SCI, V40, P1808
   LUTTY GA, 1983, INVEST OPHTH VIS SCI, V24, P52
   LUTTY GA, 1985, J CELL SCI, V76, P53
   Lutty GA, 2003, PROG RETIN EYE RES, V22, P95, DOI 10.1016/S1350-9462(02)00058-7
   Ma JX, 2005, CURR DIABETES REV, V1, P183, DOI 10.2174/1573399054022839
   MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451
   Ma JX, 1996, CURR EYE RES, V15, P1117, DOI 10.3109/02713689608995143
   MAASSEN J, 2005, PURTSCHERS RETINOPAT
   Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   McColm J, 2004, MOL VIS, V10, P512
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P474
   MCLEOD DS, 1987, MICROVASC RES, V33, P257, DOI 10.1016/0026-2862(87)90021-5
   Meneses PI, 2001, GENE THER, V8, P646, DOI 10.1038/sj.gt.3301423
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   Michaelson I.C, 1954, BRIT J OPHTHALMOL, V38, P441, DOI [10.1136/bjo.38.7.441, DOI 10.1136/BJO.38.7.441]
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Mitamura Y, 2001, OPHTHALMOLOGICA, V215, P415, DOI 10.1159/000050900
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117
   Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Murata T, 1996, LAB INVEST, V74, P819
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Noma H, 2002, ARCH OPHTHALMOL-CHIC, V120, P1075
   Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733
   Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04-1489
   Nourhaghighi N, 2003, LAB INVEST, V83, P1211, DOI 10.1097/01.LAB.0000082383.40635.FE
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ogata N, 2001, AM J OPHTHALMOL, V132, P427, DOI 10.1016/S0002-9394(01)01021-2
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   Ohlmann AV, 2005, CURR EYE RES, V30, P27, DOI 10.1080/02713680490894333
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Ozkan H, 2006, PHYSIOL RES, V55, P267, DOI 10.33549/physiolres.930754
   Patan S, 2004, CANC TREAT, V117, P3
   PATEL B, 1994, BRIT J OPHTHALMOL, V78, P714, DOI 10.1136/bjo.78.9.714
   PEER J, 1995, LAB INVEST, V72, P638
   Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   PREIS I, 1977, AM J OPHTHALMOL, V84, P323
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Ray D, 2004, DIABETES, V53, P861, DOI 10.2337/diabetes.53.3.861
   Redlitz A, 1999, J VASC RES, V36, P28, DOI 10.1159/000025623
   Reich S, 2003, MOL VIS, V9, P210
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   ROH S, 2004, OPHTHALMOLOGY
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   ROTH HW, 1978, CONTACT INTRAOCUL LE, V4, P38
   Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sekiyama E, 2006, INVEST OPHTH VIS SCI, V47, P1352, DOI 10.1167/iovs.05-1305
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Senger DR, 1996, AM J PATHOL, V149, P293
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051
   Shao CK, 2004, INVEST OPHTH VIS SCI, V45, P1758, DOI 10.1167/iovs.03-0882
   Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shestakova MV, 2002, TERAPEVT ARKH, V74, P24
   Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com
   Singh N, 2005, INVEST OPHTH VIS SCI, V46, P1647, DOI 10.1167/iovs.04-1172
   SLOMIANY MG, 2004, AM J PHYSIOL-CELL PH, V287, pC453
   Smith Lois E H, 2003, Semin Neonatol, V8, P469, DOI 10.1016/S1084-2756(03)00119-2
   Sone H, 1997, DIABETOLOGIA, V40, P726, DOI 10.1007/s001250050740
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spranger J, 2000, DIABETOLOGIA, V43, P1404, DOI 10.1007/s001250051546
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Stone J, 1997, PROG RETIN EYE RES, V16, P157, DOI 10.1016/S1350-9462(96)00019-5
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200
   Tashimo A, 2004, DIABETIC MED, V21, P1292, DOI 10.1111/j.1464-5491.2004.01334.x
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Tolentino MJ, 1998, INT OPHTHALMOL CLIN, V38, P77, DOI 10.1097/00004397-199803810-00007
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247
   Tuszynski GP, 2002, MICROVASC RES, V64, P448, DOI 10.1006/mvre.2002.2444
   Uchida H, 2005, EXP EYE RES, V80, P23, DOI 10.1016/j.exer.2004.08.004
   Umeda N, 2003, OPHTHALMIC RES, V35, P217, DOI 10.1159/000071173
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148
   Veitonmaki N, 2004, CANCER RES, V64, P3679, DOI 10.1158/0008-5472.CAN-03-1754
   Victoria M, 1998, J AM SOC NEPHROL, V9, P1998
   Vinores SA, 2000, ADV EXP MED BIOL, V476, P129
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Wahl ML, 2005, J CELL BIOCHEM, V96, P242, DOI 10.1002/jcb.20480
   Wahl ML, 2004, RECENT PROG HORM RES, V59, P73, DOI 10.1210/rp.59.1.73
   WAHL ML, 2002, J GEN PHARM VASCULAR, V35, P1
   Wajer SD, 2000, MICROVASC RES, V60, P281, DOI 10.1006/mvre.2000.2270
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   West SK, 2004, PROG RETIN EYE RES, V23, P381, DOI 10.1016/j.preteyeres.2004.04.001
   White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100
   WISE GN, 1971, RETINAL CIRCULATION, P27
   Wong V K, 1997, Hawaii Med J, V56, P289
   Wu ZF, 2006, DEV DYNAM, V235, P1908, DOI 10.1002/dvdy.20837
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   Yu DY, 2001, CLIN EXP OPHTHALMOL, V29, P164
   Zhang D, 2001, DIABETOLOGIA, V44, P757, DOI 10.1007/s001250051685
   ZHANG HR, 1994, PROG RETIN EYE RES, V13, P243, DOI 10.1016/1350-9462(94)90012-4
   Zhang SX, 2006, J AM SOC NEPHROL, V17, P475, DOI 10.1681/ASN.2005020217
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
   Zhang SX, 2005, CURR EYE RES, V30, P681, DOI 10.1080/02713680590934102
   Zhang SX, 2005, AM J PATHOL, V166, P313, DOI 10.1016/S0002-9440(10)62255-9
   Zhang SX, 2004, DIABETOLOGIA, V47, P124, DOI 10.1007/s00125-003-1276-4
   Zhang ZH, 2005, INVEST OPHTH VIS SCI, V46, P4062, DOI 10.1167/iovs.04-1330
   Zheng M, 2001, AM J PATHOL, V159, P1021, DOI 10.1016/S0002-9440(10)61777-4
   ZHOU GX, 1992, J BIOL CHEM, V267, P25873
NR 286
TC 173
Z9 200
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2007
VL 26
IS 1
BP 1
EP 37
DI 10.1016/j.preteyeres.2006.09.002
PG 37
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 128PD
UT WOS:000243669100001
PM 17074526
DA 2022-11-30
ER

PT J
AU Zhao, DY
   Bhosale, P
   Bernstein, PS
AF Zhao, Da You
   Bhosale, Prakash
   Bernstein, Paul S.
TI Carotenoids and ocular health
SO CURRENT TOPICS IN NUTRACEUTICAL RESEARCH
LA English
DT Review
DE antioxidants; lutein; macula; oxidative stress; serum carotenoids;
   zeaxanthin
ID MACULAR PIGMENT DENSITY; AGE-RELATED MACULOPATHY; RESONANCE RAMAN
   MEASUREMENT; VITAMIN-A STATUS; BETA-CAROTENE; SERUM CAROTENOIDS;
   BINDING-PROTEIN; LUTEIN SUPPLEMENTATION; OXIDATIVE STRESS;
   OPTICAL-DENSITY
AB Lutein and zeaxanthin are isomeric xanthophyll carotenoids found abundantly in dark-green leafy vegetables, orange and yellow fruits and vegetables, and in egg yolks. They and other dietary carotenoids such as lycopene and alpha- and beta-carotene are distributed throughout human tissues, but they are the predominant carotenoids in the human retina and lens. Research studies conducted in different parts of world indicate an inverse relationship between lutein and zeaxanthin intake and/or their serum and tissue levels and both age-related macular degeneration (AMD) and cataract, indicating that that these xanthophyll carotenoids might play a protective role. The ability to raise the levels of macular carotenoid pigments in some members of a healthy population and in AMD patients encourages further study into whether the rises would benefit elderly individuals at risk for visual loss from AMD. So far, no serious side effects have been reported in xanthophyll supplementation studies or in clinical practice.
C1 [Zhao, Da You; Bhosale, Prakash; Bernstein, Paul S.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, 50 N Med Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@lisc.utah.edu
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Apushkin MA, 2005, RETINA-J RET VIT DIS, V25, P650, DOI 10.1097/00006982-200507000-00016
   Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2000, OPHTHAL PHYSL OPT, V20, P105, DOI 10.1016/S0275-5408(99)00039-3
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2003, PROG RETIN EYE RES, V22, P171, DOI 10.1016/S1350-9462(02)00060-5
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   BERMAN ER, 1991, BIOCH EYES
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2002, PURE APPL CHEM, V74, P1419, DOI 10.1351/pac200274081419
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bernstein PS, 1999, AGE RELATED MACULAR, P1
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2004, J AGR FOOD CHEM, V52, P3281, DOI 10.1021/jf035345q
   BHOSALE P, 2005, APPL MICROBIOL BIOT, V7, P1
   BHUYAN KC, 1984, CURR EYE RES, V3, P67, DOI 10.3109/02713688408997188
   Billsten HH, 2003, PHOTOCHEM PHOTOBIOL, V78, P138, DOI 10.1562/0031-8655(2003)078<0138:PPOXIC>2.0.CO;2
   Bloomenstein M R, 1996, J Am Optom Assoc, V67, P690
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   CHANG TS, 1995, AM J OPHTHALMOL, V119, P801, DOI 10.1016/S0002-9394(14)72791-6
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Clinton SK, 1999, CANCER, V86, P1629, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1629::AID-CNCR1>3.0.CO;2-4
   Cruz AAV, 2005, NUTRITION, V21, P630, DOI 10.1016/j.nut.2004.12.003
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   DELORI FC, 1977, ARCH OPHTHALMOL-CHIC, V95, P861, DOI 10.1001/archopht.1977.04450050139018
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   Ermakov IV, 2001, OPT LETT, V26, P202, DOI 10.1364/OL.26.000202
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Furr HC, 2005, PUBLIC HEALTH NUTR, V8, P596, DOI 10.1079/PHN2004715
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gellermann W, 2004, J BIOMED OPT, V9, P75, DOI 10.1117/1.1628240
   Gellermann W, 2002, OPT LETT, V27, P833, DOI 10.1364/OL.27.000833
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   Goralczyk R, 1997, INVEST OPHTH VIS SCI, V38, P741
   Gupta SK, 2003, NUTRITION, V19, P794, DOI 10.1016/S0899-9007(03)00140-0
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANKINSON SE, 1992, JAMA-J AM MED ASSOC, V268, P994, DOI 10.1001/jama.268.8.994
   Hinds TS, 1997, J CLIN PHARMACOL, V37, P551, DOI 10.1002/j.1552-4604.1997.tb04336.x
   Howard AN, 1996, INT J VITAM NUTR RES, V66, P113
   Hurst JS, 2005, EXP EYE RES, V81, P239, DOI 10.1016/j.exer.2005.04.002
   Jampol LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1533
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kabagambe EK, 2005, J NUTR, V135, P1763, DOI 10.1093/jn/135.7.1763
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Koyama Y., 1995, CAROTENOIDS B, P135
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kruger CL, 2002, FOOD CHEM TOXICOL, V40, P1535, DOI 10.1016/S0278-6915(02)00131-X
   Lakshman MR, 1999, METHOD ENZYMOL, V299, P441
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LANDRUM JT, 1997, ADV PHARMACOL, V56, P537
   Lee DH, 2004, CLIN CHEM, V50, P582, DOI 10.1373/clinchem.2003.028852
   Leo MA, 1997, J NATL CANCER I, V89, P1722, DOI 10.1093/jnci/89.22.1722
   Linebarger EJ, 1999, SURV OPHTHALMOL, V44, P123, DOI 10.1016/S0039-6257(99)00085-5
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Lyle BJ, 1999, AM J CLIN NUTR, V69, P272
   MacDonald IM, 2004, EXPERT REV MOL DIAGN, V4, P478, DOI 10.1586/14737159.4.4.478
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, INVEST OPHTH VIS SCI, V36, P276
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mohanty I, 2002, BRIT J NUTR, V88, P347, DOI 10.1079/BJN2002659
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   OJIMA F, 1993, FREE RADICAL BIO MED, V15, P377, DOI 10.1016/0891-5849(93)90037-U
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Paolini M, 2003, MUTAT RES-REV MUTAT, V543, P195, DOI 10.1016/S1383-5742(03)00002-4
   PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0
   Rao AVR, 2000, J AM COLL NUTR, V19, P563, DOI 10.1080/07315724.2000.10718953
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P270, DOI 10.1007/s003470100533
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Stahl W, 1996, ARCH BIOCHEM BIOPHYS, V336, P1, DOI 10.1006/abbi.1996.0525
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Tabunoki H, 2002, J BIOL CHEM, V277, P32133, DOI 10.1074/jbc.M204507200
   Tang CY, 2004, OPHTHAL PHYSL OPT, V24, P586, DOI 10.1111/j.1475-1313.2004.00242.x
   Tanumihardjo SA, 2005, J AM DIET ASSOC, V105, P114, DOI 10.1016/j.jada.2004.10.011
   Tavani A, 1996, ANN EPIDEMIOL, V6, P41, DOI 10.1016/1047-2797(95)00099-2
   Taylor A, 2002, AM J CLIN NUTR, V75, P540, DOI 10.1093/ajcn/75.3.540
   TAYLOR A, 1995, EXP EYE RES, V61, P55, DOI 10.1016/S0014-4835(95)80058-1
   van Herpen-Broekmans WMR, 2004, EUR J EPIDEMIOL, V19, P915, DOI 10.1007/s10654-004-5760-z
   van het Hof KH, 1999, AM J CLIN NUTR, V70, P261
   van Jaarsveld PJ, 2005, AM J CLIN NUTR, V81, P1080
   VITALE S, 1993, EPIDEMIOLOGY, V4, P195, DOI 10.1097/00001648-199305000-00003
   WANG XD, 1994, J AM COLL NUTR, V13, P314, DOI 10.1080/07315724.1994.10718416
   Welkert MP, 2006, CURR OPIN OPHTHALMOL, V17, P62
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Zhang XY, 2002, GRAEF ARCH CLIN EXP, V240, P802, DOI 10.1007/s00417-002-0554-z
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
NR 129
TC 5
Z9 5
U1 0
U2 11
PU NEW CENTURY HEALTH PUBLISHERS, LLC
PI COPPELL
PA PO BOX 175, COPPELL, TX 75019 USA
SN 1540-7535
J9 CURR TOP NUTRACEUT R
JI Curr. Top. Nutraceutical Res.
PD FEB
PY 2006
VL 4
IS 1
BP 53
EP 67
PG 15
WC Nutrition & Dietetics; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics; Pharmacology & Pharmacy
GA V44RN
UT WOS:000203019900004
DA 2022-11-30
ER

PT J
AU Mones, J
   Srivastava, SK
   Jaffe, GJ
   Tadayoni, R
   Albini, TA
   Kaiser, PK
   Holz, FG
   Korobelnik, JF
   Kim, IK
   Pruente, C
   Murray, TG
   Heier, JS
AF Mones, Jordi
   Srivastava, Sunil K.
   Jaffe, Glenn J.
   Tadayoni, Ramin
   Albini, Thomas A.
   Kaiser, Peter K.
   Holz, Frank G.
   Korobelnik, Jean-Francois
   Kim, Ivana K.
   Pruente, Christian
   Murray, Timothy G.
   Heier, Jeffrey S.
TI Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related
   Events with Brolucizumab Post Hoc Review of HAWK and HARRIER
SO OPHTHALMOLOGY
LA English
DT Review
DE brolucizumab; intraocular inflammation; neovascular age-related macular
   degeneration; retinal vasculitis; retinal vascular occlusion; retinal
   arterial occlusion; retinal occlusive vasculitis; safety
ID MACULAR DEGENERATION; RANIBIZUMAB; SAFETY
AB Purpose: An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related macular degeneration (nAMD).
   Design: A post hoc analysis of a subset of data from two 2-year, double-masked, multicenter, active-controlled randomized phase 3 trials (NCT02307682, NCT02434328).
   Participants: Patients (N = 1817) with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye were randomized and treated in HAWK/HARRIER. The SRC reviewed data from cases of investigator-reported IOI (60/1088 brolucizumab-treated eyes; 8/729 aflibercept-treated eyes).
   Methods: The SRC received details and images (color fundus photography, fluorescein angiography, and OCT) for all investigator-determined cases of IOI, retinal arterial occlusion, and endophthalmitis. Cases were reviewed in detail by >= 2 readers, then adjudicated by the SRC as a group.
   Main Outcome Measures: Within this patient subset: incidence of IOI, signs and incidence of retinal vasculitis and/or retinal vascular occlusion, and visual acuity loss; time since first brolucizumab injection to IOI event onset; and frequency of visual acuity loss after brolucizumab injection by time of first IOI event onset.
   Results: Fifty brolucizumab-treated eyes were considered to have definite/probable drug-related events within the spectrum of IOI, retinal vasculitis, and/or vascular occlusion. On the basis of these cases, incidence of definite/probable IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%). There were 8 cases (incidence 0.74%) of at least moderate visual acuity loss (>= 15 ETDRS letters) in eyes with IOI (7 in eyes with IOI + vasculitis thorn occlusion). Of the 8 cases, 5 experienced their first IOI-related event within 3 months of the first brolucizumab injection (increasing to 7/8 within 6 months). Incidence of IOI in aflibercept-treated eyes was 1.1%, with at least moderate visual acuity loss in 0.14%.
   Conclusions: This analysis of IOI cases after brolucizumab injection identified signs of retinal vasculitis with or without retinal vascular occlusion and an associated risk of visual acuity loss. The findings will help physicians to evaluate the risks and benefits of brolucizumab treatment for nAMD. (C) 2020 by the American Academy of Ophthalmology.
C1 [Mones, Jordi] Barcelona Macula Fdn, Inst Macula, Barcelona, Spain.
   [Srivastava, Sunil K.; Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Tadayoni, Ramin] Dept Hosp Univ Vis & Handicaps, Paris, France.
   [Tadayoni, Ramin] Univ Paris, Rothschild Fdn Hosp, Hop Lariboisiere, AP HP,Ophthalmol Dept, Paris, France.
   [Albini, Thomas A.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, BPH, INSERM, Bordeaux, France.
   [Kim, Ivana K.] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.
   [Pruente, Christian] Univ Basel, Dept Ophthalmol, Basel, Switzerland.
   [Pruente, Christian] Kantonsspital Baselland, Dept Ophthalmol, Liestal, Switzerland.
   [Pruente, Christian] Inst Mol & Clin Ophthalmol Basel IOB, Basel, Switzerland.
   [Murray, Timothy G.] Murray Ocular Oncol & Retina, Miami, FL USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
C3 Cleveland Clinic Foundation; Duke University; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal
   - APHP; Fondation Adolphe de Rothschild; UDICE-French Research
   Universities; Universite Paris Cite; Bascom Palmer Eye Institute;
   University of Miami; University of Bonn; CHU Bordeaux; Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux; Harvard University; Harvard
   Medical School; Massachusetts Eye & Ear Infirmary; University of Basel;
   Kantonsspital Baselland; Ophthalmic Consultants of Boston
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Tadayoni, Ramin/0000-0001-5616-3579;
   Korobelnik, Jean-Francois/0000-0002-4438-9535
CR American Society of Retina Specialists, BEOVU UPDATE ASRS ME
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bevacizumab-Ranibizumab International Trials Group, 2017, OPHTHALMOL RETINA, V1, P375
   Do D., 2020, RETINA SOC 2020 VR M
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Novartis AG, NOVARTIS PROVIDES UP
   Novartis Pharmaceuticals, 2020, BEOVUO BROLUCIZUMAB
   Novartis Pharmaceuticals, 2020, BEOVU 120 MGML SOLUT
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P805, DOI 10.1136/bjophthalmol-2018-312453
   Souied EH, 2016, OPHTHAL EPIDEMIOL, V23, P71, DOI 10.3109/09286586.2015.1090004
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Zarbin MA, 2018, OPHTHALMOL RETINA, V2, P1087, DOI 10.1016/j.oret.2018.04.018
NR 23
TC 90
Z9 92
U1 7
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2021
VL 128
IS 7
BP 1050
EP 1059
DI 10.1016/j.ophtha.2020.11.011
EA JUN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TB1BR
UT WOS:000667677700018
PM 33207259
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Qin, TY
   Gao, SS
AF Qin, Tingyu
   Gao, Shasha
TI Inhibition of Proteasome Activity Upregulates IL-6 Expression in RPE
   Cells through the Activation of P38 MAPKs
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; MACULAR DEGENERATION;
   PROTEOLYTIC PATHWAY; UBIQUITIN; PROTEIN; INFLAMMATION; KINASE;
   INTERLEUKIN-6; PATHOGENESIS
AB Purpose. As far as we know, during the development of age-related macular degeneration (AMD), the activity of proteasome in retinal pigment epithelium cells (RPE) gradually decreases. And a lot of research has shown that age-related macular degeneration is closely related to inflammation and autoimmune. Moreover, there are many cytokines (CKs) involved in the course of inflammation. In this study, we are going to investigate how the decrease of proteasome activity affects the production of interleukin-6 (IL-6) in human retinal pigment epithelium cells (ARPE-19). Methods. Cultured ARPE-19 was treated with or without MG132, a proteasome inhibitor, and the levels of IL-6 mRNA (messenger ribonucleic acid) in RPE at 1 h, 4 h, 8 h, and IL-6 protein in the culture medium at 2 h, 4 h, 6 h, 8 h, 10 h, and 12 h were measured by real-time polymerase chain reaction (real-time PCR) and enzyme-linked immunosorbent assay (ELISA). The protein levels of MCP-1 (monocyte chemoattractant protein-1) in the culture medium at 2 h, 4 h, 6 h, 8 h, 10 h, and 12 h were also measured by ELISA. Then we tested which of cell signal pathways regulating the production of IL-6 were activated when we added MG132 into the medium by Western blot and electrophoretic mobility shift assays (EMSA). After that, we put the inhibitors of these activated cell signal pathways into the medium individually to see which inhibitor can counteract the effect of upregulating the levels of IL-6 in the culture medium of RPE. Results. MG132 decreased the secretion of MCP-1 in the culture medium of RPE, but it increased the expression of IL-6 mRNA in RPE and IL-6 protein level in the culture medium of RPE. MG132 treatment was also found to enhance the level of phosphorylated p38 mitogen-activated protein kinases (MAPKs) and c-Jun N-terminal Kinase (JNK) by Western blotting. More importantly, the effect of MG132 on upregulating the levels of IL-6 was inhibited by SB203580, an inhibitor of P38 MAP kinases. But the JNK inhibitor, SP600125, cannot prevent the effect of upregulating the levels of IL-6 by MG132 in the RPE culture medium. Conclusions. We concluded that the proteasome inhibitor, MG132, upregulates IL-6 production in RPE cells through the activation of P38 MAPKs.
C1 [Qin, Tingyu; Gao, Shasha] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou 450000, Henan, Peoples R China.
C3 Zhengzhou University
RP Gao, SS (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou 450000, Henan, Peoples R China.
EM shashag@126.com
RI Qin, Tingyu/N-8323-2016
OI Qin, Tingyu/0000-0003-4108-0185; Gao, Shasha/0000-0001-5751-7105
FU Medical Science and Technology Project of Health and Family Planning
   Commission of Henan Province [201403055, 201503056]; Key Research and
   Development and Promotion Project of Henan Provincial Science and
   Technology Department [1455]; Key Scientific Research Projects of
   University of Henan Provincial Education Department [19A320059,
   19A320078]
FX The organizations that funded this research are Medical Science and
   Technology Project of Health and Family Planning Commission of Henan
   Province (201403055 and 201503056), Key Research and Development and
   Promotion Project of Henan Provincial Science and Technology Department
   in 2018 (1455/Qin Tingyu), and Key Scientific Research Projects of
   University of Henan Provincial Education Department in 2019 (19A320059
   and 19A320078).
CR Ban KC, 2011, MOL CELL BIOCHEM, V347, P191, DOI 10.1007/s11010-010-0628-x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200
   Chiu YC, 2009, J IMMUNOL, V183, P2785, DOI 10.4049/jimmunol.0802826
   Chung HY, 2006, ANTIOXID REDOX SIGN, V8, P572, DOI 10.1089/ars.2006.8.572
   Ciechanover A, 2003, BIOCHEM SOC T, V31, P474, DOI 10.1042/BST0310474
   Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753
   Di Napoli Mario, 2003, Curr Opin Investig Drugs, V4, P1333
   Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dudek EJ, 2005, FASEB J, V19, P1707, DOI 10.1096/fj.05-4049fje
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Fernandes AF, 2009, MOL BIOL CELL, V20, P3690, DOI 10.1091/mbc.E08-10-1068
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X
   Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x
   JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L
   Jung DH, 2010, INT IMMUNOPHARMACOL, V10, P1047, DOI 10.1016/j.intimp.2010.06.004
   Kavanaugh A, 2007, BULL HOSP JT DIS, V65, pS16
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kloetzel PM, 2004, NAT IMMUNOL, V5, P661, DOI 10.1038/ni1090
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Liu S. C., 2012, PLOS ONE, V7
   Liu ZZ, 2014, ADV EXP MED BIOL, V801, P237, DOI 10.1007/978-1-4614-3209-8_31
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   Mukhopadhyay S, 2009, TOXICOLOGY, V261, P143, DOI 10.1016/j.tox.2009.05.010
   Parasrampuria DA, 2003, J CLIN PHARMACOL, V43, P406, DOI 10.1177/0091270002250615
   Peter L, 2011, GEN COMP ENDOCR, V172, P39, DOI 10.1016/j.ygcen.2011.02.005
   Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503
   Qureshi N, 2005, IMMUNOL RES, V31, P243, DOI 10.1385/IR:31:3:243
   Ravn P, 1997, J IMMUNOL, V158, P1949
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Schreiber S, 2006, CLIN GASTROENTEROL H, V4, P325, DOI 10.1016/j.cgh.2005.11.013
   Sebba A, 2008, AM J HEALTH-SYST PH, V65, P1413, DOI 10.2146/ajhp070449
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shang F, 2004, EXP EYE RES, V78, P1, DOI 10.1016/j.exer.2003.10.003
   Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176
   Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029
   Shibata T, 2002, IMMUNOL CELL BIOL, V80, P226, DOI 10.1046/j.1440-1711.2002.01079.x
   Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200
   Tuyt LML, 1999, J IMMUNOL, V162, P4893
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700
   Wu WC, 2010, MOL VIS, V16, P1864
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 54
TC 6
Z9 6
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 5392432
DI 10.1155/2018/5392432
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GO3DB
UT WOS:000439866400001
PM 30116631
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Phelan, MA
   Kruczek, K
   Wilson, JH
   Brooks, MJ
   Drinnan, CT
   Regent, F
   Gerstenhaber, JA
   Swaroop, A
   Lelkes, PI
   Li, TS
AF Phelan, Michael A.
   Kruczek, Kamil
   Wilson, John H.
   Brooks, Matthew J.
   Drinnan, Charles T.
   Regent, Florian
   Gerstenhaber, Jonathan A.
   Swaroop, Anand
   Lelkes, Peter I.
   Li, Tiansen
TI Soy Protein Nanofiber Scaffolds for Uniform Maturation of Human Induced
   Pluripotent Stem Cell-Derived Retinal Pigment Epithelium
SO TISSUE ENGINEERING PART C-METHODS
LA English
DT Article
DE iRPE; nanofibrous scaffold; electrospinning; soy protein; human iPSCs;
   RNA-seq
ID DIRECTED DIFFERENTIATION; BIOMECHANICAL PROPERTIES; RPE TRANSPLANTATION;
   MOLECULAR SIGNATURE; STIFFNESS; MODULUS; MATRIX; AGE
AB Retinal pigment epithelium (RPE) differentiated from human induced pluripotent stem cells, called induced retinal pigment epithelium (iRPE), is being explored as a cell-based therapy for the treatment of retinal degenerative diseases, especially age-related macular degeneration. The success of RPE implantation is linked to the use of biomimetic scaffolds that simulate Bruch's membrane and promote RPE maturation and integration as a functional tissue. Due to difficulties associated with animal protein-derived scaffolds, including sterility and pro-inflammatory responses, current practices favor the use of synthetic polymers, such as polycaprolactone (PCL), for generating nanofibrous scaffolds. In this study, we tested the hypothesis that plant protein-derived fibrous scaffolds can provide favorable conditions permissive for the maturation of RPE tissue sheetsin vitro. Our natural, soy protein-derived nanofibrous scaffolds exhibited a J-shaped stress-strain curve that more closely resembled the mechanical properties of native tissues than PCL with significantly higher hydrophilicity of the natural scaffolds, favoringin vivoimplantation. We then demonstrate that iRPE sheets growing on these soy protein scaffolds are equivalent to iRPE monolayers cultured on synthetic PCL nanofibrous scaffolds. Immunohistochemistry demonstrated RPE-like morphology and functionality with appropriate localization of RPE markers RPE65, PMEL17, Ezrin, and ZO1 and with anticipated histotypic polarization of vascular endothelial growth factor and pigment epithelium-derived growth factor as indicated by enzyme-linked immunosorbent assay. Scanning electron microscopy revealed dense microvilli on the cell surface and homogeneous tight junctional contacts between the cells. Finally, comparative transcriptome analysis in conjunction with principal component analysis demonstrated that iRPE on nanofibrous scaffolds, either natural or synthetic, matured more consistently than on nonfibrous substrates. Taken together, our studies suggest that the maturation of cultured iRPE sheets for subsequent clinical applications might benefit from the use of nanofibrous scaffolds generated from natural proteins. Impact statement Induced retinal pigment epithelium (iRPE) from patient-derived induced pluripotent stem cells (iPSCs) may yield powerful treatments of retinal diseases, including age-related macular degeneration. Recent studies, including early human clinical trials, demonstrate the importance of selecting appropriate biomaterial scaffolds to support tissue-engineered iRPE sheets during implantation. Electrospun scaffolds show particular promise due to their similarity to the structure of the native Bruch's membrane. In this study, we describe the use of electroprocessed nanofibrous soy protein scaffolds to generate polarized sheets of human iPSC-derived iRPE sheets. Our evaluation, including RNA-seq transcriptomics, indicates that these scaffolds are viable alternatives to scaffolds electrospun from synthetic polymers.
C1 [Phelan, Michael A.; Kruczek, Kamil; Wilson, John H.; Brooks, Matthew J.; Drinnan, Charles T.; Regent, Florian; Swaroop, Anand; Li, Tiansen] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Room 338,Bldg 6,9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Phelan, Michael A.; Gerstenhaber, Jonathan A.; Lelkes, Peter I.] Temple Univ, Coll Engn, Dept Bioengn, Integrated Lab Cellular Tissue Engn & Regenerat M, Room 811,1947N 12th St, Philadelphia, PA 19122 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Temple University; University of Pennsylvania
RP Swaroop, A (通讯作者)，NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Room 338,Bldg 6,9000 Rockville Pike, Bethesda, MD 20892 USA.; Lelkes, PI (通讯作者)，Temple Univ, Coll Engn, Dept Bioengn, Integrated Lab Cellular Tissue Engn & Regenerat M, Room 811,1947N 12th St, Philadelphia, PA 19122 USA.; Li, TS (通讯作者)，NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Room 337,Bldg 6,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM swaroopa@nei.nih.gov; pilelkes@temple.edu; tiansen.li@nih.gov
RI Lelkes, Peter/HGA-2907-2022
CR Ahn S, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701175
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Badylak SF, 2009, ACTA BIOMATER, V5, P1, DOI 10.1016/j.actbio.2008.09.013
   Baiguera S., 2014, BIOMED RES INT, V2014, DOI [10.1155/2014/398069, DOI 10.1155/2014/398069]
   Barkay-Olami H, 2016, J BIOMED MATER RES B, V104, P1109, DOI 10.1002/jbm.b.33459
   Beers J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11319
   Ben M'Barek K, 2019, ADV EXP MED BIOL, V1186, P55, DOI 10.1007/978-3-030-28471-8_3
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d
   Brooks MJ, 2019, STEM CELL REP, V13, P891, DOI 10.1016/j.stemcr.2019.09.009
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Cam A, 2012, MOL NUTR FOOD RES, V56, P1569, DOI 10.1002/mnfr.201200301
   Candiello J, 2007, FEBS J, V274, P2897, DOI 10.1111/j.1742-4658.2007.05823.x
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chan W.H., 2007, INVEST OPHTHALMOL VI, V48, P2187
   Chatterjee C, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091211
   Chien KB, 2012, ACTA BIOMATER, V8, P694, DOI 10.1016/j.actbio.2011.09.036
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fanelli G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15212-z
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Guilak F, 2014, J BIOMECH, V47, P1933, DOI 10.1016/j.jbiomech.2014.04.019
   Han YL, 2018, P NATL ACAD SCI USA, V115, P4075, DOI 10.1073/pnas.1722619115
   Har-el Y., 2014, WOUND MED, V5, P9, DOI DOI 10.1016/J.WNDM.2014.04.007
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kaya KD, 2019, MOL VIS, V25, P663
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lin LK, 2013, J TISSUE ENG REGEN M, V7, P994, DOI 10.1002/term.1493
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   McKee CT, 2011, TISSUE ENG PART B-RE, V17, P155, DOI 10.1089/ten.teb.2010.0520
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Miyagishima KJ, 2017, STEM CELL TRANSL INV, V4, pe1497
   Morrison G, 2016, STEM CELL RES, V16, P140, DOI 10.1016/j.scr.2015.12.025
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Ramji K, 2014, J BIOMATER APPL, V29, P411, DOI 10.1177/0885328214530765
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shidal C, 2017, ONCOTARGET, V8, P25525, DOI 10.18632/oncotarget.16066
   Soneson C., 2015, F1000RESEARCH, V4, P1521
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sun CB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192625
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Swaroop M, 2018, HUM MOL GENET, V27, P3612, DOI 10.1093/hmg/ddy259
   Timnak A, 2018, BIOMED MATER, V13, DOI 10.1088/1748-605X/aadbbe
   Volpato V, 2018, STEM CELL REP, V11, P897, DOI 10.1016/j.stemcr.2018.08.013
   Wang XF, 2018, INVEST OPHTH VIS SCI, V59, P2808, DOI 10.1167/iovs.17-22069
   Webb K, 1998, J BIOMED MATER RES, V41, P422, DOI 10.1002/(SICI)1097-4636(19980905)41:3<422::AID-JBM12>3.0.CO;2-K
   Wells RG, 2008, HEPATOLOGY, V47, P1394, DOI 10.1002/hep.22193
   White C, 2017, J BIOMED MATER RES A, V105, P1260, DOI 10.1002/jbm.a.35992
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Xu B, 2013, BIOMATERIALS, V34, P6306, DOI 10.1016/j.biomaterials.2013.05.009
   Zhang ZY, 2012, MOL VIS, V18, P2961
NR 66
TC 7
Z9 7
U1 1
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3384
EI 1937-3392
J9 TISSUE ENG PART C-ME
JI Tissue Eng. Part C-Methods
PD AUG 1
PY 2020
VL 26
IS 8
BP 433
EP 446
DI 10.1089/ten.tec.2020.0072
PG 14
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA NB7JE
UT WOS:000560689900003
PM 32635833
OA Green Published
DA 2022-11-30
ER

PT J
AU Surrao, DC
   Greferath, U
   Chau, YQ
   Skabo, SJ
   Huynh, M
   Shelat, KJ
   Limnios, IJ
   Fletcher, EL
   Liu, Q
AF Surrao, Denver C.
   Greferath, Ursula
   Chau, Yu-Qian
   Skabo, Stuart J.
   Huynh, Mario
   Shelat, Kinnari J.
   Limnios, Ioannis J.
   Fletcher, Erica L.
   Liu, Qin
TI Design, development and characterization of synthetic Bruch's membranes
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Age-related macular degeneration (AMD); Bruch's membrane (BM); 70 nm
   electrospun nanofibrous membranes (ENMs); Human retinal pigment
   epithelium (hRPE) cells; RPE functionality; Subretinal implantation
ID RETINAL-PIGMENT EPITHELIUM; EXTRACELLULAR-MATRIX; LAMININ ADSORPTION;
   BARRIER PROPERTIES; PROTEIN; CELLS; SCAFFOLDS; PHAGOCYTOSIS;
   FIBRONECTIN; ENHANCEMENT
AB Age-related macular degeneration (AMD) is a leading cause of blindness, and dry AMD has no effective treatment. Retinal constructs comprising retinal pigment epithelium (RPE) cells supported by electro-spun scaffolds have been investigated to treat dry AMD. However, electrospun scaffolds studied to date do not mimic the structural microenvironment of human Bruch's membrane (BM), essential for native-like RPE monolayers. The aim of this study was to develop a structurally biomimetic scaffold designed to support a functional RPE monolayer, comprising porous, electrospun nanofibrous membranes (ENMs), coated with laminin, mimicking the inner collagenous layer (ICL) and basal RPE lamina respectively, the cell supporting layers of the BM. In vitro evaluation showed 70 nm PLLA ENMs adsorbed high amounts of laminin and supported functional RPE monolayers, exhibiting 3D polygonal-cobblestone morphology, apical microvilli, basal infoldings, high transepithelial resistance (TER), phagocytic activity and expression of signature RPE markers. 70 nm PLLA ENMs were successfully implanted into the subretinal space of RCS-rdy+p+/LAV rats, also commonly know as rdy rats. At week 4, in the absence of immuno-suppressants, implanted PLLA ENMs were surrounded by a significantly low number of activated microglial cells, compared to week 1, indicating no adverse long-term immune response. In conclusion, we successfully designed and tested ENMs emulating the RPE cell supporting layers of the BM, and found 70 nm PLLA ENMs to be best suited as scaffolds for fabricating retinal constructs.
   Statement of Significance
   Age related macular degeneration (AMD) is a leading cause of vision loss in the developed world, with an increasing number of people suffering from blindness or severe visual impairment. Transplantation of retinal pigment epithelium (RPE) cells supported on a synthetic, biomimetic-like Bruch's membrane (BM) is considered a promising treatment. However, the synthetic scaffolds used do not mimic the microenvironment of the RPE cell supporting layers, required for the development of a functional RPE monolayer. This study indicated that porous, laminin coated, 70 nm PLLA ENMs supported functional RPE monolayers, exhibiting 3D polygonal-cobblestone morphology, apical microvilli, basal infoldings, high transepithelial resistance (TER), phagocytic activity and expression of signature RPE markers. These findings indicate the potential clinical use of porous, laminin coated, 70 nm PLLA ENMs in fabricating retinal constructs aimed at treating dry AMD. (C) 2017 Published by Elsevier Ltd on behalf of Acta Materialia Inc.
C1 [Surrao, Denver C.; Chau, Yu-Qian; Skabo, Stuart J.; Limnios, Ioannis J.; Liu, Qin] Bond Univ, Clem Jones Res Ctr Regenerat Med, Fac Hlth Sci & Med, Gold Coast, Qld 4229, Australia.
   [Greferath, Ursula; Huynh, Mario; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic 3010, Australia.
   [Shelat, Kinnari J.] Univ Queensland, AIBN, Brisbane, Qld 4072, Australia.
   [Shelat, Kinnari J.] Univ Queensland, ANFF, Queensland Node, Brisbane, Qld 4072, Australia.
C3 Bond University; University of Melbourne; University of Queensland;
   University of Queensland
RP Surrao, DC (通讯作者)，Bond Univ, Clem Jones Res Ctr Regenerat Med, Fac Hlth Sci & Med, Gold Coast, Qld 4229, Australia.
EM dsurrao@bond.edu.au
RI ; Fletcher, Erica/E-6364-2012
OI Huynh, Mario/0000-0002-5780-1891; Greferath, Ursula/0000-0003-1028-648X;
   Surrao, Denver/0000-0002-2581-1454; Fletcher, Erica/0000-0001-9412-9523
FU Clem Jones Foundation in Brisbane, Queensland, Australia
FX This research project was funded by the Clem Jones Foundation in
   Brisbane, Queensland, Australia. Part of the physiochemical assessments
   of ENMs was performed in collaboration with the Queensland Node of
   Australian National Fabrication Facility (ANFF), a company established
   under the National Collaborative Research Infrastructure Strategy to
   provide nano and microfabrication facilities for Australia's
   researchers. We wish to thank Mr. Gene Venables, Department of Anatomy
   and Neuroscience, The University of Melbourne, for his technical
   assistance with this project.
CR Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Akrami H, 2011, BIOCHEM GENET, V49, P313, DOI 10.1007/s10528-010-9409-1
   Antognazza M. R., 2016, ADV HEALTHC MAT
   Barthes J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/921905
   Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Boochoon KS, 2014, J BIOMECH, V47, P3237, DOI 10.1016/j.jbiomech.2014.06.021
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BUSSCHER HJ, 1984, COLLOID SURFACE, V9, P319, DOI 10.1016/0166-6622(84)80175-4
   Cai KY, 2009, COLLOID SURFACE B, V72, P230, DOI 10.1016/j.colsurfb.2009.04.008
   Calabia BP., 2011, POLY LACTIC ACID SYN, P423
   Carrow JK, 2015, MACROMOL CHEM PHYS, V216, P248, DOI 10.1002/macp.201400427
   Chan W.H., 2007, INVEST OPHTHALMOL VI, V48, P2187
   Chen J, 2015, INT J NANOMED, V10, P3337, DOI 10.2147/IJN.S77706
   Curcio C.A., 2013, RETINA-J RET VIT DIS, V5th, P465
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Da Silva GR, 2015, EUR J PHARM SCI, V73, P9, DOI 10.1016/j.ejps.2015.03.003
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Dolatshahi-Pirouz A, 2010, ACS NANO, V4, P2874, DOI 10.1021/nn9017872
   Esumi N, 2009, HUM MOL GENET, V18, P128, DOI 10.1093/hmg/ddn323
   Eyckmans J, 2011, DEV CELL, V21, P35, DOI 10.1016/j.devcel.2011.06.015
   Fernandez-Robredo P., 2014, J OPHTHALMOL, V2014, P1
   Finnemann SC, 2006, ADV EXP MED BIOL, V572, P499
   FISCHER EW, 1973, KOLLOID Z Z POLYM, V251, P980, DOI 10.1007/BF01498927
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Giamblanco N, 2013, LANGMUIR, V29, P8335, DOI 10.1021/la304644z
   Hammarin G, 2014, COLLOID SURFACE B, V122, P85, DOI 10.1016/j.colsurfb.2014.06.048
   Harper C. A., 2000, MODERN PLASTICS HDB, P1
   HAYNES CA, 1994, COLLOID SURFACE B, V2, P517, DOI 10.1016/0927-7765(94)80066-9
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hotaling N. A., 2016, J OCUL PHARM THER
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Jha BS, 2015, CURR STEM CELL REP, V1, P79, DOI 10.1007/s40778-015-0014-4
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim J, 2014, TISSUE ENG PT A, V20, P2127, DOI 10.1089/ten.tea.2013.0707
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Peng SM, 2011, INVEST OPHTH VIS SCI, V52, P1392, DOI 10.1167/iovs.10-5984
   Philp NJ, 1998, AM J PHYSIOL-REG I, V274, pR1824, DOI 10.1152/ajpregu.1998.274.6.R1824
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   PITT CG, 1981, J APPL POLYM SCI, V26, P3779, DOI 10.1002/app.1981.070261124
   Popelka S, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/4/045022
   Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Ruckenstein E, 1998, J APPL POLYM SCI, V69, P1429, DOI 10.1002/(SICI)1097-4628(19980815)69:7<1429::AID-APP18>3.0.CO;2-O
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Seo JH, 2013, ACTA BIOMATER, V9, P5493, DOI 10.1016/j.actbio.2012.10.015
   Shadforth A. M. A., 2015, J TISSUE ENG REGEN M
   Sheridan C, 2005, ESSENT OPHTHALMOL, P101
   Sorkio A, 2015, TISSUE ENG PT A, V21, P2301, DOI [10.1089/ten.tea.2014.0640, 10.1089/ten.TEA.2014.0640]
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Surrao DC, 2012, ACTA BIOMATER, V8, P3997, DOI 10.1016/j.actbio.2012.07.012
   Suzuki S, 2015, J FUNCT BIOMATER, V6, P345, DOI 10.3390/jfb6020345
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Vallee A, 2014, COLLOID SURFACE B, V114, P284, DOI 10.1016/j.colsurfb.2013.09.053
   Vitte J, 2004, Eur Cell Mater, V7, P52
   von Burkersroda F, 2002, BIOMATERIALS, V23, P4221, DOI 10.1016/S0142-9612(02)00170-9
   VROMAN L, 1975, ADV CHEM SER, P255
   Vyner MC, 2013, BIOMATERIALS, V34, P9287, DOI 10.1016/j.biomaterials.2013.08.086
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   White C, 2017, J BIOMED MATER RES A, V105, P1260, DOI 10.1002/jbm.a.35992
   Wilson CJ, 2005, TISSUE ENG, V11, P1, DOI 10.1089/ten.2005.11.1
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
NR 70
TC 14
Z9 14
U1 1
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2017
VL 64
BP 357
EP 376
DI 10.1016/j.actbio.2017.09.032
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA FO1DZ
UT WOS:000416498200032
PM 28951331
DA 2022-11-30
ER

PT J
AU Jiang, R
   Wang, YX
   Wei, WB
   Xu, L
   Jonas, JB
AF Jiang, Ran
   Wang, Ya Xing
   Wei, Wen Bin
   Xu, Liang
   Jonas, Jost B.
TI Peripapillary Choroidal Thickness in Adult Chinese: The Beijing Eye
   Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE peripapillary choroidal thickness; optical coherence tomography;
   population
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   AGE-RELATED MACULOPATHY; NORMAL-TENSION GLAUCOMA; ANGLE-CLOSURE;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; DISC; VASCULOPATHY
AB PURPOSE. To measure peripapillary choroidal thickness (PPCT) and to assess its associations.
   METHODS. The population-based cross-sectional Beijing Eye Study 2011 included 3468 participants. Detailed medical and ophthalmic examinations were performed. We measured PPCT by spectral-domain optical coherence tomography (SD-OCT) with a 3.4-mm scan circle centered on the optic nerve head.
   RESULTS. Peripapillary choroidal thickness measurements were available for 3060 (88.2%) study participants with a mean age of 64.4 +/- 9.6 years (range, 50-93 years). Mean global PPCT was 134 +/- 53 mu m (range, 35-348 mu m). Peripapillary choroid was thickest in the superior region (155 +/- 60 mu m), followed by the temporal region (144 +/- 75 mu m; P < 0.001); nasal region (139 +/- 55 mu m; P < 0.001); and inferior region (110 +/- 45 mu m; P < 0.001). In multivariate analysis, thicker PPCT was associated with younger age (P < 0.001; standardized coefficient beta: -0.33; correlation coefficient B: -1.95; 95% confidence interval (CI): -2.25, -1.65); shorter axial length (P < 0.001; beta: -0.11; B: -5.39; 95% CI: -7.85, -2.93); smaller parapapillary alpha zone (P = 0.01; beta: -0.06; B: -5.46; 95% CI: -9.73, -1.19); and smaller beta zone (P < 0.001; beta: -0.14; B: -8.29; 95% CI: -11.12, -5.46); better best corrected visual acuity (logMAR; P = 0.002; beta: -0.05; B: -14.75; 95% CI: -28.59, -0.91), and higher prevalence of early age-related macular degeneration (P = 0.04; beta: 0.05; B: 9.11; 95% CI: 0.42, 17.80) and intermediate age-related macular degeneration (P = 0.001; beta: 0.08; B: 10.90; 95% CI: 4.46, 17.33). It was not significantly (all P > 0.05) associated with blood pressure, blood concentration of lipids, intraocular pressure and prevalence of glaucoma, diabetic retinopathy, and retinal vein occlusions. The decrease of PPCT with longer axial length occurred predominantly in the temporal region.
   CONCLUSIONS. Peripapillary choroidal thickness is thickest superiorly and thinnest inferiorly. It decreases by 2 mu m per year of life and by 5 mu m per diopter of myopia. Thinner PPCT is correlated with larger parapapillary a and b zones. The association of thinner PPCT with lower best corrected visual acuity may warrant further study.
C1 [Jiang, Ran; Wang, Ya Xing; Xu, Liang; Jonas, Jost B.] Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Eye Ctr, Beijing Tongren Hosp,Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Wei, Wen Bin] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, D-69115 Heidelberg, Germany.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg
RP Xu, L (通讯作者)，Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Eye Ctr, Beijing Tongren Hosp,Beijing Inst Ophthalmol, Beijing, Peoples R China.
EM xlbio1@163.com; jost.jonas@medma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
CR Arora KS, 2012, INVEST OPHTH VIS SCI, V53, P7813, DOI 10.1167/iovs.12-10483
   Brito PN, 2015, J GLAUCOMA, V24, P45, DOI 10.1097/IJG.0b013e3182883c29
   Chung Ho Seok, 2014, Korean J Ophthalmol, V28, P234, DOI 10.3341/kjo.2014.28.3.234
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ehrlich JR, 2011, EXP EYE RES, V92, P189, DOI 10.1016/j.exer.2011.01.002
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gupta P, 2015, BR J OPHTHALMOL
   Gupta P, 2015, INVEST OPHTH VIS SCI, V56, P1475, DOI 10.1167/iovs.14-15742
   HAYREH SS, 1969, BRIT J OPHTHALMOL, V53, P721, DOI 10.1136/bjo.53.11.721
   Hirooka K, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-29
   Ho J, 2011, OPHTHALMOLOGY, V118, P2001, DOI 10.1016/j.ophtha.2011.02.049
   Hosseini Hamid, 2014, J Ophthalmic Vis Res, V9, P154
   Huang WB, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-23
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe317, DOI 10.1111/j.1755-3768.2010.02022.x
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Li L, 2013, AM J OPHTHALMOL, V156, P1277, DOI 10.1016/j.ajo.2013.07.011
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P3430, DOI 10.1167/iovs.10-6600
   Oh Jaeryung, 2013, Korean J Ophthalmol, V27, P172, DOI 10.3341/kjo.2013.27.3.172
   Park HYL, 2014, J GLAUCOMA, V23, P225, DOI 10.1097/IJG.0000000000000045
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Roberts KF, 2012, ARCH OPHTHALMOL-CHIC, V130, P980, DOI 10.1001/archophthalmol.2012.371
   Schuster AK, 2014, AM J OPHTHALMOL, V158, P1342, DOI 10.1016/j.ajo.2014.09.008
   Shao L, 2014, AM J OPHTHALMOL, V158, P702, DOI 10.1016/j.ajo.2014.05.023
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Suh W, 2014, JPN J OPHTHALMOL, V58, P62, DOI 10.1007/s10384-013-0290-4
   Takahashi A, 2013, JPN J OPHTHALMOL, V57, P233, DOI 10.1007/s10384-012-0224-6
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tanabe H, 2012, RETINA-J RET VIT DIS, V32, P134, DOI 10.1097/IAE.0b013e318217ff87
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Wang YX, 2010, AM J OPHTHALMOL, V150, P917, DOI 10.1016/j.ajo.2010.06.037
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Zhang CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109683
   Zhou MW, 2013, INVEST OPHTH VIS SCI, V54, P1971, DOI 10.1167/iovs.12-11090
NR 44
TC 50
Z9 52
U1 1
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2015
VL 56
IS 6
BP 4045
EP 4052
DI 10.1167/iovs.15-16521
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM5PJ
UT WOS:000357740200070
PM 26114482
DA 2022-11-30
ER

PT J
AU Kivanc, SA
   Akova-Budak, B
   Olcaysu, OO
   Cevik, SG
AF Kivanc, Serta Argun
   Akova-Budak, Berna
   Olcaysu, Osman Okan
   Cevik, Sadik Gorkem
TI Sociodemographic status of severely disabled and visually impaired
   elderly people in Turkey
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Blindness; Cataract; Disabled people; Aging
ID OLDER-ADULTS; VISION LOSS; BLINDNESS; DISABILITY; PREVALENCE;
   POPULATION; LONELINESS; COST; TOOL
AB Purpose: To identify the prevalence of ophthalmologic diseases in elderly patients who had been classified as severely disabled and to identify the ophthalmologic conditions leading to visual impairment and blindness.
   Methods: The medical records of 2806 patients who had applied to the Health Board of the Erzurum Region Training and Research Hospital between January 2011 and December 2012 were reviewed. One hundred ninety-nine patients aged >64 years who were classified as severely disabled with disability rates of over 50%, and who were unable to care for themselves or to move and/or communicate without help were included in the study.
   Results: The most frequently seen disabilities were neurological (47.2%) and those resulting from eye diseases (17.1%). The most common ophthalmologic diseases were cataract, glaucoma, and age-related macular degeneration. The mean right and left eye visual acuities were 1.17 +/- 1.10 logMAR and 1.13 +/- 1.0 logMAR, respectively. Of the 60 patients with ophthalmologic diseases or conditions, 33 were blind (visual acuity worse than 20/400) and 10 were visually impaired (visual acuity worse than 20/70 but better than 20/400). Cataracts were the main cause of blindness. The mean age of the patients who were still being followed up at the time of application to the disability board was significantly lower than that of the others (p=0.015). Seventy-nine percent of the blind patients were from rural areas, and 88% of these had no regular follow-up. Among the blind and visually impaired, significantly more patients from urban areas had social security insurance (SSI) than those from rural areas (p-0.043). Nearly 64% of the blind patients were women. The follow-up rate was significantly lower in women (p=0.025). According to multinomial logistic regression analysis, the visually impaired and blind patients were more likely to have lower follow-up rates than the other types of severely disabled patients (OR: 0.231, 95% CI: 0.077-0.688, p=0.009).
   Conclusions: Blindness gives rise to severe disability, and the most common ophthalmologic diseases that cause severe disabilities in elderly patients are cataract, glaucoma, and age-related macular degeneration. Sociodemographic factors that may affect the accessibility of visually impaired and blind people to health services include their place of residence and gender.
C1 [Kivanc, Serta Argun; Olcaysu, Osman Okan] Erzurum Reg Training & Res Hosp, Dept Ophthalmol, Erzurum, Turkey.
   [Kivanc, Serta Argun; Akova-Budak, Berna] Uludag Univ, Sch Med, Dept Ophthalmol, Bursa, Turkey.
   [Cevik, Sadik Gorkem] Sevket Yilmaz Training & Res Hosp, Dept Ophthalmol, Bursa, Turkey.
C3 Erzurum Bolge Training & Research Hospital; Uludag University; Sevket
   Yilmaz Training & Research Hospital
RP Kivanc, SA (通讯作者)，Uludag Univ Gorukle, Dept Ophthalmol Sch Med, Bursa, Turkey.
EM sakivanc@gmail.com
RI Akova, Berna/ABE-3033-2020; Kıvanç, Sertaç Argun/AAH-6518-2021
OI Akova, Berna/0000-0003-0995-5260; 
CR Alma MA, 2011, J AGING HEALTH, V23, P843, DOI 10.1177/0898264311399758
   Avlund K, 2004, ARCH GERONTOL GERIAT, V38, P85, DOI 10.1016/j.archger.2003.08.003
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Silva JC, 2015, REV PANAM SALUD PUBL, V37, P13
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruess AF, 2011, CAN J OPHTHALMOL, V46, P315, DOI 10.1016/j.jcjo.2011.06.006
   Duerksen R, 2013, OPHTHAL EPIDEMIOL, V20, P301, DOI 10.3109/09286586.2013.821497
   Fontana L, 2009, BBA-GEN SUBJECTS, V1790, P1133, DOI 10.1016/j.bbagen.2009.02.002
   Glei DA, 2005, INT J EPIDEMIOL, V34, P864, DOI 10.1093/ije/dyi049
   Hennis AJ, 2009, OPHTHALMOLOGY, V116, P1461, DOI 10.1016/j.ophtha.2009.02.017
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Limburg H, 2009, OPHTHAL EPIDEMIOL, V16, P362, DOI 10.3109/09286580903312251
   Limburg J J, 2009, Tijdschr Gerontol Geriatr, V40, P149
   Newall NE, 2009, J SOC PERS RELAT, V26, P273, DOI 10.1177/0265407509106718
   Nowak MS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000505
   Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675
   Olcaysu OO, 2014, TURK J GERIATR, V17, P44
   Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539
   Republic of Turkey, 2011, STAT YB
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Rim TH, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007614
   Roberts CB, 2010, ARCH OPHTHALMOL-CHIC, V128, P766, DOI 10.1001/archophthalmol.2010.86
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Turkish Statistical Institute, STAT THEM POP PROJ
   Turkish Statistical Institute, 2009, TURK DIS SURV 2002
   Ustun TB, 2003, DISABIL REHABIL, V25, P565, DOI 10.1080/0963828031000137063
   WHO, 2011, WHO REP DIS 2011
   World Health Organization, 2007, GLOB IN EL AV BLINDN
   World Health Organization, 2004, GLOB BURD DIS 2004 U
NR 30
TC 7
Z9 7
U1 1
U2 18
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JAN-FEB
PY 2016
VL 79
IS 1
BP 24
EP 29
DI 10.5935/0004-2749.20160008
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD1BS
UT WOS:000369656700008
PM 26840162
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sengupta, S
   van Landingham, SW
   Solomon, SD
   Do, DV
   Friedman, DS
   Ramulu, PY
AF Sengupta, Sabyasachi
   van Landingham, Suzanne W.
   Solomon, Sharon D.
   Do, Diana V.
   Friedman, David S.
   Ramulu, Pradeep Y.
TI Driving Habits in Older Patients with Central Vision Loss
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; MACULAR DEGENERATION; ASSOCIATION; PREVALENCE;
   PATTERNS; ADULTS; EYE
AB Objective: To determine if central visual loss is associated with driving cessation, driving restriction, or other-driver preference.
   Design: Cross-sectional study.
   Participants: Sixty-four subjects with bilateral visual loss (<20/32 in better eye) or severe unilateral visual loss (<20/200) from age-related macular degeneration (AMD) and 58 normally sighted controls between 60 and 80 years of age.
   Methods: Participants self-reported driving habits. Other-driver preference was defined as preferring that another drive when there is more than 1 driver in the car. Subjects reporting 2 or more driving limitations were considered to have restricted their driving.
   Main Outcome Measures: Self-reported driving cessation, other-driver preference, and driving restriction.
   Results: Age-related macular degeneration subjects were older (74.7 vs. 69.7 years), had worse visual acuity (VA; mean better-eye VA, 0.43 vs. 0.08 logarithm of minimum angle of resolution [logMAR]) and contrast sensitivity (CS; 1.4 vs. 1.9 log units of CS [logCS]), and were more likely to be white when compared with controls (P<0.001 for all). Drivers with AMD-related vision loss were more likely to avoid driving over longer distances, beyond 1 hour, at night, and in unfamiliar conditions (P < 0.05 for all). In multivariate models, driving cessation was associated with worse better-eye VA (odds ratio [OR], 1.5 per 1-line decrement in VA; P < 0.001) and worse binocular CS (OR, 1.36 per 0.1 logCS increment; P = 0.005); however, AMD group status was not associated with driving cessation (OR, 1.9; P = 0.35). Factors predicting driving restriction were AMD (OR, 9.0; P = 0.004), worse vision (OR, 2.5 per line of VA loss; P < 0.001), lower CS (OR, 2.2 per 0.1-logCS increment; P < 0.001), and female gender (OR, 27.9; P = 0.002). Other-driver preference was more common with worse vision (OR, 1.6 per 0.1-logMAR increment; P = 0.003), female gender (OR, 4.5; P = 0.02), and being married (OR, 3.8; P = 0.04).
   Conclusions: Most patients with AMD-related central vision loss continue to drive, but demonstrate significant driving restrictions, especially with more severe VA and CS loss. Future work should determine which driving adaptations the visually impaired best balance safety and independence. (C) 2014 by the American Academy of Ophthalmology.
C1 [Sengupta, Sabyasachi; van Landingham, Suzanne W.; Solomon, Sharon D.; Do, Diana V.; Friedman, David S.; Ramulu, Pradeep Y.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Ramulu, PY (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, 600 North Wolfe St,Maumenee B-110, Baltimore, MD 21287 USA.
EM pramulu1@jhmi.edu
RI Sengupta, Sabyasachi/Y-4936-2019
OI Sengupta, Sabyasachi/0000-0001-7441-5856; Friedman,
   David/0000-0002-2055-5797
FU Dennis W. Jahnigen Memorial Award (American Geriatrics Society, New
   York, New York); National Institutes of Health, Bethesda, Maryland
   [EY018595]; Research to Prevent Blindness Robert and Helen Schaub
   Special Scholar Award, New York, New York; Intramural Research Program
   of the National Institute on Aging, National Institutes of Health,
   Bethesda, Maryland; Doris Duke Charitable Research Foundation Clinical
   Research Fellowship, New York, New York; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [K23EY018595] Funding Source: NIH RePORTER
FX Supported in part by the Dennis W. Jahnigen Memorial Award (American
   Geriatrics Society, New York, New York); the National Institutes of
   Health, Bethesda, Maryland (grant no.: EY018595); Research to Prevent
   Blindness Robert and Helen Schaub Special Scholar Award, New York, New
   York; the Intramural Research Program of the National Institute on
   Aging, National Institutes of Health, Bethesda, Maryland; and the Doris
   Duke Charitable Research Foundation Clinical Research Fellowship, New
   York, New York. All funding organizations had no role in the design or
   conduct of this research.
CR Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Bronstad PM, 2013, JAMA OPHTHALMOL, V131, P303, DOI 10.1001/jamaophthalmol.2013.1443
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Edwards JD, 2009, J GERONTOL A-BIOL, V64, P300, DOI 10.1093/gerona/gln019
   Findl O, 2003, J CATARACT REFR SURG, V29, P106, DOI 10.1016/S0886-3350(02)01509-2
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Fonda SJ, 2001, J GERONTOL B-PSYCHOL, V56, pS343, DOI 10.1093/geronb/56.6.S343
   Freeman EE, 2006, INVEST OPHTH VIS SCI, V47, P514, DOI 10.1167/iovs.05-0934
   Freeman EE, 2006, AM J PUBLIC HEALTH, V96, P1254, DOI 10.2105/AJPH.2005.069146
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Montorio I, 1996, Int Psychogeriatr, V8, P103, DOI 10.1017/S1041610296002505
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 2008, J VISUAL IMPAIR BLIN, V102, P621, DOI 10.1177/0145482X0810201007
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Turano KA, 2009, J GERONTOL B-PSYCHOL, V64, P348, DOI 10.1093/geronb/gbp017
   van Landingham SW, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-4
   WEST SK, 1993, CURR EYE RES, V12, P123, DOI 10.3109/02713689308999480
NR 28
TC 35
Z9 36
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2014
VL 121
IS 3
BP 727
EP 732
DI 10.1016/j.ophtha.2013.09.042
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AC3FT
UT WOS:000332401800023
PM 24290805
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Xu, L
   Wang, YX
   Wang, J
   Jonas, JJ
AF Xu, Liang
   Wang, Ya Xing
   Wang, Jian
   Jonas, Jost J.
TI Mortality and Ocular Diseases The Beijing Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; RETINAL MICROVASCULAR ABNORMALITIES;
   ANTERIOR-CHAMBER DEPTH; ANGLE-CLOSURE GLAUCOMA; CORONARY-HEART-DISEASE;
   VISUAL IMPAIRMENT; MACULAR DEGENERATION; ATHEROSCLEROSIS RISK;
   CARDIOVASCULAR MORTALITY; CHINESE POPULATION
AB Objective: To examine the relationship between mortality and major ocular diseases.
   Design: Population-based study.
   Participants: At baseline in 2001, the Beijing Eye Study examined 4439 subjects with an age of 40 years or more. The mean age was 56.2+/-10.6 years (range, 40-101 years). In 2006, all study participants were invited for a follow-up examination.
   Methods: The participants underwent a detailed ophthalmic examination and answered questions regarding their socioeconomic background. Rate of mortality was determined in the follow-up survey of 2006.
   Main Outcome Measures: Factors associated with mortality.
   Results: Of the 4439 subjects examined in the 2001, 3251 (73.2%) subjects returned for the follow-up examination, whereas 143 (3.2%) subjects had died and 1045 (23.5%) subjects were alive but did not agree to be reexamined. In binary logistic regression analysis, mortality was significantly associated with the systemic parameters of higher age (P<0.001; odds ratio [OR], 1.07), male gender (P = 0.01; OR, 0.55), lower level of education (P<0.001; OR, 0.65), smoking status (P = 0.023; OR, 1.25), and with the ocular parameters of level of diabetic-like retinopathy (P = 0.036; OR, 1.02), presence of angle-closure glaucoma (P = 0.013; OR, 3.74), and presence of nonglaucomatous optic nerve damage (P = 0.027; OR, 3.41). Presence of retinal vein occlusions was associated marginally with mortality (P = 0.059; OR, 2.59). Mortality was not significantly associated with best-corrected visual acuity (P = 0.14) in multivariate analysis, nor with age-related macular degeneration, open-angle glaucoma, trachoma, any type of cataract, visual field defects, intraocular pressure, or refractive error.
   Conclusions: If socioeconomic parameters, age, gender, and smoking status were taken into account, ocular parameters associated with an increased mortality were diabetic-like retinopathy, angle-closure glaucoma, and nonglaucomatous optic nerve damage. Retinal vein occlusions were marginally associated. Other major ocular disorders such as any form of cataract, open-angle glaucoma, age-related macular degeneration, trachoma, pterygia, and high myopia or high hyperopia were not significantly related to mortality.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:732-738 (C) 2009 by the American Academy of Ophthalmology.
C1 [Xu, Liang; Wang, Ya Xing; Wang, Jian; Jonas, Jost J.] Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost J.] Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou St, Beijing 100005, Peoples R China.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
FU Beijing Natural Science Foundation, Beijing, China
FX Supported by the Beijing Natural Science Foundation, Beijing, China.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Cheung N, 2007, DIABETES CARE, V30, P1742, DOI 10.2337/dc07-0264
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon NG, 1997, OPHTHALMOLOGY, V104, P1489, DOI 10.1016/S0161-6420(97)30112-2
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Cugati S, 2007, OPHTHALMOLOGY, V114, P520, DOI 10.1016/j.ophtha.2006.06.061
   DAVID HT, 1999, NEW BACH READER LIFE, P432
   Devereux JG, 2000, ARCH OPHTHALMOL-CHIC, V118, P257
   Eysteinsson T, 2005, ACTA OPHTHALMOL SCAN, V83, P734, DOI 10.1111/j.1600-0420.2005.00540.x
   Foong AWP, 2008, OPHTHALMOLOGY, V115, P802, DOI 10.1016/j.ophtha.2007.04.066
   Foster PJ, 2003, BRIT J OPHTHALMOL, V87, P1112, DOI 10.1136/bjo.87.9.1112
   Foster PJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P1105, DOI 10.1001/archopht.118.8.1105
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Hirai FE, 2007, AM J EPIDEMIOL, V166, P724, DOI 10.1093/aje/kwm126
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Juutilainen A, 2007, DIABETES CARE, V30, P292, DOI 10.2337/dc06-1747
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Lee AJ, 2006, OPHTHALMOLOGY, V113, P1069, DOI 10.1016/j.ophtha.2006.02.062
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   Leske MC, 1997, ARCH OPHTHALMOL-CHIC, V115, P105, DOI 10.1001/archopht.1997.01100150107018
   Liu HS, 2002, OPHTHALMIC EPIDEMIOL, V9, P97, DOI 10.1076/opep.9.2.97.1521
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 2005, NEUROLOGY, V65, P1005, DOI 10.1212/01.wnl.0000179177.15900.ca
   Nolan WP, 2007, OPHTHALMOLOGY, V114, P33, DOI 10.1016/j.ophtha.2006.05.073
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Rumsfeld JS, 2005, AM HEART J, V150, P961, DOI 10.1016/j.ahj.2005.02.036
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   THOMPSON JR, 1989, AGE AGEING, V18, P83, DOI 10.1093/ageing/18.2.83
   van Hecke MV, 2003, DIABETES CARE, V26, P2958, DOI 10.2337/diacare.26.10.2958
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   Varma R, 2004, OPHTHALMOLOGY, V111, P1449, DOI 10.1016/j.ophtha.2004.01.024
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang S, 2006, OPHTHALMOLOGY, V113, P1752, DOI 10.1016/j.ophtha.2006.05.019
   Wang YX, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2007.01143.x
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2003, OPHTHALMOLOGY, V110, P933, DOI 10.1016/S0161-6420(03)00084-8
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P1237
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Wu SY, 2008, ARCH OPHTHALMOL-CHIC, V126, P365, DOI 10.1001/archophthalmol.2007.77
   Xu L, 2008, EYE, V22, P434, DOI 10.1038/sj.eye.6703072
   Xu L, 2008, EXP CLIN ENDOCR DIAB, V116, P69, DOI 10.1055/s-2007-985381
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   Xu L, 2008, GRAEF ARCH CLIN EXP, V246, P923, DOI 10.1007/s00417-008-0773-z
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   Xu L, 2008, GRAEF ARCH CLIN EXP, V246, P615, DOI 10.1007/s00417-007-0731-1
   Xu L, 2007, AM J OPHTHALMOL, V144, P972, DOI 10.1016/j.ajo.2007.07.015
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
NR 55
TC 38
Z9 39
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2009
VL 116
IS 4
BP 732
EP 738
DI 10.1016/j.ophtha.2008.11.003
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 427YI
UT WOS:000264814600019
PM 19195709
DA 2022-11-30
ER

PT J
AU Robinson, DG
   Margrain, TH
   Bailey, C
   Binns, AM
AF Robinson, D. Grant
   Margrain, Tom H.
   Bailey, Clare
   Binns, Alison M.
TI An Evaluation of a Battery of Functional and Structural Tests as
   Predictors of Likely Risk of Progression of Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; visual function; progression
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-PIGMENT REGENERATION; MEDIATED
   DARK-ADAPTATION; FLICKER SENSITIVITY; FUNDUS APPEARANCE; SEVERITY SCALE;
   FELLOW EYE; ROD; CLASSIFICATION; VULNERABILITY
AB PURPOSE. To evaluate the ability of visual function and structural tests to identify the likely risk of progression from early/intermediate to advanced AMD, using the Age-Related Eye Disease Study (AREDS) simplified scale as a surrogate for risk of progression. The secondary aim was to determine the relationship between disease severity grade and the observed functional and structural deficits.
   METHODS. A total of 100 participants whose AMD status varied from early to advanced were recruited. Visual function was assessed using cone dark adaptation, 14 Hz flicker and chromatic threshold tests and retinal structure was assessed by measuring drusen volume and macular thickness. The predictive value of the tests was estimated using ordinal regression analysis. Group comparisons were assessed using analysis of covariance.
   RESULTS. Change in cone dark adaptation (cone tau) and yellow-blue (YB) chromatic sensitivity were independent predictors for AMD progression risk (cone tau, pseudo R-2 = 0.35, P < 0.001; YB chromatic threshold, pseudo R-2 = 0.16, P < 0.001). The only structural predictor was foveal thickness (R-2 = 0.05, P = 0.047). Chromatic sensitivity and cone dark adaptation were also the best functional tests at distinguishing between severity groups. Drusen characteristics clearly differentiated between participants with early and advanced disease, but were not able to differentiate between those with early AMD and controls. Mean differences in retinal thickness existed between severity groups at the foveal (P = 0.040) and inner (P = 0.001) subfields.
   CONCLUSIONS. This study indicates that cone s, YB chromatic threshold and foveal thickness are independent predictors of likely risk of AMD progression.
C1 [Robinson, D. Grant; Margrain, Tom H.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, S Glam, Wales.
   [Bailey, Clare] Bristol Eye Hosp, Lower Maudlin St, Bristol, Avon, England.
   [Binns, Alison M.] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London, England.
C3 Cardiff University; Bristol Eye Hospital; City University London
RP Margrain, TH (通讯作者)，Cardiff Univ, Cardiff Ctr Vis Sci, Coll Biomed & Life Sci, Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.
EM margrainth@cardiff.ac.uk
FU College of Optometrists Postgraduate Scholarship Award, UK
FX Supported by a research grant from The College of Optometrists
   Postgraduate Scholarship Award, UK. The sponsor (Cardiff University, UK)
   had no role in the design or conduct of this research.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Altman DG, 1991, PRACTICAL STAT MED R
   [Anonymous], 2004, B WHO, V82, P811
   Antony B, 2011, BIOMED OPT EXPRESS, V2, P2403, DOI 10.1364/BOE.2.002403
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Barbur JL, 2015, HDB COLOUR PSYCHOL
   BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   Birch J., 1993, DIAGNOSIS DEFECTIVE
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Cho NC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1393
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Gaffney AJ, 2014, DOC OPHTHALMOL, V128, P33, DOI 10.1007/s10633-013-9418-6
   Gaffney AJ, 2013, DOC OPHTHALMOL, V127, P191, DOI 10.1007/s10633-013-9400-3
   Gaffney AJ, 2012, OPTOMETRY VISION SCI, V89, P1219, DOI 10.1097/OPX.0b013e318263c6b1
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   GREENSTEIN VC, 1992, INVEST OPHTH VIS SCI, V33, P2781
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   HOLLINS M, 1973, J GEN PHYSIOL, V62, P430, DOI 10.1085/jgp.62.4.430
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   HOOD DC, 1984, INVEST OPHTH VIS SCI, V25, P864
   HOOD DC, 1988, APPL OPTICS, V27, P1025, DOI 10.1364/AO.27.001025
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Kaluzny JJ, 2009, OPHTHAL SURG LAS IM, V40, P102, DOI 10.3928/15428877-20090301-10
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P1450
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Margrain TH, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-57
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528
   O'Neill-Biba M, 2010, OPHTHAL PHYSL OPT, V30, P705, DOI 10.1111/j.1475-1313.2010.00775.x
   Odell D, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/692574
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Terry L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162001
   Thomas MM, 1999, J PHYSIOL-LONDON, V518, P479, DOI 10.1111/j.1469-7793.1999.0479p.x
   Vemala R, 2017, INVEST OPHTH VIS SCI, V58, P247, DOI 10.1167/iovs.17-21771
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828
   Westheimer G, 2008, P ROY SOC B-BIOL SCI, V275, P2777, DOI 10.1098/rspb.2008.0712
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 65
TC 5
Z9 5
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2019
VL 60
IS 2
BP 580
EP 589
DI 10.1167/iovs.18-25092
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN0LZ
UT WOS:000459881100012
PM 30721275
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Huang, L
   Liang, WT
   Zhou, KL
   Wassel, RA
   Ridge, ZD
   Ma, JX
   Wang, B
AF Huang, Li
   Liang, Wentao
   Zhou, Kelu
   Wassel, Ronald A.
   Ridge, Zachary D.
   Ma, Jian-Xing
   Wang, Bing
TI Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal
   Vascular Leakage and Neovascularization
SO BIOLOGY-BASEL
LA English
DT Article
DE fenofibrate; nanomedicine; eye drop; age-related macular degeneration;
   diabetic retinopathy; PPAR alpha; vascular leakage
ID PPAR-ALPHA AGONIST; DIABETIC-RETINOPATHY; PATHOGENIC ROLE; EXPRESSION;
   DYSLIPIDEMIA; ANGIOGENESIS; LEUKOSTASIS; INHIBITION; OUTCOMES; PROTEIN
AB Simple Summary:& nbsp;Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are the leading causes of blindness and lack non-invasive drug treatments. Macular edema and neovascularization are the key pathogenic features responsible for vision loss in AMD and DR. Clinical studies showed that fenofibrate, a PPAR
   a
   agonist, has robust therapeutic effects on macular edema and retinal neovascularization after oral administration. However, the efficacy of oral fenofibrate remains to be improved, due to limited amounts of the drug delivered to the retina after systemic administration. To increase the drug availability in the retina, this study developed a novel nano-emulsion fenofibrate eye drop. Topical administration of the fenofibrate eye drop delivered significantly higher drug concentrations to the retina/vitreous, relative to the systemic administration. The fenofibrate eye drop alleviated retinal inflammation and vascular leakage in both DR and AMD models. Further, the fenofibrate eye drop also alleviated laser-induced choroidal neovascularization. These findings suggest that topical administration of the nano-emulsion-based eye drop of a PPAR
   a
   agonist has potential to become a non-invasive therapeutic strategy for long-term treatment of DR and AMD.<br>Macular edema caused by retinal vascular leakage and ocular neovascularization are the leading causes of severe vision loss in diabetic retinopathy (DR) and age-related macular degeneration (AMD) patients. Oral administration of fenofibrate, a PPAR
   a
   agonist, has shown therapeutic effects on macular edema and retinal neovascularization in diabetic patients. To improve the drug delivery to the retina and its efficacy, we have developed a nano-emulsion-based fenofibrate eye drop formulation that delivered significantly higher amounts of the drug to the retina compared to the systemic administration, as measured by liquid chromatography-mass spectrometer (LC-MS). The fenofibrate eye drop decreased leukocytes adherent to retinal vasculature and attenuated overexpression of multiple inflammatory factors in the retina of very low-density lipoprotein receptor knockout (Vldlr(-/-)) mice, a model manifesting AMD phenotypes, and streptozotocin-induced diabetic rats. The fenofibrate eye drop also reduced retinal vascular leakage in these models. The laser-induced choroidal neovascularization was also alleviated by the fenofibrate eye drop. There were no detectable ocular toxicities associated with the fenofibrate eye drop treatment. These findings suggest that fenofibrate can be delivered efficiently to the retina through topical administration of the nano-emulsion eye drop, which has therapeutic potential for macular edema and neovascularization.
C1 [Huang, Li; Wang, Bing] Fujian Med Univ, Union Hosp, Dept Ophthalmol, 29 Xinquan Rd, Fuzhou 350001, Peoples R China.
   [Huang, Li; Liang, Wentao; Zhou, Kelu; Ma, Jian-Xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.
   [Wassel, Ronald A.; Ridge, Zachary D.] EyeCro LLC, Oklahoma City, OK 73104 USA.
C3 Fujian Medical University; University of Oklahoma System; University of
   Oklahoma Health Sciences Center
RP Wang, B (通讯作者)，Fujian Med Univ, Union Hosp, Dept Ophthalmol, 29 Xinquan Rd, Fuzhou 350001, Peoples R China.; Ma, JX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.
EM li-huang@ouhsc.edu; wentao-liang@ouhsc.edu; Kelu-zhou@ouhsc.edu;
   dwassel@eyecro.com; Zridge@eyecro.com; Jian-Xing-Ma@ouhsc.edu;
   wboph03@fjmu.edu.cn
RI Huang, Li/AGK-2582-2022
OI Liang, Wentao/0000-0002-0609-6280
FU National Institutes of Health (NIH) [GM122744, EY012231, EY028949,
   EY032930, EY032931]; Fujian Provincial Natural Science Foundation
   [EY021725, 2018J01310];  [EY019309]
FX This research was funded by National Institutes of Health (NIH) grants
   (EY019309, EY012231, EY028949, EY032930, EY032931) and Fujian Provincial
   Natural Science Foundation (Grant numbers 2018J01310).
CR Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829
   BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Calkin AC, 2008, PPAR RES, V2008, DOI 10.1155/2008/245410
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Chatziralli I, 2020, ACTA DIABETOL, V57, P1219, DOI 10.1007/s00592-020-01548-y
   Chen N, 2019, EUR REV MED PHARMACO, V23, P8630, DOI 10.26355/eurrev_201910_19180
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Chew GS, 2014, MOL CELL BIOCHEM, V388, P25, DOI 10.1007/s11010-013-1896-z
   Cooke JP, 2002, CIRCULATION, V105, P2133, DOI 10.1161/01.CIR.0000014928.45119.73
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290
   Elam M, 2011, CLIN LIPIDOL, V6, P9, DOI 10.2217/CLP.10.84
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fujimoto JG, 2003, NAT BIOTECHNOL, V21, P1361, DOI 10.1038/nbt892
   Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037
   Gervois P, 2004, J BIOL CHEM, V279, P16154, DOI 10.1074/jbc.M400346200
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Keating GM, 2011, AM J CARDIOVASC DRUG, V11, P227, DOI 10.2165/11207690-000000000-00000
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Latendresse JR, 2002, TOXICOL PATHOL, V30, P524, DOI 10.1080/01926230290105721
   Miyamoto K, 1999, Semin Ophthalmol, V14, P233, DOI 10.3109/08820539909069542
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Panigrahy D, 2008, P NATL ACAD SCI USA, V105, P985, DOI 10.1073/pnas.0711281105
   Park K, 2009, DIABETES, V58, P1902, DOI 10.2337/db08-1327
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Qiu FF, 2020, CLIN SCI, V134, P1613, DOI 10.1042/CS20200085
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Salehi E, 2012, GEN PHYSIOL BIOPHYS, V31, P255, DOI 10.4149/gpb_2012_033
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Shen Y.G.W., 2014, J CLIN EXP OPHTHALMO, V5, P5, DOI [10.4172/2155-9570.1000347, DOI 10.4172/2155-9570.1000347]
   Shin Eui Seok, 2014, J Ophthalmic Vis Res, V9, P362, DOI 10.4103/2008-322X.143378
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Suarez S, 2014, INVEST OPHTH VIS SCI, V55, P8232, DOI 10.1167/iovs.14-14217
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Tyagi A, 2018, PHARM ANAL ACTA, V09, P1, DOI [10.4172/2153-2435.1000585, DOI 10.4172/2153-2435.1000585]
   van der Wijk AE, 2017, J LEUKOCYTE BIOL, V102, P993, DOI 10.1189/jlb.3RU0417-139
   Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9
   Vinores S.A., 2010, ENCY EYE, P216
   Wang B, 2018, INVEST OPHTH VIS SCI, V59, P3630, DOI 10.1167/iovs.18-24015
   Watkins PJ, 2003, BRIT MED J, V326, P924, DOI 10.1136/bmj.326.7395.924
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
   Zhang SX, 2005, AM J PATHOL, V166, P313, DOI 10.1016/S0002-9440(10)62255-9
   Zhao YY, 2012, ANN INTERN MED, V156, P560, DOI [10.7326/0003-4819-156-8-201204170-00003, 10.7326/0003-4819-156-8-201204170-00401]
NR 56
TC 5
Z9 5
U1 2
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD DEC
PY 2021
VL 10
IS 12
AR 1328
DI 10.3390/biology10121328
PG 19
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA XX5OM
UT WOS:000736344700001
PM 34943243
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Huang, HY
   Caballero, B
   Chang, S
   Alberg, AJ
   Semba, RD
   Schneyer, CR
   Wilson, RF
   Cheng, TY
   Vassy, J
   Prokopowicz, G
   Barnes, GJ
   Bass, EB
AF Huang, Han-Yao
   Caballero, Benjamin
   Chang, Stephanie
   Alberg, Anthony J.
   Semba, Richard D.
   Schneyer, Christine R.
   Wilson, Renee F.
   Cheng, Ting-Yuan
   Vassy, Jason
   Prokopowicz, Gregory
   Barnes, George J., II
   Bass, Eric B.
TI The efficacy and safety of multivitamin and mineral supplement use to
   prevent cancer and chronic disease in adults: A systematic review for a
   National Institutes of Health State-of-the-Science Conference
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Review
ID BETA-CAROTENE; LONG-TERM; CARDIOVASCULAR-DISEASE; COGNITIVE PERFORMANCE;
   CONTROLLED-TRIAL; VITAMIN; NUTRITION; SU.VI.MAX; LINXIAN; STROKE
AB Background: Multivitamin and mineral supplements are the most commonly used dietary supplements in the United States.
   Purpose: To synthesize studies on the efficacy and safety of multivitamin/mineral supplement use in primary prevention of cancer and chronic disease in the general population.
   Data Sources: English-language literature search of the MEDLINE, EMBASE, and Cochrane databases through February 2006 and hand-searching of pertinent journals and articles.
   Study Selection: Randomized, controlled trials in adults were reviewed to assess efficacy, and randomized, controlled trials and observational studies in adults or children were reviewed to assess safety.
   Data Extraction: Paired reviewers extracted data and independently assessed study quality. Data Synthesis: 12 articles from 5 randomized, controlled trials that assessed efficacy and 8 articles from 4 randomized, controlled trials and 3 case reports on adverse effects were identified. Study quality was rated fair for the studies on cancer, cardiovascular disease, cataracts, or age-related macular degeneration and poor for the studies on hypertension. In a poorly nourished Chinese population, combined supplementation with beta-carotene, alpha-tocopherol, and selenium reduced the incidence of and mortality rate from gastric cancer and the overall mortality rate from cancer by 13% to 21%. In a French trial, combined supplementation with vitamin C, vitamin E, beta-carotene, selenium, and zinc reduced the rate of cancer by 31% in men but not in women. Multivitamin and mineral supplements had no significant effect on cardiovascular disease or cataracts, except that combined beta-carotene, selenium, a-tocopherol, retinol, and zinc supplementation reduced the mortality rate from stroke by 29% in the Linxian study and that a combination of 7 vitamins and minerals stabilized visual acuity loss in a small trial. Combined zinc and antioxidants slowed the progression of advanced age-related macular degeneration in high-risk persons. No consistent adverse effects of multivitamin and mineral supplements were evident.
   Limitations: Only randomized, controlled trials were considered for efficacy assessment. Special nutritional needs, such as use of folic acid by pregnant women to prevent birth defects, were not addressed. Findings may not apply to use of commercial multivitamin supplements by the general U.S. population.
   Conclusions: Evidence is insufficient to prove the presence or absence of benefits from use of multivitamin and mineral supplements to prevent cancer and chronic disease.
C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University
RP Huang, HY (通讯作者)，Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,E-6144, Baltimore, MD 21205 USA.
EM hyhuang@jhsph.edu
RI Vassy, Jason L./AAC-8220-2019
OI Bass, Eric/0000-0001-9106-527X; Vassy, Jason/0000-0001-6113-5564
FU NICHD NIH HHS [R01 HD032247] Funding Source: Medline; PHS HHS
   [290-02-0018] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032247] Funding
   Source: NIH RePORTER
CR AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   BLOT WJ, 1995, AM J CLIN NUTR, V62, P1424, DOI 10.1093/ajcn/62.6.1424S
   BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483
   BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   Czernichow S, 2005, J HYPERTENS, V23, P2013, DOI 10.1097/01.hjh.0000187259.94448.8a
   Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607
   Duthie SJ, 2002, J NUTR, V132, p2444S, DOI 10.1093/jn/132.8.2444S
   Gordis L., 2000, EPIDEMIOLOGY
   Granger DN, 2004, HYPERTENSION, V43, P924, DOI 10.1161/01.HYP.0000123070.31763.55
   Grouhi M, 2000, ANN ALLERG ASTHMA IM, V85, P269, DOI 10.1016/S1081-1206(10)62528-8
   Gulati R, 1999, J Assoc Physicians India, V47, P253
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335
   HUANG HY, 2006, AHRQ PUBLICATION
   *I MED NAT AC, 2006, DIET REF INT VIT
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KELLOFF GJ, 1994, J CELL BIOCHEM, P1
   Key T, 2004, PUBLIC HEALTH NUTR, V7, P187, DOI 10.1079/PHN2003588
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56
   Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230
   Lewerin C, 2005, AM J CLIN NUTR, V81, P1155
   Loke YK, 2006, BMJ-BRIT MED J, V332, P335, DOI 10.1136/bmj.38701.399942.63
   Mark SD, 1998, EPIDEMIOLOGY, V9, P9, DOI 10.1097/00001648-199801000-00005
   Meyer F, 2005, INT J CANCER, V116, P182, DOI 10.1002/ijc.21058
   Morris CD, 2003, ANN INTERN MED, V139, P56, DOI 10.7326/0003-4819-139-1-200307010-00014
   *NAT CTR CHRON DIS, 2006, GRANTM HLTH ADDR CHR
   Ohtake T, 2005, CLIN NEPHROL, V64, P236
   OMENN GS, 1994, CANCER EPIDEM BIOMAR, V3, P711
   Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207
   Reddy BS, 1996, IARC SCI PUBL, P221
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Selhub J, 2000, AM J CLIN NUTR, V71, p614S
   SHI FL, 1989, STROKE, V20, P1581, DOI 10.1161/01.STR.20.11.1581
   SLOAN E, 2006, NAT I HLTH STAT SCI, P25
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   WANG GQ, 1994, CANCER EPIDEM BIOMAR, V3, P161
   White E, 2004, AM J EPIDEMIOL, V159, P83, DOI 10.1093/aje/kwh010
   Wolters M, 2005, PREV MED, V41, P253, DOI 10.1016/j.ypmed.2004.11.007
   XUAN XZ, 1991, CANCER CAUSE CONTROL, V2, P175, DOI 10.1007/BF00056211
NR 44
TC 156
Z9 168
U1 1
U2 20
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD SEP 5
PY 2006
VL 145
IS 5
BP 372
EP 385
DI 10.7326/0003-4819-145-5-200609050-00135
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 080NZ
UT WOS:000240255900008
PM 16880453
DA 2022-11-30
ER

PT J
AU Bonds, DE
   Harrington, M
   Worrall, BB
   Bertoni, AG
   Eaton, CB
   Hsia, J
   Robinson, J
   Clemons, TE
   Fine, LJ
   Chew, EY
AF Bonds, Denise E.
   Harrington, Molly
   Worrall, Bradford B.
   Bertoni, Alain G.
   Eaton, Charles B.
   Hsia, Judy
   Robinson, Jennifer
   Clemons, Traci E.
   Fine, Lawrence J.
   Chew, Emily Y.
CA AREDS2 Res Grp
TI Effect of Long-Chain omega-3 Fatty Acids and Lutein plus Zeaxanthin
   Supplements on Cardiovascular Outcomes Results of the Age-Related Eye
   Disease Study 2 (AREDS2) Randomized Clinical Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID N-3 FATTY-ACIDS; MYOCARDIAL-INFARCTION; FISH CONSUMPTION; B-VITAMINS;
   RISK; DEATH; ATHEROSCLEROSIS; ASSOCIATION; DYSGLYCEMIA; CAROTENOIDS
AB IMPORTANCE Dietary supplements have been proposed as a mechanism to improve health and prevent disease.
   OBJECTIVE To determine if supplementing diet with long-chain omega-3 polyunsaturated fatty acids or with macular xanthophylls results in a reduced rate of cardiovascular disease (CVD).
   DESIGN, SETTING, AND PARTICIPANTS The Cardiovascular Outcome Study (COS) was an ancillary study of the Age-Related Eye Disease Study 2 (AREDS2), a factorial-designed randomized clinical trial of 4203 participants recruited from 82 US academic and community ophthalmology clinics, who were followed up for a median of 4.8 years. Individuals were eligible to participate if they were between the ages of 50 and 85 years, had intermediate or advanced age-related macular degeneration in 1 eye, and were willing to be randomized. Participants with stable, existing CVD (>12 months since initial event) were eligible to participate. Participants, staff, and outcome assessors were masked to intervention.
   INTERVENTIONS Daily supplementation with long-chain omega-3 polyunsaturated fatty acids (350-mg docosahexaenoic acid [DHA] + 650-mg eicosapentaenoic acid [EPA]), macular xanthophylls (10-mg lutein + 2-mg zeaxanthin), combination of the two, or matching placebos. These treatments were added to background therapy of the AREDS vitamin and mineral formulation for macular degeneration.
   MAIN OUTCOMES AND MEASURES A composite outcome of myocardial infarction, stroke, and cardiovascular death with 4 prespecified secondary combinations of the primary outcome with hospitalized heart failure, revascularization, or unstable angina.
   RESULTS Study participants were primarily white, married, and highly educated, with a median age at baseline of 74 years. A total of 602 cardiovascular events were adjudicated, and 459 were found to meet 1 of the study definitions for a CVD outcome. In intention-to-treat analysis, no reduction in the risk of CVD or secondary CVD outcomes was seen for the DHA + EPA (primary outcome: hazard ratio [HR], 0.95; 95% CI, 0.78-1.17) or lutein + zeaxanthin (primary outcome: HR, 0.94; 95% CI, 0.77-1.15) groups. No differences in adverse events or serious adverse event were seen by treatment group. The sample size was sufficient to detect a 25% reduction in CVD events with 80% power.
   CONCLUSIONS AND RELEVANCE Dietary supplementation of long-chain omega-3 polyunsaturated fatty acids or macular xanthophylls in addition to daily intake of minerals and vitamins did not reduce the risk of CVD in elderly participants with age-related macular degeneration.
C1 [Bonds, Denise E.; Fine, Lawrence J.] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA.
   [Harrington, Molly; Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Worrall, Bradford B.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
   [Bertoni, Alain G.] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC USA.
   [Eaton, Charles B.] Alpert Med Sch, Div Biol & Med, Dept Family Med & Epidemiol, Providence, RI USA.
   [Eaton, Charles B.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA.
   [Hsia, Judy] AstraZeneca LLP, Washington, DC USA.
   [Robinson, Jennifer] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
   [Robinson, Jennifer] Univ Iowa, Dept Med, Iowa City, IA 52242 USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Heart Lung &
   Blood Institute (NHLBI); Emmes Corporation; University of Virginia; Wake
   Forest University; Brown University; Brown University; AstraZeneca;
   University of Iowa; University of Iowa; National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI)
RP Bonds, DE (通讯作者)，NHLBI, Rockledge Ctr 2, MSC 7936,6701 Rockledge Dr,Ste 10018, Bethesda, MD 20892 USA.
EM bondsde@nhlbi.nih.gov
RI , Jennifer/AAD-8336-2019
OI Eaton, Charles/0000-0002-7723-9461; Bertoni, Alain/0000-0002-7503-6273
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services [HHS-N-260-2005-00007-C]; ADB [N01-EY-5-0007];
   National Institutes of Health (NIH): Office of Dietary Supplements;
   National Center for Complementary and Alternative Medicine, National
   Institute on Aging, National Heart, Lung, and Blood Institute; National
   Institute of Neurological Disorders and Stroke
FX The AREDS2 study is supported by the intramural program funds and
   contracts from the National Eye Institute/National Institutes of Health,
   Department of Health and Human Services (contract No.
   HHS-N-260-2005-00007-C and ADB contract No. N01-EY-5-0007). Funds were
   generously contributed to these contracts by the following National
   Institutes of Health (NIH): Office of Dietary Supplements, National
   Center for Complementary and Alternative Medicine, National Institute on
   Aging, National Heart, Lung, and Blood Institute, and National Institute
   of Neurological Disorders and Stroke.
CR Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23
   ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501
   Blacher J, 2013, INT J CARDIOL, V167, P508, DOI 10.1016/j.ijcard.2012.01.060
   Bosch J, 2012, NEW ENGL J MED, V367, P309, DOI 10.1056/NEJMoa1203859
   BURR ML, 1989, LANCET, V2, P757
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502
   Galan P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6273
   Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858
   Hak AE, 2003, CIRCULATION, V108, P802, DOI 10.1161/01.CIR.0000084546.82738.89
   Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815
   Iribarren C, 1997, ARTERIOSCL THROM VAS, V17, P1171, DOI 10.1161/01.ATV.17.6.1171
   Jung UJ, 2008, AM J CLIN NUTR, V87, p2003S, DOI 10.1093/ajcn/87.6.2003S
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2
   Osganian SK, 2003, AM J CLIN NUTR, V77, P1390, DOI 10.1093/ajcn/77.6.1390
   Rizos EC, 2012, JAMA-J AM MED ASSOC, V308, P1024, DOI 10.1001/2012.jama.11374
   Roncaglioni MC, 2013, NEW ENGL J MED, V368, P1800, DOI 10.1056/NEJMoa1205409
   Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5
   Weaver KL, 2008, J AM DIET ASSOC, V108, P1178, DOI 10.1016/j.jada.2008.04.023
   Zou ZY, 2011, ATHEROSCLEROSIS, V219, P789, DOI 10.1016/j.atherosclerosis.2011.08.006
NR 21
TC 88
Z9 89
U1 2
U2 34
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2014
VL 174
IS 5
BP 763
EP 771
DI 10.1001/jamainternmed.2014.328
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AI4NS
UT WOS:000336842700023
OA Bronze
DA 2022-11-30
ER

PT J
AU Ebneter, A
   Michels, S
   Pruente, C
   Imesch, P
   Eilenberger, F
   Oesch, S
   Thomet-Hunziker, IP
   Hatz, K
AF Ebneter, Andreas
   Michels, Stephan
   Pruente, Christian
   Imesch, Pascal
   Eilenberger, Felix
   Oesch, Susanne
   Thomet-Hunziker, Isabelle P.
   Hatz, Katja
TI Two-year outcomes of intravitreal aflibercept in a Swiss routine treat
   and extend regimen for patients with neovascular age-related macular
   degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VEGF TRAP; RANIBIZUMAB; THERAPY; NEED
AB The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in a treat and extend regimen in treatment-naive neovascular AMD patients in routine practice. This both retrospective and prospective study was conducted in four larger Swiss retina clinics (ASTERIA study). The primary endpoint was the mean change in best-corrected visual acuity (BCVA) in ETDRS letters from baseline to 12 months. Between December 2017 and August 2018, 160 patients were included. For patients with available data, the mean change in BCVA was+8.4 (+/- 14.4) letters at month 12 (n=139) and+5.0 (+/- 11.4) letters at month 24 (n=95). A mean number of 8.3 (+/- 2.4) injections were administered within the first year and 5.4 (+/- 2.9) injections during the second year. On average, the observed treatment interval at month 12 was 63.3 (+/- 22.0) days and increased to 69.1 (+/- 28.6) days at month 24. For 37% of the patients, a treatment interval >= 12 weeks was attained at month 24. In conclusion, intravitreal aflibercept in a Swiss real-life treat and extend regimen resulted in comparable anatomic and functional outcomes as were observed in the prospective registration trials of aflibercept for nAMD treatment.
C1 [Ebneter, Andreas] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Ebneter, Andreas] Univ Bern, Bern Univ Hosp, Dept BioMed Res, Inselspital, Bern, Switzerland.
   [Michels, Stephan] Augenklin Zurich West, Zurich, Switzerland.
   [Michels, Stephan] Univ Zurich, Zurich, Switzerland.
   [Pruente, Christian] Univ Basel, Dept Ophthalmol, Augenklin, Basel, Switzerland.
   [Pruente, Christian] Inst Mol & Clin Ophthalmol Basel IOB, Basel, Switzerland.
   [Imesch, Pascal] EYEPARC, Bern, Switzerland.
   [Eilenberger, Felix] Alcedis GmbH, Giessen, Germany.
   [Oesch, Susanne; Thomet-Hunziker, Isabelle P.] Bayer Schweiz AG, Zurich, Switzerland.
   [Hatz, Katja] Vista Klin, Binningen, Switzerland.
   [Hatz, Katja] Univ Basel, Fac Med, Basel, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; University of Zurich; University of Basel;
   Bayer AG; University of Basel; University of Geneva
RP Pruente, C (通讯作者)，Univ Basel, Dept Ophthalmol, Augenklin, Basel, Switzerland.; Pruente, C (通讯作者)，Inst Mol & Clin Ophthalmol Basel IOB, Basel, Switzerland.
EM christian.pruente@usb.ch
RI Imesch, Pascal/AAP-3218-2021; Ebneter, Andreas/C-5226-2017
OI Ebneter, Andreas/0000-0001-6666-2558
FU Bayer (Schweiz) AG
FX The authors would like to gratefully thank Anja Brascho beta, Sascha
   Wurmbach, and Sonja Hartmann (all Alcedis GmbH, Gie beta en, Germany)
   for project management, data management activities, and medical writing
   assistance, respectively, which was all funded by Bayer (Schweiz) AG.
CR Abdin AD, 2019, GRAEF ARCH CLIN EXP, V257, P1671, DOI 10.1007/s00417-019-04360-9
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Souied EH, 2020, INVEST OPHTH VIS SCI, V61
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
NR 23
TC 4
Z9 6
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 20
PY 2020
VL 10
IS 1
AR 20256
DI 10.1038/s41598-020-76354-1
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OZ0WK
UT WOS:000594656800016
PM 33219242
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mohamad, NA
   Ramachandran, V
   Ismail, P
   Isa, HM
   Chan, YM
   Ngah, NF
   Bakri, NM
   Ching, SM
   Hoo, FK
   Sulaiman, WAW
   Mat, LNI
   Mohamed, MH
AF Mohamad, Nur Afiqah
   Ramachandran, Vasudevan
   Ismail, Patimah
   Isa, Hazlita Mohd
   Chan, Yoke Mun
   Ngah, Nor Fariza
   Bakri, Norshakimah Md
   Ching, Siew Mooi
   Hoo, Fan Kee
   Sulaiman, Wan Aliaa Wan
   Mat, Liyana Najwa Inche
   Mohamed, Mohd Hazmi
TI Analysis of the association between CFH Y402H polymorphism and response
   to intravitreal ranibizumab in patients with neovascular age-related
   macular degeneration (nAMD)
SO BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; AMD; complement factor H; CFH;
   ranibizumab; Y402H; SNP; treatment response
ID COMPLEMENT FACTOR-H; GENETIC ASSOCIATION; PHARMACOGENETICS; AMD;
   POPULATION; BEVACIZUMAB; THERAPY; VARIANT; RISK
AB Pharmacogenetic studies indicate that a variable response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular form of AMD (nAMD) may be due to polymorphisms in the complement factor H gene (CFH). This study is the first to investigate the association between CFH Y402H polymorphism and the response to ranibizumab therapy in Malaysian patients with nAMD. We included 134 patients with nAMD, examined between September 2014 and February 2016. The diagnosis of nAMD was confirmed by ophthalmologic examination, before ranibizumab therapy was started. Each patient received an intravitreal injection of 0.5 mg/0.05 ml ranibizumab following a treat-and-extend (TE) regimen. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded after 3 and 6 months following the first injection and compared with the baseline values. Genotyping of Y402H (rs1061170) polymorphism was performed using PCR-RFLP and the amplified product was digested with MluCI restriction enzyme. Association between the Y402H genotypes and response to treatment was determined by a logistic regression analysis of responder (n = 49) and non-responder (n = 84) group. Significantly worse mean BCVA was observed for the CC genotype compared to the TT + CT genotype in the total sample after 6-month follow-up (p = 0.018). Comparing the baseline and 6-month point measurements, improved mean BCVA was observed in responder group, while worse mean BCVA was recorded for non-responder group. However, our regression analysis, adjusted for confounding factors, showed no significant association between the Y402H genotypes and response to treatment in nAMD patients under the recessive model (p > 0.05). Overall, our results suggest that factors other than Y402H polymorphism may be involved in the progression of nAMD after treatment with anti-VEGF agents, in Malaysian population.
C1 [Mohamad, Nur Afiqah; Ramachandran, Vasudevan; Chan, Yoke Mun; Bakri, Norshakimah Md] Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang 43400, Selangor De, Malaysia.
   [Ismail, Patimah] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang, Selangor De, Malaysia.
   [Isa, Hazlita Mohd] Univ Kebangsaan Malaysia, Med Ctr, Dept Ophthalmol, Kuala Lumpur, Malaysia.
   [Chan, Yoke Mun] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang, Selangor De, Malaysia.
   [Ngah, Nor Fariza] Hosp Selayang, Dept Ophthalmol, Lebuhraya Selayang Kepon, Malaysia.
   [Ching, Siew Mooi] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Family Med, Serdang, Selangor De, Malaysia.
   [Hoo, Fan Kee; Sulaiman, Wan Aliaa Wan; Mat, Liyana Najwa Inche] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Serdang, Selangor De, Malaysia.
   [Mohamed, Mohd Hazmi] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Surg, Serdang, Selangor De, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti
   Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti Putra
   Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia
RP Ramachandran, V (通讯作者)，Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang 43400, Selangor De, Malaysia.
EM vasuphd@gmail.com
RI bin Mohamed, Mohd Hazmi/G-4013-2013; Mat, Liyana Najwa
   Inche/AFV-2677-2022; ramachandran, vasudevan/C-3395-2008; Wan Sulaiman,
   Wan Aliaa Binti/AAF-8072-2021; Chan, Yoke Mun Yoke/L-2965-2015; Mat,
   Liyana Najwa Inche/AAC-1593-2022; Ching, Siew Mooi/I-5817-2013; Hoo, Fan
   Kee/J-2591-2013
OI bin Mohamed, Mohd Hazmi/0000-0003-0300-4296; ramachandran,
   vasudevan/0000-0003-0044-1626; Wan Sulaiman, Wan Aliaa
   Binti/0000-0003-4969-0308; Chan, Yoke Mun Yoke/0000-0002-3853-736X;
   Ching, Siew Mooi/0000-0002-4425-7989; Isa, Hazlita/0000-0002-2731-8233;
   Inche Mat, Liyana Najwa/0000-0003-2919-362X; Hoo, Fan
   Kee/0000-0003-1687-627X; Mohamad, Nur Afiqah/0000-0002-9015-0525
FU Putra Grant [9409800, 9432700]
FX This study was supported by Putra Grant (Grant No: 9409800 and 9432700).
   We thank all the staff at Hospital Selayang and UKMMC involved in this
   study for their continuous support. We also thank all the patients who
   participated in the study.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2016, HONG KONG J OPHTHALM, V14, P14
   Chang W, 2013, MOL VIS, V19, P702
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Habibi I, 2013, OPHTHALMIC RES, V49, P177, DOI 10.1159/000345068
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hao XF, 2015, INT J CLIN EXP PATHO, V8, P3186
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayed KM, 2011, GRAEF ARCH CLIN EXP, V249, P1449, DOI 10.1007/s00417-011-1672-2
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
NR 34
TC 3
Z9 5
U1 0
U2 3
PU ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA & HERZEGOVINA SARAJEVO
PI CEKALUSA
PA UNIV SARAJEVO, MEDICAL FAC, CEKALUSA, SARAJEVO 90, BOSNIA & HERCEG
SN 1512-8601
EI 1840-4812
J9 BOSNIAN J BASIC MED
JI Bosnian J. Basic Med. Sci.
PY 2018
VL 18
IS 3
BP 260
EP 267
DI 10.17305/bjbms.2018.2493
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GO5IA
UT WOS:000440051700008
PM 29579408
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Java, A
   Baciu, P
   Widjajahakim, R
   Sung, YJ
   Yang, J
   Kavanagh, D
   Atkinson, J
   Seddon, J
AF Java, Anuja
   Baciu, Peter
   Widjajahakim, Rafael
   Sung, Yun Ju
   Yang, Jae
   Kavanagh, David
   Atkinson, John
   Seddon, Johanna
TI Functional Analysis of Rare Genetic Variants in Complement Factor I
   (CFI) using a Serum-Based Assay in Advanced Age-related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; complement; rare genetic variants;
   Factor I; functional analysis
ID HEMOLYTIC-UREMIC SYNDROME; FACTOR-H; HIGH-RISK; MUTATIONS; SYSTEM;
   IMPACT
AB Purpose: Factor I (FI) is a serine protease regulator of the complement system. Genetic variants in CFI are associated with advanced age-relatedmacular degeneration (AAMD). However, the clinical and functional impact of these variants is unknown. This study assessed the functional significance of rare CFI variants using a serum-based assay.
   Methods: Carriers of rare variantswith (n= 78) andwithoutAAMD(n= 28), and noncarriers with (n = 49) and without AMD (n = 44) were evaluated. Function of FI was determined bymeasuring the proteolytic cleavage of C3b to iC3b, using the cofactor protein, Factor H.
   Results: CFI variants were categorized into three groups based on antigenic and functional assessments. Type 1 variants (n = 18) in 35 patients with AAMD demonstrated low serum FI levels and a corresponding decrease in FI function. Type 2 variants (n = 6) in 7 individuals demonstrated normal serum FI antigenic levels but reduced degradation of C3b to iC3b. Type 3 variants (n = 15) in 64 individuals demonstrated normal antigenic levels and degradation of C3b to iC3b. However, iC3b generation was low when measured per unit of FI. Thus most rare CFI variants demonstrate either low antigenic levels (type 1) or normal levels but reduced function (types 2 or 3).
   Conclusions: Results provide for the first time a comprehensive functional assessment in serum of CFI rare genetic variants and further establish FI's key role in the pathogenesis of AAMD.
   Translational Relevance: Stratifying patients in the clinic with a rare CFI variantwill facilitate screening and targeting patientsmost likely to benefit fromcomplement therapies.
C1 [Java, Anuja; Atkinson, John] Washington Univ, Dept Med, Div Nephrol, St Louis, MO USA.
   [Java, Anuja; Atkinson, John] Washington Univ, Dept Med, Div Rheumatol, St Louis, MO USA.
   [Baciu, Peter; Yang, Jae] Allergan Pharmaceut Inc, Irvine, CA USA.
   [Widjajahakim, Rafael; Seddon, Johanna] Univ Massachusetts, Sch Med, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.
   [Sung, Yun Ju] Washington Univ, Sch Med St Louis, Dept Psychiat, St Louis, MO USA.
   [Sung, Yun Ju] Washington Univ, Sch Med St Louis, Div Biostat, St Louis, MO USA.
   [Kavanagh, David] Newcastle Univ, Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Washington University (WUSTL); Washington University (WUSTL); AbbVie;
   Allergan; University of Massachusetts System; University of
   Massachusetts Worcester; Saint Louis University; Washington University
   (WUSTL); Saint Louis University; Washington University (WUSTL);
   Newcastle University - UK
RP Seddon, J (通讯作者)，Univ Massachusetts, Sch Med, 55 Lake Ave North,S3-119, Worcester, MA 01655 USA.
EM johanna_seddon@yahoo.com
FU NIH [R01-EY011309, R01-EY028602, 2R01 GM099111]; American Macular
   Degeneration Foundation, Northampton, MA; Macular Degeneration Center of
   Excellence, University of Massachusetts Medical School, Department of
   Ophthalmology and Visual Sciences, Worcester, MA; Wellcome Trust; MRC;
   Kidney Research UK; NIHR Biomedical Research Centre at Newcastle upon
   Tyne Hospitals; NHS Foundation Trust; Barnes Jewish Hospital Foundation
   Fund, Division of Nephrology, Washington University School of Medicine
   in St. Louis
FX Supported by NIH R01-EY011309, R01-EY028602, American Macular
   Degeneration Foundation, Northampton, MA; The Macular Degeneration
   Center of Excellence, University of Massachusetts Medical School,
   Department of Ophthalmology and Visual Sciences, Worcester, MA (JS);
   Wellcome Trust, The MRC, Kidney Research UK and the NIHR Biomedical
   Research Centre at Newcastle upon Tyne Hospitals, NHS Foundation Trust
   (DK); NIH R01-EY028602 (JA & AJ), NIH 2R01 GM099111 (JA); Barnes Jewish
   Hospital Foundation Fund, Division of Nephrology, Washington University
   School of Medicine in St. Louis (AJ).
CR Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Fremeaux-Bacchi V, 2013, CLIN J AM SOC NEPHRO, V8, P554, DOI 10.2215/CJN.04760512
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Java A, 2019, KIDNEY INT REP, V4, P1007, DOI 10.1016/j.ekir.2019.04.003
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Le Quintrec M, 2008, AM J TRANSPLANT, V8, P1694, DOI 10.1111/j.1600-6143.2008.02297.x
   Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nilsson SC, 2010, EUR J IMMUNOL, V40, P172, DOI 10.1002/eji.200939280
   Noris M, 2010, CLIN J AM SOC NEPHRO, V5, P1844, DOI 10.2215/CJN.02210310
   Okroj M, 2018, COMPLEMENT FACTSBOOK, P147
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sullivan M, 2010, ANN HUM GENET, V74, P17, DOI 10.1111/j.1469-1809.2009.00554.x
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Westra D, 2010, NEPHROL DIAL TRANSPL, V25, P2195, DOI 10.1093/ndt/gfq010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 30
TC 12
Z9 12
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD AUG
PY 2020
VL 9
IS 9
AR 37
DI 10.1167/tvst.9.9.37
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH9SL
UT WOS:000582929100037
PM 32908800
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Verma, V
   Sauer, T
   Chan, CC
   Zhou, M
   Zhang, CX
   Maminishkis, A
   Shen, D
   Tuo, JS
AF Verma, Varun
   Sauer, Theodor
   Chan, Chi-Chao
   Zhou, Min
   Zhang, Congxiao
   Maminishkis, Arvydas
   Shen, Defen
   Tuo, Jingsheng
TI Constancy of ERp29 expression in cultured retinal pigment epithelial
   cells in the Ccl2/Cx3cr1 deficient mouse model of age-related macular
   degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; animal model; cell culture; ERp29;
   retinal pigment epithelium
ID ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; CULTIVATION; MECHANISMS;
   CHAPERONES; RESIDENT; DISEASE; MICE; LINE
AB Purpose: Given the critical role of the retinal pigment epithelium (RPE) in the pathogenesis of age-related macular generation (AMD) and the links drawn between chaperone proteins and neurodegenerative disease, we aimed to culture RPE from the Ccl2(-/-)/Cx3cr1(-/-) mouse model of AMD and evaluate expression of chaperone protein ERp29. Materials and Methods: Murine RPE cells were surgically and chemically isolated and cultured. ERp29 mRNA and protein expression were evaluated by real-time RT-PCR, immunohistochemistry, and Western blot. Results: Ccl2(-/-)/Cx3cr1(-/-) RPE was successfully isolated and cultured. They presented a decreased but statistically insignificant difference in ERp29 transcript and protein expression compared to C57B6/L wild type mouse RPE. Conclusions: The effective murine RPE culture described here enables future investigation into RPE biology and AMD pathogenesis. Although we found a decrease in ERp29 expression in the Ccl2(-/-)/Cx3cr1(-/-) RPE, the difference was less than we previously observed in the whole retina. This suggests that the RPE may not contribute to the greater differential expression and ERp29 might have a more significant role in the neuroretina than in the RPE during AMD pathogenesis.
C1 [Verma, Varun; Sauer, Theodor; Chan, Chi-Chao; Zhou, Min; Shen, Defen; Tuo, Jingsheng] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Zhang, Congxiao] NEI, Sect Retinal Dis & Therapeut, NIH, Bethesda, MD 20892 USA.
   [Maminishkis, Arvydas] NEI, Sect Epithelial & Retinal Physiol & Dis, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Tuo, JS (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, Bldg 10,Rm 10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
OI Maminishkis, Arvydas/0000-0003-3345-3375; Tuo,
   Jingsheng/0000-0002-1372-7810
FU NATIONAL EYE INSTITUTE [ZIAEY000418, ZICEY000461, Z01EY000419,
   ZIAEY000222] Funding Source: NIH RePORTER; Howard Hughes Medical
   Institute Funding Source: Medline; Intramural NIH HHS [Z01 EY000418-04]
   Funding Source: Medline
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Demmer J, 1997, FEBS LETT, V402, P145, DOI 10.1016/S0014-5793(96)01513-X
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Engelmann K, 2004, GRAEF ARCH CLIN EXP, V242, P65, DOI 10.1007/s00417-003-0811-9
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Hermann VM, 2005, J BIOL CHEM, V280, P13529, DOI 10.1074/jbc.M410889200
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Macario AJL, 2005, NEW ENGL J MED, V353, P1489, DOI 10.1056/NEJMra050111
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   MAYERSON PL, 1985, INVEST OPHTH VIS SCI, V26, P1599
   MCLAREN MJ, 1993, EXP CELL RES, V204, P311, DOI 10.1006/excr.1993.1038
   Meriin AB, 2005, INT J HYPERTHER, V21, P403, DOI 10.1080/02656730500041871
   Mkrtchian S, 2006, ANTIOXID REDOX SIGN, V8, P325, DOI 10.1089/ars.2006.8.325
   NAN W, 1993, INVEST OPHTH VIS SCI, V34, P101
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Sauer T, 2008, EXPERT REV OPHTHALMO, V3, P29, DOI 10.1586/17469899.3.1.29
   Schlunck G, 2002, EXP EYE RES, V74, P571, DOI 10.1006/exer.2001.1148
   Shnyder SD, 2002, J HISTOCHEM CYTOCHEM, V50, P557, DOI 10.1177/002215540205000413
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suzuki M, 2007, MOL VIS, V13, P772
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Zheng JB, 2006, PROTEIN PEPTIDE LETT, V13, P753, DOI 10.2174/092986606777841190
NR 28
TC 5
Z9 5
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2008
VL 33
IS 8
BP 701
EP 707
DI 10.1080/02713680802236185
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 336NL
UT WOS:000258370800010
PM 18696346
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tran, THC
   Dumas, S
   Coscas, F
AF Thi Ha Chau Tran
   Dumas, Stephane
   Coscas, Florence
TI Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial
   Detachment due to Neovascular Age-Related Macular Degeneration (nAMD)
   Refractory to Ranibizumab
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF THERAPY; INTRAVITREAL AFLIBERCEPT; CHOROIDAL
   NEOVASCULARIZATION; ANATOMICAL OUTCOMES; EYES; BEVACIZUMAB; INJECTION;
   FLUID; TACHYPHYLAXIS; CONVERSION
AB Purpose. To evaluate the response of intravitreal aflibercept injection (IAI) in eyes with detachment of retinal pigment epithelium (DEP) secondary to nAMD refractory to monthly ranibizumab. Patients and Methods. This is a retrospective, multicenter study. All patients received 3 IAI then treated as needed every 4 weeks for 12 months. During the second year, the eyes were treated with a treat-and-extend regimen. Results. Forty-four eyes were included. Best-corrected visual acuity improved significantly after the loading phase (3.1 +/- 6.4 letters) and at 6 months (2.8 +/- 6.4 letters), but change was not significant at 1 year and 2 years. The height of the DEP was significantly decreased at 3 months and 6 months, but the difference did not reach statistical difference at 1 and 2 years. Rate of eyes with complete resolution of exudation was 59% after the loading phase and 34.3% at 2 years. Mean interval of anti-VEGF injection was extended from 31 +/- 2.6 days to 61 +/- 5 days after conversion. Conclusions. Aflibercept intravitreal injection in patients with fibrovascular DEP due to nAMD who respond poorly to monthly ranibizumab led to short-term functional and anatomical improvement. Reduction of intravitreal injection frequency was obtained until 2 years of follow-up.
C1 [Thi Ha Chau Tran] Lille Catholic Univ, Lille Catholic Hosp, Dept Ophthalmol, Lille, France.
   [Dumas, Stephane] Clin Louviere, Lille, France.
   [Coscas, Florence] UPEC, Ctr Ophtalmol Odeon, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Tran, THC (通讯作者)，Lille Catholic Univ, Lille Catholic Hosp, Dept Ophthalmol, Lille, France.
EM tran.hachau@ghicl.net
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU Bayer
FX The authors gratefully acknowledge Bayer for the funding of the article
   processing charge and Ms. Nhi Van for the English editorial assistance.
CR Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buckle M, 2015, EYE, V29, P403, DOI 10.1038/eye.2014.296
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Gambon R, 2014, KLIN MONATSBL AUGENH, V231, P423, DOI 10.1055/s-0034-1368292
   Gelman SK, 2014, RETINA-J RET VIT DIS, V34, P2088, DOI 10.1097/IAE.0000000000000207
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Griffin DR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/497178
   Hariri A, 2015, OSLI RETINA, V46, P195, DOI 10.3928/23258160-20150213-18
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kodjikian L, 2015, J FR OPHTALMOL, V38, P639, DOI 10.1016/j.jfo.2015.06.001
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lenk J, 2016, KLIN MONATSBL AUGENH, V233, P284, DOI 10.1055/s-0041-107001
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Nagiel Aaron, 2015, Retin Cases Brief Rep, V9, P269, DOI 10.1097/ICB.0000000000000184
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Veritti D, 2017, EUR J OPHTHALMOL, V27, P74, DOI 10.5301/ejo.5000880
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 40
TC 7
Z9 7
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2017
VL 2017
AR 8984313
DI 10.1155/2017/8984313
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI0QV
UT WOS:000411635200001
PM 29093970
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Menghini, M
   Kloeckener-Gruissem, B
   Fleischhauer, J
   Kurz-Levin, MM
   Sutter, FKP
   Berger, W
   Barthelmes, D
AF Menghini, Moreno
   Kloeckener-Gruissem, Barbara
   Fleischhauer, Johannes
   Kurz-Levin, Malaika M.
   Sutter, Florian K. P.
   Berger, Wolfgang
   Barthelmes, Daniel
TI Impact of Loading Phase, Initial Response and CFH Genotype on the
   Long-Term Outcome of Treatment for Neovascular Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; RANIBIZUMAB TREATMENT REGIMEN; INTRAVITREAL
   RANIBIZUMAB; GENETIC-FACTORS; POLYMORPHISM; MACULOPATHY; THERAPY;
   ASSOCIATION; Y402H; VEGF
AB Objective: Factors influencing the outcome of anti-VEGF treatment in neovascular AMD are still investigated. We analyzed the impact of a loading phase, the significance of an initial response for the long-term and the effect of the CFH polymorphism (p.His402Tyr) on treatment outcome.
   Methods: Patients treated with ranibizumab for neovascular AMD were analyzed over a period of 24 months by assessing effects of loading phase, initial response and genotype of CFH rs1061170 (c.1204C>T, p.His402Tyr).
   Results: 204 eyes were included. A change of +5.0 [-1;+11] letters and +1.5 [-5.5;+9.5] was observed with a median of 4 [3;7] and 10 [7;14] ranibizumab injections during 12 and 24 months, respectively. Loading phase was no significant predictor for treatment as VA outcome in eyes with and without loading phase was similar (p = 0.846 and p = 0.729) at 12 and 24 months. In contrast, initial response was a significant predictor for improving vision of 5 or more letters at 12 (p = 0.001; OR = 6.75) and 24 months (p = 0.01; OR = 4.66). Furthermore, the CT genotype at CFH rs1061170 was identified as a significant predictor for a favorable VA outcome at 12 and 24 months (OR = 6.75, p = 0.001 and OR = 4.66, p = 0.01).
   Conclusions: Our data suggest that clinical decisions regarding treatment may be guided by observing patients' initial response as well as their genotype of SNP rs1061170, while the criterion of loading phase may not bear the customary value.
C1 [Menghini, Moreno; Fleischhauer, Johannes; Kurz-Levin, Malaika M.; Sutter, Florian K. P.; Barthelmes, Daniel] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Kloeckener-Gruissem, Barbara; Berger, Wolfgang] Univ Zurich, Inst Med Mol Genet, CH-8603 Schwerzenbach, Switzerland.
   [Kloeckener-Gruissem, Barbara] Swiss Fed Inst Technol, Inst Biol, Zurich, Switzerland.
   [Berger, Wolfgang] Univ Zurich, Neurosci Ctr Zurich ZNZ, Zurich, Switzerland.
   [Berger, Wolfgang] Univ Zurich, Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
   [Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   Swiss Federal Institutes of Technology Domain; ETH Zurich; University of
   Zurich; University of Zurich; Zurich Center Integrative Human Physiology
   (ZIHP); University of Sydney
RP Menghini, M (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
EM moreno@menghini.biz
OI Menghini, Moreno/0000-0002-1432-2524
FU Novartis; Swiss National Foundation; Holcim Foundation; Walter and
   Gertrud Siegenthaler Foundation, Switzerland
FX This study was supported by an unrestricted fund from Novartis. DB was
   supported by the Swiss National Foundation, the Holcim Foundation and
   the Walter and Gertrud Siegenthaler Foundation, Switzerland. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
NR 34
TC 27
Z9 28
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 25
PY 2012
VL 7
IS 7
AR e42014
DI 10.1371/journal.pone.0042014
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 979GX
UT WOS:000306806600158
PM 22848690
OA Green Published, Green Accepted, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Luke, C
   Widder, RA
   Walter, P
   Brunner, R
   Kirchhof, B
   Borberg, T
AF Luke, C
   Widder, RA
   Walter, P
   Brunner, R
   Kirchhof, B
   Borberg, T
TI The effect of membrane differential filtration on the colloid osmotic
   pressure in patients with age-related macular degeneration: Significance
   to visual function?
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE age-related macular degeneration; colloid osmotic pressure; geographic
   atrophy; membrane differential filtration; retinal function; visual
   acuity; visual field
ID BIOCHEMICAL PARAMETERS; PLASMA VISCOSITY; BLOOD-FLOW; LIPOPROTEINS;
   MACULOPATHY
AB To investigate the effect of membrane differential filtration (MDF) on plasma colloid osmotic pressure (COP) and visual functions in age-related geographic macular degeneration (AMD). Ten consecutive patients with non-exudative AMD underwent one MDF cycle. Primary endpoint was COP Secondary endpoints were visual acuity and the mean defect of visual field. The COP was markedly reduced after one MDF cycle by 23.9% (P = 0.001). Compared with the baseline examination, visual acuity and the mean defect of visual field improved significantly after MDE A significant positive correlation was found between the improvement in visual field and the decrease in COP (Peirson's coefficient = 0.65; P = 0.04). Membrane differential filtration lowers plasma colloid osmotic pressure in patients with non-exudative AMD. Based on the observatior, that visual field and COP are correlated, one may hope for a means to improve decreased central retinal function in eyes with geographic AMD by modulation of COP plasma level.
C1 Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany.
   Deutsch Hamapherese Zentrum, Cologne, Germany.
C3 University of Cologne
RP Luke, C (通讯作者)，Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.
RI Walter, Peter/L-5982-2018
OI Walter, Peter/0000-0001-8745-6593
CR ALM A, 1987, ADLERS PHYSL EYE CLI
   BIRD AC, 1993, AGE RELATED MACULAR, P63
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   BOYER DS, 2001, M AM AC OPHTH SUBSP
   BRUNNER R, 1991, Acta Medica Austriaca, V18, P63
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Brunner R, 1995, INT J ARTIF ORGANS, V18, P794, DOI 10.1177/039139889501801208
   BRUNNER R, 1993, KLINISCHE MIKROZIRKU, P179
   BRUNNER R, 1997, TRANSFUS SCI, V17, P493
   BRUNNER R, HAMORHEOLOGISCHE THE
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Graf H, 1993, Anaesthesiol Reanim, V18, P40
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HYMAN L, 1993, AGE RELATED MACULAR, P1
   JUNG F, 1983, BIOMED TECH, V28, P249, DOI 10.1515/bmte.1983.28.11.249
   KIESEWETTER H, 1982, BIOMED TECH, V27, P209, DOI 10.1515/bmte.1982.27.9.209
   KOENIG W, 1992, CIRCULATION, V85, P2197, DOI 10.1161/01.CIR.85.6.2197
   MORISSETTE MP, 1977, CAN MED ASSOC J, V116, P897
   Rosenson RS, 1996, CLIN CHEM, V42, P1189
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SEPLOWITZ AH, 1981, ATHEROSCLEROSIS, V38, P89, DOI 10.1016/0021-9150(81)90107-6
   SOUDAVAR F, 1998, INVEST OPHTH VIS SCI, V39, P386
   Starling E H, 1896, J Physiol, V19, P312
   Tokuyama T, 1998, BRIT J OPHTHALMOL, V82, P751, DOI 10.1136/bjo.82.7.751
   Widder RA, 1998, BLOOD PURIFICAT, V16, P15, DOI 10.1159/000014308
   WIDDER RA, 1997, TRANSFUS SCI, V17, P505
NR 31
TC 7
Z9 7
U1 0
U2 1
PU BLACKWELL PUBLISHING INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148 USA
SN 1091-6660
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD APR
PY 2003
VL 7
IS 2
BP 263
EP 268
DI 10.1046/j.1526-0968.2003.00027.x
PG 6
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Urology & Nephrology
GA 716HM
UT WOS:000185022800023
PM 12918954
DA 2022-11-30
ER

PT J
AU Lie, S
   Aue, A
   Sacu, S
   Simader, C
   Polak, K
   Schmidt-Erfurth, U
AF Lie, Shilla
   Aue, Arne
   Sacu, Stefan
   Simader, Christian
   Polak, Kaija
   Schmidt-Erfurth, Ursula
TI Time-course and characteristic morphology of retinal changes following
   combination of verteporfin therapy and intravitreal triamcinolone in
   neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE morphological changes; optical coherence tomography; photodynamic
   therapy; triamcinolone acetonide
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PIGMENT-EPITHELIUM DETACHMENT;
   PHOTODYNAMIC THERAPY; VISUAL-ACUITY; INTRAOCULAR-PRESSURE; ACETONIDE;
   INJECTION; TAP
AB Purpose:
   To identify characteristic morphological changes of the retina over time and the association with visual function after combined photodynamic therapy (PDT) and intravitreal triamcinolone (IVTA).
   Methods:
   In this retrospective study, 40 patients (40 eyes) were treated with PDT and same-day IVTA. Optical coherence tomography (OCT), fluorescein angiography (FA) and evaluation of distance visual acuity (VA) were performed. The anatomical changes within intra- and subretinal compartments and their detailed analysis and grading were the main outcome measures.
   Results:
   Intraretinal fluid (IRF) and subretinal fluid (SRF) by OCT decreased until 3 months (p < 0.01). At month 3, intraretinal cystoid spaces (ICS) had resolved or decreased in 84% of eyes, SRF in 58% and pigment epithelial detachment (PED) in 50%. Mean best-corrected VA (BCVA) improved significantly at month 1 (p < 0.01). Mean central retinal thickness (CRT) increased from 334 mu m at baseline to 439 mu m at day 1 (p = 0.03) before decreasing to 286 mu m at day 7 (p = 0.06), 233 mu m at month 1 (p = 0.001) and 255 mu m at month 3 (p = 0.001).
   Conclusion:
   Combined verteporfin/IVTA therapy induces distinct time-related effects on the retina within the different intra- and subretinal compartments.
C1 [Sacu, Stefan] Med Univ Vienna, Dept Ophthalmol, AKH, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, AKH, 8I Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
OI Simader, Christian/0000-0002-1784-2883
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Fackler TK, 2006, ANN ACAD MED SINGAP, V35, P701
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rhee DJ, 2006, BRIT J OPHTHALMOL, V90, P999, DOI 10.1136/bjo.2006.090340
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   2005, RETINA, V25, P119
NR 22
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2010
VL 88
IS 2
BP 212
EP 217
DI 10.1111/j.1755-3768.2008.01405.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 560WB
UT WOS:000274933700039
PM 19016662
OA Bronze
DA 2022-11-30
ER

PT J
AU Elshout, M
   Webers, CAB
   van der Reis, MI
   Schouten, JSAG
AF Elshout, Mari
   Webers, Carroll A. B.
   van der Reis, Margriet I.
   Schouten, Jan S. A. G.
TI A systematic review on the quality, validity and usefulness of current
   cost-effectiveness studies for treatments of neovascular age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE aflibercept; bevacizumab; cost-effectiveness; exudative age-related
   macular degeneration; photodynamic therapy; ranibizumab
ID VERTEPORFIN PHOTODYNAMIC THERAPY; UTILITY ANALYSIS; CONTRAST
   SENSITIVITY; OF-LIFE; CHOROIDAL NEOVASCULARIZATION; LASER
   PHOTOCOAGULATION; RANIBIZUMAB LUCENTIS; PEGAPTANIB SODIUM;
   VISUAL-ACUITY; BEVACIZUMAB
AB Purpose Ophthalmologists increasingly depend on new drugs to advance their treatment options. These options are limited by restraints on reimbursements for new and expensive drugs. These restraints are put in place through health policy decisions based on cost-effectiveness analyses (CEA). Cost-effectiveness analyses need to be valid and of good quality to support correct decisions to create new treatment opportunities. In this study, we report the quality, validity and usefulness of CEAs for therapies for nAMD. Methods A systematic review in PubMed, EMBASE and Cochrane was performed to include CEAs. Quality and validity assessment was based on current general quality criteria and on elements that are specific to the field of ophthalmology. Results Forty-eight CEAs were included in the review. Forty-four CEAs did not meet four basic model quality and validity criteria specific to CEAs in the field of ophthalmology (both eyes analysed instead of one; a time horizon extending beyond 4 years; extrapolating VA and treatment intervals beyond trial data realistically; and including the costs of low-vision). Four CEAs aligned with the quality and validity criteria. In two of these CEAs bevacizumab as-needed (PRN) was more cost-effective than bevacizumab monthly; aflibercept (VIEW); or ranibizumab monthly or PRN. In two CEAs, ranibizumab (PRN or treat and extent) was dominant over aflibercept. In two other CEAs, aflibercept was either more cost-effective or dominant over ranibizumab monthly or PRN. Conclusion Two of the CEAs of sufficient quality and validity show that bevacizumab PRN is the most cost-effective treatment. Comparing ranibizumab and aflibercept, either treatment can be more cost-effective depending on the assumptions used for drug prices and treatment frequencies. The majority of the published CEAs are of insufficient quality and validity. They wrongly inform decision-makers at the cost of opportunities for ophthalmologists to treat patients. As such, they may negatively influence overall patient outcomes and societal costs. For future ophthalmic treatments, CEAs need to be improved and only published when they are of sufficient quality and validity.
C1 [Elshout, Mari; Webers, Carroll A. B.; van der Reis, Margriet I.; Schouten, Jan S. A. G.] Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC)
RP Elshout, M (通讯作者)，Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM m.elshout@st-anna.nl
RI Webers, Carroll A.B./D-1130-2010
FU Netherlands organization for health research and development (ZonMw),
   The Hague, The Netherlands [152001002]
FX The Netherlands organization for health research and development
   (ZonMw), The Hague, The Netherlands, grant number 152001002.
CR Alton V, 2006, INT J TECHNOL ASSESS, V22, P512, DOI 10.1017/S0266462306051452
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brennan A, 2000, PHARMACOECONOMICS, V17, P445, DOI 10.2165/00019053-200017050-00004
   Brown A, 2008, M FLINDERS PRIVATE J, P63
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Butt T, 2014, APPL HEALTH ECON HEA, V12, P289, DOI 10.1007/s40258-014-0090-0
   Claxton L, 2016, PHARMACOECONOMICS, V35, P1
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, pix
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Donati G, 2007, J FR OPHTALMOL, V30, P837, DOI 10.1016/S0181-5512(07)92619-4
   Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Elshout M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0514-3
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Ghosh W, 2016, ADV THER, V33, P1660, DOI 10.1007/s12325-016-0367-9
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Grieve R, 2009, OPHTHALMOLOGY, V116, P2471, DOI 10.1016/j.ophtha.2009.10.023
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Larouche K, 2004, EVALUATION PHOTODYNA, P101
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McKinlay RJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-67
   Meads C, 2003, Health Technol Assess, V7, pv
   Meads C, 2001, CLIN EFFECTIVENESS C, P48
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Muslera E., 2006, Arch Soc Esp Oftalmol, V81, P199
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Reeves BC, 2009, VERTEPORFIN PHOTODYN, P2463
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stroup DF, 2000, METAANALYSIS OBSERVA
   Studnicka J, 2013, OPHTHALMOLOGICA, V230, P34, DOI 10.1159/000350802
   Tengs TO, 2004, VALUE HEALTH, V7, P70, DOI 10.1111/j.1524-4733.2004.71246.x
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu B, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7689862
   Yanagi Y, 2016, J MED ECON, V20, P1
   Yanagi Y, 2011, JPN J OPHTHALMOL, V55, P35, DOI 10.1007/s10384-010-0893-y
NR 76
TC 11
Z9 11
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2018
VL 96
IS 8
BP 770
EP 778
DI 10.1111/aos.13824
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HC3IB
UT WOS:000451694500002
PM 29862641
DA 2022-11-30
ER

PT J
AU Sun, YY
   Li, SS
   Li, HP
   Yang, F
   Bai, YJ
   Zhao, M
   Guo, J
   Zhao, MW
   Zhou, P
   Khor, CC
   Huang, LZ
   Li, XX
AF Sun, Yaoyao
   Li, Shanshan
   Li, Haiping
   Yang, Fei
   Bai, Yujing
   Zhao, Min
   Guo, Jing
   Zhao, Mingwei
   Zhou, Peng
   Khor, Chiea Chuen
   Huang, Lvzhen
   Li, Xiaoxin
TI TNFRSF10A-LOC389641 rs13278062 But Not REST-C4orf14-POLR2B-IGFBP7
   rs1713985 Was Found Associated With Age-Related Macular Degeneration in
   a Chinese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE neovascular age-related macular degeneration; polypoidal choroidal
   vasculopathy; TNFRSF10A-LOC389641; REST-C4orf14-POLR2B-IGFBP7; single
   nucleotide polymorphism
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; JAPANESE POPULATION; VARIANTS; RISK
AB PURPOSE. To reassess the association between TNFRSF10-LOC389641 rs13278062 and REST-C4orf14-POLR2B-IGFBP7 rs1713985 with the risk of AMD in a Chinese case-control collection.
   METHODS. The primary study consisted of 1826 subjects, including 1226 controls, 300 cases with nAMD, and 300 cases with PCV. Genomic DNA was extracted from venous blood leukocytes. The allelic variants of rs13278062 and rs1713985 were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The difference in allele distribution between cases and controls was tested using a chi(2) test. We also performed a meta-analysis of case-control studies for rs13278062 and rs1713985 in Hong Kong and Singaporean late AMD collections of Chinese descent (1273 cases and 1652 controls) via an inverse-variance, fixed effects model as previously described. Subgroup analysis of CNV and PCV subtypes were also performed.
   RESULTS. We found no evidence to support a significant association of markers rs13278062 or rs1713985 with either nAMD or PCV, or total AMD in our Beijing study (P > 0.05 for all comparisons). Upon meta-analysis of all sample collections, we note nominally significant association between rs13278062 and increased risk of late AMD, consistent with previous findings in Japanese individuals (ORmeta = 1.17, Pmeta = 0.004). No association was detected between rs1713985 and AMD when all data were meta-analyzed.
   CONCLUSIONS. SNP rs13278062, but not rs1713985 showed nominal evidence of association with AMD in a total of 1273 cases and 1652 controls of Chinese descent. The difference between different effect sizes in our study and other studies suggested that future studies with much larger sample sizes is necessary.
C1 [Sun, Yaoyao; Li, Shanshan; Yang, Fei; Bai, Yujing; Zhao, Min; Guo, Jing; Zhao, Mingwei; Huang, Lvzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Sun, Yaoyao; Li, Shanshan; Yang, Fei; Bai, Yujing; Zhao, Min; Guo, Jing; Zhao, Mingwei; Huang, Lvzhen; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Sun, Yaoyao; Li, Shanshan; Yang, Fei; Bai, Yujing; Zhao, Min; Guo, Jing; Zhao, Mingwei; Huang, Lvzhen; Li, Xiaoxin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
   [Li, Haiping] Peking Univ, Dept Ophthalmol, Hosp 3, Beijing 100871, Peoples R China.
   [Zhou, Peng] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200433, Peoples R China.
   [Khor, Chiea Chuen] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Peking University; Peking University; Fudan University; National
   University of Singapore; Singapore National Eye Center
RP Khor, CC (通讯作者)，Genome Inst Singapore, Div Human Genet, 60 Biopolis St, Singapore 138672, Singapore.
EM khorr@gis.a-star.edu.sg; huanglvzhen@126.com; drlixiaoxin@163.com
OI Zhao, Min/0000-0003-0521-9186; Khor, Chiea Chuen/0000-0002-1128-4729
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81100666]; Research Fund
   for Science and Technology Program of Beijing [Z121100005312006]
FX Supported by the National Basic Research Program of China (973 Program,
   No. 2011CB510200), the National Natural Science Foundation of China
   (81100666), and the Research Fund for Science and Technology Program of
   Beijing (Z121100005312006).
CR Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216
   Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Barrett JC, 2009, NAT GENET, V41, P1330, DOI 10.1038/ng.483
   Bessho H, 2009, MOL VIS, V15, P1107
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen JM, 2009, AM J HUM GENET, V85, P775, DOI 10.1016/j.ajhg.2009.10.016
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 19
TC 12
Z9 12
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2013
VL 54
IS 13
BP 8199
EP 8203
DI 10.1167/iovs.13-12867
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AD1ZM
UT WOS:000333032200011
PM 24235014
DA 2022-11-30
ER

PT J
AU Told, R
   Reiter, GS
   Schranz, M
   Reumueller, A
   Hacker, V
   Mittermueller, TJ
   Roberts, PK
   Sacu, S
   Schmidt-Erfurth, U
AF Told, R.
   Reiter, G. S.
   Schranz, M.
   Reumueller, A.
   Hacker, V
   Mittermueller, T. J.
   Roberts, P. K.
   Sacu, S.
   Schmidt-Erfurth, U.
TI Correlation of Retinal Thickness and Swept-Source Optical Coherence
   Tomography Angiography Derived Vascular Changes in Patients with
   Neovascular Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Biomarker; SSOCTA; SSOCT; nAMD; CNV
AB Purpose: The aim of this study was to investigate whether structural OCT changes, in specific retinal thickness, is associated with the vascular response within the nAMD CNV lesion. In other words, whether SSOCTA derived parameters may prove suitable to assess CNV activity in future. Methods: During the first 3 months patients were prospectively followed with visits at days 7, and 14 after each anti-VEGF treatment up to day 90. At baseline, day 30 and 60 Aflibercept was administered. OCT-derrived retinal thickness (RT) and OCTA-derived CNV lesion parameters (vessel area [VA]), total vessel length [TVL], total number of junctions [TNJ], junction density [JD]) were determined. Parameters were exported from SSOCT/A (PlexElite, Zeiss) images using the semi-automated AngioTool software. Additionally, the superficial and deep vascular plexus fractal dimension of the para- and perifoveal region were identified. Consequently, all OCTA derived parameters were correlated with RT. Results: 16 consecutive patients presenting with treatment-naive, SSOCTA-positive CNV lesions were included. A weak to moderate statistically significant correlation was found between the mean RT of the inner as well as the outer ETDRS ring with the SSOCTA-derived vascular markers vessel area (VA; r(2) = -0.38, p < .001; r(2) = -0.47, p < .001, respectively), total vessel length, (TVL; r(2) = -0.38, p < .001; r(2) = -0.48, p < .001, respectively) and total number of junctions (TNJ; r(2) = -0.35, p < .001; r(2) = -0.44, p < .001, respectively). Junctions density (JD), and all variables based on fractal dimension (FD) did not show statistically significant correlations with retinal thickness measurements. Conclusions: In summary, we could confirm a moderate, however, statistically significant correlation between mean para- and perifoveal retinal thickness and the SSOCTA derived vascular parameters VA, TVL, and TNJ. This leads us to the conclusion that an SSOCTA-based activity analysis of the CNV complex is not yet a substitute for retinal thickness or in-depth fluid analysis in patients with nAMD.
C1 [Told, R.; Reiter, G. S.; Schranz, M.; Reumueller, A.; Hacker, V; Mittermueller, T. J.; Roberts, P. K.; Sacu, S.; Schmidt-Erfurth, U.] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Clin Trial Ctr VTC, Vienna, Austria.
C3 Medical University of Vienna
RP Told, R (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM reinhard.told@meduniwien.ac.at
OI Told, Reinhard/0000-0003-2046-7081; Reiter, Gregor/0000-0001-7661-4015
CR Babiuch AS, 2020, RETINA-J RET VIT DIS, V40, P672, DOI 10.1097/IAE.0000000000002443
   Bhardwaj S, 2018, RETINA-J RET VIT DIS, V38, P1816, DOI 10.1097/IAE.0000000000001774
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cennamo G, 2020, OPHTHALMOL THER, V9, P77, DOI 10.1007/s40123-019-00221-0
   Cicinelli MV, 2020, RETINA-J RET VIT DIS, V40, P499, DOI 10.1097/IAE.0000000000002452
   Faatz H, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000369
   Falavarjani KG, 2017, INVEST OPHTH VIS SCI, V58, P30, DOI 10.1167/iovs.16-20579
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Fayed AE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217109
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Khoshnood B, 2010, OPHTHAL PHYSL OPT, V30, P816, DOI 10.1111/j.1475-1313.2010.00766.x
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee SC., 2019, AM J OPHTHALMOL
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Matet A, 2017, INVEST OPHTH VIS SCI, V58, P3851, DOI 10.1167/iovs.17-22324
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Kanadani TCM, 2018, OPHTHALMOLOGICA, V240, P200, DOI 10.1159/000488254
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Parravano M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.2.8
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Souedan V, 2018, INT OPHTHALMOL, V38, P1051, DOI 10.1007/s10792-017-0559-6
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Sustronck P., 2019, ARVO 2019
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Told R, 2013, OPHTHALMOLOGE, V110, P960, DOI 10.1007/s00347-013-2813-2
   Told R, 2021, ACTA OPHTHALMOL, V99, pE240, DOI 10.1111/aos.14554
   Told R, 2020, RETINA-J RET VIT DIS, V40, P2010, DOI 10.1097/IAE.0000000000002695
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Valler D, 2020, OPHTHALMOLOGE, V117, P529, DOI 10.1007/s00347-019-01003-6
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Winegarner A, 2018, INVEST OPHTH VIS SCI, V59, P2708, DOI 10.1167/iovs.17-23437
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zahid S, 2016, INVEST OPHTH VIS SCI, V57, P4940, DOI 10.1167/iovs.16-19656
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 54
TC 5
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL 3
PY 2021
VL 46
IS 7
BP 1002
EP 1009
DI 10.1080/02713683.2020.1849734
EA MAY 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO3TL
UT WOS:000648162900001
PM 33211556
DA 2022-11-30
ER

PT J
AU Quaid, P
   Stonier, C
   Cox, MJ
AF Quaid, P
   Stonier, C
   Cox, MJ
TI Potential vision testing - the relationship between visual acuity and
   Vernier acuity in the presence of simulated cataract
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE cataract; potential vision testing; simulated cataract; Vernier acuity
ID DISPLACEMENT THRESHOLD HYPERACUITY; READING SPEED; SURGERY; METER; AGE;
   EYES; PERFORMANCE; ACCURACY; MOVEMENT; PINHOLE
AB To evaluate the utility of a computer controlled two-bar Vernier acuity measurement as a predictor of visual function in the presence of cataract we measured logMAR visual acuity and Vernier acuity in a group of 40 young normal observers under various levels of dioptric blur (0-3 D in dioptre steps). The Vernier thresholds were resistant to dioptric blur up to 2 D, but performance degraded with blur of 3 D for non-optimised Vernier stimulus parameters. The stimulus parameters, bar length and bar separation, were further investigated in two subjects under conditions of blur. By extending the Vernier bar length and increasing the bar separation the effect of blur could be further reduced even under the most blurred condition. The relationship between visual acuity and Vernier acuity was determined. Vernier acuity was measured in the presence of Vistech cataract simulating lenses and a prediction of visual acuity was made for three observers, two with no ocular abnormality and one with age-related maculopathy. The cataract simulating lenses affected the measured visual acuity in all three subjects, but had less effect on Vernier acuity. Predicted visual acuities were all within six letters (0.12 log units) of the visual acuity without the simulated cataract. As expected, the subject suffering from age-related maculopathy, whilst showing similar levels of Vernier acuity to the two ocularly healthy subjects at 1.50 of retinal eccentricity, showed much poorer Vernier acuity for stimuli presented at fixation.
C1 Univ Bradford, Dept Optometry, Bradford BD7 1DP, W Yorkshire, England.
C3 University of Bradford
RP Cox, MJ (通讯作者)，Univ Bradford, Dept Optometry, Richmond Rd, Bradford BD7 1DP, W Yorkshire, England.
OI Quaid, Patrick/0000-0001-7318-6350
CR Amato MM, 2000, INVEST OPHTH VIS SCI, V41, pS6
   Atchison D.A., 2000, OPTICS HUMAN EYE
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Barrett BT, 1995, EYE, V9, P722, DOI 10.1038/eye.1995.184
   BUENO G, 1995, INVEST OPHTH VIS SCI, V36, P686
   Cuzzani OE, 1998, J CATARACT REFR SURG, V24, P263, DOI 10.1016/S0886-3350(98)80209-5
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Devereux CJ, 2000, CLIN EXP OPHTHALMOL, V28, P414, DOI 10.1046/j.1442-9071.2000.00349.x
   DEWAARD PWT, 1992, INVEST OPHTH VIS SCI, V33, P618
   Elliott DB, 1996, BRIT J OPHTHALMOL, V80, P799, DOI 10.1136/bjo.80.9.799
   ELLIOTT DB, 1995, OPTOMETRY VISION SCI, V72, P186, DOI 10.1097/00006324-199503000-00006
   Elliott DB, 2001, INVEST OPHTH VIS SCI, V42, P1945
   ELLIOTT DB, 1988, OPHTHAL PHYSL OPT, V8, P397, DOI 10.1111/j.1475-1313.1988.tb01176.x
   Enoch JM, 1999, J GERONTOL A-BIOL, V54, pB336, DOI 10.1093/gerona/54.8.B336
   ENOCH JM, 1984, DOC OPHTHALMOL, V58, P71, DOI 10.1007/BF00140901
   Enoch JM, 1998, INT OPHTHALMOL, V22, P181, DOI 10.1023/A:1006289303132
   Enoch JM, 1998, INVEST OPHTH VIS SCI, V39, P1297
   ENOCH JM, 1995, OPT ENG, V34, P765, DOI 10.1117/12.191813
   FOSTER DH, 1991, PSYCHOL BULL, V109, P152, DOI 10.1037/0033-2909.109.1.152
   FROST N, 2001, OPTOMETRY PRAC, V2, P71
   Frost NA, 2000, BRIT J OPHTHALMOL, V84, P432, DOI 10.1136/bjo.84.4.432
   Georgeson MA, 1996, VISION RES, V36, P605, DOI 10.1016/0042-6989(96)89253-4
   Gus PI, 2000, J CATARACT REFR SURG, V26, P1238, DOI 10.1016/S0886-3350(00)00409-0
   Hofeldt AJ, 1998, OPHTHALMOLOGY, V105, P1531, DOI 10.1016/S0161-6420(98)98042-3
   HURST M, 1995, OPHTHAL PHYSL OPT, V15, P49
   HURST MA, 1993, OPTOMETRY VISION SCI, V70, P903, DOI 10.1097/00006324-199311000-00007
   KINGSMITH PE, 1994, VISION RES, V34, P885, DOI 10.1016/0042-6989(94)90039-6
   Kline DW, 2001, OPTOMETRY VISION SCI, V78, P676, DOI 10.1097/00006324-200109000-00013
   Kogure S, 1999, J CATARACT REFR SURG, V25, P569, DOI 10.1016/S0886-3350(99)80058-3
   LAKSHMINARAYANAN V, 1995, INT OPHTHALMOL, V19, P109, DOI 10.1007/BF00133181
   LASA MSM, 1995, OPHTHALMOLOGY, V102, P1007
   le Grand Y., 1935, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, V200, P490
   LEGRAND Y, 1937, FORM IM RET 2 REUN I, P6
   Li RWH, 2000, VISION RES, V40, P3775, DOI 10.1016/S0042-6989(00)00212-1
   Li RWH, 2001, INVEST OPHTH VIS SCI, V42, P1119
   Lundstrom M, 2000, J CATARACT REFR SURG, V26, P101, DOI 10.1016/S0886-3350(99)00324-7
   Lundstrom M, 1999, BRIT J OPHTHALMOL, V83, P1272, DOI 10.1136/bjo.83.11.1272
   McGraw PV, 1996, OPHTHAL PHYSL OPT, V16, pS26, DOI 10.1016/S0275-5408(96)90046-0
   Melki SA, 1999, OPHTHALMOLOGY, V106, P1262, DOI 10.1016/S0161-6420(99)00706-X
   MINKOWSKI JS, 1983, OPHTHALMOLOGY, V90, P1360
   Monestam E, 1997, ACTA OPHTHALMOL SCAN, V75, P569
   MORGAN M J, 1985, Spatial Vision, V1, P151, DOI 10.1163/156856885X00161
   Patel B, 2001, OPHTHAL PHYSL OPT, V21, P272, DOI 10.1046/j.1475-1313.2001.00594.x
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   SMITH G, 1982, OPHTHAL PHYSL OPT, V2, P5, DOI 10.1111/j.1475-1313.1982.tb00159.x
   STIGMAR G, 1971, ACTA OPHTHALMOL, V49, P364
   VANDENBERG T, 1987, DOC OPHTHALMOL, V49, P33
   VILAR EYP, 1995, J OPT SOC AM A, V12, P2293, DOI 10.1364/JOSAA.12.002293
   WHITAKER D, 1989, OPHTHAL PHYSL OPT, V9, P20, DOI 10.1111/j.1475-1313.1989.tb00799.x
   WHITAKER D, 1989, CLIN VISION SCI, V4, P61
   WILLIAMS RA, 1984, INVEST OPHTH VIS SCI, V25, P389
NR 51
TC 6
Z9 6
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0275-5408
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD NOV
PY 2002
VL 22
IS 6
BP 469
EP 481
DI 10.1046/j.1475-1313.2002.00051.x
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 620WG
UT WOS:000179555600001
PM 12477011
DA 2022-11-30
ER

PT J
AU Iu, LPL
   Chan, HY
   Ho, MRY
   Lai, FHP
   Mak, ACY
   Wong, RLM
   Young, AL
AF Iu, Lawrence P. L.
   Chan, Ho Yan
   Ho, Mary
   Lai, Frank H. P.
   Mak, Andrew C. Y.
   Wong, Raymond L. M.
   Young, Alvin L.
TI The Contemporary Role of Photodynamic Therapy in the Treatment of
   Pachychoroid Diseases
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID FOCAL CHOROIDAL EXCAVATION; CENTRAL SEROUS CHORIORETINOPATHY;
   HALF-FLUENCE; SPECTRUM DISORDERS; VASCULOPATHY; VERTEPORFIN;
   RANIBIZUMAB; EFFICACY; OUTCOMES; NEOVASCULOPATHY
AB Recent advances in retinal imaging technology have improved our understanding in the pathogenesis and evolvement of various chorioretinal diseases. Central serous chorioretinopathy and polypoidal choroidal vasculopathy are now recognized to belong to the same spectrum of disorders known as pachychoroid diseases. Pachychoroid diseases have similar pathogenesis pathway and common characteristics of thickened choroid, dilated outer choroidal vessels, and thinning of choriocapillaris. More disease entities have been identified to belong to this disease spectrum. Photodynamic therapy can induce choroidal hypoperfusion, remodeling of abnormal choroidal vessels, and reduction of choroidal congestion. It is known to be an effective treatment for chronic central serous chorioretinopathy and polypoidal choroidal vasculopathy. Many new studies are being performed to investigate its efficacy in other pachychoroid diseases. In this review, we provided an overview of the rationale, efficacy, and treatment strategies of photodynamic therapy in different pachychoroid diseases and discussed its role in the management along with other treatment modalities with most updated clinical evidence.
C1 [Iu, Lawrence P. L.; Chan, Ho Yan; Ho, Mary; Mak, Andrew C. Y.; Young, Alvin L.] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
   [Iu, Lawrence P. L.; Chan, Ho Yan; Ho, Mary; Mak, Andrew C. Y.; Wong, Raymond L. M.; Young, Alvin L.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
   [Lai, Frank H. P.] Caritas Med Ctr, Dept Ophthalmol, Sham Shui Po, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong
RP Iu, LPL (通讯作者)，Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.; Iu, LPL (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
EM dr.lawrenceiu@gmail.com; chanhyhk@gmail.com; maryhohm@gmail.com;
   franklhp@gmail.com; andrewcymak@gmail.com; raymondwlm@hotmail.com;
   youngla@ha.org.hk
OI Lai, Hiu Ping/0000-0002-4446-3790; Ho, Mary/0000-0001-8864-2988
CR Alkin Z, 2014, CLIN OPHTHALMOL, V8, P685, DOI 10.2147/OPTH.S58617
   Bae SH, 2014, OPHTHALMOLOGY, V121, P558, DOI 10.1016/j.ophtha.2013.09.024
   Banaee T, 2019, J CURR OPHTHALMOL, V31, P454, DOI 10.1016/j.joco.2019.08.004
   Belenje A, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2020-240665
   Bhayana A, 2020, BMJ CASE REP, V13, DOI 10.1136/bcr-2020-237584
   Bonyadi MHJ, 2018, INT OPHTHALMOL, V38, P815, DOI 10.1007/s10792-017-0511-9
   Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Braimah IZ, 2018, SEMIN OPHTHALMOL, V33, P161, DOI 10.1080/08820538.2016.1182634
   Castro-Navarro V, 2021, GRAEF ARCH CLIN EXP, V259, P1385, DOI 10.1007/s00417-020-04940-0
   Cerman E, 2015, SURV OPHTHALMOL, V60, P557, DOI 10.1016/j.survophthal.2015.05.004
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Corvi F, 2021, EYE, V35, P110, DOI 10.1038/s41433-020-01217-y
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Docherty Gavin, 2021, Retin Cases Brief Rep, V15, P376, DOI 10.1097/ICB.0000000000000833
   Ersoz MG, 2018, BRIT J OPHTHALMOL, V102, P473, DOI 10.1136/bjophthalmol-2017-310724
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Genovese G, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57060628
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hikichi T, 2021, EYE, V35, P3367, DOI 10.1038/s41433-021-01418-z
   Ho M, 2021, BRIT J OPHTHALMOL, V105, P555, DOI 10.1136/bjophthalmol-2020-316076
   Hwang S, 2021, RETINA-J RET VIT DIS, V41, P1762, DOI 10.1097/IAE.0000000000003067
   Iacono P, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110349
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iovino C, 2022, EYE, V36, P716, DOI 10.1038/s41433-021-01515-z
   Iwase T, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3190136
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Karacorlu M, 2018, GRAEF ARCH CLIN EXP, V256, P2319, DOI 10.1007/s00417-018-4144-0
   Karasu B, 2021, INT OPHTHALMOL, V41, P1989, DOI 10.1007/s10792-021-01754-9
   Kim H, 2015, OPHTHALMOLOGY, V122, P1534, DOI 10.1016/j.ophtha.2015.01.012
   Kim YK, 2015, GRAEF ARCH CLIN EXP, V253, P2063, DOI 10.1007/s00417-014-2926-6
   Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lai FHP, 2016, AM J OPHTHALMOL, V170, P91, DOI 10.1016/j.ajo.2016.07.026
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu HY, 2016, AM J OPHTHALMOL, V167, P57, DOI 10.1016/j.ajo.2016.04.001
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Luk FOJ, 2015, EYE, V29, P454, DOI 10.1038/eye.2015.31
   Ma JL, 2014, ACTA OPHTHALMOL, V92, pe594, DOI 10.1111/aos.12482
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Matsubara H, 2018, CASE REP OPHTHALM, V9, P388, DOI 10.1159/000492747
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7
   Miki A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248760
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Naseripour Masood, 2016, J Ophthalmic Vis Res, V11, P66, DOI 10.4103/2008-322X.180706
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Nicolo M, 2014, AM J OPHTHALMOL, V157, P1033, DOI 10.1016/j.ajo.2014.01.022
   Nishikawa Y, 2014, CLIN OPHTHALMOL, V8, P2461, DOI 10.2147/OPTH.S75558
   Okubo A, 2015, CLIN EXP OPTOM, V98, P478, DOI 10.1111/cxo.12265
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Pandolfo G, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9081067
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park W, 2019, GRAEF ARCH CLIN EXP, V257, P2155, DOI 10.1007/s00417-019-04426-8
   Peng SY, 2017, J OCUL PHARMACOL TH, V33, P466, DOI 10.1089/jop.2016.0184
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Pichi F, 2018, INDIAN J OPHTHALMOL, V66, P1716, DOI 10.4103/ijo.IJO_893_18
   Roy R, 2016, CLIN EXP OPTOM, V99, P198, DOI 10.1111/cxo.12309
   Sartini F, 2020, INT OPHTHALMOL, V40, P3577, DOI 10.1007/s10792-020-01522-1
   Shah RC, 2019, INDIAN J OPHTHALMOL, V67, P696, DOI 10.4103/ijo.IJO_1263_18
   Sharma A, 2021, EYE, V35, P1545, DOI 10.1038/s41433-021-01423-2
   Sheptulin V, 2018, GRAEF ARCH CLIN EXP, V256, P2027, DOI 10.1007/s00417-018-4086-6
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Smretschnig E, 2013, RETINA-J RET VIT DIS, V33, P316, DOI 10.1097/IAE.0b013e318280769c
   Smretschnig E, 2012, RETINA-J RET VIT DIS, V32, P2014, DOI 10.1097/IAE.0b013e318242b9ab
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P997, DOI 10.1097/IAE.0000000000003004
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Verma S, 2021, BRIT J OPHTHALMOL, V105, P1043, DOI 10.1136/bjophthalmol-2020-316992
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong IY, 2018, RETINA-J RET VIT DIS, V38, P725, DOI 10.1097/IAE.0000000000001614
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Xu D, 2022, BRIT J OPHTHALMOL, V106, P576, DOI 10.1136/bjophthalmol-2019-315550
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 86
TC 0
Z9 0
U1 1
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD OCT 23
PY 2021
VL 2021
AR 6590230
DI 10.1155/2021/6590230
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WT3OT
UT WOS:000715778100001
PM 34725570
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Pfau, M
   Goerdt, L
   Schmitz-Valckenberg, S
   Mauschitz, MM
   Mishra, DK
   Holz, FG
   Lindner, M
   Fleckenstein, M
AF Pfau, Maximilian
   Goerdt, Lukas
   Schmitz-Valckenberg, Steffen
   Mauschitz, Matthias M.
   Mishra, Divyansh K.
   Holz, Frank G.
   Lindner, Moritz
   Fleckenstein, Monika
TI Green-Light Autofluorescence Versus Combined Blue-Light Autofluorescence
   and Near-Infrared Reflectance Imaging in Geographic Atrophy Secondary to
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; age-related macular degeneration; fundus
   autofluorescence; green-light autofluorescence
ID OPTICAL COHERENCE TOMOGRAPHY; VIVO FUNDUS AUTOFLUORESCENCE; PROGRESSION;
   SEGMENTATION; IMAGES; PATTERNS; AREAS; MODEL
AB PURPOSE. To compare the intermodality and interreader agreement for geographic atrophy (GA) lesion size quantification in green-light fundus autofluorescence (GAF; excitation = 518 nm) versus combined blue-light fundus autofluorescence (BAF; excitation = 488 nm) and near-infrared reflectance (NIR; 820 nm) -based grading.
   METHODS. Confocal scanning laser ophthalmoscopy (cSLO) GAF, BAF, and NIR images of 40 eyes from 29 patients (mean age 79.7 years) with GA secondary to AMD were recorded according to a standardized protocol. GA areas were analyzed in GAF, BAF combined with NIR (BAF +/- NIR), or BAF alone, by four independent readers using semiautomated software (RegionFinder; Heidelberg Engineering, Heidelberg, Germany). A mixed-effects model was used to assess the effect of image modality on the measured square-root lesion area. The coefficient of repeatability (CR) and intraclass correlation coefficient (ICC) were assessed for the square-root lesion area, lesion perimeter, and circularity.
   RESULTS. GAF-based measurements were on average 0.062 mm (95% confidence interval [CI] 0.04-0.08 mm) larger than BAF +/- NIR-based measurements and 0.077 mm (95% CI 0.06 -0.10 mm) larger than BAF-based measurements. Interreader agreement was highest for GAF-based analysis ([CR, ICC] 0.196 mm, 0.995) followed by BAF +/- NIR (0.232 mm, 0.992) and BAF alone (0.263 mm, 0.991). The same was noted for the lesion perimeter and circularity. Post hoc review revealed that interreader differences were associated with media opacification interfering with lesion boundary demarcation to a larger extent in BAF than in GAF.
   CONCLUSIONS. cSLO-based GAF and combined BAF +/- NIR imaging with semiautomated lesion delineation allow for an accurate and reproducible quantification of GA. The slightly better interreader agreement using cSLO GAF suggests that its use may be preferable in clinical trials examining the change in lesion size as a clinical endpoint.
C1 [Pfau, Maximilian; Goerdt, Lukas; Schmitz-Valckenberg, Steffen; Mauschitz, Matthias M.; Holz, Frank G.; Lindner, Moritz; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Pfau, Maximilian; Schmitz-Valckenberg, Steffen; Mauschitz, Matthias M.; Holz, Frank G.; Fleckenstein, Monika] GRADE Reading Ctr, Bonn, Germany.
   [Mishra, Divyansh K.] Sankara Eye Hosp, Varthur Main Rd, Bangalore, Karnataka, India.
   [Lindner, Moritz] Univ Oxford, Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
C3 University of Bonn; University of Oxford
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Monika.Fleckenstein@ukbonn.de
RI Pfau, Maximilian/N-1888-2019; Lindner, Moritz/AAC-8639-2021
OI Pfau, Maximilian/0000-0001-9761-9640; Lindner,
   Moritz/0000-0002-4416-3421; Fleckenstein, Monika/0000-0001-8321-8037
FU BONFOR GEROK Program, Faculty of Medicine, University of Bonn
   [O-137.0020, O-137.0022]; DFG [FL 658/4-1, FL 658/4-2, Ho1926/3-1]
FX Supported by BONFOR GEROK Program, Faculty of Medicine, University of
   Bonn, Grants O-137.0020 (ML) and O-137.0022 (MP); DFG Grant FL 658/4-1
   and FL 658/4-2 Genentech Inc., San Francisco, CA, USA, and DFG Grant
   Ho1926/3-1. The authors alone are responsible for the content and
   writing of the paper.
CR Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Lee N, 2007, P ANN INT IEEE EMBS, P4965, DOI 10.1109/IEMBS.2007.4353455
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Pilotto E, 2015, INVEST OPHTH VIS SCI, V56, P8120, DOI 10.1167/iovs.15-17366
   R Development Core Team, 2016, R LANG ENV STAT COMP
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Sparrow JR, 1981, INVEST OPHTH VIS SCI, V41, P1981
   Teussink MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172635
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
NR 35
TC 36
Z9 37
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 6
SI SI
BP BIO121
EP BIO130
DI 10.1167/iovs.17-21764
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ3EI
UT WOS:000404593000016
PM 28632841
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Vojnikovic, B
   Coklo, M
   Bosnar, A
AF Vojnikovic, Bozidar
   Coklo, Miran
   Bosnar, Alan
TI Development and Progression of Age-Related Macular Degeneration after
   Cataract Surgery - In the Near Future It Could Become a Forensic
   Medicine Problem
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE age-related-macular degeneration; cataract surgery; forensic medicine
AB After testing all types of implanted IOLs with spectrophotometer, author estimated that filtering of sun light is not successful, leaving open the possibility of development of AMD after cataract surgery. This is especially serious problem in implantation of IOLs to children. Until recently, implantation of intraocular lenses without or with inappropriate UV protection was not considered a serious problem. Nowadays we know that, especially in children, such treatment is no longer acceptable and results in AMD. It is only a matter of time when the first lawsuit will appear on it. We suggest obligatory eye protection after cataract surgery (aphakic and pseudophakic eyes) with Medical filters (Yellow-Green: 550-600 nm) and regular ophthalmic controls.
C1 [Vojnikovic, Bozidar] Daily Eye Clin Dr Bozo Vojnikovic, Rijeka, Croatia.
   [Coklo, Miran; Bosnar, Alan] Univ Rijeka, Sch Med, Dept Forens Med, Rijeka, Croatia.
C3 University of Rijeka
RP Vojnikovic, B (通讯作者)，Antuna Barca 3B, Rijeka 51000, Croatia.
EM decv@decv.com
CR HENDERSON ST, 1997, DAYLIGHT ITS SPECTRU, V2
   VOJNIKOVIC B, 2005, EINSTEINOV ZAKON ELE
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P29
NR 3
TC 5
Z9 5
U1 0
U2 1
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD OCT
PY 2008
VL 32
SU 2
BP 3
EP 4
PG 2
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 380WK
UT WOS:000261496600002
PM 19140269
DA 2022-11-30
ER

PT J
AU Knudtson, MD
   Klein, BEK
   Klein, R
AF Knudtson, MD
   Klein, BEK
   Klein, R
TI Age-related eye disease, visual impairment, and survival - The Beaver
   Dam Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID LENS OPACITIES; MORTALITY; CATARACT; MACULOPATHY; ASSOCIATION;
   PREVALENCE; MORBIDITY; OXIDATION; GLAUCOMA; FRAILTY
AB Objective: To investigate the relationship of age-related maculopathy, cataract, glaucoma, visual impairment, and diabetic retinopathy to survival during a 14-year period.
   Methods: Persons ranging in age from 43 to 84 years in the period from September 15, 1987, to May 4, 1988, participated in the baseline examination of the population-based Beaver Dam Eye Study (n=4926). Standardized protocols, including photography, were used to determine the presence of ocular disease. Survival was followed using standardized protocols.
   Results: As of December 31, 2002, 32% of the baseline population had died (median follow-up, 13.2 years). After adjusting for age, sex, and systemic and lifestyle factors, poorer survival was associated with cortical cataract (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.06-1.37), any cataract (HR, 1.16; 95% CI, 1.03-1.32), diabetic retinopathy (HR per 1-step increase in 4-level severity, 1.36; 95% CI, 1.14-1.63), and visual impairment (HR, 1.24; 95% CI, 1.04-1.48) and marginally associated with increasing severity of nuclear sclerosis (HR, 1.07; 95% CI, 0.99-1.16). Age-related maculopathy and glaucoma were not associated with poorer survival. Associations tended to be slightly stronger in men than women.
   Conclusions: Cataract, diabetic retinopathy, and visual impairment were associated with poorer survival and not explained by traditional risk factors for mortality. These ocular conditions may serve as markers for mortality in the general population.
C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Knudtson, MD (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM knudtson@epi.ophth.wisc.edu
FU PHS HHS [AY06594] Funding Source: Medline
CR Allison P.D., 2010, SURVIVAL ANAL USING
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   Balkau B, 1999, DIABETES CARE, V22, P696, DOI 10.2337/diacare.22.5.696
   BENSON WH, 1988, OPHTHALMOLOGY, V95, P1288
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Boscia F, 2000, INVEST OPHTH VIS SCI, V41, P2461
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   COOK EF, 1989, J CLIN EPIDEMIOL, V42, P317
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Davis M D, 1979, Trans Am Ophthalmol Soc, V77, P144
   DRAKE C, 1995, INT J EPIDEMIOL, V24, P183, DOI 10.1093/ije/24.1.183
   GARLICK RL, 1984, J CLIN INVEST, V74, P1742, DOI 10.1172/JCI111592
   Gerstein HC, 1999, DIABETES CARE, V22, P659, DOI 10.2337/diacare.22.5.659
   Grodum K, 2004, GRAEF ARCH CLIN EXP, V242, P397, DOI 10.1007/s00417-004-0858-2
   Hennis A, 2001, OPHTHALMOLOGY, V108, P498, DOI 10.1016/S0161-6420(00)00542-X
   Hiller R, 1999, AM J OPHTHALMOL, V128, P440, DOI 10.1016/S0002-9394(99)00187-7
   Iyengar SK, 2004, P NATL ACAD SCI USA, V101, P14485, DOI 10.1073/pnas.0400778101
   Joffe MM, 1999, AM J EPIDEMIOL, V150, P327
   Klein Barbara E K, 2003, Trans Am Ophthalmol Soc, V101, P191
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein BEK, 2005, ARCH GERONTOL GERIAT, V41, P141, DOI 10.1016/j.archger.2005.01.002
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1487
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1991, PB91149823 NTIS
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Meddings DR, 1998, SOC SCI MED, V46, P1451, DOI 10.1016/S0277-9536(97)10138-1
   MINASSIAN DC, 1992, B WORLD HEALTH ORGAN, V70, P219
   Nucci C, 2004, GRAEF ARCH CLIN EXP, V242, P289, DOI 10.1007/s00417-003-0837-z
   *SAS I INC, 1999, SAT STAT US GUID VER
   SHARMA NK, 1980, T OPHTHAL SOC UK, V100, P83
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   STREET DA, 1992, AM J OPHTHALMOL, V113, P263, DOI 10.1016/S0002-9394(14)71577-6
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201
   THOMPSON JR, 1993, ARCH OPHTHALMOL-CHIC, V111, P675, DOI 10.1001/archopht.1993.01090050109039
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   West SK, 2000, ARCH OPHTHALMOL-CHIC, V118, P393, DOI 10.1001/archopht.118.3.393
   Williams SL, 2002, AM J EPIDEMIOL, V156, P127, DOI 10.1093/aje/kwf012
   WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9
   1976, PREV MED, V5, P207
NR 51
TC 128
Z9 129
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2006
VL 124
IS 2
BP 243
EP 249
DI 10.1001/archopht.124.2.243
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012HY
UT WOS:000235330400012
PM 16476894
OA Bronze
DA 2022-11-30
ER

PT J
AU GOUTAM, B
   Hashmi, MF
   Geem, ZW
   Bokde, ND
AF Goutam, Balla
   Hashmi, Mohammad Farukh
   Geem, Zong Woo
   Bokde, Neeraj Dhanraj
TI A Comprehensive Review of Deep Learning Strategies in Retinal Disease
   Diagnosis Using Fundus Images
SO IEEE ACCESS
LA English
DT Review
DE Retina; Medical diagnosis; Task analysis; Retinopathy; Deep learning;
   Measurement; Diabetes; Computer vision; deep learning; fundus image;
   retinal disease diagnosis; artificial intelligence; diabetic
   retinopathy; glaucoma; AMD; cataract; ROP
ID BLOOD-VESSEL SEGMENTATION; OPTIC-NERVE HEAD; DIABETIC-RETINOPATHY;
   MACULAR DEGENERATION; U-NET; EXUDATES SEGMENTATION; GLOBAL PREVALENCE;
   EYE DISEASE; NETWORK; FRAMEWORK
AB In recent years, there has been an unprecedented growth in computer vision and deep learning implementation owing to the exponential rise of computation infrastructure. The same was also reflected in retinal image analysis and successful artificial intelligence models were developed for various retinal disease diagnoses using a wide variety of visual markers obtained from eye fundus images. This article presents a comprehensive study of different deep learning strategies employed in recent times for the diagnosis of five major eye diseases, i.e., Diabetic retinopathy, Glaucoma, age-related macular degeneration, Cataract, and Retinopathy of prematurity. This article is organized according to the deep learning implementation process pipeline, where commonly used datasets, evaluation metrics, image pre-processing techniques, and deep learning backbone models are first illustrated followed by an extensive review of different strategies for each of the five mentioned retinal diseases is presented. Finally, this article summarizes eight major research directions available in the field of retinal disease diagnosis and outlines key challenges and future scope for the present research community.
C1 [Goutam, Balla; Hashmi, Mohammad Farukh] Natl Inst Technol, Dept Elect & Commun Engn, Warangal 506004, Andhra Pradesh, India.
   [Geem, Zong Woo] Gachon Univ, Coll IT Convergence, Seongnam 13120, South Korea.
   [Bokde, Neeraj Dhanraj] Aarhus Univ, Dept Civil & Architectural Engn, DK-8000 Aarhus, Denmark.
   [Bokde, Neeraj Dhanraj] Aarhus Univ, Ctr Quantitat Genet & Genom, DK-8000 Aarhus, Denmark.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Warangal; Gachon University; Aarhus University; Aarhus
   University
RP Geem, ZW (通讯作者)，Gachon Univ, Coll IT Convergence, Seongnam 13120, South Korea.
EM geem@gachon.ac.kr
RI Bokde, Neeraj Dhanraj/I-2621-2016; Geem, Zong Woo/A-2718-2008
OI Bokde, Neeraj Dhanraj/0000-0002-3493-9302; Geem, Zong
   Woo/0000-0002-0370-5562; Hashmi, Mohammad Farukh/0000-0002-3808-9122
FU National Research Foundation of Korea (NRF) - Korean Government through
   the Ministry of Science and ICT (MSIT) [2020R1A2C1A01011131]
FX This work was supported by the National Research Foundation of Korea
   (NRF) Grant funded by the Korean Government through the Ministry of
   Science and ICT (MSIT) under Grant 2020R1A2C1A01011131.
CR Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Agrawal R, 2021, J DIGIT IMAGING, V34, P932, DOI 10.1007/s10278-021-00477-8
   Almazroa A, 2018, PROC SPIE, V10579, DOI 10.1117/12.2293584
   Alyoubi WL, 2021, SENSORS-BASEL, V21, DOI 10.3390/s21113704
   [Anonymous], 2021, APPL SOFT COMPUT, V109
   [Anonymous], DIABETIC RETINOPATHY
   Araujo T, 2020, MED IMAGE ANAL, V63, DOI 10.1016/j.media.2020.101715
   Atli I, 2021, ENG SCI TECHNOL, V24, P271, DOI 10.1016/j.jestch.2020.07.008
   Badar M, 2020, COMPUT SCI REV, V35, DOI 10.1016/j.cosrev.2019.100203
   Bajwa MN, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-019-0842-8
   Baskaran M, 2015, JAMA OPHTHALMOL, V133, P874, DOI 10.1001/jamaophthalmol.2015.1110
   Bengani S, 2021, MULTIMED TOOLS APPL, V80, P3443, DOI 10.1007/s11042-020-09778-6
   Bhatkalkar BJ, 2021, IEEE ACCESS, V9, P159071, DOI 10.1109/ACCESS.2021.3127280
   Biswas R, 2020, IJST-T ELECTR ENG, V44, P505, DOI 10.1007/s40998-019-00213-7
   Bora A, 2021, LANCET DIGIT HEALTH, V3, pE10, DOI 10.1016/S2589-7500(20)30250-8
   Boudegga H, 2021, COMPUT MED IMAG GRAP, V90, DOI 10.1016/j.compmedimag.2021.101902
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Bridge J, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000569
   Budai A, 2013, INT J BIOMED IMAGING, V2013, DOI 10.1155/2013/154860
   Carmona EJ, 2008, ARTIF INTELL MED, V43, P243, DOI 10.1016/j.artmed.2008.04.005
   Chawla D, 2019, SEMIN PERINATOL, V43, P344, DOI 10.1053/j.semperi.2019.05.006
   Chen DL, 2020, SYMMETRY-BASEL, V12, DOI 10.3390/sym12071067
   Chen Qingyu, 2019, AMIA Jt Summits Transl Sci Proc, V2019, P505
   Chen SB, 2021, I S BIOMED IMAGING, P1025, DOI 10.1109/ISBI48211.2021.9434012
   Chou YB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86526-2
   Coyner Aaron S, 2020, AMIA Annu Symp Proc, V2020, P329
   Das Sraddha, 2021, Biomedical Signal Processing and Control, V68, P303, DOI 10.1016/j.bspc.2021.102600
   Dashtbozorg B, 2018, IEEE T IMAGE PROCESS, V27, P3300, DOI 10.1109/TIP.2018.2815345
   Decenciere E, 2013, IRBM, V34, P196, DOI 10.1016/j.irbm.2013.01.010
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Dharmawan DA, 2019, IEEE ACCESS, V7, P41885, DOI 10.1109/ACCESS.2019.2906344
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   Fraz MM, 2012, IEEE T BIO-MED ENG, V59, P2538, DOI 10.1109/TBME.2012.2205687
   Fu H., 2020, PROC IEEE DATAPORT, DOI [10.48550/arXiv.2202.07983, DOI 10.48550/ARXIV.2202.07983]
   Fu Huazhu, 2018, IEEE Trans Med Imaging, V37, P2493, DOI 10.1109/TMI.2018.2837012
   Fu YH, 2021, PATTERN RECOGN, V117, DOI 10.1016/j.patcog.2021.107971
   Fukutsu Kanae, 2021, Ophthalmol Sci, V1, P100004, DOI 10.1016/j.xops.2021.100004
   Fumero F, 2011, COMP MED SY
   Gegundez-Arias ME, 2021, COMPUT METH PROG BIO, V205, DOI 10.1016/j.cmpb.2021.106081
   Gheisari S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81554-4
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Govindaiah A, 2021, J PERS MED, V11, DOI 10.3390/jpm11111127
   Guo S, 2019, NEUROCOMPUTING, V349, P52, DOI 10.1016/j.neucom.2019.04.019
   Guo YM, 2016, NEUROCOMPUTING, V187, P27, DOI 10.1016/j.neucom.2015.09.116
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   He WJ, 2021, INFORM FUSION, V73, P157, DOI 10.1016/j.inffus.2021.02.017
   Hemelings R, 2020, ACTA OPHTHALMOL, V98, pE94, DOI 10.1111/aos.14193
   Heo TY, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050261
   Hervella AS, 2022, APPL SOFT COMPUT, V116, DOI 10.1016/j.asoc.2021.108347
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Hossain MR, 2020, IEEE REGION 10 SYMP, P1333
   Huang CX, 2021, NEUROCOMPUTING, V452, P521, DOI 10.1016/j.neucom.2020.07.145
   Huang YP, 2020, ELECTRONICS-SWITZ, V9, DOI 10.3390/electronics9091444
   Imran A, 2021, VISUAL COMPUT, V37, P2407, DOI 10.1007/s00371-020-01994-3
   Imran A, 2020, COMP M BIO BIO E-IV, V8, P691, DOI 10.1080/21681163.2020.1806733
   Isaacs Robert, 2004, J Agromedicine, V9, P207
   Islam MT, 2022, IEEE ACCESS, V10, P2828, DOI 10.1109/ACCESS.2021.3139160
   Jenkins Alicia J, 2015, Rev Diabet Stud, V12, P159, DOI 10.1900/RDS.2015.12.159
   Jin BX, 2020, ENTROPY-SWITZ, V22, DOI 10.3390/e22080844
   Junayed MS, 2021, IEEE ACCESS, V9, P128799, DOI 10.1109/ACCESS.2021.3112938
   Juneja M, 2020, MACH VISION APPL, V31, DOI 10.1007/s00138-020-01085-2
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kauppi T, 2007, DIARETDB1 DIABETIC R
   Kauppi T., 2006, DIARETDB0 EVALUATION
   Kaushik H, 2021, IEEE ACCESS, V9, P108276, DOI 10.1109/ACCESS.2021.3101142
   Khan MSM, 2021, 2021 IEEE WORLD AI IOT CONGRESS (AIIOT), P209, DOI [10.1109/AIIoT52608.2021.9454244, 10.1109/AIIOT52608.2021.9454244]
   Khojasteh P, 2019, BIOMED SIGNAL PROCES, V49, P240, DOI 10.1016/j.bspc.2018.12.004
   Kim M, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9153064
   Kou CX, 2020, IEEE ACCESS, V8, P185514, DOI 10.1109/ACCESS.2020.3029117
   Kumar ES, 2021, J AMB INTEL HUM COMP, DOI 10.1007/s12652-021-02977-5
   Kurilova V., 2021, SCI REP-UK, V11, P1
   Lahmiri S, 2020, BIOMED SIGNAL PROCES, V60, DOI 10.1016/j.bspc.2020.101978
   Lam C., 2018, AMIA JT SUMMITS TRAN, V(2018, P147
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Lei BY, 2021, MULTIMED TOOLS APPL, V80, P36341, DOI 10.1007/s11042-021-11208-0
   Li F, 2020, GRAEF ARCH CLIN EXP, V258, P851, DOI 10.1007/s00417-020-04609-8
   Li L, 2019, PROC CVPR IEEE, P10563, DOI 10.1109/CVPR.2019.01082
   Li L, 2020, IEEE T MED IMAGING, V39, P413, DOI 10.1109/TMI.2019.2927226
   Li T, 2021, MED IMAGE ANAL, V69, DOI 10.1016/j.media.2021.101971
   Li T, 2019, INFORM SCIENCES, V501, P511, DOI 10.1016/j.ins.2019.06.011
   Liao WM, 2020, IEEE J BIOMED HEALTH, V24, P1405, DOI 10.1109/JBHI.2019.2949075
   Liao YH, 2021, BIOCYBERN BIOMED ENG, V41, P589, DOI 10.1016/j.bbe.2021.04.005
   Liu HR, 2019, JAMA OPHTHALMOL, V137, P1353, DOI 10.1001/jamaophthalmol.2019.3501
   Liu Q, 2022, IEEE J BIOMED HEALTH, V26, P1091, DOI 10.1109/JBHI.2021.3108169
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Lowell J, 2004, IEEE T MED IMAGING, V23, P256, DOI 10.1109/TMI.2003.823261
   Majumder S., 2021, IEEE ACCESS, V9
   Maqsood S, 2021, SENSORS-BASEL, V21, DOI 10.3390/s21113865
   Martins J, 2020, COMPUT METH PROG BIO, V192, DOI 10.1016/j.cmpb.2020.105341
   Mayya V., 2021, COMPUT METHODS PROGR, V1
   Mirzania D, 2021, EUR J OPHTHALMOL, V31, P1618, DOI 10.1177/1120672120977346
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohan NJ, 2021, IEEE EMBS CONF BIO, P367, DOI 10.1109/IECBES48179.2021.9398771
   Mohanto N, 2022, J PHARM INVEST, DOI [10.1007/s10278-022-00587-x, 10.1007/s40005-022-00590-y]
   Natarajan D, 2022, INT J IMAG SYST TECH, V32, P230, DOI 10.1002/ima.22609
   Nawaz M, 2022, SENSORS-BASEL, V22, DOI 10.3390/s22020434
   Nayak DR, 2021, BIOMED SIGNAL PROCES, V67, DOI 10.1016/j.bspc.2021.102559
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   Nneji GU, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12020540
   Orlando JI, 2020, MED IMAGE ANAL, V59, DOI 10.1016/j.media.2019.101570
   Ovreiu S., 2021, PROC 13 INT C ELECT, P1
   Pan XQ, 2019, IEEE ACCESS, V7, P122634, DOI 10.1109/ACCESS.2019.2935138
   Panda R., 2021, SOCIAL NETW COMPUT S, V2, P1
   Peng Y., 2020, NPJ DIGIT MED, V3, P1
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pham QTM, 2022, COMPUT METH PROG BIO, V216, DOI 10.1016/j.cmpb.2022.106648
   Pham QTM, 2020, ELECTRONICS-SWITZ, V9, DOI 10.3390/electronics9101617
   Phene S, 2019, OPHTHALMOLOGY, V126, P1627, DOI 10.1016/j.ophtha.2019.07.024
   Porwal P, 2018, DATA, V3, DOI 10.3390/data3030025
   Pratap T, 2021, BIOMED SIGNAL PROCES, V70, DOI 10.1016/j.bspc.2021.102985
   Qiao LF, 2020, IEEE ACCESS, V8, P104292, DOI 10.1109/ACCESS.2020.2993937
   Qummar S, 2019, IEEE ACCESS, V7, P150530, DOI 10.1109/ACCESS.2019.2947484
   Ramachandran S, 2021, BIOCYBERN BIOMED ENG, V41, P362, DOI 10.1016/j.bbe.2021.02.005
   Raza A, 2021, INT CONF FRONT INFO, P137, DOI 10.1109/FIT53504.2021.00034
   Redd TK, 2019, BRIT J OPHTHALMOL, V103, P580, DOI 10.1136/bjophthalmol-2018-313156
   Rehman S. U., 2022, SOCIAL NETW APPL SCI, V4, P1
   Ronneberger O, 2015, INT C MED IM COMP CO, V9351, P234, DOI DOI 10.1007/978-3-319-24574-4_28
   Sahlsten J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47181-w
   Samuel PM, 2021, COMPUT METH PROG BIO, V198, DOI 10.1016/j.cmpb.2020.105769
   Saravanan V, 2022, J AMB INTEL HUM COMP, DOI 10.1007/s12652-021-02928-0
   Sengupta S, 2020, ARTIF INTELL MED, V102, DOI 10.1016/j.artmed.2019.101758
   Shankar K, 2020, IEEE ACCESS, V8, P118164, DOI 10.1109/ACCESS.2020.3005152
   Shankar K, 2020, PATTERN RECOGN LETT, V133, P210, DOI 10.1016/j.patrec.2020.02.026
   Shoughi A, 2021, PROC 26 INT COMPUT C, P1
   Shoukat A, 2021, INT CONF FRONT INFO, P120, DOI 10.1109/FIT53504.2021.00031
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Singh LK, 2022, EVOL SYST-GER, V13, P807, DOI 10.1007/s12530-022-09426-4
   Sivaprasad S, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-458
   Sivaswamy J, 2014, I S BIOMED IMAGING, P53, DOI 10.1109/ISBI.2014.6867807
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Swathi C, 2017, 2017 CONFERENCE ON EMERGING DEVICES AND SMART SYSTEMS (ICEDSS), P175, DOI 10.1109/ICEDSS.2017.8073677
   Tan LZ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.23
   Tian C, 2020, BIOCYBERN BIOMED ENG, V40, P583, DOI 10.1016/j.bbe.2020.01.011
   Toacar M., 2022, COMPUT METH PROG BIO, V214
   Vaghefi E, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7493419
   Veena H. N., 2021, J KING SAUD UNIV-COM, V32, P1, DOI [10.1016/j.jksuci, DOI 10.1016/J.JKSUCI]
   Wang B, 2021, IEEE J BIOMED HEALTH, V25, P1128, DOI 10.1109/JBHI.2020.3011178
   Wang DY, 2020, IEEE J BIOMED HEALTH, V24, P3384, DOI 10.1109/JBHI.2020.3002985
   Wang J, 2020, IEEE J BIOMED HEALTH, V24, P3397, DOI 10.1109/JBHI.2020.3012547
   Wang L, 2021, PATTERN RECOGN, V112, DOI 10.1016/j.patcog.2020.107810
   Wang PP, 2021, INT OPHTHALMOL, V41, P2065, DOI 10.1007/s10792-021-01762-9
   Wang XF, 2022, IEEE J BIOMED HEALTH, V26, P2216, DOI 10.1109/JBHI.2021.3119519
   Wang YF, 2019, J PHYS CONF SER, V1187, DOI 10.1088/1742-6596/1187/4/042057
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu B, 2017, COMPUT MED IMAG GRAP, V55, P106, DOI 10.1016/j.compmedimag.2016.08.001
   Wu YC, 2020, NEURAL NETWORKS, V126, P153, DOI 10.1016/j.neunet.2020.02.018
   Wu ZC, 2021, OPHTHALMOL RETINA, V5, P118, DOI 10.1016/j.oret.2020.06.026
   Xia HY, 2021, KNOWL-BASED SYST, V226, DOI 10.1016/j.knosys.2021.107140
   Xiong H, 2022, ARTIF INTELL MED, V126, DOI 10.1016/j.artmed.2022.102261
   Xu X, 2021, J BIOMED INFORM, V124, DOI 10.1016/j.jbi.2021.103939
   Xu YL, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00417-4
   Xu ZY, 2021, BRIT J OPHTHALMOL, V105, P561, DOI 10.1136/bjophthalmol-2020-315817
   Xue J, 2019, KNOWL-BASED SYST, V183, DOI 10.1016/j.knosys.2019.104887
   Yan Q, 2020, NAT MACH INTELL, V2, P141, DOI 10.1038/s42256-020-0154-9
   Yang L, 2021, NEUROCOMPUTING, V448, P168, DOI 10.1016/j.neucom.2021.03.085
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yellapragada B, 2022, OPHTHALMOL RETINA, V6, P116, DOI 10.1016/j.oret.2021.06.010
   Yildiz V, 2021, I S BIOMED IMAGING, P353, DOI 10.1109/ISBI48211.2021.9433881
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Zhang HY, 2019, COMPUT METH PROG BIO, V182, DOI 10.1016/j.cmpb.2019.07.006
   Zhang X., 2021, GRAEFES ARCH CLIN EX, V260, P1
   Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/s41467-017-01968-5, 10.1038/ncomms14542]
   Zhang XP, 2020, MACH VISION APPL, V32, DOI 10.1007/s00138-020-01119-9
   Zhang Z, 2013, C IND ELECT APPL, P228
   Zhang Z, 2010, IEEE ENG MED BIO, P3065, DOI 10.1109/IEMBS.2010.5626137
   Zhao RC, 2019, AAAI CONF ARTIF INTE, P809
   Zhao XY, 2021, SIGNAL IMAGE VIDEO P, V15, P913, DOI 10.1007/s11760-020-01815-z
   Zheng YF, 2013, INVEST OPHTH VIS SCI, V54, P2171, DOI 10.1167/iovs.12-11393
   Zhu QL, 2021, BIOMED OPT EXPRESS, V12, P6529, DOI 10.1364/BOE.434841
   Zong YS, 2020, IEEE ACCESS, V8, P167225, DOI 10.1109/ACCESS.2020.3023273
NR 174
TC 0
Z9 0
U1 30
U2 30
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2022
VL 10
BP 57796
EP 57823
DI 10.1109/ACCESS.2022.3178372
PG 28
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Telecommunications
GA 1Y3FE
UT WOS:000808028000001
OA gold
DA 2022-11-30
ER

PT J
AU Tang, ZM
   Ju, YH
   Dai, XC
   Ni, N
   Liu, Y
   Zhang, DD
   Gao, HQ
   Sun, H
   Zhang, J
   Gu, P
AF Tang, Zhimin
   Ju, Yahan
   Dai, Xiaochan
   Ni, Ni
   Liu, Yan
   Zhang, Dandan
   Gao, Huiqin
   Sun, Hao
   Zhang, Jing
   Gu, Ping
TI HO-1-mediated ferroptosis as a target for protection against retinal
   pigment epithelium degeneration
SO REDOX BIOLOGY
LA English
DT Article
DE Ferroptosis; Heme oxygenase-1; Iron chelation; Retinal pigment
   epithelium; Age-related macular degeneration; Photoreceptor
ID HEME OXYGENASE-1; OXIDATIVE STRESS; DISEASE; IRON; MECHANISMS;
   AUTOPHAGY; MEMBRANE; MODELS; INJURY; BLOOD
AB Oxidative stress-mediated retinal pigment epithelium (RPE) degeneration plays a vital role in retinal degeneration with irreversible visual impairment, most notably in age-related macular degeneration (AMD), but a key pathogenic factor and the targeted medical control remain controversial and unclear. In this work, by sophisticated high-throughput sequencing and biochemistry investigations, the major pathologic processes during RPE degeneration in the sodium iodate-induced oxidative stress model has been identified to be heme oxygenase-1 (HO-1)-regulated ferroptosis, which is controlled by the Nrf2-SLC7A11-HO-1 hierarchy, through which ferrous ion accumulation and lethal oxidative stress cause RPE death and subsequently photoreceptor degeneration. By direct knockdown of HO-1 or using HO-1 inhibitor ZnPP, the specific inhibition of HO-1 overexpression has been determined to significantly block RPE ferroptosis. In mice, treatment with ZnPP effectively rescued RPE degeneration and achieved superior therapeutic effects: substantial recovery of the retinal structure and visual function. These findings highlight that targeting HO-1-mediated RPE ferroptosis could serve as an effectively retinal-protective strategy for retinal degenerative diseases prevention, including AMD.
C1 [Tang, Zhimin; Ju, Yahan; Dai, Xiaochan; Ni, Ni; Liu, Yan; Zhang, Dandan; Gao, Huiqin; Sun, Hao; Zhang, Jing; Gu, Ping] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orbital Dis & Ocular Oncol, Dept Ophthalmol,Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, J; Gu, P (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orbital Dis & Ocular Oncol, Dept Ophthalmol,Sch Med, Shanghai 200011, Peoples R China.
EM zhjingty@126.com; guping2009@sjtu.edu.cn
FU National Natural Science Foundations of China [81870687, 82071004];
   National Key R&D program of China [2018YFC1106100]; Key program of
   Shanghai Science and Technology Commission [19JC1415503]; Municipal
   Education CommissionGaofeng Clinical Medicine Grant Support [20161316];
   Science and Technology Commission of Shanghai [17DZ2260100]
FX This work was supported by National Natural Science Foundations of China
   (81870687, 82071004), National Key R&D program of China
   (2018YFC1106100), Key program of Shanghai Science and Technology
   Commission (19JC1415503), Municipal Education CommissionGaofeng Clinical
   Medicine Grant Support (20161316), and Science and Technology Commission
   of Shanghai (17DZ2260100).
CR Adedoyin O, 2018, AM J PHYSIOL-RENAL, V314, pF702, DOI 10.1152/ajprenal.00044.2017
   Ahmad AS, 2006, NEUROSCIENCE, V141, P1703, DOI 10.1016/j.neuroscience.2006.05.035
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Castilho AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042428
   Catanzaro M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00844
   Chang LC, 2018, CANCER LETT, V416, P124, DOI 10.1016/j.canlet.2017.12.025
   Chen H, 2016, BRAIN INJURY, V30, P36, DOI 10.3109/02699052.2015.1084648
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Daruich A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau9940
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Fang XX, 2019, P NATL ACAD SCI USA, V116, P2672, DOI 10.1073/pnas.1821022116
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gaschler MM, 2018, NAT CHEM BIOL, V14, P507, DOI 10.1038/s41589-018-0031-6
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002
   Hassannia B, 2018, J CLIN INVEST, V128, P3341, DOI 10.1172/JCI99032
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437
   Jiang Q, 2020, J CLIN INVEST, V130, P3833, DOI 10.1172/JCI123353
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Kokona D, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1373-4
   Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162
   Lee JJ, 2020, BIOCHEM BIOPH RES CO, V521, P414, DOI 10.1016/j.bbrc.2019.10.138
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mohamed R., 2017, SCI REP-UK, V7
   NaveenKumar SK, 2018, ACS CHEM BIOL, V13, P1996, DOI 10.1021/acschembio.8b00458
   Nowis D, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-197
   Pedrera L, 2021, CELL DEATH DIFFER, V28, P1644, DOI 10.1038/s41418-020-00691-x
   Peng C.H., 2016, ONCOTARGET, V7
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rossi M, 2018, BIOCHEM BIOPH RES CO, V503, P2820, DOI 10.1016/j.bbrc.2018.08.046
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Sapkal AU, 2018, J OPHTHAL VIS RES, V13, P419, DOI 10.4103/jovr.jovr_16_18
   Schipper HM, 2009, J NEUROCHEM, V110, P469, DOI 10.1111/j.1471-4159.2009.06160.x
   Shu WT, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101469
   Song W, 2012, J NEUROSCI, V32, P10841, DOI 10.1523/JNEUROSCI.6469-11.2012
   Southon A, 2020, BRIT J PHARMACOL, V177, P656, DOI 10.1111/bph.14881
   Stockwell BR, 2020, TRENDS CELL BIOL, V30, P478, DOI 10.1016/j.tcb.2020.02.009
   Strick DJ, 2009, INVEST OPHTH VIS SCI, V50, P2427, DOI 10.1167/iovs.08-3058
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tang ZM, 2019, BIOMATERIALS, V194, P57, DOI 10.1016/j.biomaterials.2018.12.015
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Ueda K, 2018, P NATL ACAD SCI USA, V115, P4963, DOI 10.1073/pnas.1722601115
   VERGARA O, 1989, EXP EYE RES, V49, P1115, DOI 10.1016/S0014-4835(89)80030-2
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang H, 2017, HEPATOLOGY, V66, P449, DOI 10.1002/hep.29117
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yu XJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24200
   Yuan Y, 2008, EUR J PHARMACOL, V586, P100, DOI 10.1016/j.ejphar.2008.02.033
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 54
TC 37
Z9 38
U1 9
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD JUL
PY 2021
VL 43
AR 101971
DI 10.1016/j.redox.2021.101971
EA APR 2021
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SM1KW
UT WOS:000657371800006
PM 33895485
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yamasaki, S
   Sugita, S
   Horiuchi, M
   Masuda, T
   Fujii, S
   Makabe, K
   Kawasaki, A
   Hayashi, T
   Kuwahara, A
   Kishino, A
   Kimura, T
   Takahashi, M
   Mandai, M
AF Yamasaki, Suguru
   Sugita, Sunao
   Horiuchi, Matsuri
   Masuda, Tomohiro
   Fujii, Shota
   Makabe, Kenichi
   Kawasaki, Akihiro
   Hayashi, Takuya
   Kuwahara, Atsushi
   Kishino, Akiyoshi
   Kimura, Toru
   Takahashi, Masayo
   Mandai, Michiko
TI Low Immunogenicity and Immunosuppressive Properties of Human ESC- and
   iPSC-Derived Retinas
SO STEM CELL REPORTS
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; NEURAL RETINA;
   ANIMAL-MODEL; TRANSPLANTATION; ACTIVATION; VISION; SHEETS; CRX
AB ESC- and iPSC-derived retinal transplantation is a promising therapeutic approach for disease with end-stage retinal degeneration, such as retinitis pigmentosa and age-related macular degeneration. We previously showed medium- to long-term survival, maturation, and light response of transplanted human ESC- and iPSC-retina in mouse, rat, and monkey models of end-stage retinal degeneration. Because the use of patient hiPSC-derived retina with a disease-causing gene mutation is not appropriate for therapeutic use, allogeneic transplantation using retinal tissue/cells differentiated from a stocked hESC and iPSC line would be most practical. Here, we characterize the immunological properties of hESC- and iPSC-retina and present their three major advantages: (1) hESC- and iPSC-retina expressed low levels of human leukocyte antigen (HLA) class I and little HLA class II in vitro, (2) hESC- and iPSC-retina greatly suppressed immune activation of lymphocytes in co-culture, and (3) hESC- and iPSC-retina suppressed activated immune cells partially via transforming growth factor b signaling. These results support the use of allogeneic hESC- and iPSC-retina in future clinical application.
C1 [Yamasaki, Suguru; Sugita, Sunao; Horiuchi, Matsuri; Masuda, Tomohiro; Fujii, Shota; Makabe, Kenichi; Takahashi, Masayo; Mandai, Michiko] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
   [Yamasaki, Suguru; Horiuchi, Matsuri; Kuwahara, Atsushi; Kishino, Akiyoshi; Kimura, Toru] Sumitomo Dainippon Pharma Co Ltd, Regenerat & Cellular Med Kobe Ctr, Kobe, Hyogo 6500047, Japan.
   [Kawasaki, Akihiro; Hayashi, Takuya] RIKEN Ctr Biosyst Dynam Res, Lab Brain Connect Imaging, Kobe, Hyogo 6500047, Japan.
   [Mandai, Michiko] RIKEN Cluster Sci Technol & Innovat Hub, RIKEN Program Drug Discovery & Med Technol Platfo, Wako, Saitama 3510198, Japan.
C3 RIKEN; Dainippon Sumitomo Pharmaceutical Company; RIKEN; RIKEN
RP Sugita, S; Mandai, M (通讯作者)，RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.; Mandai, M (通讯作者)，RIKEN Cluster Sci Technol & Innovat Hub, RIKEN Program Drug Discovery & Med Technol Platfo, Wako, Saitama 3510198, Japan.
EM sunao.sugita@riken.jp; michiko.mandai@riken.jp
RI Hayashi, Takuya/A-1634-2011; Kuwahara, Atsushi/ABB-5872-2021
OI Hayashi, Takuya/0000-0001-7639-0197; Kuwahara,
   Atsushi/0000-0003-2418-7853
FU JapanAgency for MedicalResearch and Development (Japan) [JP20bm0204002]
FX D. Nukaya, T. Kamei, and K. Watari for technical support and members of
   the M.T. laboratory and RACMO for discussions. We thank Mototsugu Eiraku
   for contribution to the development of the hESC-and iPSC-retina
   differentiation protocol. This study was supported by a grant from
   JapanAgency for MedicalResearch and Development (Japan) under grant
   number JP20bm0204002.We thank J. Sho for help with animal experiments;
   K. Iseki, N. Hayashi, and S. Fujino for conducting in vitro experiments.
   We thank T. Matsuyama, T. Hung-Ya, R. Akiba, Y. Wu, C. Morinaga, K.
   Matsushita,
CR Akiba R, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00016
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Barnea-Cramer AO, 2016, SCI REP, V6, P1
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Edo A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217831
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Fujii S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093077
   Fujii S, 2019, STEM CELLS DEV, V28, P28, DOI 10.1089/scd.2018.0058
   Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Gasparini SJ, 2019, PROG RETIN EYE RES, V69, P1, DOI 10.1016/j.preteyeres.2018.11.001
   Ghosh F, 1999, INVEST OPHTH VIS SCI, V40, P126
   Ghosh F, 2007, GRAEF ARCH CLIN EXP, V245, P835, DOI 10.1007/s00417-006-0437-9
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Itakura G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13522-w
   Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kruczek K, 2017, STEM CELL REP, V8, P1659, DOI 10.1016/j.stemcr.2017.04.030
   Kuwahara A., 2019, SCI REP, V9, P1
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Li HD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6601
   Lin B, 2018, EXP EYE RES, V174, P13, DOI 10.1016/j.exer.2018.05.017
   Maeda A., 2019, ANNU REV GENOM HUM G, V20
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Mandai M, 2012, CELL MED, V4, P45, DOI 10.3727/215517912X639315
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   Morizane A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00926-5
   Nakagawa M, 2014, SCI REP-UK, V4, P1, DOI [10.1038/ srep03594, DOI 10.1038/SREP03594]
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Ozaki M, 2017, STEM CELL RES, V19, P128, DOI 10.1016/j.scr.2017.01.007
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seiler MJ, 2014, GRAEF ARCH CLIN EXP, V252, P1079, DOI 10.1007/s00417-014-2638-y
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sugita S, 2006, EXP EYE RES, V83, P1459, DOI 10.1016/j.exer.2006.08.005
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Welge-Lussen U, 1999, INVEST OPHTH VIS SCI, V40, P3209
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
NR 61
TC 7
Z9 7
U1 2
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD APR 13
PY 2021
VL 16
IS 4
BP 851
EP 867
DI 10.1016/j.stemcr.2021.02.021
EA APR 2021
PG 17
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RN3QL
UT WOS:000640266900001
PM 33770500
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zeng, ZQ
   Lam, PT
   Robinson, ML
   Del Rio-Tsonis, K
   Saul, JM
AF Zeng, Ziqian
   Lam, Phuong T.
   Robinson, Michael L.
   Del Rio-Tsonis, Katia
   Saul, Justin M.
TI Design and Characterization of Biomimetic Kerateine Aerogel-Electrospun
   Polycaprolactone Scaffolds for Retinal Cell Culture
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Retina; Macular degeneration; Natural polymer; Kerateine
AB Age-related macular degeneration (AMD) is a retinal disease that affects 196 million people and causes nearly 9% of blindness worldwide. While several pharmacological approaches slow the effects of AMD, in our opinion, cell-based strategies offer the most likely path to a cure. We describe the design and initial characterization of a kerateine (obtained by reductive extraction from keratin proteins) aerogel-electrospun polycaprolactone fiber scaffold system. The scaffolds mimic key features of the choroid and the Bruch's membrane, which is the basement membrane to which the cells of the retinal pigment epithelium (RPE) attach. The scaffolds had elastic moduli of 2-7.2 MPa, a similar range as native choroid and Bruch's membrane. ARPE-19 cells attached to the polycaprolactone fibers, remained viable for one week, and proliferated to form a monolayer reminiscent of that needed for retinal repair. These constructs could serve as a model system for testing cell and/or drug treatment strategies or directing ex vivo retinal tissue formation in the treatment of AMD.
C1 [Zeng, Ziqian; Saul, Justin M.] Miami Univ, Dept Chem, Paper & BioMed Engn, 650 East High St, Oxford, OH 45056 USA.
   [Lam, Phuong T.; Robinson, Michael L.; Del Rio-Tsonis, Katia] Miami Univ, Dept Biol, Oxford, OH 45056 USA.
   [Robinson, Michael L.; Del Rio-Tsonis, Katia] Miami Univ CVSMU, Ctr Visual Sci, Oxford, OH USA.
C3 University System of Ohio; Miami University; University System of Ohio;
   Miami University
RP Saul, JM (通讯作者)，Miami Univ, Dept Chem, Paper & BioMed Engn, 650 East High St, Oxford, OH 45056 USA.
EM sauljm@MiamiOH.edu
RI Zeng, Ziqian/AAR-4548-2020
OI Zeng, Ziqian/0000-0001-5300-6906
FU Miami University College of Arts and Sciences
FX No benefits in any form have been or will be received from a commercial
   party related directly or indirectly to the subject of this manuscript.
   This work was funded by a seed grant from the Miami University College
   of Arts and Sciences. The authors thank Mr. Matt Duley and Dr. Richard
   Edelmann in the Center for Advanced Microscopy and Imaging at Miami
   University for assistance with SEM sample preparation and imaging.
CR Al-Shamekh S, 2014, TRANSL RES, V163, P377, DOI 10.1016/j.trsl.2013.11.002
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Chan W.H., 2007, INVEST OPHTHALMOL VI, V48, P2187
   Chatterjee K, 2010, BIOMATERIALS, V31, P5051, DOI 10.1016/j.biomaterials.2010.03.024
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Chong EJ, 2007, ACTA BIOMATER, V3, P321, DOI 10.1016/j.actbio.2007.01.002
   Cohen DJ, 2018, TISSUE ENG PT A, V24, P1616, DOI [10.1089/ten.tea.2017.0471, 10.1089/ten.TEA.2017.0471]
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Gandhi JK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227641
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ham TR, 2016, BIOMACROMOLECULES, V17, P225, DOI 10.1021/acs.biomac.5b01328
   Han S, 2015, ACTA BIOMATER, V23, P201, DOI 10.1016/j.actbio.2015.05.013
   Haugh MG, 2011, TISSUE ENG PT A, V17, P1201, DOI [10.1089/ten.tea.2010.0590, 10.1089/ten.TEA.2010.0590]
   Heidari R, 2015, APPL BIOCHEM BIOTECH, V175, P2399, DOI 10.1007/s12010-014-1431-z
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Islam MR, 2014, SCI REP-UK, V4, DOI 10.1038/srep06043
   Kharitonov AE, 2018, ACTA NATURAE, V10, P30
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lam PT, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.21
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lynn SA, 2017, TISSUE CELL, V49, P447, DOI 10.1016/j.tice.2017.06.003
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Rath B, 2008, J BIOMECH, V41, P1095, DOI 10.1016/j.jbiomech.2007.11.024
   Rzhanova LA, 2020, RUSS J DEV BIOL+, V51, P212, DOI 10.1134/S1062360420040062
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Shahmoradi S, 2017, MAT SCI ENG C-MATER, V73, P300, DOI 10.1016/j.msec.2016.11.076
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shokoohmand A, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700221
   Sierpinski P, 2008, BIOMATERIALS, V29, P118, DOI 10.1016/j.biomaterials.2007.08.023
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sung HJ, 2004, BIOMATERIALS, V25, P5735, DOI 10.1016/j.biomaterials.2004.01.066
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tian YZ, 2019, J TISSUE ENG REGEN M, V13, P76, DOI 10.1002/term.2770
   Tomblyn S, 2016, J BIOMED MATER RES B, V104, P864, DOI 10.1002/jbm.b.33438
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   White C, 2017, J BIOMED MATER RES A, V105, P1260, DOI 10.1002/jbm.a.35992
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
NR 44
TC 7
Z9 7
U1 3
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0090-6964
EI 1573-9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD JUL
PY 2021
VL 49
IS 7
BP 1633
EP 1644
DI 10.1007/s10439-021-02756-5
EA APR 2021
PG 12
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA TS8IK
UT WOS:000637479800001
PM 33825081
DA 2022-11-30
ER

PT J
AU Purnyn, H
AF Purnyn, H.
TI Correction of Pathological Morphofunctional Changes in the Mammalian
   Retina
SO NEUROPHYSIOLOGY
LA English
DT Review
DE retina; neuropathies; degeneration; genetic pathology; gene therapy
ID GANGLION-CELL DEATH; LEBERS CONGENITAL AMAUROSIS; PROMOTES AXONAL
   REGENERATION; REPLACEMENT GENE-THERAPY; INDUCED PRIMATE GLAUCOMA;
   OPTIC-NERVE HEAD; ADULT-RATS; DIABETIC-RETINOPATHY; NEONATAL-RAT; MOUSE
   MODEL
AB The retina (a peripheral link of the visual analyzer) is a complex system whose adequate functioning is necessary for normal functioning of the eye. The loss of any cell type in the retina resulting from some diseases or trauma destroys complex neuronal chains that play a key role in the control of visual function. To gain an insight into the mechanisms underlying different pathological processes in the retina, which lead in humans to hereditary or acquired loss of vision, modeling of the corresponding pathological states in experiments on laboratory animals is used. Achievements in molecular and cellular biology led to significant progress in the development of new techniques for therapy of different visual disturbances. In the literature, techniques for neurotrophic and gene therapy used in experiments have been described. The successful use of techniques of gene therapy in experiments on laboratory animals allowed researchers to initiate phase-I clinical trials of treatment of retinoblastoma, age-related macular degeneration, and Leber's congenital amaurosis. It this review, we discuss the possibilities for application of gene therapy to a wider range of eye diseases.
C1 [Purnyn, H.] Natl Acad Sci Ukraine, Bogomolets Inst Physiol, Kiev, Ukraine.
C3 National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of
   Physiology
RP Purnyn, H (通讯作者)，Natl Acad Sci Ukraine, Bogomolets Inst Physiol, Kiev, Ukraine.
EM riss@biph.kiev.ua
RI Purnyn, Helen E/D-3381-2016; Purnyn, Helen/ABA-4331-2021
OI Purnyn, Helen E/0000-0003-3346-5819; Purnyn, Helen/0000-0003-3346-5819
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Alton E, 2007, GENE THER, V14, P1439, DOI 10.1038/sj.gt.3303001
   Amado D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000659
   Aramant RB, 2002, PROG RETIN EYE RES, V21, P57, DOI 10.1016/S1350-9462(01)00020-9
   Bainbridge J, 2007, EXPERT REV OPHTHALMO, V2, P517, DOI 10.1586/17469899.2.4.517
   Bainbridge J, 2008, EXPERT REV OPHTHALMO, V3, P357, DOI 10.1586/17469899.3.4.357
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bakalash S, 2002, INVEST OPHTH VIS SCI, V43, P2648
   Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X
   Bennett J, 2006, HUM GENE THER, V17, P177, DOI 10.1089/hum.2006.17.177
   Bennett J, 2009, NEW ENGL J MED, V361, P2483, DOI 10.1056/NEJMcibr0908643
   BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994
   Berkowitz BA, 2004, DIABETES, V53, P173, DOI 10.2337/diabetes.53.1.173
   BLAU HM, 1995, NEW ENGL J MED, V333, P1204, DOI 10.1056/NEJM199511023331808
   Bok Dean, 2005, Retina, V25, pS43, DOI 10.1097/00006982-200512001-00017
   Cai X, 2010, FASEB J, V24, P1178, DOI 10.1096/fj.09-139147
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2011, HUM GENE THER, V22, P523, DOI 10.1089/hum.2011.050
   Carter-Dawson L, 2002, INVEST OPHTH VIS SCI, V43, P2633
   Cavazzana-Calvo M, 2007, J CLIN INVEST, V117, P1456, DOI 10.1172/JCI30953
   Cehajic-Kapetanovic J, 2015, CURR BIOL, V25, P2111, DOI 10.1016/j.cub.2015.07.029
   Ceriello A, 2003, DIABETES CARE, V26, P1589, DOI 10.2337/diacare.26.5.1589
   Chader Gerald J, 2005, Retina, V25, pS15, DOI 10.1097/00006982-200512001-00006
   Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Chierzi S, 2001, RESTOR NEUROL NEUROS, V19, P109
   CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Clarke DB, 1998, VISION RES, V38, P1517, DOI 10.1016/S0042-6989(97)00341-6
   COHEN A, 1994, J NEUROBIOL, V25, P953, DOI 10.1002/neu.480250805
   Corral-Debrinski M, 2008, EXPERT REV OPHTHALMO, V3, P599, DOI 10.1586/17469899.3.6.599
   COSTA T, 1985, AM J MED GENET, V21, P231, DOI 10.1002/ajmg.1320210205
   Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760
   Danias J, 2003, INVEST OPHTH VIS SCI, V44, P5151, DOI 10.1167/iovs.02-1101
   Dejneka NS, 2003, DEV OPHTHALMOL, V37, P188
   Dubinin N. P., 1978, MUTAGENESIS ENV
   Fagiolini M, 1997, J NEUROSCI, V17, P7045
   Felgner Jiin, 1993, Methods (Orlando), V5, P67, DOI 10.1006/meth.1993.1009
   Fischer D, 2001, EXP NEUROL, V172, P257, DOI 10.1006/exnr.2001.7822
   Friedrich MJ, 2010, JAMA-J AM MED ASSOC, V304, P1543, DOI 10.1001/jama.2010.1412
   GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Gresch O, 2004, METHODS, V33, P151, DOI 10.1016/j.ymeth.2003.11.009
   Gross Ronald L, 2003, Trans Am Ophthalmol Soc, V101, P163
   Grozdanic SD, 2003, INVEST OPHTH VIS SCI, V44, P4337, DOI 10.1167/iovs.03-0015
   Hartwick ATE, 2008, J PHYSIOL-LONDON, V586, P3425, DOI 10.1113/jphysiol.2008.154609
   Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002
   Heath H, 1967, Diabetologia, V3, P515, DOI 10.1007/BF01213570
   Ho AC, 2015, OPHTHALMOLOGY, V122, P1547, DOI 10.1016/j.ophtha.2015.04.032
   Isenmann S, 2003, PROG RETIN EYE RES, V22, P483, DOI 10.1016/S1350-9462(03)00027-2
   John Simon W M, 2014, J Glaucoma, V23, pS68, DOI 10.1097/IJG.0000000000000121
   Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431
   JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335
   Koenekoop RK, 2008, EXPERT REV OPHTHALMO, V3, P397, DOI 10.1586/17469899.3.4.397
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   Laquis S, 1998, BRAIN RES, V784, P100, DOI 10.1016/S0006-8993(97)01189-X
   Le Meur G, 2005, ARCH OPHTHALMOL-CHIC, V123, P500, DOI 10.1001/archopht.123.4.500
   Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000
   Lev S, 2001, CELL MOL NEUROBIOL, V21, P575, DOI 10.1023/A:1015183500719
   Li YM, 2003, J NEUROSCI, V23, P7830
   Liu XY, 2007, CAN J OPHTHALMOL, V42, P447, DOI 10.3129/i07-049
   Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004
   Mabuchi F, 2003, INVEST OPHTH VIS SCI, V44, P4321, DOI 10.1167/iovs.03-0138
   Mabuchi F., 2003, INVEST OPHTH VIS SCI, V44, P4314
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Mancuso K, 2009, NATURE, V461, P784, DOI 10.1038/nature08401
   Mao HY, 2011, HUM GENE THER, V22, P567, DOI 10.1089/hum.2010.140
   Martin KRG, 2004, EYE, V18, P1049, DOI 10.1038/sj.eye.6701579
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   Martin KRG, 2002, METHODS, V28, P267, DOI 10.1016/S1046-2023(02)00232-3
   McClements ME, 2013, TRANSL RES, V161, P241, DOI 10.1016/j.trsl.2012.12.007
   Millington-Ward S, 2011, MOL THER, V19, P642, DOI 10.1038/mt.2010.293
   Miyazaki M, 2011, HUM GENE THER, V22, P559, DOI 10.1089/hum.2010.132
   Morrison J. C., 1998, OPHTHALMIC PRACT, V16, P12
   Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200
   Neitz J, 2011, VISION RES, V51, P633, DOI 10.1016/j.visres.2010.12.002
   Nickells RW, 1996, J GLAUCOMA, V5, P345
   Ola M. Sh, 2006, AM J PHYSIOL-ENDOC M, V290, pE1057
   Orgul S, 1996, INVEST OPHTH VIS SCI, V37, P1860
   Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588
   Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   Pawlyk BS, 2010, HUM GENE THER, V21, P993, DOI 10.1089/hum.2009.218
   PEDERSON JE, 1984, ARCH OPHTHALMOL-CHIC, V102, P1689, DOI 10.1001/archopht.1984.01040031373030
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   RABACCHI SA, 1994, NEUROSCIENCE, V63, P969, DOI 10.1016/0306-4522(94)90565-7
   RABACCHI SA, 1994, J NEUROSCI, V14, P5292
   RADIUS RL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1693, DOI 10.1001/archopht.1984.01040031377031
   Sefton A.J., 2004, RAT NERVOUS SYSTEM, P1083
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Stout JT, 2011, HUM GENE THER, V22, P531, DOI 10.1089/hum.2011.060
   Toda N, 2007, PROG RETIN EYE RES, V26, P205, DOI 10.1016/j.preteyeres.2007.01.004
   VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103
   Watson Andrea, 1996, Methods (Orlando), V10, P289, DOI 10.1006/meth.1996.0105
   Weinreb RN, 1999, ARCH OPHTHALMOL-CHIC, V117, P1540
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004
   Yip HK, 2000, PROG RETIN EYE RES, V19, P559, DOI 10.1016/S1350-9462(00)00009-4
   Zhan XQ, 2008, MOL CELL PROTEOMICS, V7, P864, DOI 10.1074/mcp.M700417-MCP200
NR 101
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-2977
EI 1573-9007
J9 NEUROPHYSIOLOGY+
JI Neurophysiology
PD OCT
PY 2015
VL 47
IS 5
BP 408
EP 418
DI 10.1007/s11062-016-9549-y
PG 11
WC Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Physiology
GA DG1EV
UT WOS:000371809300007
DA 2022-11-30
ER

PT J
AU Wiley, LA
   Burnight, ER
   Songstad, AE
   Drack, AV
   Mullins, RF
   Stone, EM
   Tucker, BA
AF Wiley, Luke A.
   Burnight, Erin R.
   Songstad, Allison E.
   Drack, Arlene V.
   Mullins, Robert F.
   Stone, Edwin M.
   Tucker, Budd A.
TI Patient-specific induced pluripotent stem cells (iPSCs) for the study
   and treatment of retinal degenerative diseases
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Induced pluripotent stem cells; Retinal degeneration; Gene therapy;
   CRISPR-based genome editing; Cell transplantation
ID COMPLEMENT FACTOR-H; RECESSIVE RETINITIS-PIGMENTOSA; CEP290/NPHP6
   MUTATIONS RESULT; GLUTAMIC-ACID DECARBOXYLASE; MEMBRANE ATTACK COMPLEX;
   GROWTH-FACTOR SECRETION; VESICLE-LIKE STRUCTURES; MACULAR DEGENERATION;
   GENE-THERAPY; EFFICIENT GENERATION
AB Vision is the sense that we use to navigate the world around us. Thus it is not surprising that blindness is one of people's most feared maladies. Heritable diseases of the retina, such as age-related macular degeneration and retinitis pigmentosa, are the leading cause of blindness in the developed world, collectively affecting as many as one-third of all people over the age of 75, to some degree. For decades, scientists have dreamed of preventing vision loss or of restoring the vision of patients affected with retinal degeneration through drug therapy, gene augmentation or a cell-based transplantation approach. In this review we will discuss the use of the induced pluripotent stem cell technology to model and develop various treatment modalities for the treatment of inherited retinal degenerative disease. We will focus on the use of iPSCs for interrogation of disease pathophysiology, analysis of drug and gene therapeutics and as a source of autologous cells for cell transplantation and replacement. (C) 2014 Published by Elsevier Ltd.
C1 [Wiley, Luke A.; Burnight, Erin R.; Songstad, Allison E.; Drack, Arlene V.; Mullins, Robert F.; Stone, Edwin M.; Tucker, Budd A.] Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa
RP Tucker, BA (通讯作者)，Univ Iowa, Carver Coll Med, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, 375 Newton Rd, Iowa City, IA 52242 USA.
EM budd-tucker@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Drack, Arlene/0000-0002-8195-8426; Mullins, Robert/0000-0002-5006-0891;
   Tucker, Budd/0000-0003-2178-1742; Stone, Edwin M./0000-0003-3343-4414;
   Wiley, Luke/0000-0003-0136-2364
FU NIH [1-DP2-OD007483-01, F32 EY022834]; NEI [EY017451]; HHMI; Foundation
   Fighting Blindness; Stephen A. Wynn Foundation; Grousbeck Family
   Foundation; Leo, Jacques & Marion Hauser Family Vision Restoration Fund;
   NATIONAL EYE INSTITUTE [F32EY022834, R01EY017451] Funding Source: NIH
   RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH
   [DP2OD007483] Funding Source: NIH RePORTER
FX We would like to graciously thank the following funding organizations:
   NIH Directors New Innovator Award 1-DP2-OD007483-01; NEI EY017451; HHMI;
   Foundation Fighting Blindness; Stephen A. Wynn Foundation; Grousbeck
   Family Foundation; Leo, Jacques & Marion Hauser Family Vision
   Restoration Fund; NIH F32 EY022834.
CR Abramoff MD, 2013, INVEST OPHTH VIS SCI, V54, P3721, DOI 10.1167/iovs.13-11812
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Aftab U, 2009, EXP EYE RES, V89, P301, DOI 10.1016/j.exer.2009.03.025
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson RM, 2002, DEVELOPMENT, V129, P4975
   [Anonymous], 2009, Q ESSAY, V36, P106, DOI DOI 10.1073/PNAS.0901471106
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Balaggan KS, 2012, GENE THER, V19, P145, DOI 10.1038/gt.2011.153
   Ban H, 2011, P NATL ACAD SCI USA, V108, P14234, DOI 10.1073/pnas.1103509108
   Baranov PY, 2014, TISSUE ENG PT A, V20, P1465, DOI [10.1089/ten.tea.2013.0361, 10.1089/ten.TEA.2013.0361]
   Bardet PL, 2008, P NATL ACAD SCI USA, V105, P13901, DOI 10.1073/pnas.0806983105
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Burnight E.R., 2014, GENE THER
   Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0
   Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106
   Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670
   Cerignoli F, 2012, J PHARMACOL TOX MET, V66, P246, DOI 10.1016/j.vascn.2012.08.167
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1
   Chatoo W, 2010, STEM CELLS, V28, P1412, DOI 10.1002/stem.462
   Chattopadhyay S, 2002, HUM MOL GENET, V11, P1421, DOI 10.1093/hmg/11.12.1421
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Choi KD, 2009, STEM CELLS, V27, P559, DOI 10.1634/stemcells.2008-0922
   Choi SM, 2013, HEPATOLOGY, V57, P2458, DOI 10.1002/hep.26237
   Christian M, 2010, GENETICS, V186, P757, DOI 10.1534/genetics.110.120717
   Cideciyan AV, 2007, HUM MUTAT, V28, P1074, DOI 10.1002/humu.20565
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Coppieters F, 2010, HUM MUTAT, V31, P1097, DOI 10.1002/humu.21337
   Craige B, 2010, J CELL BIOL, V190, P927, DOI 10.1083/jcb.201006105
   Crane IJ, 2008, SEMIN IMMUNOPATHOL, V30, P165, DOI 10.1007/s00281-008-0106-7
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   DAVANGER M, 1971, NATURE, V229, P560, DOI 10.1038/229560a0
   de Almeida PE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4903
   de los Reyes E, 2004, J CHILD NEUROL, V19, P42, DOI 10.1177/08830738040190010703
   Desbordes SC, 2013, NAT PROTOC, V8, P111, DOI 10.1038/nprot.2012.139
   Dianov GL, 2013, NUCLEIC ACIDS RES, V41, P3483, DOI 10.1093/nar/gkt076
   Drack A.V., 2014, OPHTHALMIC GENET
   Drivas TG, 2013, J CLIN INVEST, V123, P4525, DOI 10.1172/JCI69448
   Du C, 2014, BIOMATERIALS, V35, P6006, DOI 10.1016/j.biomaterials.2014.04.011
   Duan J., 2014, CELL RES
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egawa N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004052
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fontes Andrew, 2013, Methods Mol Biol, V997, P57, DOI 10.1007/978-1-62703-348-0_6
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guell M., 2014, BIOINFORMATICS
   GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622
   Hafler BP, 2012, P NATL ACAD SCI USA, V109, P7882, DOI 10.1073/pnas.1203138109
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hockemeyer D, 2011, NAT BIOTECHNOL, V29, P731, DOI 10.1038/nbt.1927
   Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647
   Hu Kejin, 2013, Methods Mol Biol, V997, P163, DOI 10.1007/978-1-62703-348-0_13
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P1722, DOI 10.1167/iovs.12-10578
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Inoue H, 2011, CLIN PHARMACOL THER, V89, P655, DOI 10.1038/clpt.2011.38
   Jadhav AR, 2006, DEVELOPMENT, V133, P913, DOI 10.1242/dev.02245
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   KAPLAN HJ, 1977, J IMMUNOL, V118, P809
   Katz ML, 1999, J NEUROSCI RES, V57, P551
   Kay CN, 2012, ARCH OPHTHALMOL-CHIC, V130, P357, DOI 10.1001/archophthalmol.2011.363
   Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045
   Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436
   Kim K, 2011, NAT BIOTECHNOL, V29, P1117, DOI 10.1038/nbt.2052
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Ladewig J, 2013, NAT REV MOL CELL BIO, V14, P225, DOI 10.1038/nrm3543
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Li DL, 2013, NAT BIOTECHNOL, V31, P681, DOI 10.1038/nbt.2661
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maeder ML, 2013, NAT METHODS, V10, P977, DOI [10.1038/nmeth.2598, 10.1038/NMETH.2598]
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261
   McEwen DP, 2007, P NATL ACAD SCI USA, V104, P15917, DOI 10.1073/pnas.0704140104
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Miller JC, 2007, NAT BIOTECHNOL, V25, P778, DOI 10.1038/nbt1319
   Mitchison HM, 1999, NEUROBIOL DIS, V6, P321, DOI 10.1006/nbdi.1999.0267
   Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3
   Mordwinkin NM, 2013, J CARDIOVASC TRANSL, V6, P22, DOI 10.1007/s12265-012-9423-2
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7
   Mullins R.F., 2014, AM J PATHOL
   Mullins RF, 2005, ARCH OPHTHALMOL-CHIC, V123, P1588, DOI 10.1001/archopht.123.11.1588
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   Mullins RF, 2012, INVEST OPHTH VIS SCI, V53, P1883, DOI 10.1167/iovs.12-9477
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595
   Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9
   Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Pang JJ, 2006, MOL VIS, V12, P756
   Park CY, 2014, P NATL ACAD SCI USA, V111, P9253, DOI 10.1073/pnas.1323941111
   Park TS, 2014, CIRCULATION, V129, P359, DOI 10.1161/CIRCULATIONAHA.113.003000
   Pattanayak V, 2013, NAT BIOTECHNOL, V31, P839, DOI 10.1038/nbt.2673
   Pearce DA, 2004, NEUROLOGY, V63, P2001, DOI 10.1212/01.WNL.0000145836.72059.3B
   Pera EM, 2001, DEV CELL, V1, P655, DOI 10.1016/S1534-5807(01)00069-7
   Perrault Isabelle, 2007, Hum Mutat, V28, P416, DOI 10.1002/humu.9485
   Petrs-Silva H, 2014, CLIN OPHTHALMOL, V8, P127, DOI 10.2147/OPTH.S38041
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Porteus MH, 2003, SCIENCE, V300, P763, DOI 10.1126/science.1078395
   Qiu P, 2004, BIOTECHNIQUES, V36, P702, DOI 10.2144/04364PF01
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Read SP, 2010, MOL THER, V18, P1917, DOI 10.1038/mt.2010.167
   Read SP, 2010, J GENE MED, V12, P86, DOI 10.1002/jgm.1415
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rompani SB, 2008, P NATL ACAD SCI USA, V105, P192, DOI 10.1073/pnas.0709979104
   Rowan S, 2004, DEVELOPMENT, V131, P5139, DOI 10.1242/dev.01300
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schmitt S, 2009, INVEST OPHTH VIS SCI, V50, P5901, DOI 10.1167/iovs.08-3067
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Seehafer SS, 2011, J NEUROIMMUNOL, V230, P169, DOI 10.1016/j.jneuroim.2010.08.024
   Shiragami C, 1998, BRIT J OPHTHALMOL, V82, P1056, DOI 10.1136/bjo.82.9.1056
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sluch VM, 2014, DEV OPHTHALMOL, V53, P111, DOI 10.1159/000358409
   Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Soldner F, 2011, CELL, V146, P318, DOI 10.1016/j.cell.2011.06.019
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Stone E.M., 2007, AM J OPHTHALMOL
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   Stone EM, 2011, INVEST OPHTH VIS SCI, V52, P9665, DOI 10.1167/iovs.11-8527
   STREILEIN JW, 1981, J EXP MED, V153, P1058, DOI 10.1084/jem.153.5.1058
   STREILEIN JW, 1987, FASEB J, V1, P199, DOI 10.1096/fasebj.1.3.2957263
   Sun N, 2012, BIOTECHNOL J, V7, DOI 10.1002/biot.201200038
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892
   Tsang WY, 2008, DEV CELL, V15, P187, DOI 10.1016/j.devcel.2008.07.004
   Tucker Budd A, 2014, J Stem Cell Res Ther, V3, P161
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Van Dooremaal J.C., 1873, GRAEFE ARCH OPHTHAL, V19, P359
   Vasireddy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061396
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Waddington C. H, 1957, STRATEGY GENES DISCU
   Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025
   Warren L, 2012, SCI REP-UK, V2, DOI 10.1038/srep00657
   Weismann A., 1893, GERM PLASM THEORY HE
   Welsbie DS, 2013, P NATL ACAD SCI USA, V110, P4045, DOI 10.1073/pnas.1211284110
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wright A.F., 2013, PROG RETIN EYE RES, V37, P163
   Wu YX, 2013, CELL STEM CELL, V13, P659, DOI 10.1016/j.stem.2013.10.016
   Xu XH, 2013, STEM CELL RES, V10, P213, DOI 10.1016/j.scr.2012.11.005
   Yahata N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025788
   Yamanaka Shinya, 2006, Tanpakushitsu Kakusan Koso, V51, P2346
   Yang GS, 2002, J VIROL, V76, P7651, DOI 10.1128/JVI.76.15.7651-7660.2002
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yao J, 2011, BIOMATERIALS, V32, P1041, DOI 10.1016/j.biomaterials.2010.09.063
   Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yulin X, 2012, FOLIA BIOL-PRAGUE, V58, P221
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
NR 211
TC 82
Z9 87
U1 1
U2 56
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2015
VL 44
BP 15
EP 35
DI 10.1016/j.preteyeres.2014.10.002
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA0TC
UT WOS:000348628300002
PM 25448922
DA 2022-11-30
ER

PT J
AU Adini, I
   Ghosh, K
   Adini, A
   Chi, ZL
   Yoshimura, T
   Benny, O
   Connor, KM
   Rogers, MS
   Bazinet, L
   Birsner, AE
   Bielenberg, DR
   D'Amato, RJ
AF Adini, Irit
   Ghosh, Kaustabh
   Adini, Avner
   Chi, Zai-Long
   Yoshimura, Takeru
   Benny, Ofra
   Connor, Kip M.
   Rogers, Michael S.
   Bazinet, Lauren
   Birsner, Amy E.
   Bielenberg, Diane R.
   D'Amato, Robert J.
TI Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID MACULAR DEGENERATION; IN-VIVO; GROWTH-FACTOR; DIFFERENTIAL EXPRESSION;
   ENDOTHELIAL-CELLS; UVEAL MELANOMA; UNITED-STATES; MOUSE CORNEA;
   COLLAGEN; TYROSINASE
AB Studies have established that pigmentation can provide strong, protective effects against certain human diseases. For example, angiogenesis-dependent diseases such as wet age-related macular degeneration and infantile hemangioma are more common in light-skinned individuals of mixed European descent than in African-Americans. Here we found that melanocytes from light-skinned humans and albino mice secrete high levels of fibromodulin (FMOD), which we determined to be a potent angiogenic factor. FMOD treatment stimulated angiogenesis in numerous in vivo systems, including laser-induced choroidal neovascularization, growth factor-induced corneal neovascularization, wound healing, and Matrigel plug assays. Additionally, FMOD enhanced vascular sprouting during normal retinal development. Deletion of Fmod in albino mice resulted in a marked reduction in the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, and Matrigel plugs. Our data implicate the melanocyte-secreted factor FMOD as a key regulator of angiogenesis and suggest an underlying mechanism for epidemiological differences between light-skinned individuals of mixed European descent and African-Americans. Furthermore, inhibition of FMOD in humans has potential as a therapeutic strategy for treating angiogenesis-dependent diseases.
C1 [Adini, Irit; Adini, Avner; Chi, Zai-Long; Yoshimura, Takeru; Benny, Ofra; Rogers, Michael S.; Bazinet, Lauren; Birsner, Amy E.; Bielenberg, Diane R.; D'Amato, Robert J.] Harvard Univ, Sch Med, Boston Childrens Hosp, Vasc Biol Program,Dept Surg, Boston, MA 02115 USA.
   [Ghosh, Kaustabh] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
   [Connor, Kip M.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02115 USA.
   [D'Amato, Robert J.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of California System; University of California Riverside;
   Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School
RP Adini, I (通讯作者)，Harvard Univ, Sch Med, Boston Childrens Hosp, Vasc Biol Program,Dept Surg, 300 Longwood Ave, Boston, MA 02115 USA.
EM irit.adini@childrens.harvard.edu
RI Chi, Zai-Long/L-1523-2019; Rogers, Michael S/A-9814-2009; Adini,
   Avner/AAD-6141-2022; Benny, Ofra/AAB-3294-2021
OI Rogers, Michael S/0000-0002-5250-8434; Connor, Kip/0000-0002-2048-9080;
   Yoshimura, Takeru/0000-0002-5983-7193
FU NIH [R01EY012726]; NATIONAL EYE INSTITUTE [R01EY012726] Funding Source:
   NIH RePORTER
FX We acknowledge Ake Oldberg for generously sharing Fmod-KO mice. We also
   thank Alexeev Y. Vitali for murine melanocyte cells. This study was
   supported in part by a grant from the NIH (R01EY012726).
CR ABDELMALEK Z, 1994, PIGM CELL RES, V7, P326, DOI 10.1111/j.1600-0749.1994.tb00635.x
   ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789
   Adini A, 2009, J IMMUNOL METHODS, V342, P78, DOI 10.1016/j.jim.2008.11.016
   Alexeev V, 1998, NAT BIOTECHNOL, V16, P1343, DOI 10.1038/4322
   Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065
   Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0848com
   ANTONSSON P, 1991, J BIOL CHEM, V266, P16859
   Benedito E, 1997, BBA-GEN SUBJECTS, V1336, P59, DOI 10.1016/S0304-4165(97)00011-1
   Chakravarti S, 2002, GLYCOCONJUGATE J, V19, P287, DOI 10.1023/A:1025348417078
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costin GE, 2007, FASEB J, V21, P976, DOI 10.1096/fj.06-6649rev
   Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966
   Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779
   Fedorow H, 2005, PROG NEUROBIOL, V75, P109, DOI 10.1016/j.pneurobio.2005.02.001
   FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217
   Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022
   Gori F, 2001, J CELL BIOCHEM, V82, P46, DOI 10.1002/jcb.1115
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145
   HEDBOM E, 1989, J BIOL CHEM, V264, P6898
   HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4
   Hornyak TJ, 2000, J INVEST DERMATOL, V115, P106, DOI 10.1046/j.1523-1747.2000.00030.x
   Hu DN, 2005, AM J OPHTHALMOL, V140, P612, DOI 10.1016/j.ajo.2005.05.034
   KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x
   Ley CD, 2004, MICROVASC RES, V68, P161, DOI 10.1016/j.mvr.2004.06.002
   Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x
   Oldberg A, 2007, P NATL ACAD SCI USA, V104, P13966, DOI 10.1073/pnas.0702014104
   PROTA G, 1993, J INVEST DERMATOL, V100, pS156, DOI 10.1111/1523-1747.ep12465079
   Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   Sarangarajan R, 2005, MOL VIS, V11, P482
   Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007
   Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806
   Shao ES, 2009, BLOOD, V114, P2197, DOI 10.1182/blood-2009-01-199166
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Soo C, 2000, AM J PATHOL, V157, P423, DOI 10.1016/S0002-9440(10)64555-5
   Svensson L, 2000, FEBS LETT, V470, P178, DOI 10.1016/S0014-5793(00)01314-4
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Weis E, 2006, ARCH OPHTHALMOL-CHIC, V124, P54, DOI 10.1001/archopht.124.1.54
   WINDER A, 1994, CELL MOL BIOL RES, V40, P613
   YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5
   Zhang H, 2007, JPN J OPHTHALMOL, V51, P251, DOI 10.1007/s10384-007-0445-2
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 46
TC 48
Z9 48
U1 2
U2 20
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN
PY 2014
VL 124
IS 1
BP 425
EP 436
DI 10.1172/JCI69404
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 284PX
UT WOS:000329333500047
PM 24355922
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Boucherie, C
   Mukherjee, S
   Henckaerts, E
   Thrasher, AJ
   Sowden, JC
   Ali, RR
AF Boucherie, Cedric
   Mukherjee, Sayandip
   Henckaerts, Els
   Thrasher, Adrian J.
   Sowden, Jane C.
   Ali, Robin R.
TI Brief Report: Self-Organizing Neuroepithelium from Human Pluripotent
   Stem Cells Facilitates Derivation of Photoreceptors
SO STEM CELLS
LA English
DT Article
DE Embryonic; Induced pluripotent; Retina; Photoreceptors; Extracellular
   matrix; Three-dimensional culture
ID NUCLEAR RECEPTOR NR2E3; RETINAL PROGENITOR CELLS; ROD PHOTORECEPTORS;
   GENERATION; MOUSE; DIFFERENTIATION; TRANSPLANTATION; PRECURSORS; GENES;
   EXPRESSION
AB Retinitis pigmentosa, other inherited retinal diseases, and age-related macular degeneration lead to untreatable blindness because of the loss of photoreceptors. We have recently shown that transplantation of mouse photoreceptors can result in improved vision. It is therefore timely to develop protocols for efficient derivation of photoreceptors from human pluripotent stem (hPS) cells. Current methods for photoreceptor derivation from hPS cells require long periods of culture and are rather inefficient. Here, we report that formation of a transient self-organized neuroepithelium from human embryonic stem cells cultured together with extracellular matrix is sufficient to induce a rapid conversion into retinal progenitors in 5 days. These retinal progenitors have the ability to differentiate very efficiently into Crx(+) photoreceptor precursors after only 10 days and subsequently acquire rod photoreceptor identity within 4 weeks. Directed differentiation into photoreceptors using this protocol is also possible with human-induced pluripotent stem (hiPS) cells, facilitating the use of patient-specific hiPS cell lines for regenerative medicine and disease modeling. STEM CELLS 2013;31:408-414
C1 [Boucherie, Cedric; Ali, Robin R.] UCL Inst Ophthalmol, Dept Genet, London EC1V 9EL, England.
   [Mukherjee, Sayandip; Thrasher, Adrian J.; Ali, Robin R.] UCL Inst Child Hlth, Mol Immunol Unit, London, England.
   [Mukherjee, Sayandip; Thrasher, Adrian J.; Ali, Robin R.] UCL Inst Child Hlth, Ctr Immunodeficiency, London, England.
   [Sowden, Jane C.] UCL Inst Child Hlth, Dev Biol Unit, London, England.
   [Henckaerts, Els] Kings Coll London, Sch Med, Guys Hosp, Div Immunol Infect & Inflammatory Dis, London WC2R 2LS, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; University of London; University College London; Guy's & St
   Thomas' NHS Foundation Trust; University of London; King's College
   London
RP Ali, RR (通讯作者)，UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
EM r.ali@ucl.ac.uk
RI Henckaerts, Els/S-2727-2018
OI Thrasher, Adrian/0000-0002-6097-6115; Henckaerts, Els Jeanny
   V/0000-0002-4624-7856; Sowden, Jane/0000-0003-0937-2479
FU Medical Research Council U.K. [G03000341, G0901550 MR/J004553/1];
   Millers Trust; Great Ormond Street Hospital Children's Charity;
   Department of Health's National Institute for Health Research Biomedical
   Research Centre at Moorfields Eye Hospital; Medical Research Council
   [G0901550, MR/J004553/1, G0700438] Funding Source: researchfish;
   National Institute for Health Research [NF-SI-0508-10130,
   NF-SI-0611-10001] Funding Source: researchfish; Great Ormond Street
   Hospital Childrens Charity [V1257, V1259, V1223] Funding Source:
   researchfish; Fight for Sight [1351/52] Funding Source: researchfish;
   MRC [MR/J004553/1, G0700438, G0901550] Funding Source: UKRI
FX This work was supported by the Medical Research Council U.K. (G03000341,
   G0901550 MR/J004553/1) and by a grant from The Millers Trust. J.C.S. is
   supported by Great Ormond Street Hospital Children's Charity. R. R. A is
   partially funded by the Department of Health's National Institute for
   Health Research Biomedical Research Centre at Moorfields Eye Hospital.
CR Akita Y, 2008, FEBS J, V275, P3995, DOI 10.1111/j.1742-4658.2008.06557.x
   Boucherie C, 2011, REGEN MED, V6, P469, DOI [10.2217/RME.11.37, 10.2217/rme.11.37]
   Chambers SM, 2012, NAT BIOTECHNOL, V30, P715, DOI 10.1038/nbt.2249
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3
   Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173
   Cheng H, 2006, HUM MOL GENET, V15, P2588, DOI 10.1093/hmg/ddl185
   Cheng H, 2011, HUM MOL GENET, V20, P4102, DOI 10.1093/hmg/ddr334
   Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Eshghi S, 2007, J CELL BIOL, V177, P871, DOI 10.1083/jcb.200702080
   Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Kazanis I, 2010, J NEUROSCI, V30, P9771, DOI 10.1523/JNEUROSCI.0700-10.2010
   Kerever A, 2007, STEM CELLS, V25, P2146, DOI 10.1634/stemcells.2007-0082
   Kraehenbuehl TP, 2011, NAT METHODS, V8, P731, DOI 10.1038/nmeth.1671
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Li XJ, 2009, DEVELOPMENT, V136, P4055, DOI 10.1242/dev.036624
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mathers PH, 2000, CELL MOL LIFE SCI, V57, P186, DOI 10.1007/PL00000683
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Mellough CB, 2012, STEM CELLS, V30, P673, DOI 10.1002/stem.1037
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Muto A, 2009, EXP EYE RES, V89, P549, DOI 10.1016/j.exer.2009.05.006
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   O'Brien KMB, 2004, INVEST OPHTH VIS SCI, V45, P2807, DOI 10.1167/iovs.03-1317
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070
   Poche RA, 2008, J COMP NEUROL, V510, P237, DOI 10.1002/cne.21746
   Rider CC, 2006, BIOCHEM SOC T, V34, P458, DOI 10.1042/BST0340458
   Saha K, 2007, J BIOMED MATER RES A, V81A, P240, DOI 10.1002/jbm.a.30986
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
NR 39
TC 64
Z9 71
U1 0
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2013
VL 31
IS 2
BP 408
EP 414
DI 10.1002/stem.1268
PG 7
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 088YE
UT WOS:000314873000019
PM 23132794
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kanonidou, E
AF Kanonidou, E.
TI Reading performance and central field loss
SO HIPPOKRATIA
LA English
DT Review
DE reading; age-related macular degeneration; central field loss; review
ID EYE-MOVEMENTS; VISUAL IMPAIRMENT; RETINAL LOCUS; FIXATION; SPEED;
   PREVALENCE; VISION; ATTENTION; SCOTOMAS; FOVEAL
AB Age-related macular degeneration is a major cause of blindness in Europe and the U. S. and a leading cause of significant loss of visual acuity in elderly patients. Reading is a key visual task in everyday living involving a synthesis of a number of different motor, sensory and cognitive functions. When the centre of a reader's visual field is obscured, reading speed declines and oculomotor pattern differs, compared to normal reading. Improvement in the generation of visual stimuli using computer-generated images and projection/display systems as well as advances in eye movement recording techniques, including infrared pupil tracking and magnetic search coils, have contributed greatly to our understanding of these sensorimotor abnormalities. The developed reading strategies have been thoroughly investigated in individuals with central field loss either induced artificially or related to eye pathology.
   The following review aims at presenting the contemporary literature regarding the sensory and oculomotor deficits in reading ability, resulting from central field loss and should contribute to a greater understanding of the functional visual deficit caused by this visual impairment. Hippokratia 2011; 15 (2): 103-108
C1 [Kanonidou, E.] Gen Hosp Veria, Dept Ophthalmol, Veria, Greece.
RP Kanonidou, E (通讯作者)，Gen Hosp Veria, Dept Ophthalmol, 97 Vlasi Gavriilidi St, GR-55131 Thessaloniki, Greece.
EM evkanon@hotmail.com
CR Altpeter E, 2000, VISION RES, V40, P1539, DOI 10.1016/S0042-6989(00)00059-6
   Battista Josephine, 2005, Clin Exp Optom, V88, P313
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Chung STL, 2004, OPTOMETRY VISION SCI, V81, P525, DOI 10.1097/00006324-200407000-00014
   Chung STL, 2002, INVEST OPHTH VIS SCI, V43, P1270
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Decharms RC, 2008, NAT REV NEUROSCI, V9, P720, DOI 10.1038/nrn2414
   Deruaz A, 2004, BRIT J OPHTHALMOL, V88, P461, DOI 10.1136/bjo.2003.025601
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fine EM, 1999, VISION RES, V39, P1039, DOI 10.1016/S0042-6989(98)00208-9
   Fine EM, 1999, VISION RES, V39, P4274, DOI 10.1016/S0042-6989(99)00132-7
   Fine EM, 1999, VISION RES, V39, P747, DOI 10.1016/S0042-6989(98)00142-4
   Fornos AP, 2006, INVEST OPHTH VIS SCI, V47, P1439, DOI 10.1167/iovs.05-0973
   Frennesson C, 2007, ACTA OPHTHALMOL SCAN, V85, P868, DOI 10.1111/j.1600-0420.2007.00984.x
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Latham K, 1996, VISION RES, V36, P2665, DOI 10.1016/0042-6989(96)00022-3
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372
   RAYNER K, 1981, J EXP PSYCHOL HUMAN, V7, P167, DOI 10.1037/0096-1523.7.1.167
   RAYNER K, 1978, PSYCHOL BULL, V85, P618, DOI 10.1037/0033-2909.85.3.618
   Reichle ED, 2003, BEHAV BRAIN SCI, V26, P445, DOI 10.1017/S0140525X03000104
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   Safran AB, 1999, BRIT J OPHTHALMOL, V83, P1341, DOI 10.1136/bjo.83.12.1341
   Schlaggar BL, 2007, ANNU REV NEUROSCI, V30, P475, DOI 10.1146/annurev.neuro.28.061604.135645
   Seland JH, 2009, ACTA OPHTHALMOL
   Shaywitz BA, 2006, DEV NEUROPSYCHOL, V30, P613, DOI 10.1207/s15326942dn3001_5
   Shaywitz SE, 2008, DEV PSYCHOPATHOL, V20, P1329, DOI 10.1017/S0954579408000631
   Starr MS, 2001, TRENDS COGN SCI, V5, P156, DOI 10.1016/S1364-6613(00)01619-3
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 39
TC 5
Z9 5
U1 0
U2 3
PU LITHOGRAPHIA
PI THESSALONIKI
PA ANTONIADIS I-PSARRAS TH G P, NEA REDESTOS, THESSALONIKI, 00000, GREECE
SN 1108-4189
J9 HIPPOKRATIA
JI Hippokratia
PY 2011
VL 15
IS 2
BP 103
EP 108
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 759OD
UT WOS:000290256600001
PM 22110289
DA 2022-11-30
ER

PT J
AU Rao, C
   Yuan, XH
   Zhang, SJ
   Wang, QL
   Huang, YS
AF Rao, Cheng
   Yuan, Xiang-Hui
   Zhang, Si-Jie
   Wang, Qiu-Lin
   Huang, You-Shu
TI Epiretinal prosthesis for outer retinal degenerative diseases
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE outer retinal degeneration; retinal prosthesis; age-related macular
   degeneration; retinitis pigmentosa; epiretinal electrical stimulation;
   epiretinal prosthesis
AB Age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are common outer retinal degenerative problems, and also the predominant causes of most blinding retinal diseases. Retinal prosthesis is a promising solution for such photoreceptor degeneration diseases. Most of current concepts for a retinal prosthesis are based on neuronal electrical stimulation. In the past twenty years, retinal prosthesis has been developed in two different directions: epiretinal prosthesis and subretinal prosthesis Each prosthesis technique has its advantages and disadvantages. For epiretinal prosthesis, it is easier to be implanted and has the advantage of keeping most of the electronics in the vitreous cavity off the retinal surface, which greatly helps in dissipating the heat generated by the implant device. In this paper, a brief overview of retinal prostheses concepts is introduced. After that, several important aspects of epiretinal electrical stimulation will be discussed. Moreover, some practical epiretinal prosthesis devices developed by researchers in United States, Germany and Japan in the past have been reviewed. We hope that the devices will be used widely in the near future.
C1 [Rao, Cheng; Yuan, Xiang-Hui; Wang, Qiu-Lin; Huang, You-Shu] Chongqing Univ, Key Lab Optoelect Technol & Syst, Minist Educ, Chongqing 400044, Peoples R China.
   [Zhang, Si-Jie] Chongqing Univ, Key Lab Biomech & Tissue Engn, Minist Educ, Chongqing 400044, Peoples R China.
   [Wang, Qiu-Lin] Well Logging Co, Sichuan Petr Adm, Chongqing 400021, Peoples R China.
C3 Chongqing University; Chongqing University
RP Rao, C (通讯作者)，Chongqing Univ, Key Lab Optoelect Technol & Syst, Minist Educ, Chongqing 400044, Peoples R China.
EM guanyrc@sohu.com
FU National Natural Science Foundation of China [30470469]
FX Foundation item: National Natural Science Foundation of China (No.
   30470469)
CR BRUMMER SB, 1983, ANN NY ACAD SCI, V405, P159, DOI 10.1111/j.1749-6632.1983.tb31628.x
   BRUMMER SB, 1975, BIOELECTROCH BIOENER, V2, P13, DOI 10.1016/0302-4598(75)80002-X
   DEJUAN E, 1992, Patent No. 5109844
   Dokos S, 2005, IEEE T NEUR SYS REH, V13, P137, DOI 10.1109/TNSRE.2005.847390
   Humayun M S, 2001, Trans Am Ophthalmol Soc, V99, P271
   Kendir GA, 2005, IEEE T CIRCUITS-I, V52, P857, DOI 10.1109/TCSI.2005.846208
   Kolb H, 2003, AM SCI, V91, P28, DOI 10.1511/2003.11.841
   LIU W, 2000, MULTIPLE UNIT ARTIFI, pCH2
   Liu WT, 2000, IEEE J SOLID-ST CIRC, V35, P1487, DOI 10.1109/4.871327
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Mazza M, 2005, IEEE SENS J, V5, P32, DOI 10.1109/JSEN.2004.839895
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Piyathaisere DV, 2001, INVEST OPHTH VIS SCI, V42, pS814
   Rattay F, 1998, IEEE T BIO-MED ENG, V45, P766, DOI 10.1109/10.678611
   Schwarz M, 2000, SENSOR ACTUAT A-PHYS, V83, P40, DOI 10.1016/S0924-4247(00)00290-9
   Sivaprakasam M, 2005, IEEE J SOLID-ST CIRC, V40, P763, DOI 10.1109/JSSC.2005.843630
   Szlavik RB, 2000, IEEE T BIO-MED ENG, V47, P1202, DOI 10.1109/10.867947
   TANG Y, 2006, INT J OPHTHALMOL, V6, P1393
   Uehara A, 2003, ELECTRON LETT, V39, P1102, DOI 10.1049/el:20030742
   Ziegler D, 2004, SENSOR ACTUAT A-PHYS, V110, P11, DOI 10.1016/j.sna.2003.09.040
NR 20
TC 2
Z9 2
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2008
VL 1
IS 3
BP 273
EP 276
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V13QY
UT WOS:000207682500017
DA 2022-11-30
ER

PT J
AU Okuda, T
   Nishimura, A
   Kobayashi, A
   Sugiyama, K
AF Okuda, Tetsuhiko
   Nishimura, Akira
   Kobayashi, Akira
   Sugiyama, Kazuhisa
TI Postoperative retinal break after 25-gauge transconjunctival sutureless
   vitrectomy: report of four cases
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE 25-gauge transconjunctival sutureless vitrectomy; retinal break; macular
   hole
ID VITREOUS SURGERY; MACULAR HOLES; COMPLICATIONS; OUTCOMES; SYSTEM
AB Background: A 25-gauge transconjunctival sutureless vitrectomy (TSV) has been reported effective. However, complications such as postoperative retinal detachment have been reported. In this study, we report four cases of retinal breaks found after 25-gauge TSV. In this study, we investigated factors contributing to occurrence of postoperative complications.
   Methods: Seventy-five patients (75 eyes) underwent 25-gauge TSV surgery at Kanazawa University hospital between April 2004 and September 2005. Postoperative follow-up monitoring was done for at least 3 months. The surgical charts were reviewed.
   Results: Retinal breaks not accompanied by retinal detachment were noted postoperatively in four patients. All four of these patients had preoperative idiopathic macular holes. In all cases, there was no vitreous traction around the retinal break and photo coagulation was performed. One eye with age-related macular degeneration developed intraoperative rhegmatogenous retinal detachment. No other complications were observed during the intraoperative and postoperative periods.
   Conclusions: Upon performing 25-gauge TSV for macular hole repair, care should be taken to detect retinal breaks and retinal detachment intraoperatively and postoperatively.
C1 Kanazawa Univ, Grad Sch Med Sci, Dept Ophthalmol, Kanazawa, Ishikawa 920, Japan.
C3 Kanazawa University
RP Nishimura, A (通讯作者)，Kanazawa Univ, Grad Sch Med Sci, Dept Ophthalmol, Kanazawa, Ishikawa 920, Japan.
EM eyenishi@med.kanazawa-u.ac.jp
CR Banker AS, 1997, OPHTHALMOLOGY, V104, P1442, DOI 10.1016/S0161-6420(97)30118-3
   DEJUAN E, 1990, AM J OPHTHALMOL, V109, P218, DOI 10.1016/S0002-9394(14)75990-2
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1814, DOI 10.1016/S0161-6420(02)01119-3
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   Ibarra MS, 2005, AM J OPHTHALMOL, V139, P831, DOI 10.1016/j.ajo.2004.12.002
   Lakhanpal RR, 2005, OPHTHALMOLOGY, V112, P817, DOI 10.1016/j.ophtha.2004.11.053
   PARK SS, 1995, OPHTHALMOLOGY, V102, P775, DOI 10.1016/S0161-6420(95)30956-6
   WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1671
NR 8
TC 19
Z9 20
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2007
VL 245
IS 1
BP 155
EP 157
DI 10.1007/s00417-006-0354-y
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 111OE
UT WOS:000242461600020
PM 16710667
DA 2022-11-30
ER

PT J
AU Padhy, B
   Alone, DP
AF Padhy, Biswajit
   Alone, Debasmita Pankaj
TI Is pseudoexfoliation glaucoma a neurodegenerative disorder?
SO JOURNAL OF BIOSCIENCES
LA English
DT Review
DE Alzheimer's disease; extracellular matrix; glaucoma; neurodegenerative
   disorders; optic nerve head cells; pseudoexfoliation
ID OPEN-ANGLE GLAUCOMA; SHOCK TRANSCRIPTION FACTOR-1; APOLIPOPROTEIN-E
   GENOTYPES; GENOME-WIDE ASSOCIATION; RETINAL GANGLION-CELLS;
   NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; RISK-FACTOR; OXIDATIVE
   STRESS; MACULAR DEGENERATION
AB Pseudoexfoliation (PEX) is a systemic age-related progressive disorder with ocular manifestations. The earlier stage of the disease, pseudoexfoliation syndrome (PEXS) involves deposition of white fibrillar aggregates on anterior and posterior eye tissues. It is also the cause of most common form of secondary glaucoma known as pseudoexfoliation glaucoma (PEXG). Studies in the past decade highlight the role of many genetic and environmental factors as the underlying cause of PEX pathogenesis. Latest research findings by various researchers and us present the view of PEX as a type of neurodegenerative disorder. Epidemiological studies have shown association of PEX with different forms of neurodegenerative diseases like Alzheimer's, age-related macular degeneration and open angle glaucoma. Also, sharing of common genetic risk factors, abnormal protein aggregation and most importantly, progressive degeneration of neurons with age are some of the identifiable features seen in both PEX and other neurodegenerative diseases. In this review, we have compared the pathological symptoms and factors involved in the disease manifestation of PEXG with various forms of neurodegenerative disorders and categorized PEXG as a progressive neurodegenerative disorder.
C1 [Padhy, Biswajit; Alone, Debasmita Pankaj] Natl Inst Sci Educ & Res NISER, Sch Biol Sci, Bhubaneswar 752050, Khurda, India.
C3 National Institute of Science Education & Research (NISER)
RP Alone, DP (通讯作者)，Natl Inst Sci Educ & Res NISER, Sch Biol Sci, Bhubaneswar 752050, Khurda, India.
EM debasmita@niser.ac.in
FU Microbes and Disease Biology Project, National Institute of Science
   Education and Research, Department of Atomic Energy (India)
   [XII-RD-NIS-5.04-02]; Science and Engineering Research Board (India)
   [CRG/2019/002705]
FX The authors thank their Clinical Collaborator, Dr. Pranjya P. Mohanty
   and Dr. Rohit Mendke for sharing the picture of a PEX affected eye. The
   authors also thank Ms. Ramani Shyam Kapuganti and Dr. Bushra Hayat for
   their feedback with editing. This work was supported by the
   institutional intramural grant to Debasmita P. Alone from Microbes and
   Disease Biology Project (Project No.: XII-R&D-NIS-5.04-02), National
   Institute of Science Education and Research, Department of Atomic Energy
   (India); and extramural research grant (Project No.: CRG/2019/002705)
   from Science and Engineering Research Board (India).
CR Abe T, 2000, ARCH OPHTHALMOL-CHIC, V118, P1415
   Abraham S, 2005, INDIAN J MED RES, V121, P111
   Abu-Amero KK, 2008, MOL VIS, V14, P425
   Abu-Amero KK, 2011, MOL VIS, V17, P2769
   Akarsu C, 2005, EYE, V19, P1297, DOI 10.1038/sj.eye.6701776
   Allingham RR, 2001, BRIT J OPHTHALMOL, V85, P702, DOI 10.1136/bjo.85.6.702
   AMARI F, 1994, INVEST OPHTH VIS SCI, V35, P3962
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984
   Andrich J, 2004, MOVEMENT DISORD, V19, P226, DOI 10.1002/mds.10629
   Andrikopoulos GK, 2014, WORLD J CARDIOL, V6, P847, DOI 10.4330/wjc.v6.i8.847
   Ansari R, 2014, J CLIN NEUROL, V10, P281, DOI 10.3988/jcn.2014.10.4.281
   Arlt S, 2012, J ALZHEIMERS DIS, V31, P751, DOI 10.3233/JAD-2012-112138
   Arnarsson AM, 2010, ACTA OPHTHALMOL, V88, P8, DOI 10.1111/j.1755-3768.2009.01806.x
   Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103
   Aung T, 2015, NAT GENET, V47, P387, DOI 10.1038/ng.3226
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   Bayer AU, 2002, EYE, V16, P209, DOI 10.1038/sj/EYE/6700034
   Beyer K, 2009, INT J MOL SCI, V10, P724, DOI 10.3390/ijms10030724
   Blasco H, 2014, CURR MED CHEM, V21, P3551, DOI 10.2174/0929867321666140916120118
   Bleich S, 2004, AM J OPHTHALMOL, V138, P162, DOI 10.1016/j.ajo.2004.02.027
   Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9
   Brandstatter JH, 1998, VISION RES, V38, P1385, DOI 10.1016/S0042-6989(97)00176-4
   Braunsmann C, 2012, INVEST OPHTH VIS SCI, V53, P2960, DOI 10.1167/iovs.11-8409
   Brkic M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/620581
   Browne JG, 2011, INVEST OPHTH VIS SCI, V52, P3660, DOI 10.1167/iovs.10-5209
   Burdon KP, 2008, MOL VIS, V14, P1727
   Burton T, 2002, BIOCHEM BIOPH RES CO, V295, P713, DOI 10.1016/S0006-291X(02)00725-8
   Caccamo AE, 2004, BIOCHEM J, V382, P157, DOI 10.1042/BJ20040158
   Cady J, 2014, JAMA NEUROL, V71, P449, DOI 10.1001/jamaneurol.2013.6237
   Cahill M, 2002, EYE, V16, P261, DOI 10.1038/sj.eye.6700011
   Caraci F, 2011, CNS NEUROSCI THER, V17, P237, DOI 10.1111/j.1755-5949.2009.00115.x
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chapuis J, 2017, ACTA NEUROPATHOL, V133, P955, DOI 10.1007/s00401-016-1652-z
   Chaudhary P, 1998, BRAIN RES, V792, P154, DOI 10.1016/S0006-8993(98)00212-1
   Chen YC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002672
   Chiras Dimitrios, 2013, Mol Vis, V19, P1006
   Citirik M, 2007, EYE, V21, P11, DOI 10.1038/sj.eye.6702177
   Collier TJ, 2011, NAT REV NEUROSCI, V12, P359, DOI 10.1038/nrn3039
   Cumurcu T, 2013, SEMIN OPHTHALMOL, V28, P224, DOI 10.3109/08820538.2013.793726
   Daimon M, 2011, METABOLISM, V60, P815, DOI 10.1016/j.metabol.2010.07.033
   Damji K F, 1998, Ophthalmic Genet, V19, P175
   Davis AA, 2018, ANNU REV CELL DEV BI, V34, P545, DOI 10.1146/annurev-cellbio-100617-062636
   DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299
   Denier C, 2001, ARCH NEUROL-CHICAGO, V58, P292, DOI 10.1001/archneur.58.2.292
   Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1422, DOI 10.1001/archneur.57.10.1422
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Domingues C, 2017, CURR ALZHEIMER RES, V14, P870, DOI 10.2174/1567205014666170317113606
   Dourlen P, 2017, MOL PSYCHIATR, V22, P874, DOI 10.1038/mp.2016.59
   Duits FH, 2015, J ALZHEIMERS DIS, V48, P711, DOI 10.3233/JAD-143186
   Dursan F, 2015, INT J OPHTHALMOL-CHI, V8, P985, DOI 10.3980/j.issn.2222-3959.2015.05.24
   Dursun A, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3545180
   Ekstrom C, 2014, ACTA OPHTHALMOL, V92, P355, DOI 10.1111/aos.12184
   Faideau M, 2010, HUM MOL GENET, V19, P3053, DOI 10.1093/hmg/ddq212
   Fan BJ, 2005, MOL VIS, V11, P625
   Fang F, 2018, HUM MOL GENET, V27, P1002, DOI 10.1093/hmg/ddy017
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   Fifita JA, 2017, AMYOTROPH LAT SCL FR, V18, P126, DOI 10.1080/21678421.2016.1218517
   Flaherty E, 2017, NPJ SCHIZOPHR, V3, DOI 10.1038/s41537-017-0033-5
   Fountoulakis N, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-69
   Friedman JI, 2008, MOL PSYCHIATR, V13, P261, DOI 10.1038/sj.mp.4002049
   Friend KL, 1999, HUM GENET, V105, P261, DOI 10.1007/s004390051099
   Fujimoto M, 2005, J BIOL CHEM, V280, P34908, DOI 10.1074/jbc.M506288200
   Fyfe I, 2020, NAT REV NEUROL, V16, P185, DOI 10.1038/s41582-020-0335-5
   Gao JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024211
   Ghiso Jorge, 2010, Hirosaki Igaku, V61, pS111
   Giri M, 2016, CLIN INTERV AGING, V11, P665, DOI 10.2147/CIA.S105769
   Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211
   Gomez-Pastor R, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14405
   Gonzalez-Iglesias H, 2014, J PROTEOMICS, V98, P65, DOI 10.1016/j.jprot.2013.12.006
   Guerreiro R, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0232-5
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hayat B, 2020, J HUM GENET, V65, P517, DOI 10.1038/s10038-020-0736-8
   Hayat B, 2019, EXP EYE RES, V181, P197, DOI 10.1016/j.exer.2019.02.004
   HENRY JC, 1987, OPHTHALMOLOGY, V94, P545, DOI 10.1016/S0161-6420(87)33413-X
   Hindle JV, 2010, AGE AGEING, V39, P156, DOI 10.1093/ageing/afp223
   Honjo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141293
   Honti Viktor, 2005, Neuropsychiatr Dis Treat, V1, P125, DOI 10.2147/nedt.1.2.125.61044
   Horresh I, 2008, J NEUROSCI, V28, P14213, DOI 10.1523/JNEUROSCI.3398-08.2008
   Hosseini H, 2011, EYE, V25, P1245, DOI 10.1038/eye.2011.140
   Huang WJ, 2016, BIOMED REP, V4, P519, DOI 10.3892/br.2016.630
   Huang YD, 2014, NEUROBIOL DIS, V72, P3, DOI 10.1016/j.nbd.2014.08.025
   Hussain AA, 2017, J NEURODEGENER DIS, V2017
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Infante J, 2015, NEUROBIOL AGING, V36, P1105, DOI 10.1016/j.neurobiolaging.2014.10.039
   Ingre C, 2015, CLIN EPIDEMIOL, V7, P181, DOI 10.2147/CLEP.S37505
   Irvine GB, 2008, MOL MED, V14, P451, DOI 10.2119/2007-00100.Irvine
   Itzhaki RF, 2016, J ALZHEIMERS DIS, V51, P979, DOI 10.3233/JAD-160152
   Janciauskiene S, 2001, ACTA OPHTHALMOL SCAN, V79, P328, DOI 10.1034/j.1600-0420.2001.790327.x
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jay TR, 2017, J NEUROSCI, V37, P637, DOI [10.1523/JNEUROSCI.2110-16.2016, 10.1523/JNEUROSCI.2110-16.2017]
   Jelodari-Mamaghani S, 2013, MOL VIS, V19, P333
   Jeng SM, 2007, J GLAUCOMA, V16, P117, DOI 10.1097/01.ijg.0000243470.13343.8b
   Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291
   Jiang YQ, 2013, BRAIN RES, V1519, P105, DOI 10.1016/j.brainres.2013.04.059
   Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaja S, 2010, J NEUROPHYSIOL, V104, P1445, DOI 10.1152/jn.00012.2010
   Kamphuis W, 2014, NEUROBIOL AGING, V35, P492, DOI 10.1016/j.neurobiolaging.2013.09.035
   Kang JH, 2014, AM J OPHTHALMOL, V158, P605, DOI 10.1016/j.ajo.2014.05.015
   Kara S, 2014, CLIN OPHTHALMOL, V8, P305, DOI 10.2147/OPTH.S55914
   Karagiannis D, 2015, CLIN INTERV AGING, V10, P879, DOI 10.2147/CIA.S77630
   Kempf SJ, 2016, ONCOTARGET, V7, P71817, DOI 10.18632/oncotarget.12376
   Khalef Nervana, 2017, Electron Physician, V9, P3833, DOI 10.19082/3833
   Khan MI, 2009, MOL VIS, V15, P2861
   Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609
   Kivinen N, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13753
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kondo N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2417
   Koola MM, 2016, INDIAN J PSYCHOL MED, V38, P97, DOI 10.4103/0253-7176.178766
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Kravietz A, 2017, ENVIRON RES, V154, P50, DOI 10.1016/j.envres.2016.12.008
   KRIEGLSTEIN K, 1994, NEUROSCIENCE, V63, P1189, DOI 10.1016/0306-4522(94)90583-5
   Krumbiegel M, 2011, EUR J HUM GENET, V19, P186, DOI 10.1038/ejhg.2010.144
   Krumbiegel M, 2010, J GLAUCOMA, V19, P561, DOI 10.1097/IJG.0b013e3181ca76c4
   Krumbiegel M, 2009, INVEST OPHTH VIS SCI, V50, P2796, DOI 10.1167/iovs.08-2339
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lattante S, 2013, NEUROBIOL AGING, V34, DOI 10.1016/j.neurobiolaging.2013.04.030
   Lesiewska H, 2015, ACTA OPHTHALMOL, V93, pE322, DOI 10.1111/aos.12612
   Lesiewska-Junk H, 2013, ACTA OPHTHALMOL, V91, pE648, DOI 10.1111/aos.12206
   Li J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142887
   Li S, 1997, J NEUROPATH EXP NEUR, V56, P901, DOI 10.1097/00005072-199708000-00008
   LI ZY, 1988, CURR EYE RES, V7, P1163, DOI 10.3109/02713688809033220
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Linner E, 2001, ACTA OPHTHALMOL SCAN, V79, P283, DOI 10.1034/j.1600-0420.2001.790314.x
   LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288
   Lippa CF, 1995, NEURODEGENERATION, V4, P425, DOI 10.1006/neur.1995.0051
   Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302
   Liu ZZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02647
   Lorenzl S, 2002, EXP NEUROL, V178, P13, DOI 10.1006/exnr.2002.8019
   Malukiewicz G, 2011, ACTA OPHTHALMOL, V89, pE64, DOI 10.1111/j.1755-3768.2010.02083.x
   Marcus DL, 1998, EXP NEUROL, V150, P40, DOI 10.1006/exnr.1997.6750
   Mariani LL, 2016, JAMA NEUROL, V73, P1105, DOI 10.1001/jamaneurol.2016.2215
   Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449
   May CA, 2015, OPEN OPHTHALMOL J, V9, P20, DOI 10.2174/1874364101509010020
   Mitchell P, 1997, AM J OPHTHALMOL, V124, P685, DOI 10.1016/S0002-9394(14)70908-0
   Mohammed FF, 2003, ANN RHEUM DIS, V62, P43
   Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Neef DW, 2011, NAT REV DRUG DISCOV, V10, P930, DOI 10.1038/nrd3453
   Nelson JW, 2014, PROSTAG OTH LIPID M, V113, P30, DOI 10.1016/j.prostaglandins.2014.09.003
   O'Hare F, 2012, CLIN EXP OPHTHALMOL, V40, P895, DOI 10.1111/j.1442-9071.2012.02812.x
   Omar Rawhi A., 1999, J Alzheimers Dis, V1, P139
   Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140
   Ovodenko B, 2007, INVEST OPHTH VIS SCI, V48, P1447, DOI 10.1167/iovs.06-0411
   Padhy B, 2019, EUR J HUM GENET, V27, P1858, DOI 10.1038/s41431-019-0482-6
   Padhy B, 2017, HUM MOL GENET, V26, P4519, DOI 10.1093/hmg/ddx329
   Padhy B, 2014, EXP EYE RES, V127, P69, DOI 10.1016/j.exer.2014.07.005
   Park BC, 2007, GENES CELLS, V12, P969, DOI 10.1111/j.1365-2443.2007.01102.x
   Pasutto F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15466
   Pena JDO, 1998, EXP EYE RES, V67, P517, DOI 10.1006/exer.1998.0539
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Poot M, 2015, MOL SYNDROMOL, V6, P7, DOI 10.1159/000371594
   Pottier C, 2015, ACTA NEUROPATHOL, V130, P77, DOI 10.1007/s00401-015-1436-x
   Pradotto L, 2016, J NEUROL SCI, V371, P81, DOI 10.1016/j.jns.2016.10.029
   Ravaglia G, 2005, AM J CLIN NUTR, V82, P636, DOI 10.1093/ajcn/82.3.636
   Reeve A, 2014, AGEING RES REV, V14, P19, DOI 10.1016/j.arr.2014.01.004
   Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231
   Reniewska Barbara, 2004, Klin Oczna, V106, P107
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Ritch R, 2003, PROG RETIN EYE RES, V22, P253, DOI 10.1016/S1350-9462(02)00014-9
   Ritch R, 1994, J Glaucoma, V3, P176
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   Rodenas-Cuadrado P, 2014, EUR J HUM GENET, V22, P171, DOI 10.1038/ejhg.2013.100
   Roher AE, 2009, ALZHEIMERS DEMENT, V5, P18, DOI 10.1016/j.jalz.2008.10.004
   Ronci M, 2013, J PROTEOMICS, V82, P27, DOI 10.1016/j.jprot.2013.01.008
   Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0
   Rothstein JD, 2009, ANN NEUROL, V65, pS3, DOI 10.1002/ana.21543
   Saadat P, 2018, PARKINSONS DIS-US, V2018, DOI 10.1155/2018/5813084
   Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018
   Sasaki K, 2002, ACTA NEUROPATHOL, V104, P225, DOI 10.1007/s00401-002-0546-4
   Schlotzer-Schrehardt U, 2006, AM J OPHTHALMOL, V141, P921, DOI 10.1016/j.ajo.2006.01.047
   Schlotzer-Schrehardt U, 2001, CURR EYE RES, V22, P154, DOI 10.1076/ceyr.22.2.154.5522
   SCHLOTZERSCHREHARDT U, 1995, INVEST OPHTH VIS SCI, V36, P1750
   SCHLOTZERSCHREHARDT U, 1992, CURR EYE RES, V11, P343, DOI 10.3109/02713689209001788
   SCHLOTZERSCHREHARDT UM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1752, DOI 10.1001/archopht.1992.01080240092038
   Schober A, 2007, NEUROBIOL DIS, V25, P378, DOI 10.1016/j.nbd.2006.10.005
   Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498
   Schwab C, 2012, NEUROSCI LETT, V506, P149, DOI 10.1016/j.neulet.2011.10.070
   SCUDIERO DA, 1986, MUTAT RES, V159, P125, DOI 10.1016/0027-5107(86)90121-1
   Serrano-Pozo A, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006189
   Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613
   Sharma S, 2009, EXP EYE RES, V89, P479, DOI 10.1016/j.exer.2009.05.001
   Shazly TA, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-18
   Silvestroni A, 2009, NEUROREPORT, V20, P1098, DOI 10.1097/WNR.0b013e32832e34ee
   Simpson JE, 2010, NEUROBIOL AGING, V31, P578, DOI 10.1016/j.neurobiolaging.2008.05.015
   Sims R, 2017, NAT GENET, V49, P1373, DOI 10.1038/ng.3916
   Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170
   Sorkhabi Rana, 2013, Oman Med J, V28, P16, DOI 10.5001/omj.2013.04
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stein JD, 2011, ARCH OPHTHALMOL-CHIC, V129, P1053, DOI 10.1001/archophthalmol.2011.191
   STREETEN BW, 1990, AM J OPHTHALMOL, V110, P490, DOI 10.1016/S0002-9394(14)77871-7
   STREETEN BW, 1992, ARCH OPHTHALMOL-CHIC, V110, P1757, DOI 10.1001/archopht.1992.01080240097039
   Strzalka-Mrozik B, 2013, MOL VIS, V19, P1341
   Su F, 2016, NEUROSCI BULL, V32, P469, DOI 10.1007/s12264-016-0055-4
   Sundaramoorthy V, 2015, HUM MOL GENET, V24, P3830, DOI 10.1093/hmg/ddv126
   Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699
   Tanito M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049680
   Tantsis EM, 2016, DEV MED CHILD NEUROL, V58, P639, DOI 10.1111/dmcn.13033
   TERRY RD, 1981, ANN NEUROL, V10, P184, DOI 10.1002/ana.410100209
   Thomas R, 2005, INVEST OPHTH VIS SCI, V46, P1170, DOI 10.1167/iovs.04-1062
   Tojo N, 2016, J GLAUCOMA, V25, pE463, DOI 10.1097/IJG.0000000000000292
   Tomaszewski BT, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/123683
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   Troncone L, 2016, J AM COLL CARDIOL, V68, P2395, DOI 10.1016/j.jacc.2016.08.073
   Trotti D, 2001, J BIOL CHEM, V276, P576, DOI 10.1074/jbc.M003779200
   Turkcu FM, 2013, MEDICINA-LITHUANIA, V49, P214, DOI 10.3390/medicina49050034
   Usdin K, 2000, CELL MOL LIFE SCI, V57, P914, DOI 10.1007/PL00000734
   van Abel D, 2012, J ALZHEIMERS DIS, V31, P793, DOI 10.3233/JAD-2012-120472
   van Dijk KD, 2013, PARKINSONISM RELAT D, V19, P1079, DOI 10.1016/j.parkreldis.2013.07.016
   Varea O, 2015, P NATL ACAD SCI USA, V112, P6176, DOI 10.1073/pnas.1423205112
   Vazquez Luis E, 2014, Int Ophthalmol Clin, V54, P1, DOI 10.1097/IIO.0000000000000047
   Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
   von Bernhardi R, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00426
   Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618
   Vulovic TSS, 2016, INT J OPHTHALMOL-CHI, V9, P1138, DOI 10.18240/ijo.2016.08.09
   Wallace DM, 2013, INVEST OPHTH VIS SCI, V54, P7836, DOI 10.1167/iovs.13-12494
   Wang K, 2019, ACTA BIOCH BIOPH SIN, V51, P1, DOI 10.1093/abbs/gmy145
   Wang KX, 2018, AM J MED SCI, V356, P552, DOI 10.1016/j.amjms.2018.08.018
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang XX, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/908636
   Wang X, 2014, J NEUROSCI, V34, P7253, DOI 10.1523/JNEUROSCI.4936-13.2014
   Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114
   Weil R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01243
   Wojsiat J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6435861
   Wu YR, 2004, HUM GENET, V114, P236, DOI 10.1007/s00439-003-1050-1
   Yagci R, 2008, EYE, V22, P128, DOI 10.1038/sj.eye.6702751
   Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com
   Yildirim Z, 2013, INT J OPHTHALMOL-CHI, V6, P50, DOI 10.3980/j.issn.2222-3959.2013.01.10
   Yilmaz A, 2005, EXP EYE RES, V80, P871, DOI 10.1016/j.exer.2004.12.018
   Yilmaz A, 2011, AM J OPHTHALMOL, V151, P272, DOI 10.1016/j.ajo.2010.08.032
   Yin J, 2016, TRAFFIC, V17, P1286, DOI 10.1111/tra.12451
   Yuksel N, 2006, GRAEF ARCH CLIN EXP, V244, P316, DOI 10.1007/s00417-004-0942-7
   Zenkel M, 2005, INVEST OPHTH VIS SCI, V46, P3742, DOI 10.1167/iovs.05-0249
   Zenkel M, 2006, INVEST OPHTH VIS SCI, V47, P1982, DOI 10.1167/iovs.05-1580
   Zenkel M, 2010, AM J PATHOL, V176, P2868, DOI 10.2353/ajpath.2010.090914
   Zheng SQ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000838
   Zhou Q, 2012, AM J HUM GENET, V91, P713, DOI 10.1016/j.ajhg.2012.08.006
NR 239
TC 1
Z9 1
U1 3
U2 4
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-5991
EI 0973-7138
J9 J BIOSCIENCES
JI J. Biosci.
PD DEC
PY 2021
VL 46
IS 4
AR 97
DI 10.1007/s12038-021-00217-8
PG 24
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA WT3MA
UT WOS:000715771000002
PM 34785624
DA 2022-11-30
ER

PT J
AU Suzumura, A
   Terao, R
   Kaneko, H
AF Suzumura, Ayana
   Terao, Ryo
   Kaneko, Hiroki
TI Protective Effects and Molecular Signaling of n-3 Fatty Acids on
   Oxidative Stress and Inflammation in Retinal Diseases
SO ANTIOXIDANTS
LA English
DT Review
DE oxidative stress; n-3 fatty acid; eicosapentaenoic acid; docosahexaenoic
   acid; retinopathy of prematurity; diabetic retinopathy; age-related
   macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B;
   PRORESOLVING LIPID MEDIATORS; OXYGEN-INDUCED RETINOPATHY; NITRIC-OXIDE
   PRODUCTION; BIRTH-WEIGHT INFANTS; ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC
   ACID; MACULAR DEGENERATION
AB Oxidative stress and inflammation play crucial roles in the development and progression of retinal diseases. Retinal damage by various etiologies can result in retinopathy of prematurity (ROP), diabetic retinopathy (DR), and age-related macular degeneration (AMD). n-3 fatty acids are essential fatty acids and are necessary for homeostasis. They are important retinal membrane components and are involved in energy storage. n-3 fatty acids also have antioxidant and anti-inflammatory properties, and their suppressive effects against ROP, DR, and AMD have been previously evaluated. alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and their metabolites have been shown to alleviate retinal oxidative stress and inflammation involving various biological signaling pathways. In this review, we summarize the current understanding of the n-3 fatty acids effects on the mechanisms of these retinal diseases and how they exert their therapeutic effects, focusing on ALA, EPA, DHA, and their metabolites. This knowledge may provide new remedial strategies for n-3 fatty acids in the prevention and treatment of retinal diseases associated with oxidative stress and inflammation.
C1 [Suzumura, Ayana; Kaneko, Hiroki] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
   [Terao, Ryo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.
C3 Nagoya University; University of Tokyo
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
EM a.suzumura@med.nagoya-u.ac.jp; rterao-tky@umin.ac.jp;
   h-kaneko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022; Terao, Ryo/AAV-3334-2020
OI Kaneko, Hiroki/0000-0003-0731-6465; Terao, Ryo/0000-0001-6182-4343
FU JSPS KAKENHI [19K09988]; Eye Research Foundation for the Aged (ERFA);
   Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen
   Pharmaceutical's Founder; Bayer RetinaAward Foundation; Ichihara
   International Scholarship Foundation
FX We thank Robert Blakytny, DPhil, from Edanz Group
   (https://en-author-services.edanzgroup.com/ac) for editing a draft of
   this manuscript. This work was partially supported by Grants-in-Aid for
   Scientific Research (C) (H.K., 19K09988) from JSPS KAKENHI
   (http://www.jsps.go.jp/), the Eye Research Foundation for the Aged
   (ERFA, H.K.), the Charitable Trust Fund for Ophthalmic Research in
   Commemoration of Santen Pharmaceutical's Founder (H.K.), the Bayer
   RetinaAward Foundation (H.K.), and Ichihara International Scholarship
   Foundation (H.K.).
CR Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912
   Bang SS, 2018, J CLIN INVEST, V128, P3568, DOI 10.1172/JCI99888
   Barcelo-Coblijn G, 2009, PROG LIPID RES, V48, P355, DOI 10.1016/j.plipres.2009.07.002
   Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4
   Bathina S, 2017, BIOCHEM BIOPH RES CO, V486, P406, DOI 10.1016/j.bbrc.2017.03.054
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Beharry KD, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7110160
   Beken S, 2014, EARLY HUM DEV, V90, P27, DOI 10.1016/j.earlhumdev.2013.11.002
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bernabe-Garcia M, 2019, JPEN-PARENTER ENTER, V43, P874, DOI 10.1002/jpen.1497
   Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205
   Bouwens M, 2009, AM J CLIN NUTR, V90, P415, DOI 10.3945/ajcn.2009.27680
   Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Busch EM, 1999, VISION RES, V39, P1233, DOI 10.1016/S0042-6989(98)00233-8
   Byfield G, 2009, INVEST OPHTH VIS SCI, V50, P3360, DOI 10.1167/iovs.08-3256
   Cai M, 2015, BRIT J OPHTHALMOL, V99, P125, DOI 10.1136/bjophthalmol-2014-305690
   Calandria JM, 2009, J BIOL CHEM, V284, P17877, DOI 10.1074/jbc.M109.003988
   Calderon GD, 2017, EYE, V31, P1122, DOI 10.1038/eye.2017.64
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   CARLSON SE, 1993, P NATL ACAD SCI USA, V90, P1073, DOI 10.1073/pnas.90.3.1073
   Casanova MA, 2017, J AM SOC HYPERTENS, V11, P10, DOI 10.1016/j.jash.2016.10.004
   Cecilia OM, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/8562408
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choudhary R, 2017, J CURR OPHTHALMOL, V29, P7, DOI 10.1016/j.joco.2016.09.009
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18930-6
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cox R, 2015, AM J RESP CELL MOL, V53, P422, DOI 10.1165/rcmb.2014-0339OC
   Coyne GS, 2011, THERIOGENOLOGY, V75, P500, DOI 10.1016/j.theriogenology.2010.09.018
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Deliyanti D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00751-w
   Dey A, 2017, BIOTECHNOL ADV, V35, P178, DOI 10.1016/j.biotechadv.2016.12.005
   Dimmeler S, 2000, REGUL PEPTIDES, V90, P19, DOI 10.1016/S0167-0115(00)00105-1
   Ding J, 2012, DIABETES CARE, V35, P1098, DOI 10.2337/dc11-1341
   Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222
   Dutot M, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-39
   Ebrahimi M, 2009, ACTA CARDIOL, V64, P321, DOI 10.2143/AC.64.3.2038016
   El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Fan R, 2019, BBA-MOL CELL BIOL L, V1864, P59, DOI 10.1016/j.bbalip.2018.04.012
   Fang IM, 2007, EXP EYE RES, V85, P667, DOI 10.1016/j.exer.2007.07.021
   Fiala M, 2017, FASEB J, V31, P3229, DOI [10.1096/fj.201700065R, 10.1096/fj.201700065r]
   Fliesler SJ, 2010, J LIPID RES, V51, P1, DOI 10.1194/jlr.E003533-JLR200
   Frey RS, 2009, ANTIOXID REDOX SIGN, V11, P791, DOI 10.1089/ARS.2008.2220
   Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5
   Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052
   Golbidi S, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00069
   Goldstein GP, 2019, J PERINATOL, V39, P964, DOI 10.1038/s41372-019-0357-2
   Gorusupudi A, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801058
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Gubitosi-Klug RA, 2008, DIABETES, V57, P1387, DOI 10.2337/db07-1217
   HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7
   Harris WS, 2015, J PERINATOL, V35, P1, DOI 10.1038/jp.2014.195
   Hartnett ME, 2015, OPHTHALMOLOGY, V122, P200, DOI 10.1016/j.ophtha.2014.07.050
   Hartnett ME, 2010, DOC OPHTHALMOL, V120, P25, DOI 10.1007/s10633-009-9181-x
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hellstrom A, 2003, PEDIATRICS, V112, P1016, DOI 10.1542/peds.112.5.1016
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holub DJ, 2004, MOL CELL BIOCHEM, V263, P217, DOI 10.1023/B:MCBI.0000041863.11248.8d
   Hong HK, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-87
   Hong S, 2014, CHEM BIOL, V21, P1318, DOI 10.1016/j.chembiol.2014.06.010
   Hoppe G, 2016, P NATL ACAD SCI USA, V113, pE2516, DOI 10.1073/pnas.1523005113
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Hussain T, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7432797
   Idelchik MDS, 2017, SEMIN CANCER BIOL, V47, P57, DOI 10.1016/j.semcancer.2017.04.005
   Ikram MK, 2013, DIABETES CARE, V36, P750, DOI 10.2337/dc12-1554
   Innes JK, 2018, PROSTAG LEUKOTR ESS, V132, P41, DOI 10.1016/j.plefa.2018.03.004
   Innis SM, 2008, BRAIN RES, V1237, P35, DOI 10.1016/j.brainres.2008.08.078
   Innis SM, 2005, PLACENTA, V26, pS70, DOI 10.1016/j.placenta.2005.01.005
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jeffrey BG, 2001, LIPIDS, V36, P859, DOI 10.1007/s11745-001-0796-3
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kan E, 2017, INT OPHTHALMOL, V37, P1269, DOI 10.1007/s10792-016-0396-z
   Kanda A, 2019, J DIABETES INVEST, V10, P6, DOI 10.1111/jdi.12842
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kang JX, 2011, WORLD REV NUTR DIET, V102, P22, DOI 10.1159/000327787
   Kaur C, 2009, INVEST OPHTH VIS SCI, V50, P5364, DOI 10.1167/iovs.09-3552
   Khalesi N, 2018, CURR PHARM DESIGN, V24, P1845, DOI 10.2174/1381612824666180601094849
   Kim S, 2000, PHARMACOL REV, V52, P11
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169
   Koriyama Y, 2013, BRAIN RES, V1499, P145, DOI 10.1016/j.brainres.2012.12.041
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kowluru RA, 2014, DIABETOLOGIA, V57, P1047, DOI 10.1007/s00125-014-3194-z
   Kris-Etherton PM, 2009, PROSTAG LEUKOTR ESS, V81, P99, DOI 10.1016/j.plefa.2009.05.011
   Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kwon Y, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201900824
   Kytikova O, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060284
   Lafuente M, 2017, RETINA-J RET VIT DIS, V37, P1277, DOI 10.1097/IAE.0000000000001363
   Lamoureux EL, 2011, DIABETES CARE, V34, P1066, DOI 10.2337/dc11-0225
   Lan AP, 2016, BIOMETALS, V29, P665, DOI 10.1007/s10534-016-9942-4
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lee HN, 2013, BIOCHEM PHARMACOL, V86, P759, DOI 10.1016/j.bcp.2013.07.002
   Lee J, 2012, SEMIN FETAL NEONAT M, V17, P26, DOI 10.1016/j.siny.2011.08.007
   Lee SG, 2012, CLIN EXP OPHTHALMOL, V40, pE47, DOI 10.1111/j.1442-9071.2011.02695.x
   Leske MC, 2005, OPHTHALMOLOGY, V112, P799, DOI 10.1016/j.ophtha.2004.11.054
   Lin J, 2006, DIABETOLOGIA, V49, P1089, DOI 10.1007/s00125-006-0174-y
   Liou YA, 2007, J NUTR, V137, P945, DOI 10.1093/jn/137.4.945
   Litman BJ, 1996, LIPIDS, V31, pS193, DOI 10.1007/BF02637075
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Lu B, 2017, OPHTHALMIC RES, V57, P252, DOI 10.1159/000452282
   Lu QY, 2014, INT J CLIN EXP PATHO, V7, P7268
   Mahmoudabadi Mohammad Mehdi Shakouri, 2014, Oman Med J, V29, P39, DOI 10.5001/omj.2014.09
   Maisto R, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00235
   Makino Y, 2019, J SURG RES, V233, P104, DOI 10.1016/j.jss.2018.07.049
   Matesanz N, 2010, INVEST OPHTH VIS SCI, V51, P6815, DOI 10.1167/iovs.10-5339
   Matsumoto T, 2009, J PHARMACOL EXP THER, V329, P324, DOI 10.1124/jpet.108.148718
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Moon J, 2017, INTEGR BIOL-UK, V9, P436, DOI 10.1039/c7ib00032d
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P4342, DOI 10.1167/iovs.06-1473
   Najm S, 2017, CLIN NUTR ESPEN, V20, P17, DOI 10.1016/j.clnesp.2017.04.004
   Nathan DM, 2015, JAMA-J AM MED ASSOC, V314, P1052, DOI 10.1001/jama.2015.9536
   Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187
   Neff LM, 2011, J NUTR, V141, P207, DOI 10.3945/jn.110.130021
   Negi G, 2011, BIOCHEM BIOPH RES CO, V408, P1, DOI 10.1016/j.bbrc.2011.03.087
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505
   Newsholme P, 2016, BIOCHEM J, V473, P4527, DOI 10.1042/BCJ20160503C
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Okuda Y, 1997, BIOCHEM BIOPH RES CO, V232, P487, DOI 10.1006/bbrc.1997.6328
   Ola MS, 2013, CELL MOL NEUROBIOL, V33, P359, DOI 10.1007/s10571-012-9901-8
   Opreanu M, 2010, INVEST OPHTH VIS SCI, V51, P3253, DOI 10.1167/iovs.09-4731
   Ozawa Yoko, 2011, Exp Diabetes Res, V2011, P108328, DOI 10.1155/2011/108328
   Pallot C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44476-w
   Papsdorf K, 2019, TRENDS CELL BIOL, V29, P97, DOI 10.1016/j.tcb.2018.09.004
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Pawlik D, 2014, JPEN-PARENTER ENTER, V38, P711, DOI 10.1177/0148607113499373
   Pawlik D, 2011, PEDIATRICS, V127, P223, DOI 10.1542/peds.2010-2427
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perez-Munuzuri A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088781
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   Pirault J, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01273
   Pitocco D, 2013, INT J MOL SCI, V14, P21525, DOI 10.3390/ijms141121525
   Politi L, 2001, LIPIDS, V36, P927, DOI 10.1007/s11745-001-0803-8
   Prasad S, 2017, CANCER LETT, V387, P95, DOI 10.1016/j.canlet.2016.03.042
   Prokopiou E, 2017, BMJ OPEN OPHTHALMOL, V2, DOI [10.1136/bmjophth-2016-000056corr1, 10.1136/bmjophth-2016-000056]
   Qin Q, 2008, PROSTAG LEUKOTR ESS, V79, P201, DOI 10.1016/j.plefa.2008.09.022
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Rajaram S, 2014, AM J CLIN NUTR, V100, p443S, DOI 10.3945/ajcn.113.071514
   Rathi S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01868
   Rathnasamy G, 2014, INVEST OPHTH VIS SCI, V55, P5878, DOI 10.1167/iovs.13-13718
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Rivera JC, 2011, NEONATOLOGY, V100, P343, DOI 10.1159/000330174
   Rogers LK, 2013, PHARMACOL RES, V70, P13, DOI 10.1016/j.phrs.2012.12.003
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Sala-Vila A, 2016, JAMA OPHTHALMOL, V134, P1142, DOI 10.1001/jamaophthalmol.2016.2906
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.10
   Sasaki F, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96902
   Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004
   Sears JE, 2008, P NATL ACAD SCI USA, V105, P19898, DOI 10.1073/pnas.0805817105
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   Shannon H, 2000, NEW ENGL J MED, V342, P381
   Sheets KG, 2013, MOL VIS, V19, P1747
   Sheets KG, 2010, MOL VIS, V16, P320
   Shen HH, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060489
   Shen JH, 2013, ARCH MED RES, V44, P514, DOI 10.1016/j.arcmed.2013.09.010
   Shu YS, 2016, BIOMOL THER, V24, P132, DOI 10.4062/biomolther.2015.088
   Sifuentes-Franco S, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/1673081
   Skyler JS, 2017, DIABETES, V66, P241, DOI 10.2337/db16-0806
   Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030
   Solberg R, 2017, NEONATOLOGY, V112, P1, DOI 10.1159/000454982
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Stitt AW, 1997, AM J PATHOL, V150, P523
   Stone WL, 2016, FRONT BIOSCI-LANDMRK, V21, P165, DOI 10.2741/4382
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Suzumura A, 2020, DIABETES, V69, P724, DOI 10.2337/db19-0550
   Swanson D, 2012, ADV NUTR, V3, P1, DOI 10.3945/an.111.000893
   Takamiya R, 2012, FEBS OPEN BIO, V2, P328, DOI 10.1016/j.fob.2012.10.001
   Talahalli R, 2010, INVEST OPHTH VIS SCI, V51, P1699, DOI 10.1167/iovs.09-3557
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tang S, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/2380319
   Tang S, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/2438247
   Tao LF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0489-7
   Tavazzi L, 2008, LANCET, V372, P1223, DOI 10.1016/S0140-6736(08)61239-8
   Terao R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134758
   Terao R, 2019, PROSTAG OTH LIPID M, V145, DOI 10.1016/j.prostaglandins.2019.106365
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tian HB, 2009, INVEST OPHTH VIS SCI, V50, P3613, DOI 10.1167/iovs.08-3146
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tremblay S, 2013, INVEST OPHTH VIS SCI, V54, P8125, DOI 10.1167/iovs.13-12496
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Veluthakal R, 2015, CELL PHYSIOL BIOCHEM, V36, P208, DOI 10.1159/000374065
   Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019
   Viola JR, 2016, CIRC RES, V119, P1030, DOI 10.1161/CIRCRESAHA.116.309492
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang HB, 2014, MOL VIS, V20, P231
   Wang HB, 2012, AM J PATHOL, V180, P1243, DOI 10.1016/j.ajpath.2011.11.031
   Wang MH, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060520
   Wang XZ, 2015, ALZHEIMERS DEMENT, V11, P40, DOI 10.1016/j.jalz.2013.12.024
   Werdich XQ, 2004, EXP EYE RES, V79, P623, DOI 10.1016/j.exer.2004.07.006
   Weylandt KH, 2011, CARCINOGENESIS, V32, P897, DOI 10.1093/carcin/bgr049
   Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Xu JW, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109606
   Xu ZH, 2014, DIABETOLOGIA, V57, P204, DOI 10.1007/s00125-013-3093-8
   Yang CT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021971
   Yang YC, 2013, J NUTR BIOCHEM, V24, P204, DOI 10.1016/j.jnutbio.2012.05.003
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yee P, 2010, INVEST OPHTH VIS SCI, V51, P1755, DOI 10.1167/iovs.09-3792
   Yin YZ, 2017, MOL VIS, V23, P242
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Yuda K, 2012, AM J PATHOL, V181, P1464, DOI 10.1016/j.ajpath.2012.06.028
   Zendedel A, 2015, J NEUROIMMUNOL, V278, P200, DOI 10.1016/j.jneuroim.2014.11.007
   Zgorzynska E, 2017, PHARMACOL REP, V69, P935, DOI 10.1016/j.pharep.2017.04.009
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhao Y, 2004, J AM COLL NUTR, V23, P71, DOI 10.1080/07315724.2004.10719345
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
NR 239
TC 20
Z9 20
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD OCT
PY 2020
VL 9
IS 10
AR 920
DI 10.3390/antiox9100920
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA OJ7MP
UT WOS:000584140800001
PM 32993153
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Satish, S
   Philipose, H
   Rosales, MAB
   Saint-Geniez, M
AF Satish, Sangeeta
   Philipose, Hannah
   Rosales, Mariana Aparecida Brunini
   Saint-Geniez, Magali
TI Pharmaceutical Induction of PGC-1 alpha Promotes Retinal Pigment
   Epithelial Cell Metabolism and Protects against Oxidative Damage
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID SODIUM IODATE; AGE; STRESS; SUSCEPTIBILITY; DEATH
AB Retinal pigment epithelium (RPE) dysfunction due to accumulation of reactive oxygen species and oxidative damage is a key event in the development of age-related macular degeneration (AMD). Here, we examine the therapeutic potential of ZLN005, a selective PGC-1 alpha transcriptional regulator, in protecting RPE from cytotoxic oxidative damage. Gene expression analysis on ARPE-19 cells treated with ZLN005 shows robust upregulation of PGC-1 alpha and its associated transcription factors, antioxidant enzymes, and mitochondrial genes. Energetic profiling shows that ZLN005 treatment enhances RPE mitochondrial function by increasing basal and maximal respiration rates, and spare respiratory capacity. In addition, ZLN005 robustly protects ARPE-19 cells from cell death caused by H2O2, ox-LDL, and NaIO3 without exhibiting any cytotoxicity under basal conditions. ZLN005 protection against H2O2,-mediated cell death was lost in PGC-1 alpha-silenced cells. Our data indicates that ZLN005 efficiently protects RPE cells from oxidative damage through selective induction of PGC-1 alpha and its target antioxidant enzymes. ZLN005 may serve as a novel therapeutic agent for retinal diseases associated with RPE dystrophies.
C1 [Satish, Sangeeta] Boston Univ, Grad Med Sci, Sch Med, Boston, MA 02118 USA.
   [Satish, Sangeeta; Philipose, Hannah; Rosales, Mariana Aparecida Brunini; Saint-Geniez, Magali] Mass Eye & Ear, Schepens Eye Res Inst, Boston, MA 02114 USA.
   [Rosales, Mariana Aparecida Brunini; Saint-Geniez, Magali] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
C3 Boston University; Harvard University; Schepens Eye Research Institute;
   Harvard University; Harvard Medical School
RP Saint-Geniez, M (通讯作者)，Mass Eye & Ear, Schepens Eye Res Inst, Boston, MA 02114 USA.; Saint-Geniez, M (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
EM magali_saintgeniez@meei.harvard.edu
RI SAINT-GENIEZ, MAGALI/P-3509-2019; Rosales, Mariana A B/K-7965-2014
OI SAINT-GENIEZ, MAGALI/0000-0001-9897-138X; Rosales, Mariana A
   B/0000-0001-8042-0483
FU Alcon Research Institute Young Investigator Research Grant; Research to
   Prevent Blindness Dolly Green Special Scholar Award; Grimshaw
   Foundation; National Eye Institute Core Grant [P30EYE003790]
FX This work was supported by the Alcon Research Institute Young
   Investigator Research Grant (M.S.G.), the Research to Prevent Blindness
   Dolly Green Special Scholar Award (M.S.G.), the Grimshaw Foundation
   (M.S.G.), and the National Eye Institute Core Grant P30EYE003790.
CR Bartolome A, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00441-17
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Clark J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048925
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Fern R, 2003, J NEUROSCI RES, V71, P759, DOI 10.1002/jnr.10553
   Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Guo XX, 2014, AM J PATHOL, V184, P1017, DOI 10.1016/j.ajpath.2013.12.012
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hoffman DL, 2009, J BIOL CHEM, V284, P16236, DOI 10.1074/jbc.M809512200
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Li WJ, 2016, EXP CELL RES, V345, P25, DOI 10.1016/j.yexcr.2016.05.012
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Nickens KP, 2013, MITOCHONDRION, V13, P662, DOI 10.1016/j.mito.2013.09.005
   Panieri E, 2013, FREE RADICAL BIO MED, V57, P176, DOI 10.1016/j.freeradbiomed.2012.12.024
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tsunemi T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003799
   Vainshtein A, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0033-y
   Veal EA, 2007, MOL CELL, V26, P1, DOI 10.1016/j.molcel.2007.03.016
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Zhang LN, 2013, DIABETES, V62, P1297, DOI 10.2337/db12-0703
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
NR 39
TC 23
Z9 24
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2018
VL 2018
AR 9248640
DI 10.1155/2018/9248640
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HB0SU
UT WOS:000450728800001
PM 30524663
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Parente, R
   Clark, SJ
   Inforzato, A
   Day, AJ
AF Parente, Raffaella
   Clark, Simon J.
   Inforzato, Antonio
   Day, Anthony J.
TI Complement factor H in host defense and immune evasion
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Complement cascade; Complement factor H; Glycan markers; Inflammatory
   diseases; Cancer immunology; Innate immunity
ID C-REACTIVE PROTEIN; HEMOLYTIC-UREMIC SYNDROME; LONG PENTRAXIN PTX3;
   BRUCHS MEMBRANE IMPLICATIONS; DENSE DEPOSIT DISEASE; ADULT HUMAN RETINA;
   MACULAR DEGENERATION; C4B-BINDING PROTEIN; EXTRACELLULAR-MATRIX;
   ALTERNATIVE PATHWAY
AB Complement is the major humoral component of the innate immune system. It recognizes pathogen- and damage-associated molecular patterns, and initiates the immune response in coordination with innate and adaptive immunity. When activated, the complement system unleashes powerful cytotoxic and inflammatory mechanisms, and thus its tight control is crucial to prevent damage to host tissues and allow restoration of immune homeostasis. Factor H is the major soluble inhibitor of complement, where its binding to self markers (i.e., particular glycan structures) prevents complement activation and amplification on host surfaces. Not surprisingly, mutations and polymorphisms that affect recognition of self by factor H are associated with diseases of complement dysregulation, such as age-related macular degeneration and atypical haemolytic uremic syndrome. In addition, pathogens (i.e., non-self) and cancer cells (i.e., altered-self) can hijack factor H to evade the immune response. Here we review recent (and not so recent) literature on the structure and function of factor H, including the emerging roles of this protein in the pathophysiology of infectious diseases and cancer.
C1 [Parente, Raffaella; Inforzato, Antonio] Humanitas Clin & Res Ctr, Via Manzoni 56, I-20089 Milan, Italy.
   [Clark, Simon J.] Univ Manchester, Sch Biol Sci, Div Evolut & Genom Med, Fac Biol Med & Hlth, Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Inforzato, Antonio] Univ Milan, Dept Med Biotechnol & Translat Med, Via Vanvitelli 32, I-20129 Milan, Italy.
   [Day, Anthony J.] Univ Manchester, Sch Biol Sci, Div Cell Matrix Biol & Regenerat Med, Wellcome Trust Ctr Cell Matrix Res,Fac Biol Med &, Oxford Rd, Manchester M13 9PT, Lancs, England.
C3 University of Manchester; University of Milan; University of Manchester
RP Inforzato, A (通讯作者)，Humanitas Clin & Res Ctr, Via Manzoni 56, I-20089 Milan, Italy.; Inforzato, A (通讯作者)，Univ Milan, Dept Med Biotechnol & Translat Med, Via Vanvitelli 32, I-20129 Milan, Italy.; Day, AJ (通讯作者)，Univ Manchester, Sch Biol Sci, Div Cell Matrix Biol & Regenerat Med, Wellcome Trust Ctr Cell Matrix Res,Fac Biol Med &, Oxford Rd, Manchester M13 9PT, Lancs, England.
EM Antonio.inforzato@humanitasresearch.it; anthony.day@manchester.ac.uk
RI Inforzato, Antonio/ABG-4513-2020; Parente, Raffaella/HDM-3960-2022
OI Inforzato, Antonio/0000-0001-8110-0027; Parente,
   Raffaella/0000-0003-3607-1380; Clark, Simon/0000-0001-8394-8355
FU Ministero della Salute [GR-2011-02349539]; Fight for Sight; Macular
   Society; Medical Research Council (UK); MRC [MR/K004441/1, G0900538,
   MR/K024418/1, MC_U138274352, G0501816] Funding Source: UKRI; Medical
   Research Council [G0900538, G0501816, MR/K004441/1, MR/K024418/1,
   MC_U138274352] Funding Source: researchfish
FX AI is recipient of a Young Investigator Grant from Ministero della
   Salute (GR-2011-02349539), which also funds RP's Ph.D. studentship. AJD
   and SJC would like to thank Fight for Sight, the Macular Society and the
   Medical Research Council (UK) for their funding of studies into
   complement and age-related macular degeneration.
CR Agarwal S, 2010, J IMMUNOL, V185, P4344, DOI 10.4049/jimmunol.0904191
   Agarwal V, 2010, J BIOL CHEM, V285, P23484, DOI 10.1074/jbc.M110.142703
   Alcorlo M, 2015, FEBS J, V282, P3883, DOI 10.1111/febs.13399
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   AVERY VM, 1993, J IMMUNOL, V151, P5545
   Barbour TD, 2013, SEMIN NEPHROL, V33, P493, DOI 10.1016/j.semnephrol.2013.08.002
   Berger BE, 2016, AM J MED SCI, V352, P177, DOI 10.1016/j.amjms.2016.05.003
   Bhattacharjee A, 2015, J BIOL CHEM, V290, P9500, DOI 10.1074/jbc.M114.630871
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Blom AM, 2009, MOL IMMUNOL, V46, P2808, DOI 10.1016/j.molimm.2009.04.025
   Bonavita E, 2015, CELL, V160, P700, DOI 10.1016/j.cell.2015.01.004
   Bottazzi B, 2016, J HEPATOL, V64, P1416, DOI 10.1016/j.jhep.2016.02.029
   Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305
   Braunschweig A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023991
   BREVIARIO F, 1992, J BIOL CHEM, V267, P22190
   BROOIMANS RA, 1990, J IMMUNOL, V144, P3835
   Bushey RT, 2016, CELL REP, V15, P1505, DOI 10.1016/j.celrep.2016.04.038
   Campa MJ, 2015, CANCER IMMUNOL RES, V3, P1325, DOI 10.1158/2326-6066.CIR-15-0122
   Carroll MC, 2004, MOL IMMUNOL, V41, P141, DOI 10.1016/j.molimm.2004.03.017
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen ZA, 2016, MOL CELL PROTEOMICS, V15, P2730, DOI 10.1074/mcp.M115.056473
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Corrales L, 2012, J IMMUNOL, V189, P4674, DOI 10.4049/jimmunol.1201654
   Daigo K, 2016, IMMUNOL REV, V274, P202, DOI 10.1111/imr.12476
   De Groot AS, 2015, IMMUNOL CELL BIOL, V93, P189, DOI 10.1038/icb.2014.89
   de Paula PF, 2003, SCAND J IMMUNOL, V58, P572, DOI 10.1046/j.1365-3083.2003.01326.x
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Delvaeye M, 2009, NEW ENGL J MED, V361, P345, DOI 10.1056/NEJMoa0810739
   DEVINE DV, 1987, P NATL ACAD SCI USA, V84, P5873, DOI 10.1073/pnas.84.16.5873
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Dunkelberger JR, 2010, MOL IMMUNOL, V47, P2176, DOI 10.1016/j.molimm.2010.05.008
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296
   Fakhouri F, 2010, KIDNEY INT, V78, P279, DOI 10.1038/ki.2010.132
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4
   Francis NJ, 2012, BLOOD, V119, P591, DOI 10.1182/blood-2011-03-339903
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garlanda C, 2009, J REPROD IMMUNOL, V83, P128, DOI 10.1016/j.jri.2009.05.006
   Goodship THJ, 2012, MOL IMMUNOL, V52, P200, DOI 10.1016/j.molimm.2012.05.009
   Gorter A, 1999, IMMUNOL TODAY, V20, P576, DOI 10.1016/S0167-5699(99)01537-6
   Gude DR, 2008, FASEB J, V22, P2629, DOI 10.1096/fj.08-107169
   Haapasalo K, 2015, J BIOL CHEM, V290, P28977, DOI 10.1074/jbc.M115.669226
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAMMANN KP, 1981, IMMUNOBIOLOGY, V160, P289, DOI 10.1016/S0171-2985(81)80055-1
   Happonen KE, 2012, IMMUNOBIOLOGY, V217, P1088, DOI 10.1016/j.imbio.2012.07.013
   Happonen KE, 2009, J IMMUNOL, V182, P1518, DOI 10.4049/jimmunol.182.3.1518
   Haupt K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000250
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heinegard D, 2009, INT J EXP PATHOL, V90, P575, DOI 10.1111/j.1365-2613.2009.00695.x
   Heinekamp T, 2015, SEMIN IMMUNOPATHOL, V37, P141, DOI 10.1007/s00281-014-0465-1
   Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200
   Herbert AP, 2015, J IMMUNOL, V195, P4986, DOI 10.4049/jimmunol.1501388
   Heurich M, 2016, THROMB RES, V145, P84, DOI 10.1016/j.thromres.2016.07.017
   Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138
   Hyvarinen S, 2016, BLOOD, V127, P2701, DOI 10.1182/blood-2015-11-680009
   Hyvarinen S, 2014, J BIOL CHEM, V289, P4295, DOI 10.1074/jbc.M113.527416
   Inforzato A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00407
   Inforzato A, 2013, SEMIN IMMUNOL, V25, P79, DOI 10.1016/j.smim.2013.05.002
   Inforzato A, 2012, ADV EXP MED BIOL, V946, P1, DOI 10.1007/978-1-4614-0106-3_1
   Inforzato A, 2010, J BIOL CHEM, V285, P17681, DOI 10.1074/jbc.M109.085639
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Kalchishkova N, 2011, J BIOL CHEM, V286, P27915, DOI 10.1074/jbc.M111.242834
   Kang YH, 2012, IMMUNOBIOLOGY, V217, P455, DOI 10.1016/j.imbio.2011.10.008
   KATZ Y, 1988, J IMMUNOL, V141, P559
   Kavanagh D, 2010, PEDIATR NEPHROL, V25, P2431, DOI 10.1007/s00467-010-1555-5
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994
   Kemper C, 2014, MOL IMMUNOL, V61, P56, DOI 10.1016/j.molimm.2014.07.004
   Kennedy AT, 2016, J IMMUNOL, V196, P1239, DOI 10.4049/jimmunol.1501581
   Khattab A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003513
   Khatua B, 2010, FEBS LETT, V584, P555, DOI 10.1016/j.febslet.2009.11.087
   Kiraz Y, 2016, TUMOR BIOL, V37, P8471, DOI 10.1007/s13277-016-5035-9
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   Kovacs GG, 2004, NEUROBIOL DIS, V15, P21, DOI 10.1016/j.nbd.2003.09.010
   Kraiczy P, 2004, INT J MED MICROBIOL, V293, P152, DOI 10.1016/S1433-1128(04)80029-9
   Kwan WH, 2012, IMMUNOL RES, V54, P247, DOI 10.1007/s12026-012-8327-1
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   LAMBRIS JD, 1980, J EXP MED, V152, P1625, DOI 10.1084/jem.152.6.1625
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   Lu JH, 2008, NATURE, V456, P989, DOI 10.1038/nature07468
   Makou E, 2015, BIOCHEM SOC T, V43, P812, DOI 10.1042/BST20150074
   Makou E, 2013, BIOCHEMISTRY-US, V52, P3949, DOI 10.1021/bi4003452
   Makou E, 2012, J MOL BIOL, V424, P295, DOI 10.1016/j.jmb.2012.09.013
   Malhotra R, 1999, BIOCHEM J, V341, P61, DOI 10.1042/0264-6021:3410061
   Mamidi S, 2017, IMMUNOBIOLOGY, V222, P45, DOI 10.1016/j.imbio.2015.11.008
   Mantovani A, 2013, ANN NY ACAD SCI, V1285, P1, DOI 10.1111/nyas.12043
   McHarg S, 2015, JOVE-J VIS EXP, DOI 10.3791/53382
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Melin M, 2010, INFECT IMMUN, V78, P2089, DOI 10.1128/IAI.00811-09
   Meri S, 2008, VACCINE, V26, pI113, DOI 10.1016/j.vaccine.2008.11.058
   Meri S, 2016, FEBS LETT, V590, P2418, DOI 10.1002/1873-3468.12284
   Meri T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003308
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Mnjoyan Z, 2008, PLATELETS, V19, P512, DOI 10.1080/09537100802238494
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Morgan HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032187
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377
   Nester CM, 2015, MOL IMMUNOL, V67, P31, DOI 10.1016/j.molimm.2015.03.246
   Ng PML, 2007, EMBO J, V26, P3431, DOI 10.1038/sj.emboj.7601762
   Nozal P, 2012, CLIN KIDNEY J, V5, P133, DOI 10.1093/ckj/sfs002
   OHTSUKA H, 1993, IMMUNOLOGY, V80, P140
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Olivar R, 2016, J IMMUNOL, V196, P4274, DOI 10.4049/jimmunol.1500455
   Orth D, 2009, J IMMUNOL, V182, P6394, DOI 10.4049/jimmunol.0900151
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Pizza M, 2008, VACCINE, V26, pI46, DOI 10.1016/j.vaccine.2008.11.068
   Poolpol K, 2014, MOL IMMUNOL, V58, P77, DOI 10.1016/j.molimm.2013.11.009
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Qiang XL, 2008, MOL MED, V14, P443, DOI 10.2119/2008-00015.Qiang
   Ray PE, 2001, PEDIATR NEPHROL, V16, P823, DOI 10.1007/s004670100660
   Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x
   Ricklin D, 2016, NAT REV NEPHROL, V12, P383, DOI 10.1038/nrneph.2016.70
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   de Cordoba SR, 2014, SEMIN THROMB HEMOST, V40, P422, DOI 10.1055/s-0034-1375296
   Rossi R, 2016, INFECT IMMUN, V84, P1735, DOI 10.1128/IAI.01491-15
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schmidt CQ, 2010, J MOL BIOL, V395, P105, DOI 10.1016/j.jmb.2009.10.010
   Schneider AE, 2016, MOL IMMUNOL, V72, P37, DOI 10.1016/j.molimm.2016.02.011
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seib KL, 2015, EXPERT REV VACCINES, V14, P841, DOI 10.1586/14760584.2015.1016915
   Serruto D, 2010, NAT REV MICROBIOL, V8, P393, DOI 10.1038/nrmicro2366
   Shaughnessy J, 2016, J IMMUNOL, V196, P1732, DOI 10.4049/jimmunol.1500292
   Shaughnessy J, 2011, J BIOL CHEM, V286, P22235, DOI 10.1074/jbc.M111.225516
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sim RB, 2015, MOL IMMUNOL, V68, P45, DOI 10.1016/j.molimm.2015.06.006
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003
   Sjoberg AP, 2008, MOL IMMUNOL, V45, P3213, DOI 10.1016/j.molimm.2008.02.023
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612
   Sjoberg AP, 2009, MOL IMMUNOL, V46, P830, DOI 10.1016/j.molimm.2008.09.018
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852
   Svoboda E, 2015, IMMUNOL LETT, V168, P13, DOI 10.1016/j.imlet.2015.08.009
   Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200
   Truman LA, 2008, BLOOD, V112, P5026, DOI 10.1182/blood-2008-06-162404
   Vaziri-Sani F, 2005, J THROMB HAEMOST, V3, P154, DOI 10.1111/j.1538-7836.2004.01010.x
   Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004
   Vogl G, 2008, MOL IMMUNOL, V45, P1485, DOI 10.1016/j.molimm.2007.08.011
   VOLANAKIS JE, 1974, J IMMUNOL, V113, P9
   Warwicker P, 1999, NEPHROL DIAL TRANSPL, V14, P1229, DOI 10.1093/ndt/14.5.1229
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501
   Wilczek E, 2008, INT J CANCER, V122, P2030, DOI 10.1002/ijc.23238
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Ying LH, 1999, AM J HUM GENET, V65, P1538, DOI 10.1086/302673
   Zhou WD, 2012, IMMUNOBIOLOGY, V217, P225, DOI 10.1016/j.imbio.2011.07.016
   Zudaire E, 2006, J LEUKOCYTE BIOL, V80, P237, DOI 10.1189/jlb.0206123
NR 184
TC 106
Z9 108
U1 1
U2 25
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2017
VL 74
IS 9
BP 1605
EP 1624
DI 10.1007/s00018-016-2418-4
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ER9KJ
UT WOS:000399144900003
PM 27942748
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jia, YP
   Sun, L
   Yu, HS
   Liang, LP
   Li, W
   Ding, H
   Song, XB
   Zhang, LJ
AF Jia, Yu-Ping
   Sun, Lei
   Yu, He-Shui
   Liang, Li-Peng
   Li, Wei
   Ding, Hui
   Song, Xin-Bo
   Zhang, Li-Juan
TI The Pharmacological Effects of Lutein and Zeaxanthin on Visual Disorders
   and Cognition Diseases
SO MOLECULES
LA English
DT Review
DE lutein; zeaxanthin; carotenoids; AMD; ARC; cataract; cognition; ADI
ID PIGMENT OPTICAL-DENSITY; AGE-RELATED CATARACT; MACULAR DEGENERATION; EYE
   DISEASE; OXIDATIVE STRESS; BETA-CAROTENE; PLASMA LUTEIN; DIETARY
   ANTIOXIDANTS; NUCLEAR CATARACT; ALPHA-TOCOPHEROL
AB Lutein (L) and zeaxanthin (Z) are dietary carotenoids derived from dark green leafy vegetables, orange and yellow fruits that form the macular pigment of the human eyes. It was hypothesized that they protect against visual disorders and cognition diseases, such as age-related macular degeneration (AMD), age-related cataract (ARC), cognition diseases, ischemic/hypoxia induced retinopathy, light damage of the retina, retinitis pigmentosa, retinal detachment, uveitis and diabetic retinopathy. The mechanism by which they are involved in the prevention of eye diseases may be due their physical blue light filtration properties and local antioxidant activity. In addition to their protective roles against light-induced oxidative damage, there are increasing evidences that L and Z may also improve normal ocular function by enhancing contrast sensitivity and by reducing glare disability. Surveys about L and Z supplementation have indicated that moderate intakes of L and Z are associated with decreased AMD risk and less visual impairment. Furthermore, this review discusses the appropriate consumption quantities, the consumption safety of L, side effects and future research directions.
C1 [Jia, Yu-Ping; Sun, Lei; Yu, He-Shui; Liang, Li-Peng; Li, Wei; Song, Xin-Bo; Zhang, Li-Juan] Tianjin Univ Tradit Chinese Med, Coll Pharmaceut Engn Tradit Chinese Med, Tianjin 300193, Peoples R China.
   [Ding, Hui] Tianjin Zhongyi Pharmaceut Co Ltd, Tianjin 300193, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine
RP Zhang, LJ (通讯作者)，Tianjin Univ Tradit Chinese Med, Coll Pharmaceut Engn Tradit Chinese Med, Tianjin 300193, Peoples R China.
EM 15692232675@163.com; sunleitj2013@163.com; hs_yu08@163.com;
   15692232573@163.com; cheercathy@163.com; dinghui.hn@163.com;
   songxinbo@tjutcm.edu.cn; zhanglijuan@tjutcm.edu.cn
FU Science and Technology Program of Tianjin [14TXZYJC00440, 15PTCYSY00030]
FX This work was financially supported by the Science and Technology
   Program of Tianjin (14TXZYJC00440, 15PTCYSY00030).
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Abdel-Aal EM, 2010, J AGR FOOD CHEM, V58, P10109, DOI 10.1021/jf102400t
   Al-Holou S, 2014, INVEST OPHTH VIS SCI, V55
   Alassane S, 2016, INVEST OPHTH VIS SCI, V57, P1160, DOI 10.1167/iovs.15-18007
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Andley UP, 2009, CURR MOL MED, V9, P887, DOI 10.2174/156652409789105598
   [Anonymous], 2013, NIH STUD PROV CLAR S
   [Anonymous], 2010, EFSA J, V8, P1678, DOI [10.2903/j.efsa.2010.1678, DOI 10.2903/J.EFSA.2010.1678]
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Barker FM, 2010, CURR MED RES OPIN, V26, P2011, DOI 10.1185/03007995.2010.494549
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Beebe DC, 2010, OPHTHALMIC RES, V44, P155, DOI 10.1159/000316481
   Bernstein PS, 2015, ACTA HORTIC, V1106, P153, DOI 10.17660/ActaHortic.2015.1106.24
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Berrow E. J., 2013, BR J NUTR, V109, P1
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Britton G., 2004, CAROTENOIDS HDB, DOI 10.1080/10715760410001727849
   Buonocore G., 2001, BIOL NEONATE, V79, P455
   Burri BJ, 1998, ADV EXP MED BIOL, V445, P225
   Cabot F, 2013, AM J OPHTHALMOL, V155, P629, DOI 10.1016/j.ajo.2012.11.005
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Catanuto P, 2009, EXP EYE RES, V88, P99, DOI 10.1016/j.exer.2008.10.013
   Charters L, 2013, FORMULARY, V48, P229
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Choi RY, 2016, JAMA OPHTHALMOL, V134, P1445, DOI 10.1001/jamaophthalmol.2016.4117
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Crabtree DV, 2001, BIOORGAN MED CHEM, V9, P1967, DOI 10.1016/S0968-0896(01)00103-1
   Cruickshanks K. J., 1998, ARCH OPHTHALMOL-CHIC, V116, P714
   Dachtler M, 2001, ANAL CHEM, V73, P667, DOI 10.1021/ac000635g
   Davis R. L., 2015, ADV OPHTHALMOL VIS S, V2
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Devore EE, 2010, ARCH NEUROL-CHICAGO, V67, P819, DOI 10.1001/archneurol.2010.144
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   European Food Safety Authority (EFSA), 2008, EFSA J, V823, P1
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fan XJ, 2009, J BIOL CHEM, V284, P34618, DOI 10.1074/jbc.M109.032094
   Fatani AJ, 2016, NEUROCHEM J+, V10, P69, DOI 10.1134/S1819712416010074
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   Fernandez MM, 2011, CURR OPIN OPHTHALMOL, V22, P2, DOI 10.1097/ICU.0b013e3283416742
   Fernandez-Robredo P., 2013, OXID MED CELL LONGEV, V2013, P433
   Ferrandez A. M., 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Ghaem M. H., 2012, INVESTIG OPHTHALMOL, V54, P641
   Gong XM, 2015, ARCH BIOCHEM BIOPHYS, V572, P40, DOI 10.1016/j.abb.2015.02.004
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Granado-Lorencio F, 2006, EUR J CLIN NUTR, V60, P1000, DOI 10.1038/sj.ejcn.1602411
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Hennis A, 2004, ARCH OPHTHALMOL-CHIC, V122, P525, DOI 10.1001/archopht.122.4.525
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hoffmann K.G., 2015, OPHTHALMOL RES INT J, V4, P1, DOI [10.9734/OR/2015/17131, DOI 10.9734/OR/2015/17131]
   Institute of Medicine (US), 2000, DIET REF INT VIT C V
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Johnson E. J., 2012, J AGING RES, V2013, P214
   Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Johnson EJ, 2012, AM J CLIN NUTR, V96, p1161S, DOI 10.3945/ajcn.112.034611
   Johnson Elizabeth J, 2002, Nutr Clin Care, V5, P56, DOI 10.1046/j.1523-5408.2002.00004.x
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Joint F.A.O., 2005, EV CERT FOOD ADD 63, P23
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Karppi J, 2012, BRIT J NUTR, V108, P148, DOI 10.1017/S0007114511005332
   Kelm MA, 2001, LIPIDS, V36, P1277, DOI 10.1007/s11745-001-0842-1
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Knickmeyer RC, 2008, J NEUROSCI, V28, P12176, DOI 10.1523/JNEUROSCI.3479-08.2008
   Koo E, 2013, OPHTHAL EPIDEMIOL, V20, P71, DOI 10.3109/09286586.2012.759598
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kuchan M., 2013, ADV CONTR CLIN NUTR
   Kull DR, 1997, J AGR FOOD CHEM, V45, P4201, DOI 10.1021/jf960945t
   Lakshminarayana R, 2013, CHEM-BIOL INTERACT, V203, P448, DOI 10.1016/j.cbi.2013.03.006
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   Lienau A, 2003, J NUTR BIOCHEM, V14, P663, DOI 10.1016/j.jnutbio.2003.08.004
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindbergh C, 2016, ARCH CLIN NEUROPSYCH, V31, P574, DOI 10.1093/arclin/acw042.04
   Liu XH, 2014, NUTRIENTS, V6, P452, DOI 10.3390/nu6010452
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Ma L, 2014, GRAEF ARCH CLIN EXP, V252, P63, DOI 10.1007/s00417-013-2492-3
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Maharshak N, 2003, INT J DERMATOL, V42, P178, DOI 10.1046/j.1365-4362.2003.01657.x
   Mares JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P738, DOI 10.1001/archophthalmol.2010.84
   Markesbery WR, 2007, ARCH NEUROL-CHICAGO, V64, P954, DOI 10.1001/archneur.64.7.954
   Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449
   Mauer K., 2003, B HIST MED, V78, P728
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moukarzel Adib A, 2009, J Med Liban, V57, P261
   Muni RH, 2008, RETINA-J RET VIT DIS, V28, P1421, DOI 10.1097/IAE.0b013e3181814470
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   [Нероев В.В. Neroev V.V.], 2015, [Вопросы современной педиатрии, Current pediatrics, Voprosy sovremennoi pediatrii], V14, P265, DOI 10.15690/vsp.v14i2.1296
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Obermajer N, 2008, CONNECT TISSUE RES, V49, P193, DOI 10.1080/03008200802143158
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Olmedilla B, 2002, CLIN SCI, V102, P447, DOI 10.1042/CS20010159
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Ong SY, 2012, ARCH OPHTHALMOL-CHIC, V130, P895, DOI 10.1001/archophthalmol.2012.152
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Pitlick JM, 2012, ANN PHARMACOTHER, V46, P290, DOI 10.1345/aph.1Q471
   Pons M, 2010, AM J PATHOL, V177, P1198, DOI 10.2353/ajpath.2010.091108
   Preethi KC, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810701876265
   Rao GN, 2011, CURR OPIN OPHTHALMOL, V22, P4, DOI 10.1097/ICU.0b013e3283414fc8
   Ravindran RD, 2011, OPHTHALMOLOGY, V118, P1958, DOI 10.1016/j.ophtha.2011.03.016
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Renzi LM, 2014, NEUROBIOL AGING, V35, P1695, DOI 10.1016/j.neurobiolaging.2013.12.024
   Renzi LM, 2013, NUTR NEUROSCI, V16, P262, DOI 10.1179/1476830513Y.0000000054
   Renzi LM, 2010, EXP EYE RES, V91, P896, DOI 10.1016/j.exer.2010.09.015
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rogers MAM, 2010, AM J EPIDEMIOL, V171, P728, DOI 10.1093/aje/kwp453
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Sale A, 2009, TRENDS NEUROSCI, V32, P233, DOI 10.1016/j.tins.2008.12.004
   Satia J. A., 2009, AM J EPIDEMIOL, V170, P401
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Seddon JM, 2010, MOL VIS, V16, P2412
   Selin JZ, 2013, AM J EPIDEMIOL, V177, P548, DOI 10.1093/aje/kws279
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Song X., 2007, CHIN PUBLIC HLTH, V23, P1378
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Sugino IK, 2003, MOL NEUROBIOL, V28, P177, DOI 10.1385/MN:28:2:177
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tan AG, 2008, AM J CLIN NUTR, V87, P1899, DOI 10.1093/ajcn/87.6.1899
   Terry D., 2014, ARCH CLIN NEUROPSYCH, V29, P506
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Vishwanathan R, 2014, J PEDIATR GASTR NUTR, V59, P659, DOI 10.1097/MPG.0000000000000389
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Vishwanathan R, 2013, NUTR NEUROSCI, V16, P21, DOI 10.1179/1476830512Y.0000000024
   von Lintig J, 2012, J BIOL CHEM, V287, P1627, DOI 10.1074/jbc.R111.303990
   Wang Z., 2010, FOOD NUTR CHINA, V2010, P77
   Wang Z. X., 2009, J NUTR, V31, P6
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2007, NUTR RES, V27, P462, DOI 10.1016/j.nutres.2007.05.011
   Woo JH, 2009, EYE, V23, P2271, DOI 10.1038/eye.2009.4
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Xing KY, 2010, INVEST OPHTH VIS SCI, V51, P6598, DOI 10.1167/iovs.10-5672
   Xu XR, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/862806
   Yao LH, 2000, LIPIDS, V35, P339, DOI 10.1007/s11745-000-0531-0
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Zhang F., 2012, ENV OCCUP MED, V29, P563
   Zhang J, 2012, INVEST OPHTH VIS SCI, V53, P7276, DOI 10.1167/iovs.12-10482
   Zimmer JP, 2007, CLIN OPHTHALMOL, V1, P25
   Zimmerman D., 2014, DISS THESES GRADWORK, V52, P2014
NR 184
TC 57
Z9 61
U1 0
U2 42
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD APR
PY 2017
VL 22
IS 4
AR 610
DI 10.3390/molecules22040610
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EZ2CQ
UT WOS:000404517800108
PM 28425969
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Logan, S
   Agbaga, MP
   Chan, MD
   Kabir, N
   Mandal, NA
   Brush, RS
   Anderson, RE
AF Logan, Sreemathi
   Agbaga, Martin-Paul
   Chan, Michael D.
   Kabir, Nabila
   Mandal, Nawajes A.
   Brush, Richard S.
   Anderson, Robert E.
TI Deciphering mutant ELOVL4 activity in autosomal-dominant Stargardt
   macular dystrophy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Stargardt disease; condensing enzyme; photoreceptor degeneration
ID POLYENOIC FATTY-ACIDS; PERMEABILITY BARRIER FUNCTION; LONG-CHAIN;
   HISTIDINE-RESIDUES; PROTEIN ELOVL4; WILD-TYPE; DESATURASE; ELONGATION;
   MUTATIONS; MECHANISM
AB Autosomal-dominant Stargardt-like macular dystrophy [Stargardt3 (STGD3)] results from single allelic mutations in the elongation of very-long-chain fatty acids-like 4 (ELOVL4), whereas recessive mutations lead to skin and brain dysfunction. ELOVL4 protein localizes to the endoplasmic reticulum, where it mediates the condensation reaction catalyzing the formation of very-long-chain (VLC) (C-28 to C40) fatty acids, saturated and polyunsaturated (PUFA). The defective gene product is truncated at the C terminus, leading to mislocalization and aggregation in other organelles. We hypothesized that the STGD3 truncated mutant may generate mislocalized, and therefore toxic, keto intermediates of fatty acid elongation, thereby contributing to the disease process. Using cell-based and cell-free microsome assays, we found that the truncated protein lacked innate condensation activity. Coexpression of different forms of wild-type and mutant ELOVL4 revealed a large dominant-negative effect of mutant protein on ELOVL4 localization and enzymatic activity, resulting in reduced VLC-PUFA synthesis. The reduction in VLC-PUFA levels in STGD3 and age-related macular degeneration may be a contributing factor to their retinal pathology.
C1 [Logan, Sreemathi; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Agbaga, Martin-Paul; Chan, Michael D.; Kabir, Nabila; Mandal, Nawajes A.; Brush, Richard S.; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
   [Logan, Sreemathi; Agbaga, Martin-Paul; Chan, Michael D.; Mandal, Nawajes A.; Brush, Richard S.; Anderson, Robert E.] Dean A McGee Eye Inst, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center
RP Anderson, RE (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
EM Robert-Anderson@ouhsc.edu
RI Logan, Sreemathi/AAV-1098-2021
OI Logan, Sreemathi/0000-0001-9160-0383
FU National Institutes of Health [EY000871, EY004149, EY021725, RR017703,
   EY012190]; Foundation Fighting Blindness; Research to Prevent Blindness;
   NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017703] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [P30EY012190, P30EY021725, R01EY004149,
   R01EY000871] Funding Source: NIH RePORTER
FX We thank Dr. Albert O. Edwards (University of Oregon) for providing the
   VLC-PUFA 34:5n3, Dr. Scott M. Plafker (Oklahoma Medical Research
   Foundation) for the pKH3 triple HA-tag vector, Drs. Todd Wuest and David
   M. Sherry (University of Oklahoma Health Sciences Center) for help with
   confocal imaging, and Drs. Xue Cai and James McGinnis (Dean McGee Eye
   Institute) for the ATF6 antibody. This work was supported by National
   Institutes of Health Grants EY000871, EY004149, EY021725, RR017703, and
   EY012190, the Foundation Fighting Blindness, and Research to Prevent
   Blindness.
CR Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Aldahmesh MA, 2011, AM J HUM GENET, V89, P745, DOI 10.1016/j.ajhg.2011.10.011
   Ambasudhan R, 2004, GENOMICS, V83, P615, DOI 10.1016/j.ygeno.2003.10.004
   AVELANGEMACHEREL MH, 1995, FEBS LETT, V361, P111, DOI 10.1016/0014-5793(95)00163-4
   AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1172
   Bank IM, 2008, PEDIATR NEUROL, V39, P429, DOI 10.1016/j.pediatrneurol.2008.08.013
   BERNERT JT, 1977, J BIOL CHEM, V252, P6736
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Cameron DJ, 2007, INT J BIOL SCI, V3, P111
   Chertemps T, 2007, P NATL ACAD SCI USA, V104, P4273, DOI 10.1073/pnas.0608142104
   COURI D, 1982, ANNU REV PHARMACOL, V22, P145, DOI 10.1146/annurev.pa.22.040182.001045
   Denic V, 2007, CELL, V130, P663, DOI 10.1016/j.cell.2007.06.031
   Edwards AO, 2001, INVEST OPHTH VIS SCI, V42, P2652
   GALTEAU MM, 1985, EMBO J, V4, P2793, DOI 10.1002/j.1460-2075.1985.tb04005.x
   GRAHAM DG, 1995, CRIT REV TOXICOL, V25, P91, DOI 10.3109/10408449509021609
   Grayson C, 2005, J BIOL CHEM, V280, P32521, DOI 10.1074/jbc.M503411200
   HAJRA AK, 1986, METHOD ENZYMOL, V122, P50
   HILLMAN RE, 1974, PEDIATRICS, V53, P221
   Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Karan G, 2004, MOL VIS, V10, P248
   Kimura I, 2011, P NATL ACAD SCI USA, V108, P8030, DOI 10.1073/pnas.1016088108
   Konishi H, 2010, J BIOCHEM, V148, P617, DOI 10.1093/jb/mvq092
   Kuppermann N, 2008, ARCH PEDIAT ADOL MED, V162, P544, DOI 10.1001/archpedi.162.6.544
   Li WM, 2007, INT J BIOL SCI, V3, P120
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Mandal MNA, 2004, GENOMICS, V83, P626, DOI 10.1016/j.ygeno.2003.09.020
   Maugeri A, 2004, INVEST OPHTH VIS SCI, V45, P4263, DOI 10.1167/iovs.04-0078
   McMahon A, 2007, MOL VIS, V13, P258
   McPherson PAC, 2012, J PHYSIOL BIOCHEM, V68, P141, DOI 10.1007/s13105-011-0112-4
   Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200
   Naganuma T, 2011, FEBS LETT, V585, P3337, DOI 10.1016/j.febslet.2011.09.024
   NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6
   Okuda A, 2010, MOL VIS, V16, P2438
   Paul S, 2006, J BIOL CHEM, V281, P9018, DOI 10.1074/jbc.M507723200
   POULOS A, 1986, BIOCHEM J, V235, P607, DOI 10.1042/bj2350607
   POULOS A, 1986, BIOCHEM J, V240, P891, DOI 10.1042/bj2400891
   Roe CR, 2007, MOL GENET METAB, V92, P346, DOI 10.1016/j.ymgme.2007.07.012
   SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510
   SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009
   Sommer JR, 2011, BRIT J OPHTHALMOL, V95, P1749, DOI 10.1136/bjophthalmol-2011-300417
   SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991
   Vasireddy V, 2005, MOL VIS, V11, P665
   Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480
   WATMOUGH NJ, 1989, BIOCHEM J, V262, P261, DOI 10.1042/bj2620261
   Yu M, 2012, J LIPID RES, V53, P494, DOI 10.1194/jlr.M021386
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 49
TC 36
Z9 36
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 2
PY 2013
VL 110
IS 14
BP 5446
EP 5451
DI 10.1073/pnas.1217251110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 131ZP
UT WOS:000318037800051
PM 23509295
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Furtado, JM
   Lansingh, VC
   Carter, MJ
   Milanese, MF
   Pena, BN
   Ghersi, HA
   Bote, PL
   Nano, ME
   Silva, JC
AF Furtado, Joao M.
   Lansingh, Van C.
   Carter, Marissa J.
   Milanese, Maria F.
   Pena, Brenda N.
   Ghersi, Hernan A.
   Bote, Paula L.
   Nano, Maria E.
   Silva, Juan C.
TI Causes of Blindness and Visual Impairment in Latin America
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE Latin America; epidemiology; blindness; visual impairment
ID LOW-BIRTH-WEIGHT; OPEN-ANGLE GLAUCOMA; RIO-DE-JANEIRO; TYPE-2
   DIABETES-MELLITUS; ONCHOCERCA-VOLVULUS TRANSMISSION; UNCORRECTED
   REFRACTIVE ERROR; NON-HISPANIC WHITES; SAO-PAULO STATE; RISK-FACTORS;
   MACULAR DEGENERATION
AB We review what is known in each country of the Latin American region with regards to blindness and visual impairment and make some comparisons to Hispanic populations in the United States. Prevalence of blindness varied from 1.1% in Argentina to 4.1% in Guatemala in people 50 years of age and older, with the major cause being cataract. Diabetic retinopathy and glaucoma are starting to make serious inroads, although epidemiological data are limited, and age-related macular degeneration is now a concern in some populations. Infectious diseases such as trachoma and onchocerciasis are quickly diminishing. Although progress has been made, retinopathy of prematurity remains the major cause of childhood blindness. If VISION 2020 is to succeed, many more epidemiological studies will be needed to set priorities, although some can be of the Rapid Assessment of Avoidable Blindness design. Developing the infrastructure for screening and treatment of ophthalmic disease in Latin America continues to be a challenge. (Surv Ophthalmol 57:149-177, 2012. (C) 2012 Elsevier Inc. All rights reserved.)
C1 [Carter, Marissa J.] Strateg Solut Inc, Cody, WY 82414 USA.
   [Furtado, Joao M.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Lansingh, Van C.] Int Agcy Prevent Blindness VIS 2020, Buenos Aires, DF, Argentina.
   [Milanese, Maria F.; Pena, Brenda N.; Ghersi, Hernan A.; Bote, Paula L.; Nano, Maria E.] Fdn Hugo Nano, Buenos Aires, DF, Argentina.
   [Silva, Juan C.] Pan Amer Hlth Org, Santa Fe De Bogota Dc, Colombia.
C3 Oregon Health & Science University; Pan American Health Organization
RP Carter, MJ (通讯作者)，Strateg Solut Inc, 1143 Salsbury Ave, Cody, WY 82414 USA.
EM mcarter@strategic-solutions-inc.com
RI Furtado, Joao M./AAB-5356-2022; Furtado, Joao/D-4436-2012; Silva, Juan
   Carlos/N-9113-2019; Lansingh, Van/C-8672-2018
OI Furtado, Joao M./0000-0003-2490-5747; Silva, Juan
   Carlos/0000-0003-4855-5008; Lansingh, Van/0000-0002-0090-4195
FU ORBIS; Casey Eye Institute VISION
FX Publication of this article was funded in part by a grant from ORBIS.
   JMF was supported by the Casey Eye Institute VISION 2020 International
   Fellowship program.
CR Caligaris LSA, 2011, REV PANAM SALUD PUBL, V29, P428, DOI 10.1590/S1020-49892011000600008
   Caligaris LSA, 2006, OPHTHAL EPIDEMIOL, V13, P365, DOI 10.1080/09286580601013078
   Aguila LP, 2005, REV PANAM SALUD PUBL, V17, P387
   Álvarez G., 2010, Arch Soc Esp Oftalmol, V85, P202, DOI 10.1016/j.oftal.2010.07.001
   Alves APX, 2002, OPHTHALMIC EPIDEMIOL, V9, P29
   Cecchetti DFA, 2008, ARQ BRAS OFTALMOL, V71, P635, DOI 10.1590/S0004-27492008000500005
   Anand A, 2007, EYE, V21, P40, DOI 10.1038/sj.eye.6702114
   [Anonymous], 2006, Arch. argent. pediatr., V104, P69
   [Anonymous], 2010, Wkly Epidemiol Rec, V85, P321
   Araujo A, 2008, ARQ BRAS OFTALMOL, V71, P246, DOI 10.1590/S0004-27492008000200021
   Arias YG, 2008, REV MISION MILAGRO, V2
   Arieta CEL, 2003, OPHTHAL EPIDEMIOL, V10, P15, DOI 10.1076/opep.10.1.15.13774
   Armas MM, 2008, VIS PAN AM, V7, P12
   Arruda Rafael Fávaro, 2004, Rev. Assoc. Med. Bras., V50, P148, DOI 10.1590/S0104-42302004000200029
   Asociacion Mexicana de Retina, 2005, REV MEX OFTALMOL, V79, P88
   Aung T, 2010, AM J OPHTHALMOL, V149, P697, DOI 10.1016/j.ajo.2010.03.003
   Baker RS, 1996, AM J OPHTHALMOL, V122, P213, DOI 10.1016/S0002-9394(14)72012-4
   Banic DM, 2009, ACTA TROP, V112, P125, DOI 10.1016/j.actatropica.2009.07.009
   Baranano AE, 2008, OPHTHALMOLOGY, V115, P815, DOI 10.1016/j.ophtha.2007.05.052
   Ferraz LCB, 2010, ARQ BRAS OFTALMOL, V73, P433, DOI 10.1590/S0004-27492010000500009
   Barria F, 2005, ARCH CHILENOS OFTALM, V62, P9
   Barria von-Bischoffshausen F, 2007, ARCH CHIL OFTALMOL, V64, P69
   Barroso S, 2001, ARCH CHIL OFTALMOL, V58, P29
   Beltranena F, 2007, OPHTHALMOLOGY, V114, P1558, DOI 10.1016/j.ophtha.2006.11.015
   Bernucci E, 1993, REV BRAS OFTALMOL, V52, P43
   Blanks J, 1998, Rev Panam Salud Publica, V3, P367, DOI 10.1590/S1020-49891998000600002
   Bonotto Ligia Beatriz, 2007, Arq. Bras. Oftalmol., V70, P55, DOI 10.1590/S0004-27492007000100011
   Borchert M, 2010, OPHTHALMOLOGY, V117, P148, DOI 10.1016/j.ophtha.2009.06.008
   Bosch-Driessen LEH, 2002, OPHTHALMOLOGY, V109, P869, DOI 10.1016/S0161-6420(02)00990-9
   Botto C., 2005, Parassitologia (Rome), V47, P145
   Bouzas L, 2007, An Pediatr (Barc), V66, P551, DOI 10.1157/13107388
   Brito PR, 2000, ARQ BRAS OFTALMOL, V63, P49
   Broman AT, 2005, ARCH OPHTHALMOL-CHIC, V123, P1231, DOI 10.1001/archopht.123.9.1231
   Camacho AC, 2008, REV SOC COL OFTALMOL, V41, P686
   Campos FJ, 1995, REV PERU OFTALMOL, V19, P26
   Campos JC, 2010, REV BRAS OFTALMOL, V69, P222, DOI 10.1590/S0034-72802010000400003
   Cano Miriam Rafaela, 2007, Community Eye Health, V20, P10
   Cariello Angelino Julio, 2007, Arq. Bras. Oftalmol., V70, P271, DOI 10.1590/S0004-27492007000200015
   Carlos GA, 2009, ARQ BRAS OFTALMOL, V72, P375, DOI 10.1590/S0004-27492009000300018
   Cass H, 2006, CLIN EXP OPHTHALMOL, V34, P146, DOI 10.1111/j.1442-9071.2006.01172.x
   Castillo LP, 2008, REV MISION MILAGRO, V2
   Chacon DC, 2008, REV MISION MILAGRO, V2
   Chiang PPC, 2011, OPHTHAL EPIDEMIOL, V18, P109, DOI 10.3109/09286586.2011.560745
   Chibas AR, 2009, REV MISION MILAGRO, V3, P54
   Chopra V, 2008, OPHTHALMOLOGY, V115, P227, DOI 10.1016/j.ophtha.2007.04.049
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   COOPER PJ, 1995, BRIT J OPHTHALMOL, V79, P157, DOI 10.1136/bjo.79.2.157
   Cortinez MF, 2008, OPHTHAL EPIDEMIOL, V15, P10, DOI 10.1080/09286580701755560
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   Couto Júnior Abelardo de Souza, 2007, Rev. bras.oftalmol., V66, P304, DOI 10.1590/S0034-72802007000500003
   Couto AD, 2010, REV BRAS OFTALMOL, V69, P7, DOI 10.1590/S0034-72802010000100002
   Cruz AAV, 2008, OPHTHAL EPIDEMIOL, V15, P272, DOI 10.1080/09286580802080090
   D'Amaral Rosa Kazuye Koda, 2005, Cad. Saúde Pública, V21, P1701, DOI 10.1590/S0102-311X2005000600017
   Silva AMTDP, 2010, ARQ BRAS OFTALMOL, V73, P266, DOI 10.1590/S0004-27492010000300011
   de Carvalho KM, 1998, J PEDIAT OPHTH STRAB, V35, P162
   de Oliveira DF, 2008, CAD SAUDE PUBLICA, V24, P2440, DOI 10.1590/S0102-311X2008001000024
   de Senne FMB, 2002, ACTA OPHTHALMOL SCAN, V80, P262, DOI 10.1034/j.1600-0420.2002.800306.x
   De-La-Torre A, 2009, BRIT J OPHTHALMOL, V93, P1001, DOI 10.1136/bjo.2008.155861
   De-La-Torre A, 2007, AM J OPHTHALMOL, V143, P354, DOI 10.1016/j.ajo.2006.09.048
   De-La-Torre A, 2009, CLIN EXP OPHTHALMOL, V37, P458, DOI 10.1111/j.1442-9071.2009.02082.x
   DiNuzzo AR, 2001, J GERONTOL A-BIOL, V56, pM548, DOI 10.1093/gerona/56.9.M548
   Dominguez SL, 2008, REV MISION MILAGRO, V2
   Duarte Wladimir Ribeiro, 2003, Cad. Saúde Pública, V19, P551, DOI 10.1590/S0102-311X2003000200022
   Duerksen R, 2003, OPHTHAL EPIDEMIOL, V10, P349, DOI 10.1076/opep.10.5.349.17326
   Dulanto V, 1999, REV PERU OFTALMOL, V23, P91
   Eliason KJ, 2007, J AAPOS, V11, P447, DOI 10.1016/j.jaapos.2007.02.012
   Emanuelli Andres, 2005, P R Health Sci J, V24, P287
   Esposito YM, 2008, REV MISION MILAGRO, V2
   Estacia Paulo, 2007, Rev. bras.oftalmol., V66, P297, DOI 10.1590/S0034-72802007000500002
   Esteso P, 2007, INVEST OPHTH VIS SCI, V48, P4949, DOI 10.1167/iovs.07-0052
   Esteves JF, 2009, REV ASSOC MED BRAS, V55, P268, DOI 10.1590/S0104-42302009000300017
   Nano ME, 2006, OPHTHAL EPIDEMIOL, V13, P191, DOI 10.1080/09286580600584699
   Fabiani R, 2007, OFTALMOL CLIN EXP, V1, P12
   Damasceno RWF, 2009, ARQ BRAS OFTALMOL, V72, P355, DOI 10.1590/S0004-27492009000300014
   FERRERO R, 2005, ARCH MED INT, V27, P7
   Flores-Santos R, 2007, ARCH MED RES, V38, P440, DOI 10.1016/j.arcmed.2006.12.002
   Fortes JB, 2009, EYE, V23, P25, DOI 10.1038/sj.eye.6702924
   Fortes JB, 2009, OPHTHALMOLOGICA, V223, P177, DOI 10.1159/000197114
   Fortes JB, 2009, REV PANAM SALUD PUBL, V26, P216
   Filho JBF, 2007, J PEDIAT-BRAZIL, V83, P209, DOI 10.2223/JPED.1611
   Fortes JB, 2010, GRAEF ARCH CLIN EXP, V248, P893, DOI 10.1007/s00417-009-1248-6
   Fortes JB, 2009, REV BRAS OFTALMOL, V68, P22, DOI 10.1590/S0034-72802009000100005
   Fortes JB, 2009, J PEDIAT-BRAZIL, V85, P48, DOI 10.2223/JPED.1870
   Fortes JB, 2009, GRAEF ARCH CLIN EXP, V247, P831, DOI 10.1007/s00417-008-1012-3
   Foster Allen, 2008, Community Eye Health, V21, P37
   Fozailoff A, 2011, OPHTHALMOLOGY, V118, P284, DOI 10.1016/j.ophtha.2010.06.038
   Freile H, 2004, OFTALMOL SANTA LUCIA, V3
   Portes ALF, 2010, REV BRAS OFTALMOL, V69, P389, DOI 10.1590/S0034-72802010000600008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gaiotto Paulo Cesar, 2002, Medicina (Ribeirao Preto), V35, P487
   Galvis Ramirez V, 2009, MEDUNAB, V12, P66
   Garcia CAD, 2004, OPHTHAL EPIDEMIOL, V11, P301, DOI 10.1080/0928650490515170
   Garcia Carlos Alexandre de Amorim, 2005, Arq. Bras. Oftalmol., V68, P321, DOI 10.1590/S0004-27492005000300009
   Garcia Carlos Alexandre de Amorim, 2005, Arq. Bras. Oftalmol., V68, P75, DOI 10.1590/S0004-27492005000100013
   Garcia-Alcolea E, 2009, REV MEX OFTALMOL, V83, P158
   Garcia-Alcolea EE, 2008, REV MISION MILAGRO, V2
   Garcia-Alcolea EE, 2009, REV SOC COL OFTALMOL, V42, P167
   Garcia-Alcolea EE., 2009, REV MEX OFTALMOL, V83, P87
   Gaviria ML, 2004, REV SOC COL OFTALMOL, V37, P28
   Gerchman F, 2008, BRAZ J MED BIOL RES, V41, P668, DOI 10.1590/S0100-879X2008005000034
   GILBERT C, 1995, OPHTHALMIC GENET, V16, P1, DOI 10.3109/13816819509057847
   Gilbert C, 2005, PEDIATRICS, V115, pE518, DOI 10.1542/peds.2004-1180
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   GILBERT CE, 1994, DEV MED CHILD NEUROL, V36, P326, DOI 10.1111/j.1469-8749.1994.tb11853.x
   GILBERT CE, 1993, EYE, V7, P184, DOI 10.1038/eye.1993.39
   Gilbert C, 2008, EARLY HUM DEV, V84, P77, DOI 10.1016/j.earlhumdev.2007.11.009
   Gilbert CE, 2008, INVEST OPHTH VIS SCI, V49, P877, DOI 10.1167/iovs.07-0973
   Gilbert RE, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000277
   Gilbert-Lucido ME, 2010, REV MEX OFTALMOL, V84, P86
   Gismondi J, 1999, REV PERU OFTALMOL, V23, P60
   GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5
   Goldschmidt P, 2007, REV PANAM SALUD PUBL, V22, P29, DOI 10.1590/S1020-49892007000600004
   Escariao PHG, 2008, ARQ BRAS OFTALMOL, V71, P172, DOI 10.1590/S0004-27492008000200008
   Gonzalez RJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000404
   Gonzalez T, 2004, REV OFTALMOL VENEZ, V60, P144
   Gonzalez Villalpando M E, 1994, Arch Med Res, V25, P355
   Gonzalez-Urquidi O., 2004, REV MEX OFTALMOL, V78, P1
   Gonzalez-Villalpando C, 1999, REV INVEST CLIN, V51, P141
   Guemez-Sandoval E, 2002, REV MEX OFTALMOL, V76, P15
   Haddad MAO, 2007, J PEDIAT OPHTH STRAB, V44, P232, DOI 10.3928/01913913-20070701-04
   Haddad Maria Aparecida Onuki, 2006, Clinics, V61, P239, DOI 10.1590/S1807-59322006000300009
   Harris MI, 1998, DIABETES CARE, V21, P1230, DOI 10.2337/diacare.21.8.1230
   Hernandez EA, 2008, REV MISION MILAGRO, V2
   Neto GH, 2009, ACTA TROP, V112, P115, DOI 10.1016/j.actatropica.2009.07.006
   Holguin AMC, 2006, INVEST OPHTH VIS SCI, V47, P925, DOI 10.1167/iovs.05-0895
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Iribarren R, 2009, OPHTHAL EPIDEMIOL, V16, P84, DOI 10.1080/09286580802624442
   Isaac DLC, 2003, OPHTHALMOLOGICA, V217, P431, DOI 10.1159/000073075
   Jimenez JR, 2004, JPN J OPHTHALMOL, V48, P163, DOI 10.1007/s10384-003-0041-z
   JOSE NK, 1990, INT OPHTHALMOL, V14, P155, DOI 10.1007/BF00158313
   Jost BS, 2010, ARQ BRAS OFTALMOL, V73, P259, DOI 10.1590/S0004-27492010000300010
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kempen JH, 2011, OPHTHAL EPIDEMIOL, V18, P99, DOI 10.3109/09286586.2011.588908
   Khan A, 2007, P NATL ACAD SCI USA, V104, P14872, DOI 10.1073/pnas.0702356104
   Kim E, 2010, CURR OPIN OPHTHALMOL, V21, P100, DOI 10.1097/ICU.0b013e3283360b1e
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kleisinger J, 2011, OFTALMOL CLIN EXP
   Koizumi IK, 2005, REV SAUDE PUBL, V39, P937, DOI 10.1590/S0034-89102005000600011
   Kuper Hannah, 2006, Community Eye Health, V19, P68
   Lam B L, 2000, Ophthalmic Epidemiol, V7, P73
   Lam BL, 2009, OPHTHAL EPIDEMIOL, V16, P144, DOI 10.1080/09286580902863007
   Lansingh VC, 2010, OPHTHAL EPIDEMIOL, V17, P75, DOI 10.3109/09286581003624962
   Laurencio L, 2009, OFTALMOL CLIN EXP, V3, P83
   Layaun S, 1992, RER BRAS OFTALMOL, V1, P47
   Leal Fernando Antônio de Macedo, 2003, Arq. Bras. Oftalmol., V66, P57, DOI 10.1590/S0004-27492003000100011
   Lee DJ, 1998, OPHTHALMOLOGY, V105, P552, DOI 10.1016/S0161-6420(98)93042-1
   Arieta CEL, 2009, OPHTHAL EPIDEMIOL, V16, P58, DOI 10.1080/09286580802575032
   Lermann Viviane Levy, 2006, J. Pediatr. (Rio J.), V82, P27, DOI 10.1590/S0021-75572006000100007
   Lesso-Zamora J, 2009, REV MEX OFTALMOL, V83, P11
   Lima-Gomez V, 2007, CIR CIR, V75, P65
   Lima-Gomez Virgilio, 2010, Cir Cir, V78, P302
   Lima-Gomez V, 2010, CIR CIR, V78, P209
   Lima-Gomez Virgilio, 2005, Cir Cir, V73, P251
   Lima-Gomez Virgilio, 2004, Cir Cir, V72, P447
   Limburg H, 2008, BRIT J OPHTHALMOL, V92, P315, DOI 10.1136/bjo.2007.125906
   Limburg Hans, 2002, Community Eye Health, V15, P51
   Limburg H, 2009, REV PANAM SALUD PUBL, V25, P449, DOI 10.1590/S1020-49892009000500011
   Lindblade KA, 2007, AM J TROP MED HYG, V77, P334, DOI 10.4269/ajtmh.2007.77.334
   Lindblade KA, 2009, AM J TROP MED HYG, V81, P438, DOI 10.4269/ajtmh.2009.81.438
   Lisboa Hugo Roberto Kurtz, 2008, Rev. bras.oftalmol., V67, P297, DOI 10.1590/S0034-72802008000600006
   Lomuto CC, 2010, ARCH ARGENT PEDIATR, V108, P136, DOI 10.1590/S0325-00752010000200008
   Lomuto CC, 2010, ARCH ARGENT PEDIATR, V108, P24, DOI 10.1590/S0325-00752010000100006
   Lopez GL, 2006, B MED UAS, V2, P12
   Lowery J P, 2008, Optometry, V79, P70, DOI 10.1016/j.optm.2007.04.103
   Lucena AD, 2010, ARQ BRAS OFTALMOL, V73, P271, DOI 10.1590/S0004-27492010000300012
   Lucena Abrahão da Rocha, 2004, Arq. Bras. Oftalmol., V67, P197, DOI 10.1590/S0004-27492004000200003
   Luna CP, 2003, CIENC TECNOL SALUD V, V1, P11
   LUNA EJA, 1992, INT J EPIDEMIOL, V21, P169, DOI 10.1093/ije/21.1.169
   Martin ED, 2008, REV MISION MILAGRO, V3
   Martin-Tellaeche A, 1998, ANN TROP MED PARASIT, V92, pS117, DOI 10.1080/00034989859645
   Martinez NG, 2008, REV MISION MILAGRO, V2
   Mathenge W, 2007, OPHTHALMOLOGY, V114, P599, DOI 10.1016/j.ophtha.2006.06.057
   Maul E, 2000, AM J OPHTHALMOL, V129, P445, DOI 10.1016/S0002-9394(99)00454-7
   McKean-Cowdin R, 2008, OPHTHALMOLOGY, V115, P941, DOI 10.1016/j.ophtha.2007.08.037
   Medina NH, 1998, REV SAUDE PUBL, V32, P59, DOI 10.1590/S0034-89101998000100008
   MEDINA NH, 1992, TROP MED PARASITOL, V43, P121
   Medina Norma Helen, 2002, Cad. Saúde Pública, V18, P1537, DOI 10.1590/S0102-311X2002000600006
   Melamed J, 2010, EYE, V24, P528, DOI 10.1038/eye.2009.140
   Memarzadeh F, 2010, INVEST OPHTH VIS SCI, V51, P2872, DOI 10.1167/iovs.08-2956
   Mérula Rafael Vidal, 2005, Arq. Bras. Oftalmol., V68, P299, DOI 10.1590/S0004-27492005000300005
   Merula RV, 2008, ARQ BRAS OFTALMOL, V71, P389, DOI 10.1590/S0004-27492008000300016
   Mitchell JP, 2008, J NATL MED ASSOC, V100, P435, DOI 10.1016/S0027-9684(15)31278-5
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   MORAN DJ, 1984, BRIT J OPHTHALMOL, V68, P343, DOI 10.1136/bjo.68.5.343
   Motta Mário Martins dos Santos, 2008, Rev. bras.oftalmol., V67, P292, DOI 10.1590/S0034-72802008000600005
   Multi-ethnic Pediatric Eye Disease Study Group, 2008, OPHTHALMOLOGY, V115
   Multi-Ethnic Pediatric Eye Disease Study Group, 2010, OPHTHALMOLOGY, V117, p[140, e3]
   Multi-Ethnic Pediatric Eye Disease Study (MEPEDS) Group, 2009, OPHTHALMOLOGY, V116
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   Neena J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002867
   Neto EC, 2000, INT J EPIDEMIOL, V29, P941, DOI 10.1093/ije/29.5.941
   Ojeda CC, 2009, ACTA MED PERU, V26, P17
   Oliveira AM, 2010, REV BRAS OFTALMOL, V69, P110, DOI 10.1590/S0034-72802010000200008
   Olortegui A, 1994, REV PERU EPIDEMIOL, V7, P34, DOI DOI 10.1016/S1091-8531(03)00182-4
   Haddad MAO, 2009, CLINICS, V64, P725, DOI 10.1590/S1807-59322009000800003
   Orozco-Gomez LP, 2006, CIR CIR, V74, P3
   Osaki Tammy Hentona, 2010, International Ophthalmology, V30, P361, DOI 10.1007/s10792-010-9355-2
   Paula JS, 2006, EYE, V20, P533, DOI 10.1038/sj.eye.6701917
   Paula JS, 2002, BRAZ J MED BIOL RES, V35, P1153, DOI 10.1590/S0100-879X2002001000007
   Pena FY, 2011, OFTALMOL CLIN EXP
   Perdomo JCM, 2008, OFTALMOL CLIN EXP, V2, P94
   Phillips Margaret, 1994, Boletin de la Oficina Sanitaria Panamericana, V117, P307
   Picotti C, 2008, ARCH OPHTHALMOL BUEN, V79, P41
   Pinheiro AM, 2009, ARQ BRAS OFTALMOL, V72, P451, DOI 10.1590/S0004-27492009000400005
   Pierre PDP, 2010, REV BRAS OFTALMOL, V69, P12, DOI 10.1590/S0034-72802010000100003
   Povoa CA, 2001, ARQ BRAS OFTALMOL, V64, P303
   Prado Junior J, 1996, Rev Hosp Clin Fac Med Sao Paulo, V51, P44
   Prado-Serrano A, 2005, REV MEX OFTALMOL, V79, P187
   Prado-Serrano A, 2009, REV MEX OFTALMOL, V83, P261
   Aleixo ALQD, 2009, REV SOC BRAS MED TRO, V42, P165, DOI 10.1590/S0037-86822009000200014
   Quiroz-Mercado H, 2000, REV MEX OFTALMOL, V74, P263
   Ramírez-Ortíz Marco A., 2008, Bol. Med. Hosp. Infant. Mex., V65, P179
   Ramirez-Sanchez EV, 2003, REV MEX OFTALMOL, V77, P120
   Reis Ana do Carmo Paula Pessoa dos, 2002, Arq. Bras. Oftalmol., V65, P79, DOI 10.1590/S0004-27492002000100015
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Resnikoff S, 2001, B WORLD HEALTH ORGAN, V79, P222
   Richter GM, 2009, OPHTHALMOLOGY, V116, P2327, DOI 10.1016/j.ophtha.2009.05.040
   Rodrigues TC, 2010, REV ASSOC MED BRAS, V56, P67, DOI 10.1590/S0104-42302010000100019
   Rodriguez FJ, 2009, REV SOC COL OFTALMOL, V42, P117
   Rodriguez FJ, 2009, REV SOC COL OFTALMOL, V42, P197
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Rodriguez-Abrego G, 2005, SALUD PUBLICA MEXICO, V47, P258
   Rodriguez-Perez MA, 2008, AM J TROP MED HYG, V79, P239, DOI 10.4269/ajtmh.2008.79.239
   Rodriguez-Perez MA, 2008, AM J TROP MED HYG, V78, P147, DOI 10.4269/ajtmh.2008.78.147
   Rodriguez-Saldana J, 2010, REV PANAM SALUD PUBL, V28, P440
   Rodriguez-Villalobos Elvia, 2005, Cir Cir, V73, P79
   Romani Flávio Antônio, 2005, Arq. Bras. Oftalmol., V68, P649, DOI 10.1590/S0004-27492005000500015
   Romero AC, 2008, REV MISION MILAGRO, V2
   Rosas P, 1993, REV PERU OFTALMOL, V17, P21
   Rothova Aniki, 2003, Curr Opin Ophthalmol, V14, P384, DOI 10.1097/00055735-200312000-00011
   Sáfadi Marco A. P., 2003, Braz J Infect Dis, V7, P325, DOI 10.1590/S1413-86702003000500007
   Sakata K, 2007, INVEST OPHTH VIS SCI, V48, P4974, DOI 10.1167/iovs.07-0342
   Salcedo SM, 1998, REV PERU OFTALMOL, V22, P33
   Salomao SR, 2008, INVEST OPHTH VIS SCI, V49, P4308, DOI 10.1167/iovs.08-2073
   Salomao SR, 2008, OPHTHAL EPIDEMIOL, V15, P167, DOI 10.1080/09286580701843812
   Salomao SR, 2009, AM J OPHTHALMOL, V148, P199, DOI 10.1016/j.ajo.2009.02.019
   Sanchez M E, 2010, J Pediatr Ophthalmol Strabismus, V47 Online, pe1, DOI 10.3928/01913913-20100324-06
   Sanchez-Buenfil E, 2008, REV MEX OFTAL, V82, P381
   Santos KG, 2005, BRAZ J MED BIOL RES, V38, P221, DOI 10.1590/S0100-879X2005000200010
   Santos Laura Patrícia Ferreira, 2005, Arq. Bras. Oftalmol., V68, P229, DOI 10.1590/S0004-27492005000200014
   Sauerbrey M, 2008, ANN TROP MED PARASIT, V102, P25, DOI 10.1179/136485908X337454
   Schellini SA, 2008, VISION PAN AM, V7, P110
   Schellini SA, 2010, ARQ BRAS OFTALMOL, V73, P358, DOI 10.1590/S0004-27492010000400012
   Schellini SA, 2009, BMC OPHTHALMOL, V9, DOI 10.1186/1471-2415-9-8
   Schellini Silvana Artioli, 2005, Arq. Bras. Oftalmol., V68, P291, DOI 10.1590/S0004-27492005000300003
   Schellini SA, 2009, OPHTHAL EPIDEMIOL, V16, P90, DOI 10.1080/09286580902737524
   Scheufele Tina A, 2004, Tex Med, V100, P60
   Schneider MC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000964
   Schumann RD, 2010, ARQ BRAS OFTALMOL, V73, P47, DOI 10.1590/S0004-27492010000100008
   Serrano JC, 2003, ARCH OPHTHALMOL-CHIC, V121, P1439, DOI 10.1001/archopht.121.10.1439
   Shinsato RN, 2010, ARQ BRAS OFTALMOL, V73, P60, DOI 10.1590/S0004-27492010000100011
   de Oliveira CAS, 2009, ARQ BRAS OFTALMOL, V72, P194, DOI 10.1590/S0004-27492009000200012
   Silber Paulo Caldas, 2002, Arq. Bras. Oftalmol., V65, P441, DOI 10.1590/S0004-27492002000400009
   Silva JR, 2006, REV CUB OFTALMOL, V19, P1
   SILVEIRA C, 1988, AM J OPHTHALMOL, V106, P362, DOI 10.1016/0002-9394(88)90382-0
   Silveira C, 2001, AM J OPHTHALMOL, V131, P351, DOI 10.1016/S0002-9394(00)00830-8
   Siso F, 2005, REV OFTAMOL VENEZ, V61, P112
   Stein JD, 2011, OPHTHALMOLOGY, V118, P1031, DOI 10.1016/j.ophtha.2010.10.024
   Strohl A, 1999, OPHTHALMOLOGE, V96, P359, DOI 10.1007/s003470050418
   Tarczy-Hornoch K, 2006, INVEST OPHTH VIS SCI, V47, P1845, DOI 10.1167/iovs.05-1153
   Tarelo-Saucedo A, 2001, REV MEX OFTALMOL, V75, P1
   TAYLOR HR, 1985, B WORLD HEALTH ORGAN, V63, P559
   Taylor HR, 2000, BRIT J OPHTHALMOL, V84, P1, DOI 10.1136/bjo.84.1.1
   Teran R, 2003, ARCH CHIL OFTALMOL, V60, P90
   Thorn F, 2005, OPTOMETRY VISION SCI, V82, P267, DOI 10.1097/01.OPX.0000159371.25986.67
   Threlfall TJ, 1999, AM J OPHTHALMOL, V128, P280, DOI 10.1016/S0002-9394(99)00161-0
   Torres ML, 2009, REV MISION MILAGRO, V3, P33
   Tudor SM, 1998, DIABETES CARE, V21, P53, DOI 10.2337/diacare.21.1.53
   Ugalde-Palacios R, 2000, REV MEX OFTALMOL, V74, P11
   Urbano Andréia Peltier, 2003, Arq. Bras. Oftalmol., V66, P61, DOI 10.1590/S0004-27492003000100012
   Uribe JA, 2011, OPHTHALMOLOGY, V118, P805, DOI 10.1016/j.ophtha.2010.09.015
   Uzcategui M, 2005, REV OFTALMOL VENEZ, V61, P159
   Vargas WR, 2007, REV MEX OFTALMOL, V81, P142
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2010, AM J OPHTHALMOL, V149, p[728, e1]
   Varma R, 2010, AM J OPHTHALMOL, V149
   Varma R, 2008, INVEST OPHTH VIS SCI, V49, P5264, DOI 10.1167/iovs.08-1814
   Varma R, 2008, MED CARE, V46, P497, DOI 10.1097/MLR.0b013e31816080fe
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Varma R, 2010, AM J OPHTHALMOL, V149, P713, DOI 10.1016/j.ajo.2009.12.011
   Vasconcelos-Santos DV, 2009, OPHTHALMOLOGY, V116, P2199
   Verdaguer J, 2001, ARCH CHIL OFTALMOL, V58, P39
   Viana JM, 1995, REV PERU OFTALMOL, V19, P23
   Vieira Geraldo Magela, 2007, Arq. Bras. Oftalmol., V70, P797, DOI 10.1590/S0004-27492007000500013
   Vieira JC, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-9
   Villalobos ER, 1999, DIABETES CARE, V22, P1905, DOI 10.2337/diacare.22.11.1905
   Villalpando CG, 1997, ARCH MED RES, V28, P129
   Villalpando MEG, 1997, DIABETES CARE, V20, P773, DOI 10.2337/diacare.20.5.773
   Villarreal GM, 2003, OPTOMETRY VISION SCI, V80, P369, DOI 10.1097/00006324-200305000-00011
   Viviani AS, 2003, ARCH CHIL OFTALMOL, V60, P47
   Voorduin S, 2005, REV MEX OFTALMOL, V79, P193
   Waisman V, 2010, OFTALMOL CLIN EXP, V4, P54
   Waisman V, 2007, OFTALMOL CLIN EXP, V1, P5
   Walia Tony, 2008, Community Eye Health, V21, P58
   West S, 2009, BRIT J OPHTHALMOL, V93, P1287, DOI 10.1136/bjo.2008.152694
   West SK, 2002, AM J OPHTHALMOL, V134, P390, DOI 10.1016/S0002-9394(02)01595-7
   West SK, 2001, DIABETES CARE, V24, P1204, DOI 10.2337/diacare.24.7.1204
   Weyll Mônica, 2005, Arq. Bras. Oftalmol., V68, P505, DOI 10.1590/S0004-27492005000400015
   Wilson CJ, 2008, ETHN DIS S2, V18, pS2
   WILSON MR, 1991, J NATL MED ASSOC, V83, P697
   Winthrop KL, 2006, AM J TROP MED HYG, V75, P1058
   Wong C., 1995, ARCH PERUANOS OFTALM, V7, P10
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Wu M, 2008, OPHTHALMOLOGY, V115, P969, DOI 10.1016/j.ophtha.2007.08.002
   Zepeda-Romero LC, 2011, BR J OPHTHALMOL
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zin A, 2001, Community Eye Health, V14, P58
   Zin AA, 2010, PEDIATRICS, V126, pE410, DOI 10.1542/peds.2010-0090
   Zuluaga Claudia, 2005, Colomb. Med., V36, P235
NR 314
TC 88
Z9 95
U1 1
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2012
VL 57
IS 2
BP 149
EP 177
DI 10.1016/j.survophthal.2011.07.002
PG 29
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 902JN
UT WOS:000301034500004
PM 22137039
DA 2022-11-30
ER

PT J
AU Skeie, JM
   Mahajan, VB
AF Skeie, Jessica M.
   Mahajan, Vinit B.
TI Dissection of Human Vitreous Body Elements for Proteomic Analysis
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 47; vitreous; retina; dissection; hyaloid; vitreous
   base; vitreous cortex; vitreous core; protein analysis
ID DIABETIC-RETINOPATHY
AB The vitreous is an optically clear, collagenous extracellular matrix that fills the inside of the eye and overlies the retina. (1,2) Abnormal interactions between vitreous substructures and the retina underlie several vitreoretinal diseases, including retinal tear and detachment, macular pucker, macular hole, age-related macular degeneration, vitreomacular traction, proliferative vitreoretinopathy, proliferative diabetic retinopathy, and inherited vitreoretinopathies. (1,2) The molecular composition of the vitreous substructures is not known. Since the vitreous body is transparent with limited surgical access, it has been difficult to study its substructures at the molecular level. We developed a method to separate and preserve these tissues for proteomic and biochemical analysis. The dissection technique in this experimental video shows how to isolate vitreous base, anterior hyaloid, vitreous core, and vitreous cortex from postmortem human eyes. One-dimensional SDS-PAGE analyses of each vitreous component showed that our dissection technique resulted in four unique protein profiles corresponding to each substructure of the human vitreous body. Identification of differentially compartmentalized proteins will reveal candidate molecules underlying various vitreoretinal diseases.
C1 [Skeie, Jessica M.; Mahajan, Vinit B.] Univ Iowa, Dept Ophthalmol & Visual Sci, Omics Lab, Iowa City, IA 52242 USA.
C3 University of Iowa
RP Mahajan, VB (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Omics Lab, Iowa City, IA 52242 USA.
EM mahajanlab@gmail.com
OI Mahajan, Vinit/0000-0003-1886-1741
FU Fight for Sight; NATIONAL EYE INSTITUTE [F32EY022280] Funding Source:
   NIH RePORTER
FX Funding was provided by Fight for Sight. Tissues were obtained from the
   Iowa Lions Eye Bank.
CR Azimzadeh O, 2010, J PROTEOME RES, V9, P4710, DOI 10.1021/pr1004168
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Izuta H, 2009, MOL VIS, V15, P2663
   Sebag J, 2005, Trans Am Ophthalmol Soc, V103, P473
   Yoshimura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008158
NR 6
TC 11
Z9 11
U1 1
U2 3
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JAN
PY 2011
IS 47
AR e2455
DI 10.3791/2455
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V36LF
UT WOS:000209212800042
PM 21304469
OA Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Sherwin, JC
   Hewitt, AW
   Ruddle, JB
   Mackey, DA
AF Sherwin, Justin C.
   Hewitt, Alex W.
   Ruddle, Jonathan B.
   Mackey, David A.
TI Genetic Isolates in Ophthalmic Diseases
SO OPHTHALMIC GENETICS
LA English
DT Review
DE Founder effect; complex disease; glaucoma; macular degeneration;
   refractive error
ID PRIMARY CONGENITAL GLAUCOMA; RECESSIVE RETINITIS-PIGMENTOSA; LINKED
   JUVENILE RETINOSCHISIS; HEREDITARY OPTIC NEUROPATHY; MACULAR
   CORNEAL-DYSTROPHY; OPEN-ANGLE GLAUCOMA; PERIPAPILLARY CHORIORETINAL
   DEGENERATION; COMPLEMENT FACTOR-H; CONE-ROD DYSTROPHY; OLD ORDER AMISH
AB In recent years, noteworthy gains have been made in unravelling the genetic contribution to some complex ocular diseases, principally age-related macular degeneration. Yet, a relatively poor understanding of the genetic aetiology for many other heritable blinding diseases, Such as glaucoma, keratoconus and myopia, remains. Genetic isolates, populations with varying degrees of geographical or cultural seclusion, provide an effective means for investigating the molecular mechanisms involved in human diseases. This is particularly true for rare diseases in which founded alleles can be rapidly driven to a high frequency due to restriction of gene flow in the population. Recent success in complex gene mapping has resulted from the widened linkage disequilibrium (LD) in the genome of genetically isolated populations. An improved understanding of the predisposing genetic risk factors allows for enhanced screening modalities and paves the foundations for the translation of genomic technology into the clinic. This review focuses on the role population isolates have had in the investigation of genes underlying complex eye diseases and discusses their likely usefulness given the expansion of large-scale case-control association studies.
C1 [Sherwin, Justin C.; Hewitt, Alex W.; Ruddle, Jonathan B.; Mackey, David A.] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Mackey, David A.] Univ Tasmania, Royal Hobart Hosp, Dept Ophthalmol, Hobart, Tas, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Royal Hobart
   Hospital; University of Tasmania
RP Mackey, DA (通讯作者)，Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM D.Mackey@utas.edu.au
RI Mackey, David A/H-5340-2014; Hewitt, Alex W/D-1936-2013
OI Mackey, David A/0000-0001-7914-4709; Hewitt, Alex W/0000-0002-5123-5999
CR Alagramam KN, 2001, HUM MOL GENET, V10, P1709, DOI 10.1093/hmg/10.16.1709
   Alfadhli S, 2006, AM J OPHTHALMOL, V141, P512, DOI 10.1016/j.ajo.2005.11.001
   ALITALO T, 1991, GENOMICS, V9, P505, DOI 10.1016/0888-7543(91)90417-D
   ALITALO T, 1988, AM J HUM GENET, V43, P476
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allingham RR, 2001, BRIT J OPHTHALMOL, V85, P702, DOI 10.1136/bjo.85.6.702
   ALSBIRK PH, 1978, ACTA OPHTHALMOL, V56, P105
   Angelicheva D, 1999, EUR J HUM GENET, V7, P560, DOI 10.1038/sj.ejhg.5200319
   Angius A, 2001, HUM GENET, V109, P198, DOI 10.1007/s004390100557
   Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576
   Arcos-Burgos M, 2002, CLIN GENET, V61, P233, DOI 10.1034/j.1399-0004.2002.610401.x
   Baird PN, 2005, AM J OPHTHALMOL, V140, P760, DOI 10.1016/j.ajo.2005.04.043
   Baird PN, 2003, HUM GENET, V112, P110, DOI 10.1007/s00439-002-0865-5
   Bayes M, 1998, J MED GENET, V35, P141, DOI 10.1136/jmg.35.2.141
   Bedri A, 1999, E AFR MED J, V76, P278
   Bejjani BA, 2000, HUM MOL GENET, V9, P367, DOI 10.1093/hmg/9.3.367
   Belmouden A, 2002, CLIN GENET, V62, P334, DOI 10.1034/j.1399-0004.2002.620415.x
   Benatiya Andaloussi I, 2006, B SOC BELG OPHTHALM, P57
   Bessant DAR, 2000, EUR J HUM GENET, V8, P783, DOI 10.1038/sj.ejhg.5200538
   Bessant DAR, 1998, J MED GENET, V35, P773, DOI 10.1136/jmg.35.9.773
   Biino G, 2005, HUM GENET, V116, P152, DOI 10.1007/s00439-004-1231-6
   BonneTamir B, 1997, AM J PHYS ANTHROPOL, V104, P193, DOI 10.1002/(SICI)1096-8644(199710)104:2<193::AID-AJPA5>3.0.CO;2-#
   BONNETAMIR B, 1994, GENOMICS, V20, P36, DOI 10.1006/geno.1994.1124
   BRODY JA, 1970, LANCET, V1, P1253
   Broman KW, 1999, GENET EPIDEMIOL, V16, P337, DOI 10.1002/(SICI)1098-2272(1999)16:4<337::AID-GEPI1>3.0.CO;2-T
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chakarova C, 2006, MOL VIS, V12, P909
   Chakrabarti S, 2006, INVEST OPHTH VIS SCI, V47, P43, DOI 10.1167/iovs.05-0912
   Chakravarti A, 2003, NATURE, V421, P412, DOI 10.1038/nature01401
   Chiang AP, 2006, P NATL ACAD SCI USA, V103, P6287, DOI 10.1073/pnas.0600158103
   Coleman AL, 1999, LANCET, V354, P1803, DOI 10.1016/S0140-6736(99)04240-3
   Collin GB, 1997, HUM MOL GENET, V6, P213, DOI 10.1093/hmg/6.2.213
   CROSS HE, 1976, AM J OPHTHALMOL, V81, P300, DOI 10.1016/0002-9394(76)90244-0
   DeBraekeleer M, 1996, HUM BIOL, V68, P371
   Dreyer B, 2001, AM J HUM GENET, V69, P228, DOI 10.1086/321269
   Duquette P, 1997, NEUROMUSCULAR DISORD, V7, pS12, DOI 10.1016/S0960-8966(97)00075-8
   Eaves IA, 2000, NAT GENET, V25, P320
   Ebermann I, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r47
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards AO, 1999, AM J OPHTHALMOL, V127, P426, DOI 10.1016/S0002-9394(98)00331-6
   Eichers ER, 2002, AM J HUM GENET, V70, P955, DOI 10.1086/339688
   El-Ashry MF, 2007, J GLAUCOMA, V16, P104, DOI 10.1097/01.ijg.0000212288.00917.e1
   Engle EC, 2007, ARCH OPHTHALMOL-CHIC, V125, P189, DOI 10.1001/archopht.125.2.189
   Eriksson A W, 1972, Duodecim, V88, P43
   Falk MJ, 2004, AM J MED GENET A, V128A, P23, DOI 10.1002/ajmg.a.30033
   Fan Y, 2004, INT J OBESITY, V28, P680, DOI 10.1038/sj.ijo.0802601
   Fan YL, 2005, HUM GENET, V116, P62, DOI 10.1007/s00439-004-1184-9
   Faucher M, 2002, HUM MOL GENET, V11, P2077, DOI 10.1093/hmg/11.18.2077
   Feingold J, 1998, CR ACAD SCI III-VIE, V321, P553, DOI 10.1016/S0764-4469(98)80456-3
   Felbor U, 1997, AM J HUM GENET, V60, P57
   Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011
   FERAK V, 1982, HUM GENET, V61, P198, DOI 10.1007/BF00296441
   Finckh U, 1998, GENOMICS, V48, P341, DOI 10.1006/geno.1997.5194
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   FORSIUS H, 1971, Birth Defects Original Article Series, V7, P83
   Forsius H, 1998, ACTA OPHTHALMOL SCAN, V76, P196, DOI 10.1034/j.1600-0420.1998.760215.x
   Forsius H, 2002, ACTA OPHTHALMOL SCAN, V80, P478, DOI 10.1034/j.1600-0420.2002.800504.x
   FORSIUS H, 1992, ACTA OPHTHALMOL, V70, P26
   FORSIUS H, 1979, T OPHTHAL SOC UK, V99, P296
   FORSIUS H, 1973, CAN J OPHTHALMOL, V8, P274
   FORSIUS H, 1974, ACTA OPHTHALMOL, V52, P421
   FORSIUS H, 1963, Klin Monbl Augenheilkd, V143, P806
   Forsman E, 2007, ACTA OPHTHALMOL SCAN, V85, P500, DOI 10.1111/j.1600-0420.2007.00978.x
   Fossarello M, 1996, ARCH OPHTHALMOL-CHIC, V114, P448, DOI 10.1001/archopht.1996.01100130444016
   Fossarello Maurizio, 1996, International Ophthalmology, V20, P1
   FOSSDAL R, 1995, HUM MOL GENET, V4, P479, DOI 10.1093/hmg/4.3.479
   Fossdal R, 2004, HUM MOL GENET, V13, P975, DOI 10.1093/hmg/ddh106
   Fuchs Josefine, 2005, Ophthalmic Genet, V26, P9, DOI 10.1080/13816810590918406
   Fullerton J, 2002, HUM GENET, V110, P462, DOI 10.1007/s00439-002-0705-7
   Gasch AT, 2003, ARCH OPHTHALMOL-CHIC, V121, P920, DOI 10.1001/archopht.121.6.920-a
   Gehrig A, 1999, J MED GENET, V36, P932
   GENCIK A, 1982, HUM GENET, V61, P193, DOI 10.1007/BF00296440
   Gencik A, 1989, Dev Ophthalmol, V16, P76
   Gerber S, 2000, HUM GENET, V107, P276, DOI 10.1007/s004390000350
   Ghiasvand NM, 1998, AM J MED GENET, V78, P226, DOI 10.1002/(SICI)1096-8628(19980707)78:3<226::AID-AJMG3>3.3.CO;2-F
   Ginns EI, 1996, NAT GENET, V12, P431, DOI 10.1038/ng0496-431
   Grodum K, 2005, OPHTHALMOLOGY, V112, P386, DOI 10.1016/j.ophtha.2004.09.024
   Hameed A, 2001, INVEST OPHTH VIS SCI, V42, P1436
   Hanein Sylvain, 2002, Hum Mutat, V20, P322, DOI 10.1002/humu.9067
   Hardie JG, 2005, EYE, V19, P1280, DOI 10.1038/sj.eye.6701767
   Hayashi H, 2008, AM J OPHTHALMOL, V145, P582, DOI 10.1016/j.ajo.2007.10.023
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   Hewitt AW, 2008, HUM MOL GENET, V17, P710, DOI 10.1093/hmg/ddm342
   Hewitt AW, 2007, MOL VIS, V13, P487
   Hewitt AW, 2005, CLIN EXP OPHTHALMOL, V33, P233, DOI 10.1111/j.1442-9071.2005.01018.x
   Howell N, 2003, AM J HUM GENET, V72, P1460, DOI 10.1086/375537
   HOWELL N, 1991, AM J HUM GENET, V49, P939
   Hulsman CAA, 2002, CLIN GENET, V61, P160, DOI 10.1034/j.1399-0004.2002.610213.x
   Huopaniemi L, 1999, EUR J HUM GENET, V7, P368, DOI 10.1038/sj.ejhg.5200300
   Huopaniemi L, 1997, AM J HUM GENET, V60, P1139
   Ibay Grace, 2004, BMC Med Genet, V5, P20, DOI 10.1186/1471-2350-5-20
   Ismail M, 2006, J HUM GENET, V51, P827, DOI 10.1007/s10038-006-0028-y
   Jalkanen R, 2003, J MED GENET, V40, P418, DOI 10.1136/jmg.40.6.418
   Joensuu T, 2001, AM J HUM GENET, V69, P673, DOI 10.1086/323610
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, EYE, V17, P747, DOI 10.1038/sj.eye.6700374
   Katsanis N, 1999, AM J HUM GENET, V65, P1672, DOI 10.1086/302684
   Khaliq S, 1999, AM J HUM GENET, V65, P571, DOI 10.1086/302493
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koenekoop RK, 2003, AM J OPHTHALMOL, V136, P678, DOI 10.1016/S0002-9394(03)00331-3
   KONDO I, 1990, AM J MED GENET, V37, P109, DOI 10.1002/ajmg.1320370126
   Kumar A, 2004, MOL VIS, V10, P399
   Laberge AM, 2005, CLIN GENET, V68, P287, DOI 10.1111/j.1399-0004.2005.00497.x
   Laberge AM, 2005, AM J HUM GENET, V77, P313, DOI 10.1086/432491
   Lemmela S, 2004, MOL VIS, V10, P260
   LEUTELT J, 1995, CLIN GENET, V47, P122
   Liu NP, 2006, MOL VIS, V12, P1148
   Liu NP, 1998, AM J HUM GENET, V63, P912, DOI 10.1086/302001
   Liu NP, 2000, MOL VIS, V6, P261
   Macmillan C, 2000, AM J HUM GENET, V66, P332, DOI 10.1086/302716
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MAGNUSSON L, 1981, ACTA OPHTHALMOL, V59, P659, DOI 10.1111/j.1755-3768.1981.tb08731.x
   MANTYJARVI M, 1989, ACTA OPHTHALMOL, V67, P234
   Martin SN, 2000, J MED GENET, V37, P422, DOI 10.1136/jmg.37.6.422
   MARTINEZFRIAS ML, 1992, J MED GENET, V29, P483
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Mears AJ, 1999, AM J HUM GENET, V64, P897, DOI 10.1086/302298
   MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197
   Mitchell P, 1999, ARCH OPHTHALMOL-CHIC, V117, P1319, DOI 10.1001/archopht.117.10.1319
   MORISSETTE J, 1995, AM J HUM GENET, V56, P1431
   Nakano M, 2001, NAT GENET, V29, P315, DOI 10.1038/ng744
   Nallasamy S, 2007, MOL VIS, V13, P229
   Ness SL, 2003, J MED GENET, V40, P767, DOI 10.1136/jmg.40.10.767
   Nirmalan PK, 2006, OPHTHAL EPIDEMIOL, V13, P7, DOI 10.1080/09286580500473795
   NORIO R, 1973, ANN CLIN RES, V5, P109
   Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2
   OBRIEN E, 1988, AM J PHYS ANTHROPOL, V75, P477, DOI 10.1002/ajpa.1330750405
   Okamoto H, 2006, MOL VIS, V12, P156
   Ouyang XM, 2003, CLIN GENET, V63, P150, DOI 10.1046/j.0009-9163.2002.00004.x
   Payne AM, 1998, AM J HUM GENET, V62, P192, DOI 10.1086/301679
   Peet JA, 2007, INVEST OPHTH VIS SCI, V48, P4002, DOI 10.1167/iovs.06-1388
   PELIAS MZ, 1988, CYTOGENET CELL GENET, V47, P111, DOI 10.1159/000132524
   Peltonen Leena, 1996, Methods (Orlando), V9, P129, DOI 10.1006/meth.1996.0017
   Plasilova M, 1998, HUM HERED, V48, P30
   Plasilova M, 1998, Cesk Slov Oftalmol, V54, P281
   Poehner WJ, 2000, MOL VIS, V6, P192
   Puomila A, 2007, EUR J HUM GENET, V15, P1079, DOI 10.1038/sj.ejhg.5201828
   Puska Paivi, 2005, Ophthalmic Genet, V26, P17, DOI 10.1080/13816810590918208
   Ramprasad VL, 2007, OPHTHALMIC GENET, V28, P17, DOI 10.1080/13816810701199449
   RAVIA Y, 1993, HUM MOL GENET, V2, P1295, DOI 10.1093/hmg/2.8.1295
   Reddy ABM, 2004, MOL VIS, V10, P696
   Richter A, 1999, AM J HUM GENET, V64, P768, DOI 10.1086/302274
   Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185
   Rojas CV, 2002, EUR J HUM GENET, V10, P638, DOI 10.1038/sj.ejhg.5200856
   Rozzo C, 1999, EUR J HUM GENET, V7, P574, DOI 10.1038/sj.ejhg.5200332
   RUDANKO SL, 1993, ACTA OPHTHALMOL, V71, P586
   Sack J, 1996, OPHTHALMIC GENET, V17, P209, DOI 10.3109/13816819609057895
   Samra D, 1988, Metab Pediatr Syst Ophthalmol (1985), V11, P83
   Sankila E M, 2000, Hum Mutat, V16, P94, DOI 10.1002/1098-1004(200007)16:1<94::AID-HUMU25>3.0.CO;2-T
   Saouda M, 1998, HUM GENET, V103, P193, DOI 10.1007/s004390050806
   Schreyer-Shafir Nira, 2006, Hum Mutat, V27, P1158, DOI 10.1002/humu.9463
   Seitsonen S, 2006, MOL VIS, V12, P796
   Senecky Y, 2001, AM J MED GENET, V101, P195, DOI 10.1002/ajmg.1361
   Shifman S, 2001, NAT GENET, V28, P309, DOI 10.1038/91060
   SHOKEIR MHK, 1985, AM J MED GENET, V22, P495, DOI 10.1002/ajmg.1320220307
   Soley GC, 2003, J GLAUCOMA, V12, P27, DOI 10.1097/00061198-200302000-00005
   Stambolian D, 2005, AM J OPHTHALMOL, V140, P469, DOI 10.1016/j.ajo.2005.04.014
   Stambolian D, 2004, AM J HUM GENET, V75, P448, DOI 10.1086/423789
   Stambolian D, 2006, MOL VIS, V12, P1499
   Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Sundin OH, 2000, NAT GENET, V25, P289, DOI 10.1038/77162
   SVEINSSON K, 1974, ACTA OPHTHALMOL, V52, P596
   TAHVANAINEN E, 1995, GENOMICS, V26, P290, DOI 10.1016/0888-7543(95)80213-6
   Tahvanainen E, 1996, GENOME RES, V6, P249, DOI 10.1101/gr.6.4.249
   TARKKANEN A, 1965, ACTA OPHTHALMOL, V43, P679
   Tay T, 2007, CLIN EXP OPHTHALMOL, V35, P348, DOI 10.1111/j.1442-9071.2007.01484.x
   TEIKARI J, 1990, ACTA GENET MED GEMEL, V39, P133, DOI 10.1017/S0001566000005651
   Thiselton DL, 2001, HUM GENET, V109, P498, DOI 10.1007/s004390100600
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Tischfield MA, 2005, NAT GENET, V37, P1035, DOI 10.1038/ng1636
   Tyynismaa H, 2002, INVEST OPHTH VIS SCI, V43, P3160
   VAINIOMATTILA B, 1969, ACTA OPHTHALMOL, V47, P1135
   van Koolwijk LME, 2007, INVEST OPHTH VIS SCI, V48, P3669, DOI 10.1167/iovs.06-1519
   Vance JM, 1996, AM J HUM GENET, V58, P757
   VANSOEST S, 1994, GENOMICS, V22, P499, DOI 10.1006/geno.1994.1422
   Varilo T, 2004, CURR OPIN GENET DEV, V14, P316, DOI 10.1016/j.gde.2004.04.008
   Vastinsalo H, 2006, MOL VIS, V12, P1093
   Vogt G, 2006, AM J MED GENET A, V140A, P1148, DOI 10.1002/ajmg.a.31276
   Wada Y, 2000, INVEST OPHTH VIS SCI, V41, P1894
   Wang SM, 1998, AM J HUM GENET, V63, P517, DOI 10.1086/301980
   WEISS JS, 1992, CORNEA, V11, P93, DOI 10.1097/00003226-199203000-00001
   Wijesuriya SD, 1996, GENOME RES, V6, P92, DOI 10.1101/gr.6.2.92
   Wojciechowski R, 2006, HUM GENET, V119, P389, DOI 10.1007/s00439-006-0153-x
   Young TL, 2007, ARCH OPHTHALMOL-CHIC, V125, P38, DOI 10.1001/archopht.125.1.38
   Young TL, 1999, AM J HUM GENET, V65, P1680, DOI 10.1086/302686
   Yzer S, 2003, J MED GENET, V40, P709, DOI 10.1136/jmg.40.9.709
   Zlotogora J, 2007, ANN HUM GENET, V71, P202, DOI 10.1111/j.1469-1809.2006.00308.x
   Zlotogora J, 2002, AM J MED GENET, V109, P176, DOI 10.1002/ajmg.10328
   ZLOTOGORA J, 1994, AM J MED GENET, V49, P10, DOI 10.1002/ajmg.1320490104
   Zlotogora J, 2007, EUR J HUM GENET, V15, P272, DOI 10.1038/sj.ejhg.5201760
NR 191
TC 21
Z9 21
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD DEC
PY 2008
VL 29
IS 4
BP 149
EP 161
DI 10.1080/13816810802334341
PG 13
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 403FC
UT WOS:000263067500001
PM 19005985
DA 2022-11-30
ER

PT J
AU Massin, P
   Kaloustian, E
AF Massin, P.
   Kaloustian, E.
TI The elderly diabetic's eyes
SO DIABETES & METABOLISM
LA English
DT Article
DE diabetes mellitus; diabetic retinopathy; elderly people; quality of life
ID OPEN-ANGLE GLAUCOMA; VISUAL-ACUITY; INTRAOCULAR-PRESSURE; GLYCEMIC
   CONTROL; INSULIN THERAPY; RISK-FACTORS; RETINOPATHY; PREVALENCE;
   MELLITUS; PROGRESSION
AB This review article attempts to clarify current and future issues concerning diabetic retinopathy in the elderly. This retinopathy is often part of multiple geriatric ophthalmological diseases (cataract, glaucoma, age-related macular degeneration [ARMD]). Current management is insufficient. A variety of factors come together to aggravate the situation: the increase in the number of elderly diabetic patients and the decrease in the number of ophthalmologists.
   Through a review of the literature, seriously lacking in prospective studies specific to the geriatric population, we discuss the epidemiology, the screening problems, and the various issues concerning the overall ophthalmologic and diabetologic management inherent to these patients' age and condition. We stress the seriousness of the visual disability of the older subject, but also the overall morbidity and mortality. We observe that recommendations can only be based on expert opinion. Each section includes a warning on the high iatrogenic risk in this area. The caregiver should avoid two pitfalls: a lax attitude related to fear or defeatism and excessive interventionism that may be inappropriate to the patient's condition. (c) 2007 Elsevier Masson SAS. All rights reserved.
C1 Hop Lariboisiere, APHP, Serv Ophtalmol, F-75475 Paris 10, France.
   Ctr Hosp Compiegne, Serv Med Interne Endocrinol, Compiegne, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Ambroise-Pare - APHP; Hopital Universitaire Lariboisiere-Fernand-Widal -
   APHP; UDICE-French Research Universities; Universite Paris Cite
RP Massin, P (通讯作者)，Hop Lariboisiere, APHP, Serv Ophtalmol, F-75475 Paris 10, France.
EM pascale.massin@lrb.aphp.fr
CR Bauduceau B, 2005, DIABETES METAB, V31
   Blickle JF, 1999, DIABETES METAB, V25, P84
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Cahill M, 1997, BRIT J OPHTHALMOL, V81, P218, DOI 10.1136/bjo.81.3.218
   Cugati S, 2006, DIABETES RES CLIN PR, V74, P301, DOI 10.1016/j.diabres.2006.04.002
   de Voogd S, 2006, OPHTHALMOLOGY, V113, P1827, DOI 10.1016/j.ophtha.2006.03.063
   DOWLER JGF, 1995, EYE, V9, P313, DOI 10.1038/eye.1995.61
   Ellis JD, 2000, BRIT J OPHTHALMOL, V84, P1218, DOI 10.1136/bjo.84.11.1218
   Fagot-Campagna A, 2005, DIABETES METAB, V31, pS35, DOI 10.1016/S1262-3636(05)73650-8
   FAGOTCAMPAGNA A, 2005, BEH, V12, P48
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Giuffre G, 2004, GRAEF ARCH CLIN EXP, V242, P535, DOI 10.1007/s00417-004-0880-4
   Henricsson M, 1997, DIABETIC MED, V14, P123, DOI 10.1002/(SICI)1096-9136(199702)14:2<123::AID-DIA306>3.0.CO;2-U
   Idil A, 2004, EUR J OPHTHALMOL, V14, P298, DOI 10.1177/112067210401400404
   Kato S, 2002, DIABETES RES CLIN PR, V58, P187, DOI 10.1016/S0168-8227(02)00155-9
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Klein B E, 1995, Ophthalmic Epidemiol, V2, P49, DOI 10.3109/09286589509071451
   KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P1356
   KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   Kohner EM, 2001, DIABETIC MED, V18, P178
   Le A, 2003, INVEST OPHTH VIS SCI, V44, P3783, DOI 10.1167/iovs.03-0077
   Massin P, 1996, DIABETES METAB, V22, P203
   Massin P, 2003, DIABETIC MED, V20, P635, DOI 10.1046/j.1464-5491.2003.01002.x
   Massin P, 2006, ACTA OPHTHALMOL SCAN, V84, P466, DOI 10.1111/j.1600-0420.2006.00694.x
   NIELSEN NV, 1983, ACTA OPHTHALMOL, V61, P662
   Olivarius ND, 2001, GRAEF ARCH CLIN EXP, V239, P664, DOI 10.1007/s004170100324
   Patel JI, 2006, BRIT J OPHTHALMOL, V90, P697, DOI 10.1136/bjo.2005.087403
   Prospective UK, 1998, LANCET, V354, P602
   ROYSARKAR TK, 1993, AM J OPHTHALMOL, V115, P569, DOI 10.1016/S0002-9394(14)71452-7
   SEGATO T, 1991, DIABETIC MED, V8, pS11, DOI 10.1111/j.1464-5491.1991.tb02149.x
   Sinclair AJ, 2000, AGE AGEING, V29, P335, DOI 10.1093/ageing/29.4.335
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Suto C, 2006, ARCH OPHTHALMOL-CHIC, V124, P38, DOI 10.1001/archopht.124.1.38
   TIELSCH JM, 1995, OPHTHALMOLOGY, V102, P48
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Younis N, 2003, LANCET, V361, P195, DOI 10.1016/S0140-6736(03)12267-2
   1999, DIABETES METAB S2, V25, P35
NR 39
TC 14
Z9 14
U1 0
U2 4
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 1262-3636
EI 1878-1780
J9 DIABETES METAB
JI Diabetes Metab.
PD APR
PY 2007
VL 33
SU 1
BP S4
EP S9
DI 10.1016/S1262-3636(07)80052-8
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 171ZO
UT WOS:000246774100003
PM 17702094
DA 2022-11-30
ER

PT J
AU Morales, AM
   Lapuente, CR
   Peyman, GA
   Kivilcim, M
AF Morales, Ana Munoz
   Lapuente, Carlos Ruiz
   Peyman, Gholam A.
   Kivilcim, Muhamet
TI Absorption of diode 810 nm used for transpupillary thermotherapy by
   blood. An in vitro study
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; in vitro
   study; laser transmission
ID CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; THRESHOLD
   PARAMETERS; EYES
AB Background and Objectives: To evaluate the in vitro energy attenuation by transpupillary thermotherapy (TTT) using an 810-nm diode laser after the treatment of exudative age-related macular degeneration.
   Study Design/Materials and Methods: In this experiment, an 810-nm diode laser was coupled to a slit lamp to deliver laser energy to a laser-power sensor adjusted in the track of the laser light. The spotlight was 0.5 mm in diameter; duration of exposure, 3 seconds. Citrated Pasteur pipettes were filled with blood diluted in saline in several concentrations and placed in the path of the laser light. The absorption of the light measured by the power sensor was tested for various delivered irradiances between 50.92 and 509.29 W/cm(2). The differences were analyzed statistically.
   Results: There were significant differences in laser blockage comparing various conditions for all power levels (P<0.05). Increasing the proportion of blood resulted in more laser blockage with all irradiances (P<0.05).
   Conclusions: Blood significantly blocks the transmission of the 810-nm diode TTT laser.
C1 Tulane Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA.
   Virgen Rocio Hosp, Dept Ophthalmol, Seville, Spain.
C3 Tulane University; Virgen del Rocio University Hospital
RP Peyman, GA (通讯作者)，Tulane Univ, Hlth Sci Ctr, Dept Ophthalmol, 1430 Tulane Ave SL-69, New Orleans, LA 70112 USA.
EM gpeyman@tulane.edu
CR Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   CARMACK B, 2004, ARVO
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connolly BP, 2003, OPHTHALMOLOGY, V110, P415, DOI 10.1016/S0161-6420(02)01561-0
   Desmettre T, 2001, INVEST OPHTH VIS SCI, V42, P2976
   ESCOTO RM, 2004, ARVO, P5277
   ITO Y, 2002, ARVO
   KIM SM, 2002, ARVO, P4418
   MAINSTER MA, 1970, J OPT SOC AM, V60, P264, DOI 10.1364/JOSA.60.000264
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Morimura Y, 2004, ARCH OPHTHALMOL-CHIC, V122, P1510, DOI 10.1001/archopht.122.10.1510
   MOSHFEGHI AA, 2002, ARVO
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P505
   Peyman GA, 2003, RETINA-J RET VIT DIS, V23, P378, DOI 10.1097/00006982-200306000-00015
   Peyman GA, 2003, RETINA-J RET VIT DIS, V23, P371, DOI 10.1097/00006982-200306000-00014
   Piccolino FC, 2003, EUR J OPHTHALMOL, V13, P453, DOI 10.1177/112067210301300506
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P648
   Shields CL, 1998, OPHTHALMOLOGY, V105, P581, DOI 10.1016/S0161-6420(98)94008-8
   YAMAJI H, 2002, ARVO
NR 23
TC 0
Z9 0
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PD JUL
PY 2006
VL 38
IS 6
BP 643
EP 646
DI 10.1002/lsm.20330
PG 4
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology; Surgery
GA 072VL
UT WOS:000239701000009
PM 16615134
DA 2022-11-30
ER

PT J
AU Gastaldello, A
   Giampieri, F
   Quiles, JL
   Navarro-Hortal, MD
   Aparicio, S
   Villena, EG
   Pifarre, KT
   De Giuseppe, R
   Grosso, G
   Cianciosi, D
   Forbes-Hernandez, TY
   Nabavi, SM
   Battino, M
AF Gastaldello, Annalisa
   Giampieri, Francesca
   Quiles, Jose L.
   Navarro-Hortal, Maria D.
   Aparicio, Silvia
   Garcia Villena, Eduardo
   Tutusaus Pifarre, Kilian
   De Giuseppe, Rachele
   Grosso, Giuseppe
   Cianciosi, Danila
   Forbes-Hernandez, Tamara Y.
   Nabavi, Seyed M.
   Battino, Maurizio
TI Adherence to the Mediterranean-Style Eating Pattern and Macular
   Degeneration: A Systematic Review of Observational Studies
SO NUTRIENTS
LA English
DT Review
DE macular degeneration; retinal disease; eye disease; maculopathy; drusen;
   Mediterranean diet; plant-based diets; dietary pattern; eating pattern
ID AGE-RELATED MACULOPATHY; EUROPEAN-EYE; COIMBRA EYE; DIET; PROGRESSION;
   PREVALENCE; PIGMENT; ASSOCIATION; CLASSIFICATION; SURVIVAL
AB Age-related macular degeneration (AMD) is a serious degenerative disease affecting the eyes, and is the main cause of severe vision loss among people >55 years of age in developed countries. Its onset and progression have been associated with several genetic and lifestyle factors, with diet appearing to play a pivotal role in the latter. In particular, dietary eating patterns rich in plant foods have been shown to lower the risk of developing the disease, and to decrease the odds of progressing to more advanced stages in individuals already burdened with early AMD. We systematically reviewed the literature to analyse the relationship between the adherence to a Mediterranean diet, a mainly plant-based dietary pattern, and the onset/progression of AMD. Eight human observational studies were analysed. Despite some differences, they consistently indicate that higher adherence to a Mediterranean eating pattern lowers the odds of developing AMD and decreases the risk of progression to more advanced stages of the disease, establishing the way for preventative measures emphasizing dietary patterns rich in plant-foods.
C1 [Gastaldello, Annalisa; Giampieri, Francesca; Quiles, Jose L.; Aparicio, Silvia; Garcia Villena, Eduardo; Tutusaus Pifarre, Kilian; Battino, Maurizio] Univ Europea Atlantico, Res Grp Foods Nutr Biochem & Hlth, Isabel Torres 21, Santander 39011, Spain.
   [Giampieri, Francesca] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah 80200, Saudi Arabia.
   [Quiles, Jose L.; Navarro-Hortal, Maria D.; Forbes-Hernandez, Tamara Y.] Univ Granada, Biomed Res Ctr, Inst Nutr & Food Technol Jose Mataix, Dept Physiol, Granada 18100, Spain.
   [Aparicio, Silvia] Univ Int Cuanza Bairro Kaluanda, Fac Ciencias Sociais & Humanas, Cuito EN 250, Bie, Angola.
   [Garcia Villena, Eduardo; Tutusaus Pifarre, Kilian] Univ Int Iberoamer Campeche, Dept Salud, Imi 24560, Campeche, Mexico.
   [De Giuseppe, Rachele] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Lab Dietet & Clin Nutr, I-27100 Pavia, Italy.
   [Grosso, Giuseppe] Univ Catania, Dept Biomed & Biotechnol Sci, I-95124 Catania, Italy.
   [Cianciosi, Danila; Battino, Maurizio] Polytech Univ Marche, Dept Clin Sci, I-60131 Ancona, Italy.
   [Nabavi, Seyed M.] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran 1435916471, Iran.
   [Battino, Maurizio] Jiangsu Univ, Int Joint Res Lab Intelligent Agr & Agriprod Proc, Zhenjiang 212013, Jiangsu, Peoples R China.
C3 King Abdulaziz University; University of Granada; University of Pavia;
   University of Catania; Marche Polytechnic University; Baqiyatallah
   University of Medical Sciences (BMSU); Jiangsu University
RP Giampieri, F; Battino, M (通讯作者)，Univ Europea Atlantico, Res Grp Foods Nutr Biochem & Hlth, Isabel Torres 21, Santander 39011, Spain.; Giampieri, F (通讯作者)，King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah 80200, Saudi Arabia.; Battino, M (通讯作者)，Polytech Univ Marche, Dept Clin Sci, I-60131 Ancona, Italy.; Battino, M (通讯作者)，Jiangsu Univ, Int Joint Res Lab Intelligent Agr & Agriprod Proc, Zhenjiang 212013, Jiangsu, Peoples R China.
EM annalisa80it@yahoo.it; f.giampieri@univpm.it; jlquiles@ugr.es;
   mdnavarro@ugr.es; silvia.aparicio@uneatlantico.es;
   eduardo.garcia@uneatlantico.es; kilian.tutusaus@uneatlantico.es;
   rachele.degiuseppe@unipv.it; giuseppe.grosso@unict.it;
   d.cianciosi@pm.univpm.it; tforbes@ugr.es; nabavi208@gmail.com;
   m.a.battino@univpm.it
RI Navarro-Hortal, María D./AAB-9805-2019; Giampieri,
   Francesca/I-1911-2015; Grosso, Giuseppe/K-6730-2016; Cianciosi,
   Danila/H-7405-2019; Quiles, Jose L./C-6911-2013; De Giuseppe,
   Rachele/K-4899-2018; Battino, Maurizio/E-6103-2012
OI Giampieri, Francesca/0000-0002-8151-9132; Grosso,
   Giuseppe/0000-0003-3930-5285; Quiles, Jose L./0000-0002-9048-9086; De
   Giuseppe, Rachele/0000-0002-5583-7735; Navarro-Hortal, Maria
   D./0000-0002-6225-8379; Cianciosi, Danila/0000-0002-8781-3535;
   Gastaldello, Annalisa/0000-0002-4365-1191; Aparicio Obregon,
   Silvia/0000-0001-5777-6967; Garcia Villena, Eduardo/0000-0001-7549-3733;
   Battino, Maurizio/0000-0002-7250-1782
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Dow C, 2018, EUR J EPIDEMIOL, V33, P141, DOI 10.1007/s10654-017-0338-8
   Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jacobs DR, 2003, AM J CLIN NUTR, V78, p508S, DOI 10.1093/ajcn/78.3.508S
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Langer RD, 2003, ANN EPIDEMIOL, V13, pS107, DOI 10.1016/S1047-2797(03)00047-4
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lien EL, 2011, PROG RETIN EYE RES, V30, P188, DOI 10.1016/j.preteyeres.2011.01.001
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Martinez-Gonzalez MA, 2004, EUR J CLIN NUTR, V58, P1550, DOI 10.1038/sj.ejcn.1602004
   Martinez-Gonzalez MA, 2002, EUR J NUTR, V41, P153, DOI 10.1007/s00394-002-0370-6
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Merle BMJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.17
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Modesti PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147601
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1016/j.ijsu.2021.105906, 10.1136/bmj.n71]
   Pallauf K, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/707421
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sickel W, 1972, Adv Exp Med Biol, V24, P101
   Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673
   Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wells GA., NEWCASTLE OTTAWA SCA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 63
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD MAY
PY 2022
VL 14
IS 10
AR 2028
DI 10.3390/nu14102028
PG 19
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 1R3FC
UT WOS:000803257800001
PM 35631175
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Radhakrishnan, R
   Dronamraju, VR
   Leung, M
   Gruesen, A
   Solanki, AK
   Walterhouse, S
   Roehrich, H
   Song, G
   Monsanto, RD
   Cureoglu, S
   Martin, R
   Kondkar, AA
   van Kuijk, FJ
   Montezuma, SR
   Knoelker, HJ
   Hufnagel, RB
   Lobo, GP
AF Radhakrishnan, Rakesh
   Dronamraju, Venkateshwara R.
   Leung, Matthias
   Gruesen, Andrew
   Solanki, Ashish K.
   Walterhouse, Stephen
   Roehrich, Heidi
   Song, Grace
   da Costa Monsanto, Rafael
   Cureoglu, Sebahattin
   Martin, Rene
   Kondkar, Altaf A.
   van Kuijk, Frederik J.
   Montezuma, Sandra R.
   Knoelker, Hans-Joachim
   Hufnagel, Robert B.
   Lobo, Glenn P.
TI The role of motor proteins in photoreceptor protein transport and visual
   function
SO OPHTHALMIC GENETICS
LA English
DT Review
DE Motor protein; Myosin 1C; photoreceptor; Rhodopsin; protein
   localization; outer segments; visual function; actin; trafficking;
   retinal degeneration
ID DOMINANT RETINITIS-PIGMENTOSA; ROD OUTER SEGMENTS; BORDER MYOSIN-I;
   INTRAFLAGELLAR TRANSPORT; UNCONVENTIONAL MYOSIN; MELANOSOME
   DISTRIBUTION; RETINAL DEGENERATION; RHODOPSIN MUTATIONS; ENDOCYTIC
   VESICLES; CYTOPLASMIC TAIL
AB Background Rods and cones are photoreceptor neurons in the retina that are required for visual sensation in vertebrates, wherein the perception of vision is initiated when these neurons respond to photons in the light stimuli. The photoreceptor cell is structurally studied as outer segments (OS) and inner segments (IS) where proper protein sorting, localization, and compartmentalization are critical for phototransduction, visual function, and survival. In human retinal diseases, improper protein transport to the OS or mislocalization of proteins to the IS and other cellular compartments could lead to impaired visual responses and photoreceptor cell degeneration that ultimately cause loss of visual function. Results Therefore, studying and identifying mechanisms involved in facilitating and maintaining proper protein transport in photoreceptor cells would help our understanding of pathologies involving retinal cell degeneration in inherited retinal dystrophies, age-related macular degeneration, and Usher Syndrome. Conclusions Our mini-review will discuss mechanisms of protein transport within photoreceptors and introduce a novel role for an unconventional motor protein, MYO1C, in actin-based motor transport of the visual chromophore Rhodopsin to the OS, in support of phototransduction and visual function.
C1 [Radhakrishnan, Rakesh; Dronamraju, Venkateshwara R.; Leung, Matthias; Gruesen, Andrew; Roehrich, Heidi; Lobo, Glenn P.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55905 USA.
   [Solanki, Ashish K.; Walterhouse, Stephen; Lobo, Glenn P.] Med Univ South Carolina, Dept Med Drug Discovery Bldg, Columbia, SC USA.
   [Song, Grace; da Costa Monsanto, Rafael; Cureoglu, Sebahattin] Univ Minnesota, Dept Otolaryngol, Minneapolis, MN USA.
   [Martin, Rene; Knoelker, Hans-Joachim] Tech Univ Dresden, Fac Chem, Dresden, Germany.
   [Kondkar, Altaf A.] King Saud Univ, Coll Med, Dept Ophthalmol Glaucoma Res Chair Ophthalmol, Riyadh, Saudi Arabia.
   [Kondkar, Altaf A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
   [van Kuijk, Frederik J.; Montezuma, Sandra R.] NEI, Natl Inst Hlth, Ophthalm Genet & Visual Funct Branch, Bethesda, MD USA.
   [Hufnagel, Robert B.] Med Univ South Carolina, Dept Ophthalmol, Columbia, SC USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   Medical University of South Carolina; University of Minnesota System;
   University of Minnesota Twin Cities; Technische Universitat Dresden;
   King Saud University; University of Minnesota System; University of
   Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Medical University of South Carolina
RP Lobo, GP (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55905 USA.
EM lobo0023@umn.edu
RI Kondkar, Altaf/ACU-8038-2022; Solanki, Ashish K/F-5210-2017
OI Kondkar, Altaf/0000-0002-5516-6951; Solanki, Ashish
   K/0000-0002-5043-1699
CR Adamek N, 2011, CELL MOL LIFE SCI, V68, P139, DOI 10.1007/s00018-010-0448-x
   Arshavsky VY, 2012, J BIOL CHEM, V287, P1620, DOI 10.1074/jbc.R111.305243
   Aschenbrenner L, 2004, MOL BIOL CELL, V15, P2253, DOI 10.1091/mbc.E04-01-0002
   Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767
   Athanasiou D, 2018, PROG RETIN EYE RES, V62, P1, DOI 10.1016/j.preteyeres.2017.10.002
   Athanasiou D, 2012, MOL BIOL CELL, V23, P3522, DOI 10.1091/mbc.E12-02-0168
   Avasthi P, 2009, J NEUROSCI, V29, P14287, DOI 10.1523/JNEUROSCI.3976-09.2009
   Baek JI, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-60
   BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375
   Bales KL, 2018, MOL VIS, V24, P153
   Bales KL, 2016, EXP EYE RES, V150, P71, DOI 10.1016/j.exer.2015.11.007
   Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177
   Biovia D.S., 2017, DISCOVERY STUDIO MOD
   Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004
   Calabro KR, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01255
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204
   Chen AH, 2001, ARCH OTOLARYNGOL, V127, P921, DOI 10.1001/archotol.127.8.921
   Chinthalapudi K, 2011, J BIOL CHEM, V286, P29700, DOI 10.1074/jbc.M111.239210
   Concepcion F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010904
   Cordonnier MN, 2001, MOL BIOL CELL, V12, P4013, DOI 10.1091/mbc.12.12.4013
   Crouse JA, 2014, CYTOSKELETON, V71, P302, DOI 10.1002/cm.21173
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Davenport SLH, 1977, 5 INT C BIRTH DEF MO
   Deretic D, 2005, P NATL ACAD SCI USA, V102, P3301, DOI 10.1073/pnas.0500095102
   Deretic D, 1998, P NATL ACAD SCI USA, V95, P10620, DOI 10.1073/pnas.95.18.10620
   Donaudy F, 2003, AM J HUM GENET, V72, P1571, DOI 10.1086/375654
   Durrbach A, 1996, P NATL ACAD SCI USA, V93, P7053, DOI 10.1073/pnas.93.14.7053
   ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171
   Fanelli F, 2021, PFLUG ARCH EUR J PHY, V473, P1339, DOI 10.1007/s00424-021-02546-x
   Feng D, 2017, J BIOL CHEM, V292, P17375, DOI 10.1074/jbc.M117.784017
   Fishilevich S, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw030
   Foth BJ, 2006, P NATL ACAD SCI USA, V103, P3681, DOI 10.1073/pnas.0506307103
   Futter CE, 2004, MOL BIOL CELL, V15, P2264, DOI 10.1091/mbc.E03-10-0772
   Garcia JA, 1998, J NEUROSCI, V18, P8637
   Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580
   GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0
   Gillespie PG, 2001, J CELL BIOL, V155, P703, DOI 10.1083/jcb.200110032
   Gorbatyuk MS, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100860
   Gross AK, 2003, BIOCHEMISTRY-US, V42, P2002, DOI 10.1021/bi020612r
   Gupta P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180301
   Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174
   Hagstrom SA, 2001, INVEST OPHTH VIS SCI, V42, P1955
   Hagstrom SA, 2012, ADV EXP MED BIOL, V723, P783, DOI 10.1007/978-1-4614-0631-0_100
   HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815
   Hofmann L, 2015, PROG RETIN EYE RES, V49, P46, DOI 10.1016/j.preteyeres.2015.07.004
   HOGAN MJ, 1974, NATURE, V252, P305, DOI 10.1038/252305a0
   Hollingsworth TJ, 2012, INT REV CEL MOL BIO, V293, P1, DOI 10.1016/B978-0-12-394304-0.00006-3
   Holt JR, 2002, CELL, V108, P371, DOI 10.1016/S0092-8674(02)00629-3
   Imanishi Y, 2019, ANNU REV VIS SCI, V5, P73, DOI 10.1146/annurev-vision-091718-014843
   Insinna C, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-12
   Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200
   Jastrzebska B, 2013, AMINO ACIDS, V45, P1303, DOI 10.1007/s00726-013-1593-y
   Jiang M, 2020, J CELL SCI, V133, DOI 10.1242/jcs.242214
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2
   Kim SV, 2006, SCIENCE, V314, P136, DOI 10.1126/science.1131920
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Kitamoto J, 2005, EXP EYE RES, V81, P116, DOI 10.1016/j.exer.2005.02.014
   Kong SS, 2013, CELL RES, V23, P835, DOI 10.1038/cr.2013.59
   Krendel M, 2009, J AM SOC NEPHROL, V20, P86, DOI 10.1681/ASN.2007111172
   Krock BL, 2009, INVEST OPHTH VIS SCI, V50, P5463, DOI 10.1167/iovs.09-3828
   Kryger Z, 1998, VISUAL NEUROSCI, V15, P685, DOI 10.1017/S0952523898154081
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176
   Libby RT, 2004, J CELL SCI, V117, P4509, DOI 10.1242/jcs.01316
   Lin-Jones J, 2009, J COMP NEUROL, V513, P209, DOI 10.1002/cne.21958
   Liu XR, 1999, J NEUROSCI, V19, P6267
   Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2
   Liu XR, 1998, NAT GENET, V19, P117, DOI 10.1038/470
   Liu XZ, 1998, AM J HUM GENET, V63, P909, DOI 10.1086/302026
   Lobo GP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151806
   Lobo GP, 2016, ADV EXP MED BIOL, V854, P223, DOI 10.1007/978-3-319-17121-0_30
   LONG KO, 1986, EXP EYE RES, V43, P193, DOI 10.1016/S0014-4835(86)80087-2
   Lopes VS, 2011, HUM MOL GENET, V20, P2560, DOI 10.1093/hmg/ddr155
   Lopes VS, 2010, MOL BIOL CELL, V21, P4076, DOI 10.1091/mbc.E10-08-0715
   Luby-Phelps K, 2008, VISION RES, V48, P413, DOI 10.1016/j.visres.2007.08.022
   Maeda A, 2010, P NATL ACAD SCI USA, V107, P8428, DOI 10.1073/pnas.1000640107
   Malanson KM, 2009, PROG MOL BIOL TRANSL, V88, P1, DOI 10.1016/S1877-1173(09)88001-0
   Maravillas-Montero JL, 2014, EUR J IMMUNOL, V44, P877, DOI 10.1002/eji.201343873
   Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4
   Mathur P, 2015, BBA-MOL BASIS DIS, V1852, P406, DOI 10.1016/j.bbadis.2014.11.020
   Mazelova J, 2009, EMBO J, V28, P183, DOI 10.1038/emboj.2008.267
   Mazzolini R, 2012, P NATL ACAD SCI USA, V109, P1530, DOI 10.1073/pnas.1108411109
   Mburu Philomena, 1997, Genes and Function, V1, P191
   Mele C, 2011, NEW ENGL J MED, V365, P295, DOI 10.1056/NEJMoa1101273
   Mochizuki E, 2010, EXP ANIM TOKYO, V59, P57, DOI 10.1538/expanim.59.57
   Munnich S, 2013, ACTA CRYSTALLOGR F, V69, P1020, DOI 10.1107/S1744309113020988
   Mustafi D, 2009, PROG RETIN EYE RES, V28, P289, DOI 10.1016/j.preteyeres.2009.05.003
   Nemet I, 2015, PROG MOL BIOL TRANSL, V132, P39, DOI 10.1016/bs.pmbts.2015.02.007
   Newport TD, 2019, NUCLEIC ACIDS RES, V47, pD390, DOI 10.1093/nar/gky1047
   Nolen RM, 2020, OPHTHALMIC GENET, V41, P401, DOI 10.1080/13816810.2020.1747090
   Orban T, 2014, CURR OPIN CELL BIOL, V27, P32, DOI 10.1016/j.ceb.2013.11.001
   Ortega Joseph T, 2022, Adv Exp Med Biol, V1371, P61, DOI 10.1007/5584_2021_682
   Phillips KR, 2006, J NEUROSCI, V26, P10777, DOI 10.1523/JNEUROSCI.1847-06.2006
   Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952
   Ross JL, 2008, BIOPHYS J, V94, P3115, DOI 10.1529/biophysj.107.120014
   RUPPERT C, 1995, J CELL SCI, V108, P3775
   Sakai T, 2011, P NATL ACAD SCI USA, V108, P7028, DOI 10.1073/pnas.1009188108
   Sakami S, 2011, J BIOL CHEM, V286, P10551, DOI 10.1074/jbc.M110.209759
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Schlamp CL, 1996, EXP EYE RES, V63, P613, DOI 10.1006/exer.1996.0155
   Sengillo JD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11679-y
   SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405
   SJOSTRAND FS, 1953, J CELL COMPAR PHYSL, V42, P45, DOI 10.1002/jcp.1030420104
   Skeie JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082140
   Skowron JF, 1998, CELL MOTIL CYTOSKEL, V41, P308, DOI 10.1002/(SICI)1097-0169(1998)41:4<308::AID-CM4>3.3.CO;2-A
   SMITH RJH, 1994, AM J MED GENET, V50, P32, DOI 10.1002/ajmg.1320500107
   Solanki AK, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061322
   ?sterberg G, 1935, ACTA OPHTHALMOL, V13, P1
   Stewart EEM, 2020, J VISION, V20, DOI 10.1167/jov.20.12.2
   Steyger PS, 1998, J NEUROSCI, V18, P4603
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Sukumaran S, 2009, VISION RES, V49, P479, DOI 10.1016/j.visres.2008.12.009
   Sun CJ, 2021, J CELL MOL MED, V25, P9084, DOI 10.1111/jcmm.16882
   SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481
   SUNG CH, 1993, J BIOL CHEM, V268, P26645
   SUNG CH, 1994, J NEUROSCI, V14, P5818
   Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4
   Taki T, 2005, ONCOGENE, V24, P5191, DOI 10.1038/sj.onc.1208711
   Tam BM, 2014, J NEUROSCI, V34, P13336, DOI 10.1523/JNEUROSCI.1655-14.2014
   Tam BM, 2004, MOL BIOL CELL, V15, P2027, DOI 10.1091/mbc.E03-09-0650
   Tassopoulou-Fishell M, 2012, AM J ORTHOD DENTOFAC, V141, P51, DOI 10.1016/j.ajodo.2011.06.033
   Trivedi D, 2012, J NEUROSCI, V32, P10587, DOI 10.1523/JNEUROSCI.0015-12.2012
   Tsujikawa M, 2004, NEURON, V42, P703, DOI 10.1016/S0896-6273(04)00268-5
   Tyska MJ, 2005, MOL BIOL CELL, V16, P2443, DOI 10.1091/mbc.E04-12-1116
   Udovichenko IP, 2002, J CELL SCI, V115, P445
   Umeki N, 2009, P NATL ACAD SCI USA, V106, P8483, DOI 10.1073/pnas.0812930106
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Verhey KJ, 2011, ANNU REV BIOPHYS, V40, P267, DOI 10.1146/annurev-biophys-042910-155310
   VERNON M, 1969, J CHRON DIS, V22, P133, DOI 10.1016/0021-9681(69)90055-1
   Wan A, 2019, HUM MUTAT, V40, P1127, DOI 10.1002/humu.23762
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wang J, 2012, EMBO J, V31, P4057, DOI 10.1038/emboj.2012.253
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Wensel TG, 2008, VISION RES, V48, P2052, DOI 10.1016/j.visres.2008.03.010
   WIKLER KC, 1990, J NEUROSCI, V10, P3390
   Williams DS, 2011, BIOCHEM SOC T, V39, P1207, DOI 10.1042/BST0391207
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Yang Y, 2009, P NATL ACAD SCI USA, V106, P4189, DOI 10.1073/pnas.0808682106
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1974, EXP EYE RES, V18, P215, DOI 10.1016/0014-4835(74)90150-X
   Zadro C, 2009, BBA-MOL BASIS DIS, V1792, P27, DOI 10.1016/j.bbadis.2008.10.017
NR 146
TC 0
Z9 0
U1 5
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD MAY 4
PY 2022
VL 43
IS 3
BP 285
EP 300
DI 10.1080/13816810.2022.2062391
EA APR 2022
PG 16
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 1W7TA
UT WOS:000787705600001
PM 35470760
OA hybrid
DA 2022-11-30
ER

PT J
AU Lee, SSY
   Nilagiri, VK
   Mackey, DA
AF Lee, Samantha S. Y.
   Nilagiri, Vinay K.
   Mackey, David A.
TI Sleep and eye disease: A review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; eye disease; glaucoma; sleep; sleep
   apnoea
ID ISCHEMIC OPTIC NEUROPATHY; CENTRAL SEROUS CHORIORETINOPATHY; FIBER LAYER
   THICKNESS; IDIOPATHIC INTRACRANIAL HYPERTENSION; APNEA-HYPOPNEA
   SYNDROME; AIRWAY PRESSURE THERAPY; NORMAL-TENSION GLAUCOMA; DIABETIC
   MACULAR EDEMA; INTRAOCULAR-PRESSURE; CPAP THERAPY
AB There is a growing body of literature on the effects of sleep disorders, in particular obstructive sleep apnoea (OSA), on ocular health, with consistent evidence of an increased risk of floppy eyelid syndrome, non-arteritic anterior ischaemic optic neuropathy, diabetic macular oedema, and other retinal vasculature changes in individuals with OSA. However, reports on OSA's associations with glaucoma, papilloedema, diabetic retinopathy, central serous chorioretinopathy, and keratoconus have been conflicting, while links between OSA and age-related macular degeneration have only been described fairly recently. Despite numerous suggestions that OSA treatment may reduce risk of these eye diseases, well-designed studies to support these claims are lacking. In particular, the ocular hypertensive effects of continuous positive airway pressure (CPAP) therapy for OSA requires further investigation into its potential impact on glaucoma risk and management. Reports of ocular surface complications secondary to leaking CPAP masks highlights the importance of ensuring good mask fit. Poor sleep habits have also been linked with increased myopia risk; however, the evidence on this association remains weak.
C1 [Lee, Samantha S. Y.; Nilagiri, Vinay K.; Mackey, David A.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Incorporating Lions Eye Inst, Perth, WA, Australia.
   [Mackey, David A.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Mackey, David A.] Univ Tasmania, Menzies Res Inst Tasmania, Sch Med, Hobart, Tas, Australia.
C3 Lions Eye Institute; University of Western Australia; Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital; University of
   Melbourne; University of Tasmania; Menzies Institute for Medical
   Research
RP Lee, SSY (通讯作者)，Lions Eye Inst Australia, 2 Verdun St, Nedlands, WA 6009, Australia.
EM samantha.sy.lee29@gmail.com
RI Mackey AO, David/H-5340-2014
OI Mackey AO, David/0000-0001-7914-4709; Lee, Sze-Yee/0000-0001-6635-1098;
   Kumar, Vinay/0000-0003-4061-6582
FU NHMRC Program Grant [APP1150144]; NHMRC Practitioner Fellowship
   [APP1154518]
FX This work is funded by a NHMRC Program Grant (APP1150144). David A.
   Mackey is supported by a NHMRC Practitioner Fellowship, Grant/Award
   Number: (APP1154518)
CR Altaf QA, 2017, AM J RESP CRIT CARE, V196, P892, DOI 10.1164/rccm.201701-0175OC
   Aptel F, 2015, JAMA OPHTHALMOL, V133, P797, DOI 10.1001/jamaophthalmol.2015.0893
   Aptel F, 2014, SLEEP MED, V15, P576, DOI 10.1016/j.sleep.2013.11.790
   Arda H, 2013, BRIT J OPHTHALMOL, V97, P206, DOI 10.1136/bjophthalmol-2012-302598
   Assefa SZ, 2015, AIMS NEUROSCI, V2, P155, DOI 10.3934/Neuroscience.2015.3.155
   Ayaki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33902
   Bak-Nielsen S, 2019, ACTA OPHTHALMOL, V97, P497, DOI 10.1111/aos.13961
   Batum M, 2020, INT OPHTHALMOL, V40, P2475, DOI 10.1007/s10792-020-01426-0
   Berg Erich J, 2018, Am J Ophthalmol Case Rep, V10, P87, DOI 10.1016/j.ajoc.2018.02.007
   Bilgin G, 2013, J NEURO-OPHTHALMOL, V33, P232, DOI 10.1097/WNO.0b013e31828eecbd
   Brodie FL, 2016, RETINA-J RET VIT DIS, V36, P657, DOI 10.1097/IAE.0000000000000980
   Brodie FL, 2015, RETINA-J RET VIT DIS, V35, P238, DOI 10.1097/IAE.0000000000000326
   Bruce BB, 2009, NEUROLOGY, V72, P304, DOI 10.1212/01.wnl.0000333254.84120.f5
   Casas P, 2013, GRAEF ARCH CLIN EXP, V251, P1625, DOI 10.1007/s00417-013-2268-9
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chatziralli I, 2017, CURR EYE RES, V42, P1069, DOI 10.1080/02713683.2016.1276196
   Chiang JF, 2021, AM J OPHTHALMOL, V226, P217, DOI 10.1016/j.ajo.2021.01.022
   Chou KT, 2012, AM J OPHTHALMOL, V154, P200, DOI 10.1016/j.ajo.2012.01.011
   Cohen Y, 2015, GRAEF ARCH CLIN EXP, V253, P2263, DOI 10.1007/s00417-015-3153-5
   CULBERTSON WW, 1994, CORNEA, V13, P33, DOI 10.1097/00003226-199401000-00007
   DONNENFELD ED, 1991, OPHTHALMOLOGY, V98, P1674
   Ekinci M, 2013, CURR EYE RES, V38, P1104, DOI 10.3109/02713683.2013.804578
   Ely JR, 2006, J CLIN SLEEP MED, V2, P330
   ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9
   Eom Youngsub, 2012, Korean J Ophthalmol, V26, P260, DOI 10.3341/kjo.2012.26.4.260
   Fan YY, 2019, EYE, V33, P1459, DOI 10.1038/s41433-019-0430-2
   Fayers T, 2007, CORNEA, V26, P1292, DOI 10.1097/ICO.0b013e31814923aa
   Ferrandez B, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0216-2
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Geyer O, 2003, AM J OPHTHALMOL, V136, P1093, DOI 10.1016/S0002-9394(03)00709-8
   Girkin CA, 2006, BRIT J OPHTHALMOL, V90, P679, DOI 10.1136/bjo.2005.086082
   Gupta PK, 2012, CORNEA, V31, P595, DOI 10.1097/ICO.0b013e31823f8acd
   Han XK, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01973-y
   Hattenhauer MG, 1997, AM J OPHTHALMOL, V123, P103, DOI 10.1016/S0002-9394(14)70999-7
   Himori N, 2020, GRAEF ARCH CLIN EXP, V258, P939, DOI 10.1007/s00417-019-04483-z
   Hong SN, 2017, JAMA OTOLARYNGOL, V143, P996, DOI 10.1001/jamaoto.2017.1367
   Hou CY, 2014, J APPL MATH, DOI 10.1155/2014/424191
   Huon LK, 2016, SLEEP BREATH, V20, P1145, DOI 10.1007/s11325-016-1358-4
   Huseyinoglu N, 2014, SLEEP BREATH, V18, P95, DOI 10.1007/s11325-013-0854-z
   IMBERT P, 1990, J FR OPHTALMOL, V13, P223
   Jain AK, 2010, GRAEF ARCH CLIN EXP, V248, P1037, DOI 10.1007/s00417-009-1257-5
   Jee D, 2016, ACTA OPHTHALMOL, V94, pE204, DOI 10.1111/aos.12776
   Muniesa MJ, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.4.10
   Kadyan A, 2010, EYE, V24, P843, DOI 10.1038/eye.2009.212
   Kario K, 2009, HYPERTENS RES, V32, P537, DOI 10.1038/hr.2009.73
   Keenan TDL, 2017, BRIT J OPHTHALMOL, V101, P155, DOI 10.1136/bjophthalmol-2015-308278
   Kiekens S, 2008, INVEST OPHTH VIS SCI, V49, P934, DOI 10.1167/iovs.06-1418
   Kim KE, 2016, ASIA-PAC J OPHTHALMO, V5, P23, DOI 10.1097/APO.0000000000000177
   Kremmer S, 2003, SLEEP, V26, P161, DOI 10.1093/sleep/26.2.161
   Kremmer S, 2001, KLIN MONATSBL AUGENH, V218, P262, DOI 10.1055/s-2001-14923
   Lee HK, 2020, CORNEA, V39, P348, DOI 10.1097/ICO.0000000000002206
   Lee JY, 2018, BRIT J OPHTHALMOL, V102, P936, DOI 10.1136/bjophthalmol-2017-311140
   Lee SSY, 2019, OPHTHALMOLOGY, V126, P1372, DOI 10.1016/j.ophtha.2019.04.041
   Lee SSY, 2020, J GLAUCOMA, V29, P337, DOI 10.1097/IJG.0000000000001485
   Leong WB, 2016, DIABETIC MED, V33, P158, DOI 10.1111/dme.12817
   Leveque TK, 2007, SLEEP BREATH, V11, P253, DOI 10.1007/s11325-007-0112-3
   Li J, 2007, BRIT J OPHTHALMOL, V91, P1524, DOI 10.1136/bjo.2006.113803
   Lin CC, 2013, OPHTHALMOLOGY, V120, P1559, DOI 10.1016/j.ophtha.2013.01.006
   Lin KK, 2021, AM J OPHTHALMOL, V223, P140, DOI 10.1016/j.ajo.2020.09.040
   Lin PW, 2019, ANN OTO RHINOL LARYN, V128, P938, DOI 10.1177/0003489419849082
   Lin PW, 2011, J GLAUCOMA, V20, P553, DOI 10.1097/IJG.0b013e3181f3eb81
   Lin QC, 2012, SLEEP BREATH, V16, P571, DOI 10.1007/s11325-011-0544-7
   Liu PK, 2020, RETINA-J RET VIT DIS, V40, P2034, DOI 10.1097/IAE.0000000000002702
   Liu SL, 2016, J GLAUCOMA, V25, P1, DOI 10.1097/IJG.0000000000000357
   Liu XN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74348-7
   Malhotra A, 2002, LANCET, V360, P237, DOI 10.1016/S0140-6736(02)09464-3
   Markey KA, 2016, LANCET NEUROL, V15, P78, DOI 10.1016/S1474-4422(15)00298-7
   McNab AA, 2005, CLIN EXP OPHTHALMOL, V33, P117, DOI 10.1111/j.1442-9071.2005.00969.x
   Mcnab AA, 2007, SLEEP MED REV, V11, P269, DOI 10.1016/j.smrv.2007.03.006
   McNicholas WT, 2007, EUR RESPIR J, V29, P156, DOI 10.1183/09031936.00027406
   Modarreszadeh S, 2014, PHYSIOL BEHAV, V135, P112, DOI 10.1016/j.physbeh.2014.05.017
   Mojon DS, 2002, ARCH OPHTHALMOL-CHIC, V120, P601, DOI 10.1001/archopht.120.5.601
   MORTEMOUSQUE B, 1995, J FR OPHTALMOL, V18, P542
   Royo MM, 2015, CORNEA, V34, P521, DOI 10.1097/ICO.0000000000000396
   Naderan M, 2015, BRIT J OPHTHALMOL, V99, P1675, DOI 10.1136/bjophthalmol-2015-306665
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Oikonomakis K, 2017, CASE REP OPHTHALM, V8, P416, DOI 10.1159/000478925
   Palombi K, 2006, BRIT J OPHTHALMOL, V90, P879, DOI 10.1136/bjo.2005.087452
   Pamidi S, 2012, DIABETES CARE, V35, P2384, DOI 10.2337/dc12-0841
   Pan CK, 2020, AM J OPHTHALMOL, V218, P148, DOI 10.1016/j.ajo.2020.05.040
   Pan CW, 2019, OPHTHAL EPIDEMIOL, V26, P155, DOI 10.1080/09286586.2018.1554159
   Pellegrini M, 2020, OPTOMETRY VISION SCI, V97, P9, DOI 10.1097/OPX.0000000000001467
   Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342
   Peter L, 2007, J SLEEP RES, V16, P313, DOI 10.1111/j.1365-2869.2007.00598.x
   Punjabi NM, 2002, AM J RESP CRIT CARE, V165, P677, DOI 10.1164/ajrccm.165.5.2104087
   Rayapoulle A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88756-w
   Rossiter JD, 2002, BRIT J OPHTHALMOL, V86, P483, DOI 10.1136/bjo.86.4.483
   Rudrappa S, 2012, BRIT J OPHTHALMOL, V96, P1535, DOI 10.1136/bjophthalmol-2012-301991
   Sahebjada S, 2021, INT OPHTHALMOL, V41, P891, DOI 10.1007/s10792-020-01644-6
   Saidel MA, 2012, CORNEA, V31, P600, DOI 10.1097/ICO.0b013e318243e446
   Schaal S, 2016, RETINA-J RET VIT DIS, V36, P791, DOI 10.1097/IAE.0000000000000981
   Schlotzer-Schrehardt U, 2005, OPHTHALMOLOGY, V112, P694, DOI 10.1016/j.ophtha.2004.11.031
   Sensaki S, 2018, ASIA-PAC J OPHTHALMO, V7, P102, DOI 10.22608/APO.2017390
   Shi YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115625
   Simpson L, 2013, SLEEP BREATH, V17, P967, DOI 10.1007/s11325-012-0785-0
   Smith JP, 2019, OPTOMETRY VISION SCI, V96, P874, DOI 10.1097/OPX.0000000000001446
   Stafford-Bell N, 2022, OPHTHAL PHYSL OPT, V42, P19, DOI 10.1111/opo.12905
   STAUFFER JL, 1984, CHEST, V86, P802, DOI 10.1378/chest.86.5.802a
   Stein JD, 2011, AM J OPHTHALMOL, V152, P989, DOI 10.1016/j.ajo.2011.04.030
   Steiropoulos P, 2009, SLEEP MED, V10, P887, DOI 10.1016/j.sleep.2008.10.004
   Stone RA, 2013, EXP EYE RES, V114, P35, DOI 10.1016/j.exer.2013.01.001
   SUGITA Y, 1985, ELECTROEN CLIN NEURO, V60, P214, DOI 10.1016/0013-4694(85)90033-1
   Sun CL, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004499
   Sun MH, 2019, ACTA OPHTHALMOL, V97, pE64, DOI 10.1111/aos.13832
   Tahrani A, 2013, CURR OPIN PULM MED, V19, P631, DOI 10.1097/MCP.0b013e3283659da5
   Thurtell MJ, 2013, J NEUROL, V260, P1748, DOI 10.1007/s00415-013-6858-6
   Tong JY, 2017, AM J OPHTHALMOL, V182, P72, DOI 10.1016/j.ajo.2017.07.012
   Tsai DC, 2014, RETINA-J RET VIT DIS, V34, P1867, DOI 10.1097/IAE.0000000000000159
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   Vgontzas AN, 2005, SLEEP MED REV, V9, P211, DOI 10.1016/j.smrv.2005.01.006
   Vie AL, 2019, RETINA-J RET VIT DIS, V39, P274, DOI 10.1097/IAE.0000000000001954
   Vieira MJ, 2021, CURR EYE RES, V46, P31, DOI 10.1080/02713683.2020.1776332
   Wang JS, 2016, INT J OPHTHALMOL-CHI, V9, P1651, DOI 10.18240/ijo.2016.11.19
   Wang W, 2017, CURR EYE RES, V42, P796, DOI 10.1080/02713683.2016.1238942
   Wardly DE, 2014, MED HYPOTHESES, V83, P792, DOI 10.1016/j.mehy.2014.10.011
   Wei SF, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.37
   West SD, 2010, DIABETIC MED, V27, P423, DOI 10.1111/j.1464-5491.2010.02962.x
   Woodward MA, 2016, OPHTHALMOLOGY, V123, P457, DOI 10.1016/j.ophtha.2015.10.035
   Wozniak D, 2018, THORAX, V73, pA130, DOI 10.1136/thorax-2018-212555.214
   Wu CY, 2018, RETINA-J RET VIT DIS, V38, P1642, DOI 10.1097/IAE.0000000000002117
   Wu XH, 2015, INT J CLIN EXP MED, V8, P297
   Wu Y, 2016, CURR EYE RES, V41, P987, DOI 10.3109/02713683.2015.1075221
   Xu CL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0574-4
   Yang HK, 2019, BRIT J OPHTHALMOL, V103, P1123, DOI 10.1136/bjophthalmol-2018-312910
   Yavas GF, 2014, CURR EYE RES, V39, P88, DOI 10.3109/02713683.2013.824986
   Yiangou A, 2022, J NEUROL, V269, P1945, DOI 10.1007/s00415-021-10700-9
   Yu JG, 2016, OPHTHALMIC RES, V56, P57, DOI 10.1159/000444301
   Zhao XJ, 2016, J GLAUCOMA, V25, pE413, DOI 10.1097/IJG.0000000000000349
   Zhu ZL, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4737064
NR 129
TC 3
Z9 3
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2022
VL 50
IS 3
BP 334
EP 344
DI 10.1111/ceo.14071
EA MAR 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0F6RH
UT WOS:000769476600001
PM 35263016
OA Green Published
DA 2022-11-30
ER

PT J
AU Sarhan, MH
   Nasseri, MA
   Zapp, D
   Maier, M
   Lohmann, CP
   Navab, N
   Eslami, A
AF Sarhan, Mhd Hasan
   Nasseri, M. Ali
   Zapp, Daniel
   Maier, Mathias
   Lohmann, Chris P.
   Navab, Nassir
   Eslami, Abouzar
TI Machine Learning Techniques for Ophthalmic Data Processing: A Review
SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
LA English
DT Review
DE Image segmentation; Diabetes; Retinopathy; Machine learning; Lesions;
   Retina; Ophthalmic diagnostics; deep learning; diabetic retinopathy;
   age-related macular degeneration; glaucoma
ID COHERENCE TOMOGRAPHY IMAGES; FULLY AUTOMATED DETECTION; DIABETIC MACULAR
   EDEMA; VESSEL SEGMENTATION; LESION DETECTION; RETINAL IMAGES;
   BLOOD-VESSELS; EYE DISEASES; DEEP; DEGENERATION
AB Machine learning and especially deep learning techniques are dominating medical image and data analysis. This article reviews machine learning approaches proposed for diagnosing ophthalmic diseases during the last four years. Three diseases are addressed in this survey, namely diabetic retinopathy, age-related macular degeneration, and glaucoma. The review covers over 60 publications and 25 public datasets and challenges related to the detection, grading, and lesion segmentation of the three considered diseases. Each section provides a summary of the public datasets and challenges related to each pathology and the current methods that have been applied to the problem. Furthermore, the recent machine learning approaches used for retinal vessels segmentation, and methods of retinal layers and fluid segmentation are reviewed. Two main imaging modalities are considered in this survey, namely color fundus imaging, and optical coherence tomography. Machine learning approaches that use eye measurements and visual field data for glaucoma detection are also included in the survey. Finally, the authors provide their views, expectations and the limitations of the future of these techniques in the clinical practice.
C1 [Sarhan, Mhd Hasan; Eslami, Abouzar] Carl Zeiss Meditec, Translat Res Lab, D-85748 Munich, Germany.
   [Sarhan, Mhd Hasan; Navab, Nassir] Tech Univ Munich, Comp Aided Med Procedures Chair, D-80333 Munich, Germany.
   [Nasseri, M. Ali; Zapp, Daniel; Maier, Mathias; Lohmann, Chris P.] Tech Univ Munich, Dept Ophthalmol, Klinikum Rechts Isar, D-80333 Munich 80333, Germany.
   [Navab, Nassir] Johns Hopkins Univ, Whiting Sch Engn, Baltimore, MD 21218 USA.
C3 Technical University of Munich; Technical University of Munich; Johns
   Hopkins University
RP Sarhan, MH (通讯作者)，Carl Zeiss Meditec, Translat Res Lab, D-85748 Munich, Germany.; Sarhan, MH (通讯作者)，Tech Univ Munich, Comp Aided Med Procedures Chair, D-80333 Munich, Germany.
EM hasan.sarhan@tum.de; ali.nasseri@mri.tum.de; daniel.zapp@mri.tum.de;
   mathias.maier@mri.tum.de; chris.lohmann@mri.tum.de; nassir.navab@tum.de;
   abouzar.eslami@zeiss.com
FU Carl Zeiss Meditec
FX The work of Mhd Hasan Sarhan was supported by Carl Zeiss Meditec.
CR Abbasi-Sureshjani S, 2017, LECT NOTES COMPUT SC, V10554, P210, DOI 10.1007/978-3-319-67561-9_24
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   [Anonymous], 2017, INVESTIGATIVE OPHTHA
   [Anonymous], 2002, INT CLIN DIAB RET DI
   [Anonymous], **DATA OBJECT**, DOI DOI 10.21227/H25W98
   Apostolopoulos S., 2017, PATHOLOGICAL OCT RET, P294, DOI DOI 10.1007/978-3-319-66179-7_34
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Carmona EJ, 2008, ARTIF INTELL MED, V43, P243, DOI 10.1016/j.artmed.2008.04.005
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Cheng J, 2013, IEEE T MED IMAGING, V32, P1019, DOI 10.1109/TMI.2013.2247770
   Cheplygina V, 2019, MED IMAGE ANAL, V54, P280, DOI 10.1016/j.media.2019.03.009
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Costa P, 2018, IEEE T MED IMAGING, V37, P781, DOI 10.1109/TMI.2017.2759102
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Decenciere E, 2013, IRBM, V34, P196, DOI 10.1016/j.irbm.2013.01.010
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Deng JJ, 2016, LECT NOTES COMPUT SC, V9730, P707, DOI 10.1007/978-3-319-41501-7_79
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Fumero F, 2011, COMP MED SY
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gondal WM, 2017, IEEE IMAGE PROC, P2069, DOI 10.1109/ICIP.2017.8296646
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   Gopinath K, 2019, IEEE J BIOMED HEALTH, V23, P273, DOI 10.1109/JBHI.2018.2793534
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Greenspan H, 2016, IEEE T MED IMAGING, V35, P1153, DOI 10.1109/TMI.2016.2553401
   Gu YK, 2018, BIOMED OPT EXPRESS, V9, P5147, DOI 10.1364/BOE.9.005147
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Higgins I, 2017, P INT C LEARN REPR
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Huang GB, 2006, NEUROCOMPUTING, V70, P489, DOI 10.1016/j.neucom.2005.12.126
   Huang H., 2017, NEUROCOMPUTING, P210
   Huazhu Fu, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P132, DOI 10.1007/978-3-319-46723-8_16
   Ji ZX, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.1
   Kaggle, 2015, KAGGL DIAB RET DET C
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kauppi T, 2007, DIARETDB1 DIABETIC R
   Kauppi T., 2010, EYE FUNDUS IMAGE ANA
   Kauppi T., 2006, DIARETDB0 EVALUATION
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kim SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177726
   Krizhevsky Alex, 2017, Communications of the ACM, V60, P84, DOI 10.1145/3065386
   Lam C, 2018, INVEST OPHTH VIS SCI, V59, P590, DOI 10.1167/iovs.17-22721
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lee HY, 2018, LECT NOTES COMPUT SC, V11205, P36, DOI 10.1007/978-3-030-01246-5_3
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Leopold HA, 2017, PROC SPIE, V10068, DOI 10.1117/12.2252988
   Levenkova A, 2018, PROC SPIE, V10575, DOI 10.1117/12.2293434
   Li QL, 2016, IEEE T MED IMAGING, V35, P109, DOI 10.1109/TMI.2015.2457891
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Lin ZW, 2018, LECT NOTES COMPUT SC, V11071, P74, DOI 10.1007/978-3-030-00934-2_9
   Liskowski P, 2016, IEEE T MED IMAGING, V35, P2369, DOI 10.1109/TMI.2016.2546227
   Maninis Kevis-Kokitsi, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P140, DOI 10.1007/978-3-319-46723-8_17
   Mitra, 2016, ARXIV160304833
   Nielsen KB, 2019, OPHTHALMOL RETINA, V3, P294, DOI 10.1016/j.oret.2018.10.014
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   OPTIMA, 2015, P MICC 2015 OPT CYST
   Orlando JI, 2020, MED IMAGE ANAL, V59, DOI 10.1016/j.media.2019.101570
   Orlando JI, 2018, COMPUT METH PROG BIO, V153, P115, DOI 10.1016/j.cmpb.2017.10.017
   Owen CG, 2009, INVEST OPHTH VIS SCI, V50, P2004, DOI 10.1167/iovs.08-3018
   Pires R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096814
   Pratt H, 2016, PROCEDIA COMPUT SCI, V90, P200, DOI 10.1016/j.procs.2016.07.014
   Prentasic P, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.075008
   Quellec G, 2017, MED IMAGE ANAL, V39, P178, DOI 10.1016/j.media.2017.04.012
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Sarhan Mhd Hasan, 2019, Domain Adaptation and Representation Transfer and Medical Image Learning with Less Labels and Imperfect Data. First MICCAI Workshop, DART 2019 and First International Workshop, MIL3ID 2019 Shenzhen, Held in Conjunction with MICCAI 2019. Proceedings. Lecture Notes in Computer Science (LNCS 11795), P37, DOI 10.1007/978-3-030-33391-1_5
   Sarhan MH, 2019, LECT NOTES COMPUT SC, V11764, P174, DOI 10.1007/978-3-030-32239-7_20
   Sarhan MH, 2019, INVEST OPHTH VIS SCI, V60
   Schlegl T, 2019, MED IMAGE ANAL, V54, P30, DOI 10.1016/j.media.2019.01.010
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Silva PS, 2012, AM J OPHTHALMOL, V154, P549, DOI 10.1016/j.ajo.2012.03.019
   Simonyan K., 2015, P INT C LEARN REP RE
   Sivaswamy J, 2014, I S BIOMED IMAGING, P53, DOI 10.1109/ISBI.2014.6867807
   Sng CC, 2012, OPHTHALMOLOGY, V119, P1143, DOI 10.1016/j.ophtha.2012.01.011
   Son J., 2017, ARXIV170609318
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srivastava R, 2015, I S BIOMED IMAGING, P768, DOI 10.1109/ISBI.2015.7163985
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308
   Tan JH, 2017, J COMPUT SCI-NETH, V20, P70, DOI 10.1016/j.jocs.2017.02.006
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Venhuizen FG, 2017, BIOMED OPT EXPRESS, V8, P3292, DOI 10.1364/BOE.8.003292
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Wang SL, 2015, NEUROCOMPUTING, V149, P708, DOI 10.1016/j.neucom.2014.07.059
   Wang Z., 2018, P WORKSH 32 AAAI C A
   Xie SN, 2015, IEEE I CONF COMP VIS, P1395, DOI 10.1109/ICCV.2015.164
   Xue J, 2018, BIOMED OPT EXPRESS, V9, P3208, DOI 10.1364/BOE.9.003208
   Yehui Yang, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10435, P533, DOI 10.1007/978-3-319-66179-7_61
   Zadeh SG, 2017, LECT NOTES COMPUT SC, V10553, P65, DOI 10.1007/978-3-319-67558-9_8
   Zhang Z, 2010, IEEE ENG MED BIO, P3065, DOI 10.1109/IEMBS.2010.5626137
   Zhe Wang, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10435, P267, DOI 10.1007/978-3-319-66179-7_31
   Zhou B, 2016, PROC CVPR IEEE, P2921, DOI 10.1109/CVPR.2016.319
   Zilly J, 2017, COMPUT MED IMAG GRAP, V55, P28, DOI 10.1016/j.compmedimag.2016.07.012
NR 107
TC 15
Z9 16
U1 3
U2 29
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2168-2194
EI 2168-2208
J9 IEEE J BIOMED HEALTH
JI IEEE J. Biomed. Health Inform.
PD DEC
PY 2020
VL 24
IS 12
BP 3338
EP 3350
DI 10.1109/JBHI.2020.3012134
PG 13
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Mathematical & Computational Biology;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematical & Computational Biology; Medical
   Informatics
GA PC7JM
UT WOS:000597173000002
PM 32750971
OA hybrid
DA 2022-11-30
ER

PT J
AU He, HJ
   Wei, DH
   Liu, H
   Zhu, C
   Lu, Y
   Ke, ZW
   Jiang, S
   Huang, JH
AF He, Huijun
   Wei, Daheng
   Liu, Hua
   Zhu, Chen
   Lu, Yue
   Ke, Zongwen
   Jiang, Shuang
   Huang, Jianhua
TI Glycyrrhizin protects against sodium iodate-induced RPE and retinal
   injury though activation of AKT and Nrf2/HO-1 pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE glycyrrhizin; Nrf2/HO-1 pathway; retinal injury AKT pathway; retinal
   pigment epithelium
ID MACULAR DEGENERATION; CHRONIC HEPATITIS; ACID; STRESS; CELLS
AB Glycyrrhizin is a bioactive triterpenoid saponin extracted from a traditional Chinese medicinal herb, glycyrrhiza, and has been reported to protect the organs such as liver and heart from injuries. However, there is no report about the effects of glycyrrhizin on atrophic age-related macular degeneration (AMD). This study investigated the effects of glycyrrhizin on retinal pigment epithelium (RPE) in vitro and retina of mice in vivo treated with sodium iodate (SI). Glycyrrhizin significantly inhibited SI-induced reactive oxygen species (ROS), and decreased apoptosis of RPE in vitro. The underlying mechanisms included increased phosphorylation of Akt, and increased expression of nuclear factor erythroid 2-related factor2 (Nrf-2) and HO-1, thereby protecting RPE from SI-induced ROS and apoptosis. Furthermore, glycyrrhizin significantly decreased the apoptosis of retinal cells in vivo, resulting in the inhibition of thinning of retina, decreasing the number of drusen and improving the function of retina. These findings suggested that glycyrrhizin may be a potential candidate for the treatment of atrophic AMD in clinical practice.
C1 [He, Huijun; Wei, Daheng; Huang, Jianhua] Jinzhou Med Univ, Affiliated Hosp 1, Jinzhou, Peoples R China.
   [He, Huijun; Zhu, Chen; Lu, Yue; Ke, Zongwen] Jinzhou Med Univ, Grad Sch, Jinzhou, Peoples R China.
   [Liu, Hua; Jiang, Shuang] Jinzhou Med Univ, Affiliated Hosp 3, Jinzhou, Peoples R China.
   [Huang, Jianhua] Jinzhou Med Univ, Life Sci Inst, Jinzhou, Peoples R China.
C3 Jinzhou Medical University; Jinzhou Medical University; Jinzhou Medical
   University; Jinzhou Medical University
RP Huang, JH (通讯作者)，Jinzhou Med Univ, Affiliated Hosp 1, Jinzhou, Peoples R China.; Liu, H (通讯作者)，Jinzhou Med Univ, Affiliated Hosp 3, Jinzhou, Peoples R China.
EM lh5095153@163.com; hjhuadr@163.com
FU Natural Science Foundation of Liaoning Province [201602287]; National
   Natural Science Foundation of China [8147038]; Liaoning Distinguished
   Professor Project; Key Laboratory Program of Liaoning Provincial
   Department of Education Ministration [LZ2015051]
FX Natural Science Foundation of Liaoning Province, Grant/Award Number:
   201602287; National Natural Science Foundation of China, Grant/Award
   Number: 8147038; Liaoning Distinguished Professor Project; the Key
   Laboratory Program of Liaoning Provincial Department of Education
   Ministration, Grant/Award Number: LZ2015051
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Baird L, 2013, P NATL ACAD SCI USA, V110, P15259, DOI 10.1073/pnas.1305687110
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Farrukh MR, 2015, J PHOTOCH PHOTOBIO B, V148, P351, DOI 10.1016/j.jphotobiol.2015.05.003
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450
   Huang JH, 2009, ANGIOGENESIS, V12, P243, DOI 10.1007/s10456-009-9144-6
   Huo XW, 2018, MOLECULES, V23, DOI 10.3390/molecules23071623
   Iino S, 2001, HEPATOL RES, V19, P31, DOI 10.1016/S1386-6346(00)00079-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Kwak MK, 2004, MUTAT RES-FUND MOL M, V555, P133, DOI 10.1016/j.mrfmmm.2004.06.041
   Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381
   Narayanan R, 2017, CURR PHARM DESIGN, V23, P542, DOI 10.2174/1381612822666161221154424
   Piao WH, 2010, ANGIOGENESIS, V13, P203, DOI 10.1007/s10456-010-9169-x
   Redfern WS, 2011, J PHARMACOL TOXICOL, V63, P102, DOI 10.1016/j.vascn.2010.06.008
   RINGVOLD A, 1981, EXP EYE RES, V33, P361, DOI 10.1016/S0014-4835(81)80088-7
   Seo DY, 2018, KOREAN J PHYSIOL PHA, V22, P235, DOI 10.4196/kjpp.2018.22.3.235
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   So HS, 2006, CELL DEATH DIFFER, V13, P1763, DOI 10.1038/sj.cdd.4401863
   Sugden PH, 2003, CIRC RES, V93, P1179, DOI 10.1161/01.RES.0000106132.04301.F5
   Sun XJ, 2018, EXP CELL RES, V369, P112, DOI 10.1016/j.yexcr.2018.05.012
   Teng LS, 2014, INT J MOL MED, V34, P742, DOI 10.3892/ijmm.2014.1830
   Van Rossum TGJ, 1998, ALIMENT PHARM THER, V12, P199
   Wang LQ, 2017, J NAT MED-TOKYO, V71, P27, DOI 10.1007/s11418-016-1023-z
   Wang YK, 2015, CLIN LAB, V61, P1561, DOI 10.7754/Clin.Lab.2015.150215
NR 31
TC 16
Z9 19
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAY
PY 2019
VL 23
IS 5
BP 3495
EP 3504
DI 10.1111/jcmm.14246
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HW7AC
UT WOS:000466841100041
PM 30821111
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shah, M
   Cabrera-Ghayouri, S
   Christie, LA
   Held, KS
   Viswanath, V
AF Shah, Mihir
   Cabrera-Ghayouri, Sara
   Christie, Lori-Ann
   Held, Katherine S.
   Viswanath, Veena
TI Translational Preclinical Pharmacologic Disease Models for Ophthalmic
   Drug Development
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE Age-related macular degeneration; diabetic retinopathy; dry eye disease;
   glaucoma; ocular allergy
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; DRY EYE DISEASE;
   3-PERCENT DIQUAFOSOL SODIUM; LACRIMAL GLAND EXCISION; EXPERIMENTAL
   CHOROIDAL NEOVASCULARIZATION; CARBONIC-ANHYDRASE INHIBITORS; INDUCED
   OCULAR HYPERTENSION; RETINAL-PIGMENT EPITHELIUM; BLOOD-AQUEOUS BARRIER
AB Preclinical models of human diseases are critical to our understanding of disease etiology, pathology, and progression and enable the development of effective treatments. An ideal model of human disease should capture anatomical features and pathophysiological mechanisms, mimic the progression pattern, and should be amenable to evaluating translational endpoints and treatment approaches. Preclinical animal models have been developed for a variety of human ophthalmological diseases to mirror disease mechanisms, location of the affected region in the eye and severity. These models offer clues to aid in our fundamental understanding of disease pathogenesis and enable progression of new therapies to clinical development by providing an opportunity to gain proof of concept (POC). Here, we review preclinical animal models associated with development of new therapies for diseases of the ocular surface, glaucoma, presbyopia, and retinal diseases, including diabetic retinopathy and age-related macular degeneration (AMD). We have focused on summarizing the models critical to new drug development and described the translational features of the models that contributed to our understanding of disease pathogenesis and establishment of preclinical POC.
C1 [Shah, Mihir; Cabrera-Ghayouri, Sara; Christie, Lori-Ann; Held, Katherine S.; Viswanath, Veena] Allergan Plc, Biol Res, 2525 Dupont Dr, Irvine, CA 92612 USA.
C3 AbbVie; Allergan
RP Viswanath, V (通讯作者)，Allergan Plc, Biol Res, 2525 Dupont Dr, Irvine, CA 92612 USA.
EM viswanath_veena@allergan.com
CR Abdelkader A, 2015, EYE CONTACT LENS, V41, P323, DOI 10.1097/ICL.0000000000000137
   ABELSON MB, 1988, OPHTHALMOLOGY, V95, P1494
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Addo E., 2016, OCULAR DRUG DELIVERY, P11, DOI [10.1007/978-3-319-47691-9_2, DOI 10.1007/978-3-319-47691-9_2]
   Adkins JC, 1998, DRUG AGING, V12, P225, DOI 10.2165/00002512-199812030-00005
   Agarwal R, 2017, EXPERT OPIN DRUG DIS, V12, P261, DOI 10.1080/17460441.2017.1281244
   Agarwal R, 2009, INDIAN J OPHTHALMOL, V57, P257, DOI 10.4103/0301-4738.53049
   Ahadome SD, 2016, JCI INSIGHT, V1
   Ahn S, 2018, CURR EYE RES, V43, P580, DOI 10.1080/02713683.2018.1434895
   Aicher SA, 2015, INVEST OPHTH VIS SCI, V56, P6981, DOI 10.1167/iovs.15-17497
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al Dhibi HA, 2013, WORLD J DIABETES, V4, P295, DOI 10.4239/wjd.v4.i6.295
   Chiaradia PA, 2017, CURR PHARM DESIGN, V23, P608, DOI 10.2174/1381612822666161208094841
   Almasieh M, 2017, ANNU REV VIS SCI, V3, P91, DOI 10.1146/annurev-vision-102016-061422
   Alqawlaq AFJS JM, 2018, EXP EYE RES
   Amano S, 2017, CLIN OPHTHALMOL, V11, P1677, DOI 10.2147/OPTH.S148167
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794
   Anderson MG, 2001, BMC, V2
   [Anonymous], 1991, Ophthalmology, V98, P786
   [Anonymous], 2010, LAST ALC OPHTH SOL N
   [Anonymous], 2007, COMB BRIM TARTR TIM
   [Anonymous], 2001, ALPH P BRIM TARTR OP
   [Anonymous], 1998, AZ BRINZ OPHTH SUSP
   [Anonymous], 2001, LUM BIM OPHTH SOL NE
   [Anonymous], 2012, SIMBR BRINZ BRIM TAR
   [Anonymous], 1994, TRUS DORZ HYDR OPHTH
   [Anonymous], 2017, RHOPR NET OPHTH SOL
   [Anonymous], 2011, COS PF DORZ HYDR TIM
   [Anonymous], 2018, FDA APPR 1 DRUG NEUR
   [Anonymous], 2017, VYZ LAT BUN OPHTH SO
   [Anonymous], 1998, COS DORZ HCL TIM MAL
   [Anonymous], 2016, XIIDR LIF OPHTH SOL
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Arthur S, 2011, EXP EYE RES, V93, P271, DOI 10.1016/j.exer.2011.04.002
   Askew B, 2018, SF0166 TOPICALLY ADM
   Atorf J, 2013, DOC OPHTHALMOL, V126, P221, DOI 10.1007/s10633-013-9380-3
   Barabino S, 2004, INVEST OPHTH VIS SCI, V45, P1641, DOI 10.1167/iovs.03-1055
   Bayer AU, 2001, INVEST OPHTH VIS SCI, V42, P1258
   Belmonte C, 2004, EXP EYE RES, V78, P513, DOI 10.1016/j.exer.2003.09.023
   Belmonte Carlos, 2015, Curr Ophthalmol Rep, V3, P111
   Bereiter DA, 2018, INVEST OPHTH VIS SCI, V59, P3739, DOI 10.1167/iovs.18-24304
   Beyazyildiz E, 2014, J OCUL PHARMACOL TH, V30, P306, DOI 10.1089/jop.2013.0129
   Bouhenni RA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/692609
   Boyer DS, 2015, OPHTHALMOLOGY, V122, P2504, DOI 10.1016/j.ophtha.2015.08.006
   Boyer DS, 2013, THER ADV ENDOCRINOL, V4, P151, DOI 10.1177/2042018813512360
   Boyer J, 2013, INVEST OPHTH VIS SCI, V54
   Bressler SB, 2012, ARCH OPHTHALMOL-CHIC, V130, P1153, DOI 10.1001/archophthalmol.2012.1107
   Brock JA, 2001, J PHYSIOL-LONDON, V533, P493, DOI 10.1111/j.1469-7793.2001.0493a.x
   Bron AJ, 2017, OCUL SURF, V15, P438, DOI 10.1016/j.jtos.2017.05.011
   Bundoc VG, 2003, CURR OPIN ALLERGY CL, V3, P375, DOI 10.1097/01.all.0000092609.76804.5c
   Burke J, 1996, SURV OPHTHALMOL, V41, pS9, DOI 10.1016/S0039-6257(96)82027-3
   Butrus Salim, 2005, Ophthalmol Clin North Am, V18, P485
   Caceres-del-Carpio J, 2016, DEV OPHTHALMOL, V55, P221, DOI 10.1159/000431198
   Calkins DJ, 2012, PROG RETIN EYE RES, V31, P702, DOI 10.1016/j.preteyeres.2012.07.001
   Calonge M, 2003, CURR ALLERGY ASTHM R, V3, P345, DOI 10.1007/s11882-003-0097-3
   Cao J, 2005, SYSTEMIC ADM VEGF TR
   Cao J, 2006, INTRAVITREAL ADM VEG
   Cao JT, 2018, INVEST OPHTH VIS SCI, V59, P1033, DOI 10.1167/iovs.17-22897
   CARRERAS I, 1993, BRIT J OPHTHALMOL, V77, P509, DOI 10.1136/bjo.77.8.509
   Chen GL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158868
   Chen Liwen, 2016, Vision (Basel), V1, DOI 10.3390/vision1010004
   Chen SD, 2014, EXPERT REV OPHTHALMO, V9, P285, DOI 10.1586/17469899.2014.939171
   Chen Y, 2014, MUCOSAL IMMUNOL, V7, P38, DOI 10.1038/mi.2013.20
   Chen YH, 2013, INVEST OPHTH VIS SCI, V54, P2457, DOI 10.1167/iovs.12-11121
   Cheung GCM, 2014, DUAL INHIBITION ANGI
   CHEUNG GCM, 2014, INVEST OPHTH VIS SCI, V55
   Chi ZL, 2010, HUM MOL GENET, V19, P2606, DOI 10.1093/hmg/ddq146
   Chowdhury UR, 2015, INVEST OPHTH VIS SCI, V56, P2993, DOI 10.1167/iovs.15-16744
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Coassin M, 2005, GRAEF ARCH CLIN EXP, V243, P151, DOI 10.1007/s00417-004-0955-2
   Collier RJ, 2012, AL 78898A INHIBITS C
   Conrady CD, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7542929
   Copland DA, 2010, CLIN EXP IMMUNOL, V159, P303, DOI 10.1111/j.1365-2249.2009.04070.x
   Corcoran P, 2017, J OCUL PHARMACOL TH, V33, P686, DOI 10.1089/jop.2017.0050
   Cousins S, 2015, RETINA TODAY BMC MAY
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   Danesh-Meyer HV, 2011, CURR OPIN OPHTHALMOL, V22, P78, DOI 10.1097/ICU.0b013e32834372ec
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Daniel S, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0069-y
   David A, 2006, METHODS TREATING RET
   de Souza RG, 2018, J OCUL PHARMACOL TH, V34, P543, DOI 10.1089/jop.2018.0047
   Djalilian AR, 2010, 10 PEARLS OCULAR SUR
   Dodi PL, 2015, VET MED-RES REP, V6, P341, DOI 10.2147/VMRR.S66705
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Durairaj C, 2014, PHARM RES-DORDR, V31, P2095, DOI 10.1007/s11095-014-1311-9
   Dursun D, 2002, INVEST OPHTH VIS SCI, V43, P632
   DW ADLGMWS, 2017, INVEST OPHTHALMOL VI, V58
   Edelman JL, 2010, OPHTHALMOLOGICA, V224, P25, DOI 10.1159/000315158
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Elhawy E, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-22
   Fernandes KA, 2015, EXP EYE RES, V141, P42, DOI 10.1016/j.exer.2015.06.019
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Formica R, 2016, SUSTAINED SUPPRESSIO
   Foxton RH, 2018, EVALUATION EFFECTS V
   Fujihara T, 2001, INVEST OPHTH VIS SCI, V42, P96
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Furfine E, 2013, INVEST OPHTH VIS SCI, V54
   GAASTERLAND D, 1974, INVEST OPHTH VISUAL, V13, P455
   Gandolfi S, 2001, ADV THER, V18, P110, DOI 10.1007/BF02850299
   Gao J, 2011, INVEST OPHTHALMOL VI, V52
   Gao JP, 2013, INVEST OPHTH VIS SCI, V54, P4717, DOI 10.1167/iovs.13-11681
   Gao JP, 1998, CORNEA, V17, P654, DOI 10.1097/00003226-199811000-00014
   Gao JP, 1998, ADV EXP MED BIOL, V438, P453
   Gaudreault J, 2003, OCULAR PHARMACOKINET
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gelatt KN, 2002, J OCUL PHARMACOL TH, V18, P525, DOI 10.1089/108076802321021072
   GELATT KN, 1995, AM J VET RES, V56, P1325
   GELATT KN, 1979, AM J VET RES, V40, P334
   GELATT KN, 1977, AM J VET RES, V38, P515
   Gelatt KNGG, 1981, AM J VET RES, V41, P1808
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   Ghosn C, 2017, INVEST OPHTH VIS SCI, V58
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Glasser A, 2006, CURR OPIN OPHTHALMOL, V17, P12, DOI 10.1097/01.icu.0000193069.32369.e1
   Glasser A, 1999, OPHTHALMOLOGY, V106, P863, DOI 10.1016/S0161-6420(99)00502-3
   Gomes PJ, 2014, CURR OPIN ALLERGY CL, V14, P451, DOI 10.1097/ACI.0000000000000100
   GONZALEZ GG, 1993, INVEST OPHTH VIS SCI, V34, P3329
   Grillo-Antonelli S, 2014, ACTA OPHTHALMOL, V92, DOI 10.1111/j.1755-3768.2014.T017.x
   Grishanin R, 2018, 7M8 AFLIBERCEPT PROV
   Gupta D, 2016, AM FAM PHYSICIAN, V93, P668
   Gupta SK, 2007, METHOD FIND EXP CLIN, V29, P665, DOI 10.1358/mf.2007.29.10.1147765
   Gupta SK, 2008, INDIAN J PHARMACOL, V40, P197, DOI 10.4103/0253-7613.44151
   Guymer C, 2018, CLIN EXP OPHTHALMOL
   Guzman M, 2016, EXP EYE RES, V151, P19, DOI 10.1016/j.exer.2016.07.004
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hagan S, 2018, INVEST OPHTH VIS SCI, V59, P1443, DOI 10.1167/iovs.17-23479
   Harada T, 2007, J CLIN INVEST, V2
   Hare W, 2001, SURV OPHTHALMOL, V45, pS284, DOI 10.1016/S0039-6257(01)00200-4
   Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2640, DOI 10.1167/iovs.03-0567
   Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2878
   HARRISON R, 1977, ARCH OPHTHALMOL-CHIC, V95, P1368, DOI 10.1001/archopht.1977.04450080078007
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hernandez C, 2017, J ENDOCRINOL INVEST, V40, P925, DOI 10.1007/s40618-017-0648-4
   Herrera DG, 2005, 30 WORLD SMALL AN VE
   Herrero-Vanrell R., 2007, Arch Soc Esp Oftalmol, V82, P733
   Higginbotham EJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1286, DOI 10.1001/archopht.120.10.1286
   HODAPP E, 1981, ARCH OPHTHALMOL-CHIC, V99, P1208
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hori Y, 2017, J OCUL PHARMACOL TH, V33, P493, DOI 10.1089/jop.2016.0092
   Huang JF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.017
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   IGLESIAS B, 2018, INVEST OPHTH VIS SCI, V59
   Iglesias B, 2018, AFLIBERCEPT COMBINAT
   Ikeda K, 2018, GRAEF ARCH CLIN EXP, V256, P739, DOI 10.1007/s00417-018-3932-x
   Irkec MT, 2012, CURR OPIN ALLERGY CL, V12, P534, DOI 10.1097/ACI.0b013e328357a21b
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jain P, 2011, EXP EYE RES, V93, P503, DOI 10.1016/j.exer.2011.06.014
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Johnson TV, 2010, BRAIN RES BULL, V81, P349, DOI 10.1016/j.brainresbull.2009.04.004
   Jones L, 2017, OCUL SURF, V15, P575, DOI 10.1016/j.jtos.2017.05.006
   Joossen C, 2016, EXP EYE RES, V146, P172, DOI 10.1016/j.exer.2016.03.006
   Kanemaki N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074372
   KASWAN R, 1994, ADV EXP MED BIOL, V350, P583
   Katagiri A, 2015, NEUROSCIENCE, V290, P204, DOI 10.1016/j.neuroscience.2015.01.046
   Kato K, 2009, MOL VIS, V15, P2470
   KAUFMAN PL, 1982, T OPHTHAL SOC UK, V102, P323
   Kaushik S, 2003, J Postgrad Med, V49, P90
   Kern TS, 2018, ASSESSMENT MACULAR T
   Kojima T, 2015, INVEST OPHTH VIS SCI, V56, P8382, DOI 10.1167/iovs.15-18295
   Kojima T, 2014, MOL VIS, V20, P929
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Kovacs I, 2016, PAIN, V157, P399, DOI 10.1097/j.pain.0000000000000455
   Krupin T, 2005, OPHTHALMOLOGY, V112, P376, DOI 10.1016/j.ophtha.2004.10.034
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuchtey J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001306
   Kunert KS, 2000, ARCH OPHTHALMOL-CHIC, V118, P1489
   Kuppermann BD, 2017, INVEST OPHTH VIS SCI, V58
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambiase A, 2009, INVEST OPHTH VIS SCI, V50, P4622, DOI 10.1167/iovs.08-2716
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Lee HS, 2015, INVEST OPHTH VIS SCI, V56, P3140, DOI 10.1167/iovs.14-16186
   Levin LA, 2001, EUR J OPHTHALMOL, V11, pS23
   Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402
   Li GR, 2018, INVEST OPHTH VIS SCI, V59, P383, DOI 10.1167/iovs.17-23212
   Li HY, 2014, NEURAL REGEN RES, V9, P565, DOI 10.4103/1673-5374.130093
   Li Y, 2010, EFFECTIVENESS DEXAME
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2015, INVEST OPHTH VIS SCI, V56, P2359
   Liu Y, 2015, SYSTEMIC ADM ANTIANG
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Luo LH, 2007, CORNEA, V26, P452, DOI 10.1097/ICO.0b013e318030d259
   Lutty GA, 2011, INVEST OPHTH VIS SCI, V52, P4039, DOI 10.1167/iovs.10-6798
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   MacKay EO, 2012, VET OPHTHALMOL, V15, P31, DOI 10.1111/j.1463-5224.2011.00934.x
   MacPherson TC, 2017, COADMINISTRATION ANT
   MACPHERSON TC, 2017, INVEST OPHTH VIS SCI, V58
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Maliartchouk S, 2000, MOL PHARMACOL, V57, P385
   Marc RE, 2008, MOL VIS, V14, P782
   Maria NI, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0678-2
   Maslanka T, 2015, VET J, V203, P278, DOI 10.1016/j.tvjl.2014.12.017
   May CA, 2006, ACTA NEUROPATHOL, V111, P158, DOI 10.1007/s00401-005-0011-2
   MCDONALD TO, 1969, ARCH OPHTHALMOL-CHIC, V82, P381, DOI 10.1001/archopht.1969.00990020383017
   Meng ID, 2015, INVEST OPHTH VIS SCI, V56, P3347, DOI 10.1167/iovs.15-16717
   MerayoLloves J, 1996, J ALLERGY CLIN IMMUN, V97, P1129, DOI 10.1016/S0091-6749(96)70268-3
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Minegishi Y, 2013, HUM MOL GENET, V22, P3559, DOI 10.1093/hmg/ddt210
   Moreno-Montanes J, 2018, EXPERT OPIN INV DRUG, V27, P421, DOI 10.1080/13543784.2018.1457647
   Morgan JE, 2015, EXP EYE RES, V141, P9, DOI 10.1016/j.exer.2015.06.020
   Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184
   Mruthyunjaya P, 2006, ARCH OPHTHALMOL-CHIC, V124, P1012, DOI 10.1001/archopht.124.7.1012
   Murphy CJ, 2011, INVEST OPHTH VIS SCI, V52, P3174, DOI 10.1167/iovs.09-5078
   Murugesan N, 2018, NOVEL ORAL PLASMA KA
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Nazarali S, 2018, BR J OPHTHALMOL
   Nehme A, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-58
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Noecker RS, 2003, AM J OPHTHALMOL, V135, P55, DOI 10.1016/S0002-9394(02)01827-5
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Ogata N, 2001, AM J OPHTHALMOL, V132, P427, DOI 10.1016/S0002-9394(01)01021-2
   Ohguchi T, 2013, INVEST OPHTH VIS SCI, V54, P7793, DOI 10.1167/iovs.13-13128
   Okada Y, 2015, CORNEA, V34, pS136, DOI 10.1097/ICO.0000000000000602
   Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Overby DR, 2014, INVEST OPHTH VIS SCI, V55, P4922, DOI 10.1167/iovs.14-14429
   Park YG, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/769213
   Parra A, 2010, NAT MED, V16, P1396, DOI 10.1038/nm.2264
   Parrish RK, 2003, AM J OPHTHALMOL, V135, P688, DOI 10.1016/S0002-9394(03)00098-9
   Pattabiraman PP, 2016, EUR J PHARMACOL, V787, P32, DOI 10.1016/j.ejphar.2016.04.048
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Peck AB, 2017, CLIN IMMUNOL, V182, P14, DOI 10.1016/j.clim.2017.05.001
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pflugfelder SC, 2007, CURR OPIN ALLERGY CL, V7, P450, DOI 10.1097/ACI.0b013e3282ef69e3
   Pflugfelder SC, 2017, J OCUL PHARMACOL TH, V33, P5, DOI 10.1089/jop.2016.0105
   Quallo T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8150
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Rahman M, 2015, PAIN, V156, P942, DOI 10.1097/j.pain.0000000000000135
   Rao VR, 2010, INVEST OPHTH VIS SCI, V51, P5198, DOI 10.1167/iovs.09-5144
   Razali N, 2015, CLIN EXP OPHTHALMOL, V43, P54, DOI 10.1111/ceo.12375
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Reinoso R, 2011, INVEST OPHTH VIS SCI, V52, P4819, DOI 10.1167/iovs.10-6073
   Renard RA, 2006, INTRAVITREAL ADM VEG
   Renna A, 2017, EYE VISION, V4, DOI 10.1186/s40662-017-0068-8
   Reyes NJ, 2018, METHODS MOL BIOL, V1799, P49, DOI 10.1007/978-1-4939-7896-0_5
   Reyes NJ, 2014, CURR OPIN ALLERGY CL, V14, P477, DOI 10.1097/ACI.0000000000000088
   Reyes NJ, 2018, SCI TRANSL MED, V10
   Rhee MK, 2017, OPHTHALMOLOGY, V124, pS14, DOI 10.1016/j.ophtha.2017.08.029
   Rodrigues GA, 2018, IN VITRO IN VIVO CHA
   ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0
   Rosenthal P, 2012, OCUL SURF, V10, P2, DOI 10.1016/j.jtos.2012.01.002
   Ruiz-Ederra J, 2009, INVEST OPHTH VIS SCI, V50, P2132, DOI 10.1167/iovs.08-3033
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sadiq MA, 2016, DEV OPHTHALMOL, V55, P310, DOI 10.1159/000438953
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sappington RM, 2010, INVEST OPHTH VIS SCI, V51, P207, DOI 10.1167/iovs.09-3947
   Sarao V, 2014, THESCIENTIFICWORLDJO, V2014
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Scaria A, 2010, SAFETY EFFICACY INTR
   Schlamp CL, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-66
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schrader Stefan, 2008, Dev Ophthalmol, V41, P298, DOI 10.1159/000131097
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SEARS D, 1974, AM J OPHTHALMOL, V77, P378, DOI 10.1016/0002-9394(74)90744-2
   SHAREEF SR, 1995, EXP EYE RES, V61, P379, DOI 10.1016/S0014-4835(05)80131-9
   Sharif NA, 2018, J OCUL PHARMACOL TH, V34, P7, DOI 10.1089/jop.2017.0125
   Shen J, 2014, J CLIN INVEST
   SHEN JK, 2017, INVEST OPHTH VIS SCI, V58
   Shinomiya K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19578-6
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stapleton F, 2017, OCUL SURF, V15, P334, DOI 10.1016/j.jtos.2017.05.003
   Stern ME, 2004, EXP EYE RES, V78, P409, DOI 10.1016/j.exer.2003.09.003
   Stevenson W, 2014, CORNEA, V33, P1336, DOI 10.1097/ICO.0000000000000264
   Stevenson W, 2014, CORNEA, V33, P177, DOI 10.1097/ICO.0000000000000019
   Stewart MW, 2012, CURR DIABETES REV, V8, P237, DOI 10.2174/157339912800840488
   Stewart WC, 2011, BRIT J OPHTHALMOL, V95, P1355, DOI 10.1136/bjo.2010.188508
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Tan NYQ, 2018, CLIN EXP OPHTHALMOL, V46, P177, DOI 10.1111/ceo.13126
   Tanito M, 2010, EXP EYE RES, V91, P111, DOI 10.1016/j.exer.2010.04.012
   Thelin WR, 2012, J OCUL PHARMACOL TH, V28, P433, DOI 10.1089/jop.2011.0157
   THORPE RM, 1967, ARCH OPHTHALMOL-CHIC, V77, P238
   Tseng CL, 2015, TRANSFUS APHER SCI, V53, P95, DOI 10.1016/j.transci.2015.05.016
   Tseng CL, 2016, PLOS ONE, V11
   UDELL IJ, 1981, AM J OPHTHALMOL, V91, P226, DOI 10.1016/0002-9394(81)90178-1
   Ueda J, 1998, JPN J OPHTHALMOL, V42, P337, DOI 10.1016/S0021-5155(98)00026-4
   Urashima H, 2004, CORNEA, V23, P613, DOI 10.1097/01.ico.0000126436.25751.fb
   Urashima H, 2012, J OCUL PHARMACOL TH, V28, P264, DOI 10.1089/jop.2011.0147
   Urias EA, 2017, VISION RES, V139, P221, DOI 10.1016/j.visres.2017.06.015
   Van Bergen T, 2017, EXP EYE RES, V165, P136, DOI 10.1016/j.exer.2017.09.012
   Viau S, 2008, GRAEF ARCH CLIN EXP, V246, P857, DOI 10.1007/s00417-008-0784-9
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Wang Q, 2002, ANTIANGIOGENIC PROPE
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Watson S, 2018, AUST PRESCR, V41, P67, DOI 10.18773/austprescr.2018.016
   Wells JA, 2016, OPHTHALMOLOGY
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wendt M, 2008, EXP EYE RES, V86, P746, DOI 10.1016/j.exer.2008.01.022
   Whitcup SM, 2018, INVEST OPHTH VIS SCI, V59, P1, DOI 10.1167/iovs.17-22259
   Wiegand SJ, 2014, ANTI PDGFR BETA ANTI
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Willcox MDP, 2017, OCUL SURF, V15, P366, DOI 10.1016/j.jtos.2017.03.006
   Willis AM, 2004, VET CLIN N AM-SMALL, V34, P755, DOI 10.1016/j.cvsm.2004.02.001
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   WoldeMussie E, 2002, J GLAUCOMA, V11, P474, DOI 10.1097/00061198-200212000-00003
   Woodward DF, 2004, TRENDS PHARMACOL SCI, V25, P238, DOI 10.1016/j.tips.2004.03.002
   Wright CB, 2017, HANDB EXP PHARMACOL, V242, P321, DOI 10.1007/164_2016_36
   Wu L, 2013, WORLD J DIABETES, V4, P290, DOI 10.4239/wjd.v4.i6.290
   Yang JM, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0495-2
   Yang Q, 2012, INVEST OPHTH VIS SCI, V53, P3733, DOI 10.1167/iovs.12-9814
   Yang QM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071393
   Yanni JM, 1996, J OCUL PHARMACOL TH, V12, P389, DOI 10.1089/jop.1996.12.389
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yoles E, 1998, SURV OPHTHALMOL, V42, P367, DOI 10.1016/S0039-6257(97)00123-9
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zernii EY, 2016, CNS NEUROL DISORD-DR, V15, P267, DOI 10.2174/1871527315666151110124957
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhang XY, 2008, DIABETES, V57, P1026, DOI 10.2337/db07-0982
   Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542
   Zhong YS, 2013, BBA-GEN SUBJECTS, V1830, P2882, DOI 10.1016/j.bbagen.2013.01.005
   Ziaei M, 2018, ADV DRUG DELIVER REV, V126, P162, DOI 10.1016/j.addr.2018.01.006
   Zoukhri D, 2007, EXP EYE RES, V84, P894, DOI 10.1016/j.exer.2007.01.015
NR 326
TC 25
Z9 25
U1 2
U2 12
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD APR
PY 2019
VL 36
IS 4
AR 58
DI 10.1007/s11095-019-2588-5
PG 34
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA HM9QJ
UT WOS:000459819800001
PM 30805711
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Thao, MT
   Renfus, DJ
   Dillon, J
   Gaillard, ER
AF Thao, Mai T.
   Renfus, Daniel J.
   Dillon, James
   Gaillard, Elizabeth R.
TI A2E-Mediated Photochemical Modification to Fibronectin and its
   Implications to Age-Related Changes in Bruch's Membrane
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GLYCATION END-PRODUCTS;
   EXTRACELLULAR-MATRIX; LIPOFUSCIN FLUOROPHORE; MACULAR DEGENERATION; A2E;
   LIGHT; ACCUMULATION; REATTACHMENT; APOPTOSIS
AB Lipofuscin accumulates normally with age and is more pronounced in retinal dystrophies such as age-related macular degeneration. The major bis-retinoid component of lipofuscin is A2E. In addition to cell damage effects by A2E, we have previously demonstrated that blue-light-mediated A2E leads to modifications in the basement membrane protein laminin. Therefore, the purpose of this study was to advance the understanding of A2E photooxidation effects on fibronectin, the major glycoprotein of Bruch's membrane. In this study, A2E was irradiated with blue light in the presence of a fibronectin peptide consisting of amino acids from the integrin binding region. The modification sites were identified via LC/MS. Our research indicated that blue light irradiation caused cleavage throughout the A2E molecule closest to the pyridinium ring, and attached to the fibronectin peptide preferentially at lysine and arginine residues. All of these reactions are similar to the Maillard reaction. Altogether this study suggests that blue-light-irradiated A2E modifies peptides and forms advance glycation endproducts. Furthermore, these results can be used to identify modifications that occur in Bruch's membrane in vivo.
C1 [Thao, Mai T.; Renfus, Daniel J.; Dillon, James; Gaillard, Elizabeth R.] No Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA.
C3 Northern Illinois University
RP Gaillard, ER (通讯作者)，No Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA.
EM gaillard@niu.edu
RI Gaillard, Elizabeth/M-2627-2019
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Biesemeier A, 2011, EXP EYE RES, V93, P29, DOI 10.1016/j.exer.2011.04.004
   Dillon J, 2000, PHOTOCHEM PHOTOBIOL, V71, P225, DOI 10.1562/0031-8655(2000)071<0225:TSOLTT>2.0.CO;2
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Keil B, 1987, Protein Seq Data Anal, V1, P13
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Murdaugh LS, 2009, EXP EYE RES, V89, P187, DOI 10.1016/j.exer.2009.03.021
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367
   Reszka K, 1995, PHOTOCHEM PHOTOBIOL, V62, P1005
   Sarici SU, 1999, ACTA PAEDIATR, V88, P1249, DOI 10.1080/080352599750030374
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
NR 34
TC 8
Z9 8
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD MAR
PY 2014
VL 90
IS 2
BP 329
EP 334
DI 10.1111/php.12200
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AC8HP
UT WOS:000332774400010
PM 24303925
DA 2022-11-30
ER

PT J
AU Eveleth, DD
AF Eveleth, David D.
TI Cell-Based Therapies for Ocular Disease
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; HUMAN NEURAL PROGENITORS; STEM-CELL; MACULAR
   DEGENERATION; VISUAL FUNCTION; NEUROTROPHIC FACTORS; TRABECULAR
   MESHWORK; LIMBO-KERATOPLASTY; GEOGRAPHIC ATROPHY; ROYAL-COLLEGE
AB Cell therapy for ocular disease has made significant progress within the last decade. Stem and progenitor populations for many ocular cell types have been identified, and their behavior is now understood well enough to enable clinical application. Corneal epithelial progenitor cell therapy has benefited many patients and is now transitioning from a research technique to established clinical therapy. The application of embryonic stem cell-based therapy is in clinical development for Stargardt's macular dystrophy and dry age-related macular degeneration. These advances have been made possible, in part, by the inherent advantages of the eye as a place to develop and apply cell therapies and the foundation built on transplantation studies. Despite these advances, there are still areas of high unmet need that could benefit from cell therapy when further research identifies methods to identify, generate, and manipulate the progenitor populations. This review discusses, in practical terms, the application of cell therapies to the eye, progress that has been made and progress which remains to be made in the application of cell therapy to ocular disease.
C1 E&B Technol LLC, San Diego, CA 92130 USA.
RP Eveleth, DD (通讯作者)，E&B Technol LLC, 4868 Almondwood Way, San Diego, CA 92130 USA.
EM develeth@san.rr.com
CR Agrawal RN, 2007, NAT PROTOC, V2, P67, DOI 10.1038/nprot.2007.4
   Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029
   Baker PS, 2009, CURR OPIN OPHTHALMOL, V20, P175, DOI 10.1097/ICU.0b013e328329b5f2
   Basu S, 2012, BRIT J OPHTHALMOL, V96, P1504, DOI 10.1136/bjophthalmol-2012-301869
   Bhatia B, 2009, EXP EYE RES, V89, P373, DOI 10.1016/j.exer.2009.04.005
   Bull ND, 2009, INVEST OPHTH VIS SCI, V50, P4244, DOI 10.1167/iovs.08-3239
   Caramoy A, 2011, ACTA OPHTHALMOL, V89, pe666, DOI 10.1111/j.1755-3768.2010.02018.x
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Carr AJ, 2011, MOL VIS, V17, P1701
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chan AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056831
   Chen GC, 2012, CELL TRANSPLANT, V21, P2621, DOI 10.3727/096368912X647153
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Cunningham JJ, 2012, NAT BIOTECHNOL, V30, P849, DOI 10.1038/nbt.2329
   Czekaj M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041798
   Del Debbio CB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012425
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Du YQ, 2013, INVEST OPHTH VIS SCI, V54, P1450, DOI 10.1167/iovs.12-11056
   Du YQ, 2012, INVEST OPHTH VIS SCI, V53, P1566, DOI 10.1167/iovs.11-9134
   Eandi CM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006928.pub2
   Eberwein P, 2012, OPHTHALMOLOGY, V119, P930, DOI 10.1016/j.ophtha.2011.10.039
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Ghaderi S, 2011, STEM CELLS DEV, V20, P1615, DOI 10.1089/scd.2010.0390
   Gias C, 2007, EUR J NEUROSCI, V25, P1940, DOI 10.1111/j.1460-9568.2007.05459.x
   Hambright D, 2012, MOL VIS, V18, P920
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Iqbal M, 2012, CAN J OPHTHALMOL, V47, pE52, DOI 10.1016/j.jcjo.2012.06.004
   Jiang CH, 2010, MOL VIS, V16, P983
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Joyce NC, 2012, EXP EYE RES, V95, P16, DOI 10.1016/j.exer.2011.08.014
   KENYON KR, 1989, OPHTHALMOLOGY, V96, P709
   Khera S, 2012, CURR EYE RES, V37, P606, DOI 10.3109/02713683.2012.664673
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   KINOSHITA S, 1981, INVEST OPHTH VIS SCI, V21, P434
   Klassen H., 2012, STEM CELLS INT, V2012
   Klassen H, 2008, CLONING STEM CELLS, V10, P391, DOI 10.1089/clo.2008.0010
   Klassen H, 2007, VET OPHTHALMOL, V10, P245, DOI 10.1111/j.1463-5224.2007.00547.x
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Krishna Y, 2011, BRIT J OPHTHALMOL, V95, P569, DOI 10.1136/bjo.2009.169953
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724
   Levkovitch-Verbin H, 2010, INVEST OPHTH VIS SCI, V51, P6394, DOI 10.1167/iovs.09-4310
   Li JY, 2012, OPHTHALMOLOGY, V119, P1126, DOI 10.1016/j.ophtha.2011.12.037
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Lu B, 2010, INVEST OPHTH VIS SCI, V51, P2269, DOI 10.1167/iovs.09-4526
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Ming M, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-53
   Montey KL, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1312
   Nakamura T, 2010, OPHTHALMOLOGY, V117, P2247, DOI 10.1016/j.ophtha.2010.04.003
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Patel SV, 2005, AM J OPHTHALMOL, V139, P311, DOI 10.1016/j.ajo.2004.09.045
   Peh GSL, 2011, TRANSPLANTATION, V91, P811, DOI 10.1097/TP.0b013e3182111f01
   Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Pinnamaneni N, 2012, STEM CELLS, V30, P1059, DOI 10.1002/stem.1100
   Prockop DJ, 2012, STEM CELLS, V30, P1051, DOI 10.1002/stem.1103
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955
   Reinhard T, 2004, OPHTHALMOLOGY, V111, P775, DOI 10.1016/j.ophtha.2003.07.013
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler Magdalene J, 2005, Semin Ophthalmol, V20, P31, DOI 10.1080/08820530590921873
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Shortt AJ, 2010, OCUL SURF, V8, P80, DOI 10.1016/S1542-0124(12)70072-1
   Takeuchi K, 2012, EYE, V26, P52, DOI 10.1038/eye.2011.302
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Tseng SCG, 2010, CURR MOL MED, V10, P841
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4
   TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0
   Umazume K, 2012, INVEST OPHTH VIS SCI, V53, P4910, DOI 10.1167/iovs.12-9768
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   Wollensak G, 1999, EXP EYE RES, V68, P341, DOI 10.1006/exer.1998.0611
   Yu WY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/412743
   Zhao TT, 2011, GRAEF ARCH CLIN EXP, V249, P1021, DOI 10.1007/s00417-011-1635-7
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
NR 90
TC 5
Z9 11
U1 0
U2 182
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC 1
PY 2013
VL 29
IS 10
BP 844
EP 854
DI 10.1089/jop.2013.0028
PG 11
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 262ZS
UT WOS:000327777000002
PM 24050306
DA 2022-11-30
ER

PT J
AU Burton, AE
   Shaw, RL
   Gibson, JM
AF Burton, A. E.
   Shaw, R. L.
   Gibson, J. M.
TI 'I'd like to know what causes it, you know, anything I've done?' Are we
   meeting the information and support needs of patients with macular
   degeneration? A qualitative study
SO BMJ OPEN
LA English
DT Article
DE Qualitative Research; Ophthalmology
ID AGE
AB Objective To examine patients' experiences of information and support provision for age-related macular degeneration (AMD) in the UK.
   Study design Exploratory qualitative study investigating patient experiences of healthcare consultations and living with AMD over 18months.
   Setting Specialist eye clinics at a Birmingham hospital.
   Participants 13 patients diagnosed with AMD.
   Main outcome measures Analysis of patients' narratives to identify key themes and issues relating to information and support needs.
   Results Information was accessed from a variety of sources. There was evidence of clear information deficits prior to diagnosis, following diagnosis and ongoing across the course of the condition. Patients were often ill informed and therefore unable to self-advocate and recognise when support was needed, what support was available and how to access support.
   Conclusions AMD patients have a variety of information needs that are variable across the course of the condition. Further research is needed to determine whether these experiences are typical and identify ways of translating the guidelines into practice. Methods of providing information need to be investigated and improved for this patient group.
C1 [Burton, A. E.] Staffordshire Univ, Fac Hlth Sci, Stoke On Trent ST4 2DE, Staffs, England.
   [Shaw, R. L.; Gibson, J. M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
C3 Staffordshire University; Aston University
RP Burton, AE (通讯作者)，Staffordshire Univ, Fac Hlth Sci, Stoke On Trent ST4 2DE, Staffs, England.
EM amy.burton@staffs.ac.uk
RI Burton, Amy/AAZ-5499-2020; , Rachel/L-9107-2019; Burton,
   Amy/GNP-1659-2022
OI , Rachel/0000-0002-0438-7666; Burton, Amy/0000-0002-3698-0712; Gibson,
   Jonathan M/0000-0002-9281-5244
FU Aston Research Centre for Healthy Ageing (ARCHA), Aston University
FX This work was supported by a studentship provided by Aston Research
   Centre for Healthy Ageing (ARCHA), Aston University.
CR Access Economics, 2009, EC IMP PART SIGHT BL
   Angus D, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-4
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Burton AE, BR J VISION IN PRESS
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Douglas G, 2012, OPTHALMIC PHYSL OPTI, V30, P748
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38
   Fylan F, 2005, HEALTH EXPECT, V8, P18, DOI 10.1111/j.1369-7625.2004.00309.x
   Garcia-Gutierrez S, 2012, HLTH EXPECT, DOI 101111/j1369-7625201200801x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Lacey J, 2009, EYE, V23, P924, DOI 10.1038/eye.2008.103
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   National Institute for Health and Clinical Excellence, 2007, RAN PEG AG REL MAC D
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Peel E, 2004, BRIT J GEN PRACT, V54, P183
   Pinder R., 1990, MANAGEMENT CHRONIC I
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Royal College of Ophthalmologists, 2009, AG REL MAC DEG GUID
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sharts-Hopko NC, 2010, HOLIST NURS PRACT, V24, P284, DOI 10.1097/HNP.0b013e3181f1ac5c
NR 27
TC 8
Z9 8
U1 0
U2 16
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2013
VL 3
IS 11
AR e003306
DI 10.1136/bmjopen-2013-003306
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 293AL
UT WOS:000329943700051
PM 24202055
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Chang, JY
   Bora, PS
   Bora, NS
AF Chang, Jason Y.
   Bora, Puran S.
   Bora, Nalini S.
TI Prevention of Oxidative Stress-Induced Retinal Pigment Epithelial Cell
   Death by the PPAR gamma Agonist, 15-Deoxy-Delta 12, 14-Prostaglandin
   J(2)
SO PPAR RESEARCH
LA English
DT Review
ID ACTIVATED RECEPTOR-GAMMA; RPE CELLS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN
   J(2); CYCLOPENTENONE PROSTAGLANDINS; MITOCHONDRIAL DYSFUNCTION;
   POTENTIAL INDUCERS; UP-REGULATION; APOPTOSIS; PROTECTS; EXPRESSION
AB Cellular oxidative stress plays an important role in retinal pigment epithelial (RPE) cell death during aging and the development of age-related macular degeneration. Early reports indicate that during phagocytosis of rod outer segments, there is an increase of RPE oxidative stress and an upregulation of PPAR gamma mRNA in these cells. These studies suggest that activation of PPAR gamma may modulate cellular oxidative stress. This paper presents a brief review of recent studies that investigate RPE oxidative stress under various experimental conditions. This is followed by a detailed review on those reports that examine the protective effect of the natural PPAR gamma ligand, 15d-PGJ(2), against RPE oxidative stress. This agent can upregulate glutathione and prevent oxidant-induced intracellular reactive oxygen species accumulation, mitochondrial depolarization, and apoptosis. The cytoprotective effect of this agent, however, is not shared by other PPAR gamma agonists. Nonetheless, this property of 15d-PGJ2 may be useful in future development of pharmacological tools against retinal diseases caused by oxidative stress. Copyright (C) 2008 Jason Y. Chang et al.
C1 [Chang, Jason Y.; Bora, Puran S.] Univ Arkansas Med Sci, Dept Neurobiol & Dev Sci, Little Rock, AR 72205 USA.
   [Chang, Jason Y.; Bora, Puran S.; Bora, Nalini S.] Univ Arkansas Med Sci, Dept Ophthalmol, Little Rock, AR 72205 USA.
   [Bora, Nalini S.] Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences
RP Chang, JY (通讯作者)，Univ Arkansas Med Sci, Dept Neurobiol & Dev Sci, Little Rock, AR 72205 USA.
EM changjasony@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU Research to Prevent Blindness (NY, USA)
FX This work was supported by funds from Research to Prevent Blindness (NY,
   USA).
CR Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Aoun P, 2003, INVEST OPHTH VIS SCI, V44, P2999, DOI 10.1167/iovs.02-1060
   Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000
   Chang J Y, 2001, BMC Pharmacol, V1, P10, DOI 10.1186/1471-2210-1-10
   Chang JY, 1998, CURR EYE RES, V17, P95, DOI 10.1076/ceyr.17.1.95.5252
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Garg Tarun K., 2004, BMC Pharmacology, V4, P6, DOI 10.1186/1471-2210-4-6
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Geiger RC, 2005, INVEST OPHTH VIS SCI, V46, P3435, DOI 10.1167/iovs.04-1487
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Harris SG, 2002, IMMUNOLOGY, V105, P23, DOI 10.1046/j.0019-2805.2001.01340.x
   Itoh K, 2004, MOL CELL BIOL, V24, P36, DOI 10.1128/MCB.24.1.36-45.2004
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Jha P, 2006, INVEST OPHTH VIS SCI, V47, P1030, DOI 10.1167/iovs.05-1062
   Jha P, 2006, J IMMUNOL, V176, P7221, DOI 10.4049/jimmunol.176.12.7221
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291
   Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200
   Koppal T, 2000, BRAIN RES, V867, P115, DOI 10.1016/S0006-8993(00)02270-8
   Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488
   Li LY, 2001, J BIOL CHEM, V276, P38152
   Liang FQ, 2005, EXP EYE RES, V80, P113, DOI 10.1016/j.exer.2004.08.017
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Matsui H, 2001, INVEST OPHTH VIS SCI, V42, P2935
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Na HK, 2003, BIOCHEM PHARMACOL, V66, P1381, DOI 10.1016/S0006-2952(03)00488-X
   O'Connell S. R., 1999, VITREORETINAL DIS ES, P213
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941
   Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Saito Y, 2007, J NEUROCHEM, V102, P1625, DOI 10.1111/j.1471-4159.2007.04701.x
   Satoh T, 2003, EUR J NEUROSCI, V17, P2249, DOI 10.1046/j.1460-9568.2003.02688.x
   Shamsi FA, 2007, CURR EYE RES, V32, P575, DOI 10.1080/02713680701363833
   Singhal SS, 1999, INVEST OPHTH VIS SCI, V40, P2652
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, pS145
   Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081
   Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967
   Tanito M, 2005, J NEUROSCI, V25, P2396, DOI 10.1523/JNEUROSCI.4866-04.2005
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, pS520
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
   Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098
   Voloboueva LA, 2007, FASEB J, V21, P4077, DOI 10.1096/fj.07-8396com
   Wang ZY, 2006, J BIOL CHEM, V281, P21377, DOI 10.1074/jbc.M601201200
   Winkler BS, 1999, MOL VIS, V5
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
   Zander T, 2002, J NEUROCHEM, V81, P1052, DOI 10.1046/j.1471-4159.2002.00899.x
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
NR 68
TC 18
Z9 18
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-4757
EI 1687-4765
J9 PPAR RES
JI PPAR Res.
PY 2008
VL 2008
AR 720163
DI 10.1155/2008/720163
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V13ZS
UT WOS:000207705300001
PM 18382621
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
   Boyer, DS
   Bressler, NM
   Fish, G
   Grizzard, WS
   Hao, Y
   Hnik, P
   Hudson, HL
   Singerman, L
   Slakter, JS
   Grp, VS
AF Rosenfeld, Philip J.
   Boyer, David S.
   Bressler, Neil M.
   Fish, Gary
   Grizzard, W. Sanderson
   Hao, Yong
   Hnik, Peter
   Hudson, Henry L.
   Singerman, Lawrence
   Slakter, Jason S.
   Grp, V. A. L. I. O. Study
TI Verteporfin therapy of subfoveal occult choroidal neovascularization in
   AMD using delayed light application: One-year results of the VALIO study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY
AB PURPOSE: To compare photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) using either standard or delayed light application.
   DESIGN: Phase II, multicenter, masked, randomized clinical trial.
   METHODS: Sixty patients with occult with no classic choroidal neovascularization (CNV) resulting from age-related macular degeneration were assigned randomly (1:1) to verteporfin infusion followed by light application either at 15 minutes (standard light) or 30 minutes (delayed light) after the start of the infusion. The assigned treatment was repeated every three months if fluorescein leakage was detected.
   RESULTS: At month 12, patients lost a mean of 15.7 letters and 11.4 letters from baseline in the standard and delayed light groups, respectively (P=.38). Twelve (52%) of 23 patients in the standard light group and 11 (42%) of 26 in the delayed light group lost at least 15 letters of visual acuity (P=.57).
   CONCLUSIONS: There were no statistically significant differences between verteporfin therapy using the delayed light regimen of 30 minutes or the standard light regimen of 15 minutes in eyes with occult with no classic CNV.
C1 Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   Retina Vitreous Assoc Med Grp, Beverly Hills, CA USA.
   Wilmer Ophthalmol Inst, Baltimore, MD USA.
   Texas Retina Assoc, Dallas, TX USA.
   Retina Assoc Florida, Tampa, FL USA.
   QLT Inc, Vancouver, BC, Canada.
   Retina Ctr PC, Tucson, AZ USA.
   Retina Assoc Cleveland Inc, Beachwood, OH USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
C3 Bascom Palmer Eye Institute; Retina Vitreous Associates Medical Group;
   Johns Hopkins University; Johns Hopkins Medicine; Retina Associates of
   Cleveland, Inc.; Manhattan Eye Ear & Throat Hospital
RP Rosenfeld, PJ (通讯作者)，900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
NR 4
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2007
VL 144
IS 6
BP 970
EP 972
DI 10.1016/j.ajo.2007.08.017
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 238TI
UT WOS:000251470100025
PM 18036873
DA 2022-11-30
ER

PT J
AU Verma, S
   Singh, A
   Varshney, A
   Chandru, RA
   Acharya, M
   Rajput, J
   Sangwan, VS
   Tiwari, AK
   Bhowmick, T
   Tiwari, A
AF Verma, Sudhir
   Singh, Aastha
   Varshney, Akhil
   Chandru, R. Arun
   Acharya, Manisha
   Rajput, Jyoti
   Sangwan, Virender Singh
   Tiwari, Amit K.
   Bhowmick, Tuhin
   Tiwari, Anil
TI Infectious Keratitis: An Update on Role of Epigenetics
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE keratitis; epigenetics; methylation; histone modifications; infectious
ID BACTERIAL; MECHANISMS; EXPRESSION; THERAPY; METHYLATION; MICROSCOPY;
   PROFILE; GROWTH
AB Epigenetic mechanisms modulate gene expression and function without altering the base sequence of DNA. These reversible, heritable, and environment-influenced mechanisms generate various cell types during development and orchestrate the cellular responses to external stimuli by regulating the expression of genome. Also, the epigenetic modifications influence common pathological and physiological responses including inflammation, ischemia, neoplasia, aging and neurodegeneration etc. In recent past, the field of epigenetics has gained momentum and become an increasingly important area of biomedical research As far as eye is concerned, epigenetic mechanisms may play an important role in many complex diseases such as corneal dystrophy, cataract, glaucoma, diabetic retinopathy, ocular neoplasia, uveitis, and age-related macular degeneration. Focusing on the epigenetic mechanisms in ocular diseases may provide new understanding and insights into the pathogenesis of complex eye diseases and thus can aid in the development of novel treatments for these diseases. In the present review, we summarize the clinical perspective of infectious keratitis, role of epigenetics in infectious keratitis, therapeutic potential of epigenetic modifiers and the future perspective.
C1 [Verma, Sudhir] Univ Delhi, Deen Dayal Upadhyaya Coll, Dept Zool, New Delhi, India.
   [Singh, Aastha; Varshney, Akhil; Acharya, Manisha; Sangwan, Virender Singh; Tiwari, Anil] Dr Shroffs Char Eye Hosp, Dept Cornea & Uveitis, New Delhi, India.
   [Chandru, R. Arun; Rajput, Jyoti; Bhowmick, Tuhin] Pandorum Technol Ltd, Bangalore Bioinnovat Ctr, Bangalore, Karnataka, India.
   [Tiwari, Amit K.] Univ Toledo, Dept Pharmacol & Expt Therapeut, 2801 W Bancroft St, Toledo, OH 43606 USA.
C3 Deen Dayal Upadhyaya College; University of Delhi; University System of
   Ohio; University of Toledo
RP Tiwari, A (通讯作者)，Dr Shroffs Char Eye Hosp, Dept Cornea & Uveitis, New Delhi, India.; Bhowmick, T (通讯作者)，Pandorum Technol Ltd, Bangalore Bioinnovat Ctr, Bangalore, Karnataka, India.
EM tuhin@pandorumtechnologies.in; anil.tiwari@sceh.net
RI Sangwan, Virender Singh/AAA-1091-2022
OI Sangwan, Virender Singh/0000-0002-8229-4158
FU Department of Biotechnology (DBT), Government of India; Department of
   Science and Technology (DST), Government of India
FX AT thanks Department of Biotechnology (DBT), Government of India for
   Ramalingaswami Fellowship. AV thanks Department of Science and
   Technology (DST), Government of India, for Ramanujan Fellowship.
CR Acharya M, 2020, J CURR OPHTHALMOL, V32, P249, DOI 10.4103/JOCO.JOCO_113_20
   Adamiak K, 2020, INT J BIOL MACROMOL, V161, P550, DOI 10.1016/j.ijbiomac.2020.06.075
   Alkozi HA, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00144
   Atia R, 2018, J FR OPHTALMOL, V41, P560, DOI 10.1016/j.jfo.2017.12.007
   Austin A, 2017, OPHTHALMOLOGY, V124, P1678, DOI 10.1016/j.ophtha.2017.05.012
   Baer-Dubowska W, 2011, PHARMACOL REP, V63, P293, DOI 10.1016/S1734-1140(11)70498-4
   Bannister S, 2020, EPIGENETICS-US, V15, P555, DOI 10.1080/15592294.2020.1712814
   Berdasco M, 2019, NAT REV GENET, V20, P109, DOI 10.1038/s41576-018-0074-2
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Bloom DC, 2010, BBA-GENE REGUL MECH, V1799, P246, DOI 10.1016/j.bbagrm.2009.12.001
   Bonini S, 2000, OPHTHALMOLOGY, V107, P1347, DOI 10.1016/S0161-6420(00)00163-9
   Boomiraj H, 2015, INVEST OPHTH VIS SCI, V56, P7939, DOI 10.1167/iovs.15-17619
   Choudhuri S, 2011, TOXICOL MECH METHOD, V21, P252, DOI 10.3109/15376516.2011.559695
   Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26
   Danaher RJ, 2005, J NEUROVIROL, V11, P306, DOI 10.1080/13550280590952817
   Davidsohn N, 2020, P NATL ACAD SCI USA, V117, P790, DOI 10.1073/pnas.1921234117
   Duguid IGM, 1997, OPHTHALMOLOGY, V104, P1587, DOI 10.1016/S0161-6420(97)30092-X
   Dutt S, 2016, INDIAN J OPHTHALMOL, V64, P292, DOI 10.4103/0301-4738.182940
   Gallego-Perez D, 2017, NAT NANOTECHNOL, V12, P974, DOI [10.1038/nnano.2017.134, 10.1038/NNANO.2017.134]
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gopinathan U, 2002, CORNEA, V21, P555, DOI 10.1097/00003226-200208000-00004
   Grabiec AM, 2018, CRIT REV MICROBIOL, V44, P336, DOI 10.1080/1040841X.2017.1373063
   Green M, 2008, CORNEA, V27, P22, DOI 10.1097/ICO.0b013e318156caf2
   Gupta Noopur, 2013, Indian J Community Med, V38, P198, DOI 10.4103/0970-0218.120153
   Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009
   Hamrah P, 2010, OPHTHALMOLOGY, V117, P1930, DOI 10.1016/j.ophtha.2010.07.010
   Handy DE, 2011, CIRCULATION, V123, P2145, DOI 10.1161/CIRCULATIONAHA.110.956839
   He SK, 2013, MOL VIS, V19, P665
   Henikoff S, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019364
   Huang P, 2017, CORNEA, V36, P927, DOI 10.1097/ico.0000000000001239
   Jayasudha R, 2018, J BIOSCIENCES, V43, P835, DOI 10.1007/s12038-018-9798-6
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   JONES DB, 1979, SURV OPHTHALMOL, V24, P97, DOI 10.1016/0039-6257(79)90128-0
   Joo SY, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04237-5
   Kanherkar RR, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00049
   Khor WB, 2018, AM J OPHTHALMOL, V195, P161, DOI 10.1016/j.ajo.2018.07.040
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lanza M, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/2424956
   Lee HA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01506-20
   Li XH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46361-y
   Liu MM, 2013, CURR GENOMICS, V14, P166, DOI 10.2174/1389202911314030002
   Lu YC, 2020, NATURE, V588, P124, DOI 10.1038/s41586-020-2975-4
   Maier P, 2019, DTSCH ARZTEBL INT, V116, P184, DOI 10.3238/arztebl.2019.0184
   Martire S, 2020, NAT REV MOL CELL BIO, V21, P522, DOI 10.1038/s41580-020-0262-8
   Mazzio EA, 2012, EPIGENETICS-US, V7, P119, DOI 10.4161/epi.7.2.18764
   Moon EK, 2017, KOREAN J PARASITOL, V55, P115, DOI 10.3347/kjp.2017.55.2.115
   Nehme Z, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0654-9
   Nepali K, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-021-00721-x
   Prachayasittikul V, 2017, EXPERT OPIN DRUG DIS, V12, P345, DOI 10.1080/17460441.2017.1295954
   Rao Rajesh C, 2011, Int Ophthalmol Clin, V51, P117, DOI 10.1097/IIO.0b013e31822d6966
   Sacchetti M, 2014, CLIN OPHTHALMOL, V8, P571, DOI 10.2147/OPTH.S45921
   Samanta S, 2017, BBA-MOL BASIS DIS, V1863, P518, DOI 10.1016/j.bbadis.2016.11.030
   Sarkar TJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15174-3
   Shah A, 2011, BRIT J OPHTHALMOL, V95, P762, DOI 10.1136/bjo.2009.169607
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sundaramoorthy Ramasubramian, 2020, F1000Res, V9, DOI 10.12688/f1000research.21933.1
   Szczesniak MW, 2017, DATABASE-OXFORD, DOI 10.1093/database/baw168
   Thangavel J, 2014, AM J PATHOL, V184, P2237, DOI 10.1016/j.ajpath.2014.05.008
   Tian R, 2020, INDIAN J OPHTHALMOL, V68, P39, DOI 10.4103/ijo.IJO_65_19
   Ting DSJ, 2021, EYE, V35, P1084, DOI 10.1038/s41433-020-01339-3
   Ung L, 2019, SURV OPHTHALMOL, V64, P255, DOI 10.1016/j.survophthal.2018.12.003
   VAJPAYEE RB, 1993, ANN OPHTHALMOL, V25, P68
   Varanasi SK, 2017, J VIROL, V91, DOI 10.1128/JVI.02367-16
   Versura P, 2018, EYE BRAIN, V10, P37, DOI 10.2147/EB.S117261
   Wang C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23353-z
   Wei JW, 2017, ONCOL REP, V37, P3, DOI 10.3892/or.2016.5236
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Zhang L, 2020, ADV EXP MED BIOL, V1253, P3, DOI 10.1007/978-981-15-3449-2_1
   Zhu HQ, 2010, J BIOL CHEM, V285, P9429, DOI 10.1074/jbc.M109.071274
NR 69
TC 1
Z9 1
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 30
PY 2021
VL 12
AR 765890
DI 10.3389/fimmu.2021.765890
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA XO0RR
UT WOS:000729903100001
PM 34917084
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sarialtin, SY
   Coban, T
AF Sarialtin, Sezen Yilmaz
   Coban, Tulay
TI An Overview on the Role of Macular Xanthophylls in Ocular Diseases
SO RECORDS OF NATURAL PRODUCTS
LA English
DT Review
DE Eye diseases; lutein; macular xanthophylls; ocular diseases; zeaxanthin
ID PIGMENT OPTICAL-DENSITY; AGE-RELATED CATARACT; LUTEIN SUPPLEMENTATION;
   PLASMA LUTEIN; ULTRAVIOLET-RADIATION; ISCHEMIA-REPERFUSION; ZEAXANTHIN
   ISOMERS; LIPID-PEROXIDATION; OXIDATIVE STRESS; LIVER-DISEASE
AB Macula lutea, is the center of the retina of the eye, contains high concentrations of lutein and zeaxanthin which can act as a filter against short-wavelength (blue) light. Lutein and zeaxanthin are the only carotenoids detected in human lens which exhibit highly strong free radical scavenging activity. Many epidemiological studies, clinical trials, animal experiments have suggested that lutein and zeaxanthin have anti-inflammatory potential with their high antioxidant properties. Several eye diseases including, age-related macular degeneration, uveitis and retinitis pigmentosa are caused by ocular inflammation. Some studies have shown that lutein and zeaxanthin could be protective, curative and preventive against ocular inflammation induced diseases and other ocular disorders such as cataract, glaucoma and choroideremia. The mechanisms responsible for these effects are absorption of near-ultraviolet and blue light, reduction of oxidative stress, inflammation and angiogenesis. Lutein and zeaxanthin can be taken from dietary supplements or a diet high in fruits, vegetables such as kale, spinach and turnip greens. The aim of this review is to evaluate the relationship between the consumption of lutein and zeaxanthin and eye diseases.
C1 [Sarialtin, Sezen Yilmaz; Coban, Tulay] Ankara Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR-06100 Ankara, Turkey.
C3 Ankara University
RP Sarialtin, SY (通讯作者)，Ankara Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR-06100 Ankara, Turkey.
EM Sezen.Yilmaz@ankara.edu.tr
RI YILMAZ, Sezen/A-4724-2017
OI Yilmaz-Sarialtin, Sezen/0000-0002-8387-4146
CR Antwi SO, 2015, CANCER EPIDEMIOL, V39, P752, DOI 10.1016/j.canep.2015.06.008
   Apanasenko IE, 2015, ARCH BIOCHEM BIOPHYS, V572, P58, DOI 10.1016/j.abb.2014.12.010
   Arnal E, 2010, NEUROSCIENCE, V166, P271, DOI 10.1016/j.neuroscience.2009.12.028
   Ashton A. Q., 2013, XANTHOPHYLLS ADV RES
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Britton G., 2008, CAROTENOIDS
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Crichton G, 2015, NUTRIENTS, V7, P8058, DOI 10.3390/nu7095378
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dilsiz N, 2006, GRAEF ARCH CLIN EXP, V244, P627, DOI 10.1007/s00417-005-0084-6
   Doherty JA, 2013, INT J MOL EPIDEMIOL, V4, P11
   Du SY, 2015, INT J CLIN EXP MED, V8, P8785
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Freitas A, 2015, J SCI FOOD AGR, V95, P44, DOI 10.1002/jsfa.6751
   Fujimura S, 2016, CLIN OPHTHALMOL, V10, P2149, DOI 10.2147/OPTH.S119251
   Giaconi JA, 2012, AM J OPHTHALMOL, V154, P635, DOI 10.1016/j.ajo.2012.03.048
   Goutham G, 2017, BIOMED PHARMACOTHER, V86, P232, DOI 10.1016/j.biopha.2016.11.141
   Grether-Beck S, 2017, BRIT J DERMATOL, V176, P1231, DOI 10.1111/bjd.15080
   Hammond BR, 2015, INVEST OPHTH VIS SCI, V56, P7866, DOI 10.1167/iovs.15-18407
   Hashimoto H, 2016, SUBCELL BIOCHEM, V79, P111, DOI 10.1007/978-3-319-39126-7_4
   Hayashi R, 2014, EXP EYE RES, V129, P5, DOI 10.1016/j.exer.2014.10.009
   Haytowitz D., 2011, USDA NAT NUTR DAT ST
   He RR, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-38
   Honarvar NM, 2017, J MOL NEUROSCI, V61, P289, DOI 10.1007/s12031-016-0857-x
   Hu BJ, 2011, INT J OPHTHALMOL-CHI, V4, P303, DOI 10.3980/j.issn.2222-3959.2011.03.19
   Huang Fei-fei, 2014, Beijing Da Xue Xue Bao Yi Xue Ban, V46, P237
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Igras E, 2013, BRIT J OPHTHALMOL, V97, P994, DOI 10.1136/bjophthalmol-2013-303153
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Juturu V, 2016, CLIN COSMET INVESTI, V9, P325, DOI 10.2147/CCID.S115519
   KAPLAN LA, 1990, CLIN PHYSIOL BIOCH, V8, P1
   Karppi J, 2012, BRIT J NUTR, V108, P148, DOI 10.1017/S0007114511005332
   Kelly D, 2015, J ALZHEIMERS DIS, V48, P261, DOI 10.3233/JAD-150199
   Korkaric M, 2015, AQUAT TOXICOL, V167, P209, DOI 10.1016/j.aquatox.2015.08.008
   Leermakers ETM, 2015, BRIT J NUTR, V114, P970, DOI 10.1017/S0007114515002779
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Liu XH, 2014, NUTRIENTS, V6, P452, DOI 10.3390/nu6010452
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2014, GRAEF ARCH CLIN EXP, V252, P63, DOI 10.1007/s00417-013-2492-3
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Manayi A, 2016, CRIT REV BIOTECHNOL, V36, P829, DOI 10.3109/07388551.2015.1049510
   Mares J, 2016, ANNU REV NUTR, V36, P571, DOI 10.1146/annurev-nutr-071715-051110
   Vianna LMM, 2014, ARQ BRAS OFTALMOL, V77, P173, DOI 10.5935/0004-2749.20140044
   Moshetova L K, 2015, Vestn Oftalmol, V131, P34, DOI 10.17116/oftalma2015131334-44
   Murthy RK, 2014, CUTAN OCUL TOXICOL, V33, P132, DOI 10.3109/15569527.2013.812108
   Muthusamy A, 2014, J CEREBR BLOOD F MET, V34, P522, DOI 10.1038/jcbfm.2013.230
   Nataraj J, 2016, NUTR NEUROSCI, V19, P237, DOI 10.1179/1476830515Y.0000000010
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   OH J, 2013, MEDIAT INFLAMM, V2013, DOI DOI 10.1155/2013/787042
   Pei Ying-xin, 2007, Sichuan Da Xue Xue Bao Yi Xue Ban, V38, P629
   Pescosolido N, 2016, INT J OPHTHALMOL-CHI, V9, P1506, DOI 10.18240/ijo.2016.10.23
   Philips N, 2007, ARCH DERMATOL RES, V299, P373, DOI 10.1007/s00403-007-0779-0
   Pongcharoen S, 2013, BIOL RES, V46, P39, DOI 10.4067/S0716-97602013000100006
   Qiu X, 2015, WORLD J GASTROENTERO, V21, P8061, DOI 10.3748/wjg.v21.i26.8061
   Rafi MM, 2015, J MED FOOD, V18, P173, DOI 10.1089/jmf.2014.0003
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Riccioni G, 2012, INT J VITAM NUTR RES, V82, P15, DOI 10.1024/0300-9831/a000090
   Roberts JE, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/687173
   Roberts RL, 2009, CLIN DERMATOL, V27, P195, DOI 10.1016/j.clindermatol.2008.01.011
   Sahli MW, 2016, OPHTHAL EPIDEMIOL, V23, P99, DOI 10.3109/09286586.2015.1129426
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Siah WF, 2015, OPHTHALMOLOGY, V122, P2029, DOI 10.1016/j.ophtha.2015.06.028
   Skiljic D, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0392-0
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sousa-Martins D, 2012, RETINA-J RET VIT DIS, V32, P1328, DOI 10.1097/IAE.0b013e318239e2b6
   Stuetz W, 2017, FOOD CHEM, V221, P222, DOI 10.1016/j.foodchem.2016.10.065
   Sulich Agnieszka, 2015, Rocz Panstw Zakl Hig, V66, P55
   Sun YX, 2014, J ASIAN NAT PROD RES, V16, P1084, DOI 10.1080/10286020.2014.939584
   U.S. Department of Agriculture Agricultural Research Service, 2009, USDA NAT NUTR DAT ST
   US Department of Agriculture Agricultural Research Service Nutrient Data Laboratory, 2015, USDA NAT NUTR DAT ST
   van der Made SM, 2014, J NUTR, V144, P1370, DOI 10.3945/jn.114.195503
   Vishwanathan R, 2016, NUTR NEUROSCI, V19, P95, DOI 10.1179/1476830514Y.0000000141
   Vishwanathan R, 2013, NUTR NEUROSCI, V16, P21, DOI 10.1179/1476830512Y.0000000024
   Vogelsang A, 2009, INT J VITAM NUTR RES, V79, P288, DOI 10.1024/0300-9831.79.56.288
   Wang MX, 2013, ATHEROSCLEROSIS, V227, P380, DOI 10.1016/j.atherosclerosis.2013.01.021
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Woo TTY, 2013, GRAEF ARCH CLIN EXP, V251, P41, DOI 10.1007/s00417-012-2128-z
   Wu WQ, 2015, MOL NUTR FOOD RES, V59, P1663, DOI 10.1002/mnfr.201500109
   Xu Xianrong, 2010, Wei Sheng Yan Jiu, V39, P689
   Xue CY, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/523027
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Zaripheh S, 2002, J NUTR, V132, p531S, DOI 10.1093/jn/132.3.531S
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
NR 94
TC 8
Z9 8
U1 0
U2 39
PU ACG PUBLICATIONS
PI GEBZE-KOCAELI
PA YENIKENT MAHALLESI, FIRAT CADDESI, 1-3, GEBZE-KOCAELI, 41400, TURKEY
SN 1307-6167
J9 REC NAT PROD
JI Rec. Nat. Prod.
PD MAR-APR
PY 2018
VL 12
IS 2
BP 107
EP 120
DI 10.25135/rnp.14.17.04.067
PG 14
WC Plant Sciences; Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Chemistry; Pharmacology & Pharmacy
GA FO6KI
UT WOS:000416971500001
OA gold
DA 2022-11-30
ER

PT J
AU Zieger, M
   Punzo, C
AF Zieger, Marina
   Punzo, Claudio
TI Improved cell metabolism prolongs photoreceptor survival upon
   retinal-pigmented epithelium loss in the sodium iodate induced model of
   geographic atrophy
SO ONCOTARGET
LA English
DT Article
DE AMD; cone degeneration; rod degeneration; geographic atrophy; mTORC1;
   Gerotarget
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; MOUSE MODEL;
   RETINITIS-PIGMENTOSA; CRE RECOMBINASE; TRANSGENIC MICE; VISUAL FUNCTION;
   CONE SURVIVAL; EXPRESSION; GENE
AB Age-related macular degeneration (AMD) is characterized by malfunction and loss of retinal-pigmented epithelium (RPE) cells. Because the RPE transfers nutrients from the choriocapillaris to photoreceptor (PR), PRs are affected as well. Geographic atrophy (GA) is an advanced form of AMD characterized by severe vision impairment due to RPE loss over large areas. Currently there is no treatment to delay the degeneration of nutrient deprived PRs once RPE cells die. Here we show that cell-autonomous activation of the key regulator of cell metabolism, the kinase mammalian target of rapamycin complex 1 (mTORC1), delays PR death in the sodium iodate induced model of RPE atrophy. Consistent with this finding loss of mTORC1 in cones accelerates cone death as cones fail to balance demand with supply. Interestingly, promoting rod survival does not promote cone survival in this model of RPE atrophy as both, rods and cones suffer from a sick and dying RPE. The findings suggest that activation of metabolic genes downstream of mTORC1 can serve as a strategy to prolong PR survival when RPE cells malfunction or die.
C1 [Zieger, Marina; Punzo, Claudio] Univ Massachusetts, Sch Med, Dept Ophthalmol, Worcester, MA USA.
   [Zieger, Marina; Punzo, Claudio] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester
RP Punzo, C (通讯作者)，Univ Massachusetts, Sch Med, Dept Ophthalmol, Worcester, MA USA.; Punzo, C (通讯作者)，Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA USA.
EM Claudio.Punzo@umassmed.edu
RI Punzo, Claudio/AAJ-8291-2021; Zieger, Marina/AAF-3355-2020
OI Punzo, Claudio/0000-0001-5207-0041; Zieger, Marina/0000-0003-2693-3901
FU International Retinal Research Foundation; National Institute of Health
   [RO1 EY023570]; NATIONAL EYE INSTITUTE [R21EY030166, R01EY023570]
   Funding Source: NIH RePORTER
FX This work was supported by a grant from the International Retinal
   Research Foundation to C.P. and the National Institute of Health (RO1
   EY023570).
CR Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002
   Bergersen L, 1999, NEUROSCIENCE, V90, P319, DOI 10.1016/S0306-4522(98)00427-8
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Chazotte B., 2010, COLD SPRING HARB PRO, V2010
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garcia JM, 2015, WORLD J STEM CELLS, V7, P160, DOI 10.4252/wjsc.v7.i1.160
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525
   Le YZ, 2006, MOL VIS, V12, P389
   Le YZ, 2004, MOL VIS, V10, P1011
   Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036
   Li S, 2005, GENESIS, V41, P73, DOI 10.1002/gene.20097
   Lim Lik Thai, 2012, Oman J Ophthalmol, V5, P67, DOI 10.4103/0974-620X.94793
   Ma S, 2015, EXP EYE RES, V135, P1, DOI 10.1016/j.exer.2015.04.006
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Matsumoto H, 2014, INVEST OPHTH VIS SCI, V55, P4165, DOI 10.1167/iovs.14-14238
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Steinberg Roy H., 1994, Current Opinion in Neurobiology, V4, P515, DOI 10.1016/0959-4388(94)90052-3
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   SUGASAWA K, 1994, CELL STRUCT FUNCT, V19, P21, DOI 10.1247/csf.19.21
   Venkatesh Aditya, 2013, Curr Protoc Microbiol, VChapter 14, DOI 10.1002/9780471729259.mc14d04s28
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zinchuk V, 2011, NAT PROTOC, V6, P1554, DOI 10.1038/nprot.2011.384
NR 48
TC 23
Z9 23
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 1
PY 2016
VL 7
IS 9
BP 9620
EP 9633
DI 10.18632/oncotarget.7330
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL5JI
UT WOS:000375672900002
PM 26883199
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Pakzad-Vaezi, K
   Mehta, H
   Mammo, Z
   Tufail, A
AF Pakzad-Vaezi, Kaivon
   Mehta, Hemal
   Mammo, Zaid
   Tufail, Adnan
TI Vascular endothelial growth factor inhibitor use and treatment approach
   for choroidal neovascularization secondary to pathologic myopia
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE Aflibercept; anti-VEGF; chorioretinal atrophy; choroidal
   neovascularization; myopia; pathologic myopia; ranibizumab
ID DOME-SHAPED MACULA; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED
   CLINICAL-TRIAL; OCULAR RISK-FACTORS; ANTI-VEGF THERAPY; TERM-FOLLOW-UP;
   INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; REFRACTIVE ERRORS;
   FLUORESCEIN ANGIOGRAPHY
AB Introduction: Myopic choroidal neovascularization (CNV) is the most common cause of CNV in those under 50years of age. It is a significant cause of visual loss in those with pathologic myopia. The current standard of care involves therapy with intravitreal inhibitors of vascular endothelial growth factor (VEGF).Areas Covered: The epidemiology of myopia, high myopia, pathologic myopia, and myopic CNV is reviewed, along with a brief discussion of historical treatments. The pharmacology of the three most commonly used anti-VEGF agents is discussed, with an emphasis on the licensed drugs, ranibizumab and aflibercept. A comprehensive clinical approach to diagnosis and treatment of myopic CNV is presented.Expert Opinion: The current standard of care for myopic CNV is intravitreal inhibition of VEGF, with ranibizumab and aflibercept licensed for intraocular use. The diagnosis, OCT features of disease activity and retreatment algorithm for myopic CNV is different from wet age-related macular degeneration. In the long-term, myopic CNV may be associated with gradual, irreversible visual loss due to progressive chorioretinal atrophy, for which there is currently no treatment.
C1 [Pakzad-Vaezi, Kaivon; Mehta, Hemal; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, Dept Med Retina, London, England.
   [Mammo, Zaid] Univ British Columbia, Ophthalmol & Visual Sci, Vancouver, BC V5Z 1M9, Canada.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of British Columbia
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Dept Med Retina, London, England.
EM Adnan.Tufail@moorfields.nhs.uk
OI Tufail, Adnan/0000-0001-6131-7640
CR Adatia FA, 2015, SURV OPHTHALMOL, V60, P204, DOI 10.1016/j.survophthal.2014.10.002
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Attebo K, 1999, OPHTHALMOLOGY, V106, P1066, DOI 10.1016/S0161-6420(99)90251-8
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Brue C, 2016, EYE, V30, P139, DOI 10.1038/eye.2015.199
   Ceklic L, 2014, OPHTHALMOLOGY, V121, P2288, DOI 10.1016/j.ophtha.2014.06.012
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Channa R, 2012, J OPHTHALMIC INFLAMM, V2, P113, DOI 10.1007/s12348-011-0054-6
   Cohen SY, 2015, JPN J OPHTHALMOL, V59, P36, DOI 10.1007/s10384-014-0363-z
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Curtin B J, 1970, Trans Am Ophthalmol Soc, V68, P312
   DAUBS JG, 1984, OPHTHAL PHYSL OPT, V4, P143, DOI 10.1111/j.1475-1313.1984.tb00348.x
   Errera MH, 2014, GRAEF ARCH CLIN EXP, V252, P499, DOI 10.1007/s00417-013-2561-7
   Farinha CL, 2014, OPHTHALMOLOGICA, V231, P211, DOI 10.1159/000357290
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Freitas-da-Costa P, 2014, OPHTHALMOLOGICA, V232, P57, DOI 10.1159/000360307
   Gaucher D, 2008, AM J OPHTHALMOL, V145, P909, DOI 10.1016/j.ajo.2008.01.012
   Gharbiya M, 2010, AM J OPHTHALMOL, V149, P458, DOI 10.1016/j.ajo.2009.10.010
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Hashemi S, 2014, EXPERT OPIN BIOL TH, V14, P1837, DOI 10.1517/14712598.2014.967210
   Hayashi K, 2005, GRAEF ARCH CLIN EXP, V243, P13, DOI 10.1007/s00417-004-0960-5
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hayashi K, 2009, AM J OPHTHALMOL, V148, P396, DOI 10.1016/j.ajo.2009.03.026
   Hayashi K, 2009, GRAEF ARCH CLIN EXP, V247, P609, DOI 10.1007/s00417-008-1021-2
   Hefner L, 2013, KLIN MONATSBL AUGENH, V230, P401, DOI 10.1055/s-0032-1328366
   Iacono P, 2014, OPHTHALMIC RES, V52, P25, DOI 10.1159/000358331
   Iacono P, 2012, RETINA-J RET VIT DIS, V32, P1539, DOI 10.1097/IAE.0b013e31826956b7
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Ikuno Y, 2010, AM J OPHTHALMOL, V149, P140, DOI 10.1016/j.ajo.2009.08.008
   Imamura Y, 2011, AM J OPHTHALMOL, V151, P297, DOI 10.1016/j.ajo.2010.08.014
   Introini U, 2012, EYE, V26, P976, DOI 10.1038/eye.2012.75
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   JALKH AE, 1987, OPHTHALMIC SURG LAS, V18, P721
   Kang HM, 2013, RETINA-J RET VIT DIS, V33, P1613, DOI 10.1097/IAE.0b013e318285cc24
   Katz J, 1997, INVEST OPHTH VIS SCI, V38, P334
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Kojima A, 2006, GRAEF ARCH CLIN EXP, V244, P1474, DOI 10.1007/s00417-006-0324-4
   Krishnaiah S, 2009, CLIN OPHTHALMOL, V3, P17
   Kung YH, 2014, ACTA OPHTHALMOL, V92, pe615, DOI 10.1111/aos.12457
   Ladaique M, 2015, KLIN MONATSBL AUGENH, V232, P542, DOI 10.1055/s-0035-1545817
   Leveziel N, 2013, AM J OPHTHALMOL, V155, P913, DOI 10.1016/j.ajo.2012.11.021
   Leveziel N, 2012, INVEST OPHTH VIS SCI, V53, P5004, DOI 10.1167/iovs.12-9538
   Liang IC, 2015, OPHTHALMOLOGY, V122, P1591, DOI 10.1016/j.ophtha.2015.04.012
   Lin LLK, 2004, ANN ACAD MED SINGAP, V33, P27
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehdizadeh M, 2008, AM J OPHTHALMOL, V146, P478, DOI 10.1016/j.ajo.2008.05.045
   Miyake M, 2013, INVEST OPHTH VIS SCI, V54, P4208, DOI 10.1167/iovs.13-12280
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Ng DSC, 2015, RETINA-J RET VIT DIS, V35, P2457, DOI 10.1097/IAE.0000000000000610
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-012-2022-8
   Pan CW, 2011, INVEST OPHTH VIS SCI, V52, P3166, DOI 10.1167/iovs.10-6210
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parodi MB, 2016, RETINA-J RET VIT DIS, V36, P104, DOI 10.1097/IAE.0000000000000684
   Parodi MB, 2015, AM J OPHTHALMOL, V160, P322, DOI 10.1016/j.ajo.2015.04.030
   Parodi MB, 2010, ARCH OPHTHALMOL-CHIC, V128, P437, DOI 10.1001/archophthalmol.2009.408
   Parravano M, 2014, RETINA-J RET VIT DIS, V34, P2053, DOI 10.1097/IAE.0000000000000201
   Pece A, 2015, GRAEF ARCH CLIN EXP, V253, P1867, DOI 10.1007/s00417-014-2886-x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P1693, DOI 10.1136/bjo.2008.147611
   Ruiz-Moreno JM, 2015, RETINA-J RET VIT DIS, V35, P2450, DOI 10.1097/IAE.0000000000000632
   Ruiz-Moreno JM, 2012, ACTA OPHTHALMOL, V90, pE82, DOI 10.1111/j.1755-3768.2010.02070.x
   Ruiz-Moreno JM, 2011, GRAEF ARCH CLIN EXP, V249, P595, DOI 10.1007/s00417-010-1599-z
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tang YT, 2015, OPHTHALMOLOGY, V122, P1480, DOI 10.1016/j.ophtha.2015.03.022
   Tufail A, 2013, EYE, V27, P709, DOI 10.1038/eye.2013.8
   Van Newkirk M R, 1997, Trans Am Ophthalmol Soc, V95, P715
   Verhoeven VJM, 2015, OPHTHALMOLOGY, V122, P101, DOI 10.1016/j.ophtha.2014.07.030
   Virgili G., 2005, COCHRANE DB SYST REV, V4
   Vitale S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1111, DOI 10.1001/archopht.126.8.1111
   Wakabayashi T, 2011, RETINA-J RET VIT DIS, V31, P880, DOI 10.1097/IAE.0b013e3181f2a293
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Wang EQ, 2013, RETINA-J RET VIT DIS, V33, P1375, DOI 10.1097/IAE.0b013e31827d260a
   WATZKE RC, 1984, AM J OPHTHALMOL, V98, P572, DOI 10.1016/0002-9394(84)90243-5
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Williams KM, 2015, OPHTHALMOLOGY, V122, P1489, DOI 10.1016/j.ophtha.2015.03.018
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yang HS, 2013, AM J OPHTHALMOL, V156, P1201, DOI 10.1016/j.ajo.2013.08.002
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
NR 89
TC 1
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PY 2016
VL 16
IS 7
BP 873
EP 881
DI 10.1517/14712598.2016.1167868
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DO6ZP
UT WOS:000377932300004
PM 26985834
DA 2022-11-30
ER

PT J
AU Leung, KW
   Gvritishvili, A
   Liu, YL
   Tombran-Tink, J
AF Leung, Kar Wah
   Gvritishvili, Anzor
   Liu, Yanling
   Tombran-Tink, Joyce
TI ZIP2 and ZIP4 Mediate Age-Related Zinc Fluxes Across the Retinal Pigment
   Epithelium
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE RPE cells; Aging; Zinc transporters; Zinc transport; Retina; Age-related
   macular degeneration
ID VITAMIN-A; SYNAPTIC-TRANSMISSION; MACULAR DEGENERATION; TRANSPORTER-3
   ZNT-3; N-CAM; CELLS; EXPRESSION; LOCALIZATION; DISEASE; BINDING
AB Decreases in systemic and cellular levels of zinc (Zn2+) during normal aging correlate with several age-related pathologies including age-related macular degeneration. Zn2+ homeostasis in tissues is not only dependent on dietary intake but also on optimal expression and function of its influx (ZIP) and efflux (ZnT) transporters. We recently showed that many of the Zn2+ transporters are expressed by the retinal pigment epithelial (RPE) cells. In this study, we present evidence that RPE cells contain less endogenous Zn2+ with increased aging and transport this ion vectorially with greater transport from the basal to apical direction. Expression of two Zn2+ influx transporters, ZIP2 and ZIP4, is reduced as a function of RPE age. Gene silencing of ZIP2 and ZIP4 in RPE cells from young donors or their overexpression in cells from older donors confirms that these two transporters are essential in controlling Zn2+ influx and sequestration in RPE cells. Both transporters are distributed on the basal surface of the RPE where they are likely to control Zn2+ homeostasis in the outer retina.
C1 [Tombran-Tink, Joyce] Penn State Univ, Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA.
   [Leung, Kar Wah; Gvritishvili, Anzor; Liu, Yanling; Tombran-Tink, Joyce] Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health
RP Tombran-Tink, J (通讯作者)，Penn State Univ, Coll Med, Dept Ophthalmol, 500 Univ Dr Hershey, Hershey, PA 17033 USA.
EM jttink@aol.com
RI liu, yan/HCI-5542-2022
FU Ben Franklin Foundation, PA, USA; NEI [P30 EY01931]; Research to Prevent
   Blindness, Inc.
FX This work was supported by grants from the Ben Franklin Foundation, PA,
   USA and NEI Core Grant P30 EY01931 and by an unrestricted grant from
   Research to Prevent Blindness, Inc. to the Medical College of Wisconsin
   (PI: Dr. Janice M Burke)
CR Adlard PA, 2010, J NEUROSCI, V30, P1631, DOI 10.1523/JNEUROSCI.5255-09.2010
   Akagi T, 2001, J HISTOCHEM CYTOCHEM, V49, P87, DOI 10.1177/002215540104900109
   BARTLES JR, 1985, J CELL BIOL, V100, P1126, DOI 10.1083/jcb.100.4.1126
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   BOTCHKIN LM, 1994, P NATL ACAD SCI USA, V91, P4564, DOI 10.1073/pnas.91.10.4564
   Bringmann A, 2000, INVEST OPHTH VIS SCI, V41, P2791
   CAMERON JD, 1986, BRIT J OPHTHALMOL, V70, P662, DOI 10.1136/bjo.70.9.662
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Dong J, 2008, J ALZHEIMERS DIS, V15, P443
   DOREA JG, 1986, J NUTR, V116, P121, DOI 10.1093/jn/116.1.121
   Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200
   Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200
   Dufner-Beattie J, 2007, HUM MOL GENET, V16, P1391, DOI 10.1093/hmg/ddm088
   Ebadi M, 1996, NEUROCHEM INT, V29, P159, DOI 10.1016/0197-0186(95)00116-6
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Francke M, 1996, EUR J NEUROSCI, V8, P2662, DOI 10.1111/j.1460-9568.1996.tb01561.x
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Girijashanker K, 2008, MOL PHARMACOL, V73, P1413, DOI 10.1124/mol.107.043588
   GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335
   He L, 2006, MOL PHARMACOL, V70, P171, DOI 10.1124/mol.106.021521
   Ho LH, 2004, J IMMUNOL, V172, P7750, DOI 10.4049/jimmunol.172.12.7750
   Huang ZL, 2006, DEV BIOL, V295, P571, DOI 10.1016/j.ydbio.2006.03.045
   Hyun HJ, 2001, INVEST OPHTH VIS SCI, V42, P460
   Iguchi K, 2006, BIOL TRACE ELEM RES, V112, P159, DOI 10.1385/BTER:112:2:159
   Iguchi K, 2011, J ANDROL, V32, P144, DOI 10.2164/jandrol.110.011205
   John SK, 2000, MOL VIS, V6, P204
   Kanazawa S, 2002, GRAEF ARCH CLIN EXP, V240, P1011, DOI 10.1007/s00417-002-0586-4
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KENNEDY CJ, 1994, EXP CELL RES, V210, P209, DOI 10.1006/excr.1994.1031
   Kokkinou D, 2005, GRAEF ARCH CLIN EXP, V243, P1050, DOI 10.1007/s00417-005-1197-7
   Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699
   Lemire J, 2008, J APPL TOXICOL, V28, P175, DOI 10.1002/jat.1263
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Leung KW, 2008, INVEST OPHTH VIS SCI, V49, P1221, DOI 10.1167/iovs.07-0781
   LEUREDUPREE AE, 1982, INVEST OPHTH VIS SCI, V23, P425
   Lima L, 2001, NUTR NEUROSCI, V4, P439, DOI 10.1080/1028415X.2001.11747379
   Lu J, 2008, BIOCHEM SOC T, V36, P1317, DOI 10.1042/BST0361317
   Mackenzie GG, 2002, J BIOL CHEM, V277, P34610, DOI 10.1074/jbc.M203616200
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Maret W, 2006, J TRACE ELEM MED BIO, V20, P3, DOI 10.1016/j.jtemb.2006.01.006
   Marmorstein AD, 1996, J CELL SCI, V109, P3025
   Martin KRG, 2002, INVEST OPHTH VIS SCI, V43, P2236
   MCCLAIN CJ, 1985, PROG FOOD NUTR SCI, V9, P185
   MCCLAIN CJ, 1979, ALCOHOL CLIN EXP RES, V3, P135, DOI 10.1111/j.1530-0277.1979.tb05287.x
   MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176
   Medvedeva YV, 2009, J NEUROSCI, V29, P1105, DOI 10.1523/JNEUROSCI.4604-08.2009
   MICELI MV, 1994, EXP EYE RES, V59, P271, DOI 10.1006/exer.1994.1108
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moreno CB, 2006, REV NEUROLOGIA, V42, P754, DOI 10.33588/rn.4212.2005552
   MORRISON SA, 1978, AM J CLIN NUTR, V31, P276, DOI 10.1093/ajcn/31.2.276
   Nachev PC, 1996, TRACE ELEM ELECTROLY, V13, P55
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Nusetti S, 2005, NEUROCHEM RES, V30, P1483, DOI 10.1007/s11064-005-8825-9
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x
   Pannicke T, 2004, MOL CELL NEUROSCI, V26, P493, DOI 10.1016/j.mcn.2004.04.005
   PAPAZAFIRI P, 1995, NEUROSCI LETT, V186, P65, DOI 10.1016/0304-3940(95)11285-5
   POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0
   Prasad AS, 2004, MET IONS BIOL SYST, V41, P103
   Qian HH, 1997, J NEUROPHYSIOL, V78, P2402, DOI 10.1152/jn.1997.78.5.2402
   Redenti S, 2004, VISION RES, V44, P3317, DOI 10.1016/j.visres.2004.07.038
   Rezaei KA, 2008, INVEST OPHTH VIS SCI, V49, P1665, DOI 10.1167/iovs.07-0959
   Rosenthal R, 2002, ADV EXP MED BIOL, V514, P225
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Smith J C Jr, 1980, Ann N Y Acad Sci, V355, P62, DOI 10.1111/j.1749-6632.1980.tb21328.x
   Smith JL, 2006, NEUROSCIENCE, V140, P879, DOI 10.1016/j.neuroscience.2006.02.049
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Tate DJ, 1999, FREE RADICAL BIO MED, V26, P704, DOI 10.1016/S0891-5849(98)00253-6
   TOSKES PP, 1979, NEW ENGL J MED, V300, P942, DOI 10.1056/NEJM197904263001702
   Tougu V, 2008, J NEUROCHEM, V104, P1249, DOI 10.1111/j.1471-4159.2007.05061.x
   TUCKER SB, 1984, INT J DERMATOL, V23, P686, DOI 10.1111/j.1365-4362.1984.tb01236.x
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Ugarte M, 1999, EXP EYE RES, V69, P459, DOI 10.1006/exer.1999.0727
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   Wei QQ, 2004, AM J PHYSIOL-RENAL, V287, pF492, DOI 10.1152/ajprenal.00083.2004
   Weng TX, 2002, AM J PHYSIOL-CELL PH, V283, pC839, DOI 10.1152/ajpcell.00445.2001
   Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676
   WU SM, 1994, ANNU REV PHYSIOL, V56, P141
   YAMAGUCHI M, 1982, BIOCHEM PHARMACOL, V31, P1289
   YASSUR Y, 1981, BRIT J OPHTHALMOL, V65, P184, DOI 10.1136/bjo.65.3.184
   Zhang DQ, 2002, J NEUROPHYSIOL, V88, P1245, DOI 10.1152/jn.2002.88.3.1245
   Zhang LH, 2008, BRAIN RES BULL, V77, P55, DOI 10.1016/j.brainresbull.2008.03.014
NR 87
TC 13
Z9 14
U1 0
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD JAN
PY 2012
VL 46
IS 1
BP 122
EP 137
DI 10.1007/s12031-011-9536-0
PG 16
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 879MA
UT WOS:000299332200013
PM 21603979
DA 2022-11-30
ER

PT J
AU Hohman, TC
AF Hohman, Thomas C.
TI OPPORTUNITIES AND CHALLENGES IN THE DEVELOPMENT OF COMBINATION THERAPY
   FOR THE TREATMENT OF RETINAL DISEASES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth factor
   therapies; ranibizumab
AB Ranibizumab, a humanized monoclonal antibody fragment (fragment, antigen binding, FAB) that neutralizes all of the soluble isoforms of vascular endothelial growth factor (VEGF)-A, was a significant step forward in the control of age-related macular degeneration. However, this agent, like others with the same mechanism, has several limitations. Although ranibizumab preserves vision in almost all patients, only a fraction achieves a halving of the visual angle. By inhibiting the activities of VEGF, ranibizumab blocks the continued growth of choroidal neovascularization, but existing neovascular lesions do not regress. Further, ranibizumab addresses only the increased production of VEGF; it does not address the underlying cause of enhanced cytokine production. Although ranibizumab is well tolerated, the course of the disease is unpredictable, necessitating frequent patient monitoring and treatment. Although strategies that guide retreatment based on the reoccurrence of retinal edema can be used to reduce treatment burden, this strategy may not provide optimal patient benefit. Because of these limitations, the identification of effective adjunctive therapies is considered an urgent goal. RETINA 29:S51-S53, 2009
C1 Alcon Res LTD, Retina Prod, Ft Worth, TX 76134 USA.
C3 Novartis; Alcon
RP Hohman, TC (通讯作者)，Alcon Res LTD, Retina Prod, Ft Worth, TX 76134 USA.
EM hohman@alconlabs.com
CR Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
NR 3
TC 0
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S51
EP S53
DI 10.1097/IAE.0b013e3181ad23b5
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700019
PM 19553804
DA 2022-11-30
ER

PT J
AU Lim, JI
   Spee, C
   Hangai, M
   Rocha, J
   Ying, HS
   Ryan, SJ
   Hinton, DR
AF Lim, JI
   Spee, C
   Hangai, M
   Rocha, J
   Ying, HS
   Ryan, SJ
   Hinton, DR
TI Neuropilin-1 expression by endothelial cells and retinal pigment
   epithelial cells in choroidal neovascular membranes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR VEGF; VASCULAR-PERMEABILITY FACTOR; ANGIOGENESIS;
   INHIBITION; RECEPTOR; ISOFORM; FLK-1; RPE
AB PURPOSE: To determine if vascular endothelial growth factor (VEGF) coreceptor neuropilin-1 (NP-1) is expressed in choroidal neovascularization (CNV) and to localize the expression.
   DESIGN: Laboratory investigation.
   METHODS: Six CNV membranes (CNVMs) obtained from patients with subfoveal CNV attributable to age, related macular degeneration (AMD) underwent immunohistochemistry for VEGF receptor,2 (VEGFR-2) and NP-1. The positive cell types were identified by double staining with anticytokeratin, anti-CD31, and antismooth muscle actin (SMA).
   RESULTS: Immunohistochemical staining revealed positivity for VEGFR-2 and NP-1 in all six CNVMs. Both receptors were strongly expressed by new choroidal endothelial cell forming vessels and CD,31,positive cells in the nonvascular area. They were also expressed in the pigmented retinal pigment epithelial layer and by cytokeratin, positive, nonpigmented retinal pigment epithelium cells in the nonvascular area. The nonpigmented retinal pigment epithelium cells positive for VEGFR,2 and NP-1 were highly colocalized with SMA.
   CONCLUSIONS: The presence of both VEGF and NP-1 suggest that NP-1 may play a role in the evolution of CNV in AMD.
C1 Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   Doheny Eye Inst, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Dept Ophthalmol, Los Angeles, CA USA.
   Dept Pathol, Los Angeles, CA USA.
   Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA USA.
   Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA.
   Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Baltimore, MD 21218 USA.
C3 University of Southern California; Doheny Eye Institute; Doheny Eye
   Institute; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins Medicine
RP Lim, JI (通讯作者)，Univ So Calif, Keck Sch Med, 1450 San Pablo St,Suite 3612, Los Angeles, CA 90033 USA.
EM jennifil@usc.edu
FU NATIONAL EYE INSTITUTE [R01EY001545, P30EY003040] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY 01545, EY 03040] Funding Source: Medline
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Casey R, 1997, AM J OPHTHALMOL, V124, P521, DOI 10.1016/S0002-9394(14)70868-2
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   Hoffmann S, 2000, INVEST OPHTH VIS SCI, V41, P2389
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649
   Ishihama H, 2001, INVEST OPHTH VIS SCI, V42, P1172
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Matthies AM, 2002, AM J PATHOL, V160, P289, DOI 10.1016/S0002-9440(10)64372-6
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Oh H, 2002, P NATL ACAD SCI USA, V99, P383, DOI 10.1073/pnas.012074399
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Yang XJ, 1996, J NEUROSCI, V16, P6089
   Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008
NR 29
TC 18
Z9 18
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2005
VL 140
IS 6
BP 1044
EP 1050
DI 10.1016/j.ajo.2005.07.021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000QA
UT WOS:000234475900012
PM 16376649
DA 2022-11-30
ER

PT J
AU Framme, C
   Roider, J
   Sachs, HG
   Brinkmann, R
   Gabel, VP
AF Framme, Carsten
   Roider, Johann
   Sachs, Helmut G.
   Brinkmann, Ralf
   Gabel, Veit-Peter
TI Noninvasive Imaging and Monitoring of Retinal Pigment Epithelium
   Patterns Using Fundus Autofluorescence - Review
SO CURRENT MEDICAL IMAGING
LA English
DT Review
DE Fundus autofluorescence; retinal pigment epithelium; RPE; lipofuscin;
   age-related macular degeneration; macular holes; laser photocoagulation;
   selective RPE laser treatment; online autofluorescence
ID LASER PHOTOCOAGULATION; GEOGRAPHIC ATROPHY; MACULAR DISEASES; PRIMATE
   RETINA; CELL-DAMAGE; RPE CELLS; LIPOFUSCIN; FLUORESCENCE; DENSITY;
   FLUOROPHORES
AB Non-invasive imaging of the retinal pigment epithelium (RPE) using autofluorescence became recently available with the introduction of confocal laser scanning ophthalmoscopes. Fundus autofluorescence is usually excited at a wavelength of 488nm and the emitted light is detected above 500nm. This intrinsic autofluorescence was shown to derive from the lipofuscin accumulating within the RPE either with age or also due to different hereditary or degenerative diseases of the macula as e. g. age-related macular degeneration. Since a variety of macular diseases correlate with distinct RPE changes, specific patterns of autofluorescence could be evaluated within the recent years for diagnostic and prognostic reasons in those RPE-related diseases. Moreover autofluorescence can also be regarded as a monitoring tool after therapeutic applications as macular surgery or laser treatment. Other new applications try to determine macular pigment density using autofluorescence or use it to evaluate oxygen-dependent cell metabolism. This review summarizes the recent findings of autofluorescent patterns in specific diseases and therapeutic approaches and emphasizes on the tremendous potential of this novel imaging method.
C1 [Framme, Carsten; Sachs, Helmut G.; Gabel, Veit-Peter] Univ Eye Hosp Regensburg, D-93042 Regensburg, Germany.
   [Roider, Johann] Univ Eye Hosp Kiel, D-24105 Kiel, Germany.
   [Brinkmann, Ralf] Med Laser Ctr Luebeck, D-23562 Lubeck, Germany.
C3 University of Regensburg; University of Kiel; Schleswig Holstein
   University Hospital
RP Framme, C (通讯作者)，Univ Eye Hosp Regensburg, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.
EM carsten.framme@klinik.uni-regensburg.de
RI Brinkmann, Ralf/E-6701-2012; Roider, Johann/E-4513-2010; Brinkmann,
   Ralf/HDL-7611-2022
OI Brinkmann, Ralf/0000-0002-0445-8102; 
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Birngruber R, 1984, Fortschr Ophthalmol, V81, P147
   BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>3.0.CO;2-1
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1994, APPL OPTICS, V33, P7439, DOI 10.1364/AO.33.007439
   DELORI FC, 1994, INVEST OPHTH VIS SCI, V35, P2145
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DELPRIORE LV, 1989, ARCH OPHTHALMOL-CHIC, V107, P119, DOI 10.1001/archopht.1989.01070010121039
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dorey K, 1993, RETINAL DEGENERATION, P3
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   EINBOCK W, 2002, INVEST OPHTHALMOL VI, V43
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1993, NATURE, V364, P396
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Framme C, 2004, GRAEF ARCH CLIN EXP, V242, P863, DOI 10.1007/s00417-004-0938-3
   Framme C, 2004, OPHTHAL SURG LAS IM, V35, P131, DOI 10.3928/1542-8877-20040301-08
   Framme C, 2002, BRIT J OPHTHALMOL, V86, P1099, DOI 10.1136/bjo.86.10.1099
   Framme C, 2002, OPHTHALMOLOGICA, V216, P320, DOI 10.1159/000066184
   Framme C, 2002, RETINA-J RET VIT DIS, V22, P653, DOI 10.1097/00006982-200210000-00023
   Framme C, 2001, OPHTHALMIC SURG LAS, V32, P383
   FRAMME C, OPHT SURG LASE UNPUB
   FRAMME C, ACTA OPHTHALMO UNPUB
   FRAMME C, 2004, CURR EYE RE IN PRESS
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115
   Gabel V. P., 1978, 23 CONCILIUM OPHTHAL, P658
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HALL LS, 1999, RETINA VITREOUS MACU, V1, P206
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2001, OPHTHALMOLOGE, V98, P10, DOI 10.1007/s003470170194
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   HOLZ FG, 2004, M GERM SOC OPHTH BER
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P109
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   Lorenz B, 2004, OPHTHALMOLOGY, V111, P1585, DOI 10.1016/j.ophtha.2004.01.033
   Lorenz B, 1989, Fortschr Ophthalmol, V86, P644
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P657, DOI 10.1136/bjo.63.10.657
   MARSHALL J, 1968, EXP EYE RES, V7, P225, DOI 10.1016/S0014-4835(68)80071-5
   Marshall J, 1984, DOC OPHTHALMOL P SER, P21
   MATSUMOTO M, 1994, INVEST OPHTH VIS SCI, V35, P4245
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   POLLACK A, 1986, OPHTHALMOLOGY, V93, P1113
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   RODRIGUEZBOULAN EJ, 2002, AGE LIPID A2E SELECT
   Roider J, 2000, BRIT J OPHTHALMOL, V84, P40, DOI 10.1136/bjo.84.1.40
   Roider J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1028
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   ROIDER J, 1993, P NATL ACAD SCI USA, V90, P8643, DOI 10.1073/pnas.90.18.8643
   Schule G, 2001, PROC SPIE, V4433, P92, DOI 10.1117/12.446507
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Schweitzer D., 2001, International Ophthalmology, V23, P399, DOI 10.1023/A:1014475219117
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P774, DOI 10.1007/s00347-002-0656-3
   SMIDDY WE, 1984, ARCH OPHTHALMOL-CHIC, V102, P1086, DOI 10.1001/archopht.1984.01040030880039
   SMIDDY WE, 1985, ARCH OPHTHALMOL-CHIC, V103, P428, DOI 10.1001/archopht.1985.01050030124037
   SMIDDY WE, 1986, ARCH OPHTHALMOL-CHIC, V104, P1065, DOI 10.1001/archopht.1986.01050190123051
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   TSO MOM, 1980, ARCH OPHTHALMOL-CHIC, V98, P2032
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   von Ruckmann A, 1998, BRIT J OPHTHALMOL, V82, P346, DOI 10.1136/bjo.82.4.346
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   VONRUCKMANN A, 1998, RETINAL PIGMENT EPIT, P224
   VONRUCKMANN A, 1995, BR J OPHTHALMOL, V119, P543
   WABBELS BK, 2004, FUNDUS AUTOFLUORESCE
   WALLOW IH, 1984, ARCH OPHTHALMOL-CHIC, V102, P126
   WALLOW IHL, 1975, ADV OPHTHALMOL, V31, P159
   WEINBERGER AWA, 1998, OPHTHALMIC RES, V30, P164
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   WOLF MD, 1992, ARCH OPHTHALMOL-CHIC, V110, P750, DOI 10.1001/archopht.1992.01080180020004
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   [No title captured]
NR 83
TC 11
Z9 18
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4056
EI 1875-6603
J9 CURR MED IMAGING
JI Curr. Med. Imaging
PD JAN
PY 2005
VL 1
IS 1
BP 89
EP 103
DI 10.2174/1573405052952994
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA V04PA
UT WOS:000207069100013
DA 2022-11-30
ER

PT J
AU King, A
   Gottlieb, E
   Brooks, DG
   Murphy, MP
   Dunaief, JL
AF King, A
   Gottlieb, E
   Brooks, DG
   Murphy, MP
   Dunaief, JL
TI Mitochondria-derived reactive oxygen species mediate if blue
   light-induced death of retinal pigment epithelial cells
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; MACULAR DEGENERATION; INDUCED APOPTOSIS;
   CYTOCHROME-OXIDASE; ALZHEIMERS-DISEASE; FLUORESCENT LIGHT; PROTEIN
   OXIDATION; AGE PIGMENT; RAT RETINA; BEEF HEART
AB Throughout the lifetime of an individual, light is focused onto the retina. The resulting photooxidative stress can cause acute or chronic retinal damage. The pathogenesis of age-related macular degeneration (AMD), the leading cause of legal blindness in the developed world, involves oxidative stress and death of the retinal pigment epithelium (RPE) followed by death of the overlying photoreceptors. Evidence suggests that damage due to exposure to light plays a role in AMD and other age-related eye diseases. In this work a system for light-induced damage and death of the RPE, based on the human ARPE-19 cell line, was used. Induction of mitochondria-derived reactive oxygen species (ROS) is shown to play a critical role in the death of cells exposed to short-wavelength blue light (425 +/- 20 nm). ROS and cell death are blocked either by inhibiting the mitochondrial electron transport chain or by mitochondria-specific antioxidants. These results show that mitochondria are an important source of toxic oxygen radicals in blue light-exposed RPE cells and may indicate new approaches for treating AMD using mitochondria-targeted antioxidants.
C1 Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Stellar Chance Labs 205, Philadelphia, PA 19104 USA.
   Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   Univ Penn, Div Med Genet, Dept Med, Philadelphia, PA 19104 USA.
   MRC, Dunn Human Nutr Unit, Cambridge, England.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; UK
   Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC
   Human Nutrition Research
RP Dunaief, JL (通讯作者)，Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Stellar Chance Labs 205, 422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
RI Murphy, Michael P/C-2120-2009; Gottlieb, Eyal/G-6450-2010
OI Murphy, Michael P/0000-0003-1115-9618; Gottlieb,
   Eyal/0000-0002-9770-0956
FU NEI NIH HHS [EY00417] Funding Source: Medline
CR Adams JD, 2001, CURR MED CHEM, V8, P809, DOI 10.2174/0929867013372995
   Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   CHEN EP, 1993, GRAEF ARCH CLIN EXP, V231, P416, DOI 10.1007/BF00919652
   Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386
   Dontsov AE, 1999, FREE RADICAL BIO MED, V26, P1436, DOI 10.1016/S0891-5849(99)00003-9
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HATEFI Y, 1968, P NATL ACAD SCI USA, V60, P733, DOI 10.1073/pnas.60.2.733
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255
   Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   KING MP, 2002, COCHRANE DATABASE SY, V1, P304
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Moellering D, 1999, FREE RADICAL BIO MED, V26, P1138, DOI 10.1016/S0891-5849(98)00300-1
   NINNEMAN.H, 1970, BIOCHIM BIOPHYS ACTA, V205, P507, DOI 10.1016/0005-2728(70)90116-7
   NINNEMANN H, 1974, FEBS LETT, V39, P353, DOI 10.1016/0014-5793(74)80148-1
   Nohl H, 2003, REDOX REP, V8, P135, DOI 10.1179/135100003225001502
   OBERG K. E., 1961, EXPTL CELL RES, V24, P163, DOI 10.1016/0014-4827(61)90263-4
   Ottonello S, 2000, OPHTHALMOLOGICA, V214, P78, DOI 10.1159/000027474
   Pang JJ, 1998, GRAEF ARCH CLIN EXP, V236, P696, DOI 10.1007/s004170050143
   PARSHAD R, 1978, P NATL ACAD SCI USA, V75, P1830, DOI 10.1073/pnas.75.4.1830
   PAUTLER EL, 1990, PHOTOCHEM PHOTOBIOL, V51, P599, DOI 10.1111/j.1751-1097.1990.tb01972.x
   Rando TA, 2002, AM J PHYS MED REHAB, V81, pS175, DOI 10.1097/00002060-200211001-00018
   Reme C, 1996, GRAEF ARCH CLIN EXP, V234, P2, DOI 10.1007/BF00186512
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Scanlon JM, 1998, J NEUROCHEM, V71, P2392
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   vanBest JA, 1997, MICROSC RES TECHNIQ, V36, P77, DOI 10.1002/(SICI)1097-0029(19970115)36:2<77::AID-JEMT1>3.0.CO;2-S
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wallace D C, 2001, Novartis Found Symp, V235, P247
   WANG RJ, 1975, PHOTOCHEM PHOTOBIOL, V21, P373, DOI 10.1111/j.1751-1097.1975.tb06688.x
   Wu JM, 1999, GRAEF ARCH CLIN EXP, V237, P855, DOI 10.1007/s004170050323
   Wu JM, 1999, EYE, V13, P577, DOI 10.1038/eye.1999.142
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 46
TC 189
Z9 216
U1 1
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD MAY
PY 2004
VL 79
IS 5
BP 470
EP 475
DI 10.1562/LE-03-17.1
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 821KQ
UT WOS:000221459700013
PM 15191057
DA 2022-11-30
ER

PT J
AU Ni, SB
   Khan, S
   Nguyen, TTP
   Ng, R
   Lujan, BJ
   Tan, O
   Huang, D
   Jian, YF
AF Ni, Shuibin
   Khan, Shanjida
   Nguyen, Thanh-Tin P.
   Ng, Ringo
   Lujan, Brandon J.
   Tan, Ou
   Huang, David
   Jian, Yifan
TI Volumetric directional optical coherence tomography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OUTER NUCLEAR LAYER; GEOGRAPHIC ATROPHY; FIBER LAYER; DEGENERATION;
   REFLECTANCE; HEALTHY; RETINA; MACULA
AB Photoreceptor loss and resultant thinning of the outer nuclear layer (ONL) is an important pathological feature of retinal degenerations and may serve as a useful imaging biomarker for age-related macular degeneration. However, the demarcation between the ONL and the adjacent Henle's fiber layer (HFL) is difficult to visualize with standard optical coherence tomography (OCT). A dedicated OCT system that can precisely control and continuously and synchronously update the imaging beam entry points during scanning has not been realized yet. In this paper, we introduce a novel imaging technology, Volumetric Directional OCT (VD-OCT), which can dynamically adjust the incident beam on the pupil without manual adjustment during a volumetric OCT scan. We also implement a customized spoke-circular scanning pattern to observe the appearance of HFL with sufficient optical contrast in continuous cross-sectional scans through the entire volume. The application of VD-OCT for retinal imaging to exploit directional reflectivity properties of tissue layers has the potential to allow for early identification of retinal diseases.
C1 [Ni, Shuibin; Khan, Shanjida; Nguyen, Thanh-Tin P.; Lujan, Brandon J.; Tan, Ou; Huang, David; Jian, Yifan] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Ni, Shuibin; Khan, Shanjida; Huang, David; Jian, Yifan] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.
   [Ng, Ringo] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC V5A 1S6, Canada.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Simon Fraser University
RP Jian, YF (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.; Jian, YF (通讯作者)，Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.
EM jian@ohsu.edu
OI Jian, Yifan/0000-0001-7988-7385; Ni, Shuibin/0000-0003-3146-5006
FU National Institutes of Health [P30 EY010572, R01 EY023285, R01
   HD107494]; Research to Prevent Blindness (Career Advancement Award,
   unrestricted departmental)
FX National Institutes of Health (P30 EY010572, R01 EY023285, R01
   HD107494); Research to Prevent Blindness (Career Advancement Award,
   unrestricted departmental funding grant).
CR American National Standards Institute, 2016, Z80362016 ANSI
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Borkovkina S, 2020, BIOMED OPT EXPRESS, V11, P3968, DOI 10.1364/BOE.395279
   Camino A, 2020, BIOMED OPT EXPRESS, V11, P3952, DOI 10.1364/BOE.396829
   Camino A, 2020, OPT LETT, V45, P2612, DOI 10.1364/OL.390134
   Carrasco-Zevallos O, 2015, BIOMED OPT EXPRESS, V6, P3405, DOI 10.1364/BOE.6.003405
   Chui TYP, 2012, INVEST OPHTH VIS SCI, V53, P3545, DOI 10.1167/iovs.11-8694
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Draelos M, 2021, NAT BIOMED ENG, V5, P726, DOI 10.1038/s41551-021-00753-6
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Fischer MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007507
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao WH, 2008, OPT EXPRESS, V16, P6486, DOI 10.1364/OE.16.006486
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P101, DOI 10.1167/iovs.10-5799
   Huang XR, 2006, INVEST OPHTH VIS SCI, V47, P5363, DOI 10.1167/iovs.06-0451
   Jian YF, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.026002
   Knighton RW, 2000, J GLAUCOMA, V9, P56
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Meleppat RK, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.6.066011
   Ni SB, 2021, BIOMED OPT EXPRESS, V12, P3553, DOI 10.1364/BOE.425411
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   Ryals RC, 2017, INVEST OPHTH VIS SCI, V58, P1378, DOI 10.1167/iovs.16-20363
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Terzibasi E, 2009, NEUROBIOL AGING, V30, P819, DOI 10.1016/j.neurobiolaging.2007.08.017
   Wartak A, 2017, BIOMED OPT EXPRESS, V8, P5560, DOI 10.1364/BOE.8.005560
   Xu J, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.2.026001
   Yehoshua Z., 2010, OPHTHALMIC SURG LASE, V41, P1373
   Yiu G, 2018, EXP EYE RES, V168, P69, DOI 10.1016/j.exer.2018.01.012
NR 35
TC 0
Z9 0
U1 1
U2 4
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2022
VL 13
IS 2
BP 950
EP 961
AR 447882
DI 10.1364/BOE.447882
PG 12
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA YS7NY
UT WOS:000750860500001
PM 35284155
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Halasi, M
   Grinstein, M
   Adini, A
   Adini, I
AF Halasi, Marianna
   Grinstein, Mor
   Adini, Avner
   Adini, Irit
TI Fibromodulin Ablation Exacerbates the Severity of Acute Colitis
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Article
DE inflammatory bowel disease; ulcerative colitis; fibromodulin; tight
   junction; dendritic cells
ID PLASMACYTOID DENDRITIC CELLS; EXTRACELLULAR-MATRIX; MELANOCYTE
   PIGMENTATION; EXPRESSION; PROTEINS; PROTEOGLYCAN; COMPLEMENT;
   ACTIVATION; BARRIER; GENE
AB Introduction: Epidemiological studies have associated pigment production with protection against certain human diseases. In contrast to African Americans, European descendants are more likely to suffer from angiogenesis-dependent and inflammatory diseases, such as wet age-related macular degeneration (ARMD) and ulcerative colitis (UC), respectively.Methods: In a mouse model of dextran sulfate sodium (DSS)-induced acute colitis, the effect of fibromodulin (FMOD) depletion was examined on colitis severity.Results: In this study, albino mice that produce high levels of FMOD developed less severe acute colitis compared with mice lacking in FMOD as assessed by clinical symptoms and histopathological changes. FMOD depletion affected the expression of tight junction proteins, contributing to the destruction of the epithelial barrier. Furthermore, this study revealed a stronger inflammatory response after DSS treatment in the absence of FMOD, where FMOD depletion led to an increase in activated T cells, plasmacytoid dendritic cells (pDCs), and type I interferon (IFN) production.Discussion: These findings point to FMOD as a potential biomarker of disease severity in UC among light-skinned individuals of European descent.
C1 [Halasi, Marianna; Adini, Irit] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Engn Med & Surg, Dept Surg, Boston, MA 02115 USA.
   [Grinstein, Mor] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Regenerat Med, Dept Med, Boston, MA USA.
   [Adini, Avner] Harvard Med Sch, Boston Childrens Hosp, Dept Med, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts General
   Hospital; Harvard University; Harvard Medical School; Massachusetts
   General Hospital; Harvard University; Boston Children's Hospital;
   Harvard Medical School
RP Adini, I (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Ctr Engn Med & Surg, Dept Surg, Boston, MA 02115 USA.
EM iadini@mgh.harvard.edu
FU NIH [RO1EY024046]
FX Acknowledgment The authors thank Professors Rivka Dresner-Pollak, MD,
   Martin L. Yarmush, MD, PhD and Yuval Tal, MD, PhD for fruitful
   discussions. This study was supported in part by a grant from NIH
   (RO1EY024046) .
CR Adini I, 2015, FASEB J, V29, P662, DOI 10.1096/fj.14-255398
   Adini I, 2014, J CLIN INVEST, V124, P425, DOI 10.1172/JCI69404
   Arimura K, 2017, MUCOSAL IMMUNOL, V10, P957, DOI 10.1038/mi.2016.96
   Arseneau KO, 2015, CLIN PHARMACOL THER, V97, P22, DOI 10.1002/cpt.6
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bencze D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084190
   Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7
   Brand U, 1998, EUR J IMMUNOL, V28, P1673, DOI 10.1002/(SICI)1521-4141(199805)28:05<1673::AID-IMMU1673>3.0.CO;2-J
   Hall LJ, 2011, DIGEST DIS SCI, V56, P79, DOI 10.1007/s10620-010-1240-3
   Heeger PS, 2012, IMMUNOBIOLOGY, V217, P216, DOI 10.1016/j.imbio.2011.06.004
   HEINEGARD D, 1986, J BIOL CHEM, V261, P3866
   Houston SA, 2016, MUCOSAL IMMUNOL, V9, P468, DOI 10.1038/mi.2015.77
   Howe KL, 2005, AM J PATHOL, V167, P1587, DOI 10.1016/S0002-9440(10)61243-6
   Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435
   Iozzo RV, 2015, MATRIX BIOL, V42, P11, DOI 10.1016/j.matbio.2015.02.003
   Jan AT, 2016, INT J BIOCHEM CELL B, V80, P66, DOI 10.1016/j.biocel.2016.09.023
   Kel JM, 2010, J IMMUNOL, V185, P3248, DOI 10.4049/jimmunol.1000981
   Kontos CD, 2014, J CLIN INVEST, V124, P76, DOI 10.1172/JCI73559
   Lee EJ, 2016, FASEB J, V30, P2708, DOI 10.1096/fj.201500133R
   Lee JY, 2018, PROTEOMES, V6, DOI 10.3390/proteomes6020017
   Lee YH, 2011, J BIOL CHEM, V286, P6414, DOI 10.1074/jbc.M110.168682
   Lood C, 2009, ARTHRITIS RHEUM-US, V60, P3081, DOI 10.1002/art.24852
   Martini E, 2017, CELL MOL GASTROENTER, V4, P33, DOI 10.1016/j.jcmgh.2017.03.007
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Mikaelsson E, 2005, BLOOD, V105, P4828, DOI 10.1182/blood-2004-10-3941
   Mormone E, 2012, GASTROENTEROLOGY, V142, P612, DOI 10.1053/j.gastro.2011.11.029
   Noth R, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-109
   Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0
   Paris L, 2008, BBA-BIOMEMBRANES, V1778, P646, DOI 10.1016/j.bbamem.2007.08.004
   Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617
   Poritz LS, 2007, J SURG RES, V140, P12, DOI 10.1016/j.jss.2006.07.050
   Poritz LS, 2011, DIGEST DIS SCI, V56, P2802, DOI 10.1007/s10620-011-1688-9
   Rescigno M, 1999, IMMUNOL TODAY, V20, P200, DOI 10.1016/S0167-5699(98)01427-3
   Schaefer L, 2000, KIDNEY INT, V58, P1557, DOI 10.1046/j.1523-1755.2000.00317.x
   Schultz HS, 2015, J IMMUNOL, V194, P3169, DOI 10.4049/jimmunol.1402800
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Son M, 2012, P NATL ACAD SCI USA, V109, pE3160, DOI 10.1073/pnas.1212753109
   Torres J, 2017, LANCET, V389, P1741, DOI 10.1016/S0140-6736(16)31711-1
   Velde AAT, 2007, INFLAMM BOWEL DIS, V13, P325, DOI 10.1002/ibd.20079
   Yan YT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006073
   Zeng-Brouwers J, 2020, J HISTOCHEM CYTOCHEM, V68, P887, DOI 10.1369/0022155420930303
   Zheng Z, 2014, PRS-GLOB OPEN, V2, DOI 10.1097/GOX.0000000000000243
   Zheng Z, 2012, BIOMATERIALS, V33, P5821, DOI 10.1016/j.biomaterials.2012.04.049
   Zhou JF, 2018, CELL MOL IMMUNOL, V15, P1047, DOI 10.1038/s41423-018-0030-2
   Zou JF, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00014-21
NR 45
TC 0
Z9 0
U1 3
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2022
VL 15
BP 4515
EP 4526
DI 10.2147/JIR.S366290Journalof
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 3R4HJ
UT WOS:000838875700001
PM 35966006
DA 2022-11-30
ER

PT J
AU Jung, SA
   Jin, S
   Chae, JB
   Jo, G
   Chung, H
   Lyu, J
   Lee, JH
AF Jung, Sun-Ah
   Jin, Soomin
   Chae, Jae-Byoung
   Jo, GukHeui
   Chung, Hyewon
   Lyu, Jungmook
   Lee, Joon H.
TI Recombinant sulfated CCR2 peptide trap reduces retinal degeneration in
   mice
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Tyrosine sulfation; Macrophageinfiltration; Recombinant sulfated CCR2
   peptide trap; Retinal degeneration
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACULAR DEGENERATION; TYROSINE
   SULFATION; CHEMOTACTIC PROTEIN-1; SODIUM IODATE; RECOGNITION; RECEPTOR;
   IDENTIFICATION; ACCUMULATION; MACROPHAGES
AB Chemokine receptors are generally sulfated at tyrosine residues of the N-terminal region. Tyrosine sulfation of the C-C chemokine receptor type 2 (CCR2) enhances its interaction with the chemokine ligand CCL2. Here, we generated a recombinant sulfated CCR2 peptide trap (mCCR2-S2) and investigated its effects on retinal degeneration in mice. Treatment with mCCR2-S2 reduced choroidal neovascularization (CNV) in a laser-induced CNV mouse model. In NaIO3-injected mice, treatment with mCCR2-S2 increased the outer nuclear layer thickness and rhodopsin expression in the retinas compared to that in mice treated with mCCR2-wild-type or glutathione S-transferase controls. Furthermore, glial fibrillary acidic protein (GFAP) expression and macrophage infiltration were decreased in mCCR2-S2treated retinas. Recombinant mCCR2-S2 suppressed CNV development and retinal degeneration, possibly by regulating macrophage infiltration. Thus, the sulfated form of the CCR2 peptide trap may be a useful tool for treating patients with retinal degeneration, such as those with age-related macular degeneration and intraocular inflammatory disorders. (C) 2021 The Authors. Published by Elsevier Inc.
C1 [Chae, Jae-Byoung; Chung, Hyewon] Konkuk Univ, Dept Ophthalmol, Sch Med, Seoul, South Korea.
   [Jin, Soomin; Lyu, Jungmook] Konyang Univ, Dept Med Sci, 158 Gwanjeodong Ro, Daejeon 35365, South Korea.
   [Jung, Sun-Ah; Jo, GukHeui; Lee, Joon H.] Konyang Univ, Kims Eye Hosp, Myung Gok Eye Res Inst, Coll Med, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Konyang University;
   Konyang University; Konyang University Hospital
RP Lyu, J (通讯作者)，Konyang Univ, Dept Med Sci, 158 Gwanjeodong Ro, Daejeon 35365, South Korea.; Lee, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Myung Gok Eye Res Inst, Coll Med, Seoul, South Korea.
EM lyujm@konyang.ac.kr; joonhlee@konyang.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea - Ministry of Education [20171D1A1B04031530]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea funded by the Ministry of
   Education [grant number 20171D1A1B04031530].
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Benny O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012515
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duma L, 2007, J MOL BIOL, V365, P1063, DOI 10.1016/j.jmb.2006.10.040
   Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   FURIE MB, 1995, AM J PATHOL, V146, P1287
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m
   Itaya M, 2007, INVEST OPHTH VIS SCI, V48, P5677, DOI 10.1167/iovs.07-0156
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   Kim SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11872
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu CC, 2009, NAT PROTOC, V4, P1784, DOI 10.1038/nprot.2009.188
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   Power Christine A., 2001, Current Opinion in Pharmacology, V1, P417, DOI 10.1016/S1471-4892(01)00072-8
   RINGVOLD A, 1981, EXP EYE RES, V33, P361, DOI 10.1016/S0014-4835(81)80088-7
   Seibert C, 2008, BIOCHEMISTRY-US, V47, P11251, DOI 10.1021/bi800965m
   Simpson LS, 2009, CHEM BIOL, V16, P153, DOI 10.1016/j.chembiol.2008.12.007
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4
   Stone MJ, 2009, NEW BIOTECHNOL, V25, P299, DOI 10.1016/j.nbt.2009.03.011
   Strieter RM, 1996, J IMMUNOL, V156, P3583
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tan JHY, 2013, J BIOL CHEM, V288, P10024, DOI 10.1074/jbc.M112.447359
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Veldkamp CT, 2006, J MOL BIOL, V359, P1400, DOI 10.1016/j.jmb.2006.04.052
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Zhu JZ, 2011, BIOCHEMISTRY-US, V50, P1524, DOI 10.1021/bi101240v
NR 41
TC 1
Z9 1
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 1
PY 2021
VL 572
BP 171
EP 177
DI 10.1016/j.bbrc.2021.08.002
EA AUG 2021
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA TW9WQ
UT WOS:000682741000001
PM 34371259
OA hybrid
DA 2022-11-30
ER

PT J
AU Chinchilla, B
   Foltopoulou, P
   Fernandez-Godino, R
AF Chinchilla, Blanca
   Foltopoulou, Parthena
   Fernandez-Godino, Rosario
TI Tick-over-mediated complement activation is sufficient to cause basal
   deposit formation in cell-based models of macular degeneration
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE tick-over; complement; retinal pigment epithelium; basal deposits;
   age-related macular degeneration
ID DRUSEN FORMATION; C3; COMPSTATIN; EPITHELIUM; PATHWAY; IDENTIFICATION;
   INHIBITION; THIOESTER; MECHANISM; MUTATION
AB Despite numerous unsuccessful clinical trials for anti-complement drugs to treat age-related macular degeneration (AMD), the complement system has not been fully explored as a target to stop drusen growth in patients with dry AMD. We propose that the resilient autoactivation of C3 by hydrolysis of its internal thioester (tick-over), which cannot be prevented by existing drugs, plays a critical role in the formation of drusenoid deposits underneath the retinal pigment epithelium (RPE). We have combined gene editing tools with stem cell technology to generate cell-based models that allow the role of the tick-over in sub-RPE deposit formation to be studied. The results demonstrate that structurally or genetically driven pathological events affecting the RPE and Bruch's membrane can lead to dysregulation of the tick-over, which is sufficient to stimulate the formation of sub-RPE deposits. This can be prevented with therapies that downregulate C3 expression. (c) 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Chinchilla, Blanca; Foltopoulou, Parthena; Fernandez-Godino, Rosario] Harvard Med Sch, Ocular Genom Inst, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Fernandez-Godino, R (通讯作者)，Harvard Med Sch, Ocular Genom Inst, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM rosario_godino@meei.harvard.edu
RI Rodriguez, Blanca Chinchilla/AAA-3695-2021
OI Rodriguez, Blanca Chinchilla/0000-0002-0679-9023
FU Brightfocus Foundation [M2018115]; Alice Adler Eleanor and Miles Shore
   Faculty Development Awards Program; Microscopy Core of the Center for
   Systems Biology/Program in Membrane Biology [DK043351]; Boston Area
   Diabetes and Endocrinology Research Center (BADERC) Award [DK057521];
   National Science Foundation [1541959]
FX We are grateful to Dr Eric A Pierce for helpful discussions and Dr
   Thaddeus Dryja for revising the manuscript. This work was supported by
   the Brightfocus Foundation (grant #M2018115) and the Alice Adler Eleanor
   and Miles Shore Faculty Development Awards Program. We thank Diane Capen
   for her excellent technical assistance with the TEM [supported by the
   Microscopy Core of the Center for Systems Biology/Program in Membrane
   Biology, which is partially an Inflammatory Bowel Disease Grant,
   DK043351, and a Boston Area Diabetes and Endocrinology Research Center
   (BADERC) Award, DK057521]. The SEM work was performed in part at the
   Center of Nanoscale Systems (CNS), a member of the National
   Nanotechnology Coordinated Infrastructure Network (NNCI), which is
   supported by the National Science Foundation under NSF award No 1541959.
   The CNS is part of Harvard University.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Brydon EM, 2019, MOL THER-METH CLIN D, V15, P392, DOI 10.1016/j.omtm.2019.10.014
   Chen GK, 2011, NAT METHODS, V8, P424, DOI [10.1038/NMETH.1593, 10.1038/nmeth.1593]
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Elvington M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00703
   Fernandez-Godino R, 2018, ADV EXP MED BIOL, V1074, P29, DOI 10.1007/978-3-319-75402-4_4
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foltz LP, 2017, JOVE-J VIS EXP, DOI 10.3791/56274
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hu KJ, 2011, BLOOD, V117, pE109, DOI 10.1182/blood-2010-07-298331
   ISAAC L, 1992, J BIOL CHEM, V267, P10062
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Lenis TL, 2017, P NATL ACAD SCI USA, V114, P3987, DOI 10.1073/pnas.1620299114
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Martinez-Barricarte R, 2010, J CLIN INVEST, V120, P3702, DOI 10.1172/JCI43343
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   NICOL PAE, 1973, IMMUNOLOGY, V24, P259
   NILSSON B, 1986, INT ARCH ALLER A IMM, V80, P312, DOI 10.1159/000234071
   Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ricklin D, 2017, MOL IMMUNOL, V89, P10, DOI 10.1016/j.molimm.2017.05.013
   Ricklin D, 2016, SEMIN IMMUNOL, V28, P208, DOI 10.1016/j.smim.2016.06.001
   Ricklin D, 2013, ADV EXP MED BIOL, V735, P1, DOI 10.1007/978-1-4614-4118-2_1
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Sehnal D., 2018, P WORKSH MOL GRAPH V, DOI 10.2312/molva.20181103
   Shah N, 2018, BBA-MOL BASIS DIS, V1864, P2610, DOI 10.1016/j.bbadis.2018.04.016
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Torres R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019794
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 51
TC 1
Z9 1
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD OCT
PY 2021
VL 255
IS 2
BP 120
EP 131
DI 10.1002/path.5747
EA JUL 2021
PG 12
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA UN3BH
UT WOS:000678534500001
PM 34155630
DA 2022-11-30
ER

PT J
AU Fernandez-Albarral, JA
   De Julian-Lopez, E
   Soler-Dominguez, C
   de Hoz, R
   Lopez-Cuenca, I
   Salobrar-Garcia, E
   Ramirez, JM
   Pinazo-Duran, MD
   Salazar, JJ
   Ramirez, AI
AF Fernandez-Albarral, Jose A.
   De Julian-Lopez, Esther
   Soler-Dominguez, Carmen
   de Hoz, Rosa
   Lopez-Cuenca, Ines
   Salobrar-Garcia, Elena
   Ramirez, Jose M.
   Pinazo-Duran, Maria D.
   Salazar, Juan J.
   Ramirez, Ana, I
TI The Role of Autophagy in Eye Diseases
SO LIFE-BASEL
LA English
DT Review
DE autophagy; ocular pathology; glaucoma; cataract; diabetic retinopathy;
   AMD
ID RETINAL-PIGMENT EPITHELIUM; ACTIVATED PROTEIN-KINASE; COPY NUMBER
   VARIATIONS; OXIDATIVE STRESS; CIRCADIAN-RHYTHM; DRUSEN FORMATION;
   GANGLION-CELLS; DEGENERATION; OPTINEURIN; MTOR
AB Autophagy is a catabolic process that ensures homeostasis in the cells of our organism. It plays a crucial role in protecting eye cells against oxidative damage and external stress factors. Ocular pathologies of high incidence, such as age-related macular degeneration, cataracts, glaucoma, and diabetic retinopathy are of multifactorial origin and are associated with genetic, environmental factors, age, and oxidative stress, among others; the latter factor is one of the most influential in ocular diseases, directly affecting the processes of autophagy activity. Alteration of the normal functioning of autophagy processes can interrupt organelle turnover, leading to the accumulation of cellular debris and causing physiological dysfunction of the eye. The aim of this study is to review research on the role of autophagy processes in the main ocular pathologies, which have a high incidence and result in high costs for the health system. Considering the role of autophagy processes in cell homeostasis and cell viability, the control and modulation of autophagy processes in ocular pathologies could constitute a new therapeutic approach.
C1 [Fernandez-Albarral, Jose A.; De Julian-Lopez, Esther; Soler-Dominguez, Carmen; de Hoz, Rosa; Lopez-Cuenca, Ines; Salobrar-Garcia, Elena; Ramirez, Jose M.; Salazar, Juan J.; Ramirez, Ana, I] Univ Complutense Madrid UCM, Inst Invest Oftalmol Ramon Castroviejo, Madrid 28040, Spain.
   [de Hoz, Rosa; Salobrar-Garcia, Elena; Ramirez, Jose M.; Pinazo-Duran, Maria D.; Salazar, Juan J.; Ramirez, Ana, I] Inst Hlth Carlos III, OFTARED Spanish Net Ophthalm Pathol, Madrid 28029, Spain.
   [de Hoz, Rosa; Salobrar-Garcia, Elena; Salazar, Juan J.; Ramirez, Ana, I] UCM, Dept Inmunol, Fac Opt & Optometria, Oftalmol & ORL, Madrid 28037, Spain.
   [Ramirez, Jose M.] UCM, Dept Inmunol, Fac Med, Oftalmol & ORL, Madrid 28040, Spain.
   [Pinazo-Duran, Maria D.] Univ Valencia, Ophthalm Res Unit Santiago Grisolia, FISABIO, Valencia 46017, Spain.
   [Pinazo-Duran, Maria D.] Univ Valencia, Cellular & Mol Ophthalmobiol Unit, Valencia 46017, Spain.
C3 Complutense University of Madrid; Complutense University of Madrid;
   Complutense University of Madrid; University of Valencia; University of
   Valencia
RP Salazar, JJ; Ramirez, AI (通讯作者)，Univ Complutense Madrid UCM, Inst Invest Oftalmol Ramon Castroviejo, Madrid 28040, Spain.; Salazar, JJ; Ramirez, AI (通讯作者)，Inst Hlth Carlos III, OFTARED Spanish Net Ophthalm Pathol, Madrid 28029, Spain.; Salazar, JJ; Ramirez, AI (通讯作者)，UCM, Dept Inmunol, Fac Opt & Optometria, Oftalmol & ORL, Madrid 28037, Spain.
EM joseaf08@ucm.es; estherdejul@yahoo.es; mcsoldo@hotmail.com;
   rdehoz@med.ucm.es; inelopez@ucm.es; elenasalobrar@med.ucm.es;
   ramirers@med.ucm.es; dolores.pinazo@uv.es; jjsalazar@med.ucm.es;
   airamirez@med.ucm.es
RI Ramírez, Ana I/ABF-4789-2021; Salobrar-Garcia, Elena/I-6908-2019;
   Fernández-Albarral, Jose A./AAG-4357-2020; Ramirez, Jose M./L-6325-2014;
   Salazar, Juan J/L-6887-2014
OI Ramírez, Ana I/0000-0002-2656-4723; Salobrar-Garcia,
   Elena/0000-0001-5939-5551; Fernández-Albarral, Jose
   A./0000-0003-0399-7996; Ramirez, Jose M./0000-0002-5145-5094; De Hoz,
   Rosa/0000-0002-1581-087X; Salazar, Juan J/0000-0001-5480-5902
FU Ophthalmological Network OFTARED (Enfermedades oculares: Prevencion,
   deteccion precoz, tratamiento y rehabilitacion de las patologias
   oculares) of the Institute of Health of Carlos III of the Spanish
   Ministry of Economy [RD16/0008/0005, RD16/0008/0026]; European programme
   FEDER; Network RETiBRAIN (La retina un modelo para investigar
   Neuroproteccion en patologias del Sistema Nervioso Central) of Spanish
   Ministry of Science and Innovation [RED2018-102499-T]; Spanish Ministry
   of Science, Innovation, and Universities [FPU17/01023]; Complutense
   University of Madrid [CT42/18-CT43/18]
FX This research was funded by the Ophthalmological Network OFTARED
   (Enfermedades oculares: Prevencion, deteccion precoz, tratamiento y
   rehabilitacion de las patologias oculares) (RD16/0008/0005 and
   RD16/0008/0026) of the Institute of Health of Carlos III of the Spanish
   Ministry of Economy and by the European programme FEDER; and Network
   RETiBRAIN (La retina un modelo para investigar Neuroproteccion en
   patologias del Sistema Nervioso Central) (RED2018-102499-T) of Spanish
   Ministry of Science and Innovation. And J.A.F.-A. is currently funded by
   a Predoctoral Fellowship (FPU17/01023) from the Spanish Ministry of
   Science, Innovation, and Universities; and I.L.-C. is currently funded
   by a Predoctoral Fellowship (CT42/18-CT43/18) from the Complutense
   University of Madrid.
CR Awadalla MS, 2015, AM J OPHTHALMOL, V159, P124, DOI 10.1016/j.ajo.2014.09.044
   Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5
   Bell K, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0257-4
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Boya P, 2017, EYE, V31, P185, DOI 10.1038/eye.2016.278
   Cadwell K, 2016, NAT REV IMMUNOL, V16, P661, DOI 10.1038/nri.2016.100
   Cai JJ, 2019, EXP CELL RES, V374, P231, DOI 10.1016/j.yexcr.2018.11.028
   Chai PW, 2016, INT J BIOL SCI, V12, P1332, DOI 10.7150/ijbs.16245
   Chalasani ML, 2007, INVEST OPHTH VIS SCI, V48, P1607, DOI 10.1167/iovs.06-0834
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Chen JJ, 2011, AM J HUM GENET, V88, P827, DOI 10.1016/j.ajhg.2011.05.008
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Chi ZL, 2010, HUM MOL GENET, V19, P2606, DOI 10.1093/hmg/ddq146
   COOLEY PL, 1990, VET CLIN N AM-SMALL, V20, P681, DOI 10.1016/S0195-5616(90)50057-1
   Costello MJ, 2013, EXP EYE RES, V116, P141, DOI 10.1016/j.exer.2013.08.017
   Davis LK, 2011, INVEST OPHTH VIS SCI, V52, P7122, DOI 10.1167/iovs.10-5606
   de Jong PTVM, 2015, GRAEF ARCH CLIN EXP, V253, P2061, DOI 10.1007/s00417-015-3180-2
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Farre JC, 2016, NAT REV MOL CELL BIO, V17, P537, DOI 10.1038/nrm.2016.74
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Fu CT, 2012, INVEST OPHTH VIS SCI, V53, P76, DOI 10.1167/iovs.11-8546
   Fu D, 2012, DIABETOLOGIA, V55, P3128, DOI 10.1007/s00125-012-2692-0
   Fu J, 2010, NEURO-ONCOLOGY, V12, P328, DOI 10.1093/neuonc/nop005
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Ge XL, 2014, SCI REP-UK, V4, DOI 10.1038/srep04121
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Grimmel M, 2015, CELLS-BASEL, V4, P202, DOI 10.3390/cells4020202
   Han DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33552-2
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Harris J, 2009, VET IMMUNOL IMMUNOP, V128, P37, DOI 10.1016/j.vetimm.2008.10.293
   Hirt J, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0077-y
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Jin MY, 2013, CELL, V152, P368, DOI 10.1016/j.cell.2013.01.004
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaden TR, 2013, ASIA-PAC J OPHTHALMO, V2, P341, DOI 10.1097/APO.0b013e31829d3e33
   Karantza-Wadsworth V, 2007, AUTOPHAGY, V3, P610, DOI 10.4161/auto.4867
   Kauppinen A, 2013, ACTA OPHTHALMOL, V91, DOI 10.1111/j.1755-3768.2013.4661.x
   Kawashima M, 2013, EXP GERONTOL, V48, P1096, DOI 10.1016/j.exger.2013.04.002
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim SH, 2008, J NEUROSCI RES, V86, P2943, DOI 10.1002/jnr.21738
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Korolchuk VI, 2017, EBIOMEDICINE, V21, P7, DOI 10.1016/j.ebiom.2017.03.020
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394
   Levine B, 2015, J CLIN INVEST, V125, P14, DOI 10.1172/JCI73938
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Li YJ, 2015, CELL PHYSIOL BIOCHEM, V35, P1663, DOI 10.1159/000373980
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   McMonnies CW, 2015, CLIN EXP OPTOM, V98, P122, DOI 10.1111/cxo.12203
   McWilliams TG, 2019, AUTOPHAGY, V15, P1296, DOI 10.1080/15548627.2019.1580509
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Morishita H, 2013, J BIOL CHEM, V288, P11436, DOI 10.1074/jbc.M112.437103
   Motoi Y, 2014, ACS CHEM NEUROSCI, V5, P434, DOI 10.1021/cn500056q
   Nishida K, 2009, CELL DEATH DIFFER, V16, P31, DOI 10.1038/cdd.2008.163
   OBRIEN IAD, 1986, CLIN ENDOCRINOL, V24, P359, DOI 10.1111/j.1365-2265.1986.tb01639.x
   Volpe CMO, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0135-z
   Orsi A, 2012, MOL BIOL CELL, V23, P1860, DOI 10.1091/mbc.E11-09-0746
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park HYL, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.26
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Piano I, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00042
   Pinazo-Duran MD, 2018, CURR NEUROPHARMACOL, V16, P903, DOI 10.2174/1570159X15666170705101910
   Piras A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022514
   Porter K, 2015, BBA-MOL BASIS DIS, V1852, P379, DOI 10.1016/j.bbadis.2014.11.021
   Porter K, 2013, AUTOPHAGY, V9, P581, DOI 10.4161/auto.23568
   Porter KM, 2014, BBA-MOL CELL RES, V1843, P1054, DOI 10.1016/j.bbamcr.2014.02.010
   Pulliero A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098106
   Rehen SK, 1999, EUR J NEUROSCI, V11, P4349, DOI 10.1046/j.1460-9568.1999.00868.x
   REME C, 1986, BRAIN RES, V369, P356, DOI 10.1016/0006-8993(86)90550-0
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Russo R, 2015, PROG BRAIN RES, V220, P87, DOI 10.1016/bs.pbr.2015.04.009
   Ryan TA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01024
   Sagona AP, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/974393
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sidjanin DJ, 2016, AUTOPHAGY, V12, P1759, DOI 10.1080/15548627.2016.1199300
   Sinha D, 2008, MOL CELL NEUROSCI, V37, P85, DOI 10.1016/j.mcn.2007.08.016
   Sirohi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138289
   Su WR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099719
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Szatmari-Toth M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040926
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301
   Tian Y, 2010, CELL, V141, P1042, DOI 10.1016/j.cell.2010.04.034
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang Q, 2014, INVEST OPHTH VIS SCI, V55, P3986, DOI 10.1167/iovs.13-13076
   Wang Q, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095028, 10.1371/journal.pone.0089149]
   Wang S, 2019, MOL MED REP, V19, P927, DOI 10.3892/mmr.2018.9759
   Wei QQ, 2018, DRUG DES DEV THER, V12, P2715, DOI 10.2147/DDDT.S176349
   Wei T, 2015, EXP THER MED, V9, P476, DOI 10.3892/etm.2014.2084
   Wignes JA, 2013, EXP EYE RES, V115, P263, DOI 10.1016/j.exer.2013.06.026
   Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405
   Yang X, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5763658
   Yao J, 2014, CELL PHYSIOL BIOCHEM, V33, P107, DOI 10.1159/000356654
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
   Zhou JJ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4856431
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
   Zoukhri D, 2008, INVEST OPHTH VIS SCI, V49, P4399, DOI 10.1167/iovs.08-1730
NR 129
TC 8
Z9 8
U1 2
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-1729
J9 LIFE-BASEL
JI Life-Basel
PD MAR
PY 2021
VL 11
IS 3
AR 189
DI 10.3390/life11030189
PG 19
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Microbiology
GA RE0FV
UT WOS:000633842600001
PM 33673657
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Patil, R
   Wang, HS
   Sharif, NA
   Mitra, A
AF Patil, Rajkumar
   Wang, Haishan
   Sharif, Najam A.
   Mitra, Alok
TI Aquaporins: Novel Targets for Age-Related Ocular Disorders
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
DE aquaporin; aquaporin inhibitors; macular degeneration; glaucoma;
   angiogenesis; aqueous humor dynamics
ID OPEN-ANGLE GLAUCOMA; WATER CHANNEL PROTEIN; MACULAR DEGENERATION;
   OPTIC-NERVE; RAT RETINA; INTRAOCULAR-PRESSURE; REDUCED EXPRESSION;
   PHENOTYPE ANALYSIS; GLOBAL PREVALENCE; CLINICAL MEDICINE
AB Aquaporins (AQPs), a large family of membrane protein channels that facilitate transport of water and other small solutes, play important roles in physiological functions and human diseases. Up till now, 13 types of AQPs, numbered 0 through 12, have been identified in various mammalian tissues. Homologous genes for AQPs in amphibians, insects, and bacteria highlight the evolutionary conservation and, thus, the importance of these membrane channels. Many members of the AQP family are expressed in the eye. AQP1, which is a water-selective channel, is expressed in the anterior chamber (cornea, ciliary body, trabecular meshwork) and posterior chamber (retina and microvessels in choroid), controlling the fluid homeostasis in the eye. Mice knockout studies have indicated that AQP1 plays an important function in the eye by suggesting its role in aqueous humor dynamics and retina angiogenesis. This review will focus on the role of AQP1 as a novel target for ocular disorders such as glaucoma and age-related macular degeneration, and it will discuss challenges and advances in identifying modulators of AQP1 function that could be useful in clinical applications.
C1 [Patil, Rajkumar] Singapore Eye Res Inst, Singapore 169856, Singapore.
   [Patil, Rajkumar] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Wang, Haishan] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore.
   [Sharif, Najam A.] Santen Inc, Emeryville, CA USA.
   [Mitra, Alok] Univ Auckland, Sch Biol Sci, Auckland, New Zealand.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Agency for Science Technology &
   Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology
   (IMCB); University of Auckland
RP Patil, R (通讯作者)，Singapore Eye Res Inst, Singapore 169856, Singapore.
EM raj.patil@seri.com.sg
RI Wang, Haishan/F-4763-2015
OI Wang, Haishan/0000-0002-7959-7377
CR Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Andricopulo AD, 2009, CURR TOP MED CHEM, V9, P771, DOI 10.2174/156802609789207127
   Baetz NW, 2009, EXP EYE RES, V89, P95, DOI 10.1016/j.exer.2009.02.018
   Beitz E, 1999, CURR MED CHEM, V6, P457
   Brooks HL, 2000, MOL PHARMACOL, V57, P1021
   Calkins DJ, 2012, INVEST OPHTH VIS SCI, V53, P2482, DOI 10.1167/iovs.12-9483i
   Camerino GM, 2006, CELL MOL BIOL, V52, P51, DOI 10.1170/T750
   Caprioli J, 2008, OPHTHALMOLOGY, V115, P1123, DOI 10.1016/j.ophtha.2007.10.031
   Caprioli J, 2010, AM J OPHTHALMOL, V149, P704, DOI 10.1016/j.ajo.2010.01.018
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Cavet ME, 2014, INVEST OPHTH VIS SCI, V55, P5005, DOI 10.1167/iovs.14-14515
   Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517
   Delporte C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020166
   Dibas A, 2007, PHARMACOL RES, V55, P378, DOI 10.1016/j.phrs.2007.01.021
   Dibas A, 2010, MOL VIS, V16, P330
   El Hindy N, 2013, ANTICANCER RES, V33, P609
   Endo M, 1999, MICROVASC RES, V58, P89, DOI 10.1006/mvre.1999.2158
   Esteva-Font C, 2016, MOL PHARMACOL, V89, P686, DOI 10.1124/mol.116.103929
   Esteva-Font C, 2014, FASEB J, V28, P1446, DOI 10.1096/fj.13-245621
   Flammer J, 1998, PROG RETIN EYE RES, V17, P267, DOI 10.1016/S1350-9462(97)00006-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gan SW, 2012, NEUROSCI LETT, V516, P135, DOI 10.1016/j.neulet.2012.03.075
   Gao JW, 2006, ANAL BIOCHEM, V350, P165, DOI 10.1016/j.ab.2006.01.003
   Gonen T, 2005, NATURE, V438, P633, DOI 10.1038/nature04321
   Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332
   Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001
   Han ZQ, 2000, CURR EYE RES, V20, P242, DOI 10.1076/0271-3683(200003)20:3;1-9;FT242
   Han ZQ, 2000, BIOCHEM BIOPH RES CO, V273, P328, DOI 10.1006/bbrc.2000.2944
   Henderson AJ, 2010, BIOORG MED CHEM LETT, V20, P1137, DOI 10.1016/j.bmcl.2009.12.012
   Ho JD, 2009, P NATL ACAD SCI USA, V106, P7437, DOI 10.1073/pnas.0902725106
   Hollborn M, 2012, CURR EYE RES, V37, P524, DOI 10.3109/02713683.2012.658133
   Huber VJ, 2009, BIOORGAN MED CHEM, V17, P411, DOI 10.1016/j.bmc.2007.12.040
   Huber VJ, 2009, BIOORGAN MED CHEM, V17, P418, DOI 10.1016/j.bmc.2007.12.038
   Ihekoromadu N, 2015, INVEST OPHTHALMOL VI, V56
   Ikarashi N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071172
   INASE N, 1995, J BIOL CHEM, V270, P17913, DOI 10.1074/jbc.270.30.17913
   Kaneko K, 2008, MICROVASC RES, V75, P297, DOI 10.1016/j.mvr.2007.12.003
   Kaufman PL, 2012, INVEST OPHTH VIS SCI, V53, P2495, DOI 10.1167/iovs.12-9483m
   Kawashima R., 2014, INVEST OPHTH VIS SCI, V55, pE2276
   Kersey T, 2013, INDIAN J MED RES, V137, P659
   Kesters D, 2013, EMBO REP, V14, P49, DOI 10.1038/embor.2012.189
   Kim IB, 2002, J COMP NEUROL, V452, P178, DOI 10.1002/cne.10359
   Kim IB, 1998, NEUROSCI LETT, V244, P52, DOI 10.1016/S0304-3940(98)00104-9
   King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469
   King LS, 1996, J CLIN INVEST, V97, P2183, DOI 10.1172/JCI118659
   KIRIHARA T, 2015, INVEST OPHTH VIS SCI, V56
   Kitchen P, 2015, BBA-GEN SUBJECTS, V1850, P2410, DOI 10.1016/j.bbagen.2015.08.023
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kontopidis G, 2004, ACTA CRYSTALLOGR D, V60, P479, DOI 10.1107/S0907444904000174
   Kopczynski CC, 2014, J OCUL PHARMACOL TH, V30, P85, DOI 10.1089/jop.2013.0197
   Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851
   Krizaj D, 2014, CURR EYE RES, V39, P105, DOI 10.3109/02713683.2013.836541
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Lee MD, 1997, CHEST, V111, pS111, DOI 10.1378/chest.111.6_Supplement.111S
   MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195
   Mallick Jyotiranjan, 2016, J Ophthalmic Vis Res, V11, P204, DOI 10.4103/2008-322X.183914
   Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088
   Martinez-De-La-Casa JM, 2014, INVEST OPHTH VIS SCI, V55, P8343, DOI 10.1167/iovs.14-15501
   McElnea EM, 2011, MOL VIS, V17, P1182
   Medeiros FA, 2016, AM J OPHTHALMOL, V168, P250, DOI 10.1016/j.ajo.2016.05.012
   Miki A, 2013, AM J PATHOL, V182, P1727, DOI 10.1016/j.ajpath.2013.01.027
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Mizokami J, 2011, CURR EYE RES, V36, P1064, DOI 10.3109/02713683.2011.611610
   Moeller HB, 2016, BEST PRACT RES CL EN, V30, P277, DOI 10.1016/j.beem.2016.02.012
   Monzani E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006167
   Muller EM, 2008, PFLUG ARCH EUR J PHY, V456, P663, DOI 10.1007/s00424-007-0422-0
   MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010
   Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519
   Murray CW, 2010, J MED CHEM, V53, P5942, DOI 10.1021/jm100059d
   Nagaraju GP, 2016, CANCER LETT, V373, P12, DOI 10.1016/j.canlet.2016.01.003
   Naka M, 2010, INVEST OPHTH VIS SCI, V51, P4618, DOI 10.1167/iovs.09-4712
   Newby ZER, 2009, NAT PROTOC, V4, P619, DOI 10.1038/nprot.2009.27
   Nicchia GP, 2013, J MOL MED, V91, P613, DOI 10.1007/s00109-012-0977-x
   Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001
   NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371
   Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0
   Ortak H, 2013, CORNEA, V32, P1375, DOI 10.1097/ICO.0b013e31829b6d2a
   Osborne NN, 2016, EUR J PHARMACOL, V787, P127, DOI 10.1016/j.ejphar.2016.04.032
   Pasquale LR, 2016, CURR OPIN OPHTHALMOL, V27, P94, DOI 10.1097/ICU.0000000000000245
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Patil R.V., 2005, CURR TOP PHARM, V9, P97
   Patil RV, 2016, CHEM BIOL DRUG DES, V87, P794, DOI 10.1111/cbdd.12713
   Patil RV, 1997, BIOCHEM BIOPH RES CO, V238, P392, DOI 10.1006/bbrc.1997.7310
   Patil RV, 2001, AM J PHYSIOL-CELL PH, V281, pC1139, DOI 10.1152/ajpcell.2001.281.4.C1139
   Patil RV, 1997, EXP EYE RES, V64, P203, DOI 10.1006/exer.1996.0196
   Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764
   Pelagalli A., 2016, INT J MOL SCI, V17, DOI [10. 3390/ijms17081213 27472320, DOI 10.3390/ijms17081213, 10.3390/ijms17081213]
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110
   Previch LE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071146
   Rajappa M, 2010, ADV CLIN CHEM, V50, P103, DOI 10.1016/S0065-2423(10)50006-4
   Ransom BR, 1997, GLIA, V21, P134
   Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ruiz-Ederra J, 2009, EXP EYE RES, V89, P159, DOI 10.1016/j.exer.2009.03.002
   Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460
   Saadoun S, 2002, BRIT J CANCER, V87, P621, DOI 10.1038/sj.bjc.6600512
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schey KL, 2014, BBA-GEN SUBJECTS, V1840, P1513, DOI 10.1016/j.bbagen.2013.10.037
   Seeliger D, 2013, ACS CHEM BIOL, V8, P249, DOI 10.1021/cb300153z
   Sharif NA., 2017, INT J OPHTHALMOL VIS, V2, P22, DOI [10.11648/j.ijovs.20170202.11, DOI 10.11648/J.IJOVS.20170202.11]
   Simmons KJ, 2010, NAT REV MICROBIOL, V8, P501, DOI 10.1038/nrmicro2349
   Sogaard R, 2008, PFLUG ARCH EUR J PHY, V456, P285, DOI 10.1007/s00424-007-0392-2
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   Stamer WD, 2001, INVEST OPHTH VIS SCI, V42, P1803
   Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a
   Suto F, 2015, INVEST OPHTH VIS SCI, V56, P7963, DOI 10.1167/iovs.15-18166
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Talele TT, 2010, CURR TOP MED CHEM, V10, P127, DOI 10.2174/156802610790232251
   Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thomas D., 2000, MED SCI RES, V28, P87
   Vacca A, 2001, BRIT J HAEMATOL, V113, P415, DOI 10.1046/j.1365-2141.2001.02738.x
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   VANHOEK AN, 1995, BIOCHEMISTRY-US, V34, P2212, DOI 10.1021/bi00007a015
   Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226
   Verkman Alan S, 2009, Handb Exp Pharmacol, P359, DOI 10.1007/978-3-540-79885-9_18
   Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x
   Verkman AS, 2003, EXP EYE RES, V76, P137, DOI 10.1016/S0014-4835(02)00303-2
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xun W, 2009, PREP BIOCHEM BIOTECH, V39, P208, DOI 10.1080/10826060902800882
   Yamane S, 2015, INVEST OPHTH VIS SCI, V56, P2547, DOI 10.1167/iovs.14-16181
   Yang MH, 2013, BIOSCIENCE REP, V33, P379, DOI 10.1042/BSR20130005
   Yasui M, 2004, J PHARMACOL SCI, V96, P260, DOI 10.1254/jphs.FMJ04004X4
   Yool Andrea J, 2002, BMC Physiol, V2, P4, DOI 10.1186/1472-6793-2-4
   Yool AJ, 2010, CLIN EXP PHARMACOL P, V37, P403, DOI 10.1111/j.1440-1681.2009.05244.x
   Zelenina M, 2004, J BIOL CHEM, V279, P51939, DOI 10.1074/jbc.M407645200
   Zhang JX, 2012, MED ONCOL, V29, P656, DOI 10.1007/s12032-011-9960-6
NR 134
TC 8
Z9 9
U1 0
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAR
PY 2018
VL 34
IS 1-2
SI SI
BP 177
EP 187
DI 10.1089/jop.2017.0024
PG 11
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA FW5FJ
UT WOS:000425341400019
PM 28632458
DA 2022-11-30
ER

PT J
AU Kim, JW
   Kim, YT
AF Kim, Ji Won
   Kim, Yun Taek
TI Clinical application of 3D display device in ophthalmology: measurement
   of metamorphopsia
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE Amsler grid; macula; macular degeneration; metamorphopsia
ID MACULAR DEGENERATION; QUANTIFICATION; DISEASE; EYES
AB Purpose: To develop a new tool for detecting metamorphopsia.
   Method: Evaluation of diagnostic test. Novel tool for measuring metamorphopsia was developed using commercial 3D display. Fifty-eight patients diagnosed with macular disease, which included epiretinal membrane, age-related macular degeneration, central serous chorioretinopathy and macular hole, as confirmed by macular optical coherence tomography were tested with Amsler grid and novel method. The subjective perception of metamorphopsia and its effect on the lives of the participants with macular disease was also evaluated using a brief questionnaire. The sensitivity and specificity to subjective perception of metamorphopsia were compared.
   Results: The sensitivity and specificity were 66.7% and 97.7%, respectively, using the Amsler grid test, and 100% and 90.7%, respectively, using the 3D novel metamorphopsia test developed for this study.
   Conclusions: The detection rate of metamorphopsia in macular disease using novel metamorphopsia test was significantly higher than that using the Amsler grid test. This novel approach to detecting for metamorphopsia can also be used at home for self-assessment.
C1 [Kim, Ji Won; Kim, Yun Taek] Ewha Womans Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
C3 Ewha Womans University
RP Kim, YT (通讯作者)，Ewha Womans Univ, Mok Dong Hosp, Dept Ophthalmol, 911-1 Mok Dong, Seoul 158710, South Korea.
EM jjongofhim@hanmail.net
FU Basic Science Research Program through National Research Foundation of
   Korea (NRF) - Ministry of Education, Science and Technology, Seoul,
   Korea [2013R1A1A1060545]; Busan Sungmo eye hospital Sodam scholarship
   committee, Busan, Korea [N-A]
FX This study was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science and Technology, Seoul, Korea (Grant No:
   2013R1A1A1060545); Busan Sungmo eye hospital Sodam scholarship
   committee, Busan, Korea (Grant No: N-A). The sponsors or funding
   organization had no role in the design or conduct of this research.
CR Arimura E, 2007, ACTA OPHTHALMOL SCAN, V85, P55, DOI 10.1111/j.1600-0420.2006.00729.x
   Augustin AJ, 2005, RETINA-J RET VIT DIS, V25, P443, DOI 10.1097/00006982-200506000-00008
   Azuma Noriyuki, 2000, Nippon Ganka Gakkai Zasshi, V104, P960
   Cavanagh P, 1999, NEURONAL BASIS PSYCH, P41
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Fukuda S, 2009, BRIT J OPHTHALMOL, V93, P1595, DOI 10.1136/bjo.2008.155440
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Matsumoto C, 2003, INVEST OPHTH VIS SCI, V44, P4012, DOI 10.1167/iovs.03-0117
   Nomoto H, 2013, EYE, V27, P924, DOI 10.1038/eye.2013.108
   Parkes L, 2001, NAT NEUROSCI, V4, P739, DOI 10.1038/89532
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
NR 13
TC 6
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2016
VL 94
IS 1
BP E54
EP E58
DI 10.1111/aos.12795
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB7YB
UT WOS:000368732300009
PM 26109491
OA Bronze
DA 2022-11-30
ER

PT J
AU McClements, L
   Annett, S
   Yakkundi, A
   Robson, T
AF McClements, Lana
   Annett, Stephanie
   Yakkundi, Anita
   Robson, Tracy
TI The Role of Peptidyl Prolyl Isomerases in Ageing and Vascular Diseases
SO CURRENT MOLECULAR PHARMACOLOGY
LA English
DT Article
DE Ageing; age-related diseases; CypA; FKBPs; Pin1; PPIases; vascular
ID CHRONIC KIDNEY-DISEASE; FK506-BINDING PROTEIN 1B/12.6; AMYLOID PRECURSOR
   PROTEIN; FKBP FAMILY PROTEINS; C-ASSOCIATED PROTEIN; CANCER STEM-CELLS;
   CYCLOPHILIN-A; IMMUNOPHILIN FKBP52; PROSTATE-CANCER; LIFE-SPAN
AB Peptidyl prolyl isomerases (PPIases) are proteins belonging to the immunophilin family and are characterised by their cis-trans isomerization activity at the X-Pro peptide bond, in addition to their tetratricopeptide repeat (TPR) domain, important for interaction with the molecular chaperone, Hsp90. Due to this unique structure these proteins are able to facilitate protein-protein interactions which can impact significantly on a range of cellular processes such as cell signalling, differentiation, cell cycle progression, metabolic activity and apoptosis. Malfunction and/ or dysregulation of most members of this class of proteins promotes cellular damage and tissue/organ failure, predisposing to ageing and age-related diseases. Many individual genes within the PPIase family are associated with several age-related diseases including cardiovascular diseases (CVDs), atherosclerosis, type II diabetes mellitus (T2D), chronic kidney disease (CDK), neurodegeneration, cancer and age-related macular degeneration (AMD), in addition to the ageing process itself. This review will focus on the different roles of PPIases, and their therapeutic/biomarker potential in these age-related vascular diseases.
C1 [McClements, Lana; Annett, Stephanie; Yakkundi, Anita; Robson, Tracy] Queens Univ Belfast, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
C3 Queens University Belfast
RP Robson, T (通讯作者)，Queens Univ Belfast, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM t.robson@qub.ac.uk
RI McClements, Lana/S-9458-2019
OI McClements, Lana/0000-0002-4911-1014; Robson, Tracy/0000-0003-4262-6872
FU BBSRC [BB/I006958/1] Funding Source: UKRI; MRC [G1001473] Funding
   Source: UKRI; Medical Research Council [G1001473] Funding Source:
   Medline
CR Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198
   Ahearn IM, 2011, MOL CELL, V41, P173, DOI 10.1016/j.molcel.2011.01.001
   Alam M. R., 2014, J MOL CELL CARDIOL
   Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899
   Amler LC, 2000, CANCER RES, V60, P6134
   Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404
   Arora K, 2005, J IMMUNOL, V175, P517, DOI 10.4049/jimmunol.175.1.517
   Balsevich G, 2014, J ENDOCRINOL, V222, P15, DOI 10.1530/JOE-14-0129
   Bane FT, 2009, J PHARMACOL EXP THER, V329, P38, DOI 10.1124/jpet.108.148130
   Bannon JH, 2012, CELL CYCLE, V11, P1340, DOI 10.4161/cc.19711
   Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5
   Bartke A, 2008, CELL CYCLE, V7, P3338, DOI 10.4161/cc.7.21.7012
   Barton M, 2013, CURR OPIN PHARMACOL, V13, P226, DOI 10.1016/j.coph.2013.05.005
   Beitz Janice M, 2014, Front Biosci (Schol Ed), V6, P65
   Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087
   Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200
   Bernstein HS, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt108
   Blagosklonny MV, 2008, CELL CYCLE, V7, P3344, DOI 10.4161/cc.7.21.6965
   Blagosklonny MV, 2005, CANCER BIOL THER, V4, P621, DOI 10.4161/cbt.4.6.1818
   Blankenberg S, 2010, CIRCULATION, V121, P2388, DOI 10.1161/CIRCULATIONAHA.109.901413
   Bonafe M, 2009, MOL CELL ENDOCRINOL, V299, P118, DOI 10.1016/j.mce.2008.10.038
   Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Bublik DR, 2010, J BIOL CHEM, V285, P5274, DOI 10.1074/jbc.M109.045948
   Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9
   Cao WH, 2011, J BIOSCIENCES, V36, P493, DOI 10.1007/s12038-011-9080-7
   Chambraud B, 2007, FASEB J, V21, P2787, DOI 10.1096/fj.06-7667com
   Chiasson VL, 2011, HYPERTENSION, V57, P1167, DOI 10.1161/HYPERTENSIONAHA.110.162917
   Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759
   Chung WH, 2010, AGEING RES REV, V9, pS67, DOI 10.1016/j.arr.2010.08.001
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Conejero-Goldberg C, 2011, MOL PSYCHIATR, V16, P836, DOI 10.1038/mp.2010.57
   Corella D, 2014, AGEING RES REV, V18, P53, DOI 10.1016/j.arr.2014.08.002
   Cox M. B., 2007, HAPTER, V2
   Cox MB SD, 2000, FUNCTIONS HSP90 BIND
   Damsker JM, 2009, IMMUNOLOGY, V126, P55, DOI 10.1111/j.1365-2567.2008.02877.x
   De Leon JT, 2011, P NATL ACAD SCI USA, V108, P11878, DOI 10.1073/pnas.1105160108
   De Tata V, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00138
   Desgraz R, 2011, TRENDS ENDOCRIN MET, V22, P34, DOI 10.1016/j.tem.2010.09.004
   Desmetz C, 2009, CLIN CANCER RES, V15, P4733, DOI 10.1158/1078-0432.CCR-08-3307
   Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899
   Driessen HE, 2014, NETH HEART J, V22, P198, DOI 10.1007/s12471-014-0549-5
   Edlich F, 2011, CURR OPIN PHARMACOL, V11, P348, DOI 10.1016/j.coph.2011.03.011
   Elrod JW, 2010, J CLIN INVEST, V120, P3680, DOI 10.1172/JCI43171
   Erlejman AG, 2013, FUTURE MED CHEM, V5, P591, DOI [10.4155/FMC.13.7, 10.4155/fmc.13.7]
   Fang F, 2009, AM J PATHOL, V174, P297, DOI 10.2353/ajpath.2009.080753
   Flisiak R, 2009, HEPATOLOGY, V49, P1460, DOI 10.1002/hep.22835
   Galat A, 2013, CELL MOL LIFE SCI, V70, P3243, DOI 10.1007/s00018-012-1206-z
   Gant JC, 2014, EUR J PHARMACOL, V739, P74, DOI 10.1016/j.ejphar.2013.10.070
   Gant JC, 2011, J NEUROSCI, V31, P1693, DOI 10.1523/JNEUROSCI.4805-10.2011
   Gerdes LU, 2000, GENET EPIDEMIOL, V19, P202, DOI 10.1002/1098-2272(200010)19:3<202::AID-GEPI2>3.0.CO;2-Q
   Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004
   Glew Robert H, 2014, World J Nephrol, V3, P122, DOI 10.5527/wjn.v3.i4.122
   Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4
   Gumz M., 2014, FASEB J, V28, P744
   Hafner AV, 2010, AGING-US, V2, P914, DOI 10.18632/aging.100252
   Han IS, 2002, J KOREAN MED SCI, V17, P41, DOI 10.3346/jkms.2002.17.1.41
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harrison D. E., 2010, HETEROGENEOUS MICE, V460, P392
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hausch F, 2013, CELL CYCLE, V12, P2366, DOI 10.4161/cc.25508
   Henique C, 2012, CURR OPIN NEPHROL HY, V21, P417, DOI 10.1097/MNH.0b013e328354a598
   Henriksen R, 2011, TUMOR BIOL, V32, P671, DOI 10.1007/s13277-011-0167-4
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hicks C, 2014, BIOMARK INSIGHTS, V9, P39, DOI [10.4137/BMIMI.S13729, 10.4137/BMI.S13729]
   Higgins JPT, 2003, AM J SURG PATHOL, V27, P58, DOI 10.1097/00000478-200301000-00007
   Hindle JV, 2010, AGE AGEING, V39, P156, DOI 10.1093/ageing/afp223
   Hoffmann H, 2014, BIOL CHEM, V395, P721, DOI 10.1515/hsz-2014-0125
   Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219
   Howcroft TK, 2013, AGING-US, V5, P84, DOI 10.18632/aging.100531
   Hu F., 2013, PROTEIN CELL
   Huo DH, 2008, BIOCHEM BIOPH RES CO, V372, P14, DOI 10.1016/j.bbrc.2008.04.178
   Ivanovski O, 2013, KIDNEY INT, V83, P998, DOI 10.1038/ki.2013.41
   Jaaskelainen T, 2011, CURR OPIN PHARMACOL, V11, P326, DOI 10.1016/j.coph.2011.04.006
   Jeck WR, 2012, AGING CELL, V11, P727, DOI 10.1111/j.1474-9726.2012.00871.x
   Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X
   Jinwal UK, 2010, J NEUROSCI, V30, P591, DOI 10.1523/JNEUROSCI.4815-09.2010
   Johnson N, 1999, EUR J BIOCHEM, V263, P353, DOI 10.1046/j.1432-1327.1999.00490.x
   Junnila RK, 2013, NAT REV ENDOCRINOL, V9, P366, DOI 10.1038/nrendo.2013.67
   Kadish I, 2009, J NEUROSCI, V29, P1805, DOI 10.1523/JNEUROSCI.4599-08.2009
   Kalia LV, 2013, ANN NEUROL, V73, P155, DOI 10.1002/ana.23746
   Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028
   Kang CB, 2008, NEUROSIGNALS, V16, P318, DOI 10.1159/000123041
   Karasik D, 2005, J GERONTOL A-BIOL, V60, P574, DOI 10.1093/gerona/60.5.574
   Keddis MT, 2013, CURR OPIN NEPHROL HY, V22, P390, DOI 10.1097/MNH.0b013e32836214b9
   Kim J, 2008, J CELL SCI, V121, P3636, DOI 10.1242/jcs.028654
   Komers R, 2013, LAB INVEST, V93, P543, DOI 10.1038/labinvest.2013.47
   Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092
   Kumar R, 2009, J CLIN INVEST, V119, P2887, DOI 10.1172/JCI40784
   Kushner JA, 2013, J CLIN INVEST, V123, P990, DOI 10.1172/JCI64095
   Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58
   Lam YW, 2008, PROTEOMICS, V8, P2750, DOI 10.1002/pmic.200700986
   Lamoureux F, 2011, CLIN CANCER RES, V17, P2301, DOI 10.1158/1078-0432.CCR-10-3077
   Lanner JT, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003996
   Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290
   Lee J, 2010, J INT MED RES, V38, P1561, DOI 10.1177/147323001003800501
   Lee TH, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001906
   Lee TH, 2009, NAT CELL BIOL, V11, P97, DOI 10.1038/ncb1818
   Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X
   Levey AS, 2012, LANCET, V379, P165, DOI 10.1016/S0140-6736(11)60178-5
   Li BY, 2012, PEDIATR CARDIOL, V33, P988, DOI 10.1007/s00246-012-0298-4
   Li Hanhan, 2014, World J Nephrol, V3, P237, DOI 10.5527/wjn.v3.i4.237
   Li Ji, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P203, DOI 10.3969/j.issn.1672-7347.2011.03.003
   Li Yue-Ying, 2007, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V15, P733
   Li ZY, 2013, CANCER CHEMOTH PHARM, V72, P1001, DOI 10.1007/s00280-013-2285-8
   Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099
   Liu FL, 2006, BIOCHEM BIOPH RES CO, V350, P472, DOI 10.1016/j.bbrc.2006.09.073
   Liu FL, 2014, J BIOSCIENCES, V39, P85, DOI 10.1007/s12038-013-9400-1
   Loffing J, 2009, PFLUG ARCH EUR J PHY, V458, P111, DOI 10.1007/s00424-009-0656-0
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Lu JH, 2014, MOL CELL BIOCHEM, V389, P17, DOI 10.1007/s11010-013-1922-1
   Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261
   Lu MK, 2011, CELL CYCLE, V10, P3415, DOI 10.4161/cc.10.20.17686
   MacMillan D, 2013, EUR J PHARMACOL, V700, P181, DOI 10.1016/j.ejphar.2012.12.029
   Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010
   Malagelada C, 2008, J NEUROSCI, V28, P14363, DOI 10.1523/JNEUROSCI.3928-08.2008
   Marti-Soler H, 2014, HEART, V100, P1517, DOI 10.1136/heartjnl-2014-305623
   Maruyama M, 2011, CIRC RES, V108, P1042, DOI 10.1161/CIRCRESAHA.110.237867
   McClements L, 2013, CLIN CANCER RES, V19, P3881, DOI 10.1158/1078-0432.CCR-13-0595
   McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x
   McKeen HD, 2008, ENDOCRINOLOGY, V149, P5724, DOI 10.1210/en.2008-0168
   McKeen HD, 2010, CANCER RES, V70, P1090, DOI 10.1158/0008-5472.CAN-09-2515
   Merscher S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00127
   Michaelson D. M., 2014, ALZHEIMERS DEMENT
   Michaud M, 2013, J AM MED DIR ASSOC, V14, P877, DOI 10.1016/j.jamda.2013.05.009
   Montesanto A, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-6
   Morley JE, 2008, CLIN GERIATR MED, V24, P395, DOI 10.1016/j.cger.2008.03.005
   Mukaide H, 2008, CANCER INVEST, V26, P385, DOI 10.1080/07357900701799228
   Murphy C. T., 2003, GENES ACT DOWNSTREAM, P277
   Nagase Miki, 2012, Nihon Rinsho, V70, P1504
   Nagase R, 2012, CLIN EXP NEPHROL, V16, P739, DOI 10.1007/s10157-012-0625-3
   Nasrallah R, 2014, AM J PHYSIOL-RENAL, V307, pF243, DOI 10.1152/ajprenal.00224.2014
   Neff F., 2013, RAPAMYCIN EXTENDS MU, P123
   Newgard CB, 2013, J CLIN INVEST, V123, P946, DOI 10.1172/JCI68833
   Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410
   Nigro P, 2011, J EXP MED, V208, P53, DOI 10.1084/jem.20101174
   North BJ, 2012, CIRC RES, V110, P1097, DOI 10.1161/CIRCRESAHA.111.246876
   O' Neill C, 2013, EXP GERONTOL, V48, P647, DOI 10.1016/j.exger.2013.02.025
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Obchoei S, 2009, MED SCI MONITOR, V15, pRA221
   Oh JY, 2014, STEM CELLS, V32, P1553, DOI 10.1002/stem.1608
   Olesen SH, 2005, MOL CELL PROTEOMICS, V4, P534, DOI 10.1074/mcp.M400217-MCP200
   Pagani Lucia, 2011, Int J Alzheimers Dis, V2011, P925050, DOI 10.4061/2011/925050
   Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016
   Pereira MJ, 2014, METABOLISM, V63, P1198, DOI 10.1016/j.metabol.2014.05.015
   Petrovich E, 2014, J STEROID BIOCHEM, V139, P78, DOI 10.1016/j.jsbmb.2013.10.006
   Ponda MP, 2006, CLIN J AM SOC NEPHRO, V1, P668, DOI 10.2215/CJN.00120106
   Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103
   Qi YJ, 2008, J CELL BIOCHEM, V104, P1625, DOI 10.1002/jcb.21727
   Quinn MCJ, 2013, INT J ONCOL, V42, P912, DOI 10.3892/ijo.2013.1797
   Ramachandran S, 2012, CAN J PHYSIOL PHARM, V90, P1005, DOI [10.1139/Y2012-038, 10.1139/y2012-038]
   Reeve A, 2014, AGEING RES REV, V14, P19, DOI 10.1016/j.arr.2014.01.004
   Resnick HE, 2000, DIABETES CARE, V23, P176, DOI 10.2337/diacare.23.2.176
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Robson T, 2000, INT J RADIAT BIOL, V76, P617
   Robson T, 2012, DRUG DISCOV TODAY, V17, P544, DOI 10.1016/j.drudis.2012.01.002
   Roderick P, 2011, J EPIDEMIOL COMMUN H, V65, pA12, DOI 10.1136/jech.2011.143586.26
   Romano S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.109
   Romano S, 2008, HAEMATOL-HEMATOL J, V93, P1039, DOI 10.3324/haematol.12402
   Romano S, 2011, CURR OPIN PHARMACOL, V11, P288, DOI 10.1016/j.coph.2011.04.011
   Rose G, 2003, EXP GERONTOL, V38, P1065, DOI 10.1016/S0531-5565(03)00209-2
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227
   Sakhaee K, 2012, J CLIN ENDOCR METAB, V97, P1847, DOI 10.1210/jc.2011-3492
   Salminen A, 2011, PROG NEUROBIOL, V93, P99, DOI 10.1016/j.pneurobio.2010.10.006
   Sanokawa-Akakura R, 2004, J BIOL CHEM, V279, P27845, DOI 10.1074/jbc.C400118200
   Sanokawa-Akakura R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008626
   Satoh K, 2008, CIRCULATION, V117, P3088, DOI 10.1161/CIRCULATIONAHA.107.756106
   Satoh K, 2013, CIRC J, V77, P447, DOI 10.1253/circj.CJ-12-0805
   Satoh K, 2011, ARTERIOSCL THROM VAS, V31, P1116, DOI 10.1161/ATVBAHA.110.214601
   Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241
   Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488
   SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511
   Shimamoto S, 2014, BIOCHEM J, V458, P141, DOI 10.1042/BJ20130924
   Shimizu T, 2005, J CEREBR BLOOD F MET, V25, P325, DOI 10.1038/sj.jcbfm.9600029
   Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894
   Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146
   Siamakpour-Reihani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020412
   SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9
   Sivils JC, 2011, CURR OPIN PHARMACOL, V11, P314, DOI 10.1016/j.coph.2011.03.010
   Slagboom PE, 2011, PHILOS T R SOC B, V366, P35, DOI 10.1098/rstb.2010.0284
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smyth LJ, 2014, AM J PHYSIOL-RENAL, V307, pF757, DOI 10.1152/ajprenal.00306.2014
   Smyth LJ, 2014, EPIGENETICS-US, V9, P366, DOI 10.4161/epi.27161
   Soerensen M, 2010, AGING CELL, V9, P1010, DOI 10.1111/j.1474-9726.2010.00627.x
   Solassol J, 2011, CURR OPIN PHARMACOL, V11, P320, DOI 10.1016/j.coph.2011.03.012
   Stechschulte LA, 2011, CURR OPIN PHARMACOL, V11, P332, DOI 10.1016/j.coph.2011.04.012
   Stern S, 2003, CIRCULATION, V108, pE99, DOI 10.1161/01.CIR.0000086898.96021.B9
   Storer CL, 2011, TRENDS ENDOCRIN MET, V22, P481, DOI 10.1016/j.tem.2011.08.001
   Sudarsanam S, 2010, CURR OPIN DRUG DISC, V13, P31
   Sunnotel O, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-22
   Suzuki J, 2006, CIRC RES, V98, P811, DOI 10.1161/01.RES.0000216405.85080.a6
   Suzuki Y, 2010, INT J UROL, V17, P281, DOI 10.1111/j.1442-2042.2010.02450.x
   Takahashi K, 2007, ONCOGENE, V26, P3835, DOI 10.1038/sj.onc.1210153
   Tavecchio M, 2013, J BIOL CHEM, V288, P5553, DOI 10.1074/jbc.M112.433045
   Thompson LM, 2008, NATURE, V452, P707, DOI 10.1038/452707a
   Toko H, 2013, CIRC RES, V112, P1244, DOI 10.1161/CIRCRESAHA.113.301084
   Toledo F, 2007, MOL CELL BIOL, V27, P1425, DOI 10.1128/MCB.00999-06
   Tomek M, 2012, J PHARM PHARMACOL, V64, P1695, DOI 10.1111/j.2042-7158.2012.01526.x
   Tonelli M, 2014, KIDNEY INT, V85, P486, DOI 10.1038/ki.2013.467
   Torlakovic EE, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-251
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Ueda K, 2014, BIOCHEM BIOPH RES CO, V445, P132, DOI 10.1016/j.bbrc.2014.01.125
   Valentine A, 2011, CLIN CANCER RES, V17, P1044, DOI 10.1158/1078-0432.CCR-10-2241
   van der Horst A, 2009, CANCER RES, V69, P6651, DOI 10.1158/0008-5472.CAN-09-0825
   Vandiedonck Claire, 2009, Briefings in Functional Genomics & Proteomics, V8, P379, DOI 10.1093/bfgp/elp010
   Wang HQ, 2005, HUM MOL GENET, V14, P1889, DOI 10.1093/hmg/ddi195
   Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226
   Ward BK, 1999, BREAST CANCER RES TR, V58, P267
   Ward BK, 2001, J CANCER RES CLIN, V127, P109, DOI 10.1007/s004320000182
   Watanabe S, 2005, AM J PHYSIOL-RENAL, V288, pF40, DOI 10.1152/ajprenal.00218.2004
   Whaley-Connell A, 2012, CURR HYPERTENS REP, V14, P360, DOI 10.1007/s11906-012-0279-2
   Wheaton K, 2010, AGING CELL, V9, P747, DOI 10.1111/j.1474-9726.2010.00601.x
   Whiffin N, 2014, HUM MOL GENET, V23, P4729, DOI 10.1093/hmg/ddu177
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200
   Yakkundi A., 2014, RECENT RES DEV ENDOC, V5, P21
   Yakkundi A, 2015, ARTERIOSCL THROM VAS, V35, P845, DOI 10.1161/ATVBAHA.114.304539
   Yakkundi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055075
   Yan JC, 2012, CLIN CHIM ACTA, V413, P691, DOI 10.1016/j.cca.2011.12.009
   Yang HR, 2007, BIOCHEM BIOPH RES CO, V361, P763, DOI 10.1016/j.bbrc.2007.07.085
   Yang J, 2011, CANCER BIOL THER, V11, P535, DOI 10.4161/cbt.11.5.14678
   Yu DH, 2014, J CLIN INVEST, V124, P3708, DOI 10.1172/JCI76507
   Zaha VG, 2012, CIRC RES, V111, P800, DOI 10.1161/CIRCRESAHA.111.255505
   Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200
NR 227
TC 11
Z9 11
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1874-4672
EI 1874-4702
J9 CURR MOL PHARMACOL
JI Curr. Molec. Pharmacol.
PY 2016
VL 9
IS 2
BP 165
EP 179
DI 10.2174/1874467208666150519115729
PG 15
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA FB5YE
UT WOS:000406217400007
PM 25986561
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Montserrat-de la Paz, S
   Naranjo, MC
   Bermudez, B
   Lopez, S
   Moreda, W
   Abia, R
   Muriana, FJG
AF Montserrat-de la Paz, Sergio
   Carmen Naranjo, M.
   Bermudez, Beatriz
   Lopez, Sergio
   Moreda, Wenceslao
   Abia, Rocio
   Muriana, Francisco J. G.
TI Postprandial dietary fatty acids exert divergent inflammatory responses
   in retinal-pigmented epithelium cells
SO FOOD & FUNCTION
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; VIRGIN OLIVE OIL; OXIDATIVE STRESS;
   INNATE IMMUNITY; ACTIVATION; LIPOPROTEINS; EXPRESSION; INCREASE; TLR4
AB Postprandial triglyceride-rich lipoproteins (TRLs) lead to a complex series of events that are potentially oxidative and inflammatory. The main goal of this study was to characterize the influence of postprandial TRLs with different fatty acid compositions (mainly SFAs, MUFAs or MUFAs plus omega-3 PUFAs) on oxidative and inflammatory markers in RPE cells, which play a pivotal role in age-related macular degeneration (AMD). Compared to TRL-SFAs, TRL-MUFAs and TRL-MUFAs plus omega-3 PUFAs decreased the production of ROS and nitrite, and the gene expression and secretion of IL-1 beta, IL-6, TNF-alpha, IFN gamma and VEGF. For the first time we show that postprandial TRLs are metabolic entities able to induce RPE oxidative stress and inflammation in a fatty acid-dependent manner, TRL-SFAs >>> TRL-MUFAs = TRL-MUFAs plus omega-3 PUFAs. These exciting findings open new opportunities for developing novel nutritional strategies with olive oil as the principal dietary source of oleic acid to prevent the development and progression of AMD.
C1 [Montserrat-de la Paz, Sergio; Carmen Naranjo, M.; Lopez, Sergio; Abia, Rocio; Muriana, Francisco J. G.] CSIC, Inst Grasa, Lab Cellular & Mol Nutr, Ctra Utrera Km 1, Seville 41013, Spain.
   [Bermudez, Beatriz] Univ Seville, Sch Pharm, Dept Pharmacol, Prof Garcia Gonzalez 2, E-41012 Seville, Spain.
   [Moreda, Wenceslao] CSIC, Inst Grasa, Lab Olive Oil Qual Pur & Technol, Ctra Utrera Km 1, Seville 41013, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de la Grasa (IG); University of Sevilla; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG)
RP Montserrat-de la Paz, S (通讯作者)，CSIC, Inst Grasa, Lab Cellular & Mol Nutr, Ctra Utrera Km 1, Seville 41013, Spain.
EM delapaz@us.es
RI Abia, Rocio/P-1678-2016; Muriana, Francisco José García/S-1825-2016;
   Lopez, Sergio/G-3300-2016; la Paz, Sergio Montserrat-de/Z-3447-2019;
   Moreda, Wenceslao/M-2455-2014
OI Abia, Rocio/0000-0003-2741-189X; Lopez, Sergio/0000-0001-5952-3568; la
   Paz, Sergio Montserrat-de/0000-0001-5400-3192; Moreda,
   Wenceslao/0000-0001-8906-6548; Naranjo, MC/0000-0002-1516-8098
CR Alipour A, 2008, ARTERIOSCL THROM VAS, V28, P792, DOI 10.1161/ATVBAHA.107.159749
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Bellido C, 2004, AM J CLIN NUTR, V80, P1487, DOI 10.1093/ajcn/80.6.1487
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Botham KM, 2013, PROG LIPID RES, V52, P446, DOI 10.1016/j.plipres.2013.06.001
   Cacicedo JM, 2011, INVEST OPHTH VIS SCI, V52, P3630, DOI 10.1167/iovs.10-5784
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cardeno A, 2015, J FUNCT FOODS, V14, P779, DOI 10.1016/j.jff.2015.03.009
   Chan DC, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0309-9
   Chang Jihoon, 2014, Immune Netw, V14, P30, DOI [10.4110/in.2014.14.1.30, 10.41110/in.2014.14.1.30]
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Fang IM, 2014, MOL NUTR FOOD RES, V58, P2053, DOI 10.1002/mnfr.201400196
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Huang SR, 2012, J LIPID RES, V53, P2002, DOI 10.1194/jlr.D029546
   Hussey SE, 2014, DIABETOLOGIA, V57, P582, DOI 10.1007/s00125-013-3111-x
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Kitaura Y, 2015, FEBS OPEN BIO, V5, P485, DOI 10.1016/j.fob.2015.05.008
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liu HQ, 2013, NUTR RES, V33, P849, DOI 10.1016/j.nutres.2013.07.004
   Lopez S, 2014, BBA-BIOMEMBRANES, V1838, P1638, DOI 10.1016/j.bbamem.2014.01.007
   Lopez S, 2013, J NUTR, V143, P620, DOI 10.3945/jn.113.174656
   Losso JN, 2010, J AGR FOOD CHEM, V58, P8246, DOI 10.1021/jf1012067
   Ma WC, 2014, INVEST OPHTH VIS SCI, V55, P6187, DOI 10.1167/iovs.14-14352
   Mamatha BS, 2011, NUTRITION, V27, P960, DOI 10.1016/j.nut.2010.10.011
   Maraki MI, 2015, AM J PHYSIOL-ENDOC M, V309, pE440, DOI 10.1152/ajpendo.00245.2015
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   McEvoy CT, 2013, INVEST OPHTH VIS SCI, V54, P1337, DOI 10.1167/iovs.12-11065
   Montserrat-de la Paz S, 2013, J FUNCT FOODS, V5, P1279, DOI 10.1016/j.jff.2013.04.012
   Murumalla RK, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-175
   Volpe CMO, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/479587
   Ortega A, 2012, FOOD FUNCT, V3, P22, DOI 10.1039/c1fo10085h
   Park YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085068
   Promsote W, 2014, MOL VIS, V20, P73
   Quintero-Florez A, 2015, J AGR FOOD CHEM, V63, P6731, DOI 10.1021/acs.jafc.5b01626
   Schwartz EA, 2010, ARTERIOSCL THROM VAS, V30, P802, DOI 10.1161/ATVBAHA.109.201681
   Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Stewart EA, 2015, EXP EYE RES, V138, P114, DOI 10.1016/j.exer.2015.06.012
   Sur A, 2014, P NATL ACAD SCI USA, V111, P16754, DOI 10.1073/pnas.1419576111
   Tishinsky JM, 2014, APPL PHYSIOL NUTR ME, V39, P28, DOI 10.1139/apnm-2013-0135
   Varela LM, 2014, MOL NUTR FOOD RES, V58, P1349, DOI 10.1002/mnfr.201300749
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 51
TC 24
Z9 24
U1 0
U2 17
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042-6496
EI 2042-650X
J9 FOOD FUNCT
JI Food Funct.
PY 2016
VL 7
IS 3
BP 1345
EP 1353
DI 10.1039/c6fo00136j
PG 9
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA DG7FZ
UT WOS:000372251500012
PM 26914244
DA 2022-11-30
ER

PT J
AU Mittal, D
   Kumari, K
AF Mittal, Deepti
   Kumari, Kajal
TI Automated detection and segmentation of drusen in retinal fundus images
SO COMPUTERS & ELECTRICAL ENGINEERING
LA English
DT Article
DE Drusen; Age-related macular degeneration; Segmentation; Boundary
   extraction; Retinal fundus images; Grading
ID MACULAR DEGENERATION; SYSTEM
AB The druse, an abnormal yellow/white deposit on retina, is a dominant characteristic of age-related macular degeneration (AMD) which is a retinal disorder associated With age. The early detection of drusen is useful for ophthalmologists to diagnose the patients that suffer from AMD. An automated method has been proposed in this work to detect and segment drusen using retinal fundus images by (i) gradient based segmentation to find true edges of drusen, (ii) connected component labeling to remove suspicious pixels from drusen region and (iii) edge linking to connect all labeled pixels into a meaningful boundary. The proposed method outperforms other existing methods in detection of drusen with an accuracy/sensitivity/specificity of 96.17/89.81/99.00 on two publicly available retinal image databases. In order to grade the severity of AMD, the detected drusen by the proposed method are further quantified into small, intermediate and large with an accuracy of 88.46, 98.55, and 8837%, respectively. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Mittal, Deepti; Kumari, Kajal] Thapar Univ, Elect & Instrumentat Engn Dept, Patiala 147004, Punjab, India.
C3 Thapar Institute of Engineering & Technology
RP Mittal, D (通讯作者)，Thapar Univ, Elect & Instrumentat Engn Dept, Patiala 147004, Punjab, India.
EM deepti.mittal@thapar.edu; Kajalkumari0503@gmail.com
RI Mittal, Deepti/ABB-9128-2020
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barakat MR, 2004, INVESTIG OPHTHALMOL, V48, P2260
   Bhuiyan A., 2013, J CLIN EXP OPHTHALMO, V4, P2
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fan CN, 2011, PATTERN RECOGN LETT, V32, P1468, DOI 10.1016/j.patrec.2011.03.023
   Ghita O, 2002, J ELECTRON IMAGING, V11, P479, DOI 10.1117/1.1501574
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kumari K, 2015, J BIOMED ENG MED IMA, V2, P18
   Kumari K, 2015, ADV IMAGE VIDEO PROC, V3, P28, DOI [10.14738/aivp.33.1291, DOI 10.14738/AIVP.33.1291]
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Prasath AR, 2015, RES J INF TECHNOL, V7, P70
   Raza G, 2013, P 2013 IEEE JORD C A, P1
   Remeseiro B, 2009, LECT NOTES COMPUT SC, V5717, P187, DOI 10.1007/978-3-642-04772-5_25
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Waseem Saima, 2014, 7th International Conference on Information and Automation for Sustainability (ICIAfS), P1, DOI 10.1109/ICIAFS.2014.7069581
   Wong DWK, 2013, I S BIOMED IMAGING, P884
   World Health Organization, BLINDN VIS DIS 3
   Zheng YJ, 2013, I S BIOMED IMAGING, P1448
NR 23
TC 24
Z9 24
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-7906
EI 1879-0755
J9 COMPUT ELECTR ENG
JI Comput. Electr. Eng.
PD OCT
PY 2015
VL 47
BP 82
EP 95
DI 10.1016/j.compeleceng.2015.08.014
PG 14
WC Computer Science, Hardware & Architecture; Computer Science,
   Interdisciplinary Applications; Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA DA2PB
UT WOS:000367637200006
DA 2022-11-30
ER

PT J
AU Myles, ME
   Neumann, DM
   Hill, JM
AF Myles, ME
   Neumann, DM
   Hill, JM
TI Recent progress in ocular drug delivery for posterior segment disease:
   Emphasis on transscleral iontophoresis
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE macula; lontophoresis; retina; choroid; sclera; uveitis
ID ENDOTOXIN-INDUCED-UVEITIS; COULOMB-CONTROLLED IONTOPHORESIS; RABBIT EYE;
   GENE-TRANSFER; HUMAN SCLERA; OPTIC-NERVE; IN-VIVO; GENTAMICIN; AGE;
   CORNEA
AB Age-related macular degeneration, diabetic retinopathy, posterior uveitis, and retinitis due to glaucoma are leading causes of vision loss in the United States and other developed countries. Because these diseases are located in the posterior segment of the eye, topical application of ophthalmic medicines is of limited benefit, since topically applied drugs rarely reach therapeutic levels in the affected posterior tissues such as the choroid and retina. Intravitreal injections can deliver drugs to the posterior segment without the side effects associated with systemic administration. However, the repeated and long-term injections often needed may cause complications, such as vitreous hemorrhage, retinal detachment, or endophthalmitis. Recent advances in ocular drug delivery methods and the development of novel biopharmaceutical agents could lead to new regimens for the treatment of disease of the posterior retina, choroids, and macula. This review will summarize recent literature concerning ocular drug delivery of bioactive compounds to the posterior segment of the eye with emphasis on transscleral iontophoresis. (c) 2005 Elsevier B.V. All rights reserved.
C1 Louisiana State Univ, Ctr Eye, Dept Ophthalmol, New Orleans, LA 70112 USA.
   Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA.
   LSU, Hlth Sci Ctr, Neurosci Ctr, New Orleans, LA USA.
   LSU, Hlth Sci Ctr, Dept Microbiol, New Orleans, LA USA.
   LSU, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA USA.
C3 Louisiana State University System; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans; Louisiana
   State University System; Louisiana State University Health Sciences
   Center New Orleans; Louisiana State University System; Louisiana State
   University Health Sciences Center New Orleans; Louisiana State
   University System; Louisiana State University Health Sciences Center New
   Orleans
RP Hill, JM (通讯作者)，Louisiana State Univ, Ctr Eye, Dept Ophthalmol, 2020 Gravier St,Suite B, New Orleans, LA 70112 USA.
EM jhill@lsuhsc.edu
CR Acheampong AA, 2002, DRUG METAB DISPOS, V30, P421, DOI 10.1124/dmd.30.4.421
   AHMED I, 1985, INVEST OPHTH VIS SCI, V26, P584
   AHMED I, 1987, J PHARM SCI, V76, P583, DOI 10.1002/jps.2600760802
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027
   Asahara T, 2001, JPN J OPHTHALMOL, V45, P31, DOI 10.1016/S0021-5155(00)00291-4
   Ashburn MA, 1997, CLIN J PAIN, V13, P22, DOI 10.1097/00002508-199703000-00005
   BANGA AK, 1993, PHARMACEUT RES, V10, P697, DOI 10.1023/A:1018955631835
   BARZA M, 1986, OPHTHALMOLOGY, V93, P133
   BARZA M, 1987, INVEST OPHTH VIS SCI, V28, P1033
   BAZAN HEP, 1985, CURR EYE RES, V4, P175, DOI 10.3109/02713688509000847
   Behar-Cohen FF, 2002, EXP EYE RES, V74, P51, DOI 10.1006/exer.2001.1098
   Behar-Cohen FF, 1998, INVEST OPHTH VIS SCI, V39, P897
   BeharCohen FF, 1997, EXP EYE RES, V65, P533, DOI 10.1006/exer.1997.0364
   Benz MS, 2000, ARCH OPHTHALMOL-CHIC, V118, P577
   Bhisitkul RB, 1997, INT OPHTHALMOL CLIN, V37, P201, DOI 10.1097/00004397-199703740-00017
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Chan HSL, 1996, CLIN CANCER RES, V2, P1499
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Davies JB, 2003, MOL VIS, V9, P569
   Davies NM, 2000, CLIN EXP PHARMACOL P, V27, P558, DOI 10.1046/j.1440-1681.2000.03288.x
   Eljarrat-Binstock E, 2004, J BIOMAT SCI-POLYM E, V15, P397, DOI 10.1163/156856204323005271
   Eljarrat-Binstock E, 2004, INVEST OPHTH VIS SCI, V45, P2543, DOI 10.1167/iovs.03-1294
   ERLANGER G, 1954, OPHTHALMOLOGICA, V128, P232, DOI 10.1159/000302420
   Fischer G. A., 2002, DRUG DELIV TECH, V2, P50
   FISHMAN PH, 1984, INVEST OPHTH VIS SCI, V25, P343
   Frucht-Pery J, 1999, J OCUL PHARMACOL TH, V15, P251, DOI 10.1089/jop.1999.15.251
   Frucht-Pery J, 2004, EXP EYE RES, V78, P745, DOI 10.1016/S0014-4835(03)00215-X
   GANGAROSA LP, 1978, J PROSTHET DENT, V39, P173, DOI 10.1016/S0022-3913(78)80017-1
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   GIBSON LE, 1959, PEDIATRICS, V23, P545
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   GROSSMAN RE, 1990, INVEST OPHTH VIS SCI, V31, P909
   Halhal M, 2004, EXP EYE RES, V78, P751, DOI 10.1016/j.exer.2003.10.017
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   Hauswirth WW, 2000, INVEST OPHTH VIS SCI, V41, P2821
   Hayden BC, 2004, INVEST OPHTH VIS SCI, V45, P3644, DOI 10.1167/iovs.04-0228
   HILL JM, 1993, OPHTHALMIC DRUG DELI, P331
   HUGHES L, 1984, Archives of Ophthalmology, V102, P1825
   Isowaki A, 2003, BIOL PHARM BULL, V26, P69, DOI 10.1248/bpb.26.69
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   KAHLER CM, 1994, EUR J PHARMACOL, V262, P261, DOI 10.1016/0014-2999(94)90740-4
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Koevary SB, 2002, INVEST OPHTH VIS SCI, V43, P797
   Koevary Steven B, 2002, Arch Soc Esp Oftalmol, V77, P347
   Kralinger MT, 2003, OPHTHALMIC RES, V35, P102, DOI 10.1159/000069129
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LAM TT, 1989, ARCH OPHTHALMOL-CHIC, V107, P1368, DOI 10.1001/archopht.1989.01070020438050
   Li SK, 2004, INVEST OPHTH VIS SCI, V45, P1224, DOI 10.1167/iovs.03-0821
   Liu Mimi, 2004, Curr Opin Ophthalmol, V15, P221, DOI 10.1097/01.icu.0000122122.24016.f1
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Maurice D, 1997, INVEST OPHTH VIS SCI, V38, P2177
   MAURICE DM, 1986, OPHTHALMOLOGY, V93, P128
   McCarty MF, 1998, MED HYPOTHESES, V50, P435, DOI 10.1016/S0306-9877(98)90217-1
   Myles M. E., 2002, OPHTHALMIC DRUG DELI, P309
   Okabe K, 2003, INVEST OPHTH VIS SCI, V44, P2702, DOI 10.1167/iovs.02-0956
   Olsen TW, 1998, AM J OPHTHALMOL, V125, P237, DOI 10.1016/S0002-9394(99)80096-8
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Oshima Y, 1998, GENE THER, V5, P1347, DOI 10.1038/sj.gt.3300725
   Parkinson TM, 2003, J OCUL PHARMACOL TH, V19, P145, DOI 10.1089/108076803321637672
   ROOTMAN DS, 1988, INVEST OPHTH VIS SCI, V29, P1397
   RUIZMORENO JM, 1992, OPHTHALMIC RES, V24, P162, DOI 10.1159/000267163
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sakamoto T, 1999, HUM GENE THER, V10, P2551, DOI 10.1089/10430349950016889
   Sanchez-Thorin JC, 1998, INT OPHTHALMOL CLIN, V38, P11
   SARRAF D, 1994, J OCUL PHARMACOL, V10, P69, DOI 10.1089/jop.1994.10.69
   TORIS CB, 1995, ARCH OPHTHALMOL-CHIC, V113, P1514, DOI 10.1001/archopht.1995.01100120044006
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Voigt M, 2002, BIOCHEM BIOPH RES CO, V295, P336, DOI 10.1016/S0006-291X(02)00656-3
   Voigt M, 2002, INVEST OPHTH VIS SCI, V43, P3299
   Vollmer DL, 2002, J OCUL PHARMACOL TH, V18, P549, DOI 10.1089/108076802321021090
   WATSKY MA, 1988, CURR EYE RES, V7, P483, DOI 10.3109/02713688809031801
   Wheeler LA, 1999, EUR J OPHTHALMOL, V9, pS17, DOI 10.1177/112067219900901S09
   WHITELOCKE RA, 1973, ARCH OPHTHALMOL-CHIC, V89, P495
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yoshizumi MO, 1997, J OCUL PHARMACOL TH, V13, P529, DOI 10.1089/jop.1997.13.529
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zempsky W T, 1998, Am J Anesthesiol, V25, P158
   Zempsky WT, 2003, DERMATOL SURG, V29, P627, DOI 10.1046/j.1524-4725.2003.29142.x
NR 83
TC 120
Z9 132
U1 1
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 13
PY 2005
VL 57
IS 14
BP 2063
EP 2079
DI 10.1016/j.addr.2005.08.006
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 996QD
UT WOS:000234188300007
PM 16310884
DA 2022-11-30
ER

PT J
AU Saleh, GA
   Batouty, NM
   Haggag, S
   Elnakib, A
   Khalifa, F
   Taher, F
   Mohamed, MA
   Farag, R
   Sandhu, H
   Sewelam, A
   El-Baz, A
AF Saleh, Gehad A.
   Batouty, Nihal M.
   Haggag, Sayed
   Elnakib, Ahmed
   Khalifa, Fahmi
   Taher, Fatma
   Mohamed, Mohamed Abdelazim
   Farag, Rania
   Sandhu, Harpal
   Sewelam, Ashraf
   El-Baz, Ayman
TI The Role of Medical Image Modalities and AI in the Early Detection,
   Diagnosis and Grading of Retinal Diseases: A Survey
SO BIOENGINEERING-BASEL
LA English
DT Review
DE retinal diseases; artificial intelligence; diabetic retinopathy; macular
   degeneration; modalities
AB Traditional dilated ophthalmoscopy can reveal diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), retinal tear, epiretinal membrane, macular hole, retinal detachment, retinitis pigmentosa, retinal vein occlusion (RVO), and retinal artery occlusion (RAO). Among these diseases, AMD and DR are the major causes of progressive vision loss, while the latter is recognized as a world-wide epidemic. Advances in retinal imaging have improved the diagnosis and management of DR and AMD. In this review article, we focus on the variable imaging modalities for accurate diagnosis, early detection, and staging of both AMD and DR. In addition, the role of artificial intelligence (AI) in providing automated detection, diagnosis, and staging of these diseases will be surveyed. Furthermore, current works are summarized and discussed. Finally, projected future trends are outlined. The work done on this survey indicates the effective role of AI in the early detection, diagnosis, and staging of DR and/or AMD. In the future, more AI solutions will be presented that hold promise for clinical applications.
C1 [Saleh, Gehad A.; Batouty, Nihal M.] Mansoura Univ, Fac Med, Dept Diagnost & Intervent Radiol, Mansoura 35516, Egypt.
   [Haggag, Sayed; Mohamed, Mohamed Abdelazim] Mansoura Univ, Fac Engn, Elect & Commun Dept, Mansoura 35516, Egypt.
   [Elnakib, Ahmed; Khalifa, Fahmi; Sandhu, Harpal; El-Baz, Ayman] Univ Louisville, Bioengn Dept, Louisville, KY 40292 USA.
   [Taher, Fatma] Zayed Univ, Coll Technol Innovat, Dubai 19282, U Arab Emirates.
   [Farag, Rania; Sewelam, Ashraf] Mansoura Univ, Fac Med, Ophthalm Dept, Mansoura 35516, Egypt.
C3 Egyptian Knowledge Bank (EKB); Mansoura University; Egyptian Knowledge
   Bank (EKB); Mansoura University; University of Louisville; Zayed
   University; Egyptian Knowledge Bank (EKB); Mansoura University
RP El-Baz, A (通讯作者)，Univ Louisville, Bioengn Dept, Louisville, KY 40292 USA.
EM aselba01@louisville.edu
RI Elnakib, Ahmed/C-1326-2019; Khalifa, Fahmi/I-5663-2018
OI Elnakib, Ahmed/0000-0001-6084-3622; Khalifa, Fahmi/0000-0003-3318-2851;
   Taher, Dr. Fatma/0000-0001-8358-9081; Saleh, Gehad/0000-0002-4817-4478
FU Academy of Scientific Research and Technology (ASRT) in Egypt
FX This research received external funding from the Academy of Scientific
   Research and Technology (ASRT) in Egypt (Project No. JESOR 5246).
CR Abdelsalam MM, 2021, IEEE ACCESS, V9, P22844, DOI 10.1109/ACCESS.2021.3054743
   Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Adhi M, 2016, AM J OPHTHALMOL, V162, P140, DOI 10.1016/j.ajo.2015.10.025
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alam M, 2020, RETINA-J RET VIT DIS, V40, P322, DOI 10.1097/IAE.0000000000002373
   Alksas A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91634-0
   An GZ, 2019, IEEE ENG MED BIO, P2049, DOI 10.1109/EMBC.2019.8857468
   An L, 2013, BIOMED OPT EXPRESS, V4, P245, DOI 10.1364/BOE.4.000245
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   [Anonymous], 1981, Invest Ophthalmol Vis Sci, V21, P1
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Baumal C.R., 2017, CURRENT MANAGEMENT D
   Bessho K, 2009, GRAEF ARCH CLIN EXP, V247, P729, DOI 10.1007/s00417-008-1033-y
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Bhatkar AP, 2015, 2015 IEEE International Symposium on Nanoelectronic and Information Systems, P331, DOI 10.1109/iNIS.2015.30
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Burns SA, 2014, BIOMED OPT EXPRESS, V5, P961, DOI 10.1364/BOE.5.000961
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Carrera EV, 2017, PROCEEDINGS OF THE 2017 IEEE XXIV INTERNATIONAL CONFERENCE ON ELECTRONICS, ELECTRICAL ENGINEERING AND COMPUTING (INTERCON), DOI 10.1109/INTERCON.2017.8079692
   Cereda MG, 2019, RETINA-J RET VIT DIS, V39, P415, DOI 10.1097/IAE.0000000000001953
   Chakrabarty N, 2018, 2018 5TH IEEE UTTAR PRADESH SECTION INTERNATIONAL CONFERENCE ON ELECTRICAL, ELECTRONICS AND COMPUTER ENGINEERING (UPCON), P13
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chaudhury M, 2021, J CLIN DIAGN RES, V15, pTC7, DOI 10.7860/JCDR/2021/49509.15523
   Chen Q, 2015, J DIGIT IMAGING, V28, P346, DOI 10.1007/s10278-014-9742-8
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Chung H, 2012, OPHTHALMOLOGY, V119, P1056, DOI 10.1016/j.ophtha.2011.11.018
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Cohen SY, 2017, RETINA-J RET VIT DIS, V37, P1625, DOI 10.1097/IAE.0000000000001695
   Colas E, 2016, ACTA OPHTHALMOL, V94, DOI 10.1111/j.1755-3768.2016.0635
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Costa P, 2018, IEEE ACCESS, V6, P18747, DOI 10.1109/ACCESS.2018.2816003
   Costa RA, 2007, RETINA-J RET VIT DIS, V27, P141, DOI 10.1097/IAE.0b013e31802eff83
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Cui Dong, 2015, Open Biomed Eng J, V9, P194, DOI 10.2174/1874120701509010194
   Cunningham J, 2017, JAAPA-J AM ACAD PHYS, V30, P18, DOI 10.1097/01.JAA.0000512227.85313.05
   Das S, 2022, MULTIMED TOOLS APPL, V81, P8007, DOI 10.1007/s11042-021-11824-w
   De Carlo TE, 2015, RETINA-J RET VIT DIS, V35, P2364, DOI 10.1097/IAE.0000000000000882
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dimitrova G, 2017, INVEST OPHTH VIS SCI, V58, P190, DOI 10.1167/iovs.16-20531
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Drexler W, 2007, INVEST OPHTH VIS SCI, V48, P5340, DOI 10.1167/iovs.07-0895
   Dutta S, 2018, INT J GRID DISTRIB, V11, P89, DOI 10.14257/ijgdc.2018.11.1.09
   Ehlers JP, 2015, JAMA OPHTHALMOL, V133, P1124, DOI 10.1001/jamaophthalmol.2015.2376
   Ehlers JP, 2014, AM J OPHTHALMOL, V158, P999, DOI 10.1016/j.ajo.2014.07.034
   Eladawi N, 2018, INT C PATT RECOG, P3886, DOI 10.1109/ICPR.2018.8546250
   Elsharkawy M, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12020461
   ElTanboly A, 2018, I S BIOMED IMAGING, P1431, DOI 10.1109/ISBI.2018.8363841
   ElTanboly A, 2017, MED PHYS, V44, P914, DOI 10.1002/mp.12071
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Fleckenstein M., 2013, RETINA-J RET VIT DIS, P111
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fraccaro P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10
   Friberg TR, 2008, OPHTHAL SURG LAS IM, V39, P304, DOI 10.3928/15428877-20080701-06
   Friberg TR, 2003, OPHTHAL SURG LAS IM, V34, P488
   Fujimoto JG, 2009, OPT EXPRESS, V17, P3978, DOI 10.1364/OE.17.003978
   Gao ZY, 2022, GRAEF ARCH CLIN EXP, V260, P1663, DOI 10.1007/s00417-021-05503-7
   Garcia-Floriano A, 2019, COMPUT ELECTR ENG, V75, P218, DOI 10.1016/j.compeleceng.2017.11.008
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Ghazal M, 2020, IEEE ACCESS, V8, P34387, DOI 10.1109/ACCESS.2020.2974158
   Ghosh R, 2017, 2017 4TH INTERNATIONAL CONFERENCE ON SIGNAL PROCESSING AND INTEGRATED NETWORKS (SPIN), P550, DOI 10.1109/SPIN.2017.8050011
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Hassan T, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1078-3
   Hathwar SB, 2019, IEEE I C SIGNAL IMAG, P73, DOI 10.1109/ICSIPA45851.2019.8977760
   He AL, 2021, IEEE T MED IMAGING, V40, P143, DOI 10.1109/TMI.2020.3023463
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Heisler M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.20
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Horani M, 2019, OPHTHALMOL THER, V8, P235, DOI 10.1007/s40123-019-0177-7
   Hsieh YT, 2021, J FORMOS MED ASSOC, V120, P165, DOI 10.1016/j.jfma.2020.03.024
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Islam M., 2017, J BIOMED SCI ENG, V10, P86, DOI [10.4236/jbise.2017.105B010, DOI 10.4236/JBISE.2017.105B010]
   Jiang F, 2017, STROKE VASC NEUROL, V2, P230, DOI 10.1136/svn-2017-000101
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Jonnal RS, 2016, INVEST OPHTH VIS SCI, V57, pOCT51, DOI 10.1167/iovs.16-19103
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kanclerz P, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11101802
   Karampelas M, 2020, OPHTHALMOL THER, V9, P739, DOI 10.1007/s40123-020-00291-5
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kauppi T, 2007, P BRIT MACH VIS C, P1, DOI [10.5244/C.21.15, DOI 10.5244/C.21.15]
   Keane P.A., 2013, CURR OPHTHALMOL REP, V1, P1, DOI [10.1007/s40135-012-0005-x, DOI 10.1007/S40135-012-0005-X]
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Kernt M, 2012, DIABETES CARE, V35, P2459, DOI 10.2337/dc12-0346
   Khan Z, 2021, IEEE ACCESS, V9, P61408, DOI 10.1109/ACCESS.2021.3074422
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016/j.ajo.2006.04.023
   Kim NR, 2009, BRIT J OPHTHALMOL, V93, P901, DOI 10.1136/bjo.2008.152553
   Kothari AR, 2013, INDIAN J OPHTHALMOL, V61, P230, DOI 10.4103/0301-4738.97081
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Kwasigroch Arkadiusz, 2018, 2018 International Interdisciplinary PhD Workshop (IIPhDW), P111, DOI 10.1109/IIPHDW.2018.8388337
   Labhade JD, 2016, 2016 INTERNATIONAL CONFERENCE ON AUTOMATIC CONTROL AND DYNAMIC OPTIMIZATION TECHNIQUES (ICACDOT), P175, DOI 10.1109/ICACDOT.2016.7877573
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lammer J, 2016, INVEST OPHTH VIS SCI, V57, P6624, DOI 10.1167/iovs.16-19537
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li F, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.4
   Li F, 2019, GRAEF ARCH CLIN EXP, V257, P495, DOI 10.1007/s00417-018-04224-8
   Li HK, 2010, INVEST OPHTH VIS SCI, V51, P3184, DOI 10.1167/iovs.09-4886
   Li XC, 2019, NEUROCOMPUTING, V369, P134, DOI 10.1016/j.neucom.2019.08.079
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Liu HZ, 2020, OSA CONTINUUM, V3, P2630, DOI 10.1364/OSAC.402623
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Liu ZP, 2021, IEEE ACCESS, V9, P51689, DOI 10.1109/ACCESS.2021.3056430
   Lombardo M, 2013, RETINA-J RET VIT DIS, V33, P1630, DOI 10.1097/IAE.0b013e3182899326
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Mahendran G, 2015, COMPUT ELECTR ENG, V45, P312, DOI 10.1016/j.compeleceng.2015.01.013
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Metan Ali Can, 2019, 2019 IEEE 4th International Conference on Image, Vision and Computing (ICIVC), P392, DOI 10.1109/ICIVC47709.2019.8981096
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Michl M, 2022, BRIT J OPHTHALMOL, V106, P113, DOI 10.1136/bjophthalmol-2020-317416
   Miller DT, 2011, EYE, V25, P321, DOI 10.1038/eye.2011.1
   Mohamed IE, 2018, EUR J RADIOL OPEN, V5, P79, DOI 10.1016/j.ejro.2018.05.002
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Moreno J.M.R., 2019, MANUAL RETINA SERV
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Muller P.L., 2019, HIGH RESOLUTION IMAG, P87
   Nagasawa T, 2019, INT OPHTHALMOL, V39, P2153, DOI 10.1007/s10792-019-01074-z
   Narayanan BN, 2020, J MED IMAGING, V7, DOI 10.1117/1.JMI.7.3.034501
   Nesper PL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169926
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Palanisamy G, 2020, BIOCYBERN BIOMED ENG, V40, P752, DOI 10.1016/j.bbe.2020.02.006
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pece A, 2010, OPHTHALMOLOGICA, V224, P230, DOI 10.1159/000260229
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Pilotto E, 2013, GRAEF ARCH CLIN EXP, V251, P27, DOI 10.1007/s00417-012-2031-7
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Prager F, 2009, BRIT J OPHTHALMOL, V93, P452, DOI 10.1136/bjo.2008.141085
   Prasad Deepthi K., 2015, 2015 IEEE Recent Advances in Intelligent Computational Systems (RAICS), P240, DOI 10.1109/RAICS.2015.7488421
   Quellec G, 2017, MED IMAGE ANAL, V39, P178, DOI 10.1016/j.media.2017.04.012
   Qummar S, 2019, IEEE ACCESS, V7, P150530, DOI 10.1109/ACCESS.2019.2947484
   Rahim Sarni Suhaila, 2016, Brain Inform, V3, P249, DOI 10.1007/s40708-016-0045-3
   Rasmussen ML, 2015, J DIABETES COMPLICAT, V29, P99, DOI 10.1016/j.jdiacomp.2014.08.009
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ryan S.J., 2012, RETINA-J RET VIT DIS
   Ryu G, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02479-6
   Saeed F, 2021, IEEE ACCESS, V9, P41344, DOI 10.1109/ACCESS.2021.3065273
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Salz DA, 2016, JAMA OPHTHALMOL, V134, P644, DOI 10.1001/jamaophthalmol.2016.0600
   Salz DA, 2015, MIDDLE EAST AFR J OP, V22, P145, DOI 10.4103/0974-9233.151887
   Sandhu HS, 2020, AM J OPHTHALMOL, V216, P201, DOI 10.1016/j.ajo.2020.01.016
   Sayres R, 2019, OPHTHALMOLOGY, V126, P552, DOI 10.1016/j.ophtha.2018.11.016
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmoll T, 2011, BIOMED OPT EXPRESS, V2, P1159, DOI 10.1364/BOE2.001159
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Scuteri D, 2019, NEURAL REGEN RES, V14, P1445, DOI 10.4103/1673-5374.253528
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sengupta S, 2019, PROC SPIE, V11139, DOI 10.1117/12.2529450
   Shankar K, 2020, PATTERN RECOGN LETT, V133, P210, DOI 10.1016/j.patrec.2020.02.026
   Sharafeldeen A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83735-7
   Shinar Z, 2011, J EMERG MED, V40, P53, DOI 10.1016/j.jemermed.2009.06.001
   Somasundaram SK, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0853-x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Sudo K, 2013, PROC SPIE, V8567, DOI 10.1117/12.2004165
   Takahashi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179790
   Talks SJ, 2017, ASIA-PAC J OPHTHALMO, V6, P498, DOI 10.22608/APO.2017305
   Tam J, 2011, INVEST OPHTH VIS SCI, V52, P9257, DOI 10.1167/iovs.11-8481
   Tan CSH, 2016, INDIAN J OPHTHALMOL, V64, P76, DOI 10.4103/0301-4738.178145
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Tekkesin AI, 2019, ANATOL J CARDIOL, V22, P8, DOI 10.14744/AnatolJCardiol.2019.28661
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Tsai CY, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19031204
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Victor A.A., 2019, VISUAL IMPAIRMENT BL
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008081.pub3
   Vujosevic S, 2011, INVEST OPHTH VIS SCI, V52, P442, DOI 10.1167/iovs.10-5588
   Wang XG, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.7.31
   Wang YL, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3445
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Welikala RA, 2015, COMPUT MED IMAG GRAP, V43, P64, DOI 10.1016/j.compmedimag.2015.03.003
   Wessel MM, 2012, BRIT J OPHTHALMOL, V96, P694, DOI 10.1136/bjophthalmol-2011-300774
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagihara RT, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.11
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yazdanfar S, 2000, OPT LETT, V25, P1448, DOI 10.1364/OL.25.001448
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzurihara D, 2004, JPN J OPHTHALMOL, V48, P490, DOI 10.1007/s10384-004-0102-y
   Zang PX, 2021, IEEE T BIO-MED ENG, V68, P1859, DOI 10.1109/TBME.2020.3027231
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhang QX, 2012, INVEST OPHTH VIS SCI, V53, P8139, DOI 10.1167/iovs.12-10732
   Zhang QX, 2015, SCI REP-UK, V5, DOI 10.1038/srep09595
   Zhang XM, 2018, PROC SPIE, V10836, DOI 10.1117/12.2503883
   Zhe Wang, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10435, P267, DOI 10.1007/978-3-319-66179-7_31
   Zia F, 2022, CMC-COMPUT MATER CON, V70, P2261, DOI 10.32604/cmc.2022.017820
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 210
TC 0
Z9 0
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2306-5354
J9 BIOENGINEERING-BASEL
JI Bioengineering-Basel
PD AUG
PY 2022
VL 9
IS 8
AR 366
DI 10.3390/bioengineering9080366
PG 35
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 4C2EG
UT WOS:000846273100001
PM 36004891
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chopra, R
   Preston, GC
   Keenan, TDL
   Mulholland, P
   Patel, PJ
   Balaskas, K
   Hamilton, RD
   Keane, PA
AF Chopra, Reena
   Preston, Gabriella C.
   Keenan, Tiarnan D. L.
   Mulholland, Padraig
   Patel, Praveen J.
   Balaskas, Konstantinos
   Hamilton, Robin D.
   Keane, Pearse A.
TI Intravitreal injections: past trends and future projections within a UK
   tertiary hospital
SO EYE
LA English
DT Article
ID DIABETIC MACULAR EDEMA; AFLIBERCEPT; RETINOPATHY; PREVALENCE; EYE;
   RANIBIZUMAB; OUTCOMES; HEALTH
AB Aims To describe past trends and future projections for the number of intravitreal injections being administered at a large tertiary hospital in London, United Kingdom. Methods Retrospective data from Moorfields Eye Hospital were collected using the electronic medical record system. Descriptive statistics were used to visualise overall trends. Time series forecasting was used to predict the number of injections that will be administered up to and including the year 2029. Results The number of injections has increased nearly 11-fold from 2009 to 2019, with a total of 44,924 injections delivered in 2019. The majority of injections were given for the treatment of neovascular age-related macular degeneration. Aflibercept formed 87% of injections administered in 2019. The number of injections is predicted to continue to increase every year, with nearly 83,000 injections forecasted in the year 2029. Conclusion The demand for intravitreal injections has increased substantially over the last decade and is predicted to further increase. Healthcare systems will need to adapt to accommodate the high demand. Other solutions may include longer-acting therapies to reduce the treatment burden.
C1 [Chopra, Reena; Preston, Gabriella C.; Mulholland, Padraig; Patel, Praveen J.; Balaskas, Konstantinos; Hamilton, Robin D.; Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Chopra, Reena; Preston, Gabriella C.; Mulholland, Padraig; Patel, Praveen J.; Balaskas, Konstantinos; Hamilton, Robin D.; Keane, Pearse A.] UCL, Inst Ophthalmol, London, England.
   [Keenan, Tiarnan D. L.] NIH, Div Epidemiol & Clin Applicat, NEI, Bldg 10, Bethesda, MD 20892 USA.
   [Mulholland, Padraig] Ulster Univ, Ctr Optometry & Vis Sci Res, Sch Biomed Sci, Coleraine, Londonderry, North Ireland.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Ulster University
RP Keane, PA (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.; Keane, PA (通讯作者)，UCL, Inst Ophthalmol, London, England.
EM p.keane@ucl.ac.uk
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Keane,
   Pearse/0000-0002-9239-745X
FU College of Optometrists, United Kingdom; Heidelberg Engineering;
   Moorfields Eye Charity Career Development Award [R190028A]; UK Research
   & Innovation Future Leaders Fellowship [MR/T019050/1]
FX RC receives studentship support from the College of Optometrists, United
   Kingdom. PM receives research support from Heidelberg Engineering. PAK
   is supported by a Moorfields Eye Charity Career Development Award
   (R190028A) and a UK Research & Innovation Future Leaders Fellowship
   (MR/T019050/1).
CR Boyer DS, 2015, OPHTHALMOLOGY, V122, P2504, DOI 10.1016/j.ophtha.2015.08.006
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Center for drug evaluation and research, 2006, BLA APPL NUM 125156
   Center for drug evaluation and research, 2011, BLA APPL 125387ORIG1
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   CHANDRA S, 2020, EYE
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Denniston AK, 2019, BRIT J OPHTHALMOL, V103, P837, DOI 10.1136/bjophthalmol-2018-312568
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   European Medicines Agency, 2018, EYL
   European Medicines Agency, 2018, LUC
   Facebook, THE PROPHET
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holman N, 2011, DIABETIC MED, V28, P575, DOI 10.1111/j.1464-5491.2010.03216.x
   JAFFE G, 2020, OPHTHALMOLOGY
   Jorstad OK, 2020, ACTA OPHTHALMOL, V98, P774, DOI 10.1111/aos.14177
   Keenan TDL, 2013, EYE, V27, P1397, DOI 10.1038/eye.2013.196
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   McCormick E, 2017, OCT ROLLOUT EVERY SP
   Minassian DC, 2012, BRIT J OPHTHALMOL, V96, P345, DOI 10.1136/bjo.2011.204040
   National Institute for Health and Care Excellence (NICE), 2015, AFL TREAT DIAB MAC O
   National Institute for Health and Care Excellence (NICE), 2014, AFL TREAT VIS IMP CA
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG 82 AG R
   National Institute for Health and Care Excellence (NICE), 2016, AFL TREAT IMP CAUS M
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   National Institute for Health and Care Excellence (NICE), 2013, AFL SOL INJ TREAT WE
   NICE, 2013, RAN TREAT DIAB MAC O
   Roche, 2020, ROCH PORT DEL SYST R
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Sivaprasad S, 2017, LANCET, V389, P2193, DOI 10.1016/S0140-6736(17)31193-5
   Taylor SJ, 2018, AM STAT, V72, P37, DOI 10.1080/00031305.2017.1380080
   Wang X, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/5142628
   Wickham L, 2020, EYE, V34, P1189, DOI 10.1038/s41433-020-0957-2
NR 37
TC 5
Z9 5
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2022
VL 36
IS 7
BP 1373
EP 1378
DI 10.1038/s41433-021-01646-3
EA JUN 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2J2KS
UT WOS:000667029700008
PM 34172943
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Cunningham, F
   Van Bergen, T
   Canning, P
   Lengyel, I
   Feyen, JHM
   Stitt, AW
AF Cunningham, Fiona
   Van Bergen, Tine
   Canning, Paul
   Lengyel, Imre
   Feyen, Jean H. M.
   Stitt, Alan W.
TI The Placental Growth Factor Pathway and Its Potential Role in Macular
   Degenerative Disease
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; neovascular age-related macular
   degeneration; geographic atrophy; placental growth factor; vascular
   endothelial growth factor receptor-1
ID RETINAL-PIGMENT EPITHELIUM; TRANSITION-LIKE CHANGES; OXIDATIVE-STRESS;
   DIABETIC-RETINOPATHY; MONOCYTE ACTIVATION; AEROBIC GLYCOLYSIS; RECEPTOR
   FLT-1; FACTOR-I; AGE; VEGF
AB There is growing evidence that placental growth factor (PlGF) is an important player in multiple pathologies, including tumorigenesis, inflammatory disorders and degenerative retinopathies. PlGF is a member of the vascular endothelial growth factor (VEGF) family and in the retina, binding of this growth factor to specific receptors is associated with pathological angiogenesis, vascular leakage, neurodegeneration and inflammation. Although they share some receptor signalling pathways, many of the actions of PlGF are distinct from VEGF and this has revealed the enticing prospect that it could be a useful therapeutic target for treating early and late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD). Recent research suggests that modulation of PlGF could also be important in the geographic atrophy (GA) form of late AMD by protecting the outer retina and the retinal pigment epithelium (RPE). This review discusses PlGF and its signalling pathways and highlights the potential of blocking the bioactivity of this growth factor to treat irreversible visual loss due to the two main forms of AMD.
C1 [Cunningham, Fiona; Canning, Paul; Lengyel, Imre; Stitt, Alan W.] Queens Univ Belfast, Ctr Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
   [Van Bergen, Tine; Feyen, Jean H. M.] Oxurion NV, Leuven, Belgium.
C3 Queens University Belfast
RP Stitt, AW (通讯作者)，Queens Univ Belfast, Ctr Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM a.stitt@qub.ac.uk
RI Lengyel, Imre/B-5217-2009
OI Lengyel, Imre/0000-0001-7467-2174; Stitt, Alan/0000-0002-8647-9918
FU Department for Education (DfE) CAST/CASE Scheme in Northern Ireland
FX This project is funded through the Department for Education (DfE)
   CAST/CASE Scheme in Northern Ireland with enhanced running costs
   provided by Oxurion NV.
CR Al Kahtani E, 2017, EYE, V31, P529, DOI 10.1038/eye.2016.246
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Apicella I, 2018, CELL REP, V23, P3635, DOI 10.1016/j.celrep.2018.05.067
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Ban Y, 2000, DEV BRAIN RES, V121, P89
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyer NP, 2012, PHOTOCHEM PHOTOBIOL, V88, P1373, DOI 10.1111/j.1751-1097.2012.01127.x
   Cachafeiro M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.303
   Cao RH, 2010, P NATL ACAD SCI USA, V107, P856, DOI 10.1073/pnas.0911661107
   Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chen JF, 2008, J CELL BIOCHEM, V105, P313, DOI 10.1002/jcb.21831
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chou HD, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0497-0
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Clegg LE, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005445
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Ding XY, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0886-z
   Domigan CK, 2015, J CELL SCI, V128, P2236, DOI 10.1242/jcs.163774
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4
   Freitas-Andrade M, 2012, J CEREBR BLOOD F MET, V32, P663, DOI 10.1038/jcbfm.2011.167
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gigante B, 2006, FASEB J, V20, P970, DOI 10.1096/fj.05-4481fje
   Gigante Bruna, 2004, Angiogenesis, V7, P277, DOI 10.1007/s10456-004-4179-1
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hollborn M, 2006, GRAEF ARCH CLIN EXP, V244, P732, DOI 10.1007/s00417-005-0154-9
   Hou HH, 2014, AUTOPHAGY, V10, P1509, DOI 10.4161/auto.29190
   Huang H, 2015, DIABETES, V64, P200, DOI 10.2337/db14-0016
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang J, 2009, MOL VIS, V15, P223
   Huang W, 2014, INT J CLIN EXP PATHO, V7, P8506
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Indraccolo S, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1008307
   Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649
   Izawa H, 2015, INVEST OPHTH VIS SCI, V56, P6914, DOI 10.1167/iovs.15-16748
   Julien S, 2008, MOL VIS, V14, P1358
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Kelly M, 2016, FASEB J, V30, P2985, DOI 10.1096/fj.201600446R
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khurana R, 2005, CIRCULATION, V111, P2828, DOI 10.1161/CIRCULATIONAHA.104.495887
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kowalczuk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017462
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Kuse Y, 2018, J PHARMACOL SCI, V137, P407, DOI 10.1016/j.jphs.2018.07.010
   Li X, 2017, J CELL MOL MED, V21, P2370, DOI 10.1111/jcmm.13158
   Lim JI, 2005, AM J OPHTHALMOL, V140, P1044, DOI 10.1016/j.ajo.2005.07.021
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   MAGLIONE D, 1993, ONCOGENE, V8, P925
   Marin-Castano ME, 2013, AGE RELATED MACULAR, P39, DOI [10.5772/53958, DOI 10.5772/53958]
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   Mpollo MSEM, 2016, J CLIN INVEST, V126, P571, DOI 10.1172/JCI77250
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nourinia Ramin, 2013, J Ophthalmic Vis Res, V8, P4
   Parra-Bonilla G, 2010, AM J PHYSIOL-LUNG C, V299, pL513, DOI 10.1152/ajplung.00274.2009
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Ratsep MT, 2014, PLACENTA, V35, P772, DOI 10.1016/j.placenta.2014.07.006
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Saddala MS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34955-x
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Sawano A, 1996, CELL GROWTH DIFFER, V7, P213
   Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423
   Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036
   Strau O, 2014, HEAT MASS TRANSFER, V50, P303, DOI 10.1007/s00231-013-1267-z
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tjwa M, 2003, CELL TISSUE RES, V314, P5, DOI 10.1007/s00441-003-0776-3
   Treps L, 2016, PHARMACOL REV, V68, P872, DOI 10.1124/pr.116.012492
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Van Bergen T, 2019, PROG RETIN EYE RES, V69, P116, DOI 10.1016/j.preteyeres.2018.10.006
   Van Bergen T, 2017, EXP EYE RES, V165, P136, DOI 10.1016/j.exer.2017.09.012
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu D, 2016, INT J CHRONIC OBSTR, V11, P3031, DOI 10.2147/COPD.S120849
   Wu LE, 2014, DIABETES, V63, P2656, DOI 10.2337/db13-1665
   Xu BH, 2018, INVEST OPHTH VIS SCI, V59
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Yang W, 2003, J REPROD IMMUNOL, V60, P53, DOI 10.1016/S0165-0378(03)00082-2
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yoo SA, 2009, ARTHRITIS RHEUM-US, V60, P345, DOI 10.1002/art.24289
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zhang L, 2015, EUR REV MED PHARMACO, V19, P2621
   Zhang L, 2016, BASIC CLIN PHARMACOL, V119, P498, DOI 10.1111/bcpt.12616
   Zhang L, 2016, INT IMMUNOPHARMACOL, V38, P167, DOI 10.1016/j.intimp.2016.05.028
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
   Zhang Y, 2018, MOL VIS, V24, P340
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao JF, 2015, EXP THER MED, V10, P1404, DOI 10.3892/etm.2015.2697
NR 121
TC 5
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG 3
PY 2019
VL 44
IS 8
BP 813
EP 822
DI 10.1080/02713683.2019.1614197
EA MAY 2019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS7QM
UT WOS:000469678400001
PM 31055948
DA 2022-11-30
ER

PT J
AU Wang, YF
   Liu, CH
   Ji, TJ
   Mehta, M
   Wang, WP
   Marino, E
   Chen, J
   Kohane, DS
AF Wang, Yanfei
   Liu, Chi-Hsiu
   Ji, Tianjiao
   Mehta, Manisha
   Wang, Weiping
   Marino, Elizabeth
   Chen, Jing
   Kohane, Daniel S.
TI Intravenous treatment of choroidal neovascularization by photo-targeted
   nanoparticles
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DRUG-DELIVERY; ANGIOGENESIS; THERAPY;
   PEPTIDE; MODEL; GENE; RGD
AB Choroidal neovascularization (CNV) is the major cause of vision loss in wet age-related macular degeneration (AMD). Current therapies require repeated intravitreal injections, which are painful and can cause infection, bleeding, and retinal detachment. Here we develop nanoparticles (NP-[CPP]) that can be administered intravenously and allow local drug delivery to the diseased choroid via light-triggered targeting. NP-[CPP] is formed by PEG-PLA chains modified with a cell penetrating peptide (CPP). Attachment of a DEACM photocleavable group to the CPP inhibits cellular uptake of NP-[CPP]. Irradiation with blue light cleaves DEACM from the CPP, allowing the CPP to migrate from the NP core to the surface, rendering it active. In mice with laser-induced CNV, intravenous injection of NP-[CPP] coupled to irradiation of the eye allows NP accumulation in the neovascular lesions. When loaded with doxorubicin, irradiated NP-[CPP] significantly reduces neovascular lesion size. We propose a strategy for non-invasive treatment of CNV and enhanced drug accumulation specifically in diseased areas of the eye.
C1 [Wang, Yanfei; Ji, Tianjiao; Mehta, Manisha; Wang, Weiping; Marino, Elizabeth; Kohane, Daniel S.] Harvard Med Sch, Boston Childrens Hosp, Div Crit Care Med, Lab Biomat & Drug Delivery,Dept Anesthesiol, 300 Longwood Ave, Boston, MA 02115 USA.
   [Liu, Chi-Hsiu; Chen, Jing] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Boston Children's Hospital; Harvard Medical School
RP Kohane, DS (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Div Crit Care Med, Lab Biomat & Drug Delivery,Dept Anesthesiol, 300 Longwood Ave, Boston, MA 02115 USA.
EM daniel.kohane@childrens.harvard.edu
RI Wang, Yin/HCI-9352-2022; ji, tianjiao/HCH-4631-2022; Wang,
   Weiping/C-6087-2008; Wang, Yanbo/HFZ-8018-2022; wang, yan/GSE-6489-2022
OI Wang, Weiping/0000-0001-7511-3497; 
FU National Institutes of Health [GM 116920, R01EY024963, R01EY028100];
   NATIONAL EYE INSTITUTE [R01EY028100, R01EY024963] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM116920]
   Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health GM 116920
   (to D.S.K.), R01EY024963 and R01EY028100 (to J.C.).
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Chu YC, 2017, INT J NANOMED, V12, P1353, DOI 10.2147/IJN.S126865
   Dvir T, 2010, NANO LETT, V10, P250, DOI 10.1021/nl903411s
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Farokhzad OC, 2008, EXPERT OPIN DRUG DEL, V5, P927, DOI [10.1517/17425247.5.9.927, 10.1517/17425247.5.9.927 ]
   Giuliari GP, 2012, CURR DIABETES REV, V8, P32, DOI 10.2174/157339912798829188
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Greaves P., 2012, HISTOPATHOLOGY PRECL, V4, P225
   Hennig R, 2015, EUR J PHARM BIOPHARM, V95, P294, DOI 10.1016/j.ejpb.2015.02.027
   Ideta R, 2004, FEBS LETT, V557, P21, DOI 10.1016/S0014-5793(03)01315-2
   Iriyama A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028560
   Iwase T, 2013, J CONTROL RELEASE, V172, P625, DOI 10.1016/j.jconrel.2013.10.008
   Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k
   Kimura H, 2001, ADV DRUG DELIVER REV, V52, P79, DOI 10.1016/S0169-409X(01)00190-9
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Liu Q, 2016, NANO LETT, V16, P4516, DOI 10.1021/acs.nanolett.6b01730
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Maeshima K, 2004, RETINA-J RET VIT DIS, V24, P507, DOI 10.1097/00006982-200408000-00002
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Murase T, 2013, B CHEM SOC JPN, V86, P510, DOI 10.1246/bcsj.20120314
   Nasongkla N, 2004, ANGEW CHEM INT EDIT, V43, P6323, DOI 10.1002/anie.200460800
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Rwei AY, 2015, NANO TODAY, V10, P451, DOI 10.1016/j.nantod.2015.06.004
   Salehi-Had H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018864
   Shembekar VR, 2007, BIOCHEMISTRY-US, V46, P5479, DOI 10.1021/bi700280e
   Shi JJ, 2011, ACCOUNTS CHEM RES, V44, P1123, DOI 10.1021/ar200054n
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Timko BP, 2010, ADV MATER, V22, P4925, DOI 10.1002/adma.201002072
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Trabulo S, 2010, PHARMACEUTICALS, V3, P961, DOI 10.3390/ph3040961
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Huu VAN, 2015, J CONTROL RELEASE, V200, P71, DOI 10.1016/j.jconrel.2015.01.001
   Wang WP, 2015, NANO LETT, V15, P6332, DOI 10.1021/acs.nanolett.5b01325
   Wang YF, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.20
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Yang R, 2017, ADV MATER, V29, DOI 10.1002/adma.201606596
NR 41
TC 41
Z9 42
U1 9
U2 73
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 18
PY 2019
VL 10
AR 804
DI 10.1038/s41467-019-08690-4
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HL6RZ
UT WOS:000458864600007
PM 30778060
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU DiCarlo, JE
   Mahajan, VB
   Tsang, SH
AF DiCarlo, James E.
   Mahajan, Vinit B.
   Tsang, Stephen H.
TI Gene therapy and genome surgery in the retina
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Review
ID LEBER CONGENITAL AMAUROSIS; HEREDITARY OPTIC NEUROPATHY; X-LINKED
   RETINOSCHISIS; DUAL AAV VECTORS; OCULAR SUBRETINAL INJECTION; PIGMENTOSA
   GTPASE REGULATOR; CNGA3(-/-) MOUSE MODEL; DOUBLE-STRAND BREAKS; PHASE-I
   TRIAL; ADENOASSOCIATED VIRUS
AB Precision medicine seeks to treat disease with molecular specificity. Advances in genome sequence analysis, gene delivery, and genome surgery have allowed clinician-scientists to treat genetic conditions at the level of their pathology. As a result, progress in treating retinal disease using genetic tools has advanced tremendously over the past several decades. Breakthroughs in gene delivery vectors, both viral and nonviral, have allowed the delivery of genetic payloads in preclinical models of retinal disorders and have paved the way for numerous successful clinical trials. Moreover, the adaptation of CRISPR-Cas systems for genome engineering have enabled the correction of both recessive and dominant pathogenic alleles, expanding the disease-modifying power of gene therapies. Here, we highlight the translational progress of gene therapy and genome editing of several retinal disorders, including RPE65-, CEP290-, and GUY2D-associated Leber congenital amaurosis, as well as choroideremia, achromatopsia, Mer tyrosine kinase-(MERTK-) and RPGR X-linked retinitis pigmentosa, Usher syndrome, neovascular age-related macular degeneration, X-linked retinoschisis, Stargardt disease, and Leber hereditary optic neuropathy.
C1 [DiCarlo, James E.; Tsang, Stephen H.] Columbia Univ, Coll Phys & Surg, Inst Human Nutr,Columbia Stem Cell Initiat, Dept Ophthalmol,Jonas Childrens Vis Care & Bernar, New York, NY USA.
   [DiCarlo, James E.; Tsang, Stephen H.] Columbia Univ, Coll Phys & Surg, Inst Human Nutr,Columbia Stem Cell Initiat, Dept Pathol & Cell Biol,Jonas Childrens Vis Care, New York, NY USA.
   [DiCarlo, James E.; Tsang, Stephen H.] New York Presbyterian Hosp, Edward S Harkness Eye Inst, New York, NY USA.
   [Mahajan, Vinit B.] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Omics Lab, Palo Alto, CA 94304 USA.
   [Mahajan, Vinit B.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
C3 Columbia University; Columbia University; NewYork-Presbyterian Hospital;
   Stanford University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System
RP Tsang, SH (通讯作者)，Columbia Univ, Med Ctr, 635 West 165th St,Box 112, New York, NY 10032 USA.
EM sht2@columbia.edu
RI DiCarlo, James/AAJ-1579-2021
OI DiCarlo, James/0000-0003-4728-3186; Mahajan, Vinit/0000-0003-1886-1741
FU NIH [5P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437,
   R01EY024665, R01EY025225, P30EY026877]; National Cancer Institute Core
   [5P30CA013696]; Research to Prevent Blindness (RPB) Physician-Scientist
   Award; RPB (New York, New York, USA); Tistou and Charlotte Kerstan
   Foundation; Schneeweiss Stem Cell Fund of New York State [C029572];
   Foundation Fighting Blindness New York Regional Research Center grant
   [C-NY05-0705-0312]; Crowley Family Fund; Gebroe Family Foundation;
   Research to Prevent Blindness (RPB) organization; NATIONAL CANCER
   INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY025225, R01EY024665, R01EY018213, P30EY026877,
   R01EY026682, P30EY019007, R01EY024698] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R21AG050437] Funding Source: NIH RePORTER
FX The authors would like to thank Tarun Sharma (Edward S. Harkness Eye
   Institute, New York-Presbyterian Hospital) for clinical examples of
   LCA10, as well as Sophie Park and Christine Xu (Department of
   Ophthalmology, Columbia University) for their assistance with the
   manuscript submission. The Jonas Children's Vision Care is supported by
   the NIH (5P30EY019007, R01EY018213, R01EY024698, R01EY026682, and
   R21AG050437); the National Cancer Institute Core (5P30CA013696); a
   Research to Prevent Blindness (RPB) Physician-Scientist Award; and
   unrestricted funds from RPB (New York, New York, USA). SHT is a member
   of the RD-CURE Consortium and is supported by the Tistou and Charlotte
   Kerstan Foundation; the Schneeweiss Stem Cell Fund of New York State
   (C029572); a Foundation Fighting Blindness New York Regional Research
   Center grant (C-NY05-0705-0312); the Crowley Family Fund; and the Gebroe
   Family Foundation. VBM is supported by grants from the NIH (R01EY026682,
   R01EY024665, R01EY025225, R01EY024698, R21AG050437, and P30EY026877) and
   the Research to Prevent Blindness (RPB) organization.
CR A Kotterman Melissa, 2015, Neurogenesis (Austin), V2, pe1122700, DOI 10.1080/23262133.2015.1122700
   Abu-Safieh L, 2013, GENOME RES, V23, P236, DOI 10.1101/gr.144105.112
   Alexander JJ, 2007, NAT MED, V13, P685, DOI 10.1038/nm1596
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Appaiahgari MB, 2015, EXPERT OPIN BIOL TH, V15, P337, DOI 10.1517/14712598.2015.993374
   Arshavsky VY, 2012, J BIOL CHEM, V287, P1620, DOI 10.1074/jbc.R111.305243
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bakondi B, 2016, EXPERT REV OPHTHALMO, V11, P397, DOI 10.1080/17469899.2016.1251316
   Bakondi B, 2016, MOL THER, V24, P556, DOI 10.1038/mt.2015.220
   Balaggan KS, 2006, J GENE MED, V8, P275, DOI 10.1002/jgm.845
   Banin E, 2015, MOL THER, V23, P1423, DOI 10.1038/mt.2015.114
   Barrangou R, 2016, NAT BIOTECHNOL, V34, P933, DOI 10.1038/nbt.3659
   Bashar AE, 2016, MOL VIS, V22, P718
   Bassuk AG, 2016, SCI REP-UK, V6, DOI 10.1038/srep19969
   Beltran WA, 2014, COLD SPRING HARB PER, V5
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   Bennett J, 2016, LANCET, V388, P661, DOI 10.1016/S0140-6736(16)30371-3
   Bonnet C, 2012, CURR OPIN NEUROL, V25, P42, DOI 10.1097/WCO.0b013e32834ef8b2
   Boye SL, 2015, HUM GENE THER, V26, P575, DOI 10.1089/hum.2015.053
   Burke TR, 2011, OPHTHALMIC GENET, V32, P165, DOI 10.3109/13816810.2011.565397
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Busskamp V, 2012, GENE THER, V19, P169, DOI 10.1038/gt.2011.155
   Byrne LC, 2014, GENE THER, V21, P585, DOI 10.1038/gt.2014.31
   Cabral T, 2017, CURR OPIN OPHTHALMOL, V28, P252, DOI 10.1097/ICU.0000000000000359
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Carvalho LS, 2011, HUM MOL GENET, V20, P3161, DOI 10.1093/hmg/ddr218
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Castle MJ, 2016, METHODS MOL BIOL, V1382, P133, DOI 10.1007/978-1-4939-3271-9_10
   Chen Y, 2006, INVEST OPHTH VIS SCI, V47, P1177, DOI 10.1167/iovs.05-0965
   Christie KA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16279-4
   Chung DC, 2009, J AAPOS, V13, P587, DOI 10.1016/j.jaapos.2009.10.004
   Churchill JD, 2013, INVEST OPHTH VIS SCI, V54, P1411, DOI 10.1167/iovs.12-11541
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Coffin J.M., 1997, RETROVIRUSES
   Colella P, 2014, GENE THER, V21, P450, DOI 10.1038/gt.2014.8
   Colella P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072027
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Coppieters F, 2010, HUM MUTAT, V31, P1097, DOI 10.1002/humu.21337
   Dang YL, 2017, EXP EYE RES, V158, P73, DOI 10.1016/j.exer.2016.04.023
   Deng WT, 2012, INVEST OPHTH VIS SCI, V53, P1895, DOI 10.1167/iovs.11-8831
   Deverman BE, 2016, NAT BIOTECHNOL, V34, P204, DOI 10.1038/nbt.3440
   DiCarlo JE, 2017, ADV EXP MED BIOL, V1016, P3, DOI 10.1007/978-3-319-63904-8_1
   DiCarlo JE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.13
   Ding XQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007410
   Dyka FM, 2014, HUM GENE THER METHOD, V25, P166, DOI 10.1089/hgtb.2013.212
   Edwards TL, 2016, NEW ENGL J MED, V374, P1996, DOI 10.1056/NEJMc1509501
   Ellouze S, 2008, AM J HUM GENET, V83, P373, DOI 10.1016/j.ajhg.2008.08.013
   Feuer WJ, 2016, OPHTHALMOLOGY, V123, P558, DOI 10.1016/j.ophtha.2015.10.025
   Finsterer J, 2016, CLIN OPHTHALMOL, V10, P2187, DOI 10.2147/OPTH.S120197
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garanto A, 2016, HUM MOL GENET, V25, P2552, DOI 10.1093/hmg/ddw118
   Gaub BM, 2015, MOL THER, V23, P1562, DOI 10.1038/mt.2015.121
   GEORGE NDL, 1995, BRIT J OPHTHALMOL, V79, P697, DOI 10.1136/bjo.79.7.697
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4
   Hashimoto T, 2007, GENE THER, V14, P584, DOI 10.1038/sj.gt.3302897
   Hassall MM, 2017, YALE J BIOL MED, V90, P543
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Heidenreich M, 2016, NAT REV NEUROSCI, V17, P36, DOI 10.1038/nrn.2015.2
   Hoffman LM, 1997, INVEST OPHTH VIS SCI, V38, P2224
   Hong DH, 2002, INVEST OPHTH VIS SCI, V43, P3373
   Hong DH, 2004, INVEST OPHTH VIS SCI, V45, P36, DOI 10.1167/iovs.03-0787
   Hong DH, 2000, P NATL ACAD SCI USA, V97, P3649, DOI 10.1073/pnas.060037497
   Huang WC, 2012, INVEST OPHTH VIS SCI, V53, P5594, DOI 10.1167/iovs.12-10070
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Ivanova E, 2010, INVEST OPHTH VIS SCI, V51, P5288, DOI 10.1167/iovs.10-5389
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Julien S, 2008, MOL VIS, V14, P1358
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526
   Kocher T, 2017, MOL THER, V25, P2585, DOI 10.1016/j.ymthe.2017.08.015
   Kohl S, 2005, EUR J HUM GENET, V13, P302, DOI 10.1038/sj.ejhg.5201269
   Kohl S, 2015, NAT GENET, V47, P757, DOI 10.1038/ng.3319
   Kole C, 2018, MOL THER, V26, P219, DOI 10.1016/j.ymthe.2017.09.007
   Komaromy AM, 2010, HUM MOL GENET, V19, P2581, DOI 10.1093/hmg/ddq136
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Ksantini M, 2012, EUR J OPHTHALMOL, V22, P647, DOI 10.5301/ejo.5000096
   Lai Y, 2010, MOL THER, V18, P75, DOI 10.1038/mt.2009.256
   Lai Y, 2009, J CLIN INVEST, V119, P624, DOI 10.1172/JCI36612
   Latella MC, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2016.92
   Leber T., 1871, GRAEFES ARCH OPHTHAL, V17, P249, DOI 10.1007/BF01694557
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315
   Lopes VS, 2013, GENE THER, V20, P824, DOI 10.1038/gt.2013.3
   Lu LJ, 2017, GRAEF ARCH CLIN EXP, V255, P1057, DOI 10.1007/s00417-017-3619-8
   Lv JN, 2017, SCI REP-UK, V7, DOI 10.1038/srep43062
   Mackay DS, 2010, MOL VIS, V16, P369
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514
   McClements M, 2014, INVEST OPHTH VIS SCI, V55
   MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58
   Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35
   Meyerson C, 2015, CLIN OPHTHALMOL, V9, P1165, DOI 10.2147/OPTH.S62021
   Michalakis S, 2012, ADV EXP MED BIOL, V723, P183, DOI 10.1007/978-1-4614-0631-0_25
   Michalakis S, 2010, MOL THER, V18, P2057, DOI 10.1038/mt.2010.149
   Mihelec M, 2011, HUM GENE THER, V22, P1179, DOI 10.1089/hum.2011.069
   Moosajee M, 2016, HUM MOL GENET, V25, P3416, DOI 10.1093/hmg/ddw184
   Moosajee M, 2009, INVEST OPHTH VIS SCI, V50, P3009, DOI 10.1167/iovs.08-2755
   Mullin E, MIT TECHNOLOGY REV
   Nakai H, 2001, J VIROL, V75, P6969, DOI 10.1128/JVI.75.15.6969-6976.2001
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Olshevskaya EV, 2012, J NEUROSCI, V32, P7208, DOI 10.1523/JNEUROSCI.0976-12.2012
   Palfi S, 2014, LANCET, V383, P1138, DOI 10.1016/S0140-6736(13)61939-X
   Pang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035250
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Park TK, 2009, GENE THER, V16, P916, DOI 10.1038/gt.2009.61
   Parker MA, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.5.10
   Patel N, 2016, GENET MED, V18, P554, DOI 10.1038/gim.2015.127
   Patircio MI, 2017, MOL THER-NUCL ACIDS, V6, P198, DOI 10.1016/j.omtn.2016.12.006
   Perrault I, 1999, MOL GENET METAB, V68, P200, DOI 10.1006/mgme.1999.2906
   Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461
   Perrault Isabelle, 2007, Hum Mutat, V28, P416, DOI 10.1002/humu.9485
   Plossl K, 2017, MOL BIOL CELL, V28, P2178, DOI 10.1091/mbc.E17-01-0064
   PUCHTA H, 1993, NUCLEIC ACIDS RES, V21, P5034, DOI 10.1093/nar/21.22.5034
   Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P1, DOI 10.1167/iovs.06-0789
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Remmer MH, 2015, CURR OPIN OPHTHALMOL, V26, P333, DOI 10.1097/ICU.0000000000000189
   Rosenberg T, 1997, CLIN GENET, V51, P314
   ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096
   Ruan GX, 2017, MOL THER, V25, P331, DOI 10.1016/j.ymthe.2016.12.006
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   SANKILA EM, 1992, NAT GENET, V1, P109, DOI 10.1038/ng0592-109
   Schornack Muriel M, 2007, Optometry, V78, P17, DOI 10.1016/j.optm.2006.07.012
   SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507
   SELLON DC, 1992, J VIROL, V66, P5906, DOI 10.1128/JVI.66.10.5906-5913.1992
   Sengillo JD, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020053
   Sengillo JD, 2016, AM J MED GENET C, V172, P349, DOI 10.1002/ajmg.c.31534
   Sharon D, 2018, PROG RETIN EYE RES, V63, P69, DOI 10.1016/j.preteyeres.2017.10.003
   Shin J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701620
   Simunovic MP, 2017, JAMA OPHTHALMOL, V135, P234, DOI 10.1001/jamaophthalmol.2016.5630
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   Stein-Streilein J, 2007, J LEUKOCYTE BIOL, V81, P593, DOI 10.1189/jlb.0606383
   Takahashi Y, 2015, FEBS LETT, V589, P1143, DOI 10.1016/j.febslet.2015.03.010
   Tantri A, 2004, SURV OPHTHALMOL, V49, P214, DOI 10.1016/j.survophthal.2003.12.007
   Trapani I, 2018, METHODS MOL BIOL, V1715, P153, DOI 10.1007/978-1-4939-7522-8_11
   Trapani I, 2015, HUM MOL GENET, V24, P6811, DOI 10.1093/hmg/ddv386
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   Tsai YT, OPHTHALMOLOGY, DOI DOI 10.1016/OPHTHA.2018.04.001
   Ueyama K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108071
   Vasireddy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061396
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wan X, 2016, SCI REP-UK, V6, DOI 10.1038/srep21587
   Wang HB, 2016, MOL VIS, V22, P189
   Wang HP, 2013, INT J MOL MED, V31, P377, DOI 10.3892/ijmm.2012.1197
   Weber BHF, 2002, P NATL ACAD SCI USA, V99, P6222, DOI 10.1073/pnas.092528599
   Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232
   Weiss ER, 2001, J NEUROSCI, V21, P9175, DOI 10.1523/JNEUROSCI.21-23-09175.2001
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Wu WH, 2016, MOL THER, V24, P1388, DOI 10.1038/mt.2016.107
   Xu Z, 2005, GENE THER, V12, P1159, DOI 10.1038/sj.gt.3302537
   Yan D, 2010, J HUM GENET, V55, P327, DOI 10.1038/jhg.2010.29
   Yang Y, 1996, GENE THER, V3, P137
   Ye GJ, 2016, HUM GENE THER, V27, P72, DOI 10.1089/hum.2015.130
   Ye GJ, 2015, HUM GENE THER CL DEV, V26, P177, DOI 10.1089/humc.2015.077
   Ye GJ, 2015, HUM GENE THER CL DEV, V26, P165, DOI 10.1089/humc.2015.076
   Zallocchi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094272
   Zeng Y, 2004, INVEST OPHTH VIS SCI, V45, P3279, DOI 10.1167/iovs.04-0576
   Zhang LJ, 2016, J CLIN INVEST, V126, P4659, DOI 10.1172/JCI86905
   Zhang Q, 2002, HUM MOL GENET, V11, P993, DOI 10.1093/hmg/11.9.993
   Zhang W, 2018, HUM GENE THER, V29, P42, DOI 10.1089/hum.2017.049
NR 177
TC 67
Z9 70
U1 1
U2 29
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN 1
PY 2018
VL 128
IS 6
BP 2177
EP 2188
DI 10.1172/JCI120429
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GH8HM
UT WOS:000433908900003
PM 29856367
OA Bronze, Green Published
DA 2022-11-30
ER

EF